

APPROVED DRUG PRODUCTS

WITH

**THERAPEUTIC
EQUIVALENCE
EVALUATIONS**

37th EDITION

**THE PRODUCTS IN THIS LIST HAVE BEEN APPROVED UNDER
SECTION 505 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT.**

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
OFFICE OF MEDICAL PRODUCTS AND TOBACCO
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF GENERIC DRUGS
OFFICE OF GENERIC DRUG POLICY

2017

APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS

The products in this list have been approved under section 505 of the Federal Food, Drug, and Cosmetic Act. This volume is current through December 31, 2016.

37th EDITION



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
OFFICE OF MEDICAL PRODUCTS AND TOBACCO
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF GENERIC DRUGS
OFFICE OF GENERIC DRUG POLICY

2017

**FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH**

**APPROVED DRUG PRODUCTS
With
Therapeutic Equivalence Evaluations**

CONTENTS

	<i>PAGE</i>
PREFACE TO THIRTY SEVENTH EDITION.....	iv
1 INTRODUCTION.....	vi
1.1 Content and Exclusion	vi
1.2 Therapeutic Equivalence-Related Terms	vi
1.3 Further Guidance on Bioequivalence	ix
1.4 Reference Listed Drug and Reference Standard.....	ix
1.5 General Policies and Legal Status	x
1.6 Practitioner/User Responsibilities	x
1.7 Therapeutic Equivalence Evaluations Codes	xii
1.8 Description of Certain Special Situations	xx
1.9 Therapeutic Equivalence Code Change for a Drug Entity	xxiii
1.10 Change of the Therapeutic Equivalence Evaluation for a Single Product.....	xxiii
1.11 Discontinued Section	xxiv
1.12 Changes to the Orange Book.....	xxiv
1.13 Availability of the Edition	xxv
2 HOW TO USE THE DRUG PRODUCTS LISTS	2-1
2.1 Key Sections for Using the Drug Product Lists	2-1
2.2 Drug Product Illustration	2-3
2.3 Therapeutic Equivalence Evaluations Illustration	2-4
DRUG PRODUCT LISTS	
Prescription Drug Product List	3-1
OTC Drug Product List	4-1
Drug Products with Approval under Section 505 of the FD&C Act Administered by the Center for Biologics Evaluation and Research List	5-1
Discontinued Drug Product List	6-1
Orphan Products Designations and Approvals List	7-1
Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	8-1
APPENDICES	
A. Product Name Index	A-1
B. Product Name Index Listed by Applicant	B-1
C. Uniform Terms	C-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	AD1
A. Patent and Exclusivity Lists	ADA1
B. Patent and Exclusivity Terms	ADB1

**FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH**

**APPROVED DRUG PRODUCTS
With
Therapeutic Equivalence Evaluations**

PREFACE TO THIRTY SEVENTH EDITION

The publication, *Approved Drug Products With Therapeutic Equivalence Evaluations* (the list, commonly known as the Orange Book), identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the FD&C Act). The main criterion for the inclusion of any product is that the product is the subject of an application with an approval that has not been withdrawn for safety or efficacy reasons. Inclusion of products in the Orange Book is independent of any current regulatory action through administrative or judicial means against a drug product. In addition, the Orange Book contains therapeutic equivalence evaluations for approved multisource prescription drug products. These evaluations have been prepared to serve as public information and advice to state health agencies, prescribers, and pharmacists to promote public education in the area of drug product selection and to foster containment of health care costs. Therapeutic equivalence evaluations in this publication are not official FDA actions affecting the legal status of products under the FD&C Act.

Background of the Publication. To contain drug costs, virtually every state has adopted laws and/or regulations that encourage the substitution of drug products. These state laws generally require either that substitution be limited to drugs on a specific list (the positive formulary approach) or that it be permitted for all drugs except those prohibited by a particular list (the negative formulary approach). Because of the number of requests in the late 1970s for FDA assistance in preparing both positive and negative formularies, it became apparent that FDA could not serve the needs of each state on an individual basis. The Agency also recognized that providing a single list based on common criteria would be preferable to evaluating drug products on the basis of differing definitions and criteria in various state laws. As a result, on May 31, 1978, the Commissioner of the Food and Drug Administration sent a letter to officials of each state stating FDA's intent to provide a list of all prescription drug products that are approved by FDA for safety and effectiveness, along with therapeutic equivalence determinations for multisource prescription products.

The Orange Book was distributed as a proposal in January 1979. It included only currently marketed prescription drug products approved by FDA through new drug applications (NDAs) and abbreviated new drug applications (ANDAs) under the provisions of Section 505 of the FD&C Act.

The therapeutic equivalence evaluations in the Orange Book reflect FDA's application of specific criteria to the multisource prescription drug products listed in the Orange Book and approved under Section 505 of the FD&C Act. These evaluations are presented in the form of code letters that indicate the basis for the evaluation made. An explanation of the code appears in the *Introduction*.

A complete discussion of the background and basis of FDA's therapeutic equivalence evaluation policy was published in the *Federal Register* on January 12, 1979 (44 FR 2932). The final rule, which includes FDA's responses to the public comments on the proposal, was published in the *Federal Register* on October 31, 1980 (45 FR 72582). The first publication, October 1980, of the final version of the Orange Book incorporated appropriate corrections and additions. Each subsequent edition has included the new approvals and made appropriate changes in data.

On September 24, 1984, the President signed into law the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Amendments). The Hatch-Waxman Amendments require that FDA, among other things, make publicly available a list of approved drug products with monthly supplements. The Orange Book and its monthly Cumulative Supplements satisfy this requirement. The *Addendum* to this publication identifies drugs that qualify under the FD&C Act for periods of exclusivity and provides patent information concerning the listed drugs which also may delay the approval of ANDAs or 505(b)(2) applications. The *Addendum* also provides additional information that may be helpful to those submitting a new drug application to the Agency.

The Agency intends to use this publication to further its objective of obtaining input and comment on the publication itself and related Agency procedures. Therefore, if you have comments on how the publication can be improved, please send them to the Director, Division of Legal and Regulatory Support, Office of Generic Drug Policy, Office of Generic Drugs, Center for Drug Evaluation and Research, 7620 Standish Place, Rockville, MD 20855-2773. Comments received are publicly available to the extent allowable under the Freedom of Information Act and FDA regulations.

1. INTRODUCTION

1.1 Content and Exclusion

The Orange Book is composed of four parts: (1) approved prescription drug products with therapeutic equivalence evaluations; (2) approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; (3) drug products with approval under Section 505 of the FD&C Act administered by the Center for Biologics Evaluation and Research; and (4) a cumulative list of approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing.¹ This publication also includes indices of prescription and OTC drug products by trade name (proprietary name) or established name (if no trade name exists) and by applicant name (holder of the approved application). All established names for active ingredients generally conform to official compendial names or *United States Adopted Names* (USAN) as described in (21 CFR 299.4(e)). The latter list includes applicants' names as abbreviated in this publication; in addition, a list of uniform terms is provided in Appendix C.

An *Addendum* contains patent and exclusivity information for the Prescription, OTC, Discontinued Drug Product Lists, and for the Drug Products with Approval under Section 505 of the FD&C Act Administered by the Center for Biologics Evaluation and Research. The publication may include additional information that the Agency deems appropriate to disseminate.

Prior to the 6th Edition, the publication had excluded OTC drug products and drug products with approval under Section 505 of the FD&C Act administered by the Center for Biologics Evaluation and Research. The Hatch-Waxman Amendments required the Agency to begin publishing an up-to-date list of all marketed drug products, OTC as well as prescription, that have been approved for safety and efficacy and for which new drug applications are required.

Under the FD&C Act, some drug products are given tentative approvals. The Agency will not include drug products with tentative approvals in the Orange Book. Tentative approval lists are available on FDA's website at [Drug Approval Reports](#). When the tentative approval becomes a final approval through a subsequent action letter to the applicant, the Agency will list the drug product and the date of approval in the appropriate approved drug product list.

Distributors or repackagers of products listed in the Orange Book are not identified. Because distributors or repackagers are not required to notify FDA when they shift their sources of supply from one approved manufacturer to another, it is not possible to maintain complete information linking product approval with the distributor or repackager handling the products.

1.2 Therapeutic Equivalence-Related Terms

¹ Newly approved products are added to parts 1, 2, or 3, of the Orange Book, depending on the dispensing requirements (prescription or OTC) or approval authority, unless the Orange Book staff is otherwise notified before publication.

Pharmaceutical Equivalents. Drug products are considered pharmaceutical equivalents if they contain the same active ingredient(s), are of the same dosage form, route of administration and are formulated to contain the same amount of active ingredient, and to meet the same or compendial or other applicable standards (i.e., strength, quality, purity, and identity). They may differ in characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration time, and, within certain limits, labeling.

Pharmaceutical Alternatives. Drug products are considered pharmaceutical alternatives if they contain the same therapeutic moiety, but are different salts, esters, or complexes of that moiety, or are different dosage forms or strengths (e.g., tetracycline hydrochloride, 250mg capsules vs. tetracycline phosphate complex, 250mg capsules; quinidine sulfate, 200mg tablets vs. quinidine sulfate, 200mg capsules). Different dosage forms and strengths within a product line by a single manufacturer are thus pharmaceutical alternatives, as are extended-release products when compared with immediate-release or standard-release formulations of the same active ingredient.

Therapeutic Equivalents. Drug products are considered to be therapeutic equivalents only if they are pharmaceutical equivalents for which bioequivalence has been demonstrated, and they can be expected to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling.

FDA classifies as therapeutically equivalent those products that meet the following general criteria: (1) they are approved as safe and effective; (2) they are pharmaceutical equivalents in that they (a) contain identical amounts of the same active drug ingredient in the same dosage form and route of administration, and (b) meet compendial or other applicable standards of strength, quality, purity, and identity; (3) they are bioequivalent in that (a) they do not present a known or potential bioequivalence problem, and they meet an acceptable *in vitro* standard, or (b) if they do present such a known or potential problem, they are shown to meet an appropriate bioequivalence standard; (4) they are adequately labeled; and (5) they are manufactured in compliance with Current Good Manufacturing Practice regulations. *The concept of therapeutic equivalence, as used to develop the Orange Book, applies only to drug products containing the same active ingredient(s) and does not encompass a comparison of different therapeutic agents used for the same condition (e.g., meperidine hydrochloride vs. morphine sulfate for the treatment of pain).* Any drug product in the Orange Book repackaged and/or distributed by other than the applicant is considered to be therapeutically equivalent to the applicant's drug product even if the applicant's drug product is single source or coded as non-equivalent (e.g., **BN**). Also, distributors or repackagers of an applicant's drug product are considered to have the same code as the applicant.

FDA considers drug products to be therapeutically equivalent if they meet the criteria outlined above, even though they may differ in certain other characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time and minor aspects of labeling (e.g., the presence of specific pharmacokinetic information), and storage conditions. When such differences are important in the care of a particular patient, it may be appropriate for the prescribing physician to require that a specific product be dispensed as a medical necessity. With this limitation, however, FDA believes that products classified as therapeutically equivalent can be substituted with the full expectation that the substituted product will produce the same clinical effect and safety profile as the prescribed product.

Strength. Strength refers to the amount of drug substance contained in, delivered, or deliverable from a drug product, which includes: (1)(a) the total quantity of drug substance in mass or units of activity in a dosage unit or container closure (e.g., weight/unit dose, weight/volume or weight/weight in a container closure, or units/volume or units/weight in a container closure); and/or, as applicable, (b) the concentration of the drug substance in mass or units of activity per unit volume or mass (e.g., weight/weight, weight/volume, or units/volume); or (2) such other criteria the Agency establishes for determining the amount of drug substance contained in, delivered, or deliverable from a drug product if the weights and measures described in clause (1)(a) do not apply (e.g., certain drug-device combination products for which the amount of drug substance is emitted per use or unit time). Note that if the criteria the Agency establishes for determining and expressing the amount of drug substance in a product evolves over time, the Agency generally does not intend to revise the expressions of strength for drug products already included in the Orange Book, but rather intends to apply the criteria prospectively to drug products added to the Orange Book.

The strength of drug products in the Orange Book is generally expressed in terms of the amount of drug substance (active ingredient) in the drug product, but is sometimes expressed in terms of the amount of the active moiety. For example, certain drug products included in the Orange Book include a designation of "EQ" next to their expression of strength. This "EQ" designation generally is used in connection with salt drug products to indicate that the strength of such drug product is being expressed in terms of the equivalent strength of the active moiety (e.g., "EQ 200MG BASE"), rather than in terms of the strength of the active ingredient.

Bioavailability. This term means the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of drug action. For drug products that are not intended to be absorbed into the bloodstream, bioavailability may be assessed by scientifically valid measurements intended to reflect the rate and extent to which the active ingredient or active moiety becomes available at the site of drug action.

Bioequivalent Drug Products. This term describes pharmaceutical equivalent or pharmaceutical alternative products that display comparable bioavailability when studied under similar experimental conditions. Section 505 (j)(8)(B) of the FD&C Act describes one set of conditions under which a test and reference listed drug (see Section 1.4) shall be considered bioequivalent:

the rate and extent of absorption of the [test] drug do not show a significant difference from the rate and extent of absorption of the [reference] drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses; or

the extent of absorption of the [test] drug does not show a significant difference from the extent of absorption of the [reference] drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses and the difference from the [reference] drug in the rate of absorption of the drug is intentional, is reflected in its proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug.

Where these above methods are not applicable (e.g., for drug products that are not intended to be absorbed into the bloodstream), other scientifically valid *in vivo* or *in vitro* test methods to demonstrate bioequivalence may be appropriate.

For example, bioequivalence may sometimes be demonstrated using an *in vitro* bioequivalence standard, especially when such an *in vitro* test has been correlated with human *in vivo* bioavailability data. In other situations, bioequivalence may sometimes be demonstrated through comparative clinical trials or pharmacodynamic studies.

1.3 Further Guidance on Bioequivalence

FDA's regulations and guidance documents provide additional information regarding bioequivalence and bioavailability, including methodologies and statistical criteria used to establish the bioequivalence of drug products.²

1.4 Reference Listed Drug and Reference Standard

A reference listed drug (21 CFR 314.3(b)) means the listed drug identified by FDA as the drug product upon which an applicant relies in seeking approval of its ANDA. Generally, a reference listed drug is a drug product approved in a new drug application under section 505(c) of the FD&C Act based on full reports of investigations of safety and effectiveness. A reference standard is the drug product selected by FDA that an applicant seeking approval of an ANDA must use in conducting an *in vivo* bioequivalence study required for approval. FDA generally selects a single reference standard that ANDA applicants must use in *in vivo* bioequivalence testing. Ordinarily, FDA will select the reference listed drug as the reference standard. However, in some instances (e.g., where the reference listed drug has been withdrawn from sale and an ANDA is selected as the reference standard), the reference listed drug and the reference standard may be different.

FDA has identified reference listed drugs in the Prescription Drug Product and OTC Drug Product Lists. Forthcoming, FDA will identify reference listed drugs in the Discontinued Drug Product List. These identified reference listed drugs represent drug products upon which an applicant can rely in seeking approval of an ANDA. FDA intends to update periodically the reference listed drugs identified in the Prescription Drug Product, OTC Drug Product, and Discontinued Drug Product Lists, as appropriate.

FDA also has identified in the Prescription Drug Product and OTC Drug Product Lists reference standards to which the *in vivo* bioequivalence is compared. These identified reference standards represent the FDA's best judgment at this time as to the appropriate comparator for purposes of *in vivo* bioequivalence testing.

In some instances when a listed drug is not designated as a reference listed drug, such listed drug may be shielded from generic competition. If FDA has not designated a reference listed drug for a drug product the applicant intends to duplicate, the potential applicant may ask FDA to

² We note that prior editions of the Preface to the Orange Book included a section entitled "Statistical Criteria for Bioequivalence." Please see FDA's regulations and guidance documents for additional information regarding bioequivalence and bioavailability. See FDA Drugs guidance Web page at <http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm>; FDA Drugs guidance (Product-Specific Recommendations for Generic Drug Development) Web page at <http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm075207.htm>; see generally 21 CFR part 320.

designate a reference listed drug for that drug product. Potential applicants should consult agency guidance related to referencing approved drug products in ANDA submissions for information on submitting such a request. If the request is granted, the listed drug will be designated as a reference listed drug, in which case an ANDA citing the designated reference listed drug may be submitted. Section 1.7, *Therapeutic Equivalence Evaluations Codes (products meeting necessary bioequivalence requirements)* explains the character coding system (e.g., **AB**, **AB1**, **AB2**, **AB3**...) for multisource drug products listed under the same heading with two reference listed drugs.

A potential applicant should consult agency guidance related to referencing approved drug products in ANDA submissions for information on submitting a request for selection of a reference standard. FDA may, on its own initiative, select a new reference standard when doing so will help to ensure that potential applicants have adequate information required for *in vivo* bioequivalence studies, e.g., in the event that the listed drug currently selected as the reference standard has been withdrawn from sale for other than safety and efficacy reasons. Historically, there were two situations in which two listed drugs that had been shown to be bioequivalent to each other had both been identified by the symbol "+" in the Orange Book. The first situation was when the *in vivo* determination of bioequivalence is self-evident and a waiver of any *in vivo* bioequivalence may be granted. The second situation was when the bioequivalence of two listed products may be determined through *in vitro* methodology.

If an applicant has a question related to the appropriate reference standard, it is recommended that an applicant planning to conduct an *in vivo* bioequivalence study submit a controlled correspondence to the Office of Generic Drugs.

1.5 General Policies and Legal Status

The Orange Book contains public information and advice. It does not mandate the drug products that are purchased, prescribed, dispensed, or substituted for one another, nor does it, conversely, mandate the products that should be avoided. To the extent that the Orange Book sets forth FDA's evaluations of the therapeutic equivalence of drug products that have been approved, it contains FDA's advice to the public, to practitioners, and to the states regarding drug product selection. These evaluations do not constitute determinations that any product is in violation of the FD&C Act or that any product is preferable to any other. Therapeutic equivalence evaluations are a scientific judgment based upon evidence, while generic substitution may involve social and economic policy administered by the states, intended to reduce the cost of drugs to consumers. To the extent that the Orange Book identifies drug products approved under Section 505 of the FD&C Act, it sets forth information that the Agency is required to publish and that the public is entitled to under the Freedom of Information Act. Exclusion of a drug product from the Orange Book does not necessarily mean that the drug product is either in violation of Section 505 of the FD&C Act, that such a product is not safe or effective, or that such a product is not therapeutically equivalent to other drug products. Rather, the exclusion is based on the fact that FDA has not evaluated the safety, effectiveness, and quality of the drug product.

1.6 Practitioner/User Responsibilities

Professional care and judgment should be exercised in using the Orange Book. Evaluations of therapeutic equivalence for prescription drugs are based

on scientific and medical evaluations by FDA. Products evaluated as therapeutically equivalent can be expected, in the judgment of FDA, to have equivalent clinical effect and no difference in their potential for adverse effects when used under the conditions of their labeling. However, these products may differ in other characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time, and, in some instances, labeling. If products with such differences are substituted for each other, there is a potential for patient confusion due to differences in color or shape of tablets, inability to provide a given dose using a partial tablet if the proper scoring configuration is not available, or decreased patient acceptance of certain products because of flavor. For example, there may also be allergic reactions in rare cases due to a coloring or a preservative ingredient, as well as differences in cost to the patient.

FDA evaluation of therapeutic equivalence in no way relieves practitioners of their professional responsibilities in prescribing and dispensing such products with due care and with appropriate information to individual patients. In those circumstances where the characteristics of a specific product, other than its active ingredient, are important in the therapy of a particular patient, the physician's specification of that product is appropriate. Pharmacists must also be familiar with the expiration dates/times and labeling directions for storage of the different products, particularly for reconstituted products, to assure that patients are properly advised when one product is substituted for another.

Multisource and single-source drug products. In the Orange Book, FDA has evaluated for therapeutic equivalence only multisource prescription drug products approved under Section 505 of the FD&C Act, which in most instances means those pharmaceutical equivalents available from more than one manufacturer. For such products, a therapeutic equivalence code is included and, in addition, product information is highlighted in bold face and underlined. Those products with approved applications that are single-source (i.e., there is only one approved product available for that active ingredient, dosage form, route of administration, and strength) are also included in the Orange Book, but no therapeutic equivalence code is included with such products. Any drug product in the Orange Book repackaged and/or distributed by other than the applicant (e.g., an authorized generic) is considered to be therapeutically equivalent to the applicant's drug product even if the applicant's drug product is single source or coded as non-equivalent (e.g., **BN**). Also, although not identified in the Orange Book, distributors or repackagers of an applicant's drug product are considered to have the same code as the applicant. The details of these codes and the policies underlying them are discussed in Section 1.7, *Therapeutic Equivalence Evaluations Codes*.

Products in the Orange Book are identified by the names of the holders of approved applications (applicants) who may not necessarily be the manufacturer of the product. There are numerous entities other than the applicant that may be involved in the development, manufacturing, and/or marketing of a product. The applicant may have had its product manufactured by a contract manufacturer and may simply be distributing the product for which it has obtained approval. In many instances, however, the manufacturer of the product is also the applicant. The name of the manufacturer is permitted by regulation to appear on the label, even when the manufacturer is not the marketer.

Although the products in the Orange Book are identified by the names of the applicants, circumstances, such as changing corporate ownership, have sometimes made identification of the applicant difficult. The Agency believes, based on continuing document review and communication with firms,

that the applicant designations in the Orange Book are, in most cases, correct.

To relate firm name information on a product label to that in the Orange Book, the following should be noted: the applicant's name always appears in the Orange Book. This applies whether the applicant (firm name on the Form FDA 356h in the application) is the marketer (firm name in largest letters on the label) or not. However, the applicant's name may not always appear on the label of the product.

If the applicant is the marketer, its name appears in the Orange Book and on the label; if the applicant is not the marketer, and the Agency is aware of a corporate relationship (e.g., parent and subsidiary) between the applicant and the marketer, the name of the applicant appears in the Orange Book and both firm names may appear on the label. Firms with known corporate relationships are displayed in Appendix B. If there is no known corporate relationship between the applicant and the marketer, the applicant's name appears in the Orange Book; however, unless the applicant is the manufacturer, packager, or distributor, the applicant's name may not appear on the label. In this case, the practitioner, from labeling alone, will not be able to relate the marketed product to an applicant cited in the Orange Book, and hence to a specific approved drug product. In such cases, to assure that the product in question is the subject of an approved application, the firm named on the label should be contacted.

To relate trade name (proprietary name) information on a product label to that in the Orange Book, the following should be noted: if the applicant is the marketer, its name appears in the Orange Book and on the label; if the Agency is aware of a corporate relationship between the applicant and the marketer, the trade name (proprietary name) of the drug product (established name of the active ingredient, if no trade name exists) appears in the Orange Book. If a corporate relationship exists between an applicant and a marketer and both firms are distributing the drug product, the FDA reserves the right to select the trade name of either the marketer or the applicant to appear in the Orange Book. If there is no known corporate relationship between the applicant and the marketer, the established drug name (i.e., non-proprietary name) appears in the Orange Book.

Every product in the Orange Book is subject at all times to regulatory action. From time to time, approved products may be found in violation of one or more provisions of the FD&C Act. In such circumstances, the Agency may commence appropriate enforcement action to correct the violation, if necessary, by securing removal of the product from the market by voluntary recall, seizure, or other enforcement actions. Such regulatory actions are, however, independent of the inclusion of a product in the Orange Book. The main criterion for inclusion of a product is that it has an application that has been approved and that has not been withdrawn for safety or efficacy reasons. FDA believes that retention of a violative product in the Orange Book will not have any significant adverse health consequences, because other legal mechanisms are available to the Agency to prevent the product's actual marketing. FDA may however, change a product's therapeutic equivalence rating if the circumstances giving rise to the violation change or otherwise call into question the Agency's assessment of whether a product meets the criteria for therapeutic equivalence.

1.7 Therapeutic Equivalence Evaluations Codes

The coding system for therapeutic equivalence evaluations is constructed to allow users to determine quickly whether the Agency has evaluated a particular approved product as therapeutically equivalent to other

pharmaceutically equivalent products (first letter) and to provide additional information on the basis of FDA's evaluations (second letter). With some exceptions (e.g., therapeutic equivalence evaluations for certain 505(b)(2) applications), the therapeutic equivalence evaluation date is the same as the approval date.

The two basic categories into which multisource drugs have been placed are indicated by the first letter of the relevant therapeutic equivalence code as follows:

A Drug products that FDA considers to be therapeutically equivalent to other pharmaceutically equivalent products, i.e., drug products for which:

- (1) there are no known or suspected bioequivalence problems. These are designated **AA, AN, AO, AP, or AT**, depending on the dosage form; or
- (2) actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting bioequivalence. These are designated **AB**.

B Drug products that FDA at this time, considers not to be therapeutically equivalent to other pharmaceutically equivalent products, i.e.,

drug products for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence. Often the problem is with specific dosage forms rather than with the active ingredients. These are designated **BC, BD, BE, BN, BP, BR, BS, BT, BX, or B***.

Individual drug products have been evaluated as therapeutically equivalent to the reference product in accordance with the definitions and policies outlined below:

"A" CODES

Drug products that are considered to be therapeutically equivalent to other pharmaceutically equivalent products.

"A" products are those for which there are no known or suspected bioequivalence problems or for which actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting bioequivalence. Drug products designated with an "A" code fall under one of two main policies:

- (1) for those active ingredients or dosage forms for which no *in vivo* bioequivalence issue is known or suspected, the information necessary to show bioequivalence between pharmaceutically equivalent products is presumed and considered self-evident based on other data in the application for some dosage forms (e.g., solutions) or satisfied by a showing that an acceptable *in vitro* dissolution standard is met. A therapeutically equivalent rating is assigned such products so long as they are manufactured in accordance with Current Good Manufacturing Practice regulations and meet the other requirements of their approved applications (these are designated **AA, AN, AO, AP, or AT**, depending on the dosage form, as described below); or
- (2) for those Drug Efficacy Study Implementation (DESI) drug products containing active ingredients or dosage forms that have been identified by FDA as having actual or potential bioequivalence problems, and for

post-1962 drug products in a dosage form presenting a potential bioequivalence problem, an evaluation of therapeutic equivalence is assigned to pharmaceutical equivalents only if the approved application contains adequate scientific evidence establishing through *in vivo* and/or *in vitro* studies the bioequivalence of the product to a selected reference product (these products are designated as **AB**).

There are some general principles that may affect the substitution of pharmaceutically equivalent products in specific cases. Prescribers and dispensers of drugs should be alert to these principles so as to deal appropriately with situations that require professional judgment and discretion.

There may be labeling differences among pharmaceutically equivalent products that require attention on the part of the health professional. For example, pharmaceutically equivalent powders to be reconstituted for administration as oral or injectable liquids may vary with respect to their expiration time or storage conditions after reconstitution. An FDA evaluation that such products are therapeutically equivalent is applicable only when each product is reconstituted, stored, and used under the conditions specified in the labeling of that product.

The Agency may use notes in this publication to point out special situations such as potential differences between two drug products that have been evaluated as bioequivalent and otherwise therapeutically equivalent, when they should be brought to the attention of health professionals. These notes are contained in Section 1.8, *Description of Certain Special Situations*.

For example, in rare instances, there may be variations among therapeutically equivalent products in their use or in conditions of administration. Such differences may be due to patent or exclusivity rights associated with such use. When such variations may, in the Agency's opinion, affect prescribing or substitution decisions by health professionals, a note may be added to Section 1.8.

Also, occasionally a situation may arise in which changes in a listed drug product after its approval (for example, a change in dosing interval) may have an impact on the substitutability of already approved generic versions of that product that were rated by the Agency as therapeutically equivalent to the listed product. When such changes in the listed drug product are considered by the Agency to have a significant impact on therapeutic equivalence, the Agency will change the therapeutic equivalence ratings for other versions of the drug product unless the manufacturers of those other versions of the product provide additional information to assure equivalence under the changed conditions. Pending receipt of the additional data, the Agency may add a note to Section 1.8, or, in rare cases, may even change the therapeutic equivalence rating.

In some cases (e.g., Isolyte® S w/ Dextrose 5% in Plastic Container and Plasma-Lyte® 148 and Dextrose 5% in Plastic Container), closely related products are listed as containing the same active ingredients, but in somewhat different amounts. In determining which of these products are pharmaceutically equivalent, generally the Agency has considered products to be pharmaceutically equivalent with labeled strengths of an ingredient that do not vary by more than 1%.

Different salts, esters or other noncovalent derivatives (such as a complex, chelate, or clathrate) of the same active moiety are regarded as different active ingredients. For the purpose of this publication, products containing such different active ingredients are considered pharmaceutical

alternatives and thus not therapeutically equivalent. Anhydrous and hydrated entities, as well as different polymorphs, are considered to be the same active ingredient and are expected to meet the same standards for identity to be considered pharmaceutical equivalents and therapeutic equivalents.

The codes in this book are not intended to preclude health care professionals from converting pharmaceutically different concentrations into pharmaceutical equivalents using accepted professional practice.

Where package size variations have therapeutic implications, products so packaged have not been considered pharmaceutically equivalent. For example, some oral contraceptives are supplied in 21-tablet and 28-tablet packets; the 28-tablet packets contain 7 placebo or iron tablets. These two packaging configurations are not regarded as pharmaceutically equivalent; thus, they are not designated as therapeutically equivalent.

Preservatives may differ among some therapeutically equivalent drug products. Differences in preservatives and other inactive ingredients do not affect FDA's evaluation of therapeutic equivalence except in cases where these components may influence bioequivalence or routes of administration.

The specific sub-codes for those drugs evaluated as therapeutically equivalent and the policies underlying these sub-codes follow:

AA Products in conventional dosage forms not presenting bioequivalence problems

Products coded as **AA** contain active ingredients and dosage forms that are not regarded as presenting either actual or potential bioequivalence problems or drug quality or standards issues. However, all oral dosage forms must, nonetheless, meet an appropriate *in vitro* bioequivalence standard that is acceptable to the Agency in order to be approved.

AB, AB1, AB2, AB3... Products meeting necessary bioequivalence requirements

Multisource drug products listed under the same heading (i.e., identical active ingredient(s), dosage form, and route(s) of administration) and having the same strength (see Section 1.2, *Therapeutic Equivalence-Related Terms, Strength*) generally will be coded **AB** if data and information are submitted demonstrating bioequivalence.

In certain instances, a number is added to the end of the **AB** code to make a three character code (i.e., **AB1, AB2, AB3, etc.**). Three-character codes generally are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference listed drug products that are not identified as bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against. For example, Adalat® CC and Procardia XL®, extended-release tablets, are listed under the active ingredient nifedipine. These drug products, listed under the same heading, are not bioequivalent to each other. Adalat® CC and Procardia XL® have been assigned ratings of **AB1** and **AB2**, respectively. Generic drug products deemed by FDA to be bioequivalent to Adalat® CC and Procardia XL® have been approved. As a result, the generic drug products bioequivalent to Adalat® CC have been assigned a rating of **AB1** and those bioequivalent to Procardia XL® have been assigned a rating of **AB2**. (The assignment of an **AB1** or **AB2** rating to a specific product does not imply product preference.) Even though drug products of distributors and/or

repackagers are not included in the Orange Book, they are considered therapeutically equivalent to the applicant's drug product if the applicant's drug product is rated either with an **AB** or three-character code or is single source in the Orange Book. Drugs coded as **AB** under a heading are considered therapeutically equivalent only to other drugs coded as **AB** under that heading. Drugs coded with a three-character code under a heading are considered therapeutically equivalent only to other drugs coded with the same three-character code under that heading.

AN Solutions and powders for aerosolization

Uncertainty regarding the therapeutic equivalence of aerosolized products arises primarily because of differences in the drug delivery system. Solutions and powders intended for aerosolization that are marketed for use in any of several delivery systems are considered to be pharmaceutically and therapeutically equivalent and are coded **AN**. Those products that are compatible only with a specific delivery system or those products that are packaged in and with a specific delivery system are coded **BN**, unless they have met an appropriate bioequivalence standard and are otherwise determined to be therapeutically equivalent. Solutions or suspensions in a specific delivery system will be coded **AN** if the bioequivalence standard is based upon *in vitro* methodology, if bioequivalence needs to be demonstrated by *in vivo* methodology then the drug products will be coded **AB**.

AO Injectable oil solutions

The absorption of drugs in injectable (parenteral) oil solutions may vary substantially with the type of oil employed as a vehicle and the concentration of the active ingredient. Injectable oil solutions are therefore considered to be pharmaceutically and therapeutically equivalent only when the active ingredient, its concentration, and the type of oil used as a vehicle are all identical.

AP Injectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions

It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, historically some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling.

Certain commonly used large volume intravenous products in glass containers are not included in the Orange Book (e.g., dextrose injection

5%, dextrose injection 10%, sodium chloride injection 0.9%) since these products are on the market without FDA approval and the FDA has not published conditions for marketing such parenteral products under approved NDAs. When packaged in plastic containers, however, FDA regulations require approved applications prior to marketing. Approval then depends on, among other things, the extent of the available safety data involving the specific plastic component of the product. All large volume parenteral products are manufactured under similar standards, regardless of whether they are packaged in glass or plastic. Thus, FDA has no reason to believe that the packaging container of large volume parenteral drug products that are pharmaceutically equivalent would have any effect on their therapeutic equivalence.

Consistent with the definition of strength included in Section 1.2, *Therapeutic Equivalence-Related Terms*, the strength of parenteral drug products generally is identified by both the total drug content and the concentration of drug substance in a container approved by FDA.³ In the past, the strength of liquid parenteral drug products in the Orange Book has not been fully displayed. Rather, the strength of liquid parenteral drug products in the Orange Book has been displayed in terms of concentration, expressed as xmg/mL. Generally, the amount of dry powder or lyophilized powder in a container is identified as the strength, expressed as xmg/vial.

With the finalization of the Hatch-Waxman Amendments that characterized each strength of a drug product as a listed drug, it became evident that the format of the Orange Book should be changed to reflect each strength of a parenteral solution. To this end, the Orange Book now displays the strength of all new approvals of parenteral solutions. Previously, we would have displayed only the concentration of an approved parenteral solution, e.g. 50mg/mL. If this drug product had a 20 mL and 60 mL container approved, we would now display two product strengths for this product, listing both total drug content and concentration of drug substance in the relevant approved container, e.g. 1Gm / 20mL (50mg/mL) and 3Gm / 60mL (50mg/mL).

AT Topical products

There are a variety of topical dosage forms available for dermatologic, ophthalmic, otic, rectal, and vaginal administration, including creams, gels, lotions, oils, ointments, pastes, solutions, sprays and suppositories. Even though different topical dosage forms may contain the same active ingredient and potency, these dosage forms are not considered pharmaceutically equivalent. Therefore, they are not considered therapeutically equivalent. All solutions and DESI drug products containing the same active ingredient in the same topical dosage form for which a waiver of *in vivo* bioequivalence has been granted and for which chemistry and manufacturing processes are adequate to demonstrate bioequivalence, are considered therapeutically equivalent and coded **AT**. Pharmaceutically equivalent topical products that raise questions of bioequivalence, including all post-1962 non-solution topical drug products, are coded **AB** when supported by adequate bioequivalence data, and **BT** in the absence of such data.

"B" CODES

³ The strengths of certain parenteral drug products, including contrast agents, may be expressed as a percentage.

Drug products that FDA, at this time, considers not to be therapeutically equivalent to other pharmaceutically equivalent products.

"B" products, for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence, often have a problem with specific dosage forms rather than with the active ingredients. Drug products designated with a "B" code fall under one of three main policies:

- (1) the drug products contain active ingredients or are manufactured in dosage forms that have been identified by the Agency as having documented bioequivalence problems or a significant potential for such problems and for which no adequate studies demonstrating bioequivalence have been submitted to FDA; or
- (2) the quality standards are inadequate or FDA has an insufficient basis to determine therapeutic equivalence; or
- (3) the drug products are under regulatory review.

The specific coding definitions and policies for the "B" sub-codes are as follows:

B* Drug products requiring further FDA investigation and review to determine therapeutic equivalence

The code **B*** is assigned to products previously assigned an **A** or **B** code when FDA receives new information that raises a significant question regarding therapeutic equivalence that can be resolved only through further Agency investigation and/or review of data and information submitted by the applicant. The **B*** code signifies that the Agency will take no position regarding the therapeutic equivalence of the product until the Agency completes its investigation and review.

BC Extended-release dosage forms (capsules, injectables and tablets)

Extended-release tablets are formulated in such a manner as to make the contained drug substance available over an extended period of time following ingestion.

Although bioavailability studies have been conducted on these dosage forms, they may be subject to bioavailability differences, primarily because applicants developing extended-release products for the same active ingredient rarely employ the same formulation approach. FDA, therefore, does not consider different extended-release dosage forms containing the same active ingredient in equal strength to be therapeutically equivalent unless equivalence between individual products in both rate and extent has been specifically demonstrated through appropriate bioequivalence studies. Extended-release products for which such bioequivalence data have not been submitted are coded **BC**, while those for which such data are available have been coded **AB**.

BD Active ingredients and dosage forms with documented bioequivalence problems

The **BD** code denotes products containing active ingredients with known bioequivalence problems and for which adequate studies have not been submitted to FDA demonstrating bioequivalence. Where studies showing bioequivalence have been submitted, the product has been coded **AB**.

BE Delayed-release oral dosage forms

Where the drug may be destroyed or inactivated by the gastric juice or where it may irritate the gastric mucosa, the use of "enteric" coatings is indicated. Such coatings are intended to delay the release of the medication until the tablet has passed through the stomach. Drug products in delayed-release dosage forms containing the same active ingredients are subject to significant differences in absorption. Unless otherwise specifically noted, the Agency considers different delayed-release products containing the same active ingredients as presenting a potential bioequivalence problem and codes these products **BE** in the absence of *in vivo* studies showing bioequivalence. If adequate *in vivo* studies have demonstrated the bioequivalence of specific delayed-release products, such products are coded **AB**.

BN Products in aerosol-nebulizer drug delivery systems

This code applies to drug solutions or powders that are marketed only as a component of, or as compatible with, a specific drug delivery system. There may, for example, be significant differences in the dose of drug and particle size delivered by different products of this type. Therefore, the Agency does not consider different metered aerosol dosage forms containing the same active ingredient(s) in equal strengths to be therapeutically equivalent unless the drug products meet an appropriate bioequivalence standard; such products are coded **AB**.

BP Active ingredients and dosage forms with potential bioequivalence problems

FDA's bioequivalence regulations (21 CFR 320.33) contain criteria and procedures for determining whether a specific active ingredient in a specific dosage form has a potential for causing a bioequivalence problem. It is FDA's policy to consider an ingredient meeting these criteria as having a potential bioequivalence problem even in the absence of positive data demonstrating inequivalence. Pharmaceutically equivalent products containing these ingredients in oral dosage forms are coded **BP** until adequate bioequivalence data are submitted, after which such products are coded **AB**. Injectable suspensions containing an active ingredient suspended in an aqueous or oleaginous vehicle have also been coded **BP**. Injectable suspensions are subject to bioequivalence problems because differences in particle size, polymorphic structure of the suspended active ingredient, or the suspension formulation can significantly affect the rate of release and absorption. FDA does not consider pharmaceutical equivalents of these products bioequivalent without adequate evidence of bioequivalence; such products would be coded **AB**.

BR Suppositories or enemas that deliver drugs for systemic absorption

The absorption of active ingredients from suppositories or enemas that are intended to have a systemic effect (as distinct from suppositories administered for local effect) can vary significantly from product to product. Therefore, FDA considers pharmaceutically equivalent systemic suppositories or enemas bioequivalent only if *in vivo* evidence of bioequivalence is available. In those cases where *in vivo* evidence is available, the product is coded **AB**. If such evidence is not available, the products are coded **BR**.

BS Products having drug standard deficiencies

If the drug standards for an active ingredient in a particular dosage form are found by FDA to be deficient so as to prevent an FDA evaluation of either pharmaceutical or therapeutic equivalence, all drug products containing that active ingredient in that dosage form are coded **BS**. For example, if the standards permit a wide variation in pharmacologically active components of the active ingredient such that pharmaceutical equivalence is in question, all products containing that active ingredient in that dosage form are coded **BS**.

BT Topical products with bioequivalence issues

This code applies mainly to post-1962 dermatologic, ophthalmic, otic, rectal, and vaginal products for topical administration, including creams, ointments, gels, lotions, pastes, and sprays, as well as suppositories not intended for systemic drug absorption. Topical products evaluated as having acceptable clinical performance, but that are not bioequivalent to other pharmaceutically equivalent products or that lack sufficient evidence of bioequivalence, will be coded **BT**.

BX Drug products for which the data are insufficient to determine therapeutic equivalence

The code **BX** is assigned to specific drug products for which the data that have been reviewed by the Agency are insufficient to determine therapeutic equivalence under the policies stated in this document. In these situations, the drug products are presumed to be therapeutically inequivalent until the Agency has determined that there is adequate information to make a full evaluation of therapeutic equivalence.

1.8 Description of Certain Special Situations

Certain drugs listed in the Orange Book present special situations that merit further discussion. The following are descriptions of certain examples of those special situations:

Amino Acid and Protein Hydrolysate Injections. These products differ in the amount and kinds of amino acids they contain and, therefore, are not considered pharmaceutical equivalents. For this reason, these products are not considered therapeutically equivalent. At the same time, the Agency believes that it is appropriate to point out that where nitrogen balance is the sole therapeutic objective and individual amino acid content is not a consideration, pharmaceutical alternatives with the same total amount of nitrogen content may be considered therapeutically equivalent.

Gaviscon®. Gaviscon® is an OTC product that has been marketed since September 1970. The active ingredients in this product, aluminum hydroxide and magnesium trisilicate, were reviewed by the Agency's OTC Antacid Panel and were considered to be safe and effective ingredients (Category I) by that Panel. However, the tablet failed to pass the antacid test that is required of all antacid products. The Agency, therefore, placed the tablet in Category III for lack of effectiveness. A full NDA with clinical studies was submitted by Marion Laboratories, Inc., and approved by FDA on December 9, 1983. Gaviscon®'s activity in treating reflux acidity is made possible by the physical-chemical properties of the inactive ingredients, sodium bicarbonate and alginic acid. Therefore, *all ANDAs that cite Gaviscon® tablets as the reference listed drug must contain the inactive ingredients*

sodium bicarbonate and alginic acid. A full NDA will be required to support the effectiveness of the drug product if different inactive ingredients are to be substituted for sodium bicarbonate or alginic acid or if different proportions of these ingredients are to be used.

Levothyroxine Sodium. Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharms NDA 021301), Synthroid (Abbvie NDA 021402), and Levo-T (Alara NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.⁴

The chart outlines TE codes for all 0.025 mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001

⁴ Lloyd's Levotheroid tablets (NDA 021116) is currently listed in the Discontinued Drug Product List section of the Orange Book and Mylan's levothyroxine product (ANDA 076187) has been selected as the reference standard for ANDA applicants to use to establish bioequivalence to Levotheroid. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	021342	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHROID	LLOYD	0.025MG	N/A ⁵	021116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

Patent Certification(s) and Reference Standard based upon a suitability petition. An ANDA that utilizes as a reference standard a product approved pursuant to a suitability petition must demonstrate that the proposed product can be expected to have the same therapeutic effect as the reference listed drug. It must include appropriate patent certification(s) and an exclusivity statement with respect to the reference listed drug that served as the basis for the approved suitability petition. (This concept also generally applies to an ANDA applicant that utilizes a reference standard that is not a reference listed drug, i.e., such an application must include appropriate patent certification(s) and an exclusivity statement with respect to the reference listed drug.)

Waived exclusivity. If an NDA submitted under section 505(b) of the FD&C Act qualifies for exclusivity under the FD&C Act, the exclusivity is generally listed in the Patent and Exclusivity Section of the Orange Book. If a drug product has received this exclusivity, the FDA will not accept for review and/or will not approve a 505(b)(2) application or an ANDA under section 505(j) of the FD&C Act, as applicable, in accordance with the relevant exclusivity. If the listed drug is also protected by one or more patents, the approval date for the ANDA or 505(b)(2) application will be determined by analysis of the applicant's patent certification(s) or statement(s) for each relevant patent and the effect of relevant exclusivity listed in the Orange Book. However, the holder of the NDA may waive its exclusivity as to any or all ANDAs and 505(b)(2) applications that might otherwise be blocked by such exclusivity. If an NDA sponsor waives its right to the exclusivity protection, qualified ANDAs or 505(b)(2) applications may be accepted for review and/or approved, as applicable, pursuant to the NDA holder's exclusivity being waived. An NDA for which the holder has waived its exclusivity as to all ANDAs and 505(b)(2) applications will be coded with a "W" in the Patent and Exclusivity Section of the Orange Book. The applicant whose product might otherwise be blocked by this exclusivity should indicate in the exclusivity statement in its application that the holder of the listed drug has waived its exclusivity.

⁵ Levothroid is in the Discontinued Drug Product List and therefore no longer is assigned a TE code.

1.9 Therapeutic Equivalence Code Change for a Drug Entity

The Agency will use the following procedures when, in response to a petition or on its own initiative, it is considering a change in the therapeutic equivalence code for approved multisource drug products. Such changes will generally occur when the Agency becomes aware of new scientific information affecting the therapeutic equivalence of an entire category of drug products in the Orange Book (e.g., information concerning the active ingredient or the dosage form), rather than information concerning a single drug product within the category. These procedures will be used when a change in therapeutic equivalence code is under consideration for all drug products found in the Prescription Drug Product List under a specific drug entity and dosage form. The change may be from the code signifying that the drug does not present a bioequivalence problem (e.g., **AA**) to a code signifying an actual or potential bioequivalence problem (e.g., **BP**), or vice versa. This procedure does not apply to a change of a particular product code (e.g., a change from **BP** to **AB** or from **AB** to **BX**).

Before making a change in a therapeutic equivalence code for an entire category of drugs, the Agency will announce in the *Introduction* to the Cumulative Supplement that it is considering the change and will invite comment. Comments, along with scientific data, may be sent to the Director, Office of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research, HFD-650, 7620 Standish Place, Rockville, MD 20855.

The comment period will generally be 60 days in length, and the closing date for comments will be listed in the description of the proposed change for each drug entity.

The most useful type of scientific data submitted to support comments is an *in vivo* bioavailability/bioequivalence study conducted on batches of the subject drug products. These submissions should present a full description of the analytical procedures and equipment used, a validation of the analytical methodology, including the standard curve, a description of the method of calculating results, and a description of the pharmacokinetic and statistical models used in analyzing the data. Anecdotal or testimonial information is the least useful to the Agency, and such submissions are discouraged. Copies of supporting reports published in the scientific literature or unpublished material, however, are welcome.

1.10 Change of the Therapeutic Equivalence Evaluation for a Single Product

The aforementioned procedure described in Section 1.9 does not apply to a change in a single drug product code. For example, a change in a single drug product's code from **BP** to **AB** as a result of the submission of an acceptable bioequivalence study ordinarily will not be the subject of notice and comment in the Cumulative Supplement. Likewise, a change in a single drug product's code from **AB** to **BX** (e.g., as a result of new information raising a significant question as to bioequivalence) does not require notice and comment. The Agency's responsibility to provide the public with the Agency's most current information related to therapeutic equivalence may require a change in a drug product's code prior to any formal notice and opportunity for the applicant to be heard. The publication in the *Federal Register* of a proposal to withdraw approval of a drug product will ordinarily result in a change in a product's code from **AB** to **BX** if this action has not already been taken.

We recognize that certain drug products approved in 505(b)(2) applications may not have therapeutic equivalence codes, and that FDA may undertake therapeutic equivalence evaluations with respect to such drug products. A person seeking to have a therapeutic equivalence rating for a drug product approved in a 505(b)(2) application may petition the Agency through the citizen petition procedure (see 21 CFR 10.25(a) and 21 CFR 10.30).

1.11 Discontinued Section

Those drug products in the discontinued section of the Orange Book (Discontinued Drug Product List) for which a determination has already been made that the products were not withdrawn for safety or effectiveness reasons have "***Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**" following the product strength. The determinations listed in Orange Book are only reflective of determinations made since 1995 and published in the Federal Register. The identification of these drug products in the Discontinued Drug Product List should avoid the submission of multiple citizen petitions for the same drug product. The Orange Book [FR Safety or Effectiveness Determinations List](#), available on FDA's website, lists products that have notices. The list is updated quarterly. Notices issued during the year routinely are added to the [Electronic Orange Book](#) on FDA's website.

Generally, approved products are added to the Discontinued Drug Product List when the applicant notifies the Orange Book staff of the products' not-marketed status. Products may also be added to the Discontinued Drug Product List if annual reports indicate the product is no longer marketed or as a result of other Agency administrative actions. Changes to the Orange Book are not affected by the drug registration and listing requirements of Section 510 of the FD&C Act.

1.12 Changes to the Orange Book

Every effort is made to ensure the Annual Edition is current and accurate. Applicants are requested to inform the FDA Orange Book staff of any changes or corrections, including any change in a product's marketing status that would result in the product being moved to the Discontinued Drug Product List. FDA notes that 21 CFR 314.81(b)(3)(iv) requires an applicant to submit a notice to the Agency within fifteen working days of the withdrawal from sale of a drug product. In addition, a request to include a newly approved product in the Discontinued Drug Product List, rather than parts 1, 2 or 3 of the Orange Book (as discussed in Section 1.1), must be submitted to the Orange Book staff by the end of the month in which the product is approved to ensure that the product is not included in the "active" portions of the next published Orange Book update. To the extent that conventions for describing product identification information (i.e., active ingredients, dosage forms, routes of administration, product names, applicants, strengths) evolve over time, the Agency generally does not intend to revise such information for drug products already included in the Orange Book, but rather intends to apply the change prospectively to drug products added to the Orange Book.

We can be contacted by email at orangebook@fda.hhs.gov. Send Changes by mail to:

FDA/CDER Orange Book Staff
Office of Generic Drug Policy
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.13 Availability of the Edition

Commencing with the 25th edition, the Annual Edition and current monthly Cumulative Supplement are available in a Portable Document Format (PDF) at the EOB home page, [Electronic Orange Book](#), by clicking on Publications. The PDF annual format duplicates previous paper versions except for the Orphan Products Designations and Approvals List. An annual subscription of the PDF format may be obtained from the U.S. Government Publishing Office, 866-512-1800.

2. HOW TO USE THE DRUG PRODUCT LISTS

2.1 Key Sections for Using the Drug Product Lists

This publication contains illustrations, along with Drug Product Lists, indices, and lists of abbreviations and terms which facilitate their use.

Illustrations. The annotated *Drug Product Illustration*, see Section 2.2, and the *Therapeutic Equivalence Evaluations Illustration*, see Section 2.3, are offered to provide further clarification. These depict the format found in the Prescription Drug Product List (the only list in which therapeutic equivalence evaluation codes are displayed).

Drug Product Lists. The Prescription and OTC Drug Product Lists, arranged alphabetically by active ingredient(s), contain product identification information (active ingredients, dosage forms, routes of administration, product names, applicants, strengths) for single and multiple ingredient drug products. Also shown are the application number and drug product number (FDA internal computer data use only) and approval dates for those drug products approved on or after January 1, 1982. The application number preceded by "N" is a New Drug Application (NDA or commonly the innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or commonly the generic).

The Discontinued Drug Product List, arranged alphabetically by active ingredient(s), contains product identification information (dosage form, product name, strength, and application number).

If a prescription drug product is available from more than one source (multisource), a therapeutic equivalence code will appear in front of the applicant's name. If a product is therapeutically equivalent to one or more products or to an appropriate reference, it will be designated with a code beginning with "A" and the entry will be underlined and printed in bold font for emphasis.

Active ingredient headings for multiple ingredient (combination) drug products are arranged alphabetically. For purposes of this publication, this alphabetical sort takes precedence over United States Pharmacopeia official monograph order (i.e., Reserpine, Hydralazine Hydrochloride, Hydrochlorothiazide). For example, product information labeled as Reserpine, Hydrochlorothiazide and Hydralazine Hydrochloride appears under the active ingredient heading *Hydralazine Hydrochloride; Hydrochlorothiazide; Reserpine*. A cross-reference to the product information (for prescription and OTC products) appears for each additional active ingredient in the product. For combination drug products, the ingredient strengths are separated by semicolons and appear in the same relative sequence as the ingredients in the heading. Available strengths of the dosage form from an applicant appear on separate lines.

To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if necessary. Then, find the ingredient in the applicable Drug Product List. Proceed to the dosage form and route of administration and compare products within that ingredient heading only. Therapeutic equivalence or inequivalence for prescription products is determined on the basis of the therapeutic equivalence codes provided within that specific dosage form and route heading. The OTC Drug Product List, Discontinued Drug Product List, and

Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List have their data arranged similarly.

The Discontinued Drug Product List contains approved products that have never been marketed, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, are for military use, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing. All products having a "@" in the December Cumulative Supplement of the previous Edition List have been added to the Discontinued Drug Product List appearing in this Edition. In addition, approved drug products that are not in the commercial distribution channel e.g., approved drug products in applications for export only are also listed in the Discontinued Drug Product List.

Product Name Index (*Prescription and OTC Drug Product Lists*). This is an index of drug products by trade name or established name of the active ingredient, if no trade name exists. The second term of each entry indicates the active ingredient name under which product information can be found in the appropriate Drug Product List. For those drug products with multiple active ingredients, only the first active ingredient (in alphabetical order) will appear. OTC products are so designated.

Product Name Index Listed by Applicant (*Prescription and OTC Drug Product Lists*). This is an index that cross-references applicants to drug products. The bolded and underlined entry represents the applicant name abbreviation used in this publication. Each complete applicant name that is represented by the abbreviated name is marked with an asterisk (*). Listed under each complete applicant name is the first alphabetically arranged ingredient under which product information can be found in the appropriate Drug Product List. OTC products are so designated. To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if appropriate.

Uniform Terms. To improve readability, uniform terms are used to designate dosage forms, routes of administration, and abbreviations used to express strengths. These terms are listed in Appendix C. In some cases, the terms used may differ from those used in product labels and other labeling.

2.2 DRUG PRODUCT ILLUSTRATION

SINGLE INGREDIENT

ACTIVE INGREDIENT	→	<u>MEPERIDINE HYDROCHLORIDE</u>
DOSAGE FORM; ROUTE OF ADMINISTRATION	→	INJECTABLE; INJECTION
TRADE OR GENERIC NAMES	→	<u>HEXANON</u>
REFERENCE LISTED DRUG* (+)	→	<u>AP</u> +! PAGE PHARMA <u>25MG/ML</u> <u>N013111</u> <u>001</u> AUG 22, 1983
REFERENCE STANDARD * (!)	→	<u>AP</u> +! <u>50MG/ML</u> <u>N013111</u> <u>002</u> AUG 22, 1983
	→	<u>AP</u> +! <u>75MG/ML</u> <u>N013111</u> <u>003</u> AUG 22, 1983
	→	<u>AP</u> +! <u>100MG/ML</u> <u>N013111</u> <u>004</u> JAN 04, 1989
	→	<u>MEPERIDINE HCL</u>
THERAPEUTIC EQUIVALENCE (TE)	→	<u>AP</u> GREENBERG PHARM <u>25MG/ML</u> <u>A064890</u> 001 FEB 29, 1987
CODE FOR MULTISOURCE PRODUCT	→	<u>AP</u> <u>50MG/ML</u> <u>A064890</u> 002 FEB 29, 1987
	→	<u>AP</u> <u>75MG/ML</u> <u>A064890</u> 003 FEB 29, 1987
	→	<u>AP</u> <u>100MG/ML</u> <u>A064890</u> 004 MAR 08, 1992
SINGLE SOURCE PRODUCT (NO TE CODE)	→	! TIMOKIM LLC 10MG/ML A099225 001 DEC 12, 1995
	→	<u>AP</u> JOHNSON MED <u>25MG/ML</u> <u>A099226</u> <u>001</u> NOV 27, 1993
	→	! KENDRA PHARM 150MG/ML A079444 001 OCT 31, 1999
APPLICANT	→	↑
AVAILABLE STRENGTH(S) OF A PRODUCT	→	↑
APPLICATION NUMBER AND PRODUCT NUMBER	→	↑
PRODUCT NUMBER IS FOR FDA INTERNAL COMPUTER DATA USE ONLY	→	↑
APPROVAL DATE	→	↑

*NOTE: REFERENCE LISTED DRUG AND REFERENCE STANDARD ARE DISCUSSED IN THE PREFACE SECTION 1.4

MULTIPLE INGREDIENTS WITH PRODUCT INFORMATION

ALPHABETICALLY SORTED BY	→	<u>HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE</u>
PRODUCT INFORMATION	→	TABLET; ORAL
	→	HYDROCHLOROTHIAZIDE, RESERPINE AND HYDRALAZINE HCL
	→	REINWALD LABS 25MG;15MG;0.1MG A069808 001 JAN 18, 1982

THIS EXAMPLE IS FOR PURPOSE OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

2.3 THERAPEUTIC EQUIVALENCE EVALUATIONS ILLUSTRATION

DRUG PRODUCTS CODED **AB** (OR ANY CODE BEGINNING WITH AN "A") UNDER AN INGREDIENT AND DOSAGE FORM HEADING ARE CONSIDERED THERAPEUTICALLY EQUIVALENT ONLY TO OTHER PRODUCTS CODED **AB** (OR ANY CODE BEGINNING WITH AN "A") AND **NOT** TO THOSE CODED **BP** (OR ANY CODE BEGINNING WITH "B") AND ANY PRODUCTS NOT LISTED. DRUG PRODUCTS CODED **BP** (OR ANY CODE BEGINNING WITH A "B") ARE **NOT** CONSIDERED THERAPEUTICALLY EQUIVALENT TO ANY OTHER PRODUCT. FOR A COMPLETE EXPLANATION OF THE **TE** CODES REFER TO SECTION 1.7 OF THE *INTRODUCTION*.

SULFASALAZINE

TABLET; ORAL

FAZINE

AB PARKLAND **500MG** **A042999** **001**

SULAZINE

AB URSA **500MG** **A042222** **001**

SULFASALAZINE

BP BROWN 500MG A041297 001

SULFASALAZINE

TABLET; ORAL

FAZINE


AB PARKLAND **500MG** **A042999** **001**

SULFASALAZINE

BP BROWN 500MG A041297 001

SOUTH 500MG A067627 001

PRODUCTS CONSIDERED THERAPEUTICALLY EQUIVALENT TO EACH OTHER



PRODUCTS CONSIDERED **NOT** THERAPEUTICALLY EQUIVALENT TO ANY OTHER PRODUCTS LISTED

PRODUCTS CONSIDERED **NOT** THERAPEUTICALLY EQUIVALENT TO EACH OTHER

NOTE: BOLD FONT AND UNDERLINING DENOTES MULTISOURCE PRODUCTS WHICH ARE CONSIDERED THERAPEUTICALLY EQUIVALENT.

THIS EXAMPLE IS FOR PURPOSES OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

PRESCRIPTION DRUG PRODUCT LIST

ABACAVIR SULFATE

SOLUTION;ORAL

ABACAVIR SULFATE**AA** HETERO LABS LTD III **EQ 20MG BASE/ML** **A201107 001** Sep 26, 2016ZIAGEN**AA** + VIIIV HLTHCARE **EQ 20MG BASE/ML** **N020978 001** Dec 17, 1998
TABLET;ORALABACAVIR SULFATE**AB** APOTEX INC **EQ 300MG BASE** **A201570 001** Dec 17, 2012**AB** AUROBINDO PHARMA LTD **EQ 300MG BASE** **A077844 001** Dec 17, 2012**AB** HETERO LABS LTD III **EQ 300MG BASE** **A091560 001** Sep 13, 2013**AB** MYLAN PHARMS INC **EQ 300MG BASE** **A091294 001** Jun 18, 2012**AB** STRIDES PHARMA **EQ 300MG BASE** **A091050 001** Oct 28, 2016ZIAGEN**AB** + VIIIV HLTHCARE **EQ 300MG BASE** **N020977 001** Dec 17, 1998ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

TABLET;ORAL

TRIUMEQ+ VIIIV HLTHCARE **EQ 600MG BASE;EQ 50MG BASE;300MG** **N205551 001** Aug 22, 2014ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL

ABACAVIR SULFATE AND LAMIVUDINE**AB** TEVA PHARMS USA **EQ 600MG BASE;300MG** **A079246 001** Sep 29, 2016EPZICOM**AB** + VIIIV HLTHCARE **EQ 600MG BASE;300MG** **N021652 001** Aug 02, 2004ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL

ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE**AB** LUPIN LTD **EQ 300MG BASE;150MG;300MG** **A202912 001** Dec 05, 2013TRIZIVIR**AB** + VIIIV HLTHCARE **EQ 300MG BASE;150MG;300MG** **N021205 001** Nov 14, 2000ABIRATERONE ACETATE

TABLET;ORAL

ZYTIGA+ JANSSEN BIOTECH **250MG** **N202379 001** Apr 28, 2011ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL

ACAMPROSATE CALCIUM**AB** BARR LABS DIV TEVA **333MG** **A200143 001** Nov 18, 2013**AB** + GLENMARK GENERICS **333MG** **A202229 001** Jul 16, 2013**AB** MYLAN PHARMS INC **333MG** **A200142 001** Mar 11, 2014ACARBOSE

TABLET;ORAL

ACARBOSE**AB** EMCURE PHARMS LTD **25MG** **A202271 001** Feb 07, 2012**AB** **50MG** **A202271 002** Feb 07, 2012**AB** **100MG** **A202271 003** Feb 07, 2012**AB** IMPAX LABS **25MG** **A078441 001** May 14, 2009**AB** **50MG** **A078441 002** May 14, 2009**AB** **100MG** **A078441 003** May 14, 2009**AB** MYLAN **25MG** **A091053 001** Jan 06, 2011**AB** **50MG** **A091053 002** Jan 06, 2011**AB** **100MG** **A091053 003** Jan 06, 2011**AB** STRIDES PHARMA **25MG** **A090912 001** Jul 27, 2011**AB** **50MG** **A090912 002** Jul 27, 2011**AB** **100MG** **A090912 003** Jul 27, 2011**AB** VIRTUS PHARM **25MG** **A091343 001** Oct 17, 2013**AB** **50MG** **A091343 002** Oct 17, 2013**AB** **100MG** **A091343 003** Oct 17, 2013**AB** WATSON LABS **25MG** **A077532 001** May 07, 2008**AB** **50MG** **A077532 002** May 07, 2008**AB** **100MG** **A077532 003** May 07, 2008**AB** WEST-WARD PHARMS INT **25MG** **A078470 001** May 07, 2008**AB** **50MG** **A078470 002** May 07, 2008**AB** **100MG** **A078470 003** May 07, 2008PRECOSE**AB** + BAYER HLTHCARE **25MG** **N020482 004** May 29, 1997**AB** **50MG** **N020482 001** Sep 06, 1995**AB** **100MG** **N020482 002** Sep 06, 1995

PRESCRIPTION DRUG PRODUCT LIST

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL

ACEBUTOLOL HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARM	<u>EQ 200MG BASE</u>	<u>A075047 001</u>	Dec 30, 1999
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A075047 002</u>	Dec 30, 1999
<u>AB</u>	MYLAN	<u>EQ 200MG BASE</u>	<u>A074288 001</u>	Apr 24, 1995
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A074288 002</u>	Apr 24, 1995
<u>SECTRAL</u>				
<u>AB</u>	PROMIUS PHARMA	<u>EQ 200MG BASE</u>	<u>N018917 001</u>	Dec 28, 1984
<u>AB</u>	+	<u>EQ 400MG BASE</u>	<u>N018917 003</u>	Dec 28, 1984

ACETAMINOPHEN

SOLUTION; IV (INFUSION)

ACETAMINOPHEN

<u>AP</u>	PADDOCK LLC	<u>1GM/100ML (10MG/ML)</u>	<u>A202605 001</u>	Jun 13, 2016
<u>AP</u>	SANDOZ INC	<u>1GM/100ML (10MG/ML)</u>	<u>A204052 001</u>	Mar 22, 2016
<u>OFIRMEV</u>				
<u>AP</u>	+	<u>1GM/100ML (10MG/ML)</u>	<u>N022450 001</u>	Nov 02, 2010
<u>ACETAMINOPHEN</u>				
	FRESENIUS KABI USA	1GM/100ML (10MG/ML)	N204767 001	Oct 28, 2015

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL

BUTALBITAL AND ACETAMINOPHEN

<u>AA</u>	CNTY LINE PHARMS	<u>325MG; 50MG</u>	<u>A205120 001</u>	Oct 30, 2015
<u>AA</u>	LARKEN LABS INC	<u>325MG; 50MG</u>	<u>A203484 002</u>	Dec 04, 2015
<u>AA</u>	MIKART INC	<u>300MG; 50MG</u>	<u>A207386 001</u>	Nov 15, 2016
<u>AA</u>	+	<u>300MG; 50MG</u>	<u>A090956 001</u>	Aug 23, 2011
<u>BUTAPAP</u>				
<u>AA</u>	+	<u>325MG; 50MG</u>	<u>A089987 001</u>	Oct 26, 1992
<u>ALLZITAL</u>				
	LARKEN LABS INC	325MG; 25MG	A203484 001	Dec 04, 2015

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

<u>AB</u>	+	<u>300MG; 50MG; 40MG</u>	<u>A040885 001</u>	Nov 16, 2009
<u>AB</u>	NUVO PHARM INC	<u>300MG; 50MG; 40MG</u>	<u>A207118 001</u>	Oct 28, 2016
	+	325MG; 50MG; 40MG	A089007 001	Mar 17, 1986
<u>SOLUTION; ORAL</u>				
<u>BUTALBITAL, ACETAMINOPHEN AND CAFFEINE</u>				
	+	325MG/15ML; 50MG/15ML; 40MG/15ML	A040387 001	Jan 31, 2003

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

<u>AA</u>	CNTY LINE PHARMS	<u>325MG; 50MG; 40MG</u>	<u>A204984 001</u>	Jan 10, 2017
<u>AA</u>	HIKMA PHARMS LLC	<u>325MG; 50MG; 40MG</u>	<u>A089718 001</u>	Jun 12, 1995
<u>AA</u>	LANNETT HOLDINGS INC	<u>325MG; 50MG; 40MG</u>	<u>A200243 001</u>	Sep 13, 2012
<u>AA</u>	MALLINCKRODT	<u>325MG; 50MG; 40MG</u>	<u>A087804 001</u>	Jan 24, 1985
<u>AA</u>	MIKART	<u>325MG; 50MG; 40MG</u>	<u>A089175 001</u>	Jan 21, 1987
<u>AA</u>	+	<u>325MG; 50MG; 40MG</u>	<u>A040511 001</u>	Aug 27, 2003

FIORICET

<u>AA</u>	ACTAVIS LABS UT INC	<u>325MG; 50MG; 40MG</u>	<u>A088616 001</u>	Nov 09, 1984
-----------	---------------------	--------------------------	--------------------	--------------

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

<u>AB</u>	HIKMA INTL PHARMS	<u>325MG; 50MG; 40MG; 30MG</u>	<u>A075618 001</u>	Mar 23, 2001
<u>AB</u>	NEXGEN PHARMA INC	<u>325MG; 50MG; 40MG; 30MG</u>	<u>A076560 001</u>	Jun 10, 2004
<u>AB</u>	VINTAGE PHARMS	<u>325MG; 50MG; 40MG; 30MG</u>	<u>A075929 001</u>	Apr 22, 2002

FIORICET W/ CODEINE

<u>AB</u>	+	<u>325MG; 50MG; 40MG; 30MG</u>	<u>N020232 001</u>	Jul 30, 1992
<u>BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE</u>				
	NEXGEN PHARMA INC	300MG; 50MG; 40MG; 30MG	A076560 002	Jul 19, 2012

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

TREZIX

	WRASER PHARMS LLC	320.5MG; 30MG; 16MG	A204785 001	Nov 26, 2014
--	-------------------	---------------------	-------------	--------------

TABLET; ORAL

ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE

	LARKEN LABS INC	325MG; 30MG; 16MG	A204209 001	Sep 30, 2016
--	-----------------	-------------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

<u>AA</u>	HI TECH PHARMA	<u>120MG/5ML;12MG/5ML</u>	<u>A040119</u>	<u>001</u>	Apr 26, 1996
<u>AA</u>	MIKART	<u>120MG/5ML;12MG/5ML</u>	<u>A089450</u>	<u>001</u>	Oct 27, 1992
<u>AA</u>	+ PHARM ASSOC	<u>120MG/5ML;12MG/5ML</u>	<u>A087508</u>	<u>001</u>	
<u>AA</u>	VINTAGE PHARMS	<u>120MG/5ML;12MG/5ML</u>	<u>A091238</u>	<u>001</u>	Nov 10, 2011
<u>AA</u>	WOCKHARDT	<u>120MG/5ML;12MG/5ML</u>	<u>A087006</u>	<u>001</u>	

SUSPENSION;ORAL

CAPITAL AND CODEINE

+ VALEANT PHARMS LLC

120MG/5ML;12MG/5ML

A086024 001

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

<u>AA</u>	AMNEAL PHARMS NY	<u>300MG;30MG</u>	<u>A040779</u>	<u>001</u>	May 29, 2008
<u>AA</u>	AUROLIFE PHARMA LLC	<u>300MG;15MG</u>	<u>A202800</u>	<u>001</u>	Apr 15, 2013
<u>AA</u>		<u>300MG;30MG</u>	<u>A202800</u>	<u>002</u>	Apr 15, 2013
<u>AA</u>		<u>300MG;60MG</u>	<u>A202800</u>	<u>003</u>	Apr 15, 2013
<u>AA</u>	+ MALLINCKRODT INC	<u>300MG;15MG</u>	<u>A040419</u>	<u>001</u>	May 31, 2001
<u>AA</u>		<u>300MG;30MG</u>	<u>A040419</u>	<u>002</u>	May 31, 2001
<u>AA</u>		<u>300MG;60MG</u>	<u>A040419</u>	<u>003</u>	May 31, 2001
<u>AA</u>	SUN PHARM INDS LTD	<u>300MG;30MG</u>	<u>A085868</u>	<u>001</u>	
<u>AA</u>		<u>300MG;60MG</u>	<u>A087083</u>	<u>001</u>	
<u>AA</u>	TEVA	<u>300MG;15MG</u>	<u>A088627</u>	<u>001</u>	Mar 06, 1985
<u>AA</u>		<u>300MG;30MG</u>	<u>A088628</u>	<u>001</u>	Mar 06, 1985
<u>AA</u>	+ VINTAGE	<u>300MG;60MG</u>	<u>A088629</u>	<u>001</u>	Mar 06, 1985
<u>AA</u>		<u>300MG;15MG</u>	<u>A089990</u>	<u>001</u>	Sep 30, 1988
<u>AA</u>		<u>300MG;30MG</u>	<u>A089805</u>	<u>001</u>	Sep 30, 1988
<u>AA</u>	VINTAGE PHARMS	<u>300MG;60MG</u>	<u>A089828</u>	<u>001</u>	Sep 30, 1988

TYLENOL W/ CODEINE NO. 3

<u>AA</u>	+ JANSSEN PHARMS	<u>300MG;30MG</u>	<u>A085055</u>	<u>003</u>	
-----------	------------------	-------------------	----------------	------------	--

TYLENOL W/ CODEINE NO. 4

<u>AA</u>	JANSSEN PHARMS	<u>300MG;60MG</u>	<u>A085055</u>	<u>004</u>	
-----------	----------------	-------------------	----------------	------------	--

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

<u>AA</u>	+ MIKART	<u>325MG/15ML;7.5MG/15ML</u>	<u>A040482</u>	<u>001</u>	Sep 25, 2003
<u>AA</u>	PHARM ASSOC	<u>325MG/15ML;7.5MG/15ML</u>	<u>A040838</u>	<u>001</u>	May 10, 2013
<u>AA</u>	VINTAGE PHARMS	<u>325MG/15ML;7.5MG/15ML</u>	<u>A040894</u>	<u>001</u>	Jul 19, 2011
<u>AA</u>	VISTAPHARM	<u>325MG/15ML;7.5MG/15ML</u>	<u>A200343</u>	<u>001</u>	Jan 25, 2012
<u>AA</u>	<u>ZYFREL</u>				
<u>AA</u>	CYPRESS PHARM INC	<u>325MG/15ML;7.5MG/15ML</u>	<u>A090468</u>	<u>001</u>	Apr 14, 2016
	HYDROCODONE BITARTRATE AND ACETAMINOPHEN				
	+ MIKART	300MG/15ML;10MG/15ML	A040881	001	Feb 25, 2010
	+ PHARM ASSOC	325MG/15ML;10MG/15ML	A040834	001	Apr 18, 2008

TABLET;ORAL

ANEXSIA 5/325

<u>AA</u>	MALLINCKRODT	<u>325MG;5MG</u>	<u>A040409</u>	<u>001</u>	Oct 20, 2000
-----------	--------------	------------------	----------------	------------	--------------

ANEXSIA 7.5/325

<u>AA</u>	MALLINCKRODT	<u>325MG;7.5MG</u>	<u>A040405</u>	<u>001</u>	Sep 08, 2000
-----------	--------------	--------------------	----------------	------------	--------------

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

<u>AA</u>	ACTAVIS LABS FL INC	<u>300MG;5MG</u>	<u>A206470</u>	<u>001</u>	Jun 02, 2016
<u>AA</u>		<u>300MG;7.5MG</u>	<u>A206470</u>	<u>002</u>	Jun 02, 2016
<u>AA</u>		<u>300MG;10MG</u>	<u>A206470</u>	<u>003</u>	Jun 02, 2016
<u>AA</u>	AMNEAL PHARMS	<u>300MG;10MG</u>	<u>A207137</u>	<u>001</u>	Nov 29, 2016
<u>AA</u>	AMNEAL PHARMS NY	<u>325MG;5MG</u>	<u>A040736</u>	<u>001</u>	Aug 25, 2006
<u>AA</u>		<u>325MG;7.5MG</u>	<u>A040746</u>	<u>002</u>	May 10, 2016
<u>AA</u>		<u>325MG;10MG</u>	<u>A040746</u>	<u>001</u>	Aug 25, 2006
<u>AA</u>	AUROLIFE PHARMA LLC	<u>325MG;5MG</u>	<u>A201013</u>	<u>001</u>	Apr 11, 2012
<u>AA</u>		<u>325MG;7.5MG</u>	<u>A201013</u>	<u>002</u>	Apr 11, 2012
<u>AA</u>		<u>325MG;10MG</u>	<u>A201013</u>	<u>003</u>	Apr 11, 2012
<u>AA</u>	LARKEN LABS INC	<u>325MG;5MG</u>	<u>A202935</u>	<u>002</u>	Jun 15, 2016
<u>AA</u>		<u>325MG;7.5MG</u>	<u>A202935</u>	<u>003</u>	Jun 15, 2016
<u>AA</u>		<u>325MG;10MG</u>	<u>A202935</u>	<u>004</u>	Jun 15, 2016
<u>AA</u>	MALLINCKRODT	<u>325MG;10MG</u>	<u>A040400</u>	<u>001</u>	Jul 26, 2000
<u>AA</u>	+ MIKART	<u>300MG;5MG</u>	<u>A040658</u>	<u>001</u>	Jan 19, 2006
<u>AA</u>	+ PHARM ASSOC	<u>300MG;7.5MG</u>	<u>A040556</u>	<u>002</u>	Mar 24, 2006
<u>AA</u>	+ VINTAGE	<u>300MG;10MG</u>	<u>A040556</u>	<u>001</u>	Jun 23, 2004
<u>AA</u>	+ WOCKHARDT	<u>325MG;2.5MG</u>	<u>A040846</u>	<u>001</u>	Jun 09, 2010
<u>AA</u>		<u>325MG;7.5MG</u>	<u>A040432</u>	<u>001</u>	Jan 22, 2003
<u>AA</u>	NOVEL LABS INC	<u>300MG;5MG</u>	<u>A206142</u>	<u>001</u>	Nov 14, 2016
<u>AA</u>		<u>300MG;7.5MG</u>	<u>A206142</u>	<u>002</u>	Nov 14, 2016
<u>AA</u>		<u>300MG;10MG</u>	<u>A206142</u>	<u>003</u>	Nov 14, 2016

PRESCRIPTION DRUG PRODUCT LIST

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

<u>AA</u>		<u>325MG; 5MG</u>	<u>A206245 001</u>	Dec 01, 2016
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A206245 002</u>	Dec 01, 2016
<u>AA</u>		<u>325MG; 10MG</u>	<u>A206245 003</u>	Dec 01, 2016
<u>AA</u>	PAR PHARM	<u>300MG; 5MG</u>	<u>A205001 001</u>	Jul 05, 2016
<u>AA</u>		<u>300MG; 7.5MG</u>	<u>A205001 002</u>	Jul 05, 2016
<u>AA</u>		<u>300MG; 10MG</u>	<u>A205001 003</u>	Jul 05, 2016
<u>AA</u>	RHODES PHARMS	<u>325MG; 5MG</u>	<u>A202991 001</u>	Apr 12, 2016
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A202991 002</u>	Apr 12, 2016
<u>AA</u>		<u>325MG; 10MG</u>	<u>A202991 003</u>	Apr 12, 2016
<u>AA</u>	SUN PHARM INDS INC	<u>325MG; 5MG</u>	<u>A090118 001</u>	Dec 23, 2008
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A090118 002</u>	Dec 23, 2008
<u>AA</u>		<u>325MG; 10MG</u>	<u>A090118 003</u>	Dec 23, 2008
<u>AA</u>	TRIS PHARMA INC	<u>300MG; 5MG</u>	<u>A202214 004</u>	Mar 15, 2016
<u>AA</u>		<u>300MG; 7.5MG</u>	<u>A202214 005</u>	Mar 15, 2016
<u>AA</u>		<u>300MG; 10MG</u>	<u>A202214 006</u>	Mar 15, 2016
<u>AA</u>		<u>325MG; 5MG</u>	<u>A202214 001</u>	Mar 27, 2013
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A202214 002</u>	Mar 27, 2013
<u>AA</u>		<u>325MG; 10MG</u>	<u>A202214 003</u>	Mar 27, 2013
<u>AA</u>	VINTAGE PHARMS	<u>300MG; 5MG</u>	<u>A090415 001</u>	Jan 24, 2011
<u>AA</u>		<u>300MG; 7.5MG</u>	<u>A090415 002</u>	Jan 24, 2011
<u>AA</u>		<u>300MG; 10MG</u>	<u>A090415 003</u>	Jan 24, 2011
<u>AA</u>		<u>325MG; 5MG</u>	<u>A040655 001</u>	Jan 19, 2006
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A040656 001</u>	Jan 19, 2006
<u>AA</u>		<u>325MG; 10MG</u>	<u>A040355 001</u>	May 31, 2000
<u>NORCO</u>				
<u>AA</u>	APIL	<u>325MG; 2.5MG</u>	<u>A040148 004</u>	Jul 07, 2014
<u>AA</u>	+	<u>325MG; 5MG</u>	<u>A040099 001</u>	Jun 25, 1997
<u>AA</u>		<u>325MG; 5MG</u>	<u>A040148 005</u>	Jul 07, 2014
<u>AA</u>	+	<u>325MG; 7.5MG</u>	<u>A040148 003</u>	Sep 12, 2000
<u>AA</u>	+	<u>325MG; 10MG</u>	<u>A040148 001</u>	Feb 14, 1997

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL

OXYCODONE AND ACETAMINOPHEN

<u>AA</u>	+	MALLINCKRODT INC	<u>325MG/5ML; 5MG/5ML</u>	<u>A040680 001</u>	Sep 29, 2006
<u>OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN</u>					
<u>AA</u>		VINTAGE PHARMS	<u>325MG/5ML; 5MG/5ML</u>	<u>A203573 001</u>	Dec 18, 2014

TABLET; ORAL

OXYCET

<u>AA</u>		MALLINCKRODT	<u>325MG; 5MG</u>	<u>A087463 001</u>	Dec 07, 1983
<u>OXYCODONE AND ACETAMINOPHEN</u>					
<u>AA</u>		ACTAVIS ELIZABETH	<u>325MG; 2.5MG</u>	<u>A201447 001</u>	Apr 12, 2013
<u>AA</u>			<u>325MG; 5MG</u>	<u>A201447 002</u>	Apr 12, 2013
<u>AA</u>			<u>325MG; 7.5MG</u>	<u>A201447 003</u>	Apr 12, 2013
<u>AA</u>			<u>325MG; 10MG</u>	<u>A201447 004</u>	Apr 12, 2013
<u>AA</u>		ALVOGEN MALTA	<u>325MG; 5MG</u>	<u>A202677 003</u>	Mar 08, 2016
<u>AA</u>			<u>325MG; 7.5MG</u>	<u>A202677 001</u>	Jul 26, 2012
<u>AA</u>			<u>325MG; 10MG</u>	<u>A202677 002</u>	Jul 26, 2012
<u>AA</u>		AMNEAL PHARMS NY	<u>325MG; 5MG</u>	<u>A040777 001</u>	Nov 27, 2007
<u>AA</u>			<u>325MG; 7.5MG</u>	<u>A040778 002</u>	Jun 27, 2014
<u>AA</u>			<u>325MG; 10MG</u>	<u>A040778 001</u>	Nov 27, 2007
<u>AA</u>		AUROLIFE PHARMA LLC	<u>325MG; 2.5MG</u>	<u>A201972 001</u>	Jul 15, 2013
<u>AA</u>			<u>325MG; 5MG</u>	<u>A201972 002</u>	Jul 15, 2013
<u>AA</u>			<u>325MG; 7.5MG</u>	<u>A201972 003</u>	Jul 15, 2013
<u>AA</u>			<u>325MG; 10MG</u>	<u>A201972 004</u>	Jul 15, 2013
<u>AA</u>		CEROVENE INC	<u>325MG; 5MG</u>	<u>A207574 001</u>	Dec 13, 2016
<u>AA</u>		MALLINCKRODT	<u>325MG; 7.5MG</u>	<u>A040545 001</u>	Jun 30, 2004
<u>AA</u>			<u>325MG; 10MG</u>	<u>A040545 002</u>	Jun 30, 2004
<u>AA</u>		MAYNE PHARMA INC	<u>325MG; 2.5MG</u>	<u>A090177 001</u>	Oct 20, 2008
<u>AA</u>			<u>325MG; 5MG</u>	<u>A090177 002</u>	Oct 20, 2008
<u>AA</u>			<u>325MG; 7.5MG</u>	<u>A090177 003</u>	Oct 20, 2008
<u>AA</u>			<u>325MG; 10MG</u>	<u>A090177 004</u>	Oct 20, 2008
<u>AA</u>		RHODES PHARMS	<u>325MG; 5MG</u>	<u>A201278 001</u>	Aug 28, 2014
<u>AA</u>			<u>325MG; 7.5MG</u>	<u>A201278 002</u>	Aug 28, 2014
<u>AA</u>			<u>325MG; 10MG</u>	<u>A201278 003</u>	Aug 28, 2014
<u>AA</u>		SUN PHARM INDS INC	<u>325MG; 2.5MG</u>	<u>A090535 001</u>	Dec 26, 2013
<u>AA</u>			<u>325MG; 5MG</u>	<u>A090535 002</u>	Dec 26, 2013
<u>AA</u>			<u>325MG; 7.5MG</u>	<u>A090535 003</u>	Dec 26, 2013
<u>AA</u>			<u>325MG; 10MG</u>	<u>A090535 004</u>	Dec 26, 2013
<u>AA</u>		VINTAGE PHARMS	<u>325MG; 2.5MG</u>	<u>A090733 001</u>	Jul 11, 2013

PRESCRIPTION DRUG PRODUCT LIST

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

<u>AA</u>		<u>325MG; 5MG</u>	<u>A040105 001</u>	Jul 30, 1996
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A090734 001</u>	Jul 11, 2013
<u>AA</u>		<u>325MG; 10MG</u>	<u>A090734 002</u>	Jul 11, 2013
<u>AA</u>	WATSON LABS	<u>325MG; 5MG</u>	<u>A040171 001</u>	Oct 30, 1997
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A040535 001</u>	Sep 05, 2003
<u>AA</u>		<u>325MG; 10MG</u>	<u>A040535 002</u>	Sep 05, 2003

PERCOCT

<u>AA</u>	+	VINTAGE PHARMS LLC	<u>325MG; 2.5MG</u>	<u>A040330 001</u>	Jun 25, 1999
<u>AA</u>	+		<u>325MG; 5MG</u>	<u>A040330 002</u>	Jun 25, 1999
<u>AA</u>	+		<u>325MG; 7.5MG</u>	<u>A040434 001</u>	Nov 23, 2001
<u>AA</u>	+		<u>325MG; 10MG</u>	<u>A040434 002</u>	Nov 23, 2001

ROXICET

<u>AA</u>	WEST-WARD PHARMS INT	<u>325MG; 5MG</u>	<u>A087003 001</u>		
	OXYCODONE AND ACETAMINOPHEN				
	+	MIKART	300MG; 2.5MG	A040608 001	Dec 30, 2005
	+		300MG; 5MG	A040608 002	Dec 30, 2005
	+		300MG; 7.5MG	A040608 003	Dec 30, 2005
	+		300MG; 10MG	A040608 004	Dec 30, 2005

TABLET, EXTENDED RELEASE; ORAL

XARTEMIS XR

	+	MALLINCKRODT INC	325MG; 7.5MG	N204031 001	Mar 11, 2014
--	---	------------------	--------------	-------------	--------------

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

<u>AB</u>	AMNEAL PHARMS	<u>325MG; 37.5MG</u>	<u>A090485 001</u>	Dec 09, 2009
<u>AB</u>	APOTEX INC	<u>325MG; 37.5MG</u>	<u>A078778 001</u>	Apr 07, 2014
<u>AB</u>	ATLAS PHARMS LLC	<u>325MG; 37.5MG</u>	<u>A202076 001</u>	Mar 30, 2012
<u>AB</u>	MICRO LABS LTD INDIA	<u>325MG; 37.5MG</u>	<u>A201952 001</u>	Dec 14, 2012
<u>AB</u>	MYLAN	<u>325MG; 37.5MG</u>	<u>A077858 001</u>	Sep 26, 2008
<u>AB</u>	PAR PHARM	<u>325MG; 37.5MG</u>	<u>A076475 001</u>	Apr 21, 2005
<u>AB</u>	SUN PHARM INDS INC	<u>325MG; 37.5MG</u>	<u>A077184 001</u>	Dec 16, 2005
<u>AB</u>	ZYDUS PHARMS USA INC	<u>325MG; 37.5MG</u>	<u>A090460 001</u>	Sep 06, 2012

ULTRACET

<u>AB</u>	+	JANSSEN PHARMS	<u>325MG; 37.5MG</u>	<u>N021123 001</u>	Aug 15, 2001
-----------	---	----------------	----------------------	--------------------	--------------

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

ACETAZOLAMIDE

<u>AB</u>	HERITAGE PHARMS INC	<u>500MG</u>	<u>A090779 001</u>	Jul 14, 2011
<u>AB</u>	NOSTRUM LABS INC	<u>500MG</u>	<u>A204691 001</u>	Mar 29, 2016
<u>AB</u>	NOVAST LABS LTD	<u>500MG</u>	<u>A203434 001</u>	Sep 30, 2016
<u>AB</u>	ZYDUS PHARMS USA INC	<u>500MG</u>	<u>A040904 001</u>	Dec 10, 2008

DIAMOX

<u>AB</u>	+	TEVA BRANDED PHARM	<u>500MG</u>	<u>N012945 001</u>	
-----------	---	--------------------	--------------	--------------------	--

TABLET; ORAL

ACETAZOLAMIDE

<u>AB</u>	HERITAGE PHARMA	<u>125MG</u>	<u>A205530 001</u>	Oct 27, 2016
<u>AB</u>		<u>250MG</u>	<u>A205530 002</u>	Oct 27, 2016
<u>AB</u>	LANNETT	<u>250MG</u>	<u>A084840 001</u>	
<u>AB</u>	MUTUAL PHARM	<u>125MG</u>	<u>A089752 001</u>	Jun 22, 1988
<u>AB</u>	TARO	<u>125MG</u>	<u>A040195 001</u>	May 28, 1997
<u>AB</u>	+		<u>A040195 002</u>	May 28, 1997

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

<u>AP</u>	SAGENT AGILA	<u>EQ 500MG BASE/VIAL</u>	<u>A200880 001</u>	May 09, 2012	
<u>AP</u>	WEST-WARD PHARMS INT	<u>EQ 500MG BASE/VIAL</u>	<u>A040089 001</u>	Feb 28, 1995	
<u>AP</u>	+	X GEN PHARMS	<u>EQ 500MG BASE/VIAL</u>	<u>A040784 001</u>	Dec 10, 2008

ACETAZOLAMIDE SODIUM

<u>AP</u>	EMCURE PHARMS LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A202693 001</u>	Dec 19, 2014
-----------	-------------------	---------------------------	--------------------	--------------

ACETIC ACID, GLACIAL

SOLUTION; IRRIGATION, URETHRAL

ACETIC ACID 0.25% IN PLASTIC CONTAINER

<u>AT</u>	B BRAUN	<u>250MG/100ML</u>	<u>N018161 001</u>	
<u>AT</u>	BAXTER HLTHCARE	<u>250MG/100ML</u>	<u>N018523 001</u>	Feb 19, 1982
<u>AT</u>	HOSPIRA	<u>250MG/100ML</u>	<u>N017656 001</u>	

PRESCRIPTION DRUG PRODUCT LIST

ACETIC ACID, GLACIAL

SOLUTION/DROPS;OTIC

ACETIC ACID

<u>AT</u>	TARO	<u>2%</u>	<u>A088638</u>	<u>001</u>	Sep 06, 1984
<u>AT</u>	VINTAGE	<u>2%</u>	<u>A040607</u>	<u>001</u>	Feb 24, 2005
<u>AT</u>	+ WOCKHARDT	<u>2%</u>	<u>A040166</u>	<u>001</u>	Jul 26, 1996

VOSOL

<u>AT</u>	HI TECH PHARMA	<u>2%</u>	<u>N012179</u>	<u>001</u>	
-----------	----------------	-----------	----------------	------------	--

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS;OTIC

ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE

	+ BAUSCH AND LOMB	<u>2%;0.79%</u>	A040063	001	Feb 25, 1994
--	-------------------	-----------------	---------	-----	--------------

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS;OTIC

ACETASOL HC

<u>AT</u>	ACTAVIS MID ATLANTIC	<u>2%;1%</u>	<u>A087143</u>	<u>001</u>	Jan 13, 1982
-----------	----------------------	--------------	----------------	------------	--------------

HYDROCORTISONE AND ACETIC ACID

<u>AT</u>	TARO	<u>2%;1%</u>	<u>A088759</u>	<u>001</u>	Mar 04, 1985
<u>AT</u>	VINTAGE	<u>2%;1%</u>	<u>A040609</u>	<u>001</u>	Feb 06, 2006

VOSOL HC

<u>AT</u>	+ HI TECH PHARMA	<u>2%;1%</u>	<u>N012770</u>	<u>001</u>	
-----------	------------------	--------------	----------------	------------	--

ACETOHYDROXAMIC ACID

TABLET;ORAL

LITHOSTAT

	+ MISSION PHARMA	250MG	N018749	001	May 31, 1983
--	------------------	-------	---------	-----	--------------

ACETYLCHOLINE CHLORIDE

FOR SOLUTION;OPHTHALMIC

MIOCHOL-E

	+ BAUSCH AND LOMB	20MG/VIAL	N020213	001	Sep 22, 1993
--	-------------------	-----------	---------	-----	--------------

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS

ACETADOTE

<u>AP</u>	+ CUMBERLAND PHARMS	<u>6GM/30ML (200MG/ML)</u>	<u>N021539</u>	<u>001</u>	Jan 23, 2004
-----------	---------------------	----------------------------	----------------	------------	--------------

ACETYLCYSTEINE

<u>AP</u>	AKORN INC	<u>6GM/30ML (200MG/ML)</u>	<u>A203173</u>	<u>001</u>	Mar 24, 2015
<u>AP</u>	AUROBINDO PHARMA LTD	<u>6GM/30ML (200MG/ML)</u>	<u>A207358</u>	<u>001</u>	Feb 29, 2016
<u>AP</u>	FRESENIUS KABI USA	<u>6GM/30ML (200MG/ML)</u>	<u>A200644</u>	<u>001</u>	Nov 07, 2012
<u>AP</u>	MYLAN INSTITUTIONAL	<u>6GM/30ML (200MG/ML)</u>	<u>A203624</u>	<u>001</u>	Jun 19, 2015

SOLUTION;INHALATION, ORAL

ACETYLCYSTEINE

<u>AN</u>	ALVOGEN INC	<u>10%</u>	<u>A204674</u>	<u>001</u>	Feb 11, 2014
<u>AN</u>		<u>20%</u>	<u>A203853</u>	<u>001</u>	Jun 21, 2012
<u>AN</u>	HOSPIRA	<u>10%</u>	<u>A073664</u>	<u>001</u>	Aug 30, 1994
<u>AN</u>		<u>20%</u>	<u>A074037</u>	<u>001</u>	Aug 30, 1994
<u>AN</u>	+ LUITPOLD	<u>10%</u>	<u>A072489</u>	<u>001</u>	Jul 28, 1995
<u>AN</u>	+	<u>20%</u>	<u>A072547</u>	<u>001</u>	Jul 28, 1995

TABLET, EFFERVESCENT;ORAL

CETYLEV

	ARBOR PHARMS LLC	500MG	N207916	001	Jan 29, 2016
	+	2.5GM	N207916	002	Jan 29, 2016

ACITRETIN

CAPSULE;ORAL

ACITRETIN

<u>AB</u>	BARR LABS INC	<u>10MG</u>	<u>A091455</u>	<u>001</u>	Apr 04, 2013
<u>AB</u>		<u>25MG</u>	<u>A091455</u>	<u>002</u>	Apr 04, 2013
<u>AB</u>	IMPAX LABS INC	<u>10MG</u>	<u>A202552</u>	<u>001</u>	Dec 23, 2015
<u>AB</u>		<u>17.5MG</u>	<u>A202552</u>	<u>002</u>	Dec 23, 2015
<u>AB</u>		<u>22.5MG</u>	<u>A202552</u>	<u>003</u>	Dec 23, 2015
<u>AB</u>		<u>25MG</u>	<u>A202552</u>	<u>004</u>	Dec 23, 2015
<u>AB</u>	MYLAN PHARMS INC	<u>10MG</u>	<u>A202148</u>	<u>001</u>	Sep 10, 2015
<u>AB</u>		<u>17.5MG</u>	<u>A203707</u>	<u>001</u>	Sep 10, 2015
<u>AB</u>		<u>22.5MG</u>	<u>A203707</u>	<u>002</u>	Sep 10, 2015
<u>AB</u>		<u>25MG</u>	<u>A202148</u>	<u>002</u>	Sep 10, 2015
<u>AB</u>	SIGMAPHARM LABS LLC	<u>10MG</u>	<u>A204633</u>	<u>001</u>	May 22, 2015
<u>AB</u>		<u>17.5MG</u>	<u>A204633</u>	<u>002</u>	May 22, 2015
<u>AB</u>		<u>22.5MG</u>	<u>A204633</u>	<u>003</u>	May 22, 2015
<u>AB</u>		<u>25MG</u>	<u>A204633</u>	<u>004</u>	May 22, 2015
<u>AB</u>	TEVA PHARMS USA	<u>17.5MG</u>	<u>A202897</u>	<u>001</u>	Apr 04, 2013
<u>AB</u>		<u>22.5MG</u>	<u>A202897</u>	<u>002</u>	Apr 04, 2013

PRESCRIPTION DRUG PRODUCT LIST

ACITRETIN

CAPSULE;ORAL

SORIATANE

<u>AB</u>	STIEFEL LABS INC	<u>10MG</u>	<u>N019821</u>	<u>001</u>	Oct 28, 1996
<u>AB</u>		<u>17.5MG</u>	<u>N019821</u>	<u>003</u>	Aug 06, 2009
<u>AB</u>		<u>22.5MG</u>	<u>N019821</u>	<u>004</u>	Aug 06, 2009
<u>AB</u>	+	<u>25MG</u>	<u>N019821</u>	<u>002</u>	Oct 28, 1996

ACLIDINIUM BROMIDE

POWDER, METERED;INHALATION

TUDORZA PRESSAIR

+	ASTRAZENECA PHARMS	0.4MG/INH	N202450	001	Jul 23, 2012
---	--------------------	-----------	---------	-----	--------------

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE;ORAL

SEMPREX-D

+	AUXILIUM PHARMS INC	8MG;60MG	N019806	001	Mar 25, 1994
---	---------------------	----------	---------	-----	--------------

ACYCLOVIR

CAPSULE;ORAL

ACYCLOVIR

<u>AB</u>	APOTEX INC	<u>200MG</u>	<u>A075677</u>	<u>001</u>	Sep 28, 2005
<u>AB</u>	CADILA PHARMS LTD	<u>200MG</u>	<u>A201445</u>	<u>001</u>	Mar 06, 2014
<u>AB</u>	DAVA PHARMS INC	<u>200MG</u>	<u>A074833</u>	<u>001</u>	Apr 22, 1997
<u>AB</u>	MYLAN	<u>200MG</u>	<u>A074727</u>	<u>001</u>	Apr 22, 1997
<u>AB</u>	STASON	<u>200MG</u>	<u>A075090</u>	<u>001</u>	Jan 26, 1999
<u>AB</u>	TEVA	<u>200MG</u>	<u>A074578</u>	<u>001</u>	Apr 22, 1997
<u>AB</u>	ZYDUS PHARMS USA INC	<u>200MG</u>	<u>A204313</u>	<u>001</u>	Mar 25, 2016

ZOVIRAX

<u>AB</u>	+	DELCOR ASSET CORP	<u>200MG</u>	<u>N018828</u>	<u>001</u>	Jan 25, 1985
-----------	---	-------------------	--------------	----------------	------------	--------------

CREAM;TOPICAL

ZOVIRAX

+	VIB	5%	N021478	001	Dec 30, 2002
---	-----	----	---------	-----	--------------

OINTMENT;TOPICAL

ACYCLOVIR

<u>AB</u>	AMNEAL PHARMS	<u>5%</u>	<u>A204605</u>	<u>001</u>	Jun 18, 2014
<u>AB</u>	FOUGERA PHARMS INC	<u>5%</u>	<u>A206633</u>	<u>001</u>	May 11, 2016
<u>AB</u>	MYLAN PHARMS INC	<u>5%</u>	<u>A202459</u>	<u>001</u>	Apr 03, 2013
<u>AB</u>	TARO	<u>5%</u>	<u>A205469</u>	<u>001</u>	Dec 21, 2016

ZOVIRAX

<u>AB</u>	+	VALEANT BERMUDA	<u>5%</u>	<u>N018604</u>	<u>001</u>	Mar 29, 1982
-----------	---	-----------------	-----------	----------------	------------	--------------

SUSPENSION;ORAL

ACYCLOVIR

<u>AB</u>	ACTAVIS MID ATLANTIC	<u>200MG/5ML</u>	<u>A074738</u>	<u>001</u>	Apr 28, 1997
<u>AB</u>	HI TECH PHARMA	<u>200MG/5ML</u>	<u>A077026</u>	<u>001</u>	Jun 07, 2005

ZOVIRAX

<u>AB</u>	+	DELCOR ASSET	<u>200MG/5ML</u>	<u>N019909</u>	<u>001</u>	Dec 22, 1989
-----------	---	--------------	------------------	----------------	------------	--------------

TABLET;BUCCAL

SITAVIG

+	CIPHER PHARMS US	50MG	N203791	001	Apr 12, 2013
---	------------------	------	---------	-----	--------------

TABLET;ORAL

ACYCLOVIR

<u>AB</u>	APOTEX INC	<u>400MG</u>	<u>A077309</u>	<u>001</u>	Sep 29, 2005
<u>AB</u>		<u>800MG</u>	<u>A077309</u>	<u>002</u>	Sep 29, 2005
<u>AB</u>	CADILA PHARMS LTD	<u>400MG</u>	<u>A202168</u>	<u>001</u>	Nov 15, 2013
<u>AB</u>		<u>800MG</u>	<u>A202168</u>	<u>002</u>	Nov 15, 2013
<u>AB</u>	CARLSBAD	<u>400MG</u>	<u>A075382</u>	<u>001</u>	Apr 30, 1999
<u>AB</u>		<u>800MG</u>	<u>A075382</u>	<u>002</u>	Apr 30, 1999
<u>AB</u>	DAVA PHARMS INC	<u>400MG</u>	<u>A074946</u>	<u>001</u>	Nov 19, 1997
<u>AB</u>		<u>800MG</u>	<u>A074946</u>	<u>002</u>	Nov 19, 1997
<u>AB</u>	HETERO LABS LTD V	<u>400MG</u>	<u>A203834</u>	<u>001</u>	Oct 29, 2013
<u>AB</u>		<u>800MG</u>	<u>A203834</u>	<u>002</u>	Oct 29, 2013
<u>AB</u>	MYLAN	<u>400MG</u>	<u>A075211</u>	<u>001</u>	Sep 28, 1998
<u>AB</u>		<u>800MG</u>	<u>A075211</u>	<u>002</u>	Sep 28, 1998
<u>AB</u>	TEVA	<u>400MG</u>	<u>A074556</u>	<u>002</u>	Apr 22, 1997
<u>AB</u>		<u>800MG</u>	<u>A074556</u>	<u>003</u>	Apr 22, 1997
<u>AB</u>	ZYDUS PHARMS USA INC	<u>400MG</u>	<u>A204314</u>	<u>001</u>	Aug 19, 2014
<u>AB</u>		<u>800MG</u>	<u>A204314</u>	<u>002</u>	Aug 19, 2014

ZOVIRAX

<u>AB</u>	DELCOR ASSET CORP	<u>400MG</u>	<u>N020089</u>	<u>001</u>	Apr 30, 1991
-----------	-------------------	--------------	----------------	------------	--------------

<u>AB</u>	+		<u>800MG</u>	<u>N020089</u>	<u>002</u>	Apr 30, 1991
-----------	---	--	--------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 50MG BASE/ML</u>	<u>A203701 001</u>	Oct 11, 2013
<u>AP</u>	+ FRESENIUS KABI USA	<u>EQ 50MG BASE/ML</u>	<u>A074930 001</u>	May 13, 1998
<u>AP</u>	+ HIKMA PHARMS LLC	<u>EQ 500MG BASE/VIAL</u>	<u>A075015 001</u>	Apr 30, 1998
<u>AP</u>	+ HIKMA PHARMS LLC	<u>EQ 500MG BASE/VIAL</u>	<u>A205771 001</u>	Feb 29, 2016
		EQ 1GM BASE/VIAL	A205771 002	Feb 29, 2016

ACYCLOVIR; HYDROCORTISONE

CREAM; TOPICAL

XERESE

	+ VALEANT BERMUDA	5%; 1%	N022436 001	Jul 31, 2009
--	-------------------	--------	-------------	--------------

ADAPALENE

CREAM; TOPICAL

ADAPALENE

<u>AB</u>	FOUGERA PHARMS	<u>0.1%</u>	<u>A090824 001</u>	Jun 30, 2010
-----------	----------------	-------------	--------------------	--------------

DIFFERIN

<u>AB</u>	+ GALDERMA LABS LP	<u>0.1%</u>	<u>N020748 001</u>	May 26, 2000
-----------	--------------------	-------------	--------------------	--------------

GEL; TOPICAL

ADAPALENE

<u>AB</u>	ACTAVIS MID ATLANTIC	<u>0.3%</u>	<u>A201000 001</u>	Oct 27, 2014
-----------	----------------------	-------------	--------------------	--------------

<u>AB</u>	GLENMARK GENERICS	<u>0.1%</u>	<u>A091314 001</u>	Jul 01, 2010
-----------	-------------------	-------------	--------------------	--------------

<u>AB</u>	PLIVA HRVATSKA DOO	<u>0.1%</u>	<u>A090962 001</u>	Jun 02, 2010
-----------	--------------------	-------------	--------------------	--------------

<u>AB</u>	TARO	<u>0.3%</u>	<u>A208322 001</u>	Jun 23, 2016
-----------	------	-------------	--------------------	--------------

<u>AB</u>	TOLMAR	<u>0.3%</u>	<u>A200298 001</u>	Jun 14, 2012
-----------	--------	-------------	--------------------	--------------

DIFFERIN

<u>AB</u>	+ GALDERMA LABS LP	<u>0.3%</u>	<u>N021753 001</u>	Jun 19, 2007
-----------	--------------------	-------------	--------------------	--------------

LOTION; TOPICAL

DIFFERIN

	+ GALDERMA LABS LP	0.1%	N022502 001	Mar 17, 2010
--	--------------------	------	-------------	--------------

SOLUTION; TOPICAL

ADAPALENE

<u>AB</u>	CALL INC	<u>0.1%</u>	<u>A203981 001</u>	Sep 23, 2016
-----------	----------	-------------	--------------------	--------------

<u>AB</u>	+ CALL INC	<u>0.1%</u>	<u>A204593 001</u>	Jan 05, 2016
-----------	------------	-------------	--------------------	--------------

ADAPALENE; BENZOYL PEROXIDE

GEL; TOPICAL

ADAPALENE AND BENZOYL PEROXIDE

<u>AB</u>	ACTAVIS MID ATLANTIC	<u>0.1%; 2.5%</u>	<u>A203790 001</u>	Sep 30, 2015
-----------	----------------------	-------------------	--------------------	--------------

EPIDUO

<u>AB</u>	+ GALDERMA LABS LP	<u>0.1%; 2.5%</u>	<u>N022320 001</u>	Dec 08, 2008
-----------	--------------------	-------------------	--------------------	--------------

EPIDUO FORTE

	+ GALDERMA LABS	0.3%; 2.5%	N207917 001	Jul 15, 2015
--	-----------------	------------	-------------	--------------

ADEFOVIR DIPIVOXIL

TABLET; ORAL

ADEFOVIR DIPIVOXIL

<u>AB</u>	SIGMAPHARM LABS LLC	<u>10MG</u>	<u>A202051 001</u>	Aug 29, 2013
-----------	---------------------	-------------	--------------------	--------------

HEPSERA

<u>AB</u>	+ GILEAD	<u>10MG</u>	<u>N021449 001</u>	Sep 20, 2002
-----------	----------	-------------	--------------------	--------------

ADENOSINE

INJECTABLE; INJECTION

ADENOCARD

<u>AP</u>	+ ASTELLAS	<u>3MG/ML</u>	<u>N019937 002</u>	Oct 30, 1989
-----------	------------	---------------	--------------------	--------------

ADENOSINE

<u>AP</u>	AKORN	<u>3MG/ML</u>	<u>A078076 001</u>	Oct 31, 2008
-----------	-------	---------------	--------------------	--------------

<u>AP</u>	EUROHLTH INTL SARL	<u>3MG/ML</u>	<u>A076404 001</u>	Jun 16, 2004
-----------	--------------------	---------------	--------------------	--------------

<u>AP</u>		<u>3MG/ML</u>	<u>A076500 001</u>	Jun 16, 2004
-----------	--	---------------	--------------------	--------------

<u>AP</u>	FRESENIUS KABI USA	<u>3MG/ML</u>	<u>A077133 001</u>	Apr 27, 2005
-----------	--------------------	---------------	--------------------	--------------

<u>AP</u>	GLAND PHARMA LTD	<u>3MG/ML</u>	<u>A077283 001</u>	Jun 14, 2007
-----------	------------------	---------------	--------------------	--------------

<u>AP</u>	LUITPOLD	<u>3MG/ML</u>	<u>A090010 001</u>	Apr 28, 2009
-----------	----------	---------------	--------------------	--------------

<u>AP</u>	MYLAN LABS LTD	<u>3MG/ML</u>	<u>A078640 001</u>	Mar 21, 2014
-----------	----------------	---------------	--------------------	--------------

<u>AP</u>		<u>3MG/ML</u>	<u>A078686 001</u>	May 13, 2009
-----------	--	---------------	--------------------	--------------

SOLUTION; IV (INFUSION)

ADENOSINE

<u>AP</u>	AKORN	<u>60MG/20ML (3MG/ML)</u>	<u>A090450 001</u>	Oct 02, 2014
-----------	-------	---------------------------	--------------------	--------------

<u>AP</u>		<u>90MG/30ML (3MG/ML)</u>	<u>A090450 002</u>	Oct 02, 2014
-----------	--	---------------------------	--------------------	--------------

<u>AP</u>	EMCURE PHARMS LTD	<u>60MG/20ML (3MG/ML)</u>	<u>A202313 001</u>	Sep 15, 2014
-----------	-------------------	---------------------------	--------------------	--------------

<u>AP</u>		<u>90MG/30ML (3MG/ML)</u>	<u>A202313 002</u>	Sep 15, 2014
-----------	--	---------------------------	--------------------	--------------

<u>AP</u>	HOSPIRA INC	<u>60MG/20ML (3MG/ML)</u>	<u>A203883 001</u>	Mar 24, 2014
-----------	-------------	---------------------------	--------------------	--------------

<u>AP</u>		<u>90MG/30ML (3MG/ML)</u>	<u>A203883 002</u>	Mar 24, 2014
-----------	--	---------------------------	--------------------	--------------

<u>AP</u>	SAGENT STRIDES	<u>60MG/20ML (3MG/ML)</u>	<u>A090212 001</u>	Mar 28, 2014
-----------	----------------	---------------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ADENOSINE

SOLUTION; IV (INFUSION)

ADENOSINE

<u>AP</u>		<u>90MG/30ML (3MG/ML)</u>	<u>A090212 002</u>	Mar 28, 2014
<u>AP</u>	+	TEVA PHARMS USA <u>60MG/20ML (3MG/ML)</u>	<u>A077425 001</u>	Aug 29, 2013
<u>AP</u>	+	<u>90MG/30ML (3MG/ML)</u>	<u>A077425 002</u>	Aug 29, 2013

AFATINIB DIMALEATE

TABLET; ORAL

GILOTRIF

		BOEHRINGER INGELHEIM	EQ 20MG BASE	N201292 001	Jul 12, 2013
			EQ 30MG BASE	N201292 002	Jul 12, 2013
	+		EQ 40MG BASE	N201292 003	Jul 12, 2013

ALBENDAZOLE

TABLET; ORAL

ALBENZA

	+	AMEDRA PHARMS LLC	200MG	N020666 001	Jun 11, 1996
--	---	-------------------	-------	-------------	--------------

ALBUMIN HUMAN

INJECTABLE; INJECTION

OPTISON

	+	GE HEALTHCARE	10MG/ML	N020899 001	Dec 31, 1997
--	---	---------------	---------	-------------	--------------

ALBUMIN IODINATED I-125 SERUM

INJECTABLE; INJECTION

JEANATOPE

		ISO TEX	100uCi/10ML (10uCi/ML)	N017836 003	Jun 08, 2004
			500uCi/0.5ML	N017836 001	
	+		1,000uCi/ML	N017836 002	

ALBUMIN IODINATED I-131 SERUM

INJECTABLE; INJECTION

MEGATOPE

	+	ISO TEX	0.5mCi/VIAL	N017837 001	
	+		1mCi/VIAL	N017837 002	

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION

PROAIR HFA

BX	+	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N021457 001	Oct 29, 2004
		PROVENTIL-HFA			
BX	+	3M	EQ 0.09MG BASE/INH	N020503 001	Aug 15, 1996
		VENTOLIN HFA			
BX	+	GLAXOSMITHKLINE	EQ 0.09MG BASE/INH	N020983 001	Apr 19, 2001
		POWDER, METERED; INHALATION			
		PROAIR RESPICLICK			
	+	TEVA BRANDED PHARM	EQ 0.090MG BASE/INH	N205636 001	Mar 31, 2015
		SOLUTION; INHALATION			

ACCUNEB

<u>AN</u>	+	MYLAN SPECLT	<u>EQ 0.021% BASE</u>	<u>N020949 002</u>	Apr 30, 2001
<u>AN</u>	+		<u>EQ 0.042% BASE</u>	<u>N020949 001</u>	Apr 30, 2001

ALBUTEROL SULFATE

<u>AN</u>	+	BAUSCH AND LOMB	<u>EQ 0.5% BASE</u>	<u>A075050 001</u>	Jun 18, 1998
<u>AN</u>		HI TECH PHARMA	<u>EQ 0.5% BASE</u>	<u>A074543 001</u>	Jan 15, 1998
<u>AN</u>		NEPHRON	<u>EQ 0.021% BASE</u>	<u>A076355 002</u>	Mar 31, 2010
<u>AN</u>			<u>EQ 0.042% BASE</u>	<u>A076355 001</u>	Jun 28, 2004
<u>AN</u>	+		<u>EQ 0.083% BASE</u>	<u>A074880 001</u>	Sep 17, 1997
<u>AN</u>			<u>EQ 0.5% BASE</u>	<u>A075664 001</u>	Jun 26, 2001
<u>AN</u>		RITEDOSE CORP	<u>EQ 0.083% BASE</u>	<u>A077839 001</u>	Dec 16, 2008
<u>AN</u>		WATSON LABS	<u>EQ 0.021% BASE</u>	<u>A077772 001</u>	Sep 25, 2007
<u>AN</u>			<u>EQ 0.042% BASE</u>	<u>A077772 002</u>	Sep 25, 2007

SYRUP; ORAL

ALBUTEROL SULFATE

<u>AA</u>		AMNEAL PHARMS	<u>EQ 2MG BASE/5ML</u>	<u>A079241 001</u>	May 12, 2010
<u>AA</u>		G AND W LABS INC	<u>EQ 2MG BASE/5ML</u>	<u>A074454 001</u>	Sep 25, 1995
<u>AA</u>		HI TECH PHARMA	<u>EQ 2MG BASE/5ML</u>	<u>A074749 001</u>	Jan 30, 1998
<u>AA</u>	+	TEVA	<u>EQ 2MG BASE/5ML</u>	<u>A073419 001</u>	Mar 30, 1992
<u>AA</u>		VINTAGE	<u>EQ 2MG BASE/5ML</u>	<u>A078105 001</u>	Dec 27, 2006
<u>AA</u>		VISTAPHARM	<u>EQ 2MG BASE/5ML</u>	<u>A077788 001</u>	Jun 26, 2007

TABLET; ORAL

ALBUTEROL SULFATE

<u>AB</u>		MYLAN	<u>EQ 2MG BASE</u>	<u>A072894 002</u>	Jan 17, 1991
<u>AB</u>	+		<u>EQ 4MG BASE</u>	<u>A072894 001</u>	Jan 17, 1991
<u>AB</u>		SUN PHARM INDS	<u>EQ 2MG BASE</u>	<u>A072637 002</u>	Dec 05, 1989

PRESCRIPTION DRUG PRODUCT LIST

ALBUTEROL SULFATE

TABLET;ORAL

ALBUTEROL SULFATE

AB		EQ 4MG BASE	A072637 001	Dec 05, 1989
TABLET, EXTENDED RELEASE;ORAL				

ALBUTEROL SULFATE

AB	MYLAN	EQ 4MG BASE	A078092 002	Jan 29, 2007
AB		EQ 8MG BASE	A078092 001	Jan 29, 2007

VOSPIRE ER

AB	DAVA PHARMS INC	EQ 4MG BASE	A076130 002	Sep 26, 2002
AB	+	EQ 8MG BASE	A076130 003	Sep 26, 2002

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION;INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

AN	CIPLA LTD	EQ 0.083% BASE;0.017%	A077559 001	Dec 31, 2007
AN	NEPHRON	EQ 0.083% BASE;0.017%	A076749 001	Dec 31, 2007
AN	RITEDOSE CORP	EQ 0.083% BASE;0.017%	A202496 001	Oct 01, 2012
AN	TEVA PHARMS	EQ 0.083% BASE;0.017%	A076724 001	Dec 31, 2007
AN	WATSON LABS	EQ 0.083% BASE;0.017%	A077063 001	Dec 31, 2007
SPRAY, METERED;INHALATION				
COMBIVENT RESPIMAT				
	+	BOEHRINGER INGELHEIM	EQ 0.1MG BASE/INH;0.02MG/INH	N021747 001 Oct 07, 2011

ALCAFTADINE

SOLUTION/DROPS;OPHTHALMIC

LASTACFT

+	ALLERGAN	0.25%	N022134 001	Jul 28, 2010
---	----------	-------	-------------	--------------

ALCLOMETASONE DIPROPIONATE

CREAM;TOPICAL

ALCLOMETASONE DIPROPIONATE

AB	+	FOUGERA PHARMS	0.05%	A076973 001	Jul 12, 2005
AB		GLENMARK GENERICS	0.05%	A079061 001	Jun 23, 2009
AB		TARO	0.05%	A076587 001	Sep 15, 2005

OINTMENT;TOPICAL

ALCLOMETASONE DIPROPIONATE

AB	+	FOUGERA PHARMS	0.05%	A076884 001	Jul 18, 2005
AB		GLENMARK GENERICS	0.05%	A079227 001	Jul 30, 2009
AB		TARO	0.05%	A076730 001	Jul 29, 2004

ALECTINIB HYDROCHLORIDE

CAPSULE;ORAL

ALECENSA

+	HOFFMANN-LA ROCHE	EQ 150MG BASE	N208434 001	Dec 11, 2015
---	-------------------	---------------	-------------	--------------

ALENDRONATE SODIUM

SOLUTION;ORAL

ALENDRONATE SODIUM

+	WEST-WARD PHARMS INT	EQ 70MG BASE/75ML	A090520 001	Feb 25, 2013
---	----------------------	-------------------	-------------	--------------

TABLET;ORAL

ALENDRONATE SODIUM

AB	APOTEX	EQ 5MG BASE	A077982 001	Aug 04, 2008
AB		EQ 10MG BASE	A077982 002	Aug 04, 2008
AB		EQ 35MG BASE	A077982 003	Aug 04, 2008
AB		EQ 70MG BASE	A077982 004	Aug 04, 2008
AB	AUROBINDO PHARMA	EQ 10MG BASE	A090124 001	Aug 04, 2008
AB		EQ 35MG BASE	A090124 002	Aug 04, 2008
AB		EQ 70MG BASE	A090124 003	Aug 04, 2008
AB	AUSTARPHARMA LLC	EQ 5MG BASE	A090258 001	Sep 24, 2009
AB		EQ 10MG BASE	A090258 002	Sep 24, 2009
AB		EQ 35MG BASE	A090258 003	Sep 24, 2009
AB		EQ 70MG BASE	A090258 004	Sep 24, 2009
AB	CIPLA LTD	EQ 5MG BASE	A076768 001	Aug 04, 2008
AB		EQ 10MG BASE	A076768 002	Aug 04, 2008
AB		EQ 35MG BASE	A076768 003	Aug 04, 2008
AB		EQ 40MG BASE	A076768 004	Aug 04, 2008
AB		EQ 70MG BASE	A076768 005	Aug 04, 2008
AB	DR REDDYS LABS LTD	EQ 5MG BASE	A079049 003	Aug 04, 2008
AB		EQ 10MG BASE	A079049 004	Aug 04, 2008
AB		EQ 35MG BASE	A079049 001	Aug 04, 2008
AB		EQ 70MG BASE	A079049 002	Aug 04, 2008
AB	IMPAX LABS INC	EQ 5MG BASE	A075710 001	Feb 06, 2008
AB		EQ 10MG BASE	A075710 002	Feb 06, 2008
AB		EQ 35MG BASE	A075710 003	Feb 06, 2008

PRESCRIPTION DRUG PRODUCT LIST

ALENDRONATE SODIUM

TABLET; ORAL

ALENDRONATE SODIUM

<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A075710 004</u>	Feb 06, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A075710 005</u>	Feb 06, 2008
<u>AB</u>	JUBILANT CADISTA	<u>EQ 5MG BASE</u>	<u>A090557 001</u>	Feb 18, 2010
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090557 002</u>	Feb 18, 2010
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A090557 003</u>	Feb 18, 2010
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A090557 004</u>	Feb 18, 2010
<u>AB</u>	MYLAN	<u>EQ 5MG BASE</u>	<u>A076584 001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076584 002</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A076584 003</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A076584 004</u>	Aug 04, 2008
<u>AB</u>	SUN PHARMA GLOBAL	<u>EQ 5MG BASE</u>	<u>A090022 001</u>	Sep 10, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090022 002</u>	Sep 10, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A090022 003</u>	Sep 10, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A090022 004</u>	Sep 10, 2008
<u>AB</u>	WATSON LABS	<u>EQ 35MG BASE</u>	<u>A076984 001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076984 002</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A076984 003</u>	Aug 04, 2008

FOSAMAX

<u>AB</u>	+ MERCK AND CO INC	<u>EQ 70MG BASE</u>	<u>N020560 005</u>	Oct 20, 2000
	TABLET, EFFERVESCENT; ORAL			
	BINOSTO			
	+ MISSION PHARMA	EQ 70MG BASE	N202344 001	Mar 12, 2012

ALENDRONATE SODIUM; CHOLECALCIFEROL

TABLET; ORAL

FOSAMAX PLUS D

MERCCK

+

EQ 70MG BASE; 2,800 IU

N021762 001 Apr 07, 2005

EQ 70MG BASE; 5,600 IU

N021762 002 Apr 26, 2007

ALFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

ALFENTA

<u>AP</u>	+ AKORN	<u>EQ 0.5MG BASE/ML</u>	<u>N019353 001</u>	Dec 29, 1986
	<u>ALFENTANIL</u>			
<u>AP</u>	HOSPIRA	<u>EQ 0.5MG BASE/ML</u>	<u>A075221 001</u>	Oct 28, 1999

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALFUZOSIN HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>10MG</u>	<u>A079013 001</u>	Jul 18, 2011
<u>AB</u>	AUROBINDO PHARMA LTD	<u>10MG</u>	<u>A079060 001</u>	Aug 30, 2012
<u>AB</u>	INVAGEN PHARMS	<u>10MG</u>	<u>A090284 001</u>	Jan 17, 2012
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A079014 001</u>	Jul 18, 2011
<u>AB</u>	SUN PHARMA GLOBAL	<u>10MG</u>	<u>A079057 001</u>	Jul 18, 2011
<u>AB</u>	TEVA PHARMS	<u>10MG</u>	<u>A079056 001</u>	Jul 18, 2011
<u>AB</u>	TORRENT PHARMS	<u>10MG</u>	<u>A079054 001</u>	Jul 18, 2011
<u>AB</u>	UNICHEM LABS LTD	<u>10MG</u>	<u>A203192 001</u>	Jan 28, 2016

UROXATRAL

<u>AB</u>	+ CONCORDIA PHARMS INC	<u>10MG</u>	<u>N021287 001</u>	Jun 12, 2003
-----------	------------------------	-------------	--------------------	--------------

ALISKIREN HEMIFUMARATE

TABLET; ORAL

TEKTURNA

NODEN PHARMA

+

EQ 150MG BASE

N021985 001 Mar 05, 2007

EQ 300MG BASE

N021985 002 Mar 05, 2007

ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

TEKTURNA HCT

NODEN PHARMA

+

+

EQ 150MG BASE; 12.5MG

N022107 001 Jan 18, 2008

EQ 150MG BASE; 25MG

N022107 002 Jan 18, 2008

EQ 300MG BASE; 12.5MG

N022107 003 Jan 18, 2008

EQ 300MG BASE; 25MG

N022107 004 Jan 18, 2008

ALITRETINOIN

GEL; TOPICAL

PANRETIN

+ EISAI INC

EQ 0.1% BASE

N020886 001 Feb 02, 1999

PRESCRIPTION DRUG PRODUCT LIST

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

<u>AB</u>	ACCORD HLTHCARE	<u>100MG</u>	<u>A203154 001</u>	May 06, 2013
<u>AB</u>		<u>300MG</u>	<u>A203154 002</u>	May 06, 2013
<u>AB</u>	APOTEX INC	<u>100MG</u>	<u>A077353 001</u>	Sep 08, 2005
<u>AB</u>		<u>300MG</u>	<u>A077353 002</u>	Sep 08, 2005
<u>AB</u>	INDOCO REMEDIES	<u>100MG</u>	<u>A204467 001</u>	Jul 28, 2016
<u>AB</u>		<u>300MG</u>	<u>A204467 002</u>	Jul 28, 2016
<u>AB</u>	IPCA LABS LTD	<u>100MG</u>	<u>A090637 001</u>	Mar 16, 2011
<u>AB</u>		<u>300MG</u>	<u>A090637 002</u>	Mar 16, 2011
<u>AB</u>	MUTUAL PHARM	<u>100MG</u>	<u>A071449 001</u>	Jan 09, 1987
<u>AB</u>	MYLAN	<u>100MG</u>	<u>A018659 001</u>	Oct 24, 1986
<u>AB</u>		<u>300MG</u>	<u>A018659 002</u>	Oct 24, 1986
<u>AB</u>	NORTHSTAR HLTHCARE	<u>100MG</u>	<u>A078253 001</u>	Sep 11, 2007
<u>AB</u>		<u>300MG</u>	<u>A078253 002</u>	Sep 11, 2007
<u>AB</u>	SUN PHARM INDS	<u>300MG</u>	<u>A071450 001</u>	Jan 09, 1987
<u>AB</u>	SUN PHARM INDS INC	<u>100MG</u>	<u>A078390 001</u>	Aug 30, 2007
<u>AB</u>		<u>300MG</u>	<u>A078390 002</u>	Aug 30, 2007
<u>AB</u>	VINTAGE PHARMS	<u>100MG</u>	<u>A075798 001</u>	Jun 27, 2003
<u>AB</u>		<u>300MG</u>	<u>A075798 002</u>	Jun 27, 2003
<u>AB</u>	WATSON LABS	<u>100MG</u>	<u>N018832 002</u>	Sep 28, 1984
<u>AB</u>		<u>300MG</u>	<u>N018877 001</u>	Sep 28, 1984

LOPURIN

<u>AB</u>	DR REDDYS LA	<u>100MG</u>	<u>A071586 001</u>	Apr 02, 1987
<u>AB</u>		<u>300MG</u>	<u>A071587 001</u>	Apr 02, 1987

ZYLOPRIM

<u>AB</u>	SEBELA IRELAND LTD	<u>100MG</u>	<u>N016084 001</u>	
<u>AB</u>	+	<u>300MG</u>	<u>N016084 002</u>	

ALLOPURINOL SODIUM

INJECTABLE; INJECTION

ALLOPURINOL SODIUM

<u>AP</u>	WEST-WARD PHARMS INT	<u>EQ 500MG BASE/VIAL</u>	<u>A076870 001</u>	Aug 26, 2004
<u>AP</u>	+	<u>EQ 500MG BASE/VIAL</u>	<u>N020298 001</u>	May 17, 1996

ALMOTRIPTAN MALATE

TABLET; ORAL

ALMOTRIPTAN MALATE

<u>AB</u>	AJANTA PHARMA LTD	<u>EQ 6.25MG BASE</u>	<u>A205523 001</u>	Mar 03, 2016
<u>AB</u>		<u>EQ 12.5MG BASE</u>	<u>A205523 002</u>	Mar 03, 2016
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 6.25MG BASE</u>	<u>A205171 001</u>	Nov 09, 2015
<u>AB</u>		<u>EQ 12.5MG BASE</u>	<u>A205171 002</u>	Nov 09, 2015
<u>AB</u>	TEVA PHARMS USA	<u>EQ 6.25MG BASE</u>	<u>A078027 001</u>	Jul 07, 2015
<u>AB</u>		<u>EQ 12.5MG BASE</u>	<u>A078027 002</u>	Jul 07, 2015

AXERT

<u>AB</u>	JANSSEN PHARMS	<u>EQ 6.25MG BASE</u>	<u>N021001 001</u>	May 07, 2001
<u>AB</u>	+	<u>EQ 12.5MG BASE</u>	<u>N021001 002</u>	May 07, 2001

ALOGLIPTIN BENZOATE

TABLET; ORAL

NESINA

	TAKEDA PHARMS USA	EQ 6.25MG BASE	N022271 001	Jan 25, 2013
		EQ 12.5MG BASE	N022271 002	Jan 25, 2013
	+	EQ 25MG BASE	N022271 003	Jan 25, 2013

ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

KAZANO

	TAKEDA PHARMS USA	EQ 12.5MG BASE;500MG	N203414 001	Jan 25, 2013
	+	EQ 12.5MG BASE;1GM	N203414 002	Jan 25, 2013

ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

OSEN

	TAKEDA PHARMS USA	EQ 12.5MG BASE;EQ 15MG BASE	N022426 004	Jan 25, 2013
		EQ 12.5MG BASE;EQ 30MG BASE	N022426 005	Jan 25, 2013
		EQ 12.5MG BASE;EQ 45MG BASE	N022426 006	Jan 25, 2013
		EQ 25MG BASE;EQ 15MG BASE	N022426 001	Jan 25, 2013
		EQ 25MG BASE;EQ 30MG BASE	N022426 002	Jan 25, 2013
	+	EQ 25MG BASE;EQ 45MG BASE	N022426 003	Jan 25, 2013

PRESCRIPTION DRUG PRODUCT LIST

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

ALOSETRON HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARMS	<u>EQ 0.5MG BASE</u>	<u>A206647 001</u>	Dec 22, 2016
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A206647 002</u>	Dec 22, 2016
<u>AB</u>	WEST-WARD PHARMS INT	<u>EQ 0.5MG BASE</u>	<u>A200652 001</u>	May 04, 2015
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A200652 002</u>	May 04, 2015
<u>LOTRONEX</u>				
<u>AB</u>	SEBELA IRELAND LTD	<u>EQ 0.5MG BASE</u>	<u>N021107 002</u>	Dec 23, 2003
<u>AB</u>	+	<u>EQ 1MG BASE</u>	<u>N021107 001</u>	Feb 09, 2000

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

INJECTABLE; INJECTION

INFUVITE ADULT

+ SANDOZ

2 IU/ML; 40MG/ML; 12MCG/ML; 40
IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1
.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660
IU/ML; 0.03MG/ML

N021163 001 May 18, 2000

INJECTABLE; IV (INFUSION)

INFUVITE ADULT

+ SANDOZ

2 IU/ML; 40MG/ML; 12MCG/ML; 40
IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1
.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660
IU/ML; 30MCG/ML

N021559 001 Jun 16, 2003

ALPRAZOLAM

CONCENTRATE; ORAL

ALPRAZOLAM

+ WEST-WARD PHARMS INT

1MG/ML

A074312 001 Oct 31, 1993

TABLET; ORAL

ALPRAZOLAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>0.25MG</u>	<u>A074342 001</u>	Oct 31, 1993
<u>AB</u>		<u>0.5MG</u>	<u>A074342 002</u>	Oct 31, 1993
<u>AB</u>		<u>1MG</u>	<u>A074342 003</u>	Oct 31, 1993
<u>AB</u>		<u>2MG</u>	<u>A074342 004</u>	Oct 31, 1993
<u>AB</u>	APOTEX INC	<u>0.25MG</u>	<u>A077741 001</u>	Jan 19, 2007
<u>AB</u>		<u>0.5MG</u>	<u>A077741 002</u>	Jan 19, 2007
<u>AB</u>		<u>1MG</u>	<u>A077741 003</u>	Jan 19, 2007
<u>AB</u>		<u>2MG</u>	<u>A077741 004</u>	Jan 19, 2007
<u>AB</u>	AUROBINDO PHARMA LTD	<u>0.25MG</u>	<u>A203346 001</u>	Jul 31, 2015
<u>AB</u>		<u>0.5MG</u>	<u>A203346 002</u>	Jul 31, 2015
<u>AB</u>		<u>1MG</u>	<u>A203346 003</u>	Jul 31, 2015
<u>AB</u>		<u>2MG</u>	<u>A203346 004</u>	Jul 31, 2015
<u>AB</u>	DAVA INTL INC	<u>0.25MG</u>	<u>A074174 001</u>	Oct 19, 1993
<u>AB</u>		<u>0.5MG</u>	<u>A074174 002</u>	Oct 19, 1993
<u>AB</u>		<u>1MG</u>	<u>A074174 003</u>	Oct 19, 1993
<u>AB</u>		<u>2MG</u>	<u>A074174 004</u>	Oct 19, 1993
<u>AB</u>	MYLAN	<u>0.25MG</u>	<u>A074215 001</u>	Jan 27, 1994
<u>AB</u>		<u>0.5MG</u>	<u>A074215 002</u>	Jan 27, 1994
<u>AB</u>		<u>1MG</u>	<u>A074215 003</u>	Jan 27, 1994
<u>AB</u>		<u>2MG</u>	<u>A074215 004</u>	Jan 27, 1994
<u>AB</u>	MYLAN PHARMS INC	<u>0.25MG</u>	<u>A074046 001</u>	Oct 19, 1993
<u>AB</u>		<u>0.5MG</u>	<u>A074046 002</u>	Oct 19, 1993
<u>AB</u>		<u>1MG</u>	<u>A074046 003</u>	Oct 19, 1993
<u>AB</u>		<u>2MG</u>	<u>A074046 004</u>	May 07, 1997
<u>AB</u>	NATCO PHARMA LTD	<u>0.25MG</u>	<u>A200739 001</u>	Apr 15, 2015
<u>AB</u>		<u>0.5MG</u>	<u>A200739 002</u>	Apr 15, 2015
<u>AB</u>		<u>1MG</u>	<u>A200739 003</u>	Apr 15, 2015
<u>AB</u>		<u>2MG</u>	<u>A200739 004</u>	Apr 15, 2015
<u>AB</u>	SANDOZ	<u>0.25MG</u>	<u>A074112 001</u>	Dec 29, 1995
<u>AB</u>		<u>0.5MG</u>	<u>A074112 002</u>	Dec 29, 1995
<u>AB</u>		<u>1MG</u>	<u>A074112 003</u>	Dec 29, 1995
<u>AB</u>		<u>2MG</u>	<u>A074909 001</u>	Mar 25, 1998
<u>AB</u>	SUN PHARMA GLOBAL	<u>0.25MG</u>	<u>A090082 001</u>	Jun 17, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090082 002</u>	Jun 17, 2010
<u>AB</u>		<u>1MG</u>	<u>A090082 003</u>	Jun 17, 2010
<u>AB</u>		<u>2MG</u>	<u>A090082 004</u>	Jun 17, 2010
<u>AB</u>	VINTAGE	<u>0.25MG</u>	<u>A078491 001</u>	Sep 25, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078491 002</u>	Sep 25, 2008
<u>AB</u>		<u>1MG</u>	<u>A078491 003</u>	Sep 25, 2008
<u>AB</u>		<u>2MG</u>	<u>A078491 004</u>	Dec 12, 2008
<u>AB</u>	VINTAGE PHARMS	<u>0.25MG</u>	<u>A090248 001</u>	Sep 17, 2010

PRESCRIPTION DRUG PRODUCT LIST

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

<u>AB</u>		<u>0.5MG</u>	<u>A090248</u>	<u>002</u>	Sep 17, 2010
<u>AB</u>		<u>1MG</u>	<u>A090248</u>	<u>003</u>	Sep 17, 2010
<u>AB</u>		<u>2MG</u>	<u>A090248</u>	<u>004</u>	Sep 17, 2010

XANAX

<u>AB</u>	PHARMACIA AND UPJOHN	<u>0.25MG</u>	<u>N018276</u>	<u>001</u>	
<u>AB</u>		<u>0.5MG</u>	<u>N018276</u>	<u>002</u>	
<u>AB</u>	+	<u>1MG</u>	<u>N018276</u>	<u>003</u>	
<u>AB</u>		<u>2MG</u>	<u>N018276</u>	<u>004</u>	Nov 27, 1985

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>0.5MG</u>	<u>A078056</u>	<u>001</u>	Feb 13, 2007
<u>AB</u>		<u>1MG</u>	<u>A078056</u>	<u>002</u>	Feb 13, 2007
<u>AB</u>		<u>2MG</u>	<u>A078056</u>	<u>003</u>	Feb 13, 2007
<u>AB</u>		<u>3MG</u>	<u>A078056</u>	<u>004</u>	Feb 13, 2007
<u>AB</u>	AMNEAL PHARMS NY	<u>0.5MG</u>	<u>A078387</u>	<u>001</u>	May 30, 2008
<u>AB</u>		<u>1MG</u>	<u>A078387</u>	<u>002</u>	May 30, 2008
<u>AB</u>		<u>2MG</u>	<u>A078387</u>	<u>003</u>	May 30, 2008
<u>AB</u>		<u>3MG</u>	<u>A078387</u>	<u>004</u>	May 30, 2008
<u>AB</u>	ANCHEN PHARMS	<u>0.5MG</u>	<u>A078469</u>	<u>001</u>	Sep 29, 2011
<u>AB</u>		<u>1MG</u>	<u>A078469</u>	<u>002</u>	Sep 29, 2011
<u>AB</u>		<u>2MG</u>	<u>A078469</u>	<u>003</u>	Sep 29, 2011
<u>AB</u>		<u>3MG</u>	<u>A078469</u>	<u>004</u>	Sep 29, 2011
<u>AB</u>	ANI PHARMS INC	<u>0.5MG</u>	<u>A077725</u>	<u>001</u>	Jul 31, 2006
<u>AB</u>		<u>1MG</u>	<u>A077725</u>	<u>002</u>	Jul 31, 2006
<u>AB</u>		<u>2MG</u>	<u>A077725</u>	<u>004</u>	Jul 31, 2006
<u>AB</u>		<u>3MG</u>	<u>A077725</u>	<u>003</u>	Jul 31, 2006
<u>AB</u>	APOTEX INC	<u>0.5MG</u>	<u>A078449</u>	<u>001</u>	Nov 12, 2008
<u>AB</u>		<u>1MG</u>	<u>A078449</u>	<u>004</u>	Dec 23, 2015
<u>AB</u>		<u>2MG</u>	<u>A078449</u>	<u>002</u>	Nov 12, 2008
<u>AB</u>		<u>3MG</u>	<u>A078449</u>	<u>003</u>	Nov 12, 2008
<u>AB</u>	AUROBINDO PHARMA USA	<u>0.5MG</u>	<u>A090871</u>	<u>001</u>	Jun 07, 2011
<u>AB</u>		<u>1MG</u>	<u>A090871</u>	<u>002</u>	Jun 07, 2011
<u>AB</u>		<u>2MG</u>	<u>A090871</u>	<u>003</u>	Jun 07, 2011
<u>AB</u>		<u>3MG</u>	<u>A090871</u>	<u>004</u>	Jun 07, 2011
<u>AB</u>	HERITAGE PHARMS INC	<u>0.5MG</u>	<u>A078489</u>	<u>001</u>	Oct 17, 2008
<u>AB</u>		<u>1MG</u>	<u>A078489</u>	<u>002</u>	Oct 17, 2008
<u>AB</u>		<u>2MG</u>	<u>A078489</u>	<u>003</u>	Oct 17, 2008
<u>AB</u>		<u>3MG</u>	<u>A078489</u>	<u>004</u>	Oct 17, 2008
<u>AB</u>	MYLAN	<u>0.5MG</u>	<u>A077391</u>	<u>002</u>	Jan 26, 2006
<u>AB</u>		<u>1MG</u>	<u>A077391</u>	<u>003</u>	Jan 26, 2006
<u>AB</u>		<u>2MG</u>	<u>A077391</u>	<u>004</u>	Jan 26, 2006
<u>AB</u>		<u>3MG</u>	<u>A077391</u>	<u>001</u>	Jan 26, 2006

XANAX XR

<u>AB</u>	PHARMACIA AND UPJOHN	<u>0.5MG</u>	<u>N021434</u>	<u>001</u>	Jan 17, 2003
<u>AB</u>		<u>1MG</u>	<u>N021434</u>	<u>002</u>	Jan 17, 2003
<u>AB</u>		<u>2MG</u>	<u>N021434</u>	<u>003</u>	Jan 17, 2003
<u>AB</u>	+	<u>3MG</u>	<u>N021434</u>	<u>004</u>	Jan 17, 2003

TABLET, ORALLY DISINTEGRATING; ORAL

ALPRAZOLAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>0.25MG</u>	<u>A078561</u>	<u>001</u>	Mar 16, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A078561</u>	<u>002</u>	Mar 16, 2010
<u>AB</u>		<u>1MG</u>	<u>A078561</u>	<u>003</u>	Mar 16, 2010
<u>AB</u>		<u>2MG</u>	<u>A078561</u>	<u>004</u>	Mar 16, 2010
<u>AB</u>	PAR PHARM	<u>0.25MG</u>	<u>A078088</u>	<u>001</u>	Jan 09, 2009
<u>AB</u>		<u>0.5MG</u>	<u>A078088</u>	<u>002</u>	Jan 09, 2009
<u>AB</u>	+	<u>1MG</u>	<u>A078088</u>	<u>003</u>	Jan 09, 2009
<u>AB</u>		<u>2MG</u>	<u>A078088</u>	<u>004</u>	Jan 09, 2009

ALPROSTADIL

INJECTABLE; INJECTION

ALPROSTADIL

<u>AP</u>	TEVA PHARMS USA	<u>0.5MG/ML</u>	<u>A075196</u>	<u>001</u>	Apr 30, 1999
<u>AP</u>	WEST-WARD PHARMS INT	<u>0.5MG/ML</u>	<u>A074815</u>	<u>001</u>	Jan 20, 1998

CAVERJECT

<u>AP</u>	PHARMACIA AND UPJOHN	<u>0.01MG/VIAL</u>	<u>N020379</u>	<u>001</u>	Jul 06, 1995
<u>AP</u>	+	<u>0.02MG/VIAL</u>	<u>N020379</u>	<u>002</u>	Jul 06, 1995
<u>AP</u>	+	<u>0.04MG/VIAL</u>	<u>N020379</u>	<u>004</u>	May 19, 1997

EDEX

<u>AP</u>	AUXILIUM PHARMS INC	<u>0.01MG/VIAL</u>	<u>N020649</u>	<u>002</u>	Jun 12, 1997
<u>AP</u>		<u>0.02MG/VIAL</u>	<u>N020649</u>	<u>003</u>	Jun 12, 1997

PRESCRIPTION DRUG PRODUCT LIST

ALPROSTADIL

INJECTABLE; INJECTION

EDEX

AP	+		<u>0.04MG/VIAL</u>	<u>N020649 004</u>	Jun 12, 1997
		<u>PROSTIN VR PEDIATRIC</u>			
AP	+	PHARMACIA AND UPJOHN	<u>0.5MG/ML</u>	<u>N018484 001</u>	
		CAVERJECT			
		PHARMACIA AND UPJOHN	0.005MG/VIAL	N020379 003	Jun 27, 1996
		CAVERJECT IMPULSE			
		PHARMACIA AND UPJOHN	0.01MG/VIAL	N021212 001	Jun 11, 2002
			0.02MG/VIAL	N021212 002	Jun 11, 2002
		<u>EDEX</u>			
	+	AUXILIUM PHARMS INC	0.01MG/VIAL	N020649 005	Jul 30, 1998
	+		0.02MG/VIAL	N020649 006	Jul 30, 1998
	+		0.04MG/VIAL	N020649 007	Jul 30, 1998
		<u>SUPPOSITORY; URETHRAL</u>			
		<u>MUSE</u>			
	+	MEDA PHARMS	0.125MG	N020700 001	Nov 19, 1996
	+		0.25MG	N020700 002	Nov 19, 1996
	+		0.5MG	N020700 003	Nov 19, 1996
	+		1MG	N020700 004	Nov 19, 1996

ALTRETAMINE

CAPSULE; ORAL

HEXALEN

	+	EISAI INC	50MG	N019926 001	Dec 26, 1990
--	---	-----------	------	-------------	--------------

ALVIMOPAN

CAPSULE; ORAL

ENTEREG

	+	CUBIST PHARMS	12MG	N021775 001	May 20, 2008
--	---	---------------	------	-------------	--------------

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

AB		BIONPHARMA INC	<u>100MG</u>	<u>A078720 001</u>	May 29, 2008
AB		NEWGEN PHARMS LLC	<u>100MG</u>	<u>A207570 001</u>	Sep 30, 2016
AB	+	SANDOZ	<u>100MG</u>	<u>A071293 001</u>	Feb 18, 1987
AB		USL PHARMA	<u>100MG</u>	<u>A070589 001</u>	Aug 05, 1986
AB		WATSON LABS INC	<u>100MG</u>	<u>A208107 001</u>	Dec 06, 2016
AB		ZYDUS PHARMS USA INC	<u>100MG</u>	<u>A208278 001</u>	May 31, 2016

SYRUP; ORAL

AMANTADINE HYDROCHLORIDE

AA	+	CAROLINA MEDCL	<u>50MG/5ML</u>	<u>A075819 001</u>	Sep 11, 2002
AA	+	HI TECH PHARMA	<u>50MG/5ML</u>	<u>A074170 001</u>	Oct 28, 1994
AA	+	MIKART	<u>50MG/5ML</u>	<u>A074028 001</u>	Jun 28, 1993
AA	+	PHARM ASSOC	<u>50MG/5ML</u>	<u>A074509 001</u>	Jul 17, 1995
AA	+	WOCKHARDT	<u>50MG/5ML</u>	<u>A075060 001</u>	Dec 24, 1998

TABLET; ORAL

AMANTADINE HYDROCHLORIDE

AB	+	USL PHARMA	<u>100MG</u>	<u>A076186 001</u>	Dec 16, 2002
AB		WATSON LABS INC	<u>100MG</u>	<u>A208096 001</u>	Dec 15, 2016

AMBRISENTAN

TABLET; ORAL

LETAIRIS

		GILEAD	5MG	N022081 001	Jun 15, 2007
	+		10MG	N022081 002	Jun 15, 2007

AMCINONIDE

CREAM; TOPICAL

AMCINONIDE

AB	+	FOUGERA PHARMS	<u>0.1%</u>	<u>A076065 001</u>	May 15, 2003
AB		TARO PHARM INDS	<u>0.1%</u>	<u>A076229 001</u>	May 31, 2002

LOTION; TOPICAL

AMCINONIDE

	+	FOUGERA PHARMS	0.1%	A076329 001	Nov 06, 2002
--	---	----------------	------	-------------	--------------

OINTMENT; TOPICAL

AMCINONIDE

AB	+	FOUGERA PHARMS	<u>0.1%</u>	<u>A076096 001</u>	Nov 19, 2002
AB		TARO PHARM INDS	<u>0.1%</u>	<u>A076367 001</u>	Mar 19, 2003

PRESCRIPTION DRUG PRODUCT LIST

AMIFOSTINE

INJECTABLE; INJECTION

AMIFOSTINE

<u>AP</u>	SUN PHARMA GLOBAL	<u>500MG/VIAL</u>	<u>A077126 001</u>	Mar 14, 2008
<u>ETHYOL</u>				
<u>AP</u>	+ CLINIGEN HLTHCARE	<u>500MG/VIAL</u>	<u>N020221 001</u>	Dec 08, 1995

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

<u>AP</u>	+ EMCURE PHARMS LTD	<u>EQ 250MG BASE/ML</u>	<u>A204040 001</u>	Dec 12, 2013
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 50MG BASE/ML</u>	<u>A205605 001</u>	Dec 09, 2015
<u>AP</u>		<u>EQ 250MG BASE/ML</u>	<u>A205604 001</u>	Dec 09, 2015
<u>AP</u>	SAGENT PHARMS	<u>EQ 250MG BASE/ML</u>	<u>A203323 001</u>	May 12, 2016
<u>AP</u>	TEVA PHARMS USA	<u>EQ 250MG BASE/ML</u>	<u>A064045 002</u>	Sep 28, 1993
<u>AP</u>	+ WEST-WARD PHARMS INT	<u>EQ 50MG BASE/ML</u>	<u>A063313 001</u>	Apr 11, 1994
<u>AP</u>		<u>EQ 250MG BASE/ML</u>	<u>A063315 001</u>	Apr 11, 1994

AMILORIDE HYDROCHLORIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE

<u>AB</u>	+ PAR PHARM	<u>5MG</u>	<u>A070346 001</u>	Jan 22, 1986
<u>AB</u>	SIGMAPHARM LABS LLC	<u>5MG</u>	<u>A079133 001</u>	Jan 30, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>5MG</u>	<u>A204180 001</u>	Aug 07, 2015

MIDAMOR

<u>AB</u>	PADDOCK LLC	<u>5MG</u>	<u>N018200 001</u>	
-----------	-------------	------------	--------------------	--

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	BARR	<u>EQ 5MG ANHYDROUS; 50MG</u>	<u>A071111 001</u>	May 10, 1988
<u>AB</u>	+ MYLAN	<u>EQ 5MG ANHYDROUS; 50MG</u>	<u>A073209 001</u>	Oct 31, 1991

AMINO ACIDS

INJECTABLE; INJECTION

AMINO ACIDS

B BRAUN	15% (150GM/1000ML)	A091112 001	Apr 13, 2012
	15% (300GM/2000ML)	A091112 002	Apr 13, 2012
AMINOSYN 10%			
HOSPIRA	10% (10GM/100ML)	N017673 003	
AMINOSYN 10% (PH6)			
HOSPIRA	10% (10GM/100ML)	N017673 008	Nov 18, 1985
AMINOSYN 3.5%			
HOSPIRA	3.5% (3.5GM/100ML)	N017789 004	
AMINOSYN 5%			
HOSPIRA	5% (5GM/100ML)	N017673 001	
AMINOSYN 7%			
HOSPIRA	7% (7GM/100ML)	N017673 002	
AMINOSYN 7% (PH6)			
HOSPIRA	7% (7GM/100ML)	N017673 006	Nov 18, 1985
AMINOSYN 8.5%			
HOSPIRA	8.5% (8.5GM/100ML)	N017673 004	
AMINOSYN 8.5% (PH6)			
HOSPIRA	8.5% (8.5GM/100ML)	N017673 007	Nov 18, 1985
AMINOSYN II 10%			
HOSPIRA	10% (10GM/100ML)	N019438 005	Apr 03, 1986
AMINOSYN II 10% IN PLASTIC CONTAINER			
HOSPIRA	10% (10GM/100ML)	N020015 001	Dec 19, 1991
AMINOSYN II 15% IN PLASTIC CONTAINER			
HOSPIRA	15% (15GM/100ML)	N020041 001	Dec 19, 1991
AMINOSYN II 7%			
HOSPIRA	7% (7GM/100ML)	N019438 003	Apr 03, 1986
AMINOSYN II 8.5%			
HOSPIRA	8.5% (8.5GM/100ML)	N019438 004	Apr 03, 1986
AMINOSYN-HBC 7%			
HOSPIRA	7% (7GM/100ML)	N019374 001	Jul 12, 1985
AMINOSYN-HF 8%			
HOSPIRA	8% (8GM/100ML)	A020345 001	Apr 04, 1996
AMINOSYN-PF 10%			
HOSPIRA	10% (10GM/100ML)	N019492 002	Oct 17, 1986
AMINOSYN-PF 7%			
HOSPIRA	7% (7GM/100ML)	N019398 001	Sep 06, 1985
AMINOSYN-RF 5.2%			
HOSPIRA	5.2% (5.2GM/100ML)	N018429 001	

PRESCRIPTION DRUG PRODUCT LIST

AMINO ACIDS

INJECTABLE; INJECTION

CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER				
BAXTER HLTHCARE	15% (15GM/100ML)	A020512	001	Aug 30, 1996
FREAMINE HBC 6.9%				
B BRAUN	6.9% (6.9GM/100ML)	N016822	006	May 17, 1983
FREAMINE III 10%				
B BRAUN	10% (10GM/100ML)	N016822	005	
FREAMINE III 8.5%				
B BRAUN	8.5% (8.5GM/100ML)	N016822	004	
HEPATAMINE 8%				
B BRAUN	8% (8GM/100ML)	N018676	001	Aug 03, 1982
NEPHRAMINE 5.4%				
B BRAUN	5.4% (5.4GM/100ML)	N017766	001	
PREMASOL 10% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	10% (10GM/100ML)	A075880	002	Jun 19, 2003
PREMASOL 6% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	6% (6GM/100ML)	A075880	001	Jun 19, 2003
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	20% (20GM/100ML)	N020849	001	Aug 26, 1998
TRAVASOL 10% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	10% (10GM/100ML)	N018931	003	Aug 23, 1984
TRAVASOL 5.5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	5.5% (5.5GM/100ML)	N018931	001	Aug 23, 1984
TRAVASOL 8.5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	8.5% (8.5GM/100ML)	N018931	002	Aug 23, 1984
TROPHAMINE				
+ B BRAUN	6% (6GM/100ML)	N019018	001	Jul 20, 1984
TROPHAMINE 10%				
+ B BRAUN	10% (10GM/100ML)	N019018	003	Sep 07, 1988

AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PROCALAMINE				
B BRAUN	3%;26MG/100ML;3GM/100ML;54MG/100ML;41MG /100ML;150MG/100ML;200MG/100ML;120MG/10 0ML	N018582	001	May 08, 1982

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	2.75%;33MG/100ML;10GM/100ML;51MG/100ML; 261MG/100ML;217MG/100ML;112MG/100ML	N020678	002	Mar 26, 1997
CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	2.75%;33MG/100ML;25GM/100ML;51MG/100ML; 261MG/100ML;217MG/100ML;112MG/100ML	N020678	005	Mar 26, 1997
CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	2.75%;33MG/100ML;5GM/100ML;51MG/100ML;2 61MG/100ML;217MG/100ML;112MG/100ML	N020678	001	Mar 26, 1997
CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	4.25%;33MG/100ML;10GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML;77MG/100ML	N020678	009	Mar 26, 1997
CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	4.25%;33MG/100ML;20GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML;77MG/100ML	N020678	011	Mar 26, 1997
CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	4.25%;33MG/100ML;25GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML;77MG/100ML	N020678	012	Mar 26, 1997
CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	4.25%;33MG/100ML;5GM/100ML;51MG/100ML;2 61MG/100ML;297MG/100ML;77MG/100ML	N020678	008	Mar 26, 1997
CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	5%;33MG/100ML;10GM/100ML;51MG/100ML;261 MG/100ML;340MG/100ML;59MG/100ML	N020678	016	Mar 26, 1997
CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	5%;33MG/100ML;15GM/100ML;51MG/100ML;261 MG/100ML;340MG/100ML;59MG/100ML	N020678	017	Mar 26, 1997
CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	5%;33MG/100ML;20GM/100ML;51MG/100ML;261 MG/100ML;340MG/100ML;59MG/100ML	N020678	018	Mar 26, 1997
CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	5%;33MG/100ML;25GM/100ML;51MG/100ML;261 MG/100ML;340MG/100ML;59MG/100ML	N020678	019	Mar 26, 1997

PRESCRIPTION DRUG PRODUCT LIST

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER
 + BAXTER HLTHCARE 5%; 33MG/100ML; 35GM/100ML; 51MG/100ML; 261 N020678 021 Mar 26, 1997
 MG/100ML; 340MG/100ML; 59MG/100ML

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL

EMULSION; IV (INFUSION)

KABIVEN IN PLASTIC CONTAINER

FRESENIUS KABI USA 3.3%; 29MG/100ML; 9.8GM/100ML; 96MG/100ML; N200656 004 Aug 25, 2014
 174MG/100ML; 239MG/100ML
 ; 147MG/100ML; 3.9GM/100ML (1026ML)
 3.3%; 29MG/100ML; 9.8GM/100ML; 96MG/100ML; N200656 005 Aug 25, 2014
 174MG/100ML; 239MG/100ML; 147MG/100ML; 3.9
 GM/100ML (1540ML)
 3.3%; 29MG/100ML; 9.8GM/100ML; 96MG/100ML; N200656 006 Aug 25, 2014
 174MG/100ML; 239MG/100ML; 147MG/100ML; 3.9
 GM/100ML (2053ML)
 + 3.3%; 29MG/100ML; 9.8GM/100ML; 96MG/100ML; N200656 007 Aug 25, 2014
 174MG/100ML; 239MG/100ML; 147MG/100ML; 3.9
 GM/100ML (2566ML)
 PERIKABIVEN IN PLASTIC CONTAINER
 FRESENIUS KABI USA 2.4%; 20MG/100ML; 6.8GM/100ML; 68MG/100ML; N200656 001 Aug 25, 2014
 124MG/100ML; 170MG/100ML; 105MG/100ML; 3.5
 GM/100ML (1440ML)
 2.4%; 20MG/100ML; 6.8GM/100ML; 68MG/100ML; N200656 002 Aug 25, 2014
 124MG/100ML; 170MG/100ML; 105MG/100ML; 3.5
 GM/100ML (1920ML)
 2.4%; 20MG/100ML; 6.8GM/100ML; 68MG/100ML; N200656 003 Aug 25, 2014
 124MG/100ML; 170MG/100ML
 ; 105MG/100ML; 3.5GM/100ML (2400ML)

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER
 BAXTER HLTHCARE 2.75%; 10GM/100ML N020734 002 Sep 29, 1997
 CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER
 BAXTER HLTHCARE 2.75%; 25GM/100ML N020734 005 Sep 29, 1997
 CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER
 BAXTER HLTHCARE 2.75%; 5GM/100ML N020734 001 Sep 29, 1997
 CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER
 BAXTER HLTHCARE 4.25%; 10GM/100ML N020734 008 Sep 29, 1997
 CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER
 BAXTER HLTHCARE 4.25%; 20GM/100ML N020734 010 Sep 29, 1997
 CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER
 BAXTER HLTHCARE 4.25%; 25GM/100ML N020734 011 Sep 29, 1997
 CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER
 BAXTER HLTHCARE 4.25%; 5GM/100ML N020734 007 Sep 29, 1997
 CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER
 BAXTER HLTHCARE 5%; 10GM/100ML N020734 014 Sep 29, 1997
 CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER
 BAXTER HLTHCARE 5%; 15GM/100ML N020734 015 Sep 29, 1997
 CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER
 BAXTER HLTHCARE 5%; 20GM/100ML N020734 016 Sep 29, 1997
 CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER
 BAXTER HLTHCARE 5%; 25GM/100ML N020734 017 Sep 29, 1997
 CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER
 BAXTER HLTHCARE 5%; 35GM/100ML N020734 018 Sep 29, 1997

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE; INJECTION

FREAMINE III 8.5% W/ ELECTROLYTES
 B BRAUN 8.5%; 110MG/100ML; 230MG/100ML; 10MG/100ML N016822 007 Jul 01, 1988
 ; 440MG/100ML; 690MG/100ML

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M
 HOSPIRA 3.5%; 21MG/100ML; 40MG/100ML; 128MG/100ML; N017789 003
 234MG/100ML

PRESCRIPTION DRUG PRODUCT LIST

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

FREAMINE III 3% W/ ELECTROLYTES

B BRAUN	3%; 54MG/100ML; 40MG/100ML; 150MG/100ML; 200MG/100ML; 120MG/100ML	N016822 003	
---------	---	-------------	--

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 10% W/ ELECTROLYTES

HOSPIRA	10%; 102MG/100ML; 45MG/100ML; 522MG/100ML; 410MG/100ML	N019437 004	Apr 03, 1986
---------	--	-------------	--------------

AMINOSYN II 8.5% W/ ELECTROLYTES

HOSPIRA	8.5%; 102MG/100ML; 45MG/100ML; 522MG/100ML; 410MG/100ML	N019437 005	Apr 03, 1986
---------	---	-------------	--------------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 7% W/ ELECTROLYTES

HOSPIRA	7%; 102MG/100ML; 522MG/100ML; 410MG/100ML	N017789 002	
---------	---	-------------	--

AMINOSYN 8.5% W/ ELECTROLYTES

HOSPIRA	8.5%; 102MG/100ML; 522MG/100ML; 410MG/100ML	N017673 005	
---------	---	-------------	--

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMINOCAPROIC ACID

AP	LUITPOLD	250MG/ML	A071192 001	Dec 01, 1987
-----------	----------	-----------------	--------------------	--------------

AMINOCAPROIC ACID IN PLASTIC CONTAINER

AP	+ HOSPIRA	250MG/ML	A070010 001	Mar 09, 1987
-----------	-----------	-----------------	--------------------	--------------

SYRUP; ORAL

AMICAR

AA	+ CLOVER PHARMS	1.25GM/5ML	N015230 002	
-----------	-----------------	-------------------	--------------------	--

AMINOCAPROIC ACID

AA	AKORN	1.25GM/5ML	A074759 001	Sep 02, 1998
-----------	-------	-------------------	--------------------	--------------

TABLET; ORAL

AMICAR

AB	CLOVER PHARMS	500MG	N015197 001	
-----------	---------------	--------------	--------------------	--

AMINOCAPROIC

AB	AKORN	500MG	A075602 001	May 24, 2001
-----------	-------	--------------	--------------------	--------------

AMICAR

	+ CLOVER PHARMS	1GM	N015197 002	Jun 24, 2004
--	-----------------	-----	-------------	--------------

AMINOLEVULINIC ACID HYDROCHLORIDE

GEL; TOPICAL

AMELUZ

	+ BIOFRONTERA	10%	N208081 001	May 10, 2016
--	---------------	-----	-------------	--------------

SOLUTION; TOPICAL

LEVULAN

	+ DUSA	20%	N020965 001	Dec 03, 1999
--	--------	-----	-------------	--------------

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLINE

AP	+ HOSPIRA	25MG/ML	A087242 001	Oct 26, 1983
-----------	-----------	----------------	--------------------	--------------

AP	LUITPOLD	25MG/ML	A087600 001	
-----------	----------	----------------	--------------------	--

AMINOSALICYLIC ACID

GRANULE, DELAYED RELEASE; ORAL

PASER

	+ JACOBUS	4GM/PACKET	A074346 001	Jun 30, 1994
--	-----------	------------	-------------	--------------

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

AP	+ AKORN	50MG/ML	A076232 001	Jul 05, 2006
-----------	---------	----------------	--------------------	--------------

AP	+ FRESENIUS KABI USA	50MG/ML	A075761 001	Oct 15, 2002
-----------	----------------------	----------------	--------------------	--------------

AP	+ GLAND PHARMA LTD	50MG/ML	A077161 001	Apr 20, 2005
-----------	--------------------	----------------	--------------------	--------------

AP	HIKMA FARMACEUTICA	50MG/ML	A077234 001	Feb 25, 2008
-----------	--------------------	----------------	--------------------	--------------

AP	+ HOSPIRA	50MG/ML	A075955 001	Oct 18, 2002
-----------	-----------	----------------	--------------------	--------------

AP	HOSPIRA INC	50MG/ML	A203884 001	Nov 25, 2013
-----------	-------------	----------------	--------------------	--------------

AP		50MG/ML	A203885 001	Nov 25, 2013
-----------	--	----------------	--------------------	--------------

AP	+ MYLAN INSTITUTIONAL	50MG/ML	A076217 001	Oct 15, 2002
-----------	-----------------------	----------------	--------------------	--------------

AP	WOCKHARDT	50MG/ML	A077610 001	Oct 30, 2008
-----------	-----------	----------------	--------------------	--------------

AP		50MG/ML	A077834 001	Oct 30, 2008
-----------	--	----------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

NEXTERONE

AP	BAXTER HLTHCARE	50MG/ML	N022325 001	Dec 24, 2008
	+	150MG/100ML (1.5MG/ML)	N022325 002	Nov 16, 2010
	+	360MG/200ML (1.8MG/ML)	N022325 003	Nov 16, 2010

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

AB	APOTEX INC	200MG	A078578 001	Nov 06, 2008
AB	AUROBINDO PHARMA LTD	200MG	A204742 001	Jun 03, 2016
AB	MURTY PHARMS	100MG	A077069 003	Oct 04, 2016
AB		200MG	A077069 001	Apr 08, 2005
AB		400MG	A077069 002	Apr 08, 2005
AB	MYLAN	200MG	A075188 001	Feb 24, 1999
AB	SANDOZ	200MG	A075315 001	Dec 23, 1998
AB		400MG	A075315 002	Jun 30, 2000
AB	SWAN PHARMS LLC	200MG	A075389 001	Jan 25, 2001
AB	TARO	100MG	A075424 002	Dec 18, 2002
AB		200MG	A075424 001	Mar 30, 2001
AB		400MG	A076362 001	Nov 29, 2002
AB	TEVA PHARMS	200MG	A074739 001	Nov 30, 1998
AB	ZYDUS PHARMS USA INC	200MG	A079029 001	Sep 16, 2008

CORDARONE

AB	+	WYETH PHARMS INC	200MG	N018972 001	Dec 24, 1985
-----------	---	------------------	--------------	--------------------	--------------

PACERONE

AB	UPSHER SMITH	100MG	A075135 002	Apr 12, 2005
AB		200MG	A075135 001	Apr 30, 1998

AMIODARONE HYDROCHLORIDE

TARO

300MG

A076362 002 Dec 02, 2003

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB	ACCORD HLTHCARE	10MG	A202446 001	Jun 04, 2014
AB		25MG	A202446 002	Jun 04, 2014
AB		50MG	A202446 003	Jun 04, 2014
AB		75MG	A202446 004	Jun 04, 2014
AB		100MG	A202446 005	Jun 04, 2014
AB		150MG	A202446 006	Jun 04, 2014
AB	MYLAN	10MG	A086009 002	
AB		25MG	A086009 003	
AB		50MG	A086009 001	
AB		75MG	A086009 004	
AB		100MG	A086009 005	
AB		150MG	A086009 006	
AB	SANDOZ	10MG	A085969 001	
AB	+	25MG	A085966 001	
AB		50MG	A085968 001	
AB		75MG	A085971 001	
AB		100MG	A085967 001	
AB		150MG	A085970 001	
AB	VINTAGE PHARMS	10MG	A040218 001	Sep 11, 1997
AB		25MG	A040218 002	Sep 11, 1997
AB		50MG	A040218 003	Sep 11, 1997
AB		75MG	A040218 004	Sep 11, 1997
AB		100MG	A040218 005	Sep 11, 1997
AB		150MG	A040218 006	Sep 11, 1997

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

MYLAN PHARMS INC

EQ 12.5MG BASE; 5MG

A071297 002 Dec 10, 1986

+

EQ 25MG BASE; 10MG

A071297 001 Dec 10, 1986

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

MYLAN

10MG; 2MG

A071443 002 Nov 10, 1988

10MG; 4MG

A071443 003 Nov 10, 1988

+

25MG; 2MG

A071443 004 Nov 10, 1988

+

25MG; 4MG

A071443 005 Nov 10, 1988

+

50MG; 4MG

A071443 001 Nov 10, 1988

PRESCRIPTION DRUG PRODUCT LIST

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 2.5MG BASE</u>	<u>A202553 001</u>	Apr 29, 2013
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A202553 002</u>	Apr 29, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A202553 003</u>	Apr 29, 2013
<u>AB</u>	ALKEM	<u>EQ 2.5MG BASE</u>	<u>A078925 001</u>	May 04, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078925 002</u>	May 04, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078925 003</u>	May 04, 2009
<u>AB</u>	AMNEAL PHARMS NY	<u>EQ 2.5MG BASE</u>	<u>A078477 001</u>	Jan 16, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078477 002</u>	Jan 16, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078477 003</u>	Jan 16, 2008
<u>AB</u>	APOTEX	<u>EQ 2.5MG BASE</u>	<u>A076719 001</u>	May 23, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076719 002</u>	May 23, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076719 003</u>	May 23, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 2.5MG BASE</u>	<u>A078021 001</u>	Jul 17, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078021 002</u>	Jul 17, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078021 003</u>	Jul 17, 2007
<u>AB</u>	CHINA RESOURCES	<u>EQ 2.5MG BASE</u>	<u>A090752 003</u>	May 16, 2016
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090752 001</u>	Apr 15, 2011
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090752 002</u>	Apr 15, 2011
<u>AB</u>	CIPLA LTD	<u>EQ 2.5MG BASE</u>	<u>A077073 001</u>	Sep 26, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077073 002</u>	Sep 26, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077073 003</u>	Sep 26, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 2.5MG BASE</u>	<u>A076692 001</u>	Jul 20, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076692 002</u>	Jul 20, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076692 003</u>	Jul 20, 2007
<u>AB</u>	EPIC PHARMA LLC	<u>EQ 2.5MG BASE</u>	<u>A078552 001</u>	Apr 08, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078552 002</u>	Apr 08, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078552 003</u>	Apr 08, 2009
<u>AB</u>	HIKMA PHARMS	<u>EQ 2.5MG BASE</u>	<u>A077771 001</u>	Apr 12, 2011
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077771 002</u>	Apr 12, 2011
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077771 003</u>	Apr 12, 2011
<u>AB</u>	INVAGEN PHARMS	<u>EQ 2.5MG BASE</u>	<u>A077955 001</u>	Aug 28, 2007
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A206367 001</u>	Dec 10, 2015
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077955 002</u>	Aug 28, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A206367 002</u>	Dec 10, 2015
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077955 003</u>	Aug 28, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A206367 003</u>	Dec 10, 2015
<u>AB</u>	LUPIN	<u>EQ 2.5MG BASE</u>	<u>A078043 001</u>	Jul 12, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078043 002</u>	Jul 12, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078043 003</u>	Jul 12, 2007
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 5MG BASE</u>	<u>A201380 001</u>	Apr 13, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A201380 002</u>	Apr 13, 2012
<u>AB</u>	MYLAN	<u>EQ 2.5MG BASE</u>	<u>A076418 001</u>	Oct 03, 2005
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076418 002</u>	Oct 03, 2005
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076418 003</u>	Oct 03, 2005
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 2.5MG BASE</u>	<u>A078224 001</u>	Feb 27, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078224 002</u>	Feb 27, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078224 003</u>	Feb 27, 2008
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 2.5MG BASE</u>	<u>A078453 001</u>	Jul 02, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078453 002</u>	Jul 02, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078453 003</u>	Jul 02, 2009
<u>AB</u>	POLYGEN PHARMS	<u>EQ 2.5MG BASE</u>	<u>A207821 001</u>	Jul 11, 2016
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A207821 002</u>	Jul 11, 2016
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A207821 003</u>	Jul 11, 2016
<u>AB</u>	SOVEREIGN PHARMS	<u>EQ 2.5MG BASE</u>	<u>A204900 001</u>	Jul 23, 2015
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A204900 002</u>	Jul 23, 2015
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A204900 003</u>	Jul 23, 2015
<u>AB</u>	SUN PHARM INDS INC	<u>EQ 2.5MG BASE</u>	<u>A078231 001</u>	Nov 30, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078231 002</u>	Nov 30, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078231 003</u>	Nov 30, 2007
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 2.5MG BASE</u>	<u>A077974 001</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077974 002</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077974 003</u>	Jul 09, 2007
<u>AB</u>	TEVA	<u>EQ 2.5MG BASE</u>	<u>A076846 001</u>	Jun 28, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076846 002</u>	Jun 28, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076846 003</u>	Jun 28, 2007
<u>AB</u>	TORRENT PHARMS	<u>EQ 2.5MG BASE</u>	<u>A078573 001</u>	Sep 22, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078573 002</u>	Sep 22, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078573 003</u>	Sep 22, 2008
<u>AB</u>	UNICHEM LABS LTD	<u>EQ 2.5MG BASE</u>	<u>A203245 001</u>	Oct 21, 2013

PRESCRIPTION DRUG PRODUCT LIST

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A203245 002</u>	Oct 21, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203245 003</u>	Oct 21, 2013
<u>AB</u>	UPSHER SMITH	<u>EQ 2.5MG BASE</u>	<u>A077759 001</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077759 002</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077759 003</u>	Jul 09, 2007
<u>AB</u>	VINTAGE	<u>EQ 2.5MG BASE</u>	<u>A078414 001</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078414 002</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078414 003</u>	Apr 07, 2010
<u>AB</u>	VIVIMED LABS	<u>EQ 2.5MG BASE</u>	<u>A077516 001</u>	Jul 11, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077516 002</u>	Jul 11, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077516 003</u>	Jul 11, 2007
<u>AB</u>	WATSON LABS	<u>EQ 2.5MG BASE</u>	<u>A077671 001</u>	Jul 19, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077671 002</u>	Jul 19, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077671 003</u>	Jul 19, 2007
<u>AB</u>	WEST-WARD PHARMS INT	<u>EQ 2.5MG BASE</u>	<u>A077262 001</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077262 002</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077262 003</u>	Jul 09, 2007
<u>AB</u>	WOCKHARDT	<u>EQ 2.5MG BASE</u>	<u>A078500 001</u>	Sep 06, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078500 002</u>	Sep 06, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078500 003</u>	Sep 06, 2007
<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 2.5MG BASE</u>	<u>A078226 001</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078226 002</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078226 003</u>	Jul 09, 2007
<u>NORVASC</u>				
<u>AB</u>	PFIZER	<u>EQ 2.5MG BASE</u>	<u>N019787 001</u>	Jul 31, 1992
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>N019787 002</u>	Jul 31, 1992
<u>AB</u>	+	<u>EQ 10MG BASE</u>	<u>N019787 003</u>	Jul 31, 1992

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET; ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 2.5MG BASE;EQ 10MG BASE</u>	<u>A203874 001</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 2.5MG BASE;EQ 20MG BASE</u>	<u>A203874 002</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 2.5MG BASE;EQ 40MG BASE</u>	<u>A203874 003</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 5MG BASE;EQ 10MG BASE</u>	<u>A203874 004</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 5MG BASE;EQ 20MG BASE</u>	<u>A203874 005</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 5MG BASE;EQ 40MG BASE</u>	<u>A203874 006</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 5MG BASE;EQ 80MG BASE</u>	<u>A203874 007</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 10MG BASE;EQ 10MG BASE</u>	<u>A203874 008</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 10MG BASE;EQ 20MG BASE</u>	<u>A203874 009</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 10MG BASE;EQ 40MG BASE</u>	<u>A203874 010</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 10MG BASE;EQ 80MG BASE</u>	<u>A203874 011</u>	Mar 07, 2014
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 2.5MG BASE;EQ 10MG BASE</u>	<u>A200465 001</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 2.5MG BASE;EQ 20MG BASE</u>	<u>A200465 002</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 2.5MG BASE;EQ 40MG BASE</u>	<u>A200465 003</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 5MG BASE;EQ 10MG BASE</u>	<u>A200465 004</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 5MG BASE;EQ 20MG BASE</u>	<u>A200465 005</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 5MG BASE;EQ 40MG BASE</u>	<u>A200465 006</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 5MG BASE;EQ 80MG BASE</u>	<u>A200465 007</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 10MG BASE;EQ 10MG BASE</u>	<u>A200465 008</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 10MG BASE;EQ 20MG BASE</u>	<u>A200465 009</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 10MG BASE;EQ 40MG BASE</u>	<u>A200465 010</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 10MG BASE;EQ 80MG BASE</u>	<u>A200465 011</u>	Nov 29, 2013
<u>CADUET</u>				
<u>AB</u>	PFIZER	<u>EQ 2.5MG BASE;EQ 10MG BASE</u>	<u>N021540 009</u>	Jul 29, 2004
<u>AB</u>		<u>EQ 2.5MG BASE;EQ 20MG BASE</u>	<u>N021540 010</u>	Jul 29, 2004
<u>AB</u>		<u>EQ 2.5MG BASE;EQ 40MG BASE</u>	<u>N021540 011</u>	Jul 29, 2004
<u>AB</u>		<u>EQ 5MG BASE;EQ 10MG BASE</u>	<u>N021540 001</u>	Jan 30, 2004
<u>AB</u>		<u>EQ 5MG BASE;EQ 20MG BASE</u>	<u>N021540 002</u>	Jan 30, 2004
<u>AB</u>		<u>EQ 5MG BASE;EQ 40MG BASE</u>	<u>N021540 003</u>	Jan 30, 2004
<u>AB</u>		<u>EQ 5MG BASE;EQ 80MG BASE</u>	<u>N021540 004</u>	Jan 30, 2004
<u>AB</u>		<u>EQ 10MG BASE;EQ 10MG BASE</u>	<u>N021540 005</u>	Jan 30, 2004
<u>AB</u>		<u>EQ 10MG BASE;EQ 20MG BASE</u>	<u>N021540 006</u>	Jan 30, 2004
<u>AB</u>		<u>EQ 10MG BASE;EQ 40MG BASE</u>	<u>N021540 007</u>	Jan 30, 2004
<u>AB</u>	+	<u>EQ 10MG BASE;EQ 80MG BASE</u>	<u>N021540 008</u>	Jan 30, 2004

PRESCRIPTION DRUG PRODUCT LIST

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

AB	APOTEX INC	EQ 2.5MG BASE;10MG	A091431 001	Dec 30, 2013
AB		EQ 5MG BASE;10MG	A091431 002	Dec 30, 2013
AB		EQ 5MG BASE;20MG	A091431 003	Dec 30, 2013
AB		EQ 5MG BASE;40MG	A091431 004	Dec 30, 2013
AB		EQ 10MG BASE;20MG	A091431 005	Dec 30, 2013
AB		EQ 10MG BASE;40MG	A091431 006	Dec 30, 2013
AB	AUROBINDO PHARMA LTD	EQ 2.5MG BASE;10MG	A202239 001	Sep 05, 2012
AB		EQ 5MG BASE;10MG	A202239 002	Sep 05, 2012
AB		EQ 5MG BASE;20MG	A202239 003	Sep 05, 2012
AB		EQ 5MG BASE;40MG	A202239 004	Sep 05, 2012
AB		EQ 10MG BASE;20MG	A202239 005	Sep 05, 2012
AB		EQ 10MG BASE;40MG	A202239 006	Sep 05, 2012
AB	DR REDDYS LABS INC	EQ 2.5MG BASE;10MG	A077183 001	Apr 15, 2010
AB		EQ 5MG BASE;10MG	A077183 002	Apr 15, 2010
AB		EQ 5MG BASE;20MG	A077183 003	Apr 15, 2010
AB		EQ 5MG BASE;40MG	A090149 001	Jul 05, 2011
AB		EQ 10MG BASE;20MG	A077183 004	Apr 15, 2010
AB		EQ 10MG BASE;40MG	A090149 002	Jul 05, 2011
AB	LUPIN PHARMS	EQ 2.5MG BASE;10MG	A078466 001	Feb 05, 2010
AB		EQ 5MG BASE;10MG	A078466 002	Feb 05, 2010
AB		EQ 5MG BASE;20MG	A078466 003	Feb 05, 2010
AB		EQ 5MG BASE;40MG	A078466 005	Jul 05, 2011
AB		EQ 10MG BASE;20MG	A078466 004	Feb 05, 2010
AB		EQ 10MG BASE;40MG	A078466 006	Jul 05, 2011
AB	MYLAN	EQ 2.5MG BASE;10MG	A077375 001	May 21, 2010
AB		EQ 5MG BASE;10MG	A077375 002	May 21, 2010
AB		EQ 5MG BASE;20MG	A077375 003	May 21, 2010
AB		EQ 5MG BASE;40MG	A079047 001	Jul 05, 2011
AB		EQ 10MG BASE;20MG	A077375 004	May 21, 2010
AB		EQ 10MG BASE;40MG	A079047 002	Jul 05, 2011
AB	PAR PHARM	EQ 2.5MG BASE;10MG	A078381 001	Jul 29, 2010
AB		EQ 5MG BASE;10MG	A078381 002	Jul 29, 2010
AB		EQ 5MG BASE;20MG	A078381 003	Jul 29, 2010
AB		EQ 5MG BASE;40MG	A078381 005	Jul 29, 2010
AB		EQ 10MG BASE;20MG	A078381 004	Jul 29, 2010
AB		EQ 10MG BASE;40MG	A078381 006	Jul 29, 2010
AB	TEVA PHARMS	EQ 2.5MG BASE;10MG	A077179 001	May 18, 2007
AB		EQ 5MG BASE;10MG	A077179 002	May 18, 2007
AB		EQ 5MG BASE;20MG	A077179 003	May 18, 2007
AB		EQ 5MG BASE;40MG	A077179 005	Jul 05, 2011
AB		EQ 10MG BASE;20MG	A077179 004	May 18, 2007
AB		EQ 10MG BASE;40MG	A077179 006	Jul 05, 2011
AB	WATSON LABS	EQ 2.5MG BASE;10MG	A077890 001	Oct 14, 2010
AB		EQ 5MG BASE;10MG	A077890 002	Oct 14, 2010
AB		EQ 5MG BASE;20MG	A077890 003	Oct 14, 2010
AB		EQ 10MG BASE;20MG	A077890 004	Oct 14, 2010
AB	WATSON LABS INC	EQ 5MG BASE;40MG	A090364 001	Jul 05, 2011
AB		EQ 10MG BASE;40MG	A090364 002	Jul 05, 2011
LOTREL				
AB	NOVARTIS	EQ 2.5MG BASE;10MG	N020364 002	Mar 03, 1995
AB		EQ 5MG BASE;10MG	N020364 003	Mar 03, 1995
AB		EQ 5MG BASE;20MG	N020364 004	Mar 03, 1995
AB		EQ 5MG BASE;40MG	N020364 007	Apr 11, 2006
AB		EQ 10MG BASE;20MG	N020364 005	Jun 20, 2002
AB	+	EQ 10MG BASE;40MG	N020364 006	Apr 11, 2006

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE

AB	PAR PHARM INC	EQ 5MG BASE;12.5MG;20MG	A206137 001	Oct 26, 2016
AB		EQ 5MG BASE;12.5MG;40MG	A206137 002	Oct 26, 2016
AB		EQ 5MG BASE;25MG;40MG	A206137 003	Oct 26, 2016
AB		EQ 10MG BASE;12.5MG;40MG	A206137 004	Oct 26, 2016
AB		EQ 10MG BASE;25MG;40MG	A206137 005	Oct 26, 2016
AB	TEVA PHARMS USA	EQ 5MG BASE;12.5MG;20MG	A202491 001	Nov 03, 2016
AB		EQ 5MG BASE;12.5MG;40MG	A202491 002	Nov 03, 2016
AB		EQ 5MG BASE;25MG;40MG	A202491 003	Nov 03, 2016
AB		EQ 10MG BASE;12.5MG;40MG	A202491 004	Nov 03, 2016
AB		EQ 10MG BASE;25MG;40MG	A202491 005	Nov 03, 2016
AB	TORRENT PHARMS LTD	EQ 5MG BASE;12.5MG;20MG	A203580 001	Oct 26, 2016

PRESCRIPTION DRUG PRODUCT LIST

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE

<u>AB</u>		<u>EQ 5MG BASE;12.5MG;40MG</u>	<u>A203580 002</u>	Oct 26, 2016
<u>AB</u>		<u>EQ 5MG BASE;25MG;40MG</u>	<u>A203580 003</u>	Oct 26, 2016
<u>AB</u>		<u>EQ 10MG BASE;12.5MG;40MG</u>	<u>A203580 004</u>	Oct 26, 2016
<u>AB</u>		<u>EQ 10MG BASE;25MG;40MG</u>	<u>A203580 005</u>	Oct 26, 2016

TRIBENZOR

<u>AB</u>	DAIICHI SANKYO	<u>EQ 5MG BASE;12.5MG;20MG</u>	<u>N200175 001</u>	Jul 23, 2010
<u>AB</u>		<u>EQ 5MG BASE;12.5MG;40MG</u>	<u>N200175 002</u>	Jul 23, 2010
<u>AB</u>		<u>EQ 5MG BASE;25MG;40MG</u>	<u>N200175 003</u>	Jul 23, 2010
<u>AB</u>		<u>EQ 10MG BASE;12.5MG;40MG</u>	<u>N200175 004</u>	Jul 23, 2010
<u>AB</u>	+	<u>EQ 10MG BASE;25MG;40MG</u>	<u>N200175 005</u>	Jul 23, 2010

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

<u>AB</u>	LUPIN LTD	<u>5MG;12.5MG;160MG</u>	<u>A200797 001</u>	Jun 03, 2015
<u>AB</u>		<u>5MG;25MG;160MG</u>	<u>A200797 002</u>	Jun 03, 2015
<u>AB</u>		<u>10MG;12.5MG;160MG</u>	<u>A200797 003</u>	Jun 03, 2015
<u>AB</u>		<u>10MG;25MG;160MG</u>	<u>A200797 004</u>	Jun 03, 2015
<u>AB</u>		<u>10MG;25MG;320MG</u>	<u>A200797 005</u>	Jun 03, 2015
<u>AB</u>	PAR PHARM	<u>5MG;12.5MG;160MG</u>	<u>A201087 001</u>	Jun 01, 2015
<u>AB</u>		<u>5MG;25MG;160MG</u>	<u>A201087 002</u>	Jun 01, 2015
<u>AB</u>		<u>10MG;12.5MG;160MG</u>	<u>A201087 003</u>	Jun 01, 2015
<u>AB</u>		<u>10MG;25MG;160MG</u>	<u>A201087 004</u>	Jun 01, 2015
<u>AB</u>		<u>10MG;25MG;320MG</u>	<u>A201087 005</u>	Jun 01, 2015
<u>AB</u>	TEVA PHARMS	<u>5MG;12.5MG;160MG</u>	<u>A200435 001</u>	Sep 25, 2012
<u>AB</u>		<u>5MG;25MG;160MG</u>	<u>A200435 002</u>	Sep 25, 2012
<u>AB</u>		<u>10MG;12.5MG;160MG</u>	<u>A200435 005</u>	Sep 25, 2012
<u>AB</u>		<u>10MG;25MG;160MG</u>	<u>A200435 003</u>	Sep 25, 2012
<u>AB</u>		<u>10MG;25MG;320MG</u>	<u>A200435 004</u>	Sep 25, 2012
<u>AB</u>	TORRENT PHARMS LTD	<u>5MG;12.5MG;160MG</u>	<u>A201593 001</u>	Jun 03, 2015
<u>AB</u>		<u>5MG;25MG;160MG</u>	<u>A201593 002</u>	Jun 03, 2015
<u>AB</u>		<u>10MG;12.5MG;160MG</u>	<u>A201593 003</u>	Jun 03, 2015
<u>AB</u>		<u>10MG;25MG;160MG</u>	<u>A201593 004</u>	Jun 03, 2015
<u>AB</u>		<u>10MG;25MG;320MG</u>	<u>A201593 005</u>	Jun 03, 2015
<u>AB</u>	NOVARTIS	<u>5MG;12.5MG;160MG</u>	<u>N022314 001</u>	Apr 30, 2009
<u>AB</u>		<u>5MG;25MG;160MG</u>	<u>N022314 002</u>	Apr 30, 2009
<u>AB</u>		<u>10MG;12.5MG;160MG</u>	<u>N022314 003</u>	Apr 30, 2009
<u>AB</u>		<u>10MG;25MG;160MG</u>	<u>N022314 004</u>	Apr 30, 2009
<u>AB</u>	+	<u>10MG;25MG;320MG</u>	<u>N022314 005</u>	Apr 30, 2009

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

<u>AB</u>	AJANTA PHARMA LTD	<u>EQ 5MG BASE;20MG</u>	<u>A207216 001</u>	Oct 28, 2016
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A207216 002</u>	Oct 28, 2016
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A207216 003</u>	Oct 28, 2016
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A207216 004</u>	Oct 28, 2016
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 5MG BASE;20MG</u>	<u>A206884 001</u>	Oct 26, 2016
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A206884 003</u>	Oct 26, 2016
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A206884 002</u>	Oct 26, 2016
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A206884 004</u>	Oct 26, 2016
<u>AB</u>	TEVA PHARMS USA	<u>EQ 5MG BASE;20MG</u>	<u>A091154 001</u>	Oct 26, 2016
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A091154 002</u>	Oct 26, 2016
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A091154 003</u>	Oct 26, 2016
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A091154 004</u>	Oct 26, 2016
<u>AB</u>	TORRENT PHARMS LLC	<u>EQ 5MG BASE;20MG</u>	<u>A202933 001</u>	Nov 25, 2016
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A202933 002</u>	Nov 25, 2016
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A202933 003</u>	Nov 25, 2016
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A202933 004</u>	Nov 25, 2016
<u>AB</u>	AZOR			
<u>AB</u>	DAIICHI SANKYO	<u>EQ 5MG BASE;20MG</u>	<u>N022100 001</u>	Sep 26, 2007
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>N022100 002</u>	Sep 26, 2007
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>N022100 003</u>	Sep 26, 2007
<u>AB</u>	+	<u>EQ 10MG BASE;40MG</u>	<u>N022100 004</u>	Sep 26, 2007

PRESCRIPTION DRUG PRODUCT LIST

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE

TABLET; ORAL

PRESTALIA

	SYMPLMED PHARMS LLC	EQ 2.5MG BASE;3.5MG	N205003	001	Jan 21, 2015
		EQ 5MG BASE;7MG	N205003	002	Jan 21, 2015
+		EQ 10MG BASE;14MG	N205003	003	Jan 21, 2015

AMLODIPINE BESYLATE; TELMISARTAN

TABLET; ORAL

TELMISARTAN AND AMLODIPINE

AB	ALEMBIC PHARMS LTD	<u>EQ 5MG BASE;40MG</u>	<u>A205234</u>	<u>001</u>	Nov 17, 2016
AB		<u>EQ 5MG BASE;80MG</u>	<u>A205234</u>	<u>003</u>	Nov 17, 2016
AB		<u>EQ 10MG BASE;40MG</u>	<u>A205234</u>	<u>002</u>	Nov 17, 2016
AB		<u>EQ 10MG BASE;80MG</u>	<u>A205234</u>	<u>004</u>	Nov 17, 2016
AB	LUPIN LTD	<u>EQ 5MG BASE;40MG</u>	<u>A201586</u>	<u>001</u>	Jan 08, 2014
AB		<u>EQ 5MG BASE;80MG</u>	<u>A201586</u>	<u>003</u>	Jan 08, 2014
AB		<u>EQ 10MG BASE;40MG</u>	<u>A201586</u>	<u>002</u>	Jan 08, 2014
AB		<u>EQ 10MG BASE;80MG</u>	<u>A201586</u>	<u>004</u>	Jan 08, 2014
AB	MYLAN PHARMS INC	<u>EQ 5MG BASE;40MG</u>	<u>A202516</u>	<u>001</u>	Aug 26, 2014
AB		<u>EQ 5MG BASE;80MG</u>	<u>A202516</u>	<u>003</u>	Aug 26, 2014
AB		<u>EQ 10MG BASE;40MG</u>	<u>A202516</u>	<u>002</u>	Aug 26, 2014
AB		<u>EQ 10MG BASE;80MG</u>	<u>A202516</u>	<u>004</u>	Aug 26, 2014
AB	TORRENT PHARMS LTD	<u>EQ 5MG BASE;40MG</u>	<u>A202517</u>	<u>001</u>	Jan 08, 2014
AB		<u>EQ 5MG BASE;80MG</u>	<u>A202517</u>	<u>003</u>	Jan 08, 2014
AB		<u>EQ 10MG BASE;40MG</u>	<u>A202517</u>	<u>002</u>	Jan 08, 2014
AB		<u>EQ 10MG BASE;80MG</u>	<u>A202517</u>	<u>004</u>	Jan 08, 2014
	<u>TWYNSTA</u>				
AB	BOEHRINGER INGELHEIM	<u>EQ 5MG BASE;40MG</u>	<u>N022401</u>	<u>001</u>	Oct 16, 2009
AB		<u>EQ 5MG BASE;80MG</u>	<u>N022401</u>	<u>003</u>	Oct 16, 2009
AB		<u>EQ 10MG BASE;40MG</u>	<u>N022401</u>	<u>002</u>	Oct 16, 2009
AB	+	<u>EQ 10MG BASE;80MG</u>	<u>N022401</u>	<u>004</u>	Oct 16, 2009

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB	ALEMBIC PHARMS LTD	<u>EQ 5MG BASE;160MG</u>	<u>A202713</u>	<u>001</u>	Apr 03, 2015
AB		<u>EQ 5MG BASE;320MG</u>	<u>A202713</u>	<u>003</u>	Apr 03, 2015
AB		<u>EQ 10MG BASE;160MG</u>	<u>A202713</u>	<u>002</u>	Apr 03, 2015
AB		<u>EQ 10MG BASE;320MG</u>	<u>A202713</u>	<u>004</u>	Apr 03, 2015
AB	AUROBINDO PHARMA LTD	<u>EQ 5MG BASE;160MG</u>	<u>A206512</u>	<u>001</u>	Apr 22, 2016
AB		<u>EQ 5MG BASE;320MG</u>	<u>A206512</u>	<u>002</u>	Apr 22, 2016
AB		<u>EQ 10MG BASE;160MG</u>	<u>A206512</u>	<u>003</u>	Apr 22, 2016
AB		<u>EQ 10MG BASE;320MG</u>	<u>A206512</u>	<u>004</u>	Apr 22, 2016
AB	INVAGEN PHARMS	<u>EQ 5MG BASE;160MG</u>	<u>A205137</u>	<u>001</u>	Sep 16, 2016
AB		<u>EQ 5MG BASE;320MG</u>	<u>A205137</u>	<u>003</u>	Sep 16, 2016
AB		<u>EQ 10MG BASE;160MG</u>	<u>A205137</u>	<u>002</u>	Sep 16, 2016
AB		<u>EQ 10MG BASE;320MG</u>	<u>A205137</u>	<u>004</u>	Sep 16, 2016
AB	LUPIN	<u>EQ 5MG BASE;160MG</u>	<u>A090245</u>	<u>001</u>	Mar 30, 2015
AB		<u>EQ 5MG BASE;320MG</u>	<u>A090245</u>	<u>003</u>	Mar 30, 2015
AB		<u>EQ 10MG BASE;160MG</u>	<u>A090245</u>	<u>002</u>	Mar 30, 2015
AB		<u>EQ 10MG BASE;320MG</u>	<u>A090245</u>	<u>004</u>	Mar 30, 2015
AB	MYLAN PHARMS INC	<u>EQ 5MG BASE;160MG</u>	<u>A090483</u>	<u>001</u>	Mar 30, 2015
AB		<u>EQ 5MG BASE;320MG</u>	<u>A090483</u>	<u>003</u>	Mar 30, 2015
AB		<u>EQ 10MG BASE;160MG</u>	<u>A090483</u>	<u>002</u>	Mar 30, 2015
AB		<u>EQ 10MG BASE;320MG</u>	<u>A090483</u>	<u>004</u>	Mar 30, 2015
AB	NOVEL LABS INC	<u>EQ 5MG BASE;160MG</u>	<u>A202829</u>	<u>001</u>	Mar 30, 2015
AB		<u>EQ 5MG BASE;320MG</u>	<u>A202829</u>	<u>003</u>	Mar 30, 2015
AB		<u>EQ 10MG BASE;160MG</u>	<u>A202829</u>	<u>002</u>	Mar 30, 2015
AB		<u>EQ 10MG BASE;320MG</u>	<u>A202829</u>	<u>004</u>	Mar 30, 2015
AB	PAR PHARM INC	<u>EQ 5MG BASE;160MG</u>	<u>A090011</u>	<u>001</u>	Mar 28, 2013
AB		<u>EQ 5MG BASE;320MG</u>	<u>A090011</u>	<u>003</u>	Mar 28, 2013
AB		<u>EQ 10MG BASE;160MG</u>	<u>A090011</u>	<u>002</u>	Mar 28, 2013
AB		<u>EQ 10MG BASE;320MG</u>	<u>A090011</u>	<u>004</u>	Mar 28, 2013
AB	TEVA PHARMS USA	<u>EQ 5MG BASE;160MG</u>	<u>A091235</u>	<u>001</u>	Mar 30, 2015
AB		<u>EQ 5MG BASE;320MG</u>	<u>A091235</u>	<u>003</u>	Mar 30, 2015
AB		<u>EQ 10MG BASE;160MG</u>	<u>A091235</u>	<u>002</u>	Mar 30, 2015
AB		<u>EQ 10MG BASE;320MG</u>	<u>A091235</u>	<u>004</u>	Mar 30, 2015
AB	TORRENT PHARMS LTD	<u>EQ 5MG BASE;160MG</u>	<u>A202377</u>	<u>001</u>	Mar 30, 2015
AB		<u>EQ 5MG BASE;320MG</u>	<u>A202377</u>	<u>002</u>	Mar 30, 2015
AB		<u>EQ 10MG BASE;160MG</u>	<u>A202377</u>	<u>003</u>	Mar 30, 2015
AB		<u>EQ 10MG BASE;320MG</u>	<u>A202377</u>	<u>004</u>	Mar 30, 2015
	<u>EXFORGE</u>				
AB	NOVARTIS	<u>EQ 5MG BASE;160MG</u>	<u>N021990</u>	<u>002</u>	Jun 20, 2007

PRESCRIPTION DRUG PRODUCT LIST

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL

EXFORGE

<u>AB</u>		<u>EQ 5MG BASE;320MG</u>	<u>N021990 004</u>	Jun 20, 2007
<u>AB</u>	+	<u>EQ 10MG BASE;160MG</u>	<u>N021990 003</u>	Jun 20, 2007
<u>AB</u>	+	<u>EQ 10MG BASE;320MG</u>	<u>N021990 005</u>	Jun 20, 2007

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

<u>AP</u>	3D IMAGING DRUG	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203779 001</u>	Oct 19, 2015
<u>AP</u>	BIOMEDCL RES FDN	<u>48.75mCi-487.5mCi/13ML (3.75-37.5mCi/ML)</u>	<u>A204352 001</u>	May 01, 2015
<u>AP</u>	BRIGHAM WOMENS HOSP	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203783 001</u>	Oct 30, 2014
<u>AP</u>	CARDINAL HEALTH 414	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203700 001</u>	Feb 25, 2013
<u>AP</u>	+	<u>FEINSTEIN</u>	<u>N022119 001</u>	Aug 23, 2007
<u>AP</u>	GLOBAL ISOTOPES LLC	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204465 001</u>	Oct 23, 2014
<u>AP</u>	IBA MOLECULAR N AM	<u>18.8mCi-188mCi/5ML (3.75-37.5mCi/ML)</u>	<u>A204667 001</u>	Apr 22, 2015
<u>AP</u>	JOHNS HOPKINS UNIV	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204514 001</u>	Aug 19, 2014
<u>AP</u>	KREITCHMAN PET CTR	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203938 001</u>	Dec 09, 2013
<u>AP</u>	MA GENERAL HOSP	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A207025 001</u>	Feb 03, 2016
<u>AP</u>	MCPRF	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203321 001</u>	Feb 25, 2013
<u>AP</u>	MIDWEST MEDCL	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204457 001</u>	Nov 18, 2015
<u>AP</u>	MIPS CRF	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204535 001</u>	Nov 20, 2014
<u>AP</u>	PETNET	<u>30mCi-300mCi (3.75-37.5mCi/ML)</u>	<u>A204510 001</u>	Nov 02, 2015
<u>AP</u>	SPECTRON MRC LLC	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204455 001</u>	Apr 23, 2015
<u>AP</u>	UCLA BIOMEDICAL	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203812 001</u>	Jun 27, 2013
<u>AP</u>	UCSF RODIOPHARM	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204496 001</u>	Mar 28, 2014
<u>AP</u>	UNIV TX MD ANDERSON	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203933 001</u>	Jun 27, 2014
<u>AP</u>	WA UNIV SCH MED	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204506 001</u>	Feb 07, 2014
	ESSENTIAL ISOTOPES	3.75-260mCi/ML	A205687	001 Dec 17, 2015
	HOUSTON CYCLOTRON	3.75-260mCi/ML	A203543	001 Dec 14, 2012
	NCM USA BRONX LLC	3.75-260mCi/mL	A204515	001 Feb 04, 2015
	PRECISION NUCLEAR	3.75-260mCi/ML	A204547	001 Aug 14, 2015
	SHERTECH LABS LLC	3.75-260mCi/ML	A204366	001 Sep 19, 2014
	WI MEDCL CYCLOTRON	3.75-260mCi/ML	A204356	001 Dec 18, 2014

AMMONIUM CHLORIDE

INJECTABLE; INJECTION

AMMONIUM CHLORIDE IN PLASTIC CONTAINER

+ HOSPIRA

5MEQ/ML

A088366 001 Jun 13, 1984

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

<u>AB</u>	+	PERRIGO NEW YORK	<u>EQ 12% BASE</u>	<u>A075774 001</u>	May 01, 2002
<u>AB</u>		TARO	<u>EQ 12% BASE</u>	<u>A075883 001</u>	Apr 10, 2003
<u>AB</u>		WATSON LABS INC	<u>EQ 12% BASE</u>	<u>A076829 001</u>	Feb 07, 2006

LOTION; TOPICAL

AMMONIUM LACTATE

<u>AB</u>	+	PERRIGO NEW YORK	<u>EQ 12% BASE</u>	<u>A075570 001</u>	Jun 23, 2004
<u>AB</u>		TARO	<u>EQ 12% BASE</u>	<u>A076216 001</u>	May 28, 2004
<u>AB</u>		WATSON LABS INC	<u>EQ 12% BASE</u>	<u>A075575 001</u>	Jun 11, 2002

AMOXAPINE

TABLET; ORAL

AMOXAPINE

WATSON LABS

25MG

A072688 001 Aug 28, 1992

50MG

A072689 001 Aug 28, 1992

100MG

A072690 001 Aug 28, 1992

+

150MG

A072691 001 Aug 28, 1992

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

<u>AB</u>	AM ANTI-BIOTICS	<u>250MG</u>	<u>A062058 001</u>	
<u>AB</u>		<u>500MG</u>	<u>A062058 002</u>	
<u>AB</u>	AUROBINDO	<u>250MG</u>	<u>A065271 001</u>	Nov 09, 2005
<u>AB</u>		<u>500MG</u>	<u>A065271 002</u>	Nov 09, 2005
<u>AB</u>	DAVA PHARMS INC	<u>250MG</u>	<u>A062884 001</u>	Feb 25, 1988
<u>AB</u>		<u>500MG</u>	<u>A062881 001</u>	Feb 25, 1988
<u>AB</u>	HIKMA PHARMS	<u>250MG</u>	<u>A065291 001</u>	Feb 05, 2007
<u>AB</u>		<u>500MG</u>	<u>A065291 002</u>	Feb 05, 2007
<u>AB</u>	SANDOZ	<u>250MG</u>	<u>A064076 001</u>	Sep 30, 1994
<u>AB</u>		<u>500MG</u>	<u>A064076 002</u>	Sep 30, 1994

PRESCRIPTION DRUG PRODUCT LIST

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

<u>AB</u>	TEVA	<u>250MG</u>	<u>A061926</u>	<u>001</u>	
<u>AB</u>	+	<u>500MG</u>	<u>A061926</u>	<u>003</u>	

AMOXIL

<u>AB</u>	DR REDDYS LABS INC	<u>250MG</u>	<u>A062216</u>	<u>001</u>	
<u>AB</u>		<u>500MG</u>	<u>A062216</u>	<u>004</u>	

FOR SUSPENSION; ORAL

AMOXICILLIN

<u>AB</u>	AUROBINDO	<u>200MG/5ML</u>	<u>A065334</u>	<u>001</u>	Dec 28, 2006
<u>AB</u>		<u>400MG/5ML</u>	<u>A065334</u>	<u>002</u>	Dec 28, 2006
<u>AB</u>	AUROBINDO PHARMA LTD	<u>125MG/5ML</u>	<u>A204030</u>	<u>001</u>	Sep 15, 2014
<u>AB</u>		<u>250MG/5ML</u>	<u>A204030</u>	<u>002</u>	Sep 15, 2014
<u>AB</u>	DAVA PHARMS INC	<u>125MG/5ML</u>	<u>A062927</u>	<u>001</u>	Nov 25, 1988
<u>AB</u>		<u>250MG/5ML</u>	<u>A062927</u>	<u>002</u>	Nov 25, 1988
<u>AB</u>	HIKMA	<u>125MG/5ML</u>	<u>A065322</u>	<u>002</u>	Jun 19, 2006
<u>AB</u>		<u>200MG/5ML</u>	<u>A065325</u>	<u>002</u>	Jun 19, 2006
<u>AB</u>		<u>250MG/5ML</u>	<u>A065322</u>	<u>001</u>	Jun 19, 2006
<u>AB</u>		<u>400MG/5ML</u>	<u>A065325</u>	<u>001</u>	Jun 19, 2006
<u>AB</u>	SANDOZ	<u>125MG/5ML</u>	<u>A065387</u>	<u>001</u>	Mar 26, 2007
<u>AB</u>		<u>200MG/5ML</u>	<u>A065378</u>	<u>001</u>	Mar 26, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065387</u>	<u>002</u>	Mar 26, 2007
<u>AB</u>		<u>400MG/5ML</u>	<u>A065378</u>	<u>002</u>	Mar 26, 2007
<u>AB</u>	TEVA	<u>125MG/5ML</u>	<u>A061931</u>	<u>001</u>	
<u>AB</u>		<u>200MG/5ML</u>	<u>A065119</u>	<u>001</u>	Dec 04, 2002
<u>AB</u>	+	<u>250MG/5ML</u>	<u>A061931</u>	<u>002</u>	
<u>AB</u>	+	<u>400MG/5ML</u>	<u>A065119</u>	<u>002</u>	Dec 04, 2002
<u>AB</u>	WOCKHARDT	<u>400MG/5ML</u>	<u>A065319</u>	<u>002</u>	Jun 18, 2007

AMOXICILLIN PEDIATRIC

<u>AB</u>	TEVA	<u>50MG/ML</u>	<u>A061931</u>	<u>003</u>	Dec 01, 1982
-----------	------	----------------	----------------	------------	--------------

AMOXIL

<u>AB</u>	DR REDDYS LABS INC	<u>50MG/ML</u>	<u>A062226</u>	<u>005</u>	
<u>AB</u>		<u>125MG/5ML</u>	<u>A062226</u>	<u>001</u>	
<u>AB</u>		<u>200MG/5ML</u>	<u>N050760</u>	<u>001</u>	Apr 15, 1999
<u>AB</u>		<u>250MG/5ML</u>	<u>A062226</u>	<u>002</u>	
<u>AB</u>		<u>400MG/5ML</u>	<u>N050760</u>	<u>002</u>	Apr 15, 1999

LAROTID

<u>AB</u>	DR REDDYS LABS INC	<u>125MG/5ML</u>	<u>A062226</u>	<u>003</u>	
<u>AB</u>		<u>250MG/5ML</u>	<u>A062226</u>	<u>004</u>	

TABLET; ORAL

AMOXICILLIN

<u>AB</u>	AUROBINDO	<u>500MG</u>	<u>A065256</u>	<u>001</u>	Nov 09, 2005
<u>AB</u>		<u>875MG</u>	<u>A065256</u>	<u>002</u>	Nov 09, 2005
<u>AB</u>	HIKMA	<u>875MG</u>	<u>A065255</u>	<u>001</u>	Mar 29, 2006
<u>AB</u>	SANDOZ	<u>500MG</u>	<u>A065228</u>	<u>001</u>	Jul 13, 2005
<u>AB</u>		<u>875MG</u>	<u>A065228</u>	<u>002</u>	Jul 13, 2005
<u>AB</u>	TEVA	<u>500MG</u>	<u>A065056</u>	<u>001</u>	Sep 18, 2000
<u>AB</u>	+	<u>875MG</u>	<u>A065056</u>	<u>002</u>	Sep 18, 2000

AMOXIL

<u>AB</u>	DR REDDYS LABS INC	<u>500MG</u>	<u>N050754</u>	<u>002</u>	Jul 10, 1998
<u>AB</u>		<u>875MG</u>	<u>N050754</u>	<u>001</u>	Jul 10, 1998

TABLET, CHEWABLE; ORAL

AMOXICILLIN

<u>AB</u>	TEVA	<u>125MG</u>	<u>A064013</u>	<u>002</u>	Sep 11, 1995
<u>AB</u>	+	<u>250MG</u>	<u>A064013</u>	<u>001</u>	Dec 22, 1992

AMOXIL

<u>AB</u>	DR REDDYS LABS INC	<u>125MG</u>	<u>N050542</u>	<u>002</u>	
<u>AB</u>		<u>250MG</u>	<u>N050542</u>	<u>001</u>	

TABLET, EXTENDED RELEASE; ORAL

MOXATAG

+	VERNALIS R AND D LTD	775MG	N050813	001	Jan 23, 2008
---	----------------------	-------	---------	-----	--------------

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET; ORAL

LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN

<u>AB</u>	RISING PHARMS INC	<u>500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A, 30MG</u>	<u>A206006</u>	<u>001</u>	Oct 07, 2016
<u>AB</u>	SANDOZ INC	<u>500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A, 30MG</u>	<u>A202588</u>	<u>001</u>	Mar 04, 2014
<u>AB</u>	TEVA PHARMS USA	<u>500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A, 30MG</u>	<u>A200218</u>	<u>001</u>	Aug 30, 2013

PRESCRIPTION DRUG PRODUCT LIST

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET; ORAL

PREVPAC

AB	+	TAKEDA PHARMS USA	<u>500MG, N/A, N/A, N/A, 500MG, N/A, N/A, N/A, 30MG</u>	<u>N050757</u>	<u>001</u>	Dec 02, 1997
-----------	---	-------------------	---	----------------	------------	--------------

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED RELEASE; ORAL

OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

	+	GASTROENTERO	<u>500MG, N/A, N/A, N/A, 500MG, N/A, N/A, N/A, 20MG</u>	<u>N050824</u>	<u>001</u>	Feb 08, 2011
--	---	--------------	---	----------------	------------	--------------

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB		AUROBINDO PHARMA LTD	<u>200MG/5ML; EQ 28.5MG BASE/5ML</u>	<u>A201090</u>	<u>001</u>	Dec 20, 2011
AB			<u>400MG/5ML; EQ 57MG BASE/5ML</u>	<u>A201090</u>	<u>002</u>	Dec 20, 2011
AB			<u>600MG/5ML; EQ 42.9MG BASE/5ML</u>	<u>A201091</u>	<u>001</u>	Dec 20, 2011
AB		HIKMA PHARMS	<u>200MG/5ML; EQ 28.5MG BASE/5ML</u>	<u>A065191</u>	<u>002</u>	Jan 25, 2005
AB			<u>400MG/5ML; EQ 57MG BASE/5ML</u>	<u>A065191</u>	<u>001</u>	Jan 25, 2005
AB			<u>600MG/5ML; EQ 42.9MG BASE/5ML</u>	<u>A065373</u>	<u>001</u>	Nov 09, 2007
AB		SANDOZ	<u>200MG/5ML; EQ 28.5MG BASE/5ML</u>	<u>A065066</u>	<u>001</u>	Jun 05, 2002
AB			<u>400MG/5ML; EQ 57MG BASE/5ML</u>	<u>A065066</u>	<u>002</u>	Jun 05, 2002
AB		SANDOZ INC	<u>200MG/5ML; EQ 28.5MG BASE/5ML</u>	<u>A065098</u>	<u>001</u>	Dec 16, 2002
AB			<u>400MG/5ML; EQ 57MG BASE/5ML</u>	<u>A065098</u>	<u>002</u>	Dec 16, 2002
AB			<u>600MG/5ML; EQ 42.9MG BASE/5ML</u>	<u>A065358</u>	<u>001</u>	Aug 13, 2007
AB		TEVA	<u>200MG/5ML; EQ 28.5MG BASE/5ML</u>	<u>A065089</u>	<u>001</u>	May 25, 2004
AB	+		<u>400MG/5ML; EQ 57MG BASE/5ML</u>	<u>A065089</u>	<u>002</u>	May 25, 2004
AB	+		<u>600MG/5ML; EQ 42.9MG BASE/5ML</u>	<u>A065162</u>	<u>001</u>	Mar 12, 2004
AB		WOCKHARDT	<u>250MG/5ML; EQ 62.5MG BASE/5ML</u>	<u>A065431</u>	<u>001</u>	Nov 25, 2008
AB		WOCKHARDT EU OPERATN	<u>600MG/5ML; EQ 42.9MG BASE/5ML</u>	<u>A065420</u>	<u>001</u>	Dec 02, 2013

AUGMENTIN '125'

AB		DR REDDYS LABS INC	<u>125MG/5ML; EQ 31.25MG BASE/5ML</u>	<u>N050575</u>	<u>001</u>	Aug 06, 1984
-----------	--	--------------------	---------------------------------------	----------------	------------	--------------

AUGMENTIN '200'

AB		DR REDDYS LABS INC	<u>200MG/5ML; EQ 28.5MG BASE/5ML</u>	<u>N050725</u>	<u>001</u>	May 31, 1996
-----------	--	--------------------	--------------------------------------	----------------	------------	--------------

AUGMENTIN '250'

AB	+	DR REDDYS LABS INC	<u>250MG/5ML; EQ 62.5MG BASE/5ML</u>	<u>N050575</u>	<u>002</u>	Aug 06, 1984
-----------	---	--------------------	--------------------------------------	----------------	------------	--------------

AUGMENTIN '400'

AB		DR REDDYS LABS INC	<u>400MG/5ML; EQ 57MG BASE/5ML</u>	<u>N050725</u>	<u>002</u>	May 31, 1996
-----------	--	--------------------	------------------------------------	----------------	------------	--------------

AUGMENTIN ES-600

AB		DR REDDYS LABS INC	<u>600MG/5ML; EQ 42.9MG BASE/5ML</u>	<u>N050755</u>	<u>001</u>	Jun 22, 2001
-----------	--	--------------------	--------------------------------------	----------------	------------	--------------

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB		AUROBINDO PHARMA LTD	<u>250MG; EQ 125MG BASE</u>	<u>A091569</u>	<u>001</u>	Jan 20, 2012
AB			<u>500MG; EQ 125MG BASE</u>	<u>A091569</u>	<u>002</u>	Jan 20, 2012
AB			<u>875MG; EQ 125MG BASE</u>	<u>A091568</u>	<u>001</u>	Jan 20, 2012
AB		HIKMA PHARMS	<u>875MG; EQ 125MG BASE</u>	<u>A203824</u>	<u>001</u>	Aug 23, 2016
AB		MICRO LABS LTD INDIA	<u>250MG; EQ 125MG BASE</u>	<u>A205707</u>	<u>001</u>	Dec 30, 2016
AB			<u>500MG; EQ 125MG BASE</u>	<u>A205707</u>	<u>002</u>	Dec 30, 2016
AB			<u>875MG; EQ 125MG BASE</u>	<u>A204755</u>	<u>003</u>	Dec 30, 2016
AB		SANDOZ	<u>250MG; EQ 125MG BASE</u>	<u>A065189</u>	<u>001</u>	Aug 23, 2005
AB			<u>500MG; EQ 125MG BASE</u>	<u>A065064</u>	<u>001</u>	Mar 15, 2002
AB			<u>875MG; EQ 125MG BASE</u>	<u>A065063</u>	<u>001</u>	Mar 14, 2002
AB		SANDOZ INC	<u>500MG; EQ 125MG BASE</u>	<u>A065117</u>	<u>001</u>	Nov 27, 2002
AB			<u>875MG; EQ 125MG BASE</u>	<u>A065093</u>	<u>001</u>	Nov 21, 2002
AB		TEVA	<u>500MG; EQ 125MG BASE</u>	<u>A065101</u>	<u>001</u>	Oct 30, 2002
AB		TEVA PHARMS USA	<u>875MG; EQ 125MG BASE</u>	<u>A065096</u>	<u>001</u>	Oct 29, 2002

AUGMENTIN '250'

AB	+	DR REDDYS LABS INC	<u>250MG; EQ 125MG BASE</u>	<u>N050564</u>	<u>001</u>	Aug 06, 1984
-----------	---	--------------------	-----------------------------	----------------	------------	--------------

AUGMENTIN '500'

AB	+	DR REDDYS LABS INC	<u>500MG; EQ 125MG BASE</u>	<u>N050564</u>	<u>002</u>	Aug 06, 1984
-----------	---	--------------------	-----------------------------	----------------	------------	--------------

AUGMENTIN '875'

AB	+	DR REDDYS LABS INC	<u>875MG; EQ 125MG BASE</u>	<u>N050720</u>	<u>001</u>	Feb 13, 1996
-----------	---	--------------------	-----------------------------	----------------	------------	--------------

TABLET, CHEWABLE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB		TEVA	<u>200MG; EQ 28.5MG BASE</u>	<u>A065205</u>	<u>001</u>	Feb 09, 2005
AB	+		<u>400MG; EQ 57MG BASE</u>	<u>A065205</u>	<u>002</u>	Feb 09, 2005
		<u>AUGMENTIN '200'</u>				
AB		DR REDDYS LABS INC	<u>200MG; EQ 28.5MG BASE</u>	<u>N050726</u>	<u>001</u>	May 31, 1996
		<u>AUGMENTIN '400'</u>				
AB		DR REDDYS LABS INC	<u>400MG; EQ 57MG BASE</u>	<u>N050726</u>	<u>002</u>	May 31, 1996

PRESCRIPTION DRUG PRODUCT LIST

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET, EXTENDED RELEASE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	SANDOZ	<u>1GM;EQ 62.5MG BASE</u>	<u>A090227 001</u>	Apr 21, 2010
-----------	--------	---------------------------	--------------------	--------------

AUGMENTIN XR

AB	+ DR REDDYS LABS INC	<u>1GM;EQ 62.5MG BASE</u>	<u>N050785 001</u>	Sep 25, 2002
-----------	----------------------	---------------------------	--------------------	--------------

AMPHETAMINE

SUSPENSION, EXTENDED RELEASE;ORAL

DYANAVEL XR

	+ TRIS PHARMA INC	EQ 2.5MG BASE/ML	N208147 001	Oct 19, 2015
--	-------------------	------------------	-------------	--------------

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

ADZENYS XR-ODT

	NEOS THERAPS	EQ 3.1MG BASE	N204326 001	Jan 27, 2016
--	--------------	---------------	-------------	--------------

		EQ 6.3MG BASE	N204326 002	Jan 27, 2016
--	--	---------------	-------------	--------------

		EQ 9.4MG BASE	N204326 003	Jan 27, 2016
--	--	---------------	-------------	--------------

		EQ 12.5MG BASE	N204326 004	Jan 27, 2016
--	--	----------------	-------------	--------------

		EQ 15.7MG BASE	N204326 005	Jan 27, 2016
--	--	----------------	-------------	--------------

	+	EQ 18.8MG BASE	N204326 006	Jan 27, 2016
--	---	----------------	-------------	--------------

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

ADDERALL XR 10

AB	SHIRE	<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>N021303 001</u>	Oct 11, 2001
-----------	-------	--------------------------------	--------------------	--------------

ADDERALL XR 15

AB	SHIRE	<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>N021303 006</u>	May 22, 2002
-----------	-------	------------------------------------	--------------------	--------------

ADDERALL XR 20

AB	SHIRE	<u>5MG;5MG;5MG;5MG</u>	<u>N021303 002</u>	Oct 11, 2001
-----------	-------	------------------------	--------------------	--------------

ADDERALL XR 25

AB	SHIRE	<u>6.25MG;6.25MG;6.25MG;6.25MG</u>	<u>N021303 004</u>	May 22, 2002
-----------	-------	------------------------------------	--------------------	--------------

ADDERALL XR 30

AB	+ SHIRE	<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>N021303 003</u>	Oct 11, 2001
-----------	---------	--------------------------------	--------------------	--------------

ADDERALL XR 5

AB	SHIRE	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>N021303 005</u>	May 22, 2002
-----------	-------	------------------------------------	--------------------	--------------

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ACTAVIS ELIZABETH	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A077302 001</u>	Jun 22, 2012
-----------	-------------------	------------------------------------	--------------------	--------------

AB		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A077302 002</u>	Jun 22, 2012
-----------	--	--------------------------------	--------------------	--------------

AB		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A077302 003</u>	Jun 22, 2012
-----------	--	------------------------------------	--------------------	--------------

AB		<u>5MG;5MG;5MG;5MG</u>	<u>A077302 004</u>	Jun 22, 2012
-----------	--	------------------------	--------------------	--------------

AB		<u>6.25MG;6.25MG;6.25MG;6.25MG</u>	<u>A077302 005</u>	Jun 22, 2012
-----------	--	------------------------------------	--------------------	--------------

AB		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A077302 006</u>	Jun 22, 2012
-----------	--	--------------------------------	--------------------	--------------

AB	IMPAX LABS	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A076852 001</u>	Feb 16, 2016
-----------	------------	------------------------------------	--------------------	--------------

AB		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A076852 002</u>	Feb 16, 2016
-----------	--	--------------------------------	--------------------	--------------

AB		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A076852 003</u>	Feb 16, 2016
-----------	--	------------------------------------	--------------------	--------------

AB		<u>5MG;5MG;5MG;5MG</u>	<u>A076852 004</u>	Feb 16, 2016
-----------	--	------------------------	--------------------	--------------

AB		<u>6.25MG;6.25MG;6.25MG;6.25MG</u>	<u>A076852 005</u>	Feb 16, 2016
-----------	--	------------------------------------	--------------------	--------------

AB		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A076852 006</u>	Feb 16, 2016
-----------	--	--------------------------------	--------------------	--------------

AB	TEVA	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A077488 001</u>	Apr 29, 2013
-----------	------	------------------------------------	--------------------	--------------

AB		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A077488 002</u>	Apr 29, 2013
-----------	--	--------------------------------	--------------------	--------------

AB		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A077488 003</u>	Apr 29, 2013
-----------	--	------------------------------------	--------------------	--------------

AB		<u>5MG;5MG;5MG;5MG</u>	<u>A077488 004</u>	Apr 29, 2013
-----------	--	------------------------	--------------------	--------------

AB		<u>6.25MG;6.25MG;6.25MG;6.25MG</u>	<u>A077488 005</u>	Apr 29, 2013
-----------	--	------------------------------------	--------------------	--------------

AB		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A077488 006</u>	Apr 29, 2013
-----------	--	--------------------------------	--------------------	--------------

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	BARR LABS INC	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A076536 001</u>	Feb 12, 2013
-----------	---------------	------------------------------------	--------------------	--------------

AB		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A076536 002</u>	Feb 12, 2013
-----------	--	--------------------------------	--------------------	--------------

AB		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A076536 003</u>	Feb 12, 2013
-----------	--	------------------------------------	--------------------	--------------

AB		<u>5MG;5MG;5MG;5MG</u>	<u>A076536 004</u>	Feb 12, 2013
-----------	--	------------------------	--------------------	--------------

AB		<u>6.25MG;6.25MG;6.25MG;6.25MG</u>	<u>A076536 005</u>	Feb 12, 2013
-----------	--	------------------------------------	--------------------	--------------

AB		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A076536 006</u>	Feb 12, 2013
-----------	--	--------------------------------	--------------------	--------------

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ACTAVIS ELIZABETH	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A040456 001</u>	May 06, 2003
-----------	-------------------	------------------------------------	--------------------	--------------

AB		<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A206340 001</u>	Feb 05, 2016
-----------	--	------------------------------------	--------------------	--------------

AB		<u>1.875MG;1.875MG;1.875MG;1.875MG</u>	<u>A206340 002</u>	Feb 05, 2016
-----------	--	--	--------------------	--------------

AB		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A040456 002</u>	May 06, 2003
-----------	--	--------------------------------	--------------------	--------------

AB		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A206340 003</u>	Feb 05, 2016
-----------	--	--------------------------------	--------------------	--------------

AB		<u>3.125MG;3.125MG;3.125MG;3.125MG</u>	<u>A206340 004</u>	Feb 05, 2016
-----------	--	--	--------------------	--------------

AB		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A206340 005</u>	Feb 05, 2016
-----------	--	------------------------------------	--------------------	--------------

AB		<u>5MG;5MG;5MG;5MG</u>	<u>A040456 003</u>	May 06, 2003
-----------	--	------------------------	--------------------	--------------

AB		<u>5MG;5MG;5MG;5MG</u>	<u>A206340 006</u>	Feb 05, 2016
-----------	--	------------------------	--------------------	--------------

AB		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A040456 004</u>	May 06, 2003
-----------	--	--------------------------------	--------------------	--------------

AB		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A206340 007</u>	Feb 05, 2016
-----------	--	--------------------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

<u>AB</u>	AUROLIFE PHARMA LLC	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A202424 001</u>	Nov 27, 2013
<u>AB</u>		<u>1.875MG;1.875MG;1.875MG;1.875MG</u>	<u>A202424 002</u>	Nov 27, 2013
<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A202424 003</u>	Nov 27, 2013
<u>AB</u>		<u>3.125MG;3.125MG;3.125MG;3.125MG</u>	<u>A202424 004</u>	Nov 27, 2013
<u>AB</u>		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A202424 005</u>	Nov 27, 2013
<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A202424 006</u>	Nov 27, 2013
<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A202424 007</u>	Nov 27, 2013
<u>AB</u>	BARR	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A040422 001</u>	Feb 11, 2002
<u>AB</u>		<u>1.875MG;1.875MG;1.875MG;1.875MG</u>	<u>A040422 005</u>	Mar 19, 2003
<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A040422 002</u>	Feb 11, 2002
<u>AB</u>		<u>3.125MG;3.125MG;3.125MG;3.125MG</u>	<u>A040422 006</u>	Mar 19, 2003
<u>AB</u>		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A040422 007</u>	Mar 19, 2003
<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A040422 003</u>	Feb 11, 2002
<u>AB</u>	+	<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A040422 004</u>	Feb 11, 2002
<u>AB</u>	COREPHARMA	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A040444 001</u>	Jun 19, 2002
<u>AB</u>		<u>1.875MG;1.875MG;1.875MG;1.875MG</u>	<u>A040444 005</u>	Nov 03, 2014
<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A040444 002</u>	Jun 19, 2002
<u>AB</u>		<u>3.125MG;3.125MG;3.125MG;3.125MG</u>	<u>A040444 006</u>	Nov 03, 2014
<u>AB</u>		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A040444 007</u>	Nov 03, 2014
<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A040444 003</u>	Jun 19, 2002
<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A040444 004</u>	Jun 19, 2002
<u>AB</u>	MALLINCKRODT INC	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A040440 001</u>	Oct 07, 2003
<u>AB</u>		<u>1.875MG;1.875MG;1.875MG;1.875MG</u>	<u>A040440 002</u>	Oct 07, 2003
<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A040440 003</u>	Oct 07, 2003
<u>AB</u>		<u>3.125MG;3.125MG;3.125MG;3.125MG</u>	<u>A040440 004</u>	Oct 07, 2003
<u>AB</u>		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A040440 005</u>	Oct 07, 2003
<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A040440 006</u>	Oct 07, 2003
<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A040440 007</u>	Oct 07, 2003
<u>AB</u>	MYLAN PHARMS INC	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A206721 001</u>	Nov 10, 2015
<u>AB</u>		<u>1.875MG;1.875MG;1.875MG;1.875MG</u>	<u>A206721 002</u>	Nov 10, 2015
<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A206721 003</u>	Nov 10, 2015
<u>AB</u>		<u>3.125MG;3.125MG;3.125MG;3.125MG</u>	<u>A206721 004</u>	Nov 10, 2015
<u>AB</u>		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A206721 005</u>	Nov 10, 2015
<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A206721 006</u>	Nov 10, 2015
<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A206721 007</u>	Nov 10, 2015
<u>AB</u>	SANDOZ	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A040439 004</u>	Sep 27, 2002
<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A040439 001</u>	Jun 14, 2002
<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A040439 002</u>	Jun 14, 2002
<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A040439 003</u>	Jun 14, 2002
<u>AB</u>	SUN PHARM INDS	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A040480 001</u>	Sep 09, 2003
<u>AB</u>		<u>1.875MG;1.875MG;1.875MG;1.875MG</u>	<u>A040480 002</u>	Sep 09, 2003
<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A040480 003</u>	Sep 09, 2003
<u>AB</u>		<u>3.125MG;3.125MG;3.125MG;3.125MG</u>	<u>A040480 004</u>	Sep 09, 2003
<u>AB</u>		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A040480 005</u>	Sep 09, 2003
<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A040480 006</u>	Sep 09, 2003
<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A040480 007</u>	Sep 09, 2003

AMPHETAMINE SULFATE

TABLET; ORAL

EVEKEO

ARBOR PHARMS LLC

5MG

A200166 001 Aug 09, 2012

+

10MG

A200166 002 Aug 09, 2012

AMPHOTERICIN B

INJECTABLE; INJECTION

AMPHOTERICIN B

+ X GEN PHARMS

50MG/VIAL

A063206 001 Apr 29, 1992

INJECTABLE, LIPID COMPLEX; INJECTION

ABELCET

+ SIGMA TAU

5MG/ML

N050724 001 Nov 20, 1995

INJECTABLE, LIPOSOMAL; INJECTION

AMBISOME

+ ASTELLAS

50MG/VIAL

N050740 001 Aug 11, 1997

PRESCRIPTION DRUG PRODUCT LIST

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

AP	ACS DOBFAR SPA	<u>EQ 500MG BASE/VIAL</u>	<u>A090884 001</u>	Apr 03, 2013
AP		<u>EQ 1GM BASE/VIAL</u>	<u>A090884 002</u>	Apr 03, 2013
AP		<u>EQ 2GM BASE/VIAL</u>	<u>A090884 003</u>	Apr 03, 2013
AP		<u>EQ 10GM BASE/VIAL</u>	<u>A090889 001</u>	Apr 03, 2013
AP	ANTIBIOTICE	<u>EQ 250MG BASE/VIAL</u>	<u>A090354 001</u>	Dec 28, 2009
AP		<u>EQ 500MG BASE/VIAL</u>	<u>A090354 002</u>	Dec 28, 2009
AP		<u>EQ 1GM BASE/VIAL</u>	<u>A090354 003</u>	Dec 28, 2009
AP		<u>EQ 2GM BASE/VIAL</u>	<u>A090354 004</u>	Dec 28, 2009
AP	AUROBINDO PHARMA	<u>EQ 125MG BASE/VIAL</u>	<u>A065499 001</u>	Aug 17, 2010
AP		<u>EQ 250MG BASE/VIAL</u>	<u>A065499 002</u>	Aug 17, 2010
AP		<u>EQ 500MG BASE/VIAL</u>	<u>A065499 003</u>	Aug 17, 2010
AP		<u>EQ 1GM BASE/VIAL</u>	<u>A065499 004</u>	Aug 17, 2010
AP		<u>EQ 2GM BASE/VIAL</u>	<u>A065499 005</u>	Aug 17, 2010
AP		<u>EQ 10GM BASE/VIAL</u>	<u>A065493 001</u>	Aug 17, 2010
AP	HANFORD GC	<u>EQ 250MG BASE/VIAL</u>	<u>A063145 001</u>	Apr 15, 1993
AP		<u>EQ 500MG BASE/VIAL</u>	<u>A063146 001</u>	Apr 15, 1993
AP		<u>EQ 1GM BASE/VIAL</u>	<u>A062772 001</u>	Apr 15, 1993
AP		<u>EQ 2GM BASE/VIAL</u>	<u>A063140 001</u>	Apr 15, 1993
AP		<u>EQ 10GM BASE/VIAL</u>	<u>A063142 001</u>	Apr 15, 1993
AP	HOSPIRA INC	<u>EQ 250MG BASE/VIAL</u>	<u>A202864 001</u>	Sep 04, 2015
AP		<u>EQ 500MG BASE/VIAL</u>	<u>A202864 002</u>	Sep 04, 2015
AP		<u>EQ 1GM BASE/VIAL</u>	<u>A202864 003</u>	Sep 04, 2015
AP		<u>EQ 2GM BASE/VIAL</u>	<u>A202864 004</u>	Sep 04, 2015
AP		<u>EQ 10GM BASE/VIAL</u>	<u>A202865 001</u>	Sep 04, 2015
AP	ISTITUTO BIO ITA SPA	<u>EQ 10GM BASE/VIAL</u>	<u>A201404 001</u>	Dec 20, 2013
AP		<u>EQ 125MG BASE/VIAL</u>	<u>A062797 001</u>	Jul 12, 1993
AP		<u>EQ 250MG BASE/VIAL</u>	<u>A062719 001</u>	May 12, 1987
AP		<u>EQ 500MG BASE/VIAL</u>	<u>A062719 003</u>	May 12, 1987
AP		<u>EQ 1GM BASE/VIAL</u>	<u>A062719 002</u>	May 12, 1987
AP		<u>EQ 2GM BASE/VIAL</u>	<u>A062797 002</u>	Jul 12, 1993
AP	MYLAN LABS LTD	<u>EQ 250MG BASE/VIAL</u>	<u>A201025 001</u>	Apr 09, 2014
AP		<u>EQ 500MG BASE/VIAL</u>	<u>A201025 002</u>	Apr 09, 2014
AP		<u>EQ 1GM BASE/VIAL</u>	<u>A201025 003</u>	Apr 09, 2014
AP		<u>EQ 2GM BASE/VIAL</u>	<u>A201025 004</u>	Apr 09, 2014
AP		<u>EQ 10GM BASE/VIAL</u>	<u>A202198 001</u>	Apr 07, 2014
AP	SAGENT PHARMS	<u>EQ 125MG BASE/VIAL</u>	<u>A090583 001</u>	Nov 27, 2015
AP		<u>EQ 250MG BASE/VIAL</u>	<u>A090583 002</u>	Nov 27, 2015
AP		<u>EQ 500MG BASE/VIAL</u>	<u>A090583 003</u>	Nov 27, 2015
AP		<u>EQ 1GM BASE/VIAL</u>	<u>A090583 004</u>	Nov 27, 2015
AP		<u>EQ 2GM BASE/VIAL</u>	<u>A090583 005</u>	Nov 27, 2015
AP		<u>EQ 10GM BASE/VIAL</u>	<u>A090581 001</u>	Oct 20, 2015
AP	+ SANDOZ	<u>EQ 125MG BASE/VIAL</u>	<u>A061395 001</u>	
AP	+	<u>EQ 250MG BASE/VIAL</u>	<u>A061395 002</u>	
AP	+	<u>EQ 500MG BASE/VIAL</u>	<u>A061395 003</u>	
AP	+	<u>EQ 1GM BASE/VIAL</u>	<u>A061395 004</u>	
AP	+	<u>EQ 2GM BASE/VIAL</u>	<u>A061395 005</u>	
AP	+	<u>EQ 10GM BASE/VIAL</u>	<u>A061395 006</u>	

POWDER; INTRAVENOUS

AMPICILLIN SODIUM

AP	+ SANDOZ	<u>EQ 1GM BASE/VIAL</u>	<u>A062738 001</u>	Feb 19, 1987
AP	+	<u>EQ 2GM BASE/VIAL</u>	<u>A062738 002</u>	Feb 19, 1987

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

AP	ACS DOBFAR	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065406 001</u>	Dec 22, 2009
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065406 002</u>	Dec 22, 2009
AP		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065403 001</u>	Dec 23, 2009
AP	ANTIBIOTICS SA	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A201406 001</u>	Dec 07, 2015
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A201406 002</u>	Dec 07, 2015
AP	AUROBINDO PHARMA	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A090340 001</u>	Sep 20, 2010
AP		<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A090349 001</u>	Sep 20, 2010
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A090340 002</u>	Sep 20, 2010
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A090349 002</u>	Sep 20, 2010
AP		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A090339 001</u>	Sep 20, 2010
AP	EUROHLTH INTL SARL	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065074 001</u>	Mar 19, 2002
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065074 002</u>	Mar 19, 2002
AP		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065076 001</u>	Mar 19, 2002
AP	HANFORD GC	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065176 001</u>	Nov 30, 2005
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065176 002</u>	Nov 30, 2005

PRESCRIPTION DRUG PRODUCT LIST

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

AP		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065188</u>	<u>001</u>	Nov 25, 2005
AP	HOSPIRA INC	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A090375</u>	<u>001</u>	Dec 21, 2011
AP		<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A090653</u>	<u>001</u>	Dec 21, 2011
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A090375</u>	<u>002</u>	Dec 21, 2011
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A090653</u>	<u>002</u>	Dec 21, 2011
AP		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A090646</u>	<u>001</u>	Dec 21, 2011
AP	ISTITUTO BIO ITA SPA	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065222</u>	<u>001</u>	Nov 29, 2005
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065222</u>	<u>002</u>	Nov 29, 2005
AP		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065314</u>	<u>001</u>	Nov 27, 2006
AP	MUSTAFA NEVZAT ILAC	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065316</u>	<u>001</u>	Jun 29, 2007
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065316</u>	<u>002</u>	Jun 29, 2007
AP	MYLAN LABS LTD	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A201024</u>	<u>001</u>	Apr 07, 2014
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A201024</u>	<u>002</u>	Apr 07, 2014
AP		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A202197</u>	<u>001</u>	Apr 07, 2014
AP	SAGENT PHARMS	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A090579</u>	<u>001</u>	Jan 08, 2016
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A090579</u>	<u>002</u>	Jan 08, 2016
AP		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A090578</u>	<u>001</u>	Jan 11, 2016
AP	SANDOZ	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065241</u>	<u>001</u>	Jul 25, 2006
AP		<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065310</u>	<u>001</u>	Jul 25, 2006
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065241</u>	<u>002</u>	Jul 25, 2006
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065310</u>	<u>002</u>	Jul 25, 2006
AP		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065240</u>	<u>001</u>	Jul 25, 2006

UNASYN

AP	+	PFIZER	<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A062901</u>	<u>002</u>	Feb 27, 1992
AP	+		<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A062901</u>	<u>001</u>	Nov 23, 1988
AP	+		<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>N050608</u>	<u>002</u>	Dec 31, 1986
AP	+		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>N050608</u>	<u>001</u>	Dec 31, 1986
AP	+		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>N050608</u>	<u>005</u>	Dec 10, 1993

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMPICILLIN TRIHYDRATE

AB	DAVA PHARMS INC	<u>EQ 250MG BASE</u>	<u>A062883</u>	<u>001</u>	Feb 25, 1988	
AB	+		<u>EQ 500MG BASE</u>	<u>A062882</u>	<u>001</u>	Feb 25, 1988
AB	SANDOZ	<u>EQ 250MG BASE</u>	<u>A064082</u>	<u>001</u>	Aug 29, 1995	
AB		<u>EQ 500MG BASE</u>	<u>A064082</u>	<u>002</u>	Aug 29, 1995	

FOR SUSPENSION; ORAL

AMPICILLIN TRIHYDRATE

	DAVA PHARMS INC	EQ 125MG BASE/5ML	A062982	001	Feb 10, 1989
	+	EQ 250MG BASE/5ML	A062982	002	Feb 10, 1989

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

AGRYLIN

AB	SHIRE LLC	<u>EQ 0.5MG BASE</u>	<u>N020333</u>	<u>001</u>	Mar 14, 1997
----	-----------	----------------------	----------------	------------	--------------

ANAGRELIDE HYDROCHLORIDE

AB	BARR	<u>EQ 0.5MG BASE</u>	<u>A076530</u>	<u>001</u>	Apr 18, 2005	
AB		<u>EQ 1MG BASE</u>	<u>A076530</u>	<u>002</u>	Apr 18, 2005	
AB	IMPAX LABS	<u>EQ 0.5MG BASE</u>	<u>A076910</u>	<u>001</u>	Apr 18, 2005	
AB		<u>EQ 1MG BASE</u>	<u>A076910</u>	<u>002</u>	Apr 18, 2005	
AB	IVAX SUB TEVA PHARMS	<u>EQ 0.5MG BASE</u>	<u>A076468</u>	<u>001</u>	Apr 18, 2005	
AB	+		<u>EQ 1MG BASE</u>	<u>A076468</u>	<u>002</u>	Apr 18, 2005
AB	MYLAN	<u>EQ 0.5MG BASE</u>	<u>A076811</u>	<u>001</u>	Apr 18, 2005	
AB		<u>EQ 1MG BASE</u>	<u>A076811</u>	<u>002</u>	Apr 18, 2005	
AB	MYLAN PHARMS INC	<u>EQ 0.5MG BASE</u>	<u>A077613</u>	<u>001</u>	Jun 27, 2006	
AB		<u>EQ 1MG BASE</u>	<u>A077613</u>	<u>002</u>	Jun 27, 2006	

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

AB	ACCORD HLTHCARE	<u>1MG</u>	<u>A090568</u>	<u>001</u>	Jun 28, 2010
AB	APOTEX INC	<u>1MG</u>	<u>A200654</u>	<u>001</u>	May 11, 2012
AB	CIPLA LTD	<u>1MG</u>	<u>A091164</u>	<u>001</u>	Jun 28, 2010
AB	DR REDDYS LABS LTD	<u>1MG</u>	<u>A090732</u>	<u>001</u>	Jun 28, 2010
AB	FRESENIUS KABI ONCOL	<u>1MG</u>	<u>A090088</u>	<u>001</u>	Jun 28, 2010
AB	MYLAN	<u>1MG</u>	<u>A091051</u>	<u>001</u>	Jun 28, 2010
AB	NATCO PHARMA LTD	<u>1MG</u>	<u>A079220</u>	<u>001</u>	Jun 28, 2010
AB	SANTOS BIOTECH	<u>1MG</u>	<u>A078944</u>	<u>001</u>	Jun 28, 2010
AB	SUN PHARM INDS LTD	<u>1MG</u>	<u>A091177</u>	<u>001</u>	Jul 15, 2011
AB	TEVA PHARMS	<u>1MG</u>	<u>A078058</u>	<u>001</u>	Jun 28, 2010
AB	WEST-WARD PHARMS INT	<u>1MG</u>	<u>A078485</u>	<u>001</u>	Jun 28, 2010

PRESCRIPTION DRUG PRODUCT LIST

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

AB	ZYDUS PHARMS USA INC	1MG	A078921 001	Jun 28, 2010
-----------	----------------------	------------	--------------------	--------------

ARIMIDEX

AB	+ ASTRAZENECA	1MG	N020541 001	Dec 27, 1995
-----------	---------------	------------	--------------------	--------------

ANIDULAFUNGIN

INJECTABLE; IV (INFUSION)

ERAXIS

+	VICURON	50MG/VIAL	N021632 001	Feb 17, 2006
---	---------	-----------	-------------	--------------

+		100MG/VIAL	N021632 002	Nov 14, 2006
---	--	------------	-------------	--------------

APIXABAN

TABLET; ORAL

ELIQUIS

	BRISTOL MYERS SQUIBB	2.5MG	N202155 001	Dec 28, 2012
--	----------------------	-------	-------------	--------------

+		5MG	N202155 002	Dec 28, 2012
---	--	-----	-------------	--------------

APOMORPHINE HYDROCHLORIDE

INJECTABLE; SUBCUTANEOUS

APOKYN

+	US WORLDMEDS	30MG/3ML (10MG/ML)	N021264 002	Apr 20, 2004
---	--------------	--------------------	-------------	--------------

APRACLONIDINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

APRACLONIDINE HYDROCHLORIDE

AT	AKORN INC	EQ 0.5% BASE	A077764 001	Mar 12, 2009
-----------	-----------	---------------------	--------------------	--------------

IOPIDINE

AT	+ NOVARTIS PHARMS CORP	EQ 0.5% BASE	N020258 001	Jul 30, 1993
-----------	------------------------	---------------------	--------------------	--------------

+		EQ 1% BASE	N019779 001	Dec 31, 1987
---	--	------------	-------------	--------------

APREMILAST

TABLET; ORAL

OTEZLA

	CELGENE CORP	10MG	N205437 001	Mar 21, 2014
--	--------------	------	-------------	--------------

		20MG	N205437 002	Mar 21, 2014
--	--	------	-------------	--------------

+		30MG	N205437 003	Mar 21, 2014
---	--	------	-------------	--------------

APREPITANT

CAPSULE; ORAL

APREPITANT

AB	SANDOZ	40MG	A090999 001	Sep 24, 2012
-----------	--------	-------------	--------------------	--------------

AB		80MG	A090999 002	Sep 24, 2012
-----------	--	-------------	--------------------	--------------

AB		125MG	A090999 003	Sep 24, 2012
-----------	--	--------------	--------------------	--------------

EMEND

AB	MERCK	40MG	N021549 003	Jun 30, 2006
-----------	-------	-------------	--------------------	--------------

AB		80MG	N021549 001	Mar 26, 2003
-----------	--	-------------	--------------------	--------------

AB	+	125MG	N021549 002	Mar 26, 2003
-----------	---	--------------	--------------------	--------------

FOR SUSPENSION; ORAL

EMEND

+	MSD MERCK CO	125MG/KIT	N207865 001	Dec 17, 2015
---	--------------	-----------	-------------	--------------

ARFORMOTEROL TARTRATE

SOLUTION; INHALATION

BROVANA

+	SUNOVION	EQ 0.015MG BASE/2ML	N021912 001	Oct 06, 2006
---	----------	---------------------	-------------	--------------

ARGATROBAN

INJECTABLE; INJECTION

ARGATROBAN

AP	FRESENIUS KABI USA	250MG/2.5ML (100MG/ML)	N201811 001	Mar 23, 2015
-----------	--------------------	-------------------------------	--------------------	--------------

AP	HIKMA PHARM CO LTD	250MG/2.5ML (100MG/ML)	N203049 001	Jan 05, 2012
-----------	--------------------	-------------------------------	--------------------	--------------

AP	HOSPIRA INC	250MG/2.5ML (100MG/ML)	A204120 001	Sep 21, 2016
-----------	-------------	-------------------------------	--------------------	--------------

AP	MYLAN INSTITUTIONAL	250MG/2.5ML (100MG/ML)	A202626 001	Jun 30, 2014
-----------	---------------------	-------------------------------	--------------------	--------------

AP	PAR STERILE PRODUCTS	250MG/2.5ML (100MG/ML)	A091665 001	Jun 30, 2014
-----------	----------------------	-------------------------------	--------------------	--------------

AP	+	250MG/2.5ML (100MG/ML)	N020883 001	Jun 30, 2000
-----------	---	-------------------------------	--------------------	--------------

INJECTABLE; IV (INFUSION)

ARGATROBAN IN 0.9% SODIUM CHLORIDE

	TEVA PHARMS USA	250MG/250ML (1MG/ML)	N206769 001	Dec 15, 2014
--	-----------------	----------------------	-------------	--------------

ARGATROBAN IN SODIUM CHLORIDE

+	EAGLE PHARMS	50MG/50ML (1MG/ML)	N022434 001	Jun 29, 2011
---	--------------	--------------------	-------------	--------------

+	SANDOZ	125MG/125ML (1MG/ML)	N022485 001	May 09, 2011
---	--------	----------------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LISTARGININE HYDROCHLORIDE

INJECTABLE; INJECTION

R-GENE 10

+ PHARMACIA AND UPJOHN 10GM/100ML N016931 001

ARIPIRAZOLE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

ABILIFY MAINTENA KIT

OTSUKA PHARM CO LTD 300MG/VIAL

N202971 001 Feb 28, 2013

300MG

N202971 003 Sep 29, 2014

+ 400MG/VIAL

N202971 002 Feb 28, 2013

400MG

N202971 004 Sep 29, 2014

SOLUTION; ORAL

ARIPIRAZOLEAA + AMNEAL PHARMS 1MG/ML A203906 001 Aug 14, 2015AA APOTEX INC 1MG/ML A204094 001 Sep 30, 2015AA SILARX PHARMS INC 1MG/ML A204171 001 Aug 14, 2015

TABLET; ORAL

ABILIFYAB OTSUKA 2MG N021436 006 Nov 15, 2002AB + 5MG N021436 005 Nov 15, 2002AB + 10MG N021436 001 Nov 15, 2002AB 15MG N021436 002 Nov 15, 2002AB 20MG N021436 003 Nov 15, 2002AB 30MG N021436 004 Nov 15, 2002ARIPIRAZOLEAB ACCORD HLTHCARE 2MG A206251 001 Dec 07, 2016AB 5MG A206251 002 Dec 07, 2016AB 10MG A206251 003 Dec 07, 2016AB 15MG A206251 004 Dec 07, 2016AB 20MG A206251 005 Dec 07, 2016AB 30MG A206251 006 Dec 07, 2016AB AJANTA PHARMA LTD 2MG A206174 001 Sep 12, 2016AB 5MG A206174 002 Sep 12, 2016AB 10MG A206174 003 Sep 12, 2016AB 15MG A206174 004 Sep 12, 2016AB 20MG A206174 005 Sep 12, 2016AB 30MG A206174 006 Sep 12, 2016AB ALEMBIC PHARMS LTD 2MG A202101 001 Apr 28, 2015AB 5MG A202101 002 Apr 28, 2015AB 10MG A202101 003 Apr 28, 2015AB 15MG A202101 004 Apr 28, 2015AB 20MG A202101 005 Apr 28, 2015AB 30MG A202101 006 Apr 28, 2015AB AMNEAL PHARMS 2MG A204838 001 Jun 17, 2016AB 5MG A204838 002 Jun 17, 2016AB 10MG A204838 003 Jun 17, 2016AB 15MG A204838 004 Jun 17, 2016AB 20MG A204838 005 Jun 17, 2016AB 30MG A204838 006 Jun 17, 2016AB APOTEX INC 2MG A078583 001 Jul 24, 2015AB 5MG A078583 002 Jul 24, 2015AB 10MG A078583 003 Jul 24, 2015AB 15MG A078583 004 Jul 24, 2015AB 20MG A078583 005 Jul 24, 2015AB 30MG A078583 006 Jul 24, 2015AB AUROBINDO PHARMA LTD 2MG A203908 001 Oct 08, 2015AB 5MG A203908 002 Oct 08, 2015AB 10MG A203908 003 Oct 08, 2015AB 15MG A203908 004 Oct 08, 2015AB 20MG A203908 005 Oct 08, 2015AB 30MG A203908 006 Oct 08, 2015AB HETERO LABS LTD V 2MG A205064 001 Apr 28, 2015AB 5MG A205064 002 Apr 28, 2015AB 10MG A205064 003 Apr 28, 2015AB 15MG A205064 004 Apr 28, 2015AB 20MG A205064 005 Apr 28, 2015AB 30MG A205064 006 Apr 28, 2015AB MACLEODS PHARMS LTD 2MG A204111 001 Oct 07, 2016AB 5MG A204111 002 Oct 07, 2016AB 10MG A204111 003 Oct 07, 2016AB 15MG A204111 004 Oct 07, 2016AB 20MG A204111 005 Oct 07, 2016

PRESCRIPTION DRUG PRODUCT LIST

ARIPIPIRAZOLE

TABLET; ORAL

ARIPIPIRAZOLE

<u>AB</u>		<u>30MG</u>	<u>A204111 006</u>	Oct 07, 2016
<u>AB</u>	SCIEGEN PHARMS INC	<u>2MG</u>	<u>A206383 001</u>	Sep 29, 2016
<u>AB</u>		<u>5MG</u>	<u>A206383 002</u>	Sep 29, 2016
<u>AB</u>		<u>10MG</u>	<u>A206383 003</u>	Sep 29, 2016
<u>AB</u>		<u>15MG</u>	<u>A206383 004</u>	Sep 29, 2016
<u>AB</u>		<u>20MG</u>	<u>A206383 005</u>	Sep 29, 2016
<u>AB</u>		<u>30MG</u>	<u>A206383 006</u>	Sep 29, 2016
<u>AB</u>	STASON PHARMS	<u>2MG</u>	<u>A091279 001</u>	Jan 09, 2017
<u>AB</u>		<u>5MG</u>	<u>A091279 002</u>	Jan 09, 2017
<u>AB</u>		<u>10MG</u>	<u>A091279 003</u>	Jan 09, 2017
<u>AB</u>		<u>15MG</u>	<u>A091279 004</u>	Jan 09, 2017
<u>AB</u>		<u>20MG</u>	<u>A091279 005</u>	Jan 09, 2017
<u>AB</u>		<u>30MG</u>	<u>A091279 006</u>	Jan 09, 2017
<u>AB</u>	TEVA PHARMS USA	<u>2MG</u>	<u>A078607 001</u>	Apr 28, 2015
<u>AB</u>		<u>5MG</u>	<u>A078607 002</u>	Apr 28, 2015
<u>AB</u>		<u>10MG</u>	<u>A078608 001</u>	Apr 28, 2015
<u>AB</u>		<u>15MG</u>	<u>A078708 001</u>	Apr 28, 2015
<u>AB</u>		<u>20MG</u>	<u>A078708 002</u>	Apr 28, 2015
<u>AB</u>		<u>30MG</u>	<u>A078708 003</u>	Apr 28, 2015
<u>AB</u>	TORRENT PHARMS LTD	<u>2MG</u>	<u>A201519 001</u>	Apr 28, 2015
<u>AB</u>		<u>10MG</u>	<u>A201519 003</u>	Apr 28, 2015
<u>AB</u>		<u>5MG</u>	<u>A201519 002</u>	Apr 28, 2015
<u>AB</u>		<u>15MG</u>	<u>A201519 004</u>	Apr 28, 2015
<u>AB</u>		<u>20MG</u>	<u>A201519 005</u>	Apr 28, 2015
<u>AB</u>		<u>30MG</u>	<u>A201519 006</u>	Apr 28, 2015
TABLET, ORALLY DISINTEGRATING; ORAL				
ARIPIPIRAZOLE				
	+ ALEMBIC PHARMS LTD	10MG	A202102 001	Apr 28, 2015
		15MG	A202102 002	Apr 28, 2015

ARIPIPIRAZOLE LAUROXIL

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

ARISTADA

	ALKERMES INC	441MG/1.6ML (275.63MG/ML)	N207533 001	Oct 05, 2015
		662MG/2.4ML (275.83MG/ML)	N207533 002	Oct 05, 2015
	+	882MG/3.2ML (275.63MG/ML)	N207533 003	Oct 05, 2015

ARMODAFINIL

TABLET; ORAL

ARMODAFINIL

<u>AB</u>	LUPIN LTD	<u>50MG</u>	<u>A200751 001</u>	Nov 28, 2016
<u>AB</u>		<u>150MG</u>	<u>A200751 003</u>	Nov 28, 2016
<u>AB</u>		<u>200MG</u>	<u>A200751 004</u>	Nov 28, 2016
<u>AB</u>		<u>250MG</u>	<u>A200751 005</u>	Nov 28, 2016
<u>AB</u>	MYLAN PHARMS INC	<u>50MG</u>	<u>A200043 001</u>	Jun 01, 2012
<u>AB</u>		<u>150MG</u>	<u>A200043 002</u>	Jun 01, 2012
<u>AB</u>		<u>250MG</u>	<u>A200043 003</u>	Jun 01, 2012
<u>AB</u>	NATCO PHARMA LTD	<u>50MG</u>	<u>A202768 001</u>	Nov 28, 2016
<u>AB</u>		<u>150MG</u>	<u>A202768 002</u>	Nov 28, 2016
<u>AB</u>		<u>250MG</u>	<u>A202768 003</u>	Nov 28, 2016
<u>NUVIGIL</u>				
<u>AB</u>	CEPHALON	<u>50MG</u>	<u>N021875 001</u>	Jun 15, 2007
<u>AB</u>		<u>150MG</u>	<u>N021875 003</u>	Jun 15, 2007
<u>AB</u>		<u>200MG</u>	<u>N021875 005</u>	Mar 26, 2009
<u>AB</u>	+	<u>250MG</u>	<u>N021875 004</u>	Jun 15, 2007

ARSENIC TRIOXIDE

INJECTABLE; INJECTION

TRISENOX

	+ CEPHALON	1MG/ML	N021248 001	Sep 25, 2000
--	------------	--------	-------------	--------------

ARTEMETHER; LUMEFANTRINE

TABLET; ORAL

COARTEM

	+ NOVARTIS	20MG; 120MG	N022268 001	Apr 07, 2009
--	------------	-------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ARTICAINA HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

ARTICAINA HYDROCHLORIDE AND EPINEPHRINE BITARTRATE

AP	HOSPIRA	4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)	A079138 001	Jun 18, 2010
-----------	---------	--	--------------------	--------------

SEPTOCAINE

AP	+ DEPROCO	4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)	N020971 001	Apr 03, 2000
-----------	-----------	--	--------------------	--------------

ORABLOC

PIERREL

4%;EQ 0.009MG BASE/1.8ML (EQ 0.005MG BASE/ML)

N022466 001 Feb 26, 2010

+

4%;EQ 0.018MG BASE/1.8ML (EQ 0.01MG BASE/ML)

N022466 002 Feb 26, 2010

SEPTOCAINE

+ DEPROCO

4%;EQ 0.0085MG BASE/1.7ML (4%;EQ 0.005MG BASE/ML)

N022010 001 Mar 30, 2006

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; IV (INFUSION)

INFUVITE PEDIATRIC

+ SANDOZ

80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL

N021265 001 Feb 21, 2001

INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)

+ SANDOZ

80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL

N021646 001 Jan 29, 2004

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION; IV (INFUSION)

M.V.I. PEDIATRIC

+ HOSPIRA

80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL;5MG/VIAL;0.01MG/VIAL;0.14MG/VIAL;17MG/VIAL;0.2MG/VIAL;1MG/VIAL;1.4MG/VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/VIAL

N018920 001 Sep 21, 2000

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12 (WITHOUT VITAMIN K)

+ HOSPIRA

20MG/ML;0.006MG/ML;0.05MCG/ML;1.5MG/ML;0.0005MG/ML;0.06MG/ML;4MG/ML;0.6MG/ML;0.36MG/ML;0.6MG/ML;0.1MG/ML;1MG/ML

N008809 006 Sep 09, 2004

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E; VITAMIN K

INJECTABLE; IV (INFUSION)

M.V.I. ADULT

+ HOSPIRA

200MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;0.005MG/VIAL;0.6MG/VIAL;40MG/VIAL;6MG/VIAL;3.6MG/VIAL;6MG/VIAL;1MG/VIAL;10MG/VIAL;0.15MG/VIAL

N021625 001 Jan 30, 2004

M.V.I. ADULT (PHARMACY BULK PACKAGE)

+ HOSPIRA

200MG/5ML;0.06MG/5ML;0.005MG/5ML;15MG/5ML;0.005MG/5ML;0.6MG/5ML;40MG/5ML;6MG/5ML;3.6MG/5ML;6MG/5ML;1MG/5ML;10MG/5ML;0.15MG/5ML

N021643 001 Feb 18, 2004

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

MOVIPREP

+ SALIX PHARMS

4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM

N021881 001 Aug 02, 2006

ASENAPINE MALEATE

TABLET; SUBLINGUAL

SAPHRIS

FOREST LABS LLC

EQ 2.5 BASE

N022117 003 Mar 12, 2015

EQ 5MG BASE

N022117 001 Aug 13, 2009

+

EQ 10MG BASE

N022117 002 Aug 13, 2009

PRESCRIPTION DRUG PRODUCT LIST

ASPIRIN

CAPSULE, EXTENDED RELEASE; ORAL

DURLAZA

+ NEW HAVEN PHARMS 162.5MG

N200671 001 Sep 04, 2015

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

FIORINAL**AA** + ALLERGAN SALES LLC 325MG; 50MG; 40MG**N017534 005** Apr 16, 1986LANORINAL**AA** LANNETT 325MG; 50MG; 40MG**A086996 002** Oct 11, 1985

TABLET; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE**AA** + HIKMA INTL PHARMS 325MG; 50MG; 40MG**A086162 002** Feb 16, 1984**AA** PHARMACEUTICS INTL 325MG; 50MG; 40MG**A204195 001** Sep 22, 2016ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE PHOSPHATE**AB** MAYNE PHARMA INC 325MG; 50MG; 40MG; 30MG**A203335 001** Oct 30, 2015BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE**AB** NEXGEN PHARMA INC 325MG; 50MG; 40MG; 30MG**A075231 001** Nov 30, 2001**AB** STEVENS J 325MG; 50MG; 40MG; 30MG**A074951 001** Aug 31, 1998FIORINAL W/CODEINE**AB** + ALLERGAN SALES LLC 325MG; 50MG; 40MG; 30MG**N019429 003** Oct 26, 1990ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

SYNALGOS-DC

+ SUN PHARM INDS 356.4MG; 30MG; 16MG

N011483 004 Sep 06, 1983

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

SANDOZ 385MG; 30MG; 25MG

A074654 001 Dec 31, 1996

+ 770MG; 60MG; 50MG

A074654 002 Dec 31, 1996

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN**AB** + HERITAGE PHARMS INC 325MG; 200MG**A089594 001** Mar 31, 1989**AB** INGENUS PHARMS NJ 325MG; 200MG**A040832 001** Jan 07, 2010**AB** OXFORD PHARMS 325MG; 200MG**A040252 001** Dec 10, 1997**AB** SANDOZ 325MG; 200MG**A040116 001** Apr 25, 1996ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE**AB** INGENUS PHARMS NJ 325MG; 200MG; 16MG**A040860 001** Jan 07, 2010**AB** + SANDOZ 325MG; 200MG; 16MG**A040118 001** Apr 16, 1996ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE; ORAL

AGGRENOLX**AB** + BOEHRINGER INGELHEIM 25MG; 200MG**N020884 001** Nov 22, 1999ASPIRIN AND DIPYRIDAMOLE**AB** AMNEAL PHARMS 25MG; 200MG**A206392 001** Mar 08, 2016**AB** BARR 25MG; 200MG**A078804 001** Aug 14, 2009ASPIRIN; METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL AND ASPIRIN

+ STEVENS J 325MG; 400MG

A081145 001 Jan 31, 1995

ASPIRIN; OMEPRAZOLE

TABLET, DELAYED RELEASE; ORAL

YOSPRALA

+ ARALEZ PHARMS 81MG; 40MG

N205103 001 Sep 14, 2016

+ 325MG; 40MG

N205103 002 Sep 14, 2016

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ASPIRIN**AA** ACTAVIS LABS FL INC 325MG; 4.8355MG**A090084 001** Mar 22, 2011**AA** MAYNE PHARMA INC 325MG; 4.8355MG**A091670 001** Mar 16, 2011PERCODAN**AA** + ENDO PHARMS 325MG; 4.8355MG**N007337 007** Aug 05, 2005

PRESCRIPTION DRUG PRODUCT LIST

ATAZANAVIR SULFATE

CAPSULE; ORAL

ATAZANAVIR SULFATE

<u>AB</u>	TEVA PHARMS USA	<u>EQ 150MG BASE</u>	<u>A091673 002</u>	Apr 22, 2014
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A091673 003</u>	Apr 22, 2014
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A091673 004</u>	Apr 22, 2014

REYATAZ

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>EQ 150MG BASE</u>	<u>N021567 002</u>	Jun 20, 2003
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>N021567 003</u>	Jun 20, 2003
<u>AB</u>	+	<u>EQ 300MG BASE</u>	<u>N021567 004</u>	Oct 16, 2006
	ATAZANAVIR SULFATE			
	TEVA PHARMS USA	EQ 100MG BASE	A091673 001	Apr 22, 2014
	POWDER; ORAL			
	REYATAZ			
	+	BRISTOL MYERS SQUIBB	EQ 50MG BASE/PACKET	N206352 001 Jun 02, 2014

ATAZANAVIR SULFATE; COBICISTAT

TABLET; ORAL

EVOTAZ

	+	BRISTOL-MYERS SQUIBB	EQ 300MG BASE; 150MG	N206353 001 Jan 29, 2015
--	---	----------------------	----------------------	--------------------------

ATENOLOL

TABLET; ORAL

ATENOLOL

<u>AB</u>	ALVOGEN MALTA	<u>25MG</u>	<u>A073646 001</u>	Jul 31, 1992
<u>AB</u>		<u>50MG</u>	<u>A072303 001</u>	Jul 15, 1988
<u>AB</u>		<u>100MG</u>	<u>A072304 001</u>	Jul 15, 1988
<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A078512 001</u>	Oct 31, 2007
<u>AB</u>		<u>50MG</u>	<u>A078512 002</u>	Oct 31, 2007
<u>AB</u>		<u>100MG</u>	<u>A078512 003</u>	Oct 31, 2007
<u>AB</u>	DAVA PHARMS INC	<u>50MG</u>	<u>A073542 001</u>	Dec 19, 1991
<u>AB</u>		<u>100MG</u>	<u>A073543 001</u>	Dec 19, 1991
<u>AB</u>	IPCA LABS LTD	<u>25MG</u>	<u>A077877 001</u>	Dec 27, 2006
<u>AB</u>		<u>50MG</u>	<u>A077877 002</u>	Dec 27, 2006
<u>AB</u>		<u>100MG</u>	<u>A077877 003</u>	Dec 27, 2006
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A073457 002</u>	Apr 26, 1999
<u>AB</u>		<u>50MG</u>	<u>A073457 003</u>	Jan 24, 1992
<u>AB</u>		<u>100MG</u>	<u>A073457 001</u>	Jan 24, 1992
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A074052 001</u>	May 01, 1992
<u>AB</u>		<u>50MG</u>	<u>A073025 001</u>	Sep 17, 1991
<u>AB</u>		<u>100MG</u>	<u>A073026 001</u>	Sep 17, 1991
<u>AB</u>	SUN PHARM INDS	<u>25MG</u>	<u>A074499 001</u>	Jul 30, 1997
<u>AB</u>		<u>50MG</u>	<u>A073475 001</u>	Mar 30, 1993
<u>AB</u>		<u>100MG</u>	<u>A073476 001</u>	Mar 30, 1993
<u>AB</u>	SUN PHARM INDS INC	<u>25MG</u>	<u>A078210 001</u>	Jul 10, 2007
<u>AB</u>		<u>50MG</u>	<u>A078210 002</u>	Jul 10, 2007
<u>AB</u>		<u>100MG</u>	<u>A078210 003</u>	Jul 10, 2007
<u>AB</u>	TEVA	<u>25MG</u>	<u>A074056 003</u>	Jul 19, 2004
<u>AB</u>		<u>50MG</u>	<u>A074056 001</u>	Jan 18, 1995
<u>AB</u>		<u>100MG</u>	<u>A074056 002</u>	Jan 18, 1995
<u>AB</u>	UNIQUE PHARM LABS	<u>25MG</u>	<u>A077443 001</u>	Sep 13, 2006
<u>AB</u>		<u>50MG</u>	<u>A077443 002</u>	Sep 13, 2006
<u>AB</u>		<u>100MG</u>	<u>A077443 003</u>	Sep 13, 2006
<u>AB</u>	ZYDUS PHARMS USA	<u>25MG</u>	<u>A076900 001</u>	Jan 28, 2005
<u>AB</u>		<u>50MG</u>	<u>A076900 002</u>	Jan 28, 2005
<u>AB</u>		<u>100MG</u>	<u>A076900 003</u>	Jan 28, 2005

TENORMIN

<u>AB</u>	ALVOGEN MALTA	<u>25MG</u>	<u>N018240 004</u>	Apr 09, 1990
<u>AB</u>		<u>50MG</u>	<u>N018240 001</u>	
<u>AB</u>	+	<u>100MG</u>	<u>N018240 002</u>	

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

<u>AB</u>	ALVOGEN MALTA	<u>50MG; 25MG</u>	<u>A072301 001</u>	May 31, 1990
<u>AB</u>		<u>100MG; 25MG</u>	<u>A072302 001</u>	May 31, 1990
<u>AB</u>	MUTUAL PHARM	<u>50MG; 25MG</u>	<u>A073581 001</u>	Apr 29, 1993
<u>AB</u>	MYLAN	<u>50MG; 25MG</u>	<u>A074203 001</u>	Oct 31, 1993
<u>AB</u>		<u>100MG; 25MG</u>	<u>A074203 002</u>	Oct 31, 1993
<u>AB</u>	SUN PHARM INDS	<u>100MG; 25MG</u>	<u>A073582 001</u>	Apr 29, 1993
<u>AB</u>	WATSON LABS	<u>50MG; 25MG</u>	<u>A073665 001</u>	Jul 02, 1992
<u>AB</u>		<u>100MG; 25MG</u>	<u>A073665 002</u>	Jul 02, 1992

PRESCRIPTION DRUG PRODUCT LIST

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

TENORETIC 100

<u>AB</u>	+	ALVOGEN MALTA	<u>100MG; 25MG</u>	<u>N018760 001</u>	Jun 08, 1984
-----------	---	---------------	--------------------	--------------------	--------------

TENORETIC 50

<u>AB</u>		ALVOGEN MALTA	<u>50MG; 25MG</u>	<u>N018760 002</u>	Jun 08, 1984
-----------	--	---------------	-------------------	--------------------	--------------

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

STRATTERA

LILLY

10MG

N021411 002 Nov 26, 2002

18MG

N021411 003 Nov 26, 2002

25MG

N021411 004 Nov 26, 2002

40MG

N021411 005 Nov 26, 2002

+

60MG

N021411 006 Nov 26, 2002

80MG

N021411 007 Feb 14, 2005

100MG

N021411 008 Feb 14, 2005

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

<u>AB</u>		APOTEX INC	<u>EQ 10MG BASE</u>	<u>A090548 001</u>	May 29, 2012
-----------	--	------------	---------------------	--------------------	--------------

<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A090548 002</u>	May 29, 2012
-----------	--	--	---------------------	--------------------	--------------

<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A090548 003</u>	May 29, 2012
-----------	--	--	---------------------	--------------------	--------------

<u>AB</u>			<u>EQ 80MG BASE</u>	<u>A090548 004</u>	May 29, 2012
-----------	--	--	---------------------	--------------------	--------------

<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 10MG BASE</u>	<u>A091650 001</u>	Jul 17, 2012
-----------	--	--------------------	---------------------	--------------------	--------------

<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A091650 002</u>	Jul 17, 2012
-----------	--	--	---------------------	--------------------	--------------

<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A091650 003</u>	Jul 17, 2012
-----------	--	--	---------------------	--------------------	--------------

<u>AB</u>			<u>EQ 80MG BASE</u>	<u>A202357 001</u>	Jul 17, 2012
-----------	--	--	---------------------	--------------------	--------------

<u>AB</u>		INVAGEN PHARMS	<u>EQ 10MG BASE</u>	<u>A204846 001</u>	Jan 09, 2017
-----------	--	----------------	---------------------	--------------------	--------------

<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A204846 002</u>	Jan 09, 2017
-----------	--	--	---------------------	--------------------	--------------

<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A204846 003</u>	Jan 09, 2017
-----------	--	--	---------------------	--------------------	--------------

<u>AB</u>			<u>EQ 80MG BASE</u>	<u>A204846 004</u>	Jan 09, 2017
-----------	--	--	---------------------	--------------------	--------------

<u>AB</u>		KREMERS URBAN PHARMS	<u>EQ 10MG BASE</u>	<u>A091624 001</u>	Apr 05, 2013
-----------	--	----------------------	---------------------	--------------------	--------------

<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A091624 002</u>	Apr 05, 2013
-----------	--	--	---------------------	--------------------	--------------

<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A091624 003</u>	Apr 05, 2013
-----------	--	--	---------------------	--------------------	--------------

<u>AB</u>			<u>EQ 80MG BASE</u>	<u>A091624 004</u>	Apr 05, 2013
-----------	--	--	---------------------	--------------------	--------------

<u>AB</u>		MYLAN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A091226 001</u>	May 29, 2012
-----------	--	------------------	---------------------	--------------------	--------------

<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A091226 002</u>	May 29, 2012
-----------	--	--	---------------------	--------------------	--------------

<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A091226 003</u>	May 29, 2012
-----------	--	--	---------------------	--------------------	--------------

<u>AB</u>			<u>EQ 80MG BASE</u>	<u>A091226 004</u>	May 29, 2012
-----------	--	--	---------------------	--------------------	--------------

<u>AB</u>		SANDOZ INC	<u>EQ 10MG BASE</u>	<u>A077575 001</u>	May 29, 2012
-----------	--	------------	---------------------	--------------------	--------------

<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A077575 002</u>	May 29, 2012
-----------	--	--	---------------------	--------------------	--------------

<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A077575 003</u>	May 29, 2012
-----------	--	--	---------------------	--------------------	--------------

<u>AB</u>			<u>EQ 80MG BASE</u>	<u>A077575 004</u>	May 29, 2012
-----------	--	--	---------------------	--------------------	--------------

<u>AB</u>		SCIEGEN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A205519 001</u>	May 19, 2016
-----------	--	--------------------	---------------------	--------------------	--------------

<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A205519 002</u>	May 19, 2016
-----------	--	--	---------------------	--------------------	--------------

<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A205519 003</u>	May 19, 2016
-----------	--	--	---------------------	--------------------	--------------

<u>AB</u>			<u>EQ 80MG BASE</u>	<u>A205519 004</u>	May 19, 2016
-----------	--	--	---------------------	--------------------	--------------

<u>AB</u>		SUN PHARM INDS LTD	<u>EQ 10MG BASE</u>	<u>A076477 001</u>	Nov 30, 2011
-----------	--	--------------------	---------------------	--------------------	--------------

<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A076477 002</u>	Nov 30, 2011
-----------	--	--	---------------------	--------------------	--------------

<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A076477 003</u>	Nov 30, 2011
-----------	--	--	---------------------	--------------------	--------------

<u>AB</u>			<u>EQ 80MG BASE</u>	<u>A076477 004</u>	Nov 30, 2011
-----------	--	--	---------------------	--------------------	--------------

LIPITOR

<u>AB</u>		PFIZER	<u>EQ 10MG BASE</u>	<u>N020702 001</u>	Dec 17, 1996
-----------	--	--------	---------------------	--------------------	--------------

<u>AB</u>			<u>EQ 20MG BASE</u>	<u>N020702 002</u>	Dec 17, 1996
-----------	--	--	---------------------	--------------------	--------------

<u>AB</u>			<u>EQ 40MG BASE</u>	<u>N020702 003</u>	Dec 17, 1996
-----------	--	--	---------------------	--------------------	--------------

<u>AB</u>	+		<u>EQ 80MG BASE</u>	<u>N020702 004</u>	Apr 07, 2000
-----------	---	--	---------------------	--------------------	--------------

ATOVAQUONE

SUSPENSION; ORAL

ATOVAQUONE

<u>AB</u>		AMNEAL PHARMS	<u>750MG/5ML</u>	<u>A202960 001</u>	Mar 18, 2014
-----------	--	---------------	------------------	--------------------	--------------

MEPRON

<u>AB</u>	+	GLAXOSMITHKLINE LLC	<u>750MG/5ML</u>	<u>N020500 001</u>	Feb 08, 1995
-----------	---	---------------------	------------------	--------------------	--------------

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

<u>AB</u>		GLENMARK GENERICS	<u>62.5MG; 25MG</u>	<u>A091211 002</u>	Apr 06, 2015
-----------	--	-------------------	---------------------	--------------------	--------------

<u>AB</u>			<u>250MG; 100MG</u>	<u>A091211 001</u>	Jan 12, 2011
-----------	--	--	---------------------	--------------------	--------------

<u>AB</u>		MYLAN PHARMS INC	<u>62.5MG; 25MG</u>	<u>A202362 001</u>	May 27, 2014
-----------	--	------------------	---------------------	--------------------	--------------

<u>AB</u>			<u>250MG; 100MG</u>	<u>A202362 002</u>	May 27, 2014
-----------	--	--	---------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL

MALARONE

AB	+	GLAXOSMITHKLINE	250MG;100MG	N021078 001	Jul 14, 2000
-----------	---	-----------------	--------------------	--------------------	--------------

MALARONE PEDIATRIC

AB		GLAXOSMITHKLINE	62.5MG;25MG	N021078 002	Jul 14, 2000
-----------	--	-----------------	--------------------	--------------------	--------------

ATRAURIUM BESYLATE

INJECTABLE; INJECTION

ATRAURIUM BESYLATE

AP		AUROBINDO PHARMA LTD	10MG/ML	A206011 001	Apr 08, 2015
-----------	--	----------------------	----------------	--------------------	--------------

AP		HOSPIRA INC	10MG/ML	A090761 001	Oct 18, 2012
-----------	--	-------------	----------------	--------------------	--------------

AP		NANJING KING-FRIEND	10MG/ML	A091489 001	Feb 17, 2012
-----------	--	---------------------	----------------	--------------------	--------------

AP	+	WEST-WARD PHARMS INT	10MG/ML	A074901 001	Jul 18, 1997
-----------	---	----------------------	----------------	--------------------	--------------

ATRAURIUM BESYLATE PRESERVATIVE FREE

AP		AUROBINDO PHARMA LTD	10MG/ML	A206010 001	Apr 08, 2015
-----------	--	----------------------	----------------	--------------------	--------------

AP		HOSPIRA INC	10MG/ML	A090782 001	Oct 18, 2012
-----------	--	-------------	----------------	--------------------	--------------

AP		NANJING KING-FRIEND	10MG/ML	A091488 001	Feb 17, 2012
-----------	--	---------------------	----------------	--------------------	--------------

AP	+	WEST-WARD PHARMS INT	10MG/ML	A074900 001	Jul 18, 1997
-----------	---	----------------------	----------------	--------------------	--------------

ATROPINE

INJECTABLE; INJECTION

ATROPEN

+	MERIDIAN MEDCL TECHN	EQ 0.25MG SULFATE/0.3ML	N017106 004	Sep 17, 2004
---	----------------------	-------------------------	-------------	--------------

+		EQ 0.5MG SULFATE/0.7ML	N017106 003	Jun 19, 2003
---	--	------------------------	-------------	--------------

+		EQ 1MG SULFATE/0.7ML	N017106 002	Jun 19, 2003
---	--	----------------------	-------------	--------------

+		EQ 2MG SULFATE/0.7ML	N017106 001	
---	--	----------------------	-------------	--

ATROPINE SULFATE

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

ATROPINE SULFATE ANSYR PLASTIC SYRINGE

+	HOSPIRA	0.05MG/ML	N021146 002	Jul 09, 2001
---	---------	-----------	-------------	--------------

+		0.1MG/ML	N021146 001	Jul 09, 2001
---	--	----------	-------------	--------------

SOLUTION/DROPS; OPHTHALMIC

ATROPINE SULFATE

+	AKORN	1%	N206289 001	Jul 18, 2014
---	-------	----	-------------	--------------

ISOPTO ATROPINE

	NOVARTIS PHARMS CORP	1%	N208151 001	Dec 01, 2016
--	----------------------	----	-------------	--------------

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL

MOTOFEN

+	SEBELA IRELAND LTD	0.025MG;1MG	N017744 002	
---	--------------------	-------------	-------------	--

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA	+	WEST-WARD PHARMS INT	0.025MG/5ML;2.5MG/5ML	A087708 001	May 03, 1982
-----------	---	----------------------	------------------------------	--------------------	--------------

TABLET; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA		LANNETT	0.025MG;2.5MG	A085372 001	
-----------	--	---------	----------------------	--------------------	--

AA		MYLAN	0.025MG;2.5MG	A085762 001	
-----------	--	-------	----------------------	--------------------	--

AA		PAR PHARM	0.025MG;2.5MG	A040357 001	May 02, 2000
-----------	--	-----------	----------------------	--------------------	--------------

LOMOTIL

AA	+	GD SEARLE LLC	0.025MG;2.5MG	N012462 001	
-----------	---	---------------	----------------------	--------------------	--

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

ENLON-PLUS

+	MYLAN INSTITUTIONAL	0.14MG/ML;10MG/ML	N019678 001	Nov 06, 1991
---	---------------------	-------------------	-------------	--------------

ATROPINE; PRALIDOXIME CHLORIDE

INJECTABLE; INTRAMUSCULAR

DUODOTE

+	MERIDIAN MEDCL	2.1MG/0.7ML;600MG/2ML	N021983 001	Sep 28, 2006
---	----------------	-----------------------	-------------	--------------

AURANOFIN

CAPSULE; ORAL

RIDAURA

+	SEBELA IRELAND LTD	3MG	N018689 001	May 24, 1985
---	--------------------	-----	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

AVANAFIL

TABLET; ORAL

STENDRA

METUCHEN PHARMS	50MG	N202276 001	Apr 27, 2012
	100MG	N202276 002	Apr 27, 2012
+	200MG	N202276 003	Apr 27, 2012

AVIBACTAM SODIUM; CEFTAZIDIME

POWDER; IV (INFUSION)

AVYCAZ

+ CEREXA INC	EQ 0.5GM BASE; 2GM/VIAL	N206494 001	Feb 25, 2015
--------------	-------------------------	-------------	--------------

AXITINIB

TABLET; ORAL

INLYTA

PF PRISM CV	1MG	N202324 001	Jan 27, 2012
+	5MG	N202324 002	Jan 27, 2012

AZACITIDINE

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

AZACITIDINE

AP	DR REDDYS LABS LTD	100MG/VIAL	A201537 001	Sep 16, 2013
AP	MYLAN INSTITUTIONAL	100MG/VIAL	A204949 001	Apr 28, 2016
AP	SHILPA MEDICARE	100MG/VIAL	A207518 001	Sep 29, 2016

VIDAZA

AP	+ CELGENE	100MG/VIAL	N050794 001	May 19, 2004
-----------	-----------	-------------------	--------------------	--------------

POWDER; IV (INFUSION), SUBCUTANEOUS
AZACITIDINE

ACTAVIS LLC	100MG/VIAL	N208216 001	Apr 29, 2016
-------------	------------	-------------	--------------

AZATHIOPRINE

TABLET; ORAL

AZASAN

AB	AAIPHARMA LLC	25MG	A075252 002	Feb 03, 2003
AB		50MG	A075252 001	Jun 07, 1999
AB		75MG	A075252 003	Feb 03, 2003
AB		100MG	A075252 004	Feb 03, 2003

AZATHIOPRINE

AB	AMNEAL PHARMS LLC	50MG	A074069 001	Feb 16, 1996
AB	MYLAN	50MG	A075568 001	Dec 13, 1999
AB	ZYDUS PHARMS USA	25MG	A077621 002	Sep 05, 2008
AB		50MG	A077621 001	Mar 15, 2007
AB		75MG	A077621 003	Sep 05, 2008
AB		100MG	A077621 004	Sep 05, 2008

IMURAN

AB	+ SEBELA IRELAND LTD	50MG	N016324 001	
-----------	----------------------	-------------	--------------------	--

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION

AZATHIOPRINE SODIUM

+ WEST-WARD PHARMS INT	EQ 100MG BASE/VIAL	A074419 001	Mar 31, 1995
------------------------	--------------------	-------------	--------------

AZELAIC ACID

AEROSOL, FOAM; TOPICAL

FINACEA

+ BAYER HLTHCARE	15%	N207071 001	Jul 29, 2015
------------------	-----	-------------	--------------

CREAM; TOPICAL

AZELEX

+ ALLERGAN	20%	N020428 001	Sep 13, 1995
------------	-----	-------------	--------------

GEL; TOPICAL

FINACEA

+ BAYER HLTHCARE	15%	N021470 001	Dec 24, 2002
------------------	-----	-------------	--------------

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AZELASTINE HYDROCHLORIDE

AT	AKORN	0.05%	A203660 001	Nov 08, 2016
AT	ALCON PHARMA	0.05%	A202305 001	May 31, 2012
AT	APOTEX INC	0.05%	A078621 001	Aug 03, 2009
AT	SUN PHARMA GLOBAL	0.05%	A078738 001	Jun 21, 2010

OPTIVAR

AT	+ MEDA PHARMS	0.05%	N021127 001	May 22, 2000
-----------	---------------	--------------	--------------------	--------------

SPRAY, METERED; NASAL

ASTELIN

AB	+ MEDA PHARMS	EQ 0.125MG BASE/SPRAY	N020114 001	Nov 01, 1996
-----------	---------------	------------------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL

ASTEPRO

AB	+	MEDA PHARMS	<u>EQ 0.1876MG BASE/SPRAY</u>	<u>N022203 002</u>	Aug 31, 2009
-----------	---	-------------	--------------------------------------	---------------------------	--------------

AZELASTINE HYDROCHLORIDE

AB		APOTEX INC	<u>EQ 0.125MG BASE/SPRAY</u>	<u>A077954 001</u>	Apr 30, 2009
AB			<u>EQ 0.1876MG BASE/SPRAY</u>	<u>A201846 001</u>	Aug 31, 2012
AB		BRECKENRIDGE PHARMS	<u>EQ 0.125MG BASE/SPRAY</u>	<u>A090176 001</u>	Jul 28, 2015
AB		PERRIGO ISRAEL	<u>EQ 0.1876MG BASE/SPRAY</u>	<u>A202743 001</u>	May 08, 2014
AB		SUN PHARMA GLOBAL	<u>EQ 0.125MG BASE/SPRAY</u>	<u>A090423 001</u>	May 23, 2012
AB		WEST-WARD PHARMS INT	<u>EQ 0.125MG BASE/SPRAY</u>	<u>A091444 001</u>	Oct 24, 2014

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

DYMISTA

+ MEDA PHARMS

EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY

N202236 001 May 01, 2012

AZILSARTAN KAMEDOXOMIL

TABLET;ORAL

EDARBI

ARBOR PHARMS LLC

EQ 40MG MEDOXOMIL

N200796 001 Feb 25, 2011

+

EQ 80MG MEDOXOMIL

N200796 002 Feb 25, 2011

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET;ORAL

EDARBYCLOR

ARBOR PHARMS LLC

EQ 40MG MEDOXOMIL;12.5MG

N202331 001 Dec 20, 2011

+

EQ 40MG MEDOXOMIL;25MG

N202331 002 Dec 20, 2011

AZITHROMYCIN

FOR SUSPENSION;ORAL

AZITHROMYCIN

AB		PLIVA	<u>EQ 100MG BASE/5ML</u>	<u>A065246 002</u>	Jul 05, 2006
AB			<u>EQ 200MG BASE/5ML</u>	<u>A065246 001</u>	Jul 05, 2006
AB		TEVA PHARMS	<u>EQ 100MG BASE/5ML</u>	<u>A065419 001</u>	Jun 24, 2008
AB			<u>EQ 200MG BASE/5ML</u>	<u>A065419 002</u>	Jun 24, 2008

ZITHROMAX

AB		PFIZER	<u>EQ 100MG BASE/5ML</u>	<u>N050710 001</u>	Oct 19, 1995
AB	+		<u>EQ 200MG BASE/5ML</u>	<u>N050710 002</u>	Oct 19, 1995
		AZITHROMYCIN			
BX		LUPIN LTD	EQ 100MG BASE/5ML	A065488 001	May 15, 2015
BX			EQ 200MG BASE/5ML	A065488 002	May 15, 2015
		ZITHROMAX			
	+	PFIZER	EQ 1GM BASE/PACKET	N050693 001	Sep 28, 1994
		FOR SUSPENSION, EXTENDED RELEASE;ORAL			
		ZMAX			
	+	PF PRISM CV	EQ 2GM BASE/BOT	N050797 001	Jun 10, 2005
		INJECTABLE;INJECTION			

AZITHROMYCIN

AP		AUROBINDO PHARMA LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A203294 001</u>	Jun 19, 2015
AP		FRESENIUS KABI USA	<u>EQ 500MG BASE/VIAL</u>	<u>A065179 001</u>	Dec 13, 2005
AP		GLAND PHARMA LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A065501 001</u>	Nov 09, 2009
AP		HOSPIRA	<u>EQ 500MG BASE/VIAL</u>	<u>A065500 001</u>	Jun 26, 2009
AP			<u>EQ 500MG BASE/VIAL</u>	<u>A065511 001</u>	Jun 26, 2009
AP		SAGENT STRIDES	<u>EQ 500MG BASE/VIAL</u>	<u>A065506 001</u>	Mar 24, 2009
AP		SUN PHARM INDS LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A090923 001</u>	Apr 02, 2013

ZITHROMAX

AP	+	PFIZER	<u>EQ 500MG BASE/VIAL</u>	<u>N050733 001</u>	Jan 30, 1997
-----------	---	--------	----------------------------------	---------------------------	--------------

SOLUTION/DROPS;OPHTHALMIC

AZASITE

+ OAK PHARMS INC

1%

N050810 001 Apr 27, 2007

TABLET;ORAL

AZITHROMYCIN

AB		APOTEX CORP	<u>EQ 250MG BASE</u>	<u>A065507 001</u>	Jul 13, 2011
AB			<u>EQ 500MG BASE</u>	<u>A065509 001</u>	Jul 13, 2011
AB			<u>EQ 600MG BASE</u>	<u>A065508 001</u>	Jul 13, 2011
AB		LUPIN LTD	<u>EQ 250MG BASE</u>	<u>A065398 001</u>	May 15, 2015
AB			<u>EQ 500MG BASE</u>	<u>A065399 001</u>	May 15, 2015
AB			<u>EQ 600MG BASE</u>	<u>A065400 001</u>	May 15, 2015
AB		MYLAN	<u>EQ 250MG BASE</u>	<u>A065365 001</u>	May 30, 2007
AB			<u>EQ 500MG BASE</u>	<u>A065366 001</u>	May 30, 2007
AB			<u>EQ 600MG BASE</u>	<u>A065360 001</u>	Jan 08, 2007
AB		PLIVA	<u>EQ 250MG BASE</u>	<u>A065225 001</u>	Nov 14, 2005
AB			<u>EQ 500MG BASE</u>	<u>A065223 001</u>	Nov 14, 2005

PRESCRIPTION DRUG PRODUCT LIST

AZITHROMYCIN

TABLET; ORAL

AZITHROMYCIN

<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A065218 001</u>	Nov 14, 2005
<u>AB</u>	SANDOZ	<u>EQ 250MG BASE</u>	<u>A065211 001</u>	Nov 14, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065212 001</u>	Nov 14, 2005
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A065209 001</u>	Nov 14, 2005
<u>AB</u>	TEVA	<u>EQ 250MG BASE</u>	<u>A065153 001</u>	Nov 14, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065193 001</u>	Nov 14, 2005
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A065150 001</u>	Nov 14, 2005
<u>AB</u>	WOCKHARDT	<u>EQ 250MG BASE</u>	<u>A065404 001</u>	Feb 11, 2008
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065405 001</u>	Feb 11, 2008
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A065302 003</u>	Feb 11, 2008
<u>ZITHROMAX</u>				
<u>AB</u>	PFIZER	<u>EQ 250MG BASE</u>	<u>N050711 001</u>	Jul 18, 1996
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>N050784 001</u>	May 24, 2002
<u>AB</u>	+	<u>EQ 600MG BASE</u>	<u>N050730 001</u>	Jun 12, 1996

AZTREONAM

FOR SOLUTION; INHALATION

CAYSTON

+ GILEAD

75MG/VIAL

N050814 001 Feb 22, 2010

INJECTABLE; INJECTION

AZACTAM

<u>AP</u>	+	BRISTOL MYERS SQUIBB	<u>1GM/VIAL</u>	<u>N050580 002</u>	Dec 31, 1986
<u>AP</u>	+		<u>2GM/VIAL</u>	<u>N050580 003</u>	Dec 31, 1986

AZTREONAM

<u>AP</u>		FRESENIUS KABI USA	<u>1GM/VIAL</u>	<u>A065439 002</u>	Jun 18, 2010
<u>AP</u>			<u>2GM/VIAL</u>	<u>A065439 003</u>	Jun 18, 2010
AZACTAM IN PLASTIC CONTAINER					
	+	BRISTOL MYERS SQUIBB	20MG/ML	N050632 002	May 24, 1989
	+		40MG/ML	N050632 001	May 24, 1989
AZTREONAM					
		FRESENIUS KABI USA	500MG/VIAL	A065439 001	Jun 18, 2010

BACITRACIN

INJECTABLE; INJECTION

BACIIM

<u>AP</u>		X GEN PHARMS	<u>50,000 UNITS/VIAL</u>	<u>A064153 001</u>	May 09, 1997
-----------	--	--------------	--------------------------	--------------------	--------------

BACITRACIN

<u>AP</u>		FRESENIUS KABI USA	<u>50,000 UNITS/VIAL</u>	<u>A065116 001</u>	Dec 03, 2002
<u>AP</u>	+	PHARMACIA AND UPJOHN	<u>50,000 UNITS/VIAL</u>	<u>A060733 002</u>	
<u>AP</u>		SAGENT STRIDES	<u>50,000 UNITS/VIAL</u>	<u>A090211 001</u>	May 11, 2010
<u>AP</u>		XELLIA PHARMS APS	<u>50,000 UNITS/VIAL</u>	<u>A203177 001</u>	Aug 25, 2014
		PHARMACIA AND UPJOHN	10,000 UNITS/VIAL	A060733 001	

OINTMENT; OPHTHALMIC

BACITRACIN

+ PERRIGO CO TENNESSEE

500 UNITS/GM

A061212 001

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

<u>AT</u>		AKORN	<u>400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A065213 001</u>	Jul 25, 2012
<u>AT</u>	+	BAUSCH AND LOMB	<u>400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A064068 001</u>	Oct 30, 1995

OINTMENT; TOPICAL

CORTISPORIN

+ MONARCH PHARMS

400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM

N050168 002 May 04, 1984

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

<u>AT</u>		AKORN	<u>400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A065088 001</u>	Feb 06, 2004
<u>AT</u>	+	BAUSCH AND LOMB	<u>400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A064064 001</u>	Oct 30, 1995
<u>AT</u>		PERRIGO CO TENNESSEE	<u>400 UNITS/GM;EQ 3.5MG BASE;10,000 UNITS/GM</u>	<u>A060764 002</u>	

PRESCRIPTION DRUG PRODUCT LIST

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT	AKORN	<u>500 UNITS/GM;10,000 UNITS/GM</u>	<u>A064028 001</u>	Jan 30, 1995
AT	+ BAUSCH AND LOMB	<u>500 UNITS/GM;10,000 UNITS/GM</u>	<u>A064046 001</u>	Jan 26, 1995
AT	PERRIGO CO TENNESSEE	<u>500 UNITS/GM;10,000 UNITS/GM</u>	<u>A065022 001</u>	Feb 27, 2002

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

	+ PERRIGO CO TENNESSEE	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166 002	
--	------------------------	--	-------------	--

BACLOFEN

INJECTABLE;INTRATHECAL

BACLOFEN

AP	SINETTICA SA	<u>0.05MG/ML</u>	<u>A091193 001</u>	May 03, 2016
AP		<u>0.5MG/ML</u>	<u>A091193 002</u>	May 03, 2016
AP		<u>2MG/ML</u>	<u>A091193 003</u>	May 03, 2016

GABLOFEN

AP	MALLINCKRODT INC	<u>0.05MG/ML</u>	<u>N022462 001</u>	Nov 19, 2010
AP		<u>0.5MG/ML</u>	<u>N022462 002</u>	Nov 19, 2010
AP		<u>2MG/ML</u>	<u>N022462 003</u>	Nov 19, 2010

LIORESAL

AP	+ SAOL THERAPS RES LTD	<u>0.05MG/ML</u>	<u>N020075 003</u>	Nov 07, 1996
AP	+	<u>0.5MG/ML</u>	<u>N020075 001</u>	Jun 17, 1992
AP	+	<u>2MG/ML</u>	<u>N020075 002</u>	Jun 17, 1992

GABLOFEN

	MALLINCKRODT INC	1MG/ML	N022462 004	Jun 22, 2012
--	------------------	--------	-------------	--------------

TABLET;ORAL

BACLOFEN

AB	CARACO	<u>10MG</u>	<u>A077984 001</u>	Aug 14, 2006
AB	IMPAX LABS	<u>10MG</u>	<u>A077971 001</u>	Oct 26, 2007
AB		<u>20MG</u>	<u>A077971 002</u>	Oct 26, 2007
AB	IVAX SUB TEVA PHARMS	<u>10MG</u>	<u>A072234 001</u>	Jul 21, 1988
AB	+	<u>20MG</u>	<u>A072235 001</u>	Jul 21, 1988
AB	LANNETT	<u>10MG</u>	<u>A077241 002</u>	Jul 06, 2007
AB		<u>20MG</u>	<u>A077241 001</u>	Dec 20, 2005
AB	MYLAN	<u>10MG</u>	<u>A077181 001</u>	Jul 29, 2005
AB		<u>20MG</u>	<u>A077121 002</u>	Jul 29, 2005
AB	MYLAN PHARMS INC	<u>10MG</u>	<u>A090334 001</u>	Feb 18, 2010
AB		<u>20MG</u>	<u>A090334 002</u>	Feb 18, 2010
AB	NORTHSTAR HLTHCARE	<u>10MG</u>	<u>A078401 002</u>	Sep 18, 2009
AB		<u>20MG</u>	<u>A078401 001</u>	Sep 18, 2009
AB	OXFORD PHARMS	<u>10MG</u>	<u>A077089 001</u>	Oct 31, 2007
AB		<u>20MG</u>	<u>A077088 001</u>	Oct 31, 2007
AB	SUN PHARM INDS INC	<u>20MG</u>	<u>A077862 002</u>	Aug 14, 2006
AB	USL PHARMA	<u>10MG</u>	<u>A074584 001</u>	Aug 19, 1996
AB		<u>20MG</u>	<u>A074584 002</u>	Aug 19, 1996
AB	VINTAGE PHARMS	<u>10MG</u>	<u>A077156 001</u>	Aug 30, 2005
AB		<u>20MG</u>	<u>A077068 001</u>	Aug 30, 2005

BALSALAZIDE DISODIUM

CAPSULE;ORAL

BALSALAZIDE DISODIUM

AB	APOTEX INC	<u>750MG</u>	<u>A077883 001</u>	Dec 28, 2007
AB	MYLAN	<u>750MG</u>	<u>A077807 001</u>	Dec 28, 2007
AB	WEST-WARD PHARMS INT	<u>750MG</u>	<u>A077806 001</u>	Dec 28, 2007

COLAZAL

AB	+ VALEANT PHARMS INTL	<u>750MG</u>	<u>N020610 001</u>	Jul 18, 2000
-----------	-----------------------	--------------	--------------------	--------------

TABLET;ORAL

BALSALAZIDE DISODIUM

AB	PAR PHARM INC	<u>1.1GM</u>	<u>A206336 001</u>	Sep 08, 2015
-----------	---------------	--------------	--------------------	--------------

GIAZO

AB	+ VALEANT PHARMS INTL	<u>1.1GM</u>	<u>N022205 001</u>	Feb 03, 2012
-----------	-----------------------	--------------	--------------------	--------------

BARIIUM SULFATE

FOR SUSPENSION;ORAL

E-Z-HD

	+ BRACCO	334GM/BOTTLE	N208036 001	Jan 11, 2016
--	----------	--------------	-------------	--------------

PASTE;ORAL

VARIBAR

	+ BRACCO	40% (92GM/230ML)	N208844 001	Oct 14, 2016
--	----------	------------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

BARIUM SULFATE

SUSPENSION; ORAL

READI-CAT 2

+ BRACCO 2% (9GM/450ML)

N208143 001 Jan 15, 2016

READI-CAT 2 SMOOTHIES

BRACCO 2% (9GM/450ML)

N208143 002 Jan 15, 2016

BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED

TABLET; ORAL

DUAVEE

+ WYETH PHARMS PFIZER EQ 20MG BASE; 0.45MG

N022247 001 Oct 03, 2013

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION

QVAR 40

+ TEVA BRANDED PHARM 0.04MG/INH

N020911 002 Sep 15, 2000

QVAR 80

+ TEVA BRANDED PHARM 0.08MG/INH

N020911 001 Sep 15, 2000

AEROSOL, METERED; NASAL

QNASL

TEVA BRANDED PHARM 0.04MG/ACTUATION

N202813 002 Dec 17, 2014

+ 0.08MG/ACTUATION

N202813 001 Mar 23, 2012

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED; NASAL

BECONASE AQ

+ GLAXOSMITHKLINE EQ 0.042MG DIPROP/SPRAY

N019389 001 Jul 27, 1987

BEDAQUILINE FUMARATE

TABLET; ORAL

SIRTURO

+ JANSSEN THERAP EQ 100MG BASE

N204384 001 Dec 28, 2012

BELINOSTAT

POWDER; IV (INFUSION)

BELEODAQ

+ SPECTRUM PHARMS 500MG/VIAL

N206256 001 Jul 03, 2014

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

AB	AMNEAL PHARMS LLC	5MG	A076820 001	Feb 03, 2006
AB		10MG	A076820 002	Feb 03, 2006
AB		20MG	A076820 003	Feb 03, 2006
AB		40MG	A076820 004	Feb 03, 2006
AB	APOTEX INC	5MG	A077128 001	Mar 08, 2006
AB		10MG	A077128 002	Mar 08, 2006
AB		20MG	A077128 003	Mar 08, 2006
AB		40MG	A077128 004	Mar 08, 2006
AB	AUROBINDO PHARMA	10MG	A078212 001	May 22, 2008
AB		20MG	A078212 002	May 22, 2008
AB		40MG	A078212 003	May 22, 2008
AB	IVAX SUB TEVA PHARMS	5MG	A076333 001	Feb 11, 2004
AB		10MG	A076333 002	Feb 11, 2004
AB		20MG	A076333 003	Feb 11, 2004
AB		40MG	A076333 004	Feb 11, 2004
AB	MYLAN	5MG	A076430 001	Feb 11, 2004
AB		10MG	A076430 002	Feb 11, 2004
AB		20MG	A076430 003	Feb 11, 2004
AB		40MG	A076430 004	Feb 11, 2004
AB	PRINSTON INC	5MG	A076118 001	Feb 11, 2004
AB		10MG	A076118 002	Feb 11, 2004
AB		20MG	A076118 003	Feb 11, 2004
AB		40MG	A076118 004	Feb 11, 2004
AB	SANDOZ	5MG	A076402 001	Feb 11, 2004
AB		10MG	A076402 002	Feb 11, 2004
AB		20MG	A076402 003	Feb 11, 2004
AB		40MG	A076402 004	Feb 11, 2004
AB	SUN PHARM INDS LTD	5MG	A076344 001	Feb 11, 2004
AB		10MG	A076344 002	Feb 11, 2004
AB		20MG	A076344 003	Feb 11, 2004
AB		40MG	A076344 004	Feb 11, 2004
AB	TEVA	5MG	A076211 001	Feb 11, 2004
AB		10MG	A076211 002	Feb 11, 2004
AB		20MG	A076211 003	Feb 11, 2004

PRESCRIPTION DRUG PRODUCT LIST

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

<u>AB</u>		<u>40MG</u>	<u>A076211 004</u>	Feb 11, 2004
<u>AB</u>	ZYDUS PHARMS USA	<u>5MG</u>	<u>A078848 001</u>	May 23, 2008
<u>AB</u>		<u>10MG</u>	<u>A078848 002</u>	May 23, 2008
<u>AB</u>		<u>20MG</u>	<u>A078848 003</u>	May 23, 2008
<u>AB</u>		<u>40MG</u>	<u>A078848 004</u>	May 23, 2008
<u>LOTENSIN</u>				
<u>AB</u>	US PHARMS HOLDINGS I	<u>5MG</u>	<u>N019851 001</u>	Jun 25, 1991
<u>AB</u>		<u>10MG</u>	<u>N019851 002</u>	Jun 25, 1991
<u>AB</u>		<u>20MG</u>	<u>N019851 003</u>	Jun 25, 1991
<u>AB</u>	+	<u>40MG</u>	<u>N019851 004</u>	Jun 25, 1991

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	APOTEX INC	<u>5MG; 6.25MG</u>	<u>A078794 001</u>	Aug 21, 2014
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A078794 002</u>	Aug 21, 2014
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A078794 003</u>	Aug 21, 2014
<u>AB</u>		<u>20MG; 25MG</u>	<u>A078794 004</u>	Aug 21, 2014
<u>AB</u>	MYLAN	<u>5MG; 6.25MG</u>	<u>A076688 001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A076688 002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A076688 003</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 25MG</u>	<u>A076688 004</u>	Feb 11, 2004
<u>AB</u>	SANDOZ	<u>5MG; 6.25MG</u>	<u>A076631 001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A076631 002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A076631 003</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 25MG</u>	<u>A076631 004</u>	Feb 11, 2004
<u>LOTENSIN HCT</u>				
<u>AB</u>	US PHARMS HOLDINGS I	<u>5MG; 6.25MG</u>	<u>N020033 001</u>	May 19, 1992
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>N020033 002</u>	May 19, 1992
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>N020033 004</u>	May 19, 1992
<u>AB</u>	+	<u>20MG; 25MG</u>	<u>N020033 003</u>	May 19, 1992

BENDAMUSTINE HYDROCHLORIDE

POWDER; IV (INFUSION)

BENDAMUSTINE HYDROCHLORIDE

<u>AP</u>	ACCORD HLTHCARE	<u>25MG/VIAL</u>	<u>A205574 001</u>	May 19, 2016
<u>AP</u>		<u>100MG/VIAL</u>	<u>A205574 002</u>	May 19, 2016
<u>AP</u>	BRECKENRIDGE PHARM	<u>25MG/VIAL</u>	<u>A205447 001</u>	Dec 29, 2016
<u>AP</u>		<u>100MG/VIAL</u>	<u>A205447 002</u>	Dec 29, 2016
<u>AP</u>	GLENMARK PHARMS LTD	<u>25MG/VIAL</u>	<u>A204771 001</u>	Mar 24, 2016
<u>AP</u>		<u>100MG/VIAL</u>	<u>A204771 002</u>	Mar 24, 2016
<u>AP</u>	HOSPIRA INC	<u>25MG/VIAL</u>	<u>A204086 001</u>	May 20, 2016
<u>AP</u>		<u>100MG/VIAL</u>	<u>A204086 002</u>	May 20, 2016
<u>AP</u>	INNOPHARMA LICENSING	<u>25MG/VIAL</u>	<u>A205476 001</u>	Mar 24, 2016
<u>AP</u>		<u>100MG/VIAL</u>	<u>A205476 002</u>	Mar 24, 2016

TREANDA

<u>AP</u>	+	CEPHALON	<u>25MG/VIAL</u>	<u>N022249 002</u>	May 01, 2009
<u>AP</u>	+		<u>100MG/VIAL</u>	<u>N022249 001</u>	Mar 20, 2008

SOLUTION; IV (INFUSION)

BENDEKA

+ EAGLE PHARMS

100MG/4ML (25MG/ML)

N208194 001 Dec 07, 2015

TREANDA

+ CEPHALON

45MG/0.5ML (90MG/ML)

N022249 003 Sep 13, 2013

+

180MG/2ML (90MG/ML)

N022249 004 Sep 13, 2013

BENDROFLUMETHIAZIDE; NADOLOL

TABLET; ORAL

CORZIDE

<u>AB</u>	KING PHARMS	<u>5MG; 40MG</u>	<u>N018647 001</u>	May 25, 1983
<u>AB</u>	+	<u>5MG; 80MG</u>	<u>N018647 002</u>	May 25, 1983

NADOLOL AND BENDROFLUMETHIAZIDE

<u>AB</u>	IMPAX LABS	<u>5MG; 40MG</u>	<u>A077833 001</u>	Mar 30, 2007
<u>AB</u>		<u>5MG; 80MG</u>	<u>A077833 002</u>	Mar 30, 2007
<u>AB</u>	MYLAN	<u>5MG; 40MG</u>	<u>A078688 001</u>	Feb 15, 2008
<u>AB</u>		<u>5MG; 80MG</u>	<u>A078688 002</u>	Feb 15, 2008

PRESCRIPTION DRUG PRODUCT LIST

BENZONATATE

CAPSULE; ORAL

BENZONATATE

<u>AA</u>	APOTEX INC	<u>100MG</u>	<u>A091310 001</u>	Jan 16, 2015
<u>AA</u>		<u>200MG</u>	<u>A091310 002</u>	Jan 16, 2015
<u>AA</u>	BIONPHARMA INC	<u>100MG</u>	<u>A081297 001</u>	Jan 29, 1993
<u>AA</u>		<u>200MG</u>	<u>A081297 002</u>	Oct 30, 2007
<u>AA</u>	CSPC NBP PHARM CO	<u>200MG</u>	<u>A202765 001</u>	Jul 31, 2015
<u>AA</u>	MIKART	<u>100MG</u>	<u>A040851 001</u>	Nov 09, 2009
<u>AA</u>		<u>150MG</u>	<u>A040851 002</u>	Nov 09, 2009
<u>AA</u>		<u>200MG</u>	<u>A040851 003</u>	Nov 09, 2009
<u>AA</u>	ORIT LABS LLC	<u>100MG</u>	<u>A040682 001</u>	Jul 30, 2007
<u>AA</u>		<u>200MG</u>	<u>A040682 002</u>	Jul 30, 2007
<u>AA</u>	STRIDES PHARMA	<u>100MG</u>	<u>A091133 001</u>	Jul 30, 2015
<u>AA</u>		<u>200MG</u>	<u>A091133 002</u>	Jul 30, 2015
<u>AA</u>	SUN PHARM INDS INC	<u>100MG</u>	<u>A040587 001</u>	Mar 19, 2008
<u>AA</u>		<u>200MG</u>	<u>A040587 002</u>	Mar 19, 2008
<u>AA</u>	+ THE PHARMA NETWORK	<u>100MG</u>	<u>A040627 001</u>	Mar 30, 2007
<u>AA</u>	+	<u>200MG</u>	<u>A040749 001</u>	Jul 25, 2007
<u>AA</u>	+ THEPHARMANETWORK LLC	<u>150MG</u>	<u>A201209 001</u>	Sep 24, 2014
<u>AA</u>	ZYDUS PHARMS USA	<u>100MG</u>	<u>A040597 001</u>	Jun 08, 2007
<u>AA</u>		<u>200MG</u>	<u>A040597 002</u>	Jun 08, 2007

TESSALON

<u>AA</u>	PFIZER	<u>100MG</u>	<u>N011210 001</u>	
-----------	--------	--------------	--------------------	--

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

ACANYA

<u>AB</u>	+ DOW PHARM	<u>2.5%;EQ 1.2% BASE</u>	<u>N050819 001</u>	Oct 23, 2008
-----------	-------------	--------------------------	--------------------	--------------

BENZACLIN

<u>AB</u>	+ VALEANT BERMUDA	<u>5%;EO 1% BASE</u>	<u>N050756 001</u>	Dec 21, 2000
-----------	-------------------	----------------------	--------------------	--------------

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

<u>AB</u>	ACTAVIS LABS UT INC	<u>2.5%;EQ 1.2% BASE</u>	<u>A205128 001</u>	Jun 19, 2015
<u>AB</u>	MYLAN PHARMS INC	<u>5%;EO 1% BASE</u>	<u>A065443 001</u>	Aug 11, 2009
<u>AB</u>	PERRIGO ISRAEL	<u>5%;EQ 1% BASE</u>	<u>A202440 001</u>	Sep 21, 2015
<u>AB</u>		<u>5%;1.2%</u>	<u>A090979 001</u>	Jun 26, 2012
<u>AB</u>	TOLMAR	<u>5%;1.2%</u>	<u>A203688 001</u>	Aug 25, 2016

DUAC

<u>AB</u>	+ STIEFEL	<u>5%;1.2%</u>	<u>N050741 001</u>	Aug 26, 2002
	ONEXTON			
	+ DOW PHARM	<u>3.75%;EQ 1.2% BASE</u>	<u>N050819 002</u>	Nov 24, 2014

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

BENZAMYCIN

<u>AB</u>	+ VALEANT INTL	<u>5%;3%</u>	<u>N050557 001</u>	Oct 26, 1984
-----------	----------------	--------------	--------------------	--------------

ERYTHROMYCIN AND BENZOYL PEROXIDE

<u>AB</u>	LYNE	<u>5%;3%</u>	<u>A065385 001</u>	Sep 18, 2015
<u>AB</u>	TOLMAR	<u>5%;3%</u>	<u>A065112 001</u>	Mar 29, 2004
	AKTIPAK			
	+ CUTANEA	<u>5%;3%</u>	<u>N050769 001</u>	Nov 27, 2000

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

<u>AA</u>	EMCURE PHARMS LTD	<u>50MG</u>	<u>A202061 001</u>	Jan 27, 2012
<u>AA</u>	EPIC PHARMA LLC	<u>50MG</u>	<u>A090346 001</u>	Dec 15, 2015
<u>AA</u>	+ KVK TECH	<u>50MG</u>	<u>A090968 001</u>	Jul 20, 2010
<u>AA</u>	MALLINCKRODT INC	<u>50MG</u>	<u>A040773 001</u>	Apr 25, 2007
<u>AA</u>	MIKART	<u>25MG</u>	<u>A090473 001</u>	Sep 15, 2010
<u>AA</u>		<u>50MG</u>	<u>A090473 002</u>	Sep 15, 2010
<u>AA</u>	PADDOCK	<u>50MG</u>	<u>A040578 001</u>	Apr 17, 2006
<u>AA</u>	TEDOR PHARM	<u>25MG</u>	<u>A040747 002</u>	Nov 20, 2015
<u>AA</u>		<u>50MG</u>	<u>A040747 001</u>	Mar 30, 2007

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

<u>AP</u>	FRESENIUS KABI USA	<u>1MG/ML</u>	<u>A090233 001</u>	Jul 28, 2009
<u>AP</u>	HIKMA FARMACEUTICA	<u>1MG/ML</u>	<u>A090287 001</u>	Aug 31, 2009
<u>AP</u>	LUITPOLD	<u>1MG/ML</u>	<u>A091152 001</u>	Mar 29, 2010
<u>AP</u>	NAVINTA LLC	<u>1MG/ML</u>	<u>A091525 001</u>	Feb 05, 2013

COGENTIN

<u>AP</u>	+ OAK PHARMS AKORN	<u>1MG/ML</u>	<u>N012015 001</u>	
-----------	--------------------	---------------	--------------------	--

PRESCRIPTION DRUG PRODUCT LIST

BENZTROPINE MESYLATE

TABLET; ORAL

BENZTROPINE MESYLATE

<u>AA</u>	ASPEN GLOBAL INC	<u>0.5MG</u>	<u>A204713 001</u>	Apr 14, 2015
<u>AA</u>		<u>1MG</u>	<u>A204713 002</u>	Apr 14, 2015
<u>AA</u>		<u>2MG</u>	<u>A204713 003</u>	Apr 14, 2015
<u>AA</u>	COREPHARMA	<u>0.5MG</u>	<u>A072264 001</u>	Feb 27, 1989
<u>AA</u>		<u>1MG</u>	<u>A072265 001</u>	Feb 27, 1989
<u>AA</u>		<u>2MG</u>	<u>A072266 001</u>	Feb 27, 1989
<u>AA</u>	INVAGEN PHARMS	<u>0.5MG</u>	<u>A090294 001</u>	Mar 29, 2010
<u>AA</u>		<u>1MG</u>	<u>A090294 002</u>	Mar 29, 2010
<u>AA</u>		<u>2MG</u>	<u>A090294 003</u>	Mar 29, 2010
<u>AA</u>	LEADING PHARMA LLC	<u>0.5MG</u>	<u>A090168 001</u>	Nov 28, 2012
<u>AA</u>		<u>1MG</u>	<u>A090168 002</u>	Nov 28, 2012
<u>AA</u>		<u>2MG</u>	<u>A090168 003</u>	Nov 28, 2012
<u>AA</u>	PLIVA	<u>0.5MG</u>	<u>A089058 001</u>	Aug 10, 1988
<u>AA</u>		<u>1MG</u>	<u>A089059 001</u>	Aug 10, 1988
<u>AA</u>		<u>2MG</u>	<u>A089060 001</u>	Aug 10, 1988
<u>AA</u>	+ USL PHARMA	<u>0.5MG</u>	<u>A040103 001</u>	Dec 12, 1996
<u>AA</u>	+	<u>1MG</u>	<u>A040103 002</u>	Dec 12, 1996
<u>AA</u>	+	<u>2MG</u>	<u>A040103 003</u>	Dec 12, 1996
<u>AA</u>	VINTAGE	<u>0.5MG</u>	<u>A040715 001</u>	Aug 27, 2007
<u>AA</u>		<u>1MG</u>	<u>A040715 002</u>	Aug 27, 2007
<u>AA</u>		<u>2MG</u>	<u>A040715 003</u>	Aug 27, 2007

BENZYL ALCOHOL

LOTION; TOPICAL

ULESFIA

+ SHIONOGI INC

5%

N022129 001 Apr 09, 2009

BENZYL PENICILLOYL POLYLYSINE

INJECTABLE; INJECTION

PRE-PEN

+ ALLERQUEST

60UMOLAR

N050114 001

BEPOTASTINE BESILATE

SOLUTION/DROPS; OPHTHALMIC

BEPREVE

+ BAUSCH AND LOMB INC

1.5%

N022288 001 Sep 08, 2009

BERACTANT

SUSPENSION; INTRATRACHEAL

SURVANTA

+ ABBVIE

25MG/ML

N020032 001 Jul 01, 1991

BESIFLOXACIN HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

BESIVANCE

+ BAUSCH AND LOMB

EQ 0.6% BASE

N022308 001 May 28, 2009

BETAINE HYDROCHLORIDE

FOR SOLUTION; ORAL

CYSTADANE

+ RARE DIS THERAP

1GM/SCOOPFUL

N020576 001 Oct 25, 1996

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

<u>AB</u>	LUITPOLD	<u>3MG/ML;EQ 3MG BASE/ML</u>	<u>A090747 001</u>	Jul 31, 2009
-----------	----------	------------------------------	--------------------	--------------

CELESTONE SOLUSPAN

<u>AB</u>	+ MERCK SHARP DOHME	<u>3MG/ML;EQ 3MG BASE/ML</u>	<u>N014602 001</u>	
-----------	---------------------	------------------------------	--------------------	--

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

BETAMETHASONE DIPROPIONATE

<u>AB</u>	ACTAVIS MID ATLANTIC	<u>EQ 0.05% BASE</u>	<u>A070885 001</u>	Feb 03, 1987
-----------	----------------------	----------------------	--------------------	--------------

<u>AB</u>	+ FOUGERA PHARMS	<u>EQ 0.05% BASE</u>	<u>N019137 001</u>	Jun 26, 1984
-----------	------------------	----------------------	--------------------	--------------

<u>AB</u>	TARO	<u>EQ 0.05% BASE</u>	<u>A073552 001</u>	Apr 30, 1992
-----------	------	----------------------	--------------------	--------------

CREAM, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

<u>AB</u>	FOUGERA PHARMS	<u>EQ 0.05% BASE</u>	<u>A076215 001</u>	Dec 09, 2003
-----------	----------------	----------------------	--------------------	--------------

<u>AB</u>	GLENMARK GENERICS	<u>EQ 0.05% BASE</u>	<u>A078930 001</u>	Sep 23, 2008
-----------	-------------------	----------------------	--------------------	--------------

<u>AB</u>	PERRIGO NEW YORK	<u>EQ 0.05% BASE</u>	<u>A076592 001</u>	Dec 09, 2003
-----------	------------------	----------------------	--------------------	--------------

<u>AB</u>	TARO	<u>EQ 0.05% BASE</u>	<u>A076543 001</u>	Dec 09, 2003
-----------	------	----------------------	--------------------	--------------

<u>AB</u>	TOLMAR	<u>EQ 0.05% BASE</u>	<u>A076603 001</u>	Jan 23, 2004
-----------	--------	----------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

BETAMETHASONE DIPROPIONATE

CREAM, AUGMENTED; TOPICAL

DIPROLENE AF

AB	+ MERCK SHARP DOHME	EQ 0.05% BASE	N019555 001	Apr 27, 1987
-----------	---------------------	----------------------	--------------------	--------------

GEL, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	+ FOUGERA PHARMS	EQ 0.05% BASE	A075276 001	May 13, 2003
-----------	------------------	----------------------	--------------------	--------------

AB	TARO	EQ 0.05% BASE	A076508 001	Dec 02, 2003
-----------	------	----------------------	--------------------	--------------

LOTION; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	ACTAVIS MID ATLANTIC	EQ 0.05% BASE	A070281 001	Jul 31, 1985
-----------	----------------------	----------------------	--------------------	--------------

AB	+ FOUGERA	EQ 0.05% BASE	A070275 001	Aug 12, 1985
-----------	-----------	----------------------	--------------------	--------------

AB	G AND W LABS INC	EQ 0.05% BASE	A071467 001	Aug 10, 1987
-----------	------------------	----------------------	--------------------	--------------

AB	PERRIGO NEW YORK	EQ 0.05% BASE	A072538 001	Jan 31, 1990
-----------	------------------	----------------------	--------------------	--------------

LOTION, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	FOUGERA PHARMS	EQ 0.05% BASE	A077111 001	May 21, 2007
-----------	----------------	----------------------	--------------------	--------------

AB	TARO	EQ 0.05% BASE	A077477 001	May 21, 2007
-----------	------	----------------------	--------------------	--------------

DIPROLENE

AB	+ MERCK SHARP DOHME	EQ 0.05% BASE	N019716 001	Aug 01, 1988
-----------	---------------------	----------------------	--------------------	--------------

OINTMENT; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	ACTAVIS MID ATLANTIC	EQ 0.05% BASE	A071012 001	Feb 03, 1987
-----------	----------------------	----------------------	--------------------	--------------

AB	+ FOUGERA	EQ 0.05% BASE	N019141 001	Sep 04, 1984
-----------	-----------	----------------------	--------------------	--------------

AB	TARO	EQ 0.05% BASE	A074271 001	Sep 15, 1994
-----------	------	----------------------	--------------------	--------------

OINTMENT, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	ACTAVIS MID ATLANTIC	EQ 0.05% BASE	A074304 001	Aug 31, 1995
-----------	----------------------	----------------------	--------------------	--------------

AB	FOUGERA PHARMS	EQ 0.05% BASE	A075373 001	Jun 22, 1999
-----------	----------------	----------------------	--------------------	--------------

AB	TARO	EQ 0.05% BASE	A076753 001	Oct 12, 2004
-----------	------	----------------------	--------------------	--------------

DIPROLENE

AB	+ MERCK SHARP DOHME	EQ 0.05% BASE	N018741 001	Jul 27, 1983
-----------	---------------------	----------------------	--------------------	--------------

SPRAY; TOPICAL

SERNIVO

	+ PROMIUS PHARMA LLC	EQ 0.05% BASE/SPRAY	N208079 001	Feb 05, 2016
--	----------------------	----------------------------	--------------------	--------------

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

AEROSOL, FOAM; TOPICAL

ENSTILAR

	+ LEO PHARMA AS	0.064%; 0.005%	N207589 001	Oct 16, 2015
--	-----------------	-----------------------	--------------------	--------------

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE

OINTMENT; TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

AB	PERRIGO ISRAEL	0.064%; 0.005%	A200174 001	Dec 12, 2014
-----------	----------------	-----------------------	--------------------	--------------

AB	TOLMAR	0.064%; 0.005%	A201615 001	Jan 14, 2013
-----------	--------	-----------------------	--------------------	--------------

TACLONEX

AB	+ LEO PHARMA AS	0.064%; 0.005%	N021852 001	Jan 09, 2006
-----------	-----------------	-----------------------	--------------------	--------------

SUSPENSION; TOPICAL

TACLONEX

	+ LEO PHARMA AS	0.064%; 0.005%	N022185 001	May 09, 2008
--	-----------------	-----------------------	--------------------	--------------

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB	ACTAVIS MID ATLANTIC	EQ 0.05% BASE; 1%	A076002 001	Aug 02, 2002
-----------	----------------------	--------------------------	--------------------	--------------

AB	FOUGERA PHARMS	EQ 0.05% BASE; 1%	A075502 001	Jun 05, 2001
-----------	----------------	--------------------------	--------------------	--------------

AB	GLENMARK PHARMS	EQ 0.05% BASE; 1%	A202894 001	Oct 30, 2015
-----------	-----------------	--------------------------	--------------------	--------------

AB	TARO	EQ 0.05% BASE; 1%	A075673 001	May 29, 2001
-----------	------	--------------------------	--------------------	--------------

LOTRISONE

AB	+ MERCK SHARP DOHME	EQ 0.05% BASE; 1%	N018827 001	Jul 10, 1984
-----------	---------------------	--------------------------	--------------------	--------------

LOTION; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB	FOUGERA PHARMS	EQ 0.05% BASE; 1%	A076516 001	Jun 16, 2005
-----------	----------------	--------------------------	--------------------	--------------

AB	TARO	EQ 0.05% BASE; 1%	A076493 001	Jul 28, 2004
-----------	------	--------------------------	--------------------	--------------

LOTRISONE

AB	+ MERCK SHARP DOHME	EQ 0.05% BASE; 1%	N020010 001	Dec 08, 2000
-----------	---------------------	--------------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

BETAMETHASONE VALERATE

AEROSOL, FOAM;TOPICAL

BETAMETHASONE VALERATEAB PERRIGO 0.12% A078337 001 Nov 26, 2012LUXIQAB + DELCOR ASSET CORP 0.12% N020934 001 Feb 28, 1999
CREAM;TOPICALBETA-VALAB G AND W LABS INC EQ 0.1% BASE N018642 001 Mar 24, 1983BETAMETHASONE VALERATEAB + FOUGERA EQ 0.1% BASE N018861 001 Aug 31, 1983DERMABETAB TARO EQ 0.1% BASE A072041 001 Jan 06, 1988VALNACAB ACTAVIS MID ATLANTIC EQ 0.1% BASE A070050 001 Oct 10, 1984
LOTION;TOPICALBETA-VALAB G AND W LABS INC EQ 0.1% BASE A070072 001 Jun 27, 1985BETAMETHASONE VALERATEAB + FOUGERA EQ 0.1% BASE N018866 001 Aug 31, 1983AB STI PHARMA LLC EQ 0.1% BASE A070052 001 Jul 31, 1985
OINTMENT;TOPICALBETA-VALAB G AND W LABS INC EQ 0.1% BASE A070069 001 Dec 19, 1985BETAMETHASONE VALERATEAB ACTAVIS MID ATLANTIC EQ 0.1% BASE A070051 001 Oct 10, 1984AB + FOUGERA EQ 0.1% BASE N018865 001 Aug 31, 1983BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

BETAXOLOL HYDROCHLORIDEAT AKORN EQ 0.5% BASE A075386 001 Jun 30, 2000AT TELIGENT PHARMA INC EQ 0.5% BASE A075630 001 Apr 12, 2001AT WOCKHARDT EQ 0.5% BASE A078694 001 Nov 16, 2009BETOPTICAT + ALCON EQ 0.5% BASE N019270 001 Aug 30, 1985

SUSPENSION/DROPS;OPHTHALMIC

BETOPTIC SAB + NOVARTIS PHARMS CORP EQ 0.25% BASE N019845 001 Dec 29, 1989
TABLET;ORALBETAXOLOL HYDROCHLORIDEAB EPIC PHARMA 10MG A075541 001 Oct 22, 1999AB + 20MG A075541 002 Oct 22, 1999AB KVK TECH 10MG A078962 001 Jun 27, 2008AB 20MG A078962 002 Jun 27, 2008BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDEAA AMNEAL PHARM 5MG A040855 001 Nov 21, 2007AA 10MG A040855 002 Nov 21, 2007AA 25MG A040855 003 Nov 21, 2007AA 50MG A040855 004 Nov 21, 2007AA HERITAGE PHARMA 5MG A091256 001 May 04, 2010AA 10MG A091256 002 May 04, 2010AA 25MG A091256 003 May 04, 2010AA 50MG A091256 004 May 04, 2010AA LANNETT 10MG A040704 001 Mar 27, 2008AA 25MG A040678 003 Mar 27, 2008AA LANNETT HOLDINGS INC 5MG A040703 001 Mar 27, 2008AA 50MG A040677 001 Mar 27, 2008AA PHARMAX 5MG A040725 001 Oct 26, 2007AA 10MG A040726 001 Oct 26, 2007AA 25MG A040727 001 Oct 26, 2007AA 50MG A040728 001 Oct 26, 2007AA UPSHER SMITH 5MG A040633 001 Jun 01, 2005AA 10MG A040634 001 Jun 01, 2005AA 25MG A040635 001 Jun 01, 2005AA 50MG A040636 001 Jun 01, 2005AA WOCKHARDT 5MG A040532 001 Sep 29, 2003AA 10MG A040533 001 Sep 29, 2003AA 25MG A040534 001 Sep 29, 2003AA 50MG A040518 001 Sep 29, 2003

PRESCRIPTION DRUG PRODUCT LIST

BETHANECHOL CHLORIDE

TABLET; ORAL

DUVOID

<u>AA</u>	BI-COASTAL PHARMA	<u>10MG</u>	<u>A086262</u>	<u>001</u>	
<u>AA</u>		<u>25MG</u>	<u>A086263</u>	<u>001</u>	
<u>AA</u>		<u>50MG</u>	<u>A085882</u>	<u>003</u>	
<u>URECHOLINE</u>					
<u>AA</u>	+ ODYSSEY PHARMS	<u>5MG</u>	<u>A089095</u>	<u>001</u>	Dec 19, 1985
<u>AA</u>	+	<u>10MG</u>	<u>A088440</u>	<u>001</u>	May 29, 1984
<u>AA</u>	+	<u>25MG</u>	<u>A088441</u>	<u>001</u>	May 29, 1984
<u>AA</u>	+	<u>50MG</u>	<u>A089096</u>	<u>001</u>	Dec 19, 1985

BEXAROTENE

CAPSULE; ORAL

BEXAROTENE

<u>AB</u>	BIONPHARMA INC	<u>75MG</u>	<u>A203174</u>	<u>001</u>	Aug 12, 2014
<u>TARGRETIN</u>					
<u>AB</u>	+ VALEANT LUXEMBOURG	<u>75MG</u>	<u>N021055</u>	<u>001</u>	Dec 29, 1999
GEL; TOPICAL					
TARGRETIN					
	+ VALEANT LUXEMBOURG	1%	N021056	001	Jun 28, 2000

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

<u>AB</u>	ACCORD HLTHCARE	<u>50MG</u>	<u>A078917</u>	<u>001</u>	Jul 06, 2009
<u>AB</u>	ACTAVIS TOTOWA	<u>50MG</u>	<u>A078634</u>	<u>001</u>	Aug 28, 2009
<u>AB</u>	APOTEX INC	<u>50MG</u>	<u>A200274</u>	<u>001</u>	May 21, 2015
<u>AB</u>	FRESENIUS KABI ONCOL	<u>50MG</u>	<u>A079045</u>	<u>001</u>	May 13, 2010
<u>AB</u>	MYLAN	<u>50MG</u>	<u>A079185</u>	<u>001</u>	Jul 06, 2009
<u>AB</u>	SANDOZ	<u>50MG</u>	<u>A078575</u>	<u>001</u>	Jul 06, 2009
<u>AB</u>	STASON PHARMS	<u>50MG</u>	<u>A091011</u>	<u>001</u>	Jun 10, 2015
<u>AB</u>	SUN PHARMA GLOBAL	<u>50MG</u>	<u>A079110</u>	<u>001</u>	Jul 06, 2009
<u>AB</u>	TEVA	<u>50MG</u>	<u>A076932</u>	<u>001</u>	Jul 06, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>50MG</u>	<u>A079089</u>	<u>001</u>	Jul 06, 2009
<u>CASODEX</u>					
<u>AB</u>	+ ASTRAZENECA	<u>50MG</u>	<u>N020498</u>	<u>001</u>	Oct 04, 1995

BIMATOPROST

SOLUTION/DROPS; OPHTHALMIC

BIMATOPROST

<u>AT</u>	ALCON RES LTD	<u>0.03%</u>	<u>A202565</u>	<u>001</u>	May 05, 2015
<u>AT</u>	APOTEX INC	<u>0.03%</u>	<u>A090449</u>	<u>001</u>	Jul 20, 2015
<u>AT</u>	+ LUPIN LTD	<u>0.03%</u>	<u>A203991</u>	<u>001</u>	Feb 20, 2015
LUMIGAN					
	+ ALLERGAN	0.01%	N022184	001	Aug 31, 2010
SOLUTION/DROPS; TOPICAL					
<u>BIMATOPROST</u>					
<u>AT</u>	APOTEX INC	<u>0.03%</u>	<u>A201894</u>	<u>001</u>	Dec 01, 2014
<u>AT</u>	SANDOZ INC	<u>0.03%</u>	<u>A202719</u>	<u>001</u>	Apr 19, 2016
<u>LATISSE</u>					
<u>AT</u>	+ ALLERGAN	<u>0.03%</u>	<u>N022369</u>	<u>001</u>	Dec 24, 2008

BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION, TABLET, DELAYED RELEASE; ORAL

PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL

+	NOVEL LABS INC	5MG, N/A; N/A, 210GM; N/A, 0.74GM; N/A, 2.86GM	A202217	001	Aug 20, 2014
		; N/A, 5.6GM			

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE

CAPSULE; ORAL

PYLERA

+	FOREST LABS LLC	140MG; 125MG; 125MG	N050786	001	Sep 28, 2006
---	-----------------	---------------------	---------	-----	--------------

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A077910</u>	<u>001</u>	Dec 27, 2006
<u>AB</u>		<u>10MG</u>	<u>A077910</u>	<u>002</u>	Dec 27, 2006
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A075831</u>	<u>001</u>	Dec 14, 2005
<u>AB</u>	+	<u>10MG</u>	<u>A075831</u>	<u>002</u>	Dec 14, 2005
<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A075643</u>	<u>001</u>	Nov 16, 2000
<u>AB</u>		<u>10MG</u>	<u>A075643</u>	<u>002</u>	Nov 16, 2000
<u>AB</u>	TEVA PHARMS	<u>5MG</u>	<u>A075644</u>	<u>001</u>	Jun 26, 2001
<u>AB</u>		<u>10MG</u>	<u>A075644</u>	<u>002</u>	Jun 26, 2001
<u>AB</u>	UNICHEM PHARMS (USA)	<u>5MG</u>	<u>A078635</u>	<u>001</u>	Aug 18, 2009

PRESCRIPTION DRUG PRODUCT LIST

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

<u>AB</u>		<u>10MG</u>	<u>A078635 002</u>	Aug 18, 2009
-----------	--	-------------	--------------------	--------------

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	MYLAN	<u>2.5MG; 6.25MG</u>	<u>A075768 001</u>	Sep 25, 2000
<u>AB</u>		<u>5MG; 6.25MG</u>	<u>A075768 002</u>	Sep 25, 2000
<u>AB</u>		<u>10MG; 6.25MG</u>	<u>A075768 003</u>	Sep 25, 2000
<u>AB</u>	SANDOZ	<u>2.5MG; 6.25MG</u>	<u>A075579 001</u>	Sep 25, 2000
<u>AB</u>		<u>5MG; 6.25MG</u>	<u>A075579 002</u>	Sep 25, 2000
<u>AB</u>		<u>10MG; 6.25MG</u>	<u>A075579 003</u>	Sep 25, 2000
<u>AB</u>	UNICHEM	<u>2.5MG; 6.25MG</u>	<u>A079106 001</u>	Jul 28, 2010
<u>AB</u>		<u>5MG; 6.25MG</u>	<u>A079106 002</u>	Jul 28, 2010
<u>AB</u>		<u>10MG; 6.25MG</u>	<u>A079106 003</u>	Jul 28, 2010
<u>ZIAC</u>				
<u>AB</u>	TEVA WOMENS	<u>2.5MG; 6.25MG</u>	<u>N020186 003</u>	Mar 26, 1993
<u>AB</u>		<u>5MG; 6.25MG</u>	<u>N020186 001</u>	Mar 26, 1993
<u>AB</u>	+	<u>10MG; 6.25MG</u>	<u>N020186 002</u>	Mar 26, 1993

BIVALIRUDIN

INJECTABLE; INTRAVENOUS

ANGIOMAX

<u>AP</u>	+	THE MEDICINES CO	<u>250MG/VIAL</u>	<u>N020873 001</u>	Dec 15, 2000
-----------	---	------------------	-------------------	--------------------	--------------

BIVALIRUDIN

<u>AP</u>		FRESENIUS KABI USA	<u>250MG/VIAL</u>	<u>A090189 001</u>	Oct 28, 2016
<u>AP</u>		HOSPIRA INC	<u>250MG/VIAL</u>	<u>A090811 001</u>	Jul 14, 2015
<u>AP</u>			<u>250MG/VIAL</u>	<u>A090816 001</u>	Jul 14, 2015

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLEOMYCIN SULFATE

<u>AP</u>	+	FRESENIUS KABI USA	<u>EQ 15 UNITS BASE/VIAL</u>	<u>A065185 001</u>	Jan 28, 2008
<u>AP</u>	+		<u>EQ 30 UNITS BASE/VIAL</u>	<u>A065185 002</u>	Jan 28, 2008
<u>AP</u>		HOSPIRA	<u>EQ 15 UNITS BASE/VIAL</u>	<u>A065031 001</u>	Mar 10, 2000
<u>AP</u>			<u>EQ 30 UNITS BASE/VIAL</u>	<u>A065031 002</u>	Mar 10, 2000
<u>AP</u>		TEVA PHARMS USA	<u>EQ 15 UNITS BASE/VIAL</u>	<u>A065033 001</u>	Jun 27, 2000
<u>AP</u>			<u>EQ 30 UNITS BASE/VIAL</u>	<u>A065033 002</u>	Jun 27, 2000
<u>AP</u>		WEST-WARD PHARMS INT	<u>EQ 15 UNITS BASE/VIAL</u>	<u>A065042 002</u>	Oct 17, 2001
<u>AP</u>			<u>EQ 30 UNITS BASE/VIAL</u>	<u>A065042 001</u>	Oct 17, 2001

BORTEZOMIB

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

VELCADE

	+	MILLENNIUM PHARMS	<u>3.5MG/VIAL</u>	<u>N021602 001</u>	May 13, 2003
--	---	-------------------	-------------------	--------------------	--------------

BOSENTAN

TABLET; ORAL

TRACLEER

		ACTELION PHARMS LTD	<u>62.5MG</u>	<u>N021290 001</u>	Nov 20, 2001
	+		<u>125MG</u>	<u>N021290 002</u>	Nov 20, 2001

BOSUTINIB MONOHYDRATE

TABLET; ORAL

BOSULIF

	+	PF PRISM CV	<u>EQ 100MG BASE</u>	<u>N203341 001</u>	Sep 04, 2012
			<u>EQ 500MG BASE</u>	<u>N203341 002</u>	Sep 04, 2012

BREXPIPIRAZOLE

TABLET; ORAL

REXULTI

		OTSUKA PHARM CO LTD	<u>0.25MG</u>	<u>N205422 001</u>	Jul 10, 2015
			<u>0.5MG</u>	<u>N205422 002</u>	Jul 10, 2015
			<u>1MG</u>	<u>N205422 003</u>	Jul 10, 2015
			<u>2MG</u>	<u>N205422 004</u>	Jul 10, 2015
			<u>3MG</u>	<u>N205422 005</u>	Jul 10, 2015
	+		<u>4MG</u>	<u>N205422 006</u>	Jul 10, 2015

PRESCRIPTION DRUG PRODUCT LIST

BRIMONIDINE TARTRATE

GEL; TOPICAL

MIRVASO

+ GALDERMA LABS LP EQ 0.33% BASE

N204708 001 Aug 23, 2013

SOLUTION/DROPS; OPHTHALMIC

ALPHAGAN P**AT** + ALLERGAN **0.15%****N021262 001** Mar 16, 2001BRIMONIDINE TARTRATE**AT** AKORN **0.2%****A076439 001** Mar 14, 2006**AT** ALCON PHARMS LTD **0.2%****A076254 001** Sep 16, 2003**AT** + BAUSCH AND LOMB **0.2%****A076260 001** May 28, 2003**AT** INDOCO REMEDIES **0.2%****A091691 001** Nov 18, 2014**AT** SANDOZ **0.2%****A078075 001** Jan 30, 2008QOLIANA**AT** ALCON PHARMS LTD **0.15%****N021764 001** May 22, 2006

ALPHAGAN P

+ ALLERGAN 0.1%

N021770 001 Aug 19, 2005

BRIMONIDINE TARTRATE; BRINZOLAMIDE

SUSPENSION/DROPS; OPHTHALMIC

SIMBRINZA

+ NOVARTIS PHARMS CORP 0.2%; 1%

N204251 001 Apr 19, 2013

BRIMONIDINE TARTRATE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

COMBIGAN

+ ALLERGAN 0.2%; EQ 0.5% BASE

N021398 001 Oct 30, 2007

BRINZOLAMIDE

SUSPENSION/DROPS; OPHTHALMIC

AZOPT

+ NOVARTIS PHARMS CORP 1%

N020816 001 Apr 01, 1998

BRIVARACETAM

SOLUTION; INTRAVENOUS

BRIVIACT

+ UCB INC 50MG/5ML (10MG/ML)

N205837 001 May 12, 2016

SOLUTION; ORAL

BRIVIACT

+ UCB INC 10MG/ML

N205838 001 May 12, 2016

TABLET; ORAL

BRIVIACT

UCB INC 10MG

N205836 001 May 12, 2016

25MG

N205836 002 May 12, 2016

50MG

N205836 003 May 12, 2016

75MG

N205836 004 May 12, 2016

+ 100MG

N205836 005 May 12, 2016

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

BROMFENAC SODIUM**AT1** APOTEX INC **EQ 0.09% ACID****A202435 001** Jun 19, 2014**AT1** + COASTAL PHARMS **EQ 0.09% ACID****A201211 001** May 11, 2011**AT1** LUITPOLD **EQ 0.09% ACID****A202030 001** Jan 09, 2013**AT1** PADDOCK LLC **EQ 0.09% ACID****A201941 001** Feb 10, 2015**AT2** APOTEX INC **EQ 0.09% ACID****A202620 001** Jun 23, 2014**AT2** HI-TECH PHARMACAL **EQ 0.09% ACID****A203395 001** Jan 22, 2014

BROMSITE

+ SUN PHARMA GLOBAL EQ 0.075% ACID

N206911 001 Apr 08, 2016

PROLENSA

+ BAUSCH AND LOMB EQ 0.07% ACID

N203168 001 Apr 05, 2013

BROMOCRIPTINE MESYLATE

CAPSULE; ORAL

BROMOCRIPTINE MESYLATE**AB** + MYLAN **EQ 5MG BASE****A077226 001** Apr 04, 2005**AB** ZYDUS PHARMS USA INC **EQ 5MG BASE****A078899 001** Jul 30, 2008PARLODEL**AB** US PHARMS HOLDINGS I **EQ 5MG BASE****N017962 002** Mar 01, 1982

TABLET; ORAL

BROMOCRIPTINE MESYLATE**AB** MYLAN **EQ 2.5MG BASE****A076962 001** Sep 24, 2004**AB** + PADDOCK LLC **EQ 2.5MG BASE****A077646 001** Oct 01, 2008**AB** SANDOZ INC **EQ 2.5MG BASE****A074631 001** Jan 13, 1998

PRESCRIPTION DRUG PRODUCT LIST

BROMOCRIPTINE MESYLATE

TABLET; ORAL

PARLODEL

<u>AB</u>	US PHARMS HOLDINGS I	<u>EQ 2.5MG BASE</u>	<u>N017962 001</u>	
	CYCLOSET			
	+ VEROSCIENCE	EQ 0.8MG BASE	N020866 001	May 05, 2009

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

BROMFED-DM

<u>AA</u>	+ WOCKHARDT	<u>2MG/5ML; 10MG/5ML; 30MG/5ML</u>	<u>A088811 001</u>	Jun 07, 1985
<u>AA</u>	ACELLA PHARMS LLC	<u>2MG/5ML; 10MG/5ML; 30MG/5ML</u>	<u>A203375 001</u>	Sep 20, 2016
<u>AA</u>	PADDOCK LLC	<u>2MG/5ML; 10MG/5ML; 30MG/5ML</u>	<u>A205292 001</u>	Jul 15, 2014
<u>AA</u>	VINTAGE PHARMS	<u>2MG/5ML; 10MG/5ML; 30MG/5ML</u>	<u>A202940 001</u>	Jul 21, 2014

BUDESONIDE

AEROSOL, FOAM; RECTAL

UCERIS

+ VALEANT PHARMS INTL 2MG/ACTUATION N205613 001 Oct 07, 2014

CAPSULE; ORAL

BUDESONIDE

<u>AB</u>	ALVOGEN MALTA	<u>3MG</u>	<u>A206724 001</u>	Nov 23, 2016
<u>AB</u>	BARR LABS DIV TEVA	<u>3MG</u>	<u>A090379 001</u>	Apr 02, 2014
<u>AB</u>	MAYNE PHARMA	<u>3MG</u>	<u>A206623 001</u>	Apr 08, 2016
<u>AB</u>	MYLAN	<u>3MG</u>	<u>A090410 001</u>	May 16, 2011
<u>AB</u>	+ PERRIGO PHARMA INTL	<u>3MG</u>	<u>N021324 001</u>	Oct 02, 2001
	POWDER, METERED; INHALATION			
	PULMICORT FLEXHALER			
	ASTRAZENECA	0.08MG/INH	N021949 001	Jul 12, 2006
	+	0.16MG/INH	N021949 002	Jul 12, 2006

SUSPENSION; INHALATION

BUDESONIDE

<u>AN</u>	APOTEX INC	<u>0.25MG/2ML</u>	<u>A078202 001</u>	Mar 30, 2009
<u>AN</u>		<u>0.5MG/2ML</u>	<u>A078202 002</u>	Mar 30, 2009
<u>AN</u>	IMPAX LABS INC	<u>0.25MG/2ML</u>	<u>A078404 001</u>	Jul 31, 2012
<u>AN</u>		<u>0.5MG/2ML</u>	<u>A078404 002</u>	Jul 31, 2012
<u>AN</u>	SANDOZ INC	<u>0.25MG/2ML</u>	<u>A201966 003</u>	Sep 27, 2013
<u>AN</u>		<u>0.5MG/2ML</u>	<u>A201966 002</u>	Sep 27, 2013
<u>AN</u>		<u>1MG/2ML</u>	<u>A201966 001</u>	Sep 27, 2013
<u>AN</u>	TEVA PHARMS	<u>0.25MG/2ML</u>	<u>A077519 001</u>	Nov 18, 2008
<u>AN</u>		<u>0.5MG/2ML</u>	<u>A077519 002</u>	Nov 18, 2008
<u>AN</u>	TEVA PHARMS USA	<u>1MG/2ML</u>	<u>A204548 001</u>	Mar 08, 2016

PULMICORT RESPULES

<u>AN</u>	ASTRAZENECA PHARMS	<u>0.25MG/2ML</u>	<u>N020929 001</u>	Aug 08, 2000
<u>AN</u>		<u>0.5MG/2ML</u>	<u>N020929 002</u>	Aug 08, 2000
<u>AN</u>	+	<u>1MG/2ML</u>	<u>N020929 003</u>	Aug 08, 2000

TABLET, EXTENDED RELEASE; ORAL

UCERIS

+ VALEANT PHARMS INTL 9MG N203634 001 Jan 14, 2013

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

AEROSOL, METERED; INHALATION

SYMBICORT

+ ASTRAZENECA 0.08MG/INH; 0.0045MG/INH N021929 001 Jul 21, 2006

+ 0.16MG/INH; 0.0045MG/INH N021929 002 Jul 21, 2006

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

<u>AP</u>	+ AMPHASTAR PHARMS INC	<u>0.25MG/ML</u>	<u>A074441 001</u>	Jan 27, 1995
<u>AP</u>	EUROHLTH INTL SARL	<u>0.25MG/ML</u>	<u>A079196 001</u>	Apr 30, 2008
<u>AP</u>	HOSPIRA	<u>0.25MG/ML</u>	<u>A074332 001</u>	Oct 31, 1994

TABLET; ORAL

BUMETANIDE

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>0.5MG</u>	<u>A074225 001</u>	Apr 24, 1995
<u>AB</u>		<u>1MG</u>	<u>A074225 002</u>	Apr 24, 1995
<u>AB</u>		<u>2MG</u>	<u>A074225 003</u>	Apr 24, 1995
<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A074700 001</u>	Nov 21, 1996
<u>AB</u>		<u>1MG</u>	<u>A074700 002</u>	Nov 21, 1996
<u>AB</u>	+	<u>2MG</u>	<u>A074700 003</u>	Nov 21, 1996

BUMEX

<u>AB</u>	VALIDUS PHARMS INC	<u>0.5MG</u>	<u>N018225 002</u>	Feb 28, 1983
-----------	--------------------	--------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

BUMETANIDE

TABLET; ORAL

BUMEX

<u>AB</u>		<u>1MG</u>	<u>N018225</u>	<u>001</u>	Feb 28, 1983
<u>AB</u>		<u>2MG</u>	<u>N018225</u>	<u>003</u>	Jun 14, 1985

BUPIVACAINE

INJECTABLE, LIPOSOMAL; INJECTION

EXPAREL

+	PACIRA PHARMS INC	133MG/10ML (13.3MG/ML)	N022496	001	Oct 28, 2011
+		266MG/20ML (13.3MG/ML)	N022496	002	Oct 28, 2011

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE

<u>AP</u>	AUROBINDO PHARMA LTD	<u>0.25%</u>	<u>A207183</u>	<u>001</u>	May 13, 2016
<u>AP</u>		<u>0.5%</u>	<u>A207183</u>	<u>002</u>	May 13, 2016
<u>AP</u>	HOSPIRA	<u>0.25%</u>	<u>A070583</u>	<u>001</u>	Feb 17, 1987
<u>AP</u>		<u>0.25%</u>	<u>A070586</u>	<u>001</u>	Mar 03, 1987
<u>AP</u>		<u>0.25%</u>	<u>A070590</u>	<u>001</u>	Feb 17, 1987
<u>AP</u>		<u>0.25%</u>	<u>N018053</u>	<u>002</u>	
<u>AP</u>		<u>0.5%</u>	<u>A070584</u>	<u>001</u>	Feb 17, 1986
<u>AP</u>		<u>0.5%</u>	<u>A070597</u>	<u>001</u>	Mar 03, 1987
<u>AP</u>		<u>0.5%</u>	<u>A070609</u>	<u>001</u>	Mar 03, 1987
<u>AP</u>		<u>0.5%</u>	<u>N018053</u>	<u>001</u>	
<u>AP</u>		<u>0.75%</u>	<u>A070585</u>	<u>001</u>	Mar 03, 1987
<u>AP</u>		<u>0.75%</u>	<u>N018053</u>	<u>003</u>	
<u>AP</u>	SAGENT AGILA	<u>0.25%</u>	<u>A091503</u>	<u>001</u>	Oct 18, 2011
<u>AP</u>		<u>0.5%</u>	<u>A091503</u>	<u>002</u>	Oct 18, 2011

BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	AUROBINDO PHARMA LTD	<u>0.25%</u>	<u>A203895</u>	<u>001</u>	Nov 05, 2013
<u>AP</u>		<u>0.5%</u>	<u>A203895</u>	<u>002</u>	Nov 05, 2013
<u>AP</u>		<u>0.75%</u>	<u>A203895</u>	<u>003</u>	Nov 05, 2013
<u>AP</u>	SAGENT AGILA	<u>0.25%</u>	<u>A091487</u>	<u>002</u>	Oct 18, 2011
<u>AP</u>		<u>0.5%</u>	<u>A091487</u>	<u>001</u>	Oct 18, 2011
<u>AP</u>		<u>0.75%</u>	<u>A091487</u>	<u>003</u>	Oct 18, 2011

MARCAINE HYDROCHLORIDE

<u>AP</u>	+ HOSPIRA	<u>0.25%</u>	<u>N016964</u>	<u>001</u>	
<u>AP</u>	+ HOSPIRA	<u>0.5%</u>	<u>N016964</u>	<u>006</u>	

MARCAINE HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	+ HOSPIRA	<u>0.25%</u>	<u>N016964</u>	<u>012</u>	
<u>AP</u>	+ HOSPIRA	<u>0.5%</u>	<u>N016964</u>	<u>005</u>	
<u>AP</u>	+ HOSPIRA	<u>0.75%</u>	<u>N016964</u>	<u>009</u>	

SENSORCAINE

<u>AP</u>	FRESENIUS KABI USA	<u>0.25%</u>	<u>A070552</u>	<u>001</u>	May 21, 1986
<u>AP</u>		<u>0.25%</u>	<u>N018304</u>	<u>001</u>	
<u>AP</u>		<u>0.5%</u>	<u>A070553</u>	<u>001</u>	May 21, 1986
<u>AP</u>		<u>0.5%</u>	<u>N018304</u>	<u>002</u>	
<u>AP</u>		<u>0.75%</u>	<u>A070554</u>	<u>001</u>	May 21, 1986
<u>AP</u>		<u>0.75%</u>	<u>N018304</u>	<u>003</u>	

INJECTABLE; SPINAL

BUPIVACAINE HYDROCHLORIDE

<u>AP</u>	CLARIS	<u>0.75%</u>	<u>A207266</u>	<u>001</u>	Jul 25, 2016
<u>AP</u>	HOSPIRA	<u>0.75%</u>	<u>A071810</u>	<u>001</u>	Dec 11, 1987

MARCAINE

<u>AP</u>	+ HOSPIRA	<u>0.75%</u>	<u>N018692</u>	<u>001</u>	May 04, 1984
-----------	-----------	--------------	----------------	------------	--------------

SENSORCAINE

<u>AP</u>	FRESENIUS KABI USA	<u>0.75%</u>	<u>A071202</u>	<u>001</u>	Apr 15, 1987
-----------	--------------------	--------------	----------------	------------	--------------

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

<u>AP</u>	+ HOSPIRA	<u>0.5%;0.005MG/ML</u>	<u>A071168</u>	<u>001</u>	Jun 16, 1988
<u>AP</u>		<u>0.5%;0.005MG/ML</u>	<u>A071170</u>	<u>001</u>	Jun 16, 1988
	+	0.25%;0.005MG/ML	A071165	001	Jun 16, 1988
		0.25%;0.005MG/ML	A071167	001	Jun 16, 1988

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

<u>AP</u>	SEPTODONT	<u>0.5%;0.0091MG/ML</u>	<u>A077250</u>	<u>001</u>	Sep 27, 2006
-----------	-----------	-------------------------	----------------	------------	--------------

BUPIVACAINE HYDROCHLORIDE W/EPINEPHRINE

<u>AP</u>	+ HOSPIRA	<u>0.5%;0.0091MG/ML</u>	<u>N022046</u>	<u>001</u>	Jul 13, 1983
-----------	-----------	-------------------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

MARCAINE HYDROCHLORIDE W/ EPINEPHRINE

<u>AP</u>	+	HOSPIRA	<u>0.25%;0.0091MG/ML</u>	<u>N016964</u>	<u>004</u>	
<u>AP</u>	+		<u>0.5%;0.0091MG/ML</u>	<u>N016964</u>	<u>008</u>	

MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE

<u>AP</u>	+	HOSPIRA	<u>0.25%;0.0091MG/ML</u>	<u>N016964</u>	<u>013</u>	
<u>AP</u>	+		<u>0.5%;0.0091MG/ML</u>	<u>N016964</u>	<u>007</u>	
<u>AP</u>	+		<u>0.75%;0.0091MG/ML</u>	<u>N016964</u>	<u>010</u>	

SENSORCAINE

<u>AP</u>		FRESENIUS KABI USA	<u>0.25%;0.0091MG/ML</u>	<u>A070966</u>	<u>001</u>	Oct 13, 1987
<u>AP</u>			<u>0.25%;0.0091MG/ML</u>	<u>A070967</u>	<u>001</u>	Oct 13, 1987
<u>AP</u>			<u>0.5%;0.0091MG/ML</u>	<u>A070968</u>	<u>001</u>	Oct 13, 1987
<u>AP</u>			<u>0.5%;0.0091MG/ML</u>	<u>N018304</u>	<u>004</u>	Sep 02, 1983
<u>AP</u>			<u>0.75%;0.0091MG/ML</u>	<u>N018304</u>	<u>005</u>	Sep 02, 1983

BUPRENORPHINE

FILM, EXTENDED RELEASE; TRANSDERMAL

BUTRANS

		PURDUE PHARMA LP	5MCG/HR	N021306	001	Jun 30, 2010
			7.5MCG/HR	N021306	005	Jun 30, 2014
			10MCG/HR	N021306	002	Jun 30, 2010
			15MCG/HR	N021306	004	Jul 25, 2013
	+		20MCG/HR	N021306	003	Jun 30, 2010

BUPRENORPHINE HYDROCHLORIDE

FILM; BUCCAL

BELBUCA

		ENDO PHARMS INC	EQ 0.075MG BASE	N207932	001	Oct 23, 2015
			EQ 0.15MG BASE	N207932	002	Oct 23, 2015
			EQ 0.3MG BASE	N207932	003	Oct 23, 2015
			EQ 0.45MG BASE	N207932	004	Oct 23, 2015
			EQ 0.6MG BASE	N207932	005	Oct 23, 2015
			EQ 0.75MG BASE	N207932	006	Oct 23, 2015
	+		EQ 0.9MG BASE	N207932	007	Oct 23, 2015

IMPLANT; IMPLANTATION

PROBUPHINE

	+	BRAEBURN PHARMS INC	EQ 80MG BASE/IMPLANT	N204442	001	May 26, 2016
--	---	---------------------	----------------------	---------	-----	--------------

INJECTABLE; INJECTION

BUPRENEX

<u>AP</u>	+	INDIVIOR INC	<u>EQ 0.3MG BASE/ML</u>	<u>N018401</u>	<u>001</u>	
-----------	---	--------------	-------------------------	----------------	------------	--

BUPRENORPHINE HYDROCHLORIDE

<u>AP</u>		HOSPIRA	<u>EQ 0.3MG BASE/ML</u>	<u>A074137</u>	<u>001</u>	Jun 03, 1996
<u>AP</u>		LUITPOLD	<u>EQ 0.3MG BASE/ML</u>	<u>A078331</u>	<u>001</u>	Mar 27, 2007
<u>AP</u>		PAR STERILE PRODUCTS	<u>EQ 0.3MG BASE/ML</u>	<u>A206586</u>	<u>001</u>	Jul 28, 2015
<u>AP</u>		WEST-WARD PHARMS INT	<u>EQ 0.3MG BASE/ML</u>	<u>A076931</u>	<u>001</u>	Mar 02, 2005

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

<u>AB</u>		ACTAVIS ELIZABETH	<u>EQ 2MG BASE</u>	<u>A090819</u>	<u>001</u>	Feb 19, 2015
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A090819</u>	<u>002</u>	Feb 19, 2015
<u>AB</u>		BARR	<u>EQ 2MG BASE</u>	<u>A090360</u>	<u>001</u>	May 07, 2010
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A090360</u>	<u>002</u>	May 07, 2010
<u>AB</u>		ETHYPHARM	<u>EQ 2MG BASE</u>	<u>A090622</u>	<u>001</u>	Sep 24, 2010
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A090622</u>	<u>002</u>	Sep 24, 2010
<u>AB</u>		MYLAN PHARMS INC	<u>EQ 2MG BASE</u>	<u>A201066</u>	<u>001</u>	Mar 06, 2015
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A201066</u>	<u>002</u>	Mar 06, 2015
<u>AB</u>		SANDOZ INC	<u>EQ 2MG BASE</u>	<u>A090279</u>	<u>001</u>	Jun 10, 2015
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A090279</u>	<u>002</u>	Jun 10, 2015
<u>AB</u>		SUN PHARM INDS LTD	<u>EQ 2MG BASE</u>	<u>A201760</u>	<u>001</u>	Jan 29, 2016
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A201760</u>	<u>002</u>	Jan 29, 2016
<u>AB</u>		WEST-WARD PHARMS INT	<u>EQ 2MG BASE</u>	<u>A078633</u>	<u>001</u>	Oct 08, 2009
<u>AB</u>	+		<u>EQ 8MG BASE</u>	<u>A078633</u>	<u>002</u>	Oct 08, 2009

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM; BUCCAL

BUNAVAIL

		BIODELIVERY SCI INTL	EQ 2.1MG BASE;EQ 0.3MG BASE	N205637	001	Jun 06, 2014
			EQ 4.2MG BASE;EQ 0.7MG BASE	N205637	002	Jun 06, 2014
	+		EQ 6.3MG BASE;EQ 1MG BASE	N205637	003	Jun 06, 2014

FILM; BUCCAL, SUBLINGUAL

SUBOXONE

		INDIVIOR INC	EQ 2MG BASE;EQ 0.5MG BASE	N022410	001	Aug 30, 2010
			EQ 4MG BASE;EQ 1MG BASE	N022410	003	Aug 10, 2012
			EQ 8MG BASE;EQ 2MG BASE	N022410	002	Aug 30, 2010

PRESCRIPTION DRUG PRODUCT LIST

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

<u>AB1</u>	SCIEGEN PHARMS INC	<u>100MG</u>	<u>A205794 001</u>	Mar 01, 2016
<u>AB1</u>		<u>150MG</u>	<u>A205794 002</u>	Mar 01, 2016
<u>AB1</u>		<u>200MG</u>	<u>A205794 003</u>	Mar 01, 2016
<u>AB1</u>	SUN PHARMA GLOBAL	<u>100MG</u>	<u>A078866 001</u>	Apr 06, 2010
<u>AB1</u>		<u>150MG</u>	<u>A078866 002</u>	Apr 06, 2010
<u>AB1</u>		<u>200MG</u>	<u>A078866 003</u>	Apr 06, 2010
<u>AB1</u>	TORRENT PHARMS LTD	<u>100MG</u>	<u>A203969 001</u>	Oct 31, 2014
<u>AB1</u>		<u>150MG</u>	<u>A203969 002</u>	Oct 31, 2014
<u>AB1</u>		<u>200MG</u>	<u>A203969 003</u>	Oct 31, 2014
<u>AB1</u>	WATSON LABS INC	<u>100MG</u>	<u>A077455 001</u>	Jul 19, 2010
<u>AB1</u>		<u>150MG</u>	<u>A077455 002</u>	Mar 12, 2008
<u>AB1</u>		<u>200MG</u>	<u>A077455 003</u>	Jul 19, 2010

WELLBUTRIN SR

<u>AB1</u>	GLAXOSMITHKLINE	<u>100MG</u>	<u>N020358 002</u>	Oct 04, 1996
<u>AB1</u>		<u>150MG</u>	<u>N020358 003</u>	Oct 04, 1996
<u>AB1</u>	+	<u>200MG</u>	<u>N020358 004</u>	Jun 14, 2002

BUPROPION HYDROCHLORIDE

<u>AB2</u>	ACTAVIS LABS FL INC	<u>150MG</u>	<u>A079094 001</u>	Mar 24, 2009
<u>AB2</u>	ANCHEN PHARMS	<u>150MG</u>	<u>A091520 001</u>	Jun 09, 2011
<u>AB2</u>	IMPAX LABS	<u>150MG</u>	<u>A075914 001</u>	May 27, 2004
<u>AB2</u>	JUBILANT GENERICS	<u>150MG</u>	<u>A202775 001</u>	Oct 11, 2013
<u>AB2</u>	MYLAN	<u>150MG</u>	<u>A090941 001</u>	May 03, 2010
<u>AB2</u>	SANDOZ INC	<u>150MG</u>	<u>A077475 001</u>	Mar 12, 2008
<u>AB2</u>	SCIEGEN PHARMS INC	<u>150MG</u>	<u>A206122 001</u>	Aug 17, 2016

ZYBAN

<u>AB2</u>	+	GLAXOSMITHKLINE	<u>150MG</u>	<u>N020711 003</u>	May 14, 1997
------------	---	-----------------	--------------	--------------------	--------------

BUPROPION HYDROCHLORIDE

<u>AB3</u>	ACTAVIS LABS FL INC	<u>150MG</u>	<u>A077715 001</u>	Nov 26, 2008
<u>AB3</u>	ANCHEN PHARMS	<u>150MG</u>	<u>A077284 001</u>	Dec 14, 2006
<u>AB3</u>		<u>300MG</u>	<u>A077284 002</u>	Dec 14, 2006
<u>AB3</u>	IMPAX LABS	<u>150MG</u>	<u>A077415 001</u>	Nov 26, 2008
<u>AB3</u>	INVAGEN PHARMS	<u>150MG</u>	<u>A206556 001</u>	Aug 26, 2016
<u>AB3</u>		<u>300MG</u>	<u>A206556 002</u>	Aug 26, 2016
<u>AB3</u>	MYLAN	<u>150MG</u>	<u>A090942 001</u>	Jul 14, 2010
<u>AB3</u>		<u>300MG</u>	<u>A090942 002</u>	Jul 14, 2010
<u>AB3</u>	SUN PHARMA GLOBAL	<u>150MG</u>	<u>A200695 001</u>	Dec 18, 2014
<u>AB3</u>	WATSON LABS INC	<u>150MG</u>	<u>A077285 001</u>	Nov 26, 2008
<u>AB3</u>		<u>300MG</u>	<u>A077285 002</u>	Aug 15, 2008
<u>AB3</u>	WOCKHARDT LTD	<u>150MG</u>	<u>A202189 001</u>	Nov 21, 2012
<u>AB3</u>	ZYDUS PHARMS USA INC	<u>300MG</u>	<u>A201567 001</u>	Jan 17, 2014

WELLBUTRIN XL

<u>AB3</u>	VALEANT INTL	<u>150MG</u>	<u>N021515 001</u>	Aug 28, 2003
<u>AB3</u>	+		<u>N021515 002</u>	Aug 28, 2003
	FORFIVO XL			
	+	EDGEMONT PHARMS LLC	N022497 001	Nov 10, 2011

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CONTRAVE

+	OREXIGEN	90MG; 8MG	N200063 001	Sep 10, 2014
---	----------	-----------	-------------	--------------

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

<u>AB</u>	ACCORD HLTHCARE	<u>5MG</u>	<u>A202557 001</u>	Dec 30, 2014
<u>AB</u>		<u>7.5MG</u>	<u>A202557 002</u>	Dec 30, 2014
<u>AB</u>		<u>10MG</u>	<u>A202557 003</u>	Dec 30, 2014
<u>AB</u>		<u>15MG</u>	<u>A202557 004</u>	Dec 30, 2014
<u>AB</u>		<u>30MG</u>	<u>A202557 005</u>	Dec 30, 2014
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A078246 001</u>	Feb 27, 2009
<u>AB</u>		<u>10MG</u>	<u>A078246 002</u>	Feb 27, 2009
<u>AB</u>		<u>15MG</u>	<u>A078246 003</u>	Feb 27, 2009
<u>AB</u>		<u>30MG</u>	<u>A078246 004</u>	Feb 27, 2009
<u>AB</u>	HERITAGE PHARMA	<u>5MG</u>	<u>A204582 001</u>	Sep 18, 2015
<u>AB</u>		<u>10MG</u>	<u>A204582 002</u>	Sep 18, 2015
<u>AB</u>		<u>15MG</u>	<u>A204582 003</u>	Sep 18, 2015
<u>AB</u>		<u>30MG</u>	<u>A204582 004</u>	Sep 18, 2015
<u>AB</u>	IMPAX LABS INC	<u>5MG</u>	<u>A074253 001</u>	Mar 28, 2001
<u>AB</u>		<u>10MG</u>	<u>A074253 002</u>	Mar 28, 2001
<u>AB</u>		<u>15MG</u>	<u>A074253 003</u>	Mar 13, 2002

PRESCRIPTION DRUG PRODUCT LIST

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

<u>AB</u>	MYLAN	<u>5MG</u>	<u>A075467 001</u>	Feb 28, 2002
<u>AB</u>		<u>5MG</u>	<u>A076008 003</u>	Mar 01, 2002
<u>AB</u>		<u>7.5MG</u>	<u>A075467 002</u>	Mar 28, 2001
<u>AB</u>		<u>7.5MG</u>	<u>A076008 002</u>	Jul 08, 2013
<u>AB</u>		<u>10MG</u>	<u>A075467 003</u>	Feb 28, 2002
<u>AB</u>		<u>10MG</u>	<u>A076008 004</u>	Mar 01, 2002
<u>AB</u>		<u>15MG</u>	<u>A075467 004</u>	Feb 28, 2002
<u>AB</u>		<u>15MG</u>	<u>A076008 005</u>	Mar 28, 2001
<u>AB</u>		<u>30MG</u>	<u>A076008 001</u>	Jun 28, 2001
<u>AB</u>	ORION CORP ORION	<u>5MG</u>	<u>A202087 001</u>	Dec 16, 2015
<u>AB</u>		<u>10MG</u>	<u>A202087 002</u>	Dec 16, 2015
<u>AB</u>		<u>15MG</u>	<u>A202087 003</u>	Dec 16, 2015
<u>AB</u>		<u>30MG</u>	<u>A202087 004</u>	Dec 16, 2015
<u>AB</u>	OXFORD PHARMS	<u>30MG</u>	<u>A078302 001</u>	Dec 17, 2007
<u>AB</u>	STRIDES ARCOLAB LTD	<u>5MG</u>	<u>A202330 001</u>	Aug 25, 2014
<u>AB</u>		<u>10MG</u>	<u>A202330 002</u>	Aug 25, 2014
<u>AB</u>		<u>15MG</u>	<u>A202330 003</u>	Aug 25, 2014
<u>AB</u>		<u>30MG</u>	<u>A202330 004</u>	Aug 25, 2014
<u>AB</u>	TEVA	<u>5MG</u>	<u>A075022 001</u>	Feb 28, 2002
<u>AB</u>		<u>10MG</u>	<u>A075022 002</u>	Feb 28, 2002
<u>AB</u>	+	<u>15MG</u>	<u>A075022 003</u>	Feb 28, 2002
<u>AB</u>		<u>30MG</u>	<u>A075022 004</u>	Mar 25, 2004
<u>AB</u>	ZYDUS PHARMS USA INC	<u>5MG</u>	<u>A078888 001</u>	Feb 07, 2014
<u>AB</u>		<u>10MG</u>	<u>A078888 002</u>	Feb 07, 2014
<u>AB</u>		<u>15MG</u>	<u>A078888 003</u>	Feb 07, 2014
<u>AB</u>		<u>30MG</u>	<u>A078888 004</u>	Feb 07, 2014

BUSULFAN

INJECTABLE; INJECTION

BUSULFAN

<u>AP</u>	LUITPOLD PHARMS INC	<u>6MG/ML</u>	<u>A202259 001</u>	Dec 22, 2015
-----------	---------------------	---------------	--------------------	--------------

BUSULFEX

<u>AP</u>	+	OTSUKA PHARM	<u>6MG/ML</u>	<u>N020954 001</u>	Feb 04, 1999
-----------	---	--------------	---------------	--------------------	--------------

TABLET; ORAL

MYLERAN

+ ASPEN GLOBAL

2MG

N009386 001

BUTABARBITAL SODIUM

TABLET; ORAL

BUTISOL SODIUM

+ MEDA PHARMS

30MG

N000793 004

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL

MENTAX

+ MYLAN

1%

N020524 001 Oct 18, 1996

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

GYNAZOLE-1

+ PERRIGO ISRAEL

2%

A200923 001 May 18, 2012

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

<u>AP</u>	EUROHLTH INTL SARL	<u>2MG/ML</u>	<u>A075046 001</u>	Aug 12, 1998
-----------	--------------------	---------------	--------------------	--------------

<u>AP</u>	HIKMA FARMACEUTICA	<u>1MG/ML</u>	<u>A078400 001</u>	May 01, 2009
-----------	--------------------	---------------	--------------------	--------------

<u>AP</u>		<u>2MG/ML</u>	<u>A078400 002</u>	May 01, 2009
-----------	--	---------------	--------------------	--------------

BUTORPHANOL TARTRATE PRESERVATIVE FREE

<u>AP</u>	EUROHLTH INTL SARL	<u>1MG/ML</u>	<u>A075045 001</u>	Aug 12, 1998
-----------	--------------------	---------------	--------------------	--------------

<u>AP</u>		<u>2MG/ML</u>	<u>A075045 002</u>	Aug 12, 1998
-----------	--	---------------	--------------------	--------------

<u>AP</u>	HOSPIRA	<u>1MG/ML</u>	<u>A074626 001</u>	Jan 23, 1997
-----------	---------	---------------	--------------------	--------------

<u>AP</u>		<u>2MG/ML</u>	<u>A074626 002</u>	Jan 23, 1997
-----------	--	---------------	--------------------	--------------

SPRAY, METERED; NASAL

BUTORPHANOL TARTRATE

<u>AB</u>	APOTEX INC	<u>1MG/SPRAY</u>	<u>A075499 001</u>	Dec 04, 2002
-----------	------------	------------------	--------------------	--------------

<u>AB</u>	+	MYLAN	<u>1MG/SPRAY</u>	<u>A075759 001</u>	Aug 08, 2001
-----------	---	-------	------------------	--------------------	--------------

<u>AB</u>	WEST-WARD PHARMS INT	<u>1MG/SPRAY</u>	<u>A075824 001</u>	Mar 12, 2002
-----------	----------------------	------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

CABAZITAXEL

SOLUTION; IV (INFUSION)

JEVTANA KIT

+ SANOFI AVENTIS US 60MG/1.5ML (40MG/ML) N201023 001 Jun 17, 2010

CABERGOLINE

TABLET; ORAL

CABERGOLINE

AB	ACTAVIS LABS FL INC	0.5MG	A078035 001	Apr 21, 2008
AB	APOTEX CORP	0.5MG	A201503 001	Mar 08, 2013
AB	IVAX SUB TEVA PHARMS	0.5MG	A077750 001	Mar 07, 2007
AB	MYLAN PHARMS INC	0.5MG	A202947 001	Dec 02, 2013
AB	+ PAR PHARM	0.5MG	A076310 001	Dec 29, 2005

CABOZANTINIB S-MALATE

CAPSULE; ORAL

COMETRIQ

EXELIXIS EQ 20MG BASE N203756 001 Nov 29, 2012

+ EQ 80MG BASE N203756 002 Nov 29, 2012

TABLET; ORAL

CABOMETYX

EXELIXIS INC EQ 20MG BASE N208692 001 Apr 25, 2016

EQ 40MG BASE N208692 002 Apr 25, 2016

+ EQ 60MG BASE N208692 003 Apr 25, 2016

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS

CAF CIT**AP** + WEST-WARD PHARMS INT **EQ 30MG BASE/3ML (EQ 10MG BASE/ML)** **N020793 001** Sep 21, 1999CAFFEINE CITRATE**AP** AUROBINDO PHARMA LTD **EQ 30MG BASE/3ML (EQ 10MG BASE/ML)** **A205013 001** Sep 22, 2015**AP** EXELA PHARMA SCIENCE **EQ 30MG BASE/3ML (EQ 10MG BASE/ML)** **A077233 001** Sep 21, 2006**AP** FRESenius KABI USA **EQ 30MG BASE/3ML (EQ 10MG BASE/ML)** **A077997 001** Jul 20, 2007**AP** LUITPOLD **EQ 30MG BASE/3ML (EQ 10MG BASE/ML)** **A077906 001** May 15, 2007**AP** SAGENT PHARMS **EQ 30MG BASE/3ML (EQ 10MG BASE/ML)** **A090827 001** Aug 29, 2012**AP** SUN PHARMA GLOBAL **EQ 30MG BASE/3ML (EQ 10MG BASE/ML)** **A090077 001** Sep 30, 2009

SOLUTION; ORAL

CAF CIT**AA** + WEST-WARD PHARMS INT **EQ 30MG BASE/3ML (EQ 10MG BASE/ML)** **N020793 002** Apr 12, 2000CAFFEINE CITRATE**AA** EXELA PHARMA SCS LLC **EQ 30MG BASE/3ML (EQ 10MG BASE/ML)** **A077304 001** Sep 21, 2006**AA** FRESenius KABI USA **EQ 30MG BASE/3ML (EQ 10MG BASE/ML)** **A078002 001** Jan 31, 2008**AA** LUITPOLD **EQ 30MG BASE/3ML (EQ 10MG BASE/ML)** **A090064 001** Nov 20, 2009**AA** SAGENT PHARMS **EQ 30MG BASE/3ML (EQ 10MG BASE/ML)** **A091102 001** Aug 29, 2012**AA** SUN PHARMA GLOBAL **EQ 30MG BASE/3ML (EQ 10MG BASE/ML)** **A090357 001** Sep 30, 2009CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL

MIGERGOT

+ HORIZON PHARMA 100MG; 2MG A086557 001 Oct 04, 1983

TABLET; ORAL

CAFERGOT**AA** + SANDOZ **100MG; 1MG** **A084294 001**ERGOTAMINE TARTRATE AND CAFFEINE**AA** HIKMA INTL PHARMS **100MG; 1MG** **A040510 001** Sep 17, 2004**AA** MIKART **100MG; 1MG** **A040590 001** Sep 16, 2005CALCIFEDIOL

CAPSULE, EXTENDED RELEASE; ORAL

RAYALDEE

+ OPKO IRELAND GLOBAL 0.03MG N208010 001 Jun 17, 2016

CALCIPOTRIENE

AEROSOL, FOAM; TOPICAL

SORILUX

+ STIEFEL LABS INC 0.005% N022563 001 Oct 06, 2010

CREAM; TOPICAL

CALCIPOTRIENE**AB** GLENMARK PHARMS **0.005%** **A205772 001** Jun 09, 2015**AB** TOLMAR **0.005%** **A200935 001** May 30, 2012DOVONEX**AB** + LEO PHARMA AS **0.005%** **N020554 001** Jul 22, 1996

OINTMENT; TOPICAL

CALCIPOTRIENE

+ GLENMARK GENERICS 0.005% A090633 001 Mar 24, 2010

PRESCRIPTION DRUG PRODUCT LIST

CALCIPOTRIENE

SOLUTION; TOPICAL

CALCIPOTRIENE

<u>AT</u>	FOUGERA PHARMS	<u>0.005%</u>	<u>A078305</u>	<u>001</u>	May 06, 2008
<u>AT</u>	G AND W LABS INC	<u>0.005%</u>	<u>A078468</u>	<u>001</u>	Mar 24, 2011
<u>AT</u>	HI TECH PHARMA	<u>0.005%</u>	<u>A077579</u>	<u>001</u>	Nov 19, 2009
<u>AT</u>	+ TOLMAR	<u>0.005%</u>	<u>A077029</u>	<u>001</u>	Nov 20, 2009

CALCITONIN SALMON

INJECTABLE; INJECTION

MIACALCIN

+ MYLAN IRELAND LTD 200 IU/ML N017808 002 Mar 29, 1991

SPRAY, METERED; NASAL

CALCITONIN-SALMON

<u>AB</u>	APOTEX INC	<u>200 IU/SPRAY</u>	<u>A076396</u>	<u>001</u>	Nov 17, 2008
<u>AB</u>	PAR PHARM	<u>200 IU/SPRAY</u>	<u>A076979</u>	<u>001</u>	Jun 08, 2009
<u>AB</u>	+ MYLAN IRELAND LTD	<u>200 IU/SPRAY</u>	<u>N020313</u>	<u>002</u>	Aug 17, 1995

CALCITRIOL

CAPSULE; ORAL

CALCITRIOL

<u>AB</u>	BIONPHARMA INC	<u>0.25MCG</u>	<u>A091174</u>	<u>001</u>	May 24, 2013
<u>AB</u>		<u>0.5MCG</u>	<u>A091174</u>	<u>002</u>	May 24, 2013
<u>AB</u>	STRIDES PHARMA	<u>0.25MCG</u>	<u>A091356</u>	<u>001</u>	Dec 12, 2014
<u>AB</u>		<u>0.5MCG</u>	<u>A091356</u>	<u>002</u>	Dec 12, 2014
<u>AB</u>	TEVA	<u>0.25MCG</u>	<u>A075765</u>	<u>001</u>	Oct 12, 2001
<u>AB</u>		<u>0.5MCG</u>	<u>A075765</u>	<u>002</u>	Oct 12, 2001
<u>AB</u>	WEST-WARD PHARMS INT	<u>0.25MCG</u>	<u>A076917</u>	<u>001</u>	Mar 27, 2006

ROCALTROL

<u>AB</u>	VALIDUS PHARMS	<u>0.25MCG</u>	<u>N018044</u>	<u>001</u>	
<u>AB</u>	+	<u>0.5MCG</u>	<u>N018044</u>	<u>002</u>	

INJECTABLE; INJECTION

CALCITRIOL

AKORN 0.001MG/ML A078066 001 Jan 29, 2008

OINTMENT; TOPICAL

VECTICAL

+ GALDERMA LABS LP 3MCG/GM N022087 001 Jan 23, 2009

SOLUTION; ORAL

CALCITRIOL

<u>AA</u>	WEST-WARD PHARMS INT	<u>1MCG/ML</u>	<u>A076242</u>	<u>001</u>	Jul 18, 2003
-----------	----------------------	----------------	----------------	------------	--------------

ROCALTROL

<u>AA</u>	+ VALIDUS PHARMS	<u>1MCG/ML</u>	<u>N021068</u>	<u>001</u>	Nov 20, 1998
-----------	------------------	----------------	----------------	------------	--------------

CALCIUM ACETATE

CAPSULE; ORAL

CALCIUM ACETATE

<u>AB</u>	AMNEAL PHARMS	<u>667MG</u>	<u>A201658</u>	<u>001</u>	Oct 06, 2014
<u>AB</u>	ECI PHARMS LLC	<u>667MG</u>	<u>A203298</u>	<u>001</u>	Jul 26, 2016
<u>AB</u>	HERITAGE PHARMS INC	<u>667MG</u>	<u>A202315</u>	<u>001</u>	Jun 29, 2015
<u>AB</u>	INVAGEN PHARMS	<u>667MG</u>	<u>A203135</u>	<u>001</u>	Feb 07, 2013
<u>AB</u>	LUPIN LTD	<u>667MG</u>	<u>A202127</u>	<u>001</u>	Jul 09, 2015
<u>AB</u>	NOSTRUM LABS INC	<u>667MG</u>	<u>A203179</u>	<u>001</u>	Oct 26, 2015
<u>AB</u>	PADDOCK LLC	<u>667MG</u>	<u>A091312</u>	<u>001</u>	Jun 01, 2012
<u>AB</u>	WEST-WARD PHARMS INT	<u>667MG</u>	<u>A077728</u>	<u>001</u>	Feb 26, 2008

PHOSLO GELCAPS

<u>AB</u>	+ FRESENIUS MEDCL	<u>667MG</u>	<u>N021160</u>	<u>003</u>	Apr 02, 2001
-----------	-------------------	--------------	----------------	------------	--------------

SOLUTION; ORAL

PHOSLYRA

+ FRESENIUS MEDCL 667MG/5ML N022581 001 Apr 18, 2011

TABLET; ORAL

CALCIUM ACETATE

<u>AB</u>	HERITAGE PHARMS INC	<u>667MG</u>	<u>A202885</u>	<u>001</u>	Jan 22, 2015
<u>AB</u>	INVAGEN PHARMS	<u>667MG</u>	<u>A202420</u>	<u>001</u>	Feb 05, 2013
<u>AB</u>	PADDOCK LLC	<u>667MG</u>	<u>A091561</u>	<u>001</u>	Apr 13, 2011

ELIPHOS

<u>AB</u>	+ CYPRESS PHARM	<u>667MG</u>	<u>A078502</u>	<u>001</u>	Nov 25, 2008
-----------	-----------------	--------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

CALCIUM CHLORIDE

INJECTABLE; INJECTION

CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER

+ HOSPIRA 100MG/ML

N021117 001 Jan 28, 2000

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION

BSS PLUS

AT + ALCON

0.154MG/ML; 0.92MG/ML; 0.184MG/ML; 0.2MG/ML; 0.38MG/ML; 2.1MG/ML; 7.14MG/ML; 0.42MG/ML

N018469 001

ENDOSOL EXTRA

AT + AKORN

0.154MG/ML; 0.92MG/ML; 0.184MG/ML; 0.2MG/ML; 0.38MG/ML; 2.1MG/ML; 7.14MG/ML; 0.42MG/ML

N020079 001 Nov 27, 1991

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER

+ BAXTER HLTHCARE N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.157GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)

N021703 010 Oct 10, 2008

PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER

+ BAXTER HLTHCARE N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)

N021703 011 Oct 10, 2008

PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)

N021703 013 Oct 10, 2008

PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)

N021703 006 Oct 25, 2006

PRISMASOL BGK 2/0 IN PLASTIC CONTAINER

+ BAXTER HLTHCARE N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)

N021703 002 Oct 25, 2006

PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)

N021703 003 Oct 25, 2006

PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER

+ BAXTER HLTHCARE N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)

N021703 015 Oct 10, 2008

PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)

N021703 004 Oct 25, 2006

PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER

+ BAXTER HLTHCARE N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)

N021703 014 Oct 10, 2008

PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 5.15GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)

N021703 001 Oct 25, 2006

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT FRESENIUS MEDCL

25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 5.67MG/100ML; 392MG/100ML

N018883 001 Nov 30, 1984

DELFLX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER

AT FRESENIUS MEDCL

25.7MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 5.38MG/100ML; 448MG/100ML

N018883 004 Nov 30, 1984

DELFLX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT FRESENIUS MEDCL

18.4MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 5.38MG/100ML; 448MG/100ML

N020171 001 Aug 19, 1992

DELFLX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT FRESENIUS MEDCL

25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 5.67MG/100ML; 392MG/100ML

N018883 002 Nov 30, 1984

DELFLX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER

AT FRESENIUS MEDCL

25.7MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 5.38MG/100ML; 448MG/100ML

N018883 005 Nov 30, 1984

PRESCRIPTION DRUG PRODUCT LIST

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE
SOLUTION; INTRAPERITONEAL

DELFLX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT FRESANIUS MEDCL 18.4MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 5.38MG/100ML; 448MG/100ML N020171 002 Aug 19, 1992

DELFLX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT FRESANIUS MEDCL 25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML N018883 003 Nov 30, 1984

DELFLX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER

AT FRESANIUS MEDCL 25.7MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML N018883 006 Nov 30, 1984

DELFLX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT FRESANIUS MEDCL 18.4MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML N020171 003 Aug 19, 1992

DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 67MG/100ML; 392MG/100ML N017512 001

DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 67MG/100ML; 392MG/100ML N017512 003

DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML N017512 002

DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 18.3MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 38MG/100ML; 448MG/100ML N020183 001 Dec 04, 1992

DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 67MG/100ML; 392MG/100ML N017512 007 Jul 09, 1984

DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 67MG/100ML; 392MG/100ML N017512 008 Jul 09, 1984

DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML N017512 009 Jul 09, 1984

DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 18.3MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 38MG/100ML; 448MG/100ML N017512 004

AT 25.7MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 38MG/100ML; 448MG/100ML N020163 001 Dec 04, 1992

DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 38MG/100ML; 448MG/100ML N017512 005

AT 25.7MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 38MG/100ML; 448MG/100ML N020163 002 Dec 04, 1992

DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML N017512 006

AT 25.7MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML N020163 003 Dec 04, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE 18.3MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 38MG/100ML; 448MG/100ML N020183 002 Dec 04, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE 18.3MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 38MG/100ML; 448MG/100ML N020183 003 Dec 04, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

BAXTER HLTHCARE 18.3MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML N020183 004 Dec 04, 1992

DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE 25.7MG/100ML; 3.5GM/100ML; 15.2MG/100ML; 67MG/100ML; 392MG/100ML N017512 010 Nov 18, 1985

DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE 25.7MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 38MG/100ML; 448MG/100ML N017512 011 Nov 18, 1985

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INTRATHECAL

ELLIOTTS B SOLUTION

+ LUKARE MEDICAL LLC 0.2MG/ML; 0.8MG/ML; 0.3MG/ML; 0.3MG/ML; 1.9MG/ML; 7.3MG/ML; 0.2MG/ML N020577 001 Sep 27, 1996

PRESCRIPTION DRUG PRODUCT LIST

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER

<u>AP</u>	HOSPIRA	<u>33MG/100ML; 5GM/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N018254 001</u>	
-----------	---------	---	--------------------	--

DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>33MG/100ML; 5GM/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N020000 001</u>	Apr 17, 1992
-----------	---------	---	--------------------	--------------

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

<u>AP</u>	HOSPIRA	<u>20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N017608 001</u>	
-----------	---------	--	--------------------	--

DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019634 003</u>	Feb 24, 1988
-----------	---------	--	--------------------	--------------

LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N016679 001</u>	
-----------	-----------------	--	--------------------	--

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>20MG/100ML; 5GM/100ML; 254MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019367 006</u>	Apr 05, 1985
-----------	-----------------	---	--------------------	--------------

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>20MG/100ML; 5GM/100ML; 179MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019367 004</u>	Apr 05, 1985
-----------	-----------------	---	--------------------	--------------

<u>AP</u>		<u>20MG/100ML; 5GM/100ML; 328MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019367 005</u>	Apr 05, 1985
-----------	--	---	--------------------	--------------

<u>AP</u>	HOSPIRA	<u>20MG/100ML; 5GM/100ML; 179MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019685 002</u>	Oct 17, 1988
-----------	---------	---	--------------------	--------------

<u>AP</u>		<u>20MG/100ML; 5GM/100ML; 328MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019685 008</u>	Oct 17, 1988
-----------	--	---	--------------------	--------------

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>20MG/100ML; 5GM/100ML; 254MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019367 007</u>	Apr 05, 1985
-----------	-----------------	---	--------------------	--------------

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>20MG/100ML; 5GM/100ML; 328MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019367 008</u>	Apr 05, 1985
-----------	-----------------	---	--------------------	--------------

<u>AP</u>	HOSPIRA	<u>20MG/100ML; 5GM/100ML; 328MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019685 004</u>	Oct 17, 1988
-----------	---------	---	--------------------	--------------

DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER

	B BRAUN	<u>10MG/100ML; 2.5GM/100ML; 15MG/100ML; 300MG/100ML; 160MG/100ML</u>	<u>N019634 001</u>	Feb 24, 1988
--	---------	--	--------------------	--------------

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

	BAXTER HLTHCARE	<u>20MG/100ML; 5GM/100ML; 105MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019367 002</u>	Apr 05, 1985
--	-----------------	---	--------------------	--------------

		<u>20MG/100ML; 5GM/100ML; 179MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019367 003</u>	Apr 05, 1985
--	--	---	--------------------	--------------

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

	BAXTER HLTHCARE	<u>20MG/100ML; 5GM/100ML; 105MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019367 001</u>	Apr 05, 1985
--	-----------------	---	--------------------	--------------

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER

	+ HOSPIRA	<u>16.5MG/ML; 25.4MG/ML; 74.6MG/ML; 121MG/ML; 16.1MG/ML</u>	<u>N018895 001</u>	Jul 20, 1984
--	-----------	---	--------------------	--------------

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SOLUTION; IRRIGATION

BALANCED SALT

<u>AT</u>	AKORN	<u>0.48MG/ML; 0.3MG/ML; 0.75MG/ML; 3.9MG/ML; 6.4MG/ML; 1.7MG/ML</u>	<u>A075503 001</u>	Sep 27, 2006
-----------	-------	---	--------------------	--------------

<u>AT</u>	B BRAUN	<u>0.48MG/ML; 0.3MG/ML; 0.75MG/ML; 3.9MG/ML; 6.4MG/ML; 1.7MG/ML</u>	<u>A091387 001</u>	Feb 03, 2010
-----------	---------	---	--------------------	--------------

BSS

<u>AT</u>	+ ALCON	<u>0.48MG/ML; 0.3MG/ML; 0.75MG/ML; 3.9MG/ML; 6.4MG/ML; 1.7MG/ML</u>	<u>N020742 001</u>	Dec 10, 1997
-----------	---------	---	--------------------	--------------

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE; INJECTION

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER

	+ BAXTER HLTHCARE	<u>N/A/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 6.95GM/1000ML; 0.187GM/1000ML (5000ML)</u>	<u>N207026 002</u>	Jan 13, 2015
--	-------------------	---	--------------------	--------------

PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

	+ BAXTER HLTHCARE	<u>3.68GM/1000ML; 3.05GM/1000ML; 0.314</u>	<u>N207026 001</u>	Jan 13, 2015
--	-------------------	--	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE; INJECTION

PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

GM/1000ML

; 3.09GM/1000ML; 6.34GM/1000ML; 0.187GM/10

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; PERFUSION, CARDIAC

CARDIOPLEGIC IN PLASTIC CONTAINER

AT	BAXTER HLTHCARE	17.6MG/100ML; 325.3MG/100ML; 119.3MG/100ML; 643MG/100ML	A075323 001	Apr 21, 2000
-----------	-----------------	--	--------------------	--------------

PLEGISOL IN PLASTIC CONTAINER

AT	+ HOSPIRA	17.6MG/100ML; 325.3MG/100ML; 119.3MG/100ML; 643MG/100ML	N018608 001	Feb 26, 1982
-----------	-----------	--	--------------------	--------------

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

RINGER'S IN PLASTIC CONTAINER

AP	B BRAUN	33MG/100ML; 30MG/100ML; 860MG/100ML	N020002 001	Apr 17, 1992
-----------	---------	--	--------------------	--------------

AP	BAXTER HLTHCARE	33MG/100ML; 30MG/100ML; 860MG/100ML	N016693 001	
-----------	-----------------	--	--------------------	--

AP	HOSPIRA	33MG/100ML; 30MG/100ML; 860MG/100ML	N018251 001	
-----------	---------	--	--------------------	--

SOLUTION; IRRIGATION

RINGER'S IN PLASTIC CONTAINER

AT	B BRAUN	33MG/100ML; 30MG/100ML; 860MG/100ML	N018156 001	
-----------	---------	--	--------------------	--

AT	BAXTER HLTHCARE	33MG/100ML; 30MG/100ML; 860MG/100ML	N018495 001	Feb 19, 1982
-----------	-----------------	--	--------------------	--------------

AT	HOSPIRA	33MG/100ML; 30MG/100ML; 860MG/100ML	N017635 001	
-----------	---------	--	--------------------	--

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

AP	B BRAUN	20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N019632 001	Feb 29, 1988
-----------	---------	---	--------------------	--------------

AP	+ BAXTER HLTHCARE	20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N016682 001	
-----------	-------------------	---	--------------------	--

AP	HOSPIRA	20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N017641 001	
-----------	---------	---	--------------------	--

SOLUTION; IRRIGATION

LACTATED RINGER'S IN PLASTIC CONTAINER

AT	+ B BRAUN	20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N018681 001	Dec 27, 1982
-----------	-----------	---	--------------------	--------------

AT	BAXTER HLTHCARE	20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N018494 001	Feb 19, 1982
-----------	-----------------	---	--------------------	--------------

AT	+ HOSPIRA	20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N018921 001	Apr 03, 1984
-----------	-----------	---	--------------------	--------------

AT	+ HOSPIRA	20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N019416 001	Jan 17, 1986
-----------	-----------	---	--------------------	--------------

CALFACTANT

SUSPENSION; INTRATRACHEAL

INFASURF PRESERVATIVE FREE

+ ONY 35MG/ML

N020521 001 Jul 01, 1998

CANAGLIFLOZIN

TABLET; ORAL

INVOKANA

JANSSEN PHARMS 100MG

N204042 001 Mar 29, 2013

+ 300MG

N204042 002 Mar 29, 2013

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL

INVOKAMET

JANSSEN PHARMS 50MG; 500MG

N204353 001 Aug 08, 2014

50MG; 1GM

N204353 002 Aug 08, 2014

150MG; 500MG

N204353 003 Aug 08, 2014

+ 150MG; 1GM

N204353 004 Aug 08, 2014

TABLET, EXTENDED RELEASE; ORAL

INVOKAMET XR

JANSSEN PHARMS 50MG; 500MG

N205879 001 Sep 20, 2016

50MG; 1GM

N205879 002 Sep 20, 2016

150MG; 500MG

N205879 003 Sep 20, 2016

+ 150MG; 1GM

N205879 004 Sep 20, 2016

PRESCRIPTION DRUG PRODUCT LIST

CANDESARTAN CILEXETIL

TABLET; ORAL

ATACAND

<u>AB</u>	ASTRAZENECA	<u>4MG</u>	<u>N020838 001</u>	Jun 04, 1998
<u>AB</u>		<u>8MG</u>	<u>N020838 002</u>	Jun 04, 1998
<u>AB</u>		<u>16MG</u>	<u>N020838 003</u>	Jun 04, 1998
<u>AB</u>	+	<u>32MG</u>	<u>N020838 004</u>	Jun 04, 1998

CANDESARTAN CILEXETIL

<u>AB</u>	APOTEX INC	<u>4MG</u>	<u>A202079 001</u>	Jan 10, 2014
<u>AB</u>		<u>8MG</u>	<u>A202079 002</u>	Jan 10, 2014
<u>AB</u>		<u>16MG</u>	<u>A202079 003</u>	Jan 10, 2014
<u>AB</u>		<u>32MG</u>	<u>A202079 004</u>	Jan 10, 2014
<u>AB</u>	MACLEODS PHARMS LTD	<u>4MG</u>	<u>A203813 001</u>	Dec 05, 2016
<u>AB</u>		<u>8MG</u>	<u>A203813 002</u>	Dec 05, 2016
<u>AB</u>		<u>16MG</u>	<u>A203813 003</u>	Dec 05, 2016
<u>AB</u>		<u>32MG</u>	<u>A203813 004</u>	Dec 05, 2016
<u>AB</u>	SANDOZ	<u>4MG</u>	<u>A078702 001</u>	May 03, 2013
<u>AB</u>		<u>8MG</u>	<u>A078702 002</u>	May 03, 2013
<u>AB</u>		<u>16MG</u>	<u>A078702 003</u>	May 03, 2013
<u>AB</u>		<u>32MG</u>	<u>A078702 004</u>	May 03, 2013

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ATACAND HCT

<u>AB</u>	ASTRAZENECA	<u>16MG; 12.5MG</u>	<u>N021093 001</u>	Sep 05, 2000
<u>AB</u>		<u>32MG; 12.5MG</u>	<u>N021093 002</u>	Sep 05, 2000
<u>AB</u>	+	<u>32MG; 25MG</u>	<u>N021093 003</u>	May 16, 2008

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

<u>AB</u>	APOTEX INC	<u>16MG; 12.5MG</u>	<u>A202884 001</u>	Dec 04, 2012
<u>AB</u>		<u>32MG; 12.5MG</u>	<u>A202884 002</u>	Dec 04, 2012
<u>AB</u>		<u>32MG; 25MG</u>	<u>A202884 003</u>	Jun 03, 2013
<u>AB</u>	DR REDDYS LABS LTD	<u>16MG; 12.5MG</u>	<u>A202965 001</u>	Jun 03, 2013
<u>AB</u>		<u>32MG; 12.5MG</u>	<u>A202965 002</u>	Jun 03, 2013
<u>AB</u>		<u>32MG; 25MG</u>	<u>A202965 003</u>	Jun 03, 2013
<u>AB</u>	MACLEODS PHARMS LTD	<u>16MG; 12.5MG</u>	<u>A204100 001</u>	Feb 27, 2015
<u>AB</u>		<u>32MG; 12.5MG</u>	<u>A204100 002</u>	Feb 27, 2015
<u>AB</u>		<u>32MG; 25MG</u>	<u>A204100 003</u>	Feb 27, 2015
<u>AB</u>	MYLAN LABS	<u>16MG; 12.5MG</u>	<u>A090704 001</u>	Dec 04, 2012
<u>AB</u>		<u>32MG; 12.5MG</u>	<u>A090704 002</u>	Dec 04, 2012
<u>AB</u>		<u>32MG; 25MG</u>	<u>A090704 003</u>	Dec 04, 2012

CANGRELOR

POWDER; IV (INFUSION)

KENGREAL

+	CHIESI USA INC	50MG/VIAL	N204958 001	Jun 22, 2015
---	----------------	-----------	-------------	--------------

CAPECITABINE

TABLET; ORAL

CAPECITABINE

<u>AB</u>	ACCORD HLTHCARE	<u>150MG</u>	<u>A202593 001</u>	Apr 23, 2015
<u>AB</u>		<u>500MG</u>	<u>A202593 002</u>	Apr 23, 2015
<u>AB</u>	MYLAN PHARMS INC	<u>150MG</u>	<u>A090943 001</u>	Aug 08, 2014
<u>AB</u>		<u>500MG</u>	<u>A090943 002</u>	Aug 08, 2014
<u>AB</u>	SHILPA MEDICARE LTD	<u>150MG</u>	<u>A207456 001</u>	Dec 12, 2016
<u>AB</u>		<u>500MG</u>	<u>A207456 002</u>	Dec 12, 2016
<u>AB</u>	TEVA PHARMS USA	<u>150MG</u>	<u>A091649 001</u>	Sep 16, 2013
<u>AB</u>		<u>500MG</u>	<u>A091649 002</u>	Sep 16, 2013
<u>AB</u>	WEST-WARD PHARMS INT	<u>150MG</u>	<u>A200483 001</u>	Jul 14, 2016
<u>AB</u>		<u>500MG</u>	<u>A200483 002</u>	Jul 14, 2016

XELODA

<u>AB</u>	HOFFMANN LA ROCHE	<u>150MG</u>	<u>N020896 001</u>	Apr 30, 1998
<u>AB</u>	+	<u>500MG</u>	<u>N020896 002</u>	Apr 30, 1998

CAPREOMYCIN SULFATE

INJECTABLE; INJECTION

CAPASTAT SULFATE

+	AKORN	EQ 1GM BASE/VIAL	N050095 001	
---	-------	------------------	-------------	--

CAPSAICIN

PATCH; TOPICAL

QUTENZA

+	ACORDA	8%	N022395 001	Nov 16, 2009
---	--------	----	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

<u>AB</u>	HIKMA INTL PHARMS	<u>12.5MG</u>	<u>A074505 001</u>	Feb 13, 1996
<u>AB</u>		<u>25MG</u>	<u>A074505 002</u>	Feb 13, 1996
<u>AB</u>		<u>50MG</u>	<u>A074505 003</u>	Feb 13, 1996
<u>AB</u>		<u>100MG</u>	<u>A074505 004</u>	Feb 13, 1996
<u>AB</u>	MYLAN	<u>12.5MG</u>	<u>A074434 001</u>	Feb 13, 1996
<u>AB</u>		<u>25MG</u>	<u>A074434 002</u>	Feb 13, 1996
<u>AB</u>		<u>50MG</u>	<u>A074434 003</u>	Feb 13, 1996
<u>AB</u>		<u>100MG</u>	<u>A074434 004</u>	Feb 13, 1996
<u>AB</u>	+ PRINSTON INC	<u>12.5MG</u>	<u>A074477 001</u>	Feb 13, 1996
<u>AB</u>		<u>25MG</u>	<u>A074477 002</u>	Feb 13, 1996
<u>AB</u>		<u>50MG</u>	<u>A074477 003</u>	Feb 13, 1996
<u>AB</u>		<u>100MG</u>	<u>A074477 004</u>	Feb 13, 1996
<u>AB</u>	TEVA	<u>12.5MG</u>	<u>A074322 001</u>	Feb 13, 1996
<u>AB</u>		<u>25MG</u>	<u>A074322 002</u>	Feb 13, 1996
<u>AB</u>		<u>50MG</u>	<u>A074322 003</u>	Feb 13, 1996
<u>AB</u>		<u>100MG</u>	<u>A074322 004</u>	Feb 13, 1996
<u>AB</u>	WATSON LABS	<u>12.5MG</u>	<u>A074386 001</u>	May 23, 1996
<u>AB</u>		<u>25MG</u>	<u>A074386 002</u>	May 23, 1996
<u>AB</u>		<u>50MG</u>	<u>A074386 003</u>	May 23, 1996
<u>AB</u>		<u>100MG</u>	<u>A074386 004</u>	May 23, 1996
<u>AB</u>	WOCKHARDT	<u>12.5MG</u>	<u>A074532 001</u>	Mar 28, 1997
<u>AB</u>		<u>25MG</u>	<u>A074532 002</u>	Mar 28, 1997
<u>AB</u>		<u>50MG</u>	<u>A074532 003</u>	Mar 28, 1997
<u>AB</u>		<u>100MG</u>	<u>A074532 004</u>	Mar 28, 1997

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

<u>AB</u>	G AND W LABS INC	<u>25MG; 15MG</u>	<u>A074827 001</u>	Dec 29, 1997
<u>AB</u>		<u>25MG; 25MG</u>	<u>A074827 002</u>	Dec 29, 1997
<u>AB</u>		<u>50MG; 15MG</u>	<u>A074827 004</u>	Dec 29, 1997
<u>AB</u>		<u>50MG; 25MG</u>	<u>A074827 003</u>	Dec 29, 1997
<u>AB</u>	MYLAN	<u>25MG; 15MG</u>	<u>A074896 001</u>	Dec 29, 1997
<u>AB</u>		<u>25MG; 25MG</u>	<u>A074896 002</u>	Dec 29, 1997
<u>AB</u>	+	<u>50MG; 15MG</u>	<u>A074896 004</u>	Dec 29, 1997
<u>AB</u>		<u>50MG; 25MG</u>	<u>A074896 003</u>	Dec 29, 1997

CARBACHOL

SOLUTION; INTRAOCULAR

MIOSTAT

+ ALCON

0.01%

N016968 001

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

<u>AB</u>	APOTEX INC	<u>100MG</u>	<u>A078986 001</u>	Nov 25, 2011
<u>AB</u>		<u>200MG</u>	<u>A078986 002</u>	Nov 25, 2011
<u>AB</u>		<u>300MG</u>	<u>A078986 003</u>	Nov 25, 2011
<u>AB</u>	MYLAN IRELAND LTD	<u>100MG</u>	<u>A076697 001</u>	May 20, 2011
<u>AB</u>		<u>200MG</u>	<u>A076697 002</u>	May 20, 2011
<u>AB</u>		<u>300MG</u>	<u>A076697 003</u>	May 20, 2011
<u>AB</u>	TARO	<u>100MG</u>	<u>A201106 001</u>	Jun 21, 2013
<u>AB</u>		<u>200MG</u>	<u>A201106 002</u>	Jun 21, 2013
<u>AB</u>		<u>300MG</u>	<u>A201106 003</u>	Jun 21, 2013
<u>AB</u>	TEVA PHARMS	<u>100MG</u>	<u>A078592 001</u>	Sep 20, 2012
<u>AB</u>		<u>200MG</u>	<u>A078592 002</u>	Sep 20, 2012
<u>AB</u>		<u>300MG</u>	<u>A078592 003</u>	Sep 20, 2012

CARBATROL

<u>AB</u>	SHIRE	<u>100MG</u>	<u>N020712 003</u>	Sep 30, 1997
<u>AB</u>		<u>200MG</u>	<u>N020712 001</u>	Sep 30, 1997
<u>AB</u>		<u>300MG</u>	<u>N020712 002</u>	Sep 30, 1997

EQUETRO

VALIDUS PHARMS INC

100MG

N021710 001 Dec 10, 2004

200MG

N021710 002 Dec 10, 2004

300MG

N021710 003 Dec 10, 2004

SOLUTION; IV (INFUSION)

CARNEXIV

+ LUNDBECK LLC

200MG/20ML (10MG/ML)

N206030 001 Oct 07, 2016

PRESCRIPTION DRUG PRODUCT LIST

CARBAMAZEPINE

SUSPENSION; ORAL

CARBAMAZEPINE

AB	WOCKHARDT	100MG/5ML	A075714 001	Jun 05, 2002
	TEGRETOL			
AB	+ NOVARTIS	100MG/5ML	N018927 001	Dec 18, 1987
	TERIL			
AB	TARO	100MG/5ML	A076729 001	Sep 20, 2004

TABLET; ORAL

CARBAMAZEPINE

AB	APOTEX INC	200MG	A075948 001	Feb 27, 2002
AB	TARO	200MG	A074649 001	Oct 03, 1996
AB	TORRENT PHARMS	200MG	A077272 002	Dec 07, 2005
	EPITOL			
AB	TEVA	200MG	A070541 001	Sep 17, 1986
	TEGRETOL			
AB	+ NOVARTIS	200MG	N016608 001	
	CARBAMAZEPINE			
	TORRENT PHARMS	100MG	A077272 001	Dec 07, 2005
		300MG	A077272 003	Dec 07, 2005
		400MG	A077272 004	Dec 07, 2005

TABLET, CHEWABLE; ORAL

CARBAMAZEPINE

AB	TARO PHARM INDS	100MG	A075687 001	Oct 24, 2000
AB	TORRENT PHARMS	100MG	A075712 001	Jul 05, 2001
	EPITOL			
AB	TEVA	100MG	A073524 001	Jul 29, 1992
	TEGRETOL			
AB	+ NOVARTIS	100MG	N018281 001	
	CARBAMAZEPINE			
	+ TARO PHARM INDS	200MG	A075687 002	Jul 29, 2002

TABLET, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

AB	TARO	100MG	A078115 001	Mar 31, 2009
AB		200MG	A078115 002	Mar 31, 2009
AB		400MG	A078115 003	Mar 31, 2009
	TEGRETOL-XR			
AB	NOVARTIS	100MG	N020234 001	Mar 25, 1996
AB		200MG	N020234 002	Mar 25, 1996
AB	+	400MG	N020234 003	Mar 25, 1996

CARBIDOPA

TABLET; ORAL

CARBIDOPA

AB	ALVOGEN MALTA	25MG	A204291 001	Jan 08, 2016
AB	AMERIGEN PHARMS LTD	25MG	A203261 001	Mar 10, 2014
AB	EDENBRIDGE PHARMS	25MG	A205304 001	Feb 17, 2016
	LODOSYN			
AB	+ ATON	25MG	N017830 001	

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

AB	SUN PHARMA GLOBAL	25MG;200MG;100MG	A079085 001	May 10, 2012
AB		37.5MG;200MG;150MG	A079085 002	May 10, 2012
AB	WOCKHARDT LTD	12.5MG;200MG;50MG	A090786 001	Nov 20, 2012
AB		18.75MG;200MG;75MG	A090833 001	Nov 20, 2012
AB		25MG;200MG;100MG	A090833 002	Nov 20, 2012
AB		31.25MG;200MG;125MG	A090833 003	Nov 20, 2012
AB		37.5MG;200MG;150MG	A090833 004	Nov 20, 2012
AB		50MG;200MG;200MG	A090833 005	Nov 20, 2012
	STALEVO 100			
AB	ORION PHARMA	25MG;200MG;100MG	N021485 002	Jun 11, 2003
	STALEVO 125			
AB	ORION PHARMA	31.25MG;200MG;125MG	N021485 006	Aug 29, 2008
	STALEVO 150			
AB	ORION PHARMA	37.5MG;200MG;150MG	N021485 003	Jun 11, 2003
	STALEVO 200			
AB	+ ORION PHARMA	50MG;200MG;200MG	N021485 004	Aug 02, 2007
	STALEVO 50			
AB	+ ORION PHARMA	12.5MG;200MG;50MG	N021485 001	Jun 11, 2003
	STALEVO 75			
AB	ORION PHARMA	18.75MG;200MG;75MG	N021485 005	Aug 29, 2008

PRESCRIPTION DRUG PRODUCT LIST

CARBIDOPA; LEVODOPA

CAPSULE, EXTENDED RELEASE; ORAL

RYTARY

IMPAX LABS INC	23.75MG;95MG	N203312 001	Jan 07, 2015
	36.25MG;145MG	N203312 002	Jan 07, 2015
	48.75MG;195MG	N203312 003	Jan 07, 2015
+	61.25MG;245MG	N203312 004	Jan 07, 2015

SUSPENSION; ENTERAL

DUOPA

+ ABBVIE INC	4.63MG/ML;20MG/ML	N203952 001	Jan 09, 2015
--------------	-------------------	-------------	--------------

TABLET; ORAL

CARBIDOPA AND LEVODOPA

<u>AB</u>	ACTAVIS ELIZABETH	<u>10MG;100MG</u>	<u>A074260 001</u>	Sep 03, 1993
<u>AB</u>		<u>25MG;100MG</u>	<u>A074260 002</u>	Sep 03, 1993
<u>AB</u>		<u>25MG;250MG</u>	<u>A074260 003</u>	Sep 03, 1993
<u>AB</u>	APOTEX INC	<u>10MG;100MG</u>	<u>A077120 001</u>	Jun 02, 2008
<u>AB</u>		<u>25MG;100MG</u>	<u>A077120 002</u>	Jun 02, 2008
<u>AB</u>		<u>25MG;250MG</u>	<u>A077120 003</u>	Jun 02, 2008
<u>AB</u>	MAYNE PHARMA	<u>10MG;100MG</u>	<u>A073618 001</u>	Aug 28, 1992
<u>AB</u>		<u>25MG;100MG</u>	<u>A073589 001</u>	Aug 28, 1992
<u>AB</u>		<u>25MG;250MG</u>	<u>A073607 001</u>	Aug 28, 1992
<u>AB</u>	MYLAN	<u>10MG;100MG</u>	<u>A090324 001</u>	Sep 28, 2009
<u>AB</u>		<u>25MG;100MG</u>	<u>A090324 002</u>	Sep 28, 2009
<u>AB</u>		<u>25MG;250MG</u>	<u>A090324 003</u>	Sep 28, 2009
<u>AB</u>	SUN PHARM INDS	<u>10MG;100MG</u>	<u>A078536 001</u>	Oct 28, 2008
<u>AB</u>		<u>25MG;100MG</u>	<u>A078536 002</u>	Oct 28, 2008
<u>AB</u>		<u>25MG;250MG</u>	<u>A078536 003</u>	Oct 28, 2008

SINEMET

<u>AB</u>	MERCK SHARP DOHME	<u>10MG;100MG</u>	<u>N017555 001</u>
<u>AB</u>		<u>25MG;100MG</u>	<u>N017555 003</u>
<u>AB</u>	+	<u>25MG;250MG</u>	<u>N017555 002</u>

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

<u>AB</u>	ACCORD HLTHCARE	<u>25MG;100MG</u>	<u>A202323 001</u>	Feb 08, 2013
<u>AB</u>		<u>50MG;200MG</u>	<u>A202323 002</u>	Feb 08, 2013
<u>AB</u>	APOTEX	<u>25MG;100MG</u>	<u>A076212 001</u>	Jun 16, 2004
<u>AB</u>		<u>50MG;200MG</u>	<u>A076212 002</u>	Jun 16, 2004
<u>AB</u>	IMPAX LABS	<u>25MG;100MG</u>	<u>A076521 001</u>	May 14, 2004
<u>AB</u>		<u>50MG;200MG</u>	<u>A076521 002</u>	May 14, 2004
<u>AB</u>	MYLAN	<u>25MG;100MG</u>	<u>A075091 002</u>	Apr 21, 2000
<u>AB</u>		<u>50MG;200MG</u>	<u>A075091 001</u>	Sep 30, 1999
<u>AB</u>	SUN PHARM INDS	<u>25MG;100MG</u>	<u>A077828 001</u>	Aug 23, 2007
<u>AB</u>		<u>50MG;200MG</u>	<u>A077828 002</u>	Aug 23, 2007

SINEMET CR

<u>AB</u>	MERCK SHARP DOHME	<u>25MG;100MG</u>	<u>N019856 002</u>	Dec 24, 1992
<u>AB</u>	+	<u>50MG;200MG</u>	<u>N019856 001</u>	May 30, 1991

TABLET, ORALLY DISINTEGRATING; ORAL

CARBIDOPA AND LEVODOPA

<u>AB</u>	MYLAN	<u>10MG;100MG</u>	<u>A078893 001</u>	Sep 18, 2008
<u>AB</u>		<u>25MG;100MG</u>	<u>A078893 002</u>	Sep 18, 2008
<u>AB</u>	+	<u>25MG;250MG</u>	<u>A078893 003</u>	Sep 18, 2008
<u>AB</u>	SUN PHARMA GLOBAL	<u>10MG;100MG</u>	<u>A078690 001</u>	Jul 31, 2009
<u>AB</u>		<u>25MG;100MG</u>	<u>A078690 002</u>	Jul 31, 2009
<u>AB</u>		<u>25MG;250MG</u>	<u>A078690 003</u>	Jul 31, 2009

CARBINOXAMINE MALEATE

SOLUTION; ORAL

CARBINOXAMINE MALEATE

<u>AA</u>	CYPRESS PHARM	<u>4MG/5ML</u>	<u>A090418 001</u>	May 04, 2010
<u>AA</u>	+	<u>4MG/5ML</u>	<u>A040458 001</u>	Apr 25, 2003
<u>AA</u>	VINTAGE PHARMS	<u>4MG/5ML</u>	<u>A040814 001</u>	Feb 26, 2008

SUSPENSION, EXTENDED RELEASE; ORAL

KARBINAL ER

+ TRIS PHARMA INC	4MG/5ML	N022556 001	Mar 28, 2013
-------------------	---------	-------------	--------------

TABLET; ORAL

CARBINOXAMINE MALEATE

<u>AA</u>	CYPRESS PHARM	<u>4MG</u>	<u>A090417 001</u>	Aug 23, 2010
<u>AA</u>	INVAGEN PHARMS	<u>4MG</u>	<u>A090435 001</u>	Apr 15, 2010
<u>AA</u>	+	<u>4MG</u>	<u>A040442 001</u>	Mar 19, 2003
<u>AA</u>	MISSION PHARMACAL CO	<u>4MG</u>	<u>A090756 001</u>	May 27, 2011
<u>AA</u>	VINTAGE PHARMS	<u>4MG</u>	<u>A040639 002</u>	May 30, 2008
	MIKART INC	6MG	A207484 001	May 31, 2016

PRESCRIPTION DRUG PRODUCT LIST

CARBOPLATIN

INJECTABLE; IV (INFUSION)

CARBOPLATIN

<u>AP</u>	AKORN	<u>50MG/5ML (10MG/ML)</u>	<u>A090475 001</u>	Jul 29, 2009
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A090475 002</u>	Jul 29, 2009
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A090475 003</u>	Jul 29, 2009
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A091268 002</u>	Jul 28, 2010
<u>AP</u>	CIPLA LTD	<u>50MG/5ML (10MG/ML)</u>	<u>A077861 001</u>	Jan 18, 2007
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077861 002</u>	Jan 18, 2007
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077861 003</u>	Jan 18, 2007
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A077861 004</u>	Jan 18, 2007
<u>AP</u>	FRESENIUS KABI ONCOL	<u>50MG/5ML (10MG/ML)</u>	<u>A077432 001</u>	Sep 29, 2006
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077432 002</u>	Sep 29, 2006
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077432 003</u>	Sep 29, 2006
<u>AP</u>	FRESENIUS KABI USA	<u>450MG/45ML (10MG/ML)</u>	<u>A077247 003</u>	Oct 21, 2004
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077266 003</u>	Feb 15, 2006
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A077266 004</u>	Feb 15, 2006
<u>AP</u>	HOSPIRA	<u>50MG/5ML (10MG/ML)</u>	<u>A076517 001</u>	Oct 14, 2004
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A076517 002</u>	Oct 14, 2004
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A076517 003</u>	Oct 14, 2004
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A077059 001</u>	Nov 23, 2004
<u>AP</u>	MYLAN INSTITUTIONAL	<u>50MG/5ML (10MG/ML)</u>	<u>A077998 001</u>	Apr 24, 2007
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077998 002</u>	Apr 24, 2007
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077998 003</u>	Apr 24, 2007
<u>AP</u>	MYLAN LABS LTD	<u>50MG/5ML (10MG/ML)</u>	<u>A091063 001</u>	Nov 09, 2011
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A091063 002</u>	Nov 09, 2011
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A091063 003</u>	Nov 09, 2011
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A091063 004</u>	Nov 09, 2011
<u>AP</u>	NANJING KING-FRIEND	<u>50MG/5ML (10MG/ML)</u>	<u>A077096 001</u>	Jun 14, 2005
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077096 002</u>	Jun 14, 2005
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077096 003</u>	Jun 14, 2005
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A077096 004</u>	Jun 03, 2013
<u>AP</u>	+ PHARMACHEMIE BV	<u>50MG/5ML (10MG/ML)</u>	<u>A077269 001</u>	Oct 14, 2004
<u>AP</u>	+	<u>150MG/15ML (10MG/ML)</u>	<u>A077269 002</u>	Oct 14, 2004
<u>AP</u>	+	<u>450MG/45ML (10MG/ML)</u>	<u>A077269 003</u>	Oct 14, 2004
<u>AP</u>	+	<u>600MG/60ML (10MG/ML)</u>	<u>A077269 004</u>	Dec 28, 2007
<u>AP</u>	PLIVA LACHEMA	<u>50MG/5ML (10MG/ML)</u>	<u>A078631 001</u>	Dec 02, 2008
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A078631 002</u>	Dec 02, 2008
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A078631 003</u>	Dec 02, 2008
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A078631 004</u>	Dec 02, 2008
<u>AP</u>	SANDOZ INC	<u>50MG/5ML (10MG/ML)</u>	<u>A078280 001</u>	May 08, 2008
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A078280 002</u>	May 08, 2008
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A078280 003</u>	May 08, 2008
<u>AP</u>	SANJA PHARMS CO	<u>50MG/5ML (10MG/ML)</u>	<u>A205487 001</u>	Mar 28, 2016
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A205487 002</u>	Mar 28, 2016
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A205487 003</u>	Mar 28, 2016
<u>AP</u>	SUN PHARMA GLOBAL	<u>50MG/5ML (10MG/ML)</u>	<u>A077926 001</u>	Sep 19, 2008
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077926 002</u>	Sep 19, 2008
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077926 003</u>	Sep 19, 2008
<u>AP</u>	+ TEVA PHARMS USA	<u>50MG/5ML (10MG/ML)</u>	<u>A077139 001</u>	Sep 21, 2005
<u>AP</u>	+	<u>150MG/15ML (10MG/ML)</u>	<u>A077139 002</u>	Sep 21, 2005
<u>AP</u>	+	<u>450MG/45ML (10MG/ML)</u>	<u>A077139 003</u>	Sep 21, 2005
<u>AP</u>	+	<u>600MG/60ML (10MG/ML)</u>	<u>A077139 004</u>	Sep 21, 2005
<u>AP</u>	WEST-WARD PHARMS INT	<u>50MG/5ML (10MG/ML)</u>	<u>A077244 001</u>	Oct 15, 2004
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077244 002</u>	Oct 15, 2004
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077244 003</u>	Oct 15, 2004
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A077244 004</u>	Jan 20, 2006
	+ MYLAN LABS LTD	1GM/100ML (10MG/ML)	A091478 001	Nov 23, 2011

CARBOPROST TROMETHAMINE

INJECTABLE; INJECTION

HEMABATE

+ PHARMACIA AND UPJOHN EQ 0.25MG BASE/ML N017989 001

CARFILZOMIB

POWDER; INTRAVENOUS

KYPROLIS

	ONYX THERAP	30MG/VIAL	N202714 002	Jun 03, 2016
	+	60MG/VIAL	N202714 001	Jul 20, 2012

PRESCRIPTION DRUG PRODUCT LIST

CARGLUMIC ACID

TABLET; ORAL

CARBAGLU

+ ORPHAN EUROPE

200MG

N022562 001 Mar 18, 2010

CARIPRAZINE HYDROCHLORIDE

CAPSULE; ORAL

VRAYLAR

FOREST RES INST INC

EQ 1.5MG BASE

N204370 001 Sep 17, 2015

EQ 3MG BASE

N204370 002 Sep 17, 2015

EQ 4.5MG BASE

N204370 003 Sep 17, 2015

+

EQ 6MG BASE

N204370 004 Sep 17, 2015

CARISOPRODOL

TABLET; ORAL

CARISOPRODOLAA ACCELRX LABS350MGA040576 001 Jun 07, 2005AA AUROBINDO PHARMA350MGA040792 001 Aug 06, 2009AA INGENUS PHARMS NJ350MGA040823 001 Oct 22, 2008AA NATCO PHARMA LTD350MGA090988 001 Oct 28, 2014AA ORIENT PHARMA CO LTD350MGA205085 001 Oct 28, 2014AA SCIEGEN PHARMS INC350MGA203374 001 Jan 27, 2014AA STRIDES PHARMA350MGA205513 002 Nov 12, 2015AA SUN PHARM INDS350MGA089346 001 Oct 17, 1991AA SUN PHARM INDS LTD350MGA040755 001 Feb 27, 2007AA VINTAGE PHARMS350MGA040245 001 Sep 08, 1997AA WATSON LABS350MGA087499 001 Apr 20, 1982AA WILSHIRE PHARMS INC350MGA205126 002 Jul 08, 2015SOMAAA MEDA PHARMS350MGN011792 001CARISOPRODOLAB AUROBINDO PHARMA250MGA040792 002 Nov 08, 2016AB STRIDES PHARMA250MGA205513 001 Nov 12, 2015AB WILSHIRE PHARMS INC250MGA205126 001 Jul 08, 2015SOMAAB + MEDA PHARMS250MGN011792 004 Sep 13, 2007CARMUSTINE

IMPLANT; INTRACRANIAL

GLIADEL

+ ARBOR PHARMS LLC

7.7MG

N020637 001 Sep 23, 1996

INJECTABLE; INJECTION

BICNU

+ EMCURE PHARMS LTD

100MG/VIAL

N017422 001

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CARTEOLOL HYDROCHLORIDEAT ALCON1%A075476 001 Jan 03, 2000AT BAUSCH AND LOMB1%A075546 001 Jan 20, 2000OCUPRESSAT + NOVARTIS1%N019972 001 May 23, 1990CARVEDILOL

TABLET; ORAL

CARVEDILOLAB APOTEX INC3.125MGA078165 001 Sep 05, 2007AB6.25MGA078165 002 Sep 05, 2007AB12.5MGA078165 003 Sep 05, 2007AB25MGA078165 004 Sep 05, 2007AB AUROBINDO PHARMA3.125MGA078332 001 Sep 05, 2007AB6.25MGA078332 002 Sep 05, 2007AB12.5MGA078332 003 Sep 05, 2007AB25MGA078332 004 Sep 05, 2007AB BEXIMCO USA3.125MGA078384 001 Sep 05, 2007AB6.25MGA078384 002 Sep 05, 2007AB12.5MGA078384 003 Sep 05, 2007AB25MGA078384 004 Sep 05, 2007AB CIPLA LTD3.125MGA077474 001 Sep 05, 2007AB6.25MGA077474 002 Sep 05, 2007AB12.5MGA077474 003 Sep 05, 2007AB25MGA077474 004 Sep 05, 2007AB DR REDDYS LABS LTD3.125MGA076649 001 Sep 05, 2007AB6.25MGA076649 002 Sep 05, 2007AB12.5MGA076649 003 Sep 05, 2007

PRESCRIPTION DRUG PRODUCT LIST

CARVEDILOL

TABLET; ORAL

CARVEDILOL

<u>AB</u>		<u>25MG</u>	<u>A076649 004</u>	Sep 05, 2007
<u>AB</u>	GLENMARK GENERICS	<u>3.125MG</u>	<u>A078251 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078251 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078251 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078251 004</u>	Sep 05, 2007
<u>AB</u>	LUPIN	<u>3.125MG</u>	<u>A078217 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078217 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078217 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078217 004</u>	Sep 05, 2007
<u>AB</u>	MYLAN	<u>3.125MG</u>	<u>A077316 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077316 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077316 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077316 004</u>	Sep 05, 2007
<u>AB</u>	PLIVA HRVATSKA DOO	<u>3.125MG</u>	<u>A078240 001</u>	Oct 30, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078240 002</u>	Oct 30, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078240 003</u>	Oct 30, 2007
<u>AB</u>		<u>25MG</u>	<u>A078240 004</u>	Oct 30, 2007
<u>AB</u>	SANDOZ	<u>3.125MG</u>	<u>A078227 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078227 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078227 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078227 004</u>	Sep 05, 2007
<u>AB</u>	SUN PHARM INDS INC	<u>3.125MG</u>	<u>A077346 004</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077346 001</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077346 002</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077346 003</u>	Sep 05, 2007
<u>AB</u>	SUN PHARM INDS LTD	<u>3.125MG</u>	<u>A076989 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A076989 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A076989 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A076989 004</u>	Sep 05, 2007
<u>AB</u>	TARO	<u>3.125MG</u>	<u>A077780 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077780 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077780 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077780 004</u>	Sep 05, 2007
<u>AB</u>	TEVA	<u>3.125MG</u>	<u>A076373 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A076373 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A076373 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A076373 004</u>	Sep 05, 2007
<u>AB</u>	ZYDUS PHARMS USA INC	<u>3.125MG</u>	<u>A077614 004</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077614 001</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077614 002</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077614 003</u>	Sep 05, 2007
	<u>COREG</u>			
<u>AB</u>	SMITHKLINE BEECHAM	<u>3.125MG</u>	<u>N020297 004</u>	May 29, 1997
<u>AB</u>		<u>6.25MG</u>	<u>N020297 003</u>	Sep 14, 1995
<u>AB</u>	+	<u>12.5MG</u>	<u>N020297 002</u>	Sep 14, 1995
<u>AB</u>		<u>25MG</u>	<u>N020297 001</u>	Sep 14, 1995

CARVEDILOL PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL

COREG CR

SMITHKLINE BEECHAM	10MG	N022012 001	Oct 20, 2006
	20MG	N022012 002	Oct 20, 2006
+	40MG	N022012 003	Oct 20, 2006
	80MG	N022012 004	Oct 20, 2006

CASPOFUNGIN ACETATE

INJECTABLE; IV (INFUSION)

CANCIDAS

+ MERCK	50MG/VIAL	N021227 001	Jan 26, 2001
+	70MG/VIAL	N021227 002	Jan 26, 2001

POWDER; IV (INFUSION)

CASPOFUNGIN ACETATE

<u>AP</u>	FRESENIUS KABI USA	<u>50MG/VIAL</u>	<u>N206110 001</u>	Dec 30, 2016
<u>AP</u>		<u>70MG/VIAL</u>	<u>N206110 002</u>	Dec 30, 2016

PRESCRIPTION DRUG PRODUCT LIST

CEFACTOR

CAPSULE;ORAL

CEFACTOR

<u>AB</u>	HIKMA	<u>EQ 250MG BASE</u>	<u>A065350 001</u>	Apr 03, 2007
<u>AB</u>	+	<u>EQ 500MG BASE</u>	<u>A065350 002</u>	Apr 03, 2007
<u>AB</u>	YUNG SHIN PHARM	<u>EQ 250MG BASE</u>	<u>A065146 001</u>	Jan 22, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065146 002</u>	Jan 22, 2004

FOR SUSPENSION;ORAL

CEFACTOR

<u>AB</u>	YUNG SHIN PHARM	<u>EQ 125MG BASE/5ML</u>	<u>A065412 001</u>	Feb 17, 2012
<u>AB</u>		<u>EQ 187MG BASE/5ML</u>	<u>A065412 002</u>	Feb 17, 2012
<u>AB</u>		<u>EQ 250MG BASE/5ML</u>	<u>A065412 003</u>	Feb 17, 2012
<u>AB</u>	+	<u>EQ 375MG BASE/5ML</u>	<u>A065412 004</u>	Feb 17, 2012

TABLET, EXTENDED RELEASE;ORAL

CEFACTOR

	TEVA	EQ 375MG BASE	A065058 001	Sep 04, 2002
+		EQ 500MG BASE	A065058 002	Sep 04, 2002

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE;ORAL

CEFADROXIL

<u>AB</u>	AUROBINDO PHARMA	<u>EQ 500MG BASE</u>	<u>A065352 001</u>	Jan 25, 2007
<u>AB</u>	HIKMA	<u>EQ 500MG BASE</u>	<u>A065311 001</u>	Feb 07, 2006
<u>AB</u>	LUPIN	<u>EQ 500MG BASE</u>	<u>A065392 001</u>	May 29, 2007
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 500MG BASE</u>	<u>A065309 001</u>	Sep 18, 2006
<u>AB</u>	SANDOZ	<u>EQ 500MG BASE</u>	<u>A062291 001</u>	
<u>AB</u>	+	<u>EQ 500MG BASE</u>	<u>A065282 001</u>	Jan 20, 2006

FOR SUSPENSION;ORAL

CEFADROXIL

<u>AB</u>	AUROBINDO	<u>EQ 250MG BASE/5ML</u>	<u>A065349 001</u>	Apr 25, 2013
<u>AB</u>		<u>EQ 500MG BASE/5ML</u>	<u>A065349 002</u>	Apr 25, 2013
<u>AB</u>	HIKMA PHARMS	<u>EQ 250MG BASE/5ML</u>	<u>A091036 001</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 500MG BASE/5ML</u>	<u>A091036 002</u>	Nov 28, 2012
<u>AB</u>	LUPIN	<u>EQ 250MG BASE/5ML</u>	<u>A065396 001</u>	Feb 21, 2008
<u>AB</u>	+	<u>EQ 500MG BASE/5ML</u>	<u>A065396 002</u>	Feb 21, 2008
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 250MG BASE/5ML</u>	<u>A065307 002</u>	Oct 16, 2006
<u>AB</u>		<u>EQ 500MG BASE/5ML</u>	<u>A065307 003</u>	Oct 16, 2006

TABLET;ORAL

CEFADROXIL

<u>AB</u>	HIKMA	<u>EQ 1GM BASE</u>	<u>A065260 001</u>	Mar 30, 2006
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 1GM BASE</u>	<u>A065301 001</u>	Sep 18, 2006
+	TEVA PHARMS	EQ 1GM BASE	A062774 001	Apr 08, 1987

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

<u>AP</u>	ACS DOBFAR	<u>EQ 500MG BASE/VIAL</u>	<u>A065303 001</u>	Oct 22, 2008
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065303 002</u>	Oct 22, 2008
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065306 001</u>	Oct 22, 2008
<u>AP</u>		<u>EQ 20GM BASE/VIAL</u>	<u>A065306 002</u>	Aug 18, 2014
<u>AP</u>	FACTA FARMA	<u>EQ 500MG BASE/VIAL</u>	<u>A063214 001</u>	Dec 27, 1991
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A063207 001</u>	Dec 27, 1991
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A063209 001</u>	Dec 27, 1991
<u>AP</u>	+	<u>EQ 20GM BASE/VIAL</u>	<u>A063209 002</u>	Apr 30, 1999
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 500MG BASE/VIAL</u>	<u>A065047 001</u>	Sep 18, 2001
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065047 002</u>	Sep 18, 2001
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065143 001</u>	Oct 18, 2004
<u>AP</u>	+	<u>EQ 500MG BASE/VIAL</u>	<u>A065226 001</u>	Apr 21, 2005
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>A065226 002</u>	Apr 21, 2005
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>A065244 001</u>	Aug 12, 2005
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A201654 001</u>	Feb 03, 2016
<u>AP</u>	+	<u>EQ 10GM BASE/VIAL</u>	<u>A065247 001</u>	Aug 12, 2005
<u>AP</u>	QILU PHARM CO LTD	<u>EQ 1GM BASE/VIAL</u>	<u>A203661 001</u>	Dec 28, 2015
<u>AP</u>	SANDOZ	<u>EQ 500MG BASE/VIAL</u>	<u>A062831 001</u>	Dec 09, 1988
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A062831 002</u>	Dec 09, 1988
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065345 001</u>	May 09, 2007
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A062831 003</u>	Sep 25, 1992

KEFZOL

<u>AP</u>	ACS DOBFAR	<u>EQ 500MG BASE/VIAL</u>	<u>A061773 002</u>	
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A061773 003</u>	
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A061773 004</u>	

ANCEF IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	EQ 10MG BASE/ML	A063002 001	Mar 28, 1991
---	-----------------	-----------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

ANCEF IN PLASTIC CONTAINER

+ EQ 20MG BASE/ML A063002 002 Mar 28, 1991

CEFAZOLIN AND DEXTROSE

+ B BRAUN EQ 1GM BASE/VIAL N050779 002 Jul 27, 2000

EQ 2GM BASE/VIAL N050779 003 Jan 13, 2012

CEFAZOLIN SODIUM

+ SAMSON MEDCL EQ 100GM BASE/VIAL A065141 001 Nov 29, 2006

+ EQ 300GM BASE/VIAL A065141 002 Nov 29, 2006

SOLUTION; INTRAVENOUS

CEFAZOLIN IN PLASTIC CONTAINER

BAXTER HLTHCARE EQ 2GM BASE/100ML (EQ 20MG BASE/ML) N207131 001 Aug 07, 2015

CEFDINIR

CAPSULE; ORAL

CEFDINIRAB AUROBINDO PHARMA 300MG A065434 001 Jan 07, 2008AB LUPIN 300MG A065264 001 May 19, 2006AB ORCHID HLTHCARE 300MG A065418 001 Jul 18, 2007AB + SANDOZ 300MG A065330 001 Apr 06, 2007AB TEVA PHARMS 300MG A065368 001 May 09, 2007

FOR SUSPENSION; ORAL

CEFDINIRAB AUROBINDO PHARMA 125MG/5ML A065473 001 Dec 14, 2007AB 250MG/5ML A065473 002 Dec 14, 2007AB LUPIN 125MG/5ML A065259 001 May 31, 2006AB 250MG/5ML A065259 002 May 07, 2007AB ORCHID HLTHCARE 125MG/5ML A065429 001 Jul 18, 2007AB 250MG/5ML A065429 002 Jul 18, 2007AB SANDOZ 125MG/5ML A065337 001 Apr 06, 2007AB + 250MG/5ML A065337 002 Apr 06, 2007AB TEVA PHARMS 125MG/5ML A065332 001 May 04, 2007AB 250MG/5ML A065332 002 May 04, 2007CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDEAP ACS DOBFAR EQ 1GM BASE/VIAL A065441 001 Mar 20, 2008AP EQ 2GM BASE/VIAL A065441 002 Mar 20, 2008AP HOSPIRA INC EQ 500MG BASE/VIAL A065369 001 Jun 18, 2007AP EQ 1GM BASE/VIAL A065369 002 Jun 18, 2007AP EQ 1GM BASE/VIAL A202268 001 Jul 30, 2012AP EQ 2GM BASE/VIAL A065369 003 Jun 18, 2007AP EQ 2GM BASE/VIAL A202268 002 Jul 30, 2012AP QILU PHARM CO LTD EQ 500MG BASE/VIAL A203704 001 Feb 01, 2016AP EQ 1GM BASE/VIAL A203704 002 Feb 01, 2016AP EQ 2GM BASE/VIAL A203704 003 Feb 01, 2016AP SAGENT PHARMS EQ 1GM BASE/VIAL A091048 001 Jan 04, 2017AP EQ 2GM BASE/VIAL A091048 002 Jan 04, 2017MAXIPIMEAP + HOSPIRA INC EQ 500MG BASE/VIAL N050679 001 Jan 18, 1996AP + EQ 1GM BASE/VIAL N050679 002 Jan 18, 1996AP + EQ 2GM BASE/VIAL N050679 003 Jan 18, 1996

CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER

B BRAUN EQ 1GM BASE/VIAL N050821 001 May 06, 2010

EQ 2GM BASE/VIAL N050821 002 May 06, 2010

CEFEPIME IN PLASTIC CONTAINER

+ BAXTER HLTHCARE EQ 1GM BASE/50ML (EQ 20MG BASE/ML) N050817 001 Aug 05, 2008

+ EQ 2GM BASE/100ML (EQ 20MG BASE/ML) N050817 002 Aug 05, 2008

CEFIXIME

CAPSULE; ORAL

SUPRAX

+ LUPIN LTD 400MG N203195 001 Jun 01, 2012

FOR SUSPENSION; ORAL

CEFIXIMEAB AUROBINDO PHARMA LTD 100MG/5ML A204835 001 Apr 14, 2015AB 200MG/5ML A204835 002 Apr 14, 2015SUPRAXAB LUPIN PHARMS 100MG/5ML A065129 001 Feb 23, 2004AB 200MG/5ML A065355 001 Apr 10, 2007

+ LUPIN LTD 500MG/5ML N202091 001 Feb 20, 2013

PRESCRIPTION DRUG PRODUCT LIST

CEFIXIME

TABLET; ORAL

SUPRAX

+ LUPIN PHARMS

400MG

A065130 001 Feb 12, 2004

TABLET, CHEWABLE; ORAL

SUPRAX

LUPIN LTD

100MG

A065380 001 Oct 25, 2010

150MG

A065380 002 Oct 25, 2010

+

200MG

A065380 003 Oct 25, 2010

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME

AP HIKMA

EQ 500MG BASE/VIALA065072 001 Nov 20, 2002

AP

EQ 1GM BASE/VIALA065072 002 Nov 20, 2002

AP

EQ 2GM BASE/VIALA065072 003 Nov 20, 2002

AP

EQ 10GM BASE/VIALA065071 001 Nov 20, 2002

AP

WOCKHARDT

EQ 1GM BASE/VIALA065197 001 Aug 29, 2006CEFOTAXIME SODIUM

AP HOSPIRA INC

EQ 500MG BASE/VIALA065290 001 Aug 11, 2006

AP

EQ 1GM BASE/VIALA065290 002 Aug 11, 2006

AP

EQ 1GM BASE/VIALA065293 001 Aug 10, 2006

AP

EQ 1GM BASE/VIALA203132 001 Feb 19, 2016

AP

EQ 2GM BASE/VIALA065290 003 Aug 11, 2006

AP

EQ 2GM BASE/VIALA065293 002 Aug 10, 2006

AP

EQ 2GM BASE/VIALA203132 002 Feb 19, 2016

AP

EQ 10GM BASE/VIALA065292 001 Aug 10, 2006

AP

LUPIN

EQ 500MG BASE/VIALA065124 001 Sep 24, 2003

AP

EQ 1GM BASE/VIALA065124 002 Sep 24, 2003

AP

EQ 2GM BASE/VIALA065124 003 Sep 24, 2003

AP

WOCKHARDT

EQ 500MG BASE/VIALA065197 002 Jun 20, 2008

AP

EQ 2GM BASE/VIALA065197 003 Jun 20, 2008CLAFORAN

AP + SANOFI AVENTIS US

EQ 1GM BASE/VIALA062659 001 Jan 13, 1987

AP

+

EQ 2GM BASE/VIALA062659 002 Jan 13, 1987

AP

+ US PHARM HOLDINGS

EQ 500MG BASE/VIALN050547 001

AP

+

EQ 1GM BASE/VIALN050547 002

AP

+

EQ 2GM BASE/VIALN050547 003

AP

+

EQ 10GM BASE/VIALN050547 004 Dec 29, 1983CEFOTETAN DISODIUM

INJECTABLE; INJECTION

CEFOTAN

AP TELIGENT PHARMA INC

EQ 1GM BASE/VIALN050588 001 Dec 27, 1985

AP

EQ 2GM BASE/VIALN050588 002 Dec 27, 1985CEFOTETAN

AP + FRESENIUS KABI USA

EQ 1GM BASE/VIALA065374 001 Aug 09, 2007

AP

+

EQ 2GM BASE/VIALA065374 002 Aug 09, 2007

AP

+

EQ 10GM BASE/VIALA065375 001 Aug 09, 2007

AP

HIKMA FARMACEUTICA

EQ 1GM BASE/VIALA091031 001 Oct 26, 2011

AP

EQ 2GM BASE/VIALA091031 002 Oct 26, 2011

AP

WEST-WARD PHARM CORP

EQ 10GM BASE/VIALA091030 001 Oct 26, 2011

CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER

+ B BRAUN

EQ 1GM BASE/VIAL

N065430 001 Aug 09, 2007

+

EQ 2GM BASE/VIAL

N065430 002 Aug 09, 2007

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

AP + ACS DOBFAR

EQ 1GM BASE/VIALA065414 001 Jun 12, 2009

AP

+

EQ 2GM BASE/VIALA065414 002 Jun 12, 2009

AP

+

EQ 10GM BASE/VIALA065415 001 May 19, 2010

AP

ACS DOBFAR SPA

EQ 1GM BASE/VIALA065467 001 Aug 31, 2011

AP

EQ 2GM BASE/VIALA065467 002 Aug 31, 2011

AP

EQ 10GM BASE/VIALA065464 001 Aug 31, 2011

AP

EUROHLTH INTL SARL

EQ 1GM BASE/VIALA065051 001 Sep 11, 2000

AP

EQ 2GM BASE/VIALA065051 002 Sep 11, 2000

AP

EQ 10GM BASE/VIALA065050 001 Sep 11, 2000

AP

HIKMA FARMACEUTICA

EQ 1GM BASE/VIALA065238 001 Mar 12, 2010

AP

EQ 2GM BASE/VIALA065238 002 Mar 12, 2010

AP

EQ 10GM BASE/VIALA065239 001 Mar 02, 2010

AP

HOSPIRA INC

EQ 1GM BASE/VIALA065313 001 Jan 23, 2006

AP

EQ 2GM BASE/VIALA065313 002 Jan 23, 2006

AP

EQ 10GM BASE/VIALA065312 001 Feb 13, 2006

PRESCRIPTION DRUG PRODUCT LIST

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER

<u>AP</u>	+	B BRAUN	<u>EQ 1GM BASE/VIAL</u>	<u>N065214</u>	<u>001</u>	Mar 10, 2006
<u>AP</u>	+		<u>EQ 2GM BASE/VIAL</u>	<u>N065214</u>	<u>002</u>	Mar 10, 2006
MEFOXIN IN PLASTIC CONTAINER						
	+	MYLAN INSTITUTIONAL	EQ 20MG BASE/ML	A063182	001	Jan 25, 1993
	+		EQ 40MG BASE/ML	A063182	002	Jan 25, 1993
POWDER; IV (INFUSION)						
CEFOXITIN IN PLASTIC CONTAINER						
		SAMSON MEDCL	EQ 100GM BASE	A200938	001	Nov 16, 2015

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL

CEFPODOXIME PROXETIL

<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 50MG BASE/5ML</u>	<u>A065409</u>	<u>001</u>	Jun 08, 2007
<u>AB</u>			<u>EQ 100MG BASE/5ML</u>	<u>A065409</u>	<u>002</u>	Jun 08, 2007
<u>AB</u>		SANDOZ	<u>EQ 50MG BASE/5ML</u>	<u>A090031</u>	<u>001</u>	Jan 14, 2009
<u>AB</u>	+		<u>EQ 100MG BASE/5ML</u>	<u>A090031</u>	<u>002</u>	Jan 14, 2009

TABLET; ORAL

CEFPODOXIME PROXETIL

<u>AB</u>		AUROBINDO PHARMA	<u>EQ 100MG BASE</u>	<u>A065370</u>	<u>001</u>	Jun 11, 2007
<u>AB</u>			<u>EQ 200MG BASE</u>	<u>A065370</u>	<u>002</u>	Jun 11, 2007
<u>AB</u>		ORCHID HLTHCARE	<u>EQ 100MG BASE</u>	<u>A065388</u>	<u>001</u>	Nov 14, 2007
<u>AB</u>			<u>EQ 200MG BASE</u>	<u>A065388</u>	<u>002</u>	Nov 14, 2007
<u>AB</u>		SANDOZ	<u>EQ 100MG BASE</u>	<u>A065462</u>	<u>001</u>	May 28, 2008
<u>AB</u>	+		<u>EQ 200MG BASE</u>	<u>A065462</u>	<u>002</u>	May 28, 2008

CEFPROZIL

FOR SUSPENSION; ORAL

CEFPROZIL

<u>AB</u>		APOTEX INC	<u>125MG/5ML</u>	<u>A065351</u>	<u>001</u>	Feb 29, 2012
<u>AB</u>			<u>250MG/5ML</u>	<u>A065351</u>	<u>002</u>	Feb 29, 2012
<u>AB</u>		AUROBINDO PHARMA	<u>125MG/5ML</u>	<u>A065381</u>	<u>001</u>	Jan 30, 2007
<u>AB</u>			<u>250MG/5ML</u>	<u>A065381</u>	<u>002</u>	Jan 30, 2007
<u>AB</u>		LUPIN	<u>125MG/5ML</u>	<u>A065261</u>	<u>001</u>	Dec 19, 2005
<u>AB</u>	+		<u>250MG/5ML</u>	<u>A065261</u>	<u>002</u>	Dec 19, 2005
<u>AB</u>		ORCHID HLTHCARE	<u>125MG/5ML</u>	<u>A065284</u>	<u>002</u>	Dec 30, 2005
<u>AB</u>			<u>250MG/5ML</u>	<u>A065284</u>	<u>001</u>	Dec 30, 2005
<u>AB</u>		SANDOZ	<u>125MG/5ML</u>	<u>A065257</u>	<u>001</u>	Dec 08, 2005
<u>AB</u>			<u>250MG/5ML</u>	<u>A065257</u>	<u>002</u>	Dec 08, 2005
<u>AB</u>		TEVA PHARMS	<u>125MG/5ML</u>	<u>A065236</u>	<u>001</u>	Dec 08, 2005
<u>AB</u>			<u>250MG/5ML</u>	<u>A065236</u>	<u>002</u>	Dec 08, 2005

TABLET; ORAL

CEFPROZIL

<u>AB</u>		APOTEX INC	<u>250MG</u>	<u>A065327</u>	<u>001</u>	Mar 26, 2008
<u>AB</u>			<u>500MG</u>	<u>A065327</u>	<u>002</u>	Mar 26, 2008
<u>AB</u>		AUROBINDO PHARMA LTD	<u>250MG</u>	<u>A065340</u>	<u>001</u>	May 24, 2007
<u>AB</u>			<u>500MG</u>	<u>A065340</u>	<u>002</u>	May 24, 2007
<u>AB</u>		LUPIN	<u>250MG</u>	<u>A065276</u>	<u>001</u>	Dec 08, 2005
<u>AB</u>	+		<u>500MG</u>	<u>A065276</u>	<u>002</u>	Dec 08, 2005
<u>AB</u>		ORCHID HLTHCARE	<u>250MG</u>	<u>A065267</u>	<u>001</u>	Dec 19, 2005
<u>AB</u>			<u>500MG</u>	<u>A065267</u>	<u>002</u>	Dec 19, 2005
<u>AB</u>		SANDOZ	<u>250MG</u>	<u>A065235</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>			<u>500MG</u>	<u>A065235</u>	<u>002</u>	Nov 14, 2005
<u>AB</u>		TEVA	<u>250MG</u>	<u>A065208</u>	<u>001</u>	Dec 06, 2005
<u>AB</u>			<u>500MG</u>	<u>A065208</u>	<u>002</u>	Dec 06, 2005
<u>AB</u>		WOCKHARDT	<u>250MG</u>	<u>A065428</u>	<u>001</u>	Jun 14, 2007
<u>AB</u>			<u>500MG</u>	<u>A065428</u>	<u>002</u>	Jun 14, 2007

CEFTAROLINE FOSAMIL

POWDER; IV (INFUSION)

TEFLARO

		CEREXA	400MG/VIAL	N200327	001	Oct 29, 2010
	+		600MG/VIAL	N200327	002	Oct 29, 2010

CEFTAZIDIME

INJECTABLE; INJECTION

CEFTAZIDIME

<u>AP</u>		ACS DOBFAR	<u>500MG/VIAL</u>	<u>A062640</u>	<u>001</u>	Nov 20, 1985
<u>AP</u>			<u>1GM/VIAL</u>	<u>A062640</u>	<u>002</u>	Nov 20, 1985
<u>AP</u>			<u>2GM/VIAL</u>	<u>A062640</u>	<u>003</u>	Nov 20, 1985
<u>AP</u>			<u>6GM/VIAL</u>	<u>A062640</u>	<u>004</u>	Feb 03, 1992
<u>AP</u>		WOCKHARDT	<u>1GM/VIAL</u>	<u>A065196</u>	<u>001</u>	Oct 15, 2008

PRESCRIPTION DRUG PRODUCT LIST

CEFTAZIDIME

INJECTABLE; INJECTION

FORTAZ

<u>AP</u>	+	IGI LABS INC	<u>500MG/VIAL</u>	<u>N050578 001</u>	Jul 19, 1985
<u>AP</u>	+		<u>1GM/VIAL</u>	<u>N050578 002</u>	Jul 19, 1985
<u>AP</u>	+		<u>2GM/VIAL</u>	<u>N050578 003</u>	Jul 19, 1985
<u>AP</u>	+		<u>6GM/VIAL</u>	<u>N050578 004</u>	Jul 19, 1985

TAZICEF

<u>AP</u>		HOSPIRA	<u>500MG/VIAL</u>	<u>A062662 001</u>	Mar 06, 1986
<u>AP</u>			<u>1GM/VIAL</u>	<u>A062662 002</u>	Mar 06, 1986
<u>AP</u>			<u>1GM/VIAL</u>	<u>A064032 001</u>	Oct 31, 1993
<u>AP</u>			<u>2GM/VIAL</u>	<u>A062662 003</u>	Mar 06, 1986
<u>AP</u>			<u>2GM/VIAL</u>	<u>A064032 002</u>	Oct 31, 1993
<u>AP</u>			<u>6GM/VIAL</u>	<u>A062662 004</u>	Mar 06, 1986
		CEFTAZIDIME IN DEXTROSE CONTAINER			
		B BRAUN	EQ 1GM BASE	N050823 001	Jun 13, 2011
	+		EQ 2GM BASE	N050823 002	Jun 13, 2011

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

FORTAZ IN PLASTIC CONTAINER

	+	IGI LABS INC	EQ 20MG BASE/ML	N050634 002	Apr 28, 1989
	+		EQ 40MG BASE/ML	N050634 003	Apr 28, 1989

CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM

POWDER; IV (INFUSION)

ZERBAXA

	+	CUBIST PHARMS LLC	EQ 1GM BASE/VIAL; EQ 0.5GM BASE/VIAL	N206829 001	Dec 19, 2014
--	---	-------------------	--------------------------------------	-------------	--------------

CEFTRIAOXONE SODIUM

INJECTABLE; INJECTION

CEFTRIAOXONE

<u>AP</u>		ACS DOBFAR	<u>EQ 500MG BASE/VIAL</u>	<u>A065329 001</u>	Jul 24, 2008
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A065329 002</u>	Jul 24, 2008
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A065329 003</u>	Jul 24, 2008
<u>AP</u>			<u>EQ 10GM BASE/VIAL</u>	<u>A065328 001</u>	Jul 24, 2008
<u>AP</u>		BEDFORD	<u>EQ 10GM BASE/VIAL</u>	<u>A065475 001</u>	Aug 18, 2008
<u>AP</u>		FACTA FARMA	<u>EQ 10GM BASE/VIAL</u>	<u>A065269 001</u>	Feb 28, 2007
<u>AP</u>		HOSPIRA INC	<u>EQ 10GM BASE/VIAL</u>	<u>A065232 001</u>	Aug 02, 2005
<u>AP</u>		LUPIN	<u>EQ 10GM BASE/VIAL</u>	<u>A065263 001</u>	Sep 12, 2006
<u>AP</u>	+	SANDOZ	<u>EQ 10GM BASE/VIAL</u>	<u>A065168 001</u>	May 17, 2005
<u>AP</u>	+	SANDOZ INC	<u>EQ 1GM BASE/VIAL</u>	<u>A065204 001</u>	May 03, 2005
<u>AP</u>	+		<u>EQ 2GM BASE/VIAL</u>	<u>A065204 002</u>	May 03, 2005
<u>AP</u>		WOCKHARDT	<u>EQ 1GM BASE/VIAL</u>	<u>A065180 001</u>	May 12, 2006
		CEFTRIAOXONE AND DEXTROSE IN DUPLIX CONTAINER			
<u>AP</u>	+	B BRAUN	<u>EQ 1GM BASE/VIAL</u>	<u>N050796 001</u>	Apr 20, 2005
<u>AP</u>	+		<u>EQ 2GM BASE/VIAL</u>	<u>N050796 002</u>	Apr 20, 2005
		CEFTRIAOXONE			
		SAMSON MEDCL	EQ 100GM BASE/VIAL	A090057 001	Apr 25, 2014
		CEFTRIAOXONE IN PLASTIC CONTAINER			
	+	BAXTER HLTHCARE	EQ 20MG BASE/ML	A065224 001	Aug 23, 2005
	+		EQ 40MG BASE/ML	A065224 002	Aug 23, 2005

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFTRIAOXONE

<u>AP</u>		AKORN INC	<u>EQ 250MG BASE/VIAL</u>	<u>A065305 001</u>	Jan 11, 2008
<u>AP</u>			<u>EQ 500MG BASE/VIAL</u>	<u>A065305 002</u>	Jan 11, 2008
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A065305 003</u>	Jan 11, 2008
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A065305 004</u>	Jan 11, 2008
<u>AP</u>		HIKMA FARMACEUTICA	<u>EQ 250MG BASE/VIAL</u>	<u>A065342 001</u>	Jan 10, 2008
<u>AP</u>			<u>EQ 500MG BASE/VIAL</u>	<u>A065342 002</u>	Jan 10, 2008
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A065342 003</u>	Jan 10, 2008
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A065342 004</u>	Jan 10, 2008
<u>AP</u>		HOSPIRA INC	<u>EQ 250MG BASE/VIAL</u>	<u>A065230 001</u>	Aug 02, 2005
<u>AP</u>			<u>EQ 500MG BASE/VIAL</u>	<u>A065230 002</u>	Aug 02, 2005
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A065230 003</u>	Aug 02, 2005
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A065230 004</u>	Aug 02, 2005
<u>AP</u>		LUPIN	<u>EQ 250MG BASE/VIAL</u>	<u>A065125 001</u>	Sep 30, 2003
<u>AP</u>			<u>EQ 500MG BASE/VIAL</u>	<u>A065125 002</u>	Sep 30, 2003
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A065125 003</u>	Sep 30, 2003
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A065125 004</u>	Sep 30, 2003
<u>AP</u>		QILU PHARM CO LTD	<u>EQ 250MG BASE/VIAL</u>	<u>A203702 001</u>	Jun 29, 2016
<u>AP</u>			<u>EQ 500MG BASE/VIAL</u>	<u>A203702 002</u>	Jun 29, 2016
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A203702 003</u>	Jun 29, 2016
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A203702 004</u>	Jun 29, 2016

PRESCRIPTION DRUG PRODUCT LIST

CEFTRIAXONE SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFTRIAXONE

<u>AP</u>	+	SANDOZ	<u>EQ 250MG BASE/VIAL</u>	<u>A065169 001</u>	May 09, 2005
<u>AP</u>	+		<u>EQ 500MG BASE/VIAL</u>	<u>A065169 002</u>	May 09, 2005
<u>AP</u>	+		<u>EQ 1GM BASE/VIAL</u>	<u>A065169 003</u>	May 09, 2005
<u>AP</u>	+		<u>EQ 2GM BASE/VIAL</u>	<u>A065169 004</u>	May 09, 2005
<u>AP</u>		WOCKHARDT	<u>EQ 250MG BASE/VIAL</u>	<u>A065391 001</u>	Apr 12, 2007
<u>AP</u>			<u>EQ 500MG BASE/VIAL</u>	<u>A065391 002</u>	Apr 12, 2007
<u>AP</u>			<u>EQ 2GM BASE/VIAL</u>	<u>A065391 003</u>	Apr 12, 2007

CEFUROXIME AXETIL

FOR SUSPENSION; ORAL

CEFTIN

GLAXOSMITHKLINE

EQ 125MG BASE/5ML

N050672 001 Jun 30, 1994

+

EQ 250MG BASE/5ML

N050672 002 Apr 29, 1997

TABLET; ORAL

CEFTIN

<u>AB</u>		GLAXOSMITHKLINE	<u>EQ 125MG BASE</u>	<u>N050605 001</u>	Dec 28, 1987
<u>AB</u>			<u>EQ 250MG BASE</u>	<u>N050605 002</u>	Dec 28, 1987
<u>AB</u>	+		<u>EQ 500MG BASE</u>	<u>N050605 003</u>	Dec 28, 1987

CEFUROXIME AXETIL

<u>AB</u>		ALKEM LABS LTD	<u>EQ 250MG BASE</u>	<u>A065496 001</u>	Jun 07, 2010
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A065496 002</u>	Jun 07, 2010
<u>AB</u>		ANI PHARMS INC	<u>EQ 250MG BASE</u>	<u>A065190 001</u>	Oct 18, 2004
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A065190 002</u>	Oct 18, 2004
<u>AB</u>		APOTEX	<u>EQ 250MG BASE</u>	<u>A065069 001</u>	Oct 02, 2002
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A065069 002</u>	Oct 02, 2002
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 125MG BASE</u>	<u>A065308 001</u>	Mar 29, 2006
<u>AB</u>			<u>EQ 250MG BASE</u>	<u>A065308 002</u>	Mar 29, 2006
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A065308 003</u>	Mar 29, 2006
<u>AB</u>		LUPIN	<u>EQ 250MG BASE</u>	<u>A065135 001</u>	Jul 25, 2003
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A065135 002</u>	Jul 25, 2003
<u>AB</u>		ORCHID HLTHCARE	<u>EQ 125MG BASE</u>	<u>A065359 001</u>	Feb 15, 2008
<u>AB</u>			<u>EQ 250MG BASE</u>	<u>A065359 002</u>	Feb 15, 2008
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A065359 003</u>	Feb 15, 2008
<u>AB</u>		WOCKHARDT	<u>EQ 125MG BASE</u>	<u>A065166 001</u>	Jul 29, 2005
<u>AB</u>			<u>EQ 250MG BASE</u>	<u>A065166 002</u>	Jul 29, 2005
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A065166 003</u>	Jul 29, 2005

CEFUROXIME SODIUM

INJECTABLE; INJECTION

CEFUROXIME AND DEXTROSE IN DUPLIX CONTAINER

<u>AP</u>	+	B BRAUN	<u>EQ 750MG BASE/VIAL</u>	<u>N050780 001</u>	Feb 21, 2001
<u>AP</u>	+		<u>EQ 1.5GM BASE/VIAL</u>	<u>N050780 002</u>	Feb 21, 2001

CEFUROXIME SODIUM

<u>AP</u>		FACTA FARMA	<u>EQ 1.5GM BASE/VIAL</u>	<u>A064125 002</u>	May 30, 1997
<u>AP</u>			<u>EQ 7.5GM BASE/VIAL</u>	<u>A064124 001</u>	May 30, 1997
<u>AP</u>		HIKMA FARMACEUTICA	<u>EQ 1.5GM BASE/VIAL</u>	<u>A065048 002</u>	Jan 09, 2004
<u>AP</u>			<u>EQ 7.5GM BASE/VIAL</u>	<u>A065046 001</u>	Jan 09, 2004
<u>AP</u>		HOSPIRA INC	<u>EQ 1.5GM BASE/VIAL</u>	<u>A065483 002</u>	Oct 15, 2008
<u>AP</u>			<u>EQ 1.5GM BASE/VIAL</u>	<u>A065503 001</u>	Oct 15, 2008
<u>AP</u>			<u>EQ 7.5GM BASE/VIAL</u>	<u>A065484 001</u>	Oct 15, 2008

ZINACEF

<u>AP</u>	+	IGI LABS INC	<u>EQ 1.5GM BASE/VIAL</u>	<u>N050558 003</u>	Oct 19, 1983
<u>AP</u>	+		<u>EQ 7.5GM BASE/VIAL</u>	<u>N050558 004</u>	Oct 23, 1986

ZINACEF IN PLASTIC CONTAINER

+

IGI LABS INC

EQ 30MG BASE/ML

N050643 002 Apr 28, 1989

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFUROXIME SODIUM

<u>AB</u>		FACTA FARMA	<u>EQ 750MG BASE/VIAL</u>	<u>A064125 001</u>	May 30, 1997
<u>AB</u>		HIKMA FARMACEUTICA	<u>EQ 750MG BASE/VIAL</u>	<u>A065048 001</u>	Jan 09, 2004

ZINACEF

<u>AB</u>	+	IGI LABS INC	<u>EQ 750MG BASE/VIAL</u>	<u>N050558 002</u>	Oct 19, 1983
-----------	---	--------------	---------------------------	--------------------	--------------

CEFUROXIME SODIUM

<u>AP</u>		HOSPIRA INC	<u>EQ 750MG BASE/VIAL</u>	<u>A065483 001</u>	Oct 15, 2008
-----------	--	-------------	---------------------------	--------------------	--------------

CELECOXIB

CAPSULE; ORAL

CELEBREX

<u>AB</u>		GD SEARLE	<u>50MG</u>	<u>N020998 004</u>	Dec 15, 2006
<u>AB</u>			<u>100MG</u>	<u>N020998 001</u>	Dec 31, 1998
<u>AB</u>			<u>200MG</u>	<u>N020998 002</u>	Dec 31, 1998
<u>AB</u>	+		<u>400MG</u>	<u>N020998 003</u>	Aug 29, 2002

PRESCRIPTION DRUG PRODUCT LIST

CELECOXIB

CAPSULE; ORAL

CELECOXIB

<u>AB</u>	ALEMBIC PHARMS LTD	<u>50MG</u>	<u>A204519 001</u>	Aug 21, 2015
<u>AB</u>		<u>100MG</u>	<u>A204519 002</u>	Aug 21, 2015
<u>AB</u>		<u>200MG</u>	<u>A204519 003</u>	Aug 21, 2015
<u>AB</u>		<u>400MG</u>	<u>A204519 004</u>	Aug 21, 2015
<u>AB</u>	APOTEX INC	<u>50MG</u>	<u>A204197 001</u>	Jun 02, 2015
<u>AB</u>		<u>100MG</u>	<u>A204197 002</u>	Jun 02, 2015
<u>AB</u>		<u>200MG</u>	<u>A204197 003</u>	Jun 02, 2015
<u>AB</u>	AUROBINDO PHARMA LTD	<u>50MG</u>	<u>A206827 001</u>	Feb 01, 2016
<u>AB</u>		<u>100MG</u>	<u>A206827 002</u>	Feb 01, 2016
<u>AB</u>		<u>200MG</u>	<u>A206827 003</u>	Feb 01, 2016
<u>AB</u>		<u>400MG</u>	<u>A206827 004</u>	Feb 01, 2016
<u>AB</u>	CIPLA LTD	<u>50MG</u>	<u>A207446 001</u>	Sep 23, 2015
<u>AB</u>		<u>100MG</u>	<u>A207446 002</u>	Sep 23, 2015
<u>AB</u>		<u>200MG</u>	<u>A207446 003</u>	Sep 23, 2015
<u>AB</u>		<u>400MG</u>	<u>A207446 004</u>	Sep 23, 2015
<u>AB</u>	LUPIN LTD	<u>50MG</u>	<u>A202240 001</u>	Oct 29, 2014
<u>AB</u>		<u>100MG</u>	<u>A202240 002</u>	Jun 09, 2015
<u>AB</u>		<u>200MG</u>	<u>A202240 003</u>	Jun 09, 2015
<u>AB</u>		<u>400MG</u>	<u>A202240 004</u>	Jun 09, 2015
<u>AB</u>	MACLEODS PHARMS LTD	<u>50MG</u>	<u>A204590 001</u>	Mar 16, 2016
<u>AB</u>		<u>100MG</u>	<u>A204590 002</u>	Mar 16, 2016
<u>AB</u>		<u>200MG</u>	<u>A204590 003</u>	Mar 16, 2016
<u>AB</u>		<u>400MG</u>	<u>A204590 004</u>	Mar 16, 2016
<u>AB</u>	MYLAN PHARMS INC	<u>50MG</u>	<u>A078857 001</u>	May 30, 2014
<u>AB</u>		<u>100MG</u>	<u>A078857 002</u>	Feb 11, 2015
<u>AB</u>		<u>200MG</u>	<u>A078857 003</u>	Feb 11, 2015
<u>AB</u>		<u>400MG</u>	<u>A078857 004</u>	Feb 11, 2015
<u>AB</u>	TEVA	<u>50MG</u>	<u>A076898 001</u>	May 30, 2014
<u>AB</u>		<u>100MG</u>	<u>A076898 002</u>	May 30, 2014
<u>AB</u>		<u>200MG</u>	<u>A076898 003</u>	May 30, 2014
<u>AB</u>		<u>400MG</u>	<u>A076898 004</u>	May 30, 2014
<u>AB</u>	TORRENT PHARMS LTD	<u>50MG</u>	<u>A207677 001</u>	Dec 23, 2015
<u>AB</u>		<u>100MG</u>	<u>A207677 002</u>	Dec 23, 2015
<u>AB</u>		<u>200MG</u>	<u>A207677 003</u>	Dec 23, 2015
<u>AB</u>		<u>400MG</u>	<u>A207677 004</u>	Dec 23, 2015
<u>AB</u>	WATSON LABS INC	<u>50MG</u>	<u>A200562 001</u>	Feb 11, 2015
<u>AB</u>		<u>100MG</u>	<u>A200562 002</u>	Feb 11, 2015
<u>AB</u>		<u>200MG</u>	<u>A200562 003</u>	Feb 11, 2015
<u>AB</u>		<u>400MG</u>	<u>A200562 004</u>	Feb 11, 2015

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

<u>AB</u>	ALKEM LABS LTD	<u>EQ 250MG BASE</u>	<u>A090836 001</u>	Dec 20, 2010
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A090836 002</u>	Dec 20, 2010
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A090836 004</u>	Mar 29, 2013
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 250MG BASE</u>	<u>A065253 001</u>	Nov 16, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065253 002</u>	Nov 16, 2005
<u>AB</u>	BELCHER PHARMS	<u>EQ 250MG BASE</u>	<u>A062713 001</u>	Jul 15, 1988
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A062713 002</u>	Jul 15, 1988
<u>AB</u>	HIKMA	<u>EQ 250MG BASE</u>	<u>A065215 001</u>	Jan 24, 2006
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065215 002</u>	Jan 24, 2006
<u>AB</u>	LUPIN	<u>EQ 250MG BASE</u>	<u>A065229 001</u>	Nov 25, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065229 002</u>	Nov 25, 2005
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 250MG BASE</u>	<u>A065248 001</u>	Jun 28, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065248 002</u>	Jun 28, 2005
<u>AB</u>	SUN PHARM INDS (IN)	<u>EQ 250MG BASE</u>	<u>A062791 001</u>	Jun 11, 1987
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A062791 002</u>	Jun 11, 1987
<u>AB</u>	TEVA	<u>EQ 250MG BASE</u>	<u>A062702 001</u>	Feb 13, 1987
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A062702 002</u>	Feb 13, 1987
<u>AB</u>	YUNG SHIN PHARM	<u>EQ 250MG BASE</u>	<u>A065152 001</u>	Feb 24, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065152 002</u>	Feb 24, 2005

KEFLEX

<u>AB</u>	PRAGMA PHARMS LLC	<u>EQ 250MG BASE</u>	<u>N050405 002</u>	
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>N050405 003</u>	
<u>AB</u>	+	<u>EQ 750MG BASE</u>	<u>N050405 005</u>	May 12, 2006
	CEPHALEXIN			
	ALKEM LABS LTD	<u>EQ 333MG BASE</u>	<u>A090836 003</u>	Mar 29, 2013

PRESCRIPTION DRUG PRODUCT LIST

CEPHALEXIN

FOR SUSPENSION; ORAL

CEPHALEXIN

<u>AB</u>	LUPIN	<u>EQ 125MG BASE/5ML</u>	<u>A065234 001</u>	Aug 17, 2005
<u>AB</u>		<u>EQ 250MG BASE/5ML</u>	<u>A065234 002</u>	Aug 17, 2005
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 125MG BASE/5ML</u>	<u>A065326 001</u>	Jul 10, 2006
<u>AB</u>		<u>EQ 250MG BASE/5ML</u>	<u>A065326 002</u>	Jul 10, 2006
<u>AB</u>	TEVA	<u>EQ 125MG BASE/5ML</u>	<u>A062703 001</u>	Feb 13, 1987
<u>AB</u>	+	<u>EQ 250MG BASE/5ML</u>	<u>A062703 002</u>	Feb 13, 1987
TABLET; ORAL				
CEPHALEXIN				
	TEVA	EQ 250MG BASE	A063023 001	Jan 12, 1989
	+	EQ 500MG BASE	A063024 001	Jan 12, 1989

CERITINIB

CAPSULE; ORAL

ZYKADIA

+	NOVARTIS PHARMS CORP	150MG	N205755 001	Apr 29, 2014
---	----------------------	-------	-------------	--------------

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

<u>AA</u>	AMNEAL PHARMS	<u>5MG/5ML</u>	<u>A090766 001</u>	Oct 07, 2009
<u>AA</u>	BIO PHARM INC	<u>5MG/5ML</u>	<u>A078870 001</u>	Apr 27, 2009
<u>AA</u>	BRECKENRIDGE PHARM	<u>5MG/5ML</u>	<u>A078488 001</u>	Oct 06, 2008
<u>AA</u>	NOSTRUM LABS INC	<u>5MG/5ML</u>	<u>A090191 001</u>	Nov 12, 2009
<u>AA</u>	+	<u>5MG/5ML</u>	<u>A078398 001</u>	Jun 17, 2008
<u>AA</u>	SILARX	<u>5MG/5ML</u>	<u>A078876 001</u>	May 11, 2012
<u>AA</u>	TARO	<u>5MG/5ML</u>	<u>A076601 001</u>	Jun 20, 2008
<u>AA</u>	TEVA PHARMS	<u>5MG/5ML</u>	<u>A077279 001</u>	May 27, 2008
<u>AA</u>	VINTAGE	<u>5MG/5ML</u>	<u>A078496 001</u>	Sep 25, 2009

CETRORELIX

INJECTABLE; INJECTION

CETROTIDE

+	EMD SERONO INC	EQ 0.25MG BASE/ML	N021197 001	Aug 11, 2000
---	----------------	-------------------	-------------	--------------

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL

CEVIMELINE HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>30MG</u>	<u>A091260 001</u>	Aug 25, 2011
<u>AB</u>	NOVEL LABS INC	<u>30MG</u>	<u>A204746 001</u>	Dec 30, 2016
<u>AB</u>	PACK PHARMS LLC	<u>30MG</u>	<u>A203775 001</u>	Jun 04, 2014
<u>AB</u>	WEST-WARD PHARMS INT	<u>30MG</u>	<u>A091591 001</u>	Jul 08, 2013
<u>EVOXAC</u>				
<u>AB</u>	+	<u>30MG</u>	<u>N020989 002</u>	Jan 11, 2000

CHENODIOL

TABLET; ORAL

CHENODIOL

+	NEXGEN PHARMA	250MG	A091019 001	Oct 22, 2009
---	---------------	-------	-------------	--------------

CHLORAMBUCIL

TABLET; ORAL

LEUKERAN

+	ASPEN GLOBAL INC	2MG	N010669 002	
---	------------------	-----	-------------	--

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION

CHLORAMPHENICOL SODIUM SUCCINATE

+	FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A062365 001	Aug 25, 1982
---	--------------------	------------------	-------------	--------------

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

<u>AB</u>	BARR	<u>5MG</u>	<u>A084768 001</u>	
<u>AB</u>		<u>10MG</u>	<u>A083116 001</u>	
<u>AB</u>		<u>25MG</u>	<u>A084769 001</u>	
<u>AB</u>	USL PHARMA	<u>10MG</u>	<u>A084623 001</u>	
<u>LIBRIUM</u>				
<u>AB</u>	VALEANT PHARM INTL	<u>5MG</u>	<u>A085461 001</u>	
<u>AB</u>		<u>10MG</u>	<u>A085472 001</u>	
<u>AB</u>	+	<u>25MG</u>	<u>A085475 001</u>	

PRESCRIPTION DRUG PRODUCT LIST

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

CAPSULE; ORAL

LIBRAX

+ VALEANT PHARMS 5MG; 2.5MG N012750 001

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE**AT** HI TECH PHARMA 0.12% **A074356 001** May 07, 1996**AT** LYNE 0.12% **A074291 001** Dec 28, 1995**AT** TEVA 0.12% **A074522 001** Dec 15, 1995**AT** WOCKHARDT 0.12% **A075006 001** Mar 03, 2004**AT** XTTRIUM 0.12% **A077789 001** Jun 18, 2009PAROEX**AT** SUNSTAR AMERICAS 0.12% **A076434 001** Nov 29, 2005PERIDEX**AT** + 3M 0.12% **N019028 001** Aug 13, 1986PERIOGARD**AT** COLGATE 0.12% **A073695 001** Jan 14, 1994**AT** COLGATE-PALMOLIVE CO 0.12% **A203212 001** Jan 28, 2016

TABLET; DENTAL

PERIOCHIP

+ DEXCEL PHARMA 2.5MG N020774 001 May 15, 1998

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHLOROPROCAINE HYDROCHLORIDE**AP** HOSPIRA 2% **A087447 001** Apr 16, 1982**AP** 3% **A087446 001** Apr 16, 1982**AP** WEST-WARD PHARMS INT 2% **A040273 001** Sep 09, 1998**AP** 3% **A040273 002** Sep 09, 1998NESACAINE**AP** FRESENIUS KABI USA 2% **N009435 002**NESACAINE-MPF**AP** + FRESENIUS KABI USA 2% **N009435 006** May 02, 1996**AP** + 3% **N009435 007** May 02, 1996

NESACAINE

+ FRESENIUS KABI USA 1% N009435 001

CHLOROQUINE PHOSPHATE

TABLET; ORAL

ARALEN**AA** + SANOFI AVENTIS US EQ 300MG BASE **N006002 001**CHLOROQUINE PHOSPHATE**AA** + HIKMA PHARMS LLC EQ 150MG BASE **A083082 001****AA** EQ 300MG BASE **A083082 002** Sep 17, 1999**AA** IPCA LABS LTD EQ 150MG BASE **A090610 001** Dec 03, 2009**AA** EQ 300MG BASE **A090249 001** Dec 03, 2009**AA** NATCO PHARMA LTD EQ 150MG BASE **A091621 001** Jan 21, 2011**AA** EQ 300MG BASE **A090612 001** Jan 21, 2011CHLOROTHIAZIDE

SUSPENSION; ORAL

DIURIL

+ SALIX PHARMS 250MG/5ML N011870 001

TABLET; ORAL

CHLOROTHIAZIDE

+ MYLAN 250MG A084388 001

500MG A084217 001

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION

CHLOROTHIAZIDE SODIUM**AP** FRESENIUS KABI USA EQ 500MG BASE/VIAL **A090896 001** Oct 16, 2009**AP** LUITPOLD EQ 500MG BASE/VIAL **A202561 001** Apr 22, 2013**AP** MYLAN INSTITUTIONAL EQ 500MG BASE/VIAL **A202493 001** Jun 18, 2014**AP** SAGENT PHARMS EQ 500MG BASE/VIAL **A202462 001** May 29, 2015**AP** SUN PHARMA GLOBAL EQ 500MG BASE/VIAL **A091546 001** Jul 26, 2011DIURIL**AP** + OAK PHARMS AKORN EQ 500MG BASE/VIAL **N011145 005**

PRESCRIPTION DRUG PRODUCT LIST

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE

AA	TRIS PHARMA INC	<u>4MG/5ML;5MG/5ML</u>	A206438 001	Jan 27, 2015
-----------	-----------------	------------------------	--------------------	--------------

VITUZ

AA	+ CYPRESS PHARM	<u>4MG/5ML;5MG/5ML</u>	N204307 001	Feb 20, 2013
-----------	-----------------	------------------------	--------------------	--------------

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AA	TRIS PHARMA INC	<u>4MG/5ML;5MG/5ML;60MG/5ML</u>	A203838 001	Nov 26, 2014
-----------	-----------------	---------------------------------	--------------------	--------------

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AA	PADDOCK LLC	<u>4MG/5ML;5MG/5ML;60MG/5ML</u>	A204627 001	Apr 29, 2014
-----------	-------------	---------------------------------	--------------------	--------------

HYDROCODONE BITARTRATE,CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AA	MAYNE PHARMA INC	<u>4MG/5ML;5MG/5ML;60MG/5ML</u>	A205657 001	Aug 03, 2015
-----------	------------------	---------------------------------	--------------------	--------------

ZUTRIPRO

AA	+ CYPRESS PHARM	<u>4MG/5ML;5MG/5ML;60MG/5ML</u>	N022439 001	Jun 08, 2011
-----------	-----------------	---------------------------------	--------------------	--------------

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

TUZISTRA XR

	+ VERNALIS R AND D LTD	EQ 2.8MG BASE/5ML;EQ 14.7MG BASE/5ML	N207768 001	Apr 30, 2015
--	------------------------	--------------------------------------	-------------	--------------

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

CAPSULE, EXTENDED RELEASE;ORAL

TUSSICAPS

	ECR PHARMA	EQ 4MG MALEATE;EQ 5MG BITARTRATE	A077273 002	Sep 24, 2007
--	------------	----------------------------------	-------------	--------------

	+	EQ 8MG MALEATE;EQ 10MG BITARTRATE	A077273 001	Sep 24, 2007
--	---	-----------------------------------	-------------	--------------

SUSPENSION, EXTENDED RELEASE;ORAL

HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX

AB	TRIS PHARMA INC	<u>EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML</u>	A091632 001	Oct 01, 2010
-----------	-----------------	--	--------------------	--------------

HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX

AB	NEOS THERAP INC	<u>EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML</u>	A091671 001	Jun 29, 2012
-----------	-----------------	--	--------------------	--------------

TUSSIONEX PENNKINETIC

AB	+ UCB INC	<u>EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML</u>	N019111 001	Dec 31, 1987
-----------	-----------	--	--------------------	--------------

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

CHLORPROMAZINE HYDROCHLORIDE

	+ EUROHLTH INTL SARL	25MG/ML	A083329 001	
--	----------------------	---------	-------------	--

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

BP	USL PHARMA	10MG	A083386 001	
----	------------	------	-------------	--

BP		25MG	A084112 001	
----	--	------	-------------	--

BP		50MG	A084113 001	
----	--	------	-------------	--

BP		100MG	A084114 001	
----	--	-------	-------------	--

BP		200MG	A084115 001	
----	--	-------	-------------	--

CHLORPROPAMIDE

TABLET;ORAL

CHLORPROPAMIDE

AB	ANI PHARMS INC	<u>100MG</u>	A088921 001	Apr 12, 1985
-----------	----------------	--------------	--------------------	--------------

AB		<u>250MG</u>	A088922 001	Apr 12, 1985
-----------	--	--------------	--------------------	--------------

AB	MYLAN	<u>100MG</u>	A088549 002	Jun 01, 1984
-----------	-------	--------------	--------------------	--------------

AB		<u>250MG</u>	A088549 001	Jun 01, 1984
-----------	--	--------------	--------------------	--------------

DIABINESE

AB	PFIZER	<u>100MG</u>	N011641 003	
-----------	--------	--------------	--------------------	--

AB	+	<u>250MG</u>	N011641 006	
-----------	---	--------------	--------------------	--

CHLORTHALIDONE

TABLET;ORAL

CHLORTHALIDONE

AB	MYLAN	<u>25MG</u>	A086831 002	
-----------	-------	-------------	--------------------	--

AB	+	<u>50MG</u>	A086831 001	
-----------	---	-------------	--------------------	--

AB	SUN PHARM INDS	<u>25MG</u>	A089286 002	Jul 21, 1986
-----------	----------------	-------------	--------------------	--------------

AB		<u>50MG</u>	A089286 001	Jul 21, 1986
-----------	--	-------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLORPRES

MYLAN	15MG; 0.1MG	A071325 003	Feb 09, 1987
	15MG; 0.2MG	A071325 002	Feb 09, 1987
+	15MG; 0.3MG	A071325 001	Feb 09, 1987

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

<u>AA</u>	BARR	<u>500MG</u>	<u>A089895 001</u>	May 04, 1988
<u>AA</u>	+ WATSON LABS	<u>500MG</u>	<u>A089859 001</u>	May 04, 1988
	MIKART	375MG	A040861 001	Jun 01, 2010
	+	750MG	A040861 002	Jun 01, 2010
	+ MIKART INC	250MG	A207483 001	Jun 24, 2016

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE

<u>AB</u>	PAR PHARM	<u>EQ 4GM RESIN/PACKET</u>	<u>A077204 001</u>	Aug 26, 2005
<u>AB</u>		<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A077204 002</u>	Aug 26, 2005
<u>AB</u>	+ SANDOZ	<u>EQ 4GM RESIN/PACKET</u>	<u>A074557 001</u>	Aug 15, 1996
<u>AB</u>		<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A074557 002</u>	Aug 15, 1996

CHOLESTYRAMINE LIGHT

<u>AB</u>	PAR PHARM	<u>EQ 4GM RESIN/PACKET</u>	<u>A077203 001</u>	Aug 26, 2005
<u>AB</u>		<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A077203 002</u>	Aug 26, 2005
<u>AB</u>	+ SANDOZ	<u>EQ 4GM RESIN/PACKET</u>	<u>A074558 001</u>	Aug 15, 1996
<u>AB</u>		<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A074558 002</u>	Aug 15, 1996

PREVALITE

<u>AB</u>	UPSHER SMITH	<u>EQ 4GM RESIN/PACKET</u>	<u>A073263 001</u>	Feb 22, 1996
<u>AB</u>		<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A073263 002</u>	Oct 30, 1997

CHOLIC ACID

CAPSULE; ORAL

CHOLBAM

RTRX	50MG	N205750 001	Mar 17, 2015
+	250MG	N205750 002	Mar 17, 2015

CHOLINE C-11

INJECTABLE; INTRAVENOUS

CHOLINE C-11

<u>AP</u>	GLOBAL ISOTOPES LLC	<u>4-33.1mCi/ML</u>	<u>A206319 001</u>	Nov 13, 2015
<u>AP</u>	+ MCPRF	<u>4-33.1mCi/ML</u>	<u>N203155 001</u>	Sep 12, 2012
<u>AP</u>	UNIV TX MD ANDERSON	<u>4-33.1mCi/ML</u>	<u>A205690 001</u>	Oct 29, 2015
<u>AP</u>	WA UNIV SCH MED	<u>4-33.1mCi/ML</u>	<u>A208413 001</u>	Jan 10, 2017

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

FENOFIBRIC ACID

<u>AB</u>	ACTAVIS ELIZABETH	<u>EQ 45MG FENOFIBRIC ACID</u>	<u>A200920 001</u>	Oct 07, 2015
<u>AB</u>		<u>EQ 135MG FENOFIBRIC ACID</u>	<u>A200920 002</u>	Oct 07, 2015
<u>AB</u>	ANCHEN PHARMS	<u>EQ 45MG FENOFIBRIC ACID</u>	<u>A201573 002</u>	Jul 18, 2013
<u>AB</u>		<u>EQ 135MG FENOFIBRIC ACID</u>	<u>A201573 001</u>	Jul 18, 2013
<u>AB</u>	IMPAX LABS INC	<u>EQ 45MG FENOFIBRIC ACID</u>	<u>A200264 001</u>	Sep 07, 2016
<u>AB</u>		<u>EQ 135MG FENOFIBRIC ACID</u>	<u>A200264 002</u>	Sep 07, 2016
<u>AB</u>	LUPIN LTD	<u>EQ 45MG FENOFIBRIC ACID</u>	<u>A200750 001</u>	Dec 04, 2013
<u>AB</u>		<u>EQ 135MG FENOFIBRIC ACID</u>	<u>A200750 002</u>	Dec 04, 2013
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 45MG FENOFIBRIC ACID</u>	<u>A200913 001</u>	Mar 25, 2013
<u>AB</u>		<u>EQ 135MG FENOFIBRIC ACID</u>	<u>A200913 002</u>	Mar 25, 2013

TRILIPIX

<u>AB</u>	ABBVIE	<u>EQ 45MG FENOFIBRIC ACID</u>	<u>N022224 001</u>	Dec 15, 2008
<u>AB</u>	+	<u>EQ 135MG FENOFIBRIC ACID</u>	<u>N022224 002</u>	Dec 15, 2008

CHORIOGONADOTROPIN ALFA

INJECTABLE; SUBCUTANEOUS

OVIDREL

+	EMD SERONO	EQ 0.25MG /0.5ML	N021149 002	Oct 06, 2003
---	------------	------------------	-------------	--------------

CHROMIC CHLORIDE

INJECTABLE; INJECTION

CHROMIC CHLORIDE IN PLASTIC CONTAINER

+	HOSPIRA	EQ 0.004MG CHROMIUM/ML	N018961 001	Jun 26, 1986
---	---------	------------------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

CICLESONIDE

AEROSOL, METERED; INHALATION

ALVESCO

+ TAKEDA GMBH

0.08MG/INH

N021658 002 Jan 10, 2008

+

0.16MG/INH

N021658 003 Jan 10, 2008

AEROSOL, METERED; NASAL

ZETONNA

+ TAKEDA GMBH

0.037MG/INH

N202129 001 Jan 20, 2012

SPRAY, METERED; NASAL

OMNARIS

+ TAKEDA GMBH

0.05MG/INH

N022004 001 Oct 20, 2006

CICLOPIROX

CREAM; TOPICAL

CICLOPIROXAB FOUGERA PHARMS0.77%A076435 001 Dec 29, 2004AB G AND W LABS INC0.77%A078463 001 Dec 20, 2010AB GLENMARK PHARMS0.77%A090273 001 Nov 10, 2009AB PERRIGO0.77%A077364 001 Mar 03, 2006AB TARO0.77%A076790 001 Apr 12, 2005LOPROXAB + MEDIMETRIKS PHARMS0.77%N018748 001 Dec 30, 1982

GEL; TOPICAL

CICLOPIROXAB FOUGERA PHARMS0.77%A077896 001 Jun 10, 2008AB GLENMARK GENERICS0.77%A091595 001 Feb 29, 2012AB PADDOCK LLC0.77%A078266 001 Jan 07, 2009LOPROXAB + CNTY LINE PHARMS0.77%N020519 001 Jul 21, 1997

SHAMPOO; TOPICAL

CICLOPIROXAT ACTAVIS MID ATLANTIC1%A090490 001 Nov 24, 2009AT FOUGERA PHARMS1%A090146 001 May 25, 2010AT PERRIGO1%A078594 001 Feb 16, 2010AT TARO1%A090269 001 Feb 23, 2011LOPROXAT + MEDICIS1%N021159 001 Feb 28, 2003

SOLUTION; TOPICAL

CICLOPIROXAT ACTAVIS MID ATLANTIC8%A078046 001 Sep 18, 2007AT AKORN8%A078975 001 Feb 17, 2010AT APOTEX INC8%A078172 001 Sep 18, 2007AT CIPLA LTD8%A078124 001 Sep 18, 2007AT G AND W LABS8%A078233 001 Sep 18, 2007AT HI TECH PHARMA8%A078270 001 Sep 18, 2007AT PERRIGO NEW YORK8%A077623 001 Sep 18, 2007AT TARO PHARM INDS8%A078144 001 Sep 18, 2007AT TOLMAR8%A077687 001 Sep 18, 2007PENLACAT + VALEANT BERMUDA8%N021022 001 Dec 17, 1999

SUSPENSION; TOPICAL

CICLOPIROXAB FOUGERA PHARMS0.77%A076422 001 Aug 06, 2004AB PERRIGO NEW YORK0.77%A077676 001 Dec 15, 2006AB TARO0.77%A077092 001 Aug 10, 2005LOPROXAB + MEDIMETRIKS PHARMS0.77%N019824 001 Dec 30, 1988CIDOFOVIR

INJECTABLE; INJECTION

CIDOFOVIRAP EMCURE PHARMS LTDEQ 75MG BASE/MLA202501 001 Jul 26, 2012AP + MYLAN INSTITUTIONALEQ 75MG BASE/MLA201276 001 Jun 27, 2012CILASTATIN SODIUM; IMPENEM

POWDER; INTRAVENOUS

IMPENEM AND CILASTATINAP ACS DOBFAREQ 250MG BASE/VIAL; 250MG/VIALA090577 001 Dec 21, 2011AP HOSPIRA INCEQ 500MG BASE/VIAL; 500MG/VIALA090577 002 Dec 21, 2011AP HOSPIRA INCEQ 250MG BASE/VIAL; 250MG/VIALA090825 001 Nov 16, 2011AP HOSPIRA INCEQ 500MG BASE/VIAL; 500MG/VIALA090825 002 Nov 16, 2011AP HOSPIRA INCEQ 500MG BASE/VIAL; 500MG/VIALA091007 001 Nov 16, 2011

PRESCRIPTION DRUG PRODUCT LIST

CILASTATIN SODIUM; IMPENEM

POWDER; INTRAVENOUS

PRIMAXIN

<u>AP</u>	+	MERCK	<u>EQ 250MG BASE/VIAL;250MG/VIAL</u>	<u>N050587 001</u>	Nov 26, 1985
<u>AP</u>	+		<u>EQ 500MG BASE/VIAL;500MG/VIAL</u>	<u>N050587 002</u>	Nov 26, 1985

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

<u>AB</u>		APOTEX INC	<u>50MG</u>	<u>A077030 001</u>	Dec 10, 2004
<u>AB</u>			<u>100MG</u>	<u>A077030 002</u>	Dec 10, 2004
<u>AB</u>		BIOKEY	<u>50MG</u>	<u>A077722 001</u>	Sep 24, 2012
<u>AB</u>			<u>100MG</u>	<u>A077831 001</u>	Sep 24, 2012
<u>AB</u>		BRECKENRIDGE PHARM	<u>50MG</u>	<u>A077708 001</u>	Sep 28, 2009
<u>AB</u>			<u>100MG</u>	<u>A077708 002</u>	Sep 28, 2009
<u>AB</u>		MYLAN	<u>50MG</u>	<u>A077323 002</u>	Apr 20, 2006
<u>AB</u>			<u>100MG</u>	<u>A077323 001</u>	Apr 20, 2006
<u>AB</u>		MYLAN PHARMS INC	<u>50MG</u>	<u>A077019 001</u>	Nov 23, 2004
<u>AB</u>			<u>100MG</u>	<u>A077019 002</u>	Nov 23, 2004
<u>AB</u>		PLIVA HRVATSKA DOO	<u>50MG</u>	<u>A077898 001</u>	Oct 29, 2007
<u>AB</u>			<u>100MG</u>	<u>A077898 002</u>	Oct 29, 2007
<u>AB</u>		SANDOZ	<u>50MG</u>	<u>A077310 001</u>	Nov 08, 2005
<u>AB</u>			<u>100MG</u>	<u>A077021 001</u>	Nov 23, 2004
<u>AB</u>	+	TEVA	<u>50MG</u>	<u>A077027 001</u>	Nov 24, 2004
<u>AB</u>	+		<u>100MG</u>	<u>A077027 002</u>	Nov 24, 2004
<u>AB</u>		WEST-WARD PHARMS INT	<u>50MG</u>	<u>A077024 001</u>	May 17, 2005
<u>AB</u>			<u>100MG</u>	<u>A077024 002</u>	May 17, 2005

CIMETIDINE

TABLET; ORAL

CIMETIDINE

<u>AB</u>		APOTEX	<u>200MG</u>	<u>A074890 001</u>	Dec 18, 1998
<u>AB</u>			<u>300MG</u>	<u>A074890 002</u>	Dec 18, 1998
<u>AB</u>			<u>400MG</u>	<u>A074890 003</u>	Dec 18, 1998
<u>AB</u>			<u>800MG</u>	<u>A074890 004</u>	Dec 18, 1998
<u>AB</u>		MYLAN	<u>200MG</u>	<u>A074246 001</u>	May 17, 1994
<u>AB</u>			<u>300MG</u>	<u>A074246 002</u>	May 17, 1994
<u>AB</u>			<u>400MG</u>	<u>A074246 003</u>	May 17, 1994
<u>AB</u>	+		<u>800MG</u>	<u>A074246 004</u>	May 17, 1994
<u>AB</u>		PLIVA	<u>800MG</u>	<u>A074566 001</u>	Feb 27, 1997
<u>AB</u>		TEVA	<u>200MG</u>	<u>A074151 001</u>	May 17, 1994
<u>AB</u>			<u>300MG</u>	<u>A074151 002</u>	May 17, 1994
<u>AB</u>			<u>400MG</u>	<u>A074151 003</u>	May 17, 1994
<u>AB</u>			<u>800MG</u>	<u>A074463 001</u>	May 17, 1994

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HYDROCHLORIDE

<u>AP</u>		DAVA PHARMS INC	<u>EQ 300MG BASE/2ML</u>	<u>A074428 001</u>	Apr 25, 1996
-----------	--	-----------------	--------------------------	--------------------	--------------

SOLUTION; ORAL

CIMETIDINE HYDROCHLORIDE

<u>AA</u>		ANI PHARMS INC	<u>EQ 300MG BASE/5ML</u>	<u>A074610 001</u>	Sep 26, 1996
<u>AA</u>	+	HI TECH PHARMA	<u>EQ 300MG BASE/5ML</u>	<u>A074664 001</u>	Oct 28, 1997
<u>AA</u>		PHARM ASSOC	<u>EQ 300MG BASE/5ML</u>	<u>A074553 001</u>	Jan 27, 1997
<u>AA</u>		WOCKHARDT	<u>EQ 300MG BASE/5ML</u>	<u>A074757 001</u>	Oct 17, 1997

CINACALCET HYDROCHLORIDE

TABLET; ORAL

SENSIPAR

		AMGEN	EQ 30MG BASE	N021688 001	Mar 08, 2004
			EQ 60MG BASE	N021688 002	Mar 08, 2004
	+		EQ 90MG BASE	N021688 003	Mar 08, 2004

CIPROFLOXACIN

FOR SUSPENSION; ORAL

CIPRO

<u>AB</u>		BAYER HLTHCARE	<u>250MG/5ML</u>	<u>N020780 001</u>	Sep 26, 1997
<u>AB</u>	+		<u>500MG/5ML</u>	<u>N020780 002</u>	Sep 26, 1997

CIPROFLOXACIN

<u>AB</u>		LUPIN LTD	<u>250MG/5ML</u>	<u>A200563 001</u>	Mar 05, 2014
<u>AB</u>			<u>500MG/5ML</u>	<u>A200563 002</u>	Mar 05, 2014

INJECTABLE; INJECTION

CIPRO

<u>AP</u>	+	BAYER HLTHCARE	<u>400MG/40ML (10MG/ML)</u>	<u>N019847 001</u>	Dec 26, 1990
<u>AP</u>	+		<u>200MG/20ML (10MG/ML)</u>	<u>N019847 002</u>	Dec 26, 1990

PRESCRIPTION DRUG PRODUCT LIST

CIPROFLOXACIN

INJECTABLE; INJECTION

CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	BAYER HLTHCARE	<u>200MG/100ML</u>	<u>N019857 001</u>	Dec 26, 1990
<u>AP</u>	+		<u>400MG/200ML</u>	<u>N019857 002</u>	Dec 26, 1990

CIPROFLOXACIN

<u>AP</u>		CLARIS	<u>200MG/20ML (10MG/ML)</u>	<u>A078062 001</u>	Apr 29, 2008
<u>AP</u>			<u>400MG/40ML (10MG/ML)</u>	<u>A078062 002</u>	Apr 29, 2008
<u>AP</u>		HIKMA FARMACEUTICA	<u>200MG/20ML (10MG/ML)</u>	<u>A076717 001</u>	Dec 22, 2009
<u>AP</u>			<u>400MG/40ML (10MG/ML)</u>	<u>A076717 002</u>	Dec 22, 2009
<u>AP</u>		HOSPIRA	<u>200MG/20ML (10MG/ML)</u>	<u>A077245 001</u>	Aug 28, 2006
<u>AP</u>			<u>400MG/40ML (10MG/ML)</u>	<u>A077245 002</u>	Aug 28, 2006

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>		ACS DOBFAR INFO SA	<u>200MG/100ML</u>	<u>A078252 001</u>	Mar 18, 2008
<u>AP</u>			<u>400MG/200ML</u>	<u>A078252 002</u>	Mar 18, 2008
<u>AP</u>		CLARIS	<u>200MG/100ML</u>	<u>A078024 001</u>	Mar 18, 2008
<u>AP</u>			<u>400MG/200ML</u>	<u>A078024 002</u>	Mar 18, 2008
<u>AP</u>		HIKMA FARMACEUTICA	<u>400MG/200ML</u>	<u>A078431 001</u>	Nov 18, 2009
<u>AP</u>		HOSPIRA	<u>200MG/100ML</u>	<u>A077753 001</u>	Mar 18, 2008
<u>AP</u>			<u>400MG/200ML</u>	<u>A077753 002</u>	Mar 18, 2008

INJECTABLE, SUSPENSION; OTIC

OTIPRIO

+	OTONOMY INC	6% (60MG/ML)	N207986 001	Dec 10, 2015
---	-------------	--------------	-------------	--------------

CIPROFLOXACIN HYDROCHLORIDE

OINTMENT; OPHTHALMIC

CILOXAN

+	NOVARTIS PHARMS CORP	EQ 0.3% BASE	N020369 001	Mar 30, 1998
---	----------------------	--------------	-------------	--------------

SOLUTION/DROPS; OPHTHALMIC

CILOXAN

<u>AT</u>	+	NOVARTIS PHARMS CORP	<u>EQ 0.3% BASE</u>	<u>N019992 001</u>	Dec 31, 1990
-----------	---	----------------------	---------------------	--------------------	--------------

CIPROFLOXACIN HYDROCHLORIDE

<u>AT</u>		AKORN INC	<u>EQ 0.3% BASE</u>	<u>A076555 001</u>	Dec 11, 2008
<u>AT</u>		FDC LTD	<u>EQ 0.3% BASE</u>	<u>A077568 001</u>	Jun 30, 2008
<u>AT</u>		PHARMAFORCE	<u>EQ 0.3% BASE</u>	<u>A078598 001</u>	Jan 16, 2008
<u>AT</u>		RISING PHARMS INC	<u>EQ 0.3% BASE</u>	<u>A077689 001</u>	Dec 13, 2006
<u>AT</u>		TELIGENT PHARMA INC	<u>EQ 0.3% BASE</u>	<u>A076754 001</u>	Jun 09, 2004
<u>AT</u>		WATSON LABS INC	<u>EQ 0.3% BASE</u>	<u>A076673 001</u>	Jan 21, 2005

SOLUTION/DROPS; OTIC

CETRALAX

+	WRASER PHARMS	EQ 0.2% BASE	N021918 001	May 01, 2009
---	---------------	--------------	-------------	--------------

TABLET; ORAL

CIPRO

<u>AB</u>		BAYER HLTHCARE	<u>EQ 100MG BASE</u>	<u>N019537 001</u>	Apr 08, 1996
<u>AB</u>			<u>EQ 250MG BASE</u>	<u>N019537 002</u>	Oct 22, 1987
<u>AB</u>	+		<u>EQ 500MG BASE</u>	<u>N019537 003</u>	Oct 22, 1987
<u>AB</u>			<u>EQ 750MG BASE</u>	<u>N019537 004</u>	Oct 22, 1987

CIPROFLOXACIN HYDROCHLORIDE

<u>AB</u>		APOTEX	<u>EQ 250MG BASE</u>	<u>A076896 001</u>	Nov 04, 2004
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A076896 002</u>	Nov 04, 2004
<u>AB</u>			<u>EQ 750MG BASE</u>	<u>A076896 003</u>	Nov 04, 2004
<u>AB</u>		AUROBINDO PHARMA	<u>EQ 250MG BASE</u>	<u>A077859 001</u>	Apr 26, 2007
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A077859 002</u>	Apr 26, 2007
<u>AB</u>			<u>EQ 750MG BASE</u>	<u>A077859 003</u>	Apr 26, 2007
<u>AB</u>		CARLSBAD	<u>EQ 250MG BASE</u>	<u>A076126 002</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A076126 003</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 750MG BASE</u>	<u>A076126 004</u>	Jun 09, 2004
<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 100MG BASE</u>	<u>A075593 002</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 250MG BASE</u>	<u>A075593 003</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A075593 004</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 750MG BASE</u>	<u>A075593 001</u>	Jun 09, 2004
<u>AB</u>		HIKMA	<u>EQ 250MG BASE</u>	<u>A076558 002</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A076558 003</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 750MG BASE</u>	<u>A076558 004</u>	Jun 09, 2004
<u>AB</u>		IVAX SUB TEVA PHARMS	<u>EQ 250MG BASE</u>	<u>A076089 002</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A076089 003</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 750MG BASE</u>	<u>A076089 004</u>	Jun 09, 2004
<u>AB</u>		MYLAN	<u>EQ 100MG BASE</u>	<u>A075817 001</u>	Jun 25, 2007
<u>AB</u>			<u>EQ 250MG BASE</u>	<u>A075685 002</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 250MG BASE</u>	<u>A075817 002</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A075685 003</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A075817 003</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 750MG BASE</u>	<u>A075685 001</u>	Jun 09, 2004

PRESCRIPTION DRUG PRODUCT LIST

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A075817 004</u>	Jun 09, 2004
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 250MG BASE</u>	<u>A075747 001</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A075747 002</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A075747 003</u>	Jun 09, 2004
<u>AB</u>	TARO	<u>EQ 100MG BASE</u>	<u>A076912 001</u>	Feb 18, 2005
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A076912 002</u>	Oct 06, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A076912 003</u>	Oct 06, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A076912 004</u>	Oct 06, 2004
<u>AB</u>	UNIQUE PHARM LABS	<u>EQ 250MG BASE</u>	<u>A076639 001</u>	Sep 10, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A076639 002</u>	Sep 10, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A076639 003</u>	Sep 10, 2004
<u>AB</u>	WATSON LABS	<u>EQ 100MG BASE</u>	<u>A076794 001</u>	Feb 10, 2005
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A076794 002</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A076794 003</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A076794 004</u>	Jun 09, 2004

CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE

SOLUTION/DROPS; OTIC

OTOVEL

+ LABORATORIOS SALVAT EQ 0.3% BASE; 0.025% N208251 001 Apr 29, 2016

CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

SUSPENSION/DROPS; OTIC

CIPRO HC

+ NOVARTIS PHARMS CORP EQ 0.2% BASE; 1% N020805 001 Feb 10, 1998

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPROFLOXACIN EXTENDED RELEASE

<u>AB</u>	ANCHEN PHARMS	<u>212.6MG;EQ 287.5MG BASE</u>	<u>A078166 002</u>	Nov 27, 2007
<u>AB</u>		<u>425.2MG;EQ 574.9MG BASE</u>	<u>A078166 001</u>	Nov 27, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>425.2MG;EQ 574.9MG BASE</u>	<u>A077701 001</u>	Mar 26, 2007
<u>AB</u>	+ MYLAN PHARMS INC	<u>212.6MG;EQ 287.5MG BASE</u>	<u>A078183 001</u>	Mar 22, 2007
<u>AB</u>	+	<u>425.2MG;EQ 574.9MG BASE</u>	<u>A078183 002</u>	Mar 22, 2007

CIPROFLOXACIN; DEXAMETHASONE

SUSPENSION/DROPS; OTIC

CIPRODEX

+ NOVARTIS PHARMS CORP 0.3%; 0.1% N021537 001 Jul 18, 2003

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 2MG BASE/ML</u>	<u>A203183 001</u>	Feb 26, 2015
<u>AP</u>	SANDOZ INC	<u>EQ 2MG BASE/ML</u>	<u>A200159 001</u>	Feb 03, 2012

CISATRACURIUM BESYLATE PRESERVATIVE FREE

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 2MG BASE/ML</u>	<u>A203182 001</u>	Feb 26, 2015
<u>AP</u>		<u>EQ 10MG BASE/ML</u>	<u>A203182 002</u>	Feb 26, 2015
<u>AP</u>	SANDOZ INC	<u>EQ 2MG BASE/ML</u>	<u>A200154 001</u>	Feb 03, 2012
<u>AP</u>		<u>EQ 10MG BASE/ML</u>	<u>A200154 002</u>	Feb 03, 2012

NIMBEX

<u>AP</u>	+ ABBVIE	<u>EQ 2MG BASE/ML</u>	<u>N020551 001</u>	Dec 15, 1995
-----------	----------	-----------------------	--------------------	--------------

NIMBEX PRESERVATIVE FREE

<u>AP</u>	+ ABBVIE	<u>EQ 2MG BASE/ML</u>	<u>N020551 003</u>	Dec 15, 1995
<u>AP</u>	+	<u>EQ 10MG BASE/ML</u>	<u>N020551 002</u>	Dec 15, 1995

CISPLATIN

INJECTABLE; INJECTION

CISPLATIN

<u>AP</u>	ACCORD HLTHCARE	<u>1MG/ML</u>	<u>A206774 001</u>	Aug 18, 2015
<u>AP</u>	+ FRESENIUS KABI USA	<u>1MG/ML</u>	<u>A074735 001</u>	Jul 16, 1999
<u>AP</u>	HQ SPCLT PHARMA	<u>1MG/ML</u>	<u>N018057 004</u>	Nov 08, 1988
<u>AP</u>	MYLAN LABS LTD	<u>1MG/ML</u>	<u>A091062 001</u>	Apr 18, 2012
<u>AP</u>	PHARMACHEMIE BV	<u>1MG/ML</u>	<u>A074656 001</u>	May 16, 2000
<u>AP</u>	WEST-WARD PHARMS INT	<u>1MG/ML</u>	<u>A075036 001</u>	Nov 07, 2000

CITALOPRAM HYDROBROMIDE

CAPSULE; ORAL

CITALOPRAM HYDROBROMIDE

	MYLAN PHARMS INC	EQ 10MG BASE	A077668 001	Feb 28, 2007
		EQ 20MG BASE	A077668 002	Feb 28, 2007
+		EQ 40MG BASE	A077668 003	Feb 28, 2007

PRESCRIPTION DRUG PRODUCT LIST

CITALOPRAM HYDROBROMIDE

SOLUTION;ORAL

CITALOPRAM HYDROBROMIDE

<u>AA</u>	AUROBINDO PHARMA LTD	<u>EQ 10MG BASE/5ML</u>	<u>A077812 001</u>	Aug 28, 2006
<u>AA</u>	HETERO LABS LTD III	<u>EQ 10MG BASE/5ML</u>	<u>A201450 001</u>	Dec 15, 2015
<u>AA</u>	SILARX	<u>EQ 10MG BASE/5ML</u>	<u>A077629 001</u>	Jun 15, 2006
<u>AA</u>	+ WEST-WARD PHARMS INT	<u>EQ 10MG BASE/5ML</u>	<u>A077043 001</u>	Dec 13, 2004

TABLET;ORAL

CELEXA

<u>AB</u>	FOREST LABS	<u>EQ 10MG BASE</u>	<u>N020822 001</u>	Apr 27, 2000
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>N020822 002</u>	Jul 17, 1998
<u>AB</u>	+	<u>EQ 40MG BASE</u>	<u>N020822 003</u>	Jul 17, 1998

CITALOPRAM HYDROBROMIDE

<u>AB</u>	AMNEAL PHARMS NY	<u>EQ 10MG BASE</u>	<u>A077289 001</u>	Nov 30, 2006
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077289 002</u>	Nov 30, 2006
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077289 003</u>	Nov 30, 2006
<u>AB</u>	APOTEX INC	<u>EQ 10MG BASE</u>	<u>A077046 001</u>	Nov 24, 2004
<u>AB</u>	AUROBINDO	<u>EQ 10MG BASE</u>	<u>A077031 001</u>	Oct 28, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077031 002</u>	Oct 28, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077031 003</u>	Oct 28, 2004
<u>AB</u>	CIPLA LTD	<u>EQ 10MG BASE</u>	<u>A077044 001</u>	Nov 05, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077044 002</u>	Nov 05, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077044 003</u>	Nov 05, 2004
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 10MG BASE</u>	<u>A077038 001</u>	Oct 28, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077038 002</u>	Oct 28, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077038 003</u>	Oct 28, 2004
<u>AB</u>	EPIC PHARMA	<u>EQ 10MG BASE</u>	<u>A077045 003</u>	Apr 29, 2005
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077045 002</u>	Apr 29, 2005
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077045 001</u>	Apr 29, 2005
<u>AB</u>	G AND W LABS INC	<u>EQ 10MG BASE</u>	<u>A077048 001</u>	Nov 16, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077048 002</u>	Nov 16, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077048 003</u>	Nov 16, 2004
<u>AB</u>	GLENMARK GENERICS	<u>EQ 10MG BASE</u>	<u>A077654 001</u>	Feb 27, 2009
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077654 002</u>	Feb 27, 2009
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077654 003</u>	Feb 27, 2009
<u>AB</u>	INVAGEN PHARMS	<u>EQ 10MG BASE</u>	<u>A077534 001</u>	Oct 03, 2006
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077534 002</u>	Oct 03, 2006
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077534 003</u>	Oct 03, 2006
<u>AB</u>	JUBILANT GENERICS	<u>EQ 10MG BASE</u>	<u>A205407 001</u>	Dec 23, 2015
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A205407 002</u>	Dec 23, 2015
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A205407 003</u>	Dec 23, 2015
<u>AB</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A077039 001</u>	Feb 03, 2005
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077042 001</u>	Nov 05, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077039 002</u>	Feb 03, 2005
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077042 002</u>	Nov 05, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077039 003</u>	Feb 03, 2005
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077042 003</u>	Nov 05, 2004
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A077037 001</u>	Nov 05, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077037 002</u>	Nov 05, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077037 003</u>	Nov 05, 2004
<u>AB</u>	PLIVA	<u>EQ 10MG BASE</u>	<u>A077232 001</u>	Oct 31, 2005
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077232 002</u>	Oct 31, 2005
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077232 003</u>	Oct 31, 2005
<u>AB</u>	SUN PHARM INDS INC	<u>EQ 10MG BASE</u>	<u>A077032 001</u>	Nov 12, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077032 002</u>	Nov 12, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077032 003</u>	Nov 12, 2004
<u>AB</u>	TORPHARM	<u>EQ 20MG BASE</u>	<u>A077046 002</u>	Nov 24, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077046 003</u>	Nov 24, 2004
<u>AB</u>	TORRENT PHARMS	<u>EQ 10MG BASE</u>	<u>A078216 001</u>	Mar 27, 2007
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078216 002</u>	Mar 27, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078216 003</u>	Mar 27, 2007

CITRIC ACID; GLUCONOLACTONE; MAGNESIUM CARBONATE

SOLUTION;IRRIGATION

RENACIDIN

+	UNITED GUARDIAN	6.602GM/100ML;198MG/100ML;3.177GM/100ML	N019481 001	Oct 02, 1990
---	-----------------	---	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

FOR SOLUTION;ORAL

PREPOPIK

+ FERRING PHARMS AS 12GM/PACKET;3.5GM/PACKET;10MG/PACKET N202535 001 Jul 16, 2012

CITRIC ACID; UREA C-13

FOR SOLUTION, TABLET, FOR SOLUTION;ORAL

IDKIT:HP

+ EXALENZ BIOSCIENCE N/A, 4GM; 75MG, N/A N021314 001 Dec 17, 2002

CLADRIBINE

INJECTABLE; INJECTION

CLADRIBINE

<u>AP</u>	+	FRESENIUS KABI USA	<u>1MG/ML</u>	<u>A076571</u>	<u>001</u>	Apr 22, 2004
<u>AP</u>		MYLAN LABS LTD	<u>1MG/ML</u>	<u>A200510</u>	<u>001</u>	Oct 06, 2011
<u>AP</u>		WEST-WARD PHARMS INT	<u>1MG/ML</u>	<u>A075405</u>	<u>001</u>	Feb 28, 2000

CLARITHROMYCIN

FOR SUSPENSION;ORAL

BIAXIN

<u>AB</u>		ABBVIE	<u>125MG/5ML</u>	<u>N050698</u>	<u>001</u>	Dec 23, 1993
<u>AB</u>	+		<u>250MG/5ML</u>	<u>N050698</u>	<u>002</u>	Dec 23, 1993

CLARITHROMYCIN

<u>AB</u>		SANDOZ	<u>125MG/5ML</u>	<u>A065283</u>	<u>002</u>	Sep 04, 2007
<u>AB</u>			<u>250MG/5ML</u>	<u>A065283</u>	<u>003</u>	Sep 04, 2007
<u>AB</u>		SUN PHARM INDS LTD	<u>125MG/5ML</u>	<u>A065382</u>	<u>001</u>	Aug 30, 2007
<u>AB</u>			<u>250MG/5ML</u>	<u>A065382</u>	<u>002</u>	Aug 30, 2007

TABLET;ORAL

BIAXIN

<u>AB</u>	+	ABBVIE	<u>250MG</u>	<u>N050662</u>	<u>001</u>	Oct 31, 1991
<u>AB</u>	+		<u>500MG</u>	<u>N050662</u>	<u>002</u>	Oct 31, 1991

CLARITHROMYCIN

<u>AB</u>		ALLIED PHARMA INC	<u>250MG</u>	<u>A202710</u>	<u>001</u>	Jun 10, 2013
<u>AB</u>			<u>500MG</u>	<u>A202710</u>	<u>002</u>	Jun 10, 2013
<u>AB</u>		APOTEX CORP	<u>250MG</u>	<u>A065384</u>	<u>001</u>	Aug 20, 2007
<u>AB</u>			<u>500MG</u>	<u>A065384</u>	<u>002</u>	Aug 20, 2007
<u>AB</u>		AUROBINDO	<u>250MG</u>	<u>A065489</u>	<u>001</u>	Jul 25, 2012
<u>AB</u>			<u>500MG</u>	<u>A065489</u>	<u>002</u>	Jul 25, 2012
<u>AB</u>		HEC PHARM USA INC	<u>250MG</u>	<u>A203584</u>	<u>001</u>	Sep 28, 2015
<u>AB</u>			<u>500MG</u>	<u>A203584</u>	<u>002</u>	Sep 28, 2015
<u>AB</u>		MYLAN	<u>250MG</u>	<u>A065195</u>	<u>001</u>	Mar 11, 2005
<u>AB</u>			<u>500MG</u>	<u>A065195</u>	<u>002</u>	Mar 11, 2005
<u>AB</u>		SANDOZ	<u>250MG</u>	<u>A065144</u>	<u>001</u>	Oct 18, 2005
<u>AB</u>			<u>500MG</u>	<u>A065136</u>	<u>001</u>	Aug 25, 2005
<u>AB</u>		SUN PHARM INDS LTD	<u>250MG</u>	<u>A065174</u>	<u>001</u>	Sep 24, 2004
<u>AB</u>			<u>500MG</u>	<u>A065174</u>	<u>002</u>	Sep 24, 2004
<u>AB</u>		TEVA	<u>250MG</u>	<u>A065155</u>	<u>001</u>	May 31, 2005
<u>AB</u>			<u>500MG</u>	<u>A065155</u>	<u>002</u>	May 31, 2005
<u>AB</u>		WEST-WARD PHARMS INT	<u>250MG</u>	<u>A065178</u>	<u>002</u>	May 25, 2004
<u>AB</u>			<u>500MG</u>	<u>A065178</u>	<u>001</u>	May 25, 2004
<u>AB</u>		WOCKHARDT	<u>250MG</u>	<u>A065266</u>	<u>001</u>	May 31, 2006
<u>AB</u>			<u>500MG</u>	<u>A065266</u>	<u>002</u>	May 31, 2006

TABLET, EXTENDED RELEASE;ORAL

CLARITHROMYCIN

<u>AB</u>		ACTAVIS LABS FL INC	<u>500MG</u>	<u>A065145</u>	<u>001</u>	Jun 24, 2004
<u>AB</u>		ALLIED PHARMA INC	<u>500MG</u>	<u>A203243</u>	<u>001</u>	Feb 29, 2016
<u>AB</u>		LUPIN LTD	<u>500MG</u>	<u>A202532</u>	<u>001</u>	Sep 15, 2015
<u>AB</u>	+	MAYNE PHARMA	<u>500MG</u>	<u>A065154</u>	<u>001</u>	May 18, 2005

CLEMASTINE FUMARATE

SYRUP;ORAL

CLEMASTINE FUMARATE

<u>AA</u>	+	TEVA	<u>EQ 0.5MG BASE/5ML</u>	<u>A073399</u>	<u>001</u>	Jun 30, 1994
<u>AA</u>		WOCKHARDT	<u>EQ 0.5MG BASE/5ML</u>	<u>A074863</u>	<u>001</u>	Mar 13, 1998

TABLET;ORAL

CLEMASTINE FUMARATE

<u>AB</u>		SANDOZ	<u>2.68MG</u>	<u>A073459</u>	<u>001</u>	Oct 31, 1993
<u>AB</u>	+	TEVA	<u>2.68MG</u>	<u>A073283</u>	<u>001</u>	Jan 31, 1992

PRESCRIPTION DRUG PRODUCT LIST

CLEVIDIPINE

EMULSION; INTRAVENOUS

CLEVIPREX

+	CHIESI USA INC	25MG/50ML (0.5MG/ML)	N022156	001	Aug 01, 2008
+		50MG/100ML (0.5MG/ML)	N022156	002	Aug 01, 2008
+		125MG/250ML (0.5MG/ML)	N022156	003	Nov 08, 2013

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLEOCIN HYDROCHLORIDE

AB	PHARMACIA AND UPJOHN	<u>EQ 75MG BASE</u>	<u>N050162</u>	<u>001</u>	
AB		<u>EQ 150MG BASE</u>	<u>N050162</u>	<u>002</u>	
AB	+	<u>EQ 300MG BASE</u>	<u>N050162</u>	<u>003</u>	Apr 14, 1988
	<u>CLINDAMYCIN HYDROCHLORIDE</u>				
AB	AUROBINDO PHARMA	<u>EQ 150MG BASE</u>	<u>A065442</u>	<u>001</u>	Aug 26, 2009
AB		<u>EQ 300MG BASE</u>	<u>A065442</u>	<u>002</u>	Aug 26, 2009
AB	COREPHARMA	<u>EQ 150MG BASE</u>	<u>A065194</u>	<u>001</u>	Mar 22, 2004
AB		<u>EQ 300MG BASE</u>	<u>A065194</u>	<u>002</u>	Mar 22, 2004
AB	G AND W LABS INC	<u>EQ 150MG BASE</u>	<u>A063029</u>	<u>001</u>	Sep 20, 1989
AB		<u>EQ 300MG BASE</u>	<u>A063029</u>	<u>002</u>	Aug 05, 2005
AB	LANNETT	<u>EQ 75MG BASE</u>	<u>A065242</u>	<u>001</u>	Aug 12, 2005
AB		<u>EQ 150MG BASE</u>	<u>A065242</u>	<u>002</u>	Aug 12, 2005
AB		<u>EQ 300MG BASE</u>	<u>A065243</u>	<u>001</u>	Aug 12, 2005
AB	MYLAN PHARMS INC	<u>EQ 75MG BASE</u>	<u>A091225</u>	<u>001</u>	May 31, 2011
AB		<u>EQ 150MG BASE</u>	<u>A091225</u>	<u>002</u>	May 31, 2011
AB		<u>EQ 300MG BASE</u>	<u>A091225</u>	<u>003</u>	May 31, 2011
AB	SUN PHARM INDS LTD	<u>EQ 150MG BASE</u>	<u>A065061</u>	<u>001</u>	Feb 02, 2001
AB		<u>EQ 300MG BASE</u>	<u>A065061</u>	<u>002</u>	Feb 02, 2001
AB	WATSON LABS	<u>EQ 150MG BASE</u>	<u>A063083</u>	<u>001</u>	Jul 31, 1991
AB		<u>EQ 300MG BASE</u>	<u>A063083</u>	<u>002</u>	Mar 18, 2003
AB	ZYDUS PHARMS USA	<u>EQ 75MG BASE</u>	<u>A065217</u>	<u>001</u>	Jan 31, 2005
AB		<u>EQ 150MG BASE</u>	<u>A065217</u>	<u>002</u>	Jan 31, 2005
AB		<u>EQ 300MG BASE</u>	<u>A065217</u>	<u>003</u>	Jan 31, 2005

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLEOCIN

AA	+	PHARMACIA AND UPJOHN	<u>EQ 75MG BASE/5ML</u>	<u>A062644</u>	<u>001</u>	Apr 07, 1986
		<u>CLINDAMYCIN PALMITATE HYDROCHLORIDE</u>				
AA		AMNEAL PHARMS	<u>EQ 75MG BASE/5ML</u>	<u>A203513</u>	<u>001</u>	Mar 13, 2014
AA		AUROBINDO PHARMA LTD	<u>EQ 75MG BASE/5ML</u>	<u>A202409</u>	<u>001</u>	Apr 30, 2013
AA		LYNE	<u>EQ 75MG BASE/5ML</u>	<u>A201821</u>	<u>001</u>	Aug 28, 2012
AA		MYLAN PHARMS INC	<u>EQ 75MG BASE/5ML</u>	<u>A203063</u>	<u>001</u>	May 25, 2016
AA		PADDOCK LABS	<u>EQ 75MG BASE/5ML</u>	<u>A090902</u>	<u>001</u>	Jul 07, 2010

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM; TOPICAL

CLINDAMYCIN PHOSPHATE

AT		PERRIGO UK FINCO	<u>1%</u>	<u>A090785</u>	<u>001</u>	Mar 31, 2010
-----------	--	------------------	-----------	----------------	------------	--------------

EVOCLIN

AT	+	DELCOR ASSET CORP	<u>1%</u>	<u>N050801</u>	<u>001</u>	Oct 22, 2004
-----------	---	-------------------	-----------	----------------	------------	--------------

CREAM; VAGINAL

CLEOCIN

AB	+	PHARMACIA AND UPJOHN	<u>EQ 2% BASE</u>	<u>N050680</u>	<u>002</u>	Mar 02, 1998
-----------	---	----------------------	-------------------	----------------	------------	--------------

CLINDAMYCIN PHOSPHATE

AB		FOUGERA PHARMS	<u>EQ 2% BASE</u>	<u>A065139</u>	<u>001</u>	Dec 27, 2004
-----------	--	----------------	-------------------	----------------	------------	--------------

CLINDESSE

+	PERRIGO PHARMA INTL	EQ 2% BASE	N050793	001	Nov 30, 2004
---	---------------------	------------	---------	-----	--------------

GEL; TOPICAL

CLEOCIN T

AB	+	PHARMACIA AND UPJOHN	<u>EQ 1% BASE</u>	<u>N050615</u>	<u>001</u>	Jan 07, 1987
-----------	---	----------------------	-------------------	----------------	------------	--------------

CLINDAMYCIN PHOSPHATE

AB		FOUGERA PHARMS	<u>EQ 1% BASE</u>	<u>A064160</u>	<u>001</u>	Jan 28, 2000
-----------	--	----------------	-------------------	----------------	------------	--------------

CLINDAGEL

BT	+	PRECISION DERMAT	EQ 1% BASE	N050782	001	Nov 27, 2000
-----------	---	------------------	------------	---------	-----	--------------

INJECTABLE; INJECTION

CLEOCIN PHOSPHATE

AP		PHARMACIA AND UPJOHN	<u>EQ 150MG BASE/ML</u>	<u>A062803</u>	<u>001</u>	Oct 16, 1987
-----------	--	----------------------	-------------------------	----------------	------------	--------------

AP	+		<u>EQ 150MG BASE/ML</u>	<u>N050441</u>	<u>001</u>	
-----------	---	--	-------------------------	----------------	------------	--

CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	PHARMACIA AND UPJOHN	<u>EQ 6MG BASE/ML</u>	<u>N050639</u>	<u>001</u>	Aug 30, 1989
-----------	---	----------------------	-----------------------	----------------	------------	--------------

AP	+		<u>EQ 12MG BASE/ML</u>	<u>N050639</u>	<u>002</u>	Aug 30, 1989
-----------	---	--	------------------------	----------------	------------	--------------

AP	+		<u>EQ 18MG BASE/ML</u>	<u>N050639</u>	<u>003</u>	Apr 10, 1991
-----------	---	--	------------------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE

AP	ALVOGEN INC	<u>EQ 150MG BASE/ML</u>	<u>A062800 001</u>	Jul 24, 1987
AP		<u>EQ 150MG BASE/ML</u>	<u>A062801 001</u>	Jul 24, 1987
AP		<u>EQ 150MG BASE/ML</u>	<u>A062943 001</u>	Sep 29, 1988
AP	EUROHLTH INTL SARL	<u>EQ 150MG BASE/ML</u>	<u>A065206 001</u>	Sep 24, 2004
AP	FRESENIUS KABI USA	<u>EQ 150MG BASE/ML</u>	<u>A065346 001</u>	Mar 29, 2007
AP		<u>EQ 150MG BASE/ML</u>	<u>A065347 001</u>	May 09, 2007
AP	SAGENT PHARMS	<u>EQ 150MG BASE/ML</u>	<u>A090108 001</u>	Sep 30, 2011
AP	SAGENT STRIDES	<u>EQ 150MG BASE/ML</u>	<u>A090109 001</u>	Sep 30, 2011
AP	WEST-WARD PHARMS INT	<u>EQ 150MG BASE/ML</u>	<u>A062889 001</u>	Apr 25, 1988

CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER

AP	AKORN INC	<u>EQ 6MG BASE/ML</u>	<u>A203048 001</u>	Apr 04, 2013
AP		<u>EQ 12MG BASE/ML</u>	<u>A203048 002</u>	Apr 04, 2013
AP		<u>EQ 18MG BASE/ML</u>	<u>A203048 003</u>	Apr 04, 2013
AP	SANDOZ INC	<u>EQ 6MG BASE/ML</u>	<u>A201692 001</u>	May 31, 2012
AP		<u>EQ 12MG BASE/ML</u>	<u>A201692 002</u>	May 31, 2012
AP		<u>EQ 18MG BASE/ML</u>	<u>A201692 003</u>	May 31, 2012

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%

+ ABRAXIS PHARM

EQ 900MG BASE/100ML

N050635 001 Dec 22, 1989

LOTION; TOPICAL

CLEOCIN T

AB	+ PHARMACIA AND UPJOHN	<u>EQ 1% BASE</u>	<u>N050600 001</u>	May 31, 1989
----	------------------------	-------------------	--------------------	--------------

CLINDAMYCIN PHOSPHATE

AB	FOUGERA PHARMS	<u>EQ 1% BASE</u>	<u>A065067 001</u>	Jan 31, 2002
----	----------------	-------------------	--------------------	--------------

SOLUTION; TOPICAL

CLEOCIN T

AT	+ PHARMACIA AND UPJOHN	<u>EQ 1% BASE</u>	<u>N050537 001</u>	
----	------------------------	-------------------	--------------------	--

CLINDA-DERM

AT	PADDOCK LLC	<u>EQ 1% BASE</u>	<u>A063329 001</u>	Sep 30, 1992
----	-------------	-------------------	--------------------	--------------

CLINDAMYCIN PHOSPHATE

AT	FOUGERA	<u>EQ 1% BASE</u>	<u>A064159 001</u>	Jun 05, 1997
AT	FOUGERA PHARMS	<u>EQ 1% BASE</u>	<u>A065254 001</u>	Feb 14, 2006
AT	G AND W LABS INC	<u>EQ 1% BASE</u>	<u>A062811 001</u>	Sep 01, 1988
AT	PERRIGO NEW YORK	<u>EQ 1% BASE</u>	<u>A064050 001</u>	Nov 30, 1995
AT	TARO PHARM INDS	<u>EQ 1% BASE</u>	<u>A065184 001</u>	Mar 31, 2004
AT	TELIGENT PHARMA INC	<u>EQ 1% BASE</u>	<u>A206945 001</u>	Dec 30, 2016
AT	VINTAGE PHARMS	<u>EQ 1% BASE</u>	<u>A203343 001</u>	May 29, 2015
AT	WOCKHARDT	<u>EQ 1% BASE</u>	<u>A063304 001</u>	Jul 15, 1997

SUPPOSITORY; VAGINAL

CLEOCIN

+ PHARMACIA AND UPJOHN

100MG

N050767 001 Aug 13, 1999

SWAB; TOPICAL

CLEOCIN

AT	PHARMACIA AND UPJOHN	<u>EQ 1% BASE</u>	<u>N050537 002</u>	Feb 22, 1994
----	----------------------	-------------------	--------------------	--------------

CLINDAMYCIN PHOSPHATE

AT	AKORN	<u>EQ 1% BASE</u>	<u>A065513 001</u>	Jun 17, 2010
AT	PERRIGO NEW YORK	<u>EQ 1% BASE</u>	<u>A065049 001</u>	May 25, 2000

CLINDETS

AT	PERRIGO	<u>EQ 1% BASE</u>	<u>A064136 001</u>	Sep 30, 1996
----	---------	-------------------	--------------------	--------------

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL; TOPICAL

CLINDAMYCIN PHOSPHATE AND TRETINOIN

AB	ACTAVIS MID ATLANTIC	<u>1.2%;0.025%</u>	<u>A202564 001</u>	Jun 12, 2015
----	----------------------	--------------------	--------------------	--------------

ZIANA

AB	+ MEDICIS	<u>1.2%;0.025%</u>	<u>N050802 001</u>	Nov 07, 2006
----	-----------	--------------------	--------------------	--------------

VELTIN

BX	+ AQUA PHARMS LLC	<u>1.2%;0.025%</u>	N050803 001	Jul 16, 2010
----	-------------------	--------------------	-------------	--------------

CLOBAZAM

SUSPENSION; ORAL

ONFI

+ LUNDBECK LLC

2.5MG/ML

N203993 001 Dec 14, 2012

TABLET; ORAL

ONFI

LUNDBECK LLC

10MG

N202067 002 Oct 21, 2011

+

20MG

N202067 003 Oct 21, 2011

PRESCRIPTION DRUG PRODUCT LIST

CLOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL

CLOBETASOL PROPIONATEAB1 PERRIGO ISRAEL 0.05% A077763 001 Mar 10, 2008OLUXAB1 + DELCOR ASSET CORP 0.05% N021142 001 May 26, 2000CLOBETASOL PROPIONATEAB2 PERRIGO ISRAEL 0.05% A201402 001 Aug 14, 2012OLUX EAB2 + DELCOR ASSET 0.05% N022013 001 Jan 12, 2007

CREAM; TOPICAL

CLOBETASOL PROPIONATEAB1 FOUGERA 0.05% A074392 001 Sep 30, 1996AB1 G AND W LABS INC 0.05% A074139 001 Aug 03, 1994AB1 TARO 0.05% A074249 001 Jul 08, 1996CORMAXAB1 + HI TECH PHARMA 0.05% A074220 001 May 16, 1997CLOBETASOL PROPIONATE (EMOLLIENT)AB2 + FOUGERA PHARMS 0.05% A075430 001 May 26, 1999AB2 TARO 0.05% A075633 001 May 17, 2000EMBELINE EAB2 HI TECH PHARMA 0.05% A075325 001 Dec 24, 1998

GEL; TOPICAL

CLOBETASOL PROPIONATEAB + FOUGERA PHARMS 0.05% A075368 001 Feb 15, 2000AB PERRIGO 0.05% A075027 001 Oct 31, 1997AB TARO 0.05% A075279 001 May 28, 1999EMBELINEAB HI TECH PHARMA 0.05% A076141 001 Apr 12, 2002

LOTION; TOPICAL

CLOBETASOL PROPIONATEAB ACTAVIS MID ATLANTIC 0.05% A078223 001 Dec 04, 2008AB TARO 0.05% A200302 001 Jul 02, 2012AB TELIGENT PHARMA INC 0.05% A208667 001 Nov 29, 2016CLOBEXAB + GALDERMA LABS LP 0.05% N021535 001 Jul 24, 2003

OINTMENT; TOPICAL

CLOBETASOL PROPIONATEAB + FOUGERA PHARMS 0.05% A074407 001 Feb 23, 1996AB G AND W LABS INC 0.05% A074089 001 Feb 16, 1994AB TARO 0.05% A074248 001 Jul 12, 1996EMBELINEAB HI TECH PHARMA 0.05% A074221 001 Mar 31, 1995

SHAMPOO; TOPICAL

CLOBETASOL PROPIONATEAB ACTAVIS MID ATLANTIC 0.05% A078854 001 Jun 07, 2011AB PERRIGO ISRAEL 0.05% A090974 001 Aug 09, 2012CLOBEXAB + GALDERMA LABS 0.05% N021644 001 Feb 05, 2004

SOLUTION; TOPICAL

CLOBETASOL PROPIONATEAT FOUGERA PHARMS 0.05% A075391 001 Feb 08, 1999AT G AND W LABS INC 0.05% A074331 001 Dec 15, 1995AT NOVEL LABS INC 0.05% A206075 001 Nov 23, 2015AT TARO 0.05% A075224 001 Nov 16, 1998AT 0.05% A075363 001 Dec 29, 2000AT TOLMAR 0.05% A076977 001 Aug 05, 2005AT WOCKHARDT 0.05% A075205 001 Nov 13, 1998EMBELINEAT + HI TECH PHARMA 0.05% A074222 001 Dec 06, 1995

SPRAY; TOPICAL

CLOBETASOL PROPIONATEAT PADDOCK LLC 0.05% A090898 001 Jun 16, 2011CLOBEXAT + GALDERMA LABS LP 0.05% N021835 001 Oct 27, 2005CLOCORTOLONE PIVALATE

CREAM; TOPICAL

CLODERM

AT + PROMIUS PHARMA LLC 0.1% N017765 001

PRESCRIPTION DRUG PRODUCT LIST

CLOFARABINE

INJECTABLE; IV (INFUSION)

CLOLAR

+ GENZYME

20MG/20ML (1MG/ML)

N021673 001 Dec 28, 2004

CLOFAZIMINE

CAPSULE; ORAL

LAMPRENE

+ NOVARTIS

50MG

N019500 002 Dec 15, 1986

CLOMIPHENE CITRATE

TABLET; ORAL

CLOMIDAB + SANOFI AVENTIS US50MGN016131 002CLOMIPHENE CITRATEAB PAR PHARM50MGA075528 001 Aug 30, 1999CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

ANAFRANILAB + MALLINCKRODT LLC25MGN019906 001 Dec 29, 1989AB 50MGN019906 002 Dec 29, 1989AB 75MGN019906 003 Dec 29, 1989CLOMIPRAMINE HYDROCHLORIDEAB MYLAN25MGA074947 001 Apr 30, 1998AB 50MGA074947 002 Apr 30, 1998AB 75MGA074947 003 Apr 30, 1998AB SANDOZ25MGA074364 001 Mar 29, 1996AB 50MGA074364 002 Mar 29, 1996AB 75MGA074364 003 Mar 29, 1996AB TARO25MGA074694 001 Dec 31, 1996AB 50MGA074694 002 Dec 31, 1996AB 75MGA074694 003 Dec 31, 1996AB TEVA25MGA074958 001 Aug 26, 1997AB 50MGA074958 002 Aug 26, 1997AB 75MGA074958 003 Aug 26, 1997CLONAZEPAM

TABLET; ORAL

CLONAZEPAMAB ACCORD HLTHCARE0.5MGA077147 001 May 02, 2005AB 1MGA077147 002 May 02, 2005AB 2MGA077147 003 May 02, 2005AB ACTAVIS ELIZABETH0.5MGA074869 001 Oct 31, 1996AB 1MGA074869 002 Oct 31, 1996AB 2MGA074869 003 Oct 31, 1996AB MYLAN0.5MGA075150 001 Oct 05, 1998AB 1MGA075150 002 Oct 05, 1998AB 2MGA075150 003 Oct 05, 1998AB MYLAN PHARMS INC0.5MGA074940 001 Oct 30, 1997AB 1MGA074940 002 Oct 30, 1997AB 2MGA074940 003 Oct 30, 1997AB SANDOZ0.5MGA074979 001 Aug 29, 1997AB 1MGA074979 002 Aug 29, 1997AB 2MGA074979 003 Aug 29, 1997AB SUN PHARM INDS INC0.5MGA075423 001 Apr 27, 2001AB 1MGA075423 002 Apr 27, 2001AB 2MGA075423 003 Apr 27, 2001AB TEVA0.5MGA074569 001 Sep 10, 1996AB 1MGA074569 002 Sep 10, 1996AB 2MGA074569 003 Sep 10, 1996AB VINTAGE PHARMS0.5MGA077856 001 Jun 28, 2006AB 1MGA077856 002 Jun 28, 2006AB 2MGA077856 003 Jun 28, 2006AB WATSON LABS0.5MGA074964 001 Dec 30, 1997AB 1MGA074964 002 Dec 30, 1997AB 2MGA074964 003 Dec 30, 1997KLONOPINAB ROCHE0.5MGN017533 001AB +1MGN017533 002AB 2MGN017533 003

TABLET, ORALLY DISINTEGRATING; ORAL

CLONAZEPAMAB BARR0.125MGA077194 001 Aug 10, 2005

PRESCRIPTION DRUG PRODUCT LIST

CLONAZEPAM

TABLET, ORALLY DISINTEGRATING;ORAL

CLONAZEPAM

<u>AB</u>		<u>0.25MG</u>	<u>A077194 002</u>	Aug 10, 2005
<u>AB</u>		<u>0.5MG</u>	<u>A077194 003</u>	Aug 10, 2005
<u>AB</u>		<u>1MG</u>	<u>A077194 004</u>	Aug 10, 2005
<u>AB</u>		<u>2MG</u>	<u>A077194 005</u>	Aug 10, 2005
<u>AB</u>	PAR PHARM	<u>0.125MG</u>	<u>A077171 001</u>	Aug 03, 2005
<u>AB</u>		<u>0.25MG</u>	<u>A077171 002</u>	Aug 03, 2005
<u>AB</u>		<u>0.5MG</u>	<u>A077171 003</u>	Aug 03, 2005
<u>AB</u>	+	<u>1MG</u>	<u>A077171 004</u>	Aug 03, 2005
<u>AB</u>		<u>2MG</u>	<u>A077171 005</u>	Aug 03, 2005
<u>AB</u>	SUN PHARM INDS INC	<u>0.125MG</u>	<u>A078654 001</u>	Aug 27, 2014
<u>AB</u>		<u>0.25MG</u>	<u>A078654 002</u>	Aug 27, 2014
<u>AB</u>		<u>0.5MG</u>	<u>A078654 003</u>	Aug 27, 2014
<u>AB</u>		<u>1MG</u>	<u>A078654 004</u>	Aug 27, 2014
<u>AB</u>		<u>2MG</u>	<u>A078654 005</u>	Aug 27, 2014

CLONIDINE

FILM, EXTENDED RELEASE;TRANSDERMAL

CATAPRES-TTS-1

<u>AB</u>	BOEHRINGER INGELHEIM	<u>0.1MG/24HR</u>	<u>N018891 001</u>	Oct 10, 1984
-----------	----------------------	-------------------	--------------------	--------------

CATAPRES-TTS-2

<u>AB</u>	BOEHRINGER INGELHEIM	<u>0.2MG/24HR</u>	<u>N018891 002</u>	Oct 10, 1984
-----------	----------------------	-------------------	--------------------	--------------

CATAPRES-TTS-3

<u>AB</u>	+	<u>0.3MG/24HR</u>	<u>N018891 003</u>	Oct 10, 1984
-----------	---	-------------------	--------------------	--------------

CLONIDINE

<u>AB</u>	ACTAVIS LABS UT INC	<u>0.1MG/24HR</u>	<u>A090873 001</u>	May 06, 2014
<u>AB</u>		<u>0.2MG/24HR</u>	<u>A090873 002</u>	May 06, 2014
<u>AB</u>		<u>0.3MG/24HR</u>	<u>A090873 003</u>	May 06, 2014
<u>AB</u>	AVEVA	<u>0.1MG/24HR</u>	<u>A076157 001</u>	Aug 18, 2009
<u>AB</u>		<u>0.2MG/24HR</u>	<u>A076157 002</u>	Aug 18, 2009
<u>AB</u>		<u>0.3MG/24HR</u>	<u>A076157 003</u>	Aug 18, 2009
<u>AB</u>	MAYNE PHARMA	<u>0.1MG/24HR</u>	<u>A079090 001</u>	Aug 20, 2010
<u>AB</u>		<u>0.2MG/24HR</u>	<u>A079090 002</u>	Aug 20, 2010
<u>AB</u>		<u>0.3MG/24HR</u>	<u>A079090 003</u>	Aug 20, 2010
<u>AB</u>	MYLAN TECHNOLOGIES	<u>0.1MG/24HR</u>	<u>A076166 001</u>	Jul 16, 2010
<u>AB</u>		<u>0.2MG/24HR</u>	<u>A076166 002</u>	Jul 16, 2010
<u>AB</u>		<u>0.3MG/24HR</u>	<u>A076166 003</u>	Jul 16, 2010

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CLONIDINE HYDROCHLORIDE

<u>AP</u>	EXELA PHARMA SCS LLC	<u>1MG/10ML (0.1MG/ML)</u>	<u>A203167 001</u>	Oct 29, 2013
<u>AP</u>		<u>5MG/10ML (0.5MG/ML)</u>	<u>A203167 002</u>	Oct 29, 2013
<u>AP</u>	FRESENIUS KABI USA	<u>1MG/10ML (0.1MG/ML)</u>	<u>A200673 001</u>	Jul 08, 2011
<u>AP</u>		<u>5MG/10ML (0.5MG/ML)</u>	<u>A200673 002</u>	Jul 08, 2011
<u>AP</u>	HIKMA FARMACEUTICA	<u>1MG/10ML (0.1MG/ML)</u>	<u>A200300 001</u>	Jan 26, 2011
<u>AP</u>		<u>5MG/10ML (0.5MG/ML)</u>	<u>A200300 002</u>	Jan 26, 2011
<u>AP</u>	LUITPOLD	<u>1MG/10ML (0.1MG/ML)</u>	<u>A091104 001</u>	Oct 08, 2009
<u>AP</u>		<u>5MG/10ML (0.5MG/ML)</u>	<u>A091104 002</u>	Oct 08, 2009
<u>AP</u>	ZYDUS PHARMS USA INC	<u>1MG/10ML (0.1MG/ML)</u>	<u>A202601 001</u>	Feb 20, 2014
<u>AP</u>		<u>5MG/10ML (0.5MG/ML)</u>	<u>A202601 002</u>	Feb 20, 2014

DURACLON

<u>AP</u>	MYLAN INSTITUTIONAL	<u>1MG/10ML (0.1MG/ML)</u>	<u>N020615 001</u>	Oct 02, 1996
<u>AP</u>	+	<u>5MG/10ML (0.5MG/ML)</u>	<u>N020615 002</u>	Apr 27, 1999

TABLET;ORAL

CATAPRES

<u>AB</u>	BOEHRINGER INGELHEIM	<u>0.1MG</u>	<u>N017407 001</u>	
<u>AB</u>		<u>0.2MG</u>	<u>N017407 002</u>	
<u>AB</u>	+	<u>0.3MG</u>	<u>N017407 003</u>	

CLONIDINE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>0.1MG</u>	<u>A070974 001</u>	Dec 16, 1986
<u>AB</u>		<u>0.2MG</u>	<u>A070975 001</u>	Dec 16, 1986
<u>AB</u>		<u>0.3MG</u>	<u>A070976 001</u>	Dec 16, 1986
<u>AB</u>	ALEMBIC PHARMS LTD	<u>0.1MG</u>	<u>A091368 001</u>	Dec 06, 2011
<u>AB</u>		<u>0.2MG</u>	<u>A091368 002</u>	Dec 06, 2011
<u>AB</u>		<u>0.3MG</u>	<u>A091368 003</u>	Dec 06, 2011
<u>AB</u>	FRONTIDA BIOPHARM	<u>0.1MG</u>	<u>A070925 001</u>	Sep 04, 1987
<u>AB</u>		<u>0.2MG</u>	<u>A070924 001</u>	Sep 04, 1987
<u>AB</u>		<u>0.3MG</u>	<u>A070923 001</u>	Sep 04, 1987
<u>AB</u>	IMPAX LABS	<u>0.1MG</u>	<u>A078099 001</u>	Aug 27, 2009
<u>AB</u>		<u>0.2MG</u>	<u>A078099 002</u>	Aug 27, 2009

PRESCRIPTION DRUG PRODUCT LIST

CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLONIDINE HYDROCHLORIDE

<u>AB</u>		<u>0.3MG</u>	<u>A078099 003</u>	Aug 27, 2009
<u>AB</u>	MYLAN	<u>0.1MG</u>	<u>A070317 002</u>	Jul 09, 1987
<u>AB</u>		<u>0.2MG</u>	<u>A070317 003</u>	Jun 09, 1987
<u>AB</u>		<u>0.3MG</u>	<u>A070317 001</u>	Jun 09, 1987
<u>AB</u>	SUN PHARM INDS INC	<u>0.1MG</u>	<u>A090329 001</u>	Jul 03, 2014
<u>AB</u>		<u>0.2MG</u>	<u>A090329 002</u>	Jul 03, 2014
<u>AB</u>		<u>0.3MG</u>	<u>A090329 003</u>	Jul 03, 2014
<u>AB</u>	UNICHEM	<u>0.1MG</u>	<u>A078895 001</u>	Aug 26, 2009
<u>AB</u>		<u>0.2MG</u>	<u>A078895 002</u>	Aug 26, 2009
<u>AB</u>		<u>0.3MG</u>	<u>A078895 003</u>	Aug 26, 2009
<u>AB</u>	VINTAGE	<u>0.1MG</u>	<u>A077901 001</u>	Mar 09, 2007
<u>AB</u>		<u>0.2MG</u>	<u>A077901 002</u>	Mar 09, 2007
<u>AB</u>		<u>0.3MG</u>	<u>A077901 003</u>	Mar 09, 2007
<u>AB</u>	YUNG SHIN PHARM	<u>0.1MG</u>	<u>A202297 001</u>	Jun 13, 2013
<u>AB</u>		<u>0.2MG</u>	<u>A202297 002</u>	Jun 13, 2013
<u>AB</u>		<u>0.3MG</u>	<u>A202297 003</u>	Jun 13, 2013

TABLET, EXTENDED RELEASE; ORAL

CLONIDINE HYDROCHLORIDE

<u>AB1</u>	ACTAVIS ELIZABETH	<u>0.1MG</u>	<u>A203320 001</u>	May 15, 2015
	<u>CLONIDINE HYDROCHLORIDE</u>			
<u>AB1</u>	ANCHEN PHARMS	<u>0.1MG</u>	<u>A202984 001</u>	Sep 30, 2013
	<u>KAPVAY</u>			
<u>AB1</u>	+ CONCORDIA PHARMS INC	<u>0.1MG</u>	<u>N022331 003</u>	Sep 28, 2010
	<u>CLONIDINE HYDROCHLORIDE</u>			
<u>AB2</u>	ACTAVIS ELIZABETH	<u>0.1MG</u>	<u>A202792 001</u>	May 15, 2015

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 75MG BASE</u>	<u>A202925 001</u>	Mar 27, 2013
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A202925 002</u>	Mar 27, 2013
<u>AB</u>	AMNEAL PHARMS	<u>EQ 75MG BASE</u>	<u>A203751 001</u>	Apr 11, 2014
<u>AB</u>	APOTEX INC	<u>EQ 75MG BASE</u>	<u>A076274 001</u>	May 17, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A076274 002</u>	Mar 04, 2014
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 75MG BASE</u>	<u>A090540 001</u>	May 17, 2012
<u>AB</u>	DR REDDYS LABS INC	<u>EQ 75MG BASE</u>	<u>A076273 001</u>	Jan 14, 2008
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 300MG BASE</u>	<u>A091023 001</u>	May 17, 2012
<u>AB</u>	GATE PHARMS	<u>EQ 300MG BASE</u>	<u>A091216 001</u>	May 17, 2012
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 75MG BASE</u>	<u>A202928 001</u>	Feb 10, 2014
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 75MG BASE</u>	<u>A077665 001</u>	May 17, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A077665 002</u>	May 17, 2012
<u>AB</u>	ROXANE	<u>EQ 75MG BASE</u>	<u>A078004 001</u>	May 17, 2012
<u>AB</u>	SCIEGEN PHARMS INC	<u>EQ 75MG BASE</u>	<u>A204165 001</u>	Sep 15, 2014
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A204165 002</u>	Sep 15, 2014
<u>AB</u>	SUN PHARM INDS	<u>EQ 75MG BASE</u>	<u>A078133 001</u>	Jun 10, 2013
<u>AB</u>	SUN PHARMA GLOBAL	<u>EQ 75MG BASE</u>	<u>A090494 001</u>	May 17, 2012
<u>AB</u>	TEVA	<u>EQ 75MG BASE</u>	<u>A076999 001</u>	May 17, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 300MG BASE</u>	<u>A090625 001</u>	May 17, 2012
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 75MG BASE</u>	<u>A090844 001</u>	May 17, 2012
<u>AB</u>	WOCKHARDT LTD	<u>EQ 75MG BASE</u>	<u>A202266 001</u>	Aug 14, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A202266 002</u>	Nov 20, 2012
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 75MG BASE</u>	<u>A201686 001</u>	Oct 10, 2012
	<u>PLAVIX</u>			
<u>AB</u>	SANOFI AVENTIS US	<u>EQ 75MG BASE</u>	<u>N020839 001</u>	Nov 17, 1997
<u>AB</u>	+	<u>EQ 300MG BASE</u>	<u>N020839 002</u>	Sep 20, 2007

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM

<u>AB</u>	MYLAN	<u>3.75MG</u>	<u>A071858 002</u>	Jul 17, 1987
<u>AB</u>		<u>7.5MG</u>	<u>A071858 003</u>	Jul 17, 1987
<u>AB</u>		<u>15MG</u>	<u>A071858 001</u>	Jul 17, 1987
<u>AB</u>	SUN PHARM INDS LTD	<u>3.75MG</u>	<u>A076911 001</u>	Sep 29, 2004
<u>AB</u>		<u>7.5MG</u>	<u>A076911 002</u>	Sep 29, 2004
<u>AB</u>		<u>15MG</u>	<u>A076911 003</u>	Sep 29, 2004
<u>AB</u>	TARO	<u>3.75MG</u>	<u>A075731 003</u>	Apr 27, 2000
<u>AB</u>		<u>7.5MG</u>	<u>A075731 002</u>	Apr 27, 2000
<u>AB</u>		<u>15MG</u>	<u>A075731 001</u>	Apr 27, 2000

GEN-XENE

<u>AB</u>	ALRA	<u>3.75MG</u>	<u>A071787 001</u>	Apr 26, 1988
-----------	------	---------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL

GEN-XENE

<u>AB</u>		<u>7.5MG</u>	<u>A071788</u>	<u>001</u>	Apr 26, 1988
<u>AB</u>		<u>15MG</u>	<u>A071789</u>	<u>001</u>	Apr 26, 1988

TRANXENE

<u>AB</u>	RECORDATI RARE	<u>7.5MG</u>	<u>N017105</u>	<u>007</u>	
<u>AB</u>	+	<u>15MG</u>	<u>N017105</u>	<u>008</u>	

CLOTTRIMAZOLE

CREAM; TOPICAL

CLOTTRIMAZOLE

<u>AB</u>	FOUGERA PHARMS	<u>1%</u>	<u>A078338</u>	<u>001</u>	Sep 02, 2008
<u>AB</u>	GLENMARK PHARMS	<u>1%</u>	<u>A090219</u>	<u>001</u>	Aug 03, 2010
<u>AB</u>	+	<u>1%</u>	<u>A072640</u>	<u>001</u>	Aug 31, 1993

SOLUTION; TOPICAL

CLOTTRIMAZOLE

<u>AT</u>	+	TARO	<u>1%</u>	<u>A074580</u>	<u>001</u>	Jul 29, 1996
<u>AT</u>		TEVA	<u>1%</u>	<u>A073306</u>	<u>001</u>	Feb 28, 1995

TROCHE/LOZENGE; ORAL

CLOTTRIMAZOLE

<u>AB</u>	PADDOCK LLC	<u>10MG</u>	<u>A076763</u>	<u>001</u>	Oct 28, 2005	
<u>AB</u>	+	WEST-WARD PHARMS INT	<u>10MG</u>	<u>A076387</u>	<u>001</u>	Jul 29, 2004

CLOZAPINE

SUSPENSION; ORAL

VERSACLOZ

+	JAZZ PHARMS III	50MG/ML	N203479	001	Feb 06, 2013
---	-----------------	---------	---------	-----	--------------

TABLET; ORAL

CLOZAPINE

<u>AB</u>	ACCORD HLTHCARE	<u>25MG</u>	<u>A202873</u>	<u>001</u>	Nov 25, 2015
<u>AB</u>		<u>100MG</u>	<u>A202873</u>	<u>002</u>	Nov 25, 2015
<u>AB</u>	AUROBINDO PHARMA LTD	<u>25MG</u>	<u>A206433</u>	<u>001</u>	Nov 29, 2016
<u>AB</u>		<u>50MG</u>	<u>A206433</u>	<u>002</u>	Nov 29, 2016
<u>AB</u>		<u>100MG</u>	<u>A206433</u>	<u>003</u>	Nov 29, 2016
<u>AB</u>		<u>200MG</u>	<u>A206433</u>	<u>004</u>	Nov 29, 2016
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>12.5MG</u>	<u>A074949</u>	<u>003</u>	Jul 31, 2003
<u>AB</u>		<u>25MG</u>	<u>A074949</u>	<u>001</u>	Nov 26, 1997
<u>AB</u>		<u>50MG</u>	<u>A074949</u>	<u>004</u>	Apr 25, 2005
<u>AB</u>		<u>50MG</u>	<u>A076809</u>	<u>003</u>	Dec 16, 2005
<u>AB</u>		<u>100MG</u>	<u>A074949</u>	<u>002</u>	Nov 26, 1997
<u>AB</u>		<u>100MG</u>	<u>A076809</u>	<u>002</u>	Dec 16, 2005
<u>AB</u>		<u>200MG</u>	<u>A076809</u>	<u>001</u>	Dec 16, 2005
<u>AB</u>	MAYNE PHARMA	<u>25MG</u>	<u>A203807</u>	<u>001</u>	Sep 17, 2015
<u>AB</u>		<u>100MG</u>	<u>A203807</u>	<u>002</u>	Sep 17, 2015
<u>AB</u>	MYLAN	<u>12.5MG</u>	<u>A075417</u>	<u>003</u>	Apr 15, 2010
<u>AB</u>		<u>25MG</u>	<u>A075417</u>	<u>001</u>	May 27, 1999
<u>AB</u>		<u>50MG</u>	<u>A075417</u>	<u>004</u>	Apr 15, 2010
<u>AB</u>		<u>100MG</u>	<u>A075417</u>	<u>002</u>	May 27, 1999
<u>AB</u>		<u>200MG</u>	<u>A075417</u>	<u>005</u>	Apr 15, 2010
<u>AB</u>	SUN PHARM INDS INC	<u>25MG</u>	<u>A075713</u>	<u>001</u>	Nov 15, 2002
<u>AB</u>		<u>50MG</u>	<u>A075713</u>	<u>003</u>	Aug 19, 2005
<u>AB</u>		<u>100MG</u>	<u>A075713</u>	<u>002</u>	Nov 15, 2002

CLOZARIL

<u>AB</u>	HERITAGE LIFE	<u>25MG</u>	<u>N019758</u>	<u>001</u>	Sep 26, 1989
<u>AB</u>	+	<u>100MG</u>	<u>N019758</u>	<u>002</u>	Sep 26, 1989

TABLET, ORALLY DISINTEGRATING; ORAL

CLOZAPINE

<u>AB</u>	BARR LABS INC	<u>25MG</u>	<u>A090308</u>	<u>001</u>	Nov 25, 2015
<u>AB</u>		<u>100MG</u>	<u>A090308</u>	<u>002</u>	Nov 25, 2015
<u>AB</u>	MYLAN PHARMS INC	<u>25MG</u>	<u>A201824</u>	<u>002</u>	Sep 15, 2015
<u>AB</u>		<u>100MG</u>	<u>A201824</u>	<u>003</u>	Sep 15, 2015
<u>AB</u>	TEVA PHARMS USA	<u>150MG</u>	<u>A203039</u>	<u>001</u>	Nov 25, 2015
<u>AB</u>		<u>200MG</u>	<u>A203039</u>	<u>002</u>	Nov 25, 2015

FAZACLO ODT

<u>AB</u>	JAZZ PHARMS III	<u>25MG</u>	<u>N021590</u>	<u>001</u>	Feb 10, 2004
<u>AB</u>	+	<u>100MG</u>	<u>N021590</u>	<u>002</u>	Feb 10, 2004
<u>AB</u>		<u>150MG</u>	<u>N021590</u>	<u>005</u>	Jul 09, 2010
<u>AB</u>		<u>200MG</u>	<u>N021590</u>	<u>006</u>	Jul 09, 2010
		12.5MG	N021590	004	May 30, 2007

PRESCRIPTION DRUG PRODUCT LIST

COBICISTAT

TABLET; ORAL

TYBOST

+ GILEAD SCIENCES INC 150MG N203094 001 Sep 24, 2014

COBICISTAT; DARUNAVIR ETHANOLATE

TABLET; ORAL

PREZCOBIX

+ JANSSEN PRODS 150MG; EQ 800MG BASE N205395 001 Jan 29, 2015

COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET; ORAL

GENVOYA

+ GILEAD SCIENCES INC 150MG; 150MG; 200MG; EQ 10MG BASE N207561 001 Nov 05, 2015

COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

STRIBILD

+ GILEAD SCIENCES INC 150MG; 150MG; 200MG; 300MG N203100 001 Aug 27, 2012

COBIMETINIB FUMARATE

TABLET; ORAL

COTELLIC

+ GENENTECH INC EQ 20MG BASE N206192 001 Nov 10, 2015

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATEAA VINTAGE 10MG/5ML; 5MG/5ML; 6.25MG/5ML A040660 001 Dec 07, 2006PROMETH VC W/ CODEINEAA + ACTAVIS MID ATLANTIC 10MG/5ML; 5MG/5ML; 6.25MG/5ML A088764 001 Oct 31, 1984PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATEAA HI-TECH PHARMA CO 10MG/5ML; 5MG/5ML; 6.25MG/5ML A040674 001 Dec 23, 2014PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATEAA AMNEAL PHARMS 10MG/5ML; 5MG/5ML; 6.25MG/5ML A200963 001 Aug 26, 2015CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATEAA + ACTAVIS MID ATLANTIC 10MG/5ML; 6.25MG/5ML A088763 001 Oct 31, 1984AA AMNEAL PHARMS 10MG/5ML; 6.25MG/5ML A200894 001 Apr 24, 2013AA HI TECH PHARMA 10MG/5ML; 6.25MG/5ML A040151 001 Aug 26, 1997AA NOSTRUM LABS INC 10MG/5ML; 6.25MG/5ML A090180 001 Mar 17, 2010AA TRIS PHARMA INC 10MG/5ML; 6.25MG/5ML A200386 001 Jun 29, 2012AA WOCKHARDT 10MG/5ML; 6.25MG/5ML A088875 001 Dec 17, 1984PROMETHAZINE WITH CODEINEAA VINTAGE 10MG/5ML; 6.25MG/5ML A040650 001 Jan 31, 2006CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

TRIACIN-C

+ STI PHARMA LLC 10MG/5ML; 30MG/5ML; 1.25MG/5ML A088704 001 Mar 22, 1985

CODEINE SULFATE

TABLET; ORAL

CODEINE SULFATEAB LANNETT HOLDINGS INC 15MG A203046 001 Jun 13, 2014AB 30MG A203046 002 Jun 13, 2014AB 60MG A203046 003 Jun 13, 2014AB ROXANE 15MG N022402 001 Jul 16, 2009AB 30MG N022402 002 Jul 16, 2009AB + 60MG N022402 003 Jul 16, 2009COLCHICINE

CAPSULE; ORAL

MITIGARE

+ HIKMA INTL PHARMS 0.6MG N204820 001 Sep 26, 2014

TABLET; ORAL

COLCRYS

+ TAKEDA PHARMS USA 0.6MG N022352 001 Jul 29, 2009

PRESCRIPTION DRUG PRODUCT LISTCOLCHICINE; PROBENECID

TABLET; ORAL

COL-PROBENECID

AB	+ WATSON LABS	0.5MG;500MG	A084279 001	
	<u>PROBENECID AND COLCHICINE</u>			
AB	INGENUS PHARMS NJ	0.5MG;500MG	A040618 001	May 13, 2008

COLESEVELAM HYDROCHLORIDE

FOR SUSPENSION; ORAL

WELCHOL

	DAIICHI SANKYO	1.875GM/PACKET	N022362 001	Oct 02, 2009
+		3.75GM/PACKET	N022362 002	Oct 02, 2009

TABLET; ORAL

WELCHOL

+	DAIICHI SANKYO	625MG	N021176 001	May 26, 2000
---	----------------	-------	-------------	--------------

COLESTIPOL HYDROCHLORIDE

GRANULE; ORAL

COLESTID

AB	PHARMACIA AND UPJOHN	5GM/SCOOPFUL	N017563 003	Sep 22, 1995
AB	+	5GM/PACKET	N017563 004	Sep 22, 1995
	<u>COLESTIPOL HYDROCHLORIDE</u>			
AB	IMPAX LABS	5GM/SCOOPFUL	A077277 001	May 02, 2006
AB		5GM/PACKET	A077277 002	May 02, 2006
	FLAVORED COLESTID			
	PHARMACIA AND UPJOHN	5GM/PACKET	N017563 001	
		5GM/SCOOPFUL	N017563 002	

TABLET; ORAL

COLESTID

AB	+ PHARMACIA AND UPJOHN	1GM	N020222 001	Jul 19, 1994
	<u>COLESTIPOL HYDROCHLORIDE</u>			
AB	IMPAX LABS	1GM	A077510 001	Oct 24, 2006

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLISTIMETHATE SODIUM

AP	EMCURE PHARMS LTD	EQ 150MG BASE/VIAL	A202359 001	Sep 28, 2012
AP	FRESENIUS KABI USA	EQ 150MG BASE/VIAL	A065364 001	Apr 17, 2008
AP	PADDOCK LLC	EQ 150MG BASE/VIAL	A065177 001	Mar 19, 2004
AP	SAGENT PHARMS	EQ 150MG BASE/VIAL	A201365 001	Feb 19, 2014
AP	X GEN PHARMS	EQ 150MG BASE/VIAL	A064216 001	Feb 26, 1999
AP	XELLIA PHARMS APS	EQ 150MG BASE/VIAL	A205356 001	May 29, 2015

COLY-MYCIN M

AP	+ PAR STERILE PRODUCTS	EQ 150MG BASE/VIAL	N050108 002	
-----------	------------------------	---------------------------	--------------------	--

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS; OTIC

COLY-MYCIN S

+	ENDO PHARMS INC	EQ 3MG BASE/ML;10MG/ML;EQ 3.3MG BASE/ML;0.5MG/ML	N050356 001	
---	-----------------	---	-------------	--

CONIVAPTAN HYDROCHLORIDE

INJECTABLE; IV (INFUSION)

VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

+	CUMBERLAND PHARMS	20MG/100ML (0.2MG/ML)	N021697 002	Oct 08, 2008
---	-------------------	-----------------------	-------------	--------------

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE

PARAGARD T 380A

+	TEVA WOMENS	309MG/COPPER	N018680 001	Nov 15, 1984
---	-------------	--------------	-------------	--------------

CORTICORELIN OVINE TRIFLUATATE

INJECTABLE; INJECTION

ACTHREL

+	FERRING	EQ 0.1MG BASE/VIAL	N020162 001	May 23, 1996
---	---------	--------------------	-------------	--------------

CORTICOTROPIN

INJECTABLE; INJECTION

H.P. ACTHAR GEL

+	MALLINCKRODT ARD	80 UNITS/ML	N008372 008	
---	------------------	-------------	-------------	--

PRESCRIPTION DRUG PRODUCT LIST

CORTISONE ACETATE

TABLET; ORAL

CORTISONE ACETATE

+ HIKMA INTL PHARMS 25MG

A080776 002

COSYNTROPIN

INJECTABLE; INJECTION

CORTROSYNAP + AMPHASTAR PHARMS INC 0.25MG/VIALN016750 001COSYNTROPINAP MYLAN INSTITUTIONAL 0.25MG/VIALA090574 001 Dec 17, 2009AP SANDOZ 0.25MG/VIALA202147 001 Jun 29, 2012CRISABOROLE

OINTMENT; TOPICAL

EUCRISA

+ ANACOR PHARMS INC 2%

N207695 001 Dec 14, 2016

CRIZOTINIB

CAPSULE; ORAL

XALKORI

PF PRISM CV 200MG

N202570 001 Aug 26, 2011

+ 250MG

N202570 002 Aug 26, 2011

CROFELEMER

TABLET, DELAYED RELEASE; ORAL

FULYZAQ

+ NAPO PHARMS INC 125MG

N202292 001 Dec 31, 2012

CROMOLYN SODIUM

CONCENTRATE; ORAL

CROMOLYN SODIUMAA MICRO LABS LTD INDIA 100MG/5MLA202745 001 Apr 04, 2013AA PACK PHARMS LLC 100MG/5MLA202583 001 Oct 27, 2011GASTROCROMAA + MEDA PHARMS 100MG/5MLN020479 001 Feb 29, 1996

SOLUTION; INHALATION

CROMOLYN SODIUMAN BAUSCH AND LOMB 10MG/MLA075585 001 Dec 21, 2000AN MYLAN SPECLT 10MG/MLA074209 001 Apr 26, 1994AN + TEVA PHARMS 10MG/MLA075271 001 Jan 18, 2000AN WOCKHARDT 10MG/MLA075346 001 Oct 25, 1999

SOLUTION/DROPS; OPHTHALMIC

CROLOMAT BAUSCH AND LOMB 4%A074443 001 Jan 30, 1995CROMOLYN SODIUMAT + AKORN 4%A074706 001 Apr 29, 1998AT ALCON 4%A075282 001 Jun 16, 1999CROTAMITON

CREAM; TOPICAL

EURAX

+ RANBAXY 10%

N006927 001

LOTION; TOPICAL

CROTANAT MARNEL PHARMS 10%A087204 001EURAXAT + RANBAXY 10%N009112 003CUPRIC CHLORIDE

INJECTABLE; INJECTION

CUPRIC CHLORIDE IN PLASTIC CONTAINER

+ HOSPIRA EQ 0.4MG COPPER/ML

N018960 001 Jun 26, 1986

CYANOCOBALAMIN

INJECTABLE; INJECTION

CYANOCOBALAMINAP + LUITPOLD 1MG/MLA080737 001AP SOMERSET THERAPS LLC 1MG/MLA206503 001 Dec 11, 2015AP WEST-WARD PHARMS INT 1MG/MLA080515 002VIBISONEAP + FRESENIUS KABI USA 1MG/MLA080557 003

SPRAY, METERED; NASAL

NASCOBAL

+ ENDO PHARMS INC 0.5MG/SPRAY

N021642 001 Jan 31, 2005

PRESCRIPTION DRUG PRODUCT LIST

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

AMRIX

TEVA PHARMS INTL

15MG

N021777 001 Feb 01, 2007

+

30MG

N021777 002 Feb 01, 2007

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

<u>AB</u>	ACTAVIS LABS FL INC	<u>5MG</u>	<u>A071611 002</u>	Feb 03, 2006
<u>AB</u>		<u>7.5MG</u>	<u>A071611 003</u>	Feb 03, 2006
<u>AB</u>		<u>10MG</u>	<u>A071611 001</u>	May 03, 1989
<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A078643 001</u>	Sep 26, 2008
<u>AB</u>		<u>10MG</u>	<u>A078643 002</u>	Sep 26, 2008
<u>AB</u>	FRONTIDA BIOPHARM	<u>5MG</u>	<u>A073541 002</u>	Apr 06, 2006
<u>AB</u>		<u>10MG</u>	<u>A073541 001</u>	May 23, 1995
<u>AB</u>	INVAGEN PHARMS	<u>5MG</u>	<u>A090478 001</u>	Jul 23, 2010
<u>AB</u>		<u>10MG</u>	<u>A090478 002</u>	Jul 23, 2010
<u>AB</u>	JUBILANT CADISTA	<u>5MG</u>	<u>A077563 001</u>	Apr 19, 2006
<u>AB</u>		<u>10MG</u>	<u>A077563 002</u>	Apr 19, 2006
<u>AB</u>	KVK TECH	<u>5MG</u>	<u>A078048 001</u>	Feb 28, 2011
<u>AB</u>		<u>10MG</u>	<u>A078048 002</u>	Feb 28, 2011
<u>AB</u>	MYLAN PHARMS INC	<u>5MG</u>	<u>A073144 002</u>	Feb 03, 2006
<u>AB</u>		<u>7.5MG</u>	<u>A073144 003</u>	Mar 25, 2013
<u>AB</u>	+	<u>10MG</u>	<u>A073144 001</u>	May 30, 1991
<u>AB</u>	ORIT LABS LLC	<u>5MG</u>	<u>A078218 002</u>	Jun 19, 2015
<u>AB</u>		<u>10MG</u>	<u>A078218 001</u>	Apr 18, 2008
<u>AB</u>	OXFORD PHARMS	<u>10MG</u>	<u>A077209 001</u>	Oct 04, 2005
<u>AB</u>	PLIVA	<u>10MG</u>	<u>A074421 001</u>	Sep 29, 1995
<u>AB</u>	SUN PHARM INDS LTD	<u>5MG</u>	<u>A078722 001</u>	May 12, 2008
<u>AB</u>		<u>7.5MG</u>	<u>A078722 002</u>	May 12, 2008
<u>AB</u>		<u>10MG</u>	<u>A078722 003</u>	May 12, 2008
<u>AB</u>	VINTAGE PHARMS	<u>5MG</u>	<u>A077797 001</u>	Feb 28, 2007
<u>AB</u>		<u>10MG</u>	<u>A077797 002</u>	Feb 28, 2007

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AKPENTOLATE

<u>AT</u>	AKORN	<u>1%</u>	<u>A040164 001</u>	Jan 13, 1997
-----------	-------	-----------	--------------------	--------------

CYCLOGYL

<u>AT</u>	+	NOVARTIS PHARMS CORP	<u>0.5%</u>	<u>A084109 001</u>
-----------	---	----------------------	-------------	--------------------

<u>AT</u>	+		<u>1%</u>	<u>A084110 001</u>
-----------	---	--	-----------	--------------------

CYCLOPENTOLATE HYDROCHLORIDE

<u>AT</u>	AKORN INC	<u>0.5%</u>	<u>A205937 001</u>	Dec 09, 2015
-----------	-----------	-------------	--------------------	--------------

PENTOLAIR

<u>AT</u>	BAUSCH AND LOMB	<u>1%</u>	<u>A040075 001</u>	Apr 29, 1994
-----------	-----------------	-----------	--------------------	--------------

CYCLOGYL

	+	NOVARTIS PHARMS CORP	<u>2%</u>	A084108 001
--	---	----------------------	-----------	-------------

CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CYCLOMYDRIL

	+	NOVARTIS PHARMS CORP	<u>0.2%; 1%</u>	A084300 001
--	---	----------------------	-----------------	-------------

CYCLOPHOSPHAMIDE

CAPSULE; ORAL

CYCLOPHOSPHAMIDE

ROXANE

25MG

N203856 001 Sep 16, 2013

+

50MG

N203856 002 Sep 16, 2013

INJECTABLE; INJECTION

CYCLOPHOSPHAMIDE

<u>AP</u>	+	BAXTER HLTHCARE	<u>500MG/VIAL</u>	<u>A040745 001</u>	May 21, 2008
-----------	---	-----------------	-------------------	--------------------	--------------

<u>AP</u>	+		<u>1GM/VIAL</u>	<u>A040745 002</u>	May 21, 2008
-----------	---	--	-----------------	--------------------	--------------

<u>AP</u>	+		<u>2GM/VIAL</u>	<u>A040745 003</u>	May 21, 2008
-----------	---	--	-----------------	--------------------	--------------

<u>AP</u>	JIANGSU HENGRUI MED	<u>500MG/VIAL</u>	<u>A204555 001</u>	Oct 31, 2014
-----------	---------------------	-------------------	--------------------	--------------

<u>AP</u>		<u>1GM/VIAL</u>	<u>A204555 002</u>	Oct 31, 2014
-----------	--	-----------------	--------------------	--------------

<u>AP</u>		<u>2GM/VIAL</u>	<u>A204555 003</u>	Oct 31, 2014
-----------	--	-----------------	--------------------	--------------

CYCLOSERINE

CAPSULE; ORAL

SEROMYCIN

+ PURDUE GMP

250MG

A060593 001

PRESCRIPTION DRUG PRODUCT LIST

CYCLOSPORINE

CAPSULE; ORAL

CYCLOSPORINE

<u>AB1</u>	IVAX SUB TEVA PHARMS	<u>25MG</u>	<u>A065110</u>	<u>003</u>	Mar 29, 2005
<u>AB1</u>		<u>50MG</u>	<u>A065110</u>	<u>001</u>	Mar 29, 2005
<u>AB1</u>		<u>100MG</u>	<u>A065110</u>	<u>002</u>	Mar 29, 2005
<u>AB1</u>	MAYNE PHARMA	<u>25MG</u>	<u>A065044</u>	<u>002</u>	Dec 20, 2000
<u>AB1</u>		<u>100MG</u>	<u>A065044</u>	<u>001</u>	Dec 20, 2000
<u>AB1</u>	SANDOZ	<u>25MG</u>	<u>A065017</u>	<u>002</u>	Jan 13, 2000
<u>AB1</u>		<u>100MG</u>	<u>A065017</u>	<u>001</u>	Jan 13, 2000

GENGRAF

<u>AB1</u>	ABBVIE	<u>25MG</u>	<u>A065003</u>	<u>001</u>	May 12, 2000
<u>AB1</u>		<u>50MG</u>	<u>A065003</u>	<u>002</u>	May 12, 2000
<u>AB1</u>		<u>100MG</u>	<u>A065003</u>	<u>003</u>	May 12, 2000

NEORAL

<u>AB1</u>	NOVARTIS	<u>25MG</u>	<u>N050715</u>	<u>001</u>	Jul 14, 1995
<u>AB1</u>	+	<u>100MG</u>	<u>N050715</u>	<u>002</u>	Jul 14, 1995

CYCLOSPORINE

<u>AB2</u>	APOTEX	<u>25MG</u>	<u>A065040</u>	<u>001</u>	May 09, 2002
<u>AB2</u>		<u>100MG</u>	<u>A065040</u>	<u>002</u>	May 09, 2002

SANDIMMUNE

<u>AB2</u>	NOVARTIS	<u>25MG</u>	<u>N050625</u>	<u>001</u>	Mar 02, 1990
<u>AB2</u>	+	<u>100MG</u>	<u>N050625</u>	<u>002</u>	Mar 02, 1990
BX		50MG	N050625	003	Nov 23, 1992

EMULSION; OPHTHALMIC

RESTASIS

+ ALLERGAN 0.05% N050790 001 Dec 23, 2002

RESTASIS MULTIDOSE

+ ALLERGAN 0.05% N050790 002 Oct 27, 2016

INJECTABLE; INJECTION

CYCLOSPORINE

<u>AP</u>	LUITPOLD	<u>50MG/ML</u>	<u>A065151</u>	<u>001</u>	Oct 07, 2003
<u>AP</u>	WEST-WARD PHARMS INT	<u>50MG/ML</u>	<u>A065004</u>	<u>001</u>	Oct 29, 1999

SANDIMMUNE

<u>AP</u>	+	<u>NOVARTIS</u>	<u>50MG/ML</u>	<u>N050573</u>	<u>001</u>	Nov 14, 1983
-----------	---	-----------------	----------------	----------------	------------	--------------

SOLUTION; ORAL

CYCLOSPORINE

<u>AB1</u>	ABBVIE	<u>100MG/ML</u>	<u>A065025</u>	<u>001</u>	Mar 03, 2000
<u>AB1</u>	IVAX SUB TEVA PHARMS	<u>100MG/ML</u>	<u>A065078</u>	<u>001</u>	Mar 25, 2005
<u>AB1</u>	MAYNE PHARMA	<u>100MG/ML</u>	<u>A065054</u>	<u>001</u>	Dec 18, 2001

NEORAL

<u>AB1</u>	+	<u>NOVARTIS</u>	<u>100MG/ML</u>	<u>N050716</u>	<u>001</u>	Jul 14, 1995
------------	---	-----------------	-----------------	----------------	------------	--------------

CYCLOSPORINE

<u>AB2</u>	WOCKHARDT	<u>100MG/ML</u>	<u>A065133</u>	<u>001</u>	Sep 17, 2004
------------	-----------	-----------------	----------------	------------	--------------

SANDIMMUNE

<u>AB2</u>	+	<u>NOVARTIS</u>	<u>100MG/ML</u>	<u>N050574</u>	<u>001</u>	Nov 14, 1983
------------	---	-----------------	-----------------	----------------	------------	--------------

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

CYPROHEPTADINE HYDROCHLORIDE

<u>AA</u>	+	<u>LYNE</u>	<u>2MG/5ML</u>	<u>A040668</u>	<u>001</u>	Jun 28, 2006
<u>AA</u>		<u>PATRIN PHARMA INC</u>	<u>2MG/5ML</u>	<u>A204823</u>	<u>001</u>	Dec 27, 2016
<u>AA</u>		<u>PHARM ASSOC</u>	<u>2MG/5ML</u>	<u>A091295</u>	<u>001</u>	Mar 28, 2013

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

<u>AA</u>		<u>APEX PHARMS INC</u>	<u>4MG</u>	<u>A207783</u>	<u>001</u>	Dec 29, 2016
<u>AA</u>		<u>APPCO PHARMA LLC</u>	<u>4MG</u>	<u>A206553</u>	<u>001</u>	Nov 29, 2016
<u>AA</u>		<u>COREPHARMA</u>	<u>4MG</u>	<u>A040537</u>	<u>001</u>	Sep 30, 2003
<u>AA</u>		<u>INGENUS PHARMS NJ</u>	<u>4MG</u>	<u>A205087</u>	<u>001</u>	Sep 23, 2015
<u>AA</u>	+	<u>IVAX SUB TEVA PHARMS</u>	<u>4MG</u>	<u>A087056</u>	<u>001</u>	
<u>AA</u>		<u>PAR PHARM</u>	<u>4MG</u>	<u>A087129</u>	<u>001</u>	
<u>AA</u>		<u>STASON PHARMS</u>	<u>4MG</u>	<u>A040644</u>	<u>001</u>	May 30, 2006

CYSTEAMINE BITARTRATE

CAPSULE; ORAL

CYSTAGON

MYLAN EQ 50MG BASE N020392 001 Aug 15, 1994

+ EQ 150MG BASE N020392 002 Aug 15, 1994

CAPSULE, DELAYED RELEASE; ORAL

PROCYSBI

RAPTOR INC EQ 25MG BASE N203389 001 Apr 30, 2013

+ EQ 75MG BASE N203389 002 Apr 30, 2013

PRESCRIPTION DRUG PRODUCT LIST

CYSTEAMINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CYSTARAN

+ SIGMA TAU

EQ 0.44% BASE

N200740 001 Oct 02, 2012

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

<u>AP</u>	+	FRESENIUS KABI USA	<u>100MG/ML</u>	<u>A076512</u>	<u>001</u>	Jan 15, 2004
<u>AP</u>	+	HOSPIRA	<u>20MG/ML</u>	<u>A071868</u>	<u>001</u>	Jun 04, 1990
<u>AP</u>	+		<u>20MG/ML</u>	<u>A072168</u>	<u>001</u>	Aug 31, 1990
<u>AP</u>	+		<u>20MG/ML</u>	<u>A072945</u>	<u>001</u>	Feb 28, 1994
<u>AP</u>			<u>100MG/ML</u>	<u>A075383</u>	<u>001</u>	Nov 22, 1999
<u>AP</u>		MYLAN LABS LTD	<u>20MG/ML</u>	<u>A200914</u>	<u>001</u>	Dec 13, 2011
<u>AP</u>			<u>100MG/ML</u>	<u>A201784</u>	<u>001</u>	Jan 30, 2012
<u>AP</u>		MYLAN PHARMS INC	<u>20MG/ML</u>	<u>A200915</u>	<u>001</u>	Dec 13, 2011
<u>AP</u>			<u>20MG/ML</u>	<u>A200916</u>	<u>001</u>	Dec 13, 2011
<u>AP</u>		WEST-WARD PHARMS INT	<u>100MG/VIAL</u>	<u>A071471</u>	<u>001</u>	Aug 02, 1989
<u>AP</u>			<u>500MG/VIAL</u>	<u>A071472</u>	<u>001</u>	Aug 02, 1989
<u>AP</u>			<u>1GM/VIAL</u>	<u>A074245</u>	<u>001</u>	Aug 31, 1994
<u>AP</u>			<u>2GM/VIAL</u>	<u>A074245</u>	<u>002</u>	Aug 31, 1994

CYTOSAR-U

<u>AP</u>		TEVA PHARMS USA	<u>100MG/VIAL</u>	<u>A075206</u>	<u>001</u>	Dec 30, 1998
<u>AP</u>	+		<u>500MG/VIAL</u>	<u>A075206</u>	<u>002</u>	Dec 30, 1998
<u>AP</u>	+		<u>1GM/VIAL</u>	<u>A075206</u>	<u>004</u>	Dec 30, 1998
<u>AP</u>	+		<u>2GM/VIAL</u>	<u>A075206</u>	<u>003</u>	Dec 30, 1998

INJECTABLE, LIPOSOMAL; INJECTION

DEPOCYT

+ PACIRA PHARMS INC

10MG/ML

N021041 001 Apr 01, 1999

DABIGATRAN ETEXILATE MESYLATE

CAPSULE; ORAL

PRADAXA

BOEHRINGER INGELHEIM

EQ 75MG BASE

N022512 001 Oct 19, 2010

EQ 110MG BASE

N022512 003 Nov 20, 2015

+

EQ 150MG BASE

N022512 002 Oct 19, 2010

DABRAFENIB MESYLATE

CAPSULE; ORAL

TAFINLAR

NOVARTIS PHARMS CORP

EQ 50MG BASE

N202806 001 May 29, 2013

+

EQ 75MG BASE

N202806 002 May 29, 2013

DACARBAZINE

INJECTABLE; INJECTION

DACARBAZINE

<u>AP</u>		FRESENIUS KABI USA	<u>100MG/VIAL</u>	<u>A075371</u>	<u>001</u>	Aug 27, 1999
<u>AP</u>			<u>200MG/VIAL</u>	<u>A075371</u>	<u>002</u>	Aug 27, 1999
<u>AP</u>		HOSPIRA	<u>200MG/VIAL</u>	<u>A075940</u>	<u>001</u>	Oct 18, 2001
<u>AP</u>		TEVA PHARMS USA	<u>200MG/VIAL</u>	<u>A075259</u>	<u>002</u>	Aug 27, 1998
<u>AP</u>	+		<u>500MG/VIAL</u>	<u>A075259</u>	<u>001</u>	Sep 22, 2000
<u>AP</u>		WEST-WARD PHARMS INT	<u>200MG/VIAL</u>	<u>A075812</u>	<u>001</u>	Jun 15, 2001
<u>AP</u>			<u>500MG/VIAL</u>	<u>A075812</u>	<u>002</u>	Oct 31, 2002

DTIC-DOME

<u>AP</u>	+	BAYER HLTHCARE	<u>100MG/VIAL</u>	<u>N017575</u>	<u>001</u>	
<u>AP</u>	+		<u>200MG/VIAL</u>	<u>N017575</u>	<u>002</u>	

DACLATASVIR DIHYDROCHLORIDE

TABLET; ORAL

DAKLINZA

BRISTOL-MYERS SQUIBB

EQ 30MG BASE

N206843 001 Jul 24, 2015

+

EQ 60MG BASE

N206843 002 Jul 24, 2015

EQ 90MG BASE

N206843 003 Apr 13, 2016

DACTINOMYCIN

INJECTABLE; INJECTION

COSMEGEN

<u>AP</u>	+	RECORDATI RARE	<u>0.5MG/VIAL</u>	<u>N050682</u>	<u>001</u>	
-----------	---	----------------	-------------------	----------------	------------	--

DACTINOMYCIN

<u>AP</u>		LUITPOLD PHARMS INC	<u>0.5MG/VIAL</u>	<u>A202562</u>	<u>001</u>	Aug 23, 2013
-----------	--	---------------------	-------------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

DALBAVANCIN HYDROCHLORIDE

POWDER; IV (INFUSION)

DALVANCE

+ DURATA THERAPS INTL EQ 500MG BASE/VIAL N021883 001 May 23, 2014

DALFAMPRIDINE

TABLET, EXTENDED RELEASE; ORAL

AMPYRA

+ ACORDA 10MG N022250 001 Jan 22, 2010

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE; IV (INFUSION)

SYNERCID

+ KING PHARMS 350MG/VIAL; 150MG/VIAL N050748 001 Sep 21, 1999

DALTEPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

FRAGMIN

PFIZER INC

2,500IU/0.2ML (12,500IU/ML) N020287 001 Dec 22, 1994

5,000IU/0.2ML (25,000IU/ML) N020287 003 Mar 18, 1996

7,500IU/0.3ML (25,000IU/ML) N020287 005 Apr 04, 2002

10,000IU/ML (10,000IU/ML) N020287 004 Jan 30, 1998

12,500IU/0.5ML (25,000IU/ML) N020287 009 May 01, 2007

15,000IU/0.6ML (25,000IU/ML) N020287 010 May 01, 2007

18,000IU/0.72ML (25,000IU/ML) N020287 011 May 01, 2007

+ 95,000IU/3.8ML (25,000IU/ML) N020287 006 Apr 04, 2002

DANAZOL

CAPSULE; ORAL

DANAZOLAB BARR 50MG A074582 003 May 29, 1998AB 100MG A074582 002 May 29, 1998AB + 200MG A074582 001 Aug 09, 1996AB LANNETT 50MG A077246 002 Apr 19, 2007AB 100MG A077246 003 Apr 19, 2007AB 200MG A077246 001 Sep 28, 2005DANTROLENE SODIUM

CAPSULE; ORAL

DANTRIUMAB PAR STERILE PRODUCTS 25MG N017443 001AB 50MG N017443 003AB + 100MG N017443 002DANTROLENE SODIUMAB ELITE LABS INC 25MG A076686 001 Oct 24, 2005AB 50MG A076686 002 Oct 24, 2005AB 100MG A076686 003 Oct 24, 2005AB IMPAX LABS 25MG A076856 001 Mar 01, 2005AB 50MG A076856 002 Mar 01, 2005AB 100MG A076856 003 Mar 01, 2005

FOR SUSPENSION; INTRAVENOUS

RYANODEX

+ EAGLE PHARMS 250MG/VIAL N205579 001 Jul 22, 2014

INJECTABLE; INJECTION

DANTRIUMAP + PAR STERILE PRODUCTS 20MG/VIAL N018264 001DANTROLENE SODIUMAP MYLAN INSTITUTIONAL 20MG/VIAL A205239 001 Feb 18, 2016REVONTOAP US WORLDMEDS 20MG/VIAL A078378 001 Jul 24, 2007DAPAGLIFLOZIN PROPANEDIOL

TABLET; ORAL

FARXIGA

ASTRAZENECA AB

EQ 5MG BASE N202293 001 Jan 08, 2014

+ EQ 10MG BASE N202293 002 Jan 08, 2014

DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

XIGDUO XR

ASTRAZENECA AB

EQ 5MG BASE; 500MG N205649 001 Oct 29, 2014

EQ 5MG BASE; 1GM N205649 002 Oct 29, 2014

EQ 10MG BASE; 500MG N205649 003 Oct 29, 2014

+ EQ 10MG BASE; 1GM N205649 004 Oct 29, 2014

PRESCRIPTION DRUG PRODUCT LIST

DAPSONE

GEL; TOPICAL

ACZONE

+ ALLERGAN

5%

N021794 001 Jul 07, 2005

+ ALLERGAN INC

7.5%

N207154 001 Feb 24, 2016

TABLET; ORAL

DAPSONEAB ALVOGEN25MGA205429 001 Jan 07, 2016AB100MGA205429 002 Jan 07, 2016AB JACOBUS25MGA086841 001AB +100MGA086842 001AB NORTH CREEK PHARMS25MGA204074 001 May 10, 2016AB100MGA204074 002 May 10, 2016AB NOSTRUM LABS INC25MGA203887 001 May 06, 2016AB100MGA203887 002 May 06, 2016AB PAR PHARM INC25MGA206505 001 Dec 01, 2016AB100MGA206505 002 Dec 01, 2016DAPTOMYCIN

POWDER; INTRAVENOUS

CUBICINAP + CUBIST PHARMS LLC500MG/VIALN021572 002 Sep 12, 2003DAPTOMYCINAP CRANE PHARMS LLC500MG/VIALA206005 001 Jun 15, 2016AP HOSPIRA INC500MG/VIALA202857 001 Sep 12, 2014AP TEVA PARENTERAL500MG/VIALA091039 001 Mar 25, 2016

CUBICIN RF

+ CUBIST PHARMS LLC

500MG/VIAL

N021572 003 Jul 06, 2016

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

DARIFENACIN HYDROBROMIDEAB ANCHEN PHARMSEQ 7.5MG BASEA091190 001 Mar 13, 2015ABEQ 15MG BASEA091190 002 Mar 13, 2015AB AUROBINDO PHARMA LTDEQ 7.5MG BASEA206743 001 Sep 19, 2016ABEQ 15MG BASEA206743 002 Sep 19, 2016AB CIPLA LTDEQ 7.5MG BASEA207664 001 Sep 01, 2016ABEQ 15MG BASEA207664 002 Sep 01, 2016AB JUBILANT GENERICSEQ 7.5MG BASEA205550 001 Oct 12, 2016ABEQ 15MG BASEA205550 002 Oct 12, 2016AB TORRENT PHARMS LTDEQ 7.5MG BASEA205209 001 Nov 17, 2016ABEQ 15MG BASEA205209 002 Nov 17, 2016ENABLEXAB APILEQ 7.5MG BASEN021513 001 Dec 22, 2004AB +EQ 15MG BASEN021513 002 Dec 22, 2004DARUNAVIR ETHANOLATE

SUSPENSION; ORAL

PREZISTA

+ JANSSEN PRODS

EQ 100MG BASE/ML

N202895 001 Dec 16, 2011

TABLET; ORAL

PREZISTA

JANSSEN PRODS

EQ 75MG BASE

N021976 004 Dec 18, 2008

EQ 150MG BASE

N021976 005 Dec 18, 2008

EQ 600MG BASE

N021976 002 Feb 25, 2008

+

EQ 800MG BASE

N021976 006 Nov 09, 2012

DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR

TABLET, TABLET; ORAL

VIEKIRA PAK (COPACKAGED)

+ ABBVIE INC

EQ 250MG BASE, N/A, N/A, N/A;
N/A, 12.5MG, 75MG, 50MG

N206619 001 Dec 19, 2014

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR

TABLET, EXTENDED RELEASE; ORAL

VIEKIRA XR

+ ABBVIE INC

EQ 200MG BASE; 8.33MG; 50MG; 33.33MG

N208624 001 Jul 22, 2016

DASATINIB

TABLET; ORAL

DASATINIBAB APOTEX INC20MGA202103 001 Jun 10, 2016AB50MGA202103 002 Jun 10, 2016AB70MGA202103 003 Jun 10, 2016AB100MGA202103 004 Jun 10, 2016

PRESCRIPTION DRUG PRODUCT LIST

DASATINIB

TABLET; ORAL

SPRYCEL

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>20MG</u>	<u>N021986 001</u>	Jun 28, 2006
<u>AB</u>		<u>50MG</u>	<u>N021986 002</u>	Jun 28, 2006
<u>AB</u>		<u>70MG</u>	<u>N021986 003</u>	Jun 28, 2006
<u>AB</u>	+	<u>100MG</u>	<u>N021986 004</u>	May 30, 2008
		80MG	N021986 005	Oct 28, 2010
		140MG	N021986 006	Oct 28, 2010

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

CERUBIDINE

<u>AP</u>	+	WEST-WARD PHARMS INT	<u>EQ 20MG BASE/VIAL</u>	<u>A064103 001</u>	Feb 03, 1995
-----------	---	----------------------	--------------------------	--------------------	--------------

DAUNORUBICIN HYDROCHLORIDE

<u>AP</u>		FRESENIUS KABI USA	<u>EQ 20MG BASE/VIAL</u>	<u>A065000 001</u>	May 25, 1999
<u>AP</u>		TEVA PHARMS USA	<u>EQ 5MG BASE/ML</u>	<u>A065035 001</u>	Jan 24, 2000
<u>AP</u>	+	WEST-WARD PHARMS INT	<u>EQ 5MG BASE/ML</u>	<u>N050731 001</u>	Jan 30, 1998
		FRESENIUS KABI USA	EQ 5MG BASE/VIAL	A065034 001	Nov 20, 2001

DECITABINE

INJECTABLE; INTRAVENOUS

DACOGEN

<u>AP</u>	+	OTSUKA PHARM CO LTD	<u>50MG/VIAL</u>	<u>N021790 001</u>	May 02, 2006
-----------	---	---------------------	------------------	--------------------	--------------

DECITABINE

<u>AP</u>		DR REDDYS LABS LTD	<u>50MG/VIAL</u>	<u>A203131 001</u>	Jul 11, 2013
<u>AP</u>		SANDOZ INC	<u>50MG/VIAL</u>	<u>A202969 001</u>	Aug 28, 2014

POWDER; INTRAVENOUS

DECITABINE

	+	SUN PHARMA GLOBAL	50MG/VIAL	N205582 001	Jan 28, 2014
--	---	-------------------	-----------	-------------	--------------

DEFERASIROX

TABLET; ORAL

JADENU

		NOVARTIS PHARMS CORP	90MG	N206910 001	Mar 30, 2015
			180MG	N206910 002	Mar 30, 2015
	+		360MG	N206910 003	Mar 30, 2015

TABLET, FOR SUSPENSION; ORAL

DEFERASIROX

<u>AB</u>		ACTAVIS ELIZABETH	<u>125MG</u>	<u>A203560 001</u>	Jan 26, 2016
<u>AB</u>			<u>250MG</u>	<u>A203560 002</u>	Jan 26, 2016
<u>AB</u>			<u>500MG</u>	<u>A203560 003</u>	Jan 26, 2016

EXJADE

<u>AB</u>		NOVARTIS	<u>125MG</u>	<u>N021882 001</u>	Nov 02, 2005
<u>AB</u>			<u>250MG</u>	<u>N021882 002</u>	Nov 02, 2005
<u>AB</u>	+		<u>500MG</u>	<u>N021882 003</u>	Nov 02, 2005

DEFERIPRONE

SOLUTION; ORAL

FERRIPROX

	+	AOPHARMA INC	100MG/ML	N208030 001	Sep 09, 2015
--	---	--------------	----------	-------------	--------------

TABLET; ORAL

FERRIPROX

	+	AOPHARMA INC	500MG	N021825 001	Oct 14, 2011
--	---	--------------	-------	-------------	--------------

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION

DEFEROXAMINE MESYLATE

<u>AP</u>		FRESENIUS KABI USA	<u>500MG/VIAL</u>	<u>A078718 001</u>	Sep 15, 2009
<u>AP</u>			<u>2GM/VIAL</u>	<u>A078718 002</u>	Sep 15, 2009
<u>AP</u>		HOSPIRA	<u>500MG/VIAL</u>	<u>A076019 001</u>	Mar 17, 2004
<u>AP</u>			<u>2GM/VIAL</u>	<u>A076019 002</u>	Mar 17, 2004
<u>AP</u>		WEST-WARD PHARMS INT	<u>500MG/VIAL</u>	<u>A078086 001</u>	May 30, 2007
<u>AP</u>			<u>2GM/VIAL</u>	<u>A078086 002</u>	May 30, 2007

DESFERAL

<u>AP</u>	+	NOVARTIS	<u>500MG/VIAL</u>	<u>N016267 001</u>	
<u>AP</u>	+		<u>2GM/VIAL</u>	<u>N016267 002</u>	May 25, 2000

DEFIBROTIDE SODIUM

SOLUTION; IV (INFUSION)

DEFITELIO

	+	JAZZ PHARMS INC	200MG/2.5ML (80MG/ML)	N208114 001	Mar 30, 2016
--	---	-----------------	-----------------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

DEGARELIX ACETATE

POWDER; SUBCUTANEOUS

FIRMAGON

FERRING

EQ 80MG BASE/VIAL

N022201 001 Dec 24, 2008

+

EQ 120MG BASE/VIAL

N022201 002 Dec 24, 2008

DELAVIDINE MESYLATE

TABLET; ORAL

RESCRIPTOR

VIIV HLTHCARE

100MG

N020705 001 Apr 04, 1997

+

200MG

N020705 002 Jul 14, 1999

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DEMECLOCYCLINE HYDROCHLORIDEAB AKORN150MGA065389 001 Dec 01, 2008AB300MGA065389 002 Dec 01, 2008AB AMNEAL PHARM150MGA065425 001 Feb 27, 2008AB +300MGA065425 002 Feb 27, 2008AB BARR150MGA065171 001 Dec 13, 2004AB300MGA065171 002 Dec 13, 2004AB EPIC PHARMA LLC150MGA065447 001 Aug 18, 2015AB300MGA065447 002 Aug 18, 2015DEOXYCHOLIC ACID

SOLUTION; SUBCUTANEOUS

KYBELLA

+ KYTHERA BIOPHARMS

20MG/2ML (10MG/ML)

N206333 001 Apr 29, 2015

DESLURANE

LIQUID; INHALATION

SUPRANE

+ BAXTER HLTHCARE

99.9%

N020118 001 Sep 18, 1992

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDEAB ACTAVIS TOTOWA10MGA074430 001 Feb 09, 1996AB25MGA071601 001 Jun 05, 1987AB50MGA071588 001 Jun 05, 1987AB75MGA071602 001 Oct 05, 1987AB100MGA071766 001 Oct 05, 1987AB150MGA074430 002 Feb 09, 1996AB AMNEAL PHARMS CO10MGA208105 001 Mar 17, 2016AB25MGA208105 002 Mar 17, 2016AB50MGA208105 003 Mar 17, 2016AB75MGA208105 004 Mar 17, 2016AB100MGA208105 005 Mar 17, 2016AB150MGA208105 006 Mar 17, 2016AB COREPHARMA10MGA205153 001 Oct 28, 2016AB25MGA205153 002 Oct 28, 2016AB50MGA205153 003 Oct 28, 2016AB75MGA205153 004 Oct 28, 2016AB100MGA205153 005 Oct 28, 2016AB150MGA205153 006 Oct 28, 2016AB HERITAGE PHARMS INC10MGA207433 001 May 05, 2016AB25MGA207433 002 May 05, 2016AB50MGA207433 003 May 05, 2016AB75MGA207433 004 May 05, 2016AB100MGA207433 005 May 05, 2016AB150MGA207433 006 May 05, 2016AB SANDOZ10MGA072099 001 May 24, 1988AB25MGA072100 001 May 24, 1988AB50MGA072101 001 May 24, 1988AB75MGA072102 001 Jun 20, 1988AB100MGA072103 001 Jun 20, 1988AB150MGA072104 001 Jun 20, 1988NORPRAMINAB US PHARM HOLDINGS10MGN014399 007 Feb 11, 1982AB25MGN014399 001AB50MGN014399 003AB75MGN014399 004AB +100MGN014399 005AB150MGN014399 006

PRESCRIPTION DRUG PRODUCT LIST

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

ANI PHARMS INC

25MG

A071803 002 Dec 08, 1987

50MG

A071803 003 Dec 08, 1987

75MG

A071803 004 Dec 08, 1987

150MG

A071803 005 May 29, 1997

DESIRUDIN RECOMBINANT

INJECTABLE; SUBCUTANEOUS

IPRIVASK

+ VALEANT PHARMS NORTH

15MG/VIAL

N021271 001 Apr 04, 2003

DESLORATADINE

SOLUTION; ORAL

CLARINEXAA + MERCK SHARP DOHME0.5MG/MLN021300 001 Sep 01, 2004DESLORATADINEAA TARO0.5MG/MLA202936 001 May 26, 2016AA TARO PHARM INDS0.5MG/MLA202592 001 Jun 30, 2015

TABLET; ORAL

CLARINEXAB + MERCK SHARP DOHME5MGN021165 001 Dec 21, 2001DESLORATADINEAB BELCHER PHARMS5MGA078355 001 Apr 19, 2012AB DR REDDYS LABS LTD5MGA078365 001 Mar 08, 2011AB LUPIN PHARMS5MGA078352 001 Oct 25, 2010AB MYLAN PHARMS INC5MGA078351 001 Feb 10, 2012AB ORCHID HLTHCARE5MGA078357 001 Feb 19, 2010AB FERRIGO R AND D5MGA078361 001 Dec 22, 2011AB SANDOZ5MGA078364 001 Dec 03, 2010AB SUN PHARM INDS5MGA078359 001 Nov 16, 2010

TABLET, ORALLY DISINTEGRATING; ORAL

CLARINEXAB MERCK SHARP DOHME2.5MGN021312 002 Jul 14, 2005AB +5MGN021312 001 Jun 26, 2002DESLORATADINEAB REDDYS2.5MGA078367 001 Jul 12, 2010AB5MGA078367 002 Jul 12, 2010DESLORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARINEX D 24 HOURAB + MERCK SHARP DOHME5MG;240MGN021605 001 Mar 03, 2005DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOURAB DR REDDYS LABS LTD5MG;240MGA078366 001 Apr 26, 2011

CLARINEX-D 12 HOUR

+ MERCK SHARP DOHME

2.5MG;120MG

N021313 001 Feb 01, 2006

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

DDAVPAP + FERRING PHARMS INC0.004MG/MLN018938 001 Mar 30, 1984DESMOPRESSIN ACETATEAP HOSPIRA0.004MG/MLA075220 001 Aug 28, 2000AP SUN PHARM INDS LTD0.004MG/MLA091280 001 Jan 25, 2013AP TEVA PHARMS USA0.004MG/MLA074888 001 Oct 15, 1997

SOLUTION; NASAL

DDAVPAB + FERRING PHARMS INC0.01%N017922 001DESMOPRESSIN ACETATEAB SUN PHARM INDS0.01%A077212 001 Apr 12, 2012

SPRAY, METERED; NASAL

DDAVP (NEEDS NO REFRIGERATION)AB + FERRING PHARMS INC0.01MG/SPRAYN017922 003 Aug 07, 1996DESMOPRESSIN ACETATEAB + BAUSCH AND LOMB0.01MG/SPRAYA074830 001 Jan 25, 1999DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)AB APOTEX INC0.01MG/SPRAYA076703 001 Jan 27, 2005AB SUN PHARMA GLOBAL0.01MG/SPRAYA078271 001 Dec 23, 2013MINIRINAB + FERRING0.01MG/SPRAYN021333 001 Sep 16, 2002

STIMATE (NEEDS NO REFRIGERATION)

+ CSL BEHRING

0.15MG/SPRAY

N020355 002 Oct 24, 2007

PRESCRIPTION DRUG PRODUCT LIST

DESMOPRESSIN ACETATE

TABLET; ORAL

DDAVP

<u>AB</u>	FERRING PHARMS INC	<u>0.1MG</u>	<u>N019955 001</u>	Sep 06, 1995
<u>AB</u>	+	<u>0.2MG</u>	<u>N019955 002</u>	Sep 06, 1995

DESMOPRESSIN ACETATE

<u>AB</u>	ACTAVIS LABS FL INC	<u>0.1MG</u>	<u>A076470 001</u>	Jul 01, 2005
<u>AB</u>		<u>0.2MG</u>	<u>A076470 002</u>	Jul 01, 2005
<u>AB</u>	APOTEX INC	<u>0.1MG</u>	<u>A077414 001</u>	Mar 07, 2006
<u>AB</u>		<u>0.2MG</u>	<u>A077414 002</u>	Mar 07, 2006
<u>AB</u>	GLENMARK PHARMS LTD	<u>0.1MG</u>	<u>A201831 001</u>	May 28, 2015
<u>AB</u>		<u>0.2MG</u>	<u>A201831 002</u>	May 28, 2015
<u>AB</u>	IMPAX LABS INC	<u>0.1MG</u>	<u>A077122 001</u>	Jan 25, 2006
<u>AB</u>		<u>0.2MG</u>	<u>A077122 002</u>	Jan 25, 2006
<u>AB</u>	MYLAN PHARMS INC	<u>0.1MG</u>	<u>A200653 001</u>	Jun 27, 2014
<u>AB</u>		<u>0.2MG</u>	<u>A200653 002</u>	Jun 27, 2014

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

BEKYREE

<u>AB</u>	LUPIN LTD	<u>0.15MG, N/A; 0.02MG, 0.01MG</u>	<u>A202226 001</u>	Aug 12, 2015
-----------	-----------	------------------------------------	--------------------	--------------

CYCLESSA

<u>AB</u>	+	<u>ASPEN GLOBAL INC</u>	<u>0.1MG, 0.125MG, 0.15MG; 0.025MG, 0.025MG, 0.025MG</u>	<u>N021090 001</u>	Dec 20, 2000
-----------	---	-------------------------	--	--------------------	--------------

DESOGEN

<u>AB</u>	ORGANON USA INC	<u>0.15MG; 0.03MG</u>	<u>N020071 002</u>	Dec 10, 1992
-----------	-----------------	-----------------------	--------------------	--------------

DESOGESTREL AND ETHINYL ESTRADIOL

<u>AB</u>	+	DURAMED PHARMS BARR	<u>0.15MG; 0.03MG</u>	<u>A075256 002</u>	Aug 12, 1999
<u>AB</u>		JAI PHARMA LTD	<u>0.15MG, N/A; 0.02MG, 0.01MG</u>	<u>A202296 001</u>	Aug 30, 2013
<u>AB</u>			<u>0.15MG; 0.03MG</u>	<u>A202085 001</u>	May 20, 2015
<u>AB</u>		MAYNE PHARMA	<u>0.15MG, N/A; 0.02MG, 0.01MG</u>	<u>A076916 001</u>	Dec 29, 2008
<u>AB</u>			<u>0.1MG, 0.125MG, 0.15MG; 0.025MG, 0.025MG, 0.025MG</u>	<u>A077182 001</u>	Jan 24, 2006
<u>AB</u>		NOVAST LABS LTD	<u>0.15MG; 0.03MG</u>	<u>A091234 001</u>	Jul 12, 2013
<u>AB</u>		WATSON LABS	<u>0.15MG; 0.03MG</u>	<u>A076915 001</u>	Jul 29, 2005

EMOQUETTE

<u>AB</u>	VINTAGE PHARMS LLC	<u>0.15MG; 0.03MG</u>	<u>A076675 001</u>	Feb 25, 2011
-----------	--------------------	-----------------------	--------------------	--------------

ENSKYCE

<u>AB</u>	LUPIN LTD	<u>0.15MG; 0.03MG</u>	<u>A201887 001</u>	Mar 07, 2013
-----------	-----------	-----------------------	--------------------	--------------

ISIBLOOM

<u>AB</u>	SANDOZ INC	<u>0.15MG; 0.03MG</u>	<u>A202789 001</u>	Aug 12, 2015
-----------	------------	-----------------------	--------------------	--------------

KARIVA

<u>AB</u>	+	BARR	<u>0.15MG, N/A; 0.02MG, 0.01MG</u>	<u>A075863 001</u>	Apr 05, 2002
-----------	---	------	------------------------------------	--------------------	--------------

KIMIDESS

<u>AB</u>	VINTAGE PHARMS	<u>0.15MG, N/A; 0.02MG, 0.01MG</u>	<u>A076681 001</u>	Apr 30, 2015
-----------	----------------	------------------------------------	--------------------	--------------

PIMTREA

<u>AB</u>	NOVAST LABS LTD	<u>0.15MG, N/A; 0.02MG, 0.01MG</u>	<u>A091247 001</u>	Aug 01, 2013
-----------	-----------------	------------------------------------	--------------------	--------------

VELIVET

<u>AB</u>	DURAMED PHARMS BARR	<u>0.1MG, 0.125MG, 0.15MG; 0.025MG, 0.025MG, 0.025MG</u>	<u>A076455 001</u>	Feb 24, 2004
-----------	---------------------	--	--------------------	--------------

VIORELE

<u>AB</u>	GLENMARK GENERICS	<u>0.15MG, N/A; 0.02MG, 0.01MG</u>	<u>A091346 001</u>	Apr 02, 2012
-----------	-------------------	------------------------------------	--------------------	--------------

VOLNEA

<u>AB</u>	SANDOZ INC	<u>0.15MG, N/A; 0.02MG, 0.01MG</u>	<u>A202689 001</u>	Sep 09, 2016
-----------	------------	------------------------------------	--------------------	--------------

DESONIDE

AEROSOL, FOAM; TOPICAL

VERDESO

+ AQUA PHARMS

0.05%

N021978 001 Sep 19, 2006

CREAM; TOPICAL

DESONIDE

<u>AB</u>	G AND W LABS INC	<u>0.05%</u>	<u>A074027 001</u>	Sep 28, 1992
<u>AB</u>	+	PERRIGO NEW YORK	<u>0.05%</u>	<u>N017010 001</u>
<u>AB</u>	TARO	<u>0.05%</u>	<u>A073548 001</u>	Jun 30, 1992

DESOWEN

<u>AB</u>	GALDERMA LABS LP	<u>0.05%</u>	<u>N019048 001</u>	Dec 14, 1984
-----------	------------------	--------------	--------------------	--------------

GEL; TOPICAL

DESONATE

+ BAYER HLTHCARE

0.05%

N021844 001 Oct 20, 2006

LOTION; TOPICAL

DESONIDE

<u>AB</u>	FOUGERA PHARMS	<u>0.05%</u>	<u>A075860 001</u>	Mar 19, 2002
<u>AB</u>	TARO	<u>0.05%</u>	<u>A202161 001</u>	Oct 31, 2014

PRESCRIPTION DRUG PRODUCT LIST

DESONIDE

LOTION; TOPICAL

DESOWEN

AB	+ GALDERMA LABS LP	<u>0.05%</u>	<u>A072354</u>	<u>001</u>	Jan 24, 1992
-----------	--------------------	--------------	----------------	------------	--------------

OINTMENT; TOPICAL

DESONIDE

AB	FOUGERA PHARMS	<u>0.05%</u>	<u>A075751</u>	<u>001</u>	Mar 12, 2001
AB	+ PERRIGO NEW YORK	<u>0.05%</u>	<u>N017426</u>	<u>001</u>	
AB	TARO	<u>0.05%</u>	<u>A074254</u>	<u>001</u>	Aug 03, 1994

DESOWEN

AB	GALDERMA LABS LP	<u>0.05%</u>	<u>A071425</u>	<u>001</u>	Jun 15, 1988
-----------	------------------	--------------	----------------	------------	--------------

DESOXIMETASONE

CREAM; TOPICAL

DESOXIMETASONE

AB	ACTAVIS MID ATLANTIC	<u>0.25%</u>	<u>A205082</u>	<u>001</u>	Sep 04, 2015
AB	AKORN	<u>0.05%</u>	<u>A203787</u>	<u>001</u>	Jan 06, 2017
AB		<u>0.25%</u>	<u>A203234</u>	<u>001</u>	Jun 12, 2015
AB	FOUGERA PHARMS	<u>0.25%</u>	<u>A078369</u>	<u>001</u>	Jun 29, 2010
AB	LUPIN ATLANTIS	<u>0.05%</u>	<u>A208163</u>	<u>001</u>	Jan 10, 2017
AB		<u>0.25%</u>	<u>A208164</u>	<u>001</u>	Jan 09, 2017
AB	PERRIGO NEW YORK	<u>0.25%</u>	<u>A076510</u>	<u>001</u>	Jul 01, 2003

TOPICORT

AB	+ TARO	<u>0.05%</u>	<u>A073210</u>	<u>001</u>	Nov 30, 1990
AB	+ TARO	<u>0.25%</u>	<u>A073193</u>	<u>001</u>	Nov 30, 1990

GEL; TOPICAL

DESOXIMETASONE

AB	AKORN	<u>0.05%</u>	<u>A090727</u>	<u>001</u>	Mar 10, 2011
AB	GROUPE PARIMA INC	<u>0.05%</u>	<u>A204675</u>	<u>001</u>	Aug 12, 2016
AB	PERRIGO NEW YORK	<u>0.05%</u>	<u>A077552</u>	<u>001</u>	Jan 09, 2006

TOPICORT

AB	+ TARO	<u>0.05%</u>	<u>A074904</u>	<u>001</u>	Jul 14, 1998
-----------	--------	--------------	----------------	------------	--------------

OINTMENT; TOPICAL

DESOXIMETASONE

AB	ACTAVIS MID ATLANTIC	<u>0.25%</u>	<u>A204965</u>	<u>001</u>	Nov 07, 2016
AB	AKORN	<u>0.25%</u>	<u>A201005</u>	<u>001</u>	Apr 24, 2014
AB	FOUGERA PHARMS	<u>0.25%</u>	<u>A078657</u>	<u>001</u>	Sep 28, 2012
AB	G AND W LABS INC	<u>0.25%</u>	<u>A206740</u>	<u>001</u>	Dec 23, 2016
AB	GLENMARK GENERICS	<u>0.25%</u>	<u>A202838</u>	<u>001</u>	Sep 20, 2013
AB	GROUPE PARIMA INC	<u>0.25%</u>	<u>A204272</u>	<u>001</u>	Nov 30, 2016
AB	LUPIN ATLANTIS	<u>0.05%</u>	<u>A208044</u>	<u>001</u>	Dec 12, 2016
AB		<u>0.25%</u>	<u>A208104</u>	<u>001</u>	Dec 01, 2016
AB	NOVEL LABS INC	<u>0.25%</u>	<u>A206792</u>	<u>001</u>	May 10, 2016
AB	PERRIGO ISRAEL	<u>0.25%</u>	<u>A077770</u>	<u>001</u>	Apr 20, 2015
AB	TELIGENT PHARMA INC	<u>0.25%</u>	<u>A208101</u>	<u>001</u>	Feb 25, 2016

TOPICORT

AB	+ TARO	<u>0.25%</u>	<u>A074286</u>	<u>001</u>	Jun 07, 1996
AB	+ TARO PHARMS NORTH	<u>0.05%</u>	<u>N018594</u>	<u>001</u>	Jan 17, 1985

SPRAY; TOPICAL

TOPICORT

+ TARO

0.25%	N204141	001	Apr 11, 2013
-------	---------	-----	--------------

DESVENLAFAXINE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE

BC	+ ALEMBIC PHARMS LTD	50MG	N204150	001	Mar 04, 2013
BC	+ KHEDEZLA	100MG	N204150	002	Mar 04, 2013
BC	OSMOTICA PHARM CORP	50MG	N204683	001	Jul 10, 2013
BC		100MG	N204683	002	Jul 10, 2013

DESVENLAFAXINE FUMARATE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE

+ SUN PHARMA GLOBAL

EQ 50MG BASE

N205583	001	Jan 28, 2014
---------	-----	--------------

+

EQ 100MG BASE

N205583	002	Jan 28, 2014
---------	-----	--------------

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE SUCCINATE

AB	ACTAVIS LABS FL INC	<u>EQ 25MG BASE</u>	<u>A204065</u>	<u>001</u>	Jul 29, 2016
AB		<u>EQ 50MG BASE</u>	<u>A204065</u>	<u>002</u>	Jul 29, 2016
AB		<u>EQ 100MG BASE</u>	<u>A204065</u>	<u>003</u>	Jul 29, 2016
AB	ALEMBIC PHARMS LTD	<u>EQ 50MG BASE</u>	<u>A204003</u>	<u>001</u>	Jun 29, 2015

PRESCRIPTION DRUG PRODUCT LIST

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE SUCCINATE

<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A204003 002</u>	Jun 29, 2015
<u>AB</u>	LUPIN LTD	<u>EQ 50MG BASE</u>	<u>A204172 001</u>	Jun 29, 2015
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A204172 002</u>	Jun 29, 2015
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 50MG BASE</u>	<u>A204095 001</u>	Jun 29, 2015
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A204095 002</u>	Jun 29, 2015
<u>AB</u>	SANDOZ INC	<u>EQ 50MG BASE</u>	<u>A204028 001</u>	Jun 29, 2015
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A204028 002</u>	Jun 29, 2015
<u>AB</u>	WEST-WARD PHARMS INT	<u>EQ 50MG BASE</u>	<u>A204082 001</u>	Feb 16, 2016
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A204083 001</u>	Feb 16, 2016
<u>PRISTIO</u>				
<u>AB</u>	WYETH PHARMS INC	<u>EQ 25MG BASE</u>	<u>N021992 003</u>	Aug 20, 2014
<u>AB</u>	+	<u>EQ 50MG BASE</u>	<u>N021992 001</u>	Feb 29, 2008
<u>AB</u>	+	<u>EQ 100MG BASE</u>	<u>N021992 002</u>	Feb 29, 2008

DEXAMETHASONE

CONCENTRATE;ORAL

DEXAMETHASONE INTENSOL

+ WEST-WARD PHARMS INT 1MG/ML

A088252 001 Sep 01, 1983

ELIXIR;ORAL

DEXAMETHASONE

<u>AA</u>	LYNE	<u>0.5MG/5ML</u>	<u>A090891 001</u>	Jul 12, 2011
<u>AA</u>	+	<u>0.5MG/5ML</u>	<u>A084754 001</u>	
<u>AA</u>	STI PHARMA LLC	<u>0.5MG/5ML</u>	<u>A091188 001</u>	May 11, 2011
<u>AA</u>	VINTAGE PHARMS	<u>0.5MG/5ML</u>	<u>A088254 001</u>	Jul 27, 1983
<u>AA</u>	WOCKHARDT EU OPERATN	<u>0.5MG/5ML</u>		
IMPLANT;INTRAVITREAL				
OZURDEX				
	+ ALLERGAN	0.7MG	N022315 001	Jun 17, 2009
SOLUTION;ORAL				
DEXAMETHASONE				
	+ WEST-WARD PHARMS INT	0.5MG/5ML	A088248 001	Sep 01, 1983
SUSPENSION/DROPS;OPHTHALMIC				
MAXIDEX				
	+ NOVARTIS PHARMS CORP	0.1%	N013422 001	
TABLET;ORAL				

DEXAMETHASONE

<u>AB</u>	ECR	<u>1.5MG</u>	<u>A040700 001</u>	Aug 15, 2008
<u>AB</u>	WEST-WARD PHARMS INT	<u>1.5MG</u>	<u>A084610 001</u>	
BP	PAR PHARM	0.5MG	A088148 001	Apr 28, 1983
BP		0.75MG	A088160 001	Apr 28, 1983
BP		1.5MG	A088237 001	Apr 28, 1983
BP		4MG	A088238 001	Apr 28, 1983
BP	+	6MG	A088481 001	Nov 28, 1983
BP	WEST-WARD PHARMS INT	0.5MG	A084611 001	
BP		0.75MG	A084613 001	
BP		1MG	A088306 001	Sep 15, 1983
BP		2MG	A087916 001	Aug 26, 1982
BP		4MG	A084612 001	
BP	+	6MG	A088316 001	Sep 15, 1983

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 4MG PHOSPHATE/ML</u>	<u>A206781 001</u>	Dec 01, 2015
<u>AP</u>	+	<u>EQ 10MG PHOSPHATE/ML</u>	<u>A087702 001</u>	Sep 07, 1982
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 4MG PHOSPHATE/ML</u>	<u>A084916 001</u>	
<u>AP</u>		<u>EQ 4MG PHOSPHATE/ML</u>	<u>A203129 001</u>	Sep 30, 2015
<u>AP</u>	+	<u>EQ 10MG PHOSPHATE/ML</u>	<u>A040572 001</u>	Apr 22, 2005
<u>AP</u>	+	<u>EQ 4MG PHOSPHATE/ML</u>	<u>A087440 001</u>	Jul 21, 1982
<u>AP</u>	MYLAN LABS LTD	<u>EQ 4MG PHOSPHATE/ML</u>	<u>A040803 001</u>	Aug 29, 2008
<u>AP</u>		<u>EQ 10MG PHOSPHATE/ML</u>	<u>A040802 001</u>	Aug 29, 2008
<u>DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE</u>				
<u>AP</u>	+	<u>EQ 10MG PHOSPHATE/ML</u>	<u>A040491 001</u>	Apr 11, 2003
SOLUTION/DROPS;OPHTHALMIC, OTIC				
<u>DEXAMETHASONE SODIUM PHOSPHATE</u>				
<u>AT</u>	+	<u>EQ 0.1% PHOSPHATE</u>	<u>A088771 001</u>	Jan 16, 1985
<u>AT</u>	BAUSCH AND LOMB	<u>EQ 0.1% PHOSPHATE</u>	<u>A040069 001</u>	Jul 26, 1996

PRESCRIPTION DRUG PRODUCT LIST

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

MAXITROL

AT	+	NOVARTIS PHARMS CORP	<u>0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>N050065</u>	<u>002</u>	
-----------	---	----------------------	--	----------------	------------	--

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

AT		BAUSCH AND LOMB	<u>0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A064063</u>	<u>001</u>	Jul 25, 1994
-----------	--	-----------------	--	----------------	------------	--------------

AT		PERRIGO CO TENNESSEE	<u>0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A062938</u>	<u>001</u>	Jul 31, 1989
-----------	--	----------------------	--	----------------	------------	--------------

SUSPENSION/DROPS;OPHTHALMIC

DEXASPORIN

AT		BAUSCH AND LOMB	<u>0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A064135</u>	<u>001</u>	Sep 13, 1995
-----------	--	-----------------	--	----------------	------------	--------------

MAXITROL

AT		ALCON	<u>0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A062341</u>	<u>001</u>	May 22, 1984
-----------	--	-------	--	----------------	------------	--------------

AT	+	NOVARTIS PHARMS CORP	<u>0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>N050023</u>	<u>002</u>	
-----------	---	----------------------	--	----------------	------------	--

DEXAMETHASONE; TOBRAMYCIN

OINTMENT;OPHTHALMIC

TOBRADEX

+	NOVARTIS PHARMS CORP	0.1%;0.3%				
---	----------------------	-----------	--	--	--	--

N050616	001	Sep 28, 1988
---------	-----	--------------

SUSPENSION/DROPS;OPHTHALMIC

TOBRADEX

AB	+	NOVARTIS PHARMS CORP	<u>0.1%;0.3%</u>	<u>N050592</u>	<u>001</u>	Aug 18, 1988
-----------	---	----------------------	------------------	----------------	------------	--------------

TOBRAMYCIN AND DEXAMETHASONE

AB		BAUSCH AND LOMB	<u>0.1%;0.3%</u>	<u>A064134</u>	<u>001</u>	Oct 27, 1999
-----------	--	-----------------	------------------	----------------	------------	--------------

TOBRADEX ST

+	NOVARTIS PHARMS CORP	0.05%;0.3%				
---	----------------------	------------	--	--	--	--

N050818	001	Feb 13, 2009
---------	-----	--------------

DEXCHLORPHENIRAMINE MALEATE

SYRUP;ORAL

DEXCHLORPHENIRAMINE MALEATE

+	WOCKHARDT	2MG/5ML				
---	-----------	---------	--	--	--	--

A088251	001	Mar 23, 1984
---------	-----	--------------

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE;ORAL

DEXILANT

	TAKEDA PHARMS USA	30MG				
--	-------------------	------	--	--	--	--

N022287	001	Jan 30, 2009
---------	-----	--------------

+		60MG				
---	--	------	--	--	--	--

N022287	002	Jan 30, 2009
---------	-----	--------------

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

DEXILANT SOLUTAB

+	TAKEDA PHARMS USA	30MG				
---	-------------------	------	--	--	--	--

N208056	001	Jan 26, 2016
---------	-----	--------------

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP		ACCORD HLTHCARE INC	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A204023</u>	<u>001</u>	Feb 09, 2016
-----------	--	---------------------	---	----------------	------------	--------------

AP		ACTAVIS INC	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A204686</u>	<u>001</u>	Oct 17, 2016
-----------	--	-------------	---	----------------	------------	--------------

AP		AKORN INC	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A202585</u>	<u>001</u>	Nov 24, 2014
-----------	--	-----------	---	----------------	------------	--------------

AP		AUROBINDO PHARMA LTD	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A205867</u>	<u>001</u>	Mar 17, 2016
-----------	--	----------------------	---	----------------	------------	--------------

AP		FRESENIUS KABI USA	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A201072</u>	<u>001</u>	Sep 18, 2015
-----------	--	--------------------	---	----------------	------------	--------------

AP		MYLAN INSTITUTIONAL	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A202881</u>	<u>001</u>	Aug 18, 2014
-----------	--	---------------------	---	----------------	------------	--------------

AP		PAR STERILE PRODUCTS	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A203972</u>	<u>001</u>	Aug 18, 2014
-----------	--	----------------------	---	----------------	------------	--------------

AP		SANDOZ INC	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A091465</u>	<u>001</u>	Jun 14, 2016
-----------	--	------------	---	----------------	------------	--------------

AP		SUN PHARM INDS INC	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A202126</u>	<u>001</u>	Aug 20, 2015
-----------	--	--------------------	---	----------------	------------	--------------

PRECEDEX

AP	+	HOSPIRA	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>N021038</u>	<u>001</u>	Dec 17, 1999
-----------	---	---------	---	----------------	------------	--------------

+		EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)				
---	--	--------------------------------------	--	--	--	--

N021038	004	Nov 14, 2014
---------	-----	--------------

+		EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)				
---	--	---------------------------------------	--	--	--	--

N021038	002	Mar 13, 2013
---------	-----	--------------

+		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)				
---	--	--	--	--	--	--

N021038	003	Mar 13, 2013
---------	-----	--------------

SOLUTION;IV (INFUSION)

DEXMEDETOMIDINE HYDROCHLORIDE

+	HQ SPCLT PHARMA	EQ 1MG BASE/10ML (EQ 100MCG BASE/ML)				
---	-----------------	--------------------------------------	--	--	--	--

N206628	002	Oct 21, 2015
---------	-----	--------------

		EQ 400MCG BASE/4ML (EQ 100MCG BASE/ML)				
--	--	--	--	--	--	--

N206628	001	Oct 21, 2015
---------	-----	--------------

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB		IMPAX LABS INC	<u>5MG</u>	<u>A079108</u>	<u>001</u>	Aug 05, 2015
-----------	--	----------------	------------	----------------	------------	--------------

AB			<u>10MG</u>	<u>A079108</u>	<u>002</u>	Aug 05, 2015
-----------	--	--	-------------	----------------	------------	--------------

AB			<u>15MG</u>	<u>A079108</u>	<u>003</u>	May 19, 2014
-----------	--	--	-------------	----------------	------------	--------------

AB			<u>20MG</u>	<u>A079108</u>	<u>004</u>	Dec 21, 2015
-----------	--	--	-------------	----------------	------------	--------------

AB			<u>30MG</u>	<u>A079108</u>	<u>005</u>	Nov 21, 2013
-----------	--	--	-------------	----------------	------------	--------------

AB		INTELLIPHARMACEUTICS	<u>15MG</u>	<u>A078992</u>	<u>003</u>	Nov 18, 2013
-----------	--	----------------------	-------------	----------------	------------	--------------

AB			<u>30MG</u>	<u>A078992</u>	<u>004</u>	Nov 18, 2013
-----------	--	--	-------------	----------------	------------	--------------

AB		MYLAN PHARMS INC	<u>5MG</u>	<u>A204266</u>	<u>001</u>	Aug 25, 2015
-----------	--	------------------	------------	----------------	------------	--------------

AB			<u>10MG</u>	<u>A204266</u>	<u>002</u>	Aug 25, 2015
-----------	--	--	-------------	----------------	------------	--------------

AB			<u>15MG</u>	<u>A204266</u>	<u>003</u>	Aug 25, 2015
-----------	--	--	-------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>		<u>20MG</u>	<u>A204266 004</u>	Dec 21, 2015
<u>AB</u>		<u>30MG</u>	<u>A202580 001</u>	Aug 28, 2013
<u>AB</u>		<u>40MG</u>	<u>A204266 007</u>	Aug 25, 2015
<u>AB</u>	PAR PHARM INC	<u>5MG</u>	<u>A202842 001</u>	Nov 30, 2016
<u>AB</u>		<u>10MG</u>	<u>A202842 002</u>	Nov 30, 2016
<u>AB</u>		<u>15MG</u>	<u>A202842 003</u>	Nov 30, 2016
<u>AB</u>		<u>20MG</u>	<u>A202842 004</u>	Nov 30, 2016
<u>AB</u>		<u>25MG</u>	<u>A202842 005</u>	Nov 30, 2016
<u>AB</u>		<u>30MG</u>	<u>A202842 006</u>	Nov 30, 2016
<u>AB</u>		<u>35MG</u>	<u>A202842 007</u>	Nov 30, 2016
<u>AB</u>		<u>40MG</u>	<u>A202842 008</u>	Nov 30, 2016
<u>AB</u>	TEVA PHARMS USA	<u>5MG</u>	<u>A078908 001</u>	Nov 19, 2013
<u>AB</u>		<u>10MG</u>	<u>A078908 002</u>	Nov 19, 2013
<u>AB</u>		<u>15MG</u>	<u>A078908 004</u>	May 19, 2014
<u>AB</u>		<u>20MG</u>	<u>A078908 003</u>	Nov 19, 2013
<u>AB</u>		<u>30MG</u>	<u>A202731 003</u>	May 19, 2014
<u>AB</u>		<u>40MG</u>	<u>A202731 002</u>	Nov 19, 2013

FOCALIN XR

<u>AB</u>	NOVARTIS	<u>5MG</u>	<u>N021802 001</u>	May 26, 2005
<u>AB</u>		<u>10MG</u>	<u>N021802 002</u>	May 26, 2005
<u>AB</u>		<u>15MG</u>	<u>N021802 004</u>	Aug 01, 2006
<u>AB</u>		<u>20MG</u>	<u>N021802 003</u>	May 26, 2005
<u>AB</u>		<u>25MG</u>	<u>N021802 008</u>	Apr 21, 2011
<u>AB</u>		<u>30MG</u>	<u>N021802 005</u>	Oct 23, 2009
<u>AB</u>		<u>35MG</u>	<u>N021802 007</u>	Apr 21, 2011
<u>AB</u>	+	<u>40MG</u>	<u>N021802 006</u>	Aug 11, 2010

TABLET;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>	ABHAI INC	<u>2.5MG</u>	<u>A206931 001</u>	Dec 04, 2015
<u>AB</u>		<u>5MG</u>	<u>A206931 002</u>	Dec 04, 2015
<u>AB</u>		<u>10MG</u>	<u>A206931 003</u>	Dec 04, 2015
<u>AB</u>	NOVEL LABS INC	<u>2.5MG</u>	<u>A204534 001</u>	Dec 04, 2015
<u>AB</u>		<u>5MG</u>	<u>A204534 002</u>	Dec 04, 2015
<u>AB</u>		<u>10MG</u>	<u>A204534 003</u>	Dec 04, 2015
<u>AB</u>	SUN PHARM INDS	<u>2.5MG</u>	<u>A201231 001</u>	Sep 24, 2015
<u>AB</u>		<u>5MG</u>	<u>A201231 002</u>	Sep 24, 2015
<u>AB</u>		<u>10MG</u>	<u>A201231 003</u>	Sep 24, 2015
<u>AB</u>	TEVA PHARMS	<u>2.5MG</u>	<u>A077107 003</u>	Jan 29, 2007
<u>AB</u>		<u>5MG</u>	<u>A077107 001</u>	Jan 29, 2007
<u>AB</u>		<u>10MG</u>	<u>A077107 002</u>	Jan 29, 2007
<u>AB</u>	TRIS PHARMA INC	<u>2.5MG</u>	<u>A207901 001</u>	Aug 26, 2016
<u>AB</u>		<u>5MG</u>	<u>A207901 002</u>	Aug 26, 2016
<u>AB</u>		<u>10MG</u>	<u>A207901 003</u>	Aug 26, 2016

FOCALIN

<u>AB</u>	NOVARTIS	<u>2.5MG</u>	<u>N021278 001</u>	Nov 13, 2001
<u>AB</u>		<u>5MG</u>	<u>N021278 002</u>	Nov 13, 2001
<u>AB</u>	+	<u>10MG</u>	<u>N021278 003</u>	Nov 13, 2001

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE;INJECTION

DEXRAZOXANE HYDROCHLORIDE

<u>AP</u>	GLAND PHARMA LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A207321 001</u>	Nov 28, 2016	
<u>AP</u>	MYLAN INSTITUTIONAL	<u>EQ 250MG BASE/VIAL</u>	<u>A200752 001</u>	Oct 19, 2011	
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A200752 002</u>	Oct 19, 2011	
<u>AP</u>	WEST-WARD PHARMS INT	<u>EQ 250MG BASE/VIAL</u>	<u>A076068 001</u>	Sep 28, 2004	
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A076068 002</u>	Sep 28, 2004	
<u>AP</u>	+				
<u>AP</u>	PHARMACIA AND UPJOHN	<u>EQ 250MG BASE/VIAL</u>	<u>N020212 001</u>	May 26, 1995	
<u>AP</u>	+	<u>EQ 500MG BASE/VIAL</u>	<u>N020212 002</u>	May 26, 1995	
	TOTECT				
	+	CLINIGEN HLTHCARE	<u>EQ 500MG BASE/VIAL</u>	<u>N022025 001</u>	Sep 06, 2007

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXEDRINE

<u>AB</u>	AMEDRA PHARMS	<u>5MG</u>	<u>N017078 001</u>	
<u>AB</u>		<u>10MG</u>	<u>N017078 002</u>	
<u>AB</u>	+	<u>15MG</u>	<u>N017078 003</u>	

DEXTROAMPHETAMINE SULFATE

<u>AB</u>	ACTAVIS ELIZABETH	<u>5MG</u>	<u>A203901 001</u>	Nov 30, 2012
-----------	-------------------	------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMPHETAMINE SULFATE

<u>AB</u>		<u>10MG</u>	<u>A203901</u>	<u>002</u>	Nov 30, 2012
<u>AB</u>		<u>15MG</u>	<u>A203901</u>	<u>003</u>	Nov 30, 2012
<u>AB</u>	MALLINCKRODT	<u>5MG</u>	<u>A076353</u>	<u>001</u>	May 06, 2003
<u>AB</u>		<u>10MG</u>	<u>A076353</u>	<u>002</u>	May 06, 2003
<u>AB</u>		<u>15MG</u>	<u>A076353</u>	<u>003</u>	May 06, 2003
<u>AB</u>	MAYNE PHARMA	<u>5MG</u>	<u>A076137</u>	<u>001</u>	Jan 18, 2002
<u>AB</u>		<u>10MG</u>	<u>A076137</u>	<u>002</u>	Jan 18, 2002
<u>AB</u>		<u>15MG</u>	<u>A076137</u>	<u>003</u>	Jan 18, 2002
<u>AB</u>	MYLAN PHARMS INC	<u>5MG</u>	<u>A206735</u>	<u>001</u>	Jan 27, 2016
<u>AB</u>		<u>10MG</u>	<u>A206735</u>	<u>002</u>	Jan 27, 2016
<u>AB</u>		<u>15MG</u>	<u>A206735</u>	<u>003</u>	Jan 27, 2016

SOLUTION;ORAL

DEXTROAMPHETAMINE SULFATE

<u>AA</u>	+	OUTLOOK PHARMS	<u>5MG/5ML</u>	<u>A040776</u>	<u>001</u>	Jan 29, 2008
<u>AA</u>		TRIS PHARMA INC	<u>5MG/5ML</u>	<u>A203644</u>	<u>001</u>	May 29, 2013

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

<u>AA</u>		AUROLIFE PHARMA LLC	<u>5MG</u>	<u>A202893</u>	<u>001</u>	Jul 31, 2013
<u>AA</u>			<u>10MG</u>	<u>A202893</u>	<u>002</u>	Jul 31, 2013
<u>AA</u>		AVANTHI INC	<u>5MG</u>	<u>A203548</u>	<u>001</u>	Nov 23, 2015
<u>AA</u>			<u>10MG</u>	<u>A203548</u>	<u>002</u>	Nov 23, 2015
<u>AA</u>		BARR	<u>5MG</u>	<u>A040361</u>	<u>001</u>	Jan 31, 2001
<u>AA</u>	+		<u>10MG</u>	<u>A040361</u>	<u>002</u>	Jan 31, 2001
<u>AA</u>		MALLINCKRODT	<u>5MG</u>	<u>A040436</u>	<u>001</u>	Jan 29, 2002
<u>AA</u>			<u>10MG</u>	<u>A040436</u>	<u>002</u>	Jan 29, 2002
<u>AA</u>		MIKART	<u>5MG</u>	<u>A090533</u>	<u>002</u>	Oct 25, 2011
<u>AA</u>			<u>10MG</u>	<u>A090533</u>	<u>004</u>	Oct 25, 2011
<u>AA</u>		NESHER PHARMS	<u>5MG</u>	<u>A206588</u>	<u>001</u>	Mar 28, 2016
<u>AA</u>			<u>10MG</u>	<u>A206588</u>	<u>002</u>	Mar 28, 2016
<u>AA</u>		NOVEL LABS INC	<u>5MG</u>	<u>A204330</u>	<u>001</u>	Mar 16, 2016
<u>AA</u>			<u>10MG</u>	<u>A204330</u>	<u>002</u>	Mar 16, 2016
		MIKART	2.5MG	A090533	001	Oct 25, 2011
			7.5MG	A090533	003	Oct 25, 2011
			15MG	A090533	005	Oct 25, 2011
			20MG	A090533	006	Oct 25, 2011
			30MG	A090533	007	Oct 25, 2011

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETH W/ DEXTROMETHORPHAN

<u>AA</u>		G AND W LABS INC	<u>15MG/5ML; 6.25MG/5ML</u>	<u>A088762</u>	<u>001</u>	Oct 31, 1984
<u>AA</u>	+	VINTAGE	<u>15MG/5ML; 6.25MG/5ML</u>	<u>A040649</u>	<u>001</u>	Feb 14, 2006
<u>AA</u>		HI TECH PHARMA	<u>15MG/5ML; 6.25MG/5ML</u>	<u>A040027</u>	<u>001</u>	Jul 31, 1996
<u>AA</u>		WOCKHARDT	<u>15MG/5ML; 6.25MG/5ML</u>	<u>A088864</u>	<u>001</u>	Jan 04, 1985

DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE

CAPSULE;ORAL

NUDEXTA

	+	AVANIR PHARMS	20MG;10MG	N021879	001	Oct 29, 2010
--	---	---------------	-----------	---------	-----	--------------

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER

<u>AP</u>	+	B BRAUN	<u>10GM/100ML</u>	<u>N019626</u>	<u>004</u>	Feb 02, 1988
<u>AP</u>	+	BAXTER HLTHCARE	<u>10GM/100ML</u>	<u>N016694</u>	<u>001</u>	
<u>AP</u>	+	HOSPIRA	<u>10GM/100ML</u>	<u>N018080</u>	<u>001</u>	

DEXTROSE 20% IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>20GM/100ML</u>	<u>N017521</u>	<u>004</u>	
<u>AP</u>	+	HOSPIRA	<u>20GM/100ML</u>	<u>N018564</u>	<u>001</u>	Mar 23, 1982

DEXTROSE 30% IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>30GM/100ML</u>	<u>N017521</u>	<u>003</u>	
<u>AP</u>	+	HOSPIRA	<u>30GM/100ML</u>	<u>N019345</u>	<u>001</u>	Jan 26, 1985

DEXTROSE 40% IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>40GM/100ML</u>	<u>N017521</u>	<u>002</u>	
<u>AP</u>	+	HOSPIRA	<u>40GM/100ML</u>	<u>N018562</u>	<u>001</u>	Mar 23, 1982

DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	B BRAUN	<u>50MG/ML</u>	<u>N016730</u>	<u>002</u>	
<u>AP</u>	+		<u>5GM/100ML</u>	<u>N016730</u>	<u>001</u>	

PRESCRIPTION DRUG PRODUCT LIST

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+		<u>5GM/100ML</u>	<u>N019626 002</u>	Feb 02, 1988
<u>AP</u>	+	BAXTER HLTHCARE	<u>50MG/ML</u>	<u>N016673 003</u>	Oct 30, 1985
<u>AP</u>	+		<u>50MG/ML</u>	<u>N020179 002</u>	Dec 07, 1992
<u>AP</u>	+		<u>5GM/100ML</u>	<u>N016673 001</u>	
<u>AP</u>	+		<u>5GM/100ML</u>	<u>N020179 001</u>	Dec 07, 1992
<u>AP</u>	+	FRESENIUS KABI USA	<u>50MG/ML</u>	<u>A207449 001</u>	Oct 21, 2016
<u>AP</u>	+	HOSPIRA	<u>50MG/ML</u>	<u>N016367 002</u>	
<u>AP</u>	+		<u>50MG/ML</u>	<u>N019222 001</u>	Jul 13, 1984
<u>AP</u>	+		<u>5GM/100ML</u>	<u>N019466 001</u>	Jul 15, 1985
<u>AP</u>	+		<u>5GM/100ML</u>	<u>N019479 001</u>	Sep 17, 1985

DEXTROSE 50% IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>50GM/100ML</u>	<u>N017521 001</u>	
<u>AP</u>	+		<u>50GM/100ML</u>	<u>N020047 001</u>	Jul 02, 1991
<u>AP</u>	+	HOSPIRA	<u>50GM/100ML</u>	<u>N018563 001</u>	Mar 23, 1982

DEXTROSE 60% IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>60GM/100ML</u>	<u>N017521 005</u>	Mar 26, 1982
-----------	---	-----------------	-------------------	--------------------	--------------

DEXTROSE 70% IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>70GM/100ML</u>	<u>N017521 006</u>	Mar 26, 1982
<u>AP</u>	+		<u>70GM/100ML</u>	<u>N020047 003</u>	Jul 02, 1991
<u>AP</u>	+	HOSPIRA	<u>70GM/100ML</u>	<u>N018561 001</u>	Mar 23, 1982
<u>AP</u>	+		<u>70GM/100ML</u>	<u>N019893 001</u>	Dec 26, 1989

DEXTROSE 25%					
+	HOSPIRA	250MG/ML		N019445 002	Nov 23, 1998

DEXTROSE 50%					
	HOSPIRA	500MG/ML		N019445 003	Sep 03, 2014

DEXTROSE 50% IN PLASTIC CONTAINER					
	HOSPIRA	500MG/ML		N019445 001	Jun 03, 1986

DEXTROSE; MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML; 32MG/100ML; 128MG/100ML; 234MG/100ML	N017385 001
-----------------	---	-------------

DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML; 21MG/100ML; 128MG/100ML; 234MG/100ML	N017610 001
---------	---	-------------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION

ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 31MG/100ML; 130MG/100ML; 26MG/100ML; 320MG/100ML	N019873 001	Jun 10, 1993
---------	---	-------------	--------------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML; 31MG/100ML; 141MG/100ML; 20MG/100ML; 12MG/100ML; 260MG/100ML	N017484 001
-----------------	---	-------------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE; INJECTION

IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML; 30MG/100ML; 141MG/100ML; 15MG/100ML; 260MG/100ML; 25MG/100ML	N019513 001	May 08, 1986
---------	---	-------------	--------------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 30MG/100ML; 97MG/100ML; 220MG/100ML; 140MG/100ML	N019844 001	Jun 10, 1993
---------	---	-------------	--------------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML; 30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG/100ML; 502MG/100ML	N017609 001
---------	--	-------------

PRESCRIPTION DRUG PRODUCT LIST

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

<u>DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER</u>		
AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML N017634 001
<u>DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER</u>		
AP	BAXTER HLTHCARE	5GM/100ML;224MG/100ML N017634 003
<u>DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER</u>		
AP	BAXTER HLTHCARE	5GM/100ML;300MG/100ML N017634 002
<u>POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER</u>		
AP	B BRAUN	5GM/100ML;150MG/100ML N019699 004 Sep 29, 1989
<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER</u>		
AP	B BRAUN	5GM/100ML;300MG/100ML N019699 006 Sep 29, 1989
<u>POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER</u>		
AP	HOSPIRA	5GM/100ML;224MG/100ML N018371 003
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER		
	BAXTER HLTHCARE	5GM/100ML;75MG/100ML N017634 004
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER		
	HOSPIRA	5GM/100ML;149MG/100ML N018371 001
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER		
	HOSPIRA	5GM/100ML;298MG/100ML N018371 002

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;150MG/100ML;130MG/100ML;280MG /100ML;91MG/100ML N019870 001 Jun 10, 1993
--	---------	--

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

<u>DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ</u>		
AP	BAXTER HLTHCARE	5GM/100ML;75MG/100ML;200MG/100ML N018037 006 Apr 13, 1982
AP		5GM/100ML;150MG/100ML;200MG/100ML N018037 007 Apr 13, 1982
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K)</u>		
AP	BAXTER HLTHCARE	5GM/100ML;224MG/100ML;200MG/100ML N018037 004
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ</u>		
AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML;200MG/100ML N018037 008 Apr 13, 1982
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K)</u>		
AP	BAXTER HLTHCARE	5GM/100ML;300MG/100ML;200MG/100ML N018037 001
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ</u>		
AP	BAXTER HLTHCARE	5GM/100ML;224MG/100ML;200MG/100ML N018037 005 Apr 13, 1982
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ</u>		
AP	BAXTER HLTHCARE	5GM/100ML;300MG/100ML;200MG/100ML N018037 009 Apr 13, 1982
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ</u>		
AP	BAXTER HLTHCARE	5GM/100ML;75MG/100ML;200MG/100ML N018037 002
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K)</u>		
AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML;200MG/100ML N018037 003
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER</u>		
AP	BAXTER HLTHCARE	5GM/100ML;75MG/100ML;330MG/100ML N018629 005 Mar 23, 1982
AP		5GM/100ML;150MG/100ML;330MG/100ML N018629 002 Mar 23, 1982
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER</u>		
AP	BAXTER HLTHCARE	5GM/100ML;224MG/100ML;330MG/100ML N018629 003 Mar 23, 1982
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER</u>		
AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML;330MG/100ML N018629 004 Mar 23, 1982
AP		5GM/100ML;300MG/100ML;330MG/100ML N018629 006 Mar 23, 1982
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER</u>		
AP	BAXTER HLTHCARE	5GM/100ML;224MG/100ML;330MG/100ML N018629 007 Mar 23, 1982
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER</u>		
AP	BAXTER HLTHCARE	5GM/100ML;300MG/100ML;330MG/100ML N018629 008 Mar 23, 1982
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER</u>		
AP	BAXTER HLTHCARE	5GM/100ML;75MG/100ML;330MG/100ML N018629 001 Mar 23, 1982
<u>DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER</u>		
AP	BAXTER HLTHCARE	5GM/100ML;300MG/100ML;450MG/100ML N018008 010
<u>POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>		
AP	B BRAUN	5GM/100ML;75MG/100ML;200MG/100ML N019630 008 Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>		
AP	B BRAUN	5GM/100ML;75MG/100ML;330MG/100ML N019630 014 Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>		
AP	B BRAUN	5GM/100ML;75MG/100ML;450MG/100ML N019630 020 Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>		
AP	B BRAUN	5GM/100ML;75MG/100ML;900MG/100ML N019630 026 Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>		
AP	B BRAUN	5GM/100ML;150MG/100ML;200MG/100ML N019630 010 Feb 17, 1988

PRESCRIPTION DRUG PRODUCT LIST

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

	<u>POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>		
AP	B BRAUN	5GM/100ML;150MG/100ML;330MG/100ML	N019630 016 Feb 17, 1988
	<u>POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>		
AP	B BRAUN	5GM/100ML;150MG/100ML;450MG/100ML	N019630 022 Feb 17, 1988
	<u>POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>		
AP	B BRAUN	5GM/100ML;150MG/100ML;900MG/100ML	N019630 028 Feb 17, 1988
	<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>		
AP	B BRAUN	5GM/100ML;300MG/100ML;200MG/100ML	N019630 012 Feb 17, 1988
	<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>		
AP	B BRAUN	5GM/100ML;300MG/100ML;330MG/100ML	N019630 018 Feb 17, 1988
	<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>		
AP	B BRAUN	5GM/100ML;300MG/100ML;450MG/100ML	N019630 024 Feb 17, 1988
	<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>		
AP	B BRAUN	5GM/100ML;300MG/100ML;900MG/100ML	N019630 030 Feb 17, 1988
	<u>POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>		
AP	BAXTER HLTHCARE	5GM/100ML;75MG/100ML;450MG/100ML	N018008 005 Apr 28, 1982
AP		5GM/100ML;150MG/100ML;450MG/100ML	N018008 006 Apr 28, 1982
AP	HOSPIRA	5GM/100ML;74.5MG/100ML;450MG/100ML	N018362 005 Mar 28, 1988
AP		5GM/100ML;74.5MG/100ML;450MG/100ML	N018362 009 Jul 05, 1983
	<u>POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>		
AP	BAXTER HLTHCARE	5GM/100ML;75MG/100ML;900MG/100ML	N019308 004 Apr 05, 1985
AP		5GM/100ML;150MG/100ML;900MG/100ML	N019308 002 Apr 05, 1985
AP	HOSPIRA	5GM/100ML;74.5MG/100ML;900MG/100ML	N019691 002 Mar 24, 1988
AP		5GM/100ML;149MG/100ML;900MG/100ML	N019691 004 Mar 24, 1988
	<u>POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>		
AP	HOSPIRA	5GM/100ML;224MG/100ML;450MG/100ML	N018362 006 Mar 28, 1988
	<u>POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>		
AP	HOSPIRA	5GM/100ML;224MG/100ML;900MG/100ML	N019691 006 Mar 24, 1988
	<u>POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>		
AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML;450MG/100ML	N018008 007 Apr 28, 1982
AP	HOSPIRA	5GM/100ML;149MG/100ML;450MG/100ML	N018362 010 Jul 05, 1983
AP		5GM/100ML;298MG/100ML;450MG/100ML	N018362 007 Mar 28, 1988
	<u>POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>		
AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML;900MG/100ML	N019308 005 Apr 05, 1985
AP		5GM/100ML;300MG/100ML;900MG/100ML	N019308 003 Apr 05, 1985
AP	HOSPIRA	5GM/100ML;149MG/100ML;900MG/100ML	N019691 005 Mar 24, 1988
AP		5GM/100ML;298MG/100ML;900MG/100ML	N019691 008 Mar 24, 1988
	<u>POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>		
AP	BAXTER HLTHCARE	5GM/100ML;224MG/100ML;450MG/100ML	N018008 008 Apr 28, 1982
AP	HOSPIRA	5GM/100ML;224MG/100ML;450MG/100ML	N018362 002
	<u>POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>		
AP	BAXTER HLTHCARE	5GM/100ML;224MG/100ML;900MG/100ML	N019308 006 Apr 05, 1985
AP	HOSPIRA	5GM/100ML;224MG/100ML;900MG/100ML	N019691 007 Mar 24, 1988
	<u>POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>		
AP	BAXTER HLTHCARE	5GM/100ML;300MG/100ML;450MG/100ML	N018008 009 Apr 28, 1982
AP	HOSPIRA	5GM/100ML;298MG/100ML;450MG/100ML	N018362 003
	<u>POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>		
AP	BAXTER HLTHCARE	5GM/100ML;300MG/100ML;900MG/100ML	N019308 007 Apr 05, 1985
AP	HOSPIRA	5GM/100ML;298MG/100ML;900MG/100ML	N019691 009 Mar 24, 1988
	<u>POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>		
AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML;450MG/100ML	N018008 004
AP	HOSPIRA	5GM/100ML;74.5MG/100ML;450MG/100ML	N018362 008 Mar 28, 1988
AP		5GM/100ML;149MG/100ML;450MG/100ML	N018362 004 Mar 28, 1988
	<u>POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>		
AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML;900MG/100ML	N019308 001 Apr 05, 1985
AP	HOSPIRA	5GM/100ML;74.5MG/100ML;900MG/100ML	N019691 001 Mar 24, 1988
AP		5GM/100ML;149MG/100ML;900MG/100ML	N019691 003 Mar 24, 1988
	POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER		
	B BRAUN	10GM/100ML;37MG/100ML;200MG/100ML	N019630 031 Feb 17, 1988
	POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER		
	B BRAUN	10GM/100ML;37MG/100ML;450MG/100ML	N019630 037 Feb 17, 1988
	POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER		
	B BRAUN	10GM/100ML;37MG/100ML;900MG/100ML	N019630 043 Feb 17, 1988
	POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER		
	B BRAUN	5GM/100ML;37MG/100ML;110MG/100ML	N019630 001 Feb 17, 1988
	POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER		
	B BRAUN	5GM/100ML;37MG/100ML;200MG/100ML	N019630 007 Feb 17, 1988
	POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER		
	B BRAUN	5GM/100ML;37MG/100ML;330MG/100ML	N019630 013 Feb 17, 1988

PRESCRIPTION DRUG PRODUCT LIST

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	
B BRAUN	5GM/100ML; 37MG/100ML; 450MG/100ML N019630 019 Feb 17, 1988
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	
B BRAUN	5GM/100ML; 37MG/100ML; 900MG/100ML N019630 025 Feb 17, 1988
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER	
B BRAUN	10GM/100ML; 75MG/100ML; 200MG/100ML N019630 032 Feb 17, 1988
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	
B BRAUN	10GM/100ML; 75MG/100ML; 450MG/100ML N019630 038 Feb 17, 1988
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	
B BRAUN	10GM/100ML; 75MG/100ML; 900MG/100ML N019630 044 Feb 17, 1988
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER	
B BRAUN	3.3GM/100ML; 75MG/100ML; 300MG/100ML N019630 049 May 07, 1992
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER	
B BRAUN	5GM/100ML; 75MG/100ML; 110MG/100ML N019630 002 Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER	
B BRAUN	10GM/100ML; 110MG/100ML; 200MG/100ML N019630 033 Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	
B BRAUN	10GM/100ML; 110MG/100ML; 450MG/100ML N019630 039 Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	
B BRAUN	10GM/100ML; 110MG/100ML; 900MG/100ML N019630 045 Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER	
B BRAUN	3.3GM/100ML; 110MG/100ML; 300MG/100ML N019630 050 May 07, 1992
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER	
B BRAUN	5GM/100ML; 110MG/100ML; 110MG/100ML N019630 003 Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER	
B BRAUN	5GM/100ML; 110MG/100ML; 200MG/100ML N019630 009 Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER	
B BRAUN	5GM/100ML; 110MG/100ML; 330MG/100ML N019630 015 Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	
B BRAUN	5GM/100ML; 110MG/100ML; 450MG/100ML N019630 021 Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	
B BRAUN	5GM/100ML; 110MG/100ML; 900MG/100ML N019630 027 Feb 17, 1988
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER	
B BRAUN	10GM/100ML; 150MG/100ML; 200MG/100ML N019630 034 Feb 17, 1988
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	
B BRAUN	10GM/100ML; 150MG/100ML; 450MG/100ML N019630 040 Feb 17, 1988
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	
B BRAUN	10GM/100ML; 150MG/100ML; 900MG/100ML N019630 046 Feb 17, 1988
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER	
B BRAUN	3.3GM/100ML; 150MG/100ML; 300MG/100ML N019630 051 May 07, 1992
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER	
B BRAUN	5GM/100ML; 150MG/100ML; 110MG/100ML N019630 004 Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER	
B BRAUN	10GM/100ML; 220MG/100ML; 200MG/100ML N019630 035 Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	
B BRAUN	10GM/100ML; 220MG/100ML; 450MG/100ML N019630 041 Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	
B BRAUN	10GM/100ML; 220MG/100ML; 900MG/100ML N019630 047 Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER	
B BRAUN	3.3GM/100ML; 220MG/100ML; 300MG/100ML N019630 052 May 07, 1992
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER	
B BRAUN	5GM/100ML; 220MG/100ML; 110MG/100ML N019630 005 Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER	
B BRAUN	5GM/100ML; 220MG/100ML; 200MG/100ML N019630 011 Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER	
B BRAUN	5GM/100ML; 220MG/100ML; 330MG/100ML N019630 017 Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	
B BRAUN	5GM/100ML; 220MG/100ML; 450MG/100ML N019630 023 Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	
B BRAUN	5GM/100ML; 220MG/100ML; 900MG/100ML N019630 029 Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER	
B BRAUN	10GM/100ML; 300MG/100ML; 200MG/100ML N019630 036 Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	
B BRAUN	10GM/100ML; 300MG/100ML; 450MG/100ML N019630 042 Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	
B BRAUN	10GM/100ML; 300MG/100ML; 900MG/100ML N019630 048 Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER	
B BRAUN	3.3GM/100ML; 300MG/100ML; 300MG/100ML N019630 053 May 07, 1992
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER	
B BRAUN	5GM/100ML; 300MG/100ML; 110MG/100ML N019630 006 Feb 17, 1988

PRESCRIPTION DRUG PRODUCT LIST

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ	IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.225%	IN	PLASTIC CONTAINER	
HOSPIRA		5GM/100ML;74.5MG/100ML;225MG/100ML		N018365 002	Jul 05, 1983
		5GM/100ML;149MG/100ML;225MG/100ML		N018365 006	Mar 28, 1988
POTASSIUM CHLORIDE 10MEQ	IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.3%	IN	PLASTIC CONTAINER	
HOSPIRA		5GM/100ML;74.5MG/100ML;300MG/100ML		N018876 001	Jan 17, 1986
		5GM/100ML;149MG/100ML;300MG/100ML		N018876 006	Mar 28, 1988
POTASSIUM CHLORIDE 15MEQ	IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.225%	IN	PLASTIC CONTAINER	
HOSPIRA		5GM/100ML;224MG/100ML;225MG/100ML		N018365 008	Mar 28, 1988
POTASSIUM CHLORIDE 15MEQ	IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.3%	IN	PLASTIC CONTAINER	
HOSPIRA		5GM/100ML;224MG/100ML;300MG/100ML		N018876 007	Mar 28, 1988
POTASSIUM CHLORIDE 20MEQ	IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.225%	IN	PLASTIC CONTAINER	
HOSPIRA		5GM/100ML;149MG/100ML;225MG/100ML		N018365 001	
		5GM/100ML;298MG/100ML;225MG/100ML		N018365 009	Mar 28, 1988
POTASSIUM CHLORIDE 20MEQ	IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.3%	IN	PLASTIC CONTAINER	
HOSPIRA		5GM/100ML;298MG/100ML;300MG/100ML		N018876 008	Mar 28, 1988
POTASSIUM CHLORIDE 20MEQ	IN	DEXTROSE 5% IN SODIUM CHLORIDE 0.3%	IN	PLASTIC CONTAINER	
HOSPIRA		5GM/100ML;149MG/100ML;300MG/100ML		N018876 002	Jan 17, 1986
POTASSIUM CHLORIDE 30MEQ	IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.225%	IN	PLASTIC CONTAINER	
HOSPIRA		5GM/100ML;224MG/100ML;225MG/100ML		N018365 003	Jul 05, 1983
POTASSIUM CHLORIDE 30MEQ	IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.3%	IN	PLASTIC CONTAINER	
HOSPIRA		5GM/100ML;224MG/100ML;300MG/100ML		N018876 003	Jan 17, 1986
POTASSIUM CHLORIDE 40MEQ	IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.225%	IN	PLASTIC CONTAINER	
HOSPIRA		5GM/100ML;298MG/100ML;225MG/100ML		N018365 004	Jul 05, 1983
POTASSIUM CHLORIDE 40MEQ	IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.3%	IN	PLASTIC CONTAINER	
HOSPIRA		5GM/100ML;298MG/100ML;300MG/100ML		N018876 004	Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ	IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.225%	IN	PLASTIC CONTAINER	
HOSPIRA		5GM/100ML;74.5MG/100ML;225MG/100ML		N018365 005	Mar 28, 1988
		5GM/100ML;149MG/100ML;225MG/100ML		N018365 007	Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ	IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.3%	IN	PLASTIC CONTAINER	
HOSPIRA		5GM/100ML;74.5MG/100ML;300MG/100ML		N018876 005	Mar 28, 1988
		5GM/100ML;149MG/100ML;300MG/100ML		N018876 009	Mar 28, 1988

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

<u>DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
<u>AP</u>	B BRAUN	<u>10GM/100ML;900MG/100ML</u>		<u>N019631 015</u>	Feb 24, 1988
<u>AP</u>	BAXTER HLTHCARE	<u>10GM/100ML;900MG/100ML</u>		<u>N016696 001</u>	
<u>DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>					
<u>AP</u>	B BRAUN	<u>2.5GM/100ML;450MG/100ML</u>		<u>N019631 004</u>	Feb 24, 1988
<u>AP</u>	+ BAXTER HLTHCARE	<u>2.5GM/100ML;450MG/100ML</u>		<u>N016697 001</u>	
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>					
<u>AP</u>	B BRAUN	<u>5GM/100ML;200MG/100ML</u>		<u>N019631 007</u>	Feb 24, 1988
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>					
<u>AP</u>	B BRAUN	<u>5GM/100ML;330MG/100ML</u>		<u>N019631 008</u>	Feb 24, 1988
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>					
<u>AP</u>	B BRAUN	<u>5GM/100ML;450MG/100ML</u>		<u>N019631 009</u>	Feb 24, 1988
<u>AP</u>	HOSPIRA	<u>5GM/100ML;450MG/100ML</u>		<u>N017607 001</u>	
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
<u>AP</u>	B BRAUN	<u>5GM/100ML;900MG/100ML</u>		<u>N019631 010</u>	Feb 24, 1988
<u>AP</u>	HOSPIRA	<u>5GM/100ML;900MG/100ML</u>		<u>N017585 001</u>	
<u>DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>					
<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;200MG/100ML</u>		<u>N016689 001</u>	
<u>DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>					
<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;330MG/100ML</u>		<u>N016687 001</u>	
<u>DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>					
<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;450MG/100ML</u>		<u>N016683 001</u>	
<u>DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
<u>AP</u>	BAXTER HLTHCARE	<u>5GM/100ML;900MG/100ML</u>		<u>N016678 001</u>	
<u>DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER</u>					
	B BRAUN	10GM/100ML;110MG/100ML		N019631 011	Feb 24, 1988
<u>DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>					
	B BRAUN	10GM/100ML;200MG/100ML		N019631 012	Feb 24, 1988
<u>DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>					
	B BRAUN	10GM/100ML;330MG/100ML		N019631 013	Feb 24, 1988
<u>DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>					
	B BRAUN	10GM/100ML;450MG/100ML		N019631 014	Feb 24, 1988
<u>DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER</u>					
	B BRAUN	2.5GM/100ML;110MG/100ML		N019631 001	Feb 24, 1988
<u>DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>					
	B BRAUN	2.5GM/100ML;200MG/100ML		N019631 002	Feb 24, 1988

PRESCRIPTION DRUG PRODUCT LIST

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER B BRAUN 2.5GM/100ML; 330MG/100ML	N019631 003	Feb 24, 1988
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER B BRAUN 2.5GM/100ML; 900MG/100ML	N019631 005	Feb 24, 1988
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER B BRAUN 3.3GM/100ML; 300MG/100ML	N019631 016	Jan 19, 1990
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER B BRAUN 5GM/100ML; 110MG/100ML	N019631 006	Feb 24, 1988
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER + HOSPIRA 5GM/100ML; 225MG/100ML	N017606 001	
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER + HOSPIRA 5GM/100ML; 300MG/100ML	N017799 001	

DIATRIZOATE MEGLUMINE

SOLUTION; URETHRAL

CYSTOGRAFIN

BRACCO 30%	N010040 018	
CYSTOGRAFIN DILUTE BRACCO 18%	N010040 022	Nov 09, 1982

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

MD-76R

AP + LIEBEL-FLARSHEIM **66%;10%** **N019292 001** Sep 29, 1989

RENOGRAFIN-76

AP + BRACCO **66%;10%** **N010040 001**

SOLUTION; ORAL, RECTAL

GASTROGRAFIN

AA + BRACCO **66%;10%** **N011245 003**

MD-GASTROVIEW

AA LIEBEL-FLARSHEIM **66%;10%** **A087388 001**

DIATRIZOATE MEGLUMINE; IODIPAMIDE MEGLUMINE

SOLUTION; INTRAUTERINE

SINOGRAFIN

+ BRACCO 52.7%; 26.8% N011324 002

DIAZEPAM

CONCENTRATE; ORAL

DIAZEPAM

AA LANNETT HOLDINGS INC **5MG/ML** **A204433 001** Apr 14, 2014

DIAZEPAM INTENSOL

AA + WEST-WARD PHARMS INT **5MG/ML** **A071415 001** Apr 03, 1987

GEL; RECTAL

DIASTAT

VALEANT PHARMS NORTH 2.5MG/0.5ML (5MG/ML) N020648 001 Jul 29, 1997

DIASTAT ACUDIAL

VALEANT PHARMS NORTH 10MG/2ML (5MG/ML) N020648 007 Sep 15, 2005

+ 20MG/4ML (5MG/ML) N020648 006 Sep 15, 2005

INJECTABLE; INJECTION

DIAZEPAM

+ HOSPIRA 10MG/2ML (5MG/ML) A072079 001 Dec 20, 1988

+ 50MG/10ML (5MG/ML) A071583 001 Oct 13, 1987

SOLUTION; ORAL

DIAZEPAM

AA LANNETT HOLDINGS INC **5MG/5ML** **A206477 001** Jun 24, 2016

AA + WEST-WARD PHARMS INT **5MG/5ML** **A070928 001** Apr 03, 1987

TABLET; ORAL

DIAZEPAM

AB BARR **2MG** **A070152 001** Nov 01, 1985

AB **10MG** **A070154 001** Nov 01, 1985

AB IVAX SUB TEVA PHARMS **2MG** **A071307 001** Dec 10, 1986

AB **5MG** **A071321 001** Dec 10, 1986

AB **10MG** **A071322 001** Dec 10, 1986

AB MAYNE PHARMA **2MG** **A071134 001** Feb 03, 1987

AB **5MG** **A071135 001** Feb 03, 1987

AB **10MG** **A071136 001** Feb 03, 1987

AB MYLAN **2MG** **A070325 002** Sep 04, 1985

AB **5MG** **A070325 003** Sep 04, 1985

AB **10MG** **A070325 001** Sep 04, 1985

AB VINTAGE PHARMS **2MG** **A077749 001** Mar 31, 2006

AB **5MG** **A077749 002** Mar 31, 2006

PRESCRIPTION DRUG PRODUCT LIST

DIAZEPAM

TABLET; ORAL

DIAZEPAM**AB** 10MG **A077749 003** Mar 31, 2006VALIUM**AB** ROCHE **2MG** **N013263 002****AB** **5MG** **N013263 004****AB** + **10MG** **N013263 006**

DIAZEPAM

DAVA PHARMS INC 2MG A070228 002 Sep 26, 1985

5MG A070228 003 Sep 26, 1985

DIAZOXIDE

SUSPENSION; ORAL

PROGLYCEM

+ TEVA BRANDED PHARM 50MG/ML N017453 001

DICHLORPHENAMIDE

TABLET; ORAL

KEVEYIS

STRONGBRIDGE US 50MG N011366 002 Aug 07, 2015

DICLOFENAC

CAPSULE; ORAL

ZORVOLEX

IROKO PHARMS LLC 18MG N204592 001 Oct 18, 2013

+ 35MG N204592 002 Oct 18, 2013

DICLOFENAC EPOLAMINE

PATCH; TOPICAL

FLECTOR

+ INST BIOCHEM 1.3% N021234 001 Jan 31, 2007

DICLOFENAC POTASSIUM

CAPSULE; ORAL

DICLOFENAC POTASSIUM**AB** BIONPHARMA INC **25MG** **A204648 001** Feb 23, 2016ZIPSOR**AB** + DEPOMED INC **25MG** **N022202 001** Jun 16, 2009

FOR SOLUTION; ORAL

CAMBIA**AB** + DEPOMED INC **50MG** **N022165 001** Jun 17, 2009DICLOFENAC POTASSIUM**AB** PAR FORM **50MG** **A202964 001** May 02, 2016

TABLET; ORAL

DICLOFENAC POTASSIUM**AB** APOTEX **50MG** **A076561 001** Mar 18, 2004**AB** + MYLAN **50MG** **A075463 001** Jul 26, 1999**AB** SANDOZ **50MG** **A075229 001** Nov 20, 1998**AB** TEVA **50MG** **A075219 001** Aug 06, 1998DICLOFENAC SODIUM

GEL; TOPICAL

DICLOFENAC SODIUM**AB** ACTAVIS MID ATLANTIC **3%** **A206493 001** Dec 02, 2015**AB** AMNEAL PHARMS **1%** **A208077 001** Mar 18, 2016**AB** GLENMARK PHARMS LTD **3%** **A208301 001** Sep 13, 2016**AB** TARO **3%** **A206298 001** Apr 28, 2016DICLOFENAC SODIUM**AB** TOLMAR **3%** **A200936 001** Oct 28, 2013SOLARAZE**AB** + FOUGERA PHARMS **3%** **N021005 001** Oct 16, 2000VOLTAREN**AB** + GLAXOSMITHKLINE CONS **1%** **N022122 001** Oct 17, 2007

SOLUTION; INTRAVENOUS

DYLOJECT

+ JAVELIN PHARMS INC 37.5MG/ML (37.5MG/ML) N022396 001 Dec 23, 2014

SOLUTION; TOPICAL

DICLOFENAC SODIUM**AT** AMNEAL PHARMS **1.5%** **A206116 001** Sep 02, 2016**AT** APOTEX INC **1.5%** **A202027 001** May 27, 2014**AT** LUPIN LTD **1.5%** **A204132 001** Aug 20, 2015**AT** NOVEL LABS INC **1.5%** **A205878 001** Dec 09, 2015**AT** PADDOCK LLC **1.5%** **A202393 001** Nov 24, 2014**AT** TARO **1.5%** **A203818 001** Nov 26, 2014

PRESCRIPTION DRUG PRODUCT LIST

DICLOFENAC SODIUM

SOLUTION; TOPICAL

DICLOFENAC SODIUM

AT	TELIGENT PHARMA INC	1.5%	A202769 001	Jul 08, 2015
AT	WATSON LABS INC	1.5%	A202852 001	Nov 24, 2014

PENNSAID

AT	+ NUVO RES INC	1.5%	N020947 001	Nov 04, 2009
	+ HORIZON PHARMA	2%	N204623 001	Jan 16, 2014

SOLUTION/DROPS; OPHTHALMIC

DICLOFENAC SODIUM

AT	AKORN	0.1%	A077845 001	Apr 17, 2008
AT	ALCON PHARMS LTD	0.1%	A078031 001	Feb 06, 2008
AT	ALTAIRE PHARMS INC	0.1%	A203383 001	Nov 16, 2015
AT	BAUSCH AND LOMB	0.1%	A078792 001	Dec 28, 2007
AT	RISING PHARMS INC	0.1%	A078553 001	Dec 28, 2007

VOLTAREN

AT	+ NOVARTIS	0.1%	N020037 001	Mar 28, 1991
-----------	------------	-------------	--------------------	--------------

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

AB	ACTAVIS ELIZABETH	50MG	A074514 001	Mar 26, 1996
AB		75MG	A074514 002	Mar 26, 1996
AB	CARLSBAD	25MG	A075185 002	Nov 13, 1998
AB		50MG	A075185 003	Nov 13, 1998
AB		75MG	A075185 001	Nov 13, 1998
AB	MYLAN PHARMS INC	50MG	A075281 002	Feb 12, 2002
AB		75MG	A075281 003	Feb 12, 2002
AB	+ SANDOZ	25MG	A074376 001	Sep 28, 1995
AB	+	50MG	A074376 002	Sep 28, 1995
AB	+	75MG	A074394 001	Nov 30, 1995
AB	UNIQUE PHARM LABS	25MG	A090066 001	Dec 01, 2010
AB		50MG	A090066 002	Dec 01, 2010
AB		75MG	A077863 003	Jun 08, 2007

TABLET, EXTENDED RELEASE; ORAL

DICLOFENAC SODIUM

AB	+ ACTAVIS ELIZABETH	100MG	A075910 001	Jan 07, 2002
AB	DEXCEL LTD	100MG	A076201 001	Nov 06, 2002
AB	MYLAN	100MG	A076152 001	Dec 13, 2001
AB	VPNA	100MG	A075492 001	Feb 11, 2000

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE; ORAL

ARTHROTEC

AB	GD SEARLE LLC	50MG; 0.2MG	N020607 001	Dec 24, 1997
AB	+	75MG; 0.2MG	N020607 002	Dec 24, 1997

DICLOFENAC SODIUM AND MISOPROSTOL

AB	ACTAVIS LABS FL INC	50MG; 0.2MG	A201089 001	Jul 09, 2012
AB		75MG; 0.2MG	A201089 002	Jul 09, 2012
AB	AMNEAL PHARMS	50MG; 0.2MG	A203995 001	Nov 25, 2016
AB		75MG; 0.2MG	A203995 002	Nov 25, 2016
AB	EXELA PHARMA SCS LLC	50MG; 0.2MG	A200540 001	Mar 14, 2014
AB		75MG; 0.2MG	A200540 002	Mar 14, 2014
AB	SANDOZ	50MG; 0.2MG	A200158 001	May 09, 2013
AB		75MG; 0.2MG	A200158 002	May 09, 2013

DICLOXACILLIN SODIUM

CAPSULE; ORAL

DICLOXACILLIN SODIUM

AB	SANDOZ	EQ 250MG BASE	A061454 001	
AB	+	EQ 500MG BASE	A061454 003	
AB	TEVA	EQ 250MG BASE	A062286 001	Jun 03, 1982
AB		EQ 500MG BASE	A062286 002	Jun 03, 1982
	SANDOZ	EQ 125MG BASE	A061454 002	

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

BENTYL

AB	+ FOREST LABS INC	10MG	N007409 003	Oct 15, 1984
-----------	-------------------	-------------	--------------------	--------------

DICYCLOMINE HYDROCHLORIDE

AB	LANNETT	10MG	A084285 001	
AB	MYLAN	10MG	A040319 001	Sep 07, 1999
AB	WATSON LABS	10MG	A085082 001	Jun 19, 1986

PRESCRIPTION DRUG PRODUCT LIST

DICYCLOMINE HYDROCHLORIDE

INJECTABLE; INJECTION

BENTYLAP + FOREST LABS INC 10MG/ML N008370 001 Oct 15, 1984BENTYL PRESERVATIVE FREEAP + FOREST LABS INC 10MG/ML N008370 002 Oct 15, 1984DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE)AP WEST-WARD PHARMS INT 10MG/ML A040465 001 Jun 30, 2003

SYRUP; ORAL

DICYCLOMINE HYDROCHLORIDE

+ MIKART

10MG/5ML

A040169 001 Mar 24, 2005

TABLET; ORAL

BENTYLAB + FOREST LABS INC 20MG N007409 001 Oct 15, 1984DICYCLOMINE HYDROCHLORIDEAB LANNETT 20MG A040230 001 Feb 26, 1999AB MYLAN 20MG A040317 001 Sep 07, 1999AB WATSON LABS 20MG A085223 001 Jul 30, 1986DIDANOSINE

CAPSULE, DELAYED REL PELLETS; ORAL

DIDANOSINEAB AUROBINDO PHARMA 125MG A090094 001 Sep 24, 2008AB 200MG A090094 002 Sep 24, 2008AB 250MG A090094 003 Sep 24, 2008AB 400MG A090094 004 Sep 24, 2008AB BARR 200MG A077167 001 Dec 03, 2004AB 250MG A077167 002 Dec 03, 2004AB 400MG A077167 003 Dec 03, 2004AB MYLAN PHARMS INC 125MG A090788 001 Apr 08, 2010AB 200MG A090788 002 Apr 08, 2010AB 250MG A090788 003 Apr 08, 2010AB 400MG A090788 004 Apr 08, 2010VIDEX ECAB BRISTOL MYERS SQUIBB 125MG N021183 001 Oct 31, 2000AB 200MG N021183 002 Oct 31, 2000AB 250MG N021183 003 Oct 31, 2000AB + 400MG N021183 004 Oct 31, 2000

FOR SOLUTION; ORAL

DIDANOSINEAA AUROBINDO PHARMA 10MG/ML A078112 001 Mar 08, 2007VIDEXAA + BRISTOL MYERS SQUIBB 10MG/ML N020156 001 Oct 09, 1991

TABLET, FOR SUSPENSION; ORAL

DIDANOSINE

AUROBINDO

100MG

A077275 001 Aug 14, 2012

150MG

A077275 002 Aug 14, 2012

+

200MG

A077275 003 Aug 14, 2012

DIENOGEST; ESTRADIOL VALERATE

TABLET; ORAL

ESTRADIOL VALERATE AND DIENOGESTAB WATSON LABS INC N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1MG, N/A A202349 001 May 06, 2016NATAZIAAB + BAYER HLHCARE N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1MG, N/A N022252 001 May 06, 2010DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

DIETHYLPROPION HYDROCHLORIDEAA AVANTHI INC 25MG A201212 001 Dec 22, 2010AA LANNETT HOLDINGS INC 25MG A200177 001 Jul 18, 2011TENUATEAA + ACTAVIS LABS UT INC 25MG N011722 002

TABLET, EXTENDED RELEASE; ORAL

DIETHYLPROPION HYDROCHLORIDEAB LANNETT HOLDINGS INC 75MG A091680 001 Oct 24, 2011TENUATE DOSPANAB + ACTAVIS LABS UT INC 75MG N012546 001

PRESCRIPTION DRUG PRODUCT LIST

DIFLORASONE DIACETATE

CREAM; TOPICAL

DIFLORASONE DIACETATE

BX	+	FOUGERA PHARMS	0.05%	A076263	001	Dec 20, 2002
BX	+	TARO	0.05%	A075508	001	Apr 24, 2000

OINTMENT; TOPICAL

DIFLORASONE DIACETATE

AB		AKORN	0.05%	A206572	001	Jul 24, 2015
AB		FOUGERA PHARMS	0.05%	A075374	001	Apr 27, 1999
AB	+	TARO	0.05%	A075331	001	May 14, 1999

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

AB		HERITAGE PHARMA	500MG	A202845	001	Mar 08, 2012
AB	+	TEVA	500MG	A073673	001	Jul 31, 1992

DIFLUPREDNATE

EMULSION; OPHTHALMIC

DUREZOL

	+	NOVARTIS PHARMS CORP	0.05%	N022212	001	Jun 23, 2008
--	---	----------------------	-------	---------	-----	--------------

DIGOXIN

ELIXIR; ORAL

DIGOXIN

	+	ROXANE	0.05MG/ML	N021648	001	Aug 26, 2004
--	---	--------	-----------	---------	-----	--------------

INJECTABLE; INJECTION

DIGOXIN

AP		EUROHLTH INTL SARL	0.25MG/ML	A083391	001	
AP		SANDOZ	0.25MG/ML	A040481	001	Aug 21, 2003

LANOXIN

AP	+	COVIS PHARMA SARL	0.25MG/ML	N009330	002	
		LANOXIN PEDIATRIC				
	+	COVIS PHARMA SARL	0.1MG/ML	N009330	004	

TABLET; ORAL

DIGOXIN

AB		HIKMA INTL PHARMS	0.125MG	A077002	002	Oct 30, 2007
AB			0.25MG	A077002	001	Oct 30, 2007
AB		IMPAX LABS	0.125MG	A078556	001	Jul 20, 2009
AB			0.25MG	A078556	002	Jul 20, 2009
AB		MYLAN PHARMS INC	0.125MG	A040282	001	Dec 23, 1999
AB			0.25MG	A040282	002	Dec 23, 1999
AB		STEVENS J	0.125MG	A076268	001	Jul 26, 2002
AB			0.25MG	A076268	002	Jul 26, 2002
AB		SUN PHARM INDS INC	0.125MG	A076363	001	Jan 31, 2003
AB			0.25MG	A076363	002	Jan 31, 2003

LANOXIN

AB		CONCORDIA PHARMS INC	0.125MG	N020405	002	Sep 30, 1997
AB	+		0.25MG	N020405	004	Sep 30, 1997
			0.0625MG	N020405	001	Sep 30, 1997
			0.1875MG	N020405	003	Sep 30, 1997

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION

D.H.E. 45

AP	+	VALEANT	1MG/ML	N005929	001	
-----------	---	---------	---------------	----------------	------------	--

DIHYDROERGOTAMINE MESYLATE

AP		EUROHLTH INTL SARL	1MG/ML	A040453	001	Jun 09, 2003
AP		PADDOCK LLC	1MG/ML	A040475	001	Apr 28, 2003

SPRAY, METERED; NASAL

MIGRANAL

	+	VALEANT	0.5MG/INH	N020148	001	Dec 08, 1997
--	---	---------	-----------	---------	-----	--------------

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILTIAZEM HYDROCHLORIDE

AB2		APOTEX	120MG	A074943	003	Dec 19, 2000
AB2			180MG	A074943	002	Dec 19, 2000
AB2			240MG	A074943	001	Aug 06, 1998
AB2		MYLAN	120MG	A075124	002	Mar 18, 1998
AB2			180MG	A075124	003	Mar 18, 1998
AB2	+		240MG	A075124	001	Mar 18, 1998

CARDIZEM CD

AB3		VALEANT INTL	120MG	N020062	001	Aug 10, 1992
AB3			180MG	N020062	002	Dec 27, 1991

PRESCRIPTION DRUG PRODUCT LIST

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

CARDIZEM CD

<u>AB3</u>		<u>240MG</u>	<u>N020062</u>	<u>003</u>	Dec 27, 1991
<u>AB3</u>		<u>300MG</u>	<u>N020062</u>	<u>004</u>	Dec 27, 1991
<u>AB3</u>	+	<u>360MG</u>	<u>N020062</u>	<u>005</u>	Aug 24, 1999

CARTIA XT

<u>AB3</u>	ACTAVIS LABS FL INC	<u>120MG</u>	<u>A074752</u>	<u>002</u>	Jul 09, 1998
<u>AB3</u>		<u>180MG</u>	<u>A074752</u>	<u>001</u>	Jul 09, 1998
<u>AB3</u>		<u>240MG</u>	<u>A074752</u>	<u>003</u>	Jul 09, 1998
<u>AB3</u>		<u>300MG</u>	<u>A074752</u>	<u>004</u>	Jul 09, 1998

DILTIAZEM HYDROCHLORIDE

<u>AB3</u>	ACTAVIS ELIZABETH	<u>360MG</u>	<u>A202463</u>	<u>001</u>	Dec 07, 2012
<u>AB3</u>	PAR PHARM	<u>120MG</u>	<u>A074984</u>	<u>001</u>	Dec 20, 1999
<u>AB3</u>		<u>180MG</u>	<u>A074984</u>	<u>002</u>	Dec 20, 1999
<u>AB3</u>		<u>240MG</u>	<u>A074984</u>	<u>003</u>	Dec 20, 1999
<u>AB3</u>		<u>300MG</u>	<u>A074984</u>	<u>004</u>	Dec 20, 1999
<u>AB3</u>	SUN PHARMA GLOBAL	<u>120MG</u>	<u>A090492</u>	<u>001</u>	Oct 28, 2011
<u>AB3</u>		<u>180MG</u>	<u>A090492</u>	<u>002</u>	Oct 28, 2011
<u>AB3</u>		<u>240MG</u>	<u>A090492</u>	<u>003</u>	Oct 28, 2011
<u>AB3</u>		<u>300MG</u>	<u>A090492</u>	<u>004</u>	Oct 28, 2011
<u>AB3</u>		<u>360MG</u>	<u>A090492</u>	<u>005</u>	Oct 28, 2011
<u>AB3</u>	VALEANT PHARMS NORTH	<u>120MG</u>	<u>A075116</u>	<u>001</u>	Dec 23, 1999
<u>AB3</u>		<u>180MG</u>	<u>A075116</u>	<u>002</u>	Dec 23, 1999
<u>AB3</u>		<u>240MG</u>	<u>A075116</u>	<u>003</u>	Dec 23, 1999
<u>AB3</u>		<u>300MG</u>	<u>A075116</u>	<u>004</u>	Dec 23, 1999
<u>AB4</u>	SANDOZ	<u>120MG</u>	<u>A091022</u>	<u>001</u>	Sep 28, 2012
<u>AB4</u>		<u>180MG</u>	<u>A091022</u>	<u>002</u>	Sep 28, 2012
<u>AB4</u>		<u>240MG</u>	<u>A091022</u>	<u>003</u>	Sep 28, 2012
<u>AB4</u>		<u>300MG</u>	<u>A091022</u>	<u>004</u>	Sep 28, 2012
<u>AB4</u>		<u>360MG</u>	<u>A091022</u>	<u>005</u>	Sep 28, 2012
<u>AB4</u>		<u>420MG</u>	<u>A091022</u>	<u>006</u>	Sep 28, 2012
<u>AB4</u>	SUN PHARMA GLOBAL	<u>120MG</u>	<u>A090421</u>	<u>001</u>	Nov 15, 2010
<u>AB4</u>		<u>180MG</u>	<u>A090421</u>	<u>002</u>	Nov 15, 2010
<u>AB4</u>		<u>240MG</u>	<u>A090421</u>	<u>003</u>	Nov 15, 2010
<u>AB4</u>		<u>300MG</u>	<u>A090421</u>	<u>004</u>	Nov 15, 2010
<u>AB4</u>		<u>360MG</u>	<u>A090421</u>	<u>005</u>	Nov 15, 2010

DILTIZAC

<u>AB4</u>	APOTEX INC	<u>120MG</u>	<u>A076395</u>	<u>001</u>	Feb 01, 2006
<u>AB4</u>		<u>180MG</u>	<u>A076395</u>	<u>002</u>	Feb 01, 2006
<u>AB4</u>		<u>240MG</u>	<u>A076395</u>	<u>003</u>	Feb 01, 2006
<u>AB4</u>		<u>300MG</u>	<u>A076395</u>	<u>004</u>	Feb 01, 2006
<u>AB4</u>		<u>360MG</u>	<u>A076395</u>	<u>005</u>	Feb 01, 2006

TAZTIA XT

<u>AB4</u>	ACTAVIS LABS FL INC	<u>120MG</u>	<u>A075401</u>	<u>001</u>	Apr 10, 2003
<u>AB4</u>		<u>180MG</u>	<u>A075401</u>	<u>002</u>	Apr 10, 2003
<u>AB4</u>		<u>240MG</u>	<u>A075401</u>	<u>003</u>	Apr 10, 2003
<u>AB4</u>		<u>300MG</u>	<u>A075401</u>	<u>004</u>	Apr 10, 2003
<u>AB4</u>		<u>360MG</u>	<u>A075401</u>	<u>005</u>	Apr 10, 2003

TIAZAC

<u>AB4</u>	VALEANT PHARMS NORTH	<u>120MG</u>	<u>N020401</u>	<u>001</u>	Sep 11, 1995
<u>AB4</u>		<u>180MG</u>	<u>N020401</u>	<u>002</u>	Sep 11, 1995
<u>AB4</u>		<u>240MG</u>	<u>N020401</u>	<u>003</u>	Sep 11, 1995
<u>AB4</u>		<u>300MG</u>	<u>N020401</u>	<u>004</u>	Sep 11, 1995
<u>AB4</u>		<u>360MG</u>	<u>N020401</u>	<u>005</u>	Sep 11, 1995
<u>AB4</u>	+	<u>420MG</u>	<u>N020401</u>	<u>006</u>	Oct 16, 1998

BC	+	MYLAN	120MG	A074910	003	May 02, 1997
			60MG	A074910	001	May 02, 1997
			90MG	A074910	002	May 02, 1997

INJECTABLE; INJECTION

DILTIAZEM HYDROCHLORIDE

<u>AP</u>	AKORN INC	<u>5MG/ML</u>	<u>A075086</u>	<u>001</u>	Apr 09, 1998	
<u>AP</u>	+	AMPHASTAR PHARMS INC	<u>5MG/ML</u>	<u>A074617</u>	<u>001</u>	Feb 28, 1996
<u>AP</u>		EUROHLTH INTL SARL	<u>5MG/ML</u>	<u>A078538</u>	<u>001</u>	Dec 17, 2008
<u>AP</u>		HIKMA FARMACEUTICA	<u>5MG/ML</u>	<u>A202651</u>	<u>001</u>	Aug 09, 2012
<u>AP</u>		HOSPIRA	<u>5MG/ML</u>	<u>A074941</u>	<u>001</u>	Apr 15, 1998
<u>AP</u>		INTL MEDICATION	<u>5MG/ML</u>	<u>A075749</u>	<u>001</u>	Nov 21, 2001
	+	HOSPIRA	100MG/VIAL	A075853	001	Dec 17, 2002

TABLET; ORAL

CARDIZEM

<u>AB</u>	VALEANT INTL	<u>30MG</u>	<u>N018602</u>	<u>001</u>	Nov 05, 1982
-----------	--------------	-------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

DILTIAZEM HYDROCHLORIDE

TABLET; ORAL

CARDIZEM

<u>AB</u>		<u>60MG</u>	<u>N018602</u>	<u>002</u>	Nov 05, 1982
<u>AB</u>		<u>90MG</u>	<u>N018602</u>	<u>003</u>	Dec 08, 1986
<u>AB</u>	+	<u>120MG</u>	<u>N018602</u>	<u>004</u>	Dec 08, 1986

DILTIAZEM HYDROCHLORIDE

<u>AB</u>	MYLAN	<u>30MG</u>	<u>A072838</u>	<u>004</u>	Nov 05, 1992
<u>AB</u>		<u>60MG</u>	<u>A072838</u>	<u>003</u>	Nov 05, 1992
<u>AB</u>		<u>90MG</u>	<u>A072838</u>	<u>002</u>	Nov 05, 1992
<u>AB</u>		<u>120MG</u>	<u>A072838</u>	<u>001</u>	Nov 05, 1992
<u>AB</u>	TEVA	<u>30MG</u>	<u>A074185</u>	<u>001</u>	May 31, 1995
<u>AB</u>		<u>60MG</u>	<u>A074185</u>	<u>002</u>	May 31, 1995
<u>AB</u>		<u>90MG</u>	<u>A074185</u>	<u>003</u>	May 31, 1995
<u>AB</u>		<u>120MG</u>	<u>A074185</u>	<u>004</u>	May 31, 1995

TABLET, EXTENDED RELEASE; ORAL

CARDIZEM LA

<u>AB</u>	VALEANT INTL	<u>120MG</u>	<u>N021392</u>	<u>001</u>	Feb 06, 2003
<u>AB</u>		<u>180MG</u>	<u>N021392</u>	<u>002</u>	Feb 06, 2003
<u>AB</u>		<u>240MG</u>	<u>N021392</u>	<u>003</u>	Feb 06, 2003
<u>AB</u>		<u>300MG</u>	<u>N021392</u>	<u>004</u>	Feb 06, 2003
<u>AB</u>		<u>360MG</u>	<u>N021392</u>	<u>005</u>	Feb 06, 2003
<u>AB</u>	+	<u>420MG</u>	<u>N021392</u>	<u>006</u>	Feb 06, 2003

DILTIAZEM HYDROCHLORIDE

<u>AB</u>	ACTAVIS LABS FL INC	<u>120MG</u>	<u>A077686</u>	<u>006</u>	Mar 15, 2010
<u>AB</u>		<u>180MG</u>	<u>A077686</u>	<u>005</u>	Mar 15, 2010
<u>AB</u>		<u>240MG</u>	<u>A077686</u>	<u>004</u>	Mar 15, 2010
<u>AB</u>		<u>300MG</u>	<u>A077686</u>	<u>003</u>	Mar 15, 2010
<u>AB</u>		<u>360MG</u>	<u>A077686</u>	<u>002</u>	Mar 15, 2010
<u>AB</u>		<u>420MG</u>	<u>A077686</u>	<u>001</u>	Mar 15, 2010

DIMENHYDRINATE

INJECTABLE; INJECTION

DIMENHYDRINATE

+	FRESENIUS KABI USA	50MG/ML	A040519	001	Jun 23, 2004
---	--------------------	---------	---------	-----	--------------

DIMERCAPROL

INJECTABLE; INJECTION

BAL

+	AKORN	10%	N005939	001	
---	-------	-----	---------	-----	--

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE; ORAL

TECFIDERA

	BIOGEN IDEC INC	120MG	N204063	001	Mar 27, 2013
+		240MG	N204063	002	Mar 27, 2013

DIMETHYL SULFOXIDE

SOLUTION; INTRAVESICAL

DIMETHYL SULFOXIDE

<u>AT</u>	MYLAN INSTITUTIONAL	<u>50%</u>	<u>A076185</u>	<u>001</u>	Nov 29, 2002
-----------	---------------------	------------	----------------	------------	--------------

RIMSO-50

<u>AT</u>	+	MYLAN INSTITUTIONAL	<u>50%</u>	<u>N017788</u>	<u>001</u>
-----------	---	---------------------	------------	----------------	------------

DINOPROSTONE

GEL; ENDOCERVICAL

PREPIDIL

+	PHARMACIA AND UPJOHN	0.5MG/3GM	N019617	001	Dec 09, 1992
---	----------------------	-----------	---------	-----	--------------

INSERT, EXTENDED RELEASE; VAGINAL

CERVIDIL

+	FERRING PHARMS INC	10MG	N020411	001	Mar 30, 1995
---	--------------------	------	---------	-----	--------------

SUPPOSITORY; VAGINAL

PROSTIN E2

+	PHARMACIA AND UPJOHN	20MG	N017810	001	
---	----------------------	------	---------	-----	--

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

+	BARR	50MG	A080738	001	
---	------	------	---------	-----	--

ELIXIR; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

+	PHARM ASSOC	12.5MG/5ML	A087513	001	Feb 10, 1982
---	-------------	------------	---------	-----	--------------

INJECTABLE; INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE

<u>AP</u>	APP PHARMS	<u>50MG/ML</u>	<u>A040466</u>	<u>001</u>	May 28, 2002
-----------	------------	----------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE

<u>AP</u>	+	EUROHLTH INTL SARL	<u>50MG/ML</u>	<u>A080817</u>	<u>002</u>	
<u>AP</u>		HOSPIRA	<u>50MG/ML</u>	<u>A040140</u>	<u>001</u>	Nov 20, 1998
<u>AP</u>		MYLAN INSTITUTIONAL	<u>50MG/ML</u>	<u>A040498</u>	<u>001</u>	Jul 12, 2005

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>		FRESENIUS KABI USA	<u>50MG/ML</u>	<u>A091526</u>	<u>001</u>	Mar 26, 2013
-----------	--	--------------------	----------------	----------------	------------	--------------

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

<u>AP</u>	+	AMPHASTAR PHARMS INC	<u>5MG/ML</u>	<u>A074939</u>	<u>001</u>	Apr 13, 1998
<u>AP</u>		FRESENIUS KABI USA	<u>5MG/ML</u>	<u>A074956</u>	<u>001</u>	Sep 30, 1998
<u>AP</u>		WEST-WARD PHARMS INT	<u>5MG/ML</u>	<u>A074521</u>	<u>001</u>	Oct 18, 1996

TABLET; ORAL

DIPYRIDAMOLE

<u>AB</u>		BARR	<u>25MG</u>	<u>A087184</u>	<u>001</u>	Oct 03, 1990
<u>AB</u>			<u>50MG</u>	<u>A087716</u>	<u>001</u>	Oct 03, 1990
<u>AB</u>			<u>75MG</u>	<u>A087717</u>	<u>001</u>	Oct 03, 1990
<u>AB</u>		IMPAX LABS	<u>25MG</u>	<u>A040782</u>	<u>001</u>	Jul 18, 2007
<u>AB</u>			<u>50MG</u>	<u>A040782</u>	<u>002</u>	Jul 18, 2007
<u>AB</u>			<u>75MG</u>	<u>A040782</u>	<u>003</u>	Jul 18, 2007
<u>AB</u>		MURTY PHARMS	<u>25MG</u>	<u>A040733</u>	<u>001</u>	Feb 13, 2007
<u>AB</u>			<u>50MG</u>	<u>A040733</u>	<u>002</u>	Feb 13, 2007
<u>AB</u>			<u>75MG</u>	<u>A040733</u>	<u>003</u>	Feb 13, 2007
<u>AB</u>		ZYDUS PHARMS USA INC	<u>25MG</u>	<u>A040874</u>	<u>001</u>	Jan 28, 2008
<u>AB</u>			<u>50MG</u>	<u>A040874</u>	<u>002</u>	Jan 28, 2008
<u>AB</u>			<u>75MG</u>	<u>A040874</u>	<u>003</u>	Jan 28, 2008

PERSANTINE

<u>AB</u>		BOEHRINGER INGELHEIM	<u>25MG</u>	<u>N012836</u>	<u>003</u>	Dec 22, 1986
<u>AB</u>			<u>50MG</u>	<u>N012836</u>	<u>004</u>	Feb 06, 1987
<u>AB</u>	+		<u>75MG</u>	<u>N012836</u>	<u>005</u>	Feb 06, 1987

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE

<u>AB</u>		MAYNE PHARMA	<u>EQ 100MG BASE</u>	<u>A070173</u>	<u>001</u>	May 31, 1985
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A070174</u>	<u>001</u>	May 31, 1985
<u>AB</u>		TEVA	<u>EQ 100MG BASE</u>	<u>A070101</u>	<u>001</u>	Feb 22, 1985
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A070102</u>	<u>001</u>	Feb 22, 1985

NORPACE

<u>AB</u>		GD SEARLE LLC	<u>EQ 100MG BASE</u>	<u>N017447</u>	<u>001</u>	
<u>AB</u>	+		<u>EQ 150MG BASE</u>	<u>N017447</u>	<u>002</u>	

CAPSULE, EXTENDED RELEASE; ORAL

NORPACE CR

<u>AB</u>	+	GD SEARLE LLC	<u>EQ 150MG BASE</u>	<u>N018655</u>	<u>002</u>	Jul 20, 1982
			<u>EQ 100MG BASE</u>	<u>N018655</u>	<u>001</u>	Jul 20, 1982

DISULFIRAM

TABLET; ORAL

ANTABUSE

<u>AB</u>		ODYSSEY PHARMS	<u>250MG</u>	<u>A088482</u>	<u>001</u>	Dec 08, 1983
<u>AB</u>	+		<u>500MG</u>	<u>A088483</u>	<u>001</u>	Dec 08, 1983

DISULFIRAM

<u>AB</u>		MYLAN PHARMS INC	<u>250MG</u>	<u>A203916</u>	<u>001</u>	Mar 04, 2015
<u>AB</u>			<u>500MG</u>	<u>A203916</u>	<u>002</u>	Mar 04, 2015
<u>AB</u>		SIGMAPHARM LABS LLC	<u>250MG</u>	<u>A091619</u>	<u>001</u>	Mar 28, 2011
<u>AB</u>			<u>500MG</u>	<u>A091619</u>	<u>002</u>	Mar 28, 2011
<u>AB</u>		VINTAGE PHARMS	<u>250MG</u>	<u>A091563</u>	<u>001</u>	Dec 31, 2012
<u>AB</u>			<u>500MG</u>	<u>A091563</u>	<u>002</u>	Dec 31, 2012
<u>AB</u>		WEST-WARD PHARMS INT	<u>250MG</u>	<u>A202652</u>	<u>001</u>	Feb 05, 2014
<u>AB</u>			<u>500MG</u>	<u>A202652</u>	<u>002</u>	Feb 05, 2014

DISULFIRAM

<u>AB</u>		ALVOGEN MALTA	<u>250MG</u>	<u>A091681</u>	<u>001</u>	Aug 08, 2013
-----------	--	---------------	--------------	----------------	------------	--------------

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS; ORAL

DEPAKOTE

<u>AB</u>	+	ABBVIE	<u>EQ 125MG VALPROIC ACID</u>	<u>N019680</u>	<u>001</u>	Sep 12, 1989
-----------	---	--------	-------------------------------	----------------	------------	--------------

DIVALPROEX SODIUM

<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 125MG VALPROIC ACID</u>	<u>A078979</u>	<u>001</u>	Jan 23, 2009
<u>AB</u>		MYLAN	<u>EQ 125MG VALPROIC ACID</u>	<u>A090407</u>	<u>001</u>	Mar 28, 2011
<u>AB</u>		ZYDUS PHARMS USA INC	<u>EQ 125MG VALPROIC ACID</u>	<u>A078919</u>	<u>001</u>	Jan 27, 2009

PRESCRIPTION DRUG PRODUCT LIST

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE;ORAL

DEPAKOTE

<u>AB</u>	ABBVIE	<u>EQ 125MG VALPROIC ACID</u>	<u>N018723 003</u>	Oct 26, 1984
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>N018723 001</u>	Mar 10, 1983
<u>AB</u>	+	<u>EQ 500MG VALPROIC ACID</u>	<u>N018723 002</u>	Mar 10, 1983

DIVALPROEX SODIUM

<u>AB</u>	ACTAVIS LABS FL INC	<u>EQ 500MG VALPROIC ACID</u>	<u>A079080 001</u>	Feb 25, 2011
<u>AB</u>	ANCHEN PHARMS	<u>EQ 500MG VALPROIC ACID</u>	<u>A078411 001</u>	Nov 03, 2008
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 125MG VALPROIC ACID</u>	<u>A090554 001</u>	Apr 21, 2011
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A090554 002</u>	Apr 21, 2011
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A090554 003</u>	Apr 21, 2011
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 125MG VALPROIC ACID</u>	<u>A078755 001</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078755 002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078755 003</u>	Jul 29, 2008
<u>AB</u>	LUPIN	<u>EQ 125MG VALPROIC ACID</u>	<u>A078790 001</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078790 002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078790 003</u>	Jul 29, 2008
<u>AB</u>	MYLAN	<u>EQ 125MG VALPROIC ACID</u>	<u>A090062 001</u>	Mar 17, 2009
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A090062 002</u>	Mar 17, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A090062 003</u>	Mar 17, 2009
<u>AB</u>	NU PHARM	<u>EQ 125MG VALPROIC ACID</u>	<u>A077615 003</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A077615 002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A077615 001</u>	Jul 29, 2008
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 125MG VALPROIC ACID</u>	<u>A078853 001</u>	Nov 25, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078853 002</u>	Nov 25, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078853 003</u>	Nov 25, 2008
<u>AB</u>	SANDOZ	<u>EQ 125MG VALPROIC ACID</u>	<u>A078290 003</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078290 002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078290 001</u>	Jul 29, 2008
<u>AB</u>	SUN PHARM INDS	<u>EQ 125MG VALPROIC ACID</u>	<u>A078597 001</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078597 002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078597 003</u>	Jul 29, 2008
<u>AB</u>	TEVA	<u>EQ 125MG VALPROIC ACID</u>	<u>A076941 001</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A076941 002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A076941 003</u>	Jul 29, 2008
<u>AB</u>	UNICHEM LABS LTD	<u>EQ 125MG VALPROIC ACID</u>	<u>A079163 001</u>	Apr 05, 2011
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A079163 002</u>	Apr 05, 2011
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A079163 003</u>	Apr 05, 2011
<u>AB</u>	UPSHER SMITH	<u>EQ 125MG VALPROIC ACID</u>	<u>A078182 001</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078182 002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078182 003</u>	Jul 29, 2008
<u>AB</u>	VINTAGE	<u>EQ 125MG VALPROIC ACID</u>	<u>A090210 001</u>	Nov 30, 2009
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A090210 002</u>	Nov 30, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A090210 003</u>	Nov 30, 2009
<u>AB</u>	WOCKHARDT	<u>EQ 125MG VALPROIC ACID</u>	<u>A077296 001</u>	Jul 31, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A077296 002</u>	Jul 31, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A077296 003</u>	Jul 31, 2008
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 125MG VALPROIC ACID</u>	<u>A077100 001</u>	Mar 05, 2009
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A077100 002</u>	Mar 05, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A077100 003</u>	Mar 05, 2009

TABLET, EXTENDED RELEASE;ORAL

DEPAKOTE ER

<u>AB</u>	ABBVIE	<u>EQ 250MG VALPROIC ACID</u>	<u>N021168 002</u>	May 31, 2002
<u>AB</u>	+	<u>EQ 500MG VALPROIC ACID</u>	<u>N021168 001</u>	Aug 04, 2000

DIVALPROEX SODIUM

<u>AB</u>	AMNEAL PHARMS	<u>EQ 250MG VALPROIC ACID</u>	<u>A203730 001</u>	May 29, 2015
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A203730 002</u>	May 29, 2015
<u>AB</u>	ANCHEN PHARMS	<u>EQ 250MG VALPROIC ACID</u>	<u>A078445 001</u>	Feb 26, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078445 002</u>	Aug 04, 2009
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 250MG VALPROIC ACID</u>	<u>A202419 001</u>	Jun 02, 2014
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A202419 002</u>	Jun 02, 2014
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 250MG VALPROIC ACID</u>	<u>A090161 001</u>	Mar 15, 2012
<u>AB</u>	IMPAX LABS	<u>EQ 250MG VALPROIC ACID</u>	<u>A078791 001</u>	May 06, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078791 002</u>	Aug 04, 2009
<u>AB</u>	MYLAN	<u>EQ 250MG VALPROIC ACID</u>	<u>A077567 001</u>	Jan 29, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A077567 002</u>	Jan 29, 2009
<u>AB</u>	REDDYS	<u>EQ 500MG VALPROIC ACID</u>	<u>A090070 001</u>	Mar 12, 2012
<u>AB</u>	WOCKHARDT	<u>EQ 250MG VALPROIC ACID</u>	<u>A078705 002</u>	Feb 10, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078705 001</u>	Aug 04, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 250MG VALPROIC ACID</u>	<u>A078239 001</u>	Feb 27, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078239 002</u>	Aug 04, 2009

PRESCRIPTION DRUG PRODUCT LIST

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HYDROCHLORIDE

<u>AP</u>	HOSPIRA	<u>EQ 12.5MG BASE/ML</u>	<u>A074086 001</u>	Nov 29, 1993
<u>AP</u>	+	<u>EQ 12.5MG BASE/ML</u>	<u>A074292 001</u>	Feb 16, 1995
<u>AP</u>	WEST-WARD PHARMS INT	<u>EQ 12.5MG BASE/ML</u>	<u>A074277 001</u>	Oct 31, 1994

DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>EQ 50MG BASE/100ML</u>	<u>N020255 001</u>	Oct 19, 1993
<u>AP</u>	+		<u>EQ 100MG BASE/100ML</u>	<u>N020255 003</u>	Oct 19, 1993
<u>AP</u>	+		<u>EQ 200MG BASE/100ML</u>	<u>N020255 004</u>	Oct 19, 1993
<u>AP</u>	+		<u>EQ 400MG BASE/100ML</u>	<u>N020255 005</u>	Oct 19, 1993
<u>AP</u>	+	HOSPIRA	<u>EQ 50MG BASE/100ML</u>	<u>N020201 003</u>	Oct 19, 1993
<u>AP</u>	+		<u>EQ 100MG BASE/100ML</u>	<u>N020201 002</u>	Oct 19, 1993
<u>AP</u>	+		<u>EQ 200MG BASE/100ML</u>	<u>N020201 001</u>	Oct 19, 1993
<u>AP</u>	+		<u>EQ 400MG BASE/100ML</u>	<u>N020201 006</u>	Jul 07, 1994

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

<u>AP</u>	ACCORD HLTHCARE	<u>20MG/ML (20MG/ML)</u>	<u>N201195 003</u>	Apr 20, 2012	
<u>AP</u>		<u>80MG/4ML (20MG/ML)</u>	<u>N201195 004</u>	Apr 20, 2012	
<u>AP</u>	+	<u>160MG/8ML (20MG/ML)</u>	<u>N201195 005</u>	Apr 20, 2012	
<u>AP</u>	ACTAVIS INC	<u>20MG/ML (20MG/ML)</u>	<u>N203551 001</u>	Apr 12, 2013	
<u>AP</u>		<u>80MG/4ML (20MG/ML)</u>	<u>N203551 002</u>	Apr 12, 2013	
<u>AP</u>	DR REDDYS LABS LTD	<u>20MG/ML (20MG/ML)</u>	<u>A204193 001</u>	Nov 05, 2014	
<u>AP</u>		<u>80MG/4ML (20MG/ML)</u>	<u>A204193 002</u>	Nov 05, 2014	
<u>AP</u>	+	HOSPIRA INC	<u>20MG/2ML (10MG/ML)</u>	<u>N022234 001</u>	Mar 08, 2011
<u>AP</u>	+		<u>80MG/8ML (10MG/ML)</u>	<u>N022234 002</u>	Mar 08, 2011
<u>AP</u>	+		<u>160MG/16ML (10MG/ML)</u>	<u>N022234 003</u>	Mar 08, 2011
<u>AP</u>	SANDOZ	<u>20MG/2ML (10MG/ML)</u>	<u>N201525 001</u>	Jun 29, 2011	
<u>AP</u>		<u>80MG/8ML (10MG/ML)</u>	<u>N201525 002</u>	Jun 29, 2011	
<u>AP</u>		<u>160MG/16ML (10MG/ML)</u>	<u>N201525 003</u>	Jun 29, 2011	
<u>AP</u>	TEVA PHARMS USA	<u>20MG/ML (20MG/ML)</u>	<u>A203877 001</u>	Sep 16, 2015	
<u>AP</u>		<u>80MG/4ML (20MG/ML)</u>	<u>A203877 002</u>	Sep 16, 2015	

TAXOTERE

<u>AP</u>	+	SANOFI AVENTIS US	<u>20MG/ML (20MG/ML)</u>	<u>N020449 003</u>	Aug 03, 2010
<u>AP</u>	+		<u>80MG/4ML (20MG/ML)</u>	<u>N020449 004</u>	Aug 02, 2010
<u>AP</u>	+		<u>160MG/8ML (20MG/ML)</u>	<u>N020449 005</u>	Apr 13, 2012

DOCEFREZ

+	SUN PHARMA GLOBAL	20MG/VIAL	N022534 001	May 03, 2011
+		80MG/VIAL	N022534 002	May 03, 2011

DOCETAXEL

ACCORD HLTHCARE	20MG/0.5ML (40MG/ML)	N201195 001	Jun 08, 2011
	80MG/2ML (40MG/ML)	N201195 002	Jun 08, 2011
ACTAVIS INC	140MG/7ML (20MG/ML)	N203551 003	Apr 12, 2013
HOSPIRA INC	20MG/ML (20MG/ML)	N022234 004	Jun 23, 2016
	80MG/4ML (20MG/ML)	N022234 005	Jun 23, 2016
	120MG/6ML (20MG/ML)	N022234 006	Jun 23, 2016
PFIZER LABS	20MG/2ML (10MG/ML)	N202356 001	Mar 13, 2014
	80MG/8ML (10MG/ML)	N202356 002	Mar 13, 2014
	130MG/13ML (10MG/ML)	N202356 003	Mar 13, 2014
	200MG/20ML (10MG/ML)	N202356 004	Mar 13, 2014

SOLUTION; IV (INFUSION)

DOCETAXEL

EAGLE PHARMS	20MG/ML (20MG/ML)	N205934 001	Dec 22, 2015
	80MG/4ML (20MG/ML)	N205934 002	Dec 22, 2015
	160MG/8ML (20MG/ML)	N205934 003	Dec 22, 2015

DOFETILIDE

CAPSULE; ORAL

DOFETILIDE

<u>AB</u>	TIGER PHARMS LLC	<u>0.125MG</u>	<u>A207058 001</u>	Jun 06, 2016
<u>AB</u>		<u>0.25MG</u>	<u>A207058 002</u>	Jun 06, 2016
<u>AB</u>		<u>0.5MG</u>	<u>A207058 003</u>	Jun 06, 2016

TIKOSYN

<u>AB</u>	PFIZER	<u>0.125MG</u>	<u>N020931 001</u>	Oct 01, 1999
<u>AB</u>		<u>0.25MG</u>	<u>N020931 002</u>	Oct 01, 1999
<u>AB</u>	+	<u>0.5MG</u>	<u>N020931 003</u>	Oct 01, 1999

PRESCRIPTION DRUG PRODUCT LIST

DOLASETRON MESYLATE

INJECTABLE; INJECTION

ANZEMET

+	US PHARM HOLDINGS	12.5MG/0.625ML (20MG/ML)	N020624	002	Sep 11, 1997
+		100MG/5ML (20MG/ML)	N020624	001	Sep 11, 1997

TABLET; ORAL

ANZEMET

	US PHARM HOLDINGS	50MG	N020623	001	Sep 11, 1997
+		100MG	N020623	002	Sep 11, 1997

DOLUTEGRAVIR SODIUM

TABLET; ORAL

TIVICAY

	VIIV HLTHCARE	EQ 10MG BASE	N204790	002	Jun 09, 2016
		EQ 25MG BASE	N204790	003	Jun 09, 2016
+		EQ 50MG BASE	N204790	001	Aug 12, 2013

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

ARICEPT

<u>AB</u>	EISAI INC	<u>5MG</u>	<u>N020690</u>	<u>002</u>	Nov 25, 1996
<u>AB</u>	+	<u>10MG</u>	<u>N020690</u>	<u>001</u>	Nov 25, 1996
<u>AB</u>	+	<u>23MG</u>	<u>N022568</u>	<u>001</u>	Jul 23, 2010

DONEPEZIL HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>23MG</u>	<u>A202415</u>	<u>001</u>	Dec 17, 2015
<u>AB</u>	ALEMBIC PHARMS LTD	<u>5MG</u>	<u>A201724</u>	<u>001</u>	Feb 25, 2013
<u>AB</u>		<u>10MG</u>	<u>A201724</u>	<u>002</u>	Feb 25, 2013
<u>AB</u>	APOTEX	<u>5MG</u>	<u>A078841</u>	<u>001</u>	Jun 02, 2011
<u>AB</u>		<u>10MG</u>	<u>A078841</u>	<u>002</u>	Jun 02, 2011
<u>AB</u>	AUROBINDO	<u>5MG</u>	<u>A090056</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090056</u>	<u>002</u>	May 31, 2011
<u>AB</u>	CIPLA LTD	<u>5MG</u>	<u>A077518</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A077518</u>	<u>002</u>	May 31, 2011
<u>AB</u>	CSPC OUYI PHARM CO	<u>5MG</u>	<u>A202114</u>	<u>001</u>	Jul 05, 2013
<u>AB</u>		<u>10MG</u>	<u>A202114</u>	<u>002</u>	Jul 05, 2013
<u>AB</u>	DEXCEL PHARMA	<u>23MG</u>	<u>A203713</u>	<u>001</u>	Feb 19, 2016
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A201001</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A201001</u>	<u>002</u>	May 31, 2011
<u>AB</u>		<u>23MG</u>	<u>A202723</u>	<u>001</u>	Jul 24, 2013
<u>AB</u>	HETERO LABS LTD V	<u>5MG</u>	<u>A203034</u>	<u>001</u>	Jan 30, 2015
<u>AB</u>		<u>10MG</u>	<u>A203034</u>	<u>002</u>	Jan 30, 2015
<u>AB</u>	INDICUS PHARMA	<u>5MG</u>	<u>A201634</u>	<u>001</u>	Jun 13, 2012
<u>AB</u>		<u>10MG</u>	<u>A201634</u>	<u>002</u>	Jun 13, 2012
<u>AB</u>		<u>23MG</u>	<u>A203419</u>	<u>001</u>	Apr 12, 2016
<u>AB</u>	JUBILANT GENERICS	<u>5MG</u>	<u>A090768</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090768</u>	<u>002</u>	May 31, 2011
<u>AB</u>	LUPIN LTD	<u>23MG</u>	<u>A202782</u>	<u>001</u>	Oct 30, 2015
<u>AB</u>	MACLEODS PHARMS LTD	<u>5MG</u>	<u>A201146</u>	<u>001</u>	Aug 17, 2012
<u>AB</u>		<u>10MG</u>	<u>A201146</u>	<u>002</u>	Aug 17, 2012
<u>AB</u>		<u>23MG</u>	<u>A202631</u>	<u>001</u>	Jan 22, 2014
<u>AB</u>	MYLAN PHARMS INC	<u>5MG</u>	<u>A090521</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090521</u>	<u>002</u>	May 31, 2011
<u>AB</u>		<u>23MG</u>	<u>A202656</u>	<u>001</u>	Oct 22, 2015
<u>AB</u>	OSMOTICA PHARM US	<u>23MG</u>	<u>A203114</u>	<u>001</u>	Jan 26, 2016
<u>AB</u>	PAR PHARM	<u>23MG</u>	<u>A202542</u>	<u>001</u>	Jul 24, 2013
<u>AB</u>	PLIVA HRVATSKA DOO	<u>5MG</u>	<u>A090425</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090425</u>	<u>002</u>	May 31, 2011
<u>AB</u>	PRINSTON INC	<u>5MG</u>	<u>A200292</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A200292</u>	<u>002</u>	May 31, 2011
<u>AB</u>	ROXANE	<u>5MG</u>	<u>A078662</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A078662</u>	<u>002</u>	May 31, 2011
<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A090290</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090290</u>	<u>002</u>	May 31, 2011
<u>AB</u>	SCIEGEN PHARMS INC	<u>5MG</u>	<u>A203907</u>	<u>001</u>	Oct 29, 2014
<u>AB</u>		<u>10MG</u>	<u>A203907</u>	<u>002</u>	Oct 29, 2014
<u>AB</u>	SUN PHARM INDS	<u>5MG</u>	<u>A090493</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090493</u>	<u>002</u>	May 31, 2011
<u>AB</u>	SUN PHARM INDS LTD	<u>5MG</u>	<u>A076786</u>	<u>001</u>	Nov 26, 2010
<u>AB</u>		<u>10MG</u>	<u>A076786</u>	<u>002</u>	Nov 26, 2010
<u>AB</u>		<u>23MG</u>	<u>A204293</u>	<u>001</u>	Jun 05, 2015
<u>AB</u>	TEVA	<u>5MG</u>	<u>A077344</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A077344</u>	<u>002</u>	May 31, 2011
<u>AB</u>	TORRENT PHARMS	<u>5MG</u>	<u>A090686</u>	<u>001</u>	May 31, 2011

PRESCRIPTION DRUG PRODUCT LIST

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

<u>AB</u>		<u>10MG</u>	<u>A090686</u>	<u>002</u>	May 31, 2011
<u>AB</u>	TWI PHARMS INC	<u>23MG</u>	<u>A203104</u>	<u>001</u>	Oct 29, 2014
<u>AB</u>	UNICHEM LABS LTD	<u>5MG</u>	<u>A203656</u>	<u>001</u>	Jun 23, 2016
<u>AB</u>		<u>10MG</u>	<u>A203656</u>	<u>002</u>	Jun 23, 2016
<u>AB</u>	VIVIMED LABS	<u>5MG</u>	<u>A090551</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090551</u>	<u>002</u>	May 31, 2011
<u>AB</u>	WOCKHARDT	<u>5MG</u>	<u>A091267</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A091267</u>	<u>002</u>	May 31, 2011
<u>AB</u>	ZYDUS PHARMS USA INC	<u>5MG</u>	<u>A090100</u>	<u>001</u>	Oct 24, 2012
<u>AB</u>		<u>10MG</u>	<u>A090100</u>	<u>002</u>	Oct 24, 2012

TABLET, ORALLY DISINTEGRATING; ORAL

ARICEPT ODT

<u>AB</u>	EISAI INC	<u>5MG</u>	<u>N021720</u>	<u>001</u>	Oct 18, 2004
<u>AB</u>	+	<u>10MG</u>	<u>N021720</u>	<u>002</u>	Oct 18, 2004

DONEPEZIL HYDROCHLORIDE

<u>AB</u>	BARR	<u>5MG</u>	<u>A078388</u>	<u>002</u>	Nov 26, 2010
<u>AB</u>		<u>10MG</u>	<u>A078388</u>	<u>001</u>	Nov 26, 2010
<u>AB</u>	MACLEODS PHARMS LTD	<u>5MG</u>	<u>A201787</u>	<u>001</u>	Dec 14, 2012
<u>AB</u>		<u>10MG</u>	<u>A201787</u>	<u>002</u>	Dec 14, 2012
<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A091198</u>	<u>001</u>	May 10, 2011
<u>AB</u>		<u>10MG</u>	<u>A091198</u>	<u>002</u>	May 10, 2011
<u>AB</u>	UNICHEM LABS LTD	<u>5MG</u>	<u>A204831</u>	<u>001</u>	Nov 10, 2016
<u>AB</u>		<u>10MG</u>	<u>A204831</u>	<u>002</u>	Nov 10, 2016
<u>AB</u>	ZYDUS PHARMS USA INC	<u>5MG</u>	<u>A090175</u>	<u>001</u>	May 10, 2011
<u>AB</u>		<u>10MG</u>	<u>A090175</u>	<u>002</u>	May 10, 2011

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

NAMZARIC

	FOREST LABS LLC	10MG; 7MG	N206439	003	Jul 18, 2016
		10MG; 14MG	N206439	001	Dec 23, 2014
		10MG; 21MG	N206439	004	Jul 18, 2016
	+	10MG; 28MG	N206439	002	Dec 23, 2014

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HYDROCHLORIDE

<u>AP</u>	+	HOSPIRA	<u>40MG/ML</u>	<u>N018132</u>	<u>001</u>
<u>AP</u>	+		<u>80MG/100ML</u>	<u>N018132</u>	<u>002</u>
<u>AP</u>	+		<u>80MG/ML</u>	<u>N018132</u>	<u>004</u>
<u>AP</u>	+		<u>160MG/100ML</u>	<u>N018132</u>	<u>003</u>
<u>AP</u>	+	LUITPOLD	<u>40MG/ML</u>	<u>A070799</u>	<u>001</u>
<u>AP</u>	+		<u>80MG/ML</u>	<u>A070820</u>	<u>001</u>
<u>AP</u>	+		<u>160MG/ML</u>	<u>A070826</u>	<u>001</u>

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%

<u>AP</u>	+	B BRAUN	<u>80MG/100ML</u>	<u>N019099</u>	<u>002</u>
<u>AP</u>	+		<u>320MG/100ML</u>	<u>N019099</u>	<u>004</u>

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	B BRAUN	<u>160MG/100ML</u>	<u>N019099</u>	<u>003</u>
-----------	---	---------	--------------------	----------------	------------

DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>80MG/100ML</u>	<u>N019615</u>	<u>001</u>
<u>AP</u>	+		<u>160MG/100ML</u>	<u>N019615</u>	<u>002</u>
<u>AP</u>	+		<u>320MG/100ML</u>	<u>N019615</u>	<u>003</u>
<u>AP</u>	+	HOSPIRA	<u>80MG/100ML</u>	<u>N018826</u>	<u>001</u>
<u>AP</u>	+		<u>160MG/100ML</u>	<u>N018826</u>	<u>002</u>
<u>AP</u>	+		<u>320MG/100ML</u>	<u>N018826</u>	<u>003</u>

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER

+ B BRAUN 40MG/100ML N019099 001 Oct 15, 1986

DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 640MG/100ML N019615 004 Mar 27, 1987

DORIPENEM

INJECTABLE; IV (INFUSION)

DORIBAX

	SHIONOGI INC	250MG/VIAL	N022106	002	Oct 05, 2010
	+	500MG/VIAL	N022106	001	Oct 12, 2007

PRESCRIPTION DRUG PRODUCT LIST

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

<u>AT</u>	ALCON PHARMS LTD	<u>EQ 2% BASE</u>	<u>A078981 001</u>	Apr 13, 2009
<u>AT</u>	BAUSCH AND LOMB	<u>EQ 2% BASE</u>	<u>A090143 001</u>	Jun 25, 2009
<u>AT</u>	HI TECH PHARMA	<u>EQ 2% BASE</u>	<u>A077846 001</u>	Oct 28, 2008
<u>AT</u>	LUITPOLD	<u>EQ 2% BASE</u>	<u>A079186 001</u>	Nov 18, 2009
<u>AT</u>	SANDOZ	<u>EQ 2% BASE</u>	<u>A078748 001</u>	Nov 06, 2008
<u>AT</u>	TEVA PHARMS	<u>EQ 2% BASE</u>	<u>A078756 001</u>	Dec 04, 2008
<u>AT</u>	WATSON LABS INC	<u>EQ 2% BASE</u>	<u>A202053 001</u>	Sep 11, 2014
<u>AT</u>	ZACH SYSTEMS	<u>EQ 2% BASE</u>	<u>A091034 001</u>	Dec 04, 2013

TRUSOPT

<u>AT</u>	+ MERCK	<u>EQ 2% BASE</u>	<u>N020408 001</u>	Dec 09, 1994
-----------	---------	-------------------	--------------------	--------------

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

COSOPT

<u>AT</u>	+ OAK PHARMS INC	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>N020869 001</u>	Apr 07, 1998
-----------	------------------	--------------------------------	--------------------	--------------

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

<u>AT</u>	AKORN INC	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A203058 001</u>	Sep 22, 2014
<u>AT</u>	ALCON RES	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A090604 001</u>	Nov 18, 2009
<u>AT</u>	BAUSCH AND LOMB	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A090037 001</u>	Jul 14, 2009
<u>AT</u>	HI TECH PHARMA	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A077847 001</u>	Oct 28, 2008
<u>AT</u>	SANDOZ	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A078749 001</u>	Nov 06, 2008
<u>AT</u>	TEVA PHARMS	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A078704 001</u>	Sep 28, 2009
<u>AT</u>	WATSON LABS INC	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A202054 001</u>	Sep 03, 2014
<u>AT</u>	ZACH SYSTEMS	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A091180 001</u>	Dec 04, 2013

COSOPT PF

	+ OAK PHARMS INC	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>N202667 001</u>	Feb 01, 2012
--	------------------	--------------------------------	--------------------	--------------

DOXAPRAM HYDROCHLORIDE

INJECTABLE;INJECTION

DOPRAM

<u>AP</u>	+ WEST-WARD PHARMS INT	<u>20MG/ML</u>	<u>N014879 001</u>	
-----------	------------------------	----------------	--------------------	--

DOXAPRAM HYDROCHLORIDE

<u>AP</u>	AMPHASTAR PHARMS INC	<u>20MG/ML</u>	<u>A076266 001</u>	Jan 10, 2003
-----------	----------------------	----------------	--------------------	--------------

DOXAZOSIN MESYLATE

TABLET;ORAL

CARDURA

<u>AB</u>	+ PFIZER	<u>EQ 1MG BASE</u>	<u>N019668 001</u>	Nov 02, 1990
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>N019668 002</u>	Nov 02, 1990
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>N019668 003</u>	Nov 02, 1990
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>N019668 004</u>	Nov 02, 1990

DOXAZOSIN MESYLATE

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 1MG BASE</u>	<u>A202824 001</u>	Jun 11, 2014
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A202824 002</u>	Jun 11, 2014
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A202824 003</u>	Jun 11, 2014
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A202824 004</u>	Jun 11, 2014
<u>AB</u>	APOTEX	<u>EQ 1MG BASE</u>	<u>A075580 001</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075580 002</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A075580 003</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A075580 004</u>	Oct 18, 2000
<u>AB</u>	DAVA PHARMS INC	<u>EQ 1MG BASE</u>	<u>A076161 001</u>	Jun 10, 2004
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A076161 002</u>	Jun 10, 2004
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076161 003</u>	Jun 10, 2004
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A076161 004</u>	Jun 10, 2004
<u>AB</u>	MYLAN	<u>EQ 1MG BASE</u>	<u>A075509 001</u>	Oct 19, 2000
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075509 002</u>	Oct 19, 2000
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A075509 003</u>	Oct 19, 2000
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A075509 004</u>	Oct 19, 2000
<u>AB</u>	PLIVA	<u>EQ 1MG BASE</u>	<u>A075750 001</u>	Jun 08, 2001
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075750 002</u>	Jun 08, 2001
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A075750 003</u>	Jun 08, 2001
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A075750 004</u>	Jun 08, 2001
<u>AB</u>	TEVA	<u>EQ 1MG BASE</u>	<u>A075536 001</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075536 002</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A075536 003</u>	Oct 18, 2000
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A075536 004</u>	Oct 18, 2000

TABLET, EXTENDED RELEASE;ORAL

CARDURA XL

	PFIZER	<u>EQ 4MG BASE</u>	<u>N021269 001</u>	Feb 22, 2005
	+	<u>EQ 8MG BASE</u>	<u>N021269 002</u>	Feb 22, 2005

PRESCRIPTION DRUG PRODUCT LIST

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

<u>AB</u>	MYLAN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A070791 002</u>	May 13, 1986
<u>AB</u>	+	<u>EQ 25MG BASE</u>	<u>A070791 003</u>	May 13, 1986
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A070791 001</u>	May 13, 1986
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A070791 004</u>	May 13, 1986
<u>AB</u>	+	<u>EQ 100MG BASE</u>	<u>A070791 005</u>	May 13, 1986
	+ PAR PHARM	EQ 150MG BASE	A071669 001	Nov 09, 1987

CONCENTRATE; ORAL

DOXEPIN HYDROCHLORIDE

<u>AA</u>	SILARX	<u>EQ 10MG BASE/ML</u>	<u>A074721 001</u>	Dec 29, 1998
<u>AA</u>	+	<u>EQ 10MG BASE/ML</u>	<u>A071609 001</u>	Nov 09, 1987
<u>AA</u>	WOCKHARDT	<u>EQ 10MG BASE/ML</u>	<u>A071918 001</u>	Jul 20, 1988

CREAM; TOPICAL

ZONALON

	+	DELCOR ASSET CORP	5%	N020126 001	Apr 01, 1994
--	---	-------------------	----	-------------	--------------

TABLET; ORAL

DOXEPIN HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>EQ 3MG BASE</u>	<u>A201951 001</u>	Jul 26, 2013
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A201951 002</u>	Jul 26, 2013
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 3MG BASE</u>	<u>A202337 001</u>	Jan 20, 2016
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A202337 002</u>	Jan 20, 2016

SILENOR

<u>AB</u>	PERNIX THERAPS LLC	<u>EQ 3MG BASE</u>	<u>N022036 001</u>	Mar 17, 2010
<u>AB</u>	+	<u>EQ 6MG BASE</u>	<u>N022036 002</u>	Mar 17, 2010

DOXERCALCIFEROL

CAPSULE; ORAL

DOXERCALCIFEROL

<u>AB</u>	RISING PHARMS INC	<u>0.5MCG</u>	<u>A201518 001</u>	Sep 09, 2016
<u>AB</u>		<u>1MCG</u>	<u>A201518 002</u>	Sep 09, 2016
<u>AB</u>		<u>2.5MCG</u>	<u>A201518 003</u>	Sep 09, 2016
<u>AB</u>	WEST-WARD PHARMS INT	<u>0.5MCG</u>	<u>A091433 001</u>	Sep 23, 2011
<u>AB</u>		<u>1MCG</u>	<u>A091433 002</u>	Jan 14, 2014
<u>AB</u>		<u>2.5MCG</u>	<u>A091433 003</u>	Jan 14, 2014

HECTOROL

<u>AB</u>	GENZYME CORP	<u>0.5MCG</u>	<u>N020862 002</u>	Apr 23, 2004
<u>AB</u>		<u>1MCG</u>	<u>N020862 003</u>	Jul 13, 2009
<u>AB</u>	+	<u>2.5MCG</u>	<u>N020862 001</u>	Jun 09, 1999

INJECTABLE; INJECTION

DOXERCALCIFEROL

<u>AP</u>	AKORN INC	<u>2MCG/ML (2MCG/ML)</u>	<u>A203929 002</u>	Mar 28, 2016
<u>AP</u>		<u>4MCG/2ML (2MCG/ML)</u>	<u>A203929 001</u>	May 07, 2015
<u>AP</u>	HIKMA PHARMS LLC	<u>4MCG/2ML (2MCG/ML)</u>	<u>A091101 001</u>	Aug 30, 2013
<u>AP</u>	SANDOZ INC	<u>4MCG/2ML (2MCG/ML)</u>	<u>A091333 001</u>	May 05, 2014
<u>AP</u>		<u>4MCG/2ML (2MCG/ML)</u>	<u>A200926 001</u>	Feb 04, 2014

HECTOROL

<u>AP</u>	GENZYME CORP	<u>2MCG/ML (2MCG/ML)</u>	<u>N021027 002</u>	Apr 06, 2000
<u>AP</u>	+	<u>4MCG/2ML (2MCG/ML)</u>	<u>N021027 001</u>	Apr 06, 2000

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

<u>AP</u>	ACTAVIS INC	<u>2MG/ML</u>	<u>A203622 001</u>	Jun 27, 2014
<u>AP</u>		<u>200MG/100ML</u>	<u>A203622 002</u>	Jun 27, 2014
<u>AP</u>	ALVOGEN INC	<u>2MG/ML</u>	<u>A065515 001</u>	Nov 08, 2012
<u>AP</u>	FRESENIUS KABI USA	<u>2MG/ML</u>	<u>A063277 001</u>	Oct 26, 1995
<u>AP</u>	MYLAN LABS LTD	<u>2MG/ML</u>	<u>A200901 001</u>	Feb 14, 2012
<u>AP</u>		<u>10MG/VIAL</u>	<u>A200170 001</u>	Oct 28, 2011
<u>AP</u>		<u>50MG/VIAL</u>	<u>A200170 002</u>	Oct 28, 2011
<u>AP</u>	PHARMACHEMIE BV	<u>2MG/ML</u>	<u>A063336 001</u>	Feb 28, 1995
<u>AP</u>		<u>10MG/VIAL</u>	<u>A063097 001</u>	May 21, 1990
<u>AP</u>		<u>20MG/VIAL</u>	<u>A063097 002</u>	May 21, 1990
<u>AP</u>		<u>50MG/VIAL</u>	<u>A063097 003</u>	May 21, 1990
<u>AP</u>		<u>200MG/100ML</u>	<u>A063336 004</u>	Feb 28, 1995
<u>AP</u>	+	<u>2MG/ML</u>	<u>N050629 001</u>	Dec 23, 1987
<u>AP</u>	+	<u>200MG/100ML</u>	<u>N050629 002</u>	May 03, 1988
<u>AP</u>	SAGENT PHARMS	<u>2MG/ML</u>	<u>A091495 001</u>	Mar 18, 2013
<u>AP</u>	SUN PHARM INDS	<u>2MG/ML</u>	<u>A091418 001</u>	Feb 15, 2012
<u>AP</u>	TEVA PHARMS USA	<u>2MG/ML</u>	<u>A064140 001</u>	Jul 28, 1995
<u>AP</u>		<u>200MG/100ML</u>	<u>A064140 002</u>	Jul 28, 1995
<u>AP</u>	WEST-WARD PHARMS INT	<u>2MG/ML</u>	<u>A062975 001</u>	Mar 17, 1989

PRESCRIPTION DRUG PRODUCT LIST

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

<u>AP</u>	+	<u>10MG/VIAL</u>	<u>A062921 001</u>	Mar 17, 1989
<u>AP</u>	+	<u>20MG/VIAL</u>	<u>A062921 002</u>	Mar 17, 1989
<u>AP</u>	+	<u>50MG/VIAL</u>	<u>A062921 003</u>	Mar 17, 1989
<u>AP</u>		<u>200MG/100ML</u>	<u>A064097 001</u>	Sep 13, 1994
	PHARMACIA AND UPJOHN	150MG/75ML	N050629 003	Mar 28, 2011

INJECTABLE, LIPOSOMAL; INJECTION

DOXIL (LIPOSOMAL)

<u>AB</u>	JANSSEN RES AND DEV	<u>20MG/10ML (2MG/ML)</u>	<u>N050718 001</u>	Nov 17, 1995	
<u>AB</u>		<u>50MG/25ML (2MG/ML)</u>	<u>N050718 002</u>	Jun 13, 2000	
	<u>DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)</u>				
<u>AB</u>	+	SUN PHARMA GLOBAL	<u>20MG/10ML (2MG/ML)</u>	<u>A203263 001</u>	Feb 04, 2013
<u>AB</u>	+		<u>50MG/25ML (2MG/ML)</u>	<u>A203263 002</u>	Feb 04, 2013

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

<u>AB</u>	G AND W LABS INC	<u>EQ 50MG BASE</u>	<u>A204446 001</u>	May 28, 2015	
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A204446 002</u>	May 28, 2015	
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A204446 003</u>	May 28, 2015	
<u>AB</u>	IMPAX LABS INC	<u>EQ 150MG BASE</u>	<u>A200065 001</u>	Feb 17, 2011	
<u>AB</u>	LUPIN LTD	<u>EQ 50MG BASE</u>	<u>A204234 001</u>	Mar 05, 2014	
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A204234 002</u>	Mar 05, 2014	
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A204234 003</u>	Mar 05, 2014	
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 150MG BASE</u>	<u>A202778 001</u>	Jun 08, 2012	
<u>AB</u>	PAR PHARM	<u>EQ 50MG BASE</u>	<u>A065055 001</u>	Dec 01, 2000	
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065055 002</u>	Dec 01, 2000	
<u>AB</u>	+		<u>EQ 150MG BASE</u>	<u>A065055 003</u>	Jul 15, 2005
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 50MG BASE</u>	<u>A065053 001</u>	Nov 22, 2000	
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065053 003</u>	Sep 10, 2003	
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065053 002</u>	Nov 22, 2000	
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 50MG BASE</u>	<u>A205115 001</u>	Feb 18, 2016	
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A205115 002</u>	Feb 18, 2016	
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A205115 003</u>	Feb 18, 2016	

MONODOX

<u>AB</u>	AQUA PHARMS	<u>EQ 50MG BASE</u>	<u>N050641 002</u>	Feb 10, 1992	
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>N050641 003</u>	Oct 18, 2006	
<u>AB</u>	+		<u>EQ 100MG BASE</u>	<u>N050641 001</u>	Dec 29, 1989
	ORACEA				
	+	GALDERMA LABS LP	40MG	N050805 001	May 26, 2006
	FOR SUSPENSION; ORAL				

DOXYCYCLINE

<u>AB</u>	CHARTWELL LIFE SCI	<u>EQ 25MG BASE/5ML</u>	<u>A065454 001</u>	Jul 16, 2008
<u>AB</u>	LUPIN LTD	<u>EQ 25MG BASE/5ML</u>	<u>A201678 001</u>	Mar 18, 2013

VIBRAMYCIN

<u>AB</u>	+	PFIZER	<u>EQ 25MG BASE/5ML</u>	<u>N050006 001</u>
	TABLET; ORAL			

DOXYCYCLINE

<u>AB</u>	HERITAGE PHARMS INC	<u>EQ 50MG BASE</u>	<u>A091605 001</u>	Dec 20, 2011	
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A091605 002</u>	Dec 20, 2011	
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A091605 003</u>	Dec 20, 2011	
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A091605 004</u>	Dec 20, 2011	
<u>AB</u>	LANNETT	<u>EQ 50MG BASE</u>	<u>A065285 001</u>	Dec 08, 2005	
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065285 003</u>	Jul 30, 2008	
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065285 002</u>	Dec 08, 2005	
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A065285 004</u>	Jul 30, 2008	
<u>AB</u>	MYLAN	<u>EQ 50MG BASE</u>	<u>A065377 001</u>	Nov 07, 2006	
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065377 002</u>	Nov 07, 2006	
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065377 003</u>	Nov 07, 2006	
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A065427 001</u>	Jun 07, 2007	
<u>AB</u>	PAR PHARM	<u>EQ 50MG BASE</u>	<u>A065070 001</u>	Dec 15, 2000	
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065070 003</u>	Dec 30, 2002	
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065070 002</u>	Dec 15, 2000	
<u>AB</u>	+		<u>EQ 150MG BASE</u>	<u>A065070 004</u>	Jul 14, 2005
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 50MG BASE</u>	<u>A065356 001</u>	May 31, 2006	
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065356 002</u>	May 31, 2006	
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065356 003</u>	May 31, 2006	

PRESCRIPTION DRUG PRODUCT LIST

DOXYCYCLINE CALCIUM

SUSPENSION; ORAL

VIBRAMYCIN

+ PFIZER

EQ 50MG BASE/5ML

N050480 001

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

<u>AB</u>	ACTAVIS LABS FL INC	<u>EQ 50MG BASE</u>	<u>A062031 002</u>	Oct 13, 1982
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062031 001</u>	
<u>AB</u>	AMNEAL PHARMS	<u>EQ 100MG BASE</u>	<u>A207289 001</u>	Jun 27, 2016
<u>AB</u>	CHARTWELL LIFE SCI	<u>EQ 50MG BASE</u>	<u>A062500 001</u>	Sep 11, 1984
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062500 002</u>	Sep 11, 1984
<u>AB</u>	HIKMA INTL PHARMS	<u>EQ 50MG BASE</u>	<u>A062396 002</u>	Nov 07, 1984
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062396 001</u>	May 07, 1984
<u>AB</u>	MUTUAL PHARM	<u>EQ 50MG BASE</u>	<u>A062675 001</u>	Jul 10, 1986
<u>AB</u>	MYLAN	<u>EQ 50MG BASE</u>	<u>A062337 001</u>	Mar 29, 1982
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062337 002</u>	Mar 29, 1982
<u>AB</u>	SUN PHARM INDS	<u>EQ 100MG BASE</u>	<u>A062676 001</u>	Jul 10, 1986

VIBRAMYCIN

<u>AB</u>	+ PFIZER	<u>EQ 100MG BASE</u>	<u>N050007 002</u>	
	ACTICLATE CAP			
	+ AQUA PHARMS	EQ 75MG BASE	N208253 001	Apr 26, 2016
	DOXYCYCLINE HYCLATE			
	+ HIKMA INTL PHARMS	EQ 20MG BASE	A065103 001	May 13, 2005
	CAPSULE, DELAYED RELEASE; ORAL			
	DOXYCYCLINE HYCLATE			
	MEDICIS	EQ 75MG BASE	A065281 001	Dec 21, 2005
	+	EQ 100MG BASE	A065281 002	Dec 21, 2005
	INJECTABLE; INJECTION			

DOXY 100

<u>AP</u>	+ FRESENIUS KABI USA	<u>EQ 100MG BASE/VIAL</u>	<u>A062475 001</u>	Dec 09, 1983
	<u>DOXYCYCLINE</u>			
<u>AP</u>	MYLAN LABS LTD	<u>EQ 100MG BASE/VIAL</u>	<u>A091406 001</u>	Aug 21, 2012
<u>AP</u>	+ WEST-WARD PHARMS INT	<u>EQ 100MG BASE/VIAL</u>	<u>A062569 001</u>	Mar 09, 1988
	DOXY 200			
	+ FRESENIUS KABI USA	EQ 200MG BASE/VIAL	A062475 002	Dec 09, 1983
	SYSTEM, EXTENDED RELEASE; PERIODONTAL			
	ATRIDOX			
	+ TOLMAR	50MG	N050751 001	Sep 03, 1998
	TABLET; ORAL			

DOXYCYCLINE HYCLATE

<u>AB</u>	ACTAVIS LABS FL INC	<u>EQ 100MG BASE</u>	<u>A062421 001</u>	Feb 02, 1983
<u>AB</u>	BLU CARIBE INC	<u>EQ 100MG BASE</u>	<u>A062269 002</u>	Nov 08, 1982
<u>AB</u>	CHARTWELL LIFE SCI	<u>EQ 100MG BASE</u>	<u>A062505 001</u>	Sep 11, 1984
<u>AB</u>	+ HIKMA INTL PHARMS	<u>EQ 100MG BASE</u>	<u>A065095 001</u>	Jul 02, 2003
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 20MG BASE</u>	<u>A065163 001</u>	May 13, 2005
<u>AB</u>	+ LANNETT	<u>EQ 20MG BASE</u>	<u>A065277 001</u>	Nov 10, 2005
<u>AB</u>	LARKEN LABS	<u>EQ 20MG BASE</u>	<u>A065287 001</u>	Feb 28, 2006
<u>AB</u>	MYLAN	<u>EQ 100MG BASE</u>	<u>A062432 001</u>	Feb 15, 1983
<u>AB</u>	SUN PHARM INDS	<u>EQ 20MG BASE</u>	<u>A065134 001</u>	May 13, 2005
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062677 001</u>	Jul 10, 1986
	ACTICLATE			
	AQUA PHARMS LLC	EQ 75MG BASE	N205931 001	Jul 25, 2014
	+	EQ 150MG BASE	N205931 002	Jul 25, 2014
	TABLET, DELAYED RELEASE; ORAL			

DORYX

<u>AB</u>	MAYNE PHARMA	<u>EQ 50MG BASE</u>	<u>N050795 006</u>	Dec 19, 2014
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>N050795 001</u>	May 06, 2005
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>N050795 004</u>	Apr 11, 2013
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>N050795 002</u>	May 06, 2005
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>N050795 003</u>	Jun 20, 2008
<u>AB</u>	+	<u>EQ 200MG BASE</u>	<u>N050795 005</u>	Apr 11, 2013

DOXYCYCLINE HYCLATE

<u>AB</u>	ACTAVIS ELIZABETH	<u>EQ 75MG BASE</u>	<u>A090134 001</u>	Dec 14, 2011
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090134 002</u>	Dec 14, 2011
<u>AB</u>	HERITAGE PHARMS INC	<u>EQ 75MG BASE</u>	<u>A200856 001</u>	Apr 30, 2013
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A200856 002</u>	Apr 30, 2013
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A200856 003</u>	Apr 30, 2013
<u>AB</u>	MYLAN	<u>EQ 50MG BASE</u>	<u>A090431 003</u>	May 23, 2016
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090431 001</u>	Dec 28, 2010
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A090431 004</u>	Apr 29, 2016
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090431 002</u>	Dec 28, 2010

PRESCRIPTION DRUG PRODUCT LIST

DOXYCYCLINE HYCLATE

TABLET, DELAYED RELEASE;ORAL

DOXYCYCLINE HYCLATE

AB		EQ 200MG BASE	A090431 005	May 19, 2016
AB	MYLAN PHARMS INC	EQ 150MG BASE	A091052 001	Feb 08, 2012
AB	PRINSTON INC	EQ 150MG BASE	A207494 001	Nov 15, 2016
AB		EQ 200MG BASE	A207494 002	Nov 15, 2016
	DORYX MPC			
	MAYNE PHARMA	EQ 60MG BASE	N050795 007	May 20, 2016
	+	EQ 120MG BASE	N050795 008	May 20, 2016

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, DELAYED RELEASE;ORAL

DICLEGIS

AB	+	DUCHESNAY	10MG;10MG	N021876 001	Apr 08, 2013
-----------	---	-----------	------------------	--------------------	--------------

DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE

AB		ACTAVIS LABS FL INC	10MG;10MG	A205811 001	Aug 19, 2016
-----------	--	---------------------	------------------	--------------------	--------------

TABLET, EXTENDED RELEASE;ORAL

BONJESTA

	+	DUCHESNAY	20MG;20MG	N209661 001	Nov 07, 2016
--	---	-----------	-----------	-------------	--------------

DRONABINOL

CAPSULE;ORAL

DRONABINOL

AB		AKORN INC	2.5MG	A079217 001	Jun 20, 2014
AB			5MG	A079217 002	Jun 20, 2014
AB			10MG	A079217 003	Jun 20, 2014
AB		SVC PHARMA	2.5MG	A078292 001	Jun 27, 2008
AB			5MG	A078292 002	Jun 27, 2008
AB			10MG	A078292 003	Jun 27, 2008

MARINOL

AB		ABBVIE	2.5MG	N018651 001	May 31, 1985
AB	+		5MG	N018651 002	May 31, 1985
AB			10MG	N018651 003	May 31, 1985

DRONEDARONE HYDROCHLORIDE

TABLET;ORAL

MULTAQ

	+	SANOFI AVENTIS US	EQ 400MG BASE	N022425 001	Jul 01, 2009
--	---	-------------------	---------------	-------------	--------------

DROPERIDOL

INJECTABLE;INJECTION

DROPERIDOL

AP		HOSPIRA	2.5MG/ML	A071981 001	Feb 29, 1988
AP		LUITPOLD	2.5MG/ML	A072123 001	Oct 24, 1988

INAPSINE

AP	+	AKORN INC	2.5MG/ML	N016796 001	
-----------	---	-----------	-----------------	--------------------	--

DROSPIRENONE; ESTRADIOL

TABLET;ORAL

ANGELIQ

		BAYER HLTHCARE	0.25MG;0.5MG	N021355 001	Feb 29, 2012
	+		0.5MG;1MG	N021355 002	Sep 28, 2005

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

AB		BARR	3MG;0.02MG	A078515 001	Mar 30, 2009
AB		GLENMARK PHARMS LTD	3MG;0.02MG	A204296 001	Aug 17, 2015
AB		JAI PHARMA LTD	3MG;0.02MG	A202594 001	Oct 22, 2015
AB		WATSON LABS	3MG;0.02MG	A078833 001	Nov 28, 2011

LORYNA

AB		SANDOZ	3MG;0.02MG	A079221 001	Mar 28, 2011
-----------	--	--------	-------------------	--------------------	--------------

MELAMISA

AB		NOVAST LABS LTD	3MG;0.02MG	A202016 001	Jan 26, 2016
-----------	--	-----------------	-------------------	--------------------	--------------

NIKKI

AB		LUPIN LTD	3MG;0.02MG	A201661 001	May 27, 2014
-----------	--	-----------	-------------------	--------------------	--------------

YAZ

AB	+	BAYER HLTHCARE	3MG;0.02MG	N021676 001	Mar 16, 2006
-----------	---	----------------	-------------------	--------------------	--------------

TABLET;ORAL-28

DROSPIRENONE AND ETHINYL ESTRADIOL

AB		ACCORD HLTHCARE	3MG;0.03MG	A207245 001	Nov 22, 2016
AB		APOTEX INC	3MG;0.03MG	A205876 001	Sep 21, 2016
AB		BARR	3MG;0.03MG	A077527 001	May 09, 2008
AB		GLENMARK PHARMS LTD	3MG;0.03MG	A204848 001	Mar 25, 2016

PRESCRIPTION DRUG PRODUCT LIST

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL-28

DROSPIRENONE AND ETHINYL ESTRADIOL

<u>AB</u>	JAI PHARMA LTD	<u>3MG;0.03MG</u>	<u>A202131</u>	<u>001</u>	May 04, 2015
<u>AB</u>	LUPIN LTD	<u>3MG;0.03MG</u>	<u>A201663</u>	<u>001</u>	Dec 18, 2012
<u>AB</u>	MAYNE PHARMA	<u>3MG;0.03MG</u>	<u>A090081</u>	<u>001</u>	Sep 07, 2010
<u>SYEDA</u>					
<u>AB</u>	SANDOZ	<u>3MG;0.03MG</u>	<u>A090114</u>	<u>001</u>	Mar 28, 2011
<u>YAELA</u>					
<u>AB</u>	NOVAST LABS LTD	<u>3MG;0.03MG</u>	<u>A202015</u>	<u>001</u>	Nov 19, 2014
<u>YASMIN</u>					
<u>AB</u>	+ BAYER HLTHCARE	<u>3MG;0.03MG</u>	<u>N021098</u>	<u>001</u>	May 11, 2001

DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM

TABLET; ORAL

BEYAZ

<u>AB</u>	BAYER HLTHCARE	<u>3MG,N/A:0.02MG,N/A:0.451MG,0.451MG</u>	<u>N022532</u>	<u>001</u>	Sep 24, 2010
-----------	----------------	---	----------------	------------	--------------

DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM

<u>AB</u>	WATSON LABS INC	<u>3MG,N/A:0.02MG,N/A:0.451MG,0.451MG</u>	<u>A203593</u>	<u>001</u>	Oct 11, 2016
<u>AB</u>		<u>3MG,N/A:0.03MG,N/A:0.451MG,0.451MG</u>	<u>A203594</u>	<u>001</u>	Oct 11, 2016

SAFYRAL

<u>AB</u>	+ BAYER HLTHCARE	<u>3MG,N/A:0.03MG,N/A:0.451MG,0.451MG</u>	<u>N022574</u>	<u>001</u>	Dec 16, 2010
-----------	------------------	---	----------------	------------	--------------

DROXIDOPA

CAPSULE; ORAL

NORTHERA

	LUNDBECK NA LTD	100MG	N203202	001	Feb 18, 2014
		200MG	N203202	002	Feb 18, 2014
	+	300MG	N203202	003	Feb 18, 2014

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS; ORAL

CYMBALTA

<u>AB</u>	LILLY	<u>EQ 20MG BASE</u>	<u>N021427</u>	<u>001</u>	Aug 03, 2004
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>N021427</u>	<u>002</u>	Aug 03, 2004
<u>AB</u>	+	<u>EQ 60MG BASE</u>	<u>N021427</u>	<u>004</u>	Aug 03, 2004

DULOXETINE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>EQ 20MG BASE</u>	<u>A090776</u>	<u>001</u>	Dec 17, 2013
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A090776</u>	<u>002</u>	Dec 17, 2013
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A090776</u>	<u>003</u>	Dec 17, 2013
<u>AB</u>	AJANTA PHARMA LTD	<u>EQ 20MG BASE</u>	<u>A208706</u>	<u>001</u>	Jan 06, 2017
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A208706</u>	<u>002</u>	Jan 06, 2017
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A208706</u>	<u>003</u>	Jan 06, 2017
<u>AB</u>	ALEMBIC PHARMS LTD	<u>EQ 20MG BASE</u>	<u>A202949</u>	<u>001</u>	Jun 09, 2014
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A202949</u>	<u>002</u>	Jun 09, 2014
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A202949</u>	<u>003</u>	Jun 09, 2014
<u>AB</u>	ALKEM LABS LTD	<u>EQ 20MG BASE</u>	<u>A203197</u>	<u>001</u>	Aug 26, 2015
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A203197</u>	<u>002</u>	Aug 26, 2015
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A203197</u>	<u>003</u>	Aug 26, 2015
<u>AB</u>	ANCHEN PHARMS	<u>EQ 20MG BASE</u>	<u>A090780</u>	<u>001</u>	Oct 28, 2015
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A090780</u>	<u>002</u>	Oct 28, 2015
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A090780</u>	<u>003</u>	Oct 28, 2015
<u>AB</u>	APOTEX INC	<u>EQ 20MG BASE</u>	<u>A202045</u>	<u>001</u>	Jun 11, 2014
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A202045</u>	<u>002</u>	Jun 11, 2014
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A202045</u>	<u>003</u>	Jun 11, 2014
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 20MG BASE</u>	<u>A090778</u>	<u>001</u>	Dec 11, 2013
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A090778</u>	<u>002</u>	Dec 11, 2013
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A090778</u>	<u>003</u>	Dec 11, 2013
<u>AB</u>	BRECKENRIDGE PHARM	<u>EQ 20MG BASE</u>	<u>A203088</u>	<u>001</u>	Jun 11, 2014
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A203088</u>	<u>002</u>	Jun 11, 2014
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A203088</u>	<u>003</u>	Jun 11, 2014
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 20MG BASE</u>	<u>A090723</u>	<u>001</u>	Dec 11, 2013
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A090723</u>	<u>002</u>	Dec 11, 2013
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A090723</u>	<u>003</u>	Dec 11, 2013
<u>AB</u>	HETERO LABS LTD III	<u>EQ 20MG BASE</u>	<u>A204343</u>	<u>001</u>	Aug 03, 2016
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A204343</u>	<u>002</u>	Aug 03, 2016
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A204343</u>	<u>003</u>	Aug 03, 2016
<u>AB</u>	INVENTIA HLTHCARE	<u>EQ 20MG BASE</u>	<u>A202336</u>	<u>001</u>	Oct 28, 2015
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A202336</u>	<u>002</u>	Oct 28, 2015
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A202336</u>	<u>003</u>	Oct 28, 2015
<u>AB</u>	LUPIN LTD	<u>EQ 20MG BASE</u>	<u>A090694</u>	<u>001</u>	Dec 11, 2013
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A090694</u>	<u>002</u>	Dec 11, 2013
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A090694</u>	<u>004</u>	Dec 11, 2013
<u>AB</u>	SUN PHARMA GLOBAL	<u>EQ 20MG BASE</u>	<u>A090745</u>	<u>001</u>	Dec 11, 2013

PRESCRIPTION DRUG PRODUCT LIST

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

DULOXETINE HYDROCHLORIDE

<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A090745 002</u>	Dec 11, 2013
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A090745 003</u>	Dec 11, 2013
<u>AB</u>	TEVA PHARMS USA	<u>EQ 20MG BASE</u>	<u>A090783 001</u>	Dec 11, 2013
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A090783 002</u>	Dec 11, 2013
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A090783 003</u>	Dec 11, 2013
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 20MG BASE</u>	<u>A090774 001</u>	Dec 11, 2013
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A090774 002</u>	Dec 11, 2013
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A090774 003</u>	Dec 11, 2013
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 20MG BASE</u>	<u>A090728 001</u>	Jan 08, 2014
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A090739 001</u>	Jan 08, 2014
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A090728 002</u>	Jan 08, 2014
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A090739 002</u>	Jan 08, 2014
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A090728 003</u>	Jan 08, 2014
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A090739 003</u>	Jan 08, 2014
	LUPIN LTD	EQ 40MG BASE	A090694 003	Dec 11, 2013

DUTASTERIDE

CAPSULE;ORAL

AVODART

<u>AB</u>	+ GLAXOSMITHKLINE	<u>0.5MG</u>	<u>N021319 001</u>	Nov 20, 2001
-----------	-------------------	--------------	--------------------	--------------

DUTASTERIDE

<u>AB</u>	ACTAVIS LABS FL INC	<u>0.5MG</u>	<u>A202808 001</u>	Nov 20, 2015
<u>AB</u>	AMNEAL PHARMS	<u>0.5MG</u>	<u>A203118 001</u>	Nov 20, 2015
<u>AB</u>	APOTEX INC	<u>0.5MG</u>	<u>A204292 001</u>	Nov 24, 2015
<u>AB</u>	ASCENT PHARMS INC	<u>0.5MG</u>	<u>A206574 001</u>	Oct 21, 2016
<u>AB</u>	AUROLIFE PHARMA LLC	<u>0.5MG</u>	<u>A202660 001</u>	Nov 20, 2015
<u>AB</u>	BARR	<u>0.5MG</u>	<u>A090095 001</u>	Dec 21, 2010
<u>AB</u>	BIONPHARMA INC	<u>0.5MG</u>	<u>A200899 001</u>	Nov 20, 2015
<u>AB</u>	BRECKENRIDGE PHARM	<u>0.5MG</u>	<u>A204705 001</u>	Nov 20, 2015
<u>AB</u>	INTERGEL PHARMS INC	<u>0.5MG</u>	<u>A206373 001</u>	Mar 17, 2016
<u>AB</u>	MYLAN PHARMS INC	<u>0.5MG</u>	<u>A203241 001</u>	Jun 14, 2016
<u>AB</u>	RISING PHARMS INC	<u>0.5MG</u>	<u>A202530 001</u>	Nov 20, 2015
<u>AB</u>	STRIDES PHARMA	<u>0.5MG</u>	<u>A204262 001</u>	Nov 20, 2015
<u>AB</u>	VINTAGE PHARMS LLC	<u>0.5MG</u>	<u>A202421 001</u>	Nov 20, 2015
<u>AB</u>	WEST-WARD PHARMS INT	<u>0.5MG</u>	<u>A202204 001</u>	Nov 23, 2015

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

<u>AB</u>	ACTAVIS LABS FL INC	<u>0.5MG;0.4MG</u>	<u>A202975 001</u>	Nov 20, 2015
<u>AB</u>	ANCHEN PHARMS	<u>0.5MG;0.4MG</u>	<u>A202509 001</u>	Feb 26, 2014

JALYN

<u>AB</u>	+ GLAXOSMITHKLINE	<u>0.5MG;0.4MG</u>	<u>N022460 001</u>	Jun 14, 2010
-----------	-------------------	--------------------	--------------------	--------------

ECHOTHIOPHATE IODIDEFOR SOLUTION;OPHTHALMIC
PHOSPHOLINE IODIDE

	+ WYETH PHARMS INC	0.125%	N011963 001	
--	--------------------	--------	-------------	--

ECONAZOLE NITRATEAEROSOL, FOAM;TOPICAL
ECOZA

	+ EXELTIS SUISSE	1%	N205175 001	Oct 24, 2013
--	------------------	----	-------------	--------------

CREAM;TOPICAL

ECONAZOLE NITRATE

<u>AB</u>	FOUGERA PHARMS	<u>1%</u>	<u>A076075 001</u>	Nov 26, 2002
<u>AB</u>	+ PERRIGO NEW YORK	<u>1%</u>	<u>A076479 001</u>	Jun 23, 2004
<u>AB</u>	TARO	<u>1%</u>	<u>A076005 001</u>	Nov 26, 2002
<u>AB</u>	TELIGENT PHARMA INC	<u>1%</u>	<u>A076574 001</u>	Dec 17, 2004

EDETATE CALCIUM DISODIUM

INJECTABLE;INJECTION

CALCIUM DISODIUM VERSENATE

	+ MEDICIS	200MG/ML	N008922 001	
--	-----------	----------	-------------	--

EDOXABAN TOSYLATE

TABLET;ORAL

SAVAYSA

	DAIICHI SANKYO INC	EQ 15MG BASE	N206316 001	Jan 08, 2015
		EQ 30MG BASE	N206316 002	Jan 08, 2015
	+	EQ 60MG BASE	N206316 003	Jan 08, 2015

PRESCRIPTION DRUG PRODUCT LIST

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

ENLON

+ MYLAN INSTITUTIONAL 10MG/ML

A088873 001 Aug 06, 1985

EFAVIRENZ

CAPSULE; ORAL

SUSTIVA

BRISTOL MYERS SQUIBB 50MG

N020972 001 Sep 17, 1998

+ 200MG

N020972 003 Sep 17, 1998

TABLET; ORAL

EFAVIRENZ**AB** MYLAN PHARMS INC **600MG****A091471 001** Feb 17, 2016**SUSTIVA****AB** + BRISTOL MYERS SQUIBB **600MG****N021360 002** Feb 01, 2002EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

ATRIPLA

+ GILEAD 600MG; 200MG; 300MG

N021937 001 Jul 12, 2006

EFINACONAZOLE

SOLUTION; TOPICAL

JUBLIA

+ DOW PHARM 10%

N203567 001 Jun 06, 2014

EFLORNITHINE HYDROCHLORIDE

CREAM; TOPICAL

VANIQA

+ SKINMEDICA 13.9%

N021145 001 Jul 27, 2000

ELBASVIR; GRAZOPREXIVIR

TABLET; ORAL

ZEPATIER

+ MERCK SHARP DOHME 50MG; 100MG

N208261 001 Jan 28, 2016

ELETRIPTAN HYDROBROMIDE

TABLET; ORAL

RELPAX

PFIZER IRELAND EQ 20MG BASE

N021016 001 Dec 26, 2002

+ EQ 40MG BASE

N021016 002 Dec 26, 2002

ELIGLUSTAT TARTRATE

CAPSULE; ORAL

CERDELGA

+ GENZYME CORP EQ 84MG BASE

N205494 001 Aug 19, 2014

ELTROMBOPAG OLAMINE

FOR SUSPENSION; ORAL

PROMACTA

+ NOVARTIS PHARMS CORP EQ 25MG ACID/PACKET

N207027 001 Aug 24, 2015

TABLET; ORAL

PROMACTA

NOVARTIS PHARMS CORP EQ 12.5MG ACID

N022291 004 Oct 20, 2011

EQ 25MG ACID

N022291 001 Nov 20, 2008

EQ 50MG ACID

N022291 002 Nov 20, 2008

+ EQ 75MG ACID

N022291 003 Sep 08, 2009

+ EQ 100MG ACID

N022291 005 Nov 16, 2012

ELUXADOLINE

TABLET; ORAL

VIBERZI

ALLERGAN HOLDINGS 75MG

N206940 001 May 27, 2015

+ 100MG

N206940 002 May 27, 2015

ELVITEGRAVIR

TABLET; ORAL

VITEKTA

GILEAD SCIENCES INC 85MG

N203093 001 Sep 24, 2014

+ 150MG

N203093 002 Sep 24, 2014

EMEDASTINE DIFUMARATE

SOLUTION/DROPS; OPHTHALMIC

EMADINE

+ NOVARTIS PHARMS CORP 0.05%

N020706 001 Dec 29, 1997

PRESCRIPTION DRUG PRODUCT LIST

EMPAGLIFLOZIN

TABLET; ORAL

JARDIANCE

BOEHRINGER INGELHEIM	10MG	N204629	001	Aug 01, 2014
+	25MG	N204629	002	Aug 01, 2014

EMPAGLIFLOZIN; LINAGLIPTIN

TABLET; ORAL

GLYXAMBI

BOEHRINGER INGELHEIM	10MG; 5MG	N206073	001	Jan 30, 2015
+	25MG; 5MG	N206073	002	Jan 30, 2015

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL

SYNJARDY

BOEHRINGER INGELHEIM	5MG; 500MG	N206111	001	Aug 26, 2015
	5MG; 1GM	N206111	002	Aug 26, 2015
	12.5MG; 500MG	N206111	003	Aug 26, 2015
+	12.5MG; 1GM	N206111	004	Aug 26, 2015

TABLET, EXTENDED RELEASE; ORAL

SYNJARDY XR

BOEHRINGER INGELHEIM	5MG; 1GM	N208658	001	Dec 09, 2016
	10MG; 1GM	N208658	002	Dec 09, 2016
	12.5MG; 1GM	N208658	003	Dec 09, 2016
+	25MG; 1GM	N208658	004	Dec 09, 2016

EMTRICITABINE

CAPSULE; ORAL

EMTRIVA

+ GILEAD	200MG	N021500	001	Jul 02, 2003
----------	-------	---------	-----	--------------

SOLUTION; ORAL

EMTRIVA

+ GILEAD	10MG/ML	N021896	001	Sep 28, 2005
----------	---------	---------	-----	--------------

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET; ORAL

ODEFSEY

+ GILEAD SCIENCES INC	200MG; EQ 25MG BASE; EQ 25MG BASE	N208351	001	Mar 01, 2016
-----------------------	-----------------------------------	---------	-----	--------------

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

COMPLERA

+ GILEAD SCIENCES INC	200MG; EQ 25MG BASE; 300MG	N202123	001	Aug 10, 2011
-----------------------	----------------------------	---------	-----	--------------

EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET; ORAL

DESCOVY

+ GILEAD SCIENCES INC	200MG; EQ 25MG BASE	N208215	001	Apr 04, 2016
-----------------------	---------------------	---------	-----	--------------

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

TRUVADA

GILEAD	100MG; 150MG	N021752	002	Mar 10, 2016
	133MG; 200MG	N021752	003	Mar 10, 2016
	167MG; 250MG	N021752	004	Mar 10, 2016
+	200MG; 300MG	N021752	001	Aug 02, 2004

ENALAPRIL MALEATE

FOR SOLUTION; ORAL

EPANED KIT

+ SILVERGATE PHARMS	1MG/ML	N204308	001	Aug 13, 2013
---------------------	--------	---------	-----	--------------

SOLUTION; ORAL

EPANED

SILVERGATE PHARMS	1MG/ML	N208686	001	Sep 20, 2016
-------------------	--------	---------	-----	--------------

TABLET; ORAL

ENALAPRIL MALEATE

AB	APOTEX	2.5MG	A075178 002	Mar 23, 2001
AB		5MG	A075178 001	Mar 23, 2001
AB		10MG	A075178 003	Mar 23, 2001
AB		20MG	A075178 004	Mar 23, 2001
AB	MYLAN	2.5MG	A075480 001	Aug 22, 2000
AB		5MG	A075480 002	Aug 22, 2000
AB		10MG	A075480 003	Aug 22, 2000
AB		20MG	A075480 004	Aug 22, 2000
AB	SANDOZ INC	2.5MG	A075496 001	Aug 22, 2000
AB		5MG	A075496 002	Aug 22, 2000

PRESCRIPTION DRUG PRODUCT LIST

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

<u>AB</u>		<u>10MG</u>	<u>A075459 001</u>	Aug 22, 2000
<u>AB</u>		<u>20MG</u>	<u>A075459 002</u>	Aug 22, 2000
<u>AB</u>	TARO	<u>2.5MG</u>	<u>A075657 001</u>	Jan 23, 2001
<u>AB</u>		<u>5MG</u>	<u>A075657 002</u>	Jan 23, 2001
<u>AB</u>		<u>10MG</u>	<u>A075657 003</u>	Jan 23, 2001
<u>AB</u>		<u>20MG</u>	<u>A075657 004</u>	Jan 23, 2001
<u>AB</u>	TEVA	<u>2.5MG</u>	<u>A075479 001</u>	Aug 22, 2000
<u>AB</u>		<u>5MG</u>	<u>A075479 002</u>	Aug 22, 2000
<u>AB</u>		<u>10MG</u>	<u>A075479 003</u>	Aug 22, 2000
<u>AB</u>		<u>20MG</u>	<u>A075479 004</u>	Aug 22, 2000
<u>AB</u>	WOCKHARDT USA	<u>2.5MG</u>	<u>A075483 001</u>	Aug 22, 2000
<u>AB</u>		<u>5MG</u>	<u>A075483 002</u>	Aug 22, 2000
<u>AB</u>		<u>10MG</u>	<u>A075483 003</u>	Aug 22, 2000
<u>AB</u>		<u>20MG</u>	<u>A075483 004</u>	Aug 22, 2000
<u>VASOTEC</u>				
<u>AB</u>	VALEANT PHARMS NORTH	<u>2.5MG</u>	<u>N018998 005</u>	Jul 26, 1988
<u>AB</u>		<u>5MG</u>	<u>N018998 001</u>	Dec 24, 1985
<u>AB</u>		<u>10MG</u>	<u>N018998 002</u>	Dec 24, 1985
<u>AB</u>	+	<u>20MG</u>	<u>N018998 003</u>	Dec 24, 1985

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	APOTEX INC	<u>5MG;12.5MG</u>	<u>A076486 001</u>	Oct 27, 2004
<u>AB</u>		<u>10MG;25MG</u>	<u>A076486 002</u>	Oct 27, 2004
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG;12.5MG</u>	<u>A075909 001</u>	Oct 15, 2001
<u>AB</u>		<u>10MG;25MG</u>	<u>A075909 002</u>	Oct 15, 2001
<u>AB</u>	G AND W LABS INC	<u>5MG;12.5MG</u>	<u>A075727 001</u>	Sep 18, 2001
<u>AB</u>		<u>10MG;25MG</u>	<u>A075727 002</u>	Sep 18, 2001
<u>AB</u>	MYLAN	<u>5MG;12.5MG</u>	<u>A075624 001</u>	Sep 18, 2001
<u>AB</u>		<u>10MG;25MG</u>	<u>A075624 002</u>	Sep 18, 2001
<u>AB</u>	TARO PHARM INDS	<u>5MG;12.5MG</u>	<u>A075788 001</u>	Sep 18, 2001
<u>AB</u>		<u>10MG;25MG</u>	<u>A075788 002</u>	Sep 18, 2001
<u>VASERETIC</u>				
<u>AB</u>	VALEANT INTL	<u>5MG;12.5MG</u>	<u>N019221 003</u>	Jul 12, 1995
<u>AB</u>	+	<u>10MG;25MG</u>	<u>N019221 001</u>	Oct 31, 1986

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

<u>AP</u>	+	AMPHASTAR PHARMS INC	<u>1.25MG/ML</u>	<u>A075634 001</u>	Aug 22, 2000
<u>AP</u>		HIKMA FARMACEUTICA	<u>1.25MG/ML</u>	<u>A078687 001</u>	Dec 23, 2008
<u>AP</u>	+	HOSPIRA	<u>1.25MG/ML</u>	<u>A075458 001</u>	Aug 22, 2000
<u>AP</u>		TEVA PHARMS USA	<u>1.25MG/ML</u>	<u>A075578 001</u>	Aug 22, 2000

ENFUVRTIDE

INJECTABLE; SUBCUTANEOUS

FUZEON

+ ROCHE

90MG/VIAL

N021481 001 Mar 13, 2003

ENOXAPARIN SODIUM

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

ENOXAPARIN SODIUM

<u>AB</u>	SANDOZ INC	<u>300MG/3ML (100MG/ML)</u>	<u>A078660 001</u>	Nov 28, 2011
<u>LOVENOX</u>				
<u>AB</u>	SANOFI AVENTIS US	<u>300MG/3ML (100MG/ML)</u>	<u>N020164 009</u>	Jan 23, 2003

INJECTABLE; SUBCUTANEOUS

ENOXAPARIN SODIUM (PRESERVATIVE FREE)

<u>AP</u>	AMPHASTAR PHARM	<u>30MG/0.3ML (100MG/ML)</u>	<u>A076684 001</u>	Sep 19, 2011
<u>AP</u>		<u>40MG/0.4ML (100MG/ML)</u>	<u>A076684 002</u>	Sep 19, 2011
<u>AP</u>		<u>60MG/0.6ML (100MG/ML)</u>	<u>A076684 003</u>	Sep 19, 2011
<u>AP</u>		<u>80MG/0.8ML (100MG/ML)</u>	<u>A076684 004</u>	Sep 19, 2011
<u>AP</u>		<u>100MG/ML (100MG/ML)</u>	<u>A076684 005</u>	Sep 19, 2011
<u>AP</u>		<u>120MG/0.8ML (150MG/ML)</u>	<u>A076684 006</u>	Sep 19, 2011
<u>AP</u>		<u>150MG/ML (150MG/ML)</u>	<u>A076684 007</u>	Sep 19, 2011
<u>AP</u>	SANDOZ	<u>30MG/0.3ML (100MG/ML)</u>	<u>A077857 002</u>	Jul 23, 2010
<u>AP</u>		<u>40MG/0.4ML (100MG/ML)</u>	<u>A077857 003</u>	Jul 23, 2010
<u>AP</u>		<u>60MG/0.6ML (100MG/ML)</u>	<u>A077857 004</u>	Jul 23, 2010
<u>AP</u>		<u>80MG/0.8ML (100MG/ML)</u>	<u>A077857 005</u>	Jul 23, 2010
<u>AP</u>		<u>100MG/ML (100MG/ML)</u>	<u>A077857 001</u>	Jul 23, 2010
<u>AP</u>		<u>120MG/0.8ML (150MG/ML)</u>	<u>A077857 006</u>	Jul 23, 2010

PRESCRIPTION DRUG PRODUCT LIST

ENOXAPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

ENOXAPARIN SODIUM (PRESERVATIVE FREE)

<u>AP</u>		<u>150MG/ML (150MG/ML)</u>	<u>A077857 007</u>	Jul 23, 2010
<u>AP</u>	TEVA	<u>30MG/0.3ML (100MG/ML)</u>	<u>A076726 001</u>	Jun 23, 2014
<u>AP</u>		<u>40MG/0.4ML (100MG/ML)</u>	<u>A076726 002</u>	Jun 23, 2014
<u>AP</u>		<u>60MG/0.6ML (100MG/ML)</u>	<u>A076726 003</u>	Jun 23, 2014
<u>AP</u>		<u>80MG/0.8ML (100MG/ML)</u>	<u>A076726 004</u>	Jun 23, 2014
<u>AP</u>		<u>100MG/ML (100MG/ML)</u>	<u>A076726 005</u>	Jun 23, 2014
<u>AP</u>		<u>120MG/0.8ML (150MG/ML)</u>	<u>A076726 006</u>	Jun 23, 2014
<u>AP</u>		<u>150MG/ML (150MG/ML)</u>	<u>A076726 007</u>	Jun 23, 2014

LOVENOX (PRESERVATIVE FREE)

<u>AP</u>	SANOFI AVENTIS US	<u>30MG/0.3ML (100MG/ML)</u>	<u>N020164 001</u>	Mar 29, 1993
<u>AP</u>		<u>40MG/0.4ML (100MG/ML)</u>	<u>N020164 002</u>	Jan 30, 1998
<u>AP</u>		<u>60MG/0.6ML (100MG/ML)</u>	<u>N020164 003</u>	Mar 27, 1998
<u>AP</u>		<u>80MG/0.8ML (100MG/ML)</u>	<u>N020164 004</u>	Mar 27, 1998
<u>AP</u>	+	<u>100MG/ML (100MG/ML)</u>	<u>N020164 005</u>	Mar 27, 1998
<u>AP</u>		<u>120MG/0.8ML (150MG/ML)</u>	<u>N020164 007</u>	Jun 02, 2000
<u>AP</u>		<u>150MG/ML (150MG/ML)</u>	<u>N020164 008</u>	Jun 02, 2000

ENTACAPONE

TABLET; ORAL

COMTAN

<u>AB</u>	+	ORION PHARMA	<u>200MG</u>	<u>N020796 001</u>	Oct 19, 1999
-----------	---	--------------	--------------	--------------------	--------------

ENTACAPONE

<u>AB</u>		AUROBINDO PHARMA LTD	<u>200MG</u>	<u>A203437 001</u>	Jun 19, 2015
<u>AB</u>		MYLAN PHARMS INC	<u>200MG</u>	<u>A202394 001</u>	May 13, 2013
<u>AB</u>		SUN PHARMA GLOBAL	<u>200MG</u>	<u>A090690 001</u>	Jul 16, 2012
<u>AB</u>		WOCKHARDT LTD	<u>200MG</u>	<u>A078941 001</u>	Aug 16, 2012

ENTECAVIR

SOLUTION; ORAL

BARACLUDE

+	BRISTOL MYERS SQUIBB	0.05MG/ML	N021798 001	Mar 29, 2005
---	----------------------	-----------	-------------	--------------

TABLET; ORAL

BARACLUDE

<u>AB</u>		BRISTOL MYERS SQUIBB	<u>0.5MG</u>	<u>N021797 001</u>	Mar 29, 2005
<u>AB</u>	+		<u>1MG</u>	<u>N021797 002</u>	Mar 29, 2005

ENTECAVIR

<u>AB</u>		AMNEAL PHARMS	<u>0.5MG</u>	<u>A206652 001</u>	Nov 12, 2015
<u>AB</u>			<u>1MG</u>	<u>A206652 002</u>	Nov 12, 2015
<u>AB</u>		AUROBINDO PHARMA LTD	<u>0.5MG</u>	<u>A206217 001</u>	Aug 26, 2015
<u>AB</u>			<u>1MG</u>	<u>A206217 002</u>	Aug 26, 2015
<u>AB</u>		CIPLA LTD	<u>0.5MG</u>	<u>A206872 001</u>	Dec 06, 2016
<u>AB</u>			<u>1MG</u>	<u>A206872 002</u>	Dec 06, 2016
<u>AB</u>		HETERO LABS LTD V	<u>0.5MG</u>	<u>A205740 001</u>	Aug 21, 2015
<u>AB</u>			<u>1MG</u>	<u>A205740 002</u>	Aug 21, 2015
<u>AB</u>		PAR PHARM INC	<u>0.5MG</u>	<u>A206294 001</u>	Nov 23, 2016
<u>AB</u>			<u>1MG</u>	<u>A206294 002</u>	Nov 23, 2016
<u>AB</u>		TEVA PHARMS USA	<u>0.5MG</u>	<u>A202122 001</u>	Aug 26, 2014
<u>AB</u>			<u>1MG</u>	<u>A202122 002</u>	Aug 26, 2014

ENZALUTAMIDE

CAPSULE; ORAL

XTANDI

+	ASTELLAS	40MG	N203415 001	Aug 31, 2012
---	----------	------	-------------	--------------

EPHEDRINE SULFATE

SOLUTION; INTRAVENOUS

AKOVAZ

+	FLAMEL IRELAND LTD	50MG/ML	N208289 001	Apr 29, 2016
---	--------------------	---------	-------------	--------------

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ELESTAT

<u>AT</u>	+	ALLERGAN	<u>0.05%</u>	<u>N021565 001</u>	Oct 16, 2003
-----------	---	----------	--------------	--------------------	--------------

EPINASTINE HYDROCHLORIDE

<u>AT</u>		ALCON RES LTD	<u>0.05%</u>	<u>A203384 001</u>	Dec 07, 2016
<u>AT</u>		APOTEX	<u>0.05%</u>	<u>A090919 001</u>	Oct 31, 2011
<u>AT</u>		BRECKENRIDGE PHARM	<u>0.05%</u>	<u>A090870 001</u>	Mar 14, 2011
<u>AT</u>		SOMERSET THERAPS LLC	<u>0.05%</u>	<u>A090951 001</u>	Oct 31, 2011
<u>AT</u>		SUN PHARM INDS	<u>0.05%</u>	<u>A091626 001</u>	Oct 31, 2011

PRESCRIPTION DRUG PRODUCT LIST

EPINEPHRINE

INJECTABLE; INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS

ADRENALIN

+ PAR STERILE PRODUCTS EQ 1MG BASE/ML (EQ 1MG BASE/ML)

N204200 001 Dec 07, 2012

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

ADRENACLICK

BX + AMEDRA PHARMS EQ 0.15MG/DELIVERY

N020800 003 Nov 25, 2009

BX + EQ 0.3MG/DELIVERY

N020800 004 Nov 25, 2009

AUVI-Q

BX + KALEO INC EQ 0.15MG/DELIVERY

N201739 002 Aug 10, 2012

BX EQ 0.3MG/DELIVERY

N201739 001 Aug 10, 2012

EPIPEN

BX + MYLAN SPECPLT 0.3MG/DELIVERY

N019430 001 Dec 22, 1987

EPIPEN JR.

BX + MYLAN SPECPLT 0.15MG/DELIVERY

N019430 002 Dec 22, 1987

ADRENALIN

+ PAR STERILE PRODUCTS EQ 30MG BASE/30ML (EQ 1MG BASE/ML)

N204640 001 Dec 18, 2013

SOLUTION; IV (INFUSION), INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS

EPINEPHRINE

BELCHER PHARMS LLC EQ 1MG BASE/ML (EQ 1MG BASE/ML)

N205029 001 Jul 29, 2014

EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIGNOSPAN FORTE

+ DEPROCO EQ 0.02MG BASE/ML; 2%

A088389 001 Jan 22, 1985

LIGNOSPAN STANDARD

+ DEPROCO EQ 0.01MG BASE/ML; 2%

A088390 001 Jan 22, 1985

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST FORTE DENTAL

AP + DENTSPLY PHARM 0.005MG/ML; 4%

N021383 001

PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE

AP SEPTODONT INC 0.005MG/ML; 4%

A078959 001 Aug 30, 2011

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

AP EASTMAN KODAK 0.01MG/ML; 2%

A040057 002 Feb 26, 1993

AP 0.02MG/ML; 2%

A040057 001 Feb 26, 1993

AP HOSPIRA 0.005MG/ML; 0.5%

A089635 001 Jun 21, 1988

AP 0.005MG/ML; 1.5%

A088571 001 Sep 13, 1985

AP 0.005MG/ML; 1.5%

A089645 001 Jun 21, 1988

AP 0.005MG/ML; 2%

A089651 001 Jun 21, 1988

AP 0.01MG/ML; 1%

A089644 001 Jun 21, 1988

AP 0.01MG/ML; 2%

A078772 001 May 12, 2008

AP 0.01MG/ML; 2%

A089646 001 Jun 21, 1988

AP 0.02MG/ML; 2%

A078772 002 May 12, 2008

OCTOCAINE

AP + SEPTODONT 0.01MG/ML; 2%

A084048 001

AP + 0.02MG/ML; 2%

A084048 002

XYLOCAINE W/ EPINEPHRINE

AP + FRESENIUS KABI USA 0.005MG/ML; 0.5%

N006488 012

AP + 0.005MG/ML; 1%

N006488 018 Nov 13, 1986

AP + 0.005MG/ML; 1.5%

N006488 017

AP + 0.005MG/ML; 2%

N006488 019 Nov 13, 1986

AP + 0.01MG/ML; 1%

N006488 004

AP + 0.02MG/ML; 2%

N006488 005

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

ELLEENCE

AP + PFIZER INC 200MG/100ML (2MG/ML)

N050778 001 Sep 15, 1999

AP 50MG/25ML (2MG/ML)

N050778 002 Sep 15, 1999

EPIRUBICIN HYDROCHLORIDE

AP ACTAVIS TOTOWA 10MG/5ML (2MG/ML)

A065445 001 Sep 18, 2008

AP 50MG/25ML (2MG/ML)

A065445 002 Sep 18, 2008

AP 200MG/100ML (2MG/ML)

A065445 003 Sep 18, 2008

AP AKORN INC 50MG/25ML (2MG/ML)

A090163 001 Jun 24, 2009

AP CIPLA LTD 50MG/25ML (2MG/ML)

A065361 001 Oct 22, 2007

AP 200MG/100ML (2MG/ML)

A065361 002 Oct 22, 2007

AP FRESENIUS KABI ONCOL 200MG/100ML (2MG/ML)

A065411 001 Aug 20, 2007

AP 50MG/25ML (2MG/ML)

A065411 002 Aug 20, 2007

AP FRESENIUS KABI USA 10MG/5ML (2MG/ML)

A065408 001 Oct 15, 2007

PRESCRIPTION DRUG PRODUCT LIST

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

<u>AP</u>		<u>50MG/25ML (2MG/ML)</u>	<u>A065408 002</u>	Oct 15, 2007
<u>AP</u>		<u>150MG/75ML (2MG/ML)</u>	<u>A065408 003</u>	Oct 15, 2007
<u>AP</u>		<u>200MG/100ML (2MG/ML)</u>	<u>A065408 004</u>	Oct 15, 2007
<u>AP</u>	HISUN PHARM HANGZHOU	<u>50MG/25ML (2MG/ML)</u>	<u>A090075 001</u>	Mar 25, 2010
<u>AP</u>		<u>200MG/100ML (2MG/ML)</u>	<u>A090075 002</u>	Mar 25, 2010
<u>AP</u>	HOSPIRA	<u>10MG/5ML (2MG/ML)</u>	<u>A065343 001</u>	Apr 19, 2007
<u>AP</u>		<u>150MG/75ML (2MG/ML)</u>	<u>A065343 003</u>	Apr 19, 2007
<u>AP</u>		<u>200MG/100ML (2MG/ML)</u>	<u>A065343 004</u>	Apr 19, 2007
<u>AP</u>	IMPAX LABS INC	<u>50MG/25ML (2MG/ML)</u>	<u>A065331 001</u>	Aug 09, 2007
<u>AP</u>		<u>200MG/100ML (2MG/ML)</u>	<u>A065331 002</u>	Aug 09, 2007
<u>AP</u>	MYLAN LABS LTD	<u>50MG/25ML (2MG/ML)</u>	<u>A091599 001</u>	Mar 12, 2012
<u>AP</u>		<u>200MG/100ML (2MG/ML)</u>	<u>A091599 002</u>	Mar 12, 2012
<u>AP</u>	WEST-WARD PHARMS INT	<u>50MG/25ML (2MG/ML)</u>	<u>A065289 001</u>	Jun 27, 2007
<u>AP</u>		<u>200MG/100ML (2MG/ML)</u>	<u>A065289 002</u>	Jun 27, 2007

EPLERENONE

TABLET; ORAL

EPLERENONE

<u>AB</u>	APOTEX	<u>25MG</u>	<u>A078482 001</u>	Jul 30, 2008
<u>AB</u>		<u>50MG</u>	<u>A078482 002</u>	Jul 30, 2008
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A078510 001</u>	Aug 01, 2008
<u>AB</u>		<u>50MG</u>	<u>A078510 002</u>	Aug 01, 2008
	<u>INSPRA</u>			
<u>AB</u>	GD SEARLE LLC	<u>25MG</u>	<u>N021437 001</u>	Sep 27, 2002
<u>AB</u>	+	<u>50MG</u>	<u>N021437 002</u>	Sep 27, 2002

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION

EPOPROSTENOL SODIUM

<u>AP</u>	TEVA PHARMS USA	<u>EQ 0.5MG BASE/VIAL</u>	<u>A078396 001</u>	Apr 23, 2008	
<u>AP</u>		<u>EQ 1.5MG BASE/VIAL</u>	<u>A078396 002</u>	Apr 23, 2008	
	<u>FLOLAN</u>				
<u>AP</u>	+	<u>GLAXOSMITHKLINE LLC</u>	<u>EQ 0.5MG BASE/VIAL</u>	<u>N020444 001</u>	Sep 20, 1995
<u>AP</u>	+		<u>EQ 1.5MG BASE/VIAL</u>	<u>N020444 002</u>	Sep 20, 1995
	<u>VELETRI</u>				
	ACTELION PHARMS LTD	<u>EQ 0.5MG BASE/VIAL</u>	<u>N022260 002</u>	Jun 28, 2012	
	+	<u>EQ 1.5MG BASE/VIAL</u>	<u>N022260 001</u>	Jun 27, 2008	

EPROSARTAN MESYLATE

TABLET; ORAL

EPROSARTAN MESYLATE

<u>AB</u>	MYLAN PHARMS INC	<u>EQ 400MG BASE</u>	<u>A202012 001</u>	Nov 16, 2011
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A202012 002</u>	Nov 16, 2011
	<u>TEVETEN</u>			
<u>AB</u>	ABBVIE	<u>EQ 400MG BASE</u>	<u>N020738 005</u>	Dec 22, 1997
<u>AB</u>	+	<u>EQ 600MG BASE</u>	<u>N020738 006</u>	May 27, 1999

EPTIFIBATIDE

INJECTABLE; INJECTION

EPTIFIBATIDE

<u>AP</u>	AMNEAL PHARMS	<u>2MG/ML</u>	<u>A205581 001</u>	Dec 08, 2016	
<u>AP</u>		<u>75MG/100ML</u>	<u>A205581 002</u>	Dec 08, 2016	
<u>AP</u>	AUROBINDO PHARMA LTD	<u>2MG/ML</u>	<u>A206127 001</u>	Dec 08, 2015	
<u>AP</u>		<u>75MG/100ML</u>	<u>A206127 002</u>	Dec 08, 2015	
<u>AP</u>	TEVA PHARMS USA	<u>2MG/ML</u>	<u>A090854 001</u>	Jun 12, 2015	
	<u>INTEGRILIN</u>				
<u>AP</u>	+	<u>SCHERING</u>	<u>2MG/ML</u>	<u>N020718 001</u>	May 18, 1998
<u>AP</u>	+		<u>75MG/100ML</u>	<u>N020718 002</u>	May 18, 1998

ERGOCALCIFEROL

CAPSULE; ORAL

DRISDOL

<u>AA</u>	+	<u>US PHARM HOLDINGS</u>	<u>50,000 IU</u>	<u>N003444 001</u>
-----------	---	--------------------------	------------------	--------------------

ERGOCALCIFEROL

<u>AA</u>	ORIT LABS LLC	<u>50,000 IU</u>	<u>A040833 001</u>	May 20, 2009
<u>AA</u>	SIGMAPHARM LABS LLC	<u>50,000 IU</u>	<u>A091004 001</u>	Jul 14, 2010
<u>AA</u>	STRIDES PHARMA	<u>50,000 IU</u>	<u>A090455 001</u>	Aug 03, 2010
<u>AA</u>	SUN PHARM INDS INC	<u>50,000 IU</u>	<u>A040865 001</u>	Dec 29, 2009
	<u>VITAMIN D</u>			
<u>AA</u>	BIONPHARMA INC	<u>50,000 IU</u>	<u>A080704 001</u>	

PRESCRIPTION DRUG PRODUCT LIST

ERGOLOID MESYLATES

TABLET; ORAL

ERGOLOID MESYLATES**AB** SUN PHARM INDS **1MG** **A081113 001** Oct 31, 1991HYDERGINE**AB** + NOVARTIS **1MG** **N017993 001**ERGOTAMINE TARTRATE

TABLET; SUBLINGUAL

ERGOMAR

+ TERSERA THERAP 2MG A087693 001 Feb 24, 1983

ERIBULIN MESYLATE

SOLUTION; INTRAVENOUS

HALAVEN

+ EISAI INC 1MG/2ML (0.5MG/ML) N201532 001 Nov 15, 2010

ERLOTINIB HYDROCHLORIDE

TABLET; ORAL

TARCEVA

OSI PHARMS

EQ 25MG BASE

N021743 001 Nov 18, 2004

EQ 100MG BASE

N021743 002 Nov 18, 2004

+

EQ 150MG BASE

N021743 003 Nov 18, 2004

ERTAPENEM SODIUM

INJECTABLE; INTRAMUSCULAR, IV (INFUSION)

INVANZ

+ MERCK SHARP DOHME EQ 1GM BASE/VIAL N021337 001 Nov 21, 2001

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

ERYC**AB** + MAYNE PHARMA **250MG** **N050536 001**ERYTHROMYCIN**AB** ARBOR PHARMS LLC **250MG** **A062746 001** Dec 22, 1986

GEL; TOPICAL

ERYGEL**AT** + DELCOR ASSET CORP **2%** **N050617 001** Oct 21, 1987ERYTHROMYCIN**AT** FOUGERA PHARMS **2%** **A064184 001** Sep 30, 1997**AT** PERRIGO **2%** **A063211 001** Jan 29, 1993

OINTMENT; OPHTHALMIC

ERYTHROMYCIN**AT** AKORN **0.5%** **A064030 001** Jul 18, 1996**AT** BAUSCH AND LOMB **0.5%** **A064067 001** Jul 29, 1994**AT** + PERRIGO CO TENNESSEE **0.5%** **A062447 001** Sep 26, 1983

OINTMENT; TOPICAL

AKNE-MYCIN

+ DOW PHARM 2% N050584 001 Jan 10, 1985

SOLUTION; TOPICAL

ERYTHROMYCIN**AT** + FOUGERA PHARMS **2%** **A064187 001** Sep 30, 1997**AT** PERRIGO NEW YORK **2%** **A063038 001** Jan 11, 1991**AT** WOCKHARDT **2%** **A062825 001** Oct 23, 1987

SWAB; TOPICAL

ERYTHROMYCIN**AT** AKORN **2%** **A090215 001** May 12, 2010**AT** + PERRIGO **2%** **A064126 001** Jul 03, 1996

TABLET; ORAL

ERYTHROMYCIN

ARBOR PHARMS LLC

250MG

A061621 001

+

PCE

ARBOR PHARMS LLC

333MG

N050611 001 Sep 09, 1986

+

PCE

ARBOR PHARMS LLC

500MG

N050611 002 Aug 22, 1990

TABLET, DELAYED RELEASE; ORAL

ERY-TAB

ARBOR PHARMS LLC

250MG

A062298 001

+

PCE

ARBOR PHARMS LLC

333MG

A062298 003 Mar 29, 1982

+

PCE

ARBOR PHARMS LLC

500MG

A062298 002

PRESCRIPTION DRUG PRODUCT LIST

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL

E.E.S.

AB	ARBOR PHARMS LLC	EQ 200MG BASE/5ML	N050207 001	
ERYPED				
AB	ARBOR PHARMS LLC	EQ 200MG BASE/5ML	N050207 003	Mar 30, 1987
	+	EQ 400MG BASE/5ML	N050207 002	
TABLET; ORAL				
E.E.S. 400				
BX	+ ARBOR PHARMS LLC	EQ 400MG BASE	A061905 002	Aug 12, 1982
ERYTHROMYCIN ETHYLSUCCINATE				
BX	+ ARBOR PHARMS LLC	EQ 400MG BASE	A061904 001	

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

GRANULE; ORAL

ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL

+ BARR

EQ 200MG BASE/5ML; EQ 600MG BASE/5ML**A062759 001** May 20, 1988ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

ERYTHROCIN

AP	HOSPIRA	EQ 500MG BASE/VIAL	A062638 001	Oct 31, 1986
AP	+	EQ 500MG BASE/VIAL	N050609 001	Sep 24, 1986
	+	EQ 1GM BASE/VIAL	A062638 002	Oct 31, 1986

ERYTHROMYCIN STEARATE

TABLET; ORAL

ERYTHROCIN STEARATE

+ ARBOR PHARMS LLC

EQ 250MG BASE**A060359 001**ESCITALOPRAM OXALATE

SOLUTION; ORAL

ESCITALOPRAM OXALATE

AA	AMNEAL PHARMS	EQ 5MG BASE/5ML	A202227 001	Mar 14, 2012
AA	ANTRIM PHARMS LLC	EQ 5MG BASE/5ML	A203967 001	May 26, 2015
AA	AUROBINDO PHARMA LTD	EQ 5MG BASE/5ML	A079062 001	Apr 02, 2012
AA	HETERO LABS LTD III	EQ 5MG BASE/5ML	A202221 001	Jun 12, 2012
AA	MACLEODS PHARMS LTD	EQ 5MG BASE/5ML	A202754 001	Mar 31, 2016
AA	SILARX PHARMS INC	EQ 5MG BASE/5ML	A090477 001	Jun 12, 2013
AA	TARO	EQ 5MG BASE/5ML	A079121 001	May 03, 2012
LEXAPRO				
AA	+ FOREST LABS	EQ 5MG BASE/5ML	N021365 001	Nov 27, 2002

TABLET; ORAL

ESCITALOPRAM OXALATE

AB	ACCORD HLTHCARE	EQ 5MG BASE	A202389 001	Sep 11, 2012
AB		EQ 10MG BASE	A202389 002	Sep 11, 2012
AB		EQ 20MG BASE	A202389 003	Sep 11, 2012
AB	APOTEX INC	EQ 5MG BASE	A078777 001	Sep 11, 2012
AB		EQ 10MG BASE	A078777 002	Sep 11, 2012
AB		EQ 20MG BASE	A078777 003	Sep 11, 2012
AB	AUROBINDO PHARMA LTD	EQ 5MG BASE	A090432 001	Sep 11, 2012
AB		EQ 10MG BASE	A090432 002	Sep 11, 2012
AB		EQ 20MG BASE	A090432 003	Sep 11, 2012
AB	HIKMA PHARMS	EQ 5MG BASE	A078766 001	Sep 11, 2012
AB		EQ 10MG BASE	A078766 002	Sep 11, 2012
AB		EQ 20MG BASE	A078766 003	Sep 11, 2012
AB	INVAGEN PHARMS	EQ 5MG BASE	A078604 001	Sep 11, 2012
AB		EQ 10MG BASE	A078604 002	Sep 11, 2012
AB		EQ 20MG BASE	A078604 003	Sep 11, 2012
AB	JUBILANT GENERICS	EQ 5MG BASE	A202280 001	Sep 12, 2012
AB		EQ 10MG BASE	A202280 002	Sep 12, 2012
AB		EQ 20MG BASE	A202280 003	Sep 12, 2012
AB	LUPIN LTD	EQ 5MG BASE	A078169 001	Sep 11, 2012
AB		EQ 10MG BASE	A078169 002	Sep 11, 2012
AB		EQ 20MG BASE	A078169 003	Sep 11, 2012
AB	MACLEODS PHARMS LTD	EQ 5MG BASE	A202210 001	Sep 11, 2012
AB		EQ 10MG BASE	A202210 002	Sep 11, 2012
AB		EQ 20MG BASE	A202210 003	Sep 11, 2012
AB	MYLAN PHARMS INC	EQ 5MG BASE	A077550 001	May 14, 2015
AB		EQ 10MG BASE	A077550 002	May 14, 2015
AB		EQ 20MG BASE	A077550 003	May 14, 2015
AB	PRINSTON INC	EQ 5MG BASE	A078032 001	Aug 28, 2015
AB		EQ 10MG BASE	A078032 002	Aug 28, 2015
AB		EQ 20MG BASE	A078032 003	Aug 28, 2015

PRESCRIPTION DRUG PRODUCT LIST

ESCITALOPRAM OXALATE

TABLET; ORAL

ESCITALOPRAM OXALATE

<u>AB</u>	STI PHARMA LLC	<u>EQ 5MG BASE</u>	<u>A077512 001</u>	Sep 12, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077512 002</u>	Sep 12, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077512 003</u>	Sep 12, 2012
<u>AB</u>	TEVA PHARMS USA	<u>EQ 5MG BASE</u>	<u>A076765 001</u>	Mar 14, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076765 002</u>	Mar 14, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076765 003</u>	Mar 14, 2012
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 5MG BASE</u>	<u>A090939 001</u>	Sep 11, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090939 002</u>	Sep 11, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A090939 003</u>	Sep 11, 2012
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 5MG BASE</u>	<u>A077734 001</u>	Sep 11, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077734 002</u>	Sep 11, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077734 003</u>	Sep 11, 2012

LEXAPRO

<u>AB</u>	FOREST LABS	<u>EQ 5MG BASE</u>	<u>N021323 001</u>	Aug 14, 2002
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>N021323 002</u>	Aug 14, 2002
<u>AB</u>	+	<u>EQ 20MG BASE</u>	<u>N021323 003</u>	Aug 14, 2002

ESLICARBAZEPINE ACETATE

TABLET; ORAL

APTOM

	SUNOVION PHARMS INC	200MG	N022416 001	Nov 08, 2013
		400MG	N022416 002	Nov 08, 2013
		600MG	N022416 003	Nov 08, 2013
	+	800MG	N022416 004	Nov 08, 2013

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

BREVIBLOC

<u>AP</u>	+	BAXTER HLTHCARE	<u>10MG/ML</u>	<u>N019386 006</u>	Feb 25, 2003
-----------	---	-----------------	----------------	--------------------	--------------

ESMOLOL HYDROCHLORIDE

<u>AP</u>	AUROBINDO PHARMA LTD	<u>10MG/ML</u>	<u>A205520 001</u>	Jul 23, 2015
<u>AP</u>	FRESENIUS KABI USA	<u>10MG/ML</u>	<u>A076573 001</u>	May 02, 2005
<u>AP</u>	LUITPOLD PHARMS INC	<u>10MG/ML</u>	<u>A201126 001</u>	Feb 20, 2015
<u>AP</u>	MYLAN INSTITUTIONAL	<u>10MG/ML</u>	<u>A076474 001</u>	May 02, 2005
<u>AP</u>	WEST-WARD PHARMS INT	<u>10MG/ML</u>	<u>A076323 001</u>	Aug 10, 2004

BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	2GM/100ML	N019386 005	Jan 27, 2003
---	-----------------	-----------	-------------	--------------

BREVIBLOC IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	1GM/100ML	N019386 004	Feb 16, 2001
---	-----------------	-----------	-------------	--------------

SOLUTION; INTRAVENOUS

ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER

+	HQ SPCLT PHARMA	2GM/100ML (20MG/ML)	N205703 002	Apr 07, 2016
---	-----------------	---------------------	-------------	--------------

ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER

+	HQ SPCLT PHARMA	2.5GM/250ML (10MG/ML)	N205703 001	Apr 07, 2016
---	-----------------	-----------------------	-------------	--------------

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL

ESOMEPRAZOLE MAGNESIUM

<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 20MG BASE</u>	<u>A205606 001</u>	Apr 21, 2016
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A205606 002</u>	Apr 21, 2016
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 20MG BASE</u>	<u>A078279 001</u>	Sep 25, 2015
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078279 002</u>	Sep 25, 2015
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 20MG BASE</u>	<u>A078003 001</u>	Jan 26, 2015
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078003 002</u>	Jan 26, 2015
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 20MG BASE</u>	<u>A078936 001</u>	Aug 02, 2015
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078936 002</u>	Aug 03, 2015
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 20MG BASE</u>	<u>A203636 001</u>	Oct 19, 2015
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A203636 002</u>	Oct 19, 2015

NEXIUM

<u>AB</u>	ASTRAZENECA PHARMS	<u>EQ 20MG BASE</u>	<u>N021153 001</u>	Feb 20, 2001
<u>AB</u>	+	<u>EQ 40MG BASE</u>	<u>N021153 002</u>	Feb 20, 2001

ESOMEPRAZOLE MAGNESIUM

BX	HETERO LABS LTD III	EQ 20MG BASE	A202784 001	Sep 21, 2015
BX		EQ 40MG BASE	A202784 002	Sep 21, 2015

FOR SUSPENSION, DELAYED RELEASE; ORAL

NEXIUM

	ASTRAZENECA PHARMS	EQ 2.5MG BASE/PACKET	N021957 003	Dec 15, 2011
		EQ 5MG BASE/PACKET	N021957 004	Dec 15, 2011
		EQ 10MG BASE/PACKET	N022101 001	Feb 27, 2008
		EQ 20MG BASE/PACKET	N021957 001	Oct 20, 2006
	+	EQ 40MG BASE/PACKET	N021957 002	Oct 20, 2006

PRESCRIPTION DRUG PRODUCT LIST

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE;ORAL

NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 20MG BASE;375MG</u>	<u>A202461 001</u>	Sep 27, 2013
<u>AB</u>		<u>EQ 20MG BASE;500MG</u>	<u>A202461 002</u>	Sep 27, 2013

VIMOVO

<u>AB</u>	HORIZON PHARMA USA	<u>EQ 20MG BASE;375MG</u>	<u>N022511 002</u>	Apr 30, 2010
<u>AB</u>	+	<u>EQ 20MG BASE;500MG</u>	<u>N022511 001</u>	Apr 30, 2010

ESOMEPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS

ESOMEPRAZOLE SODIUM

<u>AP</u>	ACCORD HLTHCARE	<u>EQ 40MG BASE/VIAL</u>	<u>A205379 001</u>	Sep 25, 2015
<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 20MG BASE/VIAL</u>	<u>A204657 001</u>	Aug 10, 2016
<u>AP</u>		<u>EQ 40MG BASE/VIAL</u>	<u>A204657 002</u>	Aug 10, 2016
<u>AP</u>	SUN PHARMA GLOBAL	<u>EQ 20MG BASE/VIAL</u>	<u>A200882 001</u>	Mar 18, 2013
<u>AP</u>		<u>EQ 40MG BASE/VIAL</u>	<u>A200882 002</u>	Mar 18, 2013

NEXIUM IV

<u>AP</u>	+	ASTRAZENECA PHARMS	<u>EQ 20MG BASE/VIAL</u>	<u>N021689 001</u>	Mar 31, 2005
<u>AP</u>	+		<u>EQ 40MG BASE/VIAL</u>	<u>N021689 002</u>	Mar 31, 2005

ESOMEPRAZOLE STRONTIUM

CAPSULE, DELAYED RELEASE;ORAL

ESOMEPRAZOLE STRONTIUM

	R2 PHARMA LLC	24.65MG	N202342 001	Aug 06, 2013
	+	49.3MG	N202342 002	Aug 06, 2013

ESTAZOLAM

TABLET;ORAL

ESTAZOLAM

<u>AB</u>	MAYNE PHARMA	<u>1MG</u>	<u>A074921 001</u>	Jul 10, 1997
<u>AB</u>	+	<u>2MG</u>	<u>A074921 002</u>	Jul 10, 1997
<u>AB</u>	PAR PHARM	<u>1MG</u>	<u>A074826 001</u>	Jul 03, 1997
<u>AB</u>		<u>2MG</u>	<u>A074826 002</u>	Jul 03, 1997
<u>AB</u>	WATSON LABS	<u>1MG</u>	<u>A074818 001</u>	Aug 19, 1997
<u>AB</u>		<u>2MG</u>	<u>A074818 002</u>	Aug 19, 1997

ESTRADIOL

CREAM;VAGINAL

ESTRACE

	+	ALLERGAN SALES LLC	0.01%	A086069 001	Jan 31, 1984
--	---	--------------------	-------	-------------	--------------

FILM, EXTENDED RELEASE;TRANSDERMAL

CLIMARA

<u>AB</u>	BAYER HLTHCARE	<u>0.0375MG/24HR</u>	<u>N020375 005</u>	May 27, 2003
<u>AB</u>		<u>0.06MG/24HR</u>	<u>N020375 006</u>	May 27, 2003

ESTRADIOL

<u>AB</u>	MYLAN TECHNOLOGIES	<u>0.0375MG/24HR</u>	<u>A075182 004</u>	Jul 20, 2006
<u>AB</u>		<u>0.06MG/24HR</u>	<u>A075182 005</u>	Jul 20, 2006
<u>AB1</u>		<u>0.025MG/24HR</u>	<u>A201675 001</u>	Dec 19, 2014
<u>AB1</u>		<u>0.0375MG/24HR</u>	<u>A201675 002</u>	Dec 19, 2014
<u>AB1</u>		<u>0.05MG/24HR</u>	<u>A201675 003</u>	Dec 19, 2014
<u>AB1</u>		<u>0.075MG/24HR</u>	<u>A201675 004</u>	Dec 19, 2014
<u>AB1</u>		<u>0.1MG/24HR</u>	<u>A201675 005</u>	Dec 19, 2014

VIVELLE

<u>AB1</u>	NOVARTIS	<u>0.05MG/24HR</u>	<u>N020323 002</u>	Oct 28, 1994
<u>AB1</u>		<u>0.1MG/24HR</u>	<u>N020323 004</u>	Oct 28, 1994

VIVELLE-DOT

<u>AB1</u>	NOVARTIS	<u>0.025MG/24HR</u>	<u>N020538 009</u>	May 03, 2002
<u>AB1</u>		<u>0.0375MG/24HR</u>	<u>N020538 005</u>	Jan 08, 1999
<u>AB1</u>		<u>0.05MG/24HR</u>	<u>N020538 006</u>	Jan 08, 1999
<u>AB1</u>		<u>0.075MG/24HR</u>	<u>N020538 007</u>	Jan 08, 1999
<u>AB1</u>	+	<u>0.1MG/24HR</u>	<u>N020538 008</u>	Jan 08, 1999

CLIMARA

<u>AB2</u>	BAYER HLTHCARE	<u>0.025MG/24HR</u>	<u>N020375 004</u>	Mar 05, 1999
<u>AB2</u>		<u>0.05MG/24HR</u>	<u>N020375 001</u>	Dec 22, 1994
<u>AB2</u>		<u>0.075MG/24HR</u>	<u>N020375 003</u>	Mar 23, 1998
<u>AB2</u>	+	<u>0.1MG/24HR</u>	<u>N020375 002</u>	Dec 22, 1994

ESTRADIOL

<u>AB2</u>	MYLAN TECHNOLOGIES	<u>0.025MG/24HR</u>	<u>A075182 003</u>	Jan 26, 2005
<u>AB2</u>		<u>0.05MG/24HR</u>	<u>A075182 006</u>	Feb 24, 2000
<u>AB2</u>		<u>0.075MG/24HR</u>	<u>A075182 002</u>	Jan 26, 2005
<u>AB2</u>		<u>0.1MG/24HR</u>	<u>A075182 001</u>	Feb 24, 2000

ALORA

<u>BX</u>	ALLERGAN SALES LLC	0.025MG/24HR	N020655 004	Apr 05, 2002
-----------	--------------------	--------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ESTRADIOL

FILM, EXTENDED RELEASE;TRANSDERMAL

ALORA

BX		0.05MG/24HR	N020655 001	Dec 20, 1996
BX		0.075MG/24HR	N020655 002	Dec 20, 1996
BX		0.1MG/24HR	N020655 003	Dec 20, 1996

ESTRADERM

BX	NOVARTIS	0.05MG/24HR	N019081 002	Sep 10, 1986
BX	+	0.1MG/24HR	N019081 003	Sep 10, 1986

MENOSTAR

+	BAYER HLTHCARE	0.014MG/24HR	N021674 001	Jun 08, 2004
---	----------------	--------------	-------------	--------------

MINIVELLE

	NOVEN	0.025MG/24HR	N203752 005	Sep 23, 2014
--	-------	--------------	-------------	--------------

		0.0375MG/24HR	N203752 001	Oct 29, 2012
--	--	---------------	-------------	--------------

		0.05MG/24HR	N203752 003	Oct 29, 2012
--	--	-------------	-------------	--------------

		0.075MG/24HR	N203752 002	Oct 29, 2012
--	--	--------------	-------------	--------------

+		0.1MG/24HR	N203752 004	Oct 29, 2012
---	--	------------	-------------	--------------

GEL;TRANSDERMAL

DIVIGEL

	VERTICAL PHARMS LLC	0.1% (0.25GM/PACKET)	N022038 001	Jun 04, 2007
--	---------------------	----------------------	-------------	--------------

		0.1% (0.5GM/PACKET)	N022038 002	Jun 04, 2007
--	--	---------------------	-------------	--------------

+		0.1% (1GM/PACKET)	N022038 003	Jun 04, 2007
---	--	-------------------	-------------	--------------

GEL, METERED;TRANSDERMAL

ELESTRIN

+	MEDA PHARMS	0.06% (0.87GM/ACTIVATION)	N021813 001	Dec 15, 2006
---	-------------	---------------------------	-------------	--------------

ESTROGEL

+	ASCEND THERAPS US	0.06% (1.25GM/ACTIVATION)	N021166 002	Feb 09, 2004
---	-------------------	---------------------------	-------------	--------------

INSERT, EXTENDED RELEASE;VAGINAL

ESTRING

+	PHARMACIA AND UPJOHN	0.0075MG/24HR	N020472 001	Apr 26, 1996
---	----------------------	---------------	-------------	--------------

SPRAY;TRANSDERMAL

EVAMIST

+	ELAN PHARMA INTL LTD	1.53MG/SPRAY	N022014 001	Jul 27, 2007
---	----------------------	--------------	-------------	--------------

TABLET;ORAL

ESTRADIOL

<u>AB</u>	BARR LABS INC	<u>0.5MG</u>	<u>A040197 001</u>	Oct 22, 1997
-----------	---------------	--------------	--------------------	--------------

<u>AB</u>		<u>1MG</u>	<u>A040197 002</u>	Oct 22, 1997
-----------	--	------------	--------------------	--------------

<u>AB</u>	+	<u>2MG</u>	<u>A040197 003</u>	Oct 22, 1997
-----------	---	------------	--------------------	--------------

<u>AB</u>	EPIC PHARMA INC	<u>0.5MG</u>	<u>A040275 001</u>	Dec 29, 1998
-----------	-----------------	--------------	--------------------	--------------

<u>AB</u>		<u>1MG</u>	<u>A040275 002</u>	Dec 29, 1998
-----------	--	------------	--------------------	--------------

<u>AB</u>		<u>2MG</u>	<u>A040275 003</u>	Dec 29, 1998
-----------	--	------------	--------------------	--------------

<u>AB</u>	MAYNE PHARMA	<u>0.5MG</u>	<u>A040114 003</u>	Mar 14, 1996
-----------	--------------	--------------	--------------------	--------------

<u>AB</u>		<u>1MG</u>	<u>A040114 001</u>	Mar 14, 1996
-----------	--	------------	--------------------	--------------

<u>AB</u>		<u>2MG</u>	<u>A040114 002</u>	Mar 14, 1996
-----------	--	------------	--------------------	--------------

<u>AB</u>	MYLAN	<u>0.5MG</u>	<u>A040326 001</u>	Apr 21, 1999
-----------	-------	--------------	--------------------	--------------

<u>AB</u>		<u>1MG</u>	<u>A040326 002</u>	Apr 21, 1999
-----------	--	------------	--------------------	--------------

<u>AB</u>		<u>2MG</u>	<u>A040326 003</u>	Apr 21, 1999
-----------	--	------------	--------------------	--------------

TABLET;VAGINAL

ESTRADIOL

<u>AB</u>	AMNEAL PHARMS	<u>10MCG</u>	<u>A205256 001</u>	May 29, 2015
-----------	---------------	--------------	--------------------	--------------

VAGIFEM

<u>AB</u>	+	<u>NOVO NORDISK INC</u>	<u>10MCG</u>	<u>N020908 002</u>	Nov 25, 2009
-----------	---	-------------------------	--------------	--------------------	--------------

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE;VAGINAL

FEMRING

	APIL	EQ 0.05MG BASE/24HR	N021367 001	Mar 20, 2003
--	------	---------------------	-------------	--------------

+		EQ 0.1MG BASE/24HR	N021367 002	Mar 20, 2003
---	--	--------------------	-------------	--------------

TABLET;ORAL

FEMTRACE

	APIL	0.45MG	N021633 001	Aug 20, 2004
--	------	--------	-------------	--------------

		0.9MG	N021633 002	Aug 20, 2004
--	--	-------	-------------	--------------

+		1.8MG	N021633 003	Aug 20, 2004
---	--	-------	-------------	--------------

ESTRADIOL CYPIONATE

INJECTABLE;INJECTION

DEPO-ESTRADIOL

+	PHARMACIA AND UPJOHN	5MG/ML	A085470 003	
---	----------------------	--------	-------------	--

PRESCRIPTION DRUG PRODUCT LIST

ESTRADIOL HEMIHYDRATE

EMULSION; TOPICAL

ESTRASORB

+ EXELTIS USA INC 0.25% N021371 001 Oct 09, 2003

ESTRADIOL VALERATE

INJECTABLE; INJECTION

DELESTROGEN**AO** + PAR STERILE PRODUCTS **20MG/ML** **N009402 004****AO** + **40MG/ML** **N009402 003**ESTRADIOL VALERATE**AO** LUITPOLD **20MG/ML** **A090920 001** Jan 19, 2010**AO** **40MG/ML** **A090920 002** Jan 19, 2010

DELESTROGEN

+ PAR STERILE PRODUCTS 10MG/ML N009402 002

ESTRADIOL; LEVONORGESTREL

FILM, EXTENDED RELEASE; TRANSDERMAL

CLIMARA PRO

+ BAYER HLTHCARE 0.045MG/24HR; 0.015MG/24HR N021258 001 Nov 21, 2003

ESTRADIOL; NORETHINDRONE ACETATE

FILM, EXTENDED RELEASE; TRANSDERMAL

COMBIPATCH

NOVEN PHARMS INC 0.05MG/24HR; 0.14MG/24HR N020870 001 Aug 07, 1998

+ 0.05MG/24HR; 0.25MG/24HR N020870 002 Aug 07, 1998

TABLET; ORAL

ACTIVELLA**AB** AMNEAL PHARMS LLC **0.5MG; 0.1MG** **N020907 002** Dec 28, 2006**AB** + **1MG; 0.5MG** **N020907 001** Nov 18, 1998AMABELZ**AB** LUPIN LTD **0.5MG; 0.1MG** **A203339 001** Jun 20, 2016**AB** **1MG; 0.5MG** **A203339 002** Jun 20, 2016ESTRADIOL AND NORETHINDRONE ACETATE**AB** BARR **1MG; 0.5MG** **A079193 001** May 11, 2010**AB** BRECKENRIDGE PHARM **0.5MG; 0.1MG** **A078324 002** Jun 09, 2011**AB** **1MG; 0.5MG** **A078324 001** Apr 17, 2008**AB** TEVA PHARMS USA **0.5MG; 0.1MG** **A200747 001** Mar 08, 2012ESTRADIOL; NORGESTIMATE

TABLET; ORAL

ESTRADIOL AND NORGESTIMATE

+ BARR 1MG, 1MG; N/A, 0.09MG A076812 001 Apr 29, 2005

ESTRAMUSTINE PHOSPHATE SODIUM

CAPSULE; ORAL

EMCYT

+ PHARMACIA AND UPJOHN EQ 140MG PHOSPHATE N018045 001

ESTROGENS, CONJUGATED

CREAM; TOPICAL, VAGINAL

PREMARIN

+ WYETH PHARMS INC 0.625MG/GM N020216 001

INJECTABLE; INJECTION

PREMARIN

+ WYETH PHARMS INC 25MG/VIAL N010402 001

TABLET; ORAL

PREMARIN

WYETH PHARMS INC 0.3MG N004782 003

0.45MG N004782 006 Jul 16, 2003

+ 0.625MG N004782 004

+ 0.9MG N004782 005 Jan 26, 1984

+ 1.25MG N004782 001

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET; ORAL

ENJUWIA

TEVA WOMENS 0.3MG N021443 001 Dec 20, 2004

0.45MG N021443 002 Dec 20, 2004

0.9MG N021443 005 Apr 27, 2007

PRESCRIPTION DRUG PRODUCT LIST

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET; ORAL-28

PREMPHASE 14/14

+	WYETH PHARMS INC	0.625MG; 0.625MG; N/A, 5MG	N020527	002	Nov 17, 1995
PREMPRO					
+	WYETH PHARMS INC	0.3MG; 1.5MG	N020527	005	Jun 04, 2003
+		0.45MG; 1.5MG	N020527	004	Mar 12, 2003
+		0.625MG; 2.5MG	N020527	001	Nov 17, 1995
+		0.625MG; 5MG	N020527	003	Jan 09, 1998

ESTROGENS, ESTERIFIED

TABLET; ORAL

MENEST

	MONARCH PHARMS	0.3MG	A084951	001	
		0.625MG	A084948	001	
		1.25MG	A084950	001	
+		2.5MG	A084949	001	

ESTROPIPATE

TABLET; ORAL

ESTROPIPATE

AB	BARR	0.75MG	A040135	001	Nov 27, 1996
AB		1.5MG	A040135	002	Nov 27, 1996
AB		3MG	A040135	003	Nov 27, 1996
AB	MYLAN	0.75MG	A040359	001	Aug 26, 1999
AB		1.5MG	A040359	002	Aug 26, 1999
AB	WATSON LABS	0.75MG	A081213	001	Sep 23, 1993
AB		1.5MG	A081214	001	Sep 23, 1993
AB		3MG	A081215	001	Sep 23, 1993
<u>OGEN .625</u>					
AB	PHARMACIA AND UPJOHN	0.75MG	A083220	001	
<u>OGEN 1.25</u>					
AB	PHARMACIA AND UPJOHN	1.5MG	A083220	002	
<u>OGEN 2.5</u>					
AB	+ PHARMACIA AND UPJOHN	3MG	A083220	003	
OGEN 5					
	PHARMACIA AND UPJOHN	6MG	A083220	004	

ESZOPICLONE

TABLET; ORAL

ESZOPICLONE

AB	AUROBINDO PHARMA LTD	1MG	A208451	001	Sep 15, 2016
AB		2MG	A208451	002	Sep 15, 2016
AB		3MG	A208451	003	Sep 15, 2016
AB	DR REDDYS LABS LTD	1MG	A091024	001	Apr 15, 2014
AB		2MG	A091024	002	Apr 15, 2014
AB		3MG	A091024	003	Apr 15, 2014
AB	GLENMARK GENERICS	1MG	A091166	001	Apr 15, 2014
AB		2MG	A091166	002	Apr 15, 2014
AB		3MG	A091166	003	Apr 15, 2014
AB	LUPIN LTD	1MG	A091124	001	Sep 13, 2011
AB		2MG	A091124	002	Sep 13, 2011
AB		3MG	A091124	003	Sep 13, 2011
AB	MACLEODS PHARMS LTD	1MG	A202929	001	Jan 30, 2015
AB		2MG	A202929	002	Jan 30, 2015
AB		3MG	A202929	003	Jan 30, 2015
AB	MYLAN PHARMS INC	1MG	A091151	001	Mar 26, 2013
AB		2MG	A091151	002	Mar 26, 2013
AB		3MG	A091151	003	Mar 26, 2013
AB	ORCHID HLTHCARE	1MG	A091113	001	Jun 10, 2014
AB		2MG	A091113	002	Jun 10, 2014
AB		3MG	A091113	003	Jun 10, 2014
AB	SUN PHARMA GLOBAL	1MG	A091103	001	Apr 03, 2013
AB		2MG	A091103	002	Apr 03, 2013
AB		3MG	A091103	003	Apr 03, 2013
AB	TEVA	1MG	A091169	001	May 23, 2011
AB		2MG	A091169	002	May 23, 2011
AB		3MG	A091169	003	May 23, 2011
AB	WEST-WARD PHARMS INT	1MG	A091153	001	Apr 15, 2014
AB		2MG	A091153	002	Apr 15, 2014
AB		3MG	A091153	003	Apr 15, 2014
<u>LUNESTA</u>					
AB	SUNOVION PHARMS INC	1MG	N021476	001	Dec 15, 2004
AB		2MG	N021476	002	Dec 15, 2004

PRESCRIPTION DRUG PRODUCT LIST

ESZOPICLONE

TABLET; ORAL

LUNESTA

AB	+		3MG		<u>N021476</u>	<u>003</u>	Dec 15, 2004
-----------	---	--	------------	--	-----------------------	-------------------	--------------

ETEPLIRSEN

SOLUTION; IV (INFUSION)

EXONDYS 51

	+	SAREPTA THERAPS INC	100MG/2ML (50MG/ML)		<u>N206488</u>	<u>001</u>	Sep 19, 2016
--	---	---------------------	---------------------	--	-----------------------	-------------------	--------------

	+		500MG/10ML (50MG/ML)		<u>N206488</u>	<u>002</u>	Sep 19, 2016
--	---	--	----------------------	--	-----------------------	-------------------	--------------

ETHACRYNATE SODIUM

INJECTABLE; INJECTION

EDECRIIN

AP	+	ATON	<u>EQ 50MG BASE/VIAL</u>		<u>N016093</u>	<u>001</u>	
-----------	---	------	---------------------------------	--	-----------------------	-------------------	--

ETHACRYNATE SODIUM

AP		MYLAN INSTITUTIONAL	<u>EQ 50MG BASE/VIAL</u>		<u>A204634</u>	<u>001</u>	Aug 23, 2016
-----------	--	---------------------	---------------------------------	--	-----------------------	-------------------	--------------

AP		PAR STERILE PRODUCTS	<u>EQ 50MG BASE/VIAL</u>		<u>A205473</u>	<u>001</u>	Jul 29, 2015
-----------	--	----------------------	---------------------------------	--	-----------------------	-------------------	--------------

ETHACRYNIC ACID

TABLET; ORAL

EDECRIIN

AB	+	ATON	25MG		<u>N016092</u>	<u>001</u>	
-----------	---	------	-------------	--	-----------------------	-------------------	--

ETHACRYNIC ACID

AB		EDENBRIDGE PHARMS	25MG		<u>A205609</u>	<u>001</u>	Jun 30, 2016
-----------	--	-------------------	-------------	--	-----------------------	-------------------	--------------

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

ETHAMBUTOL HYDROCHLORIDE

AB		AKORN	100MG		<u>A075095</u>	<u>001</u>	Nov 30, 1999
-----------	--	-------	--------------	--	-----------------------	-------------------	--------------

AB			400MG		<u>A075095</u>	<u>002</u>	Nov 30, 1999
-----------	--	--	--------------	--	-----------------------	-------------------	--------------

AB		BARR	400MG		<u>A076057</u>	<u>001</u>	Nov 26, 2001
-----------	--	------	--------------	--	-----------------------	-------------------	--------------

AB		LUPIN	100MG		<u>A078939</u>	<u>001</u>	Jun 17, 2009
-----------	--	-------	--------------	--	-----------------------	-------------------	--------------

AB			400MG		<u>A078939</u>	<u>002</u>	Jun 17, 2009
-----------	--	--	--------------	--	-----------------------	-------------------	--------------

MYAMBUTOL

AB		STI PHARMA LLC	100MG		<u>N016320</u>	<u>001</u>	
-----------	--	----------------	--------------	--	-----------------------	-------------------	--

AB	+		400MG		<u>N016320</u>	<u>003</u>	
-----------	---	--	--------------	--	-----------------------	-------------------	--

ETHANOLAMINE OLEATE

INJECTABLE; INJECTION

ETHAMOLIN

	+	QOL MEDCL	50MG/ML		<u>N019357</u>	<u>001</u>	Dec 22, 1988
--	---	-----------	---------	--	-----------------------	-------------------	--------------

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-28

ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL

AB		JAI PHARMA LTD	<u>0.05MG; 1MG</u>		<u>A204704</u>	<u>001</u>	Feb 09, 2016
-----------	--	----------------	---------------------------	--	-----------------------	-------------------	--------------

KELNOR

AB		BARR	<u>0.035MG; 1MG</u>		<u>A076785</u>	<u>001</u>	May 23, 2005
-----------	--	------	----------------------------	--	-----------------------	-------------------	--------------

ZOVIA 1/35E-28

AB		MAYNE PHARMA	<u>0.035MG; 1MG</u>		<u>A072721</u>	<u>001</u>	Dec 30, 1991
-----------	--	--------------	----------------------------	--	-----------------------	-------------------	--------------

ZOVIA 1/50E-28

AB	+	WATSON LABS	<u>0.05MG; 1MG</u>		<u>A072723</u>	<u>001</u>	Dec 30, 1991
-----------	---	-------------	---------------------------	--	-----------------------	-------------------	--------------

ETHINYL ESTRADIOL; ETONOGESTREL

RING; VAGINAL

NUVARING

	+	ORGANON USA INC	0.015MG/24HR; 0.12MG/24HR		<u>N021187</u>	<u>001</u>	Oct 03, 2001
--	---	-----------------	---------------------------	--	-----------------------	-------------------	--------------

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

ASHLYNA

AB		GLENMARK GENERICS	<u>0.03MG, 0.01MG; 0.15MG, N/A</u>		<u>A203163</u>	<u>001</u>	Feb 23, 2015
-----------	--	-------------------	---	--	-----------------------	-------------------	--------------

DAYSEE

AB		LUPIN LTD	<u>0.03MG, 0.01MG; 0.15MG, N/A</u>		<u>A091467</u>	<u>001</u>	Apr 10, 2013
-----------	--	-----------	---	--	-----------------------	-------------------	--------------

FAYOSIM

AB		LUPIN LTD	<u>0.02MG, 0.15MG; 0.025MG, 0.15MG; 0.03MG, 0.15MG; 0.01MG, N/A</u>		<u>A205943</u>	<u>001</u>	Mar 29, 2016
-----------	--	-----------	--	--	-----------------------	-------------------	--------------

INTROVALE

AB		SANDOZ	<u>0.03MG; 0.15MG</u>		<u>A079064</u>	<u>001</u>	Sep 27, 2010
-----------	--	--------	------------------------------	--	-----------------------	-------------------	--------------

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB		AMNEAL PHARMS	<u>0.03MG; 0.15MG</u>		<u>A203871</u>	<u>001</u>	Nov 13, 2015
-----------	--	---------------	------------------------------	--	-----------------------	-------------------	--------------

AB			<u>0.03MG, 0.01MG; 0.15MG, N/A</u>		<u>A203872</u>	<u>001</u>	Dec 22, 2015
-----------	--	--	---	--	-----------------------	-------------------	--------------

AB		GLENMARK GENERICS	<u>0.02MG; 0.09MG</u>		<u>A202791</u>	<u>001</u>	Apr 09, 2015
-----------	--	-------------------	------------------------------	--	-----------------------	-------------------	--------------

AB		GLENMARK PHARMS LTD	<u>0.03MG; 0.15MG</u>		<u>A203164</u>	<u>001</u>	Jun 12, 2015
-----------	--	---------------------	------------------------------	--	-----------------------	-------------------	--------------

AB		JAI PHARMA LTD	<u>0.03MG; 0.15MG</u>		<u>A200490</u>	<u>001</u>	Apr 21, 2015
-----------	--	----------------	------------------------------	--	-----------------------	-------------------	--------------

AB		LUPIN LTD	<u>0.02MG, 0.01MG; 0.1MG, N/A</u>		<u>A091674</u>	<u>001</u>	Oct 26, 2011
-----------	--	-----------	--	--	-----------------------	-------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL AND ETHINYL ESTRADIOL

<u>AB</u>		<u>0.03MG;0.15MG</u>	<u>A091440 001</u>	Oct 23, 2012
<u>AB</u>	MAYNE PHARMA	<u>0.02MG,0.01MG;0.1MG,N/A</u>	<u>A200407 001</u>	Oct 25, 2011
<u>AB</u>	+ WATSON LABS	<u>0.02MG;0.09MG</u>	<u>A079218 001</u>	Jun 06, 2011

LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL

<u>AB</u>	JAI PHARMA LTD	<u>0.02MG,0.01MG;0.1MG,N/A</u>	<u>A200493 001</u>	Jun 17, 2015
<u>AB</u>		<u>0.03MG,0.01MG;0.15MG,N/A</u>	<u>A200492 001</u>	May 27, 2015
<u>AB</u>	MAYNE PHARMA	<u>0.03MG,0.01MG;0.15MG,N/A</u>	<u>A078834 001</u>	May 31, 2011

LOSEASONIQUE

<u>AB</u>	TEVA BRANDED PHARM	<u>0.02MG,0.01MG;0.1MG,N/A</u>	<u>N022262 001</u>	Oct 24, 2008
-----------	--------------------	--------------------------------	--------------------	--------------

QUARTETTE

<u>AB</u>	+ TEVA BRANDED PHARM	<u>0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A</u>	<u>N204061 001</u>	Mar 28, 2013
-----------	----------------------	--	--------------------	--------------

QUASENSE

<u>AB</u>	WATSON LABS	<u>0.03MG;0.15MG</u>	<u>A077101 001</u>	Sep 06, 2006
-----------	-------------	----------------------	--------------------	--------------

SEASONALE

<u>AB</u>	+ TEVA BRANDED PHARM	<u>0.03MG;0.15MG</u>	<u>N021544 001</u>	Sep 05, 2003
-----------	----------------------	----------------------	--------------------	--------------

SEASONIQUE

<u>AB</u>	+ TEVA BRANDED PHARM	<u>0.03MG,0.01MG;0.15MG,N/A</u>	<u>N021840 001</u>	May 25, 2006
-----------	----------------------	---------------------------------	--------------------	--------------

SETLAKIN

<u>AB</u>	NOVAST LABS LTD	<u>0.03MG;0.15MG</u>	<u>A090716 001</u>	Sep 15, 2014
-----------	-----------------	----------------------	--------------------	--------------

TABLET; ORAL-28

ALTAVERA

<u>AB</u>	SANDOZ	<u>0.03MG;0.15MG</u>	<u>A079102 001</u>	Aug 03, 2010
-----------	--------	----------------------	--------------------	--------------

AYUNA

<u>AB</u>	AUROBINDO PHARMA LTD	<u>0.03MG;0.15MG</u>	<u>A206866 001</u>	Sep 23, 2016
-----------	----------------------	----------------------	--------------------	--------------

ELIFEMME

<u>AB</u>	SANDOZ INC	<u>0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG</u>	<u>A202507 001</u>	Dec 04, 2015
-----------	------------	--	--------------------	--------------

ENPRESSE-28

<u>AB</u>	DURAMED PHARMS BARR	<u>0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG</u>	<u>A075809 002</u>	Jul 16, 2001
-----------	---------------------	--	--------------------	--------------

KURVELO

<u>AB</u>	LUPIN LTD	<u>0.03MG;0.15MG</u>	<u>A091408 001</u>	Oct 17, 2012
-----------	-----------	----------------------	--------------------	--------------

LEVONEST

<u>AB</u>	NOVAST LABS LTD	<u>0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG</u>	<u>A090719 001</u>	Dec 29, 2010
-----------	-----------------	--	--------------------	--------------

LEVONORGESTREL AND ETHINYL ESTRADIOL

<u>AB</u>	AMNEAL PHARMS	<u>0.03MG;0.15MG</u>	<u>A201095 001</u>	Dec 08, 2014
<u>AB</u>	JAI PHARMA LTD	<u>0.03MG;0.15MG</u>	<u>A091663 001</u>	Dec 21, 2012
<u>AB</u>	LUPIN LTD	<u>0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG</u>	<u>A200248 001</u>	Nov 19, 2015

LEVORA 0.15/30-28

<u>AB</u>	+ MAYNE PHARMA	<u>0.03MG;0.15MG</u>	<u>A073594 001</u>	Dec 13, 1993
-----------	----------------	----------------------	--------------------	--------------

MARLISSA

<u>AB</u>	GLENMARK GENERICS	<u>0.03MG;0.15MG</u>	<u>A091452 001</u>	Feb 29, 2012
-----------	-------------------	----------------------	--------------------	--------------

MYZILRA

<u>AB</u>	VINTAGE PHARMS LLC	<u>0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG</u>	<u>A077502 001</u>	Nov 23, 2011
-----------	--------------------	--	--------------------	--------------

PORTIA-28

<u>AB</u>	BARR	<u>0.03MG;0.15MG</u>	<u>A075866 002</u>	May 23, 2002
-----------	------	----------------------	--------------------	--------------

TRIVORA-28

<u>AB</u>	+ MAYNE PHARMA	<u>0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG</u>	<u>A074538 002</u>	Dec 18, 1997
-----------	----------------	--	--------------------	--------------

AFIRMELLE

<u>AB1</u>	AUROBINDO PHARMA LTD	<u>0.02MG;0.1MG</u>	<u>A206886 001</u>	Nov 14, 2016
------------	----------------------	---------------------	--------------------	--------------

AVIANE-28

<u>AB1</u>	DURAMED PHARMS BARR	<u>0.02MG;0.1MG</u>	<u>A075796 001</u>	Apr 30, 2001
------------	---------------------	---------------------	--------------------	--------------

FALMINA

<u>AB1</u>	NOVAST LABS LTD	<u>0.02MG;0.1MG</u>	<u>A090721 001</u>	Mar 28, 2012
------------	-----------------	---------------------	--------------------	--------------

LEVONORGESTREL AND ETHINYL ESTRADIOL

<u>AB1</u>	AMNEAL PHARMS	<u>0.02MG;0.1MG</u>	<u>A201108 001</u>	Feb 05, 2014
<u>AB1</u>	JAI PHARMA LTD	<u>0.02MG;0.1MG</u>	<u>A200245 001</u>	Oct 09, 2013
<u>AB1</u>	LUPIN LTD	<u>0.02MG;0.1MG</u>	<u>A091425 001</u>	Jan 18, 2013
<u>AB1</u>	+ MAYNE PHARMA	<u>0.02MG;0.1MG</u>	<u>A076625 001</u>	Nov 18, 2004

ORSYTHIA

<u>AB1</u>	VINTAGE PHARMS LLC	<u>0.02MG;0.1MG</u>	<u>A077099 001</u>	May 11, 2011
------------	--------------------	---------------------	--------------------	--------------

VIENVA

<u>AB1</u>	SANDOZ INC	<u>0.02MG;0.1MG</u>	<u>A201088 001</u>	May 21, 2015
------------	------------	---------------------	--------------------	--------------

LESSINA-28

<u>AB2</u>	BARR	<u>0.02MG;0.1MG</u>	<u>A075803 002</u>	Mar 20, 2002
------------	------	---------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-28

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB2	JAI PHARMA LTD	<u>0.02MG;0.1MG</u>	<u>A202247</u>	<u>001</u>	Dec 08, 2014
AB2	+ MAYNE PHARMA	<u>0.02MG;0.1MG</u>	<u>A077681</u>	<u>001</u>	May 31, 2006

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE; TRANSDERMAL

XULANE

AB	+ MYLAN TECHNOLOGIES	<u>0.035MG/24HR:0.15MG/24HR</u>	<u>A200910</u>	<u>001</u>	Apr 16, 2014
-----------	----------------------	---------------------------------	----------------	------------	--------------

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

NORINYL 1+35 21-DAY

AB	ALLERGAN SALES LLC	<u>0.035MG;1MG</u>	<u>N017565</u>	<u>001</u>	
-----------	--------------------	--------------------	----------------	------------	--

NORTREL 1/35-21

AB	BARR	<u>0.035MG;1MG</u>	<u>A072693</u>	<u>001</u>	Feb 28, 1992
-----------	------	--------------------	----------------	------------	--------------

NORTREL 7/7/7

BARR

		<u>0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG</u>	<u>A075478</u>	<u>001</u>	Aug 30, 2002
--	--	---	----------------	------------	--------------

TABLET; ORAL-28

ALYACEN 1/35

AB	GLENMARK GENERICS	<u>0.035MG;1MG</u>	<u>A091634</u>	<u>001</u>	Jan 19, 2012
-----------	-------------------	--------------------	----------------	------------	--------------

ALYACEN 7/7/7

AB	GLENMARK GENERICS	<u>0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG</u>	<u>A091636</u>	<u>001</u>	Jan 19, 2012
-----------	-------------------	---	----------------	------------	--------------

G

ARANELLE

AB	BARR	<u>0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG</u>	<u>A076783</u>	<u>001</u>	Sep 29, 2004
-----------	------	--	----------------	------------	--------------

BALZIVA-28

AB	BARR	<u>0.035MG;0.4MG</u>	<u>A076238</u>	<u>001</u>	Apr 22, 2004
-----------	------	----------------------	----------------	------------	--------------

BREVICON 28-DAY

AB	ALLERGAN SALES LLC	<u>0.035MG;0.5MG</u>	<u>N017743</u>	<u>001</u>	
-----------	--------------------	----------------------	----------------	------------	--

BRIELLYN

AB	GLENMARK GENERICS	<u>0.035MG;0.4MG</u>	<u>A090538</u>	<u>001</u>	Mar 22, 2011
-----------	-------------------	----------------------	----------------	------------	--------------

CYCLAFEM 0.5/35

AB	VINTAGE PHARMS	<u>0.035MG;0.5MG</u>	<u>A203413</u>	<u>001</u>	Dec 16, 2015
-----------	----------------	----------------------	----------------	------------	--------------

CYCLAFEM 1/35

AB	VINTAGE PHARMS LLC	<u>0.035MG;1MG</u>	<u>A076337</u>	<u>001</u>	Nov 12, 2010
-----------	--------------------	--------------------	----------------	------------	--------------

CYCLAFEM 7/7/7

AB	VINTAGE PHARMS LLC	<u>0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG</u>	<u>A076338</u>	<u>001</u>	Nov 16, 2010
-----------	--------------------	---	----------------	------------	--------------

G

CYONANZ

AB	AUROBINDO PHARMA LTD	<u>0.035MG;0.5MG</u>	<u>A207055</u>	<u>001</u>	Oct 21, 2016
-----------	----------------------	----------------------	----------------	------------	--------------

DASETTA 1/35

AB	NOVAST LABS LTD	<u>0.035MG;1MG</u>	<u>A090948</u>	<u>001</u>	Dec 22, 2011
-----------	-----------------	--------------------	----------------	------------	--------------

DASETTA 7/7/7

AB	NOVAST LABS LTD	<u>0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG</u>	<u>A090946</u>	<u>001</u>	Dec 22, 2011
-----------	-----------------	---	----------------	------------	--------------

G

GILDAGIA

AB	VINTAGE PHARMS	<u>0.035MG;0.4MG</u>	<u>A078376</u>	<u>001</u>	Nov 06, 2012
-----------	----------------	----------------------	----------------	------------	--------------

MODICON 28

AB	+ JANSSEN PHARMS	<u>0.035MG;0.5MG</u>	<u>N017735</u>	<u>001</u>	
-----------	------------------	----------------------	----------------	------------	--

NORETHINDRONE AND ETHINYL ESTRADIOL

AB	+ JAI PHARMA LTD	<u>0.035MG;0.4MG</u>	<u>A200897</u>	<u>001</u>	May 11, 2015
-----------	------------------	----------------------	----------------	------------	--------------

AB		<u>0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG</u>	<u>A200486</u>	<u>001</u>	Dec 28, 2015
-----------	--	---	----------------	------------	--------------

G

AB		<u>0.035MG;0.5MG</u>	<u>A200488</u>	<u>001</u>	Oct 21, 2015
-----------	--	----------------------	----------------	------------	--------------

AB		<u>0.035MG;1MG</u>	<u>A200489</u>	<u>001</u>	Oct 21, 2015
-----------	--	--------------------	----------------	------------	--------------

AB	MAYNE PHARMA	<u>0.035MG;0.5MG</u>	<u>A070686</u>	<u>001</u>	Jan 29, 1987
-----------	--------------	----------------------	----------------	------------	--------------

AB	WATSON LABS	<u>0.035MG;0.4MG</u>	<u>A078323</u>	<u>001</u>	Feb 04, 2010
-----------	-------------	----------------------	----------------	------------	--------------

AB		<u>0.035MG;1MG</u>	<u>A070687</u>	<u>001</u>	Jan 29, 1987
-----------	--	--------------------	----------------	------------	--------------

NORINYL 1+35 28-DAY

AB	ALLERGAN SALES LLC	<u>0.035MG;1MG</u>	<u>N017565</u>	<u>002</u>	
-----------	--------------------	--------------------	----------------	------------	--

NORTREL 0.5/35-28

AB	BARR	<u>0.035MG;0.5MG</u>	<u>A072695</u>	<u>001</u>	Feb 28, 1992
-----------	------	----------------------	----------------	------------	--------------

NORTREL 1/35-28

AB	BARR	<u>0.035MG;1MG</u>	<u>A072696</u>	<u>001</u>	Feb 28, 1992
-----------	------	--------------------	----------------	------------	--------------

NORTREL 7/7/7

AB	BARR	<u>0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG</u>	<u>A075478</u>	<u>002</u>	Aug 30, 2002
-----------	------	---	----------------	------------	--------------

G

NYLIA 1/35

AB	AUROBINDO PHARMA LTD	<u>0.035MG;1MG</u>	<u>A207056</u>	<u>001</u>	Oct 21, 2016
-----------	----------------------	--------------------	----------------	------------	--------------

NYLIA 7/7/7

AB	AUROBINDO PHARMA LTD	<u>0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG</u>	<u>A207054</u>	<u>001</u>	Oct 21, 2016
-----------	----------------------	---	----------------	------------	--------------

G

PRESCRIPTION DRUG PRODUCT LIST

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

ORTHO-NOVUM 1/35-28

AB	+	JANSSEN PHARMS	<u>0.035MG;1MG</u>	<u>N017919</u>	<u>002</u>	
-----------	---	----------------	--------------------	----------------	------------	--

ORTHO-NOVUM 7/7/7-28

AB	+	JANSSEN PHARMS	<u>0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG</u>	<u>N018985</u>	<u>002</u>	Apr 04, 1984
-----------	---	----------------	---	----------------	------------	--------------

PHILITH

AB		NOVAST LABS LTD	<u>0.035MG;0.4MG</u>	<u>A090947</u>	<u>001</u>	Dec 22, 2011
-----------	--	-----------------	----------------------	----------------	------------	--------------

PIRMELLA 1/35

AB		LUPIN LTD	<u>0.035MG;1MG</u>	<u>A201512</u>	<u>001</u>	Apr 24, 2013
-----------	--	-----------	--------------------	----------------	------------	--------------

PIRMELLA 7/7/7

AB		LUPIN LTD	<u>0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG</u>	<u>A201510</u>	<u>001</u>	Apr 24, 2013
-----------	--	-----------	---	----------------	------------	--------------

TRI-NORINYL 28-DAY

AB	+	MAYNE PHARMA	<u>0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG</u>	<u>N018977</u>	<u>002</u>	Apr 13, 1984
-----------	---	--------------	--	----------------	------------	--------------

VYFEMLA

AB		LUPIN LTD	<u>0.035MG;0.4MG</u>	<u>A201886</u>	<u>001</u>	Sep 26, 2013
-----------	--	-----------	----------------------	----------------	------------	--------------

WERA

AB		NOVAST LABS LTD	<u>0.035MG;0.5MG</u>	<u>A091204</u>	<u>001</u>	Mar 27, 2012
-----------	--	-----------------	----------------------	----------------	------------	--------------

NORETHINDRONE AND ETHINYL ESTRADIOL

	+	JAI PHARMA LTD	<u>0.05MG;1MG</u>	<u>A203006</u>	<u>001</u>	Aug 05, 2013
--	---	----------------	-------------------	----------------	------------	--------------

NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)

		WATSON LABS	<u>0.035MG,0.035MG;0.5MG,1MG</u>	<u>A071044</u>	<u>001</u>	Apr 01, 1988
--	--	-------------	----------------------------------	----------------	------------	--------------

TABLET, CHEWABLE; ORAL

FEMCON FE

AB	+	APIL	<u>0.035MG;0.4MG</u>	<u>N021490</u>	<u>001</u>	Nov 14, 2003
-----------	---	------	----------------------	----------------	------------	--------------

KAITLIB FE

AB		LUPIN LTD	<u>0.025MG;0.8MG</u>	<u>A203448</u>	<u>001</u>	Dec 17, 2015
-----------	--	-----------	----------------------	----------------	------------	--------------

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB		AMNEAL PHARMS	<u>0.035MG;0.4MG</u>	<u>A078892</u>	<u>001</u>	Sep 26, 2011
-----------	--	---------------	----------------------	----------------	------------	--------------

AB	+	APIL	<u>0.025MG;0.8MG</u>	<u>N022573</u>	<u>001</u>	Dec 22, 2010
-----------	---	------	----------------------	----------------	------------	--------------

AB		BARR	<u>0.035MG;0.4MG</u>	<u>A078965</u>	<u>001</u>	Aug 05, 2010
-----------	--	------	----------------------	----------------	------------	--------------

AB		JAI PHARMA LTD	<u>0.025MG;0.8MG</u>	<u>A203371</u>	<u>001</u>	Apr 23, 2014
-----------	--	----------------	----------------------	----------------	------------	--------------

AB			<u>0.035MG;0.4MG</u>	<u>A202086</u>	<u>001</u>	Apr 01, 2015
-----------	--	--	----------------------	----------------	------------	--------------

AB		LUPIN LTD	<u>0.035MG;0.4MG</u>	<u>A091332</u>	<u>001</u>	Mar 23, 2016
-----------	--	-----------	----------------------	----------------	------------	--------------

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE; ORAL

TAYTULLA

	+	APIL	<u>0.02MG;1MG</u>	<u>N204426</u>	<u>001</u>	Apr 19, 2013
--	---	------	-------------------	----------------	------------	--------------

TABLET; ORAL

BLISOVI 24 FE

AB		LUPIN LTD	<u>0.02MG;1MG</u>	<u>A091398</u>	<u>001</u>	Oct 28, 2015
-----------	--	-----------	-------------------	----------------	------------	--------------

FEMHRT

AB		APIL	<u>0.0025MG;0.5MG</u>	<u>N021065</u>	<u>001</u>	Jan 14, 2005
-----------	--	------	-----------------------	----------------	------------	--------------

FYAVOLV

AB		LUPIN LTD	<u>0.005MG;1MG</u>	<u>A204213</u>	<u>002</u>	Dec 10, 2015
-----------	--	-----------	--------------------	----------------	------------	--------------

AB			<u>0.0025MG;0.5MG</u>	<u>A204213</u>	<u>001</u>	Dec 10, 2015
-----------	--	--	-----------------------	----------------	------------	--------------

GILDESS 24 FE

AB		VINTAGE PHARMS	<u>0.02MG;1MG</u>	<u>A090293</u>	<u>001</u>	Dec 01, 2014
-----------	--	----------------	-------------------	----------------	------------	--------------

LARIN 24 FE

AB		NOVAST LABS LTD	<u>0.02MG;1MG</u>	<u>A202994</u>	<u>001</u>	Feb 18, 2015
-----------	--	-----------------	-------------------	----------------	------------	--------------

LERIBANE

AB		NOVAST LABS LTD	<u>0.0025MG;0.5MG</u>	<u>A203435</u>	<u>002</u>	Jun 03, 2016
-----------	--	-----------------	-----------------------	----------------	------------	--------------

AB			<u>0.005MG;1MG</u>	<u>A203435</u>	<u>001</u>	Jun 03, 2016
-----------	--	--	--------------------	----------------	------------	--------------

LO LOESTRIN FE

AB	+	APIL	<u>0.01MG,0.01MG;1MG,N/A</u>	<u>N022501</u>	<u>001</u>	Oct 21, 2010
-----------	---	------	------------------------------	----------------	------------	--------------

LOESTRIN 24 FE

AB		APIL	<u>0.02MG;1MG</u>	<u>N021871</u>	<u>001</u>	Feb 17, 2006
-----------	--	------	-------------------	----------------	------------	--------------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB	+	BARR LABS INC	<u>0.005MG;1MG</u>	<u>A076221</u>	<u>001</u>	Nov 06, 2009
-----------	---	---------------	--------------------	----------------	------------	--------------

AB		GLENMARK GENERICS	<u>0.0025MG;0.5MG</u>	<u>A203038</u>	<u>001</u>	Apr 02, 2015
-----------	--	-------------------	-----------------------	----------------	------------	--------------

AB			<u>0.005MG;1MG</u>	<u>A203038</u>	<u>002</u>	Apr 02, 2015
-----------	--	--	--------------------	----------------	------------	--------------

AB		JAI PHARMA LTD	<u>0.005MG;1MG</u>	<u>A207259</u>	<u>001</u>	Dec 27, 2016
-----------	--	----------------	--------------------	----------------	------------	--------------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB		JAI PHARMA LTD	<u>0.01MG,0.01MG;1MG,N/A</u>	<u>A205049</u>	<u>001</u>	May 31, 2016
-----------	--	----------------	------------------------------	----------------	------------	--------------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	+	AMNEAL PHARMS	<u>0.02MG;1MG</u>	<u>A078267</u>	<u>001</u>	Sep 01, 2009
-----------	---	---------------	-------------------	----------------	------------	--------------

AB		BARR LABS INC	<u>0.02MG;1MG</u>	<u>A090938</u>	<u>001</u>	Dec 01, 2014
-----------	--	---------------	-------------------	----------------	------------	--------------

AB		JAI PHARMA LTD	<u>0.02MG;1MG</u>	<u>A202742</u>	<u>001</u>	Oct 30, 2014
-----------	--	----------------	-------------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-21

GILDESS 1.5/30

AB	VINTAGE PHARMS LLC	<u>0.03MG;1.5MG</u>	<u>A077075 002</u>	Jul 24, 2012
-----------	--------------------	---------------------	--------------------	--------------

GILDESS 1/20

AB	VINTAGE PHARMS LLC	<u>0.02MG;1MG</u>	<u>A077077 002</u>	Jul 24, 2012
-----------	--------------------	-------------------	--------------------	--------------

JUNEL 1.5/30

AB	BARR	<u>0.03MG;1.5MG</u>	<u>A076381 001</u>	May 30, 2003
-----------	------	---------------------	--------------------	--------------

JUNEL 1/20

AB	BARR	<u>0.02MG;1MG</u>	<u>A076380 001</u>	May 30, 2003
-----------	------	-------------------	--------------------	--------------

LARIN 1.5/30

AB	NOVAST LABS LTD	<u>0.03MG;1.5MG</u>	<u>A202996 001</u>	Mar 20, 2014
-----------	-----------------	---------------------	--------------------	--------------

LARIN 1/20

AB	NOVAST LABS LTD	<u>0.02MG;1MG</u>	<u>A202995 001</u>	Dec 04, 2013
-----------	-----------------	-------------------	--------------------	--------------

LOESTRIN 21 1.5/30

AB	APIL	<u>0.03MG;1.5MG</u>	<u>N017875 001</u>	
-----------	------	---------------------	--------------------	--

LOESTRIN 21 1/20

AB	APIL	<u>0.02MG;1MG</u>	<u>N017876 001</u>	
-----------	------	-------------------	--------------------	--

MICROGESTIN 1.5/30

AB	MAYNE PHARMA	<u>0.03MG;1.5MG</u>	<u>A075548 002</u>	Jul 30, 2003
-----------	--------------	---------------------	--------------------	--------------

MICROGESTIN 1/20

AB	MAYNE PHARMA	<u>0.02MG;1MG</u>	<u>A075647 002</u>	Jul 30, 2003
-----------	--------------	-------------------	--------------------	--------------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB	GLENMARK PHARMS LTD	<u>0.02MG;1MG</u>	<u>A206969 001</u>	Jan 20, 2016
-----------	---------------------	-------------------	--------------------	--------------

AB	JAI PHARMA LTD	<u>0.02MG;1MG</u>	<u>A202771 001</u>	Nov 06, 2013
-----------	----------------	-------------------	--------------------	--------------

AB		<u>0.03MG;1.5MG</u>	<u>A202770 001</u>	Feb 19, 2015
-----------	--	---------------------	--------------------	--------------

TRI-LEGEST 21

	BARR	<u>0.02MG,0.03MG,0.035MG;1MG,1MG,1MG</u>	<u>A076405 001</u>	Oct 26, 2007
--	------	--	--------------------	--------------

TABLET; ORAL-28

BLISOVI FE 1.5/30

AB	LUPIN LTD	<u>0.03MG;1.5MG</u>	<u>A201585 001</u>	Nov 18, 2015
-----------	-----------	---------------------	--------------------	--------------

BLISOVI FE 1/20

AB	LUPIN LTD	<u>0.02MG;1MG</u>	<u>A201584 001</u>	Nov 18, 2015
-----------	-----------	-------------------	--------------------	--------------

ESTROSTEP FE

AB	+ APIL	<u>0.02MG,0.03MG,0.035MG;1MG,1MG,1MG</u>	<u>N020130 002</u>	Oct 09, 1996
-----------	--------	--	--------------------	--------------

GILDESS FE 1.5/30

AB	VINTAGE PHARMS LLC	<u>0.03MG;1.5MG</u>	<u>A077075 001</u>	Apr 28, 2005
-----------	--------------------	---------------------	--------------------	--------------

GILDESS FE 1/20

AB	VINTAGE PHARMS LLC	<u>0.02MG;1MG</u>	<u>A077077 001</u>	May 20, 2005
-----------	--------------------	-------------------	--------------------	--------------

JUNEL FE 1.5/30

AB	BARR	<u>0.03MG;1.5MG</u>	<u>A076064 001</u>	Sep 18, 2003
-----------	------	---------------------	--------------------	--------------

JUNEL FE 1/20

AB	BARR	<u>0.02MG;1MG</u>	<u>A076081 001</u>	Sep 18, 2003
-----------	------	-------------------	--------------------	--------------

LARIN FE 1.5/30

AB	NOVAST LABS LTD	<u>0.03MG;1.5MG</u>	<u>A091453 001</u>	Aug 23, 2013
-----------	-----------------	---------------------	--------------------	--------------

LARIN FE 1/20

AB	NOVAST LABS LTD	<u>0.02MG;1MG</u>	<u>A091454 001</u>	Aug 26, 2013
-----------	-----------------	-------------------	--------------------	--------------

LOESTRIN FE 1.5/30

AB	+ APIL	<u>0.03MG;1.5MG</u>	<u>N017355 001</u>	
-----------	--------	---------------------	--------------------	--

LOESTRIN FE 1/20

AB	APIL	<u>0.02MG;1MG</u>	<u>N017354 001</u>	
-----------	------	-------------------	--------------------	--

MICROGESTIN FE 1.5/30

AB	MAYNE PHARMA	<u>0.03MG;1.5MG</u>	<u>A075548 001</u>	Feb 05, 2001
-----------	--------------	---------------------	--------------------	--------------

MICROGESTIN FE 1/20

AB	MAYNE PHARMA	<u>0.02MG;1MG</u>	<u>A075647 001</u>	Feb 05, 2001
-----------	--------------	-------------------	--------------------	--------------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB	JAI PHARMA LTD	<u>0.02MG;1MG</u>	<u>A202772 001</u>	Nov 14, 2013
-----------	----------------	-------------------	--------------------	--------------

AB		<u>0.03MG;1.5MG</u>	<u>A202741 001</u>	Feb 20, 2015
-----------	--	---------------------	--------------------	--------------

AB	MAYNE PHARMA	<u>0.02MG,0.03MG,0.035MG;1MG,1MG,1MG</u>	<u>A076629 001</u>	Mar 18, 2010
-----------	--------------	--	--------------------	--------------

TRI-LEGEST FE

AB	BARR	<u>0.02MG,0.03MG,0.035MG;1MG,1MG,1MG</u>	<u>A076105 001</u>	Oct 26, 2007
-----------	------	--	--------------------	--------------

TABLET, CHEWABLE; ORAL

MIBELAS 24 FE

AB	LUPIN ATLANTIS	<u>0.02MG;1MG</u>	<u>A206287 001</u>	May 24, 2016
-----------	----------------	-------------------	--------------------	--------------

MINASTRIN 24 FE

AB	+ APIL	<u>0.02MG;1MG</u>	<u>N203667 001</u>	May 08, 2013
-----------	--------	-------------------	--------------------	--------------

TABLET, CHEWABLE, TABLET; ORAL

LO MINASTRIN FE

	+ APIL	<u>0.01MG,0.01MG,N/A;1MG,N/A,N/A</u>	<u>N204654 001</u>	Jul 24, 2013
--	--------	--------------------------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL

NORGESTIMATE AND ETHINYL ESTRADIOL

<u>AB</u>	GLENMARK GENERICS	<u>0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG</u>	<u>A200494 001</u>	Jun 17, 2011
-----------	-------------------	---	--------------------	--------------

TABLET; ORAL-28

ESTARYLLA

<u>AB</u>	SANDOZ	<u>0.035MG; 0.25MG</u>	<u>A090794 001</u>	Jan 30, 2013
-----------	--------	------------------------	--------------------	--------------

MILI

<u>AB</u>	AUROBINDO PHARMA LTD	<u>0.035MG; 0.25MG</u>	<u>A205449 001</u>	Jul 07, 2016
-----------	----------------------	------------------------	--------------------	--------------

MONO-LINYAH

<u>AB</u>	NOVAST LABS LTD	<u>0.035MG; 0.25MG</u>	<u>A090523 001</u>	May 23, 2012
-----------	-----------------	------------------------	--------------------	--------------

NORGESTIMATE AND ETHINYL ESTRADIOL

<u>AB</u>	AMNEAL PHARMS	<u>0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG</u>	<u>A203870 001</u>	Nov 12, 2015
-----------	---------------	---	--------------------	--------------

<u>AB</u>		<u>0.035MG; 0.25MG</u>	<u>A203865 001</u>	Oct 27, 2015
-----------	--	------------------------	--------------------	--------------

<u>AB</u>	GLENMARK GENERICS	<u>0.035MG; 0.25MG</u>	<u>A200538 001</u>	Apr 05, 2012
-----------	-------------------	------------------------	--------------------	--------------

<u>AB</u>	GLENMARK PHARMS	<u>0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.215MG, 0.25MG</u>	<u>A204057 001</u>	Feb 23, 2016
-----------	-----------------	---	--------------------	--------------

<u>AB</u>	HAUPT PHARMA	<u>0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.215MG, 0.25MG</u>	<u>A203873 001</u>	May 12, 2016
-----------	--------------	---	--------------------	--------------

<u>AB</u>	JAI PHARMA LTD	<u>0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.215MG, 0.25MG</u>	<u>A202132 001</u>	Sep 09, 2015
-----------	----------------	---	--------------------	--------------

<u>AB</u>		<u>0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG</u>	<u>A201897 001</u>	Jan 27, 2016
-----------	--	---	--------------------	--------------

<u>AB</u>		<u>0.035MG; 0.25MG</u>	<u>A201896 001</u>	Jan 27, 2016
-----------	--	------------------------	--------------------	--------------

<u>AB</u>	LUPIN LTD	<u>0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG</u>	<u>A205588 001</u>	Apr 26, 2016
-----------	-----------	---	--------------------	--------------

<u>AB</u>		<u>0.035MG; 0.25MG</u>	<u>A205630 001</u>	Oct 27, 2016
-----------	--	------------------------	--------------------	--------------

<u>AB</u>	LUPIN PHARMS	<u>0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.215MG, 0.25MG</u>	<u>A200541 001</u>	Jun 25, 2012
-----------	--------------	---	--------------------	--------------

<u>AB</u>	OC PHARMA	<u>0.035MG; 0.035MG; 0.035MG; 0.18MG; 0.215MG; 0.25MG</u>	<u>A200383 001</u>	Apr 07, 2015
-----------	-----------	---	--------------------	--------------

<u>AB</u>		<u>0.035MG; 0.25MG</u>	<u>A200384 001</u>	Apr 07, 2015
-----------	--	------------------------	--------------------	--------------

ORTHO CYCLEN-28

<u>AB</u>	+ JANSSEN PHARMS	<u>0.035MG; 0.25MG</u>	<u>N019653 002</u>	Dec 29, 1989
-----------	------------------	------------------------	--------------------	--------------

ORTHO TRI-CYCLEN

<u>AB</u>	+ JANSSEN PHARMS	<u>0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG</u>	<u>N019697 001</u>	Jul 03, 1992
-----------	------------------	---	--------------------	--------------

ORTHO TRI-CYCLEN LO

<u>AB</u>	+ JANSSEN PHARMS	<u>0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.215MG, 0.25MG</u>	<u>N021241 001</u>	Aug 22, 2002
-----------	------------------	---	--------------------	--------------

PREVIFEM

<u>AB</u>	VINTAGE PHARMS LLC	<u>0.035MG; 0.25MG</u>	<u>A076334 001</u>	Jan 09, 2004
-----------	--------------------	------------------------	--------------------	--------------

SPRINTEC

<u>AB</u>	BARR	<u>0.035MG; 0.25MG</u>	<u>A075804 001</u>	Sep 25, 2002
-----------	------	------------------------	--------------------	--------------

TRI LO SPRINTEC

<u>AB</u>	BARR LABS INC	<u>0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.215MG, 0.25MG</u>	<u>A076784 001</u>	Jun 29, 2009
-----------	---------------	---	--------------------	--------------

TRI-ESTARYLLA

<u>AB</u>	SANDOZ	<u>0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG</u>	<u>A090793 001</u>	Jan 30, 2013
-----------	--------	---	--------------------	--------------

TRI-LINYAH

<u>AB</u>	NOVAST LABS LTD	<u>0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG</u>	<u>A090524 001</u>	May 30, 2012
-----------	-----------------	---	--------------------	--------------

TRI-LO-ESTARYLLA

<u>AB</u>	SANDOZ INC	<u>0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.215MG, 0.25MG</u>	<u>A091232 001</u>	Jun 29, 2015
-----------	------------	---	--------------------	--------------

TRI-LO-MILI

<u>AB</u>	AUROBINDO PHARMA LTD	<u>0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.215MG, 0.25MG</u>	<u>A205762 001</u>	Nov 04, 2016
-----------	----------------------	---	--------------------	--------------

TRI-MILI

<u>AB</u>	AUROBINDO PHARMA LTD	<u>0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG</u>	<u>A205441 001</u>	Jul 06, 2016
-----------	----------------------	---	--------------------	--------------

TRI-PREVIFEM

<u>AB</u>	VINTAGE PHARMS LLC	<u>0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG</u>	<u>A076335 001</u>	Mar 26, 2004
-----------	--------------------	---	--------------------	--------------

TRI-SPRINTEC

<u>AB</u>	BARR	<u>0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG</u>	<u>A075808 001</u>	Dec 29, 2003
-----------	------	---	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

CRYSELLE

AB DURAMED PHARMS BARR **0.03MG;0.3MG** **A075840 001** Nov 30, 2001
TABLET; ORAL-28

CRYSELLE

AB DURAMED PHARMS BARR **0.03MG;0.3MG** **A075840 002** Nov 30, 2001

ELINEST

AB NOVAST LABS LTD **0.03MG;0.3MG** **A091105 001** Mar 28, 2012

LOW-OGESTREL-28

AB MAYNE PHARMA **0.03MG;0.3MG** **A075288 002** Jul 28, 1999

NORGESTREL AND ETHINYL ESTRADIOL

AB JAI PHARMA LTD **0.03MG;0.3MG** **A201828 001** Jun 21, 2016

OGESTREL 0.5/50-28

+ WATSON LABS 0.05MG;0.5MG A075406 002 Dec 15, 1999

ETHIODIZED OIL

OIL; INTRALYMPHATIC, INTRAUTERINE

LIPIODOL

+ GUERBET EQ 4.8GM IODINE/10ML (EQ 480MG IODINE/ML) N009190 001

ETHIONAMIDE

TABLET; ORAL

TRECATOR

+ WYETH PHARMS INC 250MG N013026 002

ETHOSUXIMIDE

CAPSULE; ORAL

ETHOSUXIMIDE

AB AKORN **250MG** **A040686 001** May 28, 2008

AB BIONPHARMA INC **250MG** **A040430 001** Oct 28, 2002

AB HERITAGE PHARMS INC **250MG** **A200892 001** Sep 25, 2012

ZARONTIN

AB + PARKE DAVIS **250MG** **N012380 001**

SYRUP; ORAL

ETHOSUXIMIDE

AA MIKART **250MG/5ML** **A040506 001** Dec 22, 2003

AA PHARM ASSOC **250MG/5ML** **A040253 001** Nov 22, 2000

AA TEVA PHARMS **250MG/5ML** **A081306 001** Jul 30, 1993

ZARONTIN

AA + PARKE DAVIS **250MG/5ML** **A080258 001**

ETHOTOIN

TABLET; ORAL

PEGANONE

+ RECORDATI RARE 250MG N010841 001

ETIDRONATE DISODIUM

TABLET; ORAL

DIDRONEL

AB APIL **200MG** **N017831 001**

AB + **400MG** **N017831 002**

ETIDRONATE DISODIUM

AB MYLAN **200MG** **A075800 001** Jan 24, 2003

AB **400MG** **A075800 002** Jan 24, 2003

ETODOLAC

CAPSULE; ORAL

ETODOLAC

AB ANI PHARMS INC **200MG** **A075126 001** Sep 16, 1999

AB **300MG** **A075126 002** Sep 16, 1999

AB APOTEX **200MG** **A075419 001** Jul 28, 2000

AB **300MG** **A075419 002** Jul 28, 2000

AB TARO **200MG** **A075078 001** Apr 30, 1998

AB + **300MG** **A075078 002** Apr 30, 1998

TABLET; ORAL

ETODOLAC

AB APOTEX INC **400MG** **A076004 001** Dec 03, 2002

AB **500MG** **A076004 002** Dec 03, 2002

AB MYLAN **400MG** **A075104 001** Feb 06, 1998

AB **500MG** **A075104 002** Nov 20, 1998

AB SANDOZ **400MG** **A074903 001** Apr 11, 1997

AB **500MG** **A074903 002** Apr 19, 1999

AB TARO PHARM INDS **400MG** **A075074 001** Mar 11, 1998

AB + **500MG** **A075074 002** Apr 25, 2000

PRESCRIPTION DRUG PRODUCT LIST

ETODOLAC

TABLET; ORAL

ETODOLAC

<u>AB</u>	TEVA	<u>400MG</u>	<u>A075009</u>	<u>001</u>	Nov 26, 1997
<u>AB</u>		<u>500MG</u>	<u>A075009</u>	<u>002</u>	Dec 28, 1999

TABLET, EXTENDED RELEASE; ORAL

ETODOLAC

<u>AB</u>	TARO	<u>400MG</u>	<u>A076174</u>	<u>001</u>	Mar 13, 2003
<u>AB</u>		<u>500MG</u>	<u>A076174</u>	<u>002</u>	Mar 13, 2003
<u>AB</u>		<u>600MG</u>	<u>A076174</u>	<u>003</u>	Mar 13, 2003
<u>AB</u>	TEVA	<u>400MG</u>	<u>A075665</u>	<u>003</u>	Feb 05, 2001
<u>AB</u>		<u>500MG</u>	<u>A075665</u>	<u>002</u>	Jul 31, 2000
<u>AB</u>	+	<u>600MG</u>	<u>A075665</u>	<u>001</u>	Jul 31, 2000
<u>AB</u>	ZYDUS PHARMS USA INC	<u>400MG</u>	<u>A091134</u>	<u>001</u>	Jan 23, 2014
<u>AB</u>		<u>500MG</u>	<u>A091134</u>	<u>002</u>	Jan 23, 2014
<u>AB</u>		<u>600MG</u>	<u>A091134</u>	<u>003</u>	Jan 23, 2014

ETOMIDATE

INJECTABLE; INJECTION

AMIDATE

<u>AP</u>	+	HOSPIRA	<u>2MG/ML</u>	<u>N018227</u>	<u>001</u>	Sep 07, 1982
-----------	---	---------	---------------	----------------	------------	--------------

ETOMIDATE

<u>AP</u>		EMCURE PHARMS LTD	<u>2MG/ML</u>	<u>A204618</u>	<u>001</u>	Aug 13, 2014
<u>AP</u>		EUROHLTH INTL SARL	<u>2MG/ML</u>	<u>A074593</u>	<u>001</u>	Nov 04, 1996
<u>AP</u>		HIKMA FARMACEUTICA	<u>2MG/ML</u>	<u>A202354</u>	<u>001</u>	Feb 25, 2016
<u>AP</u>		LUITPOLD	<u>2MG/ML</u>	<u>A078867</u>	<u>001</u>	Dec 22, 2009
<u>AP</u>		MYLAN LABS LTD	<u>2MG/ML</u>	<u>A078289</u>	<u>001</u>	Jan 02, 2009
<u>AP</u>		PAR STERILE PRODUCTS	<u>2MG/ML</u>	<u>A091297</u>	<u>001</u>	Jun 20, 2012
<u>AP</u>		ZYDUS PHARMS USA INC	<u>2MG/ML</u>	<u>A202360</u>	<u>001</u>	Jul 18, 2014

ETONOGESTREL

IMPLANT; IMPLANTATION

NEXPLANON

+	ORGANON USA INC	68MG/IMPLANT	N021529	002	May 31, 2011
---	-----------------	--------------	---------	-----	--------------

ETOPOSIDE

CAPSULE; ORAL

ETOPOSIDE

+	MYLAN	50MG	A075635	001	Sep 19, 2001
---	-------	------	---------	-----	--------------

INJECTABLE; INJECTION

ETOPOSIDE

<u>AP</u>		ACCORD HLTHCARE	<u>20MG/ML</u>	<u>A074513</u>	<u>001</u>	Mar 14, 1996
<u>AP</u>	+	FRESENIUS KABI USA	<u>20MG/ML</u>	<u>A074983</u>	<u>001</u>	Sep 30, 1998
<u>AP</u>		TEVA PHARMS USA	<u>20MG/ML</u>	<u>A074529</u>	<u>001</u>	Jul 24, 1996
<u>AP</u>		WEST-WARD PHARMS INT	<u>20MG/ML</u>	<u>A074290</u>	<u>001</u>	Jul 17, 1995

ETOPOSIDE PHOSPHATE

INJECTABLE; INJECTION

ETOPOPHOS PRESERVATIVE FREE

+	BRISTOL MYERS SQUIBB	EQ 100MG BASE/VIAL	N020457	001	May 17, 1996
---	----------------------	--------------------	---------	-----	--------------

ETRAVIRINE

TABLET; ORAL

INTELENCE

JANSSEN R AND D	25MG	N022187	003	Mar 26, 2012
-----------------	------	---------	-----	--------------

	100MG	N022187	001	Jan 18, 2008
--	-------	---------	-----	--------------

+		200MG	N022187	002	Dec 22, 2010
---	--	-------	---------	-----	--------------

EVEROLIMUS

TABLET; ORAL

AFINITOR

NOVARTIS	2.5MG	N022334	003	Jul 09, 2010
----------	-------	---------	-----	--------------

	5MG	N022334	001	Mar 30, 2009
--	-----	---------	-----	--------------

	7.5MG	N022334	004	Mar 30, 2012
--	-------	---------	-----	--------------

+		10MG	N022334	002	Mar 30, 2009
---	--	------	---------	-----	--------------

ZORTRESS

NOVARTIS	0.25MG	N021560	001	Apr 20, 2010
----------	--------	---------	-----	--------------

	0.5MG	N021560	002	Apr 20, 2010
--	-------	---------	-----	--------------

+		0.75MG	N021560	003	Apr 20, 2010
---	--	--------	---------	-----	--------------

TABLET, FOR SUSPENSION; ORAL

AFINITOR DISPERZ

NOVARTIS PHARM	2MG	N203985	001	Aug 29, 2012
----------------	-----	---------	-----	--------------

	3MG	N203985	002	Aug 29, 2012
--	-----	---------	-----	--------------

+		5MG	N203985	003	Aug 29, 2012
---	--	-----	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

EXEMESTANE

TABLET; ORAL

AROMASIN

AB	+	PHARMACIA AND UPJOHN	25MG	N020753	001	Oct 21, 1999
-----------	---	----------------------	-------------	----------------	------------	--------------

EXEMESTANE

AB		ALVOGEN MALTA	25MG	A200898	001	Jul 28, 2014
-----------	--	---------------	-------------	----------------	------------	--------------

AB		WEST-WARD PHARMS INT	25MG	A077431	001	Apr 01, 2011
-----------	--	----------------------	-------------	----------------	------------	--------------

EXENATIDE SYNTHETIC

FOR SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS

BYDUREON

	+	ASTRAZENECA AB	2MG/VIAL	N022200	001	Jan 27, 2012
--	---	----------------	----------	---------	-----	--------------

BYDUREON PEN

	+	ASTRAZENECA AB	2MG	N022200	002	Feb 28, 2014
--	---	----------------	-----	---------	-----	--------------

INJECTABLE; SUBCUTANEOUS

BYETTA

	+	ASTRAZENECA AB	300MCG/1.2ML (250MCG/ML)	N021773	001	Apr 28, 2005
--	---	----------------	--------------------------	---------	-----	--------------

	+		600MCG/2.4ML (250MCG/ML)	N021773	002	Apr 28, 2005
--	---	--	--------------------------	---------	-----	--------------

EZETIMIBE

TABLET; ORAL

EZETIMIBE

AB		GLENMARK PHARMS LTD	10MG	A078560	001	Jun 26, 2015
-----------	--	---------------------	-------------	----------------	------------	--------------

ZETIA

AB	+	MSD INTL GMBH	10MG	N021445	001	Oct 25, 2002
-----------	---	---------------	-------------	----------------	------------	--------------

EZETIMIBE; SIMVASTATIN

TABLET; ORAL

VYTORIN

		MSD INTL	10MG; 10MG	N021687	001	Jul 23, 2004
--	--	----------	------------	---------	-----	--------------

			10MG; 20MG	N021687	002	Jul 23, 2004
--	--	--	------------	---------	-----	--------------

			10MG; 40MG	N021687	003	Jul 23, 2004
--	--	--	------------	---------	-----	--------------

	+		10MG; 80MG	N021687	004	Jul 23, 2004
--	---	--	------------	---------	-----	--------------

EZOZABINE

TABLET; ORAL

POTIGA

		GLAXOSMITHKLINE	50MG	N022345	001	Jun 10, 2011
--	--	-----------------	------	---------	-----	--------------

			200MG	N022345	002	Jun 10, 2011
--	--	--	-------	---------	-----	--------------

			300MG	N022345	003	Jun 10, 2011
--	--	--	-------	---------	-----	--------------

	+		400MG	N022345	004	Jun 10, 2011
--	---	--	-------	---------	-----	--------------

FAMCICLOVIR

TABLET; ORAL

FAMCICLOVIR

AB		APOTEX	125MG	A091480	001	Jul 22, 2011
-----------	--	--------	--------------	----------------	------------	--------------

AB			250MG	A091480	002	Jul 22, 2011
-----------	--	--	--------------	----------------	------------	--------------

AB			500MG	A091480	003	Jul 22, 2011
-----------	--	--	--------------	----------------	------------	--------------

AB		AUROBINDO PHARMA LTD	125MG	A091114	001	Mar 21, 2011
-----------	--	----------------------	--------------	----------------	------------	--------------

AB			250MG	A091114	002	Mar 21, 2011
-----------	--	--	--------------	----------------	------------	--------------

AB			500MG	A091114	003	Mar 21, 2011
-----------	--	--	--------------	----------------	------------	--------------

AB		CIPLA LTD	125MG	A078278	001	Mar 21, 2011
-----------	--	-----------	--------------	----------------	------------	--------------

AB			250MG	A078278	002	Mar 21, 2011
-----------	--	--	--------------	----------------	------------	--------------

AB			500MG	A078278	003	Mar 21, 2011
-----------	--	--	--------------	----------------	------------	--------------

AB		HETERO LABS LTD V	125MG	A202438	001	Sep 10, 2014
-----------	--	-------------------	--------------	----------------	------------	--------------

AB			250MG	A202438	002	Sep 10, 2014
-----------	--	--	--------------	----------------	------------	--------------

AB			500MG	A202438	003	Sep 10, 2014
-----------	--	--	--------------	----------------	------------	--------------

AB		MACLEODS PHARMS LTD	125MG	A201022	001	Jan 12, 2012
-----------	--	---------------------	--------------	----------------	------------	--------------

AB			250MG	A201022	002	Jan 12, 2012
-----------	--	--	--------------	----------------	------------	--------------

AB			500MG	A201022	003	Jan 12, 2012
-----------	--	--	--------------	----------------	------------	--------------

AB		MYLAN	125MG	A201333	001	Mar 24, 2011
-----------	--	-------	--------------	----------------	------------	--------------

AB			250MG	A201333	002	Mar 24, 2011
-----------	--	--	--------------	----------------	------------	--------------

AB			500MG	A201333	003	Mar 24, 2011
-----------	--	--	--------------	----------------	------------	--------------

AB		TEVA PHARMS	125MG	A077487	001	Aug 24, 2007
-----------	--	-------------	--------------	----------------	------------	--------------

AB			250MG	A077487	002	Aug 24, 2007
-----------	--	--	--------------	----------------	------------	--------------

AB			500MG	A077487	003	Aug 24, 2007
-----------	--	--	--------------	----------------	------------	--------------

AB		WEST-WARD PHARMS INT	125MG	A090128	001	Mar 21, 2011
-----------	--	----------------------	--------------	----------------	------------	--------------

AB			250MG	A090128	002	Mar 21, 2011
-----------	--	--	--------------	----------------	------------	--------------

AB			500MG	A090128	003	Mar 21, 2011
-----------	--	--	--------------	----------------	------------	--------------

FAMVIR

AB		NOVARTIS	125MG	N020363	003	Dec 11, 1995
-----------	--	----------	--------------	----------------	------------	--------------

AB			250MG	N020363	001	Apr 26, 1996
-----------	--	--	--------------	----------------	------------	--------------

AB	+		500MG	N020363	002	Jun 29, 1994
-----------	---	--	--------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

FAMOTIDINE

FOR SUSPENSION; ORAL

FAMOTIDINE

<u>AB</u>	HI-TECH PHARMA CO	<u>40MG/5ML</u>	<u>A201995</u>	<u>001</u>	May 30, 2014
<u>AB</u>	LUPIN LTD	<u>40MG/5ML</u>	<u>A090440</u>	<u>001</u>	Jun 29, 2010
<u>AB</u>	NAVINTA LLC	<u>40MG/5ML</u>	<u>A091020</u>	<u>001</u>	May 27, 2010

PEPCID

<u>AB</u>	+ SALIX PHARMS	<u>40MG/5ML</u>	<u>N019527</u>	<u>001</u>	Feb 02, 1987
-----------	----------------	-----------------	----------------	------------	--------------

INJECTABLE; INJECTION

FAMOTIDINE

<u>AP</u>	AMPHASTAR PHARMS INC	<u>10MG/ML</u>	<u>A075651</u>	<u>001</u>	Apr 16, 2001
<u>AP</u>		<u>10MG/ML</u>	<u>A075684</u>	<u>001</u>	Apr 16, 2001
<u>AP</u>	+ EUROHLTH INTL SARL	<u>10MG/ML</u>	<u>A075488</u>	<u>001</u>	Apr 16, 2001
<u>AP</u>	FRESENIUS KABI USA	<u>10MG/ML</u>	<u>A075709</u>	<u>001</u>	Apr 16, 2001
<u>AP</u>	MYLAN LABS LTD	<u>10MG/ML</u>	<u>A078641</u>	<u>001</u>	Jun 25, 2008

FAMOTIDINE PRESERVATIVE FREE

<u>AP</u>	AMPHASTAR PHARMS INC	<u>10MG/ML</u>	<u>A075622</u>	<u>001</u>	Apr 16, 2001
<u>AP</u>		<u>10MG/ML</u>	<u>A075825</u>	<u>001</u>	Apr 17, 2001
<u>AP</u>	+ EUROHLTH INTL SARL	<u>10MG/ML</u>	<u>A075486</u>	<u>001</u>	Apr 16, 2001
<u>AP</u>	FRESENIUS KABI USA	<u>10MG/ML</u>	<u>A075813</u>	<u>001</u>	Apr 16, 2001
<u>AP</u>	MYLAN LABS LTD	<u>10MG/ML</u>	<u>A078642</u>	<u>001</u>	Jun 25, 2008

FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER

<u>AP</u>	+ BAXTER HLTHCARE	<u>0.4MG/ML</u>	<u>A075591</u>	<u>001</u>	May 10, 2001
-----------	-------------------	-----------------	----------------	------------	--------------

SUSPENSION; ORAL

FAMOTIDINE

<u>AB</u>	NOVEL LABS INC	<u>40MG/5ML</u>	<u>A201695</u>	<u>001</u>	Dec 17, 2012
-----------	----------------	-----------------	----------------	------------	--------------

TABLET; ORAL

FAMOTIDINE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>20MG</u>	<u>A078916</u>	<u>001</u>	May 22, 2009
<u>AB</u>		<u>40MG</u>	<u>A078916</u>	<u>002</u>	May 22, 2009
<u>AB</u>	APOTEX	<u>20MG</u>	<u>A075611</u>	<u>001</u>	Jul 23, 2001
<u>AB</u>		<u>40MG</u>	<u>A075611</u>	<u>002</u>	Jul 23, 2001
<u>AB</u>	AUROBINDO PHARMA LTD	<u>20MG</u>	<u>A206530</u>	<u>001</u>	Dec 22, 2015
<u>AB</u>		<u>40MG</u>	<u>A206530</u>	<u>002</u>	Dec 22, 2015
<u>AB</u>	CARLSBAD	<u>20MG</u>	<u>A075805</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075805</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	DR REDDYS LABS LTD	<u>20MG</u>	<u>A075718</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075718</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>20MG</u>	<u>A075511</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075511</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	MYLAN	<u>20MG</u>	<u>A075704</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075704</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	PERRIGO	<u>20MG</u>	<u>A077352</u>	<u>002</u>	Jul 27, 2005
<u>AB</u>		<u>40MG</u>	<u>A077352</u>	<u>001</u>	Jul 27, 2005
<u>AB</u>	TEVA	<u>20MG</u>	<u>A075311</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075311</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	WOCKHARDT	<u>20MG</u>	<u>A075786</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075786</u>	<u>002</u>	Apr 16, 2001

PEPCID

<u>AB</u>	VALEANT PHARMS NORTH	<u>20MG</u>	<u>N019462</u>	<u>001</u>	Oct 15, 1986
<u>AB</u>	+	<u>40MG</u>	<u>N019462</u>	<u>002</u>	Oct 15, 1986

FAMOTIDINE; IBUPROFEN

TABLET; ORAL

DUEXIS

+ HORIZON PHARMA

26.6MG; 800MG

N022519 001 Apr 23, 2011

FEBUXOSTAT

TABLET; ORAL

ULORIC

TAKEDA PHARMS USA

40MG

N021856 001 Feb 13, 2009

+

80MG

N021856 002 Feb 13, 2009

FELBAMATE

SUSPENSION; ORAL

FELBAMATE

<u>AB</u>	AMNEAL PHARMS	<u>600MG/5ML</u>	<u>A202385</u>	<u>001</u>	Dec 16, 2011
-----------	---------------	------------------	----------------	------------	--------------

FELBATOL

<u>AB</u>	+ MEDA PHARMS	<u>600MG/5ML</u>	<u>N020189</u>	<u>003</u>	Jul 29, 1993
-----------	---------------	------------------	----------------	------------	--------------

TABLET; ORAL

FELBAMATE

<u>AB</u>	ALVOGEN MALTA	<u>400MG</u>	<u>A204595</u>	<u>001</u>	Jan 11, 2016
<u>AB</u>		<u>600MG</u>	<u>A204595</u>	<u>002</u>	Jan 11, 2016
<u>AB</u>	AMNEAL PHARMS	<u>400MG</u>	<u>A201680</u>	<u>001</u>	Sep 13, 2011

PRESCRIPTION DRUG PRODUCT LIST

FELBAMATE

TABLET; ORAL

FELBAMATE

<u>AB</u>		<u>600MG</u>	<u>A201680</u>	<u>002</u>	Sep 13, 2011
<u>AB</u>	COREPHARMA	<u>400MG</u>	<u>A202284</u>	<u>001</u>	Nov 04, 2015
<u>AB</u>		<u>600MG</u>	<u>A202284</u>	<u>002</u>	Nov 04, 2015

FELBATOL

<u>AB</u>	MEDA PHARMS	<u>400MG</u>	<u>N020189</u>	<u>001</u>	Jul 29, 1993
<u>AB</u>	+	<u>600MG</u>	<u>N020189</u>	<u>002</u>	Jul 29, 1993

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

FELODIPINE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>2.5MG</u>	<u>A203417</u>	<u>001</u>	Jan 17, 2013
<u>AB</u>		<u>5MG</u>	<u>A203417</u>	<u>002</u>	Jan 17, 2013
<u>AB</u>		<u>10MG</u>	<u>A203417</u>	<u>003</u>	Jan 17, 2013
<u>AB</u>	GLENMARK GENERICS	<u>2.5MG</u>	<u>A090365</u>	<u>001</u>	Dec 17, 2010
<u>AB</u>		<u>5MG</u>	<u>A090365</u>	<u>002</u>	Dec 17, 2010
<u>AB</u>		<u>10MG</u>	<u>A090365</u>	<u>003</u>	Dec 17, 2010
<u>AB</u>	HERITAGE PHARMS INC	<u>2.5MG</u>	<u>A201964</u>	<u>001</u>	Nov 08, 2013
<u>AB</u>		<u>5MG</u>	<u>A201964</u>	<u>002</u>	Nov 08, 2013
<u>AB</u>		<u>10MG</u>	<u>A201964</u>	<u>003</u>	Nov 08, 2013
<u>AB</u>	JUBILANT GENERICS	<u>2.5MG</u>	<u>A203983</u>	<u>001</u>	Aug 19, 2016
<u>AB</u>		<u>5MG</u>	<u>A203983</u>	<u>002</u>	Aug 19, 2016
<u>AB</u>		<u>10MG</u>	<u>A203983</u>	<u>003</u>	Aug 19, 2016
<u>AB</u>	MYLAN	<u>2.5MG</u>	<u>A078855</u>	<u>001</u>	Apr 17, 2008
<u>AB</u>		<u>5MG</u>	<u>A078855</u>	<u>002</u>	Apr 17, 2008
<u>AB</u>	+	<u>10MG</u>	<u>A078855</u>	<u>003</u>	Apr 17, 2008
<u>AB</u>	ORCHID HLTHCARE	<u>2.5MG</u>	<u>A203032</u>	<u>001</u>	May 21, 2015
<u>AB</u>		<u>5MG</u>	<u>A203032</u>	<u>002</u>	May 21, 2015
<u>AB</u>		<u>10MG</u>	<u>A203032</u>	<u>003</u>	May 21, 2015
<u>AB</u>	SUN PHARM INDS	<u>2.5MG</u>	<u>A075896</u>	<u>001</u>	Nov 02, 2004
<u>AB</u>		<u>5MG</u>	<u>A075896</u>	<u>002</u>	Nov 02, 2004
<u>AB</u>		<u>10MG</u>	<u>A075896</u>	<u>003</u>	Nov 02, 2004
<u>AB</u>	SUN PHARM INDS LTD	<u>2.5MG</u>	<u>A091200</u>	<u>001</u>	Dec 13, 2013
<u>AB</u>		<u>5MG</u>	<u>A091200</u>	<u>002</u>	Dec 13, 2013
<u>AB</u>		<u>10MG</u>	<u>A091200</u>	<u>003</u>	Dec 13, 2013
<u>AB</u>	TORRENT PHARMS LTD	<u>2.5MG</u>	<u>A202170</u>	<u>001</u>	Nov 28, 2011
<u>AB</u>		<u>5MG</u>	<u>A202170</u>	<u>002</u>	Nov 28, 2011
<u>AB</u>		<u>10MG</u>	<u>A202170</u>	<u>003</u>	Nov 28, 2011
<u>AB</u>	VINTAGE PHARMS LLC	<u>2.5MG</u>	<u>A200815</u>	<u>001</u>	Oct 28, 2011
<u>AB</u>		<u>5MG</u>	<u>A200815</u>	<u>002</u>	Oct 28, 2011
<u>AB</u>		<u>10MG</u>	<u>A200815</u>	<u>003</u>	Oct 28, 2011

FENOFIBRATE

CAPSULE; ORAL

ANTARA (MICRONIZED)

<u>AB</u>	LUPIN ATLANTIS	<u>43MG</u>	<u>N021695</u>	<u>001</u>	Nov 30, 2004
<u>AB</u>	+	<u>130MG</u>	<u>N021695</u>	<u>003</u>	Nov 30, 2004

FENOFIBRATE

<u>AB</u>	SUN PHARM INDS LTD	<u>43MG</u>	<u>A201748</u>	<u>001</u>	Oct 31, 2014
<u>AB</u>		<u>130MG</u>	<u>A201748</u>	<u>002</u>	Oct 31, 2014

FENOFIBRATE (MICRONIZED)

<u>AB</u>	APOTEX INC	<u>43MG</u>	<u>A202252</u>	<u>001</u>	Jul 26, 2013
<u>AB</u>		<u>130MG</u>	<u>A202252</u>	<u>002</u>	Jul 26, 2013
<u>AB</u>	DR REDDYS LABS SA	<u>43MG</u>	<u>A090859</u>	<u>001</u>	Mar 01, 2012
<u>AB</u>		<u>130MG</u>	<u>A090859</u>	<u>002</u>	Mar 01, 2012
<u>AB</u>	IMPAX LABS	<u>67MG</u>	<u>A075868</u>	<u>001</u>	Oct 27, 2003
<u>AB</u>		<u>134MG</u>	<u>A075868</u>	<u>002</u>	Oct 27, 2003
<u>AB</u>		<u>200MG</u>	<u>A075868</u>	<u>003</u>	Oct 27, 2003
<u>AB</u>	MYLAN PHARMS INC	<u>43MG</u>	<u>A202579</u>	<u>001</u>	Jan 10, 2013
<u>AB</u>		<u>67MG</u>	<u>A202676</u>	<u>001</u>	Oct 23, 2012
<u>AB</u>		<u>130MG</u>	<u>A202579</u>	<u>002</u>	Jan 10, 2013
<u>AB</u>		<u>134MG</u>	<u>A202676</u>	<u>002</u>	Oct 23, 2012
<u>AB</u>		<u>200MG</u>	<u>A202676</u>	<u>003</u>	Oct 23, 2012
<u>AB</u>	RHODES PHARMS	<u>67MG</u>	<u>A075753</u>	<u>001</u>	Sep 03, 2002
<u>AB</u>		<u>134MG</u>	<u>A075753</u>	<u>002</u>	Apr 09, 2002
<u>AB</u>	+	<u>200MG</u>	<u>A075753</u>	<u>003</u>	Apr 09, 2002

ANTARA (MICRONIZED)

	LUPIN ATLANTIS	30MG	N021695	004	Oct 18, 2013
		90MG	N021695	005	Oct 18, 2013

LIPOFEN

	CIPHER PHARMS INC	50MG	N021612	001	Jan 11, 2006
--	-------------------	------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

FENOFIBRATE

CAPSULE; ORAL

LIPOFEN

+

150MG

N021612 003 Jan 11, 2006

TABLET; ORAL

FENOFIBRATE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>48MG</u>	<u>A205118</u>	<u>001</u>	May 05, 2016
<u>AB</u>		<u>145MG</u>	<u>A205118</u>	<u>002</u>	May 05, 2016
<u>AB</u>	CIPLA LTD	<u>48MG</u>	<u>A208709</u>	<u>001</u>	Dec 15, 2016
<u>AB</u>		<u>145MG</u>	<u>A208709</u>	<u>002</u>	Dec 15, 2016
<u>AB</u>	HETERO LABS LTD III	<u>48MG</u>	<u>A204598</u>	<u>001</u>	Jul 12, 2016
<u>AB</u>		<u>145MG</u>	<u>A204598</u>	<u>002</u>	Jul 12, 2016
<u>AB</u>	IMPAX LABS	<u>54MG</u>	<u>A076509</u>	<u>001</u>	Mar 26, 2008
<u>AB</u>		<u>160MG</u>	<u>A076509</u>	<u>002</u>	Mar 26, 2008
<u>AB</u>	LUPIN LTD	<u>48MG</u>	<u>A090856</u>	<u>001</u>	Dec 23, 2011
<u>AB</u>		<u>54MG</u>	<u>A204019</u>	<u>001</u>	Aug 17, 2015
<u>AB</u>		<u>145MG</u>	<u>A090856</u>	<u>002</u>	Dec 23, 2011
<u>AB</u>		<u>160MG</u>	<u>A204019</u>	<u>002</u>	Aug 17, 2015
<u>AB</u>	MYLAN	<u>40MG</u>	<u>A204475</u>	<u>001</u>	Jun 23, 2016
<u>AB</u>		<u>54MG</u>	<u>A076520</u>	<u>001</u>	Oct 25, 2007
<u>AB</u>		<u>120MG</u>	<u>A204475</u>	<u>002</u>	Jun 23, 2016
<u>AB</u>		<u>160MG</u>	<u>A076520</u>	<u>003</u>	Oct 25, 2007
<u>AB</u>	MYLAN PHARMS INC	<u>48MG</u>	<u>A202856</u>	<u>001</u>	Dec 07, 2012
<u>AB</u>		<u>145MG</u>	<u>A202856</u>	<u>002</u>	Dec 07, 2012
<u>AB</u>	RHODES PHARMS	<u>54MG</u>	<u>A076433</u>	<u>001</u>	May 13, 2005
<u>AB</u>	+	<u>160MG</u>	<u>A076433</u>	<u>002</u>	May 13, 2005
<u>AB</u>	SUN PHARM INDS LTD	<u>54MG</u>	<u>A076635</u>	<u>001</u>	Oct 31, 2005
<u>AB</u>		<u>160MG</u>	<u>A076635</u>	<u>003</u>	Oct 31, 2005
<u>AB</u>	VALEANT PHARMS NORTH	<u>48MG</u>	<u>A090715</u>	<u>001</u>	Apr 05, 2012
<u>AB</u>		<u>145MG</u>	<u>A090715</u>	<u>002</u>	Apr 05, 2012

FENOGLIDE

<u>AB</u>	SANTARUS INC	<u>40MG</u>	<u>N022118</u>	<u>001</u>	Aug 10, 2007
<u>AB</u>	+	<u>120MG</u>	<u>N022118</u>	<u>002</u>	Aug 10, 2007
	<u>TRICOR</u>				
<u>AB</u>	ABBVIE	<u>48MG</u>	<u>N021656</u>	<u>001</u>	Nov 05, 2004
<u>AB</u>	+	<u>145MG</u>	<u>N021656</u>	<u>002</u>	Nov 05, 2004
	TRIGLIDE				
BX	+	SKYEPHARMA AG	160MG	N021350	002 May 07, 2005
	FENOFIBRATE				
	SUN PHARM INDS LTD	107MG	A076635	002	Oct 31, 2005

FENOFIBRIC ACID

TABLET; ORAL

FIBRICOR

ARALEZ PHARMS INC

35MG

N022418 001 Aug 14, 2009

+

105MG

N022418 002 Aug 14, 2009

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION

CORLOPAM

<u>AP</u>	+	HOSPIRA	<u>EQ 10MG BASE/ML</u>	<u>N019922</u>	<u>001</u>	Sep 23, 1997
		<u>FENOLDOPAM MESYLATE</u>				
<u>AP</u>		SANDOZ	<u>EQ 10MG BASE/ML</u>	<u>A077155</u>	<u>001</u>	Feb 15, 2005
<u>AP</u>		WEST-WARD PHARMS INT	<u>EQ 10MG BASE/ML</u>	<u>A076582</u>	<u>001</u>	Oct 12, 2004

FENOPROFEN CALCIUM

CAPSULE; ORAL

NALFON

+ XSPIRE

EQ 200MG BASE

N017604 003

EQ 400MG BASE

N017604 004 Jul 21, 2009

TABLET; ORAL

FENOPROFEN CALCIUM

+ MYLAN PHARMS INC

EQ 600MG BASE

A072267 001 Aug 17, 1988

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

DURAGESIC-100

<u>AB</u>	JANSSEN PHARMS	<u>100MCG/HR</u>	<u>N019813</u>	<u>001</u>	Aug 07, 1990	
	<u>DURAGESIC-12</u>					
<u>AB</u>	JANSSEN PHARMS	<u>12.5MCG/HR</u>	<u>N019813</u>	<u>005</u>	Feb 04, 2005	
	<u>DURAGESIC-25</u>					
<u>AB</u>	+	JANSSEN PHARMS	<u>25MCG/HR</u>	<u>N019813</u>	<u>004</u>	Aug 07, 1990
	<u>DURAGESIC-50</u>					
<u>AB</u>	JANSSEN PHARMS	<u>50MCG/HR</u>	<u>N019813</u>	<u>003</u>	Aug 07, 1990	

PRESCRIPTION DRUG PRODUCT LIST

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

DURAGESIC-75

AB	JANSSEN PHARMS	75MCG/HR	N019813 002	Aug 07, 1990
-----------	----------------	-----------------	--------------------	--------------

FENTANYL-100

AB	3M DRUG DELIVERY	100MCG/HR	A202097 005	Nov 04, 2016
AB	ACTAVIS LABS UT INC	100MCG/HR	A076709 004	Aug 20, 2007
AB	AVEVA	100MCG/HR	A077449 004	Oct 20, 2008
AB	LAVIPHARM LABS	100MCG/HR	A077051 004	Aug 04, 2006
AB	MALLINCKRODT INC	100MCG/HR	A077154 004	Feb 09, 2011
AB	MYLAN TECHNOLOGIES	100MCG/HR	A076258 004	Jan 28, 2005
AB	PAR PHARM INC	100MCG/HR	A077062 004	Aug 20, 2007

FENTANYL-12

AB	3M DRUG DELIVERY	12.5MCG/HR	A202097 001	Nov 04, 2016
AB	AVEVA	12.5MCG/HR	A077449 005	Sep 11, 2015
AB	MALLINCKRODT INC	12.5MCG/HR	A077154 005	Jun 11, 2015
AB	MYLAN TECHNOLOGIES	12.5MCG/HR	A076258 005	Jan 23, 2007

FENTANYL-25

AB	3M DRUG DELIVERY	25MCG/HR	A202097 002	Nov 04, 2016
AB	ACTAVIS LABS UT INC	25MCG/HR	A076709 001	Aug 20, 2007
AB	AVEVA	25MCG/HR	A077449 001	Oct 20, 2008
AB	LAVIPHARM LABS	25MCG/HR	A077051 001	Aug 04, 2006
AB	MALLINCKRODT INC	25MCG/HR	A077154 001	Feb 09, 2011
AB	MYLAN TECHNOLOGIES	25MCG/HR	A076258 001	Jan 28, 2005
AB	PAR PHARM INC	25MCG/HR	A077062 001	Aug 20, 2007

FENTANYL-50

AB	3M DRUG DELIVERY	50MCG/HR	A202097 003	Nov 04, 2016
AB	ACTAVIS LABS UT INC	50MCG/HR	A076709 002	Aug 20, 2007
AB	AVEVA	50MCG/HR	A077449 002	Oct 20, 2008
AB	LAVIPHARM LABS	50MCG/HR	A077051 002	Aug 04, 2006
AB	MALLINCKRODT INC	50MCG/HR	A077154 002	Feb 09, 2011
AB	MYLAN TECHNOLOGIES	50MCG/HR	A076258 002	Jan 28, 2005
AB	PAR PHARM INC	50MCG/HR	A077062 002	Aug 20, 2007

FENTANYL-75

AB	3M DRUG DELIVERY	75MCG/HR	A202097 004	Nov 04, 2016
AB	ACTAVIS LABS UT INC	75MCG/HR	A076709 003	Aug 20, 2007
AB	AVEVA	75MCG/HR	A077449 003	Oct 20, 2008
AB	LAVIPHARM LABS	75MCG/HR	A077051 003	Aug 04, 2006
AB	MALLINCKRODT INC	75MCG/HR	A077154 003	Feb 09, 2011
AB	MYLAN TECHNOLOGIES	75MCG/HR	A076258 003	Jan 28, 2005
AB	PAR PHARM INC	75MCG/HR	A077062 003	Aug 20, 2007

FENTANYL-37

	MYLAN TECHNOLOGIES	37.5MCG/HR	A076258 006	Dec 29, 2014
--	--------------------	------------	-------------	--------------

FENTANYL-62

	MYLAN TECHNOLOGIES	62.5MCG/HR	A076258 007	Dec 29, 2014
--	--------------------	------------	-------------	--------------

FENTANYL-87

	MYLAN TECHNOLOGIES	87.5MCG/HR	A076258 008	Dec 29, 2014
--	--------------------	------------	-------------	--------------

SPRAY; SUBLINGUAL

SUBSYS

	INSYS THERAP	0.1MG	N202788 001	Jan 04, 2012
		0.2MG	N202788 002	Jan 04, 2012
+		0.4MG	N202788 003	Jan 04, 2012
		0.6MG	N202788 004	Jan 04, 2012
		0.8MG	N202788 005	Jan 04, 2012
		1.2MG	N202788 006	Aug 30, 2012
		1.6MG	N202788 007	Aug 30, 2012

FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE

AP	HOSPIRA	EQ 0.05MG BASE/ML	N019115 001	Jan 12, 1985
-----------	---------	--------------------------	--------------------	--------------

FENTANYL CITRATE PRESERVATIVE FREE

AP	HOSPIRA	EQ 0.05MG BASE/ML	A072786 001	Sep 24, 1991
AP	+ WEST-WARD PHARMS INT	EQ 0.05MG BASE/ML	N019101 001	Jul 11, 1984

SUBLIMAZE PRESERVATIVE FREE

AP	+ AKORN	EQ 0.05MG BASE/ML	N016619 001	
-----------	---------	--------------------------	--------------------	--

SPRAY, METERED; NASAL

LAZANDA

	DEPOMED INC	EQ 0.1MG BASE	N022569 001	Jun 30, 2011
		EQ 0.3MG BASE	N022569 003	Dec 21, 2015
+		EQ 0.4MG BASE	N022569 002	Jun 30, 2011

PRESCRIPTION DRUG PRODUCT LIST

FENTANYL CITRATE

TABLET;BUCCAL, SUBLINGUAL

FENTORA

CEPHALON	EQ 0.1MG BASE	N021947 001	Sep 25, 2006
	EQ 0.2MG BASE	N021947 002	Sep 25, 2006
+	EQ 0.4MG BASE	N021947 003	Sep 25, 2006
	EQ 0.6MG BASE	N021947 004	Sep 25, 2006
	EQ 0.8MG BASE	N021947 005	Sep 25, 2006

TABLET;SUBLINGUAL

ABSTRAL

SENTYNL THERAPS INC	EQ 0.1MG BASE	N022510 001	Jan 07, 2011
	EQ 0.2MG BASE	N022510 002	Jan 07, 2011
	EQ 0.3MG BASE	N022510 003	Jan 07, 2011
+	EQ 0.4MG BASE	N022510 004	Jan 07, 2011
	EQ 0.6MG BASE	N022510 005	Jan 07, 2011
	EQ 0.8MG BASE	N022510 006	Jan 07, 2011

TROCHE/LOZENGE; TRANSMUCOSAL

ACTIQ

<u>AB</u>	CEPHALON	<u>EQ 0.2MG BASE</u>	<u>N020747 001</u>	Nov 04, 1998
<u>AB</u>	+	<u>EQ 0.4MG BASE</u>	<u>N020747 002</u>	Nov 04, 1998
<u>AB</u>		<u>EQ 0.6MG BASE</u>	<u>N020747 003</u>	Nov 04, 1998
<u>AB</u>		<u>EQ 0.8MG BASE</u>	<u>N020747 004</u>	Nov 04, 1998
<u>AB</u>		<u>EQ 1.2MG BASE</u>	<u>N020747 005</u>	Nov 04, 1998
<u>AB</u>		<u>EQ 1.6MG BASE</u>	<u>N020747 006</u>	Nov 04, 1998

FENTANYL CITRATE

<u>AB</u>	MALLINCKRODT	<u>EQ 0.2MG BASE</u>	<u>A078907 001</u>	Oct 30, 2009
<u>AB</u>		<u>EQ 0.4MG BASE</u>	<u>A078907 002</u>	Oct 30, 2009
<u>AB</u>		<u>EQ 0.6MG BASE</u>	<u>A078907 003</u>	Oct 30, 2009
<u>AB</u>		<u>EQ 0.8MG BASE</u>	<u>A078907 004</u>	Oct 30, 2009
<u>AB</u>		<u>EQ 1.2MG BASE</u>	<u>A078907 005</u>	Oct 30, 2009
<u>AB</u>		<u>EQ 1.6MG BASE</u>	<u>A078907 006</u>	Oct 30, 2009
<u>AB</u>	PAR PHARM	<u>EQ 0.2MG BASE</u>	<u>A077312 001</u>	Oct 30, 2009
<u>AB</u>		<u>EQ 0.4MG BASE</u>	<u>A077312 002</u>	Oct 30, 2009
<u>AB</u>		<u>EQ 0.6MG BASE</u>	<u>A077312 003</u>	Oct 30, 2009
<u>AB</u>		<u>EQ 0.8MG BASE</u>	<u>A077312 004</u>	Oct 30, 2009
<u>AB</u>		<u>EQ 1.2MG BASE</u>	<u>A077312 005</u>	Oct 30, 2009
<u>AB</u>		<u>EQ 1.6MG BASE</u>	<u>A077312 006</u>	Oct 30, 2009

FENTANYL HYDROCHLORIDE

SYSTEM; IONTOPHORESIS, TRANSDERMAL

IONSYS

+	THE MEDICINES CO	EQ 40MCG BASE/ACTIVATION	N021338 001	May 22, 2006
---	------------------	--------------------------	-------------	--------------

FERRIC CARBOXYMALTOSE

INJECTABLE; INTRAVENOUS

INJECTAFER

+	LUITPOLD PHARMS INC	750MG IRON/15ML (50MG IRON/ML)	N203565 001	Jul 25, 2013
---	---------------------	--------------------------------	-------------	--------------

FERRIC CITRATE

TABLET; ORAL

AURYXIA

+	KERYX BIOPHARMS	EQ 210MG IRON	N205874 001	Sep 05, 2014
---	-----------------	---------------	-------------	--------------

FERRIC HEXACYANOFERRATE(II)

CAPSULE; ORAL

RADIOGARDASE (PRUSSIAN BLUE)

+	HEYL CHEMISCH	500MG	N021626 001	Oct 02, 2003
---	---------------	-------	-------------	--------------

FERRIC PYROPHOSPHATE CITRATE

FOR SOLUTION; INTRAVENOUS

TRIFERIC

+	ROCKWELL MEDICAL INC	272MG IRON/PACKET	N208551 001	Apr 25, 2016
---	----------------------	-------------------	-------------	--------------

SOLUTION; IV (INFUSION)

TRIFERIC

+	ROCKWELL MEDICAL INC	27.2MG IRON/5ML (5.44MG IRON/ML)	N206317 001	Jan 23, 2015
		272MG IRON/50ML (5.44MG IRON/ML)	N206317 002	Sep 04, 2015

FERUMOXYTOL

SOLUTION; INTRAVENOUS

FERAHEME

+	AMAG PHARMS INC	EQ 510MG IRON/17ML (EQ 30MG IRON/ML)	N022180 001	Jun 30, 2009
---	-----------------	--------------------------------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

TOVIAZ

<u>AB</u>	PFIZER	<u>4MG</u>	<u>N022030</u>	<u>001</u>	Oct 31, 2008
<u>AB</u>	+	<u>8MG</u>	<u>N022030</u>	<u>002</u>	Oct 31, 2008

FEXOFENADINE HYDROCHLORIDE

SUSPENSION;ORAL

ALLEGRA

<u>AB</u>	+	SANOFI AVENTIS US	<u>30MG/5ML</u>	<u>N021963</u>	<u>001</u>	Oct 16, 2006
-----------	---	-------------------	-----------------	----------------	------------	--------------

FEXOFENADINE HYDROCHLORIDE

<u>AB</u>		ACTAVIS MID ATLANTIC	<u>30MG/5ML</u>	<u>A201311</u>	<u>001</u>	Jul 25, 2012
-----------	--	----------------------	-----------------	----------------	------------	--------------

TABLET;ORAL

FEXOFENADINE HYDROCHLORIDE

<u>AB</u>		BARR	<u>30MG</u>	<u>A076191</u>	<u>001</u>	Aug 31, 2005
<u>AB</u>			<u>60MG</u>	<u>A076191</u>	<u>002</u>	Aug 31, 2005
<u>AB</u>			<u>180MG</u>	<u>A076191</u>	<u>003</u>	Aug 31, 2005
<u>AB</u>		DR REDDYS LABS LTD	<u>30MG</u>	<u>A076502</u>	<u>001</u>	Apr 11, 2006
<u>AB</u>			<u>60MG</u>	<u>A076502</u>	<u>002</u>	Apr 11, 2006
<u>AB</u>			<u>180MG</u>	<u>A076502</u>	<u>003</u>	Apr 11, 2006
<u>AB</u>		MYLAN	<u>30MG</u>	<u>A077081</u>	<u>002</u>	Apr 11, 2008
<u>AB</u>			<u>60MG</u>	<u>A077081</u>	<u>003</u>	Apr 11, 2008
<u>AB</u>			<u>180MG</u>	<u>A077081</u>	<u>001</u>	Apr 16, 2007
<u>AB</u>		TEVA	<u>30MG</u>	<u>A076447</u>	<u>001</u>	Sep 01, 2005
<u>AB</u>			<u>60MG</u>	<u>A076447</u>	<u>002</u>	Sep 01, 2005
<u>AB</u>			<u>180MG</u>	<u>A076447</u>	<u>003</u>	Sep 01, 2005

FIDAXOMICIN

TABLET;ORAL

DIFICID

	+	CUBIST PHARMS LLC	200MG	N201699	001	May 27, 2011
--	---	-------------------	-------	---------	-----	--------------

FINAFLOXACIN

SUSPENSION/DROPS;OTIC

XTORO

	+	NOVARTIS PHARMS CORP	0.3%	N206307	001	Dec 17, 2014
--	---	----------------------	------	---------	-----	--------------

FINASTERIDE

TABLET;ORAL

FINASTERIDE

<u>AB</u>		ACCORD HLTHCARE	<u>5MG</u>	<u>A090121</u>	<u>001</u>	Feb 23, 2010
<u>AB</u>		ACCORD HLTHCARE INC	<u>1MG</u>	<u>A091643</u>	<u>001</u>	Nov 05, 2013
<u>AB</u>		ACTAVIS TOTOWA	<u>1MG</u>	<u>A078371</u>	<u>001</u>	Nov 05, 2013
<u>AB</u>			<u>5MG</u>	<u>A077914</u>	<u>001</u>	Mar 28, 2007
<u>AB</u>		ALKEM LABS LTD	<u>1MG</u>	<u>A207750</u>	<u>001</u>	Jan 06, 2017
<u>AB</u>			<u>5MG</u>	<u>A204304</u>	<u>001</u>	Jan 05, 2017
<u>AB</u>		AUROBINDO PHARMA	<u>5MG</u>	<u>A078341</u>	<u>001</u>	Oct 30, 2007
<u>AB</u>		AUROBINDO PHARMA LTD	<u>1MG</u>	<u>A203687</u>	<u>001</u>	Nov 05, 2013
<u>AB</u>		CIPLA LTD	<u>1MG</u>	<u>A077335</u>	<u>001</u>	Nov 20, 2014
<u>AB</u>		DR REDDYS LABS INC	<u>1MG</u>	<u>A076436</u>	<u>001</u>	Jul 28, 2006
<u>AB</u>		DR REDDYS LABS LTD	<u>5MG</u>	<u>A076437</u>	<u>001</u>	Feb 28, 2007
<u>AB</u>		GEDEON RICHTER USA	<u>5MG</u>	<u>A077251</u>	<u>001</u>	Dec 22, 2006
<u>AB</u>		HETERO LABS LTD III	<u>1MG</u>	<u>A090060</u>	<u>001</u>	Jul 01, 2013
<u>AB</u>			<u>5MG</u>	<u>A090061</u>	<u>001</u>	Jun 07, 2010
<u>AB</u>		MYLAN	<u>5MG</u>	<u>A077578</u>	<u>001</u>	Dec 18, 2006
<u>AB</u>		MYLAN PHARMS INC	<u>1MG</u>	<u>A078161</u>	<u>001</u>	Nov 05, 2013
<u>AB</u>		SUN PHARMA GLOBAL	<u>1MG</u>	<u>A090508</u>	<u>001</u>	Jul 01, 2013
<u>AB</u>			<u>5MG</u>	<u>A090507</u>	<u>001</u>	Aug 16, 2011
<u>AB</u>		TEVA	<u>1MG</u>	<u>A076905</u>	<u>001</u>	Nov 05, 2013
<u>AB</u>			<u>5MG</u>	<u>A076511</u>	<u>001</u>	Dec 15, 2006
<u>AB</u>		ZYDUS PHARMS USA INC	<u>5MG</u>	<u>A078900</u>	<u>001</u>	Dec 28, 2009

PROPECIA

<u>AB</u>	+	MERCK	<u>1MG</u>	<u>N020788</u>	<u>001</u>	Dec 19, 1997
-----------	---	-------	------------	----------------	------------	--------------

PROSCAR

<u>AB</u>	+	MERCK	<u>5MG</u>	<u>N020180</u>	<u>001</u>	Jun 19, 1992
-----------	---	-------	------------	----------------	------------	--------------

FINGOLIMOD

CAPSULE;ORAL

GILENYA

	+	NOVARTIS	0.5MG	N022527	001	Sep 21, 2010
--	---	----------	-------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL

EMULSION; INTRAVENOUS

SMOFLIPID 20%

+	FRESENIUS KABI USA	3GM/100ML; 6GM/100ML; 5GM/100ML; 6GM/100ML (100ML)	N207648 001	Jul 13, 2016
+		3GM/100ML; 6GM/100ML; 5GM/100ML; 6GM/100ML (250ML)	N207648 002	Jul 13, 2016
+		3GM/100ML; 6GM/100ML; 5GM/100ML; 6GM/100ML (500ML)	N207648 003	Jul 13, 2016

FLAVOXATE HYDROCHLORIDE

TABLET; ORAL

FLAVOXATE HYDROCHLORIDE

AB	EPIC PHARMA	100MG	A076835 001	Nov 30, 2005
AB	+ PADDOCK LLC	100MG	A076831 001	Dec 16, 2004

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

AB	AMNEAL PHARM	50MG	A075442 001	Jul 31, 2001
AB		100MG	A075442 002	Jul 31, 2001
AB		150MG	A075442 003	Jul 31, 2001
AB	ANI PHARMS INC	50MG	A075882 001	Oct 28, 2002
AB		100MG	A075882 002	Oct 28, 2002
AB		150MG	A075882 003	Oct 28, 2002
AB	AUROBINDO PHARMA LTD	50MG	A202821 001	Jul 08, 2015
AB		100MG	A202821 002	Jul 08, 2015
AB		150MG	A202821 003	Jul 08, 2015
AB	SUN PHARM INDS LTD	50MG	A076421 001	Mar 28, 2003
AB		100MG	A076421 002	Mar 28, 2003
AB		150MG	A076421 003	Mar 28, 2003
AB	WEST-WARD PHARMS INT	50MG	A076278 001	Jan 14, 2003
AB		100MG	A076278 002	Jan 14, 2003
AB	+	150MG	A076278 003	Jan 14, 2003
	TAMBOCOR			
AB	CNTY LINE PHARMS	50MG	N018830 004	Aug 23, 1988
AB		100MG	N018830 001	Oct 31, 1985
AB		150MG	N018830 003	Jun 03, 1988

FLIBANSERIN

TABLET; ORAL

ADDYI

+	SPROUT PHARMS	100MG	N022526 001	Aug 18, 2015
---	---------------	-------	-------------	--------------

FLORBETABEN F-18

SOLUTION; INTRAVENOUS

NEURACEQ

+	PIRAMAL IMAGING	30ML (1.4-135mCi/ML)	N204677 001	Mar 19, 2014
---	-----------------	----------------------	-------------	--------------

FLORBETAPIR F-18

SOLUTION; INTRAVENOUS

AMYVID

+	AVID RADIOPHARMS INC	10-30ML (13.5-51mCi/ML)	N202008 002	Apr 06, 2012
+		10-50ML (13.5-51mCi/ML)	N202008 003	Apr 06, 2012

FLOXURIDINE

INJECTABLE; INJECTION

FLOXURIDINE

AP	FRESENIUS KABI USA	500MG/VIAL	A075837 001	Feb 22, 2001
AP	+ WEST-WARD PHARMS INT	500MG/VIAL	A075387 001	Apr 16, 2000

FLUCICLOVINE F-18

SOLUTION; INTRAVENOUS

AXUMIN

+	BLUE EARTH	9-221mCi/ML	N208054 001	May 27, 2016
---	------------	-------------	-------------	--------------

FLUCONAZOLE

FOR SUSPENSION; ORAL

DIFLUCAN

AB	PFIZER	50MG/5ML	N020090 001	Dec 23, 1993
AB	+	200MG/5ML	N020090 002	Dec 23, 1993

FLUCONAZOLE

AB	AUROBINDO PHARM	50MG/5ML	A079150 001	Sep 18, 2009
AB		200MG/5ML	A079150 002	Sep 18, 2009
AB	IVAX SUB TEVA PHARMS	50MG/5ML	A077523 001	Sep 12, 2007
AB		200MG/5ML	A077523 002	Sep 12, 2007
AB	WEST-WARD PHARMS INT	50MG/5ML	A076246 001	Jul 29, 2004

PRESCRIPTION DRUG PRODUCT LIST

FLUCONAZOLE

FOR SUSPENSION; ORAL

FLUCONAZOLE

AB 200MG/5ML **A076246 002** Jul 29, 2004
INJECTABLE; INJECTION

DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP + PFIZER 200MG/100ML (2MG/ML) **N019950 003** Sep 29, 1992
AP + 400MG/200ML (2MG/ML) **N019950 005** Jul 08, 1994

DIFLUCAN IN SODIUM CHLORIDE 0.9%

AP + PFIZER 200MG/100ML (2MG/ML) **N019950 001** Jan 29, 1990
AP + 400MG/200ML (2MG/ML) **N019950 006** Jan 29, 1990

DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP + PFIZER 200MG/100ML (2MG/ML) **N019950 002** Jan 29, 1990
AP + 400MG/200ML (2MG/ML) **N019950 004** Jan 29, 1990

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP CLARIS 200MG/100ML (2MG/ML) **A077988 001** May 26, 2010
AP 400MG/200ML (2MG/ML) **A077988 002** May 26, 2010
AP HIKMA FARMACEUTICA 200MG/100ML (2MG/ML) **A078764 001** Jan 30, 2012
AP 400MG/200ML (2MG/ML) **A078764 002** Jan 30, 2012
AP HOSPIRA 200MG/100ML (2MG/ML) **A076304 001** Jul 29, 2004
AP 400MG/200ML (2MG/ML) **A076304 002** Jul 29, 2004

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

AP CLARIS 200MG/100ML (2MG/ML) **A077947 001** May 26, 2010
AP 400MG/200ML (2MG/ML) **A077947 002** May 26, 2010
AP EUROHLTH INTL SARL 200MG/100ML (2MG/ML) **A076087 001** Jul 29, 2004
AP 400MG/200ML (2MG/ML) **A076087 003** Jul 29, 2004
AP FRESENIUS KABI USA 200MG/100ML (2MG/ML) **A076145 001** Jul 29, 2004
AP 400MG/200ML (2MG/ML) **A076145 002** Jul 29, 2004
AP HIKMA FARMACEUTICA 200MG/100ML (2MG/ML) **A076736 001** Aug 23, 2005

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP ACS DOBFAR INFO SA 200MG/100ML (2MG/ML) **A079104 001** Jul 30, 2009
AP 400MG/200ML (2MG/ML) **A079104 002** Jul 30, 2009
AP BAXTER HLTHCARE 200MG/100ML (2MG/ML) **A076766 001** Jul 29, 2004
AP 400MG/200ML (2MG/ML) **A076766 002** Jul 29, 2004
AP CLARIS 200MG/100ML (2MG/ML) **A077909 001** May 26, 2010
AP 400MG/200ML (2MG/ML) **A077909 002** May 26, 2010
AP EUROHLTH INTL SARL 200MG/100ML (2MG/ML) **A078107 001** Jul 30, 2008
AP 400MG/200ML (2MG/ML) **A078107 002** Jul 30, 2008
AP HIKMA FARMACEUTICA 200MG/100ML (2MG/ML) **A078698 001** Jan 30, 2012
AP 400MG/200ML (2MG/ML) **A078698 002** Jan 30, 2012
AP HOSPIRA 200MG/100ML (2MG/ML) **A076303 001** Jul 29, 2004
AP 400MG/200ML (2MG/ML) **A076303 002** Jul 29, 2004

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

EUROHLTH INTL SARL 100MG/50ML (2MG/ML) **A076087 002** Sep 26, 2008

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

CLARIS 100MG/50ML (2MG/ML) **A077909 003** Apr 20, 2015

TABLET; ORAL

DIFLUCAN

AB PFIZER 50MG **N019949 001** Jan 29, 1990
AB 100MG **N019949 002** Jan 29, 1990
AB 150MG **N019949 004** Jun 30, 1994
AB + 200MG **N019949 003** Jan 29, 1990

FLUCONAZOLE

AB APOTEX 50MG **A076665 001** Jul 29, 2004
AB 100MG **A076665 002** Jul 29, 2004
AB 150MG **A076665 003** Jul 29, 2004
AB 200MG **A076665 004** Jul 29, 2004
AB AUROBINDO PHARMA 50MG **A077731 001** Oct 07, 2008
AB 100MG **A077731 002** Oct 07, 2008
AB 150MG **A077731 003** Oct 07, 2008
AB 200MG **A077731 004** Oct 07, 2008
AB DR REDDYS LABS INC 50MG **A076658 001** Jul 29, 2004
AB 100MG **A076658 002** Jul 29, 2004
AB 150MG **A076658 003** Jul 29, 2004
AB 200MG **A076658 004** Jul 29, 2004
AB GLENMARK GENERICS 50MG **A077253 001** Jan 25, 2006
AB 100MG **A077253 002** Jan 25, 2006
AB 150MG **A077253 003** Jan 25, 2006
AB 200MG **A077253 004** Jan 25, 2006
AB HARRIS PHARM 50MG **A078423 001** Mar 07, 2011
AB 100MG **A078423 002** Mar 07, 2011
AB 150MG **A078423 003** Mar 07, 2011

PRESCRIPTION DRUG PRODUCT LIST

FLUCONAZOLE

TABLET; ORAL

FLUCONAZOLE

<u>AB</u>		<u>200MG</u>	<u>A078423</u>	<u>004</u>	Mar 07, 2011
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>50MG</u>	<u>A076077</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>		<u>100MG</u>	<u>A076077</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>		<u>150MG</u>	<u>A076077</u>	<u>003</u>	Jul 29, 2004
<u>AB</u>		<u>200MG</u>	<u>A076077</u>	<u>004</u>	Jul 29, 2004
<u>AB</u>	MYLAN	<u>50MG</u>	<u>A076351</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>		<u>100MG</u>	<u>A076351</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>		<u>150MG</u>	<u>A076351</u>	<u>003</u>	Jul 29, 2004
<u>AB</u>		<u>200MG</u>	<u>A076351</u>	<u>004</u>	Jul 29, 2004
<u>AB</u>	TARO	<u>50MG</u>	<u>A076507</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>		<u>100MG</u>	<u>A076507</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>		<u>150MG</u>	<u>A076507</u>	<u>003</u>	Jul 29, 2004
<u>AB</u>		<u>200MG</u>	<u>A076507</u>	<u>004</u>	Jul 29, 2004
<u>AB</u>	TEVA	<u>50MG</u>	<u>A074681</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>		<u>100MG</u>	<u>A074681</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>		<u>150MG</u>	<u>A074681</u>	<u>003</u>	Jul 29, 2004
<u>AB</u>		<u>200MG</u>	<u>A074681</u>	<u>004</u>	Jul 29, 2004
<u>AB</u>	UNIQUE PHARM LABS	<u>50MG</u>	<u>A076957</u>	<u>001</u>	Sep 28, 2005
<u>AB</u>		<u>100MG</u>	<u>A076957</u>	<u>002</u>	Sep 28, 2005
<u>AB</u>		<u>200MG</u>	<u>A076957</u>	<u>003</u>	Sep 28, 2005

FLUCYTOSINE

CAPSULE; ORAL

ANCOBON

<u>AB</u>	VALEANT	<u>250MG</u>	<u>N017001</u>	<u>001</u>	
<u>AB</u>	+	<u>500MG</u>	<u>N017001</u>	<u>002</u>	
	<u>FLUCYTOSINE</u>				
<u>AB</u>	SIGMAPHARM LABS LLC	<u>250MG</u>	<u>A201566</u>	<u>001</u>	Jun 28, 2011
<u>AB</u>		<u>500MG</u>	<u>A201566</u>	<u>002</u>	Jun 28, 2011

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARABINE PHOSPHATE

<u>AP</u>	ACTAVIS TOTOWA	<u>50MG/VIAL</u>	<u>A078610</u>	<u>001</u>	Feb 11, 2009
<u>AP</u>	+	<u>50MG/2ML (25MG/ML)</u>	<u>A078393</u>	<u>001</u>	Oct 15, 2007
<u>AP</u>		<u>50MG/VIAL</u>	<u>A078544</u>	<u>001</u>	Oct 15, 2007
<u>AP</u>	+	<u>50MG/VIAL</u>	<u>A077790</u>	<u>001</u>	Apr 06, 2007
<u>AP</u>	MUSTAFA NEVZAT ILAC	<u>50MG/2ML (25MG/ML)</u>	<u>A090724</u>	<u>001</u>	Sep 27, 2010
<u>AP</u>	MYLAN LABS LTD	<u>50MG/2ML (25MG/ML)</u>	<u>A200647</u>	<u>001</u>	Dec 21, 2011
<u>AP</u>		<u>50MG/VIAL</u>	<u>A200648</u>	<u>001</u>	Oct 16, 2012
<u>AP</u>	SAGENT PHARMS	<u>50MG/VIAL</u>	<u>A076349</u>	<u>001</u>	Aug 28, 2003
<u>AP</u>		<u>50MG/2ML (25MG/ML)</u>	<u>A076661</u>	<u>001</u>	Apr 28, 2004
<u>AP</u>	+	<u>50MG/2ML (25MG/ML)</u>	<u>N022137</u>	<u>001</u>	Sep 21, 2007

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

<u>AP</u>	3D IMAGING DRUG	<u>20-300mCi/ML</u>	<u>A203778</u>	<u>001</u>	Oct 30, 2015
<u>AP</u>	BIOMEDCL RES FDN	<u>20-300mCi/ML</u>	<u>A203710</u>	<u>001</u>	May 01, 2015
<u>AP</u>		<u>20-300mCi/ML</u>	<u>A203837</u>	<u>001</u>	May 01, 2015
<u>AP</u>	BRIGHAM WOMENS	<u>20-300mCi/ML</u>	<u>A203816</u>	<u>001</u>	Oct 30, 2014
<u>AP</u>	CARDINAL HEALTH 414	<u>20-300mCi/ML</u>	<u>A203603</u>	<u>001</u>	Nov 13, 2015
<u>AP</u>	CHILDRENS HOSP MI	<u>20-300mCi/ML</u>	<u>A204385</u>	<u>001</u>	Oct 29, 2014
<u>AP</u>	CPDC	<u>20-300mCi/ML</u>	<u>A204525</u>	<u>001</u>	Oct 29, 2014
<u>AP</u>	ESSENTIAL ISOTOPES	<u>20-300mCi/ML</u>	<u>A203946</u>	<u>001</u>	Feb 05, 2014
<u>AP</u>	+	<u>20-200mCi/ML</u>	<u>N021870</u>	<u>001</u>	Aug 19, 2005
<u>AP</u>	+	<u>20-400mCi/ML</u>	<u>N021870</u>	<u>002</u>	Nov 21, 2008
<u>AP</u>	GLOBAL ISOTOPES LLC	<u>20-300mCi/ML</u>	<u>A204463</u>	<u>001</u>	Oct 21, 2014
<u>AP</u>	+	<u>20-500mCi/ML</u>	<u>A203665</u>	<u>001</u>	Feb 14, 2013
<u>AP</u>	KETTERING MEDCTR	<u>4-40mCi/ML</u>	<u>A204759</u>	<u>001</u>	Oct 27, 2015
<u>AP</u>	KREITCHMAN PET CTR	<u>10-100mCi/ML</u>	<u>A203942</u>	<u>001</u>	Apr 11, 2016
<u>AP</u>	LANTHEUS MEDICAL	<u>20-200mCi/ML</u>	<u>A203664</u>	<u>001</u>	Feb 04, 2014
<u>AP</u>	MA GENERAL HOSP	<u>20-300mCi/ML</u>	<u>A204333</u>	<u>001</u>	Sep 25, 2014
<u>AP</u>	MCPRF	<u>20-240mCi/ML</u>	<u>A203612</u>	<u>001</u>	Aug 05, 2013
<u>AP</u>	MEM SLOAN-KETTERING	<u>20-300mCi/ML</u>	<u>A208679</u>	<u>001</u>	Dec 08, 2016
<u>AP</u>	METHODIST HOSP RES	<u>20-300mCi/ML</u>	<u>A203904</u>	<u>001</u>	Apr 23, 2015
<u>AP</u>	MIDWEST MEDCL	<u>20-200mCi/ML</u>	<u>A203736</u>	<u>001</u>	Nov 19, 2015
<u>AP</u>	MIPS CRF	<u>20-300mCi/ML</u>	<u>A204472</u>	<u>001</u>	Sep 11, 2015
<u>AP</u>	NCM USA BRONX LLC	<u>20-300mCi/ML</u>	<u>A204512</u>	<u>001</u>	Jan 07, 2015
<u>AP</u>	PETNET	<u>20-200mCi/ML</u>	<u>A079086</u>	<u>001</u>	Feb 25, 2011
<u>AP</u>	+	<u>10-100mCi/ML</u>	<u>A203771</u>	<u>001</u>	Aug 31, 2015

PRESCRIPTION DRUG PRODUCT LIST

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

<u>AP</u>	SHERTECH LABS LLC	<u>20-300mCi/ML</u>	<u>A204264</u>	<u>001</u>	Dec 18, 2014
<u>AP</u>	TRIAD ISOTOPES INC	<u>20-300mCi/ML</u>	<u>A203920</u>	<u>001</u>	Jun 23, 2015
<u>AP</u>	TRUSTEES UNIV PA	<u>20-200mCi/ML</u>	<u>A203801</u>	<u>001</u>	Oct 29, 2014
<u>AP</u>	+ UCLA BIOMEDICAL	<u>4-40mCi/ML</u>	<u>A203811</u>	<u>001</u>	Jun 27, 2013
<u>AP</u>	UCSF RODIOPHARM	<u>20-300mCi/ML</u>	<u>A203902</u>	<u>001</u>	May 09, 2014
<u>AP</u>	UIHC PET IMAGING	<u>20-300mCi/ML</u>	<u>A203990</u>	<u>001</u>	Aug 06, 2014
<u>AP</u>	UNIV MICHIGAN	<u>20-300mCi/ML</u>	<u>A204531</u>	<u>001</u>	Jul 17, 2015
<u>AP</u>	UNIV TX MD ANDERSON	<u>20-300mCi/ML</u>	<u>A203246</u>	<u>002</u>	Jan 13, 2014
<u>AP</u>	UNIV UTAH CYCLOTRON	<u>20-300mCi/ML</u>	<u>A204498</u>	<u>001</u>	Jun 23, 2015
<u>AP</u>	WI MEDCL CYCLOTRON	<u>20-500mCi/ML</u>	<u>A203709</u>	<u>001</u>	Oct 23, 2013
<u>AP</u>	WUSM CYCLOTRON	<u>20-300mCi/ML</u>	<u>A203935</u>	<u>001</u>	Feb 05, 2014
<u>AP</u>	ZEVACOR PHARMA INC	<u>20-300mCi/ML</u>	<u>A203591</u>	<u>001</u>	Aug 31, 2015
	HOT SHOTS NM LLC	4-500mCi/ML	A203937	001	Oct 30, 2014
	PRECISION NUCLEAR	20-500mCi/ML	A204546	001	Apr 07, 2015
	SPECTRON MRC LLC	4-500mCi/ML	A203911	001	Apr 22, 2015
	UNIV NORTH DAKOTA	4-500mCi/ML	A203994	001	Feb 04, 2015
	UNIV TX MD ANDERSON	20-150mCi/ML	A203246	001	Jan 13, 2014

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLUDROCORTISONE ACETATE

<u>AB</u>	BARR	<u>0.1MG</u>	<u>A040425</u>	<u>001</u>	Jan 21, 2003
<u>AB</u>	HIKMA PHARMS	<u>0.1MG</u>	<u>A091302</u>	<u>001</u>	Jul 22, 2011
<u>AB</u>	+ IMPAX LABS	<u>0.1MG</u>	<u>A040431</u>	<u>001</u>	Mar 18, 2002

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

<u>AP</u>	EUROHLTH INTL SARL	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A076256</u>	<u>002</u>	Oct 12, 2004
<u>AP</u>		<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A076787</u>	<u>002</u>	Oct 12, 2004
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A076256</u>	<u>001</u>	Oct 12, 2004
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A076787</u>	<u>001</u>	Oct 12, 2004
<u>AP</u>	FRESENIUS KABI USA	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A076955</u>	<u>002</u>	Oct 12, 2004
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A076955</u>	<u>001</u>	Oct 12, 2004
<u>AP</u>	HIKMA FARMACEUTICA	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A078527</u>	<u>001</u>	Mar 23, 2009
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A078527</u>	<u>002</u>	Mar 23, 2009
<u>AP</u>	MYLAN LABS LTD	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A078595</u>	<u>001</u>	May 13, 2008
<u>AP</u>	+ SAGENT PHARMS	<u>1MG/10ML (0.1MG/ML)</u>	<u>A078595</u>	<u>002</u>	May 13, 2008
<u>AP</u>		<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A090584</u>	<u>001</u>	Aug 28, 2012
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A090584</u>	<u>002</u>	Aug 28, 2012
<u>AP</u>	SANDOZ	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A077071</u>	<u>001</u>	May 03, 2005
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A077071</u>	<u>002</u>	May 03, 2005

FLUNISOLIDE

AEROSOL, METERED; INHALATION

AEROSPAN HFA

+ MEDA PHARMS

0.078MG/INH

N021247 001 Jan 27, 2006

SPRAY, METERED; NASAL

FLUNISOLIDE

<u>AB</u>	+ BAUSCH AND LOMB	<u>0.025MG/SPRAY</u>	<u>A074805</u>	<u>001</u>	Feb 20, 2002
<u>AB</u>	HI TECH PHARMA CO	<u>0.025MG/SPRAY</u>	<u>A077704</u>	<u>001</u>	Aug 03, 2006
	+ APOTEX INC	0.029MG/SPRAY	A077436	001	Aug 09, 2007

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

FLUOCINOLONE ACETONIDE

<u>AT</u>	FOUGERA	<u>0.01%</u>	<u>A088170</u>	<u>001</u>	Dec 16, 1982
<u>AT</u>		<u>0.025%</u>	<u>A088169</u>	<u>001</u>	Dec 16, 1982
<u>AT</u>	G AND W LABS	<u>0.01%</u>	<u>A089526</u>	<u>001</u>	Jul 26, 1988
<u>AT</u>		<u>0.025%</u>	<u>A089525</u>	<u>001</u>	Jul 26, 1988
<u>AT</u>	TARO	<u>0.025%</u>	<u>A087104</u>	<u>001</u>	Apr 27, 1982
	<u>SYNALAR</u>				
<u>AT</u>	+ MEDIMETRIKS PHARMS	<u>0.01%</u>	<u>N012787</u>	<u>004</u>	
<u>AT</u>	+	<u>0.025%</u>	<u>N012787</u>	<u>002</u>	
<u>AT</u>	+	<u>0.025%</u>	<u>N012787</u>	<u>005</u>	

IMPLANT; INTRAVITREAL

ILUVIEN

+ ALIMERA SCIENCES INC

0.19MG

N201923 001 Sep 26, 2014

RETISERT

+ BAUSCH AND LOMB

0.59MG

N021737 001 Apr 08, 2005

PRESCRIPTION DRUG PRODUCT LIST

FLUOCINOLONE ACETONIDE

OIL; TOPICAL

DERMA-SMOOTH/FS

<u>AT</u>	+	HILL DERMAC	<u>0.01%</u>	<u>N019452</u>	<u>001</u>	Feb 03, 1988
<u>AT</u>	+		<u>0.01%</u>	<u>N019452</u>	<u>002</u>	Nov 09, 2005

FLUOCINOLONE ACETONIDE

<u>AT</u>		AKORN	<u>0.01%</u>	<u>A091514</u>	<u>001</u>	Jun 25, 2015
<u>AT</u>		IDENTI PHARMS INC	<u>0.01%</u>	<u>A201759</u>	<u>001</u>	Oct 17, 2011
<u>AT</u>			<u>0.01%</u>	<u>A201764</u>	<u>001</u>	Oct 17, 2011
<u>AT</u>		LYNE	<u>0.01%</u>	<u>A090982</u>	<u>001</u>	Apr 25, 2016
<u>AT</u>			<u>0.01%</u>	<u>A203377</u>	<u>001</u>	Apr 25, 2016
<u>AT</u>		PERRIGO ISRAEL	<u>0.01%</u>	<u>A202847</u>	<u>001</u>	Aug 09, 2013
<u>AT</u>			<u>0.01%</u>	<u>A202848</u>	<u>001</u>	Aug 09, 2013
<u>AT</u>		TARO	<u>0.01%</u>	<u>A202368</u>	<u>001</u>	May 19, 2016
<u>AT</u>			<u>0.01%</u>	<u>A209336</u>	<u>001</u>	May 19, 2016

OIL/DROPS; OTIC

DERMOTIC

<u>AT</u>	+	HILL DERMAC	<u>0.01%</u>	<u>N019452</u>	<u>003</u>	Nov 09, 2005
-----------	---	-------------	--------------	----------------	------------	--------------

FLUOCINOLONE ACETONIDE

<u>AT</u>		AKORN	<u>0.01%</u>	<u>A202705</u>	<u>001</u>	Sep 09, 2016
<u>AT</u>		IDENTI PHARMS INC	<u>0.01%</u>	<u>A091306</u>	<u>001</u>	Oct 17, 2011
<u>AT</u>		LYNE	<u>0.01%</u>	<u>A203378</u>	<u>001</u>	Apr 25, 2016

OINTMENT; TOPICAL

FLUOCINOLONE ACETONIDE

<u>AT</u>		FOUGERA	<u>0.025%</u>	<u>A088168</u>	<u>001</u>	Dec 16, 1982
<u>AT</u>		G AND W LABS	<u>0.025%</u>	<u>A089524</u>	<u>001</u>	Jul 26, 1988
<u>AT</u>		TARO	<u>0.025%</u>	<u>A040041</u>	<u>001</u>	Sep 15, 1994

SYNALAR

<u>AT</u>	+	MEDIMETRIKS PHARMS	<u>0.025%</u>	<u>N013960</u>	<u>001</u>	
-----------	---	--------------------	---------------	----------------	------------	--

SHAMPOO; TOPICAL

CAPEX

	+	GALDERMA LABS LP	0.01%	N020001	001	Aug 27, 1990
--	---	------------------	-------	---------	-----	--------------

SOLUTION; TOPICAL

FLUOCINOLONE ACETONIDE

<u>AT</u>		ACTAVIS LABS UT INC	<u>0.01%</u>	<u>A208386</u>	<u>001</u>	Oct 21, 2016
<u>AT</u>		FOUGERA	<u>0.01%</u>	<u>A088167</u>	<u>001</u>	Dec 16, 1982
<u>AT</u>		G AND W LABS INC	<u>0.01%</u>	<u>A207441</u>	<u>001</u>	Sep 28, 2016
<u>AT</u>		GAVIS PHARMS LLC	<u>0.01%</u>	<u>A206422</u>	<u>001</u>	Sep 02, 2015
<u>AT</u>		TARO	<u>0.01%</u>	<u>A089124</u>	<u>001</u>	Sep 11, 1985

SYNALAR

<u>AT</u>	+	MEDIMETRIKS PHARMS	<u>0.01%</u>	<u>N015296</u>	<u>001</u>	
-----------	---	--------------------	--------------	----------------	------------	--

FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN

CREAM; TOPICAL

TRI-LUMA

	+	GALDERMA LABS LP	0.01%; 4%; 0.05%	N021112	001	Jan 18, 2002
--	---	------------------	------------------	---------	-----	--------------

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-SYNALAR

	+	MEDIMETRIKS PHARMS	0.025%; EQ 3.5MG BASE/GM	A060700	001	
--	---	--------------------	--------------------------	---------	-----	--

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE

<u>AB</u>		FOUGERA PHARMS INC	<u>0.1%</u>	<u>A200735</u>	<u>001</u>	Jul 14, 2014
<u>AB</u>		GLENMARK GENERICS	<u>0.1%</u>	<u>A091282</u>	<u>001</u>	Jul 14, 2014
<u>AB</u>		PERRIGO ISRAEL	<u>0.1%</u>	<u>A090256</u>	<u>001</u>	Jan 14, 2014
<u>AB</u>		TARO	<u>0.1%</u>	<u>A200734</u>	<u>001</u>	Jul 14, 2014

VANOS

<u>AB</u>	+	MEDICIS	<u>0.1%</u>	<u>N021758</u>	<u>001</u>	Feb 11, 2005
-----------	---	---------	-------------	----------------	------------	--------------

FLUOCINONIDE

<u>AB1</u>		FOUGERA	<u>0.05%</u>	<u>A073030</u>	<u>001</u>	Oct 17, 1994
<u>AB1</u>		G AND W LABS INC	<u>0.05%</u>	<u>A073085</u>	<u>001</u>	Feb 14, 1992
<u>AB1</u>	+	TARO	<u>0.05%</u>	<u>N019117</u>	<u>001</u>	Jun 26, 1984
<u>AB1</u>		TEVA	<u>0.05%</u>	<u>A072488</u>	<u>001</u>	Feb 06, 1989

FLUOCINONIDE EMULSIFIED BASE

<u>AB2</u>		FOUGERA PHARMS	<u>0.05%</u>	<u>A076586</u>	<u>001</u>	Jun 23, 2004
<u>AB2</u>	+	TARO	<u>0.05%</u>	<u>A072494</u>	<u>001</u>	Jan 19, 1989
<u>AB2</u>		TEVA	<u>0.05%</u>	<u>A072490</u>	<u>001</u>	Feb 07, 1989

GEL; TOPICAL

FLUOCINONIDE

<u>AB</u>		FOUGERA	<u>0.05%</u>	<u>A072933</u>	<u>001</u>	Dec 30, 1994
<u>AB</u>		G AND W LABS INC	<u>0.05%</u>	<u>A072537</u>	<u>001</u>	Feb 07, 1989

PRESCRIPTION DRUG PRODUCT LIST

FLUOCINONIDE

GEL; TOPICAL

FLUOCINONIDE

AB + TARO 0.05% A074935 001 Jul 29, 1997
OINTMENT; TOPICAL

FLUOCINONIDE

AB FOUGERA PHARMS 0.05% A074905 001 Aug 26, 1997
AB + TARO 0.05% A075008 001 Jun 30, 1999
AB TEVA 0.05% A073481 001 Dec 27, 1991

LIDEX

AB CNTY LINE PHARMS 0.05% N016909 002
SOLUTION; TOPICAL

FLUOCINONIDE

AT FOUGERA 0.05% A072934 001 Feb 27, 1995
AT G AND W LABS INC 0.05% A071535 001 Dec 02, 1988
AT + TARO 0.05% A074799 001 Dec 31, 1996
AT TEVA 0.05% A072511 001 Feb 07, 1989

LIDEX

AT CNTY LINE PHARMS 0.05% N018849 001 Apr 06, 1984

FLUORESCEIN SODIUM

INJECTABLE; INTRAVENOUS

AK-FLUOR 10%

AP AKORN EQ 500MG BASE/5ML (EQ 100MG BASE/ML) N022186 001 Aug 08, 2008

FLUORESCITE

AP + NOVARTIS PHARMS CORP EQ 500MG BASE/5ML (EQ 100MG BASE/ML) N021980 001 Mar 28, 2006
AK-FLUOR 25%
+ AKORN EQ 500MG BASE/2ML (EQ 250MG BASE/ML) N022186 002 Aug 08, 2008

FLUOROMETHOLONE

OINTMENT; OPHTHALMIC

FML

+ ALLERGAN 0.1% N017760 001 Sep 04, 1985

SUSPENSION/DROPS; OPHTHALMIC

FML

+ ALLERGAN 0.1% N016851 002 Jul 28, 1982

FML FORTE

ALLERGAN 0.25% N019216 001 Apr 23, 1986

FLUOROMETHOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

FLAREX

+ NOVARTIS PHARMS CORP 0.1% N019079 001 Feb 11, 1986

FLUOROURACIL

CREAM; TOPICAL

CARAC

AB + VALEANT PHARMS NORTH 0.5% N020985 001 Oct 27, 2000

EFUDEX

AB + VALEANT PHARM INTL 5% N016831 003

FLUOROURACIL

AB SPEAR PHARMS 5% A077524 001 Apr 11, 2008
AB SPEAR PHARMS INC 0.5% A203122 001 Apr 20, 2015
AB TARO 5% A090368 001 Mar 05, 2010

FLUOROPLEX

+ AQUA PHARMS 1% N016988 001

TOLAK

+ HILL DERMACEUTICALS 4% N022259 001 Sep 18, 2015

INJECTABLE; INJECTION

FLUOROURACIL

AP + ACCORD HLTHCARE 500MG/10ML (50MG/ML) A040743 002 Apr 26, 2007
AP + 1GM/20ML (50MG/ML) A040743 001 Apr 26, 2007
AP + 2.5GM/50ML (50MG/ML) A040798 002 Apr 26, 2007
AP + 5GM/100ML (50MG/ML) A040798 001 Apr 26, 2007
AP + FRESENIUS KABI USA 500MG/10ML (50MG/ML) A040279 002 Sep 30, 1998
AP + 1GM/20ML (50MG/ML) A040279 001 Sep 30, 1998
AP + 2.5GM/50ML (50MG/ML) A040278 001 Sep 30, 1998
AP + 5GM/100ML (50MG/ML) A040278 002 Sep 30, 1998
AP MYLAN LABS LTD 500MG/10ML (50MG/ML) A202668 001 Jul 17, 2012
AP 1GM/20ML (50MG/ML) A202668 002 Jul 17, 2012
AP 2.5GM/50ML (50MG/ML) A202669 001 Jul 17, 2012
AP 5GM/100ML (50MG/ML) A202669 002 Jul 17, 2012
AP SAGENT PHARMS 2.5GM/50ML (50MG/ML) A203609 001 Feb 17, 2016
AP 5GM/100ML (50MG/ML) A203609 002 Feb 17, 2016

PRESCRIPTION DRUG PRODUCT LIST

FLUOROURACIL

INJECTABLE; INJECTION

FLUOROURACIL

<u>AP</u>	SANDOZ	<u>2.5GM/50ML (50MG/ML)</u>	<u>A091299 001</u>	May 02, 2011
<u>AP</u>		<u>5GM/100ML (50MG/ML)</u>	<u>A091299 002</u>	May 02, 2011
<u>AP</u>	+ TEVA PHARMS USA	<u>500MG/10ML (50MG/ML)</u>	<u>A040333 001</u>	Jan 27, 2000
<u>AP</u>	+	<u>2.5GM/50ML (50MG/ML)</u>	<u>A040334 001</u>	Feb 25, 2000
<u>AP</u>	+	<u>5GM/100ML (50MG/ML)</u>	<u>A040334 002</u>	Feb 25, 2000
	+ SPECTRUM PHARMS	2.5GM/50ML (50MG/ML)	N012209 002	Jul 29, 2016

SOLUTION; TOPICAL

EFUDEX

<u>AT</u>	+ VALEANT PHARM INTL	<u>2%</u>	<u>N016831 001</u>	
<u>AT</u>	+	<u>5%</u>	<u>N016831 002</u>	

FLUOROURACIL

<u>AT</u>	TARO	<u>2%</u>	<u>A076526 001</u>	Nov 05, 2003
<u>AT</u>		<u>5%</u>	<u>A076526 002</u>	Nov 05, 2003

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>EQ 40MG BASE</u>	<u>A090223 003</u>	Mar 19, 2009
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 40MG BASE</u>	<u>A078619 003</u>	Jan 31, 2008
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 40MG BASE</u>	<u>A075465 003</u>	Aug 02, 2001
<u>AB</u>	HERITAGE PHARMS INC	<u>EQ 40MG BASE</u>	<u>A201336 003</u>	Oct 01, 2012
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 40MG BASE</u>	<u>A075245 003</u>	Sep 28, 2004
<u>AB</u>	MYLAN	<u>EQ 40MG BASE</u>	<u>A075207 003</u>	May 25, 2007
<u>AB</u>	PAR PHARM	<u>EQ 40MG BASE</u>	<u>A076922 003</u>	Dec 16, 2004
<u>AB</u>	SANDOZ	<u>EQ 40MG BASE</u>	<u>A075049 003</u>	Jan 29, 2002
<u>AB</u>	SCIEGEN PHARMS INC	<u>EQ 40MG BASE</u>	<u>A204597 003</u>	Mar 16, 2015
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 40MG BASE</u>	<u>A076990 001</u>	Dec 13, 2004
<u>AB</u>	TEVA	<u>EQ 40MG BASE</u>	<u>A075452 003</u>	Jan 29, 2002

PROZAC

<u>AB</u>	+ ELI LILLY AND CO	<u>EQ 40MG BASE</u>	<u>N018936 003</u>	Jun 15, 1999
-----------	--------------------	---------------------	--------------------	--------------

FLUOXETINE HYDROCHLORIDE

<u>AB1</u>	ALEMBIC PHARMS LTD	<u>EQ 10MG BASE</u>	<u>A090223 001</u>	Mar 19, 2009
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A090223 002</u>	Mar 19, 2009
<u>AB1</u>	AUROBINDO PHARMA	<u>EQ 10MG BASE</u>	<u>A078619 001</u>	Jan 31, 2008
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A078619 002</u>	Jan 31, 2008
<u>AB1</u>	BARR	<u>EQ 10MG BASE</u>	<u>A074803 002</u>	Jan 30, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A074803 001</u>	Aug 02, 2001
<u>AB1</u>	DR REDDYS LABS LTD	<u>EQ 10MG BASE</u>	<u>A075465 001</u>	Jan 29, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075465 002</u>	Jan 29, 2002
<u>AB1</u>	HERITAGE PHARMS INC	<u>EQ 10MG BASE</u>	<u>A201336 001</u>	Oct 01, 2012
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A201336 002</u>	Oct 01, 2012
<u>AB1</u>	IVAX SUB TEVA PHARMS	<u>EQ 10MG BASE</u>	<u>A075245 002</u>	Jan 31, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075245 001</u>	Jan 31, 2002
<u>AB1</u>	LANDELA PHARM	<u>EQ 10MG BASE</u>	<u>A075464 001</u>	Jan 30, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075464 002</u>	Jan 30, 2002
<u>AB1</u>	MALLINCKRODT	<u>EQ 10MG BASE</u>	<u>A075658 001</u>	Jan 29, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075658 002</u>	Jan 29, 2002
<u>AB1</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A075207 001</u>	Jan 30, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075207 002</u>	Jan 30, 2002
<u>AB1</u>	MYLAN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A075577 001</u>	Jan 29, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075577 002</u>	Jan 29, 2002
<u>AB1</u>	SANDOZ	<u>EQ 10MG BASE</u>	<u>A075049 001</u>	Aug 02, 2001
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075049 002</u>	Jan 29, 2002
<u>AB1</u>	SCIEGEN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A204597 001</u>	Mar 16, 2015
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A204597 002</u>	Mar 16, 2015
<u>AB1</u>	TEVA	<u>EQ 10MG BASE</u>	<u>A075452 001</u>	Jan 29, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075452 002</u>	Jan 29, 2002
<u>AB1</u>	TEVA PHARMS USA	<u>EQ 10MG BASE</u>	<u>A076001 001</u>	Jan 29, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A076001 002</u>	Jan 29, 2002

PROZAC

<u>AB1</u>	ELI LILLY AND CO	<u>EQ 10MG BASE</u>	<u>N018936 006</u>	Dec 23, 1992
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>N018936 001</u>	Dec 29, 1987

FLUOXETINE HYDROCHLORIDE

	MYLAN	EQ 10MG BASE	A078045 001	Nov 17, 2008
	+	EQ 20MG BASE	A078045 002	Nov 17, 2008

CAPSULE, DELAYED REL PELLETS; ORAL

FLUOXETINE HYDROCHLORIDE

<u>AB</u>	BARR	<u>EQ 90MG BASE</u>	<u>A076237 001</u>	Mar 24, 2010
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 90MG BASE</u>	<u>A078572 001</u>	Mar 22, 2010

PRESCRIPTION DRUG PRODUCT LIST

FLUOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

PROZAC WEEKLY

<u>AB</u>	+	LILLY	<u>EQ 90MG BASE</u>	<u>N021235 001</u>	Feb 26, 2001
-----------	---	-------	---------------------	--------------------	--------------

SOLUTION;ORAL

FLUOXETINE HYDROCHLORIDE

<u>AA</u>		AUROBINDO PHARM	<u>EQ 20MG BASE/5ML</u>	<u>A079209 001</u>	Mar 20, 2009
<u>AA</u>		MALLINCKRODT	<u>EQ 20MG BASE/5ML</u>	<u>A075920 001</u>	Jan 29, 2002
<u>AA</u>	+	PHARM ASSOC	<u>EQ 20MG BASE/5ML</u>	<u>A076015 001</u>	Jan 30, 2002
<u>AA</u>		SILARX	<u>EQ 20MG BASE/5ML</u>	<u>A077849 001</u>	Feb 09, 2007
<u>AA</u>		TEVA	<u>EQ 20MG BASE/5ML</u>	<u>A075506 001</u>	Aug 02, 2001
<u>AA</u>		WOCKHARDT	<u>EQ 20MG BASE/5ML</u>	<u>A075514 001</u>	Aug 29, 2002

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

<u>AB</u>		DR REDDYS LABS INC	<u>EQ 10MG BASE</u>	<u>A076006 001</u>	Jan 30, 2002
<u>AB</u>		MYLAN	<u>EQ 10MG BASE</u>	<u>A075755 001</u>	Aug 02, 2001
<u>AB</u>	+		<u>EQ 20MG BASE</u>	<u>A075755 002</u>	Aug 02, 2001
<u>AB</u>		PAR FORM	<u>EQ 10MG BASE</u>	<u>A203836 001</u>	Aug 19, 2016
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A203836 002</u>	Aug 19, 2016
<u>AB</u>		TEVA	<u>EQ 10MG BASE</u>	<u>A075872 001</u>	Jan 29, 2002
<u>AB1</u>		TORRENT PHARMS LTD	<u>EQ 10MG BASE</u>	<u>A206937 001</u>	Oct 21, 2016
<u>AB1</u>			<u>EQ 20MG BASE</u>	<u>A206937 002</u>	Oct 21, 2016

SARAFEM

<u>AB1</u>		APIL	<u>EQ 10MG BASE</u>	<u>N021860 001</u>	May 19, 2006
<u>AB1</u>			<u>EQ 15MG BASE</u>	<u>N021860 002</u>	May 19, 2006
<u>AB1</u>	+		<u>EQ 20MG BASE</u>	<u>N021860 003</u>	May 19, 2006

SELFEMRA

<u>AB1</u>		TEVA PHARMS USA	<u>EQ 10MG BASE</u>	<u>A200151 001</u>	Feb 03, 2014
<u>AB1</u>			<u>EQ 15MG BASE</u>	<u>A200151 002</u>	Feb 03, 2014
<u>AB1</u>			<u>EQ 20MG BASE</u>	<u>A200151 003</u>	Feb 03, 2014

FLUOXETINE HYDROCHLORIDE

+ EDMONT PHARMS LLC EQ 60MG BASE

N202133 001 Oct 06, 2011

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE;ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

<u>AB</u>		PAR PHARM	<u>EQ 25MG BASE;EQ 3MG BASE</u>	<u>A077742 001</u>	Nov 02, 2012
<u>AB</u>			<u>EQ 25MG BASE;EQ 6MG BASE</u>	<u>A077742 002</u>	Nov 02, 2012
<u>AB</u>			<u>EQ 25MG BASE;EQ 12MG BASE</u>	<u>A077742 003</u>	Nov 02, 2012
<u>AB</u>			<u>EQ 50MG BASE;EQ 6MG BASE</u>	<u>A077742 004</u>	Nov 02, 2012
<u>AB</u>			<u>EQ 50MG BASE;EQ 12MG BASE</u>	<u>A077742 005</u>	Nov 02, 2012
<u>AB</u>		SANDOZ	<u>EQ 25MG BASE;EQ 3MG BASE</u>	<u>A078901 005</u>	Nov 16, 2012
<u>AB</u>			<u>EQ 25MG BASE;EQ 6MG BASE</u>	<u>A078901 001</u>	Nov 16, 2012
<u>AB</u>			<u>EQ 25MG BASE;EQ 12MG BASE</u>	<u>A078901 003</u>	Nov 16, 2012
<u>AB</u>			<u>EQ 50MG BASE;EQ 6MG BASE</u>	<u>A078901 002</u>	Nov 16, 2012
<u>AB</u>			<u>EQ 50MG BASE;EQ 12MG BASE</u>	<u>A078901 004</u>	Nov 16, 2012
<u>AB</u>		TEVA PHARMS	<u>EQ 25MG BASE;EQ 3MG BASE</u>	<u>A202074 001</u>	Mar 25, 2013
<u>AB</u>			<u>EQ 25MG BASE;EQ 6MG BASE</u>	<u>A077528 001</u>	Jun 19, 2012
<u>AB</u>			<u>EQ 25MG BASE;EQ 12MG BASE</u>	<u>A077528 002</u>	Jun 19, 2012
<u>AB</u>			<u>EQ 50MG BASE;EQ 6MG BASE</u>	<u>A077528 003</u>	Jun 19, 2012
<u>AB</u>			<u>EQ 50MG BASE;EQ 12MG BASE</u>	<u>A077528 004</u>	Jun 19, 2012

SYMBYAX

<u>AB</u>		LILLY	<u>EQ 25MG BASE;EQ 3MG BASE</u>	<u>N021520 001</u>	Apr 09, 2007
<u>AB</u>			<u>EQ 25MG BASE;EQ 6MG BASE</u>	<u>N021520 002</u>	Dec 24, 2003
<u>AB</u>			<u>EQ 25MG BASE;EQ 12MG BASE</u>	<u>N021520 004</u>	Dec 24, 2003
<u>AB</u>	+		<u>EQ 50MG BASE;EQ 6MG BASE</u>	<u>N021520 003</u>	Dec 24, 2003
<u>AB</u>			<u>EQ 50MG BASE;EQ 12MG BASE</u>	<u>N021520 005</u>	Dec 24, 2003

FLUOXYMESTERONE

TABLET;ORAL

FLUOXYMESTERONE

+ USL PHARMA 10MG

A088342 001 Oct 21, 1983

FLUPHENAZINE DECANOATE

INJECTABLE;INJECTION

FLUPHENAZINE DECANOATE

<u>AO</u>	+	FRESENIUS KABI USA	<u>25MG/ML</u>	<u>A071413 001</u>	Jul 14, 1987
<u>AO</u>		PAR STERILE PRODUCTS	<u>25MG/ML</u>	<u>A203732 001</u>	Jul 03, 2014
<u>AO</u>		WEST-WARD PHARMS INT	<u>25MG/ML</u>	<u>A074531 001</u>	Aug 30, 1996

PRESCRIPTION DRUG PRODUCT LIST

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

FLUPHENAZINE HYDROCHLORIDE

+ PHARM ASSOC

5MG/ML

A074725 001 Sep 16, 1996

ELIXIR; ORAL

FLUPHENAZINE HYDROCHLORIDE

+ PHARM ASSOC

2.5MG/5ML

A040146 001 Aug 21, 1996

INJECTABLE; INJECTION

FLUPHENAZINE HYDROCHLORIDE

+ FRESENIUS KABI USA

2.5MG/ML

A089556 001 Apr 16, 1987

TABLET; ORAL

FLUPHENAZINE HYDROCHLORIDE**AB** LANNETT**1MG****A089743 002** Aug 25, 1988**AB****2.5MG****A089743 003** Aug 25, 1988**AB****5MG****A089743 004** Aug 25, 1988**AB****10MG****A089743 001** Aug 25, 1988**AB** MYLAN**1MG****A089804 002** Aug 12, 1988**AB****2.5MG****A089804 003** Aug 12, 1988**AB****5MG****A089804 004** Aug 12, 1988**AB** +**10MG****A089804 001** Aug 12, 1988**AB** SANDOZ**1MG****A089586 002** Oct 16, 1987**AB****2.5MG****A089586 003** Oct 16, 1987**AB****5MG****A089586 004** Oct 16, 1987**AB****10MG****A089586 001** Oct 16, 1987FLURANDRENOLIDE

CREAM; TOPICAL

CORDRAN SP**AT** + AQUA PHARMS**0.05%****N012806 002**FLURANDRENOLIDE**AT** TELIGENT PHARMA INC**0.05%****A205342 001** Apr 13, 2016

CORDRAN SP

+ AQUA PHARMS

0.025%

N012806 003

LOTION; TOPICAL

CORDRAN**AT** + AQUA PHARMS**0.05%****N013790 001**FLURANDRENOLIDE**AT** PERRIGO UK FINCO**0.05%****A207133 001** Aug 30, 2016**AT** TELIGENT PHARMA INC**0.05%****A205343 001** Dec 22, 2016

OINTMENT; TOPICAL

CORDRAN**AT** + AQUA PHARMS**0.05%****N012806 001**FLURANDRENOLIDE**AT** TELIGENT PHARMA INC**0.05%****A207851 001** Dec 30, 2016

TAPE; TOPICAL

CORDRAN

+ ALLERGAN SALES LLC

0.004MG/SQ CM

N016455 001

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

FLURAZEPAM HYDROCHLORIDE

MYLAN PHARMS INC

15MG

A070345 002 Nov 27, 1985

+

30MG

A070345 001 Nov 27, 1985

FLURBIPROFEN

TABLET; ORAL

FLURBIPROFEN**AB** MYLAN**50MG****A074358 001** Jun 20, 1994**AB** +**100MG****A074358 002** Jun 20, 1994**AB** SUN PHARM INDS INC**50MG****A075058 001** Apr 27, 2001**AB****100MG****A075058 002** Apr 27, 2001**AB** TEVA**100MG****A074431 001** May 31, 1995FLURBIPROFEN SODIUM

SOLUTION/DROPS; OPHTHALMIC

FLURBIPROFEN SODIUM**AT** BAUSCH AND LOMB**0.03%****A074447 001** Jan 04, 1995OCUFEN**AT** + ALLERGAN**0.03%****N019404 001** Dec 31, 1986

PRESCRIPTION DRUG PRODUCT LIST

FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE

AB	ACTAVIS LABS FL INC	125MG	A075820 001	Sep 18, 2001
AB	+ CIPLA LTD	125MG	A075780 001	Sep 19, 2001
AB	MYLAN	125MG	A076224 001	May 09, 2003
AB	PAR PHARM	125MG	A075298 001	Sep 18, 2001

FLUTEMETAMOL F-18

INJECTABLE; INTRAVENOUS

VIZAMYL

+	GE HEALTHCARE	40.5mCi/10ML (4.05mCi/ML)	N203137 001	Oct 25, 2013
+		121.5mCi/30ML (4.05mCi/ML)	N203137 002	Oct 25, 2013

FLUTICASONE FUROATE

POWDER; INHALATION

ARNUITY ELLIPTA

+	GLAXOSMITHKLINE	0.1MG/INH	N205625 001	Aug 20, 2014
+		0.2MG/INH	N205625 002	Aug 20, 2014

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

POWDER; INHALATION

BREQ ELLIPTA

+	GLAXO GRP LTD	0.1MG/INH;EQ 0.025MG BASE/INH	N204275 001	May 10, 2013
+		0.2MG/INH;EQ 0.025MG BASE/INH	N204275 002	Apr 30, 2015

FLUTICASONE PROPIONATE

AEROSOL, METERED; INHALATION

FLOVENT HFA

+	GLAXO GRP LTD	0.044MG/INH	N021433 003	May 14, 2004
+		0.11MG/INH	N021433 002	May 14, 2004
+		0.22MG/INH	N021433 001	May 14, 2004

CREAM; TOPICAL

FLUTICASONE PROPIONATE

AB	FOUGERA PHARMS	0.05%	A076451 001	May 14, 2004
AB	G AND W LABS	0.05%	A077055 001	Jun 30, 2006
AB	+ PERRIGO NEW YORK	0.05%	A076793 001	May 14, 2004
AB	TOLMAR	0.05%	A076633 001	May 14, 2004

LOTION; TOPICAL

CUTIVATE

AB	+ FOUGERA PHARMS	0.05%	N021152 001	Mar 31, 2005
-----------	------------------	--------------	--------------------	--------------

FLUTICASONE PROPIONATE

AB	GLENMARK GENERICS	0.05%	A090759 001	May 02, 2011
AB	PERRIGO ISRAEL	0.05%	A091553 001	Jul 30, 2013

OINTMENT; TOPICAL

CUTIVATE

AB	+ FOUGERA PHARMS	0.005%	N019957 001	Dec 14, 1990
-----------	------------------	---------------	--------------------	--------------

FLUTICASONE PROPIONATE

AB	FOUGERA PHARMS	0.005%	A076300 001	May 14, 2004
AB	G AND W LABS	0.005%	A077168 001	Mar 03, 2006
AB	PERRIGO NEW YORK	0.005%	A076668 001	May 14, 2004

POWDER; INHALATION

FLOVENT DISKUS 100

+	GLAXO GRP LTD	0.1MG/INH	N020833 002	Sep 29, 2000
---	---------------	-----------	-------------	--------------

FLOVENT DISKUS 250

+	GLAXO GRP LTD	0.25MG/INH	N020833 003	Sep 29, 2000
---	---------------	------------	-------------	--------------

FLOVENT DISKUS 50

+	GLAXO GRP LTD	0.05MG/INH	N020833 001	Sep 29, 2000
---	---------------	------------	-------------	--------------

SPRAY, METERED; NASAL

FLUTICASONE PROPIONATE

AB	APOTEX INC	0.05MG/SPRAY	A077538 001	Sep 12, 2007
AB	HI TECH PHARMA	0.05MG/SPRAY	A077570 001	Jan 16, 2008
AB	WEST-WARD PHARMS INT	0.05MG/SPRAY	A076504 001	Feb 22, 2006
AB	WOCKHARDT	0.05MG/SPRAY	A078492 001	Jan 09, 2012

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

AEROSOL, METERED; INHALATION

ADVAIR HFA

+	GLAXO GRP LTD	0.045MG/INH;EQ 0.021MG BASE/INH	N021254 001	Jun 08, 2006
---	---------------	---------------------------------	-------------	--------------

+		0.115MG/INH;EQ 0.021MG BASE/INH	N021254 002	Jun 08, 2006
---	--	---------------------------------	-------------	--------------

+		0.23MG/INH;EQ 0.021MG BASE/INH	N021254 003	Jun 08, 2006
---	--	--------------------------------	-------------	--------------

POWDER; INHALATION

ADVAIR DISKUS 100/50

+	GLAXO GRP LTD	0.1MG/INH;EQ 0.05MG BASE/INH	N021077 001	Aug 24, 2000
---	---------------	------------------------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

POWDER; INHALATION

ADVAIR DISKUS 250/50					
+ GLAXO GRP LTD	0.25MG/INH;EQ 0.05MG BASE/INH		N021077	002	Aug 24, 2000
ADVAIR DISKUS 500/50					
+ GLAXO GRP LTD	0.5MG/INH;EQ 0.05MG BASE/INH		N021077	003	Aug 24, 2000

FLUVASTATIN SODIUM

CAPSULE; ORAL

FLUVASTATIN SODIUM

<u>AB</u>	MYLAN PHARMS INC	<u>EQ 20MG BASE</u>	<u>A090595</u>	<u>001</u>	Apr 11, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A090595</u>	<u>002</u>	Apr 11, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 20MG BASE</u>	<u>A078407</u>	<u>001</u>	Jun 12, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078407</u>	<u>002</u>	Jun 12, 2012

LESCOL

<u>AB</u>	NOVARTIS	<u>EQ 20MG BASE</u>	<u>N020261</u>	<u>001</u>	Dec 31, 1993
<u>AB</u>	+	<u>EQ 40MG BASE</u>	<u>N020261</u>	<u>002</u>	Dec 31, 1993

TABLET, EXTENDED RELEASE; ORAL

FLUVASTATIN SODIUM

<u>AB</u>	MYLAN PHARMS INC	<u>EQ 80MG BASE</u>	<u>A202458</u>	<u>001</u>	Sep 11, 2015
<u>AB</u>	TEVA PHARMS USA	<u>EQ 80MG BASE</u>	<u>A079011</u>	<u>001</u>	Jan 27, 2016

LESCOL XL

<u>AB</u>	+	NOVARTIS	<u>EQ 80MG BASE</u>	<u>N021192</u>	<u>001</u>	Oct 06, 2000
-----------	---	----------	---------------------	----------------	------------	--------------

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

FLUVOXAMINE MALEATE

<u>AB</u>	ACTAVIS ELIZABETH	<u>100MG</u>	<u>A091482</u>	<u>001</u>	Apr 23, 2013
<u>AB</u>		<u>150MG</u>	<u>A091482</u>	<u>002</u>	Nov 18, 2013
<u>AB</u>	ANCHEN PHARMS	<u>100MG</u>	<u>A091476</u>	<u>001</u>	Mar 13, 2013
<u>AB</u>		<u>150MG</u>	<u>A091476</u>	<u>002</u>	Mar 13, 2013
<u>AB</u>	TORRENT PHARMS LTD	<u>100MG</u>	<u>A203240</u>	<u>001</u>	Oct 31, 2014
<u>AB</u>		<u>150MG</u>	<u>A203240</u>	<u>002</u>	Oct 31, 2014

LUVOX CR

<u>AB</u>	JAZZ PHARMS	<u>100MG</u>	<u>N022033</u>	<u>001</u>	Feb 28, 2008
<u>AB</u>	+	<u>150MG</u>	<u>N022033</u>	<u>002</u>	Feb 28, 2008

TABLET; ORAL

FLUVOXAMINE MALEATE

<u>AB</u>	ANI PHARMS INC	<u>25MG</u>	<u>A075897</u>	<u>001</u>	Jan 25, 2001
<u>AB</u>		<u>50MG</u>	<u>A075897</u>	<u>002</u>	Jan 25, 2001
<u>AB</u>		<u>100MG</u>	<u>A075897</u>	<u>003</u>	Jan 25, 2001
<u>AB</u>	APOTEX	<u>25MG</u>	<u>A075902</u>	<u>001</u>	May 07, 2001
<u>AB</u>		<u>50MG</u>	<u>A075902</u>	<u>002</u>	May 07, 2001
<u>AB</u>		<u>100MG</u>	<u>A075902</u>	<u>003</u>	May 07, 2001
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A075889</u>	<u>001</u>	Nov 29, 2000
<u>AB</u>		<u>50MG</u>	<u>A075889</u>	<u>002</u>	Nov 29, 2000
<u>AB</u>		<u>100MG</u>	<u>A075889</u>	<u>003</u>	Nov 29, 2000
<u>AB</u>	TEVA	<u>25MG</u>	<u>A075893</u>	<u>001</u>	Sep 10, 2002
<u>AB</u>		<u>50MG</u>	<u>A075893</u>	<u>002</u>	Sep 10, 2002
<u>AB</u>		<u>100MG</u>	<u>A075893</u>	<u>003</u>	Sep 10, 2002
<u>AB</u>	UPSHER-SMITH LABS	<u>25MG</u>	<u>A075888</u>	<u>001</u>	Nov 29, 2000
<u>AB</u>		<u>50MG</u>	<u>A075888</u>	<u>002</u>	Nov 29, 2000
<u>AB</u>	+	<u>100MG</u>	<u>A075888</u>	<u>003</u>	Nov 29, 2000

LUVOX

<u>AB</u>	ANI PHARMS	<u>25MG</u>	<u>N021519</u>	<u>001</u>	Dec 20, 2007
<u>AB</u>		<u>50MG</u>	<u>N021519</u>	<u>002</u>	Dec 20, 2007
<u>AB</u>		<u>100MG</u>	<u>N021519</u>	<u>003</u>	Dec 20, 2007

FOLIC ACID

INJECTABLE; INJECTION

FOLIC ACID					
+ FRESENIUS KABI USA	5MG/ML		A089202	001	Feb 18, 1986

TABLET; ORAL

FOLIC ACID

<u>AA</u>	AIPING PHARM INC	<u>1MG</u>	<u>A091145</u>	<u>001</u>	Jul 12, 2013	
<u>AA</u>	+	AMNEAL PHARM	<u>1MG</u>	<u>A040625</u>	<u>001</u>	Jul 21, 2005
<u>AA</u>	CADILA PHARMS LTD	<u>1MG</u>	<u>A202437</u>	<u>001</u>	Jan 27, 2014	
<u>AA</u>	CONTRACT PHARMACAL	<u>1MG</u>	<u>A085061</u>	<u>001</u>		
<u>AA</u>	HIKMA PHARMS LLC	<u>1MG</u>	<u>A080600</u>	<u>001</u>		
<u>AA</u>	INVAGEN PHARMS	<u>1MG</u>	<u>A090035</u>	<u>001</u>	Jun 09, 2009	
<u>AA</u>	LEADING PHARMA LLC	<u>1MG</u>	<u>A040796</u>	<u>001</u>	Jan 12, 2009	
<u>AA</u>	NUVO PHARM INC	<u>1MG</u>	<u>A204418</u>	<u>001</u>	Jul 28, 2015	
<u>AA</u>	VINTAGE	<u>1MG</u>	<u>A040756</u>	<u>001</u>	Jun 04, 2010	
<u>AA</u>	+	WATSON LABS	<u>1MG</u>	<u>A080680</u>	<u>001</u>	

PRESCRIPTION DRUG PRODUCT LIST

FOLLITROPIN ALFA/BETA

INJECTABLE; SUBCUTANEOUS

FOLLISTIM AQ

+	ORGANON USA INC	300 IU/0.36ML	N021211 001	Mar 23, 2004
+		600 IU/0.72ML	N021211 002	Mar 23, 2004
+		900 IU/1.08ML	N021211 004	Feb 11, 2005

GONAL-F

+	EMD SERONO	450 IU/VIAL	N020378 005	Mar 26, 2004
		1,050 IU/VIAL	N020378 004	Feb 28, 2001

GONAL-F RFF

+	EMD SERONO	75 IU/VIAL	N021765 002	Mar 25, 2004
---	------------	------------	-------------	--------------

GONAL-F RFF REDI-JECT

+	EMD SERONO	300 IU/0.5ML	N021684 001	May 25, 2004
+		450 IU/0.75ML	N021684 002	May 25, 2004
+		900 IU/1.5ML	N021684 003	May 25, 2004

FOMEPIZOLE

INJECTABLE; INJECTION

ANTIZOL

AP	+	PAR PHARM INC	<u>1.5GM/1.5ML (1GM/ML)</u>	<u>N020696 001</u>	Dec 04, 1997
-----------	---	---------------	------------------------------------	---------------------------	--------------

FOMEPIZOLE

AP		LUITPOLD	<u>1.5GM/1.5ML (1GM/ML)</u>	<u>A078368 001</u>	Dec 14, 2007
AP		MYLAN INSTITUTIONAL	<u>1.5GM/1.5ML (1GM/ML)</u>	<u>A078639 001</u>	Mar 03, 2008
AP		NAVINTA LLC	<u>1.5GM/1.5ML (1GM/ML)</u>	<u>A078537 001</u>	Mar 06, 2008

FONDAPARINUX SODIUM

INJECTABLE; SUBCUTANEOUS

ARIIXTRA

AP	+	MYLAN IRELAND LTD	<u>2.5MG/0.5ML</u>	<u>N021345 001</u>	Dec 07, 2001
AP	+		<u>5MG/0.4ML</u>	<u>N021345 002</u>	May 28, 2004
AP	+		<u>7.5MG/0.6ML</u>	<u>N021345 003</u>	May 28, 2004
AP	+		<u>10MG/0.8ML</u>	<u>N021345 004</u>	May 28, 2004

FONDAPARINUX SODIUM

AP		DR REDDYS LABS LTD	<u>2.5MG/0.5ML</u>	<u>A091316 001</u>	Jul 11, 2011
AP			<u>5MG/0.4ML</u>	<u>A091316 002</u>	Jul 11, 2011
AP			<u>7.5MG/0.6ML</u>	<u>A091316 003</u>	Jul 11, 2011
AP			<u>10MG/0.8ML</u>	<u>A091316 004</u>	Jul 11, 2011

FORMOTEROL FUMARATE

POWDER; INHALATION

FORADIL

+	NOVARTIS	0.012MG/INH	N020831 001	Feb 16, 2001
---	----------	-------------	-------------	--------------

SOLUTION; INHALATION

PERFORMIST

+	MYLAN SPECLT	0.02MG/2ML	N022007 001	May 11, 2007
---	--------------	------------	-------------	--------------

FORMOTEROL FUMARATE; GLYCOPYRROLATE

AEROSOL, METERED; INHALATION

BEVESPI AEROSPHERE

+	PEARL THERAPS INC	0.0048MG/INH;0.0090MG/INH	N208294 001	Apr 25, 2016
---	-------------------	---------------------------	-------------	--------------

FORMOTEROL FUMARATE; MOMETASONE FUROATE

AEROSOL, METERED; INHALATION

DULERA

+	MERCK SHARP DOHME	0.005MG/INH;0.1MG/INH	N022518 001	Jun 22, 2010
+		0.005MG/INH;0.2MG/INH	N022518 002	Jun 22, 2010

FOSAMPRENAVIR CALCIUM

SUSPENSION; ORAL

LEXIVA

+	VIIV HLTHCARE	EQ 50MG BASE/ML	N022116 001	Jun 14, 2007
---	---------------	-----------------	-------------	--------------

TABLET; ORAL

FOSAMPRENAVIR CALCIUM

AB		MYLAN PHARMS INC	<u>EQ 700MG BASE</u>	<u>A204060 001</u>	Apr 15, 2016
-----------	--	------------------	-----------------------------	---------------------------	--------------

LEXIVA

AB	+	VIIV HLTHCARE	<u>EQ 700MG BASE</u>	<u>N021548 001</u>	Oct 20, 2003
-----------	---	---------------	-----------------------------	---------------------------	--------------

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS

EMEND

AP	+	MERCK AND CO INC	<u>EQ 150MG BASE/VIAL</u>	<u>N022023 002</u>	Nov 12, 2010
-----------	---	------------------	----------------------------------	---------------------------	--------------

FOSAPREPITANT DIMEGLUMINE

AP		FRESENIUS KABI USA	<u>EQ 150MG BASE/VIAL</u>	<u>A206197 001</u>	Jun 09, 2016
-----------	--	--------------------	----------------------------------	---------------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

FOSCARNET SODIUM

INJECTABLE; INJECTION

FOSCARNET SODIUM

<u>AP</u>	HOSPIRA	<u>2.4GM/100ML</u>	<u>A077174</u>	<u>001</u>	May 31, 2005
-----------	---------	--------------------	----------------	------------	--------------

FOSCAVIR

<u>AP</u>	+ CLINIGEN HLTHCARE	<u>2.4GM/100ML</u>	<u>N020068</u>	<u>001</u>	Sep 27, 1991
-----------	---------------------	--------------------	----------------	------------	--------------

FOSFOMYCIN TROMETHAMINE

FOR SUSPENSION; ORAL

MONUROL

+ ZAMBON SPA

EQ 3GM BASE/PACKET

N050717 001 Dec 19, 1996

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

<u>AB</u>	APOTEX INC	<u>10MG</u>	<u>A076906</u>	<u>001</u>	May 17, 2005
<u>AB</u>		<u>20MG</u>	<u>A076906</u>	<u>002</u>	May 17, 2005
<u>AB</u>		<u>40MG</u>	<u>A076906</u>	<u>003</u>	May 17, 2005
<u>AB</u>	AUROBINDO PHARMA LTD	<u>10MG</u>	<u>A091163</u>	<u>001</u>	Mar 30, 2011
<u>AB</u>		<u>20MG</u>	<u>A091163</u>	<u>002</u>	Mar 30, 2011
<u>AB</u>		<u>40MG</u>	<u>A091163</u>	<u>003</u>	Mar 30, 2011
<u>AB</u>	INVAGEN PHARMS	<u>10MG</u>	<u>A077222</u>	<u>001</u>	Apr 20, 2005
<u>AB</u>		<u>20MG</u>	<u>A077222</u>	<u>002</u>	Apr 20, 2005
<u>AB</u>		<u>40MG</u>	<u>A077222</u>	<u>003</u>	Apr 20, 2005
<u>AB</u>	PRINSTON INC	<u>10MG</u>	<u>A205670</u>	<u>001</u>	Aug 29, 2016
<u>AB</u>		<u>20MG</u>	<u>A205670</u>	<u>002</u>	Aug 29, 2016
<u>AB</u>		<u>40MG</u>	<u>A205670</u>	<u>003</u>	Aug 29, 2016
<u>AB</u>	TEVA	<u>10MG</u>	<u>A076139</u>	<u>001</u>	Nov 25, 2003
<u>AB</u>		<u>20MG</u>	<u>A076139</u>	<u>002</u>	Nov 25, 2003
<u>AB</u>	+	<u>40MG</u>	<u>A076139</u>	<u>003</u>	Nov 25, 2003
<u>AB</u>	UPSHER-SMITH LABS	<u>10MG</u>	<u>A076483</u>	<u>001</u>	Apr 23, 2004
<u>AB</u>		<u>20MG</u>	<u>A076483</u>	<u>002</u>	Apr 23, 2004
<u>AB</u>		<u>40MG</u>	<u>A076483</u>	<u>003</u>	Apr 23, 2004

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

<u>AB</u>	AUROBINDO PHARMA	<u>10MG;12.5MG</u>	<u>A079245</u>	<u>001</u>	Jul 09, 2009
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A079245</u>	<u>002</u>	Jul 09, 2009
<u>AB</u>	EMCURE PHARMS INDIA	<u>10MG;12.5MG</u>	<u>A079025</u>	<u>001</u>	Sep 17, 2010
<u>AB</u>	+	<u>20MG;12.5MG</u>	<u>A079025</u>	<u>002</u>	Sep 17, 2010
<u>AB</u>	INVAGEN PHARMS	<u>10MG;12.5MG</u>	<u>A090228</u>	<u>001</u>	Jul 09, 2009
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A090228</u>	<u>002</u>	Jul 09, 2009
<u>AB</u>	SANDOZ	<u>10MG;12.5MG</u>	<u>A076961</u>	<u>001</u>	Sep 28, 2005
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A076961</u>	<u>002</u>	Sep 28, 2005

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

CEREBYX

<u>AP</u>	+ PARKE DAVIS	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>N020450</u>	<u>001</u>	Aug 05, 1996
-----------	---------------	--------------------------------	----------------	------------	--------------

FOSPHENYTOIN SODIUM

<u>AP</u>	AMNEAL PHARMS CO	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078476</u>	<u>001</u>	Mar 18, 2008
<u>AP</u>	EUROHLTH INTL SARL	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A077481</u>	<u>001</u>	Aug 06, 2007
<u>AP</u>		<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A077989</u>	<u>001</u>	Aug 06, 2007
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078765</u>	<u>001</u>	Dec 02, 2009
<u>AP</u>	HOSPIRA	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078158</u>	<u>001</u>	Aug 06, 2007
<u>AP</u>	LUITPOLD	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078277</u>	<u>001</u>	Aug 06, 2007
<u>AP</u>		<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A090099</u>	<u>001</u>	May 13, 2010
<u>AP</u>	MYLAN LABS LTD	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078736</u>	<u>001</u>	Jun 08, 2010
<u>AP</u>	SUN PHARMA GLOBAL	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078417</u>	<u>001</u>	Mar 18, 2008
<u>AP</u>	WOCKHARDT	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078137</u>	<u>001</u>	Aug 06, 2007

FROVATRIPTAN SUCCINATE

TABLET; ORAL

FROVA

<u>AB</u>	+ ENDO PHARMS	<u>EQ 2.5MG BASE</u>	<u>N021006</u>	<u>001</u>	Nov 08, 2001
-----------	---------------	----------------------	----------------	------------	--------------

FROVATRIPTAN SUCCINATE

<u>AB</u>	GLENMARK PHARMS LTD	<u>EQ 2.5MG BASE</u>	<u>A204730</u>	<u>001</u>	Mar 11, 2016
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 2.5MG BASE</u>	<u>A202931</u>	<u>001</u>	Aug 28, 2014

PRESCRIPTION DRUG PRODUCT LIST

FULVESTRANT

INJECTABLE; INTRAMUSCULAR

FASLODEX

+ ASTRAZENECA

50MG/ML

N021344 001 Apr 25, 2002

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

<u>AP</u>	AMNEAL PHARMS CO	<u>10MG/ML</u>	<u>A207552</u>	<u>001</u>	Jul 20, 2016
<u>AP</u>	CLARIS	<u>10MG/ML</u>	<u>A202747</u>	<u>001</u>	Jan 27, 2014
<u>AP</u>	EMCURE PHARMS LTD	<u>10MG/ML</u>	<u>A203428</u>	<u>001</u>	Aug 26, 2014
<u>AP</u>	FRESENIUS KABI USA	<u>10MG/ML</u>	<u>N018902</u>	<u>001</u>	May 22, 1984
<u>AP</u>	HOSPIRA	<u>10MG/ML</u>	<u>A075241</u>	<u>001</u>	May 28, 1999
<u>AP</u>		<u>10MG/ML</u>	<u>N018667</u>	<u>001</u>	May 28, 1982
<u>AP</u>	WOCKHARDT	<u>10MG/ML</u>	<u>A077941</u>	<u>001</u>	Mar 22, 2007

SOLUTION; ORAL

FUROSEMIDE

<u>AA</u>	+ WEST-WARD PHARMS INT	<u>10MG/ML</u>	<u>A070434</u>	<u>001</u>	Apr 22, 1987
<u>AA</u>	WOCKHARDT	<u>10MG/ML</u>	<u>A070655</u>	<u>001</u>	Oct 02, 1987
	WEST-WARD PHARMS INT	40MG/5ML	A070433	001	Apr 22, 1987

TABLET; ORAL

FUROSEMIDE

<u>AB</u>	IPCA LABS LTD	<u>20MG</u>	<u>A078010</u>	<u>001</u>	Sep 18, 2006
<u>AB</u>		<u>40MG</u>	<u>A078010</u>	<u>002</u>	Sep 18, 2006
<u>AB</u>		<u>80MG</u>	<u>A078010</u>	<u>003</u>	Sep 18, 2006
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>20MG</u>	<u>N018413</u>	<u>001</u>	Nov 30, 1983
<u>AB</u>		<u>40MG</u>	<u>N018413</u>	<u>002</u>	Nov 30, 1983
<u>AB</u>	LEADING PHARMA LLC	<u>20MG</u>	<u>A077293</u>	<u>001</u>	Nov 09, 2005
<u>AB</u>		<u>40MG</u>	<u>A077293</u>	<u>002</u>	Nov 09, 2005
<u>AB</u>		<u>80MG</u>	<u>A077293</u>	<u>003</u>	Nov 09, 2005
<u>AB</u>	MYLAN	<u>20MG</u>	<u>N018487</u>	<u>001</u>	
<u>AB</u>		<u>40MG</u>	<u>N018487</u>	<u>002</u>	
<u>AB</u>		<u>80MG</u>	<u>A070082</u>	<u>001</u>	Oct 29, 1986
<u>AB</u>	ROXANE	<u>20MG</u>	<u>N018823</u>	<u>001</u>	Nov 10, 1983
<u>AB</u>		<u>40MG</u>	<u>N018823</u>	<u>002</u>	Nov 10, 1983
<u>AB</u>	SANDOZ	<u>20MG</u>	<u>N018569</u>	<u>002</u>	
<u>AB</u>		<u>40MG</u>	<u>N018569</u>	<u>001</u>	
<u>AB</u>		<u>80MG</u>	<u>N018569</u>	<u>005</u>	Aug 14, 1984
<u>AB</u>	SUN PHARM INDS INC	<u>20MG</u>	<u>A091258</u>	<u>001</u>	Apr 01, 2014
<u>AB</u>		<u>40MG</u>	<u>A091258</u>	<u>002</u>	Apr 01, 2014
<u>AB</u>		<u>80MG</u>	<u>A091258</u>	<u>003</u>	Apr 01, 2014
<u>AB</u>	VINTAGE PHARMS	<u>20MG</u>	<u>A076796</u>	<u>001</u>	Mar 26, 2004
<u>AB</u>		<u>40MG</u>	<u>A076796</u>	<u>002</u>	Mar 26, 2004
<u>AB</u>		<u>80MG</u>	<u>A076796</u>	<u>003</u>	Mar 26, 2004
<u>AB</u>	WEST-WARD PHARMS INT	<u>80MG</u>	<u>A070086</u>	<u>001</u>	Jan 24, 1986

LASIX

<u>AB</u>	US PHARM HOLDINGS	<u>20MG</u>	<u>N016273</u>	<u>002</u>	
<u>AB</u>		<u>40MG</u>	<u>N016273</u>	<u>001</u>	
<u>AB</u>	+	<u>80MG</u>	<u>N016273</u>	<u>003</u>	

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

<u>AB</u>	ACTAVIS ELIZABETH	<u>100MG</u>	<u>A075350</u>	<u>001</u>	Sep 12, 2003
<u>AB</u>		<u>300MG</u>	<u>A075350</u>	<u>002</u>	Sep 12, 2003
<u>AB</u>		<u>400MG</u>	<u>A075350</u>	<u>003</u>	Sep 12, 2003
<u>AB</u>	ALKEM	<u>100MG</u>	<u>A090858</u>	<u>001</u>	Dec 17, 2010
<u>AB</u>		<u>300MG</u>	<u>A090858</u>	<u>002</u>	Dec 17, 2010
<u>AB</u>		<u>400MG</u>	<u>A090858</u>	<u>003</u>	Dec 17, 2010
<u>AB</u>	AMNEAL PHARMS NY	<u>100MG</u>	<u>A078428</u>	<u>001</u>	Jul 25, 2007
<u>AB</u>		<u>300MG</u>	<u>A078428</u>	<u>002</u>	Jul 25, 2007
<u>AB</u>		<u>400MG</u>	<u>A078428</u>	<u>003</u>	Jul 25, 2007
<u>AB</u>	APOTEX INC	<u>100MG</u>	<u>A075360</u>	<u>001</u>	Apr 06, 2005
<u>AB</u>		<u>300MG</u>	<u>A075360</u>	<u>002</u>	Apr 06, 2005
<u>AB</u>		<u>400MG</u>	<u>A075360</u>	<u>003</u>	Apr 06, 2005
<u>AB</u>	AUROBINDO PHARM	<u>100MG</u>	<u>A078787</u>	<u>001</u>	Jan 31, 2008
<u>AB</u>		<u>300MG</u>	<u>A078787</u>	<u>002</u>	Jan 31, 2008
<u>AB</u>		<u>400MG</u>	<u>A078787</u>	<u>003</u>	Jan 31, 2008
<u>AB</u>	INVAGEN PHARMS	<u>100MG</u>	<u>A090705</u>	<u>001</u>	Dec 30, 2009
<u>AB</u>		<u>300MG</u>	<u>A090705</u>	<u>002</u>	Dec 30, 2009
<u>AB</u>		<u>400MG</u>	<u>A090705</u>	<u>003</u>	Dec 30, 2009
<u>AB</u>	MARKSANS PHARMA	<u>100MG</u>	<u>A090007</u>	<u>001</u>	Jul 21, 2011
<u>AB</u>		<u>300MG</u>	<u>A090007</u>	<u>002</u>	Jul 21, 2011

PRESCRIPTION DRUG PRODUCT LIST

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

<u>AB</u>		<u>400MG</u>	<u>A090007</u>	<u>003</u>	Jul 21, 2011
<u>AB</u>	MYLAN	<u>100MG</u>	<u>A090158</u>	<u>001</u>	Feb 14, 2011
<u>AB</u>		<u>300MG</u>	<u>A090158</u>	<u>002</u>	Feb 14, 2011
<u>AB</u>		<u>400MG</u>	<u>A090158</u>	<u>003</u>	Feb 14, 2011
<u>AB</u>	SCIEGEN PHARMS INC	<u>100MG</u>	<u>A204989</u>	<u>001</u>	Feb 18, 2016
<u>AB</u>		<u>300MG</u>	<u>A204989</u>	<u>002</u>	Feb 18, 2016
<u>AB</u>		<u>400MG</u>	<u>A204989</u>	<u>003</u>	Feb 18, 2016
<u>AB</u>	SUN PHARM INDS LTD	<u>100MG</u>	<u>A077242</u>	<u>001</u>	Aug 24, 2006
<u>AB</u>		<u>300MG</u>	<u>A077242</u>	<u>002</u>	Aug 24, 2006
<u>AB</u>		<u>400MG</u>	<u>A077242</u>	<u>003</u>	Aug 24, 2006
<u>AB</u>	TARO	<u>100MG</u>	<u>A077261</u>	<u>001</u>	Aug 02, 2013
<u>AB</u>		<u>300MG</u>	<u>A077261</u>	<u>002</u>	Aug 02, 2013
<u>AB</u>		<u>400MG</u>	<u>A077261</u>	<u>003</u>	Aug 02, 2013
<u>AB</u>	TEVA PHARMS	<u>100MG</u>	<u>A075435</u>	<u>001</u>	Oct 08, 2004
<u>AB</u>		<u>300MG</u>	<u>A075435</u>	<u>002</u>	Oct 08, 2004
<u>AB</u>		<u>400MG</u>	<u>A075435</u>	<u>003</u>	Oct 08, 2004

NEURONTIN

<u>AB</u>	PFIZER PHARMS	<u>100MG</u>	<u>N020235</u>	<u>001</u>	Dec 30, 1993
<u>AB</u>		<u>300MG</u>	<u>N020235</u>	<u>002</u>	Dec 30, 1993
<u>AB</u>	+	<u>400MG</u>	<u>N020235</u>	<u>003</u>	Dec 30, 1993

SOLUTION; ORAL

GABAPENTIN

<u>AA</u>	ACELLA PHARMS LLC	<u>250MG/5ML</u>	<u>A076403</u>	<u>001</u>	May 01, 2012
<u>AA</u>	AMNEAL PHARMS	<u>250MG/5ML</u>	<u>A202024</u>	<u>001</u>	Mar 23, 2012
<u>AA</u>	HI TECH PHARMA	<u>250MG/5ML</u>	<u>A078974</u>	<u>001</u>	Feb 18, 2011
<u>AA</u>	TARO	<u>250MG/5ML</u>	<u>A076672</u>	<u>001</u>	Jul 03, 2013
<u>AA</u>	TRIS PHARMA INC	<u>250MG/5ML</u>	<u>A091286</u>	<u>001</u>	Mar 14, 2016

NEURONTIN

<u>AA</u>	+	PARKE DAVIS	<u>250MG/5ML</u>	<u>N021129</u>	<u>001</u>	Mar 02, 2000
-----------	---	-------------	------------------	----------------	------------	--------------

TABLET; ORAL

GABAPENTIN

<u>AB</u>	ACI HEALTHCARE LTD	<u>600MG</u>	<u>A203244</u>	<u>002</u>	Jul 12, 2013
<u>AB</u>		<u>800MG</u>	<u>A203244</u>	<u>001</u>	Jul 12, 2013
<u>AB</u>	ACTAVIS ELIZABETH	<u>600MG</u>	<u>A075694</u>	<u>001</u>	Oct 21, 2004
<u>AB</u>		<u>800MG</u>	<u>A075694</u>	<u>002</u>	Oct 21, 2004
<u>AB</u>	ALKEM LABS LTD	<u>600MG</u>	<u>A206402</u>	<u>001</u>	Dec 23, 2015
<u>AB</u>		<u>800MG</u>	<u>A206402</u>	<u>002</u>	Dec 23, 2015
<u>AB</u>	APOTEX INC	<u>100MG</u>	<u>A077894</u>	<u>001</u>	Oct 10, 2006
<u>AB</u>		<u>300MG</u>	<u>A077894</u>	<u>002</u>	Oct 10, 2006
<u>AB</u>		<u>400MG</u>	<u>A077894</u>	<u>003</u>	Oct 10, 2006
<u>AB</u>		<u>600MG</u>	<u>A077661</u>	<u>004</u>	Sep 13, 2006
<u>AB</u>		<u>800MG</u>	<u>A077661</u>	<u>005</u>	Sep 13, 2006
<u>AB</u>	AUROBINDO PHARMA LTD	<u>600MG</u>	<u>A200651</u>	<u>001</u>	Oct 06, 2011
<u>AB</u>		<u>800MG</u>	<u>A200651</u>	<u>002</u>	Oct 06, 2011
<u>AB</u>	GLENMARK GENERICS	<u>600MG</u>	<u>A077662</u>	<u>001</u>	Aug 18, 2006
<u>AB</u>		<u>800MG</u>	<u>A077662</u>	<u>002</u>	Aug 18, 2006
<u>AB</u>	INVAGEN PHARMS	<u>600MG</u>	<u>A202764</u>	<u>001</u>	Oct 16, 2012
<u>AB</u>		<u>800MG</u>	<u>A202764</u>	<u>002</u>	Oct 16, 2012
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>100MG</u>	<u>A076017</u>	<u>001</u>	Apr 28, 2004
<u>AB</u>		<u>300MG</u>	<u>A076017</u>	<u>002</u>	Apr 28, 2004
<u>AB</u>		<u>400MG</u>	<u>A076017</u>	<u>003</u>	Apr 28, 2004
<u>AB</u>		<u>600MG</u>	<u>A076017</u>	<u>004</u>	Apr 29, 2005
<u>AB</u>		<u>800MG</u>	<u>A076017</u>	<u>005</u>	Apr 29, 2005
<u>AB</u>	MYLAN PHARMS INC	<u>600MG</u>	<u>A090335</u>	<u>001</u>	Jun 01, 2010
<u>AB</u>		<u>800MG</u>	<u>A090335</u>	<u>002</u>	Jun 01, 2010
<u>AB</u>	SCIEGEN PHARMS INC	<u>600MG</u>	<u>A205101</u>	<u>001</u>	Feb 04, 2016
<u>AB</u>		<u>800MG</u>	<u>A205101</u>	<u>002</u>	Feb 04, 2016
<u>AB</u>	SUN PHARM INDS LTD	<u>600MG</u>	<u>A077525</u>	<u>001</u>	Aug 24, 2006
<u>AB</u>		<u>800MG</u>	<u>A077525</u>	<u>002</u>	Aug 24, 2006
<u>AB</u>	ZYDUS PHARMS USA INC	<u>600MG</u>	<u>A078926</u>	<u>001</u>	Feb 11, 2011
<u>AB</u>		<u>800MG</u>	<u>A078926</u>	<u>002</u>	Feb 11, 2011

NEURONTIN

<u>AB</u>	PFIZER PHARMS	<u>600MG</u>	<u>N020882</u>	<u>001</u>	Oct 09, 1998
<u>AB</u>	+	<u>800MG</u>	<u>N020882</u>	<u>002</u>	Oct 09, 1998

GRALISE

BX	+	DEPOMED INC	300MG	N022544	001	Jan 28, 2011
BX	+		600MG	N022544	002	Jan 28, 2011

PRESCRIPTION DRUG PRODUCT LIST

GABAPENTIN ENACARBIL

TABLET, EXTENDED RELEASE; ORAL

HORIZANT

ARBOR PHARMS LLC	300MG	N022399 002	Dec 13, 2011
+	600MG	N022399 001	Apr 06, 2011

GADOBENATE DIMEGLUMINE

INJECTABLE; INTRAVENOUS

MULTIHANCE

+ BRACCO	2.645GM/5ML (529MG/ML)	N021357 001	Nov 23, 2004
+	5.29GM/10ML (529MG/ML)	N021357 002	Nov 23, 2004
+	7.935GM/15ML (529MG/ML)	N021357 003	Nov 23, 2004
+	10.58GM/20ML (529MG/ML)	N021357 004	Nov 23, 2004

MULTIHANCE MULTIPACK

+ BRACCO	26.45GM/50ML (529MG/ML)	N021358 001	Nov 23, 2004
+	52.9GM/100ML (529MG/ML)	N021358 002	Nov 23, 2004

GADOBUTROL

SOLUTION; INTRAVENOUS

GDAVIST

+ BAYER HLTHCARE	1.20944GM/2ML (604.72MG/ML)	N201277 006	Dec 18, 2013
+	4.5354GM/7.5ML (604.72MG/ML)	N201277 001	Mar 14, 2011
+	6.0472GM/10ML (604.72MG/ML)	N201277 002	Mar 14, 2011
+	9.0708GM/15ML (604.72MG/ML)	N201277 003	Mar 14, 2011
+	18.1416GM/30ML (604.72MG/ML)	N201277 004	Mar 14, 2011
+	39.3068GM/65ML (604.72MG/ML)	N201277 005	Mar 14, 2011

GADODIAMIDE

INJECTABLE; INJECTION

OMNISCAN

+ GE HEALTHCARE	287MG/ML	N020123 001	Jan 08, 1993
+	28.7GM/100ML (287MG/ML)	N022066 002	Sep 05, 2007

GADOPENTETATE DIMEGLUMINE

INJECTABLE; INJECTION

MAGNEVIST

+ BAYER HLTHCARE	469.01MG/ML	N019596 001	Jun 02, 1988
+	469.01MG/ML	N021037 001	Mar 10, 2000

GADOTERATE MEGLUMINE

SOLUTION; INTRAVENOUS

DOTAREM

+ GUERBET	37.69GM/100ML (376.9MG/ML)	N204781 001	Mar 20, 2013
+	3.769GM/10ML (376.9MG/ML)	N204781 002	Mar 20, 2013
+	5.6535GM/15ML (376.9MG/ML)	N204781 003	Mar 20, 2013
+	7.538GM/20ML (376.9MG/ML)	N204781 004	Mar 20, 2013

GADOTERIDOL

INJECTABLE; INJECTION

PROHANCE

+ BRACCO	279.3MG/ML	N020131 001	Nov 16, 1992
PROHANCE MULTIPACK			
+ BRACCO	279.3MG/ML	N021489 001	Oct 09, 2003

GADOVERSETAMIDE

INJECTABLE; INJECTION

OPTIMARK

+ LIEBEL-FLARSHEIM	1654.5MG/5ML (330.9MG/ML)	N020937 001	Dec 08, 1999
+	3309MG/10ML (330.9MG/ML)	N020937 002	Dec 08, 1999
+	4963.5MG/15ML (330.9MG/ML)	N020937 003	Dec 08, 1999
+	6618MG/20ML (330.9MG/ML)	N020937 004	Dec 08, 1999
+	16.545GM/50ML (330.9MG/ML)	N020975 001	Dec 08, 1999

OPTIMARK IN PLASTIC CONTAINER

+ LIEBEL-FLARSHEIM	3309MG/10ML (330.9MG/ML)	N020976 002	Dec 08, 1999
+	4963.5MG/15ML (330.9MG/ML)	N020976 003	Dec 08, 1999
+	6618MG/20ML (330.9MG/ML)	N020976 004	Dec 08, 1999
+	9927MG/30ML (330.9MG/ML)	N020976 001	Dec 08, 1999

GADOXETATE DISODIUM

SOLUTION; INTRAVENOUS

EOVIST

+ BAYER HLTHCARE	1.8143GM/10ML (181.43MG/ML)	N022090 001	Jul 03, 2008
	2.72145GM/15ML (181.43MG/ML)	N022090 002	Feb 04, 2013

PRESCRIPTION DRUG PRODUCT LIST

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL

GALANTAMINE HYDROBROMIDE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 8MG BASE</u>	<u>A204895 001</u>	Aug 05, 2016
<u>AB</u>		<u>EQ 16MG BASE</u>	<u>A204895 002</u>	Aug 05, 2016
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A204895 003</u>	Aug 05, 2016
<u>AB</u>	BARR	<u>EQ 8MG BASE</u>	<u>A078189 001</u>	Sep 15, 2008
<u>AB</u>		<u>EQ 16MG BASE</u>	<u>A078189 002</u>	Sep 15, 2008
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A078189 003</u>	Sep 15, 2008
<u>AB</u>	MYLAN	<u>EQ 8MG BASE</u>	<u>A090900 001</u>	Jan 24, 2011
<u>AB</u>		<u>EQ 16MG BASE</u>	<u>A090900 002</u>	Jan 24, 2011
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A090900 003</u>	Jan 24, 2011
<u>AB</u>	SUN PHARMA GLOBAL	<u>EQ 8MG BASE</u>	<u>A090178 001</u>	Feb 02, 2011
<u>AB</u>		<u>EQ 16MG BASE</u>	<u>A090178 002</u>	Feb 02, 2011
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A090178 003</u>	Feb 02, 2011
<u>AB</u>	WATSON LABS	<u>EQ 8MG BASE</u>	<u>A079028 001</u>	Dec 15, 2008
<u>AB</u>		<u>EQ 16MG BASE</u>	<u>A079028 002</u>	Dec 15, 2008
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A079028 003</u>	Dec 15, 2008
<u>RAZADYNE ER</u>				
<u>AB</u>	+ JANSSEN PHARMS	<u>EQ 8MG BASE</u>	<u>N021615 001</u>	Apr 01, 2005
<u>AB</u>		<u>EQ 16MG BASE</u>	<u>N021615 002</u>	Apr 01, 2005
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>N021615 003</u>	Apr 01, 2005

SOLUTION; ORAL

GALANTAMINE HYDROBROMIDE
+ WEST-WARD PHARMS INT

4MG/ML

A078185 001 Jan 30, 2009

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

<u>AB</u>	APOTEX INC	<u>EQ 4MG BASE</u>	<u>A077781 001</u>	Sep 27, 2011
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077781 002</u>	Sep 27, 2011
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A077781 003</u>	Sep 27, 2011
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 4MG BASE</u>	<u>A090957 001</u>	Mar 29, 2011
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A090957 002</u>	Mar 29, 2011
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A090957 003</u>	Mar 29, 2011
<u>AB</u>	BARR	<u>EQ 4MG BASE</u>	<u>A077605 001</u>	Aug 28, 2008
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077605 002</u>	Aug 28, 2008
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A077605 003</u>	Aug 28, 2008
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE</u>	<u>A077593 001</u>	Sep 11, 2008
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077593 002</u>	Sep 11, 2008
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A077593 003</u>	Sep 11, 2008
<u>AB</u>	MYLAN	<u>EQ 4MG BASE</u>	<u>A077590 001</u>	May 29, 2009
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A077603 001</u>	Aug 28, 2008
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077590 002</u>	May 29, 2009
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077603 002</u>	Aug 28, 2008
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A077590 003</u>	May 29, 2009
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A077603 003</u>	Aug 28, 2008
<u>AB</u>	SANDOZ	<u>EQ 4MG BASE</u>	<u>A077589 001</u>	Jun 22, 2009
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077589 002</u>	Jun 22, 2009
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A077589 003</u>	Jun 22, 2009
<u>AB</u>	TEVA PHARMS	<u>EQ 4MG BASE</u>	<u>A077587 001</u>	Jul 09, 2009
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077587 002</u>	Jul 09, 2009
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A077587 003</u>	Jul 09, 2009
<u>AB</u>	WEST-WARD PHARMS INT	<u>EQ 4MG BASE</u>	<u>A077608 001</u>	Feb 11, 2009
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077608 002</u>	Feb 11, 2009
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A077608 003</u>	Feb 11, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 4MG BASE</u>	<u>A078898 001</u>	Feb 17, 2011
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A078898 002</u>	Feb 17, 2011
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A078898 003</u>	Feb 17, 2011
<u>RAZADYNE</u>				
<u>AB</u>	+ JANSSEN PHARMS	<u>EQ 4MG BASE</u>	<u>N021169 001</u>	Feb 28, 2001
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>N021169 002</u>	Feb 28, 2001
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>N021169 003</u>	Feb 28, 2001

GALLIUM CITRATE GA-67

INJECTABLE; INJECTION

GALLIUM CITRATE GA 67

BS	LANTHEUS MEDCL	2mCi/ML	N017478 001	
BS	MALLINKRODT NUCLEAR	2mCi/ML	N018058 001	

PRESCRIPTION DRUG PRODUCT LIST

GALLIUM DOTATATE GA-68

POWDER; INTRAVENOUS

NETSPOT

+ AAA USA INC

2.1-5.5mCi/ML

N208547 001 Jun 01, 2016

GANCICLOVIR

GEL; OPHTHALMIC

ZIRGAN

+ BAUSCH AND LOMB

0.15%

N022211 001 Sep 15, 2009

GANCICLOVIR SODIUM

INJECTABLE; INJECTION

CYTOVENEAP + ROCHE PALOEQ 500MG BASE/VIALN019661 001 Jun 23, 1989GANCICLOVIRAP FRESENIUS KABI USAEQ 500MG BASE/VIALA090658 001 Jun 21, 2010AP LUITPOLD PHARMS INCEQ 500MG BASE/VIALA202624 001 Sep 18, 2013AP PAR STERILE PRODUCTSEQ 500MG BASE/VIALA204950 001 Dec 06, 2016GANIRELIX ACETATE

INJECTABLE; INJECTION

GANIRELIX ACETATE

+ ORGANON USA INC

EQ 250MCG BASE/0.5ML

N021057 001 Jul 29, 1999

GATIFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

GATIFLOXACINAT ALCON RES LTD0.5%A204227 001 Jul 11, 2016AT HI-TECH PHARMA CO0.5%A203189 001 Sep 03, 2014AT LUPIN LTD0.5%A202653 001 Aug 28, 2013ZYMAXIDAT + ALLERGAN0.5%N022548 001 May 18, 2010

ZYMAR

+ ALLERGAN

0.3%

N021493 001 Mar 28, 2003

GEFITINIB

TABLET; ORAL

IRESSA

+ ASTRAZENECA PHARMS

250MG

N206995 001 Jul 13, 2015

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDEAP ACCORD HLTHCAREEQ 200MG BASE/VIALA091594 001 Jul 25, 2011APEQ 1GM BASE/VIALA091594 002 Jul 25, 2011APEQ 2GM BASE/VIALA091594 003 Jul 25, 2011AP ACTAVIS INC200MG/5.26ML (38MG/ML)A204549 001 Apr 11, 2016AP1GM/26.3ML (38MG/ML)A204549 002 Apr 11, 2016AP2GM/52.6ML (38MG/ML)A204549 003 Apr 11, 2016AP ACTAVIS TOTOWAEQ 200MG BASE/VIALA079160 001 Jul 25, 2011APEQ 1GM BASE/VIALA079160 002 Jul 25, 2011AP CIPLA LTDEQ 200MG BASE/VIALA078759 001 Jul 25, 2011APEQ 1GM BASE/VIALA078759 002 Jul 25, 2011AP DR REDDYS LABS LTDEQ 200MG BASE/VIALA091365 001 Jul 25, 2011APEQ 1GM BASE/VIALA091365 002 Jul 25, 2011APEQ 2GM BASE/VIALA202997 001 May 07, 2013AP EMCURE PHARMS LTDEQ 200MG BASE/VIALA202063 001 Sep 11, 2012APEQ 1GM BASE/VIALA202063 002 Sep 11, 2012AP FRESENIUS KABI ONCOLEQ 200MG BASE/VIALA090799 001 Jul 25, 2011APEQ 1GM BASE/VIALA090799 002 Jul 25, 2011APEQ 2GM BASE/VIALA090799 003 May 16, 2011AP FRESENIUS KABI USAEQ 2GM BASE/VIALA090242 003 May 16, 2011APEQ 200MG BASE/VIALA204520 001 Jan 05, 2016APEQ 1GM BASE/VIALA204520 002 Jan 05, 2016AP HAMELN RDS GMBHEQ 200MG BASE/VIALA090663 001 Sep 10, 2012APEQ 1GM BASE/VIALA090663 002 Sep 10, 2012AP HOSPIRAEQ 200MG BASE/VIALA078339 001 Jul 25, 2011APEQ 1GM BASE/VIALA078339 002 Jul 25, 2011AP + HOSPIRA INC200MG/5.26ML (38MG/ML)N200795 001 Aug 04, 2011AP +1GM/26.3ML (38MG/ML)N200795 002 Aug 04, 2011AP +EQ 2GM BASE/VIALA079183 001 Nov 15, 2010AP +2GM/52.6ML (38MG/ML)N200795 003 Aug 04, 2011AP JIANGSU HANSON PHARMEQ 200MG BASE/VIALA202485 001 May 07, 2013APEQ 1GM BASE/VIALA202485 002 May 07, 2013AP LUITPOLD PHARMS INCEQ 200MG BASE/VIALA202031 001 May 07, 2013

PRESCRIPTION DRUG PRODUCT LIST

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A202031 002</u>	May 07, 2013
<u>AP</u>	MYLAN LABS LTD	<u>EQ 200MG BASE/VIAL</u>	<u>A200145 001</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A200145 002</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A200145 003</u>	Jul 25, 2011
<u>AP</u>	SAGENT PHARMS	<u>EQ 200MG BASE/VIAL</u>	<u>A091597 001</u>	May 07, 2013
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A091597 002</u>	May 07, 2013
<u>AP</u>	SUN PHARMA GLOBAL	<u>EQ 200MG BASE/VIAL</u>	<u>A078433 001</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A078433 002</u>	Jul 25, 2011
<u>AP</u>	TEVA PHARMS	<u>EQ 200MG BASE/VIAL</u>	<u>A077983 002</u>	Jan 25, 2011
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A077983 001</u>	Jan 25, 2011
<u>GEMZAR</u>				
<u>AP</u>	+ LILLY	<u>EQ 200MG BASE/VIAL</u>	<u>N020509 001</u>	May 15, 1996
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>N020509 002</u>	May 15, 1996

GEMFIBROZIL

TABLET; ORAL

GEMFIBROZIL

<u>AB</u>	APOTEX	<u>600MG</u>	<u>A075034 001</u>	Jul 20, 1998
<u>AB</u>	AUROBINDO PHARMA LTD	<u>600MG</u>	<u>A202726 001</u>	Sep 16, 2015
<u>AB</u>	BLU CARIBE	<u>600MG</u>	<u>A078012 001</u>	Mar 26, 2007
<u>AB</u>	CADILA PHARMS LTD	<u>600MG</u>	<u>A203266 001</u>	Jun 17, 2016
<u>AB</u>	CHARTWELL MOLECULES	<u>600MG</u>	<u>A074270 001</u>	Sep 27, 1993
<u>AB</u>	HIKMA PHARMS	<u>600MG</u>	<u>A078599 001</u>	Aug 16, 2010
<u>AB</u>	IMPAX PHARMS	<u>600MG</u>	<u>A078207 001</u>	Jun 01, 2007
<u>AB</u>	INVAGEN PHARMS	<u>600MG</u>	<u>A077836 001</u>	Jul 27, 2006
<u>AB</u>	NORTHSTAR HLTHCARE	<u>600MG</u>	<u>A079072 001</u>	Sep 13, 2010
<u>AB</u>	SUN PHARM INDS INC	<u>600MG</u>	<u>A079239 001</u>	Dec 29, 2008
<u>AB</u>	TEVA	<u>600MG</u>	<u>A074256 001</u>	Oct 31, 1993
<u>LOPID</u>				
<u>AB</u>	+ PFIZER PHARMS	<u>600MG</u>	<u>N018422 003</u>	Nov 20, 1986

GEMIFLOXACIN MESYLATE

TABLET; ORAL

FACTIVE

<u>AB</u>	+ LG LIFE SCIENCES	<u>EQ 320MG BASE</u>	<u>N021158 001</u>	Apr 04, 2003
<u>GEMIFLOXACIN MESYLATE</u>				
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 320MG BASE</u>	<u>A090466 001</u>	Jun 15, 2015

GENTAMICIN SULFATE

CREAM; TOPICAL

GENTAMICIN SULFATE

<u>AT</u>	+ FOUGERA	<u>EQ 0.1% BASE</u>	<u>A062531 001</u>	Jul 05, 1984
<u>AT</u>	G AND W LABS INC	<u>EQ 0.1% BASE</u>	<u>A064056 001</u>	Apr 29, 1994
<u>AT</u>	PERRIGO NEW YORK	<u>EQ 0.1% BASE</u>	<u>A062307 001</u>	
<u>AT</u>	TARO	<u>EQ 0.1% BASE</u>	<u>A062427 001</u>	May 26, 1983

INJECTABLE; INJECTION

GENTAMICIN SULFATE

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 10MG BASE/ML</u>	<u>A062366 002</u>	Feb 06, 1986
<u>AP</u>	+	<u>EQ 40MG BASE/ML</u>	<u>A062366 001</u>	Aug 04, 1983
<u>AP</u>	HOSPIRA	<u>EQ 10MG BASE/ML</u>	<u>A062420 001</u>	Aug 15, 1983
<u>AP</u>		<u>EQ 10MG BASE/ML</u>	<u>A062612 004</u>	Feb 20, 1986
<u>AP</u>		<u>EQ 40MG BASE/ML</u>	<u>A062420 002</u>	Aug 15, 1983

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE	<u>EQ 1.2MG BASE/ML</u>	<u>A062373 007</u>	Sep 07, 1982
<u>AP</u>		<u>EQ 1.6MG BASE/ML</u>	<u>A062373 008</u>	Sep 07, 1982
<u>AP</u>		<u>EQ 80MG BASE/100ML</u>	<u>A062373 002</u>	Sep 07, 1982
<u>AP</u>		<u>EQ 100MG BASE/100ML</u>	<u>A062373 005</u>	Sep 07, 1982
<u>AP</u>	HOSPIRA	<u>EQ 1.2MG BASE/ML</u>	<u>A062414 001</u>	Aug 15, 1983
<u>AP</u>		<u>EQ 1.6MG BASE/ML</u>	<u>A062414 003</u>	Aug 15, 1983
<u>AP</u>		<u>EQ 80MG BASE/100ML</u>	<u>A062414 008</u>	Aug 15, 1983
<u>AP</u>		<u>EQ 100MG BASE/100ML</u>	<u>A062414 010</u>	Aug 15, 1983
	+ BAXTER HLTHCARE	<u>EQ 2MG BASE/ML</u>	<u>A062373 009</u>	Sep 07, 1982
	+	<u>EQ 120MG BASE/100ML</u>	<u>A062373 006</u>	Sep 07, 1982

OINTMENT; OPHTHALMIC

GENTAMICIN SULFATE

<u>AT</u>	+ AKORN	<u>EQ 0.3% BASE</u>	<u>A064093 001</u>	Aug 31, 1995
<u>AT</u>	PERRIGO CO TENNESSEE	<u>EQ 0.3% BASE</u>	<u>A065024 001</u>	Jul 30, 2004

OINTMENT; TOPICAL

GENTAMICIN SULFATE

<u>AT</u>	FOUGERA	<u>EQ 0.1% BASE</u>	<u>A062533 001</u>	Oct 05, 1984
<u>AT</u>	+ PERRIGO NEW YORK	<u>EQ 0.1% BASE</u>	<u>A062351 001</u>	Feb 18, 1982

PRESCRIPTION DRUG PRODUCT LIST

GENTAMICIN SULFATE

OINTMENT; TOPICAL

GENTAMICIN SULFATE

AT TARO **EQ 0.1% BASE** **A062477 001** Dec 23, 1983
SOLUTION/DROPS; OPHTHALMIC

GENOPTIC

AT ALLERGAN **EQ 0.3% BASE** **A062452 001** Oct 10, 1984

GENTAK

AT AKORN **EQ 0.3% BASE** **A064163 001** Oct 12, 2001

GENTAMICIN SULFATE

AT AKORN **EQ 0.3% BASE** **A062635 001** Jan 08, 1987

AT ALCON RES LTD **EQ 0.3% BASE** **A062196 001**

AT + BAUSCH AND LOMB **EQ 0.3% BASE** **A064048 001** May 11, 1994

AT PERRIGO CO TENNESSEE **EQ 0.3% BASE** **A065121 001** Jan 30, 2004

GENTAMICIN SULFATE; PREDNISOLONE ACETATE

OINTMENT; OPHTHALMIC

PRED-G

+ ALLERGAN **EQ 0.3% BASE; 0.6%** N050612 001 Dec 01, 1989

SUSPENSION/DROPS; OPHTHALMIC

PRED-G

+ ALLERGAN **EQ 0.3% BASE; 1%** N050586 001 Jun 10, 1988

GLATIRAMER ACETATE

INJECTABLE; SUBCUTANEOUS

COPAXONE

AP + TEVA PHARMS USA **20MG/ML** **N020622 002** Feb 12, 2002

GLATOPIA

AP SANDOZ INC **20MG/ML** **A090218 001** Apr 16, 2015

COPAXONE

+ TEVA PHARMS USA 40MG/ML N020622 003 Jan 28, 2014

GLIMEPIRIDE

TABLET; ORAL

AMARYL

AB + SANOFI AVENTIS US **1MG** **N020496 001** Nov 30, 1995

AB **2MG** **N020496 002** Nov 30, 1995

AB **4MG** **N020496 003** Nov 30, 1995

GLIMEPIRIDE

AB ACCORD HLTHCARE **1MG** **A078181 001** Aug 23, 2007

AB **2MG** **A078181 002** Aug 23, 2007

AB **4MG** **A078181 003** Aug 23, 2007

AB AUROBINDO PHARMA LTD **1MG** **A202759 001** Jun 29, 2012

AB **2MG** **A202759 002** Jun 29, 2012

AB **4MG** **A202759 003** Jun 29, 2012

AB CARLSBAD **1MG** **A077911 001** Sep 22, 2009

AB **2MG** **A077911 002** Sep 22, 2009

AB **4MG** **A077911 003** Sep 22, 2009

AB DR REDDYS LABS LTD **1MG** **A077091 001** Oct 06, 2005

AB **2MG** **A077091 002** Oct 06, 2005

AB **4MG** **A077091 003** Oct 06, 2005

AB INDOCO REMEDIES **1MG** **A202112 001** Apr 17, 2013

AB **2MG** **A202112 002** Apr 17, 2013

AB **4MG** **A202112 003** Apr 17, 2013

AB INVAGEN PHARMS **1MG** **A077295 001** Oct 06, 2005

AB **2MG** **A077295 002** Oct 06, 2005

AB **4MG** **A077295 003** Oct 06, 2005

AB MICRO LABS LTD INDIA **1MG** **A091220 001** Jun 29, 2012

AB **2MG** **A091220 002** Jun 29, 2012

AB **4MG** **A091220 004** Jun 29, 2012

AB **8MG** **A091220 006** Jun 29, 2012

AB MYLAN **1MG** **A077624 001** Nov 28, 2005

AB **2MG** **A077624 002** Nov 28, 2005

AB **4MG** **A077624 003** Nov 28, 2005

AB TEVA **1MG** **A076802 001** Oct 06, 2005

AB **2MG** **A076802 002** Oct 06, 2005

AB **4MG** **A076802 003** Oct 06, 2005

AB VINTAGE **1MG** **A077370 001** Dec 23, 2005

AB **2MG** **A077370 002** Dec 23, 2005

AB **4MG** **A077370 003** Dec 23, 2005

AB **8MG** **A077370 004** Dec 23, 2005

MICRO LABS LTD INDIA 3MG A091220 003 Jun 29, 2012

6MG A091220 005 Jun 29, 2012

PRESCRIPTION DRUG PRODUCT LIST

GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

DUETACT

<u>AB</u>	+	TAKEDA PHARMS USA	<u>2MG;30MG</u>	<u>N021925</u>	<u>001</u>	Jul 28, 2006
<u>AB</u>			<u>4MG;30MG</u>	<u>N021925</u>	<u>002</u>	Jul 28, 2006

PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE

<u>AB</u>		SANDOZ	<u>2MG;30MG</u>	<u>A201049</u>	<u>001</u>	Jan 04, 2013
<u>AB</u>			<u>4MG;30MG</u>	<u>A201049</u>	<u>002</u>	Jan 04, 2013

GLIMEPIRIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

ROSIGLITAZONE MALEATE AND GLIMEPIRIDE

+	TEVA PHARMS USA	1MG;4MG	A078709	001	Apr 01, 2016
		2MG;4MG	A078709	002	Apr 01, 2016
		2MG;8MG	A078709	004	Apr 01, 2016
		4MG;4MG	A078709	003	Apr 01, 2016
		4MG;8MG	A078709	005	Apr 01, 2016

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

<u>AB</u>		ACCORD HLTHCARE	<u>5MG</u>	<u>A074550</u>	<u>001</u>	Sep 11, 1997
<u>AB</u>			<u>10MG</u>	<u>A074550</u>	<u>002</u>	Sep 11, 1997
<u>AB</u>		ANI PHARMS INC	<u>5MG</u>	<u>A074497</u>	<u>001</u>	Aug 31, 1995
<u>AB</u>			<u>10MG</u>	<u>A074497</u>	<u>002</u>	Aug 31, 1995
<u>AB</u>		APOTEX	<u>5MG</u>	<u>A075795</u>	<u>001</u>	Jun 13, 2001
<u>AB</u>			<u>10MG</u>	<u>A075795</u>	<u>002</u>	Jun 13, 2001
<u>AB</u>		MYLAN	<u>5MG</u>	<u>A074226</u>	<u>001</u>	May 10, 1994
<u>AB</u>			<u>5MG</u>	<u>A074438</u>	<u>001</u>	Jun 20, 1995
<u>AB</u>			<u>10MG</u>	<u>A074226</u>	<u>002</u>	May 10, 1994
<u>AB</u>			<u>10MG</u>	<u>A074438</u>	<u>002</u>	Jun 20, 1995
<u>AB</u>		SANDOZ	<u>5MG</u>	<u>A074305</u>	<u>001</u>	Apr 07, 1995
<u>AB</u>			<u>10MG</u>	<u>A074305</u>	<u>002</u>	Apr 07, 1995
<u>AB</u>		SUN PHARM INDS INC	<u>5MG</u>	<u>A077820</u>	<u>001</u>	Jul 11, 2006
<u>AB</u>			<u>10MG</u>	<u>A077820</u>	<u>002</u>	Jul 11, 2006
<u>AB</u>		WATSON LABS	<u>5MG</u>	<u>A074223</u>	<u>001</u>	Feb 27, 1995
<u>AB</u>			<u>10MG</u>	<u>A074223</u>	<u>002</u>	Feb 27, 1995

GLUCOTROL

<u>AB</u>		PFIZER	<u>5MG</u>	<u>N017783</u>	<u>001</u>	May 08, 1984
<u>AB</u>	+		<u>10MG</u>	<u>N017783</u>	<u>002</u>	May 08, 1984

TABLET, EXTENDED RELEASE; ORAL

GLIPIZIDE

<u>AB</u>		MYLAN PHARMS INC	<u>2.5MG</u>	<u>A202298</u>	<u>001</u>	May 19, 2015
<u>AB</u>			<u>5MG</u>	<u>A202298</u>	<u>002</u>	May 19, 2015
<u>AB</u>			<u>10MG</u>	<u>A202298</u>	<u>003</u>	May 19, 2015
<u>AB</u>		PAR PHARM	<u>5MG</u>	<u>A076159</u>	<u>002</u>	Sep 20, 2013
<u>AB</u>			<u>10MG</u>	<u>A076159</u>	<u>001</u>	Sep 20, 2013
<u>AB</u>		UNIQUE PHARM LABS	<u>2.5MG</u>	<u>A204720</u>	<u>001</u>	Dec 29, 2016
<u>AB</u>			<u>5MG</u>	<u>A204720</u>	<u>002</u>	Dec 29, 2016
<u>AB</u>			<u>10MG</u>	<u>A204720</u>	<u>003</u>	Dec 29, 2016
<u>AB</u>		WATSON LABS	<u>2.5MG</u>	<u>A076467</u>	<u>003</u>	Mar 27, 2006
<u>AB</u>			<u>5MG</u>	<u>A076467</u>	<u>001</u>	Sep 08, 2003
<u>AB</u>			<u>10MG</u>	<u>A076467</u>	<u>002</u>	Nov 07, 2003

GLUCOTROL XL

<u>AB</u>		PFIZER	<u>2.5MG</u>	<u>N020329</u>	<u>003</u>	Aug 10, 1999
<u>AB</u>			<u>5MG</u>	<u>N020329</u>	<u>001</u>	Apr 26, 1994
<u>AB</u>	+		<u>10MG</u>	<u>N020329</u>	<u>002</u>	Apr 26, 1994

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

<u>AB</u>		COREPHARMA	<u>2.5MG;250MG</u>	<u>A077507</u>	<u>001</u>	Oct 27, 2005
<u>AB</u>			<u>2.5MG;500MG</u>	<u>A077507</u>	<u>002</u>	Oct 27, 2005
<u>AB</u>			<u>5MG;500MG</u>	<u>A077507</u>	<u>003</u>	Oct 27, 2005
<u>AB</u>		HERITAGE PHARMS INC	<u>2.5MG;250MG</u>	<u>A078728</u>	<u>001</u>	Jun 23, 2010
<u>AB</u>			<u>2.5MG;500MG</u>	<u>A078728</u>	<u>002</u>	Jun 23, 2010
<u>AB</u>			<u>5MG;500MG</u>	<u>A078728</u>	<u>003</u>	Jun 23, 2010
<u>AB</u>		MYLAN	<u>2.5MG;250MG</u>	<u>A078083</u>	<u>001</u>	Apr 12, 2007
<u>AB</u>			<u>2.5MG;500MG</u>	<u>A078083</u>	<u>002</u>	Apr 12, 2007
<u>AB</u>			<u>5MG;500MG</u>	<u>A078083</u>	<u>003</u>	Apr 12, 2007
<u>AB</u>		SUN PHARM INDS INC	<u>2.5MG;250MG</u>	<u>A077620</u>	<u>001</u>	Jan 11, 2008
<u>AB</u>			<u>2.5MG;500MG</u>	<u>A077620</u>	<u>002</u>	Jan 11, 2008
<u>AB</u>			<u>5MG;500MG</u>	<u>A077620</u>	<u>003</u>	Jan 11, 2008
<u>AB</u>		TEVA PHARMS	<u>2.5MG;250MG</u>	<u>A077270</u>	<u>001</u>	Oct 28, 2005

PRESCRIPTION DRUG PRODUCT LIST

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

<u>AB</u>		<u>2.5MG;500MG</u>	<u>A077270 002</u>	Oct 28, 2005
<u>AB</u>	+	<u>5MG;500MG</u>	<u>A077270 003</u>	Oct 28, 2005
<u>AB</u>	ZYDUS PHARMS USA INC	<u>2.5MG;250MG</u>	<u>A078905 001</u>	Jan 31, 2011
<u>AB</u>		<u>2.5MG;500MG</u>	<u>A078905 002</u>	Jan 31, 2011
<u>AB</u>		<u>5MG;500MG</u>	<u>A078905 003</u>	Jan 31, 2011

GLUCAGON HYDROCHLORIDE

POWDER; INTRAMUSCULAR, INTRAVENOUS

GLUCAGON

+	FRESENIUS KABI USA	EQ 1MG BASE/VIAL	N201849 001	May 08, 2015
---	--------------------	------------------	-------------	--------------

GLUCAGON HYDROCHLORIDE RECOMBINANT

INJECTABLE; INJECTION

GLUCAGEN

+	NOVO NORDISK	EQ 1MG BASE/VIAL	N020918 001	Jun 22, 1998
---	--------------	------------------	-------------	--------------

GLUCAGON RECOMBINANT

INJECTABLE; INJECTION

GLUCAGON

+	LILLY	1MG/VIAL	N020928 001	Sep 11, 1998
---	-------	----------	-------------	--------------

GLUTAMINE

FOR SOLUTION; ORAL

NUTRESTORE

+	EMMAUS MEDCL	5GM/PACKET	N021667 001	Jun 10, 2004
---	--------------	------------	-------------	--------------

GLYBURIDE

TABLET; ORAL

GLYBURIDE (MICRONIZED)

<u>AB</u>	DAVA PHARMS INC	<u>1.5MG</u>	<u>A074591 001</u>	Dec 22, 1997
<u>AB</u>		<u>3MG</u>	<u>A074591 002</u>	Dec 22, 1997
<u>AB</u>		<u>4.5MG</u>	<u>A074591 003</u>	Dec 22, 1997
<u>AB</u>		<u>6MG</u>	<u>A074591 004</u>	Dec 22, 1997
<u>AB</u>	HIKMA	<u>1.5MG</u>	<u>A075890 001</u>	Jul 31, 2003
<u>AB</u>		<u>3MG</u>	<u>A075890 002</u>	Jul 31, 2003
<u>AB</u>		<u>6MG</u>	<u>A075890 003</u>	Jul 31, 2003
<u>AB</u>	MYLAN	<u>1.5MG</u>	<u>A074792 001</u>	Jun 26, 1998
<u>AB</u>		<u>3MG</u>	<u>A074792 002</u>	Jun 26, 1998
<u>AB</u>		<u>6MG</u>	<u>A074792 003</u>	Aug 17, 1999
<u>AB</u>	TEVA	<u>1.5MG</u>	<u>A074686 001</u>	Apr 20, 1999
<u>AB</u>		<u>3MG</u>	<u>A074686 002</u>	Apr 20, 1999
<u>AB</u>		<u>4.5MG</u>	<u>A074686 003</u>	Apr 20, 1999
<u>AB</u>		<u>6MG</u>	<u>A074686 004</u>	Apr 20, 1999

GLYNASE

<u>AB</u>	PHARMACIA AND UPJOHN	<u>1.5MG</u>	<u>N020051 001</u>	Mar 04, 1992
<u>AB</u>		<u>3MG</u>	<u>N020051 002</u>	Mar 04, 1992
<u>AB</u>	+	<u>6MG</u>	<u>N020051 004</u>	Sep 24, 1993

GLYBURIDE

<u>AB1</u>	AUROBINDO PHARMA	<u>1.25MG</u>	<u>A077537 001</u>	Oct 18, 2007
<u>AB1</u>		<u>2.5MG</u>	<u>A077537 002</u>	Oct 18, 2007
<u>AB1</u>		<u>5MG</u>	<u>A077537 003</u>	Oct 18, 2007
<u>AB1</u>	COREPHARMA	<u>1.25MG</u>	<u>A076257 001</u>	Jun 27, 2002
<u>AB1</u>		<u>2.5MG</u>	<u>A076257 002</u>	Jun 27, 2002
<u>AB1</u>		<u>5MG</u>	<u>A076257 003</u>	Jun 27, 2002
<u>AB1</u>	HERITAGE PHARMS INC	<u>1.25MG</u>	<u>A090937 001</u>	Feb 28, 2011
<u>AB1</u>		<u>2.5MG</u>	<u>A090937 002</u>	Feb 28, 2011
<u>AB1</u>		<u>5MG</u>	<u>A090937 003</u>	Feb 28, 2011
<u>AB1</u>	PHARMADAX INC	<u>1.25MG</u>	<u>A203581 001</u>	Apr 14, 2016
<u>AB1</u>		<u>2.5MG</u>	<u>A203581 002</u>	Apr 14, 2016
<u>AB1</u>		<u>5MG</u>	<u>A203581 003</u>	Apr 14, 2016
<u>AB1</u>	TEVA	<u>1.25MG</u>	<u>A074388 001</u>	Aug 29, 1995
<u>AB1</u>		<u>2.5MG</u>	<u>A074388 002</u>	Aug 29, 1995
<u>AB1</u>	+	<u>5MG</u>	<u>A074388 003</u>	Aug 29, 1995
<u>AB1</u>	ZYDUS PHARMS USA INC	<u>1.25mg</u>	<u>A206749 001</u>	May 10, 2016
<u>AB1</u>		<u>2.5mg</u>	<u>A206749 002</u>	May 10, 2016
<u>AB1</u>		<u>5MG</u>	<u>A206749 003</u>	May 10, 2016

DIABETA

<u>AB2</u>	SANOFI AVENTIS US	<u>1.25MG</u>	<u>N017532 001</u>	May 01, 1984
<u>AB2</u>		<u>2.5MG</u>	<u>N017532 002</u>	May 01, 1984
<u>AB2</u>	+	<u>5MG</u>	<u>N017532 003</u>	May 01, 1984

PRESCRIPTION DRUG PRODUCT LISTGLYBURIDE

TABLET; ORAL

GLYBURIDE

<u>AB2</u>	COREPHARMA	<u>1.25MG</u>	<u>A206079 001</u>	Sep 30, 2015
<u>AB2</u>		<u>2.5MG</u>	<u>A206079 002</u>	Sep 30, 2015
<u>AB2</u>		<u>5MG</u>	<u>A206079 003</u>	Sep 30, 2015

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLUCOVANCE

<u>AB</u>	+	BRISTOL MYERS SQUIBB	<u>2.5MG;500MG</u>	<u>N021178 002</u>	Jul 31, 2000
<u>AB</u>			<u>5MG;500MG</u>	<u>N021178 003</u>	Jul 31, 2000

GLYBURIDE AND METFORMIN HYDROCHLORIDE

<u>AB</u>		ACTAVIS ELIZABETH	<u>1.25MG;250MG</u>	<u>A076716 001</u>	Jun 28, 2005
<u>AB</u>			<u>2.5MG;500MG</u>	<u>A076716 002</u>	Jun 28, 2005
<u>AB</u>			<u>5MG;500MG</u>	<u>A076716 003</u>	Jun 28, 2005
<u>AB</u>		AUROBINDO PHARMA	<u>1.25MG;250MG</u>	<u>A077870 001</u>	Nov 14, 2007
<u>AB</u>			<u>2.5MG;500MG</u>	<u>A077870 002</u>	Nov 14, 2007
<u>AB</u>			<u>5MG;500MG</u>	<u>A077870 003</u>	Nov 14, 2007
<u>AB</u>		HERITAGE PHARMS INC	<u>1.25MG;250MG</u>	<u>A079009 001</u>	Jun 03, 2009
<u>AB</u>			<u>2.5MG;500MG</u>	<u>A079009 002</u>	Jun 03, 2009
<u>AB</u>			<u>5MG;500MG</u>	<u>A079009 003</u>	Jun 03, 2009
<u>AB</u>		IMPAX LABS INC	<u>1.25MG;250MG</u>	<u>A076345 001</u>	Feb 18, 2004
<u>AB</u>			<u>2.5MG;500MG</u>	<u>A076345 002</u>	Feb 18, 2004
<u>AB</u>			<u>5MG;500MG</u>	<u>A076345 003</u>	Feb 18, 2004
<u>AB</u>		ZYDUS PHARMS USA INC	<u>1.25MG;250MG</u>	<u>A206748 001</u>	Feb 29, 2016
<u>AB</u>			<u>2.5MG;500MG</u>	<u>A206748 002</u>	Feb 29, 2016
<u>AB</u>			<u>5MG;500MG</u>	<u>A206748 003</u>	Feb 29, 2016

GLYCEROL PHENYLBUTYRATE

LIQUID; ORAL

RAVICTI

	+	HORIZON THERAPS INC	1.1GM/ML	N203284 001	Feb 01, 2013
--	---	---------------------	----------	-------------	--------------

GLYCINE

SOLUTION; IRRIGATION

AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER

<u>AT</u>		BAXTER HLTHCARE	<u>1.5GM/100ML</u>	<u>N017865 001</u>	
<u>AT</u>		B BRAUN	<u>1.5GM/100ML</u>	<u>N016784 001</u>	
<u>AT</u>		HOSPIRA	<u>1.5GM/100ML</u>	<u>N018315 001</u>	

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

<u>AP</u>	+	HIKMA FARMACEUTICA	<u>0.2MG/ML</u>	<u>A090963 001</u>	Sep 21, 2011
<u>AP</u>		LUITPOLD	<u>0.2MG/ML</u>	<u>A089335 001</u>	Jul 23, 1986

POWDER; INHALATION

SEEBRI

	+	NOVARTIS PHARMS CORP	15.6MCG/INH	N207923 001	Oct 29, 2015
--	---	----------------------	-------------	-------------	--------------

SOLUTION; ORAL

CUVPOSA

	+	MERZ PHARMS	1MG/5ML	N022571 001	Jul 28, 2010
--	---	-------------	---------	-------------	--------------

TABLET; ORAL

GLYCOPYRROLATE

<u>AA</u>		APPCO PHARMA LLC	<u>1MG</u>	<u>A207201 001</u>	Jan 03, 2017
<u>AA</u>			<u>2MG</u>	<u>A207201 002</u>	Jan 03, 2017
<u>AA</u>		AUROLIFE PHARMA LLC	<u>1MG</u>	<u>A202675 001</u>	Apr 15, 2013
<u>AA</u>		DR REDDYS LABS LTD	<u>1MG</u>	<u>A040847 001</u>	Mar 21, 2008
<u>AA</u>			<u>2MG</u>	<u>A040847 002</u>	Mar 21, 2008
<u>AA</u>		LEADING PHARMA LLC	<u>1MG</u>	<u>A090195 001</u>	Sep 21, 2012
<u>AA</u>			<u>2MG</u>	<u>A090195 002</u>	Sep 21, 2012
<u>AA</u>		NATCO PHARMA LTD	<u>1MG</u>	<u>A091413 001</u>	Jun 20, 2016
<u>AA</u>			<u>2MG</u>	<u>A091413 002</u>	Jun 20, 2016
<u>AA</u>		NEXGEN PHARMA	<u>1.5MG</u>	<u>A091522 001</u>	Mar 12, 2012
<u>AA</u>		PAR PHARM	<u>1MG</u>	<u>A040653 001</u>	Aug 31, 2006
<u>AA</u>			<u>2MG</u>	<u>A040653 002</u>	Aug 31, 2006
<u>AA</u>		RISING PHARMS INC	<u>1MG</u>	<u>A040821 001</u>	Dec 29, 2008
<u>AA</u>			<u>2MG</u>	<u>A040821 002</u>	Dec 29, 2008
<u>AA</u>		STASON PHARMS	<u>1MG</u>	<u>A091182 001</u>	Feb 03, 2014
<u>AA</u>			<u>2MG</u>	<u>A091182 002</u>	Feb 03, 2014
<u>AA</u>		SUN PHARM INDS LTD	<u>1MG</u>	<u>A040844 001</u>	Aug 18, 2009
<u>AA</u>			<u>2MG</u>	<u>A040844 002</u>	Aug 18, 2009
<u>AA</u>		VINTAGE PHARMS	<u>1MG</u>	<u>A090020 001</u>	Oct 19, 2011

PRESCRIPTION DRUG PRODUCT LIST

GLYCOPYRROLATE

TABLET; ORAL

GLYCOPYRROLATE

<u>AA</u>		<u>2MG</u>	<u>A090020 002</u>	Oct 19, 2011
	<u>ROBINUL</u>			
<u>AA</u>	+ CASPER PHARMA LLC	<u>1MG</u>	<u>N012827 001</u>	
	<u>ROBINUL FORTE</u>			
<u>AA</u>	+ CASPER PHARMA LLC	<u>2MG</u>	<u>N012827 002</u>	

GLYCOPYRROLATE ; INDACATEROL MALEATE

POWDER; INHALATION

UTIBRON

	+ NOVARTIS PHARMS CORP	15.6MCG/INH;27.5MCG/INH	N207930 001	Oct 29, 2015
--	------------------------	-------------------------	-------------	--------------

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION

CHORIONIC GONADOTROPIN

<u>AP</u>	+ FERRING	<u>10,000 UNITS/VIAL</u>	<u>N017016 007</u>	
<u>AP</u>	+ FRESENIUS KABI USA	<u>10,000 UNITS/VIAL</u>	<u>N017067 002</u>	
	<u>PREGNYL</u>			
<u>AP</u>	+ ORGANON USA INC	<u>10,000 UNITS/VIAL</u>	<u>N017692 001</u>	

GOSERELIN ACETATE

IMPLANT; IMPLANTATION

ZOLADEX

	+ ASTRAZENECA	EQ 3.6MG BASE	N019726 001	Dec 29, 1989
		EQ 10.8MG BASE	N020578 001	Jan 11, 1996

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

<u>AT</u>	+ BAUSCH AND LOMB	<u>0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML</u>	<u>A064047 001</u>	Jan 31, 1996
<u>AT</u>	LUITPOLD	<u>0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML</u>	<u>A065187 001</u>	Oct 28, 2005
	<u>NEOSPORIN</u>			
<u>AT</u>	+ MONARCH PHARMS	<u>0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML</u>	<u>A060582 001</u>	

GRANISETRON

FILM, EXTENDED RELEASE; TRANSDERMAL

SANCUSO

	+ KYOWA KIRIN	3.1MG/24HR	N022198 001	Sep 12, 2008
--	---------------	------------	-------------	--------------

INJECTION, EXTENDED RELEASE; SUBCUTANEOUS

SUSTOL

	+ HERON THERAPS INC	10MG/0.4ML (10MG/0.4ML)	N022445 001	Aug 09, 2016
--	---------------------	-------------------------	-------------	--------------

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

<u>AP</u>	AKORN INC	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A079119 001</u>	Sep 10, 2009
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A079078 001</u>	Sep 14, 2009
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A079078 002</u>	Sep 14, 2009
<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A204238 001</u>	Jul 06, 2016
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A204238 002</u>	Jul 06, 2016
<u>AP</u>	BIONPHARMA INC	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078863 001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078880 001</u>	Jun 30, 2008
<u>AP</u>	CIPLA LTD	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078262 001</u>	Dec 31, 2007
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078258 001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078258 002</u>	Jun 30, 2008
<u>AP</u>	EUROHLTH INTL SARL	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A077913 001</u>	Jun 26, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A077186 001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A077187 001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A077177 001</u>	Dec 31, 2007
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078522 001</u>	Dec 31, 2007
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078090 001</u>	Jun 30, 2008
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078629 001</u>	Dec 23, 2009
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078629 002</u>	Dec 23, 2009
<u>AP</u>	LUITPOLD	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A091274 001</u>	Sep 22, 2010
<u>AP</u>	SAGENT AGILA	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A091137 002</u>	Apr 09, 2010
<u>AP</u>	SAGENT STRIDES	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A091136 001</u>	Apr 09, 2010
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A091136 002</u>	Apr 09, 2010
<u>AP</u>	SANDOZ	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078534 001</u>	Apr 30, 2009
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078531 001</u>	Apr 30, 2009
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078531 002</u>	Apr 30, 2009
<u>AP</u>	SANDOZ INC	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078835 001</u>	Jun 30, 2008

PRESCRIPTION DRUG PRODUCT LIST

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078835 002</u>	Jun 30, 2008
<u>AP</u>	+	<u>TEVA PHARMS USA</u> <u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078392 001</u>	Dec 31, 2007
<u>AP</u>	+	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A077963 001</u>	Jan 03, 2008
<u>AP</u>	+	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A077297 001</u>	Jun 30, 2008
<u>AP</u>		<u>WOCKHARDT USA</u> <u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078566 001</u>	Feb 29, 2008
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078564 001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078565 001</u>	Jun 30, 2008

GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>		<u>BIONPHARMA INC</u> <u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078863 002</u>	Jun 30, 2008
<u>AP</u>	+	<u>FRESENIUS KABI USA</u> <u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078096 001</u>	Jun 30, 2008

TABLET; ORAL

GRANISETRON HYDROCHLORIDE

<u>AB</u>		<u>APOTEX INC</u> <u>EQ 1MG BASE</u>	<u>A078843 001</u>	Feb 27, 2008
<u>AB</u>		<u>CIPLA LTD</u> <u>EQ 1MG BASE</u>	<u>A078037 001</u>	Feb 27, 2008
<u>AB</u>		<u>DR REDDYS LABS LTD</u> <u>EQ 1MG BASE</u>	<u>A078846 001</u>	Feb 27, 2009
<u>AB</u>		<u>MYLAN</u> <u>EQ 1MG BASE</u>	<u>A078725 001</u>	Jan 30, 2008
<u>AB</u>		<u>NATCO PHARMA</u> <u>EQ 1MG BASE</u>	<u>A078969 001</u>	Jun 22, 2009
<u>AB</u>		<u>ORCHID HLTHCARE</u> <u>EQ 1MG BASE</u>	<u>A078678 001</u>	Feb 13, 2008
<u>AB</u>		<u>TARO</u> <u>EQ 1MG BASE</u>	<u>A090817 001</u>	May 28, 2010
<u>AB</u>	+	<u>TEVA PHARMS</u> <u>EQ 1MG BASE</u>	<u>A078080 001</u>	Dec 31, 2007
<u>AB</u>		<u>WEST-WARD PHARMS INT</u> <u>EQ 1MG BASE</u>	<u>A077842 001</u>	Dec 31, 2007

GRISEOFULVIN, MICROSIZE

SUSPENSION; ORAL

GRISEOFULVIN

<u>AB</u>	+	<u>ACTAVIS MID ATLANTIC</u> <u>125MG/5ML</u>	<u>A065394 001</u>	Jul 06, 2007
<u>AB</u>		<u>CIPLA LTD</u> <u>125MG/5ML</u>	<u>A065354 001</u>	Sep 10, 2007
<u>AB</u>		<u>PERRIGO CO TENNESSEE</u> <u>125MG/5ML</u>	<u>A065200 001</u>	Mar 02, 2005
<u>AB</u>		<u>VINTAGE PHARMS</u> <u>125MG/5ML</u>	<u>A065438 001</u>	Oct 08, 2010

TABLET; ORAL

GRISEOFULVIN

<u>AB</u>	+	<u>SANDOZ INC</u> <u>500MG</u>	<u>A091592 002</u>	Aug 07, 2013
<u>AB</u>		<u>SIGMAPHARM LABS LLC</u> <u>500MG</u>	<u>A202482 001</u>	Oct 22, 2012
		<u>SANDOZ INC</u> <u>250MG</u>	<u>A091592 001</u>	Aug 07, 2013

GRISEOFULVIN, ULTRAMICROSIZE

TABLET; ORAL

GRIS-PEG

<u>AB</u>		<u>VALEANT PHARMS INC</u> <u>125MG</u>	<u>N050475 001</u>	
<u>AB</u>	+	<u>250MG</u>	<u>N050475 002</u>	

GRISEOFULVIN, ULTRAMICROSIZE

<u>AB</u>		<u>RICONPHARMA LLC</u> <u>125MG</u>	<u>A204371 001</u>	Jan 09, 2014
<u>AB</u>		<u>250MG</u>	<u>A204371 002</u>	Jan 09, 2014

GRISEOFULVIN, ULTRAMICROSIZE

<u>AB</u>		<u>SIGMAPHARM LABS LLC</u> <u>125MG</u>	<u>A202545 001</u>	Oct 22, 2012
<u>AB</u>		<u>250MG</u>	<u>A202545 002</u>	Oct 22, 2012

GUAIFENESIN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

FLOWTUSS

MISSION PHARMACAL CO 200MG/5ML; 2.5MG/5ML N022424 001 May 14, 2015

OBREDON

+ SOVEREIGN PHARMS 200MG/5ML; 2.5MG/5ML N205474 001 Nov 14, 2014

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYCOFENIX

+ MISSION PHARMACAL CO 200MG/5ML; 2.5MG/5ML; 30MG/5ML N022279 001 May 14, 2015

GUANABENZ ACETATE

TABLET; ORAL

GUANABENZ ACETATE

ANI PHARMS INC EQ 4MG BASE A074149 001 Apr 07, 1995

+ EQ 8MG BASE A074149 002 Apr 07, 1995

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

<u>AB</u>		<u>AMNEAL PHARM</u> <u>EQ 1MG BASE</u>	<u>A075109 001</u>	Nov 25, 1998
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075109 002</u>	Nov 25, 1998
<u>AB</u>		<u>EPIC PHARMA LLC</u> <u>EQ 1MG BASE</u>	<u>A074673 001</u>	Feb 28, 1997
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A074673 002</u>	Feb 28, 1997

PRESCRIPTION DRUG PRODUCT LIST

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

AB	MYLAN	EQ 1MG BASE	A074796 001	Jan 27, 1997
AB		EQ 2MG BASE	A074796 002	Jan 27, 1997
AB	WATSON LABS	EQ 1MG BASE	A074145 001	Oct 17, 1995
AB		EQ 2MG BASE	A074145 002	Oct 17, 1995
TENEX				
AB	PROMIUS PHARMA	EQ 1MG BASE	N019032 001	Oct 27, 1986
AB	+	EQ 2MG BASE	N019032 002	Nov 07, 1988

TABLET, EXTENDED RELEASE; ORAL

GUANFACINE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	EQ 1MG BASE	A200881 001	Oct 05, 2012
AB		EQ 2MG BASE	A200881 002	Oct 05, 2012
AB		EQ 3MG BASE	A200881 003	Oct 05, 2012
AB		EQ 4MG BASE	A200881 004	Oct 05, 2012
AB	MYLAN PHARMS INC	EQ 1MG BASE	A202578 001	Jun 02, 2015
AB		EQ 2MG BASE	A202578 002	Jun 02, 2015
AB		EQ 3MG BASE	A202578 003	Jun 02, 2015
AB		EQ 4MG BASE	A202578 004	Jun 02, 2015
AB	SANDOZ INC	EQ 1MG BASE	A202568 001	Jun 03, 2015
AB		EQ 2MG BASE	A202568 002	Jun 03, 2015
AB		EQ 3MG BASE	A202568 003	Jun 03, 2015
AB		EQ 4MG BASE	A202568 004	Jun 03, 2015
AB	TEVA PHARMS USA	EQ 1MG BASE	A201382 001	Jun 02, 2015
AB		EQ 2MG BASE	A201382 002	Jun 02, 2015
AB		EQ 3MG BASE	A201382 003	Jun 02, 2015
AB		EQ 4MG BASE	A201382 004	Jun 02, 2015
AB	TWI PHARMS INC	EQ 1MG BASE	A201408 001	Jun 02, 2015
AB		EQ 2MG BASE	A201408 002	Jun 02, 2015
AB		EQ 3MG BASE	A201408 003	Jun 02, 2015
AB		EQ 4MG BASE	A201408 004	Jun 02, 2015
INTUNIV				
AB	SHIRE	EQ 1MG BASE	N022037 001	Sep 02, 2009
AB		EQ 2MG BASE	N022037 002	Sep 02, 2009
AB		EQ 3MG BASE	N022037 003	Sep 02, 2009
AB	+	EQ 4MG BASE	N022037 004	Sep 02, 2009

GUANIDINE HYDROCHLORIDE

TABLET; ORAL

GUANIDINE HYDROCHLORIDE

MERCK SHARP DOHME 125MG N001546 001

HALCINONIDE

CREAM; TOPICAL

HALOG

+ RANBAXY 0.1% N017556 001

OINTMENT; TOPICAL

HALOG

+ RANBAXY 0.1% N017824 001

HALOBETASOL PROPIONATE

CREAM; TOPICAL

HALOBETASOL PROPIONATE

AB	FOUGERA PHARMS	0.05%	A077001 001	Dec 16, 2004
AB	G AND W LABS	0.05%	A078162 001	Apr 24, 2007
AB	PERRIGO ISRAEL	0.05%	A077123 001	Dec 16, 2004
AB	TARO	0.05%	A077227 001	Aug 04, 2005
ULTRAVATE				
AB	+	0.05%	N019967 001	Dec 27, 1990
LOTION; TOPICAL				
ULTRAVATE				
	+	0.05%	N208183 001	Nov 06, 2015
OINTMENT; TOPICAL				
<u>HALOBETASOL PROPIONATE</u>				
AB	G AND W LABS	0.05%	A077721 001	Sep 07, 2006
AB	PERRIGO	0.05%	A076872 001	Dec 16, 2004
AB	TARO	0.05%	A076994 001	Dec 16, 2004
ULTRAVATE				
AB	+	0.05%	N019968 001	Dec 17, 1990

PRESCRIPTION DRUG PRODUCT LIST

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

<u>AB</u>	MYLAN	<u>0.5MG</u>	<u>A070278 006</u>	Jun 10, 1986
<u>AB</u>		<u>1MG</u>	<u>A070278 004</u>	Jun 10, 1986
<u>AB</u>		<u>2MG</u>	<u>A070278 001</u>	Jun 10, 1986
<u>AB</u>		<u>5MG</u>	<u>A070278 005</u>	Jun 10, 1986
<u>AB</u>		<u>10MG</u>	<u>A070278 002</u>	Jul 16, 2009
<u>AB</u>		<u>20MG</u>	<u>A070278 003</u>	Jul 16, 2009
<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A071206 001</u>	Nov 17, 1986
<u>AB</u>		<u>1MG</u>	<u>A071207 001</u>	Nov 17, 1986
<u>AB</u>	+	<u>2MG</u>	<u>A071208 001</u>	Nov 17, 1986
<u>AB</u>		<u>5MG</u>	<u>A071209 001</u>	Nov 17, 1986
<u>AB</u>		<u>10MG</u>	<u>A071210 001</u>	Mar 11, 1988
<u>AB</u>		<u>20MG</u>	<u>A071211 001</u>	Mar 11, 1988
<u>AB</u>	ZYDUS PHARMS USA	<u>5MG</u>	<u>A077580 003</u>	Nov 29, 2007
<u>AB</u>		<u>10MG</u>	<u>A077580 004</u>	Nov 29, 2007
<u>AB</u>		<u>20MG</u>	<u>A077580 005</u>	Nov 29, 2007

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALDOL

<u>AO</u>	+	JANSSEN PHARMS	<u>EQ 50MG BASE/ML</u>	<u>N018701 001</u>	Jan 14, 1986
<u>AO</u>	+		<u>EQ 100MG BASE/ML</u>	<u>N018701 002</u>	Jan 31, 1997

HALOPERIDOL DECANOATE

<u>AO</u>		FRESENIUS KABI USA	<u>EQ 50MG BASE/ML</u>	<u>A074893 001</u>	Dec 19, 1997
<u>AO</u>			<u>EQ 100MG BASE/ML</u>	<u>A074893 002</u>	Dec 19, 1997
<u>AO</u>		MYLAN LABS LTD	<u>EQ 50MG BASE/ML</u>	<u>A075440 001</u>	Feb 28, 2000
<u>AO</u>			<u>EQ 100MG BASE/ML</u>	<u>A075440 002</u>	Feb 28, 2000
<u>AO</u>		TEVA PHARMS USA	<u>EQ 50MG BASE/ML</u>	<u>A075393 001</u>	May 11, 1999
<u>AO</u>			<u>EQ 100MG BASE/ML</u>	<u>A075393 002</u>	May 11, 1999
<u>AO</u>		WEST-WARD PHARMS INT	<u>EQ 50MG BASE/ML</u>	<u>A074811 001</u>	Jan 30, 1998
<u>AO</u>			<u>EQ 100MG BASE/ML</u>	<u>A075305 001</u>	Sep 28, 1998

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALOPERIDOL

<u>AA</u>		PHARM ASSOC	<u>EQ 2MG BASE/ML</u>	<u>A073037 001</u>	Feb 26, 1993
<u>AA</u>		SILARX	<u>EQ 2MG BASE/ML</u>	<u>A073364 001</u>	Sep 28, 1993
<u>AA</u>	+	TEVA PHARMS	<u>EQ 2MG BASE/ML</u>	<u>A071617 001</u>	Dec 01, 1988

INJECTABLE; INJECTION

HALDOL

<u>AP</u>	+	JANSSEN PHARMS	<u>EQ 5MG BASE/ML</u>	<u>N015923 001</u>	
-----------	---	----------------	-----------------------	--------------------	--

HALOPERIDOL

<u>AP</u>		FRESENIUS KABI USA	<u>EQ 5MG BASE/ML</u>	<u>A075689 001</u>	Mar 09, 2001
<u>AP</u>		GLAND PHARMA LTD	<u>EQ 5MG BASE/ML</u>	<u>A076774 001</u>	Aug 25, 2004
<u>AP</u>		MYLAN LABS LTD	<u>EQ 5MG BASE/ML</u>	<u>A078347 001</u>	Sep 14, 2009
<u>AP</u>		SAGENT PHARMS	<u>EQ 5MG BASE/ML</u>	<u>A091637 001</u>	Sep 02, 2011
<u>AP</u>			<u>EQ 5MG BASE/ML</u>	<u>A200742 001</u>	Sep 02, 2011
<u>AP</u>		TEVA PHARMS USA	<u>EQ 5MG BASE/ML</u>	<u>A076035 001</u>	Aug 29, 2001
<u>AP</u>		WEST-WARD PHARMS INT	<u>EQ 5MG BASE/ML</u>	<u>A075858 001</u>	Jun 18, 2001

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

<u>AP</u>	+	FRESENIUS KABI USA	<u>1,000 UNITS/ML</u>	<u>N017029 001</u>	
<u>AP</u>			<u>5,000 UNITS/ML</u>	<u>A206552 001</u>	Jun 10, 2016
<u>AP</u>	+		<u>5,000 UNITS/ML</u>	<u>N017651 006</u>	
<u>AP</u>	+		<u>10,000 UNITS/ML</u>	<u>N017029 003</u>	
<u>AP</u>	+		<u>20,000 UNITS/ML</u>	<u>N017029 004</u>	
<u>AP</u>		HOSPIRA INC	<u>1,000 UNITS/ML</u>	<u>A090571 001</u>	Aug 31, 2009
<u>AP</u>			<u>5,000 UNITS/ML</u>	<u>A090571 002</u>	Aug 31, 2009
<u>AP</u>			<u>10,000 UNITS/ML</u>	<u>A090571 003</u>	Aug 31, 2009
<u>AP</u>		SAGENT PHARMS	<u>1,000 UNITS/ML</u>	<u>A090808 001</u>	Jun 30, 2010
<u>AP</u>			<u>5,000 UNITS/ML</u>	<u>A090808 002</u>	Jun 30, 2010
<u>AP</u>			<u>10,000 UNITS/ML</u>	<u>A090808 003</u>	Jun 30, 2010
<u>AP</u>			<u>20,000 UNITS/ML</u>	<u>A090809 001</u>	Jun 30, 2010
<u>AP</u>		SANDOZ	<u>1,000 UNITS/ML</u>	<u>A091682 001</u>	Jun 08, 2011
<u>AP</u>			<u>5,000 UNITS/ML</u>	<u>A091659 001</u>	Jun 08, 2011
<u>AP</u>			<u>5,000 UNITS/ML</u>	<u>A091682 002</u>	Jun 08, 2011
<u>AP</u>			<u>10,000 UNITS/ML</u>	<u>A201002 001</u>	Jun 08, 2011
<u>AP</u>		SHENZHEN TECHDOW	<u>1,000 UNITS/ML</u>	<u>A202957 001</u>	Jun 12, 2014
<u>AP</u>			<u>5,000 UNITS/ML</u>	<u>A202733 001</u>	Jun 12, 2014
<u>AP</u>			<u>5,000 UNITS/ML</u>	<u>A202957 002</u>	Jun 12, 2014

PRESCRIPTION DRUG PRODUCT LIST

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

<u>AP</u>		<u>10,000 UNITS/ML</u>	<u>A203198 001</u>	Jun 12, 2014
<u>AP</u>		<u>20,000 UNITS/ML</u>	<u>A203198 002</u>	Jun 12, 2014
<u>AP</u>	+ WEST-WARD PHARMS INT	<u>1,000 UNITS/ML</u>	<u>N017037 001</u>	
<u>AP</u>	+	<u>5,000 UNITS/ML</u>	<u>N017037 002</u>	
<u>AP</u>	+	<u>10,000 UNITS/ML</u>	<u>N017037 003</u>	
	<u>HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>			
<u>AP</u>	BAXTER HLTHCARE	<u>200 UNITS/100ML</u>	<u>N018609 001</u>	Apr 28, 1982
	<u>HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>			
<u>AP</u>	+ B BRAUN	<u>200 UNITS/100ML</u>	<u>N019953 001</u>	Jul 20, 1992
<u>AP</u>	HOSPIRA	<u>200 UNITS/100ML</u>	<u>N018916 010</u>	Jun 23, 1989
	<u>HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER</u>			
<u>AP</u>	HOSPIRA	<u>10,000 UNITS/100ML</u>	<u>N019339 003</u>	Mar 27, 1985
	<u>HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>			
<u>AP</u>	BAXTER HLTHCARE	<u>200 UNITS/100ML</u>	<u>N018609 002</u>	Apr 28, 1982
	<u>HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>			
<u>AP</u>	HOSPIRA	<u>200 UNITS/100ML</u>	<u>N018916 011</u>	Jun 23, 1989
	<u>HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER</u>			
<u>AP</u>	+ B BRAUN	<u>4,000 UNITS/100ML</u>	<u>N019952 001</u>	Jul 20, 1992
<u>AP</u>	HOSPIRA	<u>4,000 UNITS/100ML</u>	<u>N019805 001</u>	Jan 25, 1989
	<u>HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER</u>			
<u>AP</u>	+ B BRAUN	<u>5,000 UNITS/100ML</u>	<u>N019952 004</u>	Jul 20, 1992
<u>AP</u>	+	<u>10,000 UNITS/100ML</u>	<u>N019952 005</u>	Jul 20, 1992
<u>AP</u>	HOSPIRA	<u>5,000 UNITS/100ML</u>	<u>N019339 004</u>	Mar 27, 1985
<u>AP</u>		<u>5,000 UNITS/100ML</u>	<u>N019805 002</u>	Jan 25, 1989
<u>AP</u>		<u>10,000 UNITS/100ML</u>	<u>N019339 002</u>	Mar 27, 1985
	<u>HEPARIN SODIUM IN PLASTIC CONTAINER</u>			
<u>AP</u>	+ FRESENIUS KABI USA	<u>1,000 UNITS/ML</u>	<u>N017029 013</u>	Dec 05, 1985
<u>AP</u>	+	<u>5,000 UNITS/ML</u>	<u>N017029 014</u>	Dec 05, 1985
<u>AP</u>	+	<u>10,000 UNITS/ML</u>	<u>N017029 015</u>	Dec 05, 1985
<u>AP</u>	+	<u>20,000 UNITS/ML</u>	<u>N017029 016</u>	Dec 05, 1985
	<u>HEPARIN SODIUM PRESERVATIVE FREE</u>			
<u>AP</u>	+ FRESENIUS KABI USA	<u>1,000 UNITS/ML</u>	<u>N017029 010</u>	Apr 28, 1986
<u>AP</u>	SAGENT PHARMS	<u>1,000 UNITS/ML</u>	<u>A090810 001</u>	Jun 30, 2010
<u>AP</u>	SHENZHEN TECHDOW	<u>1,000 UNITS/ML</u>	<u>A202732 001</u>	Jun 12, 2014
	HEPARIN SODIUM			
	+ FRESENIUS KABI USA	10,000 UNITS/ML	N017029 020	Mar 31, 2011
	+ HOSPIRA	5,000 UNITS/ML	A088100 001	Apr 28, 1983
	+ PFIZER	1,000 UNITS/ML	N201370 001	Jul 21, 2011
	+	5,000 UNITS/ML	N201370 002	Jul 21, 2011
	+	10,000 UNITS/ML	N201370 003	Jul 21, 2011
	HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER			
	HOSPIRA	5,000 UNITS/100ML	N019339 001	Mar 27, 1985
	HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
	HOSPIRA	5,000 UNITS/100ML	N018916 006	Jan 31, 1984
	HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
	HOSPIRA	5,000 UNITS/100ML	N018916 007	Jan 31, 1984
		10,000 UNITS/100ML	N018916 008	Jan 31, 1984
	HEPARIN SODIUM PRESERVATIVE FREE			
	+ FRESENIUS KABI USA	10,000 UNITS/ML	N017029 019	Nov 22, 2010
	+ HOSPIRA	10,000 UNITS/ML	A089522 001	May 04, 1987
	+ PFIZER	1,000 UNITS/ML	N201370 004	Jul 21, 2011

HEXACHLOROPHENE

SPONGE; TOPICAL

PRE-OPAT + DAVIS AND GECK 480MG N017433 001PRE-OP IIAT DAVIS AND GECK 480MG N017433 002HEXAMINOLEVULINATE HYDROCHLORIDE

FOR SOLUTION; INTRAVESICAL

CYSVIEW KIT

+ PHOTOCURE ASA 100MG/VIAL N022555 001 May 28, 2010

HISTRELIN ACETATE

IMPLANT; SUBCUTANEOUS

SUPPRELIN LA

+ ENDO PHARM 50MG N022058 001 May 03, 2007

VANTAS

+ ENDO PHARM 50MG N021732 001 Oct 12, 2004

PRESCRIPTION DRUG PRODUCT LIST

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

<u>AA</u>	ACTAVIS MID ATLANTIC	<u>1.5MG/5ML;5MG/5ML</u>	<u>A088017</u>	<u>001</u>	Jul 05, 1983
<u>AA</u>	+ HI TECH PHARMA	<u>1.5MG/5ML;5MG/5ML</u>	<u>A040613</u>	<u>001</u>	Feb 08, 2008
<u>AA</u>	WOCKHARDT	<u>1.5MG/5ML;5MG/5ML</u>	<u>A088008</u>	<u>001</u>	Mar 03, 1983

TABLET; ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

<u>AA</u>	NOVEL LABS INC	<u>1.5MG;5MG</u>	<u>A091528</u>	<u>001</u>	Apr 20, 2011
<u>AA</u>	+ KING PHARMS	<u>1.5MG;5MG</u>	<u>A088508</u>	<u>001</u>	Jul 30, 1985

HYALURONIDASE

INJECTABLE; INJECTION

AMPHADASE

	+ AMPHASTAR PHARM	150 UNITS/ML	N021665	001	Oct 26, 2004
	VITRASE				
	+ BAUSCH AND LOMB	200 UNITS/VIAL	N021640	002	Dec 02, 2004

HYALURONIDASE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HYLENEX RECOMBINANT

	+ HALOZYME THERAP	150 UNITS/ML	N021859	001	Dec 02, 2005
--	-------------------	--------------	---------	-----	--------------

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE

<u>AP</u>	+ AKORN	<u>20MG/ML</u>	<u>A040730</u>	<u>001</u>	Apr 21, 2009
<u>AP</u>	FRESENIUS KABI USA	<u>20MG/ML</u>	<u>A040388</u>	<u>001</u>	Mar 13, 2001
<u>AP</u>	LUITPOLD	<u>20MG/ML</u>	<u>A040136</u>	<u>001</u>	Jun 30, 1997
<u>AP</u>	MYLAN INSTITUTIONAL	<u>20MG/ML</u>	<u>A204680</u>	<u>001</u>	Apr 28, 2016
<u>AP</u>	NAVINTA LLC	<u>20MG/ML</u>	<u>A202938</u>	<u>001</u>	Mar 28, 2013
<u>AP</u>	X-GEN PHARMS INC	<u>20MG/ML</u>	<u>A203110</u>	<u>001</u>	Jun 29, 2015

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

<u>AA</u>	ALKEM LABS LTD	<u>10MG</u>	<u>A200737</u>	<u>001</u>	Dec 07, 2012
<u>AA</u>		<u>25MG</u>	<u>A200737</u>	<u>002</u>	Dec 07, 2012
<u>AA</u>		<u>50MG</u>	<u>A200737</u>	<u>003</u>	Dec 07, 2012
<u>AA</u>		<u>100MG</u>	<u>A200737</u>	<u>004</u>	Dec 07, 2012
<u>AA</u>	CADILA PHARMS LTD	<u>25MG</u>	<u>A203845</u>	<u>001</u>	Sep 18, 2014
<u>AA</u>		<u>50MG</u>	<u>A203845</u>	<u>002</u>	Sep 18, 2014
<u>AA</u>		<u>100MG</u>	<u>A203845</u>	<u>003</u>	Sep 18, 2014
<u>AA</u>	GLENMARK PHARMS LTD	<u>10MG</u>	<u>A090527</u>	<u>001</u>	May 27, 2009
<u>AA</u>		<u>25MG</u>	<u>A090527</u>	<u>002</u>	May 27, 2009
<u>AA</u>		<u>50MG</u>	<u>A090527</u>	<u>003</u>	May 27, 2009
<u>AA</u>		<u>100MG</u>	<u>A090527</u>	<u>004</u>	May 27, 2009
<u>AA</u>	HERITAGE PHARMS INC	<u>10MG</u>	<u>A086242</u>	<u>001</u>	Feb 04, 2010
<u>AA</u>		<u>25MG</u>	<u>A086242</u>	<u>003</u>	
<u>AA</u>		<u>50MG</u>	<u>A086242</u>	<u>002</u>	
<u>AA</u>		<u>100MG</u>	<u>A086242</u>	<u>004</u>	Feb 04, 2010
<u>AA</u>	HETERO LABS LTD III	<u>10MG</u>	<u>A040901</u>	<u>001</u>	Sep 12, 2008
<u>AA</u>		<u>25MG</u>	<u>A040901</u>	<u>002</u>	Sep 12, 2008
<u>AA</u>		<u>50MG</u>	<u>A040901</u>	<u>003</u>	Sep 12, 2008
<u>AA</u>		<u>100MG</u>	<u>A040901</u>	<u>004</u>	Sep 12, 2008
<u>AA</u>	INVAGEN PHARMS	<u>10MG</u>	<u>A090255</u>	<u>001</u>	Dec 15, 2008
<u>AA</u>		<u>25MG</u>	<u>A090255</u>	<u>002</u>	Dec 15, 2008
<u>AA</u>		<u>50MG</u>	<u>A090255</u>	<u>003</u>	Dec 15, 2008
<u>AA</u>		<u>100MG</u>	<u>A090255</u>	<u>004</u>	Dec 15, 2008
<u>AA</u>	MYLAN	<u>10MG</u>	<u>A090413</u>	<u>001</u>	Dec 08, 2010
<u>AA</u>		<u>25MG</u>	<u>A090413</u>	<u>002</u>	Dec 08, 2010
<u>AA</u>		<u>50MG</u>	<u>A090413</u>	<u>003</u>	Dec 08, 2010
<u>AA</u>		<u>100MG</u>	<u>A090413</u>	<u>004</u>	Dec 08, 2010
<u>AA</u>	PAR PHARM	<u>10MG</u>	<u>A087836</u>	<u>001</u>	Oct 05, 1982
<u>AA</u>		<u>25MG</u>	<u>A086961</u>	<u>002</u>	
<u>AA</u>		<u>50MG</u>	<u>A086962</u>	<u>001</u>	
<u>AA</u>		<u>100MG</u>	<u>A088391</u>	<u>001</u>	Sep 27, 1983
<u>AA</u>	+ PLIVA	<u>10MG</u>	<u>A089097</u>	<u>001</u>	Dec 18, 1985
<u>AA</u>		<u>25MG</u>	<u>A088467</u>	<u>001</u>	May 01, 1984
<u>AA</u>		<u>50MG</u>	<u>A088468</u>	<u>001</u>	May 01, 1984
<u>AA</u>		<u>100MG</u>	<u>A089098</u>	<u>001</u>	Dec 18, 1985
<u>AA</u>	STRIDES PHARMA	<u>25MG</u>	<u>A200770</u>	<u>001</u>	May 03, 2013
<u>AA</u>		<u>50MG</u>	<u>A200770</u>	<u>002</u>	May 03, 2013
<u>AA</u>		<u>100MG</u>	<u>A200770</u>	<u>003</u>	May 03, 2013

PRESCRIPTION DRUG PRODUCT LIST

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDRA-ZIDE

PAR PHARM

25MG; 25MG

A088957 001 Oct 21, 1985

+

50MG; 50MG

A088946 001 Oct 21, 1985

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET; ORAL

BIDIL

+ ARBOR PHARMS LLC

37.5MG; 20MG

N020727 001 Jun 23, 2005

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>12.5MG</u>	<u>A200645 001</u>	Nov 30, 2010
<u>AB</u>	APOTEX	<u>12.5MG</u>	<u>A078389 001</u>	May 16, 2008
<u>AB</u>	AUROBINDO PHARMA	<u>12.5MG</u>	<u>A078164 001</u>	Sep 18, 2007
<u>AB</u>	IPCA LABS LTD	<u>12.5MG</u>	<u>A079237 001</u>	Apr 02, 2009
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>12.5MG</u>	<u>A077005 001</u>	Jul 13, 2005
<u>AB</u>	JUBILANT CADISTA	<u>12.5MG</u>	<u>A078391 001</u>	Feb 11, 2008
<u>AB</u>	MYLAN	<u>12.5MG</u>	<u>A075640 001</u>	Jan 28, 2000
<u>AB</u>	SUN PHARM INDS INC	<u>12.5MG</u>	<u>A090651 001</u>	Apr 07, 2014
<u>AB</u>	UNICHEM	<u>12.5MG</u>	<u>A090510 001</u>	Jan 19, 2010
<u>AB</u>	VINTAGE PHARMS	<u>12.5MG</u>	<u>A075907 001</u>	Sep 17, 2002

MICROZIDE

<u>AB</u>	+ ALLERGAN SALES LLC	<u>12.5MG</u>	<u>N020504 001</u>	Dec 27, 1996
-----------	----------------------	---------------	--------------------	--------------

TABLET; ORAL

HYDROCHLOROTHIAZIDE

<u>AB</u>	ACCORD HLTHCARE	<u>12.5MG</u>	<u>A202556 001</u>	Sep 24, 2012
<u>AB</u>		<u>25MG</u>	<u>A202556 002</u>	Sep 24, 2012
<u>AB</u>		<u>50MG</u>	<u>A202556 003</u>	Sep 24, 2012
<u>AB</u>	ACTAVIS ELIZABETH	<u>12.5MG</u>	<u>A040707 001</u>	Feb 27, 2007
<u>AB</u>	APOTEX	<u>25MG</u>	<u>A040774 001</u>	Oct 03, 2007
<u>AB</u>		<u>50MG</u>	<u>A040774 002</u>	Oct 03, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A040780 001</u>	Jul 20, 2007
<u>AB</u>		<u>50MG</u>	<u>A040780 002</u>	Jul 20, 2007
<u>AB</u>	DAVA PHARMS INC	<u>25MG</u>	<u>A087059 001</u>	
<u>AB</u>		<u>50MG</u>	<u>A087068 001</u>	
<u>AB</u>	HERITAGE PHARMS INC	<u>25MG</u>	<u>A085182 002</u>	
<u>AB</u>		<u>50MG</u>	<u>A085182 001</u>	
<u>AB</u>	HIKMA INTL PHARMS	<u>50MG</u>	<u>A084878 001</u>	
<u>AB</u>	IPCA LABS LTD	<u>12.5MG</u>	<u>A040807 001</u>	Jul 20, 2007
<u>AB</u>		<u>25MG</u>	<u>A040807 002</u>	Jul 20, 2007
<u>AB</u>		<u>50MG</u>	<u>A040807 003</u>	Jul 20, 2007
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>25MG</u>	<u>A083177 001</u>	
<u>AB</u>	+ JUBILANT CADISTA	<u>50MG</u>	<u>A083177 002</u>	
<u>AB</u>		<u>25MG</u>	<u>A040809 001</u>	Sep 04, 2007
<u>AB</u>		<u>50MG</u>	<u>A040809 002</u>	Sep 04, 2007
<u>AB</u>	LEADING PHARMA LLC	<u>25MG</u>	<u>A040702 001</u>	Mar 16, 2007
<u>AB</u>		<u>50MG</u>	<u>A040702 002</u>	Mar 16, 2007
<u>AB</u>	MYLAN PHARMS INC	<u>12.5MG</u>	<u>A040770 001</u>	Jan 23, 2007
<u>AB</u>		<u>25MG</u>	<u>A040735 002</u>	Jan 23, 2007
<u>AB</u>		<u>50MG</u>	<u>A040735 003</u>	Jan 23, 2007
<u>AB</u>	SCIEGEN PHARMS INC	<u>25MG</u>	<u>A203018 001</u>	Jul 23, 2014
<u>AB</u>		<u>50MG</u>	<u>A203018 002</u>	Jul 23, 2014
<u>AB</u>	SUN PHARM INDS INC	<u>12.5MG</u>	<u>A040857 001</u>	May 30, 2008
<u>AB</u>		<u>25MG</u>	<u>A040810 001</u>	Mar 27, 2007
<u>AB</u>		<u>50MG</u>	<u>A040810 002</u>	Mar 27, 2007
<u>AB</u>	UNICHEM	<u>25MG</u>	<u>A040907 001</u>	Aug 15, 2008
<u>AB</u>		<u>50MG</u>	<u>A040907 002</u>	Aug 15, 2008
<u>AB</u>	VINTAGE PHARMS	<u>25MG</u>	<u>A040412 001</u>	Mar 29, 2002
<u>AB</u>		<u>50MG</u>	<u>A040412 002</u>	Mar 29, 2002

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

<u>AB</u>	+ SANOFI AVENTIS US	<u>12.5MG; 150MG</u>	<u>N020758 002</u>	Sep 30, 1997
<u>AB</u>	+	<u>12.5MG; 300MG</u>	<u>N020758 003</u>	Aug 31, 1998

IRBESARTAN AND HYDROCHLOROTHIAZIDE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>12.5MG; 150MG</u>	<u>A091370 001</u>	Oct 15, 2012
<u>AB</u>		<u>12.5MG; 300MG</u>	<u>A091370 002</u>	Oct 15, 2012
<u>AB</u>		<u>25MG; 300MG</u>	<u>A091370 003</u>	Oct 12, 2016
<u>AB</u>	APOTEX INC	<u>12.5MG; 150MG</u>	<u>A201505 001</u>	Oct 15, 2012
<u>AB</u>		<u>12.5MG; 300MG</u>	<u>A201505 002</u>	Oct 15, 2012

PRESCRIPTION DRUG PRODUCT LIST

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>12.5MG;150MG</u>	<u>A203630 001</u>	Feb 22, 2013
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A203630 002</u>	Feb 22, 2013
<u>AB</u>		<u>25MG;300MG</u>	<u>A203630 003</u>	Mar 31, 2016
<u>AB</u>	DR REDDYS LABS LTD	<u>12.5MG;150MG</u>	<u>A203500 001</u>	Sep 27, 2012
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A203500 002</u>	Sep 27, 2012
<u>AB</u>	HISUN PHARM HANGZHOU	<u>12.5MG;150MG</u>	<u>A207896 001</u>	Oct 14, 2016
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A207896 002</u>	Oct 14, 2016
<u>AB</u>	INTL SPECLT CHEMS	<u>12.5MG;150MG</u>	<u>A203036 001</u>	Jan 15, 2016
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A203036 002</u>	Jan 15, 2016
<u>AB</u>		<u>25MG;300MG</u>	<u>A203036 003</u>	Jan 15, 2016
<u>AB</u>	LUPIN LTD	<u>12.5MG;150MG</u>	<u>A201524 001</u>	Feb 27, 2013
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A201524 002</u>	Feb 27, 2013
<u>AB</u>	MACLEODS PHARMS LTD	<u>12.5MG;150MG</u>	<u>A202414 001</u>	Sep 27, 2012
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A202414 002</u>	Sep 27, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>12.5MG;150MG</u>	<u>A077969 001</u>	Sep 27, 2012
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A077969 002</u>	Sep 27, 2012
<u>AB</u>		<u>25MG;300MG</u>	<u>A077969 003</u>	Jul 20, 2016
<u>AB</u>	PRINSTON INC	<u>12.5MG;150MG</u>	<u>A203072 001</u>	May 09, 2014
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A203072 002</u>	May 09, 2014
<u>AB</u>	SANDOZ	<u>12.5MG;150MG</u>	<u>A077446 001</u>	Sep 27, 2012
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A077446 002</u>	Sep 27, 2012
<u>AB</u>	TEVA	<u>12.5MG;150MG</u>	<u>A077369 001</u>	Mar 30, 2012
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A077369 002</u>	Mar 30, 2012
<u>AB</u>	WEST-WARD PHARMS INT	<u>12.5MG;150MG</u>	<u>A090351 001</u>	Oct 15, 2012
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A090351 002</u>	Oct 15, 2012

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

<u>AB</u>	APOTEX INC	<u>12.5MG;10MG</u>	<u>A076674 001</u>	Oct 05, 2004
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076674 002</u>	Oct 05, 2004
<u>AB</u>		<u>25MG;20MG</u>	<u>A076674 003</u>	Oct 05, 2004
<u>AB</u>	AUROBINDO	<u>12.5MG;10MG</u>	<u>A077606 001</u>	Mar 14, 2006
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A077606 002</u>	Mar 14, 2006
<u>AB</u>		<u>25MG;20MG</u>	<u>A077606 003</u>	Mar 14, 2006
<u>AB</u>	HIKMA INTL PHARMS	<u>12.5MG;10MG</u>	<u>A076265 001</u>	Jul 08, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076265 002</u>	Jul 08, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076265 003</u>	Jul 08, 2002
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>12.5MG;10MG</u>	<u>A075776 001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A075776 002</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A075776 003</u>	Jul 01, 2002
<u>AB</u>	LUPIN	<u>12.5MG;10MG</u>	<u>A077912 001</u>	Sep 27, 2006
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A077912 002</u>	Sep 27, 2006
<u>AB</u>		<u>25MG;20MG</u>	<u>A077912 003</u>	Sep 27, 2006
<u>AB</u>	MYLAN	<u>12.5MG;10MG</u>	<u>A076113 001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076113 002</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076113 003</u>	Jul 01, 2002
<u>AB</u>	PRINSTON INC	<u>12.5MG;10MG</u>	<u>A076230 001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076230 002</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076230 003</u>	Jul 01, 2002
<u>AB</u>	SANDOZ	<u>12.5MG;10MG</u>	<u>A076262 001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076262 002</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076262 003</u>	Jul 01, 2002
<u>AB</u>	SUN PHARM INDS LTD	<u>12.5MG;10MG</u>	<u>A076007 001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076007 002</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076007 003</u>	Jul 01, 2002
<u>AB</u>	WATSON LABS	<u>12.5MG;10MG</u>	<u>A076194 003</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076194 001</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076194 002</u>	Jul 01, 2002
<u>ZESTORETIC</u>				
<u>AB</u>	ALVOGEN MALTA	<u>12.5MG;10MG</u>	<u>N019888 003</u>	Nov 18, 1993
<u>AB</u>	+	<u>12.5MG;20MG</u>	<u>N019888 001</u>	Sep 20, 1990
<u>AB</u>	+	<u>25MG;20MG</u>	<u>N019888 002</u>	Jul 20, 1989

PRESCRIPTION DRUG PRODUCT LIST

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

HYZAAR

<u>AB</u>	MERCK SHARP DOHME	<u>12.5MG;50MG</u>	<u>N020387 001</u>	Apr 28, 1995
<u>AB</u>		<u>12.5MG;100MG</u>	<u>N020387 003</u>	Oct 20, 2005
<u>AB</u>	+	<u>25MG;100MG</u>	<u>N020387 002</u>	Nov 10, 1998
	<u>LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE</u>			
<u>AB</u>	ALEMBIC PHARMS LTD	<u>12.5MG;50MG</u>	<u>A091617 001</u>	Feb 17, 2012
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A091617 002</u>	Feb 17, 2012
<u>AB</u>		<u>25MG;100MG</u>	<u>A091617 003</u>	Feb 17, 2012
<u>AB</u>	APOTEX	<u>12.5MG;50MG</u>	<u>A090150 001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A090150 002</u>	Aug 11, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A090150 003</u>	Oct 06, 2010
<u>AB</u>	AUROBINDO PHARMA	<u>12.5MG;50MG</u>	<u>A091629 001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A091629 002</u>	Oct 06, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A091629 003</u>	Jan 06, 2010
<u>AB</u>	CADISTA PHARMS	<u>12.5MG;50MG</u>	<u>A201845 001</u>	Sep 18, 2012
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A201845 002</u>	Sep 18, 2012
<u>AB</u>		<u>25MG;100MG</u>	<u>A201845 003</u>	Sep 18, 2012
<u>AB</u>	IPCA LABS LTD	<u>12.5MG;50MG</u>	<u>A201682 001</u>	Mar 01, 2013
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A201682 002</u>	Mar 01, 2013
<u>AB</u>		<u>25MG;100MG</u>	<u>A201682 003</u>	Mar 01, 2013
<u>AB</u>	LUPIN LTD	<u>12.5MG;50MG</u>	<u>A078245 001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A078245 002</u>	May 21, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A078245 003</u>	Oct 06, 2010
<u>AB</u>	MACLEODS PHARMS LTD	<u>12.5MG;50MG</u>	<u>A202289 001</u>	Aug 09, 2012
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A202289 002</u>	Aug 09, 2012
<u>AB</u>		<u>25MG;100MG</u>	<u>A202289 003</u>	Aug 09, 2012
<u>AB</u>	MYLAN	<u>12.5MG;50MG</u>	<u>A091652 001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A091652 002</u>	Apr 06, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A091652 003</u>	Oct 06, 2010
<u>AB</u>	SANDOZ	<u>12.5MG;50MG</u>	<u>A077948 001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A077948 003</u>	Aug 19, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A077948 002</u>	Oct 06, 2010
<u>AB</u>	TEVA PHARMS	<u>12.5MG;50MG</u>	<u>A077157 001</u>	Apr 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A077157 002</u>	Apr 06, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A077157 003</u>	Apr 06, 2010
<u>AB</u>	TORRENT PHARMS	<u>12.5MG;50MG</u>	<u>A090528 001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A090528 003</u>	Apr 06, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A090528 002</u>	Oct 06, 2010
<u>AB</u>	WEST-WARD PHARMS INT	<u>12.5MG;50MG</u>	<u>A077732 002</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A077732 001</u>	Apr 06, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A077732 003</u>	Oct 06, 2010
<u>AB</u>	ZYDUS PHARMS USA INC	<u>12.5MG;50MG</u>	<u>A078385 001</u>	Oct 06, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A078385 002</u>	Oct 06, 2010

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

	MYLAN	15MG;250MG	A070265 002	Jan 23, 1986
	+	25MG;250MG	A070265 001	Jan 23, 1986

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DUTOPROL

	CONCORDIA PHARMS INC	12.5MG;EQ 25MG TARTRATE	N021956 001	Aug 28, 2006
		12.5MG;EQ 50MG TARTRATE	N021956 002	Aug 28, 2006
	+	12.5MG;EQ 100MG TARTRATE	N021956 003	Aug 28, 2006

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR HCT

<u>AB</u>	US PHARMS HOLDINGS I	<u>25MG;50MG</u>	<u>N018303 001</u>	Dec 31, 1984
<u>AB</u>	+	<u>25MG;100MG</u>	<u>N018303 002</u>	Dec 31, 1984
	<u>METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE</u>			
<u>AB</u>	ALEMBIC PHARMS LTD	<u>25MG;50MG</u>	<u>A202870 001</u>	Nov 06, 2013
<u>AB</u>		<u>25MG;100MG</u>	<u>A202870 002</u>	Nov 06, 2013
<u>AB</u>		<u>50MG;100MG</u>	<u>A202870 003</u>	Nov 06, 2013
<u>AB</u>	MYLAN	<u>25MG;50MG</u>	<u>A076792 001</u>	Aug 20, 2004
<u>AB</u>		<u>25MG;100MG</u>	<u>A076792 002</u>	Aug 20, 2004
<u>AB</u>		<u>50MG;100MG</u>	<u>A076792 003</u>	Aug 20, 2004
<u>AB</u>	SUN PHARM INDS	<u>25MG;50MG</u>	<u>A090654 001</u>	Jan 19, 2012
<u>AB</u>		<u>25MG;100MG</u>	<u>A090654 002</u>	Jan 19, 2012
<u>AB</u>		<u>50MG;100MG</u>	<u>A090654 003</u>	Jan 19, 2012

PRESCRIPTION DRUG PRODUCT LIST

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	GLENMARK PHARMS	<u>12.5MG;7.5MG</u>	<u>A090718 001</u>	Mar 17, 2010
<u>AB</u>		<u>12.5MG;15MG</u>	<u>A090718 002</u>	Mar 17, 2010
<u>AB</u>		<u>25MG;15MG</u>	<u>A090718 003</u>	Mar 17, 2010
<u>AB</u>	TEVA	<u>12.5MG;7.5MG</u>	<u>A076980 001</u>	Mar 07, 2007
<u>AB</u>		<u>12.5MG;15MG</u>	<u>A076980 003</u>	Mar 07, 2007
<u>AB</u>	+	<u>25MG;15MG</u>	<u>A076980 002</u>	Mar 07, 2007

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	HERITAGE PHARMS INC	<u>12.5MG;7.5MG</u>	<u>A202150 001</u>	Mar 07, 2014
<u>AB</u>		<u>12.5MG;15MG</u>	<u>A202150 002</u>	Mar 07, 2014
<u>AB</u>		<u>25MG;15MG</u>	<u>A202150 003</u>	Mar 07, 2014

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

BENICAR HCT

<u>AB</u>	DAIICHI SANKYO	<u>12.5MG;20MG</u>	<u>N021532 002</u>	Jun 05, 2003
<u>AB</u>		<u>12.5MG;40MG</u>	<u>N021532 003</u>	Jun 05, 2003
<u>AB</u>	+	<u>25MG;40MG</u>	<u>N021532 005</u>	Jun 05, 2003

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

<u>AB</u>	MYLAN PHARMS INC	<u>12.5MG;20MG</u>	<u>A078827 001</u>	Oct 26, 2016
<u>AB</u>		<u>12.5MG;40MG</u>	<u>A078827 002</u>	Oct 26, 2016
<u>AB</u>		<u>25MG;40MG</u>	<u>A078827 003</u>	Oct 26, 2016

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	ANI PHARMS INC	<u>25MG;40MG</u>	<u>A072042 001</u>	Mar 14, 1988
<u>AB</u>		<u>25MG;80MG</u>	<u>A072043 001</u>	Mar 14, 1988
<u>AB</u>	+	<u>25MG;40MG</u>	<u>A070947 002</u>	Mar 04, 1987
<u>AB</u>	+	<u>25MG;80MG</u>	<u>A070947 001</u>	Apr 01, 1987

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

ACCURETIC

<u>AB</u>	PFIZER PHARMS	<u>12.5MG;EQ 10MG BASE</u>	<u>N020125 001</u>	Dec 28, 1999
<u>AB</u>		<u>12.5MG;EQ 20MG BASE</u>	<u>N020125 002</u>	Dec 28, 1999
<u>AB</u>	+	<u>25MG;EQ 20MG BASE</u>	<u>N020125 003</u>	Dec 28, 1999

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	APOTEX CORP	<u>12.5MG;EQ 10MG BASE</u>	<u>A091524 001</u>	Mar 12, 2013
<u>AB</u>		<u>12.5MG;EQ 20MG BASE</u>	<u>A091524 002</u>	Mar 12, 2013
<u>AB</u>		<u>25MG;EQ 20MG BASE</u>	<u>A091524 003</u>	Mar 12, 2013
<u>AB</u>	AUROBINDO PHARMA	<u>12.5MG;EQ 10MG BASE</u>	<u>A078450 001</u>	Aug 24, 2007
<u>AB</u>		<u>12.5MG;EQ 20MG BASE</u>	<u>A078450 002</u>	Aug 24, 2007
<u>AB</u>		<u>25MG;EQ 20MG BASE</u>	<u>A078450 003</u>	Aug 24, 2007
<u>AB</u>	INVAGEN PHARMS	<u>12.5MG;10MG</u>	<u>A201356 001</u>	Apr 20, 2011
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A201356 002</u>	Apr 20, 2011
<u>AB</u>		<u>25MG;20MG</u>	<u>A201356 003</u>	Apr 20, 2011
<u>AB</u>	MYLAN	<u>12.5MG;EQ 10MG BASE</u>	<u>A077093 001</u>	Mar 28, 2005
<u>AB</u>		<u>12.5MG;EQ 20MG BASE</u>	<u>A077093 002</u>	Mar 28, 2005
<u>AB</u>		<u>25MG;EQ 20MG BASE</u>	<u>A077093 003</u>	Mar 28, 2005
<u>AB</u>	SUN PHARM INDS LTD	<u>12.5MG;EQ 10MG BASE</u>	<u>A078211 001</u>	Mar 04, 2009
<u>AB</u>		<u>12.5MG;EQ 20MG BASE</u>	<u>A078211 002</u>	Mar 04, 2009
<u>AB</u>		<u>25MG;EQ 20MG BASE</u>	<u>A078211 003</u>	Mar 04, 2009

QUINARETIC

<u>AB</u>	GAVIS PHARMS	<u>12.5MG;EQ 10MG BASE</u>	<u>A076374 001</u>	Mar 31, 2004
<u>AB</u>		<u>12.5MG;EQ 20MG BASE</u>	<u>A076374 002</u>	Mar 31, 2004
<u>AB</u>		<u>25MG;EQ 20MG BASE</u>	<u>A076374 003</u>	Mar 31, 2004

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

ALDACTAZIDE

<u>AB</u>	GD SEARLE LLC	<u>25MG;25MG</u>	<u>N012616 004</u>	Dec 30, 1982
-----------	---------------	------------------	--------------------	--------------

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	MYLAN	<u>25MG;25MG</u>	<u>A086513 001</u>	
<u>AB</u>	SUN PHARM INDS	<u>25MG;25MG</u>	<u>A089534 001</u>	Jul 02, 1987

ALDACTAZIDE

+	GD SEARLE LLC	<u>50MG;50MG</u>	<u>N012616 005</u>	Dec 30, 1982
---	---------------	------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

MICARDIS HCT

<u>AB</u>	BOEHRINGER INGELHEIM	<u>12.5MG; 40MG</u>	<u>N021162 001</u>	Nov 17, 2000
<u>AB</u>		<u>12.5MG; 80MG</u>	<u>N021162 002</u>	Nov 17, 2000
<u>AB</u>	+	<u>25MG; 80MG</u>	<u>N021162 003</u>	Apr 19, 2004

TELMISARTAN AND HYDROCHLOROTHIAZIDE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>12.5MG; 40MG</u>	<u>A203010 001</u>	Feb 25, 2014
<u>AB</u>		<u>12.5MG; 80MG</u>	<u>A203010 002</u>	Feb 25, 2014
<u>AB</u>		<u>25MG; 80MG</u>	<u>A203010 003</u>	Feb 25, 2014
<u>AB</u>	AUROBINDO PHARMA LTD	<u>12.5MG; 40MG</u>	<u>A208727 001</u>	Dec 15, 2016
<u>AB</u>		<u>12.5MG; 80MG</u>	<u>A208727 002</u>	Dec 15, 2016
<u>AB</u>		<u>25MG; 80MG</u>	<u>A208727 003</u>	Dec 15, 2016
<u>AB</u>	LUPIN LTD	<u>12.5MG; 40MG</u>	<u>A091351 001</u>	Aug 07, 2014
<u>AB</u>		<u>12.5MG; 80MG</u>	<u>A091351 002</u>	Aug 07, 2014
<u>AB</u>		<u>25MG; 80MG</u>	<u>A091351 003</u>	Aug 07, 2014
<u>AB</u>	MACLEODS PHARMS LTD	<u>12.5MG; 40MG</u>	<u>A204169 001</u>	Nov 02, 2015
<u>AB</u>		<u>12.5MG; 80MG</u>	<u>A204169 002</u>	Nov 02, 2015
<u>AB</u>		<u>25MG; 80MG</u>	<u>A204169 003</u>	Nov 02, 2015
<u>AB</u>	MYLAN PHARMS INC	<u>12.5MG; 40MG</u>	<u>A091648 001</u>	Feb 25, 2014
<u>AB</u>		<u>12.5MG; 80MG</u>	<u>A091648 002</u>	Feb 25, 2014
<u>AB</u>		<u>25MG; 80MG</u>	<u>A091648 003</u>	Feb 25, 2014
<u>AB</u>	TORRENT PHARMS LTD	<u>12.5MG; 40MG</u>	<u>A201192 001</u>	Feb 25, 2014
<u>AB</u>		<u>12.5MG; 80MG</u>	<u>A201192 002</u>	Feb 25, 2014
<u>AB</u>		<u>25MG; 80MG</u>	<u>A201192 003</u>	Feb 25, 2014

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

DYAZIDE

<u>AB</u>	+	GLAXOSMITHKLINE LLC	<u>25MG; 37.5MG</u>	<u>N016042 003</u>	Mar 03, 1994
-----------	---	---------------------	---------------------	--------------------	--------------

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	DURAMED PHARMS BARR	<u>25MG; 37.5MG</u>	<u>A075052 001</u>	Jun 18, 1999
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>25MG; 50MG</u>	<u>A074259 001</u>	Mar 30, 1995
<u>AB</u>	LANNETT HOLDINGS INC	<u>25MG; 37.5MG</u>	<u>A201407 001</u>	Dec 09, 2011
<u>AB</u>	MYLAN	<u>25MG; 37.5MG</u>	<u>A074701 001</u>	Jun 07, 1996
<u>AB</u>	SANDOZ	<u>25MG; 37.5MG</u>	<u>A074821 001</u>	Jun 05, 1997
<u>AB</u>	+		<u>A073191 001</u>	Jul 31, 1991

TABLET; ORAL

MAXZIDE

<u>AB</u>	+	MYLAN PHARMS INC	<u>50MG; 75MG</u>	<u>N019129 001</u>	Oct 22, 1984
-----------	---	------------------	-------------------	--------------------	--------------

MAXZIDE-25

<u>AB</u>	MYLAN PHARMS INC	<u>25MG; 37.5MG</u>	<u>N019129 003</u>	May 13, 1988
-----------	------------------	---------------------	--------------------	--------------

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	ANI PHARMS INC	<u>50MG; 75MG</u>	<u>A073467 001</u>	Jan 31, 1996
<u>AB</u>	APOTEX INC	<u>25MG; 37.5MG</u>	<u>A071251 002</u>	May 05, 1998
<u>AB</u>		<u>50MG; 75MG</u>	<u>A071251 001</u>	Apr 17, 1988
<u>AB</u>	PLIVA	<u>25MG; 37.5MG</u>	<u>A074026 001</u>	Apr 26, 1996
<u>AB</u>	SANDOZ	<u>25MG; 37.5MG</u>	<u>A073281 001</u>	Apr 30, 1992
<u>AB</u>		<u>50MG; 75MG</u>	<u>A072011 001</u>	Jun 17, 1988
<u>AB</u>	WATSON LABS	<u>25MG; 37.5MG</u>	<u>A073449 001</u>	Sep 23, 1993
<u>AB</u>		<u>50MG; 75MG</u>	<u>A071851 001</u>	Nov 30, 1988

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

DIOVAN HCT

<u>AB</u>	NOVARTIS	<u>12.5MG; 80MG</u>	<u>N020818 001</u>	Mar 06, 1998
<u>AB</u>		<u>12.5MG; 160MG</u>	<u>N020818 002</u>	Mar 06, 1998
<u>AB</u>		<u>12.5MG; 320MG</u>	<u>N020818 004</u>	Apr 28, 2006
<u>AB</u>		<u>25MG; 160MG</u>	<u>N020818 003</u>	Jan 17, 2002
<u>AB</u>	+	<u>25MG; 320MG</u>	<u>N020818 005</u>	Apr 28, 2006

VALSARTAN AND HYDROCHLOROTHIAZIDE

<u>AB</u>	ALEMBIC LTD	<u>12.5MG; 80MG</u>	<u>A201662 001</u>	Mar 21, 2013
<u>AB</u>		<u>12.5MG; 160MG</u>	<u>A201662 002</u>	Mar 21, 2013
<u>AB</u>		<u>12.5MG; 320MG</u>	<u>A201662 003</u>	Mar 21, 2013
<u>AB</u>		<u>25MG; 160MG</u>	<u>A201662 004</u>	Mar 21, 2013
<u>AB</u>		<u>25MG; 320MG</u>	<u>A201662 005</u>	Mar 21, 2013
<u>AB</u>	APOTEX INC	<u>12.5MG; 80MG</u>	<u>A203026 001</u>	Mar 21, 2013
<u>AB</u>		<u>12.5MG; 160MG</u>	<u>A203026 002</u>	Mar 21, 2013
<u>AB</u>		<u>12.5MG; 320MG</u>	<u>A203026 003</u>	Mar 21, 2013
<u>AB</u>		<u>25MG; 160MG</u>	<u>A203026 004</u>	Mar 21, 2013
<u>AB</u>		<u>25MG; 320MG</u>	<u>A203026 005</u>	Mar 21, 2013
<u>AB</u>	AUROBINDO PHARMA LTD	<u>12.5MG; 80MG</u>	<u>A202519 001</u>	Mar 21, 2013
<u>AB</u>		<u>12.5MG; 160MG</u>	<u>A202519 002</u>	Mar 21, 2013

PRESCRIPTION DRUG PRODUCT LIST

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

<u>AB</u>		<u>12.5MG;320MG</u>	<u>A202519 003</u>	Mar 21, 2013
<u>AB</u>		<u>25MG;160MG</u>	<u>A202519 004</u>	Mar 21, 2013
<u>AB</u>		<u>25MG;320MG</u>	<u>A202519 005</u>	Mar 21, 2013
<u>AB</u>	LUPIN LTD	<u>12.5MG;80MG</u>	<u>A078946 003</u>	Mar 21, 2013
<u>AB</u>		<u>12.5MG;160MG</u>	<u>A078946 004</u>	Mar 21, 2013
<u>AB</u>		<u>12.5MG;320MG</u>	<u>A078946 001</u>	Mar 21, 2013
<u>AB</u>		<u>25MG;160MG</u>	<u>A078946 005</u>	Mar 21, 2013
<u>AB</u>		<u>25MG;320MG</u>	<u>A078946 002</u>	Mar 21, 2013
<u>AB</u>	MACLEODS PHARMS LTD	<u>12.5MG;80MG</u>	<u>A203145 001</u>	Apr 19, 2013
<u>AB</u>		<u>12.5MG;160MG</u>	<u>A203145 002</u>	Apr 19, 2013
<u>AB</u>		<u>12.5MG;320MG</u>	<u>A203145 003</u>	Apr 19, 2013
<u>AB</u>		<u>25MG;160MG</u>	<u>A203145 004</u>	Apr 19, 2013
<u>AB</u>		<u>25MG;320MG</u>	<u>A203145 005</u>	Apr 19, 2013
<u>AB</u>	MYLAN PHARMS INC	<u>12.5MG;80MG</u>	<u>A078020 001</u>	Sep 21, 2012
<u>AB</u>		<u>12.5MG;160MG</u>	<u>A078020 002</u>	Sep 21, 2012
<u>AB</u>		<u>12.5MG;320MG</u>	<u>A078020 004</u>	Sep 21, 2012
<u>AB</u>		<u>25MG;160MG</u>	<u>A078020 003</u>	Sep 21, 2012
<u>AB</u>		<u>25MG;320MG</u>	<u>A078020 005</u>	Sep 21, 2012
<u>AB</u>	PRINSTON INC	<u>12.5MG;80MG</u>	<u>A206083 001</u>	Feb 08, 2016
<u>AB</u>		<u>12.5MG;160MG</u>	<u>A206083 002</u>	Feb 08, 2016
<u>AB</u>		<u>12.5MG;320MG</u>	<u>A206083 003</u>	Feb 08, 2016
<u>AB</u>		<u>25MG;160MG</u>	<u>A206083 004</u>	Feb 08, 2016
<u>AB</u>		<u>25MG;320MG</u>	<u>A206083 005</u>	Feb 08, 2016
<u>AB</u>	WATSON LABS INC	<u>12.5MG;80MG</u>	<u>A091519 001</u>	Mar 21, 2013
<u>AB</u>		<u>12.5MG;160MG</u>	<u>A091519 002</u>	Mar 21, 2013
<u>AB</u>		<u>12.5MG;320MG</u>	<u>A091519 003</u>	Mar 21, 2013
<u>AB</u>		<u>25MG;160MG</u>	<u>A091519 004</u>	Mar 21, 2013
<u>AB</u>		<u>25MG;320MG</u>	<u>A091519 005</u>	Mar 21, 2013

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

ZOHYDRO ER

+	PERNIX IRELAND PAIN	10MG	N202880 001	Oct 25, 2013
		15MG	N202880 002	Oct 25, 2013
		20MG	N202880 003	Oct 25, 2013
		30MG	N202880 004	Oct 25, 2013
		40MG	N202880 005	Oct 25, 2013
		50MG	N202880 006	Oct 25, 2013

TABLET, EXTENDED RELEASE; ORAL

HYSINGLA

+	PURDUE PHARMA LP	20MG	N206627 001	Nov 20, 2014
		30MG	N206627 002	Nov 20, 2014
		40MG	N206627 003	Nov 20, 2014
		60MG	N206627 004	Nov 20, 2014
		80MG	N206627 005	Nov 20, 2014
		100MG	N206627 006	Nov 20, 2014
		120MG	N206627 007	Nov 20, 2014

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

<u>AB</u>	ACTAVIS LABS FL INC	<u>7.5MG;200MG</u>	<u>A076604 001</u>	Dec 31, 2003
<u>AB</u>	AMNEAL PHARMS NY	<u>5MG;200MG</u>	<u>A076642 002</u>	Mar 18, 2004
<u>AB</u>		<u>7.5MG;200MG</u>	<u>A076642 001</u>	Oct 12, 2004
<u>AB</u>	AUROLIFE PHARMA LLC	<u>7.5MG;200MG</u>	<u>A204575 001</u>	Jun 02, 2016
<u>AB</u>	SUN PHARM INDS INC	<u>2.5MG;200MG</u>	<u>A091633 001</u>	May 28, 2013
<u>AB</u>		<u>5MG;200MG</u>	<u>A091633 002</u>	May 28, 2013
<u>AB</u>		<u>7.5MG;200MG</u>	<u>A091633 003</u>	May 28, 2013
<u>AB</u>		<u>10MG;200MG</u>	<u>A091633 004</u>	May 28, 2013
<u>AB</u>	TEVA	<u>7.5MG;200MG</u>	<u>A076023 001</u>	Apr 11, 2003
<u>AB</u>	VINTAGE PHARMS	<u>5MG;200MG</u>	<u>A077727 001</u>	Nov 06, 2006
<u>AB</u>		<u>7.5MG;200MG</u>	<u>A077723 001</u>	Nov 06, 2006
<u>AB</u>		<u>10MG;200MG</u>	<u>A077723 002</u>	Nov 06, 2006

REPREXAIN

<u>AB</u>	AMNEAL PHARMS NY	<u>2.5MG;200MG</u>	<u>A076642 003</u>	Oct 19, 2007
<u>AB</u>		<u>10MG;200MG</u>	<u>A076642 004</u>	Oct 19, 2007
<u>AB</u>	+	<u>7.5MG;200MG</u>	<u>N020716 001</u>	Sep 23, 1997

PRESCRIPTION DRUG PRODUCT LIST

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

<u>AA</u>	COASTAL PHARMS	<u>5MG/5ML; 60MG/5ML</u>	<u>A205658 001</u>	Nov 17, 2015
<u>AA</u>	PADDOCK LLC	<u>5MG/5ML; 60MG/5ML</u>	<u>A204658 001</u>	Apr 29, 2014
<u>AA</u>	TRIS PHARMA INC	<u>5MG/5ML; 60MG/5ML</u>	<u>A203839 001</u>	Oct 28, 2014

REZIRA

<u>AA</u>	+ CYPRESS PHARM	<u>5MG/5ML; 60MG/5ML</u>	<u>N022442 001</u>	Jun 08, 2011
-----------	-----------------	--------------------------	--------------------	--------------

HYDROCORTISONE

CREAM; TOPICAL

ALA-CORT

<u>AT</u>	CROWN LABS	<u>2.5%</u>	<u>A080706 007</u>	Jan 05, 2016
<u>AT</u>		<u>1%</u>	<u>A080706 006</u>	

ANUSOL HC

<u>AT</u>	SALIX PHARMS	<u>2.5%</u>	<u>A088250 001</u>	Jun 06, 1984
-----------	--------------	-------------	--------------------	--------------

HYDROCORTISONE

<u>AT</u>	ACTAVIS MID ATLANTIC	<u>1%</u>	<u>A087795 001</u>	May 03, 1983
<u>AT</u>		<u>2.5%</u>	<u>A089682 001</u>	Mar 10, 1988
<u>AT</u>	+ FOUGERA	<u>1%</u>	<u>A080693 003</u>	
<u>AT</u>	+	<u>2.5%</u>	<u>A089414 001</u>	Dec 16, 1986
<u>AT</u>	PERRIGO NEW YORK	<u>2.5%</u>	<u>A085025 001</u>	
<u>AT</u>	RISING PHARMS INC	<u>2.5%</u>	<u>A040879 001</u>	Aug 20, 2010
<u>AT</u>	TARO	<u>2.5%</u>	<u>A088799 001</u>	Nov 09, 1984
<u>AT</u>	VINTAGE PHARMS	<u>2.5%</u>	<u>A040503 001</u>	Mar 12, 2004

SYNACORT

<u>AT</u>	MEDICIS	<u>1%</u>	<u>A087458 001</u>	
<u>AT</u>		<u>2.5%</u>	<u>A087457 001</u>	

ENEMA; RECTAL

COLOCORT

<u>AB</u>	PADDOCK LLC	<u>100MG/60ML</u>	<u>A075172 001</u>	Dec 03, 1999
-----------	-------------	-------------------	--------------------	--------------

CORTENEMA

<u>AB</u>	+ ANI PHARMS	<u>100MG/60ML</u>	<u>N016199 001</u>	
-----------	--------------	-------------------	--------------------	--

HYDROCORTISONE

<u>AB</u>	TEVA PHARMS	<u>100MG/60ML</u>	<u>A074171 001</u>	May 27, 1994
-----------	-------------	-------------------	--------------------	--------------

LOTION; TOPICAL

HYDROCORTISONE

<u>AT</u>	+ FOUGERA PHARMS	<u>2.5%</u>	<u>A040351 001</u>	Jul 25, 2000
<u>AT</u>	TARO	<u>2.5%</u>	<u>A040247 001</u>	Jul 23, 1999
<u>AT</u>	VINTAGE PHARMS	<u>2.5%</u>	<u>A040417 001</u>	Jul 30, 2003

STIE-CORT

<u>AT</u>	PERRIGO	<u>2.5%</u>	<u>A089074 001</u>	Nov 26, 1985
-----------	---------	-------------	--------------------	--------------

ALA-SCALP

	CROWN LABS	2%	A083231 001	
--	------------	----	-------------	--

OINTMENT; TOPICAL

HYDROCORTISONE

<u>AT</u>	ACTAVIS MID ATLANTIC	<u>1%</u>	<u>A087796 001</u>	Oct 13, 1982
<u>AT</u>	+ FOUGERA	<u>2.5%</u>	<u>A081203 001</u>	May 28, 1993
<u>AT</u>	+ FOUGERA PHARMS	<u>1%</u>	<u>A080692 001</u>	
<u>AT</u>	PERRIGO NEW YORK	<u>2.5%</u>	<u>A085027 001</u>	
<u>AT</u>	TARO	<u>1%</u>	<u>A086257 001</u>	

HYDROCORTISONE IN ABSORBASE

<u>AT</u>	CAROLINA MEDCL	<u>1%</u>	<u>A088138 001</u>	Sep 06, 1985
-----------	----------------	-----------	--------------------	--------------

SOLUTION; TOPICAL

TEXACORT

	+ MISSION PHARMA	2.5%	A081271 001	Apr 17, 1992
--	------------------	------	-------------	--------------

TABLET; ORAL

CORTEF

<u>AB</u>	PHARMACIA AND UPJOHN	<u>5MG</u>	<u>N008697 003</u>	
<u>AB</u>		<u>10MG</u>	<u>N008697 001</u>	
<u>AB</u>	+	<u>20MG</u>	<u>N008697 002</u>	

HYDROCORTISONE

<u>AB</u>	HIKMA INTL PHARMS	<u>5MG</u>	<u>A083365 002</u>	Feb 23, 2015
<u>AB</u>		<u>10MG</u>	<u>A083365 003</u>	Feb 23, 2015
<u>AB</u>		<u>20MG</u>	<u>A083365 001</u>	
<u>AB</u>	IMPAX LABS INC	<u>5MG</u>	<u>A040646 001</u>	Mar 30, 2007
<u>AB</u>		<u>10MG</u>	<u>A040646 002</u>	Mar 30, 2007
<u>AB</u>		<u>20MG</u>	<u>A040646 003</u>	Mar 30, 2007
<u>AB</u>	PHARMACEUTICS INTL	<u>5MG</u>	<u>A207029 001</u>	Apr 26, 2016
<u>AB</u>		<u>10MG</u>	<u>A207029 002</u>	Apr 26, 2016
<u>AB</u>		<u>20MG</u>	<u>A207029 003</u>	Apr 26, 2016
<u>AB</u>	VINTAGE	<u>5MG</u>	<u>A040761 001</u>	Jul 16, 2007
<u>AB</u>		<u>10MG</u>	<u>A040761 002</u>	Jul 16, 2007

PRESCRIPTION DRUG PRODUCT LIST

HYDROCORTISONE

TABLET; ORAL

HYDROCORTISONE

AB	20MG	A040761 003	Jul 16, 2007
-----------	-------------	--------------------	--------------

HYDROCORTISONE ACETATE

AEROSOL, METERED; RECTAL

CORTIFOAM

+ MEDA PHARMS

10%

N017351 001 Feb 10, 1982

CREAM; TOPICAL

HYDROCORTISONE ACETATE

+ FERNDAL LABS

2.5%

A040259 001 Jul 29, 1999

MICORT-HC

+ SEBELA IRELAND LTD

2%

A040398 001 Mar 29, 2002

2.5%

A040396 001 Feb 27, 2001

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM; TOPICAL

CORTISPORIN

+ MONARCH PHARMS

0.5%; EQ 3.5MG BASE/GM; 10,000 UNITS/GM

N050218 001 Aug 09, 1985

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL

EPIFOAM

BX MEDA PHARMS

1%; 1%

A086457 001

PROCTOFOAM HC

BX MEDA PHARMS

1%; 1%

A086195 001

CREAM; TOPICAL

PRAMOSONE

SEBELA IRELAND LTD

0.5%; 1%

A083778 001

1%; 1%

A085368 001

LOTION; TOPICAL

PRAMOSONE

SEBELA IRELAND LTD

1%; 1%

A085980 001

2.5%; 1%

A085979 001

HYDROCORTISONE ACETATE; UREA

CREAM; TOPICAL

U-CORT

TARO

1%; 10%

A089472 001 Jun 13, 1988

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL

HYDROCORTISONE BUTYRATE**AB1** TARO PHARM INDS**0.1%****A076654 001** Aug 03, 2005LOCROID**AB1** + PRECISION DERMAT**0.1%****N018514 001** Mar 31, 1982HYDROCORTISONE BUTYRATE**AB2** GLENMARK GENERICS**0.1%****A202145 001** Sep 27, 2013LOCROID LIPOCREAM**AB2** + PRECISION DERMAT**0.1%****N020769 001** Sep 08, 1997

LOTION; TOPICAL

LOCROID

+ PRECISION DERMAT

0.1%

N022076 001 May 18, 2007

OINTMENT; TOPICAL

HYDROCORTISONE BUTYRATE**AB** TARO**0.1%****A076842 001** Dec 27, 2004LOCROID**AB** + PRECISION DERMAT**0.1%****N018652 001** Oct 29, 1982

SOLUTION; TOPICAL

HYDROCORTISONE BUTYRATE**AT** TARO PHARM INDS**0.1%****A076364 001** Jan 14, 2004LOCROID**AT** + PRECISION DERMAT**0.1%****N019116 001** Feb 25, 1987HYDROCORTISONE PROBUTATE

CREAM; TOPICAL

PANDEL

+ FOUGERA PHARMS

0.1%

N020453 001 Feb 28, 1997

PRESCRIPTION DRUG PRODUCT LIST

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-HYDROCORT

<u>AP</u>	HOSPIRA	<u>EQ 100MG BASE/VIAL</u>	<u>A040666</u>	<u>001</u>	Apr 06, 2006
<u>SOLU-CORTEF</u>					
<u>AP</u>	+	PHARMACIA AND UPJOHN	<u>EQ 100MG BASE/VIAL</u>	<u>N009866</u>	<u>001</u>
<u>AP</u>	+		<u>EQ 250MG BASE/VIAL</u>	<u>N009866</u>	<u>002</u>
<u>AP</u>	+		<u>EQ 500MG BASE/VIAL</u>	<u>N009866</u>	<u>003</u>
<u>AP</u>	+		<u>EQ 1GM BASE/VIAL</u>	<u>N009866</u>	<u>004</u>

HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATE

<u>AB</u>	PERRIGO NEW YORK	<u>0.2%</u>	<u>A075666</u>	<u>001</u>	May 24, 2000
<u>AB</u>	+	TARO	<u>0.2%</u>	<u>A075042</u>	<u>001</u>
OINTMENT; TOPICAL					
HYDROCORTISONE VALERATE					
	+	TARO	0.2%	A075043	001
					Aug 25, 1998

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

CORTISPORIN

<u>AT</u>	+	MONARCH PHARMS	<u>1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>N050479</u>	<u>001</u>
<u>NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE</u>					
<u>AT</u>		ALCON PHARMS LTD	<u>1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A062423</u>	<u>001</u>
<u>AT</u>		BAUSCH AND LOMB	<u>1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A064053</u>	<u>001</u>
<u>AT</u>		LUITPOLD	<u>1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A065216</u>	<u>001</u>
SUSPENSION/DROPS; OPHTHALMIC					
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE					
	+	ALCON PHARMS LTD	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062874	001
					May 11, 1988

SUSPENSION/DROPS; OTIC

CORTISPORIN

<u>AT</u>	+	CASPER PHARMA LLC	<u>1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>N060613</u>	<u>001</u>
<u>NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE</u>					
<u>AT</u>		ALCON PHARMS LTD	<u>1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A062488</u>	<u>001</u>
<u>AT</u>		LUITPOLD	<u>1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A065219</u>	<u>001</u>
<u>OTICAIR</u>					
<u>AT</u>		BAUSCH AND LOMB	<u>1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A064065</u>	<u>001</u>
					Aug 28, 1996

HYDROFLUMETHIAZIDE

TABLET; ORAL

SALURON

<u>AB</u>	+	SHIRE LLC	<u>50MG</u>	<u>N011949</u>	<u>001</u>
-----------	---	-----------	-------------	----------------	------------

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

DILAUDID

<u>AP</u>	+	PURDUE PHARM PRODS	<u>1MG/ML</u>	<u>N019034</u>	<u>003</u>
<u>AP</u>	+		<u>2MG/ML</u>	<u>N019034</u>	<u>004</u>
<u>AP</u>	+		<u>4MG/ML</u>	<u>N019034</u>	<u>005</u>

DILAUDID-HP

<u>AP</u>	+	PURDUE PHARM PRODS	<u>10MG/ML</u>	<u>N019034</u>	<u>001</u>
					Jan 11, 1984

HYDROMORPHONE HYDROCHLORIDE

<u>AP</u>		AKORN	<u>10MG/ML</u>	<u>A078228</u>	<u>001</u>
<u>AP</u>			<u>10MG/ML</u>	<u>A078261</u>	<u>001</u>
<u>AP</u>		BARR	<u>10MG/ML</u>	<u>A076444</u>	<u>001</u>
<u>AP</u>		HOSPIRA	<u>10MG/ML</u>	<u>A074598</u>	<u>001</u>
<u>AP</u>		HOSPIRA INC	<u>1MG/ML</u>	<u>N200403</u>	<u>001</u>
<u>AP</u>			<u>2MG/ML</u>	<u>N200403</u>	<u>002</u>
<u>AP</u>			<u>4MG/ML</u>	<u>N200403</u>	<u>003</u>
<u>AP</u>			<u>10MG/ML</u>	<u>A078591</u>	<u>001</u>
					Jun 17, 2008

SOLUTION; ORAL

DILAUDID

<u>AA</u>	+	PURDUE PHARM PRODS	<u>5MG/5ML</u>	<u>N019891</u>	<u>001</u>
					Dec 07, 1992

HYDROMORPHONE HYDROCHLORIDE

<u>AA</u>		WEST-WARD PHARMS INT	<u>5MG/5ML</u>	<u>A074653</u>	<u>001</u>
					Jul 29, 1998

TABLET; ORAL

DILAUDID

<u>AB</u>		PURDUE PHARM PRODS	<u>2MG</u>	<u>N019892</u>	<u>003</u>
<u>AB</u>			<u>4MG</u>	<u>N019892</u>	<u>002</u>
<u>AB</u>	+		<u>8MG</u>	<u>N019892</u>	<u>001</u>
					Dec 07, 1992

HYDROMORPHONE HYDROCHLORIDE

<u>AB</u>		AUROLIFE PHARMA LLC	<u>2MG</u>	<u>A205814</u>	<u>001</u>
<u>AB</u>			<u>4MG</u>	<u>A205814</u>	<u>002</u>
					May 13, 2016
					May 13, 2016

PRESCRIPTION DRUG PRODUCT LIST

HYDROMORPHONE HYDROCHLORIDE

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

<u>AB</u>		<u>8MG</u>	<u>A205814</u>	<u>003</u>	May 13, 2016
<u>AB</u>	ELITE LABS	<u>8MG</u>	<u>A076723</u>	<u>001</u>	Oct 18, 2005
<u>AB</u>	LANNETT	<u>2MG</u>	<u>A077471</u>	<u>002</u>	Dec 09, 2009
<u>AB</u>		<u>2MG</u>	<u>A078439</u>	<u>001</u>	Dec 09, 2009
<u>AB</u>		<u>4MG</u>	<u>A077471</u>	<u>003</u>	Dec 09, 2009
<u>AB</u>		<u>4MG</u>	<u>A078439</u>	<u>002</u>	Dec 09, 2009
<u>AB</u>		<u>8MG</u>	<u>A077471</u>	<u>001</u>	Dec 09, 2009
<u>AB</u>	MALLINCKRODT	<u>2MG</u>	<u>A076855</u>	<u>002</u>	Sep 19, 2007
<u>AB</u>		<u>4MG</u>	<u>A076855</u>	<u>003</u>	Sep 19, 2007
<u>AB</u>		<u>8MG</u>	<u>A076855</u>	<u>001</u>	Dec 23, 2004
<u>AB</u>	WEST-WARD PHARMS INT	<u>4MG</u>	<u>A074597</u>	<u>003</u>	May 29, 2009
<u>AB</u>		<u>8MG</u>	<u>A074597</u>	<u>001</u>	Jul 29, 1998

TABLET, EXTENDED RELEASE; ORAL

EXALGO

<u>AB</u>	MALLINCKRODT INC	<u>8MG</u>	<u>N021217</u>	<u>001</u>	Mar 01, 2010
<u>AB</u>		<u>12MG</u>	<u>N021217</u>	<u>002</u>	Mar 01, 2010
<u>AB</u>		<u>16MG</u>	<u>N021217</u>	<u>003</u>	Mar 01, 2010
<u>AB</u>	+	<u>32MG</u>	<u>N021217</u>	<u>004</u>	Aug 24, 2012

HYDROMORPHONE HYDROCHLORIDE

<u>AB</u>	ACTAVIS LABS FL INC	<u>8MG</u>	<u>A202144</u>	<u>001</u>	May 12, 2014
<u>AB</u>		<u>12MG</u>	<u>A202144</u>	<u>002</u>	May 12, 2014
<u>AB</u>		<u>16MG</u>	<u>A202144</u>	<u>003</u>	May 12, 2014
<u>AB</u>		<u>32MG</u>	<u>A202144</u>	<u>004</u>	Jun 30, 2016
<u>AB</u>	OSMOTICA	<u>8MG</u>	<u>A205629</u>	<u>001</u>	Jul 07, 2016
<u>AB</u>		<u>12MG</u>	<u>A205629</u>	<u>002</u>	Jul 07, 2016
<u>AB</u>		<u>16MG</u>	<u>A205629</u>	<u>003</u>	Jul 07, 2016
<u>AB</u>		<u>32MG</u>	<u>A205629</u>	<u>004</u>	Jul 07, 2016
<u>AB</u>	PADDOCK LLC	<u>8MG</u>	<u>A204278</u>	<u>001</u>	Apr 06, 2015
<u>AB</u>		<u>12MG</u>	<u>A204278</u>	<u>002</u>	Apr 06, 2015
<u>AB</u>		<u>16MG</u>	<u>A204278</u>	<u>003</u>	Apr 06, 2015

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

CYANOKIT

+	SERB SA	5GM/VIAL (5GM/KIT)	N022041	001	Apr 08, 2011
	HYDROXOCOBALAMIN				
+	WATSON LABS	1MG/ML	A085998	001	

HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

PAREMYD

+	AKORN	1%; 0.25%	N019261	001	Jan 30, 1992
---	-------	-----------	---------	-----	--------------

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

<u>AB</u>	HIKMA PHARMS LLC	<u>200MG</u>	<u>A040760</u>	<u>001</u>	Aug 15, 2007
<u>AB</u>	IPCA LABS LTD	<u>200MG</u>	<u>A040766</u>	<u>001</u>	Jun 14, 2007
<u>AB</u>	MYLAN	<u>200MG</u>	<u>A040274</u>	<u>001</u>	May 29, 1998
<u>AB</u>	SANDOZ	<u>200MG</u>	<u>A040104</u>	<u>001</u>	Nov 30, 1995
<u>AB</u>	TEVA PHARMS	<u>200MG</u>	<u>A040081</u>	<u>001</u>	Sep 30, 1994
<u>AB</u>	WATSON LABS	<u>200MG</u>	<u>A040133</u>	<u>001</u>	Nov 30, 1995
<u>AB</u>	ZYDUS PHARMS USA INC	<u>200MG</u>	<u>A040657</u>	<u>001</u>	Sep 21, 2007

PLAQUENIL

<u>AB</u>	+	CONCORDIA PHARMS INC	<u>200MG</u>	<u>N009768</u>	<u>001</u>
-----------	---	----------------------	--------------	----------------	------------

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION

HYDROXYPROGESTERONE CAPROATE

+	ASPEN GLOBAL INC	250MG/ML	A200271	001	Aug 24, 2015
---	------------------	----------	---------	-----	--------------

SOLUTION; INTRAMUSCULAR

MAKENA

+	AMAG PHARMA USA	1250MG/5ML (250MG/ML)	N021945	001	Feb 03, 2011
---	-----------------	-----------------------	---------	-----	--------------

MAKENA PRESERVATIVE FREE

+	AMAG PHARMA USA	250MG/ML (250MG/ML)	N021945	002	Feb 19, 2016
---	-----------------	---------------------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

HYDROXYPROPYL CELLULOSE

INSERT;OPHTHALMIC

LACRISERT

+ ATON

5MG

N018771 001

HYDROXYUREA

CAPSULE;ORAL

HYDREAAB + BRISTOL MYERS SQUIBB500MGN016295 001HYDROXYUREAAB BARR500MGA075143 001 Oct 16, 1998AB PAR PHARM500MGA075340 001 Feb 24, 1999

DROXIA

BRISTOL MYERS SQUIBB

200MG

N016295 002 Feb 25, 1998

300MG

N016295 003 Feb 25, 1998

400MG

N016295 004 Feb 25, 1998

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE HYDROCHLORIDEAP + FRESENIUS KABI USA25MG/MLA087329 001AP +50MG/MLA087329 002AP LUITPOLD25MG/MLA087408 001AP50MG/MLA087408 002

SYRUP;ORAL

HYDROXYZINE HYDROCHLORIDEAA + HI TECH PHARMA10MG/5MLA040010 001 Oct 28, 1994AA SILARX PHARMS INC10MG/5MLA201674 001 Aug 21, 2013AA + VINTAGE PHARMS10MG/5MLA040391 001 Apr 10, 2002AA + WOCKHARDT10MG/5MLA087294 001 Apr 12, 1982

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDEAB AMNEAL PHARM10MGA040808 001 Sep 24, 2008AB25MGA040808 002 Sep 24, 2008AB50MGA040808 003 Sep 24, 2008AB ECI PHARMS LLC10MGA040804 001 Jun 30, 2008AB25MGA040804 002 Jun 30, 2008AB50MGA040804 003 Jun 30, 2008AB ELITE LABS INC10MGA040604 002 Dec 28, 2004AB25MGA040604 003 Dec 28, 2004AB50MGA040604 001 Dec 28, 2004AB HERITAGE PHARMA10MGA204279 001 Aug 20, 2014AB25MGA204279 002 Aug 20, 2014AB50MGA204279 003 Aug 20, 2014AB HETERO LABS LTD III10MGA040805 001 May 29, 2008AB25MGA040805 002 May 29, 2008AB50MGA040805 003 May 29, 2008AB INVAGEN PHARMS10MGA040812 001 Mar 12, 2008AB25MGA040812 002 Mar 12, 2008AB50MGA040812 003 Mar 12, 2008AB KVK TECH10MGA040786 001 Mar 20, 2007AB25MGA040787 001 Mar 20, 2007AB50MGA040788 001 Mar 20, 2007AB MYLAN10MGA091176 001 Jun 07, 2010AB25MGA091176 002 Jun 07, 2010AB50MGA091176 003 Jun 07, 2010AB NORTHSTAR HLTHCARE10MGA040840 002 Mar 31, 2008AB25MGA040840 003 Mar 31, 2008AB50MGA040840 001 Mar 31, 2008AB + PLIVA10MGA088617 001 Jan 10, 1986AB +25MGA088618 001 Jan 10, 1986AB +50MGA088619 001 Jan 10, 1986AB SUN PHARM INDS INC10MGA040899 001 Jun 10, 2008AB25MGA040899 002 Jun 10, 2008AB50MGA040899 003 Jun 10, 2008AB VINTAGE PHARMS10MGA040579 001 May 27, 2005AB25MGA040574 001 May 27, 2005AB50MGA040580 001 May 27, 2005

PRESCRIPTION DRUG PRODUCT LIST

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

<u>AB</u>	BARR	<u>EQ 25MG HCL</u>	<u>A088496 001</u>	Jun 15, 1984
<u>AB</u>		<u>EQ 50MG HCL</u>	<u>A088487 001</u>	Jun 15, 1984
<u>AB</u>	HERITAGE PHARMA	<u>EQ 25MG HYDROCHLORIDE</u>	<u>A201507 001</u>	Jun 03, 2013
<u>AB</u>		<u>EQ 50MG HYDROCHLORIDE</u>	<u>A201507 002</u>	Jun 03, 2013
<u>AB</u>	IMPAX LABS INC	<u>EQ 25MG HCL</u>	<u>A040156 001</u>	Jul 15, 1996
<u>AB</u>		<u>EQ 50MG HCL</u>	<u>A040156 002</u>	Jul 15, 1996
<u>AB</u>	SANDOZ	<u>EQ 25MG HCL</u>	<u>A087479 001</u>	
<u>AB</u>		<u>EQ 50MG HCL</u>	<u>A086183 001</u>	

VISTARIL

<u>AB</u>	PFIZER	<u>EQ 25MG HCL</u>	<u>N011459 002</u>	
<u>AB</u>	+	<u>EQ 50MG HCL</u>	<u>N011459 004</u>	
	HYDROXYZINE PAMOATE			
	BARR	EQ 100MG HCL	A088488 001	Jun 15, 1984

IBANDRONATE SODIUM

INJECTABLE; INTRAVENOUS

BONIVA

<u>AP</u>	+	ROCHE	<u>EQ 3MG BASE/3ML</u>	<u>N021858 001</u>	Jan 06, 2006
		<u>IBANDRONATE SODIUM</u>			
<u>AP</u>		ACCORD HLTHCARE	<u>EQ 3MG BASE/3ML</u>	<u>A206058 001</u>	Feb 05, 2016
<u>AP</u>		APOTEX INC	<u>EQ 3MG BASE/3ML</u>	<u>A204222 001</u>	Oct 16, 2015
<u>AP</u>		AUROBINDO PHARMA LTD	<u>EQ 3MG BASE/3ML</u>	<u>A205332 001</u>	Aug 19, 2015
<u>AP</u>		EMCURE PHARMS LTD	<u>EQ 3MG BASE/3ML</u>	<u>A203987 001</u>	Sep 02, 2014
<u>AP</u>		MYLAN LABS LTD	<u>EQ 3MG BASE/3ML</u>	<u>A202671 001</u>	Sep 02, 2014
<u>AP</u>		SAGENT PHARMS	<u>EQ 3MG BASE/3ML</u>	<u>A202235 001</u>	Sep 02, 2014
<u>AP</u>		SUN PHARM INDS LTD	<u>EQ 3MG BASE/3ML</u>	<u>A090853 001</u>	Feb 14, 2014

TABLET; ORAL

BONIVA

<u>AB</u>	+	HOFFMANN LA ROCHE	<u>EQ 150MG BASE</u>	<u>N021455 002</u>	Mar 24, 2005
		<u>IBANDRONATE SODIUM</u>			
<u>AB</u>		APOTEX INC	<u>EQ 150MG BASE</u>	<u>A078948 001</u>	Mar 19, 2012
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 150MG BASE</u>	<u>A204502 001</u>	Mar 11, 2016
<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 150MG BASE</u>	<u>A078997 001</u>	Apr 30, 2012
<u>AB</u>		MYLAN PHARMS INC	<u>EQ 150MG BASE</u>	<u>A078995 001</u>	Mar 19, 2012
<u>AB</u>		ORCHID HLTHCARE	<u>EQ 150MG BASE</u>	<u>A078998 001</u>	Mar 19, 2012
<u>AB</u>		SUN PHARM INDS	<u>EQ 150MG BASE</u>	<u>A078996 001</u>	Aug 15, 2012
<u>AB</u>		WATSON LABS INC	<u>EQ 150MG BASE</u>	<u>A079003 001</u>	Mar 20, 2012

IBRUTINIB

CAPSULE; ORAL

IMBRUVICA

	+	PHARMACYCLICS INC	140MG	N205552 001	Nov 13, 2013
--	---	-------------------	-------	-------------	--------------

IBUPROFEN

SOLUTION; INTRAVENOUS

CALDOLOR

	+	CUMBERLAND PHARMS	800MG/8ML (100MG/ML)	N022348 002	Jun 11, 2009
--	---	-------------------	----------------------	-------------	--------------

SUSPENSION; ORAL

IBUPROFEN

<u>AB</u>	+	ACTAVIS MID ATLANTIC	<u>100MG/5ML</u>	<u>A074978 001</u>	Mar 25, 1998
<u>AB</u>		HI-TECH PHARMACAL	<u>100MG/5ML</u>	<u>A205647 001</u>	Nov 03, 2016
<u>AB</u>		PERRIGO R AND D	<u>100MG/5ML</u>	<u>A076925 001</u>	Sep 23, 2004

TABLET; ORAL

IBU-TAB

<u>AB</u>		ALRA	<u>400MG</u>	<u>A071058 001</u>	Aug 11, 1988
<u>AB</u>			<u>600MG</u>	<u>A071059 001</u>	Aug 11, 1988

IBUPROFEN

<u>AB</u>		AIPING PHARM INC	<u>400MG</u>	<u>A202413 001</u>	Nov 23, 2016
<u>AB</u>			<u>600MG</u>	<u>A202413 002</u>	Nov 23, 2016
<u>AB</u>			<u>800MG</u>	<u>A202413 003</u>	Nov 23, 2016
<u>AB</u>		AMNEAL PHARMS NY	<u>400MG</u>	<u>A071334 001</u>	Nov 25, 1986
<u>AB</u>			<u>400MG</u>	<u>A078558 001</u>	Jun 18, 2007
<u>AB</u>			<u>600MG</u>	<u>A071335 001</u>	Nov 25, 1986
<u>AB</u>			<u>600MG</u>	<u>A078558 002</u>	Jun 18, 2007
<u>AB</u>			<u>800MG</u>	<u>A071935 001</u>	Oct 13, 1987
<u>AB</u>			<u>800MG</u>	<u>A078558 003</u>	Jun 18, 2007
<u>AB</u>		CONTRACT PHARMACAL	<u>400MG</u>	<u>A071268 002</u>	Oct 15, 1986
<u>AB</u>			<u>600MG</u>	<u>A071268 001</u>	Oct 15, 1986
<u>AB</u>			<u>800MG</u>	<u>A071268 003</u>	Jul 01, 1988
<u>AB</u>		DR REDDYS LA	<u>400MG</u>	<u>A075682 001</u>	Nov 14, 2001
<u>AB</u>			<u>600MG</u>	<u>A075682 002</u>	Nov 14, 2001

PRESCRIPTION DRUG PRODUCT LIST

IBUPROFEN

TABLET; ORAL

IBUPROFEN

<u>AB</u>	+		<u>800MG</u>	<u>A075682</u>	<u>003</u>	Nov 14, 2001
<u>AB</u>		DR REDDYS LABS INC	<u>400MG</u>	<u>A076112</u>	<u>001</u>	Oct 31, 2001
<u>AB</u>			<u>600MG</u>	<u>A076112</u>	<u>002</u>	Oct 31, 2001
<u>AB</u>			<u>800MG</u>	<u>A076112</u>	<u>003</u>	Oct 31, 2001
<u>AB</u>		GRANULES INDIA LTD	<u>400MG</u>	<u>A091625</u>	<u>001</u>	Sep 15, 2015
<u>AB</u>			<u>600MG</u>	<u>A091625</u>	<u>002</u>	Sep 15, 2015
<u>AB</u>			<u>800MG</u>	<u>A091625</u>	<u>003</u>	Sep 15, 2015
<u>AB</u>		MARKSANS PHARMA	<u>400MG</u>	<u>A090796</u>	<u>001</u>	Dec 21, 2010
<u>AB</u>			<u>600MG</u>	<u>A090796</u>	<u>002</u>	Dec 21, 2010
<u>AB</u>			<u>800MG</u>	<u>A090796</u>	<u>003</u>	Dec 21, 2010
<u>AB</u>		PERRIGO R AND D	<u>400MG</u>	<u>A077114</u>	<u>001</u>	Jul 18, 2005
<u>AB</u>			<u>600MG</u>	<u>A077114</u>	<u>002</u>	Jul 18, 2005
<u>AB</u>			<u>800MG</u>	<u>A077114</u>	<u>003</u>	Jul 18, 2005
<u>AB</u>		STRIDES PHARMA	<u>400MG</u>	<u>A078329</u>	<u>001</u>	Feb 05, 2009
<u>AB</u>			<u>600MG</u>	<u>A078329</u>	<u>002</u>	Feb 05, 2009
<u>AB</u>			<u>800MG</u>	<u>A078329</u>	<u>003</u>	Feb 05, 2009
<u>AB</u>		VINTAGE PHARMS	<u>400MG</u>	<u>A071644</u>	<u>001</u>	Feb 01, 1988

IBUPROFEN LYSINE

INJECTABLE; INTRAVENOUS

IBUPROFEN LYSINE

<u>AP</u>		EXELA PHARMA SCIENCE	<u>EQ 20MG BASE/2ML (EQ 10MG BASE/ML)</u>	<u>A202402</u>	<u>001</u>	Mar 30, 2016
<u>AP</u>	+	RECORDATI RARE	<u>EQ 20MG BASE/2ML (EQ 10MG BASE/ML)</u>	<u>N021903</u>	<u>001</u>	Apr 13, 2006

IBUPROFEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE HYDROCHLORIDE AND IBUPROFEN

<u>AB</u>		ACTAVIS ELIZABETH	<u>400MG; 5MG</u>	<u>A078769</u>	<u>001</u>	Jan 04, 2008
<u>AB</u>	+	BARR LABS INC	<u>400MG; 5MG</u>	<u>A078316</u>	<u>001</u>	Nov 29, 2007
<u>AB</u>		WATSON LABS	<u>400MG; 5MG</u>	<u>A078394</u>	<u>001</u>	Nov 26, 2007

IBUTILIDE FUMARATE

INJECTABLE; INJECTION

CORVERT

<u>AP</u>	+	PHARMACIA AND UPJOHN	<u>0.1MG/ML</u>	<u>N020491</u>	<u>001</u>	Dec 28, 1995
<u>AP</u>		LUITPOLD	<u>0.1MG/ML</u>	<u>A090240</u>	<u>001</u>	Jan 11, 2010
<u>AP</u>		MYLAN INSTITUTIONAL	<u>0.1MG/ML</u>	<u>A090643</u>	<u>001</u>	Jan 11, 2010
<u>AP</u>			<u>0.1MG/ML</u>	<u>A090924</u>	<u>001</u>	Jan 11, 2010

ICATIBANT ACETATE

INJECTABLE; SUBCUTANEOUS

FIRAZYR

	+	SHIRE ORPHAN THERAP	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>N022150</u>	<u>001</u>	Aug 25, 2011
--	---	---------------------	---	----------------	------------	--------------

ICODEXTRIN

SOLUTION; INTRAPERITONEAL

EXTRANEAL

	+	BAXTER HLTHCARE	<u>7.5GM/100ML</u>	<u>N021321</u>	<u>001</u>	Dec 20, 2002
--	---	-----------------	--------------------	----------------	------------	--------------

ICOSAPENT ETHYL

CAPSULE; ORAL

VASCEPA

	+	AMARIN PHARMS	<u>1GM</u>	<u>N202057</u>	<u>001</u>	Jul 26, 2012
--	---	---------------	------------	----------------	------------	--------------

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDAMYCIN PFS

<u>AP</u>	+	PHARMACIA AND UPJOHN	<u>1MG/ML</u>	<u>N050734</u>	<u>001</u>	Feb 17, 1997
<u>AP</u>		FRESENIUS KABI USA	<u>1MG/ML</u>	<u>A065440</u>	<u>001</u>	Aug 04, 2009
<u>AP</u>		MYLAN LABS LTD	<u>1MG/ML</u>	<u>A200144</u>	<u>001</u>	Oct 11, 2012
<u>AP</u>		WEST-WARD PHARMS INT	<u>1MG/ML</u>	<u>A065275</u>	<u>001</u>	Dec 14, 2006
<u>AP</u>			<u>1MG/ML</u>	<u>A065288</u>	<u>001</u>	May 15, 2007
<u>AP</u>		TEVA PHARMS USA	<u>1MG/ML</u>	<u>A065036</u>	<u>001</u>	May 01, 2002

PRESCRIPTION DRUG PRODUCT LIST

IDELALISIB

TABLET; ORAL

ZYDELIG

GILEAD SCIENCES INC
+100MG
150MGN205858 001 Jul 23, 2014
N205858 002 Jul 23, 2014IDOXURIDINE

SOLUTION/DROPS; OPHTHALMIC

DENDRID

+ ALCON

0.1%

N014169 001

IFOSFAMIDE

INJECTABLE; INJECTION

IFEXAP BAXTER HLTHCARE1GM/VIALN019763 001 Dec 30, 1988AP3GM/VIALN019763 002 Dec 30, 1988IFOSFAMIDEAP + FRESENIUS KABI USA1GM/VIALA076078 001 May 28, 2002AP1GM/20ML (50MG/ML)A090181 001 Sep 22, 2009AP +3GM/VIALA076078 002 May 28, 2002AP3GM/60ML (50MG/ML)A090181 002 Sep 22, 2009AP MYLAN LABS LTD1GM/20ML (50MG/ML)A201689 001 Nov 26, 2012AP3GM/60ML (50MG/ML)A201689 002 Nov 26, 2012AP + TEVA PHARMS USA1GM/20ML (50MG/ML)A076657 001 Apr 04, 2007AP +3GM/60ML (50MG/ML)A076657 002 Apr 04, 2007AP WEST-WARD PHARMS INT1GM/20ML (50MG/ML)A076619 001 Jun 29, 2011AP3GM/60ML (50MG/ML)A076619 002 Jun 29, 2011IFOSFAMIDE; MESNA

INJECTABLE; INTRAVENOUS

IFOSFAMIDE/MESNA KIT

+ TEVA PHARMS USA

1GM/20ML; 1GM/10ML (50MG/ML; 100MG/ML)

A075874 001 Feb 26, 2002

+

3GM/60ML; 1GM/10ML (50MG/ML; 100MG/ML)

A075874 002 Feb 26, 2002

ILOPERIDONE

TABLET; ORAL

FANAPTAB + VANDA PHARMS INC1MGN022192 001 May 06, 2009AB2MGN022192 002 May 06, 2009AB4MGN022192 003 May 06, 2009AB6MGN022192 004 May 06, 2009AB8MGN022192 005 May 06, 2009AB10MGN022192 006 May 06, 2009AB12MGN022192 007 May 06, 2009ILOPERIDONEAB INVENTIA HLTHCARE1MGA207231 001 Nov 28, 2016AB2MGA207231 002 Nov 28, 2016AB4MGA207231 003 Nov 28, 2016AB6MGA207231 004 Nov 28, 2016AB8MGA207231 005 Nov 28, 2016AB10MGA207231 006 Nov 28, 2016AB12MGA207231 007 Nov 28, 2016ILOPROST

SOLUTION; INHALATION

VENTAVIS

+ ACTELION PHARMS LTD

10MCG/ML (10MCG/ML)

N021779 002 Dec 08, 2005

+

20MCG/ML (20MCG/ML)

N021779 003 Aug 07, 2009

IMATINIB MESYLATE

TABLET; ORAL

GLEEVECAB NOVARTISEQ 100MG BASEN021588 001 Apr 18, 2003AB +EQ 400MG BASEN021588 002 Apr 18, 2003IMATINIB MESYLATEAB APOTEX INCEQ 100MG BASEA079179 001 Aug 05, 2016ABEQ 400MG BASEA079179 002 Aug 05, 2016AB SUN PHARMA GLOBALEQ 100MG BASEA078340 001 Dec 03, 2015ABEQ 400MG BASEA078340 002 Dec 03, 2015AB TEVA PHARMS USAEQ 100MG BASEA204285 001 Aug 04, 2016ABEQ 400MG BASEA204285 002 Aug 04, 2016

PRESCRIPTION DRUG PRODUCT LIST

IMIGLUCERASE

INJECTABLE; INJECTION

CEREZYME

GENZYME

200 UNITS/VIAL

N020367 001 May 23, 1994

+

400 UNITS/VIAL

N020367 002 Sep 22, 1999

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDEAB LEADING PHARMA LLC10MGA040903 001 Oct 24, 2012AB 25MGA040903 002 Oct 24, 2012AB 50MGA040903 003 Oct 24, 2012AB LUPIN LTD10MGA090441 002 Mar 11, 2010AB 25MGA090441 003 Mar 11, 2010AB 50MGA090441 001 Mar 11, 2010AB PAR PHARM10MGA088292 001 Oct 21, 1983AB 10MGA089422 001 Jul 14, 1987AB 25MGA088262 001 Oct 21, 1983AB 50MGA088276 001 Oct 21, 1983AB SANDOZ10MGA084936 002AB 25MGA083745 001AB 50MGA084937 001AB SUN PHARM INDS10MGA081048 001 Jun 05, 1990AB 25MGA081049 001 Jun 05, 1990AB 50MGA081050 001 Jun 05, 1990TOFRANILAB MALLINCKRODT INC10MGA087844 001 May 22, 1984AB 25MGA087845 001 May 22, 1984AB + 50MGA087846 001 May 22, 1984IMIPRAMINE PAMOATE

CAPSULE; ORAL

IMIPRAMINE PAMOATEAB LUPIN LTDEQ 75MG HCLA090444 001 Apr 16, 2010AB EQ 100MG HCLA090444 002 Apr 16, 2010AB EQ 125MG HCLA090444 003 Apr 16, 2010AB EQ 150MG HCLA090444 004 Apr 16, 2010AB MYLAN PHARMS INCEQ 75MG HCLA202338 001 Jun 28, 2013AB EQ 100MG HCLA202338 002 Jun 28, 2013AB EQ 125MG HCLA202338 003 Jun 28, 2013AB EQ 150MG HCLA202338 004 Jun 28, 2013AB + WEST-WARD PHARMS INTEQ 75MG HCLA091099 001 Apr 16, 2010AB EQ 100MG HCLA091099 002 Apr 16, 2010AB EQ 125MG HCLA091099 003 Apr 16, 2010AB EQ 150MG HCLA091099 004 Apr 16, 2010IMIQUIMOD

CREAM; TOPICAL

ALDARAAB + MEDICIS5%N020723 001 Feb 27, 1997IMIQUIMODAB APOTEX INC5%A091308 001 Apr 06, 2012AB FOUGERA PHARMS5%A078548 001 Feb 25, 2010AB G AND W LABS INC5%A200481 001 Apr 18, 2011AB GLENMARK GENERICS5%A201994 001 Mar 06, 2012AB PERRIGO ISRAEL5%A078837 001 Sep 07, 2010AB STRIDES PHARMA5%A202002 001 Jun 24, 2014AB TARO5%A200173 001 Apr 15, 2011AB TOLMAR5%A091044 001 Feb 28, 2011

ZYCLARA

+ MEDICIS

2.5%

N022483 002 Jul 15, 2011

+

3.75%

N022483 001 Mar 25, 2010

INAMRINONE LACTATE

INJECTABLE; INJECTION

AMRINONE LACTATE

+ WEST-WARD PHARMS INT

EQ 5MG BASE/ML

A075513 001 May 09, 2000

INDACATEROL MALEATE

POWDER; INHALATION

ARCAPTA NEOHALER

+ NOVARTIS

EQ 75MCG BASE

N022383 001 Jul 01, 2011

PRESCRIPTION DRUG PRODUCT LIST

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>1.25MG</u>	<u>A074722</u>	<u>001</u>	Jun 17, 1996
<u>AB</u>		<u>2.5MG</u>	<u>A074722</u>	<u>002</u>	Jun 17, 1996
<u>AB</u>	AMERIGEN PHARMS LTD	<u>1.25MG</u>	<u>A075201</u>	<u>001</u>	Dec 04, 1998
<u>AB</u>		<u>2.5MG</u>	<u>A075201</u>	<u>002</u>	Dec 04, 1998
<u>AB</u>	ANI PHARMS INC	<u>1.25MG</u>	<u>A074299</u>	<u>002</u>	Apr 29, 1996
<u>AB</u>		<u>2.5MG</u>	<u>A074299</u>	<u>001</u>	Jul 27, 1995
<u>AB</u>	MYLAN	<u>1.25MG</u>	<u>A074461</u>	<u>002</u>	Mar 26, 1997
<u>AB</u>	+	<u>2.5MG</u>	<u>A074461</u>	<u>001</u>	Mar 27, 1996
<u>AB</u>	MYLAN PHARMS INC	<u>1.25MG</u>	<u>A075105</u>	<u>001</u>	Jul 23, 1998
<u>AB</u>		<u>2.5MG</u>	<u>A075105</u>	<u>002</u>	Jul 23, 1998

INDINAVIR SULFATE

CAPSULE; ORAL

CRIXIVAN

	MERCK SHARP DOHME	EQ 200MG BASE	N020685	003	Mar 13, 1996
+		EQ 400MG BASE	N020685	001	Mar 13, 1996

INDIUM IN-111 CHLORIDE

INJECTABLE; INJECTION

INDICLOR

+	GE HEALTHCARE	2mCi/0.2ML	N019862	001	Dec 29, 1992
	INDIUM IN 111 CHLORIDE				
+	MALLINKRODT NUCLEAR	5mCi/0.5ML	N019841	001	Sep 27, 1994

INDIUM IN-111 OXYQUINOLINE

INJECTABLE; INJECTION

INDIUM IN 111 OXYQUINOLINE

+	GE HEALTHCARE	1mCi/ML	N019044	001	Dec 24, 1985
---	---------------	---------	---------	-----	--------------

INDIUM IN-111 PENTETATE DISODIUM

INJECTABLE; INTRATHECAL

MPI INDIUM DTPA IN 111

+	GE HEALTHCARE	1mCi/ML	N017707	001	Feb 18, 1982
---	---------------	---------	---------	-----	--------------

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE; INJECTION

OCTREOSCAN

+	MALLINKRODT NUCLEAR	3mCi/ML	N020314	001	Jun 02, 1994
---	---------------------	---------	---------	-----	--------------

INDOCYANINE GREEN

INJECTABLE; INJECTION

IC-GREEN

<u>AP</u>	+	AKORN	<u>25MG/VIAL</u>	<u>N011525</u>	<u>001</u>
<u>AP</u>		DIAGNOSTIC GREEN	<u>25MG/VIAL</u>	<u>A040811</u>	<u>001</u> Nov 21, 2007

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN

<u>AB</u>	GLENMARK GENERICS	<u>25MG</u>	<u>A091276</u>	<u>001</u>	Dec 22, 2010
<u>AB</u>		<u>50MG</u>	<u>A091276</u>	<u>002</u>	Dec 22, 2010
<u>AB</u>	HERITAGE PHARMS INC	<u>25MG</u>	<u>N018851</u>	<u>001</u>	May 18, 1984
<u>AB</u>		<u>50MG</u>	<u>N018851</u>	<u>002</u>	May 18, 1984
<u>AB</u>	HETERO LABS LTD III	<u>25MG</u>	<u>A091240</u>	<u>001</u>	Apr 12, 2011
<u>AB</u>		<u>50MG</u>	<u>A091240</u>	<u>002</u>	Apr 12, 2011
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>25MG</u>	<u>A070719</u>	<u>001</u>	Feb 12, 1986
<u>AB</u>		<u>50MG</u>	<u>A070756</u>	<u>001</u>	Feb 12, 1986
<u>AB</u>	MYLAN	<u>25MG</u>	<u>N018858</u>	<u>001</u>	Apr 20, 1984
<u>AB</u>	+	<u>50MG</u>	<u>A070624</u>	<u>001</u>	Sep 04, 1985
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A070673</u>	<u>001</u>	Apr 29, 1987
<u>AB</u>		<u>50MG</u>	<u>A070674</u>	<u>001</u>	Apr 29, 1987
<u>AB</u>	SUN PHARM INDS INC	<u>25MG</u>	<u>A091401</u>	<u>001</u>	Mar 28, 2013
<u>AB</u>		<u>50MG</u>	<u>A091401</u>	<u>002</u>	Mar 28, 2013
<u>AB</u>	ZYDUS PHARMS USA INC	<u>25MG</u>	<u>A090403</u>	<u>001</u>	Nov 15, 2010
<u>AB</u>		<u>50MG</u>	<u>A090403</u>	<u>002</u>	Nov 15, 2010
	TIVORBEX				
	IROKO PHARMS LLC	20MG	N204768	001	Feb 24, 2014
+		40MG	N204768	002	Feb 24, 2014

CAPSULE, EXTENDED RELEASE; ORAL

INDOMETHACIN

<u>AB</u>	AMNEAL PHARMS	<u>75MG</u>	<u>A091549</u>	<u>001</u>	Dec 01, 2010
<u>AB</u>	AUROBINDO PHARMA LTD	<u>75MG</u>	<u>A204243</u>	<u>001</u>	Dec 27, 2016
<u>AB</u>	AVANTHI INC	<u>75MG</u>	<u>A079175</u>	<u>001</u>	Mar 06, 2009

PRESCRIPTION DRUG PRODUCT LIST

INDOMETHACIN

CAPSULE, EXTENDED RELEASE; ORAL

INDOMETHACIN

AB	HETERO LABS LTD III	75MG	A201807 001	Sep 28, 2012
AB	JUBILANT GENERICS	75MG	A202706 001	Oct 05, 2015
AB	MYLAN PHARMS INC	75MG	A202139 001	Mar 20, 2014
AB	PADDOCK LLC	75MG	A200529 001	Nov 30, 2010
AB	+ SANDOZ	75MG	A074464 001	May 28, 1998
AB	WATSON LABS INC	75MG	A202572 001	Dec 09, 2013

INJECTABLE; INJECTION

INDOMETHACIN

+ FRESENIUS KABI USA EQ 1MG BASE/VIAL N022536 001 Mar 17, 2010

SUPPOSITORY; RECTAL

INDOMETHACIN

+ G AND W LABS 50MG A073314 001 Aug 31, 1992

SUSPENSION; ORAL

INDOCIN

+ IROKO PHARMS 25MG/5ML N018332 001 Oct 10, 1985

INDOMETHACIN SODIUM

INJECTABLE; INJECTION

INDOCIN

AP	+ RECORDATI RARE	EQ 1MG BASE/VIAL	N018878 001	Jan 30, 1985
-----------	------------------	-------------------------	--------------------	--------------

INDOMETHACIN SODIUM

AP	HOSPIRA INC	EQ 1MG BASE/VIAL	A204118 001	Apr 19, 2016
-----------	-------------	-------------------------	--------------------	--------------

AP	WEST-WARD PHARMS INT	EQ 1MG BASE/VIAL	A078713 001	Jul 16, 2008
-----------	----------------------	-------------------------	--------------------	--------------

INGENOL MEBUTATE

GEL; TOPICAL

PICATO

+ LEO LABS 0.015% N202833 001 Jan 23, 2012

+ 0.05% N202833 002 Jan 23, 2012

INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT

INJECTABLE; SUBCUTANEOUS

NOVOLOG MIX 70/30

+ NOVO NORDISK INC 700 UNITS/10ML; 300 UNITS/10ML (70 UNITS/ML; 30 UNITS/ML) N021172 001 Nov 01, 2001

NOVOLOG MIX 70/30 FLEXPEN

+ NOVO NORDISK INC 210 UNITS/3ML; 90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML) N021172 004 May 03, 2002

INSULIN ASPART RECOMBINANT

INJECTABLE; SUBCUTANEOUS

NOVOLOG

+ NOVO NORDISK INC 1000 UNITS/10ML (100 UNITS/ML) N020986 001 Jun 07, 2000

NOVOLOG FLEXPEN

+ NOVO NORDISK INC 300 UNITS/3ML (100 UNITS/ML) N020986 003 Jan 19, 2001

NOVOLOG FLEXTOUCH

+ NOVO NORDISK INC 300 UNITS/3ML (100 UNITS/ML) N020986 005 Oct 31, 2013

NOVOLOG PENFILL

+ NOVO NORDISK INC 300 UNITS/3ML (100 UNITS/ML) N020986 002 Jun 07, 2000

INSULIN ASPART; INSULIN DEGLUDEC

SOLUTION; SUBCUTANEOUS

RYZODEG 70/30

+ NOVO NORDISK INC 90 UNITS/3ML; 210 UNITS/3ML (30 UNITS/ML; 70 UNITS/ML) N203313 001 Sep 25, 2015

INSULIN DEGLUDEC

SOLUTION; SUBCUTANEOUS

TRESIBA

+ NOVO NORDISK INC 300 UNITS/3ML (100 UNITS/ML) N203314 001 Sep 25, 2015

+ 600 UNITS/3ML (200 UNITS/ML) N203314 002 Sep 25, 2015

INSULIN DEGLUDEC; LIRAGLUTIDE

SOLUTION; SUBCUTANEOUS

XULTOPHY 100/3.6

+ NOVO NORDISK INC 300 UNITS/3ML; 10.8MG/3ML (100 UNITS/ML; 3.6MG/ML) N208583 001 Nov 21, 2016

PRESCRIPTION DRUG PRODUCT LIST

INSULIN DETEMIR RECOMBINANT

INJECTABLE; SUBCUTANEOUS

LEVEMIR

+ NOVO NORDISK INC 1000 UNITS/10ML (100 UNITS/ML) N021536 001 Jun 16, 2005

LEVEMIR FLEXTOUCH

+ NOVO NORDISK INC 300 UNITS/3ML (100 UNITS/ML) N021536 005 Oct 31, 2013

INSULIN GLARGINE

SOLUTION; SUBCUTANEOUS

BASAGLAR

ELI LILLY AND CO 300 UNITS/3ML (100 UNITS/ML) N205692 001 Dec 16, 2015

INSULIN GLARGINE RECOMBINANT

INJECTABLE; INJECTION

LANTUS

+ SANOFI AVENTIS US 100 UNITS/ML N021081 001 Apr 20, 2000

LANTUS SOLOSTAR

+ SANOFI AVENTIS US 300 UNITS/3ML (100 UNITS/ML) N021081 002 Apr 27, 2007

SOLUTION; SUBCUTANEOUS

TOUJEO SOLOSTAR

+ SANOFI US SERVICES 300 UNITS/ML (300 UNITS/ML) N206538 001 Feb 25, 2015

INSULIN GLARGINE; LIXISENATIDE

SOLUTION; SUBCUTANEOUS

SOLIQUA 100/33

+ SANOFI-AVENTIS US 300 UNITS/3ML; 99MCG/3ML (100 UNITS/ML; 33MCG/ML) N208673 001 Nov 21, 2016

INSULIN GLULISINE RECOMBINANT

INJECTABLE; IV (INFUSION), SUBCUTANEOUS

APIDRA

+ SANOFI AVENTIS US 1000 UNITS/10ML (100 UNITS/ML) N021629 001 Apr 16, 2004

+ 300 UNITS/3ML (100 UNITS/ML) N021629 002 Dec 20, 2005

INJECTABLE; SUBCUTANEOUS

APIDRA SOLOSTAR

SANOFI AVENTIS US 300 UNITS/3ML N021629 003 Feb 24, 2009

INSULIN HUMAN

SOLUTION; SUBCUTANEOUS

HUMULIN R

+ LILLY 10000 UNITS/20ML (500 UNITS/ML) N018780 004 Mar 31, 1994

HUMULIN R KWIKPEN

+ LILLY 1500 UNITS/3ML (500 UNITS/ML) N018780 002 Dec 29, 2015

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

HUMALOG MIX 50/50

+ LILLY 50 UNITS/ML; 50 UNITS/ML N021018 001 Dec 22, 1999

HUMALOG MIX 50/50 KWIKPEN

+ LILLY 50 UNITS/ML; 50 UNITS/ML N021018 002 Sep 06, 2007

HUMALOG MIX 75/25

+ LILLY 75 UNITS/ML; 25 UNITS/ML N021017 001 Dec 22, 1999

HUMALOG MIX 75/25 KWIKPEN

+ LILLY 75 UNITS/ML; 25 UNITS/ML N021017 002 Sep 06, 2007

INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

HUMALOG

+ LILLY 100 UNITS/ML N020563 001 Jun 14, 1996

HUMALOG KWIKPEN

+ LILLY 100 UNITS/ML N020563 003 Sep 06, 2007

SOLUTION; SUBCUTANEOUS

HUMALOG KWIKPEN

+ ELI LILLY AND CO 200 UNITS/ML N205747 001 May 26, 2015

INSULIN RECOMBINANT HUMAN

POWDER; INHALATION

AFREZZA

MANNKIND 4 UNITS/INH N022472 001 Jun 27, 2014

+ 8 UNITS/INH N022472 002 Jun 27, 2014

12 UNITS/INH N022472 003 Apr 17, 2015

PRESCRIPTION DRUG PRODUCT LIST

IOBENGUANE SULFATE I-123

SOLUTION; INTRAVENOUS

ADREVIEW

+ GE HEALTHCARE

10mCi/5ML (2mCi/ML)

N022290 001 Sep 19, 2008

IODIPAMIDE MEGLUMINE

INJECTABLE; INJECTION

CHOLOGRAFIN MEGLUMINE

+ BRACCO

52%

N009321 003

IODIXANOL

INJECTABLE; INJECTION

VISIPAQUE 270

+ GE HEALTHCARE

55%

N020351 001 Mar 22, 1996

55%

N020808 001 Aug 29, 1997

VISIPAQUE 320

+ GE HEALTHCARE

65.2%

N020351 002 Mar 22, 1996

65.2%

N020808 002 Aug 29, 1997

IOFLUPANE I-123

SOLUTION; INTRAVENOUS

DATSCAN

+ GE HLTHCARE INC

5mCi/2.5ML (2mCi/ML)

N022454 001 Jan 14, 2011

IOHEXOL

FOR SOLUTION; ORAL

ORALTAG

INTERPHARMA PRAHA AS

9.7GM/BOT

N205383 001 Mar 26, 2015

INJECTABLE; INJECTION

OMNIPAQUE 140

+ GE HEALTHCARE

30.2%

N018956 005 Nov 30, 1988

SOLUTION; INJECTION, ORAL

OMNIPAQUE 350

+ GE HEALTHCARE

75.5%

N018956 004 Dec 26, 1985

75.5%

N020608 003 Oct 24, 1995

SOLUTION; INJECTION, ORAL, RECTAL

OMNIPAQUE 180

+ GE HEALTHCARE

38.8%

N018956 001 Dec 26, 1985

OMNIPAQUE 240

+ GE HEALTHCARE

51.8%

N018956 002 Dec 26, 1985

51.8%

N020608 001 Oct 24, 1995

OMNIPAQUE 300

+ GE HEALTHCARE

64.7%

N018956 003 Dec 26, 1985

64.7%

N020608 002 Oct 24, 1995

IOPAMIDOL

INJECTABLE; INJECTION

ISOVUE-300**AP** + BRACCO**61%****N018735 002** Dec 31, 1985**ISOVUE-370****AP** + BRACCO**76%****N018735 003** Dec 31, 1985**SCANLUX-300****AP** MYLAN INSTITUTIONAL**61%****A090394 001** Jun 18, 2010**SCANLUX-370****AP** MYLAN INSTITUTIONAL**76%****A090394 002** Jun 18, 2010

ISOVUE-200

+ BRACCO

41%

N018735 006 Jul 07, 1987

ISOVUE-250

+ BRACCO

51%

N018735 007 Jul 06, 1992

+

51%

N020327 002 Oct 12, 1994

ISOVUE-300

+ BRACCO

61%

N020327 003 Oct 12, 1994

ISOVUE-370

+ BRACCO

76%

N020327 004 Oct 12, 1994

ISOVUE-M 200

+ BRACCO

41%

N018735 001 Dec 31, 1985

ISOVUE-M 300

+ BRACCO

61%

N018735 004 Dec 31, 1985

PRESCRIPTION DRUG PRODUCT LIST

IOPROMIDE

INJECTABLE; INJECTION

ULTRAVIST (PHARMACY BULK)

+ BAYER HLTHCARE	49.9%	N021425 003	Mar 12, 2004
+	62.3%	N021425 001	Sep 20, 2002
+	76.9%	N021425 002	Sep 20, 2002

ULTRAVIST 150

+ BAYER HLTHCARE	31.2%	N020220 004	May 10, 1995
------------------	-------	-------------	--------------

ULTRAVIST 240

+ BAYER HLTHCARE	49.9%	N020220 003	May 10, 1995
------------------	-------	-------------	--------------

ULTRAVIST 300

+ BAYER HLTHCARE	62.3%	N020220 002	May 10, 1995
------------------	-------	-------------	--------------

ULTRAVIST 300 IN PLASTIC CONTAINER

+ BAYER HLTHCARE	62.3%	N020220 005	Nov 18, 2008
------------------	-------	-------------	--------------

ULTRAVIST 370

+ BAYER HLTHCARE	76.9%	N020220 001	May 10, 1995
------------------	-------	-------------	--------------

IOTHALAMATE MEGLUMINE

INJECTABLE; INJECTION

CONRAY

+ LIEBEL-FLARSHEIM	60%	N013295 001	
--------------------	-----	-------------	--

CONRAY 30

+ LIEBEL-FLARSHEIM	30%	N016983 001	
--------------------	-----	-------------	--

CONRAY 43

+ LIEBEL-FLARSHEIM	43%	N013295 002	
--------------------	-----	-------------	--

SOLUTION; INTRAVESICAL

CYSTO-CONRAY II

LIEBEL-FLARSHEIM	17.2%	N017057 002	
------------------	-------	-------------	--

IOTHALAMATE SODIUM I-125

INJECTABLE; INJECTION

GLOFIL-125

ISOTEX	250-300uCi/ML	N017279 001	
--------	---------------	-------------	--

IOVERSOL

INJECTABLE; INJECTION

OPTIRAY 240

+ LIEBEL-FLARSHEIM	51%	N019710 002	Dec 30, 1988
--------------------	-----	-------------	--------------

OPTIRAY 300

+ LIEBEL-FLARSHEIM	64%	N019710 004	Jan 22, 1992
--------------------	-----	-------------	--------------

+	64%	N020923 004	May 13, 1999
---	-----	-------------	--------------

OPTIRAY 320

+ LIEBEL-FLARSHEIM	68%	N019710 001	Dec 30, 1988
--------------------	-----	-------------	--------------

+	68%	N020923 002	May 29, 1998
---	-----	-------------	--------------

OPTIRAY 350

+ LIEBEL-FLARSHEIM	74%	N019710 005	Jan 22, 1992
--------------------	-----	-------------	--------------

+	74%	N020923 003	May 28, 1998
---	-----	-------------	--------------

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

ATROVENT HFA

+ BOEHRINGER INGELHEIM	0.021MG/INH	N021527 001	Nov 27, 2004
------------------------	-------------	-------------	--------------

SOLUTION; INHALATION

IPRATROPIUM BROMIDE

AN	AUROBINDO PHARMA LTD	0.02%	A206543 001	Oct 27, 2016
AN	BAUSCH AND LOMB INC	0.02%	A075835 001	Oct 15, 2001
AN	LANDELA PHARM	0.02%	A077072 001	Jul 19, 2005
AN	NEPHRON	0.02%	A075562 001	Sep 27, 2001
AN	+ RITEDOSE CORP	0.02%	A075693 001	Jan 26, 2001
AN	SUN PHARMA GLOBAL	0.02%	A207903 001	Jan 03, 2017
AN	WATSON LABS	0.02%	A076291 001	May 09, 2005

SPRAY, METERED; NASAL

ATROVENT

AB	+ BOEHRINGER INGELHEIM	0.021MG/SPRAY	N020393 001	Oct 20, 1995
AB	+	0.042MG/SPRAY	N020394 001	Oct 20, 1995

IPRATROPIUM BROMIDE

AB	BAUSCH AND LOMB	0.021MG/SPRAY	A076025 001	Mar 31, 2003
AB		0.042MG/SPRAY	A076103 001	Mar 31, 2003
AB	MYLAN SPECLT	0.021MG/SPRAY	A075552 001	Mar 31, 2003
AB		0.042MG/SPRAY	A075553 001	Mar 31, 2003
AB	WEST-WARD PHARMS INT	0.021MG/SPRAY	A076664 001	Nov 05, 2003
AB		0.042MG/SPRAY	A076598 001	Nov 05, 2003

PRESCRIPTION DRUG PRODUCT LIST

IRBESARTAN

TABLET; ORAL

AVAPRO

<u>AB</u>	SANOFI AVENTIS US	<u>75MG</u>	<u>N020757 001</u>	Sep 30, 1997
<u>AB</u>		<u>150MG</u>	<u>N020757 002</u>	Sep 30, 1997
<u>AB</u>	+	<u>300MG</u>	<u>N020757 003</u>	Sep 30, 1997

IRBESARTAN

<u>AB</u>	AJANTA PHARMA LTD	<u>75MG</u>	<u>A203685 001</u>	Dec 10, 2015
<u>AB</u>		<u>150MG</u>	<u>A203685 002</u>	Dec 10, 2015
<u>AB</u>		<u>300MG</u>	<u>A203685 003</u>	Dec 10, 2015
<u>AB</u>	ALEMBIC PHARMS LTD	<u>75MG</u>	<u>A091236 001</u>	Oct 15, 2012
<u>AB</u>		<u>150MG</u>	<u>A091236 002</u>	Oct 15, 2012
<u>AB</u>		<u>300MG</u>	<u>A091236 003</u>	Oct 15, 2012
<u>AB</u>	APOTEX INC	<u>75MG</u>	<u>A200832 001</u>	Oct 15, 2012
<u>AB</u>		<u>150MG</u>	<u>A200832 002</u>	Oct 15, 2012
<u>AB</u>		<u>300MG</u>	<u>A200832 003</u>	Oct 15, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>75MG</u>	<u>A203081 001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A203081 002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A203081 003</u>	Sep 27, 2012
<u>AB</u>	CIPLA LTD	<u>75MG</u>	<u>A077205 001</u>	Nov 14, 2012
<u>AB</u>		<u>150MG</u>	<u>A077205 002</u>	Nov 14, 2012
<u>AB</u>		<u>300MG</u>	<u>A077205 003</u>	Nov 14, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>75MG</u>	<u>A203161 001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A203161 002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A203161 003</u>	Sep 27, 2012
<u>AB</u>	HETERO LABS LTD V	<u>75MG</u>	<u>A202910 001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A202910 002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A202910 003</u>	Sep 27, 2012
<u>AB</u>	HISUN PHARM HANGZHOU	<u>75MG</u>	<u>A206194 001</u>	Jun 14, 2016
<u>AB</u>		<u>150MG</u>	<u>A206194 002</u>	Jun 14, 2016
<u>AB</u>		<u>300MG</u>	<u>A206194 003</u>	Jun 14, 2016
<u>AB</u>	JUBILANT GENERICS	<u>75MG</u>	<u>A203534 001</u>	Feb 23, 2015
<u>AB</u>		<u>150MG</u>	<u>A203534 002</u>	Feb 23, 2015
<u>AB</u>		<u>300MG</u>	<u>A203534 003</u>	Feb 23, 2015
<u>AB</u>	LUPIN LTD	<u>75MG</u>	<u>A201531 001</u>	Oct 15, 2012
<u>AB</u>		<u>150MG</u>	<u>A201531 002</u>	Oct 15, 2012
<u>AB</u>		<u>300MG</u>	<u>A201531 003</u>	Oct 15, 2012
<u>AB</u>	MACLEODS PHARMS LTD	<u>75MG</u>	<u>A202254 001</u>	Oct 03, 2012
<u>AB</u>		<u>150MG</u>	<u>A202254 002</u>	Oct 03, 2012
<u>AB</u>		<u>300MG</u>	<u>A202254 003</u>	Oct 03, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>75MG</u>	<u>A200461 001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A200461 002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A200461 003</u>	Sep 27, 2012
<u>AB</u>	PRINSTON INC	<u>75MG</u>	<u>A203071 001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A203071 002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A203071 003</u>	Sep 27, 2012
<u>AB</u>	SANDOZ	<u>75MG</u>	<u>A077466 001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A077466 002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A077466 003</u>	Sep 27, 2012
<u>AB</u>	SCIEGEN PHARMS INC	<u>75MG</u>	<u>A204774 001</u>	Dec 07, 2015
<u>AB</u>		<u>150MG</u>	<u>A204774 002</u>	Dec 07, 2015
<u>AB</u>		<u>300MG</u>	<u>A204774 003</u>	Dec 07, 2015
<u>AB</u>	TEVA PHARMS	<u>75MG</u>	<u>A077159 001</u>	Mar 30, 2012
<u>AB</u>		<u>150MG</u>	<u>A077159 002</u>	Mar 30, 2012
<u>AB</u>		<u>300MG</u>	<u>A077159 003</u>	Mar 30, 2012
<u>AB</u>	UNICHEM LABS LTD	<u>75MG</u>	<u>A203020 001</u>	Dec 07, 2015
<u>AB</u>		<u>150MG</u>	<u>A203020 002</u>	Dec 07, 2015
<u>AB</u>		<u>300MG</u>	<u>A203020 003</u>	Dec 07, 2015
<u>AB</u>	WEST-WARD PHARMS INT	<u>75MG</u>	<u>A090201 001</u>	Oct 15, 2012
<u>AB</u>		<u>150MG</u>	<u>A090201 002</u>	Oct 15, 2012
<u>AB</u>		<u>300MG</u>	<u>A090201 003</u>	Oct 15, 2012
<u>AB</u>	ZYDUS PHARMS USA INC	<u>75MG</u>	<u>A079213 001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A079213 002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A079213 003</u>	Sep 27, 2012

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

CAMPTOSAR

<u>AP</u>	+	PFIZER INC	<u>40MG/2ML (20MG/ML)</u>	<u>N020571 001</u>	Jun 14, 1996
<u>AP</u>	+		<u>100MG/5ML (20MG/ML)</u>	<u>N020571 002</u>	Jun 14, 1996
<u>AP</u>	+		<u>300MG/15ML (20MG/ML)</u>	<u>N020571 003</u>	Aug 05, 2010

PRESCRIPTION DRUG PRODUCT LIST

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

AP	ACCORD HLTHCARE	<u>40MG/2ML (20MG/ML)</u>	<u>A079068 001</u>	Nov 21, 2008
AP		<u>100MG/5ML (20MG/ML)</u>	<u>A079068 002</u>	Nov 21, 2008
AP	ACTAVIS TOTOWA	<u>40MG/2ML (20MG/ML)</u>	<u>A078589 001</u>	Feb 27, 2008
AP		<u>100MG/5ML (20MG/ML)</u>	<u>A078589 002</u>	Feb 27, 2008
AP		<u>500MG/25ML (20MG/ML)</u>	<u>A078589 003</u>	Nov 18, 2015
AP	AKORN	<u>40MG/2ML (20MG/ML)</u>	<u>A090726 001</u>	Sep 16, 2009
AP		<u>100MG/5ML (20MG/ML)</u>	<u>A090726 002</u>	Sep 16, 2009
AP	CIPLA LTD	<u>40MG/2ML (20MG/ML)</u>	<u>A077219 001</u>	Feb 20, 2008
AP		<u>100MG/5ML (20MG/ML)</u>	<u>A077219 002</u>	Feb 20, 2008
AP	DR REDDYS LABS LTD	<u>40MG/2ML (20MG/ML)</u>	<u>A078953 001</u>	Apr 15, 2010
AP		<u>100MG/5ML (20MG/ML)</u>	<u>A078953 002</u>	Apr 15, 2010
AP	EMCURE PHARMS LTD	<u>40MG/2ML (20MG/ML)</u>	<u>A200771 001</u>	Feb 14, 2012
AP		<u>100MG/5ML (20MG/ML)</u>	<u>A200771 002</u>	Feb 14, 2012
AP	EUROHLTH INTL SARL	<u>40MG/2ML (20MG/ML)</u>	<u>A078753 001</u>	Dec 24, 2008
AP		<u>100MG/5ML (20MG/ML)</u>	<u>A078753 002</u>	Dec 24, 2008
AP	FRESENIUS KABI ONCOL	<u>40MG/2ML (20MG/ML)</u>	<u>A078188 001</u>	Feb 27, 2008
AP		<u>100MG/5ML (20MG/ML)</u>	<u>A078188 002</u>	Feb 27, 2008
AP	FRESENIUS KABI USA	<u>40MG/2ML (20MG/ML)</u>	<u>A077776 001</u>	Feb 27, 2008
AP		<u>100MG/5ML (20MG/ML)</u>	<u>A077776 002</u>	Feb 27, 2008
AP	HIKMA FARMACEUTICA	<u>40MG/2ML (20MG/ML)</u>	<u>A091032 001</u>	Dec 20, 2010
AP		<u>100MG/5ML (20MG/ML)</u>	<u>A091032 002</u>	Dec 20, 2010
AP	HISUN PHARM HANGZHOU	<u>40MG/2ML (20MG/ML)</u>	<u>A090016 001</u>	Jan 28, 2009
AP		<u>100MG/5ML (20MG/ML)</u>	<u>A090016 002</u>	Jan 28, 2009
AP	HOSPIRA	<u>40MG/2ML (20MG/ML)</u>	<u>A077915 001</u>	Feb 27, 2008
AP		<u>100MG/5ML (20MG/ML)</u>	<u>A077915 002</u>	Feb 27, 2008
AP	+	<u>500MG/25ML (20MG/ML)</u>	<u>A078796 001</u>	Feb 27, 2008
AP	JIANGSU HENGRUI MED	<u>40MG/2ML (20MG/ML)</u>	<u>A090675 002</u>	Dec 16, 2011
AP		<u>100MG/5ML (20MG/ML)</u>	<u>A090675 001</u>	Dec 16, 2011
AP	MUSTAFA NEVZAT ILAC	<u>40MG/2ML (20MG/ML)</u>	<u>A090393 002</u>	May 13, 2011
AP		<u>100MG/5ML (20MG/ML)</u>	<u>A090393 003</u>	May 13, 2011
AP	PLIVA LACHEMA	<u>40MG/2ML (20MG/ML)</u>	<u>A078122 001</u>	Oct 31, 2008
AP		<u>100MG/5ML (20MG/ML)</u>	<u>A078122 002</u>	Oct 31, 2008
AP	QILU PHARM CO LTD	<u>40MG/2ML (20MG/ML)</u>	<u>A203380 001</u>	May 03, 2016
AP		<u>100MG/5ML (20MG/ML)</u>	<u>A203380 002</u>	May 03, 2016
AP		<u>300MG/15ML (20MG/ML)</u>	<u>A203380 003</u>	May 03, 2016
AP	SANDOZ INC	<u>40MG/2ML (20MG/ML)</u>	<u>A090137 001</u>	Nov 12, 2009
AP		<u>100MG/5ML (20MG/ML)</u>	<u>A090137 002</u>	Nov 12, 2009
AP	SUN PHARMA GLOBAL	<u>40MG/2ML (20MG/ML)</u>	<u>A078805 001</u>	Apr 21, 2008
AP		<u>100MG/5ML (20MG/ML)</u>	<u>A078805 002</u>	Apr 21, 2008
AP	TEVA PHARMS USA	<u>40MG/2ML (20MG/ML)</u>	<u>A090101 002</u>	Feb 27, 2008
AP		<u>100MG/5ML (20MG/ML)</u>	<u>A090101 003</u>	Feb 27, 2008
AP		<u>500MG/25ML (20MG/ML)</u>	<u>A090101 001</u>	Nov 26, 2008

INJECTABLE, LIPOSOMAL; IV (INFUSION)

ONIVYDE

+ MERRIMACK PHARMS EQ 43MG BASE/10ML (EQ 4.3MG BASE/ML) N207793 001 Oct 22, 2015

IRON DEXTRAN

INJECTABLE; INJECTION

DEXFERRUM

BP	LUITPOLD	EQ 50MG IRON/ML	N040024 001	Feb 23, 1996
	INFED			
BP	+ ALLERGAN SALES LLC	EQ 50MG IRON/ML	N017441 001	
	PROFERDEX			
BP	NEW RIVER	EQ 50MG IRON/ML	N017807 001	

IRON SUCROSE

INJECTABLE; INTRAVENOUS

VENOFER

	LUITPOLD	EQ 50MG BASE/2.5ML (EQ 20MG BASE/ML)	N021135 002	Mar 20, 2005
+		EQ 100MG BASE/5ML (EQ 20MG BASE/ML)	N021135 001	Nov 06, 2000
		EQ 200MG BASE/10ML (EQ 20MG BASE/ML)	N021135 004	Feb 09, 2007

ISAVUCONAZONIUM SULFATE

CAPSULE; ORAL

CRESEMBA

+ ASTELLAS 186MG N207500 001 Mar 06, 2015

POWDER; IV (INFUSION)

CRESEMBA

+ ASTELLAS 372MG N207501 001 Mar 06, 2015

PRESCRIPTION DRUG PRODUCT LIST

ISOCARBOXAZID

TABLET; ORAL

MARPLAN

+ VALIDUS PHARMS INC

10MG

N011961 001

ISOFLURANE

LIQUID; INHALATION

FORANEAN + BAXTER HLTHCARE 99.9%N017624 001ISOFLURANEAN HALOCARBON PRODS 99.9%A075225 001 Oct 20, 1999AN HOSPIRA 99.9%A074097 001 Jan 25, 1993AN PIRAMAL CRITICAL 99.9%A074416 001 Sep 30, 1994AN PIRAMAL ENT 99.9%A074502 001 Jun 27, 1995ISONIAZID

INJECTABLE; INJECTION

ISONIAZID

+ SANDOZ

100MG/ML

A040648 001 Jul 05, 2005

SYRUP; ORAL

ISONIAZID

+ CAROLINA MEDCL

50MG/5ML

A088235 001 Nov 10, 1983

TABLET; ORAL

ISONIAZIDAA BARR 100MGA080936 001AA 300MGA080937 002AA MIKART 100MGA040090 001 Jun 26, 1997AA 300MGA040090 002 Jun 26, 1997AA + SANDOZ 100MGN008678 002AA + 300MGN008678 003AA THEPHARMANETWORK LLC 100MGA202610 001 Oct 29, 2014AA 300MGA202610 002 Oct 29, 2014LANIAZIDAA LANNETT 300MGA089776 001 Jun 13, 1988ISONIAZID; PYRAZINAMIDE; RIFAMPIN

TABLET; ORAL

RIFATER

+ SANOFI AVENTIS US

50MG; 300MG; 120MG

N050705 001 May 31, 1994

ISONIAZID; RIFAMPIN

CAPSULE; ORAL

RIFAMATE

+ SANOFI AVENTIS US

150MG; 300MG

A061884 001

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

ISUPREL

+ HOSPIRA

0.2MG/ML

N010515 001

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL

DILATRATE-SR

+ AUXILIUM PHARMS LLC

40MG

N019790 001 Sep 02, 1988

TABLET; ORAL

ISORDILAB VALEANT PHARMS NORTH 5MGN012093 007 Jul 29, 1988ISOSORBIDE DINITRATEAB HIKMA INTL PHARMS 5MGA086067 001 Oct 29, 1987AB 10MGA086066 001 Oct 29, 1987AB 20MGA088088 001 Nov 02, 1987AB 30MGA040591 001 Jan 10, 2007AB PAR PHARM 5MGA086923 001 Mar 12, 1987AB 10MGA086925 001 Mar 12, 1987AB 20MGA087537 001 Oct 02, 1987AB + 30MGA087946 001 Jan 12, 1988AB SANDOZ 5MGA086221 001 Jan 07, 1988AB 10MGA086223 001 Jan 07, 1988AB 20MGA089367 001 Apr 07, 1988

ISORDIL

+ VALEANT PHARMS NORTH

40MG

N012093 001 Jul 29, 1988

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE DINITRATE

+ SUN PHARM INDS INC

40MG

A040009 001 Dec 30, 1998

PRESCRIPTION DRUG PRODUCT LIST

ISOSORBIDE MONONITRATE

TABLET; ORAL

ISOSORBIDE MONONITRATE

<u>AB</u>	ACTAVIS ELIZABETH	<u>10MG</u>	<u>A075037 002</u>	Oct 30, 1998
<u>AB</u>		<u>20MG</u>	<u>A075037 001</u>	Oct 30, 1998
<u>AB</u>	ANI PHARMS INC	<u>20MG</u>	<u>A075147 001</u>	Nov 27, 1998
<u>AB</u>	HIKMA PHARMS LLC	<u>20MG</u>	<u>A075361 001</u>	Oct 05, 2000

MONOKET

<u>AB</u>	KREMERS URBAN PHARMS	<u>10MG</u>	<u>N020215 002</u>	Jun 30, 1993
<u>AB</u>	+	<u>20MG</u>	<u>N020215 001</u>	Jun 30, 1993

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE MONONITRATE

<u>AB</u>	DEXCEL LTD	<u>30MG</u>	<u>A075522 002</u>	Sep 20, 2016
<u>AB</u>		<u>60MG</u>	<u>A075522 001</u>	Apr 17, 2000
<u>AB</u>	HIKMA PHARMS	<u>30MG</u>	<u>A076813 002</u>	Mar 30, 2006
<u>AB</u>		<u>60MG</u>	<u>A076813 001</u>	Jan 07, 2005
<u>AB</u>	KREMERS URBAN PHARMS	<u>30MG</u>	<u>A075155 002</u>	Jan 13, 2000
<u>AB</u>		<u>60MG</u>	<u>A075155 001</u>	Oct 30, 1998
<u>AB</u>	+	<u>120MG</u>	<u>A075155 003</u>	Aug 04, 2000
<u>AB</u>	NESHER PHARMS	<u>30MG</u>	<u>A075395 001</u>	Mar 16, 2000
<u>AB</u>		<u>60MG</u>	<u>A075395 002</u>	Mar 16, 2000
<u>AB</u>		<u>120MG</u>	<u>A075395 003</u>	Mar 16, 2000
<u>AB</u>	TORRENT PHARMS	<u>30MG</u>	<u>A200270 001</u>	Jun 03, 2011
<u>AB</u>		<u>60MG</u>	<u>A200495 001</u>	Jun 03, 2011
<u>AB</u>		<u>120MG</u>	<u>A200495 002</u>	Jun 03, 2011
<u>AB</u>	VINTAGE PHARMS	<u>30MG</u>	<u>A090598 001</u>	Aug 11, 2010
<u>AB</u>		<u>60MG</u>	<u>A090598 002</u>	Aug 11, 2010
<u>AB</u>		<u>120MG</u>	<u>A090598 003</u>	Aug 11, 2010

ISOSULFAN BLUE

INJECTABLE; INJECTION

ISOSULFAN BLUE

<u>AP</u>	AUROBINDO PHARMA LTD	<u>1%</u>	<u>A206831 001</u>	Feb 02, 2016
<u>AP</u>	+	<u>1%</u>	<u>A090874 001</u>	Jul 20, 2010

ISOTRETINOIN

CAPSULE; ORAL

AMNESTEEM

<u>AB</u>	MYLAN PHARMS INC	<u>10MG</u>	<u>A075945 001</u>	Nov 08, 2002
<u>AB</u>		<u>20MG</u>	<u>A075945 002</u>	Nov 08, 2002
<u>AB</u>		<u>40MG</u>	<u>A075945 003</u>	Nov 08, 2002

CLARAVIS

<u>AB</u>	TEVA PHARMS USA	<u>10MG</u>	<u>A076356 001</u>	Apr 11, 2003
<u>AB</u>		<u>20MG</u>	<u>A076135 002</u>	Apr 11, 2003
<u>AB</u>		<u>30MG</u>	<u>A076135 003</u>	May 11, 2006
<u>AB</u>	+	<u>40MG</u>	<u>A076135 001</u>	Apr 11, 2003

MYORISAN

<u>AB</u>	DOUGLAS PHARMS	<u>10MG</u>	<u>A076485 001</u>	Jan 19, 2012
<u>AB</u>		<u>20MG</u>	<u>A076485 002</u>	Jan 19, 2012
<u>AB</u>		<u>30MG</u>	<u>A076485 004</u>	Aug 25, 2015
<u>AB</u>		<u>40MG</u>	<u>A076485 003</u>	Jan 19, 2012

ZENATANE

<u>AB</u>	DR REDDYS LABS LTD	<u>10MG</u>	<u>A202099 001</u>	Mar 25, 2013
<u>AB</u>		<u>20MG</u>	<u>A202099 002</u>	Mar 25, 2013
<u>AB</u>		<u>30MG</u>	<u>A202099 004</u>	Feb 23, 2015
<u>AB</u>		<u>40MG</u>	<u>A202099 003</u>	Mar 25, 2013

ABSORICA

BX	RANBAXY	10MG	N021951 001	May 25, 2012
BX		20MG	N021951 002	May 25, 2012
BX		30MG	N021951 003	May 25, 2012
BX	+	40MG	N021951 004	May 25, 2012
		25MG	N021951 005	Aug 15, 2014
		35MG	N021951 006	Aug 15, 2014

ISRADIPINE

CAPSULE; ORAL

ISRADIPINE

<u>AB</u>	ELITE LABS INC	<u>2.5MG</u>	<u>A077169 001</u>	Apr 24, 2006
<u>AB</u>		<u>5MG</u>	<u>A077169 002</u>	Apr 24, 2006
<u>AB</u>	WATSON LABS	<u>2.5MG</u>	<u>A077317 001</u>	Jan 05, 2006
<u>AB</u>	+	<u>5MG</u>	<u>A077317 002</u>	Jan 05, 2006

PRESCRIPTION DRUG PRODUCT LIST

ISRADIPINE

TABLET, EXTENDED RELEASE;ORAL

ISRADIPINE

MYLAN PHARMS INC

5MG

A201067 001 Nov 27, 2015

10MG

A201067 002 Nov 27, 2015

ITRACONAZOLE

CAPSULE;ORAL

ITRACONAZOLE

AB	ACCORD HLTHCARE	100MG	A205991 001	May 26, 2016
AB	ALEMBIC PHARMS LTD	100MG	A206741 001	Dec 13, 2016
AB	AMNEAL PHARMS	100MG	A205080 001	Sep 26, 2016
AB	MYLAN PHARMS INC	100MG	A200463 001	Jul 20, 2012
AB	PAR PHARM INC	100MG	A205724 001	Dec 13, 2016
AB	SANDOZ	100MG	A076104 001	May 28, 2004

SPORANOX

AB	+ JANSSEN PHARMS	100MG	N020083 001	Sep 11, 1992
SOLUTION;ORAL				
SPORANOX				
	+ JANSSEN PHARMS	10MG/ML	N020657 001	Feb 21, 1997
TABLET;ORAL				
ONMEL				
	+ SEBELA IRELAND LTD	200MG	N022484 001	Apr 29, 2010

IVABRADINE HYDROCHLORIDE

TABLET;ORAL

CORLANOR

AMGEN INC

EQ 5MG BASE

N206143 001 Apr 15, 2015

+

EQ 7.5MG BASE

N206143 002 Apr 15, 2015

IVACAFTOR

GRANULE;ORAL

KALYDECO

VERTEX PHARMS INC

50MG/PACKET

N207925 001 Mar 17, 2015

+

75MG/PACKET

N207925 002 Mar 17, 2015

TABLET;ORAL

KALYDECO

+ VERTEX PHARMS

150MG

N203188 001 Jan 31, 2012

IVACAFTOR; LUMACAF TOR

TABLET;ORAL

ORKAMBI

VERTEX PHARMS INC

125MG;100MG

N206038 002 Sep 28, 2016

+

125MG;200MG

N206038 001 Jul 02, 2015

IVERMECTIN

CREAM;TOPICAL

SOOLANTRA

+ GALDERMA LABS LP

1%

N206255 001 Dec 19, 2014

LOTION;TOPICAL

SKLICE

+ ARBOR PHARMS LLC

0.5%

N202736 001 Feb 07, 2012

TABLET;ORAL

IVERMECTIN

AB	EDENBRIDGE PHARMS	3MG	A204154 001	Oct 24, 2014
<u>STROMECTOL</u>				
AB	+ MERCK SHARP DOHME	3MG	N050742 002	Oct 08, 1998

IXABEPILONE

INJECTABLE;IV (INFUSION)

IXEMPRA KIT

+ R-PHARM US LLC

15MG/VIAL

N022065 001 Oct 16, 2007

+

45MG/VIAL

N022065 002 Oct 16, 2007

IXAZOMIB CITRATE

CAPSULE;ORAL

NINLARO

MILLENNIUM PHARMS

EQ 2.3MG BASE

N208462 001 Nov 20, 2015

EQ 3MG BASE

N208462 002 Nov 20, 2015

+

EQ 4MG BASE

N208462 003 Nov 20, 2015

PRESCRIPTION DRUG PRODUCT LIST

KANAMYCIN SULFATE

INJECTABLE; INJECTION

KANAMYCIN SULFATE

FRESENIUS KABI USA	EQ 500MG BASE/2ML	A065111	001	Dec 17, 2002
+	EQ 1GM BASE/3ML	A065111	002	Dec 17, 2002

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

KETALAR

<u>AP</u>	+	PAR STERILE PRODUCTS	<u>EQ 10MG BASE/ML</u>	<u>N016812</u>	<u>001</u>	
<u>AP</u>	+		<u>EQ 50MG BASE/ML</u>	<u>N016812</u>	<u>002</u>	
<u>AP</u>	+		<u>EQ 100MG BASE/ML</u>	<u>N016812</u>	<u>003</u>	

KETAMINE HYDROCHLORIDE

<u>AP</u>		HOSPIRA	<u>EQ 50MG BASE/ML</u>	<u>A074549</u>	<u>001</u>	Jun 27, 1996
<u>AP</u>			<u>EQ 100MG BASE/ML</u>	<u>A074549</u>	<u>002</u>	Jun 27, 1996
<u>AP</u>		MYLAN INSTITUTIONAL	<u>EQ 10MG BASE/ML</u>	<u>A076092</u>	<u>001</u>	Sep 30, 2008
<u>AP</u>			<u>EQ 50MG BASE/ML</u>	<u>A076092</u>	<u>002</u>	Dec 28, 2001
<u>AP</u>			<u>EQ 100MG BASE/ML</u>	<u>A076092</u>	<u>003</u>	Oct 25, 2002
<u>AP</u>		WEST-WARD PHARMS INT	<u>EQ 50MG BASE/ML</u>	<u>A074524</u>	<u>001</u>	Mar 22, 1996
<u>AP</u>			<u>EQ 100MG BASE/ML</u>	<u>A074524</u>	<u>002</u>	Mar 22, 1996

KETOCONAZOLE

AEROSOL, FOAM; TOPICAL

EXTINA

<u>AT</u>	+	DELCOR ASSET CORP	<u>2%</u>	<u>N021738</u>	<u>001</u>	Jun 12, 2007
-----------	---	-------------------	-----------	----------------	------------	--------------

KETOCONAZOLE

<u>AT</u>		PERRIGO ISRAEL	<u>2%</u>	<u>A091550</u>	<u>001</u>	Aug 25, 2011
-----------	--	----------------	-----------	----------------	------------	--------------

CREAM; TOPICAL

KETOCONAZOLE

<u>AB</u>		FOUGERA PHARMS	<u>2%</u>	<u>A076294</u>	<u>001</u>	Apr 28, 2004
<u>AB</u>	+	TEVA	<u>2%</u>	<u>A075581</u>	<u>001</u>	Apr 25, 2000

KETOZOLE

<u>AB</u>		TARO	<u>2%</u>	<u>A075638</u>	<u>001</u>	Dec 18, 2002
-----------	--	------	-----------	----------------	------------	--------------

GEL; TOPICAL

XOLEGEL

+	AQUA PHARMS	<u>2%</u>	N021946	001	Jul 28, 2006
---	-------------	-----------	---------	-----	--------------

SHAMPOO; TOPICAL

KETOCONAZOLE

<u>AB</u>		PERRIGO NEW YORK	<u>2%</u>	<u>A076419</u>	<u>001</u>	Jan 07, 2004
-----------	--	------------------	-----------	----------------	------------	--------------

<u>AB</u>		TOLMAR	<u>2%</u>	<u>A076942</u>	<u>001</u>	Apr 11, 2005
-----------	--	--------	-----------	----------------	------------	--------------

NIZORAL

<u>AB</u>	+	JANSSEN PHARMS	<u>2%</u>	<u>N019927</u>	<u>001</u>	Aug 31, 1990
-----------	---	----------------	-----------	----------------	------------	--------------

TABLET; ORAL

KETOCONAZOLE

<u>AB</u>		MYLAN	<u>200MG</u>	<u>A075597</u>	<u>001</u>	Dec 23, 1999
-----------	--	-------	--------------	----------------	------------	--------------

<u>AB</u>		TARO	<u>200MG</u>	<u>A075319</u>	<u>001</u>	Jun 15, 1999
-----------	--	------	--------------	----------------	------------	--------------

<u>AB</u>	+	TEVA	<u>200MG</u>	<u>A075273</u>	<u>001</u>	Jun 15, 1999
-----------	---	------	--------------	----------------	------------	--------------

KETOPROFEN

CAPSULE; ORAL

KETOPROFEN

<u>AB</u>		DORADO PHARMA	<u>50MG</u>	<u>A074014</u>	<u>002</u>	Jan 29, 1993
-----------	--	---------------	-------------	----------------	------------	--------------

<u>AB</u>			<u>75MG</u>	<u>A074014</u>	<u>003</u>	Jan 29, 1993
-----------	--	--	-------------	----------------	------------	--------------

<u>AB</u>		MYLAN	<u>50MG</u>	<u>A074035</u>	<u>002</u>	Dec 31, 1996
-----------	--	-------	-------------	----------------	------------	--------------

<u>AB</u>			<u>75MG</u>	<u>A074035</u>	<u>003</u>	Dec 31, 1996
-----------	--	--	-------------	----------------	------------	--------------

<u>AB</u>		TEVA	<u>50MG</u>	<u>A073516</u>	<u>001</u>	Dec 22, 1992
-----------	--	------	-------------	----------------	------------	--------------

<u>AB</u>	+		<u>75MG</u>	<u>A073517</u>	<u>001</u>	Dec 22, 1992
-----------	---	--	-------------	----------------	------------	--------------

DORADO PHARMA	<u>25MG</u>	A074014	001	Jan 29, 1993
---------------	-------------	---------	-----	--------------

CAPSULE, EXTENDED RELEASE; ORAL

KETOPROFEN

<u>AB</u>		ACTAVIS LABS FL INC	<u>100MG</u>	<u>A075270</u>	<u>002</u>	Mar 24, 1999
-----------	--	---------------------	--------------	----------------	------------	--------------

<u>AB</u>			<u>150MG</u>	<u>A075270</u>	<u>003</u>	Mar 24, 1999
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>			<u>200MG</u>	<u>A075270</u>	<u>001</u>	Mar 24, 1999
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>		MYLAN	<u>100MG</u>	<u>A075679</u>	<u>003</u>	Feb 20, 2002
-----------	--	-------	--------------	----------------	------------	--------------

<u>AB</u>			<u>150MG</u>	<u>A075679</u>	<u>002</u>	Feb 20, 2002
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>	+		<u>200MG</u>	<u>A075679</u>	<u>001</u>	Feb 20, 2002
-----------	---	--	--------------	----------------	------------	--------------

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

<u>AP</u>		AMPHASTAR PHARM	<u>15MG/ML</u>	<u>A076209</u>	<u>001</u>	Jul 21, 2004
-----------	--	-----------------	----------------	----------------	------------	--------------

<u>AP</u>			<u>30MG/ML</u>	<u>A076209</u>	<u>002</u>	Jul 21, 2004
-----------	--	--	----------------	----------------	------------	--------------

<u>AP</u>		FRESENIUS KABI USA	<u>15MG/ML</u>	<u>A075784</u>	<u>001</u>	Jan 11, 2002
-----------	--	--------------------	----------------	----------------	------------	--------------

<u>AP</u>			<u>15MG/ML</u>	<u>A203242</u>	<u>001</u>	Oct 07, 2015
-----------	--	--	----------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

<u>AP</u>		<u>30MG/ML</u>	<u>A075784 002</u>	Jan 11, 2002
<u>AP</u>		<u>30MG/ML</u>	<u>A203242 002</u>	Oct 07, 2015
<u>AP</u>	GLAND PHARMA LTD	<u>15MG/ML</u>	<u>A204216 001</u>	Nov 01, 2016
<u>AP</u>		<u>30MG/ML</u>	<u>A204216 002</u>	Nov 01, 2016
<u>AP</u>	+ HOSPIRA	<u>15MG/ML</u>	<u>A074802 001</u>	Jun 05, 1997
<u>AP</u>		<u>15MG/ML</u>	<u>A074993 001</u>	Jan 27, 1999
<u>AP</u>	+	<u>30MG/ML</u>	<u>A074802 002</u>	Jun 05, 1997
<u>AP</u>		<u>30MG/ML</u>	<u>A074993 002</u>	Jan 27, 1999
<u>AP</u>	MYLAN LABS LTD	<u>15MG/ML</u>	<u>A078299 001</u>	Jul 16, 2007
<u>AP</u>		<u>15MG/ML</u>	<u>A201155 001</u>	Aug 04, 2014
<u>AP</u>		<u>30MG/ML</u>	<u>A078299 002</u>	Jul 16, 2007
<u>AP</u>		<u>30MG/ML</u>	<u>A201155 002</u>	Aug 04, 2014
<u>AP</u>	SAGENT PHARMS	<u>15MG/ML</u>	<u>A091065 001</u>	Nov 27, 2013
<u>AP</u>		<u>30MG/ML</u>	<u>A091065 002</u>	Nov 27, 2013
<u>AP</u>	SANDOZ	<u>30MG/ML</u>	<u>A076271 002</u>	Oct 06, 2004
<u>AP</u>	WOCKHARDT	<u>15MG/ML</u>	<u>A077942 001</u>	Mar 27, 2007
<u>AP</u>		<u>30MG/ML</u>	<u>A077942 002</u>	Mar 27, 2007

SOLUTION/DROPS; OPHTHALMIC

ACULAR

<u>AT</u>	+ ALLERGAN	<u>0.5%</u>	<u>N019700 001</u>	Nov 09, 1992
-----------	------------	-------------	--------------------	--------------

ACULAR LS

<u>AT</u>	+ ALLERGAN	<u>0.4%</u>	<u>N021528 001</u>	May 30, 2003
-----------	------------	-------------	--------------------	--------------

ACUVAIL

<u>AT</u>	+ ALLERGAN	<u>0.45%</u>	<u>N022427 001</u>	Jul 22, 2009
-----------	------------	--------------	--------------------	--------------

KETOROLAC TROMETHAMINE

<u>AT</u>	AKORN	<u>0.4%</u>	<u>A078399 001</u>	Nov 05, 2009
<u>AT</u>		<u>0.5%</u>	<u>A078434 001</u>	Nov 05, 2009
<u>AT</u>	ALCON PHARMS LTD	<u>0.4%</u>	<u>A078721 001</u>	Nov 05, 2009
<u>AT</u>		<u>0.5%</u>	<u>A076583 001</u>	Nov 05, 2009
<u>AT</u>	APOTEX INC	<u>0.4%</u>	<u>A077308 001</u>	Nov 05, 2009
<u>AT</u>		<u>0.5%</u>	<u>A076109 001</u>	Nov 05, 2009
<u>AT</u>	SUN PHARMA GLOBAL	<u>0.5%</u>	<u>A090017 001</u>	Nov 05, 2009

SPRAY, METERED; NASAL

SPRIX

	+ EGALET US INC	15.75MG/SPRAY	N022382 001	May 14, 2010
--	-----------------	---------------	-------------	--------------

TABLET; ORAL

KETOROLAC TROMETHAMINE

<u>AB</u>	+ MYLAN	<u>10MG</u>	<u>A074761 001</u>	May 16, 1997
<u>AB</u>	PLIVA	<u>10MG</u>	<u>A075284 001</u>	Jun 23, 1999
<u>AB</u>	TEVA	<u>10MG</u>	<u>A074754 001</u>	May 16, 1997

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; IRRIGATION

OMIDRIA

	+ OMEROS	EQ 0.3% BASE; EQ 1% BASE	N205388 001	May 30, 2014
--	----------	--------------------------	-------------	--------------

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HYDROCHLORIDE

<u>AP</u>	AKORN INC	<u>5MG/ML</u>	<u>A075431 001</u>	Nov 29, 1999
<u>AP</u>		<u>5MG/ML</u>	<u>A075524 001</u>	Nov 29, 1999
<u>AP</u>	GLAND PHARMA LTD	<u>5MG/ML</u>	<u>A090699 001</u>	Apr 03, 2012
<u>AP</u>	+ HOSPIRA	<u>5MG/ML</u>	<u>A075239 001</u>	Nov 29, 1999
<u>AP</u>	+	<u>5MG/ML</u>	<u>A075240 001</u>	Nov 29, 1999
<u>AP</u>	SAGENT STRIDES	<u>5MG/ML</u>	<u>A079134 001</u>	Feb 03, 2010
<u>AP</u>	WEST-WARD PHARMS INT	<u>5MG/ML</u>	<u>A075303 001</u>	May 28, 1999

TABLET; ORAL

LABETALOL HYDROCHLORIDE

<u>AB</u>	ALLIED PHARMA INC	<u>100MG</u>	<u>A075215 001</u>	Jul 29, 1999
<u>AB</u>		<u>200MG</u>	<u>A075215 002</u>	Jul 29, 1999
<u>AB</u>		<u>300MG</u>	<u>A075215 003</u>	Jul 29, 1999
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>100MG</u>	<u>A074787 001</u>	Aug 03, 1998
<u>AB</u>		<u>200MG</u>	<u>A074787 002</u>	Aug 03, 1998
<u>AB</u>		<u>300MG</u>	<u>A074787 003</u>	Aug 03, 1998
<u>AB</u>	PAR FORM	<u>100MG</u>	<u>A200908 001</u>	Jul 10, 2012
<u>AB</u>		<u>200MG</u>	<u>A200908 002</u>	Jul 10, 2012
<u>AB</u>		<u>300MG</u>	<u>A200908 003</u>	Jul 10, 2012
<u>AB</u>	SANDOZ	<u>100MG</u>	<u>A075113 001</u>	Aug 04, 1998
<u>AB</u>	+	<u>200MG</u>	<u>A075113 002</u>	Aug 04, 1998
<u>AB</u>		<u>300MG</u>	<u>A075113 003</u>	Aug 04, 1998

PRESCRIPTION DRUG PRODUCT LIST

LABETALOL HYDROCHLORIDE

TABLET; ORAL

LABETALOL HYDROCHLORIDE

<u>AB</u>	WATSON LABS	<u>100MG</u>	<u>A075133 001</u>	Aug 03, 1998
<u>AB</u>		<u>200MG</u>	<u>A075133 002</u>	Aug 03, 1998
<u>AB</u>		<u>300MG</u>	<u>A075133 003</u>	Aug 03, 1998

TRANDATE

<u>AB</u>	CNTY LINE PHARMS	<u>100MG</u>	<u>N018716 001</u>	May 24, 1985
<u>AB</u>		<u>200MG</u>	<u>N018716 002</u>	Aug 01, 1984
<u>AB</u>		<u>300MG</u>	<u>N018716 003</u>	Aug 01, 1984

LACOSAMIDE

SOLUTION; INTRAVENOUS

VIMPAT

+ UCB INC

200MG/20ML (10MG/ML)

N022254 001 Oct 28, 2008

SOLUTION; ORAL

LACOSAMIDE

<u>AA</u>	AMNEAL PHARMS	<u>10MG/ML</u>	<u>A204839 001</u>	Apr 28, 2016
-----------	---------------	----------------	--------------------	--------------

VIMPAT

<u>AA</u>	+ UCB INC	<u>10MG/ML</u>	<u>N022255 001</u>	Apr 20, 2010
-----------	-----------	----------------	--------------------	--------------

TABLET; ORAL

LACOSAMIDE

<u>AB</u>	ACTAVIS LABS FL INC	<u>50MG</u>	<u>A204855 001</u>	Apr 28, 2016
<u>AB</u>		<u>100MG</u>	<u>A204855 002</u>	Apr 28, 2016
<u>AB</u>		<u>150MG</u>	<u>A204855 003</u>	Apr 28, 2016
<u>AB</u>		<u>200MG</u>	<u>A204855 004</u>	Apr 28, 2016
<u>AB</u>	ALEMBIC PHARMS LTD	<u>50MG</u>	<u>A204974 001</u>	Apr 28, 2016
<u>AB</u>		<u>100MG</u>	<u>A204974 002</u>	Apr 28, 2016
<u>AB</u>		<u>150MG</u>	<u>A204974 003</u>	Apr 28, 2016
<u>AB</u>		<u>200MG</u>	<u>A204974 004</u>	Apr 28, 2016
<u>AB</u>	AMNEAL PHARMS	<u>50MG</u>	<u>A204857 001</u>	Sep 09, 2016
<u>AB</u>		<u>100MG</u>	<u>A204857 002</u>	Sep 09, 2016
<u>AB</u>		<u>150MG</u>	<u>A204857 003</u>	Sep 09, 2016
<u>AB</u>		<u>200MG</u>	<u>A204857 004</u>	Sep 09, 2016
<u>AB</u>	AUROBINDO PHARMA LTD	<u>50MG</u>	<u>A204994 001</u>	Apr 28, 2016
<u>AB</u>		<u>100MG</u>	<u>A204994 002</u>	Apr 28, 2016
<u>AB</u>		<u>150MG</u>	<u>A204994 003</u>	Apr 28, 2016
<u>AB</u>		<u>200MG</u>	<u>A204994 004</u>	Apr 28, 2016
<u>AB</u>	MSN LABS PVT LTD	<u>50MG</u>	<u>A204921 001</u>	Apr 28, 2016
<u>AB</u>		<u>100MG</u>	<u>A204921 002</u>	Apr 28, 2016
<u>AB</u>		<u>150MG</u>	<u>A204921 003</u>	Apr 28, 2016
<u>AB</u>		<u>200MG</u>	<u>A204921 004</u>	Apr 28, 2016
<u>AB</u>	MYLAN PHARMS INC	<u>50MG</u>	<u>A205026 001</u>	Apr 28, 2016
<u>AB</u>		<u>100MG</u>	<u>A205026 002</u>	Apr 28, 2016
<u>AB</u>		<u>150MG</u>	<u>A205026 003</u>	Apr 28, 2016
<u>AB</u>		<u>200MG</u>	<u>A205026 004</u>	Apr 28, 2016
<u>AB</u>	SUN PHARMA GLOBAL	<u>50MG</u>	<u>A205031 001</u>	Apr 28, 2016
<u>AB</u>		<u>100MG</u>	<u>A205031 002</u>	Apr 28, 2016
<u>AB</u>		<u>150MG</u>	<u>A205031 003</u>	Apr 28, 2016
<u>AB</u>		<u>200MG</u>	<u>A205031 004</u>	Apr 28, 2016

VIMPAT

<u>AB</u>	UCB INC	<u>50MG</u>	<u>N022253 001</u>	Oct 28, 2008
<u>AB</u>		<u>100MG</u>	<u>N022253 002</u>	Oct 28, 2008
<u>AB</u>		<u>150MG</u>	<u>N022253 003</u>	Oct 28, 2008
<u>AB</u>	+	<u>200MG</u>	<u>N022253 004</u>	Oct 28, 2008

LACTULOSE

FOR SOLUTION; ORAL

LACTULOSE

+ CUMBERLAND PHARMS

10GM/PACKET

A074712 001 Dec 10, 1997

+

20GM/PACKET

A074712 002 Dec 10, 1997

SOLUTION; ORAL

CONSTILAC

<u>AA</u>	ALRA	<u>10GM/15ML</u>	<u>A071054 001</u>	Jul 26, 1988
-----------	------	------------------	--------------------	--------------

LACTULOSE

<u>AA</u>	ANI PHARMS	<u>10GM/15ML</u>	<u>A078430 001</u>	Nov 28, 2007
<u>AA</u>	FRESENIUS KABI	<u>10GM/15ML</u>	<u>A090503 001</u>	Jan 25, 2012
<u>AA</u>	+ HI TECH PHARMA	<u>10GM/15ML</u>	<u>A074076 001</u>	Jul 03, 1995
<u>AA</u>	MORTON GROVE	<u>10GM/15ML</u>	<u>A074602 001</u>	Nov 14, 1996
<u>AA</u>	PHARM ASSOC	<u>10GM/15ML</u>	<u>A074623 001</u>	Jul 30, 1996
<u>AA</u>	VINTAGE PHARMS	<u>10GM/15ML</u>	<u>A075993 001</u>	Jul 26, 2001
<u>AA</u>	VISTAPHARM	<u>10GM/15ML</u>	<u>A074138 001</u>	Sep 30, 1992
<u>AA</u>	WEST-WARD PHARMS INT	<u>10GM/15ML</u>	<u>A073591 001</u>	May 29, 1992

PRESCRIPTION DRUG PRODUCT LIST

LACTULOSE

SOLUTION;ORAL, RECTAL

CHOLAC

AA	ALRA	<u>10GM/15ML</u>	<u>A071331</u>	<u>001</u>	Jul 26, 1988
-----------	------	------------------	----------------	------------	--------------

ENULOSE

AA	+ ACTAVIS MID ATLANTIC	<u>10GM/15ML</u>	<u>A071548</u>	<u>001</u>	Aug 15, 1988
-----------	------------------------	------------------	----------------	------------	--------------

GENERLAC

AA	MORTON GROVE PHARMS	<u>10GM/15ML</u>	<u>A074603</u>	<u>001</u>	Oct 31, 1996
-----------	---------------------	------------------	----------------	------------	--------------

LACTULOSE

AA	ANI PHARMS	<u>10GM/15ML</u>	<u>A090426</u>	<u>001</u>	Nov 21, 2008
-----------	------------	------------------	----------------	------------	--------------

AA	BIO-PHARM INC	<u>10GM/15ML</u>	<u>A203762</u>	<u>001</u>	Mar 27, 2015
-----------	---------------	------------------	----------------	------------	--------------

AA	FRESENIUS KABI	<u>10GM/15ML</u>	<u>A090502</u>	<u>001</u>	Jan 25, 2012
-----------	----------------	------------------	----------------	------------	--------------

AA	HI TECH PHARMA	<u>10GM/15ML</u>	<u>A074077</u>	<u>001</u>	Jul 03, 1995
-----------	----------------	------------------	----------------	------------	--------------

LAMIVUDINE

SOLUTION;ORAL

EPIVIR

AA	+ VIIV HLTHCARE	<u>10MG/ML</u>	<u>N020596</u>	<u>001</u>	Nov 17, 1995
-----------	-----------------	----------------	----------------	------------	--------------

LAMIVUDINE

AA	AUROBINDO PHARMA LTD	<u>10MG/ML</u>	<u>A077695</u>	<u>001</u>	Nov 21, 2016
-----------	----------------------	----------------	----------------	------------	--------------

AA	SILARX PHARMS INC	<u>10MG/ML</u>	<u>A203564</u>	<u>001</u>	Oct 31, 2014
-----------	-------------------	----------------	----------------	------------	--------------

EPIVIR-HBV

	+ GLAXOSMITHKLINE	5MG/ML	N021004	001	Dec 08, 1998
--	-------------------	--------	---------	-----	--------------

TABLET;ORAL

EPIVIR

AB	VIIV HLTHCARE	<u>150MG</u>	<u>N020564</u>	<u>001</u>	Nov 17, 1995
-----------	---------------	--------------	----------------	------------	--------------

AB	+	<u>300MG</u>	<u>N020564</u>	<u>003</u>	Jun 24, 2002
-----------	---	--------------	----------------	------------	--------------

EPIVIR-HBV

AB	+ GLAXOSMITHKLINE	<u>100MG</u>	<u>N021003</u>	<u>001</u>	Dec 08, 1998
-----------	-------------------	--------------	----------------	------------	--------------

LAMIVUDINE

AB	APOTEX	<u>150MG</u>	<u>A091606</u>	<u>001</u>	Dec 02, 2011
-----------	--------	--------------	----------------	------------	--------------

AB		<u>300MG</u>	<u>A091606</u>	<u>002</u>	Dec 02, 2011
-----------	--	--------------	----------------	------------	--------------

AB	APOTEX INC	<u>100MG</u>	<u>A202941</u>	<u>001</u>	Jan 02, 2014
-----------	------------	--------------	----------------	------------	--------------

AB	APPCO PHARMA LLC	<u>150MG</u>	<u>A206974</u>	<u>001</u>	Nov 21, 2016
-----------	------------------	--------------	----------------	------------	--------------

AB		<u>300MG</u>	<u>A206974</u>	<u>002</u>	Nov 21, 2016
-----------	--	--------------	----------------	------------	--------------

AB	AUROBINDO PHARMA LTD	<u>150MG</u>	<u>A077464</u>	<u>001</u>	Nov 21, 2016
-----------	----------------------	--------------	----------------	------------	--------------

AB		<u>150MG</u>	<u>A202032</u>	<u>001</u>	Nov 17, 2011
-----------	--	--------------	----------------	------------	--------------

AB		<u>300MG</u>	<u>A077464</u>	<u>002</u>	Nov 21, 2016
-----------	--	--------------	----------------	------------	--------------

AB		<u>300MG</u>	<u>A202032</u>	<u>002</u>	Nov 17, 2011
-----------	--	--------------	----------------	------------	--------------

AB	CENTAUR PHARMS PVT	<u>150MG</u>	<u>A203586</u>	<u>001</u>	Nov 21, 2016
-----------	--------------------	--------------	----------------	------------	--------------

AB	HETERO LABS LTD V	<u>100MG</u>	<u>A203260</u>	<u>001</u>	Jan 02, 2014
-----------	-------------------	--------------	----------------	------------	--------------

AB		<u>150MG</u>	<u>A203277</u>	<u>001</u>	Jan 06, 2014
-----------	--	--------------	----------------	------------	--------------

AB		<u>300MG</u>	<u>A203277</u>	<u>002</u>	Jan 06, 2014
-----------	--	--------------	----------------	------------	--------------

AB	LUPIN LTD	<u>150MG</u>	<u>A205217</u>	<u>001</u>	Dec 18, 2014
-----------	-----------	--------------	----------------	------------	--------------

AB		<u>300MG</u>	<u>A205217</u>	<u>002</u>	Dec 18, 2014
-----------	--	--------------	----------------	------------	--------------

AB	MYLAN PHARMS INC	<u>100MG</u>	<u>A204002</u>	<u>001</u>	Dec 31, 2014
-----------	------------------	--------------	----------------	------------	--------------

AB		<u>150MG</u>	<u>A204528</u>	<u>001</u>	Mar 04, 2016
-----------	--	--------------	----------------	------------	--------------

AB		<u>300MG</u>	<u>A204528</u>	<u>002</u>	Mar 04, 2016
-----------	--	--------------	----------------	------------	--------------

LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL

COMBIVIR

AB	+ VIIV HLTHCARE	<u>150MG;300MG</u>	<u>N020857</u>	<u>001</u>	Sep 26, 1997
-----------	-----------------	--------------------	----------------	------------	--------------

LAMIVUDINE AND ZIDOVUDINE

AB	AUROBINDO PHARMA LTD	<u>150MG;300MG</u>	<u>A202418</u>	<u>001</u>	May 15, 2012
-----------	----------------------	--------------------	----------------	------------	--------------

AB	HETERO LABS LTD III	<u>150MG;300MG</u>	<u>A079124</u>	<u>001</u>	Sep 17, 2015
-----------	---------------------	--------------------	----------------	------------	--------------

AB	HETERO LABS LTD V	<u>150MG;300MG</u>	<u>A203259</u>	<u>001</u>	Feb 03, 2014
-----------	-------------------	--------------------	----------------	------------	--------------

AB	LUPIN LTD	<u>150MG;300MG</u>	<u>A090246</u>	<u>001</u>	May 15, 2012
-----------	-----------	--------------------	----------------	------------	--------------

AB	MYLAN PHARMS INC	<u>150MG;300MG</u>	<u>A204005</u>	<u>001</u>	Aug 28, 2014
-----------	------------------	--------------------	----------------	------------	--------------

AB	STRIDES PHARMA	<u>150MG;300MG</u>	<u>A079128</u>	<u>001</u>	May 13, 2015
-----------	----------------	--------------------	----------------	------------	--------------

AB	TEVA PHARMS	<u>150MG;300MG</u>	<u>A079081</u>	<u>001</u>	May 25, 2011
-----------	-------------	--------------------	----------------	------------	--------------

LAMOTRIGINE

TABLET;ORAL

LAMICTAL

AB	+ GLAXOSMITHKLINE LLC	<u>25MG</u>	<u>N020241</u>	<u>005</u>	Dec 27, 1994
-----------	-----------------------	-------------	----------------	------------	--------------

AB		<u>100MG</u>	<u>N020241</u>	<u>001</u>	Dec 27, 1994
-----------	--	--------------	----------------	------------	--------------

AB		<u>150MG</u>	<u>N020241</u>	<u>002</u>	Dec 27, 1994
-----------	--	--------------	----------------	------------	--------------

AB		<u>200MG</u>	<u>N020241</u>	<u>003</u>	Dec 27, 1994
-----------	--	--------------	----------------	------------	--------------

LAMOTRIGINE

AB	ALEMBIC PHARMS LTD	<u>25MG</u>	<u>A090607</u>	<u>001</u>	Jan 13, 2011
-----------	--------------------	-------------	----------------	------------	--------------

AB		<u>100MG</u>	<u>A090607</u>	<u>002</u>	Jan 13, 2011
-----------	--	--------------	----------------	------------	--------------

AB		<u>150MG</u>	<u>A090607</u>	<u>003</u>	Jan 13, 2011
-----------	--	--------------	----------------	------------	--------------

AB		<u>200MG</u>	<u>A090607</u>	<u>004</u>	Jan 13, 2011
-----------	--	--------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

<u>AB</u>	ALKEM LABS LTD	<u>25MG</u>	<u>A200694</u>	<u>001</u>	Jun 14, 2013
<u>AB</u>		<u>100MG</u>	<u>A200694</u>	<u>002</u>	Jun 14, 2013
<u>AB</u>		<u>150MG</u>	<u>A200694</u>	<u>003</u>	Jun 14, 2013
<u>AB</u>		<u>200MG</u>	<u>A200694</u>	<u>004</u>	Jun 14, 2013
<u>AB</u>	APOTEX INC	<u>25MG</u>	<u>A078625</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078625</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A078625</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078625</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A078956</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078956</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A078956</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078956</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	CIPLA LTD	<u>25MG</u>	<u>A077783</u>	<u>001</u>	Nov 01, 2010
<u>AB</u>		<u>100MG</u>	<u>A077783</u>	<u>002</u>	Nov 01, 2010
<u>AB</u>		<u>150MG</u>	<u>A077783</u>	<u>003</u>	Nov 01, 2010
<u>AB</u>		<u>200MG</u>	<u>A077783</u>	<u>004</u>	Nov 01, 2010
<u>AB</u>	DR REDDYS LABS LTD	<u>25MG</u>	<u>A076708</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076708</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A076708</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076708</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	GLENMARK GENERICS	<u>25MG</u>	<u>A090169</u>	<u>001</u>	May 12, 2012
<u>AB</u>		<u>100MG</u>	<u>A090169</u>	<u>002</u>	May 12, 2012
<u>AB</u>		<u>150MG</u>	<u>A090169</u>	<u>003</u>	May 12, 2012
<u>AB</u>		<u>200MG</u>	<u>A090169</u>	<u>004</u>	May 12, 2012
<u>AB</u>	JUBILANT CADISTA	<u>25MG</u>	<u>A079132</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A079132</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A079132</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A079132</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	LUPIN LTD	<u>25MG</u>	<u>A078691</u>	<u>001</u>	Jun 01, 2010
<u>AB</u>		<u>100MG</u>	<u>A078691</u>	<u>002</u>	Jun 01, 2010
<u>AB</u>		<u>150MG</u>	<u>A078691</u>	<u>003</u>	Jun 01, 2010
<u>AB</u>		<u>200MG</u>	<u>A078691</u>	<u>004</u>	Jun 01, 2010
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A077420</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A077420</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A077420</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A077420</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	TARO PHARM INDS	<u>25MG</u>	<u>A078525</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078525</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A078525</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078525</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	TEVA	<u>25MG</u>	<u>A076388</u>	<u>001</u>	Aug 30, 2006
<u>AB</u>		<u>100MG</u>	<u>A076388</u>	<u>002</u>	Aug 30, 2006
<u>AB</u>		<u>150MG</u>	<u>A076388</u>	<u>003</u>	Aug 30, 2006
<u>AB</u>		<u>200MG</u>	<u>A076388</u>	<u>004</u>	Aug 30, 2006
<u>AB</u>	TORRENT PHARMS	<u>25MG</u>	<u>A078947</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078947</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A078947</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078947</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	UNICHEM LABS LTD	<u>25MG</u>	<u>A090170</u>	<u>001</u>	Oct 06, 2011
<u>AB</u>		<u>100MG</u>	<u>A090170</u>	<u>002</u>	Oct 06, 2011
<u>AB</u>		<u>150MG</u>	<u>A090170</u>	<u>003</u>	Oct 06, 2011
<u>AB</u>		<u>200MG</u>	<u>A090170</u>	<u>004</u>	Oct 06, 2011
<u>AB</u>	ZYDUS PHARMS USA	<u>25MG</u>	<u>A077633</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A077633</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A077633</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A077633</u>	<u>005</u>	Jan 27, 2009
		50MG	A077633	002	Jan 27, 2009
		250MG	A077633	006	Jan 27, 2009

TABLET, CHEWABLE; ORAL

LAMICTAL CD

<u>AB</u>	GLAXOSMITHKLINE LLC	<u>2MG</u>	<u>N020764</u>	<u>004</u>	Sep 08, 2000
<u>AB</u>		<u>5MG</u>	<u>N020764</u>	<u>001</u>	Aug 24, 1998
<u>AB</u>	+	<u>25MG</u>	<u>N020764</u>	<u>002</u>	Aug 24, 1998
<u>AB</u>	ALEMBIC PHARMS LTD	<u>5MG</u>	<u>A201168</u>	<u>001</u>	Jun 12, 2014
<u>AB</u>		<u>25MG</u>	<u>A201168</u>	<u>002</u>	Jun 12, 2014
<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A090401</u>	<u>002</u>	Nov 04, 2009
<u>AB</u>		<u>25MG</u>	<u>A090401</u>	<u>003</u>	Nov 04, 2009
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A076701</u>	<u>001</u>	Jan 22, 2009

PRESCRIPTION DRUG PRODUCT LIST

LAMOTRIGINE

TABLET, CHEWABLE;ORAL

LAMOTRIGINE

<u>AB</u>		<u>25MG</u>	<u>A076701 002</u>	Jan 22, 2009
<u>AB</u>	GLENMARK GENERICS	<u>5MG</u>	<u>A079099 001</u>	Feb 19, 2009
<u>AB</u>		<u>25MG</u>	<u>A079099 002</u>	Feb 19, 2009
<u>AB</u>	JUBILANT GENERICS	<u>5MG</u>	<u>A200220 001</u>	Feb 28, 2011
<u>AB</u>		<u>25MG</u>	<u>A200220 002</u>	Feb 28, 2011
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A076630 001</u>	Jan 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A076630 002</u>	Jan 22, 2009
<u>AB</u>	TARO	<u>5MG</u>	<u>A079204 001</u>	Feb 04, 2009
<u>AB</u>		<u>25MG</u>	<u>A079204 002</u>	Feb 04, 2009
<u>AB</u>	TEVA	<u>5MG</u>	<u>A076420 001</u>	Jun 21, 2006
<u>AB</u>		<u>25MG</u>	<u>A076420 002</u>	Jun 21, 2006
<u>AB</u>	WATSON LABS	<u>2MG</u>	<u>A076928 001</u>	Jan 22, 2009
<u>AB</u>		<u>5MG</u>	<u>A076928 002</u>	Jan 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A076928 003</u>	Jan 22, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>5MG</u>	<u>A078009 002</u>	Jan 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A078009 003</u>	Jan 22, 2009

TABLET, EXTENDED RELEASE;ORAL

LAMICTAL XR

<u>AB</u>	GLAXOSMITHKLINE LLC	<u>25MG</u>	<u>N022115 001</u>	May 29, 2009
<u>AB</u>	+	<u>50MG</u>	<u>N022115 002</u>	May 29, 2009
<u>AB</u>		<u>100MG</u>	<u>N022115 003</u>	May 29, 2009
<u>AB</u>	+	<u>200MG</u>	<u>N022115 004</u>	May 29, 2009
<u>AB</u>		<u>250MG</u>	<u>N022115 006</u>	Jun 21, 2011
<u>AB</u>		<u>300MG</u>	<u>N022115 005</u>	Apr 14, 2010

LAMOTRIGINE

<u>AB</u>	ACTAVIS ELIZABETH	<u>100MG</u>	<u>A200672 003</u>	Oct 17, 2013
<u>AB</u>		<u>200MG</u>	<u>A200672 004</u>	Oct 17, 2013
<u>AB</u>		<u>25MG</u>	<u>A200672 001</u>	Oct 17, 2013
<u>AB</u>		<u>50MG</u>	<u>A200672 002</u>	Oct 17, 2013
<u>AB</u>		<u>250MG</u>	<u>A203733 001</u>	Nov 13, 2013
<u>AB</u>		<u>300MG</u>	<u>A200672 005</u>	Oct 17, 2013
<u>AB</u>	ANCHEN PHARMS	<u>25MG</u>	<u>A201374 001</u>	Dec 26, 2012
<u>AB</u>		<u>50MG</u>	<u>A201374 002</u>	Dec 26, 2012
<u>AB</u>		<u>100MG</u>	<u>A201374 003</u>	Dec 26, 2012
<u>AB</u>		<u>200MG</u>	<u>A201374 004</u>	Dec 26, 2012
<u>AB</u>		<u>250MG</u>	<u>A201374 005</u>	Dec 26, 2012
<u>AB</u>		<u>300MG</u>	<u>A201374 006</u>	Dec 26, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>25MG</u>	<u>A202383 001</u>	Jun 19, 2013
<u>AB</u>		<u>50MG</u>	<u>A202383 002</u>	Jun 19, 2013
<u>AB</u>		<u>100MG</u>	<u>A202383 003</u>	Jun 19, 2013
<u>AB</u>		<u>200MG</u>	<u>A202383 004</u>	Jun 19, 2013
<u>AB</u>		<u>300MG</u>	<u>A202383 005</u>	Jun 19, 2013
<u>AB</u>	PAR PHARM	<u>25MG</u>	<u>A201791 001</u>	Jan 18, 2013
<u>AB</u>		<u>50MG</u>	<u>A201791 002</u>	Jan 18, 2013
<u>AB</u>		<u>100MG</u>	<u>A201791 003</u>	Jan 18, 2013
<u>AB</u>		<u>200MG</u>	<u>A201791 004</u>	Jan 18, 2013
<u>AB</u>		<u>250MG</u>	<u>A201791 005</u>	Jan 18, 2013
<u>AB</u>		<u>300MG</u>	<u>A201791 006</u>	Jan 18, 2013
<u>AB</u>	TORRENT PHARMS LTD	<u>25MG</u>	<u>A203370 001</u>	Dec 23, 2013
<u>AB</u>		<u>50MG</u>	<u>A203370 002</u>	Dec 23, 2013
<u>AB</u>		<u>100MG</u>	<u>A203370 003</u>	Dec 23, 2013
<u>AB</u>		<u>200MG</u>	<u>A203370 004</u>	Dec 23, 2013
<u>AB</u>	WILSHIRE PHARMS INC	<u>25MG</u>	<u>A202887 001</u>	Jun 17, 2013
<u>AB</u>		<u>50MG</u>	<u>A202887 002</u>	Jun 17, 2013
<u>AB</u>		<u>100MG</u>	<u>A202887 003</u>	Jun 17, 2013
<u>AB</u>		<u>200MG</u>	<u>A202887 004</u>	Jun 17, 2013
<u>AB</u>	WOCKHARDT LTD	<u>25MG</u>	<u>A202498 001</u>	Jan 04, 2013
<u>AB</u>		<u>50MG</u>	<u>A202498 002</u>	Jan 04, 2013
<u>AB</u>		<u>100MG</u>	<u>A202498 003</u>	Jan 04, 2013
<u>AB</u>		<u>200MG</u>	<u>A202498 004</u>	Jan 04, 2013
<u>AB</u>		<u>300MG</u>	<u>A202498 005</u>	Jan 04, 2013

TABLET, ORALLY DISINTEGRATING;ORAL

LAMICTAL ODT

<u>AB</u>	GLAXOSMITHKLINE LLC	<u>25MG</u>	<u>N022251 001</u>	May 08, 2009
<u>AB</u>	+	<u>50MG</u>	<u>N022251 002</u>	May 08, 2009
<u>AB</u>		<u>100MG</u>	<u>N022251 003</u>	May 08, 2009
<u>AB</u>		<u>200MG</u>	<u>N022251 004</u>	May 08, 2009

LAMOTRIGINE

<u>AB</u>	IMPAX LABS INC	<u>25MG</u>	<u>A200828 001</u>	Jul 15, 2013
-----------	----------------	-------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

LAMOTRIGINE

TABLET, ORALLY DISINTEGRATING;ORAL

LAMOTRIGINE

<u>AB</u>		<u>50MG</u>	<u>A200828</u>	<u>002</u>	Jul 15, 2013
<u>AB</u>		<u>100MG</u>	<u>A200828</u>	<u>003</u>	Jul 15, 2013
<u>AB</u>		<u>200MG</u>	<u>A200828</u>	<u>004</u>	Jul 15, 2013
<u>AB</u>	PAR PHARM	<u>25MG</u>	<u>A204158</u>	<u>001</u>	Oct 27, 2015
<u>AB</u>		<u>50MG</u>	<u>A204158</u>	<u>002</u>	Oct 27, 2015
<u>AB</u>		<u>100MG</u>	<u>A204158</u>	<u>003</u>	Oct 27, 2015
<u>AB</u>		<u>200MG</u>	<u>A204158</u>	<u>004</u>	Oct 27, 2015
<u>AB</u>	SCIEGEN PHARMS INC	<u>25MG</u>	<u>A206382</u>	<u>001</u>	Jun 17, 2016
<u>AB</u>		<u>50MG</u>	<u>A206382</u>	<u>002</u>	Jun 17, 2016
<u>AB</u>		<u>100MG</u>	<u>A206382</u>	<u>003</u>	Jun 17, 2016
<u>AB</u>		<u>200MG</u>	<u>A206382</u>	<u>004</u>	Jun 17, 2016

LANREOTIDE ACETATE

SOLUTION;SUBCUTANEOUS

SOMATULINE DEPOT

+	IPSEN PHARMA	EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML)	N022074	001	Aug 30, 2007
+		EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML)	N022074	002	Aug 30, 2007
+		EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML)	N022074	003	Aug 30, 2007

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

<u>AB</u>	AJANTA PHARMA LTD	<u>15MG</u>	<u>A203957</u>	<u>001</u>	Oct 14, 2016
<u>AB</u>		<u>30MG</u>	<u>A203957</u>	<u>002</u>	Oct 14, 2016
<u>AB</u>	DR REDDYS LABS LTD	<u>15MG</u>	<u>A091269</u>	<u>001</u>	Oct 15, 2010
<u>AB</u>		<u>30MG</u>	<u>A091269</u>	<u>002</u>	Oct 15, 2010
<u>AB</u>	LABS LICONSA	<u>15MG</u>	<u>A203203</u>	<u>001</u>	Jul 25, 2016
<u>AB</u>		<u>30MG</u>	<u>A203203</u>	<u>002</u>	Jul 25, 2016
<u>AB</u>	MYLAN PHARMS INC	<u>15MG</u>	<u>A090763</u>	<u>001</u>	Nov 10, 2009
<u>AB</u>		<u>30MG</u>	<u>A090763</u>	<u>002</u>	Nov 10, 2009
<u>AB</u>	NATCO PHARMA LTD	<u>15MG</u>	<u>A201921</u>	<u>001</u>	Dec 18, 2012
<u>AB</u>		<u>30MG</u>	<u>A201921</u>	<u>002</u>	Dec 18, 2012
<u>AB</u>	SANDOZ	<u>15MG</u>	<u>A090331</u>	<u>001</u>	Apr 23, 2010
<u>AB</u>		<u>30MG</u>	<u>A090331</u>	<u>002</u>	Apr 23, 2010
<u>AB</u>	SUN PHARM INDS LTD	<u>15MG</u>	<u>A202637</u>	<u>001</u>	Sep 13, 2013
<u>AB</u>		<u>30MG</u>	<u>A091509</u>	<u>001</u>	Sep 13, 2013
<u>AB</u>	TEVA PHARMS	<u>15MG</u>	<u>A077255</u>	<u>001</u>	Nov 10, 2009
<u>AB</u>		<u>30MG</u>	<u>A077255</u>	<u>002</u>	Nov 10, 2009
<u>AB</u>	WOCKHARDT USA	<u>15MG</u>	<u>A202176</u>	<u>001</u>	Sep 14, 2012
<u>AB</u>		<u>30MG</u>	<u>A202176</u>	<u>002</u>	Sep 14, 2012
<u>AB</u>	ZYDUS HLTHCARE	<u>15MG</u>	<u>A202366</u>	<u>001</u>	Aug 19, 2013
<u>AB</u>		<u>30MG</u>	<u>A202366</u>	<u>002</u>	Aug 19, 2013

LANSOPRAZOLE

<u>AB</u>	KRKA TOVARNA ZDRAVIL	<u>15MG</u>	<u>A091212</u>	<u>001</u>	Sep 16, 2013
<u>AB</u>		<u>30MG</u>	<u>A091212</u>	<u>002</u>	Sep 16, 2013

PREVACID

<u>AB</u>	TAKEDA PHARMS USA	<u>15MG</u>	<u>N020406</u>	<u>001</u>	May 10, 1995
<u>AB</u>	+	<u>30MG</u>	<u>N020406</u>	<u>002</u>	May 10, 1995

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL

PREVACID

+	TAKEDA PHARMS USA	15MG	N021428	001	Aug 30, 2002
+		30MG	N021428	002	Aug 30, 2002

LANTHANUM CARBONATE

POWDER;ORAL

FOSRENOL

+	SHIRE DEV LLC	EQ 750MG BASE	N204734	001	Sep 24, 2014
+		EQ 1GM BASE	N204734	002	Sep 24, 2014

TABLET, CHEWABLE;ORAL

FOSRENOL

+	SHIRE LLC	EQ 500MG BASE	N021468	002	Oct 26, 2004
+		EQ 750MG BASE	N021468	003	Nov 23, 2005
+		EQ 1GM BASE	N021468	004	Nov 23, 2005

LAPATINIB DITOSYLATE

TABLET;ORAL

TYKERB

+	NOVARTIS PHARMS CORP	EQ 250MG BASE	N022059	001	Mar 13, 2007
---	----------------------	---------------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC

LATANOPROST

<u>AT</u>	AKORN	<u>0.005%</u>	<u>A090887</u>	<u>001</u>	Jul 19, 2011
<u>AT</u>	ALCON RES	<u>0.005%</u>	<u>A091449</u>	<u>001</u>	Mar 22, 2011
<u>AT</u>	BAUSCH AND LOMB	<u>0.005%</u>	<u>A201006</u>	<u>001</u>	Mar 22, 2011
<u>AT</u>	DR REDDYS LABS LTD	<u>0.005%</u>	<u>A202077</u>	<u>001</u>	Feb 11, 2013
<u>AT</u>	FDC LTD	<u>0.005%</u>	<u>A202442</u>	<u>001</u>	Apr 22, 2016
<u>AT</u>	LUITPOLD	<u>0.005%</u>	<u>A200925</u>	<u>001</u>	Mar 22, 2011
<u>AT</u>	MYLAN	<u>0.005%</u>	<u>A201786</u>	<u>001</u>	Mar 22, 2011

XALATAN

<u>AT</u>	+ PHARMACIA AND UPJOHN	<u>0.005%</u>	<u>N020597</u>	<u>001</u>	Jun 05, 1996
-----------	------------------------	---------------	----------------	------------	--------------

LEDIPASVIR; SOFOSBUVIR

TABLET;ORAL

HARVONI

	+ GILEAD SCIENCES INC	90MG;400MG	N205834	001	Oct 10, 2014
--	-----------------------	------------	---------	-----	--------------

LEFLUNOMIDE

TABLET;ORAL

ARAVA

<u>AB</u>	SANOFI AVENTIS US	<u>10MG</u>	<u>N020905</u>	<u>001</u>	Sep 10, 1998
<u>AB</u>	+	<u>20MG</u>	<u>N020905</u>	<u>002</u>	Sep 10, 1998

LEFLUNOMIDE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>10MG</u>	<u>A091369</u>	<u>001</u>	Nov 21, 2011
<u>AB</u>		<u>20MG</u>	<u>A091369</u>	<u>002</u>	Nov 21, 2011
<u>AB</u>	APOTEX INC	<u>10MG</u>	<u>A077090</u>	<u>001</u>	Sep 13, 2005
<u>AB</u>		<u>20MG</u>	<u>A077090</u>	<u>002</u>	Sep 13, 2005
<u>AB</u>	BARR	<u>10MG</u>	<u>A077083</u>	<u>001</u>	Sep 13, 2005
<u>AB</u>		<u>20MG</u>	<u>A077083</u>	<u>002</u>	Sep 13, 2005
<u>AB</u>	HERITAGE PHARMS INC	<u>10MG</u>	<u>A077086</u>	<u>001</u>	Sep 13, 2005
<u>AB</u>		<u>20MG</u>	<u>A077086</u>	<u>002</u>	Sep 13, 2005
<u>AB</u>	TEVA PHARMS	<u>10MG</u>	<u>A077084</u>	<u>001</u>	Sep 13, 2005
<u>AB</u>		<u>20MG</u>	<u>A077084</u>	<u>002</u>	Sep 13, 2005
	ARAVA				
	+ SANOFI AVENTIS US	100MG	N020905	003	Sep 10, 1998

LENALIDOMIDE

CAPSULE;ORAL

REVLIMID

	CELGENE	2.5MG	N021880	005	Dec 21, 2011
		5MG	N021880	001	Dec 27, 2005
		10MG	N021880	002	Dec 27, 2005
		15MG	N021880	003	Jun 29, 2006
		20MG	N021880	006	Jun 05, 2013
	+	25MG	N021880	004	Jun 29, 2006

LENVATINIB MESYLATE

CAPSULE;ORAL

LENVIMA

	EISAI INC	EQ 4MG BASE	N206947	001	Feb 13, 2015
	+	EQ 10MG BASE	N206947	002	Feb 13, 2015

LESINURAD

TABLET;ORAL

ZURAMPIC

	+ IRONWOOD PHARMS INC	200MG	N207988	001	Dec 22, 2015
--	-----------------------	-------	---------	-----	--------------

LETROZOLE

TABLET;ORAL

FEMARA

<u>AB</u>	+ NOVARTIS PHARMS	<u>2.5MG</u>	<u>N020726</u>	<u>001</u>	Jul 25, 1997
-----------	-------------------	--------------	----------------	------------	--------------

LETROZOLE

<u>AB</u>	ACCORD HLTHCARE	<u>2.5MG</u>	<u>A090934</u>	<u>001</u>	Jun 03, 2011
<u>AB</u>	APOTEX INC	<u>2.5MG</u>	<u>A091303</u>	<u>001</u>	Apr 19, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>2.5MG</u>	<u>A091191</u>	<u>001</u>	Jun 03, 2011
<u>AB</u>	FRESENIUS KABI ONCOL	<u>2.5MG</u>	<u>A090491</u>	<u>001</u>	Jun 03, 2011
<u>AB</u>	HIKMA PHARMS	<u>2.5MG</u>	<u>A203796</u>	<u>001</u>	Jun 03, 2016
<u>AB</u>	INDICUS PHARMA	<u>2.5MG</u>	<u>A201804</u>	<u>001</u>	Jun 03, 2011
<u>AB</u>	JIANGSU HENGRUI MED	<u>2.5MG</u>	<u>A202716</u>	<u>001</u>	May 16, 2013
<u>AB</u>	KREMERS URBAN PHARMS	<u>2.5MG</u>	<u>A091098</u>	<u>001</u>	Jun 03, 2011
<u>AB</u>	LANNETT HOLDINGS INC	<u>2.5MG</u>	<u>A202048</u>	<u>001</u>	Oct 29, 2014
<u>AB</u>	MYLAN	<u>2.5MG</u>	<u>A078190</u>	<u>001</u>	Dec 24, 2008
<u>AB</u>	NATCO PHARMA LTD	<u>2.5MG</u>	<u>A200161</u>	<u>001</u>	Jun 03, 2011
<u>AB</u>	SUN PHARM INDS LTD	<u>2.5MG</u>	<u>A091466</u>	<u>001</u>	Jun 03, 2011

PRESCRIPTION DRUG PRODUCT LIST

LETROZOLE

TABLET; ORAL

LETROZOLE

<u>AB</u>	TEVA PHARMS	<u>2.5MG</u>	<u>A090289</u>	<u>001</u>	Jun 03, 2011
<u>AB</u>	VINTAGE PHARMS LLC	<u>2.5MG</u>	<u>A090789</u>	<u>001</u>	Jun 03, 2011
<u>AB</u>	WEST-WARD PHARMS INT	<u>2.5MG</u>	<u>A090838</u>	<u>001</u>	Jun 03, 2011

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

<u>AP</u>	TEVA PHARMS USA	<u>EQ 100MG BASE/VIAL</u>	<u>A081277</u>	<u>001</u>	Sep 28, 1993
<u>AP</u>		<u>EQ 350MG BASE/VIAL</u>	<u>A040174</u>	<u>001</u>	Jun 12, 1997
<u>AP</u>	+ WEST-WARD PHARMS INT	<u>EQ 50MG BASE/VIAL</u>	<u>A089384</u>	<u>001</u>	Sep 14, 1987
<u>AP</u>	+	<u>EQ 100MG BASE/VIAL</u>	<u>A089717</u>	<u>001</u>	Mar 28, 1988

LEUCOVORIN CALCIUM PRESERVATIVE FREE

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 200MG BASE/VIAL</u>	<u>A040258</u>	<u>001</u>	Feb 26, 1999
<u>AP</u>	SAGENT PHARMS	<u>EQ 50MG BASE/VIAL</u>	<u>A200753</u>	<u>001</u>	Sep 06, 2012
<u>AP</u>		<u>EQ 100MG BASE/VIAL</u>	<u>A200753</u>	<u>002</u>	Sep 06, 2012
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A200753</u>	<u>003</u>	Sep 06, 2012
<u>AP</u>		<u>EQ 350MG BASE/VIAL</u>	<u>A200855</u>	<u>001</u>	Sep 06, 2012
<u>AP</u>	+ WEST-WARD PHARMS INT	<u>EQ 200MG BASE/VIAL</u>	<u>A040056</u>	<u>001</u>	May 23, 1995
<u>AP</u>	+	<u>EQ 350MG BASE/VIAL</u>	<u>A040335</u>	<u>001</u>	Apr 20, 2000
	+ FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A040286	001	Feb 26, 1999
	+ WEST-WARD PHARMS INT	EQ 10MG BASE/ML	A040347	001	Apr 25, 2000

TABLET; ORAL

LEUCOVORIN CALCIUM

<u>AB</u>	BARR	<u>EQ 5MG BASE</u>	<u>A071198</u>	<u>001</u>	Sep 24, 1987
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A071199</u>	<u>001</u>	Sep 24, 1987
<u>AB</u>	WEST-WARD PHARMS INT	<u>EQ 5MG BASE</u>	<u>A072733</u>	<u>001</u>	Feb 22, 1993
<u>AB</u>	+	<u>EQ 25MG BASE</u>	<u>A072736</u>	<u>001</u>	Feb 22, 1993
		EQ 10MG BASE	A072734	001	Feb 22, 1993
		EQ 15MG BASE	A072735	001	Feb 22, 1993

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LEUPROLIDE ACETATE

<u>AP</u>	+ SANDOZ	<u>1MG/0.2ML</u>	<u>A074728</u>	<u>001</u>	Aug 04, 1998
<u>AP</u>	SUN PHARMA GLOBAL	<u>1MG/0.2ML</u>	<u>A078885</u>	<u>001</u>	Mar 09, 2009
<u>AP</u>	TEVA PHARMS USA	<u>1MG/0.2ML</u>	<u>A075471</u>	<u>001</u>	Oct 25, 2000

LUPRON DEPOT

	+ ABBVIE ENDOCRINE INC	3.75MG	N020011	002	Oct 26, 1995
	+	7.5MG/VIAL	N019732	001	Jan 26, 1989
	+	11.25MG/VIAL	N020708	001	Mar 07, 1997
	+	22.5MG/VIAL	N020517	001	Dec 22, 1995
	+	30MG/VIAL	N020517	002	May 30, 1997
	+	45MG/VIAL	N020517	003	Jun 17, 2011

LUPRON DEPOT-PED

	+ ABBVIE ENDOCRINE INC	7.5MG/VIAL	N020263	002	Apr 16, 1993
	+	11.25MG/VIAL	N020263	005	Jan 21, 1994
	+	11.25MG/VIAL	N020263	007	Aug 15, 2011
	+	15MG/VIAL	N020263	006	Jan 21, 1994
	+	30MG/VIAL	N020263	008	Aug 15, 2011

INJECTABLE; SUBCUTANEOUS

ELIGARD

	+ TOLMAR THERAP	7.5MG/VIAL	N021343	001	Jan 23, 2002
	+	22.5MG/VIAL	N021379	001	Jul 24, 2002
	+	30MG/VIAL	N021488	001	Feb 13, 2003
	+	45MG/VIAL	N021731	001	Dec 14, 2004

LEUPROLIDE ACETATE; NORETHINDRONE ACETATE

INJECTABLE, TABLET; INTRAMUSCULAR, ORAL

LUPANETA PACK

	ABBVIE ENDOCRINE	3.75MG/VIAL, N/A; N/A, 5MG	N203696	001	Dec 14, 2012
	+	11.25MG/VIAL, N/A; N/A, 5MG	N203696	002	Dec 14, 2012

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

<u>AN</u>	AUROBINDO PHARMA LTD	<u>EQ 0.0103% BASE</u>	<u>A207625</u>	<u>001</u>	Dec 30, 2016
<u>AN</u>		<u>EQ 0.021% BASE</u>	<u>A207625</u>	<u>002</u>	Dec 30, 2016
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A207625</u>	<u>003</u>	Dec 30, 2016
<u>AN</u>	CIPLA LTD	<u>EQ 0.021% BASE</u>	<u>A078171</u>	<u>002</u>	Dec 13, 2013
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A078171</u>	<u>003</u>	Dec 13, 2013
<u>AN</u>		<u>EQ 0.0103% BASE</u>	<u>A078171</u>	<u>001</u>	Dec 13, 2013

PRESCRIPTION DRUG PRODUCT LIST

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

<u>AN</u>	IMPAX LABS INC	<u>EQ 0.0103% BASE</u>	<u>A077756 003</u>	Apr 09, 2008
<u>AN</u>		<u>EQ 0.021% BASE</u>	<u>A077756 001</u>	Apr 09, 2008
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A077756 002</u>	Apr 09, 2008
<u>AN</u>	MYLAN SPECLT	<u>EQ 0.0103% BASE</u>	<u>A077800 001</u>	Mar 15, 2013
<u>AN</u>		<u>EQ 0.021% BASE</u>	<u>A077800 002</u>	Mar 15, 2013
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A077800 003</u>	Mar 15, 2013
<u>AN</u>		<u>EQ 0.25% BASE</u>	<u>A078309 001</u>	Mar 20, 2009
<u>AN</u>	RITEDOSE CORP	<u>EQ 0.0103% BASE</u>	<u>A203653 001</u>	Mar 22, 2016
<u>AN</u>		<u>EQ 0.021% BASE</u>	<u>A203653 002</u>	Mar 22, 2016
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A203653 003</u>	Mar 22, 2016
<u>AN</u>	TEVA PARENTERAL	<u>EQ 0.25% BASE</u>	<u>A200875 001</u>	Sep 11, 2014
<u>AN</u>	TEVA PHARMS USA	<u>EQ 0.0103% BASE</u>	<u>A090297 001</u>	Apr 26, 2013
<u>AN</u>		<u>EQ 0.021% BASE</u>	<u>A090297 002</u>	Apr 26, 2013
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A090297 003</u>	Apr 26, 2013

XOPENEX

<u>AN</u>	+ OAK PHARMS INC	<u>EQ 0.0103% BASE</u>	<u>N020837 003</u>	Jan 30, 2002
<u>AN</u>	+	<u>EQ 0.021% BASE</u>	<u>N020837 001</u>	Mar 25, 1999
<u>AN</u>	+	<u>EQ 0.042% BASE</u>	<u>N020837 002</u>	Mar 25, 1999
<u>AN</u>	+	<u>EQ 0.25% BASE</u>	<u>N020837 004</u>	Jul 18, 2003

LEVALBUTEROL TARTRATE

AEROSOL, METERED; INHALATION

XOPENEX HFA

+ SUNOVION

EQ 0.045MG BASE/INH

N021730 001 Mar 11, 2005

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

KEPPRA

<u>AP</u>	+ UCB INC	<u>500MG/5ML (100MG/ML)</u>	<u>N021872 001</u>	Jul 31, 2006
-----------	-----------	-----------------------------	--------------------	--------------

LEVETIRACETAM

<u>AP</u>	AUROBINDO PHARMA LTD	<u>500MG/5ML (100MG/ML)</u>	<u>A204312 001</u>	Feb 01, 2016
<u>AP</u>	FRESENIUS KABI USA	<u>500MG/5ML (100MG/ML)</u>	<u>A090813 001</u>	May 26, 2010
<u>AP</u>		<u>500MG/5ML (100MG/ML)</u>	<u>A090876 001</u>	Aug 13, 2015
<u>AP</u>	HIKMA FARMACEUTICA	<u>500MG/5ML (100MG/ML)</u>	<u>A090981 001</u>	Oct 13, 2011
<u>AP</u>	HOSPIRA INC	<u>500MG/5ML (100MG/ML)</u>	<u>A202869 001</u>	Apr 06, 2012
<u>AP</u>	JUBILANT LIFE	<u>500MG/5ML (100MG/ML)</u>	<u>A206838 001</u>	Jun 02, 2016
<u>AP</u>	LUITPOLD	<u>500MG/5ML (100MG/ML)</u>	<u>A202143 001</u>	Jan 31, 2012
<u>AP</u>	MYLAN LABS LTD	<u>500MG/5ML (100MG/ML)</u>	<u>A203308 001</u>	Sep 16, 2016
<u>AP</u>	SAGENT PHARMS	<u>500MG/5ML (100MG/ML)</u>	<u>A091627 001</u>	Jun 26, 2013
<u>AP</u>	SUN PHARM INDS LTD	<u>500MG/5ML (100MG/ML)</u>	<u>A090754 001</u>	Jun 16, 2010
<u>AP</u>	X GEN PHARMS	<u>500MG/5ML (100MG/ML)</u>	<u>A091485 001</u>	Aug 05, 2011

LEVETIRACETAM IN SODIUM CHLORIDE

<u>AP</u>	AUROBINDO PHARMA LTD	<u>500MG/100ML (5MG/ML)</u>	<u>A207160 001</u>	Jan 04, 2017
<u>AP</u>		<u>100MG/100ML (10MG/ML)</u>	<u>A207160 002</u>	Jan 04, 2017
<u>AP</u>		<u>1500MG/100ML (15MG/ML)</u>	<u>A207160 003</u>	Jan 04, 2017
<u>AP</u>	+ HQ SPECIALITY PHARMA	<u>500MG/100ML (5MG/ML)</u>	<u>N202543 001</u>	Nov 09, 2011
<u>AP</u>	+	<u>100MG/100ML (10MG/ML)</u>	<u>N202543 002</u>	Nov 09, 2011
<u>AP</u>	+	<u>1500MG/100ML (15MG/ML)</u>	<u>N202543 003</u>	Nov 09, 2011

SOLUTION; ORAL

KEPPRA

<u>AA</u>	+ UCB INC	<u>100MG/ML</u>	<u>N021505 001</u>	Jul 15, 2003
-----------	-----------	-----------------	--------------------	--------------

LEVETIRACETAM

<u>AA</u>	ACTAVIS MID ATLANTIC	<u>100MG/ML</u>	<u>A078976 001</u>	Jan 15, 2009
<u>AA</u>	AMNEAL PHARMS	<u>100MG/ML</u>	<u>A090992 001</u>	Oct 27, 2009
<u>AA</u>	AUROBINDO PHARM	<u>100MG/ML</u>	<u>A079063 001</u>	Jan 15, 2009
<u>AA</u>	BRECKENRIDGE PHARM	<u>100MG/ML</u>	<u>A079120 001</u>	Jan 16, 2009
<u>AA</u>	HETERO LABS LTD III	<u>100MG/ML</u>	<u>A203052 001</u>	Feb 28, 2013
<u>AA</u>	HI-TECH PHARMACAL	<u>100MG/ML</u>	<u>A090601 001</u>	Feb 28, 2012
<u>AA</u>	LUPIN LTD	<u>100MG/ML</u>	<u>A090893 001</u>	Oct 17, 2011
<u>AA</u>	ORIT LABS LLC	<u>100MG/ML</u>	<u>A203067 001</u>	May 09, 2013
<u>AA</u>	PHARM ASSOC	<u>100MG/ML</u>	<u>A201157 001</u>	Jun 04, 2015
<u>AA</u>	ROXANE	<u>100MG/ML</u>	<u>A078582 001</u>	Jan 15, 2009
<u>AA</u>	SILARX	<u>100MG/ML</u>	<u>A090263 001</u>	Apr 03, 2009
<u>AA</u>	TARO	<u>100MG/ML</u>	<u>A078774 001</u>	Feb 10, 2009
<u>AA</u>	TOLMAR	<u>100MG/ML</u>	<u>A079107 001</u>	Jan 15, 2009
<u>AA</u>	TRIS PHARMA INC	<u>100MG/ML</u>	<u>A090461 001</u>	Sep 30, 2010
<u>AA</u>	VINTAGE PHARMS	<u>100MG/ML</u>	<u>A090079 001</u>	Apr 11, 2012
<u>AA</u>	WOCKHARDT	<u>100MG/ML</u>	<u>A090028 001</u>	Mar 03, 2010

PRESCRIPTION DRUG PRODUCT LIST

LEVETIRACETAM

TABLET;ORAL

KEPPRA

<u>AB</u>	UCB INC	<u>250MG</u>	<u>N021035</u>	<u>001</u>	Nov 30, 1999
<u>AB</u>		<u>500MG</u>	<u>N021035</u>	<u>002</u>	Nov 30, 1999
<u>AB</u>		<u>750MG</u>	<u>N021035</u>	<u>003</u>	Nov 30, 1999
<u>AB</u>	+	<u>1GM</u>	<u>N021035</u>	<u>004</u>	Jan 06, 2006

LEVETIRACETAM

<u>AB</u>	ACCORD HLTHCARE	<u>250MG</u>	<u>A090843</u>	<u>001</u>	Feb 14, 2011
<u>AB</u>		<u>500MG</u>	<u>A090843</u>	<u>002</u>	Feb 14, 2011
<u>AB</u>		<u>750MG</u>	<u>A090843</u>	<u>003</u>	Feb 14, 2011
<u>AB</u>		<u>1GM</u>	<u>A090843</u>	<u>004</u>	Feb 14, 2011
<u>AB</u>	AJANTA PHARMA	<u>250MG</u>	<u>A201293</u>	<u>001</u>	Jun 14, 2011
<u>AB</u>		<u>500MG</u>	<u>A201293</u>	<u>002</u>	Jun 14, 2011
<u>AB</u>		<u>750MG</u>	<u>A201293</u>	<u>003</u>	Jun 14, 2011
<u>AB</u>		<u>1GM</u>	<u>A201293</u>	<u>004</u>	Jun 14, 2011
<u>AB</u>	APOTEX INC	<u>250MG</u>	<u>A078869</u>	<u>001</u>	Mar 13, 2009
<u>AB</u>		<u>500MG</u>	<u>A078869</u>	<u>002</u>	Mar 13, 2009
<u>AB</u>		<u>750MG</u>	<u>A078869</u>	<u>003</u>	Mar 13, 2009
<u>AB</u>		<u>1GM</u>	<u>A078869</u>	<u>004</u>	Mar 13, 2009
<u>AB</u>	AUROBINDO PHARMA	<u>250MG</u>	<u>A078993</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078993</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078993</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A078993</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>	BRECKENRIDGE PHARM	<u>250MG</u>	<u>A090511</u>	<u>001</u>	Aug 18, 2011
<u>AB</u>		<u>500MG</u>	<u>A090511</u>	<u>002</u>	Aug 18, 2011
<u>AB</u>		<u>750MG</u>	<u>A090511</u>	<u>003</u>	Aug 18, 2011
<u>AB</u>		<u>1GM</u>	<u>A090511</u>	<u>004</u>	Aug 18, 2011
<u>AB</u>	DR REDDYS LABS LTD	<u>250MG</u>	<u>A076920</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A076920</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A076920</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A078904</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>	HETERO LABS LTD III	<u>250MG</u>	<u>A090515</u>	<u>001</u>	Oct 08, 2010
<u>AB</u>		<u>500MG</u>	<u>A090515</u>	<u>002</u>	Oct 08, 2010
<u>AB</u>		<u>750MG</u>	<u>A090515</u>	<u>003</u>	Oct 08, 2010
<u>AB</u>		<u>1GM</u>	<u>A090515</u>	<u>004</u>	Oct 08, 2010
<u>AB</u>	INVAGEN PHARMS	<u>250MG</u>	<u>A078234</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078234</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078234</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>	LOTUS PHARM CO LTD	<u>500MG</u>	<u>A090906</u>	<u>001</u>	Nov 05, 2010
<u>AB</u>	LUPIN	<u>250MG</u>	<u>A078154</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078154</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078154</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A090025</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>	METHAPHARM	<u>250MG</u>	<u>A090767</u>	<u>001</u>	Jul 28, 2010
<u>AB</u>		<u>500MG</u>	<u>A090767</u>	<u>002</u>	Jul 28, 2010
<u>AB</u>		<u>750MG</u>	<u>A090767</u>	<u>003</u>	Jul 28, 2010
<u>AB</u>		<u>1GM</u>	<u>A090767</u>	<u>004</u>	Jul 28, 2010
<u>AB</u>	MYLAN	<u>250MG</u>	<u>A076919</u>	<u>001</u>	Nov 04, 2008
<u>AB</u>		<u>500MG</u>	<u>A076919</u>	<u>002</u>	Nov 04, 2008
<u>AB</u>		<u>750MG</u>	<u>A076919</u>	<u>003</u>	Nov 04, 2008
<u>AB</u>		<u>1GM</u>	<u>A090261</u>	<u>001</u>	Dec 08, 2009
<u>AB</u>	ORCHID HLTHCARE	<u>250MG</u>	<u>A078526</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078526</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078526</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A090484</u>	<u>001</u>	Aug 05, 2010
<u>AB</u>	PRINSTON INC	<u>250MG</u>	<u>A078106</u>	<u>001</u>	Feb 10, 2009
<u>AB</u>		<u>500MG</u>	<u>A078106</u>	<u>002</u>	Feb 10, 2009
<u>AB</u>		<u>750MG</u>	<u>A078106</u>	<u>003</u>	Feb 10, 2009
<u>AB</u>		<u>1GM</u>	<u>A078106</u>	<u>004</u>	Feb 10, 2009
<u>AB</u>	ROXANE	<u>250MG</u>	<u>A078042</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078042</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078042</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A078042</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>	SECAN PHARMS	<u>500MG</u>	<u>A205102</u>	<u>004</u>	Dec 16, 2015
<u>AB</u>		<u>1GM</u>	<u>A205102</u>	<u>003</u>	Dec 16, 2015
<u>AB</u>	TARO	<u>250MG</u>	<u>A078960</u>	<u>004</u>	Feb 01, 2010
<u>AB</u>		<u>500MG</u>	<u>A078960</u>	<u>003</u>	Feb 01, 2010
<u>AB</u>		<u>750MG</u>	<u>A078960</u>	<u>002</u>	Feb 01, 2010
<u>AB</u>		<u>1GM</u>	<u>A078960</u>	<u>001</u>	Feb 01, 2010
<u>AB</u>	TEVA PHARMS	<u>250MG</u>	<u>A078101</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078101</u>	<u>002</u>	Jan 15, 2009

PRESCRIPTION DRUG PRODUCT LIST

LEVETIRACETAM

TABLET;ORAL

LEVETIRACETAM

<u>AB</u>		<u>750MG</u>	<u>A078101 003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A078101 004</u>	Jan 15, 2009
<u>AB</u>	TORRENT PHARMS	<u>250MG</u>	<u>A078858 001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078858 002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078858 003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A078858 004</u>	Jan 15, 2009
<u>AB</u>	VINTAGE PHARMS	<u>250MG</u>	<u>A077319 001</u>	Mar 20, 2009
<u>AB</u>		<u>250MG</u>	<u>A091491 001</u>	Dec 14, 2010
<u>AB</u>		<u>500MG</u>	<u>A077319 002</u>	Mar 20, 2009
<u>AB</u>		<u>500MG</u>	<u>A091491 002</u>	Dec 14, 2010
<u>AB</u>		<u>750MG</u>	<u>A077319 003</u>	Mar 20, 2009
<u>AB</u>		<u>750MG</u>	<u>A091491 003</u>	Dec 14, 2010
<u>AB</u>		<u>1GM</u>	<u>A091491 004</u>	Dec 14, 2010
<u>AB</u>	WOCKHARDT	<u>250MG</u>	<u>A079042 001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A079042 002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A079042 003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A079042 004</u>	Jan 15, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>250MG</u>	<u>A078918 001</u>	Apr 29, 2009
<u>AB</u>		<u>1GM</u>	<u>A078918 002</u>	Apr 29, 2009

TABLET, EXTENDED RELEASE;ORAL

KEPPRA XR

<u>AB</u>	UCB INC	<u>500MG</u>	<u>N022285 001</u>	Sep 12, 2008
<u>AB</u>	+	<u>750MG</u>	<u>N022285 002</u>	Feb 12, 2009

LEVETIRACETAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>500MG</u>	<u>A091557 001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091557 002</u>	Sep 12, 2011
<u>AB</u>	ACTAVIS LABS FL INC	<u>500MG</u>	<u>A091093 001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091093 002</u>	Sep 12, 2011
<u>AB</u>	ANCHEN PHARMS	<u>500MG</u>	<u>A091360 001</u>	Oct 04, 2011
<u>AB</u>		<u>750MG</u>	<u>A091360 002</u>	Oct 04, 2011
<u>AB</u>	APOTEX INC	<u>500MG</u>	<u>A091261 001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091261 002</u>	Sep 12, 2011
<u>AB</u>	DEXCEL PHARMA	<u>500MG</u>	<u>A202167 001</u>	Sep 04, 2015
<u>AB</u>		<u>750MG</u>	<u>A202167 002</u>	Sep 04, 2015
<u>AB</u>	INTELLIPHARMACEUTICS	<u>500MG</u>	<u>A204511 001</u>	Feb 23, 2016
<u>AB</u>		<u>750MG</u>	<u>A204511 002</u>	Feb 23, 2016
<u>AB</u>	LOTUS PHARM CO LTD	<u>500MG</u>	<u>A202095 002</u>	Jun 06, 2016
<u>AB</u>		<u>750MG</u>	<u>A202095 001</u>	Jun 06, 2016
<u>AB</u>	LUPIN LTD	<u>500MG</u>	<u>A091399 001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091399 002</u>	Sep 12, 2011
<u>AB</u>	MYLAN PHARMS INC	<u>500MG</u>	<u>A200475 001</u>	Dec 19, 2011
<u>AB</u>		<u>750MG</u>	<u>A200475 002</u>	Dec 19, 2011
<u>AB</u>	NOSTRUM LABS INC	<u>500MG</u>	<u>A204754 001</u>	Aug 26, 2016
<u>AB</u>		<u>750MG</u>	<u>A204754 002</u>	Aug 26, 2016
<u>AB</u>	PAR PHARM	<u>500MG</u>	<u>A091291 001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091291 002</u>	Sep 12, 2011
<u>AB</u>	PHARMADAX INC	<u>500MG</u>	<u>A201464 001</u>	May 25, 2012
<u>AB</u>		<u>750MG</u>	<u>A201464 002</u>	May 25, 2012
<u>AB</u>	PRINSTON INC	<u>500MG</u>	<u>A203468 001</u>	May 21, 2015
<u>AB</u>		<u>750MG</u>	<u>A203468 002</u>	May 21, 2015
<u>AB</u>	ROUSES POINT PHARMS	<u>500MG</u>	<u>A202524 001</u>	Aug 27, 2012
<u>AB</u>		<u>750MG</u>	<u>A202524 002</u>	Aug 27, 2012
<u>AB</u>	SUN PHARM INDS	<u>500MG</u>	<u>A091285 001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091285 002</u>	Sep 12, 2011
<u>AB</u>	SUN PHARMA GLOBAL	<u>500MG</u>	<u>A203059 001</u>	Sep 09, 2013
<u>AB</u>		<u>750MG</u>	<u>A203059 002</u>	Sep 09, 2013
<u>AB</u>	TEVA PHARMS	<u>500MG</u>	<u>A091430 001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091430 002</u>	Sep 12, 2011
<u>AB</u>	TORRENT PHARMS LTD	<u>500MG</u>	<u>A091338 001</u>	May 29, 2012
<u>AB</u>		<u>750MG</u>	<u>A091338 002</u>	May 29, 2012
<u>AB</u>	VINTAGE PHARMS LLC	<u>500MG</u>	<u>A202533 001</u>	Jul 20, 2012
<u>AB</u>		<u>750MG</u>	<u>A202533 002</u>	Jul 20, 2012
<u>AB</u>	APOTEX INC	1GM	A202958 001	Feb 25, 2015
<u>AB</u>	MYLAN PHARMS INC	1GM	A200475 003	Dec 07, 2015

TABLET, FOR SUSPENSION;ORAL

SPRITAM

	APRECIA PHARMS CO	250MG	N207958 001	Jul 31, 2015
		500MG	N207958 002	Jul 31, 2015
		750MG	N207958 003	Jul 31, 2015

PRESCRIPTION DRUG PRODUCT LIST

LEVETIRACETAM

TABLET, FOR SUSPENSION;ORAL

SPRITAM

+

1GM

N207958 004 Jul 31, 2015

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

AKBETAAT AKORN0.25%A074779 001 Oct 29, 1996AT0.5%A074780 001 Oct 29, 1996BETAGANAT + ALLERGAN0.25%N019814 001 Jun 28, 1989AT +0.5%N019219 002 Dec 19, 1985LEVOBUNOLOL HYDROCHLORIDEAT ALCON LABS INC0.25%A074851 001 Oct 28, 1996AT ALCON RES LTD0.5%A074850 001 Oct 28, 1996AT BAUSCH AND LOMB0.25%A074307 001 Mar 04, 1994AT0.5%A074326 001 Mar 04, 1994LEVOCARNITINE

INJECTABLE; INJECTION

CARNITORAP + SIGMA TAU200MG/MLN020182 001 Dec 16, 1992LEVOCARNITINEAP LUITPOLD200MG/MLA075861 001 Jun 22, 2001AP WEST-WARD PHARMS INT200MG/MLA075567 001 Mar 29, 2001

SOLUTION;ORAL

CARNITORAA + SIGMA TAU1GM/10MLN019257 001 Apr 10, 1986CARNITOR SFAA SIGMA TAU1GM/10MLN019257 002 Mar 28, 2007LEVOCARNITINEAA HI TECH PHARMA1GM/10MLA077399 001 Oct 25, 2007AA LYNE1GM/10MLA076851 001 Aug 10, 2004

TABLET;ORAL

CARNITORAB + SIGMA TAU330MGN018948 001 Dec 27, 1985LEVOCARNITINEAB COREPHARMA330MGA076858 001 Sep 20, 2004LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDEAA APOTEX INC2.5MG/5MLA202915 001 Aug 21, 2014AA L PERRIGO CO2.5MG/5MLA091263 001 Nov 07, 2011AA TARO PHARM INDS2.5MG/5MLA202673 001 Jul 26, 2013XYZALAA + UCB INC2.5MG/5MLN022157 001 Jan 28, 2008

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDEAB APOTEX INC5MGA203027 001 Feb 13, 2015AB DR REDDYS LABS LTD5MGA090392 001 Feb 24, 2011AB GLENMARK GENERICS5MGA090385 001 Feb 24, 2011AB HETERO LABS LTD III5MGA091264 001 Jun 29, 2012AB MACLEODS PHARMS LTD5MGA205564 001 Jan 11, 2016AB MICRO LABS LTD INDIA5MGA202046 001 Sep 17, 2013AB NOSTRUM LABS INC5MGA204323 001 Dec 20, 2016AB SCIEGEN PHARMS INC5MGA203646 001 Sep 09, 2014AB SUN PHARM INDS LTD5MGA201653 001 Jun 26, 2015AB SUN PHARMA GLOBAL5MGA090362 001 Jan 31, 2013AB SYNTHON PHARMS5MGA090229 001 Nov 26, 2010AB TEVA PHARMS5MGA090199 001 Aug 22, 2011XYZALAB + UCB INC5MGN022064 001 May 25, 2007LEVOFLOXACIN

INJECTABLE; INJECTION

LEVAQUINAP + JANSSEN PHARMSEQ 500MG/20ML (EQ 25MG/ML)N020635 001 Dec 20, 1996AP +EQ 750MG/30ML (EQ 25MG/ML)N020635 004 Dec 20, 1996LEVOFLOXACINAP AUROBINDO PHARMA LTDEQ 500MG/20ML (EQ 25MG/ML)A202328 001 Jan 24, 2013APEQ 750MG/30ML (EQ 25MG/ML)A202328 002 Jan 24, 2013AP CLARISEQ 500MG/20ML (EQ 25MG/ML)A091436 001 Jun 05, 2013

PRESCRIPTION DRUG PRODUCT LIST

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVOFLOXACIN

<u>AP</u>	EMCURE PHARMS LTD	<u>EQ 500MG/20ML (EQ 25MG/ML)</u>	<u>A202590 001</u>	Jan 24, 2013
<u>AP</u>		<u>EQ 750MG/30ML (EQ 25MG/ML)</u>	<u>A202590 002</u>	Jan 24, 2013
<u>AP</u>	SAGENT PHARMS	<u>EQ 500MG/20ML (EQ 25MG/ML)</u>	<u>A200560 001</u>	Jun 20, 2011
<u>AP</u>		<u>EQ 750MG/30ML (EQ 25MG/ML)</u>	<u>A200560 002</u>	Jun 20, 2011
<u>LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER</u>				
<u>AP</u>	+ ACS DOBFAR INFO SA	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>A090343 001</u>	Jul 07, 2011
<u>AP</u>		<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>A090343 002</u>	Jul 07, 2011
<u>AP</u>		<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>A090343 003</u>	Jul 07, 2011
<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>A206919 001</u>	Feb 10, 2016
<u>AP</u>		<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>A206919 002</u>	Feb 10, 2016
<u>AP</u>		<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>A206919 003</u>	Feb 10, 2016
<u>AP</u>	CLARIS	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>A091397 001</u>	Aug 08, 2013
<u>AP</u>		<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>A091397 002</u>	Aug 08, 2013
<u>AP</u>		<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>A091397 003</u>	Aug 08, 2013
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>A200674 001</u>	Jun 19, 2013
<u>AP</u>		<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>A200674 002</u>	Jun 19, 2013
<u>AP</u>		<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>A200674 003</u>	Jun 19, 2013
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>A091375 001</u>	Sep 16, 2011
<u>AP</u>		<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>A091375 002</u>	Sep 16, 2011
<u>AP</u>		<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>A091375 003</u>	Sep 16, 2011
<u>AP</u>	HOSPIRA INC	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>A078579 001</u>	Sep 03, 2015
<u>AP</u>		<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>A078579 002</u>	Sep 03, 2015
<u>AP</u>		<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>A078579 003</u>	Sep 03, 2015

SOLUTION; ORAL

LEVAQUIN

<u>AA</u>	+ JANSSEN PHARMS	<u>250MG/10ML</u>	<u>N021721 001</u>	Oct 21, 2004
-----------	------------------	-------------------	--------------------	--------------

LEVOFLOXACIN

<u>AA</u>	HI TECH PHARMA	<u>250MG/10ML</u>	<u>A091678 001</u>	Jun 20, 2011
-----------	----------------	-------------------	--------------------	--------------

SOLUTION/DROPS; OPHTHALMIC

LEVOFLOXACIN

<u>AT</u>	AKORN	<u>0.5%</u>	<u>A090268 001</u>	Dec 20, 2010
<u>AT</u>	+ RISING PHARMS INC	<u>0.5%</u>	<u>A077700 001</u>	Dec 20, 2010
<u>AT</u>	WATSON LABS INC	<u>0.5%</u>	<u>A076826 001</u>	Feb 10, 2011

TABLET; ORAL

LEVAQUIN

<u>AB</u>	JANSSEN PHARMS	<u>250MG</u>	<u>N020634 001</u>	Dec 20, 1996
<u>AB</u>		<u>500MG</u>	<u>N020634 002</u>	Dec 20, 1996
<u>AB</u>		<u>750MG</u>	<u>N020634 003</u>	Sep 08, 2000

LEVOFLOXACIN

<u>AB</u>	APOTEX INC	<u>250MG</u>	<u>A090787 001</u>	Sep 29, 2011
<u>AB</u>		<u>500MG</u>	<u>A090787 002</u>	Sep 29, 2011
<u>AB</u>		<u>750MG</u>	<u>A090787 003</u>	Sep 29, 2011
<u>AB</u>	AUROBINDO PHARMA LTD	<u>250MG</u>	<u>A201043 001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A201043 002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A201043 003</u>	Jun 20, 2011
<u>AB</u>	CIPLA LTD	<u>250MG</u>	<u>A076890 001</u>	Mar 30, 2012
<u>AB</u>		<u>500MG</u>	<u>A076890 002</u>	Mar 30, 2012
<u>AB</u>		<u>750MG</u>	<u>A076890 003</u>	Mar 30, 2012
<u>AB</u>	DR REDDYS LABS INC	<u>250MG</u>	<u>A076710 001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A076710 002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A076710 003</u>	Jun 20, 2011
<u>AB</u>	GLENMARK GENERICS	<u>250MG</u>	<u>A200250 001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A200250 002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A200250 003</u>	Jun 20, 2011
<u>AB</u>	HETERO LABS LTD V	<u>250MG</u>	<u>A202801 001</u>	Jan 08, 2015
<u>AB</u>		<u>500MG</u>	<u>A202801 002</u>	Jan 08, 2015
<u>AB</u>		<u>750MG</u>	<u>A202801 003</u>	Jan 08, 2015
<u>AB</u>	JUBILANT GENERICS	<u>250MG</u>	<u>A203613 001</u>	Jun 19, 2015
<u>AB</u>		<u>500MG</u>	<u>A203613 002</u>	Jun 19, 2015
<u>AB</u>	LUPIN	<u>250MG</u>	<u>A078424 001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A078424 002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A078424 003</u>	Jun 20, 2011
<u>AB</u>	MACLEODS PHARMS LTD	<u>250MG</u>	<u>A200839 001</u>	Mar 22, 2012
<u>AB</u>		<u>500MG</u>	<u>A200839 002</u>	Mar 22, 2012
<u>AB</u>		<u>750MG</u>	<u>A200839 003</u>	Mar 22, 2012
<u>AB</u>	MYLAN	<u>250MG</u>	<u>A076276 001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A076276 002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A077097 001</u>	Jun 20, 2011
<u>AB</u>	ORCHID HLTHCARE	<u>250MG</u>	<u>A202200 001</u>	Jan 30, 2012

PRESCRIPTION DRUG PRODUCT LIST

LEVOFLOXACIN

TABLET; ORAL

LEVOFLOXACIN

<u>AB</u>		<u>500MG</u>	<u>A202200 002</u>	Jan 30, 2012
<u>AB</u>		<u>750MG</u>	<u>A202200 003</u>	Jan 30, 2012
<u>AB</u>	SANDOZ	<u>250MG</u>	<u>A077438 001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A077438 002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A077438 003</u>	Jun 20, 2011
<u>AB</u>	TEVA	<u>250MG</u>	<u>A076361 001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A076361 002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A076361 003</u>	Jun 20, 2011
<u>AB</u>	TORRENT PHARMS	<u>250MG</u>	<u>A090722 001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A090722 002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A090722 003</u>	Jun 20, 2011
<u>AB</u>	WOCKHARDT	<u>250MG</u>	<u>A090367 001</u>	Jun 20, 2011
<u>AB</u>		<u>500MG</u>	<u>A090367 002</u>	Jun 20, 2011
<u>AB</u>		<u>750MG</u>	<u>A090367 003</u>	Jun 20, 2011
<u>AB</u>	ZYDUS PHARMS USA INC	<u>250MG</u>	<u>A077652 001</u>	Sep 07, 2012
<u>AB</u>		<u>500MG</u>	<u>A077652 002</u>	Sep 07, 2012
<u>AB</u>		<u>750MG</u>	<u>A077652 003</u>	Sep 07, 2012

LEVOLEUCOVORIN CALCIUM

POWDER; IV (INFUSION)

FUSILEV

<u>AP</u>	+ SPECTRUM PHARMS	<u>EQ 50MG BASE/VIAL</u>	<u>N020140 001</u>	Mar 07, 2008
	<u>LEVOLEUCOVORIN CALCIUM</u>			
<u>AP</u>	WEST-WARD PHARMS INT	<u>EQ 50MG BASE/VIAL</u>	<u>A206263 001</u>	Jun 16, 2016
	ACTAVIS LLC	<u>EQ 175MG BASE/VIAL</u>	<u>N208723 001</u>	Sep 29, 2016
	SOLUTION; IV (INFUSION)			
	<u>LEVOLEUCOVORIN CALCIUM</u>			
<u>AP</u>	MYLAN TEORANTA	<u>EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)</u>	<u>A203576 001</u>	Oct 20, 2015
<u>AP</u>		<u>EQ 250MG BASE/25ML (EQ 10MG BASE/ML)</u>	<u>A203576 002</u>	Oct 20, 2015
<u>AP</u>	SANDOZ INC	<u>EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)</u>	<u>A203563 001</u>	Mar 09, 2015
<u>AP</u>	+	<u>EQ 250MG BASE/25ML (EQ 10MG BASE/ML)</u>	<u>A203563 002</u>	Mar 09, 2015

LEVOMILNACIPRAN HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

FETZIMA

	FOREST LABS INC	<u>EQ 20MG BASE</u>	<u>N204168 001</u>	Jul 25, 2013
		<u>EQ 40MG BASE</u>	<u>N204168 002</u>	Jul 25, 2013
		<u>EQ 80MG BASE</u>	<u>N204168 003</u>	Jul 25, 2013
	+	<u>EQ 120MG BASE</u>	<u>N204168 004</u>	Jul 25, 2013

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

SCANDONEST L

	+ DEPROCO	<u>0.05MG/ML; 2%</u>	<u>A088388 001</u>	Oct 10, 1984
--	-----------	----------------------	--------------------	--------------

LEVONORGESTREL

INTRAUTERINE DEVICE; INTRAUTERINE

KYLEENA

	+ BAYER HLTHCARE	<u>19.5MG</u>	<u>N208224 001</u>	Sep 16, 2016
--	------------------	---------------	--------------------	--------------

LILETTA

	MEDICINES360	<u>52MG</u>	<u>N206229 001</u>	Feb 26, 2015
--	--------------	-------------	--------------------	--------------

MIRENA

	+ BAYER HLTHCARE	<u>52MG</u>	<u>N021225 001</u>	Dec 06, 2000
--	------------------	-------------	--------------------	--------------

SKYLA

	+ BAYER HLTHCARE	<u>13.5MG</u>	<u>N203159 001</u>	Jan 09, 2013
--	------------------	---------------	--------------------	--------------

TABLET; ORAL

LEVONORGESTREL

<u>AB</u>	JAI PHARMA LTD	<u>0.75MG</u>	<u>A202740 001</u>	Sep 02, 2016
<u>AB</u>	LOTUS PHARM CO LTD	<u>0.75MG</u>	<u>A202684 001</u>	Sep 02, 2016
<u>AB</u>	+ PERRIGO R AND D	<u>0.75MG</u>	<u>A090740 001</u>	Dec 30, 2010

LEVORPHANOL TARTRATE

TABLET; ORAL

LEVORPHANOL TARTRATE

	+ SENTYNL THERAPS INC	<u>2MG</u>	<u>A074278 001</u>	Mar 31, 2000
--	-----------------------	------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

LEVOTHYROXINE SODIUM

CAPSULE; ORAL

TIROSINT

INST BIOCHIMIQUE	0.013MG	N022121	001	Aug 01, 2007
INSTITUT BIOCHIMIQUE	0.025MG	N021924	002	Oct 13, 2006
	0.05MG	N021924	003	Oct 13, 2006
	0.075MG	N021924	004	Oct 13, 2006
	0.088MG	N021924	010	Oct 02, 2009
	0.1MG	N021924	005	Oct 13, 2006
	0.112MG	N021924	008	Oct 02, 2009
	0.125MG	N021924	006	Oct 13, 2006
	0.137MG	N021924	009	Oct 02, 2009
+	0.15MG	N021924	007	Oct 13, 2006

POWDER; INTRAVENOUS

LEVOTHYROXINE SODIUM

AP	FERA PHARMS LLC	<u>100MCG/VIAL</u>	<u>A206163</u>	<u>001</u>	Jun 29, 2016
AP		<u>500MCG/VIAL</u>	<u>A206163</u>	<u>002</u>	Jun 29, 2016
AP	+ FRESENIUS KABI USA	<u>100MCG/VIAL</u>	<u>N202231</u>	<u>001</u>	Jun 24, 2011
AP	+	<u>200MCG/VIAL</u>	<u>N202231</u>	<u>002</u>	Jun 24, 2011
AP	+	<u>500MCG/VIAL</u>	<u>N202231</u>	<u>003</u>	Jun 24, 2011
AP	PAR STERILE PRODUCTS	<u>200MCG/VIAL</u>	<u>A205366</u>	<u>001</u>	Dec 07, 2015

SOLUTION; ORAL

TIROSINT-SOL

IBSA INST BIO	13MCG/ML	N206977	001	Dec 15, 2016
	25MCG/ML	N206977	002	Dec 15, 2016
	50MCG/ML	N206977	003	Dec 15, 2016
	75MCG/ML	N206977	004	Dec 15, 2016
	88MCG/ML	N206977	005	Dec 15, 2016
	100MCG/ML	N206977	006	Dec 15, 2016
	112MCG/ML	N206977	007	Dec 15, 2016
	125MCG/ML	N206977	008	Dec 15, 2016
	137MCG/ML	N206977	009	Dec 15, 2016
	150MCG/ML	N206977	010	Dec 15, 2016
	175MCG/ML	N206977	011	Dec 15, 2016
+	200MCG/ML	N206977	012	Dec 15, 2016

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET; ORAL

SYNTHROID

-->	ABBVIE	--> <u>AB1, AB2</u>	<u>0.025MG</u>	N021402	001	Jul 24, 2002
-->		--> <u>AB1, AB2</u>	<u>0.05MG</u>	N021402	002	Jul 24, 2002
-->		--> <u>AB1, AB2</u>	<u>0.075MG</u>	N021402	003	Jul 24, 2002
-->		--> <u>AB1, AB2</u>	<u>0.088MG</u>	N021402	004	Jul 24, 2002
-->		--> <u>AB1, AB2</u>	<u>0.1MG</u>	N021402	005	Jul 24, 2002
-->		--> <u>AB1, AB2</u>	<u>0.112MG</u>	N021402	006	Jul 24, 2002
-->		--> <u>AB1, AB2</u>	<u>0.125MG</u>	N021402	007	Jul 24, 2002
-->		--> <u>AB1, AB2</u>	<u>0.137MG</u>	N021402	008	Jul 24, 2002
-->		--> <u>AB1, AB2</u>	<u>0.15MG</u>	N021402	009	Jul 24, 2002
-->		--> <u>AB1, AB2</u>	<u>0.175MG</u>	N021402	010	Jul 24, 2002
-->		--> <u>AB1, AB2</u>	<u>0.2MG</u>	N021402	012	Jul 24, 2002
-->	+	--> <u>AB1, AB2</u>	<u>0.3MG</u>	N021402	011	Jul 24, 2002

LEVO-T

-->	ALARA PHARM	--> <u>AB1, AB2, AB3</u>	<u>0.025MG</u>	N021342	001	Mar 01, 2002
-->		--> <u>AB1, AB2, AB3</u>	<u>0.05MG</u>	N021342	002	Mar 01, 2002
-->		--> <u>AB1, AB2, AB3</u>	<u>0.075MG</u>	N021342	003	Mar 01, 2002
-->		--> <u>AB1, AB2, AB3</u>	<u>0.088MG</u>	N021342	004	Mar 01, 2002
-->		--> <u>AB1, AB2, AB3</u>	<u>0.1MG</u>	N021342	005	Mar 01, 2002
-->		--> <u>AB1, AB2, AB3</u>	<u>0.112MG</u>	N021342	006	Mar 01, 2002
-->		--> <u>AB1, AB2, AB3</u>	<u>0.125MG</u>	N021342	007	Mar 01, 2002
-->		--> <u>AB1, AB2, AB3</u>	<u>0.137MG</u>	N021342	012	Dec 08, 2003
-->		--> <u>AB1, AB2, AB3</u>	<u>0.15MG</u>	N021342	008	Mar 01, 2002
-->		--> <u>AB1, AB2, AB3</u>	<u>0.175MG</u>	N021342	009	Mar 01, 2002
-->		--> <u>AB1, AB2, AB3</u>	<u>0.2MG</u>	N021342	010	Mar 01, 2002

PRESCRIPTION DRUG PRODUCT LIST

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

LEVO-T--> + --> AB1,AB2,AB3 0.3MG N021342 011 Mar 01, 2002UNITHROID--> STEVENS J --> AB1,AB2,AB3 0.025MG N021210 001 Aug 21, 2000--> --> AB1,AB2,AB3 0.05MG N021210 002 Aug 21, 2000--> --> AB1,AB2,AB3 0.075MG N021210 003 Aug 21, 2000--> --> AB1,AB2,AB3 0.088MG N021210 004 Aug 21, 2000--> --> AB1,AB2,AB3 0.1MG N021210 005 Aug 21, 2000--> --> AB1,AB2,AB3 0.112MG N021210 006 Aug 21, 2000--> --> AB1,AB2,AB3 0.125MG N021210 007 Aug 21, 2000--> --> AB1,AB2,AB3 0.137MG N021210 012 Feb 08, 2008--> --> AB1,AB2,AB3 0.15MG N021210 008 Aug 21, 2000--> --> AB1,AB2,AB3 0.175MG N021210 009 Aug 21, 2000--> --> AB1,AB2,AB3 0.2MG N021210 010 Aug 21, 2000--> + --> AB1,AB2,AB3 0.3MG N021210 011 Aug 21, 2000LEVOTHYROXINE SODIUM--> MYLAN --> 0.025MG A076187 001 Jun 05, 2002--> --> AB1,AB2,AB3,AB4 0.05MG A076187 002 Jun 05, 2002--> --> AB1,AB2,AB3,AB4 0.075MG A076187 003 Jun 05, 2002--> --> AB1,AB2,AB3,AB4 0.088MG A076187 004 Jun 05, 2002--> --> AB1,AB2,AB3,AB4 0.1MG A076187 005 Jun 05, 2002--> --> AB1,AB2,AB3,AB4 0.112MG A076187 006 Jun 05, 2002--> --> AB1,AB2,AB3,AB4 0.125MG A076187 007 Jun 05, 2002--> --> AB1,AB2,AB3,AB4 0.137MG A076187 012 Dec 13, 2006--> --> AB1,AB2,AB3,AB4 0.15MG A076187 008 Jun 05, 2002--> --> AB1,AB2,AB3,AB4 0.175MG A076187 009 Jun 05, 2002--> --> AB1,AB2,AB3,AB4 0.2MG A076187 010 Jun 05, 2002--> + --> AB1,AB2,AB3,AB4 0.3MG A076187 011 Jun 05, 2002LEVOXYL--> KING PHARMS R AND D --> AB1,AB3 0.025MG N021301 001 May 25, 2001--> --> AB1,AB3 0.05MG N021301 002 May 25, 2001--> --> AB1,AB3 0.075MG N021301 003 May 25, 2001--> --> AB1,AB3 0.088MG N021301 004 May 25, 2001--> --> AB1,AB3 0.1MG N021301 005 May 25, 2001--> --> AB1,AB3 0.112MG N021301 006 May 25, 2001--> --> AB1,AB3 0.125MG N021301 007 May 25, 2001--> --> AB1,AB3 0.137MG N021301 008 May 25, 2001--> --> AB1,AB3 0.15MG N021301 009 May 25, 2001--> --> AB1,AB3 0.175MG N021301 010 May 25, 2001--> + --> AB1,AB3 0.2MG N021301 011 May 25, 2001LIDOCAINE

OINTMENT;TOPICAL

LIDOCAINE**AT** AMNEAL PHARMS **5%** **A206297 001** Aug 07, 2015**AT** + FOUGERA **5%** **A080198 001****AT** GLENMARK PHARMS LTD **5%** **A206498 001** Sep 09, 2016**AT** SEPTODONT INC **5%** **A040911 001** May 23, 2011**AT** TARO **5%** **A086724 001****AT** TELIGENT PHARMA INC **5%** **A205318 001** Feb 01, 2016

PRESCRIPTION DRUG PRODUCT LIST

LIDOCAINE

PATCH; TOPICAL

LIDOCAINE

<u>AB</u>	ACTAVIS LABS UT INC	<u>5%</u>	<u>A200675</u>	<u>001</u>	Aug 23, 2012
<u>AB</u>	MYLAN TECHNOLOGIES	<u>5%</u>	<u>A202346</u>	<u>001</u>	Aug 07, 2015

LIDODERM

<u>AB</u>	+ TEIKOKU PHARMA USA	<u>5%</u>	<u>N020612</u>	<u>001</u>	Mar 19, 1999
-----------	----------------------	-----------	----------------	------------	--------------

LIDOCAINE HYDROCHLORIDE

GEL; OPHTHALMIC

AKTEN

+ AKORN 3.5%

N022221 001 Oct 07, 2008

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE

<u>AP</u>	HOSPIRA	<u>0.5%</u>	<u>A088328</u>	<u>001</u>	May 17, 1984
<u>AP</u>		<u>1%</u>	<u>A083158</u>	<u>001</u>	
<u>AP</u>		<u>1%</u>	<u>A088329</u>	<u>001</u>	May 17, 1984
<u>AP</u>		<u>2%</u>	<u>A040078</u>	<u>001</u>	Jun 23, 1995
<u>AP</u>		<u>2%</u>	<u>A083158</u>	<u>002</u>	
<u>AP</u>		<u>2%</u>	<u>A088294</u>	<u>001</u>	May 17, 1984
<u>AP</u>		<u>20%</u>	<u>A083158</u>	<u>003</u>	
<u>AP</u>	INTL MEDICATION	<u>1%</u>	<u>A083173</u>	<u>001</u>	
<u>AP</u>		<u>2%</u>	<u>A083173</u>	<u>002</u>	
<u>AP</u>	LUITPOLD	<u>1%</u>	<u>A080850</u>	<u>001</u>	
<u>AP</u>	LUITPOLD PHARMS INC	<u>1%</u>	<u>A091564</u>	<u>001</u>	Aug 14, 2015
<u>AP</u>	MYLAN LABS LTD	<u>0.5%</u>	<u>A091056</u>	<u>001</u>	Dec 08, 2010
<u>AP</u>		<u>0.5%</u>	<u>A091058</u>	<u>001</u>	Sep 30, 2010
<u>AP</u>		<u>1%</u>	<u>A091056</u>	<u>002</u>	Dec 08, 2010
<u>AP</u>		<u>1%</u>	<u>A091058</u>	<u>002</u>	Sep 30, 2010
<u>AP</u>		<u>2%</u>	<u>A202242</u>	<u>001</u>	Apr 11, 2014

LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>200MG/100ML</u>	<u>N019830</u>	<u>002</u>	Apr 08, 1992
<u>AP</u>	BAXTER HLTHCARE	<u>200MG/100ML</u>	<u>N018461</u>	<u>002</u>	

LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>400MG/100ML</u>	<u>N019830</u>	<u>003</u>	Apr 08, 1992
<u>AP</u>	BAXTER HLTHCARE	<u>400MG/100ML</u>	<u>N018461</u>	<u>003</u>	

LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>800MG/100ML</u>	<u>N019830</u>	<u>004</u>	Apr 08, 1992
<u>AP</u>	BAXTER HLTHCARE	<u>800MG/100ML</u>	<u>N018461</u>	<u>004</u>	Feb 22, 1982

LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER

<u>AP</u>	FRESENIUS KABI USA	<u>1%</u>	<u>A088586</u>	<u>001</u>	Jul 24, 1985
<u>AP</u>	HOSPIRA	<u>0.5%</u>	<u>A088325</u>	<u>001</u>	Jul 31, 1984
<u>AP</u>		<u>1%</u>	<u>A088299</u>	<u>001</u>	Jul 31, 1984
<u>AP</u>		<u>2%</u>	<u>A088327</u>	<u>001</u>	Jul 31, 1984

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	AUROBINDO PHARMA LTD	<u>1%</u>	<u>A203040</u>	<u>001</u>	Mar 14, 2013
<u>AP</u>		<u>1%</u>	<u>A203082</u>	<u>001</u>	Mar 14, 2013
<u>AP</u>		<u>2%</u>	<u>A203040</u>	<u>002</u>	Mar 14, 2013
<u>AP</u>		<u>2%</u>	<u>A203082</u>	<u>002</u>	Mar 14, 2013
<u>AP</u>	FRESENIUS KABI USA	<u>1%</u>	<u>A080404</u>	<u>002</u>	
<u>AP</u>		<u>2%</u>	<u>A080404</u>	<u>003</u>	
<u>AP</u>		<u>2%</u>	<u>N017584</u>	<u>001</u>	
<u>AP</u>		<u>4%</u>	<u>N017584</u>	<u>002</u>	
<u>AP</u>	HOSPIRA	<u>1%</u>	<u>A080408</u>	<u>001</u>	
<u>AP</u>		<u>1.5%</u>	<u>A080408</u>	<u>002</u>	
<u>AP</u>		<u>4%</u>	<u>A088295</u>	<u>001</u>	May 17, 1984
<u>AP</u>	INTL MEDICATION	<u>20%</u>	<u>N017702</u>	<u>001</u>	
<u>AP</u>	MYLAN LABS LTD	<u>2%</u>	<u>A090665</u>	<u>001</u>	Sep 27, 2010

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER

<u>AP</u>	HOSPIRA	<u>1%</u>	<u>A040302</u>	<u>001</u>	Sep 28, 1998
<u>AP</u>		<u>2%</u>	<u>A040302</u>	<u>002</u>	Sep 28, 1998

XYLOCAINE

<u>AP</u>	+ FRESENIUS KABI USA	<u>0.5%</u>	<u>N006488</u>	<u>008</u>	
<u>AP</u>	+	<u>1%</u>	<u>N006488</u>	<u>007</u>	
<u>AP</u>	+	<u>1.5%</u>	<u>N006488</u>	<u>010</u>	
<u>AP</u>	+	<u>2%</u>	<u>N006488</u>	<u>002</u>	

XYLOCAINE 4% PRESERVATIVE FREE

<u>AP</u>	+ FRESENIUS KABI USA	<u>4%</u>	<u>N010417</u>	<u>001</u>	
-----------	----------------------	-----------	----------------	------------	--

XYLOCAINE PRESERVATIVE FREE

<u>AP</u>	+ FRESENIUS KABI USA	<u>1%</u>	<u>N016801</u>	<u>005</u>	Jan 19, 1988
<u>AP</u>	+	<u>2%</u>	<u>N016801</u>	<u>001</u>	
<u>AP</u>	+	<u>4%</u>	<u>N016801</u>	<u>002</u>	
<u>AP</u>	+	<u>20%</u>	<u>N016801</u>	<u>004</u>	

PRESCRIPTION DRUG PRODUCT LIST

LIDOCAINE HYDROCHLORIDE

INJECTABLE; SPINAL

LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%
+ HOSPIRA 5%

A083914 001

JELLY; TOPICAL

GLYDO**AT** SAGENT PHARMS **2%****A201094 001** Apr 28, 2014LIDOCAINE HYDROCHLORIDE**AT** AKORN **2%****A040433 001** Feb 12, 2003**AT** INTL MEDICATION **2%****A086283 001****AT** WATSON LABS INC **2%****A040837 001** Mar 23, 2011XYLOCAINE**AT** + OAK PHARMS **2%****N008816 001**

SOLUTION; ORAL

LIDOCAINE HYDROCHLORIDE**AT** HI TECH PHARMA **2%****A040014 001** Jul 10, 1995**AT** WOCKHARDT **2%****A087872 001** Nov 18, 1982LIDOCAINE HYDROCHLORIDE VISCOUS**AT** + VINTAGE **2%****A040708 001** Feb 27, 2007LIDOCAINE VISCOUS**AT** WEST-WARD PHARMS INT **2%****A088802 001** Apr 26, 1985

SOLUTION; TOPICAL

LARYNG-O-JET KIT**AT** INTL MEDICATION **4%****A086364 001**LIDOCAINE HYDROCHLORIDE**AT** TELIGENT PHARMA INC **4%****A204494 001** Mar 12, 2014**AT** VINTAGE **4%****A040710 001** Feb 27, 2007**AT** WEST-WARD PHARMS INT **4%****A088803 001** Apr 03, 1985**AT** WOCKHARDT **4%****A087881 001** Nov 18, 1982LTA II KIT**AT** HOSPIRA **4%****A080409 001**XYLOCAINE 4% PRESERVATIVE FREE**AT** + FRESENIUS KABI USA **4%****N010417 002**

SYSTEM; INTRADERMAL

ZINGO

POWDER PHARMS 0.5MG

N022114 001 Aug 16, 2007

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

EMLA**AB** + ACTAVIS LABS UT INC **2.5%; 2.5%****N019941 001** Dec 30, 1992LIDOCAINE AND PRILOCAINE**AB** FOUGERA PHARMS **2.5%; 2.5%****A076453 001** Aug 18, 2003**AB** HI TECH PHARMA **2.5%; 2.5%****A076290 001** Sep 25, 2003**AB** TOLMAR **2.5%; 2.5%****A076320 001** Aug 27, 2003

GEL; PERIODONTAL

ORAQIX

+ DENTSPLY PHARM 2.5%; 2.5%

N021451 001 Dec 19, 2003

LIDOCAINE; TETRACAINE

CREAM; TOPICAL

PLIAGLIS

+ GALDERMA LABS LP 7%; 7%

N021717 001 Jun 29, 2006

PATCH; TOPICAL

SYNERA

+ GALEN SPECIALTY 70MG; 70MG

N021623 001 Jun 23, 2005

LIFITEGRAST

SOLUTION/DROPS; OPHTHALMIC

XIIDRA

+ SHIRE DEV LLC 5%

N208073 001 Jul 11, 2016

LINACLOTIDE

CAPSULE; ORAL

LINZESS

FOREST LABS LLC 145MCG

N202811 001 Aug 30, 2012

+ 290MCG

N202811 002 Aug 30, 2012

LINAGLIPTIN

TABLET; ORAL

TRADJENTA

+ BOEHRINGER INGELHEIM 5MG

N201280 001 May 02, 2011

PRESCRIPTION DRUG PRODUCT LIST

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL

JENTADUETO

BOEHRINGER INGELHEIM 2.5MG;500MG

N201281 001 Jan 30, 2012

2.5MG;850MG

N201281 002 Jan 30, 2012

+

2.5MG;1GM

N201281 003 Jan 30, 2012

TABLET, EXTENDED RELEASE; ORAL

JENTADUETO XR

BOEHRINGER INGELHEIM 2.5MG;1GM

N208026 001 May 27, 2016

+

5MG;1GM

N208026 002 May 27, 2016

LINCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

LINCOCINAP + PHARMACIA AND UPJOHN EQ 300MG BASE/MLN050317 001LINCOMYCINAP X-GEN PHARMS INC EQ 300MG BASE/MLA201746 001 Jun 04, 2015LINDANE

LOTION; TOPICAL

LINDANEAT OLTA PHARMS 1%A087313 001AT + WOCKHARDT 1%A088190 001 Aug 16, 1984

SHAMPOO; TOPICAL

LINDANEAT OLTA PHARMS 1%A087266 001AT + WOCKHARDT 1%A088191 001 Sep 18, 1984LINEZOLID

FOR SUSPENSION; ORAL

LINEZOLIDAB WEST-WARD PHARMS INT 100MG/5MLA200068 001 Jun 03, 2015ZYVOXAB + PHARMACIA AND UPJOHN 100MG/5MLN021132 001 Apr 18, 2000

SOLUTION; IV (INFUSION)

LINEZOLIDAP AUROBINDO PHARMA LTD 600MG/300ML (2MG/ML) A206917 001 Aug 04, 2016AP FRESENIUS KABI USA 600MG/300ML (2MG/ML) A204764 001 Mar 15, 2016AP HOSPIRA INC 600MG/300ML (2MG/ML) A205442 001 Jul 07, 2015AP NANG KUANG PHARM CO 200MG/100ML (2MG/ML) A207354 001 Dec 20, 2016AP 600MG/300ML (2MG/ML) A207354 002 Dec 20, 2016AP SANDOZ INC 200MG/100ML (2MG/ML) A200904 001 Jul 16, 2015AP 600MG/300ML (2MG/ML) A200904 002 Jul 16, 2015AP TEVA PHARMS 600MG/300ML (2MG/ML) A200222 001 Jun 27, 2012ZYVOXAP PHARMACIA AND UPJOHN 200MG/100ML (2MG/ML) N021131 001 Apr 18, 2000AP + 600MG/300ML (2MG/ML) N021131 003 Apr 18, 2000

LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+ HOSPIRA INC 600MG/300ML (2MG/ML)

N206473 001 Jun 18, 2015

ZYVOX

PHARMACIA AND UPJOHN 400MG/200ML (2MG/ML)

N021131 002 Apr 18, 2000

TABLET; ORAL

LINEZOLIDAB ALEMBIC PHARMS LTD 600MG A205233 001 Dec 21, 2015AB ALKEM LABS LTD 600MG A205517 001 Dec 21, 2015AB AMNEAL PHARMS 600MG A204536 001 Dec 21, 2015AB GATE PHARMS 600MG A091210 001 Feb 05, 2016AB GLENMARK PHARMS 600MG A078987 001 Dec 21, 2015AB HETERO LABS LTD V 600MG A204239 001 Dec 21, 2015AB MYLAN PHARMS INC 600MG A078845 001 Dec 21, 2015AB NOVEL LABS INC 600MG A207526 001 Aug 22, 2016AB TEVA PHARMS USA 600MG A078061 001 May 18, 2015ZYVOXAB + PHARMACIA AND UPJOHN 600MG N021130 002 Apr 18, 2000LIOTHYRONINE SODIUM

INJECTABLE; INJECTION

LIOTHYRONINE SODIUMAP X GEN PHARMS EQ 0.01MG BASE/ML A076923 001 Aug 17, 2005TRIOSTATAP + PAR STERILE PRODUCTS EQ 0.01MG BASE/ML N020105 001 Dec 31, 1991

TABLET; ORAL

CYTOMELAB KING PHARMS R AND D EQ 0.005MG BASE N010379 001

PRESCRIPTION DRUG PRODUCT LIST

LIOTHYRONINE SODIUM

TABLET; ORAL

CYTOMEL

<u>AB</u>		<u>EQ 0.025MG BASE</u>	<u>N010379 002</u>	
<u>AB</u>	+	<u>EQ 0.05MG BASE</u>	<u>N010379 003</u>	
<u>AB</u>	MAYNE PHARMA INC	<u>EQ 0.005MG BASE</u>	<u>A090097 001</u>	Mar 20, 2009
<u>AB</u>		<u>EQ 0.025MG BASE</u>	<u>A090097 002</u>	Mar 20, 2009
<u>AB</u>		<u>EQ 0.05MG BASE</u>	<u>A090097 003</u>	Mar 20, 2009
<u>AB</u>	MYLAN	<u>EQ 0.005MG BASE</u>	<u>A090326 001</u>	Jul 14, 2009
<u>AB</u>		<u>EQ 0.025MG BASE</u>	<u>A090326 002</u>	Jul 14, 2009
<u>AB</u>		<u>EQ 0.05MG BASE</u>	<u>A090326 003</u>	Jul 14, 2009
<u>AB</u>	SIGMAPHARM LABS LLC	<u>EQ 0.005MG BASE</u>	<u>A200295 001</u>	Nov 29, 2012
<u>AB</u>		<u>EQ 0.025MG BASE</u>	<u>A200295 002</u>	Nov 29, 2012
<u>AB</u>		<u>EQ 0.05MG BASE</u>	<u>A200295 003</u>	Nov 29, 2012
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 0.005MG BASE</u>	<u>A091382 001</u>	Apr 20, 2016
<u>AB</u>		<u>EQ 0.025MG BASE</u>	<u>A091382 002</u>	Apr 20, 2016
<u>AB</u>		<u>EQ 0.05MG BASE</u>	<u>A091382 003</u>	Apr 20, 2016

LIOTRIX (T4;T3)

TABLET; ORAL

THYROLAR-0.25

FOREST LABS

0.0125MG;0.0031MG

N016807 001

THYROLAR-0.5

FOREST LABS

0.025MG;0.0063MG

N016807 005

THYROLAR-1

FOREST LABS

0.05MG;0.0125MG

N016807 004

THYROLAR-2

FOREST LABS

0.1MG;0.025MG

N016807 002

THYROLAR-3

+ FOREST LABS

0.15MG;0.0375MG

N016807 003

LIRAGLUTIDE RECOMBINANT

SOLUTION; SUBCUTANEOUS

SAXENDA

+ NOVO NORDISK INC

18MG/3ML (6MG/ML)

N206321 001 Dec 23, 2014

VICTOZA

+ NOVO NORDISK INC

18MG/3ML (6MG/ML)

N022341 001 Jan 25, 2010

LISDEXAMFETAMINE DIMESYLATE

CAPSULE; ORAL

VYVANSE

SHIRE DEVELOPMENT

10MG

N021977 007 Oct 30, 2014

20MG

N021977 004 Dec 10, 2007

30MG

N021977 001 Feb 23, 2007

40MG

N021977 005 Dec 10, 2007

50MG

N021977 002 Feb 23, 2007

60MG

N021977 006 Dec 10, 2007

+

70MG

N021977 003 Feb 23, 2007

LISINAPRIL

SOLUTION; ORAL

QBRELIS

+ SILVERGATE PHARMS

1MG/ML

N208401 001 Jul 29, 2016

TABLET; ORAL

LISINAPRIL

<u>AB</u>	ACCORD HLTHCARE	<u>2.5MG</u>	<u>A202554 001</u>	Jul 30, 2013
<u>AB</u>		<u>5MG</u>	<u>A202554 002</u>	Jul 30, 2013
<u>AB</u>		<u>10MG</u>	<u>A202554 003</u>	Jul 30, 2013
<u>AB</u>		<u>20MG</u>	<u>A202554 004</u>	Jul 30, 2013
<u>AB</u>		<u>30MG</u>	<u>A202554 005</u>	Jul 30, 2013
<u>AB</u>		<u>40MG</u>	<u>A202554 006</u>	Jul 30, 2013
<u>AB</u>	APOTEX INC	<u>2.5MG</u>	<u>A076102 001</u>	Sep 30, 2002
<u>AB</u>		<u>5MG</u>	<u>A076102 002</u>	Sep 30, 2002
<u>AB</u>		<u>10MG</u>	<u>A076102 003</u>	Sep 30, 2002
<u>AB</u>		<u>20MG</u>	<u>A076102 004</u>	Sep 30, 2002
<u>AB</u>		<u>30MG</u>	<u>A076102 005</u>	Sep 30, 2002
<u>AB</u>		<u>40MG</u>	<u>A076102 006</u>	Sep 30, 2002
<u>AB</u>	AUROBINDO	<u>2.5MG</u>	<u>A077622 001</u>	Feb 22, 2006
<u>AB</u>		<u>5MG</u>	<u>A077622 002</u>	Feb 22, 2006
<u>AB</u>		<u>10MG</u>	<u>A077622 003</u>	Feb 22, 2006
<u>AB</u>		<u>20MG</u>	<u>A077622 004</u>	Feb 22, 2006
<u>AB</u>		<u>30MG</u>	<u>A077622 005</u>	Feb 22, 2006
<u>AB</u>		<u>40MG</u>	<u>A077622 006</u>	Feb 22, 2006

PRESCRIPTION DRUG PRODUCT LIST

LISINAPRIL

TABLET; ORAL

LISINAPRIL

<u>AB</u>	HIKMA INTL PHARMS	<u>2.5MG</u>	<u>A076063 001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A076063 002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A076063 003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A076063 004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A076063 006</u>	Jun 27, 2003
<u>AB</u>		<u>40MG</u>	<u>A076063 005</u>	Jul 01, 2002
<u>AB</u>	INVAGEN PHARMS	<u>2.5MG</u>	<u>A203508 001</u>	Oct 29, 2013
<u>AB</u>		<u>5MG</u>	<u>A203508 002</u>	Oct 29, 2013
<u>AB</u>		<u>10MG</u>	<u>A203508 003</u>	Oct 29, 2013
<u>AB</u>		<u>20MG</u>	<u>A203508 004</u>	Oct 29, 2013
<u>AB</u>		<u>30MG</u>	<u>A203508 005</u>	Oct 29, 2013
<u>AB</u>		<u>40MG</u>	<u>A203508 006</u>	Oct 29, 2013
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>2.5MG</u>	<u>A075752 001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075752 002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075752 003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075752 004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A075752 005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A075752 006</u>	Jul 01, 2002
<u>AB</u>	LUPIN	<u>2.5MG</u>	<u>A077321 001</u>	Sep 09, 2005
<u>AB</u>		<u>5MG</u>	<u>A077321 002</u>	Sep 09, 2005
<u>AB</u>		<u>10MG</u>	<u>A077321 003</u>	Sep 09, 2005
<u>AB</u>		<u>20MG</u>	<u>A077321 004</u>	Sep 09, 2005
<u>AB</u>		<u>30MG</u>	<u>A077321 005</u>	Sep 09, 2005
<u>AB</u>		<u>40MG</u>	<u>A077321 006</u>	Sep 09, 2005
<u>AB</u>	MYLAN	<u>2.5MG</u>	<u>A076071 001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A076071 002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A076071 003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A076071 004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A076071 005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A076071 006</u>	Jul 01, 2002
<u>AB</u>	PRINSTON INC	<u>2.5MG</u>	<u>A076180 001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A076180 002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A076180 003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A076164 001</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A076164 002</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A076164 003</u>	Jul 01, 2002
<u>AB</u>	SANDOZ	<u>2.5MG</u>	<u>A075994 001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075994 002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075994 003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075994 004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A075994 005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A075994 006</u>	Jul 01, 2002
<u>AB</u>	SUN PHARM INDS LTD	<u>2.5MG</u>	<u>A075944 001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075944 002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075944 003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075944 004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A075944 006</u>	Feb 11, 2003
<u>AB</u>		<u>40MG</u>	<u>A075944 005</u>	Jul 01, 2002
<u>AB</u>	VINTAGE	<u>2.5MG</u>	<u>A075743 001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075743 002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075743 003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075743 004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A075743 005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A075743 006</u>	Jul 01, 2002
<u>AB</u>	WATSON LABS	<u>2.5MG</u>	<u>A076059 001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A076059 002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A076059 003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A076059 004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A076059 005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A076059 006</u>	Jul 01, 2002
<u>AB</u>	WOCKHARDT	<u>2.5MG</u>	<u>A078402 001</u>	Apr 19, 2007
<u>AB</u>		<u>5MG</u>	<u>A078402 002</u>	Apr 19, 2007
<u>AB</u>		<u>10MG</u>	<u>A078402 003</u>	Apr 19, 2007
<u>AB</u>		<u>20MG</u>	<u>A078402 004</u>	Apr 19, 2007
<u>AB</u>		<u>30MG</u>	<u>A078402 005</u>	Apr 19, 2007
<u>AB</u>		<u>40MG</u>	<u>A078402 006</u>	Apr 19, 2007
<u>PRINIVIL</u>				
<u>AB</u>	MERCK	<u>5MG</u>	<u>N019558 001</u>	Dec 29, 1987
<u>AB</u>		<u>10MG</u>	<u>N019558 002</u>	Dec 29, 1987

PRESCRIPTION DRUG PRODUCT LIST

LISINAPRIL

TABLET; ORAL

PRINIVIL

<u>AB</u>		<u>20MG</u>	<u>N019558</u>	<u>003</u>	Dec 29, 1987
<u>AB</u>		<u>40MG</u>	<u>N019558</u>	<u>004</u>	Oct 25, 1988

ZESTRIL

<u>AB</u>	ALVOGEN MALTA	<u>2.5MG</u>	<u>N019777</u>	<u>005</u>	Apr 29, 1993
<u>AB</u>		<u>5MG</u>	<u>N019777</u>	<u>001</u>	May 19, 1988
<u>AB</u>		<u>10MG</u>	<u>N019777</u>	<u>002</u>	May 19, 1988
<u>AB</u>		<u>20MG</u>	<u>N019777</u>	<u>003</u>	May 19, 1988
<u>AB</u>		<u>30MG</u>	<u>N019777</u>	<u>006</u>	Jan 20, 1999
<u>AB</u>	+	<u>40MG</u>	<u>N019777</u>	<u>004</u>	May 19, 1988

LITHIUM CARBONATE

CAPSULE; ORAL

LITHIUM CARBONATE

<u>AB</u>	ALEMBIC LTD	<u>150MG</u>	<u>A079159</u>	<u>001</u>	Jan 12, 2009
<u>AB</u>		<u>300MG</u>	<u>A079159</u>	<u>002</u>	Jan 12, 2009
<u>AB</u>		<u>600MG</u>	<u>A079159</u>	<u>003</u>	Jan 12, 2009
<u>AB</u>	DELacor ASSET CORP	<u>150MG</u>	<u>A076243</u>	<u>002</u>	Feb 24, 2003
<u>AB</u>		<u>300MG</u>	<u>A076243</u>	<u>001</u>	Jun 27, 2002
<u>AB</u>		<u>600MG</u>	<u>A078763</u>	<u>001</u>	Apr 15, 2008
<u>AB</u>	GLENMARK GENERICS	<u>150MG</u>	<u>A079139</u>	<u>001</u>	Feb 03, 2009
<u>AB</u>		<u>300MG</u>	<u>A079139</u>	<u>002</u>	Feb 03, 2009
<u>AB</u>		<u>600MG</u>	<u>A079139</u>	<u>003</u>	Feb 03, 2009
<u>AB</u>	HETERO LABS LTD III	<u>150MG</u>	<u>A090702</u>	<u>001</u>	Sep 25, 2009
<u>AB</u>		<u>300MG</u>	<u>A090702</u>	<u>002</u>	Sep 25, 2009
<u>AB</u>		<u>600MG</u>	<u>A090702</u>	<u>003</u>	Sep 25, 2009
<u>AB</u>	ROXANE	<u>150MG</u>	<u>N017812</u>	<u>002</u>	Jan 28, 1987
<u>AB</u>		<u>300MG</u>	<u>N017812</u>	<u>001</u>	
<u>AB</u>	+	<u>600MG</u>	<u>N017812</u>	<u>003</u>	Jan 28, 1987

TABLET; ORAL

LITHIUM CARBONATE

<u>AB</u>	+	ROXANE	<u>300MG</u>	<u>N018558</u>	<u>001</u>	Jan 29, 1982
<u>AB</u>		SUN PHARM INDS INC	<u>300MG</u>	<u>A091027</u>	<u>001</u>	Jun 24, 2010

TABLET, EXTENDED RELEASE; ORAL

LITHIUM CARBONATE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>300MG</u>	<u>A204445</u>	<u>001</u>	Jun 10, 2015	
<u>AB</u>	GLENMARK GENERICS	<u>450MG</u>	<u>A091616</u>	<u>001</u>	Feb 14, 2011	
<u>AB</u>	GLENMARK PHARMS INC	<u>300MG</u>	<u>A091544</u>	<u>001</u>	Dec 27, 2010	
<u>AB</u>	HERITAGE PHARMA	<u>300MG</u>	<u>A205532</u>	<u>001</u>	Sep 29, 2016	
<u>AB</u>	MYLAN PHARMS INC	<u>300MG</u>	<u>A202288</u>	<u>001</u>	Jun 29, 2012	
<u>AB</u>		<u>450MG</u>	<u>A202219</u>	<u>001</u>	Aug 08, 2012	
<u>AB</u>	UNIQUE PHARM LABS	<u>300MG</u>	<u>A204779</u>	<u>001</u>	Jul 27, 2015	
<u>AB</u>	WEST-WARD PHARMS INT	<u>300MG</u>	<u>A076832</u>	<u>001</u>	Oct 28, 2004	
<u>AB</u>	+	<u>450MG</u>	<u>A076691</u>	<u>001</u>	Jan 05, 2004	
<u>AB</u>	+	ANI PHARMS INC	<u>300MG</u>	<u>N018027</u>	<u>001</u>	

LITHIUM CITRATE

SYRUP; ORAL

LITHIUM CITRATE

<u>AA</u>	+	ROXANE	<u>EQ 300MG CARBONATE/5ML</u>	<u>N018421</u>	<u>001</u>	
<u>AA</u>		WOCKHARDT	<u>EQ 300MG CARBONATE/5ML</u>	<u>A070755</u>	<u>001</u>	May 21, 1986

LIXISENATIDE

SOLUTION; SUBCUTANEOUS

ADLYXIN

+	SANOFI-AVENTIS US	0.15MG/3ML (0.05MG/ML)	N208471	001	Jul 27, 2016
+		0.3MG/3ML (0.1MG/ML)	N208471	002	Jul 27, 2016

LODOXAMIDE TROMETHAMINE

SOLUTION/DROPS; OPHTHALMIC

ALOMIDE

+	NOVARTIS PHARMS CORP	EQ 0.1% BASE	N020191	001	Sep 23, 1993
---	----------------------	--------------	---------	-----	--------------

LOMITAPIDE MESYLATE

CAPSULE; ORAL

JUXTAPID

	AEGERION	EQ 5MG BASE	N203858	001	Dec 21, 2012
		EQ 10MG BASE	N203858	002	Dec 21, 2012
		EQ 20MG BASE	N203858	003	Dec 21, 2012
		EQ 30MG BASE	N203858	004	Apr 23, 2015
		EQ 40MG BASE	N203858	005	Apr 23, 2015
+		EQ 60MG BASE	N203858	006	Apr 23, 2015

PRESCRIPTION DRUG PRODUCT LIST

LOMUSTINE

CAPSULE; ORAL

GLEOSTINE

CORDEN PHARMA	5MG	N017588 004	Dec 19, 2014
	10MG	N017588 001	
	40MG	N017588 002	
+	100MG	N017588 003	

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL

LOPERAMIDE HYDROCHLORIDE

AB	+	MYLAN	2MG	A072741 001	Sep 18, 1991
AB		TEVA	2MG	A073192 001	Apr 30, 1992

LOPINAVIR; RITONAVIR

SOLUTION; ORAL

KALETRA

AA	+	ABBVIE	80MG/ML ; 20MG/ML	N021251 001	Sep 15, 2000
-----------	---	--------	--------------------------	--------------------	--------------

LOPINAVIR AND RITONAVIR

AA		SILARX PHARMS INC	80MG/ML ; 20MG/ML	A207407 001	Dec 27, 2016
-----------	--	-------------------	--------------------------	--------------------	--------------

TABLET; ORAL

KALETRA

ABBVIE	100MG; 25MG	N021906 002	Nov 09, 2007
+	200MG; 50MG	N021906 001	Oct 28, 2005

LORAZEPAM

CONCENTRATE; ORAL

LORAZEPAM

AA		AMNEAL PHARMS	2MG/ML	A091383 001	Dec 23, 2009
AA		HI-TECH PHARMA CO	2MG/ML	A200169 001	Jan 30, 2012
AA		LUPIN LTD	2MG/ML	A091407 001	Feb 19, 2013
AA		PADDOCK LLC	2MG/ML	A079244 001	Apr 28, 2009
AA		PHARM ASSOC	2MG/ML	A090260 001	Jun 15, 2010

LORAZEPAM INTENSOL

AA	+	WEST-WARD PHARMS INT	2MG/ML	A072755 001	Jun 28, 1991
-----------	---	----------------------	---------------	--------------------	--------------

INJECTABLE; INJECTION

ATIVAN

AP	+	WEST-WARD PHARMS INT	2MG/ML	N018140 001	
AP	+		4MG/ML	N018140 002	

LORAZEPAM

AP		AKORN	2MG/ML	A075025 001	Jul 23, 1998
AP		HOSPIRA	2MG/ML	A074243 001	Apr 12, 1994
AP			2MG/ML	A074282 001	May 27, 1994
AP			4MG/ML	A074243 002	Apr 12, 1994
AP			4MG/ML	A074282 002	May 27, 1994
AP		INTL MEDICATION SYS	2MG/ML	A076150 001	Nov 15, 2004

LORAZEPAM PRESERVATIVE FREE

AP		BEDFORD LABS	2MG/ML	A077074 001	Jul 13, 2005
AP			4MG/ML	A077074 002	Jul 13, 2005

TABLET; ORAL

ATIVAN

AB		VALEANT INTL	0.5MG	N017794 001	
AB			1MG	N017794 002	
AB	+		2MG	N017794 003	

LORAZEPAM

AB		AMNEAL PHARMS	0.5MG	A078826 001	Jun 23, 2010
AB			1MG	A078826 002	Jun 23, 2010
AB			2MG	A078826 003	Jun 23, 2010
AB		ANI PHARMS INC	0.5MG	A077396 001	Dec 13, 2006
AB			1MG	A077396 002	Dec 13, 2006
AB			2MG	A077396 003	Dec 13, 2006
AB		LEADING PHARMA LLC	0.5MG	A078203 001	Jul 30, 2007
AB			1MG	A078203 002	Jul 30, 2007
AB			2MG	A078203 003	Jul 30, 2007
AB		MYLAN	0.5MG	A071589 001	Oct 13, 1987
AB			0.5MG	A077657 001	Mar 16, 2006
AB			1MG	A071590 001	Oct 13, 1987
AB			1MG	A077657 002	Mar 16, 2006
AB			2MG	A071591 001	Oct 13, 1987
AB			2MG	A077657 003	Mar 16, 2006
AB		SANDOZ	0.5MG	A071403 001	Apr 21, 1987
AB			1MG	A071404 001	Apr 21, 1987
AB			2MG	A071141 001	Apr 21, 1987
AB		SUN PHARM INDS LTD	0.5MG	A076045 001	Aug 29, 2001

PRESCRIPTION DRUG PRODUCT LIST

LORAZEPAM

TABLET; ORAL

LORAZEPAM

<u>AB</u>		<u>1MG</u>	<u>A076045</u>	<u>002</u>	Aug 29, 2001
<u>AB</u>		<u>2MG</u>	<u>A076045</u>	<u>003</u>	Aug 29, 2001
<u>AB</u>	VINTAGE PHARMS	<u>0.5MG</u>	<u>A077754</u>	<u>001</u>	May 10, 2006
<u>AB</u>		<u>1MG</u>	<u>A077754</u>	<u>002</u>	May 10, 2006
<u>AB</u>		<u>2MG</u>	<u>A077754</u>	<u>003</u>	May 10, 2006
<u>AB</u>	WATSON LABS	<u>0.5MG</u>	<u>A072926</u>	<u>001</u>	Oct 31, 1991
<u>AB</u>		<u>1MG</u>	<u>A072927</u>	<u>001</u>	Oct 31, 1991
<u>AB</u>		<u>2MG</u>	<u>A072928</u>	<u>001</u>	Oct 31, 1991

LORCASERIN HYDROCHLORIDE

TABLET; ORAL

BELVIQ

+ EISAI INC

10MG

N022529 001 Jun 27, 2012

TABLET, EXTENDED RELEASE; ORAL

BELVIQ XR

+ EISAI INC

20MG

N208524 001 Jul 15, 2016

LOSARTAN POTASSIUM

TABLET; ORAL

COZAAR

<u>AB</u>	MERCK SHARP DOHME	<u>25MG</u>	<u>N020386</u>	<u>001</u>	Apr 14, 1995
<u>AB</u>		<u>50MG</u>	<u>N020386</u>	<u>002</u>	Apr 14, 1995
<u>AB</u>	+	<u>100MG</u>	<u>N020386</u>	<u>003</u>	Oct 13, 1998

LOSARTAN POTASSIUM

<u>AB</u>	ALEMBIC PHARMS LTD	<u>25MG</u>	<u>A090428</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090428</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090428</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	APOTEX CORP	<u>25MG</u>	<u>A090790</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090790</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090790</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A090083</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090083</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090083</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	CADISTA PHARMS	<u>25MG</u>	<u>A201170</u>	<u>001</u>	Sep 18, 2012
<u>AB</u>		<u>50MG</u>	<u>A201170</u>	<u>002</u>	Sep 18, 2012
<u>AB</u>		<u>100MG</u>	<u>A201170</u>	<u>003</u>	Sep 18, 2012
<u>AB</u>	IPCA LABS LTD	<u>25MG</u>	<u>A200290</u>	<u>001</u>	Aug 30, 2013
<u>AB</u>		<u>50MG</u>	<u>A200290</u>	<u>002</u>	Aug 30, 2013
<u>AB</u>		<u>100MG</u>	<u>A200290</u>	<u>003</u>	Aug 30, 2013
<u>AB</u>	LUPIN LTD	<u>25MG</u>	<u>A078232</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A078232</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A078232</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	MACLEODS PHARMS LTD	<u>25MG</u>	<u>A202230</u>	<u>001</u>	May 30, 2012
<u>AB</u>		<u>50MG</u>	<u>A202230</u>	<u>002</u>	May 30, 2012
<u>AB</u>		<u>100MG</u>	<u>A202230</u>	<u>003</u>	May 30, 2012
<u>AB</u>	MICRO LABS LTD INDIA	<u>25MG</u>	<u>A091541</u>	<u>001</u>	Sep 24, 2012
<u>AB</u>		<u>50MG</u>	<u>A091541</u>	<u>002</u>	Sep 24, 2012
<u>AB</u>		<u>100MG</u>	<u>A091541</u>	<u>003</u>	Sep 24, 2012
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A091590</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A091590</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A091590</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	PRINSTON INC	<u>25MG</u>	<u>A091497</u>	<u>001</u>	Jun 06, 2011
<u>AB</u>		<u>50MG</u>	<u>A091497</u>	<u>002</u>	Jun 06, 2011
<u>AB</u>		<u>100MG</u>	<u>A091497</u>	<u>003</u>	Jun 06, 2011
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A077424</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A077424</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A077424</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	TEVA	<u>25MG</u>	<u>A076958</u>	<u>001</u>	Apr 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A076958</u>	<u>002</u>	Apr 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A076958</u>	<u>003</u>	Apr 06, 2010
<u>AB</u>	TORRENT PHARMS	<u>25MG</u>	<u>A090467</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090467</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090467</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	UNICHEM LABS LTD	<u>25MG</u>	<u>A203030</u>	<u>001</u>	Oct 14, 2015
<u>AB</u>		<u>50MG</u>	<u>A203030</u>	<u>002</u>	Oct 14, 2015
<u>AB</u>		<u>100MG</u>	<u>A203030</u>	<u>003</u>	Oct 14, 2015
<u>AB</u>	UPSHER SMITH	<u>25MG</u>	<u>A090544</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090544</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090544</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	VIVIMED LABS	<u>25MG</u>	<u>A090382</u>	<u>001</u>	Oct 06, 2010

PRESCRIPTION DRUG PRODUCT LIST

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

<u>AB</u>		<u>50MG</u>	<u>A090382</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090382</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	WATSON LABS	<u>25MG</u>	<u>A091129</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A091129</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A091129</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	WEST-WARD PHARMS INT	<u>25MG</u>	<u>A077459</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A077459</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A077459</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	ZYDUS PHARMS USA INC	<u>25MG</u>	<u>A078243</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A078243</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A078243</u>	<u>003</u>	Oct 06, 2010
BX	HETERO LABS LTD V	25MG	A203835	001	Aug 12, 2015
BX		50MG	A203835	002	Aug 12, 2015
BX		100MG	A203835	003	Aug 12, 2015

LOTEPREDNOL ETABONATE

GEL; OPHTHALMIC

LOTEMAX

+ BAUSCH AND LOMB INC 0.5%

N202872 001 Sep 28, 2012

OINTMENT; OPHTHALMIC

LOTEMAX

+ BAUSCH AND LOMB 0.5%

N200738 001 Apr 15, 2011

SUSPENSION/DROPS; OPHTHALMIC

ALREX

+ BAUSCH AND LOMB 0.2%

N020803 001 Mar 09, 1998

LOTEMAX

+ BAUSCH AND LOMB 0.5%

N020583 001 Mar 09, 1998

LOTEPREDNOL ETABONATE; TOBRAMYCIN

SUSPENSION/DROPS; OPHTHALMIC

ZYLET

+ BAUSCH AND LOMB 0.5%; 0.3%

N050804 001 Dec 14, 2004

LOVASTATIN

TABLET; ORAL

LOVASTATIN

<u>AB</u>	ACTAVIS ELIZABETH	<u>10MG</u>	<u>A075828</u>	<u>001</u>	Dec 17, 2001
<u>AB</u>		<u>20MG</u>	<u>A075828</u>	<u>002</u>	Dec 17, 2001
<u>AB</u>		<u>40MG</u>	<u>A075828</u>	<u>003</u>	Dec 17, 2001
<u>AB</u>	APOTEX INC	<u>10MG</u>	<u>A077748</u>	<u>001</u>	Feb 28, 2007
<u>AB</u>		<u>20MG</u>	<u>A077748</u>	<u>002</u>	Feb 28, 2007
<u>AB</u>		<u>40MG</u>	<u>A077748</u>	<u>003</u>	Feb 28, 2007
<u>AB</u>	CARLSBAD	<u>10MG</u>	<u>A075991</u>	<u>001</u>	Jun 05, 2002
<u>AB</u>		<u>20MG</u>	<u>A075991</u>	<u>002</u>	Jun 05, 2002
<u>AB</u>	+	<u>40MG</u>	<u>A075991</u>	<u>003</u>	Jun 05, 2002
<u>AB</u>	LUPIN	<u>10MG</u>	<u>A078296</u>	<u>001</u>	Mar 14, 2008
<u>AB</u>		<u>20MG</u>	<u>A078296</u>	<u>002</u>	Nov 01, 2007
<u>AB</u>		<u>40MG</u>	<u>A078296</u>	<u>003</u>	Nov 01, 2007
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A075451</u>	<u>001</u>	Dec 17, 2001
<u>AB</u>		<u>10MG</u>	<u>A075935</u>	<u>001</u>	Dec 17, 2001
<u>AB</u>		<u>20MG</u>	<u>A075451</u>	<u>002</u>	Dec 17, 2001
<u>AB</u>		<u>20MG</u>	<u>A075935</u>	<u>002</u>	Dec 17, 2001
<u>AB</u>		<u>40MG</u>	<u>A075451</u>	<u>003</u>	Dec 17, 2001
<u>AB</u>		<u>40MG</u>	<u>A075935</u>	<u>003</u>	Dec 17, 2001
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A075300</u>	<u>001</u>	Dec 17, 2001
<u>AB</u>		<u>10MG</u>	<u>A075636</u>	<u>001</u>	Dec 17, 2001
<u>AB</u>		<u>20MG</u>	<u>A075300</u>	<u>002</u>	Dec 17, 2001
<u>AB</u>		<u>20MG</u>	<u>A075636</u>	<u>002</u>	Dec 17, 2001
<u>AB</u>		<u>40MG</u>	<u>A075300</u>	<u>003</u>	Dec 17, 2001
<u>AB</u>		<u>40MG</u>	<u>A075636</u>	<u>003</u>	Dec 17, 2001
<u>AB</u>	SUN PHARM INDS	<u>10MG</u>	<u>A077520</u>	<u>001</u>	Apr 14, 2006
<u>AB</u>		<u>20MG</u>	<u>A077520</u>	<u>002</u>	Apr 14, 2006
<u>AB</u>		<u>40MG</u>	<u>A077520</u>	<u>003</u>	Apr 14, 2006
<u>AB</u>	TEVA	<u>10MG</u>	<u>A075551</u>	<u>003</u>	Dec 17, 2001
<u>AB</u>		<u>20MG</u>	<u>A075551</u>	<u>002</u>	Dec 17, 2001
<u>AB</u>		<u>40MG</u>	<u>A075551</u>	<u>001</u>	Dec 17, 2001

TABLET, EXTENDED RELEASE; ORAL

ALTOPREV

COVIS PHARMA SARL 20MG

N021316 002 Jun 26, 2002

40MG

N021316 003 Jun 26, 2002

+ 60MG

N021316 004 Jun 26, 2002

PRESCRIPTION DRUG PRODUCT LIST

LOXAPINE

POWDER; INHALATION

ADASUVE

+ ALEXZA PHARMS

10MG

N022549 001 Dec 21, 2012

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXAPINE SUCCINATEAB ELITE LABS INCEQ 5MG BASEA076868 001 Aug 04, 2005ABEQ 10MG BASEA076868 002 Aug 04, 2005ABEQ 25MG BASEA076868 003 Aug 04, 2005ABEQ 50MG BASEA076868 004 Aug 04, 2005AB LANNETT HOLDINGS INCEQ 5MG BASEA090695 001 Sep 26, 2011ABEQ 10MG BASEA090695 002 Sep 26, 2011ABEQ 25MG BASEA090695 003 Sep 26, 2011ABEQ 50MG BASEA090695 004 Sep 26, 2011AB MYLANEQ 5MG BASEA076762 001 Nov 01, 2004ABEQ 10MG BASEA076762 002 Nov 01, 2004ABEQ 25MG BASEA076762 003 Nov 01, 2004ABEQ 50MG BASEA076762 004 Nov 01, 2004AB WATSON LABSEQ 5MG BASEA072204 001 Jun 15, 1988ABEQ 10MG BASEA072205 001 Jun 15, 1988AB +EQ 25MG BASEA072206 001 Jun 15, 1988ABEQ 50MG BASEA072062 001 Jun 15, 1988LUBIPROSTONE

CAPSULE; ORAL

AMITIZA

SUCAMPO PHARMA LLC

8MCG

N021908 002 Apr 29, 2008

+

24MCG

N021908 001 Jan 31, 2006

LULICONAZOLE

CREAM; TOPICAL

LUZU

+ MEDICIS

1%

N204153 001 Nov 14, 2013

LURASIDONE HYDROCHLORIDE

TABLET; ORAL

LATUDA

SUNOVION PHARMS INC

20MG

N200603 003 Dec 07, 2011

+

40MG

N200603 001 Oct 28, 2010

60MG

N200603 005 Jul 12, 2013

80MG

N200603 002 Oct 28, 2010

120MG

N200603 004 Apr 26, 2012

MACITENTAN

TABLET; ORAL

OPSUMIT

+ ACTELION PHARMS LTD

10MG

N204410 001 Oct 18, 2013

MAFENIDE ACETATE

CREAM; TOPICAL

SULFAMYLON

+ MYLAN INSTITUTIONAL

EQ 85MG BASE/GM

N016763 001

FOR SOLUTION; TOPICAL

MAFENIDE ACETATEAT PAR FORM5%A201511 001 Feb 12, 2013SULFAMYLONAT + MYLAN INSTITUTIONAL5%N019832 003 Jun 05, 1998MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

ISOLYTE S PH 7.4 IN PLASTIC CONTAINER

+ B BRAUN

30MG/100ML; 37MG/100ML; 0.82MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML; 12MG/100ML

N019696 001 Sep 29, 1989

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINERAP BAXTER HLTHCARE30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100MLN017378 001PLASMA-LYTE A IN PLASTIC CONTAINERAP BAXTER HLTHCARE30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100MLN017378 002 Nov 22, 1982

PRESCRIPTION DRUG PRODUCT LIST

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

ISOLYTE S IN PLASTIC CONTAINER

B BRAUN	30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG /100ML; 500MG/100ML	N019711 001	Sep 29, 1989
---------	---	-------------	--------------

NORMOSOL-R IN PLASTIC CONTAINER

HOSPIRA	30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG /100ML; 502MG/100ML	N017586 001	
---------	---	-------------	--

SOLUTION; IRRIGATION

PHYSIOLYTE IN PLASTIC CONTAINER

B BRAUN	30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG /100ML; 500MG/100ML	N019024 001	Jun 08, 1984
---------	---	-------------	--------------

PHYSIOSOL IN PLASTIC CONTAINER

HOSPIRA	30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG /100ML; 502MG/100ML	N017637 002	Jul 08, 1982
---------	---	-------------	--------------

MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

SOLUTION; INJECTION

NORMOCARB HF 25

+ DIALYSIS SUPS	0.21GM/100ML; 2.8GM/100ML; 9.07GM/100ML	N021910 001	Jul 26, 2006
-----------------	---	-------------	--------------

NORMOCARB HF 35

+ DIALYSIS SUPS	0.21GM/100ML; 3.97GM/100ML; 8.3GM/100ML	N021910 002	Jul 26, 2006
-----------------	---	-------------	--------------

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	FRESENIUS KABI USA	<u>1GM/100ML</u>	A206486 001	Mar 07, 2016
-----------	--------------------	------------------	--------------------	--------------

AP	+ HOSPIRA	<u>1GM/100ML</u>	N020488 001	Jul 11, 1995
-----------	-----------	------------------	--------------------	--------------

AP	HQ SPLT PHARMA	<u>1GM/100ML</u>	A207349 001	Mar 02, 2016
-----------	----------------	------------------	--------------------	--------------

MAGNESIUM SULFATE IN PLASTIC CONTAINER

AP	FRESENIUS KABI USA	<u>4GM/100ML (40MG/ML)</u>	A206485 001	Mar 15, 2016
-----------	--------------------	----------------------------	--------------------	--------------

AP		<u>4GM/50ML (80MG/ML)</u>	A206485 002	Mar 15, 2016
-----------	--	---------------------------	--------------------	--------------

AP		<u>2GM/50ML (40MG/ML)</u>	A206485 003	Mar 15, 2016
-----------	--	---------------------------	--------------------	--------------

AP		<u>20GM/500ML (40MG/ML)</u>	A206485 004	Mar 15, 2016
-----------	--	-----------------------------	--------------------	--------------

AP		<u>40GM/1000ML (40MG/ML)</u>	A206485 005	Mar 15, 2016
-----------	--	------------------------------	--------------------	--------------

AP	HOSPIRA	<u>2GM/50ML (40MG/ML)</u>	N020309 003	Jan 26, 2007
-----------	---------	---------------------------	--------------------	--------------

AP	+ HOSPIRA	<u>4GM/100ML (40MG/ML)</u>	N020309 001	Jun 24, 1994
-----------	-----------	----------------------------	--------------------	--------------

AP	+ HOSPIRA	<u>4GM/50ML (80MG/ML)</u>	N020309 002	Jun 24, 1994
-----------	-----------	---------------------------	--------------------	--------------

AP		<u>20GM/500ML (40MG/ML)</u>	N020309 004	Jan 18, 1995
-----------	--	-----------------------------	--------------------	--------------

AP		<u>40GM/1000ML (40MG/ML)</u>	N020309 005	Jan 18, 1995
-----------	--	------------------------------	--------------------	--------------

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

+ HOSPIRA	2GM/100ML	N020488 002	Jul 11, 1995
-----------	-----------	-------------	--------------

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

AP	EXELA PHARMA SCS LLC	<u>5GM/10ML (500MG/ML)</u>	A206039 001	Dec 18, 2014
-----------	----------------------	----------------------------	--------------------	--------------

AP	+ FRESENIUS KABI USA	<u>5GM/10ML (500MG/ML)</u>	N019316 001	Sep 08, 1986
-----------	----------------------	----------------------------	--------------------	--------------

AP	+ HOSPIRA	<u>5GM/10ML (500MG/ML)</u>	A075151 001	Apr 25, 2000
-----------	-----------	----------------------------	--------------------	--------------

+ FRESENIUS KABI USA	10GM/20ML (500MG/ML)	N019316 003	Jan 29, 2016
----------------------	----------------------	-------------	--------------

+ HOSPIRA INC	25GM/50ML (500MG/ML)	N019316 004	Jan 29, 2016
---------------	----------------------	-------------	--------------

	10GM/20ML (500MG/ML)	A202411 001	May 14, 2015
--	----------------------	-------------	--------------

MAGNESIUM SULFATE

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

+ FRESENIUS KABI USA	1GM/2ML (500MG/ML)	N019316 002	Sep 08, 1986
----------------------	--------------------	-------------	--------------

MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATE

SOLUTION; ORAL

SUPREP BOWEL PREP KIT

+ BRAINTREE LABS	1.6GM/BOT; 3.13GM/BOT; 17.5GM/BOT	N022372 001	Aug 05, 2010
------------------	-----------------------------------	-------------	--------------

MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION

TIS-U-SOL

AT	BAXTER HLTHCARE	<u>20MG/100ML; 40MG/100ML; 6.25MG/100ML; 800MG/100ML; 8.75MG/100ML</u>	N018508 001	Feb 19, 1982
-----------	-----------------	--	--------------------	--------------

TIS-U-SOL IN PLASTIC CONTAINER

AT	BAXTER HLTHCARE	<u>20MG/100ML; 40MG/100ML; 6.25MG/100ML; 800MG/100ML; 8.75MG/100ML</u>	N018336 001	
-----------	-----------------	--	--------------------	--

PRESCRIPTION DRUG PRODUCT LIST

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

POWDER; ORAL

COLPREP KIT

+ GATOR PHARMS

1.6GM/BOT; 3.13GM/BOT; 17.5GM/BOT

N204553 001 Dec 27, 2016

MALATHION

LOTION; TOPICAL

MALATHIONAT SUVEN LIFE0.5%A091559 001 May 23, 2012OVIDEAT + TARO PHARMS NORTH0.5%N018613 001 Aug 02, 1982MANGANESE CHLORIDE

INJECTABLE; INJECTION

MANGANESE CHLORIDE IN PLASTIC CONTAINER

HOSPIRA

EQ 0.1MG MANGANESE/ML

N018962 001 Jun 26, 1986

MANNITOL

INJECTABLE; INJECTION

MANNITOL 10% IN PLASTIC CONTAINERAP B BRAUN10GM/100MLN020006 002 Jul 26, 1993AP HOSPIRA10GM/100MLN019603 002 Jan 08, 1987MANNITOL 15% IN PLASTIC CONTAINERAP B BRAUN15GM/100MLN020006 003 Jul 26, 1993AP HOSPIRA15GM/100MLN019603 003 Jan 08, 1990MANNITOL 20% IN PLASTIC CONTAINERAP B BRAUN20GM/100MLN020006 004 Jul 26, 1993AP HOSPIRA20GM/100MLN019603 004 Jan 08, 1990MANNITOL 25%AP FRESENIUS KABI USA12.5GM/50MLA080677 001AP HOSPIRA12.5GM/50MLN016269 006 Aug 25, 1994AP INTL MEDICATION12.5GM/50MLA083051 001AP LUITPOLD12.5GM/50MLA087409 001 Jan 21, 1982MANNITOL 5% IN PLASTIC CONTAINERAP B BRAUN5GM/100MLN020006 001 Jul 26, 1993AP HOSPIRA5GM/100MLN019603 001 Jan 08, 1987OSMITROL 10% IN WATERAP BAXTER HLTHCARE10GM/100MLN013684 002OSMITROL 10% IN WATER IN PLASTIC CONTAINERAP BAXTER HLTHCARE10GM/100MLN013684 006OSMITROL 15% IN WATERAP BAXTER HLTHCARE15GM/100MLN013684 004OSMITROL 15% IN WATER IN PLASTIC CONTAINERAP BAXTER HLTHCARE15GM/100MLN013684 008OSMITROL 20% IN WATERAP BAXTER HLTHCARE20GM/100MLN013684 003OSMITROL 20% IN WATER IN PLASTIC CONTAINERAP BAXTER HLTHCARE20GM/100MLN013684 007OSMITROL 5% IN WATERAP BAXTER HLTHCARE5GM/100MLN013684 001OSMITROL 5% IN WATER IN PLASTIC CONTAINERAP BAXTER HLTHCARE5GM/100MLN013684 005

SOLUTION; IRRIGATION

RESECTISOL IN PLASTIC CONTAINER

B BRAUN

5GM/100ML

N016772 002

MANNITOL; SORBITOL

SOLUTION; IRRIGATION

SORBITOL-MANNITOL IN PLASTIC CONTAINER

HOSPIRA

540MG/100ML; 2.7GM/100ML

N018316 001

MAPROTILINE HYDROCHLORIDE

TABLET; ORAL

MAPROTILINE HYDROCHLORIDE

MYLAN

25MG

A072285 002 Oct 03, 1988

+

50MG

A072285 001 Oct 03, 1988

75MG

A072285 003 Oct 03, 1988

MARAVIROC

SOLUTION; ORAL

SELZENTRY

+ VIIV HLTHCARE

20MG/ML

N208984 001 Nov 04, 2016

TABLET; ORAL

SELZENTRY

VIIV HLTHCARE

25MG

N022128 003 Nov 04, 2016

PRESCRIPTION DRUG PRODUCT LIST

MARAVIROCTABLET; ORAL
SELZENTRY

	75MG	N022128 004	Nov 04, 2016
	150MG	N022128 001	Aug 06, 2007
+	300MG	N022128 002	Aug 06, 2007

MEBENDAZOLE

TABLET, CHEWABLE; ORAL

EMVERM

+	AMEDRA PHARMS LLC	100MG	A073580 001	Jan 04, 1995
---	-------------------	-------	-------------	--------------

VERMOX

+	JANSSEN PHARMS	500MG	N208398 001	Oct 19, 2016
---	----------------	-------	-------------	--------------

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL

MECAMYLAMINE HYDROCHLORIDE

NEXGEN PHARMA

2.5MG	A204054 001	Mar 19, 2013
-------	-------------	--------------

MECASERMIN RECOMBINANT

INJECTABLE; SUBCUTANEOUS

INCRELEX

+	IPSEN INC	40MG/4ML (10MG/ML)	N021839 001	Aug 30, 2005
---	-----------	--------------------	-------------	--------------

MECHLORETHAMINE HYDROCHLORIDE

GEL; TOPICAL

VALCHLOR

+	ACTELION PHARMS LTD	EQ 0.016% BASE	N202317 001	Aug 23, 2013
---	---------------------	----------------	-------------	--------------

INJECTABLE; INJECTION

MUSTARGEN

+	RECORDATI RARE	10MG/VIAL	N006695 001
---	----------------	-----------	-------------

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

AA	AMNEAL PHARMS	12.5MG	A201451 001	Feb 23, 2011
AA		25MG	A201451 002	Feb 23, 2011
AA	EPIC PHARMA LLC	12.5MG	A200294 001	Apr 13, 2012
AA		25MG	A200294 002	Apr 13, 2012
AA	JUBILANT CADISTA	12.5MG	A040659 001	Jun 04, 2010
AA		25MG	A040659 002	Jun 04, 2010
AA	MYLAN PHARMS INC	12.5MG	A202640 001	Sep 17, 2012
AA		25MG	A202640 002	Sep 17, 2012
AA	PAR PHARM	12.5MG	A087127 001	
AA		25MG	A087128 001	
AA	SANDOZ	12.5MG	A084843 002	May 22, 1989
AA		25MG	A084092 003	May 22, 1989

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLOFENAMATE SODIUM

MYLAN

EQ 50MG BASE	A071081 002	Sep 03, 1986
--------------	-------------	--------------

+		EQ 100MG BASE	A071081 001	Sep 03, 1986
---	--	---------------	-------------	--------------

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

DEPO-PROVERA

AB	+	PHARMACIA AND UPJOHN	150MG/ML	N020246 001	Oct 29, 1992
-----------	---	----------------------	-----------------	--------------------	--------------

MEDROXYPROGESTERONE ACETATE

AB	SANDOZ	150MG/ML	A078711 001	May 20, 2009
-----------	--------	-----------------	--------------------	--------------

AB	TEVA PHARMS USA	150MG/ML	A076553 001	Jul 28, 2004
-----------	-----------------	-----------------	--------------------	--------------

DEPO-PROVERA

+	PHARMACIA AND UPJOHN	400MG/ML	N012541 003
---	----------------------	----------	-------------

INJECTABLE; SUBCUTANEOUS

DEPO-SUBQ PROVERA 104

+	PHARMACIA AND UPJOHN	104MG/0.65ML	N021583 001	Dec 17, 2004
---	----------------------	--------------	-------------	--------------

TABLET; ORAL

MEDROXYPROGESTERONE ACETATE

AB	BARR	2.5MG	A040159 001	Aug 09, 1996
-----------	------	--------------	--------------------	--------------

AB		5MG	A040159 002	Aug 09, 1996
-----------	--	------------	--------------------	--------------

AB		10MG	A040159 003	Aug 09, 1996
-----------	--	-------------	--------------------	--------------

PROVERA

AB	PHARMACIA AND UPJOHN	2.5MG	N011839 001
-----------	----------------------	--------------	--------------------

AB		5MG	N011839 003
-----------	--	------------	--------------------

AB	+	10MG	N011839 004
-----------	---	-------------	--------------------

PRESCRIPTION DRUG PRODUCT LIST

MEFENAMIC ACID

CAPSULE; ORAL

MEFENAMIC ACID

<u>AB</u>	BRECKENRIDGE PHARM	<u>250MG</u>	<u>A090359</u>	<u>001</u>	Feb 05, 2013
<u>AB</u>	LUPIN LTD	<u>250MG</u>	<u>A091322</u>	<u>001</u>	Jul 22, 2011
<u>AB</u>	MICRO LABS LTD	<u>250MG</u>	<u>A090562</u>	<u>001</u>	Nov 19, 2010
<u>AB</u>	VINTAGE PHARMS LLC	<u>250MG</u>	<u>A091608</u>	<u>001</u>	Jun 02, 2014

PONSTEL

<u>AB</u>	+ SHIONOGI INC	<u>250MG</u>	<u>N015034</u>	<u>003</u>	
-----------	----------------	--------------	----------------	------------	--

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

MEFLOQUINE HYDROCHLORIDE

<u>AB</u>	BARR	<u>250MG</u>	<u>A076392</u>	<u>001</u>	Dec 29, 2003
<u>AB</u>	+ SANDOZ	<u>250MG</u>	<u>A076175</u>	<u>001</u>	Feb 20, 2002
<u>AB</u>	WEST-WARD PHARMS INT	<u>250MG</u>	<u>A076523</u>	<u>001</u>	Oct 01, 2004

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGACE

<u>AB</u>	+ BRISTOL MYERS SQUIBB	<u>40MG/ML</u>	<u>N020264</u>	<u>001</u>	Sep 10, 1993
-----------	------------------------	----------------	----------------	------------	--------------

MEGACE ES

<u>AB</u>	+ ENDO PHARMS INC	<u>125MG/ML</u>	<u>N021778</u>	<u>001</u>	Jul 05, 2005
-----------	-------------------	-----------------	----------------	------------	--------------

MEGESTROL ACETATE

<u>AB</u>	PAR PHARM	<u>40MG/ML</u>	<u>A075671</u>	<u>001</u>	Jul 25, 2001
<u>AB</u>	TEVA PHARMS	<u>40MG/ML</u>	<u>A075681</u>	<u>001</u>	May 05, 2003
<u>AB</u>	TWI PHARMS INC	<u>125MG/ML</u>	<u>A203139</u>	<u>001</u>	Aug 27, 2014
<u>AB</u>	WEST-WARD PHARMS INT	<u>40MG/ML</u>	<u>A075997</u>	<u>001</u>	Feb 15, 2002
<u>AB</u>	WOCKHARDT	<u>40MG/ML</u>	<u>A076721</u>	<u>001</u>	Nov 01, 2004

TABLET; ORAL

MEGESTROL ACETATE

<u>AB</u>	BARR	<u>20MG</u>	<u>A074621</u>	<u>002</u>	Aug 16, 1996
<u>AB</u>		<u>40MG</u>	<u>A074621</u>	<u>001</u>	Nov 30, 1995
<u>AB</u>	PAR PHARM	<u>20MG</u>	<u>A072422</u>	<u>001</u>	Aug 08, 1988
<u>AB</u>	+	<u>40MG</u>	<u>A072423</u>	<u>001</u>	Aug 08, 1988
<u>AB</u>	WEST-WARD PHARMS INT	<u>20MG</u>	<u>A074458</u>	<u>001</u>	Sep 29, 1995
<u>AB</u>		<u>40MG</u>	<u>A074458</u>	<u>002</u>	Sep 29, 1995

MELOXICAM

CAPSULE; ORAL

VIVLODEX

IROKO PHARMS LLC

5MG

N207233 001 Oct 22, 2015

+

10MG

N207233 002 Oct 22, 2015

SUSPENSION; ORAL

MOBIC

+ BOEHRINGER INGELHEIM

7.5MG/5ML

N021530 001 Jun 01, 2004

TABLET; ORAL

MELOXICAM

<u>AB</u>	APOTEX INC	<u>7.5MG</u>	<u>A077882</u>	<u>001</u>	Jul 20, 2006
<u>AB</u>		<u>15MG</u>	<u>A077882</u>	<u>002</u>	Jul 20, 2006
<u>AB</u>	AUROBINDO PHARMA	<u>7.5MG</u>	<u>A078008</u>	<u>001</u>	Oct 02, 2006
<u>AB</u>		<u>15MG</u>	<u>A078008</u>	<u>002</u>	Oct 02, 2006
<u>AB</u>	BRECKENRIDGE PHARM	<u>7.5MG</u>	<u>A077920</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077920</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	CIPLA LTD	<u>7.5MG</u>	<u>A077929</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077929</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	DR REDDYS LABS INC	<u>7.5MG</u>	<u>A077931</u>	<u>001</u>	Jul 25, 2006
<u>AB</u>		<u>15MG</u>	<u>A077931</u>	<u>002</u>	Jul 25, 2006
<u>AB</u>	GLENMARK GENERICS	<u>7.5MG</u>	<u>A077932</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077932</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	LUPIN PHARMS	<u>7.5MG</u>	<u>A077944</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077944</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	MYLAN	<u>7.5MG</u>	<u>A077923</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077923</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	PURACAP PHARM	<u>7.5MG</u>	<u>A077938</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077938</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	STRIDES PHARMA	<u>7.5MG</u>	<u>A077928</u>	<u>001</u>	May 13, 2009
<u>AB</u>		<u>15MG</u>	<u>A077928</u>	<u>002</u>	May 13, 2009
<u>AB</u>	SUN PHARM INDS INC	<u>7.5MG</u>	<u>A077937</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077937</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	TARO	<u>7.5MG</u>	<u>A078102</u>	<u>001</u>	Nov 07, 2006
<u>AB</u>		<u>15MG</u>	<u>A078102</u>	<u>002</u>	Nov 07, 2006
<u>AB</u>	TEVA PHARMS	<u>7.5MG</u>	<u>A077936</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077936</u>	<u>002</u>	Jul 19, 2006

PRESCRIPTION DRUG PRODUCT LIST

MELOXICAM

TABLET; ORAL

MELOXICAM

<u>AB</u>	UNICHEM	<u>7.5MG</u>	<u>A077927 001</u>	Dec 20, 2006
<u>AB</u>		<u>15MG</u>	<u>A077927 002</u>	Dec 20, 2006
<u>AB</u>	YUNG SHIN PHARM	<u>7.5MG</u>	<u>A077918 001</u>	Dec 07, 2006
<u>AB</u>		<u>15MG</u>	<u>A077918 002</u>	Dec 07, 2006
<u>AB</u>	ZYDUS PHARMS USA	<u>7.5MG</u>	<u>A077921 001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077921 002</u>	Jul 19, 2006

MOBIC

<u>AB</u>	BOEHRINGER INGELHEIM	<u>7.5MG</u>	<u>N020938 001</u>	Apr 13, 2000
<u>AB</u>	+	<u>15MG</u>	<u>N020938 002</u>	Aug 23, 2000

MELPHALAN

TABLET; ORAL

ALKERAN

+ APOTEX INC

2MG

N014691 002

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

ALKERAN

<u>AP</u>	+	APOTEX INC	<u>EQ 50MG BASE/VIAL</u>	<u>N020207 001</u>	Nov 18, 1992
-----------	---	------------	--------------------------	--------------------	--------------

MELPHALAN HYDROCHLORIDE

<u>AP</u>	ACTAVIS LLC	<u>EQ 50MG BASE/VIAL</u>	<u>A206018 001</u>	Dec 19, 2016
<u>AP</u>	MYLAN INSTITUTIONAL	<u>EQ 50MG BASE/VIAL</u>	<u>A090270 001</u>	Jun 09, 2009
<u>AP</u>	PAR STERILE PRODUCTS	<u>EQ 50MG BASE/VIAL</u>	<u>A204773 001</u>	Aug 22, 2016
<u>AP</u>	WEST-WARD PHARMS INT	<u>EQ 50MG BASE/VIAL</u>	<u>A090303 001</u>	Oct 28, 2010

POWDER; IV (INFUSION)

EVOMELA

SPECTRUM PHARMS

EQ 50MG BASE/VIAL

N207155 001 Mar 10, 2016

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MEMANTINE HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARMS	<u>7MG</u>	<u>A205825 001</u>	Oct 12, 2016
<u>AB</u>		<u>14MG</u>	<u>A205825 002</u>	Oct 12, 2016
<u>AB</u>		<u>21MG</u>	<u>A205825 003</u>	Oct 12, 2016
<u>AB</u>		<u>28MG</u>	<u>A205825 004</u>	Oct 12, 2016
<u>AB</u>	APOTEX INC	<u>7MG</u>	<u>A206135 001</u>	Nov 22, 2016
<u>AB</u>		<u>14MG</u>	<u>A206135 002</u>	Nov 22, 2016
<u>AB</u>		<u>21MG</u>	<u>A206135 003</u>	Nov 22, 2016
<u>AB</u>		<u>28MG</u>	<u>A206135 004</u>	Nov 22, 2016
<u>AB</u>	LUPIN LTD	<u>7MG</u>	<u>A206028 001</u>	Sep 28, 2016
<u>AB</u>		<u>14MG</u>	<u>A206028 002</u>	Sep 28, 2016
<u>AB</u>		<u>21MG</u>	<u>A206028 003</u>	Sep 28, 2016
<u>AB</u>		<u>28MG</u>	<u>A206028 004</u>	Sep 28, 2016
<u>AB</u>	MYLAN PHARMS INC	<u>7MG</u>	<u>A206032 001</u>	Sep 28, 2016
<u>AB</u>		<u>14MG</u>	<u>A206032 002</u>	Sep 28, 2016
<u>AB</u>		<u>21MG</u>	<u>A206032 003</u>	Sep 28, 2016
<u>AB</u>		<u>28MG</u>	<u>A206032 004</u>	Sep 28, 2016
<u>AB</u>	SUN PHARMA GLOBAL	<u>7MG</u>	<u>A205905 001</u>	Sep 28, 2016
<u>AB</u>		<u>14MG</u>	<u>A205905 002</u>	Sep 28, 2016
<u>AB</u>		<u>21MG</u>	<u>A205905 003</u>	Sep 28, 2016
<u>AB</u>		<u>28MG</u>	<u>A205905 004</u>	Sep 28, 2016

NAMENDA XR

<u>AB</u>	FOREST LABS LLC	<u>7MG</u>	<u>N022525 001</u>	Jun 21, 2010
<u>AB</u>		<u>14MG</u>	<u>N022525 002</u>	Jun 21, 2010
<u>AB</u>		<u>21MG</u>	<u>N022525 003</u>	Jun 21, 2010
<u>AB</u>	+	<u>28MG</u>	<u>N022525 004</u>	Jun 21, 2010

SOLUTION; ORAL

MEMANTINE HYDROCHLORIDE

<u>AA</u>	BIO-PHARM INC	<u>2MG/ML</u>	<u>A205446 001</u>	Dec 07, 2015
<u>AA</u>	MACLEODS PHARMS LTD	<u>2MG/ML</u>	<u>A202790 001</u>	Oct 13, 2015
<u>AA</u>	SILARX PHARMS INC	<u>2MG/ML</u>	<u>A204033 001</u>	Oct 13, 2015

NAMENDA

<u>AA</u>	+	FOREST LABS LLC	<u>2MG/ML</u>	<u>N021627 001</u>	Apr 18, 2005
-----------	---	-----------------	---------------	--------------------	--------------

TABLET; ORAL

MEMANTINE HYDROCHLORIDE

<u>AB</u>	AJANTA PHARMA LTD	<u>5MG</u>	<u>A206528 001</u>	Nov 30, 2015
<u>AB</u>		<u>10MG</u>	<u>A206528 002</u>	Nov 30, 2015
<u>AB</u>	ALEMBIC PHARMS LTD	<u>5MG</u>	<u>A200891 001</u>	Oct 13, 2015
<u>AB</u>		<u>10MG</u>	<u>A200891 002</u>	Oct 13, 2015
<u>AB</u>	AMNEAL PHARMS	<u>5MG</u>	<u>A090041 001</u>	Apr 10, 2015
<u>AB</u>		<u>10MG</u>	<u>A090041 002</u>	Apr 10, 2015

PRESCRIPTION DRUG PRODUCT LIST

MEMANTINE HYDROCHLORIDE

TABLET; ORAL

MEMANTINE HYDROCHLORIDE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>5MG</u>	<u>A203175 001</u>	Oct 13, 2015
<u>AB</u>		<u>10MG</u>	<u>A203175 002</u>	Oct 13, 2015
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A090048 001</u>	Apr 14, 2010
<u>AB</u>		<u>10MG</u>	<u>A090048 002</u>	Apr 14, 2010
<u>AB</u>	JUBILANT GENERICS	<u>5MG</u>	<u>A091585 001</u>	Oct 13, 2015
<u>AB</u>		<u>10MG</u>	<u>A091585 002</u>	Oct 13, 2015
<u>AB</u>	LUPIN LTD	<u>5MG</u>	<u>A090051 001</u>	Apr 10, 2015
<u>AB</u>		<u>10MG</u>	<u>A090051 002</u>	Apr 10, 2015
<u>AB</u>	MACLEODS PHARMS LTD	<u>5MG</u>	<u>A202840 001</u>	Oct 13, 2015
<u>AB</u>		<u>10MG</u>	<u>A202840 002</u>	Oct 13, 2015
<u>AB</u>	MYLAN PHARMS INC	<u>5MG</u>	<u>A079225 001</u>	Jan 30, 2015
<u>AB</u>		<u>10MG</u>	<u>A079225 002</u>	Jan 30, 2015
<u>AB</u>	PURACAP PHARM LLC	<u>5MG</u>	<u>A206855 001</u>	Nov 17, 2015
<u>AB</u>		<u>10MG</u>	<u>A206855 002</u>	Nov 17, 2015
<u>AB</u>	SILARX PHARMS INC	<u>5MG</u>	<u>A207236 001</u>	Nov 10, 2016
<u>AB</u>		<u>10MG</u>	<u>A207236 002</u>	Nov 10, 2016
<u>AB</u>	SUN PHARMA GLOBAL	<u>5MG</u>	<u>A090058 001</u>	May 05, 2010
<u>AB</u>		<u>10MG</u>	<u>A090058 002</u>	May 05, 2010
<u>AB</u>	TEVA PHARMS	<u>5MG</u>	<u>A090052 001</u>	Oct 25, 2011
<u>AB</u>		<u>10MG</u>	<u>A090052 002</u>	Oct 25, 2011
<u>AB</u>	TORRENT PHARMS LTD	<u>5MG</u>	<u>A200155 001</u>	Oct 13, 2015
<u>AB</u>		<u>10MG</u>	<u>A200155 002</u>	Oct 13, 2015
<u>AB</u>	UNICHEM LABS LTD	<u>5MG</u>	<u>A200022 001</u>	Oct 13, 2015
<u>AB</u>		<u>10MG</u>	<u>A200022 002</u>	Oct 13, 2015
<u>AB</u>	UPSHER-SMITH LABS	<u>5MG</u>	<u>A090043 001</u>	Jul 31, 2015
<u>AB</u>		<u>10MG</u>	<u>A090043 002</u>	Jul 31, 2015
<u>AB</u>	WOCKHARDT LTD	<u>5MG</u>	<u>A090073 001</u>	Sep 04, 2015
<u>AB</u>		<u>10MG</u>	<u>A090073 002</u>	Sep 04, 2015

NAMENDA

<u>AB</u>	FOREST LABS LLC	<u>5MG</u>	<u>N021487 001</u>	Oct 16, 2003
<u>AB</u>	+	<u>10MG</u>	<u>N021487 002</u>	Oct 16, 2003

MENOTROPINS (FSH; LH)

INJECTABLE; SUBCUTANEOUS

MENOPUR

+ FERRING

75 IU/VIAL; 75 IU/VIAL

N021663 001 Oct 29, 2004

MEPENZOLATE BROMIDE

TABLET; ORAL

CANTIL

+ SANOFI AVENTIS US

25MG

N010679 003

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEMEROL

<u>AP</u>	+	HOSPIRA	<u>25MG/ML</u>	<u>N021171 001</u>
<u>AP</u>	+		<u>50MG/ML</u>	<u>N021171 002</u>
<u>AP</u>	+		<u>75MG/ML</u>	<u>N021171 003</u>
<u>AP</u>	+		<u>100MG/ML</u>	<u>N021171 004</u>

MEPERIDINE HYDROCHLORIDE

<u>AP</u>	EUROHLTH INTL SARL	<u>25MG/ML</u>	<u>A080445 001</u>
<u>AP</u>		<u>25MG/ML</u>	<u>A080455 007</u>
<u>AP</u>		<u>50MG/ML</u>	<u>A080445 002</u>
<u>AP</u>		<u>50MG/ML</u>	<u>A080455 008</u>
<u>AP</u>		<u>75MG/ML</u>	<u>A080445 003</u>
<u>AP</u>		<u>75MG/ML</u>	<u>A080455 009</u>
<u>AP</u>		<u>100MG/ML</u>	<u>A080445 004</u>
<u>AP</u>		<u>100MG/ML</u>	<u>A080455 010</u>

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	EUROHLTH INTL SARL	<u>10MG/ML</u>	<u>A081002 001</u>	Jul 30, 1993	
<u>AP</u>	+	HOSPIRA	<u>10MG/ML</u>	<u>A088432 001</u>	Aug 16, 1984

SYRUP; ORAL

MEPERIDINE HYDROCHLORIDE

+ WEST-WARD PHARMS INT

50MG/5ML

A088744 001 Jan 30, 1985

TABLET; ORAL

DEMEROL

<u>AA</u>	+	US PHARM HOLDINGS	<u>50MG</u>	<u>N005010 001</u>
<u>AA</u>	+		<u>100MG</u>	<u>N005010 004</u>

MEPERIDINE HYDROCHLORIDE

<u>AA</u>	BARR	<u>50MG</u>	<u>A088639 001</u>	Jul 02, 1984
<u>AA</u>		<u>100MG</u>	<u>A088640 001</u>	Sep 19, 1984

PRESCRIPTION DRUG PRODUCT LIST

MEPERIDINE HYDROCHLORIDE

TABLET; ORAL

MEPERIDINE HYDROCHLORIDE

<u>AA</u>	EPIC PHARMA	<u>50MG</u>	<u>A040331 001</u>	May 28, 1999
<u>AA</u>		<u>100MG</u>	<u>A040331 002</u>	May 28, 1999
<u>AA</u>	MALLINCKRODT	<u>50MG</u>	<u>A040352 001</u>	Jun 13, 2000
<u>AA</u>		<u>100MG</u>	<u>A040352 002</u>	Jun 13, 2000
<u>AA</u>	MIKART	<u>50MG</u>	<u>A040893 001</u>	Jun 24, 2009
<u>AA</u>		<u>100MG</u>	<u>A040893 003</u>	Jun 24, 2009
<u>AA</u>	SUN PHARM INDS INC	<u>50MG</u>	<u>A040446 001</u>	Aug 08, 2002
<u>AA</u>		<u>100MG</u>	<u>A040446 002</u>	Aug 08, 2002
<u>AA</u>	VINTAGE PHARMS	<u>50MG</u>	<u>A040191 001</u>	Dec 17, 1998
<u>AA</u>		<u>100MG</u>	<u>A040191 002</u>	Dec 17, 1998
<u>AA</u>	WEST-WARD PHARMS INT	<u>50MG</u>	<u>A040110 001</u>	Mar 12, 1997
<u>AA</u>		<u>100MG</u>	<u>A040110 002</u>	Mar 12, 1997
	MIKART	75MG	A040893 002	Jun 24, 2009
		150MG	A040893 004	Jun 24, 2009

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CARBOCAINE

<u>AP</u>	+ HOSPIRA	<u>1%</u>	<u>N012250 001</u>	
<u>AP</u>	+	<u>1.5%</u>	<u>N012250 005</u>	
<u>AP</u>	+	<u>2%</u>	<u>N012250 002</u>	

ISOCAINE HYDROCHLORIDE

<u>AP</u>	+ NOVOCOL	<u>3%</u>	<u>A080925 001</u>	
-----------	-----------	-----------	--------------------	--

MEPIVACAINE HYDROCHLORIDE

<u>AP</u>	HOSPIRA INC	<u>3%</u>	<u>A040806 001</u>	Apr 28, 2008
-----------	-------------	-----------	--------------------	--------------

POLOCAINE

<u>AP</u>	FRESENIUS KABI USA	<u>1%</u>	<u>A089407 001</u>	Dec 01, 1986
<u>AP</u>		<u>2%</u>	<u>A089410 001</u>	Dec 01, 1986

POLOCAINE-MPF

<u>AP</u>	FRESENIUS KABI USA	<u>1%</u>	<u>A089406 001</u>	Dec 01, 1986
<u>AP</u>		<u>1.5%</u>	<u>A089408 001</u>	Dec 01, 1986
<u>AP</u>		<u>2%</u>	<u>A089409 001</u>	Dec 01, 1986

SCANDONEST PLAIN

<u>AP</u>	+ DEPROCO	<u>3%</u>	<u>A088387 001</u>	Oct 10, 1984
-----------	-----------	-----------	--------------------	--------------

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

<u>AA</u>	ALEMBIC PHARMS LTD	<u>200MG</u>	<u>A090122 001</u>	Feb 18, 2009
<u>AA</u>		<u>400MG</u>	<u>A090122 002</u>	Feb 18, 2009
<u>AA</u>	INVAGEN PHARMS	<u>200MG</u>	<u>A040797 001</u>	Feb 27, 2008
<u>AA</u>		<u>400MG</u>	<u>A040797 002</u>	Feb 27, 2008
<u>AA</u>	+ WATSON LABS	<u>200MG</u>	<u>A083304 001</u>	
<u>AA</u>	+	<u>400MG</u>	<u>A083308 001</u>	

MERCAPTOPYRINE

SUSPENSION; ORAL

PURIXAN

+ NOVA LABS LTD

20MG/ML

N205919 001 Apr 28, 2014

TABLET; ORAL

MERCAPTOPYRINE

<u>AB</u>	DR REDDYS LABS INTL	<u>50MG</u>	<u>A040461 001</u>	Feb 11, 2004
<u>AB</u>	MYLAN	<u>50MG</u>	<u>A040594 001</u>	Jul 01, 2005
<u>AB</u>	+ WEST-WARD PHARMS INT	<u>50MG</u>	<u>A040528 001</u>	Feb 13, 2004

PURINETHOL

<u>AB</u>	STASON PHARMS	<u>50MG</u>	<u>N009053 002</u>	
-----------	---------------	-------------	--------------------	--

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

<u>AP</u>	ACS DOBFAR	<u>500MG/VIAL</u>	<u>A091404 001</u>	Oct 26, 2011
<u>AP</u>		<u>1GM/VIAL</u>	<u>A091404 002</u>	Oct 26, 2011
<u>AP</u>	AMNEAL PHARMS	<u>500MG/VIAL</u>	<u>A205883 001</u>	Apr 12, 2016
<u>AP</u>		<u>1GM/VIAL</u>	<u>A205883 002</u>	Apr 12, 2016
<u>AP</u>	DAEWOONG PHARM CO	<u>500MG/VIAL</u>	<u>A204854 001</u>	Dec 18, 2015
<u>AP</u>		<u>1GM/VIAL</u>	<u>A204854 002</u>	Dec 18, 2015
<u>AP</u>	GLAND PHARMA LTD	<u>500MG/VIAL</u>	<u>A206141 001</u>	Jun 08, 2016
<u>AP</u>		<u>1GM/VIAL</u>	<u>A206141 002</u>	Jun 08, 2016
<u>AP</u>	HOSPIRA INC	<u>500MG/VIAL</u>	<u>A090940 001</u>	Jun 22, 2010
<u>AP</u>		<u>1GM/VIAL</u>	<u>A090940 002</u>	Jun 22, 2010
<u>AP</u>	PAR STERILE PRODUCTS	<u>500MG/VIAL</u>	<u>A204139 001</u>	Jun 09, 2016

PRESCRIPTION DRUG PRODUCT LIST

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

<u>AP</u>		<u>1GM/VIAL</u>	<u>A204139 002</u>	Jun 09, 2016
<u>AP</u>	SANDOZ	<u>500MG/VIAL</u>	<u>A091201 001</u>	Mar 29, 2011
<u>AP</u>		<u>1GM/VIAL</u>	<u>A091201 002</u>	Mar 29, 2011
<u>AP</u>	SAVIOR LIFETEC CORP	<u>500MG/VIAL</u>	<u>A206086 001</u>	Apr 19, 2016
<u>AP</u>		<u>1GM/VIAL</u>	<u>A206086 002</u>	Apr 19, 2016

MERREM

<u>AP</u>	+ ASTRAZENECA	<u>500MG/VIAL</u>	<u>N050706 003</u>	Jun 21, 1996
<u>AP</u>	+	<u>1GM/VIAL</u>	<u>N050706 001</u>	Jun 21, 1996

POWDER; IV (INFUSION)

MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

B BRAUN MEDICAL INC	500MG/VIAL	N202106 001	Apr 30, 2015
	1GM/VIAL	N202106 002	Apr 30, 2015

MESALAMINE

CAPSULE, DELAYED RELEASE; ORAL

DELZICOL

+ APIL	400MG	N204412 001	Feb 01, 2013
--------	-------	-------------	--------------

CAPSULE, EXTENDED RELEASE; ORAL

APRISO

+ VALEANT PHARMS INTL	375MG	N022301 001	Oct 31, 2008
-----------------------	-------	-------------	--------------

PENTASA

SHIRE	250MG	N020049 001	May 10, 1993
-------	-------	-------------	--------------

+	500MG	N020049 002	Jul 08, 2004
---	-------	-------------	--------------

ENEMA; RECTAL

MESALAMINE

<u>AB</u>	G AND W LABS INC	<u>4GM/60ML</u>	<u>A076841 001</u>	Sep 30, 2004
-----------	------------------	-----------------	--------------------	--------------

<u>AB</u>	PERRIGO ISRAEL	<u>4GM/60ML</u>	<u>A076751 001</u>	Sep 17, 2004
-----------	----------------	-----------------	--------------------	--------------

ROWASA

<u>AB</u>	+ MEDA PHARMS	<u>4GM/60ML</u>	<u>N019618 001</u>	Dec 24, 1987
-----------	---------------	-----------------	--------------------	--------------

SFROWASA

<u>AB</u>	MEDA PHARMS	<u>4GM/60ML</u>	<u>N019618 002</u>	Jun 20, 2008
-----------	-------------	-----------------	--------------------	--------------

SUPPOSITORY; RECTAL

CANASA

<u>AB</u>	+ FOREST LABS LLC	<u>1GM</u>	<u>N021252 002</u>	Nov 05, 2004
-----------	-------------------	------------	--------------------	--------------

MESALAMINE

<u>AB</u>	MYLAN PHARMS INC	<u>1GM</u>	<u>A204354 001</u>	Nov 24, 2015
-----------	------------------	------------	--------------------	--------------

TABLET, DELAYED RELEASE; ORAL

ASACOL HD

+ APIL	800MG	N021830 001	May 29, 2008
--------	-------	-------------	--------------

LIALDA

+ SHIRE	1.2GM	N022000 001	Jan 16, 2007
---------	-------	-------------	--------------

MESNA

INJECTABLE; INTRAVENOUS

MESNA

<u>AP</u>	FRESENIUS KABI USA	<u>100MG/ML</u>	<u>A075811 001</u>	Apr 26, 2001
-----------	--------------------	-----------------	--------------------	--------------

<u>AP</u>	MYLAN INSTITUTIONAL	<u>100MG/ML</u>	<u>A076488 001</u>	Mar 08, 2012
-----------	---------------------	-----------------	--------------------	--------------

<u>AP</u>	MYLAN LABS LTD	<u>100MG/ML</u>	<u>A203364 001</u>	Jul 18, 2014
-----------	----------------	-----------------	--------------------	--------------

<u>AP</u>	SAGENT PHARMS	<u>100MG/ML</u>	<u>A090913 001</u>	Apr 13, 2010
-----------	---------------	-----------------	--------------------	--------------

<u>AP</u>	TEVA PHARMS USA	<u>100MG/ML</u>	<u>A075764 001</u>	Apr 27, 2001
-----------	-----------------	-----------------	--------------------	--------------

<u>AP</u>	WEST-WARD PHARMS INT	<u>100MG/ML</u>	<u>A075739 001</u>	Jan 09, 2004
-----------	----------------------	-----------------	--------------------	--------------

MESNEX

<u>AP</u>	+ BAXTER HLTHCARE	<u>100MG/ML</u>	<u>N019884 001</u>	Dec 30, 1988
-----------	-------------------	-----------------	--------------------	--------------

TABLET; ORAL

MESNEX

+ BAXTER HLTHCARE	400MG	N020855 001	Mar 21, 2002
-------------------	-------	-------------	--------------

MESTRANOL; NORETHINDRONE

TABLET; ORAL-28

NORINYL 1+50 28-DAY

+ ACTAVIS LABS UT INC	0.05MG; 1MG	N016659 001	
-----------------------	-------------	-------------	--

METAPROTERENOL SULFATE

SYRUP; ORAL

METAPROTERENOL SULFATE

+ SILARX	10MG/5ML	A073632 001	Jul 22, 1992
----------	----------	-------------	--------------

TABLET; ORAL

METAPROTERENOL SULFATE

PAR PHARM	10MG	A072024 001	Jun 28, 1988
-----------	------	-------------	--------------

+	20MG	A072025 001	Jun 28, 1988
---	------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

METARAMINOL BITARTRATE

INJECTABLE; INJECTION

METARAMINOL BITARTRATE

+ FRESenius KABI USA

EQ 10MG BASE/ML

A080722 001

METAXALONE

TABLET; ORAL

METAXALONEAB AMNEAL PHARMS800MGA203399 001 Jun 21, 2013AB LANNETT HOLDINGS INC800MGA204770 001 Nov 22, 2016AB SANDOZ800MGA040445 001 Mar 31, 2010SKELAXINAB + KING PHARMS800MGN013217 003 Aug 30, 2002

METAXALONE

COREPHARMA

400MG

A040486 001 Feb 27, 2015

METFORMIN HYDROCHLORIDE

SOLUTION; ORAL

RIOMET

+ SUN PHARM INDS LTD

500MG/5ML

N021591 001 Sep 11, 2003

TABLET; ORAL

GLUCOPHAGEAB BRISTOL MYERS SQUIBB500MGN020357 001 Mar 03, 1995AB850MGN020357 002 Mar 03, 1995AB +1GMN020357 005 Nov 05, 1998METFORMIN HYDROCHLORIDEAB ALKEM500MGA091184 001 Nov 01, 2010AB850MGA091184 002 Nov 01, 2010AB1GMA091184 003 Nov 01, 2010AB AMNEAL PHARMS NY500MGA077880 001 Jun 05, 2006AB850MGA077880 002 Jun 05, 2006AB1GMA077880 003 Jun 05, 2006AB APOTEX500MGA075984 001 Apr 23, 2002AB500MGA090666 001 Dec 07, 2011AB850MGA075984 002 Apr 23, 2002AB850MGA090666 002 Dec 07, 2011AB1GMA075984 003 Apr 23, 2002AB1GMA090666 003 Dec 07, 2011AB ATLAS PHARMS LLC500MGA076033 001 Jan 24, 2002AB850MGA076033 002 Jan 24, 2002AB1GMA076033 003 Jan 24, 2002AB AUROBINDO500MGA077095 001 Jan 14, 2005AB850MGA077095 002 Jan 14, 2005AB1GMA077095 003 Jan 14, 2005AB CHARTWELL LIFE SCI500MGA075972 001 Jan 24, 2002AB850MGA075972 002 Jan 24, 2002AB1GMA075972 003 Jan 24, 2002AB CSPC OUYI PHARM CO500MGA205096 001 Jul 11, 2016AB850MGA205096 002 Jul 11, 2016AB1GMA205096 003 Jul 11, 2016AB DR REDDYS LABS INC500MGA077787 001 Aug 23, 2006AB850MGA077787 002 Aug 23, 2006AB1GMA077787 003 Aug 23, 2006AB GLENMARK GENERICS500MGA078170 001 May 23, 2008AB850MGA078170 002 May 23, 2008AB1GMA078170 003 May 23, 2008AB GRANULES INDIA500MGA090564 001 Apr 22, 2010AB850MGA090564 002 Apr 22, 2010AB1GMA090564 003 Apr 22, 2010AB INDICUS PHARMA500MGA079148 001 Nov 25, 2008AB850MGA079148 002 Nov 25, 2008AB1GMA079148 003 Nov 25, 2008AB MARKSANS PHARMA500MGA090888 001 Mar 12, 2012AB850MGA090888 002 Mar 12, 2012AB1GMA090888 003 Mar 12, 2012AB MYLAN500MGA075973 001 Jan 25, 2002AB500MGA075976 001 Jan 24, 2002AB850MGA075973 002 Jan 25, 2002AB850MGA075976 002 Jan 24, 2002AB1GMA075973 003 Jan 25, 2002AB1GMA075976 003 Jan 24, 2002AB MYLAN PHARMS INC500MGA075969 001 Jan 29, 2002AB850MGA075969 002 Jan 29, 2002

PRESCRIPTION DRUG PRODUCT LIST

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

<u>AB</u>		<u>1GM</u>	<u>A075969</u>	<u>003</u>	Jan 29, 2002
<u>AB</u>	PROVIDENT PHARM	<u>500MG</u>	<u>A077853</u>	<u>001</u>	Jul 28, 2006
<u>AB</u>		<u>850MG</u>	<u>A077853</u>	<u>002</u>	Jul 28, 2006
<u>AB</u>		<u>1GM</u>	<u>A077853</u>	<u>003</u>	Jul 28, 2006
<u>AB</u>	SANDOZ	<u>500MG</u>	<u>A075965</u>	<u>001</u>	Jan 25, 2002
<u>AB</u>		<u>500MG</u>	<u>A075985</u>	<u>001</u>	Jan 25, 2002
<u>AB</u>		<u>850MG</u>	<u>A075965</u>	<u>002</u>	Jan 25, 2002
<u>AB</u>		<u>850MG</u>	<u>A075985</u>	<u>002</u>	Jan 25, 2002
<u>AB</u>		<u>1GM</u>	<u>A075965</u>	<u>003</u>	Jan 25, 2002
<u>AB</u>		<u>1GM</u>	<u>A075985</u>	<u>003</u>	Jan 25, 2002
<u>AB</u>	SCIEGEN PHARMS INC	<u>500MG</u>	<u>A203769</u>	<u>001</u>	Sep 11, 2013
<u>AB</u>		<u>850MG</u>	<u>A203769</u>	<u>002</u>	Sep 11, 2013
<u>AB</u>		<u>1GM</u>	<u>A203769</u>	<u>003</u>	Sep 11, 2013
<u>AB</u>	SUN PHARM INDS	<u>500MG</u>	<u>A076038</u>	<u>001</u>	Feb 21, 2002
<u>AB</u>		<u>850MG</u>	<u>A076038</u>	<u>002</u>	Feb 21, 2002
<u>AB</u>		<u>1GM</u>	<u>A076038</u>	<u>003</u>	Feb 21, 2002
<u>AB</u>	SUN PHARM INDS INC	<u>500MG</u>	<u>A075967</u>	<u>001</u>	Jan 29, 2002
<u>AB</u>		<u>850MG</u>	<u>A075967</u>	<u>002</u>	Jan 29, 2002
<u>AB</u>		<u>1GM</u>	<u>A075967</u>	<u>003</u>	Jan 29, 2002
<u>AB</u>	TEVA	<u>500MG</u>	<u>A075978</u>	<u>001</u>	Jan 25, 2002
<u>AB</u>		<u>850MG</u>	<u>A075978</u>	<u>002</u>	Jan 25, 2002
<u>AB</u>		<u>1GM</u>	<u>A075978</u>	<u>003</u>	Nov 05, 2002
<u>AB</u>	TORRENT PHARMS	<u>500MG</u>	<u>A077711</u>	<u>001</u>	Jan 24, 2007
<u>AB</u>		<u>850MG</u>	<u>A077711</u>	<u>002</u>	Jan 24, 2007
<u>AB</u>		<u>1GM</u>	<u>A077711</u>	<u>003</u>	Jan 24, 2007
<u>AB</u>	WATSON LABS FLORIDA	<u>500MG</u>	<u>A075961</u>	<u>001</u>	Jan 25, 2002
<u>AB</u>		<u>850MG</u>	<u>A075961</u>	<u>002</u>	Jan 25, 2002
<u>AB</u>		<u>1GM</u>	<u>A075961</u>	<u>003</u>	Jan 25, 2002
<u>AB</u>	ZYDUS HLTHCARE	<u>500MG</u>	<u>A203686</u>	<u>001</u>	Aug 28, 2014
<u>AB</u>		<u>850MG</u>	<u>A203686</u>	<u>002</u>	Aug 28, 2014
<u>AB</u>		<u>1GM</u>	<u>A203686</u>	<u>003</u>	Aug 28, 2014
<u>AB</u>	ZYDUS PHARMS USA	<u>500MG</u>	<u>A077064</u>	<u>001</u>	Apr 18, 2005
<u>AB</u>		<u>850MG</u>	<u>A077064</u>	<u>002</u>	Apr 18, 2005
<u>AB</u>		<u>1GM</u>	<u>A077064</u>	<u>003</u>	Apr 18, 2005
	CHARTWELL LIFE SCI	625MG	A075972	005	Jan 24, 2002
		750MG	A075972	004	Jan 24, 2002

TABLET, EXTENDED RELEASE; ORAL

GLUCOPHAGE XR

<u>AB</u>	+ BRISTOL MYERS SQUIBB	<u>750MG</u>	<u>N021202</u>	<u>004</u>	Apr 11, 2003
-----------	------------------------	--------------	----------------	------------	--------------

METFORMIN HYDROCHLORIDE

<u>AB</u>	ACTAVIS LABS FL INC	<u>750MG</u>	<u>A076869</u>	<u>001</u>	Apr 12, 2005
<u>AB</u>	AMNEAL PHARMS NY	<u>750MG</u>	<u>A078596</u>	<u>002</u>	Jan 03, 2008
<u>AB</u>	APOTEX	<u>750MG</u>	<u>A076706</u>	<u>002</u>	Dec 29, 2005
<u>AB</u>	AUROBINDO PHARMA LTD	<u>750MG</u>	<u>A079118</u>	<u>002</u>	Jul 20, 2012
<u>AB</u>	BARR	<u>750MG</u>	<u>A076863</u>	<u>001</u>	Oct 14, 2004
<u>AB</u>	BEXIMCO PHARMS USA	<u>750MG</u>	<u>A207427</u>	<u>002</u>	Dec 13, 2016
<u>AB</u>	CSPC OUYI PHARM CO	<u>750MG</u>	<u>A078321</u>	<u>002</u>	Apr 17, 2008
<u>AB</u>	MACLEODS PHARMS LTD	<u>750MG</u>	<u>A206955</u>	<u>002</u>	Dec 07, 2016
<u>AB</u>	MARKSANS PHARMA	<u>750MG</u>	<u>A090295</u>	<u>002</u>	Apr 29, 2016
<u>AB</u>	MYLAN	<u>750MG</u>	<u>A077113</u>	<u>001</u>	Sep 08, 2005
<u>AB</u>	NOSTRUM PHARMS LLC	<u>750MG</u>	<u>A076756</u>	<u>002</u>	Dec 12, 2011
<u>AB</u>	SUN PHARM INDS (IN)	<u>750MG</u>	<u>A077336</u>	<u>002</u>	Feb 09, 2006
<u>AB</u>	TEVA	<u>750MG</u>	<u>A076864</u>	<u>001</u>	Apr 12, 2005
<u>AB</u>	ZYDUS PHARMS USA	<u>750MG</u>	<u>A077078</u>	<u>001</u>	Apr 21, 2005

GLUCOPHAGE XR

<u>AB1</u>	BRISTOL MYERS SQUIBB	<u>500MG</u>	<u>N021202</u>	<u>001</u>	Oct 13, 2000
------------	----------------------	--------------	----------------	------------	--------------

METFORMIN HYDROCHLORIDE

<u>AB1</u>	ACTAVIS LABS FL INC	<u>500MG</u>	<u>A076172</u>	<u>001</u>	Jun 16, 2004
<u>AB1</u>	AMNEAL PHARMS NY	<u>500MG</u>	<u>A078596</u>	<u>001</u>	Jan 03, 2008
<u>AB1</u>	APOTEX	<u>500MG</u>	<u>A076706</u>	<u>001</u>	Dec 14, 2004
<u>AB1</u>	AUROBINDO PHARMA LTD	<u>500MG</u>	<u>A079118</u>	<u>001</u>	Jul 20, 2012
<u>AB1</u>	BEXIMCO PHARMS USA	<u>500MG</u>	<u>A207427</u>	<u>001</u>	Dec 13, 2016
<u>AB1</u>	CSPC OUYI PHARM CO	<u>500MG</u>	<u>A078321</u>	<u>001</u>	Apr 17, 2008
<u>AB1</u>	INVENTIA HLTHCARE	<u>500MG</u>	<u>A201991</u>	<u>001</u>	Jan 18, 2012
<u>AB1</u>	MACLEODS PHARMS LTD	<u>500MG</u>	<u>A206955</u>	<u>001</u>	Dec 07, 2016
<u>AB1</u>	MARKSANS PHARMA	<u>500MG</u>	<u>A090295</u>	<u>001</u>	Apr 29, 2016
<u>AB1</u>	MYLAN	<u>500MG</u>	<u>A076650</u>	<u>001</u>	Sep 13, 2005
<u>AB1</u>	NOSTRUM PHARMS LLC	<u>500MG</u>	<u>A076756</u>	<u>001</u>	Jul 26, 2006
<u>AB1</u>	SANDOZ	<u>500MG</u>	<u>A076873</u>	<u>001</u>	Dec 14, 2004

PRESCRIPTION DRUG PRODUCT LIST

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

METFORMIN HYDROCHLORIDE

<u>AB1</u>	SUN PHARM INDS (IN)	<u>500MG</u>	<u>A077336</u>	<u>001</u>	Feb 09, 2006
<u>AB1</u>	TEVA	<u>500MG</u>	<u>A076269</u>	<u>001</u>	Jun 18, 2004
<u>AB1</u>	TORRENT PHARM	<u>500MG</u>	<u>A090014</u>	<u>001</u>	Dec 30, 2009
<u>AB1</u>	ZYDUS PHARMS USA	<u>500MG</u>	<u>A077060</u>	<u>001</u>	Apr 20, 2005

FORTAMET

<u>AB2</u>	ANDRX LABS LLC	<u>500MG</u>	<u>N021574</u>	<u>001</u>	Apr 27, 2004
<u>AB2</u>	+	<u>1GM</u>	<u>N021574</u>	<u>002</u>	Apr 27, 2004

METFORMIN HYDROCHLORIDE

<u>AB2</u>	LUPIN LTD	<u>500MG</u>	<u>A090692</u>	<u>001</u>	Jun 29, 2011
<u>AB2</u>		<u>1GM</u>	<u>A090692</u>	<u>002</u>	Jun 29, 2011
<u>AB2</u>	MYLAN PHARMS INC	<u>500MG</u>	<u>A200690</u>	<u>001</u>	Aug 01, 2012
<u>AB2</u>		<u>1GM</u>	<u>A200690</u>	<u>002</u>	Aug 01, 2012

GLUMETZA

<u>AB3</u>	SANTARUS INC	<u>500MG</u>	<u>N021748</u>	<u>001</u>	Jun 03, 2005
<u>AB3</u>	+	<u>1GM</u>	<u>N021748</u>	<u>002</u>	Jun 03, 2005

METFORMIN HYDROCHLORIDE

<u>AB3</u>	ACTAVIS LABS FL INC	<u>500MG</u>	<u>A203755</u>	<u>001</u>	Aug 01, 2016
<u>AB3</u>		<u>1GM</u>	<u>A203755</u>	<u>002</u>	Aug 01, 2016
<u>AB3</u>	LUPIN LTD	<u>500MG</u>	<u>A091664</u>	<u>001</u>	Jul 19, 2013
<u>AB3</u>		<u>1GM</u>	<u>A091664</u>	<u>002</u>	Jul 19, 2013
<u>AB3</u>	SUN PHARMA GLOBAL	<u>500MG</u>	<u>A202917</u>	<u>001</u>	Aug 01, 2016
<u>AB3</u>		<u>1GM</u>	<u>A202917</u>	<u>002</u>	Aug 01, 2016

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

ACTOPLUS MET

<u>AB</u>	TAKEDA PHARMS USA	<u>500MG;EQ 15MG BASE</u>	<u>N021842</u>	<u>001</u>	Aug 29, 2005
<u>AB</u>	+	<u>850MG;EQ 15MG BASE</u>	<u>N021842</u>	<u>002</u>	Aug 29, 2005

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>500MG;EQ 15MG BASE</u>	<u>A200823</u>	<u>001</u>	Feb 13, 2013
<u>AB</u>		<u>850MG;EQ 15MG BASE</u>	<u>A200823</u>	<u>002</u>	Feb 13, 2013
<u>AB</u>	MACLEODS PHARMS LTD	<u>500MG;EQ 15MG BASE</u>	<u>A204802</u>	<u>001</u>	Nov 05, 2015
<u>AB</u>		<u>850MG;EQ 15MG BASE</u>	<u>A204802</u>	<u>002</u>	Nov 05, 2015
<u>AB</u>	MYLAN	<u>500MG;EQ 15MG BASE</u>	<u>A090406</u>	<u>001</u>	Feb 25, 2011
<u>AB</u>		<u>850MG;EQ 15MG BASE</u>	<u>A090406</u>	<u>002</u>	Feb 25, 2011
<u>AB</u>	SANDOZ	<u>500MG;EQ 15MG BASE</u>	<u>A091273</u>	<u>001</u>	Apr 16, 2013
<u>AB</u>		<u>850MG;EQ 15MG BASE</u>	<u>A091273</u>	<u>002</u>	Apr 16, 2013
<u>AB</u>	TEVA PHARMS USA	<u>500MG;EQ 15MG BASE</u>	<u>A091155</u>	<u>001</u>	Mar 10, 2014
<u>AB</u>		<u>850MG;EQ 15MG BASE</u>	<u>A091155</u>	<u>002</u>	Mar 10, 2014
<u>AB</u>	TORRENT PHARMS LTD	<u>500MG;EQ 15MG BASE</u>	<u>A202001</u>	<u>001</u>	Feb 13, 2013
<u>AB</u>		<u>850MG;EQ 15MG BASE</u>	<u>A202001</u>	<u>002</u>	Feb 13, 2013

TABLET, EXTENDED RELEASE;ORAL

ACTOPLUS MET XR

	TAKEDA PHARMS USA	1GM;EQ 15MG BASE	N022024	001	May 12, 2009
	+	1GM;EQ 30MG BASE	N022024	002	May 12, 2009

METFORMIN HYDROCHLORIDE; REPAGLINIDE

TABLET;ORAL

PRANDIMET

<u>AB</u>	NOVO NORDISK INC	<u>500MG;1MG</u>	<u>N022386</u>	<u>001</u>	Jun 23, 2008
<u>AB</u>	+	<u>500MG;2MG</u>	<u>N022386</u>	<u>002</u>	Jun 23, 2008

REPAGLINIDE AND METFORMIN HYDROCHLORIDE

<u>AB</u>	LUPIN LTD	<u>500MG;1MG</u>	<u>A200624</u>	<u>001</u>	Jul 15, 2015
<u>AB</u>		<u>500MG;2MG</u>	<u>A200624</u>	<u>002</u>	Jul 15, 2015

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET;ORAL

ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE

	TEVA	500MG;EQ 2MG BASE	A077337	001	May 07, 2014
		500MG;EQ 4MG BASE	A077337	002	May 07, 2014
	+	1GM;EQ 4MG BASE	A077337	004	May 07, 2014
		1GM;EQ 2MG BASE	A077337	003	May 07, 2014

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

KOMBIGLYZE XR

	ASTRAZENECA AB	500MG;EQ 5MG BASE	N200678	001	Nov 05, 2010
		1GM;EQ 2.5MG BASE	N200678	003	Nov 05, 2010
	+	1GM;EQ 5MG BASE	N200678	002	Nov 05, 2010

PRESCRIPTION DRUG PRODUCT LIST

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUMET

MERCK SHARP DOHME	500MG;EQ 50MG BASE	N022044 001	Mar 30, 2007
+	1GM;EQ 50MG BASE	N022044 002	Mar 30, 2007

TABLET, EXTENDED RELEASE; ORAL

JANUMET XR

MERCK SHARP DOHME	500MG;EQ 50MG BASE	N202270 001	Feb 02, 2012
	1GM;EQ 50MG BASE	N202270 002	Feb 02, 2012
+	1GM;EQ 100MG BASE	N202270 003	Feb 02, 2012

METHACHOLINE CHLORIDE

FOR SOLUTION; INHALATION

PROVOCHOLINE

+	METHAPHARM	100MG/VIAL	N019193 001	Oct 31, 1986
		1600MG/VIAL	N019193 002	Aug 29, 2016

METHADONE HYDROCHLORIDE

CONCENTRATE; ORAL

METHADONE HYDROCHLORIDE

<u>AA</u>	VISTAPHARM	<u>10MG/ML</u>	<u>A040088 001</u>	Nov 30, 1994
<u>AA</u>	WEST-WARD PHARMS INT	<u>10MG/ML</u>	<u>A040180 001</u>	Apr 30, 1998

METHADONE HYDROCHLORIDE INTENSOL

<u>AA</u>	WEST-WARD PHARMS INT	<u>10MG/ML</u>	<u>A089897 001</u>	Sep 06, 1988
-----------	----------------------	----------------	--------------------	--------------

METHADOSE

<u>AA</u>	+	MALLINCKRODT	<u>10MG/ML</u>	<u>N017116 002</u>
-----------	---	--------------	----------------	--------------------

INJECTABLE; INJECTION

METHADONE HYDROCHLORIDE

+	MYLAN INSTITUTIONAL	10MG/ML	N021624 001
---	---------------------	---------	-------------

POWDER; FOR RX COMPOUNDING

METHADONE HYDROCHLORIDE

MALLINCKRODT	50GM/BOT	N006383 002
	100GM/BOT	N006383 003
	500GM/BOT	N006383 004

SOLUTION; ORAL

METHADONE HYDROCHLORIDE

<u>AA</u>	VISTAPHARM	<u>5MG/5ML</u>	<u>A090707 001</u>	Jun 30, 2010	
<u>AA</u>		<u>10MG/5ML</u>	<u>A090707 002</u>	Jun 30, 2010	
<u>AA</u>	+	WEST-WARD PHARMS INT	<u>5MG/5ML</u>	<u>A087393 001</u>	
<u>AA</u>	+		<u>10MG/5ML</u>	<u>A087997 001</u>	Aug 30, 1982

TABLET; ORAL

DOLOPHINE HYDROCHLORIDE

<u>AA</u>	+	ROXANE	<u>5MG</u>	<u>N006134 002</u>
<u>AA</u>	+		<u>10MG</u>	<u>N006134 010</u>

METHADONE HYDROCHLORIDE

<u>AA</u>	AUROLIFE PHARMA LLC	<u>5MG</u>	<u>A203502 001</u>	Aug 31, 2015
<u>AA</u>		<u>10MG</u>	<u>A203502 002</u>	Aug 31, 2015
<u>AA</u>	COREPHARMA	<u>5MG</u>	<u>A090065 001</u>	Aug 18, 2015
<u>AA</u>		<u>10MG</u>	<u>A090065 002</u>	Aug 18, 2015
<u>AA</u>	MALLINCKRODT	<u>5MG</u>	<u>A040517 001</u>	Apr 27, 2004
<u>AA</u>		<u>10MG</u>	<u>A040517 002</u>	Apr 27, 2004
<u>AA</u>	SANDOZ	<u>10MG</u>	<u>A040241 002</u>	May 29, 1998
<u>AA</u>	THE PHARMANETWORK	<u>10MG</u>	<u>A090635 001</u>	Nov 25, 2009

METHADOSE

<u>AA</u>	MALLINCKRODT	<u>5MG</u>	<u>A040050 001</u>	Apr 15, 1993
<u>AA</u>		<u>10MG</u>	<u>A040050 002</u>	Apr 15, 1993

TABLET, FOR SUSPENSION; ORAL

METHADONE HYDROCHLORIDE

<u>AA</u>	MALLINCKRODT INC	<u>40MG</u>	<u>A077142 001</u>	Jul 12, 2005
<u>AA</u>	+	ROXANE	<u>40MG</u>	<u>N017058 001</u>
<u>AA</u>	SANDOZ	<u>40MG</u>	<u>A075082 001</u>	Mar 25, 1998

METHADOSE

<u>AA</u>	MALLINCKRODT INC	<u>40MG</u>	<u>A074184 001</u>	Apr 29, 1993
-----------	------------------	-------------	--------------------	--------------

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

DESOXYN

<u>AA</u>	+	RECORDATI RARE	<u>5MG</u>	<u>N005378 002</u>
-----------	---	----------------	------------	--------------------

METHAMPHETAMINE HYDROCHLORIDE

<u>AA</u>	MAYNE PHARMA INC	<u>5MG</u>	<u>A091189 001</u>	Apr 21, 2010
<u>AA</u>	WEST-WARD PHARMS INT	<u>5MG</u>	<u>A203846 001</u>	Nov 17, 2015

PRESCRIPTION DRUG PRODUCT LIST

METHAZOLAMIDE

TABLET; ORAL

METHAZOLAMIDE

<u>AB</u>	ANI PHARMS INC	<u>25MG</u>	<u>A040001</u>	<u>001</u>	Jun 30, 1993
<u>AB</u>		<u>50MG</u>	<u>A040001</u>	<u>002</u>	Jun 30, 1993
<u>AB</u>	MIKART	<u>25MG</u>	<u>A040062</u>	<u>001</u>	Jan 27, 1994
<u>AB</u>	+	<u>50MG</u>	<u>A040062</u>	<u>002</u>	Jan 27, 1994
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A040036</u>	<u>001</u>	Jun 30, 1993
<u>AB</u>		<u>50MG</u>	<u>A040036</u>	<u>002</u>	Jun 30, 1993

METHENAMINE HIPPURATE

TABLET; ORAL

HIPREX

<u>AB</u>	+	US PHARM HOLDINGS	<u>1GM</u>	<u>N017681</u>	<u>001</u>
-----------	---	-------------------	------------	----------------	------------

METHENAMINE HIPPURATE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>1GM</u>	<u>A205661</u>	<u>001</u>	Jul 05, 2016
<u>AB</u>	COREPHARMA	<u>1GM</u>	<u>A076411</u>	<u>001</u>	Jun 20, 2003

UREX

<u>AB</u>	CNTY LINE PHARMS	<u>1GM</u>	<u>N016151</u>	<u>001</u>	
-----------	------------------	------------	----------------	------------	--

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

<u>AB</u>	ECI PHARMS LLC	<u>5MG</u>	<u>A040547</u>	<u>001</u>	Feb 18, 2005
<u>AB</u>		<u>10MG</u>	<u>A040547</u>	<u>002</u>	Feb 18, 2005
<u>AB</u>	HERITAGE PHARMA	<u>5MG</u>	<u>A040734</u>	<u>001</u>	Dec 14, 2007
<u>AB</u>		<u>10MG</u>	<u>A040734</u>	<u>002</u>	Dec 14, 2007
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A040350</u>	<u>001</u>	Mar 29, 2000
<u>AB</u>	+	<u>10MG</u>	<u>A040350</u>	<u>002</u>	Mar 29, 2000
<u>AB</u>	RISING PHARMS INC	<u>5MG</u>	<u>A202068</u>	<u>001</u>	Mar 07, 2012
<u>AB</u>		<u>10MG</u>	<u>A202068</u>	<u>002</u>	Mar 07, 2012
<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A040411</u>	<u>001</u>	Mar 27, 2001
<u>AB</u>		<u>10MG</u>	<u>A040411</u>	<u>002</u>	Mar 27, 2001
<u>AB</u>	SUN PHARM INDS INC	<u>5MG</u>	<u>A040870</u>	<u>001</u>	Sep 25, 2007
<u>AB</u>		<u>10MG</u>	<u>A040870</u>	<u>002</u>	Sep 25, 2007

TAPAZOLE

<u>AB</u>	KING PHARMS	<u>5MG</u>	<u>A040320</u>	<u>001</u>	Mar 31, 2000
<u>AB</u>		<u>10MG</u>	<u>A040320</u>	<u>002</u>	Mar 31, 2000

METHOCARBAMOL

SOLUTION; IM-IV

METHOCARBAMOL

<u>AP</u>	AUROBINDO PHARMA LTD	<u>1GM/10ML (100MG/ML)</u>	<u>A206128</u>	<u>001</u>	May 27, 2016
<u>AP</u>	MONTEREY PHARMS LLC	<u>1GM/10ML (100MG/ML)</u>	<u>A205354</u>	<u>001</u>	Oct 27, 2016
<u>AP</u>	MYLAN INSTITUTIONAL	<u>1GM/10ML (100MG/ML)</u>	<u>A204404</u>	<u>001</u>	Dec 05, 2014

ROBAXIN

<u>AP</u>	+	WEST-WARD PHARMS INT	<u>1GM/10ML (100MG/ML)</u>	<u>N011790</u>	<u>001</u>
-----------	---	----------------------	----------------------------	----------------	------------

TABLET; ORAL

METHOCARBAMOL

<u>AA</u>	AUSTARPHARMA LLC	<u>500MG</u>	<u>A200958</u>	<u>001</u>	Oct 21, 2011
<u>AA</u>		<u>750MG</u>	<u>A200958</u>	<u>002</u>	Oct 21, 2011
<u>AA</u>	HETERO LABS LTD III	<u>500MG</u>	<u>A090200</u>	<u>001</u>	Nov 06, 2009
<u>AA</u>		<u>750MG</u>	<u>A090200</u>	<u>002</u>	Nov 06, 2009
<u>AA</u>	HIKMA INTL PHARMS	<u>500MG</u>	<u>A085159</u>	<u>001</u>	
<u>AA</u>		<u>750MG</u>	<u>A085123</u>	<u>001</u>	
<u>AA</u>	PRINSTON INC	<u>500MG</u>	<u>A086989</u>	<u>001</u>	
<u>AA</u>		<u>750MG</u>	<u>A086988</u>	<u>001</u>	
<u>AA</u>	VINTAGE PHARMS	<u>500MG</u>	<u>A040489</u>	<u>001</u>	Jan 29, 2003
<u>AA</u>		<u>750MG</u>	<u>A040489</u>	<u>002</u>	Jan 29, 2003
<u>AA</u>	WATSON LABS	<u>500MG</u>	<u>A084277</u>	<u>001</u>	
<u>AA</u>		<u>750MG</u>	<u>A084276</u>	<u>002</u>	

ROBAXIN

<u>AA</u>	+	AUXILIUM PHARMS LLC	<u>500MG</u>	<u>N011011</u>	<u>004</u>
-----------	---	---------------------	--------------	----------------	------------

ROBAXIN-750

<u>AA</u>	+	AUXILIUM PHARMS LLC	<u>750MG</u>	<u>N011011</u>	<u>006</u>
-----------	---	---------------------	--------------	----------------	------------

METHOHEXITAL SODIUM

INJECTABLE; INJECTION

BREVITAL SODIUM

+	PAR STERILE PRODUCTS	500MG/VIAL	N011559	001	
+		2.5GM/VIAL	N011559	002	

PRESCRIPTION DRUG PRODUCT LIST

METHOTREXATE

SOLUTION; SUBCUTANEOUS

OTREXUP

ANTARES PHARMA INC

10MG/0.4ML (10MG/0.4ML)
 12.5MG/0.4ML (12.5MG/0.4ML)
 15MG/0.4ML (15MG/0.4ML)
 17.5MG/0.4ML (17.5MG/0.4ML)
 20MG/0.4ML (20MG/0.4ML)
 22.5MG/0.4ML (22.5MG/0.4ML)
 25MG/0.4ML (25MG/0.4ML)

N204824 001 Oct 11, 2013
 N204824 006 Mar 24, 2016
 N204824 002 Oct 11, 2013
 N204824 007 Mar 24, 2016
 N204824 003 Oct 11, 2013
 N204824 008 Mar 24, 2016
 N204824 004 Oct 11, 2013

+

RASUVO

MEDAC PHARMA INC

7.5MG/0.15ML (7.5MG/0.15ML)
 10MG/0.20ML (10MG/0.20ML)
 12.5MG/0.25ML (12.5MG/0.25ML)
 15MG/0.30ML (15MG/0.30ML)
 17.5MG/0.35ML (17.5MG/0.35ML)
 20MG/0.4ML (20MG/0.4ML)
 22.5MG/0.45ML (22.5MG/0.45ML)
 25MG/0.5ML (25MG/0.5ML)
 27.5MG/0.55ML (27.5MG/0.55ML)
 30MG/0.6ML (30MG/0.6ML)

N205776 001 Jul 10, 2014
 N205776 002 Jul 10, 2014
 N205776 003 Jul 10, 2014
 N205776 004 Jul 10, 2014
 N205776 005 Jul 10, 2014
 N205776 006 Jul 10, 2014
 N205776 007 Jul 10, 2014
 N205776 008 Jul 10, 2014
 N205776 009 Jul 10, 2014
 N205776 010 Jul 10, 2014

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE PRESERVATIVE FREE

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 25MG BASE/ML</u>	<u>A040265 001</u>	Feb 26, 1999
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A040266 001</u>	Feb 26, 1999
<u>AP</u>	PHARMACHEMIE BV	<u>EQ 100MG BASE/4ML (EQ 25MG BASE/ML)</u>	<u>A200171 001</u>	Feb 27, 2012

METHOTREXATE SODIUM

<u>AP</u>	+	FRESENIUS KABI USA	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A040263 001</u>	Feb 26, 1999
<u>AP</u>	+		<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A040263 002</u>	Feb 26, 1999
<u>AP</u>	+	HOSPIRA	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>N011719 010</u>	Dec 15, 2004
<u>AP</u>	+	WEST-WARD PHARMS INT	<u>EQ 100MG BASE/4ML (EQ 25MG BASE/ML)</u>	<u>A089341 001</u>	Sep 16, 1986

METHOTREXATE SODIUM PRESERVATIVE FREE

<u>AP</u>	+	ACCORD HLTHCARE	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A040767 001</u>	Apr 30, 2007
<u>AP</u>	+		<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A040768 001</u>	Apr 30, 2007
<u>AP</u>	+		<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A040716 001</u>	Apr 30, 2007
<u>AP</u>	+	HOSPIRA	<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>N011719 012</u>	Apr 13, 2005
<u>AP</u>		MYLAN LABS LTD	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A201529 001</u>	Mar 29, 2012
<u>AP</u>			<u>EQ 100MG BASE/4ML (EQ 25MG BASE/ML)</u>	<u>A201529 002</u>	Mar 29, 2012
<u>AP</u>			<u>EQ 200MG BASE/8ML (EQ 25MG BASE/ML)</u>	<u>A201529 003</u>	Mar 29, 2012
<u>AP</u>			<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A201529 004</u>	Mar 29, 2012
<u>AP</u>			<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A201530 001</u>	Mar 29, 2012
<u>AP</u>		PHARMACHEMIE BV	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A040850 001</u>	Jan 11, 2010
<u>AP</u>			<u>EQ 250MG/10ML (EQ 25MG BASE/ML)</u>	<u>A040853 001</u>	Jan 11, 2010
<u>AP</u>			<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A040843 001</u>	Jan 11, 2010
<u>AP</u>		SANDOZ INC	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A090039 001</u>	Mar 31, 2009
<u>AP</u>			<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A090039 002</u>	Mar 31, 2009
<u>AP</u>			<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A090029 001</u>	Mar 31, 2009
<u>AP</u>	+	WEST-WARD PHARMS INT	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A089340 001</u>	Sep 16, 1986
<u>AP</u>	+		<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A089343 001</u>	Sep 16, 1986

METHOTREXATE SODIUM

+ WEST-WARD PHARMS INT

EQ 200MG BASE/8ML (EQ 25MG BASE/ML)

A089342 001 Sep 16, 1986

METHOTREXATE SODIUM PRESERVATIVE FREE

+ WEST-WARD PHARMS INT

EQ 1GM BASE/VIAL

A040632 001 Aug 12, 2005

TABLET; ORAL

METHOTREXATE SODIUM

<u>AB</u>	BARR	<u>EQ 2.5MG BASE</u>	<u>A081099 001</u>	Oct 15, 1990
<u>AB</u>	+	DAVA PHARMS INC	<u>EQ 2.5MG BASE</u>	<u>N008085 002</u>
<u>AB</u>	HQ SPCLT PHARMA	<u>EQ 2.5MG BASE</u>	<u>A201749 001</u>	May 21, 2015
<u>AB</u>	MYLAN	<u>EQ 2.5MG BASE</u>	<u>A081235 001</u>	May 15, 1992
<u>AB</u>	WEST-WARD PHARMS INT	<u>EQ 2.5MG BASE</u>	<u>A040054 001</u>	Aug 01, 1994

TREXALL

BARR

EQ 5MG BASE
 EQ 7.5MG BASE
 EQ 10MG BASE
 EQ 15MG BASE

A040385 001 Mar 21, 2001
 A040385 002 Mar 21, 2001
 A040385 003 Mar 21, 2001
 A040385 004 Mar 21, 2001

+

PRESCRIPTION DRUG PRODUCT LIST

METHOXSALEN

CAPSULE; ORAL

METHOXSALEN

AB	ACTAVIS INC	10MG	A202603 001	Jun 09, 2015
AB	STRIDES PHARMA	10MG	A202687 001	Jun 05, 2014
<u>OXSORALEN-ULTRA</u>				
AB	+ DOW PHARM	10MG	N019600 001	Oct 30, 1986
	8-MOP			
	+ VALEANT PHARM INTL	10MG	N009048 001	
INJECTABLE; INJECTION				
	UVADEX			
	+ MALLINCKRODT HOSP	0.02MG/ML	N020969 001	Feb 25, 1999
LOTION; TOPICAL				
	OXSORALEN			
	+ VALEANT PHARM INTL	1%	N009048 002	

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

METHSCOPOLAMINE BROMIDE

AA	BAYSHORE PHARMS LLC	2.5MG	A200602 001	Sep 24, 2012
AA		5MG	A200602 002	Sep 24, 2012
AA	BRECKENRIDGE PHARM	2.5MG	A040642 001	Dec 06, 2011
AA		5MG	A040642 002	Dec 06, 2011
AA	+ VINTAGE PHARMS	2.5MG	A040624 001	Dec 28, 2006
AA	+	5MG	A040624 002	Dec 28, 2006

METHSUXIMIDE

CAPSULE; ORAL

CELONTIN

PARKE DAVIS

+

150MG

N010596 007

300MG

N010596 008

METHYLCLOTHIAZIDE

TABLET; ORAL

METHYLCLOTHIAZIDE

+ MYLAN PHARMS INC

5MG

A087672 001 Aug 17, 1982

METHYLDOPA

TABLET; ORAL

METHYLDOPA

AB	ACCORD HLTHCARE	250MG	A070084 001	Oct 15, 1985
AB		500MG	A070085 001	Oct 15, 1985
AB	IVAX SUB TEVA PHARMS	250MG	A070098 001	Feb 20, 1986
AB		500MG	A070343 001	Feb 20, 1986
AB	MYLAN	250MG	A070076 002	Apr 18, 1985
AB	+	500MG	A070076 001	Apr 18, 1985
AB	WATSON LABS	500MG	A070625 001	Jun 06, 1986

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

METHYLDOPATE HYDROCHLORIDE

AP	+ LUITPOLD	50MG/ML	A071279 001	Oct 02, 1987
-----------	------------	----------------	--------------------	--------------

METHYLENE BLUE

SOLUTION; INTRAVENOUS

PROVAYBLUE

+ PROVEPHARM SAS

50MG/10ML (5MG/ML)

N204630 001 Apr 08, 2016

METHYLERGONOVINE MALEATE

INJECTABLE; INJECTION

METHERGINE

AP	+ EDISON THERAPS LLC	0.2MG/ML	N006035 004	
<u>METHYLERGONOVINE MALEATE</u>				
AP	ERGOJECT	0.2MG/ML	A040889 001	Sep 13, 2010
AP	LUITPOLD	0.2MG/ML	A090193 001	Nov 24, 2008

TABLET; ORAL

METHYLERGONOVINE MALEATE

+ NOVEL LABS INC

0.2MG

A091577 001 May 02, 2011

METHYLNALTREXONE BROMIDE

SOLUTION; SUBCUTANEOUS

RELISTOR

+ SALIX PHARMS

8MG/0.4ML (8MG/0.4ML)

N021964 002 Sep 27, 2010

+

12MG/0.6ML (12MG/0.6ML)

N021964 001 Apr 24, 2008

+

12MG/0.6ML (12MG/0.6ML)

N021964 003 Sep 27, 2010

PRESCRIPTION DRUG PRODUCT LIST

METHYLNALTREXONE BROMIDE

TABLET;ORAL

RELISTOR

+ SALIX PHARMS INC 150MG N208271 001 Jul 19, 2016

METHYLPHENIDATE

FILM, EXTENDED RELEASE;TRANSDERMAL

DAYTRANA

NOVEN PHARMS INC 10MG/9HR (1.1MG/HR) N021514 001 Apr 06, 2006
15MG/9HR (1.6MG/HR) N021514 002 Apr 06, 2006
20MG/9HR (2.2MG/HR) N021514 003 Apr 06, 2006
+ 30MG/9HR (3.3MG/HR) N021514 004 Apr 06, 2006METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

<u>AB1</u>	BARR LABS INC	<u>10MG</u>	<u>A079031 004</u>	Oct 15, 2014
<u>AB1</u>		<u>20MG</u>	<u>A079031 001</u>	Jul 13, 2012
<u>AB1</u>		<u>30MG</u>	<u>A079031 002</u>	Jul 13, 2012
<u>AB1</u>		<u>40MG</u>	<u>A079031 003</u>	Jul 13, 2012
<u>AB1</u>	MAYNE PHARMA	<u>20MG</u>	<u>A078458 001</u>	Dec 01, 2011
<u>AB1</u>		<u>30MG</u>	<u>A078458 002</u>	Dec 01, 2011
<u>AB1</u>		<u>40MG</u>	<u>A078458 003</u>	Dec 01, 2011
<u>AB1</u>		<u>60MG</u>	<u>A078458 004</u>	Jun 23, 2016

RITALIN LA

<u>AB1</u>	NOVARTIS	<u>10MG</u>	<u>N021284 004</u>	Apr 10, 2004
<u>AB1</u>		<u>20MG</u>	<u>N021284 001</u>	Jun 05, 2002
<u>AB1</u>		<u>30MG</u>	<u>N021284 002</u>	Jun 05, 2002
<u>AB1</u>		<u>40MG</u>	<u>N021284 003</u>	Jun 05, 2002
<u>AB1</u>	+	<u>60MG</u>	<u>N021284 005</u>	Oct 27, 2014

METADATE CD

<u>AB2</u>	UCB INC	<u>10MG</u>	<u>N021259 003</u>	May 27, 2003
<u>AB2</u>		<u>20MG</u>	<u>N021259 001</u>	Apr 03, 2001
<u>AB2</u>		<u>30MG</u>	<u>N021259 002</u>	Jun 19, 2003
<u>AB2</u>		<u>40MG</u>	<u>N021259 004</u>	Feb 19, 2006
<u>AB2</u>		<u>50MG</u>	<u>N021259 005</u>	Feb 19, 2006
<u>AB2</u>	+	<u>60MG</u>	<u>N021259 006</u>	Feb 19, 2006

METHYLPHENIDATE HYDROCHLORIDE

<u>AB2</u>	COREPHARMA	<u>10MG</u>	<u>A205105 001</u>	Jul 28, 2016
<u>AB2</u>		<u>20MG</u>	<u>A205105 002</u>	Jul 28, 2016
<u>AB2</u>		<u>30MG</u>	<u>A205105 003</u>	Jul 28, 2016
<u>AB2</u>		<u>40MG</u>	<u>A205105 004</u>	Jul 28, 2016
<u>AB2</u>		<u>50MG</u>	<u>A205105 005</u>	Jul 28, 2016
<u>AB2</u>		<u>60MG</u>	<u>A205105 006</u>	Jul 28, 2016
<u>AB2</u>	MALLINCKRODT INC	<u>10MG</u>	<u>A203583 001</u>	Sep 29, 2015
<u>AB2</u>		<u>20MG</u>	<u>A203583 002</u>	Sep 29, 2015
<u>AB2</u>		<u>30MG</u>	<u>A203583 003</u>	Sep 29, 2015
<u>AB2</u>		<u>40MG</u>	<u>A203583 004</u>	Sep 29, 2015
<u>AB2</u>		<u>50MG</u>	<u>A203583 005</u>	Sep 29, 2015
<u>AB2</u>		<u>60MG</u>	<u>A203583 006</u>	Sep 29, 2015
<u>AB2</u>	TEVA PHARMS	<u>10MG</u>	<u>A077707 001</u>	Jul 19, 2012
<u>AB2</u>		<u>20MG</u>	<u>A077707 002</u>	Jul 19, 2012
<u>AB2</u>		<u>30MG</u>	<u>A077707 003</u>	Jul 19, 2012
<u>AB2</u>		<u>40MG</u>	<u>A078873 001</u>	Jul 19, 2012
<u>AB2</u>		<u>50MG</u>	<u>A078873 002</u>	Jul 19, 2012
<u>AB2</u>		<u>60MG</u>	<u>A078873 003</u>	Jul 19, 2012

APTENSIO XR

	RHODES PHARMS	10MG	N205831 001	Apr 17, 2015
		15MG	N205831 002	Apr 17, 2015
		20MG	N205831 003	Apr 17, 2015
		30MG	N205831 004	Apr 17, 2015
		40MG	N205831 005	Apr 17, 2015
		50MG	N205831 006	Apr 17, 2015
	+	60MG	N205831 007	Apr 17, 2015

FOR SUSPENSION, EXTENDED RELEASE;ORAL

QUILLIVANT XR

+ NEXTWAVE PHARMS 5MG/ML N202100 001 Sep 27, 2012

SOLUTION;ORAL

METHYLIN

<u>AA</u>	+	MALLINCKRODT	<u>5MG/5ML</u>	<u>N021419 001</u>	Dec 19, 2002
<u>AA</u>	+		<u>10MG/5ML</u>	<u>N021419 002</u>	Dec 19, 2002

METHYLPHENIDATE HYDROCHLORIDE

<u>AA</u>	ABHAI	<u>5MG/5ML</u>	<u>A207485 001</u>	Nov 18, 2016
-----------	-------	----------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

METHYLPHENIDATE HYDROCHLORIDE

SOLUTION;ORAL

METHYLPHENIDATE HYDROCHLORIDE

<u>AA</u>		<u>10MG/5ML</u>	<u>A207485</u>	<u>002</u>	Nov 18, 2016
<u>AA</u>	NOSTRUM LABS INC	<u>5MG/5ML</u>	<u>A201466</u>	<u>001</u>	Nov 12, 2013
<u>AA</u>		<u>10MG/5ML</u>	<u>A201466</u>	<u>002</u>	Nov 12, 2013
<u>AA</u>	NOVEL LABS INC	<u>5MG/5ML</u>	<u>A204602</u>	<u>001</u>	Aug 14, 2015
<u>AA</u>		<u>10MG/5ML</u>	<u>A204602</u>	<u>002</u>	Aug 14, 2015
<u>AA</u>	TRIS PHARMA INC	<u>5MG/5ML</u>	<u>A091601</u>	<u>001</u>	Jul 23, 2010
<u>AA</u>		<u>10MG/5ML</u>	<u>A091601</u>	<u>002</u>	Jul 23, 2010

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>	ACTAVIS LABS FL INC	<u>5MG</u>	<u>A040220</u>	<u>001</u>	Aug 29, 1997
<u>AB</u>		<u>10MG</u>	<u>A040220</u>	<u>002</u>	Aug 29, 1997
<u>AB</u>		<u>20MG</u>	<u>A040220</u>	<u>003</u>	Aug 29, 1997
<u>AB</u>	ASCENT PHARMS INC	<u>5MG</u>	<u>A207416</u>	<u>001</u>	Sep 22, 2015
<u>AB</u>		<u>10MG</u>	<u>A207416</u>	<u>002</u>	Sep 22, 2015
<u>AB</u>		<u>20MG</u>	<u>A207416</u>	<u>003</u>	Sep 22, 2015
<u>AB</u>	CNTY LINE PHARMS	<u>5MG</u>	<u>A206840</u>	<u>001</u>	Sep 15, 2016
<u>AB</u>		<u>10MG</u>	<u>A206840</u>	<u>002</u>	Sep 15, 2016
<u>AB</u>		<u>20MG</u>	<u>A206840</u>	<u>003</u>	Sep 15, 2016
<u>AB</u>	COREPHARMA	<u>5MG</u>	<u>A091159</u>	<u>001</u>	Mar 12, 2014
<u>AB</u>		<u>10MG</u>	<u>A091159</u>	<u>002</u>	Mar 12, 2014
<u>AB</u>		<u>20MG</u>	<u>A091159</u>	<u>003</u>	Mar 12, 2014
<u>AB</u>	MALLINCKRODT	<u>5MG</u>	<u>A040300</u>	<u>001</u>	Nov 27, 1998
<u>AB</u>		<u>10MG</u>	<u>A040300</u>	<u>002</u>	Nov 27, 1998
<u>AB</u>		<u>20MG</u>	<u>A040300</u>	<u>003</u>	Nov 27, 1998
<u>AB</u>	NOVEL LABS INC	<u>5MG</u>	<u>A207884</u>	<u>001</u>	Nov 13, 2015
<u>AB</u>		<u>10MG</u>	<u>A207884</u>	<u>002</u>	Nov 13, 2015
<u>AB</u>		<u>20MG</u>	<u>A207884</u>	<u>003</u>	Nov 13, 2015
<u>AB</u>	SUN PHARM INDS INC	<u>5MG</u>	<u>A090710</u>	<u>001</u>	Mar 15, 2012
<u>AB</u>		<u>10MG</u>	<u>A090710</u>	<u>002</u>	Mar 15, 2012
<u>AB</u>		<u>20MG</u>	<u>A090710</u>	<u>003</u>	Mar 15, 2012
<u>AB</u>	UCB INC	<u>5MG</u>	<u>A086429</u>	<u>001</u>	
<u>AB</u>		<u>10MG</u>	<u>A085799</u>	<u>001</u>	
<u>AB</u>		<u>20MG</u>	<u>A086428</u>	<u>001</u>	
<u>AB</u>	VINTAGE PHARMS	<u>5MG</u>	<u>A202892</u>	<u>001</u>	Sep 23, 2014
<u>AB</u>		<u>10MG</u>	<u>A202892</u>	<u>002</u>	Sep 23, 2014
<u>AB</u>		<u>20MG</u>	<u>A202892</u>	<u>003</u>	Sep 23, 2014
<u>RITALIN</u>					
<u>AB</u>	NOVARTIS	<u>5MG</u>	<u>N010187</u>	<u>003</u>	
<u>AB</u>		<u>10MG</u>	<u>N010187</u>	<u>006</u>	
<u>AB</u>	+	<u>20MG</u>	<u>N010187</u>	<u>010</u>	

TABLET, CHEWABLE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>	NOVEL LABS INC	<u>2.5MG</u>	<u>A204115</u>	<u>001</u>	Feb 25, 2015
<u>AB</u>		<u>5MG</u>	<u>A204115</u>	<u>002</u>	Feb 25, 2015
<u>AB</u>	+	<u>10MG</u>	<u>A204115</u>	<u>003</u>	Feb 25, 2015
<u>AB</u>	TEDOR PHARMA INC	<u>2.5MG</u>	<u>A205756</u>	<u>001</u>	Nov 07, 2016
<u>AB</u>		<u>5MG</u>	<u>A205756</u>	<u>002</u>	Nov 07, 2016
<u>AB</u>		<u>10MG</u>	<u>A205756</u>	<u>003</u>	Nov 07, 2016

TABLET, EXTENDED RELEASE;ORAL

CONCERTA

<u>AB</u>	JANSSEN PHARMS	<u>18MG</u>	<u>N021121</u>	<u>001</u>	Aug 01, 2000
<u>AB</u>		<u>27MG</u>	<u>N021121</u>	<u>004</u>	Apr 01, 2002
<u>AB</u>		<u>36MG</u>	<u>N021121</u>	<u>002</u>	Aug 01, 2000
<u>AB</u>	+	<u>54MG</u>	<u>N021121</u>	<u>003</u>	Dec 08, 2000

METADATE ER

<u>AB</u>	+	<u>20MG</u>	<u>A089601</u>	<u>001</u>	Jun 01, 1988
-----------	---	-------------	----------------	------------	--------------

METHYLIN ER

<u>AB</u>	MALLINCKRODT INC	<u>10MG</u>	<u>A075629</u>	<u>001</u>	May 09, 2000
<u>AB</u>		<u>20MG</u>	<u>A075629</u>	<u>002</u>	May 09, 2000

METHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>	ABHAI	<u>10MG</u>	<u>A207488</u>	<u>001</u>	Jun 09, 2015
<u>AB</u>		<u>20MG</u>	<u>A207488</u>	<u>002</u>	Jun 09, 2015
<u>AB</u>	CNTY LINE PHARMS	<u>10MG</u>	<u>A204772</u>	<u>001</u>	Feb 29, 2016
<u>AB</u>		<u>20MG</u>	<u>A204772</u>	<u>002</u>	Feb 29, 2016
<u>AB</u>	MYLAN PHARMS INC	<u>18MG</u>	<u>A206726</u>	<u>001</u>	Oct 21, 2016
<u>AB</u>		<u>27MG</u>	<u>A206726</u>	<u>002</u>	Oct 21, 2016
<u>AB</u>		<u>36MG</u>	<u>A206726</u>	<u>003</u>	Oct 21, 2016
<u>AB</u>		<u>54MG</u>	<u>A206726</u>	<u>004</u>	Oct 21, 2016

PRESCRIPTION DRUG PRODUCT LIST

METHYLPHENIDATE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

RITALIN-SR

AB	NOVARTIS	20MG	<u>N018029</u>	<u>001</u>	Mar 30, 1982
	METHYLPHENIDATE HYDROCHLORIDE				
BX	KREMERS URBAN PHARMS	18MG	A091695	001	Jul 09, 2013
BX		27MG	A091695	002	Jul 09, 2013
BX		36MG	A091695	003	Sep 23, 2013
BX		54MG	A091695	004	Sep 23, 2013
BX	MALLINCKRODT INC	27MG	A202608	001	Dec 28, 2012
BX		36MG	A202608	002	Dec 28, 2012
BX		54MG	A202608	003	Dec 28, 2012
	TABLET, EXTENDED RELEASE, CHEWABLE;ORAL				
	QUILLICHEW ER				
	PFIZER INC	20MG	N207960	001	Dec 04, 2015
		30MG	N207960	002	Dec 04, 2015
	+	40MG	N207960	003	Dec 04, 2015

METHYLPREDNISOLONE

TABLET;ORAL

MEDROL

AB	PHARMACIA AND UPJOHN	2MG	<u>N011153</u>	<u>002</u>	
AB		4MG	<u>N011153</u>	<u>001</u>	
AB		8MG	<u>N011153</u>	<u>004</u>	
AB		16MG	<u>N011153</u>	<u>003</u>	
AB	+	32MG	<u>N011153</u>	<u>006</u>	
	<u>METHYLPREDNISOLONE</u>				
AB	DURAMED PHARMS BARR	4MG	<u>A088497</u>	<u>001</u>	Feb 21, 1984
AB	JUBILANT CADISTA	4MG	<u>A040189</u>	<u>001</u>	Oct 31, 1997
AB		8MG	<u>A040189</u>	<u>002</u>	Oct 31, 1997
AB		16MG	<u>A040189</u>	<u>003</u>	Jul 20, 2007
AB		32MG	<u>A040189</u>	<u>004</u>	Jul 20, 2007
AB	SANDOZ	4MG	<u>A040194</u>	<u>001</u>	Oct 31, 1997
AB	VINTAGE PHARMS	4MG	<u>A040183</u>	<u>001</u>	Dec 22, 1998
AB	WATSON LABS	4MG	<u>A040232</u>	<u>001</u>	Oct 16, 1997

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

DEPO-MEDROL

AB	+	PHARMACIA AND UPJOHN	40MG/ML	<u>N011757</u>	<u>001</u>	
AB	+		80MG/ML	<u>N011757</u>	<u>004</u>	
		<u>METHYLPREDNISOLONE ACETATE</u>				
AB		SANDOZ	40MG/ML	<u>A040719</u>	<u>001</u>	Jan 29, 2009
AB			40MG/ML	<u>A040794</u>	<u>001</u>	Mar 05, 2009
AB			80MG/ML	<u>A040719</u>	<u>002</u>	Jan 29, 2009
AB			80MG/ML	<u>A040794</u>	<u>002</u>	Mar 05, 2009
AB		TEVA PHARMS USA	40MG/ML	<u>A040557</u>	<u>001</u>	Feb 23, 2005
AB			40MG/ML	<u>A040620</u>	<u>001</u>	Oct 27, 2006
AB			80MG/ML	<u>A040557</u>	<u>002</u>	Feb 23, 2005
AB			80MG/ML	<u>A040620</u>	<u>002</u>	Oct 27, 2006
	DEPO-MEDROL					
	+	PHARMACIA AND UPJOHN	20MG/ML	N011757	002	

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

AP	HOSPIRA	EQ 40MG BASE/VIAL	<u>A040664</u>	<u>001</u>	Dec 20, 2005
AP		EQ 125MG BASE/VIAL	<u>A040665</u>	<u>001</u>	Dec 20, 2005
AP	HOSPIRA INC	EQ 40MG BASE/VIAL	<u>A040793</u>	<u>001</u>	Nov 25, 2008
AP		EQ 125MG BASE/VIAL	<u>A040827</u>	<u>001</u>	Nov 25, 2008
	<u>METHYLPREDNISOLONE SODIUM SUCCINATE</u>				
AP	AMNEAL PHARMS CO	EQ 40MG BASE/VIAL	<u>A207549</u>	<u>001</u>	Nov 09, 2016
AP		EQ 125MG BASE/VIAL	<u>A207549</u>	<u>002</u>	Nov 09, 2016
AP	AUROBINDO PHARMA LTD	EQ 40MG BASE/VIAL	<u>A207667</u>	<u>001</u>	Dec 15, 2015
AP		EQ 125MG BASE/VIAL	<u>A207667</u>	<u>002</u>	Dec 15, 2015
AP		EQ 500MG BASE/VIAL	<u>A207667</u>	<u>003</u>	Dec 15, 2015
AP		EQ 2GM BASE/VIAL	<u>A207667</u>	<u>004</u>	Dec 15, 2015
AP	FRESENIUS KABI USA	EQ 40MG BASE/VIAL	<u>A040583</u>	<u>001</u>	Jul 30, 2004
AP		EQ 125MG BASE/VIAL	<u>A040583</u>	<u>002</u>	Jul 30, 2004
AP		EQ 1GM BASE/VIAL	<u>A040612</u>	<u>001</u>	Aug 12, 2004
AP	HIKMA FARMACEUTICA	EQ 500MG BASE/VIAL	<u>A202691</u>	<u>001</u>	Feb 16, 2016
AP		EQ 1GM BASE/VIAL	<u>A202691</u>	<u>002</u>	Feb 16, 2016
AP	SAGENT PHARMS	EQ 40MG BASE/VIAL	<u>A040888</u>	<u>001</u>	Jul 18, 2011
AP		EQ 125MG BASE/VIAL	<u>A040888</u>	<u>002</u>	Jul 18, 2011

PRESCRIPTION DRUG PRODUCT LIST

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A040888 003</u>	Jul 18, 2011
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A040888 004</u>	Jul 18, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A040888 005</u>	Jul 18, 2011

SOLU-MEDROL

<u>AP</u>	+	PHARMACIA AND UPJOHN	<u>EQ 40MG BASE/VIAL</u>	<u>N011856 003</u>	
<u>AP</u>	+		<u>EQ 125MG BASE/VIAL</u>	<u>N011856 004</u>	
<u>AP</u>	+		<u>EQ 500MG BASE/VIAL</u>	<u>N011856 005</u>	
<u>AP</u>	+		<u>EQ 1GM BASE/VIAL</u>	<u>N011856 006</u>	
<u>AP</u>	+		<u>EQ 2GM BASE/VIAL</u>	<u>N011856 007</u>	Feb 27, 1985

METHYLTESTOSTERONE

CAPSULE; ORAL

METHYLTESTOSTERONE

<u>AB</u>		IMPAX LABS INC	<u>10MG</u>	<u>A204851 001</u>	Sep 21, 2015
		<u>TESTRED</u>			
<u>AB</u>	+	VALEANT PHARM INTL	<u>10MG</u>	<u>A083976 001</u>	
		TABLET; ORAL			
		ANDROID 25			
BP		VALEANT PHARM INTL	25MG	A087147 001	
		METHYLTESTOSTERONE			
BP		IMPAX LABS	10MG	A080767 002	

METIPRANOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

METIPRANOLOL

<u>AT</u>		ALCON RES LTD	<u>0.3%</u>	<u>A075720 001</u>	Aug 06, 2001
		<u>OPTIPRANOLOL</u>			
<u>AT</u>	+	BAUSCH AND LOMB	<u>0.3%</u>	<u>N019907 001</u>	Dec 29, 1989

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE

<u>AP</u>		EMCURE PHARMS LTD	<u>EQ 5MG BASE/ML</u>	<u>A204756 001</u>	Dec 20, 2013
		<u>METOCLOPRAMIDE HYDROCHLORIDE</u>			
<u>AP</u>		FRESENIUS KABI USA	<u>EQ 5MG BASE/ML</u>	<u>A091392 001</u>	Apr 19, 2013
<u>AP</u>	+	HOSPIRA	<u>EQ 5MG BASE/ML</u>	<u>A073118 001</u>	Jan 17, 1991
<u>AP</u>		TEVA PHARMS USA	<u>EQ 5MG BASE/ML</u>	<u>A073135 001</u>	Nov 27, 1991

SOLUTION; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

<u>AA</u>		ANI PHARMS	<u>EQ 5MG BASE/5ML</u>	<u>A071402 001</u>	Jun 25, 1993
<u>AA</u>		PHARM ASSOC	<u>EQ 5MG BASE/5ML</u>	<u>A072744 001</u>	May 28, 1991
<u>AA</u>		VISTAPHARM	<u>EQ 5MG BASE/5ML</u>	<u>A075051 001</u>	Jan 26, 2001
<u>AA</u>	+	WOCKHARDT	<u>EQ 5MG BASE/5ML</u>	<u>A074703 001</u>	Oct 31, 1997

TABLET; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

<u>AB</u>		IMPAX LABS INC	<u>EQ 5MG BASE</u>	<u>A071250 002</u>	Dec 28, 1995
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A071250 001</u>	Feb 03, 1988
<u>AB</u>		IPCA LABS LTD	<u>EQ 5MG BASE</u>	<u>A078807 001</u>	Jun 12, 2008
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A078807 002</u>	Jun 12, 2008
<u>AB</u>		NORTHSTAR HLTHCARE	<u>EQ 5MG BASE</u>	<u>A078374 001</u>	Nov 30, 2007
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A078374 002</u>	Nov 30, 2007
<u>AB</u>		PAR PHARM INC	<u>EQ 10MG BASE</u>	<u>A070581 001</u>	Oct 17, 1985
<u>AB</u>		SUN PHARM INDS	<u>EQ 5MG BASE</u>	<u>A071536 002</u>	Jan 16, 1997
<u>AB</u>		TEVA	<u>EQ 5MG BASE</u>	<u>A072801 001</u>	Jun 15, 1993
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A070184 001</u>	Jul 29, 1985
<u>AB</u>		VINTAGE PHARMS	<u>EQ 5MG BASE</u>	<u>A077878 001</u>	Aug 28, 2006
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A077878 002</u>	Aug 28, 2006

REGLAN

<u>AB</u>		ANI PHARMS	<u>EQ 5MG BASE</u>	<u>N017854 002</u>	May 05, 1987
<u>AB</u>	+		<u>EQ 10MG BASE</u>	<u>N017854 001</u>	

TABLET, ORALLY DISINTEGRATING; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

<u>AB</u>		NOVEL LABS INC	<u>EQ 5MG BASE</u>	<u>A202191 001</u>	Aug 15, 2014
		<u>METZOZOLV ODT</u>			
<u>AB</u>	+	SALIX PHARMS	<u>EQ 5MG BASE</u>	<u>N022246 001</u>	Sep 04, 2009
		METOCLOPRAMIDE HYDROCHLORIDE			
		NOVEL LABS INC	EQ 10MG BASE	A202191 002	Aug 15, 2014

PRESCRIPTION DRUG PRODUCT LIST

METOLAZONE

TABLET; ORAL

METOLAZONE

<u>AB</u>	MYLAN	<u>2.5MG</u>	<u>A076698 001</u>	Dec 23, 2003
<u>AB</u>		<u>5MG</u>	<u>A076698 002</u>	Oct 19, 2004
<u>AB</u>		<u>10MG</u>	<u>A076698 003</u>	Oct 19, 2004
<u>AB</u>	SANDOZ	<u>2.5MG</u>	<u>A076732 001</u>	Dec 19, 2003
<u>AB</u>		<u>5MG</u>	<u>A076466 001</u>	Dec 19, 2003
<u>AB</u>		<u>10MG</u>	<u>A076466 002</u>	Dec 19, 2003

ZAROXOLYN

<u>AB</u>	UCB INC	<u>2.5MG</u>	<u>N017386 001</u>	
<u>AB</u>	+	<u>5MG</u>	<u>N017386 002</u>	
<u>AB</u>	+	<u>10MG</u>	<u>N017386 003</u>	

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

<u>AB</u>	ACTAVIS ELIZABETH	<u>EQ 25MG TARTRATE</u>	<u>A204161 001</u>	Nov 25, 2016
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A204161 002</u>	Nov 25, 2016
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>A204161 003</u>	Nov 25, 2016
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A204161 004</u>	Nov 25, 2016
<u>AB</u>	ACTAVIS LABS FL INC	<u>EQ 25MG TARTRATE</u>	<u>A077118 001</u>	Aug 03, 2009
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A076862 001</u>	Aug 03, 2009
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>A077298 001</u>	Apr 15, 2010
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A077298 002</u>	Apr 15, 2010
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 25MG TARTRATE</u>	<u>A090617 001</u>	Aug 01, 2012
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A090617 002</u>	Aug 01, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 25MG TARTRATE</u>	<u>A202033 001</u>	Dec 15, 2011
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A202033 002</u>	Dec 15, 2011
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>A202033 003</u>	Dec 15, 2011
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A202033 004</u>	Dec 15, 2011
<u>AB</u>	REDDYS	<u>EQ 100MG TARTRATE</u>	<u>A078889 001</u>	Aug 15, 2012
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A078889 002</u>	Aug 15, 2012
<u>AB</u>	WOCKHARDT	<u>EQ 25MG TARTRATE</u>	<u>A090615 001</u>	Jul 22, 2010
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A090615 002</u>	Jul 22, 2010
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>A090615 003</u>	Jul 22, 2010
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A090615 004</u>	Jul 22, 2010

TOPROL-XL

<u>AB</u>	ASTRAZENECA PHARMS	<u>EQ 25MG TARTRATE</u>	<u>N019962 004</u>	Feb 05, 2001
<u>AB</u>	+	<u>EQ 50MG TARTRATE</u>	<u>N019962 001</u>	Jan 10, 1992
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>N019962 002</u>	Jan 10, 1992
<u>AB</u>	+	<u>EQ 200MG TARTRATE</u>	<u>N019962 003</u>	Jan 10, 1992

METOPROLOL TARTRATE

INJECTABLE; INJECTION

LOPRESSOR

<u>AP</u>	+	NOVARTIS	<u>1MG/ML</u>	<u>N018704 001</u>	Mar 30, 1984
-----------	---	----------	---------------	--------------------	--------------

METOPROLOL TARTRATE

<u>AP</u>		CLARIS	<u>1MG/ML</u>	<u>A078950 001</u>	Apr 29, 2013
<u>AP</u>		EUROHLTH INTL SARL	<u>1MG/ML</u>	<u>A076495 001</u>	Jul 07, 2003
<u>AP</u>		FRESENIUS KABI USA	<u>1MG/ML</u>	<u>A091045 001</u>	Oct 25, 2010
<u>AP</u>		GLAND PHARMA LTD	<u>1MG/ML</u>	<u>A204205 001</u>	Aug 27, 2014
<u>AP</u>		HIKMA FARMACEUTICA	<u>1MG/ML</u>	<u>A077761 001</u>	May 30, 2007
<u>AP</u>		HOSPIRA	<u>1MG/ML</u>	<u>A074133 001</u>	Dec 21, 1993
<u>AP</u>			<u>1MG/ML</u>	<u>A075160 001</u>	Jul 06, 1998
<u>AP</u>			<u>1MG/ML</u>	<u>A078085 001</u>	Apr 29, 2008
<u>AP</u>		LUITPOLD	<u>1MG/ML</u>	<u>A090386 001</u>	Sep 30, 2009
<u>AP</u>			<u>1MG/ML</u>	<u>A091307 001</u>	Dec 29, 2010
<u>AP</u>		SAGENT STRIDES	<u>1MG/ML</u>	<u>A090317 001</u>	Apr 19, 2010
<u>AP</u>		SANDOZ	<u>1MG/ML</u>	<u>A077360 001</u>	Oct 02, 2007

TABLET; ORAL

LOPRESSOR

<u>AB</u>	US PHARMS HOLDINGS I	<u>50MG</u>	<u>N017963 001</u>	
<u>AB</u>		<u>100MG</u>	<u>N017963 002</u>	

METOPROLOL TARTRATE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>25MG</u>	<u>A202871 001</u>	May 28, 2013
<u>AB</u>		<u>50MG</u>	<u>A202871 002</u>	May 28, 2013
<u>AB</u>		<u>100MG</u>	<u>A202871 003</u>	May 28, 2013
<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A077739 001</u>	Sep 11, 2007
<u>AB</u>		<u>50MG</u>	<u>A077739 002</u>	Sep 11, 2007
<u>AB</u>		<u>100MG</u>	<u>A077739 003</u>	Sep 11, 2007
<u>AB</u>	IPCA LABS LTD	<u>25MG</u>	<u>A078459 001</u>	Jun 17, 2008
<u>AB</u>		<u>50MG</u>	<u>A078459 002</u>	Jun 17, 2008

PRESCRIPTION DRUG PRODUCT LIST

METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE

<u>AB</u>		<u>100MG</u>	<u>A078459 003</u>	Jun 17, 2008
<u>AB</u>	MUTUAL PHARM	<u>50MG</u>	<u>A073653 001</u>	Dec 21, 1993
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A076704 001</u>	Jan 16, 2004
<u>AB</u>		<u>50MG</u>	<u>A076704 002</u>	Jan 16, 2004
<u>AB</u>	+	<u>100MG</u>	<u>A076704 003</u>	Jan 16, 2004
<u>AB</u>	RUBICON RES PVT LTD	<u>25MG</u>	<u>A200981 001</u>	Oct 28, 2014
<u>AB</u>		<u>50MG</u>	<u>A200981 002</u>	Oct 28, 2014
<u>AB</u>		<u>100MG</u>	<u>A200981 003</u>	Oct 28, 2014
<u>AB</u>	SUN PHARM INDS	<u>25MG</u>	<u>A073654 002</u>	Jul 15, 2009
<u>AB</u>		<u>100MG</u>	<u>A073654 001</u>	Dec 21, 1993
<u>AB</u>	SUN PHARM INDS INC	<u>25MG</u>	<u>A076670 001</u>	Jan 15, 2004
<u>AB</u>		<u>50MG</u>	<u>A074644 001</u>	Dec 10, 1996
<u>AB</u>		<u>100MG</u>	<u>A074644 002</u>	Dec 10, 1996
<u>AB</u>	TEVA	<u>50MG</u>	<u>A074141 001</u>	Jan 31, 1995
<u>AB</u>		<u>100MG</u>	<u>A074141 002</u>	Jan 31, 1995
<u>AB</u>	WATSON LABS	<u>50MG</u>	<u>A074217 001</u>	May 27, 1994
<u>AB</u>		<u>100MG</u>	<u>A074217 002</u>	May 27, 1994
	MYLAN	37.5MG	A076704 004	Mar 18, 2015
		75MG	A076704 005	Mar 18, 2015

METRONIDAZOLE

CAPSULE; ORAL

FLAGYL

<u>AB</u>	+	GD SEARLE LLC	<u>375MG</u>	<u>N020334 001</u>	May 03, 1995
<u>AB</u>		ALEMBIC LTD	<u>375MG</u>	<u>A079065 001</u>	Jun 23, 2009
<u>AB</u>		PAR PHARM	<u>375MG</u>	<u>A076522 001</u>	Jan 29, 2004

CREAM; TOPICAL

METROCREAM

<u>AB</u>	+	GALDERMA LABS LP	<u>0.75%</u>	<u>N020531 001</u>	Sep 20, 1995
<u>AB</u>		FOUGERA PHARMS	<u>0.75%</u>	<u>A076408 001</u>	May 28, 2004
<u>AB</u>		G AND W LABS	<u>0.75%</u>	<u>A077549 001</u>	Dec 19, 2007
		NORITATE			
	+	VALEANT PHARMS NORTH	1%	N020743 001	Sep 26, 1997

GEL; TOPICAL

METROGEL

<u>AB</u>	+	GALDERMA LABS LP	<u>0.75%</u>	<u>N019737 001</u>	Nov 22, 1988
<u>AB</u>	+		<u>1%</u>	<u>N021789 001</u>	Jun 30, 2005
<u>AB</u>		FOUGERA PHARMS	<u>0.75%</u>	<u>A077018 001</u>	Jun 06, 2006
<u>AB</u>		G AND W LABS INC	<u>0.75%</u>	<u>A078178 001</u>	Jan 19, 2011
<u>AB</u>		TARO	<u>0.75%</u>	<u>A077819 001</u>	Jul 18, 2006
<u>AB</u>		TOLMAR	<u>0.75%</u>	<u>A077547 001</u>	Jul 13, 2006
<u>AB</u>			<u>1%</u>	<u>A090903 001</u>	Jul 22, 2011

GEL; VAGINAL

METROGEL-VAGINAL

<u>AB</u>	+	MEDICIS	<u>0.75%</u>	<u>N020208 001</u>	Aug 17, 1992
<u>AB</u>		TOLMAR	<u>0.75%</u>	<u>A077264 001</u>	Oct 31, 2006
		VANAZOLE			
BX		TEVA PHARMS	0.75%	N021806 001	May 20, 2005
		NUVESSA			
	+	ALLERGAN SALES LLC	1.3%	N205223 001	Mar 24, 2014

INJECTABLE; INJECTION

FLAGYL I.V. RTU IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>500MG/100ML</u>	<u>N018657 001</u>	
<u>AP</u>	+	B BRAUN	<u>500MG/100ML</u>	<u>N018900 001</u>	Sep 29, 1983
<u>AP</u>		CLARIS	<u>500MG/100ML</u>	<u>A078084 001</u>	Mar 31, 2008
<u>AP</u>	+	HOSPIRA	<u>500MG/100ML</u>	<u>N018890 002</u>	Nov 18, 1983

LOTION; TOPICAL

METROLOTION

<u>AB</u>	+	GALDERMA LABS LP	<u>0.75%</u>	<u>N020901 001</u>	Nov 24, 1998
<u>AB</u>		FOUGERA PHARMS	<u>0.75%</u>	<u>A077197 001</u>	May 24, 2006

PRESCRIPTION DRUG PRODUCT LIST

METRONIDAZOLE

TABLET; ORAL

FLAGYL

AB	GD SEARLE LLC	250MG	N012623	001	
AB	+	500MG	N012623	003	

METRONIDAZOLE

AB	ALEMBIC PHARMS LTD	250MG	A079067	001	Mar 13, 2009
AB		500MG	A079067	002	Mar 13, 2009
AB	ALLIED PHARMA INC	250MG	A070772	001	Jul 16, 1986
AB		500MG	A070773	001	Jul 16, 1986
AB	APPCO PHARMA LLC	250MG	A205245	001	Sep 23, 2015
AB		500MG	A205245	002	Sep 23, 2015
AB	AUROBINDO PHARMA LTD	250MG	A203974	001	May 29, 2015
AB		500MG	A203974	002	May 29, 2015
AB	FLAMINGO PHARMS	250MG	A207309	001	May 16, 2016
AB		500MG	A207309	002	May 16, 2016
AB	PLIVA	500MG	A070033	001	Dec 06, 1984
AB	STRIDES PHARMA	250MG	A208162	001	May 25, 2016
AB		500MG	A208162	002	May 25, 2016
AB	TEVA PHARMS USA	250MG	A070027	001	Nov 06, 1984
AB	UNICHEM LABS LTD	250MG	A203458	001	Jan 22, 2014
AB		500MG	A203458	002	Jan 22, 2014
AB	VIVIMED LABS	250MG	A070040	001	Jan 29, 1985
AB		500MG	A070039	001	Jan 29, 1985
AB	WATSON LABS	250MG	A070035	001	Dec 20, 1984
AB	WATSON LABS INC	500MG	A070044	001	Feb 08, 1985
AB	ZYDUS PHARMS USA INC	250MG	A206560	001	Nov 16, 2016
AB		500MG	A206560	002	Nov 16, 2016

TABLET, EXTENDED RELEASE; ORAL

FLAGYL ER

AB	+	GD SEARLE LLC	750MG	N020868	001	Nov 26, 1997
-----------	---	---------------	--------------	----------------	------------	--------------

METRONIDAZOLE

AB	ALEMBIC LTD	750MG	A090222	001	May 05, 2010
-----------	-------------	--------------	----------------	------------	--------------

METYRAPONE

CAPSULE; ORAL

METOPIRONE

+	HRA PHARMA	250MG	N012911	002	Aug 09, 1996
---	------------	-------	---------	-----	--------------

METYROSINE

CAPSULE; ORAL

DEMSEER

+	ATON PHARMA VPNA	250MG	N017871	001	
---	------------------	-------	---------	-----	--

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

	TEVA	150MG	A074377	001	May 16, 1995
		200MG	A074377	002	May 16, 1995
+		250MG	A074377	003	May 16, 1995

MICAFUNGIN SODIUM

INJECTABLE; IV (INFUSION)

MYCAMINE

+	ASTELLAS	EQ 50MG BASE/VIAL	N021506	002	Mar 16, 2005
---	----------	-------------------	---------	-----	--------------

+		EQ 100MG BASE/VIAL	N021506	003	Jun 27, 2006
---	--	--------------------	---------	-----	--------------

MICONAZOLE

TABLET; BUCCAL

ORAVIG

+	MIDATECH PHARMA US	50MG	N022404	001	Apr 16, 2010
---	--------------------	------	---------	-----	--------------

MICONAZOLE NITRATE

SUPPOSITORY; VAGINAL

MICONAZOLE NITRATE

AB	ACTAVIS MID ATLANTIC	200MG	A073508	001	Nov 19, 1993
-----------	----------------------	--------------	----------------	------------	--------------

MONISTAT 3

AB	+	MEDTECH PRODUCTS	200MG	N018888	001	Aug 15, 1984
-----------	---	------------------	--------------	----------------	------------	--------------

MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE

OINTMENT; TOPICAL

VUSION

+	DELCOR ASSET CORP	0.25%; 81.35%; 15%	N021026	001	Feb 16, 2006
---	-------------------	--------------------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

<u>AP</u>	AKORN INC	<u>EQ 1MG BASE/ML</u>	<u>A075494 001</u>	Jun 30, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075481 001</u>	Jun 30, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075494 002</u>	Jun 30, 2000
<u>AP</u>	EUROHLTH INTL SARL	<u>EQ 1MG BASE/ML</u>	<u>A075243 001</u>	Jun 20, 2000
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A075247 002</u>	Jun 23, 2000
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A075324 001</u>	Jun 20, 2000
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A075421 002</u>	Jun 20, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075243 002</u>	Jun 20, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075247 001</u>	Jun 23, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075324 002</u>	Jun 20, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075421 001</u>	Jun 20, 2000
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 1MG BASE/ML</u>	<u>A075154 002</u>	Jun 20, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075154 001</u>	Jun 20, 2000
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 1MG BASE/ML</u>	<u>A090696 001</u>	Feb 29, 2012
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A090850 001</u>	Jan 25, 2012
<u>AP</u>	+ HOSPIRA	<u>EQ 1MG BASE/ML</u>	<u>A075293 001</u>	Jun 20, 2000
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A075856 001</u>	Jun 13, 2002
<u>AP</u>	+	<u>EQ 5MG BASE/ML</u>	<u>A075293 002</u>	Jun 20, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075856 002</u>	Jun 13, 2002

MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 1MG BASE/ML</u>	<u>A203460 001</u>	Aug 22, 2014
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A203460 002</u>	Aug 22, 2014
<u>AP</u>	+ HOSPIRA	<u>EQ 1MG BASE/ML</u>	<u>A075857 001</u>	Jul 22, 2002
<u>AP</u>	+	<u>EQ 5MG BASE/ML</u>	<u>A075857 002</u>	Jul 22, 2002
<u>AP</u>	SAGENT STRIDES	<u>EQ 1MG BASE/ML</u>	<u>A090315 001</u>	Nov 29, 2010
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A090315 002</u>	Nov 29, 2010

MIDOZALAM HYDROCHLORIDE

<u>AP</u>	SAGENT STRIDES	<u>EQ 1MG BASE/ML</u>	<u>A090316 001</u>	May 04, 2011
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A090316 002</u>	May 04, 2011

SYRUP; ORAL

MIDAZOLAM HYDROCHLORIDE

<u>AA</u>	HI TECH PHARMA	<u>EQ 2MG BASE/ML</u>	<u>A075958 001</u>	Sep 04, 2003
<u>AA</u>	PADDOCK LLC	<u>EQ 2MG BASE/ML</u>	<u>A076379 001</u>	May 02, 2005
<u>AA</u>	SUN PHARM INDS LTD	<u>EQ 2MG BASE/ML</u>	<u>A076058 001</u>	Mar 15, 2002
<u>AA</u>	+ WEST-WARD PHARMS INT	<u>EQ 2MG BASE/ML</u>	<u>A075873 001</u>	Apr 30, 2002

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>2.5MG</u>	<u>A077746 001</u>	Sep 12, 2006
<u>AB</u>		<u>5MG</u>	<u>A077746 002</u>	Sep 12, 2006
<u>AB</u>		<u>10MG</u>	<u>A077746 003</u>	Sep 12, 2006
<u>AB</u>	IMPAX PHARMS	<u>2.5MG</u>	<u>A076449 001</u>	May 27, 2004
<u>AB</u>		<u>5MG</u>	<u>A076449 002</u>	May 27, 2004
<u>AB</u>		<u>10MG</u>	<u>A076449 003</u>	Dec 16, 2005
<u>AB</u>	MYLAN PHARMS INC	<u>2.5MG</u>	<u>A076577 001</u>	Sep 10, 2003
<u>AB</u>	+	<u>5MG</u>	<u>A076577 002</u>	Sep 10, 2003
<u>AB</u>		<u>10MG</u>	<u>A076577 003</u>	Sep 10, 2003
<u>AB</u>	SANDOZ	<u>2.5MG</u>	<u>A076514 001</u>	Sep 11, 2003
<u>AB</u>		<u>5MG</u>	<u>A076514 002</u>	Sep 11, 2003
<u>AB</u>		<u>10MG</u>	<u>A076514 003</u>	Jul 02, 2004
<u>ORVATEN</u>				
<u>AB</u>	UPSHER SMITH	<u>2.5MG</u>	<u>A076725 001</u>	Nov 03, 2004
<u>AB</u>		<u>5MG</u>	<u>A076725 002</u>	Nov 03, 2004
<u>AB</u>		<u>10MG</u>	<u>A076725 003</u>	Nov 03, 2004

MIFEPRISTONE

TABLET; ORAL

KORLYM

+ CORCEPT THERAP

300MG

N202107 001 Feb 17, 2012

MIFEPREX

+ DANCO LABS LLC

200MG

N020687 001 Sep 28, 2000

MIGLITOL

TABLET; ORAL

GLYSET

<u>AB</u>	+ PHARMACIA AND UPJOHN	<u>25MG</u>	<u>N020682 001</u>	Dec 18, 1996
<u>AB</u>		<u>50MG</u>	<u>N020682 002</u>	Dec 18, 1996
<u>AB</u>		<u>100MG</u>	<u>N020682 003</u>	Dec 18, 1996

PRESCRIPTION DRUG PRODUCT LIST

MIGLITOL

TABLET; ORAL

MIGLITOL

<u>AB</u>	ORIENT PHARMA CO LTD	<u>25MG</u>	<u>A203965</u>	<u>001</u>	Feb 24, 2015
<u>AB</u>		<u>50MG</u>	<u>A203965</u>	<u>002</u>	Feb 24, 2015
<u>AB</u>		<u>100MG</u>	<u>A203965</u>	<u>003</u>	Feb 24, 2015

MIGLUSTAT

CAPSULE; ORAL

ZAVESCA

	+ ACTELION PHARMS LTD	100MG	N021348	001	Jul 31, 2003
--	-----------------------	-------	---------	-----	--------------

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

MILNACIPRAN HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARMS	<u>12.5MG</u>	<u>A205081</u>	<u>001</u>	Apr 22, 2016
<u>AB</u>		<u>25MG</u>	<u>A205081</u>	<u>002</u>	Apr 22, 2016
<u>AB</u>		<u>50MG</u>	<u>A205081</u>	<u>003</u>	Apr 22, 2016
<u>AB</u>		<u>100MG</u>	<u>A205081</u>	<u>004</u>	Apr 22, 2016

SAVELLA

<u>AB</u>	CYPRESS BIOSCIENCE	<u>12.5MG</u>	<u>N022256</u>	<u>001</u>	Jan 14, 2009
<u>AB</u>		<u>25MG</u>	<u>N022256</u>	<u>002</u>	Jan 14, 2009
<u>AB</u>	+	<u>50MG</u>	<u>N022256</u>	<u>003</u>	Jan 14, 2009
<u>AB</u>		<u>100MG</u>	<u>N022256</u>	<u>004</u>	Jan 14, 2009

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

<u>AP</u>	EUROHLTH INTL SARL	<u>EQ 1MG BASE/ML</u>	<u>A075530</u>	<u>001</u>	May 28, 2002
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A075660</u>	<u>001</u>	May 28, 2002
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 1MG BASE/ML</u>	<u>A075936</u>	<u>001</u>	May 28, 2002
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 1MG BASE/ML</u>	<u>A077190</u>	<u>001</u>	Oct 31, 2006
<u>AP</u>	+	<u>EQ 1MG BASE/ML</u>	<u>A077966</u>	<u>001</u>	Dec 03, 2010
<u>AP</u>	HOSPIRA INC	<u>EQ 1MG BASE/ML</u>	<u>A203280</u>	<u>001</u>	Sep 03, 2014
<u>AP</u>	INTL MEDICATED	<u>EQ 1MG BASE/ML</u>	<u>A076013</u>	<u>001</u>	Aug 02, 2002

MILRINONE LACTATE IN DEXTROSE 5%

<u>AP</u>	CLARIS	<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A077151</u>	<u>002</u>	Jul 20, 2005
-----------	--------	--	----------------	------------	--------------

MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A075834</u>	<u>001</u>	May 28, 2002
<u>AP</u>	+	<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A075834</u>	<u>002</u>	May 28, 2002
<u>AP</u>	EUROHLTH INTL SARL	<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A078113</u>	<u>001</u>	May 21, 2008
<u>AP</u>		<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A078113</u>	<u>002</u>	May 21, 2008
<u>AP</u>	HOSPIRA	<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A075885</u>	<u>001</u>	May 28, 2002
<u>AP</u>		<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A075885</u>	<u>002</u>	May 28, 2002

MILRINONE LACTATE IN PLASTIC CONTAINER

<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A090038</u>	<u>001</u>	Jan 21, 2010
<u>AP</u>		<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A090038</u>	<u>002</u>	Jan 21, 2010

MILTEFOSINE

CAPSULE; ORAL

IMPAVIDO

	+ KNIGHT THERAPS	50MG	N204684	001	Mar 19, 2014
--	------------------	------	---------	-----	--------------

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

DYNACIN

<u>AB</u>	CNTY LINE PHARMS	<u>EQ 75MG BASE</u>	<u>A063067</u>	<u>002</u>	Sep 15, 1999
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A063067</u>	<u>001</u>	Jul 31, 1990

MINOCIN

<u>AB</u>	PRECISION DERMAT	<u>EQ 50MG BASE</u>	<u>N050649</u>	<u>001</u>	May 31, 1990
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>N050649</u>	<u>002</u>	May 31, 1990

MINOCYCLINE HYDROCHLORIDE

<u>AB</u>	AUROBINDO PHARMA	<u>EQ 50MG BASE</u>	<u>A065470</u>	<u>001</u>	Mar 11, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065470</u>	<u>002</u>	Mar 11, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065470</u>	<u>003</u>	Mar 11, 2008
<u>AB</u>	IMPAX LABS	<u>EQ 50MG BASE</u>	<u>A065005</u>	<u>001</u>	Mar 23, 1999
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065005</u>	<u>003</u>	Apr 18, 2001
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065005</u>	<u>002</u>	Mar 23, 1999
<u>AB</u>	SUN PHARM INDS INC	<u>EQ 50MG BASE</u>	<u>A090867</u>	<u>001</u>	May 13, 2013
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090867</u>	<u>002</u>	May 13, 2013
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090867</u>	<u>003</u>	May 13, 2013
<u>AB</u>	TORRENT PHARMA INC	<u>EQ 50MG BASE</u>	<u>A065062</u>	<u>001</u>	Nov 30, 2000
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065062</u>	<u>002</u>	Nov 30, 2000
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065062</u>	<u>003</u>	Nov 30, 2000
<u>AB</u>	WATSON LABS	<u>EQ 50MG BASE</u>	<u>A063181</u>	<u>001</u>	Dec 30, 1991

PRESCRIPTION DRUG PRODUCT LIST

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

MINOCYCLINE HYDROCHLORIDE

<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A063065</u>	<u>002</u>	Jun 10, 1999
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A063065</u>	<u>001</u>	Dec 30, 1991
<u>AB</u>	ZYDUS WORLDWIDE	<u>EQ 50MG BASE</u>	<u>A063011</u>	<u>001</u>	Mar 02, 1992
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A063009</u>	<u>002</u>	Aug 12, 2003
<u>AB</u>	+	<u>EQ 100MG BASE</u>	<u>A063009</u>	<u>001</u>	Mar 02, 1992

INJECTABLE; INJECTION

MINOCIN

+ REMPEX PHARMS INC

EQ 100MG BASE/VIAL

N050444 001

POWDER, EXTENDED RELEASE; DENTAL

ARESTIN

+ ORAPHARMA

EQ 1MG BASE

N050781 001 Feb 16, 2001

TABLET; ORAL

MINOCYCLINE HYDROCHLORIDE

<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 50MG BASE</u>	<u>A065436</u>	<u>001</u>	Dec 26, 2007
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065436</u>	<u>002</u>	Dec 26, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065436</u>	<u>003</u>	Dec 26, 2007
<u>AB</u>	PAR PHARM	<u>EQ 50MG BASE</u>	<u>A065131</u>	<u>001</u>	Apr 16, 2003
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065131</u>	<u>002</u>	Apr 16, 2003
<u>AB</u>	+	<u>EQ 100MG BASE</u>	<u>A065131</u>	<u>003</u>	Apr 16, 2003
<u>AB</u>	SUN PHARM INDS	<u>EQ 50MG BASE</u>	<u>A090217</u>	<u>001</u>	Jan 29, 2016
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090217</u>	<u>002</u>	Jan 29, 2016
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090217</u>	<u>003</u>	Jan 29, 2016
<u>AB</u>	TORRENT PHARMA INC	<u>EQ 50MG BASE</u>	<u>A065156</u>	<u>001</u>	Jan 06, 2004
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065156</u>	<u>002</u>	Jan 06, 2004
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065156</u>	<u>003</u>	Jan 06, 2004

TABLET, EXTENDED RELEASE; ORAL

MINOCYCLINE HYDROCHLORIDE

<u>AB</u>	ALKEM LABS LTD	<u>EQ 45MG BASE</u>	<u>A204453</u>	<u>001</u>	Sep 28, 2016
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A204453</u>	<u>002</u>	Sep 28, 2016
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A204453</u>	<u>003</u>	Sep 28, 2016
<u>AB</u>		<u>EQ 105MG BASE</u>	<u>A204453</u>	<u>004</u>	Sep 28, 2016
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A204453</u>	<u>005</u>	Sep 28, 2016
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 45MG BASE</u>	<u>A202261</u>	<u>001</u>	Nov 19, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A202261</u>	<u>006</u>	Jun 13, 2016
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A202261</u>	<u>003</u>	Nov 19, 2012
<u>AB</u>		<u>EQ 105MG BASE</u>	<u>A202261</u>	<u>007</u>	Jun 13, 2016
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A202261</u>	<u>005</u>	Nov 19, 2012
<u>AB</u>	LUPIN LTD	<u>EQ 45MG BASE</u>	<u>A091424</u>	<u>001</u>	Nov 30, 2011
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A091424</u>	<u>003</u>	Nov 30, 2011
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A091424</u>	<u>004</u>	Nov 30, 2011
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 45MG BASE</u>	<u>A090911</u>	<u>001</u>	Jul 20, 2010
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A203443</u>	<u>002</u>	Aug 22, 2014
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A090911</u>	<u>002</u>	Jul 20, 2010
<u>AB</u>		<u>EQ 105MG BASE</u>	<u>A203443</u>	<u>003</u>	Aug 22, 2014
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A090911</u>	<u>003</u>	Jul 20, 2010
<u>AB</u>	SANDOZ	<u>EQ 45MG BASE</u>	<u>A090422</u>	<u>001</u>	Aug 13, 2009
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A090422</u>	<u>002</u>	Aug 13, 2009
<u>AB</u>	+	<u>EQ 135MG BASE</u>	<u>A090422</u>	<u>003</u>	Aug 13, 2009
<u>AB</u>	SIDMAK LABS INDIA	<u>EQ 45MG BASE</u>	<u>A204394</u>	<u>001</u>	Dec 30, 2015
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A204394</u>	<u>004</u>	Dec 30, 2015
<u>AB</u>		<u>EQ 105MG BASE</u>	<u>A204394</u>	<u>005</u>	Dec 30, 2015
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A204394</u>	<u>007</u>	Dec 30, 2015
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 45MG BASE</u>	<u>A091118</u>	<u>001</u>	Sep 25, 2014
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A091118</u>	<u>004</u>	Sep 25, 2014
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A091118</u>	<u>005</u>	Sep 25, 2014
<u>AB</u>		<u>EQ 105MG BASE</u>	<u>A091118</u>	<u>006</u>	Sep 25, 2014
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A091118</u>	<u>008</u>	Sep 25, 2014

SOLODYN

<u>AB</u>	MEDICIS	<u>EQ 80MG BASE</u>	<u>N050808</u>	<u>007</u>	Aug 27, 2010
<u>AB</u>		<u>EQ 105MG BASE</u>	<u>N050808</u>	<u>006</u>	Aug 27, 2010
		EQ 55MG BASE	N050808	008	Aug 27, 2010
		EQ 65MG BASE	N050808	004	Jul 23, 2009
	+	EQ 115MG BASE	N050808	005	Jul 23, 2009

PRESCRIPTION DRUG PRODUCT LIST

MINOXIDIL

TABLET; ORAL

MINOXIDIL

<u>AB</u>	MUTUAL PHARM	<u>2.5MG</u>	<u>A072708</u>	<u>001</u>	Dec 14, 1995
<u>AB</u>	PAR PHARM	<u>2.5MG</u>	<u>A071826</u>	<u>001</u>	Nov 14, 1988
<u>AB</u>		<u>10MG</u>	<u>A071839</u>	<u>001</u>	Nov 14, 1988
<u>AB</u>	SUN PHARM INDS	<u>10MG</u>	<u>A072709</u>	<u>001</u>	Dec 14, 1995
<u>AB</u>	WATSON LABS	<u>2.5MG</u>	<u>A071344</u>	<u>001</u>	Mar 03, 1987
<u>AB</u>	+	<u>10MG</u>	<u>A071345</u>	<u>001</u>	Mar 03, 1987

MIPOMERSEN SODIUM

SOLUTION; SUBCUTANEOUS

KYNAMRO

+	KASTLE THERAPS LLC	200MG/ML (200MG/ML)	N203568	001	Jan 29, 2013
---	--------------------	---------------------	---------	-----	--------------

MIRABEGRON

TABLET, EXTENDED RELEASE; ORAL

MYRBETRIQ

	APGDI	25MG	N202611	001	Jun 28, 2012
+		50MG	N202611	002	Jun 28, 2012

MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

<u>AB</u>	APOTEX INC	<u>15MG</u>	<u>A077666</u>	<u>001</u>	Aug 22, 2007
<u>AB</u>		<u>30MG</u>	<u>A077666</u>	<u>002</u>	Aug 22, 2007
<u>AB</u>		<u>45MG</u>	<u>A077666</u>	<u>003</u>	Aug 22, 2007
<u>AB</u>	AUROBINDO	<u>7.5MG</u>	<u>A076921</u>	<u>001</u>	Oct 22, 2004
<u>AB</u>		<u>15MG</u>	<u>A076921</u>	<u>002</u>	Oct 22, 2004
<u>AB</u>		<u>30MG</u>	<u>A076921</u>	<u>003</u>	Oct 22, 2004
<u>AB</u>		<u>45MG</u>	<u>A076921</u>	<u>004</u>	Oct 22, 2004
<u>AB</u>	MYLAN	<u>15MG</u>	<u>A076122</u>	<u>001</u>	Jun 19, 2003
<u>AB</u>		<u>30MG</u>	<u>A076122</u>	<u>002</u>	Jun 19, 2003
<u>AB</u>		<u>45MG</u>	<u>A076122</u>	<u>003</u>	Jun 19, 2003
<u>AB</u>	MYLAN PHARMS INC	<u>15MG</u>	<u>A076176</u>	<u>001</u>	Jun 19, 2003
<u>AB</u>		<u>30MG</u>	<u>A076176</u>	<u>002</u>	Jun 19, 2003
<u>AB</u>		<u>45MG</u>	<u>A076176</u>	<u>003</u>	Jun 19, 2003
<u>AB</u>	SUN PHARM INDS INC	<u>7.5MG</u>	<u>A076541</u>	<u>004</u>	Apr 22, 2004
<u>AB</u>		<u>15MG</u>	<u>A076541</u>	<u>001</u>	Apr 22, 2004
<u>AB</u>		<u>30MG</u>	<u>A076541</u>	<u>002</u>	Apr 22, 2004
<u>AB</u>		<u>45MG</u>	<u>A076541</u>	<u>003</u>	Apr 22, 2004
<u>AB</u>	TEVA	<u>15MG</u>	<u>A076119</u>	<u>001</u>	Jan 24, 2003
<u>AB</u>		<u>30MG</u>	<u>A076119</u>	<u>002</u>	Jan 24, 2003
<u>AB</u>		<u>45MG</u>	<u>A076119</u>	<u>003</u>	Jun 19, 2003
<u>AB</u>	UPSHER-SMITH LABS	<u>15MG</u>	<u>A076219</u>	<u>001</u>	Jun 19, 2003
<u>AB</u>		<u>30MG</u>	<u>A076219</u>	<u>002</u>	Jun 19, 2003
<u>AB</u>		<u>45MG</u>	<u>A076219</u>	<u>003</u>	Jun 19, 2003
<u>AB</u>	WATSON LABS	<u>15MG</u>	<u>A076312</u>	<u>001</u>	Jun 19, 2003
<u>AB</u>		<u>30MG</u>	<u>A076312</u>	<u>002</u>	Jun 19, 2003
<u>AB</u>		<u>45MG</u>	<u>A076312</u>	<u>003</u>	Jun 19, 2003

REMERON

<u>AB</u>	+	ORGANON USA INC	<u>15MG</u>	<u>N020415</u>	<u>001</u>	Jun 14, 1996
<u>AB</u>			<u>30MG</u>	<u>N020415</u>	<u>002</u>	Jun 14, 1996
<u>AB</u>			<u>45MG</u>	<u>N020415</u>	<u>003</u>	Mar 17, 1997

TABLET, ORALLY DISINTEGRATING; ORAL

MIRTAZAPINE

<u>AB</u>	ACTAVIS LABS FL INC	<u>15MG</u>	<u>A076307</u>	<u>001</u>	Dec 17, 2003
<u>AB</u>		<u>30MG</u>	<u>A076307</u>	<u>002</u>	Dec 17, 2003
<u>AB</u>		<u>45MG</u>	<u>A076307</u>	<u>003</u>	Feb 28, 2006
<u>AB</u>	AUROBINDO PHARMA LTD	<u>15MG</u>	<u>A077376</u>	<u>002</u>	Dec 08, 2005
<u>AB</u>		<u>30MG</u>	<u>A077376</u>	<u>003</u>	Dec 08, 2005
<u>AB</u>		<u>45MG</u>	<u>A077376</u>	<u>004</u>	Feb 28, 2006
<u>AB</u>	IMPAX LABS INC	<u>15MG</u>	<u>A076901</u>	<u>001</u>	Jun 28, 2005
<u>AB</u>		<u>30MG</u>	<u>A076901</u>	<u>002</u>	Jun 28, 2005
<u>AB</u>		<u>45MG</u>	<u>A076901</u>	<u>003</u>	Jun 28, 2005

REMERON SOLTAB

<u>AB</u>	+	ORGANON USA INC	<u>15MG</u>	<u>N021208</u>	<u>001</u>	Jan 12, 2001
<u>AB</u>			<u>30MG</u>	<u>N021208</u>	<u>002</u>	Jan 12, 2001
<u>AB</u>			<u>45MG</u>	<u>N021208</u>	<u>003</u>	Jan 12, 2001

PRESCRIPTION DRUG PRODUCT LIST

MISOPROSTOL

TABLET; ORAL

CYTOTEC

<u>AB</u>	GD SEARLE LLC	<u>0.1MG</u>	<u>N019268 003</u>	Sep 21, 1990
<u>AB</u>	+	<u>0.2MG</u>	<u>N019268 001</u>	Dec 27, 1988

MISOPROSTOL

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>0.1MG</u>	<u>A076095 001</u>	Jul 10, 2002
<u>AB</u>		<u>0.2MG</u>	<u>A076095 002</u>	Jul 10, 2002
<u>AB</u>	NOVEL LABS INC	<u>0.1MG</u>	<u>A091667 001</u>	Jul 25, 2012
<u>AB</u>		<u>0.2MG</u>	<u>A091667 002</u>	Jul 25, 2012

MITOMYCIN

FOR SOLUTION; TOPICAL

MITOSOL

+ MOBIUS THERAP

0.2MG/VIAL

N022572 001 Feb 07, 2012

INJECTABLE; INJECTION

MITOMYCIN

<u>AP</u>	+	ACCORD HLTHCARE	<u>5MG/VIAL</u>	<u>A064144 001</u>	Apr 30, 1998
<u>AP</u>	+		<u>20MG/VIAL</u>	<u>A064144 002</u>	Apr 30, 1998
<u>AP</u>	+		<u>40MG/VIAL</u>	<u>A064144 003</u>	Aug 11, 2009
<u>AP</u>		EUROHLTH INTL SARL	<u>5MG/VIAL</u>	<u>A064117 001</u>	Apr 19, 1995
<u>AP</u>			<u>5MG/VIAL</u>	<u>A064180 001</u>	Dec 23, 1999
<u>AP</u>			<u>20MG/VIAL</u>	<u>A064117 002</u>	Apr 19, 1995
<u>AP</u>			<u>20MG/VIAL</u>	<u>A064180 002</u>	Dec 23, 1999

MITOTANE

TABLET; ORAL

LYSODREN

+ BRISTOL MYERS SQUIBB

500MG

N016885 001

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

<u>AP</u>		FRESENIUS KABI USA	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A077496 001</u>	Apr 11, 2006
<u>AP</u>			<u>EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)</u>	<u>A077496 002</u>	Apr 11, 2006
<u>AP</u>			<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A077496 003</u>	Apr 11, 2006
<u>AP</u>	+	HOSPIRA	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A076871 001</u>	Apr 11, 2006
<u>AP</u>	+		<u>EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)</u>	<u>A076871 002</u>	Apr 11, 2006
<u>AP</u>	+		<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A076871 003</u>	Apr 11, 2006
<u>AP</u>		MYLAN INSTITUTIONAL	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A078980 001</u>	Apr 13, 2009
<u>AP</u>			<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A078980 002</u>	Apr 13, 2009
<u>AP</u>		MYLAN LABS LTD	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A201014 001</u>	Dec 11, 2012
<u>AP</u>		TEVA PHARMS USA	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A077356 001</u>	Apr 11, 2006
<u>AP</u>			<u>EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)</u>	<u>A077356 002</u>	Apr 11, 2006
<u>AP</u>			<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A077356 003</u>	Apr 11, 2006
<u>AP</u>		WEST-WARD PHARMS INT	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A076611 001</u>	Apr 11, 2006
<u>AP</u>			<u>EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)</u>	<u>A076611 002</u>	Apr 11, 2006
<u>AP</u>			<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A076611 003</u>	Apr 11, 2006

MIVACURIUM CHLORIDE

SOLUTION; INTRAVENOUS

MIVACRON

ABBVIE

EQ 10MG BASE/5ML (EQ 2MG BASE/ML)

N020098 004 Jan 22, 1992

+

EQ 20MG BASE/10ML (EQ 2MG BASE/ML)

N020098 005 Jan 22, 1992

MODAFINIL

TABLET; ORAL

MODAFINIL

<u>AB</u>		ALEMBIC LTD	<u>100MG</u>	<u>A202700 001</u>	Oct 18, 2012
<u>AB</u>			<u>200MG</u>	<u>A202700 002</u>	Oct 18, 2012
<u>AB</u>		APOTEX INC	<u>100MG</u>	<u>A077667 001</u>	Feb 03, 2014
<u>AB</u>			<u>200MG</u>	<u>A077667 002</u>	Feb 03, 2014
<u>AB</u>		AUROBINDO PHARMA LTD	<u>100MG</u>	<u>A202566 001</u>	Sep 27, 2012
<u>AB</u>			<u>200MG</u>	<u>A202566 002</u>	Sep 27, 2012
<u>AB</u>		HIKMA PHARMS	<u>100MG</u>	<u>A090543 001</u>	Sep 26, 2012
<u>AB</u>			<u>200MG</u>	<u>A090543 002</u>	Sep 26, 2012
<u>AB</u>		MYLAN PHARMS INC	<u>100MG</u>	<u>A076594 001</u>	Jul 16, 2012
<u>AB</u>			<u>200MG</u>	<u>A076594 002</u>	Jul 16, 2012
<u>AB</u>		ORCHID HLTHCARE	<u>100MG</u>	<u>A078963 001</u>	Sep 26, 2012
<u>AB</u>			<u>200MG</u>	<u>A078963 002</u>	Sep 26, 2012
<u>AB</u>		WATSON LABS INC	<u>100MG</u>	<u>A076715 001</u>	Nov 01, 2012
<u>AB</u>			<u>200MG</u>	<u>A076715 002</u>	Nov 01, 2012
		<u>PROVIGIL</u>			
<u>AB</u>		CEPHALON	<u>100MG</u>	<u>N020717 001</u>	Dec 24, 1998
<u>AB</u>	+		<u>200MG</u>	<u>N020717 002</u>	Dec 24, 1998

PRESCRIPTION DRUG PRODUCT LIST

MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>7.5MG</u>	<u>A078454 001</u>	Jun 02, 2008
<u>AB</u>		<u>15MG</u>	<u>A078454 002</u>	Jun 02, 2008
<u>AB</u>	GLENMARK GENERICS	<u>7.5MG</u>	<u>A090416 001</u>	Mar 30, 2010
<u>AB</u>		<u>15MG</u>	<u>A090416 002</u>	Mar 30, 2010
<u>AB</u>	PADDOCK LLC	<u>7.5MG</u>	<u>A077536 001</u>	Nov 30, 2006
<u>AB</u>		<u>15MG</u>	<u>A077536 002</u>	Nov 30, 2006
<u>AB</u>	TEVA	<u>7.5MG</u>	<u>A076204 001</u>	May 08, 2003
<u>AB</u>	+	<u>15MG</u>	<u>A076204 002</u>	May 08, 2003

MOLINDONE HYDROCHLORIDE

TABLET; ORAL

MOLINDONE HYDROCHLORIDE

COREPHARMA

+

5MG
10MG
25MGA090453 001 Mar 20, 2015
A090453 002 Mar 20, 2015
A090453 003 Mar 20, 2015MOMETASONE FUROATE

AEROSOL, METERED; INHALATION

ASMANEX HFA

MERCK SHARP DOHME

+

0.10MG/INH
0.20MG/INHN205641 001 Apr 25, 2014
N205641 002 Apr 25, 2014

CREAM; TOPICAL

ELOCON

<u>AB</u>	+	MERCK SHARP DOHME	<u>0.1%</u>	<u>N019625 002</u>	Apr 19, 2013
-----------	---	-------------------	-------------	--------------------	--------------

MOMETASONE FUROATE

<u>AB</u>		FOUGERA PHARMS	<u>0.1%</u>	<u>A076171 001</u>	Apr 08, 2005
<u>AB</u>		G AND W LABS	<u>0.1%</u>	<u>A077447 001</u>	May 22, 2006
<u>AB</u>		GLENMARK GENERICS	<u>0.1%</u>	<u>A078541 001</u>	May 28, 2008
<u>AB</u>		TARO	<u>0.1%</u>	<u>A076679 001</u>	Dec 21, 2004
<u>AB</u>		TOLMAR	<u>0.1%</u>	<u>A076591 001</u>	Apr 18, 2007

LOTION; TOPICAL

ELOCON

<u>AB</u>	+	MERCK SHARP DOHME	<u>0.1%</u>	<u>N019796 001</u>	Mar 30, 1989
-----------	---	-------------------	-------------	--------------------	--------------

MOMETASONE FUROATE

<u>AB</u>		FOUGERA PHARMS	<u>0.1%</u>	<u>A075919 001</u>	Nov 29, 2007
<u>AB</u>		G AND W LABS	<u>0.1%</u>	<u>A077678 001</u>	Nov 21, 2007
<u>AB</u>		GLENMARK GENERICS	<u>0.1%</u>	<u>A090506 001</u>	Aug 09, 2010
<u>AB</u>		PERRIGO	<u>0.1%</u>	<u>A077180 001</u>	Apr 06, 2005
<u>AB</u>		TARO	<u>0.1%</u>	<u>A076788 001</u>	Mar 15, 2006
<u>AB</u>		TOLMAR	<u>0.1%</u>	<u>A076499 001</u>	Nov 21, 2007

OINTMENT; TOPICAL

ELOCON

<u>AB</u>	+	MERCK SHARP DOHME	<u>0.1%</u>	<u>N019543 001</u>	Apr 30, 1987
-----------	---	-------------------	-------------	--------------------	--------------

MOMETASONE FUROATE

<u>AB</u>		FOUGERA PHARMS	<u>0.1%</u>	<u>A077061 001</u>	Mar 28, 2005
<u>AB</u>		G AND W LABS	<u>0.1%</u>	<u>A077401 001</u>	Jun 20, 2006
<u>AB</u>		GLENMARK GENERICS	<u>0.1%</u>	<u>A078571 001</u>	May 28, 2008
<u>AB</u>		PERRIGO NEW YORK	<u>0.1%</u>	<u>A076067 001</u>	Mar 18, 2002
<u>AB</u>		TOLMAR	<u>0.1%</u>	<u>A076481 001</u>	Nov 14, 2003

POWDER; INHALATION

ASMANEX TWISTHALER

MERCK SHARP DOHME

+

0.11MG/INH
0.22MG/INHN021067 002 Feb 01, 2008
N021067 001 Mar 30, 2005

SPRAY, METERED; NASAL

MOMETASONE FUROATE

<u>AB</u>		APOTEX INC	<u>EQ 0.05MG BASE/SPRAY</u>	<u>A091161 001</u>	Mar 22, 2016
-----------	--	------------	-----------------------------	--------------------	--------------

NASONEX

<u>AB</u>	+	MERCK SHARP DOHME	<u>EQ 0.05MG BASE/SPRAY</u>	<u>N020762 001</u>	Oct 01, 1997
-----------	---	-------------------	-----------------------------	--------------------	--------------

MONTELUKAST SODIUM

GRANULE; ORAL

MONTELUKAST SODIUM

<u>AB</u>		AJANTA PHARMA LTD	<u>EQ 4MG BASE/PACKET</u>	<u>A203438 001</u>	Jul 31, 2015
<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 4MG BASE/PACKET</u>	<u>A202906 001</u>	Sep 17, 2012
<u>AB</u>		MYLAN PHARMS INC	<u>EQ 4MG BASE/PACKET</u>	<u>A202776 001</u>	Dec 18, 2012
<u>AB</u>		TEVA PHARMS	<u>EQ 4MG BASE/PACKET</u>	<u>A090955 001</u>	Aug 03, 2012

SINGULAIR

<u>AB</u>	+	MERCK	<u>EQ 4MG BASE/PACKET</u>	<u>N021409 001</u>	Jul 26, 2002
-----------	---	-------	---------------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

MONTELUKAST SODIUM

TABLET; ORAL

MONTELUKAST SODIUM

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 10MG BASE</u>	<u>A202717 001</u>	Sep 21, 2012
<u>AB</u>	AJANTA PHARMA LTD	<u>EQ 10MG BASE</u>	<u>A203432 001</u>	Jul 31, 2015
<u>AB</u>	AMNEAL PHARMS	<u>EQ 10MG BASE</u>	<u>A204604 001</u>	Sep 04, 2015
<u>AB</u>	ANBISON LAB CO LTD	<u>EQ 10MG BASE</u>	<u>A205683 001</u>	Jan 12, 2016
<u>AB</u>	APOTEX CORP	<u>EQ 10MG BASE</u>	<u>A201294 001</u>	Aug 03, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 10MG BASE</u>	<u>A202468 001</u>	Aug 03, 2012
<u>AB</u>	CIPLA LTD	<u>EQ 10MG BASE</u>	<u>A207463 001</u>	Oct 28, 2016
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 10MG BASE</u>	<u>A201582 001</u>	Aug 06, 2012
<u>AB</u>	GLENMARK GENERICS	<u>EQ 10MG BASE</u>	<u>A090926 001</u>	Aug 03, 2012
<u>AB</u>	HETERO LABS LTD V	<u>EQ 10MG BASE</u>	<u>A202843 001</u>	Sep 10, 2014
<u>AB</u>	KREMERS URBAN PHARMS	<u>EQ 10MG BASE</u>	<u>A201522 001</u>	Aug 03, 2012
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 10MG BASE</u>	<u>A203366 001</u>	Sep 11, 2014
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A079103 001</u>	Aug 03, 2012
<u>AB</u>	SANDOZ INC	<u>EQ 10MG BASE</u>	<u>A200889 001</u>	Aug 03, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 10MG BASE</u>	<u>A078605 001</u>	Aug 03, 2012
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 10MG BASE</u>	<u>A201515 001</u>	Aug 03, 2012
<u>AB</u>	UNICHEM LABS LTD	<u>EQ 10MG BASE</u>	<u>A204290 001</u>	Oct 08, 2015
<u>AB</u>	UNIMARK REMEDIES LTD	<u>EQ 10MG BASE</u>	<u>A202859 001</u>	Oct 30, 2014
<u>AB</u>	VINTAGE PHARMS LLC	<u>EQ 10MG BASE</u>	<u>A091576 001</u>	Aug 03, 2012
<u>AB</u>	WEST-WARD PHARMS INT	<u>EQ 10MG BASE</u>	<u>A090655 001</u>	Aug 03, 2012

SINGULAIR

<u>AB</u>	+ MERCK	<u>EQ 10MG BASE</u>	<u>N020829 002</u>	Feb 20, 1998
-----------	---------	---------------------	--------------------	--------------

TABLET, CHEWABLE; ORAL

MONTELUKAST SODIUM

<u>AB</u>	AJANTA PHARMA LTD	<u>EQ 4MG BASE</u>	<u>A203328 001</u>	Jul 31, 2015
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A203328 002</u>	Jul 31, 2015
<u>AB</u>	ANBISON LAB CO LTD	<u>EQ 4MG BASE</u>	<u>A205695 001</u>	Nov 05, 2015
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A205695 002</u>	Nov 05, 2015
<u>AB</u>	APOTEX INC	<u>EQ 4MG BASE</u>	<u>A201508 001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A201508 002</u>	Aug 03, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 4MG BASE</u>	<u>A202096 001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A202096 002</u>	Aug 03, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE</u>	<u>A201581 001</u>	Aug 06, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A201581 002</u>	Aug 06, 2012
<u>AB</u>	HETERO LABS LTD V	<u>EQ 4MG BASE</u>	<u>A204093 001</u>	May 22, 2015
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A204093 002</u>	May 22, 2015
<u>AB</u>	JUBILANT GENERICS	<u>EQ 4MG BASE</u>	<u>A203795 001</u>	Feb 27, 2015
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A203795 002</u>	Feb 27, 2015
<u>AB</u>	KREMERS URBAN PHARMS	<u>EQ 4MG BASE</u>	<u>A200405 001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A200405 002</u>	Aug 03, 2012
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 4MG BASE</u>	<u>A203582 001</u>	Mar 12, 2015
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A203582 002</u>	Mar 12, 2015
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 4MG BASE</u>	<u>A079142 001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A079142 002</u>	Aug 03, 2012
<u>AB</u>	SANDOZ INC	<u>EQ 4MG BASE</u>	<u>A091414 001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A091414 002</u>	Aug 03, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 4MG BASE</u>	<u>A078723 001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078723 002</u>	Aug 03, 2012
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 4MG BASE</u>	<u>A090984 001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090984 002</u>	Aug 03, 2012
<u>AB</u>	UNIMARK REMEDIES LTD	<u>EQ 4MG BASE</u>	<u>A203037 001</u>	Oct 30, 2014
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A203037 002</u>	Oct 30, 2014
<u>AB</u>	VINTAGE PHARMS LLC	<u>EQ 4MG BASE</u>	<u>A091588 001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A091588 002</u>	Aug 03, 2012
<u>AB</u>	WEST-WARD PHARMS INT	<u>EQ 4MG BASE</u>	<u>A091128 001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A091128 002</u>	Aug 03, 2012

SINGULAIR

<u>AB</u>	MERCK	<u>EQ 4MG BASE</u>	<u>N020830 002</u>	Mar 03, 2000
<u>AB</u>	+	<u>EQ 5MG BASE</u>	<u>N020830 001</u>	Feb 20, 1998

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

KADIAN

<u>AB</u>	+ ALLERGAN SALES LLC	<u>10MG</u>	<u>N020616 008</u>	Apr 20, 2007
<u>AB</u>		<u>20MG</u>	<u>N020616 001</u>	Jul 03, 1996
<u>AB</u>		<u>30MG</u>	<u>N020616 004</u>	Mar 09, 2001
<u>AB</u>		<u>40MG</u>	<u>N020616 009</u>	Jul 09, 2012
<u>AB</u>		<u>50MG</u>	<u>N020616 002</u>	Jul 03, 1996
<u>AB</u>		<u>60MG</u>	<u>N020616 005</u>	Mar 09, 2001
<u>AB</u>		<u>70MG</u>	<u>N020616 010</u>	Jul 09, 2012

PRESCRIPTION DRUG PRODUCT LIST

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

KADIAN

<u>AB</u>		<u>80MG</u>	<u>N020616</u>	<u>006</u>	Oct 27, 2006
<u>AB</u>	+	<u>100MG</u>	<u>N020616</u>	<u>003</u>	Jul 03, 1996

MORPHINE SULFATE

<u>AB</u>	IMPAX LABS INC	<u>20MG</u>	<u>A200411</u>	<u>001</u>	Apr 12, 2016
<u>AB</u>		<u>30MG</u>	<u>A200411</u>	<u>002</u>	Apr 12, 2016
<u>AB</u>		<u>50MG</u>	<u>A200411</u>	<u>003</u>	Apr 12, 2016
<u>AB</u>		<u>60MG</u>	<u>A200411</u>	<u>004</u>	Apr 12, 2016
<u>AB</u>		<u>80MG</u>	<u>A200411</u>	<u>005</u>	Apr 12, 2016
<u>AB</u>		<u>100MG</u>	<u>A200411</u>	<u>006</u>	Apr 12, 2016
<u>AB</u>	PAR PHARM INC	<u>20MG</u>	<u>A200812</u>	<u>001</u>	Nov 10, 2011
<u>AB</u>		<u>30MG</u>	<u>A200812</u>	<u>002</u>	Nov 10, 2011
<u>AB</u>		<u>50MG</u>	<u>A200812</u>	<u>003</u>	Nov 10, 2011
<u>AB</u>		<u>60MG</u>	<u>A200812</u>	<u>004</u>	Nov 10, 2011
<u>AB</u>		<u>80MG</u>	<u>A200812</u>	<u>005</u>	Nov 10, 2011
<u>AB</u>		<u>100MG</u>	<u>A200812</u>	<u>006</u>	Nov 10, 2011
<u>AB</u>	TEVA PHARMS USA	<u>20MG</u>	<u>A202718</u>	<u>001</u>	Dec 29, 2014
<u>AB</u>		<u>30MG</u>	<u>A202718</u>	<u>002</u>	Dec 29, 2014
<u>AB</u>		<u>40MG</u>	<u>A202718</u>	<u>007</u>	Jun 03, 2015
<u>AB</u>		<u>50MG</u>	<u>A202718</u>	<u>003</u>	Dec 29, 2014
<u>AB</u>		<u>60MG</u>	<u>A202718</u>	<u>004</u>	Dec 29, 2014
<u>AB</u>		<u>70MG</u>	<u>A202718</u>	<u>008</u>	Jun 03, 2015
<u>AB</u>		<u>80MG</u>	<u>A202718</u>	<u>005</u>	Dec 29, 2014
<u>AB</u>		<u>100MG</u>	<u>A202718</u>	<u>006</u>	Dec 29, 2014
<u>AB</u>	UPSHER SMITH	<u>10MG</u>	<u>A202104</u>	<u>001</u>	Jun 03, 2013
<u>AB</u>		<u>20MG</u>	<u>A202104</u>	<u>002</u>	Jun 03, 2013
<u>AB</u>		<u>30MG</u>	<u>A202104</u>	<u>003</u>	Jun 03, 2013
<u>AB</u>		<u>50MG</u>	<u>A202104</u>	<u>004</u>	Jun 03, 2013
<u>AB</u>		<u>60MG</u>	<u>A202104</u>	<u>005</u>	Jun 03, 2013
<u>AB</u>		<u>80MG</u>	<u>A202104</u>	<u>006</u>	Jun 03, 2013
<u>AB</u>		<u>100MG</u>	<u>A202104</u>	<u>007</u>	Jun 03, 2013

KADIAN

	ALLERGAN SALES LLC	130MG	N020616	011	Jul 09, 2012
		150MG	N020616	012	Jul 09, 2012
	+	200MG	N020616	007	Feb 27, 2007

MORPHINE SULFATE

	ACTAVIS ELIZABETH	30MG	A079040	001	Jan 16, 2013
		45MG	A079040	002	Jan 16, 2013
		60MG	A079040	003	Jan 16, 2013
		75MG	A079040	004	Jan 16, 2013
		90MG	A079040	005	Jan 16, 2013
	+	120MG	A079040	006	Jan 16, 2013

INJECTABLE; INJECTION

ASTRAMORPH PF

<u>AP</u>	FRESENIUS KABI USA	<u>0.5MG/ML</u>	<u>A071050</u>	<u>001</u>	Oct 07, 1986
<u>AP</u>		<u>0.5MG/ML</u>	<u>A071051</u>	<u>001</u>	Oct 07, 1986
<u>AP</u>		<u>1MG/ML</u>	<u>A071052</u>	<u>001</u>	Oct 07, 1986
<u>AP</u>		<u>1MG/ML</u>	<u>A071053</u>	<u>001</u>	Oct 07, 1986

DURAMORPH PF

<u>AP</u>	+	WEST-WARD PHARMS INT	<u>0.5MG/ML</u>	<u>N018565</u>	<u>001</u>	Sep 18, 1984
<u>AP</u>	+		<u>1MG/ML</u>	<u>N018565</u>	<u>002</u>	Sep 18, 1984

MORPHINE SULFATE

<u>AP</u>	EUROHLTH INTL SARL	<u>4MG/ML</u>	<u>A205758</u>	<u>001</u>	May 21, 2015	
<u>AP</u>		<u>8MG/ML</u>	<u>A205758</u>	<u>002</u>	May 21, 2015	
<u>AP</u>		<u>10MG/ML</u>	<u>A205758</u>	<u>003</u>	May 21, 2015	
<u>AP</u>	HOSPIRA	<u>0.5MG/ML</u>	<u>A071849</u>	<u>001</u>	May 11, 1988	
<u>AP</u>		<u>0.5MG/ML</u>	<u>A073509</u>	<u>001</u>	Sep 30, 1992	
<u>AP</u>		<u>1MG/ML</u>	<u>A071850</u>	<u>001</u>	May 11, 1988	
<u>AP</u>		<u>1MG/ML</u>	<u>A073510</u>	<u>001</u>	Sep 30, 1992	
<u>AP</u>	+		<u>1MG/ML</u>	<u>N019916</u>	<u>001</u>	Oct 30, 1992
<u>AP</u>	+	HOSPIRA INC	<u>4MG/ML</u>	<u>N202515</u>	<u>002</u>	Nov 14, 2011
<u>AP</u>	+		<u>8MG/ML</u>	<u>N202515</u>	<u>003</u>	Nov 14, 2011
<u>AP</u>	+		<u>10MG/ML</u>	<u>N202515</u>	<u>004</u>	Nov 14, 2011

INFUMORPH

	+	WEST-WARD PHARMS INT	10MG/ML	N018565	003	Jul 19, 1991
	+		25MG/ML	N018565	004	Jul 19, 1991

MORPHINE SULFATE

	+	HOSPIRA	5MG/ML	N019916	002	Oct 27, 2006
	+	HOSPIRA INC	2MG/ML	N202515	001	Nov 14, 2011
	+		15MG/ML	N202515	005	Nov 14, 2011

PRESCRIPTION DRUG PRODUCT LIST

MORPHINE SULFATE

INJECTABLE; INJECTION

MORPHINE SULFATE

+ MERIDIAN MEDCL TECHN 15MG/ML
SOLUTION; INTRAMUSCULAR, INTRAVENOUS

N019999 001 Jul 12, 1990

MORPHINE SULFATE

+ FRESENIUS KABI USA 2MG/ML (2MG/ML)
+ 4MG/ML (4MG/ML)
+ 5MG/ML (5MG/ML)
+ 8MG/ML (8MG/ML)
+ 10MG/ML (10MG/ML)N204223 001 Oct 30, 2013
N204223 002 Oct 30, 2013
N204223 003 Oct 30, 2013
N204223 004 Oct 30, 2013
N204223 005 Oct 30, 2013

SOLUTION; ORAL

MORPHINE SULFATE

AA MALLINCKRODT INC 100MG/5ML

AA NOSTRUM LABS INC 10MG/5ML

AA 20MG/5ML

AA 100MG/5ML

AA PADDOCK LLC 100MG/5ML

AA PHARM ASSOC 100MG/5ML

AA RHODES PHARMS 20MG/5ML

AA ROXANE 10MG/5ML

AA 20MG/5ML

AA + 100MG/5ML

AA TRIS PHARMA INC 10MG/5ML

AA 20MG/5ML

AA 100MG/5ML

AA VINTAGE PHARMS LLC 10MG/5ML

AA 20MG/5ML

AA VISTAPHARM 10MG/5ML

AA 20MG/5ML

LANNETT HOLDINGS INC 100MG/5ML

A202348 001 Jul 15, 2011

A201011 001 Feb 05, 2014

A201011 002 Feb 05, 2014

A204053 001 Oct 06, 2016

A201574 001 Aug 06, 2012

A206573 001 Nov 14, 2016

A206420 001 Jul 12, 2016

N022195 001 Mar 17, 2008

N022195 002 Mar 17, 2008

N022195 003 Jan 25, 2010

A203518 001 May 12, 2015

A203519 001 May 18, 2016

A203518 002 May 12, 2015

A202309 001 Nov 25, 2015

A202310 001 Oct 30, 2015

A201947 001 Jan 05, 2012

A201947 002 Jan 05, 2012

N201517 001 Jun 23, 2011

TABLET; ORAL

MORPHINE SULFATE

ROXANE 15MG
+ 30MGN022207 001 Mar 17, 2008
N022207 002 Mar 17, 2008

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

AB ACTAVIS ELIZABETH 15MG

AB 30MG

AB 60MG

AB 100MG

AB 200MG

AB COREPHARMA 15MG

AB 30MG

AB 60MG

AB 100MG

AB 200MG

AB DAVA PHARMS INC 15MG

AB MALLINCKRODT 15MG

AB 30MG

AB 60MG

AB 100MG

AB 200MG

AB MAYNE PHARMA INC 15MG

AB 30MG

AB 60MG

AB 100MG

AB MYLAN PHARMS INC 15MG

AB 30MG

AB 60MG

AB 100MG

AB 200MG

AB NESHER PHARMS 15MG

AB 30MG

AB 60MG

AB 100MG

AB 200MG

AB NOVEL LABS INC 15MG

AB 30MG

AB 60MG

AB 100MG

AB 200MG

A203849 001 Apr 06, 2015

A203849 002 Apr 06, 2015

A203849 003 Apr 06, 2015

A203849 004 Apr 06, 2015

A203849 005 Apr 06, 2015

A091357 001 Jun 23, 2016

A091357 002 Jun 23, 2016

A091357 003 Jun 23, 2016

A091357 004 Jun 23, 2016

A091357 005 Jun 23, 2016

A075407 001 Jan 28, 2000

A076412 001 Jul 31, 2003

A076412 002 Jul 31, 2003

A076412 003 Jul 31, 2003

A076438 001 Jul 03, 2003

A076438 002 Jul 03, 2003

A205386 001 Oct 28, 2016

A205386 002 Oct 28, 2016

A205386 003 Oct 28, 2016

A205386 004 Oct 28, 2016

A200824 001 Oct 18, 2011

A200824 002 Oct 18, 2011

A200824 003 Oct 18, 2011

A200824 004 Oct 18, 2011

A200824 005 Oct 18, 2011

A076733 001 May 19, 2004

A076720 002 Dec 23, 2005

A076720 001 May 19, 2004

A077855 001 Sep 27, 2007

A077855 002 Sep 27, 2007

A203602 001 Dec 16, 2015

A203602 002 Dec 16, 2015

A203602 003 Dec 16, 2015

A203602 004 Dec 16, 2015

A203602 005 Dec 16, 2015

PRESCRIPTION DRUG PRODUCT LIST

MORPHINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

<u>AB</u>	RHODES PHARMS	<u>15MG</u>	<u>A074862 001</u>	Jul 07, 1998
<u>AB</u>		<u>30MG</u>	<u>A074862 002</u>	Jul 07, 1998
<u>AB</u>		<u>60MG</u>	<u>A074862 003</u>	Jul 07, 1998
<u>AB</u>		<u>100MG</u>	<u>A074769 001</u>	Jul 02, 1998
<u>AB</u>		<u>200MG</u>	<u>A074769 002</u>	Jul 02, 1998
<u>AB</u>	SUN PHARM INDS LTD	<u>15MG</u>	<u>A078761 001</u>	May 11, 2012
<u>AB</u>		<u>15MG</u>	<u>A205634 001</u>	Aug 25, 2016
<u>AB</u>		<u>30MG</u>	<u>A078761 002</u>	May 11, 2012
<u>AB</u>		<u>30MG</u>	<u>A205634 002</u>	Aug 25, 2016
<u>AB</u>		<u>60MG</u>	<u>A078761 003</u>	May 11, 2012
<u>AB</u>		<u>60MG</u>	<u>A205634 003</u>	Aug 25, 2016
<u>AB</u>		<u>100MG</u>	<u>A078761 004</u>	May 11, 2012
<u>AB</u>		<u>100MG</u>	<u>A205634 004</u>	Aug 25, 2016
<u>AB</u>		<u>200MG</u>	<u>A078761 005</u>	May 11, 2012
<u>AB</u>		<u>200MG</u>	<u>A205634 005</u>	Aug 25, 2016
<u>AB</u>	VINTAGE PHARMS LLC	<u>15MG</u>	<u>A075295 001</u>	Oct 28, 1998
<u>AB</u>		<u>30MG</u>	<u>A075295 002</u>	Oct 28, 1998
<u>AB</u>		<u>60MG</u>	<u>A075295 003</u>	Oct 28, 1998
<u>AB</u>		<u>100MG</u>	<u>A075295 004</u>	Sep 15, 2000
<u>AB</u>		<u>200MG</u>	<u>A075295 005</u>	Sep 15, 2000

MS CONTIN

<u>AB</u>	PURDUE PHARMA LP	<u>15MG</u>	<u>N019516 003</u>	Sep 12, 1989
<u>AB</u>		<u>30MG</u>	<u>N019516 001</u>	May 29, 1987
<u>AB</u>		<u>60MG</u>	<u>N019516 002</u>	Apr 08, 1988
<u>AB</u>	+	<u>100MG</u>	<u>N019516 004</u>	Jan 16, 1990
<u>AB</u>		<u>200MG</u>	<u>N019516 005</u>	Nov 08, 1993
	MORPHABOND			
	DAIICHI SANKYO INC	15MG	N206544 001	Oct 02, 2015
		30MG	N206544 002	Oct 02, 2015
		60MG	N206544 003	Oct 02, 2015
	+	100MG	N206544 004	Oct 02, 2015

MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

EMBEDA

	ALPHARMA PHARMS	20MG;0.8MG	N022321 001	Aug 13, 2009
		30MG;1.2MG	N022321 002	Aug 13, 2009
		50MG;2MG	N022321 003	Aug 13, 2009
	+	60MG;2.4MG	N022321 004	Aug 13, 2009
		80MG;3.2MG	N022321 005	Aug 13, 2009
		100MG;4MG	N022321 006	Aug 13, 2009

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION;IV (INFUSION)

AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER

+ BAYER HLTHCARE 400MG/250ML (1.6MG/ML) N021277 001 Nov 30, 2001

MOXIFLOXACIN HYDROCHLORIDE

+ FRESENIUS KABI USA EQ 400MG BASE/250ML (EQ 1.6MG BASE/ML) N205572 001 Apr 03, 2015

SOLUTION/DROPS;OPHTHALMIC

MOXIFLOXACIN HYDROCHLORIDE

<u>AT1</u>	LUPIN LTD	<u>EQ 0.5% BASE</u>	<u>A202867 001</u>	Sep 04, 2014	
<u>AT1</u>	WATSON LABS INC	<u>EQ 0.5% BASE</u>	<u>A202525 001</u>	Mar 06, 2015	
	<u>VIGAMOX</u>				
<u>AT1</u>	+	<u>NOVARTIS PHARMS CORP</u>	<u>EQ 0.5% BASE</u>	<u>N021598 001</u>	Apr 15, 2003
	<u>MOXEZA</u>				
<u>AT2</u>	+	<u>NOVARTIS PHARMS CORP</u>	<u>EQ 0.5% BASE</u>	<u>N022428 001</u>	Nov 19, 2010
	<u>MOXIFLOXACIN HYDROCHLORIDE</u>				
<u>AT2</u>	LUPIN LTD	<u>EQ 0.5% BASE</u>	<u>A204079 001</u>	May 28, 2015	
	TABLET;ORAL				
	<u>AVELOX</u>				
<u>AB</u>	+	<u>BAYER HLTHCARE</u>	<u>EQ 400MG BASE</u>	<u>N021085 001</u>	Dec 10, 1999
	<u>MOXIFLOXACIN HYDROCHLORIDE</u>				
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 400MG BASE</u>	<u>A202632 001</u>	Mar 04, 2014	
<u>AB</u>	CROSSMEDIKA SA	<u>EQ 400MG BASE</u>	<u>A205348 001</u>	Jan 14, 2016	
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 400MG BASE</u>	<u>A076938 001</u>	Mar 04, 2014	
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 400MG BASE</u>	<u>A204635 001</u>	Aug 31, 2015	
<u>AB</u>	TEVA PHARMS USA	<u>EQ 400MG BASE</u>	<u>A077437 001</u>	Feb 18, 2014	
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 400MG BASE</u>	<u>A200160 001</u>	Apr 03, 2014	

PRESCRIPTION DRUG PRODUCT LIST

MUPIROCIN

OINTMENT; TOPICAL

BACTROBAN

AB	+	GLAXOSMITHKLINE	2%	N050591	001	Dec 31, 1987
-----------	----------	-----------------	-----------	----------------	------------	--------------

MUPIROCIN

AB		FOUGERA PHARMS	2%	A065192	001	Nov 30, 2005
AB		GLENMARK PHARMS	2%	A090480	001	Jun 08, 2011
AB		PERRIGO NEW YORK	2%	A065123	001	Nov 07, 2003
AB		TARO	2%	A065170	001	Sep 23, 2005
AB		TEVA	2%	A065085	001	Nov 07, 2003

CENTANY

EX		PERRIGO NEW YORK	2%	N050788	001	Dec 04, 2002
-----------	--	------------------	-----------	----------------	------------	--------------

MUPIROCIN CALCIUM

CREAM; TOPICAL

BACTROBAN

AB	+	GLAXOSMITHKLINE	EQ 2% BASE	N050746	001	Dec 11, 1997
-----------	----------	-----------------	-------------------	----------------	------------	--------------

MUPIROCIN

AB		GLENMARK GENERICS	EQ 2% BASE	A201587	001	Jan 24, 2013
-----------	--	-------------------	-------------------	----------------	------------	--------------

OINTMENT; NASAL

BACTROBAN

+	GLAXOSMITHKLINE	EQ 2% BASE	N050703	001	Sep 18, 1995
----------	-----------------	-------------------	----------------	------------	--------------

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL

CELLCEPT

AB	+	ROCHE PALO	250MG	N050722	001	May 03, 1995
-----------	----------	------------	--------------	----------------	------------	--------------

MYCOPHENOLATE MOFETIL

AB		ACCORD HLTHCARE	250MG	A090253	001	May 04, 2009
AB		ALKEM LABS LTD	250MG	A200197	001	Jun 13, 2013
AB		APOTEX CORP	250MG	A090419	001	Apr 22, 2009
AB		JUBILANT CADISTA	250MG	A090762	001	Dec 15, 2014
AB		MYLAN	250MG	A065520	001	May 04, 2009
AB		SANDOZ	250MG	A065379	001	Oct 15, 2008
AB		STRIDES PHARMA	250MG	A090055	001	Jun 10, 2010
AB		TEVA PHARMS	250MG	A065491	001	May 06, 2009
AB		VINTAGE PHARMS LLC	250MG	A090111	001	Dec 22, 2009
AB		WEST-WARD PHARMS INT	250MG	A065410	001	Jul 29, 2008

SUSPENSION; ORAL

CELLCEPT

AB	+	ROCHE PALO	200MG/ML	N050759	001	Oct 01, 1998
-----------	----------	------------	-----------------	----------------	------------	--------------

MYCOPHENOLATE MOFETIL

AB		ALKEM LABS LTD	200MG/ML	A203005	001	Nov 14, 2014
-----------	--	----------------	-----------------	----------------	------------	--------------

TABLET; ORAL

CELLCEPT

AB	+	ROCHE PALO	500MG	N050723	001	Jun 19, 1997
-----------	----------	------------	--------------	----------------	------------	--------------

MYCOPHENOLATE MOFETIL

AB		ACCORD HLTHCARE	500MG	A065416	001	May 04, 2009
AB		ALKEM LABS LTD	500MG	A091249	001	Nov 04, 2011
AB		APOTEX	500MG	A090499	001	Apr 22, 2009
AB		JUBILANT CADISTA	500MG	A090661	001	Dec 15, 2014
AB		MYLAN	500MG	A065521	001	May 04, 2009
AB		SANDOZ	500MG	A065451	001	Oct 15, 2008
AB		STRIDES PHARMA	500MG	A090456	001	Jun 10, 2010
AB		TEVA PHARMS	500MG	A065457	001	May 04, 2009
AB		VINTAGE PHARMS LLC	500MG	A090606	001	Jul 16, 2010
AB		WEST-WARD PHARMS INT	500MG	A065413	001	Jul 29, 2008

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE; INJECTION

CELLCEPT

AP	+	ROCHE PALO	500MG/VIAL	N050758	001	Aug 12, 1998
-----------	----------	------------	-------------------	----------------	------------	--------------

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

AP		PAR STERILE PRODUCTS	500MG/VIAL	A203575	001	Oct 28, 2016
-----------	--	----------------------	-------------------	----------------	------------	--------------

MYCOPHENOLIC ACID

TABLET, DELAYED RELEASE; ORAL

MYCOPHENOLIC ACID

AB		APOTEX INC	180MG	A091558	001	Aug 21, 2012
AB			360MG	A091558	002	Aug 19, 2014
AB		MYLAN PHARMS INC	180MG	A091248	002	Jan 08, 2014
AB			360MG	A091248	001	Jan 08, 2014
AB		TEVA PHARMS USA	180MG	A202720	001	Oct 30, 2014
AB			360MG	A202720	002	Oct 30, 2014

PRESCRIPTION DRUG PRODUCT LIST

MYCOPHENOLIC ACID

TABLET, DELAYED RELEASE;ORAL

MYFORTIC

<u>AB</u>	NOVARTIS	<u>180MG</u>	<u>N050791</u>	<u>001</u>	Feb 27, 2004
<u>AB</u>	+	<u>360MG</u>	<u>N050791</u>	<u>002</u>	Feb 27, 2004

NABILONE

CAPSULE;ORAL

CESAMET

+	MEDA PHARMS	1MG	N018677	001	Dec 26, 1985
---	-------------	-----	---------	-----	--------------

NABUMETONE

TABLET;ORAL

NABUMETONE

<u>AB</u>	APOTEX INC	<u>500MG</u>	<u>A090427</u>	<u>001</u>	Dec 30, 2011
<u>AB</u>		<u>750MG</u>	<u>A090427</u>	<u>002</u>	Dec 30, 2011
<u>AB</u>	CHARTWELL MOLECULES	<u>500MG</u>	<u>A076009</u>	<u>001</u>	Jan 24, 2003
<u>AB</u>		<u>750MG</u>	<u>A076009</u>	<u>002</u>	Jan 24, 2003
<u>AB</u>	IMPAX LABS INC	<u>500MG</u>	<u>A075189</u>	<u>001</u>	May 26, 2000
<u>AB</u>	+	<u>750MG</u>	<u>A075189</u>	<u>002</u>	Sep 24, 2001
<u>AB</u>	INVAGEN PHARMS	<u>500MG</u>	<u>A078671</u>	<u>001</u>	Mar 07, 2008
<u>AB</u>		<u>750MG</u>	<u>A078671</u>	<u>002</u>	Mar 07, 2008
<u>AB</u>	LUPIN LTD	<u>500MG</u>	<u>A090445</u>	<u>001</u>	Jan 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A090445</u>	<u>002</u>	Jan 12, 2011
<u>AB</u>	MYLAN PHARMS INC	<u>500MG</u>	<u>A090516</u>	<u>001</u>	Jul 12, 2010
<u>AB</u>		<u>750MG</u>	<u>A090516</u>	<u>002</u>	Jul 12, 2010
<u>AB</u>	SANDOZ	<u>500MG</u>	<u>A075280</u>	<u>001</u>	Feb 25, 2002
<u>AB</u>		<u>750MG</u>	<u>A075280</u>	<u>002</u>	Feb 25, 2002
<u>AB</u>	WATSON LABS	<u>500MG</u>	<u>A091083</u>	<u>001</u>	Jun 13, 2011
<u>AB</u>		<u>750MG</u>	<u>A091083</u>	<u>002</u>	Jun 13, 2011

NADOLOL

TABLET;ORAL

CORGARD

<u>AB</u>	US WORLDMEDS LLC	<u>20MG</u>	<u>N018063</u>	<u>005</u>	Oct 28, 1986
<u>AB</u>		<u>40MG</u>	<u>N018063</u>	<u>001</u>	
<u>AB</u>	+	<u>80MG</u>	<u>N018063</u>	<u>002</u>	

NADOLOL

<u>AB</u>	INVAGEN PHARMS	<u>20MG</u>	<u>A203455</u>	<u>001</u>	Dec 18, 2015
<u>AB</u>		<u>40MG</u>	<u>A203455</u>	<u>002</u>	Dec 18, 2015
<u>AB</u>		<u>80MG</u>	<u>A203455</u>	<u>003</u>	Dec 18, 2015
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>20MG</u>	<u>A074229</u>	<u>001</u>	Aug 30, 1996
<u>AB</u>		<u>40MG</u>	<u>A074229</u>	<u>002</u>	Aug 30, 1996
<u>AB</u>		<u>80MG</u>	<u>A074255</u>	<u>001</u>	Jan 24, 1996
<u>AB</u>	MYLAN	<u>20MG</u>	<u>A074172</u>	<u>001</u>	Oct 31, 1993
<u>AB</u>		<u>40MG</u>	<u>A074172</u>	<u>002</u>	Oct 31, 1993
<u>AB</u>		<u>80MG</u>	<u>A074172</u>	<u>003</u>	Oct 31, 1993
<u>AB</u>	ORION CORP ORION	<u>40MG</u>	<u>A201893</u>	<u>001</u>	Sep 16, 2015
<u>AB</u>		<u>80MG</u>	<u>A201893</u>	<u>002</u>	Sep 16, 2015
<u>AB</u>	SANDOZ	<u>20MG</u>	<u>A074501</u>	<u>001</u>	Nov 09, 1995
<u>AB</u>		<u>40MG</u>	<u>A074501</u>	<u>002</u>	Nov 09, 1995
<u>AB</u>		<u>80MG</u>	<u>A074501</u>	<u>003</u>	Nov 09, 1995

NAFARELIN ACETATE

SPRAY, METERED;NASAL

SYNAREL

+	GD SEARLE LLC	EQ 0.2MG BASE/SPRAY	N019886	001	Feb 13, 1990
---	---------------	---------------------	---------	-----	--------------

NAFCILLIN SODIUM

INJECTABLE;INJECTION

NAFCILLIN SODIUM

<u>AP</u>	ANTIBIOTICE	<u>EQ 1GM BASE/VIAL</u>	<u>A090560</u>	<u>001</u>	Oct 03, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A090560</u>	<u>002</u>	Oct 03, 2011
<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 1GM BASE/VIAL</u>	<u>A091613</u>	<u>001</u>	Dec 26, 2012
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A091613</u>	<u>002</u>	Dec 26, 2012
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A091614</u>	<u>001</u>	Dec 26, 2012
<u>AP</u>	ISTITUTO BIO ITA SPA	<u>EQ 1GM BASE/VIAL</u>	<u>A090002</u>	<u>001</u>	Jun 30, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A090002</u>	<u>002</u>	Jun 30, 2011
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A090005</u>	<u>001</u>	Apr 20, 2011
<u>AP</u>	MYLAN LABS LTD	<u>EQ 1GM BASE/VIAL</u>	<u>A200002</u>	<u>001</u>	Apr 07, 2014
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A200002</u>	<u>002</u>	Apr 07, 2014
<u>AP</u>	SAGENT PHARMS	<u>EQ 1GM BASE/VIAL</u>	<u>A090582</u>	<u>001</u>	Aug 24, 2012
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A090582</u>	<u>002</u>	Aug 24, 2012
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A090580</u>	<u>001</u>	Aug 24, 2012
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>A062527</u>	<u>002</u>	Aug 02, 1984

PRESCRIPTION DRUG PRODUCT LIST

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NAFCILLIN SODIUM

<u>AP</u>	+		<u>EQ 1GM BASE/VIAL</u>	<u>A062732 001</u>	Dec 23, 1986
<u>AP</u>	+		<u>EQ 2GM BASE/VIAL</u>	<u>A062527 003</u>	Aug 02, 1984
<u>AP</u>	+		<u>EQ 2GM BASE/VIAL</u>	<u>A062732 002</u>	Dec 23, 1986
<u>AP</u>	+		<u>EQ 10GM BASE/VIAL</u>	<u>A062527 004</u>	Aug 02, 1984

NALLPEN IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	EQ 20MG BASE/ML	N050655 001	Oct 31, 1989
+		EQ 2GM BASE/100ML	N050655 002	Oct 31, 1989

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL

NAFTIFINE HYDROCHLORIDE

<u>AB</u>		TARO	<u>1%</u>	<u>A205975 001</u>	Sep 08, 2016
<u>AB</u>			<u>2%</u>	<u>A206901 001</u>	Jan 06, 2016

NAFTIN

<u>AB</u>	+	SEBELA IRELAND LTD	<u>1%</u>	<u>N019599 001</u>	Feb 29, 1988
<u>AB</u>	+		<u>2%</u>	<u>N019599 002</u>	Jan 13, 2012

GEL; TOPICAL

NAFTIN

+	SEBELA IRELAND LTD	1%	N019356 001	Jun 18, 1990
+		2%	N204286 001	Jun 27, 2013

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NALBUPHINE HYDROCHLORIDE

<u>AP</u>	+	HOSPIRA	<u>10MG/ML</u>	<u>A070914 001</u>	Feb 03, 1989
<u>AP</u>	+		<u>10MG/ML</u>	<u>A070915 001</u>	Feb 03, 1989
<u>AP</u>	+		<u>20MG/ML</u>	<u>A070916 001</u>	Feb 03, 1989
<u>AP</u>	+		<u>20MG/ML</u>	<u>A070918 001</u>	Feb 03, 1989

NALOXEGOL OXALATE

TABLET; ORAL

MOVANTI

	ASTRAZENECA PHARMS	EQ 12.5MG BASE	N204760 001	Sep 16, 2014
+		EQ 25MG BASE	N204760 002	Sep 16, 2014

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

<u>AP</u>		WEST-WARD PHARMS INT	<u>0.4MG/ML</u>	<u>A070299 001</u>	Sep 24, 1986
-----------	--	----------------------	-----------------	--------------------	--------------

NALOXONE HYDROCHLORIDE

<u>AP</u>	+	HOSPIRA	<u>0.4MG/ML</u>	<u>A070172 001</u>	Sep 24, 1986
<u>AP</u>	+		<u>0.4MG/ML</u>	<u>A070254 001</u>	Jan 07, 1987
<u>AP</u>	+		<u>0.4MG/ML</u>	<u>A070256 001</u>	Jan 07, 1987
<u>AP</u>	+		<u>0.4MG/ML</u>	<u>A070257 001</u>	Jan 07, 1987
<u>AP</u>		INTL MEDICATION	<u>0.4MG/ML</u>	<u>A070639 001</u>	Sep 24, 1986
<u>AP</u>	+		<u>1MG/ML</u>	<u>A072076 001</u>	Mar 24, 1988
<u>AP</u>		MYLAN INSTITUTIONAL	<u>0.4MG/ML</u>	<u>A204997 001</u>	Mar 06, 2014
<u>AP</u>			<u>0.4MG/ML</u>	<u>A205014 001</u>	Jun 29, 2016

SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS

EVZIO

+	KALEO INC	0.4MG/0.4ML (0.4MG/0.4ML)	N205787 001	Apr 03, 2014
+		2MG/0.4ML (2MG/0.4ML)	N209862 001	Oct 19, 2016

SPRAY, METERED; NASAL

NARCAN

+	ADAPT	4MG/SPRAY	N208411 001	Nov 18, 2015
---	-------	-----------	-------------	--------------

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE

<u>AB</u>		GAVIS PHARMS	<u>EQ 0.5MG BASE;EQ 50MG BASE</u>	<u>A075735 001</u>	Jul 11, 2001
<u>AB</u>		SUN PHARM INDS LTD	<u>EQ 0.5MG BASE;EQ 50MG BASE</u>	<u>A075523 001</u>	Mar 17, 2000
<u>AB</u>	+	WATSON LABS	<u>EQ 0.5MG BASE;EQ 50MG BASE</u>	<u>A074736 001</u>	Jan 21, 1997

NALTREXONE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

VIVITROL

+	ALKERMES	380MG/VIAL	N021897 001	Apr 13, 2006
---	----------	------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

<u>AB</u>	ACCORD HLTHCARE	<u>50MG</u>	<u>A091205</u>	<u>001</u>	Aug 17, 2011
<u>AB</u>	BARR	<u>50MG</u>	<u>A074918</u>	<u>001</u>	May 08, 1998
<u>AB</u>	ELITE LABS	<u>50MG</u>	<u>A075274</u>	<u>001</u>	May 26, 1999
<u>AB</u>	+ MALLINCKRODT	<u>50MG</u>	<u>A076264</u>	<u>002</u>	Mar 22, 2002
<u>AB</u>	SUN PHARMA GLOBAL	<u>50MG</u>	<u>A090356</u>	<u>001</u>	Feb 24, 2012
	MALLINCKRODT	25MG	A076264	001	Mar 22, 2002
		100MG	A076264	003	Mar 22, 2002

NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

TROXYCA ER

	PFIZER INC	1.2MG;10MG	N207621	001	Aug 19, 2016
		2.4MG;20MG	N207621	002	Aug 19, 2016
		3.6MG;30MG	N207621	003	Aug 19, 2016
		4.8MG;40MG	N207621	004	Aug 19, 2016
		7.2MG;60MG	N207621	005	Aug 19, 2016
		9.6MG;80MG	N207621	006	Aug 19, 2016

NANDROLONE DECANOATE

INJECTABLE; INJECTION

NANDROLONE DECANOATE

	+ PHARMAFORCE	200MG/ML	A091252	001	Aug 30, 2010
--	---------------	----------	---------	-----	--------------

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

NAPHAZOLINE HYDROCHLORIDE

	+ AKORN INC	0.1%	A083590	001	
--	-------------	------	---------	-----	--

NAPROXEN

SUSPENSION; ORAL

NAPROSYN

<u>AB</u>	+ ATNAHS PHARMA US	<u>25MG/ML</u>	<u>N018965</u>	<u>001</u>	Mar 23, 1987
-----------	--------------------	----------------	----------------	------------	--------------

NAPROXEN

<u>AB</u>	WEST-WARD PHARMS INT	<u>25MG/ML</u>	<u>A074190</u>	<u>001</u>	Mar 30, 1994
-----------	----------------------	----------------	----------------	------------	--------------

TABLET; ORAL

NAPROSYN

<u>AB</u>	ATNAHS PHARMA US	<u>250MG</u>	<u>N017581</u>	<u>002</u>	
<u>AB</u>		<u>375MG</u>	<u>N017581</u>	<u>003</u>	
<u>AB</u>	+	<u>500MG</u>	<u>N017581</u>	<u>004</u>	Apr 15, 1982

NAPROXEN

<u>AB</u>	AMNEAL PHARMS NY	<u>250MG</u>	<u>A075927</u>	<u>001</u>	Dec 18, 2001
<u>AB</u>		<u>375MG</u>	<u>A075927</u>	<u>002</u>	Dec 18, 2001
<u>AB</u>		<u>500MG</u>	<u>A075927</u>	<u>003</u>	Dec 18, 2001
<u>AB</u>	AUROBINDO PHARMA USA	<u>250MG</u>	<u>A200429</u>	<u>001</u>	Nov 08, 2011
<u>AB</u>		<u>375MG</u>	<u>A200429</u>	<u>002</u>	Nov 08, 2011
<u>AB</u>		<u>500MG</u>	<u>A200429</u>	<u>003</u>	Nov 08, 2011
<u>AB</u>	GLENMARK GENERICS	<u>250MG</u>	<u>A078250</u>	<u>001</u>	Mar 28, 2007
<u>AB</u>		<u>375MG</u>	<u>A078250</u>	<u>002</u>	Mar 28, 2007
<u>AB</u>		<u>500MG</u>	<u>A078250</u>	<u>003</u>	Mar 28, 2007
<u>AB</u>	HIKMA INTL PHARMS	<u>250MG</u>	<u>A076494</u>	<u>001</u>	Jan 14, 2004
<u>AB</u>		<u>375MG</u>	<u>A076494</u>	<u>002</u>	Jan 14, 2004
<u>AB</u>		<u>500MG</u>	<u>A076494</u>	<u>003</u>	Jan 14, 2004
<u>AB</u>	INVAGEN PHARMS	<u>250MG</u>	<u>A091305</u>	<u>001</u>	Aug 24, 2011
<u>AB</u>		<u>375MG</u>	<u>A091305</u>	<u>002</u>	Aug 24, 2011
<u>AB</u>		<u>500MG</u>	<u>A091305</u>	<u>003</u>	Aug 24, 2011
<u>AB</u>	MARKSANS PHARMA	<u>250MG</u>	<u>A091416</u>	<u>001</u>	Feb 14, 2011
<u>AB</u>		<u>375MG</u>	<u>A091416</u>	<u>002</u>	Feb 14, 2011
<u>AB</u>		<u>500MG</u>	<u>A091416</u>	<u>003</u>	Feb 14, 2011
<u>AB</u>	MYLAN	<u>250MG</u>	<u>A074121</u>	<u>001</u>	Dec 21, 1993
<u>AB</u>		<u>375MG</u>	<u>A074121</u>	<u>002</u>	Dec 21, 1993
<u>AB</u>		<u>500MG</u>	<u>A074121</u>	<u>003</u>	Dec 21, 1993
<u>AB</u>	PERRIGO R AND D	<u>250MG</u>	<u>A077339</u>	<u>001</u>	Apr 27, 2005
<u>AB</u>		<u>375MG</u>	<u>A077339</u>	<u>002</u>	Apr 27, 2005
<u>AB</u>		<u>500MG</u>	<u>A077339</u>	<u>003</u>	Apr 27, 2005
<u>AB</u>	TEVA	<u>250MG</u>	<u>A074201</u>	<u>001</u>	Dec 21, 1993
<u>AB</u>		<u>375MG</u>	<u>A074201</u>	<u>002</u>	Dec 21, 1993
<u>AB</u>		<u>500MG</u>	<u>A074201</u>	<u>003</u>	Dec 21, 1993
<u>AB</u>	ZYDUS PHARMS USA	<u>250MG</u>	<u>A078620</u>	<u>001</u>	Jun 07, 2007
<u>AB</u>		<u>375MG</u>	<u>A078620</u>	<u>002</u>	Jun 07, 2007
<u>AB</u>		<u>500MG</u>	<u>A078620</u>	<u>003</u>	Jun 07, 2007

PRESCRIPTION DRUG PRODUCT LIST

NAPROXEN

TABLET, DELAYED RELEASE;ORAL

EC-NAPROSYN

<u>AB</u>	+	ATNAHS PHARMA US	<u>375MG</u>	<u>N020067</u>	<u>002</u>	Oct 14, 1994
<u>AB</u>	+		<u>500MG</u>	<u>N020067</u>	<u>003</u>	Oct 14, 1994

NAPROXEN

<u>AB</u>		INVAGEN PHARMS	<u>375MG</u>	<u>A091432</u>	<u>001</u>	Sep 19, 2011
<u>AB</u>			<u>500MG</u>	<u>A091432</u>	<u>002</u>	Sep 19, 2011
<u>AB</u>		MYLAN PHARMS INC	<u>375MG</u>	<u>A075390</u>	<u>001</u>	Apr 19, 2001
<u>AB</u>			<u>500MG</u>	<u>A075390</u>	<u>002</u>	Apr 19, 2001
<u>AB</u>		PLIVA	<u>375MG</u>	<u>A075337</u>	<u>001</u>	May 26, 1999
<u>AB</u>			<u>500MG</u>	<u>A075337</u>	<u>002</u>	May 26, 1999
<u>AB</u>		TEVA	<u>375MG</u>	<u>A075227</u>	<u>001</u>	Jun 30, 1998
<u>AB</u>			<u>500MG</u>	<u>A075227</u>	<u>002</u>	Jun 30, 1998

NAPROXEN SODIUM

TABLET;ORAL

ANAPROX

<u>AB</u>		ATNAHS PHARMA US	<u>EQ 250MG BASE</u>	<u>N018164</u>	<u>001</u>	
-----------	--	------------------	----------------------	----------------	------------	--

ANAPROX DS

<u>AB</u>	+	ATNAHS PHARMA US	<u>EQ 500MG BASE</u>	<u>N018164</u>	<u>003</u>	Sep 30, 1987
-----------	---	------------------	----------------------	----------------	------------	--------------

NAPROXEN SODIUM

<u>AB</u>		AMNEAL PHARMS NY	<u>EQ 250MG BASE</u>	<u>A078432</u>	<u>001</u>	Apr 25, 2007
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A078432</u>	<u>002</u>	Apr 25, 2007
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 250MG BASE</u>	<u>A200629</u>	<u>001</u>	Oct 31, 2011
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A200629</u>	<u>002</u>	Oct 31, 2011
<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 250MG BASE</u>	<u>A078486</u>	<u>001</u>	Jul 26, 2007
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A078486</u>	<u>002</u>	Jul 26, 2007
<u>AB</u>		GLENMARK GENERICS	<u>EQ 250MG BASE</u>	<u>A078314</u>	<u>001</u>	Apr 27, 2007
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A078314</u>	<u>002</u>	Apr 27, 2007
<u>AB</u>		TEVA	<u>EQ 250MG BASE</u>	<u>A074198</u>	<u>001</u>	Dec 21, 1993
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A074198</u>	<u>002</u>	Dec 21, 1993

TABLET, EXTENDED RELEASE;ORAL

NAPRELAN

<u>AB</u>		ALVOGEN MALTA	<u>EQ 375MG BASE</u>	<u>N020353</u>	<u>001</u>	Jan 05, 1996
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>N020353</u>	<u>002</u>	Jan 05, 1996
<u>AB</u>	+		<u>EQ 750MG BASE</u>	<u>N020353</u>	<u>003</u>	Jan 05, 1996

NAPROXEN SODIUM

<u>AB</u>		ACTAVIS LABS FL INC	<u>EQ 375MG BASE</u>	<u>A075416</u>	<u>002</u>	Apr 23, 2003
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A075416</u>	<u>001</u>	Aug 27, 2002
<u>AB</u>			<u>EQ 750MG BASE</u>	<u>A075416</u>	<u>003</u>	Aug 11, 2016

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET;ORAL

TREXIMET

		PERNIX IRELAND LTD	<u>60MG;EQ 10MG BASE</u>	<u>N021926</u>	<u>002</u>	May 14, 2015
	+		<u>500MG;EQ 85MG BASE</u>	<u>N021926</u>	<u>001</u>	Apr 15, 2008

NARATRIPTAN HYDROCHLORIDE

TABLET;ORAL

AMERGE

<u>AB</u>		GLAXOSMITHKLINE LLC	<u>EQ 1MG BASE</u>	<u>N020763</u>	<u>002</u>	Feb 10, 1998
<u>AB</u>	+		<u>EQ 2.5MG BASE</u>	<u>N020763</u>	<u>001</u>	Feb 10, 1998

NARATRIPTAN

<u>AB</u>		APOTEX CORP	<u>EQ 1MG BASE</u>	<u>A091373</u>	<u>001</u>	Apr 22, 2011
<u>AB</u>			<u>EQ 2.5MG BASE</u>	<u>A091373</u>	<u>002</u>	Apr 22, 2011
<u>AB</u>		HERITAGE PHARMS INC	<u>EQ 1MG BASE</u>	<u>A200502</u>	<u>001</u>	Feb 28, 2011
<u>AB</u>			<u>EQ 2.5MG BASE</u>	<u>A200502</u>	<u>002</u>	Feb 28, 2011
<u>AB</u>		MYLAN PHARMS INC	<u>EQ 1MG BASE</u>	<u>A202431</u>	<u>001</u>	May 31, 2012
<u>AB</u>			<u>EQ 2.5MG BASE</u>	<u>A202431</u>	<u>002</u>	May 31, 2012
<u>AB</u>		ORCHID HLTHCARE	<u>EQ 1MG BASE</u>	<u>A091441</u>	<u>001</u>	Apr 30, 2012
<u>AB</u>			<u>EQ 2.5MG BASE</u>	<u>A091441</u>	<u>002</u>	Apr 30, 2012
<u>AB</u>		PADDOCK LLC	<u>EQ 1MG BASE</u>	<u>A091326</u>	<u>001</u>	Jul 08, 2010
<u>AB</u>			<u>EQ 2.5MG BASE</u>	<u>A091326</u>	<u>002</u>	Jul 08, 2010
<u>AB</u>		SANDOZ	<u>EQ 1MG BASE</u>	<u>A090288</u>	<u>001</u>	Jul 07, 2010
<u>AB</u>			<u>EQ 2.5MG BASE</u>	<u>A090288</u>	<u>002</u>	Jul 07, 2010
<u>AB</u>		SUN PHARM INDS LTD	<u>EQ 2.5MG BASE</u>	<u>A091552</u>	<u>001</u>	Feb 14, 2011
<u>AB</u>		TEVA PHARMS	<u>EQ 1MG BASE</u>	<u>A078751</u>	<u>001</u>	Jul 07, 2010
<u>AB</u>			<u>EQ 2.5MG BASE</u>	<u>A078751</u>	<u>002</u>	Jul 07, 2010
<u>AB</u>		WEST-WARD PHARMS INT	<u>EQ 1MG BASE</u>	<u>A090381</u>	<u>001</u>	Jul 07, 2010
<u>AB</u>			<u>EQ 2.5MG BASE</u>	<u>A090381</u>	<u>002</u>	Jul 07, 2010

PRESCRIPTION DRUG PRODUCT LIST

NATAMYCIN

SUSPENSION;OPHTHALMIC

NATACYN

+ ALCON

5%

N050514 001

NATEGLINIDE

TABLET;ORAL

NATEGLINIDE

<u>AB</u>	ALVOGEN MALTA	<u>60MG</u>	<u>A205055 001</u>	Dec 11, 2015
<u>AB</u>		<u>120MG</u>	<u>A205055 002</u>	Dec 11, 2015
<u>AB</u>	DR REDDYS LABS LTD	<u>60MG</u>	<u>A077461 001</u>	Sep 09, 2009
<u>AB</u>		<u>120MG</u>	<u>A077461 002</u>	Sep 09, 2009
<u>AB</u>	PAR PHARM	<u>60MG</u>	<u>A077463 001</u>	Sep 09, 2009
<u>AB</u>		<u>120MG</u>	<u>A077463 002</u>	Sep 09, 2009
<u>AB</u>	WATSON LABS	<u>60MG</u>	<u>A077462 001</u>	Mar 30, 2011
<u>AB</u>		<u>120MG</u>	<u>A077462 002</u>	Mar 30, 2011
<u>AB</u>	ZYDUS PHARMS USA INC	<u>60MG</u>	<u>A205248 001</u>	Jul 06, 2016
<u>AB</u>		<u>120MG</u>	<u>A205248 002</u>	Jul 06, 2016
	<u>STARLIX</u>			
<u>AB</u>	NOVARTIS	<u>60MG</u>	<u>N021204 001</u>	Dec 22, 2000
<u>AB</u>	+	<u>120MG</u>	<u>N021204 002</u>	Dec 22, 2000

NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL

BYSTOLIC

FOREST LABS

EQ 2.5MG BASE

N021742 002 Dec 17, 2007

EQ 5MG BASE

N021742 003 Dec 17, 2007

EQ 10MG BASE

N021742 004 Dec 17, 2007

+

EQ 20MG BASE

N021742 005 Oct 08, 2008

NEBIVOLOL HYDROCHLORIDE; VALSARTAN

TABLET;ORAL

BYVALSON

FOREST LABS LLC

EQ 5MG BASE;80MG

N206302 001 Jun 03, 2016

NEDOCROMIL SODIUM

SOLUTION/DROPS;OPHTHALMIC

ALOCRIIL

<u>AT</u>	+	ALLERGAN	<u>2%</u>	<u>N021009 001</u>	Dec 08, 1999
		<u>NEDOCROMIL SODIUM</u>			
<u>AT</u>		AKORN	<u>2%</u>	<u>A090638 001</u>	Aug 22, 2012

NEFAZODONE HYDROCHLORIDE

TABLET;ORAL

NEFAZODONE HYDROCHLORIDE

<u>AB</u>	TEVA	<u>50MG</u>	<u>A076037 001</u>	Sep 16, 2003
<u>AB</u>		<u>100MG</u>	<u>A076037 002</u>	Sep 16, 2003
<u>AB</u>		<u>150MG</u>	<u>A076037 003</u>	Sep 16, 2003
<u>AB</u>		<u>200MG</u>	<u>A076037 004</u>	Sep 16, 2003
<u>AB</u>	+	<u>250MG</u>	<u>A076037 005</u>	Sep 16, 2003
BX	DR REDDYS LABS INC	50MG	A076309 001	Sep 16, 2003
BX		100MG	A076309 002	Sep 16, 2003
BX		150MG	A076309 003	Sep 16, 2003
BX		200MG	A076309 004	Sep 16, 2003
BX		250MG	A076309 005	Sep 16, 2003

NELARABINE

INJECTABLE;IV (INFUSION)

ARRANON

+ NOVARTIS PHARMS CORP

250MG/50ML (5MG/ML)

N021877 001 Oct 28, 2005

NELFINAVIR MESYLATE

TABLET;ORAL

VIRACEPT

+ AGOURON

EQ 250MG BASE

N020779 001 Mar 14, 1997

+

EQ 625MG BASE

N021503 001 Apr 30, 2003

NEOMYCIN SULFATE

SOLUTION;ORAL

NEO-FRADIN

+ X GEN PHARMS

EQ 87.5MG BASE/5ML

A065010 001 May 23, 2002

TABLET;ORAL

NEOMYCIN SULFATE

<u>AA</u>	LANNETT HOLDINGS INC	<u>500MG</u>	<u>A204435 001</u>	Jun 10, 2016
<u>AA</u>	OMAN PHARM PRODUCTS	<u>500MG</u>	<u>A065468 001</u>	Mar 29, 2010
<u>AA</u>	+	<u>500MG</u>	<u>A060304 001</u>	

PRESCRIPTION DRUG PRODUCT LIST

NEOMYCIN SULFATE

TABLET; ORAL

NEOMYCIN SULFATE

<u>AA</u>	X GEN PHARMS	<u>500MG</u>	<u>A065220</u>	<u>001</u>	Jul 28, 2006
-----------	--------------	--------------	----------------	------------	--------------

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION

NEOMYCIN AND POLYMYXIN B SULFATE

<u>AT</u>	WATSON LABS	<u>EQ 40MG BASE/ML;200,000 UNITS/ML</u>	<u>A062664</u>	<u>001</u>	Apr 08, 1986
-----------	-------------	---	----------------	------------	--------------

<u>AT</u>	X GEN PHARMS	<u>EQ 40MG BASE/ML;200,000 UNITS/ML</u>	<u>A065106</u>	<u>001</u>	Jan 31, 2006
-----------	--------------	---	----------------	------------	--------------

<u>AT</u>		<u>EQ 40MG BASE/ML;200,000 UNITS/ML</u>	<u>A065108</u>	<u>001</u>	Jan 31, 2006
-----------	--	---	----------------	------------	--------------

NEOSPORIN G.U. IRRIGANT

<u>AT</u>	+ MONARCH PHARMS	<u>EQ 40MG BASE/ML;200,000 UNITS/ML</u>	<u>A060707</u>	<u>001</u>	
-----------	------------------	---	----------------	------------	--

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

BLOXIVERZ

<u>AP</u>	+ ECLAT PHARMS LLC	<u>5MG/10ML (0.5MG/ML)</u>	<u>N204078</u>	<u>001</u>	May 31, 2013
-----------	--------------------	----------------------------	----------------	------------	--------------

<u>AP</u>	+	<u>10MG/10ML (1MG/ML)</u>	<u>N204078</u>	<u>002</u>	May 31, 2013
-----------	---	---------------------------	----------------	------------	--------------

NEOSTIGMINE METHYLSULFATE

<u>AP</u>	EUROHLTH INTL SARL	<u>5MG/10ML (0.5MG/ML)</u>	<u>A207042</u>	<u>001</u>	Dec 28, 2015
-----------	--------------------	----------------------------	----------------	------------	--------------

<u>AP</u>		<u>10MG/10ML (1MG/ML)</u>	<u>A207042</u>	<u>002</u>	Dec 28, 2015
-----------	--	---------------------------	----------------	------------	--------------

	FRESENIUS KABI USA	5MG/10ML (0.5MG/ML)	N203629	001	Jan 08, 2015
--	--------------------	---------------------	---------	-----	--------------

		10MG/10ML (1MG/ML)	N203629	002	Jan 08, 2015
--	--	--------------------	---------	-----	--------------

NEPAFENAC

SUSPENSION/DROPS; OPHTHALMIC

ILEVRO

	+ NOVARTIS PHARMS CORP	0.3%	N203491	001	Oct 16, 2012
--	------------------------	------	---------	-----	--------------

NEVANAC

	+ NOVARTIS PHARMS CORP	0.1%	N021862	001	Aug 19, 2005
--	------------------------	------	---------	-----	--------------

NESIRITIDE RECOMBINANT

FOR SOLUTION; INTRAVENOUS

NATRECOR

	+ SCIOS LLC	1.5MG/VIAL	N020920	001	Aug 10, 2001
--	-------------	------------	---------	-----	--------------

NETUPITANT; PALONOSETRON HYDROCHLORIDE

CAPSULE; ORAL

AKYNZEO

	+ HELSINN HLTHCARE	300MG;EQ 0.5MG BASE	N205718	001	Oct 10, 2014
--	--------------------	---------------------	---------	-----	--------------

NEVIRAPINE

SUSPENSION; ORAL

NEVIRAPINE

<u>AA</u>	AUROBINDO	<u>50MG/5ML</u>	<u>A077702</u>	<u>001</u>	May 22, 2012
-----------	-----------	-----------------	----------------	------------	--------------

VIRAMUNE

<u>AA</u>	+ BOEHRINGER INGELHEIM	<u>50MG/5ML</u>	<u>N020933</u>	<u>001</u>	Sep 11, 1998
-----------	------------------------	-----------------	----------------	------------	--------------

TABLET; ORAL

NEVIRAPINE

<u>AB</u>	APOTEX INC	<u>200MG</u>	<u>A203021</u>	<u>001</u>	May 22, 2012
-----------	------------	--------------	----------------	------------	--------------

<u>AB</u>	AUROBINDO	<u>200MG</u>	<u>A077521</u>	<u>001</u>	May 22, 2012
-----------	-----------	--------------	----------------	------------	--------------

<u>AB</u>	CIPLA	<u>200MG</u>	<u>A077956</u>	<u>001</u>	May 22, 2012
-----------	-------	--------------	----------------	------------	--------------

<u>AB</u>	HETERO LABS LTD III	<u>200MG</u>	<u>A078584</u>	<u>001</u>	May 22, 2012
-----------	---------------------	--------------	----------------	------------	--------------

<u>AB</u>	MICRO LABS LTD	<u>200MG</u>	<u>A203080</u>	<u>001</u>	May 22, 2012
-----------	----------------	--------------	----------------	------------	--------------

<u>AB</u>	MYLAN LABS	<u>200MG</u>	<u>A078864</u>	<u>001</u>	May 22, 2012
-----------	------------	--------------	----------------	------------	--------------

<u>AB</u>	MYLAN PHARMS INC	<u>200MG</u>	<u>A202523</u>	<u>001</u>	May 22, 2012
-----------	------------------	--------------	----------------	------------	--------------

<u>AB</u>	PRINSTON INC	<u>200MG</u>	<u>A078644</u>	<u>001</u>	May 22, 2012
-----------	--------------	--------------	----------------	------------	--------------

<u>AB</u>	SCIEGEN PHARMS INC	<u>200MG</u>	<u>A203176</u>	<u>001</u>	May 22, 2012
-----------	--------------------	--------------	----------------	------------	--------------

<u>AB</u>	STRIDES PHARMA	<u>200MG</u>	<u>A078195</u>	<u>001</u>	May 22, 2012
-----------	----------------	--------------	----------------	------------	--------------

VIRAMUNE

<u>AB</u>	+ BOEHRINGER INGELHEIM	<u>200MG</u>	<u>N020636</u>	<u>001</u>	Jun 21, 1996
-----------	------------------------	--------------	----------------	------------	--------------

TABLET, EXTENDED RELEASE; ORAL

NEVIRAPINE

<u>AB</u>	ALVOGEN MALTA	<u>100MG</u>	<u>A204621</u>	<u>002</u>	Nov 09, 2015
-----------	---------------	--------------	----------------	------------	--------------

<u>AB</u>		<u>400MG</u>	<u>A204621</u>	<u>001</u>	Jul 10, 2015
-----------	--	--------------	----------------	------------	--------------

<u>AB</u>	APOTEX INC	<u>400MG</u>	<u>A205258</u>	<u>001</u>	Apr 03, 2014
-----------	------------	--------------	----------------	------------	--------------

<u>AB</u>	AUROBINDO PHARMA LTD	<u>100MG</u>	<u>A208616</u>	<u>001</u>	Nov 23, 2016
-----------	----------------------	--------------	----------------	------------	--------------

<u>AB</u>	CIPLA LTD	<u>400MG</u>	<u>A206448</u>	<u>001</u>	Oct 15, 2015
-----------	-----------	--------------	----------------	------------	--------------

<u>AB</u>	MYLAN PHARMS INC	<u>100MG</u>	<u>A206271</u>	<u>001</u>	Nov 09, 2015
-----------	------------------	--------------	----------------	------------	--------------

<u>AB</u>		<u>400MG</u>	<u>A205651</u>	<u>001</u>	Oct 27, 2014
-----------	--	--------------	----------------	------------	--------------

<u>AB</u>	SANDOZ INC	<u>400MG</u>	<u>A203411</u>	<u>001</u>	Apr 03, 2014
-----------	------------	--------------	----------------	------------	--------------

VIRAMUNE XR

<u>AB</u>	BOEHRINGER INGELHEIM	<u>100MG</u>	<u>N201152</u>	<u>002</u>	Nov 08, 2012
-----------	----------------------	--------------	----------------	------------	--------------

<u>AB</u>	+	<u>400MG</u>	<u>N201152</u>	<u>001</u>	Mar 25, 2011
-----------	---	--------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LISTNIACIN

TABLET; ORAL

NIACIN**AA** WOCKHARDT **500MG** **A081134 001** Apr 28, 1992**NIACOR****AA** + UPSHER SMITH **500MG** **A040378 001** May 03, 2000

TABLET, EXTENDED RELEASE; ORAL

NIACIN**AB** AMNEAL PHARMS **500MG** **A203578 001** Jul 24, 2015**AB** **750MG** **A204178 001** Dec 11, 2015**AB** **1GM** **A203578 002** Jul 24, 2015**AB** BARR **500MG** **A076378 001** Apr 26, 2005**AB** **750MG** **A076378 002** Apr 26, 2005**AB** **1GM** **A076250 001** Apr 14, 2005**AB** LUPIN LTD **500MG** **A090860 001** Mar 20, 2014**AB** **750MG** **A090892 001** Mar 20, 2014**AB** **1GM** **A090446 001** Mar 20, 2014**AB** SUN PHARMA GLOBAL **500MG** **A200484 001** Apr 23, 2014**AB** **750MG** **A201273 001** Apr 23, 2014**AB** **1GM** **A200484 002** Apr 23, 2014**NIASPAN****AB** ABBVIE **500MG** **N020381 002** Jul 28, 1997**AB** + **750MG** **N020381 003** Jul 28, 1997**AB** + **1GM** **N020381 004** Jul 28, 1997NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

NICARDIPINE HYDROCHLORIDE**AB** ANI PHARMS INC **20MG** **A074439 001** Dec 10, 1996**AB** **20MG** **A074540 001** Oct 28, 1996**AB** **30MG** **A074439 002** Dec 10, 1996**AB** **30MG** **A074540 002** Oct 28, 1996**AB** EPIC PHARMA **20MG** **A074928 001** Mar 19, 1998**AB** **30MG** **A074928 002** Mar 19, 1998**AB** MYLAN **20MG** **A074642 001** Jul 18, 1996**AB** + **30MG** **A074642 002** Jul 18, 1996

INJECTABLE; INJECTION

CARDENE**AP** + CHIESI USA INC **25MG/10ML (2.5MG/ML)** **N019734 001** Jan 30, 1992**NICARDIPINE HYDROCHLORIDE****AP** EUROHLTH INTL SARL **25MG/10ML (2.5MG/ML)** **A078714 001** Dec 28, 2009**AP** EXELA PHARMA SCIENCE **25MG/10ML (2.5MG/ML)** **N022276 001** Jul 24, 2008**AP** LUITPOLD PHARMS INC **25MG/10ML (2.5MG/ML)** **A090534 001** Nov 17, 2009**AP** MYLAN INSTITUTIONAL **25MG/10ML (2.5MG/ML)** **A090664 001** Nov 17, 2009**AP** NAVINTA LLC **25MG/10ML (2.5MG/ML)** **A090125 001** Nov 17, 2009**AP** SUN PHARMA GLOBAL **25MG/10ML (2.5MG/ML)** **N078405 001** Nov 17, 2009**AP** WOCKHARDT **25MG/10ML (2.5MG/ML)** **A090671 001** Nov 17, 2009

INJECTABLE; INTRAVENOUS

CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER

+ CHIESI USA INC 40MG/200ML (0.2MG/ML)

N019734 004 Nov 07, 2008

CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER

+ CHIESI USA INC 20MG/200ML (0.1MG/ML)

N019734 003 Jul 31, 2008

CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER

+ CHIESI USA INC 20MG/200ML (0.1MG/ML)

N019734 002 Jul 31, 2008

CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER

+ CHIESI USA INC 40MG/200ML (0.2MG/ML)

N019734 005 Nov 07, 2008

NICOTINE

INHALANT; ORAL

NICOTROL

+ PHARMACIA AND UPJOHN 4MG/CARTRIDGE

N020714 001 May 02, 1997

SPRAY, METERED; NASAL

NICOTROL

+ PFIZER INC 0.5MG/SPRAY

N020385 001 Mar 22, 1996

NIFEDIPINE

CAPSULE; ORAL

NIFEDIPINE**AB** ACTAVIS ELIZABETH **10MG** **A072579 001** Jan 08, 1991**AB** **20MG** **A072556 001** Sep 20, 1990**AB** HERITAGE PHARMA **10MG** **A202644 001** Apr 25, 2013**AB** **20MG** **A202644 002** Apr 25, 2013**AB** INTERGEL PHARM **10MG** **A072781 001** Jul 30, 1993**AB** VALIDUS PHARMS **10MG** **A073250 001** Oct 08, 1991

PRESCRIPTION DRUG PRODUCT LIST

NIFEDIPINE

CAPSULE; ORAL

NIFEDIPINE**AB** 20MG **A074045 001** Apr 30, 1992PROCARDIA**AB** + PFIZER 10MG **N018482 001**

TABLET, EXTENDED RELEASE; ORAL

ADALAT CC**AB1** ALVOGEN 30MG **N020198 001** Apr 21, 1993**AB1** + 60MG **N020198 002** Apr 21, 1993**AB1** + 90MG **N020198 003** Apr 21, 1993AFEDITAB CR**AB1** WATSON LABS 30MG **A075128 001** Mar 10, 2000**AB1** 60MG **A075659 001** Oct 26, 2001NIFEDIPINE**AB1** MYLAN 30MG **A201071 001** Dec 03, 2010**AB1** 60MG **A201071 002** Dec 03, 2010**AB1** 90MG **A201071 003** Dec 03, 2010**AB1** NOVAST LABS LTD 30MG **A202987 001** Aug 25, 2016**AB1** 60MG **A202987 002** Aug 25, 2016**AB1** 90MG **A202987 003** Aug 25, 2016**AB1** PAR PHARM 30MG **A077899 001** Dec 13, 2006**AB1** 60MG **A077899 002** Dec 13, 2006**AB1** 90MG **A077899 003** May 25, 2012**AB1** VALEANT PHARMS NORTH 30MG **A075269 001** Dec 04, 2000**AB1** 60MG **A075269 002** Dec 04, 2000**AB1** 90MG **A076070 001** Aug 16, 2002**AB2** MATRIX LABS LTD 30MG **A090602 001** Sep 13, 2010**AB2** 60MG **A090602 002** Sep 13, 2010**AB2** 90MG **A090602 003** Sep 13, 2010**AB2** MYLAN 30MG **A090649 001** Jun 21, 2010**AB2** 60MG **A090649 002** Jun 21, 2010**AB2** 90MG **A090649 003** Jun 21, 2010**AB2** OSMOTICA PHARM 30MG **A077410 001** Oct 03, 2007**AB2** OSMOTICA PHARM US 30MG **A077127 001** Nov 21, 2005**AB2** 60MG **A077127 002** Nov 21, 2005**AB2** TWI PHARMS INC 30MG **A203126 001** Apr 03, 2014**AB2** 60MG **A203126 002** Apr 03, 2014**AB2** 90MG **A203126 003** Apr 03, 2014**AB2** VALEANT PHARMS NORTH 30MG **A075289 002** Feb 06, 2001**AB2** 60MG **A075289 001** Sep 27, 2000PROCARDIA XL**AB2** PFIZER 30MG **N019684 001** Sep 06, 1989**AB2** 60MG **N019684 002** Sep 06, 1989**AB2** + 90MG **N019684 003** Sep 06, 1989NILOTINIB HYDROCHLORIDE MONOHYDRATE

CAPSULE; ORAL

TASIGNA

NOVARTIS EQ 150MG BASE N022068 002 Jun 17, 2010

+ EQ 200MG BASE N022068 001 Oct 29, 2007

NILUTAMIDE

TABLET; ORAL

NILANDRON**AB** + CONCORDIA PHARMS INC 150MG **N020169 002** Apr 30, 1999NILUTAMIDE**AB** ANI PHARMS INC 150MG **A207631 001** Jul 15, 2016NIMODIPINE

CAPSULE; ORAL

NIMODIPINE**AB** + BIONPHARMA INC 30MG **A076740 001** Jan 17, 2008**AB** HERITAGE PHARMS INC 30MG **A077811 001** May 02, 2007**AB** SOFGEN PHARMS 30MG **A201832 001** Jul 24, 2015**AB** SUN PHARM INDS INC 30MG **A077067 001** Apr 17, 2007**AB** THEPHARMANETWORK LLC 30MG **A090103 001** Apr 07, 2014

SOLUTION; ORAL

NYMALIZE

+ ARBOR PHARMS LLC 60MG/20ML N203340 001 May 10, 2013

PRESCRIPTION DRUG PRODUCT LIST

NINTEDANIB ESYLATE

CAPSULE; ORAL

OFEV

BOEHRINGER INGELHEIM	EQ 100MG BASE	N205832	001	Oct 15, 2014
+	EQ 150MG BASE	N205832	002	Oct 15, 2014

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL

NISOLDIPINE

AB	MYLAN	8.5MG	A091001	001	Jan 26, 2011
AB		17MG	A091001	002	Jan 26, 2011
AB		34MG	A091001	004	Jan 26, 2011

SULAR

AB	+	COVIS PHARMA SARL	8.5MG	N020356	008	Jan 02, 2008
AB	+		17MG	N020356	007	Jan 02, 2008
AB	+		34MG	N020356	005	Jan 02, 2008

NISOLDIPINE

MYLAN	20MG	A079051	001	Jul 25, 2008
	25.5MG	A091001	003	Jan 26, 2011
+	30MG	A079051	002	Jul 25, 2008
+	40MG	A079051	003	Jul 25, 2008

NITAZOXANIDE

FOR SUSPENSION; ORAL

ALINIA

+	ROMARK	100MG/5ML	N021498	001	Nov 22, 2002
---	--------	-----------	---------	-----	--------------

TABLET; ORAL

ALINIA

+	ROMARK	500MG	N021497	001	Jul 21, 2004
---	--------	-------	---------	-----	--------------

NITISINONE

CAPSULE; ORAL

ORFADIN

SWEDISH ORPHAN	2MG	N021232	001	Jan 18, 2002
	5MG	N021232	002	Jan 18, 2002
+	10MG	N021232	003	Jan 18, 2002
+	20MG	N021232	004	Jun 13, 2016

SUSPENSION; ORAL

ORFADIN

+	SWEDISH ORPHAN	4MG/ML	N206356	001	Apr 22, 2016
---	----------------	--------	---------	-----	--------------

NITRIC OXIDE

GAS; INHALATION

INOMAX

+	MALLINCKRODT HOSP	800PPM	N020845	003	Dec 23, 1999
---	-------------------	--------	---------	-----	--------------

NITROFURANTOIN

SUSPENSION; ORAL

FURADANTIN

AB	+	CASPER PHARMA LLC	25MG/5ML	N009175	001
-----------	---	-------------------	-----------------	----------------	------------

NITROFURANTOIN

AB	ACTAVIS MID ATLANTIC	25MG/5ML	A205180	001	May 03, 2016
AB	AMNEAL PHARMS	25MG/5ML	A201679	001	May 11, 2011
AB	NOSTRUM LABS INC	25MG/5ML	A201355	001	Aug 14, 2013
AB	NOVEL LABS INC	25MG/5ML	A201693	001	Sep 08, 2014

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

MACRODANTIN

AB	ALVOGEN MALTA	25MG	N016620	003
AB		50MG	N016620	001
AB	+	100MG	N016620	002

NITROFURANTOIN

AB	ACTAVIS LABS FL INC	25MG	A091095	001	Jun 18, 2015
AB		50MG	A091095	002	Jun 18, 2015
AB		100MG	A091095	003	Jun 18, 2015
AB	IMPAX LABS INC	50MG	A073671	001	Jan 28, 1993
AB		100MG	A073652	001	Jan 28, 1993
AB	MYLAN	50MG	A074967	001	Jul 09, 1997
AB		100MG	A077025	001	Aug 18, 2004
AB	SUN PHARM INDS	25MG	A201722	001	Feb 16, 2016
AB		50MG	A201722	002	Feb 16, 2016
AB		100MG	A201722	003	Feb 16, 2016

PRESCRIPTION DRUG PRODUCT LIST

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

MACROBID

AB	+	ALVOGEN MALTA	<u>75MG; 25MG</u>	<u>N020064</u>	<u>001</u>	Dec 24, 1991
-----------	---	---------------	-------------------	-----------------------	-------------------	--------------

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

AB		MYLAN	<u>75MG; 25MG</u>	<u>A076648</u>	<u>001</u>	Mar 22, 2004
AB		SANDOZ	<u>75MG; 25MG</u>	<u>A077066</u>	<u>001</u>	Apr 05, 2005
AB		WATSON LABS INC	<u>75MG; 25MG</u>	<u>A202250</u>	<u>001</u>	Jul 08, 2015

NITROGLYCERIN

AEROSOL, METERED; SUBLINGUAL

NITROMIST

+ MIST PHARMS LLC 0.4MG/SPRAY

N021780 001 Nov 02, 2006

FILM, EXTENDED RELEASE; TRANSDERMAL

MINITRAN

AB1		MEDICIS	<u>0.4MG/HR</u>	<u>A089773</u>	<u>001</u>	Aug 30, 1996
AB1		VALEANT PHARMS	<u>0.1MG/HR</u>	<u>A089771</u>	<u>001</u>	Aug 30, 1996
AB1			<u>0.6MG/HR</u>	<u>A089774</u>	<u>001</u>	Aug 30, 1996
AB1		VALEANT PHARMS NORTH	<u>0.2MG/HR</u>	<u>A089772</u>	<u>001</u>	Aug 30, 1996

NITRO-DUR

AB1	+	MERCK SHARP DOHME	<u>0.1MG/HR</u>	<u>N020145</u>	<u>001</u>	Apr 04, 1995
AB1	+		<u>0.2MG/HR</u>	<u>N020145</u>	<u>002</u>	Apr 04, 1995
AB1	+		<u>0.4MG/HR</u>	<u>N020145</u>	<u>004</u>	Apr 04, 1995
AB1	+		<u>0.6MG/HR</u>	<u>N020145</u>	<u>005</u>	Apr 04, 1995

NITROGLYCERIN

AB2		HERCON PHARM	<u>0.2MG/HR</u>	<u>A089884</u>	<u>001</u>	Oct 30, 1998
AB2			<u>0.4MG/HR</u>	<u>A089885</u>	<u>001</u>	Oct 30, 1998
AB2			<u>0.6MG/HR</u>	<u>A089886</u>	<u>001</u>	Oct 30, 1998
AB2	+	MYLAN TECHNOLOGIES	<u>0.2MG/HR</u>	<u>A074559</u>	<u>003</u>	Aug 30, 1996
AB2	+		<u>0.4MG/HR</u>	<u>A074559</u>	<u>002</u>	Aug 30, 1996
AB2	+		<u>0.6MG/HR</u>	<u>A074559</u>	<u>001</u>	Aug 30, 1996

NITRO-DUR

+ MERCK SHARP DOHME 0.3MG/HR

N020145 003 Apr 04, 1995

+ 0.8MG/HR

N020145 006 Apr 04, 1995

NITROGLYCERIN

+ MYLAN TECHNOLOGIES 0.1MG/HR

A074559 004 Feb 06, 1998

INJECTABLE; INJECTION

NITROGLYCERIN IN DEXTROSE 5%

AP	+	BAXTER HLTHCARE	<u>10MG/100ML</u>	<u>N019970</u>	<u>001</u>	Dec 29, 1989
AP	+		<u>20MG/100ML</u>	<u>N019970</u>	<u>002</u>	Dec 29, 1989
AP	+		<u>40MG/100ML</u>	<u>N019970</u>	<u>003</u>	Dec 29, 1989
AP		HOSPIRA	<u>10MG/100ML</u>	<u>A071846</u>	<u>001</u>	Aug 31, 1990
AP			<u>20MG/100ML</u>	<u>A071847</u>	<u>001</u>	Aug 31, 1990
AP			<u>40MG/100ML</u>	<u>A071848</u>	<u>001</u>	Aug 31, 1990

NITROGLYCERIN

+ LUITPOLD 5MG/ML

A072034 001 May 24, 1988

OINTMENT; INTRA-ANAL

RECTIV

+ FOREST LABS INC 0.4%

N021359 001 Jun 21, 2011

OINTMENT; TRANSDERMAL

NITROGLYCERIN

+ FOUGERA 2%

A087355 001 Jul 08, 1988

POWDER; SUBLINGUAL

GONITRO

+ POHL BOSKAMP 0.4MG/PACKET

N208424 001 Jun 08, 2016

SPRAY, METERED; SUBLINGUAL

NITROGLYCERIN

AB		PERRIGO ISRAEL	<u>0.4MG/SPRAY</u>	<u>A091496</u>	<u>001</u>	Sep 20, 2013
-----------	--	----------------	--------------------	-----------------------	-------------------	--------------

NITROLINGUAL PUMPSPRAY

AB	+	POHL BOSKAMP	<u>0.4MG/SPRAY</u>	<u>N018705</u>	<u>002</u>	Jan 10, 1997
-----------	---	--------------	--------------------	-----------------------	-------------------	--------------

TABLET; SUBLINGUAL

NITROGLYCERIN

AB		DR REDDYS LABS INC	<u>0.3MG</u>	<u>A208191</u>	<u>001</u>	Aug 26, 2016
AB			<u>0.4MG</u>	<u>A208191</u>	<u>002</u>	Aug 26, 2016
AB			<u>0.6MG</u>	<u>A208191</u>	<u>003</u>	Aug 26, 2016

NITROSTAT

AB		PFIZER PHARMS	<u>0.3MG</u>	<u>N021134</u>	<u>001</u>	May 01, 2000
AB			<u>0.4MG</u>	<u>N021134</u>	<u>002</u>	May 01, 2000
AB	+		<u>0.6MG</u>	<u>N021134</u>	<u>003</u>	May 01, 2000

PRESCRIPTION DRUG PRODUCT LIST

NIZATIDINE

CAPSULE; ORAL

NIZATIDINE

<u>AB</u>	ANI PHARMS INC	<u>150MG</u>	<u>A075668 001</u>	Sep 12, 2002
<u>AB</u>		<u>300MG</u>	<u>A075668 002</u>	Sep 12, 2002
<u>AB</u>	DR REDDYS LABS LTD	<u>150MG</u>	<u>A077314 001</u>	Sep 15, 2005
<u>AB</u>		<u>300MG</u>	<u>A077314 002</u>	Sep 15, 2005
<u>AB</u>	GLENMARK GENERICS	<u>150MG</u>	<u>A090618 001</u>	Jul 15, 2011
<u>AB</u>		<u>300MG</u>	<u>A090618 002</u>	Jul 15, 2011
<u>AB</u>	MYLAN PHARMS INC	<u>150MG</u>	<u>A075806 001</u>	Jul 05, 2002
<u>AB</u>	+	<u>300MG</u>	<u>A075806 002</u>	Jul 05, 2002
<u>AB</u>	SANDOZ	<u>150MG</u>	<u>A076178 001</u>	Jul 05, 2002
<u>AB</u>		<u>300MG</u>	<u>A076178 002</u>	Jul 05, 2002
<u>AB</u>	WATSON LABS	<u>150MG</u>	<u>A075616 001</u>	Jul 09, 2002
<u>AB</u>		<u>300MG</u>	<u>A075616 002</u>	Jul 09, 2002

SOLUTION; ORAL

NIZATIDINE

+ AMNEAL PHARMS

15MG/ML

A090576 001 Nov 18, 2009

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

LEVOPHED

<u>AP</u>	+	HOSPIRA	<u>EQ 1MG BASE/ML</u>	<u>N007513 001</u>
-----------	---	---------	-----------------------	--------------------

NOREPINEPHRINE BITARTRATE

<u>AP</u>		CLARIS	<u>EQ 1MG BASE/ML</u>	<u>A040859 001</u>	Mar 27, 2012
<u>AP</u>		EUROHLTH INTL SARL	<u>EQ 1MG BASE/ML</u>	<u>A040462 001</u>	Oct 31, 2003
<u>AP</u>		TEVA PHARMS USA	<u>EQ 1MG BASE/ML</u>	<u>A040455 001</u>	Mar 03, 2003

NORETHINDRONE

TABLET; ORAL-28

CAMILA

<u>AB1</u>		MAYNE PHARMA	<u>0.35MG</u>	<u>A076177 001</u>	Oct 21, 2002
------------	--	--------------	---------------	--------------------	--------------

HEATHER

<u>AB1</u>		GLENMARK GENERICS	<u>0.35MG</u>	<u>A090454 001</u>	Apr 23, 2010
------------	--	-------------------	---------------	--------------------	--------------

INCASSIA

<u>AB1</u>		AUROBINDO PHARMA LTD	<u>0.35MG</u>	<u>A207304 001</u>	Sep 23, 2016
------------	--	----------------------	---------------	--------------------	--------------

NOR-QD

<u>AB1</u>	+	APIL	<u>0.35MG</u>	<u>N017060 001</u>
------------	---	------	---------------	--------------------

NORETHINDRONE

<u>AB1</u>		ACCORD HLTHCARE	<u>0.35MG</u>	<u>A206807 001</u>	Dec 13, 2016
<u>AB1</u>		AMNEAL PHARMS	<u>0.35MG</u>	<u>A202260 001</u>	Aug 01, 2013
<u>AB1</u>		JAI PHARMA LTD	<u>0.35MG</u>	<u>A201483 001</u>	Jun 24, 2013
<u>AB1</u>		LUPIN LTD	<u>0.35MG</u>	<u>A091325 001</u>	Sep 19, 2011
<u>AB1</u>		NOVAST LABS LTD	<u>0.35MG</u>	<u>A202014 001</u>	Sep 13, 2013

ERRIN

<u>AB2</u>		MAYNE PHARMA	<u>0.35MG</u>	<u>A076225 001</u>	Oct 21, 2002
------------	--	--------------	---------------	--------------------	--------------

JENCYCLA

<u>AB2</u>		LUPIN LTD	<u>0.35MG</u>	<u>A091323 001</u>	Mar 28, 2013
------------	--	-----------	---------------	--------------------	--------------

MICRONOR

<u>AB2</u>	+	JANSSEN PHARMS	<u>0.35MG</u>	<u>N016954 001</u>
------------	---	----------------	---------------	--------------------

NORETHINDRONE

<u>AB2</u>		GLENMARK GENERICS	<u>0.35MG</u>	<u>A091209 001</u>	Jul 22, 2010
<u>AB2</u>		JAI PHARMA LTD	<u>0.35MG</u>	<u>A200980 001</u>	Jun 12, 2013
<u>AB2</u>		NOVAST LABS	<u>0.35MG</u>	<u>A200961 001</u>	Sep 13, 2013

NORETHINDRONE ACETATE

TABLET; ORAL

AYGESTIN

<u>AB</u>	+	DURAMED RES	<u>5MG</u>	<u>N018405 001</u>	Apr 21, 1982
-----------	---	-------------	------------	--------------------	--------------

NORETHINDRONE ACETATE

<u>AB</u>		AMNEAL PHARMS	<u>5MG</u>	<u>A200275 001</u>	Jul 30, 2012
<u>AB</u>		AUROBINDO PHARMA LTD	<u>5MG</u>	<u>A204236 001</u>	Jan 08, 2016
<u>AB</u>		BARR	<u>5MG</u>	<u>A075951 001</u>	May 25, 2001
<u>AB</u>		GLENMARK GENERICS	<u>5MG</u>	<u>A091090 001</u>	Jul 21, 2010
<u>AB</u>		JAI PHARMA LTD	<u>5MG</u>	<u>A205278 001</u>	Nov 10, 2016

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

NORTRIPTYLINE HYDROCHLORIDE

<u>AB</u>		MAYNE PHARMA	<u>EQ 10MG BASE</u>	<u>A073553 001</u>	Mar 30, 1992
<u>AB</u>			<u>EQ 25MG BASE</u>	<u>A073554 001</u>	Mar 30, 1992
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A073555 001</u>	Mar 30, 1992
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A073556 001</u>	Mar 30, 1992
<u>AB</u>		MYLAN	<u>EQ 10MG BASE</u>	<u>A074234 001</u>	Jul 26, 1993

PRESCRIPTION DRUG PRODUCT LIST

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

NORTRIPTYLINE HYDROCHLORIDE

<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A074234 002</u>	Jul 26, 1993
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A074234 003</u>	Jul 26, 1993
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A074234 004</u>	Jul 26, 1993
<u>AB</u>	TARO	<u>EQ 10MG BASE</u>	<u>A075520 004</u>	May 08, 2000
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A075520 003</u>	May 08, 2000
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A075520 001</u>	May 08, 2000
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A075520 002</u>	May 08, 2000
<u>AB</u>	TEVA	<u>EQ 10MG BASE</u>	<u>A074132 001</u>	Mar 27, 1995
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A074132 002</u>	Mar 27, 1995
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A074132 003</u>	Mar 27, 1995
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A074132 004</u>	Mar 27, 1995

PAMELOR

<u>AB</u>	MALLINCKRODT LLC	<u>EQ 10MG BASE</u>	<u>N018013 001</u>	
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>N018013 002</u>	
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>N018013 004</u>	
<u>AB</u>	+	<u>EQ 75MG BASE</u>	<u>N018013 003</u>	

SOLUTION; ORAL

NORTRIPTYLINE HYDROCHLORIDE

<u>AA</u>	+	PHARM ASSOC	<u>EQ 10MG BASE/5ML</u>	<u>A075606 001</u>	Aug 28, 2000
<u>AA</u>		TARO	<u>EQ 10MG BASE/5ML</u>	<u>A077965 001</u>	Jun 20, 2006

NUSINERSEN SODIUM

SOLUTION; INTRATHECAL

SPINRAZA

+	BIOGEN IDEC	12MG/5ML (2.4MG/ML)	N209531 001	Dec 23, 2016
---	-------------	---------------------	-------------	--------------

NYSTATIN

CREAM; TOPICAL

NYSTATIN

<u>AT</u>	ACTAVIS MID ATLANTIC	<u>100,000 UNITS/GM</u>	<u>A062949 001</u>	Jun 13, 1988
<u>AT</u>	FOUGERA PHARMS	<u>100,000 UNITS/GM</u>	<u>A062129 001</u>	
<u>AT</u>	G AND W LABS INC	<u>100,000 UNITS/GM</u>	<u>A061966 001</u>	
<u>AT</u>	PERRIGO NEW YORK	<u>100,000 UNITS/GM</u>	<u>A062225 001</u>	
<u>AT</u>	+	TARO	<u>100,000 UNITS/GM</u>	Jan 29, 1993
<u>AT</u>	VINTAGE	<u>100,000 UNITS/GM</u>	<u>A065315 001</u>	May 31, 2006

OINTMENT; TOPICAL

NYSTATIN

<u>AT</u>	ACTAVIS MID ATLANTIC	<u>100,000 UNITS/GM</u>	<u>A062840 001</u>	Nov 13, 1987
<u>AT</u>	+	FOUGERA PHARMS	<u>A062124 002</u>	Sep 23, 1982
<u>AT</u>	PERRIGO NEW YORK	<u>100,000 UNITS/GM</u>	<u>A062472 001</u>	Feb 13, 1984

POWDER; TOPICAL

NYSTATIN

<u>AT</u>	GAVIS PHARMS	<u>100,000 UNITS/GM</u>	<u>A065138 001</u>	Jul 23, 2004
<u>AT</u>	+	MAYNE PHARMA INC	<u>A065203 001</u>	Jul 15, 2004
<u>AT</u>	UPSHER SMITH	<u>100,000 UNITS/GM</u>	<u>A065183 001</u>	May 03, 2005
<u>AT</u>	X GEN PHARMS	<u>100,000 UNITS/GM</u>	<u>A065175 001</u>	Dec 17, 2004

NYSTOP

<u>AT</u>	PADDOCK LLC	<u>100,000 UNITS/GM</u>	<u>A064118 001</u>	Aug 16, 1996
-----------	-------------	-------------------------	--------------------	--------------

SUSPENSION; ORAL

NYSTATIN

<u>AA</u>	FOUGERA	<u>100,000 UNITS/ML</u>	<u>A062517 001</u>	Jun 07, 1984
<u>AA</u>	G AND W LABS INC	<u>100,000 UNITS/ML</u>	<u>A062349 001</u>	Jul 14, 1982
<u>AA</u>	HI TECH PHARMA	<u>100,000 UNITS/ML</u>	<u>A064042 001</u>	Feb 28, 1994
<u>AA</u>	PHARM ASSOC	<u>100,000 UNITS/ML</u>	<u>A203621 001</u>	Jan 07, 2016
<u>AA</u>	TARO	<u>100,000 UNITS/ML</u>	<u>A062876 001</u>	Feb 29, 1988
<u>AA</u>	VINTAGE PHARMS	<u>100,000 UNITS/ML</u>	<u>A065148 001</u>	Jun 28, 2005
<u>AA</u>	VISTAPHARM	<u>100,000 UNITS/ML</u>	<u>A064142 001</u>	Jun 25, 1998
<u>AA</u>		<u>100,000 UNITS/ML</u>	<u>A065422 001</u>	Mar 07, 2011
<u>AA</u>	+	WOCKHARDT	<u>A062512 001</u>	Oct 29, 1984

TABLET; ORAL

NYSTATIN

<u>AA</u>	HERITAGE PHARMS INC	<u>500,000 UNITS</u>	<u>A062474 001</u>	Dec 22, 1983
<u>AA</u>	SUN PHARM INDS	<u>500,000 UNITS</u>	<u>A062838 001</u>	Dec 22, 1988
<u>AA</u>	+	TEVA	<u>A062506 001</u>	Jan 16, 1984

TABLET; VAGINAL

NYSTATIN

+	ODYSSEY PHARMS	100,000 UNITS	A062615 001	Oct 17, 1985
---	----------------	---------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

MYKACET

<u>AT</u>	G AND W LABS INC	<u>100,000 UNITS/GM;0.1%</u>	<u>A062367</u>	<u>001</u>	May 28, 1985
-----------	------------------	------------------------------	----------------	------------	--------------

NYSTATIN AND TRIAMCINOLONE ACETONIDE

<u>AT</u>	DR REDDYS LABS LTD	<u>100,000 UNITS/GM;0.1%</u>	<u>A208326</u>	<u>001</u>	Oct 26, 2016
<u>AT</u>	FOUGERA	<u>100,000 UNITS/GM;0.1%</u>	<u>A062599</u>	<u>001</u>	Oct 08, 1985
<u>AT</u>	GLENMARK PHARMS LTD	<u>100,000 UNITS/GM;0.1%</u>	<u>A208136</u>	<u>001</u>	Oct 24, 2016
<u>AT</u>	+ TARO	<u>100,000 UNITS/GM;0.1%</u>	<u>A062364</u>	<u>001</u>	Dec 22, 1987

OINTMENT; TOPICAL

MYKACET

<u>AT</u>	G AND W LABS INC	<u>100,000 UNITS/GM;0.1%</u>	<u>A062733</u>	<u>001</u>	Mar 06, 1987
-----------	------------------	------------------------------	----------------	------------	--------------

NYSTATIN AND TRIAMCINOLONE ACETONIDE

<u>AT</u>	FOUGERA	<u>100,000 UNITS/GM;0.1%</u>	<u>A062602</u>	<u>001</u>	Oct 09, 1985
<u>AT</u>	GLENMARK PHARMS LTD	<u>100,000 UNITS/GM;0.1%</u>	<u>A208300</u>	<u>001</u>	Jun 23, 2016
<u>AT</u>	PERRIGO UK FINCO	<u>100,000 UNITS/GM;0.1%</u>	<u>A207380</u>	<u>001</u>	Dec 20, 2016
<u>AT</u>	RICONPHARMA LLC	<u>100,000 UNITS/GM;0.1%</u>	<u>A206785</u>	<u>001</u>	Dec 29, 2016
<u>AT</u>	+ TARO	<u>100,000 UNITS/GM;0.1%</u>	<u>A063305</u>	<u>001</u>	Mar 29, 1993
<u>AT</u>	TELIGENT PHARMA INC	<u>100,000 UNITS/GM;0.1%</u>	<u>A208287</u>	<u>001</u>	Dec 30, 2016

OBETICHOLIC ACID

TABLET; ORAL

OICALIVA

	INTERCEPT PHARMS INC	5MG	N207999	001	May 27, 2016
	+	10MG	N207999	002	May 27, 2016

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 0.2MG BASE/ML</u>	<u>A077450</u>	<u>001</u>	Feb 10, 2006
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A077450</u>	<u>002</u>	Feb 10, 2006
<u>AP</u>	SAGENT PHARMS	<u>EQ 0.2MG BASE/ML</u>	<u>A091041</u>	<u>001</u>	Nov 12, 2013
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A091041</u>	<u>002</u>	Nov 12, 2013
<u>AP</u>	SUN PHARM INDS	<u>EQ 0.05MG BASE/ML</u>	<u>A077329</u>	<u>001</u>	Mar 04, 2008
<u>AP</u>		<u>EQ 0.05MG BASE/ML</u>	<u>A077372</u>	<u>001</u>	Aug 14, 2007
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A077329</u>	<u>002</u>	Mar 04, 2008
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A077372</u>	<u>002</u>	Aug 14, 2007
<u>AP</u>		<u>EQ 0.2MG BASE/ML</u>	<u>A077330</u>	<u>001</u>	Mar 04, 2008
<u>AP</u>		<u>EQ 0.2MG BASE/ML</u>	<u>A077373</u>	<u>001</u>	Aug 14, 2007
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A077329</u>	<u>003</u>	Mar 04, 2008
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A077372</u>	<u>003</u>	Aug 14, 2007
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A077331</u>	<u>001</u>	Mar 04, 2008
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A077373</u>	<u>002</u>	Aug 14, 2007
<u>AP</u>	TEVA PHARMS USA	<u>EQ 0.05MG BASE/ML</u>	<u>A075957</u>	<u>001</u>	Oct 03, 2005
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A075957</u>	<u>002</u>	Oct 03, 2005
<u>AP</u>		<u>EQ 0.2MG BASE/ML</u>	<u>A075959</u>	<u>001</u>	Nov 21, 2005
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A075957</u>	<u>003</u>	Oct 03, 2005
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A075959</u>	<u>002</u>	Nov 21, 2005
<u>AP</u>	+ WEST-WARD PHARMS INT	<u>EQ 0.2MG BASE/ML</u>	<u>A076330</u>	<u>001</u>	Apr 08, 2005
<u>AP</u>	+	<u>EQ 1MG BASE/ML</u>	<u>A076330</u>	<u>002</u>	Apr 08, 2005

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 0.05MG BASE/ML</u>	<u>A077457</u>	<u>001</u>	Feb 10, 2006
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A077457</u>	<u>002</u>	Feb 10, 2006
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A077457</u>	<u>003</u>	Feb 10, 2006
<u>AP</u>	MYLAN INSTITUTIONAL	<u>EQ 0.05MG BASE/ML</u>	<u>A079198</u>	<u>001</u>	Feb 10, 2011
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A079198</u>	<u>002</u>	Feb 10, 2011
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A079198</u>	<u>003</u>	Feb 10, 2011
<u>AP</u>	SAGENT PHARMS	<u>EQ 0.05MG BASE/ML</u>	<u>A090834</u>	<u>001</u>	Nov 12, 2013
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A090834</u>	<u>002</u>	Nov 12, 2013
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A090834</u>	<u>003</u>	Nov 12, 2013
<u>AP</u>	+ WEST-WARD PHARMS INT	<u>EQ 0.05MG BASE/ML</u>	<u>A076313</u>	<u>001</u>	Mar 28, 2005
<u>AP</u>	+	<u>EQ 0.1MG BASE/ML</u>	<u>A076313</u>	<u>003</u>	Mar 28, 2005
<u>AP</u>	+	<u>EQ 0.5MG BASE/ML</u>	<u>A076313</u>	<u>002</u>	Mar 28, 2005

SANDOSTATIN

<u>AP</u>	+ NOVARTIS	<u>EQ 0.05MG BASE/ML</u>	<u>N019667</u>	<u>001</u>	Oct 21, 1988
<u>AP</u>	+	<u>EQ 0.1MG BASE/ML</u>	<u>N019667</u>	<u>002</u>	Oct 21, 1988
<u>AP</u>	+	<u>EQ 0.2MG BASE/ML</u>	<u>N019667</u>	<u>004</u>	Jun 12, 1991
<u>AP</u>	+	<u>EQ 0.5MG BASE/ML</u>	<u>N019667</u>	<u>003</u>	Oct 21, 1988
<u>AP</u>	+	<u>EQ 1MG BASE/ML</u>	<u>N019667</u>	<u>005</u>	Jun 12, 1991

SANDOSTATIN LAR

	NOVARTIS	EQ 10MG BASE/VIAL	N021008	001	Nov 25, 1998
		EQ 20MG BASE/VIAL	N021008	002	Nov 25, 1998
	+	EQ 30MG BASE/VIAL	N021008	003	Nov 25, 1998

PRESCRIPTION DRUG PRODUCT LIST

OFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

OCUFLOX

<u>AT</u>	+ ALLERGAN	<u>0.3%</u>	<u>N019921</u>	<u>001</u>	Jul 30, 1993
-----------	------------	-------------	----------------	------------	--------------

OFLOXACIN

<u>AT</u>	AKORN	<u>0.3%</u>	<u>A076407</u>	<u>001</u>	Apr 15, 2008
<u>AT</u>	ALCON PHARMS LTD	<u>0.3%</u>	<u>A076231</u>	<u>001</u>	May 14, 2004
<u>AT</u>	ALTAIRE PHARMS INC	<u>0.3%</u>	<u>A202692</u>	<u>001</u>	Apr 29, 2013
<u>AT</u>	ALVOGEN	<u>0.3%</u>	<u>A076830</u>	<u>001</u>	Aug 31, 2004
<u>AT</u>	BAUSCH AND LOMB	<u>0.3%</u>	<u>A076622</u>	<u>001</u>	May 14, 2004
<u>AT</u>	FDC LTD	<u>0.3%</u>	<u>A078559</u>	<u>001</u>	Feb 25, 2009
<u>AT</u>	HI TECH PHARMA	<u>0.3%</u>	<u>A076615</u>	<u>001</u>	May 14, 2004

SOLUTION/DROPS;OTIC

OFLOXACIN

<u>AT</u>	ALCON PHARMS LTD	<u>0.3%</u>	<u>A078222</u>	<u>001</u>	Mar 17, 2008
<u>AT</u>	ALVOGEN	<u>0.3%</u>	<u>A090395</u>	<u>001</u>	Aug 11, 2009
<u>AT</u>	APOTEX INC	<u>0.3%</u>	<u>A076527</u>	<u>001</u>	Sep 28, 2007
<u>AT</u>	+ BAUSCH AND LOMB	<u>0.3%</u>	<u>A076128</u>	<u>001</u>	Mar 17, 2008
<u>AT</u>	HI TECH PHARMA	<u>0.3%</u>	<u>A076616</u>	<u>001</u>	Mar 17, 2008

TABLET;ORAL

OFLOXACIN

<u>AB</u>	CADILA PHARMS LTD	<u>200MG</u>	<u>A091656</u>	<u>001</u>	Sep 18, 2014
<u>AB</u>		<u>300MG</u>	<u>A091656</u>	<u>002</u>	Sep 18, 2014
<u>AB</u>		<u>400MG</u>	<u>A091656</u>	<u>003</u>	Sep 18, 2014
<u>AB</u>	DR REDDYS LABS LTD	<u>200MG</u>	<u>A077098</u>	<u>001</u>	Feb 10, 2006
<u>AB</u>		<u>300MG</u>	<u>A077098</u>	<u>002</u>	Feb 10, 2006
<u>AB</u>		<u>400MG</u>	<u>A077098</u>	<u>003</u>	Feb 10, 2006
<u>AB</u>	LARKEN LABS	<u>400MG</u>	<u>A076093</u>	<u>003</u>	Sep 02, 2003
<u>AB</u>	TEVA	<u>200MG</u>	<u>A076182</u>	<u>001</u>	Sep 02, 2003
<u>AB</u>		<u>300MG</u>	<u>A076182</u>	<u>002</u>	Sep 02, 2003
<u>AB</u>	+	<u>400MG</u>	<u>A076182</u>	<u>003</u>	Sep 02, 2003

OLANZAPINE

INJECTABLE;INTRAMUSCULAR

OLANZAPINE

<u>AP</u>	LUITPOLD	<u>10MG/VIAL</u>	<u>A201741</u>	<u>001</u>	Mar 20, 2012
<u>AP</u>	SANDOZ INC	<u>10MG/VIAL</u>	<u>A201588</u>	<u>001</u>	Oct 24, 2011

ZYPREXA

<u>AP</u>	+ LILLY	<u>10MG/VIAL</u>	<u>N021253</u>	<u>001</u>	Mar 29, 2004
-----------	---------	------------------	----------------	------------	--------------

TABLET;ORAL

OLANZAPINE

<u>AB</u>	AJANTA PHARMA LTD	<u>2.5MG</u>	<u>A206711</u>	<u>001</u>	Aug 30, 2016
<u>AB</u>		<u>5MG</u>	<u>A206711</u>	<u>002</u>	Aug 30, 2016
<u>AB</u>		<u>7.5MG</u>	<u>A206711</u>	<u>003</u>	Aug 30, 2016
<u>AB</u>		<u>10MG</u>	<u>A206711</u>	<u>004</u>	Aug 30, 2016
<u>AB</u>		<u>15MG</u>	<u>A206711</u>	<u>005</u>	Aug 30, 2016
<u>AB</u>		<u>20MG</u>	<u>A206711</u>	<u>006</u>	Aug 30, 2016
<u>AB</u>	ALKEM LABS LTD	<u>2.5MG</u>	<u>A202295</u>	<u>001</u>	Oct 20, 2015
<u>AB</u>		<u>5MG</u>	<u>A202295</u>	<u>002</u>	Oct 20, 2015
<u>AB</u>		<u>7.5MG</u>	<u>A202295</u>	<u>003</u>	Oct 20, 2015
<u>AB</u>		<u>10MG</u>	<u>A202295</u>	<u>004</u>	Oct 20, 2015
<u>AB</u>		<u>15MG</u>	<u>A202295</u>	<u>005</u>	Oct 20, 2015
<u>AB</u>		<u>20MG</u>	<u>A202295</u>	<u>006</u>	Oct 20, 2015
<u>AB</u>	APOTEX INC	<u>2.5MG</u>	<u>A090798</u>	<u>001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A090798</u>	<u>002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A090798</u>	<u>003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A090798</u>	<u>004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A090798</u>	<u>005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A090798</u>	<u>006</u>	Apr 23, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>2.5MG</u>	<u>A202050</u>	<u>001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A202050</u>	<u>002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A202050</u>	<u>003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A202050</u>	<u>004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A202050</u>	<u>005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A202050</u>	<u>006</u>	Apr 23, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>2.5MG</u>	<u>A076255</u>	<u>001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A076255</u>	<u>002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A076255</u>	<u>003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A076255</u>	<u>004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A076133</u>	<u>001</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A076133</u>	<u>002</u>	Oct 24, 2011
<u>AB</u>	INVAGEN PHARMS	<u>2.5MG</u>	<u>A203333</u>	<u>001</u>	Mar 15, 2016
<u>AB</u>		<u>5MG</u>	<u>A203333</u>	<u>002</u>	Mar 15, 2016

PRESCRIPTION DRUG PRODUCT LIST

OLANZAPINE

TABLET; ORAL

OLANZAPINE

<u>AB</u>		<u>7.5MG</u>	<u>A203333</u>	<u>003</u>	Mar 15, 2016
<u>AB</u>		<u>10MG</u>	<u>A203333</u>	<u>004</u>	Mar 15, 2016
<u>AB</u>		<u>15MG</u>	<u>A203333</u>	<u>005</u>	Mar 15, 2016
<u>AB</u>		<u>20MG</u>	<u>A203333</u>	<u>006</u>	Mar 15, 2016
<u>AB</u>	IVAX PHARMS INC	<u>20MG</u>	<u>A077301</u>	<u>001</u>	Apr 29, 2015
<u>AB</u>	MACLEODS PHARMS LTD	<u>2.5MG</u>	<u>A202862</u>	<u>001</u>	Aug 15, 2014
<u>AB</u>		<u>5MG</u>	<u>A202862</u>	<u>002</u>	Aug 15, 2014
<u>AB</u>		<u>7.5MG</u>	<u>A202862</u>	<u>003</u>	Aug 15, 2014
<u>AB</u>		<u>10MG</u>	<u>A202862</u>	<u>004</u>	Aug 15, 2014
<u>AB</u>		<u>15MG</u>	<u>A202862</u>	<u>005</u>	Aug 15, 2014
<u>AB</u>		<u>20MG</u>	<u>A202862</u>	<u>006</u>	Aug 15, 2014
<u>AB</u>	MYLAN	<u>2.5MG</u>	<u>A076866</u>	<u>001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A076866</u>	<u>002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A076866</u>	<u>003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A076866</u>	<u>004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A076866</u>	<u>005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A076866</u>	<u>006</u>	Apr 23, 2012
<u>AB</u>	ORCHID HLTHCARE	<u>2.5MG</u>	<u>A202287</u>	<u>001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A202287</u>	<u>002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A202287</u>	<u>003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A202287</u>	<u>004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A202287</u>	<u>005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A202287</u>	<u>006</u>	Apr 23, 2012
<u>AB</u>	QILU PHARM CO LTD	<u>2.5MG</u>	<u>A204319</u>	<u>001</u>	Jan 27, 2016
<u>AB</u>		<u>5MG</u>	<u>A204319</u>	<u>002</u>	Jan 27, 2016
<u>AB</u>		<u>7.5MG</u>	<u>A204319</u>	<u>003</u>	Jan 27, 2016
<u>AB</u>		<u>10MG</u>	<u>A204319</u>	<u>004</u>	Jan 27, 2016
<u>AB</u>		<u>15MG</u>	<u>A204319</u>	<u>005</u>	Jan 27, 2016
<u>AB</u>		<u>20MG</u>	<u>A204319</u>	<u>006</u>	Jan 27, 2016
<u>AB</u>	SUN PHARM INDS	<u>2.5MG</u>	<u>A091038</u>	<u>001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A091038</u>	<u>002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A091038</u>	<u>003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A091038</u>	<u>004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A091038</u>	<u>005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A091038</u>	<u>006</u>	Apr 23, 2012
<u>AB</u>	TEVA PHARMS	<u>2.5MG</u>	<u>A076000</u>	<u>001</u>	Oct 24, 2011
<u>AB</u>		<u>5MG</u>	<u>A076000</u>	<u>002</u>	Oct 24, 2011
<u>AB</u>		<u>7.5MG</u>	<u>A076000</u>	<u>003</u>	Oct 24, 2011
<u>AB</u>		<u>10MG</u>	<u>A076000</u>	<u>004</u>	Oct 24, 2011
<u>AB</u>		<u>15MG</u>	<u>A076000</u>	<u>005</u>	Oct 24, 2011
<u>AB</u>	TORRENT PHARMS LTD	<u>2.5MG</u>	<u>A091434</u>	<u>001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A091434</u>	<u>002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A091434</u>	<u>003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A091434</u>	<u>004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A091434</u>	<u>005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A091434</u>	<u>006</u>	Apr 23, 2012

ZYPREXA

<u>AB</u>	LILLY	<u>2.5MG</u>	<u>N020592</u>	<u>001</u>	Sep 30, 1996
<u>AB</u>	+	<u>5MG</u>	<u>N020592</u>	<u>002</u>	Sep 30, 1996
<u>AB</u>		<u>7.5MG</u>	<u>N020592</u>	<u>003</u>	Sep 30, 1996
<u>AB</u>		<u>10MG</u>	<u>N020592</u>	<u>004</u>	Sep 30, 1996
<u>AB</u>		<u>15MG</u>	<u>N020592</u>	<u>005</u>	Sep 09, 1997
<u>AB</u>		<u>20MG</u>	<u>N020592</u>	<u>006</u>	Sep 09, 1997

TABLET, ORALLY DISINTEGRATING; ORAL

OLANZAPINE

<u>AB</u>	APOTEX INC	<u>5MG</u>	<u>A091265</u>	<u>001</u>	Oct 24, 2011
<u>AB</u>		<u>10MG</u>	<u>A091265</u>	<u>002</u>	Oct 24, 2011
<u>AB</u>		<u>15MG</u>	<u>A091265</u>	<u>003</u>	Oct 24, 2011
<u>AB</u>		<u>20MG</u>	<u>A091265</u>	<u>004</u>	Oct 24, 2011
<u>AB</u>	AUROBINDO PHARMA LTD	<u>5MG</u>	<u>A203708</u>	<u>001</u>	May 15, 2014
<u>AB</u>		<u>10MG</u>	<u>A203708</u>	<u>002</u>	May 15, 2014
<u>AB</u>		<u>15MG</u>	<u>A203708</u>	<u>003</u>	May 15, 2014
<u>AB</u>		<u>20MG</u>	<u>A203708</u>	<u>004</u>	May 15, 2014
<u>AB</u>	BARR LABS INC	<u>5MG</u>	<u>A077243</u>	<u>001</u>	Jan 30, 2012
<u>AB</u>		<u>10MG</u>	<u>A077243</u>	<u>002</u>	Jan 30, 2012
<u>AB</u>		<u>15MG</u>	<u>A077243</u>	<u>003</u>	Jan 30, 2012
<u>AB</u>		<u>20MG</u>	<u>A077243</u>	<u>004</u>	Jan 30, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A076534</u>	<u>001</u>	Oct 24, 2011
<u>AB</u>		<u>10MG</u>	<u>A076534</u>	<u>002</u>	Oct 24, 2011

PRESCRIPTION DRUG PRODUCT LIST

OLANZAPINE

TABLET, ORALLY DISINTEGRATING;ORAL

OLANZAPINE

<u>AB</u>		<u>15MG</u>	<u>A076534</u>	<u>003</u>	Oct 24, 2011
<u>AB</u>		<u>20MG</u>	<u>A076534</u>	<u>004</u>	Oct 24, 2011
<u>AB</u>	INVAGEN PHARMS	<u>5MG</u>	<u>A203456</u>	<u>001</u>	Mar 16, 2016
<u>AB</u>		<u>10MG</u>	<u>A203456</u>	<u>002</u>	Mar 16, 2016
<u>AB</u>		<u>15MG</u>	<u>A203456</u>	<u>003</u>	Mar 16, 2016
<u>AB</u>		<u>20MG</u>	<u>A203456</u>	<u>004</u>	Mar 16, 2016
<u>AB</u>	JUBILANT GENERICS	<u>5MG</u>	<u>A200221</u>	<u>001</u>	Sep 12, 2012
<u>AB</u>		<u>10MG</u>	<u>A200221</u>	<u>002</u>	Sep 12, 2012
<u>AB</u>		<u>15MG</u>	<u>A200221</u>	<u>003</u>	Sep 12, 2012
<u>AB</u>		<u>20MG</u>	<u>A200221</u>	<u>004</u>	Sep 12, 2012
<u>AB</u>	MACLEODS PHARMS LTD	<u>5MG</u>	<u>A203044</u>	<u>001</u>	Feb 20, 2015
<u>AB</u>		<u>10MG</u>	<u>A203044</u>	<u>002</u>	Feb 20, 2015
<u>AB</u>		<u>15MG</u>	<u>A203044</u>	<u>003</u>	Feb 20, 2015
<u>AB</u>		<u>20MG</u>	<u>A203044</u>	<u>004</u>	Feb 20, 2015
<u>AB</u>	MYLAN PHARMS INC	<u>5MG</u>	<u>A202285</u>	<u>001</u>	May 12, 2014
<u>AB</u>		<u>10MG</u>	<u>A202285</u>	<u>002</u>	May 12, 2014
<u>AB</u>		<u>15MG</u>	<u>A202285</u>	<u>003</u>	May 12, 2014
<u>AB</u>		<u>20MG</u>	<u>A202285</u>	<u>004</u>	May 12, 2014
<u>AB</u>	ORCHID HLTHCARE	<u>5MG</u>	<u>A202937</u>	<u>001</u>	Mar 02, 2015
<u>AB</u>		<u>10MG</u>	<u>A202937</u>	<u>002</u>	Mar 02, 2015
<u>AB</u>		<u>15MG</u>	<u>A202937</u>	<u>003</u>	Mar 02, 2015
<u>AB</u>		<u>20MG</u>	<u>A202937</u>	<u>004</u>	Mar 02, 2015
<u>AB</u>	PAR PHARM	<u>5MG</u>	<u>A078109</u>	<u>001</u>	Oct 24, 2011
<u>AB</u>		<u>10MG</u>	<u>A078109</u>	<u>002</u>	Oct 24, 2011
<u>AB</u>		<u>15MG</u>	<u>A078109</u>	<u>003</u>	Oct 24, 2011
<u>AB</u>		<u>20MG</u>	<u>A078109</u>	<u>004</u>	Oct 24, 2011
<u>AB</u>	SUN PHARM INDS	<u>5MG</u>	<u>A090881</u>	<u>001</u>	Feb 28, 2012
<u>AB</u>		<u>10MG</u>	<u>A090881</u>	<u>002</u>	Feb 28, 2012
<u>AB</u>		<u>15MG</u>	<u>A090881</u>	<u>003</u>	Feb 28, 2012
<u>AB</u>		<u>20MG</u>	<u>A090881</u>	<u>004</u>	Feb 28, 2012
<u>AB</u>	TORRENT PHARMS LLC	<u>5MG</u>	<u>A091415</u>	<u>001</u>	Oct 25, 2011
<u>AB</u>		<u>10MG</u>	<u>A091415</u>	<u>002</u>	Oct 25, 2011
<u>AB</u>		<u>15MG</u>	<u>A091415</u>	<u>003</u>	Oct 25, 2011
<u>AB</u>		<u>20MG</u>	<u>A091415</u>	<u>004</u>	Oct 25, 2011
<u>ZYPREXA ZYDIS</u>					
<u>AB</u>	+ LILLY	<u>5MG</u>	<u>N021086</u>	<u>001</u>	Apr 06, 2000
<u>AB</u>		<u>10MG</u>	<u>N021086</u>	<u>002</u>	Apr 06, 2000
<u>AB</u>		<u>15MG</u>	<u>N021086</u>	<u>003</u>	Apr 06, 2000
<u>AB</u>		<u>20MG</u>	<u>N021086</u>	<u>004</u>	Apr 06, 2000

OLANZAPINE PAMOATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

ZYPREXA RELPREVV

ELI LILLY CO	EQ 210MG BASE/VIAL	N022173	001	Dec 11, 2009
	EQ 300MG BASE/VIAL	N022173	002	Dec 11, 2009
+	EQ 405MG BASE/VIAL	N022173	003	Dec 11, 2009

OLAPARIB

CAPSULE;ORAL

LYNPARZA

ASTRAZENECA PHARMS	50MG	N206162	001	Dec 19, 2014
--------------------	------	---------	-----	--------------

OLIVE OIL; SOYBEAN OIL

INJECTABLE; INJECTION

CLINOLIPID 20%

+ BAXTER HLTHCARE	16% (160GM/1000ML); 4% (40GM/1000ML)	N204508	001	Oct 03, 2013
-------------------	--------------------------------------	---------	-----	--------------

OLMESARTAN MEDOXOMIL

TABLET;ORAL

BENICAR

<u>AB</u>	DAIICHI SANKYO	<u>5MG</u>	<u>N021286</u>	<u>001</u>	Apr 25, 2002
<u>AB</u>		<u>20MG</u>	<u>N021286</u>	<u>003</u>	Apr 25, 2002
<u>AB</u>	+	<u>40MG</u>	<u>N021286</u>	<u>004</u>	Apr 25, 2002

OLMESARTAN MEDOXOMIL

<u>AB</u>	MYLAN PHARMS INC	<u>5MG</u>	<u>A078276</u>	<u>001</u>	Oct 26, 2016
<u>AB</u>		<u>20MG</u>	<u>A078276</u>	<u>002</u>	Oct 26, 2016
<u>AB</u>		<u>40MG</u>	<u>A078276</u>	<u>003</u>	Oct 26, 2016

PRESCRIPTION DRUG PRODUCT LIST

OLODATEROL HYDROCHLORIDE

SPRAY, METERED; INHALATION

STRIVERDI RESPIMAT

+ BOEHRINGER INGELHEIM EQ 0.0025MG BASE/INH

N203108 001 Jul 31, 2014

OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE

SPRAY, METERED; INHALATION

STIOLTO RESPIMAT

+ BOEHRINGER INGELHEIM EQ 0.0025MG BASE/INH; EQ 0.0025MG
BASE/INH

N206756 001 May 21, 2015

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

AT	AKORN INC	EQ 0.1% BASE	A204532 001	Jan 10, 2017
AT	APOTEX INC	EQ 0.1% BASE	A078350 001	Dec 07, 2015
AT	AUROBINDO PHARMA LTD	EQ 0.1% BASE	A204812 001	Dec 18, 2015
AT	BARR LABS INC	EQ 0.2% BASE	A090848 001	Jul 13, 2015
AT	SOMERSET THERAPS LLC	EQ 0.1% BASE	A206306 001	Dec 07, 2015
AT	USV NORTH AMERICA	EQ 0.1% BASE	A203152 001	Dec 07, 2015
AT	ZACH SYSTEM SPA	EQ 0.1% BASE	A204706 001	Dec 07, 2015

PATADAY

AT	+ NOVARTIS PHARMS CORP	EQ 0.2% BASE	N021545 001	Dec 22, 2004
-----------	------------------------	---------------------	--------------------	--------------

PATANOL

AT	+ NOVARTIS PHARMS CORP	EQ 0.1% BASE	N020688 001	Dec 18, 1996
	PAZEO			
	+ NOVARTIS PHARMS CORP	EQ 0.7% BASE	N206276 001	Jan 30, 2015

SPRAY, METERED; NASAL

OLOPATADINE HYDROCHLORIDE

AB	APOTEX INC	0.665MG/SPRAY	A091572 001	Oct 08, 2014
AB	+ NOVARTIS PHARMS CORP	0.665MG/SPRAY	N021861 001	Apr 15, 2008

OLSALAZINE SODIUM

CAPSULE; ORAL

DIPENTUM

+ MEDA PHARMS 250MG

N019715 001 Jul 31, 1990

OMACETAXINE MEPESUCCINATE

POWDER; SUBCUTANEOUS

SYNRIBO

+ IVAX INTL 3.5MG/VIAL

N203585 001 Oct 26, 2012

OMBITASVIR; PARITAPREVIR; RITONAVIR

TABLET; ORAL

TECHNIVIE

+ ABBVIE INC 12.5MG; 75MG; 50MG

N207931 001 Jul 24, 2015

OMEGA-3-ACID ETHYL ESTERS

CAPSULE; ORAL

LOVAZA

AB	+ SMITHKLINE BEECHAM	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N021654 001	Nov 10, 2004
-----------	----------------------	---	--------------------	--------------

OMEGA-3-ACID ETHYL ESTERS

AB	AMNEAL PHARMS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A204940 001	Nov 27, 2015
AB	APOTEX INC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A090973 001	Sep 30, 2014
AB	PAR PHARM INC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A091018 001	Jun 24, 2014
AB	TEVA PHARMS USA	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A091028 001	Apr 07, 2014

OMEGA-3-ACID ETHYL ESTERS TYPE A

CAPSULE; ORAL

OMTRYG

+ TRYGG 1.2GM CONTAINS AT LEAST 900MG OF THE
ETHYL ESTERS OF OMEGA-3 FATTY ACIDS

N204977 001 Apr 23, 2014

OMEGA-3-CARBOXYLIC ACIDS

CAPSULE; ORAL

EPANOVA

+ ASTRAZENECA PHARMS 1GM CONTAINS AT LEAST 850MG OF
POLYUNSATURATED FATTY ACIDS

N205060 001 May 05, 2014

PRESCRIPTION DRUG PRODUCT LIST

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

OMEPRAZOLE

<u>AB</u>	ACTAVIS LABS FL INC	<u>10MG</u>	<u>A075347 001</u>	May 30, 2008
<u>AB</u>		<u>20MG</u>	<u>A075347 002</u>	May 30, 2008
<u>AB</u>		<u>40MG</u>	<u>A075347 003</u>	May 30, 2008
<u>AB</u>	APOTEX	<u>10MG</u>	<u>A076048 001</u>	Oct 22, 2007
<u>AB</u>		<u>20MG</u>	<u>A076048 002</u>	Oct 22, 2007
<u>AB</u>		<u>40MG</u>	<u>A076048 003</u>	Jan 21, 2009
<u>AB</u>	AUROBINDO PHARMA USA	<u>10MG</u>	<u>A203270 001</u>	Aug 19, 2015
<u>AB</u>		<u>20MG</u>	<u>A203270 002</u>	Aug 19, 2015
<u>AB</u>		<u>40MG</u>	<u>A203270 003</u>	Aug 19, 2015
<u>AB</u>	DR REDDYS LABS LTD	<u>10MG</u>	<u>A075576 003</u>	Oct 22, 2007
<u>AB</u>		<u>10MG</u>	<u>A078490 002</u>	Mar 16, 2009
<u>AB</u>		<u>20MG</u>	<u>A075576 002</u>	Oct 22, 2007
<u>AB</u>		<u>20MG</u>	<u>A078490 003</u>	Mar 16, 2009
<u>AB</u>		<u>40MG</u>	<u>A075576 001</u>	Jan 21, 2009
<u>AB</u>		<u>40MG</u>	<u>A078490 001</u>	Apr 17, 2009
<u>AB</u>	GLENMARK GENERICS	<u>10MG</u>	<u>A091672 001</u>	Oct 31, 2014
<u>AB</u>		<u>20MG</u>	<u>A091672 002</u>	Oct 31, 2014
<u>AB</u>		<u>40MG</u>	<u>A091672 003</u>	Oct 31, 2014
<u>AB</u>	IMPAX LABS	<u>10MG</u>	<u>A075785 001</u>	Oct 22, 2007
<u>AB</u>		<u>20MG</u>	<u>A075785 002</u>	Oct 22, 2007
<u>AB</u>		<u>40MG</u>	<u>A075785 003</u>	Jan 21, 2009
<u>AB</u>	KREMERS URBAN PHARMS	<u>10MG</u>	<u>A075410 001</u>	Nov 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075410 002</u>	Nov 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A075410 003</u>	Jan 23, 2009
<u>AB</u>	LUPIN LTD	<u>10MG</u>	<u>A202384 001</u>	Aug 25, 2015
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A075876 001</u>	May 29, 2003
<u>AB</u>		<u>20MG</u>	<u>A075876 002</u>	May 29, 2003
<u>AB</u>		<u>40MG</u>	<u>A075876 003</u>	Jan 21, 2009
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A075757 001</u>	Jan 28, 2003
<u>AB</u>	+	<u>20MG</u>	<u>A075757 002</u>	Jan 28, 2003
<u>AB</u>	+	<u>40MG</u>	<u>A076515 001</u>	Jan 21, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>10MG</u>	<u>A091352 001</u>	Nov 19, 2012
<u>AB</u>		<u>20MG</u>	<u>A091352 002</u>	Nov 19, 2012
<u>AB</u>		<u>40MG</u>	<u>A091352 003</u>	Nov 19, 2012

OMEPRAZOLE MAGNESIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL

PRIOSEC

	ASTRAZENECA PHARMS	EQ 2.5MG BASE/PACKET	N022056 001	Mar 20, 2008
	+	EQ 10MG BASE/PACKET	N022056 002	Mar 20, 2008

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

<u>AB</u>	AJANTA PHARMA LTD	<u>20MG;1.1GM</u>	<u>A204228 001</u>	Jul 15, 2016
<u>AB</u>		<u>40MG;1.1GM</u>	<u>A204228 002</u>	Jul 15, 2016
<u>AB</u>	AUROLIFE PHARMA LLC	<u>20MG;1.1GM</u>	<u>A204922 001</u>	Aug 19, 2016
<u>AB</u>		<u>40MG;1.1GM</u>	<u>A204922 002</u>	Aug 19, 2016
<u>AB</u>	DR REDDYS LABS LTD	<u>20MG;1.1GM</u>	<u>A204068 001</u>	Jul 15, 2016
<u>AB</u>		<u>40MG;1.1GM</u>	<u>A204068 002</u>	Jul 15, 2016
<u>AB</u>	PAR PHARM	<u>20MG;1.1GM</u>	<u>A078966 001</u>	May 25, 2010
<u>AB</u>		<u>40MG;1.1GM</u>	<u>A078966 002</u>	May 25, 2010
<u>AB</u>	SCIEGEN PHARMS INC	<u>20MG;1.1GM</u>	<u>A207476 001</u>	Dec 06, 2016
<u>AB</u>		<u>40MG;1.1GM</u>	<u>A207476 002</u>	Dec 06, 2016
<u>ZEGERID</u>				
<u>AB</u>	SANTARUS INC	<u>20MG;1.1GM</u>	<u>N021849 001</u>	Feb 27, 2006
<u>AB</u>	+	<u>40MG;1.1GM</u>	<u>N021849 002</u>	Feb 27, 2006

FOR SUSPENSION;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

<u>AA</u>	AJANTA PHARMA LTD	<u>20MG/PACKET;1.68GM/PACKET</u>	<u>A205545 001</u>	Jul 27, 2016
<u>AA</u>		<u>40MG/PACKET;1.68GM/PACKET</u>	<u>A205545 002</u>	Jul 27, 2016
<u>ZEGERID</u>				
<u>AA</u>	SANTARUS INC	<u>20MG/PACKET;1.68GM/PACKET</u>	<u>N021636 001</u>	Jun 15, 2004
<u>AA</u>	+	<u>40MG/PACKET;1.68GM/PACKET</u>	<u>N021636 002</u>	Dec 21, 2004

PRESCRIPTION DRUG PRODUCT LIST

ONDANSETRON

FILM;ORAL

ZUPLENZ

	MIDATECH PHARMA US	4MG	N022524	001	Jul 02, 2010
+		8MG	N022524	002	Jul 02, 2010

TABLET, ORALLY DISINTEGRATING;ORAL

ONDANSETRON

<u>AB</u>	AUROBINDO PHARMA	<u>4MG</u>	<u>A090469</u>	<u>001</u>	Apr 12, 2010
<u>AB</u>		<u>8MG</u>	<u>A090469</u>	<u>002</u>	Apr 12, 2010
<u>AB</u>	BARR	<u>4MG</u>	<u>A076693</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>8MG</u>	<u>A076693</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>	GLENMARK GENERICS	<u>4MG</u>	<u>A078152</u>	<u>001</u>	Jun 27, 2007
<u>AB</u>		<u>8MG</u>	<u>A078152</u>	<u>002</u>	Jun 27, 2007
<u>AB</u>	MYLAN	<u>4MG</u>	<u>A078139</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>8MG</u>	<u>A078139</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>	SANDOZ	<u>4MG</u>	<u>A078050</u>	<u>001</u>	Aug 13, 2007
<u>AB</u>		<u>8MG</u>	<u>A078050</u>	<u>002</u>	Aug 13, 2007
<u>AB</u>	SUN PHARM INDS	<u>4MG</u>	<u>A077557</u>	<u>001</u>	Aug 02, 2007
<u>AB</u>		<u>8MG</u>	<u>A077557</u>	<u>002</u>	Aug 02, 2007
<u>AB</u>	SUN PHARM INDS LTD	<u>4MG</u>	<u>A078602</u>	<u>001</u>	Feb 24, 2011
<u>AB</u>		<u>8MG</u>	<u>A078602</u>	<u>002</u>	Feb 24, 2011
<u>AB</u>	TEVA	<u>4MG</u>	<u>A076810</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>8MG</u>	<u>A076810</u>	<u>002</u>	Jun 25, 2007

ZOFRAN ODT

<u>AB</u>	NOVARTIS PHARMS CORP	<u>4MG</u>	<u>N020781</u>	<u>001</u>	Jan 27, 1999
<u>AB</u>	+	<u>8MG</u>	<u>N020781</u>	<u>002</u>	Jan 27, 1999

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ONDANSETRON HYDROCHLORIDE

<u>AP</u>	ACCORD HLTHCARE	<u>EQ 2MG BASE/ML</u>	<u>A206846</u>	<u>001</u>	Jul 13, 2015
<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 2MG BASE/ML</u>	<u>A202599</u>	<u>001</u>	Dec 21, 2012
<u>AP</u>	+	<u>EQ 2MG BASE/ML</u>	<u>A078288</u>	<u>001</u>	Feb 22, 2013
<u>AP</u>	EMCURE PHARMS	<u>EQ 2MG BASE/ML</u>	<u>A090424</u>	<u>001</u>	Apr 16, 2010
<u>AP</u>	EUROHLTH INTL SARL	<u>EQ 2MG BASE/ML</u>	<u>A076967</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>		<u>EQ 2MG BASE/ML</u>	<u>A077365</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 2MG BASE/ML</u>	<u>A076974</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 2MG BASE/ML</u>	<u>A079224</u>	<u>001</u>	Sep 25, 2009
<u>AP</u>		<u>EQ 2MG BASE/ML</u>	<u>A090648</u>	<u>001</u>	Jun 15, 2012
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 2MG BASE/ML</u>	<u>A076781</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	HOSPIRA	<u>EQ 2MG BASE/ML</u>	<u>A077473</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>		<u>EQ 2MG BASE/ML</u>	<u>A077840</u>	<u>001</u>	Jan 19, 2007
<u>AP</u>	LUITPOLD	<u>EQ 2MG BASE/ML</u>	<u>A079039</u>	<u>001</u>	Nov 18, 2008
<u>AP</u>	MYLAN LABS LTD	<u>EQ 2MG BASE/ML</u>	<u>A078257</u>	<u>001</u>	Apr 23, 2008
<u>AP</u>	QILU PHARM CO LTD	<u>EQ 2MG BASE/ML</u>	<u>A203711</u>	<u>001</u>	Sep 08, 2014
<u>AP</u>	SANDOZ	<u>EQ 2MG BASE/ML</u>	<u>A077430</u>	<u>001</u>	Jun 27, 2007
<u>AP</u>	SUN PHARM INDS (IN)	<u>EQ 2MG BASE/ML</u>	<u>A077172</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	TEVA	<u>EQ 2MG BASE/ML</u>	<u>A076876</u>	<u>001</u>	Nov 22, 2006
<u>AP</u>	WOCKHARDT	<u>EQ 2MG BASE/ML</u>	<u>A077577</u>	<u>001</u>	Dec 26, 2006

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	ACCORD HLTHCARE	<u>EQ 2MG BASE/ML</u>	<u>A206845</u>	<u>001</u>	Mar 10, 2016
<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 2MG BASE/ML</u>	<u>A202600</u>	<u>001</u>	Dec 21, 2012
<u>AP</u>	+	<u>EQ 2MG BASE/ML</u>	<u>A078287</u>	<u>001</u>	Feb 22, 2013
<u>AP</u>	EMCURE PHARMS LTD	<u>EQ 2MG BASE/ML</u>	<u>A078945</u>	<u>001</u>	Jan 03, 2013
<u>AP</u>	EUROHLTH INTL SARL	<u>EQ 2MG BASE/ML</u>	<u>A077011</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>		<u>EQ 2MG BASE/ML</u>	<u>A077541</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 2MG BASE/ML</u>	<u>A076972</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>		<u>EQ 2MG BASE/ML</u>	<u>A202253</u>	<u>001</u>	Jul 19, 2013
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 2MG BASE/ML</u>	<u>A076780</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	HOSPIRA	<u>EQ 2MG BASE/ML</u>	<u>A077548</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	LUITPOLD	<u>EQ 2MG BASE/ML</u>	<u>A079032</u>	<u>001</u>	Nov 18, 2008
<u>AP</u>	MYLAN LABS LTD	<u>EQ 2MG BASE/ML</u>	<u>A078244</u>	<u>001</u>	Apr 23, 2008
<u>AP</u>	SANDOZ	<u>EQ 2MG BASE/ML</u>	<u>A077551</u>	<u>001</u>	Jun 27, 2007
<u>AP</u>	SUN PHARM INDS LTD	<u>EQ 2MG BASE/ML</u>	<u>A077173</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	TEVA	<u>EQ 2MG BASE/ML</u>	<u>A076759</u>	<u>001</u>	Nov 22, 2006
<u>AP</u>	WOCKHARDT	<u>EQ 2MG BASE/ML</u>	<u>A077716</u>	<u>001</u>	Dec 26, 2006

SOLUTION;ORAL

ONDANSETRON HYDROCHLORIDE

<u>AA</u>	AMNEAL PHARMS	<u>EQ 4MG BASE/5ML</u>	<u>A091483</u>	<u>001</u>	Jan 31, 2011
<u>AA</u>	APOTEX	<u>EQ 4MG BASE/5ML</u>	<u>A078127</u>	<u>001</u>	Jun 25, 2007
<u>AA</u>	AUROBINDO PHARMA	<u>EQ 4MG BASE/5ML</u>	<u>A078776</u>	<u>001</u>	Nov 28, 2007
<u>AA</u>	SILARX	<u>EQ 4MG BASE/5ML</u>	<u>A091342</u>	<u>001</u>	Jan 27, 2011
<u>AA</u>	TARO	<u>EQ 4MG BASE/5ML</u>	<u>A077009</u>	<u>001</u>	Nov 30, 2007

PRESCRIPTION DRUG PRODUCT LIST

ONDANSETRON HYDROCHLORIDE

SOLUTION; ORAL

ONDANSETRON HYDROCHLORIDE

AA	WEST-WARD PHARMS INT	<u>EQ 4MG BASE/5ML</u>	A076960 001	Dec 26, 2006
-----------	----------------------	------------------------	--------------------	--------------

ZOFRAN

AA	+ NOVARTIS PHARMS CORP	<u>EQ 4MG BASE/5ML</u>	N020605 001	Jan 24, 1997
-----------	------------------------	------------------------	--------------------	--------------

ONDANSETRON HYDROCHLORIDE

AB	APOTEX	<u>EQ 4MG BASE</u>	A077306 001	Jun 25, 2007
AB		<u>EQ 8MG BASE</u>	A077306 002	Jun 25, 2007
AB	AUROBINDO PHARMA	<u>EQ 4MG BASE</u>	A078539 001	Jul 31, 2007
AB		<u>EQ 8MG BASE</u>	A078539 002	Jul 31, 2007
AB		<u>EQ 24MG BASE</u>	A078539 003	Jul 31, 2007
AB	DR REDDYS LABS LTD	<u>EQ 4MG BASE</u>	A076183 003	Dec 26, 2006
AB		<u>EQ 8MG BASE</u>	A076183 002	Dec 26, 2006
AB		<u>EQ 24MG BASE</u>	A076183 001	Dec 26, 2006
AB	GLENMARK GENERICS	<u>EQ 4MG BASE</u>	A077535 001	Jun 25, 2007
AB		<u>EQ 8MG BASE</u>	A077535 002	Jun 25, 2007
AB		<u>EQ 24MG BASE</u>	A077535 003	Jun 25, 2007
AB	IPCA LABS LTD	<u>EQ 4MG BASE</u>	A203761 001	Jan 23, 2014
AB		<u>EQ 8MG BASE</u>	A203761 002	Jan 23, 2014
AB	MYLAN	<u>EQ 4MG BASE</u>	A076930 001	Jun 25, 2007
AB		<u>EQ 8MG BASE</u>	A076930 002	Jun 25, 2007
AB		<u>EQ 24MG BASE</u>	A076930 004	Jun 25, 2007
AB	NATCO PHARMA LTD	<u>EQ 4MG BASE</u>	A077851 001	Jun 25, 2007
AB		<u>EQ 8MG BASE</u>	A077851 002	Jun 25, 2007
AB	PLIVA HRVATSKA DOO	<u>EQ 4MG BASE</u>	A077112 001	Jun 25, 2007
AB		<u>EQ 8MG BASE</u>	A077112 002	Jun 25, 2007
AB		<u>EQ 24MG BASE</u>	A077112 003	Jun 25, 2007
AB	SANDOZ	<u>EQ 4MG BASE</u>	A077517 001	Jun 25, 2007
AB		<u>EQ 8MG BASE</u>	A077517 002	Jun 25, 2007
AB		<u>EQ 24MG BASE</u>	A077517 003	Jun 25, 2007
AB	SUN PHARM INDS (IN)	<u>EQ 4MG BASE</u>	A077050 001	Jun 25, 2007
AB		<u>EQ 8MG BASE</u>	A077050 002	Jun 25, 2007
AB	TEVA	<u>EQ 4MG BASE</u>	A076252 001	Jun 25, 2007
AB		<u>EQ 8MG BASE</u>	A076252 002	Jun 25, 2007
AB		<u>EQ 24MG BASE</u>	A076252 003	Jun 25, 2007

ZOFRAN

AB	NOVARTIS PHARMS CORP	<u>EQ 4MG BASE</u>	N020103 001	Dec 31, 1992
AB		<u>EQ 8MG BASE</u>	N020103 002	Dec 31, 1992
AB	+ ONDANSETRON HYDROCHLORIDE	<u>EQ 24MG BASE</u>	N020103 003	Aug 27, 1999
	DR REDDYS LABS LTD	EQ 16MG BASE	A076183 004	Dec 26, 2006

ORITAVANCIN DIPHOSPHATE

POWDER; IV (INFUSION)

ORBACTIV

	+ THE MEDICINES CO	EQ 400MG BASE/VIAL	N206334 001	Aug 06, 2014
--	--------------------	--------------------	-------------	--------------

ORLISTAT

CAPSULE; ORAL

XENICAL

	+ HOFFMANN LA ROCHE	120MG	N020766 001	Apr 23, 1999
--	---------------------	-------	-------------	--------------

ORPHENADRINE CITRATE

INJECTABLE; INJECTION

ORPHENADRINE CITRATE

AP	+ AKORN	<u>30MG/ML</u>	A040484 001	May 24, 2006
AP	SAGENT PHARMS	<u>30MG/ML</u>	A090585 001	Aug 30, 2011
AP	WATSON LABS	<u>30MG/ML</u>	A084779 001	Mar 15, 1982
AP	WEST-WARD PHARMS INT	<u>30MG/ML</u>	A040463 001	Mar 04, 2003

TABLET, EXTENDED RELEASE; ORAL

ORPHENADRINE CITRATE

AB	GAVIS PHARMS	<u>100MG</u>	A040284 001	Jun 19, 1998
AB	IMPAX PHARMS	<u>100MG</u>	A040368 001	Jun 23, 2000
AB	INVAGEN PHARMS	<u>100MG</u>	A091158 001	Jul 27, 2012
AB	+ SANDOZ	<u>100MG</u>	A040327 001	Feb 15, 2000
AB	TEDOR PHARMA INC	<u>100MG</u>	A040249 001	Jan 29, 1999

PRESCRIPTION DRUG PRODUCT LIST

OSELTAMIVIR PHOSPHATE

CAPSULE; ORAL

OSELTAMIVIR PHOSPHATE

<u>AB</u>	NATCO PHARMA LTD	<u>EQ 30MG BASE</u>	<u>A202595 001</u>	Aug 03, 2016
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A202595 002</u>	Aug 03, 2016
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A202595 003</u>	Aug 03, 2016

TAMIFLU

<u>AB</u>	ROCHE	<u>EQ 30MG BASE</u>	<u>N021087 003</u>	Jul 02, 2007
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>N021087 002</u>	Jul 02, 2007
<u>AB</u>	+	<u>EQ 75MG BASE</u>	<u>N021087 001</u>	Oct 27, 1999

FOR SUSPENSION; ORAL

TAMIFLU

+ ROCHE

EQ 6MG BASE/ML

N021246 002 Mar 21, 2011

OSIMERTINIB MESYLATE

TABLET; ORAL

TAGRISSO

ASTRAZENECA PHARMS

EQ 40MG BASE

N208065 001 Nov 13, 2015

+

EQ 80MG BASE

N208065 002 Nov 13, 2015

OSPEMIFENE

TABLET; ORAL

OSPHENA

+ SHIONOGI INC

60MG

N203505 001 Feb 26, 2013

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 1GM BASE/VIAL</u>	<u>A201539 001</u>	Jan 18, 2013
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A201539 002</u>	Jan 18, 2013
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A201538 001</u>	Jan 18, 2013
<u>AP</u>	HOSPIRA INC	<u>EQ 1GM BASE/VIAL</u>	<u>A203950 001</u>	Dec 11, 2015
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A203950 002</u>	Dec 11, 2015
<u>AP</u>	MYLAN LABS LTD	<u>EQ 1GM BASE/VIAL</u>	<u>A091486 001</u>	Aug 25, 2014
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A091486 002</u>	Aug 25, 2014
<u>AP</u>	SAGENT PHARMS	<u>EQ 1GM BASE/VIAL</u>	<u>A091246 001</u>	Mar 30, 2012
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A091246 002</u>	Mar 30, 2012
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A091245 001</u>	Mar 30, 2012
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>A061490 003</u>	
<u>AP</u>	+	<u>EQ 2GM BASE/VIAL</u>	<u>A061490 004</u>	
<u>AP</u>	+	<u>EQ 10GM BASE/VIAL</u>	<u>A061490 006</u>	May 09, 1991

BACTOCILL IN PLASTIC CONTAINER

+ BAXTER HLTHCARE

EQ 20MG BASE/ML

N050640 001 Oct 26, 1989

+

EQ 40MG BASE/ML

N050640 002 Oct 26, 1989

POWDER; INTRAVENOUS

OXACILLIN SODIUM

<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>A062737 001</u>	Dec 23, 1986
<u>AP</u>	+	<u>EQ 2GM BASE/VIAL</u>	<u>A062737 002</u>	Dec 23, 1986

OXALIPLATIN

INJECTABLE; IV (INFUSION)

ELOXATIN

<u>AP</u>	+	<u>SANOFI AVENTIS US</u>	<u>50MG/10ML (5MG/ML)</u>	<u>N021759 001</u>	Jan 31, 2005
<u>AP</u>	+		<u>100MG/20ML (5MG/ML)</u>	<u>N021759 002</u>	Jan 31, 2005

OXALIPLATIN

<u>AP</u>	ACTAVIS TOTOWA	<u>50MG/VIAL</u>	<u>A078803 001</u>	Aug 08, 2012
<u>AP</u>		<u>100MG/VIAL</u>	<u>A078803 002</u>	Aug 08, 2012
<u>AP</u>	FRESENIUS KABI ONCOL	<u>50MG/10ML (5MG/ML)</u>	<u>A078811 001</u>	Jun 10, 2010
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A078811 002</u>	Jun 10, 2010
<u>AP</u>		<u>50MG/VIAL</u>	<u>A078810 001</u>	Aug 07, 2009
<u>AP</u>		<u>100MG/VIAL</u>	<u>A078810 002</u>	Aug 07, 2009
<u>AP</u>	FRESENIUS KABI USA	<u>50MG/VIAL</u>	<u>A078819 001</u>	Jun 02, 2010
<u>AP</u>		<u>100MG/VIAL</u>	<u>A078819 002</u>	Jun 02, 2010
<u>AP</u>	HOSPIRA INC	<u>50MG/VIAL</u>	<u>A078815 001</u>	Sep 30, 2009
<u>AP</u>		<u>100MG/VIAL</u>	<u>A078815 002</u>	Sep 30, 2009
<u>AP</u>	HOSPIRA WORLDWIDE	<u>50MG/10ML (5MG/ML)</u>	<u>A078813 001</u>	Aug 07, 2009
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A078813 002</u>	Aug 07, 2009
<u>AP</u>	JIANGSU HENGRUI MED	<u>50MG/10ML (5MG/ML)</u>	<u>A203869 001</u>	Jun 18, 2014
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A203869 002</u>	Jun 18, 2014
<u>AP</u>	MYLAN LABS LTD	<u>50MG/10ML (5MG/ML)</u>	<u>A091358 001</u>	Aug 07, 2012
<u>AP</u>		<u>50MG/VIAL</u>	<u>A200979 001</u>	Aug 08, 2012
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A091358 002</u>	Aug 07, 2012
<u>AP</u>		<u>100MG/VIAL</u>	<u>A200979 002</u>	Aug 08, 2012
<u>AP</u>	QILU PHARM CO LTD	<u>50MG/10ML (5MG/ML)</u>	<u>A204368 001</u>	Jun 07, 2016

PRESCRIPTION DRUG PRODUCT LIST

OXALIPLATIN

INJECTABLE; IV (INFUSION)

OXALIPLATIN

<u>AP</u>		<u>50MG/VIAL</u>	<u>A204616</u>	<u>001</u>	May 11, 2016
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A204368</u>	<u>002</u>	Jun 07, 2016
<u>AP</u>		<u>100MG/VIAL</u>	<u>A204616</u>	<u>002</u>	May 11, 2016
<u>AP</u>	SANDOZ	<u>50MG/10ML (5MG/ML)</u>	<u>A078817</u>	<u>001</u>	Jan 24, 2011
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A078817</u>	<u>002</u>	Jan 24, 2011
<u>AP</u>	+ SUN PHARMA GLOBAL	<u>50MG/VIAL</u>	<u>A078818</u>	<u>001</u>	Aug 07, 2009
<u>AP</u>		<u>50MG/10ML (5MG/ML)</u>	<u>A202922</u>	<u>001</u>	Apr 08, 2014
<u>AP</u>	+	<u>100MG/VIAL</u>	<u>A078818</u>	<u>002</u>	Aug 07, 2009
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A202922</u>	<u>002</u>	Apr 08, 2014
<u>AP</u>	+ TEVA PHARMS	<u>50MG/10ML (5MG/ML)</u>	<u>N022160</u>	<u>001</u>	Aug 07, 2009
<u>AP</u>	+	<u>100MG/20ML (5MG/ML)</u>	<u>N022160</u>	<u>002</u>	Aug 07, 2009
	+ QILU PHARM CO LTD	200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016

OXANDROLONE

TABLET; ORAL

OXANDRIN

<u>AB</u>	GEMINI LABS LLC	<u>2.5MG</u>	<u>N013718</u>	<u>001</u>	
<u>AB</u>	+	<u>10MG</u>	<u>N013718</u>	<u>002</u>	Nov 05, 2001

OXANDROLONE

<u>AB</u>	PAR PHARM	<u>2.5MG</u>	<u>A077827</u>	<u>001</u>	Jun 22, 2007
<u>AB</u>		<u>10MG</u>	<u>A077827</u>	<u>002</u>	Jun 22, 2007
<u>AB</u>	UPSHER SMITH	<u>2.5MG</u>	<u>A076761</u>	<u>001</u>	Dec 01, 2006
<u>AB</u>		<u>10MG</u>	<u>A078033</u>	<u>001</u>	Mar 22, 2007

OXAPROZIN

TABLET; ORAL

DAYPRO

<u>AB</u>	+ GD SEARLE	<u>600MG</u>	<u>N018841</u>	<u>004</u>	Oct 29, 1992
-----------	-------------	--------------	----------------	------------	--------------

OXAPROZIN

<u>AB</u>	APOTEX INC	<u>600MG</u>	<u>A075987</u>	<u>001</u>	Sep 02, 2004
<u>AB</u>	DR REDDYS LABS LTD	<u>600MG</u>	<u>A075855</u>	<u>001</u>	Jan 31, 2001
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>600MG</u>	<u>A075846</u>	<u>001</u>	May 13, 2002
<u>AB</u>	SANDOZ	<u>600MG</u>	<u>A075845</u>	<u>001</u>	Jan 31, 2001
<u>AB</u>	SUN PHARM INDS INC	<u>600MG</u>	<u>A075844</u>	<u>001</u>	Jan 03, 2002
<u>AB</u>	TEVA	<u>600MG</u>	<u>A075849</u>	<u>001</u>	Jul 03, 2002

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>10MG</u>	<u>A072251</u>	<u>001</u>	Apr 14, 1988
<u>AB</u>		<u>15MG</u>	<u>A072252</u>	<u>001</u>	Apr 14, 1988
<u>AB</u>	+	<u>30MG</u>	<u>A072253</u>	<u>001</u>	Apr 14, 1988
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A071813</u>	<u>001</u>	Apr 19, 1988
<u>AB</u>		<u>15MG</u>	<u>A071756</u>	<u>001</u>	Apr 19, 1988
<u>AB</u>		<u>30MG</u>	<u>A071814</u>	<u>001</u>	Apr 19, 1988

OXCARBAZEPINE

SUSPENSION; ORAL

OXCARBAZEPINE

<u>AB</u>	AMNEAL PHARMS	<u>300MG/5ML</u>	<u>A202961</u>	<u>001</u>	Sep 17, 2012
<u>AB</u>	SUN PHARM INDS LTD	<u>300MG/5ML</u>	<u>A078734</u>	<u>001</u>	Jun 26, 2009
<u>AB</u>	WEST-WARD PHARMS INT	<u>300MG/5ML</u>	<u>A201193</u>	<u>001</u>	Oct 03, 2012

TRILEPTAL

<u>AB</u>	+ NOVARTIS	<u>300MG/5ML</u>	<u>N021285</u>	<u>001</u>	May 25, 2001
-----------	------------	------------------	----------------	------------	--------------

TABLET; ORAL

OXCARBAZEPINE

<u>AB</u>	ANI PHARMS INC	<u>150MG</u>	<u>A078005</u>	<u>001</u>	Dec 11, 2007
<u>AB</u>		<u>300MG</u>	<u>A078005</u>	<u>002</u>	Dec 11, 2007
<u>AB</u>		<u>600MG</u>	<u>A078005</u>	<u>003</u>	Dec 11, 2007
<u>AB</u>	APOTEX INC	<u>150MG</u>	<u>A077747</u>	<u>001</u>	Apr 09, 2008
<u>AB</u>		<u>300MG</u>	<u>A077747</u>	<u>002</u>	Apr 09, 2008
<u>AB</u>		<u>600MG</u>	<u>A077747</u>	<u>003</u>	Apr 09, 2008
<u>AB</u>	BRECKENRIDGE PHARM	<u>150MG</u>	<u>A078069</u>	<u>001</u>	Jan 11, 2008
<u>AB</u>		<u>300MG</u>	<u>A078069</u>	<u>002</u>	Jan 11, 2008
<u>AB</u>		<u>600MG</u>	<u>A078069</u>	<u>003</u>	Jan 11, 2008
<u>AB</u>	CADISTA PHARMS	<u>150MG</u>	<u>A090239</u>	<u>001</u>	Jan 25, 2010
<u>AB</u>		<u>300MG</u>	<u>A090239</u>	<u>002</u>	Jan 25, 2010
<u>AB</u>		<u>600MG</u>	<u>A090239</u>	<u>003</u>	Jan 25, 2010
<u>AB</u>	GLENMARK GENERICS	<u>150MG</u>	<u>A077802</u>	<u>001</u>	Oct 09, 2007
<u>AB</u>		<u>300MG</u>	<u>A077802</u>	<u>002</u>	Oct 09, 2007
<u>AB</u>		<u>600MG</u>	<u>A077802</u>	<u>003</u>	Oct 09, 2007

PRESCRIPTION DRUG PRODUCT LIST

OXCARBAZEPINE

TABLET;ORAL

OXCARBAZEPINE

<u>AB</u>	SUN PHARM INDS	<u>150MG</u>	<u>A077794 001</u>	Oct 09, 2007
<u>AB</u>		<u>300MG</u>	<u>A077794 002</u>	Oct 09, 2007
<u>AB</u>		<u>600MG</u>	<u>A077794 003</u>	Oct 09, 2007
<u>AB</u>	TARO	<u>150MG</u>	<u>A077801 001</u>	Nov 15, 2007
<u>AB</u>		<u>300MG</u>	<u>A077801 002</u>	Nov 15, 2007
<u>AB</u>		<u>600MG</u>	<u>A077801 003</u>	Nov 15, 2007
<u>AB</u>	WEST-WARD PHARMS INT	<u>150MG</u>	<u>A077795 001</u>	Oct 09, 2007
<u>AB</u>		<u>300MG</u>	<u>A077795 002</u>	Oct 09, 2007
<u>AB</u>		<u>600MG</u>	<u>A077795 003</u>	Oct 09, 2007

TRILEPTAL

<u>AB</u>	NOVARTIS	<u>150MG</u>	<u>N021014 001</u>	Jan 14, 2000
<u>AB</u>		<u>300MG</u>	<u>N021014 002</u>	Jan 14, 2000
<u>AB</u>	+	<u>600MG</u>	<u>N021014 003</u>	Jan 14, 2000

TABLET, EXTENDED RELEASE;ORAL

OXTELLAR XR

	SUPERMUS PHARMS	150MG	N202810 001	Oct 19, 2012
		300MG	N202810 002	Oct 19, 2012
	+	600MG	N202810 003	Oct 19, 2012

OXICONAZOLE NITRATE

CREAM;TOPICAL

OXICONAZOLE NITRATE

<u>AB</u>	TARO	<u>EQ 1% BASE</u>	<u>A205076 001</u>	Mar 07, 2016
-----------	------	-------------------	--------------------	--------------

OXISTAT

<u>AB</u>	+	FOUGERA PHARMS	<u>EQ 1% BASE</u>	<u>N019828 001</u>	Dec 30, 1988
-----------	---	----------------	-------------------	--------------------	--------------

LOTION;TOPICAL

OXISTAT

	+	FOUGERA PHARMS	EQ 1% BASE	N020209 001	Sep 30, 1992
--	---	----------------	------------	-------------	--------------

OXTRIPHYLLINE

TABLET, EXTENDED RELEASE;ORAL

CHOLEDYL SA

	+	WARNER CHILCOTT LLC	400MG	A087863 001	May 24, 1983
	+		600MG	A086742 001	

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL

OXYBUTYNIN

<u>AB</u>	BARR LABS DIV TEVA	<u>3.9MG/24HR</u>	<u>A090526 001</u>	Mar 04, 2014
-----------	--------------------	-------------------	--------------------	--------------

OXYTROL

<u>AB</u>	+	ALLERGAN SALES LLC	<u>3.9MG/24HR</u>	<u>N021351 002</u>	Feb 26, 2003
-----------	---	--------------------	-------------------	--------------------	--------------

GEL, METERED;TRANSDERMAL

GELNIQUE 3%

	+	ALLERGAN SALES LLC	3%	N202513 001	Dec 07, 2011
--	---	--------------------	----	-------------	--------------

OXYBUTYNIN CHLORIDE

GEL;TRANSDERMAL

GELNIQUE

	+	ALLERGAN SALES LLC	10%(100MG/PACKET)	N022204 001	Jan 27, 2009
--	---	--------------------	-------------------	-------------	--------------

SYRUP;ORAL

OXYBUTYNIN CHLORIDE

<u>AA</u>	PHARM ASSOC	<u>5MG/5ML</u>	<u>A075137 001</u>	Dec 18, 1998
-----------	-------------	----------------	--------------------	--------------

<u>AA</u>	SILARX	<u>5MG/5ML</u>	<u>A074520 001</u>	Mar 29, 1996
-----------	--------	----------------	--------------------	--------------

<u>AA</u>	VINTAGE PHARMS	<u>5MG/5ML</u>	<u>A076682 001</u>	Dec 28, 2004
-----------	----------------	----------------	--------------------	--------------

<u>AA</u>	+	WOCKHARDT	<u>5MG/5ML</u>	<u>A074868 001</u>	Feb 12, 1997
-----------	---	-----------	----------------	--------------------	--------------

TABLET;ORAL

OXYBUTYNIN CHLORIDE

<u>AB</u>	TEVA PHARMS USA	<u>5MG</u>	<u>A071655 001</u>	Nov 14, 1988
-----------	-----------------	------------	--------------------	--------------

<u>AB</u>	USL PHARMA	<u>5MG</u>	<u>A074625 001</u>	Jul 31, 1996
-----------	------------	------------	--------------------	--------------

<u>AB</u>	+	VINTAGE PHARMS	<u>5MG</u>	<u>A075079 001</u>	Oct 31, 1997
-----------	---	----------------	------------	--------------------	--------------

TABLET, EXTENDED RELEASE;ORAL

DITROPAN XL

<u>AB</u>	JANSSEN PHARMS	<u>5MG</u>	<u>N020897 001</u>	Dec 16, 1998
-----------	----------------	------------	--------------------	--------------

<u>AB</u>		<u>10MG</u>	<u>N020897 002</u>	Dec 16, 1998
-----------	--	-------------	--------------------	--------------

<u>AB</u>	+	<u>15MG</u>	<u>N020897 003</u>	Jun 22, 1999
-----------	---	-------------	--------------------	--------------

OXYBUTYNIN CHLORIDE

<u>AB</u>	ACCORD HLTHCARE	<u>5MG</u>	<u>A207138 001</u>	Feb 29, 2016
-----------	-----------------	------------	--------------------	--------------

<u>AB</u>		<u>10MG</u>	<u>A207138 002</u>	Feb 29, 2016
-----------	--	-------------	--------------------	--------------

<u>AB</u>		<u>15MG</u>	<u>A207138 003</u>	Feb 29, 2016
-----------	--	-------------	--------------------	--------------

<u>AB</u>	AMNEAL PHARMS	<u>5MG</u>	<u>A204010 001</u>	Nov 23, 2015
-----------	---------------	------------	--------------------	--------------

<u>AB</u>		<u>10MG</u>	<u>A204010 002</u>	Nov 23, 2015
-----------	--	-------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

OXYBUTYNIN CHLORIDE

TABLET, EXTENDED RELEASE;ORAL

OXYBUTYNIN CHLORIDE

<u>AB</u>		<u>15MG</u>	<u>A204010 003</u>	Nov 23, 2015
<u>AB</u>	IMPAX PHARMS	<u>5MG</u>	<u>A076745 002</u>	May 09, 2007
<u>AB</u>		<u>10MG</u>	<u>A076745 003</u>	May 09, 2007
<u>AB</u>		<u>15MG</u>	<u>A076745 001</u>	Nov 09, 2006
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A076702 001</u>	Nov 09, 2006
<u>AB</u>	MYLAN PHARMS INC	<u>10MG</u>	<u>A076644 001</u>	Nov 09, 2006
<u>AB</u>		<u>15MG</u>	<u>A076644 002</u>	May 10, 2007
<u>AB</u>	OSMOTICA PHARM US	<u>5MG</u>	<u>A078503 001</u>	Feb 04, 2009
<u>AB</u>		<u>10MG</u>	<u>A078503 002</u>	Feb 04, 2009
<u>AB</u>		<u>15MG</u>	<u>A078503 003</u>	Feb 04, 2009
<u>AB</u>	UNIQUE PHARM LABS	<u>5MG</u>	<u>A206121 001</u>	May 27, 2016
<u>AB</u>		<u>10MG</u>	<u>A206121 002</u>	May 27, 2016
<u>AB</u>		<u>15MG</u>	<u>A206121 003</u>	May 27, 2016

OXYCODONE

CAPSULE, EXTENDED RELEASE;ORAL

XTAMPZA ER

	COLLEGIUM PHARM INC	9MG	N208090 001	Apr 26, 2016
		13.5MG	N208090 002	Apr 26, 2016
		18MG	N208090 003	Apr 26, 2016
		27MG	N208090 004	Apr 26, 2016
+		36MG	N208090 005	Apr 26, 2016

OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL

OXYCODONE HYDROCHLORIDE

<u>AB</u>	ANI PHARMS INC	<u>5MG</u>	<u>A205177 001</u>	Mar 31, 2016
<u>AB</u>	AVANTHI INC	<u>5MG</u>	<u>A202773 001</u>	Aug 17, 2015
<u>AB</u>	LANNETT HOLDINGS INC	<u>5MG</u>	<u>A203823 001</u>	Aug 01, 2014
<u>AB</u>	+ LEHIGH VALLEY	<u>5MG</u>	<u>N200534 001</u>	Oct 20, 2010
<u>AB</u>	MAYNE PHARMA INC	<u>5MG</u>	<u>A203107 001</u>	Jul 26, 2012
<u>AB</u>	NOVEL LABS INC	<u>5MG</u>	<u>A204752 001</u>	Aug 24, 2015

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

<u>AA</u>	ANI PHARMS INC	<u>5MG/5ML</u>	<u>A204979 001</u>	Jun 01, 2015
<u>AA</u>	LANNETT HOLDINGS INC	<u>100MG/5ML</u>	<u>A204085 001</u>	Sep 09, 2014
<u>AA</u>	LEHIGH VALLEY	<u>5MG/5ML</u>	<u>N200535 002</u>	Aug 22, 2013
<u>AA</u>	+	<u>100MG/5ML</u>	<u>N200535 001</u>	Oct 20, 2010
<u>AA</u>	MAYNE PHARMA INC	<u>100MG/5ML</u>	<u>A204092 001</u>	Jun 05, 2014
<u>AA</u>	NOVEL LABS INC	<u>100MG/5ML</u>	<u>A204603 001</u>	Apr 29, 2015
<u>AA</u>	+ VISTAPHARM	<u>5MG/5ML</u>	<u>N201194 001</u>	Jan 12, 2012
<u>AA</u>		<u>100MG/5ML</u>	<u>A202537 001</u>	Jul 30, 2012
<u>AA</u>	WES PHARMA INC	<u>5MG/5ML</u>	<u>A207511 001</u>	Nov 23, 2016
<u>AA</u>	WEST-WARD PHARMS INT	<u>5MG/5ML</u>	<u>A204037 001</u>	Jul 15, 2013
<u>AA</u>		<u>100MG/5ML</u>	<u>A203208 001</u>	Jul 12, 2013
<u>AA</u>	WOCKHARDT BIO AG	<u>5MG/5ML</u>	<u>A206456 001</u>	Jun 16, 2015

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>5MG</u>	<u>A076636 003</u>	Apr 07, 2015
<u>AB</u>		<u>15MG</u>	<u>A076636 001</u>	Feb 06, 2004
<u>AB</u>		<u>30MG</u>	<u>A076636 002</u>	Feb 06, 2004
<u>AB</u>	ALVOGEN MALTA	<u>5MG</u>	<u>A202116 001</u>	Dec 30, 2011
<u>AB</u>		<u>15MG</u>	<u>A202116 002</u>	Dec 30, 2011
<u>AB</u>		<u>30MG</u>	<u>A202116 003</u>	Dec 30, 2011
<u>AB</u>	AMNEAL PHARMS	<u>5MG</u>	<u>A203638 001</u>	Jun 03, 2014
<u>AB</u>		<u>10MG</u>	<u>A203638 002</u>	Jun 03, 2014
<u>AB</u>		<u>15MG</u>	<u>A203638 003</u>	Jun 03, 2014
<u>AB</u>		<u>20MG</u>	<u>A203638 004</u>	Jun 03, 2014
<u>AB</u>		<u>30MG</u>	<u>A203638 005</u>	Jun 03, 2014
<u>AB</u>	AUROLIFE PHARMA LLC	<u>5MG</u>	<u>A202160 001</u>	Nov 19, 2012
<u>AB</u>		<u>15MG</u>	<u>A202160 002</u>	Nov 19, 2012
<u>AB</u>		<u>30MG</u>	<u>A202160 003</u>	Nov 19, 2012
<u>AB</u>	AVANTHI INC	<u>5MG</u>	<u>A091393 001</u>	Aug 31, 2009
<u>AB</u>		<u>10MG</u>	<u>A091393 002</u>	Aug 31, 2009
<u>AB</u>		<u>15MG</u>	<u>A091393 003</u>	Aug 31, 2009
<u>AB</u>		<u>20MG</u>	<u>A091393 004</u>	Aug 31, 2009
<u>AB</u>		<u>30MG</u>	<u>A091393 005</u>	Aug 31, 2009
<u>AB</u>	COREPHARMA	<u>5MG</u>	<u>A090895 001</u>	Aug 24, 2009
<u>AB</u>		<u>15MG</u>	<u>A090895 002</u>	Aug 24, 2009
<u>AB</u>		<u>30MG</u>	<u>A090895 003</u>	Aug 24, 2009

PRESCRIPTION DRUG PRODUCT LIST

OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

<u>AB</u>	EPIC PHARMA LLC	<u>5MG</u>	<u>A202662 001</u>	Sep 22, 2015
<u>AB</u>		<u>10MG</u>	<u>A202662 002</u>	Sep 22, 2015
<u>AB</u>		<u>15MG</u>	<u>A202662 003</u>	Sep 22, 2015
<u>AB</u>		<u>30MG</u>	<u>A202662 004</u>	Sep 22, 2015
<u>AB</u>	KEN LIFESCIENCE	<u>5MG</u>	<u>A207119 001</u>	Apr 12, 2016
<u>AB</u>		<u>10MG</u>	<u>A207119 002</u>	Apr 12, 2016
<u>AB</u>		<u>15MG</u>	<u>A207119 003</u>	Apr 12, 2016
<u>AB</u>		<u>20MG</u>	<u>A207119 004</u>	Apr 12, 2016
<u>AB</u>		<u>30MG</u>	<u>A207119 005</u>	Apr 12, 2016
<u>AB</u>	MALLINCKRODT INC	<u>5MG</u>	<u>A076758 003</u>	Mar 19, 2007
<u>AB</u>		<u>15MG</u>	<u>A076758 001</u>	Jun 30, 2004
<u>AB</u>		<u>30MG</u>	<u>A076758 002</u>	Jun 30, 2004
<u>AB</u>	MAYNE PHARMA INC	<u>5MG</u>	<u>A091313 001</u>	Feb 18, 2011
<u>AB</u>		<u>10MG</u>	<u>A091313 004</u>	Apr 29, 2016
<u>AB</u>		<u>15MG</u>	<u>A091313 002</u>	Feb 18, 2011
<u>AB</u>		<u>20MG</u>	<u>A091313 005</u>	Apr 29, 2016
<u>AB</u>		<u>30MG</u>	<u>A091313 003</u>	Feb 18, 2011
<u>AB</u>	NESHER PHARMS	<u>5MG</u>	<u>A077290 001</u>	Dec 08, 2005
<u>AB</u>		<u>10MG</u>	<u>A077290 002</u>	Dec 08, 2005
<u>AB</u>		<u>15MG</u>	<u>A077290 003</u>	Dec 08, 2005
<u>AB</u>		<u>20MG</u>	<u>A077290 004</u>	Dec 08, 2005
<u>AB</u>		<u>30MG</u>	<u>A077290 005</u>	Dec 08, 2005
<u>AB</u>	RHODES PHARMS	<u>5MG</u>	<u>A091490 001</u>	Mar 09, 2011
<u>AB</u>		<u>10MG</u>	<u>A091490 002</u>	Mar 09, 2011
<u>AB</u>		<u>15MG</u>	<u>A091490 003</u>	Mar 09, 2011
<u>AB</u>		<u>20MG</u>	<u>A091490 004</u>	Mar 09, 2011
<u>AB</u>		<u>30MG</u>	<u>A091490 005</u>	Mar 09, 2011
<u>AB</u>	SUN PHARM INDS INC	<u>5MG</u>	<u>A090659 001</u>	Apr 10, 2009
<u>AB</u>		<u>10MG</u>	<u>A090659 005</u>	Nov 06, 2012
<u>AB</u>		<u>15MG</u>	<u>A090659 002</u>	Apr 10, 2009
<u>AB</u>		<u>20MG</u>	<u>A090659 004</u>	Nov 06, 2012
<u>AB</u>		<u>30MG</u>	<u>A090659 003</u>	Apr 10, 2009
<u>AB</u>	VINTAGE PHARMS	<u>5MG</u>	<u>A077712 003</u>	Mar 02, 2009
<u>AB</u>		<u>10MG</u>	<u>A077712 004</u>	Apr 13, 2015
<u>AB</u>		<u>15MG</u>	<u>A077712 001</u>	Jan 31, 2007
<u>AB</u>		<u>20MG</u>	<u>A077712 005</u>	Apr 13, 2015
<u>AB</u>		<u>30MG</u>	<u>A077712 002</u>	Jan 31, 2007

ROXICODONE

<u>AB</u>	MALLINCKRODT INC	<u>5MG</u>	<u>N021011 003</u>	May 15, 2009
<u>AB</u>	+	<u>15MG</u>	<u>N021011 001</u>	Aug 31, 2000
<u>AB</u>		<u>30MG</u>	<u>N021011 002</u>	Aug 31, 2000
	OXAYDO			
	EGALET US INC	5MG	N202080 001	Jun 17, 2011
		7.5MG	N202080 002	Jun 17, 2011

TABLET, EXTENDED RELEASE; ORAL

OXYCONTIN

	PURDUE PHARMA LP	10MG	N022272 001	Apr 05, 2010
		15MG	N022272 002	Apr 05, 2010
		20MG	N022272 003	Apr 05, 2010
		30MG	N022272 004	Apr 05, 2010
	+	40MG	N022272 005	Apr 05, 2010
		60MG	N022272 006	Apr 05, 2010
		80MG	N022272 007	Apr 05, 2010

OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE

SPRAY, METERED; NASAL

KOVANAZE

	+ ST RENATUS	0.1MG/SPRAY; 6MG/SPRAY	N208032 001	Jun 29, 2016
--	--------------	------------------------	-------------	--------------

OXYMETHOLONE

TABLET; ORAL

ANADROL-50

	+ MEDA PHARMS	50MG	N016848 001	
--	---------------	------	-------------	--

OXYMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

OPANA

	+ ENDO PHARMS	1MG/ML	N011707 002	
--	---------------	--------	-------------	--

PRESCRIPTION DRUG PRODUCT LIST

OXYMORPHONE HYDROCHLORIDE

TABLET;ORAL

OPANA

<u>AB</u>	ENDO PHARMS	<u>5MG</u>	<u>N021611</u>	<u>001</u>	Jun 22, 2006
<u>AB</u>	+	<u>10MG</u>	<u>N021611</u>	<u>002</u>	Jun 22, 2006
<u>OXYMORPHONE HYDROCHLORIDE</u>					
<u>AB</u>	AUROLIFE PHARMA LLC	<u>5MG</u>	<u>A204459</u>	<u>001</u>	Apr 26, 2016
<u>AB</u>		<u>10MG</u>	<u>A204459</u>	<u>002</u>	Apr 26, 2016
<u>AB</u>	AVANTHI INC	<u>5MG</u>	<u>A203601</u>	<u>001</u>	Jan 30, 2013
<u>AB</u>		<u>10MG</u>	<u>A203601</u>	<u>002</u>	Jan 30, 2013
<u>AB</u>	COREPHARMA	<u>5MG</u>	<u>A201187</u>	<u>001</u>	Dec 15, 2014
<u>AB</u>		<u>10MG</u>	<u>A201187</u>	<u>002</u>	Dec 15, 2014
<u>AB</u>	MALLINCKRODT INC	<u>5MG</u>	<u>A202321</u>	<u>001</u>	Apr 25, 2013
<u>AB</u>		<u>10MG</u>	<u>A202321</u>	<u>002</u>	Apr 25, 2013
<u>AB</u>	TEVA	<u>5MG</u>	<u>A091443</u>	<u>002</u>	Feb 15, 2011
<u>AB</u>		<u>10MG</u>	<u>A091443</u>	<u>001</u>	Feb 15, 2011
<u>AB</u>	WEST-WARD PHARMS INT	<u>5MG</u>	<u>A090964</u>	<u>001</u>	Sep 27, 2010
<u>AB</u>		<u>10MG</u>	<u>A090964</u>	<u>002</u>	Sep 27, 2010

TABLET, EXTENDED RELEASE;ORAL

OXYMORPHONE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>5MG</u>	<u>A079046</u>	<u>003</u>	Jul 11, 2013
<u>AB</u>		<u>7.5MG</u>	<u>A079046</u>	<u>001</u>	Dec 13, 2010
<u>AB</u>		<u>10MG</u>	<u>A079046</u>	<u>004</u>	Jul 11, 2013
<u>AB</u>		<u>15MG</u>	<u>A079046</u>	<u>002</u>	Dec 13, 2010
<u>AB</u>		<u>20MG</u>	<u>A079046</u>	<u>005</u>	Jul 11, 2013
<u>AB</u>		<u>30MG</u>	<u>A079046</u>	<u>006</u>	Jul 11, 2013
<u>AB</u>		<u>40MG</u>	<u>A079046</u>	<u>007</u>	Jul 11, 2013
<u>AB</u>	IMPAX LABS	<u>5MG</u>	<u>A079087</u>	<u>001</u>	Jun 14, 2010
<u>AB</u>		<u>7.5MG</u>	<u>A079087</u>	<u>002</u>	Dec 21, 2010
<u>AB</u>		<u>10MG</u>	<u>A079087</u>	<u>003</u>	Jun 14, 2010
<u>AB</u>		<u>15MG</u>	<u>A079087</u>	<u>004</u>	Dec 21, 2010
<u>AB</u>		<u>20MG</u>	<u>A079087</u>	<u>005</u>	Jun 14, 2010
<u>AB</u>		<u>30MG</u>	<u>A079087</u>	<u>006</u>	Jul 22, 2010
<u>AB</u>		<u>40MG</u>	<u>A079087</u>	<u>007</u>	Jun 14, 2010
<u>AB</u>	MALLINCKRODT INC	<u>5MG</u>	<u>A202946</u>	<u>001</u>	Jun 27, 2014
<u>AB</u>		<u>7.5MG</u>	<u>A202946</u>	<u>002</u>	Jun 27, 2014
<u>AB</u>		<u>10MG</u>	<u>A202946</u>	<u>003</u>	Jun 27, 2014
<u>AB</u>		<u>15MG</u>	<u>A202946</u>	<u>004</u>	Jun 27, 2014
<u>AB</u>		<u>20MG</u>	<u>A202946</u>	<u>005</u>	Jun 27, 2014
<u>AB</u>		<u>30MG</u>	<u>A202946</u>	<u>006</u>	Jun 27, 2014
<u>AB</u>		<u>40MG</u>	<u>A202946</u>	<u>007</u>	Jun 27, 2014
<u>AB</u>	PAR PHARM	<u>5MG</u>	<u>A200792</u>	<u>001</u>	Oct 24, 2014
<u>AB</u>		<u>7.5MG</u>	<u>A200792</u>	<u>002</u>	Oct 24, 2014
<u>AB</u>		<u>10MG</u>	<u>A200792</u>	<u>003</u>	Oct 24, 2014
<u>AB</u>		<u>15MG</u>	<u>A200792</u>	<u>004</u>	Oct 24, 2014
<u>AB</u>		<u>20MG</u>	<u>A200792</u>	<u>005</u>	Oct 24, 2014
<u>AB</u>		<u>30MG</u>	<u>A200792</u>	<u>006</u>	Oct 24, 2014
<u>AB</u>		<u>40MG</u>	<u>A200792</u>	<u>007</u>	Oct 24, 2014
<u>AB</u>	SUN PHARM INDS LTD	<u>5MG</u>	<u>A203506</u>	<u>001</u>	Apr 24, 2015
<u>AB</u>		<u>7.5MG</u>	<u>A203506</u>	<u>002</u>	Apr 24, 2015
<u>AB</u>		<u>10MG</u>	<u>A203506</u>	<u>003</u>	Apr 24, 2015
<u>AB</u>		<u>15MG</u>	<u>A203506</u>	<u>004</u>	Apr 24, 2015
<u>AB</u>		<u>20MG</u>	<u>A203506</u>	<u>005</u>	Apr 24, 2015
<u>AB</u>		<u>30MG</u>	<u>A203506</u>	<u>006</u>	Apr 24, 2015
<u>AB</u>		<u>40MG</u>	<u>A203506</u>	<u>007</u>	Apr 24, 2015
<u>AB</u>	WEST-WARD PHARMS INT	<u>5MG</u>	<u>A200822</u>	<u>002</u>	Jul 15, 2013
<u>AB</u>		<u>7.5MG</u>	<u>A200822</u>	<u>003</u>	Jul 15, 2013
<u>AB</u>		<u>10MG</u>	<u>A200822</u>	<u>004</u>	Jul 15, 2013
<u>AB</u>		<u>15MG</u>	<u>A200822</u>	<u>005</u>	Jul 15, 2013
<u>AB</u>		<u>20MG</u>	<u>A200822</u>	<u>006</u>	Jul 15, 2013
<u>AB</u>		<u>30MG</u>	<u>A200822</u>	<u>007</u>	Jul 15, 2013
<u>AB</u>		<u>40MG</u>	<u>A200822</u>	<u>001</u>	Jul 15, 2013
OPANA ER					
	ENDO PHARMS	5MG	N201655	001	Dec 09, 2011
		7.5MG	N201655	002	Dec 09, 2011
		10MG	N201655	003	Dec 09, 2011
		15MG	N201655	004	Dec 09, 2011
		20MG	N201655	005	Dec 09, 2011
		30MG	N201655	006	Dec 09, 2011
	+	40MG	N201655	007	Dec 09, 2011

PRESCRIPTION DRUG PRODUCT LIST

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

TERRAMYCIN W/ POLYMYXIN B SULFATE

+ PFIZER EQ 5MG BASE/GM;10,000 UNITS/GM A061015 001

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

<u>AP</u>	+	FRESENIUS KABI USA	<u>10USP UNITS/ML (10USP UNITS/ML)</u>	<u>N018248 001</u>	
<u>AP</u>	+		<u>100USP UNITS/10ML (10USP UNITS/ML)</u>	<u>N018248 002</u>	
<u>AP</u>		HIKMA FARMACEUTICA	<u>10USP UNITS/ML (10USP UNITS/ML)</u>	<u>A200219 001</u>	Feb 13, 2013
<u>AP</u>	+	WEST-WARD PHARMS INT	<u>10USP UNITS/ML (10USP UNITS/ML)</u>	<u>N018243 001</u>	
<u>AP</u>	+		<u>100USP UNITS/10ML (10USP UNITS/ML)</u>	<u>N018243 002</u>	Jan 10, 2007

PITOCIN

<u>AP</u>	+	PAR STERILE PRODUCTS	<u>10USP UNITS/ML (10USP UNITS/ML)</u>	<u>N018261 001</u>	
<u>AP</u>			<u>100USP UNITS/10ML (10USP UNITS/ML)</u>	<u>N018261 002</u>	Jul 27, 2007

OXYTOCIN

+ FRESENIUS KABI USA 300USP UNITS/30ML (10USP UNITS/ML) N018248 003 Jul 27, 2007

PITOCIN

PAR STERILE PRODUCTS 500USP UNITS/50ML (10USP UNITS/ML) N018261 003 Sep 05, 2012

PACLITAXEL

FOR SUSPENSION;IV (INFUSION)

ABRAXANE

+ ABRAXIS BIOSCIENCE 100MG/VIAL N021660 001 Jan 07, 2005

INJECTABLE; INJECTION

PACITAXEL

<u>AP</u>		GLAND PHARMA LTD	<u>6MG/ML</u>	<u>A207326 001</u>	Aug 23, 2016
-----------	--	------------------	---------------	--------------------	--------------

PACLITAXEL

<u>AP</u>		ACTAVIS TOTOWA	<u>6MG/ML</u>	<u>A090130 001</u>	Dec 09, 2009
<u>AP</u>		FRESENIUS KABI ONCOL	<u>6MG/ML</u>	<u>A077574 001</u>	Nov 27, 2006
<u>AP</u>	+	HOSPIRA	<u>6MG/ML</u>	<u>A076131 001</u>	May 08, 2002
<u>AP</u>		MYLAN LABS LTD	<u>6MG/ML</u>	<u>A091540 001</u>	Sep 29, 2011
<u>AP</u>		SANDOZ INC	<u>6MG/ML</u>	<u>A078167 001</u>	Dec 26, 2007
<u>AP</u>		TEVA PHARMS	<u>6MG/ML</u>	<u>A075184 001</u>	Jan 25, 2002
<u>AP</u>		WEST-WARD PHARMS INT	<u>6MG/ML</u>	<u>A075190 001</u>	Jan 28, 2002

TAXOL

<u>AP</u>		HQ SPCLT PHARMA	<u>6MG/ML</u>	<u>N020262 001</u>	Dec 29, 1992
-----------	--	-----------------	---------------	--------------------	--------------

PALBOCICLIB

CAPSULE; ORAL

IBRANCE

PFIZER INC 75MG N207103 001 Feb 03, 2015

100MG N207103 002 Feb 03, 2015

+ 125MG N207103 003 Feb 03, 2015

PALIPERIDONE

TABLET, EXTENDED RELEASE; ORAL

INVEGA

<u>AB</u>		JANSSEN PHARMS	<u>1.5MG</u>	<u>N021999 006</u>	Aug 26, 2008
<u>AB</u>			<u>3MG</u>	<u>N021999 001</u>	Dec 19, 2006
<u>AB</u>	+		<u>6MG</u>	<u>N021999 002</u>	Dec 19, 2006
<u>AB</u>			<u>9MG</u>	<u>N021999 003</u>	Dec 19, 2006

PALIPERIDONE

<u>AB</u>		ACTAVIS LABS FL INC	<u>1.5MG</u>	<u>A202645 001</u>	Aug 03, 2015
<u>AB</u>			<u>3MG</u>	<u>A202645 002</u>	Aug 03, 2015
<u>AB</u>			<u>6MG</u>	<u>A202645 003</u>	Aug 03, 2015
<u>AB</u>			<u>9MG</u>	<u>A202645 004</u>	Aug 03, 2015
<u>AB</u>		MYLAN PHARMS INC	<u>1.5MG</u>	<u>A203802 001</u>	Sep 24, 2015
<u>AB</u>			<u>3MG</u>	<u>A203802 002</u>	Sep 24, 2015
<u>AB</u>			<u>6MG</u>	<u>A203802 003</u>	Sep 24, 2015
<u>AB</u>			<u>9MG</u>	<u>A203802 004</u>	Sep 24, 2015

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

INVEGA SUSTENNA

JANSSEN PHARMS 39MG/0.25ML (39MG/0.25ML) N022264 001 Jul 31, 2009

78MG/0.5ML (78MG/0.5ML) N022264 002 Jul 31, 2009

117MG/0.75ML (117MG/0.75ML) N022264 003 Jul 31, 2009

+ 156MG/ML (156MG/ML) N022264 004 Jul 31, 2009

234MG/1.5ML (156MG/ML) N022264 005 Jul 31, 2009

INVEGA TRINZA

JANSSEN PHARMS 273MG/0.875ML (273MG/0.875ML) N207946 001 May 18, 2015

410MG/1.315ML (311.79MG/ML) N207946 002 May 18, 2015

546MG/1.75ML (312MG/ML) N207946 003 May 18, 2015

PRESCRIPTION DRUG PRODUCT LIST

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

INVEGA TRINZA

+

819MG/2.625ML (312MG/ML)

N207946 004 May 18, 2015

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

ALOXI

AP + HELSINN HLTHCARE EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML) **N021372 002** Feb 29, 2008

AP + EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) **N021372 001** Jul 25, 2003

PALONOSETRON HYDROCHLORIDE

AP DR REDDYS LABS LTD EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML) **A201533 001** Apr 21, 2016

AP EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) **A201533 002** Apr 21, 2016

AP SANDOZ INC EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) **A202521 001** Oct 13, 2015

SOLUTION; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

DR REDDYS LABS LTD

EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)

N203050 001 Mar 01, 2016

EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)

N203050 002 Mar 01, 2016

EXELA PHARMA SCIENCE

EQ 0.25MG BASE/2ML (EQ 0.125MG BASE/ML)

N207963 001 Aug 22, 2016

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

AP AREVA PHARMS 30MG/VIAL **A077433 001** Nov 26, 2008

AP 60MG/VIAL **A077433 002** Nov 26, 2008

AP 90MG/VIAL **A077433 003** Nov 26, 2008

AP FRESENIUS KABI USA 30MG/VIAL **A075773 001** May 06, 2002

AP 30MG/10ML (3MG/ML) **A076207 001** May 17, 2002

AP 90MG/VIAL **A075773 002** May 06, 2002

AP 90MG/10ML (9MG/ML) **A076207 002** May 17, 2002

AP + HOSPIRA 30MG/10ML (3MG/ML) **A075841 001** Jun 27, 2002

AP + 60MG/10ML (6MG/ML) **A075841 002** Jun 27, 2002

AP + 90MG/10ML (9MG/ML) **A075841 003** Jun 27, 2002

AP LUITPOLD 30MG/10ML (3MG/ML) **A078942 001** Jul 25, 2008

AP 90MG/10ML (9MG/ML) **A078942 002** Jul 25, 2008

AP MYLAN LABS LTD 30MG/10ML (3MG/ML) **A078520 001** Oct 31, 2008

AP 90MG/10ML (9MG/ML) **A078520 002** Oct 31, 2008

AP PLIVA LACHEMA 30MG/10ML (3MG/ML) **A078156 001** Aug 19, 2008

AP 60MG/10ML (6MG/ML) **A078156 002** Aug 19, 2008

AP 90MG/10ML (9MG/ML) **A078156 003** Aug 19, 2008

AP SAGENT PHARMS 30MG/10ML (3MG/ML) **A078373 001** Dec 23, 2008

AP 90MG/10ML (9MG/ML) **A078373 002** Dec 23, 2008

AP SUN PHARMA GLOBAL 30MG/VIAL **A077703 001** Dec 24, 2008

AP 90MG/VIAL **A077703 002** Dec 24, 2008

AP TEVA PHARMS USA 30MG/10ML (3MG/ML) **A076153 001** Mar 27, 2002

AP 90MG/10ML (9MG/ML) **A076153 002** Mar 27, 2002

AP WEST-WARD PHARMS INT 30MG/VIAL **A075290 001** Apr 30, 2001

AP + 30MG/10ML (3MG/ML) **N021113 001** Mar 04, 2002

AP 90MG/VIAL **A075290 003** Apr 30, 2001

AP + 90MG/10ML (9MG/ML) **N021113 002** Mar 04, 2002

PANCRELIPASE (AMYLASE; LIPASE; PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL

CREON

ABBVIE

60,000USP UNITS; 12,000USP UNITS; 38,000USP UNITS

N020725 002 Apr 30, 2009

15,000USP UNITS; 3,000USP UNITS; 9,500USP UNITS

N020725 004 Jul 12, 2011

30,000USP UNITS; 6,000USP UNITS; 19,000USP UNITS

N020725 001 Apr 30, 2009

180,000USP UNITS; 36,000USP UNITS; 114,000USP UNITS

N020725 005 Mar 14, 2013

+

120,000USP UNITS; 24,000USP UNITS; 76,000USP UNITS

N020725 003 Apr 30, 2009

PANCREAZE

JANSSEN PHARMS

10,850USP UNITS; 2,600USP UNITS; 6,200USP UNITS

N022523 005 Mar 07, 2014

17,500USP/ UNITS; 4,200USP/ UNITS; 10,000USP/ UNITS

N022523 001 Apr 12, 2010

43,750USP/ UNITS; 10,500USP/ UNITS; 25,000USP/ UNITS

N022523 002 Apr 12, 2010

+

61,000USP/ UNITS; 21,000USP/ UNITS; 37,000USP/ UNITS

N022523 003 Apr 12, 2010

PRESCRIPTION DRUG PRODUCT LIST

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE;ORAL

PANCREAZE

70,000USP/ UNITS;16,800USP/
UNITS;40,000USP/ UNITS N022523 004 Apr 12, 2010

PERTZYE

DIGESTIVE CARE INC 30,250USP UNITS;8,000USP
UNITS;28,750USP UNITS N022175 001 May 17, 2012

+

60,500USP UNITS;16,000USP
UNITS;57,500USP UNITS N022175 002 May 17, 2012

ULTRESA

FOREST LABS INC 27,600USP UNITS;13,800USP
UNITS;27,600USP UNITS N022222 001 Mar 01, 2012

+

41,400USP UNITS;20,700USP
UNITS;41,400USP UNITS N022222 002 Mar 01, 2012

+

46,000USP UNITS;23,000USP
UNITS;46,000USP UNITS N022222 003 Mar 01, 2012

ZENPEP

FOREST LABS INC 218,000USP UNITS; 40,00USP UNITS;
136,000 USP UNITS N022210 007 Mar 25, 2014

+

16,000USP UNITS;3,000USP
UNITS;10,000USP UNITS N022210 005 Jun 15, 2011

+

55,000USP UNITS;10,000USP
UNITS;34,000USP UNITS N022210 002 Aug 27, 2009

+

82,000USP UNITS;15,000USP
UNITS;51,000USP UNITS N022210 003 Aug 27, 2009

+

27,000USP UNITS;5,000USP
UNITS;17,000USP UNITS N022210 001 Aug 27, 2009

+

109,000USP UNITS;20,000USP
UNITS;68,000USP UNITS N022210 004 Aug 27, 2009

+

136,000USP UNITS;25,000USP
UNITS;85,000USP UNITS N022210 006 Jul 13, 2011

TABLET;ORAL

VIOKACE

FOREST LABS INC 39,150USP UNITS;10,440USP
UNITS;39,150USP UNITS N022542 001 Mar 01, 2012

+

78,300USP UNITS;20,880USP
UNITS;78,300USP UNITS N022542 002 Mar 01, 2012PANCURONIUM BROMIDE

INJECTABLE;INJECTION

PANCURONIUM BROMIDEAP HOSPIRA 1MG/ML A072320 001 Jan 19, 1989AP + TEVA PHARMS USA 1MG/ML A072759 001 Jul 31, 1990AP + 2MG/ML A072760 001 Jul 31, 1990PANOBINOSTAT LACTATE

CAPSULE;ORAL

FARYDAK

NOVARTIS PHARMS CORP EQ 10MG BASE N205353 001 Feb 23, 2015

+

EQ 15MG BASE N205353 002 Feb 23, 2015

+

EQ 20MG BASE N205353 003 Feb 23, 2015

PANTOPRAZOLE SODIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL

PROTONIX

+ WYETH PHARMS INC EQ 40MG BASE N022020 001 Nov 14, 2007

INJECTABLE;IV (INFUSION)

PANTOPRAZOLE SODIUMAP AKORN INC EQ 40MG BASE/VIAL A079197 001 Nov 08, 2012AP AUROBINDO PHARMA LTD EQ 40MG BASE/VIAL A205675 001 Mar 30, 2016AP SANDOZ INC EQ 40MG BASE/VIAL A090296 001 Jul 14, 2015PROTONIX IVAP + WYETH PHARMS INC EQ 40MG BASE/VIAL N020988 001 Mar 22, 2001

TABLET, DELAYED RELEASE;ORAL

PANTOPRAZOLE SODIUMAB ACTAVIS TOTOWA EQ 20MG BASE A090797 001 Feb 07, 2011AB EQ 40MG BASE A090797 002 Feb 07, 2011AB AMNEAL PHARMS EQ 20MG BASE A205119 001 Jan 26, 2016AB EQ 40MG BASE A205119 002 Jan 26, 2016AB APOTEX INC EQ 20MG BASE A090807 001 May 02, 2012AB EQ 40MG BASE A090807 002 May 02, 2012AB AUROBINDO PHARMA LTD EQ 20MG BASE A202038 001 Sep 28, 2012AB EQ 40MG BASE A202038 002 Sep 28, 2012AB DR REDDYS LABS LTD EQ 20MG BASE A077619 001 Jan 19, 2011

PRESCRIPTION DRUG PRODUCT LIST

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL

PANTOPRAZOLE SODIUM

<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077619 002</u>	Jan 19, 2011
<u>AB</u>	HETERO LABS LTD V	<u>EQ 20MG BASE</u>	<u>A202882 001</u>	Sep 10, 2014
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A202882 002</u>	Sep 10, 2014
<u>AB</u>	JUBILANT GENERICS	<u>EQ 20MG BASE</u>	<u>A090901 001</u>	Aug 30, 2011
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A090901 002</u>	Aug 30, 2011
<u>AB</u>	KREMERS URBAN PHARMS	<u>EQ 20MG BASE</u>	<u>A078281 001</u>	Jan 20, 2011
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078281 002</u>	Jan 20, 2011
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 20MG BASE</u>	<u>A200821 001</u>	Feb 16, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A200821 002</u>	Feb 16, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 20MG BASE</u>	<u>A090970 001</u>	Jan 19, 2011
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A090970 002</u>	Jan 19, 2011
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 20MG BASE</u>	<u>A202052 001</u>	Dec 02, 2014
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A202052 002</u>	Dec 02, 2014
<u>AB</u>	PERRIGO R AND D	<u>EQ 20MG BASE</u>	<u>A203024 001</u>	May 07, 2014
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 20MG BASE</u>	<u>A200794 001</u>	May 02, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A200794 002</u>	May 02, 2012
<u>AB</u>	SUN PHARMA GLOBAL	<u>EQ 20MG BASE</u>	<u>A077058 001</u>	Sep 10, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077058 002</u>	Sep 10, 2007
<u>AB</u>	TEVA	<u>EQ 20MG BASE</u>	<u>A077056 001</u>	Aug 02, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077056 002</u>	Aug 02, 2007
<u>AB</u>	TORRENT PHARMS	<u>EQ 20MG BASE</u>	<u>A090074 001</u>	Jan 19, 2011
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A090074 002</u>	Jan 19, 2011
<u>AB</u>	WOCKHARDT	<u>EQ 20MG BASE</u>	<u>A091231 001</u>	Jan 19, 2011
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A091231 002</u>	Jan 19, 2011

PROTONIX

<u>AB</u>	WYETH PHARMS INC	<u>EQ 20MG BASE</u>	<u>N020987 002</u>	Jun 12, 2001
<u>AB</u>	+	<u>EQ 40MG BASE</u>	<u>N020987 001</u>	Feb 02, 2000

PARICALCITOL

CAPSULE;ORAL

PARICALCITOL

<u>AB</u>	AMNEAL PHARMS	<u>1MCG</u>	<u>A204327 001</u>	Jan 13, 2016
<u>AB</u>		<u>2MCG</u>	<u>A204327 002</u>	Jan 13, 2016
<u>AB</u>		<u>4MCG</u>	<u>A204327 003</u>	Jan 13, 2016
<u>AB</u>	AUROBINDO PHARMA LTD	<u>1MCG</u>	<u>A207672 001</u>	Jan 14, 2016
<u>AB</u>		<u>2MCG</u>	<u>A207672 002</u>	Jan 14, 2016
<u>AB</u>		<u>4MCG</u>	<u>A207672 003</u>	Jan 14, 2016
<u>AB</u>	BIONPHARMA INC	<u>1MCG</u>	<u>A202539 001</u>	Mar 27, 2014
<u>AB</u>		<u>2MCG</u>	<u>A202539 002</u>	Mar 27, 2014
<u>AB</u>		<u>4MCG</u>	<u>A202539 003</u>	Mar 27, 2014
<u>AB</u>	DR REDDYS LABS LTD	<u>1MCG</u>	<u>A091412 001</u>	Jun 24, 2014
<u>AB</u>		<u>2MCG</u>	<u>A091412 002</u>	Jun 24, 2014
<u>AB</u>		<u>4MCG</u>	<u>A091412 003</u>	Jun 24, 2014
<u>AB</u>	ECI PHARMS LLC	<u>1MCG</u>	<u>A206710 001</u>	Feb 24, 2016
<u>AB</u>		<u>2MCG</u>	<u>A206710 002</u>	Feb 24, 2016
<u>AB</u>		<u>4MCG</u>	<u>A206710 003</u>	Feb 24, 2016
<u>AB</u>	MARKSANS PHARMA	<u>1MCG</u>	<u>A204948 001</u>	Oct 07, 2016
<u>AB</u>		<u>2MCG</u>	<u>A204948 002</u>	Oct 07, 2016
<u>AB</u>		<u>4MCG</u>	<u>A204948 003</u>	Oct 07, 2016
<u>AB</u>	RISING PHARMS INC	<u>1MCG</u>	<u>A202124 001</u>	Jun 24, 2014
<u>AB</u>		<u>2MCG</u>	<u>A202124 002</u>	Jun 24, 2014
<u>AB</u>		<u>4MCG</u>	<u>A202124 003</u>	Jun 24, 2014
<u>AB</u>	TEVA PHARMS USA	<u>1MCG</u>	<u>A090829 001</u>	Sep 27, 2013
<u>AB</u>		<u>2MCG</u>	<u>A090829 002</u>	Sep 27, 2013
<u>AB</u>	+	<u>4MCG</u>	<u>A090829 003</u>	Sep 27, 2013

ZEMPLAR

<u>AB</u>	ABBVIE	<u>1MCG</u>	<u>N021606 001</u>	May 26, 2005
<u>AB</u>		<u>2MCG</u>	<u>N021606 002</u>	May 26, 2005

SOLUTION;INTRAVENOUS

PARICALCITOL

<u>AP</u>	ACCORD HLTHCARE	<u>0.002MG/ML (0.002MG/ML)</u>	<u>N207174 001</u>	Feb 04, 2016
<u>AP</u>		<u>0.005MG/ML (0.005MG/ML)</u>	<u>N207174 002</u>	Feb 04, 2016
<u>AP</u>		<u>0.01MG/2ML (0.005MG/ML)</u>	<u>N207174 003</u>	Feb 04, 2016
<u>AP</u>	DR REDDYS LABS LTD	<u>0.002MG/ML (0.002MG/ML)</u>	<u>A204910 001</u>	Aug 17, 2016
<u>AP</u>		<u>0.005MG/ML (0.005MG/ML)</u>	<u>A204910 002</u>	Aug 17, 2016
<u>AP</u>		<u>0.01MG/2ML (0.005MG/ML)</u>	<u>A204910 003</u>	Aug 17, 2016
<u>AP</u>	HIKMA PHARMS	<u>0.002MG/ML (0.002MG/ML)</u>	<u>N205917 001</u>	Nov 18, 2014
<u>AP</u>		<u>0.005MG/ML (0.005MG/ML)</u>	<u>N205917 002</u>	Nov 18, 2014
<u>AP</u>		<u>0.01MG/2ML (0.005MG/ML)</u>	<u>N205917 003</u>	Nov 18, 2014
<u>AP</u>	HOSPIRA INC	<u>0.002MG/ML (0.002MG/ML)</u>	<u>N201657 001</u>	Oct 21, 2014

PRESCRIPTION DRUG PRODUCT LIST

PARICALCITOL

SOLUTION; INTRAVENOUS

PARICALCITOL

<u>AP</u>		<u>0.005MG/ML (0.005MG/ML)</u>	<u>N201657 002</u>	Oct 21, 2014
<u>AP</u>		<u>0.01MG/2ML (0.005MG/ML)</u>	<u>N201657 003</u>	Oct 21, 2014
<u>AP</u>	SANDOZ CANADA INC	<u>0.002MG/ML (0.002MG/ML)</u>	<u>A091108 001</u>	Jul 27, 2011
<u>AP</u>		<u>0.005MG/ML (0.005MG/ML)</u>	<u>A091108 002</u>	Jul 27, 2011
<u>AP</u>		<u>0.01MG/2ML (0.005MG/ML)</u>	<u>A091108 003</u>	Jul 27, 2011

ZEMPLAR

<u>AP</u>	+ ABBVIE	<u>0.002MG/ML (0.002MG/ML)</u>	<u>N020819 002</u>	Feb 01, 2000
<u>AP</u>	+	<u>0.005MG/ML (0.005MG/ML)</u>	<u>N020819 001</u>	Apr 17, 1998
<u>AP</u>	+	<u>0.01MG/2ML (0.005MG/ML)</u>	<u>N020819 003</u>	Feb 01, 2000

PAROMOMYCIN SULFATE

CAPSULE; ORAL

PAROMOMYCIN SULFATE

<u>AA</u>	HERITAGE PHARMS INC	<u>EQ 250MG BASE</u>	<u>A065173 001</u>	Dec 14, 2007
<u>AA</u>	+ SUN PHARM INDS INC	<u>EQ 250MG BASE</u>	<u>A064171 001</u>	Jun 30, 1997

PAROXETINE HYDROCHLORIDE

SUSPENSION; ORAL

PAXIL

<u>AB</u>	+ APOTEX TECHNOLOGIES	<u>EQ 10MG BASE/5ML</u>	<u>N020710 001</u>	Jun 25, 1997
-----------	-----------------------	-------------------------	--------------------	--------------

TABLET; ORAL

PAROXETINE

<u>AB</u>	PRINSTON INC	<u>EQ 10MG BASE</u>	<u>A203854 001</u>	Oct 31, 2014
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A203854 002</u>	Oct 31, 2014
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A203854 003</u>	Oct 31, 2014
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A203854 004</u>	Oct 31, 2014

PAROXETINE HYDROCHLORIDE

<u>AB</u>	APOTEX	<u>EQ 10MG BASE</u>	<u>A075356 001</u>	Jul 30, 2003
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A075356 002</u>	Jul 30, 2003
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A075356 003</u>	Jul 30, 2003
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A075356 004</u>	Jul 30, 2003
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 10MG BASE</u>	<u>A078406 001</u>	Jul 25, 2007
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078406 002</u>	Jul 25, 2007
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A078406 003</u>	Jul 25, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078406 004</u>	Jul 25, 2007
<u>AB</u>	JUBILANT GENERICS	<u>EQ 10MG BASE</u>	<u>A205528 001</u>	Nov 27, 2015
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A205528 002</u>	Nov 27, 2015
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A205528 003</u>	Nov 27, 2015
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A205528 004</u>	Nov 27, 2015
<u>AB</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A078902 001</u>	Mar 13, 2008
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078902 002</u>	Mar 13, 2008
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A078902 003</u>	Mar 13, 2008
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078902 004</u>	Mar 13, 2008
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A075716 001</u>	Mar 08, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A075716 002</u>	Mar 08, 2004
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A075716 003</u>	Mar 08, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A075716 004</u>	Mar 08, 2004
<u>AB</u>	OXFORD PHARMS	<u>EQ 10MG BASE</u>	<u>A076968 001</u>	Jun 21, 2010
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076968 002</u>	Jun 21, 2010
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A076968 003</u>	Jun 21, 2010
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076968 004</u>	Jun 21, 2010
<u>AB</u>	SUN PHARM INDS INC	<u>EQ 10MG BASE</u>	<u>A078194 001</u>	Jun 29, 2007
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078194 002</u>	Jun 29, 2007
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A078194 003</u>	Jun 29, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078194 004</u>	Jun 29, 2007
<u>AB</u>	TEVA	<u>EQ 10MG BASE</u>	<u>A076618 001</u>	Aug 15, 2005
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076618 002</u>	Aug 15, 2005
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A076618 003</u>	Aug 15, 2005
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076618 004</u>	Aug 15, 2005
<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 10MG BASE</u>	<u>A077584 001</u>	Mar 07, 2007
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077584 002</u>	Mar 07, 2007
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A077584 003</u>	Mar 07, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077584 004</u>	Mar 07, 2007

PAXIL

<u>AB</u>	APOTEX TECHNOLOGIES	<u>EQ 10MG BASE</u>	<u>N020031 001</u>	Dec 29, 1992
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>N020031 002</u>	Dec 29, 1992
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>N020031 003</u>	Dec 29, 1992
<u>AB</u>	+	<u>EQ 40MG BASE</u>	<u>N020031 005</u>	Dec 29, 1992

PRESCRIPTION DRUG PRODUCT LIST

PAROXETINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

PAROXETINE HYDROCHLORIDE

<u>AB</u>	KREMERS URBAN PHARMS	<u>EQ 12.5MG BASE</u>	<u>A204744 001</u>	Jun 10, 2016
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A204744 002</u>	Jun 10, 2016
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A204744 003</u>	Jun 10, 2016
<u>AB</u>	MYLAN	<u>EQ 12.5MG BASE</u>	<u>A077873 001</u>	Jun 29, 2007
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A077873 002</u>	Jun 29, 2007
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A091427 001</u>	Apr 14, 2011
	<u>PAXIL CR</u>			
<u>AB</u>	APOTEX TECHNOLOGIES	<u>EQ 12.5MG BASE</u>	<u>N020936 001</u>	Feb 16, 1999
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>N020936 002</u>	Feb 16, 1999
<u>AB</u>	+	<u>EQ 37.5MG BASE</u>	<u>N020936 003</u>	Dec 06, 2000

PAROXETINE MESYLATE

CAPSULE;ORAL

BRISDELLE

+ SEBELA IRELAND LTD

EQ 7.5MG BASE

N204516 001 Jun 28, 2013

TABLET;ORAL

PEXEVA

SEBELA IRELAND LTD

EQ 10MG BASE

N021299 001 Jul 03, 2003

EQ 20MG BASE

N021299 002 Jul 03, 2003

EQ 30MG BASE

N021299 003 Jul 03, 2003

+

EQ 40MG BASE

N021299 004 Jul 03, 2003

PASIREOTIDE DIASPARTATE

SOLUTION;SUBCUTANEOUS

SIGNIFOR

NOVARTIS

EQ 0.3MG BASE/ML (EQ 0.3MG BASE/ML)

N200677 001 Dec 14, 2012

EQ 0.6MG BASE/ML (EQ 0.6MG BASE/ML)

N200677 002 Dec 14, 2012

+

EQ 0.9MG BASE/ML (EQ 0.9MG BASE/ML)

N200677 003 Dec 14, 2012

PASIREOTIDE PAMOATE

POWDER;INTRAMUSCULAR

SIGNIFOR LAR

NOVARTIS PHARMS CORP

EQ 20MG BASE/VIAL

N203255 001 Dec 15, 2014

EQ 40MG BASE/VIAL

N203255 002 Dec 15, 2014

+

EQ 60MG BASE/VIAL

N203255 003 Dec 15, 2014

PATIROMER SORBITE X CALCIUM

POWDER;ORAL

VELTASSA

RELYPSA INC

EQ 8.4GM BASE/PACKET

N205739 001 Oct 21, 2015

EQ 16.8GM BASE/PACKET

N205739 002 Oct 21, 2015

+

EQ 25.2GM BASE/PACKET

N205739 003 Oct 21, 2015

PAZOPANIB HYDROCHLORIDE

TABLET;ORAL

VOTRIENT

+ NOVARTIS PHARMS CORP

EQ 200MG BASE

N022465 001 Oct 19, 2009

PEGADEMASE BOVINE

INJECTABLE;INJECTION

ADAGEN

+ SIGMA TAU

250 UNITS/ML

N019818 001 Mar 21, 1990

PEGAPTANIB SODIUM

INJECTABLE;INTRAVITREAL

MACUGEN

+ VALEANT PHARMS LLC

EQ 0.3MG ACID/0.09ML

N021756 001 Dec 17, 2004

PEGVISOMANT

INJECTABLE;SUBCUTANEOUS

SOMAVERT

+ PHARMACIA AND UPJOHN

10MG/VIAL

N021106 001 Mar 25, 2003

+

15MG/VIAL

N021106 002 Mar 25, 2003

+

20MG/VIAL

N021106 003 Mar 25, 2003

+

25MG/VIAL

N021106 004 Jul 31, 2014

+

30MG/VIAL

N021106 005 Jul 31, 2014

PEMETREXED DISODIUM

INJECTABLE;IV (INFUSION)

ALIMTA

+ LILLY

EQ 100MG BASE/VIAL

N021462 002 Sep 07, 2007

+

EQ 500MG BASE/VIAL

N021462 001 Feb 04, 2004

PRESCRIPTION DRUG PRODUCT LIST

PENCICLOVIR

CREAM; TOPICAL

DENAVIR

+ DENCO ASSET

1%

N020629 001 Sep 24, 1996

PENICILLAMINE

CAPSULE; ORAL

CUPRIMINE

+ ATON

250MG

N019853 001

TABLET; ORAL

DEPEN

+ MEDA PHARMS

250MG

N019854 001

PENICILLIN G BENZATHINE

INJECTABLE; INJECTION

BICILLIN L-A

BC + KING PHARMS

600,000 UNITS/ML

N050141 001

PERMAPEN

BC PFIZER

600,000 UNITS/ML

A060014 001

BICILLIN L-A

+ KING PHARMS

300,000 UNITS/ML

N050141 003

PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE

INJECTABLE; INJECTION

BICILLIN C-R

+ KING PHARMS

150,000 UNITS/ML; 150,000 UNITS/ML

N050138 002

+

300,000 UNITS/ML; 300,000 UNITS/ML

N050138 001

BICILLIN C-R 900/300

+ KING PHARMS

900,000 UNITS/2ML; 300,000 UNITS/2ML

N050138 003

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

PENICILLIN G POTASSIUMAP HANFORD GC5,000,000 UNITS/VIALA065149 002 Jul 23, 2009AP20,000,000 UNITS/VIALA065149 003 Jul 23, 2009AP ISTITUTO BIO ITA SPA5,000,000 UNITS/VIALA065448 001 Aug 18, 2009AP20,000,000 UNITS/VIALA065448 002 Aug 18, 2009AP SANDOZ5,000,000 UNITS/VIALA065079 002 Aug 30, 2002AP20,000,000 UNITS/VIALA065079 003 Aug 30, 2002PFIZERPENAP + PFIZER5,000,000 UNITS/VIALA060657 002AP +20,000,000 UNITS/VIALA060657 003

PENICILLIN G POTASSIUM

HANFORD GC

1,000,000 UNITS/VIAL

A065149 001 Jul 23, 2009

PENICILLIN G POTASSIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE

20,000 UNITS/ML

N050638 001 Jun 25, 1990

+

40,000 UNITS/ML

N050638 002 Jun 25, 1990

+

60,000 UNITS/ML

N050638 003 Jun 25, 1990

PENICILLIN G PROCAINE

INJECTABLE; INJECTION

PENICILLIN G PROCAINE

+ KING PHARMS

300,000 UNITS/ML

A060101 002

+

600,000 UNITS/ML

A060101 001

PENICILLIN G SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

PENICILLIN G SODIUM

+ SANDOZ

5,000,000 UNITS/VIAL

A065068 001 Feb 26, 2001

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

PENICILLIN V POTASSIUMAA DAVA PHARMS INCEQ 125MG BASE/5MLA062981 001 Feb 10, 1989AAEQ 250MG BASE/5MLA062981 002 Feb 10, 1989PENICILLIN-VKAA TEVAEQ 125MG BASE/5MLA060456 001AA +EQ 250MG BASE/5MLA060456 002

TABLET; ORAL

PENICILLIN V POTASSIUMAB AUROBINDO PHARMAEQ 250MG BASEA065435 001 Apr 29, 2008ABEQ 500MG BASEA065435 002 Apr 29, 2008AB DAVA PHARMS INCEQ 250MG BASEA062936 001 Nov 25, 1988ABEQ 500MG BASEA062935 001 Nov 23, 1988AB HIKMA PHARMSEQ 250MG BASEA090549 001 Oct 11, 2013ABEQ 500MG BASEA090549 002 Oct 11, 2013

PRESCRIPTION DRUG PRODUCT LIST

PENICILLIN V POTASSIUM

TABLET; ORAL

PENICILLIN V POTASSIUM

AB	SANDOZ	EQ 250MG BASE	A064071 001	Nov 30, 1995
AB	+	EQ 500MG BASE	A064071 002	Nov 30, 1995
<u>PENICILLIN-VK</u>				
AB	TEVA	EQ 250MG BASE	A060711 002	
AB		EQ 500MG BASE	A060711 003	

PENTAMIDINE ISETHIONATE

FOR SOLUTION; INHALATION

NEBUPENT

+ FRESENIUS KABI USA 300MG/VIAL N019887 001 Jun 15, 1989

INJECTABLE; INJECTION

PENTAM

+ FRESENIUS KABI USA 300MG/VIAL N019264 001 Oct 16, 1984

PENTAZOCINE LACTATE

INJECTABLE; INJECTION

TALWIN

+ HOSPIRA EQ 30MG BASE/ML N016194 001

PENTETATE CALCIUM TRISODIUM

SOLUTION; INHALATION, INTRAVENOUS

PENTETATE CALCIUM TRISODIUM

+ HAMELN PHARMA PLUS EQ 1GM BASE/5ML (EQ 200MG BASE/ML) N021749 001 Aug 11, 2004

PENTETATE ZINC TRISODIUM

SOLUTION; INHALATION, INTRAVENOUS

PENTETATE ZINC TRISODIUM

+ HAMELN PHARMA PLUS EQ 1GM BASE/5ML (EQ 200MG BASE/ML) N021751 001 Aug 11, 2004

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION

NEMBUTAL SODIUM**AP** + OAK PHARMS **50MG/ML** **A083246 001**PENTOBARBITAL SODIUM**AP** MYLAN INSTITUTIONAL **50MG/ML** **A206404 001** May 23, 2016PENTOSAN POLYSULFATE SODIUM

CAPSULE; ORAL

ELMIRON

+ JANSSEN PHARMS 100MG N020193 001 Sep 26, 1996

PENTOSTATIN

INJECTABLE; INJECTION

NIPENT**AP** + HOSPIRA INC **10MG/VIAL** **N020122 001** Oct 11, 1991PENTOSTATIN**AP** MYLAN INSTITUTIONAL **10MG/VIAL** **A203554 001** Sep 19, 2014**AP** WEST-WARD PHARMS INT **10MG/VIAL** **A077841 001** Aug 07, 2007PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

PENTOXIFYLLINE**AB** + APOTEX **400MG** **A075191 001** Jun 09, 1999**AB** MYLAN **400MG** **A074425 001** Jul 08, 1997**AB** VALEANT PHARMS **400MG** **A075028 001** Jul 20, 1998PENTOXIL**AB** UPSHER SMITH **400MG** **A074962 001** Mar 31, 1999PERAMIVIR

SOLUTION; IV (INFUSION)

RAPIVAB

+ BIOCRYST 200MG/20ML (10MG/ML) N206426 001 Dec 19, 2014

PERAMPANEL

SUSPENSION; ORAL

FYCOMPA

+ EISAI INC 0.5MG/ML N208277 001 Apr 29, 2016

TABLET; ORAL

FYCOMPA

EISAI INC 2MG N202834 001 Oct 22, 2012

4MG N202834 002 Oct 22, 2012

6MG N202834 003 Oct 22, 2012

8MG N202834 004 Oct 22, 2012

10MG N202834 005 Oct 22, 2012

PRESCRIPTION DRUG PRODUCT LIST

PERAMPANEL

TABLET; ORAL

FYCOMPA

+

12MG

N202834 006 Oct 22, 2012

PERFLUTREN

INJECTABLE; INTRAVENOUS

DEFINITY

+ LANTHEUS MEDCL

6.52MG/ML

N021064 001 Jul 31, 2001

PERINDOPRIL ERBUMINE

TABLET; ORAL

ACEONAB SYMPLMED PHARMS LLC2MGN020184 001 Dec 30, 1993AB 4MG N020184 002 Dec 30, 1993AB + 8MG N020184 003 Dec 30, 1993PERINDOPRIL ERBUMINEAB ANI PHARMS INC 2MG A078138 001 Nov 10, 2009AB 4MG A078138 002 Nov 10, 2009AB 8MG A078138 003 Nov 10, 2009AB APOTEX 2MG A090463 001 Aug 30, 2010AB 4MG A090463 002 Aug 30, 2010AB 8MG A090463 003 Aug 30, 2010AB AUROBINDO PHARMA 2MG A079070 001 Nov 10, 2009AB 4MG A079070 002 Nov 10, 2009AB 8MG A079070 003 Nov 10, 2009AB WEST-WARD PHARMS INT 2MG A090072 001 Nov 10, 2009AB 4MG A090072 002 Nov 10, 2009AB 8MG A090072 003 Nov 10, 2009PERMETHRIN

CREAM; TOPICAL

ELIMITEAB + RENAISSANCE PHARMA 5% N019855 001 Aug 25, 1989PERMETHRINAB ACTAVIS MID ATLANTIC 5% A074806 001 Jan 23, 1998AB PERRIGO NEW YORK 5% A076369 001 Apr 21, 2003PERPHENAZINE

TABLET; ORAL

PERPHENAZINEAB SANDOZ 2MG A089685 002 Dec 08, 1988AB 4MG A089685 003 Dec 08, 1988AB 8MG A089685 001 Dec 08, 1988AB + 16MG A089685 004 Dec 08, 1988AB VINTAGE PHARMS 2MG A040226 001 Dec 31, 1998AB 4MG A040226 002 Dec 31, 1998AB 8MG A040226 003 Dec 31, 1998AB 16MG A040226 004 Dec 31, 1998AB WATSON LABS INC 2MG A207582 001 Oct 17, 2016AB 4MG A207582 002 Oct 17, 2016AB 8MG A207582 003 Oct 17, 2016AB 16MG A207582 004 Oct 17, 2016AB WILSHIRE PHARMS INC 2MG A205973 001 Dec 17, 2015AB 4MG A205973 002 Dec 17, 2015AB 8MG A205973 003 Dec 17, 2015AB 16MG A205973 004 Dec 17, 2015PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

PHENDIMETRAZINE TARTRATE

+ SANDOZ

105MG

N018074 001

TABLET; ORAL

BONTRIL PDMAA + VALEANT 35MG A085272 001PHENDIMETRAZINE TARTRATEAA ELITE LABS INC 35MG A040762 001 Jan 28, 2008AA KVK TECH 35MG A091042 001 Aug 31, 2010AA MIKART 35MG A089452 001 Oct 30, 1991AA SANDOZ 35MG A085588 001

PRESCRIPTION DRUG PRODUCT LIST

PHENELZINE SULFATE

TABLET; ORAL

NARDIL

<u>AB</u>	+ PARKE DAVIS	<u>EQ 15MG BASE</u>	<u>N011909</u>	<u>002</u>	
<u>PHENELZINE SULFATE</u>					
<u>AB</u>	NOVEL LABS INC	<u>EQ 15MG BASE</u>	<u>A200181</u>	<u>001</u>	Dec 08, 2010

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIBENZYLINE

<u>AB</u>	+ CONCORDIA PHARMS INC	<u>10MG</u>	<u>N008708</u>	<u>001</u>	
<u>PHENOXYBENZAMINE HYDROCHLORIDE</u>					
<u>AB</u>	WEST-WARD PHARMS INT	<u>10MG</u>	<u>A201050</u>	<u>001</u>	Jul 16, 2012

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

ADIPEX-P

<u>AA</u>	+ TEVA	<u>37.5MG</u>	<u>A088023</u>	<u>001</u>	Aug 02, 1983
<u>PHENTERMINE HYDROCHLORIDE</u>					
<u>AA</u>	AUROLIFE PHARMA LLC	<u>15MG</u>	<u>A204318</u>	<u>001</u>	Nov 09, 2016
<u>AA</u>		<u>30MG</u>	<u>A204318</u>	<u>002</u>	Nov 09, 2016
<u>AA</u>	BARR	<u>15MG</u>	<u>A090591</u>	<u>001</u>	Mar 18, 2010
<u>AA</u>		<u>30MG</u>	<u>A090591</u>	<u>002</u>	Mar 18, 2010
<u>AA</u>	ELITE LABS	<u>15MG</u>	<u>A202248</u>	<u>001</u>	Sep 28, 2012
<u>AA</u>		<u>30MG</u>	<u>A202248</u>	<u>002</u>	Sep 28, 2012
<u>AA</u>	INVAGEN PHARMS	<u>15MG</u>	<u>A202858</u>	<u>001</u>	Feb 14, 2014
<u>AA</u>		<u>30MG</u>	<u>A202858</u>	<u>002</u>	Feb 14, 2014
<u>AA</u>		<u>30MG</u>	<u>A204414</u>	<u>001</u>	May 05, 2014
<u>AA</u>		<u>37.5MG</u>	<u>A202846</u>	<u>001</u>	Feb 05, 2014
<u>AA</u>	KEN LIFESCIENCE	<u>15MG</u>	<u>A205019</u>	<u>001</u>	Dec 05, 2014
<u>AA</u>		<u>30MG</u>	<u>A205019</u>	<u>002</u>	Dec 05, 2014
<u>AA</u>		<u>37.5MG</u>	<u>A205017</u>	<u>001</u>	Sep 25, 2014
<u>AA</u>	KVK TECH	<u>15MG</u>	<u>A040886</u>	<u>002</u>	Mar 31, 2008
<u>AA</u>		<u>30MG</u>	<u>A040875</u>	<u>001</u>	Mar 21, 2008
<u>AA</u>		<u>30MG</u>	<u>A040886</u>	<u>001</u>	Mar 31, 2008
<u>AA</u>		<u>37.5MG</u>	<u>A040887</u>	<u>001</u>	Apr 24, 2008
<u>AA</u>	LANNETT	<u>15MG</u>	<u>A087022</u>	<u>002</u>	Jan 20, 2012
<u>AA</u>		<u>30MG</u>	<u>A087022</u>	<u>001</u>	Feb 03, 1983
<u>AA</u>		<u>30MG</u>	<u>A091359</u>	<u>001</u>	Jul 16, 2010
<u>AA</u>	LANNETT HOLDINGS INC	<u>37.5MG</u>	<u>A201961</u>	<u>001</u>	Jul 20, 2011
<u>AA</u>	MIKAH PHARMA LLC	<u>37.5MG</u>	<u>A040228</u>	<u>001</u>	Jun 19, 1997
<u>AA</u>	+ SANDOZ	<u>15MG</u>	<u>A087190</u>	<u>002</u>	
<u>AA</u>	+	<u>30MG</u>	<u>A086945</u>	<u>001</u>	Jul 20, 1983
<u>AA</u>	+	<u>30MG</u>	<u>A087190</u>	<u>001</u>	
<u>AA</u>	SUN PHARM INDS	<u>30MG</u>	<u>A040525</u>	<u>001</u>	Oct 23, 2003

TABLET; ORAL

ADIPEX-P

<u>AA</u>	+ TEVA	<u>37.5MG</u>	<u>A085128</u>	<u>001</u>	
<u>PHENTERMINE HYDROCHLORIDE</u>					
<u>AA</u>	AUROLIFE PHARMA LLC	<u>37.5MG</u>	<u>A203068</u>	<u>001</u>	Aug 06, 2014
<u>AA</u>	BARR	<u>37.5MG</u>	<u>A090470</u>	<u>001</u>	Aug 31, 2009
<u>AA</u>	ELITE LABS	<u>37.5MG</u>	<u>A200272</u>	<u>001</u>	Jan 31, 2011
<u>AA</u>	INGENUS PHARMS NJ	<u>37.5MG</u>	<u>A091451</u>	<u>001</u>	Sep 21, 2012
<u>AA</u>	INVAGEN PHARMS	<u>37.5MG</u>	<u>A202942</u>	<u>001</u>	Feb 05, 2014
<u>AA</u>	KEN LIFESCIENCE	<u>37.5MG</u>	<u>A205008</u>	<u>001</u>	Sep 25, 2014
<u>AA</u>	KVK TECH	<u>37.5MG</u>	<u>A040876</u>	<u>001</u>	Mar 31, 2008
<u>AA</u>	LANNETT	<u>37.5MG</u>	<u>A040555</u>	<u>001</u>	Apr 15, 2005
<u>AA</u>	MIKAH PHARMA	<u>37.5MG</u>	<u>A040190</u>	<u>001</u>	May 30, 1997
<u>AA</u>	POLYGEN PHARMS	<u>37.5MG</u>	<u>A206342</u>	<u>001</u>	Nov 18, 2016
<u>AA</u>	SUN PHARM INDS	<u>37.5MG</u>	<u>A040526</u>	<u>001</u>	Oct 23, 2003
<u>AA</u>	SUN PHARM INDS INC	<u>37.5MG</u>	<u>A040790</u>	<u>001</u>	Aug 21, 2007
<u>AA</u>	VINTAGE PHARMS	<u>37.5MG</u>	<u>A040377</u>	<u>001</u>	Jan 04, 2002

LOMAIRA

+ AVANTHI INC	8MG	A203495	001	Sep 12, 2016
---------------	-----	---------	-----	--------------

PHENTERMINE HYDROCHLORIDE; TOPIRAMATE

CAPSULE, EXTENDED RELEASE; ORAL

QSYMIA

VIVUS	EQ 3.75MG BASE; 23MG	N022580	001	Jul 17, 2012
	EQ 7.5MG BASE; 46MG	N022580	002	Jul 17, 2012
	EQ 11.25MG BASE; 69MG	N022580	003	Jul 17, 2012
+	EQ 15MG BASE; 92MG	N022580	004	Jul 17, 2012

PRESCRIPTION DRUG PRODUCT LIST

PHENTOLAMINE MESYLATE

INJECTABLE; INJECTION

PHENTOLAMINE MESYLATE**AP** WEST-WARD PHARMS INT **5MG/VIAL** **A040235 001** Mar 11, 1998REGITINE**AP** + NOVARTIS **5MG/VIAL** **N008278 003**
ORAVERSE
+ SEPTODONT HOLDING 0.4MG/1.7ML N022159 001 May 09, 2008PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; IV (INFUSION)

PHENYLEPHRINE HYDROCHLORIDE

+ WEST WARD PHARM CORP 10MG/ML (10MG/ML) N203826 001 Dec 20, 2012

VAZCULEP

ECLAT PHARMS LLC 10MG/ML (10MG/ML) N204300 001 Jun 27, 2014

50MG/5ML (10MG/ML) N204300 002 Jun 27, 2014

+ 100MG/10ML (10MG/ML) N204300 003 Jun 27, 2014

SOLUTION/DROPS; OPHTHALMIC

PHENYLEPHRINE HYDROCHLORIDE

+ AKORN INC 2.5% N207926 001 Jan 15, 2015

+ 10% N207926 002 Jan 15, 2015

+ PARAGON BIOTECK 2.5% N203510 001 Mar 21, 2013

+ 10% N203510 002 Mar 21, 2013

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE**AA** HI-TECH PHARMACAL **5MG/5ML; 6.25MG/5ML** **A040675 001** Dec 23, 2014**AA** VINTAGE **5MG/5ML; 6.25MG/5ML** **A040654 001** Dec 07, 2006PROMETH VC PLAIN**AA** + G AND W LABS INC **5MG/5ML; 6.25MG/5ML** **A088761 001** Nov 08, 1984PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE**AA** AMNEAL PHARMS **5MG/5ML; 6.25MG/5ML** **A040902 001** Aug 25, 2009PHENYTOIN

SUSPENSION; ORAL

DILANTIN-125**AB** + PARKE DAVIS **125MG/5ML** **N008762 001**PHENYTOIN**AB** TARO **125MG/5ML** **A040521 001** Mar 08, 2004**AB** VISTAPHARM **125MG/5ML** **A040342 001** Jan 31, 2001**AB** **125MG/5ML** **A040610 001** Aug 18, 2005**AB** WOCKHARDT **125MG/5ML** **A040420 001** Apr 19, 2002

TABLET, CHEWABLE; ORAL

DILANTIN**AB** + PFIZER PHARMS **50MG** **A084427 001**PHENYTOIN**AB** COREPHARMA **50MG** **A040884 001** Nov 28, 2014**AB** MYLAN PHARMS INC **50MG** **A200691 001** Dec 26, 2012**AB** TARO **50MG** **A200565 001** Apr 17, 2014PHENYTOIN SODIUM

CAPSULE; ORAL

DILANTIN**AB** + PARKE DAVIS **30MG EXTENDED** **A084349 001****AB** + **100MG EXTENDED** **A084349 002**EXTENDED PHENYTOIN SODIUM**AB** AMNEAL PHARMS NY **100MG EXTENDED** **A040765 001** Nov 12, 2008**AB** MYLAN **100MG EXTENDED** **A040298 001** Dec 28, 1998**AB** SUN PHARM INDS **200MG EXTENDED** **A040731 001** Jun 30, 2008**AB** **300MG EXTENDED** **A040731 002** Jun 30, 2008**AB** SUN PHARM INDS (IN) **100MG EXTENDED** **A040621 001** Dec 11, 2006**AB** TARO **100MG EXTENDED** **A040684 001** Sep 05, 2006PHENYTEK**AB** MYLAN **200MG EXTENDED** **A040298 002** Dec 06, 2001**AB** + **300MG EXTENDED** **A040298 003** Dec 06, 2001PHENYTOIN SODIUM**AB** AUROBINDO PHARMA LTD **100MG EXTENDED** **A204309 001** Jun 10, 2015

INJECTABLE; INJECTION

PHENYTOIN SODIUM**AP** + EUROHLTH INTL SARL **50MG/ML** **A084307 001****AP** HOSPIRA **50MG/ML** **A089521 001** Mar 17, 1987**AP** LUITPOLD **50MG/ML** **A040781 001** Dec 04, 2007**AP** X-GEN PHARMS **50MG/ML** **A040573 001** Sep 13, 2006

PRESCRIPTION DRUG PRODUCT LIST

PHYTONADIONE

INJECTABLE; INJECTION

PHYTONADIONE

BP	+	INTL MEDICATION	1MG/0.5ML	A083722	001		
		VITAMIN K1					
BP	+	HOSPIRA	1MG/0.5ML	A087954	001	Jul 25, 1983	
	+		10MG/ML	A087955	001	Jul 25, 1983	
		MEPHYTON					
	+	VALEANT PHARMS	5MG	N010104	003		

PILOCARPINE HYDROCHLORIDE

SOLUTION; OPHTHALMIC

ISOPTO CARPINE

NOVARTIS PHARMS CORP

			1%	N200890	001	Jun 22, 2010	
			2%	N200890	002	Jun 22, 2010	
	+		4%	N200890	003	Jun 22, 2010	

TABLET; ORAL

PILOCARPINE HYDROCHLORIDE

AB		ELAN PHARMA INTL LTD	5MG	A076746	001	Nov 16, 2004	
AB		IMPAX LABS	5MG	A077248	001	Mar 31, 2006	
AB			7.5MG	A077248	002	Mar 31, 2006	
AB		LANNETT	5MG	A077220	001	Oct 14, 2005	
AB			7.5MG	A077220	002	May 06, 2009	
AB		ROXANE	5MG	A076963	001	Dec 22, 2004	
AB			7.5MG	A076963	002	Feb 27, 2007	

SALAGEN

AB		EISAI INC	5MG	N020237	001	Mar 22, 1994	
AB	+		7.5MG	N020237	002	Apr 18, 2003	

PIMAVANSERIN TARTRATE

TABLET; ORAL

NUPLAZID

+ ACADIA PHARMS INC

EQ 17MG BASE

N207318 001 Apr 29, 2016

PIMECROLIMUS

CREAM; TOPICAL

ELIDEL

+ VALEANT BERMUDA

1%

N021302 001 Dec 13, 2001

PIMOZIDE

TABLET; ORAL

ORAP

AB		TEVA	1MG	N017473	003	Aug 27, 1997	
AB	+		2MG	N017473	001	Jul 31, 1984	
AB		PAR PHARM	1MG	A204521	001	Sep 28, 2015	
AB			2MG	A204521	002	Sep 28, 2015	

PINDOLOL

TABLET; ORAL

PINDOLOL

AB		MYLAN PHARMS INC	5MG	A074019	001	Sep 03, 1992	
AB	+		10MG	A074019	002	Sep 03, 1992	
AB		NOSTRUM LABS INC	5MG	A205415	001	Jan 13, 2016	
AB			10MG	A205415	002	Jan 13, 2016	
AB		SUN PHARM INDS	5MG	A074063	001	Jan 27, 1994	
AB			10MG	A074063	002	Jan 27, 1994	

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

ACTOS

AB		TAKEDA PHARMS USA	EQ 15MG BASE	N021073	001	Jul 15, 1999	
AB			EQ 30MG BASE	N021073	002	Jul 15, 1999	
AB	+		EQ 45MG BASE	N021073	003	Jul 15, 1999	

PIOGLITAZONE HYDROCHLORIDE

AB		ACCORD HLTHCARE	EQ 15MG BASE	A200044	001	Feb 13, 2013	
AB			EQ 30MG BASE	A200044	002	Feb 13, 2013	
AB			EQ 45MG BASE	A200044	003	Feb 13, 2013	
AB		AUROBINDO PHARMA LTD	EQ 15MG BASE	A200268	001	Feb 13, 2013	
AB			EQ 30MG BASE	A200268	002	Feb 13, 2013	
AB			EQ 45MG BASE	A200268	003	Feb 13, 2013	
AB		BRECKENRIDGE PHARM	EQ 15MG BASE	A078472	001	Feb 13, 2013	
AB			EQ 30MG BASE	A078472	002	Feb 13, 2013	
AB			EQ 45MG BASE	A078472	003	Feb 13, 2013	

PRESCRIPTION DRUG PRODUCT LIST

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE

<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 15MG BASE</u>	<u>A078383 001</u>	Mar 12, 2013
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A078383 002</u>	Mar 12, 2013
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A078383 003</u>	Mar 12, 2013
<u>AB</u>	LUPIN LTD	<u>EQ 15MG BASE</u>	<u>A204133 001</u>	Apr 07, 2014
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A204133 002</u>	Apr 07, 2014
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A204133 003</u>	Apr 07, 2014
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 15MG BASE</u>	<u>A202467 001</u>	Feb 06, 2013
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A202467 002</u>	Feb 06, 2013
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A202467 003</u>	Feb 06, 2013
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 15MG BASE</u>	<u>A076801 001</u>	Aug 17, 2012
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A076801 002</u>	Aug 17, 2012
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A076801 003</u>	Aug 17, 2012
<u>AB</u>	SANDOZ	<u>EQ 15MG BASE</u>	<u>A078670 001</u>	Feb 13, 2013
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A078670 002</u>	Feb 13, 2013
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A078670 003</u>	Feb 13, 2013
<u>AB</u>	TEVA PHARMS USA	<u>EQ 15MG BASE</u>	<u>A077210 001</u>	Jan 10, 2014
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A077210 002</u>	Jan 10, 2014
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A077210 003</u>	Jan 10, 2014
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 15MG BASE</u>	<u>A091298 001</u>	Feb 13, 2013
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A091298 002</u>	Feb 13, 2013
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A091298 003</u>	Feb 13, 2013
<u>AB</u>	WATSON LABS	<u>EQ 15MG BASE</u>	<u>A076798 001</u>	Oct 26, 2012
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A076798 002</u>	Oct 26, 2012
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A076798 003</u>	Oct 26, 2012
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 15MG BASE</u>	<u>A202456 001</u>	Feb 13, 2013
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A202456 002</u>	Feb 13, 2013
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A202456 003</u>	Feb 13, 2013

PIPERACILLIN SODIUM

INJECTABLE; INJECTION

PIPERACILLIN

+	ISTITUTO BIO ITA SPA	EQ 2GM BASE/VIAL	A065114 001	Nov 14, 2003
+		EQ 3GM BASE/VIAL	A065114 002	Nov 14, 2003
+		EQ 4GM BASE/VIAL	A065114 003	Nov 14, 2003
+		EQ 40GM BASE/VIAL	A065157 001	Jul 12, 2004

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065498 001</u>	May 23, 2011	
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065498 002</u>	May 23, 2011	
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065498 003</u>	May 23, 2011	
<u>AP</u>	HOSPIRA INC	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065386 001</u>	Sep 15, 2009	
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065386 002</u>	Sep 15, 2009	
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065386 003</u>	Sep 15, 2009	
<u>AP</u>		<u>EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL</u>	<u>A065446 001</u>	Sep 15, 2009	
<u>AP</u>	ISTITUTO BIO ITA SPA	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065523 001</u>	May 31, 2011	
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065523 002</u>	May 31, 2011	
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065523 003</u>	May 31, 2011	
<u>AP</u>		<u>EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL</u>	<u>A090498 001</u>	May 31, 2011	
<u>AP</u>	MYLAN LABS LTD	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065458 001</u>	Aug 15, 2014	
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065458 002</u>	Aug 15, 2014	
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065458 003</u>	Aug 15, 2014	
<u>AP</u>	SANDOZ	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065362 001</u>	Oct 21, 2010	
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065363 001</u>	Oct 21, 2010	
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065362 002</u>	Oct 21, 2010	
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065363 002</u>	Oct 21, 2010	
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065362 003</u>	Oct 21, 2010	
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065363 003</u>	Oct 21, 2010	
<u>ZOSYN</u>					
<u>AP</u>	+	WYETH PHARMS INC	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>N050684 001</u>	Oct 22, 1993
<u>AP</u>	+		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>N050684 002</u>	Oct 22, 1993
<u>AP</u>	+		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>N050684 003</u>	Oct 22, 1993
<u>AP</u>	+		<u>EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL</u>	<u>N050684 004</u>	Oct 22, 1993
ZOSYN IN PLASTIC CONTAINER					
+	WYETH PHARMS INC	EQ 40MG BASE/ML;EQ 5MG BASE/ML	N050750 001	Feb 24, 1998	
+		EQ 60MG BASE/ML;EQ 7.5MG BASE/ML	N050750 002	Feb 24, 1998	
+		EQ 4GM BASE/100ML;EQ 500MG BASE/100ML	N050750 003	Feb 24, 1998	

PRESCRIPTION DRUG PRODUCT LISTPIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; IV (INFUSION)

PIPERACILLIN AND TAZOBACTAM

SANDOZ INC

EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL

A203557 001 Oct 29, 2014

PIRFENIDONE

CAPSULE; ORAL

ESBRIET

+ GENENTECH INC

267MG

N022535 001 Oct 15, 2014

PIROXICAM

CAPSULE; ORAL

FELDENEAB PFIZER10MGN018147 002 Apr 06, 1982AB +20MGN018147 003 Apr 06, 1982PIROXICAMAB FLAMINGO PHARMS10MGA207938 001 Sep 09, 2016AB20MGA207938 002 Sep 09, 2016AB MUTUAL PHARM10MGA073535 001 Mar 12, 1993AB

MYLAN

10MGA074102 001 Jul 31, 1992AB20MGA074102 002 Jul 31, 1992AB MYLAN IRELAND LTD10MGA074116 001 Jun 15, 1993AB20MGA074118 001 Jun 15, 1993AB TEVA10MGA074131 001 Dec 11, 1992AB20MGA074131 002 Dec 11, 1992PITAVASTATIN CALCIUM

TABLET; ORAL

LIVALOAB KOWA COEQ 1MG BASEN022363 001 Aug 03, 2009ABEQ 2MG BASEN022363 002 Aug 03, 2009AB +EQ 4MG BASEN022363 003 Aug 03, 2009PITAVASTATIN CALCIUMAB AUROBINDO PHARMA LTDEQ 1MG BASEA206015 001 Dec 20, 2016ABEQ 2MG BASEA206015 002 Dec 20, 2016ABEQ 4MG BASEA206015 003 Dec 20, 2016PLERIXAFOR

SOLUTION; SUBCUTANEOUS

MOZOBIL

+ GENZYME

24MG/1.2ML (20MG/ML)

N022311 001 Dec 15, 2008

PODOFILOX

GEL; TOPICAL

CONDYLOX

+ ALLERGAN SALES LLC

0.5%

N020529 001 Mar 13, 1997

SOLUTION; TOPICAL

CONDYLOXAT + ALLERGAN SALES LLC0.5%N019795 001 Dec 13, 1990PODOFILOXAT BAUSCH AND LOMB INC0.5%A090184 001 Jul 21, 2010AT PADDOCK LLC0.5%A075600 001 Jan 29, 2002POLIDOCANOL

SOLUTION; INTRAVENOUS

ASCLERA

CHEMISCH FBRK KRSSLR

10MG/2ML (5MG/ML)

N021201 001 Mar 30, 2010

+

20MG/2ML (10MG/ML)

N021201 002 Mar 30, 2010

VARITHENA

+ PROVENISIS

180MG/18ML (10MG/ML)

N205098 001 Nov 25, 2013

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

GLYCOLAXAA KREMERS URBAN PHARMS17GM/SCOOPFULA076652 001 Jul 02, 2004POLYETHYLENE GLYCOL 3350AA BRECKENRIDGE PHARM17GM/SCOOPFULA077736 001 May 26, 2006AA NEXGEN PHARMA INC17GM/SCOOPFULA077706 001 Sep 27, 2006AA PADDOCK LLC17GM/SCOOPFULA077893 001 May 26, 2006

PRESCRIPTION DRUG PRODUCT LIST

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; ORAL

LAX-LYTE WITH FLAVOR PACKS

AA	PADDOCK LLC	<u>420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT</u>	A079232 001	Feb 25, 2010
-----------	-------------	---	--------------------	--------------

NULYTELY

AA	+ BRAINTREE	<u>420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT</u>	N019797 001	Apr 22, 1991
-----------	-------------	---	--------------------	--------------

NULYTELY-FLAVORED

AA	+ BRAINTREE	<u>420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT</u>	N019797 002	Nov 18, 1994
-----------	-------------	---	--------------------	--------------

PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

AA	MYLAN	<u>420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT</u>	A090409 001	Apr 02, 2010
-----------	-------	---	--------------------	--------------

AA	NOVEL LABS INC	<u>420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT</u>	A090019 001	May 27, 2009
-----------	----------------	---	--------------------	--------------

AA	STRIDES ARCOLAB LTD	<u>420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT</u>	A204559 001	Apr 13, 2015
-----------	---------------------	---	--------------------	--------------

TRILYTE

AA	MEDA PHARMS	<u>420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT</u>	A076491 001	Feb 05, 2004
-----------	-------------	---	--------------------	--------------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

COLYTE WITH FLAVOR PACKS

AA	MEDA PHARMS	<u>240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT</u>	N018983 012	Oct 08, 1998
-----------	-------------	---	--------------------	--------------

GOLYTELY

AA	+ BRAINTREE	<u>236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT</u>	N019011 001	Jul 13, 1984
-----------	-------------	---	--------------------	--------------

PEG 3350 AND ELECTROLYTES

AA	MYLAN	<u>236GM;2.97GM;6.74GM;5.86GM;22.74GM</u>	A090928 001	Jan 28, 2010
-----------	-------	---	--------------------	--------------

AA	NOVEL LABS INC	<u>236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT</u>	A090231 001	Jun 01, 2009
-----------	----------------	---	--------------------	--------------

AA		<u>240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT</u>	A090186 001	Jun 01, 2009
-----------	--	---	--------------------	--------------

GOLYTELY

	+ BRAINTREE	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N019011 002	Jun 02, 1992
--	-------------	--	--------------------	--------------

POLYMYXIN B SULFATE

INJECTABLE; INJECTION

POLYMYCIN B SULFATE

AP	SAGENT STRIDES	<u>EQ 500,000 UNITS BASE/VIAL</u>	A090110 001	Jun 29, 2011
-----------	----------------	-----------------------------------	--------------------	--------------

POLYMYXIN B SULFATE

AP	AUROBINDO PHARMA LTD	<u>EQ 500,000 UNITS BASE/VIAL</u>	A206589 001	Apr 04, 2016
-----------	----------------------	-----------------------------------	--------------------	--------------

AP	FRESENIUS KABI USA	<u>EQ 500,000 UNITS BASE/VIAL</u>	A065372 001	Jan 10, 2008
-----------	--------------------	-----------------------------------	--------------------	--------------

AP	GLAND PHARMA LTD	<u>EQ 500,000 UNITS BASE/VIAL</u>	A207322 001	Apr 14, 2016
-----------	------------------	-----------------------------------	--------------------	--------------

AP	+ WEST-WARD PHARMS INT	<u>EQ 500,000 UNITS BASE/VIAL</u>	A060716 001	
-----------	------------------------	-----------------------------------	--------------------	--

AP	X GEN PHARMS	<u>EQ 500,000 UNITS BASE/VIAL</u>	A063000 001	Sep 30, 1994
-----------	--------------	-----------------------------------	--------------------	--------------

AP	XELLIA PHARMS APS	<u>EQ 500,000 UNITS BASE/VIAL</u>	A202766 001	Jan 15, 2014
-----------	-------------------	-----------------------------------	--------------------	--------------

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC

POLYTRIM

AT	+ ALLERGAN	<u>10,000 UNITS/ML;EQ 1MG BASE/ML</u>	N050567 001	Oct 20, 1988
-----------	------------	---------------------------------------	--------------------	--------------

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT	AKORN INC	<u>10,000 UNITS/ML;EQ 1MG BASE/ML</u>	A065006 001	Dec 17, 1998
-----------	-----------	---------------------------------------	--------------------	--------------

AT	ALCON RES LTD	<u>10,000 UNITS/ML;EQ 1MG BASE/ML</u>	A064211 001	Apr 13, 1998
-----------	---------------	---------------------------------------	--------------------	--------------

AT	BAUSCH AND LOMB	<u>10,000 UNITS/ML;EQ 1MG BASE/ML</u>	A064120 001	Feb 14, 1997
-----------	-----------------	---------------------------------------	--------------------	--------------

POMALIDOMIDE

CAPSULE; ORAL

POMALYST

	CELGENE	1MG	N204026 001	Feb 08, 2013
--	---------	-----	--------------------	--------------

		2MG	N204026 002	Feb 08, 2013
--	--	-----	--------------------	--------------

		3MG	N204026 003	Feb 08, 2013
--	--	-----	--------------------	--------------

	+ CELGENE	4MG	N204026 004	Feb 08, 2013
--	-----------	-----	--------------------	--------------

PONATINIB HYDROCHLORIDE

TABLET; ORAL

ICLUSIG

	ARIAD	EQ 15MG BASE	N203469 001	Dec 14, 2012
--	-------	--------------	--------------------	--------------

		EQ 30MG BASE	N203469 003	Apr 23, 2015
--	--	--------------	--------------------	--------------

	+ ARIAD	EQ 45MG BASE	N203469 002	Dec 14, 2012
--	---------	--------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

PORACTANT ALFA

SUSPENSION; INTRATRACHEAL
CUROSURF

+ CHIESI USA INC 80MG/ML N020744 001 Nov 18, 1999

PORFIMER SODIUM

INJECTABLE; INJECTION
PHOTOFRIN

CONCORDIA LABS INC 75MG/VIAL N020451 001 Dec 27, 1995

POSACONAZOLE

SOLUTION; IV (INFUSION)
NOXAFIL

+ MERCK SHARP DOHME 300MG/16.7ML (18MG/ML) N205596 001 Mar 13, 2014

SUSPENSION; ORAL

NOXAFIL

+ SCHERING 40MG/ML N022003 001 Sep 15, 2006

TABLET, DELAYED RELEASE; ORAL

NOXAFIL

+ MERCK SHARP DOHME 100MG N205053 001 Nov 25, 2013

POTASSIUM ACETATE

INJECTABLE; INJECTION

POTASSIUM ACETATE

AP EXELA PHARMA SCS LLC 2MEQ/ML **A206203 001** Dec 29, 2015

AP + HOSPIRA 2MEQ/ML **N018896 001** Jul 20, 1984

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

KLOR-CON

AB UPSHER-SMITH LABS 8MEQ **A203106 001** Jul 10, 2015

AB 10MEQ **A203106 002** Jul 10, 2015

MICRO-K

AB NESHER PHARMS 8MEQ **N018238 001**

MICRO-K 10

AB NESHER PHARMS 10MEQ **N018238 002** May 14, 1984

POTASSIUM CHLORIDE

AB ACTAVIS LABS FL INC 8MEQ **A077419 001** Jun 02, 2008

AB + 10MEQ **A077419 002** Jun 02, 2008

AB AMNEAL PHARMS 10MEQ **A202128 001** Feb 22, 2013

AB ANCHEN PHARMS 8MEQ **A202886 001** Dec 26, 2013

AB 10MEQ **A202886 002** Dec 26, 2013

AB GLENMARK PHARMS LTD 10MEQ **A202868 001** Jan 19, 2016

AB KREMERS URBAN PHARMS 8MEQ **A204210 001** Mar 28, 2016

AB 10MEQ **A204210 002** Mar 28, 2016

AB LUPIN LTD 8MEQ **A203002 001** Dec 18, 2015

AB 10MEQ **A203002 002** Dec 18, 2015

AB NOVEL LABS INC 8MEQ **A204828 001** Aug 16, 2016

AB 10MEQ **A204828 002** Aug 16, 2016

AB PADDOCK LLC 8MEQ **A200185 001** May 18, 2011

AB 10MEQ **A200185 002** May 18, 2011

AB PHARMACEUTICS INTL 8MEQ **A205549 001** Dec 08, 2015

AB 10MEQ **A205549 002** Dec 08, 2015

AB TRIS PHARMA INC 8MEQ **A201944 001** Mar 04, 2016

AB 10MEQ **A201944 002** Mar 04, 2016

FOR SOLUTION; ORAL

POTASSIUM CHLORIDE

+ PHARMA RES SOFTWARE 20MEQ N208019 001 Aug 19, 2015

INJECTABLE; INJECTION

POTASSIUM CHLORIDE

AP B BRAUN 2MEQ/ML **A085870 001**

AP BAXTER HLTHCARE 2MEQ/ML **A085499 001**

AP FRESENIUS KABI USA 2MEQ/ML **A080225 001**

AP + HOSPIRA 2MEQ/ML **A080205 001**

POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

AP + BAXTER HLTHCARE 14.9MG/ML **N019904 001** Dec 26, 1989

AP + 746MG/100ML **N019904 005** Dec 17, 1990

AP HOSPIRA 14.9MG/ML **N020161 005** Nov 30, 1992

AP 745MG/100ML **N020161 001** Nov 30, 1992

POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER

AP + BAXTER HLTHCARE 29.8MG/ML **N019904 002** Dec 26, 1989

AP + 1.49GM/100ML **N019904 006** Dec 17, 1990

AP + HOSPIRA 29.8MG/ML **N020161 006** Aug 11, 1998

AP 1.49GM/100ML **N020161 002** Nov 30, 1992

PRESCRIPTION DRUG PRODUCT LIST

POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>2.24GM/100ML</u>	<u>N019904 003</u>	Dec 26, 1989
<u>AP</u>	+	HOSPIRA	<u>2.24GM/100ML</u>	<u>N020161 003</u>	Aug 11, 1998

POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>2.98GM/100ML</u>	<u>N019904 004</u>	Dec 26, 1989
<u>AP</u>	+	HOSPIRA	<u>2.98GM/100ML</u>	<u>N020161 004</u>	Aug 11, 1998

POTASSIUM CHLORIDE IN PLASTIC CONTAINER

<u>AP</u>		FRESENIUS KABI USA	<u>2MEQ/ML</u>	<u>A088901 001</u>	Jan 25, 1985
<u>AP</u>		FRESENIUS KABI USA	<u>2MEQ/ML</u>	<u>A088908 001</u>	Jan 25, 1985

POTASSIUM CHLORIDE

+ FRESENIUS KABI USA 3MEQ/ML

A080225 003

SOLUTION; ORAL

POTASSIUM CHLORIDE

LEHIGH VALLEY 20MEQ/15ML

N206814 001 Dec 22, 2014

+ 40MEQ/15ML

N206814 002 Dec 22, 2014

TABLET, EXTENDED RELEASE; ORAL

KLOR-CON M10

<u>AB1</u>		UPSHER SMITH LABS	<u>10MEQ</u>	<u>A074726 002</u>	Aug 09, 2000
------------	--	-------------------	--------------	--------------------	--------------

KLOR-CON M20

<u>AB1</u>	+	UPSHER SMITH LABS	<u>20MEQ</u>	<u>A074726 001</u>	Nov 20, 1998
------------	---	-------------------	--------------	--------------------	--------------

POTASSIUM CHLORIDE

<u>AB1</u>		ACTAVIS LABS FL INC	<u>10MEQ</u>	<u>A075604 001</u>	Apr 10, 2002
------------	--	---------------------	--------------	--------------------	--------------

<u>AB1</u>			<u>20MEQ</u>	<u>A075604 002</u>	Apr 10, 2002
------------	--	--	--------------	--------------------	--------------

<u>AB1</u>		ADARE PHARMS INC	<u>20MEQ</u>	<u>A076368 001</u>	Aug 18, 2004
------------	--	------------------	--------------	--------------------	--------------

<u>AB1</u>		GLENMARK PHARMS LTD	<u>10MEQ</u>	<u>A203562 001</u>	Jul 26, 2016
------------	--	---------------------	--------------	--------------------	--------------

<u>AB1</u>			<u>20MEQ</u>	<u>A203562 002</u>	Jul 26, 2016
------------	--	--	--------------	--------------------	--------------

<u>AB1</u>		NOVEL LABS INC	<u>10MEQ</u>	<u>A206347 001</u>	Jan 21, 2016
------------	--	----------------	--------------	--------------------	--------------

<u>AB1</u>			<u>20MEQ</u>	<u>A206347 002</u>	Jan 21, 2016
------------	--	--	--------------	--------------------	--------------

KLOR-CON

<u>AB2</u>		UPSHER-SMITH LABS	<u>8MEQ</u>	<u>N019123 001</u>	Apr 17, 1986
------------	--	-------------------	-------------	--------------------	--------------

<u>AB2</u>	+		<u>10MEQ</u>	<u>N019123 002</u>	Apr 17, 1986
------------	---	--	--------------	--------------------	--------------

POTASSIUM CHLORIDE

<u>AB2</u>		MYLAN PHARMS INC	<u>8MEQ</u>	<u>A204662 001</u>	Aug 21, 2014
------------	--	------------------	-------------	--------------------	--------------

<u>AB2</u>			<u>10MEQ</u>	<u>A204662 002</u>	Aug 21, 2014
------------	--	--	--------------	--------------------	--------------

<u>AB2</u>		NOVEL LABS INC	<u>8MEQ</u>	<u>A206759 001</u>	Aug 09, 2016
------------	--	----------------	-------------	--------------------	--------------

<u>AB2</u>			<u>10MEQ</u>	<u>A206759 002</u>	Aug 09, 2016
------------	--	--	--------------	--------------------	--------------

<u>AB2</u>		PADDOCK LLC	<u>8MEQ</u>	<u>A205993 001</u>	Nov 05, 2015
------------	--	-------------	-------------	--------------------	--------------

<u>AB2</u>			<u>10MEQ</u>	<u>A205993 002</u>	Nov 05, 2015
------------	--	--	--------------	--------------------	--------------

<u>AB2</u>		SIGMAPHARM LABS LLC	<u>8MEQ</u>	<u>A207528 001</u>	Aug 19, 2016
------------	--	---------------------	-------------	--------------------	--------------

<u>AB2</u>			<u>10MEQ</u>	<u>A207528 002</u>	Aug 19, 2016
------------	--	--	--------------	--------------------	--------------

K-TAB

BC		ABBVIE	8MEQ	N018279 002	Aug 01, 1988
----	--	--------	------	-------------	--------------

BC			10MEQ	N018279 001	
----	--	--	-------	-------------	--

BC	+		20MEQ	N018279 003	Nov 25, 2013
----	---	--	-------	-------------	--------------

KLOR-CON M15

UPSHER SMITH LABS 15MEQ

A074726 003 Jun 06, 2003

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

<u>AP</u>		HOSPIRA	<u>149MG/100ML; 450MG/100ML</u>	<u>A078446 001</u>	Sep 10, 2008
-----------	--	---------	---------------------------------	--------------------	--------------

POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>150MG/100ML; 450MG/100ML</u>	<u>N017648 005</u>	Nov 26, 2002
-----------	---	-----------------	---------------------------------	--------------------	--------------

POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>		B BRAUN	<u>150MG/100ML; 900MG/100ML</u>	<u>N019708 004</u>	Sep 29, 1989
-----------	--	---------	---------------------------------	--------------------	--------------

<u>AP</u>		BAXTER HLTHCARE	<u>150MG/100ML; 900MG/100ML</u>	<u>N017648 001</u>	
-----------	--	-----------------	---------------------------------	--------------------	--

POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>		BAXTER HLTHCARE	<u>300MG/100ML; 900MG/100ML</u>	<u>N017648 002</u>	
-----------	--	-----------------	---------------------------------	--------------------	--

POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>		HOSPIRA	<u>149MG/100ML; 900MG/100ML</u>	<u>N019686 001</u>	Oct 17, 1988
-----------	--	---------	---------------------------------	--------------------	--------------

POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>		HOSPIRA	<u>298MG/100ML; 900MG/100ML</u>	<u>N019686 002</u>	Oct 17, 1988
-----------	--	---------	---------------------------------	--------------------	--------------

POTASSIUM CHLORIDE 0.224% IN SODIUM CHLORIDE 0.9%

BAXTER HLTHCARE 224MG/100ML; 900MG/100ML

N017648 003

PRESCRIPTION DRUG PRODUCT LIST

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CITRATE

<u>AB</u>	COREPHARMA	<u>5MEQ</u>	<u>A077440 001</u>	Jun 09, 2006
<u>AB</u>		<u>10MEQ</u>	<u>A077440 002</u>	Jun 09, 2006
<u>AB</u>	ZYDUS PHARMS USA INC	<u>5MEQ</u>	<u>A203546 001</u>	Aug 06, 2014
<u>AB</u>		<u>10MEQ</u>	<u>A203546 002</u>	Aug 06, 2014
<u>AB</u>		<u>15MEQ</u>	<u>A203546 003</u>	Aug 06, 2014
<u>UROCI-T-K</u>				
<u>AB</u>	MISSION PHARMA	<u>5MEQ</u>	<u>N019071 001</u>	Aug 30, 1985
<u>AB</u>		<u>10MEQ</u>	<u>N019071 002</u>	Aug 31, 1992
<u>AB</u>	+	<u>15MEQ</u>	<u>N019071 003</u>	Dec 30, 2009

POVIDONE-IODINE

SOLUTION/DROPS;OPHTHALMIC

BETADINE

+ ALCON PHARMS LTD 5% N018634 001 Dec 17, 1986

PRALATREXATE

SOLUTION;INTRAVENOUS

FOLOTYN

ALLOS 20MG/ML (20MG/ML) N022468 001 Sep 24, 2009
+ 40MG/2ML (20MG/ML) N022468 002 Sep 24, 2009PRALIDOXIME CHLORIDE

INJECTABLE;INJECTION

PRALIDOXIME CHLORIDE

+ MERIDIAN MEDCL TECHN 300MG/ML N018986 001 Apr 26, 1983

PROTOPAM CHLORIDE

+ BAXTER HLTHCARE CORP 1GM/VIAL N014134 001

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

MIRAPEX

<u>AB</u>	BOEHRINGER INGELHEIM	<u>0.125MG</u>	<u>N020667 001</u>	Jul 01, 1997
<u>AB</u>	+	<u>0.25MG</u>	<u>N020667 002</u>	Jul 01, 1997
<u>AB</u>		<u>0.5MG</u>	<u>N020667 006</u>	Feb 12, 1998
<u>AB</u>		<u>0.75MG</u>	<u>N020667 007</u>	Jul 30, 2007
<u>AB</u>		<u>1MG</u>	<u>N020667 003</u>	Jul 01, 1997
<u>AB</u>		<u>1.5MG</u>	<u>N020667 005</u>	Jul 01, 1997

PRAMIPEXOLE DIHYDROCHLORIDE

<u>AB</u>	ACTAVIS GRP PTC	<u>0.125MG</u>	<u>A091254 001</u>	Nov 30, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A091254 002</u>	Nov 30, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A091254 003</u>	Nov 30, 2010
<u>AB</u>		<u>0.75MG</u>	<u>A091254 004</u>	Nov 30, 2010
<u>AB</u>		<u>1MG</u>	<u>A091254 005</u>	Nov 30, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A091254 006</u>	Nov 30, 2010
<u>AB</u>	ALEMBIC LTD	<u>0.125MG</u>	<u>A078894 001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A078894 002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A078894 003</u>	Oct 08, 2010
<u>AB</u>		<u>1MG</u>	<u>A078894 004</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A078894 005</u>	Oct 08, 2010
<u>AB</u>	APOTEX INC	<u>0.125MG</u>	<u>A090151 001</u>	Apr 30, 2012
<u>AB</u>		<u>0.25MG</u>	<u>A090151 002</u>	Apr 30, 2012
<u>AB</u>		<u>0.5MG</u>	<u>A090151 003</u>	Apr 30, 2012
<u>AB</u>		<u>0.75MG</u>	<u>A090151 006</u>	Apr 30, 2012
<u>AB</u>		<u>1MG</u>	<u>A090151 004</u>	Apr 30, 2012
<u>AB</u>		<u>1.5MG</u>	<u>A090151 005</u>	Apr 30, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>0.125MG</u>	<u>A202633 001</u>	Oct 26, 2012
<u>AB</u>		<u>0.25MG</u>	<u>A202633 002</u>	Oct 26, 2012
<u>AB</u>		<u>0.5MG</u>	<u>A202633 003</u>	Oct 26, 2012
<u>AB</u>		<u>0.75MG</u>	<u>A202633 004</u>	Oct 26, 2012
<u>AB</u>		<u>1MG</u>	<u>A202633 005</u>	Oct 26, 2012
<u>AB</u>		<u>1.5MG</u>	<u>A202633 006</u>	Oct 26, 2012
<u>AB</u>	BARR	<u>0.125MG</u>	<u>A077724 001</u>	Feb 19, 2008
<u>AB</u>		<u>0.25MG</u>	<u>A077724 002</u>	Feb 19, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A077724 003</u>	Feb 19, 2008
<u>AB</u>		<u>1MG</u>	<u>A077724 004</u>	Feb 19, 2008
<u>AB</u>		<u>1.5MG</u>	<u>A077724 005</u>	Feb 19, 2008
<u>AB</u>	BRECKENRIDGE PHARM	<u>0.125MG</u>	<u>A091450 001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A091450 002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A091450 003</u>	Oct 08, 2010
<u>AB</u>		<u>1MG</u>	<u>A091450 004</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A091450 005</u>	Oct 08, 2010

PRESCRIPTION DRUG PRODUCT LIST

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

<u>AB</u>	GLENMARK GENERICS	<u>0.125MG</u>	<u>A090781 001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A090781 002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090781 003</u>	Oct 08, 2010
<u>AB</u>		<u>0.75MG</u>	<u>A090781 006</u>	Sep 11, 2015
<u>AB</u>		<u>1MG</u>	<u>A090781 004</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A090781 005</u>	Oct 08, 2010
<u>AB</u>	MACLEODS PHARMS LTD	<u>0.125MG</u>	<u>A202164 001</u>	Sep 20, 2012
<u>AB</u>		<u>0.25MG</u>	<u>A202164 002</u>	Sep 20, 2012
<u>AB</u>		<u>0.5MG</u>	<u>A202164 003</u>	Sep 20, 2012
<u>AB</u>		<u>1MG</u>	<u>A202164 004</u>	Sep 20, 2012
<u>AB</u>		<u>1.5MG</u>	<u>A202164 005</u>	Sep 20, 2012
<u>AB</u>	MYLAN	<u>0.125MG</u>	<u>A077854 001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A077854 002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A077854 003</u>	Oct 08, 2010
<u>AB</u>		<u>0.75MG</u>	<u>A090764 001</u>	Apr 09, 2010
<u>AB</u>		<u>1MG</u>	<u>A077854 004</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A077854 005</u>	Oct 08, 2010
<u>AB</u>	SANDOZ	<u>0.125MG</u>	<u>A090190 001</u>	Jul 06, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A090190 002</u>	Jul 06, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090190 003</u>	Jul 06, 2010
<u>AB</u>		<u>0.75MG</u>	<u>A090190 006</u>	Oct 08, 2010
<u>AB</u>		<u>1MG</u>	<u>A090190 004</u>	Jul 06, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A090190 005</u>	Jul 06, 2010
<u>AB</u>	SCIEGEN PHARMS INC	<u>0.125MG</u>	<u>A203855 001</u>	Oct 28, 2014
<u>AB</u>		<u>0.25MG</u>	<u>A203855 002</u>	Oct 28, 2014
<u>AB</u>		<u>0.5MG</u>	<u>A203855 003</u>	Oct 28, 2014
<u>AB</u>		<u>0.75MG</u>	<u>A203855 004</u>	Oct 28, 2014
<u>AB</u>		<u>1MG</u>	<u>A203855 005</u>	Oct 28, 2014
<u>AB</u>		<u>1.5MG</u>	<u>A203855 006</u>	Oct 28, 2014
<u>AB</u>	STRIDES PHARMA	<u>0.125MG</u>	<u>A202702 001</u>	Jun 03, 2014
<u>AB</u>		<u>0.25MG</u>	<u>A202702 002</u>	Jun 03, 2014
<u>AB</u>		<u>0.5MG</u>	<u>A202702 003</u>	Jun 03, 2014
<u>AB</u>		<u>0.75MG</u>	<u>A202702 004</u>	Jun 03, 2014
<u>AB</u>		<u>1MG</u>	<u>A202702 005</u>	Jun 03, 2014
<u>AB</u>		<u>1.5MG</u>	<u>A202702 006</u>	Jun 03, 2014
<u>AB</u>	SUN PHARM INDS INC	<u>0.125MG</u>	<u>A091683 001</u>	Mar 27, 2013
<u>AB</u>		<u>0.25MG</u>	<u>A091683 002</u>	Mar 27, 2013
<u>AB</u>		<u>0.5MG</u>	<u>A091683 003</u>	Mar 27, 2013
<u>AB</u>		<u>0.75MG</u>	<u>A091683 004</u>	Mar 27, 2013
<u>AB</u>		<u>1MG</u>	<u>A091683 005</u>	Mar 27, 2013
<u>AB</u>		<u>1.5MG</u>	<u>A091683 006</u>	Mar 27, 2013
<u>AB</u>	TEVA PHARMS	<u>0.125MG</u>	<u>A090241 001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A090241 002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090241 003</u>	Oct 08, 2010
<u>AB</u>		<u>0.75MG</u>	<u>A090241 004</u>	Oct 08, 2010
<u>AB</u>		<u>1MG</u>	<u>A090241 005</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A090241 006</u>	Oct 08, 2010
<u>AB</u>	TORRENT PHARMS	<u>0.125MG</u>	<u>A090865 001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A090865 002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090865 003</u>	Oct 08, 2010
<u>AB</u>		<u>0.75MG</u>	<u>A090865 004</u>	Oct 08, 2010
<u>AB</u>		<u>1MG</u>	<u>A090865 005</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A090865 006</u>	Oct 08, 2010
<u>AB</u>	ZYDUS PHARMS USA INC	<u>0.125MG</u>	<u>A078920 001</u>	Jul 06, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A078920 002</u>	Jul 06, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A078920 003</u>	Jul 06, 2010
<u>AB</u>		<u>1MG</u>	<u>A078920 004</u>	Jul 06, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A078920 005</u>	Jul 06, 2010
TABLET, EXTENDED RELEASE; ORAL				
<u>MIRAPEX ER</u>				
<u>AB</u>	+ BOEHRINGER INGELHEIM	<u>0.375MG</u>	<u>N022421 001</u>	Feb 19, 2010
<u>AB</u>		<u>0.75MG</u>	<u>N022421 002</u>	Feb 19, 2010
<u>AB</u>		<u>1.5MG</u>	<u>N022421 003</u>	Feb 19, 2010
<u>AB</u>		<u>2.25MG</u>	<u>N022421 006</u>	Jun 17, 2011
<u>AB</u>		<u>3MG</u>	<u>N022421 004</u>	Feb 19, 2010
<u>AB</u>		<u>3.75MG</u>	<u>N022421 007</u>	Jun 17, 2011
<u>AB</u>		<u>4.5MG</u>	<u>N022421 005</u>	Feb 19, 2010
<u>PRAMIPEXOLE DIHYDROCHLORIDE</u>				
<u>AB</u>	ACTAVIS ELIZABETH	<u>0.375MG</u>	<u>A201963 001</u>	Apr 21, 2016

PRESCRIPTION DRUG PRODUCT LIST

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

<u>AB</u>		<u>0.75MG</u>	<u>A201963 002</u>	Apr 21, 2016
<u>AB</u>		<u>1.5MG</u>	<u>A201963 003</u>	Apr 21, 2016
<u>AB</u>		<u>2.25MG</u>	<u>A203615 001</u>	Oct 14, 2016
<u>AB</u>		<u>3MG</u>	<u>A201963 004</u>	Apr 21, 2016
<u>AB</u>		<u>3.75MG</u>	<u>A203615 002</u>	Jan 03, 2017
<u>AB</u>		<u>4.5MG</u>	<u>A201963 005</u>	Apr 21, 2016
<u>AB</u>	ANCHEN PHARMS	<u>0.375MG</u>	<u>A202206 001</u>	Feb 06, 2014
<u>AB</u>		<u>0.75MG</u>	<u>A202206 002</u>	Feb 06, 2014
<u>AB</u>		<u>1.5MG</u>	<u>A202206 003</u>	Feb 06, 2014
<u>AB</u>		<u>2.25MG</u>	<u>A202206 004</u>	Feb 06, 2014
<u>AB</u>		<u>3MG</u>	<u>A202206 005</u>	Feb 06, 2014
<u>AB</u>		<u>3.75MG</u>	<u>A202206 006</u>	Feb 06, 2014
<u>AB</u>		<u>4.5MG</u>	<u>A202206 007</u>	Feb 06, 2014
<u>AB</u>	DR REDDYS LABS LTD	<u>0.375MG</u>	<u>A203354 001</u>	Aug 07, 2015
<u>AB</u>		<u>0.75MG</u>	<u>A203354 002</u>	Aug 07, 2015
<u>AB</u>		<u>1.5MG</u>	<u>A203354 003</u>	Aug 07, 2015
<u>AB</u>		<u>3MG</u>	<u>A203354 004</u>	Aug 07, 2015
<u>AB</u>		<u>4.5MG</u>	<u>A203354 005</u>	Aug 07, 2015
<u>AB</u>	MACLEODS PHARMS LTD	<u>0.375MG</u>	<u>A206156 001</u>	Jun 24, 2016
<u>AB</u>		<u>0.75MG</u>	<u>A206156 002</u>	Jun 24, 2016
<u>AB</u>		<u>1.5MG</u>	<u>A206156 003</u>	Jun 24, 2016
<u>AB</u>		<u>2.25MG</u>	<u>A206156 004</u>	Jun 24, 2016
<u>AB</u>		<u>3MG</u>	<u>A206156 005</u>	Jun 24, 2016
<u>AB</u>		<u>4.5MG</u>	<u>A206156 007</u>	Jun 24, 2016
<u>AB</u>	SANDOZ INC	<u>0.375MG</u>	<u>A202353 001</u>	Dec 04, 2014
<u>AB</u>		<u>0.75MG</u>	<u>A202353 002</u>	Dec 04, 2014
<u>AB</u>		<u>1.5MG</u>	<u>A202353 003</u>	Dec 04, 2014
<u>AB</u>		<u>3MG</u>	<u>A202353 004</u>	Dec 04, 2014
<u>AB</u>		<u>4.5MG</u>	<u>A202353 005</u>	Dec 04, 2014

PRAMLINTIDE ACETATE

INJECTABLE;SUBCUTANEOUS

SYMLIN

+ ASTRAZENECA AB

EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML)

N021332 002 Sep 25, 2007

+

EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)

N021332 003 Sep 25, 2007

PRASTERONE

INSERT;VAGINAL

INTRAROSA

+ ENDOCEUTICS INC

6.5MG

N208470 001 Nov 16, 2016

PRASUGREL HYDROCHLORIDE

TABLET;ORAL

EFFIENT

+ ELI LILLY AND CO

EQ 5MG BASE

N022307 001 Jul 10, 2009

+

EQ 10MG BASE

N022307 002 Jul 10, 2009

PRAVASTATIN SODIUM

TABLET;ORAL

PRAVACHOL

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>20MG</u>	<u>N019898 003</u>	Oct 31, 1991
<u>AB</u>		<u>40MG</u>	<u>N019898 004</u>	Mar 22, 1993
<u>AB</u>	+	<u>80MG</u>	<u>N019898 008</u>	Dec 18, 2001

PRAVASTATIN SODIUM

<u>AB</u>	ACCORD HLTHCARE	<u>10MG</u>	<u>A207068 001</u>	Nov 17, 2016
<u>AB</u>		<u>20MG</u>	<u>A207068 002</u>	Nov 17, 2016
<u>AB</u>		<u>40MG</u>	<u>A207068 003</u>	Nov 17, 2016
<u>AB</u>		<u>80MG</u>	<u>A207068 004</u>	Nov 17, 2016
<u>AB</u>	APOTEX INC	<u>10MG</u>	<u>A076341 001</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076341 002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076341 003</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A076341 004</u>	Dec 28, 2007
<u>AB</u>	CIPLA LTD	<u>10MG</u>	<u>A077904 001</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A077904 002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A077904 003</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A077904 004</u>	Mar 22, 2016
<u>AB</u>	DR REDDYS LABS INC	<u>10MG</u>	<u>A076714 001</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076714 002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076714 003</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A076714 004</u>	Dec 28, 2007
<u>AB</u>	GLENMARK GENERICS	<u>10MG</u>	<u>A077987 001</u>	May 11, 2007

PRESCRIPTION DRUG PRODUCT LIST

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVASTATIN SODIUM

<u>AB</u>		<u>20MG</u>	<u>A077987 002</u>	May 11, 2007
<u>AB</u>		<u>40MG</u>	<u>A077987 003</u>	May 11, 2007
<u>AB</u>		<u>80MG</u>	<u>A077987 004</u>	Dec 28, 2007
<u>AB</u>	LUPIN PHARMS	<u>10MG</u>	<u>A077917 001</u>	Jan 08, 2008
<u>AB</u>		<u>20MG</u>	<u>A077917 002</u>	Jan 08, 2008
<u>AB</u>		<u>40MG</u>	<u>A077917 003</u>	Jan 08, 2008
<u>AB</u>		<u>80MG</u>	<u>A077917 004</u>	Jan 08, 2008
<u>AB</u>	MYLAN PHARMS INC	<u>10MG</u>	<u>A079187 001</u>	May 27, 2010
<u>AB</u>		<u>20MG</u>	<u>A079187 002</u>	May 27, 2010
<u>AB</u>		<u>40MG</u>	<u>A079187 003</u>	May 27, 2010
<u>AB</u>		<u>80MG</u>	<u>A079187 004</u>	May 27, 2010
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A076397 003</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076397 002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076397 001</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A077491 001</u>	Feb 11, 2008
<u>AB</u>	TEVA	<u>10MG</u>	<u>A076056 001</u>	Apr 24, 2006
<u>AB</u>		<u>20MG</u>	<u>A076056 002</u>	Apr 24, 2006
<u>AB</u>		<u>40MG</u>	<u>A076056 003</u>	Apr 24, 2006
<u>AB</u>	TEVA PHARMS	<u>80MG</u>	<u>A077793 001</u>	Jan 15, 2008
<u>AB</u>	WATSON LABS	<u>10MG</u>	<u>A076939 004</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076939 003</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076939 002</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A076939 001</u>	Dec 28, 2007
<u>AB</u>	ZYDUS PHARMS USA	<u>10MG</u>	<u>A077751 001</u>	Apr 30, 2008
<u>AB</u>		<u>20MG</u>	<u>A077751 002</u>	Apr 30, 2008
<u>AB</u>		<u>40MG</u>	<u>A077751 003</u>	Apr 30, 2008
<u>AB</u>		<u>80MG</u>	<u>A077751 004</u>	Apr 30, 2008

PRAZIOUANTEL

TABLET; ORAL

BILTRICIDE

+ BAYER HLTHCARE

600MG

N018714 001 Dec 29, 1982

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

MINIPRESS

<u>AB</u>	PFIZER	<u>EQ 1MG BASE</u>	<u>N017442 002</u>	
<u>AB</u>	+	<u>EQ 2MG BASE</u>	<u>N017442 003</u>	
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>N017442 001</u>	

PRAZOSIN HYDROCHLORIDE

<u>AB</u>	MYLAN	<u>EQ 1MG BASE</u>	<u>A072575 003</u>	May 16, 1989
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A072575 002</u>	May 16, 1989
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A072575 001</u>	May 16, 1989
<u>AB</u>	TEVA PHARMS	<u>EQ 1MG BASE</u>	<u>A071745 002</u>	Sep 12, 1988
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A071745 003</u>	Sep 12, 1988
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A071745 001</u>	Sep 12, 1988

PREDNICARBATE

CREAM; TOPICAL

DERMATOP E EMOLLIENT

<u>AB</u>	+	VALEANT BERMUDA	<u>0.1%</u>	<u>N020279 001</u>	Oct 29, 1993
<u>AB</u>		FOUGERA PHARMS	<u>0.1%</u>	<u>A077287 001</u>	Sep 19, 2006
<u>AB</u>	+	VALEANT PHARMS NORTH	<u>0.1%</u>	<u>N019568 001</u>	Sep 23, 1991
<u>AB</u>		FOUGERA PHARMS	<u>0.1%</u>	<u>A077236 001</u>	Mar 09, 2007

PREDNISOLONE

SYRUP; ORAL

PREDNISOLONE

<u>AA</u>	ALPHARMA	<u>15MG/5ML</u>	<u>A040323 001</u>	May 13, 1999	
<u>AA</u>	+	HI TECH PHARMA CO	<u>15MG/5ML</u>	<u>A040401 001</u>	Feb 27, 2003
<u>AA</u>	PHARM ASSOC	<u>15MG/5ML</u>	<u>A040399 001</u>	Mar 05, 2003	
<u>AA</u>	VINTAGE	<u>15MG/5ML</u>	<u>A040775 001</u>	Sep 21, 2007	
<u>AA</u>	WOCKHARDT	<u>15MG/5ML</u>	<u>A040313 001</u>	Sep 10, 2003	
<u>AA</u>	TEVA	<u>15MG/5ML</u>	<u>A089081 001</u>	Feb 04, 1986	

PRESCRIPTION DRUG PRODUCT LIST

PREDNISOLONE

TABLET; ORAL

PREDNISOLONE

+ WATSON LABS

5MG

A080354 001

PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

OMNIPRED**AB** NOVARTIS PHARMS CORP **1%****N017469 001**PRED FORTE**AB** + ALLERGAN **1%****N017011 001**

PRED MILD

+ ALLERGAN

0.12%

N017100 001

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

BLEPHAMIDE S.O.P.

+ ALLERGAN

0.2%;10%

A087748 001 Dec 03, 1986

SUSPENSION; OPHTHALMIC

BLEPHAMIDE

+ ALLERGAN

0.2%;10%

N012813 002

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PEDIAAPRED**AA** + SETON PHARM **EQ 5MG BASE/5ML****N019157 001** May 28, 1986PREDNISOLONE SODIUM PHOSPHATE**AA** AMNEAL PHARMS **EQ 15MG BASE/5ML****A078345 001** Mar 10, 2009**AA** EDENBRIDGE PHARMS **EQ 10MG BASE/5ML****A203559 001** Dec 20, 2016**AA** **EQ 20MG BASE/5ML****A203559 002** Dec 20, 2016**AA** HI TECH PHARMA **EQ 5MG BASE/5ML****A075183 001** Mar 26, 2003**AA** PADDOCK LLC **EQ 5MG BASE/5ML****A075988 001** May 25, 2004**AA** + PHARM ASSOC **EQ 10MG BASE/5ML****A078465 001** Mar 07, 2008**AA** **EQ 15MG BASE/5ML****A076913 001** Apr 25, 2005**AA** + **EQ 20MG BASE/5ML****A078988 001** Jun 09, 2008**AA** VINTAGE **EQ 15MG BASE/5ML****A079010 001** May 26, 2009**AA** WOCKHARDT **EQ 5MG BASE/5ML****A075099 001** Jun 28, 2002**AA** + **EQ 15MG BASE/5ML****A076895 001** Oct 04, 2004

+ MISSION PHARMA

EQ 25MG BASE/5ML

A091396 001 Sep 13, 2010

SOLUTION/DROPS; OPHTHALMIC

PREDNISOLONE SODIUM PHOSPHATE

+ BAUSCH AND LOMB

EQ 0.9% PHOSPHATE

A040070 001 Jul 29, 1994

TABLET, ORALLY DISINTEGRATING; ORAL

ORAPRED ODT**AB** CONCORDIA PHARMS INC **EQ 10MG BASE****N021959 001** Jun 01, 2006**AB** **EQ 15MG BASE****N021959 002** Jun 01, 2006**AB** + **EQ 30MG BASE****N021959 003** Jun 01, 2006PREDNISOLONE SODIUM PHOSPHATE**AB** MYLAN PHARMS INC **EQ 10MG BASE****A202179 001** Apr 10, 2013**AB** **EQ 15MG BASE****A202179 002** Apr 10, 2013**AB** **EQ 30MG BASE****A202179 003** Apr 10, 2013PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE**AT** ALCON PHARMS LTD **EQ 0.23% PHOSPHATE;10%****A073630 001** May 27, 1993**AT** + BAUSCH AND LOMB **EQ 0.23% PHOSPHATE;10%****A074449 001** Dec 29, 1995PREDNISON

SOLUTION; ORAL

PREDNISON

+ WEST-WARD PHARMS INT

5MG/5ML

A088703 001 Nov 08, 1984

PREDNISON INTENSOL

+ WEST-WARD PHARMS INT

5MG/ML

A088810 001 Feb 20, 1985

TABLET; ORAL

PREDNISON**AB** CONTRACT PHARMACAL **5MG****A080209 001****AB** DELCOR ASSET CORP **5MG****A080292 001****AB** **10MG****A088832 001** Dec 04, 1985**AB** **20MG****A083677 001****AB** HIKMA PHARMS **2.5MG****A040538 001** Jan 08, 2004**AB** **50MG****A088465 001** Jun 01, 1984**AB** JUBILANT CADISTA **1MG****A040611 001** Jun 06, 2005**AB** **5MG****A040362 002** Aug 29, 2001**AB** **10MG****A040362 001** Aug 29, 2001

PRESCRIPTION DRUG PRODUCT LIST

PREDNISONE

TABLET; ORAL

PREDNISONE

<u>AB</u>		<u>20MG</u>	<u>A040362</u>	<u>003</u>	Jun 29, 2005
<u>AB</u>	MUTUAL PHARM	<u>5MG</u>	<u>A089245</u>	<u>001</u>	Dec 04, 1985
<u>AB</u>		<u>10MG</u>	<u>A089246</u>	<u>001</u>	Dec 04, 1985
<u>AB</u>	SUN PHARM INDS	<u>20MG</u>	<u>A089247</u>	<u>001</u>	Dec 04, 1985
<u>AB</u>	VINTAGE PHARMS	<u>1MG</u>	<u>A040584</u>	<u>001</u>	Dec 21, 2004
<u>AB</u>		<u>2.5MG</u>	<u>A040581</u>	<u>001</u>	Dec 21, 2004
<u>AB</u>		<u>5MG</u>	<u>A040256</u>	<u>001</u>	Jul 12, 2002
<u>AB</u>		<u>10MG</u>	<u>A040256</u>	<u>002</u>	Jul 12, 2002
<u>AB</u>		<u>20MG</u>	<u>A040392</u>	<u>001</u>	Feb 12, 2003
<u>AB</u>	WATSON LABS	<u>5MG</u>	<u>A080356</u>	<u>001</u>	
<u>AB</u>		<u>10MG</u>	<u>A085162</u>	<u>001</u>	
<u>AB</u>		<u>20MG</u>	<u>A085161</u>	<u>001</u>	
<u>AB</u>	+ WEST-WARD PHARMS INT	<u>1MG</u>	<u>A087800</u>	<u>001</u>	Apr 22, 1982
<u>AB</u>	+	<u>2.5MG</u>	<u>A087801</u>	<u>001</u>	Apr 22, 1982
<u>AB</u>	+	<u>5MG</u>	<u>A080352</u>	<u>001</u>	
<u>AB</u>	+	<u>10MG</u>	<u>A084122</u>	<u>001</u>	
<u>AB</u>	+	<u>20MG</u>	<u>A087342</u>	<u>001</u>	
<u>AB</u>	+	<u>50MG</u>	<u>A084283</u>	<u>001</u>	

TABLET, DELAYED RELEASE; ORAL
RAYOS

	HORIZON PHARMA	1MG	N202020	001	Jul 26, 2012
		2MG	N202020	002	Jul 26, 2012
	+	5MG	N202020	003	Jul 26, 2012

PREGABALIN

CAPSULE; ORAL

LYRICA

	PF PRISM CV	25MG	N021446	001	Dec 30, 2004
		50MG	N021446	002	Dec 30, 2004
		75MG	N021446	003	Dec 30, 2004
		100MG	N021446	004	Dec 30, 2004
		150MG	N021446	005	Dec 30, 2004
		200MG	N021446	006	Dec 30, 2004
		225MG	N021446	007	Dec 30, 2004
	+	300MG	N021446	008	Dec 30, 2004

SOLUTION; ORAL

LYRICA

	+ PF PRISM CV	20MG/ML	N022488	001	Jan 04, 2010
--	---------------	---------	---------	-----	--------------

PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

PRILOCAINE HYDROCHLORIDE

	+ SEPTODONT INC	4%	A079235	001	Sep 29, 2010
--	-----------------	----	---------	-----	--------------

PRIMAQUINE PHOSPHATE

TABLET; ORAL

PRIMAQUINE

<u>AB</u>	+ SANOFI AVENTIS US	<u>EQ 15MG BASE</u>	<u>N008316</u>	<u>001</u>	
<u>AB</u>	ALVOGEN INC	<u>EQ 15MG BASE</u>	<u>A203924</u>	<u>001</u>	Feb 03, 2014
<u>AB</u>	BAYSHORE PHARMS LLC	<u>EQ 15MG BASE</u>	<u>A204476</u>	<u>001</u>	Feb 25, 2014
<u>AB</u>	INGENUS PHARMS NJ	<u>EQ 15MG BASE</u>	<u>A206043</u>	<u>001</u>	Jun 23, 2016

PRIMIDONE

TABLET; ORAL

MYSOLINE

<u>AB</u>	+ VALEANT	<u>50MG</u>	<u>N009170</u>	<u>003</u>	
<u>AB</u>		<u>250MG</u>	<u>N009170</u>	<u>002</u>	

PRIMIDONE

<u>AB</u>	AMNEAL PHARM	<u>50MG</u>	<u>A040866</u>	<u>001</u>	Apr 23, 2008
<u>AB</u>		<u>250MG</u>	<u>A040866</u>	<u>002</u>	Apr 23, 2008
<u>AB</u>	FRONTIDA BIOPHARM	<u>50MG</u>	<u>A040626</u>	<u>001</u>	Sep 29, 2005
<u>AB</u>		<u>250MG</u>	<u>A040626</u>	<u>002</u>	Sep 29, 2005
<u>AB</u>	HIKMA INTL PHARMS	<u>250MG</u>	<u>A040667</u>	<u>002</u>	Jul 27, 2006
<u>AB</u>	LANNETT	<u>50MG</u>	<u>A084903</u>	<u>002</u>	May 24, 2001
<u>AB</u>		<u>250MG</u>	<u>A084903</u>	<u>001</u>	
<u>AB</u>	VINTAGE PHARMS	<u>50MG</u>	<u>A040586</u>	<u>001</u>	Feb 24, 2005
<u>AB</u>		<u>250MG</u>	<u>A040586</u>	<u>002</u>	Feb 24, 2005
<u>AB</u>	WATSON LABS	<u>250MG</u>	<u>A083551</u>	<u>001</u>	

PRESCRIPTION DRUG PRODUCT LIST

PROBENECID

TABLET; ORAL

PROBALAN

AB	LANNETT	500MG	A080966 001	
-----------	---------	--------------	--------------------	--

PROBENECID

AB	+ MYLAN	500MG	A084211 002	
-----------	---------	--------------	--------------------	--

AB	WATSON LABS	500MG	A084442 004	Mar 29, 1983
-----------	-------------	--------------	--------------------	--------------

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HYDROCHLORIDE

AP	+ HOSPIRA	100MG/ML	A089069 001	Feb 12, 1986
-----------	-----------	-----------------	--------------------	--------------

AP	INTL MEDICATION	100MG/ML	A088636 001	Jul 31, 1984
-----------	-----------------	-----------------	--------------------	--------------

	+ HOSPIRA	500MG/ML	A089070 001	Feb 12, 1986
--	-----------	----------	-------------	--------------

PROCARBAZINE HYDROCHLORIDE

CAPSULE; ORAL

MATULANE

	+ SIGMA TAU	EQ 50MG BASE	N016785 001	
--	-------------	--------------	-------------	--

PROCHLORPERAZINE

SUPPOSITORY; RECTAL

COMPRO

AB	PADDOCK LLC	25MG	A040246 001	Jun 28, 2000
-----------	-------------	-------------	--------------------	--------------

PROCHLORPERAZINE

AB	+ G AND W LABS	25MG	A040058 001	Nov 24, 1993
-----------	----------------	-------------	--------------------	--------------

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE

AP	+ EMCURE PHARMS LTD	EQ 5MG BASE/ML	A204147 001	Oct 15, 2013
-----------	---------------------	-----------------------	--------------------	--------------

AP	EUROHLTH INTL SARL	EQ 5MG BASE/ML	A089903 001	Aug 29, 1989
-----------	--------------------	-----------------------	--------------------	--------------

PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCHLORPERAZINE MALEATE

AB	MYLAN	EQ 5MG BASE	A040185 002	Oct 28, 1996
-----------	-------	--------------------	--------------------	--------------

AB		EQ 10MG BASE	A040185 001	Oct 28, 1996
-----------	--	---------------------	--------------------	--------------

AB	SANDOZ	EQ 5MG BASE	A040101 001	Jul 19, 1996
-----------	--------	--------------------	--------------------	--------------

AB	+	EQ 10MG BASE	A040101 002	Jul 19, 1996
-----------	---	---------------------	--------------------	--------------

AB	TEVA PHARMS	EQ 5MG BASE	A040120 001	Jul 11, 1996
-----------	-------------	--------------------	--------------------	--------------

AB		EQ 10MG BASE	A040120 002	Jul 11, 1996
-----------	--	---------------------	--------------------	--------------

PROCOMP

AB	JUBILANT CADISTA	EQ 5MG BASE	A040268 001	Feb 27, 1998
-----------	------------------	--------------------	--------------------	--------------

AB		EQ 10MG BASE	A040268 002	Feb 27, 1998
-----------	--	---------------------	--------------------	--------------

PROGESTERONE

CAPSULE; ORAL

PROGESTERONE

AB	BIONPHARMA INC	100MG	A200900 001	Aug 16, 2013
-----------	----------------	--------------	--------------------	--------------

AB		200MG	A200900 002	Aug 16, 2013
-----------	--	--------------	--------------------	--------------

AB	SOFGEN PHARMS	100MG	A200456 001	Sep 28, 2012
-----------	---------------	--------------	--------------------	--------------

AB		200MG	A200456 002	Sep 28, 2012
-----------	--	--------------	--------------------	--------------

AB	TEVA PHARMS	100MG	A202121 001	Feb 29, 2012
-----------	-------------	--------------	--------------------	--------------

AB		200MG	A202121 002	Feb 29, 2012
-----------	--	--------------	--------------------	--------------

PROMETRIUM

AB	VIRTUS PHARMS	100MG	N019781 001	May 14, 1998
-----------	---------------	--------------	--------------------	--------------

AB	+	200MG	N019781 002	Oct 15, 1999
-----------	---	--------------	--------------------	--------------

GEL; VAGINAL

CRINONE

	+ ALLERGAN SALES LLC	4%	N020701 001	Jul 31, 1997
--	----------------------	----	-------------	--------------

	+	8%	N020701 002	Jul 31, 1997
--	---	----	-------------	--------------

INJECTABLE; INJECTION

PROGESTERONE

AO	+ ALLERGAN SALES LLC	50MG/ML	N017362 002	
-----------	----------------------	----------------	--------------------	--

AO	FRESENIUS KABI USA	50MG/ML	A075906 001	Apr 25, 2001
-----------	--------------------	----------------	--------------------	--------------

AO	HIKMA FARMACEUTICA	50MG/ML	A091033 001	Oct 28, 2010
-----------	--------------------	----------------	--------------------	--------------

AO	LUITPOLD	50MG/ML	A090845 001	Jun 22, 2009
-----------	----------	----------------	--------------------	--------------

INSERT; VAGINAL

ENDOMETRIN

	+ FERRING	100MG	N022057 001	Jun 21, 2007
--	-----------	-------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-330 (of 405)

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HYDROCHLORIDE

<u>AP</u>	+	EUROHLTH INTL SARL	<u>25MG/ML</u>	<u>A083312</u>	<u>001</u>	
<u>AP</u>	+		<u>50MG/ML</u>	<u>A083312</u>	<u>002</u>	
<u>AP</u>		X-GEN PHARMS	<u>25MG/ML</u>	<u>A040737</u>	<u>001</u>	Apr 24, 2008
<u>AP</u>			<u>50MG/ML</u>	<u>A040737</u>	<u>002</u>	Apr 24, 2008

SUPPOSITORY; RECTAL

PROMETHAZINE HYDROCHLORIDE

<u>AB</u>		G AND W LABS	<u>12.5MG</u>	<u>A040428</u>	<u>002</u>	Mar 31, 2003
<u>AB</u>	+		<u>25MG</u>	<u>A040428</u>	<u>001</u>	Feb 05, 2002
<u>AB</u>		PERRIGO NEW YORK	<u>12.5MG</u>	<u>A040500</u>	<u>001</u>	Jun 30, 2003
<u>AB</u>			<u>25MG</u>	<u>A040500</u>	<u>002</u>	Jun 30, 2003
<u>AB</u>		TARO	<u>12.5MG</u>	<u>A040603</u>	<u>001</u>	Oct 26, 2006
<u>AB</u>			<u>25MG</u>	<u>A040603</u>	<u>002</u>	Oct 26, 2006
<u>AB</u>		WATSON LABS INC	<u>12.5MG</u>	<u>A040479</u>	<u>001</u>	Jun 24, 2003
<u>AB</u>			<u>25MG</u>	<u>A040479</u>	<u>002</u>	Jun 24, 2003

PROMETHEGAN

+ G AND W LABS

50MG

A087165 001 Aug 14, 1987

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE

<u>AA</u>		AMNEAL PHARMS	<u>6.25MG/5ML</u>	<u>A040882</u>	<u>001</u>	Dec 30, 2009
<u>AA</u>		HI TECH PHARMA	<u>6.25MG/5ML</u>	<u>A040026</u>	<u>001</u>	Sep 25, 1998
<u>AA</u>		NOSTRUM LABS INC	<u>6.25MG/5ML</u>	<u>A040891</u>	<u>001</u>	Mar 13, 2009
<u>AA</u>		TARO	<u>6.25MG/5ML</u>	<u>A040718</u>	<u>001</u>	Apr 04, 2007
<u>AA</u>		TRIS PHARMA INC	<u>6.25MG/5ML</u>	<u>A091675</u>	<u>001</u>	Jun 28, 2012
<u>AA</u>		VINTAGE	<u>6.25MG/5ML</u>	<u>A040643</u>	<u>001</u>	Apr 26, 2006

PROMETHAZINE PLAIN

<u>AA</u>	+	WOCKHARDT	<u>6.25MG/5ML</u>	<u>A087953</u>	<u>001</u>	Nov 15, 1982
-----------	---	-----------	-------------------	----------------	------------	--------------

TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE

<u>AB</u>		AMNEAL PHARMS NY	<u>12.5MG</u>	<u>A091179</u>	<u>001</u>	Dec 13, 2010
<u>AB</u>			<u>25MG</u>	<u>A091179</u>	<u>002</u>	Dec 13, 2010
<u>AB</u>			<u>50MG</u>	<u>A091179</u>	<u>003</u>	Dec 13, 2010
<u>AB</u>		HERITAGE PHARMA	<u>12.5MG</u>	<u>A040673</u>	<u>001</u>	Mar 05, 2008
<u>AB</u>			<u>25MG</u>	<u>A040673</u>	<u>002</u>	Mar 05, 2008
<u>AB</u>			<u>50MG</u>	<u>A040673</u>	<u>003</u>	Mar 05, 2008
<u>AB</u>		KVK TECH	<u>12.5MG</u>	<u>A040712</u>	<u>002</u>	May 04, 2007
<u>AB</u>			<u>25MG</u>	<u>A040712</u>	<u>001</u>	Jul 31, 2006
<u>AB</u>			<u>50MG</u>	<u>A040712</u>	<u>003</u>	Jul 31, 2006
<u>AB</u>		MYLAN	<u>12.5MG</u>	<u>A091054</u>	<u>001</u>	Aug 30, 2011
<u>AB</u>			<u>25MG</u>	<u>A091054</u>	<u>002</u>	Aug 30, 2011
<u>AB</u>			<u>50MG</u>	<u>A091054</u>	<u>003</u>	Aug 30, 2011
<u>AB</u>		SANDOZ	<u>25MG</u>	<u>A084176</u>	<u>003</u>	
<u>AB</u>	+		<u>50MG</u>	<u>A084176</u>	<u>001</u>	
<u>AB</u>		SUN PHARM INDS INC	<u>12.5MG</u>	<u>A040863</u>	<u>001</u>	Dec 30, 2008
<u>AB</u>			<u>25MG</u>	<u>A040863</u>	<u>002</u>	Dec 30, 2008
<u>AB</u>			<u>50MG</u>	<u>A040863</u>	<u>003</u>	Dec 30, 2008
<u>AB</u>		VINTAGE PHARMS	<u>12.5MG</u>	<u>A040622</u>	<u>001</u>	Jul 18, 2006
<u>AB</u>			<u>25MG</u>	<u>A040622</u>	<u>002</u>	Jul 18, 2006
<u>AB</u>			<u>50MG</u>	<u>A040622</u>	<u>003</u>	Jul 18, 2006
<u>AB</u>		WATSON LABS	<u>25MG</u>	<u>A083426</u>	<u>001</u>	
<u>AB</u>			<u>50MG</u>	<u>A083711</u>	<u>001</u>	
<u>AB</u>		ZYDUS PHARMS USA	<u>12.5MG</u>	<u>A040596</u>	<u>001</u>	Nov 18, 2005
<u>AB</u>			<u>25MG</u>	<u>A040596</u>	<u>002</u>	Nov 18, 2005
<u>AB</u>			<u>50MG</u>	<u>A040596</u>	<u>003</u>	Nov 18, 2005

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPAFENONE HYDROCHLORIDE

<u>AB</u>		MYLAN PHARMS INC	<u>225MG</u>	<u>A203803</u>	<u>001</u>	Apr 29, 2016
<u>AB</u>			<u>325MG</u>	<u>A203803</u>	<u>002</u>	Apr 29, 2016
<u>AB</u>			<u>425MG</u>	<u>A203803</u>	<u>003</u>	Apr 29, 2016
<u>AB</u>		PAR PHARM	<u>225MG</u>	<u>A078540</u>	<u>001</u>	Oct 18, 2010
<u>AB</u>			<u>325MG</u>	<u>A078540</u>	<u>002</u>	Oct 18, 2010
<u>AB</u>			<u>425MG</u>	<u>A078540</u>	<u>003</u>	Oct 18, 2010
<u>AB</u>		WATSON LABS INC	<u>225MG</u>	<u>A202688</u>	<u>001</u>	Aug 24, 2015
<u>AB</u>			<u>325MG</u>	<u>A202688</u>	<u>002</u>	Aug 24, 2015
<u>AB</u>			<u>425MG</u>	<u>A202688</u>	<u>003</u>	Aug 24, 2015

RYTHMOL SR

<u>AB</u>		GLAXOSMITHKLINE LLC	<u>225MG</u>	<u>N021416</u>	<u>001</u>	Sep 04, 2003
<u>AB</u>			<u>325MG</u>	<u>N021416</u>	<u>002</u>	Sep 04, 2003
<u>AB</u>	+		<u>425MG</u>	<u>N021416</u>	<u>003</u>	Sep 04, 2003

PRESCRIPTION DRUG PRODUCT LIST

PROPAFENONE HYDROCHLORIDE

TABLET; ORAL

PROPAFENONE HYDROCHLORIDE

<u>AB</u>	ANI PHARMS INC	<u>150MG</u>	<u>A076550 001</u>	Apr 23, 2004
<u>AB</u>		<u>225MG</u>	<u>A076550 002</u>	Apr 23, 2004
<u>AB</u>		<u>300MG</u>	<u>A076550 003</u>	Apr 23, 2004
<u>AB</u>	ORION CORP ORION	<u>150MG</u>	<u>A202445 001</u>	May 11, 2016
<u>AB</u>		<u>225MG</u>	<u>A202445 002</u>	May 11, 2016
<u>AB</u>		<u>300MG</u>	<u>A202445 003</u>	May 11, 2016
<u>AB</u>	SUN PHARM INDS	<u>150MG</u>	<u>A075998 001</u>	Nov 29, 2001
<u>AB</u>		<u>225MG</u>	<u>A075998 002</u>	Nov 29, 2001
<u>AB</u>		<u>300MG</u>	<u>A075998 003</u>	Nov 29, 2001
<u>AB</u>	VINTAGE PHARMS	<u>150MG</u>	<u>A075938 001</u>	Oct 17, 2002
<u>AB</u>		<u>225MG</u>	<u>A075938 002</u>	Oct 17, 2002
<u>AB</u>		<u>300MG</u>	<u>A075938 003</u>	Oct 17, 2002
<u>AB</u>	WATSON LABS	<u>150MG</u>	<u>A075203 001</u>	Oct 24, 2000
<u>AB</u>		<u>225MG</u>	<u>A075203 002</u>	Oct 24, 2000

RYTHMOL

<u>AB</u>	GLAXOSMITHKLINE LLC	<u>150MG</u>	<u>N019151 001</u>	Nov 27, 1989
<u>AB</u>		<u>225MG</u>	<u>N019151 003</u>	Nov 20, 1992
<u>AB</u>	+	<u>300MG</u>	<u>N019151 002</u>	Nov 27, 1989

PROPANTHELINE BROMIDE

TABLET; ORAL

PROPANTHELINE BROMIDE

+ WEST-WARD PHARMS INT 15MG

A080927 002

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ALCAINE

<u>AT</u>	+	NOVARTIS PHARMS CORP	<u>0.5%</u>	<u>A080027 001</u>
-----------	---	----------------------	-------------	--------------------

PROPARACAINE HYDROCHLORIDE

<u>AT</u>	AKORN INC	<u>0.5%</u>	<u>A040277 001</u>	Mar 16, 2000
<u>AT</u>	BAUSCH AND LOMB	<u>0.5%</u>	<u>A040074 001</u>	Sep 29, 1995

PROPOFOL

INJECTABLE; INJECTION

DIPRIVAN

<u>AB</u>	+	FRESENIUS KABI USA	<u>10MG/ML</u>	<u>N019627 002</u>	Jun 11, 1996
-----------	---	--------------------	----------------	--------------------	--------------

PROPOFOL

<u>AB</u>	HOSPIRA	<u>10MG/ML</u>	<u>A077908 001</u>	Mar 17, 2006
<u>AB</u>	SAGENT PHARMS	<u>10MG/ML</u>	<u>A075102 001</u>	Jan 04, 1999
<u>AB</u>	WATSON LABS INC	<u>10MG/ML</u>	<u>A205307 001</u>	Dec 22, 2015

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

INDERAL LA

<u>AB</u>	ANI PHARMS INC	<u>60MG</u>	<u>N018553 004</u>	Mar 18, 1987
<u>AB</u>		<u>80MG</u>	<u>N018553 002</u>	Apr 19, 1983
<u>AB</u>		<u>120MG</u>	<u>N018553 003</u>	Apr 19, 1983
<u>AB</u>	+	<u>160MG</u>	<u>N018553 001</u>	Apr 19, 1983

PROPRANOLOL HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>60MG</u>	<u>A078494 001</u>	Aug 10, 2007
<u>AB</u>		<u>80MG</u>	<u>A078494 002</u>	Aug 10, 2007
<u>AB</u>		<u>120MG</u>	<u>A078494 003</u>	Aug 10, 2007
<u>AB</u>		<u>160MG</u>	<u>A078494 004</u>	Aug 10, 2007
<u>AB</u>	MYLAN	<u>60MG</u>	<u>A078022 001</u>	Feb 15, 2007
<u>AB</u>		<u>80MG</u>	<u>A078022 002</u>	Feb 15, 2007
<u>AB</u>		<u>120MG</u>	<u>A078022 003</u>	Feb 15, 2007
<u>AB</u>		<u>160MG</u>	<u>A078022 004</u>	Feb 15, 2007
<u>AB</u>	NORTEC DEV ASSOC	<u>60MG</u>	<u>A078065 001</u>	Jan 26, 2007
<u>AB</u>		<u>80MG</u>	<u>A078065 002</u>	Jan 26, 2007
<u>AB</u>		<u>120MG</u>	<u>A078065 003</u>	Jan 26, 2007
<u>AB</u>		<u>160MG</u>	<u>A078065 004</u>	Jan 26, 2007
<u>AB</u>	RP SCHERER	<u>60MG</u>	<u>A078703 001</u>	Jul 15, 2011
<u>AB</u>		<u>80MG</u>	<u>A078703 002</u>	Jul 15, 2011
<u>AB</u>		<u>120MG</u>	<u>A078703 003</u>	Jul 15, 2011
<u>AB</u>		<u>160MG</u>	<u>A078703 004</u>	Jul 15, 2011
<u>AB</u>	ZYDUS PHARMS USA INC	<u>60MG</u>	<u>A090321 001</u>	Mar 25, 2011
<u>AB</u>		<u>80MG</u>	<u>A090321 002</u>	Mar 25, 2011
<u>AB</u>		<u>120MG</u>	<u>A090321 003</u>	Mar 25, 2011
<u>AB</u>		<u>160MG</u>	<u>A090321 004</u>	Mar 25, 2011

INNOPRAN XL

BX	GLAXOSMITHKLINE LLC	80MG	N021438 001	Mar 12, 2003
----	---------------------	------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

INNOPRAN XL

BX		120MG	N021438	002	Mar 12, 2003
	PROPRANOLOL HYDROCHLORIDE				
BX	UPSHER SMITH	60MG	A078311	001	Mar 06, 2009
BX		80MG	A078311	002	Mar 06, 2009
BX		120MG	A078311	003	Mar 06, 2009
BX		160MG	A078311	004	Mar 06, 2009

INJECTABLE; INJECTION

PROPRANOLOL HYDROCHLORIDE

AP	AMPHASTAR PHARMS INC	1MG/ML	A075792	001	Aug 29, 2000
AP	+ BAXTER HLTHCARE CORP	1MG/ML	N016419	001	
AP	FRESENIUS KABI USA	1MG/ML	A075826	001	Aug 31, 2001
AP	HIKMA FARMACEUTICA	1MG/ML	A077760	001	Jan 31, 2008

SOLUTION; ORAL

HEMANGEOL

+ PIERRE FABRE DERMA

PROPRANOLOL HYDROCHLORIDE

+ WEST-WARD PHARMS INT

+

		4.28MG/ML	N205410	001	Mar 14, 2014
		20MG/5ML	A070979	001	May 15, 1987
		40MG/5ML	A070690	001	May 15, 1987

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

AB	IMPAX LABS INC	10MG	A071972	001	Apr 06, 1988
AB		20MG	A071973	001	Apr 06, 1988
AB		40MG	A071974	001	Apr 06, 1988
AB		60MG	A071975	001	Apr 06, 1988
AB	+	80MG	A071976	001	Apr 06, 1988
AB	IPCA LABS LTD	10MG	A078955	001	Jun 02, 2008
AB		20MG	A078955	002	Jun 02, 2008
AB		40MG	A078955	003	Jun 02, 2008
AB		60MG	A078955	004	Jun 02, 2008
AB		80MG	A078955	005	Jun 02, 2008
AB	MYLAN	10MG	A070213	002	Nov 19, 1985
AB		20MG	A070213	003	Nov 19, 1985
AB		40MG	A070213	001	Nov 19, 1985
AB		60MG	A070213	005	Apr 08, 2011
AB		80MG	A070213	004	Nov 19, 1985
AB	NORTHSTAR HLTHCARE	10MG	A078213	001	Jan 10, 2008
AB		20MG	A078213	002	Jan 10, 2008
AB		40MG	A078213	003	Jan 10, 2008
AB		60MG	A078213	004	Jan 10, 2008
AB		80MG	A078213	005	Jan 10, 2008
AB	VINTAGE PHARMS	10MG	A070217	001	Aug 01, 1986
AB		20MG	A070218	001	Aug 01, 1986
AB		40MG	A070219	001	Aug 01, 1986
AB		60MG	A070220	001	Sep 24, 1986
AB		80MG	A070221	001	Apr 14, 1986
AB	WATSON LABS	10MG	A070175	001	May 13, 1986
AB		20MG	A070176	001	May 13, 1986
AB		40MG	A070177	001	May 13, 1986
AB		80MG	A070178	001	May 13, 1986

PROPYLTHIOURACIL

TABLET; ORAL

PROPYLTHIOURACIL

BD	ACTAVIS ELIZABETH	50MG	A080172	001	
BD	+ DAVA PHARMS INC	50MG	N006188	001	

PROTAMINE SULFATE

INJECTABLE; INJECTION

PROTAMINE SULFATE

+ FRESENIUS KABI USA

		10MG/ML	A089454	001	Apr 07, 1987
--	--	---------	---------	-----	--------------

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

PROTRIPTYLINE HYDROCHLORIDE

AB	EPIC PHARMA LLC	5MG	A202220	001	Nov 19, 2012
AB		10MG	A202220	002	Nov 19, 2012
AB	SIGMAPHARM LABS LLC	5MG	A090462	001	May 03, 2010
AB		10MG	A090462	002	May 03, 2010
AB	WEST-WARD PHARMS INT	5MG	A078913	001	Sep 16, 2008
AB		10MG	A078913	002	Sep 16, 2008

PRESCRIPTION DRUG PRODUCT LIST

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

VIVACTIL

AB	ODYSSEY PHARMS	5MG	A073644 001	Aug 24, 1995
AB	+	10MG	A073645 001	Aug 24, 1995

PYRAZINAMIDE

TABLET; ORAL

PYRAZINAMIDE

AB	AKORN	500MG	A081319 001	Jun 30, 1992
AB	+	500MG	A080157 001	

PYRIDOSTIGMINE BROMIDE

INJECTABLE; INJECTION

MESTINON

AP	+	VALEANT PHARM INTL	5MG/ML	N009830 001
-----------	---	--------------------	---------------	--------------------

REGONOL

AP	SANDOZ	5MG/ML	N017398 001	
-----------	--------	---------------	--------------------	--

SYRUP; ORAL

MESTINON

+

TABLET; ORAL

MESTINON

AB	+	VALEANT PHARMS LLC	60MG	N009829 002
-----------	---	--------------------	-------------	--------------------

PYRIDOSTIGMINE BROMIDE

AB	IMPAX LABS	60MG	A040502 001	Apr 24, 2003
-----------	------------	-------------	--------------------	--------------

AB	ZYDUS PHARMS USA INC	60MG	A205650 001	Jun 22, 2015
-----------	----------------------	-------------	--------------------	--------------

TABLET, EXTENDED RELEASE; ORAL

MESTINON

AB	+	VALEANT PHARMS LLC	180MG	N011665 001
-----------	---	--------------------	--------------	--------------------

PYRIDOSTIGMINE BROMIDE

AB	ALVOGEN MALTA	180MG	A204737 001	Jun 26, 2015
-----------	---------------	--------------	--------------------	--------------

AB	IMPAX LABS INC	180MG	A203184 001	Sep 15, 2015
-----------	----------------	--------------	--------------------	--------------

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION

PYRIDOXINE HYDROCHLORIDE

AP	+	FRESENIUS KABI USA	100MG/ML	A080618 001
-----------	---	--------------------	-----------------	--------------------

AP	MYLAN INSTITUTIONAL	100MG/ML	A204879 001	Jul 14, 2016
-----------	---------------------	-----------------	--------------------	--------------

PYRIMETHAMINE

TABLET; ORAL

DARAPRIM

+

TABLET; ORAL

QUAZEPAM

TABLET; ORAL

DORAL

+

TABLET; ORAL

QUETIAPINE FUMARATE

AB	ACCORD HLTHCARE	EQ 25MG BASE	A202152 001	Mar 27, 2012
AB		EQ 50MG BASE	A202152 002	Mar 27, 2012
AB		EQ 100MG BASE	A202152 003	Mar 27, 2012
AB		EQ 200MG BASE	A202152 004	Mar 27, 2012
AB		EQ 300MG BASE	A202152 005	Mar 27, 2012
AB		EQ 400MG BASE	A202152 006	Mar 27, 2012
AB	ALEMBIC PHARMS LTD	EQ 25MG BASE	A203390 001	Oct 28, 2014
AB		EQ 50MG BASE	A203390 002	Oct 28, 2014
AB		EQ 100MG BASE	A203390 003	Oct 28, 2014
AB		EQ 200MG BASE	A203390 004	Oct 28, 2014
AB		EQ 300MG BASE	A203390 005	Oct 28, 2014
AB		EQ 400MG BASE	A203390 006	Oct 28, 2014
AB	ALKEM LABS LTD	EQ 25MG BASE	A201504 001	Feb 12, 2013
AB		EQ 50MG BASE	A201504 002	Feb 12, 2013
AB		EQ 100MG BASE	A201504 003	Feb 12, 2013
AB		EQ 150MG BASE	A201504 004	Feb 12, 2013
AB		EQ 200MG BASE	A201504 005	Feb 12, 2013
AB		EQ 300MG BASE	A201504 006	Feb 12, 2013
AB		EQ 400MG BASE	A201504 007	Feb 12, 2013
AB	APOTEX INC	EQ 25MG BASE	A090960 001	Mar 27, 2012
AB		EQ 50MG BASE	A090960 002	Mar 27, 2012
AB		EQ 100MG BASE	A090960 003	Mar 27, 2012

PRESCRIPTION DRUG PRODUCT LIST

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A090960 004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A090960 005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A090960 006</u>	Mar 27, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 25MG BASE</u>	<u>A091388 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A091388 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A091388 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A091388 004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A091388 005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A091388 006</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A091388 007</u>	Mar 27, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 25MG BASE</u>	<u>A077380 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077380 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077380 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A077380 004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A077380 005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A077380 006</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A077380 007</u>	Mar 27, 2012
<u>AB</u>	JUBILANT GENERICS	<u>EQ 25MG BASE</u>	<u>A203150 001</u>	Nov 26, 2013
<u>AB</u>	LUPIN LTD	<u>EQ 25MG BASE</u>	<u>A201109 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A201109 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A201109 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A201109 004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A201109 005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A201109 006</u>	Mar 27, 2012
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 25MG BASE</u>	<u>A203359 001</u>	May 17, 2016
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A203359 002</u>	May 17, 2016
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A203359 003</u>	May 17, 2016
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A203359 004</u>	May 17, 2016
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A203359 005</u>	May 17, 2016
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A203359 006</u>	May 17, 2016
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 25MG BASE</u>	<u>A090323 001</u>	Mar 27, 2012
<u>AB</u>	SANDOZ	<u>EQ 25MG BASE</u>	<u>A078679 001</u>	Dec 14, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078679 002</u>	Dec 14, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078679 003</u>	Dec 14, 2012
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A078679 004</u>	Dec 14, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A078679 005</u>	Dec 14, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A078679 006</u>	Dec 14, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A078679 007</u>	Dec 14, 2012
<u>AB</u>	SUN PHARMA GLOBAL	<u>EQ 25MG BASE</u>	<u>A201190 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A201190 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A201190 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A201190 004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A201190 005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A201190 006</u>	Mar 27, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 25MG BASE</u>	<u>A077745 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077745 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077745 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A077745 004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A077745 005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A077745 006</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A077745 007</u>	Mar 27, 2012
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 25MG BASE</u>	<u>A200363 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A200363 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A200363 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A200363 004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A200363 005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A200363 006</u>	Mar 27, 2012
<u>AB</u>	UNICHEM LABS LTD	<u>EQ 25MG BASE</u>	<u>A202674 001</u>	Mar 08, 2016
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A202674 002</u>	Mar 08, 2016
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A202674 003</u>	Mar 08, 2016
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A202674 004</u>	Mar 08, 2016
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A202674 005</u>	Mar 08, 2016
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A202674 006</u>	Mar 08, 2016
<u>AB</u>	WEST-WARD PHARMS INT	<u>EQ 25MG BASE</u>	<u>A090120 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A090749 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090749 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A090749 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A090749 004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A090749 005</u>	Mar 27, 2012

PRESCRIPTION DRUG PRODUCT LIST

QUETIAPINE FUMARATE

TABLET; ORAL

SEROQUEL

<u>AB</u>	+	ASTRAZENECA PHARMS	<u>EQ 25MG BASE</u>	<u>N020639 001</u>	Sep 26, 1997
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>N020639 007</u>	Oct 04, 2005
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>N020639 002</u>	Sep 26, 1997
<u>AB</u>			<u>EQ 200MG BASE</u>	<u>N020639 003</u>	Sep 26, 1997
<u>AB</u>	+		<u>EQ 300MG BASE</u>	<u>N020639 005</u>	Jul 26, 2000
<u>AB</u>			<u>EQ 400MG BASE</u>	<u>N020639 006</u>	Oct 04, 2005

TABLET, EXTENDED RELEASE; ORAL

QUETIAPINE FUMARATE

<u>AB</u>		ACCORD HLTHCARE INC	<u>EQ 400MG BASE</u>	<u>A090681 004</u>	Nov 01, 2016
<u>AB</u>		ASTRAZENECA	<u>EQ 400MG BASE</u>	<u>N022047 004</u>	May 17, 2007
			EQ 50MG BASE	N022047 001	May 17, 2007
			EQ 150MG BASE	N022047 005	Aug 11, 2008
	+		EQ 200MG BASE	N022047 002	May 17, 2007
			EQ 300MG BASE	N022047 003	May 17, 2007

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

ACCUPRIL

<u>AB</u>		PFIZER PHARMS	<u>EQ 5MG BASE</u>	<u>N019885 001</u>	Nov 19, 1991
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>N019885 002</u>	Nov 19, 1991
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>N019885 003</u>	Nov 19, 1991
<u>AB</u>	+		<u>EQ 40MG BASE</u>	<u>N019885 004</u>	Nov 19, 1991

QUINAPRIL HYDROCHLORIDE

<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A202725 001</u>	Apr 29, 2013
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A202725 002</u>	Apr 29, 2013
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A202725 003</u>	Apr 29, 2013
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A202725 004</u>	Apr 29, 2013
<u>AB</u>		INVAGEN PHARMS	<u>EQ 5MG BASE</u>	<u>A078457 001</u>	Aug 24, 2007
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A078457 002</u>	Aug 24, 2007
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A078457 003</u>	Aug 24, 2007
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A078457 004</u>	Aug 24, 2007
<u>AB</u>		LUPIN	<u>EQ 5MG BASE</u>	<u>A077690 001</u>	Jun 20, 2006
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A077690 002</u>	Jun 20, 2006
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A077690 003</u>	Jun 20, 2006
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A077690 004</u>	Jun 20, 2006
<u>AB</u>		MYLAN	<u>EQ 5MG BASE</u>	<u>A076694 001</u>	Dec 23, 2004
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A076694 002</u>	Dec 23, 2004
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A076694 003</u>	Dec 23, 2004
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A076694 004</u>	Dec 23, 2004
<u>AB</u>		PRINSTON INC	<u>EQ 5MG BASE</u>	<u>A205823 001</u>	Sep 15, 2016
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A205823 002</u>	Sep 15, 2016
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A205823 003</u>	Sep 15, 2016
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A205823 004</u>	Sep 15, 2016
<u>AB</u>		SUN PHARM INDS LTD	<u>EQ 5MG BASE</u>	<u>A076607 001</u>	Dec 15, 2004
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A090800 001</u>	Jun 18, 2009
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A076607 002</u>	Dec 15, 2004
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A090800 002</u>	Jun 18, 2009
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A076607 003</u>	Dec 15, 2004
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A090800 003</u>	Jun 18, 2009
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A076607 004</u>	Dec 15, 2004
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A090800 004</u>	Jun 18, 2009
<u>AB</u>		TEVA	<u>EQ 5MG BASE</u>	<u>A075504 001</u>	Aug 24, 2007
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A075504 002</u>	Aug 24, 2007
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A075504 003</u>	Aug 24, 2007
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A075504 004</u>	Aug 24, 2007

QUINIDINE GLUCONATE

INJECTABLE; INJECTION

QUINIDINE GLUCONATE

+ LILLY 80MG/ML

N007529 002 Feb 10, 1989

TABLET, EXTENDED RELEASE; ORAL

QUINIDINE GLUCONATE

BX	+	SUN PHARM INDS	324MG	A089338 001	Feb 11, 1987
----	---	----------------	-------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

QUINIDINE SULFATE

TABLET; ORAL

QUINIDINE SULFATE

<u>AB</u>	SANDOZ	<u>200MG</u>	<u>A088072</u>	<u>002</u>	
<u>AB</u>		<u>300MG</u>	<u>A088072</u>	<u>001</u>	Sep 26, 1983
<u>AB</u>	SUN PHARM INDS	<u>200MG</u>	<u>A081030</u>	<u>001</u>	Apr 14, 1989
<u>AB</u>		<u>300MG</u>	<u>A081031</u>	<u>001</u>	Apr 14, 1989
<u>AB</u>	+ WATSON LABS	<u>200MG</u>	<u>A083288</u>	<u>001</u>	
<u>AB</u>	+	<u>300MG</u>	<u>A085583</u>	<u>001</u>	

TABLET, EXTENDED RELEASE; ORAL

QUINIDINE SULFATE

+ G AND W LABS INC

300MG

A040045 001 Jun 30, 1994

QUININE SULFATE

CAPSULE; ORAL

QUALAQUIN

<u>AB</u>	+ SUN PHARM INDS	<u>324MG</u>	<u>N021799</u>	<u>001</u>	Aug 12, 2005
-----------	------------------	--------------	----------------	------------	--------------

QUININE SULFATE

<u>AB</u>	AMNEAL PHARMS	<u>324MG</u>	<u>A203729</u>	<u>001</u>	Jul 15, 2015
<u>AB</u>	LUPIN LTD	<u>324MG</u>	<u>A203112</u>	<u>001</u>	Apr 24, 2015
<u>AB</u>	MYLAN PHARMS INC	<u>324MG</u>	<u>A202581</u>	<u>001</u>	Dec 14, 2012
<u>AB</u>	RICONPHARMA LLC	<u>324MG</u>	<u>A204372</u>	<u>001</u>	Jul 22, 2015
<u>AB</u>	TEVA PHARMS	<u>324MG</u>	<u>A091661</u>	<u>001</u>	Sep 28, 2012

RABEPRAZOLE SODIUM

CAPSULE, DELAYED RELEASE; ORAL

ACIPHEX SPRINKLE

FSC THERAP

5MG

N204736 001 Mar 26, 2013

+

10MG

N204736 002 Mar 26, 2013

TABLET, DELAYED RELEASE; ORAL

ACIPHEX

<u>AB</u>	+ EISAI INC	<u>20MG</u>	<u>N020973</u>	<u>002</u>	Aug 19, 1999
-----------	-------------	-------------	----------------	------------	--------------

RABEPRAZOLE SODIUM

<u>AB</u>	AMNEAL PHARMS	<u>20MG</u>	<u>A204179</u>	<u>001</u>	Jul 31, 2015
<u>AB</u>	BRECKENRIDGE PHARM	<u>20MG</u>	<u>A204237</u>	<u>001</u>	Nov 18, 2015
<u>AB</u>	DR REDDYS LABS LTD	<u>20MG</u>	<u>A076824</u>	<u>001</u>	Nov 08, 2013
<u>AB</u>	KREMERS URBAN DEV	<u>20MG</u>	<u>A090678</u>	<u>001</u>	Nov 08, 2013
<u>AB</u>	LUPIN LTD	<u>20MG</u>	<u>A078964</u>	<u>001</u>	Nov 08, 2013
<u>AB</u>	MYLAN PHARMS INC	<u>20MG</u>	<u>A076885</u>	<u>001</u>	Nov 08, 2013
<u>AB</u>	TEVA PHARMS USA	<u>20MG</u>	<u>A076822</u>	<u>001</u>	Nov 08, 2013
<u>AB</u>	TORRENT PHARMS LTD	<u>20MG</u>	<u>A202376</u>	<u>001</u>	Nov 08, 2013

RADIUM RA-223 DICHLORIDE

SOLUTION; INTRAVENOUS

XOFIGO

+ BAYER HLTHCARE

162mCi/6ML (27mCi/ML)

N203971 001 May 15, 2013

RALOXIFENE HYDROCHLORIDE

TABLET; ORAL

EVISTA

<u>AB</u>	+ LILLY	<u>60MG</u>	<u>N020815</u>	<u>001</u>	Dec 09, 1997
-----------	---------	-------------	----------------	------------	--------------

RALOXIFENE HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARMS	<u>60MG</u>	<u>A208206</u>	<u>001</u>	Apr 08, 2016
<u>AB</u>	AUROBINDO PHARMA LTD	<u>60MG</u>	<u>A204310</u>	<u>001</u>	Aug 28, 2015
<u>AB</u>	GLENMARK PHARMS LTD	<u>60MG</u>	<u>A204491</u>	<u>001</u>	Mar 22, 2016
<u>AB</u>	INVAGEN PHARMS	<u>60MG</u>	<u>A090842</u>	<u>001</u>	Sep 24, 2014
<u>AB</u>	SCIEGEN PHARMS INC	<u>60MG</u>	<u>A206384</u>	<u>001</u>	Oct 12, 2016
<u>AB</u>	TEVA PHARMS USA	<u>60MG</u>	<u>A078193</u>	<u>001</u>	Mar 04, 2014
<u>AB</u>	WATSON LABS INC	<u>60MG</u>	<u>A200825</u>	<u>001</u>	Jan 21, 2015

RALTEGRAVIR POTASSIUM

POWDER; ORAL

ISENTRESS

+ MERCK SHARP DOHME

EQ 100MG BASE/PACKET

N205786 001 Dec 20, 2013

TABLET; ORAL

ISENTRESS

+ MERCK SHARP DOHME

EQ 400MG BASE

N022145 001 Oct 12, 2007

TABLET, CHEWABLE; ORAL

ISENTRESS

MERCK SHARP DOHME

EQ 25MG BASE

N203045 001 Dec 21, 2011

+

EQ 100MG BASE

N203045 002 Dec 21, 2011

PRESCRIPTION DRUG PRODUCT LIST

RAMELTEON

TABLET; ORAL

RAMELTEON

<u>AB</u>	ACTAVIS LABS FL INC	<u>8MG</u>	<u>A091610</u>	<u>001</u>	Aug 19, 2015
<u>AB</u>	DR REDDYS LABS INTL	<u>8MG</u>	<u>A091693</u>	<u>001</u>	Jul 26, 2013

ROZEREM

<u>AB</u>	+ TAKEDA PHARMS USA	<u>8MG</u>	<u>N021782</u>	<u>001</u>	Jul 22, 2005
-----------	---------------------	------------	----------------	------------	--------------

RAMIPRIL

CAPSULE; ORAL

ALTACE

<u>AB</u>	KING PHARMS	<u>1.25MG</u>	<u>N019901</u>	<u>001</u>	Jan 28, 1991
<u>AB</u>		<u>2.5MG</u>	<u>N019901</u>	<u>002</u>	Jan 28, 1991
<u>AB</u>		<u>5MG</u>	<u>N019901</u>	<u>003</u>	Jan 28, 1991
<u>AB</u>	+	<u>10MG</u>	<u>N019901</u>	<u>004</u>	Jan 28, 1991

RAMIPRIL

<u>AB</u>	ACCORD HLTHCARE INC	<u>1.25MG</u>	<u>A202392</u>	<u>001</u>	Apr 15, 2014
<u>AB</u>		<u>2.5MG</u>	<u>A202392</u>	<u>002</u>	Apr 15, 2014
<u>AB</u>		<u>5MG</u>	<u>A202392</u>	<u>003</u>	Apr 15, 2014
<u>AB</u>		<u>10MG</u>	<u>A202392</u>	<u>004</u>	Apr 15, 2014
<u>AB</u>	APOTEX	<u>1.25MG</u>	<u>A079116</u>	<u>001</u>	Jun 20, 2008
<u>AB</u>		<u>2.5MG</u>	<u>A079116</u>	<u>002</u>	Jun 20, 2008
<u>AB</u>		<u>5MG</u>	<u>A079116</u>	<u>003</u>	Jun 20, 2008
<u>AB</u>		<u>10MG</u>	<u>A079116</u>	<u>004</u>	Jun 20, 2008
<u>AB</u>	AUROBINDO PHARMA LTD	<u>1.25MG</u>	<u>A091604</u>	<u>001</u>	Jun 08, 2011
<u>AB</u>		<u>2.5MG</u>	<u>A091604</u>	<u>002</u>	Jun 08, 2011
<u>AB</u>		<u>5MG</u>	<u>A091604</u>	<u>003</u>	Jun 08, 2011
<u>AB</u>		<u>10MG</u>	<u>A091604</u>	<u>004</u>	Jun 08, 2011
<u>AB</u>	DR REDDYS LABS LTD	<u>1.25MG</u>	<u>A078191</u>	<u>001</u>	Jun 18, 2008
<u>AB</u>		<u>2.5MG</u>	<u>A078191</u>	<u>002</u>	Jun 18, 2008
<u>AB</u>		<u>5MG</u>	<u>A078191</u>	<u>003</u>	Jun 18, 2008
<u>AB</u>		<u>10MG</u>	<u>A078191</u>	<u>004</u>	Jun 18, 2008
<u>AB</u>	INVAGEN PHARMS	<u>1.25MG</u>	<u>A078745</u>	<u>001</u>	Jun 18, 2008
<u>AB</u>		<u>2.5MG</u>	<u>A078745</u>	<u>002</u>	Jun 18, 2008
<u>AB</u>		<u>5MG</u>	<u>A078745</u>	<u>003</u>	Jun 18, 2008
<u>AB</u>		<u>10MG</u>	<u>A078745</u>	<u>004</u>	Jun 18, 2008
<u>AB</u>	LUPIN	<u>1.25MG</u>	<u>A077626</u>	<u>001</u>	Jun 09, 2008
<u>AB</u>		<u>2.5MG</u>	<u>A077626</u>	<u>002</u>	Jun 09, 2008
<u>AB</u>		<u>5MG</u>	<u>A077626</u>	<u>003</u>	Jun 09, 2008
<u>AB</u>		<u>10MG</u>	<u>A077626</u>	<u>004</u>	Jun 09, 2008
<u>AB</u>	TEVA PHARMS	<u>1.25MG</u>	<u>A077470</u>	<u>001</u>	Jun 18, 2008
<u>AB</u>		<u>2.5MG</u>	<u>A077470</u>	<u>002</u>	Jun 18, 2008
<u>AB</u>		<u>5MG</u>	<u>A077470</u>	<u>003</u>	Jun 18, 2008
<u>AB</u>		<u>10MG</u>	<u>A077470</u>	<u>004</u>	Jun 18, 2008
<u>AB</u>	WATSON LABS	<u>1.25MG</u>	<u>A076549</u>	<u>001</u>	Oct 24, 2005
<u>AB</u>		<u>2.5MG</u>	<u>A076549</u>	<u>002</u>	Oct 24, 2005
<u>AB</u>		<u>5MG</u>	<u>A076549</u>	<u>003</u>	Oct 24, 2005
<u>AB</u>		<u>10MG</u>	<u>A076549</u>	<u>004</u>	Oct 24, 2005
<u>AB</u>	WEST-WARD PHARMS INT	<u>1.25MG</u>	<u>A077900</u>	<u>001</u>	Jun 18, 2008
<u>AB</u>		<u>2.5MG</u>	<u>A077900</u>	<u>002</u>	Jun 18, 2008
<u>AB</u>		<u>5MG</u>	<u>A077900</u>	<u>003</u>	Jun 18, 2008
<u>AB</u>		<u>10MG</u>	<u>A077900</u>	<u>004</u>	Jun 18, 2008
<u>AB</u>	ZYDUS PHARMS USA	<u>1.25MG</u>	<u>A078832</u>	<u>001</u>	Sep 02, 2008
<u>AB</u>		<u>2.5MG</u>	<u>A078832</u>	<u>002</u>	Sep 02, 2008
<u>AB</u>		<u>5MG</u>	<u>A078832</u>	<u>003</u>	Sep 02, 2008
<u>AB</u>		<u>10MG</u>	<u>A078832</u>	<u>004</u>	Sep 02, 2008

TABLET; ORAL

RAMIPRIL

	APOTEX INC	1.25MG	A091069	001	Dec 02, 2015
		2.5MG	A091069	002	Dec 02, 2015
		5MG	A091069	003	Dec 02, 2015
	+	10MG	A091069	004	Dec 02, 2015

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL

RANITIDINE HYDROCHLORIDE

<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 150MG BASE</u>	<u>A075742</u>	<u>001</u>	Nov 29, 2000
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A075742</u>	<u>002</u>	Nov 29, 2000
<u>AB</u>	SANDOZ	<u>EQ 150MG BASE</u>	<u>A074655</u>	<u>001</u>	Oct 22, 1997
<u>AB</u>	+	<u>EQ 300MG BASE</u>	<u>A074655</u>	<u>002</u>	Oct 22, 1997

INJECTABLE; INJECTION

RANITIDINE HYDROCHLORIDE

<u>AP</u>	MYLAN LABS LTD	<u>EQ 25MG BASE/ML</u>	<u>A079076</u>	<u>001</u>	Jun 09, 2016
-----------	----------------	------------------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

RANITIDINE HYDROCHLORIDE

<u>AP</u>	WEST-WARD PHARMS INT	<u>EQ 25MG BASE/ML</u>	<u>A074777 001</u>	Mar 02, 2005
<u>AP</u>		<u>EQ 25MG BASE/ML</u>	<u>A077458 001</u>	Feb 16, 2006
<u>AP</u>	ZYDUS PHARMS USA INC	<u>EQ 25MG BASE/ML</u>	<u>A091534 001</u>	Feb 22, 2013

ZANTAC

<u>AP</u>	+ IGI LABS INC	<u>EQ 25MG BASE/ML</u>	<u>N019090 001</u>	Oct 19, 1984
-----------	----------------	------------------------	--------------------	--------------

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

<u>AA</u>	ACTAVIS MID ATLANTIC	<u>EQ 15MG BASE/ML</u>	<u>A076124 001</u>	Feb 21, 2007
<u>AA</u>	AMNEAL PHARMS	<u>EQ 15MG BASE/ML</u>	<u>A078312 001</u>	Sep 02, 2008
<u>AA</u>	AUROBINDO PHARM	<u>EQ 15MG BASE/ML</u>	<u>A090623 001</u>	Jul 28, 2010
<u>AA</u>	BIO PHARM INC	<u>EQ 15MG BASE/ML</u>	<u>A090102 001</u>	May 26, 2009
<u>AA</u>	BRECKENRIDGE PHARM	<u>EQ 15MG BASE/ML</u>	<u>A078684 001</u>	Aug 27, 2009
<u>AA</u>	HI TECH PHARMA	<u>EQ 15MG BASE/ML</u>	<u>A091078 001</u>	Mar 22, 2011
<u>AA</u>	NOSTRUM LABS INC	<u>EQ 15MG BASE/ML</u>	<u>A091091 001</u>	Sep 20, 2011
<u>AA</u>	PHARM ASSOC	<u>EQ 15MG BASE/ML</u>	<u>A077405 001</u>	Sep 21, 2007
<u>AA</u>	SILARX	<u>EQ 15MG BASE/ML</u>	<u>A091288 001</u>	Dec 09, 2010
<u>AA</u>	TARO	<u>EQ 15MG BASE/ML</u>	<u>A077476 001</u>	Jun 13, 2011
<u>AA</u>	TOLMAR	<u>EQ 15MG BASE/ML</u>	<u>A090054 001</u>	Nov 15, 2010
<u>AA</u>	VINTAGE PHARMS	<u>EQ 15MG BASE/ML</u>	<u>A078890 001</u>	Jul 01, 2010

ZANTAC

<u>AA</u>	+ GLAXO GRP LTD	<u>EQ 15MG BASE/ML</u>	<u>N019675 001</u>	Dec 30, 1988
-----------	-----------------	------------------------	--------------------	--------------

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARMS NY	<u>EQ 150MG BASE</u>	<u>A077824 001</u>	Oct 13, 2006
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A077824 002</u>	Oct 13, 2006
<u>AB</u>	APOTEX	<u>EQ 150MG BASE</u>	<u>A074680 001</u>	Sep 12, 1997
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A074680 002</u>	Sep 12, 1997
<u>AB</u>	DR REDDYS LABS INC	<u>EQ 150MG BASE</u>	<u>A076705 001</u>	Jul 27, 2005
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A076705 002</u>	Jul 27, 2005
<u>AB</u>	GLENMARK GENERICS	<u>EQ 150MG BASE</u>	<u>A078542 001</u>	Nov 19, 2008
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A078542 002</u>	Nov 19, 2008
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 150MG BASE</u>	<u>A075165 001</u>	Sep 30, 1998
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A075165 002</u>	Sep 30, 1998
<u>AB</u>	PAR PHARM	<u>EQ 150MG BASE</u>	<u>A075180 001</u>	Jan 28, 1999
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A075180 002</u>	Jan 28, 1999
<u>AB</u>	SANDOZ	<u>EQ 150MG BASE</u>	<u>A074467 001</u>	Aug 29, 1997
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A074467 002</u>	Aug 29, 1997
<u>AB</u>	STRIDES PHARMA	<u>EQ 150MG BASE</u>	<u>A205512 001</u>	Aug 22, 2016
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A205512 002</u>	Aug 22, 2016
<u>AB</u>	TEVA	<u>EQ 150MG BASE</u>	<u>A074488 001</u>	Jul 31, 1997
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A074488 002</u>	Jul 31, 1997
<u>AB</u>	WOCKHARDT	<u>EQ 150MG BASE</u>	<u>A075208 001</u>	Dec 17, 1998
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A075208 002</u>	Dec 17, 1998

ZANTAC 150

<u>AB</u>	GLAXO GRP LTD	<u>EQ 150MG BASE</u>	<u>N018703 001</u>	Jun 09, 1983
-----------	---------------	----------------------	--------------------	--------------

ZANTAC 300

<u>AB</u>	+ GLAXO GRP LTD	<u>EQ 300MG BASE</u>	<u>N018703 002</u>	Dec 09, 1985
-----------	-----------------	----------------------	--------------------	--------------

RANOLAZINE

TABLET, EXTENDED RELEASE; ORAL

RANEXA

<u>AB</u>	GILEAD	<u>500MG</u>	<u>N021526 002</u>	Jan 27, 2006
<u>AB</u>	+	<u>1GM</u>	<u>N021526 001</u>	Feb 12, 2007

RANOLAZINE

<u>AB</u>	LUPIN LTD	<u>500MG</u>	<u>A201046 001</u>	Jul 29, 2013
<u>AB</u>		<u>1GM</u>	<u>A201046 002</u>	Jul 29, 2013

RASAGILINE MESYLATE

TABLET; ORAL

AZILECT

<u>AB</u>	TEVA	<u>EQ 0.5MG BASE</u>	<u>N021641 001</u>	May 16, 2006
<u>AB</u>	+	<u>EQ 1MG BASE</u>	<u>N021641 002</u>	May 16, 2006

RASAGILINE MESYLATE

<u>AB</u>	APOTEX INC	<u>EQ 0.5MG BASE</u>	<u>A201950 001</u>	Sep 12, 2013
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A201950 002</u>	Sep 12, 2013
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 0.5MG BASE</u>	<u>A201970 001</u>	Mar 15, 2016
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A201970 002</u>	Mar 15, 2016
<u>AB</u>	WATSON LABS INC	<u>EQ 0.5MG BASE</u>	<u>A201823 001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A201823 002</u>	Jul 01, 2013

PRESCRIPTION DRUG PRODUCT LIST

<u>REGADENOSON</u>			
SOLUTION; INTRAVENOUS			
LEXISCAN			
	+ ASTELLAS	0.4MG/5ML (0.08MG/ML)	N022161 001 Apr 10, 2008
<u>REGORAFENIB</u>			
TABLET; ORAL			
STIVARGA			
	+ BAYER HLTHCARE	40MG	N203085 001 Sep 27, 2012
<u>REMIFENTANIL HYDROCHLORIDE</u>			
INJECTABLE; INJECTION			
ULTIVA			
	MYLAN INSTITUTIONAL	EQ 1MG BASE/VIAL	N020630 001 Jul 12, 1996
		EQ 2MG BASE/VIAL	N020630 002 Jul 12, 1996
	+	EQ 5MG BASE/VIAL	N020630 003 Jul 12, 1996
<u>REPAGLINIDE</u>			
TABLET; ORAL			
<u>PRANDIN</u>			
<u>AB</u>	NOVO NORDISK INC	<u>0.5MG</u>	<u>N020741 001</u> Dec 22, 1997
<u>AB</u>		<u>1MG</u>	<u>N020741 002</u> Dec 22, 1997
<u>AB</u>	+	<u>2MG</u>	<u>N020741 003</u> Dec 22, 1997
<u>REPAGLINIDE</u>			
<u>AB</u>	ACTAVIS TOTOWA	<u>0.5MG</u>	<u>A090008 001</u> Jan 22, 2014
<u>AB</u>		<u>1MG</u>	<u>A090008 002</u> Jan 22, 2014
<u>AB</u>		<u>2MG</u>	<u>A090008 003</u> Jan 22, 2014
<u>AB</u>	AUROBINDO PHARMA LTD	<u>0.5MG</u>	<u>A203820 001</u> Jan 22, 2014
<u>AB</u>		<u>1MG</u>	<u>A203820 002</u> Jan 22, 2014
<u>AB</u>		<u>2MG</u>	<u>A203820 003</u> Jan 22, 2014
<u>AB</u>	MYLAN PHARMS INC	<u>0.5MG</u>	<u>A090252 001</u> Aug 23, 2013
<u>AB</u>		<u>1MG</u>	<u>A090252 002</u> Jan 22, 2014
<u>AB</u>		<u>2MG</u>	<u>A090252 003</u> Jan 22, 2014
<u>AB</u>	PADDOCK LLC	<u>0.5MG</u>	<u>A201189 001</u> Jul 17, 2013
<u>AB</u>		<u>1MG</u>	<u>A201189 002</u> Jan 22, 2014
<u>AB</u>		<u>2MG</u>	<u>A201189 003</u> Jan 22, 2014
<u>AB</u>	SANDOZ INC	<u>0.5MG</u>	<u>A078555 001</u> Nov 22, 2013
<u>AB</u>		<u>1MG</u>	<u>A078555 002</u> Jan 22, 2014
<u>AB</u>		<u>2MG</u>	<u>A078555 003</u> Jan 22, 2014
<u>AB</u>	STANDARD CHEM PHARM	<u>0.5MG</u>	<u>A091517 001</u> Apr 24, 2015
<u>AB</u>		<u>1MG</u>	<u>A091517 002</u> Apr 24, 2015
<u>AB</u>		<u>2MG</u>	<u>A091517 003</u> Apr 24, 2015
<u>AB</u>	SUN PHARM INDS INC	<u>1MG</u>	<u>A077571 002</u> Jul 11, 2013
<u>AB</u>		<u>2MG</u>	<u>A077571 003</u> Jul 11, 2013
<u>RESERPINE</u>			
TABLET; ORAL			
RESERPINE			
BP	SANDOZ	0.1MG	N009838 001
BP	+	0.25MG	N009838 002
<u>RETAPAMULIN</u>			
OINTMENT; TOPICAL			
ALTABAX			
	+ AQUA PHARMS LLC	1%	N022055 001 Apr 12, 2007
<u>RIBAVIRIN</u>			
CAPSULE; ORAL			
<u>REBETOL</u>			
<u>AB</u>	+ MERCK SHARP DOHME	<u>200MG</u>	<u>N020903 002</u> Jul 25, 2001
<u>RIBASPHERE</u>			
<u>AB</u>	THREE RIVERS PHARMS	<u>200MG</u>	<u>A076203 001</u> Apr 06, 2004
<u>RIBAVARIN</u>			
<u>AB</u>	AUROBINDO PHARMA	<u>200MG</u>	<u>A079117 001</u> Sep 17, 2009
<u>RIBAVIRIN</u>			
<u>AB</u>	SANDOZ	<u>200MG</u>	<u>A076192 001</u> Apr 06, 2004
<u>AB</u>	TEVA	<u>200MG</u>	<u>A076277 001</u> Oct 04, 2004
<u>AB</u>	ZYDUS PHARMS USA	<u>200MG</u>	<u>A077224 001</u> Oct 28, 2005
FOR SOLUTION; INHALATION			
<u>RIBAVIRIN</u>			
<u>AN</u>	NAVINTA LLC	<u>6GM/VIAL</u>	<u>A207366 001</u> Oct 06, 2016
<u>VIRAZOLE</u>			
<u>AN</u>	+ VALEANT PHARM INTL	<u>6GM/VIAL</u>	<u>N018859 001</u> Dec 31, 1985

PRESCRIPTION DRUG PRODUCT LIST

RIBAVIRIN

SOLUTION; ORAL

REBETOL

+ SCHERING

40MG/ML

N021546 001 Jul 29, 2003

TABLET; ORAL

COPEGUS**AB** ROCHE **200MG** **N021511** **001** Dec 03, 2002RIBAVIRIN**AB** AUROBINDO PHARMA **200MG** **A079111** **001** Sep 17, 2009**AB** SANDOZ **200MG** **A077743** **001** Oct 03, 2006**AB** SANDOZ INC **200MG** **A202546** **001** Aug 12, 2014**AB** **400MG** **A202546** **002** Aug 12, 2014**AB** **500MG** **A202546** **003** Aug 12, 2014**AB** **600MG** **A202546** **004** Aug 12, 2014**AB** TEVA **200MG** **A077053** **001** Dec 05, 2005**AB** THREE RIVERS PHARMS **200MG** **A077456** **001** Dec 05, 2005**AB** **400MG** **A077456** **002** Dec 05, 2005**AB** + **600MG** **A077456** **003** Dec 05, 2005**AB** ZYDUS PHARMS USA **200MG** **A077094** **001** Dec 05, 2005**AB** **400MG** **A077094** **002** Mar 16, 2007**AB** **500MG** **A077094** **004** Apr 18, 2008**AB** **600MG** **A077094** **003** Mar 16, 2007RIBOFLAVIN 5'-PHOSPHATE SODIUM

SOLUTION/DROPS; OPHTHALMIC

PHOTREXA

+ AVEDRO INC

0.146%

N203324 001 Apr 15, 2016

PHOTREXA VISCOUS IN DEXTRAN 20%

+ AVEDRO INC

0.146%

N203324 002 Apr 15, 2016

RIFABUTIN

CAPSULE; ORAL

MYCOBUTIN**AB** + PHARMACIA AND UPJOHN **150MG** **N050689** **001** Dec 23, 1992RIFABUTIN**AB** LUPIN LTD **150MG** **A090033** **001** Feb 24, 2014RIFAMPIN

CAPSULE; ORAL

RIFADIN**AB** SANOFI AVENTIS US **150MG** **A062303** **001****AB** + **300MG** **N050420** **001**RIFAMPIN**AB** AKORN **150MG** **A065028** **001** Mar 14, 2001**AB** **300MG** **A065028** **002** Mar 14, 2001**AB** LANNETT **150MG** **A065390** **001** Mar 28, 2008**AB** **300MG** **A065390** **002** Mar 28, 2008**AB** LUPIN PHARMS **150MG** **A090034** **001** Aug 21, 2013**AB** **300MG** **A090034** **002** Aug 21, 2013**AB** SANDOZ **150MG** **A064150** **002** Jan 02, 1998**AB** **300MG** **A064150** **001** May 28, 1997RIMACTANE**AB** OXFORD PHARMS **300MG** **N050429** **001**

INJECTABLE; INJECTION

RIFADIN**AP** + SANOFI AVENTIS US **600MG/VIAL** **N050627** **001** May 25, 1989RIFAMPIN**AP** AKORN **600MG/VIAL** **A065502** **001** Sep 21, 2010**AP** EMCURE PHARMS LTD **600MG/VIAL** **A204101** **001** Aug 18, 2014**AP** EUROHLTH INTL SARL **600MG/VIAL** **A064217** **001** Oct 29, 1999**AP** FRESENIUS KABI USA **600MG/VIAL** **A091181** **001** Aug 21, 2014**AP** HIKMA PHARMS **600MG/VIAL** **A205039** **001** Mar 03, 2016**AP** MYLAN LABS LTD **600MG/VIAL** **A065421** **001** May 22, 2008**AP** WATSON PHARMS INC **600MG/VIAL** **A206736** **001** Jan 19, 2016RIFAPENTINE

TABLET; ORAL

PRIFTIN

+ SANOFI AVENTIS US

150MG

N021024 001 Jun 22, 1998

PRESCRIPTION DRUG PRODUCT LIST

RIFAXIMIN

TABLET; ORAL

XIFAXAN

+ SALIX PHARMS

200MG

N021361 001 May 25, 2004

+

550MG

N022554 001 Mar 24, 2010

RILPIVIRINE HYDROCHLORIDE

TABLET; ORAL

EDURANT

+ JANSSEN PRODS

EQ 25MG BASE

N202022 001 May 20, 2011

RILUZOLE

TABLET; ORAL

RILUTEKAB + COVIS PHARMA SARL50MGN020599 001 Dec 12, 1995RILUZOLEAB ALKEM LABS LTD50MGA204048 001 Mar 30, 2016AB APOTEX CORP50MGA091300 001 Jun 18, 2013AB GLENMARK GENERICS50MGA091394 001 Jun 18, 2013AB IMPAX LABS50MGA076173 001 Jan 29, 2003AB MYLAN PHARMS INC50MGA203042 001 Jul 01, 2013AB SUN PHARM INDS LTD50MGA091417 001 Jun 18, 2013RIMANTADINE HYDROCHLORIDE

TABLET; ORAL

FLUMADINEAB + CARACO100MGN019649 001 Sep 17, 1993RIMANTADINE HYDROCHLORIDEAB IMPAX LABS100MGA076132 001 Aug 30, 2002RIOCIGUAT

TABLET; ORAL

ADEMPAS

BAYER HLTHCARE

0.5MG

N204819 001 Oct 08, 2013

1MG

N204819 002 Oct 08, 2013

1.5MG

N204819 003 Oct 08, 2013

2MG

N204819 004 Oct 08, 2013

+

2.5MG

N204819 005 Oct 08, 2013

RISEDRONATE SODIUM

TABLET; ORAL

ACTONELAB APIL5MGN020835 002 Apr 14, 2000AB30MGN020835 001 Mar 27, 1998AB +35MGN020835 003 May 25, 2002AB +150MGN020835 005 Apr 22, 2008RISEDRONATE SODIUMAB APOTEX INC35MGA090877 001 Nov 30, 2015AB75MGA090877 002 Jun 10, 2014AB150MGA090877 003 Jun 10, 2014AB AUROBINDO PHARMA LTD5MGA200296 001 Nov 30, 2015AB30MGA200296 002 Nov 30, 2015AB35MGA200296 003 Nov 30, 2015AB150MGA206768 001 Oct 21, 2016AB MACLEODS PHARMS LTD5MGA203533 001 Dec 09, 2015AB30MGA203533 002 Dec 09, 2015AB35MGA203533 003 Nov 29, 2016AB MYLAN PHARMS INC5MGA200477 001 Nov 30, 2015AB30MGA200477 002 Nov 30, 2015AB35MGA200477 003 Nov 30, 2015AB75MGA200477 004 Jun 10, 2014AB150MGA200477 005 Jun 10, 2014AB SUN PHARMA GLOBAL5MGA090886 001 Nov 30, 2015AB30MGA090886 002 Nov 30, 2015AB35MGA090886 003 Nov 30, 2015AB75MGA090886 004 Jun 10, 2014AB150MGA090886 005 Jun 10, 2014AB TEVA PHARMS USA5MGA077132 001 Oct 05, 2007AB30MGA077132 002 Oct 05, 2007AB35MGA077132 003 Oct 05, 2007AB150MGA079215 001 Jun 13, 2014

TABLET, DELAYED RELEASE; ORAL

ATELVIAAB + APIL35MGN022560 001 Oct 08, 2010

PRESCRIPTION DRUG PRODUCT LIST

RISEDRONATE SODIUM

TABLET, DELAYED RELEASE; ORAL

RISEDRONATE SODIUM**AB** TEVA PHARMS USA **35MG** **A203217 001** May 18, 2015RISPERIDONE

INJECTABLE; INTRAMUSCULAR

RISPERDAL CONSTA

JANSSEN PHARMS

12.5MG/VIAL

N021346 004 Apr 12, 2007

+

25MG/VIAL

N021346 001 Oct 29, 2003

37.5MG/VIAL

N021346 002 Oct 29, 2003

50MG/VIAL

N021346 003 Oct 29, 2003

SOLUTION; ORAL

RISPERDAL**AA** + JANSSEN PHARMS **1MG/ML** **N020588 001** Jun 10, 1996RISPERIDONE**AA** AMNEAL PHARMS **1MG/ML** **A091384 001** May 25, 2011**AA** ANI PHARMS INC **1MG/ML** **A076440 001** Jan 30, 2009**AA** APOTEX INC **1MG/ML** **A077719 001** Jul 29, 2009**AA** BIO PHARM INC **1MG/ML** **A078909 001** Jul 29, 2009**AA** LIFESTAR PHARMA **1MG/ML** **A078452 001** Sep 04, 2009**AA** PRECISION DOSE **1MG/ML** **A076797 001** Jun 28, 2010**AA** TARO **1MG/ML** **A090347 001** Feb 07, 2011**AA** TRIS PHARMA INC **1MG/ML** **A079059 001** Dec 12, 2012**AA** VINTAGE **1MG/ML** **A079158 001** Dec 03, 2010**AA** WEST-WARD PHARMS INT **1MG/ML** **A076904 001** Jul 29, 2009

TABLET; ORAL

RISPERDAL**AB** JANSSEN PHARMS **0.25MG** **N020272 008** May 10, 1999**AB** **0.5MG** **N020272 007** Jan 27, 1999**AB** + **1MG** **N020272 001** Dec 29, 1993**AB** **2MG** **N020272 002** Dec 29, 1993**AB** **3MG** **N020272 003** Dec 29, 1993**AB** **4MG** **N020272 004** Dec 29, 1993RISPERIDONE**AB** AJANTA PHARMA LTD **0.25MG** **A201003 001** Aug 24, 2011**AB** **0.5MG** **A201003 002** Aug 24, 2011**AB** **1MG** **A201003 003** Aug 24, 2011**AB** **2MG** **A201003 004** Aug 24, 2011**AB** **3MG** **A201003 005** Aug 24, 2011**AB** **4MG** **A201003 006** Aug 24, 2011**AB** APOTEX INC **0.25MG** **A077953 001** Sep 15, 2008**AB** **0.5MG** **A077953 002** Sep 15, 2008**AB** **1MG** **A077953 003** Sep 15, 2008**AB** **2MG** **A077953 004** Sep 15, 2008**AB** **3MG** **A077953 005** Sep 15, 2008**AB** **4MG** **A077953 006** Sep 15, 2008**AB** AUROBINDO PHARMA **0.25MG** **A078269 001** Oct 08, 2008**AB** **0.5MG** **A078269 002** Oct 08, 2008**AB** **1MG** **A078269 003** Oct 08, 2008**AB** **2MG** **A078269 004** Oct 08, 2008**AB** **3MG** **A078269 005** Oct 08, 2008**AB** **4MG** **A078269 006** Oct 08, 2008**AB** CIPLA **0.25MG** **A077543 001** May 18, 2011**AB** **0.5MG** **A077543 002** May 18, 2011**AB** **1MG** **A077543 003** May 18, 2011**AB** **2MG** **A077543 004** May 18, 2011**AB** **3MG** **A077543 005** May 18, 2011**AB** **4MG** **A077543 006** May 18, 2011**AB** DR REDDYS LABS LTD **0.25MG** **A076879 001** Oct 24, 2008**AB** **0.5MG** **A076879 002** Oct 24, 2008**AB** **1MG** **A076879 003** Oct 24, 2008**AB** **2MG** **A076879 004** Oct 24, 2008**AB** **3MG** **A076879 005** Oct 24, 2008**AB** **4MG** **A076879 006** Oct 24, 2008**AB** MYLAN **0.25MG** **A076288 001** Sep 15, 2008**AB** **0.5MG** **A076288 002** Sep 15, 2008**AB** **1MG** **A076288 003** Sep 15, 2008**AB** **2MG** **A076288 004** Sep 15, 2008**AB** **3MG** **A076288 005** Sep 15, 2008**AB** **4MG** **A076288 006** Sep 15, 2008**AB** OXFORD PHARMS **0.25MG** **A078071 001** Jun 17, 2009**AB** **0.5MG** **A078071 002** Jun 17, 2009

PRESCRIPTION DRUG PRODUCT LIST

RISPERIDONE

TABLET; ORAL

RISPERIDONE

<u>AB</u>		<u>1MG</u>	<u>A078071</u>	<u>003</u>	Jun 17, 2009
<u>AB</u>		<u>2MG</u>	<u>A078071</u>	<u>004</u>	Jun 17, 2009
<u>AB</u>		<u>3MG</u>	<u>A078071</u>	<u>005</u>	Jun 17, 2009
<u>AB</u>		<u>4MG</u>	<u>A078071</u>	<u>006</u>	Jun 17, 2009
<u>AB</u>	PLIVA HRVATSKA DOO	<u>0.25MG</u>	<u>A077769</u>	<u>001</u>	Oct 16, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A077769</u>	<u>002</u>	Oct 16, 2008
<u>AB</u>		<u>1MG</u>	<u>A077769</u>	<u>003</u>	Oct 16, 2008
<u>AB</u>		<u>2MG</u>	<u>A077769</u>	<u>004</u>	Oct 16, 2008
<u>AB</u>		<u>3MG</u>	<u>A077769</u>	<u>005</u>	Oct 16, 2008
<u>AB</u>		<u>4MG</u>	<u>A077769</u>	<u>006</u>	Oct 16, 2008
<u>AB</u>	PRINSTON INC	<u>0.25MG</u>	<u>A077493</u>	<u>001</u>	Nov 29, 2011
<u>AB</u>		<u>0.5MG</u>	<u>A077493</u>	<u>002</u>	Nov 29, 2011
<u>AB</u>		<u>1MG</u>	<u>A077493</u>	<u>003</u>	Nov 29, 2011
<u>AB</u>		<u>2MG</u>	<u>A077493</u>	<u>004</u>	Nov 29, 2011
<u>AB</u>		<u>3MG</u>	<u>A077493</u>	<u>005</u>	Nov 29, 2011
<u>AB</u>		<u>4MG</u>	<u>A077493</u>	<u>006</u>	Nov 29, 2011
<u>AB</u>	SANDOZ	<u>0.25MG</u>	<u>A078528</u>	<u>001</u>	Oct 16, 2009
<u>AB</u>		<u>0.5MG</u>	<u>A078528</u>	<u>002</u>	Oct 16, 2009
<u>AB</u>		<u>1MG</u>	<u>A078528</u>	<u>003</u>	Oct 16, 2009
<u>AB</u>		<u>2MG</u>	<u>A078528</u>	<u>004</u>	Oct 16, 2009
<u>AB</u>		<u>3MG</u>	<u>A078528</u>	<u>005</u>	Oct 16, 2009
<u>AB</u>		<u>4MG</u>	<u>A078528</u>	<u>006</u>	Oct 16, 2009
<u>AB</u>	SUN PHARM INDS INC	<u>0.25MG</u>	<u>A078036</u>	<u>001</u>	Mar 10, 2014
<u>AB</u>		<u>0.5MG</u>	<u>A078036</u>	<u>002</u>	Mar 10, 2014
<u>AB</u>		<u>1MG</u>	<u>A078036</u>	<u>003</u>	Mar 10, 2014
<u>AB</u>		<u>2MG</u>	<u>A078036</u>	<u>004</u>	Mar 10, 2014
<u>AB</u>		<u>3MG</u>	<u>A078036</u>	<u>005</u>	Mar 10, 2014
<u>AB</u>		<u>4MG</u>	<u>A078036</u>	<u>006</u>	Mar 10, 2014
<u>AB</u>	TEVA	<u>0.25MG</u>	<u>A076228</u>	<u>001</u>	Jun 30, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A076228</u>	<u>002</u>	Jun 30, 2008
<u>AB</u>		<u>1MG</u>	<u>A076228</u>	<u>003</u>	Jun 30, 2008
<u>AB</u>		<u>2MG</u>	<u>A076228</u>	<u>004</u>	Jun 30, 2008
<u>AB</u>		<u>3MG</u>	<u>A076228</u>	<u>005</u>	Jun 30, 2008
<u>AB</u>		<u>4MG</u>	<u>A076228</u>	<u>006</u>	Jun 30, 2008
<u>AB</u>	TORRENT PHARMS	<u>0.25MG</u>	<u>A079088</u>	<u>001</u>	Oct 30, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A079088</u>	<u>002</u>	Oct 30, 2008
<u>AB</u>		<u>1MG</u>	<u>A079088</u>	<u>003</u>	Oct 30, 2008
<u>AB</u>		<u>2MG</u>	<u>A079088</u>	<u>004</u>	Oct 30, 2008
<u>AB</u>		<u>3MG</u>	<u>A079088</u>	<u>005</u>	Oct 30, 2008
<u>AB</u>		<u>4MG</u>	<u>A079088</u>	<u>006</u>	Oct 30, 2008
<u>AB</u>	VINTAGE	<u>0.25MG</u>	<u>A078707</u>	<u>001</u>	Dec 29, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078707</u>	<u>002</u>	Dec 29, 2008
<u>AB</u>		<u>1MG</u>	<u>A078707</u>	<u>003</u>	Dec 29, 2008
<u>AB</u>		<u>2MG</u>	<u>A078707</u>	<u>004</u>	Dec 29, 2008
<u>AB</u>		<u>3MG</u>	<u>A078707</u>	<u>005</u>	Dec 29, 2008
<u>AB</u>		<u>4MG</u>	<u>A078707</u>	<u>006</u>	Dec 29, 2008
<u>AB</u>	WOCKHARDT	<u>0.25MG</u>	<u>A078871</u>	<u>001</u>	Oct 09, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078871</u>	<u>002</u>	Oct 09, 2008
<u>AB</u>		<u>1MG</u>	<u>A078871</u>	<u>003</u>	Oct 09, 2008
<u>AB</u>		<u>2MG</u>	<u>A078871</u>	<u>004</u>	Oct 09, 2008
<u>AB</u>		<u>3MG</u>	<u>A078871</u>	<u>005</u>	Oct 09, 2008
<u>AB</u>		<u>4MG</u>	<u>A078871</u>	<u>006</u>	Oct 09, 2008
<u>AB</u>	ZYDUS PHARMS USA INC	<u>0.25MG</u>	<u>A078040</u>	<u>001</u>	Oct 16, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078040</u>	<u>002</u>	Oct 16, 2008
<u>AB</u>		<u>1MG</u>	<u>A078040</u>	<u>003</u>	Oct 16, 2008
<u>AB</u>		<u>2MG</u>	<u>A078040</u>	<u>004</u>	Oct 16, 2008
<u>AB</u>		<u>3MG</u>	<u>A078040</u>	<u>005</u>	Oct 16, 2008
<u>AB</u>		<u>4MG</u>	<u>A078040</u>	<u>006</u>	Oct 16, 2008

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERDAL

<u>AB</u>	JANSSEN PHARMS	<u>0.5MG</u>	<u>N021444</u>	<u>001</u>	Apr 02, 2003
<u>AB</u>	+	<u>1MG</u>	<u>N021444</u>	<u>002</u>	Apr 02, 2003
<u>AB</u>		<u>2MG</u>	<u>N021444</u>	<u>003</u>	Apr 02, 2003
<u>AB</u>		<u>3MG</u>	<u>N021444</u>	<u>004</u>	Dec 23, 2004
<u>AB</u>		<u>4MG</u>	<u>N021444</u>	<u>005</u>	Dec 23, 2004

RISPERIDONE

<u>AB</u>	ACTAVIS LABS FL INC	<u>0.5MG</u>	<u>A076996</u>	<u>001</u>	Apr 19, 2011
<u>AB</u>		<u>1MG</u>	<u>A076996</u>	<u>002</u>	Apr 19, 2011
<u>AB</u>		<u>2MG</u>	<u>A076996</u>	<u>003</u>	Apr 19, 2011

PRESCRIPTION DRUG PRODUCT LIST

RISPERIDONE

TABLET, ORALLY DISINTEGRATING;ORAL

RISPERIDONE

<u>AB</u>		<u>3MG</u>	<u>A076996</u>	<u>004</u>	Apr 19, 2011
<u>AB</u>		<u>4MG</u>	<u>A076996</u>	<u>005</u>	Apr 19, 2011
<u>AB</u>	DR REDDYS LABS LTD	<u>0.5MG</u>	<u>A077328</u>	<u>001</u>	Feb 24, 2009
<u>AB</u>		<u>1MG</u>	<u>A077328</u>	<u>002</u>	Oct 05, 2009
<u>AB</u>		<u>2MG</u>	<u>A077328</u>	<u>003</u>	Feb 24, 2009
<u>AB</u>		<u>3MG</u>	<u>A077328</u>	<u>004</u>	Nov 30, 2009
<u>AB</u>		<u>4MG</u>	<u>A077328</u>	<u>005</u>	Nov 30, 2009
<u>AB</u>	JUBILANT GENERICS	<u>0.5MG</u>	<u>A090839</u>	<u>001</u>	Nov 04, 2011
<u>AB</u>		<u>1MG</u>	<u>A090839</u>	<u>002</u>	Nov 04, 2011
<u>AB</u>		<u>2MG</u>	<u>A090839</u>	<u>003</u>	Nov 04, 2011
<u>AB</u>		<u>3MG</u>	<u>A090839</u>	<u>004</u>	Nov 04, 2011
<u>AB</u>		<u>4MG</u>	<u>A090839</u>	<u>005</u>	Nov 04, 2011
<u>AB</u>	MYLAN PHARMS INC	<u>0.25MG</u>	<u>A091537</u>	<u>006</u>	Feb 12, 2013
<u>AB</u>		<u>0.5MG</u>	<u>A091537</u>	<u>001</u>	Mar 30, 2011
<u>AB</u>		<u>1MG</u>	<u>A091537</u>	<u>002</u>	Mar 30, 2011
<u>AB</u>		<u>2MG</u>	<u>A091537</u>	<u>003</u>	Mar 30, 2011
<u>AB</u>		<u>3MG</u>	<u>A091537</u>	<u>004</u>	Mar 30, 2011
<u>AB</u>		<u>4MG</u>	<u>A091537</u>	<u>005</u>	Mar 30, 2011
<u>AB</u>	PAR PHARM	<u>0.25MG</u>	<u>A077494</u>	<u>001</u>	Apr 30, 2009
<u>AB</u>		<u>0.5MG</u>	<u>A077494</u>	<u>002</u>	Apr 30, 2009
<u>AB</u>		<u>1MG</u>	<u>A077494</u>	<u>003</u>	Oct 26, 2009
<u>AB</u>		<u>2MG</u>	<u>A077494</u>	<u>004</u>	Apr 30, 2009
<u>AB</u>		<u>3MG</u>	<u>A077494</u>	<u>005</u>	Apr 30, 2009
<u>AB</u>		<u>4MG</u>	<u>A077494</u>	<u>006</u>	Apr 30, 2009
<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A078116</u>	<u>001</u>	Dec 22, 2009
<u>AB</u>		<u>1MG</u>	<u>A078116</u>	<u>002</u>	Dec 22, 2009
<u>AB</u>		<u>2MG</u>	<u>A078116</u>	<u>003</u>	Dec 22, 2009
<u>AB</u>		<u>3MG</u>	<u>A078116</u>	<u>004</u>	Dec 22, 2009
<u>AB</u>		<u>4MG</u>	<u>A078116</u>	<u>005</u>	Dec 22, 2009
<u>AB</u>	SUN PHARM INDS LTD	<u>0.5MG</u>	<u>A077542</u>	<u>001</u>	Aug 06, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A078464</u>	<u>001</u>	Apr 08, 2013
<u>AB</u>		<u>1MG</u>	<u>A077542</u>	<u>002</u>	Aug 06, 2010
<u>AB</u>		<u>1MG</u>	<u>A078464</u>	<u>002</u>	Apr 08, 2013
<u>AB</u>		<u>2MG</u>	<u>A077542</u>	<u>003</u>	Aug 06, 2010
<u>AB</u>		<u>2MG</u>	<u>A078464</u>	<u>003</u>	Apr 08, 2013
<u>AB</u>		<u>3MG</u>	<u>A078464</u>	<u>004</u>	Apr 08, 2013
<u>AB</u>		<u>3MG</u>	<u>A078474</u>	<u>001</u>	Aug 06, 2010
<u>AB</u>		<u>4MG</u>	<u>A078464</u>	<u>005</u>	Apr 08, 2013
<u>AB</u>		<u>4MG</u>	<u>A078474</u>	<u>002</u>	Aug 06, 2010
<u>AB</u>	TEVA	<u>0.5MG</u>	<u>A076908</u>	<u>001</u>	Mar 12, 2012
<u>AB</u>		<u>1MG</u>	<u>A076908</u>	<u>002</u>	Mar 12, 2012
<u>AB</u>		<u>2MG</u>	<u>A076908</u>	<u>003</u>	Mar 12, 2012
<u>AB</u>	ZYDUS PHARMS USA	<u>0.5MG</u>	<u>A078516</u>	<u>001</u>	May 01, 2009
<u>AB</u>		<u>2MG</u>	<u>A078516</u>	<u>003</u>	May 01, 2009

RITONAVIR

CAPSULE;ORAL

NORVIR

+ ABBVIE

100MG

N020945 001 Jun 29, 1999

SOLUTION;ORAL

NORVIR

+ ABBVIE

80MG/ML

N020659 001 Mar 01, 1996

TABLET;ORAL

NORVIRAB + ABBVIE100MGN022417 001 Feb 10, 2010RITONAVIRAB WEST-WARD PHARMS INT100MGA202573 001 Jan 15, 2015RIVAROXABAN

TABLET;ORAL

XARELTO

JANSSEN PHARMS

10MG

N022406 001 Jul 01, 2011

15MG

N022406 002 Nov 04, 2011

+

20MG

N022406 003 Nov 04, 2011

PRESCRIPTION DRUG PRODUCT LIST

RIVASTIGMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

EXELON

<u>AB</u>	NOVARTIS	<u>4.6MG/24HR</u>	<u>N022083 001</u>	Jul 06, 2007
<u>AB</u>	+	<u>9.5MG/24HR</u>	<u>N022083 002</u>	Jul 06, 2007
<u>AB</u>		<u>13.3MG/24HR</u>	<u>N022083 005</u>	Aug 31, 2012

RIVASTIGMINE

<u>AB</u>	ALVOGEN MALTA	<u>4.6MG/24HR</u>	<u>A204403 001</u>	Sep 03, 2015
<u>AB</u>		<u>9.5MG/24HR</u>	<u>A204403 002</u>	Sep 03, 2015
<u>AB</u>		<u>13.3MG/24HR</u>	<u>A204403 003</u>	Aug 31, 2015

RIVASTIGMINE TARTRATE

CAPSULE;ORAL

EXELON

<u>AB</u>	+	NOVARTIS	<u>EQ 1.5MG BASE</u>	<u>N020823 003</u>	Apr 21, 2000
<u>AB</u>			<u>EQ 3MG BASE</u>	<u>N020823 004</u>	Apr 21, 2000
<u>AB</u>			<u>EQ 4.5MG BASE</u>	<u>N020823 005</u>	Apr 21, 2000
<u>AB</u>	+		<u>EQ 6MG BASE</u>	<u>N020823 006</u>	Apr 21, 2000

RIVASTIGMINE TARTRATE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>EQ 1.5MG BASE</u>	<u>A091689 001</u>	Jun 12, 2012
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A091689 002</u>	Jun 12, 2012
<u>AB</u>		<u>EQ 4.5MG BASE</u>	<u>A091689 003</u>	Jun 12, 2012
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A091689 004</u>	Jun 12, 2012
<u>AB</u>	APOTEX INC	<u>EQ 1.5MG BASE</u>	<u>A091072 001</u>	May 16, 2013
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A091072 002</u>	May 16, 2013
<u>AB</u>		<u>EQ 4.5MG BASE</u>	<u>A091072 003</u>	May 16, 2013
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A091072 004</u>	May 16, 2013
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 1.5MG BASE</u>	<u>A204572 001</u>	Mar 25, 2016
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A204572 002</u>	Mar 25, 2016
<u>AB</u>		<u>EQ 4.5MG BASE</u>	<u>A204572 003</u>	Mar 25, 2016
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A204572 004</u>	Mar 25, 2016
<u>AB</u>	DR REDDYS LABS INC	<u>EQ 1.5MG BASE</u>	<u>A077130 001</u>	Oct 31, 2007
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A077130 002</u>	Oct 31, 2007
<u>AB</u>		<u>EQ 4.5MG BASE</u>	<u>A077130 003</u>	Oct 31, 2007
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A077130 004</u>	Oct 31, 2007
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 1.5MG BASE</u>	<u>A203148 001</u>	Aug 22, 2014
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A203148 002</u>	Aug 22, 2014
<u>AB</u>		<u>EQ 4.5MG BASE</u>	<u>A203148 003</u>	Aug 22, 2014
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A203148 004</u>	Aug 22, 2014
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 1.5MG BASE</u>	<u>A090879 001</u>	Jun 10, 2015
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A090879 002</u>	Jun 10, 2015
<u>AB</u>		<u>EQ 4.5MG BASE</u>	<u>A090879 003</u>	Jun 10, 2015
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A090879 004</u>	Jun 10, 2015
<u>AB</u>	SUN PHARM INDS	<u>EQ 1.5MG BASE</u>	<u>A077131 001</u>	Oct 22, 2007
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A077131 002</u>	Oct 22, 2007
<u>AB</u>		<u>EQ 4.5MG BASE</u>	<u>A077131 003</u>	Oct 22, 2007
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A077131 004</u>	Oct 22, 2007
<u>AB</u>	WATSON LABS	<u>EQ 1.5MG BASE</u>	<u>A077129 001</u>	Jan 08, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A077129 002</u>	Jan 08, 2008
<u>AB</u>		<u>EQ 4.5MG BASE</u>	<u>A077129 003</u>	Jan 08, 2008
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A077129 004</u>	Jan 08, 2008

RIZATRIPTAN BENZOATE

TABLET;ORAL

MAXALT

<u>AB</u>	MERCK	<u>EQ 5MG BASE</u>	<u>N020864 001</u>	Jun 29, 1998
<u>AB</u>	+	<u>EQ 10MG BASE</u>	<u>N020864 002</u>	Jun 29, 1998

RIZATRIPTAN BENZOATE

<u>AB</u>	ALKEM LABS LTD	<u>EQ 5MG BASE</u>	<u>A203269 001</u>	Feb 18, 2016
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203269 002</u>	Feb 18, 2016
<u>AB</u>	APOTEX INC	<u>EQ 5MG BASE</u>	<u>A202244 001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A202244 002</u>	Dec 31, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A202490 001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A202490 002</u>	Dec 31, 2012
<u>AB</u>	CIPLA LTD	<u>EQ 5MG BASE</u>	<u>A077526 001</u>	Mar 26, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077526 002</u>	Mar 26, 2013
<u>AB</u>	EMCURE PHARMS LTD	<u>EQ 5MG BASE</u>	<u>A204090 001</u>	Nov 26, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A204090 002</u>	Nov 26, 2013
<u>AB</u>	GLENMARK GENERICS	<u>EQ 5MG BASE</u>	<u>A201967 001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A201967 002</u>	Dec 31, 2012
<u>AB</u>	INVAGEN PHARMS	<u>EQ 5MG BASE</u>	<u>A204339 001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A204339 002</u>	Jul 01, 2013
<u>AB</u>	JUBILANT GENERICS	<u>EQ 5MG BASE</u>	<u>A203252 001</u>	Dec 31, 2014

PRESCRIPTION DRUG PRODUCT LIST

RIZATRIPTAN BENZOATE

TABLET; ORAL

RIZATRIPTAN BENZOATE

<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203252 002</u>	Dec 31, 2014
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 5MG BASE</u>	<u>A203147 001</u>	Feb 11, 2014
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203147 002</u>	Feb 11, 2014
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 5MG BASE</u>	<u>A201993 001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A201993 002</u>	Dec 31, 2012
<u>AB</u>	NATCO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A200482 001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A200482 002</u>	Dec 31, 2012
<u>AB</u>	NOSTRUM LABS INC	<u>EQ 5MG BASE</u>	<u>A202047 001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A202047 002</u>	Dec 31, 2012
<u>AB</u>	SANDOZ	<u>EQ 5MG BASE</u>	<u>A079230 001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A079230 002</u>	Dec 31, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 5MG BASE</u>	<u>A077263 001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077263 002</u>	Dec 31, 2012

TABLET, ORALLY DISINTEGRATING; ORAL

MAXALT-MLT

<u>AB</u>	MERCK	<u>EQ 5MG BASE</u>	<u>N020865 001</u>	Jun 29, 1998
<u>AB</u>	+	<u>EQ 10MG BASE</u>	<u>N020865 002</u>	Jun 29, 1998

RIZATRIPTAN BENZOATE

<u>AB</u>	APOTEX INC	<u>EQ 5MG BASE</u>	<u>A202477 001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A202477 002</u>	Jul 01, 2013
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A203062 001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203062 002</u>	Jul 01, 2013
<u>AB</u>	GLENMARK GENERICS	<u>EQ 5MG BASE</u>	<u>A201914 001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A201914 002</u>	Jul 01, 2013
<u>AB</u>	JUBILANT GENERICS	<u>EQ 5MG BASE</u>	<u>A203334 001</u>	Oct 16, 2015
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203334 002</u>	Oct 16, 2015
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 5MG BASE</u>	<u>A203146 001</u>	Sep 19, 2014
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203146 002</u>	Sep 19, 2014
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 5MG BASE</u>	<u>A078173 001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078173 002</u>	Dec 31, 2012
<u>AB</u>	NATCO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A203478 001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203478 002</u>	Jul 01, 2013
<u>AB</u>	SANDOZ	<u>EQ 5MG BASE</u>	<u>A078739 001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078739 002</u>	Jul 01, 2013

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ROCURONIUM BROMIDE

<u>AP</u>	FRESENIUS KABI USA	<u>50MG/5ML (10MG/ML)</u>	<u>A078651 001</u>	Dec 29, 2008
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A078651 002</u>	Dec 29, 2008
<u>AP</u>	HOSPIRA	<u>50MG/5ML (10MG/ML)</u>	<u>A078519 001</u>	Nov 26, 2008
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A078519 002</u>	Nov 26, 2008
<u>AP</u>	MYLAN INSTITUTIONAL	<u>50MG/5ML (10MG/ML)</u>	<u>A079199 001</u>	Nov 26, 2008
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A079199 002</u>	Nov 26, 2008
<u>AP</u>	SAGENT PHARMS	<u>50MG/5ML (10MG/ML)</u>	<u>A091458 001</u>	Jul 28, 2010
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A091458 002</u>	Jul 28, 2010
<u>AP</u>	+	<u>50MG/5ML (10MG/ML)</u>	<u>A079195 001</u>	Dec 05, 2008
<u>AP</u>	+	<u>100MG/10ML (10MG/ML)</u>	<u>A079195 002</u>	Dec 05, 2008
<u>AP</u>	TAMARANG	<u>50MG/5ML (10MG/ML)</u>	<u>A091115 001</u>	Aug 27, 2012
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A091115 002</u>	Aug 27, 2012
<u>AP</u>	TEVA PHARMS	<u>50MG/5ML (10MG/ML)</u>	<u>A078717 001</u>	Nov 26, 2008
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A078717 002</u>	Nov 26, 2008

ROFLUMILAST

TABLET; ORAL

DALIRESP

+ ASTRAZENECA PHARMS

500MCG

N022522 001 Feb 28, 2011

ROLAPITANT HYDROCHLORIDE

TABLET; ORAL

VARUBI

+ TESARO INC

EQ 90MG BASE

N206500 001 Sep 01, 2015

ROMIDEPSIN

POWDER; IV (INFUSION)

ISTODAX

+ CELGENE

10MG/VIAL

N022393 001 Nov 05, 2009

PRESCRIPTION DRUG PRODUCT LIST

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

REQUIP

<u>AB</u>	+ GLAXOSMITHKLINE LLC	<u>EQ 0.25MG BASE</u>	<u>N020658 001</u>	Sep 19, 1997
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>N020658 002</u>	Sep 19, 1997
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>N020658 003</u>	Sep 19, 1997
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>N020658 004</u>	Sep 19, 1997
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>N020658 006</u>	Jan 27, 1999
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>N020658 007</u>	Jan 27, 1999
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>N020658 005</u>	Sep 19, 1997

ROPINIROLE HYDROCHLORIDE

<u>AB</u>	ALEMBIC LTD	<u>EQ 0.25MG BASE</u>	<u>A090429 001</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A090429 002</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090429 003</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A090429 004</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A090429 005</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A090429 006</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090429 007</u>	Mar 24, 2010
<u>AB</u>	APOTEX	<u>EQ 0.25MG BASE</u>	<u>A079165 001</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A079165 002</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A079165 003</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A079165 004</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A079165 005</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A079165 006</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A079165 007</u>	Feb 07, 2012
<u>AB</u>	G AND W LABS INC	<u>EQ 0.25MG BASE</u>	<u>A077460 001</u>	May 05, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A077460 002</u>	May 05, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A077460 003</u>	May 05, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A077460 004</u>	May 05, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A077460 005</u>	May 05, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A077460 006</u>	May 05, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077460 007</u>	May 19, 2008
<u>AB</u>	GLENMARK GENERICS	<u>EQ 0.25MG BASE</u>	<u>A090135 001</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A090135 002</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090135 003</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A090135 004</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A090135 005</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A090135 006</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090135 007</u>	Feb 25, 2010
<u>AB</u>	MYLAN	<u>EQ 0.25MG BASE</u>	<u>A078881 001</u>	May 05, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A078881 002</u>	May 05, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A078881 003</u>	May 05, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A078881 004</u>	May 05, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A078881 005</u>	May 05, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A078881 006</u>	May 05, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078881 007</u>	May 19, 2008
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 0.25MG BASE</u>	<u>A079229 001</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A079229 002</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A079229 003</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A079229 004</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A079229 005</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A079229 006</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A079229 007</u>	Nov 28, 2012
<u>AB</u>	PRINSTON INC	<u>EQ 0.25MG BASE</u>	<u>A078110 001</u>	May 05, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A078110 002</u>	May 05, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A078110 003</u>	May 05, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A078110 004</u>	May 05, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A078110 005</u>	May 05, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A078110 006</u>	May 05, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078110 007</u>	Jul 11, 2008
<u>AB</u>	WEST-WARD PHARMS INT	<u>EQ 0.25MG BASE</u>	<u>A077852 001</u>	May 05, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A077852 002</u>	May 05, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A077852 003</u>	May 05, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A077852 004</u>	May 05, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A077852 005</u>	May 05, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A077852 006</u>	May 05, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077852 007</u>	May 19, 2008
<u>AB</u>	WOCKHARDT	<u>EQ 0.25MG BASE</u>	<u>A079050 001</u>	May 29, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A079050 002</u>	May 29, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A079050 003</u>	May 29, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A079050 004</u>	May 29, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A079050 005</u>	May 29, 2008

PRESCRIPTION DRUG PRODUCT LIST

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A079050</u>	<u>006</u>	May 29, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A079050</u>	<u>007</u>	May 29, 2008
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 0.25MG BASE</u>	<u>A090411</u>	<u>001</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A090411</u>	<u>002</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090411</u>	<u>003</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A090411</u>	<u>004</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A090411</u>	<u>005</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A090411</u>	<u>006</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090411</u>	<u>007</u>	Jun 01, 2009

TABLET, EXTENDED RELEASE;ORAL

REQUIP XL

<u>AB</u>	+ GLAXOSMITHKLINE LLC	<u>EQ 2MG BASE</u>	<u>N022008</u>	<u>001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>N022008</u>	<u>003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>N022008</u>	<u>006</u>	Apr 10, 2009
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>N022008</u>	<u>004</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>N022008</u>	<u>005</u>	Oct 31, 2008

ROPINIROLE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>EQ 2MG BASE</u>	<u>A090869</u>	<u>001</u>	May 17, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A090869</u>	<u>002</u>	May 17, 2012
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A090869</u>	<u>003</u>	May 17, 2012
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A090869</u>	<u>004</u>	May 17, 2012
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A090869</u>	<u>005</u>	May 17, 2012
<u>AB</u>	ALEMBIC LTD	<u>EQ 2MG BASE</u>	<u>A202786</u>	<u>001</u>	Apr 22, 2013
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A202786</u>	<u>002</u>	Apr 22, 2013
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A202786</u>	<u>003</u>	Apr 22, 2013
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A202786</u>	<u>004</u>	Apr 22, 2013
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A202786</u>	<u>005</u>	Apr 22, 2013
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 2MG BASE</u>	<u>A201576</u>	<u>001</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A201576</u>	<u>002</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A201576</u>	<u>003</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A201576</u>	<u>004</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A201576</u>	<u>005</u>	Jun 06, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 2MG BASE</u>	<u>A200462</u>	<u>001</u>	Oct 15, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A200462</u>	<u>003</u>	Oct 15, 2012
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A200462</u>	<u>004</u>	Oct 15, 2012
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A200462</u>	<u>005</u>	Oct 15, 2012
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A200462</u>	<u>006</u>	Oct 15, 2012
<u>AB</u>	SANDOZ INC	<u>EQ 2MG BASE</u>	<u>A201047</u>	<u>001</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A201047</u>	<u>003</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A201047</u>	<u>004</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A201047</u>	<u>005</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A201047</u>	<u>006</u>	Jun 06, 2012
<u>AB</u>	WATSON LABS INC	<u>EQ 2MG BASE</u>	<u>A200431</u>	<u>001</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A200431</u>	<u>002</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A200431</u>	<u>003</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A200431</u>	<u>004</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A200431</u>	<u>005</u>	Jun 06, 2012
<u>AB</u>	WOCKHARDT LTD	<u>EQ 2MG BASE</u>	<u>A091395</u>	<u>001</u>	Aug 27, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A091395</u>	<u>002</u>	Aug 27, 2012
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A091395</u>	<u>003</u>	Aug 27, 2012
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A091395</u>	<u>004</u>	Aug 27, 2012
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A091395</u>	<u>005</u>	Aug 27, 2012
	MYLAN PHARMS INC	EQ 3MG BASE	A200462	002	Oct 15, 2012

ROPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ROPIVACAINE HYDROCHLORIDE

<u>AP</u>	AKORN INC	<u>5MG/ML</u>	<u>A203955</u>	<u>001</u>	Apr 11, 2016
-----------	-----------	---------------	----------------	------------	--------------

SOLUTION; INJECTION

NAROPIN

<u>AP</u>	FRESENIUS KABI USA	<u>20MG/10ML (2MG/ML)</u>	<u>N020533</u>	<u>001</u>	May 01, 1998
<u>AP</u>		<u>40MG/20ML (2MG/ML)</u>	<u>N020533</u>	<u>002</u>	Sep 24, 1996
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>N020533</u>	<u>003</u>	May 01, 1998
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>N020533</u>	<u>005</u>	Sep 24, 1996
<u>AP</u>		<u>150MG/20ML (7.5MG/ML)</u>	<u>N020533</u>	<u>004</u>	Sep 24, 1996
<u>AP</u>		<u>150MG/30ML (5MG/ML)</u>	<u>N020533</u>	<u>008</u>	Sep 24, 1996
<u>AP</u>		<u>200MG/100ML (2MG/ML)</u>	<u>N020533</u>	<u>006</u>	Sep 24, 1996
<u>AP</u>	+	<u>200MG/20ML (10MG/ML)</u>	<u>N020533</u>	<u>011</u>	Sep 24, 1996

PRESCRIPTION DRUG PRODUCT LIST

ROPIVACAINE HYDROCHLORIDE

SOLUTION; INJECTION

ROPIVACAINE HYDROCHLORIDE

<u>AP</u>	AUROBINDO PHARMA LTD	<u>40MG/20ML (2MG/ML)</u>	<u>A205612 001</u>	Jul 13, 2016
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A205612 003</u>	Jul 13, 2016
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A205612 006</u>	Jul 13, 2016
<u>AP</u>		<u>150MG/30ML (5MG/ML)</u>	<u>A205612 004</u>	Jul 13, 2016
<u>AP</u>		<u>150MG/20ML (7.5MG/ML)</u>	<u>A205612 005</u>	Jul 13, 2016
<u>AP</u>		<u>200MG/100ML (2MG/ML)</u>	<u>A205612 002</u>	Jul 13, 2016
<u>AP</u>		<u>200MG/20ML (10MG/ML)</u>	<u>A205612 007</u>	Jul 13, 2016
<u>AP</u>	HOSPIRA	<u>20MG/10ML (2MG/ML)</u>	<u>A090194 001</u>	Sep 23, 2014
<u>AP</u>		<u>40MG/20ML (2MG/ML)</u>	<u>A090194 005</u>	Sep 23, 2014
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A090194 004</u>	Sep 23, 2014
<u>AP</u>		<u>150MG/30ML (5MG/ML)</u>	<u>A090194 002</u>	Sep 23, 2014
<u>AP</u>		<u>150MG/20ML (7.5MG/ML)</u>	<u>A090194 003</u>	Sep 23, 2014
<u>AP</u>		<u>200MG/20ML (10MG/ML)</u>	<u>A090194 006</u>	Sep 23, 2014
<u>AP</u>	NAVINTA LLC	<u>150MG/30ML (5MG/ML)</u>	<u>A078601 002</u>	Jul 17, 2014
<u>AP</u>		<u>200MG/20ML (10MG/ML)</u>	<u>A078601 003</u>	Jul 17, 2014
<u>AP</u>	SAGENT STRIDES	<u>40MG/20ML (2MG/ML)</u>	<u>A090318 001</u>	Sep 23, 2014
<u>AP</u>		<u>150MG/30ML (5MG/ML)</u>	<u>A090318 002</u>	Sep 23, 2014
<u>AP</u>		<u>150MG/20ML (7.5MG/ML)</u>	<u>A090318 003</u>	Sep 23, 2014
<u>AP</u>		<u>200MG/20ML (10MG/ML)</u>	<u>A090318 004</u>	Sep 23, 2014
	NAROPIN			
	FRESENIUS KABI USA	400MG/200ML (2MG/ML)	N020533 007	Sep 24, 1996
		500MG/100ML (5MG/ML)	N020533 009	Jan 04, 2011
		1GM/200ML (5MG/ML)	N020533 010	Jan 04, 2011

ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDIA

<u>AB</u>	SB PHARMCO	<u>EQ 2MG BASE</u>	<u>N021071 002</u>	May 25, 1999
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>N021071 003</u>	May 25, 1999
<u>AB</u>	+	<u>EQ 8MG BASE</u>	<u>N021071 004</u>	May 25, 1999

ROSIGLITAZONE MALEATE

<u>AB</u>	TEVA	<u>EQ 2MG BASE</u>	<u>A076747 001</u>	Jan 25, 2013
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076747 002</u>	Jan 25, 2013
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A076747 003</u>	Jan 25, 2013

ROSUVASTATIN CALCIUM

TABLET; ORAL

CRESTOR

<u>AB</u>	IPR	<u>5MG</u>	<u>N021366 002</u>	Aug 12, 2003
<u>AB</u>		<u>10MG</u>	<u>N021366 003</u>	Aug 12, 2003
<u>AB</u>		<u>20MG</u>	<u>N021366 004</u>	Aug 12, 2003
<u>AB</u>	+	<u>40MG</u>	<u>N021366 005</u>	Aug 12, 2003

ROSUVASTATIN CALCIUM

<u>AB</u>	ACCORD HLTHCARE INC	<u>5MG</u>	<u>A206434 001</u>	Oct 31, 2016
<u>AB</u>		<u>10MG</u>	<u>A206434 002</u>	Oct 31, 2016
<u>AB</u>		<u>20MG</u>	<u>A206434 003</u>	Oct 31, 2016
<u>AB</u>		<u>40MG</u>	<u>A206434 004</u>	Oct 31, 2016
<u>AB</u>	APOTEX INC	<u>5MG</u>	<u>A079145 001</u>	Jul 19, 2016
<u>AB</u>		<u>10MG</u>	<u>A079145 002</u>	Jul 19, 2016
<u>AB</u>		<u>20MG</u>	<u>A079145 003</u>	Jul 19, 2016
<u>AB</u>		<u>40MG</u>	<u>A079145 004</u>	Jul 19, 2016
<u>AB</u>	AUROBINDO PHARMA LTD	<u>5MG</u>	<u>A079170 001</u>	Jul 19, 2016
<u>AB</u>		<u>10MG</u>	<u>A079170 002</u>	Jul 19, 2016
<u>AB</u>		<u>20MG</u>	<u>A079170 003</u>	Jul 19, 2016
<u>AB</u>		<u>40MG</u>	<u>A079170 004</u>	Jul 19, 2016
<u>AB</u>	BIOCON LTD	<u>5MG</u>	<u>A207752 001</u>	Oct 31, 2016
<u>AB</u>		<u>10MG</u>	<u>A207752 002</u>	Oct 31, 2016
<u>AB</u>		<u>20MG</u>	<u>A207752 003</u>	Oct 31, 2016
<u>AB</u>		<u>40MG</u>	<u>A207752 004</u>	Oct 31, 2016
<u>AB</u>	CADILA PHARMS LTD	<u>5MG</u>	<u>A207453 001</u>	Nov 23, 2016
<u>AB</u>		<u>10MG</u>	<u>A207453 002</u>	Nov 23, 2016
<u>AB</u>		<u>20MG</u>	<u>A207453 003</u>	Nov 23, 2016
<u>AB</u>		<u>40MG</u>	<u>A207453 004</u>	Nov 23, 2016
<u>AB</u>	CHANGZHOU PHARM	<u>5MG</u>	<u>A207408 001</u>	Oct 31, 2016
<u>AB</u>		<u>10MG</u>	<u>A207408 002</u>	Oct 31, 2016
<u>AB</u>		<u>20MG</u>	<u>A207408 003</u>	Oct 31, 2016
<u>AB</u>		<u>40MG</u>	<u>A207408 004</u>	Oct 31, 2016
<u>AB</u>	GLENMARK PHARMS	<u>5MG</u>	<u>A079172 001</u>	Jul 19, 2016
<u>AB</u>		<u>10MG</u>	<u>A079172 002</u>	Jul 19, 2016
<u>AB</u>		<u>20MG</u>	<u>A079172 003</u>	Jul 19, 2016

PRESCRIPTION DRUG PRODUCT LIST

ROSUVASTATIN CALCIUM

TABLET; ORAL

ROSUVASTATIN CALCIUM

<u>AB</u>		<u>40MG</u>	<u>A079172</u>	<u>004</u>	Jul 19, 2016
<u>AB</u>	HETERO LABS LTD V	<u>5MG</u>	<u>A207616</u>	<u>001</u>	Oct 31, 2016
<u>AB</u>		<u>10MG</u>	<u>A207616</u>	<u>002</u>	Oct 31, 2016
<u>AB</u>		<u>20MG</u>	<u>A207616</u>	<u>003</u>	Oct 31, 2016
<u>AB</u>		<u>40MG</u>	<u>A207616</u>	<u>004</u>	Oct 31, 2016
<u>AB</u>	JUBILANT GENERICS	<u>5MG</u>	<u>A207062</u>	<u>001</u>	Oct 31, 2016
<u>AB</u>		<u>10MG</u>	<u>A207062</u>	<u>002</u>	Oct 31, 2016
<u>AB</u>		<u>20MG</u>	<u>A207062</u>	<u>003</u>	Oct 31, 2016
<u>AB</u>		<u>40MG</u>	<u>A207062</u>	<u>004</u>	Oct 31, 2016
<u>AB</u>	MYLAN PHARMS INC	<u>5MG</u>	<u>A079161</u>	<u>001</u>	Jul 19, 2016
<u>AB</u>		<u>10MG</u>	<u>A079161</u>	<u>002</u>	Jul 19, 2016
<u>AB</u>		<u>20MG</u>	<u>A079161</u>	<u>003</u>	Jul 19, 2016
<u>AB</u>		<u>40MG</u>	<u>A079161</u>	<u>004</u>	Jul 19, 2016
<u>AB</u>	PAR PHARM INC	<u>5MG</u>	<u>A079168</u>	<u>001</u>	Jul 19, 2016
<u>AB</u>		<u>10MG</u>	<u>A079168</u>	<u>002</u>	Jul 19, 2016
<u>AB</u>		<u>20MG</u>	<u>A079168</u>	<u>003</u>	Jul 19, 2016
<u>AB</u>		<u>40MG</u>	<u>A079168</u>	<u>004</u>	Jul 19, 2016
<u>AB</u>	SANDOZ INC	<u>5MG</u>	<u>A079171</u>	<u>001</u>	Jul 19, 2016
<u>AB</u>		<u>10MG</u>	<u>A079171</u>	<u>002</u>	Jul 19, 2016
<u>AB</u>		<u>20MG</u>	<u>A079171</u>	<u>003</u>	Jul 19, 2016
<u>AB</u>		<u>40MG</u>	<u>A079171</u>	<u>004</u>	Jul 19, 2016
<u>AB</u>	SUN PHARMA GLOBAL	<u>5MG</u>	<u>A079169</u>	<u>001</u>	Jul 19, 2016
<u>AB</u>		<u>10MG</u>	<u>A079169</u>	<u>002</u>	Jul 19, 2016
<u>AB</u>		<u>20MG</u>	<u>A079169</u>	<u>003</u>	Jul 19, 2016
<u>AB</u>		<u>40MG</u>	<u>A079169</u>	<u>004</u>	Jul 19, 2016
<u>AB</u>	TEVA PHARMS USA	<u>5MG</u>	<u>A079166</u>	<u>001</u>	Jul 19, 2016
<u>AB</u>		<u>10MG</u>	<u>A079166</u>	<u>002</u>	Jul 19, 2016
<u>AB</u>		<u>20MG</u>	<u>A079166</u>	<u>003</u>	Jul 19, 2016
<u>AB</u>		<u>40MG</u>	<u>A079166</u>	<u>004</u>	Jul 19, 2016
<u>AB</u>	TORRENT PHARMS LLC	<u>5MG</u>	<u>A201619</u>	<u>001</u>	Oct 31, 2016
<u>AB</u>		<u>10MG</u>	<u>A201619</u>	<u>002</u>	Oct 31, 2016
<u>AB</u>		<u>20MG</u>	<u>A201619</u>	<u>003</u>	Oct 31, 2016
<u>AB</u>		<u>40MG</u>	<u>A201619</u>	<u>004</u>	Oct 31, 2016
<u>AB</u>	WATSON LABS INC	<u>5MG</u>	<u>A079167</u>	<u>001</u>	Apr 29, 2016
<u>AB</u>		<u>10MG</u>	<u>A079167</u>	<u>002</u>	Apr 29, 2016
<u>AB</u>		<u>20MG</u>	<u>A079167</u>	<u>003</u>	Apr 29, 2016
<u>AB</u>		<u>40MG</u>	<u>A079167</u>	<u>004</u>	Apr 29, 2016

ROTIGOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NEUPRO

UCB INC	1MG/24HR	N021829	004	Apr 02, 2012
+	2MG/24HR	N021829	001	May 09, 2007
	3MG/24HR	N021829	005	Apr 02, 2012
	4MG/24HR	N021829	002	May 09, 2007
	6MG/24HR	N021829	003	May 09, 2007
	8MG/24HR	N021829	006	Apr 02, 2012

RUBIDIUM CHLORIDE RB-82

INJECTABLE; INJECTION

CARDIOGEN-82

BRACCO

N/A

N019414 001 Dec 29, 1989

SOLUTION; INTRAVENOUS

RUBY-FILL

JUBILANT DRAXIMAGE

N/A

N202153 001 Sep 30, 2016

RUCAPARIB CAMSYLATE

TABLET; ORAL

RUBRACA

CLOVIS ONCOLOGY INC

EQ 200MG BASE

N209115 001 Dec 19, 2016

+

EQ 300MG BASE

N209115 002 Dec 19, 2016

RUFINAMIDE

SUSPENSION; ORAL

BANZEL

+ EISAI INC

40MG/ML

N201367 001 Mar 03, 2011

TABLET; ORAL

BANZELAB EISAI INC200MGN021911 002 Nov 14, 2008AB +400MGN021911 003 Nov 14, 2008

PRESCRIPTION DRUG PRODUCT LIST

RUFINAMIDE

TABLET; ORAL

RUFINAMIDE

AB	GLENMARK PHARMS LTD	200MG	A205075 001	May 16, 2016
AB		400MG	A205075 002	May 16, 2016
AB	MYLAN PHARMS INC	200MG	A205095 001	May 16, 2016
AB		400MG	A205095 002	May 16, 2016
AB	WEST-WARD PHARMS INT	200MG	A204988 001	May 16, 2016
AB		400MG	A204988 002	May 16, 2016

RUXOLITINIB PHOSPHATE

TABLET; ORAL

JAKAFI

	INCYTE CORP	EQ 5MG BASE	N202192 001	Nov 16, 2011
		EQ 10MG BASE	N202192 002	Nov 16, 2011
		EQ 15MG BASE	N202192 003	Nov 16, 2011
		EQ 20MG BASE	N202192 004	Nov 16, 2011
+		EQ 25MG BASE	N202192 005	Nov 16, 2011

SACROSIDASE

SOLUTION; ORAL

SUCRAID

+	QOL MEDCL	8,500 IU/ML	N020772 001	Apr 09, 1998
---	-----------	-------------	-------------	--------------

SACUBITRIL; VALSARTAN

TABLET; ORAL

ENTRESTO

	NOVARTIS PHARMS CORP	24MG; 26MG	N207620 001	Jul 07, 2015
		49MG; 51MG	N207620 002	Jul 07, 2015
+		97MG; 103MG	N207620 003	Jul 07, 2015

SALMETEROL XINAFOATE

POWDER; INHALATION

SEREVENT

+	GLAXOSMITHKLINE	EQ 0.05MG BASE/INH	N020692 001	Sep 19, 1997
---	-----------------	--------------------	-------------	--------------

SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

INJECTABLE; INJECTION

QUADRAMET

+	LANTHEUS MEDICAL	50mCi/ML	N020570 001	Mar 28, 1997
---	------------------	----------	-------------	--------------

SAPROPTERIN DIHYDROCHLORIDE

POWDER; ORAL

KUVAN

+	BIOMARIN PHARM	100MG/PACKET	N205065 001	Dec 19, 2013
		500MG/PACKET	N205065 002	Oct 27, 2015

TABLET; ORAL

KUVAN

+	BIOMARIN PHARM	100MG	N022181 001	Dec 13, 2007
---	----------------	-------	-------------	--------------

SAQUINAVIR MESYLATE

CAPSULE; ORAL

INVIRASE

+	HOFFMANN LA ROCHE	EQ 200MG BASE	N020628 001	Dec 06, 1995
---	-------------------	---------------	-------------	--------------

TABLET; ORAL

INVIRASE

+	HOFFMANN-LA ROCHE	EQ 500MG BASE	N021785 001	Dec 17, 2004
---	-------------------	---------------	-------------	--------------

SAXAGLIPTIN HYDROCHLORIDE

TABLET; ORAL

ONGLYZA

	ASTRAZENECA AB	EQ 2.5MG BASE	N022350 001	Jul 31, 2009
+		EQ 5MG BASE	N022350 002	Jul 31, 2009

SCOPOLAMINE

FILM, EXTENDED RELEASE; TRANSDERMAL

SCOPOLAMINE

AB	PERRIGO PHARMS CO	1MG/72HR	A078830 001	Jan 30, 2015
AB	+	GLAXOSMITHKLINE CON	1MG/72HR	N017874 001

PRESCRIPTION DRUG PRODUCT LISTSECOBARBITAL SODIUM

CAPSULE; ORAL

SECONAL SODIUM

+	VALEANT PHARMS NORTH	50MG	A086101	001	Oct 03, 1983
+		100MG	A086101	002	Oct 03, 1983

SECRETIN SYNTHETIC HUMAN

FOR SOLUTION; INTRAVENOUS

CHIRHOSTIM

+	CHIRHOCLIN	16MCG/VIAL	N021256	001	Apr 09, 2004
		40MCG/VIAL	N021256	002	Jun 21, 2007

SELEGILINE

FILM, EXTENDED RELEASE; TRANSDERMAL

EMSAM

+	SOMERSET	6MG/24HR	N021336	001	Feb 27, 2006
		9MG/24HR	N021336	002	Feb 27, 2006
		12MG/24HR	N021336	003	Feb 27, 2006

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL

ELDEPRYL

AB	+	SOMERSET	5MG	N020647	001	May 15, 1996
-----------	---	----------	------------	----------------	------------	--------------

SELEGILINE HYDROCHLORIDE

AB		APOTEX	5MG	A075321	001	Dec 04, 1998
-----------	--	--------	------------	----------------	------------	--------------

AB		DAVA PHARMS INC	5MG	A075352	001	Nov 30, 1998
-----------	--	-----------------	------------	----------------	------------	--------------

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

AB	+	APOTEX INC	5MG	A074871	001	Jun 06, 1997
-----------	---	------------	------------	----------------	------------	--------------

AB		MYLAN	5MG	A074866	001	Nov 26, 1997
-----------	--	-------	------------	----------------	------------	--------------

AB		STASON	5MG	A074912	001	Apr 30, 1998
-----------	--	--------	------------	----------------	------------	--------------

TABLET, ORALLY DISINTEGRATING; ORAL

ZELAPAR

+	VALEANT PHARM INTL	1.25MG	N021479	001	Jun 14, 2006
---	--------------------	--------	---------	-----	--------------

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL

SELENIUM SULFIDE

AT		PERRIGO NEW YORK	2.5%	A089996	001	Jan 10, 1991
-----------	--	------------------	-------------	----------------	------------	--------------

AT		WOCKHARDT	2.5%	A088228	001	Sep 01, 1983
-----------	--	-----------	-------------	----------------	------------	--------------

SELSUN

AT	+	CHATTEM	2.5%	N007936	001	
-----------	---	---------	-------------	----------------	------------	--

SELEXIPAG

TABLET; ORAL

UPTRAVI

		ACTELION PHARMS LTD	0.2MG	N207947	001	Dec 21, 2015
			0.4MG	N207947	002	Dec 21, 2015
			0.6MG	N207947	003	Dec 21, 2015
			0.8MG	N207947	004	Dec 21, 2015
			1MG	N207947	005	Dec 21, 2015
			1.2MG	N207947	006	Dec 21, 2015
			1.4MG	N207947	007	Dec 21, 2015
	+		1.6MG	N207947	008	Dec 21, 2015

SERTACONAZOLE NITRATE

CREAM; TOPICAL

ERTACZO

+	VALEANT LUXEMBOURG	2%	N021385	001	Dec 10, 2003
---	--------------------	----	---------	-----	--------------

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

SERTRALINE HYDROCHLORIDE

AA		AUROBINDO PHARMA	EQ 20MG BASE/ML	A078861	001	Oct 31, 2008
-----------	--	------------------	------------------------	----------------	------------	--------------

ZOLOFT

AA	+	PFIZER	EQ 20MG BASE/ML	N020990	001	Dec 07, 1999
-----------	---	--------	------------------------	----------------	------------	--------------

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

AB		ACCORD HLTHCARE	EQ 25MG BASE	A202825	001	Nov 07, 2014
-----------	--	-----------------	---------------------	----------------	------------	--------------

AB			EQ 50MG BASE	A202825	002	Nov 07, 2014
-----------	--	--	---------------------	----------------	------------	--------------

AB			EQ 100MG BASE	A202825	003	Nov 07, 2014
-----------	--	--	----------------------	----------------	------------	--------------

AB		APOTEX INC	EQ 25MG BASE	A076882	001	Feb 06, 2007
-----------	--	------------	---------------------	----------------	------------	--------------

AB			EQ 50MG BASE	A076882	002	Feb 06, 2007
-----------	--	--	---------------------	----------------	------------	--------------

AB			EQ 100MG BASE	A076882	003	Feb 06, 2007
-----------	--	--	----------------------	----------------	------------	--------------

AB		AUROBINDO PHARMA	EQ 25MG BASE	A077206	001	Feb 06, 2007
-----------	--	------------------	---------------------	----------------	------------	--------------

AB			EQ 50MG BASE	A077206	002	Feb 06, 2007
-----------	--	--	---------------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077206 003</u>	Feb 06, 2007
<u>AB</u>	AUSTARPHARMA LLC	<u>EQ 25MG BASE</u>	<u>A078677 001</u>	Mar 04, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078677 002</u>	Mar 04, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078677 003</u>	Mar 04, 2009
<u>AB</u>	INVAGEN PHARMS	<u>EQ 25MG BASE</u>	<u>A077397 001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077397 002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077397 003</u>	Feb 06, 2007
<u>AB</u>	LUPIN	<u>EQ 25MG BASE</u>	<u>A077670 001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077670 002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077670 003</u>	Feb 06, 2007
<u>AB</u>	MYLAN	<u>EQ 25MG BASE</u>	<u>A076671 001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076671 002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076671 003</u>	Feb 06, 2007
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 25MG BASE</u>	<u>A078626 001</u>	Jan 31, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078626 002</u>	Jan 31, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078626 003</u>	Jan 31, 2008
<u>AB</u>	OXFORD PHARMS	<u>EQ 25MG BASE</u>	<u>A078175 001</u>	Jul 21, 2010
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078175 002</u>	Jul 21, 2010
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078175 003</u>	Jul 21, 2010
<u>AB</u>	SUN PHARM INDS (IN)	<u>EQ 25MG BASE</u>	<u>A078108 001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078108 002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078108 003</u>	Feb 06, 2007
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 25MG BASE</u>	<u>A077977 001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077977 002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077977 003</u>	Feb 06, 2007
<u>AB</u>	TEVA	<u>EQ 25MG BASE</u>	<u>A076465 001</u>	Aug 11, 2006
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076465 002</u>	Aug 11, 2006
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076465 003</u>	Aug 11, 2006
<u>AB</u>	TORRENT PHARMS	<u>EQ 25MG BASE</u>	<u>A077765 001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077765 002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077765 003</u>	Feb 06, 2007
<u>AB</u>	WOCKHARDT	<u>EQ 25MG BASE</u>	<u>A078403 001</u>	Jan 08, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078403 002</u>	Jan 08, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078403 003</u>	Jan 08, 2008
<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 25MG BASE</u>	<u>A077106 001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077106 002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077106 003</u>	Feb 06, 2007

ZOLOFT

<u>AB</u>	PFIZER	<u>EQ 25MG BASE</u>	<u>N019839 005</u>	Mar 06, 1996
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>N019839 001</u>	Dec 30, 1991
<u>AB</u>	+	<u>EQ 100MG BASE</u>	<u>N019839 002</u>	Dec 30, 1991
	SERTRALINE HYDROCHLORIDE			
	SUN PHARM INDS LTD	EQ 150MG BASE	A077977 004	Feb 06, 2007
		EQ 200MG BASE	A077977 005	Feb 06, 2007

SEVELAMER CARBONATE

FOR SUSPENSION; ORAL

RENEVELA

GENZYME

800MG/PACKET

N022318 001

Aug 12, 2009

+

2.4GM/PACKET

N022318 002

Feb 18, 2009

TABLET; ORAL

RENEVELA

+ GENZYME

800MG

N022127 001

Oct 19, 2007

SEVELAMER HYDROCHLORIDE

TABLET; ORAL

RENAGEL

GENZYME

400MG

N021179 001

Jul 12, 2000

+

800MG

N021179 002

Jul 12, 2000

SEVOFLURANE

LIQUID; INHALATION

SEVOFLURANE

<u>AN</u>	BAXTER HLTHCARE	<u>100%</u>	<u>A075895 001</u>	Jul 02, 2002
<u>AN</u>	HALOCARBON PRODS	<u>100%</u>	<u>A078650 001</u>	Nov 19, 2007
<u>AN</u>	SHANGHAI HENGRUI	<u>100%</u>	<u>A203793 001</u>	Nov 03, 2015
	<u>SOJOURN</u>			
<u>AN</u>	PIRAMAL CRITICAL	<u>100%</u>	<u>A077867 001</u>	May 02, 2007
	<u>ULTANE</u>			
<u>AN</u>	+ ABBVIE	<u>100%</u>	<u>N020478 001</u>	Jun 07, 1995

PRESCRIPTION DRUG PRODUCT LIST

SILDENAFIL CITRATE

FOR SUSPENSION;ORAL

REVATIO
+ PFIZER EQ 10MG BASE/ML N203109 001 Aug 30, 2012
SOLUTION;INTRAVENOUS

REVATIO
AP + PFIZER EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML) N022473 001 Nov 18, 2009

SILDENAFIL CITRATE
AP AUROBINDO PHARMA LTD EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML) A203988 001 Apr 01, 2015
TABLET;ORAL

REVATIO
AB + PFIZER EQ 20MG BASE N021845 001 Jun 03, 2005

SILDENAFIL CITRATE
AB AMNEAL PHARMS EQ 20MG BASE A202025 001 Feb 28, 2013
AB APOTEX CORP EQ 20MG BASE A091379 001 Nov 06, 2012
AB AUROBINDO PHARMA LTD EQ 20MG BASE A203963 001 Nov 18, 2015
AB DR REDDYS LABS LTD EQ 20MG BASE A202598 001 Nov 06, 2012
AB HETERO LABS LTD V EQ 20MG BASE A203623 001 Nov 26, 2014
AB MACLEODS PHARMS LTD EQ 20MG BASE A203814 001 Dec 17, 2013
AB MYLAN PHARMS INC EQ 20MG BASE A201150 001 Nov 09, 2012
AB RUBICON RES PVT LTD EQ 20MG BASE A204883 001 Jun 20, 2016
AB TEVA PHARMS EQ 20MG BASE A078380 001 Jan 07, 2013
AB TORRENT PHARMS LTD EQ 20MG BASE A091479 001 Nov 06, 2012
AB WATSON LABS INC EQ 20MG BASE A202503 001 Nov 06, 2012

VIAGRA
PFIZER IRELAND EQ 25MG BASE N2020895 001 Mar 27, 1998
EQ 50MG BASE N2020895 002 Mar 27, 1998
+ EQ 100MG BASE N2020895 003 Mar 27, 1998

SILODOSIN

CAPSULE;ORAL

RAPAFLO
+ ALLERGAN SALES LLC 4MG N022206 001 Oct 08, 2008
8MG N022206 002 Oct 08, 2008

SILVER SULFADIAZINE

CREAM;TOPICAL

SILVADENE
AB + KING PHARMS 1% N017381 001

SSD
AB DR REDDYS LA 1% N018578 001 Feb 25, 1982

THERMAZENE
AB THEPHARMANETWORK LLC 1% N018810 001 Dec 23, 1985

SSD AF
BX DR REDDYS LA 1% N018578 003 Jul 11, 1990

SIMEPREVIR SODIUM

CAPSULE;ORAL

OLYSIO
+ JANSSEN PRODS EQ 150MG BASE N205123 001 Nov 22, 2013

SIMVASTATIN

SUSPENSION;ORAL

SIMVASTATIN
ROSEMONT PHARMS LTD 20MG/5ML N206679 001 Apr 21, 2016
+ 40MG/5ML N206679 002 Apr 21, 2016

TABLET;ORAL

SIMVASTATIN
AB ACCORD HLTHCARE 5MG A078155 005 Apr 05, 2013
AB 10MG A078155 002 Feb 26, 2008
AB 20MG A078155 003 Feb 26, 2008
AB 40MG A078155 004 Feb 26, 2008
AB 80MG A078155 001 Feb 26, 2008
AB AUROBINDO PHARMA 5MG A077691 001 Dec 20, 2006
AB 10MG A077691 002 Dec 20, 2006
AB 20MG A077691 003 Dec 20, 2006
AB 40MG A077691 004 Dec 20, 2006
AB 80MG A077691 005 Dec 20, 2006
AB BIOCON LIMITED 5MG A078034 001 Dec 20, 2006
AB 10MG A078034 002 Dec 20, 2006
AB 20MG A078034 003 Dec 20, 2006
AB 40MG A078034 004 Dec 20, 2006
AB 80MG A078034 005 Dec 20, 2006
AB DR REDDYS LABS INC 5MG A077752 005 Jan 23, 2008

PRESCRIPTION DRUG PRODUCT LIST

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

<u>AB</u>		<u>10MG</u>	<u>A077752</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A077752</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A077752</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A077752</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>	HETERO LABS LTD III	<u>5MG</u>	<u>A200895</u>	<u>001</u>	Nov 25, 2014
<u>AB</u>		<u>10MG</u>	<u>A200895</u>	<u>002</u>	Nov 25, 2014
<u>AB</u>		<u>20MG</u>	<u>A200895</u>	<u>003</u>	Nov 25, 2014
<u>AB</u>		<u>40MG</u>	<u>A200895</u>	<u>004</u>	Nov 25, 2014
<u>AB</u>		<u>80MG</u>	<u>A200895</u>	<u>005</u>	Nov 25, 2014
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>5MG</u>	<u>A076052</u>	<u>001</u>	Jun 23, 2006
<u>AB</u>		<u>10MG</u>	<u>A076052</u>	<u>002</u>	Jun 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076052</u>	<u>003</u>	Jun 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076052</u>	<u>004</u>	Jun 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A076052</u>	<u>005</u>	Dec 20, 2006
<u>AB</u>	LUPIN	<u>5MG</u>	<u>A078103</u>	<u>005</u>	Apr 14, 2009
<u>AB</u>		<u>10MG</u>	<u>A078103</u>	<u>001</u>	May 11, 2007
<u>AB</u>		<u>20MG</u>	<u>A078103</u>	<u>002</u>	May 11, 2007
<u>AB</u>		<u>40MG</u>	<u>A078103</u>	<u>003</u>	May 11, 2007
<u>AB</u>		<u>80MG</u>	<u>A078103</u>	<u>004</u>	May 11, 2007
<u>AB</u>	MICRO LABS LTD	<u>5MG</u>	<u>A090383</u>	<u>001</u>	Sep 16, 2011
<u>AB</u>		<u>10MG</u>	<u>A090383</u>	<u>002</u>	Sep 16, 2011
<u>AB</u>		<u>20MG</u>	<u>A090383</u>	<u>003</u>	Sep 16, 2011
<u>AB</u>		<u>40MG</u>	<u>A090383</u>	<u>004</u>	Sep 16, 2011
<u>AB</u>		<u>80MG</u>	<u>A090383</u>	<u>005</u>	Sep 16, 2011
<u>AB</u>	MYLAN PHARMS INC	<u>5MG</u>	<u>A090868</u>	<u>001</u>	Jun 08, 2010
<u>AB</u>		<u>10MG</u>	<u>A090868</u>	<u>002</u>	Jun 08, 2010
<u>AB</u>		<u>20MG</u>	<u>A090868</u>	<u>003</u>	Jun 08, 2010
<u>AB</u>		<u>40MG</u>	<u>A090868</u>	<u>004</u>	Jun 08, 2010
<u>AB</u>		<u>80MG</u>	<u>A090868</u>	<u>005</u>	Jun 08, 2010
<u>AB</u>	OXFORD PHARMS	<u>5MG</u>	<u>A078735</u>	<u>001</u>	Aug 30, 2010
<u>AB</u>		<u>10MG</u>	<u>A078735</u>	<u>002</u>	Aug 30, 2010
<u>AB</u>		<u>20MG</u>	<u>A078735</u>	<u>003</u>	Aug 30, 2010
<u>AB</u>		<u>40MG</u>	<u>A078735</u>	<u>004</u>	Aug 30, 2010
<u>AB</u>		<u>80MG</u>	<u>A078735</u>	<u>005</u>	Aug 30, 2010
<u>AB</u>	WATSON LABS	<u>5MG</u>	<u>A076685</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>10MG</u>	<u>A076685</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A076685</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A076685</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A076685</u>	<u>005</u>	Dec 20, 2006
<u>AB</u>	ZYDUS PHARMS USA	<u>5MG</u>	<u>A077837</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>10MG</u>	<u>A077837</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A077837</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A077837</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A077837</u>	<u>005</u>	Dec 20, 2006

ZOCOR

<u>AB</u>	MERCK	<u>5MG</u>	<u>N019766</u>	<u>001</u>	Dec 23, 1991
<u>AB</u>		<u>10MG</u>	<u>N019766</u>	<u>002</u>	Dec 23, 1991
<u>AB</u>		<u>20MG</u>	<u>N019766</u>	<u>003</u>	Dec 23, 1991
<u>AB</u>		<u>40MG</u>	<u>N019766</u>	<u>004</u>	Dec 23, 1991
<u>AB</u>	+	<u>80MG</u>	<u>N019766</u>	<u>005</u>	Jul 10, 1998

SINCALIDE

INJECTABLE; INJECTION

KINEVAC

+ BRACCO

0.005MG/VIAL

N017697 001

SINECATECHINS

OINTMENT; TOPICAL

VEREGEN

+ MEDIGENE AG

15%

N021902 001 Oct 31, 2006

SIROLIMUS

SOLUTION; ORAL

RAPAMUNE

+ PF PRISM CV

1MG/ML

N021083 001 Sep 15, 1999

TABLET; ORAL

RAPAMUNE

<u>AB</u>	PF PRISM CV	<u>0.5MG</u>	<u>N021110</u>	<u>004</u>	Jan 25, 2010
<u>AB</u>		<u>1MG</u>	<u>N021110</u>	<u>001</u>	Aug 25, 2000
<u>AB</u>	+	<u>2MG</u>	<u>N021110</u>	<u>002</u>	Aug 22, 2002

PRESCRIPTION DRUG PRODUCT LIST

SIROLIMUS

TABLET; ORAL

SIROLIMUS

AB	DR REDDYS LABS LTD	<u>1MG</u>	<u>A201578</u>	<u>001</u>	Oct 27, 2014
AB		<u>2MG</u>	<u>A201578</u>	<u>002</u>	Oct 27, 2014
AB	ZYDUS PHARMS USA INC	<u>0.5MG</u>	<u>A201676</u>	<u>003</u>	Jan 08, 2014

SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUVIA

	MERCK SHARP DOHME	EQ 25MG BASE	N021995	001	Oct 16, 2006
		EQ 50MG BASE	N021995	002	Oct 16, 2006
+		EQ 100MG BASE	N021995	003	Oct 16, 2006

SODIUM ACETATE ANHYDROUS

INJECTABLE; INJECTION

SODIUM ACETATE IN PLASTIC CONTAINER

+	HOSPIRA	2MEQ/ML	N018893	001	May 04, 1983
---	---------	---------	---------	-----	--------------

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION; IV (INFUSION)

AMMONUL

AP	+	MEDICIS	<u>10%;10% (5GM/50ML;5GM/50ML)</u>	<u>N020645</u>	<u>001</u>	Feb 17, 2005
<u>SODIUM PHENYLACETATE AND SODIUM BENZOATE</u>						
AP		AILEX PHARMS PVT LTD	<u>10%;10% (5GM/50ML;5GM/50ML)</u>	<u>A207096</u>	<u>001</u>	Feb 24, 2016
AP		NAVINTA LLC	<u>10%;10% (5GM/50ML;5GM/50ML)</u>	<u>A205880</u>	<u>001</u>	Aug 04, 2016

SODIUM BICARBONATE

INJECTABLE; INJECTION

SODIUM BICARBONATE

+	HOSPIRA	0.9MEQ/ML	A077394	001	Nov 09, 2005
+		1MEQ/ML	A077394	002	Nov 09, 2005
	HOSPIRA INC	0.5MEQ/ML	A202981	001	Mar 04, 2016

SODIUM CHLORIDE

INJECTABLE; INJECTION

BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		FRESENIUS KABI USA	<u>9MG/ML</u>	<u>A088911</u>	<u>001</u>	Feb 07, 1985
AP	+	HOSPIRA	<u>9MG/ML</u>	<u>N018800</u>	<u>001</u>	Oct 29, 1982

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP		B BRAUN	<u>450MG/100ML</u>	<u>N019635</u>	<u>001</u>	Mar 09, 1988
AP		BAXTER HLTHCARE	<u>450MG/100ML</u>	<u>N018016</u>	<u>001</u>	
AP	+	HOSPIRA	<u>450MG/100ML</u>	<u>N018090</u>	<u>001</u>	
AP			<u>450MG/100ML</u>	<u>N019759</u>	<u>001</u>	Jun 08, 1988

SODIUM CHLORIDE 0.9%

AP		EUROHLTH INTL SARL	<u>9MG/ML</u>	<u>A201850</u>	<u>001</u>	Jan 20, 2012
-----------	--	--------------------	---------------	-----------------------	-------------------	--------------

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	+	B BRAUN	<u>900MG/100ML</u>	<u>N017464</u>	<u>001</u>	
AP	+		<u>900MG/100ML</u>	<u>N019635</u>	<u>002</u>	Mar 09, 1988
AP	+	BAXTER HLTHCARE	<u>9MG/ML</u>	<u>N016677</u>	<u>004</u>	Oct 30, 1985
AP			<u>9MG/ML</u>	<u>N020178</u>	<u>002</u>	Dec 07, 1992
AP	+		<u>900MG/100ML</u>	<u>N016677</u>	<u>001</u>	
AP	+		<u>900MG/100ML</u>	<u>N020178</u>	<u>001</u>	Dec 07, 1992
AP	+	FRESENIUS KABI USA	<u>9MG/ML</u>	<u>A088912</u>	<u>001</u>	Jan 10, 1985
AP		FRESENIUS MEDCL	<u>900MG/100ML</u>	<u>A078177</u>	<u>001</u>	Apr 12, 2007
AP		HAEMONETICS	<u>900MG/100ML</u>	<u>A076316</u>	<u>001</u>	Oct 27, 2004
AP	+	HOSPIRA	<u>9MG/ML</u>	<u>N018803</u>	<u>001</u>	Oct 29, 1982
AP	+		<u>9MG/ML</u>	<u>N019217</u>	<u>001</u>	Jul 13, 1984
AP			<u>9MG/ML</u>	<u>N019465</u>	<u>002</u>	Jul 15, 1985
AP	+		<u>900MG/100ML</u>	<u>N016366</u>	<u>001</u>	
AP	+		<u>900MG/100ML</u>	<u>N019465</u>	<u>001</u>	Jul 15, 1985
AP	+		<u>900MG/100ML</u>	<u>N019480</u>	<u>001</u>	Sep 17, 1985
AP		JUBILANT HOLLISTRSTR	<u>9MG/ML</u>	<u>A203352</u>	<u>001</u>	May 18, 2016
AP	+	TARO PHARMS IRELAND	<u>9MG/ML</u>	<u>A077407</u>	<u>001</u>	Aug 11, 2006

SODIUM CHLORIDE 0.9%

	B BRAUN	900MG/10ML	N019635	005	Aug 11, 2016
	MEDEFIL INC	90MG/10ML (9MG/ML)	N202832	006	Jan 06, 2012

SODIUM CHLORIDE 0.9%

	EUROHLTH INTL SARL	9MG/ML	A201833	001	Sep 24, 2013
--	--------------------	--------	---------	-----	--------------

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+	LIEBEL-FLARSHEIM	405MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006
		1012.5MG/125ML (9MG/ML)	N021569	002	Jul 27, 2006

SODIUM CHLORIDE 3% IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	3GM/100ML	N019022	001	Nov 01, 1983
---	-----------------	-----------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE 5GM/100ML

N019022 002 Nov 01, 1983

SODIUM CHLORIDE IN PLASTIC CONTAINER

HOSPIRA 2.5MEQ/ML

N018897 001 Jul 20, 1984

SOLUTION; IRRIGATION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINERAT B BRAUN900MG/100MLN016733 001AT BAXTER HLTHCARE900MG/100MLN017427 001AT900MG/100MLN017867 001AT HOSPIRA900MG/100MLN017514 001AT900MG/100MLN018314 001

SOLUTION FOR SLUSH; IRRIGATION

SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER

BAXTER HLTHCARE 900MG/100ML

N019319 002 May 17, 1985

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION

FERRLECITAB + SANOFI AVENTIS US62.5MG/5MLN020955 001 Feb 18, 1999SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSEAB EUROHLTH INTL SARL62.5MG/5MLA078215 001 Mar 31, 2011SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS

SODIUM FLUORIDE F-18AP 3D IMAGING DRUG10-200mCi/MLA203777 001 Oct 19, 2015AP BIOMEDCL RES FDN10-200mCi/MLA204351 001 Jan 09, 2015AP CARDINAL HEALTH 41410-200mCi/MLA203780 001 Jul 30, 2015AP ESSENTIAL ISOTOPES10-200mCi/MLA204541 001 Oct 29, 2014AP GLOBAL ISOTOPES LLC10-200mCi/MLA204464 001 Oct 21, 2014AP HOT SHOTS NM LLC10-200mCi/MLA204530 001 Jul 29, 2015AP + HOUSTON CYCLOTRON10-200mCi/MLA203544 001 Dec 26, 2012AP KREITCHMAN PET CTR10-200mCi/MLA203936 001 May 19, 2016AP MIDWEST MEDCL10-200mCi/MLA204440 001 Nov 17, 2015AP MIPS CRF10-200mCi/MLA204517 001 Jul 21, 2015AP NCM USA BRONX LLC10-200mCi/MLA204513 001 Nov 28, 2014AP PETNET10-200mCi/MLA203890 001 Sep 28, 2015AP PRECISION NUCLEAR10-200mCi/MLA204542 001 Feb 27, 2015AP SHERTECH LABS LLC10-200mCi/MLA204315 001 Sep 22, 2014AP SPECTRON MRC LLC10-200mCi/MLA203912 001 Apr 22, 2015AP TRIAD ISOTOPES INC10-200mCi/MLA203968 001 Oct 23, 2015AP UCSF RUDIOPHARM10-200mCi/MLA204437 001 Mar 13, 2014AP UIHC PET IMAGING10-200mCi/MLA204462 001 Nov 17, 2015AP UNIV TX MD ANDERSON10-200mCi/MLA203247 001 Dec 23, 2013AP UNIV UTAH CYCLOTRON10-200mCi/MLA204497 001 Apr 20, 2015AP ZEVACOR PHARMA INC10-200mCi/MLA203592 001 Aug 18, 2015

+ MCPRF

10-91.5mCi/ML

A203605 001 Jun 28, 2013

+ THE FEINSTEIN INST

20-600mCi/ML

A204328 001 Nov 19, 2014

SODIUM IODIDE I-123

CAPSULE; ORAL

SODIUM IODIDE I 123AA + CARDINAL HEALTH 418100uCiN018671 001 May 27, 1982AA +200uCiN018671 002 May 27, 1982AA MALLINKRODT NUCLEAR100uCiA071909 001 Feb 28, 1989AA200uCiA071910 001 Feb 28, 1989SODIUM IODIDE I-131

CAPSULE; ORAL

SODIUM IODIDE I 131

JUBILANT DRAXIMAGE 0.009-0.1mCi

N021305 006 May 19, 2005

+ MALLINKRODT NUCLEAR

0.8-100mCi

N016517 001

SOLUTION; ORAL

HICON

+ JUBILANT DRAXIMAGE

250-1000mCi

N021305 007 Dec 05, 2011

SODIUM IODIDE I 131

+ MALLINKRODT NUCLEAR

3.5-150mCi/VIAL

N016515 001

PRESCRIPTION DRUG PRODUCT LIST

<u>SODIUM LACTATE</u>			
INJECTABLE; INJECTION			
SODIUM LACTATE IN PLASTIC CONTAINER			
	+ HOSPIRA	5MEQ/ML	N018947 001 Sep 05, 1984
<u>SODIUM NITRITE</u>			
SOLUTION; INTRAVENOUS			
SODIUM NITRITE			
	+ HOPE PHARMS	300MG/10ML (30MG/ML)	N203922 001 Feb 14, 2012
<u>SODIUM NITRITE; SODIUM THIOSULFATE</u>			
SOLUTION, SOLUTION; INTRAVENOUS, INTRAVENOUS			
NITHIODOTE			
	+ HOPE PHARMS	300MG/10ML (30MG/ML), N/A; N/A, 12.5GM/50ML (250MG/ML)	N201444 001 Jan 14, 2011
<u>SODIUM NITROPRUSSIDE</u>			
INJECTABLE; INJECTION			
<u>NITROPRESS</u>			
AP	+ HOSPIRA	25MG/ML	A071961 001 Aug 01, 1988
<u>SODIUM NITROPRUSSIDE</u>			
AP	NAMIGEN LLC	25MG/ML	A207426 001 Dec 08, 2016
<u>SODIUM OXYBATE</u>			
SOLUTION; ORAL			
XYREM			
	+ JAZZ PHARMS	500MG/ML	N021196 001 Jul 17, 2002
<u>SODIUM PHENYLBUTYRATE</u>			
POWDER; ORAL			
<u>BUPHENYL</u>			
AB	+ HORIZON PHARMA INC	3GM/TEASPOONFUL	N020573 001 Apr 30, 1996
<u>SODIUM PHENYLBUTYRATE</u>			
AB	PAR PHARM	3GM/TEASPOONFUL	A203918 001 Jun 15, 2016
AB	SIGMAPHARM LABS LLC	3GM/TEASPOONFUL	A202819 001 Mar 22, 2013
TABLET; ORAL			
<u>BUPHENYL</u>			
AB	+ HORIZON PHARMA INC	500MG	N020572 001 May 13, 1996
<u>SODIUM PHENYLBUTYRATE</u>			
AB	FERA PHARMS LLC	500MG	A090910 001 Nov 18, 2011
AB	PAR PHARM	500MG	A204395 001 Apr 15, 2016
<u>SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE</u>			
TABLET; ORAL			
OSMOPREP			
	+ SALIX PHARMS	0.398GM; 1.102GM	N021892 001 Mar 16, 2006
<u>SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS</u>			
INJECTABLE; INJECTION			
SODIUM PHOSPHATES IN PLASTIC CONTAINER			
	+ HOSPIRA	142MG/ML; 276MG/ML	N018892 001 May 10, 1983
<u>SODIUM POLYSTYRENE SULFONATE</u>			
POWDER; ORAL, RECTAL			
<u>KALEXATE</u>			
AA	KVK TECH	454GM/BOT	A040905 001 Mar 30, 2009
<u>KAYEXALATE</u>			
AA	+ CONCORDIA PHARMS INC	453.6GM/BOT	N011287 001
<u>KIONEX</u>			
AA	PADDOCK LLC	454GM/BOT	A040029 001 Feb 06, 1998
<u>SODIUM POLYSTYRENE SULFONATE</u>			
AA	BELCHER PHARMS LLC	454GM/BOT	A205727 001 Feb 23, 2016
AA	CAROLINA MEDCL	454GM/BOT	A089910 001 Jan 19, 1989
AA	CEDAR PHARMS	453.6GM/BOT	A090313 001 Dec 21, 2011
AA	EPIC PHARMA LLC	453.6GM/BOT	A202333 001 Mar 19, 2014
AA	INVATECH PHARMA	454GM/BOT	A206815 001 Feb 18, 2016
AA	NUVO PHARM INC	454GM/BOT	A204071 001 Nov 28, 2014
KALEXATE			
	KVK TECH	15GM/BOT	A040905 002 Apr 03, 2015
SODIUM POLYSTYRENE SULFONATE			
	NUVO PHARM INC	15GM/BOT	A204071 002 Nov 28, 2014
SUSPENSION; ORAL, RECTAL			
<u>KIONEX</u>			
AA	PADDOCK LLC	15GM/60ML	A040028 001 Sep 17, 2007
<u>SODIUM POLYSTYRENE SULFONATE</u>			
AA	PADDOCK LLC	15GM/60ML	A090590 001 May 13, 2011
AA	WEST-WARD PHARMS INT	15GM/60ML	A089049 001 Nov 17, 1986

PRESCRIPTION DRUG PRODUCT LIST

SODIUM POLYSTYRENE SULFONATE

SUSPENSION; ORAL, RECTAL

SPS

AA	+	CAROLINA MEDCL	15GM/60ML	A087859	001	Dec 08, 1982
-----------	---	----------------	------------------	----------------	------------	--------------

SODIUM TETRADECYL SULFATE

INJECTABLE; INJECTION

SOTRADECOL

	+	MYLAN INSTITUTIONAL	20MG/2ML (10MG/ML)	A040541	001	Nov 12, 2004
--	---	---------------------	--------------------	---------	-----	--------------

	+		60MG/2ML (30MG/ML)	A040541	002	Nov 12, 2004
--	---	--	--------------------	---------	-----	--------------

SODIUM THIOSULFATE

SOLUTION; INTRAVENOUS

SODIUM THIOSULFATE

	+	HOPE PHARMS	12.5GM/50ML (250MG/ML)	N203923	001	Feb 14, 2012
--	---	-------------	------------------------	---------	-----	--------------

SOFOBUVIR

TABLET; ORAL

SOVALDI

	+	GILEAD SCIENCES INC	400MG	N204671	001	Dec 06, 2013
--	---	---------------------	-------	---------	-----	--------------

SOFOBUVIR; VELPATASVIR

TABLET; ORAL

EPCLUSA

	+	GILEAD SCIENCES INC	400MG; 100MG	N208341	001	Jun 28, 2016
--	---	---------------------	--------------	---------	-----	--------------

SOLIFENACIN SUCCINATE

TABLET; ORAL

SOLIFENACIN SUCCINATE

AB		TEVA PHARMS USA	5MG	A091464	001	Apr 02, 2014
-----------	--	-----------------	------------	----------------	------------	--------------

AB			10MG	A091464	002	Apr 02, 2014
-----------	--	--	-------------	----------------	------------	--------------

VESICARE

AB		ASTELLAS	5MG	N021518	001	Nov 19, 2004
-----------	--	----------	------------	----------------	------------	--------------

AB	+		10MG	N021518	002	Nov 19, 2004
-----------	---	--	-------------	----------------	------------	--------------

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

GENOTROPIN

BX	+	PHARMACIA AND UPJOHN	5.8MG/VIAL	N020280	006	Aug 24, 1995
----	---	----------------------	------------	---------	-----	--------------

GENOTROPIN PRESERVATIVE FREE

BX		PHARMACIA AND UPJOHN	1.5MG/VIAL	N020280	004	Aug 24, 1995
----	--	----------------------	------------	---------	-----	--------------

HUMATROPE

BX	+	LILLY	5MG/VIAL	N019640	004	Mar 08, 1987
----	---	-------	----------	---------	-----	--------------

BX			6MG/VIAL	N019640	005	Feb 04, 1999
----	--	--	----------	---------	-----	--------------

NORDITROPIN FLEXPRO

BX		NOVO NORDISK INC	5MG/1.5ML	N021148	008	Mar 01, 2010
----	--	------------------	-----------	---------	-----	--------------

BX			10MG/1.5ML	N021148	009	Mar 01, 2010
----	--	--	------------	---------	-----	--------------

OMNITROPE

BX		SANDOZ	1.5MG/VIAL	N021426	002	May 30, 2006
----	--	--------	------------	---------	-----	--------------

BX			5MG/1.5ML	N021426	003	Jan 16, 2008
----	--	--	-----------	---------	-----	--------------

BX			5.8MG/VIAL	N021426	001	May 30, 2006
----	--	--	------------	---------	-----	--------------

BX			10MG/1.5ML	N021426	004	Aug 25, 2008
----	--	--	------------	---------	-----	--------------

SAIZEN

BX		EMD SERONO	5MG/VIAL	N019764	002	Oct 08, 1996
----	--	------------	----------	---------	-----	--------------

SEROSTIM

BX		EMD SERONO	4MG/VIAL	N020604	003	Jul 25, 1997
----	--	------------	----------	---------	-----	--------------

BX			5MG/VIAL	N020604	002	Aug 23, 1996
----	--	--	----------	---------	-----	--------------

BX			6MG/VIAL	N020604	001	Aug 23, 1996
----	--	--	----------	---------	-----	--------------

VALTROPIN

BX		LG LIFE	5MG/VIAL	N021905	001	Apr 19, 2007
----	--	---------	----------	---------	-----	--------------

ZOMACTON

BX	+	FERRING	5MG/VIAL	N019774	002	Jan 04, 2002
----	---	---------	----------	---------	-----	--------------

BX			10MG/VIAL	N019774	003	Mar 07, 2012
----	--	--	-----------	---------	-----	--------------

GENOTROPIN

	+	PHARMACIA AND UPJOHN	13.8MG/VIAL	N020280	007	Oct 23, 1996
--	---	----------------------	-------------	---------	-----	--------------

GENOTROPIN PRESERVATIVE FREE

		PHARMACIA AND UPJOHN	0.2MG/VIAL	N020280	001	Jan 27, 1998
--	--	----------------------	------------	---------	-----	--------------

			0.4MG/VIAL	N020280	002	Jan 27, 1998
--	--	--	------------	---------	-----	--------------

			0.6MG/VIAL	N020280	003	Jan 27, 1998
--	--	--	------------	---------	-----	--------------

			0.8MG/VIAL	N020280	005	Jan 27, 1998
--	--	--	------------	---------	-----	--------------

			1MG/VIAL	N020280	008	Jan 27, 1998
--	--	--	----------	---------	-----	--------------

			1.2MG/VIAL	N020280	009	Jan 27, 1998
--	--	--	------------	---------	-----	--------------

			1.4MG/VIAL	N020280	010	Jan 27, 1998
--	--	--	------------	---------	-----	--------------

			1.6MG/VIAL	N020280	011	Jan 27, 1998
--	--	--	------------	---------	-----	--------------

			1.8MG/VIAL	N020280	012	Jan 27, 1998
--	--	--	------------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

GENOTROPIN PRESERVATIVE FREE

+		2MG/VIAL	N020280	013	Jan 27, 1998
	HUMATROPE				
+	LILLY	12MG/VIAL	N019640	006	Feb 04, 1999
+		24MG/VIAL	N019640	007	Feb 04, 1999
	NORDITROPIN FLEXPRO				
	NOVO NORDISK INC	15MG/1.5ML	N021148	010	Mar 01, 2010
		30MG/3ML	N021148	011	Jan 23, 2015
	NUTROPIN AQ NUSPIN				
+	GENENTECH	5MG/2ML (2.5MG/ML)	N020522	003	Jan 03, 2008
+		10MG/2ML (5MG/ML)	N020522	005	Jan 03, 2008
+		20MG/2ML (10MG/ML)	N020522	004	Jan 03, 2008
	NUTROPIN AQ PEN				
+	GENENTECH	10MG/2ML (5MG/ML)	N020522	002	Apr 22, 2002
+		20MG/2ML (10MG/ML)	N020522	006	Jan 03, 2008
	SAIZEN				
+	EMD SERONO	8.8MG/VIAL	N019764	003	Aug 29, 2000
	ZORBTIVE				
+	EMD SERONO	8.8MG/VIAL	N021597	004	Dec 01, 2003

SONIDEGIB PHOSPHATE

CAPSULE; ORAL

ODOMZO

+	NOVARTIS PHARMS CORP	EQ 200MG BASE	N205266	001	Jul 24, 2015
---	----------------------	---------------	---------	-----	--------------

SORAFENIB TOSYLATE

TABLET; ORAL

NEXAVAR

+	BAYER HLTHCARE	EQ 200MG BASE	N021923	001	Dec 20, 2005
---	----------------	---------------	---------	-----	--------------

SORBITOL

SOLUTION; IRRIGATION

SORBITOL 3% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	3GM/100ML	N017863	001	
--	-----------------	-----------	---------	-----	--

SORBITOL 3.3% IN PLASTIC CONTAINER

	B BRAUN	3.3GM/100ML	N016741	001	
--	---------	-------------	---------	-----	--

SOTALOL HYDROCHLORIDE

SOLUTION; INTRAVENOUS

SOTALOL HYDROCHLORIDE

+	ALTATHERA PHARMS LLC	150MG/10ML (15MG/ML)	N022306	001	Jul 02, 2009
---	----------------------	----------------------	---------	-----	--------------

SOLUTION; ORAL

SOTYLIZE

+	ARBOR PHARMS LLC	5MG/ML (5MG/ML)	N205108	001	Oct 22, 2014
---	------------------	-----------------	---------	-----	--------------

TABLET; ORAL

BETAPACE

AB1	COVIS PHARMA SARL	80MG	N019865	001	Oct 30, 1992
AB1		120MG	N019865	005	Apr 20, 1994
AB1	+	160MG	N019865	002	Oct 30, 1992
AB1		240MG	N019865	003	Oct 30, 1992

SORINE

AB1	UPSHER SMITH	80MG	A075500	001	Apr 27, 2001
AB1		120MG	A075500	004	Apr 27, 2001
AB1		160MG	A075500	002	Apr 27, 2001
AB1		240MG	A075500	003	Apr 27, 2001

SOTALOL HYDROCHLORIDE

AB1	APOTEX INC	80MG	A076140	001	Sep 26, 2002
AB1		120MG	A076140	002	Sep 26, 2002
AB1		160MG	A076140	003	Sep 26, 2002
AB1		240MG	A076140	004	Sep 26, 2002
AB1	BEXIMCO PHARMS USA	80MG	A207428	001	Oct 21, 2016
AB1		120MG	A207428	002	Oct 21, 2016
AB1		160MG	A207428	003	Oct 21, 2016
AB1	MYLAN	80MG	A075237	001	May 01, 2000
AB1		80MG	A075725	001	Dec 19, 2000
AB1		120MG	A075237	002	May 01, 2000
AB1		120MG	A075725	002	Dec 19, 2000
AB1		160MG	A075237	003	May 01, 2000
AB1		160MG	A075725	003	Dec 19, 2000
AB1		240MG	A075237	004	May 01, 2000
AB1		240MG	A075725	004	Dec 19, 2000
AB1	TEVA	80MG	A075429	001	May 01, 2000

PRESCRIPTION DRUG PRODUCT LIST

SOTALOL HYDROCHLORIDE

TABLET; ORAL

SOTALOL HYDROCHLORIDE

<u>AB1</u>		<u>120MG</u>	<u>A075429</u>	<u>002</u>	May 01, 2000
<u>AB1</u>		<u>160MG</u>	<u>A075429</u>	<u>003</u>	May 01, 2000
<u>AB1</u>		<u>240MG</u>	<u>A075429</u>	<u>004</u>	May 01, 2000
<u>AB1</u>	UPSHER-SMITH LABS	<u>80MG</u>	<u>A075366</u>	<u>001</u>	May 01, 2000
<u>AB1</u>		<u>120MG</u>	<u>A075366</u>	<u>002</u>	May 01, 2000
<u>AB1</u>		<u>160MG</u>	<u>A075366</u>	<u>003</u>	May 01, 2000
<u>AB1</u>		<u>240MG</u>	<u>A075366</u>	<u>004</u>	May 01, 2000
<u>AB1</u>	VINTAGE PHARMS	<u>80MG</u>	<u>A075563</u>	<u>001</u>	Nov 07, 2003
<u>AB1</u>		<u>120MG</u>	<u>A075563</u>	<u>002</u>	Nov 07, 2003
<u>AB1</u>		<u>160MG</u>	<u>A075563</u>	<u>003</u>	Nov 07, 2003
<u>AB1</u>		<u>240MG</u>	<u>A075563</u>	<u>004</u>	Nov 07, 2003

BETAPACE AF

<u>AB2</u>	COVIS PHARMA SARL	<u>80MG</u>	<u>N021151</u>	<u>001</u>	Feb 22, 2000
<u>AB2</u>		<u>120MG</u>	<u>N021151</u>	<u>002</u>	Feb 22, 2000
<u>AB2</u>	+	<u>160MG</u>	<u>N021151</u>	<u>003</u>	Feb 22, 2000

SOTALOL HYDROCHLORIDE

<u>AB2</u>	APOTEX	<u>80MG</u>	<u>A076214</u>	<u>001</u>	Aug 27, 2003
<u>AB2</u>		<u>120MG</u>	<u>A076214</u>	<u>002</u>	Aug 27, 2003
<u>AB2</u>		<u>160MG</u>	<u>A076214</u>	<u>003</u>	Aug 27, 2003
<u>AB2</u>	EPIC PHARMA INC	<u>80MG</u>	<u>A077070</u>	<u>001</u>	Nov 04, 2005
<u>AB2</u>		<u>120MG</u>	<u>A077070</u>	<u>002</u>	Nov 04, 2005
<u>AB2</u>		<u>160MG</u>	<u>A077070</u>	<u>003</u>	Nov 04, 2005
<u>AB2</u>	MYLAN	<u>80MG</u>	<u>A077616</u>	<u>001</u>	Feb 07, 2007
<u>AB2</u>		<u>120MG</u>	<u>A077616</u>	<u>002</u>	Feb 07, 2007
<u>AB2</u>		<u>160MG</u>	<u>A077616</u>	<u>003</u>	Feb 07, 2007
<u>AB2</u>	TEVA	<u>80MG</u>	<u>A076883</u>	<u>001</u>	Jul 26, 2004
<u>AB2</u>		<u>120MG</u>	<u>A076883</u>	<u>002</u>	Jul 26, 2004
<u>AB2</u>		<u>160MG</u>	<u>A076883</u>	<u>003</u>	Jul 26, 2004

SOYBEAN OIL

INJECTABLE; INJECTION

INTRALIPID 10%

<u>AP</u>	+	FRESENIUS	<u>10%</u>	<u>N017643</u>	<u>001</u>	
-----------	---	-----------	------------	----------------	------------	--

INTRALIPID 20%

<u>AP</u>	+	FRESENIUS	<u>20%</u>	<u>N018449</u>	<u>001</u>	
-----------	---	-----------	------------	----------------	------------	--

<u>AP</u>	+		<u>20%</u>	<u>N020248</u>	<u>001</u>	Aug 07, 1996
-----------	---	--	------------	----------------	------------	--------------

INTRALIPID 30%

<u>AP</u>	+	FRESENIUS	<u>30%</u>	<u>N019942</u>	<u>001</u>	Dec 30, 1993
-----------	---	-----------	------------	----------------	------------	--------------

NUTRILIPID 10%

<u>AP</u>	+	B BRAUN	<u>10%</u>	<u>N019531</u>	<u>001</u>	May 28, 1993
-----------	---	---------	------------	----------------	------------	--------------

NUTRILIPID 20%

<u>AP</u>	+	B BRAUN	<u>20%</u>	<u>N019531</u>	<u>002</u>	May 28, 1993
-----------	---	---------	------------	----------------	------------	--------------

SPINOSAD

SUSPENSION; TOPICAL

NATROBA

	+	PARAPRO LLC	0.9%	<u>N022408</u>	<u>001</u>	Jan 18, 2011
--	---	-------------	------	----------------	------------	--------------

SPIRONOLACTONE

TABLET; ORAL

ALDACTONE

<u>AB</u>		GD SEARLE LLC	<u>25MG</u>	<u>N012151</u>	<u>009</u>	Dec 30, 1983
<u>AB</u>			<u>50MG</u>	<u>N012151</u>	<u>008</u>	Dec 30, 1982
<u>AB</u>	+		<u>100MG</u>	<u>N012151</u>	<u>010</u>	Dec 30, 1983

SPIRONOLACTONE

<u>AB</u>		ACCORD HLTHCARE INC	<u>25MG</u>	<u>A203512</u>	<u>001</u>	Sep 19, 2016
<u>AB</u>			<u>50MG</u>	<u>A203512</u>	<u>002</u>	Sep 19, 2016
<u>AB</u>			<u>100MG</u>	<u>A203512</u>	<u>003</u>	Sep 19, 2016
<u>AB</u>		ACTAVIS ELIZABETH	<u>25MG</u>	<u>A040353</u>	<u>003</u>	Mar 15, 2006
<u>AB</u>			<u>50MG</u>	<u>A040353</u>	<u>001</u>	Jul 29, 1999
<u>AB</u>			<u>100MG</u>	<u>A040353</u>	<u>002</u>	Jul 29, 1999
<u>AB</u>		AMNEAL PHARMS	<u>25MG</u>	<u>A091426</u>	<u>001</u>	Jun 08, 2010
<u>AB</u>			<u>50MG</u>	<u>A091426</u>	<u>002</u>	Jun 08, 2010
<u>AB</u>			<u>100MG</u>	<u>A091426</u>	<u>003</u>	Jun 08, 2010
<u>AB</u>		JUBILANT GENERICS	<u>25MG</u>	<u>A203253</u>	<u>001</u>	Apr 23, 2014
<u>AB</u>			<u>50MG</u>	<u>A203253</u>	<u>002</u>	Apr 23, 2014
<u>AB</u>			<u>100MG</u>	<u>A203253</u>	<u>003</u>	Apr 23, 2014
<u>AB</u>		MYLAN	<u>25MG</u>	<u>A040424</u>	<u>001</u>	Aug 20, 2001
<u>AB</u>			<u>50MG</u>	<u>A040424</u>	<u>002</u>	Aug 20, 2001
<u>AB</u>			<u>100MG</u>	<u>A040424</u>	<u>003</u>	Aug 20, 2001
<u>AB</u>		ORION CORP ORION	<u>25MG</u>	<u>A202187</u>	<u>001</u>	Mar 06, 2014

PRESCRIPTION DRUG PRODUCT LIST

SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE

<u>AB</u>		<u>50MG</u>	<u>A202187</u>	<u>002</u>	Mar 06, 2014
<u>AB</u>		<u>100MG</u>	<u>A202187</u>	<u>003</u>	Mar 06, 2014
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A086809</u>	<u>001</u>	
<u>AB</u>	SUN PHARM INDS	<u>25MG</u>	<u>A089424</u>	<u>001</u>	Jul 23, 1986
<u>AB</u>		<u>50MG</u>	<u>A089424</u>	<u>002</u>	Aug 11, 1999
<u>AB</u>		<u>100MG</u>	<u>A089424</u>	<u>003</u>	Aug 11, 1999
<u>AB</u>	VINTAGE	<u>25MG</u>	<u>A040750</u>	<u>001</u>	Aug 29, 2006
<u>AB</u>		<u>50MG</u>	<u>A040750</u>	<u>002</u>	Aug 29, 2006
<u>AB</u>		<u>100MG</u>	<u>A040750</u>	<u>003</u>	Aug 29, 2006

STAVUDINE

CAPSULE; ORAL

STAVUDINE

<u>AB</u>	AUROBINDO PHARMA	<u>15MG</u>	<u>A077672</u>	<u>003</u>	Dec 29, 2008
<u>AB</u>		<u>20MG</u>	<u>A077672</u>	<u>004</u>	Dec 29, 2008
<u>AB</u>		<u>30MG</u>	<u>A077672</u>	<u>001</u>	Dec 29, 2008
<u>AB</u>		<u>40MG</u>	<u>A077672</u>	<u>002</u>	Dec 29, 2008
<u>AB</u>	HETERO LABS LTD III	<u>15MG</u>	<u>A078957</u>	<u>001</u>	Dec 29, 2008
<u>AB</u>		<u>20MG</u>	<u>A078957</u>	<u>002</u>	Dec 29, 2008
<u>AB</u>		<u>30MG</u>	<u>A078957</u>	<u>003</u>	Dec 29, 2008
<u>AB</u>		<u>40MG</u>	<u>A078957</u>	<u>004</u>	Dec 29, 2008
<u>AB</u>	MATRIX LABS LTD	<u>30MG</u>	<u>A078775</u>	<u>001</u>	Jan 05, 2009
<u>AB</u>		<u>40MG</u>	<u>A078775</u>	<u>002</u>	Jan 05, 2009
<u>AB</u>	MYLAN	<u>15MG</u>	<u>A079069</u>	<u>001</u>	Dec 29, 2008
<u>AB</u>		<u>20MG</u>	<u>A079069</u>	<u>002</u>	Dec 29, 2008
<u>AB</u>		<u>30MG</u>	<u>A079069</u>	<u>003</u>	Dec 29, 2008
<u>AB</u>		<u>40MG</u>	<u>A079069</u>	<u>004</u>	Dec 29, 2008

ZERIT

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>15MG</u>	<u>N020412</u>	<u>002</u>	Jun 24, 1994
<u>AB</u>		<u>20MG</u>	<u>N020412</u>	<u>003</u>	Jun 24, 1994
<u>AB</u>		<u>30MG</u>	<u>N020412</u>	<u>004</u>	Jun 24, 1994
<u>AB</u>	+	<u>40MG</u>	<u>N020412</u>	<u>005</u>	Jun 24, 1994

FOR SOLUTION; ORAL

STAVUDINE

<u>AA</u>	AUROBINDO PHARMA	<u>1MG/ML</u>	<u>A077774</u>	<u>001</u>	Dec 29, 2008
<u>AA</u>	CIPLA LTD	<u>1MG/ML</u>	<u>A078030</u>	<u>001</u>	Mar 20, 2009

ZERIT

<u>AA</u>	+	BRISTOL MYERS SQUIBB	<u>1MG/ML</u>	<u>N020413</u>	<u>001</u>	Sep 06, 1996
-----------	---	----------------------	---------------	----------------	------------	--------------

STERILE WATER FOR INJECTION

LIQUID; N/A

BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

<u>AP</u>	+	HOSPIRA	<u>100%</u>	<u>N018802</u>	<u>001</u>	Oct 27, 1982
-----------	---	---------	-------------	----------------	------------	--------------

STERILE WATER FOR INJECTION

<u>AP</u>		EUROHLTH INTL SARL	<u>100%</u>	<u>A206369</u>	<u>001</u>	Sep 02, 2015
-----------	--	--------------------	-------------	----------------	------------	--------------

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

<u>AP</u>	+	B BRAUN	<u>100%</u>	<u>N019633</u>	<u>001</u>	Feb 29, 1988
<u>AP</u>	+	BAXTER HLTHCARE	<u>100%</u>	<u>N018632</u>	<u>001</u>	Jun 30, 1982
<u>AP</u>	+		<u>100%</u>	<u>N018632</u>	<u>002</u>	Apr 19, 1988
<u>AP</u>		FRESENIUS KABI USA	<u>100%</u>	<u>A088400</u>	<u>001</u>	Jan 16, 1984
<u>AP</u>	+	HOSPIRA	<u>100%</u>	<u>N018233</u>	<u>001</u>	
<u>AP</u>	+		<u>100%</u>	<u>N018801</u>	<u>001</u>	Oct 27, 1982
<u>AP</u>	+		<u>100%</u>	<u>N019869</u>	<u>001</u>	Dec 26, 1989
<u>AP</u>		TARO PHARMS IRELAND	<u>100%</u>	<u>A077393</u>	<u>001</u>	Aug 11, 2006

STERILE WATER FOR IRRIGATION

LIQUID; IRRIGATION

STERILE WATER

<u>AT</u>		BAXTER HLTHCARE	<u>100%</u>	<u>N017428</u>	<u>001</u>	
-----------	--	-----------------	-------------	----------------	------------	--

STERILE WATER IN PLASTIC CONTAINER

<u>AT</u>		B BRAUN	<u>100%</u>	<u>N016734</u>	<u>001</u>	
<u>AT</u>		BAXTER HLTHCARE	<u>100%</u>	<u>N017866</u>	<u>001</u>	
<u>AT</u>		HOSPIRA	<u>100%</u>	<u>N017513</u>	<u>001</u>	
<u>AT</u>			<u>100%</u>	<u>N018313</u>	<u>001</u>	

PRESCRIPTION DRUG PRODUCT LIST

<u>STREPTOMYCIN SULFATE</u>			
INJECTABLE; INJECTION			
STREPTOMYCIN SULFATE			
	+ X GEN PHARMS	EQ 1GM BASE/VIAL	A064210 001 Jun 30, 1998
<u>STREPTOZOCIN</u>			
INJECTABLE; INJECTION			
ZANOSAR			
	+ TEVA PHARMS USA	1GM/VIAL	N050577 001 May 07, 1982
<u>STRONTIUM CHLORIDE SR-89</u>			
INJECTABLE; INJECTION			
<u>METASTRON</u>			
AP	+ GE HEALTHCARE	<u>1mCi/ML</u>	<u>N020134 001</u> Jun 18, 1993
<u>STRONTIUM CHLORIDE SR-89</u>			
AP	BIO NUCLEONICS	<u>1mCi/ML</u>	<u>A075941 001</u> Jan 06, 2003
<u>SUCCIMER</u>			
CAPSULE; ORAL			
CHEMET			
	+ RECORDATI RARE	100MG	N019998 002 Jan 30, 1991
<u>SUCCINYLCHOLINE CHLORIDE</u>			
INJECTABLE; INJECTION			
<u>ANECTINE</u>			
AP	+ SANDOZ	<u>20MG/ML</u>	<u>N008453 002</u>
<u>QUELICIN</u>			
AP	+ HOSPIRA	<u>20MG/ML</u>	<u>N008845 006</u>
<u>QUELICIN PRESERVATIVE FREE</u>			
AP	+ HOSPIRA	<u>20MG/ML</u>	<u>N008845 001</u>
<u>SUCRALFATE</u>			
SUSPENSION; ORAL			
CARAFATE			
	+ FOREST LABS INC	1GM/10ML	N019183 001 Dec 16, 1993
TABLET; ORAL			
<u>CARAFATE</u>			
AB	+ FOREST LABS INC	<u>1GM</u>	<u>N018333 001</u>
<u>SUCRALFATE</u>			
AB	MYLAN IRELAND LTD	<u>1GM</u>	<u>A074415 001</u> Jun 08, 1998
AB	TEVA	<u>1GM</u>	<u>A070848 001</u> Mar 29, 1996
<u>SUCROFERRIC OXYHYDROXIDE</u>			
TABLET, CHEWABLE; ORAL			
VELPHORO			
	+ VIFOR FRESENIUS	500MG	N205109 001 Nov 27, 2013
<u>SUFENTANIL CITRATE</u>			
INJECTABLE; INJECTION			
<u>SUFENTA PRESERVATIVE FREE</u>			
AP	+ AKORN	<u>EQ 0.05MG BASE/ML</u>	<u>N019050 001</u> May 04, 1984
<u>SUFENTANIL CITRATE</u>			
AP	HOSPIRA	<u>EQ 0.05MG BASE/ML</u>	<u>A074534 001</u> Dec 11, 1996
AP	WEST-WARD PHARMS INT	<u>EQ 0.05MG BASE/ML</u>	<u>A074413 001</u> Dec 15, 1995
<u>SUGAMMADEX SODIUM</u>			
SOLUTION; INTRAVENOUS			
BRIDION			
	ORGANON SUB MERCK	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	N022225 002 Dec 15, 2015
	+	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N022225 001 Dec 15, 2015
<u>SULCONAZOLE NITRATE</u>			
CREAM; TOPICAL			
EXELDERM			
	+ RANBAXY	1%	N018737 001 Feb 28, 1989
SOLUTION; TOPICAL			
EXELDERM			
	+ SUN PHARM INDS LTD	1%	N018738 001 Aug 30, 1985
<u>SULFACETAMIDE SODIUM</u>			
LOTION; TOPICAL			
<u>KLARON</u>			
AB	+ VALEANT PHARMS NORTH	<u>10%</u>	<u>N019931 001</u> Dec 23, 1996
<u>SULFACETAMIDE SODIUM</u>			
AB	FOUGERA PHARMS	<u>10%</u>	<u>A077015 001</u> Nov 17, 2006
AB	PERRIGO CO TENNESSEE	<u>10%</u>	<u>A078649 001</u> Mar 23, 2009
AB	TARO	<u>10%</u>	<u>A078668 001</u> May 20, 2009

PRESCRIPTION DRUG PRODUCT LIST

SULFACETAMIDE SODIUM

OINTMENT;OPHTHALMIC

SULFACETAMIDE SODIUM

+ PERRIGO CO TENNESSEE 10%

A080029 001

SOLUTION/DROPS;OPHTHALMIC

BLEPH-10**AT** + ALLERGAN 10%**A080028 001**SULFACETAMIDE SODIUM**AT** AKORN 10%**A040215 001** May 25, 1999**AT** ALCON PHARMS LTD 10%**A089560 001** Oct 18, 1988**AT** BAUSCH AND LOMB 10%**A040066 001** Dec 28, 1994SULFADIAZINE

TABLET;ORAL

SULFADIAZINE

+ SANDOZ 500MG

A040091 001 Jul 29, 1994

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

SULFAMETHOXAZOLE AND TRIMETHOPRIM

+ TEVA PHARMS USA 80MG/ML;16MG/ML

A073303 001 Oct 31, 1991

SUSPENSION;ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM**AB** AUROBINDO PHARMA 200MG/5ML;40MG/5ML**A091348 001** Jun 08, 2010**AB** + HI TECH PHARMA 200MG/5ML;40MG/5ML**A074650 001** Dec 29, 1997**AB** VINTAGE 200MG/5ML;40MG/5ML**A077785 001** Jan 24, 2007SULFATRIM PEDIATRIC**AB** STI PHARMA LLC 200MG/5ML;40MG/5ML**N018615 001** Jan 07, 1983

TABLET;ORAL

BACTRIM**AB** SUN PHARM INDS 400MG;80MG**N017377 001**BACTRIM DS**AB** + SUN PHARM INDS 800MG;160MG**N017377 002**SEPTRA**AB** MONARCH PHARMS 400MG;80MG**N017376 001**SEPTRA DS**AB** MONARCH PHARMS 800MG;160MG**N017376 002**SULFAMETHOXAZOLE AND TRIMETHOPRIM**AB** AMNEAL PHARMS NY 400MG;80MG**A076899 001** Jan 27, 2005**AB** 800MG;160MG**A076899 002** Jan 27, 2005**AB** AUROBINDO PHARMA 400MG;80MG**A090624 001** Feb 16, 2010**AB** 800MG;160MG**A090624 002** Feb 16, 2010**AB** GLENMARK GENERICS 400MG;80MG**A090828 002** Dec 22, 2010**AB** 800MG;160MG**A090828 001** Dec 22, 2010**AB** SUN PHARM INDS 800MG;160MG**A071017 001** Aug 25, 1986**AB** VINTAGE 400MG;80MG**A078060 002** Jan 25, 2007**AB** 800MG;160MG**A078060 001** Jan 25, 2007**AB** VISTA PHARMS 400MG;80MG**A076817 001** Oct 07, 2005**AB** 800MG;160MG**A076817 002** Oct 07, 2005SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH**AB** TEVA 800MG;160MG**A070037 001** Jun 02, 1987SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH**AB** TEVA PHARMS 400MG;80MG**A070030 001** Jun 02, 1987SULFANILAMIDE

CREAM;VAGINAL

AVC

+ MEDA PHARMS 15%

N006530 003 Jan 27, 1987

SULFASALAZINE

SUSPENSION;ORAL

AZULFIDINE

+ PHARMACIA AND UPJOHN 250MG/5ML

A086983 001

TABLET;ORAL

AZULFIDINE**AB** + PHARMACIA AND UPJOHN 500MG**N007073 001**SULFASALAZINE**AB** VINTAGE PHARMS 500MG**A040349 001** Jan 11, 2002**AB** WATSON LABS 500MG**A085828 001**

TABLET, DELAYED RELEASE;ORAL

AZULFIDINE EN-TABS**AB** + PHARMACIA AND UPJOHN 500MG**N007073 002** Apr 06, 1983SULFASALAZINE**AB** VINTAGE PHARMS 500MG**A075339 001** Jan 11, 2002

PRESCRIPTION DRUG PRODUCT LIST

SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES

FOR SUSPENSION; INTRAVENOUS

LUMASON

+ BRACCO 60.7MG/25MG N203684 001 Oct 15, 2014

SULINDAC

TABLET; ORAL

SULINDAC

<u>AB</u>	EPIC PHARMA	<u>150MG</u>	<u>A072710</u>	<u>001</u>	Mar 25, 1991
<u>AB</u>		<u>200MG</u>	<u>A072711</u>	<u>001</u>	Mar 25, 1991
<u>AB</u>	HERITAGE PHARMS INC	<u>150MG</u>	<u>A073262</u>	<u>002</u>	Sep 06, 1991
<u>AB</u>		<u>200MG</u>	<u>A073262</u>	<u>001</u>	Sep 06, 1991
<u>AB</u>	MYLAN	<u>150MG</u>	<u>A073039</u>	<u>002</u>	Jun 22, 1993
<u>AB</u>		<u>200MG</u>	<u>A073039</u>	<u>001</u>	Jun 22, 1993
<u>AB</u>	SUN PHARM INDS	<u>150MG</u>	<u>A072050</u>	<u>001</u>	Apr 17, 1991
<u>AB</u>		<u>200MG</u>	<u>A072051</u>	<u>001</u>	Apr 17, 1991
<u>AB</u>	WATSON LABS	<u>150MG</u>	<u>A071891</u>	<u>001</u>	Apr 03, 1990
<u>AB</u>	+	<u>200MG</u>	<u>A071795</u>	<u>001</u>	Apr 03, 1990

SUMATRIPTAN

SPRAY; NASAL

IMITREX

<u>AB</u>	+	GLAXOSMITHKLINE	<u>5MG/SPRAY</u>	<u>N020626</u>	<u>001</u>	Aug 26, 1997
<u>AB</u>	+		<u>20MG/SPRAY</u>	<u>N020626</u>	<u>003</u>	Aug 26, 1997

SUMATRIPTAN

<u>AB</u>	LANNETT	<u>5MG/SPRAY</u>	<u>A204841</u>	<u>001</u>	Feb 19, 2016
<u>AB</u>		<u>20MG/SPRAY</u>	<u>A204841</u>	<u>002</u>	Feb 19, 2016

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

IMITREX STATDOSE

<u>AB</u>	+	GLAXOSMITHKLINE	<u>EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)</u>	<u>N020080</u>	<u>002</u>	Feb 01, 2006
<u>AB</u>	+		<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>N020080</u>	<u>003</u>	Dec 23, 1996

SUMATRIPTAN SUCCINATE

<u>AB</u>	ANTARES PHARMA INC	<u>EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)</u>	<u>A078319</u>	<u>001</u>	Dec 10, 2015
<u>AB</u>		<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A078319</u>	<u>002</u>	Dec 10, 2015
<u>AB</u>	DR REDDYS LABS INC	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A090495</u>	<u>001</u>	Jan 29, 2014
<u>AB</u>	SUN PHARMA GLOBAL	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A090358</u>	<u>001</u>	Jun 21, 2011

IMITREX

<u>AP</u>	+	GLAXOSMITHKLINE	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>N020080</u>	<u>001</u>	Dec 28, 1992
-----------	---	-----------------	--	----------------	------------	--------------

SUMATRIPTAN SUCCINATE

<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A202758</u>	<u>001</u>	Apr 23, 2013
<u>AP</u>	EUROHLTH INTL SARL	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A079123</u>	<u>001</u>	Feb 06, 2009
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A079242</u>	<u>001</u>	Mar 02, 2009
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A200183</u>	<u>001</u>	Sep 16, 2013
<u>AP</u>	INJECTALIA	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A090310</u>	<u>001</u>	Aug 11, 2010
<u>AP</u>	MYLAN LABS LTD	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A203322</u>	<u>001</u>	Apr 14, 2014
<u>AP</u>	PAR PHARM	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A077332</u>	<u>001</u>	Oct 09, 2009
<u>AP</u>	PAR STERILE PRODUCTS	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A077871</u>	<u>001</u>	Jul 09, 2009
<u>AP</u>	SAGENT AGILA	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A090641</u>	<u>001</u>	Jul 28, 2010
<u>AP</u>	SAGENT STRIDES	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A090314</u>	<u>001</u>	Jun 10, 2010
<u>AP</u>	TEVA PHARMS USA	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A077907</u>	<u>001</u>	Feb 06, 2009
<u>AP</u>	WOCKHARDT	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A078593</u>	<u>001</u>	Feb 06, 2009

SUMAVEL DOSEPRO

BX	+	ENDO VENTURES LTD	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N022239	002	Nov 26, 2013
BX	+		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022239	001	Jul 15, 2009

POWDER; INHALATION

ONZETRA XSAIL

+ AVANIR PHARMS EQ 11MG BASE N206099 001 Jan 27, 2016

SOLUTION; SUBCUTANEOUS

ZEMBRACE SYMTOUCH

DR REDDYS LABS LTD EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML) N208223 001 Jan 28, 2016

SYSTEM; IONTOPHORESIS

ZECUITY

+ TEVA BRANDED PHARM EQ 6.5MG BASE/4HR N202278 001 Jan 17, 2013

TABLET; ORAL

IMITREX

<u>AB</u>	GLAXOSMITHKLINE	<u>EQ 25MG BASE</u>	<u>N020132</u>	<u>002</u>	Jun 01, 1995
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>N020132</u>	<u>003</u>	Jun 01, 1995
<u>AB</u>	+	<u>EQ 100MG BASE</u>	<u>N020132</u>	<u>001</u>	Jun 01, 1995

SUMATRIPTAN SUCCINATE

<u>AB</u>	APOTEX INC	<u>EQ 25MG BASE</u>	<u>A200263</u>	<u>001</u>	Jun 19, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A200263</u>	<u>002</u>	Jun 19, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A200263</u>	<u>003</u>	Jun 19, 2012

PRESCRIPTION DRUG PRODUCT LIST

SUMATRIPTAN SUCCINATE

TABLET; ORAL

SUMATRIPTAN SUCCINATE

<u>AB</u>	AUROBINDO PHARMA	<u>EQ 25MG BASE</u>	<u>A078327 001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078327 002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078327 003</u>	Aug 10, 2009
<u>AB</u>	DR REDDYS LABS INC	<u>EQ 25MG BASE</u>	<u>A076847 001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076847 002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076847 003</u>	Aug 10, 2009
<u>AB</u>	MYLAN	<u>EQ 25MG BASE</u>	<u>A077744 001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077744 002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077744 003</u>	Aug 10, 2009
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 25MG BASE</u>	<u>A078284 001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078284 002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078284 003</u>	Aug 10, 2009
<u>AB</u>	SUN PHARM INDS	<u>EQ 25MG BASE</u>	<u>A078295 001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078295 002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078295 003</u>	Aug 10, 2009
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 25MG BASE</u>	<u>A076554 001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076554 002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076572 001</u>	Feb 09, 2009
<u>AB</u>	WATSON LABS	<u>EQ 25MG BASE</u>	<u>A076933 001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076933 002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076933 003</u>	Aug 10, 2009

SUNITINIB MALATE

CAPSULE; ORAL

SUTENT

<u>AB</u>	CPPI CV	<u>EQ 12.5MG BASE</u>	<u>N021938 001</u>	Jan 26, 2006
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>N021938 002</u>	Jan 26, 2006
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>N021938 004</u>	Mar 31, 2009
<u>AB</u>	+	<u>EQ 50MG BASE</u>	<u>N021938 003</u>	Jan 26, 2006

SUVOREXANT

TABLET; ORAL

BELSOMRA

MERCK SHARP DOHME

5MG

N204569 001 Aug 13, 2014

10MG

N204569 002 Aug 13, 2014

15MG

N204569 003 Aug 13, 2014

+

20MG

N204569 004 Aug 13, 2014

TACROLIMUS

CAPSULE; ORAL

PROGRAF

<u>AB</u>	ASTELLAS	<u>EQ 0.5MG BASE</u>	<u>N050708 003</u>	Aug 24, 1998
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>N050708 001</u>	Apr 08, 1994
<u>AB</u>	+	<u>EQ 5MG BASE</u>	<u>N050708 002</u>	Apr 08, 1994

TACROLIMUS

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 0.5MG BASE</u>	<u>A091195 001</u>	Aug 31, 2011
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A091195 002</u>	Aug 31, 2011
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A091195 003</u>	Aug 31, 2011
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 0.5MG BASE</u>	<u>A090509 001</u>	May 12, 2010
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090509 002</u>	May 12, 2010
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090509 003</u>	May 12, 2010
<u>AB</u>	MYLAN	<u>EQ 0.5MG BASE</u>	<u>A090596 001</u>	Sep 17, 2010
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090596 002</u>	Sep 17, 2010
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090596 003</u>	Sep 17, 2010
<u>AB</u>	PANACEA BIOTECH LTD	<u>EQ 0.5MG BASE</u>	<u>A090802 001</u>	Sep 28, 2012
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090802 002</u>	Sep 28, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090802 003</u>	Sep 28, 2012
<u>AB</u>	SANDOZ	<u>EQ 0.5MG BASE</u>	<u>A065461 001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A065461 002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A065461 003</u>	Aug 10, 2009
<u>AB</u>	STRIDES PHARMA	<u>EQ 0.5MG BASE</u>	<u>A090687 001</u>	Jul 22, 2014
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090687 002</u>	Jul 22, 2014
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090687 003</u>	Jul 22, 2014

CAPSULE, EXTENDED RELEASE; ORAL

ASTAGRAF XL

ASTELLAS

EQ 0.5MG BASE

N204096 001 Jul 19, 2013

EQ 1MG BASE

N204096 002 Jul 19, 2013

+

EQ 5MG BASE

N204096 003 Jul 19, 2013

PRESCRIPTION DRUG PRODUCT LIST

TACROLIMUS

INJECTABLE; INJECTION

PROGRAF

+ ASTELLAS

EQ 5MG BASE/ML

N050709 001 Apr 08, 1994

OINTMENT; TOPICAL

PROTOPICAB + LEO PHARMA AS0.03%N050777 001 Dec 08, 2000AB +0.1%N050777 002 Dec 08, 2000TACROLIMUSAB FOUGERA PHARMS INC0.03%A200744 001 Sep 09, 2014AB0.1%A200744 002 Sep 09, 2014

TABLET, EXTENDED RELEASE; ORAL

ENVARUS XR

VELOXIS PHARMS INC

EQ 0.75MG BASE

N206406 001 Jul 10, 2015

EQ 1MG BASE

N206406 002 Jul 10, 2015

+

EQ 4MG BASE

N206406 003 Jul 10, 2015

TADALAFIL

TABLET; ORAL

ADCIRCA

+ ELI LILLY CO

20MG

N022332 001 May 22, 2009

CIALIS

LILLY

2.5MG

N021368 004 Jan 07, 2008

5MG

N021368 001 Nov 21, 2003

10MG

N021368 002 Nov 21, 2003

+

20MG

N021368 003 Nov 21, 2003

TAFLUPROST

SOLUTION/DROPS; OPHTHALMIC

ZIOPTAN

+ OAK PHARMS INC

0.0015%

N202514 001 Feb 10, 2012

TALC

AEROSOL, METERED; INTRAPLEURAL

SCLEROSOL

+ LYMOL MEDCL

400MG/SPRAY

N020587 001 Dec 24, 1997

POWDER; INTRAPLEURAL

TALC

+ LYMOL MEDCL

5GM/BOT

N021388 001 Dec 15, 2003

TALIGLUCERASE ALFA

POWDER; IV (INFUSION)

ELELYSO

+ PFIZER

200 UNITS/VIAL

N022458 001 May 01, 2012

TAMOXIFEN CITRATE

SOLUTION; ORAL

SOLTAMOX

MIDATECH PHARMA US

EQ 10MG BASE/5ML

N021807 001 Oct 29, 2005

TABLET; ORAL

TAMOXIFEN CITRATEAB ACTAVIS LABS FL INCEQ 10MG BASEA070929 001 Feb 20, 2003ABEQ 20MG BASEA070929 002 Feb 20, 2003AB APOTEXEQ 10MG BASEA090878 001 Sep 23, 2011ABEQ 20MG BASEA090878 002 Sep 23, 2011AB MAYNE PHARMAEQ 10MG BASEA075797 001 Feb 20, 2003AB +EQ 20MG BASEA074858 001 Feb 20, 2003AB MYLANEQ 10MG BASEA074732 002 Feb 20, 2003ABEQ 20MG BASEA074732 001 Feb 20, 2003TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL

FLOMAXAB + BOEHRINGER INGELHEIM0.4MGN020579 001 Apr 15, 1997TAMSULOSIN HYDROCHLORIDEAB ANCHEN PHARMS0.4MGA202010 001 Jan 04, 2013AB0.4MGA202433 001 Apr 30, 2013AB IMPAX LABS0.4MGA090377 001 Mar 02, 2010AB0.4MGA090408 001 Apr 27, 2010AB SANDOZ0.4MGA078015 001 Apr 27, 2010AB0.4MGA090931 001 Jul 15, 2010AB SUN PHARM INDS LTD0.4MGA078801 001 Apr 27, 2010AB0.4MGA077630 001 Apr 27, 2010AB SYNTHON PHARMS0.4MGA078938 001 Apr 27, 2010AB0.4MGA078938 001 Apr 27, 2010AB WOCKHARDT0.4MGA078225 001 Apr 27, 2010AB0.4MGA078225 001 Apr 27, 2010AB ZYDUS PHARMS USA INC0.4MGA078225 001 Apr 27, 2010

PRESCRIPTION DRUG PRODUCT LISTTAPENTADOL HYDROCHLORIDE

SOLUTION; ORAL

NUCYNTA

+ DEPOMED INC EQ 20MG BASE/ML N203794 001 Oct 15, 2012

TABLET; ORAL

NUCYNTA

DEPOMED INC EQ 50MG BASE N022304 001 Nov 20, 2008

EQ 75MG BASE N022304 002 Nov 20, 2008

+ EQ 100MG BASE N022304 003 Nov 20, 2008

TABLET, EXTENDED RELEASE; ORAL

NUCYNTA ER

DEPOMED INC EQ 50MG BASE N200533 001 Aug 25, 2011

EQ 100MG BASE N200533 002 Aug 25, 2011

EQ 150MG BASE N200533 003 Aug 25, 2011

EQ 200MG BASE N200533 004 Aug 25, 2011

+ EQ 250MG BASE N200533 005 Aug 25, 2011

TASIMELTEON

CAPSULE; ORAL

HETLIOZ

+ VANDA PHARMS INC 20MG N205677 001 Jan 31, 2014

TAVABOROLE

SOLUTION; TOPICAL

KERYDIN

+ ANACOR PHARMS INC 5% N204427 001 Jul 07, 2014

TAZAROTENE

AEROSOL, FOAM; TOPICAL

FABIOR

+ STIEFEL LABS INC 0.1% N202428 001 May 11, 2012

CREAM; TOPICAL

AVAGE

+ ALLERGAN 0.1% N021184 003 Sep 30, 2002

TAZORAC

+ ALLERGAN 0.05% N021184 001 Sep 29, 2000

+ 0.1% N021184 002 Sep 29, 2000

GEL; TOPICAL

TAZORAC

+ ALLERGAN 0.05% N020600 001 Jun 13, 1997

+ 0.1% N020600 002 Jun 13, 1997

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION

PULMOLITE

BS JUBILANT DRAXIMAGE N/A N017776 001

TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT

BS DRAXIMAGE N/A N017881 001 Dec 30, 1987

TECHNETIUM TC-99M BICISATE KIT

INJECTABLE; INJECTION

NEUROLITE

LANTHEUS MEDCL N/A N020256 001 Nov 23, 1994

TECHNETIUM TC-99M DISOFENIN KIT

INJECTABLE; INJECTION

HEPATOLITE

PHARMALUCENCE N/A N018467 001 Mar 16, 1982

TECHNETIUM TC-99M EXAMETAZIME KIT

INJECTABLE; INJECTION

CERETEC

+ GE HEALTHCARE N/A N019829 001 Dec 30, 1988

TECHNETIUM TC-99M MEBROFENIN KIT

INJECTABLE; INJECTION

CHOLETEC**AP + BRACCO N/A N018963 001 Jan 21, 1987****TECHNETIUM TC-99M MEBROFENIN****AP PHARMALUCENCE N/A A078242 001 Jan 29, 2008**

PRESCRIPTION DRUG PRODUCT LIST

<u>TECHNETIUM TC-99M MEDRONATE</u>			
INJECTABLE; INJECTION			
DRAXIMAGE MDP-25			
	+ JUBILANT DRAXIMAGE	N/A	N018035 002 Feb 27, 2004
<u>TECHNETIUM TC-99M MEDRONATE KIT</u>			
INJECTABLE; INJECTION			
CIS-MDP			
AP	PHARMALUCENCE	N/A	<u>N018124 001</u>
MDP-BRACCO			
AP	BRACCO	N/A	<u>N018107 001</u>
<u>TECHNETIUM TC-99M MERTIATIDE KIT</u>			
INJECTABLE; INJECTION			
TECHNESCAN MAG3			
	+ MALLINKRODT NUCLEAR	N/A	N019882 001 Jun 15, 1990
<u>TECHNETIUM TC-99M OXIDRONATE KIT</u>			
INJECTABLE; INJECTION			
TECHNESCAN			
	+ MALLINKRODT NUCLEAR	N/A	N018321 001
<u>TECHNETIUM TC-99M PENTETATE KIT</u>			
INJECTABLE; INJECTION			
AN-DTPA			
AP	JUBILANT DRAXIMAGE	N/A	<u>N017714 001</u>
DTPA			
AP	DRAXIMAGE	N/A	<u>N018511 001</u> Dec 29, 1989
<u>TECHNETIUM TC-99M PYROPHOSPHATE KIT</u>			
INJECTABLE; INJECTION			
CIS-PYRO			
AP	PHARMALUCENCE	N/A	<u>N019039 001</u> Jun 30, 1987
TECHNESCAN PYP KIT			
AP	MALLINKRODT NUCLEAR	N/A	<u>N017538 001</u>
<u>TECHNETIUM TC-99M RED BLOOD CELL KIT</u>			
INJECTABLE; INJECTION			
ULTRATAG			
	MALLINKRODT NUCLEAR	N/A	N019981 001 Jun 10, 1991
<u>TECHNETIUM TC-99M SESTAMIBI KIT</u>			
INJECTABLE; INJECTION			
CARDIOLITE			
AP	+ LANTHEUS MEDCL	N/A	<u>N019785 001</u> Dec 21, 1990
TECHNETIUM TC 99M SESTAMIBI			
AP	CARDINAL HEALTH 414	N/A	<u>A078809 001</u> Apr 28, 2009
AP	DRAXIMAGE	N/A	<u>A078806 001</u> Apr 29, 2009
AP	PHARMALUCENCE	10-30mCi	<u>A079157 001</u> Jul 10, 2009
TECHNETIUM TC-99M SESTAMIBI			
AP	MALLINKRODT NUCLEAR	N/A	<u>A078098 001</u> Sep 22, 2008
<u>TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR</u>			
SOLUTION; INTRAVENOUS			
TECHNELITE			
	+ LANTHEUS MEDCL	1-20 CI/GENERATOR	N017771 002 Feb 12, 2014
ULTRA-TECHNEKOW FM			
	+ MALLINKRODT NUCLEAR	1-19 CI/GENERATOR	N017243 003 Feb 18, 2014
SOLUTION; INTRAVENOUS, ORAL			
TECHNETIUM TC 99M GENERATOR			
	+ GE HEALTHCARE	68-2703mCi/GENERATOR	N017693 002 Dec 13, 2013
<u>TECHNETIUM TC-99M SULFUR COLLOID KIT</u>			
SOLUTION; INJECTION, ORAL			
AN-SULFUR COLLOID			
	+ PHARMALUCENCE	N/A	N017858 001
<u>TECHNETIUM TC-99M TETROFOSMIN KIT</u>			
INJECTABLE; INJECTION			
MYOVUEW			
	+ GE HEALTHCARE	N/A	N020372 001 Feb 09, 1996
MYOVUEW 30ML			
	+ GE HEALTHCARE	N/A	N020372 002 Jul 07, 2005

PRESCRIPTION DRUG PRODUCT LIST

TECHNETIUM TC-99M TILMANOCEPT

INJECTABLE; INJECTION

LYMPHOSEEK KIT

+ NAVIDEA BIOPHARMS

N/A

N202207 001 Mar 13, 2013

TEDIZOLID PHOSPHATE

POWDER; IV (INFUSION)

SIVEXTRO

+ CUBIST PHARMS LLC

200MG/VIAL

N205436 001 Jun 20, 2014

TABLET; ORAL

SIVEXTRO

+ CUBIST PHARMS LLC

200MG

N205435 001 Jun 20, 2014

TEDUGLUTIDE RECOMBINANT

POWDER; SUBCUTANEOUS

GATTEX KIT

+ NPS PHARMS INC

5MG/VIAL

N203441 001 Dec 21, 2012

TELAVANCIN HYDROCHLORIDE

POWDER; IV (INFUSION)

VIBATIV

THERAVANCE BIOPHARMA

EQ 250MG BASE/VIAL

N022110 001 Sep 11, 2009

+

EQ 750MG BASE/VIAL

N022110 002 Sep 11, 2009

TELBIVUDINE

TABLET; ORAL

TYZEKA

+ NOVARTIS

600MG

N022011 001 Oct 25, 2006

TELMISARTAN

TABLET; ORAL

MICARDISAB BOEHRINGER INGELHEIM20MGN020850 003 Apr 04, 2000AB40MGN020850 001 Nov 10, 1998AB +80MGN020850 002 Nov 10, 1998TELMISARTANAB ALEMBIC PHARMS LTD20MGA202130 001 Jul 07, 2014AB40MGA202130 002 Jul 07, 2014AB80MGA202130 003 Jul 07, 2014AB AMNEAL PHARMS20MGA204415 001 Sep 08, 2015AB40MGA204415 002 Sep 08, 2015AB80MGA204415 003 Sep 08, 2015AB AUROBINDO PHARMA LTD20MGA206511 001 Sep 03, 2015AB40MGA206511 002 Sep 03, 2015AB80MGA206511 003 Sep 03, 2015AB GLENMARK GENERICS20MGA090032 001 Jul 07, 2014AB40MGA090032 002 Jul 07, 2014AB80MGA090032 003 Jul 07, 2014AB HETERO LABS LTD V20MGA205901 001 Apr 22, 2016AB40MGA205901 002 Apr 22, 2016AB80MGA205901 003 Apr 22, 2016AB INVENTIA HLTHCARE20MGA205150 001 Oct 30, 2015AB40MGA205150 002 Oct 30, 2015AB80MGA205150 003 Oct 30, 2015AB JUBILANT GENERICS20MGA204164 001 Aug 22, 2016AB40MGA204164 002 Aug 22, 2016AB80MGA204164 003 Aug 22, 2016AB MYLAN PHARMS INC20MGA202397 001 Jul 07, 2014AB40MGA202397 002 Jul 07, 2014AB80MGA202397 003 Jul 07, 2014AB SANDOZ INC20MGA203867 001 Nov 03, 2014AB40MGA203867 002 Nov 03, 2014AB80MGA203867 003 Nov 03, 2014AB TORRENT PHARMS LTD20MGA203171 001 Jul 07, 2014AB40MGA203171 002 Jul 07, 2014AB80MGA203171 003 Jul 07, 2014AB WATSON LABS20MGA078710 001 Jan 08, 2014AB40MGA078710 002 Jan 08, 2014AB80MGA078710 003 Jan 08, 2014AB ZYDUS PHARMS USA INC20MGA203325 001 Aug 26, 2014AB40MGA203325 002 Aug 26, 2014AB80MGA203325 003 Aug 26, 2014

PRESCRIPTION DRUG PRODUCT LIST

TEMAZEPAM

CAPSULE; ORAL

RESTORIL

<u>AB</u>	MALLINCKRODT INC	<u>7.5MG</u>	<u>N018163 003</u>	Oct 25, 1991
<u>AB</u>		<u>15MG</u>	<u>N018163 001</u>	
<u>AB</u>		<u>22.5MG</u>	<u>N018163 004</u>	Nov 02, 2004
<u>AB</u>	+	<u>30MG</u>	<u>N018163 002</u>	

TEMAZEPAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>15MG</u>	<u>A071638 001</u>	Aug 07, 1987
<u>AB</u>		<u>30MG</u>	<u>A071620 001</u>	Aug 07, 1987
<u>AB</u>	AMNEAL PHARMS	<u>7.5MG</u>	<u>A203482 001</u>	May 23, 2016
<u>AB</u>		<u>15MG</u>	<u>A203482 002</u>	May 23, 2016
<u>AB</u>		<u>22.5MG</u>	<u>A203482 003</u>	May 23, 2016
<u>AB</u>		<u>30MG</u>	<u>A203482 004</u>	May 23, 2016
<u>AB</u>	MYLAN	<u>7.5MG</u>	<u>A070920 002</u>	May 21, 2010
<u>AB</u>		<u>15MG</u>	<u>A070920 004</u>	Jul 07, 1986
<u>AB</u>		<u>22.5MG</u>	<u>A070920 003</u>	Jun 12, 2009
<u>AB</u>		<u>30MG</u>	<u>A070920 001</u>	Jul 10, 1986
<u>AB</u>	NOVEL LABS INC	<u>7.5MG</u>	<u>A071457 002</u>	Jun 22, 2012
<u>AB</u>		<u>15MG</u>	<u>A071456 001</u>	Apr 21, 1987
<u>AB</u>		<u>22.5MG</u>	<u>A071457 003</u>	Jun 22, 2012
<u>AB</u>		<u>30MG</u>	<u>A071457 001</u>	Apr 21, 1987
<u>AB</u>	SANDOZ	<u>15MG</u>	<u>A071427 001</u>	Jan 12, 1988
<u>AB</u>		<u>30MG</u>	<u>A071428 001</u>	Jan 12, 1988
<u>AB</u>	SUN PHARM INDS	<u>7.5MG</u>	<u>A078581 001</u>	Sep 08, 2009
<u>AB</u>		<u>22.5MG</u>	<u>A071175 002</u>	Sep 14, 2009
<u>AB</u>	VINTAGE PHARMS	<u>7.5MG</u>	<u>A201781 001</u>	Jun 04, 2015
<u>AB</u>		<u>15MG</u>	<u>A201781 002</u>	Jun 04, 2015
<u>AB</u>		<u>22.5MG</u>	<u>A201781 003</u>	Jun 04, 2015
<u>AB</u>		<u>30MG</u>	<u>A201781 004</u>	Jun 04, 2015

TEMOZOLOMIDE

CAPSULE; ORAL

TEMODAR

<u>AB</u>	MERCK SHARP DOHME	<u>5MG</u>	<u>N021029 001</u>	Aug 11, 1999
<u>AB</u>		<u>20MG</u>	<u>N021029 002</u>	Aug 11, 1999
<u>AB</u>		<u>100MG</u>	<u>N021029 003</u>	Aug 11, 1999
<u>AB</u>		<u>140MG</u>	<u>N021029 005</u>	Oct 19, 2006
<u>AB</u>		<u>180MG</u>	<u>N021029 006</u>	Oct 19, 2006
<u>AB</u>	+	<u>250MG</u>	<u>N021029 004</u>	Aug 11, 1999

TEMOZOLOMIDE

<u>AB</u>	AMERIGEN PHARMS LTD	<u>5MG</u>	<u>A203490 001</u>	Jul 13, 2016
<u>AB</u>		<u>20MG</u>	<u>A203490 002</u>	Jul 13, 2016
<u>AB</u>		<u>100MG</u>	<u>A203490 003</u>	Jul 13, 2016
<u>AB</u>		<u>140MG</u>	<u>A203490 004</u>	Jul 13, 2016
<u>AB</u>		<u>180MG</u>	<u>A203490 005</u>	Jul 13, 2016
<u>AB</u>		<u>250MG</u>	<u>A203490 006</u>	Jul 13, 2016
<u>AB</u>	AMNEAL PHARMS	<u>5MG</u>	<u>A203691 001</u>	May 08, 2015
<u>AB</u>		<u>20MG</u>	<u>A203691 002</u>	May 08, 2015
<u>AB</u>		<u>100MG</u>	<u>A203691 003</u>	May 08, 2015
<u>AB</u>		<u>140MG</u>	<u>A203691 004</u>	May 08, 2015
<u>AB</u>		<u>180MG</u>	<u>A203691 005</u>	May 08, 2015
<u>AB</u>		<u>250MG</u>	<u>A203691 006</u>	May 08, 2015
<u>AB</u>	BARR	<u>5MG</u>	<u>A078879 001</u>	Mar 01, 2010
<u>AB</u>		<u>20MG</u>	<u>A078879 002</u>	Mar 01, 2010
<u>AB</u>		<u>100MG</u>	<u>A078879 003</u>	Mar 01, 2010
<u>AB</u>		<u>140MG</u>	<u>A078879 005</u>	Mar 01, 2010
<u>AB</u>		<u>180MG</u>	<u>A078879 006</u>	Mar 01, 2010
<u>AB</u>		<u>250MG</u>	<u>A078879 004</u>	Mar 01, 2010
<u>AB</u>	CHEMI SPA	<u>5MG</u>	<u>A204639 001</u>	Nov 23, 2016
<u>AB</u>		<u>20MG</u>	<u>A204639 002</u>	Nov 23, 2016
<u>AB</u>		<u>100MG</u>	<u>A204639 003</u>	Nov 23, 2016
<u>AB</u>		<u>140MG</u>	<u>A204639 004</u>	Nov 23, 2016
<u>AB</u>		<u>180MG</u>	<u>A204639 005</u>	Nov 23, 2016
<u>AB</u>		<u>250MG</u>	<u>A204639 006</u>	Nov 23, 2016
<u>AB</u>	IDT AUSTRALIA LTD	<u>5MG</u>	<u>A206413 001</u>	Apr 12, 2016
<u>AB</u>		<u>20MG</u>	<u>A206413 002</u>	Apr 12, 2016
<u>AB</u>		<u>100MG</u>	<u>A206413 003</u>	Apr 12, 2016
<u>AB</u>		<u>140MG</u>	<u>A206413 004</u>	Apr 12, 2016
<u>AB</u>		<u>180MG</u>	<u>A206413 005</u>	Apr 12, 2016
<u>AB</u>		<u>250MG</u>	<u>A206413 006</u>	Apr 12, 2016
<u>AB</u>	KREMERS URBAN PHARMS	<u>5MG</u>	<u>A203898 001</u>	Feb 10, 2016
<u>AB</u>		<u>20MG</u>	<u>A203898 002</u>	Feb 10, 2016

PRESCRIPTION DRUG PRODUCT LIST

TEMOZOLOMIDE

CAPSULE; ORAL

TEMOZOLOMIDE

<u>AB</u>		<u>100MG</u>	<u>A203898</u>	<u>003</u>	Feb 10, 2016
<u>AB</u>		<u>140MG</u>	<u>A203898</u>	<u>004</u>	Feb 10, 2016
<u>AB</u>		<u>180MG</u>	<u>A203898</u>	<u>005</u>	Feb 10, 2016
<u>AB</u>		<u>250MG</u>	<u>A203898</u>	<u>006</u>	Feb 10, 2016
<u>AB</u>	MYLAN PHARMS INC	<u>5MG</u>	<u>A205227</u>	<u>001</u>	Jun 29, 2016
<u>AB</u>		<u>20MG</u>	<u>A205227</u>	<u>002</u>	Jun 29, 2016
<u>AB</u>		<u>100MG</u>	<u>A205227</u>	<u>003</u>	Jun 29, 2016
<u>AB</u>		<u>140MG</u>	<u>A205227</u>	<u>004</u>	Jun 29, 2016
<u>AB</u>		<u>180MG</u>	<u>A205227</u>	<u>005</u>	Jun 29, 2016
<u>AB</u>		<u>250MG</u>	<u>A205227</u>	<u>006</u>	Jun 29, 2016
<u>AB</u>	RISING PHARMS INC	<u>5MG</u>	<u>A206309</u>	<u>001</u>	Apr 27, 2016
<u>AB</u>		<u>20MG</u>	<u>A206309</u>	<u>002</u>	Apr 27, 2016
<u>AB</u>		<u>100MG</u>	<u>A206309</u>	<u>003</u>	Apr 27, 2016
<u>AB</u>		<u>140MG</u>	<u>A206309</u>	<u>004</u>	Apr 27, 2016
<u>AB</u>		<u>180MG</u>	<u>A206309</u>	<u>005</u>	Apr 27, 2016
<u>AB</u>		<u>250MG</u>	<u>A206309</u>	<u>006</u>	Apr 27, 2016
<u>AB</u>	SUN PHARMA GLOBAL	<u>5MG</u>	<u>A201742</u>	<u>001</u>	Feb 12, 2014
<u>AB</u>		<u>20MG</u>	<u>A201742</u>	<u>002</u>	Feb 12, 2014
<u>AB</u>		<u>100MG</u>	<u>A201742</u>	<u>003</u>	Feb 12, 2014
<u>AB</u>		<u>140MG</u>	<u>A201742</u>	<u>004</u>	Feb 12, 2014
<u>AB</u>		<u>180MG</u>	<u>A201742</u>	<u>005</u>	Feb 12, 2014
<u>AB</u>		<u>250MG</u>	<u>A201742</u>	<u>006</u>	Feb 12, 2014

POWDER; INTRAVENOUS

TEMODAR

+ MERCK SHARP DOHME 100MG/VIAL N022277 001 Feb 27, 2009

TEMSIROLIMUS

SOLUTION; INTRAVENOUS

TORISEL

+ PF PRISM CV 25MG/ML (25MG/ML) N022088 001 May 30, 2007

TENIPOSIDE

INJECTABLE; INJECTION

VUMON

+ HQ SPECLT PHARMA 10MG/ML N020119 001 Jul 14, 1992

TENOFOVIR ALAFENAMIDE FUMARATE

TABLET; ORAL

VEMLIDY

+ GILEAD SCIENCES INC EQ 25MG BASE N208464 001 Nov 10, 2016

TENOFOVIR DISOPROXIL FUMARATE

POWDER; ORAL

VIREAD

+ GILEAD SCIENCES INC 40MG/SCOOPFUL N022577 001 Jan 18, 2012

TABLET; ORAL

TENOFOVIR DISOPROXIL FUMARATE

<u>AB</u>	TEVA PHARMS USA	<u>300MG</u>	<u>A091612</u>	<u>001</u>	Mar 18, 2015
<u>AB</u>	+ GILEAD SCIENCES INC	<u>300MG</u>	<u>N021356</u>	<u>001</u>	Oct 26, 2001
		150MG	N021356	002	Jan 18, 2012
		200MG	N021356	003	Jan 18, 2012
		250MG	N021356	004	Jan 18, 2012

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

<u>AB</u>	APOTEX	<u>EQ 1MG BASE</u>	<u>A075498</u>	<u>001</u>	Apr 12, 2001
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075498</u>	<u>002</u>	Apr 12, 2001
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A075498</u>	<u>003</u>	Apr 12, 2001
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075498</u>	<u>004</u>	Apr 12, 2001
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 1MG BASE</u>	<u>A075614</u>	<u>002</u>	Jan 30, 2001
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075614</u>	<u>001</u>	Jan 30, 2001
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A075614</u>	<u>003</u>	Jan 30, 2001
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075614</u>	<u>004</u>	Jan 30, 2001
<u>AB</u>	JUBILANT CADISTA	<u>EQ 1MG BASE</u>	<u>A075317</u>	<u>001</u>	Dec 20, 2004
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075317</u>	<u>002</u>	Dec 20, 2004
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A075317</u>	<u>003</u>	Dec 20, 2004
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075317</u>	<u>004</u>	Dec 20, 2004
<u>AB</u>	MYLAN	<u>EQ 1MG BASE</u>	<u>A075140</u>	<u>002</u>	Feb 11, 2000
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075140</u>	<u>003</u>	Feb 11, 2000
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A075140</u>	<u>001</u>	Feb 11, 2000

PRESCRIPTION DRUG PRODUCT LIST

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075140 004</u>	Feb 11, 2000
<u>AB</u>	SANDOZ	<u>EQ 1MG BASE</u>	<u>A074823 001</u>	Mar 30, 1998
<u>AB</u>	+	<u>EQ 2MG BASE</u>	<u>A074823 002</u>	Mar 30, 1998
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A074823 003</u>	Mar 30, 1998
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A074823 004</u>	Mar 30, 1998

TERBINAFFINE HYDROCHLORIDE

GRANULE; ORAL

LAMISIL

NOVARTIS

+

TABLET; ORAL

LAMISIL

<u>AB</u>	+	NOVARTIS	<u>EQ 250MG BASE</u>	<u>N020539 001</u>	May 10, 1996
-----------	---	----------	----------------------	--------------------	--------------

TERBINAFFINE HYDROCHLORIDE

<u>AB</u>	APOTEX	<u>EQ 250MG BASE</u>	<u>A078199 001</u>	Jul 02, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 250MG BASE</u>	<u>A078297 001</u>	Jul 02, 2007
<u>AB</u>	BRECKENRIDGE PHARM	<u>EQ 250MG BASE</u>	<u>A077714 001</u>	Jun 04, 2010
<u>AB</u>	CIPLA LTD	<u>EQ 250MG BASE</u>	<u>A077137 001</u>	Jul 02, 2007
<u>AB</u>	DR REDDYS LABS INC	<u>EQ 250MG BASE</u>	<u>A076390 001</u>	Jul 02, 2007
<u>AB</u>	GLENMARK GENERICS	<u>EQ 250MG BASE</u>	<u>A078157 001</u>	Jul 02, 2007
<u>AB</u>	HARRIS PHARM	<u>EQ 250MG BASE</u>	<u>A077919 001</u>	Jul 02, 2007
<u>AB</u>	INVAGEN PHARMS	<u>EQ 250MG BASE</u>	<u>A077533 001</u>	Jul 02, 2007
<u>AB</u>	MYLAN	<u>EQ 250MG BASE</u>	<u>A077195 001</u>	Jul 02, 2007
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 250MG BASE</u>	<u>A078163 001</u>	Jul 02, 2007
<u>AB</u>	TEVA	<u>EQ 250MG BASE</u>	<u>A076377 001</u>	Jul 02, 2007

TERBUTALINE SULFATE

INJECTABLE; INJECTION

TERBUTALINE SULFATE

<u>AP</u>	AKORN	<u>1MG/ML</u>	<u>A078151 001</u>	Jan 07, 2008	
<u>AP</u>	+	AMPHASTAR PHARMS INC	<u>1MG/ML</u>	<u>A076770 001</u>	Apr 23, 2004
<u>AP</u>	FRESENIUS KABI USA	<u>1MG/ML</u>	<u>A076887 001</u>	May 26, 2004	
<u>AP</u>	HIKMA FARMACEUTICA	<u>1MG/ML</u>	<u>A078630 001</u>	May 20, 2009	
<u>AP</u>	UNITED BIOMEDCL	<u>1MG/ML</u>	<u>A200122 001</u>	Nov 08, 2013	

TABLET; ORAL

TERBUTALINE SULFATE

LANNETT

2.5MG

5MG

A077152 001 Mar 25, 2005

A077152 002 Mar 25, 2005

TERCONAZOLE

CREAM; VAGINAL

TERAZOL 3

<u>AB</u>	+	JANSSEN PHARMS	<u>0.8%</u>	<u>N019964 001</u>	Feb 21, 1991
-----------	---	----------------	-------------	--------------------	--------------

TERAZOL 7

<u>AB</u>	+	JANSSEN PHARMS	<u>0.4%</u>	<u>N019579 001</u>	Dec 31, 1987
-----------	---	----------------	-------------	--------------------	--------------

TERCONAZOLE

<u>AB</u>	FOUGERA PHARMS	<u>0.4%</u>	<u>A076712 001</u>	Feb 18, 2005	
<u>AB</u>	TARO	<u>0.4%</u>	<u>A076043 001</u>	Jan 19, 2005	
<u>AB</u>		<u>0.8%</u>	<u>A075953 001</u>	Apr 06, 2004	
BX	+	NYCOMED US	0.8%	N021735 001	Oct 01, 2004

SUPPOSITORY; VAGINAL

TERAZOL 3

<u>AB</u>	+	JANSSEN PHARMS	<u>80MG</u>	<u>N019641 001</u>	May 24, 1988
-----------	---	----------------	-------------	--------------------	--------------

TERCONAZOLE

<u>AB</u>	PERRIGO NEW YORK	<u>80MG</u>	<u>A077149 001</u>	Mar 17, 2006
<u>AB</u>	TARO	<u>80MG</u>	<u>A077553 001</u>	Mar 09, 2007

TERIFLUNOMIDE

TABLET; ORAL

AUBAGIO

SANOFI AVENTIS US

7MG

+

14MG

N202992 001 Sep 12, 2012

N202992 002 Sep 12, 2012

TERIPARATIDE RECOMBINANT HUMAN

INJECTABLE; SUBCUTANEOUS

FORTEO

+

LILLY

0.6MG/2.4ML (0.25MG/ML)

N021318 002 Jun 25, 2008

PRESCRIPTION DRUG PRODUCT LIST

<u>TESAMORELIN ACETATE</u>			
POWDER; SUBCUTANEOUS			
EGRIFTA			
	+ THERATECHNOLOGIES	EQ 1MG BASE/VIAL	N022505 001 Nov 10, 2010
<u>TESTOSTERONE</u>			
FILM, EXTENDED RELEASE; TRANSDERMAL			
ANDRODERM			
	+ ALLERGAN SALES LLC	2MG/24HR	N020489 003 Oct 20, 2011
	+	4MG/24HR	N020489 004 Oct 20, 2011
GEL; TRANSDERMAL			
<u>ANDROGEL</u>			
<u>AB1</u>	ABBVIE	<u>25MG/2.5GM PACKET</u>	<u>N021015 001</u> Feb 28, 2000
<u>AB1</u>	+	<u>50MG/5GM PACKET</u>	<u>N021015 002</u> Feb 28, 2000
<u>TESTOSTERONE</u>			
<u>AB1</u>	ACTAVIS LABS UT INC	<u>25MG/2.5GM PACKET</u>	<u>A076737 001</u> Jan 27, 2006
<u>AB1</u>		<u>50MG/5GM PACKET</u>	<u>A076737 002</u> Jan 27, 2006
<u>AB1</u>	PAR PHARM	<u>25MG/2.5GM PACKET</u>	<u>A076744 001</u> May 23, 2007
<u>AB1</u>		<u>50MG/5GM PACKET</u>	<u>A076744 002</u> May 23, 2007
<u>AB1</u>	PERRIGO ISRAEL	<u>25MG/2.5GM PACKET</u>	<u>N203098 002</u> Jan 31, 2013
<u>AB1</u>		<u>50MG/5GM PACKET</u>	<u>N203098 003</u> Jan 31, 2013
<u>TESTIM</u>			
<u>AB2</u>	+ AUXILIUM PHARMS	<u>50MG/5GM PACKET</u>	<u>N021454 001</u> Oct 31, 2002
<u>VOGELXO</u>			
<u>AB2</u>	UPSHER-SMITH LABS	<u>50MG/5GM PACKET</u>	<u>N204399 002</u> Jun 04, 2014
TESTOSTERONE			
BX	ANI PHARMS INC	25MG/2.5GM PACKET	N202763 001 Feb 14, 2012
BX		50MG/5GM PACKET	N202763 002 Feb 14, 2012
ANDROGEL			
	ABBVIE	1.62% (20.25MG/1.25GM PACKET)	N022309 002 Sep 07, 2012
	+	1.62% (40.5MG/2.5GM PACKET)	N022309 003 Sep 07, 2012
GEL, METERED; NASAL			
NATESTO			
	AYTU BIOSCIENCE INC	5.5MG/0.122GM ACTUATION	N205488 001 May 28, 2014
GEL, METERED; TRANSDERMAL			
<u>ANDROGEL</u>			
<u>AB</u>	+ ABBVIE	<u>1.62% (20.25MG/1.25GM ACTUATION)</u>	<u>N022309 001</u> Apr 29, 2011
<u>AB</u>	+	<u>12.5MG/1.25GM ACTUATION</u>	<u>N021015 003</u> Sep 26, 2003
<u>FORTESTA</u>			
<u>AB</u>	+ ENDO PHARMS	<u>10MG/0.5GM ACTUATION</u>	<u>N021463 001</u> Dec 29, 2010
<u>TESTOSTERONE</u>			
<u>AB</u>	ACTAVIS LABS UT INC	<u>10MG/0.5GM ACTUATION</u>	<u>A204571 001</u> Aug 05, 2015
<u>AB</u>		<u>12.5MG/1.25GM ACTUATION</u>	<u>A076737 003</u> Mar 09, 2015
<u>AB</u>	PERRIGO ISRAEL	<u>12.5MG/1.25GM ACTUATION</u>	<u>N203098 001</u> Jan 31, 2013
<u>AB</u>		<u>1.62% (20.25MG/1.25GM ACTUATION)</u>	<u>A204268 001</u> Aug 04, 2015
VOGELXO			
BX	UPSHER-SMITH LABS	12.5MG/1.25GM ACTUATION	N204399 003 Jun 04, 2014
PELLET; IMPLANTATION			
TESTOPEL			
	+ AUXILIUM PHARMS INC	75MG	A080911 001
SOLUTION, METERED; TRANSDERMAL			
AXIRON			
	+ ELI LILLY AND CO	30MG/1.5ML ACTUATION	N022504 001 Nov 23, 2010
TABLET, EXTENDED RELEASE; BUCCAL			
STRIANT			
	+ AUXILIUM PHARMS INC	30MG	N021543 001 Jun 19, 2003
<u>TESTOSTERONE CYPIONATE</u>			
INJECTABLE; INJECTION			
<u>DEPO-TESTOSTERONE</u>			
<u>AO</u>	+ PHARMACIA AND UPJOHN	<u>100MG/ML</u>	<u>A085635 002</u>
<u>AO</u>	+	<u>200MG/ML</u>	<u>A085635 003</u>
<u>TESTOSTERONE CYPIONATE</u>			
<u>AO</u>	EUROHLTH INTL SARL	<u>100MG/ML</u>	<u>A090387 001</u> Jul 15, 2010
<u>AO</u>		<u>200MG/ML</u>	<u>A090387 002</u> Jul 15, 2010
<u>AO</u>	HIKMA FARMACEUTICA	<u>200MG/ML</u>	<u>A091244 001</u> May 01, 2012
<u>AO</u>	MYLAN INSTITUTIONAL	<u>200MG/ML</u>	<u>A040652 001</u> Dec 11, 2006
<u>AO</u>	PADDOCK LLC	<u>200MG/ML</u>	<u>A040530 001</u> Jan 31, 2005
<u>AO</u>	SANDOZ	<u>100MG/ML</u>	<u>A040615 001</u> Aug 10, 2006
<u>AO</u>		<u>200MG/ML</u>	<u>A040615 002</u> Aug 10, 2006
<u>AO</u>	SUN PHARM INDS LTD	<u>100MG/ML</u>	<u>A201720 001</u> Jun 03, 2013
<u>AO</u>		<u>200MG/ML</u>	<u>A201720 002</u> Jun 03, 2013
<u>AO</u>	WATSON LABS	<u>200MG/ML</u>	<u>A086030 001</u>

PRESCRIPTION DRUG PRODUCT LIST

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

DELATESTRYL

<u>AO</u>	+ ENDO PHARMS	<u>200MG/ML</u>	<u>N009165</u>	<u>003</u>	
-----------	---------------	-----------------	----------------	------------	--

TESTOSTERONE ENANTHATE

<u>AO</u>	HIKMA FARMACEUTICA	<u>200MG/ML</u>	<u>A091120</u>	<u>001</u>	Sep 18, 2012
<u>AO</u>	MYLAN INSTITUTIONAL	<u>200MG/ML</u>	<u>A040647</u>	<u>001</u>	Oct 05, 2009
<u>AO</u>	PADDOCK LLC	<u>200MG/ML</u>	<u>A040575</u>	<u>001</u>	Jun 14, 2006
<u>AO</u>	WATSON LABS	<u>200MG/ML</u>	<u>A085598</u>	<u>001</u>	

TESTOSTERONE UNDECANOATE

INJECTABLE; INTRAMUSCULAR

AVEED

	+ ENDO PHARMS INC	750MG/3ML (250MG/ML)	N022219	001	Mar 05, 2014
--	-------------------	----------------------	---------	-----	--------------

TETRABENAZINE

TABLET; ORAL

TETRABENAZINE

<u>AB</u>	HETERO LABS LTD V	<u>12.5MG</u>	<u>A204574</u>	<u>001</u>	Feb 03, 2016
<u>AB</u>		<u>25MG</u>	<u>A204574</u>	<u>002</u>	Feb 03, 2016
<u>AB</u>	SUN PHARMA GLOBAL	<u>12.5MG</u>	<u>A206129</u>	<u>001</u>	Aug 17, 2015
<u>AB</u>		<u>25MG</u>	<u>A206129</u>	<u>002</u>	Aug 17, 2015

XENAZINE

<u>AB</u>	VALEANT PHARMS NORTH	<u>12.5MG</u>	<u>N021894</u>	<u>001</u>	Aug 15, 2008
<u>AB</u>	+	<u>25MG</u>	<u>N021894</u>	<u>002</u>	Aug 15, 2008

TETRACAINE HYDROCHLORIDE

SOLUTION; OPHTHALMIC

TETRACAINE HYDROCHLORIDE

	+ NOVARTIS PHARMS CORP	0.5%	N208135	001	Feb 29, 2016
--	------------------------	------	---------	-----	--------------

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

ACHROMYCIN V

<u>AB</u>	HERITAGE PHARMS INC	<u>250MG</u>	<u>N050278</u>	<u>003</u>	
<u>AB</u>	+	<u>500MG</u>	<u>N050278</u>	<u>001</u>	

TETRACYCLINE HYDROCHLORIDE

<u>AB</u>	CHARTWELL CIENCA	<u>250MG</u>	<u>A062752</u>	<u>001</u>	Aug 12, 1988
<u>AB</u>		<u>500MG</u>	<u>A062752</u>	<u>002</u>	Aug 12, 1988
<u>AB</u>	IMPAX LABS	<u>250MG</u>	<u>A060469</u>	<u>001</u>	
<u>AB</u>		<u>500MG</u>	<u>A060469</u>	<u>003</u>	
<u>AB</u>	WATSON LABS	<u>250MG</u>	<u>A061837</u>	<u>001</u>	
<u>AB</u>		<u>500MG</u>	<u>A061837</u>	<u>002</u>	
	IMPAX LABS	100MG	A060469	002	

TETRAHYDROZOLINE HYDROCHLORIDE

SOLUTION; NASAL

TYZINE

	+ FOUGERA PHARMS	0.05%	A086576	002	
		0.1%	A086576	001	

SPRAY; NASAL

TYZINE

	+ FOUGERA PHARMS	0.1%	A086576	003	
--	------------------	------	---------	-----	--

THALIDOMIDE

CAPSULE; ORAL

THALOMID

CELGENE

		50MG	N020785	001	Jul 16, 1998
		100MG	N020785	002	Jan 17, 2003
		150MG	N020785	004	Jan 10, 2007
	+	200MG	N020785	003	Jan 17, 2003

THALLOUS CHLORIDE TL-201

INJECTABLE; INJECTION

THALLOUS CHLORIDE TL 201

<u>AP</u>	+ GE HEALTHCARE	<u>1mCi/ML</u>	<u>N018110</u>	<u>002</u>	Feb 27, 1996
<u>AP</u>	+ LANTHEUS MEDCL	<u>1mCi/ML</u>	<u>N017806</u>	<u>001</u>	
<u>AP</u>	+ MALLINKRODT NUCLEAR	<u>1mCi/ML</u>	<u>N018150</u>	<u>001</u>	

INJECTABLE; INTRAVENOUS

THALLOUS CHLORIDE TL 201

<u>AP</u>	+ LANTHEUS MEDCL	<u>2mCi/ML</u>	<u>N017806</u>	<u>002</u>	Oct 09, 1998
-----------	------------------	----------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

THEO-24

	ACTIENT PHARMS	100MG	A087942	001	Aug 22, 1983
+	AUXILIUM PHARMS INC	400MG	A081034	001	Feb 28, 1992
	AUXILIUM PHARMS LLC	200MG	A087943	001	Aug 22, 1983
		300MG	A087944	001	Aug 22, 1983

INJECTABLE; INJECTION

THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	B BRAUN	<u>40MG/100ML</u>	N019826	001	Aug 14, 1992
-----------	---	---------	-------------------	----------------	------------	--------------

THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	B BRAUN	<u>80MG/100ML</u>	N019826	002	Aug 14, 1992
-----------	---	---------	-------------------	----------------	------------	--------------

THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	B BRAUN	<u>160MG/100ML</u>	N019826	003	Aug 14, 1992
-----------	---	---------	--------------------	----------------	------------	--------------

THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	B BRAUN	<u>320MG/100ML</u>	N019826	006	Aug 14, 1992
-----------	---	---------	--------------------	----------------	------------	--------------

THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	HOSPIRA INC	<u>4MG/ML</u>	N019211	007	Dec 14, 1984
-----------	---	-------------	---------------	----------------	------------	--------------

AP	+		<u>40MG/100ML</u>	N019211	001	Dec 14, 1984
-----------	---	--	-------------------	----------------	------------	--------------

AP	+		<u>160MG/100ML</u>	N019211	003	Dec 14, 1984
-----------	---	--	--------------------	----------------	------------	--------------

AP	+		<u>320MG/100ML</u>	N019211	006	Jan 20, 1988
-----------	---	--	--------------------	----------------	------------	--------------

SOLUTION; ORAL

THEOPHYLLINE

AA	+	SILARX	<u>80MG/15ML</u>	A091156	001	Apr 13, 2011
-----------	---	--------	------------------	----------------	------------	--------------

AA		TRIS PHARMA INC	<u>80MG/15ML</u>	A091586	001	Jun 15, 2012
-----------	--	-----------------	------------------	----------------	------------	--------------

SOLUTION, ELIXIR; ORAL

ELIXOPHYLLIN

AA	+	NOSTRUM LABS INC	<u>80MG/15ML</u>	A085186	001	
-----------	---	------------------	------------------	----------------	------------	--

THEOPHYLLINE

AA		PHARM ASSOC	<u>80MG/15ML</u>	A206344	001	Dec 16, 2016
-----------	--	-------------	------------------	----------------	------------	--------------

TABLET, EXTENDED RELEASE; ORAL

THEOCHRON

AB		NOSTRUM LABS INC	<u>100MG</u>	A088320	001	Feb 21, 1985
-----------	--	------------------	--------------	----------------	------------	--------------

AB			<u>200MG</u>	A088321	001	Feb 21, 1985
-----------	--	--	--------------	----------------	------------	--------------

THEOPHYLLINE

AB		ALEMBIC LTD	<u>300MG</u>	A090430	001	Oct 27, 2010
-----------	--	-------------	--------------	----------------	------------	--------------

AB			<u>450MG</u>	A090430	002	Oct 27, 2010
-----------	--	--	--------------	----------------	------------	--------------

AB		GLENMARK GENERICS	<u>400MG</u>	A090355	001	Jul 13, 2010
-----------	--	-------------------	--------------	----------------	------------	--------------

AB			<u>600MG</u>	A090355	002	Jul 13, 2010
-----------	--	--	--------------	----------------	------------	--------------

AB		MYLAN IRELAND LTD	<u>400MG</u>	A040560	003	Apr 21, 2006
-----------	--	-------------------	--------------	----------------	------------	--------------

AB	+		<u>600MG</u>	A040560	002	Apr 21, 2006
-----------	---	--	--------------	----------------	------------	--------------

AB	+	PLIVA	<u>100MG</u>	A089807	001	Apr 30, 1990
-----------	---	-------	--------------	----------------	------------	--------------

AB	+		<u>200MG</u>	A089808	001	Apr 30, 1990
-----------	---	--	--------------	----------------	------------	--------------

AB			<u>300MG</u>	A089763	001	Apr 30, 1990
-----------	--	--	--------------	----------------	------------	--------------

AB		RHODES PHARMS	<u>400MG</u>	A087571	001	Sep 01, 1982
-----------	--	---------------	--------------	----------------	------------	--------------

AB			<u>600MG</u>	A040086	001	Apr 15, 1996
-----------	--	--	--------------	----------------	------------	--------------

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HYDROCHLORIDE

AP	+	FRESENIUS KABI USA	<u>100MG/ML</u>	A080556	001	
-----------	---	--------------------	-----------------	----------------	------------	--

AP		MYLAN INSTITUTIONAL	<u>100MG/ML</u>	A091623	001	Jun 25, 2012
-----------	--	---------------------	-----------------	----------------	------------	--------------

THIOGUANINE

TABLET; ORAL

THIOGUANINE

+	ASPEN GLOBAL INC	40MG	N012429	001	
---	------------------	------	---------	-----	--

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

AB		MYLAN	<u>10MG</u>	A088004	002	Mar 15, 1983
-----------	--	-------	-------------	----------------	------------	--------------

AB			<u>25MG</u>	A088004	003	Mar 15, 1983
-----------	--	--	-------------	----------------	------------	--------------

AB			<u>50MG</u>	A088004	004	Mar 15, 1983
-----------	--	--	-------------	----------------	------------	--------------

AB	+		<u>100MG</u>	A088004	001	Nov 18, 1983
-----------	---	--	--------------	----------------	------------	--------------

AB		SUN PHARM INDS	<u>10MG</u>	A089953	004	Aug 01, 1986
-----------	--	----------------	-------------	----------------	------------	--------------

AB			<u>25MG</u>	A089953	003	Aug 01, 1986
-----------	--	--	-------------	----------------	------------	--------------

AB			<u>50MG</u>	A089953	002	Aug 01, 1986
-----------	--	--	-------------	----------------	------------	--------------

AB			<u>100MG</u>	A089953	001	Oct 07, 1988
-----------	--	--	--------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

THIOTEPA

INJECTABLE; INJECTION

THIOTEPA

+ WEST-WARD PHARMS INT 15MG/VIAL A075547 001 Apr 02, 2001

THIOTHIXENE

CAPSULE; ORAL

THIOTHIXENE

MYLAN

1MG A071093 002 Jun 23, 1987

2MG A071093 003 Jun 23, 1987

+ 5MG A071093 004 Jun 23, 1987

10MG A071093 001 Jun 23, 1987

THYROTROPIN ALFA

INJECTABLE; INJECTION

THYROGEN

+ GENZYME 1.1MG/VIAL N020898 001 Nov 30, 1998

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRIL**AB** CEPHALON **2MG** **N020646 005** Apr 16, 1999**AB** + **4MG** **N020646 001** Sep 30, 1997TIAGABINE HYDROCHLORIDE**AB** SUN PHARM INDS **2MG** **A077555 001** Nov 04, 2011**AB** **4MG** **A077555 002** Nov 04, 2011

GABITRIL

CEPHALON 12MG N020646 002 Sep 30, 1997

16MG N020646 003 Sep 30, 1997

TICAGRELOR

TABLET; ORAL

BRILINTA

ASTRAZENECA LP 60MG N022433 002 Sep 03, 2015

+ 90MG N022433 001 Jul 20, 2011

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLOPIDINE HYDROCHLORIDE**AB** APOTEX **250MG** **A075089 001** Jul 01, 1999**AB** SUN PHARM INDS INC **250MG** **A075526 001** Sep 26, 2002**AB** + TEVA **250MG** **A075149 001** Aug 20, 1999TIGECYCLINE

INJECTABLE; IV (INFUSION)

TIGECYCLINE**AP** SANDOZ INC **50MG/VIAL** **A091620 001** May 27, 2015TYGACIL**AP** + PF PRISM CV **50MG/VIAL** **N021821 001** Jun 15, 2005

POWDER; IV (INFUSION)

TIGECYCLINE**AP** FRESENIUS KABI USA **50MG/VIAL** **N205645 001** Dec 01, 2016TIMOLOL

SOLUTION/DROPS; OPHTHALMIC

BETIMOL**AT** + OAK PHARMS INC **EQ 0.25% BASE** **N020439 001** Mar 31, 1995**AT** + **EQ 0.5% BASE** **N020439 002** Mar 31, 1995TIMOLOL**AT** AKORN **EQ 0.25% BASE** **A205309 001** Sep 30, 2016**AT** **EQ 0.5% BASE** **A205309 002** Sep 30, 2016TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC

TIMOLOL MALEATE**AB** ALCON RES LTD **EQ 0.25% BASE** **N020963 001** Oct 21, 1998**AB** **EQ 0.5% BASE** **N020963 002** Oct 21, 1998TIMOPTIC-XE**AB** + VALEANT PHARMS LLC **EQ 0.25% BASE** **N020330 001** Nov 04, 1993**AB** + **EQ 0.5% BASE** **N020330 002** Nov 04, 1993

SOLUTION/DROPS; OPHTHALMIC

TIMOLOL MALEATE**AT** ALCON RES LTD **EQ 0.25% BASE** **A074261 001** Apr 28, 1995**AT** BAUSCH AND LOMB **EQ 0.25% BASE** **A074778 001** Mar 25, 1997**AT** FDC LTD **EQ 0.25% BASE** **A077259 001** Apr 30, 2008**AT** PACIFIC PHARMA **EQ 0.25% BASE** **A074746 001** Mar 25, 1997

PRESCRIPTION DRUG PRODUCT LIST

TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

TIMOLOL MALEATE

AT	WOCKHARDT	EQ 0.25% BASE	A078771 001	Sep 28, 2009
	TIMOPTIC			
AT	+ ATON	EQ 0.25% BASE	N018086 001	
	TIMOLOL MALEATE			
AT1	AKORN	EQ 0.5% BASE	A074466 001	Mar 25, 1997
AT1		EQ 0.5% BASE	A074516 001	Mar 25, 1997
AT1	ALCON RES LTD	EQ 0.5% BASE	A074262 001	Apr 28, 1995
AT1	BAUSCH AND LOMB	EQ 0.5% BASE	A074776 001	Mar 25, 1997
AT1	FDC LTD	EQ 0.5% BASE	A077259 002	Apr 30, 2008
AT1	HI TECH PHARMA	EQ 0.5% BASE	A075163 001	Sep 10, 2002
AT1	PACIFIC PHARMA	EQ 0.5% BASE	A074747 001	Mar 25, 1997
AT1	WOCKHARDT	EQ 0.5% BASE	A078771 002	Sep 28, 2009
	TIMOPTIC			
AT1	+ ATON	EQ 0.5% BASE	N018086 002	
	ISTALOL			
AT2	+ BAUSCH AND LOMB	EQ 0.5% BASE	N021516 001	Jun 04, 2004
	TIMOLOL MALEATE			
AT2	APOTEX INC	EQ 0.5% BASE	A204936 001	Apr 17, 2015
	TIMOPTIC IN OCUDOSE			
	+ ATON	EQ 0.25% BASE	N019463 001	Nov 05, 1986
	+	EQ 0.5% BASE	N019463 002	Nov 05, 1986
	TABLET;ORAL			
	TIMOLOL MALEATE			
	MYLAN	5MG	A072668 002	Jun 08, 1990
		10MG	A072668 003	Jun 08, 1990
	+	20MG	A072668 001	Jun 08, 1990

TINIDAZOLE

TABLET;ORAL

TINDAMAX

AB	MISSION PHARMA	250MG	N021618 001	May 17, 2004
AB	+	500MG	N021618 002	May 17, 2004
	TINIDAZOLE			
AB	EDENBRIDGE PHARMS	250MG	A203808 001	Aug 04, 2015
AB		500MG	A203808 002	Aug 04, 2015
AB	NOVEL LABS INC	250MG	A202044 001	Apr 30, 2012
AB		500MG	A202044 002	Apr 30, 2012
AB	WEST-WARD PHARMS INT	250MG	A201172 001	Apr 30, 2012
AB		500MG	A201172 002	Apr 30, 2012
BX	UNIQUE PHARM LABS	250MG	A202489 001	Oct 09, 2013
BX		500MG	A202489 002	Oct 09, 2013

TIOPRONIN

TABLET;ORAL

THIOLA

+ MISSION PHARMA	100MG	N019569 001	Aug 11, 1988
------------------	-------	-------------	--------------

TIOTROPIUM BROMIDE

POWDER; INHALATION

SPIRIVA

+ BOEHRINGER INGELHEIM	EQ 0.018MG BASE/INH	N021395 001	Jan 30, 2004
------------------------	---------------------	-------------	--------------

SPRAY, METERED; INHALATION

SPIRIVA RESPIMAT

BOEHRINGER INGELHEIM	EQ 0.00125MG BASE/INH	N021936 002	Sep 15, 2015
----------------------	-----------------------	-------------	--------------

+	EQ 0.0025MG BASE/INH	N021936 001	Sep 24, 2014
---	----------------------	-------------	--------------

TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE

TABLET;ORAL

LONSURF

TAIHO ONCOLOGY	EQ 6.14MG BASE;15MG	N207981 001	Sep 22, 2015
----------------	---------------------	-------------	--------------

+	EQ 8.19MG BASE;20MG	N207981 002	Sep 22, 2015
---	---------------------	-------------	--------------

TIPRANAVIR

CAPSULE;ORAL

APTIVUS

+ BOEHRINGER INGELHEIM	250MG	N021814 001	Jun 22, 2005
------------------------	-------	-------------	--------------

SOLUTION;ORAL

APTIVUS

+ BOEHRINGER INGELHEIM	100MG/ML	N022292 001	Jun 23, 2008
------------------------	----------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-379 (of 405)

TIROFIBAN HYDROCHLORIDE

INJECTABLE; INJECTION

AGGRASTAT

MEDICURE

EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)

N020913 002 May 17, 2002

+

EQ 12.5MG BASE/250ML (EQ 0.05MG
BASE/ML)

N020913 003 Apr 20, 2000

SOLUTION; INJECTION

AGGRASTAT

+ MEDICURE

EQ 3.75MG BASE/15ML (EQ 0.25MG BASE/ML)

N020912 002 Aug 31, 2016

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL

TIZANIDINE HYDROCHLORIDEAB APOTEX INCEQ 2MG BASEA078868 001 Feb 03, 2012ABEQ 4MG BASEA078868 002 Feb 03, 2012ABEQ 6MG BASEA078868 003 Feb 03, 2012AB MYLAN PHARMS INCEQ 2MG BASEA091502 001 Nov 09, 2012ABEQ 4MG BASEA091502 002 Nov 09, 2012ABEQ 6MG BASEA091502 003 Nov 09, 2012ZANAFLEXAB ACORDAEQ 2MG BASEN021447 001 Aug 29, 2002ABEQ 4MG BASEN021447 002 Aug 29, 2002AB +EQ 6MG BASEN021447 003 Aug 29, 2002

TABLET; ORAL

TIZANIDINE HYDROCHLORIDEAB APOTEXEQ 2MG BASEA076533 001 Jan 16, 2004ABEQ 4MG BASEA076533 002 Jan 16, 2004AB COREPHARMAEQ 2MG BASEA076347 001 Oct 11, 2002ABEQ 4MG BASEA076347 002 Oct 11, 2002AB DR REDDYS LABS INCEQ 2MG BASEA076286 001 Jul 03, 2002ABEQ 4MG BASEA076286 002 Jul 03, 2002AB MYLANEQ 2MG BASEA076354 001 Mar 28, 2003ABEQ 4MG BASEA076354 002 Mar 28, 2003AB OXFORD PHARMSEQ 2MG BASEA076281 001 Oct 20, 2003ABEQ 4MG BASEA076281 002 Oct 20, 2003AB SANDOZ INCEQ 2MG BASEA076280 001 Nov 26, 2002ABEQ 4MG BASEA076280 002 Jun 27, 2002AB SUN PHARM INDS INCEQ 2MG BASEA076416 001 Sep 29, 2003ABEQ 4MG BASEA076416 002 Sep 29, 2003AB TEVAEQ 2MG BASEA076284 001 Jul 03, 2002ABEQ 4MG BASEA076284 002 Jul 03, 2002AB UNICHEM LABS LTDEQ 2MG BASEA091283 001 Nov 28, 2012ABEQ 4MG BASEA091283 002 Nov 28, 2012ZANAFLEXAB + ACORDAEQ 4MG BASEN020397 001 Nov 27, 1996TOBRAMYCIN

OINTMENT; OPHTHALMIC

TOBREX

+ NOVARTIS PHARMS CORP

0.3%

N050555 001

POWDER; INHALATION

TOBI PODHALER

+ NOVARTIS

28MG

N201688 001 Mar 22, 2013

SOLUTION; INHALATION

KITABIS PAKAN PULMOFLOW INC300MG/5MLN205433 001 Dec 02, 2014TOBIAN + NOVARTIS PHARMS300MG/5MLN050753 001 Dec 22, 1997TOBRAMYCINAN AKORN INC300MG/5MLA201422 001 May 28, 2014AN AMNEAL PHARMS300MG/5MLA205501 001 Jul 13, 2015AN TEVA PHARMS USA300MG/5MLA091589 001 Oct 10, 2013

BETHKIS

+ CHIESI USA INC

300MG/4ML

N201820 001 Oct 12, 2012

SOLUTION/DROPS; OPHTHALMIC

AKTOBAT AKORN0.3%A064096 001 Jan 31, 1996TOBRAMYCINAT BAUSCH AND LOMB0.3%A064052 001 Nov 29, 1993AT FERA PHARMS0.3%A065026 001 Sep 11, 2001TOBREXAT ALCON0.3%A062535 001 Dec 13, 1984AT + NOVARTIS PHARMS CORP0.3%N050541 001

PRESCRIPTION DRUG PRODUCT LIST

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE

<u>AP</u>	AKORN	<u>EQ 40MG BASE/ML</u>	<u>A205179 001</u>	Sep 16, 2014
<u>AP</u>	CLARIS	<u>EQ 40MG BASE/ML</u>	<u>A206965 001</u>	Jul 01, 2016
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 10MG BASE/ML</u>	<u>A065122 001</u>	Nov 29, 2002
<u>AP</u>	+	<u>EQ 40MG BASE/ML</u>	<u>A065122 002</u>	Nov 29, 2002
<u>AP</u>		<u>EQ 1.2GM BASE/VIAL</u>	<u>N050789 001</u>	Jul 13, 2004
<u>AP</u>	+ HOSPIRA	<u>EQ 10MG BASE/ML</u>	<u>A063112 001</u>	Apr 30, 1991
<u>AP</u>		<u>EQ 40MG BASE/ML</u>	<u>A063111 001</u>	Apr 30, 1991
<u>AP</u>	MYLAN LABS LTD	<u>EQ 40MG BASE/ML</u>	<u>A065407 001</u>	Mar 11, 2008
<u>AP</u>	TEVA PHARMS USA	<u>EQ 40MG BASE/ML</u>	<u>A063100 001</u>	Jan 30, 1992
<u>AP</u>	WEST-WARD PHARMS INT	<u>EQ 40MG BASE/ML</u>	<u>A063117 001</u>	Apr 26, 1991
<u>AP</u>	+	<u>EQ 1.2GM BASE/VIAL</u>	<u>A065013 001</u>	Aug 17, 2001
<u>AP</u>	XELLIA PHARMS APS	<u>EQ 1.2GM BASE/VIAL</u>	<u>A205685 001</u>	Sep 16, 2014
	TOBRAMYCIN SULFATE (PHARMACY BULK)			
	+ FRESENIUS KABI USA	EQ 40MG BASE/ML	A065120 001	Nov 29, 2002
	TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
	+ HOSPIRA	EQ 1.2MG BASE/ML	A063081 003	Jul 31, 1990
	+	EQ 1.6MG BASE/ML	A063081 006	Jun 02, 1993
	+	EQ 80MG BASE/100ML	A063081 001	Jul 31, 1990

TOFACITINIB CITRATE

TABLET; ORAL

XELJANZ

+ PF PRISM CV

EQ 5MG BASE

N203214 001 Nov 06, 2012

TABLET, EXTENDED RELEASE; ORAL

XELJANZ XR

+ PFIZER INC

EQ 11MG BASE

N208246 001 Feb 23, 2016

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

MYLAN PHARMS INC

250MG

A070259 001 Jan 02, 1986

+

500MG

A070259 003 Mar 17, 1986

TOLBUTAMIDE

TABLET; ORAL

TOLBUTAMIDE

+ MYLAN PHARMS INC

500MG

A086445 001

TOLCAPONE

TABLET; ORAL

TASMARAB + VALEANT PHARMS LLC100MGN020697 001 Jan 29, 1998TOLCAPONEAB PAR PHARM INC100MGA204584 001 Mar 26, 2015TOLMETIN SODIUM

CAPSULE; ORAL

TOLMETIN SODIUMAB MYLANEQ 400MG BASEA073393 001 May 27, 1993AB + TEVAEQ 400MG BASEA073290 001 Nov 27, 1991

TABLET; ORAL

TOLMETIN SODIUMAB + MYLANEQ 600MG BASEA074473 001 Aug 30, 1994AB SUN PHARM INDSEQ 200MG BASEA073310 001 Nov 27, 1991TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

DETROL LAAB PHARMACIA AND UPJOHN2MGN021228 001 Dec 22, 2000AB +4MGN021228 002 Dec 22, 2000TOLTERODINE TARTRATEAB MYLAN PHARMS INC2MGA201486 001 Oct 31, 2013AB4MGA201486 002 Oct 31, 2013AB TEVA PHARMS USA2MGA079141 001 Nov 22, 2016AB4MGA079141 002 Nov 22, 2016AB TORRENT PHARMS LTD2MGA203016 001 Aug 11, 2015AB4MGA203016 002 Aug 11, 2015

TABLET; ORAL

DETROLAB PHARMACIA AND UPJOHN1MGN020771 001 Mar 25, 1998AB +2MGN020771 002 Mar 25, 1998

PRESCRIPTION DRUG PRODUCT LIST

TOLTERODINE TARTRATE

TABLET; ORAL

TOLTERODINE TARTRATE

<u>AB</u>	APOTEX CORP	<u>1MG</u>	<u>A200164 001</u>	Sep 25, 2012
<u>AB</u>		<u>2MG</u>	<u>A200164 002</u>	Sep 25, 2012
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>1MG</u>	<u>A077006 001</u>	Feb 23, 2015
<u>AB</u>		<u>2MG</u>	<u>A077006 002</u>	Feb 23, 2015
<u>AB</u>	MACLEODS PHARMS LTD	<u>1MG</u>	<u>A203409 001</u>	Aug 31, 2015
<u>AB</u>		<u>2MG</u>	<u>A203409 002</u>	Aug 31, 2015
<u>AB</u>	MYLAN PHARMS INC	<u>1MG</u>	<u>A202641 001</u>	Nov 27, 2012
<u>AB</u>		<u>2MG</u>	<u>A202641 002</u>	Nov 27, 2012

TOLVAPTAN

TABLET; ORAL

SAMSCA

	OTSUKA AMERICA PHARM	15MG	N022275 001	May 19, 2009
+		30MG	N022275 002	May 19, 2009

TOPIRAMATE

CAPSULE; ORAL

TOPAMAX

<u>AB</u>	JANSSEN PHARMS	<u>15MG</u>	<u>N020844 001</u>	Oct 26, 1998
<u>AB</u>	+	<u>25MG</u>	<u>N020844 002</u>	Oct 26, 1998

TOPIRAMATE

<u>AB</u>	MYLAN	<u>15MG</u>	<u>A078418 001</u>	Oct 14, 2009
<u>AB</u>		<u>25MG</u>	<u>A078418 002</u>	Oct 14, 2009
<u>AB</u>	TEVA	<u>15MG</u>	<u>A076575 001</u>	Apr 17, 2009
<u>AB</u>		<u>25MG</u>	<u>A076575 002</u>	Apr 17, 2009
<u>AB</u>	WATSON LABS	<u>15MG</u>	<u>A077868 001</u>	Apr 15, 2009
<u>AB</u>		<u>25MG</u>	<u>A077868 002</u>	Apr 15, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>15MG</u>	<u>A078877 001</u>	Oct 14, 2009
<u>AB</u>		<u>25MG</u>	<u>A078877 002</u>	Oct 14, 2009

CAPSULE, EXTENDED RELEASE; ORAL

QUDEXY XR

	UPSHER-SMITH LABS	25MG	N205122 001	Mar 11, 2014
		50MG	N205122 002	Mar 11, 2014
		100MG	N205122 003	Mar 11, 2014
		150MG	N205122 004	Mar 11, 2014
+		200MG	N205122 005	Mar 11, 2014

TROKENDI XR

	SUPERNUS PHARMS	25MG	N201635 001	Aug 16, 2013
		50MG	N201635 002	Aug 16, 2013
		100MG	N201635 003	Aug 16, 2013
+		200MG	N201635 004	Aug 16, 2013

TABLET; ORAL

TOPAMAX

<u>AB</u>	JANSSEN PHARMS	<u>25MG</u>	<u>N020505 004</u>	Dec 24, 1996
<u>AB</u>		<u>50MG</u>	<u>N020505 005</u>	Dec 24, 1996
<u>AB</u>	+	<u>100MG</u>	<u>N020505 001</u>	Dec 24, 1996
<u>AB</u>		<u>200MG</u>	<u>N020505 002</u>	Dec 24, 1996

TOPIRAMATE

<u>AB</u>	ACCORD HLTHCARE	<u>25MG</u>	<u>A076311 001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A076311 002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076311 003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076311 004</u>	Mar 27, 2009
<u>AB</u>	APOTEX INC	<u>25MG</u>	<u>A077733 001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A077733 002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A077733 003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A077733 004</u>	Mar 27, 2009
<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A078462 001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A078462 002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078462 003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078462 004</u>	Mar 27, 2009
<u>AB</u>	CIPLA LTD	<u>25MG</u>	<u>A076343 001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A076343 002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076343 003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076343 004</u>	Mar 27, 2009
<u>AB</u>	GLENMARK GENERICS	<u>25MG</u>	<u>A077627 001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A077627 002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A077627 003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A077627 004</u>	Mar 27, 2009
<u>AB</u>	INVAGEN PHARMS	<u>25MG</u>	<u>A079162 001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A079162 002</u>	Mar 27, 2009

PRESCRIPTION DRUG PRODUCT LIST

TOPIRAMATE

TABLET; ORAL

TOPIRAMATE

<u>AB</u>		<u>100MG</u>	<u>A079162</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A079162</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	LUPIN	<u>25MG</u>	<u>A078410</u>	<u>001</u>	Sep 11, 2013
<u>AB</u>		<u>50MG</u>	<u>A078410</u>	<u>002</u>	Sep 11, 2013
<u>AB</u>		<u>100MG</u>	<u>A078410</u>	<u>003</u>	Sep 11, 2013
<u>AB</u>		<u>200MG</u>	<u>A078410</u>	<u>004</u>	Sep 11, 2013
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A076314</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A076314</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076314</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076314</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	SUN PHARM INDS LTD	<u>25MG</u>	<u>A076327</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076327</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076327</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>	SUN PHARMA GLOBAL	<u>25MG</u>	<u>A090278</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A090278</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A090278</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A090278</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	TEVA	<u>25MG</u>	<u>A076317</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A076317</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076317</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076317</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	TORRENT PHARMS	<u>25MG</u>	<u>A079153</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A079153</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A079153</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A079153</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	UNICHEM LABS LTD	<u>25MG</u>	<u>A090162</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A090162</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A090162</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A090162</u>	<u>004</u>	Feb 19, 2013
<u>AB</u>	UPSHER SMITH	<u>25MG</u>	<u>A078499</u>	<u>001</u>	Jan 07, 2010
<u>AB</u>		<u>50MG</u>	<u>A078499</u>	<u>002</u>	Jan 07, 2010
<u>AB</u>		<u>100MG</u>	<u>A078499</u>	<u>003</u>	Jan 07, 2010
<u>AB</u>		<u>200MG</u>	<u>A078499</u>	<u>004</u>	Jan 07, 2010
<u>AB</u>	ZYDUS PHARMS USA INC	<u>25MG</u>	<u>A078235</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A078235</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078235</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078235</u>	<u>004</u>	Mar 27, 2009

TOPOTECAN HYDROCHLORIDE

CAPSULE; ORAL

HYCAMTIN

NOVARTIS PHARMS CORP EQ 0.25MG BASE

N020981 001 Oct 11, 2007

+

EQ 1MG BASE

N020981 002 Oct 11, 2007

INJECTABLE; INJECTION

HYCAMTIN

<u>AP</u>	+ NOVARTIS PHARMS CORP	<u>EQ 4MG BASE/VIAL</u>	<u>N020671</u>	<u>001</u>	May 28, 1996
-----------	------------------------	-------------------------	----------------	------------	--------------

TOPOTECAN HYDROCHLORIDE

<u>AP</u>	ACCORD HLTHCARE	<u>EQ 4MG BASE/VIAL</u>	<u>A202351</u>	<u>001</u>	Jun 26, 2013
<u>AP</u>	ACTAVIS TOTOWA	<u>EQ 4MG BASE/VIAL</u>	<u>A090620</u>	<u>001</u>	Dec 02, 2010
<u>AP</u>	CHEM WERTH INC	<u>EQ 4MG BASE/VIAL</u>	<u>A201166</u>	<u>001</u>	Aug 08, 2012
<u>AP</u>	CIPLA LTD	<u>EQ 4MG BASE/VIAL</u>	<u>A091199</u>	<u>001</u>	Dec 01, 2010
<u>AP</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE/VIAL</u>	<u>A201191</u>	<u>001</u>	Mar 09, 2011
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 4MG BASE/VIAL</u>	<u>A091089</u>	<u>001</u>	Nov 29, 2010
<u>AP</u>	INGENUS PHARMS LLC	<u>EQ 4MG BASE/VIAL</u>	<u>A206962</u>	<u>001</u>	Nov 30, 2016
<u>AP</u>	MYLAN LABS LTD	<u>EQ 4MG BASE/VIAL</u>	<u>A091542</u>	<u>001</u>	Aug 28, 2012
<u>AP</u>	SAGENT PHARMS	<u>EQ 4MG BASE/VIAL</u>	<u>A091284</u>	<u>001</u>	Jan 26, 2011
<u>AP</u>	SUN PHARM INDS LTD	<u>EQ 4MG BASE/VIAL</u>	<u>A202203</u>	<u>001</u>	Aug 29, 2013

SOLUTION; INTRAVENOUS

TOPOTECAN HYDROCHLORIDE

<u>AP</u>	+ HOSPIRA INC	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>N200582</u>	<u>001</u>	Feb 02, 2011
<u>AP</u>	TEVA PHARMS USA	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>N022453</u>	<u>001</u>	Dec 20, 2012

TOREMIFENE CITRATE

TABLET; ORAL

FARESTON

+ PROSTRAKAN INC

EQ 60MG BASE

N020497 001 May 29, 1997

PRESCRIPTION DRUG PRODUCT LISTTORSEMIDE

TABLET; ORAL

DEMADEX

<u>AB</u>	MEDA PHARMS	<u>5MG</u>	<u>N020136</u>	<u>001</u>	Aug 23, 1993
<u>AB</u>		<u>10MG</u>	<u>N020136</u>	<u>002</u>	Aug 23, 1993
<u>AB</u>	+	<u>20MG</u>	<u>N020136</u>	<u>003</u>	Aug 23, 1993
<u>AB</u>		<u>100MG</u>	<u>N020136</u>	<u>004</u>	Aug 23, 1993

TORSEMIDE

<u>AB</u>	APOTEX INC	<u>5MG</u>	<u>A076894</u>	<u>001</u>	May 31, 2005
<u>AB</u>		<u>10MG</u>	<u>A076894</u>	<u>002</u>	May 31, 2005
<u>AB</u>		<u>20MG</u>	<u>A076894</u>	<u>003</u>	May 31, 2005
<u>AB</u>		<u>100MG</u>	<u>A076894</u>	<u>004</u>	May 31, 2005
<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A078249</u>	<u>001</u>	Oct 17, 2007
<u>AB</u>		<u>10MG</u>	<u>A078249</u>	<u>002</u>	Oct 17, 2007
<u>AB</u>		<u>20MG</u>	<u>A078249</u>	<u>003</u>	Oct 17, 2007
<u>AB</u>		<u>100MG</u>	<u>A078249</u>	<u>004</u>	Oct 17, 2007
<u>AB</u>	HETERO LABS LTD III	<u>5MG</u>	<u>A079234</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>10MG</u>	<u>A079234</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>20MG</u>	<u>A079234</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A079234</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	PAR PHARM	<u>5MG</u>	<u>A076226</u>	<u>001</u>	May 27, 2003
<u>AB</u>		<u>10MG</u>	<u>A076226</u>	<u>002</u>	May 27, 2003
<u>AB</u>		<u>20MG</u>	<u>A076226</u>	<u>003</u>	May 27, 2003
<u>AB</u>		<u>100MG</u>	<u>A076226</u>	<u>004</u>	May 27, 2003
<u>AB</u>	PLIVA PHARM IND	<u>5MG</u>	<u>A076346</u>	<u>001</u>	May 30, 2003
<u>AB</u>		<u>10MG</u>	<u>A076346</u>	<u>002</u>	May 30, 2003
<u>AB</u>		<u>20MG</u>	<u>A076346</u>	<u>003</u>	May 30, 2003
<u>AB</u>		<u>100MG</u>	<u>A076346</u>	<u>004</u>	Oct 19, 2004
<u>AB</u>	SUN PHARM INDS	<u>5MG</u>	<u>A078478</u>	<u>001</u>	Feb 26, 2008
<u>AB</u>		<u>10MG</u>	<u>A078478</u>	<u>002</u>	Feb 26, 2008
<u>AB</u>		<u>20MG</u>	<u>A078478</u>	<u>003</u>	Feb 26, 2008
<u>AB</u>		<u>100MG</u>	<u>A078478</u>	<u>004</u>	Feb 26, 2008
<u>AB</u>	TEVA	<u>5MG</u>	<u>A076110</u>	<u>001</u>	May 14, 2002
<u>AB</u>		<u>10MG</u>	<u>A076110</u>	<u>002</u>	May 14, 2002
<u>AB</u>		<u>20MG</u>	<u>A076110</u>	<u>003</u>	May 14, 2002
<u>AB</u>		<u>100MG</u>	<u>A076110</u>	<u>004</u>	May 14, 2002
<u>AB</u>	VINTAGE PHARMS	<u>5MG</u>	<u>A090613</u>	<u>001</u>	Mar 22, 2011
<u>AB</u>		<u>10MG</u>	<u>A090613</u>	<u>002</u>	Mar 22, 2011
<u>AB</u>		<u>20MG</u>	<u>A090613</u>	<u>003</u>	Mar 22, 2011
<u>AB</u>		<u>100MG</u>	<u>A090613</u>	<u>004</u>	Mar 22, 2011
<u>AB</u>	WEST-WARD PHARMS INT	<u>5MG</u>	<u>A076943</u>	<u>001</u>	Mar 01, 2005
<u>AB</u>		<u>10MG</u>	<u>A076943</u>	<u>002</u>	Mar 01, 2005
<u>AB</u>		<u>20MG</u>	<u>A076943</u>	<u>003</u>	Mar 01, 2005

TRABECTEDIN

POWDER; IV (INFUSION)

YONDELIS

+	JANSSEN PRODS	1MG/VIAL	N207953	001	Oct 23, 2015
---	---------------	----------	---------	-----	--------------

TRAMADOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CONZIP

+	CIPHER PHARMS INC	100MG	N022370	001	May 07, 2010
		150MG	N022370	004	Aug 01, 2011
		200MG	N022370	002	May 07, 2010
		300MG	N022370	003	May 07, 2010

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

<u>AB</u>	ACCORD HLTHCARE INC	<u>50MG</u>	<u>A202390</u>	<u>001</u>	May 16, 2013
<u>AB</u>	ACI HEALTHCARE LTD	<u>50MG</u>	<u>A202075</u>	<u>001</u>	Nov 28, 2011
<u>AB</u>	AMNEAL PHARMS	<u>50MG</u>	<u>A076003</u>	<u>001</u>	Jun 20, 2002
<u>AB</u>	APOTEX	<u>50MG</u>	<u>A075981</u>	<u>001</u>	Jul 10, 2002
<u>AB</u>	AUROBINDO PHARMA LTD	<u>50MG</u>	<u>A203494</u>	<u>001</u>	Mar 31, 2014
<u>AB</u>	CSPC OUYI PHARM CO	<u>50MG</u>	<u>A091498</u>	<u>001</u>	Mar 29, 2013
<u>AB</u>	IPCA LABS LTD	<u>50MG</u>	<u>A201973</u>	<u>001</u>	Nov 16, 2012
<u>AB</u>	MACLEODS PHARMS LTD	<u>50MG</u>	<u>A205702</u>	<u>001</u>	Sep 25, 2015
<u>AB</u>	MALLINCKRODT	<u>50MG</u>	<u>A075983</u>	<u>001</u>	Jun 25, 2002
<u>AB</u>	MYLAN	<u>50MG</u>	<u>A075986</u>	<u>001</u>	Jun 21, 2002
<u>AB</u>	MYLAN PHARMS INC	<u>50MG</u>	<u>A075980</u>	<u>001</u>	Nov 21, 2002
<u>AB</u>	NORTHSTAR HLTHCARE	<u>50MG</u>	<u>A078935</u>	<u>001</u>	May 26, 2010
<u>AB</u>	PLIVA	<u>50MG</u>	<u>A075982</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>	SUN PHARM INDS	<u>50MG</u>	<u>A076100</u>	<u>001</u>	Jun 20, 2002
<u>AB</u>	SUN PHARM INDS INC	<u>50MG</u>	<u>A075964</u>	<u>001</u>	Jun 19, 2002

PRESCRIPTION DRUG PRODUCT LIST

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

<u>AB</u>	TEVA	<u>50MG</u>	<u>A075977</u>	<u>001</u>	Jun 19, 2002
<u>AB</u>	ZYDUS PHARMS USA INC	<u>50MG</u>	<u>A090404</u>	<u>001</u>	Jan 31, 2011

ULTRAM

<u>AB</u>	+ JANSSEN PHARMS	<u>50MG</u>	<u>N020281</u>	<u>002</u>	Mar 03, 1995
-----------	------------------	-------------	----------------	------------	--------------

TABLET, EXTENDED RELEASE; ORAL

TRAMADOL HYDROCHLORIDE

<u>AB1</u>	AUROBINDO PHARMA LTD	<u>100MG</u>	<u>A204421</u>	<u>001</u>	Oct 20, 2015
<u>AB1</u>		<u>200MG</u>	<u>A204421</u>	<u>002</u>	Oct 20, 2015
<u>AB1</u>		<u>300MG</u>	<u>A204421</u>	<u>003</u>	Oct 20, 2015
<u>AB1</u>	+ LUPIN LTD	<u>100MG</u>	<u>A200503</u>	<u>001</u>	Aug 29, 2011
<u>AB1</u>		<u>200MG</u>	<u>A200503</u>	<u>002</u>	Aug 29, 2011
<u>AB1</u>		<u>300MG</u>	<u>A200503</u>	<u>003</u>	Aug 29, 2011
<u>AB1</u>	MYLAN PHARMS INC	<u>100MG</u>	<u>A205257</u>	<u>001</u>	Dec 22, 2015
<u>AB1</u>		<u>200MG</u>	<u>A205257</u>	<u>002</u>	Dec 22, 2015
<u>AB1</u>		<u>300MG</u>	<u>A205257</u>	<u>003</u>	Dec 22, 2015
<u>AB1</u>	PAR PHARM INC	<u>100MG</u>	<u>A078783</u>	<u>001</u>	Nov 13, 2009
<u>AB1</u>		<u>200MG</u>	<u>A078783</u>	<u>002</u>	Nov 13, 2009
<u>AB1</u>		<u>300MG</u>	<u>A078783</u>	<u>003</u>	Sep 20, 2011
<u>AB1</u>	SUN PHARMA GLOBAL	<u>100MG</u>	<u>A201384</u>	<u>001</u>	Dec 07, 2011
<u>AB1</u>		<u>200MG</u>	<u>A201384</u>	<u>002</u>	Dec 07, 2011
<u>AB1</u>		<u>300MG</u>	<u>A201384</u>	<u>003</u>	Dec 07, 2011
<u>AB2</u>	ACTAVIS ELIZABETH	<u>100MG</u>	<u>A091609</u>	<u>001</u>	Jun 27, 2012
<u>AB2</u>		<u>200MG</u>	<u>A091609</u>	<u>002</u>	Jun 27, 2012
<u>AB2</u>		<u>300MG</u>	<u>A091609</u>	<u>003</u>	Jun 27, 2012
<u>AB2</u>	ANCHEN PHARMS	<u>100MG</u>	<u>A200491</u>	<u>001</u>	Jun 27, 2012
<u>AB2</u>		<u>200MG</u>	<u>A200491</u>	<u>002</u>	Jun 27, 2012
<u>AB2</u>		<u>300MG</u>	<u>A200491</u>	<u>003</u>	Jun 27, 2012
<u>AB2</u>	+ SUN PHARMA GLOBAL	<u>100MG</u>	<u>A091607</u>	<u>001</u>	Dec 30, 2011
<u>AB2</u>		<u>200MG</u>	<u>A091607</u>	<u>002</u>	Dec 30, 2011
<u>AB2</u>		<u>300MG</u>	<u>A091607</u>	<u>003</u>	Dec 30, 2011

TRAMETINIB DIMETHYL SULFOXIDE

TABLET; ORAL

MEKINIST

	NOVARTIS PHARMS CORP	EQ 0.5MG	N204114	001	May 29, 2013
		EQ 1MG	N204114	002	May 29, 2013
	+	EQ 2MG	N204114	003	May 29, 2013

TRANDOLAPRIL

TABLET; ORAL

MAVIK

<u>AB</u>	ABBVIE	<u>1MG</u>	<u>N020528</u>	<u>001</u>	Apr 26, 1996
<u>AB</u>		<u>2MG</u>	<u>N020528</u>	<u>002</u>	Apr 26, 1996
<u>AB</u>	+	<u>4MG</u>	<u>N020528</u>	<u>003</u>	Apr 26, 1996

TRANDOLAPRIL

<u>AB</u>	AUROBINDO PHARMA	<u>1MG</u>	<u>A078438</u>	<u>001</u>	Jun 12, 2007
<u>AB</u>		<u>2MG</u>	<u>A078438</u>	<u>002</u>	Jun 12, 2007
<u>AB</u>		<u>4MG</u>	<u>A078438</u>	<u>003</u>	Jun 12, 2007
<u>AB</u>	EPIC PHARMA	<u>1MG</u>	<u>A078508</u>	<u>003</u>	Jun 18, 2008
<u>AB</u>		<u>2MG</u>	<u>A078508</u>	<u>001</u>	Jun 18, 2008
<u>AB</u>		<u>4MG</u>	<u>A078508</u>	<u>002</u>	Jun 18, 2008
<u>AB</u>	INVAGEN PHARMS	<u>1MG</u>	<u>A078320</u>	<u>001</u>	Jun 12, 2007
<u>AB</u>		<u>2MG</u>	<u>A078320</u>	<u>002</u>	Jun 12, 2007
<u>AB</u>		<u>4MG</u>	<u>A078320</u>	<u>003</u>	Jun 12, 2007
<u>AB</u>	LUPIN	<u>1MG</u>	<u>A077522</u>	<u>001</u>	Jun 12, 2007
<u>AB</u>		<u>2MG</u>	<u>A077522</u>	<u>002</u>	Jun 12, 2007
<u>AB</u>		<u>4MG</u>	<u>A077522</u>	<u>003</u>	Jun 12, 2007
<u>AB</u>	MYLAN	<u>1MG</u>	<u>A078346</u>	<u>001</u>	Apr 28, 2008
<u>AB</u>		<u>2MG</u>	<u>A078346</u>	<u>002</u>	Apr 28, 2008
<u>AB</u>		<u>4MG</u>	<u>A078346</u>	<u>003</u>	Apr 28, 2008
<u>AB</u>	TEVA PHARMS	<u>1MG</u>	<u>A077489</u>	<u>001</u>	Dec 12, 2006
<u>AB</u>		<u>2MG</u>	<u>A077489</u>	<u>002</u>	Dec 12, 2006
<u>AB</u>		<u>4MG</u>	<u>A077489</u>	<u>003</u>	Dec 12, 2006
<u>AB</u>	WATSON LABS	<u>1MG</u>	<u>A077805</u>	<u>001</u>	Jun 12, 2007
<u>AB</u>		<u>2MG</u>	<u>A077805</u>	<u>002</u>	Jun 12, 2007
<u>AB</u>		<u>4MG</u>	<u>A077805</u>	<u>003</u>	Jun 12, 2007

PRESCRIPTION DRUG PRODUCT LIST

TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

TARKA

<u>AB</u>	ABBVIE	<u>1MG;240MG</u>	<u>N020591 003</u>	Oct 22, 1996
<u>AB</u>		<u>2MG;180MG</u>	<u>N020591 001</u>	Oct 22, 1996
<u>AB</u>		<u>2MG;240MG</u>	<u>N020591 004</u>	Oct 22, 1996
<u>AB</u>	+	<u>4MG;240MG</u>	<u>N020591 002</u>	Oct 22, 1996

TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE

<u>AB</u>	GLENMARK GENERICS	<u>1MG;240MG</u>	<u>A079135 004</u>	Aug 30, 2010
<u>AB</u>		<u>2MG;180MG</u>	<u>A079135 001</u>	May 26, 2010
<u>AB</u>		<u>2MG;240MG</u>	<u>A079135 002</u>	May 26, 2010
<u>AB</u>		<u>4MG;240MG</u>	<u>A079135 003</u>	May 05, 2010

TRANEXAMIC ACID

INJECTABLE; INJECTION

CYKLOKAPRON

<u>AP</u>	+	PHARMACIA AND UPJOHN	<u>100MG/ML</u>	<u>N019281 001</u>	Dec 30, 1986
-----------	---	----------------------	-----------------	--------------------	--------------

TRANEXAMIC ACID

<u>AP</u>		ACIC FINE CHEMS	<u>100MG/ML</u>	<u>A202436 001</u>	Feb 11, 2014
<u>AP</u>		AKORN	<u>100MG/ML</u>	<u>A202373 001</u>	Nov 17, 2011
<u>AP</u>			<u>100MG/ML</u>	<u>A206634 001</u>	Jun 09, 2016
<u>AP</u>		AUROBINDO PHARMA LTD	<u>100MG/ML</u>	<u>A205035 001</u>	Jan 14, 2016
<u>AP</u>		EMCURE PHARMS LTD	<u>100MG/ML</u>	<u>A203521 001</u>	Aug 12, 2014
<u>AP</u>		FRESENIUS KABI USA	<u>100MG/ML</u>	<u>A091596 001</u>	Mar 02, 2012
<u>AP</u>		LUITPOLD	<u>100MG/ML</u>	<u>A201885 001</u>	Aug 10, 2011
<u>AP</u>		MYLAN INSTITUTIONAL	<u>100MG/ML</u>	<u>A091657 001</u>	Nov 03, 2011
<u>AP</u>		NORTH CREEK PHARMS	<u>100MG/ML</u>	<u>A202755 001</u>	Feb 25, 2016
<u>AP</u>		X-GEN PHARMS INC	<u>100MG/ML</u>	<u>A201580 001</u>	Jun 14, 2013

TABLET; ORAL

LYSTEDA

<u>AB</u>	+	FERRING PHARMS AS	<u>650MG</u>	<u>N022430 001</u>	Nov 13, 2009
-----------	---	-------------------	--------------	--------------------	--------------

TRANEXAMIC ACID

<u>AB</u>		ACTAVIS LABS FL INC	<u>650MG</u>	<u>A202093 001</u>	Dec 27, 2012
<u>AB</u>		APOTEX INC	<u>650MG</u>	<u>A202286 001</u>	Jan 27, 2014
<u>AB</u>		MYLAN	<u>650MG</u>	<u>A205133 001</u>	Sep 21, 2015

TRANLYCYPROMINE SULFATE

TABLET; ORAL

PARNATE

<u>AB</u>	+	CONCORDIA PHARMS INC	<u>EQ 10MG BASE</u>	<u>N012342 003</u>	Aug 16, 1985
-----------	---	----------------------	---------------------	--------------------	--------------

TRANLYCYPROMINE SULFATE

<u>AB</u>		PAR PHARM	<u>EQ 10MG BASE</u>	<u>A040640 001</u>	Jun 29, 2006
-----------	--	-----------	---------------------	--------------------	--------------

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC

TRAVATAN Z

<u>AT</u>	+	NOVARTIS PHARMS CORP	<u>0.004%</u>	<u>N021994 001</u>	Sep 21, 2006
-----------	---	----------------------	---------------	--------------------	--------------

TRAVOPROST

<u>AT</u>		APOTEX INC	<u>0.004%</u>	<u>A203431 001</u>	Jul 10, 2015
	+	PAR PHARM	0.004%	A091340 001	Mar 01, 2013

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

<u>AB</u>		ALVOGEN	<u>50MG</u>	<u>A071636 001</u>	Apr 18, 1988
<u>AB</u>			<u>100MG</u>	<u>A071514 001</u>	Apr 18, 1988
<u>AB</u>		APOTEX	<u>50MG</u>	<u>A071258 001</u>	Mar 25, 1987
<u>AB</u>	+	APOTEX INC	<u>100MG</u>	<u>A071196 001</u>	Mar 25, 1987
<u>AB</u>			<u>150MG</u>	<u>A071196 002</u>	Apr 26, 1999
<u>AB</u>			<u>300MG</u>	<u>A071196 003</u>	Apr 26, 1999
<u>AB</u>		MYLAN PHARMS INC	<u>50MG</u>	<u>A090514 001</u>	Jun 02, 2009
<u>AB</u>			<u>100MG</u>	<u>A090514 002</u>	Jun 02, 2009
<u>AB</u>			<u>150MG</u>	<u>A090514 003</u>	Jun 02, 2009
<u>AB</u>			<u>300MG</u>	<u>A090514 004</u>	Jun 02, 2009
<u>AB</u>		PLIVA	<u>150MG</u>	<u>A071525 001</u>	Mar 09, 1988
<u>AB</u>		SUN PHARM INDS	<u>50MG</u>	<u>A073137 002</u>	Mar 24, 1993
<u>AB</u>			<u>100MG</u>	<u>A073137 001</u>	Mar 24, 1993
<u>AB</u>			<u>150MG</u>	<u>A073137 003</u>	Dec 22, 1995
<u>AB</u>		TEVA PHARMS USA	<u>50MG</u>	<u>A071523 001</u>	Dec 11, 1987
<u>AB</u>			<u>100MG</u>	<u>A071524 001</u>	Dec 11, 1987
<u>AB</u>		TORRENT PHARMS LTD	<u>50MG</u>	<u>A202180 001</u>	Nov 27, 2013
<u>AB</u>			<u>100MG</u>	<u>A202180 002</u>	Nov 27, 2013
<u>AB</u>			<u>150MG</u>	<u>A202180 003</u>	Nov 27, 2013
<u>AB</u>			<u>300MG</u>	<u>A202180 004</u>	Nov 27, 2013

PRESCRIPTION DRUG PRODUCT LIST

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

AB	VINTAGE	50MG	A072192 001	Feb 02, 1989
AB		100MG	A072193 001	Feb 02, 1989

TREPROSTINIL

INJECTABLE; IV (INFUSION), SUBCUTANEOUS
REMODYLIN

	UNITED THERAP	1MG/ML	N021272 001	May 21, 2002
		2.5MG/ML	N021272 002	May 21, 2002
		5MG/ML	N021272 003	May 21, 2002
	+	10MG/ML	N021272 004	May 21, 2002

SOLUTION; INHALATION
TYVASO

	+	UNITED THERAP	0.6MG/ML	N022387 001	Jul 30, 2009
--	---	---------------	----------	-------------	--------------

TREPROSTINIL DIOLAMINE

TABLET, EXTENDED RELEASE; ORAL
ORENITRAM

	UNITED THERAP	EQ 0.125MG BASE	N203496 001	Dec 20, 2013
		EQ 0.25MG BASE	N203496 002	Dec 20, 2013
		EQ 1MG BASE	N203496 003	Dec 20, 2013
	+	EQ 2.5MG BASE	N203496 004	Dec 20, 2013
		EQ 5MG BASE	N203496 005	Oct 07, 2016

TRETINOIN

CAPSULE; ORAL

TRETINOIN

AB	ANCHEN PHARMS	10MG	A201687 001	Oct 24, 2012	
AB	+	BARR LABS INC	10MG	A077684 001	Jun 22, 2007
AB		GLENMARK GENERICS	10MG	A208279 001	Dec 23, 2016

CREAM; TOPICAL

AVITA

AB	MYLAN PHARMS INC	0.025%	N020404 003	Jan 14, 1997
-----------	------------------	---------------	--------------------	--------------

RETIN-A

AB	+	VALEANT BERMUDA	0.025%	N019049 001	Sep 16, 1988
AB	+	VALEANT PHARMS NORTH	0.1%	N017340 001	

TRETINOIN

AB	PERRIGO PHARMA INTL	0.025%	A075264 001	Dec 24, 1998
AB		0.1%	A075213 001	Dec 24, 1998

RETIN-A

AB1	+	VALEANT BERMUDA	0.05%	N017522 001
------------	---	-----------------	--------------	--------------------

TRETINOIN

AB1	PERRIGO PHARMA INTL	0.05%	A075265 001	Dec 24, 1998
------------	---------------------	--------------	--------------------	--------------

RENOVA

AB2	+	VALEANT PHARMS NORTH	0.05%	N019963 001	Dec 29, 1995
------------	---	----------------------	--------------	--------------------	--------------

TRETINOIN

AB2	SUNEVA MEDCL	0.05%	A076498 001	Sep 15, 2005	
	RENOVA				
	+	VALEANT PHARMS NORTH	0.02%	N021108 001	Aug 31, 2000
	TRETINOIN				
	+	ALLERGAN SALES LLC	0.0375%	A090098 001	Mar 22, 2010
			0.075%	A202209 001	Oct 11, 2012

GEL; TOPICAL

ATRALIN

AB	+	DOW PHARM	0.05%	N022070 001	Jul 26, 2007
-----------	---	-----------	--------------	--------------------	--------------

RETIN-A

AB	+	VALEANT INTL	0.01%	N017955 001
-----------	---	--------------	--------------	--------------------

AB	+		0.025%	N017579 002
-----------	---	--	---------------	--------------------

RETIN-A MICRO

AB	+	VALEANT INTL	0.04%	N020475 002	May 10, 2002
-----------	---	--------------	--------------	--------------------	--------------

AB	+		0.1%	N020475 001	Feb 07, 1997
-----------	---	--	-------------	--------------------	--------------

TRETINOIN

AB	PERRIGO PHARMA INTL	0.01%	A075589 001	Jun 11, 2002
-----------	---------------------	--------------	--------------------	--------------

AB		0.025%	A075529 001	Feb 22, 2000
-----------	--	---------------	--------------------	--------------

AB	SPEAR PHARMS INC	0.04%	A202567 001	Jul 17, 2013
-----------	------------------	--------------	--------------------	--------------

AB		0.05%	A207955 001	Aug 13, 2015
-----------	--	--------------	--------------------	--------------

AB		0.1%	A202026 001	Jul 17, 2013
-----------	--	-------------	--------------------	--------------

AVITA

BT	MYLAN	0.025%	N020400 001	Jan 29, 1998
----	-------	--------	-------------	--------------

RETIN-A-MICRO

	+	VALEANT INTL	0.08%	N020475 003	Jan 28, 2014
--	---	--------------	-------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

TRETINOIN

SOLUTION; TOPICAL

RETIN-A

+ VALEANT INTL 0.05% N016921 001

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

<u>AT</u>	DELCOR ASSET CORP	<u>0.025%</u>	<u>N011601 003</u>	
<u>AT</u>		<u>0.1%</u>	<u>N011601 006</u>	
<u>AT</u>	+ FOUGERA PHARMS	<u>0.025%</u>	<u>A085692 001</u>	
<u>AT</u>	+	<u>0.1%</u>	<u>A085692 003</u>	
<u>AT</u>	+	<u>0.5%</u>	<u>A085692 002</u>	
<u>AT</u>	G AND W LABS	<u>0.025%</u>	<u>A089797 001</u>	May 31, 1991
<u>AT</u>		<u>0.1%</u>	<u>A089798 001</u>	May 31, 1991
<u>AT</u>	GLENMARK PHARMS LTD	<u>0.1%</u>	<u>A207117 001</u>	Aug 05, 2016
<u>AT</u>	PERRIGO NEW YORK	<u>0.025%</u>	<u>A086415 001</u>	
<u>AT</u>		<u>0.1%</u>	<u>A086414 001</u>	
<u>AT</u>		<u>0.5%</u>	<u>A086413 001</u>	
<u>AT</u>	TARO	<u>0.1%</u>	<u>A040039 001</u>	Nov 26, 1997
<u>AT</u>	VINTAGE	<u>0.025%</u>	<u>A040671 001</u>	Jun 09, 2006
<u>AT</u>		<u>0.1%</u>	<u>A040671 002</u>	Jun 09, 2006

TRIDERM

<u>AT</u>	CROWN LABS	<u>0.025%</u>	<u>A088042 002</u>	Mar 25, 2015
<u>AT</u>		<u>0.1%</u>	<u>A088042 001</u>	Mar 19, 1984
<u>AT</u>		<u>0.5%</u>	<u>A088042 003</u>	Mar 25, 2015

INJECTABLE; INJECTION

KENALOG-10

APOTHECON 10MG/ML N012041 001

KENALOG-40

+ APOTHECON 40MG/ML N014901 001

INJECTABLE; INTRAVITREAL

TRIESENCE

+ NOVARTIS PHARMS CORP 40MG/ML (40MG/ML) N022048 001 Nov 29, 2007

LOTION; TOPICAL

TRIAMCINOLONE ACETONIDE

<u>AT</u>	AKORN	<u>0.025%</u>	<u>A202374 001</u>	May 08, 2013
<u>AT</u>		<u>0.1%</u>	<u>A202374 002</u>	May 08, 2013
<u>AT</u>	FOUGERA PHARMS	<u>0.025%</u>	<u>A040467 001</u>	Apr 21, 2003
<u>AT</u>		<u>0.1%</u>	<u>A040467 002</u>	Apr 21, 2003
<u>AT</u>	G AND W LABS INC	<u>0.1%</u>	<u>A089129 001</u>	Aug 14, 1986
<u>AT</u>	TELIGENT PHARMA INC	<u>0.025%</u>	<u>A204608 001</u>	Jul 07, 2016
<u>AT</u>		<u>0.1%</u>	<u>A204606 001</u>	Jul 07, 2016
<u>AT</u>	VINTAGE	<u>0.1%</u>	<u>A040672 002</u>	Dec 13, 2006
<u>AT</u>	+ WOCKHARDT	<u>0.1%</u>	<u>A088451 001</u>	Apr 03, 1985
<u>AT</u>	+ WOCKHARDT EU OPERATN	<u>0.025%</u>	<u>A088450 001</u>	Apr 01, 1985

OINTMENT; TOPICAL

KENALOG

<u>AT</u>	DELCOR ASSET CORP	<u>0.025%</u>	<u>N011600 003</u>	
<u>AT</u>		<u>0.1%</u>	<u>N011600 001</u>	

TRIAMCINOLONE ACETONIDE

<u>AT</u>	FOUGERA PHARMS	<u>0.025%</u>	<u>A085691 001</u>	
<u>AT</u>		<u>0.1%</u>	<u>A085691 003</u>	
<u>AT</u>		<u>0.5%</u>	<u>A085691 002</u>	
<u>AT</u>	G AND W LABS	<u>0.025%</u>	<u>A089795 001</u>	Dec 23, 1988
<u>AT</u>		<u>0.1%</u>	<u>A089796 001</u>	Dec 23, 1988
<u>AT</u>	GLENMARK PHARMS LTD	<u>0.5%</u>	<u>A206379 001</u>	Jul 22, 2016
<u>AT</u>	+ PERRIGO NEW YORK	<u>0.025%</u>	<u>A087356 001</u>	
<u>AT</u>	+	<u>0.1%</u>	<u>A087357 001</u>	
<u>AT</u>	+	<u>0.5%</u>	<u>A087385 001</u>	
<u>AT</u>	TARO	<u>0.1%</u>	<u>A040037 001</u>	Sep 30, 1994
<u>AT</u>	TELIGENT PHARMA INC	<u>0.1%</u>	<u>A205373 001</u>	May 13, 2016

TRIAMCINOLONE ACETONIDE IN ABSORBABLE

+ CAROLINA MEDCL 0.05% A089595 001 Mar 23, 1995

PASTE; DENTAL

TRIAMCINOLONE ACETONIDE

<u>AT</u>	AKORN	<u>0.1%</u>	<u>A206312 001</u>	Aug 11, 2016
<u>AT</u>	LYNE	<u>0.1%</u>	<u>A040771 001</u>	Jul 01, 2010
<u>AT</u>	+ TARO	<u>0.1%</u>	<u>A070730 001</u>	Oct 01, 1986

SPRAY; TOPICAL

KENALOG

<u>AT</u>	+ RANBAXY LABS LTD	<u>0.147MG/GM</u>	<u>N012104 001</u>	
-----------	--------------------	-------------------	--------------------	--

PRESCRIPTION DRUG PRODUCT LIST

TRIAMCINOLONE ACETONIDE

SPRAY; TOPICAL

TRIAMCINOLONE ACETONIDE

AT	AKORN	0.147MG/GM	A207094 001	Dec 07, 2016
AT	PERRIGO UK FINCO	0.147MG/GM	A205782 001	Apr 13, 2015

TRIAMCINOLONE HEXACETONIDE

INJECTABLE; INJECTION

ARISTOSPAN

+	SANDOZ	5MG/ML	N016466 001	
+		20MG/ML	N016466 002	

TRIAMTERENE

CAPSULE; ORAL

DYRENIUM

	CONCORDIA PHARMS INC	50MG	N013174 001	
+		100MG	N013174 002	

TRIAZOLAM

TABLET; ORAL

HALCION

AB	PHARMACIA AND UPJOHN	0.125MG	N017892 003	Apr 26, 1985
AB	+	0.25MG	N017892 001	Nov 15, 1982

TRIAZOLAM

AB	MYLAN PHARMS INC	0.125MG	A074031 001	Mar 25, 1994
AB		0.25MG	A074031 002	Mar 25, 1994
AB	WEST-WARD PHARMS INT	0.125MG	A074224 001	Jun 01, 1994
AB		0.25MG	A074224 002	Jun 01, 1994

TRIENTINE HYDROCHLORIDE

CAPSULE; ORAL

SYPRINE

+	ATON	250MG	N019194 001	Nov 08, 1985
---	------	-------	-------------	--------------

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL

TRIFLUOPERAZINE HYDROCHLORIDE

AB	MYLAN	EQ 1MG BASE	A040209 001	Jul 07, 1997
AB		EQ 2MG BASE	A040209 002	Jul 07, 1997
AB		EQ 5MG BASE	A040209 003	Jul 07, 1997
AB	+	EQ 10MG BASE	A040209 004	Jul 07, 1997
AB	SANDOZ	EQ 1MG BASE	A085785 001	
AB		EQ 2MG BASE	A085786 001	
AB		EQ 5MG BASE	A085789 001	
AB		EQ 10MG BASE	A085788 001	

TRIFLURIDINE

SOLUTION/DROPS; OPHTHALMIC

TRIFLURIDINE

AT	ALCON PHARMS LTD	1%	A074311 001	Oct 06, 1995
AT	+	1%	N018299 001	

VIROPTICTRIHEXYPHENIDYL HYDROCHLORIDE

ELIXIR; ORAL

TRIHEXYPHENIDYL HYDROCHLORIDE

AA	MIKART	2MG/5ML	A040251 001	Sep 27, 1999
AA	+	2MG/5ML	A040177 001	Apr 17, 1997

TABLET; ORAL

TRIHEXYPHENIDYL HYDROCHLORIDE

AA	NATCO PHARMA LTD	2MG	A091630 001	Nov 17, 2010
AA		5MG	A091630 002	Nov 17, 2010
AA	VINTAGE PHARMS	2MG	A040254 001	Dec 24, 1998
AA		5MG	A040254 002	Dec 24, 1998
AA	+	2MG	A084363 001	
AA	+	5MG	A084364 001	

TRIMETHADIONE

TABLET; ORAL

TRIDIONE

+	ABBVIE	150MG	N005856 009	
---	--------	-------	-------------	--

PRESCRIPTION DRUG PRODUCT LIST

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE; ORAL

TIGAN

AB	+	KING PHARMS	300MG	N017531 006	Dec 13, 2001
-----------	---	-------------	--------------	--------------------	--------------

TRIMETHOBENZAMIDE HYDROCHLORIDE

AB		GAVIS PHARMS	300MG	A076546 001	Aug 20, 2003
-----------	--	--------------	--------------	--------------------	--------------

AB		SUN PHARM INDS	300MG	A076570 001	Aug 28, 2003
-----------	--	----------------	--------------	--------------------	--------------

INJECTABLE; INJECTION

TIGAN

AP	+	PAR STERILE PRODUCTS	100MG/ML	N017530 001	
-----------	---	----------------------	-----------------	--------------------	--

TRIMETHOBENZAMIDE HYDROCHLORIDE

AP		LUITPOLD	100MG/ML	A091330 001	Mar 08, 2011
-----------	--	----------	-----------------	--------------------	--------------

TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE

AP		LUITPOLD	100MG/ML	A091329 001	Mar 08, 2011
-----------	--	----------	-----------------	--------------------	--------------

TRIMETHOPRIM

TABLET; ORAL

TRIMETHOPRIM

AB	+	MAYNE PHARMA	100MG	N018679 001	Jul 30, 1982
-----------	---	--------------	--------------	--------------------	--------------

AB		NOVEL LABS INC	100MG	A091437 001	Jun 15, 2011
-----------	--	----------------	--------------	--------------------	--------------

AB		WATSON LABS	100MG	A070049 001	Jun 06, 1985
-----------	--	-------------	--------------	--------------------	--------------

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION; ORAL

PRIMSOL

+	AYTU BIOSCIENCE INC	EQ 50MG BASE/5ML	N074973 001	Jan 24, 2000
---	---------------------	------------------	-------------	--------------

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

SURMONTIL

AB		ODYSSEY PHARMS	EQ 25MG BASE	N016792 001	
-----------	--	----------------	---------------------	--------------------	--

AB	+		EQ 50MG BASE	N016792 002	
-----------	---	--	---------------------	--------------------	--

AB			EQ 100MG BASE	N016792 003	Sep 15, 1982
-----------	--	--	----------------------	--------------------	--------------

TRIMIPRAMINE MALEATE

AB		CROSSMEDIKA SA	EQ 25MG BASE	A208127 001	Apr 15, 2016
-----------	--	----------------	---------------------	--------------------	--------------

AB			EQ 50MG BASE	A208127 002	Apr 15, 2016
-----------	--	--	---------------------	--------------------	--------------

AB			EQ 100MG BASE	A208127 003	Apr 15, 2016
-----------	--	--	----------------------	--------------------	--------------

AB		MIKAH PHARMA	EQ 25MG BASE	A077361 001	Aug 02, 2006
-----------	--	--------------	---------------------	--------------------	--------------

AB			EQ 50MG BASE	A077361 002	Aug 02, 2006
-----------	--	--	---------------------	--------------------	--------------

AB			EQ 100MG BASE	A077361 003	Aug 02, 2006
-----------	--	--	----------------------	--------------------	--------------

TRIPTORELIN PAMOATE

INJECTABLE; INTRAMUSCULAR

TRELSTAR

+	ALLERGAN SALES LLC	EQ 3.75MG BASE/VIAL	N020715 001	Jun 15, 2000
---	--------------------	---------------------	-------------	--------------

+		EQ 11.25MG BASE/VIAL	N021288 001	Jun 29, 2001
---	--	----------------------	-------------	--------------

+		EQ 22.5MG BASE/VIAL	N022437 001	Mar 10, 2010
---	--	---------------------	-------------	--------------

TROMETHAMINE

INJECTABLE; INJECTION

THAM

+	HOSPIRA	3.6GM/100ML	N013025 002	
---	---------	-------------	-------------	--

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

MYDRIACYL

AT	+	ALCON	0.5%	A084305 001	
-----------	---	-------	-------------	--------------------	--

AT	+	NOVARTIS PHARMS CORP	1%	A084306 001	
-----------	---	----------------------	-----------	--------------------	--

TROPICACYL

AT		AKORN	0.5%	A040314 001	Sep 29, 2000
-----------	--	-------	-------------	--------------------	--------------

AT			1%	A040315 001	Sep 29, 2000
-----------	--	--	-----------	--------------------	--------------

TROPICAMIDE

AT		BAUSCH AND LOMB	0.5%	A040067 001	Jul 27, 1994
-----------	--	-----------------	-------------	--------------------	--------------

AT			1%	A040064 001	Jul 27, 1994
-----------	--	--	-----------	--------------------	--------------

TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

TROSPIUM CHLORIDE

AB	+	ACTAVIS LABS FL INC	60MG	A091289 001	Oct 12, 2012
-----------	---	---------------------	-------------	--------------------	--------------

AB		PADDOCK LLC	60MG	A201291 001	May 24, 2013
-----------	--	-------------	-------------	--------------------	--------------

TABLET; ORAL

TROSPIUM CHLORIDE

AB		APOTEX	20MG	A091513 001	Dec 06, 2011
-----------	--	--------	-------------	--------------------	--------------

AB	+	GLENMARK GENERICS	20MG	A091575 001	Aug 13, 2010
-----------	---	-------------------	-------------	--------------------	--------------

AB		HERITAGE PHARMS INC	20MG	A204945 001	Aug 30, 2016
-----------	--	---------------------	-------------	--------------------	--------------

AB		INVAGEN PHARMS	20MG	A091688 001	Aug 23, 2016
-----------	--	----------------	-------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

TROSPIUM CHLORIDE

TABLET; ORAL

TROSPIUM CHLORIDE

AB	PADDOCK LLC	20MG	A091573 001	Nov 17, 2010
-----------	-------------	-------------	--------------------	--------------

TRYPAN BLUE

SOLUTION; OPHTHALMIC

MEMBRANEBLUE

+ DORC

0.15%

N022278 001 Feb 20, 2009

VISIONBLUE

+ DORC

0.06%

N021670 001 Dec 16, 2004

ULIPRISTAL ACETATE

TABLET; ORAL

ELLA

+ LAB HRA PHARMA

30MG

N022474 001 Aug 13, 2010

UMECLIDINIUM BROMIDE

POWDER; INHALATION

INCRUSE ELLIPTA

+ GLAXO GRP ENGLAND

EQ 62.5MCG BASE/INH

N205382 001 Apr 30, 2014

UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE

POWDER; INHALATION

ANORO ELLIPTA

+ GLAXOSMITHKLINE

EQ 0.0625MG BASE/INH; EQ 0.025MG
BASE/INH

N203975 001 Dec 18, 2013

UREA, C-14

CAPSULE; ORAL

PYTEST

+ AVENT

1uCi

N020617 001 May 09, 1997

PYTEST KIT

+ AVENT

1uCi

N020617 002 May 09, 1997

URIDINE TRIACETATE

GRANULE; ORAL

VISTOGARD

+ WELLSTAT THERAP

10GM/PACKET

N208159 001 Dec 11, 2015

XURIDEN

+ WELLSTAT THERAP

2GM/PACKET

N208169 001 Sep 04, 2015

UROFOLLITROPIN

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

BRAVELLE

+ FERRING

75 IU/VIAL

N021289 001 May 06, 2002

URSODIOL

CAPSULE; ORAL

ACTIGALL

AB	+ ALLERGAN SALES LLC	300MG	N019594 002	Dec 31, 1987
-----------	----------------------	--------------	--------------------	--------------

URSODIOL

AB	COREPHARMA	300MG	A077895 001	Jul 27, 2006
-----------	------------	--------------	--------------------	--------------

AB	EPIC PHARMA	300MG	A075517 001	Mar 14, 2000
-----------	-------------	--------------	--------------------	--------------

AB	LANNETT	300MG	A079082 001	Dec 15, 2008
-----------	---------	--------------	--------------------	--------------

AB	MYLAN	300MG	A090530 001	Feb 17, 2010
-----------	-------	--------------	--------------------	--------------

AB	TEVA PHARMS	300MG	A075592 001	May 25, 2000
-----------	-------------	--------------	--------------------	--------------

TABLET; ORAL

URSO 250

AB	FOREST LABS INC	250MG	N020675 001	Dec 10, 1997
-----------	-----------------	--------------	--------------------	--------------

URSO FORTE

AB	+ FOREST LABS INC	500MG	N020675 002	Jul 21, 2004
-----------	-------------------	--------------	--------------------	--------------

URSODIOL

AB	GLENMARK GENERICS	250MG	A090801 001	Jul 12, 2011
-----------	-------------------	--------------	--------------------	--------------

AB		500MG	A090801 002	Jul 12, 2011
-----------	--	--------------	--------------------	--------------

AB	IMPAX LABS INC	250MG	A200826 001	Dec 23, 2011
-----------	----------------	--------------	--------------------	--------------

AB		500MG	A200826 002	Dec 23, 2011
-----------	--	--------------	--------------------	--------------

AB	PAR PHARM	250MG	A202540 001	Feb 14, 2013
-----------	-----------	--------------	--------------------	--------------

AB		500MG	A202540 002	Feb 14, 2013
-----------	--	--------------	--------------------	--------------

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

AB	APOTEX INC	EQ 500MG BASE	A090500 001	Apr 04, 2014
-----------	------------	----------------------	--------------------	--------------

AB		EQ 1GM BASE	A090500 002	Apr 04, 2014
-----------	--	--------------------	--------------------	--------------

AB	AUROBINDO PHARMA	EQ 500MG BASE	A090682 001	May 24, 2010
-----------	------------------	----------------------	--------------------	--------------

AB		EQ 1GM BASE	A090682 002	May 24, 2010
-----------	--	--------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LISTVALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

AB	CIPLA LTD	<u>EQ 500MG BASE</u>	<u>A077135 001</u>	May 24, 2010
AB		<u>EQ 1GM BASE</u>	<u>A077135 002</u>	May 24, 2010
AB	DR REDDYS LABS LTD	<u>EQ 500MG BASE</u>	<u>A079012 001</u>	May 24, 2010
AB		<u>EQ 1GM BASE</u>	<u>A079012 002</u>	May 24, 2010
AB	HETERO LABS LTD V	<u>EQ 500MG BASE</u>	<u>A203047 001</u>	Apr 08, 2015
AB		<u>EQ 1GM BASE</u>	<u>A203047 002</u>	Apr 08, 2015
AB	JUBILANT GENERICS	<u>EQ 500MG BASE</u>	<u>A201506 001</u>	Apr 03, 2012
AB		<u>EQ 1GM BASE</u>	<u>A201506 002</u>	Apr 03, 2012
AB	MYLAN	<u>EQ 500MG BASE</u>	<u>A078070 001</u>	May 24, 2010
AB		<u>EQ 1GM BASE</u>	<u>A078070 002</u>	May 24, 2010
AB	MYLAN PHARMS INC	<u>EQ 500MG BASE</u>	<u>A078518 001</u>	May 24, 2010
AB		<u>EQ 1GM BASE</u>	<u>A078518 002</u>	May 24, 2010
AB	SANDOZ	<u>EQ 500MG BASE</u>	<u>A077478 001</u>	May 24, 2010
AB		<u>EQ 1GM BASE</u>	<u>A077478 002</u>	May 24, 2010
AB	SUN PHARM INDS LTD	<u>EQ 500MG BASE</u>	<u>A076588 001</u>	Jan 31, 2007
AB		<u>EQ 1GM BASE</u>	<u>A076588 002</u>	Jan 31, 2007
AB	TEVA PHARMS	<u>EQ 500MG BASE</u>	<u>A077655 001</u>	May 24, 2010
AB		<u>EQ 1GM BASE</u>	<u>A077655 002</u>	May 24, 2010
AB	WATSON LABS INC	<u>EQ 500MG BASE</u>	<u>A090370 001</u>	Mar 16, 2011
AB		<u>EQ 1GM BASE</u>	<u>A090370 002</u>	Mar 16, 2011
AB	WEST-WARD PHARMS INT	<u>EQ 500MG BASE</u>	<u>A078656 001</u>	May 24, 2010
AB		<u>EQ 1GM BASE</u>	<u>A078656 002</u>	May 24, 2010
AB	WOCKHARDT	<u>EQ 500MG BASE</u>	<u>A090216 001</u>	May 24, 2010
AB		<u>EQ 1GM BASE</u>	<u>A090216 002</u>	May 24, 2010
VALTREX				
AB	GLAXOSMITHKLINE	<u>EQ 500MG BASE</u>	<u>N020487 001</u>	Jun 23, 1995
AB	+	<u>EQ 1GM BASE</u>	<u>N020487 002</u>	Jun 23, 1995

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION; ORAL

VALCYTE

AB	+	HOFFMANN LA ROCHE	<u>50MG/ML</u>	<u>N022257 001</u>	Aug 28, 2009
VALGANCICLOVIR HYDROCHLORIDE					
AB		ACTAVIS LABS FL INC	<u>50MG/ML</u>	<u>A205220 001</u>	Jul 18, 2016

TABLET; ORAL

VALCYTE

AB	+	HOFFMANN LA ROCHE	<u>EQ 450MG BASE</u>	<u>N021304 001</u>	Mar 29, 2001
VALGANCICLOVIR HYDROCHLORIDE					
AB		AUROBINDO PHARMA LTD	<u>EQ 450MG BASE</u>	<u>A204750 001</u>	Mar 31, 2016
AB		DR REDDYS LABS LTD	<u>EQ 450MG BASE</u>	<u>A203511 001</u>	Nov 04, 2014
AB		ENDO PHARMS INC	<u>EQ 450MG BASE</u>	<u>A200790 001</u>	Nov 04, 2014
AB		HETERO LABS LTD V	<u>EQ 450MG BASE</u>	<u>A205166 001</u>	Mar 18, 2016

VALPROATE SODIUM

INJECTABLE; INJECTION

DEPACON

AP	+	ABBVIE	<u>EQ 100MG BASE/ML</u>	<u>N020593 001</u>	Dec 30, 1996
VALPROATE SODIUM					
AP		AMPHASTAR PHARMS INC	<u>EQ 100MG BASE/ML</u>	<u>A076295 001</u>	Nov 14, 2002
AP		FRESENIUS KABI USA	<u>EQ 100MG BASE/ML</u>	<u>A076539 001</u>	Jun 26, 2003
AP		HIKMA FARMACEUTICA	<u>EQ 100MG BASE/ML</u>	<u>A078523 001</u>	Feb 17, 2010

VALPROIC ACID

CAPSULE; ORAL

DEPAKENE

AB	+	ABBVIE	<u>250MG</u>	<u>N018081 001</u>	
VALPROIC ACID					
AB		BIONPHARMA INC	<u>250MG</u>	<u>A073484 001</u>	Jun 29, 1993
AB		CATALENT	<u>250MG</u>	<u>A073229 001</u>	Oct 29, 1991
AB		SUN PHARM INDS LTD	<u>250MG</u>	<u>A091037 001</u>	Feb 22, 2013

SYRUP; ORAL

DEPAKENE

AA	+	ABBVIE	<u>250MG/5ML</u>	<u>N018082 001</u>	
VALPROIC ACID					
AA		ALPHARMA	<u>250MG/5ML</u>	<u>A075782 001</u>	Dec 22, 2000
AA		ANI PHARMS INC	<u>250MG/5ML</u>	<u>A073178 001</u>	Aug 25, 1992
AA		HIGH TECH PHARMA	<u>250MG/5ML</u>	<u>A074060 001</u>	Jan 13, 1995
AA		NOSTRUM LABS INC	<u>250MG/5ML</u>	<u>A090517 001</u>	May 28, 2010
AA		PHARM ASSOC	<u>250MG/5ML</u>	<u>A075379 001</u>	Dec 15, 2000
AA		VINTAGE	<u>250MG/5ML</u>	<u>A077960 001</u>	Oct 13, 2006
AA		WOCKHARDT	<u>250MG/5ML</u>	<u>A070868 001</u>	Jul 01, 1986

PRESCRIPTION DRUG PRODUCT LIST

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

VANCOMYCIN HYDROCHLORIDE

<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A065478 002</u>	Apr 09, 2012
<u>AB</u>	FRESENIUS KABI USA	<u>EQ 125MG BASE</u>	<u>A065453 001</u>	Jun 18, 2012
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A065453 002</u>	Jun 18, 2012
<u>AB</u>	LUPIN LTD	<u>EQ 125MG BASE</u>	<u>A090439 001</u>	Jan 28, 2015
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A090439 002</u>	Jan 28, 2015
<u>AB</u>	STRIDES PHARMA	<u>EQ 125MG BASE</u>	<u>A065490 001</u>	Apr 09, 2012
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A065490 002</u>	Apr 09, 2012
<u>AB</u>	WATSON LABS	<u>EQ 125MG BASE</u>	<u>A065510 001</u>	Apr 09, 2012
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A065510 002</u>	Apr 09, 2012

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

<u>AP</u>	AMNEAL PHARMS CO	<u>EQ 500MG BASE/VIAL</u>	<u>A065401 001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065401 002</u>	Jun 30, 2008
<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A205780 001</u>	Mar 31, 2016
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A205780 002</u>	Mar 31, 2016
<u>AP</u>		<u>EQ 5GM BASE/VIAL</u>	<u>A205779 001</u>	Mar 29, 2016
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A205779 002</u>	Mar 29, 2016
<u>AP</u>	CFT PHARMS LLC	<u>EQ 5GM BASE/VIAL</u>	<u>A204125 001</u>	Dec 28, 2015
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A204125 002</u>	Dec 28, 2015
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A204107 001</u>	Dec 28, 2015
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A204107 002</u>	Dec 28, 2015
<u>AP</u>	EMCURE PHARMS LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A202275 001</u>	Oct 31, 2013
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A202275 002</u>	Oct 31, 2013
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A202464 001</u>	Oct 09, 2013
<u>AP</u>		<u>EQ 5GM BASE/VIAL</u>	<u>A202274 001</u>	Oct 31, 2013
<u>AP</u>	+ FRESENIUS KABI USA	<u>EQ 500MG BASE/VIAL</u>	<u>A062663 001</u>	Mar 17, 1987
<u>AP</u>		<u>EQ 750MG BASE/VIAL</u>	<u>A062663 005</u>	Aug 17, 2016
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>A062663 002</u>	Jul 31, 1987
<u>AP</u>	+	<u>EQ 5GM BASE/VIAL</u>	<u>A062663 003</u>	Jun 03, 1988
<u>AP</u>	+	<u>EQ 10GM BASE/VIAL</u>	<u>A062663 004</u>	Nov 28, 1997
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A205694 001</u>	Jan 21, 2016
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A205694 002</u>	Jan 21, 2016
<u>AP</u>	+ HOSPIRA	<u>EQ 500MG BASE/VIAL</u>	<u>A062911 001</u>	Aug 04, 1988
<u>AP</u>	+	<u>EQ 500MG BASE/VIAL</u>	<u>A062931 001</u>	Oct 29, 1992
<u>AP</u>	+	<u>EQ 750MG BASE/VIAL</u>	<u>A062912 002</u>	Jan 07, 2009
<u>AP</u>	+	<u>EQ 750MG BASE/VIAL</u>	<u>A062933 002</u>	May 27, 2009
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>A062912 001</u>	Aug 04, 1988
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>A062933 001</u>	Oct 29, 1992
<u>AP</u>	+	<u>EQ 5GM BASE/VIAL</u>	<u>A063076 001</u>	Dec 21, 1990
<u>AP</u>	HOSPIRA INC	<u>EQ 10GM BASE/VIAL</u>	<u>A065455 001</u>	Apr 29, 2009
<u>AP</u>	MYLAN LABS LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A065397 001</u>	Dec 30, 2008
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065397 002</u>	Dec 30, 2008
<u>AP</u>		<u>EQ 5GM BASE/VIAL</u>	<u>A065432 001</u>	Dec 30, 2008
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A091469 001</u>	Jul 01, 2011
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A091554 001</u>	Sep 19, 2011
<u>AP</u>	SAGENT PHARMS	<u>EQ 5GM BASE/VIAL</u>	<u>A200837 001</u>	Aug 10, 2012
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A200837 002</u>	Sep 02, 2014
<u>AP</u>	SANDOZ	<u>EQ 500MG BASE/VIAL</u>	<u>A090250 001</u>	Apr 27, 2010
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A090250 002</u>	Apr 27, 2010
<u>AP</u>	SANDOZ INC	<u>EQ 5GM BASE/VIAL</u>	<u>A201048 001</u>	Aug 10, 2012
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A201048 002</u>	Aug 10, 2012
<u>AP</u>	TEVA PHARMS USA	<u>EQ 500MG BASE/VIAL</u>	<u>A201251 001</u>	Dec 23, 2015
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A201251 002</u>	Dec 23, 2015
<u>AP</u>		<u>EQ 5GM BASE/VIAL</u>	<u>A201250 001</u>	Dec 23, 2015
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A201250 002</u>	Dec 23, 2015
<u>AP</u>	XELLIA PHARMS APS	<u>EQ 500MG BASE/VIAL</u>	<u>A091377 001</u>	Sep 09, 2015
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A091377 002</u>	Sep 09, 2015
<u>AP</u>		<u>EQ 5GM BASE/VIAL</u>	<u>A206243 001</u>	Dec 23, 2015
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A206243 002</u>	Dec 23, 2015
	VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER			
	+ BAXTER HLTHCARE	EQ 500MG BASE/100ML	N050671 001	Apr 29, 1993
	+	EQ 750MG BASE/150ML	N050671 002	Dec 20, 2010
	POWDER; IV (INFUSION)			
	VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER			
	SAMSON MEDCL	EQ 100GM BASE	A091532 001	Jan 06, 2016

PRESCRIPTION DRUG PRODUCT LIST

VANDETANIB

TABLET; ORAL

CAPRELSA

GENZYME CORP

100MG

N022405 001 Apr 06, 2011

+

300MG

N022405 002 Apr 06, 2011

VARDENAFIL HYDROCHLORIDE

TABLET; ORAL

LEVITRAAB BAYER HLTHCARE2.5MGN021400 003 Aug 19, 2003AB 5MGN021400 001 Aug 19, 2003AB 10MGN021400 002 Aug 19, 2003AB + 20MGN021400 004 Aug 19, 2003VARDENAFIL HYDROCHLORIDEAB TEVA PHARMS2.5MGA091347 001 May 03, 2012AB 5MGA091347 002 May 03, 2012AB 10MGA091347 003 May 03, 2012AB 20MGA091347 004 May 03, 2012

TABLET, ORALLY DISINTEGRATING; ORAL

STAXYNAB + BAYER HLTHCARE10MGN200179 001 Jun 17, 2010VARDENAFIL HYDROCHLORIDEAB WATSON LABS INC10MGA203689 001 Apr 22, 2015VARENICLINE TARTRATE

TABLET; ORAL

CHANTIX

PFIZER INC

EQ 0.5MG BASE

N021928 001 May 10, 2006

+

EQ 1MG BASE

N021928 002 May 10, 2006

VASOPRESSIN

SOLUTION; IV (INFUSION)

VASOSTRICT

+ PAR STERILE PRODUCTS

20UNITS/ML (20UNITS/ML)

N204485 001 Apr 17, 2014

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDEAP EUROHLTH INTL SARL10MG/VIALA075549 001 Jun 13, 2000AP 20MG/VIALA075549 002 Jun 13, 2000AP GLAND PHARMA LTD10MG/VIALA205390 001 May 26, 2016AP 20MG/VIALA205390 002 May 26, 2016AP HOSPIRA10MG/VIALA075164 001 Oct 21, 1999AP 20MG/VIALA075164 002 Oct 21, 1999AP MYLAN LABS LTD10MG/VIALA090243 001 May 11, 2010AP 20MG/VIALA090243 002 May 11, 2010AP SAGENT PHARMS10MG/VIALA078274 001 Dec 29, 2008AP 20MG/VIALA078274 002 Dec 29, 2008AP + SUN PHARMA GLOBAL10MG/VIALA079001 001 Jun 17, 2009AP + 20MG/VIALA079001 002 Jun 17, 2009AP TEVA PHARMS USA10MG/VIALA074688 001 Aug 25, 1999AP 20MG/VIALA074688 002 Aug 25, 1999VELAGLUCERASE ALFA

INJECTABLE; IV (INFUSION)

VPRIV

SHIRE HUMAN GENETIC

400 UNITS/VIAL

N022575 001 Feb 26, 2010

VEMURAFENIB

TABLET; ORAL

ZELBORAF

+ HOFFMANN LA ROCHE

240MG

N202429 001 Aug 17, 2011

VENETOCLAX

TABLET; ORAL

VENCLEXTA

ABBVIE INC

10MG

N208573 001 Apr 11, 2016

50MG

N208573 002 Apr 11, 2016

+

100MG

N208573 003 Apr 11, 2016

PRESCRIPTION DRUG PRODUCT LISTVENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

EFFEXOR XR

<u>AB</u>	WYETH PHARMS INC	<u>EQ 37.5MG BASE</u>	<u>N020699 001</u>	Oct 20, 1997
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>N020699 002</u>	Oct 20, 1997
<u>AB</u>	+	<u>EQ 150MG BASE</u>	<u>N020699 004</u>	Oct 20, 1997
<u>VENLAFAXINE HYDROCHLORIDE</u>				
<u>AB</u>	ANCHEN PHARMS	<u>EQ 37.5MG BASE</u>	<u>A078087 001</u>	Mar 16, 2012
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078087 002</u>	Mar 16, 2012
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A078087 003</u>	Mar 16, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 37.5MG BASE</u>	<u>A200834 001</u>	Apr 14, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A200834 002</u>	Apr 14, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A200834 003</u>	Apr 14, 2011
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 37.5MG BASE</u>	<u>A078421 001</u>	May 06, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078421 002</u>	May 06, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A078421 003</u>	May 06, 2011
<u>AB</u>	MYLAN	<u>EQ 37.5MG BASE</u>	<u>A078789 001</u>	Jun 01, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078789 002</u>	Jun 01, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A078789 003</u>	Jun 01, 2011
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 37.5MG BASE</u>	<u>A091123 001</u>	Jul 11, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A091123 002</u>	Jul 11, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A091123 003</u>	Jul 11, 2011
<u>AB</u>	TEVA	<u>EQ 37.5MG BASE</u>	<u>A076565 001</u>	Jun 28, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A076565 002</u>	Jun 28, 2010
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A076565 003</u>	Jun 28, 2010
<u>AB</u>	TORRENT PHARMS LLC	<u>EQ 37.5MG BASE</u>	<u>A090899 001</u>	Jun 01, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090899 002</u>	Jun 01, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A090899 003</u>	Jun 01, 2011
<u>AB</u>	VALEANT PHARMS NORTH	<u>EQ 37.5MG BASE</u>	<u>A090071 001</u>	Apr 15, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090071 002</u>	Apr 15, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A090071 003</u>	Apr 15, 2011
<u>AB</u>	WOCKHARDT	<u>EQ 37.5MG BASE</u>	<u>A078865 001</u>	Apr 14, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078865 002</u>	Apr 14, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A078865 003</u>	Apr 14, 2011
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 37.5MG BASE</u>	<u>A090174 001</u>	Apr 14, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090174 002</u>	Apr 14, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A090174 003</u>	Apr 14, 2011

TABLET; ORAL

VENLAFAXINE HYDROCHLORIDE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>EQ 25MG BASE</u>	<u>A078932 001</u>	Dec 14, 2010
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A078932 002</u>	Dec 14, 2010
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078932 003</u>	Dec 14, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078932 004</u>	Dec 14, 2010
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078932 005</u>	Dec 14, 2010
<u>AB</u>	AMNEAL PHARMS	<u>EQ 25MG BASE</u>	<u>A079098 001</u>	May 11, 2010
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A079098 002</u>	May 11, 2010
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A079098 003</u>	May 11, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A079098 004</u>	May 11, 2010
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A079098 005</u>	May 11, 2010
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 25MG BASE</u>	<u>A090555 001</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A090555 002</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A090555 003</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090555 004</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090555 005</u>	Apr 07, 2010
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 25MG BASE</u>	<u>A078301 001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A078301 002</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078301 003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078301 004</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078301 005</u>	Jun 13, 2008
<u>AB</u>	HERITAGE PHARMS INC	<u>EQ 25MG BASE</u>	<u>A078554 001</u>	Jan 09, 2009
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A078554 002</u>	Jan 09, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078554 003</u>	Jan 09, 2009
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078554 004</u>	Jan 09, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078554 005</u>	Jan 09, 2009
<u>AB</u>	MYLAN	<u>EQ 25MG BASE</u>	<u>A077166 001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A077166 002</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077166 003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A077166 004</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077166 005</u>	Jun 13, 2008
<u>AB</u>	SUN PHARM INDS INC	<u>EQ 25MG BASE</u>	<u>A078627 001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A078627 002</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078627 003</u>	Jun 13, 2008

PRESCRIPTION DRUG PRODUCT LIST

VENLAFAXINE HYDROCHLORIDE

TABLET; ORAL

VENLAFAXINE HYDROCHLORIDE

<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078627 004</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078627 005</u>	Jun 13, 2008
<u>AB</u>	TEVA	<u>EQ 25MG BASE</u>	<u>A076690 001</u>	Aug 03, 2006
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A076690 002</u>	Aug 03, 2006
<u>AB</u>	+	<u>EQ 50MG BASE</u>	<u>A076690 003</u>	Aug 03, 2006
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A076690 004</u>	Aug 03, 2006
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076690 005</u>	Aug 03, 2006
<u>AB</u>	VINTAGE	<u>EQ 25MG BASE</u>	<u>A090027 001</u>	Aug 04, 2010
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A090027 002</u>	Aug 04, 2010
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A090027 003</u>	Aug 04, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090027 004</u>	Aug 04, 2010
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090027 005</u>	Aug 04, 2010
<u>AB</u>	YAOPHARMA CO LTD	<u>EQ 25MG BASE</u>	<u>A202036 001</u>	May 28, 2015
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A202036 002</u>	May 28, 2015
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A202036 003</u>	May 28, 2015
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A202036 004</u>	May 28, 2015
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A202036 005</u>	May 28, 2015
<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 25MG BASE</u>	<u>A077653 001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A077653 002</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077653 003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A077653 004</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077653 005</u>	Jun 13, 2008

TABLET, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

<u>AB</u>	OSMOTICA PHARM	<u>EQ 37.5MG BASE</u>	<u>N022104 001</u>	May 20, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>N022104 002</u>	May 20, 2008
<u>AB</u>	+	<u>EQ 150MG BASE</u>	<u>N022104 003</u>	May 20, 2008
<u>AB</u>	SUN PHARMA GLOBAL	<u>EQ 37.5MG BASE</u>	<u>A091272 001</u>	Aug 18, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A091272 002</u>	Aug 18, 2010
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A091272 003</u>	Aug 18, 2010
<u>AB</u>	OSMOTICA PHARM	<u>EQ 225MG BASE</u>	<u>N022104 004</u>	May 20, 2008

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VERAPAMIL HYDROCHLORIDE

<u>AB</u>	MYLAN	<u>100MG</u>	<u>A078306 001</u>	Aug 09, 2007
<u>AB</u>		<u>120MG</u>	<u>A075138 001</u>	Apr 20, 1999
<u>AB</u>		<u>180MG</u>	<u>A075138 002</u>	Apr 20, 1999
<u>AB</u>		<u>200MG</u>	<u>A078306 002</u>	Aug 09, 2007
<u>AB</u>		<u>240MG</u>	<u>A075138 003</u>	Apr 20, 1999
<u>AB</u>		<u>300MG</u>	<u>A078306 003</u>	Aug 09, 2007

VERELAN

<u>AB</u>	RECRO GAINESVILLE	<u>120MG</u>	<u>N019614 001</u>	May 29, 1990
<u>AB</u>		<u>180MG</u>	<u>N019614 003</u>	Jan 09, 1992
<u>AB</u>		<u>240MG</u>	<u>N019614 002</u>	May 29, 1990

VERELAN PM

<u>AB</u>	RECRO GAINESVILLE	<u>100MG</u>	<u>N020943 001</u>	Nov 25, 1998
<u>AB</u>		<u>200MG</u>	<u>N020943 002</u>	Nov 25, 1998
<u>AB</u>	+	<u>300MG</u>	<u>N020943 003</u>	Nov 25, 1998
<u>AB</u>	VERELAN + RECRO GAINESVILLE	<u>360MG</u>	<u>N019614 004</u>	May 10, 1996

SOLUTION; INTRAVENOUS

VERAPAMIL HYDROCHLORIDE

<u>AP</u>	EXELA PHARMA SCS LLC	<u>5MG/2ML (2.5MG/ML)</u>	<u>N018925 001</u>	Mar 30, 1984
<u>AP</u>	+	<u>10MG/4ML (2.5MG/ML)</u>	<u>A070738 001</u>	May 06, 1987
<u>AP</u>	+	<u>5MG/2ML (2.5MG/ML)</u>	<u>A075136 001</u>	Oct 20, 1998
<u>AP</u>	+	<u>5MG/2ML (2.5MG/ML)</u>	<u>A070737 001</u>	May 06, 1987
<u>AP</u>	+	<u>10MG/4ML (2.5MG/ML)</u>	<u>A070737 002</u>	May 06, 1987

TABLET; ORAL

CALAN

<u>AB</u>	GD SEARLE LLC	<u>80MG</u>	<u>N018817 001</u>	Sep 10, 1984
<u>AB</u>	+	<u>120MG</u>	<u>N018817 002</u>	Sep 10, 1984

VERAPAMIL HYDROCHLORIDE

<u>AB</u>	HERITAGE PHARMS INC	<u>40MG</u>	<u>A071881 002</u>	Oct 14, 2015
<u>AB</u>		<u>80MG</u>	<u>A071880 001</u>	Apr 05, 1988
<u>AB</u>		<u>120MG</u>	<u>A071881 001</u>	Apr 05, 1988
<u>AB</u>	MYLAN	<u>80MG</u>	<u>A071483 002</u>	Feb 15, 1989
<u>AB</u>		<u>120MG</u>	<u>A071483 001</u>	Feb 15, 1989
<u>AB</u>	WATSON LABS	<u>40MG</u>	<u>A072924 001</u>	Jun 29, 1993
<u>AB</u>		<u>80MG</u>	<u>A070995 001</u>	Oct 01, 1986

PRESCRIPTION DRUG PRODUCT LIST

VERAPAMIL HYDROCHLORIDE

TABLET; ORAL

VERAPAMIL HYDROCHLORIDEAB 120MG A070994 001 Oct 01, 1986

TABLET, EXTENDED RELEASE; ORAL

CALAN SRAB + PFIZER 120MG N019152 003 Mar 06, 1991AB + 240MG N019152 001 Dec 16, 1986VERAPAMIL HYDROCHLORIDEAB APOTEX CORP 120MG A200878 001 Apr 20, 2012AB 180MG A200878 002 Apr 20, 2012AB 240MG A200878 003 Apr 20, 2012AB GLENMARK GENERICS 120MG A090700 001 Aug 03, 2011AB + 180MG A090700 002 Aug 03, 2011AB 240MG A078906 001 Sep 17, 2009AB IVAX SUB TEVA PHARMS 120MG A073568 002 Oct 10, 1997AB 180MG A074330 001 Jan 31, 1994AB 240MG A073568 001 Jul 31, 1992AB MYLAN 120MG A074587 002 Feb 21, 1997AB 180MG A074587 003 Sep 09, 1997AB 240MG A074587 001 Mar 23, 1996AB PAR PHARM 120MG A075072 001 May 25, 1999AB 240MG A075072 003 May 25, 1999AB SUN PHARM INDS INC 120MG A090529 001 Dec 30, 2011AB 180MG A090529 002 Dec 30, 2011AB 240MG A090529 003 Dec 30, 2011

COVERA-HS

BC + GD SEARLE LLC 180MG N020552 001 Feb 26, 1996

BC + 240MG N020552 002 Feb 26, 1996

VERTEPORFIN

INJECTABLE; INJECTION

VISUDYNE

+ VALEANT LUXEMBOURG 15MG/VIAL N021119 001 Apr 12, 2000

VIGABATRIN

FOR SOLUTION; ORAL

SABRIL

+ LUNDBECK LLC 500MG/PACKET N022006 001 Aug 21, 2009

TABLET; ORAL

SABRIL

+ LUNDBECK LLC 500MG N020427 001 Aug 21, 2009

VILAZODONE HYDROCHLORIDE

TABLET; ORAL

VIIBRYD

+ FOREST LABS LLC 10MG N022567 001 Jan 21, 2011

20MG N022567 002 Jan 21, 2011

40MG N022567 003 Jan 21, 2011

VINBLASTINE SULFATE

INJECTABLE; INJECTION

VINBLASTINE SULFATE

+ FRESENIUS KABI USA 1MG/ML A089515 001 Apr 29, 1987

+ WEST-WARD PHARMS INT 10MG/VIAL A089395 001 Apr 09, 1987

VINCRISTINE SULFATE

INJECTABLE; INJECTION

VINCRISTINE SULFATE PFSAP + HOSPIRA 1MG/ML A071484 001 Apr 19, 1988AP TEVA PHARMS USA 1MG/ML A075493 001 Sep 01, 1999

INJECTABLE, LIPOSOMAL; INTRAVENOUS

MARQIBO KIT

+ TALON THERAP 5MG/5ML (1MG/ML) N202497 001 Aug 09, 2012

VINORELBINE TARTRATE

INJECTABLE; INJECTION

NAVELBINEAP + PIERRE FABRE EQ 10MG BASE/ML N020388 001 Dec 23, 1994VINORELBINE TARTRATEAP ACTAVIS TOTOWA EQ 10MG BASE/ML A078011 001 Jul 22, 2009AP DR REDDYS LABS LTD EQ 10MG BASE/ML A202017 001 Sep 12, 2013AP EUROHLTH INTL SARL EQ 10MG BASE/ML A075992 001 Jun 10, 2003AP EQ 10MG BASE/ML A076461 001 Dec 11, 2003AP FRESENIUS KABI USA EQ 10MG BASE/ML A076849 001 Apr 18, 2005

PRESCRIPTION DRUG PRODUCT LIST

VINORELBINE TARTRATE

INJECTABLE; INJECTION

VINORELBINE TARTRATE

<u>AP</u>	HOSPIRA	<u>EQ 10MG BASE/ML</u>	<u>A076827 001</u>	Jun 02, 2005
<u>AP</u>	JIANGSU HANSOH PHARM	<u>EQ 10MG BASE/ML</u>	<u>A091106 001</u>	Sep 26, 2012
<u>AP</u>	MYLAN LABS LTD	<u>EQ 10MG BASE/ML</u>	<u>A200148 001</u>	Aug 31, 2012
<u>AP</u>	TEVA PHARMS USA	<u>EQ 10MG BASE/ML</u>	<u>A076028 001</u>	Feb 03, 2003

VISMODEGIB

CAPSULE; ORAL

ERIVEDGE

+ GENENTECH

150MG

N203388 001 Jan 30, 2012

VITAMIN A PALMITATE

INJECTABLE; INJECTION

AQUASOL A

+ HOSPIRA

EQ 50,000 UNITS BASE/ML

N006823 001

VORAPAXAR SULFATE

TABLET; ORAL

ZONTIVITY

+ ARALEZ PHARMS

EQ 2.08MG BASE

N204886 001 May 08, 2014

VORICONAZOLE

FOR SUSPENSION; ORAL

VFEND

<u>AB</u>	+ PF PRISM CV	<u>200MG/5ML</u>	<u>N021630 001</u>	Dec 19, 2003
-----------	---------------	------------------	--------------------	--------------

VORICONAZOLE

<u>AB</u>	AMNEAL PHARMS	<u>200MG/5ML</u>	<u>A205034 001</u>	Apr 13, 2016
<u>AB</u>	MYLAN PHARMS INC	<u>200MG/5ML</u>	<u>A202361 001</u>	May 28, 2013
<u>AB</u>	NOVEL LABS INC	<u>200MG/5ML</u>	<u>A206799 001</u>	May 31, 2016

INJECTABLE; IV (INFUSION)

VFEND

<u>AP</u>	+ PF PRISM CV	<u>200MG/VIAL</u>	<u>N021267 001</u>	May 24, 2002
-----------	---------------	-------------------	--------------------	--------------

VORICONAZOLE

<u>AP</u>	ALVOGEN INC	<u>200MG/VIAL</u>	<u>A206398 001</u>	Mar 23, 2016
<u>AP</u>	SANDOZ INC	<u>200MG/VIAL</u>	<u>A090862 001</u>	May 30, 2012

TABLET; ORAL

VFEND

<u>AB</u>	PF PRISM CV	<u>50MG</u>	<u>N021266 001</u>	May 24, 2002
<u>AB</u>	+	<u>200MG</u>	<u>N021266 002</u>	May 24, 2002

VORICONAZOLE

<u>AB</u>	AJANTA PHARMA LTD	<u>50MG</u>	<u>A206181 001</u>	May 24, 2016
<u>AB</u>		<u>200MG</u>	<u>A206181 002</u>	May 24, 2016
<u>AB</u>	AKORN	<u>50MG</u>	<u>A207049 001</u>	Sep 07, 2016
<u>AB</u>		<u>200MG</u>	<u>A207049 002</u>	Sep 07, 2016
<u>AB</u>	APPCO PHARMA LLC	<u>50MG</u>	<u>A206762 001</u>	May 24, 2016
<u>AB</u>		<u>200MG</u>	<u>A206762 002</u>	May 24, 2016
<u>AB</u>	AUROBINDO PHARMA LTD	<u>50MG</u>	<u>A206837 001</u>	Jan 22, 2016
<u>AB</u>		<u>200MG</u>	<u>A206837 002</u>	Jan 22, 2016
<u>AB</u>	GLENMARK PHARMS LTD	<u>50MG</u>	<u>A203503 001</u>	Sep 02, 2015
<u>AB</u>		<u>200MG</u>	<u>A203503 002</u>	Sep 02, 2015
<u>AB</u>	MYLAN PHARMS INC	<u>50MG</u>	<u>A090547 001</u>	Apr 22, 2010
<u>AB</u>		<u>200MG</u>	<u>A090547 002</u>	Apr 22, 2010
<u>AB</u>	NOVEL LABS INC	<u>50MG</u>	<u>A207371 001</u>	May 24, 2016
<u>AB</u>		<u>200MG</u>	<u>A207371 002</u>	May 24, 2016
<u>AB</u>	PRINSTON INC	<u>50MG</u>	<u>A206654 001</u>	Aug 08, 2016
<u>AB</u>		<u>200MG</u>	<u>A206654 002</u>	Aug 08, 2016
<u>AB</u>	SANDOZ INC	<u>50MG</u>	<u>A200265 001</u>	Dec 12, 2011
<u>AB</u>		<u>200MG</u>	<u>A200265 002</u>	Dec 12, 2011
<u>AB</u>	TEVA PHARMS	<u>50MG</u>	<u>A091658 001</u>	Apr 06, 2012
<u>AB</u>		<u>200MG</u>	<u>A091658 002</u>	Apr 06, 2012
<u>AB</u>	ZYDUS PHARMS USA INC	<u>50MG</u>	<u>A206747 001</u>	May 24, 2016
<u>AB</u>		<u>200MG</u>	<u>A206747 002</u>	May 24, 2016

VORINOSTAT

CAPSULE; ORAL

ZOLINZA

+ MERCK

100MG

N021991 001 Oct 06, 2006

PRESCRIPTION DRUG PRODUCT LIST

VORTIOXETINE HYDROBROMIDE

TABLET; ORAL

TRINTELLIX

TAKEDA PHARMS USA	EQ 5MG BASE	N204447 001	Sep 30, 2013
	EQ 10MG BASE	N204447 002	Sep 30, 2013
	EQ 15MG BASE	N204447 003	Sep 30, 2013
+	EQ 20MG BASE	N204447 004	Sep 30, 2013

WARFARIN SODIUM

TABLET; ORAL

COUMADIN

BRISTOL MYERS SQUIBB	<u>1MG</u>	<u>N009218 022</u>	Mar 01, 1990
	<u>2MG</u>	<u>N009218 013</u>	
	<u>2.5MG</u>	<u>N009218 018</u>	
	<u>3MG</u>	<u>N009218 025</u>	Nov 18, 1996
	<u>4MG</u>	<u>N009218 023</u>	Aug 24, 1993
	<u>5MG</u>	<u>N009218 007</u>	
	<u>6MG</u>	<u>N009218 026</u>	Nov 18, 1996
	<u>7.5MG</u>	<u>N009218 016</u>	
+	<u>10MG</u>	<u>N009218 005</u>	

JANTOVEN

USL PHARMA	<u>1MG</u>	<u>A040416 001</u>	Oct 02, 2003
	<u>2MG</u>	<u>A040416 002</u>	Oct 02, 2003
	<u>2.5MG</u>	<u>A040416 003</u>	Oct 02, 2003
	<u>3MG</u>	<u>A040416 004</u>	Oct 02, 2003
	<u>4MG</u>	<u>A040416 005</u>	Oct 02, 2003
	<u>5MG</u>	<u>A040416 006</u>	Oct 02, 2003
	<u>6MG</u>	<u>A040416 007</u>	Oct 02, 2003
	<u>7.5MG</u>	<u>A040416 008</u>	Oct 02, 2003
	<u>10MG</u>	<u>A040416 009</u>	Oct 02, 2003

WARFARIN SODIUM

AMNEAL PHARMS	<u>1MG</u>	<u>A202202 001</u>	Mar 04, 2013
	<u>2MG</u>	<u>A202202 002</u>	Mar 04, 2013
	<u>2.5MG</u>	<u>A202202 003</u>	Mar 04, 2013
	<u>3MG</u>	<u>A202202 004</u>	Mar 04, 2013
	<u>4MG</u>	<u>A202202 005</u>	Mar 04, 2013
	<u>5MG</u>	<u>A202202 006</u>	Mar 04, 2013
	<u>6MG</u>	<u>A202202 007</u>	Mar 04, 2013
	<u>7.5MG</u>	<u>A202202 008</u>	Mar 04, 2013
	<u>10MG</u>	<u>A202202 009</u>	Mar 04, 2013
BARR	<u>1MG</u>	<u>A040145 001</u>	Mar 26, 1997
	<u>2MG</u>	<u>A040145 002</u>	Mar 26, 1997
	<u>2.5MG</u>	<u>A040145 003</u>	Mar 26, 1997
	<u>3MG</u>	<u>A040145 008</u>	Nov 05, 1998
	<u>4MG</u>	<u>A040145 004</u>	Mar 26, 1997
	<u>5MG</u>	<u>A040145 005</u>	Mar 26, 1997
	<u>6MG</u>	<u>A040145 009</u>	Nov 05, 1998
	<u>7.5MG</u>	<u>A040145 006</u>	Mar 26, 1997
	<u>10MG</u>	<u>A040145 007</u>	Mar 26, 1997
INVAGEN PHARMS	<u>1MG</u>	<u>A090935 001</u>	May 25, 2011
	<u>2MG</u>	<u>A090935 002</u>	May 25, 2011
	<u>2.5MG</u>	<u>A090935 003</u>	May 25, 2011
	<u>3MG</u>	<u>A090935 004</u>	May 25, 2011
	<u>4MG</u>	<u>A090935 005</u>	May 25, 2011
	<u>5MG</u>	<u>A090935 006</u>	May 25, 2011
	<u>6MG</u>	<u>A090935 007</u>	May 25, 2011
	<u>7.5MG</u>	<u>A090935 008</u>	May 25, 2011
	<u>10MG</u>	<u>A090935 009</u>	May 25, 2011
IPCA LABS LTD	<u>1MG</u>	<u>A200104 001</u>	Jun 27, 2013
	<u>2MG</u>	<u>A200104 002</u>	Jun 27, 2013
	<u>2.5MG</u>	<u>A200104 003</u>	Jun 27, 2013
	<u>3MG</u>	<u>A200104 004</u>	Jun 27, 2013
	<u>4MG</u>	<u>A200104 005</u>	Jun 27, 2013
	<u>5MG</u>	<u>A200104 006</u>	Jun 27, 2013
	<u>6MG</u>	<u>A200104 007</u>	Jun 27, 2013
	<u>7.5MG</u>	<u>A200104 008</u>	Jun 27, 2013
	<u>10MG</u>	<u>A200104 009</u>	Jun 27, 2013
MYLAN	<u>1MG</u>	<u>A040415 001</u>	Sep 27, 2004
	<u>2MG</u>	<u>A040415 002</u>	Sep 27, 2004
	<u>2.5MG</u>	<u>A040415 003</u>	Sep 29, 2004
	<u>3MG</u>	<u>A040415 004</u>	Sep 27, 2004
	<u>4MG</u>	<u>A040415 005</u>	Sep 27, 2004
	<u>5MG</u>	<u>A040415 006</u>	Sep 27, 2004

PRESCRIPTION DRUG PRODUCT LIST

WARFARIN SODIUM

TABLET; ORAL

WARFARIN SODIUM

<u>AB</u>		<u>6MG</u>	<u>A040415</u>	<u>007</u>	Sep 27, 2004
<u>AB</u>		<u>7.5MG</u>	<u>A040415</u>	<u>008</u>	Sep 27, 2004
<u>AB</u>		<u>10MG</u>	<u>A040415</u>	<u>009</u>	Sep 27, 2004
<u>AB</u>	PLIVA	<u>1MG</u>	<u>A040616</u>	<u>009</u>	Jul 05, 2006
<u>AB</u>		<u>2MG</u>	<u>A040616</u>	<u>001</u>	Jul 05, 2006
<u>AB</u>		<u>2.5MG</u>	<u>A040616</u>	<u>002</u>	Jul 05, 2006
<u>AB</u>		<u>3MG</u>	<u>A040616</u>	<u>003</u>	Jul 05, 2006
<u>AB</u>		<u>4MG</u>	<u>A040616</u>	<u>004</u>	Jul 05, 2006
<u>AB</u>		<u>5MG</u>	<u>A040616</u>	<u>005</u>	Jul 05, 2006
<u>AB</u>		<u>6MG</u>	<u>A040616</u>	<u>006</u>	Jul 05, 2006
<u>AB</u>		<u>7.5MG</u>	<u>A040616</u>	<u>007</u>	Jul 05, 2006
<u>AB</u>		<u>10MG</u>	<u>A040616</u>	<u>008</u>	Jul 05, 2006
<u>AB</u>	TARO	<u>1MG</u>	<u>A040301</u>	<u>002</u>	Jul 15, 1999
<u>AB</u>		<u>2MG</u>	<u>A040301</u>	<u>003</u>	Jul 15, 1999
<u>AB</u>		<u>2.5MG</u>	<u>A040301</u>	<u>004</u>	Jul 15, 1999
<u>AB</u>		<u>3MG</u>	<u>A040301</u>	<u>005</u>	Jul 15, 1999
<u>AB</u>		<u>4MG</u>	<u>A040301</u>	<u>006</u>	Jul 15, 1999
<u>AB</u>		<u>5MG</u>	<u>A040301</u>	<u>007</u>	Jul 15, 1999
<u>AB</u>		<u>6MG</u>	<u>A040301</u>	<u>008</u>	Jul 15, 1999
<u>AB</u>		<u>7.5MG</u>	<u>A040301</u>	<u>009</u>	Jul 15, 1999
<u>AB</u>		<u>10MG</u>	<u>A040301</u>	<u>001</u>	Jul 15, 1999
<u>AB</u>	ZYDUS PHARMS USA	<u>1MG</u>	<u>A040663</u>	<u>001</u>	May 30, 2006
<u>AB</u>		<u>2MG</u>	<u>A040663</u>	<u>002</u>	May 30, 2006
<u>AB</u>		<u>2.5MG</u>	<u>A040663</u>	<u>003</u>	May 30, 2006
<u>AB</u>		<u>3MG</u>	<u>A040663</u>	<u>004</u>	May 30, 2006
<u>AB</u>		<u>4MG</u>	<u>A040663</u>	<u>005</u>	May 30, 2006
<u>AB</u>		<u>5MG</u>	<u>A040663</u>	<u>006</u>	May 30, 2006
<u>AB</u>		<u>6MG</u>	<u>A040663</u>	<u>007</u>	May 30, 2006
<u>AB</u>		<u>7.5MG</u>	<u>A040663</u>	<u>008</u>	May 30, 2006
<u>AB</u>		<u>10MG</u>	<u>A040663</u>	<u>009</u>	May 30, 2006

XENON XE-133

GAS; INHALATION

XENON XE 133

	LANTHEUS MEDCL	10mCi/VIAL	N017284	001	
		20mCi/VIAL	N017284	002	
	MALLINKRODT NUCLEAR	10mCi/VIAL	N018327	001	Mar 09, 1982
		20mCi/VIAL	N018327	002	Mar 09, 1982

ZAFIRLUKAST

TABLET; ORAL

ACCOLATE

<u>AB</u>	PAR PHARM INC	<u>10MG</u>	<u>N020547</u>	<u>003</u>	Sep 17, 1999
<u>AB</u>	+	<u>20MG</u>	<u>N020547</u>	<u>001</u>	Sep 26, 1996
	<u>ZAFIRLUKAST</u>				
<u>AB</u>	DR REDDYS LABS LTD	<u>10MG</u>	<u>A090372</u>	<u>001</u>	Nov 18, 2010
<u>AB</u>		<u>20MG</u>	<u>A090372</u>	<u>002</u>	Nov 18, 2010

ZALEPLON

CAPSULE; ORAL

SONATA

<u>AB</u>	PFIZER	<u>5MG</u>	<u>N020859</u>	<u>001</u>	Aug 13, 1999
<u>AB</u>	+	<u>10MG</u>	<u>N020859</u>	<u>002</u>	Aug 13, 1999
	<u>ZALEPLON</u>				
<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A078829</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A078829</u>	<u>002</u>	Jun 06, 2008
<u>AB</u>	CIPLA LTD	<u>5MG</u>	<u>A077505</u>	<u>001</u>	Jun 20, 2008
<u>AB</u>		<u>10MG</u>	<u>A077505</u>	<u>002</u>	Jun 20, 2008
<u>AB</u>	HIKMA PHARMS LLC	<u>5MG</u>	<u>A078147</u>	<u>001</u>	Nov 25, 2008
<u>AB</u>		<u>10MG</u>	<u>A078147</u>	<u>002</u>	Nov 25, 2008
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A077238</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A077238</u>	<u>002</u>	Jun 06, 2008
<u>AB</u>	ORCHID HLTHCARE	<u>5MG</u>	<u>A090374</u>	<u>001</u>	Sep 17, 2009
<u>AB</u>		<u>10MG</u>	<u>A090374</u>	<u>002</u>	Sep 17, 2009
<u>AB</u>	TEVA PHARMS	<u>5MG</u>	<u>A077239</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A077239</u>	<u>002</u>	Jun 06, 2008
<u>AB</u>	UNICHEM	<u>5MG</u>	<u>A078989</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A078989</u>	<u>002</u>	Jun 06, 2008
<u>AB</u>	WEST-WARD PHARMS INT	<u>5MG</u>	<u>A077237</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A077237</u>	<u>002</u>	Jun 06, 2008

PRESCRIPTION DRUG PRODUCT LIST

ZANAMIVIR

POWDER; INHALATION

RELENZA

+ GLAXOSMITHKLINE 5MG N021036 001 Jul 26, 1999

ZICONOTIDE ACETATE

INJECTABLE; INTRATHECAL

PRIALT

+ JAZZ PHARMS INTL 100MCG/1ML (100MCG/ML) N021060 002 Dec 28, 2004

+ 500MCG/20ML (25MCG/ML) N021060 001 Dec 28, 2004

+ 500MCG/5ML (100MCG/ML) N021060 004 Dec 28, 2004

ZIDOVDINE

CAPSULE; ORAL

RETROVIR**AB** + VIVV HLTHCARE 100MG **N019655 001** Mar 19, 1987ZIDOVDINE**AB** AUROBINDO PHARMA LTD 100MG **A078128 001** Mar 27, 2006**AB** CIPLA LTD 100MG **A078349 001** May 23, 2007

INJECTABLE; INJECTION

RETROVIR**AP** + VIVV HLTHCARE 10MG/ML **N019951 001** Feb 02, 1990ZIDOVDINE**AP** LUITPOLD 10MG/ML **A091457 001** May 06, 2010

SYRUP; ORAL

RETROVIR**AA** + VIVV HLTHCARE 50MG/5ML **N019910 001** Sep 28, 1989ZIDOVDINE**AA** AUROBINDO 50MG/5ML **A077268 001** Sep 19, 2005**AA** CIPLA LTD 50MG/5ML **A077981 001** Jun 26, 2008

TABLET; ORAL

ZIDOVDINE**AB** AUROBINDO 300MG **A077267 001** Sep 19, 2005**AB** CIPLA 300MG **A090561 001** Oct 27, 2010**AB** + HETERO LABS LTD III 300MG **A090092 001** Apr 25, 2008**AB** MYLAN PHARMS INC 300MG **A078922 001** Feb 14, 2008**AB** WEST-WARD PHARMS INT 300MG **A076844 001** Sep 19, 2005ZILEUTON

TABLET; ORAL

ZYFLO

+ CHIESI USA INC 600MG N020471 003 Dec 09, 1996

TABLET, EXTENDED RELEASE; ORAL

ZYFLO CR

+ CHIESI USA INC 600MG N022052 001 May 30, 2007

ZINC ACETATE

CAPSULE; ORAL

GALZIN

TEVA EQ 25MG ZINC N020458 001 Jan 28, 1997

+ EQ 50MG ZINC N020458 002 Jan 28, 1997

ZINC CHLORIDE

INJECTABLE; INJECTION

ZINC CHLORIDE IN PLASTIC CONTAINER

+ HOSPIRA EQ 1MG ZINC/ML N018959 001 Jun 26, 1986

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

GEODON**AB** + PFIZER EQ 20MG BASE **N020825 001** Feb 05, 2001**AB** EQ 40MG BASE **N020825 002** Feb 05, 2001**AB** EQ 60MG BASE **N020825 003** Feb 05, 2001**AB** EQ 80MG BASE **N020825 004** Feb 05, 2001ZIPRASIDONE HYDROCHLORIDE**AB** APOTEX INC EQ 20MG BASE **A077561 001** Mar 02, 2012**AB** EQ 40MG BASE **A077561 002** Mar 02, 2012**AB** EQ 60MG BASE **A077561 003** Mar 02, 2012**AB** EQ 80MG BASE **A077561 004** Mar 02, 2012**AB** AUROBINDO PHARMA LTD EQ 20MG BASE **A204117 001** Dec 27, 2016**AB** EQ 40MG BASE **A204117 002** Dec 27, 2016**AB** EQ 60MG BASE **A204117 003** Dec 27, 2016**AB** EQ 80MG BASE **A204117 004** Dec 27, 2016**AB** DR REDDYS LABS INC EQ 20MG BASE **A077565 001** Mar 02, 2012**AB** EQ 40MG BASE **A077565 002** Mar 02, 2012

PRESCRIPTION DRUG PRODUCT LIST

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

ZIPRASIDONE HYDROCHLORIDE

<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A077565 003</u>	Mar 02, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A077565 004</u>	Mar 02, 2012
<u>AB</u>	LUPIN PHARMS	<u>EQ 20MG BASE</u>	<u>A077560 001</u>	Mar 02, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077560 002</u>	Mar 02, 2012
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A077560 003</u>	Mar 02, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A077560 004</u>	Mar 02, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 20MG BASE</u>	<u>A202395 001</u>	Oct 10, 2013
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A202395 002</u>	Oct 10, 2013
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A202395 003</u>	Oct 10, 2013
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A202395 004</u>	Oct 10, 2013
<u>AB</u>	SANDOZ INC	<u>EQ 20MG BASE</u>	<u>A077562 001</u>	Jun 01, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077562 002</u>	Jun 01, 2012
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A077562 003</u>	Jun 01, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A077562 004</u>	Jun 01, 2012
<u>AB</u>	WOCKHARDT LTD	<u>EQ 20MG BASE</u>	<u>A090348 001</u>	Sep 05, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A090348 002</u>	Sep 05, 2012
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A090348 003</u>	Sep 05, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A090348 004</u>	Sep 05, 2012

ZIPRASIDONE MESYLATE

INJECTABLE; INTRAMUSCULAR

GEODON

+ PFIZER

EQ 20MG BASE/ML

N020919 001 Jun 21, 2002

ZOLEDRONIC ACID

INJECTABLE; IV (INFUSION)

RECLAST

<u>AP</u>	+ NOVARTIS	<u>EQ 5MG BASE/100ML</u>	<u>N021817 001</u>	Apr 16, 2007
	<u>ZOLEDRONIC ACID</u>			
<u>AP</u>	ACCORD HLTHCARE	<u>EQ 4MG BASE/5ML</u>	<u>A205279 001</u>	Nov 28, 2016
<u>AP</u>	ACS DOBFAR INFO SA	<u>EQ 4MG BASE/100ML</u>	<u>N203231 001</u>	Aug 02, 2013
<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A202828 001</u>	Sep 23, 2013
<u>AP</u>	ACTAVIS INC	<u>EQ 4MG BASE/5ML</u>	<u>A202472 001</u>	Mar 04, 2013
<u>AP</u>	AKORN	<u>EQ 5MG BASE/100ML</u>	<u>A200918 001</u>	Aug 21, 2014
<u>AP</u>	AKORN INC	<u>EQ 4MG BASE/5ML</u>	<u>A202548 001</u>	May 22, 2014
<u>AP</u>	APOTEX INC	<u>EQ 5MG BASE/100ML</u>	<u>A204367 001</u>	Dec 24, 2015
<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 4MG BASE/5ML</u>	<u>A207751 001</u>	Sep 26, 2016
<u>AP</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE/5ML</u>	<u>A091186 001</u>	Mar 04, 2013
<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A091363 001</u>	Mar 29, 2013
<u>AP</u>	EMCURE PHARMS LTD	<u>EQ 4MG BASE/5ML</u>	<u>A201783 001</u>	Mar 12, 2013
<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A201801 001</u>	Mar 29, 2013
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 4MG BASE/5ML</u>	<u>A091516 001</u>	Apr 23, 2015
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 4MG BASE/5ML</u>	<u>A202930 001</u>	Aug 05, 2013
<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A204217 001</u>	Aug 18, 2016
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 4MG BASE/5ML</u>	<u>A202182 001</u>	Jun 03, 2013
<u>AP</u>	HOSPIRA INC	<u>EQ 4MG BASE/5ML</u>	<u>A090621 001</u>	Mar 19, 2015
<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A202837 001</u>	Apr 05, 2013
<u>AP</u>	MYLAN LABS LTD	<u>EQ 4MG BASE/5ML</u>	<u>A202650 001</u>	Mar 04, 2013
<u>AP</u>	PHARMACEUTICS	<u>EQ 4MG BASE/5ML</u>	<u>A091170 001</u>	Mar 04, 2013
<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A202163 001</u>	Aug 05, 2013
<u>AP</u>	PHARMS	<u>EQ 4MG BASE/5ML</u>	<u>A202571 001</u>	May 07, 2013
<u>AP</u>	SAGENT PHARMS	<u>EQ 4MG BASE/5ML</u>	<u>A091493 001</u>	Nov 24, 2014
<u>AP</u>	+ SUN PHARMA GLOBAL	<u>EQ 4MG BASE/VIAL</u>	<u>A090018 001</u>	Mar 04, 2013
<u>AP</u>		<u>EQ 4MG BASE/5ML</u>	<u>A202746 001</u>	Mar 04, 2013
<u>AP</u>	USV NORTH AMERICA	<u>EQ 4MG BASE/5ML</u>	<u>A202923 001</u>	Sep 04, 2014

ZOMETA

<u>AP</u>	+ NOVARTIS	<u>EQ 4MG BASE/5ML</u>	<u>N021223 002</u>	Mar 07, 2003
<u>AP</u>	+ SOLUTION; IV (INFUSION)	<u>EQ 4MG BASE/100ML</u>	<u>N021223 003</u>	Jun 17, 2011
	ZOLEDRONIC ACID			
	HOSPIRA INC	EQ 4MG BASE/100ML (EQ 0.04MG BASE/ML)	N204016 001	Dec 28, 2015

ZOLMITRIPTAN

SPRAY; NASAL

ZOMIG

ASTRAZENECA

2.5MG/SPRAY

N021450 003 Sep 16, 2013

+

5MG/SPRAY

N021450 004 Sep 30, 2003

TABLET; ORAL

ZOLMITRIPTAN

<u>AB</u>	AJANTA PHARMA LTD	<u>2.5MG</u>	<u>A204041 001</u>	May 20, 2016
<u>AB</u>		<u>5MG</u>	<u>A204041 002</u>	May 20, 2016

PRESCRIPTION DRUG PRODUCT LIST

ZOLMITRIPTAN

TABLET;ORAL

ZOLMITRIPTAN

<u>AB</u>	ALEMBIC PHARMS LTD	<u>2.5MG</u>	<u>A204232</u>	<u>001</u>	Sep 30, 2015
<u>AB</u>		<u>5MG</u>	<u>A204232</u>	<u>002</u>	Sep 30, 2015
<u>AB</u>	APOTEX INC	<u>2.5MG</u>	<u>A202078</u>	<u>001</u>	May 14, 2013
<u>AB</u>		<u>5MG</u>	<u>A202078</u>	<u>002</u>	May 14, 2013
<u>AB</u>	AUROBINDO PHARMA LTD	<u>2.5MG</u>	<u>A207021</u>	<u>001</u>	May 11, 2016
<u>AB</u>		<u>5MG</u>	<u>A207021</u>	<u>002</u>	May 11, 2016
<u>AB</u>	GLENMARK GENERICS	<u>2.5MG</u>	<u>A201779</u>	<u>001</u>	May 14, 2013
<u>AB</u>		<u>5MG</u>	<u>A201779</u>	<u>002</u>	May 14, 2013
<u>AB</u>	INVAGEN PHARMS	<u>2.5MG</u>	<u>A204284</u>	<u>001</u>	Apr 09, 2014
<u>AB</u>		<u>5MG</u>	<u>A204284</u>	<u>002</u>	Apr 09, 2014
<u>AB</u>	JUBILANT GENERICS	<u>2.5MG</u>	<u>A202279</u>	<u>001</u>	Nov 20, 2014
<u>AB</u>		<u>5MG</u>	<u>A202279</u>	<u>002</u>	Nov 20, 2014
<u>AB</u>	MACLEODS PHARMS LTD	<u>2.5MG</u>	<u>A203772</u>	<u>001</u>	Sep 30, 2015
<u>AB</u>		<u>5MG</u>	<u>A203772</u>	<u>002</u>	Sep 30, 2015
<u>AB</u>	MYLAN PHARMS INC	<u>2.5MG</u>	<u>A203186</u>	<u>001</u>	May 14, 2013
<u>AB</u>		<u>5MG</u>	<u>A203186</u>	<u>002</u>	May 14, 2013
<u>AB</u>	SUN PHARMA GLOBAL	<u>2.5MG</u>	<u>A203476</u>	<u>001</u>	Nov 13, 2014
<u>AB</u>		<u>5MG</u>	<u>A203476</u>	<u>002</u>	Nov 13, 2014
<u>AB</u>	TEVA PHARMS USA	<u>2.5MG</u>	<u>A090861</u>	<u>001</u>	Mar 04, 2014
<u>AB</u>		<u>5MG</u>	<u>A090861</u>	<u>002</u>	Mar 04, 2014

ZOMIG

<u>AB</u>	IPR	<u>2.5MG</u>	<u>N020768</u>	<u>001</u>	Nov 25, 1997
<u>AB</u>	+	<u>5MG</u>	<u>N020768</u>	<u>002</u>	Nov 25, 1997

TABLET, ORALLY DISINTEGRATING;ORAL

ZOLMITRIPTAN

<u>AB</u>	ALEMBIC PHARMS LTD	<u>2.5MG</u>	<u>A205074</u>	<u>001</u>	Dec 01, 2016
<u>AB</u>		<u>5MG</u>	<u>A205074</u>	<u>002</u>	Dec 01, 2016
<u>AB</u>	APOTEX INC	<u>2.5MG</u>	<u>A202476</u>	<u>001</u>	May 14, 2013
<u>AB</u>		<u>5MG</u>	<u>A202476</u>	<u>002</u>	May 14, 2013
<u>AB</u>	GLENMARK GENERICS	<u>2.5MG</u>	<u>A202560</u>	<u>001</u>	May 14, 2013
<u>AB</u>		<u>5MG</u>	<u>A202560</u>	<u>002</u>	May 14, 2013
<u>AB</u>	JUBILANT GENERICS	<u>2.5MG</u>	<u>A202956</u>	<u>001</u>	Sep 17, 2015
<u>AB</u>		<u>5MG</u>	<u>A202956</u>	<u>002</u>	Sep 17, 2015
<u>AB</u>	MACLEODS PHARMS LTD	<u>2.5MG</u>	<u>A204336</u>	<u>001</u>	Oct 22, 2015
<u>AB</u>		<u>5MG</u>	<u>A204336</u>	<u>002</u>	Oct 22, 2015
<u>AB</u>	ZYDUS PHARMS USA INC	<u>2.5MG</u>	<u>A202890</u>	<u>001</u>	May 15, 2013
<u>AB</u>		<u>5MG</u>	<u>A202890</u>	<u>002</u>	May 15, 2013

ZOMIG-ZMT

<u>AB</u>	ASTRAZENECA	<u>2.5MG</u>	<u>N021231</u>	<u>001</u>	Feb 13, 2001
<u>AB</u>	+	<u>5MG</u>	<u>N021231</u>	<u>002</u>	Sep 17, 2001

ZOLPIDEM TARTRATE

SPRAY, METERED;ORAL

ZOLPIMIST

+ AMHERST PHARMS LLC

5MG/SPRAY

N022196 001 Dec 19, 2008

TABLET;ORAL

AMBIEN

<u>AB</u>	SANOFI AVENTIS US	<u>5MG</u>	<u>N019908</u>	<u>001</u>	Dec 16, 1992
<u>AB</u>	+	<u>10MG</u>	<u>N019908</u>	<u>002</u>	Dec 16, 1992

ZOLPIDEM TARTRATE

<u>AB</u>	APOTEX INC	<u>5MG</u>	<u>A077884</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A077884</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A078413</u>	<u>001</u>	May 04, 2007
<u>AB</u>		<u>10MG</u>	<u>A078413</u>	<u>002</u>	May 04, 2007
<u>AB</u>	CIPLA LTD	<u>5MG</u>	<u>A077388</u>	<u>001</u>	Jul 30, 2012
<u>AB</u>		<u>10MG</u>	<u>A077388</u>	<u>002</u>	Jul 30, 2012
<u>AB</u>	INVAGEN PHARMS	<u>5MG</u>	<u>A078184</u>	<u>001</u>	Sep 07, 2007
<u>AB</u>		<u>10MG</u>	<u>A078184</u>	<u>002</u>	Sep 07, 2007
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A076578</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A076578</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>	ROXANE	<u>5MG</u>	<u>A077214</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A077214</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>	SANDOZ INC	<u>5MG</u>	<u>A077322</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A077322</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>	SUN PHARM INDS INC	<u>5MG</u>	<u>A077359</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A077359</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>	SUN PHARM INDS LTD	<u>5MG</u>	<u>A078055</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A078055</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>	TEVA	<u>5MG</u>	<u>A076410</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A076410</u>	<u>002</u>	Apr 23, 2007

PRESCRIPTION DRUG PRODUCT LIST

ZOLPIDEM TARTRATE

TABLET;ORAL

ZOLPIDEM TARTRATE

<u>AB</u>	TORRENT PHARMS	<u>5MG</u>	<u>A077903 001</u>	Aug 17, 2007
<u>AB</u>		<u>10MG</u>	<u>A077903 002</u>	Aug 17, 2007
<u>AB</u>	VINTAGE	<u>5MG</u>	<u>A078616 001</u>	Nov 21, 2008
<u>AB</u>		<u>10MG</u>	<u>A078616 002</u>	Nov 21, 2008
<u>AB</u>	WOCKHARDT	<u>5MG</u>	<u>A078426 001</u>	May 15, 2007
<u>AB</u>		<u>10MG</u>	<u>A078426 002</u>	May 15, 2007
<u>AB</u>	YUNG SHIN PHARM	<u>5MG</u>	<u>A077990 001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A077990 002</u>	Apr 23, 2007

TABLET;SUBLINGUAL

EDLUAR

<u>AB</u>	MEDA PHARMS	<u>5MG</u>	<u>N021997 001</u>	Mar 13, 2009
<u>AB</u>	+	<u>10MG</u>	<u>N021997 002</u>	Mar 13, 2009
	<u>INTERMEZZO</u>			
<u>AB</u>	PURDUE PHARMA	<u>1.75MG</u>	<u>N022328 001</u>	Nov 23, 2011
<u>AB</u>	+	<u>3.5MG</u>	<u>N022328 002</u>	Nov 23, 2011

ZOLPIDEM TARTRATE

<u>AB</u>	DR REDDYS LABS INC	<u>1.75MG</u>	<u>A204503 001</u>	Nov 18, 2016
<u>AB</u>		<u>3.5MG</u>	<u>A204503 002</u>	Nov 18, 2016
<u>AB</u>	MYLAN PHARMS INC	<u>5MG</u>	<u>A202657 001</u>	Aug 08, 2016
<u>AB</u>		<u>10MG</u>	<u>A202657 002</u>	Aug 08, 2016
<u>AB</u>	NOVEL LABS INC	<u>1.75MG</u>	<u>A204299 001</u>	Jun 03, 2015
<u>AB</u>		<u>3.5MG</u>	<u>A204299 002</u>	Jun 03, 2015
<u>AB</u>	PAR FORM	<u>5MG</u>	<u>A201509 001</u>	Aug 01, 2016
<u>AB</u>		<u>10MG</u>	<u>A201509 002</u>	Aug 01, 2016

TABLET, EXTENDED RELEASE;ORAL

AMBIEN CR

<u>AB</u>	SANOFI AVENTIS US	<u>6.25MG</u>	<u>N021774 002</u>	Sep 02, 2005
<u>AB</u>	+	<u>12.5MG</u>	<u>N021774 001</u>	Sep 02, 2005
	<u>ZOLPIDEM TARTRATE</u>			
<u>AB</u>	ACTAVIS ELIZABETH	<u>6.25MG</u>	<u>A078179 002</u>	Oct 13, 2010
<u>AB</u>		<u>12.5MG</u>	<u>A078179 001</u>	Jun 06, 2011
<u>AB</u>	ACTAVIS LABS FL INC	<u>6.25MG</u>	<u>A090153 001</u>	Mar 25, 2013
<u>AB</u>		<u>12.5MG</u>	<u>A090153 002</u>	Mar 25, 2013
<u>AB</u>	ANCHEN PHARMS	<u>6.25MG</u>	<u>A078148 002</u>	Apr 14, 2011
<u>AB</u>		<u>12.5MG</u>	<u>A078148 001</u>	Dec 03, 2010
<u>AB</u>	APOTEX INC	<u>6.25MG</u>	<u>A200266 001</u>	Sep 10, 2013
<u>AB</u>		<u>12.5MG</u>	<u>A200266 002</u>	Sep 10, 2013
<u>AB</u>	LUPIN LTD	<u>6.25MG</u>	<u>A078970 001</u>	Sep 11, 2013
<u>AB</u>		<u>12.5MG</u>	<u>A078970 002</u>	Sep 11, 2013
<u>AB</u>	SANDOZ	<u>6.25MG</u>	<u>A090107 001</u>	Jul 01, 2011
<u>AB</u>		<u>12.5MG</u>	<u>A090107 002</u>	Jul 01, 2011
<u>AB</u>	SYNTHON PHARMS	<u>6.25MG</u>	<u>A078483 001</u>	Apr 12, 2011
<u>AB</u>		<u>12.5MG</u>	<u>A078483 002</u>	Jun 06, 2011

ZONISAMIDE

CAPSULE;ORAL

ZONEGRAN

<u>AB</u>	SUNOVION PHARMS INC	<u>25MG</u>	<u>N020789 003</u>	Aug 22, 2003
<u>AB</u>		<u>50MG</u>	<u>N020789 002</u>	Aug 22, 2003
<u>AB</u>	+	<u>100MG</u>	<u>N020789 001</u>	Mar 27, 2000

ZONISAMIDE

<u>AB</u>	APOTEX INC	<u>25MG</u>	<u>A077642 001</u>	Dec 22, 2005
<u>AB</u>		<u>50MG</u>	<u>A077642 002</u>	Dec 22, 2005
<u>AB</u>		<u>100MG</u>	<u>A077642 003</u>	Dec 22, 2005
<u>AB</u>	BIONPHARMA INC	<u>25MG</u>	<u>A077813 001</u>	Aug 16, 2006
<u>AB</u>		<u>50MG</u>	<u>A077813 002</u>	Aug 16, 2006
<u>AB</u>		<u>100MG</u>	<u>A077813 003</u>	Aug 16, 2006
<u>AB</u>	GLENMARK GENERICS	<u>25MG</u>	<u>A077651 001</u>	Jan 30, 2006
<u>AB</u>		<u>50MG</u>	<u>A077651 002</u>	Jan 30, 2006
<u>AB</u>		<u>100MG</u>	<u>A077651 003</u>	Jan 30, 2006
<u>AB</u>	INVAGEN PHARMS	<u>25MG</u>	<u>A077869 001</u>	May 31, 2006
<u>AB</u>		<u>50MG</u>	<u>A077869 002</u>	May 31, 2006
<u>AB</u>		<u>100MG</u>	<u>A077869 003</u>	May 31, 2006
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A077637 001</u>	Dec 22, 2005
<u>AB</u>		<u>50MG</u>	<u>A077637 002</u>	Dec 22, 2005
<u>AB</u>		<u>100MG</u>	<u>A077637 003</u>	Dec 22, 2005
<u>AB</u>	MYLAN PHARMS INC	<u>25MG</u>	<u>A077647 001</u>	Dec 22, 2005
<u>AB</u>		<u>50MG</u>	<u>A077647 002</u>	Dec 22, 2005
<u>AB</u>		<u>100MG</u>	<u>A077647 003</u>	Dec 22, 2005
<u>AB</u>	SUN PHARM INDS (IN)	<u>25MG</u>	<u>A077634 001</u>	Mar 17, 2006

PRESCRIPTION DRUG PRODUCT LISTZONISAMIDE

CAPSULE; ORAL

ZONISAMIDE

<u>AB</u>		<u>50MG</u>	<u>A077634 002</u>	Mar 17, 2006
<u>AB</u>		<u>100MG</u>	<u>A077634 003</u>	Mar 17, 2006
<u>AB</u>	WOCKHARDT	<u>25MG</u>	<u>A077636 003</u>	Jul 27, 2006
<u>AB</u>		<u>50MG</u>	<u>A077636 002</u>	Jul 27, 2006
<u>AB</u>		<u>100MG</u>	<u>A077636 001</u>	Dec 22, 2005
<u>AB</u>	ZYDUS PHARMS USA	<u>25MG</u>	<u>A077625 001</u>	Oct 16, 2006
<u>AB</u>		<u>50MG</u>	<u>A077625 002</u>	Oct 16, 2006
<u>AB</u>		<u>100MG</u>	<u>A077625 003</u>	Oct 16, 2006

OTC DRUG PRODUCT LIST

ACETAMINOPHEN

SUPPOSITORY; RECTAL

ACEPHEN

G AND W LABS	120MG	N018060	001	
	325MG	A072344	001	Mar 27, 1992
	325MG	N018060	003	Dec 18, 1986
	650MG	A072237	001	Mar 27, 1992
	650MG	N018060	002	

ACETAMINOPHEN

PERRIGO NEW YORK	120MG	A070607	001	Apr 06, 1987
	650MG	A070608	001	Dec 01, 1986
TARO PHARMS NORTH	120MG	N018337	003	Sep 12, 1983
	325MG	N018337	002	
+	650MG	N018337	001	

INFANTS' FEVERALL

TARO PHARMS NORTH	80MG	N018337	004	Aug 26, 1992
-------------------	------	---------	-----	--------------

NEOPAP

POLYMEDICA	120MG	N016401	001	
------------	-------	---------	-----	--

TABLET, EXTENDED RELEASE; ORAL

ACETAMINOPHEN

AUROBINDO PHARMA LTD	650MG	A207229	001	Nov 09, 2016
OHM LABS	650MG	A076200	001	Mar 19, 2002
PERRIGO	650MG	A075077	001	Feb 25, 2000
SUN PHARM INDS LTD	650MG	A078569	001	Dec 14, 2011

TYLENOL

+ J AND J CONSUMER INC	650MG	N019872	001	Jun 08, 1994
+	650MG	N019872	002	Jan 11, 2001

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET; ORAL

ACETAMINOPHEN, ASPIRIN AND CAFFEINE

PERRIGO	250MG; 250MG; 65MG	A075794	001	Nov 26, 2001
---------	--------------------	---------	-----	--------------

EXCEDRIN (MIGRAINE)

+ GLAXOSMITHKLINE CONS	250MG; 250MG; 65MG	N020802	001	Jan 14, 1998
------------------------	--------------------	---------	-----	--------------

ADAPALENE

GEL; TOPICAL

DIFFERIN

+ GALDERMA LABS LP	0.1%	N020380	002	Jul 08, 2016
--------------------	------	---------	-----	--------------

ALCOHOL; CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL

AVAGARD

+ 3M	61%; 1%	N021074	001	Jun 07, 2001
------	---------	---------	-----	--------------

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE; ORAL

FOAMCOAT

GUARDIAN DRUG	80MG; 20MG	A071793	001	Sep 04, 1987
---------------	------------	---------	-----	--------------

GAVISCON

SANOFI AVENTIS US	80MG; 20MG	N018685	001	Dec 09, 1983
+	160MG; 40MG	N018685	002	Dec 09, 1983

ASPIRIN

CAPSULE; ORAL

ASPIRIN

+ PLX PHARMA	325MG	N203697	001	Jan 14, 2013
--------------	-------	---------	-----	--------------

AVOBENZONE; ECAMSULE; OCTOCRYLENE

CREAM; TOPICAL

ANTHELIOS SX

+ LOREAL USA	2%; 2%; 10%	N021502	001	Jul 21, 2006
--------------	-------------	---------	-----	--------------

CAPITAL SOLEIL 15

+ LOREAL USA	2%; 3%; 10%	N021501	001	Oct 02, 2006
--------------	-------------	---------	-----	--------------

AVOBENZONE; ECAMSULE; OCTOCRYLENE; TITANIUM DIOXIDE

CREAM; TOPICAL

ANTHELIOS 20

+ LOREAL USA	2%; 2%; 10%; 2%	N021471	001	Oct 05, 2006
--------------	-----------------	---------	-----	--------------

ANTHELIOS 40

+ LOREAL USA	2%; 3%; 10%; 5%	N022009	001	Mar 31, 2008
--------------	-----------------	---------	-----	--------------

+	2%; 3%; 10%; 5%	N022009	002	Oct 29, 2009
---	-----------------	---------	-----	--------------

OTC DRUG PRODUCT LIST

AVOBENZONE; OCTINOXATE; OXYBENZONE

LOTION; TOPICAL

SHADE UVAGUARD

+ BAYER HEALTHCARE LLC 3%; 7.5%; 3%

N020045 001 Dec 07, 1992

BENTOQUATAM

LOTION; TOPICAL

IVY BLOCK

+ STAND HOMEOPATH 5%

N020532 001 Aug 26, 1996

BUDESONIDE

SPRAY, METERED; NASAL

BUDESONIDE

APOTEX INC 0.032MG/SPRAY

A078949 002 Nov 20, 2015

RHINOCORT ALLERGY

+ ASTRAZENECA PHARMS 0.032MG/SPRAY

N020746 003 Mar 23, 2015

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL

LOTRIMIN ULTRA

+ BAYER HEALTHCARE LLC 1%

N021307 001 Dec 07, 2001

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

FEMSTAT 3

+ BAYER 2%

N020421 001 Dec 21, 1995

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE; ORAL

FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE

PERRIGO R AND D 800MG; 10MG; 165MG

A077355 001 Feb 06, 2008

800MG; 10MG; 165MG

A204782 001 Aug 29, 2016

PEPCID COMPLETE

+ J AND J CONSUMER INC 800MG; 10MG; 165MG

N020958 001 Oct 16, 2000

CETIRIZINE HYDROCHLORIDE

CAPSULE; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

APOTEX INC 10MG

A207235 001 Aug 12, 2016

BIONPHARMA INC 5MG

N022429 001 Jul 23, 2009

+ 10MG

N022429 004 Jul 23, 2009

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

BIONPHARMA INC 5MG

N022429 003 Jul 23, 2009

+ 10MG

N022429 002 Jul 23, 2009

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

AMNEAL PHARMS 5MG/5ML

A090765 002 Oct 07, 2009

AUROBINDO PHARMA 5MG/5ML

A090750 002 Feb 02, 2010

BIO PHARM INC 5MG/5ML

A090474 002 Mar 30, 2009

NOSTRUM LABS INC 5MG/5ML

A091327 001 Oct 17, 2011

PERRIGO R AND D 5MG/5ML

A204226 001 Sep 09, 2013

5MG/5ML

A090254 002 Apr 09, 2008

SILARX 5MG/5ML

A091130 001 Apr 22, 2011

TARO 5MG/5ML

A090182 002 Apr 22, 2008

5MG/5ML

A201546 001 May 20, 2011

TRIS PHARMA INC 5MG/5ML

A090572 001 Nov 16, 2012

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

AMNEAL PHARMS 5MG/5ML

A090765 001 Oct 07, 2009

AUROBINDO PHARMA 5MG/5ML

A090750 001 Feb 02, 2010

BIO PHARM INC 5MG/5ML

A090474 001 Mar 30, 2009

NOSTRUM LABS INC 5MG/5ML

A091327 002 Oct 17, 2011

PERRIGO R AND D 5MG/5ML

A090254 001 Apr 09, 2008

SILARX 5MG/5ML

A091130 002 Apr 22, 2011

TARO 5MG/5ML

A090182 001 Apr 22, 2008

5MG/5ML

A201546 002 May 20, 2011

TRIS PHARMA INC 5MG/5ML

A090572 002 Nov 16, 2012

CHILDREN'S ZYRTEC ALLERGY

+ J AND J CONSUMER INC 5MG/5ML

N022155 002 Nov 16, 2007

CHILDREN'S ZYRTEC HIVES RELIEF

+ J AND J CONSUMER INC 5MG/5ML

N022155 001 Nov 16, 2007

TABLET; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

AMNEAL PHARMS NY 5MG

A078780 001 Jan 21, 2010

10MG

A078780 004 Jan 21, 2010

APOTEX INC 5MG

A078317 001 Dec 27, 2007

OTC DRUG PRODUCT LIST

CETIRIZINE HYDROCHLORIDE

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

	10MG	A078317	002	Dec 27, 2007
AUROBINDO PHARMA LTD	5MG	A090760	001	Aug 05, 2015
	10MG	A090760	003	Aug 05, 2015
CADISTA PHARMS	5MG	A078933	001	Jun 15, 2010
	10MG	A078933	002	Jun 15, 2010
CIPLA LTD	5MG	A077318	001	Jul 25, 2013
	10MG	A077318	002	Jul 25, 2013
CONTRACT PHARMACAL	5MG	A076047	001	Dec 27, 2007
	10MG	A076047	002	Dec 27, 2007
DR REDDYS LABS LTD	5MG	A078343	004	Jan 15, 2008
	10MG	A078343	003	Jan 15, 2008
IPCA LABS LTD	5MG	A202277	002	Mar 11, 2014
	10MG	A202277	004	Mar 11, 2014
MYLAN	5MG	A076677	001	Dec 27, 2007
	10MG	A076677	002	Dec 27, 2007
ORCHID HLTHCARE	5MG	A078862	001	Feb 19, 2009
	10MG	A078862	002	Feb 19, 2009
PERRIGO R AND D	5MG	A078336	001	Dec 27, 2007
	10MG	A078336	002	Dec 27, 2007
SANDOZ	5MG	A077946	001	Dec 27, 2007
	10MG	A077946	002	Dec 27, 2007
SUN PHARM INDS INC	5MG	A077499	001	Dec 27, 2007
	10MG	A077499	002	Dec 27, 2007
SUN PHARM INDS LTD	5MG	A077498	001	Dec 27, 2007
	10MG	A077498	002	Dec 27, 2007
TARO	5MG	A078072	001	Jul 22, 2009
	5MG	A078072	003	Jul 22, 2009
TORRENT PHARMS LLC	5MG	A079191	001	Apr 15, 2010
	10MG	A079191	004	Apr 15, 2010
UNICHEM	5MG	A078680	003	Jun 26, 2009
	10MG	A078680	004	Jun 26, 2009
UNIQUE PHARM LABS	5MG	A077829	001	Aug 26, 2009
	10MG	A077829	004	Aug 26, 2009
WOCKHARDT	5MG	A078427	003	Dec 28, 2007
	10MG	A078427	004	Dec 28, 2007

CETIRIZINE HYDROCHLORIDE HIVES

CADISTA PHARMS	5MG	A078933	003	Jun 15, 2010
	10MG	A078933	004	Jun 15, 2010
DR REDDYS LABS LTD	5MG	A078343	001	Jan 15, 2008
	10MG	A078343	002	Jan 15, 2008
IPCA LABS LTD	5MG	A202277	001	Mar 11, 2014
	10MG	A202277	003	Mar 11, 2014
MYLAN	5MG	A076677	004	Dec 27, 2007
	10MG	A076677	003	Dec 27, 2007
ORCHID HLTHCARE	5MG	A078862	003	Feb 19, 2009
	10MG	A078862	004	Feb 19, 2009
PERRIGO R AND D	5MG	A078336	003	Dec 27, 2007
	10MG	A078336	004	Dec 27, 2007
SUN PHARM INDS INC	5MG	A077499	003	Dec 27, 2007
	10MG	A077499	004	Dec 27, 2007
SUN PHARM INDS LTD	5MG	A077498	003	Dec 27, 2007
	10MG	A077498	004	Dec 27, 2007
UNICHEM	5MG	A078680	001	Jun 26, 2009
	10MG	A078680	002	Jun 26, 2009
UNIQUE PHARM LABS	5MG	A077829	003	Aug 26, 2009
	10MG	A077829	002	Aug 26, 2009

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

AMNEAL PHARMS NY	5MG	A078780	003	Jan 21, 2010
	10MG	A078780	002	Jan 21, 2010
AUROBINDO PHARMA LTD	5MG	A090760	002	Aug 05, 2015
	10MG	A090760	004	Aug 05, 2015
TARO	10MG	A078072	002	Jul 22, 2009
	10MG	A078072	004	Jul 22, 2009
TORRENT PHARMS LLC	5MG	A079191	003	Apr 15, 2010
	10MG	A079191	002	Apr 15, 2010

ZYRTEC ALLERGY

J AND J CONSUMER INC	5MG	N019835	003	Nov 16, 2007
+	10MG	N019835	004	Nov 16, 2007

OTC DRUG PRODUCT LIST

CETIRIZINE HYDROCHLORIDE

TABLET;ORAL

ZYRTEC HIVES RELIEF

J AND J CONSUMER INC

5MG

N019835 005 Nov 16, 2007

+

10MG

N019835 006 Nov 16, 2007

TABLET, CHEWABLE;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

JUBILANT GENERICS

5MG

A091116 001 Feb 19, 2015

10MG

A091116 002 Feb 19, 2015

NOVEL LABS INC

5MG

A206793 001 Mar 08, 2016

10MG

A206793 002 Mar 08, 2016

SANDOZ

5MG

A078692 001 Feb 14, 2008

+

10MG

A078692 002 Feb 14, 2008

SUN PHARMA GLOBAL

5MG

A090142 001 Aug 30, 2011

10MG

A090142 002 Aug 30, 2011

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

JUBILANT GENERICS

5MG

A091116 003 Feb 19, 2015

10MG

A091116 004 Feb 19, 2015

SUN PHARMA GLOBAL

5MG

A090142 003 Aug 30, 2011

10MG

A090142 004 Aug 30, 2011

TABLET, ORALLY DISINTEGRATING;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

PAR PHARM INC

10MG

A205490 001 Sep 02, 2015

ZYRTEC ALLERGY

+ J AND J CONSUMER INC

10MG

N022578 001 Sep 03, 2010

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

IVAX SUB TEVA PHARMS

5MG;120MG

A077170 001 Feb 25, 2008

SANDOZ

5MG;120MG

A077991 001 Mar 05, 2008

SUN PHARM INDS LTD

5MG;120MG

A090922 001 Sep 28, 2012

ZYRTEC-D 12 HOUR

+ J AND J CONSUMER INC

5MG;120MG

N021150 002 Nov 09, 2007

CHLORHEXIDINE GLUCONATE

AEROSOL, METERED;TOPICAL

EXIDINE

+ XTTRIUM

4%

N019127 001 Dec 24, 1984

CLOTH;TOPICAL

CHLORHEXIDINE GLUCONATE

+ SAGE PRODS

2%

N021669 001 Apr 25, 2005

SOLUTION;TOPICAL

BRIAN CARE

SOAPCO

4%

A071419 001 Dec 17, 1987

CHG SCRUB

ECOLAB

4%

N019258 002 Jul 22, 1986

CIDA-STAT

ECOLAB

2%

N019258 001 Jul 22, 1986

DYNA-HEX

BAJAJ MEDICAL LLC

0.75%

N020111 001 Sep 11, 1997

EXIDINE

+ XTTRIUM

2%

N019422 001 Dec 17, 1985

4%

N019125 001 Dec 24, 1984

HIBICLENS

+ MOLNLYCKE HLTH

4%

N017768 001

HIBISTAT

+ MOLNLYCKE HLTH

0.5%

N018300 001

SPONGE;TOPICAL

BIOSCRUB

GRIFFEN

4%

N019822 001 Mar 31, 1989

CHLORHEXIDINE GLUCONATE

+ BECTON DICKINSON

4%

A072525 001 Oct 24, 1989

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE;TOPICAL

CHLORAPREP ONE-STEP

+ BECTON DICKINSON CO

2%;70% (3ML)

N020832 001 Jul 14, 2000

+

2%;70% (10.5ML)

N020832 004 Aug 20, 2003

+

2%;70% (26ML)

N020832 006 Nov 21, 2006

CHLORAPREP ONE-STEP FREPP

+ BECTON DICKINSON CO

2%;70% (1.5ML)

N020832 003 Apr 26, 2002

OTC DRUG PRODUCT LIST

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE; TOPICAL

CHLORAPREP WITH TINT

+ BECTON DICKINSON CO	2%;70% (26ML)	N020832 002	May 03, 2005
+	2%;70% (10.5ML)	N020832 005	Apr 03, 2006
+	2%;70% (3ML)	N020832 007	Oct 10, 2006

SWAB; TOPICAL

CHLORAPREP ONE-STEP SEPP

+ BECTON DICKINSON CO	2%;70% (0.67ML)	N021555 001	Oct 07, 2002
CHLORAPREP SINGLE SWABSTICK			
+ BECTON DICKINSON CO	2%;70% (1.75ML)	N021555 002	May 10, 2005
CHLORAPREP TRIPLE SWABSTICK			
+ BECTON DICKINSON CO	2%;70% (5.25ML)	N021555 003	Jun 10, 2009
PREVANTICS MAXI SWABSTICK			
+ PROF DSPLS	3.15%;70% (5.1ML)	N021524 003	Jun 03, 2005
PREVANTICS SWAB			
+ PROF DSPLS	3.15%;70% (1ML)	N021524 001	Jun 03, 2005
PREVANTICS SWABSTICK			
+ PROF DSPLS	3.15%;70% (1.6ML)	N021524 002	Jun 03, 2005

CHLORPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE; ORAL

CHLOR-TRIMETON

+ BAYER HEALTHCARE LLC	12MG	N007638 002	
CHLORPHENIRAMINE MALEATE			
AVANTHI INC	12MG	A040829 001	May 13, 2009

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

TABLET; ORAL

ADVIL ALLERGY AND CONGESTION RELIEF

+ PFIZER	4MG;200MG;10MG	N022113 001	Dec 21, 2011
----------	----------------	-------------	--------------

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S ADVIL ALLERGY SINUS

+ PFIZER	1MG/5ML;100MG/5ML;15MG/5ML	N021587 001	Feb 24, 2004
----------	----------------------------	-------------	--------------

TABLET; ORAL

ADVIL ALLERGY SINUS

+ PFIZER	2MG;200MG;30MG	N021441 001	Dec 19, 2002
----------	----------------	-------------	--------------

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CHLOR-TRIMETON

+ BAYER HEALTHCARE LLC	8MG;120MG	N018397 001	
------------------------	-----------	-------------	--

CIMETIDINE

TABLET; ORAL

CIMETIDINE

APOTEX	100MG	A074948 001	Jun 19, 1998
	200MG	A074948 002	Jul 26, 2002
CONTRACT PHARMACAL	200MG	A074961 001	Jun 19, 1998
	200MG	A074963 001	Jun 19, 1998
IVAX SUB TEVA PHARMS	200MG	A075345 001	Jun 16, 1999
PERRIGO	200MG	A075285 001	Oct 29, 1998
TAGAMET HB			
+ MEDTECH PRODUCTS	200MG	N020238 002	Aug 21, 1996

CLEMASTINE FUMARATE

TABLET; ORAL

CLEMASTINE FUMARATE

PERRIGO	1.34MG	A074512 001	Nov 22, 1995
SANDOZ	1.34MG	A073458 001	Oct 31, 1993
TAVIST-1			
+ NOVARTIS	1.34MG	N020925 001	Aug 21, 1992

CLOTRIMAZOLE

CREAM; VAGINAL

CLOTRIMAZOLE

ACTAVIS MID ATLANTIC	1%	A074165 001	Jul 16, 1993
TARO	1%	A072641 001	Dec 04, 1995
GYNE-LOTRIMIN			
+ BAYER HEALTHCARE LLC	1%	N018052 002	Nov 30, 1990
GYNE-LOTRIMIN 3			
+ BAYER HEALTHCARE LLC	2%	N020574 001	Nov 24, 1998

OTC DRUG PRODUCT LIST

CLOTRIMAZOLE

CREAM; VAGINAL

MYCELEX-7

BAYER HEALTHCARE LLC 1%

N018230 002 Dec 26, 1991

TRIVAGIZOLE 3

TARO 2%

N021143 001 Apr 12, 2000

CREAM, TABLET; TOPICAL, VAGINAL

GYNE-LOTRIMIN 3 COMBINATION PACK

+ BAYER HEALTHCARE LLC 1%, 200MG

N020526 002 Jul 29, 1996

GYNE-LOTRIMIN COMBINATION PACK

+ BAYER HEALTHCARE LLC 1%, 100MG

N020289 002 Apr 26, 1993

MYCELEX-7 COMBINATION PACK

BAYER HEALTHCARE LLC 1%, 100MG

N020389 002 Jun 23, 1994

TABLET; VAGINAL

GYNE-LOTRIMIN

+ BAYER HEALTHCARE LLC 100MG

N017717 002 Nov 30, 1990

GYNE-LOTRIMIN 3

+ BAYER HEALTHCARE LLC 200MG

N020525 001 Jul 29, 1996

MYCELEX-7

BAYER HEALTHCARE LLC 100MG

N018182 002 Dec 26, 1991

CROMOLYN SODIUM

SPRAY, METERED; NASAL

CROMOLYN SODIUM

+ BAUSCH AND LOMB 5.2MG/SPRAY

A075702 001 Jul 03, 2001

PERRIGO 5.2MG/SPRAY

A075427 001 Dec 12, 2001

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE

+ AVANTHI INC 6MG; 120MG

A078648 001 Feb 27, 2013

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE

ACTAVIS LABS FL INC 30MG; 60MG

A091070 001 Aug 31, 2015

60MG; 1.2GM

A091070 002 Aug 31, 2015

MUCINEX DM

RECKITT BENCKISER 30MG; 60MG

N021620 002 Apr 29, 2004

+ 60MG; 1.2GM

N021620 001 Apr 29, 2004

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

DELSYM

+ RECKITT BENCKISER EQ 30MG HBR/5ML

N018658 001 Oct 08, 1982

DEXTROMETHORPHAN POLISTIREX

TRIS PHARMA INC EQ 30MG HBR/5ML

A091135 001 May 25, 2012

DIPHENHYDRAMINE CITRATE; IBUPROFEN

TABLET; ORAL

ADVIL PM

+ PFIZER 38MG; 200MG

N021394 001 Dec 21, 2005

IBUPROFEN AND DIPHENHYDRAMINE CITRATE

DR REDDYS LABS LTD 38MG; 200MG

A090619 001 Jul 08, 2009

PERRIGO R AND D 38MG; 200MG

A079113 001 Dec 22, 2008

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE; ORAL

ADVIL PM

+ PFIZER 25MG; EQ 200MG FREE ACID AND POTASSIUM SALT

N021393 001 Dec 21, 2005

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

BIONPHARMA INC 25MG; EQ 200MG FREE ACID AND POTASSIUM SALT

A090397 001 Nov 22, 2010

STRIDES PHARMA 25MG; EQ 200MG FREE ACID AND POTASSIUM SALT

A200888 001 Mar 05, 2012

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET; ORAL

ALEVE PM

+ BAYER HLTHCARE 25MG; 220MG

N205352 001 Jan 17, 2014

OTC DRUG PRODUCT LIST

DOCOSANOL

CREAM; TOPICAL

ABREVA

+ GLAXOSMITHKLINE 10% N020941 001 Jul 25, 2000

DOXYLAMINE SUCCINATE

TABLET; ORAL

DOXYLAMINE SUCCINATE

LNK 25MG A040564 001 Aug 27, 2004

PERRIGO 25MG A040167 001 Sep 18, 1996

UNISOM

+ CHATTEM 25MG N018066 001

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE; ORAL

NEXIUM 24HR

+ ASTRAZENECA LP EQ 20MG BASE N204655 001 Mar 28, 2014

TABLET, DELAYED RELEASE; ORAL

NEXIUM 24HR

+ ASTRAZENECA LP EQ 20MG BASE N207920 01 Nov 23, 2015

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

AUROBINDO PHARMA LTD 10MG A206531 001 Apr 26, 2016

20MG A206531 002 Apr 26, 2016

DR REDDYS LABS LTD 10MG A075758 001 Aug 17, 2001

20MG A077367 001 Sep 25, 2006

IVAX SUB TEVA PHARMS 10MG A075512 001 Jul 26, 2001

MYLAN 10MG A075674 001 Dec 21, 2001

PERRIGO 10MG A075400 001 Mar 18, 2005

20MG A077351 001 Sep 25, 2006

SUN PHARM INDS LTD 10MG A090283 001 Nov 17, 2009

20MG A090283 002 Nov 17, 2009

TEVA 10MG A075312 001 May 31, 2001

WOCKHARDT 10MG A077146 001 Mar 07, 2005

20MG A090837 001 Aug 04, 2010

PEPCID AC

J AND J CONSUMER INC 10MG N020325 001 Apr 28, 1995

+ 20MG N020325 002 Sep 23, 2003

PEPCID AC

J AND J CONSUMER INC 10MG N020902 001 Aug 05, 1999

TABLET, CHEWABLE; ORAL

FAMOTIDINE

PERRIGO 10MG A075715 001 Aug 22, 2003

PEPCID AC

+ J AND J CONSUMER INC 20MG N020801 002 Dec 17, 2007

FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S ALLEGRA ALLERGY

+ SANOFI AVENTIS US 30MG/5ML N201373 001 Jan 24, 2011

CHILDREN'S ALLEGRA HIVES

+ SANOFI AVENTIS US 30MG/5ML N201373 002 Jan 24, 2011

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

ACTAVIS MID ATLANTIC 30MG/5ML A203330 001 Nov 18, 2014

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

ACTAVIS MID ATLANTIC 30MG/5ML A203330 002 Nov 18, 2014

TABLET; ORAL

ALLEGRA ALLERGY

SANOFI AVENTIS US 60MG N020872 007 Jan 24, 2011

+ 180MG N020872 010 Jan 24, 2011

ALLEGRA HIVES

SANOFI AVENTIS US 60MG N020872 008 Jan 24, 2011

+ 180MG N020872 009 Jan 24, 2011

CHILDREN'S ALLEGRA ALLERGY

SANOFI AVENTIS US 30MG N020872 005 Jan 24, 2011

CHILDREN'S ALLEGRA HIVES

SANOFI AVENTIS US 30MG N020872 006 Jan 24, 2011

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

AUROLIFE PHARMA LLC 30MG A202039 001 Nov 19, 2014

DR REDDYS LABS LTD 30MG A076502 004 Apr 12, 2011

HETERO LABS LTD V 30MG A204097 001 Aug 19, 2016

MYLAN 30MG A077081 004 Jul 21, 2011

OTC DRUG PRODUCT LIST

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

SUN PHARM INDS	30MG	A091567	002	Feb 06, 2012
TEVA	30MG	A076447	004	Apr 13, 2011
WOCKHARDT LTD	30MG	A079112	002	Feb 08, 2012

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD	30MG	A076502	005	Apr 12, 2011
MYLAN	30MG	A077081	005	Jul 21, 2011
SUN PHARM INDS	30MG	A091567	001	Feb 06, 2012
TEVA	30MG	A076447	005	Apr 13, 2011
WOCKHARDT LTD	30MG	A079112	001	Feb 08, 2012

FEXOFENADINE HYDROCHLORIDE ALLERGY

AUROLIFE PHARMA LLC	60MG	A202039	002	Nov 19, 2014
	180MG	A202039	003	Nov 19, 2014
DR REDDYS LABS LTD	60MG	A076502	006	Apr 12, 2011
	180MG	A076502	008	Apr 12, 2011
HETERO LABS LTD V	60MG	A204097	002	Aug 19, 2016
	180MG	A204097	003	Aug 19, 2016
MYLAN	60MG	A077081	006	Jul 21, 2011
	180MG	A077081	008	Jul 21, 2011
SCIEGEN PHARMS INC	60MG	A204507	002	Sep 16, 2015
	180MG	A204507	003	Sep 16, 2015
SUN PHARM INDS	60MG	A091567	004	Feb 06, 2012
	180MG	A091567	006	Feb 06, 2012
TEVA	60MG	A076447	006	Apr 13, 2011
	180MG	A076447	008	Apr 13, 2011
WOCKHARDT LTD	60MG	A079112	004	Feb 08, 2012
	180MG	A079112	006	Feb 08, 2012

FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD	60MG	A076502	007	Apr 12, 2011
	180MG	A076502	009	Apr 12, 2011
MYLAN	60MG	A077081	007	Jul 21, 2011
	180MG	A077081	009	Jul 21, 2011
SCIEGEN PHARMS INC	60MG	A204507	004	Sep 16, 2015
	180MG	A204507	005	Sep 16, 2015
SUN PHARM INDS	60MG	A091567	003	Feb 06, 2012
	180MG	A091567	005	Feb 06, 2012
TEVA	60MG	A076447	007	Apr 13, 2011
	180MG	A076447	009	Apr 13, 2011
WOCKHARDT LTD	60MG	A079112	003	Feb 08, 2012
	180MG	A079112	005	Feb 08, 2012

TABLET, ORALLY DISINTEGRATING;ORAL

CHILDREN'S ALLEGRA ALLERGY

+ SANOFI AVENTIS US	30MG	N021909	002	Jan 24, 2011
---------------------	------	---------	-----	--------------

CHILDREN'S ALLEGRA HIVES

+ SANOFI AVENTIS US	30MG	N021909	003	Jan 24, 2011
---------------------	------	---------	-----	--------------

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

DR REDDYS LABS LTD	30MG	A202978	001	Jan 18, 2013
--------------------	------	---------	-----	--------------

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD	30MG	A202978	002	Jan 18, 2013
--------------------	------	---------	-----	--------------

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

+ SANOFI AVENTIS US	60MG;120MG	N020786	002	Jan 24, 2011
---------------------	------------	---------	-----	--------------

ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION

+ SANOFI AVENTIS US	180MG;240MG	N021704	002	Jan 24, 2011
---------------------	-------------	---------	-----	--------------

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

DR REDDYS LABS LTD	60MG;120MG	A076667	001	Nov 18, 2014
	180MG;240MG	A079043	002	Jun 22, 2011
SUN PHARMA GLOBAL	60MG;120MG	A090818	001	Jan 29, 2015

FLUTICASONE FUROATE

SPRAY, METERED;NASAL

FLONASE SENSIMIST ALLERGY RELIEF

+ GLAXOSMITHKLINE	0.0275MG/SPRAY	N022051	002	Aug 02, 2016
-------------------	----------------	---------	-----	--------------

OTC DRUG PRODUCT LIST

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

FLONASE ALLERGY RELIEF

+ GLAXOSMITHKLINE CONS 0.05MG/SPRAY

N205434 001 Jul 23, 2014

FLUTICASONE PROPIONATE

APOTEX INC 0.05MG/SPRAY

A208150 001 Feb 29, 2016

WEST-WARD PHARMS INT 0.05MG/SPRAY

A207957 001 May 26, 2016

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN

ACTAVIS LABS FL INC 1.2GM

A091009 002 Sep 03, 2015

PERRIGO R AND D 600MG

A078912 001 Nov 23, 2011

MUCINEX

RECKITT BENCKISER 600MG

N021282 001 Jul 12, 2002

+ 1.2GM

N021282 002 Dec 18, 2002

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

ACTAVIS LABS FL INC 600MG;60MG

A091071 001 May 27, 2015

1.2GM;120MG

A091071 002 May 27, 2015

MUCINEX D

RECKITT BENCKISER 600MG;60MG

N021585 001 Jun 22, 2004

+ 1.2GM;120MG

N021585 002 Jun 22, 2004

IBUPROFEN

CAPSULE;ORAL

ADVIL LIQUI-GELS

+ PFIZER EQ 200MG FREE ACID AND POTASSIUM SALT

N020402 001 Apr 20, 1995

ADVIL MIGRAINE LIQUI-GELS

+ PFIZER EQ 200MG FREE ACID AND POTASSIUM SALT

N020402 002 Mar 16, 2000

IBUPROFEN

AMNEAL PHARMS EQ 200MG FREE ACID AND POTASSIUM SALT

A202300 001 Dec 23, 2011

BIONPHARMA INC EQ 200MG FREE ACID AND POTASSIUM SALT

A078682 001 Mar 24, 2009

+ CONTRACT PHARMACAL 200MG

A074782 001 Jul 06, 1998

HUMANWELL PURACAP EQ 200MG FREE ACID AND POTASSIUM SALT

A206568 001 Jun 21, 2016

MARKSANS PHARMA EQ 200MG FREE ACID AND POTASSIUM SALT

A079205 001 Jun 26, 2009

P AND L DEV LLC EQ 200MG FREE ACID AND POTASSIUM SALT

A077338 001 Jul 10, 2009

SOFGEN PHARMS EQ 200MG FREE ACID AND POTASSIUM SALT

A203599 001 Sep 07, 2016

MIDOL LIQUID GELS

+ BIONPHARMA INC 200MG

N021472 001 Oct 18, 2002

SUSPENSION;ORAL

CHILDREN'S ADVIL

PFIZER 100MG/5ML

N020589 001 Jun 27, 1996

CHILDREN'S ADVIL-FLAVORED

PFIZER 100MG/5ML

N020589 002 Nov 07, 1997

CHILDREN'S ELIXSURE

MOBERG PHARMA NORTH 100MG/5ML

N021604 001 Jan 07, 2004

CHILDREN'S IBUPROFEN

PERRIGO 100MG/5ML

A074937 001 Dec 22, 1998

CHILDREN'S MOTRIN

+ J AND J CONSUMER INC 100MG/5ML

N020516 001 Jun 16, 1995

IBUPROFEN

ACTAVIS MID ATLANTIC 100MG/5ML

A074916 001 Apr 30, 1999

AMNEAL PHARMS 100MG/5ML

A200457 001 Aug 18, 2011

SUSPENSION/DROPS;ORAL

CHILDREN'S MOTRIN

+ J AND J CONSUMER INC 40MG/ML

N020603 001 Jun 10, 1996

IBUPROFEN

PERRIGO 40MG/ML

A075217 001 Dec 16, 1998

TRIS PHARMA INC 40MG/ML

A079058 001 Aug 31, 2009

PEDIATRIC ADVIL

+ PFIZER 100MG/2.5ML

N020812 001 Jan 30, 1998

TABLET;ORAL

ADVIL

PFIZER 200MG

N018989 001 May 18, 1984

IBU-TAB 200

ALRA 200MG

A071057 001 Aug 11, 1988

IBUPROFEN

AMNEAL PHARMS 200MG

A079233 001 Mar 18, 2014

AMNEAL PHARMS NY 200MG

A071333 001 Feb 17, 1987

200MG

A072199 001 May 23, 1988

AVEMA PHARMA 200MG

A076460 001 Nov 26, 2003

OTC DRUG PRODUCT LIST

IBUPROFEN

TABLET; ORAL

IBUPROFEN

CONTRACT PHARMACAL	200MG	A071732	001	Sep 10, 1987
	200MG	A071735	001	Sep 10, 1987
	200MG	A072299	001	Jul 01, 1988
	200MG	A074931	001	Jul 20, 1998
DR REDDYS LA	200MG	A075661	001	Dec 12, 2001
DR REDDYS LABS INC	100MG	A076117	001	Nov 20, 2001
GRANULES INDIA	200MG	A079174	001	Dec 10, 2010
GRANULES INDIA LTD	200MG	A202312	001	Oct 07, 2016
LNK	100MG	A076741	001	Jun 17, 2004
	200MG	A075010	001	Mar 01, 1999
	200MG	A075139	001	Mar 01, 1999
MARKSANS PHARMA	200MG	A091237	001	Feb 08, 2011
	200MG	A091239	001	Feb 01, 2011
MCNEIL	200MG	A073019	001	Mar 30, 1994
MERRO PHARM	200MG	A070985	001	Oct 02, 1987
OHM	200MG	A071163	001	Jul 15, 1986
PAR PHARM	200MG	A070481	001	Sep 24, 1986
PERRIGO	200MG	A072096	001	Dec 08, 1987
	200MG	A075995	001	Mar 14, 2002
PERRIGO R AND D	200MG	A077349	001	Jun 21, 2005
STRIDES PHARMA	200MG	A079129	001	Mar 28, 2011
	200MG	A091355	001	Apr 04, 2011
VINTAGE PHARMS	200MG	A071229	001	Apr 01, 1987
	200MG	A071639	001	Feb 02, 1988
IBUPROHM				
OHM LABS	200MG	A071214	001	Dec 01, 1986
JUNIOR STRENGTH ADVIL				
PFIZER	100MG	N020267	002	Dec 13, 1996
JUNIOR STRENGTH IBUPROFEN				
PERRIGO	100MG	A075367	001	Apr 22, 1999
JUNIOR STRENGTH MOTRIN				
J AND J CONSUMER INC	100MG	N020602	001	Jun 10, 1996
MOTRIN IB				
+ J AND J CONSUMER INC	200MG	N019012	003	Dec 17, 1990
PROFEN				
CONTRACT PHARMACAL	200MG	A071265	001	Oct 15, 1986
TAB-PROFEN				
PERRIGO	200MG	A072095	001	Dec 08, 1987
TABLET, CHEWABLE; ORAL				
CHILDREN'S ADVIL				
PFIZER	50MG	N020944	001	Dec 18, 1998
CHILDREN'S MOTRIN				
J AND J CONSUMER INC	50MG	N020601	001	Nov 15, 1996
IBUPROFEN				
PERRIGO	50MG	A076359	001	Jan 16, 2004
	100MG	A076359	002	Jan 16, 2004
JUNIOR STRENGTH ADVIL				
PFIZER	100MG	N020944	002	Dec 18, 1998
JUNIOR STRENGTH MOTRIN				
+ J AND J CONSUMER INC	100MG	N020601	003	Nov 15, 1996

IBUPROFEN SODIUM

TABLET; ORAL

ADVIL

+ PFIZER CONS HLTHCARE	EQ 200MG BASE	N201803	001	Jun 12, 2012
IBUPROFEN SODIUM				
PERRIGO R AND D	EQ 200MG BASE	A206581	001	Aug 03, 2015

IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

TABLET; ORAL

ADVIL CONGESTION RELIEF

+ PFIZER	200MG;10MG	N022565	001	May 27, 2010
IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE				
PERRIGO R AND D	200MG;10MG	A203200	001	Jul 03, 2014

OTC DRUG PRODUCT LIST

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

ADVIL COLD AND SINUS

+ PFIZER

EQ 200MG FREE ACID AND POTASSIUM
SALT; 30MG

N021374 001 May 30, 2002

SUSPENSION; ORAL

CHILDREN'S ADVIL COLD

PFIZER

100MG/5ML; 15MG/5ML

N021373 001 Apr 18, 2002

CHILDREN'S MOTRIN COLD

+ J AND J CONSUMER INC

100MG/5ML; 15MG/5ML

N021128 001 Aug 01, 2000

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

PERRIGO

100MG/5ML; 15MG/5ML

A076478 001 Nov 05, 2003

TABLET; ORAL

ADVIL COLD AND SINUS

+ PFIZER

200MG; 30MG

N019771 001 Sep 19, 1989

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

CONTRACT PHARMACAL

200MG; 30MG

A075588 001 Apr 08, 2002

DR REDDYS LABS LTD

200MG; 30MG

A077628 001 Aug 14, 2006

IBUPROHM COLD AND SINUS

OHM LABS

200MG; 30MG

A074567 001 Apr 17, 2001

SINE-AID IB

J AND J CONSUMER INC

200MG; 30MG

N019899 001 Dec 31, 1992

INSULIN RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN R PEN

+ LILLY

100 UNITS/ML

N018780 005 Aug 06, 1998

NOVOLIN R

+ NOVO NORDISK INC

100 UNITS/ML

N019938 001 Jun 25, 1991

INSULIN RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN R

+ LILLY

100 UNITS/ML

N018780 001 Oct 28, 1982

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN 70/30

+ LILLY

30 UNITS/ML; 70 UNITS/ML

N019717 001 Apr 25, 1989

HUMULIN 70/30 PEN

+ LILLY

30 UNITS/ML; 70 UNITS/ML

N019717 002 Aug 06, 1998

NOVOLIN 70/30

+ NOVO NORDISK INC

30 UNITS/ML; 70 UNITS/ML

N019991 001 Jun 25, 1991

INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN N

+ LILLY

100 UNITS/ML

N018781 001 Oct 28, 1982

NOVOLIN N

+ NOVO NORDISK INC

100 UNITS/ML

N019959 001 Jul 01, 1991

IODINE POVACRYLEX; ISOPROPYL ALCOHOL

SPONGE; TOPICAL

DURAPREP

+ 3M

EQ 0.7% IODINE; 74% (6ML)

N021586 001 Sep 29, 2006

+

EQ 0.7% IODINE; 74% (26ML)

N021586 002 Sep 29, 2006

KETOCONAZOLE

SHAMPOO; TOPICAL

NIZORAL A-D

+ JOHNSON AND JOHNSON

1%

N020310 001 Oct 10, 1997

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC

ALAWAY

+ BAUSCH AND LOMB

EQ 0.025% BASE

N021996 001 Dec 01, 2006

EQ 0.035% BASE

N021996 002 Feb 11, 2015

KETOTIFEN FUMARATE

AKORN

EQ 0.025% BASE

A077958 001 Jul 26, 2007

+ ALCON PHARMS LTD

EQ 0.025% BASE

A077200 001 Sep 02, 2008

OTC DRUG PRODUCT LIST

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

DR REDDYS LABS LTD	15MG	A202194	001	May 18, 2012
MYLAN PHARMS INC	15MG	A203187	001	Jun 01, 2016
NATCO PHARMA LTD	15MG	A203306	001	Jan 13, 2016
PERRIGO R AND D	15MG	A202319	001	May 18, 2012
WOCKHARDT LTD	15MG	A202727	001	May 18, 2012

PREVACID 24 HR

+ GLAXOSMITHKLINE CONS	15MG	N022327	001	May 18, 2009
------------------------	------	---------	-----	--------------

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

LANSOPRAZOLE

DEXCEL PHARMA	15MG	N208025	001	Jun 07, 2016
---------------	------	---------	-----	--------------

LEVONORGESTREL

TABLET;ORAL

ATHENTIA NEXT

AUROBINDO PHARMA LTD	1.5MG	A206867	001	Dec 08, 2015
----------------------	-------	---------	-----	--------------

FALLBACK SOLO

LUPIN LTD	1.5MG	A201446	001	Jun 19, 2014
-----------	-------	---------	-----	--------------

HER STYLE

NOVAST LABS LTD	1.5MG	A207976	001	Mar 11, 2016
-----------------	-------	---------	-----	--------------

LEVONORGESTREL

GLENMARK PHARMS LTD	1.5MG	A207044	001	Mar 25, 2016
---------------------	-------	---------	-----	--------------

JAI PHARMA LTD	0.75MG	A202740	001	Sep 02, 2016
----------------	--------	---------	-----	--------------

	1.5MG	A202739	001	Oct 31, 2014
--	-------	---------	-----	--------------

LOTUS PHARM CO LTD	0.75MG	A202684	001	Sep 02, 2016
--------------------	--------	---------	-----	--------------

	1.5MG	A202246	001	Jun 05, 2015
--	-------	---------	-----	--------------

NOVEL LABS INC	1.5MG	A202508	001	Feb 22, 2013
----------------	-------	---------	-----	--------------

OC PHARMA	1.5MG	A202380	001	May 29, 2015
-----------	-------	---------	-----	--------------

+ PERRIGO R AND D	0.75MG	A090740	001	Dec 30, 2010
-------------------	--------	---------	-----	--------------

	1.5MG	A202334	001	Aug 20, 2014
--	-------	---------	-----	--------------

WATSON LABS INC	1.5MG	A200670	001	Jul 12, 2012
-----------------	-------	---------	-----	--------------

OPCICON ONE-STEP

SUN PHARM INDS LTD	1.5MG	A202635	001	Sep 11, 2014
--------------------	-------	---------	-----	--------------

PLAN B ONE-STEP

+ TEVA BRANDED PHARM	1.5MG	N021998	001	Jul 10, 2009
----------------------	-------	---------	-----	--------------

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE

BIONPHARMA INC	1MG	N021855	001	Aug 04, 2005
----------------	-----	---------	-----	--------------

+	2MG	N021855	002	Aug 04, 2005
---	-----	---------	-----	--------------

SOLUTION;ORAL

IMODIUM A-D

+ J AND J CONSUMER INC	1MG/5ML	N019487	001	Mar 01, 1988
------------------------	---------	---------	-----	--------------

LOPERAMIDE HYDROCHLORIDE

HI TECH PHARMA	1MG/5ML	A074352	001	Nov 17, 1995
----------------	---------	---------	-----	--------------

PERRIGO	1MG/5ML	A073243	001	Jan 21, 1992
---------	---------	---------	-----	--------------

ROXANE	1MG/5ML	A073079	001	Apr 30, 1992
--------	---------	---------	-----	--------------

WOCKHARDT	1MG/5ML	A074730	001	Aug 28, 1997
-----------	---------	---------	-----	--------------

SUSPENSION;ORAL

IMODIUM A-D

+ J AND J CONSUMER INC	1MG/7.5ML	N019487	002	Jul 08, 2004
------------------------	-----------	---------	-----	--------------

LOPERAMIDE HYDROCHLORIDE

PERRIGO R AND D	1MG/7.5ML	A091292	001	May 20, 2011
-----------------	-----------	---------	-----	--------------

TABLET;ORAL

IMODIUM A-D

+ J AND J CONSUMER INC	2MG	N019860	001	Nov 22, 1989
------------------------	-----	---------	-----	--------------

LOPERAMIDE HYDROCHLORIDE

AUROBINDO PHARMA LTD	2MG	A206548	001	Dec 15, 2015
----------------------	-----	---------	-----	--------------

CONTRACT PHARMACAL	2MG	A073254	001	Jul 30, 1993
--------------------	-----	---------	-----	--------------

LNK	2MG	A076497	001	Jun 10, 2003
-----	-----	---------	-----	--------------

OHM LABS	2MG	A074091	001	Dec 10, 1992
----------	-----	---------	-----	--------------

PERRIGO	2MG	A075232	001	Jan 06, 2000
---------	-----	---------	-----	--------------

TABLET, CHEWABLE;ORAL

IMODIUM A-D EZ CHEWS

+ J AND J CONSUMER INC	2MG	N020448	001	Jul 24, 1997
------------------------	-----	---------	-----	--------------

OTC DRUG PRODUCT LIST

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET; ORAL

IMODIUM MULTI-SYMPTOM RELIEF

+ J AND J CONSUMER INC 2MG;125MG

N021140 001 Nov 30, 2000

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

SUN PHARM INDS LTD 2MG;125MG

A077500 001 Sep 06, 2006

TABLET, CHEWABLE; ORAL

IMODIUM MULTI-SYMPTOM RELIEF

+ J AND J CONSUMER INC 2MG;125MG

N020606 001 Jun 26, 1996

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

PERRIGO 2MG;125MG

A076029 001 Aug 30, 2002

LORATADINE

CAPSULE; ORAL

CLARITIN

+ BAYER HEALTHCARE LLC 10MG

N021952 001 Jun 16, 2008

LORATADINE

MARKSANS PHARMA 10MG

A206214 001 Sep 23, 2016

SUSPENSION; ORAL

LORATADINE

+ TARO 1MG/ML

N021734 001 Oct 04, 2005

SYRUP; ORAL

CLARITIN

+ BAYER HEALTHCARE LLC 1MG/ML

N020641 002 Nov 27, 2002

LORATADINE

PERRIGO 1MG/ML

A075728 001 Aug 20, 2004

SILARX 1MG/ML

A077421 001 Jun 29, 2006

TARO 1MG/ML

A076805 001 Aug 20, 2004

1MG/ML

A201865 001 Jul 31, 2015

TEVA 1MG/ML

A075505 001 Nov 07, 2003

WOCKHARDT 1MG/ML

A075815 001 Aug 20, 2004

TABLET; ORAL

CLARITIN

+ BAYER HEALTHCARE LLC 10MG

N019658 002 Nov 27, 2002

CLARITIN HIVES RELIEF

+ BAYER HEALTHCARE LLC 10MG

N019658 003 Nov 19, 2003

LORATADINE

APOTEX INC 10MG

A076471 001 Feb 14, 2006

MYLAN 10MG

A075790 001 Nov 07, 2008

10MG

A076154 001 Aug 20, 2003

10MG

A078447 001 Aug 12, 2011

PERRIGO 10MG

A076301 001 Jun 25, 2004

SANDOZ 10MG

A075209 001 Jan 21, 2003

SUN PHARM INDS LTD 10MG

A076134 001 Aug 18, 2003

TABLET, CHEWABLE; ORAL

CHILDREN'S CLARITIN

+ BAYER HEALTHCARE LLC 5MG

N021891 001 Aug 23, 2006

TABLET, ORALLY DISINTEGRATING; ORAL

ALAVERT

PFIZER 10MG

N021375 001 Dec 19, 2002

CLARITIN HIVES RELIEF REDITAB

+ BAYER HEALTHCARE LLC 10MG

N020704 003 Nov 19, 2003

CLARITIN REDITABS

+ BAYER HEALTHCARE LLC 5MG

N021993 001 Dec 12, 2006

+ 10MG

N020704 002 Nov 27, 2002

LORATADINE

ACTAVIS LABS FL INC 10MG

A075990 001 Nov 03, 2003

PERRIGO PHARMA INTL 10MG

A076011 001 Sep 29, 2003

PFIZER 10MG

A075822 001 Feb 10, 2003

LORATADINE REDIDOSE

SUN PHARM INDS LTD 10MG

A077153 001 Apr 11, 2007

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARITIN-D

+ BAYER HEALTHCARE LLC 5MG;120MG

N019670 002 Nov 27, 2002

CLARITIN-D 24 HOUR

+ BAYER HEALTHCARE LLC 10MG;240MG

N020470 002 Nov 27, 2002

LORATADINE AND PSEUDOEPHEDRINE SULFATE

ACTAVIS LABS FL INC 10MG;240MG

A075706 001 Feb 21, 2003

PERRIGO PHARMA INTL 5MG;120MG

A076050 001 Jan 30, 2003

10MG;240MG

A075989 001 Mar 04, 2004

SUN PHARM INDS LTD 10MG;240MG

A076557 001 Sep 22, 2004

OTC DRUG PRODUCT LIST

MENTHOL; METHYL SALICYLATE

PATCH; TOPICAL

SALONPAS

+ HISAMITSU PHARM CO	3%;10%	N022029 001	Feb 20, 2008
	3%;10%	N022029 002	Nov 05, 2012

MICONAZOLE NITRATE

CREAM; TOPICAL, VAGINAL

MICONAZOLE 3 COMBINATION PACK

PERRIGO	2%,4%	A076357 001	Mar 30, 2004
---------	-------	-------------	--------------

MONISTAT 3 COMBINATION PACK

MEDTECH PRODUCTS	2%,4%	N021261 003	Jun 17, 2003
------------------	-------	-------------	--------------

MONISTAT 3 COMBINATION PACK (PREFILLED)

+ MEDTECH PRODUCTS	2%,4%	N021261 001	Feb 02, 2001
--------------------	-------	-------------	--------------

CREAM; VAGINAL

MICONAZOLE 3

TARO	4%	A076773 001	Mar 02, 2005
------	----	-------------	--------------

MICONAZOLE 7

ACTAVIS MID ATLANTIC	2%	A074164 001	Mar 29, 1996
----------------------	----	-------------	--------------

MICONAZOLE NITRATE

G AND W LABS INC	2%	A074366 001	Feb 22, 1996
------------------	----	-------------	--------------

PERRIGO	2%	A074760 001	May 15, 1997
---------	----	-------------	--------------

PERRIGO R AND D	4%	A091366 001	Jan 15, 2010
-----------------	----	-------------	--------------

TARO	2%	A074444 001	Jan 13, 1997
------	----	-------------	--------------

MONISTAT 3

+ MEDTECH PRODUCTS	4%	N020827 001	Mar 30, 1998
--------------------	----	-------------	--------------

MONISTAT 7

+ MEDTECH PRODUCTS	2%	N017450 002	Feb 15, 1991
--------------------	----	-------------	--------------

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

M-ZOLE 3 COMBINATION PACK

ACTAVIS MID ATLANTIC	2%,200MG	A074926 001	Apr 16, 1999
----------------------	----------	-------------	--------------

MICONAZOLE 7 COMBINATION PACK

G AND W LABS	2%,100MG	A076585 001	Mar 26, 2004
--------------	----------	-------------	--------------

MICONAZOLE NITRATE

PERRIGO R AND D	2%,1.2GM	A079114 001	Jun 02, 2010
-----------------	----------	-------------	--------------

MICONAZOLE NITRATE COMBINATION PACK

PERRIGO	2%,200MG	A075329 001	Apr 20, 1999
---------	----------	-------------	--------------

MONISTAT 1 COMBINATION PACK

+ MEDTECH PRODUCTS	2%,1.2GM	N021308 001	Jun 29, 2001
--------------------	----------	-------------	--------------

MONISTAT 3 COMBINATION PACK

+ MEDTECH PRODUCTS	2%,200MG	N020670 002	Apr 16, 1996
--------------------	----------	-------------	--------------

MONISTAT 7 COMBINATION PACK

+ MEDTECH PRODUCTS	2%,100MG	N020288 002	Apr 26, 1993
--------------------	----------	-------------	--------------

SUPPOSITORY; VAGINAL

MICONAZOLE NITRATE

ACTAVIS MID ATLANTIC	100MG	A073507 001	Nov 19, 1993
----------------------	-------	-------------	--------------

G AND W LABS	100MG	A074414 001	Apr 30, 1997
--------------	-------	-------------	--------------

+ PERRIGO	100MG	A074395 001	Mar 20, 1997
-----------	-------	-------------	--------------

MONISTAT 7

+ MEDTECH PRODUCTS	100MG	N018520 002	Feb 15, 1991
--------------------	-------	-------------	--------------

MINOXIDIL

AEROSOL, FOAM; TOPICAL

MEN'S ROGAINE

+ JOHNSON AND JOHNSON	5%	N021812 001	Jan 20, 2006
-----------------------	----	-------------	--------------

MINOXIDIL

PERRIGO ISRAEL	5%	A091344 001	Apr 28, 2011
----------------	----	-------------	--------------

WOMEN'S ROGAINE

+ JOHNSON AND JOHNSON	5%	N021812 002	Feb 28, 2014
-----------------------	----	-------------	--------------

SOLUTION; TOPICAL

MINOXIDIL (FOR MEN)

ACTAVIS MID ATLANTIC	2%	A074588 001	Apr 05, 1996
----------------------	----	-------------	--------------

HI TECH PHARMA	2%	A074731 001	Dec 24, 1996
----------------	----	-------------	--------------

PERRIGO	2%	A075357 001	Jul 30, 1999
---------	----	-------------	--------------

WOCKHARDT	2%	A074767 001	Feb 28, 1997
-----------	----	-------------	--------------

MINOXIDIL (FOR WOMEN)

HI TECH PHARMA	2%	A074731 002	May 11, 2005
----------------	----	-------------	--------------

PERRIGO	2%	A075357 002	Jul 30, 1999
---------	----	-------------	--------------

MINOXIDIL EXTRA STRENGTH (FOR MEN)

ACTAVIS MID ATLANTIC	5%	A075518 001	Nov 17, 2000
----------------------	----	-------------	--------------

AVACOR PRODS	5%	A075619 001	Nov 17, 2000
--------------	----	-------------	--------------

PERRIGO	5%	A075598 001	Jun 13, 2001
---------	----	-------------	--------------

PERRIGO NEW YORK	5%	A075737 001	Mar 15, 2002
------------------	----	-------------	--------------

OTC DRUG PRODUCT LIST

MINOXIDIL

SOLUTION;TOPICAL

MINOXIDIL EXTRA STRENGTH (FOR MEN)

WOCKHARDT	5%	A075438	001	Feb 27, 2003
ROGAINE (FOR MEN)				
+ JOHNSON AND JOHNSON	2%	N019501	002	Feb 09, 1996
ROGAINE (FOR WOMEN)				
+ JOHNSON AND JOHNSON	2%	N019501	003	Feb 09, 1996
ROGAINE EXTRA STRENGTH (FOR MEN)				
+ JOHNSON AND JOHNSON	5%	N020834	001	Nov 14, 1997
THEROXIDIL				
EI INC	2%	A078176	001	Nov 09, 2007
	5%	A076239	001	Aug 24, 2004

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS;OPHTHALMIC

NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE

AKORN INC	0.025%;0.3%	A202795	001	Jan 24, 2013
ALTAIRE PHARMS INC	0.02675%;0.315%	A078208	001	Sep 27, 2010
NAPHCN-A				
+ ALCON	0.025%;0.3%	N020226	001	Jun 08, 1994
OPCON-A				
+ BAUSCH AND LOMB	0.02675%;0.315%	N020065	001	Jun 08, 1994
VISINE-A				
+ JOHNSON AND JOHNSON	0.025%;0.3%	N020485	001	Jan 31, 1996

NAPROXEN SODIUM

CAPSULE;ORAL

NAPROXEN SODIUM

+ BIONPHARMA INC	EQ 200MG BASE	N021920	001	Feb 17, 2006
------------------	---------------	---------	-----	--------------

TABLET;ORAL

ALEVE

+ BAYER	EQ 200MG BASE	N020204	002	Jan 11, 1994
---------	---------------	---------	-----	--------------

NAPROXEN SODIUM

AMNEAL PHARMS NY	EQ 200MG BASE	A079096	001	Dec 16, 2008
AUROBINDO PHARMA LTD	EQ 200MG BASE	A205497	001	Mar 18, 2016
CONTRACT PHARMACAL	EQ 200MG BASE	A074635	001	Jan 13, 1997
	EQ 200MG BASE	A074789	001	Feb 27, 1997
DR REDDYS LABS INC	EQ 200MG BASE	A075168	001	Jul 28, 1998
GRANULES INDIA	EQ 200MG BASE	A091353	001	Sep 20, 2011
MARKSANS PHARMA	EQ 200MG BASE	A090545	001	Mar 16, 2011
PERRIGO	EQ 200MG BASE	A074661	001	Jan 13, 1997
SUN PHARM INDS LTD	EQ 200MG BASE	A091183	001	May 20, 2011

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALEVE-D SINUS & COLD

+ BAYER	200MG;120MG	N021076	001	Nov 29, 1999
---------	-------------	---------	-----	--------------

NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE

DR REDDYS LABS INC	EQ 220MG BASE;120MG	A077381	001	Sep 27, 2006
PERRIGO	EQ 200MG BASE;120MG	A076518	001	Mar 17, 2004

NICOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL

HABITROL

DR REDDYS LABS INC	7MG/24HR	N020076	004	Nov 12, 1999
	14MG/24HR	N020076	005	Nov 12, 1999
+	21MG/24HR	N020076	006	Nov 12, 1999

NICODERM CQ

SANOFI AVENTIS US	7MG/24HR	N020165	006	Aug 02, 1996
	14MG/24HR	N020165	005	Aug 02, 1996
+	21MG/24HR	N020165	004	Aug 02, 1996

NICOTINE

AVEVA	7MG/24HR	A074612	002	Jul 28, 2003
	14MG/24HR	A074612	003	Oct 20, 1997
	21MG/24HR	A074612	001	Oct 20, 1997

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICORETTE

+ GLAXOSMITHKLINE	EQ 2MG BASE	N018612	002	Feb 09, 1996
	EQ 2MG BASE	N018612	004	Sep 25, 2000
+	EQ 4MG BASE	N020066	002	Feb 09, 1996
	EQ 4MG BASE	N020066	004	Sep 25, 2000

OTC DRUG PRODUCT LIST

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICORETTE (MINT)

GLAXOSMITHKLINE

EQ 2MG BASE

N018612 003 Dec 23, 1998

EQ 4MG BASE

N020066 003 Dec 23, 1998

NICOTINE POLACRILEX

ACTAVIS LABS NY INC

EQ 2MG BASE

A074507 001 Mar 15, 1999

EQ 2MG BASE

A076569 001 Jul 29, 2004

EQ 2MG BASE

A078699 001 Dec 29, 2008

EQ 2MG BASE

A079216 001 Jul 08, 2009

EQ 2MG BASE

A204794 001 May 10, 2016

EQ 4MG BASE

A074707 001 Mar 19, 1999

EQ 4MG BASE

A076568 002 Jul 29, 2004

EQ 4MG BASE

A078697 001 Dec 29, 2008

EQ 4MG BASE

A079038 001 Jul 08, 2009

EQ 4MG BASE

A079219 001 Jul 08, 2009

EQ 4MG BASE

A204833 001 Feb 26, 2016

PERRIGO

EQ 2MG BASE

A076775 001 Sep 16, 2004

EQ 2MG BASE

A076776 001 Sep 16, 2004

EQ 2MG BASE

A076777 001 Sep 16, 2004

EQ 4MG BASE

A076778 001 Sep 16, 2004

EQ 4MG BASE

A076779 001 Sep 16, 2004

EQ 4MG BASE

A076789 001 Sep 16, 2004

PERRIGO R AND D

EQ 2MG BASE

A078325 001 Oct 30, 2006

EQ 2MG BASE

A078547 001 May 24, 2007

EQ 2MG BASE

A078967 001 Apr 23, 2008

EQ 2MG BASE

A091349 001 Jul 20, 2011

EQ 2MG BASE

A206394 001 Dec 15, 2016

EQ 4MG BASE

A078326 001 Oct 30, 2006

EQ 4MG BASE

A078546 001 May 24, 2007

EQ 4MG BASE

A078968 001 Apr 23, 2008

EQ 4MG BASE

A091354 001 Jul 20, 2011

EQ 4MG BASE

A206393 001 Dec 15, 2016

WATSON LABS

EQ 2MG BASE

A079044 001 Jul 08, 2009

THRIVE

NOVARTIS

EQ 2MG BASE

A077658 001 Jun 19, 2007

EQ 4MG BASE

A077656 001 Jun 19, 2007

TROCHE/LOZENGE;ORAL

COMMIT

GLAXOSMITHKLINE CONS

EQ 2MG BASE

N021330 001 Oct 31, 2002

+

EQ 4MG BASE

N021330 002 Oct 31, 2002

NICORETTE

GLAXOSMITHKLINE CONS

EQ 2MG BASE

N022360 001 May 18, 2009

+

EQ 4MG BASE

N022360 002 May 18, 2009

NICOTINE POLACRILEX

PERRIGO R AND D

EQ 2MG BASE

A077007 001 Jan 31, 2006

EQ 2MG BASE

A090711 001 Jul 10, 2009

EQ 2MG BASE

A090821 001 Jul 10, 2009

EQ 2MG BASE

A203690 001 Oct 09, 2012

EQ 4MG BASE

A077007 002 Jan 31, 2006

EQ 4MG BASE

A090711 002 Jul 10, 2009

EQ 4MG BASE

A090821 002 Jul 10, 2009

EQ 4MG BASE

A203690 002 Oct 09, 2012

NIZATIDINE

TABLET;ORAL

AXID AR

+

PFIZER

75MG

N020555 001 May 09, 1996

NONOXYNOL-9

SPONGE;VAGINAL

TODAY

+

MAYER LABS INC

1GM

N018683 001 Apr 01, 1983

OMEPRAZOLE

TABLET, DELAYED RELEASE;ORAL

OMEPRAZOLE

+

DEXCEL PHARMA

20MG

N022032 001 Dec 04, 2007

OTC DRUG PRODUCT LIST

OMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

OMEPRAZOLE MAGNESIUM

+ DR REDDYS LABS LTD EQ 20MG BASE

A078878 001 Jun 05, 2009

TABLET, DELAYED RELEASE;ORAL

OMEPRAZOLE MAGNESIUM

PERRIGO R AND D EQ 20MG BASE

A204152 001 Jul 30, 2015

PRILOSEC OTC

+ ASTRAZENECA PHARMS EQ 20MG BASE

N021229 001 Jun 20, 2003

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

ACTAVIS ELIZABETH 20MG;1.1GM

A204137 001 Jul 15, 2016

AUROLIFE PHARMA LLC 20MG;1.1GM

A204923 001 Nov 07, 2016

PAR PHARM 20MG;1.1GM

A201946 001 Jul 15, 2016

PERRIGO R AND D 20MG;1.1GM

A201361 001 Jul 15, 2016

ZEGERID OTC

+ BAYER HEALTHCARE LLC 20MG;1.1GM

N022281 001 Dec 01, 2009

FOR SUSPENSION;ORAL

ZEGERID OTC

+ BAYER HEALTHCARE LLC 20MG/PACKET;1.68GM/PACKET

N022283 001 Jun 17, 2013

ORLISTAT

CAPSULE;ORAL

ALLI

+ GLAXOSMITHKLINE CONS 60MG

N021887 001 Feb 07, 2007

OXYBUTYNYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL

OXYTROL FOR WOMEN

+ ALLERGAN SALES LLC 3.9MG/24HR

N202211 001 Jan 25, 2013

OXYMETAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OCUCLEAR

BAYER HEALTHCARE LLC 0.025%

N018471 001 May 30, 1986

VISINE L.R.

+ JOHNSON AND JOHNSON 0.025%

N019407 001 Mar 31, 1989

PERMETHRIN

LOTION;TOPICAL

NIX

+ MEDTECH PRODUCTS 1%

N019918 001 May 02, 1990

PERMETHRIN

ACTAVIS MID ATLANTIC 1%

A075014 001 Mar 28, 2000

PERRIGO NEW YORK 1%

A076090 001 Dec 20, 2001

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

GLYCOLAX

KREMERS URBAN PHARMS 17GM/PACKET
17GM/SCOOPFUL

A090600 001 Oct 06, 2009

A090600 002 Oct 06, 2009

MIRALAX

+ BAYER HEALTHCARE LLC 17GM/SCOOPFUL

N022015 001 Oct 06, 2006

POLYETHYLENE GLYCOL 3350

ANI PHARMS INC 17GM/SCOOPFUL

A202850 001 Dec 15, 2015

MYLAN 17GM/PACKET

A078915 001 Oct 06, 2009

17GM/SCOOPFUL

A078915 002 Oct 06, 2009

NEXGEN PHARMA 17GM/SCOOPFUL

A090812 001 Oct 07, 2009

NOVEL LABS INC 17GM/SCOOPFUL

A091077 001 Oct 06, 2009

NUVO PHARM INC 17GM/SCOOPFUL

A206105 001 Oct 28, 2016

PAR PHARM 17GM/SCOOPFUL

A079214 001 Jan 31, 2013

PERRIGO R AND D 17GM/PACKET

A090685 001 Oct 06, 2009

17GM/SCOOPFUL

A090685 002 Oct 06, 2009

RARITAN PHARMS INC 17GM/SCOOPFUL

A202071 001 Dec 28, 2012

STRIDES PHARMA 17GM/SCOOPFUL

A203928 001 Aug 24, 2016

17GM/PACKET

A203928 002 Aug 24, 2016

POTASSIUM IODIDE

SOLUTION;ORAL

POTASSIUM IODIDE

MISSION PHARMACAL CO 65MG/ML

A206211 001 Mar 24, 2016

THYROSHIELD

+ ARCO PHARMS LLC 65MG/ML

A077218 001 Jan 12, 2005

OTC DRUG PRODUCT LIST

POTASSIUM IODIDE

TABLET; ORAL

IOSAT

ANBEX	65MG	N018664	002	May 12, 2011
+	130MG	N018664	001	Oct 14, 1982
THYROSAFE				
+ RECIP	65MG	A076350	001	Sep 10, 2002

POVIDONE-IODINE

SOLUTION; TOPICAL

POVIDONE IODINE

+ ALLEGIANCE HLTHCARE	1%	N019522	001	Mar 31, 1989
-----------------------	----	---------	-----	--------------

SPONGE; TOPICAL

E-Z SCRUB 201

+ BECTON DICKINSON	20%	N019240	001	Nov 29, 1985
--------------------	-----	---------	-----	--------------

E-Z SCRUB 241

+ BECTON DICKINSON	10%	N019476	001	Jan 07, 1987
--------------------	-----	---------	-----	--------------

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PSEUDOEPHEDRINE HYDROCHLORIDE

PERRIGO	120MG	A075153	001	Feb 26, 1999
SUN PHARM INDS LTD	120MG	A077442	001	Sep 28, 2005
SUDAFED 12 HOUR				
+ MCNEIL CONS	120MG	A073585	001	Oct 31, 1991
SUDAFED 24 HOUR				
+ J AND J CONSUMER INC	240MG	N020021	002	Dec 15, 1992

PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

AFRINOL

+ SCHERING PLOUGH	120MG	N018191	001	
-------------------	-------	---------	-----	--

PURIFIED WATER

SOLUTION; OPHTHALMIC

PUR-WASH

+ NIAGARA PHARMS	98.3%	N022305	001	Sep 01, 2011
------------------	-------	---------	-----	--------------

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

APOTEX INC	EQ 75MG BASE	A075167	001	May 04, 2000
	EQ 150MG BASE	A200172	001	May 31, 2012
CONTRACT PHARMACAL	EQ 75MG BASE	A075094	001	Jun 21, 1999
DR REDDYS LABS LTD	EQ 75MG BASE	A075294	001	Mar 28, 2000
	EQ 150MG BASE	A078192	001	Aug 31, 2007
IVAX SUB TEVA PHARMS	EQ 75MG BASE	A075296	001	Jan 14, 2000
MYLAN	EQ 75MG BASE	A075497	001	Jan 14, 2000
PERRIGO	EQ 75MG BASE	A076195	001	Aug 30, 2002
PERRIGO R AND D	EQ 150MG BASE	A091429	001	May 11, 2011
	EQ 150MG BASE	A091429	002	May 11, 2011
STRIDES PHARMA	EQ 75MG BASE	A201745	001	Feb 29, 2012
SVADS HOLDINGS SA	EQ 150MG BASE	A200536	001	Jun 28, 2011
WOCKHARDT	EQ 75MG BASE	A076760	001	Feb 24, 2006
ZANTAC 150				
+ BOEHRINGER INGELHEIM	EQ 150MG BASE	N021698	001	Aug 31, 2004
	EQ 150MG BASE	N021698	002	Mar 13, 2007
ZANTAC 75				
BOEHRINGER INGELHEIM	EQ 75MG BASE	N020520	001	Dec 19, 1995

SODIUM CHLORIDE

AEROSOL, METERED; INHALATION

BRONCHO SALINE

+ BLAIREX	0.9%	N019912	001	Sep 03, 1992
-----------	------	---------	-----	--------------

SODIUM FLUORIDE; TRICLOSAN

PASTE; DENTAL

COLGATE TOTAL

+ COLGATE PALMOLIVE	0.24%; 0.3%	N020231	001	Jul 11, 1997
---------------------	-------------	---------	-----	--------------

OTC DRUG PRODUCT LIST

TERBINAFINE

GEL; TOPICAL

LAMISIL AT

+ NOVARTIS

1%

N021958 001 Jul 24, 2006

TERBINAFINE HYDROCHLORIDE

CREAM; TOPICAL

LAMISIL

+ NOVARTIS

1%

N020980 001 Mar 09, 1999

TERBINAFINE HYDROCHLORIDE

TARO

1%

A077511 001 Jul 02, 2007

SOLUTION; TOPICAL

LAMISIL AT

+ NOVARTIS

1%

N021124 001 Mar 17, 2000

SPRAY; TOPICAL

LAMISIL AT

+ NOVARTIS

1%

N021124 002 Mar 17, 2000

TIOCONAZOLE

OINTMENT; VAGINAL

TIOCONAZOLE

PERRIGO

6.5%

A075915 001 Nov 21, 2001

VAGISTAT-1

+ NOVARTIS

6.5%

N020676 001 Feb 11, 1997

TRIAMCINOLONE ACETONIDE

SPRAY, METERED; NASAL

NASACORT ALLERGY 24 HOUR

+ SANOFI AVENTIS US

0.055MG/SPRAY

N020468 002 Oct 11, 2013

TRIAMCINOLONE ACETONIDE

TEVA PHARMS

0.055MG/SPRAY

A078104 002 Nov 14, 2014

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

ANTICOAGULANT 4% SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION

NONE

HAEMONETICS

N760305

Jun 30, 1978

MANUFACTURING INC

ANTICOAGULANT CITRATE DEXTROSE SOLUTION (ACD)

INJECTABLE; INJECTION

CITRA LABS LLC

N020037

Aug 26, 2003

ACD-A SOLUTION

TERUMO BCT INC

A010228

Feb 25, 2002

ADSOL WITH ACD-A

FENWAL INC

N000922

Aug 29, 2002

ANTICOAGULANT CITRATE DEXTROSE SOLUTION FORMULA A

HAEMONETICS CORP

A980728

Feb 06, 2002

AS3 SOLUTION/ACD-A

TERUMO BCT INC

N001214

May 29, 2002

NONE

HAEMONETICS

A710497

Nov 06, 1987

MANUFACTURING INC

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC

N160918

Mar 17, 1978

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD-A)

INJECTABLE; INJECTION

NONE

ARTERIOCYTE MEDICAL
SYSTEMS, INC

A110057

May 11, 2012

ANTICOAGULANT CITRATE PHOSPHATE 2X DEXTROSE SOLUTION (CP2D)

INJECTABLE; INJECTION

CITRATE PHOSPHATE DOUBLE DEXTROSE/ADDITIVE SOLUTION 3

HAEMONETICS CORP

N000127

Jan 18, 2002

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION

INJECTABLE; INJECTION

NONE

TERUMO MEDICAL CORP

N820528

Nov 03, 1982

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION (CPDA)

INJECTABLE; INJECTION

CPDA-1 BLOOD-PACK UNIT (PL 146 PLASTIC) 250, 450, 500 ML BLOOD PACK UNITS

FENWAL INC

N770420

May 12, 1978

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION USP

INJECTABLE; INJECTION

BLOOD PACK UNIT CPDA-1 IN PLASTIC CONTAINER

FENWAL INC

N940404

Jul 28, 1994

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE-1 SOLUTION

INJECTABLE; INJECTION

NONE

HAEMONETICS

MANUFACTURING INC

N800077

Nov 06, 1980

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION

INJECTABLE; INJECTION

ADSOL IN PLASTIC CONTAINER

FENWAL INC

N900223

Dec 27, 1991

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION (CPD)

INJECTABLE; INJECTION

CPD ANTICOAGULANT IN PL 2209 PLASTIC CONTAINER

FENWAL INC

N900224

Dec 27, 1991

MACOPRODUCTIONS SAS CPD/AS-1: MACOPHARMA LEUCOFLEX MTL1 LEUKOREDUCTION SYSTEM FOR BLOOD COMPONENTS KNOWN AS MTL1-WB

MACOPRODUCTIONS SAS

N040083

Nov 21, 2005

NONE

TERUMO BCT INC

A070025

Jan 06, 2008

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC

N170401

Dec 06, 1977

N811012

Jun 28, 1983

HAEMONETICS

MANUFACTURING INC

N800222

Aug 23, 1982

TERUMO MEDICAL CORP

N781211

Jun 10, 1981

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-1:DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION

ADSOL RED BLOOD CELL PRESERVATIVE SOLUTION

FENWAL INC

N811104

May 16, 1983

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-5:DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION

OPTISOL RED BLOOD CELL PRESERVATIVE SOLUTION

TERUMO MEDICAL CORP

N880217

Oct 07, 1988

ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH:AS-3: CITRIC ACID USP; MONOBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE;
DEXTROSE USP; SODIUM CITRATE USP

INJECTABLE; INJECTION

AS-3 NUTRICEL ADDITIVE SYSTEM

HAEMONETICS

0.042GM/100ML;0.276GM/100ML;

N820915

Oct 19, 1984

MANUFACTURING INC

0.410GM/100ML;0.30GM/100ML;

1.10GM/100ML;0.588GM/100ML

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH:

AS-2: CITRIC ACID USP; DIBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE;
DEXTROSE USP; SODIUM CITRATE USP

INJECTABLE; INJECTION

AS-2 NUTRICEL ADDITIVE SYSTEM

MEDSEP CORP	0.042GM/100ML;0.285GM/100ML; 0.718GM/100ML;0.017GM/100ML; 0.396GM/100ML;0.588GM/100ML	N820915	Sep 22, 1983
-------------	---	---------	--------------

ANTICOAGULANT SODIUM CITRATE 4% SOLUTION

INJECTABLE; INJECTION

NONE

HAEMONETICS CORPORATION		N980123	Mar 03, 2000
----------------------------	--	---------	--------------

ANTICOAGULANT SODIUM CITRATE SOLUTION

INJECTABLE; INJECTION

TRICITRASOL

CYTOSOL LABORATORIES INC		N010409	Jul 10, 2003
-----------------------------	--	---------	--------------

ANTICOAGULANT SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC		N770923	Jan 20, 1978
TERUMO MEDICAL CORP		N781214	Feb 08, 1980

CORD BLOOD STERILE COLLECTION BAG, ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION (CPD)

STERILE CORD BLOOD COLLECTION UNIT

NONE

MACOPHARMA		N125552	Dec 21, 2016
------------	--	---------	--------------

DEXTRAN 1 IN SODIUM CHLORIDE 0.6%

INJECTABLE; INJECTION

PROMIT

MEDA AB		N830715	Oct 30, 1984
---------	--	---------	--------------

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION

LMD IN GLASS BOTTLE

HOSPIRA INC	10GM/100ML;5GM/100ML	A720563	Oct 30, 1992
-------------	----------------------	---------	--------------

NONE

B BRAUN MEDICAL INC	10GM/100ML;5GM/100ML	N160767	Apr 06, 1970
---------------------	----------------------	---------	--------------

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

LMD IN PLASTIC CONTAINER

HOSPIRA INC	10GM/100ML;0.9GM/100ML	A720562	Oct 30, 1992
-------------	------------------------	---------	--------------

HETASTARCH 6% IN LACTATED ELECTROLYTE INJECTION

INJECTABLE; INJECTION

HEXTEND

BIOTIME INC	6GM/100ML	N200952	Mar 31, 1999
-------------	-----------	---------	--------------

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

HETASTARCH 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

6% HETASTARCH IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

HOSPIRA INC 6GM/100ML;0.9GM/100ML A740193 Jan 30, 1995

HESPAN IN PLASTIC CONTAINER

B BRAUN MEDICAL INC 6GM/100ML;0.9GM/100ML N890105 Apr 04, 1991

NONE

TEVA PARENTERAL 6GM/100ML;0.9GM/100ML A740592 Nov 12, 1998

MEDICINES INC

HYDROXYETHYL STARCH 130/0.4 IN 6% SODIUM CHLORIDE 0.9%STORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE
INFUSED DIRECTLY TO THE PATIENT.

NONE

B. BRAUN MEDICAL A110013 Jan 09, 2015

VOLUVEN

FRESENIUS KABI 6GM/100ML;0.9GM/100ML N070012 Dec 27, 2007

DEUTSCHLAND GMBH

ISOPLATE SOLUTION IN THE 500 ML EXCEL CONTAINERSTORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE
INFUSED DIRECTLY TO THE PATIENT.

ISOPLATE SOLUTION

HAEMONETICS CORP N090067 Mar 05, 2013

LEUKOCYTE REDUCTION FILTRATION SYSTEM FOR WHOLE BLOOD WITH CPD ANTICOAGULANT AND
SOLX ADDITIVE

INJECTABLE; INJECTION

LEUKOSEP HWB-600-XL

HAEMONETICS CORP N110059 Apr 25, 2013

RED BLOOD CELL PROCESSING SOLUTIONSTORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE
INFUSED DIRECTLY TO THE PATIENT.

REJUVESOL

CITRA LABS LLC N950522 Feb 26, 1997

SODIUM CHLORIDE; SODIUM ACETATE; SODIUM CITRATE DIHYDRATE; SODIUM PHOSPHATE,
DIBASIC ANHYDROUS; SODIUM PHOSPHATE MONOBASIC, MONOHYDRATESTORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE
INFUSED DIRECTLY TO THE PATIENT.

INTERSOL SOLUTION

FENWAL INC. 2.26G/500ML; 2.21G/500ML; 1.59G/500ML; N080041 Dec 09, 2009
1.53G/500ML; 0.465G/500ML

DISCONTINUED DRUG PRODUCT LIST

ABARELIX

INJECTABLE; INTRAMUSCULAR

PLENAXIS

SPECIALITY EUROPEAN 100MG/VIAL N021320 001 Nov 25, 2003

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE; ORAL

CAMPRAL

FOREST LABS 333MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** N021431 001 Jul 29, 2004

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL

ACEBUTOLOL HYDROCHLORIDE

WATSON LABS EQ 200MG BASE A074007 001 Oct 18, 1995
EQ 400MG BASE A074007 002 Oct 18, 1995ACETAMINOPHEN

INJECTABLE; INJECTION

INJECTAPAP

ORTHO MCNEIL PHARM 100MG/ML N017785 001 Mar 07, 1986

SUPPOSITORY; RECTAL

ACEPHEN

G AND W LABS 120MG A072218 001 Mar 27, 1992

ACETAMINOPHEN

ABLE 120MG A073106 001 Feb 27, 1995

325MG A073107 001 Feb 27, 1995

650MG A073108 001 Feb 27, 1995

ROXANE 120MG A071010 001 May 12, 1987

650MG A071011 001 May 12, 1987

TYLENOL

J AND J CONSUMER INC 120MG N017756 002

650MG N017756 001

TABLET, EXTENDED RELEASE; ORAL

ACETAMINOPHEN

SUN PHARM INDS LTD 650MG A090205 001 Nov 18, 2009

ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE

CAPSULE; ORAL

ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE

MIKART 150MG; 180MG; 15MG A081095 001 Oct 26, 1990

150MG; 180MG; 30MG A081096 001 Oct 26, 1990

150MG; 180MG; 60MG A081097 001 Oct 26, 1990

CODEINE, ASPIRIN, APAP FORMULA NO. 2

SCHERER LABS 150MG; 180MG; 15MG A085640 001

CODEINE, ASPIRIN, APAP FORMULA NO. 3

SCHERER LABS 150MG; 180MG; 30MG A085639 001

CODEINE, ASPIRIN, APAP FORMULA NO. 4

SCHERER LABS 150MG; 180MG; 60MG A085638 001

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL

BANCAP

FOREST PHARMS 325MG; 50MG A088889 001 Jan 16, 1986

BUCET

MALLINCKRODT 650MG; 50MG A088991 001 Jun 28, 1985

PHRENILIN FORTE

VALEANT 650MG; 50MG A088831 001 Jun 19, 1985

TENCON

MALLINCKRODT 650MG; 50MG A089405 001 May 15, 1990

TRIAPRIN

DUNHALL 325MG; 50MG A089268 001 Jul 02, 1987

TABLET; ORAL

BUTALBITAL AND ACETAMINOPHEN

HALSEY 325MG; 50MG A089568 001 Oct 05, 1988

WATSON LABS 325MG; 50MG A087550 001 Oct 19, 1984

BUTAPAP

MIKART 650MG; 50MG A089988 001 Oct 26, 1992

PHRENILIN

VALEANT 325MG; 50MG **Federal Register

determination that product was not discontinued or withdrawn for safety or efficacy reasons** A087811 001 Jun 19, 1985

DISCONTINUED DRUG PRODUCT LISTACETAMINOPHEN; BUTALBITAL

TABLET; ORAL

SEDAPAP

MAYRAND 650MG; 50MG A088944 001 Oct 17, 1985

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

ANOQUAN

SHIRE 325MG; 50MG; 40MG A087628 001 Oct 01, 1986

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

GRAHAM DM 325MG; 50MG; 40MG A088743 001 Jul 18, 1985

325MG; 50MG; 40MG A088765 001 Mar 27, 1985

325MG; 50MG; 40MG A089067 001 Apr 19, 1985

HIKMA PHARMS LLC 500MG; 50MG; 40MG A040261 001 Oct 28, 1998

MALLINCKRODT 325MG; 50MG; 40MG A088758 001 Mar 27, 1985

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

GILBERT LABS 325MG; 50MG; 40MG **Federal Register A088825 001 Dec 05, 1984

determination that product was not discontinued or withdrawn for safety or efficacy reasons**

ESGIC-PLUS

MIKART 500MG; 50MG; 40MG A040085 001 Mar 28, 1996

FEMCET

MALLINCKRODT 325MG; 50MG; 40MG A089102 001 Jun 19, 1985

MEDIGESIC PLUS

US CHEM 325MG; 50MG; 40MG A089115 001 Jan 14, 1986

TRIAD

MALLINCKRODT 325MG; 50MG; 40MG A089023 001 Jun 19, 1985

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

ABLE 325MG; 50MG; 40MG A040390 001 Jul 23, 2001

500MG; 50MG; 40MG A040394 001 Jul 23, 2001

GILBERT LABS 325MG; 50MG; 40MG A087629 001 Nov 13, 1984

HIKMA PHARMS LLC 500MG; 50MG; 40MG A040336 001 Aug 18, 1999

INGENUS PHARMS NJ 325MG; 50MG; 40MG A040864 001 Dec 01, 2008

MIKART 750MG; 50MG; 40MG A040496 001 Dec 23, 2003

MIRROR PHARMS LLC 500MG; 50MG; 40MG A040883 001 Dec 23, 2008

SUN PHARM INDS 325MG; 50MG; 40MG A040601 001 Jul 29, 2005

VINTAGE PHARMS 500MG; 50MG; 40MG A040513 001 Aug 25, 2003

WATSON LABS 325MG; 50MG; 40MG A089536 001 Feb 16, 1988

500MG; 50MG; 40MG A040267 001 Jul 30, 1998

ESGIC

FOREST PHARMS 325MG; 50MG; 40MG A089660 001 Dec 23, 1988

ESGIC-PLUS

MIKART 500MG; 50MG; 40MG A089451 001 May 23, 1988

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

ABLE 325MG; 50MG; 40MG; 30MG A076528 001 Aug 21, 2003

PHRENILIN WITH CAFFEINE AND CODEINE

VALEANT 325MG; 50MG; 40MG; 30MG A074911 001 Aug 22, 2001

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

MIKART 356.4MG; 30MG; 16MG A040109 001 Aug 26, 1997

WRASER PHARMS LLC 356.4MG; 30MG; 16MG A040688 001 Apr 03, 2007

DHC PLUS

PHARM RES ASSOC 356.4MG; 30MG; 16MG A088584 001 Mar 04, 1986

SYNALGOS-DC-A

LEITNER PHARMS 356.4MG; 30MG; 16MG A089166 001 May 14, 1986

TABLET; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

BOCA PHARMA LLC 712.8MG; 60MG; 32MG A040701 001 Apr 03, 2007

MIKART 712.8MG; 60MG; 32MG A040316 001 Apr 28, 1999

WEST-WARD PHARM CORP 712.8MG; 60MG; 32MG A040637 001 Sep 22, 2006

ACETAMINOPHEN; CLEMASTINE FUMARATE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET; ORAL

TAVIST ALLERGY/SINUS/HEADACHE

NOVARTIS 500MG; EQ 0.25MG BASE; 30MG N021082 001 Mar 01, 2001

DISCONTINUED DRUG PRODUCT LIST

ACETAMINOPHEN; CODEINE PHOSPHATE

CAPSULE; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

TEVA	300MG;15MG	A088537	001	Jun 04, 1984
	300MG;30MG	A088324	001	Dec 29, 1983
	300MG;60MG	A088599	001	Jun 01, 1984
PHENAPHEN W/ CODEINE NO. 2				
ROBINS AH	325MG;15MG	A084444	001	
PHENAPHEN W/ CODEINE NO. 3				
ROBINS AH	325MG;30MG	A084445	001	
PHENAPHEN W/ CODEINE NO. 4				
ROBINS AH	325MG;60MG	A084446	001	
PROVAL #3				
SOLVAY	325MG;30MG	A085685	001	
TYLENOL W/ CODEINE NO. 3				
ORTHO MCNEIL PHARM	300MG;30MG	A087422	001	
TYLENOL W/ CODEINE NO. 4				
ORTHO MCNEIL PHARM	300MG;60MG	A087421	001	

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

ACTAVIS MID ATLANTIC	120MG/5ML;12MG/5ML	A085861	001	
DAVA PHARMS INC	120MG/5ML;12MG/5ML	A040098	001	Sep 20, 1996
ROXANE	120MG/5ML;12MG/5ML	A086366	001	
TYLENOL W/ CODEINE				
ORTHO MCNEIL PHARM	120MG/5ML;12MG/5ML	A085057	001	

SUSPENSION; ORAL

CAPITAL AND CODEINE

ACTAVIS MID ATLANTIC	120MG/5ML;12MG/5ML	A085883	001	
----------------------	--------------------	---------	-----	--

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

ABLE	300MG;30MG	A040452	001	Aug 01, 2002
	300MG;60MG	A040459	001	Aug 01, 2002
AM THERAP	300MG;15MG	A089478	001	Mar 03, 1987
	300MG;15MG	A089481	001	Mar 03, 1987
	300MG;30MG	A089479	001	Mar 03, 1987
	300MG;30MG	A089482	001	Mar 03, 1987
	300MG;60MG	A089480	001	Mar 03, 1987
	300MG;60MG	A089483	001	Mar 03, 1987
DURAMED PHARMS BARR	300MG;15MG	A040223	001	Nov 18, 1997
	300MG;15MG	A088353	001	Feb 06, 1984
	300MG;30MG	A040223	002	Nov 18, 1997
	300MG;30MG	A088354	001	Feb 06, 1984
	300MG;60MG	A040223	003	Nov 18, 1997
	300MG;60MG	A088355	001	Feb 06, 1984
EVERYLIFE	325MG;30MG	A085217	001	
FRONTIDA BIOPHARM	300MG;15MG	A089671	001	Feb 10, 1988
	300MG;30MG	A089672	001	Feb 10, 1988
	300MG;60MG	A089673	001	Feb 10, 1988
HALSEY	300MG;15MG	A083871	001	
	300MG;30MG	A083872	001	
	300MG;60MG	A086549	001	
KV PHARM	300MG;30MG	A085288	001	
	300MG;60MG	A085365	001	
	325MG;15MG	A085364	001	
	325MG;45MG	A085363	001	
	Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons			
LEDERLE	300MG;30MG	A087141	001	
MIKART	300MG;30MG	A089238	001	Feb 25, 1986
	300MG;60MG	A089244	001	Feb 25, 1986
	650MG;30MG	A089231	001	Mar 03, 1986
	650MG;60MG	A089363	001	Sep 09, 1991
MUTUAL PHARM	300MG;15MG	A085795	001	
	300MG;30MG	A085794	001	
	300MG;60MG	A087653	001	Apr 13, 1982
PURACAP PHARM	300MG;30MG	A087762	001	Dec 10, 1982
PUREPAC PHARM	300MG;30MG	A086681	001	
	300MG;30MG	A089080	001	Jul 17, 1986
	300MG;60MG	A086683	001	
ROXANE	300MG;15MG	A084659	001	
	300MG;30MG	A084656	001	
	300MG;60MG	A084667	001	

DISCONTINUED DRUG PRODUCT LIST

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

	500MG;15MG	A089511 001	Apr 25, 1989
	500MG;30MG	A089512 001	Apr 25, 1989
	500MG;60MG	A089513 001	Apr 25, 1989
SANDOZ	300MG;15MG	A087433 001	
	300MG;30MG	A081250 001	Jul 16, 1992
	300MG;30MG	A085291 002	
	300MG;30MG	A085917 001	
	300MG;60MG	A081249 001	Jul 16, 1992
	300MG;60MG	A085964 001	
	300MG;60MG	A087423 001	
SUPERPHARM	300MG;15MG	A089183 001	Oct 18, 1985
	300MG;30MG	A089184 001	Oct 18, 1985
	300MG;30MG	A089253 001	May 19, 1986
	300MG;60MG	A089185 001	Oct 18, 1985
	300MG;60MG	A089254 001	May 19, 1986
USL PHARMA	300MG;30MG	A087919 001	Jun 22, 1982
	300MG;60MG	A087920 001	Jun 22, 1982
VALEANT PHARM INTL	300MG;30MG	A085896 001	
VITARINE	300MG;30MG	A085676 001	
WARNER CHILCOTT	300MG;15MG	A085992 001	
	300MG;30MG	A085218 002	
	300MG;60MG	A087306 001	
WATSON LABS	300MG;15MG	A087277 001	May 26, 1982
	300MG;15MG	A089997 001	Dec 28, 1994
	300MG;30MG	A087276 001	May 26, 1982
	300MG;30MG	A089998 001	Dec 28, 1994
	300MG;60MG	A087275 001	May 26, 1982
	300MG;60MG	A089999 001	Dec 28, 1994
WATSON LABS FLORIDA	300MG;15MG	A040443 001	Jan 22, 2003
	300MG;30MG	A040443 002	Jan 22, 2003
	300MG;60MG	A040443 003	Jan 22, 2003
WHITEWORTH TOWN PLSN	300MG;30MG	A084360 001	
	300MG;60MG	A085607 001	
CAPITAL AND CODEINE			
CARNRICK	325MG;30MG	A083643 001	
CODRIX			
WATSON LABS FLORIDA	500MG;15MG	A040447 001	Feb 26, 2003
	500MG;30MG	A040441 001	Mar 27, 2003
	500MG;60MG	A040488 001	Mar 28, 2003
EMPRACET W/ CODEINE PHOSPHATE #3			
GLAXOSMITHKLINE	300MG;30MG	A083951 001	
EMPRACET W/ CODEINE PHOSPHATE #4			
GLAXOSMITHKLINE	300MG;60MG	A083951 002	
PAPA-DEINE #3			
VANGARD	300MG;30MG	A088037 001	Mar 20, 1984
PAPA-DEINE #4			
VANGARD	300MG;60MG	A088715 001	Mar 20, 1984
PHENAPHEN-650 W/ CODEINE			
ROBINS AH	650MG;30MG	A085856 001	
TYLENOL W/ CODEINE			
ORTHO MCNEIL PHARM	325MG;7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A085056 001	
	325MG;15MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A085056 002	
	325MG;30MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A085056 003	
	325MG;60MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A085056 004	
TYLENOL W/ CODEINE NO. 1			
JANSSEN PHARMS	300MG;7.5MG	A085055 001	
TYLENOL W/ CODEINE NO. 2			
JANSSEN PHARMS	300MG;15MG	A085055 002	

DISCONTINUED DRUG PRODUCT LIST

ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

DRIXORAL PLUS

SCHERING PLOUGH 500MG; 3MG; 60MG N019453 001 May 22, 1987

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN AND HYDROCODONE BITARTRATE

CENT PHARMS 500MG; 5MG A088898 001 Mar 27, 1985

ALLAY

IVAX PHARMS 500MG; 5MG A089907 001 Jan 13, 1989

BANCAP HC

FOREST PHARMS 500MG; 5MG A087961 001 Mar 17, 1983

CO-GESIC

CENT PHARMS 500MG; 5MG A089360 001 Mar 02, 1988

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

MALLINCKRODT 500MG; 5MG A088956 001 Jul 19, 1985

500MG; 5MG A089006 001 Aug 09, 1985

MIKART 500MG; 5MG A081067 001 Nov 30, 1989

500MG; 5MG A081068 001 Nov 30, 1989

500MG; 5MG A081069 001 Nov 30, 1989

500MG; 5MG A081070 001 Nov 30, 1989

500MG; 5MG A089008 001 Feb 21, 1986

LORCET-HD

MALLINCKRODT 500MG; 5MG A087336 001 Jul 08, 1982

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

MALLINCKRODT 500MG/15ML; 7.5MG/15ML A040418 001 Jun 27, 2001

MALLINCKRODT INC 500MG/15ML; 10MG/15ML A040508 001 Aug 29, 2003

MIKART 500MG/15ML; 5MG/15ML A081226 001 Oct 27, 1992

500MG/15ML; 5MG/15ML A089557 001 Apr 29, 1992

500MG/15ML; 7.5MG/15ML A081051 001 Aug 28, 1992

NESHER PHARMS 500MG/15ML; 7.5MG/15ML A040366 001 Jan 23, 2002

PHARM ASSOC 500MG/15ML; 7.5MG/15ML A040182 001 Mar 13, 1998

VINTAGE PHARMS 500MG/15ML; 7.5MG/15ML A040520 001 Oct 30, 2003

TABLET; ORAL

ANEXSIA

MALLINCKRODT 500MG; 5MG A089160 001 Apr 23, 1987

750MG; 10MG A040468 001 Oct 31, 2002

ANEXSIA 7.5/650

MALLINCKRODT 650MG; 7.5MG A089725 001 Sep 30, 1987

CO-GESIC

UCB INC 500MG; 5MG A087757 001 May 03, 1982

DURADYNE DHC

FOREST PHARMS 500MG; 5MG A087809 001 Mar 17, 1983

HY-PHEN

ASCHEP 500MG; 5MG A087677 001 May 03, 1982

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

ABLE 325MG; 5MG A040478 001 Nov 08, 2002

325MG; 7.5MG A040464 001 Oct 23, 2002

325MG; 10MG A040464 002 Oct 23, 2002

500MG; 5MG A040477 001 Nov 06, 2002

500MG; 7.5MG A040490 001 May 21, 2003

500MG; 10MG A040473 001 Nov 06, 2002

650MG; 7.5MG A040474 001 Jan 02, 2003

650MG; 10MG A040476 001 Oct 23, 2002

750MG; 7.5MG A040469 001 Oct 25, 2002

AMNEAL PHARMS NY 500MG; 5MG A040729 001 Aug 25, 2006

500MG; 7.5MG A040748 001 Aug 25, 2006

500MG; 10MG A040813 001 Feb 23, 2007

650MG; 7.5MG A040754 001 Aug 25, 2006

650MG; 10MG A040757 001 Aug 25, 2006

750MG; 7.5MG A040769 001 Aug 28, 2006

APIL 500MG; 10MG A040148 002 Feb 14, 1997

BARR 500MG; 2.5MG A040307 001 Jul 26, 2000

500MG; 5MG A040308 001 Jul 26, 2000

500MG; 5MG A088577 001 Dec 21, 1984

500MG; 7.5MG A040307 002 Jul 26, 2000

500MG; 10MG A040309 001 Jul 26, 2000

650MG; 7.5MG A040307 003 Jul 26, 2000

650MG; 10MG A040307 004 Jul 26, 2000

750MG; 7.5MG A040308 002 Jul 26, 2000

CARACO 500MG; 5MG A090265 001 Dec 23, 2008

DISCONTINUED DRUG PRODUCT LIST

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	500MG; 7.5MG	A090265	002	Dec 23, 2008
	500MG; 10MG	A090265	003	Dec 23, 2008
	650MG; 7.5MG	A090380	001	Dec 23, 2008
	650MG; 10MG	A090380	002	Dec 23, 2008
	660MG; 10MG	A090380	003	Dec 23, 2008
	750MG; 7.5MG	A090380	004	Dec 23, 2008
HALSEY	500MG; 5MG	A089554	001	Jun 12, 1987
IVAX PHARMS	500MG; 5MG	A089696	001	Apr 21, 1988
MALLINCKRODT	500MG; 5MG	A040084	002	Jun 01, 1995
	500MG; 7.5MG	A040201	001	Feb 27, 1998
	500MG; 10MG	A040201	002	Feb 27, 1998
	650MG; 10MG	A040084	004	Oct 16, 1996
	660MG; 10MG	A040084	003	Jul 29, 1996
	750MG; 7.5MG	A040084	001	Jun 01, 1995
MIKART	500MG; 2.5MG	A089698	001	Aug 25, 1989
	500MG; 5MG	A089271	001	Jul 16, 1986
	500MG; 5MG	A089697	001	Jan 28, 1992
	500MG; 7.5MG	A089699	001	Aug 25, 1989
	650MG; 5MG	A040849	001	Jun 09, 2010
	650MG; 7.5MG	A089689	001	Jun 29, 1988
	650MG; 10MG	A081223	001	May 29, 1992
MUTUAL PHARM	500MG; 5MG	A040236	001	Sep 25, 1997
	650MG; 7.5MG	A040240	002	Nov 26, 1997
	650MG; 10MG	A040240	001	Nov 26, 1997
	750MG; 7.5MG	A040236	002	Sep 25, 1997
RANBAXY	500MG; 5MG	A040825	001	Aug 16, 2007
	500MG; 10MG	A040824	001	Aug 16, 2007
RANBAXY LABS LTD	750MG; 7.5MG	A040822	001	Aug 16, 2007
SANDOZ	500MG; 5MG	A040149	001	Jan 27, 1997
	750MG; 7.5MG	A040149	002	Jan 27, 1997
SUN PHARM INDS LTD	325MG; 10MG	A040826	001	Aug 16, 2007
UCB INC	500MG; 10MG	A040210	001	Aug 13, 1997
	650MG; 7.5MG	A040134	001	Nov 21, 1996
USL PHARMA	500MG; 5MG	A089290	001	May 29, 1987
	500MG; 5MG	A089291	001	May 29, 1987
VINTAGE PHARMS	500MG; 2.5MG	A040144	002	Apr 25, 1997
	500MG; 5MG	A089831	001	Sep 07, 1988
	500MG; 5MG	A089971	001	Dec 02, 1988
	500MG; 7.5MG	A040144	001	Feb 22, 1996
	500MG; 10MG	A040356	001	May 31, 2000
	650MG; 7.5MG	A040155	001	Apr 14, 1997
	650MG; 10MG	A040143	001	Feb 22, 1996
	660MG; 10MG	A040358	001	May 31, 2000
	750MG; 7.5MG	A040157	001	Apr 12, 1996
VINTAGE PHARMS LLC	500MG; 5MG	A040281	001	Sep 30, 1998
	500MG; 7.5MG	A040280	001	Sep 30, 1998
	650MG; 7.5MG	A040280	002	Sep 30, 1998
	650MG; 10MG	A040280	003	Sep 30, 1998
	750MG; 7.5MG	A040281	002	Sep 30, 1998
WATSON LABS	325MG; 7.5MG	A040248	001	Apr 28, 2000
	325MG; 10MG	A040248	002	Apr 28, 2000
	500MG; 2.5MG	A040123	003	Mar 04, 1996
	500MG; 2.5MG	A081079	001	Aug 30, 1991
	500MG; 5MG	A040122	001	Mar 04, 1996
	500MG; 5MG	A089883	001	Dec 01, 1988
	500MG; 7.5MG	A040123	004	Mar 04, 1996
	500MG; 7.5MG	A081080	001	Aug 30, 1991
	650MG; 7.5MG	A040094	001	Sep 29, 1995
	650MG; 7.5MG	A040123	001	Mar 04, 1996
	650MG; 10MG	A040094	002	Sep 29, 1995
	650MG; 10MG	A040123	002	Mar 04, 1996
	660MG; 10MG	A040094	003	Aug 08, 2000
	750MG; 7.5MG	A040122	002	Mar 04, 1996
	750MG; 7.5MG	A081083	001	Aug 30, 1991
	750MG; 10MG	A040094	004	Mar 22, 1999
WATSON LABS FLORIDA	500MG; 5MG	A040493	001	May 28, 2003
	660MG; 10MG	A040495	001	May 28, 2003
	750MG; 7.5MG	A040494	001	May 28, 2003

DISCONTINUED DRUG PRODUCT LISTACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

LORTAB

UCB INC	500MG;5MG	A087722	001	Jul 09, 1982
	500MG;10MG	A040100	001	Jan 26, 1996
NORCET				
ABANA	500MG;5MG	A088871	001	May 15, 1986
TYCOLET				
ORTHO MCNEIL PHARM	500MG;5MG	A089385	001	Aug 27, 1986
VICODIN				
ABBOTT	500MG;5MG	A085667	001	
ABBVIE	500MG;5MG	A088058	001	Jan 07, 1983
VICODIN ES				
ABBVIE	750MG;7.5MG	A089736	001	Dec 09, 1988
VICODIN HP				
ABBVIE	660MG;10MG	A040117	001	Sep 23, 1996
ZYDONE				
VINTAGE PHARMS LLC	400MG;5MG	A040288	001	Nov 27, 1998
	400MG;7.5MG	A040288	002	Nov 27, 1998
	400MG;10MG	A040288	003	Nov 27, 1998

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN

ACTAVIS ELIZABETH	500MG;5MG	A040199	001	Dec 30, 1998
BARR	500MG;5MG	A040304	001	Oct 02, 2000
DURAMED PHARMS BARR	500MG;5MG	A040289	001	Mar 16, 1999
HALSEY	500MG;5MG	A089994	001	May 04, 1989
MALLINCKRODT	500MG;5MG	A040257	001	Aug 04, 1998
MUTUAL PHARM	500MG;5MG	A040219	001	Jan 22, 1998
VINTAGE PHARMS	500MG;5MG	A040106	001	Jul 30, 1996
VINTAGE PHARMS LLC	500MG;5MG	A040303	001	Dec 30, 1999
WATSON LABS	500MG;5MG	A040234	001	Oct 30, 1997

ROXILOX

ROXANE	500MG;5MG	A040061	001	Jul 03, 1995
--------	-----------	---------	-----	--------------

TYLOX

JANSSEN PHARMS	500MG;5MG	A088790	001	Dec 12, 1984
----------------	-----------	---------	-----	--------------

TYLOX-325

ORTHO MCNEIL PHARM	325MG;5MG	A088246	001	Nov 08, 1984
--------------------	-----------	---------	-----	--------------

SOLUTION; ORAL

ROXICET

WEST-WARD PHARMS INT	325MG/5ML;5MG/5ML	A089351	001	Dec 03, 1986
----------------------	-------------------	---------	-----	--------------

TABLET; ORAL

OXYCODONE 2.5/APAP 500

BRISTOL MYERS SQUIBB	500MG;2.5MG	A085910	001	
----------------------	-------------	---------	-----	--

OXYCODONE 5/APAP 500

BRISTOL MYERS SQUIBB	500MG;5MG	A085911	001	
----------------------	-----------	---------	-----	--

OXYCODONE AND ACETAMINOPHEN

ACTAVIS ELIZABETH	325MG;5MG	A040203	001	Mar 15, 1999
	325MG;7.5MG	A040800	001	Apr 03, 2012
	325MG;10MG	A040800	002	Apr 03, 2012
AMNEAL PHARMS NY	500MG;7.5MG	A040789	001	Nov 27, 2007
	650MG;10MG	A040789	002	Nov 27, 2007
BARR	325MG;5MG	A087406	001	
DURAMED PHARMS BARR	325MG;5MG	A040272	001	Jun 30, 1998
MALLINCKRODT	500MG;7.5MG	A040550	001	Jun 30, 2004
	650MG;10MG	A040550	002	Jun 30, 2004
MAYNE PHARMA INC	500MG;7.5MG	A090177	005	Oct 20, 2008
	650MG;10MG	A090177	006	Oct 20, 2008
MIKART	400MG;2.5MG	A040679	001	May 16, 2006
	400MG;5MG	A040687	001	Apr 27, 2006
	400MG;7.5MG	A040698	001	Apr 27, 2006
	400MG;10MG	A040692	001	Apr 27, 2006
	500MG;10MG	A040676	001	Apr 19, 2006
WATSON LABS	500MG;7.5MG	A040371	001	Dec 29, 2000
	650MG;10MG	A040371	002	Dec 29, 2000

PERCOCET

VINTAGE PHARMS LLC	325MG;5MG	A085106	002	
	500MG;7.5MG	A040341	001	Jul 26, 1999
	650MG;10MG	A040341	002	Jul 26, 1999

ROXICET 5/500

ROXANE	500MG;5MG	A089775	001	Jan 12, 1989
--------	-----------	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LISTACETAMINOPHEN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

CAPSULE; ORAL

TYLOX

ORTHO MCNEIL PHARM	500MG; 4.5MG; 0.38MG	A085375	001	
--------------------	----------------------	---------	-----	--

ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE

GAVIS PHARMS	650MG; EQ 25MG BASE	A076202	001	Aug 02, 2002
--------------	---------------------	---------	-----	--------------

WATSON LABS	650MG; EQ 25MG BASE	A074699	001	Mar 24, 2000
-------------	---------------------	---------	-----	--------------

TALACEN

SANOFI AVENTIS US	650MG; EQ 25MG BASE	N018458	001	Sep 23, 1982
-------------------	---------------------	---------	-----	--------------

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

DARVOCET

AAIPHARMA LLC	325MG; 32.5MG	N016844	001	
---------------	---------------	---------	-----	--

DOLENE AP-65

LEDERLE	650MG; 65MG	A085100	001	
---------	-------------	---------	-----	--

PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN

MYLAN	325MG; 32MG	A083689	001	
-------	-------------	---------	-----	--

	650MG; 65MG	A083978	001	
--	-------------	---------	-----	--

SANDOZ	650MG; 65MG	A089959	001	Jul 18, 1989
--------	-------------	---------	-----	--------------

VINTAGE PHARMS	650MG; 65MG	A040507	001	Jul 30, 2003
----------------	-------------	---------	-----	--------------

WATSON LABS	650MG; 65MG	A040139	001	Dec 16, 1996
-------------	-------------	---------	-----	--------------

WYGESIC

CARACO	650MG; 65MG	A084999	001	
--------	-------------	---------	-----	--

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

DARVOCET A500

XANODYNE PHARM	500MG; 100MG	A076429	001	Sep 10, 2003
----------------	--------------	---------	-----	--------------

DARVOCET-N 100

XANODYNE PHARM	650MG; 100MG	N017122	002	
----------------	--------------	---------	-----	--

DARVOCET-N 50

XANODYNE PHARM	325MG; 50MG	N017122	001	
----------------	-------------	---------	-----	--

PROPACET 100

TEVA	650MG; 100MG	A070107	001	Jun 12, 1985
------	--------------	---------	-----	--------------

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

ABLE	650MG; 100MG	A075838	001	Jul 11, 2001
------	--------------	---------	-----	--------------

ACTAVIS ELIZABETH	650MG; 100MG	A070910	001	Jan 02, 1987
-------------------	--------------	---------	-----	--------------

CORNERSTONE	325MG; 100MG	A076743	001	May 07, 2004
-------------	--------------	---------	-----	--------------

	500MG; 100MG	A076750	001	Jun 28, 2004
--	--------------	---------	-----	--------------

HALSEY	325MG; 50MG	A072105	001	May 13, 1988
--------	-------------	---------	-----	--------------

	650MG; 100MG	A072106	001	May 13, 1988
--	--------------	---------	-----	--------------

IVAX SUB TEVA PHARMS	650MG; 100MG	A070146	001	Aug 02, 1985
----------------------	--------------	---------	-----	--------------

MALLINCKRODT	650MG; 100MG	A075738	001	Feb 02, 2001
--------------	--------------	---------	-----	--------------

MIRROR PHARMS	650MG; 100MG	A077821	001	Feb 11, 2008
---------------	--------------	---------	-----	--------------

MUTUAL PHARM	325MG; 50MG	A070115	001	Jun 12, 1985
--------------	-------------	---------	-----	--------------

	650MG; 100MG	A070116	001	Jun 12, 1985
--	--------------	---------	-----	--------------

	650MG; 100MG	A070615	001	Mar 21, 1986
--	--------------	---------	-----	--------------

	650MG; 100MG	A070771	001	Mar 21, 1986
--	--------------	---------	-----	--------------

	650MG; 100MG	A070775	001	Mar 21, 1986
--	--------------	---------	-----	--------------

MYLAN	650MG; 100MG	A072195	001	Feb 16, 1988
-------	--------------	---------	-----	--------------

MYLAN PHARMS INC	650MG; 100MG	A070145	001	Jun 12, 1985
------------------	--------------	---------	-----	--------------

SANDOZ	650MG; 100MG	A070443	001	Jan 23, 1986
--------	--------------	---------	-----	--------------

SUPERPHARM	650MG; 100MG	A071319	001	Jan 06, 1987
------------	--------------	---------	-----	--------------

TEVA	650MG; 100MG	A070732	001	Jan 03, 1986
------	--------------	---------	-----	--------------

	650MG; 100MG	A074119	001	Dec 19, 1994
--	--------------	---------	-----	--------------

VINTAGE PHARMS	325MG; 50MG	A074843	002	Feb 15, 2001
----------------	-------------	---------	-----	--------------

	650MG; 100MG	A074843	001	Feb 12, 1997
--	--------------	---------	-----	--------------

WATSON LABS	325MG; 50MG	A070398	001	Dec 18, 1986
-------------	-------------	---------	-----	--------------

	650MG; 100MG	A070399	001	Dec 18, 1986
--	--------------	---------	-----	--------------

WATSON LABS FLORIDA	500MG; 100MG	A077196	001	Jun 28, 2005
---------------------	--------------	---------	-----	--------------

	650MG; 100MG	A076609	001	Nov 16, 2004
--	--------------	---------	-----	--------------

WOCKHARDT LTD	325MG; 50MG	A077677	001	Mar 16, 2007
---------------	-------------	---------	-----	--------------

	650MG; 100MG	A077677	002	Mar 16, 2007
--	--------------	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN
WATSON LABS 325MG; 37.5MG

A076914 001 Jul 26, 2006

ACETAZOLAMIDE

TABLET; ORAL

ACETAZOLAMIDE

ALRA 250MG

A083320 001

ASCOT 250MG

A087686 001 Oct 20, 1982

SUN PHARM INDS 250MG

A089753 001 Jun 22, 1988

VANGARD 250MG

A087654 001 Feb 05, 1982

WATSON LABS 250MG

A084498 002

250MG

A088882 001 Oct 22, 1985

DIAMOX

TEVA BRANDED PHARM 125MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N008943 001

250MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N008943 002

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

HOSPIRA EQ 500MG BASE/VIAL

A040108 001 Oct 30, 1995

DIAMOX

TEVA WOMENS EQ 500MG BASE/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N009388 001 Dec 05, 1990

ACETIC ACID, GLACIAL

SOLUTION/DROPS; OTIC

ACETASOL

ACTAVIS MID ATLANTIC 2%

A087146 001

ACETIC ACID

KV PHARM 2%

A085493 001

ORLEX

WARNER CHILCOTT 2%

A086845 001

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS; OTIC

BOROFAIR

PHARMAFAIR 2%; 0.79%

A088606 001 Aug 21, 1985

DOMEBORO

BAYER PHARMS 2%; 0.79%

A084476 001

ACETIC ACID, GLACIAL; DESONIDE

SOLUTION/DROPS; OTIC

TRIDESILON

BAYER PHARMS 2%; 0.05%

N017914 001

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC

ACETIC ACID W/ HYDROCORTISONE

KV PHARM 2%; 1%

A085492 001

HYDROCORTISONE AND ACETIC ACID

BAUSCH AND LOMB 2%; 1%

A040097 001 Oct 31, 1994

WOCKHARDT 2%; 1%

A040168 001 Aug 30, 1996

ORLEX HC

WARNER CHILCOTT 2%; 1%

A086844 001

ACETIC ACID, GLACIAL; HYDROCORTISONE; NEOMYCIN SULFATE

SUSPENSION/DROPS; OTIC

NEO-CORT-DOME

BAYER PHARMS 2%; 1%; EQ 0.35% BASE

N050238 001

ACETOHEXAMIDE

TABLET; ORAL

ACETOHEXAMIDE

ANI PHARMS INC 250MG

A070869 001 Feb 09, 1987

500MG

A070870 001 Feb 09, 1987

USL PHARMA 250MG

A070753 001 Nov 03, 1986

500MG

A070754 001 Nov 03, 1986

WATSON LABS 250MG

A071893 001 Nov 25, 1987

DISCONTINUED DRUG PRODUCT LIST

ACETOHEXAMIDE

TABLET; ORAL

ACETOHEXAMIDE

500MG

A071894 001 Nov 25, 1987

DYMELOR

LILLY

250MG

N013378 002

500MG

N013378 001

ACETOPHENAZINE MALEATE

TABLET; ORAL

TINDAL

SCHERING

20MG

N012254 002

ACETRIZOATE SODIUM

SOLUTION; INTRAUTERINE

SALPIX

ORTHO MCNEIL PHARM

53%

N009008 001

ACETYLCOLINE CHLORIDE

FOR SOLUTION; OPHTHALMIC

MIOCHOL

NOVARTIS

20MG/VIAL

N016211 001

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL

ACETYLCYSTEINE

HOSPIRA

10%

A071364 001 May 01, 1989

20%

A071365 001 May 01, 1989

ROXANE

10%

A072323 001 Apr 30, 1992

10%

A072621 001 Sep 30, 1992

20%

A072324 001 Apr 30, 1992

20%

A072622 001 Sep 30, 1992

MUCOMYST

APOTHECON

10% **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N013601 002

20% **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N013601 001

MUCOSIL-10

DEY

10%

A070575 001 Oct 14, 1986

MUCOSIL-20

DEY

20%

A070576 001 Oct 14, 1986

ACETYLCYSTEINE; ISOPROTERENOL HYDROCHLORIDE

SOLUTION; INHALATION

MUCOMYST W/ ISOPROTERENOL

MEAD JOHNSON

10%; 0.05%

N017366 001

ACETYLDIGITOXIN

TABLET; ORAL

ACYLANID

NOVARTIS

0.1MG

N009436 001

ACRISORCIN

CREAM; TOPICAL

AKRINOL

SCHERING

2MG/GM

N012470 001

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

ACTAVIS ELIZABETH

200MG

A074906 001 Aug 26, 1997

DAVA PHARMS INC

200MG

A074872 001 Apr 22, 1997

HERITAGE PHARMS INC

200MG

A074889 001 Oct 31, 1997

IVAX SUB TEVA PHARMS

200MG

A074674 001 Apr 22, 1997

LEK PHARM

200MG

A074750 001 Apr 22, 1997

MYLAN

200MG

A074977 001 Apr 13, 1998

RANBAXY

200MG

A074975 001 Sep 30, 1998

ROXANE

200MG

A074570 002 Apr 22, 1997

TEVA

200MG

A074828 001 Apr 22, 1997

TEVA PHARMS

200MG

A074914 001 Nov 26, 1997

WATSON LABS

200MG

A075101 001 Apr 15, 1998

DISCONTINUED DRUG PRODUCT LIST

ACYCLOVIR

TABLET; ORAL

ACYCLOVIR

ACTAVIS ELIZABETH	400MG	A074870 001	Jun 05, 1997
	800MG	A074870 002	Jun 05, 1997
DAVA PHARMS INC	400MG	A074834 001	Apr 24, 1997
	800MG	A074834 002	Apr 24, 1997
HERITAGE PHARMS INC	400MG	A074891 001	Oct 31, 1997
	800MG	A074891 002	Oct 31, 1997
IVAX SUB TEVA PHARMS	400MG	A074836 001	Apr 22, 1997
	800MG	A074836 002	Apr 22, 1997
LEK PHARM	400MG	A074658 001	Apr 22, 1997
	800MG	A074658 002	Apr 22, 1997
MYLAN	400MG	A074976 001	Apr 13, 1998
	800MG	A074976 002	Apr 13, 1998
SUN PHARM INDS LTD	400MG	A074980 001	Sep 30, 1998
	800MG	A074980 002	Sep 30, 1998
TEVA	200MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A074556 001	Apr 22, 1997
TEVA PHARMS	400MG	A075021 001	Mar 18, 1998
	800MG	A075021 002	Mar 18, 1998

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR

ABBVIE	EQ 50MG BASE/ML	A075114 001	Jul 26, 1999
ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE			
EUROHLTH INTL SARL	EQ 500MG BASE/VIAL	A074885 001	Dec 19, 1997
	EQ 1GM BASE/VIAL	A074885 002	Dec 19, 1997

ACYCLOVIR SODIUM

AMPHASTAR PHARMS INC	EQ 500MG BASE/VIAL	A074596 002	Apr 22, 1997
	EQ 1GM BASE/VIAL	A074596 001	Apr 22, 1997
APOTHECON	EQ 500MG BASE/VIAL	A074897 001	Feb 27, 1998
	EQ 1GM BASE/VIAL	A074897 002	Feb 27, 1998
EUROHLTH INTL SARL	EQ 500MG BASE/VIAL	A074913 001	Oct 15, 1997
	EQ 1GM BASE/VIAL	A074913 002	Oct 15, 1997
HOSPIRA	EQ 25MG BASE/ML	A074720 001	Apr 22, 1997
	EQ 50MG BASE/ML	A075065 001	Feb 25, 1999
	EQ 500MG BASE/VIAL	A074663 001	Apr 22, 1997
	EQ 500MG BASE/VIAL	A074758 001	Apr 22, 1997
	EQ 1GM BASE/VIAL	A074663 002	Apr 22, 1997
	EQ 1GM BASE/VIAL	A074758 002	Apr 22, 1997
TEVA PARENTERAL	EQ 50MG BASE/ML	A075627 001	Mar 28, 2001
	EQ 500MG BASE/VIAL	A074969 001	Aug 26, 1997
	EQ 1GM BASE/VIAL	A074969 002	Aug 26, 1997

ZOVIRAX

GLAXOSMITHKLINE	EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018603 003	Aug 30, 1983
	EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018603 001	Oct 22, 1982
	EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018603 002	Jun 29, 1989

ADAPALENE

SOLUTION; TOPICAL

DIFFERIN

GALDERMA LABS LP	0.1% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020338 001	May 31, 1996
------------------	---	-------------	--------------

ADENOSINE

INJECTABLE; INJECTION

ADENOSINE

EUROHLTH INTL SARL	3MG/ML	A076501 001	Jun 16, 2004
TEVA PHARMS USA	3MG/ML	A076564 001	Jun 16, 2004
	3MG/ML	A078676 001	Jul 31, 2008
WOCKHARDT	3MG/ML	A090220 001	Jul 20, 2009

DISCONTINUED DRUG PRODUCT LIST

ADENOSINE

SOLUTION; IV (INFUSION)

ADENOSCAN

ASTELLAS

60MG/20ML (3MG/ML) **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020059 001 May 18, 1995

90MG/30ML (3MG/ML) **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020059 002 May 18, 1995

ALATROFLOXACIN MESYLATE

INJECTABLE; INJECTION

TROVAN PRESERVATIVE FREE

PFIZER

EQ 200MG BASE/VIAL

N020760 001 Dec 18, 1997

EQ 300MG BASE/VIAL

N020760 002 Dec 18, 1997

ALBENDAZOLE

TABLET, CHEWABLE; ORAL

ALBENZA

AMEDRA PHARMS LLC

200MG

N207844 001 Jun 11, 2015

ALBUMIN CHROMATED CR-51 SERUM

INJECTABLE; INJECTION

CHROMALBIN

ISO TEX

100uCi/VIAL

N017835 001

250uCi/VIAL

N017835 002

500uCi/VIAL

N017835 003

ALBUMIN IODINATED I-125 SERUM

INJECTABLE; INJECTION

RADIO-IODINATED (I 125) SERUM ALBUMIN (HUMAN)

BAYER PHARMS

2.5uCi/AMP

N017846 001

RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 125

MALLINCKRODT

6.67uCi/ML

N017844 003

10uCi/ML

N017844 001

100uCi/ML

N017844 002

ALBUMIN IODINATED I-131 SERUM

INJECTABLE; INJECTION

MEGATOPE

ISO TEX

2mCi/VIAL

N017837 003

5uCi/AMP

N017837 004

20uCi/AMP

N017837 005

ALBUTEROL

AEROSOL, METERED; INHALATION

ALBUTEROL

ARMSTRONG PHARMS

0.09MG/INH

A072273 001 Aug 14, 1996

GENPHARM

0.09MG/INH

A073045 001 Aug 19, 1997

IVAX SUB TEVA PHARMS

0.09MG/INH

A073272 001 Dec 28, 1995

PLIVA

0.09MG/INH

A074072 001 Aug 01, 1996

PROVENTIL

SCHERING

0.09MG/INH

N017559 001

VENTOLIN

GLAXOSMITHKLINE

0.09MG/INH

N018473 001

ALBUTEROL SULFATE

CAPSULE; INHALATION

VENTOLIN ROTACAPS

GLAXOSMITHKLINE

EQ 0.2MG BASE

N019489 001 May 04, 1988

SOLUTION; INHALATION

ALBUTEROL SULFATE

ACTAVIS MID ATLANTIC

EQ 0.083% BASE

A073533 001 Sep 26, 1995

APOTEX INC

EQ 0.021% BASE

A078623 001 Apr 05, 2010

EQ 0.042% BASE

A078623 002 Apr 05, 2010

EQ 0.083% BASE

A075717 001 Feb 02, 2007

EQ 0.5% BASE

A076391 001 Apr 01, 2003

BAUSCH AND LOMB

EQ 0.083% BASE

A075358 001 Mar 29, 2000

COPLEY PHARM

EQ 0.083% BASE

A073495 001 May 28, 1993

EQ 0.5% BASE

A073307 001 Nov 27, 1991

HI TECH PHARMA

EQ 0.083% BASE

A075063 001 Feb 09, 1999

LANDELA PHARM

EQ 0.083% BASE

A077569 001 Apr 04, 2006

MYLAN SPECLT

EQ 0.083% BASE **Federal Register

A072652 001 Feb 21, 1992

determination that product was not
discontinued or withdrawn for safety or

DISCONTINUED DRUG PRODUCT LIST

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

		efficacy reasons**			
	ROXANE	EQ 0.083% BASE	A075129	001	Feb 13, 2001
	TEVA PHARMS	EQ 0.083% BASE	A075343	001	Nov 09, 1999
	WATSON LABS INC	EQ 0.083% BASE	A076370	001	Nov 24, 2003
	WOCKHARDT EU OPERATN	EQ 0.083% BASE	A075394	001	Nov 22, 1999
	PROVENTIL				
	SCHERING	EQ 0.083% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019243	002	Jan 14, 1987
		EQ 0.5% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019243	001	Jan 14, 1987
	VENTOLIN				
	GLAXOSMITHKLINE	EQ 0.083% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019773	001	Apr 23, 1992
		EQ 0.5% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019269	002	Jan 16, 1987
	SYRUP; ORAL				
	ALBUTEROL SULFATE				
	ACTAVIS MID ATLANTIC	EQ 2MG BASE/5ML	A075262	001	Mar 30, 1999
	MOVA	EQ 2MG BASE/5ML	A074302	001	Sep 30, 1994
	WATSON LABS	EQ 2MG BASE/5ML	A073165	001	Apr 29, 1993
	PROVENTIL				
	SCHERING	EQ 2MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018062	001	Jan 19, 1983
	VENTOLIN				
	GLAXOSMITHKLINE	EQ 2MG BASE/5ML	N019621	001	Jun 10, 1987
	TABLET; ORAL				
	ALBUTEROL SULFATE				
	AM THERAP	EQ 2MG BASE	A072449	001	Dec 05, 1989
		EQ 4MG BASE	A072450	001	Dec 05, 1989
	COPLEY PHARM	EQ 2MG BASE	A072966	001	Nov 22, 1991
		EQ 4MG BASE	A072967	001	Nov 22, 1991
	DAVA PHARMS INC	EQ 2MG BASE	A072860	002	Dec 20, 1989
		EQ 4MG BASE	A072860	001	Dec 20, 1989
	PLIVA	EQ 2MG BASE	A072316	001	Dec 05, 1989
		EQ 4MG BASE	A072317	001	Dec 05, 1989
	SANDOZ	EQ 2MG BASE	A072151	001	Dec 05, 1989
		EQ 4MG BASE	A072152	001	Dec 05, 1989
	TEVA	EQ 2MG BASE	A072619	001	Dec 05, 1989
		EQ 2MG BASE	A072779	001	Jun 25, 1993
		EQ 2MG BASE	A072938	001	Mar 30, 1990
		EQ 4MG BASE	A072620	001	Dec 05, 1989
		EQ 4MG BASE	A072780	001	Jun 25, 1993
		EQ 4MG BASE	A072939	001	Mar 30, 1990
	UCB INC	EQ 2MG BASE	A073120	001	Sep 29, 1992
		EQ 4MG BASE	A073121	001	Sep 29, 1992
	WARNER CHILCOTT	EQ 2MG BASE	A072817	001	Jan 09, 1990
		EQ 4MG BASE	A072818	001	Jan 09, 1990
	WATSON LABS	EQ 2MG BASE	A072629	001	Jan 31, 1991
		EQ 2MG BASE	A072764	001	Aug 28, 1991
		EQ 4MG BASE	A072630	001	Jan 31, 1991
		EQ 4MG BASE	A072765	001	Aug 28, 1991
	PROVENTIL				
	SCHERING	EQ 2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017853	001	May 07, 1982
		EQ 4MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017853	002	May 07, 1982
	VENTOLIN				
	GLAXOSMITHKLINE	EQ 2MG BASE	N019112	001	Jul 10, 1986

DISCONTINUED DRUG PRODUCT LIST

ALBUTEROL SULFATE

TABLET;ORAL

VENTOLIN

EQ 4MG BASE

N019112 002 Jul 10, 1986

TABLET, EXTENDED RELEASE;ORAL

PROVENTIL

SCHERING

EQ 4MG BASE

N019383 001 Jul 13, 1987

VOLMAX

MURO

EQ 4MG BASE

N019604 002 Dec 23, 1992

EQ 8MG BASE

N019604 001 Dec 23, 1992

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

COMBIVENT

BOEHRINGER INGELHEIM

EQ 0.09MG BASE/INH;0.018MG/INH

N020291 001 Oct 24, 1996

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

APOTEX INC

EQ 0.083% BASE;0.017%

A077117 001 Dec 31, 2007

SANDOZ INC

EQ 0.083% BASE;0.017%

A076867 001 Dec 21, 2006

DUONEB

MYLAN SPECLT

EQ 0.083% BASE;0.017% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N020950 001 Mar 21, 2001

ALCLOMETASONE DIPROPIONATE

CREAM; TOPICAL

ACLOVATE

FOUGERA PHARMS

0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N018707 001 Dec 14, 1982

OINTMENT; TOPICAL

ACLOVATE

FOUGERA PHARMS

0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N018702 001 Dec 14, 1982

ALCOHOL

INJECTABLE; INJECTION

ALCOHOL 5% IN DEXTROSE 5%

MILES

5ML/100ML

A083483 001

ALCOHOL; DEXTROSE

INJECTABLE; INJECTION

ALCOHOL 10% AND DEXTROSE 5%

B BRAUN

10ML/100ML;5GM/100ML

N004589 006

ALCOHOL 5% AND DEXTROSE 5%

B BRAUN

5ML/100ML;5GM/100ML

N004589 004

ALCOHOL 5% IN D5-W

HOSPIRA

5ML/100ML;5GM/100ML

A083263 001

ALCOHOL 5% IN DEXTROSE 5% IN WATER

BAXTER HLTHCARE

5ML/100ML;5GM/100ML

A083256 001

ALENDRONATE SODIUM

SOLUTION; ORAL

FOSAMAX

MERCK

EQ 70MG BASE/75ML

N021575 001 Sep 17, 2003

TABLET; ORAL

ALENDRONATE SODIUM

MYLAN

EQ 35MG BASE

A078638 001 Aug 04, 2008

EQ 70MG BASE

A078638 002 Aug 04, 2008

TEVA PHARMS

EQ 35MG BASE

A076184 002 Aug 04, 2008

EQ 70MG BASE

A076184 001 Feb 06, 2008

UPSHER-SMITH LABS

EQ 5MG BASE

A075871 001 Apr 22, 2009

EQ 10MG BASE

A075871 002 Apr 22, 2009

EQ 35MG BASE

A075871 004 Apr 22, 2009

EQ 40MG BASE

A075871 003 Apr 22, 2009

EQ 70MG BASE

A075871 005 Apr 22, 2009

FOSAMAX

MERCK AND CO INC

EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N020560 003 Apr 25, 1997

EQ 10MG BASE **Federal Register

N020560 001 Sep 29, 1995

determination that product was not

DISCONTINUED DRUG PRODUCT LIST

ALENDRONATE SODIUM

TABLET; ORAL

FOSAMAX

discontinued or withdrawn for safety or efficacy reasons**

EQ 35MG BASE **Federal Register

N020560 004 Oct 20, 2000

determination that product was not discontinued or withdrawn for safety or efficacy reasons**

EQ 40MG BASE **Federal Register

N020560 002 Sep 29, 1995

determination that product was not discontinued or withdrawn for safety or efficacy reasons**

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALFUZOSIN HYDROCHLORIDE

WOCKHARDT LTD 10MG

A090221 001 Aug 10, 2012

ALGLUCERASE

INJECTABLE; INJECTION

CEREDASE

GENZYME 10 UNITS/ML

N020057 004 May 08, 1992

80 UNITS/ML

N020057 003 Apr 05, 1991

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE

TABLET; ORAL

TEKAMLO

NOVARTIS EQ 150MG BASE; EQ 5MG BASE

N022545 001 Aug 26, 2010

EQ 150MG BASE; EQ 10MG BASE

N022545 002 Aug 26, 2010

EQ 300MG BASE; EQ 5MG BASE

N022545 003 Aug 26, 2010

EQ 300MG BASE; EQ 10MG BASE

N022545 004 Aug 26, 2010

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMTURNIDE

NOVARTIS EQ 150MG BASE; EQ 5MG BASE; 12.5MG

N200045 001 Dec 21, 2010

EQ 300MG BASE; EQ 5MG BASE; 12.5MG

N200045 002 Dec 21, 2010

EQ 300MG BASE; EQ 5MG BASE; 25MG

N200045 003 Dec 21, 2010

EQ 300MG BASE; EQ 10MG BASE; 12.5MG

N200045 004 Dec 21, 2010

EQ 300MG BASE; EQ 10MG BASE; 25MG

N200045 005 Dec 21, 2010

ALISKIREN HEMIFUMARATE; VALSARTAN

TABLET; ORAL

VALTURNIA

NOVARTIS EQ 150MG BASE; 160MG

N022217 001 Sep 16, 2009

EQ 300MG BASE; 320MG

N022217 002 Sep 16, 2009

ALKAVERVIR

TABLET; ORAL

VERILOID

3M 2MG

N007336 002

3MG

N007336 003

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

MUTUAL PHARM 100MG

A070466 001 Dec 24, 1985

300MG

A070467 001 Dec 24, 1985

PURACAP PHARM 100MG

A070150 001 Dec 10, 1985

300MG

A070147 001 Dec 10, 1985

PUREPAC PHARM 100MG

A070579 001 Apr 14, 1986

300MG

A070580 001 Apr 14, 1986

SANDOZ 100MG

A070268 001 Dec 31, 1985

300MG

A070269 001 Dec 31, 1985

SUPERPHARM 100MG

A070950 001 Nov 30, 1988

300MG

A070951 001 Nov 30, 1988

WATSON LABS 100MG

N018241 001 Nov 16, 1984

100MG

N018785 001 Sep 28, 1984

300MG

N018241 002 Nov 16, 1984

300MG

N018785 002 Sep 28, 1984

LOPURIN

ABBOTT 100MG

N018297 001

300MG

N018297 002

DISCONTINUED DRUG PRODUCT LIST

ALPRAZOLAM

SOLUTION; ORAL

ALPRAZOLAM

ROXANE

0.5MG/5ML

A074314 001 Oct 31, 1993

TABLET; ORAL

ALPRAZOLAM

ANI PHARMS INC

0.25MG

A074085 001 Feb 16, 1994

0.5MG

A074085 002 Feb 16, 1994

1MG

A074085 003 Feb 16, 1994

2MG

A074085 004 Feb 26, 1996

IVAX SUB TEVA PHARMS

0.25MG

A074294 001 Jul 29, 1994

0.5MG

A074294 002 Jul 29, 1994

1MG

A074294 003 Jul 29, 1994

2MG

A074294 004 Jul 29, 1994

ROXANE

0.25MG

A074199 001 Oct 19, 1993

0.5MG

A074199 002 Oct 19, 1993

1MG

A074199 003 Oct 19, 1993

WATSON LABS

0.25MG

A074456 001 Aug 31, 1995

0.25MG

A074479 001 Jan 21, 1997

0.5MG

A074456 002 Aug 31, 1995

0.5MG

A074479 002 Jan 21, 1997

1MG

A074456 003 Aug 31, 1995

1MG

A074479 003 Jan 21, 1997

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

ACTAVIS LABS FL INC

0.5MG

A077198 001 May 13, 2010

1MG

A077198 002 May 13, 2010

2MG

A077198 003 May 13, 2010

3MG

A077198 004 May 13, 2010

ANI PHARMS INC

0.5MG

A077979 001 Feb 28, 2007

1MG

A077979 002 Feb 28, 2007

2MG

A077979 003 Feb 28, 2007

3MG

A077979 004 Feb 28, 2007

COREPHARMA

0.5MG

A077996 001 Jan 31, 2007

1MG

A077996 002 Jan 31, 2007

2MG

A077996 003 Jan 31, 2007

3MG

A077996 004 Jan 31, 2007

IMPAX LABS

0.5MG

A077968 004 May 24, 2007

1MG

A077968 003 May 24, 2007

2MG

A077968 002 May 24, 2007

3MG

A077968 001 May 24, 2007

SANDOZ INC

0.5MG

A077777 001 Jun 30, 2006

1MG

A077777 002 Jun 30, 2006

2MG

A077777 003 Jun 30, 2006

3MG

A077777 004 Jun 30, 2006

VINTAGE PHARMS

0.5MG

A078442 001 Oct 15, 2007

1MG

A078442 002 Oct 15, 2007

2MG

A078442 003 Oct 15, 2007

3MG

A078442 004 Oct 15, 2007

TABLET, ORALLY DISINTEGRATING; ORAL

NIRAVAM

UCB INC

0.25MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021726 001 Jan 19, 2005

0.5MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021726 002 Jan 19, 2005

1MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021726 003 Jan 19, 2005

2MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021726 004 Jan 19, 2005

DISCONTINUED DRUG PRODUCT LIST

ALPROSTADIL

INJECTABLE; INJECTION

CAVERJECT

PFIZER

0.005MG/ML

N020755 001 Oct 31, 1997

0.01MG/ML

N020755 002 Oct 01, 1997

0.02MG/ML

N020755 003 Oct 01, 1997

EDEX

AUXILIUM PHARMS INC

0.005MG/VIAL

N020649 001 Jun 12, 1997

ALSEROXYLON

TABLET; ORAL

RAUTENSIN

NOVARTIS

2MG

N009215 001

RAUWILOID

3M

2MG

N008867 001

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE; ORAL

ALUMINUM HYDROXIDE AND MAGNESIUM TRISILICATE

PENNEX

80MG;20MG

A089449 001 Nov 27, 1987

FOAMICON

NOVARTIS

80MG;20MG

A072687 001 Jun 28, 1989

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

ACTAVIS ELIZABETH

100MG

A077659 001 Feb 23, 2006

WATSON LABS

100MG

A071382 001 Jan 21, 1987

SYMADINE

SOLVAY

100MG

A071000 001 Sep 04, 1986

SYMMETREL

ENDO PHARMS

100MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N016020 001

SYRUP; ORAL

AMANTADINE HYDROCHLORIDE

G AND W LABS INC

50MG/5ML

A072655 001 Oct 30, 1990

SILARX

50MG/5ML

A076352 001 Sep 10, 2004

TEVA PHARMS

50MG/5ML

A073115 001 Aug 23, 1991

VINTAGE

50MG/5ML

A077992 001 Dec 12, 2006

SYMMETREL

ENDO PHARMS

50MG/5ML

N016023 002

TABLET; ORAL

SYMMETREL

ENDO PHARMS

100MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N018101 001

AMBENONIUM CHLORIDE

TABLET; ORAL

MYTELASE

SANOFI AVENTIS US

10MG

N010155 002

AMCINONIDE

CREAM; TOPICAL

CYCLOCORT

ASTELLAS

0.025%

N018116 001

0.1%

N018116 002

LOTION; TOPICAL

CYCLOCORT

ASTELLAS

0.1%

N019729 001 Jun 13, 1988

OINTMENT; TOPICAL

CYCLOCORT

ASTELLAS

0.1%

N018498 001

AMDINOCILLIN

INJECTABLE; INJECTION

COACTIN

ROCHE

250MG/VIAL

N050565 001 Dec 21, 1984

500MG/VIAL

N050565 002 Dec 21, 1984

1GM/VIAL

N050565 003 Dec 21, 1984

DISCONTINUED DRUG PRODUCT LIST

AMIFOSTINE

INJECTABLE; INJECTION

ETHYOL

CLINIGEN HLTHCARE 375MG/VIAL N020221 002 Sep 10, 1999

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

ABBOTT EQ 250MG BASE/ML A063265 001 Nov 30, 1994

EQ 250MG BASE/ML A063266 001 Oct 31, 1994

HOSPIRA EQ 50MG BASE/ML A063263 001 Nov 30, 1994

EQ 50MG BASE/ML A063350 001 Jul 30, 1993

EQ 62.5MG BASE/ML A063283 001 Oct 31, 1994

EQ 250MG BASE/ML A063264 001 Nov 30, 1994

EQ 250MG BASE/ML A063350 002 Jul 30, 1993

EQ 250MG BASE/ML A064098 001 Jun 26, 1995

EQ 250MG BASE/ML A064099 001 Jun 20, 1995

IGI LABS INC EQ 50MG BASE/ML A063167 001 Dec 14, 1995

EQ 250MG BASE/ML A063169 001 Dec 14, 1995

TEVA PHARMS USA EQ 50MG BASE/ML A064045 001 Sep 28, 1993

WEST-WARD PHARMS INT EQ 50MG BASE/ML A063274 001 May 18, 1992

EQ 250MG BASE/ML A063275 001 May 18, 1992

AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

HOSPIRA EQ 500MG BASE/100ML A064146 001 Apr 02, 1997

AMIKIN

APOTHECON EQ 50MG BASE/ML A062311 001

EQ 50MG BASE/ML A062562 001 Sep 20, 1984

EQ 50MG BASE/ML **Federal Register

determination that product was not

discontinued or withdrawn for safety or

efficacy reasons**

EQ 250MG BASE/ML A062311 002

EQ 250MG BASE/ML A062562 002 Sep 20, 1984

EQ 250MG BASE/ML **Federal Register

determination that product was not

discontinued or withdrawn for safety or

efficacy reasons**

AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

APOTHECON EQ 5MG BASE/ML N050618 002 Nov 30, 1987

EQ 10MG BASE/ML N050618 001 Nov 30, 1987

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

SANDOZ EQ 5MG ANHYDROUS; 50MG A073357 001 Nov 27, 1991

TEVA EQ 5MG ANHYDROUS; 50MG A070795 001 Apr 17, 1988

WATSON LABS EQ 5MG ANHYDROUS; 50MG A073334 001 Jul 19, 1991

HYDRO-RIDE

PAR PHARM EQ 5MG ANHYDROUS; 50MG A070347 001 Dec 25, 1990

MODURETIC 5-50

MERCK EQ 5MG ANHYDROUS; 50MG **Federal

Register determination that product was

not discontinued or withdrawn for

safety or efficacy reasons**

AMINO ACIDS

INJECTABLE; INJECTION

AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE

HOSPIRA 5.2% (5.2GM/100ML) N018901 001 Apr 06, 1984

AMINOSYN 3.5% IN PLASTIC CONTAINER

ABBOTT 3.5% (3.5GM/100ML) N018804 001 May 15, 1984

3.5% (3.5GM/100ML) N018875 001 Aug 08, 1984

AMINOSYN II 3.5%

HOSPIRA 3.5% (3.5GM/100ML) N019438 001 Apr 03, 1986

AMINOSYN II 3.5% IN PLASTIC CONTAINER

ABBOTT 3.5% (3.5GM/100ML) N019491 001 Oct 10, 1986

AMINOSYN II 5%

HOSPIRA 5% (5GM/100ML) N019438 002 Apr 03, 1986

AMINOSYN-HBC 7% IN PLASTIC CONTAINER

ABBOTT 7% (7GM/100ML) N019400 001 Jul 23, 1986

BRANCHAMIN 4%

BAXTER HLTHCARE 4% (4GM/100ML) N018678 001 Sep 28, 1984

BRANCHAMIN 4% IN PLASTIC CONTAINER

BAXTER HLTHCARE 4% (4GM/100ML) N018684 001 Sep 28, 1984

DISCONTINUED DRUG PRODUCT LISTAMINO ACIDS

INJECTABLE; INJECTION

FREAMINE 8.5%				
B BRAUN	8.5% (8.5GM/100ML)		N016822	001
FREAMINE II 8.5%				
B BRAUN	8.5% (8.5GM/100ML)		N016822	002
HEPATASOL 8%				
BAXTER HLTHCARE	8% (8GM/100ML)		A020360	001 Apr 04, 1996
NEOPHAM 6.4%				
HOSPIRA	6.4% (6.4GM/100ML)		N018792	001 Jan 17, 1984
NOVAMINE 11.4%				
HOSPIRA INC	11.4% (11.4GM/100ML)		N017957	003 Aug 09, 1982
NOVAMINE 15%				
HOSPIRA INC	15% (75GM/500ML)		N017957	004 Nov 28, 1986
NOVAMINE 15% SULFITE FREE IN PLASTIC CONTAINER				
BAXTER HLTHCARE	15% (15GM/100ML)		N020107	001 Feb 05, 1993
NOVAMINE 8.5%				
HOSPIRA INC	8.5% (8.5GM/100ML)		N017957	002 Aug 09, 1982
RENAMIN W/O ELECTROLYTES				
BAXTER HLTHCARE	6.5% (6.5GM/100ML)		N017493	007 Oct 15, 1982
TRAVASOL 10% W/O ELECTROLYTES				
BAXTER HLTHCARE	10% (10GM/100ML)		N017493	006
TRAVASOL 5.5% W/O ELECTROLYTES				
BAXTER HLTHCARE	5.5% (5.5GM/100ML)		N017493	004
TRAVASOL 8.5% W/O ELECTROLYTES				
BAXTER HLTHCARE	8.5% (8.5GM/100ML)		N017493	005

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	3.5%; 36.8MG/100ML; 25GM/100ML; 51MG/100ML; 22.4MG/100ML; 261MG/100ML; 205MG/100ML		N019714	001 Sep 12, 1988
HOSPIRA INC	3.5%; 36.8MG/100ML; 25GM/100ML; 51MG/100ML; 22.4MG/100ML; 261MG/100ML; 205MG/100ML		N019683	001 Nov 07, 1988
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	4.25%; 36.8MG/100ML; 20GM/100ML; 51MG/100ML; 22.4MG/100ML; 261MG/100ML; 205MG/100ML		N019714	002 Sep 12, 1988
HOSPIRA INC	4.25%; 36.8MG/100ML; 20GM/100ML; 51MG/100ML; 22.4MG/100ML; 261MG/100ML; 205MG/100ML		N019683	002 Nov 07, 1988
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	4.25%; 36.8MG/100ML; 25GM/100ML; 51MG/100ML; 22.4MG/100ML; 261MG/100ML; 205MG/100ML		N019714	004 Sep 12, 1988
HOSPIRA INC	4.25%; 36.8MG/100ML; 25GM/100ML; 51MG/100ML; 22.4MG/100ML; 261MG/100ML; 205MG/100ML		N019683	003 Nov 07, 1988
AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	5%; 36.8MG/100ML; 25GM/100ML; 51MG/100ML; 22.4MG/100ML; 261MG/100ML; 205MG/100ML		N019714	003 Sep 12, 1988
HOSPIRA INC	5%; 36.8MG/100ML; 25GM/100ML; 51MG/100ML; 22.4MG/100ML; 261MG/100ML; 205MG/100ML		N019683	004 Nov 07, 1988

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	3.5%; 25GM/100ML		N019118	001 Oct 11, 1984
AMINOSYN 3.5% W/ DEXTROSE 5% IN PLASTIC CONTAINER				
ABBOTT	3.5%; 5GM/100ML		N019120	001 Oct 11, 1984
AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	4.25%; 25GM/100ML		N019119	001 Oct 11, 1984
AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	3.5%; 25GM/100ML		N019505	002 Nov 07, 1986
HOSPIRA	3.5%; 25GM/100ML		N019713	006 Sep 09, 1988
HOSPIRA	3.5%; 25GM/100ML		N019681	001 Nov 01, 1988
AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER				
ABBOTT	3.5%; 5GM/100ML		N019506	001 Nov 07, 1986
HOSPIRA	3.5%; 5GM/100ML		N019713	002 Sep 09, 1988
HOSPIRA	3.5%; 5GM/100ML		N019681	002 Nov 01, 1988
AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER				
ABBOTT	4.25%; 10GM/100ML		N019713	001 Sep 09, 1988
HOSPIRA	4.25%; 10GM/100ML		N019681	004 Nov 01, 1988

DISCONTINUED DRUG PRODUCT LISTAMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER				
ABBOTT	4.25%;20GM/100ML	N019713	004	Sep 09, 1988
HOSPIRA	4.25%;20GM/100ML	N019681	005	Nov 01, 1988
AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	4.25%;25GM/100ML	N019504	002	Nov 07, 1986
	4.25%;25GM/100ML	N019713	005	Sep 09, 1988
HOSPIRA	4.25%;25GM/100ML	N019681	003	Nov 01, 1988
AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	5%;25GM/100ML	N019565	001	Dec 17, 1986
	5%;25GM/100ML	N019713	003	Sep 09, 1988
HOSPIRA	5%;25GM/100ML	N019681	006	Nov 01, 1988
TRAVASOL 2.75% IN DEXTROSE 10% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%;10GM/100ML	N019520	002	Sep 23, 1988
TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%;15GM/100ML	N019520	003	Sep 23, 1988
TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%;20GM/100ML	N019520	004	Sep 23, 1988
TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%;25GM/100ML	N019520	005	Sep 23, 1988
TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%;5GM/100ML	N019520	001	Sep 23, 1988
TRAVASOL 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;10GM/100ML	N019520	007	Sep 23, 1988
TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;15GM/100ML	N019520	008	Sep 23, 1988
TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;20GM/100ML	N019520	009	Sep 23, 1988
TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;25GM/100ML	N019520	010	Sep 23, 1988
TRAVASOL 4.25% IN DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;5GM/100ML	N019520	006	Sep 23, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER				
ABBOTT	4.25%;10GM/100ML;51MG/100ML;176.5MG/100ML;22.4MG/100ML;104.5MG/100ML;205MG/100ML	N019712	002	Sep 08, 1988
HOSPIRA INC	4.25%;10GM/100ML;51MG/100ML;176.5MG/100ML;22.4MG/100ML;104.5MG/100ML;205MG/100ML	N019682	003	Nov 01, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	3.5%;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019564	002	Dec 16, 1986
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	4.25%;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019564	004	Dec 16, 1986

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER				
ABBOTT	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019564	001	Dec 16, 1986
	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019712	001	Sep 08, 1988
HOSPIRA INC	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019682	001	Nov 01, 1988
AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER				
ABBOTT	4.25%;10GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019564	003	Dec 16, 1986
HOSPIRA INC	4.25%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N019682	002	Nov 01, 1988

DISCONTINUED DRUG PRODUCT LISTAMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER BAXTER HLTHCARE	2.75%;10GM/100ML;51MG/100ML;261MG/100ML ;216MG/100ML;112MG/100ML	N020147 002	Oct 23, 1995
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER BAXTER HLTHCARE	2.75%;15GM/100ML;51MG/100ML;261MG/100ML ;216MG/100ML;112MG/100ML	N020147 003	Oct 23, 1995
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER BAXTER HLTHCARE	2.75%;20GM/100ML;51MG/100ML;261MG/100ML ;216MG/100ML;112MG/100ML	N020147 004	Oct 23, 1995
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER BAXTER HLTHCARE	2.75%;25GM/100ML;51MG/100ML;261MG/100ML ;216MG/100ML;112MG/100ML	N020147 005	Oct 23, 1995
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER BAXTER HLTHCARE	2.75%;5GM/100ML;51MG/100ML;261MG/100ML; 216MG/100ML;112MG/100ML	N020147 001	Oct 23, 1995
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER BAXTER HLTHCARE	4.25%;10GM/100ML;51MG/100ML;261MG/100ML ;297MG/100ML;77MG/100ML	N020147 007	Oct 23, 1995
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER BAXTER HLTHCARE	4.25%;15GM/100ML;51MG/100ML;261MG/100ML ;297MG/100ML;77MG/100ML	N020147 008	Oct 23, 1995
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER BAXTER HLTHCARE	4.25%;20GM/100ML;51MG/100ML;261MG/100ML ;297MG/100ML;77MG/100ML	N020147 009	Oct 23, 1995
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER BAXTER HLTHCARE	4.25%;25GM/100ML;51MG/100ML;261MG/100ML ;297MG/100ML;77MG/100ML	N020147 010	Oct 23, 1995
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER BAXTER HLTHCARE	4.25%;5GM/100ML;51MG/100ML;261MG/100ML; 297MG/100ML;77MG/100ML	N020147 006	Oct 23, 1995

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M IN PLASTIC CONTAINER ABBOTT	3.5%;21MG/100ML;40MG/100ML;128MG/100ML; 234MG/100ML	N018804 002	May 15, 1984
	3.5%;21MG/100ML;40MG/100ML;128MG/100ML; 234MG/100ML	N018875 002	Aug 08, 1984

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M HOSPIRA	3.5%;21MG/100ML;128MG/100ML;234MG/100ML	N017789 005	
----------------------------	---	-------------	--

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN PLASTIC CONTAINER ABBOTT	3.5%;32MG/100ML;128MG/100ML;222MG/100ML ;49MG/100ML	N019493 001	Oct 16, 1986
---	--	-------------	--------------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE; INJECTION

VEINAMINE 8% HOSPIRA INC	8%;61MG/100ML;211MG/100ML;56MG/100ML;38 8MG/100ML	N017957 001	
-----------------------------	--	-------------	--

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 7% W/ ELECTROLYTES HOSPIRA	7%;102MG/100ML;45MG/100ML;522MG/100ML;4 10MG/100ML	N019437 006	Apr 03, 1986
---	---	-------------	--------------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M HOSPIRA	3.5%;30MG/100ML;97MG/100ML;120MG/100ML; 49MG/100ML	N019437 007	Apr 03, 1986
-------------------------------	---	-------------	--------------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER BAXTER HLTHCARE	3.5%;51MG/100ML;131MG/100ML;218MG/100ML ;35MG/100ML	N020177 001	Oct 23, 1995
--	--	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TRAVASOL 3.5% W/ ELECTROLYTES

BAXTER HLTHCARE	3.5%;51MG/100ML;131MG/100ML;218MG/100ML ;35MG/100ML	N017493	003	
-----------------	--	---------	-----	--

TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER

BAXTER HLTHCARE	5.5%;102MG/100ML;522MG/100ML;431MG/100M L;224MG/100ML	N020173	001	Oct 27, 1995
-----------------	--	---------	-----	--------------

TRAVASOL 5.5% W/ ELECTROLYTES

BAXTER HLTHCARE	5.5%;102MG/100ML;522MG/100ML;431MG/100M L;224MG/100ML	N017493	001	
-----------------	--	---------	-----	--

TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER

BAXTER HLTHCARE	8.5%;102MG/100ML;522MG/100ML;594MG/100M L;154MG/100ML	N020173	002	Oct 27, 1995
-----------------	--	---------	-----	--------------

TRAVASOL 8.5% W/ ELECTROLYTES

BAXTER HLTHCARE	8.5%;102MG/100ML;522MG/100ML;594MG/100M L;154MG/100ML	N017493	002	
-----------------	--	---------	-----	--

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMICAR

CLOVER PHARMS	250MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N015229	002	
---------------	--	---------	-----	--

AMINOCAPROIC ACID

ABRAXIS PHARM	250MG/ML	A070522	001	Jun 17, 1986
BAXTER HLTHCARE	250MG/ML	N018590	001	Oct 29, 1982
HOSPIRA	250MG/ML	A070888	001	Jun 16, 1988

AMINOGLUTETHIMIDE

TABLET; ORAL

CYTADREN

NOVARTIS	250MG	N018202	001	
----------	-------	---------	-----	--

AMINOHIPPURATE SODIUM

INJECTABLE; INJECTION

AMINOHIPPURATE SODIUM

MERCK	20%	N005619	001	
-------	-----	---------	-----	--

AMINOPHYLLINE

ENEMA; RECTAL

SOMOPHYLLIN

FISONS	300MG/5ML	N018232	001	Apr 02, 1982
--------	-----------	---------	-----	--------------

INJECTABLE; INJECTION

AMINOPHYLLIN

GD SEARLE LLC	25MG/ML	A087243	001	May 24, 1982
	25MG/ML	A087621	001	May 24, 1982

AMINOPHYLLINE

ABRAXIS PHARM	25MG/ML	A084568	001	
	25MG/ML	A087200	001	
	25MG/ML	A087250	001	Jan 06, 1982
	25MG/ML	A087886	001	Aug 30, 1983
	25MG/ML	A088407	001	Jan 25, 1984
ELKINS SINN	25MG/ML	A087239	001	
HOSPIRA	25MG/ML	A087601	001	Jul 23, 1982
INTL MEDICATION	25MG/ML	A087209	001	Feb 01, 1982
	25MG/ML	A087867	001	Nov 10, 1983
	25MG/ML	A087868	001	Nov 10, 1983
KING PHARMS	25MG/ML	A086606	001	
LUITPOLD	25MG/ML	A087240	001	
LYPHOMED	25MG/ML	A087431	001	
PHARMA SERVE NY	25MG/ML	A087387	001	Jun 03, 1983
	25MG/ML	A087392	001	Dec 15, 1983
SMITH AND NEPHEW	25MG/ML	A088429	001	May 30, 1985
	25MG/ML	A088749	001	May 30, 1985
TEVA PARENTERAL	25MG/ML	A081142	001	Sep 25, 1991

AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%

HOSPIRA	100MG/100ML	A088147	002	May 03, 1983
	200MG/100ML	A088147	003	May 03, 1983

AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

HOSPIRA	100MG/100ML	N018924	001	Dec 12, 1984
	200MG/100ML	N018924	002	Dec 12, 1984
	400MG/100ML	N018924	003	Dec 12, 1984
	500MG/100ML	N018924	004	Dec 12, 1984

DISCONTINUED DRUG PRODUCT LIST

AMINOPHYLLINE

SOLUTION; ORAL

AMINOPHYLLINE

MORTON GROVE	105MG/5ML	A088156 001	Dec 05, 1983
ROXANE	105MG/5ML	A088126 001	Aug 19, 1983

AMINOPHYLLINE DYE FREE

ACTAVIS MID ATLANTIC	105MG/5ML	A087727 001	Apr 16, 1982
----------------------	-----------	-------------	--------------

SOMOPHYLLIN

FISONS	105MG/5ML	A086466 001	
--------	-----------	-------------	--

SOMOPHYLLIN-DF

FISONS	105MG/5ML	A087045 001	
--------	-----------	-------------	--

SUPPOSITORY; RECTAL

TRUPHYLLINE

G AND W LABS	250MG	A085498 001	Mar 23, 1983
	500MG	A085498 002	Jan 03, 1983

TABLET; ORAL

AMINOPHYLLIN

GD SEARLE LLC	100MG	N002386 002	
	200MG	N002386 003	

AMINOPHYLLINE

ASCOT	100MG	A087522 001	Feb 12, 1982
	200MG	A087523 001	Feb 12, 1982
BARR	100MG	A088297 001	Aug 19, 1983
	200MG	A088298 001	Aug 19, 1983
DURAMED PHARMS BARR	100MG	A088182 001	Mar 31, 1983
	200MG	A088183 001	Mar 31, 1983
HALSEY	100MG	A084674 001	
HIKMA INTL PHARMS	100MG	A084540 001	
	200MG	A085003 001	
IDT AUSTRALIA LTD	100MG	A085261 003	
	100MG	A085262 002	
	200MG	A085261 002	
IMPAX LABS	100MG	A084574 001	
	200MG	A084576 001	
KV PHARM	100MG	A085284 001	
	200MG	A085289 001	
LANNETT	100MG	A084588 001	
	200MG	A084588 002	
PAL PAK	100MG	A084533 001	
PANRAY	100MG	A084552 001	
	200MG	A084552 002	
PUREPAC PHARM	100MG	A084699 001	
	200MG	A085333 001	
ROXANE	100MG	A087500 001	Feb 09, 1982
	200MG	A087501 001	Feb 09, 1982
VALEANT PHARM INTL	200MG	A084563 001	
VANGARD	100MG	A088314 001	Oct 03, 1983
	200MG	A088319 001	Oct 03, 1983
VINTAGE PHARMS	100MG	A085409 001	
	200MG	A085410 001	
WATSON LABS	100MG	A085567 001	
	200MG	A085564 001	

TABLET, DELAYED RELEASE; ORAL

AMINOPHYLLINE

IMPAX LABS	100MG	A084577 001	
	200MG	A084575 001	
TABLICAPS	100MG	A084632 002	
VALE	100MG	A084531 001	
	200MG	A084530 001	

TABLET, EXTENDED RELEASE; ORAL

PHYLLOCONTIN

PHARM RES ASSOC	225MG	A086760 001	
-----------------	-------	-------------	--

AMINOSALICYLATE SODIUM

POWDER; ORAL

P.A.S. SODIUM

CENTURY PHARMS	4GM/PACKET	A080947 001	
----------------	------------	-------------	--

SODIUM AMINOSALICYLATE

HEXCEL	100%	A080097 001	
--------	------	-------------	--

TABLET; ORAL

PARASAL SODIUM

PANRAY	500MG	N006811 006	
	1GM	N006811 011	

DISCONTINUED DRUG PRODUCT LIST

AMINOSALICYLATE SODIUM

TABLET; ORAL

SODIUM P.A.S.

LANNETT

500MG

A080138 002

TEEBACIN

CONSOLIDATED MIDLAND

500MG

N007320 002

AMINOSALICYLATE SODIUM; AMINOSALICYLIC ACID

TABLET; ORAL

NEOPASALATE

MEDPOINTE PHARM HLC

846MG;112MG

A080059 002

AMINOSALICYLIC ACID

TABLET; ORAL

PARASAL

PANRAY

500MG

N006811 001

1GM

N006811 002

AMINOSALICYLIC ACID RESIN COMPLEX

POWDER; ORAL

REZIPAS

BRISTOL MYERS SQUIBB

EQ 500MG BASE/GM

N009052 001

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

BEDFORD

50MG/ML

A076018 001 Oct 15, 2002

BEDFORD LABS

50MG/ML

A076299 001 Oct 24, 2002

BEN VENUE

50MG/ML

A076088 001 Oct 15, 2002

HOSPIRA

50MG/ML

A076108 001 Oct 15, 2002

INTL MEDICATION SYS

50MG/ML

N021594 001 Feb 04, 2004

PAR STERILE PRODUCTS

50MG/ML

A076394 001 Apr 25, 2003

TEVA PHARMS USA

50MG/ML

A076163 001 Sep 05, 2003

CORDARONE

WYETH PHARMS INC

50MG/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020377 001 Aug 03, 1995

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

TEVA

200MG

A074895 001 Apr 16, 1999

AMITRIPTYLINE HYDROCHLORIDE

CONCENTRATE; ORAL

ENDEP

ROCHE

40MG/ML

A085749 001

INJECTABLE; INJECTION

AMITRIPTYLINE HYDROCHLORIDE

WATSON LABS

10MG/ML

A085594 001

ELAVIL

ASTRAZENECA

10MG/ML

N012704 001

TABLET; ORAL

AMITID

BRISTOL MYERS SQUIBB

10MG

A086454 001

25MG

A086454 002

50MG

A086454 003

75MG

A086454 004

100MG

A086454 005

AMITRIL

WARNER CHILCOTT

10MG

A083939 001

25MG

A083937 001

50MG

A083938 002

75MG

A084957 001

100MG

A085093 001

150MG

A086295 001

AMITRIPTYLINE HYDROCHLORIDE

AM THERAP

25MG

A088672 001 Nov 20, 1984

50MG

A088673 001 Nov 20, 1984

75MG

A088674 001 Nov 20, 1984

100MG

A088675 001 Nov 20, 1984

ANI PHARMS INC

10MG

A085031 002

25MG

A085031 001

50MG

A085031 003

75MG

A085031 004

COPLEY PHARM

10MG

A088421 001 Apr 30, 1984

DISCONTINUED DRUG PRODUCT LIST

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

	25MG	A088422	001	Apr 30, 1984
	50MG	A088423	001	Apr 30, 1984
	75MG	A088424	001	Apr 30, 1984
	100MG	A088425	001	Apr 30, 1984
	150MG	A088426	001	Apr 30, 1984
HALSEY	10MG	A085923	001	
	25MG	A085922	001	
	50MG	A085925	001	
	50MG	A087557	001	Mar 05, 1982
	75MG	A085926	001	May 20, 1983
	100MG	A085927	001	May 20, 1983
LEDERLE	10MG	A086744	001	
	10MG	A087366	001	Jan 04, 1982
	25MG	A086746	001	
	25MG	A087367	001	May 03, 1982
	50MG	A086743	001	
	50MG	A087181	001	Jan 04, 1982
	75MG	A086745	001	
	75MG	A087369	001	Jan 04, 1982
	100MG	A086747	001	
	100MG	A087368	001	May 03, 1982
	150MG	A087370	001	Jan 04, 1982
MUTUAL PHARM	10MG	A085744	001	
	25MG	A085627	001	
	50MG	A085745	001	
	75MG	A085743	001	
	100MG	A085742	002	May 11, 1982
	150MG	A089423	001	Feb 17, 1987
PAR PHARM	10MG	A088697	001	Sep 25, 1984
	25MG	A088698	001	Sep 25, 1984
	50MG	A088699	001	Sep 25, 1984
	75MG	A088700	001	Sep 25, 1984
	100MG	A088701	001	Sep 25, 1984
	150MG	A088702	001	Sep 25, 1984
PLIVA	10MG	A088883	001	Sep 26, 1984
	25MG	A088884	001	Sep 26, 1984
	50MG	A088885	001	Sep 26, 1984
	75MG	A088886	001	Sep 26, 1984
	100MG	A088887	001	Sep 26, 1984
	150MG	A088888	001	Sep 26, 1984
PUREPAC PHARM	10MG	A088075	001	Sep 16, 1983
	10MG	A088084	001	Jul 18, 1983
	25MG	A088076	001	May 20, 1983
	25MG	A088085	001	Jul 18, 1983
	50MG	A088077	001	Sep 16, 1983
	50MG	A088105	001	Jul 18, 1983
	75MG	A088078	001	Sep 16, 1983
	75MG	A088106	001	Jul 18, 1983
	100MG	A088079	001	Sep 16, 1983
	100MG	A088107	001	Jul 18, 1983
ROXANE	10MG	A086002	001	
	10MG	A086144	001	
	25MG	A085944	001	
	25MG	A086145	001	
	50MG	A085945	001	
	50MG	A086143	001	
	75MG	A086004	001	
	75MG	A086147	001	
	100MG	A086003	001	
	100MG	A086146	001	
	150MG	A086090	001	
	150MG	A086148	001	
SUN PHARM INDS INC	10MG	A040816	002	Jun 27, 2008
	10MG	A089399	002	Jul 14, 1987
	25MG	A040816	001	Jun 27, 2008
	25MG	A089399	001	Jul 14, 1987
	50MG	A040816	003	Jun 27, 2008
	50MG	A089399	003	Jul 14, 1987
	75MG	A040816	004	Jun 27, 2008

DISCONTINUED DRUG PRODUCT LIST

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

	75MG	A089399 004	Jul 14, 1987
	100MG	A040816 005	Jun 27, 2008
	100MG	A089399 005	Jul 14, 1987
	150MG	A040816 006	Jun 27, 2008
	150MG	A089399 006	Jul 14, 1987
SUPERPHARM	10MG	A088853 001	Nov 13, 1984
	25MG	A088854 001	Nov 13, 1984
	50MG	A088855 001	Nov 13, 1984
	75MG	A088856 001	Nov 13, 1984
	100MG	A088857 001	Nov 13, 1984
TEVA	10MG	A086610 001	
	25MG	A086859 001	
	50MG	A086857 001	
	75MG	A086860 001	
	100MG	A085836 001	
	100MG	A086854 001	
	150MG	A086853 001	
UCB INC	10MG	A085864 001	
	25MG	A085935 001	
	50MG	A085936 001	
	75MG	A086337 001	
	100MG	A086336 001	
	150MG	A086335 001	
USL PHARMA	25MG	A087775 001	Feb 10, 1982
VANGARD	10MG	A087632 001	Feb 01, 1982
	50MG	A087616 001	Feb 08, 1982
	75MG	A087617 001	Feb 05, 1982
	100MG	A087639 001	Feb 08, 1982
WATSON LABS	10MG	A085816 001	
	10MG	A088620 001	Mar 02, 1984
	25MG	A085817 001	
	25MG	A088621 001	Mar 02, 1984
	50MG	A085815 001	
	50MG	A088622 001	Mar 02, 1984
	75MG	A085819 001	
	75MG	A088633 001	Mar 02, 1984
	100MG	A085820 001	
	100MG	A088634 001	Mar 02, 1984
	150MG	A085821 001	
	150MG	A088635 001	Mar 02, 1984
WEST WARD	10MG	A087647 001	Mar 05, 1982
	25MG	A087278 001	
ELAVIL			
ASTRAZENECA	10MG	N012703 001	
	25MG	N012703 003	
	50MG	N012703 004	
	75MG	N012703 005	
	100MG	N012703 006	
	150MG	N012703 007	
ENDEP			
ROCHE	10MG	A083639 001	
	25MG	A083639 002	
	50MG	A083639 003	
	75MG	A083639 004	
	100MG	A083639 005	
	150MG	A085303 001	

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

FRONTIDA BIOPHARM	EQ 12.5MG BASE;5MG	A070765 001	Dec 10, 1986
	EQ 25MG BASE;10MG	A070766 001	Dec 10, 1986
PAR PHARM	EQ 12.5MG BASE;5MG	A072277 001	May 09, 1988
	EQ 25MG BASE;10MG	A072278 001	May 09, 1988
USL PHARMA	EQ 12.5MG BASE;5MG	A070477 001	Jan 12, 1988
	EQ 25MG BASE;10MG	A070478 001	Jan 12, 1988
WATSON LABS	EQ 12.5MG BASE;5MG	A072052 001	Dec 16, 1988
	EQ 25MG BASE;10MG	A072053 001	Dec 16, 1988

DISCONTINUED DRUG PRODUCT LISTAMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

LIMBITROL

HERITAGE PHARMS INC EQ 12.5MG BASE;5MG N016949 001

LIMBITROL DS

HERITAGE PHARMS INC EQ 25MG BASE;10MG **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons** N016949 002AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

ETRAFON 2-10

SCHERING 10MG;2MG N014713 007

ETRAFON 2-25

SCHERING 25MG;2MG N014713 004

ETRAFON-A

SCHERING 10MG;4MG N014713 002

ETRAFON-FORTE

SCHERING 25MG;4MG N014713 006

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

IVAX SUB TEVA PHARMS 10MG;2MG A070935 001 Sep 11, 1986

10MG;4MG A070937 001 Sep 11, 1986

25MG;2MG A070936 001 Sep 11, 1986

25MG;4MG A070938 001 Sep 11, 1986

50MG;4MG A070939 001 Sep 12, 1986

PAR PHARM 10MG;2MG A070565 001 Sep 11, 1986

10MG;4MG A070620 001 Sep 11, 1986

25MG;2MG A070621 001 Sep 11, 1986

25MG;4MG A070595 001 Sep 11, 1986

50MG;4MG A070574 001 Sep 11, 1986

SANDOZ 10MG;2MG A071062 001 Nov 27, 1987

10MG;4MG A071862 001 Dec 21, 1987

25MG;2MG A071063 001 Nov 27, 1987

25MG;4MG A071064 001 Nov 27, 1987

50MG;4MG A071863 001 Dec 21, 1987

SUN PHARM INDS 10MG;2MG A071077 001 Nov 12, 1986

10MG;4MG A071078 001 Nov 12, 1986

25MG;2MG A070297 001 Nov 12, 1986

25MG;4MG A071079 001 Nov 12, 1986

WATSON LABS 10MG;2MG A070373 001 Aug 25, 1986

10MG;2MG A072539 001 Feb 15, 1989

10MG;2MG A073007 001 Oct 17, 1991

10MG;4MG A070375 001 Aug 25, 1986

10MG;4MG A072540 001 Feb 15, 1989

10MG;4MG A073009 001 Oct 17, 1991

25MG;2MG A070374 001 Aug 25, 1986

25MG;2MG A072541 001 Feb 15, 1989

25MG;2MG A073008 001 Oct 17, 1991

25MG;4MG A070376 001 Aug 25, 1986

25MG;4MG A072134 001 Feb 15, 1989

25MG;4MG A073010 001 Oct 17, 1991

50MG;4MG A070377 001 Nov 04, 1986

50MG;4MG A071558 001 Mar 02, 1987

50MG;4MG A072135 001 Feb 15, 1989

TRIAVIL 2-10

NEW RIVER 10MG;2MG N014715 004

TRIAVIL 2-25

NEW RIVER 25MG;2MG N014715 002

TRIAVIL 4-10

NEW RIVER 10MG;4MG N014715 003

TRIAVIL 4-25

NEW RIVER 25MG;4MG N014715 005

TRIAVIL 4-50

NEW RIVER 50MG;4MG N014715 006

AMLEXANOX

PASTE; DENTAL

APHTHASOL

ULURU 5% N020511 001 Dec 17, 1996

PATCH; TOPICAL

AMLEXANOX

ULURU 2MG N021727 001 Sep 29, 2004

DISCONTINUED DRUG PRODUCT LISTAMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

GEDEON RICHTER USA	EQ 2.5MG BASE	A077333 001	Jul 17, 2007
	EQ 5MG BASE	A077333 002	Jul 17, 2007
	EQ 10MG BASE	A077333 003	Jul 17, 2007
GENPHARM	EQ 2.5MG BASE	A077362 001	Jul 09, 2007
	EQ 5MG BASE	A077362 002	Jul 09, 2007
	EQ 10MG BASE	A077362 003	Jul 09, 2007
PURACAP PHARM	EQ 2.5MG BASE	A078131 001	Sep 04, 2007
	EQ 5MG BASE	A078131 002	Sep 04, 2007
	EQ 10MG BASE	A078131 003	Sep 04, 2007
SANDOZ	EQ 2.5MG BASE	A076859 001	Sep 10, 2007
	EQ 5MG BASE	A076859 002	Sep 10, 2007
	EQ 10MG BASE	A076859 003	Sep 10, 2007
SUN PHARM INDS	EQ 2.5MG BASE	A078081 001	Jan 31, 2008
	EQ 5MG BASE	A078081 002	Jan 31, 2008
	EQ 10MG BASE	A078081 003	Jan 31, 2008
SYNTHON PHARMS	EQ 2.5MG BASE	A077080 001	Jun 27, 2007
	EQ 5MG BASE	A077080 002	Jun 27, 2007
	EQ 10MG BASE	A077080 003	Jun 27, 2007

TABLET, ORALLY DISINTEGRATING; ORAL

AMLODIPINE BESYLATE

SYNTHON PHARMS	EQ 2.5MG BASE	N022026 001	Sep 27, 2007
	EQ 5MG BASE	N022026 002	Sep 27, 2007
	EQ 10MG BASE	N022026 003	Sep 27, 2007

AMLODIPINE MALEATE

TABLET; ORAL

AMVAZ

DR REDDYS LABS INC	2.5MG	N021435 001	Oct 31, 2003
	5MG	N021435 002	Oct 31, 2003
	10MG	N021435 003	Oct 31, 2003

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

CENTRAL RADIOPHARM	3.75-260mCi/ML	A204539 001	Jun 23, 2015
--------------------	----------------	-------------	--------------

AMMONIUM CHLORIDE

INJECTABLE; INJECTION

AMMONIUM CHLORIDE

ABBOTT	5MEQ/ML	A083130 001	
GD SEARLE LLC	3MEQ/ML	A086205 001	
AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE			
MCGAW	900MG/100ML	N006580 001	
AMMONIUM CHLORIDE 2.14%			
B BRAUN	40MEQ/100ML	A085734 001	

AMMONIUM LACTATE

CREAM; TOPICAL

LAC-HYDRIN

RANBAXY	EQ 12% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020508 001	Aug 29, 1996
---------	--	-------------	--------------

LOTION; TOPICAL

LAC-HYDRIN

RANBAXY	EQ 12% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019155 001	Apr 24, 1985
---------	--	-------------	--------------

AMODIAQUINE HYDROCHLORIDE

TABLET; ORAL

CAMOQUIN HYDROCHLORIDE

PARKE DAVIS	EQ 200MG BASE	N006441 001	
-------------	---------------	-------------	--

AMOXAPINE

TABLET; ORAL

AMOXAPINE

UPSHER-SMITH LABS	25MG	A072943 001	Jun 28, 1991
	50MG	A072944 001	Jun 28, 1991
	100MG	A072878 001	Jun 28, 1991
	150MG	A072879 001	Jun 28, 1991
WATSON LABS	25MG	A072418 001	May 11, 1989

DISCONTINUED DRUG PRODUCT LIST

AMOXAPINE

TABLET; ORAL

AMOXAPINE

50MG	A072419 001	May 11, 1989
100MG	A072420 001	May 11, 1989
150MG	A072421 001	May 11, 1989

ASENDIN

LEDERLE

25MG	N018021 001	
50MG	N018021 002	
100MG	N018021 003	
150MG	N018021 004	

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

LABS ATRAL

250MG	A062528 001	Aug 07, 1985
500MG	A062528 002	Aug 07, 1985

MYLAN

250MG	A062067 001	
500MG	A062067 002	

SUN PHARM INDS LTD

250MG	A065016 001	Apr 08, 1999
500MG	A065016 002	Apr 08, 1999

TEVA

250MG	A062853 001	Dec 22, 1987
250MG	A063030 001	Feb 28, 1989
500MG	A062854 001	Dec 22, 1987
500MG	A063031 001	Feb 28, 1989

AMOXIL

GLAXOSMITHKLINE

250MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050459 001	
500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050459 002	

TRIMOX

APOTHECON

250MG	A061885 001	
250MG	A062098 001	
250MG	A062152 001	
250MG	A063099 001	Mar 20, 1992
500MG	A061885 002	
500MG	A062098 002	
500MG	A062152 002	
500MG	A063099 002	Mar 20, 1992

UTIMOX

PARKE DAVIS

250MG	A062107 001	
500MG	A062107 002	

WYMOX

WYETH AYERST

250MG	A062120 001	
500MG	A062120 002	

FOR SUSPENSION; ORAL

AMOXICILLIN

AM ANTIBIOTICS

125MG/5ML	A062059 001	
250MG/5ML	A062059 002	

MYLAN

125MG/5ML	A062090 001	
250MG/5ML	A062090 002	

SUN PHARM INDS LTD

200MG/5ML	A065113 001	Nov 29, 2002
400MG/5ML	A065113 002	Nov 29, 2002

TEVA

125MG/5ML	A062946 001	Nov 01, 1988
250MG/5ML	A063001 001	Jan 06, 1989

AMOXIL

GLAXOSMITHKLINE

50MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050460 005	
125MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050460 001	
250MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050460 002	

LAROTID

GLAXOSMITHKLINE

50MG/ML **Federal Register determination that product was not	N050460 006	
---	-------------	--

DISCONTINUED DRUG PRODUCT LISTAMOXICILLIN

FOR SUSPENSION;ORAL

LAROTID

discontinued or withdrawn for safety or efficacy reasons**

POLYMOX

APOTHECON

125MG/5ML

A061851 001

125MG/5ML

A062323 001

250MG/5ML

A061851 002

250MG/5ML

A062323 002

TRIMOX

APOTHECON

50MG/ML

A061886 001

125MG/5ML

A061886 002

125MG/5ML

A062099 001

125MG/5ML

A062154 001

125MG/5ML

A062885 001 Mar 08, 1988

250MG/5ML

A061886 003

250MG/5ML

A062099 002

250MG/5ML

A062154 002

250MG/5ML

A062885 002 Mar 08, 1988

UTIMOX

PARKE DAVIS

125MG/5ML

A062127 001

250MG/5ML

A062127 002

WYMOX

WYETH AYERST

125MG/5ML

A062131 001

250MG/5ML

A062131 002

TABLET;ORAL

AMOXICILLIN

DAVA PHARMS INC

875MG

A065344 001 Jan 15, 2009

SUN PHARM INDS LTD

500MG

A065059 001 Nov 24, 2000

875MG

A065059 002 Nov 24, 2000

TABLET, CHEWABLE;ORAL

AMOXICILLIN

APOTHECON

125MG

A064131 001 May 06, 1996

250MG

A064131 002 May 06, 1996

DAVA PHARMS INC

125MG

A064139 001 Jan 29, 1996

250MG

A064139 002 Jan 29, 1996

SUN PHARM INDS LTD

125MG

A065021 001 Dec 23, 1999

200MG

A065060 001 Nov 29, 2000

250MG

A065021 002 Dec 23, 1999

400MG

A065060 002 Nov 29, 2000

TEVA

125MG

A064031 001 Dec 19, 1996

250MG

A064031 002 Dec 19, 1996

AMOXIL

DR REDDYS LABS INC

200MG

N050761 001 Apr 15, 1999

400MG

N050761 002 Apr 15, 1999

TABLET, FOR SUSPENSION;ORAL

AMOXICILLIN

AUROBINDO PHARMA LTD

200MG

A065324 001 Jan 17, 2007

400MG

A065324 002 Jan 17, 2007

DISPERMOX

RANBAXY LABS LTD

200MG

A065080 002 Aug 11, 2003

400MG

A065080 001 Aug 11, 2003

600MG

A065159 001 Dec 04, 2003

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

SUN PHARM INDS LTD

200MG/5ML;EQ 28.5MG BASE/5ML

A065132 001 Mar 19, 2003

400MG/5ML;EQ 57MG BASE/5ML

A065132 002 Mar 19, 2003

600MG/5ML;EQ 42.9MG BASE/5ML

A065207 002 Jan 30, 2007

TABLET;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

APOTEX INC

250MG;EQ 125MG BASE

A065333 001 Feb 24, 2009

500MG;EQ 125MG BASE

A065333 002 Feb 24, 2009

875MG;EQ 125MG BASE

A065317 003 Oct 20, 2008

SUN PHARM INDS LTD

500MG;EQ 125MG BASE

A065109 001 Nov 04, 2002

875MG;EQ 125MG BASE

A065102 001 Sep 17, 2002

TABLET, CHEWABLE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

SANDOZ

200MG;EQ 28.5MG BASE

A065065 001 Apr 18, 2002

400MG;EQ 57MG BASE

A065065 002 Apr 18, 2002

SUN PHARM INDS LTD

200MG;EQ 28.5MG BASE

A065161 001 Dec 03, 2003

DISCONTINUED DRUG PRODUCT LIST

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET, CHEWABLE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM			
400MG;EQ 57MG BASE		A065161 002	Dec 03, 2003
AUGMENTIN '125'			
DR REDDYS LABS INC	125MG;EQ 31.25MG BASE **Federal	N050597 001	Jul 22, 1985
	Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**		
AUGMENTIN '250'			
DR REDDYS LABS INC	250MG;EQ 62.5MG BASE **Federal	N050597 002	Jul 22, 1985
	Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**		

AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE; DEXTROAMPHETAMINE SULFATE

CAPSULE; ORAL

DELCOBESE

TEVA

1.25MG;1.25MG;1.25MG;1.25MG	**Federal	A083564 001	
	Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**		
2.5MG;2.5MG;2.5MG;2.5MG	**Federal	A083564 002	
	Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**		
3.75MG;3.75MG;3.75MG;3.75MG	**Federal	A083564 003	
	Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**		
5MG;5MG;5MG;5MG	**Federal	A083564 004	
	Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**		

TABLET; ORAL

DELCOBESE

TEVA

1.25MG;1.25MG;1.25MG;1.25MG		A083563 004	
2.5MG;2.5MG;2.5MG;2.5MG		A083563 003	
3.75MG;3.75MG;3.75MG;3.75MG		A083563 002	
5MG;5MG;5MG;5MG		A083563 001	

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

ADDERALL 10

TEVA WOMENS

2.5MG;2.5MG;2.5MG;2.5MG	**Federal	N011522 007	Feb 13, 1996
	Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**		

ADDERALL 12.5

TEVA WOMENS

3.125MG;3.125MG;3.125MG;3.125MG		N011522 012	Aug 31, 2000
	Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons		

ADDERALL 15

TEVA WOMENS

3.75MG;3.75MG;3.75MG;3.75MG	**Federal	N011522 013	Aug 31, 2000
	Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**		

ADDERALL 20

TEVA WOMENS

5MG;5MG;5MG;5MG	**Federal	N011522 008	Feb 13, 1996
	Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**		

ADDERALL 30

TEVA WOMENS

7.5MG;7.5MG;7.5MG;7.5MG	**Federal	N011522 010	May 12, 1997
	Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**		

ADDERALL 5

TEVA WOMENS

1.25MG;1.25MG;1.25MG;1.25MG	**Federal	N011522 009	May 12, 1997
	Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**		

ADDERALL 7.5

TEVA WOMENS

1.875MG;1.875MG;1.875MG;1.875MG		N011522 011	Aug 31, 2000
	**Federal Register determination that product was not discontinued or		

DISCONTINUED DRUG PRODUCT LIST

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

ADDERALL 7.5

withdrawn for safety or efficacy
reasons**

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

TEVA PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A040472 001	Sep 30, 2003
	2.5MG;2.5MG;2.5MG;2.5MG	A040472 002	Sep 30, 2003
	5MG;5MG;5MG;5MG	A040472 003	Sep 30, 2003
	7.5MG;7.5MG;7.5MG;7.5MG	A040472 004	Sep 30, 2003

AMPHETAMINE RESIN COMPLEX; DEXTROAMPHETAMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

BIPHETAMINE 12.5

UCB INC	EQ 6.25MG BASE;EQ 6.25MG BASE	N010093 007	
---------	-------------------------------	-------------	--

BIPHETAMINE 20

UCB INC	EQ 10MG BASE;EQ 10MG BASE	N010093 003	
---------	---------------------------	-------------	--

BIPHETAMINE 7.5

UCB INC	EQ 3.75MG BASE;EQ 3.75MG BASE	N010093 009	
---------	-------------------------------	-------------	--

AMPHETAMINE SULFATE

TABLET; ORAL

AMPHETAMINE SULFATE

LANNETT	5MG	A083901 001	Aug 31, 1984
	10MG	A083901 002	Aug 31, 1984

AMPHOTERICIN B

CREAM; TOPICAL

FUNGIZONE

APOTHECON	3%	N050314 001	
-----------	----	-------------	--

INJECTABLE; INJECTION

AMPHOTERICIN B

ABBOTT	50MG/VIAL	A064141 001	Dec 23, 1996
--------	-----------	-------------	--------------

ABRAXIS PHARM	50MG/VIAL	A062728 001	Apr 13, 1987
---------------	-----------	-------------	--------------

TEVA PARENTERAL	50MG/VIAL	A064062 001	Mar 31, 1995
-----------------	-----------	-------------	--------------

FUNGIZONE

APOTHECON	50MG/VIAL	A060517 001	
-----------	-----------	-------------	--

INJECTABLE, LIPID COMPLEX; INJECTION

AMPHOTEC

ALKOPHARMA USA	50MG/VIAL	N050729 001	Nov 22, 1996
----------------	-----------	-------------	--------------

	100MG/VIAL	N050729 002	Nov 22, 1996
--	------------	-------------	--------------

LOTION; TOPICAL

FUNGIZONE

APOTHECON	3%	A060570 001	
-----------	----	-------------	--

OINTMENT; TOPICAL

FUNGIZONE

APOTHECON	3%	N050313 001	
-----------	----	-------------	--

SUSPENSION; ORAL

FUNGIZONE

BRISTOL MYERS SQUIBB	100MG/ML	N050341 003	
----------------------	----------	-------------	--

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

APOTHECON	EQ 125MG BASE/VIAL	A062860 001	Feb 05, 1988
-----------	--------------------	-------------	--------------

	EQ 250MG BASE/VIAL	A062860 002	Feb 05, 1988
--	--------------------	-------------	--------------

	EQ 500MG BASE/VIAL	A062860 003	Feb 05, 1988
--	--------------------	-------------	--------------

	EQ 1GM BASE/VIAL	A062860 004	Feb 05, 1988
--	------------------	-------------	--------------

	EQ 2GM BASE/VIAL	A062860 005	Feb 05, 1988
--	------------------	-------------	--------------

CONSOLIDATED PHARM	EQ 125MG BASE/VIAL	A061936 005	
--------------------	--------------------	-------------	--

	EQ 250MG BASE/VIAL	A061936 001	
--	--------------------	-------------	--

	EQ 500MG BASE/VIAL	A061936 002	
--	--------------------	-------------	--

	EQ 1GM BASE/VIAL	A061936 003	
--	------------------	-------------	--

	EQ 2GM BASE/VIAL	A061936 004	
--	------------------	-------------	--

EUROHLTH INTL SARL	EQ 125MG BASE/VIAL	A062692 001	Jun 24, 1986
--------------------	--------------------	-------------	--------------

	EQ 250MG BASE/VIAL	A062692 002	Jun 24, 1986
--	--------------------	-------------	--------------

	EQ 500MG BASE/VIAL	A062692 003	Jun 24, 1986
--	--------------------	-------------	--------------

	EQ 1GM BASE/VIAL	A062692 004	Jun 24, 1986
--	------------------	-------------	--------------

	EQ 2GM BASE/VIAL	A062692 005	Jun 24, 1986
--	------------------	-------------	--------------

	EQ 10GM BASE/VIAL	A062692 006	Jun 24, 1986
--	-------------------	-------------	--------------

HANFORD GC	EQ 125MG BASE/VIAL	A063143 001	Apr 15, 1993
------------	--------------------	-------------	--------------

	EQ 500MG BASE/VIAL	A063147 001	Apr 15, 1993
--	--------------------	-------------	--------------

	EQ 1GM BASE/VIAL	A063139 001	Apr 15, 1993
--	------------------	-------------	--------------

	EQ 2GM BASE/VIAL	A063141 001	Apr 15, 1993
--	------------------	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

INTL MEDICATION	EQ 1GM BASE/VIAL	A062634 002	Jan 09, 1987
	EQ 2GM BASE/VIAL	A062634 003	Jan 09, 1987
LILLY	EQ 500MG BASE/VIAL	A062565 001	Apr 04, 1985
	EQ 1GM BASE/VIAL	A062565 002	Apr 04, 1985
	EQ 2GM BASE/VIAL	A062565 003	Jun 24, 1986
WATSON LABS INC	EQ 125MG BASE/VIAL	A062816 001	Oct 24, 1988
	EQ 250MG BASE/VIAL	A062816 002	Oct 24, 1988
	EQ 500MG BASE/VIAL	A062816 003	Oct 24, 1988
	EQ 1GM BASE/VIAL	A062816 004	Oct 24, 1988
	EQ 2GM BASE/VIAL	A062816 005	Oct 24, 1988
	EQ 10GM BASE/VIAL	A062994 001	Sep 15, 1988
OMNIPEN-N			
WYETH AYERST	EQ 125MG BASE/VIAL	A060626 001	
	EQ 125MG BASE/VIAL	A062718 001	Dec 16, 1986
	EQ 250MG BASE/VIAL	A060626 002	
	EQ 250MG BASE/VIAL	A062718 002	Dec 16, 1986
	EQ 500MG BASE/VIAL	A060626 003	
	EQ 500MG BASE/VIAL	A062718 003	Dec 16, 1986
	EQ 1GM BASE/VIAL	A060626 004	
	EQ 1GM BASE/VIAL	A062718 004	Dec 16, 1986
	EQ 2GM BASE/VIAL	A060626 005	
	EQ 2GM BASE/VIAL	A062718 005	Dec 16, 1986
PENBRITIN-S			
WYETH AYERST	EQ 125MG BASE/VIAL	N050072 001	
	EQ 250MG BASE/VIAL	N050072 002	
	EQ 500MG BASE/VIAL	N050072 003	
	EQ 1GM BASE/VIAL	N050072 004	
	EQ 2GM BASE/VIAL	N050072 005	
	EQ 4GM BASE/VIAL	N050072 006	
POLYCILLIN-N			
BRISTOL	EQ 125MG BASE/VIAL	N050309 001	
	EQ 250MG BASE/VIAL	N050309 002	
	EQ 500MG BASE/VIAL	N050309 003	
	EQ 1GM BASE/VIAL	N050309 004	
	EQ 2GM BASE/VIAL	N050309 005	
TOTACILLIN-N			
GLAXOSMITHKLINE	EQ 125MG BASE/VIAL	A060677 001	
	EQ 250MG BASE/VIAL	A060677 002	
	EQ 500MG BASE/VIAL	A060677 003	
	EQ 1GM BASE/VIAL	A060677 004	
	EQ 1GM BASE/VIAL	A062727 001	Dec 19, 1986
	EQ 2GM BASE/VIAL	A060677 005	
	EQ 2GM BASE/VIAL	A062727 002	Dec 19, 1986
	EQ 10GM BASE/VIAL	A060677 006	

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

UNASYN

PFIZER	EQ 500MG BASE/VIAL;EQ 250MG BASE/VIAL	N050608 003	Dec 31, 1986
--------	---------------------------------------	-------------	--------------

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMCILL

PARKE DAVIS	EQ 250MG BASE	A062041 001	
	EQ 500MG BASE	A062041 002	
AMPICILLIN TRIHYDRATE			
AM ANTIBIOTICS	EQ 250MG BASE	A061602 001	
	EQ 500MG BASE	A061602 002	
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A060765 001	
	EQ 500MG BASE	A060765 002	
LEDERLE	EQ 250MG BASE	A062208 001	
	EQ 500MG BASE	A062208 002	
MYLAN	EQ 250MG BASE	A061755 001	
	EQ 500MG BASE	A061755 002	
PUREPAC PHARM	EQ 250MG BASE	A061853 001	
	EQ 500MG BASE	A061853 002	
TEVA	EQ 250MG BASE	A061502 001	
	EQ 500MG BASE	A061502 002	
VITARINE	EQ 250MG BASE	A061387 001	
	EQ 500MG BASE	A061387 003	

DISCONTINUED DRUG PRODUCT LIST

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

OMNIPEN (AMPICILLIN)

WYETH AYERST	250MG	A060624	001
	500MG	A060624	002

PENBRITIN

WYETH AYERST	EQ 250MG BASE	A060908	001
	EQ 500MG BASE	A060908	002

PFIZERPEN-A

PFIZER	EQ 250MG BASE	A062050	001
	EQ 500MG BASE	A062050	002

POLYCILLIN

BRISTOL	EQ 250MG BASE	N050310	001
	EQ 500MG BASE	N050310	002

PRINCIPEN

APOTHECON	EQ 250MG BASE	A062888	001	Mar 04, 1988
	EQ 500MG BASE	A062888	002	Mar 04, 1988
BRISTOL MYERS SQUIBB	EQ 250MG BASE	A061392	001	
	EQ 500MG BASE	A061392	002	

PRINCIPEN '250'

APOTHECON	EQ 250MG BASE	A062157	002
	EQ 250MG BASE	N050056	001

PRINCIPEN '500'

APOTHECON	EQ 500MG BASE	A062157	001
	EQ 500MG BASE	N050056	002

TOTACILLIN

GLAXOSMITHKLINE	EQ 250MG BASE	A060060	001
	EQ 250MG BASE	A062212	001
	EQ 500MG BASE	A060060	002
	EQ 500MG BASE	A062212	002

FOR SUSPENSION; ORAL

AMCILL

PARKE DAVIS	EQ 125MG BASE/5ML	A062030	001
	EQ 250MG BASE/5ML	A062030	002

AMPICILLIN TRIHYDRATE

AM ANTIBIOTICS	EQ 125MG BASE/5ML	A061601	001
	EQ 250MG BASE/5ML	A061601	002
MYLAN	EQ 125MG BASE/5ML	A061829	002
	EQ 250MG BASE/5ML	A061829	001
PUREPAC PHARM	EQ 125MG BASE/5ML	A061980	001
	EQ 250MG BASE/5ML	A061980	002
TEVA	EQ 125MG BASE/5ML	A061370	001
	EQ 250MG BASE/5ML	A061370	002

OMNIPEN (AMPICILLIN)

WYETH AYERST	100MG/ML	A060625	001
	125MG/5ML	A060625	002
	250MG/5ML	A060625	003
	500MG/5ML	A060625	004

PENBRITIN

WYETH AYERST	EQ 100MG BASE/ML	N050019	001
	EQ 125MG BASE/5ML	N050019	002
	EQ 250MG BASE/5ML	N050019	003

PFIZERPEN-A

PFIZER	EQ 125MG BASE/5ML	A062049	001
	EQ 250MG BASE/5ML	A062049	002

POLYCILLIN

APOTHECON	EQ 125MG BASE/5ML	A062297	001
	EQ 250MG BASE/5ML	A062297	002
BRISTOL	EQ 100MG BASE/ML	N050308	004
	EQ 125MG BASE/5ML	N050308	001
	EQ 250MG BASE/5ML	N050308	002
	EQ 500MG BASE/5ML	N050308	003

PRINCIPEN

APOTHECON	EQ 100MG BASE/ML	A061394	001
	EQ 125MG BASE/5ML	A061394	002
	EQ 250MG BASE/5ML	A061394	003

PRINCIPEN '125'

APOTHECON	EQ 125MG BASE/5ML	A060127	002
	EQ 125MG BASE/5ML	A062151	001

PRINCIPEN '250'

APOTHECON	EQ 250MG BASE/5ML	A060127	001
	EQ 250MG BASE/5ML	A062151	002

DISCONTINUED DRUG PRODUCT LIST

AMPICILLIN/AMPICILLIN TRIHYDRATE

FOR SUSPENSION;ORAL

TOTACILLIN

GLAXOSMITHKLINE	EQ 125MG BASE/5ML	A060666	001
	EQ 125MG BASE/5ML	A062223	001
	EQ 250MG BASE/5ML	A060666	002
	EQ 250MG BASE/5ML	A062223	002

TABLET, CHEWABLE;ORAL

POLYCILLIN

BRISTOL	EQ 125MG BASE	N050093	001
---------	---------------	---------	-----

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

CAPSULE;ORAL

PRINCIPEN W/ PROBENECID

APOTHECON	EQ 389MG BASE;111MG	A062150	001
	EQ 389MG BASE;111MG	N050488	001

FOR SUSPENSION;ORAL

POLYCILLIN-PRB

APOTHECON	EQ 3.5GM BASE/BOT;1GM/BOT	A061898	001
-----------	---------------------------	---------	-----

BRISTOL	EQ 3.5GM BASE/BOT;1GM/BOT	N050457	001
---------	---------------------------	---------	-----

PROBAMPACIN

G AND W LABS INC	EQ 3.5GM BASE/BOT;1GM/BOT	A061741	001
------------------	---------------------------	---------	-----

AMPRENAVIR

CAPSULE;ORAL

AGENERASE

GLAXOSMITHKLINE	50MG	N021007	001	Apr 15, 1999
	150MG	N021007	002	Apr 15, 1999

SOLUTION;ORAL

AGENERASE

GLAXOSMITHKLINE	15MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021039	001	Apr 15, 1999
-----------------	---	---------	-----	--------------

ANAGRELIDE HYDROCHLORIDE

CAPSULE;ORAL

AGRYLIN

SHIRE LLC	EQ 1MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020333	002	Mar 14, 1997
-----------	---	---------	-----	--------------

ANAGRELIDE HYDROCHLORIDE

ROXANE	EQ 0.5MG BASE	A076489	001	Apr 18, 2005
--------	---------------	---------	-----	--------------

	EQ 1MG BASE	A076489	002	Apr 18, 2005
--	-------------	---------	-----	--------------

UPSHER-SMITH LABS	EQ 0.5MG BASE	A076683	001	Apr 18, 2005
-------------------	---------------	---------	-----	--------------

	EQ 1MG BASE	A076683	002	Apr 18, 2005
--	-------------	---------	-----	--------------

WATSON LABS	EQ 0.5MG BASE	A076417	001	Apr 18, 2005
-------------	---------------	---------	-----	--------------

	EQ 1MG BASE	A076417	002	Apr 18, 2005
--	-------------	---------	-----	--------------

ANASTROZOLE

TABLET;ORAL

ANASTROZOLE

IMPAX LABS INC	1MG	A091242	001	May 31, 2012
----------------	-----	---------	-----	--------------

KREMERS URBAN PHARMS	1MG	A091331	001	Jan 05, 2011
----------------------	-----	---------	-----	--------------

SANDOZ	1MG	A079007	001	Jun 28, 2010
--------	-----	---------	-----	--------------

SYNTHON PHARMS	1MG	A078322	001	Jun 28, 2010
----------------	-----	---------	-----	--------------

WATSON LABS	1MG	A078984	001	Jun 28, 2010
-------------	-----	---------	-----	--------------

ANILERIDINE HYDROCHLORIDE

TABLET;ORAL

LERITINE

MERCK	EQ 25MG BASE	N010585	002
-------	--------------	---------	-----

ANILERIDINE PHOSPHATE

INJECTABLE;INJECTION

LERITINE

MERCK	25MG/ML	N010520	003
-------	---------	---------	-----

ANISINDIONE

TABLET;ORAL

MIRADON

SCHERING	50MG	N010909	003
----------	------	---------	-----

DISCONTINUED DRUG PRODUCT LIST

ANISOTROPINE METHYLBROMIDE

TABLET; ORAL

ANISOTROPINE METHYLBROMIDE

WATSON LABS

50MG

A086046 001

VALPIN 50

ENDO PHARMS

50MG

N013428 001

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

VASOCON-A

NOVARTIS

0.5%; 0.05%

N018746 002 Jul 11, 1994

APOMORPHINE HYDROCHLORIDE

INJECTABLE; SUBCUTANEOUS

APOKYN

US WORLDMEDS

20MG/2ML (10MG/ML)

N021264 001 Apr 20, 2004

APROTININ

INJECTABLE; INJECTION

TRASYLOL

BAYER HLHCARE

10,000KIU/ML

N020304 001 Dec 29, 1993

ARBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

GENESA

GENSIA AUTOMEDICS

0.05MG/ML

N020420 001 Sep 12, 1997

ARDEPARIN SODIUM

INJECTABLE; INJECTION

NORMIFLO

PHARMACIA AND UPJOHN

5,000 UNITS/0.5ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020227 002 May 23, 1997

10,000 UNITS/0.5ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020227 001 May 23, 1997

ARGATROBAN

SOLUTION; IV (INFUSION)

ARGATROBAN IN DEXTROSE

SANDOZ

125MG/125ML (1MG/ML)

N201743 001 May 09, 2011

ARIPIRAZOLE

INJECTABLE; INTRAMUSCULAR

ABILIFY

OTSUKA

9.75MG/1.3ML (7.5MG/ML)

N021866 001 Sep 20, 2006

SOLUTION; ORAL

ABILIFY

OTSUKA

1MG/ML **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021713 001 Dec 10, 2004

TABLET, ORALLY DISINTEGRATING; ORAL

ABILIFY

OTSUKA

10MG

N021729 002 Jun 07, 2006

15MG

N021729 003 Jun 07, 2006

20MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021729 004 Jun 07, 2006

30MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021729 005 Jun 07, 2006

ARMODAFINIL

TABLET; ORAL

ARMODAFINIL

WATSON LABS INC

100MG

A200156 002 Aug 29, 2012

200MG

A200156 004 Aug 29, 2012

NUVIGIL

CEPHALON

100MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021875 002 Mar 26, 2009

DISCONTINUED DRUG PRODUCT LIST

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE; INJECTION

BEROCCA PN

ROCHE

50MG/ML; 0.03MG/ML; 0.0025MG/ML; 7.5MG/ML;
100
IU/ML; 0.2MG/ML; 20MG/ML; 2MG/ML; 1.8MG/ML;

N006071 003 Oct 10, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.C. 9+3

ABRAXIS PHARM

10MG/ML; 0.006MG/ML; 0.5MCG/ML; 1.5MG/ML; 2
0
IU/ML; 0.04MG/ML; 4MG/ML; 0.4MG/ML; 0.36MG/

N018440 002 Aug 08, 1985

M.V.I.-12

HOSPIRA

10MG/ML; 0.006MG/ML; 0.5MCG/ML; 1.5MG/ML; 2
0
IU/ML; 0.04MG/ML; 4MG/ML; 0.4MG/ML; 0.36MG/

N008809 004 Aug 08, 1985

MVC PLUS

WATSON LABS

10MG/ML; 0.006MG/ML; 0.5MCG/ML; 1.5MG/ML; 2
0
IU/ML; 0.04MG/ML; 4MG/ML; 0.4MG/ML; 0.36MG/

N018439 002 Aug 08, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12

HOSPIRA

20MG/ML; 0.006MG/ML; 0.5MCG/ML; 1.5MG/ML; 2
0
IU/ML; 0.6MG/ML; 4MG/ML; 0.4MG/ML; 0.36MG/M

N008809 005 Apr 22, 2004

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12 LYOPHILIZED

TELIGENT PHARMA INC

100MG/VIAL; 0.06MG/VIAL; 0.005MG/VIAL; 15M
G/VIAL; 5MCG/VIAL; 0.4MG/VIAL; 40MG/VIAL; 4
MG/VIAL; 3.6MG/VIAL; 3MG/VIAL; 1MG/VIAL; 10
MG/VIAL

N018933 002 Aug 08, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE; INJECTION

VITAPED

HOSPIRA

N/A, 80MG/VIAL; N/A, 0.02MG/VIAL; N/A, 0.001
MG/VIAL; 400
IU/10ML, N/A; N/A, 0.14MG/VIAL; N/A, 17MG/VI
AL; N/A, 5MG/VIAL; 0.2MG/10ML, N/A; N/A, 1MG/
VIAL; N/A, 1.4MG/VIAL; N/A, 1.2MG/VIAL; EQ
2, 300 UNITS BASE/10ML, N/A; 7 IU/10ML, N/A

N020176 001 Dec 29, 1993

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC

NOVEL LABS INC

4.7GM; 100GM; 1.015GM; 5.9GM; 2.691GM; 7.5GM

A090145 001 Jan 25, 2012

ASPIRIN

TABLET; ORAL

BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN

BAYER

500MG

N021317 001 Oct 18, 2001

TABLET, EXTENDED RELEASE; ORAL

8-HOUR BAYER

BAYER

650MG

N016030 001

MEASURIN

BAYER

650MG

N016030 002

ASPIRIN; BUTALBITAL

TABLET; ORAL

AXOTAL

SAVAGE LABS

650MG; 50MG

A088305 001 Oct 13, 1983

DISCONTINUED DRUG PRODUCT LIST

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

NOSTRUM LABS INC	325MG; 50MG; 40MG	A078149	001	Jun 13, 2007
WATSON LABS	325MG; 50MG; 40MG	A086231	002	Feb 12, 1985

TABLET; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

ACTAVIS ELIZABETH	325MG; 50MG; 40MG	A086710	002	Aug 23, 1983
HALSEY	325MG; 50MG; 40MG	A089448	001	Dec 01, 1986
IVAX PHARMS	325MG; 50MG; 40MG	A085441	002	Oct 31, 1984
PURACAP PHARM	325MG; 50MG; 40MG	A087048	002	Dec 09, 1983
QUANTUM PHARMICS	325MG; 50MG; 40MG	A088972	001	Jun 18, 1985
SANDOZ	325MG; 50MG; 40MG	A086398	002	Apr 06, 1984
WATSON LABS	325MG; 50MG; 40MG	A086237	002	Mar 23, 1984

FIORINAL

ALLERGAN SALES LLC	325MG; 50MG; 40MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017534	003	Apr 16, 1986
--------------------	--	---------	-----	--------------

LANORINAL

LANNETT	325MG; 50MG; 40MG	A086986	002	Oct 18, 1985
---------	-------------------	---------	-----	--------------

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

VINTAGE PHARMS LLC	325MG; 50MG; 40MG; 30MG	A075351	001	Mar 05, 1999
WATSON LABS	325MG; 50MG; 40MG; 30MG	A074359	001	Aug 31, 1995

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

INVAGESIC

SANDOZ	385MG; 30MG; 25MG	A074817	001	Nov 27, 1996
--------	-------------------	---------	-----	--------------

INVAGESIC FORTE

SANDOZ	770MG; 60MG; 50MG	A074817	002	Nov 27, 1996
--------	-------------------	---------	-----	--------------

NORGESIC

MEDICIS	385MG; 30MG; 25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N013416	003	Oct 27, 1982
---------	--	---------	-----	--------------

NORGESIC FORTE

MEDICIS	770MG; 60MG; 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N013416	004	Oct 27, 1982
---------	--	---------	-----	--------------

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

STEVENS J	385MG; 30MG; 25MG	A074988	001	Apr 30, 1999
	770MG; 60MG; 50MG	A074988	002	Apr 30, 1999

ORPHENGESIC

PRINSTON INC	385MG; 30MG; 25MG	A075141	001	May 29, 1998
--------------	-------------------	---------	-----	--------------

ORPHENGESIC FORTE

PRINSTON INC	770MG; 60MG; 50MG	A075141	002	May 29, 1998
--------------	-------------------	---------	-----	--------------

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

COMPOUND 65

ALRA	389MG; 32.4MG; 65MG	A084553	002	Aug 17, 1983
------	---------------------	---------	-----	--------------

DARVON COMPOUND

XANODYNE PHARM	389MG; 32.4MG; 32MG	N010996	006	Mar 08, 1983
----------------	---------------------	---------	-----	--------------

DARVON COMPOUND-65

XANODYNE PHARM	389MG; 32.4MG; 65MG	N010996	007	Mar 08, 1983
----------------	---------------------	---------	-----	--------------

PROPOXYPHENE COMPOUND 65

IVAX SUB TEVA PHARMS	389MG; 32.4MG; 65MG	A083077	002	Dec 07, 1984
----------------------	---------------------	---------	-----	--------------

SANDOZ	389MG; 32.4MG; 65MG	A080044	002	Sep 16, 1983
--------	---------------------	---------	-----	--------------

TEVA	389MG; 32.4MG; 65MG	A089025	001	Mar 29, 1985
------	---------------------	---------	-----	--------------

PROPOXYPHENE COMPOUND-65

SANDOZ	389MG; 32.4MG; 65MG	A083101	002	Jun 24, 1985
--------	---------------------	---------	-----	--------------

PROPOXYPHENE HYDROCHLORIDE W/ ASPIRIN AND CAFFEINE

WATSON LABS	389MG; 32.4MG; 65MG	A085732	002	Sep 03, 1984
-------------	---------------------	---------	-----	--------------

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL COMPOUND

WATSON LABS	325MG; 200MG	A088809	001	Oct 03, 1985
-------------	--------------	---------	-----	--------------

SOMA COMPOUND

MEDA PHARMS	325MG; 200MG	N012365	005	Jul 11, 1983
-------------	--------------	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE
OXFORD PHARMS 325MG; 200MG; 16MG

A040283 001 Dec 29, 1998

SOMA COMPOUND W/ CODEINE
MEDA PHARMS 325MG; 200MG; 16MG

N012366 002 Jul 11, 1983

ASPIRIN; HYDROCODONE BITARTRATE

TABLET; ORAL

AZDONE

SCHWARZ PHARMA 500MG; 5MG **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

A089420 001 Jan 25, 1988

VICOPRIN

ABBOTT 500MG; 5MG

A086333 001 Sep 14, 1983

ASPIRIN; MEPROBAMATE

TABLET; ORAL

EQUAGESIC

CARACO 325MG; 200MG

N011702 003 Dec 29, 1983

MEPRO-ASPIRIN

SANDOZ 325MG; 200MG

A089127 001 Mar 02, 1987

MEPROBAMATE AND ASPIRIN

PAR PHARM 325MG; 200MG

A089126 001 Aug 19, 1986

MICRAININ

MEDPOINTE PHARM HLC 325MG; 200MG

A084978 001

Q-GESIC

QUANTUM PHARMICS 325MG; 200MG

A088740 001 Jun 01, 1984

ASPIRIN; METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL AND ASPIRIN

IVAX SUB TEVA PHARMS 325MG; 400MG

A087211 001 Dec 22, 1982

MCNEIL 325MG; 400MG

A089193 001 Feb 12, 1986

PAR PHARM 325MG; 400MG

A089657 001 Nov 04, 1988

ROBAXISAL

ROBINS AH 325MG; 400MG

N012281 001

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

CODOXY

HALSEY 325MG; 4.5MG; 0.38MG

A087464 001 Jul 01, 1982

OXYCODONE AND ASPIRIN

SUN PHARM INDS 325MG; 4.5MG; 0.38MG

A040260 001 Jul 17, 1998

325MG; 4.5MG; 0.38MG

A087794 001 May 26, 1982

WATSON LABS 325MG; 4.5MG; 0.38MG

A040255 001 Feb 27, 1998

OXYCODONE AND ASPIRIN (HALF-STRENGTH)

ROXANE 325MG; 2.25MG; 0.19MG

A087742 001 Jun 04, 1982

PERCODAN

ENDO PHARMS 325MG; 4.5MG; 0.38MG

N007337 006

PERCODAN-DEMI

ENDO PHARMS 325MG; 2.25MG; 0.19MG

N007337 005

ROXIPRIN

ROXANE 325MG; 4.5MG; 0.38MG

A087743 001 Jun 04, 1982

ASPIRIN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

TALWIN COMPOUND

SANOFI AVENTIS US 325MG; EQ 12.5MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N016891 001

ASPIRIN; PRAVASTATIN SODIUM

TABLET, TABLET; ORAL

PRAVIGARD PAC (COPACKAGED)

BRISTOL MYERS SQUIBB 325MG, N/A; N/A, 80MG

N021387 006 Jun 24, 2003

TABLET, TABLET, TABLET; ORAL

PRAVIGARD PAC (COPACKAGED)

BRISTOL MYERS SQUIBB 81MG, N/A; N/A, 20MG

N021387 001 Jun 24, 2003

81MG, N/A; N/A, 40MG

N021387 002 Jun 24, 2003

81MG, N/A; N/A, 80MG

N021387 003 Jun 24, 2003

325MG, N/A; N/A, 20MG

N021387 004 Jun 24, 2003

325MG, N/A; N/A, 40MG

N021387 005 Jun 24, 2003

DISCONTINUED DRUG PRODUCT LISTASPIRIN; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON W/ ASA

XANODYNE PHARM

325MG; 65MG

N010996 005

ASPIRIN; PROPOXYPHENE NAPSYLATE

CAPSULE; ORAL

DARVON-N W/ ASA

AAIPHARMA LLC

325MG; 100MG

N016829 001

TABLET; ORAL

DARVON-N W/ ASA

AAIPHARMA LLC

325MG; 100MG

N016863 001

ATAZANAVIR SULFATE

CAPSULE; ORAL

REYATAZ

BRISTOL MYERS SQUIBB

EQ 100MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N021567 001 Jun 20, 2003

ATENOLOL

INJECTABLE; INJECTION

TENORMIN

ASTRAZENECA

0.5MG/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N019058 001 Sep 13, 1989

TABLET; ORAL

ATENOLOL

ABLE

25MG

A076907 001 Jul 30, 2004

50MG

A076907 002 Jul 30, 2004

100MG

A076907 003 Jul 30, 2004

APOTHECON

50MG

A073317 001 Mar 20, 1992

100MG

A073318 001 Mar 20, 1992

DAVA PHARMS INC

25MG

A074099 001 Apr 28, 1992

MYLAN

25MG

A074126 003 Aug 26, 1998

50MG

A074126 001 Mar 23, 1994

100MG

A074126 002 Mar 23, 1994

NORTHSTAR HLTHCARE

25MG

A078254 001 Sep 25, 2009

50MG

A078254 002 Sep 25, 2009

100MG

A078254 003 Sep 25, 2009

NOSTRUM LABS

50MG

A074127 001 Feb 21, 1995

100MG

A074127 002 Feb 21, 1995

PLIVA

25MG

A074101 001 Jul 17, 1997

50MG

A074101 002 Jul 17, 1997

100MG

A074101 003 Jul 17, 1997

SANDOZ

25MG

A074265 001 Feb 28, 1994

50MG

A074265 002 Feb 28, 1994

100MG

A074265 003 Feb 28, 1994

SCS

50MG

A073676 001 Oct 30, 1992

100MG

A073676 002 Oct 30, 1992

TEVA

50MG

A073315 001 May 28, 1993

100MG

A073316 001 May 28, 1993

TEVA PHARMS

50MG

A074120 001 Feb 24, 1995

100MG

A074120 002 Feb 24, 1995

WATSON LABS

50MG

A073352 001 Dec 27, 1991

100MG

A073353 001 Dec 27, 1991

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

NOSTRUM LABS

50MG; 25MG

A074404 001 May 14, 1998

100MG; 25MG

A074404 002 May 14, 1998

PLIVA

50MG; 25MG

A074107 001 Sep 24, 1997

100MG; 25MG

A074107 002 Sep 24, 1997

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

ATOMOXETINE HYDROCHLORIDE

ZYDUS PHARMS USA INC

18MG

A079017 001 Sep 17, 2010

25MG

A079017 002 Sep 17, 2010

40MG

A079017 003 Sep 17, 2010

60MG

A079017 004 Sep 17, 2010

80MG

A079017 005 Sep 17, 2010

100MG

A079017 006 Sep 17, 2010

DISCONTINUED DRUG PRODUCT LIST

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

STRATTERA

LILLY

5MG

N021411 001 Nov 26, 2002

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

TEVA PHARMS

EQ 10MG BASE

A078773 001 May 29, 2012

EQ 20MG BASE

A078773 002 May 29, 2012

EQ 40MG BASE

A078773 003 May 29, 2012

EQ 80MG BASE

A078773 004 May 29, 2012

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET; ORAL

LIPTRUZET

MERCK SHARP DOHME

EQ 10MG BASE;10MG **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N200153 001 May 03, 2013

EQ 20MG BASE;10MG **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N200153 002 May 03, 2013

EQ 40MG BASE;10MG **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N200153 003 May 03, 2013

EQ 80MG BASE;10MG **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N200153 004 May 03, 2013

ATOVAQUONE

TABLET; ORAL

MEPRON

GLAXOSMITHKLINE LLC

250MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N020259 001 Nov 25, 1992

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

BAXTER HLTHCARE

10MG/ML

A074824 001 Sep 30, 1997

BAXTER HLTHCARE CORP

10MG/ML

A074753 001 Jan 23, 1997

HOSPIRA

10MG/ML

A074632 001 Dec 23, 1996

10MG/ML

A074740 001 Mar 28, 1997

TEVA PARENTERAL

10MG/ML

A074784 001 Jun 11, 1997

WATSON LABS INC

10MG/ML

A074945 001 Jul 28, 1998

ATRACURIUM BESYLATE PRESERVATIVE FREE

BAXTER HLTHCARE

10MG/ML

A074825 001 Sep 30, 1997

BAXTER HLTHCARE CORP

10MG/ML

A074768 001 Jan 23, 1997

HOSPIRA

10MG/ML

A074633 001 Dec 23, 1996

10MG/ML

A074639 001 Mar 25, 1997

10MG/ML

A074741 001 Mar 28, 1997

WATSON LABS INC

10MG/ML

A074944 001 Jul 28, 1998

TRACRIUM

HOSPIRA

10MG/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N018831 002 Jun 20, 1985

TRACRIUM PRESERVATIVE FREE

HOSPIRA

10MG/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N018831 001 Nov 23, 1983

ATROPINE

INJECTABLE; INJECTION

ATROPINE

ABBVIE

EQ 2MG SULFATE/0.7ML

A071295 001 Jan 30, 1987

DISCONTINUED DRUG PRODUCT LIST

ATROPINE SULFATE

AEROSOL, METERED; INHALATION

ATROPINE SULFATE

US ARMY

EQ 0.36MG BASE/INH

N020056 001 Sep 19, 1990

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL

MOTOFEN HALF-STRENGTH

SEBELA IRELAND LTD

0.025MG; 0.5MG

N017744 001

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENOXYLATE HYDROCHLORIDE W/ ATROPINE SULFATE

SCHERER RP

0.025MG; 2.5MG

A086440 001

SOLUTION; ORAL

COLONOID

MEDPOINTE PHARM HLC

0.025MG/5ML; 2.5MG/5ML

A085735 001

LOMANATE

ALPHARMA US PHARMS

0.025MG/5ML; 2.5MG/5ML

A085746 001

LOMOTIL

GD SEARLE LLC

0.025MG/5ML; 2.5MG/5ML

N012699 001

TABLET; ORAL

COLONOID

MEDPOINTE PHARM HLC

0.025MG; 2.5MG

A085737 001

DI-ATRO

MD PHARM

0.025MG; 2.5MG

A085266 001

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

ABLE

0.025MG; 2.5MG

A040395 001 Nov 27, 2000

ANI PHARMS INC

0.025MG; 2.5MG

A086727 001

ASCOT

0.025MG; 2.5MG

A087934 001 Jul 19, 1983

HEATHER

0.025MG; 2.5MG

A086798 001

HIKMA PHARMS LLC

0.025MG; 2.5MG

A087765 001 Mar 15, 1982

INWOOD LABS

0.025MG; 2.5MG

A085509 001

KV PHARM

0.025MG; 2.5MG

A085659 001

LEDERLE

0.025MG; 2.5MG

A086950 001

PARKE DAVIS

0.025MG; 2.5MG

A087131 001

PVT FORM

0.025MG; 2.5MG

A085766 001

R AND S PHARMA

0.025MG; 2.5MG

A085035 001

ROXANE

0.025MG; 2.5MG

A086057 001

SANDOZ

0.025MG; 2.5MG

A086173 001

SUN PHARM INDS

0.025MG; 2.5MG

A085506 001

USL PHARMA

0.025MG; 2.5MG

A087842 001 Mar 29, 1982

VALEANT PHARM INTL

0.025MG; 2.5MG

A087195 001 Feb 16, 1982

WATSON LABS

0.025MG; 2.5MG

A085876 001

LO-TROL

VANGARD

0.025MG; 2.5MG

A088009 001 Mar 25, 1983

LOGEN

SUPERPHARM

0.025MG; 2.5MG

A088962 001 May 10, 1985

LONOX

SANDOZ

0.025MG; 2.5MG

A085311 002

LOW-QUEL

HALSEY

0.025MG; 2.5MG

A085211 001

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

ENLON-PLUS

MYLAN INSTITUTIONAL

0.14MG/ML; 10MG/ML

N019677 001 Nov 06, 1991

ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

ATROPINE AND DEMEROL

ABBVIE

0.4MG/ML; 50MG/ML

A087853 001 Nov 26, 1982

0.4MG/ML; 75MG/ML

A087847 001 Nov 26, 1982

0.4MG/ML; 100MG/ML

A087848 001 Nov 26, 1982

MEPERIDINE AND ATROPINE SULFATE

WYETH AYERST

0.4MG/ML; 50MG/ML

A085121 001

0.4MG/ML; 75MG/ML

A085121 002

0.4MG/ML; 100MG/ML

A085121 003

DISCONTINUED DRUG PRODUCT LIST

ATROPINE; PRALIDOXIME CHLORIDE

INJECTABLE; INTRAMUSCULAR

ATNAA

US ARMY

2.1MG/0.7ML; 600MG/0.7ML

N021175 001 Jan 17, 2002

AZATADINE MALEATE

TABLET; ORAL

OPTIMINE

SCHERING

1MG

N017601 001

AZATADINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

TRINALIN

SCHERING

1MG; 120MG

N018506 001 Mar 23, 1982

AZATHIOPRINE

TABLET; ORAL

IMURAN

SEBELA IRELAND LTD

25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N016324 002

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION

IMURAN

SEBELA IRELAND LTD

EQ 100MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N017391 001

AZELASTINE HYDROCHLORIDE

SPRAY, METERED; NASAL

ASTEPRO

MEDA PHARMS

EQ 0.125MG BASE/SPRAY

N022203 001 Oct 15, 2008

AZITHROMYCIN

CAPSULE; ORAL

ZITHROMAX

PFIZER

EQ 250MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N050670 001 Nov 01, 1991

FOR SUSPENSION; ORAL

AZITHROMYCIN

SANDOZ

EQ 100MG BASE/5ML

A065297 001 Sep 18, 2006

EQ 200MG BASE/5ML

A065297 002 Sep 18, 2006

INJECTABLE; INJECTION

AZITHROMYCIN

PLIVA HRVATSKA DOO

EQ 500MG BASE/VIAL

A065265 001 Jan 18, 2007

TEVA PARENTERAL

EQ 500MG BASE/VIAL

N050809 001 Dec 19, 2006

EQ 2.5GM BASE/VIAL

N050809 002 Dec 19, 2006

AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE

FOR SUSPENSION, TABLET; ORAL

TROVAN/ZITHROMAX COMPLIANCE PAK

PFIZER

EQ 1GM BASE, N/A; N/A, EQ 100MG BASE

N050762 001 Dec 18, 1998

AZLOCILLIN SODIUM

INJECTABLE; INJECTION

AZLIN

BAYER PHARMS

EQ 2GM BASE/VIAL

A062388 001 Sep 08, 1982

EQ 2GM BASE/VIAL

A062417 001 Oct 12, 1982

EQ 2GM BASE/VIAL

N050562 001 Sep 03, 1982

EQ 3GM BASE/VIAL

A062388 002 Sep 08, 1982

EQ 3GM BASE/VIAL

A062417 002 Oct 12, 1982

EQ 3GM BASE/VIAL

N050562 002 Sep 03, 1982

EQ 4GM BASE/VIAL

A062388 003 Sep 08, 1982

EQ 4GM BASE/VIAL

A062417 003 Oct 12, 1982

EQ 4GM BASE/VIAL

N050562 003 Sep 03, 1982

AZTREONAM

INJECTABLE; INJECTION

AZACTAM

BRISTOL MYERS SQUIBB

500MG/VIAL

N050580 001 Dec 31, 1986

AZACTAM IN PLASTIC CONTAINER

BRISTOL MYERS SQUIBB

10MG/ML

N050632 003 May 24, 1989

DISCONTINUED DRUG PRODUCT LIST

AZTREONAM

INJECTABLE; INJECTION

AZTREONAM

WEST-WARD PHARMS INT	1GM/VIAL	A065286 001	Mar 23, 2011
	2GM/VIAL	A065286 002	Mar 23, 2011

BACAMPICILLIN HYDROCHLORIDE

FOR SUSPENSION; ORAL

SPECTROBID

PFIZER	125MG/5ML	N050556 001	Mar 23, 1982
--------	-----------	-------------	--------------

TABLET; ORAL

SPECTROBID

PFIZER	400MG	N050520 001	
	800MG	N050520 002	Sep 12, 1983

BACITRACIN

INJECTABLE; INJECTION

BACITRACIN

PFIZER	50,000 UNITS/VIAL	A060282 001	
--------	-------------------	-------------	--

OINTMENT; OPHTHALMIC

BACIGUENT

PHARMACIA AND UPJOHN	500 UNITS/GM	A060734 001	
----------------------	--------------	-------------	--

BACITRACIN

LILLY	500 UNITS/GM	A060687 001	
PHARMADERM	500 UNITS/GM	A062158 001	
PHARMAFAIR	500 UNITS/GM	A062453 001	Mar 28, 1984

OINTMENT; TOPICAL

BACITRACIN

COMBE	500 UNITS/GM	A062799 001	May 14, 1987
NASKA	500 UNITS/GM	A062857 001	Nov 13, 1987

POWDER; FOR RX COMPOUNDING

BACI-RX

X GEN PHARMS	5,000,000 UNITS/BOT	A061580 001	
--------------	---------------------	-------------	--

BACITRACIN

APOTHEKERNES	5,000,000 UNITS/BOT	A061699 001	
PADDOCK LLC	5,000,000 UNITS/BOT	A062456 001	Jul 27, 1983

BACITRACIN ZINC

POWDER; FOR RX COMPOUNDING

ZIBA-RX

X GEN PHARMS	500,000 UNITS/BOT	A061737 001	
--------------	-------------------	-------------	--

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

CORTISPORIN

CASPER PHARMA LLC	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050416 002	
-------------------	---	-------------	--

ZINC BACITRACIN, NEOMYCIN SULFATE, POLYMYXIN B SULFATE & HYDROCORTISONE

PHARMAFAIR	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062389 001	Jul 02, 1982
------------	--	-------------	--------------

OINTMENT; TOPICAL

NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE

PHARMAFAIR	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM	A062381 001	Sep 06, 1985
------------	---	-------------	--------------

BACITRACIN ZINC; LIDOCAINE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; TOPICAL

LANABIOTIC

COMBE	400 UNITS/GM;40MG/GM;EQ 5MG BASE/GM;5,000 UNITS/GM	A062499 001	Jun 03, 1985
-------	--	-------------	--------------

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE

PHARMAFAIR	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062386 001	Sep 09, 1982
------------	---	-------------	--------------

BACITRACIN-NEOMYCIN-POLYMYXIN

PHARMADERM	400 UNITS/GM;EQ 3.5MG BASE/GM;5,000 UNITS/GM	A062167 001	
------------	--	-------------	--

NEO-POLYCYCIN

DOW PHARM	500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060647 001	
-----------	---	-------------	--

NEOSPORIN

CASPER PHARMA LLC	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000	N050417 001	
-------------------	--------------------------------------	-------------	--

DISCONTINUED DRUG PRODUCT LISTBACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC
NEOSPORIN

UNITS/GM **Federal Register
determination that product was not
discontinued or withdrawn for s or e
reasons**

OINTMENT;TOPICAL

BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE

NASKA 400 UNITS/GM;EQ 3.5MG BASE/GM;5,000 UNITS/GM A062833 001 Nov 09, 1987

BACITRACIN ZINC; POLYMYXIN B SULFATE

AEROSOL;TOPICAL

POLYSPORIN

GLAXOSMITHKLINE 10,000 UNITS/GM;2,000,000 UNITS/GM N050167 002 Mar 01, 1985

OINTMENT;OPHTHALMIC

OCUMYCIN

PHARMAFAIR 500 UNITS/GM;10,000 UNITS/GM A062430 001 Apr 08, 1983

POLYSPORIN

MONARCH PHARMS

500 UNITS/GM;10,000 UNITS/GM **Federal
Register determination that product was
not discontinued or withdrawn for s or e
reasons**

A061229 001

OINTMENT;TOPICAL

BACITRACIN ZINC-POLYMYXIN B SULFATE

NASKA 500 UNITS/GM;10,000 UNITS/GM A062849 001 Nov 13, 1987

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

ALTANA 400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM A060731 002

BACITRACIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

MYCITRACIN

PHARMACIA AND UPJOHN 500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM A061048 001

BACITRACIN; POLYMYXIN B SULFATE

DISC;TOPICAL

LANABIOTIC

COMBE 500 UNITS/GM;5,000 UNITS/GM N050598 001 Sep 22, 1986

BACLOFEN

TABLET;ORAL

BACLOFEN

TEVA 10MG A073043 001 Feb 27, 1992

20MG A073044 001 Feb 27, 1992

USL PHARMA 10MG A071260 001 May 06, 1988

20MG A071261 001 May 06, 1988

WATSON LABS 10MG A072824 001 Sep 18, 1991

10MG A073092 001 Jan 28, 1994

10MG A074698 001 Aug 20, 1996

20MG A072825 001 Sep 18, 1991

20MG A073093 001 Jan 28, 1994

20MG A074698 002 Aug 20, 1996

LIORESAL

NOVARTIS

10MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N017851 001

20MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N017851 003 Jan 20, 1982

TABLET, ORALLY DISINTEGRATING;ORAL

KEMSTRO

UCB INC

10MG N021589 001 Oct 30, 2003

20MG N021589 002 Oct 30, 2003

DISCONTINUED DRUG PRODUCT LISTBECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION

BECLOVENT

GLAXOSMITHKLINE 0.042MG/INH N018153 001

VANCERIL

SCHERING 0.042MG/INH N017573 001

VANCERIL DOUBLE STRENGTH

SCHERING 0.084MG/INH N020486 001 Dec 24, 1996

AEROSOL, METERED; NASAL

BECONASE

GLAXOSMITHKLINE 0.042MG/INH N018584 001

VANCENASE

SCHERING 0.042MG/INH N018521 001

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED; NASAL

VANCENASE AQ

SCHERING EQ 0.042MG DIPROP/SPRAY N019589 001 Dec 23, 1987

EQ 0.084MG DIPROP/SPRAY N020469 001 Jun 26, 1996

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

ACTAVIS LABS FL INC 5MG A076267 001 Feb 11, 2004

10MG A076267 002 Feb 11, 2004

20MG A076267 003 Feb 11, 2004

40MG A076267 004 Feb 11, 2004

GENPHARM 5MG A076476 001 Feb 11, 2004

10MG A076476 002 Feb 11, 2004

20MG A076476 003 Feb 11, 2004

40MG A076476 004 Feb 11, 2004

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

ACTAVIS LABS FL INC 5MG; 6.25MG A076342 001 Feb 11, 2004

10MG; 12.5MG A076342 002 Feb 11, 2004

20MG; 12.5MG A076342 003 Feb 11, 2004

20MG; 25MG A076342 004 Feb 11, 2004

IVAX SUB TEVA PHARMS 5MG; 6.25MG A076348 001 Feb 11, 2004

10MG; 12.5MG A076348 002 Feb 11, 2004

20MG; 12.5MG A076348 003 Feb 11, 2004

20MG; 25MG A076348 004 Feb 11, 2004

MYLAN PHARMS INC 5MG; 6.25MG A076612 001 Feb 11, 2004

10MG; 12.5MG A076612 002 Feb 11, 2004

20MG; 12.5MG A076612 003 Feb 11, 2004

20MG; 25MG A076612 004 Feb 11, 2004

SUN PHARM INDS LTD 5MG; 6.25MG A077483 001 Sep 08, 2005

10MG; 12.5MG A077483 002 Sep 08, 2005

20MG; 12.5MG A077483 003 Sep 08, 2005

20MG; 25MG A077483 004 Sep 08, 2005

BENDROFLUMETHIAZIDE

TABLET; ORAL

NATURETIN-10

APOTHECON 10MG N012164 003

NATURETIN-2.5

APOTHECON 2.5MG N012164 001

NATURETIN-5

APOTHECON 5MG N012164 002

BENOXINATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BENOXINATE HYDROCHLORIDE

SOLA BARNES HIND 0.4% A084149 001

BENTIROMIDE

SOLUTION; ORAL

CHYMEX

SAVAGE LABS 500MG/7.5ML N018366 001 Dec 29, 1983

DISCONTINUED DRUG PRODUCT LIST

BENZONATATE

CAPSULE; ORAL

BENZONATATE

NESHER PHARMS

100MG

A040795 001 Oct 31, 2007

200MG

A040795 002 Oct 31, 2007

TESSALON

PFIZER

200MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N011210 003 Jun 25, 1999

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

BENZAACLIN

VALEANT BERMUDA

5%;EQ 1% BASE

N050756 002 Apr 20, 2007

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

COREPHARMA

50MG

A040714 001 Oct 29, 2007

IMPAX LABS

50MG

A040845 001 Nov 18, 2008

DIDREX

PHARMACIA AND UPJOHN

25MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N012427 003

50MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N012427 002

BENZQUINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

EMETE-CON

PFIZER

EQ 50MG BASE/VIAL

N016820 001

SUPPOSITORY; RECTAL

EMETE-CON

ROERIG

EQ 100MG BASE

N016818 006

BENZTHIAZIDE

TABLET; ORAL

AQUATAG

SOLVAY

25MG

N016001 001

50MG

N016001 002

BENZTHIAZIDE

PVT FORM

50MG

A083206 001

EXNA

AH ROBINS INC

50MG

N012489 001

FOVANE

PFIZER

50MG

N012128 002

URESE

PFIZER

25MG

N012128 003

BENZTROPINE MESYLATE

TABLET; ORAL

BENZTROPINE MESYLATE

FRONTIDA BIOPHARM

1MG

A081264 001 Jan 23, 1992

2MG

A081265 001 Jan 23, 1992

LANNETT HOLDINGS INC

0.5MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

A088877 001 Apr 11, 1985

1MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

A088894 001 Apr 11, 1985

2MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

A088895 001 Apr 11, 1985

OXFORD PHARMS

0.5MG

A040699 001 Feb 14, 2008

1MG

A040705 001 Feb 14, 2008

2MG

A040706 001 Feb 14, 2008

QUANTUM PHARMICS

0.5MG

A088514 001 Jan 31, 1984

1MG

A088510 001 Jan 31, 1984

2MG

A088511 001 Jan 31, 1984

USL PHARMA

0.5MG

A089211 001 Jun 14, 1988

DISCONTINUED DRUG PRODUCT LIST

BENZTROPINE MESYLATE

TABLET; ORAL

BENZTROPINE MESYLATE

1MG

A089212 001 Jun 14, 1988

2MG

A089213 001 Jun 14, 1988

COGENTIN

MERCK

0.5MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N009193 004

1MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N009193 003

2MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N009193 002

BENZYL BENZOATE

EMULSION; TOPICAL

BENZYL BENZOATE

LANNETT

50%

A084535 001

BEPRIDIL HYDROCHLORIDE

TABLET; ORAL

BEPADIN

MEDPOINTE PHARM HLC

200MG

N019001 001 Dec 28, 1990

300MG

N019001 002 Dec 28, 1990

400MG

N019001 003 Dec 28, 1990

VASCOR

JOHNSON AND JOHNSON

200MG

N019002 001 Dec 28, 1990

300MG

N019002 002 Dec 28, 1990

400MG

N019002 003 Dec 28, 1990

BETA CAROTENE

CAPSULE; ORAL

SOLATENE

ROCHE

30MG

N017589 001

BETAMETHASONE

CREAM; TOPICAL

CELESTONE

SCHERING

0.2%

N014762 001

SYRUP; ORAL

CELESTONE

MERCK SHARP DOHME

0.6MG/5ML

N014215 002

TABLET; ORAL

CELESTONE

SCHERING

0.6MG

N012657 003

BETAMETHASONE BENZOATE

CREAM; TOPICAL

UTICORT

PARKE DAVIS

0.025%

N016998 002

GEL; TOPICAL

UTICORT

PARKE DAVIS

0.025%

N017244 001

LOTION; TOPICAL

UTICORT

PARKE DAVIS

0.025%

N017528 001

OINTMENT; TOPICAL

UTICORT

PARKE DAVIS

0.025%

N018089 001

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

ALPHATREX

SAVAGE LABS

EQ 0.05% BASE

N019138 001 Jun 26, 1984

BETAMETHASONE DIPROPIONATE

PERRIGO NEW YORK

EQ 0.05% BASE

A072536 001 Jan 31, 1990

EQ 0.05% BASE

A074579 001 Nov 26, 1997

PHARMADERM

EQ 0.05% BASE

N019136 001 Jun 26, 1984

TARO

EQ 0.05% BASE

A071143 001 Jun 17, 1987

TEVA

EQ 0.05% BASE

A071476 001 Aug 10, 1987

DISCONTINUED DRUG PRODUCT LIST

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

DIPROSONE

SCHERING EQ 0.05% BASE N017536 001

CREAM, AUGMENTED; TOPICAL

DIPROLENE

SCHERING EQ 0.05% BASE N019408 001 Jan 31, 1986

DISC; TOPICAL

DIPROSONE

SCHERING EQ 0.1% BASE N017829 001

GEL, AUGMENTED; TOPICAL

DIPROLENE

SCHERING EQ 0.05% BASE N019408 002 Nov 22, 1991

LOTION; TOPICAL

ALPHATREX

SAVAGE LABS EQ 0.05% BASE A070273 001 Aug 12, 1985

BETAMETHASONE DIPROPIONATE

ALPHARMA US PHARMS EQ 0.05% BASE A071085 001 Feb 03, 1987

G AND W LABS INC EQ 0.05% BASE A071882 001 Jun 06, 1988

PHARMADERM EQ 0.05% BASE A070274 001 Aug 12, 1985

TARO EQ 0.05% BASE A072276 001 Aug 24, 1988

EQ 0.05% BASE A074272 001 Sep 30, 1994

DIPROSONE

SCHERING EQ 0.05% BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons** N017781 001

OINTMENT; TOPICAL

ALPHATREX

SAVAGE LABS EQ 0.05% BASE N019143 001 Sep 04, 1984

BETAMETHASONE DIPROPIONATE

PERRIGO NEW YORK EQ 0.05% BASE A072526 001 Jan 31, 1990

PHARMADERM EQ 0.05% BASE N019140 001 Sep 04, 1984

TEVA EQ 0.05% BASE A071477 001 Aug 10, 1987

DIPROSONE

SCHERING EQ 0.05% BASE N017691 001

BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

BETAMETHASONE SODIUM PHOSPHATE

WATSON LABS EQ 3MG BASE/ML A085738 001

CELESTONE

SCHERING EQ 3MG BASE/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons** N017561 001BETAMETHASONE VALERATE

CREAM; TOPICAL

BETADERM

ROACO EQ 0.1% BASE N018839 001 Jun 30, 1983

BETAMETHASONE VALERATE

PERRIGO NEW YORK EQ 0.1% BASE A070053 001 Jun 10, 1986

PHARMADERM EQ 0.1% BASE N018860 002 Aug 31, 1983

PHARMAFAIR EQ 0.1% BASE A070485 001 May 29, 1987

TARO EQ 0.1% BASE A070062 001 May 14, 1985

BETATREX

SAVAGE LABS EQ 0.1% BASE N018862 001 Aug 31, 1983

VALISONE

SCHERING EQ 0.01% BASE N016322 002

EQ 0.1% BASE N016322 001

LOTION; TOPICAL

BETAMETHASONE VALERATE

PHARMADERM EQ 0.1% BASE N018870 001 Aug 31, 1983

PHARMAFAIR EQ 0.1% BASE A070484 001 May 29, 1987

TEVA PHARMS EQ 0.1% BASE A071883 001 Apr 22, 1988

BETATREX

SAVAGE LABS EQ 0.1% BASE N018867 001 Aug 31, 1983

VALISONE

SCHERING EQ 0.1% BASE N016932 001

OINTMENT; TOPICAL

BETAMETHASONE VALERATE

PERRIGO NEW YORK EQ 0.1% BASE A071478 001 Dec 23, 1987

PHARMADERM EQ 0.1% BASE N018864 001 Aug 31, 1983

DISCONTINUED DRUG PRODUCT LIST

BETAMETHASONE VALERATE

OINTMENT; TOPICAL

BETAMETHASONE VALERATE

PHARMAFAIR	EQ 0.1% BASE	A070486	001	May 29, 1987
BETATREX				
SAVAGE LABS	EQ 0.1% BASE	N018863	001	Aug 31, 1983
VALISONE				
SCHERING	EQ 0.1% BASE	N016740	001	

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

APOTEX INC	EQ 0.5% BASE	A075446	001	Sep 28, 2000
TABLET; ORAL				
KERLONE				
SANOFI AVENTIS US	10MG	N019507	001	Oct 27, 1989
	20MG	N019507	002	Oct 27, 1989

BETAXOLOL HYDROCHLORIDE; CHLORTHALIDONE

TABLET; ORAL

KERLEDEX

SANOFI AVENTIS US	5MG;12.5MG	N019807	001	Oct 30, 1992
	10MG;12.5MG	N019807	002	Oct 30, 1992

BETAXOLOL HYDROCHLORIDE; PILOCARPINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

BETOPTIC PILO

ALCON	EQ 0.25% BASE;1.75%	N020619	001	Apr 17, 1997
-------	---------------------	---------	-----	--------------

BETAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION

HISTALOG

LILLY	50MG/ML	N009344	001	
-------	---------	---------	-----	--

BETHANECHOL CHLORIDE

INJECTABLE; INJECTION

URECHOLINE

ODYSSEY PHARMS	5MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N006536	001	
----------------	---	---------	-----	--

TABLET; ORAL

BETHANECHOL CHLORIDE

ABLE	5MG	A040492	001	Jul 27, 2004
	10MG	A040483	001	Jul 27, 2004
	25MG	A040485	001	Jul 27, 2004
	50MG	A040509	001	Jul 27, 2004
ACTAVIS ELIZABETH	5MG	A040552	001	Oct 28, 2004
	10MG	A040553	001	Oct 28, 2004
	25MG	A040554	001	Oct 28, 2004
	50MG	A040551	001	Oct 28, 2004
ASCOT	10MG	A088288	001	Jun 08, 1983
	25MG	A088289	001	Jun 08, 1983
IMPAX LABS	5MG	A040739	001	Nov 01, 2006
	10MG	A040741	001	Nov 01, 2006
	25MG	A040740	001	Nov 01, 2006
	50MG	A040721	004	Nov 01, 2006
IVAX SUB TEVA PHARMS	25MG	A084689	001	
LANNETT	5MG	A084702	001	
	10MG	A084712	001	
	25MG	A084074	001	
SANDOZ	5MG	A084353	001	
	10MG	A084378	001	
	10MG	A084379	001	
	25MG	A084383	001	
	25MG	A084384	001	
SUN PHARM INDS INC	5MG	A040897	001	Apr 22, 2009
	10MG	A040897	002	Apr 22, 2009
	25MG	A040897	003	Apr 22, 2009
	50MG	A040897	004	Apr 22, 2009
WATSON LABS	5MG	A084402	001	
	5MG	A085230	002	
	5MG	A085841	001	
	10MG	A084408	001	
	10MG	A085228	001	

DISCONTINUED DRUG PRODUCT LIST

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

10MG	A085842	001
25MG	A084441	001
25MG	A085229	001
25MG	A085839	001
50MG	A087397	001
50MG	A087444	001

MYOTONACHOL

GLENWOOD

5MG	A084188	001
10MG	A084188	003
25MG	A084188	004

URECHOLINE

ODYSSEY PHARMS

5MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N006536	003
10MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N006536	002
25MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N006536	004
50MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N006536	005

BETHANIDINE SULFATE

TABLET; ORAL

TENATHAN

ROBINS AH

10MG	N017675	001
25MG	N017675	002

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

KUDCO IRELAND

50MG A077995 001 Jul 06, 2009

ROXANE

50MG A078285 001 Mar 24, 2011

SYNTHON PHARMS

50MG A077973 001 Jul 06, 2009

BIMATOPROST

SOLUTION/DROPS; OPHTHALMIC

LUMIGAN

ALLERGAN

0.03%	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021275	001	Mar 16, 2001
-------	--	---------	-----	--------------

BIPERIDEN HYDROCHLORIDE

TABLET; ORAL

AKINETON

ABBVIE

2MG N012003 001

BIPERIDEN LACTATE

INJECTABLE; INJECTION

AKINETON

ABBVIE

5MG/ML N012418 002

BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION, TABLET, DELAYED RELEASE; ORAL

HALFLYTELY

BRAINTREE

5MG, N/A; N/A, 210MG; N/A, 0.74GM; N/A, 2.86GM; N/A, 5.6GM	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021551	003	Jul 16, 2010
--	--	---------	-----	--------------

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE; ORAL

HELIDAC

SEBELA IRELAND LTD

262.4MG, N/A, N/A; N/A, 250MG, N/A; N/A, N/A, 500MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050719	001	Aug 15, 1996
---	--	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

FRONTIDA BIOPHARM

5MG

A075474 001 Oct 25, 2002

10MG

A075474 002 Oct 25, 2002

ZEBETA

TEVA WOMENS

5MG

N019982 002 Jul 31, 1992

10MG

N019982 001 Jul 31, 1992

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

ACTAVIS ELIZABETH

2.5MG; 6.25MG

A075672 001 Sep 25, 2000

5MG; 6.25MG

A075672 002 Sep 25, 2000

10MG; 6.25MG

A075672 003 Sep 25, 2000

APOTHECON

2.5MG; 6.25MG

A075642 002 Dec 27, 2000

5MG; 6.25MG

A075642 001 Dec 27, 2000

10MG; 6.25MG

A075642 003 Dec 27, 2000

IVAX SUB TEVA PHARMS

2.5MG; 6.25MG

A075632 001 Sep 27, 2000

5MG; 6.25MG

A075632 002 Sep 27, 2000

10MG; 6.25MG

A075632 003 Sep 27, 2000

SANDOZ

2.5MG; 6.25MG

A075527 001 Sep 25, 2000

5MG; 6.25MG

A075527 003 Sep 25, 2000

10MG; 6.25MG

A075527 002 Sep 25, 2000

TEVA

2.5MG; 6.25MG

A075686 001 Jan 19, 2001

5MG; 6.25MG

A075686 002 Jan 19, 2001

10MG; 6.25MG

A075686 003 Jan 19, 2001

WATSON LABS

2.5MG; 6.25MG

A075469 001 Sep 25, 2000

5MG; 6.25MG

A075469 002 Sep 25, 2000

10MG; 6.25MG

A075469 003 Sep 25, 2000

BITOLTEROL MESYLATE

AEROSOL, METERED; INHALATION

TORNALATE

SANOFI AVENTIS US

0.37MG/INH

N018770 001 Dec 28, 1984

SOLUTION; INHALATION

TORNALATE

SANOFI AVENTIS US

0.2%

N019548 001 Feb 19, 1992

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLENOXANE

BRISTOL MYERS SQUIBB

EQ 15 UNITS BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N050443 001

EQ 30 UNITS BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N050443 002 Sep 07, 1995

BLEOMYCIN SULFATE

PHARMACHEMIE BV

EQ 15 UNITS BASE/VIAL

A065201 001 Dec 13, 2007

TEVA PARENTERAL

EQ 15 UNITS BASE/VIAL

A064084 001 Jun 01, 1996

EQ 30 UNITS BASE/VIAL

A064084 002 Jun 01, 1996

BOCEPREVIR

CAPSULE; ORAL

VICTRELIS

MERCK SHARP DOHME

200MG

N202258 001 May 13, 2011

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE

ABRAXIS PHARM

50MG/ML

A070134 001 Apr 29, 1986

100MG/ML

A071298 001 Feb 13, 1987

ASTRAZENECA

50MG/ML

A071151 001 Aug 10, 1987

50MG/ML

A071152 001 Aug 10, 1987

50MG/ML

A071153 001 Aug 10, 1987

EUROHLTH INTL SARL

50MG/ML

A070545 001 May 14, 1986

50MG/ML

A070546 001 May 14, 1986

HOSPIRA

50MG/ML **Federal Register

N019030 001 Apr 29, 1986

determination that product was not discontinued or withdrawn for safety or efficacy reasons**

50MG/ML

N019033 001 Apr 29, 1986

INTL MEDICATION

50MG/ML

A070119 001 Apr 29, 1986

DISCONTINUED DRUG PRODUCT LISTBRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE

LUITPOLD	50MG/ML	A070891	001	Jul 26, 1988
BRETYLIUM TOSYLATE IN DEXTROSE 5%				
ABBOTT	200MG/100ML	N019005	002	Apr 29, 1986
	400MG/100ML	N019005	003	Apr 29, 1986
	800MG/100ML	N019005	001	Apr 29, 1986
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	100MG/100ML	N019121	001	Apr 29, 1986
	200MG/100ML	N019121	002	Apr 29, 1986
	400MG/100ML	N019121	003	Apr 29, 1986
BAXTER HLTHCARE	200MG/100ML	N019837	002	Apr 12, 1989
	400MG/100ML	N019837	001	Apr 12, 1989
HOSPIRA INC	200MG/100ML	N019008	002	Apr 29, 1986
	400MG/100ML	N019008	003	Apr 29, 1986
	800MG/100ML	N019008	001	Apr 29, 1986
BRETYLOL				
HOSPIRA	50MG/ML	N017954	001	

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

ALPHAGAN

ALLERGAN	0.2% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020613	001	Sep 06, 1996
	0.5%	N020490	001	Mar 13, 1997
BRIMONIDINE TARTRATE				
TEVA PARENTERAL	0.2%	A076372	001	Sep 10, 2004

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

BROMDAY

BAUSCH AND LOMB INC	EQ 0.09% ACID **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021664	002	Oct 16, 2010
XIBROM				
BAUSCH AND LOMB INC	EQ 0.09% ACID **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021664	001	Mar 24, 2005

BROMOCRIPTINE MESYLATE

CAPSULE; ORAL

BROMOCRIPTINE MESYLATE

LEK PHARM	EQ 5MG BASE	A075100	001	Dec 10, 1998
-----------	-------------	---------	-----	--------------

BROMODIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

AMBODRYL

PARKE DAVIS	25MG	N007984	001	
-------------	------	---------	-----	--

BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE

SYRUP; ORAL

AMBENYL

FOREST LABS	12.5MG/5ML; 10MG/5ML	N009319	006	Jan 10, 1984
BROMANYL				
ALPHARMA US PHARMS	12.5MG/5ML; 10MG/5ML	A088343	001	Aug 15, 1984
BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE				
WOCKHARDT	12.5MG/5ML; 10MG/5ML	A088626	001	Oct 12, 1984

BROMPHENIRAMINE MALEATE

ELIXIR; ORAL

BROMPHENIRAMINE MALEATE

ALPHARMA US PHARMS	2MG/5ML	A086936	001	
KV PHARM	2MG/5ML	A085466	001	
PHARM ASSOC	2MG/5ML	A087517	001	
USL PHARMA	2MG/5ML	A087964	001	Jan 25, 1983

INJECTABLE; INJECTION

BROMPHENIRAMINE MALEATE

WATSON LABS	10MG/ML	A083821	001	
	100MG/ML	A083820	001	

DIMETANE-TEN

WYETH AYERST	10MG/ML	N011418	002	
--------------	---------	---------	-----	--

DISCONTINUED DRUG PRODUCT LIST

BROMPHENIRAMINE MALEATE

TABLET; ORAL

BROMPHENIRAMINE MALEATE

BARR	4MG	A084468	001	
IVAX SUB TEVA PHARMS	4MG	A084351	001	
NEWTRON PHARMS	4MG	A086987	001	
NEXGEN PHARMA INC	4MG	A086187	001	
PAR PHARM	4MG	A087009	001	
PIONEER PHARMS	4MG	A088604	001	Jul 13, 1984
UPSHER-SMITH LABS	4MG	A083215	001	
VITARINE	4MG	A085850	001	
WATSON LABS	4MG	A083123	001	
	4MG	A085769	001	

DIMETANE

WYETH CONS	4MG	N010799	003	
------------	-----	---------	-----	--

TABLET, EXTENDED RELEASE; ORAL

DIMETANE

WYETH CONS	8MG	N010799	010	Jun 10, 1983
	12MG	N010799	011	Jun 10, 1983

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

BROMANATE DM

ALPHARMA US PHARMS	2MG/5ML; 10MG/5ML; 30MG/5ML	A088722	001	Mar 07, 1985
--------------------	-----------------------------	---------	-----	--------------

BROMFED-DM

WOCKHARDT	2MG/5ML; 10MG/5ML; 30MG/5ML	A089681	001	Dec 22, 1988
-----------	-----------------------------	---------	-----	--------------

DIMETANE-DX

ROBINS AH	2MG/5ML; 10MG/5ML; 30MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019279	001	Aug 24, 1984
-----------	--	---------	-----	--------------

BROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE

ALZA	16MG; 240MG	N019672	001	Mar 29, 1996
------	-------------	---------	-----	--------------

BUCLIZINE HYDROCHLORIDE

TABLET; ORAL

BUCLADIN-S

STUART PHARMS	50MG	N010911	006	
---------------	------	---------	-----	--

BUDESONIDE

AEROSOL, METERED; NASAL

RHINOCORT

ASTRAZENECA	0.032MG/INH	N020233	001	Feb 14, 1994
-------------	-------------	---------	-----	--------------

POWDER, METERED; INHALATION

PULMICORT

ASTRAZENECA	0.16MG/INH	N020441	002	Jun 24, 1997
	0.32MG/INH	N020441	003	Jun 24, 1997

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

HOSPIRA	0.25MG/ML	A074160	001	Oct 30, 1997
TEVA PARENTERAL	0.25MG/ML	A074613	001	Nov 18, 1997

BUMEX

VALIDUS PHARMS INC	0.25MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018226	001	Feb 28, 1983
--------------------	--	---------	-----	--------------

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE

HOSPIRA	0.75%	A070587	001	Mar 03, 1987
---------	-------	---------	-----	--------------

BUPIVACAINE HYDROCHLORIDE KIT

HOSPIRA	0.075%	N019978	001	Sep 03, 1992
	0.114%	N019978	002	Sep 03, 1992
	0.23%	N019978	003	Sep 03, 1992

BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

INTL MEDICATED	0.25%	A076012	001	Jan 09, 2002
	0.5%	A076012	002	Jan 09, 2002
	0.75%	A076012	003	Jan 09, 2002

DISCONTINUED DRUG PRODUCT LIST

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

HOSPIRA	0.25%;0.005MG/ML	A071166 001	Jun 16, 1988
	0.5%;0.005MG/ML	A071169 001	Jun 16, 1988
	0.75%;0.005MG/ML	A071171 001	Jun 16, 1988

BUPIVACAINE HYDROCHLORIDE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DUOCAINE

AMPHASTAR PHARMS INC	EQ 0.375% (37.5MG/10ML);EQ 1% (100MG/10ML)	N021496 001	May 23, 2003
----------------------	--	-------------	--------------

BUPRENORPHINE HYDROCHLORIDE

TABLET; SUBLINGUAL

SUBUTEX

INDIVIOR INC	EQ 2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020732 002	Oct 08, 2002
	EQ 8MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020732 003	Oct 08, 2002

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET; SUBLINGUAL

SUBOXONE

INDIVIOR INC	EQ 2MG BASE;EQ 0.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020733 001	Oct 08, 2002
	EQ 8MG BASE;EQ 2MG BASE	N020733 002	Oct 08, 2002

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

SANDOZ	75MG	A075613 002	Oct 10, 2000
	100MG	A075613 001	Oct 10, 2000
TEVA	75MG	A075310 001	Nov 29, 1999
	100MG	A075310 002	Nov 29, 1999
WELLBUTRIN			
GLAXOSMITHKLINE	50MG	N018644 001	Dec 30, 1985
	75MG	N018644 002	Dec 30, 1985
	100MG	N018644 003	Dec 30, 1985

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

ACTAVIS LABS FL INC	300MG	A077715 002	Jun 13, 2007
IMPAX LABS	300MG	A077415 002	Dec 15, 2006
SANDOZ	100MG	A076845 001	Jul 14, 2005
	150MG	A076834 001	Jul 14, 2005
	150MG	A076845 002	Jul 14, 2005
WOCKHARDT LTD	100MG	A201331 001	Aug 30, 2012
	150MG	A201331 002	Aug 30, 2012
	200MG	A201331 003	Aug 30, 2012
WELLBUTRIN SR			
GLAXOSMITHKLINE	50MG	N020358 001	Oct 04, 1996
ZYBAN			
GLAXOSMITHKLINE	100MG	N020711 002	May 14, 1997

BUSPIRONE HYDROCHLORIDE

CAPSULE; ORAL

BUSPAR

BRISTOL MYERS SQUIBB	5MG	N021190 001	Dec 20, 2000
	7.5MG	N021190 002	Dec 20, 2000
	10MG	N021190 003	Dec 20, 2000
	15MG	N021190 004	Dec 20, 2000

TABLET; ORAL

BUSPAR

BRISTOL MYERS SQUIBB	5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018731 001	Sep 29, 1986
	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018731 002	Sep 29, 1986

DISCONTINUED DRUG PRODUCT LIST

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPAR

15MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018731 003	Apr 22, 1996
30MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018731 004	Apr 22, 1996

BUSPIRONE HYDROCHLORIDE

APOTEX

5MG	A075521 001	Apr 05, 2002
10MG	A075521 002	Apr 05, 2002
15MG	A075521 003	Apr 05, 2002

EGIS

5MG	A075119 001	Mar 14, 2002
10MG	A075119 002	Mar 14, 2002
15MG	A075119 003	Jan 23, 2003

IVAX SUB TEVA PHARMS

5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A075385 001	Mar 01, 2002
--	-------------	--------------

10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A075385 002	Mar 01, 2002
---	-------------	--------------

15MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A075385 003	Mar 01, 2002
---	-------------	--------------

NESHER PHARMS

5MG	A075572 001	Feb 27, 2002
10MG	A075572 002	Feb 27, 2002
15MG	A075572 003	Feb 27, 2002

OXFORD PHARMS

5MG	A075388 001	May 09, 2002
10MG	A075388 002	May 09, 2002
15MG	A075388 003	May 09, 2002

SANDOZ

5MG	A075413 001	Mar 19, 2002
10MG	A075413 002	Mar 19, 2002
15MG	A075413 003	Mar 19, 2002

BUTABARBITAL SODIUM

CAPSULE; ORAL

BUTICAPS

MEDPOINTE PHARM HLC

15MG	A085381 001	
30MG	A085381 002	
50MG	A085381 003	
100MG	A085381 004	

ELIXIR; ORAL

BUTABARB

ALPHARMA US PHARMS

30MG/5ML	A085873 001	
----------	-------------	--

BUTABARBITAL SODIUM

WOCKHARDT

30MG/5ML	A085383 001	
----------	-------------	--

BUTALAN

LANNETT

33.3MG/5ML	A085880 001	
------------	-------------	--

BUTISOL SODIUM

MEDA PHARMS

30MG/5ML	A085380 001	
----------	-------------	--

SARISOL

HALSEY

30MG/5ML	A084723 001	
----------	-------------	--

TABLET; ORAL

BUTABARBITAL

BUNDY

30MG	A085550 001	
------	-------------	--

BUTABARBITAL SODIUM

SANDOZ

15MG	A084292 003	Feb 09, 1982
------	-------------	--------------

15MG	A085938 001	
------	-------------	--

30MG	A084272 002	
------	-------------	--

30MG	A085934 001	
------	-------------	--

SOLVAY

16.2MG	A083606 001	
--------	-------------	--

32.4MG	A083898 001	
--------	-------------	--

48.6MG	A083897 001	
--------	-------------	--

97.2MG	A083896 001	
--------	-------------	--

TEVA

15MG	A088632 001	May 18, 1985
------	-------------	--------------

30MG	A088631 001	May 01, 1985
------	-------------	--------------

WATSON LABS

15MG	A085764 001	
------	-------------	--

30MG	A085772 001	
------	-------------	--

WHITEWORTH TOWN PLSN

15MG	A083325 002	
------	-------------	--

DISCONTINUED DRUG PRODUCT LIST

BUTABARBITAL SODIUM

TABLET; ORAL

BUTABARBITAL SODIUM	30MG	A083337	001	
BUTISOL SODIUM				
MEDA PHARMS	15MG	N000793	002	
	50MG	N000793	003	
	100MG	N000793	005	
SARISOL NO. 1				
HALSEY	15MG	A084719	001	
SARISOL NO. 2				
HALSEY	30MG	A084719	002	
SODIUM BUTABARBITAL				
HIKMA PHARMS LLC	15MG	A085418	001	
	30MG	A085432	001	
IVAX SUB TEVA PHARMS	15MG	A083484	001	
	30MG	A084040	001	
LANNETT	15MG	A085849	001	
	30MG	A085866	001	
	100MG	A085881	001	
MARSHALL PHARMA	16.2MG	A083524	001	
	32.4MG	A083858	001	

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL

MENTAX-TC

MYLAN	1%	N021408	001	Oct 17, 2002
-------	----	---------	-----	--------------

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

BUTOCONAZOLE NITRATE

PERRIGO PHARMA INTL	2%	N019881	001	Feb 07, 1997
---------------------	----	---------	-----	--------------

FEMSTAT

ROCHE PALO	2%	N019215	001	Nov 25, 1985
------------	----	---------	-----	--------------

SUPPOSITORY; VAGINAL

FEMSTAT

ROCHE PALO	100MG	N019359	001	Nov 25, 1985
------------	-------	---------	-----	--------------

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

CLARIS	2MG/ML	A075697	001	Oct 23, 2001
--------	--------	---------	-----	--------------

HIKMA FARMACEUTICA	2MG/ML	A078247	001	Apr 29, 2009
--------------------	--------	---------	-----	--------------

HOSPIRA	1MG/ML	A075342	001	Nov 04, 1999
---------	--------	---------	-----	--------------

	1MG/ML	A075559	001	Mar 20, 2000
--	--------	---------	-----	--------------

	2MG/ML	A075342	002	Nov 04, 1999
--	--------	---------	-----	--------------

	2MG/ML	A075559	002	Mar 20, 2000
--	--------	---------	-----	--------------

BUTORPHANOL TARTRATE PRESERVATIVE FREE

CLARIS	1MG/ML	A075695	001	Oct 23, 2001
--------	--------	---------	-----	--------------

	2MG/ML	A075695	002	Oct 23, 2001
--	--------	---------	-----	--------------

HOSPIRA	1MG/ML	A074620	001	Jan 22, 1997
---------	--------	---------	-----	--------------

	1MG/ML	A075170	001	Sep 28, 1998
--	--------	---------	-----	--------------

	2MG/ML	A074620	002	Jan 22, 1997
--	--------	---------	-----	--------------

	2MG/ML	A075170	002	Sep 28, 1998
--	--------	---------	-----	--------------

STADOL

APOTHECON	2MG/ML	N017857	004	
-----------	--------	---------	-----	--

STADOL PRESERVATIVE FREE

APOTHECON	1MG/ML	N017857	001	
-----------	--------	---------	-----	--

	2MG/ML	N017857	002	
--	--------	---------	-----	--

SPRAY, METERED; NASAL

STADOL

BRISTOL MYERS SQUIBB	1MG/SPRAY	N019890	001	Dec 12, 1991
----------------------	-----------	---------	-----	--------------

CABERGOLINE

TABLET; ORAL

CABERGOLINE

IMPAX LABS INC	0.5MG	A077843	001	Jul 03, 2007
----------------	-------	---------	-----	--------------

DOSTINEX

PHARMACIA AND UPJOHN	0.5MG	N020664	001	Dec 23, 1996
----------------------	-------	---------	-----	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL

CAFERGOT

NOVARTIS	100MG;2MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009000 002
----------	--	-------------

TABLET; ORAL

CAFERGOT

NOVARTIS	100MG;1MG	N006620 001
----------	-----------	-------------

WIGRAINE

ORGANON USA INC	100MG;1MG	A086562 001
-----------------	-----------	-------------

CALCIFEDIOL

CAPSULE; ORAL

CALDEROL

ORGANON USA INC	0.02MG	N018312 001
	0.05MG	N018312 002

CALCIPOTRIENE

OINTMENT; TOPICAL

DOVONEX

LEO PHARMA AS	0.005% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020273 001	Dec 29, 1993
---------------	---	-------------	--------------

SOLUTION; TOPICAL

DOVONEX

LEO PHARM	0.005% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020611 001	Mar 03, 1997
-----------	---	-------------	--------------

CALCITONIN HUMAN

INJECTABLE; INJECTION

CIBACALCIN

NOVARTIS	0.5MG/VIAL	N018470 001	Oct 31, 1986
----------	------------	-------------	--------------

CALCITONIN SALMON

INJECTABLE; INJECTION

CALCIMAR

SANOFI AVENTIS US	200 IU/ML	N017769 001
	400 IU/VIAL	N017497 001

CALCITONIN-SALMON

IGI LABS INC	200 IU/ML	A073690 001	Apr 14, 1995
--------------	-----------	-------------	--------------

MIACALCIN

MYLAN IRELAND LTD	100 IU/ML	N017808 001	Jul 03, 1986
-------------------	-----------	-------------	--------------

CALCITONIN SALMON RECOMBINANT

SPRAY, METERED; NASAL

FORTICAL

UPSHER SMITH	200 IU/SPRAY	N021406 001	Aug 12, 2005
--------------	--------------	-------------	--------------

CALCITRIOL

INJECTABLE; INJECTION

CALCIJEX

ABBVIE	0.001MG/ML	N018874 001	Sep 25, 1986
	0.002MG/ML	N018874 002	Sep 25, 1986

CALCITRIOL

AKORN	0.002MG/ML	A078066 002	Jan 29, 2008
-------	------------	-------------	--------------

FRESENIUS KABI USA	0.001MG/ML	A075836 001	Dec 31, 2002
--------------------	------------	-------------	--------------

	0.002MG/ML	A075836 002	Dec 31, 2002
--	------------	-------------	--------------

FRESENIUS MEDCL	0.001MG/ML	A075766 001	Feb 20, 2003
-----------------	------------	-------------	--------------

	0.002MG/ML	A075766 002	Feb 20, 2003
--	------------	-------------	--------------

HOSPIRA	0.001MG/ML	A075816 001	Jan 16, 2004
---------	------------	-------------	--------------

	0.002MG/ML	A075816 002	Jan 16, 2004
--	------------	-------------	--------------

LUITPOLD	0.001MG/ML	A075746 001	Sep 26, 2003
----------	------------	-------------	--------------

	0.002MG/ML	A075746 002	Sep 26, 2003
--	------------	-------------	--------------

ROCKWELL MEDCL	0.001MG/ML	A076206 001	Sep 17, 2003
----------------	------------	-------------	--------------

SAGENT PHARMS	0.001MG/ML	A077102 001	Feb 08, 2006
---------------	------------	-------------	--------------

TEVA PARENTERAL	0.001MG/ML	A075823 001	Mar 31, 2003
-----------------	------------	-------------	--------------

	0.002MG/ML	A075823 002	Mar 31, 2003
--	------------	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

CALCIUM ACETATE

CAPSULE; ORAL

PHOSLO

FRESENIUS MEDCL	333.5MG	N021160 001	Apr 02, 2001
	667MG	N021160 002	Apr 02, 2001

TABLET; ORAL

CALCIUM ACETATE

WEST-WARD PHARMS INT	667MG	A077693 001	Jan 30, 2008
----------------------	-------	-------------	--------------

PHOSLO

FRESENIUS MEDCL	667MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019976 001	Dec 10, 1990
-----------------	--	-------------	--------------

CALCIUM CARBONATE; RISEDRONATE SODIUM

TABLET, TABLET; ORAL

ACTONEL WITH CALCIUM (COPACKAGED)

WARNER CHILCOTT	EQ 500MG BASE, N/A; N/A, 35MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021823 001	Aug 12, 2005
-----------------	--	-------------	--------------

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUMBICARBONATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER

BAXTER HLTHCARE	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.157GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703 012	Oct 10, 2008
-----------------	--	-------------	--------------

PRISMASOL BGK 4/0 IN PLASTIC CONTAINER

BAXTER HLTHCARE	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703 005	Oct 25, 2006
-----------------	---	-------------	--------------

PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER

BAXTER HLTHCARE	5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703 008	Oct 25, 2006
-----------------	--	-------------	--------------

PRISMASOL BK 0/0 IN PLASTIC CONTAINER

BAXTER HLTHCARE	N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703 007	Oct 25, 2006
-----------------	--	-------------	--------------

PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER

BAXTER HLTHCARE	3.68GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703 009	Oct 25, 2006
-----------------	---	-------------	--------------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATONE; POTASSIUM CHLORIDE; SODIUMBICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION

NAVSTEL

ALCON PHARMS LTD	0.154MG/ML; 0.92MG/ML; 0.2MG/ML; 0.184MG/ML; 0.38MG/ML; 2.1MG/ML; 7.14MG/ML; 0.42MG/ML	N022193 001	Jul 24, 2008
------------------	--	-------------	--------------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	37MG/100ML; 5GM/100ML; 31MG/100ML; 120MG/100ML; 330MG/100ML; 88MG/100ML	N019864 001	Jun 10, 1993
---------	---	-------------	--------------

ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	37MG/100ML; 5GM/100ML; 31MG/100ML; 120MG/100ML; 330MG/100ML; 88MG/100ML	N018271 001	
---------	---	-------------	--

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	35MG/100ML; 5GM/100ML; 30MG/100ML; 74MG/100ML; 640MG/100ML; 500MG/100ML; 74MG/100ML	N019867 001	Dec 20, 1993
---------	---	-------------	--------------

ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	35MG/100ML; 5GM/100ML; 30MG/100ML; 74MG/100ML; 640MG/100ML; 500MG/100ML; 74MG/100ML	N018269 002	Jan 17, 1983
---------	---	-------------	--------------

DISCONTINUED DRUG PRODUCT LISTCALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	37MG/100ML; 5GM/100ML; 30MG/100ML; 119MG/100ML; 161MG/100ML; 94MG/100ML; 138MG/100ML	N017390 001
-----------------	--	-------------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SOLUTION; INTRAPERITONEAL

DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER

B BRAUN	510MG/100ML; 30GM/100ML; 200MG/100ML; 9.2GM/100ML; 9.6GM/100ML	N018807 001	Aug 26, 1983
	510MG/100ML; 30GM/100ML; 200MG/100ML; 9.4GM/100ML; 11GM/100ML	N018807 003	Aug 26, 1983

DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER

B BRAUN	510MG/100ML; 50GM/100ML; 200MG/100ML; 9.2GM/100ML; 9.6GM/100ML	N018807 002	Aug 26, 1983
	510MG/100ML; 50GM/100ML; 200MG/100ML; 9.4GM/100ML; 11GM/100ML	N018807 004	Aug 26, 1983

DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER

B BRAUN	29MG/100ML; 2.5GM/100ML; 15MG/100ML; 610MG/100ML; 560MG/100ML	N018460 006	Jan 29, 1986
---------	---	-------------	--------------

DIALYTE W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

B BRAUN	29MG/100ML; 1.5GM/100ML; 15MG/100ML; 610MG/100ML; 560MG/100ML	N018460 001
---------	---	-------------

DIALYTE W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

B BRAUN	29MG/100ML; 4.25GM/100ML; 15MG/100ML; 610MG/100ML; 560MG/100ML	N018460 003
---------	--	-------------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379 002
-----------------	---	-------------

DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379 003
-----------------	---	-------------

DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML; 3.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379 007	Jun 24, 1988
-----------------	---	-------------	--------------

DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379 001
-----------------	--	-------------

DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 38MG/100ML; 448MG/100ML	N018379 004	Jul 07, 1982
-----------------	--	-------------	--------------

DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 38MG/100ML; 448MG/100ML	N018379 005	Jul 07, 1982
-----------------	--	-------------	--------------

DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 38MG/100ML; 448MG/100ML	N018379 008	Jun 24, 1988
-----------------	--	-------------	--------------

DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N018379 006	Jul 07, 1982
-----------------	--	-------------	--------------

DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER

B BRAUN	26MG/100ML; 1.5GM/100ML; 5MG/100ML; 530MG/100ML; 450MG/100ML	N018460 007	Jan 29, 1986
---------	--	-------------	--------------

	26MG/100ML; 1.5GM/100ML; 15MG/100ML; 560MG/100ML; 390MG/100ML	N018460 002
--	---	-------------

DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER

B BRAUN	26MG/100ML; 2.5GM/100ML; 5MG/100ML; 530MG/100ML; 450MG/100ML	N018460 005	Nov 02, 1983
---------	--	-------------	--------------

	26MG/100ML; 5GM/100ML; 5MG/100ML; 530MG/100ML; 450MG/100ML	N018460 008	Jan 29, 1986
--	--	-------------	--------------

DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER

B BRAUN	26MG/100ML; 4.25GM/100ML; 5MG/100ML; 530MG/100ML; 450MG/100ML	N018460 009	Jan 29, 1986
---------	---	-------------	--------------

	26MG/100ML; 4.25GM/100ML; 15MG/100ML; 560MG/100ML; 390MG/100ML	N018460 004
--	--	-------------

INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

FRESENIUS	18.4MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 38MG/100ML; 448MG/100ML	A020374 001	Jun 13, 1994
-----------	--	-------------	--------------

INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

FRESENIUS	18.4MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 38MG/100ML; 448MG/100ML	A020374 002	Jun 13, 1994
-----------	--	-------------	--------------

DISCONTINUED DRUG PRODUCT LISTCALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

FRESENIUS	18.4MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 5.38MG/100ML; 448MG/100ML	A020374 003	Jun 13, 1994
-----------	--	-------------	--------------

INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

FRESENIUS	18.4MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 5.38MG/100ML; 448MG/100ML	A020374 004	Jun 13, 1994
-----------	---	-------------	--------------

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER

B BRAUN	20MG/100ML; 5GM/100ML; 30MG/100ML; 380MG/100ML; 600MG/100ML	N018258 001	
---------	---	-------------	--

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

B BRAUN	33MG/100ML; 5GM/100ML; 30MG/100ML; 860MG/100ML	N018256 001	
BAXTER HLTHCARE	33MG/100ML; 5GM/100ML; 30MG/100ML; 860MG/100ML	N016695 001	

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC CONTAINER

B BRAUN	4MG/100ML; 4GM/100ML; 6MG/100ML; 120MG/100ML; 62MG/100ML	N019634 002	Feb 24, 1988
---------	--	-------------	--------------

DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER

B BRAUN	20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N017510 001	
---------	---	-------------	--

MILES	20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N018499 001	
-------	---	-------------	--

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

HOSPIRA	20MG/100ML; 5GM/100ML; 104MG/100ML; 600MG/100ML; 310MG/100ML	N019685 005	Oct 17, 1988
---------	--	-------------	--------------

HOSPIRA	20MG/100ML; 5GM/100ML; 179MG/100ML; 600MG/100ML; 310MG/100ML	N019685 006	Oct 17, 1988
---------	--	-------------	--------------

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

HOSPIRA	20MG/100ML; 5GM/100ML; 254MG/100ML; 600MG/100ML; 310MG/100ML	N019685 007	Oct 17, 1988
---------	--	-------------	--------------

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

HOSPIRA	20MG/100ML; 5GM/100ML; 254MG/100ML; 600MG/100ML; 310MG/100ML	N019685 003	Oct 17, 1988
---------	--	-------------	--------------

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

HOSPIRA	20MG/100ML; 5GM/100ML; 104MG/100ML; 600MG/100ML; 310MG/100ML	N019685 001	Oct 17, 1988
---------	--	-------------	--------------

CALCIUM CHLORIDE; DEXTROSE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

INPERSOL-ZM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML; 1.5GM/100ML; 538MG/100ML; 48MG/100ML	N019395 001	Mar 26, 1986
-----------------	--	-------------	--------------

INPERSOL-ZM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML; 2.5GM/100ML; 538MG/100ML; 48MG/100ML	N019395 002	Mar 26, 1986
-----------------	--	-------------	--------------

INPERSOL-ZM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML; 4.25GM/100ML; 538MG/100ML; 48MG/100ML	N019395 003	Mar 26, 1986
-----------------	---	-------------	--------------

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER

ABBOTT	16.5MG/ML; 25.4MG/ML; 74.6MG/ML; 121MG/ML; 16.1MG/ML	N019399 001	Jun 16, 1986
--------	--	-------------	--------------

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E IN PLASTIC CONTAINER

B BRAUN	35MG/100ML; 30MG/100ML; 74MG/100ML; 640MG/100ML; 500MG/100ML; 74MG/100ML	N018899 001	Oct 31, 1983
---------	--	-------------	--------------

B BRAUN	35MG/100ML; 30MG/100ML; 74MG/100ML; 640MG/100ML; 500MG/100ML; 74MG/100ML	N019718 001	Sep 29, 1989
---------	--	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

<u>CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE</u>				
INJECTABLE; INJECTION				
PLASMA-LYTE R IN PLASTIC CONTAINER				
BAXTER HLTHCARE	36.8MG/100ML; 30.5MG/100ML; 74.6MG/100ML; 640MG/100ML; 496MG/100ML; 89.6MG/100ML	N017438	001	
<u>CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE</u>				
INJECTABLE; INJECTION				
ACETATED RINGER'S IN PLASTIC CONTAINER				
B BRAUN	20MG/100ML; 30MG/100ML; 380MG/100ML; 600MG/100ML	N018725	001	Nov 29, 1982
<u>CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE</u>				
INJECTABLE; INJECTION				
RINGER'S IN PLASTIC CONTAINER				
B BRAUN	33MG/100ML; 30MG/100ML; 860MG/100ML	N018721	001	Nov 09, 1982
SOLUTION; IRRIGATION				
RINGER'S IN PLASTIC CONTAINER				
ABBOTT	33MG/100ML; 30MG/100ML; 860MG/100ML	N018462	001	
<u>CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE</u>				
INJECTABLE; INJECTION				
LACTATED RINGER'S IN PLASTIC CONTAINER				
ABBOTT	20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N019485	001	Oct 24, 1985
B BRAUN	20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N018023	001	
MILES	20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N018417	001	
SOLUTION; IRRIGATION				
LACTATED RINGER'S IN PLASTIC CONTAINER				
BAXTER HLTHCARE	20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N019933	001	Aug 29, 1989
<u>CALCIUM GLUCEPTATE</u>				
INJECTABLE; INJECTION				
CALCIUM GLUCEPTATE				
ABBOTT	EQ 90MG CALCIUM/5ML	A080001	001	
	EQ 90MG CALCIUM/5ML	A083159	001	
ABRAXIS PHARM	EQ 90MG CALCIUM/5ML	A089373	001	Apr 30, 1987
LILLY	EQ 90MG CALCIUM/5ML	N006470	001	
<u>CALCIUM METRIZOATE; MEGLUMINE METRIZOATE; METRIZOATE MAGNESIUM; METRIZOATE SODIUM</u>				
INJECTABLE; INJECTION				
ISOPAQUE 440				
GE HEALTHCARE	0.78MG/ML; 75.9MG/ML; 0.15MG/ML; 16.6MG/ML	N016847	001	
<u>CALCIUM; MEGLUMINE; METRIZOIC ACID</u>				
INJECTABLE; INJECTION				
ISOPAQUE 280				
GE HEALTHCARE	0.35MG/ML; 140.1MG/ML; 461.8MG/ML	N017506	001	
<u>CANDICIDIN</u>				
OINTMENT; VAGINAL				
VANOBIID				
SANOFI AVENTIS US	0.6MG/GM	A061596	001	
TABLET; VAGINAL				
VANOBIID				
SANOFI AVENTIS US	3MG	A061613	001	
<u>CAPTOPRIL</u>				
TABLET; ORAL				
CAPOTEN				
PAR PHARM	12.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018343	005	Jan 17, 1985
	25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018343	002	
	37.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018343	006	Sep 17, 1986
	50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018343	001	

DISCONTINUED DRUG PRODUCT LIST

CAPTOPRIL

TABLET; ORAL

CAPOTEN

	reasons**			
	75MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018343	007	Jun 13, 1995
	100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018343	003	
	150MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018343	004	Jun 13, 1995
CAPTOPRIL				
APOTEX	12.5MG	A074737	001	Oct 28, 1998
	25MG	A074737	002	Oct 28, 1998
	50MG	A074737	003	Oct 28, 1998
	100MG	A074737	004	Oct 28, 1998
APOTHECON	12.5MG	A074472	001	Mar 31, 1995
	25MG	A074472	002	Mar 31, 1995
	50MG	A074472	003	Mar 31, 1995
	100MG	A074472	004	Mar 31, 1995
DAVA PHARMS INC	12.5MG	A074423	001	Feb 13, 1996
	25MG	A074423	002	Feb 13, 1996
	50MG	A074423	003	Feb 13, 1996
	100MG	A074423	004	Feb 13, 1996
EGIS PHARMS	12.5MG	A074748	004	May 29, 1997
	25MG	A074748	002	May 29, 1997
	50MG	A074748	001	May 29, 1997
	100MG	A074748	003	May 29, 1997
G AND W LABS INC	12.5MG	A074433	001	Feb 13, 1996
	12.5MG	A074462	001	Feb 13, 1996
	12.5MG	A074483	001	Feb 13, 1996
	12.5MG	A074590	004	Aug 30, 1996
	25MG	A074433	002	Feb 13, 1996
	25MG	A074462	002	Feb 13, 1996
	25MG	A074483	002	Feb 13, 1996
	25MG	A074590	002	Aug 30, 1996
	50MG	A074433	003	Feb 13, 1996
	50MG	A074462	003	Feb 13, 1996
	50MG	A074483	003	Feb 13, 1996
	50MG	A074590	001	Aug 30, 1996
	100MG	A074433	004	Feb 13, 1996
	100MG	A074462	004	Feb 13, 1996
	100MG	A074483	004	Feb 13, 1996
	100MG	A074590	003	Aug 30, 1996
PAR PHARM	12.5MG	A074493	001	Feb 13, 1996
	25MG	A074493	002	Feb 13, 1996
	50MG	A074493	003	Feb 13, 1996
	100MG	A074493	004	Feb 13, 1996
PUREPAC PHARM	12.5MG	A074640	001	Mar 31, 1997
	25MG	A074640	002	Mar 31, 1997
	50MG	A074640	003	Mar 31, 1997
	100MG	A074640	004	Mar 31, 1997
SANDOZ	12.5MG	A074363	001	Nov 09, 1995
	12.5MG	A074481	001	Feb 13, 1996
	12.5MG	A074519	001	Feb 13, 1996
	25MG	A074363	002	Nov 09, 1995
	25MG	A074481	002	Feb 13, 1996
	25MG	A074519	002	Feb 13, 1996
	50MG	A074363	003	Nov 09, 1995
	50MG	A074481	003	Feb 13, 1996
	50MG	A074519	003	Feb 13, 1996
	100MG	A074363	004	Nov 09, 1995
	100MG	A074481	004	Feb 13, 1996
	100MG	A074519	004	Feb 13, 1996
STASON	12.5MG	A074677	004	May 30, 1997
	25MG	A074677	002	May 30, 1997
	50MG	A074677	001	May 30, 1997
	100MG	A074677	003	May 30, 1997
VINTAGE PHARMS LLC	12.5MG	A074418	001	Feb 13, 1996

DISCONTINUED DRUG PRODUCT LIST

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

	25MG	A074418 002	Feb 13, 1996
	50MG	A074418 003	Feb 13, 1996
	100MG	A074418 004	Feb 13, 1996
WATSON LABS	12.5MG	A074451 001	Feb 13, 1996
	12.5MG	A074576 001	Apr 23, 1996
	25MG	A074451 002	Feb 13, 1996
	25MG	A074576 002	Apr 23, 1996
	50MG	A074451 003	Feb 13, 1996
	50MG	A074576 003	Apr 23, 1996
	100MG	A074451 004	Feb 13, 1996
	100MG	A074576 004	Apr 23, 1996

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPOZIDE 25/15

APOTHECON	25MG;15MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018709 001	Oct 12, 1984
-----------	--	-------------	--------------

CAPOZIDE 25/25

APOTHECON	25MG;25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018709 002	Oct 12, 1984
-----------	--	-------------	--------------

CAPOZIDE 50/15

APOTHECON	50MG;15MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018709 004	Oct 12, 1984
-----------	--	-------------	--------------

CAPOZIDE 50/25

APOTHECON	50MG;25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018709 003	Oct 12, 1984
-----------	--	-------------	--------------

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

IVAX SUB TEVA PHARMS	25MG;15MG	A075055 001	Jun 18, 1998
	25MG;25MG	A075055 002	Jun 18, 1998
	50MG;15MG	A075055 004	Jun 18, 1998
	50MG;25MG	A075055 003	Jun 18, 1998
VINTAGE PHARMS LLC	25MG;15MG	A074788 001	Dec 29, 1997
	25MG;25MG	A074788 002	Dec 29, 1997
	50MG;15MG	A074788 004	Dec 29, 1997
	50MG;25MG	A074788 003	Dec 29, 1997
WATSON LABS	50MG;25MG	A074832 001	Dec 29, 1997

CARBACHOL

SOLUTION; INTRAOCULAR

CARBACHOL

PHARMAFAIR	0.01%	A070292 001	May 21, 1986
------------	-------	-------------	--------------

CARBASTAT

NOVARTIS	0.01%	A073677 001	Apr 28, 1995
----------	-------	-------------	--------------

CARBAMAZEPINE

SUSPENSION; ORAL

CARBAMAZEPINE

TARO	100MG/5ML	A075875 001	Dec 21, 2000
------	-----------	-------------	--------------

TABLET; ORAL

CARBAMAZEPINE

ACTAVIS ELIZABETH	200MG	A071696 001	Nov 09, 1987
INWOOD LABS	200MG	A070231 001	Aug 14, 1986
PLIVA	200MG	A071479 001	Jul 24, 1987
USL PHARMA	200MG	A070300 001	May 15, 1986
WARNER CHILCOTT	200MG	A070429 001	Jan 02, 1987

TERIL

TARO	200MG	A076525 001	Sep 26, 2003
------	-------	-------------	--------------

TABLET, CHEWABLE; ORAL

CARBAMAZEPINE

JUBILANT CADISTA	100MG	A071940 001	Feb 01, 1988
------------------	-------	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

CARBENICILLIN DISODIUM

INJECTABLE; INJECTION

GEOPEN

ROERIG	EQ 1GM BASE/VIAL	N050306 001
	EQ 2GM BASE/VIAL	N050306 004
	EQ 5GM BASE/VIAL	N050306 002
	EQ 10GM BASE/VIAL	N050306 006
	EQ 30GM BASE/VIAL	N050306 007

PYOPEN

GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	N050298 001
	EQ 2GM BASE/VIAL	N050298 002
	EQ 5GM BASE/VIAL	N050298 003
	EQ 10GM BASE/VIAL	N050298 006
	EQ 20GM BASE/VIAL	N050298 007

CARBENICILLIN INDANYL SODIUM

TABLET; ORAL

GEOCILLIN

PFIZER	EQ 382MG BASE	N050435 001
--------	---------------	-------------

CARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA

IDT AUSTRALIA LTD	10MG;100MG	A073586 001	Jun 29, 1995
	25MG;100MG	A073587 001	Jun 29, 1995
	25MG;250MG	A073620 001	Jun 29, 1995
SCS	10MG;100MG	A074080 001	Mar 25, 1994
	25MG;100MG	A074080 002	Mar 25, 1994
	25MG;250MG	A074080 003	Mar 25, 1994
WATSON LABS	10MG;100MG	A073381 001	Sep 28, 1993
	25MG;100MG	A073382 001	Sep 28, 1993
	25MG;250MG	A073383 001	Sep 28, 1993

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

KV PHARM	50MG;200MG	A076663 001	Jun 24, 2004
----------	------------	-------------	--------------

TABLET, FOR SUSPENSION; ORAL

CARBILEV

RANBAXY	10MG;100MG	A076643 001	Jun 10, 2005
	25MG;100MG	A076643 002	Jun 10, 2005
	25MG;250MG	A076643 003	Jun 10, 2005

TABLET, ORALLY DISINTEGRATING; ORAL

CARBIDOPA AND LEVODOPA

IMPAX LABS	10MG;100MG	A090631 001	Jun 08, 2010
	25MG;100MG	A090631 002	Jun 08, 2010
	25MG;250MG	A090631 003	Jun 08, 2010

PARCOPA

UCB INC	10MG;100MG	A076699 001	Aug 27, 2004
	Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons		
	25MG;100MG	A076699 002	Aug 27, 2004
25MG;250MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**		
	Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	A076699 003	Aug 27, 2004

CARBINOXAMINE MALEATE

ELIXIR; ORAL

CLISTIN

MCNEIL	4MG/5ML	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N008955 001
--------	---------	--	-------------

TABLET; ORAL

CLISTIN

ORTHO MCNEIL PHARM	4MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N008915 001
--------------------	-----	--	-------------

DISCONTINUED DRUG PRODUCT LIST

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

CIPLA LTD	50MG/VIAL	A077383 001	Jan 27, 2006
	150MG/VIAL	A077383 002	Jan 27, 2006
	450MG/VIAL	A077383 003	Jan 27, 2006
FRESENIUS KABI USA	50MG/VIAL	A076235 001	Oct 14, 2004
	150MG/VIAL	A076235 002	Oct 14, 2004
	450MG/VIAL	A076235 003	Oct 14, 2004
HOSPIRA	50MG/VIAL	A076473 001	Oct 27, 2004
	150MG/VIAL	A076473 002	Oct 27, 2004
	450MG/VIAL	A076473 003	Oct 27, 2004
MYLAN LABS LTD	50MG/VIAL	A091510 001	May 29, 2012
	150MG/VIAL	A091510 002	May 29, 2012
	450MG/VIAL	A091510 003	May 29, 2012
PLIVA	50MG/VIAL	A076602 001	Nov 16, 2004
	150MG/VIAL	A076602 002	Nov 16, 2004
	450MG/VIAL	A076602 003	Nov 16, 2004
SANDOZ	50MG/VIAL	A076959 001	Mar 18, 2005
	150MG/VIAL	A076959 002	Mar 18, 2005
	450MG/VIAL	A076959 003	Mar 18, 2005
WATSON LABS	50MG/VIAL	A076162 001	Oct 14, 2004
	150MG/VIAL	A076162 002	Oct 14, 2004
	450MG/VIAL	A076162 003	Oct 14, 2004
WEST-WARD PHARMS INT	50MG/VIAL	A076099 001	Oct 14, 2004
	150MG/VIAL	A076099 002	Oct 14, 2004
	450MG/VIAL	A076099 003	Oct 14, 2004

PARAPLATIN

CORDEN PHARMA

50MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019880 001	Mar 03, 1989
150MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019880 002	Mar 03, 1989
450MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019880 003	Mar 03, 1989

INJECTABLE; IV (INFUSION)

CARBOPLATIN

ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A078732 001	Feb 06, 2012
	150MG/15ML (10MG/ML)	A078732 002	Feb 06, 2012
	450MG/45ML (10MG/ML)	A078732 003	Feb 06, 2012
	600MG/60ML (10MG/ML)	A078732 004	Feb 06, 2012
FRESENIUS KABI USA	50MG/5ML (10MG/ML)	A077247 001	Oct 21, 2004
	50MG/5ML (10MG/ML)	A077266 001	Feb 15, 2006
	150MG/15ML (10MG/ML)	A077247 002	Oct 21, 2004
	150MG/15ML (10MG/ML)	A077266 002	Feb 15, 2006
PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A077679 001	Feb 25, 2009
	150MG/15ML (10MG/ML)	A077679 002	Feb 25, 2009
	450MG/45ML (10MG/ML)	A077679 003	Feb 25, 2009
TEVA PARENTERAL	50MG/5ML (10MG/ML)	A077389 001	Mar 30, 2007
	150MG/15ML (10MG/ML)	A077389 002	Mar 30, 2007
	450MG/45ML (10MG/ML)	A077389 003	Mar 30, 2007

PARAPLATIN

CORDENPHARMA

50MG/5ML (10MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020452 001	Jul 14, 2003
150MG/15ML (10MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020452 002	Jul 14, 2003
450MG/45ML (10MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020452 003	Jul 14, 2003
600MG/60ML (10MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020452 004	Jan 15, 2004

DISCONTINUED DRUG PRODUCT LIST

CARISOPRODOL

CAPSULE; ORAL

SOMA

MEDA PHARMS 250MG N011792 003

TABLET; ORAL

CARISOPRODOL

ABLE 350MG A040421 001 Jun 21, 2001

COREPHARMA 350MG A040397 001 Sep 21, 2000

HIKMA INTL PHARMS 350MG A040124 001 Jan 24, 1996

OXFORD PHARMS 350MG A040188 001 Mar 07, 1997

PIONEER PHARMS 350MG A089390 001 Oct 13, 1988

SANDOZ 350MG A081025 001 Apr 13, 1989

350MG A089566 001 Aug 30, 1988

WATSON LABS 350MG A040152 001 Dec 03, 1996

350MG A085433 001

350MG A086179 001

RELA

SCHERING 350MG N012155 001

CARPHENAZINE MALEATE

CONCENTRATE; ORAL

PROKETAZINE

WYETH AYERST 50MG/ML N014173 001

TABLET; ORAL

PROKETAZINE

WYETH AYERST 12.5MG N012768 001

25MG N012768 002

50MG N012768 004

CARPROFEN

TABLET; ORAL

RIMADYL

ROCHE 100MG N018550 002 Dec 31, 1987

150MG N018550 003 Dec 31, 1987

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CARTEOLOL HYDROCHLORIDE

APOTEX INC 1% A076097 001 Feb 06, 2002

TABLET; ORAL

CARTROL

ABBVIE 2.5MG N019204 001 Dec 28, 1988

5MG N019204 002 Dec 28, 1988

10MG N019204 003 Dec 28, 1988

CARVEDILOL

TABLET; ORAL

CARVEDILOL

HIKMA 3.125MG A077887 001 Sep 07, 2007

6.25MG A077887 002 Sep 07, 2007

12.5MG A077887 003 Sep 07, 2007

25MG A077887 004 Sep 07, 2007

WOCKHARDT LTD 3.125MG A078786 001 Dec 22, 2009

6.25MG A078786 002 Dec 22, 2009

12.5MG A078786 003 Dec 22, 2009

25MG A078786 004 Dec 22, 2009

CEFACLOR

CAPSULE; ORAL

CECLOR

LILLY EQ 250MG BASE **Federal Register N050521 001

determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

EQ 500MG BASE **Federal Register N050521 002

determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

CEFACLOR

CEPH INTL EQ 250MG BASE A062205 001

EQ 500MG BASE A062205 002

DAVA PHARMS INC EQ 250MG BASE A064107 001 Apr 27, 1995

EQ 500MG BASE A064107 002 Apr 27, 1995

IVAX SUB TEVA PHARMS EQ 250MG BASE A064061 001 Apr 27, 1995

EQ 500MG BASE A064061 002 Apr 27, 1995

RANBAXY EQ 250MG BASE A064156 001 Aug 28, 1997

DISCONTINUED DRUG PRODUCT LIST

CEFACTOR

CAPSULE;ORAL

CEFACTOR

	EQ 500MG BASE	A064156 002	Aug 28, 1997
TEVA	EQ 250MG BASE	A064081 001	Sep 16, 1996
	EQ 250MG BASE	A064145 001	Jun 24, 1996
	EQ 500MG BASE	A064081 002	Sep 16, 1996
	EQ 500MG BASE	A064145 002	Jun 24, 1996
WATSON LABS INC	EQ 250MG BASE	A064148 001	May 23, 1996
	EQ 500MG BASE	A064148 002	May 23, 1996

FOR SUSPENSION;ORAL

CECLOR

LILLY	EQ 125MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050522 001	
	EQ 250MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050522 002	

CEFACTOR

DAVA PHARMS INC	EQ 125MG BASE/5ML	A064114 001	Apr 28, 1995
	EQ 187MG BASE/5ML	A064115 001	Apr 28, 1995
	EQ 250MG BASE/5ML	A064116 001	Apr 28, 1995
	EQ 375MG BASE/5ML	A064110 001	Apr 28, 1995
FACTA FARMA	EQ 125MG BASE/5ML	A062206 001	
	EQ 187MG BASE/5ML	A062206 003	Apr 20, 1988
	EQ 250MG BASE/5ML	A062206 002	
	EQ 375MG BASE/5ML	A062206 004	Apr 20, 1988
IVAX SUB TEVA PHARMS	EQ 125MG BASE/5ML	A064087 001	Apr 28, 1995
	EQ 187MG BASE/5ML	A064086 001	Apr 28, 1995
	EQ 250MG BASE/5ML	A064085 001	Apr 28, 1995
	EQ 375MG BASE/5ML	A064070 001	Apr 28, 1995
RANBAXY	EQ 125MG BASE/5ML	A064166 001	Oct 02, 1997
	EQ 187MG BASE/5ML	A064165 001	Oct 02, 1997
	EQ 250MG BASE/5ML	A064164 001	Oct 02, 1997
	EQ 375MG BASE/5ML	A064155 001	Oct 02, 1997
WATSON LABS INC	EQ 125MG BASE/5ML	A064204 001	Feb 18, 1998
	EQ 187MG BASE/5ML	A064205 001	Feb 18, 1998
	EQ 250MG BASE/5ML	A064206 001	Feb 18, 1998
	EQ 375MG BASE/5ML	A064207 001	Feb 18, 1998

TABLET, CHEWABLE;ORAL

RANICLOR

RANBAXY LABS LTD	EQ 125MG BASE	A065092 001	Dec 22, 2003
	EQ 187MG BASE	A065092 002	Dec 22, 2003
	EQ 250MG BASE	A065092 003	Dec 22, 2003
	EQ 375MG BASE	A065092 004	Dec 22, 2003

TABLET, EXTENDED RELEASE;ORAL

CECLOR CD

LILLY	EQ 375MG BASE	N050673 001	Jun 28, 1996
	EQ 500MG BASE	N050673 002	Jun 28, 1996

CEFACTOR

WORLD GEN	EQ 500MG BASE	A065057 001	Jan 05, 2001
-----------	---------------	-------------	--------------

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE;ORAL

CEFADROXIL

IVAX SUB TEVA PHARMS	EQ 500MG BASE	A062766 001	Mar 03, 1987
PUREPAC PHARM	EQ 500MG BASE	A063017 001	Jan 05, 1989
RANBAXY LABS LTD	EQ 500MG BASE	A065015 001	Jun 22, 1999
TEVA	EQ 500MG BASE	A062695 001	Feb 10, 1989

DURICEF

WARNER CHILCOTT	EQ 250MG BASE	N050512 002	
	EQ 500MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050512 001	

ULTRACEF

BRISTOL	EQ 500MG BASE	A062378 001	Mar 16, 1982
---------	---------------	-------------	--------------

FOR SUSPENSION;ORAL

CEFADROXIL

ANI PHARMS INC	EQ 125MG BASE/5ML	A062698 001	Mar 01, 1989
	EQ 250MG BASE/5ML	A062698 002	Mar 01, 1989
	EQ 250MG BASE/5ML	A065278 001	Jan 20, 2006

DISCONTINUED DRUG PRODUCT LIST

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION; ORAL

CEFADROXIL

	EQ 500MG BASE/5ML	A062698 003	Mar 01, 1989
	EQ 500MG BASE/5ML	A065278 002	Jan 20, 2006
APOTHECON	EQ 125MG BASE/5ML	A062334 001	
	EQ 250MG BASE/5ML	A062334 002	
	EQ 500MG BASE/5ML	A062334 003	
SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065115 001	Mar 26, 2003
	EQ 250MG BASE/5ML	A065115 002	Mar 26, 2003
	EQ 500MG BASE/5ML	A065115 003	Mar 26, 2003

DURICEF

WARNER CHILCOTT

EQ 125MG BASE/5ML	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050527 002	
EQ 250MG BASE/5ML	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050527 003	
EQ 500MG BASE/5ML	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050527 001	

ULTRACEF

BRISTOL

EQ 125MG BASE/5ML	A062376 001	Mar 16, 1982
EQ 250MG BASE/5ML	A062376 002	Mar 16, 1982
EQ 500MG BASE/5ML	A062376 003	Mar 16, 1982

TABLET; ORAL

CEFADROXIL

RANBAXY

EQ 1GM BASE	A065018 001	Apr 23, 1999
-------------	-------------	--------------

DURICEF

WARNER CHILCOTT

EQ 1GM BASE	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050528 001	
-------------	--	-------------	--

ULTRACEF

APOTHECON

EQ 1GM BASE	A062390 001	Jun 10, 1982
-------------	-------------	--------------

BRISTOL

EQ 1GM BASE	A062408 001	Aug 31, 1982
-------------	-------------	--------------

CEFAMANDOLE NAFATE

INJECTABLE; INJECTION

MANDOL

LILLY

EQ 500MG BASE/VIAL	N050504 001	
EQ 1GM BASE/VIAL	A062560 001	Sep 10, 1985
EQ 1GM BASE/VIAL	N050504 002	
EQ 2GM BASE/VIAL	A062560 002	Sep 10, 1985
EQ 2GM BASE/VIAL	N050504 003	
EQ 10GM BASE/VIAL	N050504 004	

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

ANCEF

GLAXOSMITHKLINE

EQ 250MG BASE/VIAL	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050461 001	
EQ 500MG BASE/VIAL		N050461 002	
EQ 1GM BASE/VIAL	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050461 003	
EQ 5GM BASE/VIAL	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050461 004	
EQ 10GM BASE/VIAL	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050461 005	

ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE

EQ 10MG BASE/ML	N050566 003	Jun 08, 1983
-----------------	-------------	--------------

BAXTER HLTHCARE

EQ 20MG BASE/ML	N050566 004	Jun 08, 1983
-----------------	-------------	--------------

ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

BAXTER HLTHCARE

EQ 10MG BASE/ML	N050566 001	Jun 08, 1983
-----------------	-------------	--------------

BAXTER HLTHCARE

EQ 20MG BASE/ML	N050566 002	Jun 08, 1983
-----------------	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN AND DEXTROSE

B BRAUN

EQ 500MG BASE/VIAL

N050779 001 Jul 27, 2000

CEFAZOLIN SODIUM

ABRAXIS PHARM

EQ 500MG BASE/VIAL

A062688 002 Nov 17, 1986

EQ 1GM BASE/VIAL

A062688 003 Nov 17, 1986

EQ 10GM BASE/VIAL

A062688 004 Nov 17, 1986

EQ 20GM BASE/VIAL

A062688 005 Aug 03, 1987

AUROBINDO PHARMA

EQ 500MG BASE/VIAL

A065395 001 Aug 08, 2008

EQ 1GM BASE/VIAL

A065395 002 Aug 08, 2008

BEDFORD

EQ 250MG BASE/VIAL

A062894 001 Jul 21, 1988

EQ 500MG BASE/VIAL

A062894 002 Jul 21, 1988

EQ 1GM BASE/VIAL

A062894 003 Jul 21, 1988

EQ 5GM BASE/VIAL

A062894 004 Jul 21, 1988

EQ 10GM BASE/VIAL

A062894 005 Jul 21, 1988

CEPHAZONE PHARMA

EQ 500MG BASE/VIAL

A065280 001 Mar 18, 2009

EQ 1GM BASE/VIAL

A065280 002 Mar 18, 2009

EQ 10GM BASE/VIAL

A065295 001 Mar 18, 2009

EQ 20GM BASE/VIAL

A065296 001 Mar 18, 2009

FRESENIUS KABI USA

EQ 500MG BASE/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

A064169 001 Aug 14, 1998

EQ 1GM BASE/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

A064169 002 Aug 14, 1998

EQ 10GM BASE/VIAL

A064170 001 Mar 18, 1998

EQ 20GM BASE/VIAL

A064170 002 Mar 18, 1998

GLAXOSMITHKLINE

EQ 1GM BASE/VIAL

A064033 001 Oct 31, 1993

STERI PHARMA

EQ 500MG BASE/VIAL

A063216 001 Dec 27, 1991

EQ 1GM BASE/VIAL

A063208 001 Dec 27, 1991

TEVA PHARMS

EQ 250MG BASE/VIAL

A063016 001 Mar 14, 1989

EQ 500MG BASE/VIAL

A063016 002 Mar 14, 1989

EQ 1GM BASE/VIAL

A063016 003 Mar 14, 1989

EQ 5GM BASE/VIAL

A063018 001 Mar 05, 1990

EQ 10GM BASE/VIAL

A063018 002 Mar 05, 1990

WATSON LABS INC

EQ 250MG BASE/VIAL

A062988 001 Dec 29, 1989

EQ 500MG BASE/VIAL

A062988 002 Dec 29, 1989

EQ 1GM BASE/VIAL

A062988 003 Dec 29, 1989

EQ 5GM BASE/VIAL

A062989 001 Dec 29, 1989

EQ 10GM BASE/VIAL

A062989 002 Dec 29, 1989

EQ 20GM BASE/VIAL

A062989 003 Dec 29, 1989

WEST-WARD PHARMS INT

EQ 250MG BASE/VIAL

A062807 001 Jan 12, 1988

EQ 500MG BASE/VIAL

A062807 002 Jan 12, 1988

EQ 1GM BASE/VIAL

A062807 003 Jan 12, 1988

EQ 5GM BASE/VIAL

A062807 004 Jan 12, 1988

EQ 10GM BASE/VIAL

A062807 005 Jan 12, 1988

EQ 20GM BASE/VIAL

A062807 006 Jan 12, 1988

KEFZOL

ACS DOBFAR

EQ 250MG BASE/VIAL

A061773 001

EQ 20GM BASE/VIAL

A061773 005 Sep 08, 1987

LILLY

EQ 500MG BASE/VIAL

A062557 001 Sep 10, 1985

EQ 1GM BASE/VIAL

A062557 002 Sep 10, 1985

CEFDINIR

CAPSULE; ORAL

OMNICEF

ABBVIE

300MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N050739 001 Dec 04, 1997

FOR SUSPENSION; ORAL

OMNICEF

ABBVIE

125MG/5ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N050749 001 Dec 04, 1997

250MG/5ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N050749 002 Jul 29, 2004

DISCONTINUED DRUG PRODUCT LIST

CEFDITOREN PIVOXIL

TABLET; ORAL

SPECTRACEF

VANSEN PHARMA

200MG

N021222 001 Aug 29, 2001

400MG

N021222 002 Jul 21, 2008

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

SANDOZ

EQ 500MG BASE/VIAL

A090291 001 Dec 21, 2010

EQ 1GM BASE/VIAL

A090291 002 Dec 21, 2010

EQ 2GM BASE/VIAL

A090291 003 Dec 21, 2010

CEFIXIME

FOR SUSPENSION; ORAL

SUPRAX

LEDERLE

100MG/5ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N050622 001 Apr 28, 1989

TABLET; ORAL

SUPRAX

LEDERLE

200MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N050621 001 Apr 28, 1989

400MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N050621 002 Apr 28, 1989

CEFMENOXIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFMAX

TAP PHARM

EQ 500MG BASE/VIAL

N050571 001 Dec 30, 1987

EQ 1GM BASE/VIAL

N050571 002 Dec 30, 1987

EQ 2GM BASE/VIAL

N050571 003 Dec 30, 1987

CEFMETAZOLE SODIUM

INJECTABLE; INJECTION

ZEFAZONE

PHARMACIA AND UPJOHN

EQ 1GM BASE/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N050637 001 Dec 11, 1989

EQ 2GM BASE/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N050637 002 Dec 11, 1989

ZEFAZONE IN PLASTIC CONTAINER

PHARMACIA AND UPJOHN

EQ 20MG BASE/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N050683 001 Dec 29, 1992

EQ 40MG BASE/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N050683 002 Dec 29, 1992

CEFONICID SODIUM

INJECTABLE; INJECTION

MONOCID

GLAXOSMITHKLINE

EQ 500MG BASE/VIAL

N050579 001 May 23, 1984

EQ 1GM BASE/VIAL

A063295 001 Jul 26, 1993

EQ 1GM BASE/VIAL

N050579 002 May 23, 1984

EQ 2GM BASE/VIAL

N050579 003 May 23, 1984

EQ 10GM BASE/VIAL

N050579 004 May 23, 1984

CEFOPERAZONE SODIUM

INJECTABLE; INJECTION

CEFOBID

PFIZER

EQ 1GM BASE/VIAL

A063333 001 Mar 31, 1995

EQ 1GM BASE/VIAL

N050551 001 Nov 18, 1982

EQ 2GM BASE/VIAL

A063333 002 Mar 31, 1995

EQ 2GM BASE/VIAL

N050551 002 Nov 18, 1982

EQ 10GM BASE/VIAL

N050551 003 Mar 05, 1990

CEFOBID IN PLASTIC CONTAINER

PFIZER

EQ 20MG BASE/ML

N050613 002 Jul 31, 1987

DISCONTINUED DRUG PRODUCT LIST

CEFOPERAZONE SODIUM

INJECTABLE; INJECTION

CEFOBID IN PLASTIC CONTAINER

EQ 40MG BASE/ML N050613 001 Jul 23, 1986

CEFORANIDE

INJECTABLE; INJECTION

PRECEF

APOTHECON

500MG/VIAL A062579 001 Nov 26, 1984

1GM/VIAL A062579 002 Nov 26, 1984

2GM/VIAL A062579 003 Nov 26, 1984

10GM/VIAL A062579 004 Nov 26, 1984

20GM/VIAL A062579 005 Nov 26, 1984

BRISTOL

500MG/VIAL N050554 001 May 24, 1984

1GM/VIAL N050554 002 May 24, 1984

2GM/VIAL N050554 003 May 24, 1984

10GM/VIAL N050554 004 May 24, 1984

20GM/VIAL N050554 005 May 24, 1984

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME

FRESENIUS KABI USA

EQ 500MG BASE/VIAL A064200 001 Mar 24, 2000

EQ 1GM BASE/VIAL A064200 002 Mar 24, 2000

EQ 2GM BASE/VIAL A064200 003 Mar 24, 2000

EQ 10GM BASE/VIAL A064201 001 Mar 24, 2000

EQ 20GM BASE/VIAL A064201 002 Mar 24, 2000

CEFOTAXIME AND DEXTROSE 2.4% IN PLASTIC CONTAINER

B BRAUN

EQ 2GM BASE N050792 001 Jul 29, 2004

CEFOTAXIME AND DEXTROSE 3.9% IN PLASTIC CONTAINER

B BRAUN

EQ 1GM BASE N050792 002 Jul 29, 2004

CEFOTAXIME SODIUM

AUROBINDO PHARMA

EQ 500MG BASE/VIAL A065517 001 Nov 06, 2009

EQ 1GM BASE/VIAL A065517 002 Nov 06, 2009

EQ 2GM BASE/VIAL A065517 003 Nov 06, 2009

AUROBINDO PHARMA LTD

EQ 10GM BASE/VIAL A065516 001 Nov 06, 2009

CEPHAZONE PHARMA

EQ 10GM BASE/VIAL A065348 001 Jan 25, 2010

CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER

US PHARM HOLDINGS

EQ 20MG BASE/ML N050596 002 May 20, 1985

EQ 40MG BASE/ML N050596 004 May 20, 1985

CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

US PHARM HOLDINGS

EQ 20MG BASE/ML N050596 001 May 20, 1985

EQ 40MG BASE/ML N050596 003 May 20, 1985

CEFOTETAN DISODIUM

INJECTABLE; INJECTION

CEFOTAN

TELIGENT PHARMA INC

EQ 1GM BASE/VIAL A063293 001 Apr 29, 1993

EQ 2GM BASE/VIAL A063293 002 Apr 29, 1993

EQ 10GM BASE/VIAL N050588 003 Apr 25, 1988

CEFOTAN IN PLASTIC CONTAINER

IGI LABS INC

EQ 20MG BASE/ML N050694 002 Jul 30, 1993

EQ 40MG BASE/ML N050694 001 Jul 30, 1993

CEFOTIAM HYDROCHLORIDE

INJECTABLE; INJECTION

CERADON

TAKEDA

EQ 1GM BASE/VIAL N050601 001 Dec 30, 1988

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

FRESENIUS KABI USA

EQ 1GM BASE/VIAL **Federal Register A065012 001 Jul 03, 2000

determination that product was not discontinued or withdrawn for safety or efficacy reasons**

EQ 2GM BASE/VIAL **Federal Register A065012 002 Jul 03, 2000

determination that product was not discontinued or withdrawn for safety or efficacy reasons**

EQ 10GM BASE/VIAL A065011 001 Jul 03, 2000

MEFOXIN

MYLAN INSTITUTIONAL

EQ 1GM BASE/VIAL A062757 001 Jan 08, 1987

EQ 1GM BASE/VIAL **Federal Register N050517 001

determination that product was not discontinued or withdrawn for safety or

DISCONTINUED DRUG PRODUCT LIST

CEFOXITIN SODIUM

INJECTABLE; INJECTION

MEFOXIN

	efficacy reasons**			
	EQ 2GM BASE/VIAL	A062757	002	Jan 08, 1987
	EQ 2GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050517	002	
	EQ 10GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050517	003	
MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER				
MERCK	EQ 20MG BASE/ML	N050581	003	Sep 20, 1984
	EQ 40MG BASE/ML	N050581	004	Sep 20, 1984
MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
MERCK	EQ 20MG BASE/ML	N050581	002	Sep 20, 1984
	EQ 40MG BASE/ML	N050581	001	Sep 20, 1984

CEFPYRAMIDE SODIUM

INJECTABLE; INJECTION

CEFPYRAMIDE SODIUM

WYETH AYERST

	EQ 1GM BASE/VIAL	N050633	002	Jan 31, 1989
	EQ 2GM BASE/VIAL	N050633	003	Jan 31, 1989
	EQ 10GM BASE/VIAL	N050633	005	Jan 31, 1989

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL

BANAN

SANKYO

	EQ 50MG BASE/5ML	N050688	002	Aug 07, 1992
	EQ 100MG BASE/5ML	N050688	001	Aug 07, 1992

CEFPODOXIME PROXETIL

SUN PHARM INDS LTD

	EQ 50MG BASE/5ML	A065082	001	May 31, 2002
	EQ 100MG BASE/5ML	A065082	002	May 31, 2002

VANTIN

PHARMACIA AND UPJOHN

	EQ 50MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050675	001	Aug 07, 1992
	EQ 100MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050675	002	Aug 07, 1992

TABLET; ORAL

BANAN

SANKYO

	EQ 100MG BASE	N050687	001	Aug 07, 1992
	EQ 200MG BASE	N050687	002	Aug 07, 1992

CEFPODOXIME PROXETIL

SUN PHARM INDS LTD

	EQ 100MG BASE	A065083	001	Aug 20, 2003
	EQ 200MG BASE	A065083	002	Aug 20, 2003

VANTIN

PHARMACIA AND UPJOHN

	EQ 100MG BASE	N050674	001	Aug 07, 1992
	EQ 200MG BASE	N050674	002	Aug 07, 1992

CEFPROZIL

FOR SUSPENSION; ORAL

CEFPROZIL

RANBAXY LABS LTD

	125MG/5ML	A065202	001	Jun 30, 2006
	250MG/5ML	A065202	002	Jun 30, 2006

CEFZIL

CORDEN PHARMA

	125MG/5ML	N050665	001	Dec 23, 1991
	250MG/5ML	N050665	002	Dec 23, 1991

TABLET; ORAL

CEFPROZIL

RANBAXY LABS LTD

	250MG	A065198	001	Dec 13, 2006
	500MG	A065198	002	Dec 13, 2006

CEFZIL

CORDEN PHARMA

	250MG	N050664	001	Dec 23, 1991
	500MG	N050664	002	Dec 23, 1991

DISCONTINUED DRUG PRODUCT LIST

CEFTAZIDIME

INJECTABLE; INJECTION

CEFTAZIDIME

AUROBINDO PHARMA LTD	500MG/VIAL	A065481 001	May 28, 2010
	1GM/VIAL	A065481 002	May 28, 2010
	2GM/VIAL	A065481 003	May 28, 2010
	6GM/VIAL	A065482 001	May 28, 2010

CEPTAZ

GLAXOSMITHKLINE	500MG/VIAL	N050646 001	Sep 27, 1990
	1GM/VIAL	N050646 002	Sep 27, 1990
	2GM/VIAL	N050646 003	Sep 27, 1990
	10GM/VIAL	N050646 004	Sep 27, 1990

PENTACEF

GLAXOSMITHKLINE	1GM/VIAL	A063322 001	Nov 07, 1995
	1GM/VIAL	A064006 001	Mar 31, 1992
	2GM/VIAL	A063322 002	Nov 07, 1995
	2GM/VIAL	A064006 002	Mar 31, 1992
	6GM/VIAL	A064008 001	Mar 31, 1992
	10GM/VIAL	A064008 002	Mar 31, 1992

TAZIDIME

LILLY	1GM/VIAL	A062655 001	Nov 20, 1985
	2GM/VIAL	A062655 002	Nov 20, 1985

TAZIDIME IN PLASTIC CONTAINER

LILLY	1GM/VIAL	A062739 001	Jul 10, 1986
	2GM/VIAL	A062739 002	Jul 10, 1986

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

CEFTAZIDIME SODIUM IN PLASTIC CONTAINER

BAXTER HLTHCARE	EQ 10MG BASE/ML	A063221 001	Apr 29, 1993
	EQ 20MG BASE/ML	A063221 002	Apr 29, 1993
	EQ 40MG BASE/ML	A063221 003	Apr 29, 1993

FORTAZ IN PLASTIC CONTAINER

IGI LABS INC	EQ 10MG BASE/ML	N050634 001	Apr 28, 1989
--------------	-----------------	-------------	--------------

CEFTIBUTEN DIHYDRATE

CAPSULE; ORAL

CEDAX

PERNIX THERAP	EQ 400MG BASE	N050685 002	Dec 20, 1995
---------------	---------------	-------------	--------------

FOR SUSPENSION; ORAL

CEDAX

PERNIX THERAP	EQ 90MG BASE/5ML	N050686 001	Dec 20, 1995
	EQ 180MG BASE/5ML	N050686 002	Dec 20, 1995

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION

CEFIZOX

ASTELLAS	EQ 500MG BASE/VIAL	N050560 001	Sep 15, 1983
	EQ 1GM BASE/VIAL	A063294 002	Mar 31, 1994
	EQ 1GM BASE/VIAL	N050560 002	Sep 15, 1983
	EQ 2GM BASE/VIAL	A063294 003	Mar 31, 1994
	EQ 2GM BASE/VIAL	N050560 003	Sep 15, 1983
	EQ 10GM BASE/VIAL	N050560 005	Mar 19, 1993

CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER

ASTELLAS	EQ 20MG BASE/ML	N050589 001	Oct 03, 1984
	EQ 40MG BASE/ML	N050589 002	Oct 03, 1984

CEFIZOX IN PLASTIC CONTAINER

ASTELLAS	EQ 20MG BASE/ML	N050589 003	Apr 13, 1995
	EQ 40MG BASE/ML	N050589 004	Apr 13, 1995

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

CEFTRIAXONE

AGILA SPECLTS	EQ 10GM BASE/VIAL	A091068 001	Jan 07, 2013
AUROBINDO PHARMA LTD	EQ 10GM BASE/VIAL	A065504 001	Jul 31, 2008
FRESENIUS KABI USA	EQ 10GM BASE/VIAL	A065252 001	Feb 15, 2006
HOSPIRA INC	EQ 1GM BASE/VIAL	A065231 001	Aug 02, 2005
	EQ 1GM BASE/VIAL	A202563 001	Aug 20, 2012
	EQ 2GM BASE/VIAL	A065231 002	Aug 02, 2005
	EQ 2GM BASE/VIAL	A202563 002	Aug 20, 2012
TEVA	EQ 10GM BASE/VIAL	A065274 001	May 01, 2006

ROCEPHIN

HOFFMANN LA ROCHE	EQ 250MG BASE/VIAL	A063239 001	Aug 13, 1993
	EQ 500MG BASE/VIAL	A062654 001	Apr 30, 1987

DISCONTINUED DRUG PRODUCT LIST

CEFTRIAZONE SODIUM

INJECTABLE; INJECTION

ROCEPHIN

EQ 500MG BASE/VIAL	A063239	002	Aug 13, 1993	
EQ 1GM BASE/VIAL	A062654	002	Apr 30, 1987	
EQ 1GM BASE/VIAL	A063239	003	Aug 13, 1993	
EQ 2GM BASE/VIAL	A062654	003	Apr 30, 1987	
EQ 10GM BASE/VIAL	N050585	005	Dec 21, 1984	
ROCHE	EQ 250MG BASE/VIAL	A062510	001	Mar 12, 1985
EQ 500MG BASE/VIAL	A062510	002	Mar 12, 1985	
EQ 1GM BASE/VIAL	A062510	003	Mar 12, 1985	

ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER

HOFFMANN LA ROCHE

EQ 10MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050624	001	Feb 11, 1987
EQ 20MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050624	002	Feb 11, 1987
EQ 40MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050624	003	Feb 11, 1987

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFTRIAZONE

AUROBINDO PHARMA LTD

EQ 250MG BASE/VIAL	A065505	001	Jul 31, 2008
EQ 500MG BASE/VIAL	A065505	002	Jul 31, 2008
EQ 1GM BASE/VIAL	A065505	003	Jul 31, 2008
EQ 2GM BASE/VIAL	A065505	004	Jul 31, 2008

BEDFORD

EQ 250MG BASE/VIAL	A065465	001	Aug 18, 2008
EQ 500MG BASE/VIAL	A065465	002	Aug 18, 2008
EQ 1GM BASE/VIAL	A065465	003	Aug 18, 2008
EQ 2GM BASE/VIAL	A065465	004	Aug 18, 2008

CEPHAZONE PHARMA

EQ 250MG BASE/VIAL	A065294	001	Mar 26, 2007
EQ 500MG BASE/VIAL	A065294	002	Mar 26, 2007
EQ 1GM BASE/VIAL	A065294	003	Mar 26, 2007
EQ 2GM BASE/VIAL	A065294	004	Mar 26, 2007

FACTA FARMA

EQ 1GM BASE/VIAL	A065268	001	Feb 28, 2007
EQ 2GM BASE/VIAL	A065268	002	Feb 28, 2007

FRESENIUS KABI USA

EQ 250MG BASE/VIAL	A065245	001	Feb 15, 2006
EQ 500MG BASE/VIAL	A065245	002	Feb 15, 2006
EQ 1GM BASE/VIAL	A065245	003	Feb 15, 2006
EQ 2GM BASE/VIAL	A065245	004	Feb 15, 2006

TEVA

EQ 1GM BASE/VIAL	A065262	001	Jun 29, 2006
EQ 2GM BASE/VIAL	A065262	002	Jun 29, 2006

TEVA PHARMS USA

EQ 250MG BASE/VIAL	A065227	001	Mar 15, 2007
EQ 500MG BASE/VIAL	A065227	002	Mar 15, 2007
EQ 1GM BASE/VIAL	A065227	003	Mar 15, 2007
EQ 2GM BASE/VIAL	A065227	004	Mar 15, 2007

ROCEPHIN

HOFFMANN LA ROCHE

EQ 250MG BASE/VIAL	N050585	001	Dec 21, 1984
EQ 500MG BASE/VIAL	N050585	002	Dec 21, 1984
EQ 1GM BASE/VIAL	N050585	003	Dec 21, 1984
EQ 2GM BASE/VIAL	N050585	004	Dec 21, 1984

CEFTRIAZONE SODIUM; LIDOCAINE

INJECTABLE; INJECTION

ROCEPHIN KIT

HOFFMANN LA ROCHE

EQ 500MG BASE/VIAL, N/A; N/A, 1%	N050585	007	May 08, 1996
EQ 1GM BASE/VIAL, N/A; N/A, 1%	N050585	006	May 08, 1996

CEFUROXIME AXETIL

FOR SUSPENSION; ORAL

CEFUROXIME AXETIL

SUN PHARM INDS LTD

EQ 125MG BASE/5ML	A065323	001	Feb 05, 2008
EQ 250MG BASE/5ML	A065323	002	Feb 05, 2008

TABLET; ORAL

CEFUROXIME AXETIL

RANBAXY LABS LTD

EQ 125MG BASE	A065043	003	Feb 15, 2002
EQ 250MG BASE	A065043	002	Feb 15, 2002
EQ 500MG BASE	A065043	001	Feb 15, 2002

SANDOZ

EQ 250MG BASE	A065126	001	Oct 28, 2003
EQ 500MG BASE	A065126	002	Oct 28, 2003

SUN PHARM INDS LTD

EQ 125MG BASE	A065118	001	Apr 25, 2003
---------------	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

EQ 250MG BASE	A065118	002	Apr 25, 2003
EQ 500MG BASE	A065118	003	Apr 25, 2003

CEFUROXIME SODIUM

INJECTABLE; INJECTION

CEFUROXIME SODIUM

FRESENIUS KABI USA	EQ 1.5GM BASE/VIAL	A065001	002	May 30, 2001
	EQ 7.5GM BASE/VIAL	A065002	001	Sep 28, 1998
TEVA PHARMS	EQ 7.5GM BASE/VIAL	A064191	001	Apr 16, 1998
WATSON LABS INC	EQ 1.5GM BASE/VIAL	A064035	002	Feb 26, 1993
	EQ 7.5GM BASE/VIAL	A064036	001	Feb 26, 1993

CEFUROXIME SODIUM IN PLASTIC CONTAINER

SAMSON MEDCL	EQ 75GM BASE/VIAL	A065251	001	Dec 30, 2009
	EQ 225GM BASE/VIAL	A065251	002	Dec 30, 2009

KEFUROX

ACS DOBFAR	EQ 1.5GM BASE/VIAL	A062591	002	Jan 10, 1986
	EQ 7.5GM BASE/VIAL	A062591	003	Dec 17, 1987
LILLY	EQ 1.5GM BASE/VIAL	A062592	002	Jan 10, 1986

KEFUROX IN PLASTIC CONTAINER

LILLY	EQ 1.5GM BASE/VIAL	A062590	002	Jan 10, 1986
-------	--------------------	---------	-----	--------------

ZINACEF IN PLASTIC CONTAINER

IGI LABS INC	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989
--------------	-----------------	---------	-----	--------------

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFUROXIME SODIUM

FRESENIUS KABI USA	EQ 750MG BASE/VIAL	A065001	001	May 30, 2001
TEVA PHARMS	EQ 750MG BASE/VIAL	A064192	002	Apr 16, 1998
	EQ 1.5GM BASE/VIAL	A064192	001	Apr 16, 1998
WATSON LABS INC	EQ 750MG BASE/VIAL	A064035	001	Feb 26, 1993

KEFUROX

ACS DOBFAR	EQ 750MG BASE/VIAL	A062591	001	Jan 10, 1986
------------	--------------------	---------	-----	--------------

INJECTABLE; INTRAVENOUS

KEFUROX

LILLY	EQ 750MG BASE/VIAL	A062592	001	Jan 10, 1986
-------	--------------------	---------	-----	--------------

KEFUROX IN PLASTIC CONTAINER

LILLY	EQ 750MG BASE/VIAL	A062590	001	Jan 10, 1986
-------	--------------------	---------	-----	--------------

CELLULOSE SODIUM PHOSPHATE

POWDER; ORAL

CALCIBIND

MISSION PHARMA	2.5GM/PACKET	N018757	002	Dec 28, 1982
	300GM/BOT	N018757	003	Oct 16, 1984

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

APOTHECON	EQ 250MG BASE	A062973	001	Nov 08, 1988
	EQ 250MG BASE	A063063	001	Sep 29, 1989
	EQ 250MG BASE	A063186	001	Dec 30, 1994
	EQ 500MG BASE	A062974	001	Nov 23, 1988
	EQ 500MG BASE	A063063	002	Sep 29, 1989
	EQ 500MG BASE	A063186	002	Dec 30, 1994
BARR	EQ 250MG BASE	A062773	001	Jun 26, 1987
	EQ 500MG BASE	A062775	001	Apr 22, 1987
FACTA FARMA	EQ 250MG BASE	A062118	001	
	EQ 500MG BASE	A062118	002	
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A061969	001	
	EQ 500MG BASE	A061969	002	
PUREPAC PHARM	EQ 250MG BASE	A062809	001	Apr 22, 1987
	EQ 500MG BASE	A062809	002	Apr 22, 1987
STEVENS J	EQ 250MG BASE	A062870	001	Mar 17, 1988
	EQ 500MG BASE	A062869	001	Mar 17, 1988
SUN PHARM INDS LTD	EQ 250MG BASE	A065007	001	Sep 16, 1999
	EQ 500MG BASE	A065007	002	Sep 16, 1999
TEVA	EQ 250MG BASE	A062760	001	Apr 24, 1987
	EQ 250MG BASE	A062821	001	Feb 05, 1988
	EQ 500MG BASE	A062761	001	Apr 24, 1987
	EQ 500MG BASE	A062823	001	Feb 05, 1988
YOSHITOMI	EQ 250MG BASE	A062872	001	Jun 20, 1988
	EQ 500MG BASE	A062871	001	Jul 05, 1988

DISCONTINUED DRUG PRODUCT LIST

CEPHALEXIN

CAPSULE;ORAL

KEFLEX

PRAGMA PHARMS LLC	EQ 333MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050405 004	May 12, 2006
-------------------	--	-------------	--------------

FOR SUSPENSION;ORAL

CEPHALEXIN

APOTHECON	EQ 125MG BASE/5ML	A062986 001	Apr 18, 1991
	EQ 250MG BASE/5ML	A062987 001	Jul 25, 1989
BARR	EQ 125MG BASE/5ML	A062778 001	Aug 06, 1987
	EQ 250MG BASE/5ML	A062777 001	Aug 06, 1987
FACTA FARMA	EQ 100MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons*	A062117 001	
	EQ 125MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons*	A062117 002	
	EQ 250MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons*	A062117 003	
HIKMA PHARMS	EQ 125MG BASE/5ML	A065444 001	Aug 28, 2009
	EQ 250MG BASE/5ML	A065444 002	Aug 28, 2009
SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065081 001	Jul 27, 2001
	EQ 250MG BASE/5ML	A065081 002	Jul 27, 2001
TEVA	EQ 125MG BASE/5ML	A062767 001	Jun 16, 1987
	EQ 125MG BASE/5ML	A062873 001	May 23, 1988
	EQ 250MG BASE/5ML	A062768 001	Jun 16, 1987
	EQ 250MG BASE/5ML	A062867 001	Apr 15, 1988
VITARINE	EQ 125MG BASE/5ML	A062779 001	Dec 22, 1987
	EQ 250MG BASE/5ML	A062781 001	Dec 22, 1987
YUNG SHIN PHARM	EQ 125MG BASE/5ML	A065336 001	Jul 25, 2007
	EQ 250MG BASE/5ML	A065336 002	Jul 25, 2007

KEFLEX

PRAGMA PHARMS LLC	EQ 100MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons*	N050406 003	
	EQ 125MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050406 001	
	EQ 250MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons*	N050406 002	

TABLET;ORAL

CEPHALEXIN

BARR	EQ 250MG BASE	A062826 001	Aug 17, 1987
	EQ 500MG BASE	A062827 001	Aug 17, 1987
VITARINE	EQ 250MG BASE	A062863 001	Aug 11, 1988
	EQ 500MG BASE	A062863 002	Aug 11, 1988
	EQ 1GM BASE	A062863 003	Aug 11, 1988

KEFLET

LILLY	EQ 250MG BASE	A062745 001	Dec 01, 1986
	EQ 250MG BASE	N050440 003	Feb 26, 1987
	EQ 500MG BASE	A062745 002	Dec 01, 1986
	EQ 500MG BASE	N050440 001	
	EQ 1GM BASE	N050440 002	

TABLET, FOR SUSPENSION;ORAL

PANIXINE DISPERDOSE

RANBAXY LABS LTD	EQ 125MG BASE	A065100 002	Sep 11, 2003
	EQ 250MG BASE	A065100 001	Sep 11, 2003

CEPHALEXIN HYDROCHLORIDE

TABLET;ORAL

KEFTAB

LILLY	EQ 250MG BASE	N050614 001	Oct 29, 1987
	EQ 333MG BASE	N050614 003	May 16, 1988
	EQ 500MG BASE	N050614 002	Oct 29, 1987

DISCONTINUED DRUG PRODUCT LIST

CEPHALOGLYCIN

CAPSULE; ORAL

KAFOCIN

LILLY

250MG

N050219 001

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION

CEPHALOTHIN

INTL MEDICATION

EQ 500MG BASE/VIAL

A062426 001 May 03, 1985

EQ 1GM BASE/VIAL

A062426 002 May 03, 1985

EQ 2GM BASE/VIAL

A062426 003 May 03, 1985

EQ 4GM BASE/VIAL

A062426 004 May 03, 1985

CEPHALOTHIN SODIUM

ABBOTT

EQ 1GM BASE/VIAL

A062547 001 Sep 11, 1985

EQ 1GM BASE/VIAL

A062548 001 Sep 11, 1985

EQ 2GM BASE/VIAL

A062547 002 Sep 11, 1985

EQ 2GM BASE/VIAL

A062548 002 Sep 11, 1985

ABRAXIS PHARM

EQ 1GM BASE/VIAL

A062666 002 Jun 10, 1987

EQ 2GM BASE/VIAL

A062666 001 Jun 10, 1987

BRISTOL

EQ 1GM BASE/VIAL

A062464 001 May 07, 1984

EQ 2GM BASE/VIAL

A062464 002 May 07, 1984

EQ 4GM BASE/VIAL

A062464 003 May 07, 1984

CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER

BAXTER HLTHCARE

EQ 20MG BASE/ML

A062422 003 Jan 31, 1984

EQ 20MG BASE/ML

A062422 005 Jul 16, 1991

EQ 20MG BASE/ML

A062730 001 Mar 05, 1987

EQ 40MG BASE/ML

A062422 004 Jan 31, 1984

EQ 40MG BASE/ML

A062422 006 Jul 16, 1991

EQ 40MG BASE/ML

A062730 002 Mar 05, 1987

CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER

BAXTER HLTHCARE

EQ 20MG BASE/ML

A062422 001 Jan 31, 1984

EQ 40MG BASE/ML

A062422 002 Jan 31, 1984

KEFLIN

LILLY

EQ 1GM BASE/VIAL

N050482 001

EQ 2GM BASE/VIAL

N050482 002

EQ 4GM BASE/VIAL

N050482 003

EQ 20GM BASE/VIAL

N050482 007

KEFLIN IN PLASTIC CONTAINER

LILLY

EQ 1GM BASE/VIAL

A062549 001 Sep 10, 1985

EQ 2GM BASE/VIAL

A062549 002 Sep 10, 1985

SEFFIN

GLAXOSMITHKLINE

EQ 1GM BASE/VIAL

A062435 001 Nov 15, 1983

EQ 2GM BASE/VIAL

A062435 002 Nov 15, 1983

EQ 10GM BASE/VIAL

A062435 003 Nov 15, 1983

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION

CEFADYL

APOTHECON

EQ 500MG BASE/VIAL

A062961 001 Sep 20, 1988

EQ 500MG BASE/VIAL

N050446 005

EQ 1GM BASE/VIAL

A061769 001

EQ 1GM BASE/VIAL

A062724 001 Dec 23, 1986

EQ 1GM BASE/VIAL

A062961 002 Sep 20, 1988

EQ 1GM BASE/VIAL

N050446 001

EQ 2GM BASE/VIAL

A061769 002

EQ 2GM BASE/VIAL

A062724 002 Dec 23, 1986

EQ 2GM BASE/VIAL

A062961 003 Sep 20, 1988

EQ 2GM BASE/VIAL

N050446 002

EQ 4GM BASE/VIAL

A061769 003

EQ 4GM BASE/VIAL

A062961 004 Sep 20, 1988

EQ 4GM BASE/VIAL

N050446 003

EQ 20GM BASE/VIAL

N050446 004

CEPHAPIRIN SODIUM

ABRAXIS PHARM

EQ 500MG BASE/VIAL

A062723 001 Nov 17, 1986

EQ 1GM BASE/VIAL

A062723 002 Nov 17, 1986

EQ 2GM BASE/VIAL

A062723 003 Nov 17, 1986

EQ 4GM BASE/VIAL

A062723 004 Nov 17, 1986

EQ 20GM BASE/VIAL

A062723 005 Nov 17, 1986

EUROHLTH INTL SARL

EQ 500MG BASE/VIAL

A062720 001 Jul 02, 1987

EQ 1GM BASE/VIAL

A062720 002 Jul 02, 1987

EQ 2GM BASE/VIAL

A062720 003 Jul 02, 1987

EQ 20GM BASE/VIAL

A062720 004 Jul 02, 1987

DISCONTINUED DRUG PRODUCT LIST

CEPHRADINE

CAPSULE; ORAL

ANSPOR

GLAXOSMITHKLINE	250MG	A061859	001	
	500MG	A061859	002	

CEPHRADINE

BARR	250MG	A062850	001	Apr 22, 1988
	500MG	A062851	001	Apr 22, 1988
IVAX SUB TEVA PHARMS	250MG	A062762	001	Mar 06, 1987
	500MG	A062762	002	Mar 06, 1987
TEVA	250MG	A062683	001	Jan 09, 1987
	500MG	A062683	002	Jan 09, 1987
VITARINE	250MG	A062813	001	Feb 25, 1988
	500MG	A062813	002	Feb 25, 1988

VELOSEF

APOTHECON	250MG	A061764	001	
	500MG	A061764	002	

VELOSEF '250'

ERSANA	250MG	N050548	001	
--------	-------	---------	-----	--

VELOSEF '500'

ERSANA	500MG	N050548	002	
--------	-------	---------	-----	--

FOR SUSPENSION; ORAL

ANSPOR

GLAXOSMITHKLINE	125MG/5ML	A061866	001	
	250MG/5ML	A061866	002	

CEPHRADINE

BARR	125MG/5ML	A062858	001	May 19, 1988
	250MG/5ML	A062859	001	May 19, 1988
TEVA	125MG/5ML	A062693	001	Jan 09, 1987
	250MG/5ML	A062693	002	Jan 09, 1987

VELOSEF '125'

APOTHECON	125MG/5ML	A061763	001	
-----------	-----------	---------	-----	--

VELOSEF '250'

APOTHECON	250MG/5ML	A061763	002	
-----------	-----------	---------	-----	--

INJECTABLE; INJECTION

VELOSEF

APOTHECON	250MG/VIAL	A061976	001	
	500MG/VIAL	A061976	002	
	1GM/VIAL	A061976	004	
	2GM/VIAL	A061976	003	
	4GM/VIAL	A061976	005	

TABLET; ORAL

VELOSEF

BRISTOL MYERS SQUIBB	1GM	N050530	001	
----------------------	-----	---------	-----	--

CERIVASTATIN SODIUM

TABLET; ORAL

BAYCOL

BAYER PHARMS	0.05MG	N020740	001	Jun 26, 1997
	0.1MG	N020740	002	Jun 26, 1997
	0.2MG	N020740	003	Jun 26, 1997
	0.3MG	N020740	004	Jun 26, 1997
	0.4MG	N020740	005	May 24, 1999
	0.8MG	N020740	006	Jul 24, 2000

CERULETIDE DIETHYLAMINE

INJECTABLE; INJECTION

TYMTRAN

PHARMACIA AND UPJOHN	0.02MG/ML	N018296	001	
----------------------	-----------	---------	-----	--

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	5MG/5ML	A078617	001	Feb 02, 2010
APOTEX INC	5MG/5ML	A078412	001	Jun 18, 2008
AUROBINDO PHARMA LTD	5MG/5ML	A090751	001	Dec 16, 2009
RANBAXY LABS LTD	5MG/5ML	A077472	001	Jun 18, 2008
WOCKHARDT	5MG/5ML	A078757	001	Aug 28, 2009

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

ACTAVIS MID ATLANTIC	5MG/5ML	A090378	002	May 09, 2008
APOTEX INC	5MG/5ML	A090188	002	Apr 22, 2008
CYPRESS PHARM	5MG/5ML	A090300	001	Oct 10, 2008
RANBAXY LABS LTD	5MG/5ML	A090183	002	Apr 24, 2008

DISCONTINUED DRUG PRODUCT LISTCETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

ACTAVIS MID ATLANTIC	5MG/5ML	A090378	001	May 09, 2008
APOTEX INC	5MG/5ML	A090188	001	Apr 22, 2008
CYPRESS PHARM	5MG/5ML	A090300	002	Oct 10, 2008
RANBAXY LABS LTD	5MG/5ML	A090183	001	Apr 24, 2008

ZYRTEC

J AND J CONSUMER INC	5MG/5ML	N020346	001	Sep 27, 1996
----------------------	---------	---------	-----	--------------

TABLET; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

ACTAVIS ELIZABETH	5MG	A078615	003	Dec 28, 2007
	10MG	A078615	004	Dec 28, 2007

TABLET, CHEWABLE; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

SUN PHARM INDS INC	5MG	A077631	004	Jan 11, 2008
	10MG	A077631	003	Jan 11, 2008

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

SUN PHARM INDS INC	5MG	A077631	001	Jan 11, 2008
	10MG	A077631	002	Jan 11, 2008

CHILDREN'S ZYRTEC ALLERGY

J AND J CONSUMER INC	5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021621	003	Nov 16, 2007
	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021621	004	Nov 16, 2007

CHILDREN'S ZYRTEC HIVES RELIEF

J AND J CONSUMER INC	5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021621	005	Nov 16, 2007
	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021621	006	Nov 16, 2007

CETRORELIX

INJECTABLE; INJECTION

CETROTIDE

EMD SERONO INC	EQ 3MG BASE/ML	N021197	002	Aug 11, 2000
----------------	----------------	---------	-----	--------------

CETYL ALCOHOL; COLFOSCERIL PALMITATE; TYLOXAPOL

FOR SUSPENSION; INTRATRACHEAL

EXOSURF NEONATAL

GLAXOSMITHKLINE	12MG/VIAL; 108MG/VIAL; 8MG/VIAL	N020044	001	Aug 02, 1990
-----------------	---------------------------------	---------	-----	--------------

CHENODIOL

TABLET; ORAL

CHENIX

SIGMA TAU	250MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018513	002	Jul 28, 1983
-----------	--	---------	-----	--------------

CHLOPHEDIANOL HYDROCHLORIDE

SYRUP; ORAL

ULO

3M	25MG/5ML	N012126	001	
----	----------	---------	-----	--

CHLORAMPHENICOL

CREAM; TOPICAL

CHLOROMYCETIN

PARKE DAVIS	1%	N050183	001	
-------------	----	---------	-----	--

FOR SOLUTION; OPHTHALMIC

CHLOROMYCETIN

PARKE DALE	25MG/VIAL	N050143	001	
------------	-----------	---------	-----	--

INJECTABLE; INJECTION

CHLOROMYCETIN

PARKE DAVIS	250MG/ML	N050153	001	
-------------	----------	---------	-----	--

OINTMENT; OPHTHALMIC

CHLORAMPHENICOL

ALTANA	1%	A060133	001	
--------	----	---------	-----	--

DISCONTINUED DRUG PRODUCT LIST

CHLORAMPHENICOL

OINTMENT; OPHTHALMIC

CHLOROFAIR

PHARMAFAIR

1%

A062439 001 Apr 21, 1983

CHLOROMYCETIN

PARKEDALE

1%

N050156 001

CHLOROPTIC S.O.P.

ALLERGAN

1%

A061187 001

ECONOCHLOR

ALCON

1%

A061648 001

SOLUTION/DROPS; OPHTHALMIC

CHLORAMPHENICOL

AKORN

0.5%

A062042 001

ALCON

0.5%

A062628 001 Sep 25, 1985

CHLOROFAIR

PHARMAFAIR

0.5%

A062437 001 Apr 14, 1983

CHLOROPTIC

ALLERGAN

0.5%

N050091 001

ECONOCHLOR

ALCON

0.5%

A061645 001

OPHTHOCHLOR

PARKEDALE

0.5%

A061220 001

OPTOMYCIN

OPTOPICS

0.5%

A062171 001 Mar 31, 1982

SOLUTION/DROPS; OTIC

CHLOROMYCETIN

PARKEDALE

0.5%

N050205 001

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION

CHLORAMPHENICOL

ELKINS SINN

EQ 1GM BASE/VIAL

A062406 001 Nov 09, 1982

CHLORAMPHENICOL SODIUM SUCCINATE

GRUPPO LEPETIT

EQ 1GM BASE/VIAL

A062278 001

CHLOROMYCETIN

PARKEDALE

EQ 1GM BASE/VIAL

N050155 001

MYCHEL-S

ANGUS

EQ 1GM BASE/VIAL

A060132 001

CHLORAMPHENICOL; DESOXYRIBONUCLEASE; FIBRINOLYSIN

OINTMENT; TOPICAL

ELASE-CHLOROMYCETIN

PARKE DAVIS

10MG/GM; 666 UNITS/GM; 1 UNITS/GM

N050294 001

CHLORAMPHENICOL; HYDROCORTISONE ACETATE

FOR SUSPENSION; OPHTHALMIC

CHLOROMYCETIN HYDROCORTISONE

PARKEDALE

12.5MG/VIAL; 25MG/VIAL

N050202 001

CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

OPHTHOCORT

PARKEDALE

10MG/GM; 5MG/GM; 10,000 UNITS/GM

N050201 002

CHLORAMPHENICOL; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

CHLOROMYCIN

PARKE DAVIS

1%; 10,000 UNITS/GM

N050203 002

CHLORAMPHENICOL; PREDNISOLONE

OINTMENT; OPHTHALMIC

CHLOROPTIC-P S.O.P.

ALLERGAN

1%; 0.5%

A061188 001

CHLORDIAZEPOXIDE

CAPSULE, EXTENDED RELEASE; ORAL

LIBRELEASE

VALEANT PHARM INTL

30MG

N017813 001 Sep 12, 1983

TABLET; ORAL

LIBRITABS

VALEANT PHARM INTL

5MG

A085482 001

10MG

A085481 001

25MG

A085488 001

DISCONTINUED DRUG PRODUCT LIST

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

A-POXIDE

ABBOTT

5MG

A085447 001

5MG

A085517 001

10MG

A085447 002

10MG

A085518 001

25MG

A085447 003

25MG

A085513 001

CHLORDIAZACHEL

RACHELLE

5MG

A085086 001

10MG

A084639 001

25MG

A085087 001

CHLORDIAZEPOXIDE HYDROCHLORIDE

ASCOT

5MG

A087525 001 Jan 07, 1982

10MG

A087524 001 Jan 07, 1982

25MG

A087512 001 Jan 07, 1982

FERRANTE

5MG

A085118 001

10MG

A085119 001

25MG

A085120 001

HALSEY

5MG

A085340 001

10MG

A085339 001

25MG

A084685 001

HIKMA PHARMS LLC

5MG

A085014 001

10MG

A085000 001

25MG

A085294 001

IMPAX LABS

5MG

A086213 001

10MG

A085113 001

25MG

A086212 001

IVAX SUB TEVA PHARMS

5MG

A083741 001

10MG

A083742 001

25MG

A083570 001

LEDERLE

5MG

A086892 001

5MG

A087234 001

10MG

A086876 001

10MG

A087037 001

25MG

A086893 001

25MG

A087231 001

MAST MM

10MG

A086217 001

MYLAN

5MG

A084886 001

10MG

A084601 001

25MG

A084887 001

PARKE DAVIS

5MG

A085163 001

10MG

A084598 001

25MG

A085164 001

PIONEER PHARMS

10MG

A089533 001 Jul 15, 1988

25MG

A089558 001 Jul 15, 1988

PUREPAC PHARM

5MG

A085155 001

10MG

A084939 002

25MG

A085144 001

ROXANE

5MG

A084706 001

10MG

A084700 001

25MG

A084705 001

SANDOZ

5MG

A084919 001

10MG

A084920 001

25MG

A084823 001

SUPERPHARM

5MG

A088987 001 Apr 25, 1985

10MG

A088986 001 Apr 25, 1985

25MG

A088988 001 Apr 25, 1985

TEVA

5MG

A088705 001 Jan 18, 1985

10MG

A088706 001 Jan 18, 1985

25MG

A086494 001

25MG

A088707 001 Jan 18, 1985

UPSHER-SMITH LABS

5MG

A084678 001

10MG

A084041 001

25MG

A084679 002

USL PHARMA

5MG

A084644 001

25MG

A084645 001

VANGARD

5MG

A088129 001 Mar 28, 1983

10MG

A088010 001 Mar 28, 1983

25MG

A088130 001 Mar 28, 1983

WATSON LABS

5MG

A086383 001

DISCONTINUED DRUG PRODUCT LISTCHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

10MG

A086294 001

25MG

A086382 001

LIBRIUM

VALEANT PHARM INTL

5MG

N012249 002

10MG

N012249 001

25MG

N012249 003

LYGEN

ALRA

5MG

A085107 001

10MG

A085009 001

25MG

A085108 001

INJECTABLE; INJECTION

LIBRIUM

VALEANT PHARMS LLC

100MG/AMP

N012301 001

CHLORDIAZEPOXIDE; ESTROGENS, ESTERIFIED

TABLET; ORAL

MENRIUM 10-4

ROCHE

10MG; 0.4MG

N014740 006

MENRIUM 5-2

ROCHE

5MG; 0.2MG

N014740 002

MENRIUM 5-4

ROCHE

5MG; 0.4MG

N014740 004

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE

APOTEX INC

0.12%

A075561 001 Nov 14, 2000

SOLUTION; TOPICAL

EXIDINE

XTTRIUM

2.5%

N019421 001 Dec 17, 1985

MICRODERM

J AND J

4%

A072255 001 Apr 15, 1991

PREVACARE R

J AND J

0.5%

A072292 001 Jan 28, 1992

STERI-STAT

MATRIX MEDCL

4%

A070104 001 Jul 24, 1986

SPONGE; TOPICAL

CHLORHEXIDINE GLUCONATE

KENDALL IL

4%

N019490 001 Mar 27, 1987

E-Z SCRUB

BECTON DICKINSON

4%

A073416 001 Mar 14, 2000

HIBICLENS

MOLNLYCKE HLTH

4% **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N018423 001

MICRODERM

J AND J

4%

A072295 001 Feb 28, 1991

PHARMASEAL SCRUB CARE

CAREFUSION

4%

N019793 001 Dec 02, 1988

CHLORMERODRIN HG-197

INJECTABLE; INJECTION

CHLORMERODRIN HG 197

BRACCO

0.6-1.4mCi/ML

N017269 001

CHLORMEZANONE

TABLET; ORAL

TRANCOPAL

SANOFI AVENTIS US

100MG

N011467 003

200MG

N011467 005

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

NESACAINE-MPF

FRESENIUS KABI USA

2%

N009435 003

3%

N009435 004

DISCONTINUED DRUG PRODUCT LISTCHLOROQUINE HYDROCHLORIDE

INJECTABLE; INJECTION

ARALEN HYDROCHLORIDE

SANOFI AVENTIS US EQ 40MG BASE/ML N006002 002

CHLOROQUINE PHOSPHATE

TABLET; ORAL

CHLOROQUINE PHOSPHATE

IMPAX LABS

EQ 150MG BASE

A080880 001

EQ 300MG BASE

A040516 001 Aug 29, 2003

MD PHARM

EQ 150MG BASE

A087228 001

PUREPAC PHARM

EQ 150MG BASE

A080886 001

TEVA

EQ 150MG BASE

A087504 001 Jan 13, 1982

WATSON LABS

EQ 150MG BASE

A087979 001 Dec 21, 1982

EQ 300MG BASE

A088030 001 Dec 21, 1982

CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE

TABLET; ORAL

ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE

SANOFI AVENTIS US EQ 300MG BASE; EQ 45MG BASE

N014860 002

CHLOROTHIAZIDE

TABLET; ORAL

CHLOROTHIAZIDE

ABC HOLDING

250MG

A085569 001

HIKMA INTL PHARMS

250MG

A086028 001 Jul 14, 1982

LEDERLE

500MG

A087736 001 Jul 14, 1982

LEDERLE

250MG

A086940 001

500MG

A086938 001

SANDOZ

250MG

A085485 001

WATSON LABS

250MG

A085165 001

250MG

A085173 001

250MG

A086795 001 Aug 15, 1983

500MG

A084026 001 Sep 01, 1982

500MG

A086796 001 Aug 15, 1983

DIURIL

OAK PHARMS AKORN

250MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N011145 004

500MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N011145 002

CHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

ALDOCLOR-150

MERCK

150MG; 250MG

N016016 001

ALDOCLOR-250

MERCK

250MG; 250MG

N016016 002

METHYLDOPA AND CHLOROTHIAZIDE

PAR PHARM

150MG; 250MG

A070783 001 Nov 06, 1987

250MG; 250MG

A070654 001 Nov 06, 1987

CHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

CHLOROTHIAZIDE AND RESERPINE

HIKMA PHARMS LLC

250MG; 0.125MG

A088557 001 Dec 22, 1983

500MG; 0.125MG

A088365 001 Dec 22, 1983

CHLOROTHIAZIDE W/ RESERPINE

WATSON LABS

250MG; 0.125MG

A084853 001

500MG; 0.125MG

A088151 001 Jun 09, 1983

CHLOROTHIAZIDE-RESERPINE

MYLAN

250MG; 0.125MG

A087744 001 May 06, 1982

500MG; 0.125MG

A087745 001 May 06, 1982

DIUPRES-250

MERCK

250MG; 0.125MG

N011635 003 Aug 26, 1987

DIUPRES-500

MERCK

500MG; 0.125MG

N011635 006 Aug 26, 1987

DISCONTINUED DRUG PRODUCT LISTCHLOROTRIANISENE

CAPSULE; ORAL

CHLOROTRIANISENE

BANNER PHARMACAPS 12MG A084652 001

TACE

SANOFI AVENTIS US 12MG N008102 004
 25MG N011444 001
 72MG N016235 001

CHLOROXYLINE

SHAMPOO; TOPICAL

CAPITROL

WESTWOOD SQUIBB 2% N017594 001

CHLORPHENESIN CARBAMATE

TABLET; ORAL

MAOLATE

PHARMACIA AND UPJOHN 400MG N014217 002

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

CHLORPHENIRAMINE MALEATE

AUROLIFE PHARMA LLC 12MG A070797 001 Aug 12, 1988

TELDRIN

GLAXOSMITHKLINE 8MG N017369 001
 12MG N017369 002

INJECTABLE; INJECTION

CHLOR-TRIMETON

SCHERING PLOUGH 10MG/ML N008826 001
 100MG/ML N008794 001

CHLORPHENIRAMINE MALEATE

BEL MAR 10MG/ML A080821 001
 ELKINS SINN 10MG/ML A080797 001
 WATSON LABS 10MG/ML A083593 001
 10MG/ML A086096 001
 100MG/ML A086095 001

PYRIDAMAL 100

BEL MAR 100MG/ML A083733 001

SYRUP; ORAL

CHLOR-TRIMETON

SCHERING 2MG/5ML N006921 006

CHLORPHENIRAMINE MALEATE

PHARM ASSOC 2MG/5ML A087520 001 Feb 10, 1982

TABLET; ORAL

ANTAGONATE

BAYER PHARMS 4MG A083381 001

CHLOR-TRIMETON

SCHERING 4MG N006921 002

CHLORPHENIRAMINE MALEATE

ANABOLIC 4MG A083078 001
 AUROLIFE PHARMA LLC 4MG A080961 001
 BELL PHARMA 4MG A083062 001
 ELKINS SINN 4MG A080938 001
 IMPAX LABS 4MG A080809 001
 IVAX SUB TEVA PHARMS 4MG A080779 001
 KV PHARM 4MG A087164 001
 LEDERLE 4MG A086941 001
 NEWTRON PHARMS 4MG A086519 001
 PANRAY 4MG A083243 001
 PHARMAVITE 4MG A085104 001
 PHARMERAL 4MG A083753 001
 PIONEER PHARMS 4MG A088556 001 Jul 13, 1984
 PUREPAC PHARM 4MG A086306 001
 PVT FORM 4MG A080786 001
 ROXANE 4MG A080626 001
 SUN PHARM INDS 4MG A080700 001
 VITARINE 4MG A085837 001
 WATSON LABS 4MG A080696 001
 4MG A080791 001
 4MG A085139 001

WEST WARD 4MG A083787 001

KLOROMIN

HALSEY 4MG A083629 001

DISCONTINUED DRUG PRODUCT LIST

CHLORPHENIRAMINE MALEATE

TABLET; ORAL

PHENETRON

LANNETT 4MG A080846 001

TABLET, EXTENDED RELEASE; ORAL

CHLOR-TRIMETON

BAYER HEALTHCARE LLC 8MG N007638 001

EFIDAC 24 CHLORPHENIRAMINE MALEATE

ALZA 16MG N019746 002 Nov 18, 1994

CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE

TABLET, EXTENDED RELEASE; ORAL

CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE

SPRIASO LLC 8MG; 54.3MG N206323 001 Jun 22, 2015

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

COLD CAPSULE IV

GRAHAM DM 12MG; 75MG N018793 001 Apr 25, 1985

COLD CAPSULE V

GRAHAM DM 8MG; 75MG N018794 001 Apr 23, 1985

TABLET, EXTENDED RELEASE; ORAL

TRIAMINIC-12

NOVARTIS 12MG; 75MG N018115 001

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CODIMAL-L.A. 12

SCHWARZ PHARMA 12MG; 120MG N018935 001 Apr 15, 1985

ISOCOLOR

FISONS 8MG; 120MG N018747 001 Mar 06, 1986

PSEUDOEPHEDRINE HYDROCHLORIDE AND CHLORPHENIRAMINE MALEATE

CENT PHARMS 8MG; 120MG N019428 001 Aug 02, 1988

GRAHAM DM 8MG; 120MG N018844 001 Mar 20, 1985

12MG; 120MG N018843 001 Mar 18, 1985

KV PHARM 12MG; 120MG A071455 001 Mar 01, 1989

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

CODEPREX

UCB INC EQ 4MG MALEATE/5ML; EQ 20MG BASE/5ML N021369 001 Jun 21, 2004

PENNTUSS

FISONS EQ 4MG MALEATE/5ML; EQ 10MG BASE/5ML N018928 001 Aug 14, 1985

CHLORPHENTERMINE HYDROCHLORIDE

TABLET; ORAL

PRE-SATE

PARKE DAVIS EQ 65MG BASE N014696 001

CHLORPROMAZINE

SUPPOSITORY; RECTAL

THORAZINE

GLAXOSMITHKLINE 25MG **Federal Register determination N009149 024

that product was not discontinued or
withdrawn for safety or efficacy
reasons**

100MG **Federal Register determination N009149 033

that product was not discontinued or
withdrawn for safety or efficacy
reasons**CHLORPROMAZINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

THORAZINE

GLAXOSMITHKLINE 30MG N011120 016

75MG N011120 017

150MG N011120 018

200MG N011120 019

300MG N011120 020

CONCENTRATE; ORAL

CHLORPROMAZINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC 100MG/ML A086863 001

PHARM ASSOC 30MG/ML A040231 001 Dec 30, 1999

100MG/ML A040224 001 Jan 26, 1999

WOCKHARDT 30MG/ML A087032 001 Jul 08, 1982

100MG/ML A087053 001

DISCONTINUED DRUG PRODUCT LIST

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

CHLORPROMAZINE HYDROCHLORIDE INTENSOL

CYCLE PHARMS LTD	30MG/ML	A088157	001	Apr 27, 1983
	100MG/ML	A088158	001	Apr 27, 1983

SONAZINE

SANDOZ	30MG/ML	A080983	004	
	100MG/ML	A080983	005	

THORAZINE

GLAXOSMITHKLINE	30MG/ML	**Federal Register	N009149	032	
		determination that product was not discontinued or withdrawn for safety or efficacy reasons**			
	100MG/ML	**Federal Register	N009149	043	
		determination that product was not discontinued or withdrawn for safety or efficacy reasons**			

INJECTABLE; INJECTION

CHLORPROMAZINE HYDROCHLORIDE

ABRAXIS PHARM	25MG/ML	A084911	001	
MARSAM PHARMS LLC	25MG/ML	A089563	001	Apr 15, 1988
WATSON LABS	25MG/ML	A080365	001	
	25MG/ML	A085591	001	
WYETH AYERST	25MG/ML	A080370	001	

THORAZINE

GLAXOSMITHKLINE	25MG/ML	**Federal Register	N009149	011	
		determination that product was not discontinued or withdrawn for safety or efficacy reasons**			

SYRUP; ORAL

CHLORPROMAZINE HYDROCHLORIDE

ALPHARMA US PHARMS	10MG/5ML	A086712	001	
--------------------	----------	---------	-----	--

SONAZINE

SANDOZ	10MG/5ML	A083040	001	
--------	----------	---------	-----	--

THORAZINE

GLAXOSMITHKLINE	10MG/5ML	**Federal Register	N009149	022	
		determination that product was not discontinued or withdrawn for safety or efficacy reasons**			

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

ABBOTT	10MG	A084414	001	
	25MG	A084415	001	
	50MG	A084411	001	
	100MG	A084412	001	
	200MG	A084413	001	
CYCLE PHARMS LTD	10MG	A085331	001	
	25MG	A085331	002	
	50MG	A085331	003	
	100MG	A085331	004	
	200MG	A085331	005	
IVAX SUB TEVA PHARMS	10MG	A083549	001	
	25MG	A083549	002	
	50MG	A083549	003	
	100MG	A083574	001	
	200MG	A083575	001	
KV PHARM	10MG	A085750	002	Jan 04, 1982
	25MG	A085751	001	
	50MG	A085484	001	
	100MG	A085752	001	
	200MG	A085748	002	Jan 04, 1982
LEDERLE	10MG	A084803	001	
	25MG	A084801	001	
	50MG	A084800	001	
	100MG	A084789	001	
	200MG	A084802	001	
PUREPAC PHARM	10MG	A080403	004	
	25MG	A080403	001	
	50MG	A080403	002	
	100MG	A080403	003	
	200MG	A080403	005	
PVT FORM	25MG	A080340	001	
	50MG	A080340	002	
	200MG	A080340	003	

DISCONTINUED DRUG PRODUCT LISTCHLORPROMAZINE HYDROCHLORIDE

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

SANDOZ	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A080439 001	
	25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A080439 002	
	50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A080439 003	
	100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A080439 004	
	200MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A080439 005	
VANGARD	10MG	A088038 001	Aug 16, 1982
	25MG	A087645 001	
	50MG	A087646 001	
WATSON LABS	10MG	A085959 001	
	25MG	A085956 001	
	50MG	A085960 001	
	100MG	A085957 001	
	200MG	A085958 001	
WEST WARD	10MG	A087783 001	Sep 16, 1982
	25MG	A087865 001	Sep 16, 1982
	50MG	A087878 001	Sep 15, 1982
	100MG	A087884 001	Sep 15, 1982
	200MG	A087880 001	Sep 16, 1982
PROMAPAR			
PARKE DAVIS	10MG	A086886 001	
	25MG	A084423 001	
	50MG	A086887 001	
	100MG	A086888 001	
	200MG	A086885 001	
THORAZINE			
GLAXOSMITHKLINE	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009149 002	
	25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009149 007	
	50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009149 013	
	100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009149 018	
	200MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009149 020	

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

ANI PHARMS INC	100MG	A088768 001	Oct 11, 1984
	100MG	A088812 001	Oct 19, 1984
	100MG	A088840 001	Oct 25, 1984
	100MG	A088918 001	Oct 16, 1984
	100MG	A089446 001	Nov 17, 1986
	250MG	A088813 001	Oct 19, 1984
	250MG	A088919 001	Oct 16, 1984
	250MG	A089447 001	Nov 17, 1986
AUROLIFE PHARMA LLC	100MG	A088725 001	Aug 31, 1984
	250MG	A088726 001	Aug 31, 1984

DISCONTINUED DRUG PRODUCT LIST

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

DAVA PHARMS INC	100MG	A089561 001	Sep 04, 1987
	250MG	A089562 001	Sep 04, 1987
HALSEY	100MG	A089321 001	Jan 16, 1986
	250MG	A088662 001	Jan 09, 1986
PAR PHARM	100MG	A088175 001	Feb 27, 1984
	250MG	A088176 001	Feb 27, 1984
SANDOZ	250MG	A084669 001	
SUPERPHARM	100MG	A088694 001	Sep 17, 1984
	250MG	A088695 001	Sep 17, 1984
TEVA PHARMS USA	250MG	A087353 001	
USL PHARMA	100MG	A088708 001	Aug 30, 1984
	250MG	A088709 001	Aug 30, 1984
WATSON LABS	100MG	A086865 001	Sep 24, 1984
	100MG	A088608 001	Apr 12, 1984
	250MG	A086866 001	
	250MG	A088568 001	Apr 12, 1984
WATSON LABS INC	100MG	A088852 001	Sep 26, 1984
	250MG	A088826 001	Sep 26, 1984
GLUCAMIDE			
ANI PHARMS INC	250MG	A088641 001	Oct 11, 1984

CHLORPROTHIXENE

CONCENTRATE; ORAL

TARACTAN

ROCHE	100MG/5ML	N016149 002	
-------	-----------	-------------	--

INJECTABLE; INJECTION

TARACTAN

ROCHE	12.5MG/ML	N012487 001	
-------	-----------	-------------	--

TABLET; ORAL

TARACTAN

ROCHE	10MG	N012486 005	
	25MG	N012486 004	
	50MG	N012486 003	
	100MG	N012486 001	

CHLORTETRACYCLINE HYDROCHLORIDE

OINTMENT; OPHTHALMIC

AUREOMYCIN

LEDERLE	1%	N050404 001	
---------	----	-------------	--

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

ABBOTT	25MG	A087364 001	
	50MG	A087384 001	
ASCOT	25MG	A087698 001	Oct 20, 1982
	50MG	A087699 001	Oct 20, 1982
BARR LABS INC	25MG	A088902 001	Sep 19, 1985
	50MG	A088903 001	Sep 19, 1985
DAVA PHARMS INC	25MG	A087451 001	
	50MG	A087450 001	
G AND W LABS INC	50MG	A088651 001	May 30, 1985
IVAX PHARMS	25MG	A087555 001	
	25MG	A088164 001	Jan 09, 1984
	50MG	A087176 001	
	50MG	A087947 001	Feb 27, 1984
KV PHARM	25MG	A087311 001	
	50MG	A087312 001	
MUTUAL PHARM	25MG	A087292 001	
	25MG	A089738 001	Sep 19, 1988
	50MG	A087293 001	
	50MG	A089739 001	Sep 19, 1988
PIONEER PHARMS	50MG	A089591 001	Jul 21, 1988
PUREPAC PHARM	25MG	A088139 001	Jul 16, 1986
	50MG	A088140 001	Aug 11, 1983
SANDOZ	25MG	A087380 001	
	50MG	A087118 001	
	50MG	A087381 001	
SUPERPHARM	25MG	A087473 001	Feb 09, 1983
	50MG	A087247 001	Feb 09, 1983
USL PHARMA	25MG	A089051 001	Jun 01, 1987

DISCONTINUED DRUG PRODUCT LIST

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

	50MG	A089052 001	Jun 01, 1987
VANGARD	25MG	A088012 001	Jul 14, 1982
	50MG	A088073 001	Mar 25, 1983
WARNER CHILCOTT	25MG	A087515 001	Jan 24, 1983
	50MG	A087516 001	Feb 09, 1983
WATSON LABS	25MG	A087050 001	
	25MG	A087100 001	
	25MG	A087296 001	
	25MG	A087706 001	
	50MG	A087029 001	
	50MG	A087082 001	
	50MG	A087521 001	
	50MG	A087689 001	
HYGROTON			
SANOFI AVENTIS US	25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012283 004	
	50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012283 003	
THALITONE			
CASPER PHARMA LLC	15MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019574 001	Dec 20, 1988
	25MG	N019574 002	Feb 12, 1992
MONARCH PHARMS	25MG	A088051 001	Nov 12, 1982

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLONIDINE HYDROCHLORIDE AND CHLORTHALIDONE

PAR PHARM	15MG;0.1MG	A071179 001	Dec 16, 1987
	15MG;0.2MG	A071178 001	Dec 16, 1987
	15MG;0.3MG	A071142 001	Dec 16, 1987
COMBIPRES			
BOEHRINGER INGELHEIM	15MG;0.1MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017503 001	
	15MG;0.2MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017503 002	
	15MG;0.3MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017503 003	Apr 10, 1984

CHLORTHALIDONE; METOPROLOL TARTRATE

CAPSULE; ORAL

LOPRESSIDONE

NOVARTIS	25MG;100MG	N019451 001	Dec 31, 1987
	25MG;200MG	N019451 002	Dec 31, 1987

CHLORTHALIDONE; RESERPINE

TABLET; ORAL

DEMI-REGROTON

SANOFI AVENTIS US	25MG;0.125MG	N015103 002	
REGROTON			
SANOFI AVENTIS US	50MG;0.25MG	N015103 001	

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

ACTAVIS ELIZABETH	250MG	A088928 001	May 08, 1987
	500MG	A040113 001	Sep 29, 1995
AUROLIFE PHARMA LLC	250MG	A089852 001	May 04, 1988
	500MG	A089853 001	May 04, 1988
OHM LABS	250MG	A081298 001	Dec 29, 1993
	500MG	A081299 001	Dec 29, 1993
PAR PHARM	250MG	A087981 001	Sep 20, 1983
PIONEER PHARMS	250MG	A089592 001	Jan 06, 1989

DISCONTINUED DRUG PRODUCT LIST

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

	500MG	A089948 001	Jan 06, 1989
SUN PHARM INDS	500MG	A089970 001	Sep 27, 1990
WATSON LABS	250MG	A086901 001	
	250MG	A086948 001	Aug 09, 1982
	500MG	A040137 001	Aug 09, 1996
	500MG	A081019 001	Jul 29, 1991
	500MG	A081040 001	Aug 22, 1989
PARAFLEX			
ORTHO MCNEIL PHARM	250MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011300 003	
PARAFON FORTE DSC			
JANSSEN R AND D	500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011529 002	Jun 15, 1987
STRIFON FORTE DSC			
FERNDALE LABS	500MG	A081008 001	Dec 23, 1988

CHOLESTYRAMINE

BAR, CHEWABLE; ORAL

CHOLYBAR

PARKE DAVIS	EQ 4GM RESIN/BAR	A071621 001	May 26, 1988
	EQ 4GM RESIN/BAR	A071739 001	May 26, 1988
POWDER; ORAL			
CHOLESTYRAMINE			
ANI PHARMS INC	EQ 4GM RESIN/PACKET	A074554 001	Oct 02, 1996
	EQ 4GM RESIN/SCOOPFUL	A074554 002	Oct 02, 1996
IVAX SUB TEVA PHARMS	EQ 4GM RESIN/PACKET	A074771 001	Jul 09, 1997
	EQ 4GM RESIN/SCOOPFUL	A074771 002	Jul 09, 1997
TEVA	EQ 4GM RESIN/PACKET	A074347 001	May 28, 1998
	EQ 4GM RESIN/SCOOPFUL	A074347 002	May 28, 1998
CHOLESTYRAMINE LIGHT			
TEVA	EQ 4GM RESIN/PACKET	A074348 001	May 28, 1998
	EQ 4GM RESIN/SCOOPFUL	A074348 002	May 28, 1998
TEVA PHARMS	EQ 4GM RESIN/PACKET	A074555 001	Sep 30, 1998
	EQ 4GM RESIN/SCOOPFUL	A074555 002	Sep 30, 1998
LOCHOLEST			
SANDOZ	EQ 4GM RESIN/PACKET	A074561 001	Aug 15, 1996
	EQ 4GM RESIN/SCOOPFUL	A074561 002	Aug 15, 1996
LOCHOLEST LIGHT			
SANDOZ	EQ 4GM RESIN/PACKET	A074562 001	Aug 15, 1996
	EQ 4GM RESIN/SCOOPFUL	A074562 002	Aug 15, 1996
QUESTRAN			
BRISTOL MYERS	EQ 4GM RESIN/PACKET **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016640 001	
	EQ 4GM RESIN/SCOOPFUL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016640 003	
QUESTRAN LIGHT			
BRISTOL MYERS	EQ 4GM RESIN/PACKET **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019669 001	Dec 05, 1988
	EQ 4GM RESIN/SCOOPFUL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019669 003	Dec 05, 1988
TABLET; ORAL			
QUESTRAN			
APOTHECON	EQ 800MG RESIN	A073403 002	Dec 27, 1999
	EQ 1GM RESIN	A073403 001	Apr 28, 1994

DISCONTINUED DRUG PRODUCT LIST

CHORIOGONADOTROPIN ALFA

INJECTABLE; INJECTION

OVIDREL

EMD SERONO

0.25MG/VIAL

N021149 001 Sep 20, 2000

CHROMIC CHLORIDE

INJECTABLE; INJECTION

CHROMIC CHLORIDE

ABRAXIS PHARM

EQ 0.004MG CHROMIUM/ML

N019271 001 May 05, 1987

CHROMIC PHOSPHATE P-32

INJECTABLE; INJECTION

PHOSPHOCOL P32

MALLINKRODT NUCLEAR

5mCi/ML

N017084 001

CHYMOPAPAIN

INJECTABLE; INJECTION

CHYMODIACTIN

CHART MEDCL

4,000 UNITS/VIAL

N018663 002 Aug 21, 1984

10,000 UNITS/VIAL **Federal Register

N018663 001 Nov 10, 1982

determination that product was not discontinued or withdrawn for safety or efficacy reasons**

DISCASE

ABBOTT

12,500 UNITS/VIAL

N018625 001 Jan 18, 1984

CHYMOTRYPSIN

FOR SOLUTION; OPHTHALMIC

ALPHA CHYMAR

SOLA BARNES HIND

750 UNITS/VIAL

N011837 001

CATARASE

CIBA

300 UNITS/VIAL

N016938 001

NOVARTIS

150 UNITS/VIAL

N018121 001

ZOLYSE

ALCON

750 UNITS/VIAL

N011903 001

CICLOPIROX

SOLUTION; TOPICAL

CICLOPIROX

MYLAN PHARMS INC

8%

A078567 001 Sep 18, 2007

TEVA PHARMS

8%

A078079 001 Sep 18, 2007

CIDOFOVIR

INJECTABLE; INJECTION

VISTIDE

GILEAD SCIENCES INC

EQ 75MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N020638 001 Jun 26, 1996

CILASTATIN SODIUM; IMIPENEM

INJECTABLE; INJECTION

PRIMAXIN

MERCCK

EQ 250MG BASE/VIAL; 250MG/VIAL

A062756 001 Jan 08, 1987

EQ 500MG BASE/VIAL; 500MG/VIAL

A062756 002 Jan 08, 1987

POWDER; INTRAMUSCULAR

PRIMAXIN

MERCCK

EQ 500MG BASE/VIAL; 500MG/VIAL

N050630 001 Dec 14, 1990

EQ 750MG BASE/VIAL; 750MG/VIAL

N050630 002 Dec 14, 1990

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

ACTAVIS ELIZABETH

100MG

A077028 002 Nov 26, 2004

COREPHARMA

50MG

A077150 001 Mar 11, 2005

100MG

A077022 001 Nov 23, 2004

FRONTIDA BIOPHARM

50MG

A077208 002 Mar 29, 2006

100MG

A077208 001 Mar 29, 2006

IVAX SUB TEVA PHARMS

100MG

A077020 002 Mar 01, 2005

PLETAL

OTSUKA

50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N020863 001 Jan 15, 1999

100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N020863 002 Jan 15, 1999

DISCONTINUED DRUG PRODUCT LIST

CIMETIDINE

SUSPENSION; ORAL

TAGAMET HB 200

GLAXOSMITHKLINE

200MG/20ML

N020951 001 Jul 09, 1999

TABLET; ORAL

CIMETIDINE

CYCLE PHARMS LTD

300MG

A074361 001 Dec 23, 1994

400MG

A074361 002 Dec 23, 1994

800MG

A074371 001 Dec 23, 1994

DAVA PHARMS INC

300MG

A074340 001 Jun 23, 1995

400MG

A074340 002 Jun 23, 1995

800MG

A074339 001 Jun 23, 1995

IVAX SUB TEVA PHARMS

200MG

A074401 001 May 30, 1995

200MG

A074424 001 Jul 28, 1995

300MG

A074401 002 May 30, 1995

300MG

A074424 002 Jul 28, 1995

400MG

A074401 003 May 30, 1995

400MG

A074424 003 Jul 28, 1995

800MG

A074402 001 May 30, 1995

800MG

A074424 004 Jul 28, 1995

LEK PHARMS

100MG

A075122 001 Jun 19, 1998

200MG

A074250 001 Jun 29, 1995

200MG

A075122 002 Jun 19, 1998

300MG

A074250 002 Jun 29, 1995

400MG

A074250 003 Jun 29, 1995

800MG

A074250 004 Jun 29, 1995

PERRIGO

100MG

A074972 001 Jun 19, 1998

PLIVA

200MG

A074568 001 Feb 27, 1997

300MG

A074568 002 Feb 27, 1997

400MG

A074568 003 Feb 27, 1997

SANDOZ

200MG

A074100 001 Jan 31, 1995

300MG

A074100 002 Jan 31, 1995

400MG

A074100 003 Jan 31, 1995

800MG

A074100 004 Jan 31, 1995

TEVA

200MG

A074365 001 Feb 28, 1995

300MG

A074365 002 Feb 28, 1995

400MG

A074365 003 Feb 28, 1995

800MG

A074365 004 Feb 28, 1995

UPSHER-SMITH LABS

200MG

A074506 001 Jan 24, 1996

300MG

A074506 002 Jan 24, 1996

400MG

A074506 003 Jan 24, 1996

800MG

A074506 004 Jan 24, 1996

VINTAGE PHARMS LLC

200MG

A074281 001 May 17, 1994

300MG

A074281 002 May 17, 1994

400MG

A074281 003 May 17, 1994

800MG

A074329 001 May 17, 1994

WATSON LABS

200MG

A075425 001 Jul 29, 1999

WATSON LABS INC

200MG

A074349 001 Aug 30, 1996

300MG

A074349 002 Aug 30, 1996

400MG

A074349 003 Aug 30, 1996

800MG

A074316 001 Feb 28, 1996

TAGAMET

GLAXOSMITHKLINE

200MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N017920 002

300MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N017920 003

400MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N017920 004 Dec 14, 1983

800MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N017920 005 Apr 30, 1986

TAGAMET HB

MEDTECH PRODUCTS

100MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N020238 001 Jun 19, 1995

DISCONTINUED DRUG PRODUCT LIST

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HYDROCHLORIDE

HOSPIRA	EQ 300MG BASE/2ML	A074296 001	Mar 28, 1997
	EQ 300MG BASE/2ML	A074344 001	Jan 31, 1995
	EQ 300MG BASE/2ML	A074345 001	Jan 31, 1995
	EQ 300MG BASE/2ML	A074412 001	Mar 28, 1997
	EQ 300MG BASE/2ML	A074422 001	Jan 31, 1995
LUITPOLD	EQ 300MG BASE/2ML	A074353 001	Dec 20, 1994
TEVA PARENTERAL	EQ 300MG BASE/2ML	A074252 001	Nov 26, 1997
VINTAGE PHARMS LLC	EQ 300MG BASE/2ML	A074005 001	Aug 31, 1994

CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

HOSPIRA	EQ 6MG BASE/ML	A074269 001	Dec 27, 1994
	EQ 90MG BASE/100ML	A074468 005	Dec 29, 1994
	EQ 120MG BASE/100ML	A074468 006	Dec 29, 1994
	EQ 180MG BASE/100ML	A074468 003	Dec 29, 1994
	EQ 240MG BASE/100ML	A074468 004	Dec 29, 1994
	EQ 360MG BASE/100ML	A074468 001	Dec 29, 1994
	EQ 480MG BASE/100ML	A074468 002	Dec 29, 1994

TAGAMET

GLAXOSMITHKLINE	EQ 300MG BASE/2ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017939 002	
-----------------	--	-------------	--

TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

GLAXOSMITHKLINE	EQ 6MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019434 001	Oct 31, 1985
-----------------	---	-------------	--------------

SOLUTION; ORAL

CIMETIDINE HYDROCHLORIDE

ANI PHARMS INC	EQ 300MG BASE/5ML	A074859 001	Jul 09, 1998
	EQ 300MG BASE/5ML	A075110 001	Jun 18, 1998
APOTEX INC	EQ 300MG BASE/5ML	A075560 001	Mar 15, 2000
CYCLE PHARMS LTD	EQ 300MG BASE/5ML	A074541 001	Aug 05, 1997
G AND W LABS INC	EQ 300MG BASE/5ML	A074176 001	Jun 01, 1994
VINTAGE PHARMS LLC	EQ 300MG BASE/5ML	A074251 001	Dec 22, 1994

TAGAMET

GLAXOSMITHKLINE	EQ 300MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017924 001	
-----------------	--	-------------	--

CINOXACIN

CAPSULE; ORAL

CINOBAC

LILLY	250MG	N018067 001	
	500MG	N018067 002	

CINOXACIN

TEVA	250MG	A073005 001	Feb 28, 1992
	500MG	A073006 001	Feb 28, 1992

CIPROFLOXACIN

INJECTABLE; INJECTION

CIPRO

BAYER HLTHCARE	1200MG/120ML (10MG/ML)	N019847 003	Dec 26, 1990
----------------	------------------------	-------------	--------------

CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

BAYER PHARMS	200MG/100ML	N019858 001	Dec 26, 1990
--------------	-------------	-------------	--------------

CIPROFLOXACIN

BEDFORD LABS	200MG/20ML (10MG/ML)	A076992 001	Aug 28, 2006
	400MG/40ML (10MG/ML)	A076992 002	Aug 28, 2006
	1200MG/120ML (10MG/ML)	A076993 001	Aug 28, 2006
FRESENIUS KABI USA	200MG/20ML (10MG/ML)	A076484 001	Aug 28, 2006
	400MG/40ML (10MG/ML)	A076484 002	Aug 28, 2006
TEVA PHARMS USA	200MG/20ML (10MG/ML)	A077782 001	Aug 28, 2006
	400MG/40ML (10MG/ML)	A077782 002	Aug 28, 2006

CIPROFLOXACIN IN DEXTROSE 5%

HIKMA FARMACEUTICA	200MG/100ML	A076757 001	Apr 21, 2008
--------------------	-------------	-------------	--------------

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	200MG/100ML	A077888 001	Mar 18, 2008
	400MG/200ML	A077888 002	Mar 18, 2008
BEDFORD	200MG/100ML	A078114 001	Mar 18, 2008
	400MG/200ML	A078114 002	Mar 18, 2008
TEVA PHARMS	200MG/100ML	A077138 001	Mar 18, 2008
	400MG/200ML	A077138 002	Mar 18, 2008

DISCONTINUED DRUG PRODUCT LIST

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CIPROFLOXACIN HYDROCHLORIDE

APOTEX INC EQ 0.3% BASE A075928 001 Jun 09, 2004

TABLET;ORAL

CIPROFLOXACIN HYDROCHLORIDE

BARR EQ 250MG BASE A074124 001 Jun 09, 2004

EQ 500MG BASE A074124 002 Jun 09, 2004

EQ 750MG BASE A074124 003 Jun 09, 2004

IDT AUSTRALIA LTD EQ 100MG BASE A075939 001 Mar 03, 2005

EQ 250MG BASE A075939 002 Jun 09, 2004

EQ 500MG BASE A075939 003 Jun 09, 2004

EQ 750MG BASE A075939 004 Jun 09, 2004

NOSTRUM LABS EQ 250MG BASE A076138 001 Jun 09, 2004

EQ 500MG BASE A076138 002 Jun 09, 2004

EQ 750MG BASE A076138 003 Jun 09, 2004

PLIVA EQ 100MG BASE A076426 001 Jun 15, 2005

EQ 250MG BASE A076426 002 Jun 15, 2005

EQ 500MG BASE A076426 003 Jun 15, 2005

EQ 750MG BASE A076426 004 Jun 15, 2005

SANDOZ EQ 250MG BASE A076593 002 Jun 09, 2004

EQ 500MG BASE A076593 003 Jun 09, 2004

EQ 750MG BASE A076593 004 Jun 09, 2004

TEVA EQ 250MG BASE A076136 001 Jun 09, 2004

EQ 500MG BASE A076136 002 Jun 09, 2004

EQ 750MG BASE A076136 003 Jun 09, 2004

TABLET, EXTENDED RELEASE;ORAL

PROQUIN XR

DEPOMED INC EQ 500MG BASE N021744 001 May 19, 2005

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CIPRO XR

BAYER HLTHCARE 212.6MG;EQ 287.5MG BASE N021473 001 Dec 13, 2002

425.2MG;EQ 574.9MG BASE N021473 002 Aug 28, 2003

CIPROFLOXACIN EXTENDED RELEASE

ACTAVIS LABS FL INC 212.6MG;EQ 287.5MG BASE A077417 001 Nov 30, 2010

425.2MG;EQ 574.9MG BASE A077809 001 Nov 30, 2010

DR REDDYS LABS LTD 212.6MG;EQ 287.5MG BASE A077701 002 Oct 31, 2007

SANDOZ 212.6MG;EQ 287.5MG BASE A078712 001 Dec 11, 2007

CISAPRIDE MONOHYDRATE

SUSPENSION;ORAL

PROPULSID

JANSSEN PHARMS EQ 1MG BASE/ML N020398 001 Sep 15, 1995

TABLET;ORAL

PROPULSID

JANSSEN PHARMS EQ 10MG BASE N020210 001 Jul 29, 1993

EQ 20MG BASE N020210 002 Dec 23, 1993

TABLET, ORALLY DISINTEGRATING;ORAL

PROPULSID QUICKSOLV

JANSSEN PHARMA EQ 20MG BASE N020767 001 Nov 07, 1997

CISPLATIN

INJECTABLE;INJECTION

CISPLATIN

BEDFORD 10MG/VIAL A074713 001 Nov 14, 2000

50MG/VIAL A074713 002 Nov 14, 2000

TEVA PHARMS USA 1MG/ML A074814 001 May 16, 2000

PLATINOL

HQ SPCLT PHARMA 10MG/VIAL N018057 001

50MG/VIAL N018057 002

PLATINOL-AQ

HQ SPCLT PHARMA 0.5MG/ML N018057 003 Jul 18, 1984

CITALOPRAM HYDROBROMIDE

SOLUTION;ORAL

CELEXA

FOREST LABS EQ 10MG BASE/5ML **Federal Register N021046 001 Dec 22, 1999

determination that product was not discontinued or withdrawn for safety or efficacy reasons**

CITALOPRAM HYDROBROMIDE

APOTEX INC EQ 10MG BASE/5ML A077601 001 Nov 15, 2005

DISCONTINUED DRUG PRODUCT LISTCITALOPRAM HYDROBROMIDE

TABLET; ORAL

CELEXA

FOREST LABS	EQ 60MG BASE	N020822 004	Jul 17, 1998
-------------	--------------	-------------	--------------

CITALOPRAM HYDROBROMIDE

ACTAVIS ELIZABETH	EQ 10MG BASE	A077033 001	Oct 28, 2004
	EQ 20MG BASE	A077033 002	Oct 28, 2004
	EQ 40MG BASE	A077033 003	Oct 28, 2004
COREPHARMA	EQ 10MG BASE	A077036 001	Oct 28, 2004
	EQ 20MG BASE	A077036 002	Oct 28, 2004
	EQ 40MG BASE	A077036 003	Oct 28, 2004
NATCO PHARMA LTD	EQ 20MG BASE	A077141 002	Apr 10, 2008
	EQ 40MG BASE	A077141 001	Apr 10, 2008
ROXANE	EQ 10MG BASE	A077041 001	Nov 23, 2004
	EQ 20MG BASE	A077041 002	Nov 23, 2004
	EQ 40MG BASE	A077041 003	Nov 23, 2004
SANDOZ	EQ 10MG BASE	A077035 001	Oct 28, 2004
	EQ 10MG BASE	A077040 001	Aug 17, 2005
	EQ 20MG BASE	A077035 002	Oct 28, 2004
	EQ 20MG BASE	A077040 002	Aug 17, 2005
	EQ 40MG BASE	A077035 003	Oct 28, 2004
	EQ 40MG BASE	A077040 003	Aug 17, 2005
SUN PHARM INDS	EQ 10MG BASE	A077052 001	Jul 03, 2006
	EQ 20MG BASE	A077052 002	Jul 03, 2006
	EQ 40MG BASE	A077052 003	Jul 03, 2006
TARO	EQ 10MG BASE	A077278 001	Mar 22, 2006
	EQ 20MG BASE	A077278 002	Mar 22, 2006
	EQ 40MG BASE	A077278 003	Mar 22, 2006
TEVA PHARMS	EQ 10MG BASE	A077213 001	Mar 31, 2006
	EQ 20MG BASE	A077213 002	Mar 31, 2006
	EQ 40MG BASE	A077213 003	Mar 31, 2006
WATSON LABS	EQ 10MG BASE	A077034 001	Jun 30, 2005
	EQ 20MG BASE	A077034 002	Jun 30, 2005
	EQ 40MG BASE	A077034 003	Jun 30, 2005

TABLET, ORALLY DISINTEGRATING; ORAL

CITALOPRAM HYDROBROMIDE

BIOVAIL LABS INTL	EQ 10MG BASE	N021763 001	Dec 20, 2005
	EQ 20MG BASE	N021763 002	Dec 20, 2005
	EQ 40MG BASE	N021763 003	Dec 20, 2005

CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE

SOLUTION; IRRIGATION

IRRIGATING SOLUTION G IN PLASTIC CONTAINER

BAXTER HLTHCARE	3.24GM/100ML; 380MG/100ML; 430MG/100ML	N018519 001	Jun 22, 1982
-----------------	--	-------------	--------------

UROLOGIC G IN PLASTIC CONTAINER

HOSPIRA	3.24GM/100ML; 380MG/100ML; 430MG/100ML	N018904 001	May 27, 1983
---------	--	-------------	--------------

CLADRIBINE

INJECTABLE; INJECTION

LEUSTATIN

JANSSEN PHARMS	1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020229 001	Feb 26, 1993
----------------	---	-------------	--------------

CLARITHROMYCIN

FOR SUSPENSION; ORAL

BIAXIN

ABBVIE	187MG/5ML	N050698 003	Sep 30, 1998
--------	-----------	-------------	--------------

TABLET; ORAL

CLARITHROMYCIN

IVAX SUB TEVA PHARMS	250MG	A065137 001	May 31, 2005
	500MG	A065137 002	May 31, 2005

TABLET, EXTENDED RELEASE; ORAL

BIAXIN XL

ABBVIE	500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050775 001	Mar 03, 2000
--------	--	-------------	--------------

CLARITHROMYCIN

IDT AUSTRALIA LTD	500MG	A065250 001	Aug 25, 2005
RANBAXY	1GM	A065210 001	Jan 26, 2005

DISCONTINUED DRUG PRODUCT LISTCLAVULANATE POTASSIUM; TICARCILLIN DISODIUM

INJECTABLE; INJECTION

TIMENTIN

GLAXOSMITHKLINE	EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL	A062691 001	Dec 19, 1986
	EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL	N050590 001	Apr 01, 1985
	EQ 200MG BASE/VIAL;EQ 3GM BASE/VIAL	N050590 002	Apr 01, 1985
	EQ 1GM BASE/VIAL;EQ 30GM BASE/VIAL	N050590 003	Aug 18, 1987

TIMENTIN IN PLASTIC CONTAINER

GLAXOSMITHKLINE	EQ 100MG BASE/100ML;EQ 3GM BASE/100ML	N050658 001	Dec 15, 1989
-----------------	---------------------------------------	-------------	--------------

CLEMASTINE FUMARATE

SYRUP; ORAL

CLEMASTINE FUMARATE

ACTAVIS MID ATLANTIC	EQ 0.5MG BASE/5ML	A074075 001	Oct 31, 1993
APOTEX INC	EQ 0.5MG BASE/5ML	A075703 001	Nov 27, 2000
SILARX	EQ 0.5MG BASE/5ML	A074884 001	Dec 17, 1997
TEVA PHARMS	EQ 0.5MG BASE/5ML	A073095 001	Apr 21, 1992

TAVIST

NOVARTIS	EQ 0.5MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018675 001	Jun 28, 1985
----------	--	-------------	--------------

TABLET; ORAL

CLEMASTINE FUMARATE

ANI PHARMS INC	1.34MG	A073282 001	Jan 31, 1992
	1.34MG	A073282 002	Dec 03, 1992

TAVIST

NOVARTIS	2.68MG	N017661 001	
TAVIST-1			
NOVARTIS	1.34MG	N017661 002	
	1.34MG	N017661 003	Aug 21, 1992

CLIDINIUM BROMIDE

CAPSULE; ORAL

QUARZAN

ROCHE	2.5MG	N010355 001	
	5MG	N010355 002	

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLEOCIN

PHARMACIA AND UPJOHN	EQ 75MG BASE	A061809 001	
	EQ 150MG BASE	A061809 002	

CLINDAMYCIN HYDROCHLORIDE

TEVA	EQ 75MG BASE	A063027 001	Sep 20, 1989
WATSON LABS	EQ 75MG BASE	A063082 001	Jul 31, 1991

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLEOCIN

PHARMACIA AND UPJOHN	EQ 75MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A061827 001	
----------------------	---	-------------	--

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL

CLEOCIN

PHARMACIA AND UPJOHN	EQ 2% BASE	N050680 001	Aug 11, 1992
----------------------	------------	-------------	--------------

INJECTABLE; INJECTION

CLEOCIN PHOSPHATE

PHARMACIA AND UPJOHN	EQ 150MG BASE/ML	A061839 001	
----------------------	------------------	-------------	--

CLINDAMYCIN PHOSPHATE

ABRAXIS PHARM	EQ 150MG BASE/ML	A062747 001	Jun 03, 1988
BEDFORD	EQ 150MG BASE/ML	A063163 001	Jun 30, 1994
BRISTOL MYERS SQUIBB	EQ 150MG BASE/ML	A062908 001	Feb 01, 1989
IGI LABS INC	EQ 150MG BASE/ML	A062928 001	Feb 13, 1989
LOCH	EQ 150MG BASE/ML	A062905 001	May 09, 1988
MARSAM PHARMS LLC	EQ 150MG BASE/ML	A062913 001	Oct 20, 1988
SOLOPAK	EQ 150MG BASE/ML	A062819 001	Mar 15, 1988
	EQ 150MG BASE/ML	A062852 001	Mar 17, 1988
TEVA PARENTERAL	EQ 150MG BASE/ML	A063041 001	Dec 29, 1989
	EQ 150MG BASE/ML	A063282 001	May 29, 1992
WATSON LABS	EQ 150MG BASE/ML	A062900 001	Jun 08, 1988
	EQ 150MG BASE/ML	A063079 001	Mar 05, 1990
WEST-WARD PHARMS INT	EQ 150MG BASE/ML	A062806 001	Oct 15, 1987

DISCONTINUED DRUG PRODUCT LISTCLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE

	EQ 150MG BASE/ML	A062953	001	Apr 21, 1988
	EQ 150MG BASE/ML	A063068	001	Aug 28, 1989
CLINDAMYCIN PHOSPHATE IN	DEXTROSE 5%			
ABRAXIS PHARM	EQ 12MG BASE/ML	N050636	001	Dec 22, 1989
CLINDAMYCIN PHOSPHATE IN	DEXTROSE 5% IN PLASTIC CONTAINER			
ABBVIE	EQ 6MG BASE/ML	A065027	001	Jun 29, 2001
	EQ 12MG BASE/ML	A065027	002	Jun 29, 2001
	EQ 18MG BASE/ML	A065027	003	Jun 29, 2001
BAXTER HLTHCARE	EQ 6MG BASE/ML	N050648	001	Dec 29, 1989
	EQ 12MG BASE/ML	N050648	002	Dec 29, 1989
	EQ 900MG BASE/100ML	N050648	003	Dec 29, 1989

SOLUTION; TOPICAL

CLEOCIN T

PHARMACIA AND UPJOHN	EQ 1% BASE	A062363	001	Feb 08, 1982
CLINDAMYCIN PHOSPHATE				
BOCA PHARMA LLC	EQ 1% BASE	A062944	001	Jan 11, 1989
INGENUS PHARMS LLC	EQ 1% BASE	A064108	001	Sep 27, 1996
VINTAGE PHARMS	EQ 1% BASE	A062930	001	Jun 28, 1989

CLIOQUINOL; NYSTATIN

OINTMENT; TOPICAL

NYSTAFORM

BAYER PHARMS	10MG/GM; 100,000 UNITS/GM	N050235	001	
--------------	---------------------------	---------	-----	--

CLOBAZAM

TABLET; ORAL

ONFI

LUNDBECK LLC	5MG	N202067	001	Oct 21, 2011
--------------	-----	---------	-----	--------------

CLOBETASOL PROPIONATE

CREAM; TOPICAL

CLOBETASOL PROPIONATE

RENAISSANCE PHARMA	0.05%	A075338	001	Feb 09, 2001
TEVA PHARMS USA	0.05%	A074087	001	Feb 16, 1994
CLOBETASOL PROPIONATE (EMOLLIENT)				
INGENUS PHARMS LLC	0.05%	A075733	001	Aug 22, 2001

TEMOVATE

FOUGERA PHARMS	0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019322	001	Dec 27, 1985
----------------	--	---------	-----	--------------

TEMOVATE E

FOUGERA PHARMS	0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020340	001	Jun 17, 1994
----------------	--	---------	-----	--------------

GEL; TOPICAL

TEMOVATE

FOUGERA PHARMS	0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020337	001	Apr 29, 1994
----------------	--	---------	-----	--------------

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

ACTAVIS MID ATLANTIC	0.05%	A074128	001	Aug 03, 1994
RENAISSANCE PHARMA	0.05%	A075057	001	Aug 12, 1998

TEMOVATE

FOUGERA PHARMS	0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019323	001	Dec 27, 1985
----------------	--	---------	-----	--------------

SOLUTION; TOPICAL

TEMOVATE

FOUGERA PHARMS	0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019966	001	Feb 22, 1990
----------------	--	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

CLOFAZIMINE

CAPSULE; ORAL

LAMPRENE

NOVARTIS

100MG

N019500 001 Dec 15, 1986

CLOFIBRATE

CAPSULE; ORAL

ATROMID-S

WYETH AYERST

500MG

N016099 002

CLOFIBRATE

BANNER PHARMACAPS

500MG

A073396 001 Mar 20, 1992

SANDOZ

500MG

A072191 001 May 02, 1988

TEVA

500MG

A072600 001 Jul 25, 1991

USL PHARMA

500MG

A070531 001 Jun 16, 1986

WATSON LABS

500MG

A071603 001 Sep 18, 1987

CLOMIPHENE CITRATE

TABLET; ORAL

MILOPHENE

MILEX

50MG

A072196 001 Dec 20, 1988

SEROPHENE

EMD SERONO

50MG

N018361 001 Mar 22, 1982

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

CLOMIPRAMINE HYDROCHLORIDE

SANDOZ

25MG

A074953 001 Jun 25, 1997

50MG

A074953 002 Jun 25, 1997

75MG

A074953 003 Jun 25, 1997

TEVA

25MG

A074849 001 Apr 04, 1997

50MG

A074849 002 Apr 04, 1997

75MG

A074849 003 Apr 04, 1997

WATSON LABS

25MG

A074600 001 Nov 27, 1996

25MG

A074751 001 Sep 30, 1998

50MG

A074600 002 Nov 27, 1996

50MG

A074751 002 Sep 30, 1998

75MG

A074600 003 Nov 27, 1996

75MG

A074751 003 Sep 30, 1998

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

APOTEX INC

0.5MG

A075468 001 Oct 06, 2000

1MG

A075468 002 Oct 06, 2000

2MG

A075468 003 Oct 06, 2000

SANDOZ

0.5MG

A074925 001 Sep 30, 1997

1MG

A074925 002 Sep 30, 1997

2MG

A074925 003 Sep 30, 1997

TEVA

0.5MG

A074920 001 Aug 04, 1998

1MG

A074920 002 Aug 04, 1998

2MG

A074920 003 Aug 04, 1998

KLONOPIN

ROCHE

0.125MG

N017533 005 Apr 09, 1997

0.25MG

N017533 006 Apr 09, 1997

TABLET, ORALLY DISINTEGRATING; ORAL

KLONOPIN RAPIDLY DISINTEGRATING

ROCHE

0.125MG **Federal Register

N020813 001 Dec 23, 1997

determination that product was not discontinued or withdrawn for safety or efficacy reasons**

0.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N020813 002 Dec 23, 1997

0.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N020813 003 Dec 23, 1997

1MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N020813 004 Dec 23, 1997

2MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N020813 005 Dec 23, 1997

DISCONTINUED DRUG PRODUCT LIST

CLONIDINE

SUSPENSION, EXTENDED RELEASE;ORAL

CLONIDINE

TRIS PHARMA INC EQ 0.09MG BASE/ML

N022499 001 Dec 03, 2009

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE

TRIS PHARMA INC EQ 0.17MG BASE

N022500 001 Dec 03, 2009

EQ 0.26MG BASE

N022500 002 Dec 03, 2009

CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

AM THERAP

0.1MG

A070881 001 Jul 08, 1986

0.2MG

A070882 001 Jul 08, 1986

0.3MG

A070883 001 Jul 08, 1986

AUROLIFE PHARMA LLC

0.1MG

A070887 001 Aug 31, 1988

0.2MG

A070886 001 Aug 31, 1988

0.3MG

A071294 001 Aug 31, 1988

CHARTWELL MOLECULES

0.2MG

A071784 001 Apr 05, 1988

DAVA PHARMS INC

0.1MG

A071783 001 Apr 05, 1988

0.3MG

A071785 001 Apr 05, 1988

DURAMED PHARMS BARR

0.1MG

A071103 001 Aug 14, 1986

0.2MG

A071102 001 Aug 14, 1986

0.3MG

A071101 001 Aug 14, 1986

INTERPHARM

0.1MG

A071252 001 Oct 01, 1986

0.2MG

A071253 001 Oct 01, 1986

0.3MG

A071254 001 Oct 01, 1986

PAR PHARM

0.1MG

A070461 001 Jul 08, 1986

0.2MG

A070460 001 Jul 08, 1986

0.3MG

A070459 001 Jul 08, 1986

TEVA

0.1MG

A070747 001 Jul 08, 1986

0.2MG

A070702 001 Jul 08, 1986

0.3MG

A070659 001 Jul 08, 1986

WARNER CHILCOTT

0.1MG

A072138 001 Jun 13, 1988

0.2MG

A072139 001 Jun 13, 1988

0.3MG

A072140 001 Jun 13, 1988

WATSON LABS

0.1MG

A070395 001 Mar 23, 1987

0.1MG

A070965 001 Jul 08, 1986

0.2MG

A070396 001 Mar 23, 1987

0.2MG

A070964 001 Jul 08, 1986

0.3MG

A070397 001 Mar 23, 1987

0.3MG

A070963 001 Jul 08, 1986

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

ACTAVIS ELIZABETH

0.2MG

A202792 002 May 15, 2015

0.2MG

A203320 002 May 15, 2015

ANCHEN PHARMS

0.1MG

A202983 001 Apr 02, 2014

0.2MG

A202983 002 Apr 02, 2014

CLONIDINE HYDROCHLORIDE

ANCHEN PHARMS

0.2MG

A202984 002 Sep 30, 2013

JENLOGA

CONCORDIA PHARMS INC

0.1MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N022331 001 Sep 30, 2009

0.2MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N022331 002 May 25, 2010

KAPVAY

CONCORDIA PHARMS INC

0.2MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N022331 004 Sep 28, 2010

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

ACTAVIS TOTOWA

EQ 75MG BASE

A090307 001 May 28, 2013

DISCONTINUED DRUG PRODUCT LIST

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

CLORAZEPATE DIPOTASSIUM

ABLE	3.75MG	A071777 001	Jul 14, 1987
	7.5MG	A071778 001	Jul 14, 1987
	15MG	A071779 001	Jul 14, 1987
AM THERAP	3.75MG	A071429 001	Jun 23, 1987
	7.5MG	A071430 001	Jun 23, 1987
	15MG	A071431 001	Jun 23, 1987
AUROLIFE PHARMA LLC	3.75MG	A072219 001	Aug 26, 1988
	7.5MG	A072220 001	Aug 26, 1988
	15MG	A072112 001	Aug 26, 1988
DAVA PHARMS INC	3.75MG	A071742 001	Dec 14, 1987
	7.5MG	A071743 001	Dec 14, 1987
	15MG	A071744 001	Dec 14, 1987
GD SEARLE LLC	3.75MG	A071727 001	Dec 18, 1987
	7.5MG	A071728 001	Dec 18, 1987
	15MG	A071729 001	Dec 18, 1987
MYLAN	3.75MG	A071509 001	Oct 19, 1987
	7.5MG	A071510 001	Oct 19, 1987
	15MG	A071511 001	Oct 19, 1987
PUREPAC PHARM	3.75MG	A071924 001	Apr 25, 1988
	7.5MG	A071925 001	Apr 25, 1988
	15MG	A071926 001	Apr 25, 1988
QUANTUM PHARMICS	3.75MG	A071549 001	Sep 12, 1988
	7.5MG	A071550 001	Sep 12, 1988
	15MG	A071522 001	Sep 12, 1988
USL PHARMA	3.75MG	A071242 001	Jun 23, 1987
	7.5MG	A071243 001	Jun 23, 1987
	15MG	A071244 001	Jun 23, 1987
WARNER CHILCOTT	3.75MG	A071774 001	Mar 01, 1988
	7.5MG	A071775 001	Mar 01, 1988
	15MG	A071776 001	Mar 01, 1988
WATSON LABS	3.75MG	A071878 001	Mar 15, 1988
	7.5MG	A071879 001	Mar 15, 1988
	15MG	A071860 001	Mar 15, 1988

TRANXENE

RECORDATI RARE	3.75MG	N017105 001	
	7.5MG	N017105 002	
	15MG	N017105 003	

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM

ABLE	3.75MG	A071780 001	Jun 26, 1987
	7.5MG	A071781 001	Jun 26, 1987
	15MG	A071782 001	Jun 26, 1987
AM THERAP	3.75MG	A071747 001	Jun 23, 1987
	7.5MG	A071748 001	Jun 23, 1987
	15MG	A071749 001	Jun 23, 1987
AUROLIFE PHARMA LLC	3.75MG	A072512 001	May 11, 1990
	7.5MG	A072513 001	May 11, 1990
	15MG	A072514 001	May 11, 1990
LEDERLE	3.75MG	A072013 001	Dec 15, 1987
	7.5MG	A072014 001	Dec 15, 1987
	15MG	A072015 001	Dec 15, 1987
PUREPAC PHARM	3.75MG	A072330 001	Aug 08, 1988
	7.5MG	A072331 001	Aug 08, 1988
	15MG	A072332 001	Aug 08, 1988
QUANTUM PHARMICS	3.75MG	A071730 001	Oct 26, 1987
	7.5MG	A071731 001	Oct 26, 1987
	15MG	A071702 001	Oct 26, 1987
WARNER CHILCOTT	3.75MG	A071828 001	Mar 03, 1988
	7.5MG	A071829 001	Mar 03, 1988
	15MG	A071830 001	Mar 03, 1988
WATSON LABS	3.75MG	A071852 001	Feb 09, 1988
	7.5MG	A071853 001	Feb 09, 1988
	15MG	A071854 001	Feb 09, 1988

TRANXENE

RECORDATI RARE	3.75MG	N017105 006	
----------------	--------	-------------	--

TRANXENE SD

RECORDATI RARE	11.25MG	N017105 005	
	22.5MG	N017105 004	

DISCONTINUED DRUG PRODUCT LISTCLOTRIMAZOLE

CREAM; TOPICAL

LOTRIMIN

SCHERING PLOUGH 1% N017619 001

MYCELEX

BAYER HEALTHCARE LLC 1% N018183 001

LOTION; TOPICAL

LOTRIMIN

SCHERING 1% N018813 001 Feb 17, 1984

SOLUTION; TOPICAL

LOTRIMIN

SCHERING PLOUGH 1% N017613 001

MYCELEX

BAYER HLTHCARE 1% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** N018181 001

TABLET; VAGINAL

GYNIX

TEVA PHARMS 100MG A073249 001 Feb 13, 1998

MYCELEX-G

BAYER PHARMS 500MG N019069 001 Apr 19, 1985

TROCHE/LOZENGE; ORAL

MYCELEX

BAYER HLTHCARE 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** N018713 001 Jun 17, 1983

CLOXACILLIN SODIUM

CAPSULE; ORAL

CLOXACILLIN SODIUM

APOTHECON EQ 250MG BASE A061452 001

EQ 500MG BASE A061452 002

TEVA EQ 250MG BASE A062240 001

EQ 500MG BASE A062240 002

CLOXAPEN

GLAXOSMITHKLINE EQ 250MG BASE A061806 001

EQ 250MG BASE A062233 001

EQ 500MG BASE A061806 002

EQ 500MG BASE A062233 002

FOR SOLUTION; ORAL

CLOXACILLIN SODIUM

TEVA EQ 125MG BASE/5ML A062268 001

EQ 125MG BASE/5ML A062978 001 Apr 06, 1989

TEGOPEN

APOTHECON EQ 125MG BASE/5ML A061453 001

EQ 125MG BASE/5ML N050192 001

CLOZAPINE

TABLET; ORAL

CLOZAPINE

PAR PHARM 25MG A075162 001 Apr 26, 2005

100MG A075162 002 Apr 26, 2005

SANDOZ 25MG A074546 001 Aug 30, 1996

100MG A074546 002 Aug 30, 1996

TABLET, ORALLY DISINTEGRATING; ORAL

FAZACLO ODT

JAZZ PHARMS III 50MG N021590 003 Jun 03, 2005

COBALT CHLORIDE CO-57; CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; INTRINSIC FACTOR

N/A; N/A

RUBRATOPE-57 KIT

BRACCO N/A; N/A; N/A; N/A N016089 001

COBALT CHLORIDE CO-60; CYANOCOBALAMIN; CYANOCOBALAMIN CO-60; INTRINSIC FACTOR

N/A; N/A

RUBRATOPE-60 KIT

BRACCO N/A; N/A; N/A; N/A N016090 001

DISCONTINUED DRUG PRODUCT LISTCODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHENERGAN VC W/ CODEINE

ANI PHARMS

10MG/5ML;5MG/5ML;6.25MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N008306 005 Apr 02, 1984

PHERAZINE VC W/ CODEINE

HALSEY

10MG/5ML;5MG/5ML;6.25MG/5ML

A088870 001 Mar 02, 1987

PROMETHAZINE VC W/ CODEINE

CENCI

10MG/5ML;5MG/5ML;6.25MG/5ML

A088816 001 Nov 22, 1985

WOCKHARDT

10MG/5ML;5MG/5ML;6.25MG/5ML

A088896 001 Jan 04, 1985

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHENERGAN W/ CODEINE

ANI PHARMS

10MG/5ML;6.25MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N008306 004 Apr 02, 1984

PHERAZINE W/ CODEINE

HALSEY

10MG/5ML;6.25MG/5ML

A088739 001 Dec 23, 1988

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

PHARM ASSOC

10MG/5ML;6.25MG/5ML

A089647 001 Dec 22, 1988

PROMETHAZINE W/ CODEINE

CENCI

10MG/5ML;6.25MG/5ML

A088814 001 Nov 22, 1985

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP;ORAL

ACTIFED W/ CODEINE

GLAXOSMITHKLINE

10MG/5ML;30MG/5ML;1.25MG/5ML

N012575 003 Apr 04, 1984

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES W/ CODEINE

CENCI

10MG/5ML;30MG/5ML;1.25MG/5ML

A089018 001 Jul 23, 1986

TRIPROLIDINE HCL, PSEUDOEPHEDRINE HCL AND CODEINE PHOSPHATE

WOCKHARDT

10MG/5ML;30MG/5ML;1.25MG/5ML

A088833 001 Nov 16, 1984

CODEINE SULFATE

SOLUTION;ORAL

CODEINE SULFATE

ROXANE

30MG/5ML

N202245 001 Jun 30, 2011

COLCHICINE; PROBENECID

TABLET;ORAL

COLBENEMID

MERCK

0.5MG;500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N012383 001

PROBEN-C

WATSON LABS

0.5MG;500MG

A085552 001

PROBENECID AND COLCHICINE

ANI PHARMS INC

0.5MG;500MG

A083734 001

BEECHAM

0.5MG;500MG

A084321 001

IMPAX LABS

0.5MG;500MG

A083720 002

SANDOZ

0.5MG;500MG

A086130 001

PROBENECID W/ COLCHICINE

LEDERLE

0.5MG;500MG

A086954 001

WATSON LABS

0.5MG;500MG

A083221 001

COLESEVELAM HYDROCHLORIDE

CAPSULE;ORAL

WELCHOL

DAIICHI SANKYO

375MG

N021141 001 May 26, 2000

COLISTIN SULFATE

SUSPENSION;ORAL

COLY-MYCIN S

PARKE DAVIS

EQ 25MG BASE/5ML

N050355 001

CONIVAPTAN HYDROCHLORIDE

INJECTABLE;IV (INFUSION)

VAPRISOL

CUMBERLAND PHARMS

20MG/4ML (5MG/ML)

N021697 001 Dec 29, 2005

DISCONTINUED DRUG PRODUCT LISTCOPPER

INTRAUTERINE DEVICE; INTRAUTERINE

CU-7

GD SEARLE LLC	89MG	N017408	001
TATUM-T			
GD SEARLE LLC	120MG	N018205	001

CORTICOTROPIN

INJECTABLE; INJECTION

ACTH

PARKEDALE	25 UNITS/VIAL	N008317	002
	40 UNITS/VIAL	N008317	004

ACTHAR

SANOVI AVENTIS US	25 UNITS/VIAL	N007504	002
	40 UNITS/VIAL	N007504	003

CORTICOTROPIN

ORGANICS LAGRANGE	40 UNITS/ML	N010831	001
	80 UNITS/ML	N010831	002
WATSON LABS	40 UNITS/VIAL	A088772	001

H.P. ACTHAR GEL

MALLINCKRODT ARD	40 UNITS/ML	N008372	006
------------------	-------------	---------	-----

PURIFIED CORTROPHIN GEL

ANI PHARMS	40 UNITS/ML	N008975	001
	80 UNITS/ML	N008975	002

Nov 21, 1984

CORTICOTROPIN-ZINC HYDROXIDE

INJECTABLE; INJECTION

CORTROPHIN-ZINC

ANI PHARMS	40 UNITS/ML	N009854	001
------------	-------------	---------	-----

CORTISONE ACETATE

INJECTABLE; INJECTION

CORTISONE ACETATE

PHARMACIA AND UPJOHN	25MG/ML	N008126	002
WATSON LABS	25MG/ML	A083147	003
	25MG/ML	A085677	001
	50MG/ML	A083147	004
	50MG/ML	A085677	002

CORTONE

MERCK	25MG/ML	N007110	002
	50MG/ML	N007110	003

TABLET; ORAL

CORTISONE ACETATE

BARR	25MG	A083471	001
ELKINS SINN	25MG	A080836	001
EVERYLIFE	25MG	A084246	001
HEATHER	25MG	A085736	001
IMPAX LABS	25MG	N009458	001
INWOOD LABS	25MG	A080731	001
IVAX SUB TEVA PHARMS	25MG	A080630	001
	25MG	A083536	001
LANNETT	25MG	A080694	001
PANRAY	5MG	N008284	002
	25MG	N008284	001
PHARMACIA AND UPJOHN	5MG	N008126	003
	10MG	N008126	004
	25MG	N008126	001
PUREPAC PHARM	25MG	A080493	001
VITARINE	25MG	A080333	001
WATSON LABS	25MG	A085884	001
WHITEWORTH TOWN PLSN	25MG	A080341	001

CORTONE

MERCK	25MG	N007750	003
-------	------	---------	-----

COSYNTROPIN

SOLUTION; INTRAVENOUS

COSYNTROPIN

SANDOZ	0.25MG/ML (0.25MG/ML)	N022028	001	Feb 21, 2008
--------	-----------------------	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

CROMOLYN SODIUMAEROSOL, METERED; INHALATION
INTAL

KING PFIZER 0.8MG/INH N018887 001 Dec 05, 1985

CAPSULE; INHALATION
INTALSANOFI AVENTIS US 20MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons** N016990 001

CAPSULE; ORAL

GASTROCROM

UCB INC 100MG N019188 001 Dec 22, 1989

CONCENTRATE; ORAL

CROMOLYN SODIUM

GENERA PHARMS 100MG/5ML A090954 001 Dec 18, 2009

SOLUTION; INHALATION

CROMOLYN SODIUM

ACTAVIS MID ATLANTIC 10MG/ML A075067 001 Jul 19, 1999

APOTEX INC 10MG/ML A075333 001 Apr 30, 2002

PHARMASCIENCE INC 10MG/ML A075437 001 Apr 21, 2000

ROXANE 10MG/ML A075175 001 Sep 30, 1999

WATSON LABS 10MG/ML A076469 001 Jun 17, 2005

INTAL

KING PHARMS 10MG/ML N018596 001 May 28, 1982

SOLUTION/DROPS; OPHTHALMIC

CROMOLYN SODIUM

APOTEX INC 4% A075615 001 Jan 26, 2001

CROMOPTIC

KING PHARMS 4% A075088 001 Apr 27, 1999

OPTICROM

ALLERGAN 4% **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons** N018155 001 Oct 03, 1984

SPRAY, METERED; NASAL

CROMOLYN SODIUM

ACTAVIS MID ATLANTIC 5.2MG/SPRAY A074800 001 Jul 26, 2001

HH AND P 5.2MG/SPRAY A077976 001 Sep 07, 2007

NASALCROM

BLACKSMITH BRANDS 5.2MG/SPRAY **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons** N020463 001 Jan 03, 1997CRYPTENAMINE ACETATES

INJECTABLE; INJECTION

UNITENSEN

MEDPOINTE PHARM HLC 260CSR UNIT/ML N008814 001

CRYPTENAMINE TANNATES

TABLET; ORAL

UNITENSEN

MEDPOINTE PHARM HLC 260CSR UNIT N009217 001

CUPRIC SULFATE

INJECTABLE; INJECTION

CUPRIC SULFATE

ABRAXIS PHARM EQ 0.4MG COPPER/ML N019350 001 May 05, 1987

CYANOCOBALAMIN

GEL, METERED; NASAL

NASCOBAL

PAR PHARM 0.5MG/INH N019722 001 Nov 05, 1996

INJECTABLE; INJECTION

BERUBIGEN

PHARMACIA AND UPJOHN 1MG/ML N006798 001

BETALIN 12

LILLY 0.1MG/ML A080855 001

1MG/ML A080855 002

COBAVITE

WATSON LABS 0.1MG/ML A083013 001

1MG/ML A083064 001

CYANOCOBALAMIN

ABRAXIS PHARM 0.03MG/ML A080510 003

0.1MG/ML A080510 001

DISCONTINUED DRUG PRODUCT LIST

CYANOCOBALAMIN

INJECTABLE; INJECTION

CYANOCOBALAMIN

	1MG/ML	A080510 002	
AKORN	1MG/ML	A087969 001	Nov 10, 1983
DELL LABS	0.03MG/ML	A080689 001	
	0.1MG/ML	A080689 002	
	1MG/ML	A080689 003	
FRESENIUS KABI USA	0.1MG/ML	A080557 002	
LUITPOLD	0.03MG/ML	A080668 001	
LYPHOMED	1MG/ML	A083075 001	
MYLAN INSTITUTIONAL	1MG/ML	A040451 001	Sep 23, 2003
SANOFI AVENTIS US	1MG/ML	A080564 001	
SOLOPAK	1MG/ML	A087551 001	Feb 29, 1984
WARNER CHILCOTT	1MG/ML	N007085 002	
WATSON LABS	0.1MG/ML	A080573 002	
	0.1MG/ML	A083120 001	
	1MG/ML	A080573 001	
	1MG/ML	A083120 002	
WYETH AYERST	0.1MG/ML	A080554 001	
	1MG/ML	A080554 002	
DODEX			
ORGANON SUB MERCK	1MG/ML	A083022 001	
REDISOL			
MERCK	1MG/ML	N006668 010	
RUBIVITE			
BEL MAR	0.03MG/ML	N010791 004	
	0.05MG/ML	N010791 001	
	0.1MG/ML	N010791 002	
	0.12MG/ML	N010791 005	
	1MG/ML	N010791 003	
RUBRAMIN PC			
BRISTOL MYERS SQUIBB	0.1MG/ML	N006799 002	
	1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N006799 004	
	1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N006799 010	Apr 28, 1988
RUVITE			
SAVAGE LABS	1MG/ML	A080570 002	
VI-TWEL			
BAYER HLTHCARE	1MG/ML	N007012 002	
SPRAY, METERED; NASAL			
CALOMIST			
PAR PHARM	25MCG/SPRAY	N022102 001	Jul 27, 2007
TABLET; ORAL			
CYANOCOBALAMIN			
WEST WARD	1MG	A084264 001	

CYANOCOBALAMIN CO-57

CAPSULE; ORAL

RUBRATOPE-57

BRACCO 0.5-1uCi N016089 002

CYANOCOBALAMIN CO-60

CAPSULE; ORAL

RUBRATOPE-60

BRACCO 0.5-1uCi N016090 002

CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; CYANOCOBALAMIN CO-58

N/A; N/A

DICOPAC KIT

GE HEALTHCARE N/A; N/A; N/A N017406 001

CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; INTRINSIC FACTOR

N/A; N/A

CYANOCOBALAMIN CO 57 SCHILLING TEST KIT

MALLINCKRODT 0.1MG; 0.5uCi; 60MG N016635 001

DISCONTINUED DRUG PRODUCT LIST

CYANOCOBALAMIN; TANNIC ACID; ZINC ACETATE

INJECTABLE; INJECTION

DEPINAR

ARMOUR PHARM

0.5MG/ML; 2.3MG/ML; 1MG/ML

N011208 001

CYCLACILLIN

FOR SUSPENSION; ORAL

CYCLAPEN-W

WYETH AYERST

125MG/5ML

N050508 001

250MG/5ML

N050508 002

500MG/5ML

N050508 003

TABLET; ORAL

CYCLACILLIN

TEVA

250MG

A062895 001 Aug 04, 1988

500MG

A062895 002 Aug 04, 1988

CYCLAPEN-W

WYETH AYERST

250MG

N050509 001

500MG

N050509 002

CYCLIZINE LACTATE

INJECTABLE; INJECTION

MAREZINE

GLAXOSMITHKLINE

50MG/ML

N009495 001

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

TWI PHARMS INC

15MG

A091281 001 Jan 31, 2013

30MG

A091281 002 Jan 31, 2013

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

OXFORD PHARMS

5MG

A077291 001 Feb 03, 2006

SANDOZ

10MG

A073683 001 Feb 26, 1993

UPSHER-SMITH LABS

5MG

A072854 002 Feb 03, 2006

10MG

A072854 001 Nov 19, 1991

WATSON LABS

10MG

A073143 001 Nov 27, 1991

10MG

A074436 001 Nov 30, 1994

FLEXERIL

JANSSEN RES AND DEV

5MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N017821 001

10MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N017821 002

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AK-PENTOLATE

AKORN

1%

A085555 001

AKPENTOLATE

AKORN

2%

A040165 001 Jan 13, 1997

CYCLOPENTOLATE HYDROCHLORIDE

ALCON PHARMS LTD

1%

A089162 001 Jan 24, 1991

SOLA BARNES HIND

1%

A084150 001

1%

A084863 001

PENTOLAIR

PHARMAFAIR

0.5%

A088643 001 Feb 09, 1987

1%

A088150 001 Feb 25, 1983

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYCLOPHOSPHAMIDE

BAXTER HLTHCARE

100MG/VIAL

A088371 001 Jul 03, 1986

200MG/VIAL

A088372 001 Jul 03, 1986

500MG/VIAL

A088373 001 Jul 03, 1986

1GM/VIAL

A088374 001 Sep 24, 1986

CYTOXAN

BAXTER HLTHCARE

100MG/VIAL

N012142 001

200MG/VIAL

N012142 002

CYTOXAN (LYOPHILIZED)

BAXTER HLTHCARE

500MG/VIAL

N012142 003

500MG/VIAL

N012142 008 Jan 04, 1984

1GM/VIAL

N012142 004 Aug 30, 1982

1GM/VIAL

N012142 010 Sep 24, 1985

DISCONTINUED DRUG PRODUCT LIST

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYTOXAN (LYOPHILIZED)

2GM/VIAL

N012142 005 Aug 30, 1982

2GM/VIAL

N012142 009 Dec 10, 1985

LYOPHILIZED CYTOXAN

BAXTER HLTHCARE

100MG/VIAL

N012142 006 Dec 05, 1985

200MG/VIAL

N012142 007 Dec 10, 1985

NEOSAR

BEDFORD

100MG/VIAL

A087442 001 Feb 16, 1982

200MG/VIAL

A087442 002 Feb 16, 1982

500MG/VIAL

A087442 003 Feb 16, 1982

1GM/VIAL

A087442 004 Jul 08, 1983

2GM/VIAL

A087442 005 Mar 30, 1989

TEVA PARENTERAL

100MG/VIAL

A040015 001 Apr 29, 1993

200MG/VIAL

A040015 002 Apr 29, 1993

500MG/VIAL

A040015 003 Apr 29, 1993

1GM/VIAL

A040015 004 Apr 29, 1993

2GM/VIAL

A040015 005 Apr 29, 1993

TABLET; ORAL

CYCLOPHOSPHAMIDE

ROXANE

25MG

A040032 001 Aug 17, 1999

50MG

A040032 002 Aug 17, 1999

CYTOXAN

BAXTER HLTHCARE

25MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N012141 002

50MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N012141 001

CYCLOSPORINE

CAPSULE; ORAL

NEORAL

NOVARTIS

50MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N050715 003 Jul 14, 1995

SOLUTION; ORAL

CYCLOSPORINE

APOTEX INC

100MG/ML

A065167 001 Jan 05, 2005

CYCLOTHIAZIDE

TABLET; ORAL

ANHYDRON

LILLY

2MG

N013157 002

FLUIDIL

PHARMACIA AND UPJOHN

2MG

N018173 001

CYCRIMINE HYDROCHLORIDE

TABLET; ORAL

PAGITANE

LILLY

1.25MG

N008951 001

2.5MG

N008951 002

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

CYPROHEPTADINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC

2MG/5ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

A086833 001

HALSEY

2MG/5ML

A089199 001 Jul 03, 1986

MORTON GROVE

2MG/5ML

A087001 001 Nov 04, 1982

NASKA

2MG/5ML

A089021 001 Dec 21, 1987

PERIACTIN

MERC

2MG/5ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N013220 002

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

AM THERAP

4MG

A088798 001 Feb 15, 1985

ASCOT

4MG

A087685 001 Oct 25, 1982

DISCONTINUED DRUG PRODUCT LISTCYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

DURAMED PHARMS BARR	4MG	A088232 001	Oct 25, 1983
HALSEY	4MG	A089057 001	Jul 03, 1986
KV PHARM	4MG	A086737 001	
MD PHARM	4MG	A087566 001	Nov 10, 1982
MYLAN	4MG	A086678 001	
PIONEER PHARMS	4MG	A087839 001	Feb 08, 1984
PLIVA	4MG	A088205 001	Jul 26, 1983
SANDOZ	4MG	A086808 001	
SUPERPHARM	4MG	A087405 001	
TG UNITED LABS	4MG	A088212 001	May 26, 1983
VITARINE	4MG	A087284 001	
WATSON LABS	4MG	A085245 001	
	4MG	A086165 001	
	4MG	A086580 001	

PERIACTIN

MERCCK

4MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012649 001		
--	-------------	--	--

CYSTEINE HYDROCHLORIDE

INJECTABLE; INJECTION

CYSTEINE HYDROCHLORIDE

HOSPIRA

7.25% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019523 001	Oct 22, 1986	
--	-------------	--------------	--

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

TEVA PARENTERAL

100MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016793 001		
500MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016793 002		
1GM/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016793 003	Dec 21, 1987	
2GM/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016793 004	Dec 21, 1987	

DACARBAZINE

INJECTABLE; INJECTION

DACARBAZINE

ABRAXIS PHARM

100MG/VIAL	A070962 001	Aug 28, 1986	
200MG/VIAL	A070990 001	Aug 28, 1986	

DACTINOMYCIN

INJECTABLE; INJECTION

DACTINOMYCIN

WEST-WARD PHARMS INT

0.5MG/VIAL	A090304 001	Mar 16, 2010	
------------	-------------	--------------	--

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE; IV (INFUSION)

SYNERCID

KING PHARMS

420MG/VIAL; 180MG/VIAL	N050748 002	Aug 24, 2000	
------------------------	-------------	--------------	--

DALTEPARIN SODIUM

INJECTABLE; INJECTION

FRAGMIN

PFIZER INC

7,500 IU/0.75ML	N020287 008	Apr 04, 2002	
-----------------	-------------	--------------	--

INJECTABLE; SUBCUTANEOUS

FRAGMIN

PFIZER INC

10,000IU/0.4ML (25,000IU/ML)	N020287 002	May 01, 2007	
95,000IU/9.5ML (10,000IU/ML)	N020287 007	Apr 04, 2002	

DISCONTINUED DRUG PRODUCT LISTDANAPAROID SODIUM

INJECTABLE; INJECTION

ORGARAN

ASPEN GLOBAL INC	750 UNITS/0.6ML	N020430 001	Dec 24, 1996
------------------	-----------------	-------------	--------------

DANAZOL

CAPSULE; ORAL

DANAZOL

AM THERAP	200MG	A071569 001	Dec 30, 1987
-----------	-------	-------------	--------------

DANOCRINE

SANOFI AVENTIS US	50MG	N017557 003	
	100MG	N017557 004	
	200MG	N017557 002	

DAPIPRAZOLE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DAPIPRAZOLE HYDROCHLORIDE

FERA PHARMS	0.5% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019849 001	Dec 31, 1990
-------------	---	-------------	--------------

DAPTOMYCIN

POWDER; IV (INFUSION)

CUBICIN

CUBIST PHARMS LLC	250MG/VIAL	N021572 001	Sep 12, 2003
-------------------	------------	-------------	--------------

DARUNAVIR ETHANOLATE

TABLET; ORAL

PREZISTA

JANSSEN PRODS	EQ 300MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021976 001	Jun 23, 2006
---------------	--	-------------	--------------

	EQ 400MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021976 003	Oct 21, 2008
--	--	-------------	--------------

DAUNORUBICIN CITRATE

INJECTABLE, LIPOSOMAL; INJECTION

DAUNOXOME

GALEN (UK)	EQ 2MG BASE/ML	N050704 002	Apr 08, 1996
------------	----------------	-------------	--------------

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

CERUBIDINE

SANOFI AVENTIS US	EQ 20MG BASE/VIAL	A061876 001	
WYETH AYERST	EQ 20MG BASE/VIAL	N050484 001	

DAUNORUBICIN HYDROCHLORIDE

TEVA PARENTERAL	EQ 20MG BASE/VIAL	A064212 001	Jun 23, 1998
	EQ 50MG BASE/VIAL	A064212 002	May 03, 1999

DECAMETHONIUM BROMIDE

INJECTABLE; INJECTION

SYNCURINE

GLAXOSMITHKLINE	1MG/ML	N006931 002	
-----------------	--------	-------------	--

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION

DEFEROXAMINE MESYLATE

WATSON LABS	500MG/VIAL	A076806 001	Mar 31, 2006
	2GM/VIAL	A076806 002	Mar 31, 2006

DEMECARIUM BROMIDE

SOLUTION/DROPS; OPHTHALMIC

HUMORSOL

MERCK	0.125%	N011860 002	
	0.25%	N011860 001	

DEMECLOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

DECLOMYCIN

LEDERLE	150MG	N050262 001	
---------	-------	-------------	--

SYRUP; ORAL

DECLOMYCIN

LEDERLE	75MG/5ML	N050257 001	
---------	----------	-------------	--

DISCONTINUED DRUG PRODUCT LIST

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DECLOMYCIN

COREPHARMA	75MG	N050261 001
	150MG	N050261 002
	300MG	N050261 003

DEMECLOCYCLINE HYDROCHLORIDE

IMPAX LABS	150MG	A065094 001	Mar 22, 2004
	300MG	A065094 002	Mar 22, 2004

DESERPIDINE

TABLET; ORAL

HARMONYL

ABBVIE	0.1MG	N010796 001
	0.25MG	N010796 002

DESERPIDINE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ORETICYL 25

ABBVIE	0.125MG; 25MG	N012148 001
--------	---------------	-------------

ORETICYL 50

ABBVIE	0.125MG; 50MG	N012148 003
--------	---------------	-------------

ORETICYL FORTE

ABBVIE	0.25MG; 25MG	N012148 002
--------	--------------	-------------

DESERPIDINE; METHYCLOTHIAZIDE

TABLET; ORAL

ENDURONYL

ABBOTT	0.25MG; 5MG	N012775 001
--------	-------------	-------------

ENDURONYL FORTE

ABBOTT	0.5MG; 5MG	N012775 002
--------	------------	-------------

METHYCLOTHIAZIDE AND DESERPIDINE

WATSON LABS	0.25MG; 5MG	A088486 001	Aug 10, 1984
	0.5MG; 5MG	A088452 001	Aug 10, 1984

DESIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

PERTOFRANE

SANOFI AVENTIS US	25MG	N013621 001
	50MG	N013621 002

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

ANI PHARMS INC	100MG	A071803 001	May 29, 1997
USL PHARMA	25MG	A071864 001	Sep 09, 1987
	50MG	A071865 001	Sep 09, 1987
	75MG	A071866 001	Sep 09, 1987
	100MG	A071867 001	Sep 09, 1987

DESLANOSIDE

INJECTABLE; INJECTION

CEDILANID-D

NOVARTIS	0.2MG/ML	N009282 002
----------	----------	-------------

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

DDAVP

FERRING PHARMS INC	0.015MG/ML	N018938 002	Apr 25, 1995
--------------------	------------	-------------	--------------

DESMOPRESSIN ACETATE

BEDFORD	0.004MG/ML	A074575 001	Feb 18, 2000
---------	------------	-------------	--------------

DESMOPRESSIN ACETATE PRESERVATIVE FREE

BEDFORD	0.004MG/ML	A074574 001	Feb 18, 2000
---------	------------	-------------	--------------

SOLUTION; NASAL

CONCENTRAID

FERRING	0.01%	N019776 001	Dec 26, 1990
---------	-------	-------------	--------------

SPRAY, METERED; NASAL

DDAVP

FERRING PHARMS INC	0.01MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017922 002	Feb 06, 1989
--------------------	---	-------------	--------------

STIMATE

CSL BEHRING	0.15MG/SPRAY	N020355 001	Mar 07, 1994
-------------	--------------	-------------	--------------

TABLET; ORAL

DESMOPRESSIN ACETATE

FERRING	0.1MG	N021795 001	May 08, 2008
	0.2MG	N021795 002	May 08, 2008

DISCONTINUED DRUG PRODUCT LISTDESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21

DESOGEN

ORGANON USA INC	0.15MG;0.03MG	N020071 001	Dec 10, 1992
-----------------	---------------	-------------	--------------

DESOGESTREL AND ETHINYL ESTRADIOL

DURAMED PHARMS BARR	0.15MG;0.03MG	A075256 001	Aug 12, 1999
---------------------	---------------	-------------	--------------

ORTHO-CEPT

JANSSEN PHARMS	0.15MG;0.03MG	N020301 001	Dec 14, 1992
----------------	---------------	-------------	--------------

TABLET; ORAL-28

MIRCETTE

TEVA BRANDED PHARM	0.15MG,N/A;0.02MG,0.01MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020713 001	Apr 22, 1998
--------------------	---	-------------	--------------

ORTHO-CEPT

JANSSEN PHARMS	0.15MG;0.03MG	N020301 002	Dec 14, 1992
----------------	---------------	-------------	--------------

DESOXIMETASONE

CREAM; TOPICAL

TOPICORT

TARO PHARMS NORTH	0.25% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017856 001	
-------------------	--	-------------	--

TOPICORT LP

TARO PHARMS NORTH	0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018309 001	
-------------------	--	-------------	--

GEL; TOPICAL

TOPICORT

TARO PHARMS NORTH	0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018586 001	Mar 29, 1982
-------------------	--	-------------	--------------

OINTMENT; TOPICAL

DESOXIMETASONE

ALTANA	0.25%	A073440 001	Apr 01, 1998
--------	-------	-------------	--------------

TOPICORT

TARO PHARMS NORTH	0.25% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018763 001	Sep 30, 1983
-------------------	--	-------------	--------------

DESOXYCORTICOSTERONE ACETATE

INJECTABLE; INJECTION

DOCA

ORGANON USA INC	5MG/ML	N001104 001	
-----------------	--------	-------------	--

PELLET; IMPLANTATION

PERCORTEN

NOVARTIS	125MG	N005151 001	
----------	-------	-------------	--

DESOXYCORTICOSTERONE PIVALATE

INJECTABLE; INJECTION

PERCORTEN

NOVARTIS	25MG/ML	N008822 001	
----------	---------	-------------	--

DESVENLAFAXINE FUMARATE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE

TEVA PHARMS USA	EQ 50MG BASE	N205208 001	Oct 11, 2013
	EQ 100MG BASE	N205208 002	Oct 11, 2013

DEXAMETHASONE

AEROSOL; TOPICAL

AEROSEB-DEX

ALLERGAN HERBERT	0.01% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A083296 002	
------------------	--	-------------	--

DECASPRAY

MERCK	0.04% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012731 002	
-------	--	-------------	--

DISCONTINUED DRUG PRODUCT LIST

DEXAMETHASONE

ELIXIR; ORAL

DECADRON

MERCK

0.5MG/5ML

N012376 002

DEXAMETHASONE

ALPHARMA US PHARMS

0.5MG/5ML

A088997 001 Oct 10, 1986

HEXADROL

ORGANON USA INC

0.5MG/5ML

N012674 001

GEL; TOPICAL

DECADERM

MERCK

0.1%

N013538 001

SUSPENSION/DROPS; OPHTHALMIC

DEXAMETHASONE

WATSON LABS

0.1%

A089170 001 May 09, 1989

TABLET; ORAL

DECADRON

MERCK

0.25MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N011664 004

0.5MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N011664 001

0.75MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N011664 002

1.5MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N011664 003

4MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N011664 005

6MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N011664 006 Jul 30, 1982

DEXAMETHASONE

IDT AUSTRALIA LTD

0.75MG

A080399 001

IMPAX LABS

0.75MG

A085376 001

PAR PHARM

0.25MG

A088149 001 Apr 28, 1983

PHOENIX LABS NY

0.75MG

A083806 001

PVT FORM

0.75MG

A083420 001

ROXANE

0.25MG

A084614 001

SUN PHARM INDS

0.25MG

A084013 001

0.25MG

A084764 001

0.5MG

A084084 001

0.5MG

A084766 001

0.75MG

A084081 001

0.75MG

A084765 001

1.5MG

A084086 001

1.5MG

A084763 001

UPSHER SMITH

0.75MG

A087534 001

1.5MG

A087533 001

WATSON LABS

0.25MG

A085455 001

0.5MG

A085458 001

0.75MG

A080968 001

0.75MG

A084457 001

0.75MG

A085818 001

1.5MG

A085456 001

1.5MG

A085840 001

WHITEWORTH TOWN PLSN

0.75MG

A084327 001

DEXONE 0.5

SOLVAY

0.5MG

A084991 001

DEXONE 0.75

SOLVAY

0.75MG

A084993 001

DEXONE 1.5

SOLVAY

1.5MG

A084990 001

DEXONE 4

SOLVAY

4MG

A084992 001

DISCONTINUED DRUG PRODUCT LIST

DEXAMETHASONE

TABLET; ORAL

HEXADROL

ORGANON USA INC	0.5MG	N012675 004
	0.75MG	N012675 007
	1.5MG	N012675 009
	4MG	N012675 010

DEXAMETHASONE ACETATE

INJECTABLE; INJECTION

DECADRON-LA

MERCCK

EQ 8MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016675 001
--	-------------

DEXAMETHASONE ACETATE

WATSON LABS

EQ 8MG BASE/ML	A084315 001
EQ 16MG BASE/ML	A087711 001 May 24, 1982

DEXAMETHASONE SODIUM PHOSPHATE

AEROSOL; NASAL

DEXACORT

UCB INC

EQ 0.1MG PHOSPHATE/INH	N014242 001
------------------------	-------------

AEROSOL, METERED; INHALATION

DEXACORT

UCB INC

EQ 0.1MG PHOSPHATE/INH	N013413 001
------------------------	-------------

CREAM; TOPICAL

DECADRON

MERCCK

EQ 0.1% PHOSPHATE	N011983 002
-------------------	-------------

INJECTABLE; INJECTION

DECADRON

MERCCK

EQ 4MG PHOSPHATE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012071 002
EQ 24MG PHOSPHATE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012071 004

DEXACEN-4

CENT PHARMS

EQ 4MG PHOSPHATE/ML	A084342 001
---------------------	-------------

DEXAMETHASONE

ABRAXIS PHARM

EQ 4MG PHOSPHATE/ML	A088448 001 Jan 25, 1984
---------------------	--------------------------

FRESENIUS KABI USA

EQ 10MG PHOSPHATE/ML	A088469 001 Jan 25, 1984
----------------------	--------------------------

DEXAMETHASONE SODIUM PHOSPHATE

AKORN

EQ 4MG PHOSPHATE/ML	A084493 001
---------------------	-------------

BEL MAR

EQ 4MG PHOSPHATE/ML	A084752 001
---------------------	-------------

DELL LABS

EQ 4MG PHOSPHATE/ML	A083161 001
---------------------	-------------

INTL MEDICATION

EQ 20MG PHOSPHATE/ML	A088522 001 Feb 17, 1984
----------------------	--------------------------

LYPHOMED

EQ 4MG PHOSPHATE/ML	A087065 001
---------------------	-------------

TEVA PARENTERAL

EQ 4MG PHOSPHATE/ML	A081125 001 Aug 31, 1990
---------------------	--------------------------

EQ 10MG PHOSPHATE/ML	A081126 001 Aug 31, 1990
----------------------	--------------------------

WATSON LABS

EQ 4MG PHOSPHATE/ML	A083702 001
---------------------	-------------

EQ 4MG PHOSPHATE/ML	A084355 001
---------------------	-------------

EQ 4MG PHOSPHATE/ML	A089169 001 Apr 09, 1986
---------------------	--------------------------

EQ 10MG PHOSPHATE/ML	A087668 001 Jul 01, 1982
----------------------	--------------------------

EQ 24MG PHOSPHATE/ML	A085606 001
----------------------	-------------

WEST-WARD PHARMS INT

EQ 4MG PHOSPHATE/ML	A084282 001
---------------------	-------------

WYETH AYERST

EQ 4MG PHOSPHATE/ML	A085641 001
---------------------	-------------

HEXADROL

ORGANON USA INC

EQ 4MG PHOSPHATE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N014694 002
---	-------------

EQ 10MG PHOSPHATE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N014694 003
--	-------------

EQ 20MG PHOSPHATE/ML	N014694 004
----------------------	-------------

OINTMENT; OPHTHALMIC

DECADRON

MERCCK

EQ 0.05% PHOSPHATE	N011977 001
--------------------	-------------

DEXAIR

PHARMAFAIR

EQ 0.05% PHOSPHATE	A088071 001 Dec 28, 1982
--------------------	--------------------------

DISCONTINUED DRUG PRODUCT LIST

DEXAMETHASONE SODIUM PHOSPHATE

OINTMENT;OPHTHALMIC

MAXIDEX

ALCON EQ 0.05% PHOSPHATE A083342 001

SOLUTION/DROPS;OPHTHALMIC

DEXAIR

PHARMAFAIR EQ 0.1% PHOSPHATE A088433 001 Dec 15, 1983

DEXAMETHASONE SODIUM PHOSPHATE

SOLA BARNES HIND EQ 0.1% PHOSPHATE A084170 001

EQ 0.1% PHOSPHATE A084173 001

SOLUTION/DROPS;OPHTHALMIC, OTIC

DECADRON

MERCCK EQ 0.1% PHOSPHATE N011984 001

SOLUTION/DROPS;OTIC

DEXAMETHASONE SODIUM PHOSPHATE

AKORN EQ 0.1% PHOSPHATE A084855 001

DEXAMETHASONE SODIUM PHOSPHATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

DECADRON W/ XYLOCAINE

MERCCK EQ 4MG PHOSPHATE/ML;10MG/ML N013334 002

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE

OINTMENT;OPHTHALMIC

NEODECADRON

MERCCK EQ 0.05% PHOSPHATE;EQ 3.5MG BASE/GM N050324 001

SOLUTION/DROPS;OPHTHALMIC

NEODECADRON

MERCCK EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML N050322 001

NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE

BAUSCH AND LOMB EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML A064055 001 Oct 30, 1995

NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE

ALCON PHARMS LTD EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML A062714 001 Jul 21, 1986

PHARMAFAIR EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML A062539 001 Jan 10, 1985

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

DEXACIDIN

NOVARTIS 0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM A062566 001 Feb 22, 1985

DEXASPORIN

PHARMAFAIR 0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM A062411 001 May 16, 1983

SUSPENSION/DROPS;OPHTHALMIC

DEXACIDIN

NOVARTIS 0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML A062544 001 Oct 29, 1984

DEXASPORIN

PHARMAFAIR 0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML A062428 001 May 18, 1983

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

ALCON PHARMS LTD 0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML A062721 001 Nov 17, 1986

DEXBROMPHENIRAMINE MALEATE

SYRUP;ORAL

DISOMER

SCHERING 2MG/5ML N011814 002

TABLET;ORAL

DISOMER

SCHERING 2MG N011814 001

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET;ORAL

DISOPHROL

SCHERING 2MG;60MG N012394 002

TABLET, EXTENDED RELEASE;ORAL

BROMPHERIL

COPLY PHARM 6MG;120MG A089116 001 Jan 22, 1987

DISOBROM

SANDOZ 6MG;120MG A070770 001 Sep 30, 1991

DISOPHROL

SCHERING PLOUGH 6MG;120MG N013483 004 Sep 13, 1982

DRIXORAL

SCHERING PLOUGH 6MG;120MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** N013483 003 Sep 13, 1982

RESPORAL

PIONEER PHARMS 6MG;120MG A089139 001 Jun 16, 1988

DISCONTINUED DRUG PRODUCT LIST

DEXCHLORPHENIRAMINE MALEATE

SYRUP; ORAL

POLARAMINE

SCHERING

2MG/5ML

A086837 001 Jul 19, 1982

TABLET; ORAL

DEXCHLORPHENIRAMINE MALEATE

ANI PHARMS INC

2MG

A088682 001 Jan 17, 1986

POLARAMINE

SCHERING

2MG

A086835 001

DEXTROAMPHETAMINE SULFATE

CAPSULE; ORAL

DEXAMPEX

TEVA

15MG

A085355 001

CAPSULE, EXTENDED RELEASE; ORAL

DEXTROAMPHETAMINE SULFATE

ABLE

5MG

A076814 001 Aug 25, 2004

10MG

A076814 002 Aug 25, 2004

15MG

A076814 003 Aug 25, 2004

ELIXIR; ORAL

DEXEDRINE

GLAXOSMITHKLINE

5MG/5ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

A083902 001

TABLET; ORAL

DEXAMPEX

TEVA

5MG

A083735 001

10MG

A083735 002

DEXEDRINE

GLAXOSMITHKLINE

5MG

A084935 001

DEXTROAMPHETAMINE SULFATE

COREPHARMA

5MG

A090652 001 Mar 07, 2014

10MG

A090652 002 Mar 07, 2014

HALSEY

10MG

A083930 001

IDT AUSTRALIA LTD

5MG

A085370 001

LANNETT

5MG

A083903 001

10MG

A083903 003

15MG

A085652 001

MAST MM

5MG

A086521 001

NESHER PHARMS

5MG

A040365 001 Oct 31, 2002

10MG

A040367 001 Oct 31, 2002

PUREPAC PHARM

5MG

A084125 001

SANDOZ

10MG

A085371 001

VINTAGE PHARMS LLC

5MG

A040299 001 May 13, 1999

VITARINE

5MG

A084986 001

10MG

A085892 001

DEXTROSTAT

SHIRE

5MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

A084051 001

10MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

A084051 002

FERNDEX

FERNDALE LABS

5MG

A084001 001

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHERAZINE DM

HALSEY

15MG/5ML; 6.25MG/5ML

A088913 001 Mar 02, 1987

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AMNEAL PHARMS

15MG/5ML; 6.25MG/5ML

A090575 001 Feb 08, 2011

ANI PHARMS

15MG/5ML; 6.25MG/5ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N011265 002 Apr 02, 1984

TRIS PHARMA INC

15MG/5ML; 6.25MG/5ML

A091687 001 Jun 28, 2012

DISCONTINUED DRUG PRODUCT LISTDEXTROSE

INJECTABLE; INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER

B BRAUN	10GM/100ML	N018046	001	
MILES	10GM/100ML	N018504	001	

DEXTROSE 2.5% IN PLASTIC CONTAINER

B BRAUN	2.5GM/100ML	N018358	001	
	2.5GM/100ML	N019626	001	Feb 02, 1988

DEXTROSE 38.5% IN PLASTIC CONTAINER

ABBOTT	38.5GM/100ML	N018923	001	Sep 19, 1984
--------	--------------	---------	-----	--------------

DEXTROSE 5% IN PLASTIC CONTAINER

DHL	5GM/100ML	N019971	001	Sep 28, 1995
-----	-----------	---------	-----	--------------

DEXTROSE 50% IN PLASTIC CONTAINER

HOSPIRA	50GM/100ML	N019894	001	Dec 26, 1989
---------	------------	---------	-----	--------------

DEXTROSE 60%

B BRAUN	60GM/100ML	N017995	002	Sep 22, 1982
---------	------------	---------	-----	--------------

DEXTROSE 60% IN PLASTIC CONTAINER

B BRAUN	60GM/100ML	N017995	001	
BAXTER HLTHCARE	60GM/100ML	N020047	002	Jul 02, 1991
HOSPIRA	60GM/100ML	N019346	001	Jan 25, 1985

DEXTROSE 7.7% IN PLASTIC CONTAINER

B BRAUN	7.7GM/100ML	N019626	003	Feb 02, 1988
---------	-------------	---------	-----	--------------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION

ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 31MG/100ML; 130MG/100ML; 26MG/100ML; 320MG/100ML	N019025	001	Dec 27, 1984
---------	---	---------	-----	--------------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE; INJECTION

IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML; 53MG/100ML; 100MG/100ML; 100MG/100ML; 180MG/100ML; 280MG/100ML; 16MG/100ML	N019515	001	May 08, 1986
---------	---	---------	-----	--------------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 30MG/100ML; 97MG/100ML; 220MG/100ML; 140MG/100ML	N018273	001	
---------	---	---------	-----	--

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML	N019843	001	Aug 09, 1993
---------	--	---------	-----	--------------

ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML	N018274	001	
---------	--	---------	-----	--

PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML; 30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML	N017451	001	
-----------------	--	---------	-----	--

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 37MG/100ML	N019699	001	Sep 29, 1989
---------	-----------------------	---------	-----	--------------

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 75MG/100ML	N018744	001	Nov 09, 1982
	5GM/100ML; 75MG/100ML	N019699	002	Sep 29, 1989

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 110MG/100ML	N019699	003	Sep 29, 1989
---------	------------------------	---------	-----	--------------

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 150MG/100ML	N018744	002	Nov 09, 1982
---------	------------------------	---------	-----	--------------

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 220MG/100ML	N018744	003	Nov 09, 1982
	5GM/100ML; 220MG/100ML	N019699	005	Sep 29, 1989

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 300MG/100ML	N018744	004	Nov 09, 1982
---------	------------------------	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LISTDEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE; INJECTION

IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML; 111MG/100ML; 256MG/100ML; 146MG	N019514 001	May 08, 1986
	/100ML; 207MG/100ML		

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 150MG/100ML; 130MG/100ML; 280MG	N018270 001	
	/100ML; 91MG/100ML		

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 75 IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML; 205MG/100ML; 100MG/100ML; 120MG	N018840 001	Jun 29, 1983
	/100ML; 220MG/100ML		

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.075%

B BRAUN	5GM/100ML; 75MG/100ML; 200MG/100ML	N018268 009	
---------	------------------------------------	-------------	--

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 150MG/100ML; 200MG/100ML	N018268 004	
---------	-------------------------------------	-------------	--

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 220MG/100ML; 200MG/100ML	N018268 005	
---------	-------------------------------------	-------------	--

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 300MG/100ML; 200MG/100ML	N018268 006	
---------	-------------------------------------	-------------	--

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 75MG/100ML; 330MG/100ML	N018268 011	Jan 18, 1986
---------	------------------------------------	-------------	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 150MG/100ML; 330MG/100ML	N018268 012	Jan 18, 1986
---------	-------------------------------------	-------------	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 220MG/100ML; 330MG/100ML	N018268 013	Jan 18, 1986
---------	-------------------------------------	-------------	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.30% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 300MG/100ML; 330MG/100ML	N018268 014	Jan 18, 1986
---------	-------------------------------------	-------------	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.075%

B BRAUN	5GM/100ML; 75MG/100ML; 450MG/100ML	N018268 010	
---------	------------------------------------	-------------	--

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 150MG/100ML; 450MG/100ML	N018268 001	
---------	-------------------------------------	-------------	--

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 220MG/100ML; 450MG/100ML	N018268 002	
---------	-------------------------------------	-------------	--

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 300MG/100ML; 450MG/100ML	N018268 003	
---------	-------------------------------------	-------------	--

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML; 224MG/100ML; 450MG/100ML	N018008 003	
-----------------	-------------------------------------	-------------	--

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML; 300MG/100ML; 450MG/100ML	N018008 001	
-----------------	-------------------------------------	-------------	--

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML; 75MG/100ML; 450MG/100ML	N018008 002	
-----------------	------------------------------------	-------------	--

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

B BRAUN	10GM/100ML; 200MG/100ML	N018386 001	
---------	-------------------------	-------------	--

DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN	10GM/100ML; 450MG/100ML	N018229 001	
---------	-------------------------	-------------	--

DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN	10GM/100ML; 900MG/100ML	N018047 001	
---------	-------------------------	-------------	--

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN	2.5GM/100ML; 450MG/100ML	N018030 001	
---------	--------------------------	-------------	--

HOSPIRA	2.5GM/100ML; 450MG/100ML	N018096 001	
---------	--------------------------	-------------	--

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN	2.5GM/100ML; 900MG/100ML	N018376 001	
---------	--------------------------	-------------	--

DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

ABBOTT	3.3GM/100ML; 300MG/100ML	N018055 001	
--------	--------------------------	-------------	--

DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 110MG/100ML	N018030 005	
---------	------------------------	-------------	--

DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 200MG/100ML	N018030 004	
---------	------------------------	-------------	--

MILES	5GM/100ML; 200MG/100ML	N018399 001	
-------	------------------------	-------------	--

DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

ABBOTT	5GM/100ML; 225MG/100ML	N019482 001	Oct 04, 1985
--------	------------------------	-------------	--------------

DISCONTINUED DRUG PRODUCT LISTDEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
ABBOTT	5GM/100ML; 300MG/100ML	N019486 001	Oct 04, 1985
MILES	5GM/100ML; 300MG/100ML	N018501 001	
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML; 330MG/100ML	N018030 003	
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
ABBOTT	5GM/100ML; 450MG/100ML	N019484 001	Oct 04, 1985
B BRAUN	5GM/100ML; 450MG/100ML	N018030 002	
MILES	5GM/100ML; 450MG/100ML	N018400 001	
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
ABBOTT	5GM/100ML; 900MG/100ML	N019483 001	Oct 04, 1985
B BRAUN	5GM/100ML; 900MG/100ML	N018026 001	
MILES	5GM/100ML; 900MG/100ML	N018500 001	

DEXTROTHYROXINE SODIUM

TABLET; ORAL

CHOLOXIN			
ABBVIE	1MG	N012302 005	
	2MG	N012302 002	
	4MG	N012302 004	
	6MG	N012302 006	

DEZOCINE

INJECTABLE; INJECTION

DALGAN			
ASTRAZENECA	5MG/ML	N019082 001	Dec 29, 1989
	10MG/ML	N019082 002	Dec 29, 1989
	15MG/ML	N019082 003	Dec 29, 1989

DIATRIZOATE MEGLUMINE

INJECTABLE; INJECTION

ANGIOVIST 282			
BAYER HLTHCARE	60%	A087726 001	Sep 23, 1982
CARDIOGRAFIN			
BRACCO	85%	N011620 002	
DIATRIZOATE MEGLUMINE			
BRACCO	76%	N010040 017	
HYPaque			
GE HEALTHCARE	30%	N016403 002	
	60%	N016403 001	
RENO-60			
BRACCO	60%	N010040 016	
RENO-DIP			
BRACCO	30%	N010040 012	
UROVIST MEGLUMINE DIU/CT			
BAYER HLTHCARE	30%	A087739 001	Sep 23, 1982
SOLUTION; URETERAL			
RENO-30			
BRACCO	30%	N010040 021	
UROVIST CYSTO			
BAYER HLTHCARE	30%	A087729 001	Sep 23, 1982
UROVIST CYSTO PEDIATRIC			
BAYER HLTHCARE	30%	A087731 001	Sep 23, 1982
SOLUTION; URETHRAL			
HYPaque-CYSTO			
GE HEALTHCARE	30%	N016403 003	

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

ANGIOVIST 292			
BAYER HLTHCARE	52%; 8%	A087724 001	Sep 23, 1982
ANGIOVIST 370			
BAYER HLTHCARE	66%; 10%	A087723 001	Sep 23, 1982
DIATRIZOATE-60			
INTL MEDICATION	52%; 8%	A088166 001	Jun 17, 1983
HYPaque-76			
GE HEALTHCARE	66%; 10%	A086505 001	
HYPaque-M, 75%			
GE HEALTHCARE	50%; 25%	N010220 003	
HYPaque-M, 90%			
GE HEALTHCARE	60%; 30%	N010220 002	

DISCONTINUED DRUG PRODUCT LIST

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

MD-60				
	MALLINCKRODT	52%;8%	A087074	001
MD-76				
	MALLINCKRODT	66%;10%	A087073	001
RENOCAL-76				
	BRACCO	66%;10%	A089347	001 Jun 01, 1988
RENOGRAFIN-60				
	BRACCO	52%;8%	N010040	006
RENOVIST				
	BRACCO	34.3%;35%	N010040	020
RENOVIST II				
	BRACCO	28.5%;29.1%	N010040	019
SOLUTION; ORAL, RECTAL				
GASTROVIST				
	BAYER HLTHCARE	66%;10%	A087728	001 Sep 23, 1982

DIATRIZOATE SODIUM

FOR SOLUTION; ORAL, RECTAL

	HYPaque			
	GE HEALTHCARE	100%	N011386	001
INJECTABLE; INJECTION				
	HYPaque			
	GE HEALTHCARE	25%	N009561	003
		50%	N009561	001
MD-50				
	MALLINCKRODT	50%	A087075	001
UROVIST SODIUM 300				
	BAYER HLTHCARE	50%	A087725	001 Sep 23, 1982
SOLUTION; ORAL, RECTAL				
	HYPaque			
	GE HEALTHCARE	40%	N011386	003
SOLUTION; URETERAL				
	HYPaque SODIUM 20%			
	GE HEALTHCARE	20%	N009561	002

DIAZEPAM

CAPSULE, EXTENDED RELEASE; ORAL

	VALRELEASE			
	ROCHE	15MG	N018179	001
GEL; RECTAL				
	DIASTAT			
	VALEANT PHARMS NORTH	5MG/ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020648	002 Jul 29, 1997
		10MG/2ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020648	003 Jul 29, 1997
		15MG/3ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020648	004 Jul 29, 1997
		20MG/4ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020648	005 Jul 29, 1997

INJECTABLE; INJECTION

	DIAZEPAM			
	ABRAXIS PHARM	5MG/ML	A070662	001 Jun 25, 1986
	HOSPIRA	5MG/ML	A071584	001 Oct 13, 1987
	MARSAM PHARMS LLC	5MG/ML	A072371	001 Jan 29, 1993
	PARENTA PHARMS	5MG/ML	A076815	001 Apr 15, 2004
	US ARMY	5MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020124	001 Dec 05, 1990
	WARNER CHILCOTT	5MG/ML	A071613	001 Oct 22, 1987
		5MG/ML	A071614	001 Oct 22, 1987
	WATSON LABS	5MG/ML	A070296	001 Feb 12, 1986
		5MG/ML	A070911	001 Aug 28, 1986
		5MG/ML	A070912	001 Aug 28, 1986
		5MG/ML	A070930	001 Dec 01, 1986

DISCONTINUED DRUG PRODUCT LIST

DIAZEPAM

INJECTABLE; INJECTION

DIAZEPAM

WATSON LABS INC	5MG/ML	A072370 001	Jan 29, 1993
	5MG/ML	A072397 001	Jan 29, 1993
WEST-WARD PHARMS INT	5MG/ML	A070311 001	Dec 16, 1985
	5MG/ML	A070312 001	Dec 16, 1985
	5MG/ML	A070313 001	Dec 16, 1985
	5MG/ML	A071308 001	Jul 17, 1987
	5MG/ML	A071309 001	Jul 17, 1987
	5MG/ML	A071310 001	Jul 17, 1987

DIZAC

PHARMACIA AND UPJOHN	5MG/ML	N019287 001	Jun 18, 1993
----------------------	--------	-------------	--------------

VALIUM

ROCHE	5MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016087 001	
-------	---	-------------	--

TABLET; ORAL

DIAZEPAM

ACTAVIS ELIZABETH	2MG	A070781 001	Mar 19, 1986
	5MG	A070706 001	Mar 19, 1986
	10MG	A070707 001	Mar 19, 1986
DAVA PHARMS INC	10MG	A070228 001	Sep 26, 1985
DURAMED PHARMS BARR	2MG	A070894 001	Aug 27, 1986
	5MG	A070895 001	Aug 27, 1986
	10MG	A070896 001	Aug 27, 1986
FERNDALE LABS	2MG	A070903 001	Apr 01, 1987
	5MG	A070904 001	Apr 01, 1987
	10MG	A070905 001	Apr 01, 1987
HALSEY	2MG	A070987 001	Aug 15, 1986
	5MG	A070996 001	Aug 15, 1986
	10MG	A070956 001	Aug 15, 1986
IVAX SUB TEVA PHARMS	2MG	A070360 001	Sep 04, 1985
	5MG	A070361 001	Sep 04, 1985
	10MG	A070362 001	Sep 04, 1985
MARTEC USA LLC	10MG	A072402 001	Apr 25, 1989
PAR PHARM	2MG	A070462 001	Feb 25, 1986
	5MG	A070463 001	Feb 25, 1986
	10MG	A070464 001	Feb 25, 1986
PIONEER PHARMS	2MG	A070787 001	Aug 02, 1988
	5MG	A070788 001	Aug 02, 1988
	10MG	A070776 001	Aug 02, 1988
ROXANE	2MG	A070356 001	Jun 17, 1986
	5MG	A070357 001	Jun 17, 1986
	10MG	A070358 001	Jun 17, 1986
TEVA PHARMS	5MG	A070153 001	Nov 01, 1985
UPSHER-SMITH LABS	2MG	A070302 001	Dec 20, 1985
	5MG	A070303 001	Dec 20, 1985
	10MG	A070304 001	Dec 20, 1985
WARNER CHILCOTT	2MG	A070209 001	Sep 04, 1985
	5MG	A070210 001	Sep 04, 1985
	10MG	A070222 001	Sep 04, 1985
WATSON LABS	2MG	A070456 001	Nov 01, 1985
	5MG	A070457 001	Nov 01, 1985
	10MG	A070458 001	Nov 01, 1985
Q-PAM			
QUANTUM PHARMICS	2MG	A070423 001	Dec 12, 1985
	2MG	A072431 001	Apr 29, 1988
	5MG	A070424 001	Dec 12, 1985
	5MG	A072432 001	Apr 29, 1988
	10MG	A070425 001	Dec 12, 1985
	10MG	A072433 001	Apr 29, 1988

DIAZOXIDE

CAPSULE; ORAL

PROGLYCEM

TEVA BRANDED PHARM	50MG	N017425 001	
	100MG	N017425 002	

INJECTABLE; INJECTION

DIAZOXIDE

ABRAXIS PHARM	15MG/ML	A071519 001	Aug 26, 1987
---------------	---------	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

DIAZOXIDE

INJECTABLE; INJECTION

HYPERSTAT

SCHERING

15MG/ML

N016996 001

DIBUCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

HEAVY SOLUTION NUPERCAINE

NOVARTIS

2.5MG/ML

N006203 001

DICHLORPHENAMIDE

TABLET; ORAL

DARANIDE

STRONGBRIDGE US

50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N011366 001

DICLOFENAC POTASSIUM

TABLET; ORAL

CATAFLAM

NOVARTIS

25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
50MG

N020142 001 Nov 24, 1993

N020142 002 Nov 24, 1993

DICLOFENAC POTASSIUM

SANDOZ

50MG

A075582 001 Feb 23, 2001

SUN PHARM INDS

50MG

A075470 001 Feb 21, 2002

WATSON LABS

50MG

A075152 001 Nov 27, 1998

DICLOFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

DICLOFENAC SODIUM

APOTEX INC

0.1%

A077600 001 Nov 13, 2008

FALCON PHARMS

0.1%

N020809 001 May 04, 1998

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

NOSTRUM LABS

50MG

A074986 001 Feb 26, 1999

75MG

A074986 002 Feb 26, 1999

PLIVA

50MG

A074432 002 Jul 29, 1999

75MG

A074432 003 Jul 29, 1999

ROXANE

25MG

A074391 001 Jun 29, 1995

50MG

A074391 002 Jun 29, 1995

75MG

A074391 003 Jun 29, 1995

TEVA

50MG

A074723 001 Mar 30, 1999

75MG

A074390 001 Aug 15, 1996

TEVA PHARMS

25MG

A074459 001 Jun 25, 1997

50MG

A074459 002 Jun 25, 1997

75MG

A074459 003 Jun 25, 1997

VOLTAREN

NOVARTIS

25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N019201 001 Jul 28, 1988

50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N019201 002 Jul 28, 1988

75MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N019201 003 Jul 28, 1988

TABLET, EXTENDED RELEASE; ORAL

VOLTAREN-XR

NOVARTIS

100MG

N020254 001 Mar 08, 1996

DICLOXACILLIN SODIUM

CAPSULE; ORAL

DYCILL

GLAXOSMITHKLINE

EQ 250MG BASE

A060254 002

EQ 250MG BASE

A062238 001

EQ 500MG BASE

A060254 003

EQ 500MG BASE

A062238 002

PATHOCIL

WYETH AYERST

EQ 250MG BASE

N050011 002

EQ 500MG BASE

N050011 003 Mar 28, 1983

DISCONTINUED DRUG PRODUCT LISTDICLOXACILLIN SODIUM

FOR SUSPENSION;ORAL

DICLOXACILLIN SODIUM

APOTHECON	EQ 62.5MG BASE/5ML	A061455	001
DYNAPEN			
APOTHECON	EQ 62.5MG BASE/5ML	N050337	002
PATHOCIL			
WYETH AYERST	EQ 62.5MG BASE/5ML	N050092	001

DICUMAROL

CAPSULE;ORAL

DICUMAROL

LILLY	25MG	N005509	003
	50MG	N005509	001

TABLET;ORAL

DICUMAROL

ABBVIE	25MG	N005545	003
	50MG	N005545	004
	100MG	N005545	005

DICYCLOMINE HYDROCHLORIDE

CAPSULE;ORAL

DICYCLOMINE HYDROCHLORIDE

HIKMA PHARMS LLC	10MG	A040204	001	Feb 28, 1997
PIONEER PHARMS	10MG	A089361	001	Jan 10, 1989
SUN PHARM INDS	10MG	A084505	001	Oct 21, 1986
WATSON LABS	10MG	A083179	001	Feb 12, 1986

INJECTABLE;INJECTION

DICYCLOMINE HYDROCHLORIDE

WATSON LABS	10MG/ML	A080614	001	Feb 11, 1986
-------------	---------	---------	-----	--------------

SYRUP;ORAL

BENTYL

APTALIS PHARMA US	10MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N007961	002	Oct 15, 1984
-------------------	---	---------	-----	--------------

DICYCLOMINE HYDROCHLORIDE

ALPHARMA US PHARMS	10MG/5ML	A084479	001
--------------------	----------	---------	-----

TABLET;ORAL

DICYCLOMINE HYDROCHLORIDE

HIKMA PHARMS LLC	20MG	A040161	001	Oct 01, 1996
PIONEER PHARMS	20MG	A088585	001	Aug 20, 1986
SUN PHARM INDS	20MG	A084600	001	Jul 29, 1985
WATSON LABS	20MG	A084361	001	Feb 06, 1986

DIDANOSINE

FOR SOLUTION;ORAL

VIDEX

BRISTOL MYERS SQUIBB	100MG/PACKET	N020155	003	Oct 09, 1991
	167MG/PACKET	N020155	004	Oct 09, 1991
	250MG/PACKET	N020155	005	Oct 09, 1991
	375MG/PACKET	N020155	006	Oct 09, 1991

TABLET, CHEWABLE;ORAL

VIDEX

BRISTOL MYERS SQUIBB	25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020154	002	Oct 09, 1991
	50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020154	003	Oct 09, 1991
	100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020154	004	Oct 09, 1991
	150MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020154	005	Oct 09, 1991
	200MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020154	006	Oct 28, 1999

DISCONTINUED DRUG PRODUCT LIST

DIENESTROL

CREAM; VAGINAL

DIENESTROL

ORTHO MCNEIL PHARM 0.01% N006110 005

DV

SANOFI AVENTIS US 0.01% A083518 001

ESTRAGUARD

SOLVAY 0.01% A084436 001

SUPPOSITORY; VAGINAL

DV

SANOFI AVENTIS US 0.7MG A083517 001

DIETHYLCARBAMAZINE CITRATE

TABLET; ORAL

HETRAZAN

LEDERLE 50MG N006459 001

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

DIETHYLPROPION HYDROCHLORIDE

COREPHARMA 25MG A040828 001 Nov 05, 2008

SANDOZ 25MG A085916 001

TEVA 25MG A088642 001 Sep 20, 1984

TG UNITED LABS 25MG A088267 001 Aug 25, 1983

25MG A088268 001 Aug 25, 1983

UCB INC 25MG A085544 001

WATSON LABS 25MG A085741 001

TENUATE

SANOFI AVENTIS US 25MG N017668 001

TEPANIL

3M 25MG N011673 001

TABLET, EXTENDED RELEASE; ORAL

TENUATE

SANOFI AVENTIS US 75MG N017669 001

TEPANIL TEN-TAB

3M 75MG N017956 001

DIETHYLSTILBESTROL

INJECTABLE; INJECTION

STILBESTROL

BRISTOL MYERS SQUIBB 0.2MG/ML N004056 003

0.5MG/ML N004056 004

1MG/ML N004056 005

5MG/ML N004056 006

SUPPOSITORY; VAGINAL

DIETHYLSTILBESTROL

LILLY 0.1MG N004040 001

0.5MG N004040 002

STILBESTROL

BRISTOL MYERS SQUIBB 0.1MG N004056 001

0.5MG N004056 002

TABLET; ORAL

DIETHYLSTILBESTROL

LILLY 0.1MG N004041 002

0.5MG N004041 003

1MG N004041 004

5MG N004041 005

STILBESTROL

TABLICAPS 0.5MG A083004 001

1MG A083002 001

5MG A083006 001

STILBETIN

BRISTOL MYERS SQUIBB 0.1MG N004056 007

0.25MG N004056 017

0.5MG N004056 008

1MG N004056 009

5MG N004056 010

TABLET, DELAYED RELEASE; ORAL

DIETHYLSTILBESTROL

LILLY 0.1MG N004039 002

0.25MG N004039 005

0.5MG N004039 003

1MG N004039 004

5MG N004039 006

DISCONTINUED DRUG PRODUCT LIST

DIETHYLSTILBESTROL

TABLET, DELAYED RELEASE;ORAL

STILBESTROL

TABLICAPS	0.5MG	A083003	001
	1MG	A083005	001
	5MG	A083007	001

STILBETIN

BRISTOL MYERS SQUIBB	0.1MG	N004056	011
	0.5MG	N004056	012
	1MG	N004056	013
	5MG	N004056	014

DIETHYLSTILBESTROL DIPHOSPHATE

INJECTABLE; INJECTION

STILPHOSTROL

BAYER PHARMS	250MG/5ML	N010010	001
--------------	-----------	---------	-----

TABLET; ORAL

STILPHOSTROL

BAYER PHARMS	50MG	N010010	002
--------------	------	---------	-----

DIFLORASONE DIACETATE

CREAM; TOPICAL

DIFLORASONE DIACETATE

FOUGERA PHARMS	0.05%	A075187	001	Mar 30, 1998
----------------	-------	---------	-----	--------------

FLORONE

PHARMACIA AND UPJOHN	0.05%	N017741	001
----------------------	-------	---------	-----

FLORONE E

PHARMACIA AND UPJOHN	0.05%	N019259	001	Aug 28, 1985
----------------------	-------	---------	-----	--------------

PSORCON

TARO PHARMS NORTH	0.05%	N020205	001	Nov 20, 1992
-------------------	-------	---------	-----	--------------

OINTMENT; TOPICAL

PSORCON

PHARMACIA AND UPJOHN	0.05%	N019260	001	Aug 28, 1985
----------------------	-------	---------	-----	--------------

PSORCON E

PHARMACIA AND UPJOHN	0.05%	N017994	001
----------------------	-------	---------	-----

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

IDT AUSTRALIA LTD	500MG	A074604	001	Jun 10, 1996
-------------------	-------	---------	-----	--------------

PUREPAC PHARM	250MG	A074285	001	May 07, 1996
---------------	-------	---------	-----	--------------

	500MG	A074285	002	May 07, 1996
--	-------	---------	-----	--------------

ROXANE	250MG	A073562	001	Nov 27, 1992
--------	-------	---------	-----	--------------

	500MG	A073563	001	Nov 27, 1992
--	-------	---------	-----	--------------

TEVA	250MG	A073679	001	Jul 31, 1992
------	-------	---------	-----	--------------

WATSON LABS	250MG	A074400	001	Jul 17, 1997
-------------	-------	---------	-----	--------------

	500MG	A074400	002	Jul 17, 1997
--	-------	---------	-----	--------------

DOLOBID

MERCK

250MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018445	001	Apr 19, 1982
-------	--	---------	-----	--------------

500MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018445	002	Apr 19, 1982
-------	--	---------	-----	--------------

DIGITOXIN

INJECTABLE; INJECTION

CRYSTODIGIN

LILLY	0.2MG/ML	A084100	005
-------	----------	---------	-----

DIGOXIN

CAPSULE; ORAL

LANOXICAPS

GLAXOSMITHKLINE LLC	0.05MG	N018118	002	Jul 26, 1982
---------------------	--------	---------	-----	--------------

	0.1MG	N018118	003	Jul 26, 1982
--	-------	---------	-----	--------------

	0.15MG	N018118	004	Sep 24, 1984
--	--------	---------	-----	--------------

	0.2MG	N018118	001	Jul 26, 1982
--	-------	---------	-----	--------------

INJECTABLE; INJECTION

DIGOXIN

ABRAXIS PHARM	0.25MG/ML	A083217	001
---------------	-----------	---------	-----

HOSPIRA	0.25MG/ML	A040093	001	May 16, 1996
---------	-----------	---------	-----	--------------

	0.25MG/ML	A040206	001	Aug 28, 1998
--	-----------	---------	-----	--------------

WYETH AYERST	0.25MG/ML	A084386	001
--------------	-----------	---------	-----

DISCONTINUED DRUG PRODUCT LIST

DIGOXIN

INJECTABLE; INJECTION

DIGOXIN PEDIATRIC

HOSPIRA

0.1MG/ML

A040092 001 Apr 25, 1996

TABLET; ORAL

LANOXIN

CONCORDIA PHARMS INC

0.375MG

N020405 005 Sep 30, 1997

0.5MG

N020405 006 Sep 30, 1997

DIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

EMBOLEX

NOVARTIS

0.5MG/0.5ML; 2,500

N018885 001 Nov 30, 1984

UNITS/0.5ML; 5.33MG/0.5ML

0.5MG/0.7ML; 5,000

N018885 002 Nov 30, 1984

UNITS/0.7ML; 7.46MG/0.7ML

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARDIZEM SR

BIOVAIL

60MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N019471 001 Jan 23, 1989

90MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N019471 002 Jan 23, 1989

120MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N019471 003 Jan 23, 1989

180MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N019471 004 Jan 23, 1989

DILACOR XR

ALLERGAN SALES LLC

120MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N020092 001 May 29, 1992

180MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N020092 002 May 29, 1992

240MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N020092 003 May 29, 1992

DILT-CD

APOTEX

120MG

A076151 001 May 20, 2004

180MG

A076151 002 May 20, 2004

240MG

A076151 003 May 20, 2004

300MG

A076151 004 May 20, 2004

DILTIAZEM HYDROCHLORIDE

ACTAVIS LABS FL INC

120MG

A074852 001 Oct 10, 1997

180MG

A074852 002 Oct 10, 1997

240MG

A074852 003 Oct 10, 1997

BIOVAIL

60MG

A074845 001 Sep 15, 1999

90MG

A074845 002 Sep 15, 1999

120MG

A074845 003 Sep 15, 1999

120MG

N020939 001 Jan 28, 2000

180MG

N020939 002 Jan 28, 2000

240MG

N020939 003 Jan 28, 2000

300MG

N020939 004 Jan 28, 2000

360MG

N020939 005 Sep 14, 2001

420MG

N020939 006 Sep 14, 2001

NESHER PHARMS

120MG

A076563 002 Sep 12, 2006

180MG

A076563 003 Sep 12, 2006

240MG

A076563 004 Sep 12, 2006

300MG

A076563 005 Sep 12, 2006

360MG

A076563 006 Sep 12, 2006

420MG

A076563 001 Sep 12, 2006

TEVA

60MG

A074079 001 Nov 30, 1993

90MG

A074079 002 Nov 30, 1993

120MG

A074079 003 Nov 30, 1993

DISCONTINUED DRUG PRODUCT LISTDILTIAZEM HYDROCHLORIDE

INJECTABLE; INJECTION

CARDIZEM

BIOVAIL	100MG/VIAL	N020792	001	Sep 05, 1997
BIOVAIL LABS INTL	5MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020027	001	Oct 24, 1991
	25MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020027	003	Aug 18, 1995

DILTIAZEM HYDROCHLORIDE

HOSPIRA	5MG/ML	A075004	001	Feb 16, 2000
	5MG/ML	A075106	001	Apr 29, 1999
MYLAN LABS LTD	5MG/ML	A075375	001	Sep 30, 1999
TEVA PHARMS USA	5MG/ML	A074894	001	Aug 26, 1997

TABLET; ORAL

DILTIAZEM HYDROCHLORIDE

APOTHECON	30MG	A074051	001	Mar 31, 1993
	60MG	A074051	002	Mar 31, 1993
	90MG	A074051	003	Mar 31, 1993
	120MG	A074051	004	Mar 31, 1993
DAVA PHARMS INC	30MG	A074093	001	Nov 05, 1992
	60MG	A074093	002	Nov 05, 1992
	90MG	A074093	003	Nov 05, 1992
	120MG	A074093	004	Nov 05, 1992
IVAX SUB TEVA PHARMS	30MG	A074168	001	Mar 03, 1995
	60MG	A074168	002	Mar 03, 1995
	90MG	A074168	003	Mar 03, 1995
	120MG	A074168	004	Mar 03, 1995
TEVA	30MG	A074084	001	Feb 25, 1994
	60MG	A074084	002	Feb 25, 1994
TEVA PHARMS	30MG	A074067	001	Nov 05, 1992
	60MG	A074067	002	Nov 05, 1992
	90MG	A074067	003	Nov 05, 1992
	120MG	A074067	004	Nov 05, 1992

DILTIAZEM MALATE

TABLET, EXTENDED RELEASE; ORAL

TIAMATE

MERCK	EQ 120MG HCL	N020506	001	Oct 04, 1996
	EQ 180MG HCL	N020506	002	Oct 04, 1996
	EQ 240MG HCL	N020506	003	Oct 04, 1996

DILTIAZEM MALATE; ENALAPRIL MALEATE

TABLET, EXTENDED RELEASE; ORAL

TECZEM

BIOVAIL	EQ 180MG HCL; 5MG	N020507	001	Oct 04, 1996
---------	-------------------	---------	-----	--------------

DIMENHYDRINATE

INJECTABLE; INJECTION

DIMENHYDRINATE

BAXTER HLTHCARE	50MG/ML	A084767	001	
WATSON LABS	50MG/ML	A080615	001	
	50MG/ML	A083531	001	
WYETH AYERST	50MG/ML	A084316	001	

LIQUID; ORAL

DIMENHYDRINATE

ALRA	12.5MG/4ML	A080715	001	
------	------------	---------	-----	--

TABLET; ORAL

DIMENHYDRINATE

HEATHER	50MG	A080841	001	
NEXGEN PHARMA INC	50MG	A085985	001	
WATSON LABS	50MG	A085166	001	

DIMYRISTOYL LECITHIN; PERFLEXANE

INJECTABLE; INTRAVENOUS

IMAGENT

VESSELON SPV LLC	0.92MG/VIAL; 0.092MG/VIAL	N021191	001	May 31, 2002
------------------	---------------------------	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

DINOPROST TROMETHAMINE

INJECTABLE; INJECTION

PROSTIN F2 ALPHA

PHARMACIA AND UPJOHN EQ 5MG BASE/ML N017434 001

DIPHEMANIL METHYLSULFATE

TABLET; ORAL

PRANTAL

SCHERING 100MG N008114 004

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

BENADRYL

MCNEIL CONS 25MG N005845 007

50MG N005845 001

DIPHENHYDRAMINE HYDROCHLORIDE

ALRA 25MG A080519 004

50MG A080519 003

ANABOLIC 50MG A083275 001

ELKINS SINN 25MG A085701 001

50MG A085701 002

HALSEY 50MG A087914 001 Jun 04, 1984

HEATHER 25MG A084524 001

50MG A083953 001

HIKMA INTL PHARMS 50MG A083567 001

IMPAX LABS 25MG A080807 001

50MG A080807 002

IVAX SUB TEVA PHARMS 25MG A080762 001

50MG A080762 002

LANNETT 25MG A080868 001

50MG A080868 002

LEDERLE 25MG A086874 001

50MG A086875 001

LNK 25MG A087977 001 Jan 27, 1983

50MG A087978 001 Jan 27, 1983

MK LABS 25MG A083087 001

50MG A083087 002

MUTUAL PHARM 25MG A084506 001

NEWTRON PHARMS 25MG A086543 001

50MG A086544 001

NEXGEN PHARMA INC 25MG A083634 001

PERRIGO 25MG A083061 001

50MG A083061 002

PIONEER PHARMS 25MG A089101 001 Dec 20, 1985

50MG A088880 001 Dec 20, 1985

PUREPAC PHARM 25MG A085156 001

50MG A085150 001

PVT FORM 25MG A083027 001

50MG A083027 002

ROXANE 50MG A080635 001

SANDOZ 25MG A080832 001

25MG A080845 002

50MG A080832 002

50MG A080845 001

SUN PHARM INDS 25MG A089488 001 Jan 02, 1987

50MG A089489 001 Jan 02, 1987

SUPERPHARM 25MG A089040 001 May 15, 1985

50MG A089041 001 May 15, 1985

TEVA 25MG A085874 001

50MG A085874 002

VALEANT PHARM INTL 25MG A080596 001

50MG A080592 001

VANGARD 25MG A088034 001 Oct 27, 1982

50MG A087630 001

WATSON LABS 25MG A080728 001

25MG A083797 001

25MG A085138 001

50MG A080727 001

50MG A083797 002

50MG A085083 001

WHITEWORTH TOWN PLSN 25MG A083441 001

50MG A080800 001

DISCONTINUED DRUG PRODUCT LIST

DIPHENHYDRAMINE HYDROCHLORIDE

ELIXIR; ORAL

BELIX

HALSEY	12.5MG/5ML	A086586 001	Oct 03, 1983
--------	------------	-------------	--------------

BENADRYL

MCNEIL CONS	12.5MG/5ML	N005845 004	
-------------	------------	-------------	--

DIBENIL

CENCI	12.5MG/5ML	A088304 001	Dec 16, 1983
-------	------------	-------------	--------------

DIPHEN

USL PHARMA	12.5MG/5ML	A084640 001	
------------	------------	-------------	--

DIPHENHYDRAMINE HYDROCHLORIDE

BUNDY	12.5MG/5ML	A083674 001	
-------	------------	-------------	--

CENCI	12.5MG/5ML	A087941 001	Dec 17, 1982
-------	------------	-------------	--------------

KV PHARM	12.5MG/5ML	A085621 001	
----------	------------	-------------	--

LANNETT	12.5MG/5ML	A080939 002	
---------	------------	-------------	--

LEDERLE	12.5MG/5ML	A086937 001	
---------	------------	-------------	--

MK LABS	12.5MG/5ML	A083088 002	
---------	------------	-------------	--

NASKA	12.5MG/5ML	A088680 001	May 31, 1985
-------	------------	-------------	--------------

PERRIGO	12.5MG/5ML	A083063 001	
---------	------------	-------------	--

PUREPAC PHARM	12.5MG/5ML	A083237 001	Jan 25, 1982
---------------	------------	-------------	--------------

PVT FORM	12.5MG/5ML	A085287 001	
----------	------------	-------------	--

ROXANE	12.5MG/5ML	A080643 001	
--------	------------	-------------	--

HYDRAMINE

ALPHARMA US PHARMS	12.5MG/5ML	A080763 002	
--------------------	------------	-------------	--

INJECTABLE; INJECTION

BENADRYL

MCNEIL CONS	10MG/ML	N006146 001	
-------------	---------	-------------	--

50MG/ML **Federal Register	N006146 002		
----------------------------	-------------	--	--

determination that product was not discontinued or withdrawn for safety or efficacy reasons**

BENADRYL PRESERVATIVE FREE

MCNEIL CONS	50MG/ML **Federal Register	N009486 001	
-------------	----------------------------	-------------	--

determination that product was not discontinued or withdrawn for safety or efficacy reasons**

DIPHENHYDRAMINE HYDROCHLORIDE

BEL MAR	10MG/ML	A080822 001	
---------	---------	-------------	--

EUROHLTH INTL SARL	50MG/ML	A083183 001	
--------------------	---------	-------------	--

LYPHOMED	10MG/ML	A087066 001	
----------	---------	-------------	--

WATSON LABS	10MG/ML	A083533 001	
-------------	---------	-------------	--

WATSON LABS INC	10MG/ML	A080873 001	
-----------------	---------	-------------	--

	50MG/ML	A080873 002	
--	---------	-------------	--

WYETH AYERST	50MG/ML	A080577 001	
--------------	---------	-------------	--

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

ABRAXIS PHARM	50MG/ML	A080586 002	
---------------	---------	-------------	--

INTL MEDICATION	50MG/ML	A084094 001	
-----------------	---------	-------------	--

WATSON LABS INC	50MG/ML	A080873 003	
-----------------	---------	-------------	--

SYRUP; ORAL

ANTITUSSIVE

PERRIGO	12.5MG/5ML	A071292 001	Apr 10, 1987
---------	------------	-------------	--------------

BELDIN

HALSEY	12.5MG/5ML	A089179 001	Jun 05, 1986
--------	------------	-------------	--------------

BENYLIN

PARKE DAVIS	12.5MG/5ML	N006514 004	
-------------	------------	-------------	--

DIPHEN

MORTON GROVE	12.5MG/5ML	A070118 001	Oct 01, 1985
--------------	------------	-------------	--------------

DIPHENHYDRAMINE HYDROCHLORIDE

ALPHARMA US PHARMS	12.5MG/5ML	A070497 001	Apr 25, 1989
--------------------	------------	-------------	--------------

CUMBERLAND SWAN	12.5MG/5ML	A073611 001	Aug 20, 1992
-----------------	------------	-------------	--------------

HI TECH PHARMA	12.5MG/5ML	A072416 001	Sep 28, 1990
----------------	------------	-------------	--------------

HYDRAMINE

ALPHARMA US PHARMS	12.5MG/5ML	A070205 001	Jan 28, 1986
--------------------	------------	-------------	--------------

SILPHEN

SILARX	12.5MG/5ML	A072646 001	Feb 27, 1992
--------	------------	-------------	--------------

VICKS FORMULA 44

WARNER CHILCOTT	12.5MG/5ML	A070524 001	Jan 14, 1987
-----------------	------------	-------------	--------------

DISCONTINUED DRUG PRODUCT LISTDIPHENHYDRAMINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

BENYLIN

PARKE DAVIS

12.5MG/5ML; 30MG/5ML

N019014 001 Jun 11, 1985

DIPHENIDOL HYDROCHLORIDE

TABLET; ORAL

VONTROL

GLAXOSMITHKLINE

EQ 25MG BASE

N016033 001

DIPHENYLPYRALINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

HISPRIL

GLAXOSMITHKLINE

5MG

N011945 001

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AKPRO

AKORN

0.1%

A074382 001 Sep 29, 1995

DIPIVEFRIN HYDROCHLORIDE

BAUSCH AND LOMB

0.1%

A074188 001 May 19, 1995

FALCON PHARMS

0.1%

A073636 001 Jun 30, 1994

PROPINE

ALLERGAN

0.1%

N018239 001

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

HOSPIRA

5MG/ML

A074601 001 Dec 19, 1997

MYLAN LABS LTD

5MG/ML

A075769 001 Nov 27, 2002

TEVA PHARMS USA

5MG/ML

A074952 001 Nov 26, 1997

IV PERSANTINE

BOEHRINGER INGELHEIM

5MG/ML **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N019817 001 Dec 13, 1990

TABLET; ORAL

DIPYRIDAMOLE

GLENMARK GENERICS

25MG

A088999 001 Feb 05, 1991

50MG

A089000 001 Feb 05, 1991

75MG

A089001 001 Feb 05, 1991

IDT AUSTRALIA LTD

25MG

A086944 002 Apr 16, 1991

50MG

A087562 001 Feb 25, 1992

75MG

A087561 001 Feb 25, 1992

LANNETT

25MG

A040898 001 Apr 23, 2008

50MG

A040898 002 Apr 23, 2008

75MG

A040898 003 Apr 23, 2008

OXFORD PHARMS

25MG

A040542 001 Apr 21, 2006

50MG

A040542 002 Apr 21, 2006

75MG

A040542 003 Apr 21, 2006

PUREPAC PHARM

25MG

A089425 001 Jul 12, 1990

50MG

A089426 001 Jul 12, 1990

75MG

A089427 001 Jul 12, 1990

WATSON LABS

50MG

A087160 001 Jun 07, 1996

DIRITHROMYCIN

TABLET, DELAYED RELEASE; ORAL

DYNABAC

LILLY RES LABS

250MG

N050678 001 Jun 19, 1995

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE

AUROLIFE PHARMA LLC

EQ 100MG BASE

A070470 001 Dec 10, 1985

EQ 150MG BASE

A070471 001 Dec 10, 1985

INTERPHARM

EQ 100MG BASE

A071190 001 Jan 15, 1987

EQ 150MG BASE

A071191 001 Jan 15, 1987

IVAX SUB TEVA PHARMS

EQ 100MG BASE

A070186 001 Nov 18, 1985

EQ 150MG BASE

A070187 001 Nov 18, 1985

MYLAN

EQ 100MG BASE

A070138 001 Jun 14, 1985

EQ 150MG BASE

A070139 001 Jun 14, 1985

SUN PHARM INDS

EQ 100MG BASE

A070351 001 Dec 17, 1985

EQ 150MG BASE

A070352 001 Dec 17, 1985

SUPERPHARM

EQ 100MG BASE

A070940 001 Feb 09, 1987

EQ 150MG BASE

A070941 001 Feb 09, 1987

WATSON LABS

EQ 100MG BASE

A070240 001 Feb 02, 1986

DISCONTINUED DRUG PRODUCT LIST

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE

EQ 150MG BASE

A070241 001 Feb 02, 1986

CAPSULE, EXTENDED RELEASE; ORAL

DISOPYRAMIDE PHOSPHATE

NESHER PHARMS

EQ 150MG BASE

A071200 001 Dec 15, 1987

DISULFIRAM

TABLET; ORAL

ANTABUSE

TEVA WOMENS

250MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N007883 003

500MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N007883 002

DISULFIRAM

PAR PHARM

250MG

A088792 001 Aug 14, 1984

500MG

A088793 001 Aug 14, 1984

WATSON LABS

250MG

A086889 001

250MG

A087973 001 Aug 05, 1983

500MG

A086890 001

500MG

A087974 001 Aug 05, 1983

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE; ORAL

DEPAKOTE CP

ABBOTT

EQ 250MG BASE

N019794 001 Jul 11, 1990

EQ 500MG BASE

N019794 002 Jul 11, 1990

DIVALPROEX SODIUM

MYLAN

EQ 125MG VALPROIC ACID

A077254 001 Jul 29, 2008

EQ 250MG VALPROIC ACID

A077254 002 Jul 29, 2008

EQ 500MG VALPROIC ACID

A077254 003 Jul 29, 2008

TABLET, EXTENDED RELEASE; ORAL

DIVALPROEX SODIUM

G AND W LABS INC

EQ 500MG VALPROIC ACID

A078700 001 Aug 03, 2009

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HYDROCHLORIDE

BAXTER HLTHCARE

EQ 12.5MG BASE/ML

A074381 001 Sep 26, 1996

HOSPIRA

EQ 1.25GM BASE/100ML

A074634 001 Sep 27, 1996

LUITPOLD

EQ 12.5MG BASE/ML

A074545 001 Jun 25, 1998

TELLIGENT PHARMA INC

EQ 12.5MG BASE/ML

A074098 001 Feb 21, 1995

TEVA PARENTERAL

EQ 12.5MG BASE/ML

A074206 001 Oct 19, 1993

WATSON LABS

EQ 12.5MG BASE/ML

A074114 001 Nov 30, 1993

WATSON LABS INC

EQ 12.5MG BASE/ML

A074279 001 Feb 18, 1998

EQ 12.5MG BASE/ML

A074995 001 Mar 31, 1998

DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5%

HOSPIRA

EQ 50MG BASE/100ML

N020269 001 Oct 19, 1993

EQ 100MG BASE/100ML

N020269 002 Oct 19, 1993

EQ 200MG BASE/100ML

N020269 003 Oct 19, 1993

DOBUTREX

LILLY

EQ 12.5MG BASE/ML

N017820 002

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

APOTEX INC

20MG/0.5ML (40MG/ML)

N022312 001 Jan 11, 2012

80MG/2ML (40MG/ML)

N022312 002 Jan 11, 2012

TAXOTERE

SANOFI AVENTIS US

40MG/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020449 001 May 14, 1996

DOLASETRON MESYLATE

INJECTABLE; INJECTION

ANZEMET

US PHARM HOLDINGS

500MG/25ML (20MG/ML)

N020624 003 Dec 11, 2001

DISCONTINUED DRUG PRODUCT LIST

DONEPEZIL HYDROCHLORIDE

SOLUTION;ORAL

ARICEPT

EISAI INC 5MG/5ML N021719 001 Oct 18, 2004

TABLET;ORAL

DONEPEZIL HYDROCHLORIDE

ACCORD HLTHCARE 5MG A201335 001 Aug 29, 2011

10MG A201335 002 Aug 29, 2011

HIKMA PHARMS 5MG A090247 001 May 31, 2011

10MG A090247 002 May 31, 2011

TABLET, ORALLY DISINTEGRATING;ORAL

DONEPEZIL HYDROCHLORIDE

SUN PHARM INDS 5MG A077975 002 Dec 11, 2009

10MG A077975 001 Dec 11, 2009

DOPAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOPAMINE HYDROCHLORIDE

ABBOTT 40MG/ML A070656 001 Jan 24, 1989

80MG/ML A070657 001 Jan 24, 1989

ABRAXIS PHARM 40MG/ML A070012 001 Jun 12, 1985

40MG/ML A070058 001 Mar 20, 1985

80MG/ML A070013 001 Jun 12, 1985

80MG/ML A070059 001 Mar 20, 1985

160MG/ML A070364 001 Dec 04, 1985

BAXTER HLTHCARE 40MG/ML N018398 001

80MG/ML N018398 002 Mar 22, 1982

HOSPIRA 40MG/ML A074403 001 May 23, 1996

IGI LABS INC 40MG/ML A070087 001 Oct 23, 1985

40MG/ML N018656 001 Jun 28, 1983

80MG/ML A070089 001 Oct 23, 1985

80MG/ML A070090 001 Oct 23, 1985

80MG/ML A070091 001 Oct 23, 1985

160MG/ML A070092 001 Oct 23, 1985

160MG/ML A070093 001 Oct 23, 1985

160MG/ML A070094 001 Oct 23, 1985

INTL MEDICATION 40MG/ML N018014 001

LYPHOMED 40MG/ML N018549 001 Mar 11, 1983

SMITH AND NEPHEW 40MG/ML A070011 001 Aug 29, 1985

40MG/ML A070046 001 Aug 29, 1985

80MG/ML A070047 001 Aug 29, 1985

TEVA PARENTERAL 40MG/ML A072999 001 Oct 23, 1991

80MG/ML A073000 001 Oct 23, 1991

WARNER CHILCOTT 40MG/ML A070558 001 Sep 20, 1985

40MG/ML N018138 001

80MG/ML A070559 001 Sep 20, 1985

DOPAMINE HYDROCHLORIDE IN DEXTROSE 5%

HOSPIRA 1.6MG/ML N020542 001 Aug 30, 1995

INTROPIN

HOSPIRA 40MG/ML N017395 001

80MG/ML N017395 002

160MG/ML N017395 003

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

APOTEX INC EQ 2% BASE A078395 001 Oct 28, 2008

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

APOTEX INC EQ 2% BASE;EQ 0.5% BASE A078201 001 Oct 28, 2008

LANNETT HOLDINGS INC EQ 2% BASE;EQ 0.5% BASE A201998 001 Dec 17, 2014

DOXACURIUM CHLORIDE

INJECTABLE;INJECTION

NUROMAX

ABBVIE EQ 1MG BASE/ML N019946 001 Mar 07, 1991

DISCONTINUED DRUG PRODUCT LISTDOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

DOXAPRAM HYDROCHLORIDE

WATSON LABS

20MG/ML

A073529 001 Jan 30, 1992

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

ACTAVIS ELIZABETH

EQ 1MG BASE

A075574 001 Oct 18, 2000

EQ 2MG BASE

A075574 002 Oct 18, 2000

EQ 4MG BASE

A075574 003 Oct 18, 2000

EQ 8MG BASE

A075574 004 Oct 18, 2000

GENPHARM

EQ 1MG BASE

A075466 001 Oct 18, 2000

EQ 2MG BASE

A075466 002 Oct 18, 2000

EQ 4MG BASE

A075466 003 Oct 18, 2000

EQ 8MG BASE

A075466 004 Oct 18, 2000

IDT AUSTRALIA LTD

EQ 1MG BASE

A075432 001 Oct 18, 2000

EQ 2MG BASE

A075432 002 Oct 18, 2000

EQ 4MG BASE

A075432 003 Oct 18, 2000

EQ 8MG BASE

A075432 004 Oct 18, 2000

IVAX SUB TEVA PHARMS

EQ 1MG BASE

A075453 001 Oct 18, 2000

EQ 2MG BASE

A075453 002 Oct 18, 2000

EQ 4MG BASE

A075453 003 Oct 18, 2000

EQ 8MG BASE

A075453 004 Oct 18, 2000

NESHER PHARMS

EQ 1MG BASE

A075609 001 Oct 18, 2000

EQ 2MG BASE

A075609 002 Oct 18, 2000

EQ 4MG BASE

A075609 003 Oct 18, 2000

EQ 8MG BASE

A075609 004 Oct 18, 2000

SANDOZ

EQ 1MG BASE

A075646 001 Oct 18, 2000

EQ 2MG BASE

A075646 002 Oct 18, 2000

EQ 4MG BASE

A075646 003 Oct 18, 2000

EQ 8MG BASE

A075646 004 Oct 18, 2000

TEVA

EQ 1MG BASE

A075353 001 Jan 12, 2001

EQ 2MG BASE

A075353 002 Jan 12, 2001

EQ 4MG BASE

A075353 003 Jan 12, 2001

EQ 8MG BASE

A075353 004 Jan 12, 2001

WATSON LABS INC

EQ 1MG BASE

A075426 001 Oct 18, 2000

EQ 2MG BASE

A075426 002 Oct 18, 2000

EQ 4MG BASE

A075426 003 Oct 18, 2000

EQ 8MG BASE

A075426 004 Oct 18, 2000

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

DAVA PHARMS INC

EQ 10MG BASE

A071685 001 Jan 05, 1988

EQ 25MG BASE

A071686 001 Jan 05, 1988

EQ 50MG BASE

A071673 001 Jan 05, 1988

EQ 75MG BASE

A071674 001 Jan 05, 1988

EQ 100MG BASE

A071675 001 Jan 05, 1988

EQ 150MG BASE

A071676 001 Jan 05, 1988

NEW RIVER

EQ 10MG BASE

N016987 001

EQ 25MG BASE

N016987 002

EQ 50MG BASE

N016987 003

EQ 75MG BASE

N016987 006

EQ 100MG BASE

N016987 004

EQ 150MG BASE

N016987 007 Apr 13, 1987

PAR PHARM

EQ 10MG BASE

A071697 001 Nov 09, 1987

EQ 25MG BASE

A071437 001 Nov 09, 1987

EQ 50MG BASE

A071595 001 Nov 09, 1987

EQ 75MG BASE

A071608 001 Nov 09, 1987

EQ 100MG BASE

A071422 001 Nov 09, 1987

PUREPAC PHARM

EQ 10MG BASE

A073054 001 Dec 28, 1990

EQ 25MG BASE

A072109 001 Dec 28, 1990

EQ 50MG BASE

A073055 001 Dec 28, 1990

EQ 75MG BASE

A072386 001 Sep 08, 1988

EQ 100MG BASE

A072110 001 Sep 08, 1988

EQ 150MG BASE

A072387 001 Sep 08, 1988

QUANTUM PHARMICS

EQ 10MG BASE

A070972 001 Sep 29, 1987

EQ 25MG BASE

A070973 001 Sep 29, 1987

EQ 50MG BASE

A070931 001 Sep 29, 1987

EQ 75MG BASE

A070932 001 Sep 29, 1987

EQ 100MG BASE

A072375 001 Mar 15, 1989

EQ 150MG BASE

A072376 001 Mar 15, 1989

DISCONTINUED DRUG PRODUCT LISTDOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

SANDOZ

EQ 10MG BASE

A071487 001 Mar 02, 1987

EQ 25MG BASE

A070827 001 May 15, 1986

EQ 50MG BASE

A070828 001 May 15, 1986

EQ 75MG BASE

A070825 001 May 15, 1986

EQ 100MG BASE

A071562 001 Mar 02, 1987

SUN PHARM INDS

EQ 25MG BASE

A071502 001 Feb 18, 1988

EQ 50MG BASE

A071653 001 Feb 18, 1988

EQ 75MG BASE

A071654 001 Feb 18, 1988

EQ 100MG BASE

A071521 001 Feb 18, 1988

WATSON LABS

EQ 10MG BASE

A070952 001 Mar 04, 1987

EQ 10MG BASE

A071485 001 Apr 30, 1987

EQ 10MG BASE

A072985 001 Mar 29, 1991

EQ 25MG BASE

A070953 001 May 15, 1986

EQ 25MG BASE

A071486 001 Apr 30, 1987

EQ 25MG BASE

A072986 001 Mar 29, 1991

EQ 50MG BASE

A070954 001 May 15, 1986

EQ 50MG BASE

A071238 001 Apr 30, 1987

EQ 50MG BASE

A072987 001 Mar 29, 1991

EQ 75MG BASE

A071326 001 Apr 30, 1987

EQ 75MG BASE

A071763 001 Feb 09, 1988

EQ 100MG BASE

A070955 001 May 15, 1986

EQ 100MG BASE

A071239 001 Apr 30, 1987

EQ 150MG BASE

A071764 001 Feb 09, 1988

SINEQUAN

PFIZER

EQ 10MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N016798 003

EQ 25MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N016798 001

EQ 50MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N016798 002

EQ 75MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N016798 006

EQ 100MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N016798 005

EQ 150MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N016798 007

CONCENTRATE; ORAL

DOXEPIN HYDROCHLORIDE

PHARM ASSOC

EQ 10MG BASE/ML

A075924 001 Jan 15, 2004

SINEQUAN

PFIZER

EQ 10MG BASE/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N017516 001

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

ADRIAMYCIN PFS

PHARMACIA AND UPJOHN

2MG/ML

A063165 001 Jan 30, 1991

200MG/100ML

A063165 002 Jan 30, 1991

DOXORUBICIN HYDROCHLORIDE

PHARMACIA AND UPJOHN

10MG/VIAL

N050467 001

20MG/VIAL

N050467 003 May 20, 1985

50MG/VIAL

N050467 002

150MG/VIAL

N050467 004 Jul 22, 1987

SANDOZ INC

2MG/ML

A200146 001 Jul 18, 2012

RUBEX

BRISTOL MYERS SQUIBB

10MG/VIAL

A062926 001 Apr 13, 1989

50MG/VIAL

A062926 002 Apr 13, 1989

100MG/VIAL

A062926 003 Apr 13, 1989

DISCONTINUED DRUG PRODUCT LIST

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

PAR PHARM	EQ 75MG BASE	A065055 004	Apr 18, 2005
SANDOZ INC	EQ 50MG BASE	A065032 001	Jun 30, 2000
	EQ 100MG BASE	A065032 002	Jun 30, 2000
WATSON LABS	EQ 50MG BASE	A065041 001	Apr 28, 2000
	EQ 100MG BASE	A065041 002	Apr 28, 2000

FOR SUSPENSION; ORAL

DOXYCHEL

RACHELLE	EQ 25MG BASE/5ML	A061720 001	
----------	------------------	-------------	--

TABLET; ORAL

DOXYCYCLINE

SANDOZ INC	EQ 50MG BASE	A065353 001	Nov 27, 2006
	EQ 75MG BASE	A065353 002	Nov 27, 2006
	EQ 100MG BASE	A065353 003	Nov 27, 2006
SUN PHARM INDS	EQ 50MG BASE	A065471 001	Apr 17, 2009
	EQ 75MG BASE	A065471 002	Apr 17, 2009
	EQ 100MG BASE	A065471 003	Apr 17, 2009

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXY-LEMMON

TEVA	EQ 50MG BASE	A062497 001	Aug 23, 1984
	EQ 100MG BASE	A062497 002	Jun 15, 1984

DOXYCYCLINE HYCLATE

HALSEY	EQ 50MG BASE	A062119 002	May 24, 1985
	EQ 100MG BASE	A062119 001	May 24, 1985
HEATHER	EQ 50MG BASE	A062463 001	Dec 07, 1983
	EQ 100MG BASE	A062463 002	Dec 07, 1983
INTERPHARM	EQ 50MG BASE	A062763 001	Sep 02, 1988
	EQ 100MG BASE	A062763 002	Sep 02, 1988
MUTUAL PHARM	EQ 50MG BASE	A062418 001	Jan 28, 1983
	EQ 100MG BASE	A062418 002	Jan 28, 1983
PAR PHARM	EQ 50MG BASE	A062434 001	Oct 19, 1984
	EQ 100MG BASE	A062442 001	Dec 22, 1983
PVT FORM	EQ 50MG BASE	A062631 001	Jul 24, 1986
	EQ 100MG BASE	A062631 002	Jul 24, 1986
RANBAXY	EQ 50MG BASE	A062479 001	Dec 23, 1983
	EQ 100MG BASE	A062479 002	Dec 23, 1983
SUPERPHARM	EQ 50MG BASE	A062469 001	Oct 31, 1984
	EQ 100MG BASE	A062469 002	Oct 31, 1984
WARNER CHILCOTT	EQ 50MG BASE	A062594 001	Dec 05, 1985
	EQ 100MG BASE	A062594 002	Dec 05, 1985
WATSON LABS	EQ 50MG BASE	A061717 001	
	EQ 50MG BASE	A062142 001	
	EQ 100MG BASE	A061717 002	
	EQ 100MG BASE	A062142 002	

VIBRAMYCIN

PFIZER	EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050007 001	
--------	--	-------------	--

CAPSULE, COATED PELLETS; ORAL

DOXYCYCLINE HYCLATE

PLIVA	EQ 100MG BASE	A063187 001	Jun 30, 1992
-------	---------------	-------------	--------------

CAPSULE, DELAYED RELEASE; ORAL

DORYX

MAYNE PHARMA INTL	EQ 75MG BASE	N050582 002	Aug 13, 2001
	EQ 100MG BASE	N050582 001	Jul 22, 1985
WARNER CHILCOTT	EQ 100MG BASE	A062653 001	Oct 30, 1985

INJECTABLE; INJECTION

DOXYCHEL HYCLATE

RACHELLE	EQ 100MG BASE/VIAL	A061953 001	
----------	--------------------	-------------	--

DOXYCYCLINE

WEST-WARD PHARMS INT	EQ 100MG BASE/VIAL	A062450 001	Oct 27, 1983
	EQ 200MG BASE/VIAL	A062450 002	Oct 27, 1983
	EQ 200MG BASE/VIAL	A062569 002	Mar 09, 1988

DOXYCYCLINE HYCLATE

WEST-WARD PHARMS INT	EQ 100MG BASE/VIAL	A062992 001	Feb 16, 1989
	EQ 200MG BASE/VIAL	A062992 002	Feb 16, 1989

VIBRAMYCIN

PFIZER	EQ 100MG BASE/VIAL **Federal Register	N050442 002	
--------	---------------------------------------	-------------	--

DISCONTINUED DRUG PRODUCT LIST

DOXYCYCLINE HYCLATE

INJECTABLE; INJECTION

VIBRAMYCIN

determination that product was not discontinued or withdrawn for safety or efficacy reasons**

EQ 200MG BASE/VIAL **Federal Register N050442 001

determination that product was not discontinued or withdrawn for safety or efficacy reasons**

TABLET; ORAL

DOXY-LEMMON

TEVA

EQ 100MG BASE

A062581 001 Mar 15, 1985

DOXYCYCLINE HYCLATE

BLU CARIBE INC

EQ 50MG BASE

A062269 003

COREPHARMA

EQ 20MG BASE

A065182 001 May 13, 2005

HEATHER

EQ 100MG BASE

A062462 001 May 11, 1983

INTERPHARM

EQ 100MG BASE

A062764 001 Sep 02, 1988

MUTUAL PHARM

EQ 100MG BASE

A062391 001 Sep 30, 1982

SUPERPHARM

EQ 100MG BASE

A062494 001 Feb 20, 1985

VINTAGE PHARMS

EQ 100MG BASE

A062538 001 Apr 07, 1986

WARNER CHILCOTT

EQ 100MG BASE

A062593 001 Aug 28, 1985

WATSON LABS

EQ 50MG BASE

A062392 001 Mar 31, 1983

EQ 100MG BASE

A062392 002 Mar 31, 1983

PERIOSTAT

COLLAGENEX

EQ 20MG BASE **Federal Register
determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N050744 001 Sep 30, 1998

GALDERMA LABS LP

EQ 20MG BASE **Federal Register
determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N050783 001 Feb 02, 2001

VIBRA-TABS

PFIZER

EQ 100MG BASE **Federal Register
determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N050533 001

TABLET, DELAYED RELEASE; ORAL

DOXYCYCLINE HYCLATE

IMPAX LABS INC

EQ 75MG BASE

A090505 001 Dec 28, 2010

EQ 100MG BASE

A090505 002 Dec 28, 2010

DOXYLAMINE SUCCINATE

CAPSULE; ORAL

UNISOM

PFIZER

25MG

N019440 001 Feb 05, 1986

TABLET; ORAL

DECAPRYN

SANOFI AVENTIS US

12.5MG

N006412 015

25MG

N006412 014

DOXY-SLEEP-AID

PAR PHARM

25MG

A070156 001 Jul 02, 1987

DOXYLAMINE SUCCINATE

COPLEY PHARM

25MG

A088900 002 Feb 12, 1988

QUANTUM PHARMICS

25MG

A088603 001 Aug 07, 1984

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BENDECTIN

SANOFI AVENTIS US

10MG;10MG **Federal Register
determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N010598 002

DROMOSTANOLONE PROPIONATE

INJECTABLE; INJECTION

DROLBAN

LILLY

50MG/ML

N012936 001

DRONABINOL

CAPSULE; ORAL

DRONABINOL

INSYS THERAP

2.5MG

A078501 001 Aug 19, 2011

5MG

A078501 002 Aug 19, 2011

10MG

A078501 003 Aug 19, 2011

DISCONTINUED DRUG PRODUCT LIST

DROPERIDOL

INJECTABLE; INJECTION

DROPERIDOL

ABRAXIS PHARM	2.5MG/ML	A070992 001	Nov 17, 1986
	2.5MG/ML	A070993 001	Nov 17, 1986
ASTRAZENECA	2.5MG/ML	A072018 001	Oct 20, 1988
HOSPIRA	2.5MG/ML	A071645 001	Apr 07, 1988
	2.5MG/ML	A072272 001	Aug 31, 1995
IGI LABS INC	2.5MG/ML	A072019 001	Oct 19, 1988
	2.5MG/ML	A072020 001	Oct 19, 1988
	2.5MG/ML	A072021 001	Oct 19, 1988
LUITPOLD	2.5MG/ML	A072335 001	Oct 24, 1988
SMITH AND NEPHEW	2.5MG/ML	A071750 001	Sep 06, 1988
SOLOPAK	2.5MG/ML	A071754 001	Sep 06, 1988
	2.5MG/ML	A071755 001	Sep 06, 1988
WATSON LABS	2.5MG/ML	A073520 001	Nov 27, 1991
	2.5MG/ML	A073521 001	Nov 27, 1991
	2.5MG/ML	A073523 001	Nov 27, 1991

DROPERIDOL; FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE AND DROPERIDOL

ASTRAZENECA	2.5MG/ML;EQ 0.05MG BASE/ML	A072026 001	Apr 13, 1989
	2.5MG/ML;EQ 0.05MG BASE/ML	A072027 001	Apr 13, 1989
	2.5MG/ML;EQ 0.05MG BASE/ML	A072028 001	Apr 13, 1989
HOSPIRA	2.5MG/ML;EQ 0.05MG BASE/ML	A071982 001	May 04, 1988
INNOVAR			
AKORN MFG	2.5MG/ML;EQ 0.05MG BASE/ML	N016049 001	

DYCLONINE HYDROCHLORIDE

SOLUTION; TOPICAL

DYCLONE

ASTRAZENECA	0.5% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009925 002	
	1% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009925 001	

DYDROGESTERONE

TABLET; ORAL

GYNOREST

SOLVAY	5MG	N017388 001	
	10MG	N017388 002	

DYPHYLLINE

ELIXIR; ORAL

NEOTHYLLINE

TEVA	160MG/15ML	N007794 003	
------	------------	-------------	--

INJECTABLE; INJECTION

NEOTHYLLINE

TEVA	250MG/ML	N009088 001	
------	----------	-------------	--

TABLET; ORAL

DILOR

SAVAGE LABS	200MG	A084514 001	
-------------	-------	-------------	--

DILOR-400

SAVAGE LABS	400MG	A084751 001	
-------------	-------	-------------	--

LUFYLLIN

MEDA PHARMS	200MG	A084566 001	
-------------	-------	-------------	--

	400MG	A084566 002	
--	-------	-------------	--

NEOTHYLLINE

TEVA	200MG	N007794 001	
------	-------	-------------	--

	400MG	N007794 002	
--	-------	-------------	--

ECHOTHIOPHATE IODIDE

FOR SOLUTION; OPHTHALMIC

PHOSPHOLINE IODIDE

WYETH PHARMS INC	0.03%	N011963 002	
	0.06%	N011963 004	
	0.25%	N011963 003	

DISCONTINUED DRUG PRODUCT LISTECONAZOLE NITRATECREAM; TOPICAL
SPECTAZOLE

ALVOGEN MALTA 1% N018751 001 Dec 23, 1982

EDETATE CALCIUM DISODIUM

TABLET; ORAL

CALCIUM DISODIUM VERSENATE
MEDICIS

500MG N008922 002

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

EDROPHONIUM CHLORIDE

HOSPIRA 10MG/ML A040131 001 Feb 24, 1998

WATSON LABS 10MG/ML A040044 001 Mar 20, 1996

EDROPHONIUM CHLORIDE PRESERVATIVE FREE

WATSON LABS 10MG/ML A040043 001 Mar 20, 1996

REVERSOL

ORGANON USA INC 10MG/ML A089624 001 May 13, 1988

TENSILON

TELIGENT PHARMA INC 10MG/ML **Federal Register N007959 001

determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

TENSILON PRESERVATIVE FREE

TELIGENT PHARMA INC 10MG/ML **Federal Register N007959 002

determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**EFAVIRENZ

CAPSULE; ORAL

SUSTIVA

BRISTOL MYERS SQUIBB 100MG **Federal Register determination N020972 002 Sep 17, 1998

that product was not discontinued or
withdrawn for safety or efficacy
reasons**

TABLET; ORAL

SUSTIVA

BRISTOL MYERS SQUIBB 300MG **Federal Register determination N021360 001 Feb 01, 2002

that product was not discontinued or
withdrawn for safety or efficacy
reasons**EFLORNITHINE HYDROCHLORIDE

INJECTABLE; INJECTION

ORNIDYL

SANOFI AVENTIS US 200MG/ML N019879 002 Nov 28, 1990

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

APOTHECON 2.5MG A075583 001 Aug 22, 2000

5MG A075583 002 Aug 22, 2000

10MG A075583 003 Aug 22, 2000

20MG A075583 004 Aug 22, 2000

IVAX SUB TEVA PHARMS 2.5MG A075482 001 Aug 22, 2000

5MG A075482 002 Aug 22, 2000

10MG A075482 003 Aug 22, 2000

20MG A075482 004 Aug 22, 2000

KRKA DD NOVO MESTO 2.5MG A075370 001 Aug 22, 2000

5MG A075370 002 Aug 22, 2000

10MG A075369 001 Aug 22, 2000

20MG A075369 002 Aug 22, 2000

MYLAN 2.5MG A075472 001 Aug 22, 2000

5MG A075472 002 Aug 22, 2000

10MG A075472 003 Aug 22, 2000

20MG A075472 004 Aug 22, 2000

SANDOZ 2.5MG A075048 001 Aug 22, 2000

5MG A075048 002 Aug 22, 2000

10MG A075048 003 Aug 22, 2000

20MG A075048 004 Aug 22, 2000

SANDOZ INC 2.5MG A075621 001 Aug 22, 2000

5MG A075621 002 Aug 22, 2000

10MG A075621 003 Aug 22, 2000

20MG A075621 004 Aug 22, 2000

DISCONTINUED DRUG PRODUCT LIST

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

SUN PHARM INDS LTD	2.5MG	A075556 001	Aug 22, 2000
	5MG	A075556 002	Aug 22, 2000
	10MG	A075556 003	Aug 22, 2000
	20MG	A075556 004	Aug 22, 2000
WATSON LABS	2.5MG	A075501 001	Aug 22, 2000
	5MG	A075501 002	Aug 22, 2000
	10MG	A075501 003	Aug 22, 2000
	20MG	A075501 004	Aug 22, 2000

ENALAPRIL MALEATE; FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

LEXXEL

ASTRAZENECA	5MG; 2.5MG	N020668 002	Oct 28, 1998
	5MG; 5MG	N020668 001	Dec 27, 1996

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

IVAX SUB TEVA PHARMS	5MG; 12.5MG	A075736 001	Mar 25, 2003
	10MG; 25MG	A075736 002	Mar 25, 2003
UPSHER-SMITH LABS	5MG; 12.5MG	A076116 001	Sep 19, 2001
	10MG; 25MG	A076116 002	Sep 19, 2001

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

HOSPIRA	1.25MG/ML	A075456 001	Aug 22, 2000
	1.25MG/ML	A075571 001	Aug 22, 2000

VASOTEC

BIOVAIL LABS INTL	1.25MG/ML	N019309 001	Feb 09, 1988
-------------------	-----------	-------------	--------------

ENFLURANE

LIQUID; INHALATION

ENFLURANE

ABBOTT	99.9%	A070803 001	Sep 08, 1987
PIRAMAL CRITICAL	99.9%	A074396 001	Jul 29, 1994

ETHRANE

BAXTER HLTHCARE	99.9%	N017087 001	
-----------------	-------	-------------	--

ENOXACIN

TABLET; ORAL

PENETREX

SANOFI AVENTIS US	200MG	N019616 004	Dec 31, 1991
	400MG	N019616 005	Dec 31, 1991

ENOXAPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

LOVENOX (PRESERVATIVE FREE)

SANOFI AVENTIS US	90MG/0.6ML (150MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020164 006	Jun 02, 2000
-------------------	--	-------------	--------------

EPINEPHRINE

AEROSOL, METERED; INHALATION

BRONKAID MIST

STERLING	0.25MG/INH	N016803 001	
----------	------------	-------------	--

EPINEPHRINE

ARMSTRONG PHARMS	0.2MG/INH	A087907 001	May 23, 1984
------------------	-----------	-------------	--------------

PRIMATENE MIST

WYETH CONS	0.2MG/INH	N016126 001	
------------	-----------	-------------	--

INJECTABLE; INJECTION

SUS-PHRINE SULFITE FREE

FOREST LABS	1.5MG/AMP	N007942 003	Feb 05, 1999
	5MG/ML	N007942 001	

INJECTABLE; INTRAMUSCULAR

EPI E Z PEN JR

MYLAN SPEC LT	0.15MG/DELIVERY	N019430 004	Aug 03, 1995
---------------	-----------------	-------------	--------------

EPIPEN E Z PEN

MYLAN SPEC LT	0.3MG/DELIVERY	N019430 003	Aug 03, 1995
---------------	----------------	-------------	--------------

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

TWINJECT 0.15

AMEDRA PHARMS	EQ 0.15MG/DELIVERY	N020800 002	May 28, 2004
---------------	--------------------	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

EPINEPHRINE

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

TWINJECT 0.3

AMEDRA PHARMS

EQ 0.3MG/DELIVERY

N020800 001 May 30, 2003

EPINEPHRINE BITARTRATE

AEROSOL, METERED; INHALATION

BRONITIN MIST

WYETH CONS

0.3MG/INH

N016126 002

MEDIHALER-EPI

3M

0.3MG/INH

N010374 003

EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

ASTRAZENECA

0.005MG/ML; 1% **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N017751 006

0.005MG/ML; 1.5% **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N017751 007

DENTSPLY PHARM

0.005MG/ML; 1.5% **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N021384 001

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST FORTE

ASTRAZENECA

0.005MG/ML; 4%

N014763 008

EPINEPHRINE; ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

ASTRAZENECA

0.005MG/ML; 0.5% **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N017751 004

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ALPHACAINE HYDROCHLORIDE W/ EPINEPHRINE

CARLISLE

0.01MG/ML; 2%

A084720 001

0.02MG/ML; 2%

A084732 001

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

EUROHLTH INTL SARL

0.01MG/ML; 1%

A080406 001

0.01MG/ML; 2%

A080406 002

GRAHAM CHEM

0.01MG/ML; 2%

A080504 004 Oct 19, 1983

0.02MG/ML; 2%

A080504 005 Oct 19, 1983

HOSPIRA

0.005MG/ML; 1%

A089649 001 Jun 21, 1988

0.005MG/ML; 1.5%

A089650 001 Jun 21, 1988

LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE

ABBOTT

0.01MG/ML; 1%

A083154 001

BEL MAR

0.01MG/ML; 1%

A080820 001

0.01MG/ML; 2%

A080757 001

DELL LABS

0.01MG/ML; 1%

A083389 001

0.01MG/ML; 2%

A083390 001

INTL MEDICATION

0.01MG/ML; 1%

A086402 001

WATSON LABS

0.01MG/ML; 1%

A080377 003

0.01MG/ML; 1%

A085463 001

0.01MG/ML; 2%

A080377 004

LIDOCATON

PHARMATON

0.01MG/ML; 2%

A084729 001 Aug 17, 1983

0.02MG/ML; 2%

A084728 001 Aug 17, 1983

XYLOCAINE DENTAL WITH EPINEPHRINE

DENTSPLY PHARM

0.01MG/ML; 2%

N021381 001

0.02MG/ML; 2%

N021381 002

XYLOCAINE W/ EPINEPHRINE

ASTRAZENECA

0.005MG/ML; 1%

N010418 006

0.005MG/ML; 1.5%

N010418 010

0.005MG/ML; 2%

N010418 008

FRESENIUS KABI USA

0.01MG/ML; 2%

N006488 003

DISCONTINUED DRUG PRODUCT LISTEPINEPHRINE; LIDOCAINE HYDROCHLORIDE

PATCH; IONTOPHORESIS, TOPICAL

LIDOSITE TOPICAL SYSTEM KIT

VYTERIS

1.05MG/PATCH; 100MG/PATCH

N021504 001 May 06, 2004

SOLUTION; IONTOPHORESIS

IONTOCAINE

IOMED

0.01MG/ML; 2%

N020530 001 Dec 21, 1995

SOLUTION; IONTOPHORESIS, TOPICAL

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

EMPI

0.01MG/ML; 2%

N021486 001 Oct 26, 2004

EPINEPHRINE; PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINE HYDROCHLORIDE W/ EPINEPHRINE

BEL MAR

0.02MG/ML; 1%

A080758 001

0.02MG/ML; 2%

A080759 001

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

EBEWE PHARMA

50MG/25ML (2MG/ML)

A065339 001 Dec 22, 2009

200MG/100ML (2MG/ML)

A065339 002 Dec 22, 2009

HOSPIRA

50MG/25ML (2MG/ML)

A065343 002 Apr 19, 2007

MUSTAFA NEVSAT

50MG/25ML (2MG/ML)

A090266 001 Apr 15, 2011

200MG/100ML (2MG/ML)

A090266 002 Apr 15, 2011

MYLAN INSTITUTIONAL

50MG/25ML (2MG/ML)

A065371 001 Nov 28, 2007

200MG/100ML (2MG/ML)

A065371 002 Nov 28, 2007

INJECTABLE; IV (INFUSION)

EPIRUBICIN HYDROCHLORIDE

HOSPIRA

50MG/VIAL

N050807 001 Sep 15, 2006

200MG/VIAL

N050807 002 Sep 15, 2006

EPLERENONE

TABLET; ORAL

INSPIRA

GD SEARLE LLC

100MG

N021437 003 Sep 27, 2002

EPROSARTAN MESYLATE

TABLET; ORAL

TEVETEN

ABBVIE

EQ 300MG BASE

N020738 004 Dec 22, 1997

EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

TEVETEN HCT

ABBVIE

600MG; 12.5MG

N021268 001 Nov 01, 2001

600MG; 25MG

N021268 002 Nov 01, 2001

EPTIFIBATIDE

INJECTABLE; INJECTION

EPTIFIBATIDE

TEVA PHARMS USA

75MG/100ML

A091555 001 Jun 05, 2015

ERGOCALCIFEROL

CAPSULE; ORAL

DELTALIN

LILLY

50,000 IU

A080884 001

VITAMIN D

CHASE CHEM

50,000 IU

A080747 001

EVERYLIFE

50,000 IU

A080956 001

IMPAX LABS

50,000 IU

A080951 001

LANNETT

50,000 IU

A080825 001

VITARINE

50,000 IU

A084053 001

WEST WARD

50,000 IU

A083102 001

ERGOLOID MESYLATES

CAPSULE; ORAL

HYDERGINE LC

NOVARTIS

1MG

N018706 001 Jan 18, 1983

SOLUTION; ORAL

HYDERGINE

NOVARTIS

1MG/ML

N018418 001

TABLET; ORAL

ERGOLOID MESYLATES

MUTUAL PHARM

1MG

A088891 001 Nov 01, 1985

WATSON LABS

1MG

A086433 001 May 27, 1982

DISCONTINUED DRUG PRODUCT LIST

ERGOLOID MESYLATES

TABLET; ORAL

ERGOLOID MESYLATES

1MG

A087244 001 Aug 16, 1982

GERIMAL

WATSON LABS

1MG

A088207 001 Mar 22, 1984

HYDERGINE

NOVARTIS

0.5MG

N017993 003

TABLET; SUBLINGUAL

ALKERGOT

SANDOZ

0.5MG

A085153 001

1MG

A087417 001

CIRCANOL

3M

0.5MG

A084868 001

1MG

A085809 001

DEAPRIL-ST

BRISTOL MYERS SQUIBB

1MG

A085020 002

ERGOLOID MESYLATES

KV PHARM

0.5MG

A085899 001

0.5MG

A086265 001

1MG

A085900 001

1MG

A086264 001

LEDERLE

0.5MG

A086984 001

1MG

A086985 001

SUN PHARM INDS

0.5MG

A087407 001

1MG

A087552 001

SUPERPHARM

0.5MG

A089233 001 Sep 23, 1986

1MG

A089234 001 Sep 23, 1986

VANGARD

0.5MG

A088013 001 Sep 20, 1982

1MG

A088014 001 Sep 20, 1982

WATSON LABS

0.5MG

A084930 001

0.5MG

A087233 001

1MG

A085177 001

1MG

A087183 001

GERIMAL

WATSON LABS

0.5MG

A086189 001

1MG

A086188 001

HYDERGINE

NOVARTIS

0.5MG

N009087 002

1MG

N009087 001

HYDROGENATED ERGOT ALKALOIDS

IVAX PHARMS

0.5MG

A087186 001

1MG

A087185 001

ERGOTAMINE TARTRATE

AEROSOL, METERED; INHALATION

MEDIHALER ERGOTAMINE

3M

0.36MG/INH

N012102 001

TABLET; SUBLINGUAL

ERGOSTAT

WATSON LABS INC

2MG

A088337 001 Jun 08, 1984

WIGRETTES

ORGANON USA INC

2MG

A086750 001 Jul 29, 1982

ERLOTINIB HYDROCHLORIDE

TABLET; ORAL

ERLOTINIB HYDROCHLORIDE

MYLAN PHARMS INC

EQ 25MG BASE

A091002 001 Jun 11, 2014

EQ 100MG BASE

A091002 002 Jun 11, 2014

EQ 150MG BASE

A091002 003 Jun 11, 2014

TEVA PHARMS USA

EQ 100MG BASE

A091059 002 Aug 28, 2015

EQ 150MG BASE

A091059 003 Aug 28, 2015

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

ERYC

PARKE DAVIS

250MG

A062546 001 Jul 25, 1985

250MG

A062618 001 Sep 25, 1985

WARNER CHILCOTT LLC

250MG

A062338 001

ERYC 125

PARKE DAVIS

125MG

A062648 001 Oct 24, 1985

ERYC SPRINKLES

HOSPIRA

125MG

N050593 001 Jul 22, 1985

DISCONTINUED DRUG PRODUCT LIST

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS;ORAL

ERYTHROMYCIN

BARR 250MG A063098 001 May 04, 1989

GEL;TOPICAL

E-GLADES

RENAISSANCE PHARMA 2% A065009 001 Mar 18, 2002

EMGEL

ALTANA 2% A063107 001 Aug 23, 1991

LOTION;TOPICAL

E-SOLVE 2

SYOSSET 2% A062467 001 Jul 03, 1985

OINTMENT;OPHTHALMIC

ERYTHROMYCIN

PHARMADERM 5MG/GM A062446 001 Sep 26, 1983

PHARMAFAIR 5MG/GM A062481 001 Apr 05, 1984

ILOTYCIN

DISTA 0.5% N050368 001

POWDER;FOR RX COMPOUNDING

ERYTHROMYCIN

PADDOCK LLC 100% N050610 001 Nov 07, 1986

SOLUTION;TOPICAL

A/T/S

TARO PHARMS NORTH 2% A062405 001 Nov 18, 1982

C-SOLVE-2

FOUGERA PHARMS 2% A062468 001 Jul 03, 1985

ERYDERM

ARBOR PHARMS INC 2% A062290 001

ERYMAX

MERZ PHARMS 2% A062508 002 Jul 11, 1985

ERYTHRA-DERM

PADDOCK LLC 2% A062687 001 Feb 05, 1988

ERYTHRO-STATIN

HI TECH PHARMA 2% A064101 001 Oct 22, 1996

ERYTHROMYCIN

ALPHARMA US PHARMS 1.5% A062328 001 Apr 19, 1982

2% A062326 001 Apr 19, 1982

2% A062327 001 Apr 19, 1982

2% A062342 001 Feb 25, 1982

2% A062957 001 Jul 21, 1988

2% A064039 001 Jan 27, 1994

LILLY 2% N050532 001

PHARMAFAIR 1.5% A062485 001 Jul 11, 1984

2% A062616 001 Jul 25, 1985

2% A064127 001 Feb 14, 1997

SANSAC

DOW PHARM 2% A062522 001 Jan 24, 1985

STATICIN

WESTWOOD SQUIBB 1.5% **Federal Register determination

that product was not discontinued or

withdrawn for safety or efficacy

reasons** N050526 001

T-STAT

WESTWOOD SQUIBB 2% **Federal Register determination

that product was not discontinued or

withdrawn for safety or efficacy

reasons** A062436 001 Mar 09, 1983

SWAB;TOPICAL

C-SOLVE-2

IVAX SUB TEVA PHARMS 2% A062751 001 Jul 30, 1993

ERYCETTE

JOHNSON AND JOHNSON 2% N050594 001 Feb 15, 1985

ERYTHROMYCIN

FOUGERA PHARMS 2% A065320 001 Jul 25, 2006

RENAISSANCE PHARMA 2% A064128 001 Jul 03, 1996

T-STAT

WESTWOOD SQUIBB 2% A062748 001 Jul 23, 1987

TABLET, DELAYED RELEASE;ORAL

E-BASE

BARR 333MG A063028 001 May 15, 1990

333MG A063086 001 May 15, 1990

500MG A062999 001 Nov 25, 1988

DISCONTINUED DRUG PRODUCT LIST

ERYTHROMYCIN

TABLET, DELAYED RELEASE;ORAL

E-MYCIN

ARBOR PHARMS INC	250MG	A060272 001
	333MG	A060272 002

ILOTYCIN

DISTA	250MG	A061910 001
-------	-------	-------------

R-P MYCIN

SOLVAY	250MG	A061659 001
--------	-------	-------------

ROBIMYCIN

ROBINS AH	250MG	A061633 001
-----------	-------	-------------

ERYTHROMYCIN ESTOLATE

CAPSULE;ORAL

ERYTHROMYCIN ESTOLATE

BARR	EQ 125MG BASE	A062162 001
------	---------------	-------------

	EQ 250MG BASE	A062162 002
--	---------------	-------------

IVAX SUB TEVA PHARMS	EQ 250MG BASE	A062237 001
----------------------	---------------	-------------

WATSON LABS	EQ 250MG BASE	A062087 001
-------------	---------------	-------------

ILOSONE

LILLY	EQ 125MG BASE	A061897 001
-------	---------------	-------------

	EQ 250MG BASE	A061897 002
--	---------------	-------------

FOR SUSPENSION;ORAL

ILOSONE

DISTA	EQ 125MG BASE/5ML	A061893 001
-------	-------------------	-------------

SUSPENSION;ORAL

ERYTHROMYCIN ESTOLATE

ALPHARMA US PHARMS	EQ 125MG BASE/5ML	A062353 001	Nov 18, 1982
--------------------	-------------------	-------------	--------------

	EQ 250MG BASE/5ML	A062409 001	Dec 16, 1982
--	-------------------	-------------	--------------

G AND W LABS INC	EQ 125MG BASE/5ML	A062169 001	Oct 17, 1990
------------------	-------------------	-------------	--------------

	EQ 250MG BASE/5ML	A062169 002	Oct 17, 1990
--	-------------------	-------------	--------------

LIFE LABS	EQ 250MG BASE/5ML	A062362 001	Dec 17, 1982
-----------	-------------------	-------------	--------------

ILOSONE

LILLY	EQ 125MG BASE/5ML	A061894 001
-------	-------------------	-------------

	EQ 125MG BASE/5ML	N050010 001
--	-------------------	-------------

	EQ 250MG BASE/5ML	A061894 002
--	-------------------	-------------

	EQ 250MG BASE/5ML	N050010 002
--	-------------------	-------------

SUSPENSION/DROPS;ORAL

ILOSONE

LILLY	EQ 100MG BASE/ML	A061894 003
-------	------------------	-------------

TABLET;ORAL

ILOSONE

LILLY	EQ 500MG BASE	A061896 001
-------	---------------	-------------

TABLET, CHEWABLE;ORAL

ILOSONE

DISTA	EQ 125MG BASE	A061895 001
-------	---------------	-------------

	EQ 250MG BASE	A061895 002
--	---------------	-------------

ERYTHROMYCIN ESTOLATE; SULFISOXAZOLE ACETYL

SUSPENSION;ORAL

ILOSONE SULFA

LILLY	EQ 125MG BASE/5ML;EQ 600MG BASE/5ML	N050599 001	Sep 29, 1989
-------	-------------------------------------	-------------	--------------

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE;ORAL

ERYTHROMYCIN ETHYLSUCCINATE

ANI PHARMS INC	EQ 200MG BASE/5ML	A062055 001
----------------	-------------------	-------------

PEDIAMYCIN

ROSS LABS	EQ 200MG BASE/5ML	A062305 001
-----------	-------------------	-------------

SUSPENSION;ORAL

E-MYCIN E

PHARMACIA AND UPJOHN	EQ 200MG BASE/5ML	A062198 001
----------------------	-------------------	-------------

	EQ 400MG BASE/5ML	A062198 002
--	-------------------	-------------

E.E.S. 200

ARBOR PHARMS LLC	EQ 200MG BASE/5ML	A061639 001
------------------	-------------------	-------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

E.E.S. 400

ARBOR PHARMS LLC	EQ 400MG BASE/5ML	A061639 002
------------------	-------------------	-------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

DISCONTINUED DRUG PRODUCT LIST

ERYTHROMYCIN ETHYLSUCCINATE

SUSPENSION; ORAL

ERYTHROMYCIN ETHYLSUCCINATE

ALPHARMA US PHARMS	EQ 200MG BASE/5ML	A062200 001	
	EQ 400MG BASE/5ML	A062200 002	
DISTA	EQ 200MG BASE/5ML	A062177 001	
	EQ 400MG BASE/5ML	A062177 002	
NASKA	EQ 400MG BASE/5ML	A062674 001	Mar 10, 1987
PARKE DAVIS	EQ 200MG BASE/5ML	A062231 001	
	EQ 400MG BASE/5ML	A062231 002	
PHARMAFAIR	EQ 200MG BASE/5ML	A062559 001	Mar 15, 1985
	EQ 400MG BASE/5ML	A062558 001	Mar 15, 1985

PEDIAMYCIN

ARBOR PHARMS LLC	EQ 200MG BASE/5ML	A062304 001	
------------------	-------------------	-------------	--

PEDIAMYCIN 400

ARBOR PHARMS LLC	EQ 400MG BASE/5ML	A062304 002	
------------------	-------------------	-------------	--

WYAMYCIN E

WYETH AYERST	EQ 200MG BASE/5ML	A062123 002	
	EQ 400MG BASE/5ML	A062123 001	

SUSPENSION/DROPS; ORAL

PEDIAMYCIN

ROSS LABS	EQ 100MG BASE/2.5ML	A062305 002	
-----------	---------------------	-------------	--

TABLET; ORAL

E.E.S. 400

ARBOR PHARMS LLC	EQ 400MG BASE	A061905 001	
------------------	---------------	-------------	--

ERYTHROMYCIN ETHYLSUCCINATE

BARR	EQ 400MG BASE	A062256 001	
------	---------------	-------------	--

MYLAN	EQ 400MG BASE	A062847 001	Sep 14, 1988
-------	---------------	-------------	--------------

TABLET, CHEWABLE; ORAL

E.E.S.

ARBOR PHARMS INC	EQ 200MG BASE	N050297 002	
------------------	---------------	-------------	--

ERYPED

ARBOR PHARMS INC	EQ 200MG BASE	N050297 003	Jul 05, 1988
------------------	---------------	-------------	--------------

PEDIAMYCIN

ROSS LABS	EQ 200MG BASE	A062306 001	
-----------	---------------	-------------	--

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

GRANULE; ORAL

ERYZOLE

ALRA	EQ 200MG BASE/5ML; EQ 600MG BASE/5ML	A062758 001	Jun 15, 1988
------	--------------------------------------	-------------	--------------

PEDIAZOLE

ROSS LABS	EQ 200MG BASE/5ML; EQ 600MG BASE/5ML	N050529 001	
-----------	--------------------------------------	-------------	--

ERYTHROMYCIN GLUCEPTATE

INJECTABLE; INJECTION

ILOTYCIN GLUCEPTATE

DISTA	EQ 250MG BASE/VIAL	N050370 001	
	EQ 500MG BASE/VIAL	N050370 002	
	EQ 1GM BASE/VIAL	N050370 003	

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

ERYTHROCIN

ABBOTT	EQ 500MG BASE/VIAL	A062586 001	Jan 04, 1988
	EQ 1GM BASE/VIAL	A062586 002	Jan 04, 1988
HOSPIRA	EQ 500MG BASE/VIAL	N050182 002	
	EQ 1GM BASE/VIAL	N050182 003	
	EQ 1GM BASE/VIAL	N050609 002	Sep 24, 1986

ERYTHROMYCIN

ELKINS SINN	EQ 500MG BASE/VIAL	A062563 001	Mar 28, 1985
	EQ 1GM BASE/VIAL	A062563 002	Mar 28, 1985

ERYTHROMYCIN LACTOBIONATE

ABRAXIS PHARM	EQ 500MG BASE/VIAL	A062604 001	Nov 24, 1986
	EQ 1GM BASE/VIAL	A062604 002	Nov 24, 1986
BAXTER HLTHCARE	EQ 500MG BASE/VIAL	A062993 001	May 09, 1989
	EQ 1GM BASE/VIAL	A062993 002	May 09, 1989
TEVA PARENTERAL	EQ 500MG BASE/VIAL	A063253 001	Jul 30, 1993
	EQ 1GM BASE/VIAL	A063253 002	Jul 30, 1993

DISCONTINUED DRUG PRODUCT LISTERYTHROMYCIN STEARATE

TABLET; ORAL

BRISTAMYCIN

BRISTOL	EQ 250MG BASE	A061304 001	
	EQ 250MG BASE	A061887 001	

ERYPAR

PARKE DAVIS	EQ 250MG BASE	A062032 001	
	EQ 500MG BASE	A062032 002	
WARNER CHILCOTT	EQ 250MG BASE	A062322 001	

ERYTHROCIN STEARATE

ARBOR PHARMS LLC	EQ 125MG BASE	A060359 002	
	EQ 500MG BASE	A060359 003	

ERYTHROMYCIN STEARATE

ANI PHARMS INC	EQ 250MG BASE	A061461 001	
	EQ 250MG BASE	A061591 001	
	EQ 500MG BASE	A061461 002	
	EQ 500MG BASE	A063179 001	May 15, 1990
LEDERLE	EQ 250MG BASE	A062089 001	
	EQ 500MG BASE	A062089 002	
MYLAN	EQ 250MG BASE	A061505 001	
	EQ 500MG BASE	A061505 002	
PUREPAC PHARM	EQ 250MG BASE	A061743 001	
WATSON LABS	EQ 250MG BASE	A062121 002	
	EQ 500MG BASE	A062121 001	

ETHRIL 250

BRISTOL MYERS SQUIBB	EQ 250MG BASE	A061605 001	
----------------------	---------------	-------------	--

ETHRIL 500

BRISTOL MYERS SQUIBB	EQ 500MG BASE	A061605 002	
----------------------	---------------	-------------	--

PFIZER-E

PFIZER	EQ 250MG BASE	A061791 001	
	EQ 500MG BASE	A061791 002	

WYAMYCIN S

WYETH AYERST	EQ 250MG BASE	A061675 001	
	EQ 500MG BASE	A061675 002	

ESCITALOPRAM OXALATE

CAPSULE; ORAL

ESCITALOPRAM OXALATE

MYLAN PHARMS INC	EQ 5MG BASE	A077660 001	Jul 31, 2007
	EQ 10MG BASE	A077660 002	Jul 31, 2007
	EQ 20MG BASE	A077660 003	Jul 31, 2007

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

BREVIBLOC

BAXTER HLTHCARE	10MG/ML	N019386 003	Aug 15, 1988
	20MG/ML	N019386 007	May 28, 2003

ESTAZOLAM

TABLET; ORAL

PROSOM

ABBOTT	1MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019080 001	Dec 26, 1990
	2MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019080 002	Dec 26, 1990

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

ESCLIM

WOMEN FIRST HLTHCARE	0.025MG/24HR	N020847 001	Aug 04, 1998
	0.0375MG/24HR	N020847 002	Aug 04, 1998
	0.05MG/24HR	N020847 003	Aug 04, 1998
	0.075MG/24HR	N020847 004	Aug 04, 1998
	0.1MG/24HR	N020847 005	Aug 04, 1998

ESTRADIOL

ORTHO MCNEIL PHARM	0.05MG/24HR	N021048 001	Sep 20, 1999
	0.075MG/24HR	N021048 002	Sep 20, 1999
	0.1MG/24HR	N021048 003	Sep 20, 1999

FEMPATCH

PARKE DAVIS	0.025MG/24HR	N020417 001	Dec 03, 1996
-------------	--------------	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

ESTRADIOL

FILM, EXTENDED RELEASE;TRANSDERMAL

VIVELLE

NOVARTIS	0.025MG/24HR	N020323 005	Aug 16, 2000
	0.0375MG/24HR	N020323 001	Oct 28, 1994
	0.075MG/24HR	N020323 003	Oct 28, 1994

GEL;TOPICAL

ESTROGEL

ASCEND THERAPS US	0.06%	N021166 001	Feb 09, 2004
-------------------	-------	-------------	--------------

TABLET;ORAL

ESTRACE

BRISTOL MYERS SQUIBB	0.5MG	A081295 001	Jun 30, 1993
	1MG	A084499 001	
	2MG	A084500 001	

ESTRADIOL

LANNETT HOLDINGS INC	0.5MG	A040138 001	Jan 30, 1998
	1MG	A040138 002	Jan 30, 1998
	2MG	A040138 003	Jan 30, 1998
USL PHARMA	0.5MG	A040297 001	Apr 17, 2002
	1MG	A040297 002	Apr 17, 2002
	2MG	A040297 003	Apr 17, 2002

GYNODIOL

DURAMED PHARMS BARR	0.5MG	A040212 001	Dec 29, 1997
	1MG	A040212 002	Dec 29, 1997
	1.5MG	A040212 003	Dec 29, 1997
	2MG	A040212 004	Dec 29, 1997

INNOFEM

NOVO NORDISK INC	0.5MG	A040312 001	Nov 19, 1999
	1MG	A040312 002	Nov 19, 1999
	2MG	A040312 003	Nov 19, 1999

TABLET;VAGINAL

VAGIFEM

NOVO NORDISK INC	25MCG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020908 001	Mar 26, 1999
------------------	--	-------------	--------------

ESTRADIOL CYPIONATE

INJECTABLE;INJECTION

DEPO-ESTRADIOL

PHARMACIA AND UPJOHN	1MG/ML	A085470 001	
	3MG/ML	A085470 002	

ESTRADIOL CYPIONATE

WATSON LABS	5MG/ML	A085620 001	
-------------	--------	-------------	--

ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE

INJECTABLE;INTRAMUSCULAR

LUNELLE

PHARMACIA AND UPJOHN	5MG/0.5ML;25MG/0.5ML	N020874 001	Oct 05, 2000
----------------------	----------------------	-------------	--------------

ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATE

INJECTABLE;INJECTION

DEPO-TESTADIOL

PHARMACIA AND UPJOHN	2MG/ML;50MG/ML	N017968 001	
----------------------	----------------	-------------	--

TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE

WATSON LABS	2MG/ML;50MG/ML	A085603 001	Mar 13, 1986
-------------	----------------	-------------	--------------

ESTRADIOL VALERATE

INJECTABLE;INJECTION

ESTRADIOL VALERATE

SANDOZ	10MG/ML	A040628 001	Oct 04, 2007
	20MG/ML	A040628 002	Oct 04, 2007
	40MG/ML	A040628 003	Oct 04, 2007
WATSON LABS	10MG/ML	A083546 001	
	40MG/ML	A083714 001	
WATSON LABS INC	20MG/ML	A083547 001	

ESTRADIOL VALERATE; TESTOSTERONE ENANTHATE

INJECTABLE;INJECTION

DITATE-DS

SAVAGE LABS	8MG/ML;180MG/ML	A086423 001	
-------------	-----------------	-------------	--

TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE

WATSON LABS	4MG/ML;90MG/ML	A085865 001	
	8MG/ML;180MG/ML	A085860 001	

DISCONTINUED DRUG PRODUCT LISTESTRADIOL; NORGESTIMATE

TABLET; ORAL

PREFEST

TEVA WOMENS	1MG, 1MG; N/A, 0.09MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021040 001	Oct 22, 1999
-------------	-----------------------	--	-------------	--------------

ESTROGENS, CONJUGATED

TABLET; ORAL

PREMARIN

WYETH PHARMS INC	2.5MG		N004782 002	
------------------	-------	--	-------------	--

ESTROGENS, CONJUGATED SYNTHETIC A

CREAM; VAGINAL

SYNTHETIC CONJUGATED ESTROGENS A

TEVA WOMENS	0.625MG/GM		N021788 001	Nov 28, 2008
-------------	------------	--	-------------	--------------

TABLET; ORAL

CENESTIN

TEVA BRANDED PHARM	0.3MG		N020992 001	Jun 21, 2002
	0.45MG		N020992 005	Feb 05, 2004
	0.625MG		N020992 002	Mar 24, 1999
	0.9MG		N020992 003	Mar 24, 1999
	1.25MG		N020992 004	Mar 13, 2000

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET; ORAL

ENJUWIA

TEVA WOMENS	0.625MG		N021443 003	May 10, 2004
	1.25MG		N021443 004	May 10, 2004

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET; ORAL-28

PREMPHASE (PREMARIN; CYCRIN 14/14)

WYETH PHARMS INC	0.625MG, 0.625MG; N/A, 5MG		N020303 002	Dec 30, 1994
------------------	----------------------------	--	-------------	--------------

PREMPRO (PREMARIN; CYCRIN)

WYETH PHARMS INC	0.625MG, 0.625MG; 2.5MG, 2.5MG		N020303 001	Dec 30, 1994
------------------	--------------------------------	--	-------------	--------------

ESTROGENS, CONJUGATED; MEPROBAMATE

TABLET; ORAL

MILPREM-200

MEDPOINTE PHARM HLC	0.45MG; 200MG		N011045 002	
---------------------	---------------	--	-------------	--

MILPREM-400

MEDPOINTE PHARM HLC	0.45MG; 400MG		N011045 001	
---------------------	---------------	--	-------------	--

PMB 200

WYETH AYERST	0.45MG; 200MG		N010971 005	
--------------	---------------	--	-------------	--

PMB 400

WYETH AYERST	0.45MG; 400MG		N010971 003	
--------------	---------------	--	-------------	--

ESTROGENS, ESTERIFIED

TABLET; ORAL

AMNESTROGEN

BRISTOL MYERS SQUIBB	0.3MG		A083266 001	
	0.625MG		A083266 002	
	1.25MG		A083266 003	
	2.5MG		A083266 004	

ESTERIFIED ESTROGENS

PVT FORM	0.625MG		A083414 001	
----------	---------	--	-------------	--

	1.25MG		A083765 001	
--	--------	--	-------------	--

	2.5MG		A085907 001	
--	-------	--	-------------	--

SANDOZ	1.25MG		A085302 001	
--------	--------	--	-------------	--

ESTRATAB

SOLVAY	0.3MG		A086715 001	
--------	-------	--	-------------	--

	0.625MG		A083209 001	
--	---------	--	-------------	--

	1.25MG		A083856 001	
--	--------	--	-------------	--

	2.5MG		A083857 001	
--	-------	--	-------------	--

EVEX

ROCHE PALO	0.625MG		A084215 001	
------------	---------	--	-------------	--

	1.25MG		A083376 002	
--	--------	--	-------------	--

FEMOGEN

PVT FORM	0.625MG		A085076 001	
----------	---------	--	-------------	--

	1.25MG		A085008 001	
--	--------	--	-------------	--

	2.5MG		A085007 001	
--	-------	--	-------------	--

DISCONTINUED DRUG PRODUCT LIST

ESTRONE

INJECTABLE; INJECTION

ESTROGENIC SUBSTANCE

WYETH AYERST

2MG/ML

A083488 001

ESTRONE

WATSON LABS

2MG/ML

A083397 001

5MG/ML

A085239 001

NATURAL ESTROGENIC SUBSTANCE-ESTRONE

WATSON LABS

2MG/ML

A085237 001 Nov 23, 1982

THEELIN

PARKEDALE

1MG/ML

N003977 001

2MG/ML

N003977 002

5MG/ML

N003977 003

ESTROPIPATE

CREAM; VAGINAL

OGEN

PHARMACIA AND UPJOHN

1.5MG/GM

A084710 001

TABLET; ORAL

ESTROPIPATE

DURAMED PHARMS BARR

0.75MG

A040296 001 Nov 01, 1999

1.5MG

A040296 002 Nov 01, 1999

3MG

A040296 003 Nov 01, 1999

MYLAN

3MG

A040359 003 Aug 26, 1999

WATSON LABS

6MG

A081216 001 Sep 23, 1993

ORTHO-EST

SUN PHARM INDS INC

0.75MG

A089567 001 Feb 27, 1991

1.5MG

A089582 001 Jul 17, 1991

ESZOPICLONE

TABLET; ORAL

ESZOPICLONE

WOCKHARDT LTD

1MG

A091165 001 Jul 14, 2011

2MG

A091165 002 Jul 14, 2011

3MG

A091165 003 Jul 14, 2011

ETHACRYNIC ACID

TABLET; ORAL

EDECIN

ATON

50MG

N016092 002

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

MYAMBUTOL

STI PHARMA LLC

200MG

N016320 002

500MG

N016320 004

ETHCHLORVYNOL

CAPSULE; ORAL

ETHCHLORVYNOL

BANNER PHARMACAPS

100MG

A084463 001

200MG

A084463 002

500MG

A084463 003

750MG

A084463 004

PLACIDYL

ABBVIE

100MG

N010021 004

200MG

N010021 007

500MG

N010021 002

750MG

N010021 010

ETHINAMATE

CAPSULE; ORAL

VALMID

DISTA

500MG

N009750 001

ETHINYL ESTRADIOL

TABLET; ORAL

ESTINYL

SCHERING

0.02MG

N005292 001

0.05MG

N005292 002

0.5MG

N005292 003

FEMINONE

PHARMACIA AND UPJOHN

0.05MG

N016649 001

LYNORAL

ORGANON USA INC

0.01MG

N005490 003

0.05MG

N005490 002

DISCONTINUED DRUG PRODUCT LIST

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-21

DEMULEN 1/35-21

GD SEARLE LLC

0.035MG;1MG **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N018168 001

DEMULEN 1/50-21

GD SEARLE LLC

0.05MG;1MG

N016927 001

ZOVIA 1/35E-21

WATSON LABS

0.035MG;1MG

A072720 001 Dec 30, 1991

ZOVIA 1/50E-21

WATSON LABS

0.05MG;1MG

A072722 001 Dec 30, 1991

TABLET; ORAL-28

DEMULEN 1/35-28

GD SEARLE LLC

0.035MG;1MG **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N018160 001

DEMULEN 1/50-28

GD SEARLE LLC

0.05MG;1MG **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N016936 001

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE

TABLET; ORAL-28

NORQUEST FE

GD SEARLE LLC

0.035MG;75MG;1MG

N018926 001 Jul 18, 1986

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE ACETATE

TABLET; ORAL-28

NORLESTRIN FE 1/50

PARKE DAVIS

0.05MG;75MG;1MG

N016766 001

NORLESTRIN FE 2.5/50

PARKE DAVIS

0.05MG;75MG;2.5MG

N016854 001

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

LYBREL

WYETH PHARMS INC

0.02MG;0.09MG **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N021864 001 May 22, 2007

PREVEN EMERGENCY CONTRACEPTIVE KIT

TEVA BRANDED PHARM

0.05MG;0.25MG

N020946 001 Sep 01, 1998

TABLET; ORAL-21

ALESSE

WYETH PHARMS

0.02MG;0.1MG **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020683 001 Mar 27, 1997

AVIANE-21

DURAMED PHARMS BARR

0.02MG;0.1MG

A075796 002 Apr 30, 2001

ENPRESSE-21

DURAMED PHARMS BARR

0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.1
25MG

A075809 001 Jul 16, 2001

LESSINA-21

BARR

0.02MG;0.1MG

A075803 001 Mar 20, 2002

LEVLITE

BAYER HLTHCARE

0.02MG;0.1MG **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020860 001 Jul 13, 1998

LEVONORGESTREL AND ETHINYL ESTRADIOL

BARR

0.02MG;0.1MG

A075862 001 Apr 29, 2003

LEVORA 0.15/30-21

WATSON LABS

0.03MG;0.15MG

A073592 001 Dec 13, 1993

NORDETTE-21

TEVA BRANDED PHARM

0.03MG;0.15MG

N018668 001 May 10, 1982

PORTIA-21

BARR

0.03MG;0.15MG

A075866 001 May 23, 2002

TRIPHASIL-21

WYETH PHARMS

0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.1
25MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or

N019192 001 Nov 01, 1984

DISCONTINUED DRUG PRODUCT LISTETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21

TRIPHASIL-21

efficacy reasons**

TRIVORA-21

MAYNE PHARMA

0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG

A074538 001 Dec 18, 1997

TABLET; ORAL-28

ALESSE

WYETH PHARMS

0.02MG; 0.1MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N020683 002 Mar 27, 1997

LEVLITE

BAYER HLTHCARE

0.02MG; 0.1MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N020860 002 Jul 13, 1998

LEVONORGESTREL AND ETHINYL ESTRADIOL

BARR

0.02MG; 0.1MG

A075862 002 Apr 29, 2003

NORDETTE-28

TEVA BRANDED PHARM

0.03MG; 0.15MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N018782 001 Jul 21, 1982

TRIPHASIL-28

WYETH PHARMS INC

0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N019190 001 Nov 01, 1984

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE; TRANSDERMAL

ORTHO EVRA

JANSSEN PHARMS

0.035MG/24HR; 0.15MG/24HR **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N021180 001 Nov 20, 2001

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

BALZIVA-21

BARR

0.035MG; 0.4MG

A076198 001 Apr 22, 2004

BREVICON 21-DAY

ALLERGAN SALES LLC

0.035MG; 0.5MG

N017566 001

GENCEPT 10/11-21

BARR

0.035MG, 0.035MG; 0.5MG, 1MG

A072694 001 Feb 28, 1992

MODICON 21

ORTHO MCNEIL PHARM

0.035MG; 0.5MG

N017488 001

N.E.E. 1/35 21

LPI

0.035MG; 1MG

A071541 001 Dec 14, 1987

NORCEPT-E 1/35 21

ORTHO MCNEIL PHARM

0.035MG; 1MG

A071545 001 Feb 09, 1989

NORETHIN 1/35E-21

WATSON LABS

0.035MG; 1MG

A071480 001 Apr 12, 1988

NORETHINDRONE AND ETHINYL ESTRADIOL

WATSON LABS

0.035MG; 0.4MG

A078379 001 Feb 23, 2010

0.035MG; 0.5MG

A070684 001 Jan 29, 1987

0.035MG; 1MG

A070685 001 Jan 29, 1987

NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)

WATSON LABS

0.035MG, 0.035MG; 0.5MG, 1MG

A071043 001 Apr 01, 1988

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

WATSON LABS

0.035MG, 0.035MG; 0.5MG, 1MG

A071041 001 Sep 24, 1991

NORTREL 0.5/35-21

BARR

0.035MG; 0.5MG

A072692 001 Feb 28, 1992

ORTHO-NOVUM 1/35-21

ORTHO MCNEIL PHARM

0.035MG; 1MG

N017489 002

ORTHO-NOVUM 10/11-21

ORTHO MCNEIL JANSSEN

0.035MG, 0.035MG; 0.5MG, 1MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N018354 001 Jan 11, 1982

ORTHO-NOVUM 7/14-21

ORTHO MCNEIL PHARM

0.035MG, 0.035MG; 0.5MG, 1MG

N019004 001 Apr 04, 1984

DISCONTINUED DRUG PRODUCT LISTETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

ORTHO-NOVUM 7/7/7-21

JANSSEN PHARMS

0.035MG, 0.035MG, 0.035MG; 0.5MG, 0.75MG, 1MG

N018985 001 Apr 04, 1984

OVCON-35

WARNER CHILCOTT

0.035MG; 0.4MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N018127 001

OVCON-50

WARNER CHILCOTT

0.05MG; 1MG

N018128 001

TRI-NORINYL 21-DAY

MAYNE PHARMA

0.035MG, 0.035MG, 0.035MG; 0.5MG, 1MG, 0.5MG

N018977 001 Apr 13, 1984

TABLET; ORAL-28

GENCEPT 10/11-28

BARR

0.035MG, 0.035MG; 0.5MG, 1MG

A072697 001 Feb 28, 1992

N.E.E. 1/35 28

LPI

0.035MG; 1MG

A071542 001 Dec 14, 1987

NORCEPT-E 1/35 28

ORTHO MCNEIL PHARM

0.035MG; 1MG

A071546 001 Feb 09, 1989

NORETHIN 1/35E-28

WATSON LABS

0.035MG; 1MG

A071481 001 Apr 12, 1988

NORETHINDRONE AND ETHINYL ESTRADIOL

WATSON LABS

0.035MG, 0.035MG, 0.035MG; 0.5MG, 0.75MG, 1MG

A076393 001 Feb 04, 2010

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

WATSON LABS

0.035MG, 0.035MG; 0.5MG, 1MG

A071042 001 Sep 24, 1991

ORTHO-NOVUM 10/11-28

ORTHO MCNEIL JANSSEN

0.035MG, 0.035MG; 0.5MG, 1MG

N018354 002 Jan 11, 1982

ORTHO-NOVUM 7/14-28

ORTHO MCNEIL PHARM

0.035MG, 0.035MG; 0.5MG, 1MG

N019004 002 Apr 04, 1984

OVCON-35

WARNER CHILCOTT LLC

0.035MG; 0.4MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N017716 001

OVCON-50

WARNER CHILCOTT LLC

0.05MG; 1MG

N017576 001

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

FEMHRT

APIL

0.005MG; 1MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N021065 002 Oct 15, 1999

TABLET; ORAL-21

ESTROSTEP 21

APIL

0.02MG, 0.03MG, 0.035MG; 1MG, 1MG, 1MG
Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

N020130 001 Oct 09, 1996

NORLESTRIN 21 1/50

PARKE DAVIS

0.05MG; 1MG

N016749 001

NORLESTRIN 21 2.5/50

PARKE DAVIS

0.05MG; 2.5MG

N016852 001

TABLET; ORAL-28

NORLESTRIN 28 1/50

PARKE DAVIS

0.05MG; 1MG

N016723 001

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-21

ORTHO CYCLEN-21

JANSSEN PHARMS

0.035MG; 0.25MG

N019653 001 Dec 29, 1989

ORTHO TRI-CYCLEN

JANSSEN PHARMS

0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG

N019697 002 Jul 03, 1992

TABLET; ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

WATSON LABS

0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.215MG, 0.25MG

A090479 001 Mar 09, 2011

0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG

A076626 001 Aug 17, 2006

0.035MG; 0.25MG

A076627 001 Aug 17, 2006

DISCONTINUED DRUG PRODUCT LISTETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

LO/OVRAL

PELAGIUS 0.03MG;0.3MG N017612 001

LOW-OGESTREL-21

MAYNE PHARMA 0.03MG;0.3MG A075288 001 Jul 28, 1999

OGESTREL 0.5/50-21

WATSON LABS 0.05MG;0.5MG A075406 001 Dec 15, 1999

OVRAL

WYETH PHARMS 0.05MG;0.5MG N016672 001

TABLET; ORAL-28

LO/OVRAL-28

WYETH PHARMS 0.03MG;0.3MG N017802 001

OVRAL-28

WYETH PHARMS 0.05MG;0.5MG N016806 001

ETHOPROPAZINE HYDROCHLORIDE

TABLET; ORAL

PARSIDOL

PARKE DAVIS 10MG N009078 003

50MG N009078 006

100MG N009078 008

ETHOTOIN

TABLET; ORAL

PEGANONE

RECORDATI RARE 500MG N010841 003

ETHOXZOLAMIDE

TABLET; ORAL

CARDRASE

PHARMACIA AND UPJOHN 62.5MG N011047 002

125MG N011047 001

ETHAMIDE

ALLERGAN 125MG N016144 001

ETHYLESTRENOL

ELIXIR; ORAL

MAXIBOLIN

ORGANON USA INC 2MG/5ML N014006 002

TABLET; ORAL

MAXIBOLIN

ORGANON USA INC 2MG N014005 002

ETHYNODIOL DIACETATE; MESTRANOL

TABLET; ORAL-20

OVULEN

GD SEARLE LLC 1MG;0.1MG N016029 002

TABLET; ORAL-21

OVULEN-21

GD SEARLE LLC 1MG;0.1MG N016029 003

TABLET; ORAL-28

OVULEN-28

GD SEARLE LLC 1MG;0.1MG N016705 001

ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

ASTRAZENECA 0.5% **Federal Register determination N017751 003

that product was not discontinued or
withdrawn for safety or efficacy
reasons**

1% **Federal Register determination N017751 005

that product was not discontinued or
withdrawn for safety or efficacy
reasons**ETIDRONATE DISODIUM

INJECTABLE; INJECTION

DIDRONEL

MGI PHARMA INC 50MG/ML N019545 001 Apr 20, 1987

DISCONTINUED DRUG PRODUCT LIST

ETODOLAC

CAPSULE; ORAL

ETODOLAC

ANI PHARMS INC	200MG	A074899 001	Jul 08, 1997
	300MG	A074899 002	Jul 08, 1997
IDT AUSTRALIA LTD	200MG	A074840 001	Aug 29, 1997
	300MG	A074840 002	Aug 29, 1997
LEHIGH VALLEY	300MG	A074929 001	Jan 30, 1998
MYLAN	200MG	A074932 001	May 16, 1997
	200MG	A075071 001	Sep 30, 1998
	300MG	A074932 002	May 16, 1997
	300MG	A075071 002	Sep 30, 1998
SANDOZ	200MG	A074942 001	Sep 30, 1997
	300MG	A074942 002	Sep 30, 1997
VINTAGE PHARMS LLC	200MG	A074842 001	Jul 17, 1997
	300MG	A074842 002	Jul 17, 1997
WATSON LABS	200MG	A074844 001	Dec 23, 1997
	300MG	A074844 002	Dec 23, 1997

LODINE

WYETH PHARMS INC	200MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018922 002	Jan 31, 1991
	300MG	N018922 003	Jan 31, 1991

TABLET; ORAL

ETODOLAC

IVAX SUB TEVA PHARMS	400MG	A074883 001	Feb 28, 1997
	500MG	A074883 002	Nov 20, 1998
LEHIGH VALLEY	400MG	A074927 001	Oct 30, 1997
MYLAN	400MG	A075012 001	Sep 30, 1998
	500MG	A075012 002	Sep 30, 1998
OXFORD PHARMS	400MG	A074819 001	Feb 28, 1997
	500MG	A074819 002	Apr 28, 1998
RANBAXY LABS LTD	400MG	A075226 001	Nov 24, 1998
	500MG	A075226 002	Nov 24, 1998
SANDOZ	400MG	A074839 001	Jul 11, 1997
	400MG	A074846 001	Feb 28, 1997
TEVA	400MG	A074847 001	Apr 23, 1999
	500MG	A074847 002	Apr 23, 1999
VINTAGE PHARMS LLC	400MG	A074841 001	Jun 27, 1997
WATSON LABS	400MG	A074892 001	Apr 16, 1997
	400MG	A075069 001	Apr 16, 1998
	500MG	A074892 002	Oct 29, 1998

LODINE

WYETH PHARMS INC	400MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018922 004	Jul 29, 1993
	500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018922 005	Jun 28, 1996

TABLET, EXTENDED RELEASE; ORAL

ETODOLAC

ACTAVIS ELIZABETH	400MG	A075696 001	Jul 31, 2000
IDT AUSTRALIA LTD	400MG	A075943 001	Jul 26, 2002
	500MG	A075943 002	Jul 26, 2002
	600MG	A075943 003	Jul 26, 2002
WATSON LABS FLORIDA	400MG	A075829 001	Nov 30, 2001
	500MG	A075829 002	Nov 30, 2001

LODINE XL

WYETH PHARMS INC	400MG	N020584 001	Oct 25, 1996
	500MG	N020584 003	Jan 20, 1998
	600MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020584 002	Oct 25, 1996

DISCONTINUED DRUG PRODUCT LIST

ETONOGESTREL

IMPLANT; IMPLANTATION

IMPLANON

ORGANON USA INC 68MG/IMPLANT N021529 001 Jul 17, 2006

ETOPOSIDE

CAPSULE; ORAL

VEPESID

DAVA PHARMS INC 50MG N019557 001 Dec 30, 1986

100MG N019557 002 Dec 30, 1986

INJECTABLE; INJECTION

ETOPOSIDE

HOSPIRA 20MG/ML A074320 001 Aug 30, 1995

20MG/ML A074351 001 Aug 30, 1995

PHARMACHEMIE BV 20MG/ML A074227 001 Feb 22, 1996

PIERRE FABRE 20MG/ML A074813 001 Jul 09, 1997

TEVA PARENTERAL 20MG/ML A074510 001 Jun 29, 1995

TEVA PHARMS USA 20MG/ML A074284 001 Feb 10, 1994

WATSON LABS 20MG/ML A074228 001 Oct 15, 1996

WATSON LABS INC 20MG/ML A074968 001 Jan 09, 1998

TOPOSAR

TEVA PARENTERAL 20MG/ML A074166 001 Feb 27, 1995

VEPESID

CORDEN PHARMA 20MG/ML **Federal Register N018768 001 Nov 10, 1983

determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**ETOPOSIDE PHOSPHATE

INJECTABLE; INJECTION

ETOPOPHOS PRESERVATIVE FREE

BRISTOL MYERS SQUIBB EQ 500MG BASE/VIAL N020906 001 Feb 27, 1998

EQ 1GM BASE/VIAL N020906 002 Feb 27, 1998

ETRETINATE

CAPSULE; ORAL

TEGISON

ROCHE 10MG N019369 001 Sep 30, 1986

25MG N019369 002 Sep 30, 1986

EVANS BLUE

INJECTABLE; INJECTION

EVANS BLUE

PARKE DAVIS 0.5% **Federal Register determination N008041 001

that product was not discontinued or
withdrawn for safety or efficacy
reasons**FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE

APOTEX INC 10MG/ML A075942 001 Aug 02, 2002

APOTHECON 10MG/ML A075707 001 Apr 16, 2001

EUROHLTH INTL SARL 10MG/ML A075799 001 Apr 30, 2002

HOSPIRA 10MG/ML A075705 001 Apr 16, 2001

10MG/ML A075870 001 Nov 23, 2001

10MG/ML A075905 001 Nov 23, 2001

FAMOTIDINE PRESERVATIVE FREE

APOTEX INC 10MG/ML A076324 001 Nov 27, 2002

APOTHECON 10MG/ML A075708 001 Apr 16, 2001

EUROHLTH INTL SARL 10MG/ML A075789 001 Apr 30, 2002

HOSPIRA 10MG/ML A075669 001 Apr 16, 2001

FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)

APOTEX INC 10MG/ML A076322 001 Nov 27, 2002

FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER

ABBVIE 0.4MG/ML A075729 001 Dec 17, 2001

PEPCID

MERCK 10MG/ML **Federal Register N019510 001 Nov 04, 1986

determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

PEPCID PRESERVATIVE FREE

MERCK 10MG/ML **Federal Register N019510 004 Nov 04, 1986

determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

DISCONTINUED DRUG PRODUCT LIST

FAMOTIDINE

INJECTABLE; INJECTION

PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER

MERCK SHARP DOHME	0.4MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020249 001	Feb 18, 1994
-------------------	---	-------------	--------------

TABLET; ORAL

FAMOTIDINE

ACTAVIS ELIZABETH	20MG	A075650 001	Sep 14, 2001
	40MG	A075650 002	Sep 14, 2001
APOTEX	10MG	A075610 001	Mar 12, 2002
MYLAN PHARMS INC	20MG	A075457 001	Apr 18, 2001
	40MG	A075457 002	Apr 18, 2001
SANDOZ	10MG	A076101 001	Oct 21, 2002
	20MG	A075302 001	Apr 16, 2001
	20MG	A075607 001	May 10, 2001
	20MG	A075793 001	Apr 16, 2001
	40MG	A075302 002	Apr 16, 2001
	40MG	A075607 002	May 10, 2001
	40MG	A075793 002	Apr 16, 2001
SUN PHARM INDS	20MG	A075639 002	Dec 12, 2001
	40MG	A075639 001	Dec 12, 2001
WATSON LABS	10MG	A075404 001	Nov 28, 2001
	20MG	A075062 002	Apr 16, 2001
	40MG	A075062 001	Apr 16, 2001

TABLET, CHEWABLE; ORAL

PEPCID AC

J AND J CONSUMER INC	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020801 001	Sep 24, 1998
----------------------	---	-------------	--------------

TABLET, ORALLY DISINTEGRATING; ORAL

FLUXID

UCB INC	20MG	N021712 001	Sep 24, 2004
	40MG	N021712 002	Sep 24, 2004

PEPCID RPD

MERCK	20MG	N020752 001	May 28, 1998
	40MG	N020752 002	May 28, 1998

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

FELODIPINE

WOCKHARDT LTD	2.5MG	A091484 001	Aug 15, 2012
	5MG	A091484 002	Aug 15, 2012
	10MG	A091484 003	Aug 15, 2012

PLENDIL

ASTRAZENECA	2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019834 004	Sep 22, 1994
	5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019834 001	Jul 25, 1991
	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019834 002	Jul 25, 1991

FENOFIBRATE

CAPSULE; ORAL

ANTARA (MICRONIZED)

LUPIN ATLANTIS	87MG	N021695 002	Nov 30, 2004
----------------	------	-------------	--------------

LIPIDIL

ABBVIE	100MG	N019304 001	Dec 31, 1993
--------	-------	-------------	--------------

LIPOFEN

CIPHER PHARMS INC	100MG	N021612 002	Jan 11, 2006
-------------------	-------	-------------	--------------

TRICOR (MICRONIZED)

ABBVIE	67MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019304 002	Feb 09, 1998
	134MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019304 003	Jun 30, 1999

DISCONTINUED DRUG PRODUCT LIST

FENOFIBRATE

CAPSULE; ORAL

TRICOR (MICRONIZED)

reasons**

200MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N019304 004 Jun 30, 1999

TABLET; ORAL

FENOFIBRATE

MYLAN

107MG

A076520 002 Dec 29, 2005

TRICOR

ABBOTT

54MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021203 001 Sep 04, 2001

160MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021203 003 Sep 04, 2001

TRIGLIDE

SKYEPHARMA AG

50MG

N021350 001 May 07, 2005

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION

FENOLDOPAM MESYLATE

LUITPOLD

EQ 10MG BASE/ML

A076656 001 Dec 01, 2003

TEVA PARENTERAL

EQ 10MG BASE/ML

A077826 001 Mar 07, 2007

FENOPROFEN CALCIUM

CAPSULE; ORAL

FENOPROFEN CALCIUM

AM THERAP

EQ 200MG BASE

A072307 001 Aug 22, 1988

EQ 300MG BASE

A072308 001 Aug 22, 1988

AUROLIFE PHARMA LLC

EQ 200MG BASE

A072394 001 Oct 17, 1988

EQ 300MG BASE

A072395 001 Oct 17, 1988

HALSEY

EQ 200MG BASE

A072355 001 Aug 17, 1988

EQ 300MG BASE

A072356 001 Aug 17, 1988

PAR PHARM

EQ 200MG BASE

A072437 001 Aug 22, 1988

EQ 300MG BASE

A072438 001 Aug 22, 1988

QUANTUM PHARMICS

EQ 200MG BASE

A072214 001 Aug 17, 1988

EQ 300MG BASE

A071738 001 Aug 17, 1988

WARNER CHILCOTT

EQ 200MG BASE

A072946 001 Apr 30, 1991

EQ 300MG BASE

A072472 001 Apr 30, 1991

WATSON LABS

EQ 200MG BASE

A072294 001 Aug 17, 1988

EQ 200MG BASE

A072981 001 Aug 19, 1991

EQ 300MG BASE

A072293 001 Aug 17, 1988

EQ 300MG BASE

A072982 001 Aug 19, 1991

NALFON

XSPIRE

EQ 300MG BASE

N017604 002

TABLET; ORAL

FENOPROFEN CALCIUM

ACTAVIS ELIZABETH

EQ 600MG BASE

A072274 001 May 02, 1988

AM THERAP

EQ 600MG BASE

A072309 001 Aug 17, 1988

AUROLIFE PHARMA LLC

EQ 600MG BASE

A072396 001 Oct 17, 1988

DAVA PHARMS INC

EQ 600MG BASE

A072326 001 Aug 17, 1988

HALSEY

EQ 600MG BASE

A072357 001 Aug 17, 1988

IVAX SUB TEVA PHARMS

EQ 600MG BASE

A072557 001 Aug 29, 1988

PAR PHARM

EQ 600MG BASE

A072429 001 Aug 17, 1988

QUANTUM PHARMICS

EQ 600MG BASE

A072194 001 Aug 17, 1988

SUN PHARM INDS

EQ 600MG BASE

A072902 001 Dec 21, 1990

USL PHARMA

EQ 600MG BASE

A072362 001 Aug 17, 1988

WATSON LABS

EQ 600MG BASE

A072165 001 Aug 17, 1988

EQ 600MG BASE

A072407 001 Aug 17, 1988

EQ 600MG BASE

A072602 001 Oct 11, 1988

NALFON

DISTA

EQ 600MG BASE

N017710 001

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

FENTANYL-100

NOVEN

100MCG/HR

A077775 004 Oct 16, 2009

FENTANYL-25

NOVEN

25MCG/HR

A077775 001 Oct 16, 2009

DISCONTINUED DRUG PRODUCT LIST

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

FENTANYL-50

NOVEN

50MCG/HR

A077775 002 Oct 16, 2009

FENTANYL-75

NOVEN

75MCG/HR

A077775 003 Oct 16, 2009

FENTANYL CITRATE

FILM; BUCCAL

ONSOLIS

BIODELIVERY SCI INTL

EQ 0.2MG BASE

N022266 001 Jul 16, 2009

EQ 0.4MG BASE

N022266 002 Jul 16, 2009

EQ 0.6MG BASE

N022266 003 Jul 16, 2009

EQ 0.8MG BASE

N022266 004 Jul 16, 2009

EQ 1.2MG BASE

N022266 005 Jul 16, 2009

INJECTABLE; INJECTION

FENTANYL CITRATE

ABBOTT

EQ 0.05MG BASE/ML

A070636 001 Apr 30, 1990

EQ 0.05MG BASE/ML

A070637 001 Apr 30, 1990

WATSON LABS

EQ 0.05MG BASE/ML

A073488 001 Jun 30, 1992

FENTANYL CITRATE PRESERVATIVE FREE

WATSON LABS INC

EQ 0.05MG BASE/ML

A074917 001 Feb 03, 1998

TABLET; BUCCAL, SUBLINGUAL

FENTANYL CITRATE

WATSON LABS

EQ 0.1MG BASE

A079075 001 Jan 07, 2011

EQ 0.2MG BASE

A079075 002 Jan 07, 2011

EQ 0.4MG BASE

A079075 003 Jan 07, 2011

EQ 0.6MG BASE

A079075 004 Jan 07, 2011

EQ 0.8MG BASE

A079075 005 Jan 07, 2011

FENTORA

CEPHALON

EQ 0.3MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N021947 006 Mar 02, 2007

TROCHE/LOZENGE; ORAL

FENTANYL

CEPHALON

EQ 0.1MG BASE

N020195 007 Oct 30, 1995

EQ 0.2MG BASE

N020195 001 Oct 04, 1993

EQ 0.3MG BASE

N020195 002 Oct 04, 1993

EQ 0.4MG BASE

N020195 003 Oct 04, 1993

FERRIC AMMONIUM CITRATE

FOR SOLUTION; ORAL

FERRISELTZ

OTSUKA

600MG/PACKET

N020292 001 Oct 14, 1997

FERROUS CITRATE, FE-59

INJECTABLE; INJECTION

FERROUS CITRATE FE 59

MALLINCKRODT

25uCi/ML

N016729 001

FERROUS SULFATE; FOLIC ACID

CAPSULE; ORAL

FOLVRON

LEDERLE

182MG; 0.33MG

N006012 003

FERUMOXIDES

INJECTABLE; INJECTION

FERIDEX I.V.

AMAG PHARMS INC

EQ 11.2MG IRON/ML

N020416 001 Aug 30, 1996

FERUMOXSIIL

SUSPENSION; ORAL

GASTROMARK

AMAG PHARMS INC

EQ 0.175MG IRON/ML

N020410 001 Dec 06, 1996

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE; ORAL

FESOTERODINE FUMARATE

ALKEM LABS LTD

4MG

A204827 001 Dec 10, 2015

8MG

A204827 002 Dec 10, 2015

DISCONTINUED DRUG PRODUCT LIST

FEXOFENADINE HYDROCHLORIDE

CAPSULE; ORAL

ALLEGRA

SANOFI AVENTIS US 60MG

N020625 001 Jul 25, 1996

FEXOFENADINE HYDROCHLORIDE

BARR 60MG

A076169 001 Jul 13, 2005

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

BARR 60MG; 120MG

A076236 001 Apr 14, 2005

IMPAX PHARMS 60MG; 120MG

A076298 001 Nov 12, 2010

FIBRINOGEN, I-125

INJECTABLE; INJECTION

IBRIN

GE HEALTHCARE 154uCi/VIAL

N017879 001

RADIONUCLIDE-LABELED (125 I) FIBRINOGEN (HUMAN) SENSOR

ABBOTT 140uCi/ML

N017787 001

FINASTERIDE

TABLET; ORAL

FINASTERIDE

IVAX SUB TEVA PHARMS 5MG

A076340 001 Jun 19, 2006

FLAVOXATE HYDROCHLORIDE

TABLET; ORAL

FLAVOXATE HYDROCHLORIDE

IMPAX PHARMS 100MG

A076234 001 Aug 28, 2003

URISPAS

ORTHO MCNEIL JANSSEN 100MG

N016769 001

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

APOTEX INC 50MG

A079164 001 Jul 09, 2009

100MG

A079164 002 Jul 09, 2009

150MG

A079164 003 Jul 09, 2009

IDT AUSTRALIA LTD 50MG

A076030 001 Oct 28, 2002

100MG

A076030 002 Oct 28, 2002

150MG

A076030 003 Oct 28, 2002

TAMBOCOR

CNTY LINE PHARMS 200MG

N018830 002 Oct 31, 1985

FLORBETAPIR F-18

SOLUTION; INTRAVENOUS

AMYVID

AVID RADIOPHARMS INC 10ML (13.5-51mCi/ML)

N202008 001 Apr 06, 2012

FLOXURIDINE

INJECTABLE; INJECTION

FUDR

HOSPIRA 500MG/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N016929 001

FLUCONAZOLE

FOR SUSPENSION; ORAL

FLUCONAZOLE

SUN PHARM INDS LTD 50MG/5ML

A076332 001 Jul 29, 2004

200MG/5ML

A076332 002 Jul 29, 2004

TARO PHARM INDS 50MG/5ML

A076918 001 Dec 18, 2006

200MG/5ML

A076918 002 Dec 18, 2006

INJECTABLE; INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

MYLAN LABS LTD 200MG/100ML (2MG/ML)

A076888 001 Mar 25, 2005

400MG/200ML (2MG/ML)

A076888 002 Mar 25, 2005

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

TEVA PHARMS USA 200MG/100ML (2MG/ML)

A076653 001 Jul 29, 2004

400MG/200ML (2MG/ML)

A076653 002 Jul 29, 2004

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

HOSPIRA 200MG/100ML (2MG/ML)

A076617 001 Jul 29, 2004

400MG/200ML (2MG/ML)

A076617 002 Jul 29, 2004

MYLAN LABS LTD 200MG/100ML (2MG/ML)

A076889 001 Mar 25, 2005

400MG/200ML (2MG/ML)

A076889 002 Mar 25, 2005

TEVA PHARMS 200MG/100ML (2MG/ML)

A076837 001 Jan 13, 2005

DISCONTINUED DRUG PRODUCT LIST

FLUCONAZOLE

INJECTABLE; INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
400MG/200ML (2MG/ML)

A076837 002 Jan 13, 2005

TABLET; ORAL

FLUCONAZOLE

GEDEON RICHTER USA

50MG

A076432 001 Jul 29, 2004

100MG

A076432 002 Jul 29, 2004

150MG

A076432 003 Jul 29, 2004

200MG

A076432 004 Jul 29, 2004

IDT AUSTRALIA LTD

50MG

A076086 001 Jul 29, 2004

100MG

A076086 002 Jul 29, 2004

150MG

A076086 003 Jul 29, 2004

200MG

A076086 004 Jul 29, 2004

MYLAN PHARMS INC

50MG

A076042 001 Jul 29, 2004

100MG

A076042 002 Jul 29, 2004

150MG

A076042 003 Jul 29, 2004

200MG

A076042 004 Jul 29, 2004

PLIVA

50MG

A076424 001 Jul 29, 2004

100MG

A076424 002 Jul 29, 2004

150MG

A076424 003 Jul 29, 2004

200MG

A076424 004 Jul 29, 2004

RANBAXY LABS LTD

50MG

A076386 001 Jul 29, 2004

100MG

A076386 002 Jul 29, 2004

150MG

A076386 003 Jul 29, 2004

200MG

A076386 004 Jul 29, 2004

ROXANE

50MG

A076213 001 Jul 29, 2004

100MG

A076213 002 Jul 29, 2004

150MG

A076213 003 Jul 29, 2004

200MG

A076213 004 Jul 29, 2004

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARA

GENZYME CORP

50MG/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020038 001 Apr 18, 1991

TABLET; ORAL

OFORTA

SANOFI AVENTIS US

10MG

N022273 001 Dec 18, 2008

FLUDEOXYGLUCOSE F-18

INJECTABLE; INJECTION

FLUDEOXYGLUCOSE F18

DOWNSTATE CLINCL

4-40mCi/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020306 001 Aug 19, 1994

4-90mCi/ML **Federal Register

determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020306 002 Sep 25, 2001

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

WEILL MEDCL COLL

10-100mCi/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N021768 001 Aug 05, 2004

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLORINEF

CASPER PHARMA LLC

0.1MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N010060 001

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

CLARIS

0.5MG/5ML (0.1MG/ML)

A076755 002 Oct 12, 2004

1MG/10ML (0.1MG/ML)

A076755 001 Oct 12, 2004

TEVA PHARMS USA

0.5MG/5ML (0.1MG/ML)

A076589 002 Oct 12, 2004

1MG/10ML (0.1MG/ML)

A076589 001 Oct 12, 2004

DISCONTINUED DRUG PRODUCT LIST

FLUMAZENIL

INJECTABLE; INJECTION

ROMAZICON

HOFFMANN LA ROCHE

1MG/10ML (0.1MG/ML) **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020073 001 Dec 20, 1991

0.5MG/5ML (0.1MG/ML) **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020073 002 Dec 20, 1991

FLUMETHASONE PIVALATE

CREAM; TOPICAL

LOCORTEN

NOVARTIS

0.03%

N016379 001

FLUNISOLIDE

AEROSOL, METERED; INHALATION

AEROBID

ROCHE PALO

0.25MG/INH

N018340 001 Aug 17, 1984

SPRAY, METERED; NASAL

NASALIDE

IVAX RES

0.025MG/SPRAY

N018148 001

NASAREL

TEVA BRANDED PHARM

0.029MG/SPRAY

N020409 001 Mar 08, 1995

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

FLUCET

ALPHARMA US PHARMS

0.025%

A088360 001 Jan 16, 1984

FLUOCINOLONE ACETONIDE

ALPHARMA US PHARMS

0.01%

A088361 001 Jan 16, 1984

PERRIGO NEW YORK

0.01%

A086810 001 Mar 04, 1982

PHARMADERM

0.025%

A086811 001 Mar 04, 1982

PHARMADERM

0.01%

A088047 001 Dec 16, 1982

PHARMAFAIR

0.025%

A088045 001 Dec 16, 1982

PHARMAFAIR

0.01%

A088499 001 Aug 02, 1984

PHARMAFAIR

0.025%

A088506 001 Aug 02, 1984

TARO

0.01%

A040035 001 Oct 31, 1994

TARO

0.01%

A087102 001 Apr 27, 1982

USL PHARMA

0.025%

A040042 001 Oct 31, 1994

USL PHARMA

0.01%

A088757 001 Feb 11, 1985

USL PHARMA

0.025%

A088756 001 Mar 28, 1985

FLUONID

ALLERGAN HERBERT

0.025%

A087156 002 Sep 06, 1984

FLUOTREX

SAVAGE LABS

0.01%

A088174 001 May 06, 1983

SAVAGE LABS

0.025%

A088173 001 Mar 09, 1983

SYNALAR-HP

MEDIMETRIKS PHARMS

0.2%

N016161 002

GEL; TOPICAL

FLUONID

ALLERGAN HERBERT

0.025%

A087300 001 May 27, 1982

OINTMENT; TOPICAL

FLUOCINOLONE ACETONIDE

PHARMADERM

0.025%

A088046 001 Dec 16, 1982

PHARMAFAIR

0.025%

A088507 001 Feb 27, 1984

USL PHARMA

0.025%

A088742 001 Feb 08, 1985

FLUONID

ALLERGAN HERBERT

0.025%

A087157 001 Sep 06, 1984

FLUOTREX

SAVAGE LABS

0.025%

A088172 001 Mar 09, 1983

SOLUTION; TOPICAL

FLUOCINOLONE ACETONIDE

ALPHARMA US PHARMS

0.01%

A087159 001 Jun 16, 1982

BAUSCH AND LOMB

0.01%

A040059 001 Dec 20, 1993

MORTON GROVE

0.01%

A088312 001 Jan 27, 1984

PHARMADERM

0.01%

A088048 001 Dec 16, 1982

PHARMAFAIR

0.01%

A088449 001 Feb 08, 1984

FLUONID

ALLERGAN HERBERT

0.01%

A087158 001 Mar 17, 1983

FLUOTREX

SAVAGE LABS

0.01%

A088171 001 Mar 09, 1983

DISCONTINUED DRUG PRODUCT LIST

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE

PERRIGO NEW YORK	0.05%	A071790 001	Jul 13, 1988
TARO	0.05%	A071500 001	Jun 10, 1987

FLUOCINONIDE EMULSIFIED BASE

G AND W LABS INC	0.05%	A074204 001	Jun 13, 1995
------------------	-------	-------------	--------------

LIDEX

CNTY LINE PHARMS	0.05%	N016908 002	
------------------	-------	-------------	--

LIDEX-E

CNTY LINE PHARMS	0.05%	N016908 003	
------------------	-------	-------------	--

GEL; TOPICAL

LIDEX

CNTY LINE PHARMS	0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017373 001	
------------------	--	-------------	--

SOLUTION; TOPICAL

FLUOCINONIDE

TARO	0.05%	A072857 001	Aug 02, 1989
TEVA PHARMS	0.05%	A072522 001	Sep 28, 1990

FLUORESCIN SODIUM

INJECTABLE; INJECTION

FUNDUSCEIN-25

NOVARTIS	25% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017869 001	
----------	--	-------------	--

FLUOROMETHOLONE

CREAM; TOPICAL

OXYLONE

PHARMACIA AND UPJOHN	0.025%	N011748 001	
----------------------	--------	-------------	--

SUSPENSION/DROPS; OPHTHALMIC

FLUOR-OP

NOVARTIS	0.1%	A070185 001	Feb 27, 1986
----------	------	-------------	--------------

FLUOROMETHOLONE ACETATE; TOBRAMYCIN

SUSPENSION/DROPS; OPHTHALMIC

TOBRASONE

ALCON	0.1%; 0.3%	N050628 001	Jul 21, 1989
-------	------------	-------------	--------------

FLUOROMETHOLONE; SULFACETAMIDE SODIUM

SUSPENSION/DROPS; OPHTHALMIC

FML-S

ALLERGAN	0.1%; 10%	N019525 001	Sep 29, 1989
----------	-----------	-------------	--------------

FLUOROURACIL

INJECTABLE; INJECTION

ADRUCIL

PHARMACIA AND UPJOHN	50MG/ML	A081222 001	Jun 28, 1991
	50MG/ML	N017959 001	
TEVA PARENTERAL	50MG/ML	A040023 001	Oct 18, 1991
	50MG/ML	A081225 001	Aug 28, 1991

FLUOROURACIL

ABIC	50MG/ML	A088929 001	Mar 04, 1986
------	---------	-------------	--------------

ABRAXIS PHARM	50MG/ML	A089152 001	Mar 21, 1986
---------------	---------	-------------	--------------

	50MG/ML	A089428 001	Jan 12, 1987
--	---------	-------------	--------------

	50MG/ML	A089519 001	Mar 12, 1987
--	---------	-------------	--------------

BEDFORD	50MG/ML	A089508 001	Jan 26, 1988
---------	---------	-------------	--------------

EBEWE PHARMA	500MG/10ML (50MG/ML)	A040772 001	Aug 11, 2008
--------------	----------------------	-------------	--------------

FRESENIUS KABI USA	50MG/ML	A040291 001	Mar 24, 1999
--------------------	---------	-------------	--------------

	50MG/ML	A040379 001	Nov 15, 2000
--	---------	-------------	--------------

MARCHAR	50MG/ML	A087791 001	Jan 18, 1983
---------	---------	-------------	--------------

SMITH AND NEPHEW	50MG/ML	A088766 001	Dec 28, 1984
------------------	---------	-------------	--------------

	50MG/ML	A088767 001	Dec 28, 1984
--	---------	-------------	--------------

	50MG/ML	A089434 001	Mar 26, 1987
--	---------	-------------	--------------

SPECTRUM PHARMS	50MG/ML	A087792 001	Oct 13, 1982
-----------------	---------	-------------	--------------

	500MG/10ML (50MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012209 001	
--	---	-------------	--

SOLUTION; TOPICAL

FLUOROPLEX

ELORAC	1%	N016765 001	
--------	----	-------------	--

DISCONTINUED DRUG PRODUCT LIST

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE

SUN PHARM INDS	EQ 10MG BASE	A075787 001	Jan 29, 2002
	EQ 20MG BASE	A075787 002	Jan 29, 2002
WATSON LABS	EQ 10MG BASE	A075662 001	Jan 29, 2002
	EQ 20MG BASE	A075662 002	Jan 29, 2002

FLUOXETINE HYDROCHLORIDE

ANI PHARMS INC	EQ 10MG BASE	A076287 001	May 20, 2008
	EQ 20MG BASE	A076287 002	May 20, 2008
BARR	EQ 40MG BASE	A076251 001	May 18, 2005
CARLSBAD	EQ 10MG BASE	A076022 001	Jan 30, 2002
	EQ 20MG BASE	A076022 002	Jan 30, 2002
CR DOUBLE CRANE	EQ 10MG BASE	A076165 001	Feb 01, 2002
	EQ 20MG BASE	A076165 002	Feb 01, 2002
PAR PHARM	EQ 10MG BASE	A076922 001	Dec 16, 2004
	EQ 20MG BASE	A076922 002	Dec 16, 2004
SANDOZ	EQ 10MG BASE	A075807 001	Jan 29, 2002
	EQ 10MG BASE	A077469 001	Nov 17, 2008
	EQ 20MG BASE	A075807 002	Jan 29, 2002
	EQ 20MG BASE	A077469 002	Nov 17, 2008
WOCKHARDT LTD	EQ 10MG BASE	A078143 001	Jan 16, 2008
	EQ 20MG BASE	A078143 002	Jan 16, 2008
	EQ 40MG BASE	A078143 003	Jan 16, 2008

PROZAC

ELI LILLY AND CO	EQ 60MG BASE	N018936 004	Jun 15, 1999
------------------	--------------	-------------	--------------

SARAFEM

ELI LILLY AND CO	EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018936 007	Jul 06, 2000
	EQ 20MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018936 008	Jul 06, 2000

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	EQ 20MG BASE/5ML	A075690 001	Jan 31, 2002
APOTEX INC	EQ 20MG BASE/5ML	A075292 001	Feb 07, 2002
HI TECH PHARMA	EQ 20MG BASE/5ML	A075525 001	Jun 27, 2002
LANNETT	EQ 20MG BASE/5ML	A076458 001	May 14, 2004

PROZAC

LILLY	EQ 20MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020101 001	Apr 24, 1991
-------	--	-------------	--------------

TABLET; ORAL

FLUOXETINE HYDROCHLORIDE

BARR	EQ 10MG BASE	A075810 001	Feb 01, 2002
IVAX SUB TEVA PHARMS	EQ 10MG BASE	A075865 001	Feb 28, 2002
	EQ 40MG BASE	A075865 003	Aug 30, 2004
SANDOZ	EQ 10MG BASE	A076024 001	Jan 29, 2002

PROZAC

LILLY	EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020974 001	Mar 09, 1999
	EQ 20MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020974 002	Mar 09, 1999

FLUOXYMESTERONE

TABLET; ORAL

ANDROID-F

VALEANT PHARM INTL	10MG	A087196 001	
--------------------	------	-------------	--

FLUOXYMESTERONE

VALEANT PHARM INTL	10MG	A088221 001	May 05, 1983
WATSON LABS	2MG	A088260 001	Dec 06, 1983
	5MG	A088265 001	Dec 06, 1983
	10MG	A088309 001	Dec 06, 1983

HALOTESTIN

PHARMACIA AND UPJOHN	2MG	N010611 002	
	5MG	N010611 006	
	10MG	N010611 010	

DISCONTINUED DRUG PRODUCT LIST

FLUOXYMESTERONE

TABLET; ORAL

ORA-TESTRYL

BRISTOL MYERS SQUIBB	2MG	N011359	001
	5MG	N011359	002

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

HOSPIRA	25MG/ML	A074966	001	Apr 16, 1998
MYLAN LABS LTD	25MG/ML	A075918	001	Aug 17, 2001
TEVA PARENTERAL	25MG/ML	A074795	001	Sep 10, 1996

PROLIXIN DECANOATE

BRISTOL MYERS SQUIBB	25MG/ML	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016727	001
----------------------	---------	--	---------	-----

FLUPHENAZINE ENANTHATE

INJECTABLE; INJECTION

PROLIXIN ENANTHATE

APOTHECON	25MG/ML		N016110	001
-----------	---------	--	---------	-----

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

FLUPHENAZINE HYDROCHLORIDE

TEVA PHARMS	5MG/ML	A073058	001	Aug 30, 1991
-------------	--------	---------	-----	--------------

PERMITIL

SCHERING	5MG/ML		N016008	001
----------	--------	--	---------	-----

PROLIXIN

APOTHECON	5MG/ML	A070533	001	Nov 07, 1985
-----------	--------	---------	-----	--------------

ELIXIR; ORAL

FLUPHENAZINE HYDROCHLORIDE

ANI PHARMS INC	2.5MG/5ML	A081310	001	Apr 29, 1993
----------------	-----------	---------	-----	--------------

PROLIXIN

APOTHECON	2.5MG/5ML		N012145	003
-----------	-----------	--	---------	-----

INJECTABLE; INJECTION

PROLIXIN

APOTHECON	2.5MG/ML		N011751	005
-----------	----------	--	---------	-----

TABLET; ORAL

FLUPHENAZINE HYDROCHLORIDE

WATSON LABS	1MG	A088555	001	Dec 18, 1987
-------------	-----	---------	-----	--------------

	2.5MG	A088544	001	Dec 18, 1987
--	-------	---------	-----	--------------

	5MG	A088527	001	Dec 18, 1987
--	-----	---------	-----	--------------

	10MG	A088550	001	Dec 18, 1987
--	------	---------	-----	--------------

PERMITIL

SCHERING	0.25MG		N012034	001
----------	--------	--	---------	-----

	2.5MG		N012034	004
--	-------	--	---------	-----

	5MG		N012034	005
--	-----	--	---------	-----

	10MG		N012034	006
--	------	--	---------	-----

PROLIXIN

APOTHECON	1MG		N011751	004
-----------	-----	--	---------	-----

	2.5MG		N011751	001
--	-------	--	---------	-----

	5MG		N011751	003
--	-----	--	---------	-----

	10MG		N011751	002
--	------	--	---------	-----

TABLET, EXTENDED RELEASE; ORAL

PERMITIL

SCHERING	1MG		N012419	004
----------	-----	--	---------	-----

FLUPREDNISOLONE

TABLET; ORAL

ALPHADROL

PHARMACIA AND UPJOHN	1.5MG		N012259	002
----------------------	-------	--	---------	-----

FLURANDRENOLIDE

LOTION; TOPICAL

FLURANDRENOLIDE

ALPHARMA US PHARMS	0.05%	A087203	001	Apr 29, 1982
--------------------	-------	---------	-----	--------------

OINTMENT; TOPICAL

CORDRAN

AQUA PHARMS	0.025%	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012806	004
-------------	--------	--	---------	-----

DISCONTINUED DRUG PRODUCT LIST

FLURANDRENOLIDE; NEOMYCIN SULFATE

CREAM; TOPICAL

CORDRAN N

LILLY

0.05%;EQ 3.5MG BASE/GM

N050346 001

OINTMENT; TOPICAL

CORDRAN N

LILLY

0.05%;EQ 3.5MG BASE/GM

N050345 001

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

DALMANE

VALEANT PHARM INTL

15MG

N016721 001

30MG

N016721 002

FLURAZEPAM HYDROCHLORIDE

AUROLIFE PHARMA LLC

15MG

A071716 001 Jul 31, 1991

30MG

A071717 001 Jul 31, 1991

HALSEY

15MG

A071808 001 Jan 07, 1988

30MG

A071809 001 Jan 07, 1988

HIKMA INTL PHARMS

15MG

A071107 001 Dec 08, 1986

HIKMA PHARMS LLC

30MG

A071108 001 Dec 08, 1986

PAR PHARM

15MG

A070444 001 Mar 20, 1986

30MG

A070445 001 Mar 20, 1986

PUREPAC PHARM

15MG

A071927 001 Sep 09, 1987

30MG

A071551 001 Sep 09, 1987

SUN PHARM INDS

15MG

A070454 001 Aug 04, 1986

30MG

A070455 001 Aug 04, 1986

SUPERPHARM

15MG

A071659 001 Aug 04, 1988

30MG

A071660 001 Aug 04, 1988

USL PHARMA

15MG

A070562 001 Jul 09, 1987

30MG

A070563 001 Jul 09, 1987

WARNER CHILCOTT

15MG

A071767 001 Dec 04, 1987

30MG

A071768 001 Dec 04, 1987

WATSON LABS

15MG

A071205 001 Nov 25, 1986

15MG

A072368 001 Mar 30, 1989

30MG

A071068 001 Nov 25, 1986

30MG

A072369 001 Mar 30, 1989

FLURBIPROFEN

TABLET; ORAL

ANSAID

PHARMACIA AND UPJOHN

50MG

N018766 002 Oct 31, 1988

100MG

N018766 003 Oct 31, 1988

FLURBIPROFEN

AUROLIFE PHARMA LLC

50MG

A074448 001 Jul 28, 1995

100MG

A074448 002 Jul 28, 1995

IVAX SUB TEVA PHARMS

50MG

A074411 001 May 31, 1995

100MG

A074411 002 May 31, 1995

PLIVA

50MG

A074647 001 Apr 01, 1997

100MG

A074647 002 Apr 01, 1997

TEVA

50MG

A074405 002 May 24, 1995

100MG

A074405 001 May 24, 1995

THERAGEN

100MG

A074560 002 May 16, 1997

FLUTAMIDE

CAPSULE; ORAL

EULEXIN

SCHERING

125MG

N018554 001 Jan 27, 1989

FLUTAMIDE

SANDOZ

125MG

A075818 001 Sep 18, 2001

FLUTICASONE PROPIONATE

AEROSOL, METERED; INHALATION

FLOVENT

GLAXOSMITHKLINE

0.044MG/INH

N020548 001 Mar 27, 1996

0.11MG/INH

N020548 002 Mar 27, 1996

0.22MG/INH

N020548 003 Mar 27, 1996

CREAM; TOPICAL

CUTIVATE

FOUGERA PHARMS

0.05% **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N019958 001 Dec 18, 1990

FLUTICASONE PROPIONATE

NESHER PHARMS

0.05%

A076865 001 Sep 10, 2004

DISCONTINUED DRUG PRODUCT LIST

FLUTICASONE PROPIONATE

OINTMENT; TOPICAL

FLUTICASONE PROPIONATE

TARO PHARM INDS

0.005%

A077145 001 Jun 14, 2005

POWDER; INHALATION

FLOVENT

GLAXOSMITHKLINE

0.044MG/INH

N020549 001 Nov 07, 1997

0.088MG/INH

N020549 002 Nov 07, 1997

0.22MG/INH

N020549 003 Nov 07, 1997

SPRAY, METERED; NASAL

FLONASE

GLAXOSMITHKLINE

0.05MG/SPRAY

N020121 001 Oct 19, 1994

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

ACTAVIS ELIZABETH

25MG

A075901 001 Dec 28, 2000

50MG

A075901 002 Dec 28, 2000

100MG

A075901 003 Dec 28, 2000

ANI PHARMS INC

25MG

A075898 001 Mar 12, 2001

50MG

A075898 002 Mar 12, 2001

100MG

A075898 003 Mar 12, 2001

MYLAN

50MG

A075950 001 Oct 15, 2001

100MG

A075950 002 Oct 15, 2001

NOSTRUM LABS INC

25MG

A075900 001 Feb 23, 2006

50MG

A075900 002 Feb 23, 2006

100MG

A075900 003 Feb 23, 2006

SUN PHARM INDS

25MG

A076125 001 Apr 29, 2002

50MG

A076125 002 Apr 29, 2002

100MG

A076125 003 Apr 29, 2002

SYNTHON PHARMS

25MG

A075899 001 Jan 17, 2001

50MG

A075899 002 Jan 17, 2001

100MG

A075899 003 Jan 17, 2001

UPSHER-SMITH LABS

25MG

A075887 001 Jan 05, 2001

50MG

A075887 002 Jan 05, 2001

100MG

A075887 003 Jan 05, 2001

WATSON LABS

25MG

A075894 001 Apr 18, 2001

50MG

A075894 002 Apr 18, 2001

100MG

A075894 003 Apr 18, 2001

LUVOX

SOLVAY

25MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N020243 001 Dec 05, 1994

50MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N020243 002 Dec 05, 1994

100MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N020243 003 Dec 05, 1994

150MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N020243 004 Dec 05, 1994

FOLIC ACID

INJECTABLE; INJECTION

FOLIC ACID

BEN VENUE

5MG/ML

A081066 001 Dec 29, 1993

FOLVITE

WYETH PHARMS INC

5MG/ML

N005897 008

TABLET; ORAL

FOLIC ACID

BARR

1MG

A089177 001 Jan 08, 1986

EVERYLIFE

1MG

A080755 001

HALSEY

1MG

A083598 001

IMPAX LABS

1MG

A080686 001

IVAX SUB TEVA PHARMS

1MG

A083000 001

JUBILANT CADISTA

1MG

A040514 001 Jun 14, 2005

LANNETT

1MG

A080816 001

LILLY

1MG

N006135 003

MK LABS

1MG

A083526 001

NEXGEN PHARMA INC

1MG

A084915 001

DISCONTINUED DRUG PRODUCT LIST

FOLIC ACID

TABLET; ORAL

FOLIC ACID

PHARMERAL	1MG	A084158	001	
PIONEER PHARMS	1MG	A088949	001	Sep 13, 1985
PUREPAC PHARM	1MG	A080784	001	
SANDOZ	1MG	A084472	001	
SUN PHARM INDS	1MG	A040582	001	Jul 18, 2005
TABLICAPS	1MG	A083133	002	
UDL	1MG	A088199	001	Mar 29, 1983
USL PHARMA	1MG	A087828	001	May 13, 1982
VALEANT PHARM INTL	1MG	A080903	001	
VANGARD	1MG	A088730	001	Mar 23, 1984
VINTAGE PHARMS	1MG	A086296	001	
WATSON LABS	1MG	A083141	001	
	1MG	A085141	002	
WHITEWORTH TOWN PLSN	1MG	A080691	002	
FOLICET				
MISSION PHARMA	1MG	A087438	001	
FOLVITE				
WYETH PHARMS INC	1MG	N005897	004	

FOLLITROPIN ALFA/BETA

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

FOLLISTIM

ORGANON USA INC	75 IU/VIAL	N020582	001	Sep 29, 1997
	150 IU/VIAL	N020582	002	Sep 29, 1997

INJECTABLE; SUBCUTANEOUS

FOLLISTIM AQ

ORGANON USA INC	75 IU/0.5ML	N021273	001	Aug 26, 2005
	150 IU/0.18ML	N021211	003	Feb 11, 2004
	150 IU/0.5ML	N021273	002	Aug 26, 2005

GONAL-F

EMD SERONO	37.5 IU/VIAL	N020378	003	May 25, 2000
	37.5 IU/VIAL	N021765	001	Mar 25, 2004
	75 IU/VIAL	N020378	001	Sep 29, 1997
	150 IU/VIAL	N020378	002	Sep 29, 1997
	150 IU/VIAL	N021765	003	Mar 25, 2004

FOMEPIZOLE

INJECTABLE; INJECTION

FOMEPIZOLE

MYLAN INSTITUTIONAL	1.5GM/1.5ML (1GM/ML)	A079033	001	Apr 07, 2009
---------------------	----------------------	---------	-----	--------------

FOMIVIRSEN SODIUM

INJECTABLE; INJECTION

VITRAVENE PRESERVATIVE FREE

NOVARTIS	6.6MG/ML	N020961	001	Aug 26, 1998
----------	----------	---------	-----	--------------

FORMOTEROL FUMARATE

POWDER; INHALATION

FORADIL CERTIHALER

NOVARTIS	0.0085MG/INH	N021592	001	Dec 15, 2006
----------	--------------	---------	-----	--------------

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS

EMEND

MERCK AND CO INC	EQ 115MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N022023	001	Jan 25, 2008
------------------	---	---------	-----	--------------

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

ACTAVIS LABS FL INC	10MG	A076620	001	Oct 15, 2004
	20MG	A076620	002	Oct 15, 2004
	40MG	A076620	003	Oct 15, 2004
RANBAXY LABS LTD	10MG	A076580	001	Apr 23, 2004
	20MG	A076580	002	Apr 23, 2004
	40MG	A076580	003	Apr 23, 2004
UPSHER-SMITH LABS	10MG	A076188	001	Oct 08, 2004
	20MG	A076188	002	Oct 08, 2004
	40MG	A076188	003	Oct 08, 2004
WATSON LABS	10MG	A076987	001	Dec 23, 2004
	10MG	A077531	001	Aug 31, 2006

DISCONTINUED DRUG PRODUCT LISTFOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

20MG	A076987 002	Dec 23, 2004
20MG	A077531 002	Aug 31, 2006
40MG	A076987 003	Dec 23, 2004
40MG	A077531 003	Aug 31, 2006

MONOPRIL

BRISTOL MYERS SQUIBB

10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019915 002	May 16, 1991
20MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019915 003	May 16, 1991
40MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019915 004	Mar 28, 1995

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

ACTAVIS LABS FL INC

10MG;12.5MG	A076608 001	Dec 03, 2004
20MG;12.5MG	A076608 002	Dec 03, 2004

MYLAN

10MG;12.5MG	A077705 001	Aug 14, 2006
20MG;12.5MG	A077705 002	Aug 14, 2006

SUN PHARM INDS LTD

10MG;12.5MG	A076739 001	Dec 17, 2004
20MG;12.5MG	A076739 002	Dec 17, 2004

TEVA

10MG;12.5MG	A076945 001	Jul 05, 2006
20MG;12.5MG	A076945 002	Jul 05, 2006

WATSON LABS

10MG;12.5MG	A077144 001	Aug 16, 2005
20MG;12.5MG	A077144 002	Aug 16, 2005

MONOPRIL-HCT

BRISTOL MYERS SQUIBB

10MG;12.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020286 002	Nov 30, 1994
20MG;12.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020286 001	Nov 30, 1994

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

APOTEX INC

EQ 50MG PHENYTOIN NA/ML	A078126 001	Aug 06, 2007
-------------------------	-------------	--------------

FRESENIUS KABI USA

EQ 50MG PHENYTOIN NA/ML	A078052 001	Aug 06, 2007
-------------------------	-------------	--------------

TEVA PHARMS USA

EQ 50MG PHENYTOIN NA/ML	A076886 001	Aug 06, 2007
-------------------------	-------------	--------------

FOSPROPOFOL DISODIUM

SOLUTION; INTRAVENOUS

LUSEDRA

EISAI INC

1050MG/30ML (35MG/ML)	N022244 001	Dec 12, 2008
-----------------------	-------------	--------------

FURAZOLIDONE

SUSPENSION; ORAL

FUROXONE

SHIRE

50MG/15ML	N011323 002	
-----------	-------------	--

TABLET; ORAL

FUROXONE

SHIRE

100MG	N011270 002	
-------	-------------	--

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

ABRAXIS PHARM

10MG/ML	N018507 001	Jul 30, 1982
---------	-------------	--------------

10MG/ML	N019036 001	Aug 13, 1984
---------	-------------	--------------

ASTRAZENECA

10MG/ML	A070014 001	Sep 09, 1985
---------	-------------	--------------

HOSPIRA

10MG/ML	A070578 001	Jul 08, 1987
---------	-------------	--------------

10MG/ML	A072080 001	Aug 13, 1991
---------	-------------	--------------

10MG/ML	A074337 001	Oct 31, 1994
---------	-------------	--------------

IGI LABS INC

10MG/ML	A070095 001	Sep 09, 1985
---------	-------------	--------------

10MG/ML	A070096 001	Sep 09, 1985
---------	-------------	--------------

INTL MEDICATION

10MG/ML	N018025 001	
---------	-------------	--

LUITPOLD

10MG/ML **Federal Register	N018579 001	Nov 30, 1983
----------------------------	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

determination that product was not discontinued or withdrawn for safety or efficacy reasons**

MARSAM PHARMS LLC	10MG/ML	A074017 001	Jun 30, 1994
ORGANON USA INC	10MG/ML	A070017 001	Dec 15, 1986
SMITH AND NEPHEW	10MG/ML	A070023 001	Feb 05, 1986
	10MG/ML	A070078 001	Feb 05, 1986
WARNER CHILCOTT	10MG/ML	N018420 001	Feb 26, 1982
WATSON LABS	10MG/ML	A070019 001	Sep 22, 1986
	10MG/ML	A070604 001	Jan 02, 1987
WEST-WARD PHARMS INT	10MG/ML	A071439 001	Sep 14, 1990
	10MG/ML	N018267 001	
WYETH AYERST	10MG/ML	N018670 001	Jul 20, 1982

LASIX

SANOVI AVENTIS US	10MG/ML **Federal Register	N016363 001	
-------------------	----------------------------	-------------	--

determination that product was not discontinued or withdrawn for safety or efficacy reasons**

SOLUTION; ORAL

LASIX

SANOVI AVENTIS US	10MG/ML	N017688 001	
-------------------	---------	-------------	--

TABLET; ORAL

FUROSEMIDE

DAVA PHARMS INC	20MG	N018415 001	Jul 27, 1982
	40MG	N018415 002	Jul 27, 1982
	80MG	N018415 003	Nov 26, 1984
INTL MEDICATION	20MG	N018753 001	Feb 28, 1984
	40MG	N018753 002	Feb 28, 1984
KALAPHARM	20MG	N018868 001	Jun 28, 1983
	40MG	N018868 002	Jun 28, 1983
MUTUAL PHARM	40MG	N018790 001	Nov 29, 1983
SANDOZ	40MG	N018750 002	Jul 30, 1984
SUN PHARM INDS	20MG	A070043 001	Sep 26, 1985
	80MG	A070100 001	Jan 26, 1988
SUPERPHARM	20MG	N018370 002	Jun 26, 1984
	40MG	N018370 001	Feb 10, 1983
WARNER CHILCOTT	20MG	N018419 001	Jan 31, 1983
	40MG	N018419 002	Jan 31, 1983
	80MG	N018419 003	Nov 13, 1984
WATSON LABS	20MG	A070412 001	Feb 26, 1986
	20MG	A070449 001	Nov 22, 1985
	20MG	A071379 001	Jan 02, 1987
	20MG	N018369 001	May 14, 1982
	40MG	A070413 001	Feb 26, 1986
	40MG	A070450 001	Nov 22, 1985
	40MG	N018369 002	May 14, 1982
	80MG	A070528 001	Jan 07, 1986
	80MG	A071594 001	Feb 09, 1988

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

HIKMA	100MG	A078150 001	Sep 25, 2007
	300MG	A078150 002	Sep 25, 2007
	400MG	A078150 003	Sep 25, 2007
IVAX SUB TEVA PHARMS	100MG	A075477 001	Mar 23, 2005
	300MG	A075477 002	Mar 23, 2005
	400MG	A075477 003	Mar 23, 2005
SANDOZ	100MG	A075428 001	Jan 24, 2006
	100MG	A075539 001	Apr 06, 2005
	300MG	A075428 002	Jan 24, 2006
	300MG	A075539 002	Apr 06, 2005
	400MG	A075428 003	Jan 24, 2006
	400MG	A075539 003	Apr 06, 2005
SUN PHARM INDS	100MG	A076537 001	Jun 30, 2005
	300MG	A076537 002	Jun 30, 2005
	400MG	A076537 003	Jun 30, 2005
SUN PHARM INDS LTD	100MG	A076606 001	Oct 07, 2005
	300MG	A076606 002	Oct 07, 2005
	400MG	A076606 003	Oct 07, 2005
WATSON LABS	100MG	A075485 003	May 11, 2007

DISCONTINUED DRUG PRODUCT LISTGABAPENTIN

CAPSULE; ORAL

GABAPENTIN

300MG	A075485 002	May 11, 2007
400MG	A075485 001	May 11, 2007

TABLET; ORAL

GABAPENTIN

HIKMA PHARMS	600MG	A078782 001	Jul 21, 2011
	800MG	A078782 002	Jul 21, 2011
RANBAXY	600MG	A076605 001	Sep 14, 2005
	800MG	A076605 002	Sep 14, 2005
SANDOZ	600MG	A076120 001	Jan 27, 2006
	600MG	A076877 001	Jul 06, 2006
	800MG	A076120 002	Jan 27, 2006
	800MG	A076877 002	Jul 06, 2006
TEVA	600MG	A075827 001	Dec 15, 2004
	800MG	A075827 002	Dec 15, 2004

GADODIAMIDE

INJECTABLE; INJECTION

OMNISCAN

GE HEALTHCARE	14.35GM/50ML (287MG/ML)	N022066 001	Sep 05, 2007
---------------	-------------------------	-------------	--------------

GADOFOSVESET TRISODIUM

SOLUTION; INTRAVENOUS

ABLAVAR

LANTHEUS MEDCL	2440MG/10ML (244MG/ML)	N021711 001	Dec 22, 2008
	3660MG/15ML (244MG/ML)	N021711 002	Dec 22, 2008

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL

GALANTAMINE HYDROBROMIDE

IMPAX LABS	EQ 8MG BASE	A078484 001	May 27, 2009
	EQ 16MG BASE	A078484 002	May 27, 2009
	EQ 24MG BASE	A078484 003	May 27, 2009

SOLUTION; ORAL

RAZADYNE

JANSSEN PHARMS	4MG/ML	N021224 001	Jun 22, 2001
----------------	--------	-------------	--------------

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

ACTAVIS ELIZABETH	EQ 4MG BASE	A077585 001	Sep 15, 2009
	EQ 8MG BASE	A077585 002	Sep 15, 2009
	EQ 12MG BASE	A077585 003	Sep 15, 2009
YABAO PHARM	EQ 4MG BASE	A077604 001	Feb 06, 2009
	EQ 8MG BASE	A077604 002	Feb 06, 2009
	EQ 12MG BASE	A077604 003	Feb 06, 2009

GALLAMINE TRIETHIODIDE

INJECTABLE; INJECTION

FLAXEDIL

DAVIS AND GECK	20MG/ML	N007842 001
	100MG/ML	N007842 002

GALLIUM CITRATE GA-67

INJECTABLE; INJECTION

GALLIUM CITRATE GA 67

GE HEALTHCARE	1mCi/ML	N017700 001
NEOSCAN		
GE HEALTHCARE	2mCi/ML	N017655 001

GALLIUM NITRATE

INJECTABLE; INJECTION

GANITE

CHAPTER 7 TRUSTEE	25MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019961 002	Jan 17, 1991
-------------------	--	-------------	--------------

GANCICLOVIR

CAPSULE; ORAL

CYTOVENE

ROCHE PALO	250MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020460 001	Dec 22, 1994
	500MG **Federal Register determination that product was not discontinued or	N020460 002	Dec 12, 1997

DISCONTINUED DRUG PRODUCT LIST

GANCICLOVIRCAPSULE; ORAL
CYTOVENEwithdrawn for safety or efficacy
reasons**

GANCICLOVIR

RANBAXY LABS LTD
250MG
500MGA076457 001 Jun 27, 2003
A076457 002 Jun 27, 2003

IMPLANT; IMPLANTATION

VITRASERT

BAUSCH AND LOMB
4.5MG

N020569 001 Mar 04, 1996

GANCICLOVIR SODIUM

INJECTABLE; INJECTION

GANCICLOVIR SODIUM

WEST-WARD PHARMS INT
EQ 500MG BASE/VIAL

A076222 001 Jul 16, 2003

GATIFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

GATIFLOXACIN

APOTEX INC
0.3%

A079084 001 Aug 19, 2011

GEFITINIB

TABLET; ORAL

IRESSA

ASTRAZENECA
250MG

N021399 001 May 05, 2003

GEMFIBROZIL

CAPSULE; ORAL

GEMFIBROZIL

MYLAN
300MG
PUREPAC PHARM
300MGA073466 001 Jan 25, 1993
A072929 001 Jan 29, 1993

LOPID

PFIZER PHARMS
200MG
300MGN018422 001
N018422 002

TABLET; ORAL

GEMFIBROZIL

MYLAN
600MG
PUREPAC PHARM
600MG
SANDOZ
600MG
WATSON LABS
600MGA074452 001 Feb 16, 1995
A074360 001 Aug 31, 1994
A074615 001 Sep 29, 1995
A074156 001 Oct 24, 1994
A074442 001 Apr 28, 1995GEMTUZUMAB OZOGAMICIN

INJECTABLE; INJECTION

MYLOTARG

WYETH PHARMS INC
5MG/VIAL

N021174 001 May 17, 2000

GENTAMICIN SULFATE

CREAM; TOPICAL

GARAMYCIN

SCHERING
EQ 0.1% BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

A060462 001

GENTAFAIR

PHARMAFAIR
EQ 0.1% BASE

A062458 001 Sep 01, 1983

GENTAMICIN SULFATE

ALPHARMA US PHARMS
EQ 0.1% BASE

A062471 001 Sep 27, 1983

PHARMADERM
EQ 1MG BASE/GM

A062530 001 Jul 05, 1984

INJECTABLE; INJECTION

APOGEN

KING PHARMS
EQ 10MG BASE/ML
EQ 40MG BASE/MLA062289 001
A062289 002

BRISTAGEN

BRISTOL
EQ 40MG BASE/ML

A062288 001

GARAMYCIN

SCHERING
EQ 1MG BASE/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

A061716 002

EQ 10MG BASE/ML **Federal Register

A061739 001

determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

EQ 40MG BASE/ML **Federal Register

A061716 001

determination that product was not

DISCONTINUED DRUG PRODUCT LIST

GENTAMICIN SULFATE

INJECTABLE; INJECTION

GARAMYCIN

discontinued or withdrawn for safety or efficacy reasons**

GENTAFAIR

PHARMAFAIR

EQ 40MG BASE/ML

A062493 001 Aug 28, 1985

GENTAMICIN

INTL MEDICATION

EQ 1MG BASE/ML

A062325 003 Jun 23, 1982

EQ 40MG BASE/ML

A062325 001

EQ 100MG BASE/100ML

A062325 004 Jun 23, 1982

GENTAMICIN SULFATE

ABBOTT

EQ 1.2MG BASE/ML

A062413 001 Aug 11, 1983

EQ 1.4MG BASE/ML

A062413 002 Aug 11, 1983

EQ 1.6MG BASE/ML

A062413 003 Aug 11, 1983

EQ 1.8MG BASE/ML

A062413 004 Aug 11, 1983

EQ 2MG BASE/ML

A062413 005 Aug 11, 1983

EQ 60MG BASE/100ML

A062413 006 Aug 11, 1983

EQ 70MG BASE/100ML

A062413 007 Aug 11, 1983

EQ 80MG BASE/100ML

A062413 008 Aug 11, 1983

EQ 90MG BASE/100ML

A062413 009 Aug 11, 1983

EQ 100MG BASE/100ML

A062413 010 Aug 11, 1983

FRESENIUS KABI USA

EQ 10MG BASE/ML

A062356 001 Mar 04, 1982

EQ 40MG BASE/ML

A062356 002 Mar 04, 1982

KALAPHARM

EQ 40MG BASE/ML

A062354 001 Apr 05, 1982

PHARM SPEC

EQ 40MG BASE/ML

A062340 001 Mar 28, 1983

SOLOPAK

EQ 10MG BASE/ML

A062507 001 Jun 06, 1985

EQ 40MG BASE/ML

A062507 002 Jun 06, 1985

TEVA PARENTERAL

EQ 10MG BASE/ML

A063149 001 Nov 21, 1991

EQ 40MG BASE/ML

A063106 002 Nov 21, 1991

WATSON LABS

EQ 10MG BASE/ML

A062318 002

EQ 40MG BASE/ML

A062318 001

WEST-WARD PHARMS INT

EQ 10MG BASE/ML

A062251 002

EQ 40MG BASE/ML

A062251 001

WYETH AYERST

EQ 10MG BASE/ML

A062264 001

EQ 40MG BASE/ML

A062264 002

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN

EQ 0.8MG BASE/ML

A062814 001 Aug 28, 1987

EQ 1.2MG BASE/ML

A062814 002 Aug 28, 1987

EQ 1.4MG BASE/ML

A062814 003 Aug 28, 1987

EQ 1.6MG BASE/ML

A062814 004 Aug 28, 1987

EQ 1.8MG BASE/ML

A062814 005 Aug 28, 1987

EQ 2MG BASE/ML

A062814 006 Aug 28, 1987

EQ 2.4MG BASE/ML

A062814 007 Aug 28, 1987

EQ 40MG BASE/100ML

A062814 008 Aug 28, 1987

EQ 60MG BASE/100ML

A062814 009 Aug 28, 1987

EQ 70MG BASE/100ML

A062814 010 Aug 28, 1987

EQ 80MG BASE/100ML

A062814 011 Aug 28, 1987

EQ 90MG BASE/100ML

A062814 012 Aug 28, 1987

EQ 100MG BASE/100ML

A062814 013 Aug 28, 1987

EQ 120MG BASE/100ML

A062814 014 Aug 28, 1987

BAXTER HLTHCARE

EQ 0.8MG BASE/ML

A062373 001 Sep 07, 1982

EQ 2.4MG BASE/ML

A062373 010 Sep 07, 1982

EQ 40MG BASE/100ML

A062373 003 Sep 07, 1982

EQ 60MG BASE/100ML

A062373 004 Sep 07, 1982

HOSPIRA

EQ 1.2MG BASE/ML

A062588 001 Jan 06, 1986

EQ 1.4MG BASE/ML

A062414 002 Aug 15, 1983

EQ 1.4MG BASE/ML

A062588 002 Jan 06, 1986

EQ 1.6MG BASE/ML

A062588 003 Jan 06, 1986

EQ 1.8MG BASE/ML

A062414 004 Aug 15, 1983

EQ 1.8MG BASE/ML

A062588 004 Jan 06, 1986

EQ 2MG BASE/ML

A062414 005 Aug 15, 1983

EQ 2MG BASE/ML

A062588 005 Jan 06, 1986

EQ 60MG BASE/100ML

A062414 006 Aug 15, 1983

EQ 60MG BASE/100ML

A062588 006 Jan 06, 1986

EQ 70MG BASE/100ML

A062414 007 Aug 15, 1983

EQ 70MG BASE/100ML

A062588 007 Jan 06, 1986

EQ 80MG BASE/100ML

A062588 008 Jan 06, 1986

EQ 90MG BASE/100ML

A062414 009 Aug 15, 1983

EQ 90MG BASE/100ML

A062588 009 Jan 06, 1986

EQ 100MG BASE/100ML

A062588 010 Jan 06, 1986

DISCONTINUED DRUG PRODUCT LIST

GENTAMICIN SULFATE

INJECTABLE; INJECTION

U-GENCIN

PHARMACIA AND UPJOHN	EQ 10MG BASE/ML	A062248	001	
	EQ 40MG BASE/ML	A062248	002	

INJECTABLE; INTRATHECAL

GARAMYCIN

SCHERING	EQ 2MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050505	001	
----------	---	---------	-----	--

OINTMENT; OPHTHALMIC

GARAMYCIN

SCHERING	EQ 0.3% BASE	N050425	001	
----------	--------------	---------	-----	--

GENTACIDIN

NOVARTIS	EQ 0.3% BASE	A062501	001	Jul 26, 1984
----------	--------------	---------	-----	--------------

GENTAFAIR

PHARMAFAIR	EQ 3MG BASE/GM	A062443	001	May 26, 1983
------------	----------------	---------	-----	--------------

OINTMENT; TOPICAL

GARAMYCIN

SCHERING	EQ 0.1% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A060463	001	
----------	---	---------	-----	--

GENTAFAIR

PHARMAFAIR	EQ 0.1% BASE	A062444	001	May 26, 1983
------------	--------------	---------	-----	--------------

GENTAMICIN SULFATE

ALPHARMA US PHARMS	EQ 0.1% BASE	A062496	001	Mar 14, 1984
--------------------	--------------	---------	-----	--------------

G AND W LABS INC	EQ 0.1% BASE	A064054	001	Apr 29, 1994
------------------	--------------	---------	-----	--------------

PHARMADERM	EQ 0.1% BASE	A062534	001	Oct 10, 1984
------------	--------------	---------	-----	--------------

SOLUTION/DROPS; OPHTHALMIC

GARAMYCIN

SCHERING	EQ 0.3% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050039	002	
----------	---	---------	-----	--

GENTACIDIN

NOVARTIS	EQ 0.3% BASE	A062480	001	Mar 30, 1984
----------	--------------	---------	-----	--------------

GENTAFAIR

PHARMAFAIR	EQ 0.3% BASE	A062440	001	May 03, 1983
------------	--------------	---------	-----	--------------

GENTAMICIN SULFATE

ALCON PHARMS LTD	EQ 0.3% BASE	A062523	001	Nov 25, 1985
------------------	--------------	---------	-----	--------------

PACO	EQ 3MG BASE/ML	A062932	001	Nov 07, 1988
------	----------------	---------	-----	--------------

GENTIAN VIOLET

SUPPOSITORY; VAGINAL

GVS

SAVAGE LABS	0.4%	A083513	001	
-------------	------	---------	-----	--

TAMPON; VAGINAL

GENAPAX

KEY PHARMS	5MG	A085017	001	
------------	-----	---------	-----	--

GLATIRAMER ACETATE

FOR SOLUTION; SUBCUTANEOUS

COPAXONE

TEVA PHARMS USA	20MG/VIAL	N020622	001	Dec 20, 1996
-----------------	-----------	---------	-----	--------------

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

ACTAVIS LABS FL INC	1MG	A076995	001	Apr 27, 2010
---------------------	-----	---------	-----	--------------

	2MG	A076995	002	Apr 27, 2010
--	-----	---------	-----	--------------

	4MG	A076995	003	Apr 27, 2010
--	-----	---------	-----	--------------

COREPHARMA	1MG	A077274	001	Oct 06, 2005
------------	-----	---------	-----	--------------

	2MG	A077274	002	Oct 06, 2005
--	-----	---------	-----	--------------

	4MG	A077274	003	Oct 06, 2005
--	-----	---------	-----	--------------

HIKMA PHARMS	1MG	A078952	001	Aug 01, 2013
--------------	-----	---------	-----	--------------

	2MG	A078952	002	Aug 01, 2013
--	-----	---------	-----	--------------

	4MG	A078952	003	Aug 01, 2013
--	-----	---------	-----	--------------

MYLAN	1MG	A077486	001	Feb 10, 2006
-------	-----	---------	-----	--------------

	2MG	A077486	002	Feb 10, 2006
--	-----	---------	-----	--------------

	4MG	A077486	003	Feb 10, 2006
--	-----	---------	-----	--------------

RANBAXY	3MG	A077366	001	Oct 06, 2005
---------	-----	---------	-----	--------------

	6MG	A077366	002	Oct 06, 2005
--	-----	---------	-----	--------------

RANBAXY LABS LTD	1MG	A076875	001	Oct 06, 2005
------------------	-----	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LISTGLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

	2MG	A076875 002	Oct 06, 2005
	4MG	A076875 003	Oct 06, 2005
	8MG	A076875 004	Oct 06, 2005
WATSON LABS	1MG	A077280 001	Feb 03, 2006
	2MG	A077280 002	Feb 03, 2006
	4MG	A077280 003	Feb 03, 2006

GLIMEPIRIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDARYL

SB PHARMCO

1MG;4MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021700 001	Nov 23, 2005
2MG;4MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021700 002	Nov 23, 2005
2MG;8MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021700 004	Mar 30, 2007
4MG;4MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021700 003	Nov 23, 2005
4MG;8MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021700 005	Mar 30, 2007

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

ANI PHARMS INC

BARR LABS INC

SANDOZ

VINTAGE PHARMS LLC

WATSON LABS

GLUCOTROL

PFIZER

5MG	A074387 001	Mar 04, 1996
10MG	A074387 002	Mar 04, 1996
5MG	A074619 001	Apr 04, 1997
10MG	A074619 002	Apr 04, 1997
5MG	A074542 001	Jun 20, 1995
10MG	A074542 002	Jun 20, 1995
5MG	A074378 001	Nov 28, 1994
10MG	A074378 002	Nov 28, 1994
5MG	A074370 001	Nov 22, 1994
10MG	A074370 002	Nov 22, 1994
2.5MG	N017783 003	May 11, 1993

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

METAGLIP

BRISTOL MYERS SQUIBB

2.5MG;250MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021460 001	Oct 21, 2002
2.5MG;500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021460 002	Oct 21, 2002
5MG;500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021460 003	Oct 21, 2002

GLUCAGON HYDROCHLORIDE

INJECTABLE; INJECTION

GLUCAGON

LILLY

EQ 1MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012122 001
EQ 10MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012122 002

DISCONTINUED DRUG PRODUCT LISTGLUTETHIMIDE

CAPSULE; ORAL

DORIDEN

SANOFI AVENTIS US	500MG	N009519	008	
-------------------	-------	---------	-----	--

TABLET; ORAL

DORIDEN

SANOFI AVENTIS US	250MG	N009519	002	
	500MG	N009519	005	

GLUTETHIMIDE

HALSEY	250MG	A089458	001	Oct 10, 1986
	500MG	A089459	001	Oct 10, 1986
LANNETT	250MG	A083475	001	
	500MG	A085571	001	
UCB INC	500MG	A085171	001	
UPSHER-SMITH LABS	500MG	A083234	002	
VITARINE	500MG	A087297	001	
WATSON LABS	500MG	A084362	001	
	500MG	A085763	001	

GLYBURIDE

TABLET; ORAL

GLYBURIDE

ACTAVIS ELIZABETH	1.5MG	A075947	001	Nov 14, 2002
	3MG	A075947	002	Nov 14, 2002
	6MG	A075947	003	Nov 14, 2002

GLYBURIDE (MICRONIZED)

SANDOZ

SANDOZ	1.5MG	A075174	001	Jun 22, 1998
	3MG	A075174	002	Jun 22, 1998
SANOFI AVENTIS US	1.5MG	N020055	001	Apr 17, 1992
	3MG	N020055	002	Apr 17, 1992
	6MG	N020055	003	Mar 08, 2000

GLYNASE

PHARMACIA AND UPJOHN

4.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020051	003	Sep 24, 1993
--	---------	-----	--------------

MICRONASE

PHARMACIA AND UPJOHN

1.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017498	001	May 01, 1984
2.5MG	N017498	002	May 01, 1984
5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017498	003	May 01, 1984

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLUCOVANCE

BRISTOL MYERS SQUIBB	1.25MG;250MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021178	001	Jul 31, 2000
----------------------	---	---------	-----	--------------

GLYBURIDE AND METFORMIN HYDROCHLORIDE

COREPHARMA

1.25MG;250MG	A076731	001	Nov 19, 2004
2.5MG;500MG	A076731	002	Nov 19, 2004
5MG;500MG	A076731	003	Nov 19, 2004

TEVA

1.25MG;250MG	A076821	001	Jan 27, 2005
2.5MG;500MG	A076821	002	Jan 27, 2005
5MG;500MG	A076821	003	Jan 27, 2005

GLYCINE

SOLUTION; IRRIGATION

GLYCINE 1.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	1.5GM/100ML	N018522	001	Feb 19, 1982
HOSPIRA	1.5GM/100ML	N017633	001	

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

ABRAXIS PHARM	0.2MG/ML	A088475	001	Jun 12, 1984
HOSPIRA	0.2MG/ML	A089393	001	Jun 15, 1988
TEVA PARENTERAL	0.2MG/ML	A081169	001	Sep 10, 1991
WATSON LABS	0.2MG/ML	A086947	001	Jun 24, 1983

DISCONTINUED DRUG PRODUCT LISTGLYCOPYRROLATE

INJECTABLE; INJECTION

ROBINUL

ROBINS AH	0.2MG/ML	N014764	001	
WEST-WARD PHARMS INT	0.2MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017558	001	

TABLET; ORAL

GLYCOPYRROLATE

COREPHARMA	1MG	A040568	001	Dec 22, 2004
	2MG	A040568	002	Dec 22, 2004
HIKMA INTL PHARMS	1MG	A040836	001	Mar 05, 2009
	2MG	A040836	002	Mar 05, 2009
WATSON LABS	1MG	A085562	001	
	1MG	A086902	001	
	2MG	A085563	001	
	2MG	A086178	001	
	2MG	A086900	001	

GONADORELIN ACETATE

INJECTABLE; INJECTION

LUTREPULSE KIT

FERRING	0.8MG/VIAL	N019687	001	Oct 10, 1989
	3.2MG/VIAL	N019687	002	Oct 10, 1989

GONADORELIN HYDROCHLORIDE

INJECTABLE; INJECTION

FACTREL

HIKMA (MAPLE)	EQ 0.1MG BASE/VIAL	N018123	001	Sep 30, 1982
	EQ 0.2MG BASE/VIAL	N018123	002	Sep 30, 1982
	EQ 0.5MG BASE/VIAL	N018123	003	Sep 30, 1982

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION

A.P.L.

FERRING	5,000 UNITS/VIAL	N017055	001	
	10,000 UNITS/VIAL	N017055	002	
	20,000 UNITS/VIAL	N017055	003	

CHORIONIC GONADOTROPIN

BEL MAR	5,000 UNITS/VIAL	N017054	001	
	10,000 UNITS/VIAL	N017054	002	
FERRING	2,000 UNITS/VIAL	N017016	009	Dec 27, 1984
	2,000 UNITS/VIAL	N017016	011	Feb 16, 1990
	5,000 UNITS/VIAL	N017016	006	
	15,000 UNITS/VIAL	N017016	010	Feb 15, 1985
	20,000 UNITS/VIAL	N017016	004	
FRESENIUS KABI USA	5,000 UNITS/VIAL	N017067	001	
	15,000 UNITS/VIAL	N017067	004	
	20,000 UNITS/VIAL	N017067	003	

FOLLUTEIN

BRISTOL MYERS SQUIBB	10,000 UNITS/VIAL	N017056	001	
----------------------	-------------------	---------	-----	--

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

NEO-POLYCIN

DOW PHARM	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A060427	001	
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN				
IPHARM	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A062818	001	Oct 11, 1988
WATSON LABS	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A062788	001	Jun 11, 1987
NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN				
PHARMAFAIR	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A062383	001	Aug 31, 1982

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

CLARIS	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078197	001	Dec 31, 2007
	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078198	001	Jun 30, 2008
	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078198	002	Jun 30, 2008
SANDOZ INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078808	001	Apr 29, 2008
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE				
TEVA PHARMS USA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077165	001	Dec 31, 2007

DISCONTINUED DRUG PRODUCT LIST

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

KYTRIL

ROCHE

EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)

N020239 003 Sep 17, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

EQ 1MG BASE/ML (EQ 1MG BASE/ML)

N020239 004 Mar 11, 1994

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

EQ 3MG BASE/ML **Federal Register

N020239 001 Dec 29, 1993

determination that product was not discontinued or withdrawn for safety or efficacy reasons**

EQ 4MG BASE/4ML (EQ 1MG BASE/ML)

N020239 002 Mar 11, 1994

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

SOLUTION; ORAL

GRANISOL

PEDIATRAX

EQ 2MG BASE/10ML

A078334 001 Feb 28, 2008

KYTRIL

ROCHE

EQ 2MG BASE/10ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N021238 001 Jun 27, 2001

TABLET; ORAL

GRANISETRON HYDROCHLORIDE

BARR

EQ 1MG BASE

A078221 001 Dec 31, 2007

COREPHARMA

EQ 1MG BASE

A078260 001 Dec 31, 2007

KYTRIL

ROCHE

EQ 1MG BASE **Federal Register determination that product was not withdrawn or discontinued for safety or efficacy reasons**

N020305 001 Mar 16, 1995

EQ 2MG BASE **Federal Register

N020305 002 Jun 15, 1998

determination that product was not withdrawn or discontinued for safety or efficacy reasons**

GREPAFLOXACIN HYDROCHLORIDE

TABLET; ORAL

RAXAR

OTSUKA

EQ 200MG BASE

N020695 001 Nov 06, 1997

EQ 400MG BASE

N020695 002 May 14, 1998

EQ 600MG BASE

N020695 003 May 14, 1998

GRISEOFULVIN, MICROCRYSTALLINE

CAPSULE; ORAL

GRISACTIN

WYETH AYERST

125MG

N050051 002

250MG

N050051 001

SUSPENSION; ORAL

GRIFULVIN V

JOHNSON AND JOHNSON

125MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N050448 001

TABLET; ORAL

FULVICIN-U/F

ELORAC

250MG

A060569 002

500MG

A060569 001

GRIFULVIN V

J AND J

125MG

A060618 001

250MG

A060618 002

500MG

A060618 003

VALEANT LUXEMBOURG

125MG

A062279 001

250MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

A062279 002

GRISACTIN

WYETH AYERST

500MG

A060212 001

DISCONTINUED DRUG PRODUCT LISTGRISEOFULVIN, MICROSIZE

SUSPENSION;ORAL

GRIFULVIN V

VALEANT LUXEMBOURG

125MG/5ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

A062483 001 Jan 26, 1984

TABLET;ORAL

GRIFULVIN V

VALEANT LUXEMBOURG

500MG

A062279 003

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET;ORAL

FULVICIN P/G

ELORAC

125MG

A061996 001

250MG

A061996 002

FULVICIN P/G 165

ELORAC

165MG

A061996 003 Apr 06, 1982

FULVICIN P/G 330

ELORAC

330MG

A061996 004 Apr 06, 1982

GRISACTIN ULTRA

WYETH AYERST

125MG

A062178 001

165MG

A062438 001 Nov 17, 1983

250MG

A062178 002

330MG

A062438 002 Nov 17, 1983

ULTRAGRIS-165

PLIVA

165MG

A062645 001 Jun 30, 1992

ULTRAGRIS-330

PLIVA

330MG

A062646 001 Jun 30, 1992

GUANABENZ ACETATE

TABLET;ORAL

GUANABENZ ACETATE

ANI PHARMS INC

EQ 4MG BASE

A074267 001 Jun 01, 1994

EQ 8MG BASE

A074267 002 Jun 01, 1994

SANDOZ

EQ 4MG BASE

A074517 001 Sep 30, 1998

EQ 8MG BASE

A074517 002 Sep 30, 1998

WATSON LABS

EQ 4MG BASE

A074025 001 Feb 28, 1994

EQ 8MG BASE

A074025 002 Feb 28, 1994

WYTENSIN

WYETH AYERST

EQ 4MG BASE

N018587 001 Sep 07, 1982

EQ 8MG BASE

N018587 002 Sep 07, 1982

EQ 16MG BASE

N018587 003 Sep 07, 1982

GUANADREL SULFATE

TABLET;ORAL

HYLOREL

PHARMACIA AND UPJOHN

10MG

N018104 001 Dec 29, 1982

25MG

N018104 002 Dec 29, 1982

GUANETHIDINE MONOSULFATE

TABLET;ORAL

GUANETHIDINE MONOSULFATE

WATSON LABS

EQ 10MG SULFATE

A086113 001 Mar 26, 1985

EQ 25MG SULFATE

A086114 001 Mar 26, 1985

ISMELIN

NOVARTIS

EQ 10MG SULFATE

N012329 001

EQ 25MG SULFATE

N012329 002

GUANETHIDINE MONOSULFATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

ESIMIL

NOVARTIS

10MG;25MG

N013553 001

GUANFACINE HYDROCHLORIDE

TABLET;ORAL

GUANFACINE HYDROCHLORIDE

WATSON LABS

EQ 1MG BASE

A074762 001 Jun 25, 1997

EQ 2MG BASE

A074762 002 Jun 25, 1997

TENEX

PROMIUS PHARMA

EQ 3MG BASE

N019032 003 Nov 07, 1988

TABLET, EXTENDED RELEASE;ORAL

GUANFACINE HYDROCHLORIDE

IMPAX LABS INC

EQ 1MG BASE

A202238 001 Oct 20, 2015

EQ 2MG BASE

A202238 002 Oct 20, 2015

EQ 3MG BASE

A202238 003 Oct 20, 2015

DISCONTINUED DRUG PRODUCT LIST

GUANFACINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
 GUANFACINE HYDROCHLORIDE

EQ 4MG BASE

A202238 004 Oct 20, 2015

HALAZEPAM

TABLET;ORAL
 PAXIPAM

SCHERING

20MG

N017736 003

40MG

N017736 004

HALCINONIDE

CREAM;TOPICAL

HALOG

WESTWOOD SQUIBB

0.025%

N017818 001

HALOG-E

RANBAXY

0.1%

N018234 001

OINTMENT;TOPICAL

HALOG

BRISTOL MYERS SQUIBB

0.025%

N018125 001

SOLUTION;TOPICAL

HALOG

RANBAXY

0.1%

N017823 001

HALOBETASOL PROPIONATE

OINTMENT;TOPICAL

HALOBETASOL PROPIONATE

FOUGERA PHARMS

0.05%

A076903 001 Dec 16, 2004

G AND W LABS INC

0.05%

A077109 001 Jun 14, 2005

HALOFANTRINE HYDROCHLORIDE

TABLET;ORAL

HALFAN

GLAXOSMITHKLINE

250MG

N020250 001 Jul 24, 1992

HALOPERIDOL

TABLET;ORAL

HALDOL

ORTHO MCNEIL

0.5MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N015921 001

1MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N015921 002

2MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N015921 003

5MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N015921 004

10MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N015921 005

20MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N015921 006 Feb 02, 1982

HALDOL SOLUTAB

ORTHO MCNEIL PHARM

1MG

N017079 001

HALOPERIDOL

CYCLE PHARMS LTD

0.5MG

A071128 001 Feb 17, 1987

1MG

A071129 001 Feb 17, 1987

2MG

A071130 001 Feb 17, 1987

5MG

A071131 001 Feb 17, 1987

10MG

A071132 001 May 12, 1987

20MG

A071133 001 May 12, 1987

DURAMED PHARMS BARR

0.5MG

A071216 001 Dec 04, 1986

1MG

A071217 001 Dec 04, 1986

2MG

A071218 001 Dec 04, 1986

5MG

A071219 001 Dec 04, 1986

10MG

A071220 001 Jul 07, 1987

20MG

A071221 001 Jul 07, 1987

DISCONTINUED DRUG PRODUCT LIST

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

FRONTIDA BIOPHARM	0.5MG	A071156 001	Jan 02, 1987
	1MG	A071157 001	Jan 02, 1987
	2MG	A071172 001	Jan 02, 1987
	5MG	A071212 001	Jan 07, 1988
	10MG	A071173 001	Jan 07, 1988
LEDERLE	0.5MG	A072727 001	Sep 19, 1989
	1MG	A072728 001	Sep 19, 1989
	2MG	A072729 001	Sep 19, 1989
	5MG	A072730 001	Sep 19, 1989
	10MG	A072731 001	Sep 19, 1989
	20MG	A072732 001	Sep 19, 1989
PAR PHARM	20MG	A071328 001	Jul 20, 1987
PUREPAC PHARM	0.5MG	A071071 001	Nov 03, 1986
	1MG	A071072 001	Nov 03, 1986
	2MG	A071073 001	Nov 03, 1986
	5MG	A071074 001	Nov 03, 1986
	10MG	A071075 001	Aug 04, 1987
	20MG	A071076 001	Aug 04, 1987
QUANTUM PHARMICS	0.5MG	A071255 001	Feb 17, 1987
	1MG	A071269 001	Feb 17, 1987
	2MG	A071256 001	Feb 17, 1987
	5MG	A071257 001	Feb 17, 1987
ROYCE LABS	0.5MG	A071722 001	Dec 24, 1987
	1MG	A071723 001	Dec 24, 1987
	2MG	A071724 001	Dec 24, 1987
	5MG	A071725 001	Dec 24, 1987
	10MG	A072121 001	Dec 24, 1987
	20MG	A072122 001	Dec 24, 1987
SCS	0.5MG	A070720 001	Jun 10, 1986
	1MG	A070721 001	Jun 10, 1986
	2MG	A070722 001	Jun 10, 1986
	5MG	A070723 001	Jun 10, 1986
	10MG	A070724 001	Jun 10, 1986
	20MG	A070725 001	Sep 24, 1986
SUN PHARM INDS	20MG	A071177 001	Jan 07, 1988
VINTAGE	0.5MG	A071235 002	Nov 03, 1986
	1MG	A071235 003	Nov 03, 1986
	2MG	A071235 001	Nov 03, 1986
	5MG	A071235 004	Nov 03, 1986
	10MG	A071235 005	Jul 20, 1987
WATSON LABS	0.5MG	A070981 001	Mar 06, 1987
	0.5MG	A071571 001	Jun 03, 1988
	1MG	A070982 001	Mar 06, 1987
	1MG	A071572 001	Jun 03, 1988
	2MG	A070983 001	Mar 06, 1987
	2MG	A071573 001	Jun 03, 1988
	5MG	A070984 001	Mar 06, 1987
	5MG	A071374 001	Jun 03, 1988
	10MG	A071375 001	Jun 03, 1988
	10MG	A072113 001	Aug 27, 1991
	20MG	A071376 001	Jun 03, 1988
	20MG	A072353 001	Aug 27, 1991

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

HOSPIRA	EQ 50MG BASE/ML	A075176 001	Feb 09, 2000
	EQ 100MG BASE/ML	A075176 002	Feb 09, 2000
SANDOZ	EQ 50MG BASE/ML	A076463 001	Jun 24, 2005
	EQ 100MG BASE/ML	A076463 002	Jun 24, 2005

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALDOL

ORTHO MCNEIL	EQ 2MG BASE/ML	N015922 001	
--------------	----------------	-------------	--

HALOPERIDOL

ALPHARMA	EQ 2MG BASE/ML	A070318 001	Apr 11, 1986
MORTON GROVE	EQ 2MG BASE/ML	A070710 001	Mar 07, 1986
SCS	EQ 2MG BASE/ML	A070726 001	Jun 10, 1986
TEVA	EQ 2MG BASE/ML	A071015 001	Aug 25, 1987

DISCONTINUED DRUG PRODUCT LIST

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALOPERIDOL INTENSOL

CYCLE PHARMS LTD EQ 2MG BASE/ML A072045 001 Apr 12, 1988

INJECTABLE; INJECTION

HALOPERIDOL

ABRAXIS PHARM EQ 5MG BASE/ML A071187 001 Jan 20, 1987

CLARIS EQ 5MG BASE/ML A076791 001 Aug 25, 2004

EQ 5MG BASE/ML A076828 001 Aug 25, 2004

MARSAM PHARMS LLC EQ 5MG BASE/ML A072516 001 Feb 25, 1993

EQ 5MG BASE/ML A072517 001 Feb 25, 1993

SANDOZ EQ 5MG BASE/ML A076464 001 Sep 29, 2004

SMITH AND NEPHEW EQ 5MG BASE/ML A070802 001 Dec 14, 1987

SOLOPAK EQ 5MG BASE/ML A070800 001 Dec 14, 1987

EQ 5MG BASE/ML A070801 001 Dec 14, 1987

EQ 5MG BASE/ML A070864 001 Dec 14, 1987

WATSON LABS EQ 5MG BASE/ML A070713 001 May 17, 1988

EQ 5MG BASE/ML A070714 001 May 17, 1988

EQ 5MG BASE/ML A070744 001 May 17, 1988

SOLUTION; ORAL

HALOPERIDOL LACTATE

ACTAVIS MID ATLANTIC EQ 1MG BASE/ML A074536 001 Nov 02, 1995

HALOPROGIN

CREAM; TOPICAL

HALOTEX

WESTWOOD SQUIBB 1% N016942 001

SOLUTION; TOPICAL

HALOTEX

WESTWOOD SQUIBB 1% N016943 001

HALOTHANE

LIQUID; INHALATION

FLUOTHANE

WYETH AYERST 99.99% N011338 001

HALOTHANE

BH 99.99% A084977 001

HALOCARBON 99.99% A080810 001

HOSPIRA 99.99% A083254 001

HEPARIN CALCIUM

INJECTABLE; INJECTION

CALCIPARINE

SANOFI AVENTIS US 25,000 UNITS/ML N018237 001

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN LOCK FLUSH

HOSPIRA 100 UNITS/ML N005264 010

INTL MEDICATION 10 UNITS/ML A086357 001

500 UNITS/ML A086357 002

LUITPOLD 10 UNITS/ML A089063 001 Oct 09, 1985

100 UNITS/ML A089064 001 Oct 09, 1985

PARKE DAVIS 10 UNITS/ML N017346 006

SMITH AND NEPHEW 10 UNITS/ML A087904 001 Apr 20, 1983

10 UNITS/ML A087958 001 Apr 20, 1983

10 UNITS/ML A088458 001 Jul 26, 1984

10 UNITS/ML A088580 001 Oct 25, 1984

100 UNITS/ML A087906 001 Apr 20, 1983

100 UNITS/ML A087959 001 Apr 20, 1983

100 UNITS/ML A088460 001 Jul 26, 1984

100 UNITS/ML A088581 001 Oct 25, 1984

SOLOPAK 10 UNITS/ML A087903 001 Apr 20, 1983

10 UNITS/ML A088457 001 Oct 25, 1984

100 UNITS/ML A087905 001 Apr 20, 1983

100 UNITS/ML A088459 001 Jul 26, 1984

HEPARIN SODIUM

ABRAXIS PHARM 1,000 UNITS/ML N017033 001

1,000 UNITS/ML N017979 001

5,000 UNITS/ML N017979 003

10,000 UNITS/ML N017979 002

AKORN 1,000 UNITS/ML N017486 001

5,000 UNITS/ML N017486 002

10,000 UNITS/ML N017486 003

DISCONTINUED DRUG PRODUCT LIST

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

	20,000 UNITS/ML	N017486	004	
	40,000 UNITS/ML	N017486	005	
CHAMBERLIN PARENTERL	1,000 UNITS/ML	N017130	001	
	5,000 UNITS/ML	N017130	002	
	10,000 UNITS/ML	N017130	003	
	20,000 UNITS/ML	N017130	004	
DELL LABS	1,000 UNITS/ML	N017540	001	
	5,000 UNITS/ML	N017540	002	
	10,000 UNITS/ML	N017540	003	
	20,000 UNITS/ML	N017540	004	
	40,000 UNITS/ML	N017540	005	
EUROHLTH INTL SARL	1,000 UNITS/ML	N017007	001	
	2,500 UNITS/ML	N017007	007	
	5,000 UNITS/ML	N017007	002	
	5,000 UNITS/0.5ML	N017007	010	
	7,500 UNITS/ML	N017007	003	
	10,000 UNITS/ML	N017007	004	
	15,000 UNITS/ML	N017007	005	
	20,000 UNITS/ML	N017007	006	
FRESENIUS KABI USA	1,000 UNITS/ML	N017651	005	
	5,000 UNITS/ML	N017029	002	
	10,000 UNITS/ML	N017651	003	
	20,000 UNITS/ML	N017651	008	
HOSPIRA	2,500 UNITS/ML	A088099	001	Apr 28, 1983
	10,000 UNITS/ML	A040095	001	Jul 26, 1996
LILLY	1,000 UNITS/ML	N005521	001	
	10,000 UNITS/ML	N005521	002	
	20,000 UNITS/ML	N005521	004	
LUITPOLD	1,000 UNITS/ML	A087452	001	Oct 31, 1983
ORGANON USA INC	1,000 UNITS/ML	N000552	008	
	5,000 UNITS/ML	N000552	009	
	10,000 UNITS/ML	N000552	010	
PARKE DAVIS	1,000 UNITS/ML	N017346	001	
	5,000 UNITS/ML	N017346	002	
	7,500 UNITS/ML	N017346	003	
	10,000 UNITS/ML	N017346	004	
	20,000 UNITS/ML	N017346	005	
PHARM SPEC	1,000 UNITS/ML	N017780	001	
	5,000 UNITS/ML	N017780	002	
	10,000 UNITS/ML	N017780	003	
	20,000 UNITS/ML	N017780	004	
	40,000 UNITS/ML	N017780	005	
PHARMACIA AND UPJOHN	1,000 UNITS/ML	N004570	001	
	5,000 UNITS/ML	N004570	002	
	10,000 UNITS/ML	N004570	003	
SMITH AND NEPHEW	1,000 UNITS/ML	A088239	001	Jul 26, 1984
SOLOPAK	1,000 UNITS/ML	A087043	001	
	5,000 UNITS/ML	A087077	001	
	5,000 UNITS/0.5ML	A087395	001	
	10,000 UNITS/ML	A087107	001	
	10,000 UNITS/0.5ML	A087363	001	
WATSON LABS	1,000 UNITS/ML	N017064	002	
	2,500 UNITS/ML	N017064	015	
	3,000 UNITS/ML	N017064	016	
	4,000 UNITS/ML	N017064	017	
	5,000 UNITS/ML	N017064	003	
	6,000 UNITS/ML	N017064	018	
	7,500 UNITS/ML	N017064	019	
	10,000 UNITS/ML	N017064	004	
	20,000 UNITS/ML	N017064	005	
	40,000 UNITS/ML	N017064	006	
WATSON LABS INC	1,000 UNITS/ML	A040007	001	Jun 07, 1996
	1,000 UNITS/ML	A040008	001	Oct 10, 1995
WEST-WARD PHARMS INT	5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986
HEPARIN SODIUM 1,000 UNITS	IN DEXTROSE 5% IN PLASTIC CONTAINER			
MCGAW	200 UNITS/100ML	N019130	001	Dec 31, 1984
HEPARIN SODIUM 1,000 UNITS	IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	200 UNITS/100ML	N019042	001	Mar 29, 1985

DISCONTINUED DRUG PRODUCT LIST

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	2,000 UNITS/100ML	N018814 002	Jul 09, 1985
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%			
HOSPIRA	10,000 UNITS/100ML	N018911 006	Jan 30, 1985
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%			
HOSPIRA	10,000 UNITS/100ML	N018911 001	Jan 30, 1985
	10,000 UNITS/100ML	N018916 005	Jan 31, 1984
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%			
HOSPIRA	10,000 UNITS/100ML	N018911 003	Jan 30, 1985
	10,000 UNITS/100ML	N018916 002	Jan 31, 1984
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%			
HOSPIRA	5,000 UNITS/100ML	N018911 007	Jan 30, 1985
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	5,000 UNITS/100ML	N019802 001	Jul 20, 1992
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%			
HOSPIRA	5,000 UNITS/100ML	N018911 005	Jan 30, 1985
	5,000 UNITS/100ML	N018916 003	Jan 31, 1984
HEPARIN SODIUM 2,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER			
MCGAW	200 UNITS/100ML	N019130 003	Dec 31, 1984
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	200 UNITS/100ML	N019042 002	Mar 29, 1985
HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4,000 UNITS/100ML	N018814 001	Oct 31, 1983
HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5,000 UNITS/100ML	N018814 003	Jul 09, 1985
	10,000 UNITS/100ML	N018814 004	Jul 02, 1987
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%			
HOSPIRA	5,000 UNITS/100ML	N018911 009	Jan 30, 1985
	10,000 UNITS/100ML	N018911 008	Jan 30, 1985
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	5,000 UNITS/100ML	N019134 001	Mar 29, 1985
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	5,000 UNITS/100ML	N019802 005	Jul 20, 1992
	10,000 UNITS/100ML	N019802 002	Jul 20, 1992
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9%			
HOSPIRA	5,000 UNITS/100ML	N018911 004	Jan 30, 1985
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	5,000 UNITS/100ML	N019135 001	Mar 29, 1985
	5,000 UNITS/100ML	N019802 003	Jul 20, 1992
	5,000 UNITS/100ML	N018916 009	Jan 31, 1984
HEPARIN SODIUM 5,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	500 UNITS/100ML	N018609 003	Apr 28, 1982
HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER			
MCGAW	1,000 UNITS/100ML	N019130 002	Dec 31, 1984
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45%			
HOSPIRA	100 UNITS/ML	N018911 002	Jan 30, 1985
	100 UNITS/ML	N018916 004	Jan 31, 1984
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9%			
HOSPIRA	1,000 UNITS/100ML	N018916 001	Jan 31, 1984
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	1,000 UNITS/100ML	N019042 004	Mar 29, 1985
HEPARIN SODIUM PRESERVATIVE FREE			
HOSPIRA	2,000 UNITS/ML	N005264 013	Apr 07, 1986
	2,500 UNITS/ML	N005264 014	Apr 07, 1986
PHARMA SERVE NY	1,000 UNITS/ML	A086129 001	
WATSON LABS INC	1,000 UNITS/ML	A089464 001	Jun 03, 1986
LIPO-HEPIN			
3M	1,000 UNITS/0.5ML	N017027 001	
	1,000 UNITS/ML	N017027 006	
	5,000 UNITS/0.5ML	N017027 002	
	5,000 UNITS/ML	N017027 008	
	7,500 UNITS/0.5ML	N017027 010	
	10,000 UNITS/0.5ML	N017027 003	
	10,000 UNITS/ML	N017027 009	
	15,000 UNITS/0.5ML	N017027 011	
	20,000 UNITS/0.5ML	N017027 004	
	20,000 UNITS/ML	N017027 007	
	40,000 UNITS/ML	N017027 005	
LIQUAEMIN LOCK FLUSH			
ORGANON USA INC	100 UNITS/ML	N000552 007	

DISCONTINUED DRUG PRODUCT LIST

HEPARIN SODIUM

INJECTABLE; INJECTION

LIQUAEMIN SODIUM

ORGANON USA INC	1,000 UNITS/ML	N000552 004	
	5,000 UNITS/ML	N000552 003	
	10,000 UNITS/ML	N000552 005	
	20,000 UNITS/ML	N000552 001	
	40,000 UNITS/ML	N000552 002	
LIQUAEMIN SODIUM PRESERVATIVE FREE			
ORGANON USA INC	1,000 UNITS/ML	N000552 011	Apr 11, 1986
	5,000 UNITS/ML	N000552 012	Apr 11, 1986
	10,000 UNITS/ML	N000552 013	Apr 11, 1986

PANHEPRIN

HOSPIRA

	1,000 UNITS/ML	N005264 004	
	5,000 UNITS/ML	N005264 006	
	10,000 UNITS/ML	N005264 007	
	20,000 UNITS/ML	N005264 008	
	40,000 UNITS/ML	N005264 009	

SODIUM HEPARIN

ABRAXIS PHARM

	5,000 UNITS/ML	N017033 002	
	10,000 UNITS/ML	N017033 003	
	20,000 UNITS/ML	N017033 004	

BAXTER HLTHCARE

	1,000 UNITS/ML	N017036 001	Mar 04, 1988
--	----------------	-------------	--------------

HETACILLIN

FOR SUSPENSION; ORAL

VERSAPEN

BRISTOL

	EQ 112.5MG AMPICIL/ML	A061398 001	
	EQ 112.5MG AMPICIL/5ML	N050060 001	
	EQ 112.5MG AMPICIL/ML	N050060 003	
	EQ 225MG AMPICIL/5ML	A061398 002	

HETACILLIN POTASSIUM

CAPSULE; ORAL

VERSAPEN-K

BRISTOL

	EQ 225MG AMPICIL	A061396 001	
	EQ 450MG AMPICIL	A061396 002	

HEXACHLOROPHENE

AEROSOL; TOPICAL

SEPTISOL

VESTAL LABS

	0.23%	N017424 001	
--	-------	-------------	--

TURGEX

XTTRIUM

	3%	N018375 001	
--	----	-------------	--

EMULSION; TOPICAL

HEXA-GERM

HUNTINGTON LABS

	3%	N017411 001	
--	----	-------------	--

PHISOHEX

SANOFI AVENTIS US

	3%	N006882 001	
	3%	N008402 001	

SOY-DOME

BAYER PHARMS

	3%	N017405 001	
--	----	-------------	--

TURGEX

XTTRIUM

	3%	N019055 001	Nov 30, 1984
--	----	-------------	--------------

SOAP; TOPICAL

GAMOPHEN

ARBROOK

	2%	N006270 003	
--	----	-------------	--

SOLUTION; TOPICAL

DIAL

DIAL

	0.25%	N017421 002	
--	-------	-------------	--

GERMA-MEDICA

HUNTINGTON LABS

	1%	N017412 001	
--	----	-------------	--

GERMA-MEDICA "MG"

HUNTINGTON LABS

	0.25%	N017412 002	
--	-------	-------------	--

SEPTI-SOFT

CALGON

	0.25%	N017460 001	
--	-------	-------------	--

SEPTISOL

VESTAL LABS

	0.25%	N017423 001	
--	-------	-------------	--

SPONGE; TOPICAL

E-Z SCRUB

BECTON DICKINSON

	450MG	N017452 001	
--	-------	-------------	--

HEXASCRUB

PROF DSPLS

	3%	N018363 001	
--	----	-------------	--

DISCONTINUED DRUG PRODUCT LIST

HEXACHLOROPHENE

SPONGE; TOPICAL

PHISO-SCRUB

SANOFI AVENTIS US 3%

N017446 001

SCRUBTEAM SURGICAL SPONGEBRUSH

3M 330MG

N017413 001

HEXAFLUORENIUM BROMIDE

INJECTABLE; INJECTION

MYLAXEN

MEDPOINTE PHARM HLC 20MG/ML

N009789 003

HEXOCYCLIUM METHYLSULFATE

TABLET; ORAL

TRAL

ABBVIE 25MG

N010599 001

HEXYLCAINE HYDROCHLORIDE

SOLUTION; TOPICAL

CYCLAINE

MERCK 5%

N008472 001

HISTAMINE PHOSPHATE

INJECTABLE; INJECTION

HISTAMINE PHOSPHATE

LILLY EQ 0.1MG BASE/ML

N000734 003

EQ 0.2MG BASE/ML

N000734 002

EQ 1MG BASE/ML

N000734 001

HISTRELIN ACETATE

INJECTABLE; INJECTION

SUPPRELIN

SHIRE EQ 0.2MG BASE/ML

N019836 001 Dec 24, 1991

EQ 0.5MG BASE/ML

N019836 002 Dec 24, 1991

EQ 1MG BASE/ML

N019836 003 Dec 24, 1991

HOMATROPINE METHYLBROMIDE

TABLET; ORAL

HOMAPIN-10

MISSION PHARMA 10MG

A086308 001

HOMAPIN-5

MISSION PHARMA 5MG

A086309 001

TABLET, CHEWABLE; ORAL

EQUIPIN

MISSION PHARMA 3MG

A086310 001

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYCODAN

ENDO PHARMS 1.5MG/5ML; 5MG/5ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N005213 002 Jul 26, 1988

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

IVAX SUB TEVA PHARMS 1.5MG/5ML; 5MG/5ML

A040285 001 Jul 19, 1999

HYDROFANE

HALSEY 1.5MG/5ML; 5MG/5ML

A088066 001 Jun 28, 1985

TABLET; ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

ACTAVIS ELIZABETH 1.5MG; 5MG

A040295 001 Dec 01, 2000

HYCODAN

ENDO PHARMS 1.5MG; 5MG **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N005213 001 Jul 26, 1988

HYALURONIDASE

INJECTABLE; INJECTION

HYDASE

AKORN INC 150 UNITS/ML

N021716 001 Oct 25, 2005

VITRASE

BAUSCH AND LOMB 6,200 UNITS/VIAL

N021640 001 May 05, 2004

WYDASE

BAXTER HLTHCARE 150 UNITS/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N006343 002

150 UNITS/VIAL **Federal Register

N006343 006

DISCONTINUED DRUG PRODUCT LIST

HYALURONIDASE

INJECTABLE; INJECTION

WYDASE

determination that product was not discontinued or withdrawn for safety or efficacy reasons**

1,500 UNITS/VIAL **Federal Register N006343 005

determination that product was not discontinued or withdrawn for safety or efficacy reasons**

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

APRESOLINE

NOVARTIS

20MG/ML **Federal Register
determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N008303 003

HYDRALAZINE HYDROCHLORIDE

ABRAXIS PHARM

20MG/ML

A089532 001 Aug 11, 1987

SMITH AND NEPHEW

20MG/ML

A088518 001 Apr 20, 1984

SOLOPAK

20MG/ML

A088517 001 Aug 22, 1985

TEVA PARENTERAL

20MG/ML

A040373 001 Feb 23, 2000

TABLET; ORAL

APRESOLINE

NOVARTIS

10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N008303 004

25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N008303 001

50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N008303 002

100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N008303 005

DRALZINE

TEVA

25MG

A084301 001

HYDRALAZINE HYDROCHLORIDE

ACTAVIS ELIZABETH

25MG

A088560 001 Oct 04, 1984

50MG

A088649 001 Oct 18, 1984

ACTAVIS GRP PTC

10MG

A091679 001 Mar 04, 2013

25MG

A091679 002 Mar 04, 2013

50MG

A091679 003 Mar 04, 2013

100MG

A091679 004 Mar 04, 2013

ASCOT

25MG

A088310 001 Dec 19, 1984

50MG

A088311 001 Dec 19, 1984

FRONTIDA BIOPHARM

10MG

A089359 001 Jul 25, 1986

25MG

A089258 001 May 05, 1986

50MG

A089259 001 May 05, 1986

100MG

A088729 001 Apr 11, 1985

HALSEY

10MG

A089218 001 Jan 22, 1986

25MG

A089130 001 Jan 15, 1986

50MG

A089222 001 Jan 22, 1986

100MG

A089178 001 Jan 15, 1986

HERITAGE PHARMS INC

10MG

A040858 001 Feb 26, 2010

25MG

A040858 002 Feb 26, 2010

50MG

A040858 003 Feb 26, 2010

100MG

A040858 004 Feb 26, 2010

IMPAX LABS

25MG

A084922 001

50MG

A084923 001

IVAX SUB TEVA PHARMS

10MG

A084443 001

25MG

A084437 001

50MG

A084469 002

100MG

A084581 001

MUTUAL PHARM

10MG

A088728 001 Apr 11, 1985

25MG

A084106 002

50MG

A084107 002

PUREPAC PHARM

25MG

A088177 001 Jul 29, 1983

50MG

A088178 001 Aug 15, 1983

QUANTUM PHARMICS

10MG

A088671 001 May 01, 1984

DISCONTINUED DRUG PRODUCT LISTHYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

	25MG	A088657	001	Jun 15, 1984
	50MG	A088652	001	May 08, 1984
	100MG	A088686	001	May 01, 1984
SANDOZ	50MG	A085088	001	
SUPERPHARM	10MG	A088787	001	Aug 28, 1984
	25MG	A088788	001	Aug 28, 1984
	50MG	A088789	001	Aug 28, 1984
TG UNITED LABS	10MG	A088846	001	Feb 26, 1985
	25MG	A088847	001	Feb 26, 1985
	50MG	A088848	001	Feb 26, 1985
	100MG	A088849	001	Feb 26, 1985
UPSHER-SMITH LABS	10MG	A083241	001	
	25MG	A083560	001	
	50MG	A083561	001	
USL PHARMA	25MG	A087780	001	Mar 29, 1982
	50MG	A087751	001	Mar 29, 1982
VANGARD	25MG	A087712	001	
	50MG	A087908	001	May 07, 1982
VITARINE	25MG	A086088	001	
WATSON LABS	25MG	A084504	001	
	25MG	A085532	002	May 24, 1982
	50MG	A084503	001	
	50MG	A085533	002	May 25, 1982
WEST WARD	25MG	A088240	001	May 27, 1983
	50MG	A088241	001	May 27, 1983

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

APRESAZIDE

NOVARTIS	25MG; 25MG	A084735	001	
	50MG; 50MG	A084810	001	
	100MG; 50MG	A084811	001	

HYDRA-ZIDE

PAR PHARM	100MG; 50MG	A088961	001	Oct 21, 1985
-----------	-------------	---------	-----	--------------

HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

SOLVAY	25MG; 25MG	A087608	001	Feb 08, 1982
	50MG; 50MG	A087213	001	Feb 08, 1982
	100MG; 50MG	A087609	001	Feb 08, 1982
SUPERPHARM	25MG; 25MG	A089200	001	Feb 09, 1987
	50MG; 50MG	A089201	001	Feb 09, 1987
WATSON LABS	25MG; 25MG	A085457	001	Mar 04, 1982
	50MG; 50MG	A085446	001	Mar 04, 1982
	100MG; 50MG	A085440	001	Mar 04, 1982

HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 100/50

IVAX PHARMS	100MG; 50MG	A088358	001	Apr 10, 1984
-------------	-------------	---------	-----	--------------

HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 25/25

IVAX PHARMS	25MG; 25MG	A088356	001	Apr 10, 1984
-------------	------------	---------	-----	--------------

HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 50/50

IVAX PHARMS	50MG; 50MG	A088357	001	Apr 10, 1984
-------------	------------	---------	-----	--------------

TABLET; ORAL

APRESOLINE-ESIDRIX

NOVARTIS	25MG; 15MG	N012026	002	
----------	------------	---------	-----	--

HYDRALAZINE AND HYDROCHLOROTHIAZIDE

WATSON LABS	25MG; 15MG	A085827	001	
-------------	------------	---------	-----	--

HYDROCHLOROTHIAZIDE W/ HYDRALAZINE

WATSON LABS	25MG; 15MG	A085373	001	
-------------	------------	---------	-----	--

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

CAM-AP-ES

TG UNITED LABS	25MG; 15MG; 0.1MG	A084897	001	
HYDRALAZINE HYDROCHLORIDE, HYDROCHLOROTHIAZIDE AND RESERPINE				
IVAX SUB TEVA PHARMS	25MG; 15MG; 0.1MG	A084291	001	
HYDRALAZINE HYDROCHLORIDE-HYDROCHLOROTHIAZIDE-RESERPINE				
MYLAN	25MG; 15MG; 0.1MG	A087085	001	
HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE				
WATSON LABS	25MG; 15MG; 0.1MG	A085771	001	
HYDRAP-ES				
SANDOZ	25MG; 15MG; 0.1MG	A084876	001	

DISCONTINUED DRUG PRODUCT LIST

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE			
WATSON LABS	25MG;15MG;0.1MG	A083770	001
HYDROSERPINE PLUS (R-H-H)			
IVAX SUB TEVA PHARMS	25MG;15MG;0.1MG	A083877	001
RESERPINE, HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE			
SOLVAY	25MG;15MG;0.1MG	A088376	001 Oct 28, 1983
SUN PHARM INDS	25MG;15MG;0.1MG	A088570	001 Apr 10, 1984
WATSON LABS	25MG;15MG;0.1MG	A085549	001
	25MG;15MG;0.1MG	A087556	001
RESERPINE, HYDROCHLOROTHIAZIDE, AND HYDRALAZINE HYDROCHLORIDE			
LEDERLE	25MG;15MG;0.1MG	A087709	001 May 13, 1982
SER-A-GEN			
SOLVAY	25MG;15MG;0.1MG	A087210	001
SER-AP-ES			
NOVARTIS	25MG;15MG;0.1MG	N012193	005
UNIPRES			
SOLVAY	25MG;15MG;0.1MG	A085893	001
	25MG;15MG;0.1MG	A086298	001

HYDRALAZINE HYDROCHLORIDE; RESERPINE

TABLET; ORAL

DRALSERP			
SANDOZ	25MG;0.1MG	A084617	001
SERPASIL-APRESOLINE			
NOVARTIS	25MG;0.1MG	N009296	004
	50MG;0.2MG	N009296	002

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE			
HIKMA INTL PHARMS	12.5MG	A077885	001 Nov 26, 2007
LANNETT HOLDINGS INC	12.5MG	A091662	001 Jan 27, 2012

SOLUTION; ORAL

HYDROCHLOROTHIAZIDE			
MORTON GROVE	50MG/5ML	A089661	001 Jun 20, 1988
ROXANE	50MG/5ML	A088587	001 Jul 02, 1984
HYDROCHLOROTHIAZIDE INTENSOL			
ROXANE	100MG/ML	A088588	001 Jul 02, 1984

TABLET; ORAL

ESIDRIX			
NOVARTIS	25MG	N011793	005
	50MG	N011793	008
	100MG	N011793	009
HYDRO-D			
HALSEY	25MG	A086504	001
	50MG	A083891	002
HYDROCHLOROTHIAZIDE			
ABC HOLDING	50MG	A085672	001
ACTAVIS ELIZABETH	25MG	A085054	002
	50MG	A085208	001
ALRA	25MG	A086369	001
	50MG	A083554	001
ASCOT	25MG	A087539	001 Feb 03, 1982
	50MG	A087540	001 Feb 03, 1982
AUROLIFE PHARMA LLC	25MG	A083899	001
	50MG	A085219	001
BARR	50MG	A084771	001
DAVA PHARMS INC	100MG	A087060	001
ELKINS SINN	50MG	A085152	002
HEATHER	50MG	A084135	001
HIKMA INTL PHARMS	25MG	A084878	002 Jul 12, 2006
IMPAX LABS	25MG	A084029	001
	50MG	A083607	002
	100MG	A085098	001
INWOOD LABS	25MG	A084776	001
	25MG	A085067	001
	50MG	A084776	002
IVAX SUB TEVA PHARMS	50MG	A084658	001
	100MG	A085022	001
LANNETT	25MG	A084325	001
	50MG	A084324	001

DISCONTINUED DRUG PRODUCT LIST

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

MAST MM	25MG	A086192 001	
	50MG	A086192 002	
MYLAN	25MG	A084880 001	
	50MG	A085112 001	
PVT FORM	50MG	A086597 001	
ROXANE	25MG	A085004 001	
	50MG	A084536 002	
	50MG	A085005 001	
SANDOZ	25MG	A087565 001	Mar 09, 1982
	50MG	A084912 001	
SOLVAY	25MG	A085323 001	
SUN PHARM INDS	25MG	A083972 001	
	50MG	A083972 002	
	100MG	A083972 003	
SUPERPHARM	25MG	A088827 001	Dec 28, 1984
	50MG	A088828 001	Dec 28, 1984
	100MG	A088829 001	Dec 28, 1984
TEVA	25MG	A088924 001	Feb 07, 1985
	50MG	A088923 001	Feb 07, 1985
TG UNITED LABS	25MG	A085683 001	
	50MG	A083965 001	
USL PHARMA	25MG	A087827 001	Apr 19, 1982
	50MG	A087752 001	Apr 19, 1982
VANGARD	25MG	A087638 001	
	50MG	A087610 001	
WARNER CHILCOTT	25MG	A087586 001	May 03, 1982
	50MG	A087587 001	May 03, 1982
WATSON LABS	25MG	A081189 001	Jan 24, 1992
	25MG	A083458 001	
	25MG	A085232 002	
	50MG	A083232 001	
	50MG	A083456 001	
	50MG	A085233 001	
	50MG	A086087 001	
	50MG	A086594 001	
	100MG	A081190 001	Jan 24, 1992
	100MG	A085099 001	
	100MG	A087002 001	
WEST WARD	25MG	A084899 001	
WHITEWORTH TOWN PLSN	25MG	A083809 002	
	50MG	A083809 001	
	100MG	A085347 001	

HYDRODIURIL

MERCK

25MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011835 003	
50MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011835 006	
100MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011835 007	

ORETIC

ABBVIE

25MG		N011971 001	
50MG		N011971 002	

ZIDE

SOLVAY

50MG		A083925 001	
------	--	-------------	--

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

SANOFI AVENTIS US

12.5MG;75MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020758 001	Sep 30, 1997
25MG;300MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020758 004	Mar 15, 2005

DISCONTINUED DRUG PRODUCT LIST

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

TEVA	25MG; 300MG	A077369 003	Mar 30, 2012
WATSON LABS INC	12.5MG; 150MG	A091539 001	Oct 22, 2012
	12.5MG; 300MG	A091539 002	Oct 22, 2012

HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

TABLET; ORAL

NORMOZIDE

SCHERING	25MG; 100MG	N019046 001	Apr 06, 1987
	25MG; 200MG	N019046 002	Apr 06, 1987
	25MG; 300MG	N019046 003	Apr 06, 1987
	25MG; 400MG	N019046 004	Apr 06, 1987

TRANDATE HCT

GLAXOSMITHKLINE	25MG; 100MG	N019174 001	Apr 10, 1987
	25MG; 200MG	N019174 002	Apr 10, 1987
	25MG; 300MG	N019174 003	Apr 10, 1987
	25MG; 400MG	N019174 004	Apr 10, 1987

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

SANDOZ	12.5MG; 10MG	A075926 001	Jul 01, 2002
	12.5MG; 20MG	A075926 002	Jul 01, 2002
	25MG; 20MG	A075926 003	Jul 01, 2002
TEVA	12.5MG; 10MG	A075869 001	Jul 01, 2002
	12.5MG; 20MG	A075869 002	Jul 01, 2002
	25MG; 20MG	A075869 003	Jul 01, 2002

PRINZIDE

MERCK	12.5MG; 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019778 003	Nov 18, 1993
	12.5MG; 20MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019778 001	Feb 16, 1989
	25MG; 20MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019778 002	Feb 16, 1989

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

WATSON LABS	12.5MG; 50MG	A200180 001	Jan 12, 2011
	12.5MG; 100MG	A200180 002	Jan 12, 2011
	25MG; 100MG	A200180 003	Jan 12, 2011

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

ALDORIL 15

MERCK	15MG; 250MG	N013402 001	
-------	-------------	-------------	--

ALDORIL 25

MERCK	25MG; 250MG	N013402 002	
-------	-------------	-------------	--

ALDORIL D30

MERCK	30MG; 500MG	N013402 003	
-------	-------------	-------------	--

ALDORIL D50

MERCK	50MG; 500MG	N013402 004	
-------	-------------	-------------	--

METHYLDOPA AND HYDROCHLOROTHIAZIDE

DAVA PHARMS INC	15MG; 250MG	A072507 001	Jun 02, 1989
	25MG; 250MG	A072508 001	Jun 02, 1989
	30MG; 500MG	A072509 001	Jun 02, 1989
	50MG; 500MG	A072510 001	Jun 02, 1989
IVAX SUB TEVA PHARMS	15MG; 250MG	A071458 001	Mar 08, 1988
	25MG; 250MG	A071459 001	Mar 08, 1988
	30MG; 500MG	A071460 001	Mar 08, 1988
	50MG; 500MG	A071461 001	Mar 08, 1988
PAR PHARM	15MG; 250MG	A070616 001	Feb 02, 1987
	25MG; 250MG	A070612 001	Feb 02, 1987
	30MG; 500MG	A070613 001	Feb 02, 1987
	50MG; 500MG	A070614 001	Feb 02, 1987
PARKE DAVIS	15MG; 250MG	A071897 001	Nov 23, 1987
	25MG; 250MG	A071898 001	Nov 23, 1987
	30MG; 500MG	A071899 001	Nov 23, 1987

DISCONTINUED DRUG PRODUCT LISTHYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

	50MG; 500MG	A071900	001	Nov 23, 1987
PUREPAC PHARM	15MG; 250MG	A070853	001	Oct 08, 1986
	25MG; 250MG	A070688	001	Apr 24, 1986
	30MG; 500MG	A070854	001	Oct 08, 1986
	50MG; 500MG	A070689	001	Apr 24, 1986
SANDOZ	15MG; 250MG	A070182	001	Jan 15, 1986
	15MG; 250MG	A070829	001	Mar 09, 1987
	25MG; 250MG	A070183	001	Jan 15, 1986
	25MG; 250MG	A070830	001	Mar 09, 1987
	30MG; 500MG	A070543	001	Jan 15, 1986
	50MG; 500MG	A070544	001	Jan 15, 1986
TEVA	15MG; 250MG	A071819	001	Apr 08, 1988
	25MG; 250MG	A071820	001	Apr 08, 1988
	30MG; 500MG	A071821	001	Apr 08, 1988
	50MG; 500MG	A071822	001	Apr 08, 1988
WATSON LABS	15MG; 250MG	A070365	001	Mar 19, 1986
	15MG; 250MG	A070958	001	Feb 06, 1989
	15MG; 250MG	A071920	001	Aug 29, 1988
	25MG; 250MG	A070366	001	Apr 16, 1986
	25MG; 250MG	A070959	001	Jan 19, 1989
	25MG; 250MG	A071921	001	Aug 29, 1988
	30MG; 500MG	A070367	001	Mar 19, 1986
	30MG; 500MG	A071069	001	Jan 19, 1989
	30MG; 500MG	A071922	001	Aug 29, 1988
	50MG; 500MG	A070368	001	Apr 16, 1986
	50MG; 500MG	A070960	001	Feb 06, 1989
	50MG; 500MG	A071923	001	Aug 29, 1988

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR HCT

US PHARMS HOLDINGS I	50MG; 100MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018303	003	Dec 31, 1984
----------------------	-------------	--	---------	-----	--------------

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

PADDOCK LLC	12.5MG; 7.5MG	A090096	001	Sep 25, 2008
	12.5MG; 15MG	A090096	002	Sep 25, 2008
	25MG; 15MG	A090096	003	Sep 25, 2008
UNIRETIC				
UCB INC	12.5MG; 7.5MG	N020729	001	Jun 27, 1997
	12.5MG; 15MG	N020729	003	Feb 14, 2002
	25MG; 15MG	N020729	002	Jun 27, 1997

HYDROCHLOROTHIAZIDE; PINDOLOL

TABLET; ORAL

VSKAZIDE

NOVARTIS	25MG; 5MG	N018872	001	Jul 22, 1987
	25MG; 10MG	N018872	002	Jul 22, 1987

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

INDERIDE LA 120/50

WYETH AYERST	50MG; 120MG	N019059	002	Jul 03, 1985
--------------	-------------	---------	-----	--------------

INDERIDE LA 160/50

WYETH AYERST	50MG; 160MG	N019059	003	Jul 03, 1985
--------------	-------------	---------	-----	--------------

INDERIDE LA 80/50

WYETH AYERST	50MG; 80MG	N019059	001	Jul 03, 1985
--------------	------------	---------	-----	--------------

TABLET; ORAL

INDERIDE-40/25

WYETH PHARMS INC	25MG; 40MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018031	001
------------------	------------	--	---------	-----

INDERIDE-80/25

WYETH PHARMS INC	25MG; 80MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018031	002
------------------	------------	--	---------	-----

DISCONTINUED DRUG PRODUCT LISTHYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE & HYDROCHLOROTHIAZIDE

DURAMED PHARMS BARR	25MG; 40MG	A071126	001	Mar 02, 1987
	25MG; 80MG	A071127	001	Mar 02, 1987

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

ACTAVIS ELIZABETH	25MG; 40MG	A070851	001	May 15, 1986
	25MG; 80MG	A070852	001	May 15, 1986
ANI PHARMS INC	25MG; 40MG	A070704	001	Oct 01, 1986
	25MG; 80MG	A070705	001	Oct 01, 1986
IVAX SUB TEVA PHARMS	25MG; 40MG	A071552	001	Dec 01, 1988
	25MG; 80MG	A071553	001	Dec 01, 1988
SANDOZ	25MG; 40MG	A071060	001	Aug 26, 1987
	25MG; 80MG	A071061	001	Aug 26, 1987
WARNER CHILCOTT	25MG; 40MG	A071771	001	Jan 26, 1988
	25MG; 80MG	A071772	001	Jan 26, 1988
WATSON LABS	25MG; 40MG	A070301	001	Apr 18, 1986
	25MG; 40MG	A071498	001	Dec 18, 1991
	25MG; 80MG	A070305	001	Apr 18, 1986
	25MG; 80MG	A071501	001	Dec 18, 1991

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

H.R.-50

WHITEWORTH TOWN PLSN	50MG; 0.125MG	A085338	001	
----------------------	---------------	---------	-----	--

HYDRO-RESERP

ABC HOLDING	50MG; 0.125MG	A084714	002	Jun 29, 1982
-------------	---------------	---------	-----	--------------

HYDRO-SERP "25"

SANDOZ	25MG; 0.125MG	A084827	001	
--------	---------------	---------	-----	--

HYDRO-SERP "50"

SANDOZ	50MG; 0.125MG	A085213	001	
--------	---------------	---------	-----	--

HYDROCHLOROTHIAZIDE W/ RESERPINE

IVAX SUB TEVA PHARMS	25MG; 0.1MG	A083572	001	
	25MG; 0.125MG	A083571	001	
	50MG; 0.1MG	A083568	001	
	50MG; 0.125MG	A083573	001	
PHARMERAL	25MG; 0.125MG	A085421	001	
	50MG; 0.125MG	A085420	001	
ROXANE	50MG; 0.125MG	A084603	001	
WATSON LABS	25MG; 0.125MG	A084466	001	
	25MG; 0.125MG	A085317	001	
	25MG; 0.125MG	A086330	002	
	50MG; 0.125MG	A083666	001	
	50MG; 0.125MG	A084467	001	
	50MG; 0.125MG	A086331	001	

HYDROPRES 25

MERCK	25MG; 0.125MG	N011958	002	
-------	---------------	---------	-----	--

HYDROPRES 50

MERCK	50MG; 0.125MG	N011958	003	
-------	---------------	---------	-----	--

RESERPINE AND HYDROCHLOROTHIAZIDE

BARR	25MG; 0.125MG	A084580	001	
	50MG; 0.125MG	A084579	001	

SANDOZ	50MG; 0.125MG	A088200	001	Jan 31, 1984
--------	---------------	---------	-----	--------------

RESERPINE AND HYDROCHLOROTHIAZIDE-50

WEST WARD	50MG; 0.125MG	A088189	001	May 10, 1984
-----------	---------------	---------	-----	--------------

SERPASIL-ESIDRIX #1

NOVARTIS	25MG; 0.1MG	N011878	003	
----------	-------------	---------	-----	--

SERPASIL-ESIDRIX #2

NOVARTIS	50MG; 0.1MG	N011878	005	
----------	-------------	---------	-----	--

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

ASCOT	25MG; 25MG	A088025	001	Nov 23, 1984
MUTUAL PHARM	25MG; 25MG	A087267	001	
PUREPAC PHARM	25MG; 25MG	A087999	001	Nov 06, 1985
SANDOZ	25MG; 25MG	A086881	001	
SUPERPHARM	25MG; 25MG	A089137	001	Aug 26, 1985
WATSON LABS	25MG; 25MG	A087398	001	

SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE

IVAX PHARMS	25MG; 25MG	A087004	002	May 24, 1982
LEDERLE	25MG; 25MG	A087511	001	
PARKE DAVIS	25MG; 25MG	A087948	001	Feb 22, 1983

DISCONTINUED DRUG PRODUCT LISTHYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE

PUREPAC PHARM	25MG; 25MG	A088054	001	Aug 18, 1983
UPSHER SMITH	25MG; 25MG	A087553	001	
USL PHARMA	25MG; 25MG	A087651	001	
VANGARD	25MG; 25MG	A087655	001	
WATSON LABS	25MG; 25MG	A085974	001	
	25MG; 25MG	A086026	001	

HYDROCHLOROTHIAZIDE; TIMOLOL MALEATE

TABLET; ORAL

TIMOLIDE 10-25

MERCK	25MG; 10MG	N018061	001	
-------	------------	---------	-----	--

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

DYAZIDE

GLAXOSMITHKLINE LLC	25MG; 50MG	N016042	002	
---------------------	------------	---------	-----	--

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

ANI PHARMS INC	25MG; 37.5MG	A074970	001	Jan 06, 1998
NOVARTIS	25MG; 37.5MG	A074857	001	Sep 09, 1997
VITARINE	25MG; 50MG	A071737	001	Feb 12, 1988

TABLET; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AM THERAP	50MG; 75MG	A072022	001	Apr 17, 1988
QUANTUM PHARMICS	50MG; 75MG	A071980	001	Apr 17, 1988
WATSON LABS	50MG; 75MG	A071969	001	Apr 17, 1988

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

ACTAVIS LABS FL INC	5MG; 200MG	A077454	001	Jun 23, 2010
---------------------	------------	---------	-----	--------------

HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL

CODAMINE

ALPHARMA US PHARMS	5MG/5ML; 25MG/5ML	A075103	001	Sep 29, 2000
--------------------	-------------------	---------	-----	--------------

HYDROCORTAMATE HYDROCHLORIDE

OINTMENT; TOPICAL

MAGNACORT

PFIZER	0.5%	N010554	001	
--------	------	---------	-----	--

HYDROCORTISONE

AEROSOL; TOPICAL

AEROSEB-HC

ALLERGAN HERBERT	0.5%	A085805	001	
------------------	------	---------	-----	--

CREAM; TOPICAL

CORT-DOME

BAYER PHARMS	0.5%	N009585	003	
	1%	N009585	001	

DERMACORT

MONARCH PHARMS	1%	A083011	002	
----------------	----	---------	-----	--

ELDECORT

VALEANT PHARM INTL	1%	A080459	001	
	2.5%	A084055	001	

FLEXICORT

WESTWOOD SQUIBB	0.5%	A087136	003	Apr 08, 1982
	1%	A087136	002	Apr 08, 1982
	2.5%	A087136	001	Apr 08, 1982

H-CORT

PHARM ASSOC	0.5%	A086823	001	
-------------	------	---------	-----	--

HC #1

BAYER PHARMS	0.5%	A080438	001	
--------------	------	---------	-----	--

HC #4

BAYER PHARMS	1%	A080438	002	
--------------	----	---------	-----	--

HC (HYDROCORTISONE)

C AND M PHARMA	0.5%	A080482	003	
	1%	A080482	004	

HI-COR

C AND M PHARMA	2.5%	A080483	001	
----------------	------	---------	-----	--

HYDROCORTISONE

ALPHARMA US PHARMS	2.5%	A089754	001	Feb 01, 1989
ALTANA	0.5%	A080848	002	

DISCONTINUED DRUG PRODUCT LIST

HYDROCORTISONE

CREAM; TOPICAL

HYDROCORTISONE

	1%	A080848	003	
AMBIX	1%	A086080	001	
	2.5%	A086271	001	
EVERYLIFE	0.5%	A080452	001	
	1%	A080452	002	
G AND W LABS	1%	A084059	001	
INGRAM PHARM	0.5%	A080456	002	
	1%	A080456	003	
IVAX PHARMS	1%	A085733	001	
NASKA	1%	A089706	001	Mar 10, 1988
PERRIGO NEW YORK	0.5%	A084970	002	
	1%	A085026	001	
PHARMADERM	1%	A088845	001	Feb 27, 1986
	2.5%	A089413	001	Dec 16, 1986
PHARMAFAIR	1%	A087838	001	Jul 28, 1982
STIEFEL	1%	A086170	001	
SYOSSET	0.5%	A085527	001	
TARO	0.5%	A086154	001	
	1%	A086155	001	
TEVA	0.5%	A080400	002	
	1%	A080400	003	
	1%	A085191	001	
	2.5%	A080400	004	
TOPIDERM	1%	A089273	001	Feb 17, 1989
USL PHARMA	1%	A088027	001	Sep 27, 1983
	2.5%	A088029	001	Sep 27, 1983
WHITEWORTH TOWN PLSN	1%	A080496	002	
HYTONE				
VALEANT INTL	1%	A080472	003	
	2.5%	A080472	004	
NOGENIC HC				
IVAX PHARMS	1%	A087427	001	Apr 04, 1988
NUTRACORT				
DOW PHARM	0.5%	A080442	002	
	1%	A080442	003	
PENECORT				
ALLERGAN HERBERT	1%	A088216	001	Jun 06, 1984
PROCTOCORT				
MONARCH PHARMS	1%	A083011	001	
SYNACORT				
MEDICIS	0.5%	A087459	001	
GEL; TOPICAL				
NUTRACORT				
HEALTHPOINT	1%	A084698	001	
PENECORT				
ALLERGAN HERBERT	1%	A088215	001	Jun 06, 1984
INJECTABLE; INJECTION				
CORTEF				
PHARMACIA AND UPJOHN	50MG/ML	N009864	001	
LOTION; TOPICAL				
ACTICORT				
BAKER NORTON	1%	A086535	001	
ALA-CORT				
CROWN LABS	1%	A083201	001	
BALNEOL-HC				
SOLVAY	1%	A088041	001	Dec 03, 1982
BETA-HC				
BETA DERMAC	1%	A089495	001	Jan 25, 1988
CETACORT				
DOW PHARM	0.5%	A080426	002	
	1%	A080426	001	
CORT-DOME				
BAYER PHARMS	0.5%	N009895	003	
	1%	N009895	001	
DERMACORT				
SOLVAY	0.5%	A084573	002	
	1%	A086462	001	
EPICORT				
BLULINE	0.5%	A083219	002	

DISCONTINUED DRUG PRODUCT LIST

HYDROCORTISONE

LOTION; TOPICAL

GLYCORT

HERAN 1% A087489 001 Oct 03, 1983

H-CORT

PHARM ASSOC 0.5% A086824 001

HYDROCORTISONE

ALPHARMA US PHARMS 0.5% A087317 001 Jun 07, 1982

1% A087315 001 Jun 07, 1982

MERICON 0.5% A085282 001

1% A085282 002 Feb 26, 1987

NASKA 1% A089705 001 Apr 25, 1988

PERRIGO NEW YORK 0.5% A085662 001

1% A085663 001

TARO 1% A089024 001 Feb 12, 1986

HYTONE

VALEANT INTL 1% A080473 003

2.5% A080473 004 Nov 30, 1982

NUTRACORT

DOW PHARM 0.5% A080443 002

1% A080443 003

2.5% A087644 001 Aug 24, 1982

STIE-CORT

PERRIGO CO 1% A089066 001 Nov 25, 1985

OINTMENT; TOPICAL

CORTRIL

PFIZER GLOBAL 1% N009176 001

2.5% N009176 002

HC (HYDROCORTISONE)

C AND M PHARMA 0.5% A080481 001

1% A080481 002

HYDROCORTISONE

ALTANA 0.5% A080489 002

1% A080489 003

AMBIX 1% A086079 001

2.5% A086272 001

NASKA 1% A089704 001 Mar 10, 1988

PERRIGO NEW YORK 0.5% A084969 003

1% A085028 001

PHARMADERM 1% A088842 001 Feb 09, 1987

TARO 0.5% A086256 001

2.5% A040310 001 Dec 29, 2000

USL PHARMA 1% A088061 001 Sep 27, 1983

2.5% A088039 001 Sep 27, 1983

HYTONE

DERMIK LABS 1% A080474 003

2.5% A080474 004

PENECORT

ALLERGAN HERBERT 2.5% A088217 001 Jun 06, 1984

POWDER; FOR RX COMPOUNDING

H-CORT

TORCH 100% A087834 001 Mar 29, 1982

HYDRO-RX

X GEN PHARMS 100% A085982 001

HYDROCORTISONE

PADDOCK LLC 100% A088082 001 Apr 08, 1983

SOLUTION; TOPICAL

PENECORT

ALLERGAN HERBERT 1% A088214 001 Jun 06, 1984

TEXACORT

MISSION PHARMA 1% A080425 001

TABLET; ORAL

CORTRIL

PFIZER 10MG N009127 005

20MG N009127 003

HYDROCORTISONE

BARR 20MG A083999 001

ELKINS SINN 20MG A080624 001

FERRANTE 10MG A080568 001

20MG A080568 002

IMPAX LABS 20MG A080781 001

INWOOD LABS 20MG A080732 001

DISCONTINUED DRUG PRODUCT LIST

HYDROCORTISONE

TABLET; ORAL

HYDROCORTISONE

LANNETT	20MG	A085070	001	
NEXGEN PHARMA INC	20MG	A083140	001	
PANRAY	10MG	N009659	001	
	20MG	N009659	002	
PARKE DAVIS	20MG	A084243	001	
PUREPAC PHARM	10MG	A084247	003	Aug 31, 1982
	20MG	A080395	001	
	20MG	A084247	002	
ROXANE	10MG	A088539	001	Mar 21, 1984
SANDOZ	20MG	A080642	002	
WATSON LABS	20MG	A080355	001	
WHITEWORTH TOWN PLSN	10MG	A080344	001	
	20MG	A080344	002	

HYDROCORTONE

MERCK	10MG	N008506	007	
	20MG	N008506	011	

TABLET; VAGINAL

CORTRIL

PFIPHARMECS	10MG	N009796	001	
-------------	------	---------	-----	--

HYDROCORTISONE ACETATE

CREAM; TOPICAL

HEMSOL-HC

ABLE	1%	A081274	001	Jun 19, 1992
------	----	---------	-----	--------------

HYDROCORTISONE ACETATE

CENCI	1%	A080419	001	Jan 25, 1982
PARKE DAVIS	1%	A089914	001	Jan 03, 1989
PUREPAC PHARM	0.5%	A086050	001	
	1%	A086052	001	

INJECTABLE; INJECTION

CORTEF ACETATE

PHARMACIA AND UPJOHN	50MG/ML	N009378	002	
----------------------	---------	---------	-----	--

CORTRIL

PFIZER	25MG/ML	N009164	001	
--------	---------	---------	-----	--

HYDROCORTISONE ACETATE

AKORN	25MG/ML	N009637	001	
	50MG/ML	N009637	002	
BEL MAR	25MG/ML	A083739	001	
	50MG/ML	A083739	002	
WATSON LABS	25MG/ML	A083128	001	
	25MG/ML	A083759	001	
	50MG/ML	A083759	002	
	50MG/ML	A085214	001	

HYDROCORTONE

MERCK	25MG/ML	N008228	001	
	50MG/ML	N008228	004	

LOTION; TOPICAL

DRICORT

INGRAM PHARM	0.5%	A086207	001	
--------------	------	---------	-----	--

OINTMENT; OPHTHALMIC

HYDROCORTISONE ACETATE

FERA PHARMS	0.5%	A080828	001	
-------------	------	---------	-----	--

OINTMENT; OPHTHALMIC, OTIC

HYDROCORTONE

MERCK	1.5%	N009018	003	
-------	------	---------	-----	--

OINTMENT; TOPICAL

CORTEF ACETATE

PHARMACIA AND UPJOHN	1%	N008917	002	
	2.5% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N008917	001	

PASTE; TOPICAL

ORABASE HCA

COLGATE	0.5%	A083205	001	
---------	------	---------	-----	--

POWDER; FOR RX COMPOUNDING

HYDROCORTISONE ACETATE

X GEN PHARMS	100%	A085981	001	
--------------	------	---------	-----	--

DISCONTINUED DRUG PRODUCT LISTHYDROCORTISONE ACETATE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-CORTEF

PHARMACIA AND UPJOHN	1%;EQ 3.5MG BASE/GM	A061049	001
	2.5%;EQ 3.5MG BASE/GM	A061049	002

OINTMENT; OPHTHALMIC

NEO-CORTEF

PHARMACIA AND UPJOHN	0.5%;EQ 3.5MG BASE/GM	A060610	001
	1.5%;EQ 3.5MG BASE/GM	A060610	002

OINTMENT; TOPICAL

NEO-CORTEF

PHARMACIA AND UPJOHN	0.5%;EQ 3.5MG BASE/GM	A060751	001
	1%;EQ 3.5MG BASE/GM	A060751	002
	2.5%;EQ 3.5MG BASE/GM	A060751	003

SUSPENSION/DROPS; OPHTHALMIC

COR-OTICIN

AKORN	1.5%;EQ 3.5MG BASE/ML	A060188	001
-------	-----------------------	---------	-----

NEO-CORTEF

PHARMACIA AND UPJOHN	0.5%;EQ 3.5MG BASE/ML	A060612	002
	1.5%;EQ 3.5MG BASE/ML	A060612	001

HYDROCORTISONE ACETATE; OXYTETRACYCLINE HYDROCHLORIDE

SUSPENSION; OPHTHALMIC

TERRA-CORTRIL

PFIZER	1.5%;EQ 5MG BASE/ML	A061016	001
--------	---------------------	---------	-----

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL

HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1%

VINTAGE PHARMS	1%;1%	A089440	001	May 17, 1988
----------------	-------	---------	-----	--------------

LOTION; TOPICAL

PRAMOSONE

FERNDAL LABS	0.5%;1%	A083213	002
--------------	---------	---------	-----

HYDROCORTISONE ACETATE; UREA

CREAM; TOPICAL

CARMOL HC

FOUGERA PHARMS	1%;10%	A080505	001
----------------	--------	---------	-----

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL

LOCOID

YAMANOUCHI	0.1%	N018795	001	Jan 07, 1983
------------	------	---------	-----	--------------

OINTMENT; TOPICAL

LOCOID

YAMANOUCHI	0.1%	N019106	001	Jul 03, 1984
------------	------	---------	-----	--------------

SOLUTION; TOPICAL

LOCOID

YAMANOUCHI	0.1%	N019819	001	Sep 15, 1988
------------	------	---------	-----	--------------

HYDROCORTISONE CYPIONATE

SUSPENSION; ORAL

CORTEF

PHARMACIA AND UPJOHN	EQ 10MG BASE/5ML	N009900	001
----------------------	------------------	---------	-----

HYDROCORTISONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

HYDROCORTONE

MERCK	EQ 50MG BASE/ML	N012052	001
-------	-----------------	---------	-----

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-HYDROCORT

ABBOTT	EQ 100MG BASE/VIAL	A085928	001	
	EQ 100MG BASE/VIAL	A089577	001	Apr 11, 1989
	EQ 250MG BASE/VIAL	A089578	001	Apr 11, 1989
	EQ 500MG BASE/VIAL	A089579	001	Apr 11, 1989
	EQ 1GM BASE/VIAL	A089580	001	Apr 11, 1989
HOSPIRA	EQ 100MG BASE/VIAL	A085929	001	
	EQ 250MG BASE/VIAL	A085930	001	
	EQ 500MG BASE/VIAL	A085931	001	
	EQ 1GM BASE/VIAL	A085932	001	

HYDROCORTISONE SODIUM SUCCINATE

ABRAXIS PHARM	EQ 100MG BASE/VIAL	A088667	001	Jun 08, 1984
	EQ 100MG BASE/VIAL	A088712	001	Jun 08, 1984
	EQ 250MG BASE/VIAL	A088668	001	Jun 08, 1984

DISCONTINUED DRUG PRODUCT LISTHYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

HYDROCORTISONE SODIUM SUCCINATE

	EQ 500MG BASE/VIAL	A088669 001	Jun 08, 1984
	EQ 1GM BASE/VIAL	A088670 001	Jun 08, 1984
BAXTER HLTHCARE	EQ 100MG BASE/VIAL	A086619 001	
	EQ 250MG BASE/VIAL	A087567 001	
	EQ 500MG BASE/VIAL	A087568 001	
	EQ 1GM BASE/VIAL	A087569 001	
INTL MEDICATION	EQ 100MG BASE/VIAL	A087532 001	Mar 19, 1982
WATSON LABS	EQ 100MG BASE/VIAL	A084737 002	
	EQ 100MG BASE/VIAL	A084738 001	
	EQ 250MG BASE/VIAL	A084737 001	
	EQ 500MG BASE/VIAL	A084747 001	
	EQ 1GM BASE/VIAL	A084748 001	

HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATE

G AND W LABS INC	0.2%	A074489 001	Aug 12, 1998
WESTCORT			
RANBAXY LABS LTD	0.2% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017950 001	

OINTMENT; TOPICAL

HYDROCORTISONE VALERATE

FOUGERA PHARMS	0.2%	A075085 001	Jul 31, 2001
WESTCORT			
RANBAXY	0.2% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018726 001	Aug 08, 1983

HYDROCORTISONE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-CORT-DOME

BAYER PHARMS	0.5%;EQ 3.5MG BASE/GM	N050237 006	Jun 05, 1984
	1%;EQ 3.5MG BASE/GM	N050237 005	Jun 05, 1984

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE

PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062394 001	Sep 29, 1982
OTOCORT			
WATSON LABS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A060730 002	

SUSPENSION/DROPS; OPHTHALMIC

CORTISPORIN

MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050169 001	
NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE			
PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062623 001	Sep 24, 1985

SUSPENSION/DROPS; OTIC

NEOMYCIN SULFATE, POLYMYXIN B SULFATE & HYDROCORTISONE

PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062617 001	Sep 18, 1985
OTICAIR			
PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062399 001	Nov 18, 1982
OTOBIONE			
SCHERING	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A061816 001	
OTOCORT			
ACTAVIS LABS FL INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062521 001	Jul 11, 1985
PEDIOTIC			
MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062822 001	Sep 29, 1987

HYDROCORTISONE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

OTOBiotic

SCHERING	5MG/ML;EQ 10,000 UNITS BASE/ML	A062302 001	
PYOCIDIN			
FOREST LABS	5MG/ML;EQ 10,000 UNITS BASE/ML	A061606 001	

DISCONTINUED DRUG PRODUCT LISTHYDROCORTISONE; TETRACYCLINE HYDROCHLORIDE

OINTMENT; OPHTHALMIC

ACHROMYCIN

LEDERLE

1.5%;1%

N050272 001

HYDROCORTISONE; UREA

CREAM; TOPICAL

ALPHADERM

BIOGLAN

1%;10%

A086008 001

CALMURID HC

PHARMACIA AND UPJOHN

1%;10%

A083947 001

HYDROFLUMETHIAZIDE

TABLET; ORAL

DIUCARDIN

WYETH AYERST

50MG

A083383 001

HYDROFLUMETHIAZIDE

PAR PHARM

50MG

A088850 001 May 31, 1985

WATSON LABS

50MG

A088031 001 Apr 06, 1983

50MG

A088528 001 Aug 15, 1984

HYDROFLUMETHIAZIDE; RESERPINE

TABLET; ORAL

HYDROFLUMETHIAZIDE AND RESERPINE

USL PHARMA

50MG;0.125MG

A088195 001 Oct 26, 1983

WATSON LABS

25MG;0.125MG

A088127 001 Mar 22, 1983

50MG;0.125MG

A088110 001 Mar 22, 1983

RESERPINE AND HYDROFLUMETHIAZIDE

IVAX PHARMS

50MG;0.125MG

A088932 001 Jan 11, 1985

PAR PHARM

50MG;0.125MG

A088907 001 Sep 20, 1985

SALUTENSIN

SHIRE

50MG;0.125MG

N012359 003

SALUTENSIN-DEMI

SHIRE

25MG;0.125MG

N012359 004

HYDROMORPHONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PALLADONE

PURDUE PHARMA LP

12MG

N021044 001 Sep 24, 2004

16MG

N021044 002 Sep 24, 2004

24MG

N021044 003 Sep 24, 2004

32MG

N021044 004 Sep 24, 2004

INJECTABLE; INJECTION

DILAUDID-HP

PURDUE PHARM PRODS

250MG/VIAL

N019034 002 Aug 04, 1994

HYDROMORPHONE HYDROCHLORIDE

WATSON LABS

10MG/ML

A074317 001 Aug 23, 1995

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

NESHER PHARMS

2MG

A077311 001 Nov 09, 2005

4MG

A077311 002 Nov 09, 2005

8MG

A077311 003 Nov 09, 2005

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

ALPHAREDISOL

MERCK

1MG/ML

A080778 001

CYANOKIT

SERB SA

2.5GM/VIAL (5GM/KIT)

N022041 002 Dec 15, 2006

HYDROXOCOBALAMIN

ABRAXIS PHARM

1MG/ML

A084921 001

WATSON LABS

1MG/ML

A085528 001

HYDROXOMIN

BEL MAR

1MG/ML

A084629 001

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS; OPHTHALMIC

PAREDRIINE

PHARMICS

1%

N000004 004

DISCONTINUED DRUG PRODUCT LISTHYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

SANDOZ

200MG

A040150 001 Jan 27, 1996

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION

DELALUTIN

BRISTOL MYERS SQUIBB

125MG/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N010347 004

125MG/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N016911 001

250MG/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N010347 002

250MG/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N016911 002

HYDROXYPROGESTERONE CAPROATE

AKORN

125MG/ML

N018004 001

ALLERGAN SALES LLC

125MG/ML

N017439 001

250MG/ML

N017439 002

HYDROXYSTILBAMIDINE ISETHIONATE

INJECTABLE; INJECTION

HYDROXYSTILBAMIDINE ISETHIONATE

SANOFI AVENTIS US

225MG/AMP

N009166 001

HYDROXYUREA

CAPSULE; ORAL

HYDROXYUREA

BARR

250MG

A075143 002 Sep 21, 2000

BARR LABS INC

250MG

A075020 002 Jun 26, 2000

500MG

A075020 001 Jul 30, 1998

ROXANE

500MG

A074476 001 Aug 18, 1995

TABLET; ORAL

HYDROXYUREA

BARR

1GM

A075734 001 Aug 29, 2000

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE

BAXTER HLTHCARE

50MG/ML

A085551 002

HYDROXYZINE HYDROCHLORIDE

ALTANA

25MG/ML

A087273 001 Apr 20, 1982

50MG/ML

A087273 002 Apr 20, 1982

BAXTER HLTHCARE

25MG/ML

A085551 001

FRESENIUS KABI USA

25MG/ML

A088184 001 Mar 31, 1983

50MG/ML

A088185 001 Mar 31, 1983

HOSPIRA

25MG/ML

A087416 001

50MG/ML

A086821 001

50MG/ML

A087546 001

PHARMAFAIR

25MG/ML

A088862 001 Feb 14, 1986

25MG/ML

A089106 001 Feb 14, 1986

50MG/ML

A088881 001 Feb 14, 1986

50MG/ML

A089107 001 Feb 14, 1986

SMITH AND NEPHEW

25MG/ML

A087592 001

SOLOPAK

25MG/ML

A086822 001

25MG/ML

A087591 001

50MG/ML

A087310 001

50MG/ML

A087593 001

50MG/ML

A087595 001

50MG/ML

A087596 001

WATSON LABS

25MG/ML

A085778 001

25MG/ML

A087274 001

50MG/ML

A085779 001

50MG/ML

A087274 002

WYETH AYERST

25MG/ML

A086258 001

50MG/ML

A086258 002

DISCONTINUED DRUG PRODUCT LIST

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

ORGATRAK

ORGANON USA INC	25MG/ML	A087014	001
	50MG/ML	A087014	002

VISTARIL

PFIZER	25MG/ML	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011111	001
	50MG/ML	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011111	002

SYRUP; ORAL

ATARAX

ROERIG	10MG/5ML		N010485	001
--------	----------	--	---------	-----

HYDROXYZINE HYDROCHLORIDE

ALPHARMA US PHARMS	10MG/5ML		A088785	001	Feb 03, 1988
KV PHARM	10MG/5ML		A087730	001	Jul 01, 1982
STI PHARMA LLC	10MG/5ML		A086880	001	

TABLET; ORAL

ATARAX

PFIZER	10MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N010392	001
	25MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N010392	004
	50MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N010392	006
	100MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N010392	005

HYDROXYZINE HYDROCHLORIDE

ABLE

	10MG		A040559	001	Jul 22, 2004
	25MG		A040562	001	Jul 22, 2004
	50MG		A040563	001	Jul 22, 2004
ACTAVIS ELIZABETH	10MG		A089071	001	Jul 22, 1986
	25MG		A089072	001	Jul 22, 1986
	50MG		A089073	001	Jul 22, 1986
AUROLIFE PHARMA LLC	10MG		A087869	001	Dec 20, 1982
	25MG		A087870	001	Dec 20, 1982
	50MG		A087871	001	Dec 20, 1982
HALSEY	10MG		A089366	001	May 02, 1988
	25MG		A089117	001	May 02, 1988
	50MG		A089396	001	May 02, 1988
IVAX PHARMS	10MG		A087216	001	
	25MG		A087410	001	
	50MG		A087411	001	
KV PHARM	10MG		A087819	001	Jun 23, 1982
	25MG		A087820	001	Jun 23, 1982
	50MG		A087821	001	Jun 23, 1982
	100MG		A087822	001	Jun 23, 1982
MUTUAL PHARM	10MG		A088409	001	Nov 15, 1983
	25MG		A087857	001	Apr 18, 1983
	50MG		A087860	001	Apr 18, 1983
PLIVA	100MG		A081054	001	Sep 25, 1995
PUREPAC PHARM	10MG		A088120	001	Sep 25, 1984
	25MG		A088121	001	Sep 25, 1984
	50MG		A088122	001	Sep 25, 1984
QUANTUM PHARMICS	10MG		A088540	001	Oct 22, 1985
	25MG		A088551	001	Oct 22, 1985
	50MG		A088529	001	Oct 22, 1985
SANDOZ	10MG		A087246	002	
	25MG		A085247	001	
	50MG		A087245	001	
SUN PHARM INDS	10MG		A089381	001	May 19, 1986
	25MG		A089382	001	May 19, 1986
	50MG		A089383	001	May 19, 1986

DISCONTINUED DRUG PRODUCT LIST

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

	100MG	A087862 001	Apr 18, 1983
SUPERPHARM	10MG	A088794 001	Dec 05, 1984
	25MG	A088795 001	Dec 05, 1984
	50MG	A088796 001	Dec 05, 1984
USL PHARMA	10MG	A089121 001	Mar 20, 1986
	25MG	A089122 001	Mar 20, 1986
	50MG	A089123 001	Mar 20, 1986
VINTAGE	10MG	A087602 001	Jan 22, 1982
	25MG	A087603 001	Jan 22, 1982
	50MG	A087604 001	Jan 22, 1982
WATSON LABS	10MG	A081149 001	Mar 18, 1994
	10MG	A086827 001	
	10MG	A088348 001	Sep 15, 1983
	25MG	A081150 001	Mar 18, 1994
	25MG	A086829 001	
	25MG	A088349 001	Sep 15, 1983
	50MG	A081151 001	Mar 18, 1994
	50MG	A086836 001	
	50MG	A088350 001	Sep 15, 1983

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HY-PAM "25"

TEVA

EQ 25MG HCL A088713 001 Mar 04, 1985

HYDROXYZINE PAMOATE

DURAMED PHARMS BARR

EQ 25MG HCL A088593 001 Feb 29, 1984

EQ 50MG HCL A088594 001 Feb 29, 1984

EQ 100MG HCL A088595 001 Feb 29, 1984

IVAX SUB TEVA PHARMS

EQ 25MG HCL A087761 001 Mar 05, 1982

EQ 50MG HCL A087760 001 Mar 05, 1982

PAR PHARM

EQ 25MG HCL A087656 001 Jun 11, 1982

EQ 25MG HCL A089145 001 Mar 17, 1986

EQ 50MG HCL A087657 001 Jun 11, 1982

EQ 50MG HCL A089146 001 Mar 17, 1986

EQ 100MG HCL A087658 001 Jun 11, 1982

SANDOZ

EQ 25MG HCL A081127 001 Jun 28, 1991

EQ 50MG HCL A081128 001 Jun 28, 1991

EQ 100MG HCL A081129 001 Jun 28, 1991

SUPERPHARM

EQ 25MG HCL A089031 001 Jan 02, 1987

EQ 50MG HCL A089032 001 Jan 02, 1987

EQ 100MG HCL A089033 001 Jan 02, 1987

VANGARD

EQ 25MG HCL A088392 001 Sep 19, 1983

EQ 50MG HCL A088393 001 Sep 19, 1983

WATSON LABS

EQ 25MG HYDROCHLORIDE A081165 001 Jul 31, 1991

EQ 25MG HCL A086698 001

EQ 25MG HCL A086840 001 Jul 01, 1982

EQ 50MG HCL A086695 001

EQ 50MG HCL A086705 001 Jul 01, 1982

EQ 50MG HCL A087767 001 Aug 16, 1982

EQ 100MG HCL A086697 001

EQ 100MG HCL A086728 001 Oct 05, 1982

EQ 100MG HCL A087790 001 Aug 16, 1982

VISTARIL

PFIZER

EQ 100MG HCL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons** N011459 006

SUSPENSION; ORAL

VISTARIL

PFIZER

EQ 25MG HCL/5ML N011795 001

IBANDRONATE SODIUM

TABLET; ORAL

BONIVA

HOFFMANN LA ROCHE

EQ 2.5MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons** N021455 001 May 16, 2003

DISCONTINUED DRUG PRODUCT LIST

IBUPROFEN

CAPSULE;ORAL

MIDOL

BAYER	200MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A070626	001	Sep 02, 1987
	200MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A071002	001	Sep 02, 1987

SOLUTION;INTRAVENOUS

CALDOLOR

CUMBERLAND PHARMS	400MG/4ML (100MG/ML)	N022348	001	Jun 11, 2009
-------------------	----------------------	---------	-----	--------------

SUSPENSION;ORAL

CHILDREN'S ADVIL

WYETH CONS	100MG/5ML	N019833	002	Sep 19, 1989
------------	-----------	---------	-----	--------------

IBU

ABBOTT	100MG/5ML	N019784	001	Dec 18, 1989
--------	-----------	---------	-----	--------------

MOTRIN

MCNEIL CONSUMER	100MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019842	001	Sep 19, 1989
-----------------	--	---------	-----	--------------

SUSPENSION/DROPS;ORAL

MOTRIN

MCNEIL	40MG/ML	N020476	001	May 25, 1995
--------	---------	---------	-----	--------------

TABLET;ORAL

ACHES-N-PAIN

LEDERLE	200MG	A071065	001	May 28, 1987
---------	-------	---------	-----	--------------

CAP-PROFEN

FERRIGO	200MG	A072097	001	Dec 08, 1987
---------	-------	---------	-----	--------------

IBU

BASF	400MG	A070083	001	Feb 22, 1985
	400MG	N018197	001	
	600MG	A070088	001	Feb 08, 1985
	600MG	A070099	001	Mar 29, 1985
	800MG	A070745	001	Jul 23, 1986

IBU-TAB

ALRA	800MG	A071965	001	Aug 11, 1988
------	-------	---------	-----	--------------

IBUPRIN

PLIVA	200MG	A071773	001	Jul 16, 1987
-------	-------	---------	-----	--------------

IBUPROFEN

ABBOTT	600MG	A070556	001	Jun 14, 1985
	800MG	A071264	001	Jul 25, 1986
ANI PHARMS INC	200MG	A071144	001	Jan 20, 1987
	200MG	A072901	001	Dec 19, 1991
	200MG	A072903	001	Dec 19, 1991
AUROLIFE PHARMA LLC	300MG	A070736	002	Jun 12, 1986
	400MG	A070736	003	Jun 12, 1986
	600MG	A070736	001	Jun 12, 1986
	800MG	A071938	001	Jan 14, 1988
CONTRACT PHARMACAL	200MG	A073691	001	Feb 25, 1994
HALSEY	200MG	A071027	001	Sep 29, 1987
	300MG	A071028	001	Mar 23, 1987
	400MG	A071029	001	Mar 23, 1987
	600MG	A071030	001	Mar 23, 1987
	800MG	A072137	001	Feb 05, 1988
IVAX SUB TEVA PHARMS	200MG	A071154	001	Oct 27, 1987
	200MG	A072040	001	Apr 29, 1988
	400MG	A071145	001	Sep 23, 1986
	600MG	A071146	001	Sep 23, 1986
	800MG	A071769	001	May 08, 1987
J AND J CONSUMER INC	400MG	A070081	001	Jun 16, 1986
LEDERLE	400MG	A070629	001	Sep 19, 1986
	600MG	A070630	001	Sep 19, 1986
LEINER	300MG	A071266	001	Oct 15, 1986
MCNEIL	600MG	A070476	001	Jun 16, 1986
MYLAN	200MG	A071870	001	May 05, 1988
	400MG	A070045	001	Sep 24, 1985
	600MG	A070057	001	Sep 24, 1985
	800MG	A071999	001	Dec 03, 1987
NORTHSTAR HLTHCARE	400MG	A078132	001	Sep 10, 2007
	600MG	A078132	002	Sep 10, 2007

DISCONTINUED DRUG PRODUCT LIST

IBUPROFEN

TABLET; ORAL

IBUPROFEN

	800MG	A078132 003	Sep 10, 2007
OHM LABS	400MG	A070818 001	Dec 26, 1985
PAR PHARM	200MG	A071575 001	May 08, 1987
	300MG	A070328 001	Aug 06, 1985
	400MG	A070329 001	Aug 06, 1985
	600MG	A070330 001	Aug 06, 1985
	800MG	A070986 001	Jul 25, 1986
PERRIGO	200MG	A072098 001	Dec 08, 1987
PLIVA	400MG	A071666 001	Jun 18, 1987
	600MG	A071667 001	Jun 18, 1987
	800MG	A071668 001	Jun 18, 1987
PUREPAC PHARM	200MG	A071122 001	Oct 03, 1986
	200MG	A071664 001	Feb 03, 1987
	300MG	A071123 001	Sep 19, 1986
	400MG	A071124 001	Sep 19, 1986
	600MG	A071125 001	Sep 19, 1986
	800MG	A071964 001	Feb 01, 1988
SANDOZ	200MG	A070733 001	Sep 19, 1986
	200MG	A071807 001	Feb 25, 1988
	200MG	A074525 001	Dec 15, 1995
	200MG	A074533 001	Dec 15, 1995
	400MG	A072064 001	Jan 14, 1988
	600MG	A072065 001	Jan 14, 1988
	800MG	A072169 001	Dec 11, 1987
SUN PHARM INDS	200MG	A070493 001	Dec 24, 1985
	200MG	A070908 001	Sep 26, 1986
	200MG	A071462 001	Oct 02, 1986
	400MG	A070079 001	Jul 24, 1985
	600MG	A070080 001	Jul 24, 1985
	800MG	A071448 001	Feb 18, 1987
SUPERPHARM	600MG	A070709 001	Apr 25, 1986
TEVA	200MG	A073141 001	May 29, 1992
	400MG	A073343 001	Jun 30, 1992
	600MG	A073344 001	Jun 30, 1992
	800MG	A073345 001	Jun 30, 1992
VINTAGE PHARMS	200MG	A072249 001	Jan 10, 1989
	300MG	A071230 001	Oct 22, 1986
	400MG	A071231 001	Oct 22, 1986
	600MG	A071232 001	Oct 22, 1986
	800MG	A072004 001	Nov 18, 1987
WATSON LABS	200MG	A070435 001	Mar 05, 1986
	200MG	A071765 001	Sep 04, 1987
	200MG	A071905 001	Mar 08, 1988
	300MG	A071338 001	Dec 01, 1986
	400MG	A070038 001	Sep 06, 1985
	400MG	A070436 001	Aug 21, 1985
	600MG	A070041 001	Sep 06, 1985
	600MG	A070437 001	Aug 21, 1985
	800MG	A071547 001	Jul 02, 1987
	800MG	A071911 001	Oct 13, 1987
IBUPROHM			
OHM LABS	400MG	A070469 001	Aug 29, 1985
MEDIPIREN			
MCNEIL	200MG	A070475 001	Feb 06, 1986
	200MG	A071215 001	Jun 26, 1986
MIDOL			
BAYER	200MG	A070591 001	Sep 02, 1987
	200MG	A071001 001	Sep 02, 1987
MOTRIN			
MCNEIL CONSUMER	300MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017463 003	
	400MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017463 002	
	600MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017463 004	

DISCONTINUED DRUG PRODUCT LISTIBUPROFEN

TABLET; ORAL

MOTRIN

reasons**

800MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

MCNEIL PED		N020418	001	Nov 16, 1994
MOTRIN MIGRAINE PAIN				
J AND J CONSUMER INC	200MG	N019012	004	Feb 25, 2000
NUPRIN				
BRISTOL MYERS	200MG	A072035	001	Feb 16, 1988
	200MG	A072036	001	Feb 16, 1988
J AND J CONSUMER INC	200MG	N019012	001	May 18, 1984
	200MG	N019012	002	Jul 29, 1987
RUFEN				
BASF	600MG	N018197	002	Mar 05, 1984
TABLET, CHEWABLE; ORAL				
MOTRIN				
MCNEIL PED	50MG	N020135	001	Nov 16, 1994
	100MG	N020135	002	Nov 16, 1994

IBUPROFEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

COMBUNOX

FOREST LABS	400MG; 5MG	N021378	001	Nov 26, 2004
-------------	------------	---------	-----	--------------

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDAMYCIN

PHARMACIA AND UPJOHN	5MG/VIAL	N050661	002	Sep 27, 1990
	10MG/VIAL	N050661	001	Sep 27, 1990
	20MG/VIAL	N050661	003	Apr 25, 1995

IDARUBICIN HYDROCHLORIDE

SANDOZ	1MG/ML	A091293	001	Mar 29, 2011
TEVA PARENTERAL	5MG/VIAL	A065037	003	May 01, 2002
	10MG/VIAL	A065037	002	May 01, 2002
	20MG/VIAL	A065037	001	May 01, 2002

IDOXURIDINE

OINTMENT; OPHTHALMIC

STOXIL

GLAXOSMITHKLINE	0.5%	N015868	001	
-----------------	------	---------	-----	--

SOLUTION/DROPS; OPHTHALMIC

HERPLEX

ALLERGAN	0.1%	N013935	002	
----------	------	---------	-----	--

STOXIL

GLAXOSMITHKLINE	0.1%	N013934	001	
-----------------	------	---------	-----	--

IFOSFAMIDE; MESNA

INJECTABLE; INJECTION

IFEX/MESNEX KIT

BAXTER HLTHCARE	1GM/VIAL; 100MG/ML	N019763	003	Oct 10, 1992
	3GM/VIAL; 100MG/ML	N019763	004	Oct 10, 1992

ILOPROST

SOLUTION; INHALATION

VENTAVIS

ACTELION PHARMS LTD	20MCG/2ML (10MCG/ML)	N021779	001	Dec 29, 2004
---------------------	----------------------	---------	-----	--------------

IMATINIB MESYLATE

CAPSULE; ORAL

GLEEVEC

NOVARTIS	EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021335	001	May 10, 2001
	EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021335	002	May 10, 2001

DISCONTINUED DRUG PRODUCT LIST

IMIPRAMINE HYDROCHLORIDE

CONCENTRATE; ORAL

IMIPRAMINE HYDROCHLORIDE

NOVARTIS 25MG/ML A086765 001

INJECTABLE; INJECTION

TOFRANIL

NOVARTIS 12.5MG/ML N011838 002

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

LEDERLE 10MG A086269 001

25MG A086267 001

50MG A086268 001

OXFORD PHARMS 10MG A040753 001 Feb 28, 2008

25MG A040752 001 Feb 28, 2008

50MG A040751 001 Feb 28, 2008

PAR PHARM 25MG A089497 001 Jul 14, 1987

ROXANE 10MG A083799 001

25MG A083799 002

50MG A083799 003

SANDOZ 10MG A085200 001

25MG A084869 002

50MG A085133 001

TEVA 10MG A083729 001

25MG A083729 004

50MG A083729 003

USL PHARMA 25MG A087776 001 Feb 10, 1982

VANGARD 10MG A088036 001 Nov 03, 1982

25MG A087619 001 Feb 09, 1982

50MG A087631 001 Jan 04, 1982

WATSON LABS 10MG A085220 001

10MG A085875 001

25MG A084252 002

25MG A085878 001

50MG A085221 001

50MG A085877 001

WEST WARD 25MG A088222 001 May 26, 1983

50MG A088223 001 May 26, 1983

JANIMINE

ABBOTT 10MG N017895 001

25MG N017895 002

50MG N017895 003

PRAMINE

ALRA 10MG A083827 001

25MG A083827 002

50MG A083827 003

PRESAMINE

SANOFI AVENTIS US 10MG N011836 006

25MG N011836 003

50MG N011836 007

IMIPRAMINE PAMOATE

CAPSULE; ORAL

TOFRANIL-PM

MALLINCKRODT INC EQ 75MG HCL **Federal Register N017090 001

determination that product was not discontinued or withdrawn for safety or efficacy reasons**

EQ 100MG HCL **Federal Register N017090 004

determination that product was not discontinued or withdrawn for safety or efficacy reasons**

EQ 125MG HCL **Federal Register N017090 003

determination that product was not discontinued or withdrawn for safety or efficacy reasons**

EQ 150MG HCL **Federal Register N017090 002

determination that product was not discontinued or withdrawn for safety or efficacy reasons**

DISCONTINUED DRUG PRODUCT LIST

INAMRINONE LACTATE

INJECTABLE; INJECTION

AMRINONE LACTATE

BAXTER HLTHCARE CORP	EQ 5MG BASE/ML	A075542 001	May 10, 2000
HOSPIRA	EQ 5MG BASE/ML	A074616 001	Aug 03, 1998
INOCOR			
SANOFI AVENTIS US	EQ 5MG BASE/ML	N018700 001	Jul 31, 1984

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE

ANI PHARMS INC	1.25MG	A074498 002	Feb 12, 1998
	2.5MG	A074498 001	Oct 31, 1996
SANDOZ	1.25MG	A074594 001	May 23, 1996
	2.5MG	A074594 002	May 23, 1996
TEVA	1.25MG	A074665 001	Apr 04, 1997
	2.5MG	A074665 002	Apr 04, 1997
WATSON LABS	1.25MG	A074585 001	Sep 26, 1996
	2.5MG	A074585 002	Sep 26, 1996

LOZOL

SANOFI AVENTIS US	1.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018538 002	Apr 29, 1993
	2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018538 001	Jul 06, 1983

INDECAINIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

DECABID

LILLY	EQ 50MG BASE	N019693 001	Dec 29, 1989
	EQ 75MG BASE	N019693 002	Dec 29, 1989
	EQ 100MG BASE	N019693 003	Dec 29, 1989

INDINAVIR SULFATE

CAPSULE; ORAL

CRIXIVAN

MERCK SHARP DOHME	EQ 100MG BASE	N020685 006	Apr 19, 2000
	EQ 333MG BASE	N020685 005	Dec 17, 1998

INDOCYANINE GREEN

INJECTABLE; INJECTION

IC-GREEN

AKORN	10MG/VIAL	N011525 003	
	40MG/VIAL	N011525 004	
	50MG/VIAL	N011525 002	

INDOMETHACIN

CAPSULE; ORAL

INDO-LEMMON

TEVA	25MG	A070266 001	Nov 07, 1985
	50MG	A070267 001	Nov 07, 1985

INDOCIN

IROKO PHARMS LLC	25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016059 001	
	50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016059 002	

INDOMETHACIN

ABLE	25MG	A076666 001	Dec 17, 2003
	50MG	A076666 002	Dec 17, 2003
CYCLE PHARMS LTD	25MG	A070353 001	Jun 18, 1985
	50MG	A070354 001	Jun 18, 1985
DURAMED PHARMS BARR	25MG	A070326 001	Oct 18, 1985
	50MG	A070327 001	Oct 18, 1985
HALSEY	25MG	A070782 001	Jun 03, 1987
	50MG	A070635 001	Jun 03, 1987
IVAX SUB TEVA PHARMS	25MG	N018730 001	May 04, 1984
	50MG	N018730 002	May 04, 1984
MUTUAL PHARM	25MG	A070067 001	Oct 03, 1986
	50MG	A070068 001	Oct 03, 1986

DISCONTINUED DRUG PRODUCT LISTINDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN

MYLAN	50MG	N018858 002	Apr 20, 1984
PARKE DAVIS	25MG	N018806 001	Nov 23, 1984
	50MG	N018806 002	Nov 23, 1984
PIONEER PHARMS	25MG	A070813 001	Aug 11, 1986
	50MG	A070592 001	Aug 11, 1986
PLIVA	25MG	A071148 001	Mar 18, 1987
	50MG	A071149 001	Mar 18, 1987
SUN PHARM INDS	25MG	A070900 002	Feb 09, 1987
	50MG	A070900 001	Feb 09, 1987
SUPERPHARM	25MG	A070487 001	Oct 10, 1986
	50MG	A070488 001	Oct 10, 1986
TEVA	25MG	A071342 001	Apr 18, 1988
	50MG	A071343 001	Apr 18, 1988
VINTAGE	25MG	N018829 002	Aug 06, 1984
	50MG	A070651 001	Mar 05, 1986
	50MG	N018829 001	Aug 06, 1984
WATSON LABS	25MG	A070529 001	Oct 18, 1985
	25MG	A070784 001	Aug 20, 1986
	25MG	A072996 001	Jul 31, 1991
	25MG	N018690 001	Jul 31, 1984
	50MG	A070530 001	Oct 18, 1985
	50MG	A070785 001	Aug 20, 1986
	50MG	A071635 001	May 18, 1987
	50MG	A072997 001	Jul 31, 1991
	50MG	N018690 002	Jul 31, 1984

CAPSULE, EXTENDED RELEASE; ORAL

INDOCIN SR

IROKO PHARMS	75MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018185 001	Feb 23, 1982
--------------	------	--	-------------	--------------

INDOMETHACIN

ABLE	75MG		A076114 001	Feb 06, 2002
INWOOD LABS	75MG		A072410 001	Mar 15, 1989

SUPPOSITORY; RECTAL

INDOCIN

IROKO PHARMS	50MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017814 001	Aug 13, 1984
--------------	------	--	-------------	--------------

SUSPENSION; ORAL

INDOMETHACIN

CYCLE PHARMS LTD	25MG/5ML		A071412 001	Mar 18, 1987
------------------	----------	--	-------------	--------------

INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT

INJECTABLE; SUBCUTANEOUS

NOVOLOG MIX 50/50

NOVO NORDISK INC	50 UNITS/ML; 50 UNITS/ML		N021810 001	Aug 26, 2008
------------------	--------------------------	--	-------------	--------------

NOVOLOG MIX 70/30 PENFILL

NOVO NORDISK INC	210 UNITS/3ML; 90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML)		N021172 002	Nov 01, 2001
	210 UNITS/3ML; 90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML)		N021172 003	Nov 01, 2001

INSULIN ASPART RECOMBINANT

INJECTABLE; SUBCUTANEOUS

NOVOLOG INNOLET

NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)		N020986 004	Apr 23, 2004
------------------	------------------------------	--	-------------	--------------

INSULIN DETEMIR RECOMBINANT

INJECTABLE; SUBCUTANEOUS

LEVEMIR FLEXPEN

NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)		N021536 002	Jun 16, 2005
------------------	------------------------------	--	-------------	--------------

LEVEMIR INNOLET

NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)		N021536 003	Jun 16, 2005
------------------	------------------------------	--	-------------	--------------

LEVEMIR PENFILL

NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)		N021536 004	Jun 16, 2005
------------------	------------------------------	--	-------------	--------------

DISCONTINUED DRUG PRODUCT LISTINSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

HUMALOG MIX 50/50 PEN

LILLY

50 UNITS/ML; 50 UNITS/ML

N021018 003 Dec 22, 1999

HUMALOG MIX 75/25 PEN

LILLY

75 UNITS/ML; 25 UNITS/ML

N021017 003 Dec 22, 1999

INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

HUMALOG PEN

LILLY

100 UNITS/ML

N020563 002 Aug 06, 1998

INSULIN PORK

INJECTABLE; INJECTION

ILETIN I

LILLY

500 UNITS/ML

N017931 001

INSULIN

NOVO NORDISK INC

40 UNITS/ML

N017926 001

REGULAR INSULIN

NOVO NORDISK INC

100 UNITS/ML

N017926 003

INSULIN PURIFIED BEEF

INJECTABLE; INJECTION

REGULAR ILETIN II

LILLY

100 UNITS/ML

N018478 001

INSULIN PURIFIED PORK

INJECTABLE; INJECTION

ILETIN II

LILLY

500 UNITS/ML

N018344 002

REGULAR ILETIN II (PORK)

LILLY

100 UNITS/ML

N018344 001

REGULAR PURIFIED PORK INSULIN

NOVO NORDISK INC

100 UNITS/ML

N018381 001

VELOSULIN

NOVO NORDISK INC

100 UNITS/ML

N018193 001

INSULIN PURIFIED PORK; INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE; INJECTION

INSULIN NORDISK MIXTARD (PORK)

NOVO NORDISK INC

30 UNITS/ML; 70 UNITS/ML

N018195 001

INSULIN RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN BR

LILLY

100 UNITS/ML

N019529 001 Apr 28, 1986

VELOSULIN BR

NOVO NORDISK INC

100 UNITS/ML

N021028 001 Jul 19, 1999

POWDER; INHALATION

EXUBERA

PFIZER

1MG/INH

N021868 001 Jan 27, 2006

3MG/INH

N021868 002 Jan 27, 2006

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN 50/50

LILLY

50 UNITS/ML; 50 UNITS/ML

N020100 001 Apr 29, 1992

INSULIN RECOMBINANT PURIFIED HUMAN

INJECTABLE; INJECTION

NOVOLIN R

NOVO NORDISK INC

100 UNITS/ML

N018778 001 Aug 30, 1983

VELOSULIN BR HUMAN

NOVO NORDISK INC

100 UNITS/ML

N019450 001 May 30, 1986

INSULIN RECOMBINANT PURIFIED HUMAN; INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION

MIXTARD HUMAN 70/30

BAYER PHARMS

30 UNITS/ML; 70 UNITS/ML

N019585 001 Mar 11, 1988

NOVOLIN 70/30

NOVO NORDISK INC

30 UNITS/ML; 70 UNITS/ML

N019441 001 Jul 11, 1986

DISCONTINUED DRUG PRODUCT LISTINSULIN SUSP ISOPHANE BEEF

INJECTABLE; INJECTION

NPH INSULIN

NOVO NORDISK INC	40 UNITS/ML	N017929 001
	100 UNITS/ML	N017929 003

INSULIN SUSP ISOPHANE BEEF/PORK

INJECTABLE; INJECTION

NPH ILETIN I (BEEF-PORK)

LILLY	40 UNITS/ML	N017936 001
	100 UNITS/ML	N017936 002

INSULIN SUSP ISOPHANE PURIFIED BEEF

INJECTABLE; INJECTION

NPH ILETIN II

LILLY	100 UNITS/ML	N018479 001
-------	--------------	-------------

INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE; INJECTION

INSULIN INSULATARD NPH NORDISK

NOVO NORDISK INC	100 UNITS/ML	N018194 001
------------------	--------------	-------------

NPH ILETIN II (PORK)

LILLY	100 UNITS/ML	N018345 001
-------	--------------	-------------

NPH PURIFIED PORK ISOPHANE INSULIN

NOVO NORDISK INC	100 UNITS/ML	N018623 001
------------------	--------------	-------------

INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION

INSULATARD NPH HUMAN

NOVO NORDISK INC	100 UNITS/ML	N019449 001	May 30, 1986
------------------	--------------	-------------	--------------

NOVOLIN N

NOVO NORDISK INC	100 UNITS/ML	N019065 001	Jan 23, 1985
------------------	--------------	-------------	--------------

INSULIN SUSP PROTAMINE ZINC BEEF/PORK

INJECTABLE; INJECTION

PROTAMINE ZINC & ILETIN I (BEEF-PORK)

LILLY	40 UNITS/ML	N017932 001
-------	-------------	-------------

	100 UNITS/ML	N017932 002
--	--------------	-------------

INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF

INJECTABLE; INJECTION

PROTAMINE ZINC AND ILETIN II

LILLY	100 UNITS/ML	N018476 001
-------	--------------	-------------

PROTAMINE ZINC INSULIN

BRISTOL MYERS SQUIBB	40 UNITS/ML	N017928 001
----------------------	-------------	-------------

	100 UNITS/ML	N017928 003
--	--------------	-------------

INSULIN SUSP PROTAMINE ZINC PURIFIED PORK

INJECTABLE; INJECTION

PROTAMINE ZINC AND ILETIN II (PORK)

LILLY	100 UNITS/ML	N018346 001
-------	--------------	-------------

INSULIN ZINC SUSP BEEF

INJECTABLE; INJECTION

LENTE INSULIN

NOVO NORDISK INC	40 UNITS/ML	N017998 001
------------------	-------------	-------------

	100 UNITS/ML	N017998 003
--	--------------	-------------

INSULIN ZINC SUSP EXTENDED BEEF

INJECTABLE; INJECTION

ULTRALENTE INSULIN

NOVO NORDISK INC	100 UNITS/ML	N017997 003
------------------	--------------	-------------

INSULIN ZINC SUSP EXTENDED PURIFIED BEEF

INJECTABLE; INJECTION

ULTRALENTE

NOVO NORDISK INC	100 UNITS/ML	N018385 001
------------------	--------------	-------------

INSULIN ZINC SUSP EXTENDED RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN U

LILLY	40 UNITS/ML	N019571 001	Jun 10, 1987
-------	-------------	-------------	--------------

	100 UNITS/ML	N019571 002	Jun 10, 1987
--	--------------	-------------	--------------

DISCONTINUED DRUG PRODUCT LISTINSULIN ZINC SUSP PROMPT BEEF

INJECTABLE; INJECTION

SEMILENTE INSULIN

NOVO NORDISK INC 100 UNITS/ML

N017996 003

INSULIN ZINC SUSP PROMPT PURIFIED PORK

INJECTABLE; INJECTION

SEMILENTE

NOVO NORDISK INC 100 UNITS/ML

N018382 001

INSULIN ZINC SUSP PURIFIED BEEF

INJECTABLE; INJECTION

LENTE ILETIN II

LILLY 100 UNITS/ML

N018477 001

INSULIN ZINC SUSP PURIFIED BEEF/PORK

INJECTABLE; INJECTION

LENTARD

NOVO NORDISK INC 100 UNITS/ML

N018384 001

INSULIN ZINC SUSP PURIFIED PORK

INJECTABLE; INJECTION

LENTE

NOVO NORDISK INC 100 UNITS/ML

N018383 001

LENTE ILETIN II (PORK)

LILLY 100 UNITS/ML

N018347 001

INSULIN ZINC SUSP RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN L

LILLY 100 UNITS/ML

N019377 002 Sep 30, 1985

NOVOLIN L

NOVO NORDISK INC 100 UNITS/ML

N019965 001 Jun 25, 1991

INSULIN ZINC SUSP SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION

NOVOLIN L

NOVO NORDISK INC 100 UNITS/ML

N018777 001 Aug 30, 1983

INULIN

INJECTABLE; INJECTION

INULIN AND SODIUM CHLORIDE

ISO TEX 100MG/ML

N002282 001

INVERT SUGAR

INJECTABLE; INJECTION

TRAVERT 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE 10GM/100ML

N016717 001

IOBENGUANE SULFATE I-131

INJECTABLE; INJECTION

IOBENGUANE SULFATE I 131

PHARMALUCENCE 2.3mCi/ML

N020084 001 Mar 25, 1994

IO CETAMIC ACID

TABLET; ORAL

CHOLEBRINE

MALLINCKRODT 750MG

N017129 001

IODAMIDE MEGLUMINE

INJECTABLE; INJECTION

RENOVUE-65

BRACCO 65%

N017902 001

RENOVUE-DIP

BRACCO 24%

N017903 001

IODIPAMIDE MEGLUMINE

INJECTABLE; INJECTION

CHOLOGRAFIN MEGLUMINE

BRACCO 10.3%

N009321 007

IODIPAMIDE SODIUM

INJECTABLE; INJECTION

CHOLOGRAFIN SODIUM

BRACCO 20%

N009321 001

DISCONTINUED DRUG PRODUCT LIST

IODOHIPPURATE SODIUM I-123

INJECTABLE; INJECTION

NEPHROFLOW

GE HEALTHCARE

1mCi/ML

N018289 001 Dec 28, 1984

IODOHIPPURATE SODIUM I-131

INJECTABLE; INJECTION

HIPPURAN I 131

MALLINCKRODT

0.25mCi/ML

N016666 001

HIPPUTOPE

BRACCO

1-2mCi/VIAL

N015419 002

IODOHIPPURATE SODIUM I 131

PHARMALUCENCE

0.2mCi/ML

N017313 001

IODOXAMATE MEGLUMINE

INJECTABLE; INJECTION

CHOLOVUE

BRACCO

9.9%

N018077 001

40.3%

N018076 001

IOFETAMINE HYDROCHLORIDE I-123

INJECTABLE; INJECTION

SPECTAMINE

IMP

1mCi/ML

N019432 001 Dec 24, 1987

IOHEXOL

INJECTABLE; INJECTION

OMNIPAQUE 210

GE HEALTHCARE

45.3%

N018956 006 Jun 30, 1989

SOLUTION; URETHRAL

OMNIPAQUE 70

GE HEALTHCARE

15.1%

N018956 007 Jun 01, 1994

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL

BAXTER HLTHCARE

41%

A074629 001 Nov 06, 1996

51%

A074629 004 Mar 31, 1998

61%

A074629 002 Nov 06, 1996

76%

A074629 003 Nov 06, 1996

HOSPIRA

61%

A074734 001 Dec 10, 1996

76%

A074734 002 Dec 10, 1996

IOPAMIDOL-200

COOK IMAGING

41%

A074881 001 Jul 28, 2000

HOSPIRA

41%

A074898 001 Dec 30, 1997

IOPAMIDOL-200 IN PLASTIC CONTAINER

HOSPIRA

41%

A074636 001 Dec 30, 1997

IOPAMIDOL-250

COOK IMAGING

51%

A074881 002 Jul 28, 2000

FRESENIUS KABI USA

51%

A074679 001 Apr 02, 1997

HOSPIRA

51%

A074898 002 Dec 30, 1997

51%

A075005 001 Feb 24, 1998

IOPAMIDOL-250 IN PLASTIC CONTAINER

HOSPIRA

51%

A074636 002 Dec 30, 1997

IOPAMIDOL-300

ABBVIE

61%

A074638 001 Apr 30, 1997

COOK IMAGING

61%

A074881 003 Jul 28, 2000

FRESENIUS KABI USA

61%

A074679 002 Apr 02, 1997

HOSPIRA

61%

A074898 003 Dec 30, 1997

61%

A075005 002 Feb 24, 1998

IOPAMIDOL-300 IN PLASTIC CONTAINER

HOSPIRA

61%

A074636 003 Dec 30, 1997

61%

A074637 001 Apr 03, 1997

IOPAMIDOL-370

COOK IMAGING

76%

A074881 004 Jul 28, 2000

FRESENIUS KABI USA

76%

A074679 003 Apr 02, 1997

HOSPIRA

76%

A074898 004 Dec 30, 1997

76%

A075005 003 Feb 24, 1998

IOPAMIDOL-370 IN PLASTIC CONTAINER

HOSPIRA

76%

A074636 004 Dec 30, 1997

ISOVUE-128

BRACCO

26%

N018735 005 Oct 21, 1986

ISOVUE-200

BRACCO

41%

N020327 001 Oct 12, 1994

DISCONTINUED DRUG PRODUCT LIST

IOPANOIC ACID

TABLET; ORAL

TELEPAQUE

GE HEALTHCARE 500MG N008032 001

IOPHENDYLATE

INJECTABLE; INJECTION

PANTOPAQUE

ALCON 100% N005319 001

IOTHALAMATE MEGLUMINE; IOTHALAMATE SODIUM

INJECTABLE; INJECTION

VASCORAY

MALLINCKRODT 52%; 26% N016783 001

IOTHALAMATE SODIUM

INJECTABLE; INJECTION

ANGIO-CONRAY

MALLINCKRODT 80% N013319 001

CONRAY 325

MALLINCKRODT 54.3% N017685 001

CONRAY 400

MALLINCKRODT 66.8% N014295 001

IOTROLAN

INJECTABLE; INTRATHECAL

OSMOVIST 190

BAYER HLTHCARE 40.6% N019580 001 Dec 07, 1989

OSMOVIST 240

BAYER HLTHCARE 51.3% N019580 002 Dec 07, 1989

IOVERSOL

INJECTABLE; INJECTION

OPTIRAY 160

LIEBEL-FLARSHEIM 34% N019710 003 Dec 30, 1988

OPTIRAY 240

LIEBEL-FLARSHEIM 51% N020923 001 May 28, 1998

IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM

INJECTABLE; INJECTION

HEXABRIX

GUERBET 39.3%; 19.6% N018905 002 Jul 26, 1985

IOXILAN

INJECTABLE; INJECTION

OXILAN-300

GUERBET 62% N020316 001 Dec 21, 1995

OXILAN-350

GUERBET 73% N020316 002 Dec 21, 1995

IPODATE CALCIUM

GRANULE; ORAL

ORAGRAFIN CALCIUM

BRACCO 3GM/PACKET N012968 001

IPODATE SODIUM

CAPSULE; ORAL

BILIVIST

BAYER HLTHCARE 500MG A087768 001 Aug 11, 1982

ORAGRAFIN SODIUM

BRACCO 500MG N012967 001

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

ATROVENT

BOEHRINGER INGELHEIM 0.018MG/INH N019085 001 Dec 29, 1986

SOLUTION; INHALATION

ATROVENT

BOEHRINGER INGELHEIM 0.02% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** N020228 001 Sep 29, 1993

IPRATROPIUM BROMIDE

ACTAVIS MID ATLANTIC 0.02% A075111 001 Apr 22, 1999

APOTEX INC 0.02% A075441 001 Mar 28, 2001

MYLAN SPECLT 0.02% A074755 001 Jan 10, 1997

PHARMASCIENCE INC 0.02% A075507 001 Jan 19, 2001

ROXANE 0.02% A075867 001 Jul 22, 2002

DISCONTINUED DRUG PRODUCT LIST

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

IPRATROPIUM BROMIDE

TEVA PHARMS USA

0.02%

A075313 001 Feb 07, 2000

SPRAY, METERED; NASAL

IPRATROPIUM BROMIDE

APOTEX INC

0.021MG/SPRAY

A076156 001 Apr 18, 2003

0.042MG/SPRAY

A076155 001 Apr 18, 2003

IRBESARTAN

TABLET; ORAL

IRBESARTAN

WATSON LABS INC

75MG

A090720 001 Oct 12, 2012

150MG

A090720 002 Oct 12, 2012

300MG

A090720 003 Oct 12, 2012

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

SANDOZ

40MG/2ML (20MG/ML)

A077994 001 Feb 27, 2008

100MG/5ML (20MG/ML)

A077994 002 Feb 27, 2008

IRON DEXTRAN

INJECTABLE; INJECTION

IRON DEXTRAN

SANOFI AVENTIS US

EQ 50MG IRON/ML

N010787 002

IRON SUCROSE

INJECTABLE; INTRAVENOUS

VENOFER

LUITPOLD

EQ 65MG BASE/3.25ML (EQ 20MG BASE/ML)

N021135 005 Mar 29, 2013

EQ 75MG BASE/3.75ML (EQ 20MG BASE/ML)

N021135 003 Mar 29, 2005

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

BETA-2

NEPHRON

1%

A086711 001

BRONKOSOL

SANOFI AVENTIS US

0.25%

N012339 009

1%

N012339 008

ISOETHARINE HYDROCHLORIDE

ALPHARMA US PHARMS

1%

A087101 001

ASTRAZENECA

0.062%

A087937 001 Nov 15, 1982

0.062%

A089614 001 Jun 13, 1991

0.125%

A087938 001 Nov 15, 1982

0.125%

A089615 001 Jun 13, 1991

0.167%

A088470 001 Mar 14, 1984

0.167%

A089616 001 Jun 13, 1991

0.2%

A088471 001 Mar 14, 1984

0.2%

A089617 001 Jun 13, 1991

0.25%

A088472 001 Mar 14, 1984

0.25%

A089618 001 Jun 13, 1991

BAXTER HLTHCARE

0.08%

A088144 001 Jul 29, 1983

0.14%

A088145 001 Mar 26, 1984

0.25%

A088146 001 Aug 01, 1983

DEY

0.08%

A088187 001 Dec 03, 1982

0.1%

A087389 001

0.17%

A087390 001

0.25%

A088188 001 Dec 03, 1982

1%

A086763 001

INTL MEDICATION

0.077%

A086651 001

0.08%

A086651 002

0.1%

A086651 003

0.143%

A086651 004

0.167%

A086651 005

0.2%

A086651 006

0.25%

A086651 007

1%

A086651 008

PARKE DAVIS

0.5%

A085997 001

1%

A085889 001

ROXANE

0.1%

A087396 001

0.125%

A087025 001

0.167%

A088226 001 Sep 16, 1983

0.2%

A087324 001

0.25%

A088275 001 Jun 03, 1983

DISCONTINUED DRUG PRODUCT LISTISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

ISOETHARINE HYDROCHLORIDE

1%	A086899	001	
ISOETHARINE HYDROCHLORIDE S/F			
DEY	0.08%	A089817	001 Nov 22, 1988
	0.1%	A089818	001 Nov 22, 1988
	0.17%	A089819	001 Nov 22, 1988
	0.25%	A089820	001 Nov 22, 1988
	1%	A089252	001 Sep 15, 1986

ISOETHARINE MESYLATE

AEROSOL, METERED; INHALATION

BRONKOMETER

SANOFI AVENTIS US	0.34MG/INH	N012339	007
ISOETHARINE MESYLATE			
ALPHARMA US PHARMS	0.34MG/INH	A087858	001 Aug 21, 1984

ISOFLURANE

LIQUID; INHALATION

ISOFLURANE

WATSON LABS INC	99.9%	A074393	001 May 12, 1995
-----------------	-------	---------	------------------

ISOFLUROPHATE

OINTMENT; OPHTHALMIC

FLOROPRYL

MERCK	0.025%	N010656	001
-------	--------	---------	-----

ISONIAZID

INJECTABLE; INJECTION

NYDRAZID

SANDOZ	100MG/ML	N008662	001
RIMIFON			
ROCHE	25MG/ML	N008420	002
	100MG/ML	N008420	003

SYRUP; ORAL

ISONIAZID

MIKART	50MG/5ML	A081118	001 Jul 21, 1997
LANIAZID			
LANNETT	50MG/5ML	A089243	001 Feb 03, 1986
RIMIFON			
ROCHE	50MG/5ML	N008420	001

TABLET; ORAL

DOW-ISONIAZID

DOW PHARM	300MG	A080330	002
HYZYD			
MEDPOINTE PHARM HLC	100MG	A080134	003
	300MG	A080134	004

INH

NOVARTIS	300MG	A080935	001
----------	-------	---------	-----

ISONIAZID

DURAMED PHARMS BARR	100MG	A088231	001 Mar 17, 1983
	300MG	A088119	001 Mar 17, 1983
HALSEY	50MG	A083632	001
HIKMA INTL PHARMS	100MG	A080212	001
	300MG	A087425	001
IMPAX LABS	100MG	A080153	001
IVAX SUB TEVA PHARMS	100MG	A080270	001
	300MG	A083610	001
LILLY	100MG	N008499	002
	300MG	N008499	003
MK LABS	100MG	A080941	001
NEXGEN PHARMA INC	100MG	A084050	001
PANRAY	50MG	N008428	001
	100MG	N008428	002
	300MG	N008428	003
PERRIGO	100MG	A083060	001
PHARMAVITE	100MG	A085091	001
PHOENIX LABS NY	50MG	A080368	001
	100MG	A080368	002
PUREPAC PHARM	50MG	A080132	003 Jul 14, 1982
	100MG	A080132	004 Jul 14, 1982
SUN PHARM INDS	100MG	A080136	001
	300MG	A083633	001

DISCONTINUED DRUG PRODUCT LISTISONIAZID

TABLET; ORAL

ISONIAZID

WATSON LABS	50MG	A080522	001
	100MG	A080401	001
	100MG	A080523	001
	100MG	A085790	001
	300MG	A080521	001
	300MG	A083178	001
	300MG	A085784	001
WHITEWORTH TOWN PLSN	100MG	A080120	002

LANIAZID

LANNETT	50MG	A080140	001
	100MG	A080140	002

NYDRAZID

BRISTOL MYERS SQUIBB	100MG	N008392	003
----------------------	-------	---------	-----

STANOZIDE

EVERYLIFE	100MG	A080126	001
	300MG	A080126	002

ISONIAZID; RIFAMPIN

CAPSULE; ORAL

RIFAMPIN AND ISONIAZID

HIKMA INTL PHARMS	150MG; 300MG	A065221	001	Jul 29, 2005
-------------------	--------------	---------	-----	--------------

ISOPROPAMIDE IODIDE

TABLET; ORAL

DARBID

GLAXOSMITHKLINE	EQ 5MG BASE	N010744	001
-----------------	-------------	---------	-----

ISOPROTERENOL HYDROCHLORIDE

AEROSOL, METERED; INHALATION

ISOPROTERENOL HYDROCHLORIDE

3M	0.12MG/INH	N010375	004
----	------------	---------	-----

ALPHARMA US PHARMS	0.12MG/INH	A085904	001
--------------------	------------	---------	-----

ISUPREL

SANOFI AVENTIS US	0.103MG/INH	N011178	001
-------------------	-------------	---------	-----

DISC; INHALATION

NORISODRINE AEROTROL

ABBOTT	0.25%	N016814	001
--------	-------	---------	-----

INJECTABLE; INJECTION

ISOPROTERENOL HYDROCHLORIDE

ABRAXIS PHARM	0.2MG/ML	A083431	001
---------------	----------	---------	-----

BAXTER HLTHCARE	0.2MG/ML	A083486	001
-----------------	----------	---------	-----

HOSPIRA	0.02MG/ML	A083283	001
---------	-----------	---------	-----

	0.2MG/ML	A083346	001
--	----------	---------	-----

INTL MEDICATION	0.2MG/ML	A083724	001
-----------------	----------	---------	-----

SOLUTION; INHALATION

AEROLONE

LILLY	0.25%	N007245	001
-------	-------	---------	-----

ISOPROTERENOL HYDROCHLORIDE

ARMOUR PHARM	0.031%	A087935	001	Nov 18, 1982
--------------	--------	---------	-----	--------------

	0.062%	A087936	001	Nov 18, 1982
--	--------	---------	-----	--------------

DEY	0.5%	A086764	001	Jan 04, 1982
-----	------	---------	-----	--------------

PARKE DAVIS	0.25%	A085994	001
-------------	-------	---------	-----

	0.5%	A085540	001
--	------	---------	-----

ISUPREL

SANOFI AVENTIS US	0.5%	N006327	002
-------------------	------	---------	-----

	1%	N006327	003
--	----	---------	-----

VAPO-ISO

FISONS	0.5%	N016813	001
--------	------	---------	-----

TABLET; RECTAL, SUBLINGUAL

ISUPREL

SANOFI AVENTIS US	10MG	N006328	001
-------------------	------	---------	-----

	15MG	N006328	002
--	------	---------	-----

ISOPROTERENOL HYDROCHLORIDE; PHENYLEPHRINE BITARTRATE

AEROSOL, METERED; INHALATION

DUO-MEDIHALER

3M	0.16MG/INH; 0.24MG/INH	N013296	001
----	------------------------	---------	-----

DISCONTINUED DRUG PRODUCT LIST

ISOPROTERENOL SULFATE

AEROSOL, METERED; INHALATION

MEDIHALER-ISO

3M

0.08MG/INH

N010375 003

POWDER; INHALATION

NORISODRINE

ABBVIE

10%

N006905 003

25%

N006905 002

ISOSORBIDE

SOLUTION; ORAL

ISMOTIC

ALCON

100GM/220ML

N017063 001

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL

ISORDIL

WYETH AYERST

40MG

N012882 002 Jul 29, 1988

TABLET; ORAL

ISORDIL

VALEANT PHARMS NORTH

10MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N012093 002 Jul 29, 1988

20MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N012093 006 Jul 29, 1988

30MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N012093 005 Jul 29, 1988

ISOSORBIDE DINITRATE

SUN PHARM INDS

5MG

A086166 002 Sep 19, 1986

10MG

A086169 001 Sep 19, 1986

20MG

A086167 001 Sep 19, 1986

30MG

A087564 001 Sep 18, 1986

SUPERPHARM

5MG

A089190 001 Feb 17, 1987

10MG

A089191 001 Feb 17, 1987

20MG

A089192 001 Feb 17, 1987

WATSON LABS

5MG

A086034 001 Jan 06, 1988

10MG

A086032 001 Jan 07, 1988

SORBITRATE

ASTRAZENECA

5MG

N016192 001 Apr 01, 1996

10MG

N016192 002 Apr 01, 1996

20MG

A086405 002 Aug 21, 1990

30MG

A088124 001 Aug 21, 1990

40MG

A088125 001 Aug 21, 1990

TABLET; SUBLINGUAL

ISORDIL

BIOVAIL

2.5MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N012940 004 Jul 29, 1988

5MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N012940 003 Jul 29, 1988

10MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N012940 005 Jul 29, 1988

ISOSORBIDE DINITRATE

HIKMA INTL PHARMS

2.5MG

A086054 001 Oct 29, 1987

5MG

A086055 001 Nov 02, 1987

SANDOZ

2.5MG

A086225 001 Feb 19, 1988

5MG

A086222 001 Feb 19, 1988

SUN PHARM INDS

2.5MG

A084204 001 Sep 18, 1986

5MG

A086168 001 Sep 18, 1986

10MG

A087545 001 Sep 18, 1986

WATSON LABS

2.5MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

A086033 001 Feb 26, 1988

5MG **Federal Register determination
that product was not discontinued or

A086031 001 Sep 29, 1987

DISCONTINUED DRUG PRODUCT LIST

ISOSORBIDE DINITRATE

TABLET;SUBLINGUAL

ISOSORBIDE DINITRATE

withdrawn for safety or efficacy reasons**

SORBITRATE

ASTRAZENECA

2.5MG

N016191 002 Apr 01, 1996

5MG

N016191 001 Apr 01, 1996

TABLET, CHEWABLE;ORAL

SORBITRATE

ASTRAZENECA

5MG

N016776 002 Apr 01, 1996

10MG

N016776 003 Apr 01, 1996

TABLET, EXTENDED RELEASE;ORAL

ISORDIL

WYETH AYERST

40MG

N012882 001 Jul 29, 1988

ISOSORBIDE DINITRATE

COREPHARMA

40MG

A040723 001 Mar 17, 2008

ISOSORBIDE MONONITRATE

TABLET;ORAL

ISMO

PROMIUS PHARMA

20MG

N019091 001 Dec 30, 1991

TABLET, EXTENDED RELEASE;ORAL

IMDUR

SCHERING PLOUGH

30MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N020225 001 Aug 12, 1993

60MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N020225 002 Aug 12, 1993

120MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N020225 003 Mar 30, 1995

ISOSORBIDE MONONITRATE

ACTAVIS ELIZABETH

30MG

A075306 001 Dec 31, 1998

60MG

A075306 002 Dec 31, 1998

ALKERMES GAINESVILLE

60MG

A075041 001 Sep 22, 1998

IVAX SUB TEVA PHARMS

30MG

A075448 002 Aug 07, 2001

60MG

A075448 001 Jun 19, 2000

120MG

A075448 003 Aug 07, 2001

SKYEPHARMA AG

60MG

A075166 001 Oct 07, 1999

ISOSULFAN BLUE

INJECTABLE;INJECTION

LYMPHAZURIN

COVIDIEN

1% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N018310 001

ISOTRETINOIN

CAPSULE;ORAL

ACCUTANE

HOFFMANN LA ROCHE

10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N018662 002 May 07, 1982

20MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N018662 004 Mar 28, 1983

40MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N018662 003 May 07, 1982

SOTRET

SUN PHARM INDS LTD

10MG

A076041 001 Dec 24, 2002

20MG

A076041 002 Dec 24, 2002

30MG

A076503 001 Jun 20, 2003

40MG

A076041 003 Dec 24, 2002

DISCONTINUED DRUG PRODUCT LIST

ISRADIPINE

CAPSULE; ORAL

DYNACIRC

SMITHKLINE BEECHAM

2.5MG

N019546 001 Dec 20, 1990

5MG

N019546 002 Dec 20, 1990

TABLET, EXTENDED RELEASE; ORAL

DYNACIRC CR

GLAXOSMITHKLINE LLC

5MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N020336 001 Jun 01, 1994

10MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N020336 002 Jun 01, 1994

ITRACONAZOLE

INJECTABLE; INJECTION

SPORANOX

JANSSEN PHARMS

10MG/ML

N020966 001 Mar 30, 1999

SOLUTION; ORAL

ITRACONAZOLE

AMNEAL PHARMS

10MG/ML

A205573 001 Oct 30, 2015

IVERMECTIN

TABLET; ORAL

STROMEKTOL

MERCK SHARP DOHME

6MG

N050742 001 Nov 22, 1996

KANAMYCIN SULFATE

CAPSULE; ORAL

KANTREX

APOTHECON

EQ 500MG BASE

A060516 001

EQ 500MG BASE

A061911 001

EQ 500MG BASE

A062726 001 Mar 06, 1987

INJECTABLE; INJECTION

KANAMYCIN

EUROHLTH INTL SARL

EQ 75MG BASE/2ML

A062324 001

EQ 500MG BASE/2ML

A062324 002

EQ 1GM BASE/3ML

A062324 003

KANAMYCIN SULFATE

ABRAXIS PHARM

EQ 75MG BASE/2ML

A062504 001 Apr 05, 1984

EQ 500MG BASE/2ML

A062504 002 Apr 05, 1984

EQ 1GM BASE/3ML

A062504 003 Apr 05, 1984

INTL MEDICATION

EQ 500MG BASE/2ML

A062466 001 Sep 30, 1983

EQ 1GM BASE/3ML

A062466 002 Sep 30, 1983

LOCH

EQ 75MG BASE/2ML

A063021 001 Jul 31, 1992

EQ 500MG BASE/2ML

A063022 001 Jul 31, 1992

EQ 1GM BASE/3ML

A063025 001 Jul 31, 1992

PHARMAFAIR

EQ 75MG BASE/2ML

A062668 001 May 07, 1987

EQ 500MG BASE/2ML

A062672 001 May 07, 1987

EQ 1GM BASE/3ML

A062669 001 May 07, 1987

SOLOPAK

EQ 75MG BASE/2ML

A062605 003 Feb 26, 1986

EQ 500MG BASE/2ML

A062605 001 Feb 26, 1986

EQ 1GM BASE/3ML

A062605 002 Feb 26, 1986

WARNER CHILCOTT

EQ 1GM BASE/3ML

A063092 001 Oct 11, 1989

WATSON LABS

EQ 1GM BASE/3ML

A062520 003 May 09, 1985

KANTREX

APOTHECON

EQ 75MG BASE/2ML

A061655 003

EQ 75MG BASE/2ML

A061901 003

EQ 75MG BASE/2ML

A062564 001 Sep 21, 1984

EQ 500MG BASE/2ML

A061655 001

EQ 500MG BASE/2ML

A061901 001

EQ 500MG BASE/2ML

A062564 002 Sep 21, 1984

EQ 1GM BASE/3ML

A061655 002

EQ 1GM BASE/3ML

A061901 002

EQ 1GM BASE/3ML

A062564 003 Sep 21, 1984

KLEBCIL

KING PHARMS

EQ 75MG BASE/2ML

A062170 001

EQ 500MG BASE/2ML

A062170 002

EQ 1GM BASE/3ML

A062170 003

DISCONTINUED DRUG PRODUCT LIST

KETOCONAZOLE

CREAM; TOPICAL

NIZORAL

JANSSEN PHARMA

2%

N019084 001 Dec 31, 1985

SUSPENSION; ORAL

NIZORAL

JANSSEN PHARMA

100MG/5ML

A070767 001 Nov 07, 1986

TABLET; ORAL

KETOCONAZOLE

AAIPHARMA LLC

200MG

A075341 001 Jul 27, 1999

APOTEX

200MG

A075912 001 Jan 10, 2002

PLIVA

200MG

A075362 001 Jun 15, 1999

SUN PHARM INDS

200MG

A075314 001 Jun 15, 1999

TEVA

200MG

A074971 001 Jun 15, 1999

NIZORAL

JANSSEN PHARMS

200MG

N018533 001

KETOPROFEN

CAPSULE; ORAL

KETOPROFEN

AUROLIFE PHARMA LLC

50MG

A074024 001 Dec 29, 1995

75MG

A074024 002 Dec 29, 1995

TEVA

25MG

A073515 001 Dec 22, 1992

ORUDIS

WYETH AYERST

25MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N018754 001 Jul 31, 1987

50MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N018754 002 Jan 09, 1986

75MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N018754 003 Jan 09, 1986

CAPSULE, EXTENDED RELEASE; ORAL

KETOPROFEN

ALKERMES GAINESVILLE

200MG

A074879 001 Dec 10, 1997

ORUVAIL

WYETH PHARMS INC

100MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N019816 003 Feb 08, 1995

150MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N019816 002 Feb 08, 1995

200MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N019816 001 Sep 24, 1993

FILM; ORAL

NEXCEDE

NOVARTIS

12.5MG

N022470 001 Nov 25, 2009

TABLET; ORAL

ACTRON

BAYER

12.5MG

N020499 001 Oct 06, 1995

KETOPROFEN

PERRIGO

12.5MG

A075364 001 Feb 07, 2002

ORUDIS KT

WYETH CONS

12.5MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N020429 001 Oct 06, 1995

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

APOTEX INC

30MG/ML

A075626 001 Jul 24, 2001

30MG/ML

A077201 001 Oct 14, 2005

APOTHECON

15MG/ML

A075348 001 Nov 28, 2000

30MG/ML

A075348 002 Nov 28, 2000

BEDFORD

15MG/ML

A075230 002 Oct 25, 1999

30MG/ML

A075230 001 Oct 25, 1999

CLARIS

15MG/ML

A075631 002 Jun 29, 2001

DISCONTINUED DRUG PRODUCT LIST

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

	30MG/ML	A075631 001	Jun 29, 2001
GLAND PHARMA LTD	15MG/ML	A076722 001	Jul 27, 2004
	30MG/ML	A076722 002	Jul 27, 2004
HOSPIRA	15MG/ML	A074801 001	Jun 05, 1997
	30MG/ML	A074801 002	Jun 05, 1997
LUITPOLD	15MG/ML	A078145 001	Jan 14, 2008
	30MG/ML	A078145 002	Jan 14, 2008
SANDOZ	15MG/ML	A076271 001	Oct 06, 2004
SUN PHARMA GLOBAL	15MG/ML	A078737 001	Oct 06, 2008
	30MG/ML	A078737 002	Oct 06, 2008
WEST-WARD PHARMS INT	15MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A075222 001	Apr 26, 1999
	15MG/ML	A075299 001	Nov 03, 1999
	15MG/ML	A075772 001	Jul 21, 2004
	30MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A075222 002	Apr 26, 1999
	30MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A075228 001	Apr 26, 1999
	30MG/ML	A075299 002	Nov 03, 1999
	30MG/ML	A075772 002	Jul 21, 2004
WOCKHARDT	30MG/ML	A077943 001	Mar 27, 2007
TORADOL			
ROCHE PALO	15MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019698 001	Nov 30, 1989
	30MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019698 002	Nov 30, 1989
SOLUTION/DROPS;OPHTHALMIC			
ACULAR PRESERVATIVE FREE			
ALLERGAN	0.5%	N020811 001	Nov 03, 1997
KETOROLAC TROMETHAMINE			
AKORN	0.45%	A203376 001	Feb 10, 2014
TABLET; ORAL			
KETOROLAC TROMETHAMINE			
CYCLE PHARMS LTD	10MG	A074790 001	Jun 26, 1997
WATSON LABS	10MG	A074955 001	Sep 19, 1997
TORADOL			
ROCHE PALO	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019645 001	Dec 20, 1991

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC

KETOTIFEN FUMARATE

APOTEX INC	EQ 0.025% BASE	A077354 001	May 09, 2006
ZADITOR			
ALCON PHARMA	EQ 0.025% BASE	N021066 002	Oct 19, 2006

KRYPTON, KR-81M

GAS; INHALATION

MPI KRYPTON 81M GENERATOR

GE HEALTHCARE	N/A	N018088 001	
---------------	-----	-------------	--

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HYDROCHLORIDE

APOTHECON	5MG/ML	A075355 001	Nov 29, 1999
CLARIS	5MG/ML	A076051 001	Jul 05, 2002
HOSPIRA	5MG/ML	A075242 001	Sep 30, 1999
NORMODYNE			
SCHERING	5MG/ML	N018686 001	Aug 01, 1984
TRANDATE			
SEBELA IRELAND LTD	5MG/ML **Federal Register determination	N019425 001	Dec 31, 1985

DISCONTINUED DRUG PRODUCT LIST

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

TRANDATE

that product was not discontinued or
 withdrawn for safety or efficacy
 reasons**

TABLET; ORAL

LABETALOL HYDROCHLORIDE

APOTHECON

100MG

A075223 001 Nov 20, 1998

200MG

A075223 002 Nov 20, 1998

300MG

A075223 003 Nov 20, 1998

TEVA

100MG

A074989 001 Sep 30, 1998

200MG

A074989 002 Sep 30, 1998

300MG

A074989 003 Sep 30, 1998

NORMODYNE

SCHERING

100MG **Federal Register determination
 that product was not discontinued or
 withdrawn for safety or efficacy
 reasons**

N018687 001 Aug 31, 1987

200MG **Federal Register determination
 that product was not discontinued or
 withdrawn for safety or efficacy
 reasons**

N018687 002 Aug 01, 1984

300MG **Federal Register determination
 that product was not discontinued or
 withdrawn for safety or efficacy
 reasons**

N018687 003 Aug 01, 1984

400MG **Federal Register determination
 that product was not discontinued or
 withdrawn for safety or efficacy
 reasons**

N018687 004 Aug 01, 1984

TRANDATE

CNTY LINE PHARMS

400MG **Federal Register determination
 that product was not discontinued or
 withdrawn for safety or efficacy
 reasons**

N018716 004 Aug 01, 1984

LACTULOSE

SOLUTION; ORAL

CHRONULAC

SANOFI AVENTIS US

10GM/15ML **Federal Register
 determination that product was not
 discontinued or withdrawn for safety or
 efficacy reasons**

N017884 001

CONSTULOSE

ACTAVIS MID ATLANTIC

10GM/15ML

A070288 001 Aug 15, 1988

DUPHALAC

SOLVAY

10GM/15ML

A072372 001 Mar 22, 1989

EVALOSE

TEVA PHARMS

10GM/15ML

A073497 001 May 28, 1993

LACTULOSE

APOTEX INC

10GM/15ML

A075911 001 Feb 21, 2002

MORTON GROVE

10GM/15ML

A071841 001 Sep 22, 1988

PACO

10GM/15ML

A073160 001 Aug 25, 1992

LAXILOSE

NOSTRUM LABS

10GM/15ML

A073686 001 May 28, 1993

SOLUTION; ORAL, RECTAL

ACILAC

NOSTRUM LABS

10GM/15ML

A073685 001 May 28, 1993

CEPHULAC

SANOFI AVENTIS US

10GM/15ML **Federal Register
 determination that product was not
 discontinued or withdrawn for safety or
 efficacy reasons**

N017657 001

GENERLAC

MORTON GROVE

10GM/15ML

A071842 001 Sep 27, 1988

HEPTALAC

TEVA PHARMS

10GM/15ML

A073504 001 May 28, 1993

LACTULOSE

APOTEX INC

10GM/15ML

A076645 001 Jul 28, 2003

PACO

10GM/15ML

A072029 001 Aug 25, 1992

ROXANE

10GM/15ML

A073590 001 May 29, 1992

SOLVAY

10GM/15ML

N017906 001

PORTALAC

SOLVAY

10GM/15ML

A072374 001 Mar 22, 1989

DISCONTINUED DRUG PRODUCT LISTLAMIVUDINE; RALTEGRAVIR POTASSIUM

TABLET; ORAL

DUTREBIS

MERCK SHARP DOHME	150MG;EQ 300MG BASE	N206510	001	Feb 06, 2015
-------------------	---------------------	---------	-----	--------------

LAMOTRIGINE

TABLET; ORAL

LAMICTAL

GLAXOSMITHKLINE LLC	50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020241	006	Dec 27, 1994
	250MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020241	004	Dec 27, 1994

LAMOTRIGINE

ACTAVIS TOTOWA	25MG	A078669	001	Apr 08, 2011
	100MG	A078669	002	Apr 08, 2011
	150MG	A078669	003	Apr 08, 2011
	200MG	A078669	004	Apr 08, 2011
HIKMA PHARMS	25MG	A078134	001	Apr 19, 2011
	100MG	A078134	002	Apr 19, 2011
	150MG	A078134	003	Apr 19, 2011
	200MG	A078134	004	Apr 19, 2011
MATRIX LABS LTD	25MG	A078443	001	Feb 11, 2009
	100MG	A078443	002	Feb 11, 2009
	150MG	A078443	003	Feb 11, 2009
	200MG	A078443	004	Feb 11, 2009
MYLAN	25MG	A077428	001	Jan 27, 2009
	100MG	A077428	002	Jan 27, 2009
	150MG	A077428	003	Jan 27, 2009
	200MG	A077428	004	Jan 27, 2009
PHARMASCIENCE INC	25MG	A078310	001	Feb 04, 2009
	100MG	A078310	002	Feb 04, 2009
	150MG	A078310	003	Feb 04, 2009
	200MG	A078310	004	Feb 04, 2009
ROXANE	25MG	A077392	001	Jan 27, 2009
	100MG	A077392	002	Jan 27, 2009
	150MG	A077392	003	Jan 27, 2009
	200MG	A077392	004	Jan 27, 2009
SANDOZ	25MG	A078645	001	Jan 27, 2009
	100MG	A078645	002	Jan 27, 2009
	150MG	A078645	003	Jan 27, 2009
	200MG	A078645	004	Jan 27, 2009
WOCKHARDT	25MG	A078982	001	Jan 27, 2009
	100MG	A078982	002	Jan 27, 2009
	150MG	A078982	003	Jan 27, 2009
	200MG	A078982	004	Jan 27, 2009

TABLET, CHEWABLE; ORAL

LAMICTAL CD

GLAXOSMITHKLINE LLC	100MG	N020764	003	Aug 24, 1998
SANDOZ	5MG	A078409	002	Jan 22, 2009
	25MG	A078409	003	Jan 22, 2009

LANSOPRAZOLE

FOR SUSPENSION, DELAYED RELEASE; ORAL

PREVACID

TAKEDA PHARMS NA	15MG/PACKET	N021281	001	May 03, 2001
	30MG/PACKET	N021281	002	May 03, 2001

INJECTABLE; INTRAVENOUS

PREVACID IV

TAKEDA PHARMS NA	30MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021566	001	May 27, 2004
------------------	--	---------	-----	--------------

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING; ORAL

LANSOPRAZOLE

ANI PHARMS INC	15MG	A078730	001	Oct 15, 2010
	30MG	A078730	002	Oct 15, 2010

DISCONTINUED DRUG PRODUCT LIST

LANSOPRAZOLE; NAPROXEN

CAPSULE, DELAYED REL PELLETS, TABLET;ORAL

PREVACID NAPRAPAC 250 (COPACKAGED)

TAKEDA PHARMS NA	15MG,N/A;N/A,250MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021507 002	Nov 14, 2003
------------------	--------------------	--	-------------	--------------

PREVACID NAPRAPAC 375 (COPACKAGED)

TAKEDA PHARMS NA	15MG,N/A;N/A,375MG		N021507 003	Nov 14, 2003
------------------	--------------------	--	-------------	--------------

PREVACID NAPRAPAC 500 (COPACKAGED)

TAKEDA PHARMS NA	15MG,N/A;N/A,500MG		N021507 004	Nov 14, 2003
------------------	--------------------	--	-------------	--------------

LANTHANUM CARBONATE

TABLET, CHEWABLE;ORAL

FOSRENOL

SHIRE LLC	EQ 250MG BASE		N021468 001	Oct 26, 2004
-----------	---------------	--	-------------	--------------

LAPYRIUM CHLORIDE; UNDECOYLUM CHLORIDE IODINE COMPLEX

SOLUTION;TOPICAL

VIRAC REX

CHESEBROUGH PONDS	0.5%;1.8%		N011914 001	
-------------------	-----------	--	-------------	--

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC

LATANOPROST

APOTEX INC	0.005%		A077697 001	Mar 22, 2011
------------	--------	--	-------------	--------------

LEFLUNOMIDE

TABLET;ORAL

LEFLUNOMIDE

SANDOZ	10MG		A077085 001	Sep 13, 2005
	10MG		A077087 001	Sep 13, 2005
	20MG		A077085 002	Sep 13, 2005
	20MG		A077087 002	Sep 13, 2005

LEPIRUDIN RECOMBINANT

INJECTABLE;INJECTION

REFLUDAN

BAYER HLTHCARE	50MG/VIAL		N020807 001	Mar 06, 1998
----------------	-----------	--	-------------	--------------

LETROZOLE

TABLET;ORAL

LETROZOLE

ACTAVIS TOTOWA	2.5MG		A090292 001	Jul 13, 2011
IMPAX LABS	2.5MG		A091638 001	Jun 03, 2011
SYNTHON PHARMS	2.5MG		A090196 001	Jun 03, 2011

LEUCOVORIN CALCIUM

FOR SOLUTION;ORAL

LEUCOVORIN CALCIUM

HOSPIRA	EQ 60MG BASE/VIAL		N008107 003	Jan 30, 1987
---------	-------------------	--	-------------	--------------

INJECTABLE;INJECTION

LEUCOVORIN CALCIUM

ABIC	EQ 3MG BASE/ML		A089352 001	Jun 01, 1988
	EQ 50MG BASE/VIAL		A089353 001	Jun 01, 1988
ABRAXIS PHARM	EQ 50MG BASE/VIAL		A088939 001	Dec 01, 1986
	EQ 50MG BASE/VIAL		A070480 001	Jan 02, 1987
ELKINS SINN	EQ 100MG BASE/VIAL		A081224 001	Jun 03, 1994
	EQ 3MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**		N008107 001	
HOSPIRA	EQ 50MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**		N008107 002	
	EQ 100MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**		N008107 004	May 23, 1988
HOSPIRA	EQ 350MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**		N008107 005	Apr 05, 1989
	EQ 350MG BASE/VIAL		A040262 001	Dec 15, 1999
PHARMACHEMIE	EQ 50MG BASE/VIAL		A089628 001	Apr 17, 1997
	EQ 100MG BASE/VIAL		A089915 001	Apr 17, 1997
PHARMACHEMIE USA	EQ 50MG BASE/VIAL		A081278 001	Sep 28, 1993
TEVA PARENTERAL	EQ 50MG BASE/VIAL			

DISCONTINUED DRUG PRODUCT LIST

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM PRESERVATIVE FREE

HOSPIRA	EQ 10MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A040147	001	Jun 25, 1997
---------	--	---------	-----	--------------

LUITPOLD	EQ 50MG BASE/VIAL	A040338	001	Jan 31, 2001
----------	-------------------	---------	-----	--------------

TEVA PARENTERAL	EQ 10MG BASE/ML	A040332	001	Jun 28, 1999
-----------------	-----------------	---------	-----	--------------

WELLCOVORIN

GLAXOSMITHKLINE	EQ 5MG BASE/ML	A087439	001	Oct 19, 1982
-----------------	----------------	---------	-----	--------------

	EQ 25MG BASE/VIAL	A089833	001	Jan 23, 1989
--	-------------------	---------	-----	--------------

	EQ 50MG BASE/VIAL	A089465	001	Jan 23, 1989
--	-------------------	---------	-----	--------------

	EQ 100MG BASE/VIAL	A089834	001	Jan 23, 1989
--	--------------------	---------	-----	--------------

TABLET; ORAL

LEUCOVORIN CALCIUM

COREPHARMA	EQ 5MG BASE	A074544	001	Aug 28, 1997
------------	-------------	---------	-----	--------------

	EQ 25MG BASE	A074544	002	Aug 28, 1997
--	--------------	---------	-----	--------------

IDT AUSTRALIA LTD	EQ 15MG BASE	A075327	001	Mar 24, 1999
-------------------	--------------	---------	-----	--------------

PAR PHARM	EQ 5MG BASE	A071600	001	Oct 14, 1987
-----------	-------------	---------	-----	--------------

	EQ 25MG BASE	A071598	001	Oct 14, 1987
--	--------------	---------	-----	--------------

PHARMACHEMIE	EQ 5MG BASE	A073099	001	Mar 28, 1997
--------------	-------------	---------	-----	--------------

	EQ 25MG BASE	A073101	001	Mar 28, 1997
--	--------------	---------	-----	--------------

XANODYNE PHARM	EQ 5MG BASE	N018459	001	Jan 30, 1986
----------------	-------------	---------	-----	--------------

	EQ 10MG BASE	A071962	001	Nov 19, 1987
--	--------------	---------	-----	--------------

	EQ 15MG BASE	A071104	001	Mar 04, 1987
--	--------------	---------	-----	--------------

WELLCOVORIN

GLAXOSMITHKLINE	EQ 5MG BASE	N018342	001	Jul 08, 1983
-----------------	-------------	---------	-----	--------------

	EQ 25MG BASE	N018342	002	Jul 08, 1983
--	--------------	---------	-----	--------------

LEUPROLIDE ACETATE

IMPLANT; IMPLANTATION

VIADUR

ORTHO MCNEIL JANSSEN	EQ 65MG BASE	N021088	001	Mar 03, 2000
----------------------	--------------	---------	-----	--------------

INJECTABLE; INJECTION

LEUPROLIDE ACETATE

GENZYME	1MG/0.2ML	A075721	001	Nov 29, 2001
---------	-----------	---------	-----	--------------

LUPRON

ABBVIE ENDOCRINE INC	1MG/0.2ML	N019010	001	Apr 09, 1985
----------------------	-----------	---------	-----	--------------

LUPRON DEPOT

ABBVIE ENDOCRINE INC	3.75MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020011	001	Oct 22, 1990
----------------------	--	---------	-----	--------------

LUPRON DEPOT-PED

ABBVIE ENDOCRINE INC	3.75MG/VIAL, 7.5MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020263	003	Apr 16, 1993
----------------------	--	---------	-----	--------------

	7.5MG/VIAL, 7.5MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020263	004	Apr 16, 1993
--	---	---------	-----	--------------

LEVALLORPHAN TARTRATE

INJECTABLE; INJECTION

LORFAN

ROCHE	1MG/ML	N010423	001	
-------	--------	---------	-----	--

LEVAMISOLE HYDROCHLORIDE

TABLET; ORAL

ERGAMISOL

JANSSEN PHARMA	EQ 50MG BASE	N020035	001	Jun 18, 1990
----------------	--------------	---------	-----	--------------

LEVETIRACETAM

SOLUTION; ORAL

LEVETIRACETAM

APOTEX INC	100MG/ML	A090187	001	Aug 05, 2011
------------	----------	---------	-----	--------------

TABLET; ORAL

LEVETIRACETAM

ACTAVIS LABS FL INC	250MG	A077408	001	Mar 02, 2009
---------------------	-------	---------	-----	--------------

	500MG	A077408	002	Mar 02, 2009
--	-------	---------	-----	--------------

	750MG	A077408	003	Mar 02, 2009
--	-------	---------	-----	--------------

MYLAN	250MG	A078731	001	Feb 10, 2009
-------	-------	---------	-----	--------------

	500MG	A078731	002	Feb 10, 2009
--	-------	---------	-----	--------------

	750MG	A078731	003	Feb 10, 2009
--	-------	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

LEVETIRACETAM

TABLET; ORAL

LEVETIRACETAM

	1GM	A078731 004	Feb 10, 2009
SANDOZ	250MG	A077324 001	Jan 15, 2009
	500MG	A077324 002	Jan 15, 2009
	750MG	A077324 003	Jan 15, 2009
	1GM	A077324 004	Jan 15, 2009
WATSON LABS INC	250MG	A078797 002	Jan 15, 2009
	500MG	A078797 003	Jan 15, 2009
	750MG	A078797 004	Jan 15, 2009
	1GM	A078797 001	Jan 15, 2009

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

SANDOZ	500MG	A091668 001	Nov 01, 2012
	750MG	A091668 002	Nov 01, 2012

LEVOBETAXOLOL HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

BETAXON

ALCON PHARMS LTD	EQ 0.5% BASE	N021114 001	Feb 23, 2000
------------------	--------------	-------------	--------------

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

LEVOBUNOLOL HYDROCHLORIDE

APOTEX INC	0.25%	A075473 001	Aug 03, 2000
	0.5%	A075475 001	Aug 03, 2000

LEVOBUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHIROCAINE

PURDUE PHARMA LP	EQ 2.5MG BASE/ML	N020997 001	Aug 05, 1999
	EQ 5MG BASE/ML	N020997 002	Aug 05, 1999
	EQ 7.5MG BASE/ML	N020997 003	Aug 05, 1999

LEVOCABASTINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

LIVOSTIN

NOVARTIS	EQ 0.05% BASE	N020219 001	Nov 10, 1993
----------	---------------	-------------	--------------

LEVOCARNITINE

INJECTABLE; INJECTION

LEVOCARNITINE

TEVA PHARMS USA	200MG/ML	A075881 001	Mar 29, 2001
-----------------	----------	-------------	--------------

SOLUTION; ORAL

CARNITOR

SIGMA TAU	1GM/10ML	N018948 002	Apr 27, 1988
-----------	----------	-------------	--------------

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

SANDOZ	5MG	A090486 001	Mar 26, 2013
--------	-----	-------------	--------------

LEVODOPA

CAPSULE; ORAL

BENDOPA

VALEANT PHARM INTL	100MG	N016948 003	
	250MG	N016948 001	
	500MG	N016948 002	

DOPAR

SHIRE	100MG	N016913 003	
	250MG	N016913 001	
	500MG	N016913 002	

LARODOPA

ROCHE	100MG	N016912 002	
	250MG	N016912 001	
	500MG	N016912 006	

TABLET; ORAL

DOPAR

SHIRE	250MG	N016913 004	
	500MG	N016913 005	

LARODOPA

ROCHE	100MG	N016912 005	
	250MG	N016912 003	
	500MG	N016912 004	

DISCONTINUED DRUG PRODUCT LIST

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER

JANSSEN PHARMS

EQ 250MG/50ML (EQ 5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N020635 002 Dec 20, 1996

EQ 500MG/100ML (EQ 5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N020635 003 Dec 20, 1996

EQ 750MG/150ML (EQ 5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N020635 005 Dec 20, 1996

LEVOFLOXACIN

AKORN

EQ 500MG/20ML (EQ 25MG/ML)

A091644 001 Jun 20, 2011

EQ 750MG/30ML (EQ 25MG/ML)

A091644 002 Jun 20, 2011

HOSPIRA INC

EQ 500MG/20ML (EQ 25MG/ML)

A078577 001 Aug 12, 2015

EQ 750MG/30ML (EQ 25MG/ML)

A078577 002 Aug 12, 2015

SOLUTION/DROPS; OPHTHALMIC

IQUIX

SANTEN

1.5% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N021571 001 Mar 01, 2004

LEVOFLOXACIN

APOTEX INC

0.5%

A078282 001 Dec 20, 2010

QUIXIN

SANTEN

0.5% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N021199 001 Aug 18, 2000

TABLET; ORAL

LEVOFLOXACIN

WATSON LABS INC

250MG

A201484 001 Nov 22, 2013

500MG

A201484 002 Nov 22, 2013

750MG

A201484 003 Nov 22, 2013

LEVOLEUCOVORIN CALCIUM

SOLUTION; IV (INFUSION)

FUSILEV

SPECTRUM PHARMS

EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N020140 002 Apr 29, 2011

EQ 250MG BASE/25ML (EQ 10MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N020140 003 Apr 29, 2011

LEVOMEPRMAZINE

INJECTABLE; INJECTION

LEVOPROME

IMMUNEX

20MG/ML

N015865 001

LEVOMETHADYL ACETATE HYDROCHLORIDE

CONCENTRATE; ORAL

ORLAAM

ROXANE

10MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N020315 001 Jul 09, 1993

LEVONORDEFIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFIN

SOLVAY

0.05MG/ML; 2%

A085010 001

CARBOCAINE W/ NEO-COBEFRIN

EASTMAN KODAK

0.05MG/ML; 2%

N012125 002

ISOCAINE HYDROCHLORIDE W/ LEVONORDEFIN

NOVOCOL

0.05MG/ML; 2%

A084697 001

MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFIN

GRAHAM CHEM

0.05MG/ML; 2%

A084850 002 Oct 21, 1983

DISCONTINUED DRUG PRODUCT LISTLEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

POLOCAINE W/ LEVONORDEFRIN

DENTSPLY PHARM

0.05MG/ML;2%

A089517 001 Apr 14, 1988

LEVONORDEFRIN; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

RAVOCAINE AND NOVOCAIN W/ NEO-COBEFRIN

EASTMAN KODAK

0.05MG/ML;2%;0.4%

N008592 007

LEVONORGESTREL

IMPLANT; IMPLANTATION

JADELLE

POPULATION COUNCIL

75MG/IMPLANT **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020544 001 Nov 01, 1996

LEVONORGESTREL

WYETH PHARMS INC

75MG/IMPLANT

N020627 001 Aug 15, 1996

NORPLANT

POPULATION COUNCIL

36MG/IMPLANT

N019897 001 Dec 10, 1990

NORPLANT SYSTEM IN PLASTIC CONTAINER

WYETH PHARMS INC

36MG/IMPLANT

N020088 001 Dec 10, 1990

TABLET; ORAL

LEVONORGESTREL

LUPIN LTD

0.75MG

A091328 001 Jan 23, 2013

WATSON LABS

0.75MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

A078665 001 Aug 28, 2009

0.75MG

A078666 001 Jun 24, 2009

PLAN B

TEVA BRANDED PHARM

0.75MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021045 001 Jul 28, 1999

0.75MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021045 002 Aug 24, 2006

LEVOPROPOXYPHENE NAPSYLATE ANHYDROUS

CAPSULE; ORAL

NOVRAD

LILLY

EQ 50MG BASE

N012928 006

EQ 100MG BASE

N012928 004

SUSPENSION; ORAL

NOVRAD

LILLY

EQ 50MG BASE/5ML

N012928 002

LEVORPHANOL TARTRATE

INJECTABLE; INJECTION

LEVO-DROMORAN

VALEANT PHARM INTL

2MG/ML

N008719 001 Dec 19, 1991

TABLET; ORAL

LEVO-DROMORAN

VALEANT PHARM INTL

2MG

N008720 001 Dec 19, 1991

LEVOTHYROXINE SODIUM

TABLET; ORAL

LEVOLET

LEHIGH VALLEY

0.025MG

N021137 001 Jun 06, 2003

0.05MG

N021137 002 Jun 06, 2003

0.075MG

N021137 003 Jun 06, 2003

0.088MG

N021137 004 Jun 06, 2003

0.1MG

N021137 005 Jun 06, 2003

0.112MG

N021137 006 Jun 06, 2003

0.125MG

N021137 007 Jun 06, 2003

0.137MG

N021137 008 Jun 06, 2003

0.15MG

N021137 009 Jun 06, 2003

0.175MG

N021137 010 Jun 06, 2003

0.2MG

N021137 011 Jun 06, 2003

0.3MG

N021137 012 Jun 06, 2003

LEVOTHROID

LLOYD

0.025MG **Federal Register
determination that product was not
discontinued or withdrawn for safety or

N021116 001 Oct 24, 2002

DISCONTINUED DRUG PRODUCT LIST

LEVOTHYROXINE SODIUM

TABLET; ORAL

LEVOTHROID

efficacy reasons**

0.05MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021116 002	Oct 24, 2002
0.075MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021116 003	Oct 24, 2002
0.088MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021116 010	Oct 24, 2002
0.1MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021116 004	Oct 24, 2002
0.112MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021116 011	Oct 24, 2002
0.125MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021116 005	Oct 24, 2002
0.137MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021116 012	Dec 07, 2004
0.15MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021116 006	Oct 24, 2002
0.175MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021116 007	Oct 24, 2002
0.2MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021116 008	Oct 24, 2002
0.3MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021116 009	Oct 24, 2002
LEVOTHYROXINE SODIUM MERCK KGAA	0.025MG	A076752 001 Jun 16, 2005
	0.05MG	A076752 002 Jun 16, 2005
	0.075MG	A076752 003 Jun 16, 2005
	0.088MG	A076752 004 Jun 16, 2005
	0.1MG	A076752 005 Jun 16, 2005
	0.112MG	A076752 006 Jun 16, 2005
	0.125MG	A076752 007 Jun 16, 2005
	0.15MG	A076752 008 Jun 16, 2005
	0.175MG	A076752 009 Jun 16, 2005
	0.2MG	A076752 010 Jun 16, 2005
	0.3MG	A076752 011 Jun 16, 2005
LEVOXYL KING PHARMS R AND D	0.3MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021301 012 May 25, 2001
NOVOTHYROX MERCK KGAA	0.025MG	N021292 001 May 31, 2002
	0.05MG	N021292 002 May 31, 2002
	0.075MG	N021292 003 May 31, 2002
	0.088MG	N021292 004 May 31, 2002
	0.1MG	N021292 005 May 31, 2002
	0.112MG	N021292 006 May 31, 2002
	0.125MG	N021292 007 May 31, 2002
	0.137MG	N021292 008 May 31, 2002
	0.15MG	N021292 009 May 31, 2002
	0.175MG	N021292 010 May 31, 2002
	0.2MG	N021292 011 May 31, 2002

DISCONTINUED DRUG PRODUCT LIST

LEVOTHYROXINE SODIUM

TABLET; ORAL
NOVOTHYROX

0.3MG N021292 012 May 31, 2002

LIDOCAINE

AEROSOL; ORAL

XYLOCAINE

ASTRAZENECA

10% N014394 001

FILM, EXTENDED RELEASE; BUCCAL

DENTIPATCH

NOVEN

23MG/PATCH N020575 001 May 21, 1996

OINTMENT; TOPICAL

ALPHACAINE

CARLISLE

5% A084944 001

5% A084946 001

5% A084947 001

LIDOCAINE

BELMORA LLC

5% A080210 001

XYLOCAINE

ASTRAZENECA

5% **Federal Register determination

that product was not discontinued or

withdrawn for safety or efficacy

reasons**

N008048 001

PATCH; TOPICAL

DENTIPATCH

NOVEN

46.1MG/PATCH N020575 002 May 21, 1996

SOLUTION; TOPICAL

XYLOCAINE

ASTRAZENECA

5% N014127 001

SUPPOSITORY; RECTAL

XYLOCAINE

ASTRAZENECA

100MG N013077 001

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ALPHACAINE HYDROCHLORIDE

CARLISLE

2% A084721 001

LIDOCAINE HYDROCHLORIDE

ABBOTT

10% A087980 001 Feb 02, 1983

20% A089362 001 May 25, 1988

ABRAXIS PHARM

1% A080420 001

1% A086761 001

1.5% A080420 005

2% A080420 002

2% A080420 004

2% A086761 002

2% N017508 001

4% N017508 002

20% N017508 004

AKORN

1% A085037 001

2% A085037 002

BEL MAR

1% A080710 001

2% A080760 001

DELL LABS

1% A083387 001

2% A083388 001

ELKINS SINN

0.5% A085131 001

4% A084626 001

GD SEARLE LLC

1% A083135 001

2% A083135 002

GRAHAM CHEM

2% A080504 001

HOSPIRA

1% A040013 001 Jun 23, 1995

1.5% A088330 001 May 17, 1984

2% A088331 001 May 17, 1984

INTL MEDICATION

1% N017701 002

2% N017701 001

1GM/VIAL N018543 001

2GM/VIAL N018543 002

LUITPOLD

2% A083198 001

LYPHOMED

1% A080390 001

2% A080390 002

MILES

1% A080414 001

2% A080414 002

WATSON LABS

1% A080377 001

DISCONTINUED DRUG PRODUCT LIST

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE	1%	A083627	001	
	2%	A080377	002	
	2%	A083627	002	
WEST-WARD PHARMS INT	1%	A080407	001	
	2%	A080407	002	
WYETH AYERST	1%	A083083	001	
	2%	A083083	002	
LIDOCAINE HYDROCHLORIDE 0.1% AND DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	100MG/100ML	N018461	001	
LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	200MG/100ML	N018967	001	Mar 30, 1984
LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5%				
HOSPIRA	200MG/100ML	A083158	005	
LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER				
ABBOTT	200MG/100ML	N018954	001	Jul 09, 1985
HOSPIRA	200MG/100ML	N018388	001	
LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	400MG/100ML	N018967	002	Mar 30, 1984
LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5%				
HOSPIRA	400MG/100ML	A083158	006	
LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER				
HOSPIRA	400MG/100ML	N018388	002	
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	800MG/100ML	N018967	003	Mar 30, 1984
LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER				
HOSPIRA	800MG/100ML	N018388	003	Nov 05, 1982
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER				
HOSPIRA	1.5%	A088326	001	Jul 31, 1984
	10%	A088367	001	Jul 31, 1984
	20%	A088368	001	Jul 31, 1984
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE				
INTL MEDICATION	4%	N017702	002	
WEST-WARD PHARMS INT	1%	A084625	001	
	2%	A084625	002	
LIDOCATON				
PHARMATON	2%	A084727	001	Aug 17, 1983
LIDOPEN				
MERIDIAN MEDCL TECHN	10%	N017549	001	
XYLOCAINE				
ASTRAZENECA	1%	N010418	005	
	1.5%	N010418	009	
	2%	N010418	007	
XYLOCAINE DENTAL				
DENTSPLY PHARM	2%	N021380	001	
XYLOCAINE PRESERVATIVE FREE				
FRESENIUS KABI USA	10%	N016801	003	
INJECTABLE; SPINAL				
XYLOCAINE 1.5% W/ DEXTROSE 7.5%				
FRESENIUS KABI USA	1.5%	N016297	001	
XYLOCAINE 5% W/ GLUCOSE 7.5%				
ASTRAZENECA	5%	N010496	002	Jul 07, 1982
JELLY; TOPICAL				
ANESTACON				
BIONPHARMA INC	2%	A080429	001	
LIDOCAINE HYDROCHLORIDE				
G AND W LABS INC	2%	A081318	001	Apr 29, 1993
SOLUTION; ORAL				
LIDOCAINE HYDROCHLORIDE VISCOUS				
ACTAVIS MID ATLANTIC	2%	A086578	001	
INTL MEDICATION	2%	A086389	001	Feb 02, 1982
XYLOCAINE VISCOUS				
FRESENIUS KABI USA	2%	N009470	001	
SOLUTION; TOPICAL				
LARYNGOTRACHEAL ANESTHESIA KIT				
KENDALL IL	4%	A087931	001	Jun 10, 1983
LIDOCAINE HYDROCHLORIDE				
PACO	4%	A089688	001	Jun 30, 1989
LTA II KIT				
HOSPIRA	4%	A088542	001	Jul 31, 1984

DISCONTINUED DRUG PRODUCT LIST

LIDOCAINE HYDROCHLORIDE

SOLUTION; TOPICAL

PEDIATRIC LTA KIT

ABBOTT

2%

A088572 001 Jul 31, 1984

HOSPIRA

2%

A085995 001

LIDOCAINE HYDROCHLORIDE; OXYTETRACYCLINE

INJECTABLE; INJECTION

TERRAMYCIN

PFIZER

2%; 50MG/ML

A060567 001

2%; 125MG/ML

A060567 002

LIDOCAINE; PRILOCAINE

DISC; TOPICAL

EMLA

ASTRAZENECA

2.5%; 2.5%

N020962 001 Feb 04, 1998

LINCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

LINCOCIN

PHARMACIA AND UPJOHN

EQ 250MG BASE

N050316 001

EQ 500MG BASE

N050316 002

INJECTABLE; INJECTION

LINCOMYCIN HYDROCHLORIDE

WATSON LABS

EQ 300MG BASE/ML

A063180 001 Apr 16, 1991

LINDANE

CREAM; TOPICAL

KWELL

REED AND CARNRICK

1%

A084218 001

1%

N006309 001

LOTION; TOPICAL

GAMENE

SOLA BARNES HIND

1%

A084989 001

KWELL

REED AND CARNRICK

1%

A084218 002

1%

N006309 003

SCABENE

STIEFEL

1%

A086769 001

SHAMPOO; TOPICAL

GAMENE

SOLA BARNES HIND

1%

A084988 001

KWELL

REED AND CARNRICK

1%

A084219 001

1%

N010718 001

SCABENE

STIEFEL

1%

A087940 001 Apr 08, 1983

LINEZOLID

TABLET; ORAL

ZYVOX

PHARMACIA AND UPJOHN

400MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021130 001 Apr 18, 2000

LIOTHYRONINE SODIUM

TABLET; ORAL

LIOTHYRONINE SODIUM

WATSON LABS

EQ 0.025MG BASE

A085755 001 Jan 25, 1982

EQ 0.05MG BASE

A085753 001 Feb 03, 1982

LIOTRIX (T4; T3)

TABLET; ORAL

EUTHROID-0.5

PARKE DAVIS

0.03MG; 0.0075MG

N016680 001

EUTHROID-1

PARKE DAVIS

0.06MG; 0.015MG

N016680 002

EUTHROID-2

PARKE DAVIS

0.12MG; 0.03MG

N016680 003

EUTHROID-3

PARKE DAVIS

0.18MG; 0.045MG

N016680 004

THYROLAR-5

FOREST LABS

0.25MG; 0.0625MG

N016807 006

DISCONTINUED DRUG PRODUCT LIST

LISINAPRIL

TABLET; ORAL

LISINAPRIL

SANDOZ

2.5MG

A075903 001 Jul 01, 2002

2.5MG

A075999 001 Jul 01, 2002

5MG

A075903 002 Jul 01, 2002

5MG

A075999 002 Jul 01, 2002

10MG

A075903 003 Jul 01, 2002

10MG

A075999 003 Jul 01, 2002

20MG

A075903 004 Jul 01, 2002

20MG

A075999 004 Jul 01, 2002

30MG

A075903 005 Jul 01, 2002

30MG

A075999 005 Jul 01, 2002

40MG

A075903 006 Jul 01, 2002

40MG

A075999 006 Jul 01, 2002

TEVA

2.5MG

A075783 001 Jul 01, 2002

5MG

A075783 002 Jul 01, 2002

10MG

A075783 003 Jul 01, 2002

20MG

A075783 004 Jul 01, 2002

30MG

A075783 005 Jul 01, 2002

40MG

A075783 006 Jul 01, 2002

PRINIVIL

MERCCK

2.5MG

N019558 006 Jan 28, 1994

LITHIUM CARBONATE

CAPSULE; ORAL

ESKALITH

NOVEN THERAP

300MG

N016860 001

LITHIUM CARBONATE

ABLE

150MG

A076823 001 Jun 29, 2004

300MG

A076121 001 Sep 27, 2001

300MG

A076823 002 Jun 29, 2004

600MG

A076823 003 Jun 29, 2004

APOTEX INC

300MG

A076795 001 Nov 22, 2004

USL PHARMA

300MG

A072542 001 Feb 01, 1989

WATSON LABS

300MG

A070407 001 Mar 19, 1987

LITHONATE

SOLVAY

300MG

N016782 001

TABLET; ORAL

ESKALITH

JDS PHARMS

300MG

N017971 001

LITHANE

BAYER PHARMS

300MG

N018833 001 Jul 18, 1985

LITHIUM CARBONATE

HIKMA INTL PHARMS

300MG

A078715 001 Dec 28, 2010

PFIZER

300MG

N016834 001

LITHOTABS

SOLVAY

300MG

N016980 001

TABLET, EXTENDED RELEASE; ORAL

ESKALITH CR

JDS PHARMS

450MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N018152 001 Mar 29, 1982

LITHIUM CARBONATE

ABLE

300MG

A076382 001 Apr 21, 2003

BARR

300MG

A076170 001 Jun 10, 2002

450MG

A076366 001 Aug 21, 2003

HIKMA INTL PHARMS

450MG

A076490 001 Jun 17, 2003

LITHIUM CITRATE

SYRUP; ORAL

LITHONATE

SOLVAY

EQ 300MG CARBONATE/5ML

N017672 001

LOMEFLOXACIN HYDROCHLORIDE

TABLET; ORAL

MAXAQUIN

PHARMACIA

EQ 400MG BASE

N020013 001 Feb 21, 1992

DISCONTINUED DRUG PRODUCT LISTLOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL

IMODIUM

J AND J CONSUMER INC

2MG

N017690 001

2MG

N017694 001

LOPERAMIDE HYDROCHLORIDE

ROXANE

2MG

A073080 001 Nov 27, 1991

SANDOZ

2MG

A072993 001 Aug 28, 1992

TEVA

2MG

A073122 001 Aug 30, 1991

SOLUTION; ORAL

IMODIUM

JANSSEN PHARMS

1MG/5ML

N019037 001 Jul 31, 1984

LOPERAMIDE HYDROCHLORIDE

ALPHARMA US PHARMS

1MG/5ML

A073187 001 Sep 15, 1992

DURAMED PHARMS BARR

1MG/5ML

A074991 001 Dec 29, 1997

TEVA

1MG/5ML

A073478 001 Jun 23, 1995

WATSON LABS

1MG/5ML

A073062 001 May 28, 1993

TABLET; ORAL

LOPERAMIDE HYDROCHLORIDE

ABLE

2MG

A073528 001 Nov 30, 1993

PERRIGO

2MG

A074194 001 Oct 30, 1992

LOPINAVIR; RITONAVIR

CAPSULE; ORAL

KALETRA

ABBVIE

133.3MG; 33.3MG

N021226 001 Sep 15, 2000

LORACARBEF

CAPSULE; ORAL

LORABID

KING PHARMS

200MG

N050668 001 Dec 31, 1991

400MG

N050668 002 Apr 05, 1996

FOR SUSPENSION; ORAL

LORABID

KING PHARMS

100MG/5ML

N050667 001 Dec 31, 1991

200MG/5ML

N050667 002 Dec 31, 1991

LORATADINE

SYRUP; ORAL

CLARITIN HIVES RELIEF

BAYER HEALTHCARE LLC

1MG/ML **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N020641 003 Nov 19, 2003

LORATADINE

APOTEX INC

1MG/ML

A075565 001 Oct 05, 2004

RANBAXY LABS LTD

1MG/ML

A076529 001 Aug 20, 2004

TABLET; ORAL

LORATADINE

PERRIGO

10MG

N021512 001 Jun 24, 2004

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

LORATADINE AND PSEUDOEPHEDRINE SULFATE

ACTAVIS LABS FL INC

5MG; 120MG

A076208 001 Jan 28, 2004

LORAZEPAM

INJECTABLE; INJECTION

LORAZEPAM

AKORN

2MG/ML

A074974 001 Jul 23, 1998

BEDFORD

2MG/ML

A077076 001 Jul 13, 2005

BEDFORD

4MG/ML

A077076 002 Jul 13, 2005

DAVA PHARMS INC

2MG/ML

A074793 001 Mar 16, 2000

4MG/ML

A074793 002 Mar 16, 2000

EUROHLTH INTL SARL

2MG/ML

A074496 001 Sep 28, 1998

4MG/ML

A074496 002 Sep 28, 1998

HOSPIRA

2MG/ML

A074280 001 May 27, 1994

HOSPIRA

2MG/ML

A074300 001 Apr 12, 1994

HOSPIRA

4MG/ML

A074280 002 May 27, 1994

HOSPIRA

4MG/ML

A074300 003 Mar 19, 1997

WATSON LABS

2MG/ML

A074276 001 Apr 15, 1994

WATSON LABS

4MG/ML

A074276 002 Apr 15, 1994

WATSON LABS INC

1MG/0.5ML

A074551 003 Sep 12, 1996

WATSON LABS INC

2MG/ML

A074535 001 Sep 12, 1996

WATSON LABS INC

2MG/ML

A074551 001 Sep 12, 1996

DISCONTINUED DRUG PRODUCT LIST

LORAZEPAM

INJECTABLE; INJECTION

LORAZEPAM

4MG/ML

A074535 002 Sep 12, 1996

4MG/ML

A074551 002 Sep 12, 1996

SOLUTION; ORAL

LORAZEPAM

ROXANE

0.5MG/5ML

A074648 001 Mar 18, 1997

TABLET; ORAL

LORAZ

QUANTUM PHARMICS

0.5MG

A070200 001 Aug 09, 1985

1MG

A070201 001 Aug 09, 1985

2MG

A070202 001 Aug 09, 1985

LORAZEPAM

AM THERAP

0.5MG

A070727 001 Mar 07, 1986

1MG

A070728 001 Mar 07, 1986

2MG

A070729 001 Mar 07, 1986

FRONTIDA BIOPHARM

0.5MG

A072553 001 Mar 29, 1991

1MG

A072554 001 Mar 29, 1991

2MG

A072555 001 Mar 29, 1991

HALSEY

0.5MG

A071434 001 Sep 01, 1987

1MG

A071435 001 Sep 01, 1987

2MG

A071436 001 Sep 01, 1987

MUTUAL PHARM

0.5MG

A070472 001 Dec 10, 1985

1MG

A070473 001 Dec 10, 1985

2MG

A070474 001 Dec 10, 1985

PAR PHARM

0.5MG

A070675 001 Dec 01, 1986

1MG

A070676 001 Dec 01, 1986

2MG

A070677 001 Dec 01, 1986

SANDOZ

0.5MG

A071193 001 Apr 15, 1988

1MG

A071194 001 Apr 15, 1988

2MG

A071195 001 Apr 15, 1988

SUPERPHARM

0.5MG

A071245 001 Feb 09, 1987

1MG

A071246 001 Feb 09, 1987

2MG

A071247 001 Feb 09, 1987

USL PHARMA

1MG

A070539 001 Dec 22, 1986

2MG

A070540 001 Dec 22, 1986

WARNER CHILCOTT

1MG

A071038 001 Jan 12, 1988

2MG

A071039 001 Jan 12, 1988

WATSON LABS

0.5MG

A071086 001 Mar 23, 1987

0.5MG

A071117 001 Jul 24, 1986

1MG

A071087 001 Mar 23, 1987

1MG

A071118 001 Jul 24, 1986

2MG

A071088 001 Mar 23, 1987

2MG

A071110 001 Jul 24, 1986

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS; OPHTHALMIC

LOTEMAX

PHARMOS

0.5%

N020841 001 Mar 09, 1998

LOVASTATIN

TABLET; ORAL

MEVACOR

MERCK

10MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N019643 002 Mar 28, 1991

20MG **Federal Register notice that
product was not discontinued or
withdrawn for safety or efficacy
reasons**

N019643 003 Aug 31, 1987

40MG **Federal Register notice that
product was not discontinued or
withdrawn for safety or efficacy
reasons**

N019643 004 Dec 14, 1988

TABLET, EXTENDED RELEASE; ORAL

ALTOPREV

COVIS PHARMA SARL

10MG

N021316 001 Jun 26, 2002

DISCONTINUED DRUG PRODUCT LISTLOXAPINE HYDROCHLORIDE

CONCENTRATE; ORAL

LOXITANE C

ACTAVIS LABS UT INC EQ 25MG BASE/ML N017658 001

INJECTABLE; INJECTION

LOXITANE IM

ACTAVIS LABS UT INC EQ 50MG BASE/ML N018039 001

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXITANE

ACTAVIS LABS UT INC EQ 5MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons** N017525 001EQ 10MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons** N017525 002EQ 25MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons** N017525 003EQ 50MG BASE *Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons** N017525 004

TABLET; ORAL

LOXITANE

ACTAVIS LABS UT INC EQ 10MG BASE **Federal Register
determination that product was
discontinued or withdrawn for s or e
reasons** N017525 006EQ 25MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons** N017525 007EQ 50MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons** N017525 008LUCINACTANT

SUSPENSION; INTRATRACHEAL

SURFAXIN

WINDTREE THERAP 8.5ML N021746 001 Mar 06, 2012

LUTROPIN ALFA

INJECTABLE; SUBCUTANEOUS

LUVERIS

EMD SERONO 75 IU/VIAL N021322 001 Oct 08, 2004

LYPRESSIN

SOLUTION; NASAL

DIAPID

NOVARTIS 0.185MG/ML N016755 001

MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PLASMA-LYTE 56 IN PLASTIC CONTAINER

BAXTER HLTHCARE 32MG/100ML; 128MG/100ML; 234MG/100ML N019047 001 Jun 15, 1984

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

ISOLYTE S PH 7.4 IN PLASTIC CONTAINER

B BRAUN 30MG/100ML; 37MG/100ML; 0.82MG/100ML; 370M
G/100ML; 530MG/100ML; 500MG/100ML; 12MG/10
0ML N019006 001 Apr 04, 1984MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

ISOLYTE S IN PLASTIC CONTAINER

B BRAUN 30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG
/100ML; 500MG/100ML N018252 001

SOLUTION; IRRIGATION

PHYSIOSOL IN PLASTIC CONTAINER

HOSPIRA INC 14MG/100ML; 37MG/100ML; 222MG/100ML; 526MG
/100ML; 502MG/100ML N018406 001

DISCONTINUED DRUG PRODUCT LISTMAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SOLUTION; IRRIGATION

PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER

HOSPIRA INC	30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG	N018406 002	Jul 08, 1982
	/100ML; 502MG/100ML		

SYNOVALYTE IN PLASTIC CONTAINER

BAXTER HLTHCARE	30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG	N019326 001	Jan 25, 1985
	/100ML; 502MG/100ML		

MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE

TABLET; ORAL

MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE

SANTARUS	343MG; 20MG; 750MG	N022456 001	Dec 04, 2009
	343MG; 40MG; 750MG	N022456 002	Dec 04, 2009

TABLET, CHEWABLE; ORAL

ZEGERID

SANTARUS	700MG; 20MG; 600MG	N021850 001	Mar 24, 2006
	700MG; 40MG; 600MG	N021850 002	Mar 24, 2006

MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SOLUTION; ORAL

SUCLEAR

BRAINTREE LABS	1.6GM/BOT, 3.13GM/BOT, 17.5GM/BOT, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, 210GM, 0.74GM, 2.86GM, 5.6GM **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N203595 001	Jan 18, 2013
----------------	--	-------------	--------------

MALATHION

LOTION; TOPICAL

MALATHION

MYLAN PHARMS INC	0.5%	A078743 001	Mar 06, 2009
------------------	------	-------------	--------------

MANGAFODIPIR TRISODIUM

INJECTABLE; INJECTION

TESLASCAN

GE HEALTHCARE	37.9MG/ML	N020652 001	Nov 26, 1997
---------------	-----------	-------------	--------------

MANGANESE CHLORIDE TETRAHYDRATE

FOR SOLUTION; ORAL

LUMENHANCE

BRACCO	3.49MG/GM	N020686 001	Dec 19, 1997
--------	-----------	-------------	--------------

MANGANESE SULFATE

INJECTABLE; INJECTION

MANGANESE SULFATE

ABRAXIS PHARM	EQ 0.1MG MANGANESE/ML	N019228 001	May 05, 1987
---------------	-----------------------	-------------	--------------

MANNITOL

INJECTABLE; INJECTION

MANNITOL 10%

B BRAUN	10GM/100ML	N016080 002	
HOSPIRA	10GM/100ML	N016269 002	
MILES	10GM/100ML	N016472 002	

MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER

B BRAUN	10GM/100ML	N016080 006	
---------	------------	-------------	--

MANNITOL 15%

B BRAUN	15GM/100ML	N016080 003	
HOSPIRA	15GM/100ML	N016269 003	
MILES	15GM/100ML	N016472 005	

MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%

B BRAUN	15GM/100ML	N016080 005	
---------	------------	-------------	--

MANNITOL 20%

B BRAUN	20GM/100ML	N014738 001	
	20GM/100ML	N016080 004	
HOSPIRA	20GM/100ML	N016269 004	
MILES	20GM/100ML	N016472 004	

MANNITOL 25%

ABRAXIS PHARM	12.5GM/50ML	A086754 001	
HOSPIRA	12.5GM/50ML	N016269 005	
IGI LABS INC	12.5GM/50ML	A089239 001	May 06, 1987
	12.5GM/50ML	A089240 001	May 06, 1987
MERCK	12.5GM/50ML	N005620 001	
WATSON LABS	12.5GM/50ML	A087460 001	Jun 27, 1983

DISCONTINUED DRUG PRODUCT LIST

MANNITOL

INJECTABLE; INJECTION

MANNITOL 5%

B BRAUN	5GM/100ML	N016080 001
HOSPIRA	5GM/100ML	N016269 001

MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%

B BRAUN	5GM/100ML	N016080 007
---------	-----------	-------------

POWDER; INHALATION

ARIDOL KIT

PHARMAXIS LTD	N/A, 5MG, 10MG, 20MG, 40MG	N022368 001	Oct 05, 2010
---------------	----------------------------	-------------	--------------

SOLUTION; IRRIGATION

RESECTISOL

B BRAUN	5GM/100ML	N016704 002
---------	-----------	-------------

MANNITOL; SORBITOL

SOLUTION; IRRIGATION

SORBITOL-MANNITOL

HOSPIRA	540MG/100ML; 2.7GM/100ML	A080224 001
---------	--------------------------	-------------

SORBITOL-MANNITOL IN PLASTIC CONTAINER

HOSPIRA	540MG/100ML; 2.7GM/100ML	N017636 001
---------	--------------------------	-------------

MAPROTILINE HYDROCHLORIDE

TABLET; ORAL

LUDIOMIL

NOVARTIS	25MG	N017543 001	
	50MG	N017543 002	
	75MG	N017543 003	Sep 30, 1982

MAPROTILINE HYDROCHLORIDE

AM THERAP

	25MG	A072129 001	Jan 14, 1988
	50MG	A072130 001	Jan 14, 1988
	75MG	A072131 001	Jan 14, 1988

WATSON LABS

	25MG	A071943 001	Dec 30, 1987
	25MG	A072162 001	Jun 01, 1988
	50MG	A071944 001	Dec 30, 1987
	50MG	A072163 001	Jun 01, 1988
	75MG	A071945 001	Dec 30, 1987
	75MG	A072164 001	Jun 01, 1988

MASOPROCOL

CREAM; TOPICAL

ACTINEX

UNIV AZ CANCER CTR	10%	N019940 001	Sep 04, 1992
--------------------	-----	-------------	--------------

MAZINDOL

TABLET; ORAL

MAZANOR

WYETH AYERST	1MG	N017980 002
	2MG	N017980 001

SANOREX

NOVARTIS

	1MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017247 001
	2MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017247 002

MEBENDAZOLE

TABLET, CHEWABLE; ORAL

VERMOX

JANSSEN PHARMS	100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017481 001
----------------	--	-------------

MEBUTAMATE

TABLET; ORAL

DORMATE

MEDPOINTE PHARM HLC	600MG	N017374 001
---------------------	-------	-------------

DISCONTINUED DRUG PRODUCT LIST

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL

INVERSINE

TARGACEPT	2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N010251 001	
-----------	---	-------------	--

MECASERMIN RINFABATE RECOMBINANT

INJECTABLE; SUBCUTANEOUS

IPLEX

INSMED	36MG/0.6ML	N021884 001	Dec 12, 2005
--------	------------	-------------	--------------

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

ANTIVERT

CASPER PHARMA LLC	12.5MG	N010721 006	
	25MG	N010721 004	
	50MG	N010721 001	Jan 20, 1982

MECLIZINE HYDROCHLORIDE

ABC HOLDING	12.5MG	A085253 001	
	25MG	A085252 001	
AMNEAL PHARMS	50MG	A201451 003	Feb 23, 2011
ANABOLIC	25MG	A085891 001	
ANI PHARMS INC	12.5MG	A084975 001	
	25MG	A084657 001	
BUNDY	12.5MG	A084382 001	
	25MG	A084872 001	
IVAX SUB TEVA PHARMS	12.5MG	A083784 001	
KV PHARM	12.5MG	A085524 001	
	25MG	A085523 001	
MYLAN PHARMS INC	50MG	A202640 003	Sep 17, 2012
PAR PHARM	50MG	A089674 001	Mar 31, 1988
PLIVA	12.5MG	A088732 001	Dec 11, 1985
	25MG	A088734 001	Dec 11, 1985
RISING PHARMS INC	12.5MG	A040179 001	Jan 30, 1997
	25MG	A040179 002	Jan 30, 1997
SUPERPHARM	12.5MG	A089113 001	Aug 20, 1985
	25MG	A089114 001	Aug 20, 1985
UDL	12.5MG	A088256 001	Jun 13, 1983
	25MG	A088257 001	Jun 13, 1983
VANGARD	12.5MG	A087877 001	Apr 20, 1982
	25MG	A087620 001	Jan 04, 1982
WATSON LABS	12.5MG	A085195 001	
	12.5MG	A085269 001	
	25MG	A085740 001	

TABLET, CHEWABLE; ORAL

ANTIVERT

CASPER PHARMA LLC	25MG	N010721 005	
MECLIZINE HYDROCHLORIDE			
IVAX SUB TEVA PHARMS	25MG	A084976 001	
NEXGEN PHARMA INC	25MG	A086392 001	
PLIVA	25MG	A088733 001	Dec 11, 1985

MECLOCYCLINE SULFOSALICYLATE

CREAM; TOPICAL

MECLAN

JOHNSON AND JOHNSON	1%	N050518 001	
---------------------	----	-------------	--

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLODIUM

QUANTUM PHARMICS	EQ 50MG BASE	A071380 001	Jul 14, 1987
	EQ 100MG BASE	A071381 001	Jul 14, 1987

MECLOFENAMATE SODIUM

AM THERAP	EQ 50MG BASE	A071362 001	Feb 10, 1987
	EQ 100MG BASE	A071363 001	Feb 10, 1987
BARR	EQ 50MG BASE	A072848 001	Mar 20, 1989
	EQ 100MG BASE	A072809 001	Mar 20, 1989
PAR PHARM	EQ 50MG BASE	A072077 001	Mar 10, 1988
	EQ 100MG BASE	A072078 001	Mar 10, 1988
SANDOZ	EQ 50MG BASE	A072262 001	Nov 29, 1988
	EQ 100MG BASE	A072263 001	Nov 29, 1988
USL PHARMA	EQ 50MG BASE	A071007 001	Mar 25, 1988
	EQ 100MG BASE	A071008 001	Mar 25, 1988

DISCONTINUED DRUG PRODUCT LIST

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLOFENAMATE SODIUM

VITARINE

EQ 50MG BASE

A071710 001 Jun 15, 1988

EQ 100MG BASE

A071684 001 Jun 15, 1988

WATSON LABS

EQ 50MG BASE

A070400 001 Nov 25, 1986

EQ 50MG BASE

A071468 001 Apr 15, 1987

EQ 50MG BASE

A071640 001 Aug 11, 1987

EQ 100MG BASE

A070401 001 Nov 25, 1986

EQ 100MG BASE

A071469 001 Apr 15, 1987

EQ 100MG BASE

A071641 001 Aug 11, 1987

MECLOMEN

PARKE DAVIS

EQ 50MG BASE

N018006 001

EQ 100MG BASE

N018006 002

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

DEPO-PROVERA

PHARMACIA AND UPJOHN

100MG/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N012541 002

MEDROXYPROGESTERONE ACETATE

TEVA PHARMS USA

150MG/ML

A076552 001 Oct 27, 2004

TABLET; ORAL

AMEN

AMARIN PHARMS

10MG

A083242 001

CURRETAB

SOLVAY

10MG

A085686 001

CYCRIN

ESI

2.5MG

A081239 001 Oct 30, 1992

5MG

A081240 001 Oct 30, 1992

10MG

A089386 001 Sep 09, 1987

MEDROXYPROGESTERONE ACETATE

DURAMED PHARMS BARR

2.5MG

A040311 001 Dec 01, 1999

5MG

A040311 002 Dec 01, 1999

10MG

A040311 003 Dec 01, 1999

USL PHARMA

10MG

A088484 001 Jul 26, 1984

MEDRYSONE

SUSPENSION; OPHTHALMIC

HMS

ALLERGAN

1%

N016624 003

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

LARIAM

ROCHE

250MG

N019591 001 May 02, 1989

MEFLOQUINE HYDROCHLORIDE

HIKMA INTL PHARMS

250MG

A077699 001 Apr 21, 2010

US ARMY WALTER REED

250MG

N019578 001 May 02, 1989

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGESTROL ACETATE

APOTEX INC

40MG/ML

A077404 001 Feb 16, 2006

TABLET; ORAL

MEGACE

BRISTOL MYERS SQUIBB

20MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N016979 001

40MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N016979 002

MEGESTROL ACETATE

TEVA

40MG

A074745 001 Feb 27, 1998

USL PHARMA

20MG

A070646 001 Oct 02, 1987

40MG

A070647 001 Oct 02, 1987

DISCONTINUED DRUG PRODUCT LIST

MELOXICAM

TABLET; ORAL

MELOXICAM

COREPHARMA	7.5MG	A077930 001	Jul 19, 2006
	15MG	A077930 002	Jul 19, 2006
CR DOUBLE CRANE	7.5MG	A078039 001	Dec 14, 2006
	15MG	A078039 002	Dec 14, 2006
FRONTIDA BIOPHARM	7.5MG	A077935 001	Jul 19, 2006
	15MG	A077935 002	Jul 19, 2006
MYLAN	7.5MG	A077934 001	Jul 20, 2006
	15MG	A077934 002	Jul 20, 2006
ROXANE	7.5MG	A077925 001	Jul 19, 2006
	15MG	A077925 002	Jul 19, 2006
YABAO PHARM	7.5MG	A077933 001	Jul 19, 2006
	15MG	A077933 002	Jul 19, 2006

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

MELPHALAN HYDROCHLORIDE

MYLAN INSTITUTIONAL	EQ 50MG BASE/VIAL	A090299 001	Oct 27, 2009
---------------------	-------------------	-------------	--------------

MEMANTINE HYDROCHLORIDE

TABLET; ORAL

MEMANTINE HYDROCHLORIDE

ORCHID HLTHCARE	5MG	A090044 001	Mar 12, 2012
	10MG	A090044 002	Mar 12, 2012

MENADIOL SODIUM DIPHOSPHATE

INJECTABLE; INJECTION

KAPPADIONE

LILLY	10MG/ML	N005725 001	
SYNKAYVITE			
ROCHE	5MG/ML	N003718 004	
	10MG/ML	N003718 006	
	37.5MG/ML	N003718 008	

TABLET; ORAL

SYNKAYVITE

ROCHE	5MG	N003718 010	
-------	-----	-------------	--

MENADIONE

TABLET; ORAL

MENADIONE

LILLY	5MG	N002139 003	
-------	-----	-------------	--

MENOTROPINS (FSH; LH)

INJECTABLE; INJECTION

HUMEGON

ORGANON USA INC	75 IU/VIAL;75 IU/VIAL	N020328 001	Sep 01, 1994
	150 IU/VIAL;150 IU/VIAL	N020328 002	Sep 01, 1994

MENOTROPINS

FERRING	75 IU/VIAL;75 IU/VIAL	A073598 001	Jan 30, 1997
	150 IU/VIAL;150 IU/VIAL	A073599 001	Jan 30, 1997

PERGONAL

SERONO	75 IU/AMP;75 IU/AMP	N017646 001	
	150 IU/AMP;150 IU/AMP	N017646 002	May 20, 1985

REPRONEX

FERRING	150 IU/VIAL;150 IU/VIAL	N021047 002	Aug 27, 1999
---------	-------------------------	-------------	--------------

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

REPRONEX

FERRING	75 IU/VIAL;75 IU/VIAL	N021047 001	Aug 27, 1999
---------	-----------------------	-------------	--------------

MEPENZOLATE BROMIDE

SOLUTION; ORAL

CANTIL

SANOFT AVENTIS US	25MG/5ML	N010679 004	
-------------------	----------	-------------	--

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEMEROL

US PHARM HOLDINGS	25MG/ML	N005010 007	
	50MG/ML	N005010 002	
	75MG/ML	N005010 009	
	100MG/ML	N005010 003	

MEPERIDINE HYDROCHLORIDE

ABBOTT	25MG/ML	A080388 001	
	50MG/ML	A080385 001	

DISCONTINUED DRUG PRODUCT LIST

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERIDINE HYDROCHLORIDE

	50MG/ML	A080387	001	
	75MG/ML	A080389	001	
	100MG/ML	A080386	001	
BAXTER HLTHCARE	25MG/ML	A088279	001	Jun 15, 1984
	50MG/ML	A088280	001	Jun 15, 1984
	75MG/ML	A088281	001	Jun 15, 1984
	100MG/ML	A088282	001	Jun 15, 1984
IGI LABS INC	25MG/ML	A089781	001	Mar 31, 1989
	50MG/ML	A089782	001	Mar 31, 1989
	50MG/ML	A089783	001	Mar 31, 1989
	50MG/ML	A089784	001	Mar 31, 1989
	75MG/ML	A089785	001	Mar 31, 1989
	100MG/ML	A089786	001	Mar 31, 1989
	100MG/ML	A089787	001	Mar 31, 1989
	100MG/ML	A089788	001	Mar 31, 1989
INTL MEDICATION	10MG/ML	A086332	001	
PARKE DAVIS	50MG/ML	A080364	002	
	75MG/ML	A080364	003	
	100MG/ML	A080364	001	
WATSON LABS	50MG/ML	A073444	001	Mar 17, 1992
	100MG/ML	A073445	001	Mar 17, 1992
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE				
HOSPIRA	10MG/ML	A040305	001	Mar 10, 1999
INTL MEDICATION	10MG/ML	A081309	001	Aug 30, 1993
MALLINCKRODT	10MG/ML	A040163	001	May 12, 1997
WATSON LABS	10MG/ML	A073443	001	Mar 17, 1992

SYRUP; ORAL

DEMEROL

US PHARM HOLDINGS 50MG/5ML N005010 005

TABLET; ORAL

MEPERIDINE HYDROCHLORIDE

DURAMED PHARMS BARR	50MG	A040318	001	Oct 05, 1999
	100MG	A040318	002	Oct 05, 1999
SUN PHARM INDS	50MG	A080448	001	
	100MG	A080448	002	
WATSON LABS	50MG	A040186	001	Jun 30, 1997
	100MG	A040186	002	Jun 30, 1997
WYETH AYERST	50MG	A080454	001	

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERGAN

WEST-WARD PHARMS INT 25MG/ML; 25MG/ML N011730 001

MEPHENTERMINE SULFATE

INJECTABLE; INJECTION

WYAMINE SULFATE

BAXTER HLTHCARE CORP	EQ 15MG BASE/ML	N008248	002	
	EQ 30MG BASE/ML	N008248	001	

MEPHENYTOIN

TABLET; ORAL

MESANTOIN

NOVARTIS	100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N006008	001	
----------	--	---------	-----	--

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ARESTOCAINE HYDROCHLORIDE

SOLVAY 3% A084777 002 Apr 18, 1982

CARBOCAINE

EASTMAN KODAK	3% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012125	003	
---------------	---	---------	-----	--

MEPIVACAINE HYDROCHLORIDE

GRAHAM CHEM	3%	A083559	001	
INTL MEDICATION SYS	1%	A087509	001	Oct 05, 1982
WATSON LABS	1%	A088769	001	Nov 20, 1984
	2%	A088770	001	Nov 20, 1984

DISCONTINUED DRUG PRODUCT LIST

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

POLOCAINE

DENTSPLY PHARM

3%

A088653 001 Aug 21, 1984

MEPREDNISONE

TABLET; ORAL

BETAPAR

SCHERING

4MG

N016053 002

MEPROBAMATE

CAPSULE; ORAL

EQUANIL

WYETH AYERST

400MG

N012455 002

CAPSULE, EXTENDED RELEASE; ORAL

MEPROSPAN

MEDPOINTE PHARM HLC

200MG

N011284 001

400MG

N011284 002

TABLET; ORAL

AMOSENE

FERNDALE LABS

400MG

A084030 001

BAMATE

ALRA

200MG

A080380 001

400MG

A080380 002

EQUANIL

WYETH AYERST

200MG

N010028 005

400MG

N010028 004

MEPRIAM

TEVA

400MG

N016069 001

MEPROBAMATE

AUROLIFE PHARMA LLC

400MG

A080655 001

BARR

600MG

A084230 001

ELKINS SINN

200MG

N015426 002

400MG

N015426 001

HEATHER

400MG

N016928 003

600MG

A084329 001

IMPAX LABS

200MG

N014322 002

400MG

N014322 001

IVAX SUB TEVA PHARMS

200MG

N015438 001

400MG

N015438 002

600MG

A084181 001

IVC INDS

400MG

A084153 001

LANNETT

200MG

N014882 002

400MG

N014882 001

LEDERLE

400MG

A086299 001

LEE KM

400MG

A089538 001 Nov 25, 1987

MALLARD

400MG

N015072 002

MK LABS

200MG

N014368 004

400MG

N014368 002

MYLAN

400MG

A083618 001

NEXGEN PHARMA INC

200MG

A084220 001

400MG

A084589 001

PARKE DAVIS

200MG

A084744 001

400MG

A084744 002

PERRIGO

200MG

A084546 001

400MG

A084547 001

PHARMAVITE

400MG

A084438 001

PUREPAC PHARM

200MG

A084804 001

400MG

A084804 002

PVT FORM

400MG

N014601 001

ROXANE

600MG

A084332 001

SANDOZ

200MG

N014547 002

400MG

N014547 001

SCHERER LABS

400MG

A083343 001

SOLVAY

200MG

A084435 001

STANLABS PHARM

200MG

N014474 002

400MG

N014474 004

SUN PHARM INDS

200MG

A080699 001

400MG

A080699 002

TABLICAPS

400MG

A083494 001

TARO

200MG

A200998 001 May 23, 2011

400MG

A200998 002 May 23, 2011

USL PHARMA

200MG

A087825 001 Mar 18, 1982

DISCONTINUED DRUG PRODUCT LIST

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

	400MG	A087826 001	Mar 18, 1982
VALEANT PHARM INTL	200MG	N015139 006	
	400MG	N015139 005	
VANGARD	400MG	A088011 001	Jul 14, 1982
WATSON LABS	200MG	A085720 001	
	400MG	A085721 001	
	600MG	A084274 001	
	600MG	A085719 001	
WEST WARD	200MG	N015417 003	
	400MG	N015417 002	
WHITEWORTH TOWN PLSN	200MG	A083830 001	
	400MG	A083442 001	
MILTOWN			
MEDPOINTE PHARM HLC	200MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009698 004	
	400MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009698 002	
	600MG	A083919 001	
NEURAMATE			
HALSEY	200MG	N014359 002	
	400MG	N014359 001	
TRANMEP			
SOLVAY	400MG	A084369 001	
	400MG	N016249 001	

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL

SOLAGE

AQUA PHARMS	2%;0.01%	N020922 001	Dec 10, 1999
-------------	----------	-------------	--------------

MERSALYL SODIUM; THEOPHYLLINE

INJECTABLE; INJECTION

MERSALYL-THEOPHYLLINE

WATSON LABS	100MG/ML; 50MG/ML	A084875 001	
-------------	-------------------	-------------	--

MESALAMINE

SUPPOSITORY; RECTAL

CANASA

FOREST LABS LLC	500MG	N021252 001	Jan 05, 2001
-----------------	-------	-------------	--------------

ROWASA

MEDA PHARMS	500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019919 001	Dec 18, 1990
-------------	--	-------------	--------------

TABLET, DELAYED RELEASE; ORAL

ASACOL

APIL	400MG	N019651 001	Jan 31, 1992
------	-------	-------------	--------------

MESORIDAZINE BESYLATE

CONCENTRATE; ORAL

SERENTIL

NOVARTIS	EQ 25MG BASE/ML	N016997 001	
----------	-----------------	-------------	--

INJECTABLE; INJECTION

SERENTIL

NOVARTIS	EQ 25MG BASE/ML	N016775 001	
----------	-----------------	-------------	--

TABLET; ORAL

SERENTIL

NOVARTIS	EQ 10MG BASE	N016774 001	
	EQ 25MG BASE	N016774 002	
	EQ 50MG BASE	N016774 003	
	EQ 100MG BASE	N016774 004	

MESTRANOL; NORETHINDRONE

TABLET; ORAL-20

NORINYL

ACTAVIS LABS UT INC	0.1MG; 2MG	N013625 004	
---------------------	------------	-------------	--

TABLET; ORAL-21

NORETHIN 1/50M-21

WATSON LABS	0.05MG; 1MG	A071539 001	Apr 12, 1988
-------------	-------------	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

MESTRANOL; NORETHINDRONE

TABLET; ORAL-21

NORETHINDRONE AND MESTRANOL

WATSON LABS	0.05MG;1MG	A070758	001	Jul 01, 1988
NORINYL 1+50 21-DAY				
ACTAVIS LABS UT INC	0.05MG;1MG	N013625	002	
NORINYL 1+80 21-DAY				
GD SEARLE LLC	0.08MG;1MG	N016724	001	
ORTHO-NOVUM 1/50 21				
ORTHO MCNEIL PHARM	0.05MG;1MG	N012728	004	
ORTHO-NOVUM 1/80 21				
ORTHO MCNEIL PHARM	0.08MG;1MG	N016715	001	
ORTHO-NOVUM 10-21				
ORTHO MCNEIL PHARM	0.06MG;10MG	N012728	001	
ORTHO-NOVUM 2-21				
ORTHO MCNEIL PHARM	0.1MG;2MG	N012728	005	

TABLET; ORAL-28

NORETHIN 1/50M-28

WATSON LABS	0.05MG;1MG	A071540	001	Apr 12, 1988
NORETHINDRONE AND MESTRANOL				
WATSON LABS	0.05MG;1MG	A070759	001	Jul 01, 1988
NORINYL 1+80 28-DAY				
GD SEARLE LLC	0.08MG;1MG	N016725	001	
ORTHO-NOVUM 1/50 28				
ORTHO MCNEIL JANSSEN	0.05MG;1MG	N016709	001	
ORTHO-NOVUM 1/80 28				
ORTHO MCNEIL PHARM	0.08MG;1MG	N016715	002	

MESTRANOL; NORETHYNODREL

TABLET; ORAL

ENOVID

GD SEARLE LLC	0.075MG;5MG	N010976	008	
	0.15MG;9.85MG	N010976	005	

TABLET; ORAL-20

ENOVID

GD SEARLE LLC	0.075MG;5MG	N010976	004	
ENOVID-E				
GD SEARLE LLC	0.1MG;2.5MG	N010976	006	

TABLET; ORAL-21

ENOVID-E 21

GD SEARLE LLC	0.1MG;2.5MG	N010976	007	
---------------	-------------	---------	-----	--

METAPROTERENOL SULFATE

AEROSOL, METERED; INHALATION

ALUPENT

BOEHRINGER INGELHEIM	0.65MG/INH	N016402	001	
----------------------	------------	---------	-----	--

SOLUTION; INHALATION

ALUPENT

BOEHRINGER INGELHEIM	0.4%	N018761	002	Oct 10, 1986
	0.6%	N018761	001	Jun 30, 1983
	5%	N017659	001	

METAPROTERENOL SULFATE

APOTEX INC	0.4%	A075402	001	Feb 28, 2001
	0.6%	A075403	001	Feb 28, 2001
ASTRAZENECA	0.4%	A071275	001	Jul 27, 1988
	0.6%	A071018	001	Jul 27, 1988
DEY	0.33%	A071806	001	Aug 05, 1988
	0.5%	A071805	001	Aug 05, 1988
	5%	A070805	001	Aug 17, 1987
MYLAN SPECLT	0.4%	A071786	001	Aug 05, 1988
	0.6%	A070804	001	Aug 17, 1987
NEPHRON	0.4%	A071855	001	Jul 14, 1988
	0.6%	A071726	001	Jul 14, 1988
WOCKHARDT	0.4%	A075586	001	May 30, 2002
	0.6%	A075586	002	May 30, 2002
	5%	A072190	001	Jun 07, 1988

PROMETA

MURO	5%	A073340	001	Mar 30, 1992
------	----	---------	-----	--------------

SYRUP; ORAL

ALUPENT

BOEHRINGER INGELHEIM	10MG/5ML	N017571	001	
----------------------	----------	---------	-----	--

METAPROTERENOL SULFATE

APOTEX INC	10MG/5ML	A075235	001	Jan 27, 2000
------------	----------	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

METAPROTERENOL SULFATE

SYRUP; ORAL

METAPROTERENOL SULFATE

G AND W LABS INC	10MG/5ML	A072761	001	Feb 27, 1992
	10MG/5ML	A073034	001	Aug 30, 1991
MORTON GROVE	10MG/5ML	A071656	001	Oct 13, 1987
WOCKHARDT	10MG/5ML	A074702	001	Mar 24, 1997

PROMETA

MURO	10MG/5ML	A072023	001	Sep 15, 1988
------	----------	---------	-----	--------------

TABLET; ORAL

ALUPENT

BOEHRINGER INGELHEIM	10MG	N015874	002	
	20MG	N015874	001	

METAPROTERENOL SULFATE

AM THERAP	10MG	A072054	001	Jun 23, 1988
	20MG	A072055	001	Jun 23, 1988
TEVA	10MG	A072519	001	Mar 30, 1990
	20MG	A072520	001	Mar 30, 1990
USL PHARMA	10MG	A071013	001	Jan 25, 1988
	20MG	A071014	001	Jan 25, 1988
WATSON LABS	10MG	A073013	001	Jan 31, 1991
	20MG	A072795	001	Jan 31, 1991

METARAMINOL BITARTRATE

INJECTABLE; INJECTION

ARAMINE

MERCK	EQ 10MG BASE/ML	N009509	002	Dec 22, 1987
-------	-----------------	---------	-----	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

METARAMINOL BITARTRATE

ABRAXIS PHARM	EQ 10MG BASE/ML	A080431	001	
ELKINS SINN	EQ 10MG BASE/ML	A083363	001	
GD SEARLE LLC	EQ 10MG BASE/ML	A086418	001	
	EQ 20MG BASE/ML	A086418	002	

METAXALONE

TABLET; ORAL

METAXALONE

COREPHARMA	640MG	N022503	001	Jun 01, 2015
------------	-------	---------	-----	--------------

SKELAXIN

KING PHARMS	400MG	N013217	001	
-------------	-------	---------	-----	--

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLUCOPHAGE

BRISTOL MYERS SQUIBB	625MG	N020357	003	Nov 05, 1998
----------------------	-------	---------	-----	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

	750MG	N020357	004	Nov 05, 1998
--	-------	---------	-----	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

METFORMIN HYDROCHLORIDE

BARR	500MG	A075971	001	Jan 25, 2002
	850MG	A075971	002	Jan 25, 2002
	1GM	A075971	003	Jan 25, 2002
IPCA LABS LTD	500MG	A078422	001	Aug 06, 2007
	850MG	A078422	002	Aug 06, 2007
	1GM	A078422	003	Aug 06, 2007
IVAX SUB TEVA PHARMS	500MG	A075975	001	Jan 24, 2002
	625MG	A075975	004	Jan 24, 2002
	750MG	A075975	005	Jan 24, 2002
	850MG	A075975	002	Jan 24, 2002
	1GM	A075975	003	Jan 24, 2002
TEVA	500MG	A076328	001	Dec 16, 2002
	850MG	A076328	002	Dec 16, 2002
	1GM	A076328	003	Dec 16, 2002
WATSON LABS	500MG	A075979	001	Jan 24, 2002
	850MG	A075979	002	Jan 24, 2002
	1GM	A075979	003	Jan 24, 2002

DISCONTINUED DRUG PRODUCT LISTMETFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

METFORMIN HYDROCHLORIDE

ACTAVIS ELIZABETH	500MG	A076450 001	Oct 01, 2004
	750MG	A076878 001	Apr 13, 2005
BARR	500MG	A076496 001	Nov 25, 2005
IMPAX LABS	500MG	A076249 001	Jul 30, 2004
	750MG	A076985 001	Sep 13, 2005
IVAX SUB TEVA PHARMS	500MG	A076545 001	Dec 01, 2003
RANBAXY LABS LTD	500MG	A076413 001	Jun 18, 2004
	750MG	A077211 001	Jun 29, 2005
SANDOZ	500MG	A076223 001	Dec 14, 2004
SUN PHARM INDS	500MG	A077124 001	Dec 21, 2005
TORRENT PHARMS LTD	750MG	A079226 001	Feb 18, 2010
WATSON LABS INC	500MG	A076818 001	Dec 14, 2004

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET;ORAL

AVANDAMET

SB PHARMCO	500MG;EQ 1MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021410 001	Oct 10, 2002
	500MG;EQ 2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021410 002	Oct 10, 2002
	500MG;EQ 4MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021410 003	Oct 10, 2002
	1GM;EQ 2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021410 004	Aug 25, 2003
	1GM;EQ 4MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021410 005	Aug 25, 2003

METHACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

RONDONMYCIN

MEDPOINTE PHARM HLC	EQ 140MG BASE	A060641 001	
	EQ 280MG BASE	A060641 002	

SYRUP;ORAL

RONDONMYCIN

MEDPOINTE PHARM HLC	EQ 70MG BASE/5ML	A060641 003	
---------------------	------------------	-------------	--

METHADONE HYDROCHLORIDE

SYRUP;ORAL

DOLOPHINE HYDROCHLORIDE

ROXANE	10MG/30ML	N006134 004	
--------	-----------	-------------	--

TABLET;ORAL

METHADONE HYDROCHLORIDE

ROXANE	5MG	A088108 001	Mar 08, 1983
	10MG	A088109 001	Mar 08, 1983
	40MG	A074081 001	Apr 28, 1995
SANDOZ	5MG	A040241 001	May 29, 1998

TABLET, DISPERSIBLE;ORAL

WESTADONE

SANDOZ	2.5MG	N017108 001	
--------	-------	-------------	--

TABLET, EFFERVESCENT;ORAL

WESTADONE

SANDOZ	5MG	N017108 002	
	10MG	N017108 003	
	40MG	N017108 004	

METHAMPHETAMINE HYDROCHLORIDE

TABLET;ORAL

METHAMPEX

TEVA	10MG	A083889 001	
------	------	-------------	--

METHAMPHETAMINE HYDROCHLORIDE

ABLE	5MG	A040529 001	Feb 25, 2004
REXAR	5MG	A084931 001	
	10MG	A084931 002	

DISCONTINUED DRUG PRODUCT LIST

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

METHAMPHETAMINE HYDROCHLORIDE

TEVA 5MG A086359 001

TABLET, EXTENDED RELEASE; ORAL

DESOXYN

RECORDATI RARE 5MG N005378 004

10MG N005378 003

15MG N005378 005

METHANTHELINE BROMIDE

TABLET; ORAL

BANTHINE

SHIRE 50MG N007390 001

METHARBITAL

TABLET; ORAL

GEMONIL

ABBVIE 100MG N008322 001

METHAZOLAMIDE

TABLET; ORAL

METHAZOLAMIDE

APPLIED ANAL 25MG A040011 001 Jul 17, 1997

50MG A040011 002 Jul 17, 1997

SANDOZ 25MG A040102 001 Aug 28, 1996

50MG A040102 002 Aug 28, 1996

NEPTAZANE

LEDERLE 25MG **Federal Register determination N011721 002 Nov 25, 1991

that product was not discontinued or
withdrawn for safety or efficacy
reasons**

50MG **Federal Register determination N011721 001

that product was not discontinued or
withdrawn for safety or efficacy
reasons**METHDILAZINE

TABLET, CHEWABLE; ORAL

TACARYL

WESTWOOD SQUIBB 3.6MG N011950 009

METHDILAZINE HYDROCHLORIDE

SYRUP; ORAL

METHDILAZINE HYDROCHLORIDE

ALPHARMA US PHARMS 4MG/5ML A087122 001

TACARYL

WESTWOOD SQUIBB 4MG/5ML N011950 007

TABLET; ORAL

TACARYL

WESTWOOD SQUIBB 8MG N011950 006

METHICILLIN SODIUM

INJECTABLE; INJECTION

STAPHICILLIN

APOTHECON EQ 900MG BASE/VIAL A061449 001

EQ 900MG BASE/VIAL N050117 001

EQ 3.6GM BASE/VIAL A061449 002

EQ 3.6GM BASE/VIAL N050117 002

EQ 5.4GM BASE/VIAL A061449 003

EQ 5.4GM BASE/VIAL N050117 003

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

CEDAR PHARMS 15MG A040619 003 Jul 12, 2005

ECI PHARMS LLC 20MG A040547 004 Feb 18, 2005

MYLAN 20MG A040350 003 Jun 07, 2001

TAPAZOLE

KING PHARMS 5MG **Federal Register determination N007517 002

that product was not discontinued or
withdrawn for safety or efficacy
reasons**

10MG **Federal Register determination N007517 004

that product was not discontinued or
withdrawn for safety or efficacy
reasons**

DISCONTINUED DRUG PRODUCT LISTMETHIXENE HYDROCHLORIDE

TABLET; ORAL

TREST

NOVARTIS 1MG N013420 001

METHOCARBAMOL

INJECTABLE; INJECTION

METHOCARBAMOL

MARSAM PHARMS LLC 100MG/ML A089849 001 Dec 27, 1991

WATSON LABS 100MG/ML A086459 001

TABLET; ORAL

DELAXIN

FERNDALE LABS 500MG A085454 001

FORBAXIN

FOREST LABS 750MG A085136 001

METHOCARBAMOL

ABLE 500MG A040413 001 Mar 17, 2003

750MG A040413 002 Mar 17, 2003

AM THERAP 500MG A089417 001 Feb 11, 1987

750MG A089418 001 Feb 11, 1987

ASCOT 500MG A087660 001 Oct 27, 1982

750MG A087661 001 Oct 27, 1982

CLONMEL HLTHCARE 500MG A085961 001

750MG A085963 001

HEATHER 500MG A084675 001

750MG A084924 001

IMPAX LABS 500MG A084927 001

750MG A084928 001

INWOOD LABS 500MG A085137 001

IVAX SUB TEVA PHARMS 500MG A084648 001

750MG A084649 001

KV PHARM 500MG A085660 001

750MG A085658 001

LANNETT HOLDINGS INC 500MG A084756 002 Mar 31, 2003

750MG A084756 001

MYLAN 500MG A084259 001

750MG A084323 001

NYLOS 750MG A085033 001

PIONEER PHARMS 500MG A088731 001 Dec 13, 1985

750MG A089082 001 Dec 13, 1985

PURACAP PHARM 500MG A084231 002

750MG A084471 001

PUREPAC PHARM 500MG A085718 001

750MG A085718 002

ROXANE 500MG A088646 001 Feb 29, 1984

750MG A088647 001 Feb 29, 1984

SANDOZ 500MG A084616 001

500MG A087283 001

750MG A084615 001

750MG A087282 001

SOLVAY 500MG A084448 001

750MG A084449 001

SUN PHARM INDS 500MG A084488 001

750MG A084486 001

SUPERPHARM 500MG A087589 001 Jan 22, 1982

750MG A087590 001 Jan 22, 1982

TABLICAPS 500MG A084846 001

UPSHER SMITH 500MG A087453 001

750MG A087454 001

WATSON LABS 500MG A083605 001

500MG A085180 001

750MG A083605 002

750MG A085192 001

METHOHEXITAL SODIUM

INJECTABLE; INJECTION

BREVITAL SODIUM

PAR STERILE PRODUCTS 200MG/VIAL N011559 004 Dec 21, 2012

5GM/VIAL N011559 003

DISCONTINUED DRUG PRODUCT LIST

METHOTREXATE

SOLUTION; SUBCUTANEOUS

OTREXUP

ANTARES PHARMA INC 7.5MG/0.4ML (7.5MG/0.4ML) N204824 005 Nov 07, 2014

METHOTREXATE SODIUM

INJECTABLE; INJECTION

ABITREXATE

ABIC

EQ 25MG BASE/ML A089161 001 Mar 10, 1987

EQ 50MG BASE/VIAL A089354 001 Jul 17, 1987

EQ 100MG BASE/VIAL A089355 001 Jul 17, 1987

EQ 250MG BASE/VIAL A089356 001 Jul 17, 1987

FOLEX

PHARMACIA AND UPJOHN

EQ 25MG BASE/VIAL A087695 001 Apr 08, 1983

EQ 50MG BASE/VIAL A087695 002 Apr 08, 1983

EQ 100MG BASE/VIAL A087695 003 Apr 08, 1983

EQ 250MG BASE/VIAL A088954 001 Oct 24, 1985

FOLEX PFS

PHARMACIA AND UPJOHN

EQ 25MG BASE/ML A081242 001 Aug 23, 1991

EQ 25MG BASE/ML A089180 001 Jan 03, 1986

METHOTREXATE LPF

HOSPIRA

EQ 25MG BASE/ML N011719 007 Mar 31, 1982

METHOTREXATE PRESERVATIVE FREE

HOSPIRA

EQ 20MG BASE/2ML (EQ 10MG BASE/ML) N011719 014 Apr 13, 2005

EQ 500MG BASE/20ML (EQ 25MG BASE/ML) N011719 013 Apr 13, 2005

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML) N011719 011 Apr 13, 2005

METHOTREXATE SODIUM

ABRAXIS PHARM

EQ 2.5MG BASE/ML A089323 001 Jun 13, 1986

EQ 20MG BASE/VIAL A088935 001 Oct 11, 1985

EQ 25MG BASE/ML A089263 001 Jun 13, 1986

EQ 25MG BASE/ML A089322 001 Jun 13, 1986

EQ 50MG BASE/VIAL A088936 001 Oct 11, 1985

EQ 100MG BASE/VIAL A088937 001 Oct 11, 1985

HOSPIRA

EQ 2.5MG BASE/ML N011719 004

EQ 20MG BASE/VIAL N011719 001

EQ 25MG BASE/ML N011719 005

EQ 50MG BASE/VIAL N011719 003

EQ 100MG BASE/VIAL N011719 006

NORBROOK

EQ 25MG BASE/ML A088648 001 May 09, 1986

PHARMACHEMIE USA

EQ 25MG BASE/ML A089158 001 Jul 08, 1988

METHOTREXATE SODIUM PRESERVATIVE FREE

HOSPIRA

EQ 1GM BASE/VIAL N011719 009 Apr 07, 1988

MEXATE

BRISTOL

EQ 20MG BASE/VIAL A086358 001

EQ 50MG BASE/VIAL A086358 002

EQ 100MG BASE/VIAL A086358 003

EQ 250MG BASE/VIAL A086358 004

MEXATE-AQ

BRISTOL MYERS

EQ 25MG BASE/ML A088760 001 Feb 14, 1985

MEXATE-AQ PRESERVED

BRISTOL MYERS SQUIBB

EQ 25MG BASE/ML A089887 001 Apr 14, 1989

TABLET; ORAL

METHOTREXATE SODIUM

DURAMED PHARMS BARR

EQ 2.5MG BASE A040233 001 Jun 17, 1999

METHOXAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

VASOXYL

GLAXOSMITHKLINE

10MG/ML N006772 002

20MG/ML N006772 001

METHOXSALEN

CAPSULE; ORAL

METHOXSALEN

IDT AUSTRALIA LTD

10MG A087781 001 Jun 08, 1982

DISCONTINUED DRUG PRODUCT LIST

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

METHSCOPOLAMINE BROMIDE

PVT FORM	2.5MG	A080970	001	
PAMINE				
FOUGERA PHARMS	2.5MG	N008848	001	
PAMINE FORTE				
FOUGERA PHARMS	5MG	N008848	002	Mar 25, 2003

METHYCLOTHIAZIDE

TABLET; ORAL

AQUATENSEN

MEDPOINTE PHARM HLC	5MG	N017364	001	
---------------------	-----	---------	-----	--

ENDURON

ABBVIE	2.5MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012524	001
	5MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012524	004

METHYCLOTHIAZIDE

IVAX PHARMS	2.5MG	A087913	001	Jun 03, 1982
	5MG	A087786	001	May 18, 1982
MYLAN	2.5MG	A087671	001	Aug 17, 1982
PAR PHARM	2.5MG	A089135	001	Feb 12, 1986
	5MG	A089136	001	Feb 12, 1986
SANDOZ	2.5MG	A089835	001	Aug 18, 1988
	5MG	A089837	001	Aug 18, 1988
USL PHARMA	5MG	A088745	001	Mar 21, 1985
WATSON LABS	2.5MG	A085487	001	Mar 11, 1982
	2.5MG	A088750	001	Sep 06, 1984
	5MG	A085476	001	Mar 11, 1982
	5MG	A088724	001	Sep 06, 1984

METHYCLOTHIAZIDE; PARGYLINE HYDROCHLORIDE

TABLET; ORAL

EUTRON

ABBOTT	5MG; 25MG	N016047	001	
--------	-----------	---------	-----	--

METHYCLOTHIAZIDE; RESERPINE

TABLET; ORAL

DIUTENSEN-R

MEDPOINTE PHARM HLC	2.5MG; 0.1MG	N012708	005	
---------------------	--------------	---------	-----	--

METHYL AMINOLEVULINATE HYDROCHLORIDE

CREAM; TOPICAL

METVIXIA

GALDERMA LABS LP	EQ 16.8% BASE	N021415	001	Jul 27, 2004
------------------	---------------	---------	-----	--------------

METHYLDOPA

SUSPENSION; ORAL

ALDOMET

MERCK	250MG/5ML	N018389	001	
-------	-----------	---------	-----	--

TABLET; ORAL

ALDOMET

MERCK	125MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N013400	003
	250MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N013400	001
	500MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N013400	002

METHYLDOPA

ACCORD HLTHCARE	125MG	A070070	003	Oct 15, 1985
DURAMED PHARMS BARR	250MG	A071006	001	Dec 16, 1986
	500MG	A071009	001	Dec 16, 1986
HALSEY	125MG	A071751	001	Mar 28, 1988
	250MG	A071752	001	Mar 28, 1988
	500MG	A071753	001	Mar 28, 1988
PAR PHARM	125MG	A070535	001	Jan 02, 1987

DISCONTINUED DRUG PRODUCT LIST

METHYLDOPA

TABLET; ORAL

METHYLDOPA

	250MG	A070536 001	Jan 02, 1987
	500MG	A070537 001	Jan 02, 1987
PARKE DAVIS	125MG	A070331 001	Apr 15, 1986
	250MG	A070332 001	Apr 15, 1986
	500MG	A070333 001	Apr 15, 1986
PLIVA	125MG	A072126 001	Jul 07, 1988
	250MG	A072127 001	Jul 07, 1988
	500MG	A072128 001	Jul 07, 1988
PUREPAC PHARM	125MG	A070749 001	Feb 07, 1986
	250MG	A070750 001	Feb 07, 1986
	500MG	A070452 001	Feb 07, 1986
ROXANE	125MG	A070192 001	Apr 25, 1986
	250MG	A070193 001	Apr 25, 1986
	500MG	A070194 001	Apr 25, 1986
SANDOZ	125MG	A071700 001	Mar 02, 1988
	250MG	N018934 001	Jun 29, 1984
	500MG	N018934 002	Jun 29, 1984
SUN PHARM INDS	125MG	A070073 001	Oct 09, 1986
	250MG	A070060 001	Oct 09, 1986
	500MG	A070074 001	Oct 09, 1986
SUPERPHARM	250MG	A070669 001	Jun 23, 1989
	500MG	A070670 001	Jun 23, 1989
TEVA	125MG	A071105 001	Dec 05, 1986
	250MG	A071106 001	Dec 05, 1986
	500MG	A071067 001	Dec 05, 1986
WATSON LABS	125MG	A070245 001	Feb 25, 1986
	125MG	A070260 001	Jun 24, 1985
	250MG	A070246 001	Feb 25, 1986
	250MG	A070261 001	Jun 24, 1985
	250MG	A070703 001	Jun 06, 1986
	500MG	A070247 001	Feb 25, 1986
	500MG	A070262 001	Jun 24, 1985

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

ALDOMET

MERCK

50MG/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N013401 001

METHYLDOPATE HYDROCHLORIDE

ABRAXIS PHARM

50MG/ML

A070652 001 Jun 03, 1986

BAXTER HLTHCARE

50MG/ML

A070291 001 Jul 01, 1986

HOSPIRA

50MG/ML

A070691 001 Jun 19, 1987

50MG/ML

A070698 001 Jun 15, 1987

50MG/ML

A070699 001 Jun 15, 1987

50MG/ML

A070849 001 Jun 19, 1987

MARSAM PHARMS LLC

50MG/ML

A071812 001 Dec 22, 1987

SMITH AND NEPHEW

50MG/ML

A070841 001 Jan 02, 1987

TEVA PARENTERAL

50MG/ML

A072974 001 Nov 22, 1991

METHYLERGONOVINE MALEATE

TABLET; ORAL

METHERGINE

EDISON THERAPS LLC

0.2MG

N006035 003

METHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

ABLE

5MG

A040404 001 Mar 29, 2001

10MG

A040404 002 Mar 29, 2001

20MG

A040404 003 Mar 29, 2001

ACTAVIS ELIZABETH

5MG

A040321 001 Feb 05, 2002

10MG

A040321 002 Feb 05, 2002

20MG

A040321 003 Feb 05, 2002

TABLET, CHEWABLE; ORAL

METHYLIN

MALLINCKRODT

2.5MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021475 001 Apr 15, 2003

5MG **Federal Register determination

N021475 002 Apr 15, 2003

DISCONTINUED DRUG PRODUCT LIST

METHYLPHENIDATE HYDROCHLORIDE

TABLET, CHEWABLE;ORAL

METHYLIN

that product was not discontinued or
withdrawn for safety or efficacy
reasons**

10MG **Federal Register determination

N021475 003 Apr 15, 2003

that product was not discontinued or
withdrawn for safety or efficacy
reasons**

TABLET, EXTENDED RELEASE;ORAL

METADATE ER

UCB INC 10MG

A040306 001 Oct 20, 1999

METHYLPHENIDATE HYDROCHLORIDE

ABLE 20MG

A076032 001 May 09, 2001

ACTAVIS ELIZABETH 20MG

A075450 001 Dec 21, 2001

WATSON LABS 20MG

A040410 001 Feb 09, 2001

METHYLPREDNISOLONE

TABLET;ORAL

MEDROL

PHARMACIA AND UPJOHN 24MG

N011153 005

METHYLPREDNISOLONE

HEATHER 4MG

A085650 001

PAR PHARM 16MG

A089207 001 Apr 25, 1988

24MG

A089208 001 Apr 25, 1988

32MG

A089209 001 Apr 25, 1988

SANDOZ 4MG

A087341 001

WATSON LABS 4MG

A086161 001 Feb 09, 1982

16MG

A086159 001 Feb 09, 1982

METHYLPREDNISOLONE ACETATE

ENEMA;RECTAL

MEDROL

PHARMACIA AND UPJOHN 40MG/BOT

N018102 001

INJECTABLE; INJECTION

M-PREDROL

BEL MAR 40MG/ML

A086666 001

80MG/ML

A087135 001

METHYLPREDNISOLONE ACETATE

AKORN 40MG/ML

A086903 001 Oct 20, 1982

80MG/ML

A086903 002 Oct 20, 1982

WATSON LABS 20MG/ML

A085597 001

20MG/ML

A087248 001

40MG/ML

A085374 001

40MG/ML

A085600 001

80MG/ML

A085595 001

80MG/ML

A086507 001

OINTMENT; TOPICAL

MEDROL ACETATE

PHARMACIA AND UPJOHN 0.25%

N012421 001

1%

N012421 002

METHYLPREDNISOLONE ACETATE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-MEDROL ACETATE

PHARMACIA AND UPJOHN 0.25%;EQ 3.5MG BASE/GM

A060611 002

1%;EQ 3.5MG BASE/GM

A060611 001

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

ABBOTT EQ 40MG BASE/VIAL

A089573 001 Feb 22, 1991

EQ 125MG BASE/VIAL

A089574 001 Feb 22, 1991

EQ 500MG BASE/VIAL

A089575 001 Feb 22, 1991

EQ 1GM BASE/VIAL

A089576 001 Feb 22, 1991

HOSPIRA EQ 40MG BASE/VIAL

A085853 001

EQ 125MG BASE/VIAL

A085855 001

EQ 500MG BASE/VIAL

A085854 001

EQ 500MG BASE/VIAL

A089173 001 Aug 18, 1987

EQ 1GM BASE/VIAL

A085852 001

EQ 1GM BASE/VIAL

A089174 001 Aug 18, 1987

METHYLPREDNISOLONE

ELKINS SINN EQ 125MG BASE/VIAL

A086906 002

EQ 500MG BASE/VIAL

A086906 003

DISCONTINUED DRUG PRODUCT LIST

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE

	EQ 1GM BASE/VIAL	A086906	004	
ORGANON USA INC	EQ 500MG BASE/VIAL	A087535	001	Jun 25, 1982
	EQ 1GM BASE/VIAL	A087535	002	Jun 25, 1982

METHYLPREDNISOLONE SODIUM SUCCINATE

ABRAXIS PHARM	EQ 40MG BASE/VIAL	A088676	001	Jun 08, 1984
	EQ 40MG BASE/VIAL	A089143	001	Mar 28, 1986
	EQ 125MG BASE/VIAL	A088677	001	Jun 08, 1984
	EQ 125MG BASE/VIAL	A089144	001	Mar 28, 1986
	EQ 500MG BASE/VIAL	A088678	001	Jun 08, 1984
	EQ 500MG BASE/VIAL	A089186	001	Mar 28, 1986
	EQ 500MG BASE/VIAL	A089187	001	Mar 28, 1986
	EQ 1GM BASE/VIAL	A088679	001	Jun 08, 1984
	EQ 1GM BASE/VIAL	A089188	001	Mar 28, 1986
BEDFORD LABS	EQ 1GM BASE/VIAL	A089189	001	Mar 28, 1986
	EQ 40MG BASE/VIAL	A040662	001	Feb 21, 2007
	EQ 125MG BASE/VIAL	A040641	002	Feb 21, 2007
	EQ 500MG BASE/VIAL	A040641	003	Feb 21, 2007
	EQ 500MG BASE/VIAL	A040709	001	Feb 21, 2007
	EQ 1GM BASE/VIAL	A040641	004	Feb 21, 2007
ELKINS SINN INTL MEDICATION	EQ 1GM BASE/VIAL	A040709	002	Feb 21, 2007
	EQ 40MG BASE/VIAL	A086906	001	
	EQ 40MG BASE/VIAL	A087812	001	Feb 09, 1983
TEVA PARENTERAL	EQ 125MG BASE/VIAL	A087813	001	Feb 09, 1983
	EQ 500MG BASE/VIAL	A087851	001	Feb 09, 1983
	EQ 1GM BASE/VIAL	A087852	001	Feb 09, 1983
	EQ 125MG BASE/VIAL	A081266	001	Nov 30, 1992
WATSON LABS	EQ 500MG BASE/VIAL	A081267	001	Nov 30, 1992
	EQ 1GM BASE/VIAL	A081268	001	Nov 30, 1992
	EQ 40MG BASE/VIAL	A086953	001	Jul 22, 1982
	EQ 125MG BASE/VIAL	A087030	001	Jul 22, 1982
	EQ 500MG BASE/VIAL	A088523	001	Jul 24, 1984
	EQ 1GM BASE/VIAL	A088524	001	Jul 24, 1984

METHYLPREDNISOLONE; NEOMYCIN SULFATE

OINTMENT; OPHTHALMIC

NEO-MEDROL

PHARMACIA AND UPJOHN	0.1%;EQ 3.5MG BASE/GM	A060645	001	
----------------------	-----------------------	---------	-----	--

METHYLTESTOSTERONE

CAPSULE; ORAL

METHYLTESTOSTERONE

HEATHER	10MG	A084967	001	
---------	------	---------	-----	--

VIRILON

STAR PHARMS FL	10MG	A087750	001	Nov 24, 1982
----------------	------	---------	-----	--------------

TABLET; BUCCAL

ANDROID 5

VALEANT PHARM INTL	5MG	A087222	001	
--------------------	-----	---------	-----	--

ORETON

SCHERING	10MG	A080281	001	
----------	------	---------	-----	--

TABLET; BUCCAL, SUBLINGUAL

METANDREN

NOVARTIS	5MG	N003240	004	
	10MG	N003240	001	
	10MG	N003240	005	
	25MG	N003240	003	

METHYLTESTOSTERONE

IMPAX LABS	10MG	A084287	001	
------------	------	---------	-----	--

LILLY	10MG	A080256	001	
	25MG	A080256	002	
	10MG	A080308	001	

PUREPAC PHARM	10MG	A080475	001	
	10MG	A080475	002	
	10MG	A080475	002	
	25MG	A080475	003	
	5MG	A083836	001	

PVT FORM	10MG	A080475	002	
	25MG	A080475	003	
	5MG	A083836	001	

TABLICAPS	10MG	A085125	001	
-----------	------	---------	-----	--

USL PHARMA	10MG	A080271	001	
------------	------	---------	-----	--

TABLET; ORAL

ANDROID 10

VALEANT PHARM INTL	10MG	A086450	001	
--------------------	------	---------	-----	--

DISCONTINUED DRUG PRODUCT LISTMETHYLTESTOSTERONE

TABLET; ORAL

METHYLTESTOSTERONE

IMPAX LABS	25MG	A084310	001	
INWOOD LABS	10MG	A080839	001	
	25MG	A080973	001	
KV PHARM	10MG	A084312	001	
LANNETT	10MG	A087092	001	Nov 05, 1982
	25MG	A087111	001	Jan 27, 1983
PARKE DAVIS	10MG	A084244	001	
	25MG	A084241	001	
PUREPAC PHARM	10MG	A080309	001	
	25MG	A080310	001	
PVT FORM	5MG	A080214	001	
	10MG	A080214	002	
	25MG	A080214	003	
TABLICAPS	10MG	A080313	001	
	25MG	A085270	001	
WATSON LABS	10MG	A080933	001	
	25MG	A080931	001	
WEST WARD	10MG	A084331	001	
	25MG	A084331	002	
	25MG	A084642	001	
ORETON METHYL				
SCHERING	10MG	N003158	001	
	25MG	N003158	002	

METHYPRYLON

CAPSULE; ORAL

NOLUDAR

ROCHE	300MG	N009660	008	
-------	-------	---------	-----	--

ELIXIR; ORAL

NOLUDAR

ROCHE	50MG/5ML	N009660	007	
-------	----------	---------	-----	--

TABLET; ORAL

NOLUDAR

ROCHE	50MG	N009660	002	
	200MG	N009660	004	

METHYSERGIDE MALEATE

TABLET; ORAL

SANSERT

NOVARTIS	2MG	N012516	001	
----------	-----	---------	-----	--

METOCLOPRAMIDE HYDROCHLORIDE

CONCENTRATE; ORAL

METOCLOPRAMIDE INTENSOL

ROXANE	EQ 10MG BASE/ML	A072995	001	Jan 30, 1992
--------	-----------------	---------	-----	--------------

INJECTABLE; INJECTION

METOCLOPRAMIDE HYDROCHLORIDE

BEDFORD	EQ 5MG BASE/ML	A072155	001	Mar 30, 1992
	EQ 5MG BASE/ML	A072244	001	Mar 30, 1992
	EQ 5MG BASE/ML	A072247	001	May 18, 1992
HOSPIRA	EQ 5MG BASE/ML	A070505	001	Jun 23, 1989
	EQ 5MG BASE/ML	A070506	001	Jun 22, 1989
	EQ 5MG BASE/ML	A070847	001	Nov 07, 1988
	EQ 5MG BASE/ML	A071291	001	Mar 03, 1989
	EQ 5MG BASE/ML	A071990	001	Jan 18, 1989
	EQ 5MG BASE/ML	A073117	001	Jan 17, 1991
	EQ 5MG BASE/ML	A074147	001	Aug 02, 1996
LYPHOMED	EQ 10MG BASE/2ML	A070293	001	Jan 24, 1986
NORBROOK	EQ 10MG BASE/2ML	A070892	001	Aug 26, 1988
SMITH AND NEPHEW	EQ 5MG BASE/ML	A070623	001	Mar 02, 1987
	EQ 10MG BASE/2ML	A070622	001	Mar 02, 1987
REGLAN				
WEST-WARD PHARMS INT	EQ 5MG BASE/ML	N017862	001	
	EQ 10MG BASE/ML	N017862	004	May 28, 1987

SOLUTION; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	EQ 5MG BASE/5ML	A071340	001	Aug 18, 1988
MORTON GROVE	EQ 5MG BASE/5ML	A070949	001	Mar 06, 1987
PACO	EQ 5MG BASE/5ML	A071665	001	Dec 05, 1988
ROXANE	EQ 5MG BASE/5ML	A072038	001	Dec 05, 1988
SILARX	EQ 5MG BASE/5ML	A073680	001	Oct 27, 1992

DISCONTINUED DRUG PRODUCT LIST

METOCLOPRAMIDE HYDROCHLORIDE

SOLUTION; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

TEVA	EQ 5MG BASE/5ML	A070819 001	Jul 10, 1987
	EQ 5MG BASE/5ML	A071315 001	Jun 30, 1993

REGLAN

ROBINS AH	EQ 5MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018821 001	Mar 25, 1983
-----------	--	-------------	--------------

TABLET; ORAL

CLOPRA

QUANTUM PHARMICS	EQ 5MG BASE	A072384 001	Jun 02, 1988
	EQ 10MG BASE	A070294 001	Jul 29, 1985

CLOPRA-"YELLOW"

QUANTUM PHARMICS	EQ 10MG BASE	A070632 001	Oct 28, 1985
------------------	--------------	-------------	--------------

MAXOLON

KING PHARMS	EQ 10MG BASE	A070106 001	Mar 04, 1986
-------------	--------------	-------------	--------------

METOCLOPRAMIDE HYDROCHLORIDE

CLONMEL	EQ 10MG BASE	A072639 001	May 09, 1991
HALSEY	EQ 10MG BASE	A070906 001	Oct 28, 1986
INTERPHARM	EQ 10MG BASE	A071213 001	Sep 24, 1986
MUTUAL PHARM	EQ 10MG BASE	A070660 001	Feb 10, 1987
PAR PHARM	EQ 10MG BASE	A070342 001	Mar 25, 1986
SANDOZ	EQ 5MG BASE	A072436 001	Jun 22, 1989
	EQ 5MG BASE	A074478 001	Oct 05, 1995
	EQ 10MG BASE	A070850 001	Feb 03, 1987
	EQ 10MG BASE	A072215 001	Jan 30, 1990
	EQ 10MG BASE	A074478 002	Oct 05, 1995
SCHERING	EQ 10MG BASE	A070598 001	Feb 02, 1987
SUN PHARM INDS	EQ 10MG BASE	A071536 001	Apr 28, 1993
SUPERPHARM	EQ 10MG BASE	A070926 001	Jun 26, 1987
USL PHARMA	EQ 10MG BASE	A070339 001	Jul 29, 1985
WATSON LABS	EQ 10MG BASE	A070363 001	Mar 02, 1987
	EQ 10MG BASE	A070453 001	Jun 06, 1986
	EQ 10MG BASE	A070511 001	Jan 22, 1986
	EQ 10MG BASE	A070645 001	May 11, 1987

TABLET, ORALLY DISINTEGRATING; ORAL

METOZOLV ODT

SALIX PHARMS	EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N022246 002	Sep 04, 2009
--------------	---	-------------	--------------

REGLAN ODT

MEDA PHARMS	EQ 5MG BASE	N021793 001	Jun 10, 2005
	EQ 10MG BASE	N021793 002	Jun 10, 2005

METOCURINE IODIDE

INJECTABLE; INJECTION

METUBINE IODIDE

LILLY	2MG/ML	N006632 003	
-------	--------	-------------	--

METOLAZONE

TABLET; ORAL

DIULO

GD SEARLE LLC	2.5MG	N018535 001	
	5MG	N018535 002	
	10MG	N018535 003	

METOLAZONE

ROXANE	10MG	A076482 002	Apr 29, 2004
TEVA	2.5MG	A076600 001	Jan 06, 2004
	5MG	A076833 001	Mar 01, 2004
	10MG	A075543 003	Dec 24, 2003
WATSON LABS	10MG	A076891 001	Jul 21, 2004

MYKROX

UCB INC	0.5MG	N019532 001	Oct 30, 1987
---------	-------	-------------	--------------

METOPROLOL FUMARATE

TABLET, EXTENDED RELEASE; ORAL

LOPRESSOR

NOVARTIS	EQ 100MG TARTRATE	N019786 001	Dec 27, 1989
	EQ 200MG TARTRATE	N019786 002	Dec 27, 1989
	EQ 300MG TARTRATE	N019786 003	Dec 27, 1989
	EQ 400MG TARTRATE	N019786 004	Dec 27, 1989

DISCONTINUED DRUG PRODUCT LIST

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

NESHER PHARMS	EQ 25MG TARTRATE	A077779	001	Mar 20, 2008
	EQ 50MG TARTRATE	A077176	001	May 14, 2008
	EQ 100MG TARTRATE	A076640	002	May 18, 2007
	EQ 200MG TARTRATE	A076640	001	May 18, 2007
SANDOZ	EQ 25MG TARTRATE	A076969	001	Jul 31, 2006
	EQ 50MG TARTRATE	A076969	002	May 18, 2007
	EQ 100MG TARTRATE	A076969	003	Mar 20, 2008
	EQ 200MG TARTRATE	A076969	004	Mar 20, 2008

METOPROLOL TARTRATE

INJECTABLE;INJECTION

METOPROLOL TARTRATE

WATSON LABS	1MG/ML	A074032	001	Dec 21, 1993
-------------	--------	---------	-----	--------------

TABLET;ORAL

METOPROLOL TARTRATE

APOTHECON	50MG	A074258	001	Jan 27, 1994
	100MG	A074258	002	Jan 27, 1994
MYLAN	50MG	A073666	001	Dec 21, 1993
	100MG	A073666	002	Dec 21, 1993
PRINSTON INC	50MG	A074453	001	Apr 27, 1995
	100MG	A074453	002	Apr 27, 1995
PUREPAC PHARM	50MG	A074380	001	Jul 29, 1994
	100MG	A074380	002	Jul 29, 1994
SANDOZ	50MG	A073288	001	Mar 25, 1994
	100MG	A073289	001	Mar 25, 1994
TEVA	50MG	A074143	001	Sep 30, 1994
	100MG	A074143	002	Sep 30, 1994
TEVA PHARMS	50MG	A074333	001	Jan 27, 1994
	100MG	A074333	002	Jan 27, 1994

METRIZAMIDE

INJECTABLE;INJECTION

AMIPAQUE

GE HEALTHCARE	2.5GM/VIAL	N017982	003	Sep 12, 1983
	3.75GM/VIAL	N017982	001	
	6.75GM/VIAL	N017982	002	
	13.5GM/VIAL	N017982	004	Sep 12, 1983

METRONIDAZOLE

CAPSULE;ORAL

METRONIDAZOLE

ABLE	375MG	A076505	001	Nov 13, 2003
------	-------	---------	-----	--------------

INJECTABLE;INJECTION

FLAGYL I.V. RTU IN PLASTIC CONTAINER

PFIZER	500MG/100ML	N018353	002	
--------	-------------	---------	-----	--

METRO I.V.

B BRAUN	500MG/100ML	N018674	001	Aug 31, 1982
---------	-------------	---------	-----	--------------

METRONIDAZOLE

ABBOTT	500MG/100ML	N018889	001	Nov 18, 1983
ABRAXIS PHARM	500MG/100ML	A070071	001	Dec 03, 1984
EUROHLTH INTL SARL	500MG/100ML	N018907	001	Mar 30, 1984
INTL MEDICATION	500MG/100ML	A070004	001	May 08, 1985
WATSON LABS	500MG/100ML	A070042	001	Dec 20, 1984
	500MG/100ML	A070170	001	Apr 01, 1986

TABLET;ORAL

METROMIDOL

LABS AF	250MG	A074523	001	Oct 24, 1996
	500MG	A074523	002	Oct 24, 1996

METRONIDAZOLE

ABLE	250MG	A076519	001	Jun 27, 2003
	500MG	A076519	002	Jun 27, 2003
HALSEY	250MG	A070021	001	Apr 02, 1985
	500MG	A070593	001	Feb 27, 1986
IVAX SUB TEVA PHARMS	250MG	N018517	001	
	500MG	N018517	002	May 05, 1982
LNK	250MG	N019029	001	Apr 10, 1984
MUTUAL PHARM	250MG	N018818	001	Feb 16, 1983
	500MG	N018818	002	Feb 16, 1983
PAR PHARM	250MG	N018845	001	Aug 18, 1983
	500MG	N018930	001	Aug 18, 1983
SANDOZ	250MG	N018620	001	Mar 04, 1982

DISCONTINUED DRUG PRODUCT LISTMETRONIDAZOLE

TABLET; ORAL

METRONIDAZOLE	250MG	N018740 001	Oct 22, 1982
	500MG	N018620 002	Jun 02, 1983
	500MG	N018740 002	Oct 22, 1982
SUPERPHARM	250MG	A070008 001	Dec 11, 1984
	500MG	A070009 001	Dec 11, 1984
WATSON LABS	250MG	N018599 001	Sep 17, 1982
	250MG	N018764 001	Sep 17, 1982
	500MG	N018599 002	Feb 13, 1984
	500MG	N018764 002	Dec 20, 1982
PROTOSTAT			
ORTHO MCNEIL PHARM	250MG	N018871 001	Mar 02, 1983
	500MG	N018871 002	Mar 02, 1983
SATRIC			
SAVAGE LABS	250MG	A070029 001	Mar 19, 1985
	500MG	A070731 001	Jun 08, 1987
TABLET, EXTENDED RELEASE; ORAL			
METRONIDAZOLE			
ABLE	750MG	A076462 001	Jun 25, 2003

METRONIDAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION

FLAGYL I.V.			
PFIZER	EQ 500MG BASE/VIAL	N018353 001	
METRONIDAZOLE HYDROCHLORIDE			
ABRAXIS PHARM	EQ 500MG BASE/VIAL	A070295 001	Oct 15, 1985

METYRAPONE

TABLET; ORAL

METOPIRONE			
HRA PHARMA	250MG	N012911 001	

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE			
IDT AUSTRALIA LTD	150MG	A074450 001	May 16, 1996
	200MG	A074450 002	May 16, 1996
	250MG	A074450 003	May 16, 1996
WATSON LABS	150MG	A074711 001	Feb 26, 1997
	150MG	A074865 001	Apr 13, 1998
	200MG	A074711 002	Feb 26, 1997
	200MG	A074865 002	Apr 13, 1998
	250MG	A074711 003	Feb 26, 1997
	250MG	A074865 003	Apr 13, 1998
MEXITIL			
BOEHRINGER INGELHEIM	150MG	N018873 002	Dec 30, 1985
	200MG	N018873 003	Dec 30, 1985
	250MG	N018873 004	Dec 30, 1985

MEZLOCILLIN SODIUM MONOHYDRATE

INJECTABLE; INJECTION

MEZLIN			
BAYER PHARMS	EQ 1GM BASE/VIAL	A062333 001	
	EQ 1GM BASE/VIAL	A062372 005	Jan 13, 1983
	EQ 1GM BASE/VIAL	N050549 001	
	EQ 2GM BASE/VIAL	A062333 002	
	EQ 2GM BASE/VIAL	A062372 001	May 13, 1982
	EQ 2GM BASE/VIAL	N050549 002	
	EQ 3GM BASE/VIAL	A062333 003	
	EQ 3GM BASE/VIAL	A062372 002	May 13, 1982
	EQ 3GM BASE/VIAL	A062697 001	Jan 22, 1987
	EQ 3GM BASE/VIAL	N050549 003	
	EQ 4GM BASE/VIAL	A062333 004	
	EQ 4GM BASE/VIAL	A062372 003	May 13, 1982
	EQ 4GM BASE/VIAL	A062697 002	Jan 22, 1987
	EQ 4GM BASE/VIAL	N050549 004	
	EQ 20GM BASE/VIAL	A062372 004	Mar 02, 1988
	EQ 20GM BASE/VIAL	N050549 005	Mar 02, 1988

DISCONTINUED DRUG PRODUCT LIST

MICONAZOLE

INJECTABLE; INJECTION

MONISTAT

JANSSEN PHARMA

10MG/ML

N018040 001

MICONAZOLE NITRATE

CREAM; TOPICAL

MONISTAT-DERM

INSIGHT PHARMS

2%

N017494 001

CREAM; VAGINAL

MICONAZOLE NITRATE

TEVA

2%

A074136 001 Jan 04, 1995

TEVA PHARMS

2%

A074030 001 Oct 30, 1992

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

M-ZOLE 7 DUAL PACK

ACTAVIS MID ATLANTIC

2%, 100MG

A074586 001 Jul 17, 1997

LOTION; TOPICAL

MONISTAT-DERM

INSIGHT PHARMS

2%

N017739 001

TAMPON; VAGINAL

MONISTAT 5

PERSONAL PRODS

100MG

N018592 001 Oct 27, 1989

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

APOTHECON

EQ 1MG BASE/ML

A075620 001 Nov 01, 2000

EQ 5MG BASE/ML

A075620 002 Nov 01, 2000

EQ 5MG BASE/ML

A075641 001 Oct 19, 2000

BEDFORD

EQ 5MG BASE/ML

A075249 001 Jun 23, 2000

BEN VENUE

EQ 5MG BASE/ML

A075455 001 Jun 20, 2000

CLARIS

EQ 1MG BASE/ML

A075637 001 Oct 31, 2000

EQ 5MG BASE/ML

A075637 002 Oct 31, 2000

HOSPIRA

EQ 1MG BASE/ML

A075396 001 Jun 20, 2000

EQ 5MG BASE/ML

A075396 002 Jun 20, 2000

EQ 5MG BASE/ML

A075484 001 Jun 20, 2000

HOSPIRA INC

EQ 1MG BASE/ML

A075409 002 Jun 20, 2000

EQ 5MG BASE/ML

A075409 001 Jun 20, 2000

IGI LABS INC

EQ 5MG BASE/ML

A075263 001 Jun 26, 2000

INTL MEDICATED

EQ 1MG BASE/ML

A076144 001 Jan 26, 2005

EQ 5MG BASE/ML

A076144 002 Jan 26, 2005

INTL MEDICATION

EQ 1MG BASE/ML

A076020 001 Jul 16, 2004

EQ 5MG BASE/ML

A076020 002 Jul 16, 2004

WOCKHARDT

EQ 1MG BASE/ML

A078141 001 May 30, 2008

EQ 1MG BASE/ML

A078511 001 Nov 10, 2008

EQ 5MG BASE/ML

A078141 002 May 30, 2008

EQ 5MG BASE/ML

A078511 002 Nov 10, 2008

VERSED

HLR

EQ 1MG BASE/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N018654 002 May 26, 1987

EQ 5MG BASE/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N018654 001 Dec 20, 1985

SYRUP; ORAL

MIDAZOLAM HYDROCHLORIDE

APOTEX INC

EQ 2MG BASE/ML

A077115 001 Sep 09, 2005

VERSED

ROCHE

EQ 2MG BASE/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020942 001 Oct 15, 1998

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

PROAMATINE

SHIRE LLC

2.5MG

N019815 001 Sep 06, 1996

5MG

N019815 002 Sep 06, 1996

10MG

N019815 003 Mar 20, 2002

DISCONTINUED DRUG PRODUCT LIST

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

MILNACIPRAN HYDROCHLORIDE

LIBERTY PHARMA INC	12.5MG	A205071 001	Jan 27, 2016
	25MG	A205071 002	Jan 27, 2016
	50MG	A205071 003	Jan 27, 2016
	100MG	A205071 004	Jan 27, 2016

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

APOTEX INC	EQ 1MG BASE/ML	A076427 001	Sep 21, 2004
EUROHLTH INTL SARL	EQ 1MG BASE/ML	A075852 001	May 28, 2002
HOSPIRA	EQ 1MG BASE/ML	A075830 001	May 28, 2002
	EQ 1MG BASE/ML	A075884 001	May 28, 2002
MYLAN INSTITUTIONAL	EQ 1MG BASE/ML	A076428 001	Jun 16, 2003
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A076414 001	Aug 18, 2004
BAXTER HLTHCARE	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A076259 001	Aug 08, 2002
CLARIS	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A077151 001	Jul 20, 2005
EUROHLTH INTL SARL	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A075510 001	May 28, 2002

PRIMACOR

SANOFI AVENTIS US	EQ 1MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019436 001	Dec 31, 1987
PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER			
SANOFI AVENTIS US	EQ 10MG BASE/100ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020343 001	Aug 09, 1994
	EQ 15MG BASE/100ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020343 002	Aug 09, 1994
	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020343 003	Aug 09, 1994
	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020343 004	Aug 09, 1994

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

DYNACIN

CNTY LINE PHARMS	EQ 50MG BASE	A063067 003	Aug 14, 1990
------------------	--------------	-------------	--------------

MINOCIN

PRECISION DERMAT	EQ 75MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050649 003	Feb 12, 2001
TRIAx PHARMS	EQ 50MG BASE	N050315 002	
	EQ 100MG BASE	N050315 001	

CAPSULE, EXTENDED RELEASE; ORAL

XIMINO

SUN PHARM INDS LTD	EQ 45MG BASE	N201922 001	Jul 11, 2012
	EQ 67.5MG BASE	N201922 002	Jul 11, 2012
	EQ 90MG BASE	N201922 003	Jul 11, 2012
	EQ 112.5MG BASE	N201922 004	Jul 11, 2012
	EQ 135MG BASE	N201922 005	Jul 11, 2012

INJECTABLE; INJECTION

MINOCIN

LEDERLE	EQ 100MG BASE/VIAL	A062139 001	
---------	--------------------	-------------	--

SUSPENSION; ORAL

MINOCIN

PRECISION DERMAT	EQ 50MG BASE/5ML	N050445 001	
------------------	------------------	-------------	--

TABLET; ORAL

MINOCYCLINE HYDROCHLORIDE

TRIAx PHARMS	EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050451 003	Aug 10, 1982
--------------	---	-------------	--------------

DISCONTINUED DRUG PRODUCT LISTMINOCYCLINE HYDROCHLORIDE

TABLET;ORAL

MINOCYCLINE HYDROCHLORIDE

EQ 100MG BASE	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050451	002	Aug 10, 1982
---------------	--	---------	-----	--------------

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

BARR LABS INC

EQ 45MG BASE		A065485	001	Mar 17, 2009
EQ 65MG BASE		A065485	004	May 18, 2012
EQ 90MG BASE		A065485	002	Mar 17, 2009
EQ 115MG BASE		A065485	005	May 18, 2012
EQ 135MG BASE		A065485	003	Mar 17, 2009

IMPAX LABS INC

EQ 45MG BASE		A090024	001	Feb 03, 2009
EQ 90MG BASE		A090024	002	Feb 03, 2009
EQ 135MG BASE		A090024	003	Feb 03, 2009

LUPIN LTD

EQ 55MG BASE		A091424	002	Nov 30, 2011
--------------	--	---------	-----	--------------

SOLODYN

MEDICIS

EQ 45MG BASE	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050808	001	May 08, 2006
--------------	--	---------	-----	--------------

EQ 90MG BASE	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050808	002	May 08, 2006
--------------	--	---------	-----	--------------

EQ 135MG BASE	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050808	003	May 08, 2006
---------------	--	---------	-----	--------------

MINOXIDIL

SOLUTION;TOPICAL

MINOXIDIL (FOR MEN)

APOTEX INC	2%	A074924	001	Apr 29, 1998
BAUSCH AND LOMB	2%	A074643	001	Apr 09, 1996
COPLEY PHARM	2%	A074500	001	May 23, 1996
SIGHT PHARMS	2%	A074743	002	Oct 18, 1996
TEVA	2%	A074589	001	Apr 05, 1996

MINOXIDIL (FOR WOMEN)

APOTEX INC	2%	A074924	002	Apr 29, 1998
SIGHT PHARMS	2%	A074743	001	Oct 18, 1996

MINOXIDIL EXTRA STRENGTH (FOR MEN)

APOTEX INC	5%	A075839	001	Oct 01, 2001
------------	----	---------	-----	--------------

TABLET;ORAL

LONITEN

PHARMACIA AND UPJOHN	2.5MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018154	001
----------------------	-------	--	---------	-----

10MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018154	003	
------	--	---------	-----	--

MINODYL

QUANTUM PHARMICS	2.5MG	A072153	001	Jul 13, 1988
	10MG	A071534	001	Mar 19, 1987

MINOXIDIL

ROYCE LABS	2.5MG	A071799	001	Nov 10, 1987
	10MG	A071796	001	Nov 10, 1987
USL PHARMA	2.5MG	A071537	001	Dec 16, 1988

MIRTAZAPINE

TABLET;ORAL

MIRTAZAPINE

ACTAVIS ELIZABETH	15MG	A076241	001	Jun 25, 2003
	15MG	A076308	001	Jun 20, 2003
	30MG	A076241	002	Jun 25, 2003
	30MG	A076308	002	Jun 20, 2003
	45MG	A076241	003	Jun 25, 2003
	45MG	A076308	003	Jun 20, 2003
ACTAVIS LABS FL INC	15MG	A076336	001	Jun 20, 2003
	30MG	A076336	002	Jun 20, 2003
	45MG	A076336	003	Jun 20, 2003
IVAX SUB TEVA PHARMS	15MG	A076244	001	Dec 22, 2003

DISCONTINUED DRUG PRODUCT LIST

MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

30MG	A076244 002	Dec 22, 2003
45MG	A076244 003	Dec 22, 2003
ROXANE 15MG	A076270 001	Jun 19, 2003
30MG	A076270 002	Jun 19, 2003
45MG	A076270 003	Jun 19, 2003
UPSHER-SMITH LABS 15MG	A076189 001	Jun 19, 2003
30MG	A076189 002	Jun 19, 2003
45MG	A076189 003	Jun 19, 2003

TABLET, ORALLY DISINTEGRATING; ORAL

MIRTAZAPINE

ACTAVIS ELIZABETH 15MG	A076689 001	Aug 31, 2005
15MG	A077959 001	Feb 14, 2011
30MG	A076689 002	Aug 31, 2005
30MG	A077959 002	Feb 14, 2011
45MG	A076689 003	Aug 31, 2005
45MG	A077959 003	Feb 14, 2011

MITOMYCIN

INJECTABLE; INJECTION

MITOMYCIN

HOSPIRA 20MG/VIAL	A064106 001	Nov 29, 1995
-------------------	-------------	--------------

MITOZYTREX

SUPERGEN 5MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050763 001	Nov 14, 2002
--	-------------	--------------

MUTAMYCIN

BRISTOL 5MG/VIAL	N050450 001	
20MG/VIAL	N050450 002	
BRISTOL MYERS 5MG/VIAL	A062336 001	
20MG/VIAL	A062336 002	
40MG/VIAL	A062336 003	Mar 10, 1988

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

FRESENIUS KABI ONCOL EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A078606 001	May 14, 2008
EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A078606 002	May 14, 2008
EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A078606 003	May 14, 2008

NOVANTRONE

EMD SERONO EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N019297 001	Dec 23, 1987
EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	N019297 002	Dec 23, 1987
Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons		
EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	N019297 003	Dec 23, 1987
Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons		

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION

MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBVIE EQ 0.5MG BASE/ML	N020098 002	Jan 22, 1992
EQ 50MG BASE/100ML	N020098 003	Jan 22, 1992

MIVACURIUM CHLORIDE

MYLAN LABS LTD EQ 2MG BASE/ML	A078562 001	Apr 30, 2009
-------------------------------	-------------	--------------

SOLUTION; INTRAVENOUS

MIVACRON

ABBVIE EQ 2MG BASE/ML (EQ 2MG BASE/ML)	N020098 001	Jan 22, 1992
Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons		

DISCONTINUED DRUG PRODUCT LISTMOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

UNIVASC

UCB INC

7.5MG

N020312 001 Apr 19, 1995

15MG

N020312 002 Apr 19, 1995

MOLINDONE HYDROCHLORIDE

CAPSULE; ORAL

MOBAN

ENDO PHARMS

5MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N017111 001

10MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N017111 002

25MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N017111 003

CONCENTRATE; ORAL

MOBAN

ENDO PHARMS

20MG/ML

N017938 001

TABLET; ORAL

MOBAN

ENDO PHARMS

5MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N017111 004

10MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N017111 005

25MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N017111 006

50MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N017111 007

100MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N017111 008

MOMETASONE FUROATE

CREAM; TOPICAL

ELOCON

MERCK SHARP DOHME

0.1%

N019625 001 May 06, 1987

OINTMENT; TOPICAL

MOMETASONE FUROATE

TARO

0.1%

A076624 001 Dec 03, 2004

MONOBENZONE

CREAM; TOPICAL

BENOQUIN

VALEANT PHARM INTL

20%

N008173 003

MONOCTANOIN

LIQUID; PERFUSION, BILIARY

MOCTANIN

ETHITEK

100%

N019368 001 Oct 29, 1985

MORICIZINE HYDROCHLORIDE

TABLET; ORAL

ETHMOZINE

SHIRE

200MG

N019753 001 Jun 19, 1990

250MG

N019753 002 Jun 19, 1990

300MG

N019753 003 Jun 19, 1990

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

AVINZA

KING PHARMS LLC

30MG

N021260 001 Mar 20, 2002

45MG

N021260 005 Dec 18, 2008

60MG

N021260 002 Mar 20, 2002

75MG

N021260 006 Dec 18, 2008

DISCONTINUED DRUG PRODUCT LIST

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

AVINZA

90MG	N021260	003	Mar 20, 2002
120MG	N021260	004	Mar 20, 2002

INJECTABLE;INJECTION

MORPHINE SULFATE

HOSPIRA	0.5MG/ML	N019917	001	Oct 30, 1992
MALLINCKRODT	1MG/ML	N020631	001	Jul 03, 1996
	2MG/ML	N020631	002	Jul 03, 1996
WATSON LABS	0.5MG/ML	A073373	001	Sep 30, 1991
	0.5MG/ML	A073375	001	Sep 30, 1991
	1MG/ML	A073374	001	Sep 30, 1991
	1MG/ML	A073376	001	Sep 30, 1991

INJECTABLE, LIPOSOMAL;EPIDURAL

DEPODUR

PACIRA PHARMS INC	10MG/ML (10MG/ML)	N021671	001	May 18, 2004
	15MG/1.5ML (10MG/ML)	N021671	002	May 18, 2004
	20MG/2ML (10MG/ML)	N021671	003	May 18, 2004

TABLET, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

WATSON LABS	100MG	A075656	001	Jan 30, 2001
ORAMORPH SR				
XANODYNE PHARMS INC	15MG	N019977	004	Nov 23, 1994
	30MG	N019977	001	Aug 15, 1991
	60MG	N019977	002	Aug 15, 1991
	100MG	N019977	003	Aug 15, 1991

MOXALACTAM DISODIUM

INJECTABLE;INJECTION

MOXAM

LILLY	EQ 250MG BASE/VIAL	N050550	001	
	EQ 500MG BASE/VIAL	N050550	002	
	EQ 1GM BASE/VIAL	N050550	003	
	EQ 2GM BASE/VIAL	N050550	004	
	EQ 10GM BASE/VIAL	N050550	008	

MYCOPHENOLATE MOFETIL

CAPSULE;ORAL

MYCOPHENOLATE MOFETIL

DR REDDYS LABS LTD	250MG	A091315	001	Oct 27, 2011
ZYDUS PHARMS USA INC	250MG	A065433	001	May 04, 2009

TABLET;ORAL

MYCOPHENOLATE MOFETIL

DR REDDYS LABS LTD	500MG	A090464	001	Sep 13, 2010
ZYDUS PHARMS USA INC	500MG	A065477	001	May 04, 2009

NABUMETONE

TABLET;ORAL

NABUMETONE

COPLEY PHARM	750MG	A075179	001	Jun 06, 2000
DR REDDYS LABS LTD	500MG	A078420	001	Sep 24, 2008
	750MG	A078420	002	Sep 24, 2008
OXFORD PHARMS	500MG	A079093	001	Feb 27, 2009
	750MG	A079093	002	Feb 27, 2009
SANDOZ	500MG	A075590	001	Feb 25, 2002
	750MG	A075590	002	Feb 25, 2002

RELAFEN

SMITHKLINE BEECHAM	500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019583	001	Dec 24, 1991
	750MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019583	002	Dec 24, 1991

NADOLOL

TABLET;ORAL

CORGARD

US WORLDMEDS LLC	120MG	N018063	003	
	160MG	N018063	004	

NADOLOL

IVAX SUB TEVA PHARMS	120MG	A074255	002	Jan 24, 1996
	160MG	A074255	003	Jan 24, 1996

DISCONTINUED DRUG PRODUCT LIST

NADOLOL

TABLET; ORAL

NADOLOL

TEVA PHARMS

80MG

A074368 001 Aug 31, 1994

120MG

A074368 002 Aug 31, 1994

160MG

A074368 003 Aug 31, 1994

NAFCILLIN SODIUM

CAPSULE; ORAL

UNIPEN

WYETH AYERST

EQ 250MG BASE

N050111 001

FOR SOLUTION; ORAL

UNIPEN

WYETH AYERST

EQ 250MG BASE/5ML

N050199 001

INJECTABLE; INJECTION

NAFCILLIN SODIUM

APOTHECON

EQ 500MG BASE/VIAL

A061984 001

EQ 1GM BASE/VIAL

A061984 002

EQ 2GM BASE/VIAL

A061984 003

EQ 4GM BASE/VIAL

A061984 005

SANDOZ

EQ 500MG BASE/VIAL

A062527 001 Aug 02, 1984

WATSON LABS INC

EQ 500MG BASE/VIAL

A062844 001 Oct 26, 1988

EQ 1GM BASE/VIAL

A062844 002 Oct 26, 1988

EQ 1.5GM BASE/VIAL

A062844 003 Oct 26, 1988

EQ 2GM BASE/VIAL

A062844 004 Oct 26, 1988

EQ 4GM BASE/VIAL

A062844 005 Oct 26, 1988

EQ 10GM BASE/VIAL

A063008 001 Sep 29, 1988

NALLPEN

GLAXOSMITHKLINE

EQ 500MG BASE/VIAL

A061999 001

EQ 1GM BASE/VIAL

A061999 002

EQ 1GM BASE/VIAL

A062755 001 Dec 19, 1986

EQ 2GM BASE/VIAL

A061999 003

EQ 2GM BASE/VIAL

A062755 002 Dec 19, 1986

EQ 10GM BASE/VIAL

A061999 004

UNIPEN

WYETH AYERST

EQ 500MG BASE/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

A062717 001 Dec 16, 1986

EQ 500MG BASE/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N050320 001

EQ 1GM BASE/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

A062717 002 Dec 16, 1986

EQ 2GM BASE/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

A062717 004 Dec 16, 1986

EQ 2GM BASE/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N050320 003

EQ 4GM BASE/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N050320 004

EQ 10GM BASE/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N050320 005

EQ 20GM BASE/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N050320 006

UNIPEN IN PLASTIC CONTAINER

WYETH AYERST

EQ 1GM BASE/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N050320 002

TABLET; ORAL

UNIPEN

WYETH AYERST

EQ 500MG BASE

N050462 001

DISCONTINUED DRUG PRODUCT LISTNALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NALBUPHINE

ABRAXIS PHARM	10MG/ML	A070751	001	Jul 02, 1986
	20MG/ML	A070752	001	Sep 24, 1986

NALBUPHINE HYDROCHLORIDE

ABBOTT	20MG/ML	A070917	001	Feb 03, 1989
ABBVIE	1.5MG/ML	N020200	001	Mar 12, 1993
BARR	10MG/ML	A074471	001	Mar 19, 1998
	20MG/ML	A074471	002	Mar 19, 1998
IGI LABS INC	10MG/ML	A072070	001	Apr 10, 1989
	10MG/ML	A072071	001	Apr 10, 1989
	10MG/ML	A072072	001	Apr 10, 1989
	20MG/ML	A072073	001	Apr 10, 1989
	20MG/ML	A072074	001	Apr 10, 1989
	20MG/ML	A072075	001	Apr 10, 1989

NUBAIN

PAR PHARM INC	10MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018024	001	
	20MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018024	002	May 27, 1982

NALIDIXIC ACID

SUSPENSION; ORAL

NEGGRAM

SANOFI AVENTIS US	250MG/5ML	N017430	001	
-------------------	-----------	---------	-----	--

TABLET; ORAL

NALIDIXIC ACID

SUN PHARM INDS	250MG	A070270	001	Jun 29, 1988
	500MG	A070271	001	Jun 29, 1988
	1GM	A070272	001	Jun 29, 1988
WATSON LABS	250MG	A071936	001	Jun 29, 1988
	500MG	A072061	001	Jun 29, 1988
	1GM	A071919	001	Jun 29, 1988

NEGGRAM

SANOFI AVENTIS US	250MG	N014214	002	
	500MG	N014214	004	
	1GM	N014214	005	

NALMEFENE HYDROCHLORIDE

INJECTABLE; INJECTION

REVEX

EUROHLTH INTL SARL	EQ 0.1MG BASE/ML	N020459	001	Apr 17, 1995
	EQ 1MG BASE/ML	N020459	002	Apr 17, 1995

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

EUROHLTH INTL SARL	0.4MG/ML	A070298	001	Sep 24, 1986
	0.4MG/ML	A070496	001	Sep 24, 1986
WYETH AYERST	0.02MG/ML	A070188	001	Sep 24, 1986
	0.02MG/ML	A070189	001	Sep 24, 1986
	0.4MG/ML	A070190	001	Sep 24, 1986
	0.4MG/ML	A070191	001	Sep 24, 1986

NALOXONE HYDROCHLORIDE

ABRAXIS PHARM	0.02MG/ML	A070648	001	Nov 17, 1986
	0.02MG/ML	A070661	001	Nov 17, 1986
	0.4MG/ML	A070649	001	Nov 17, 1986
	1MG/ML	A071604	001	Dec 16, 1988
ASTRAZENECA	0.02MG/ML	A072081	001	Apr 11, 1989
EUROHLTH INTL SARL	0.02MG/ML	A071272	001	May 24, 1988
	1MG/ML	A071273	001	May 24, 1988
	1MG/ML	A071274	001	May 24, 1988
	1MG/ML	A071287	001	May 24, 1988
HOSPIRA	0.02MG/ML	A070171	001	Sep 24, 1986
	0.02MG/ML	A070252	001	Jan 16, 1987
	0.02MG/ML	A070253	001	Jan 16, 1987
	0.4MG/ML	A070255	001	Jan 07, 1987
IGI LABS INC	0.02MG/ML	A072082	001	Apr 11, 1989
	0.02MG/ML	A072083	001	Apr 11, 1989
	0.02MG/ML	A072084	001	Apr 11, 1989

DISCONTINUED DRUG PRODUCT LIST

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE HYDROCHLORIDE

	0.02MG/ML	A072085	001	Apr 11, 1989
	0.4MG/ML	A072086	001	Apr 11, 1989
	0.4MG/ML	A072087	001	Apr 11, 1989
	0.4MG/ML	A072088	001	Apr 11, 1989
	0.4MG/ML	A072089	001	Apr 11, 1989
	0.4MG/ML	A072090	001	Apr 11, 1989
	1MG/ML	A072091	001	Apr 11, 1989
	1MG/ML	A072092	001	Apr 11, 1989
	1MG/ML	A072093	001	Apr 11, 1989
INTL MEDICATION	0.4MG/ML	A070417	001	Sep 24, 1986
	1MG/ML	A072115	001	Apr 27, 1988
MARSAM PHARMS LLC	0.4MG/ML	A071811	001	Jul 19, 1988
SMITH AND NEPHEW	0.02MG/ML	A071671	001	Nov 17, 1987
	0.4MG/ML	A071681	001	Nov 17, 1987
	0.4MG/ML	A071682	001	Nov 17, 1987
SOLOPAK	0.02MG/ML	A071672	001	Nov 17, 1987
	0.4MG/ML	A071683	001	Nov 17, 1987
WATSON LABS	0.4MG/ML	A071339	001	Nov 18, 1987
NARCAN				
ADAPT	0.02MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016636	002	
	0.4MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016636	001	
	1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016636	003	Jun 14, 1982
BRISTOL MYERS SQUIBB	0.4MG/ML	A071083	001	Jul 28, 1988
	1MG/ML	A071084	001	Jul 28, 1988
	1MG/ML	A071311	001	Jul 28, 1988

NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

TARGINIQ

PURDUE PHARMA LP	5MG;10MG	N205777	001	Jul 23, 2014
	10MG;20MG	N205777	002	Jul 23, 2014
	20MG;40MG	N205777	003	Jul 23, 2014

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

TALWIN NX

SANOFI AVENTIS US	EQ 0.5MG BASE;EQ 50MG BASE	N018733	001	Dec 16, 1982
-------------------	----------------------------	---------	-----	--------------

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

SANDOZ	50MG	A075434	001	Mar 08, 2000
REVIA				
TEVA WOMENS	50MG	N018932	001	Nov 20, 1984

NANDROLONE DECANOATE

INJECTABLE; INJECTION

DECA-DURABOLIN

ASPEN GLOBAL INC	50MG/ML	N013132	001	Jun 12, 1986
	100MG/ML	N013132	002	Jun 12, 1986
	200MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N013132	003	Jun 12, 1986
NANDROLONE DECANOATE				
ABRAXIS PHARM	100MG/ML	A088290	001	Oct 03, 1983
	200MG/ML	A088317	001	Oct 14, 1983
AKORN	100MG/ML	A087519	001	Sep 28, 1983
WATSON LABS	50MG/ML	A086385	001	Jan 13, 1984
	50MG/ML	A087598	001	Oct 06, 1983
	50MG/ML	A088554	001	Feb 10, 1986
	100MG/ML	A086598	001	Jan 13, 1984
	100MG/ML	A087599	001	Oct 06, 1983
	200MG/ML	A088128	001	Dec 05, 1983

DISCONTINUED DRUG PRODUCT LISTNANDROLONE PHENPROPIONATE

INJECTABLE; INJECTION

DURABOLIN

ORGANON USA INC	25MG/ML	N011891	001	
	50MG/ML	N011891	002	

NANDROLONE PHENPROPIONATE

WATSON LABS	25MG/ML	A086386	001	Jun 17, 1983
	50MG/ML	A087488	001	Jun 17, 1983

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ALBALON

ALLERGAN	0.1% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A080248	001	
----------	---	---------	-----	--

NAFAZAIR

BAUSCH AND LOMB	0.1%	A040073	001	May 25, 1994
PHARMAFAIR	0.1%	A088101	001	Apr 15, 1983

NAPHCN FORTE

ALCON	0.1%	A080229	001	
-------	------	---------	-----	--

OPCON

BAUSCH AND LOMB	0.1%	A087506	001	
-----------------	------	---------	-----	--

VASOCON

NOVARTIS	0.1%	A080235	002	Mar 24, 1983
----------	------	---------	-----	--------------

NAPROXEN

TABLET; ORAL

NAPROXEN

DAVA PHARMS INC	250MG	A074105	001	Dec 21, 1993
	250MG	A074410	001	Apr 28, 1995
	375MG	A074105	002	Dec 21, 1993
	375MG	A074410	002	Apr 28, 1995
	500MG	A074105	003	Dec 21, 1993
	500MG	A074410	003	Apr 28, 1995
HAMILTON PHARMS	250MG	A074110	001	Oct 30, 1992
	375MG	A074110	002	Oct 30, 1992
	500MG	A074110	003	Oct 30, 1992
IVAX SUB TEVA PHARMS	250MG	A074111	001	Feb 28, 1995
	375MG	A074111	002	Feb 28, 1995
	500MG	A074111	003	Feb 28, 1995
PLIVA	250MG	A074182	001	Jun 27, 1996
	375MG	A074182	002	Jun 27, 1996
	500MG	A074182	003	Jun 27, 1996
PUREPAC PHARM	250MG	A074263	001	Dec 21, 1993
	375MG	A074263	002	Dec 21, 1993
	500MG	A074263	003	Dec 21, 1993
ROXANE	250MG	A074211	001	Feb 28, 1994
	375MG	A074211	002	Feb 28, 1994
	500MG	A074211	003	Feb 28, 1994
SANDOZ	250MG	A074140	001	Dec 21, 1993
	375MG	A074140	002	Dec 21, 1993
	500MG	A074140	003	Dec 21, 1993
TEVA	250MG	A074129	001	Dec 21, 1993
	250MG	A074216	001	Apr 11, 1996
	375MG	A074129	002	Dec 21, 1993
	375MG	A074216	002	Apr 11, 1996
	500MG	A074129	003	Dec 21, 1993
	500MG	A074216	003	Apr 11, 1996
TEVA PHARMS	250MG	A074207	001	Dec 21, 1993
	375MG	A074207	002	Dec 21, 1993
	500MG	A074207	003	Dec 21, 1993
WATSON LABS	250MG	A074163	001	Feb 10, 1995
	250MG	A074457	001	May 31, 1995
	375MG	A074163	002	Feb 10, 1995
	375MG	A074457	002	May 31, 1995
	500MG	A074163	003	Feb 10, 1995
	500MG	A074457	003	May 31, 1995

TABLET, DELAYED RELEASE; ORAL

NAPROXEN

ACTAVIS ELIZABETH	375MG	A074936	001	Feb 24, 1998
	500MG	A074936	002	Feb 24, 1998
SANDOZ	375MG	A075061	001	Feb 18, 1998
	500MG	A075061	002	Feb 18, 1998

DISCONTINUED DRUG PRODUCT LIST

NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM

ABLE	EQ 250MG BASE	A076544 001	Aug 22, 2003
	EQ 500MG BASE	A076544 002	Aug 22, 2003
HAMILTON PHARMS	EQ 250MG BASE	A074106 001	Aug 31, 1993
	EQ 500MG BASE	A074106 002	Aug 31, 1993
HIKMA	EQ 250MG BASE	A074480 002	Feb 18, 1998
	EQ 500MG BASE	A074480 001	May 14, 1996
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A074230 001	Mar 14, 1995
	EQ 500MG BASE	A074230 002	Mar 14, 1995
MYLAN	EQ 250MG BASE	A074367 001	Aug 31, 1994
	EQ 500MG BASE	A074367 002	Aug 31, 1994
PLIVA	EQ 250MG BASE	A074242 001	Jun 20, 1996
	EQ 500MG BASE	A074242 002	Jun 20, 1996
PUREPAC PHARM	EQ 250MG BASE	A074319 001	Mar 20, 1995
	EQ 500MG BASE	A074319 002	Mar 20, 1995
ROXANE	EQ 250MG BASE	A074257 001	Dec 21, 1993
	EQ 500MG BASE	A074257 002	Dec 21, 1993
SANDOZ	EQ 200MG BASE	A074646 001	Jan 13, 1997
	EQ 250MG BASE	A074162 001	Dec 21, 1993
	EQ 250MG BASE	A074495 001	Dec 05, 1994
	EQ 500MG BASE	A074162 002	Dec 21, 1993
	EQ 500MG BASE	A074495 002	Dec 05, 1994
TEVA	EQ 250MG BASE	A074142 001	Dec 21, 1993
	EQ 500MG BASE	A074142 002	Dec 21, 1993
TEVA PHARMS	EQ 250MG BASE	A074289 001	Jan 27, 1994
	EQ 500MG BASE	A074289 002	Jan 27, 1994
WATSON LABS	EQ 250MG BASE	A074195 001	Dec 21, 1993
	EQ 250MG BASE	A074455 001	May 31, 1995
	EQ 500MG BASE	A074195 002	Dec 21, 1993
	EQ 500MG BASE	A074455 002	May 31, 1995

NATEGLINIDE

TABLET;ORAL

NATEGLINIDE

TEVA PHARMS	60MG	A077467 001	Sep 09, 2009
	120MG	A077467 002	Sep 09, 2009

NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL

NEBIVOLOL HYDROCHLORIDE

ALKEM LABS LTD	EQ 2.5MG BASE	A203741 001	Jun 24, 2015
	EQ 5MG BASE	A203741 002	Jun 24, 2015
	EQ 10MG BASE	A203741 003	Jun 24, 2015
	EQ 20MG BASE	A203741 004	Jun 24, 2015
AMERIGEN PHARMS LTD	EQ 2.5MG BASE	A203659 001	Apr 16, 2015
	EQ 5MG BASE	A203659 002	Apr 16, 2015
	EQ 10MG BASE	A203659 003	Apr 16, 2015
	EQ 20MG BASE	A203659 004	Apr 16, 2015
INDCHEMIE HEALTH	EQ 2.5MG BASE	A203828 001	Jul 29, 2015
	EQ 5MG BASE	A203828 002	Jul 29, 2015
	EQ 10MG BASE	A203828 003	Jul 29, 2015
	EQ 20MG BASE	A203828 004	Jul 29, 2015
WATSON LABS INC	EQ 2.5MG BASE	A203683 001	Nov 27, 2015
	EQ 5MG BASE	A203683 002	Nov 27, 2015
	EQ 10MG BASE	A203683 003	Nov 27, 2015
	EQ 20MG BASE	A203683 004	Nov 27, 2015

NEDOCROMIL SODIUM

AEROSOL, METERED; INHALATION

TILADE

KING PHARMS	1.75MG/INH	N019660 001	Dec 30, 1992
-------------	------------	-------------	--------------

SOLUTION; INHALATION

TILADE

SANOFI AVENTIS US	0.5%	N020750 001	Oct 01, 1997
-------------------	------	-------------	--------------

NEFAZODONE HYDROCHLORIDE

TABLET;ORAL

NEFAZODONE HYDROCHLORIDE

IDT AUSTRALIA LTD	50MG	A076072 001	Sep 16, 2003
	100MG	A076072 002	Sep 16, 2003
	150MG	A076072 003	Sep 16, 2003
	200MG	A076072 004	Sep 16, 2003

DISCONTINUED DRUG PRODUCT LIST

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HYDROCHLORIDE

	250MG	A076072 005	Sep 16, 2003
IVAX SUB TEVA PHARMS	50MG	A075763 001	Sep 16, 2003
	100MG	A075763 002	Sep 16, 2003
	150MG	A075763 003	Sep 16, 2003
	200MG	A075763 004	Sep 16, 2003
	250MG	A075763 005	Sep 16, 2003
MYLAN	100MG	A076129 002	Sep 16, 2003
	150MG	A076129 003	Sep 16, 2003
	200MG	A076129 004	Sep 16, 2003
	250MG	A076129 005	Sep 16, 2003
ROXANE	50MG	A076196 001	Sep 16, 2003
	100MG	A076196 002	Sep 16, 2003
	150MG	A076196 003	Sep 16, 2003
	200MG	A076196 004	Sep 16, 2003
	250MG	A076196 005	Sep 16, 2003
SANDOZ	50MG	A076302 001	Sep 16, 2003
	100MG	A076302 002	Sep 16, 2003
	150MG	A076302 003	Sep 16, 2003
	200MG	A076302 004	Sep 16, 2003
	250MG	A076302 005	Sep 16, 2003
SUN PHARM INDS LTD	50MG	A076409 001	Sep 16, 2003
	100MG	A076409 002	Sep 16, 2003
	150MG	A076409 003	Sep 16, 2003
	200MG	A076409 004	Sep 16, 2003
	250MG	A076409 005	Sep 16, 2003
WATSON LABS	100MG	A076073 002	Sep 16, 2003
	150MG	A076073 003	Sep 16, 2003
	200MG	A076073 004	Sep 16, 2003
	250MG	A076073 005	Sep 16, 2003

SERZONE

BRISTOL MYERS SQUIBB	50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020152 001	Dec 22, 1994
	100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020152 002	Dec 22, 1994
	150MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020152 003	Dec 22, 1994
	200MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020152 004	Dec 22, 1994
	250MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020152 005	Dec 22, 1994
	300MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020152 006	Dec 22, 1994

NELFINAVIR MESYLATE

POWDER; ORAL

VIRACEPT

AGOURON	EQ 50MG BASE/SCOOPFUL	N020778 001	Mar 14, 1997
---------	-----------------------	-------------	--------------

NEOMYCIN SULFATE

POWDER; FOR RX COMPOUNDING

NEO-RX

X GEN PHARMS	100%	A061579 001	
--------------	------	-------------	--

SOLUTION; ORAL

MYCIFRADIN

PHARMACIA AND UPJOHN	EQ 87.5MG BASE/5ML	N050285 001	
----------------------	--------------------	-------------	--

TABLET; ORAL

MYCIFRADIN

PHARMACIA AND UPJOHN	EQ 350MG BASE	A060520 001	
----------------------	---------------	-------------	--

NEOBIOTIC

PFIZER	EQ 350MG BASE	A060475 001	
--------	---------------	-------------	--

DISCONTINUED DRUG PRODUCT LISTNEOMYCIN SULFATE

TABLET; ORAL

NEOMYCIN SULFATE

BRISTOL MYERS SQUIBB	500MG	A060365	001
LANNETT	500MG	A060607	001
LILLY	500MG	A060385	001
ROXANE	500MG	A062173	001
SANDOZ	500MG	A061586	001

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM; TOPICAL

NEOSPORIN

GLAXOSMITHKLINE	EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050176	002	Jan 14, 1985
-----------------	----------------------------------	---------	-----	--------------

OINTMENT; OPHTHALMIC

STATROL

ALCON	EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050344	002
-------	----------------------------------	---------	-----

SOLUTION/DROPS; OPHTHALMIC

STATROL

ALCON	EQ 3.5MG BASE/ML;16,250 UNITS/ML	A062339	001	Nov 30, 1984
	EQ 3.5MG BASE/ML;16,250 UNITS/ML	N050456	001	

NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

POLY-PRED

ALLERGAN	EQ 0.35% BASE;10,000 UNITS/ML;0.5%	N050081	002
----------	------------------------------------	---------	-----

NEOMYCIN SULFATE; PREDNISOLONE ACETATE

OINTMENT; OPHTHALMIC

NEO-DELTA-CORTEF

PHARMACIA AND UPJOHN	EQ 3.5MG BASE/GM;0.25%	A061039	002
	EQ 3.5MG BASE/GM;0.5%	A061039	001

SUSPENSION/DROPS; OPHTHALMIC

NEO-DELTA-CORTEF

PHARMACIA AND UPJOHN	EQ 3.5MG BASE/ML;0.25%	A061037	001
----------------------	------------------------	---------	-----

NEOMYCIN SULFATE; PREDNISOLONE SODIUM PHOSPHATE

OINTMENT; OPHTHALMIC

NEO-HYDELTRASOL

MERCK	EQ 3.5MG BASE/GM;EQ 0.25% PHOSPHATE	N050378	001
-------	-------------------------------------	---------	-----

NEOMYCIN SULFATE; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

MYTRES A

SAVAGE LABS	EQ 3.5MG BASE/GM;0.1%	A062598	001	Jul 21, 1986
-------------	-----------------------	---------	-----	--------------

NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE

FOUGERA	EQ 3.5MG BASE/GM;0.1%	A062600	001	Jul 21, 1986
PHARMADERM	EQ 3.5MG BASE/GM;0.1%	A062595	001	Jul 21, 1986

OINTMENT; TOPICAL

MYTRES A

SAVAGE LABS	EQ 3.5MG BASE/GM;0.1%	A062609	001	May 23, 1986
-------------	-----------------------	---------	-----	--------------

NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE

FOUGERA	EQ 3.5MG BASE/GM;0.1%	A062608	001	May 23, 1986
PHARMADERM	EQ 3.5MG BASE/GM;0.1%	A062607	001	May 23, 1986

NETILMICIN SULFATE

INJECTABLE; INJECTION

NETROMYCIN

SCHERING	EQ 10MG BASE/ML	N050544	001	Feb 28, 1983
	EQ 25MG BASE/ML	N050544	002	Feb 28, 1983
	EQ 100MG BASE/ML	N050544	003	Feb 28, 1983

NIACIN

CAPSULE; ORAL

WAMPOCAP

MEDPOINTE PHARM HLC	500MG	N011073	003
---------------------	-------	---------	-----

TABLET; ORAL

NIACIN

EVERYLIFE	500MG	A083203	001
HALSEY	500MG	A083453	001
HIKMA PHARMS LLC	500MG	A083718	001
IMPAX LABS	500MG	A083115	001
IVAX SUB TEVA PHARMS	500MG	A083180	001
MK LABS	500MG	A083525	001
PUREPAC PHARM	500MG	A083271	001
SANDOZ	500MG	A083306	001
TABLICAPS	500MG	A084237	001

DISCONTINUED DRUG PRODUCT LISTNIACIN

TABLET; ORAL

NIACIN

WATSON LABS	500MG	A083136	001	
	500MG	A083305	001	
	500MG	A085172	001	

NICOLAR

SANOFI AVENTIS US	500MG	A083823	001	
-------------------	-------	---------	-----	--

TABLET, EXTENDED RELEASE; ORAL

NIASPAN

ABBVIE	375MG	N020381	001	Jul 28, 1997
--------	-------	---------	-----	--------------

NIASPAN TITRATION STARTER PACK

ABBVIE	375MG; 500MG; 750MG	N020381	005	Jul 28, 1997
--------	---------------------	---------	-----	--------------

NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; TYROSINE

SUSPENSION; ORAL

TPN

INTL MINERALS	15MG/5ML; 3.75MG/5ML; 600MG/5ML	N008378	003	
---------------	---------------------------------	---------	-----	--

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

CARDENE

CHIESI USA INC	20MG	N019488	001	Dec 21, 1988
	30MG	N019488	002	Dec 21, 1988

NICARDIPINE HYDROCHLORIDE

WATSON LABS	20MG	A074670	001	Oct 28, 1996
	30MG	A074670	002	Oct 28, 1996

CAPSULE, EXTENDED RELEASE; ORAL

CARDENE SR

CHIESI USA INC	30MG	N020005	001	Feb 21, 1992
	45MG	N020005	002	Feb 21, 1992
	60MG	N020005	003	Feb 21, 1992

NICLOSAMIDE

TABLET, CHEWABLE; ORAL

NICLOCIDE

BAYER PHARMS	500MG	N018669	001	May 14, 1982
--------------	-------	---------	-----	--------------

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NICOTROL

MCNEIL CONS	15MG/16HR	N020536	001	Jul 03, 1996
-------------	-----------	---------	-----	--------------

PROSTEP

AVEVA	11MG/24HR	N019983	003	Dec 23, 1998
	22MG/24HR	N019983	004	Dec 23, 1998

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICOTINE POLACRILEX

IVAX SUB TEVA PHARMS	EQ 2MG BASE	A076880	001	Feb 18, 2009
	EQ 4MG BASE	A077850	001	Feb 18, 2009

NIFEDIPINE

CAPSULE; ORAL

ADALAT

BAYER PHARMS	10MG	N019478	001	Nov 27, 1985
	20MG	N019478	002	Sep 17, 1986

NIFEDIPINE

CHASE LABS NJ	10MG	A072409	001	Jul 04, 1990
	20MG	A073421	001	Jun 19, 1991
TEVA	10MG	A072651	001	Feb 19, 1992

PROCARDIA

PFIZER	20MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018482	002	Jul 24, 1986
--------	---	---------	-----	--------------

TABLET, EXTENDED RELEASE; ORAL

NIFEDIPINE

MARTEC USA LLC	90MG	A075414	003	Mar 23, 2004
MYLAN	30MG	A075108	001	Dec 17, 1999

DISCONTINUED DRUG PRODUCT LIST

NILUTAMIDE

TABLET; ORAL

NILANDRON

CONCORDIA PHARMS INC 50MG

N020169 001 Sep 19, 1996

NIMODIPINE

CAPSULE; ORAL

NIMOTOP

BAYER PHARMS

30MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N018869 001 Dec 28, 1988

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL

SULAR

COVIS PHARMA SARL

10MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N020356 001 Feb 02, 1995

20MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N020356 002 Feb 02, 1995

25.5MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N020356 006 Jan 02, 2008

30MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N020356 003 Feb 02, 1995

40MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N020356 004 Feb 02, 1995

NITRIC OXIDE

GAS; INHALATION

INOMAX

MALLINCKRODT HOSP

100PPM **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N020845 002 Dec 23, 1999

NITROFURANTOIN

CAPSULE; ORAL

NITROFURANTOIN

WATSON LABS

50MG

A084326 001

100MG

A084326 002

TABLET; ORAL

FURADANTIN

PROCTER AND GAMBLE

50MG

N008693 001

100MG

N008693 002

FURALAN

LANNETT

50MG

A080017 001

100MG

A080017 002

NITROFURANTOIN

ELKINS SINN

50MG

A080003 001

100MG

A080003 002

IVAX SUB TEVA PHARMS

50MG

A080078 002

100MG

A080078 001

SANDOZ

50MG

A080043 001

100MG

A080043 002

WATSON LABS

50MG

A080447 001

50MG

A085797 001

100MG

A080447 002

100MG

A085796 001

WHITEWORTH TOWN PLSN

100MG

A084085 002

NITROFURANTOIN SODIUM

INJECTABLE; INJECTION

IVADANTIN

PROCTER AND GAMBLE

EQ 180MG BASE/VIAL

N012402 001

DISCONTINUED DRUG PRODUCT LISTNITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN

MYLAN	100MG	A074967	002	Jul 09, 1997
SANDOZ	25MG	A074336	001	Jan 25, 1995
	50MG	A074336	002	Jan 25, 1995
	100MG	A074336	003	Jan 25, 1995
WATSON LABS	25MG	A073696	001	Dec 31, 1992
	50MG	A073696	002	Dec 31, 1992
	100MG	A073696	003	Dec 31, 1992

NITROFURANTOIN MACROCRYSTALLINE

WATSON LABS	50MG	A070248	001	Jun 24, 1988
	100MG	A070249	001	Jun 24, 1988

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

RANBAXY LABS LTD	75MG; 25MG	A076951	001	Mar 30, 2005
------------------	------------	---------	-----	--------------

NITROFURAZONE

CREAM; TOPICAL

FURACIN

SHIRE	0.2%	A083789	001	
-------	------	---------	-----	--

DRESSING; TOPICAL

ACTIN-N

SHERWOOD MEDCL	0.2%	N017343	001	
----------------	------	---------	-----	--

OINTMENT; TOPICAL

FURACIN

SHIRE	0.2%	N005795	001	
-------	------	---------	-----	--

NITROFURAZONE

AMBIX	0.2%	A086077	001	
LANNETT	0.2%	A084393	001	
PERRIGO NEW YORK	0.2%	A084968	001	
TARO	0.2%	A086156	001	
WENDT	0.2%	A086766	001	

POWDER; TOPICAL

FURACIN

SHIRE	0.2%	A083791	001	
-------	------	---------	-----	--

SOLUTION; TOPICAL

NITROFURAZONE

PERRIGO NEW YORK	0.2%	A085130	001	
WENDT	0.2%	A087081	001	

NITROGLYCERIN

AEROSOL; SUBLINGUAL

NITROLINGUAL

POHL BOSKAMP	0.4MG/SPRAY	N018705	001	Oct 31, 1985
--------------	-------------	---------	-----	--------------

FILM, EXTENDED RELEASE; TRANSDERMAL

NITROGLYCERIN

KREMERS URBAN PHARMS	0.2MG/HR	A075115	001	Aug 10, 2004
	0.4MG/HR	A075115	002	Aug 10, 2004
MYLAN TECHNOLOGIES	0.1MG/HR	A074992	004	Nov 12, 1999
	0.2MG/HR	A074992	003	Nov 12, 1999
	0.4MG/HR	A074992	002	Nov 12, 1999
	0.6MG/HR	A074992	001	Nov 12, 1999

TRANSDERM-NITRO

NOVARTIS

0.1MG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**		N020144	001	Feb 27, 1996
0.2MG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**		N020144	002	Feb 27, 1996
0.4MG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**		N020144	003	Feb 27, 1996
0.6MG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**		N020144	004	Feb 27, 1996
0.8MG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**		N020144	005	Feb 27, 1996

DISCONTINUED DRUG PRODUCT LIST

NITROGLYCERIN

INJECTABLE; INJECTION

NITRO IV

POHL BOSKAMP	5MG/ML	N018672 002	Aug 30, 1983
--------------	--------	-------------	--------------

NITRO-BID

SANOFI AVENTIS US	5MG/ML	N018621 001	Jan 05, 1982
	10MG/ML	A071159 001	Feb 28, 1990

NITROGLYCERIN

ABRAXIS PHARM	5MG/ML	A070077 001	Dec 13, 1985
---------------	--------	-------------	--------------

	5MG/ML	A071203 001	May 08, 1987
--	--------	-------------	--------------

HOSPIRA	5MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018531 001	
---------	---	-------------	--

INTL MEDICATION	5MG/ML	A070026 001	Sep 10, 1985
-----------------	--------	-------------	--------------

LUITPOLD	5MG/ML	A071492 001	May 24, 1988
----------	--------	-------------	--------------

SMITH AND NEPHEW	5MG/ML	A070633 001	Jun 19, 1986
------------------	--------	-------------	--------------

	5MG/ML	A070634 001	Jun 19, 1986
--	--------	-------------	--------------

NITROGLYCERIN IN DEXTROSE 5%

HOSPIRA	0.1MG/ML	A074083 001	Oct 26, 1994
---------	----------	-------------	--------------

NITROL

RORER	0.8MG/ML	N018774 001	Jan 19, 1983
-------	----------	-------------	--------------

NITRONAL

POHL BOSKAMP	1MG/ML	N018672 001	Aug 30, 1983
--------------	--------	-------------	--------------

NITROSTAT

PARKE DAVIS	0.8MG/ML	N018588 001	
-------------	----------	-------------	--

	5MG/ML	A070863 001	Jan 08, 1987
--	--------	-------------	--------------

	5MG/ML	N018588 002	Dec 23, 1983
--	--------	-------------	--------------

	10MG/ML	A070871 001	Jan 08, 1987
--	---------	-------------	--------------

	10MG/ML	A070872 001	Jan 08, 1987
--	---------	-------------	--------------

TRIDIL

HOSPIRA	0.5MG/ML	N018537 002	Jun 16, 1983
---------	----------	-------------	--------------

	5MG/ML	N018537 001	
--	--------	-------------	--

NIZATIDINE

CAPSULE; ORAL

AXID

SMITHKLINE BEECHAM	150MG	N019508 001	Apr 12, 1988
--------------------	-------	-------------	--------------

	300MG	N019508 002	Apr 12, 1988
--	-------	-------------	--------------

NIZATIDINE

ANI PHARMS INC	150MG	A075461 001	Jul 08, 2002
----------------	-------	-------------	--------------

	300MG	A075461 002	Jul 08, 2002
--	-------	-------------	--------------

APOTEX INC	150MG	A076383 001	Jan 23, 2003
------------	-------	-------------	--------------

	300MG	A076383 002	Jan 23, 2003
--	-------	-------------	--------------

MYLAN PHARMS INC	150MG	A075934 001	Jul 09, 2002
------------------	-------	-------------	--------------

	300MG	A075934 002	Jul 09, 2002
--	-------	-------------	--------------

SOLUTION; ORAL

AXID

BRAINTREE	15MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021494 001	May 25, 2004
-----------	--	-------------	--------------

NONOXYNOL-9

AEROSOL; VAGINAL

DELFIN

PERSONAL PRODS	12.5%	N014349 002	
----------------	-------	-------------	--

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

NOREPINEPHRINE BITARTRATE

METRICS PHARM	EQ 1MG BASE/ML	A040522 001	Sep 30, 2004
---------------	----------------	-------------	--------------

NOREPINEPHRINE BITARTRATE; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

RAVOCAINE AND NOVOCAIN W/ LEVOPHED

EASTMAN KODAK	EQ 0.033MG BASE/ML; 2%; 0.4%	N008592 003	
---------------	------------------------------	-------------	--

NORETHINDRONE

TABLET; ORAL

NORLUTIN

PARKE DAVIS	5MG	N010895 002	
-------------	-----	-------------	--

DISCONTINUED DRUG PRODUCT LIST

NORETHINDRONE ACETATE

TABLET; ORAL

NORLUTATE

PARKE DAVIS

5MG

N012184 002

NORFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

CHIBROXIN

MERCK

0.3%

N019757 001 Jun 17, 1991

TABLET; ORAL

NOROXIN

MERCK

400MG

N019384 002 Oct 31, 1986

NORGESTREL

TABLET; ORAL

OVRETTE

LABORATOIRE HRA

0.075MG

N017031 001

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

AVENTYL HYDROCHLORIDE

LILLY

EQ 10MG BASE

N014684 001

EQ 25MG BASE

N014684 002

NORTRIPTYLINE HYDROCHLORIDE

AUROLIFE PHARMA LLC

EQ 10MG BASE

A074835 001 Jun 30, 1997

EQ 25MG BASE

A074835 002 Jun 30, 1997

EQ 50MG BASE

A074835 003 Jun 30, 1997

EQ 75MG BASE

A074835 004 Jun 30, 1997

IDT AUSTRALIA LTD

EQ 10MG BASE

A074054 001 Dec 31, 1992

EQ 25MG BASE

A074054 002 Dec 31, 1992

EQ 50MG BASE

A074054 003 Dec 31, 1992

EQ 75MG BASE

A074054 004 Dec 31, 1992

TEVA

EQ 10MG BASE

A073667 001 Apr 11, 1996

EQ 25MG BASE

A073667 002 Apr 11, 1996

EQ 50MG BASE

A073667 003 Apr 11, 1996

EQ 75MG BASE

A073667 004 Apr 11, 1996

SOLUTION; ORAL

AVENTYL

RANBAXY

EQ 10MG BASE/5ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N014685 001

PAMELOR

MALLINCKRODT INC

EQ 10MG BASE/5ML

N018012 001

NYSTATIN

CREAM; TOPICAL

CANDEX

BAYER PHARMS

100,000 UNITS/GM

A061810 001

MYCOSTATIN

DELCOR ASSET CORP

100,000 UNITS/GM **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

A060575 001

MYKINAC

ALPHARMA US PHARMS

100,000 UNITS/GM

A062387 001 Jul 29, 1982

NILSTAT

LEDERLE

100,000 UNITS/GM

A061445 001

NYSTATIN

TARO

100,000 UNITS/GM

A062457 001 Jul 28, 1983

LOTION; TOPICAL

CANDEX

BAYER PHARMS

100,000 UNITS/ML

N050233 001

OINTMENT; TOPICAL

MYCOSTATIN

DELCOR ASSET CORP

100,000 UNITS/GM **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

A060571 001

MYKINAC

ALPHARMA US PHARMS

100,000 UNITS/GM

A062731 001 Sep 22, 1986

NILSTAT

LEDERLE

100,000 UNITS/GM

A061444 001

DISCONTINUED DRUG PRODUCT LIST

NYSTATIN

PASTILLE;ORAL

MYCOSTATIN

BRISTOL MYERS SQUIBB 200,000 UNITS N050619 001 Apr 09, 1987

POWDER;ORAL

BARSTATIN 100

BARLAN 100% A062489 001 Apr 27, 1988

NILSTAT

DAVA PHARMS INC 100% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** N050576 001 Dec 22, 1983

NYSTATIN

PADDOCK LLC

100% A062613 001 Nov 26, 1985

POWDER;TOPICAL

MYCOSTATIN

DELCOR ASSET CORP 100,000 UNITS/GM **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** A060578 001

NYSTATIN

NESHER PHARMS

100,000 UNITS/GM A065321 001 Aug 18, 2006

SUPPOSITORY;VAGINAL

NYSERT

WARNER CHILCOTT 100,000 UNITS N050478 001

SUSPENSION;ORAL

MYCOSTATIN

DELCOR ASSET CORP 100,000 UNITS/ML A061533 001

NILSTAT

GLENMARK GENERICS 100,000 UNITS/ML N050299 001

NYSTATIN

ALPHARMA US PHARMS

100,000 UNITS/ML A062571 001 Oct 29, 1985

G AND W LABS INC

100,000 UNITS/ML A062776 001 Dec 17, 1987

MORTON GROVE

100,000 UNITS/ML A062835 001 Nov 19, 1987

PHARMADERM

100,000 UNITS/ML A062518 001 Jul 06, 1984

PHARMAFAIR

100,000 UNITS/ML A062541 001 Jan 16, 1985

ROXANE

100,000 UNITS/ML A062832 001 Dec 27, 1991

TEVA

100,000 UNITS/ML A062670 001 Jun 18, 1987

NYSTEX

SAVAGE LABS

100,000 UNITS/ML A062519 001 Jul 06, 1984

TABLET;ORAL

MYCOSTATIN

DELCOR ASSET CORP 500,000 UNITS A060574 001

NILSTAT

LEDERLE

500,000 UNITS A061151 001

NYSTATIN

QUANTUM PHARMICS

500,000 UNITS A062525 001 Oct 29, 1984

SANDOZ

500,000 UNITS A062065 001

USL PHARMA

500,000 UNITS A062524 001 Nov 26, 1985

WATSON LABS

500,000 UNITS A062402 001 Dec 16, 1982

TABLET;VAGINAL

KOROSTATIN

HOLLAND RANTOS 100,000 UNITS A061718 001

MYCOSTATIN

DELCOR ASSET CORP 100,000 UNITS A060577 001

NILSTAT

LEDERLE

100,000 UNITS A061325 001

NYSTATIN

FOUGERA

100,000 UNITS A062459 001 Nov 09, 1983

PHARMADERM

100,000 UNITS A062460 001 Nov 09, 1983

QUANTUM PHARMICS

100,000 UNITS A062509 001 Apr 03, 1984

SANDOZ

100,000 UNITS A061965 001

TEVA

100,000 UNITS A062502 001 Dec 23, 1983

WATSON LABS

100,000 UNITS A062176 001

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

MYCO-TRIACET II

TEVA 100,000 UNITS/GM;0.1% A061954 002 Sep 20, 1985

MYCOLOG-II

DELCOR ASSET CORP 100,000 UNITS/GM;0.1% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons* A060576 002 May 01, 1985

DISCONTINUED DRUG PRODUCT LIST

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

MYCOLOG-II

100,000 UNITS/GM;0.1% **Federal	A062606	001	May 15, 1985
Register determination that product was not discontinued or withdrawn for safety or efficacy reasons*			

MYTREX F

SAVAGE LABS

100,000 UNITS/GM;0.1%	A062597	001	Oct 08, 1985
-----------------------	---------	-----	--------------

NYSTATIN AND TRIAMCINOLONE ACETONIDE

ALPHARMA US PHARMS

100,000 UNITS/GM;0.1%	A063010	001	Dec 20, 1988
-----------------------	---------	-----	--------------

PERRIGO NEW YORK

100,000 UNITS/GM;0.1%	A062186	002	Jun 06, 1985
-----------------------	---------	-----	--------------

PHARMAFAIR

100,000 UNITS/GM;0.1%	A062657	001	Jul 30, 1986
-----------------------	---------	-----	--------------

TARO

100,000 UNITS/GM;0.1%	A062347	001	Mar 30, 1987
-----------------------	---------	-----	--------------

NYSTATIN TRIAMCINOLONE ACETONIDE

PHARMADERM

100,000 UNITS/GM;0.1%	A062596	001	Oct 08, 1985
-----------------------	---------	-----	--------------

OINTMENT; TOPICAL

MYCO-TRIACET II

TEVA

100,000 UNITS/GM;0.1%	A062045	002	Nov 26, 1985
-----------------------	---------	-----	--------------

MYCOLOG-II

DELCOR ASSET CORP

100,000 UNITS/GM;0.1% **Federal	A060572	001	Jun 28, 1985
Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**			

MYTREX F

SAVAGE LABS

100,000 UNITS/GM;0.1%	A062601	001	Oct 09, 1985
-----------------------	---------	-----	--------------

NYSTATIN AND TRIAMCINOLONE ACETONIDE

PERRIGO NEW YORK

100,000 UNITS/GM;0.1%	A062280	002	Oct 10, 1985
-----------------------	---------	-----	--------------

PHARMAFAIR

100,000 UNITS/GM;0.1%	A062656	001	Jul 30, 1986
-----------------------	---------	-----	--------------

NYSTATIN-TRIAMCINOLONE ACETONIDE

PHARMADERM

100,000 UNITS/GM;0.1%	A062603	001	Oct 09, 1985
-----------------------	---------	-----	--------------

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

WOCKHARDT USA

EQ 0.2MG BASE/ML	A090986	001	May 11, 2011
------------------	---------	-----	--------------

EQ 1MG BASE/ML	A090986	002	May 11, 2011
----------------	---------	-----	--------------

OCTREOTIDE ACETATE PRESERVATIVE FREE

WOCKHARDT USA

EQ 0.05MG BASE/ML	A090985	001	May 11, 2011
-------------------	---------	-----	--------------

EQ 0.1MG BASE/ML	A090985	002	May 11, 2011
------------------	---------	-----	--------------

EQ 0.5MG BASE/ML	A090985	003	May 11, 2011
------------------	---------	-----	--------------

OFLOXACIN

INJECTABLE; INJECTION

FLOXIN

ORTHO MCNEIL PHARM

20MG/ML	N020087	002	Mar 31, 1992
---------	---------	-----	--------------

40MG/ML	N020087	003	Mar 31, 1992
---------	---------	-----	--------------

FLOXIN IN DEXTROSE 5%

ORTHO MCNEIL PHARM

400MG/100ML	N020087	001	Mar 31, 1992
-------------	---------	-----	--------------

FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER

ORTHO MCNEIL PHARM

4MG/ML	N020087	004	Mar 31, 1992
--------	---------	-----	--------------

400MG/100ML	N020087	005	Mar 31, 1992
-------------	---------	-----	--------------

OFLOXACIN

BEDFORD

40MG/ML	A075762	001	Jan 16, 2002
---------	---------	-----	--------------

SOLUTION/DROPS; OPHTHALMIC

OFLOXACIN

APOTEX INC

0.3%	A076513	001	May 14, 2004
------	---------	-----	--------------

SANDOZ

0.3%	A076848	001	Nov 25, 2008
------	---------	-----	--------------

SOLUTION/DROPS; OTIC

FLOXIN OTIC

DAIICHI

0.3% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020799	001	Dec 16, 1997
---	---------	-----	--------------

TABLET; ORAL

FLOXIN

JANSSEN PHARMS

200MG	N019735	001	Dec 28, 1990
-------	---------	-----	--------------

300MG	N019735	002	Dec 28, 1990
-------	---------	-----	--------------

400MG	N019735	003	Dec 28, 1990
-------	---------	-----	--------------

OFLOXACIN

LARKEN LABS

200MG	A076093	001	Sep 02, 2003
-------	---------	-----	--------------

300MG	A076093	002	Sep 02, 2003
-------	---------	-----	--------------

RANBAXY LABS LTD

200MG	A076220	001	Sep 02, 2003
-------	---------	-----	--------------

300MG	A076220	002	Sep 02, 2003
-------	---------	-----	--------------

400MG	A076220	003	Sep 02, 2003
-------	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

PRILOSEC

ASTRAZENECA PHARMS	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019810 003	Oct 05, 1995
	20MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019810 001	Sep 14, 1989
	40MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019810 002	Jan 15, 1998

OMEPRAZOLE; SODIUM BICARBONATE

FOR SUSPENSION;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

PAR PHARM	20MG/PACKET;1.68GM/PACKET	A079182 001	Apr 19, 2013
	40MG/PACKET;1.68GM/PACKET	A079182 002	Apr 19, 2013

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL

ONDANSETRON

CHARTWELL PHARMS LLC	4MG	A076506 001	Dec 26, 2006
	8MG	A076506 002	Dec 26, 2006
	16MG	A077406 001	Dec 26, 2006
	24MG	A077406 002	Dec 26, 2006
NESHER PHARMS	4MG	A077717 001	Jun 25, 2007
	8MG	A077717 002	Jun 25, 2007

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ONDANSETRON HYDROCHLORIDE

APOTEX INC	EQ 2MG BASE/ML	A077368 001	Dec 26, 2006
HOSPIRA	EQ 2MG BASE/ML	A076695 001	Dec 26, 2006
LANNETT	EQ 2MG BASE/ML	A090116 001	Apr 14, 2010
	EQ 2MG BASE/ML	A090883 001	Aug 05, 2010
LUITPOLD	EQ 2MG BASE/ML	A077582 001	Dec 26, 2006
PLIVA HRVATSKA DOO	EQ 2MG BASE/ML	A077544 001	Dec 26, 2006
SAGENT PHARMS	EQ 2MG BASE/ML	A078180 001	Mar 26, 2007

ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER

HOSPIRA	EQ 0.64MG BASE/ML	A076978 001	Feb 26, 2007
---------	-------------------	-------------	--------------

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

APOTEX INC	EQ 2MG BASE/ML	A077343 001	Dec 26, 2006
HOSPIRA	EQ 2MG BASE/ML	A076696 001	Dec 26, 2006
LUITPOLD	EQ 2MG BASE/ML	A077387 001	Dec 26, 2006
TARO PHARMS IRELAND	EQ 2MG BASE/ML	A078014 001	Mar 21, 2008

ZOFRAN

NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007 001	Jan 04, 1991
----------------------	----------------	-------------	--------------

ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER

GLAXOSMITHKLINE	EQ 0.64MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020403 001	Jan 31, 1995
-----------------	--	-------------	--------------

ZOFRAN PRESERVATIVE FREE

NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007 003	Dec 10, 1993
----------------------	----------------	-------------	--------------

TABLET;ORAL

ONDANSETRON HYDROCHLORIDE

CHARTWELL MOLECULES	EQ 4MG BASE	A077303 001	Jun 25, 2007
	EQ 8MG BASE	A077303 002	Jun 25, 2007
	EQ 24MG BASE	A077303 004	Jun 25, 2007
HIKMA INTL PHARMS	EQ 4MG BASE	A077545 001	Sep 06, 2007
	EQ 8MG BASE	A077545 002	Sep 06, 2007
	EQ 24MG BASE	A077545 003	Sep 06, 2007
TARO	EQ 4MG BASE	A077729 001	Mar 28, 2011
	EQ 8MG BASE	A077729 002	Mar 28, 2011
	EQ 24MG BASE	A077729 003	Mar 28, 2011

DISCONTINUED DRUG PRODUCT LIST

ORPHENADRINE CITRATE

INJECTABLE; INJECTION

NORFLEX

IGI LABS INC 30MG/ML N013055 001

ORPHENADRINE CITRATE

WATSON LABS 30MG/ML A087062 001

TABLET, EXTENDED RELEASE; ORAL

NORFLEX

MEDICIS 100MG N012157 001

ORPHENADRINE CITRATE

ASCOT 100MG A088067 001 Apr 06, 1983

SANDOZ 100MG A085046 001

WATSON LABS 100MG A084303 001

ORPHENADRINE HYDROCHLORIDE

TABLET; ORAL

DISIPAL

3M 50MG N010653 001

OSELTAMIVIR PHOSPHATE

FOR SUSPENSION; ORAL

TAMIFLU

ROCHE EQ 12MG BASE/ML N021246 001 Dec 14, 2000

OXACILLIN SODIUM

CAPSULE; ORAL

BACTOCILL

GLAXOSMITHKLINE EQ 250MG BASE A061336 001

EQ 250MG BASE A062241 001

EQ 500MG BASE A061336 002

EQ 500MG BASE A062241 002

OXACILLIN SODIUM

ANI PHARMS INC EQ 250MG BASE A062222 001

EQ 500MG BASE A062222 002

APOTHECON EQ 250MG BASE A061450 002

EQ 500MG BASE A061450 001

PROSTAPHLIN

APOTHECON EQ 500MG BASE N050118 002

FOR SOLUTION; ORAL

BACTOCILL

GLAXOSMITHKLINE EQ 250MG BASE/5ML A062321 001

OXACILLIN SODIUM

APOTHECON EQ 250MG BASE/5ML A061457 001

TEVA EQ 250MG BASE/5ML A062252 001

PROSTAPHLIN

APOTHECON EQ 250MG BASE/5ML N050194 001

INJECTABLE; INJECTION

BACTOCILL

GLAXOSMITHKLINE EQ 500MG BASE/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons** A061334 009 Mar 26, 1982EQ 1GM BASE/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons** A061334 006 Mar 26, 1982EQ 1GM BASE/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons** A062736 001 Dec 19, 1986EQ 2GM BASE/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons** A061334 007 Mar 26, 1982EQ 2GM BASE/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons** A062736 002 Dec 19, 1986EQ 4GM BASE/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons** A061334 008 Mar 26, 1982EQ 10GM BASE/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons** A061334 010

DISCONTINUED DRUG PRODUCT LIST

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

APOTHECON

EQ 250MG BASE/VIAL	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050195	001		
EQ 500MG BASE/VIAL	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050195	002		
EQ 1GM BASE/VIAL	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050195	003		
EQ 2GM BASE/VIAL	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050195	004		
EQ 4GM BASE/VIAL	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050195	005		

ELKINS SINN

EQ 250MG BASE/VIAL		A062711	001	Feb 03, 1989
EQ 500MG BASE/VIAL		A062711	002	Feb 03, 1989
EQ 1GM BASE/VIAL		A062711	003	Feb 03, 1989
EQ 2GM BASE/VIAL		A062711	004	Feb 03, 1989
EQ 4GM BASE/VIAL		A062711	005	Feb 03, 1989
EQ 10GM BASE/VIAL		A062711	006	Feb 03, 1989

ISTITUTO BIO ITA SPA

EQ 125MG BASE/VIAL		A062798	003	Dec 11, 1995
EQ 250MG BASE/VIAL		A062798	004	Dec 11, 1995
EQ 500MG BASE/VIAL		A062798	005	Dec 11, 1995
EQ 1GM BASE/VIAL		A062798	001	Dec 11, 1995
EQ 2GM BASE/VIAL		A062798	002	Dec 11, 1995

SANDOZ

EQ 250MG BASE/VIAL		A061490	001	
EQ 500MG BASE/VIAL		A061490	002	

WATSON LABS INC

EQ 250MG BASE/VIAL		A062856	001	Oct 26, 1988
EQ 500MG BASE/VIAL		A062856	002	Oct 26, 1988
EQ 1GM BASE/VIAL		A062856	003	Oct 26, 1988
EQ 2GM BASE/VIAL		A062856	004	Oct 26, 1988
EQ 4GM BASE/VIAL		A062856	005	Oct 26, 1988
EQ 10GM BASE/VIAL		A062984	001	Sep 29, 1988

OXALIPLATIN

INJECTABLE; IV (INFUSION)

ELOXATIN

SANOFI AVENTIS US

50MG/VIAL	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021492	001	Aug 09, 2002
100MG/VIAL	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021492	002	Aug 09, 2002
200MG/40ML (5MG/ML)	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021759	003	Nov 17, 2006

OXALIPLATIN

SANDOZ

50MG/VIAL		A090849	001	Apr 28, 2011
100MG/VIAL		A090849	002	Apr 28, 2011

SANDOZ INC

50MG/10ML (5MG/ML)		A078812	001	Aug 07, 2009
100MG/20ML (5MG/ML)		A078812	002	Aug 07, 2009

OXAMNIOUINE

CAPSULE; ORAL

VANSIL

PFIZER

250MG		N018069	001	
-------	--	---------	-----	--

OXANDROLONE

TABLET; ORAL

OXANDROLONE

ROXANE

2.5MG		A077249	001	Jul 10, 2007
10MG		A077249	002	Jul 10, 2007

SANDOZ

2.5MG		A076897	001	Dec 01, 2006
10MG		A076897	002	Dec 01, 2006

DISCONTINUED DRUG PRODUCT LIST

OXAPROZIN

TABLET; ORAL

OXAPROZIN

ACTAVIS ELIZABETH	600MG	A075843	001	Oct 03, 2001
MYLAN	600MG	A075851	001	Aug 17, 2001
MYLAN PHARMS INC	600MG	A075847	001	Feb 28, 2001
SANDOZ	600MG	A075842	001	Apr 12, 2001
	600MG	A075850	001	Apr 27, 2001
WATSON LABS	600MG	A075848	001	Feb 09, 2001

OXAPROZIN POTASSIUM

TABLET; ORAL

DAYPRO ALTA

GD SEARLE	600MG	N020776	001	Oct 17, 2002
-----------	-------	---------	-----	--------------

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM

AM THERAP	10MG	A071955	001	Mar 03, 1988
	15MG	A071956	001	Mar 03, 1988
	30MG	A071957	001	Mar 03, 1988
FRONTIDA BIOPHARM	10MG	A071026	002	Aug 10, 1987
	15MG	A071026	003	Aug 10, 1987
	30MG	A071026	001	Aug 10, 1987
IVAX SUB TEVA PHARMS	10MG	A070943	001	Aug 03, 1987
	15MG	A070944	001	Aug 03, 1987
	30MG	A070945	001	Aug 03, 1987
MYLAN	10MG	A071713	001	Oct 20, 1987
	15MG	A071714	001	Oct 20, 1987
	30MG	A071715	001	Oct 20, 1987
WATSON LABS	10MG	A072952	001	Sep 28, 1990
	15MG	A072953	001	Sep 28, 1990
	30MG	A072954	001	Sep 28, 1990

SERAX

ALPHARMA US PHARMS	10MG	N015539	002	
	15MG	N015539	004	
	30MG	N015539	006	

ZAXOPAM

QUANTUM PHARMICS	10MG	A070650	001	Mar 01, 1988
	15MG	A070640	001	Mar 01, 1988
	30MG	A070641	001	Mar 01, 1988

TABLET; ORAL

OXAZEPAM

FRONTIDA BIOPHARM	15MG	A070683	001	Jan 16, 1987
PARKE DAVIS	15MG	A071508	001	Feb 02, 1987
WATSON LABS	15MG	A071494	001	Apr 21, 1987

SERAX

ALPHARMA US PHARMS	15MG	N015539	008	
--------------------	------	---------	-----	--

OPRENOLOL HYDROCHLORIDE

CAPSULE; ORAL

TRASICOR

NOVARTIS	20MG	N018166	001	Dec 28, 1983
	40MG	N018166	002	Dec 28, 1983
	80MG	N018166	003	Dec 28, 1983
	160MG	N018166	004	Dec 28, 1983

OXTRIPHYLLINE

SOLUTION; ORAL

CHOLEDYL

PARKE DAVIS	100MG/5ML	N009268	012	Nov 27, 1984
-------------	-----------	---------	-----	--------------

OXTRIPHYLLINE

MORTON GROVE	100MG/5ML	A088243	001	Dec 05, 1983
--------------	-----------	---------	-----	--------------

SYRUP; ORAL

CHOLEDYL

PARKE DAVIS	50MG/5ML	N009268	011	
-------------	----------	---------	-----	--

OXTRIPHYLLINE PEDIATRIC

MORTON GROVE	50MG/5ML	A088242	001	Dec 05, 1983
--------------	----------	---------	-----	--------------

TABLET, DELAYED RELEASE; ORAL

CHOLEDYL

PARKE DAVIS	100MG	N009268	003	
	200MG	N009268	007	

OXTRIPHYLLINE

WATSON LABS	100MG	A087866	001	Aug 25, 1983
-------------	-------	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

OXTRIPHYLLINE

TABLET, DELAYED RELEASE;ORAL

OXTRIPHYLLINE

200MG

A087835 001 Aug 25, 1983

OXYBUTYNIN CHLORIDE

SYRUP;ORAL

DITROPAN

ORTHO MCNEIL JANSSEN

5MG/5ML **Federal Register

N018211 001

determination that product was not discontinued or withdrawn for safety or efficacy reasons**

OXYBUTYNIN CHLORIDE

APOTEX INC

5MG/5ML

A074997 001 Oct 15, 1997

MIKART

5MG/5ML

A075039 001 Jan 29, 1999

TABLET;ORAL

DITROPAN

JANSSEN PHARMS

5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N017577 001

OXYBUTYNIN CHLORIDE

QUANTUM PHARMICS

5MG

A072296 001 Dec 08, 1988

USL PHARMA

5MG

A070746 001 Mar 10, 1988

WATSON LABS

5MG

A072485 001 Apr 19, 1989

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ROXICODONE

ROXANE

10MG

N020932 001 Oct 26, 1998

30MG

N020932 002 Oct 26, 1998

OXYMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

OPANA

ENDO PHARMS

1.5MG/ML

N011707 001

SUPPOSITORY;RECTAL

NUMORPHAN

ENDO PHARMS

5MG

N011738 004

TABLET, EXTENDED RELEASE;ORAL

OPANA ER

ENDO PHARMS

5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N021610 001 Jun 22, 2006

7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N021610 005 Feb 29, 2008

10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N021610 002 Jun 22, 2006

15MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N021610 006 Feb 29, 2008

20MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N021610 003 Jun 22, 2006

30MG

N021610 007 Feb 29, 2008

40MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N021610 004 Jun 22, 2006

OXYPHENBUTAZONE

TABLET;ORAL

OXYPHENBUTAZONE

WATSON LABS

100MG

A088399 001 Sep 17, 1984

TANDEARIL

NOVARTIS

100MG

N012542 004 Sep 03, 1982

DISCONTINUED DRUG PRODUCT LIST

OXYPHENCYCLIMINE HYDROCHLORIDE

TABLET; ORAL

DARICON

PFIZER

10MG

N011612 001

OXYPHENONIUM BROMIDE

TABLET; ORAL

ANTRENYL

NOVARTIS

5MG

N008492 002

OXYTETRACYCLINE

TABLET; ORAL

TERRAMYCIN

PFIZER

250MG

N050287 001

OXYTETRACYCLINE CALCIUM

SYRUP; ORAL

TERRAMYCIN

PFIZER

EQ 125MG BASE/5ML

A060595 001

OXYTETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

OXY-KESSO-TETRA

FERRANTE

EQ 250MG BASE

A060179 001

OXYTETRACYCLINE HYDROCHLORIDE

HIKMA PHARMS LLC

EQ 250MG BASE

A060770 001

IMPAX LABS

EQ 250MG BASE

A060760 001

PROTER

EQ 250MG BASE

A060869 001

PUREPAC PHARM

EQ 250MG BASE

A060634 001

TERRAMYCIN

PFIZER

EQ 125MG BASE

N050286 001

EQ 250MG BASE

N050286 002

INJECTABLE; INJECTION

TERRAMYCIN

PFIZER

EQ 250MG BASE/VIAL

A060586 001

EQ 500MG BASE/VIAL

A060586 002

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT; OTIC

TERRAMYCIN W/ POLYMYXIN

PFIZER

EQ 5MG BASE/GM;10,000 UNITS/GM

A061841 001

TABLET; VAGINAL

TERRAMYCIN-POLYMYXIN

PFIZER

EQ 100MG BASE;100,000 UNITS

A061009 001

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

TEVA PHARMS USA

10USP UNITS/ML (10USP UNITS/ML)

A077453 001 Jan 24, 2008

100USP UNITS/10ML (10USP UNITS/ML)

A077453 002 Jan 24, 2008

OXYTOCIN 10 USP UNITS IN DEXTROSE 5%

ABBOTT

1USP UNITS/100ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N019185 004 Mar 29, 1985

2USP UNITS/100ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N019185 003 Mar 29, 1985

OXYTOCIN 20 USP UNITS IN DEXTROSE 5%

ABBOTT

2USP UNITS/100ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N019185 002 Mar 29, 1985

OXYTOCIN 5 USP UNITS IN DEXTROSE 5%

ABBOTT

1USP UNITS/100ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N019185 001 Mar 29, 1985

SYNTOCINON

NOVARTIS

10USP UNITS/ML

N018245 001

SOLUTION; NASAL

SYNTOCINON

RTRX

40USP UNITS/ML

N012285 001

DISCONTINUED DRUG PRODUCT LIST

PACLITAXEL

INJECTABLE; INJECTION

PACLITAXEL

ACCORD HLTHCARE	6MG/ML	A075436 001	Nov 12, 2004
HOSPIRA	6MG/ML	A076233 001	Aug 01, 2002
MYLAN	6MG/ML	A075278 001	Jan 25, 2002
PLIVA LACHEMA	6MG/ML	A077413 001	Mar 12, 2008
TEVA PHARMS USA	6MG/ML	A075297 001	Jan 25, 2002

PALIPERIDONE

TABLET, EXTENDED RELEASE; ORAL

INVEGA

JANSSEN PHARMS	12MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021999 004	Dec 19, 2006
----------------	---	-------------	--------------

PALONOSETRON HYDROCHLORIDE

CAPSULE; ORAL

ALOXI

HELSINN HLTHCARE	EQ 0.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N022233 001	Aug 22, 2008
------------------	--	-------------	--------------

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

ARELIA

NOVARTIS	30MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020036 001	Oct 31, 1991
	60MG/VIAL	N020036 003	May 06, 1993
	90MG/VIAL	N020036 004	May 06, 1993

PAMIDRONATE DISODIUM

AESGEN	30MG/VIAL	A075594 001	May 06, 2002
	90MG/VIAL	A075594 002	May 06, 2002
MN PHARMS	30MG/VIAL	A078300 001	Mar 10, 2009
	90MG/VIAL	A078300 002	Mar 10, 2009

PANCRELIPASE (AMYLASE; LIPASE; PROTEASE)

CAPSULE; ORAL

COTAZYM

ORGANON USA INC	30,000USP UNITS; 8,000USP UNITS; 30,000USP UNITS	N020580 001	Dec 09, 1996
-----------------	--	-------------	--------------

PANCURONIUM BROMIDE

INJECTABLE; INJECTION

PANCURONIUM BROMIDE

ELKINS SINN	1MG/ML	A072058 001	Mar 23, 1988
	2MG/ML	A072059 001	Mar 23, 1988
	2MG/ML	A072060 001	Mar 23, 1988
HOSPIRA	2MG/ML	A072321 001	Jan 19, 1989
IGI LABS INC	1MG/ML	A072210 001	Mar 31, 1988
	2MG/ML	A072211 001	Mar 31, 1988
	2MG/ML	A072212 001	Mar 31, 1988
	2MG/ML	A072213 001	Mar 31, 1988

PAVULON

ORGANON USA INC	1MG/ML	N017015 002	
	2MG/ML	N017015 001	

PARAMETHADIONE

CAPSULE; ORAL

PARADIONE

ABBVIE	150MG	N006800 003	
	300MG	N006800 001	

SOLUTION; ORAL

PARADIONE

ABBVIE	300MG/ML	N006800 002	
--------	----------	-------------	--

PARAMETHASONE ACETATE

TABLET; ORAL

HALDRONE

LILLY	1MG	N012772 005	
	2MG	N012772 006	

DISCONTINUED DRUG PRODUCT LIST

PARGYLINE HYDROCHLORIDE

TABLET; ORAL

EUTONYL

ABBOTT

10MG

N013448 002

25MG

N013448 003

50MG

N013448 004

PARICALCITOL

CAPSULE; ORAL

ZEMPLAR

ABBVIE

4MCG

N021606 003 May 26, 2005

PAROMOMYCIN SULFATE

CAPSULE; ORAL

HUMATIN

KING PFIZER

EQ 250MG BASE

A062310 001

PARKEDALE

EQ 250MG BASE

A060521 001

SYRUP; ORAL

HUMATIN

PARKE DAVIS

EQ 125MG BASE/5ML

A060522 001

PAROXETINE HYDROCHLORIDE

CAPSULE; ORAL

PAXIL

APOTEX TECHNOLOGIES

EQ 10MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020885 001 Oct 09, 1998

EQ 20MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020885 002 Oct 09, 1998

EQ 30MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020885 003 Oct 09, 1998

EQ 40MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020885 004 Oct 09, 1998

SUSPENSION; ORAL

PAROXETINE HYDROCHLORIDE

APOTEX INC

EQ 10MG BASE/5ML

A077395 001 Dec 05, 2006

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

ROXANE

EQ 10MG BASE

A078026 001 Jun 29, 2007

EQ 20MG BASE

A078026 002 Jun 29, 2007

EQ 30MG BASE

A078026 003 Jun 29, 2007

EQ 40MG BASE

A078026 004 Jun 29, 2007

TEVA PHARMS

EQ 10MG BASE

A077082 001 Jun 29, 2007

EQ 20MG BASE

A077082 002 Jun 29, 2007

EQ 30MG BASE

A077082 003 Jun 29, 2007

EQ 40MG BASE

A077082 004 Jun 29, 2007

UPSHER-SMITH LABS

EQ 10MG BASE

A075566 001 Mar 08, 2004

EQ 20MG BASE

A075566 002 Mar 08, 2004

EQ 30MG BASE

A075566 003 Mar 08, 2004

EQ 40MG BASE

A075566 004 Mar 08, 2004

PAXIL

APOTEX TECHNOLOGIES

EQ 50MG BASE

N020031 004 Dec 29, 1992

PAZOPANIB HYDROCHLORIDE

TABLET; ORAL

VOTRIENT

NOVARTIS PHARMS CORP

EQ 400MG BASE

N022465 002 Oct 19, 2009

PEGINESATIDE ACETATE

SOLUTION; INTRAVENOUS, SUBCUTANEOUS

OMONTYS

TAKEDA PHARMS USA

EQ 10MG BASE/ML (EQ 10MG BASE/ML)

N202799 007 Mar 27, 2012

EQ 20MG BASE/2ML (EQ 10MG BASE/ML)

N202799 008 Mar 27, 2012

OMONTYS PRESERVATIVE FREE

TAKEDA PHARMS USA

EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)

N202799 001 Mar 27, 2012

EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)

N202799 002 Mar 27, 2012

EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)

N202799 003 Mar 27, 2012

EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)

N202799 004 Mar 27, 2012

EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)

N202799 005 Mar 27, 2012

DISCONTINUED DRUG PRODUCT LISTPEGINESATIDE ACETATESOLUTION;INTRAVENOUS, SUBCUTANEOUS
OMONTYS PRESERVATIVE FREE

EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML) N202799 006 Mar 27, 2012

PEMIROLAST POTASSIUM

SOLUTION/DROPS;OPHTHALMIC

ALAMAST

SANTEN

0.1%

N021079 001 Sep 24, 1999

PEMOLINE

TABLET;ORAL

CYLERT

ABBOTT

18.75MG

N016832 001

37.5MG

N016832 002

75MG

N016832 003

PEMOLINE

ACTAVIS ELIZABETH

18.75MG

A075595 001 Feb 28, 2000

37.5MG

A075595 002 Feb 28, 2000

75MG

A075595 003 Feb 28, 2000

MALLINCKRODT

18.75MG

A075726 003 Mar 30, 2001

37.5MG

A075726 002 Mar 30, 2001

75MG

A075726 001 Mar 30, 2001

SANDOZ

18.75MG

A075286 001 Dec 27, 1999

37.5MG

A075286 002 Jun 30, 1999

75MG

A075286 003 Jun 30, 1999

TEVA PHARMS

18.75MG

A075030 003 Feb 22, 2000

37.5MG

A075030 001 Jan 29, 1999

75MG

A075030 002 Jan 29, 1999

VINTAGE PHARMS

18.75MG

A075328 001 Apr 19, 2000

37.5MG

A075328 002 Apr 19, 2000

75MG

A075328 003 Apr 19, 2000

WATSON LABS

18.75MG

A075287 001 Jun 13, 2001

37.5MG

A075287 002 Sep 18, 2000

75MG

A075287 003 Sep 18, 2000

TABLET, CHEWABLE;ORAL

CYLERT

ABBOTT

37.5MG

N017703 001

PEMOLINE

ACTAVIS ELIZABETH

37.5MG

A075678 001 Jul 26, 2000

TEVA PHARMS

37.5MG

A075555 001 Feb 18, 2000

PENBUTOLOL SULFATE

TABLET;ORAL

LEVATOL

AUXILIUM PHARMS LLC

10MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N018976 001 Dec 30, 1987

20MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N018976 004 Jan 05, 1989

PENICILLAMINE

CAPSULE;ORAL

CUPRIMINE

ATON

125MG

N019853 002

PENICILLIN G BENZATHINE

INJECTABLE;INJECTION

BICILLIN L-A

WYETH AYERST

300,000 UNITS/ML

N050131 001

SUSPENSION;ORAL

BICILLIN

WYETH AYERST

300,000 UNITS/5ML

N050126 002

TABLET;ORAL

BICILLIN

WYETH AYERST

200,000 UNITS

N050128 001

DISCONTINUED DRUG PRODUCT LIST

PENICILLIN G POTASSIUM

FOR SOLUTION; ORAL

PENICILLIN

TEVA	200,000 UNITS/5ML	A060307 002
	400,000 UNITS/5ML	A060307 004

PENICILLIN G POTASSIUM

MYLAN	200,000 UNITS/5ML	A060752 003
	250,000 UNITS/5ML	A060752 002
	400,000 UNITS/5ML	A060752 001
PUREPAC PHARM	250,000 UNITS/5ML	A061740 001
	400,000 UNITS/5ML	A061740 002

PENICILLIN-2

TEVA	250,000 UNITS/5ML	A060307 003
------	-------------------	-------------

PENTIDS '200'

APOTHECON	200,000 UNITS/5ML	A062149 001
-----------	-------------------	-------------

PENTIDS '400'

APOTHECON	400,000 UNITS/5ML	A062149 002
-----------	-------------------	-------------

PFIZERPEN G

PFIZER	400,000 UNITS/5ML	A060587 001
--------	-------------------	-------------

INJECTABLE; INJECTION

PENICILLIN G POTASSIUM

APOTHECON	1,000,000 UNITS/VIAL	A060362 001
	5,000,000 UNITS/VIAL	A060362 003
	10,000,000 UNITS/VIAL	A060362 004
	20,000,000 UNITS/VIAL	A060362 002

CONSOLIDATED PHARM	500,000 UNITS/VIAL	A060806 001
	1,000,000 UNITS/VIAL	A060806 002
	5,000,000 UNITS/VIAL	A060806 003
	10,000,000 UNITS/VIAL	A060806 004

LILLY	200,000 UNITS/VIAL	A060384 004
	500,000 UNITS/VIAL	A060384 003
	1,000,000 UNITS/VIAL	A060384 002
	5,000,000 UNITS/VIAL	A060384 001
	20,000,000 UNITS/VIAL	A060384 005
	20,000,000 UNITS/VIAL	A060601 001

PARKE DAVIS	1,000,000 UNITS/VIAL	A062003 001
	5,000,000 UNITS/VIAL	A062003 002

PFIZER	20,000,000 UNITS/VIAL	A060074 003
--------	-----------------------	-------------

SANDOZ	1,000,000 UNITS/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A065079 001	Aug 30, 2002
--------	---	-------------	--------------

WATSON LABS INC	1,000,000 UNITS/VIAL	A062991 001	Sep 13, 1988
	5,000,000 UNITS/VIAL	A062991 002	Sep 13, 1988
	10,000,000 UNITS/VIAL	A062991 003	Sep 13, 1988
	20,000,000 UNITS/VIAL	A062991 004	Sep 13, 1988

PFIZERPEN

PFIZER	1,000,000 UNITS/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A060657 001
--------	---	-------------

TABLET; ORAL

PENICILLIN G POTASSIUM

APOTHECON	250,000 UNITS	A060392 003
IVAX SUB TEVA PHARMS	400,000 UNITS	A060073 004

LILLY	250,000 UNITS	A060403 001
-------	---------------	-------------

MYLAN	200,000 UNITS	A060781 001
-------	---------------	-------------

	250,000 UNITS	A060781 002
--	---------------	-------------

	400,000 UNITS	A060781 003
--	---------------	-------------

	500,000 UNITS	A060781 005
--	---------------	-------------

	800,000 UNITS	A060781 004
--	---------------	-------------

PUREPAC PHARM	200,000 UNITS	A061588 001
---------------	---------------	-------------

	250,000 UNITS	A061588 002
--	---------------	-------------

	400,000 UNITS	A061588 003
--	---------------	-------------

TEVA	200,000 UNITS	A060306 001
------	---------------	-------------

	250,000 UNITS	A060306 002
--	---------------	-------------

	400,000 UNITS	A060306 003
--	---------------	-------------

	500,000 UNITS	A060306 004
--	---------------	-------------

WYETH AYERST	200,000 UNITS	A060413 001
--------------	---------------	-------------

	250,000 UNITS	A060413 002
--	---------------	-------------

	400,000 UNITS	A060413 003
--	---------------	-------------

PENTIDS '200'

APOTHECON	200,000 UNITS	A062155 001
-----------	---------------	-------------

DISCONTINUED DRUG PRODUCT LISTPENICILLIN G POTASSIUM

TABLET; ORAL

PENTIDS '250'			
APOTHECON	250,000 UNITS		A062155 002
PENTIDS '400'			
APOTHECON	400,000 UNITS		A060392 004
	400,000 UNITS		A062155 003
PENTIDS '800'			
APOTHECON	800,000 UNITS		A060392 005
	800,000 UNITS		A062155 004
PFIZERPEN G			
PFIZER	50,000 UNITS		A060075 001
	100,000 UNITS		A060075 002
	200,000 UNITS		A060075 003
	250,000 UNITS		A060075 004
	400,000 UNITS		A060075 005
	800,000 UNITS		A060075 006

PENICILLIN G PROCAINE

INJECTABLE; INJECTION

DURACILLIN A.S.			
LILLY	300,000 UNITS/ML		A060093 001
PENICILLIN G PROCAINE			
CONSOLIDATED PHARM	300,000 UNITS/ML		A060800 001
	600,000 UNITS/1.2ML		A060800 002
PARKE DAVIS	300,000 UNITS/ML		A062029 001
PFIZER	300,000 UNITS/VIAL		A060099 001
	1,500,000 UNITS/VIAL		A060099 002
PFIZERPEN-AS			
PFIZER	300,000 UNITS/ML		A060286 001
	600,000 UNITS/ML		A060286 002

PENICILLIN G SODIUM

INJECTABLE; INJECTION

PENICILLIN G SODIUM			
BRISTOL MYERS SQUIBB	5,000,000 UNITS/VIAL		A061935 001
COPANOS	5,000,000 UNITS/VIAL		A061051 001
PHARMACIA AND UPJOHN	1,000,000 UNITS/VIAL		A061046 001

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

PENICILLIN G SODIUM			
WATSON LABS INC	5,000,000 UNITS/VIAL		A063014 001 Sep 13, 1988

PENICILLIN V

FOR SUSPENSION; ORAL

V-CILLIN			
LILLY	125MG/0.6ML		A060002 001

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

BEEPEN-VK			
GLAXOSMITHKLINE	EQ 125MG BASE/5ML		A062270 001
	EQ 250MG BASE/5ML		A062270 002
BETAPEN-VK			
APOTHECON	EQ 125MG BASE/5ML		A061149 001
	EQ 250MG BASE/5ML		A061149 002
LEDERCILLIN VK			
LEDERLE	EQ 125MG BASE/5ML		A060136 001
	EQ 250MG BASE/5ML		A060136 002
PEN-VEE K			
WYETH AYERST	EQ 125MG BASE/5ML		A060007 001
	EQ 250MG BASE/5ML		A060007 002
PENAPAR-VK			
PARKE DAVIS	EQ 125MG BASE/5ML		A062002 001
	EQ 250MG BASE/5ML		A062002 002
PENICILLIN V POTASSIUM			
AM ANTIBIOTICS	EQ 125MG BASE/5ML		A061529 001
	EQ 250MG BASE/5ML		A061529 002
MYLAN	EQ 125MG BASE/5ML		A061624 002
	EQ 250MG BASE/5ML		A061624 001
PUREPAC PHARM	EQ 125MG BASE/5ML		A061758 001
	EQ 250MG BASE/5ML		A061758 002
PFIZERPEN VK			
PFIZER	EQ 125MG BASE/5ML		A061815 001
	EQ 250MG BASE/5ML		A061815 002

DISCONTINUED DRUG PRODUCT LIST

PENICILLIN V POTASSIUM

FOR SOLUTION;ORAL

V-CILLIN K

LILLY

EQ 125MG BASE/5ML A060004 001
EQ 250MG BASE/5ML A060004 002

VEETIDS

APOTHECON

EQ 125MG BASE/5ML A061410 001
EQ 250MG BASE/5ML A061410 002

VEETIDS '125'

APOTHECON

EQ 125MG BASE/5ML A061206 001
EQ 125MG BASE/5ML A062153 001

VEETIDS '250'

APOTHECON

EQ 250MG BASE/5ML A061206 002
EQ 250MG BASE/5ML A062153 002

TABLET;ORAL

BEEPEN-VK

GLAXOSMITHKLINE

EQ 250MG BASE A062273 001
EQ 500MG BASE A062273 002

BETAPEN-VK

BRISTOL

EQ 250MG BASE A061150 001
EQ 500MG BASE A061150 002

LEDERCILLIN VK

LEDERLE

EQ 250MG BASE A060134 001
EQ 500MG BASE A060134 002

PEN-VEE K

WYETH AYERST

EQ 125MG BASE A060006 001
EQ 250MG BASE A060006 002
EQ 500MG BASE A060006 003

PENAPAR-VK

PARKE DAVIS

EQ 250MG BASE A062001 001
EQ 500MG BASE A062001 002

PENICILLIN V POTASSIUM

AM ANTIBIOTICS

EQ 250MG BASE A061528 001
EQ 500MG BASE A061528 002

IVAX SUB TEVA PHARMS

EQ 125MG BASE A060518 001
EQ 250MG BASE A060518 002
EQ 500MG BASE A060518 003

MYLAN

EQ 250MG BASE A061530 001
EQ 500MG BASE A061530 002

PUREPAC PHARM

EQ 125MG BASE A061571 001
EQ 250MG BASE A061571 002
EQ 500MG BASE A061571 003

PFIZERPEN VK

PFIZER

EQ 250MG BASE A061836 001
EQ 500MG BASE A061836 002

UTICILLIN VK

PHARMACIA AND UPJOHN

EQ 250MG BASE A061651 001
EQ 500MG BASE A061651 002

V-CILLIN K

LILLY

EQ 125MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons** A060003 001
EQ 250MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons** A060003 002
EQ 500MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons** A060003 003

VEETIDS

APOTHECON

EQ 250MG BASE A061411 001
EQ 500MG BASE A061411 002

VEETIDS '250'

APOTHECON

EQ 250MG BASE A061164 001
EQ 250MG BASE A062156 002

VEETIDS '500'

APOTHECON

EQ 500MG BASE A061164 002
EQ 500MG BASE A062156 001

DISCONTINUED DRUG PRODUCT LISTPENTAGASTRIN

INJECTABLE; INJECTION

PEPTAVLON

WYETH AYERST

0.25MG/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N017048 001

PENTAMIDINE ISETHIONATE

FOR SOLUTION; INHALATION

NEBUPENT

FRESENIUS KABI USA

600MG/VIAL

N019887 002 Mar 22, 1996

INJECTABLE; INJECTION

PENTACARINAT

ARMOUR PHARM

300MG/VIAL

A073447 001 Apr 28, 1994

PENTAMIDINE ISETHIONATE

BAXTER HLTHCARE

300MG/VIAL

A073617 001 Dec 18, 1995

HOSPIRA

300MG/VIAL

A073479 001 Jun 30, 1992

WATSON LABS

300MG/VIAL

A074303 001 Aug 17, 1995

PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

TALWIN 50

SANOFI AVENTIS US

EQ 50MG BASE

N016732 001

PENTETATE CALCIUM TRISODIUM YB-169

INJECTABLE; INJECTION

YTTERBIUM YB 169 DTPA

3M

2mCi/ML

N017518 001

PENTOBARBITAL

ELIXIR; ORAL

NEMBUTAL

OAK PHARMS

18.2MG/5ML

A083244 001

PENTOBARBITAL SODIUM

CAPSULE; ORAL

NEMBUTAL SODIUM

OAK PHARMS

30MG

A084095 001

50MG

A084093 001

100MG

A083245 001

PENTOBARBITAL SODIUM

LANNETT

50MG

A085937 001

VITARINE

100MG

A085915 001

WHITEWORTH TOWN PLSN

100MG

A083284 001

WHITWORTH TOWN PLSN

100MG

A083338 001

SODIUM PENTOBARBITAL

ANABOLIC

100MG

A084590 001

ELKINS SINN

100MG

A083368 001

EVERYLIFE

100MG

A083259 001

HALSEY

100MG

A084677 001

IVAX SUB TEVA PHARMS

50MG

A083461 001

100MG

A083461 002

PARKE DAVIS

100MG

A084156 001

PERRIGO

100MG

A084560 001

PUREPAC PHARM

100MG

A083301 001

VALEANT PHARM INTL

100MG

A083264 001

WATSON LABS

100MG

A085791 001

WYETH AYERST

100MG

A083239 001

INJECTABLE; INJECTION

PENTOBARBITAL SODIUM

ELKINS SINN

50MG/ML

A083270 001

SODIUM PENTOBARBITAL

WYETH AYERST

50MG/ML

A083261 001

SUPPOSITORY; RECTAL

NEMBUTAL

OAK PHARMS

30MG

A083247 001 Jan 25, 1982

60MG

A083247 002 Jan 25, 1982

120MG

A083247 003 Jan 25, 1982

200MG

A083247 004 Jan 25, 1982

TABLET; ORAL

PENTOBARBITAL SODIUM

VITARINE

100MG

A083285 001

SODIUM PENTOBARBITAL

NEXGEN PHARMA INC

100MG

A084238 001

DISCONTINUED DRUG PRODUCT LISTPENTOLINIUM TARTRATE

INJECTABLE; INJECTION

ANSOLYSEN

WYETH AYERST 10MG/ML N009372 001

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

PENTOXIFYLLINE

ACTAVIS ELIZABETH 400MG A074878 001 Jul 09, 1997

HERITAGE PHARMS INC 400MG A074877 001 Jul 08, 1997

IMPAX LABS 400MG A075093 001 Aug 10, 1999

PLIVA 400MG A074874 001 May 25, 1999

TEVA 400MG A075199 001 Sep 03, 1999

WATSON LABS 400MG A075107 001 Sep 04, 1998

TRENENTAL

US PHARM HOLDINGS 400MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons** N018631 001 Aug 30, 1984PERFLUBRON

LIQUID; ORAL

IMAGENT

ALLIANCE PHARM 100% N020091 001 Aug 13, 1993

PERFLUOROPOLYMETHYLISOPROPYL ETHER; POLYTETRAFLUOROETHYLENE

PASTE; TOPICAL

SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS

US ARMY 50%; 50% N021084 001 Feb 17, 2000

PERGOLIDE MESYLATE

TABLET; ORAL

PERGOLIDE MESYLATE

IVAX SUB TEVA PHARMS EQ 0.05MG BASE A076094 001 Sep 04, 2003

EQ 0.25MG BASE A076094 002 Sep 04, 2003

EQ 1MG BASE A076094 003 Sep 04, 2003

PAR PHARM EQ 0.05MG BASE A076061 001 Nov 27, 2002

EQ 0.25MG BASE A076061 002 Nov 27, 2002

EQ 1MG BASE A076061 003 Nov 27, 2002

PERMAX

VALEANT PHARM INTL EQ 0.05MG BASE N019385 001 Dec 30, 1988

EQ 0.25MG BASE N019385 002 Dec 30, 1988

EQ 1MG BASE N019385 003 Dec 30, 1988

PERINDOPRIL ERBUMINE

TABLET; ORAL

PERINDOPRIL ERBUMINE

LUPIN LTD 2MG A078263 001 Jan 27, 2010

4MG A078263 002 Jan 27, 2010

8MG A078263 003 Jan 27, 2010

PERMETHRIN

LOTION; TOPICAL

NIX

GLAXOSMITHKLINE 1% N019435 001 Mar 31, 1986

PERPHENAZINE

CONCENTRATE; ORAL

PERPHENAZINE

PHARM ASSOC 16MG/5ML A040360 001 May 25, 2001

TRILAFON

SCHERING 16MG/5ML N011557 001

INJECTABLE; INJECTION

TRILAFON

SCHERING 5MG/ML N011213 002

SYRUP; ORAL

TRILAFON

SCHERING 2MG/5ML N011294 002

TABLET; ORAL

PERPHENAZINE

ANI PHARMS INC 2MG A089707 001 Sep 10, 1987

8MG A089456 001 Sep 10, 1987

16MG A089457 001 Sep 10, 1987

TEVA PHARMS USA 4MG A089708 001 Sep 10, 1987

TRILAFON

SCHERING 2MG **Federal Register determination N010775 001

DISCONTINUED DRUG PRODUCT LIST

PERPHENAZINE

TABLET; ORAL

TRILAFON

that product was not discontinued or
withdrawn for safety or efficacy
reasons**

4MG **Federal Register determination N010775 002

that product was not discontinued or
withdrawn for safety or efficacy
reasons**

8MG **Federal Register determination N010775 003

that product was not discontinued or
withdrawn for safety or efficacy
reasons**

16MG **Federal Register determination N010775 004

that product was not discontinued or
withdrawn for safety or efficacy
reasons**

TABLET, EXTENDED RELEASE; ORAL

TRILAFON

SCHERING

8MG

N011361 002

PHENACEMIDE

TABLET; ORAL

PHENURONE

ABBVIE

500MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N007707 001

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE

TABLET; ORAL

AZO GANTANOL

ROCHE

100MG; 500MG **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N013294 001 Sep 10, 1987

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PHENAZOPYRIDINE HYDROCHLORIDE

ABLE

200MG, N/A, N/A, N/A, 800MG, 160MG

N021105 001 Jun 26, 2001

PHENAZOPYRIDINE HYDROCHLORIDE; SULFISOXAZOLE

TABLET; ORAL

AZO GANTRISIN

ROCHE

50MG; 500MG **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N019358 001 Aug 31, 1990

PHENDIMETRAZINE TARTRATE

CAPSULE; ORAL

PHENAZINE

MAST MM

35MG

A086523 001

35MG

A086524 001

35MG

A086525 001

PHENDIMETRAZINE TARTRATE

SANDOZ

35MG

A085633 001

35MG

A085694 001

35MG

A085695 001

35MG

A085702 001

VITARINE

35MG

A085634 001

35MG

A085645 001

35MG

A085670 001

35MG

A086403 001

35MG

A086408 001

35MG

A086410 001

35MG

A087424 001

SPRX-3

SOLVAY

35MG

A085897 001

STATOBEX

TEVA

35MG

A085507 001

X-TROZINE

SHIRE RICHWOOD

35MG

A087394 001 Sep 22, 1982

DISCONTINUED DRUG PRODUCT LIST

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

BONTRIL				
VALEANT	105MG	A088021	001	Sep 21, 1982
MELFIAT-105				
NUMARK	105MG	A087487	001	Oct 13, 1982
PHENDIMETRAZINE TARTRATE				
GRAHAM DM	105MG	A087214	001	May 26, 1982
	105MG	A088020	001	Aug 16, 1982
	105MG	A088028	001	Aug 16, 1982
	105MG	A088062	001	Sep 13, 1982
	105MG	A088063	001	Sep 10, 1982
	105MG	A088111	001	Oct 18, 1982
SANDOZ	105MG	A087378	001	
SPRX-105				
NUMARK	105MG	A088024	001	Dec 22, 1982
X-TROZINE L.A.				
SHIRE RICHWOOD	105MG	A087371	001	Aug 24, 1982
TABLET;ORAL				
ADPHEN				
FERNDALE LABS	35MG	A083655	001	
ALPHAZINE				
SANDOZ	35MG	A085034	001	
CAM-METRAZINE				
ABC HOLDING	35MG	A085511	001	
CAMALL	35MG	A085756	001	
TG UNITED LABS	35MG	A083922	001	
	35MG	A085318	001	
	35MG	A085320	001	
	35MG	A085321	001	
DI-METREX				
PVT FORM	35MG	A085698	001	
MELFIAT				
NUMARK	35MG	A083790	002	
METRA				
FOREST PHARMS	35MG	A083754	001	
PHENAZINE				
MAST MM	35MG	A087305	001	
PHENAZINE-35				
ABC HOLDING	35MG	A085512	001	
PHENDIMETRAZINE TARTRATE				
BARR	35MG	A083644	001	
	35MG	A083684	001	
	35MG	A083686	001	
	35MG	A083687	001	
	35MG	A084831	001	
	35MG	A084834	001	
	35MG	A084835	001	
FERNDALE LABS	35MG	A086834	001	Sep 15, 1983
INWOOD LABS	35MG	A084740	001	
	35MG	A084741	001	
	35MG	A084742	001	
	35MG	A084743	001	
IVAX PHARMS	35MG	A085611	001	
	35MG	A085612	001	
IVAX SUB TEVA PHARMS	35MG	A083682	001	
KV PHARM	35MG	A084138	001	
	35MG	A084141	001	
	35MG	A085525	001	
MFG CHEMISTS	35MG	A085914	001	
NEXGEN PHARMA INC	35MG	A086020	001	
NUMARK	35MG	A083790	001	
PVT FORM	35MG	A085199	001	
	35MG	A085697	001	
SANDOZ	35MG	A085402	001	
	35MG	A085497	001	
	35MG	A085830	001	
	35MG	A086365	001	
	35MG	A086370	001	
SOLVAY	35MG	A083993	001	
TG UNITED LABS	35MG	A085761	001	
	35MG	A085941	001	Jun 27, 1983

DISCONTINUED DRUG PRODUCT LIST

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

PHENDIMETRAZINE TARTRATE

USL PHARMA	35MG	A083805	001
	35MG	A084398	001
	35MG	A084399	001
VITARINE	35MG	A085519	001
	35MG	A086005	001
	35MG	A086106	001
WATSON LABS	35MG	A085767	001
	35MG	A085768	001
	35MG	A085770	001
	35MG	A085773	001
PLEGINE			
WYETH AYERST	35MG	N012248	001
STATOBEX			
TEVA	35MG	A086013	001
STATOBEX-G			
TEVA	35MG	A085095	001
X-TROZINE			
SHIRE RICHWOOD	35MG	A086550	001
	35MG	A086551	001
	35MG	A086552	001
	35MG	A086553	001
	35MG	A086554	001

PHENINDIONE

TABLET; ORAL

HEDULIN

SANOFI AVENTIS US	50MG	N008767	002
-------------------	------	---------	-----

PHENMETRAZINE HYDROCHLORIDE

TABLET; ORAL

PRELUDIN

BOEHRINGER INGELHEIM	25MG	N010460	005
----------------------	------	---------	-----

TABLET, EXTENDED RELEASE; ORAL

PRELUDIN

BOEHRINGER INGELHEIM	50MG	N011752	004
	75MG	N011752	003

PHENPROCOUMON

TABLET; ORAL

LIQUAMAR

ORGANON USA INC	3MG	N011228	001
-----------------	-----	---------	-----

PHENSUXIMIDE

CAPSULE; ORAL

MILONTIN

PARKE DAVIS	500MG	N008855	004
-------------	-------	---------	-----

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

FASTIN

GLAXOSMITHKLINE	30MG	N017352	001
-----------------	------	---------	-----

OBESTIN-30

FERNDAL LABS	30MG	A087144	001
--------------	------	---------	-----

OBY-TRIM

SHIRE RICHWOOD	30MG	A087764	001 Mar 18, 1982
----------------	------	---------	------------------

ONA-MAST

MAST MM	30MG	A086511	001
---------	------	---------	-----

	30MG	A086516	001
--	------	---------	-----

PHENTERMINE HYDROCHLORIDE

ABC HOLDING	30MG	A085411	001
-------------	------	---------	-----

ABLE	15MG	A040497	001 Mar 13, 2003
------	------	---------	------------------

	30MG	A040403	001 Aug 30, 2001
--	------	---------	------------------

	30MG	A040427	001 Aug 30, 2001
--	------	---------	------------------

CAMALL	15MG	A086735	001
--------	------	---------	-----

	30MG	A087226	001
--	------	---------	-----

DURAMED PHARMS BARR	30MG	A088948	001 Apr 25, 1986
---------------------	------	---------	------------------

IVAX PHARMS	30MG	A086329	001
-------------	------	---------	-----

MIKAH PHARMA	15MG	A040460	001 Jan 14, 2003
--------------	------	---------	------------------

	30MG	A040227	001 Jun 18, 1997
--	------	---------	------------------

	30MG	A040448	001 Jan 22, 2003
--	------	---------	------------------

SANDOZ	30MG	A087208	001
--------	------	---------	-----

	30MG	A087223	001
--	------	---------	-----

DISCONTINUED DRUG PRODUCT LIST

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

	37.5MG	A088414 001	Oct 19, 1983
SUN PHARM INDS	37.5MG	A040527 001	Oct 23, 2003
TEVA	30MG	A086911 001	
	30MG	A087126 001	
	30MG	A087777 001	Nov 01, 1985
	30MG	A088612 001	Apr 04, 1984
	30MG	A088613 001	Apr 09, 1984
	30MG	A088614 001	Apr 09, 1984
TG UNITED INC	30MG	A040083 001	Mar 07, 1997
TG UNITED LABS	18.75MG	A088576 001	May 23, 1984
	30MG	A085417 001	
	30MG	A086732 002	
	30MG	A087215 001	
	37.5MG	A087915 001	Dec 22, 1983
	37.5MG	A087918 001	Dec 22, 1983
	37.5MG	A087930 001	Oct 14, 1983
	37.5MG	A088610 001	Jun 04, 1984
	37.5MG	A088611 001	Jun 04, 1984
	37.5MG	A088625 001	Aug 23, 1984
USL PHARMA	30MG	A084487 001	Apr 09, 1982
	30MG	A088430 001	Mar 27, 1984
	30MG	A088797 001	Dec 10, 1984
VITARINE	30MG	A087202 001	
	30MG	A087235 001	
WATSON LABS	30MG	A086740 001	Mar 21, 1985

TABLET; ORAL

ONA-MAST

MAST MM	8MG	A086260 001	
---------	-----	-------------	--

PHENTERMINE HYDROCHLORIDE

ABLE	37.5MG	A040402 001	Aug 30, 2001
ACTAVIS ELIZABETH	37.5MG	A040276 001	Nov 25, 1998
IVAX PHARMS	8MG	A085553 001	
SANDOZ	8MG	A085671 001	
	8MG	A085689 001	
SANDOZ INC	30MG	A088605 001	Sep 28, 1987
TG UNITED LABS	8MG	A083923 001	
	8MG	A085319 001	
	37.5MG	A087805 001	Dec 06, 1982
	37.5MG	A088596 001	Apr 04, 1984
USL PHARMA	8MG	A083804 001	
	37.5MG	A088910 001	Jul 17, 1985
	37.5MG	A088917 001	Jul 17, 1985
VITARINE	8MG	A086453 001	
	8MG	A086456 001	
WATSON LABS	8MG	A085739 001	
TORA			
SOLVAY	8MG	A084035 001	
WILPO			
SANDOZ	8MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012737 001	

TABLET, ORALLY DISINTEGRATING; ORAL

SUPRENZA

CITIUS PHARMS	15MG	N202088 001	Jun 13, 2011
	30MG	N202088 002	Jun 13, 2011
	37.5MG	N202088 003	Mar 27, 2012

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

IONAMIN

UCB INC	EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011613 004	
	EQ 30MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011613 002	

PHENTERMINE RESIN 30

QUANTUM PHARMICS	EQ 30MG BASE	A089120 001	Feb 04, 1988
------------------	--------------	-------------	--------------

DISCONTINUED DRUG PRODUCT LISTPHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

PHENTERMINE RESIN COMPLEX

LANNETT HOLDINGS INC	EQ 15MG BASE	A040872	001	Jul 28, 2011
	EQ 30MG BASE	A040872	002	Jul 28, 2011

PHENYL AMINOSALICYLATE

POWDER; ORAL

PHENY-PAS-TEBAMIN

PHARM RES ASSOC	50%	N011695	002	
-----------------	-----	---------	-----	--

TABLET; ORAL

PHENY-PAS-TEBAMIN

PHARM RES ASSOC	500MG	N011695	003	
-----------------	-------	---------	-----	--

PHENYLBUTAZONE

CAPSULE; ORAL

AZOLID

SANOFI AVENTIS US	100MG	A087260	001	
-------------------	-------	---------	-----	--

BUTAZOLIDIN

NOVARTIS	100MG	N008319	009	
----------	-------	---------	-----	--

PHENYLBUTAZONE

IVAX PHARMS	100MG	A088218	001	Jun 24, 1983
-------------	-------	---------	-----	--------------

SANDOZ	100MG	A087774	001	Jun 16, 1982
--------	-------	---------	-----	--------------

SUN PHARM INDS	100MG	A088994	001	Dec 04, 1985
----------------	-------	---------	-----	--------------

WATSON LABS	100MG	A087756	001	Dec 17, 1982
-------------	-------	---------	-----	--------------

TABLET; ORAL

AZOLID

SANOFI AVENTIS US	100MG	A087091	001	
-------------------	-------	---------	-----	--

BUTAZOLIDIN

NOVARTIS	100MG	N008319	008	
----------	-------	---------	-----	--

PHENYLBUTAZONE

SANDOZ	100MG	A084339	001	
--------	-------	---------	-----	--

SUN PHARM INDS	100MG	A088863	001	Dec 04, 1985
----------------	-------	---------	-----	--------------

WATSON LABS	100MG	A086151	001	
-------------	-------	---------	-----	--

	100MG	A087674	001	Apr 21, 1982
--	-------	---------	-----	--------------

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENERGAN VC

ANI PHARMS	5MG/5ML; 6.25MG/5ML	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N008604	003	Apr 02, 1984
------------	---------------------	--	---------	-----	--------------

PHERAZINE VC

HALSEY	5MG/5ML; 6.25MG/5ML		A088868	001	Mar 02, 1987
--------	---------------------	--	---------	-----	--------------

PROMETHAZINE VC PLAIN

CENCI	5MG/5ML; 6.25MG/5ML		A088815	001	Nov 22, 1985
-------	---------------------	--	---------	-----	--------------

WOCKHARDT	5MG/5ML; 6.25MG/5ML		A088897	001	Jan 04, 1985
-----------	---------------------	--	---------	-----	--------------

PHENYLEPHRINE HYDROCHLORIDE; PYRILAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC

PREFRIN-A

ALLERGAN	0.12%; 0.1%		N007953	001	
----------	-------------	--	---------	-----	--

PHENYTOIN

SUSPENSION; ORAL

DILANTIN-30

PARKE DAVIS	30MG/5ML		N008762	002	
-------------	----------	--	---------	-----	--

PHENYTOIN

ACTAVIS MID ATLANTIC	125MG/5ML		A089892	001	Sep 25, 1992
----------------------	-----------	--	---------	-----	--------------

PHENYTOIN SODIUM

CAPSULE; ORAL

DIPHENYLAN SODIUM

LANNETT	30MG PROMPT		A080857	001	
---------	-------------	--	---------	-----	--

	100MG PROMPT		A080857	002	
--	--------------	--	---------	-----	--

EXTENDED PHENYTOIN SODIUM

ANI PHARMS INC	100MG EXTENDED		A040435	001	Jun 20, 2003
----------------	----------------	--	---------	-----	--------------

	100MG EXTENDED		A089441	001	Dec 18, 1986
--	----------------	--	---------	-----	--------------

WOCKHARDT	30MG EXTENDED		A040759	001	Dec 18, 2007
-----------	---------------	--	---------	-----	--------------

WOCKHARDT USA	100MG EXTENDED		A040732	001	Jan 30, 2008
---------------	----------------	--	---------	-----	--------------

PHENYTEX

WATSON LABS	100MG EXTENDED		A088711	001	Dec 21, 1984
-------------	----------------	--	---------	-----	--------------

PHENYTOIN SODIUM

PHARMERAL	100MG PROMPT		A085435	001	
-----------	--------------	--	---------	-----	--

WATSON LABS	100MG PROMPT		A085894	001	
-------------	--------------	--	---------	-----	--

DISCONTINUED DRUG PRODUCT LISTPHENYTOIN SODIUM

CAPSULE; ORAL

PROMPT PHENYTOIN SODIUM

ANI PHARMS INC	100MG PROMPT	A080259	001	
WATSON LABS	100MG PROMPT	A080905	001	

INJECTABLE; INJECTION

DILANTIN

PARKE DAVIS	50MG/ML	N010151	001	
-------------	---------	---------	-----	--

PHENYTOIN SODIUM

FRESENIUS KABI USA	50MG/ML	A089003	001	May 31, 1985
HOSPIRA	50MG/ML	A089744	001	Dec 18, 1987
MARSAM PHARMS LLC	50MG/ML	A089501	001	Oct 13, 1987
	50MG/ML	A089779	001	Nov 27, 1992
SMITH AND NEPHEW	50MG/ML	A088519	001	Dec 19, 1984
	50MG/ML	A088521	001	Dec 18, 1984
SOLOPAK	50MG/ML	A088520	001	Dec 17, 1984
WARNER CHILCOTT	50MG/ML	A089900	001	Mar 30, 1990
WATSON LABS	50MG/ML	A085434	001	

PHYTONADIONE

INJECTABLE; INJECTION

AQUAMEPHYTON

TELIGENT PHARMA INC	1MG/0.5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012223	002	
	10MG/ML ***Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012223	001	

KONAKION

ROCHE	1MG/0.5ML	N011745	001	
	10MG/ML	N011745	003	

PHYTONADIONE

GLAXOSMITHKLINE	1MG/0.5ML	A084060	001	
	10MG/ML	A084060	002	

VITAMIN K1

HOSPIRA	10MG/ML	A087956	001	Jul 25, 1983
---------	---------	---------	-----	--------------

PILOCARPINE

INSERT, EXTENDED RELEASE; OPHTHALMIC

OCUSERT PILO-20

AKORN	5MG	N017431	001	
-------	-----	---------	-----	--

OCUSERT PILO-40

AKORN	11MG	N017548	001	
-------	------	---------	-----	--

PILOCARPINE HYDROCHLORIDE

GEL; OPHTHALMIC

PILOPINE HS

ALCON	4%	N018796	001	Oct 01, 1984
-------	----	---------	-----	--------------

PINACIDIL

CAPSULE, EXTENDED RELEASE; ORAL

PINDAC

LEO PHARM	12.5MG	N019456	001	Dec 28, 1989
	25MG	N019456	002	Dec 28, 1989

PINDOLOL

TABLET; ORAL

PINDOLOL

G AND W LABS INC	5MG	A073661	001	Oct 31, 1993
	5MG	A073687	001	Feb 26, 1993
	5MG	A074123	001	Apr 17, 1997
	10MG	A073661	002	Oct 31, 1993
	10MG	A073687	002	Feb 26, 1993
	10MG	A074123	002	Apr 17, 1997
IDT AUSTRALIA LTD	5MG	A073608	001	Mar 29, 1993
	10MG	A073609	001	Mar 29, 1993
MYLAN PHARMS INC	5MG	A074013	001	Sep 24, 1992
	10MG	A074018	001	Sep 24, 1992
NOSTRUM LABS	5MG	A074474	001	Oct 28, 1996
	10MG	A074474	002	Oct 28, 1996
PUREPAC PHARM	5MG	A074125	001	Apr 28, 1993
	10MG	A074125	002	Apr 28, 1993
WATSON LABS	5MG	A074437	001	Feb 27, 1995
	10MG	A074437	002	Feb 27, 1995

DISCONTINUED DRUG PRODUCT LIST

PINDOLOL

TABLET; ORAL

VISKEN

NOVARTIS

5MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N018285 001 Sep 03, 1982

10MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N018285 002 Sep 03, 1982

PIPECURONIUM BROMIDE

INJECTABLE; INJECTION

ARDUAN

ORGANON USA INC

10MG/VIAL

N019638 001 Jun 26, 1990

PIPERACETAZINE

TABLET; ORAL

QUIDE

DOW PHARM

10MG

N013615 001

25MG

N013615 002

PIPERACILLIN SODIUM

INJECTABLE; INJECTION

PIPRACIL

WYETH PHARMS INC

EQ 2GM BASE/VIAL

A062750 001 Oct 13, 1987

EQ 2GM BASE/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N050545 002

EQ 3GM BASE/VIAL

A062750 002 Oct 13, 1987

EQ 3GM BASE/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N050545 003

EQ 4GM BASE/VIAL

A062750 003 Oct 13, 1987

EQ 4GM BASE/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N050545 004

EQ 40GM BASE/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N050545 006 Sep 30, 1985

PIPERAZINE CITRATE

SYRUP; ORAL

ANTEPAR

GLAXOSMITHKLINE

EQ 500MG BASE/5ML

N009102 001

BRYREL

SANOFI AVENTIS US

EQ 500MG BASE/5ML

N017796 001

MULTIFUGE

BLULINE

EQ 500MG BASE/5ML

N009452 001

PIPERAZINE CITRATE

ALPHARMA US PHARMS

EQ 500MG BASE/5ML

A080774 001

LANNETT

EQ 500MG BASE/5ML

A080963 001

LUITPOLD

EQ 500MG BASE/5ML

A080671 001

VERMIDOL

SOLVAY

EQ 500MG BASE/5ML

A080992 001

TABLET; ORAL

ANTEPAR

GLAXOSMITHKLINE

EQ 500MG BASE

N009102 003

PIPERAZINE CITRATE

IMPAX LABS

EQ 250MG BASE

A080874 001

PIPERONYL BUTOXIDE; PYRETHRINS

AEROSOL; TOPICAL

RID MOUSSE

BAYER HEALTHCARE LLC

4%;EQ 0.33% BASE

N021043 001 Mar 07, 2000

PIPOBROMAN

TABLET; ORAL

VERCYTE

ABBOTT

10MG

N016245 001

25MG

N016245 002

DISCONTINUED DRUG PRODUCT LIST

PIRBUTEROL ACETATE

AEROSOL, METERED; INHALATION

MAXAIR

MEDICIS	EQ 0.2MG BASE/INH	N020014	001	Nov 30, 1992
VALEANT PHARMS	EQ 0.2MG BASE/INH	N019009	001	Dec 30, 1986

PIROXICAM

CAPSULE; ORAL

PIROXICAM

CYCLE PHARMS LTD	10MG	A073651	001	Feb 26, 1993
	20MG	A073651	002	Feb 26, 1993
EGIS	10MG	A074808	001	Jul 08, 1997
	20MG	A074808	002	Jul 08, 1997
IVAX SUB TEVA PHARMS	10MG	A074148	001	Jun 03, 1996
	20MG	A074148	002	Jun 03, 1996
MYLAN	10MG	A074043	001	Sep 22, 1992
	20MG	A074043	002	Sep 22, 1992
SCS	10MG	A074036	001	May 29, 1992
	20MG	A074036	002	May 29, 1992
SUN PHARM INDS	20MG	A073536	001	Mar 12, 1993
TEVA	10MG	A073637	001	Jan 28, 1994
	20MG	A073638	001	Jan 28, 1994
TEVA PHARMS	10MG	A074103	001	Aug 28, 1992
	20MG	A074103	002	Aug 28, 1992
WATSON LABS	10MG	A074287	001	May 16, 1996
	10MG	A074460	001	Sep 29, 1995
	20MG	A074287	002	May 16, 1996
	20MG	A074460	002	Sep 29, 1995

PLICAMYCIN

INJECTABLE; INJECTION

MITHRACIN

PFIZER	2.5MG/VIAL	N050109	001	
--------	------------	---------	-----	--

POLYESTRADIOL PHOSPHATE

INJECTABLE; INJECTION

ESTRADURIN

WYETH AYERST	40MG/AMP	N010753	001	
--------------	----------	---------	-----	--

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

POLYETHYLENE GLYCOL 3350

PADDOCK LLC	17GM/SCOOPFUL	A090567	001	Oct 15, 2009
TEVA PHARMS	17GM/SCOOPFUL	A077445	001	May 04, 2006

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

CLENZ-LYTE

PADDOCK LLC	236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT	A090769	001	Jun 07, 2010
-------------	--	---------	-----	--------------

SOLUTION; ORAL

OCL

HOSPIRA	6GM/100ML; 75MG/100ML; 168MG/100ML; 146MG/100ML; 1.29GM/100ML	N019284	001	Apr 30, 1986
---------	---	---------	-----	--------------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATEANHYDROUS

FOR SOLUTION; ORAL

COLYTE

MEDA PHARMS	120GM/PACKET; 1.49GM/PACKET; 3.36GM/PACKET; 2.92GM/PACKET; 11.36GM/PACKET	N018983	005	Oct 26, 1984
	227.1GM/PACKET; 2.82GM/PACKET; 6.36GM/PACKET; 5.53GM/PACKET; 21.5GM/PACKET	N018983	004	Oct 26, 1984
	227.1GM/BOT; 2.82GM/BOT; 6.36GM/BOT; 5.53GM/BOT; 21.5GM/BOT	N018983	010	Jan 31, 1989
	240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT	N018983	007	Jun 12, 1987
	360GM/PACKET; 4.47GM/PACKET; 10.08GM/PACKET; 8.76GM/PACKET; 34.08GM/PACKET	N018983	006	Oct 26, 1984

COLYTE-FLAVORED

MEDA PHARMS	227.1GM/BOT; 2.82GM/BOT; 6.36GM/BOT; 5.53GM/BOT; 21.5GM/BOT	N018983	008	Nov 14, 1991
	240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT	N018983	009	Nov 14, 1991

POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES

PADDOCK LLC	240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT	A090712	001	Feb 25, 2010
-------------	--	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LISTPOLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SUSPENSION; ORAL

CO-LAV

VINTAGE PHARMS	240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT	A073428 001	Jan 28, 1992
----------------	--	-------------	--------------

COLOVAGE

DYNAPHARM	227.1GM/PACKET; 2.82GM/PACKET; 6.36GM/PACKET; 5.53GM/PACKET; 21.5GM/PACKET	A071320 001	Apr 20, 1988
-----------	--	-------------	--------------

E-Z-EM PREP LYTE

E Z EM	236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT	A071278 001	Nov 21, 1988
--------	--	-------------	--------------

GLYCOPREP

GOLDLINE	236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT	A072319 001	Dec 23, 1988
----------	--	-------------	--------------

GO-EVAC

VINTAGE PHARMS	236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT	A073433 001	Apr 28, 1992
----------------	--	-------------	--------------

PEG-LYTE

SANDOZ	236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT	A073098 001	Aug 31, 1993
--------	--	-------------	--------------

POLYMYXIN B SULFATE

INJECTABLE; INJECTION

AEROSPORIN

GLAXOSMITHKLINE	EQ 500,000 U BASE/VIAL	A062036 001	
-----------------	------------------------	-------------	--

POWDER; FOR RX COMPOUNDING

POLY-RX

X GEN PHARMS	100,000,000 UNITS/BOT	A061578 001	
--------------	-----------------------	-------------	--

POLYMYXIN B SULFATE

PADDOCK LLC	100,000,000 UNITS/BOT	A062455 001	Jul 27, 1983
-------------	-----------------------	-------------	--------------

POLYTHIAZIDE

TABLET; ORAL

RENESE

PFIZER	1MG	N012845 001	
	2MG	N012845 002	
	4MG	N012845 003	

POLYTHIAZIDE; PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

MINIZIDE

PFIZER	0.5MG; EQ 1MG BASE	N017986 001	
	0.5MG; EQ 2MG BASE	N017986 002	
	0.5MG; EQ 5MG BASE	N017986 003	

POLYTHIAZIDE; RESERPINE

TABLET; ORAL

RENESE-R

PFIZER	2MG; 0.25MG	N013636 001	
--------	-------------	-------------	--

POTASSIUM AMINOSALICYLATE

CAPSULE; ORAL

PASKALIUM

GLENWOOD	500MG	N009395 004	
----------	-------	-------------	--

POWDER; ORAL

POTASSIUM AMINOSALICYLATE

HEXCEL	100%	A080098 001	
--------	------	-------------	--

TABLET; ORAL

PASKALIUM

GLENWOOD	1GM	N009395 003	
----------	-----	-------------	--

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

K-LEASE

SAVAGE LABS	8MEQ	A073398 001	Jan 28, 1992
	10MEQ	A072427 001	Mar 28, 1990

POTASSIUM CHLORIDE

NESHER PHARMS	10MEQ	A070980 001	Feb 17, 1987
---------------	-------	-------------	--------------

TEVA	8MEQ	A073531 001	Apr 26, 1996
------	------	-------------	--------------

	10MEQ	A073532 001	Apr 26, 1996
--	-------	-------------	--------------

FOR SUSPENSION, EXTENDED RELEASE; ORAL

MICRO-K LS

KV PHARM	20MEQ/PACKET	N019561 003	Aug 26, 1988
----------	--------------	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE

ABRAXIS PHARM	2MEQ/ML	A080204	001	
	2MEQ/ML	A084290	001	
	2MEQ/ML	A086713	001	
	2MEQ/ML	A086714	001	
	2MEQ/ML	A087787	001	Apr 20, 1982
	2MEQ/ML	A087885	001	Feb 03, 1983
AKORN	2MEQ/ML	A088286	001	Sep 05, 1985
BAXTER HLTHCARE	2MEQ/ML	A080203	001	
FRESENIUS KABI USA	2MEQ/ML	A087817	001	Oct 20, 1982
GD SEARLE LLC	1MEQ/ML	A086219	001	
	2MEQ/ML	A086219	002	
	2MEQ/ML	A086220	002	
	3MEQ/ML	A086219	003	
	3MEQ/ML	A086220	001	
	4MEQ/ML	A086219	004	
HOSPIRA	1MEQ/ML	A080205	003	
	1MEQ/ML	A083345	003	
	1.5MEQ/ML	A083345	001	
	2MEQ/ML	A083345	002	
	2.4MEQ/ML	A080205	004	
	3.2MEQ/ML	A080205	005	
INTL MEDICATION	2MEQ/ML	A083163	001	
LILLY	2MEQ/ML	N007865	002	
LUITPOLD	2MEQ/ML	A080221	001	
	2MEQ/ML	A080736	001	
	2MEQ/ML	A087584	001	
	2MEQ/ML	A087585	001	
MILES	1MEQ/ML	A080195	002	
	2MEQ/ML	A080195	001	
	3MEQ/ML	A080195	003	
	4MEQ/ML	A080195	004	
PHARMA SERVE NY	2MEQ/ML	A086297	001	
	2MEQ/ML	A087362	001	Mar 08, 1983
WATSON LABS	2MEQ/ML	A086208	001	
	2MEQ/ML	A089163	001	Mar 10, 1988
	2MEQ/ML	A089421	001	Jan 02, 1987
	3MEQ/ML	A086210	001	

TABLET, EXTENDED RELEASE; ORAL

K+10

FUTURE PAK	10MEQ	A070999	001	Oct 22, 1987
------------	-------	---------	-----	--------------

K+8

FUTURE PAK	8MEQ	A070998	001	Jan 25, 1993
------------	------	---------	-----	--------------

KAON CL

SAVAGE LABS	6.7MEQ	N017046	001	
-------------	--------	---------	-----	--

KAON CL-10

SAVAGE LABS	10MEQ	N017046	002	
-------------	-------	---------	-----	--

KLOTRIX

APOTHECON	10MEQ	N017850	001	
-----------	-------	---------	-----	--

POTASSIUM CHLORIDE

COPLY PHARM	8MEQ	A070618	001	Sep 09, 1987
-------------	------	---------	-----	--------------

NESHER PHARMS	20MEQ	A076044	001	Apr 05, 2002
---------------	-------	---------	-----	--------------

SCHERING	10MEQ **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019439	002	Jun 13, 1986
----------	--	---------	-----	--------------

	20MEQ **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019439	001	Jun 13, 1986
--	--	---------	-----	--------------

SLOW-K

NOVARTIS	8MEQ	N017476	002	
----------	------	---------	-----	--

TEN-K

NOVARTIS	10MEQ	N019381	001	Apr 16, 1986
----------	-------	---------	-----	--------------

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN	37MG/100ML; 900MG/100ML	N019708	001	Sep 29, 1989
---------	-------------------------	---------	-----	--------------

POTASSIUM CHLORIDE 0.075% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN	75MG/100ML; 900MG/100ML	N019708	002	Sep 29, 1989
---------	-------------------------	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LISTPOTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	110MG/100ML; 900MG/100ML	N019708	003	Sep 29, 1989
POTASSIUM CHLORIDE 0.22% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	220MG/100ML; 900MG/100ML	N019708	005	Sep 29, 1989
POTASSIUM CHLORIDE 0.3% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	300MG/100ML; 900MG/100ML	N019708	006	Sep 29, 1989
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER				
B BRAUN	75MG/100ML; 900MG/100ML	N018722	001	Nov 09, 1982
BAXTER HLTHCARE	75MG/100ML; 900MG/100ML	N017648	004	
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER				
B BRAUN	150MG/100ML; 900MG/100ML	N018722	002	Nov 09, 1982
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER				
B BRAUN	220MG/100ML; 900MG/100ML	N018722	003	Nov 09, 1982
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
B BRAUN	300MG/100ML; 900MG/100ML	N018722	004	Nov 09, 1982

POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE

INJECTABLE; INJECTION

THAM-E

HOSPIRA	370MG/VIAL; 1.75GM/VIAL; 36GM/VIAL	N013025	001	
---------	------------------------------------	---------	-----	--

POTASSIUM CITRATE

FOR SOLUTION; ORAL

POTASSIUM CITRATE

UT SW MEDCTR

10MEQ/PACKET **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019647	002	Oct 13, 1988
20MEQ/PACKET **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019647	001	Oct 13, 1988

POTASSIUM IODIDE

SOLUTION; ORAL

POTASSIUM IODIDE

ROXANE

1GM/ML	N018551	001	Feb 19, 1982
--------	---------	-----	--------------

TABLET; ORAL

THYRO-BLOCK

MEDA PHARMS

130MG	N018307	001	
-------	---------	-----	--

POTASSIUM PERCHLORATE

CAPSULE; ORAL

PERCHLORACAP

MALLINCKRODT

200MG	N017551	001	
-------	---------	-----	--

POVIDONE-IODINE

SOLUTION; TOPICAL

E-Z PREP

CLINIPAD

10%	N019382	001	Jul 25, 1989
-----	---------	-----	--------------

SPONGE; TOPICAL

E-Z PREP

CLINIPAD

5%	N019382	002	Jul 25, 1989
----	---------	-----	--------------

E-Z PREP 220

CLINIPAD

5%	N019382	003	Jul 25, 1989
----	---------	-----	--------------

PRALIDOXIME CHLORIDE

INJECTABLE; INJECTION

PRALIDOXIME CHLORIDE

BAXTER HLTHCARE CORP

300MG/ML	N018799	001	Dec 13, 1982
----------	---------	-----	--------------

TABLET; ORAL

PROTOPAM CHLORIDE

WYETH AYERST

500MG	N014122	002	
-------	---------	-----	--

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

MIRAPEX

BOEHRINGER INGELHEIM

1.25MG	N020667	004	Jul 01, 1997
--------	---------	-----	--------------

PRAMIPEXOLE DIHYDROCHLORIDE

WATSON LABS

0.125MG	A078551	001	Oct 08, 2010
0.25MG	A078551	002	Oct 08, 2010
0.5MG	A078551	003	Oct 08, 2010
1MG	A078551	004	Oct 08, 2010
1.5MG	A078551	005	Oct 08, 2010

DISCONTINUED DRUG PRODUCT LISTPRAMLINTIDE ACETATE

INJECTABLE; SUBCUTANEOUS

SYMLIN

ASTRAZENECA AB	EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)	N021332 001	Mar 16, 2005
----------------	-------------------------------------	-------------	--------------

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVACHOL

BRISTOL MYERS SQUIBB	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019898 002	Oct 31, 1991
----------------------	---	-------------	--------------

PRAVASTATIN SODIUM

MYLAN

	10MG	A077013 001	Oct 23, 2006
	20MG	A077013 002	Oct 23, 2006
	40MG	A077013 003	Oct 23, 2006
	80MG	A077013 004	Dec 28, 2007

PLIVA HRVATSKA DOO

	10MG	A077730 001	Nov 21, 2006
	20MG	A077730 002	Nov 21, 2006
	30MG	A077730 003	Nov 21, 2006
	40MG	A077730 005	Nov 21, 2006

RANBAXY LABS LTD

	10MG	A076445 001	Apr 23, 2007
	20MG	A076445 002	Apr 23, 2007
	40MG	A076445 003	Apr 23, 2007
	80MG	A076445 004	Apr 23, 2007

PRAZEPAM

CAPSULE; ORAL

CENTRAX

PARKE DAVIS

	5MG	N018144 001	
	10MG	N018144 002	
	20MG	N018144 003	May 10, 1982

PRAZEPAM

USL PHARMA

	5MG	A070427 001	Nov 06, 1987
	10MG	A070428 001	Nov 06, 1987

TABLET; ORAL

CENTRAX

PARKE DAVIS

	10MG	N017415 001	
--	------	-------------	--

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

PRAZOSIN HYDROCHLORIDE

AM THERAP

	EQ 1MG BASE	A072782 001	May 16, 1989
	EQ 2MG BASE	A072783 001	May 16, 1989
	EQ 5MG BASE	A072784 001	May 16, 1989

DAVA PHARMS INC

	EQ 1MG BASE	A072705 001	May 16, 1989
	EQ 2MG BASE	A072706 001	May 16, 1989
	EQ 5MG BASE	A072707 001	May 16, 1989

IDT AUSTRALIA LTD

	EQ 1MG BASE	A072576 001	May 16, 1989
	EQ 2MG BASE	A072577 001	May 16, 1989
	EQ 5MG BASE	A072578 001	May 16, 1989

PUREPAC PHARM

	EQ 1MG BASE	A072991 001	May 16, 1989
	EQ 2MG BASE	A072921 001	May 16, 1989
	EQ 5MG BASE	A072992 001	May 16, 1989

WATSON LABS

	EQ 1MG BASE	A072352 001	May 16, 1989
	EQ 2MG BASE	A072333 001	May 16, 1989
	EQ 5MG BASE	A072609 001	May 16, 1989

TABLET, EXTENDED RELEASE; ORAL

MINIPRESS XL

PFIZER

	2.5MG	N019775 001	Jan 29, 1992
	5MG	N019775 002	Jan 29, 1992

PREDNISOLONE

CREAM; TOPICAL

METI-DERM

SCHERING

	0.5%	N010209 002	
--	------	-------------	--

SYRUP; ORAL

PREDNISOLONE

APOTEX INC

	5MG/5ML	A040570 001	Aug 25, 2005
	15MG/5ML	A040571 001	Aug 25, 2005

IVAX SUB TEVA PHARMS

	15MG/5ML	A040287 001	May 28, 1999
--	----------	-------------	--------------

NESHER PHARMS

	5MG/5ML	A040423 001	Oct 22, 2001
--	---------	-------------	--------------

	15MG/5ML	A040364 001	Apr 10, 2002
--	----------	-------------	--------------

TEVA PHARMS

	15MG/5ML	A040322 001	Jan 19, 2000
--	----------	-------------	--------------

WE PHARMS

	15MG/5ML	A040192 001	May 28, 1998
--	----------	-------------	--------------

DISCONTINUED DRUG PRODUCT LISTPREDNISOLONE

SYRUP; ORAL

PRELONE

MURO

5MG/5ML

A089654 001 Jan 17, 1989

TABLET; ORAL

CORTALONE

HALSEY

1MG

A080304 003

2.5MG

A080304 002

5MG

A080304 001

DELTA-CORTEF

PHARMACIA AND UPJOHN

5MG

N009987 004

FERNISOLONE-P

FERNDALE LABS

5MG

A083941 001

PREDNISOLONE

AUROLIFE PHARMA LLC

5MG

A084773 001

BARR

5MG

A084426 002

BUNDY

5MG

A083675 001

ELKINS SINN

5MG

A080625 001

EVERYLIFE

1MG

A084439 001

2.5MG

A084439 002

5MG

A084439 003

FERRANTE

2.5MG

A080562 001

5MG

A080562 002

HEATHER

5MG

A080326 001

IMPAX LABS

5MG

A080780 001

INWOOD LABS

5MG

A080748 001

IVAX SUB TEVA PHARMS

5MG

A080378 001

LANNETT

5MG

A080531 002

MARSHALL PHARMA

5MG

A080307 001

PANRAY

1MG

A080351 001

5MG

A080351 002

PERRIGO

5MG

A084542 001

PHOENIX LABS NY

5MG

A080322 001

PUREPAC PHARM

5MG

A080325 001

PVT FORM

5MG

A080211 001

ROXANE

5MG

A080327 002

SANDOZ

5MG

A080339 001

SPERTI

1MG

A080358 001

2.5MG

A080358 002

5MG

A080358 003

SUPERPHARM

5MG

A088892 001 Feb 26, 1985

TABLICAPS

5MG

A085170 001

TEVA

5MG

A080398 001

UDL

5MG

A087987 001 Jan 18, 1983

VALEANT PHARM INTL

5MG

A080236 001

VITARINE

5MG

A080534 001

WATSON LABS

5MG

A085085 002

5MG

A085415 001

5MG

A085416 001

WEST WARD

5MG

A080324 001

WHITEWORTH TOWN PLSN

5MG

A080342 001

STERANE

PFIZER

5MG

N009996 001

PREDNISOLONE ACETATE

INJECTABLE; INJECTION

METICORTEZONE

SCHERING

25MG/ML

N010255 002

PREDNISOLONE ACETATE

AKORN

25MG/ML

A083032 001

50MG/ML

A084492 001

BEL MAR

25MG/ML

A083738 001

50MG/ML

A083738 002

CENT PHARMS

25MG/ML

A084717 001

50MG/ML

A084717 002

WATSON LABS

25MG/ML

A083398 001

25MG/ML

A083654 001

40MG/ML

A083767 001

50MG/ML

A083764 001

50MG/ML

A085781 001

STERANE

PFIZER

25MG/ML

N011446 001

DISCONTINUED DRUG PRODUCT LISTPREDNISOLONE ACETATE

SUSPENSION; ORAL

FLO-PRED

TARO

EQ 5MG BASE/5ML

N022067 001 Jan 17, 2008

EQ 15MG BASE/5ML

N022067 002 Jan 17, 2008

SUSPENSION/DROPS; OPHTHALMIC

ECONOPRED

ALCON

0.125%

N017468 001

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

CETAPRED

ALCON

0.25%;10%

A087771 001 Aug 06, 1993

METIMYD

SCHERING

0.5%;10%

N010210 002 Sep 09, 1984

PREDSULFAIR

PHARMAFAIR

0.5%;10%

A088032 001 Apr 15, 1983

VASOCIDIN

NOVARTIS

0.5%;10%

A088791 001 Oct 05, 1984

SUSPENSION; OPHTHALMIC

ISOPTO CETAPRED

ALCON

0.25%;10%

A087547 001

SUSPENSION/DROPS; OPHTHALMIC

METIMYD

SCHERING

0.5%;10%

N010210 001

PREDAMIDE

AKORN

0.5%;10%

A088059 001 Jul 29, 1983

PREDSULFAIR

PHARMAFAIR

0.5%;10%

A088007 001 Apr 19, 1983

PREDSULFAIR II

PHARMAFAIR

0.2%;10%

A088837 001 Dec 24, 1985

SULPHRIN

BAUSCH AND LOMB

0.5%;10%

A088089 001 Dec 28, 1982

PREDNISOLONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

HYDELTRASOL

MERCK

EQ 20MG PHOSPHATE/ML

N011583 002

PREDNISOLONE SODIUM PHOSPHATE

WATSON LABS

EQ 20MG PHOSPHATE/ML

A080517 001

OINTMENT; OPHTHALMIC, OTIC

HYDELTRASOL

MERCK

EQ 0.25% PHOSPHATE

N011028 001

SOLUTION; ORAL

ORAPRED

CONCORDIA PHARMS INC

EQ 15MG BASE/5ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

A075117 001 Dec 14, 2000

PREDNISOLONE SODIUM PHOSPHATE

MEDICIS PHARMS

EQ 15MG BASE/5ML

A075250 001 Jul 12, 2002

NESHER PHARMS

EQ 5MG BASE/5ML

A076982 001 May 24, 2005

EQ 15MG BASE/5ML

A076988 001 May 24, 2005

PHARM ASSOC

EQ 5MG BASE/5ML

A076123 001 Dec 23, 2002

VINTAGE PHARMS

EQ 5MG BASE/5ML

A078416 001 Oct 31, 2007

WE PHARMS

EQ 5MG BASE/5ML

A075181 001 Dec 23, 2002

SOLUTION/DROPS; OPHTHALMIC

INFLAMASE FORTE

NOVARTIS

EQ 0.9% PHOSPHATE

A080751 002

INFLAMASE MILD

NOVARTIS

EQ 0.11% PHOSPHATE

A080751 001

METRETON

SCHERING

EQ 0.5% PHOSPHATE

A083834 001

PREDAIR

PHARMAFAIR

EQ 0.11% PHOSPHATE

A088415 001 Feb 29, 1984

PREDAIR FORTE

PHARMAFAIR

EQ 0.9% PHOSPHATE

A088165 001 Mar 28, 1983

PREDNISOLONE SODIUM PHOSPHATE

AKORN

EQ 0.11% PHOSPHATE

A083358 001

EQ 0.9% PHOSPHATE

A083358 002

ALCON PHARMS LTD

EQ 0.11% PHOSPHATE

A081043 001 Oct 24, 1991

EQ 0.9% PHOSPHATE

A081044 001 Oct 24, 1991

BAUSCH AND LOMB

EQ 0.11% PHOSPHATE

A040065 001 Jul 29, 1994

SOLA BARNES HIND

EQ 0.11% PHOSPHATE

A084171 001

DISCONTINUED DRUG PRODUCT LIST

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION/DROPS;OPHTHALMIC

PREDNISOLONE SODIUM PHOSPHATE

EQ 0.9% PHOSPHATE	A084168	001	
EQ 0.9% PHOSPHATE	A084169	001	
EQ 0.9% PHOSPHATE	A084172	001	

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC

SULSTER

AKORN	EQ 0.23% PHOSPHATE;10%	A074511	001	Jul 30, 1996
-------	------------------------	---------	-----	--------------

VASOCIDIN

NOVARTIS	EQ 0.23% PHOSPHATE;10% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018988	001	Aug 26, 1988
----------	---	---------	-----	--------------

PREDNISOLONE TEBUTATE

INJECTABLE; INJECTION

HYDELTRA-TBA

MERCK	20MG/ML	N010562	001	
-------	---------	---------	-----	--

PREDNISOLONE TEBUTATE

WATSON LABS	20MG/ML	A083362	001	Feb 17, 1984
-------------	---------	---------	-----	--------------

PREDNISONE

SOLUTION; ORAL

PREDNISONE

WOCKHARDT	5MG/5ML	A089726	001	Aug 02, 1988
-----------	---------	---------	-----	--------------

SYRUP; ORAL

LIQUID PRED

MURO	5MG/5ML	A087611	002	Sep 07, 1982
------	---------	---------	-----	--------------

TABLET; ORAL

CORTAN

HALSEY	20MG	A087480	001	
--------	------	---------	-----	--

DELTA-DOME

BAYER PHARMS	5MG	A080293	001	
--------------	-----	---------	-----	--

DELTASONE

PHARMACIA AND UPJOHN	2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009986	005	
	5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009986	002	
	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009986	006	
	20MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009986	007	
	50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009986	008	

FERNISONE

FERNDALE LABS	5MG	A083364	001	
---------------	-----	---------	-----	--

METICORTEN

SCHERING	1MG	N009766	002	
----------	-----	---------	-----	--

	5MG	N009766	001	
--	-----	---------	-----	--

ORASONE

SOLVAY	1MG	A083009	001	
	5MG	A083009	002	
	10MG	A083009	003	
	20MG	A083009	004	
	50MG	A085999	001	

PARACORT

PARKE DAVIS	5MG	N010962	002	
-------------	-----	---------	-----	--

PREDNICEN-M

SCHWARZ PHARMA	5MG	A084655	001	
----------------	-----	---------	-----	--

PREDNISONE

AM THERAP	5MG	A089387	001	Nov 06, 1986
	10MG	A089388	001	Nov 06, 1986
	20MG	A089389	001	Nov 06, 1986

DISCONTINUED DRUG PRODUCT LIST

PREDNISONE

TABLET; ORAL

PREDNISONE

AMNEAL PHARMS NY	5MG	A089597 001	Oct 05, 1987
	10MG	A089598 001	Oct 05, 1987
	20MG	A089599 001	Oct 05, 1987
AUROLIFE PHARMA LLC	5MG	A084774 001	
	10MG	A089983 001	Jan 12, 1989
	20MG	A085813 001	
	50MG	A089984 001	Jan 12, 1989
BUNDY	5MG	A083676 001	
DURAMED PHARMS BARR	5MG	A088394 001	Oct 04, 1983
	10MG	A088395 001	Oct 04, 1983
	20MG	A088396 001	Oct 04, 1983
ELKINS SINN	5MG	A080491 001	
	20MG	A085811 001	
EVERYLIFE	1MG	A084440 001	
	2.5MG	A084440 002	
	5MG	A084440 003	
FERRANTE	2.5MG	A080563 001	
	5MG	A080563 002	
HALSEY	5MG	A080300 001	
HEATHER	5MG	A080320 001	
	10MG	A084341 001	
	20MG	A084417 001	
	20MG	A085543 001	
	50MG	A086946 001	
HIKMA PHARMS	1MG	A040890 001	Nov 01, 2010
IMPAX LABS	5MG	A080782 001	
INWOOD LABS	1MG	A080328 001	
	2.5MG	A080306 001	
	5MG	A080279 001	
IVAX SUB TEVA PHARMS	5MG	A080283 001	
	10MG	A084133 001	
	20MG	A084134 001	
KV PHARM	5MG	A084236 001	
LANNETT	5MG	A080514 001	
	20MG	A084275 001	
LEDERLE	5MG	A086968 001	
MARSHALL PHARMA	5MG	A080301 001	
MUTUAL PHARM	5MG	A080701 001	
	10MG	A086595 001	
	20MG	A084634 001	
NYLOS	5MG	A085115 001	
PANRAY	1MG	A080350 001	
	2.5MG	A080350 002	
	5MG	A080350 003	
PERRIGO	5MG	A083059 001	
PHARMAVITE	5MG	A084662 002	
PHOENIX LABS NY	5MG	A080321 001	
	20MG	A083807 001	
PUREPAC PHARM	5MG	A080353 001	
	10MG	A086062 001	
	20MG	A086061 001	
PVT FORM	20MG	A085151 001	
REXALL	5MG	A080232 001	
ROXANE	20MG	N017109 001	
	25MG	A087833 001	May 04, 1982
SANDOZ	5MG	A080336 002	
SCHERER LABS	5MG	A080371 001	
SPERTI	1MG	A080359 001	
	2.5MG	A080359 002	
	5MG	A080359 003	
SUN PHARM INDS	50MG	A086596 001	
SUPERPHARM	5MG	A088865 001	Oct 25, 1984
	10MG	A088866 001	Oct 25, 1984
	20MG	A088867 001	Oct 25, 1984
TEVA	5MG	A080397 001	
UDL	5MG	A087984 001	Jan 18, 1983
	10MG	A087985 001	Jan 18, 1983
	20MG	A087986 001	Jan 18, 1983
UPSHER SMITH	5MG	A087471 001	

DISCONTINUED DRUG PRODUCT LIST

PREDNISONE

TABLET; ORAL

PREDNISONE

	20MG	A087470	001	
VALEANT PHARM INTL	5MG	A080237	001	
VANGARD	5MG	A087682	001	Jan 15, 1982
	20MG	A087701	001	Jan 15, 1982
VITARINE	5MG	A080334	001	
	5MG	A080506	001	
WATSON LABS	5MG	A085084	002	
	10MG	A087773	001	Jul 13, 1982
	20MG	A086813	001	
	50MG	A086867	001	
	50MG	A087772	001	Jul 13, 1982
WHITEWORTH TOWN PLSN	2.5MG	A084913	001	
	5MG	A080343	001	
	10MG	A089028	001	Jul 24, 1986
	20MG	A084913	002	
SERVISONE				
LEDERLE	5MG	A080223	001	

PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST

ASTRAZENECA	1% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N014763	004	
	2% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N014763	005	
	3% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N014763	003	
CITANEST PLAIN				
ASTRAZENECA	4% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N014763	007	
CITANEST PLAIN DENTAL				
DENTSPLY PHARM	4%	N021382	001	

PRIMIDONE

SUSPENSION; ORAL

MYSOLINE

NURO PHARMA	250MG/5ML	N010401	001	
-------------	-----------	---------	-----	--

TABLET; ORAL

PRIMIDONE

DR REDDYS LABS LTD	50MG	A040862	001	Oct 03, 2008
	250MG	A040862	002	Oct 03, 2008
HIKMA INTL PHARMS	50MG	A040667	001	Jul 27, 2006
IMPAX LABS	50MG	A040717	001	Feb 12, 2008
	250MG	A040717	002	Feb 12, 2008
WATSON LABS	250MG	A085052	001	

PROBENECID

TABLET; ORAL

BENEMID

MERCK	500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N007898	004	
PROBENECID				
IVAX SUB TEVA PHARMS	500MG	A083740	001	May 09, 1984
LEDERLE	500MG	A086917	001	
WATSON LABS	500MG	A086150	002	Apr 23, 1982

PROBUCOL

TABLET; ORAL

LORELCO

SANOFI AVENTIS US	250MG	N017535	001	
	500MG	N017535	002	Jul 06, 1988

DISCONTINUED DRUG PRODUCT LIST

PROCAINAMIDE HYDROCHLORIDE

CAPSULE; ORAL

PROCAINAMIDE HYDROCHLORIDE

ASCOT	250MG	A087542 001	Jan 08, 1982
	375MG	A087697 001	Mar 01, 1983
	500MG	A087543 001	Jan 08, 1982
IDT AUSTRALIA LTD	250MG	A089219 001	Jul 01, 1986
	375MG	A089220 001	Jul 01, 1986
	500MG	A089221 001	Jul 01, 1986
IVAX SUB TEVA PHARMS	250MG	A084604 001	
	375MG	A084595 001	
	500MG	A084606 001	
LANNETT	250MG	A083693 001	
	500MG	A084696 001	
LEDERLE	250MG	A086942 001	
	375MG	A086952 001	
	500MG	A086943 001	
ROXANE	250MG	A088989 001	Apr 26, 1985
	500MG	A088990 001	Apr 26, 1985
VANGARD	250MG	A087643 001	Jun 01, 1982
	500MG	A087875 001	Jun 01, 1982
WATSON LABS	250MG	A083287 001	
	250MG	A083795 001	
	250MG	A085167 001	
	375MG	A084403 001	
	375MG	A087020 001	
	500MG	A084280 001	
	500MG	A084357 001	
	500MG	A087021 001	
PROCAN			
PARKE DAVIS	250MG	A085804 001	
	375MG	A087502 001	
	500MG	A085079 001	
PROCAPAN			
PANRAY	250MG	A083553 002	
PRONESTYL			
APOTHECON	250MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N007335 001
	375MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N007335 004
	500MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N007335 003

INJECTABLE; INJECTION

PROCAINAMIDE HYDROCHLORIDE

ABRAXIS PHARM	100MG/ML	A089415 001	Nov 17, 1986
	500MG/ML	A089416 001	Nov 17, 1986
EUROHLTH INTL SARL	100MG/ML	A089029 001	Apr 17, 1986
	500MG/ML	A089030 001	Apr 17, 1986
HOSPIRA	500MG/ML	A089537 001	Aug 25, 1987
INTL MEDICATION	500MG/ML	A088637 001	Jul 31, 1984
PHARMAFAIR	100MG/ML	A088824 001	Nov 20, 1985
	500MG/ML	A088830 001	Nov 20, 1985
SMITH AND NEPHEW	100MG/ML	A088530 001	Mar 04, 1985
	500MG/ML	A088531 001	Mar 04, 1985
SOLOPAK	500MG/ML	A088532 001	Mar 04, 1985
WARNER CHILCOTT	100MG/ML	A089528 001	May 03, 1988
	500MG/ML	A089529 001	May 03, 1988
WATSON LABS	100MG/ML	A087079 001	
	500MG/ML	A087080 001	
PRONESTYL			
APOTHECON	100MG/ML	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N007335 002
	500MG/ML	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N007335 005

DISCONTINUED DRUG PRODUCT LISTPROCAINAMIDE HYDROCHLORIDE

TABLET; ORAL

PRONESTYL

APOTHECON	250MG	N017371 001
	375MG	N017371 002
	500MG	N017371 003

TABLET, EXTENDED RELEASE; ORAL

PROCAINAMIDE HYDROCHLORIDE

ANI PHARMS INC	250MG	A088958 001	Dec 02, 1985
	500MG	A088959 001	Dec 02, 1985
	500MG	A088974 001	Jul 22, 1985
	750MG	A089438 001	Mar 23, 1987
	1GM	A040111 001	Dec 13, 1996
IDT AUSTRALIA LTD	250MG	A089369 001	Aug 14, 1987
	500MG	A089370 001	Jan 09, 1987
	750MG	A089371 001	Aug 14, 1987
INWOOD LABS	500MG	A089840 001	Mar 06, 1989
SANDOZ	500MG	A089284 001	Jun 23, 1986
WATSON LABS	250MG	A088533 001	Dec 03, 1984
	250MG	A089026 001	Oct 22, 1985
	500MG	A088534 001	Dec 03, 1984
	500MG	A089027 001	Oct 22, 1985
	750MG	A088535 001	Nov 03, 1984
	750MG	A089042 001	Oct 22, 1985
	1GM	A089520 001	Jan 15, 1987

PROCAN SR

PARKE DAVIS	250MG	A086468 001	
PARKEDALE	500MG	A086065 001	
	750MG	A087510 001	Apr 01, 1982
	1GM	A088489 001	Jan 16, 1985

PROCANBID

KING PHARMS	500MG	N020545 001	Jan 31, 1996
	1GM	N020545 002	Jan 31, 1996

PRONESTYL-SR

APOTHECON	500MG	A087361 001
-----------	-------	-------------

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

NOVOCAIN

HOSPIRA	1%	A085362 003
	2%	A085362 004
	10%	A086797 001

PROCAINE HYDROCHLORIDE

ABRAXIS PHARM	1%	A080384 002
	1%	A080421 001
	2%	A080384 003
	2%	A080421 002
BEL MAR	1%	A080711 001
	2%	A080756 001
ELKINS SINN	1%	A083315 001
	2%	A083315 002
GD SEARLE LLC	1%	A086202 001
	2%	A086202 002
HOSPIRA	1%	A080416 001
	2%	A080416 002
MILES	1%	A080415 001
	2%	A080415 002
WATSON LABS	1%	A080658 001
	1%	A083535 001
	2%	A080658 002
	2%	A083535 002

PROCAINE HYDROCHLORIDE; TETRACYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION

ACHROMYCIN

LEDERLE	40MG/VIAL; 100MG/VIAL	N050276 001
	40MG/VIAL; 250MG/VIAL	N050276 003

TETRACYN

PFIZER	40MG/VIAL; 100MG/VIAL	A060285 002
	40MG/VIAL; 250MG/VIAL	A060285 003

DISCONTINUED DRUG PRODUCT LISTPROCAINE MERETHOXYLLINE; THEOPHYLLINE

INJECTABLE; INJECTION

DICURIN PROCAINE

LILLY

100MG/ML; 50MG/ML

N008869 001

PROCHLORPERAZINE

SUPPOSITORY; RECTAL

COMPAZINE

GLAXOSMITHKLINE

2.5MG

N011127 003

5MG

N011127 001

25MG

N011127 002

PROCHLORPERAZINE

ABLE

2.5MG

A040407 001 Jul 11, 2001

5MG

A040407 002 Jul 11, 2001

25MG

A040407 003 Jul 11, 2001

PROCHLORPERAZINE EDISYLATE

CONCENTRATE; ORAL

COMPAZINE

GLAXOSMITHKLINE

EQ 10MG BASE/ML

N011276 001

PROCHLORPERAZINE

ALPHARMA US PHARMS

EQ 10MG BASE/ML

A087153 001 Jun 08, 1982

PROCHLORPERAZINE EDISYLATE

MORTON GROVE

EQ 10MG BASE/ML

A088598 001 Oct 25, 1984

INJECTABLE; INJECTION

COMPAZINE

GLAXOSMITHKLINE

EQ 5MG BASE/ML

N010742 002

PROCHLORPERAZINE

BAXTER HLTHCARE

EQ 5MG BASE/ML

A087759 001 Oct 01, 1982

PROCHLORPERAZINE EDISYLATE

AMPHASTAR PHARMS INC

EQ 5MG BASE/ML

A040540 001 May 28, 2004

EUROHLTH INTL SARL

EQ 5MG BASE/ML

A089523 001 May 03, 1988

HOSPIRA

EQ 5MG BASE/ML

A089703 001 Apr 07, 1988

MARSAM PHARMS LLC

EQ 5MG BASE/ML

A089675 001 Dec 05, 1988

SMITH AND NEPHEW

EQ 5MG BASE/ML

A089251 001 Dec 04, 1986

TEVA PARENTERAL

EQ 5MG BASE/ML

A040505 001 May 30, 2003

WATSON LABS

EQ 5MG BASE/ML

A089530 001 Jul 08, 1987

EQ 5MG BASE/ML

A089605 001 Jul 08, 1987

EQ 5MG BASE/ML

A089606 001 Jul 08, 1987

WYETH AYERST

EQ 5MG BASE/ML

A086348 001

SYRUP; ORAL

COMPAZINE

GLAXOSMITHKLINE

EQ 5MG BASE/5ML

N011188 001

PROCHLORPERAZINE EDISYLATE

ALPHARMA US PHARMS

EQ 5MG BASE/5ML

A087154 001 Sep 01, 1982

MORTON GROVE

EQ 5MG BASE/5ML

A088597 001 Oct 25, 1984

PROCHLORPERAZINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

COMPAZINE

GLAXOSMITHKLINE

EQ 10MG BASE

N011000 001

EQ 10MG BASE

N021019 001 Oct 06, 1999

EQ 15MG BASE

N011000 002

EQ 15MG BASE

N021019 002 Oct 06, 1999

EQ 30MG BASE

N011000 003

EQ 75MG BASE

N011000 004

TABLET; ORAL

COMPAZINE

GLAXOSMITHKLINE

EQ 5MG BASE

N010571 001

EQ 10MG BASE

N010571 002

EQ 25MG BASE

N010571 003

PROCHLORPERAZINE

WATSON LABS

EQ 5MG BASE

A085580 001

EQ 10MG BASE

A085178 001

EQ 25MG BASE

A085579 001

PROCHLORPERAZINE MALEATE

DURAMED PHARMS BARR

EQ 5MG BASE

A040207 001 May 01, 1997

EQ 5MG BASE

A089484 001 Jan 20, 1987

EQ 10MG BASE

A040207 002 May 01, 1997

EQ 10MG BASE

A089485 001 Jan 20, 1987

EQ 25MG BASE

A089486 001 Jan 20, 1987

IVAX SUB TEVA PHARMS

EQ 5MG BASE

A040162 001 Jan 20, 1998

EQ 10MG BASE

A040162 002 Jan 20, 1998

SANDOZ

EQ 25MG BASE

A040101 003 Jul 19, 1996

DISCONTINUED DRUG PRODUCT LIST

PROCYCLIDINE HYDROCHLORIDE

TABLET; ORAL

KEMADRIN

MONARCH PHARMS

2MG

N009818 005

5MG

N009818 003

PROGESTERONE

CAPSULE; ORAL

PROMETRIUM

VIRTUS PHARMS

300MG

N019781 003 Oct 15, 1999

INJECTABLE; INJECTION

PROGESTERONE

LILLY

25MG/ML

N009238 002

50MG/ML

N009238 001

INSERT, EXTENDED RELEASE; INTRAUTERINE

PROGESTASERT

ALZA

38MG

N017553 001

PROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

SPARINE

WYETH AYERST

30MG/ML

N010942 001

100MG/ML

N010942 004

INJECTABLE; INJECTION

PROMAZINE HYDROCHLORIDE

WATSON LABS

25MG/ML

A084510 001

50MG/ML

A084517 001

SPARINE

BAXTER HLTHCARE CORP

25MG/ML

N010349 008

50MG/ML

N010349 006

SYRUP; ORAL

SPARINE

WYETH AYERST

10MG/5ML

N010942 003

TABLET; ORAL

SPARINE

WYETH AYERST

10MG

N010348 006

25MG

N010348 001

50MG

N010348 002

100MG

N010348 003

200MG

N010348 004

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PHENERGAN

WYETH AYERST

25MG/ML

N008857 002

50MG/ML

N008857 003

PROMETHAZINE HYDROCHLORIDE

ABBOTT

25MG/ML

A084223 001

50MG/ML

A084222 001

AKORN

25MG/ML

A083955 002

50MG/ML

A083955 001

BEDFORD LABS

25MG/ML

A040524 001 Mar 17, 2004

50MG/ML

A040524 002 Mar 17, 2004

HOSPIRA

25MG/ML

A040372 001 Jun 08, 2000

50MG/ML

A040372 002 Jun 08, 2000

50MG/ML

A083838 002

LUITPOLD

25MG/ML

A040515 001 Mar 19, 2003

MARSAM PHARMS LLC

25MG/ML

A089463 001 May 02, 1988

50MG/ML

A089477 001 May 02, 1988

MYLAN INSTITUTIONAL

25MG/ML

A040471 001 Nov 21, 2002

SANDOZ

25MG/ML

A040593 001 Nov 08, 2006

50MG/ML

A040593 002 Nov 08, 2006

TEVA PHARMS USA

25MG/ML **Federal Register

A040454 001 Aug 22, 2002

determination that product was not discontinued or withdrawn for safety or efficacy reasons**

50MG/ML **Federal Register

A040454 002 Aug 22, 2002

determination that product was not discontinued or withdrawn for safety or efficacy reasons**

WATSON LABS

25MG/ML

A083532 001

25MG/ML

A084591 001

50MG/ML

A080629 002

50MG/ML

A083532 002

WOCKHARDT

25MG/ML

A040785 001 Sep 26, 2008

DISCONTINUED DRUG PRODUCT LIST

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HYDROCHLORIDE

	50MG/ML	A040785 002	Sep 26, 2008
ZIPAN-25			
ALTANA	25MG/ML	A083997 001	
ZIPAN-50			
ALTANA	50MG/ML	A083997 002	

SUPPOSITORY; RECTAL

PHENERGAN

DELCOR ASSET CORP

	12.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N010926 002	
	25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N010926 001	
	50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011689 001	

PROMETHACON

POLYMEDICA

	25MG	A084901 001	
	50MG	A084902 001	

PROMETHAZINE HYDROCHLORIDE

ABLE

	12.5MG	A040504 001	Apr 11, 2003
	25MG	A040504 002	Apr 11, 2003
	50MG	A040449 001	Feb 27, 2003

SYRUP; ORAL

MYMETHAZINE FORTIS

USL PHARMA

	25MG/5ML	A087996 001	Jan 18, 1983
--	----------	-------------	--------------

PROMETH FORTIS

ALPHARMA US PHARMS

	25MG/5ML	A084772 001	
--	----------	-------------	--

PROMETH PLAIN

ACTAVIS MID ATLANTIC

	6.25MG/5ML	A085953 001	
--	------------	-------------	--

PROMETHAZINE

CENCI

	6.25MG/5ML	A089013 001	Sep 20, 1985
--	------------	-------------	--------------

PROMETHAZINE HYDROCHLORIDE

KV PHARM

	6.25MG/5ML	A085388 001	
	25MG/5ML	A085385 001	
	6.25MG/5ML	A087518 001	
	6.25MG/5ML	A086395 001	

PROMETHAZINE HYDROCHLORIDE PLAIN

ANI PHARMS

	6.25MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N008381 004	Apr 18, 1984
	25MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N008381 003	

TABLET; ORAL

PHENERGAN

DELCOR ASSET CORP

	12.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N007935 002	
	25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N007935 003	
	50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N007935 004	

PROMETHAZINE HYDROCHLORIDE

ABBOTT

	12.5MG	A084160 001	
	25MG	A084166 001	
	50MG	A084539 001	
ABLE	12.5MG	A040558 001	Jul 01, 2004
	25MG	A040558 002	Jul 01, 2004
	50MG	A040558 003	Jul 01, 2004
IMPAX LABS	12.5MG	A040724 001	Feb 12, 2008
	25MG	A040724 002	Feb 12, 2008
	25MG	A084214 002	Jul 07, 1982

DISCONTINUED DRUG PRODUCT LISTPROMETHAZINE HYDROCHLORIDE

TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE

	50MG	A040791 001	May 20, 2008
IVAX SUB TEVA PHARMS	12.5MG	A083604 001	
	25MG	A083603 001	
	50MG	A083613 001	
LANNETT	12.5MG	A080949 001	
	25MG	A080949 002	
	50MG	A080949 003	
PVT FORM	12.5MG	A083214 001	
	25MG	A083658 001	
SANDOZ	12.5MG	A084176 002	May 22, 2009
	12.5MG	A084233 001	
	25MG	A085146 001	
	50MG	A085146 002	
SUN PHARM INDS	12.5MG	A084555 001	
	25MG	A084554 001	
	50MG	A084557 001	
TABLICAPS	12.5MG	A084080 001	
	25MG	A084027 001	
TEVA	25MG	A089109 001	Sep 10, 1985
WATSON LABS	12.5MG	A083401 001	
	12.5MG	A083712 001	
	12.5MG	A085986 001	
	25MG	A083204 001	
	25MG	A085684 001	
	50MG	A083403 001	
	50MG	A085664 001	
REMSD			
BRISTOL MYERS SQUIBB	25MG	A083176 002	
	50MG	A083176 001	

PROPAFENONE HYDROCHLORIDE

TABLET; ORAL

PROPAFENONE HYDROCHLORIDE

NESHER PHARMS	150MG	A076193 001	Feb 07, 2002
	225MG	A076193 002	Feb 07, 2002
	300MG	A076193 003	Feb 07, 2002

PROPANTHELINE BROMIDE

INJECTABLE; INJECTION

PRO-BANTHINE

GD SEARLE LLC 30MG/VIAL N008843 001

TABLET; ORAL

PRO-BANTHINE

SHIRE 7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** N008732 003

15MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** N008732 002

PROPANTHELINE BROMIDE

ASCOT	15MG	A087663 001	Oct 25, 1982
HEATHER	15MG	A085780 001	
IMPAX LABS	15MG	A084541 002	
MYLAN	15MG	A083706 001	
PAR PHARM	15MG	A088377 001	Dec 08, 1983
PVT FORM	15MG	A080977 001	
SANDOZ	15MG	A080928 001	
TABLICAPS	15MG	A084428 001	
WATSON LABS	15MG	A083029 002	
	15MG	A083151 001	
WEST-WARD PHARMS INT	7.5MG	A080927 001	

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

KAINAIR

PHARMAFAIR 0.5% A088087 001 Jun 07, 1983

OPHTHAINE

APOTHECON 0.5% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy N008883 001

DISCONTINUED DRUG PRODUCT LIST

PROPARACAINE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
OPHTHAINEOPHTHETIC
reasons**ALLERGAN 0.5% **Federal Register determination N012583 001
that product was not discontinued or
withdrawn for safety or efficacy
reasons**PARACAINE
OPTOPICS 0.5% A087681 001 Aug 05, 1982
PROPARACAINE HYDROCHLORIDE
SOLA BARNES HIND 0.5% A084144 001
0.5% A084151 001PROPIOLACTONE

SOLUTION;IRRIGATION

BETAPRONE
FOREST LABS N/A N011657 001PROPIOMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

LARGON
EUROHLTH INTL SARL 20MG/ML N012382 002PROPOFOL

INJECTABLE; INJECTION

DIPRIVAN
FRESENIUS KABI USA 10MG/ML N019627 001 Oct 02, 1989
PROPOFOL
TEVA PARENTERAL 10MG/ML A075392 001 Sep 19, 2000
WEST-WARD PHARMS INT 10MG/ML A074848 001 Apr 19, 2005PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON
XANODYNE PHARM 32MG N010997 001
65MG N010997 003
DOLENE
HERITAGE PHARMS INC 65MG A080530 001
KESSO-GESIC
MK LABS 65MG A083544 001
PROPHENE 65
HALSEY 65MG A083538 002
PROPOXYPHENE HYDROCHLORIDE
ALRA 65MG A083184 001
IMPAX LABS 65MG A083317 001
IVAX SUB TEVA PHARMS 32MG A083597 001
MUTUAL PHARM 65MG A083186 001
MYLAN 32MG A083528 001
65MG A040569 001 Dec 16, 2004
65MG A083299 001
65MG A083185 001
NEXGEN PHARMA INC 65MG A080269 001
PAR PHARM 65MG A083278 001
PUREPAC PHARM 32MG A083464 001
PVT FORM 65MG A083113 001
ROXANE 32MG A083089 001
65MG A083089 002
SANDOZ 32MG A084014 001
65MG A083125 002
65MG A083688 001
65MG A083870 002
65MG A086495 001
TEVA 65MG A088615 001 Oct 22, 1984
VALEANT PHARM INTL 65MG A080783 001
VINTAGE PHARMS 65MG A040908 001 Jul 17, 2009
WATSON LABS 65MG A080908 002
65MG A085190 001
WEST WARD 65MG A083501 001
WHITEWORTH TOWN PLSN 65MG A084551 001
PROPOXYPHENE HYDROCHLORIDE 65
WARNER CHILCOTT 65MG A083786 001

DISCONTINUED DRUG PRODUCT LIST

PROPOXYPHENE NAPSYLATE

SUSPENSION; ORAL

DARVON-N

AAIPHARMA LLC 50MG/5ML N016861 001

TABLET; ORAL

DARVON-N

XANODYNE PHARM 100MG N016862 002

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPRANOLOL HYDROCHLORIDE

INWOOD LABS 60MG A072499 001 Apr 11, 1989

80MG A072500 001 Apr 11, 1989

120MG A072501 001 Apr 11, 1989

160MG A072502 001 Apr 11, 1989

CONCENTRATE; ORAL

PROPRANOLOL HYDROCHLORIDE INTENSOL

ROXANE 80MG/ML A071388 001 May 15, 1987

INJECTABLE; INJECTION

PROPRANOLOL HYDROCHLORIDE

SANDOZ 1MG/ML A076400 001 Feb 26, 2003

SMITH AND NEPHEW 1MG/ML A070135 001 Apr 15, 1986

1MG/ML A070137 001 Apr 15, 1986

SOLOPAK 1MG/ML A070136 001 Apr 15, 1986

SOLUTION; ORAL

PROPRANOLOL HYDROCHLORIDE

MORTON GROVE 20MG/5ML A071984 001 Mar 03, 1989

40MG/5ML A071985 001 Mar 03, 1989

SUSPENSION; ORAL

INDERAL

WYETH AYERST 10MG/ML N019536 001 Dec 12, 1986

TABLET; ORAL

INDERAL

WYETH PHARMS INC 10MG **Federal Register determination N016418 001

that product was not discontinued or
withdrawn for safety or efficacy
reasons**

20MG **Federal Register determination N016418 003

that product was not discontinued or
withdrawn for safety or efficacy
reasons**

40MG N016418 002

60MG **Federal Register determination N016418 009 Oct 18, 1982

that product was not discontinued or
withdrawn for safety or efficacy
reasons**

80MG **Federal Register determination N016418 004

that product was not discontinued or
withdrawn for safety or efficacy
reasons**

90MG **Federal Register determination N016418 010 Oct 18, 1982

that product was not discontinued or
withdrawn for safety or efficacy
reasons**

PROPRANOLOL HYDROCHLORIDE

ANI PHARMS INC 90MG A071977 001 Apr 06, 1988

DAVA PHARMS INC 10MG A070125 001 Jul 30, 1985

20MG A070126 001 Jul 30, 1985

40MG A070127 001 Jul 30, 1985

60MG A071495 001 Dec 31, 1987

80MG A070128 001 Jul 30, 1985

90MG A071496 001 Dec 31, 1987

DURAMED PHARMS BARR 10MG A070306 001 Sep 09, 1985

20MG A070307 001 Sep 09, 1985

40MG A070308 001 Sep 09, 1985

60MG A070309 001 Oct 01, 1986

80MG A070310 001 Sep 09, 1985

90MG A071327 001 Oct 01, 1986

FRONTIDA BIOPHARM 10MG A070319 001 Oct 22, 1985

20MG A070320 001 Oct 22, 1985

40MG A070103 001 Oct 22, 1985

60MG A070321 001 Sep 24, 1986

80MG A070322 001 Aug 04, 1986

INTERPHARM 10MG A071368 001 May 05, 1987

20MG A071369 001 May 05, 1987

DISCONTINUED DRUG PRODUCT LISTPROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

	40MG	A071370	001	May 05, 1987
	80MG	A071371	001	May 05, 1987
IVAX SUB TEVA PHARMS	10MG	A072063	001	Jul 29, 1988
	20MG	A072066	001	Jul 29, 1988
	40MG	A072067	001	Jul 29, 1988
	60MG	A072068	001	Jul 29, 1988
	80MG	A072069	001	Jul 29, 1988
LEDERLE	10MG	A072117	001	Jun 23, 1988
	20MG	A072118	001	Jun 23, 1988
	40MG	A072119	001	Jun 23, 1988
	80MG	A072120	001	Jun 23, 1988
MYLAN	60MG	A072275	001	Jun 09, 1989
PAR PHARM	90MG	A071288	001	Oct 22, 1986
PUREPAC PHARM	10MG	A070814	001	Nov 03, 1986
	20MG	A070815	001	Nov 03, 1986
	40MG	A070816	001	Nov 03, 1986
	60MG	A070817	001	Nov 03, 1986
	80MG	A070757	001	Nov 03, 1986
ROXANE	10MG	A070516	001	Jul 07, 1986
	20MG	A070517	001	Jul 07, 1986
	40MG	A070518	001	Jul 07, 1986
	60MG	A070519	001	Sep 24, 1986
	80MG	A070520	001	Jul 07, 1986
	90MG	A070521	001	Sep 24, 1986
SANDOZ	10MG	A070663	001	Jun 13, 1986
	10MG	A071658	001	Jul 05, 1988
	20MG	A070664	001	Jun 13, 1986
	20MG	A071687	001	Jul 05, 1988
	40MG	A070665	001	Jun 13, 1986
	40MG	A071688	001	Jul 05, 1988
	60MG	A070666	001	Oct 10, 1986
	60MG	A072197	001	Jul 05, 1988
	80MG	A070667	001	Jun 13, 1986
	80MG	A071689	001	Jul 05, 1988
	90MG	A072198	001	Jul 05, 1988
SCHERING	10MG	A070120	001	Aug 06, 1985
	20MG	A070121	001	Aug 06, 1985
	40MG	A070122	001	Aug 06, 1985
	60MG	A070123	001	Oct 29, 1986
	80MG	A070124	001	Aug 06, 1985
SUPERPHARM	10MG	A071515	001	Jun 08, 1988
	20MG	A071516	001	Jun 08, 1988
	40MG	A071517	001	Jun 08, 1988
	80MG	A071518	001	Jun 08, 1988
TEVA	10MG	A070232	001	Oct 07, 1987
	20MG	A070233	001	Jun 23, 1986
	40MG	A070234	001	Jun 23, 1986
WARNER CHILCOTT	10MG	A070438	001	Sep 15, 1986
	20MG	A070439	001	Sep 15, 1986
	40MG	A070440	001	Sep 15, 1986
	60MG	A070441	001	Sep 24, 1986
	80MG	A070442	001	Sep 15, 1986
WATSON LABS	10MG	A070140	001	Jul 30, 1985
	10MG	A070378	001	Mar 19, 1987
	10MG	A070548	001	Jul 10, 1986
	20MG	A070141	001	Jul 30, 1985
	20MG	A070379	001	Mar 19, 1987
	20MG	A070549	001	Apr 11, 1986
	40MG	A070142	001	Jul 30, 1985
	40MG	A070380	001	Mar 19, 1987
	40MG	A070550	001	Apr 11, 1986
	60MG	A070143	001	Jan 15, 1987
	60MG	A070381	001	Mar 19, 1987
	60MG	A071098	001	Oct 06, 1986
	60MG	A071791	001	Jul 15, 1987
	80MG	A070144	001	Jul 30, 1985
	80MG	A070382	001	Mar 19, 1987
	80MG	A070551	001	Jul 10, 1986
	90MG	A071183	001	Oct 06, 1986

DISCONTINUED DRUG PRODUCT LIST

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

90MG

A071792 001 Jul 15, 1987

PROPYLIODONE

SUSPENSION; INTRATRACHEAL

DIONOSIL AQUEOUS

GLAXOSMITHKLINE

50%

N009309 001

DIONOSIL OILY

GLAXOSMITHKLINE

60%

N009309 002

PROPYLTHIOURACIL

TABLET; ORAL

PROPYLTHIOURACIL

ABBOTT

50MG

A084075 001

ANABOLIC

50MG

A080285 001

ANI PHARMS INC

50MG

A080215 001

HALSEY

50MG

A080015 001

HIKMA INTL PHARMS

50MG

A080154 001

IMPAX LABS

50MG

A080159 001

LANNETT

50MG

A080016 001

LILLY

50MG

N006213 001

PERRIGO

50MG

A084543 001

SUN PHARM INDS

50MG

A083982 001

TABLICAPS

50MG

A080840 001

WATSON LABS

50MG

A080932 001

50MG

A085201 001

PROTAMINE SULFATE

INJECTABLE; INJECTION

PROTAMINE SULFATE

EUROHLTH INTL SARL

10MG/ML

A089474 001 Nov 05, 1986

10MG/ML

A089475 001 Nov 05, 1986

LILLY

10MG/ML **Federal Register

N006460 002

determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

PHARMACIA AND UPJOHN

50MG/VIAL

N007413 001

250MG/VIAL

N007413 002 Aug 02, 1984

PROTEIN HYDROLYSATE

INJECTABLE; INJECTION

AMINOSOL 5%

ABBVIE

5%

N005932 012 Jan 31, 1985

HYPROTIGEN 5%

B BRAUN

5%

N006170 003 Jan 10, 1984

PROTIRELIN

INJECTABLE; INJECTION

THYPINONE

ABBOTT

0.5MG/ML

N017638 001

THYREL TRH

FERRING

0.5MG/ML

N018087 001

PROTOKYLLOL HYDROCHLORIDE

TABLET; ORAL

VENTAIRE

SANOFI AVENTIS US

2MG

A083459 001

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

VIVACTIL

TEVA WOMENS

5MG

N016012 001

10MG

N016012 002

PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

NOVAFED

SANOFI AVENTIS US

120MG

N017603 001

SUDAFED 12 HOUR

GLAXOSMITHKLINE

120MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N017941 002

DISCONTINUED DRUG PRODUCT LISTPSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

ACTIFED

GLAXOSMITHKLINE 120MG;5MG N018996 001 Jun 17, 1985

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES

KV PHARM 120MG;5MG A071798 001 Mar 16, 1989

SYRUP;ORAL

ACTAHIST

CENCI 30MG/5ML;1.25MG/5ML A088344 001 Feb 09, 1984

HISTAFED

CENCI 30MG/5ML;1.25MG/5ML A088283 001 Apr 20, 1984

MYFED

USL PHARMA 30MG/5ML;1.25MG/5ML A088116 001 Mar 04, 1983

TRILITRON

NEWTRON PHARMS 30MG/5ML;1.25MG/5ML A088474 001 Feb 12, 1985

TABLET;ORAL

ALLERFED

PVT FORM 60MG;2.5MG A088860 001 Jan 31, 1985

CORPHED

SANDOZ 60MG;2.5MG A088602 001 Apr 11, 1985

PSEUDOEPHEDRINE HYDROCHLORIDE AND TRIPROLIDINE HYDROCHLORIDE

SANDOZ 60MG;2.5MG A088193 001 May 17, 1983

TRILITRON

NEWTRON PHARMS 60MG;2.5MG A088515 001 Jan 09, 1985

TRIPHED

TEVA 60MG;2.5MG A088630 001 May 17, 1984

TRIPROLIDINE AND PSEUDOEPHEDRINE

WATSON LABS 60MG;2.5MG A088318 002 Jan 13, 1984

WEST WARD 60MG;2.5MG A088117 001 Apr 19, 1983

TRIPROLIDINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

IVAX SUB TEVA PHARMS 60MG;2.5MG A085273 001 Dec 12, 1984

SUPERPHARM 60MG;2.5MG A088578 001 Feb 21, 1985

TABLET, EXTENDED RELEASE;ORAL

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES

KV PHARM 120MG;5MG A072758 001 Nov 25, 1991

PSEUDOEPHEDRINE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

PSEUDO-12

UCB INC EQ 60MG HCL/5ML N019401 001 Jun 19, 1987

PYRIDOSTIGMINE BROMIDE

TABLET;ORAL

PYRIDOSTIGMINE BROMIDE

ANI PHARMS INC 30MG A040512 002 Jul 20, 2005

60MG A040512 001 Oct 08, 2003

COREPHARMA 60MG A040457 001 Dec 26, 2002

SOLVAY 30MG A089572 001 Nov 27, 1990

US ARMY 30MG N020414 001 Feb 05, 2003

PYRIDOXINE HYDROCHLORIDE

INJECTABLE;INJECTION

HEXA-BETALIN

LILLY 100MG/ML A080854 001

PYRIDOXINE HYDROCHLORIDE

AKORN 100MG/ML A087967 001 Oct 01, 1982

BEL MAR 100MG/ML A080761 001

DELL LABS 50MG/ML A083771 001

100MG/ML A083772 001

ELKINS SINN 100MG/ML A080581 001

LUITPOLD 100MG/ML A080669 001

WATSON LABS 100MG/ML A080572 001

100MG/ML A083760 001

PYRILAMINE MALEATE

TABLET;ORAL

PYRILAMINE MALEATE

IMPAX LABS 25MG A080808 001

WATSON LABS 25MG A085231 001

DISCONTINUED DRUG PRODUCT LISTPYRIMETHAMINE; SULFADOXINE

TABLET; ORAL

FANSIDAR

ROCHE

25MG; 500MG

N018557 001

PYRITHIONE ZINC

LOTION; TOPICAL

HEAD & SHOULDERS CONDITIONER

WARNER CHILCOTT

0.3%

N019412 002 Mar 10, 1986

PYRVINIUM PAMOATE

SUSPENSION; ORAL

POVAN

PARKE DAVIS

EQ 50MG BASE/5ML

N011964 001

TABLET; ORAL

POVAN

PARKE DAVIS

EQ 50MG BASE

N012485 002

QUAZEPAM

TABLET; ORAL

DORAL

CUTIS HEALTH LLC

7.5MG

N018708 003 Feb 26, 1987

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

ACTAVIS GRP PTC

EQ 25MG BASE

A201762 001 Feb 27, 2013

EQ 50MG BASE

A201762 002 Feb 27, 2013

EQ 100MG BASE

A201762 003 Feb 27, 2013

EQ 150MG BASE

A201762 004 Feb 27, 2013

EQ 200MG BASE

A201762 005 Feb 27, 2013

EQ 300MG BASE

A201762 006 Feb 27, 2013

EQ 400MG BASE

A201762 007 Feb 27, 2013

SEROQUEL

ASTRAZENECA PHARMS

EQ 150MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020639 004 Dec 20, 1998

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

ACTAVIS ELIZABETH

EQ 5MG BASE

A076459 001 Dec 22, 2004

EQ 10MG BASE

A076459 002 Dec 22, 2004

EQ 20MG BASE

A076459 003 Dec 22, 2004

EQ 40MG BASE

A076459 004 Dec 22, 2004

ACTAVIS LABS FL INC

EQ 5MG BASE

A076049 001 Jan 14, 2005

EQ 10MG BASE

A076049 002 Jan 14, 2005

EQ 20MG BASE

A076049 003 Jan 14, 2005

EQ 40MG BASE

A076049 004 Jan 14, 2005

APOTEX INC

EQ 5MG BASE

A076240 001 Jan 26, 2006

EQ 10MG BASE

A076240 002 Jan 26, 2006

EQ 20MG BASE

A076240 003 Jan 26, 2006

EQ 40MG BASE

A076240 004 Jan 26, 2006

MYLAN

EQ 5MG BASE

A076036 001 Jan 28, 2005

EQ 10MG BASE

A076036 002 Jan 28, 2005

EQ 20MG BASE

A076036 003 Jan 28, 2005

EQ 40MG BASE

A076036 004 Jan 28, 2005

SANDOZ

EQ 5MG BASE

A076803 001 Mar 02, 2005

EQ 10MG BASE

A076803 002 Mar 02, 2005

EQ 20MG BASE

A076803 003 Mar 02, 2005

EQ 40MG BASE

A076803 004 Mar 02, 2005

QUINESTROL

TABLET; ORAL

ESTROVIS

PARKE DAVIS

0.1MG

N016768 002

0.2MG

N016768 003

QUINETHAZONE

TABLET; ORAL

HYDROMOX

LEDERLE

50MG

N013264 001

DISCONTINUED DRUG PRODUCT LISTQUINETHAZONE; RESERPINE

TABLET; ORAL

HYDROMOX R

LEDERLE

50MG; 0.125MG

N013927 001

QUINIDINE GLUCONATE

TABLET; ORAL

QUINACT

BAYER HLTHCARE

266MG

A085978 001

400MG

A086099 001

TABLET, EXTENDED RELEASE; ORAL

DURAQUIN

WARNER CHILCOTT

330MG

N017917 001

QUINAGLUTE

BAYER HLTHCARE

324MG

N016647 001

QUINALAN

LANNETT

324MG

A088081 001 Feb 10, 1986

QUINATIME

WATSON LABS

324MG

A087448 001

QUINIDINE GLUCONATE

ASCOT

324MG

A088582 001 Jun 17, 1985

AUROLIFE PHARMA LLC

324MG

A089894 001 Dec 15, 1988

CYCLE PHARMS LTD

324MG

A088431 001 Jan 06, 1984

HALSEY

324MG

A089476 001 Apr 10, 1987

SUPERPHARM

324MG

A089164 001 Nov 21, 1985

WATSON LABS

324MG

A087785 001 Jan 24, 1983

A087810 001 Sep 29, 1982

QUINIDINE POLYGALACTURONATE

TABLET; ORAL

CARDIOQUIN

PHARM RES ASSOC

275MG

N011642 002

QUINIDINE SULFATE

CAPSULE; ORAL

CIN-QUIN

SOLVAY

200MG

A085296 001

300MG

A085297 001

QUINIDINE SULFATE

LILLY

200MG

A085103 001

TABLET; ORAL

CIN-QUIN

SOLVAY

100MG

A085299 001

200MG

A084932 001

300MG

A085298 001

QUINIDINE SULFATE

BARR

200MG

A084177 001

CONTRACT PHARMACAL

200MG

A083808 001

CYCLE PHARMS LTD

200MG

A083640 001

300MG

A085632 001

DAVA PHARMS INC

200MG

A087011 001

ELKINS SINN

200MG

A083622 001

EVERYLIFE

200MG

A083439 001

HALSEY

200MG

A083583 001

HIKMA PHARMS LLC

200MG

A083862 001

IMPAX LABS

200MG

A083347 001

IVAX SUB TEVA PHARMS

200MG

A084549 001

KING PHARMS

200MG

A085175 001

KV PHARM

200MG

A085276 001

LANNETT

200MG

A083743 001

LEDERLE

200MG

A086176 001

LILLY

200MG

A085038 001

PERRIGO

200MG

A085322 001

PHARMAVITE

200MG

A084627 001

PUREPAC PHARM

200MG

A084003 001

SANDOZ

200MG

A084631 001

200MG

A084914 001

300MG

A089839 001 Sep 29, 1988

SCHERER LABS

200MG

A085068 001

SUN PHARM INDS

100MG

A081029 001 Apr 14, 1989

SUPERPHARM

200MG

A088973 001 Apr 10, 1985

USL PHARMA

200MG

A087837 001 Apr 14, 1982

VALEANT PHARM INTL

200MG

A083393 001

VANGARD

200MG

A087909 001 Jul 13, 1982

DISCONTINUED DRUG PRODUCT LISTQUINIDINE SULFATE

TABLET;ORAL

QUINIDINE SULFATE

VINTAGE PHARMS	200MG	A083963	001	
WARNER CHILCOTT	200MG	A083879	001	
WATSON LABS	100MG	A085584	001	
	200MG	A085140	002	
WHITEWORTH TOWN PLSN	200MG	A085444	001	

QUINORA

KEY PHARMS	200MG	A083576	001	
SCHERING	300MG	A085222	001	

TABLET, EXTENDED RELEASE;ORAL

QUINIDEX

WYETH PHARMS INC	300MG	N012796	002	
------------------	-------	---------	-----	--

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL

ACIPHEX

EISAI INC	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020973	001	May 29, 2002
-----------	---	---------	-----	--------------

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

ACTAVIS ELIZABETH	1.25MG	A077513	001	Jun 18, 2008
	2.5MG	A077513	002	Jun 18, 2008
	5MG	A077513	003	Jun 18, 2008
	10MG	A077513	004	Jun 18, 2008
CIPLA	1.25MG	A077004	001	Aug 07, 2008
	2.5MG	A077004	002	Aug 07, 2008
	5MG	A077004	003	Aug 07, 2008
	10MG	A077004	004	Aug 07, 2008
RANBAXY LABS LTD	5MG	A078849	001	Mar 06, 2009
	10MG	A078849	002	Mar 06, 2009
SANDOZ	1.25MG	A077514	001	Jun 18, 2008
	2.5MG	A077514	002	Jun 18, 2008
	5MG	A077514	003	Jun 18, 2008
	10MG	A077514	004	Jun 18, 2008

TABLET;ORAL

ALTACE

KING PFIZER	1.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N022021	001	Feb 27, 2007
	2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N022021	002	Feb 27, 2007
	5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N022021	003	Feb 27, 2007
	10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N022021	004	Feb 27, 2007

RAMIPRIL

MYLAN PHARMS INC	1.25MG	A090650	001	Jun 30, 2011
	2.5MG	A090650	002	Jun 30, 2011
	5MG	A090650	003	Jun 30, 2011
	10MG	A090650	004	Jun 30, 2011
ZYDUS PHARMS USA INC	1.25MG	A090697	001	Sep 24, 2009
	2.5MG	A090697	002	Sep 24, 2009
	5MG	A090697	003	Sep 24, 2009
	10MG	A090697	004	Sep 24, 2009

RANITIDINE BISMUTH CITRATE

TABLET;ORAL

TRITEC

GLAXOSMITHKLINE	400MG	N020559	001	Aug 08, 1996
-----------------	-------	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL

RANITIDINE HYDROCHLORIDE

MYLAN

EQ 150MG BASE

A075564 001 Oct 27, 2000

EQ 300MG BASE

A075564 002 Oct 27, 2000

TEVA

EQ 150MG BASE

A075557 001 Oct 31, 2003

EQ 300MG BASE

A075557 002 Oct 31, 2003

ZANTAC 150

GLAXOSMITHKLINE

EQ 150MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020095 001 Mar 08, 1994

ZANTAC 300

GLAXOSMITHKLINE

EQ 300MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020095 002 Mar 08, 1994

GRANULE, EFFERVESCENT; ORAL

ZANTAC 150

GLAXO GRP LTD

EQ 150MG BASE/PACKET

N020251 002 Mar 31, 1994

INJECTABLE; INJECTION

RANITIDINE HYDROCHLORIDE

BEDFORD

EQ 25MG BASE/ML

A074764 001 Nov 19, 2004

ZANTAC IN PLASTIC CONTAINER

IGI LABS INC

EQ 1MG BASE/ML

N019593 002 Sep 27, 1991

EQ 50MG BASE/100ML

N019593 001 Dec 17, 1986

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

APOTEX INC

EQ 15MG BASE/ML

A077602 001 Sep 17, 2007

RANBAXY

EQ 15MG BASE/ML

A078448 001 Dec 13, 2007

WOCKHARDT

EQ 15MG BASE/ML

A079211 001 May 26, 2009

EQ 15MG BASE/ML

A079212 001 Feb 23, 2009

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

BOEHRINGER INGELHEIM

EQ 150MG BASE

A074662 001 Aug 29, 1997

EQ 300MG BASE

A074662 002 Aug 29, 1997

MYLAN

EQ 150MG BASE

A074023 001 Aug 22, 1997

EQ 150MG BASE

A074552 001 Jul 30, 1998

EQ 300MG BASE

A074023 002 Aug 22, 1997

EQ 300MG BASE

A074552 002 Jul 30, 1998

RANBAXY

EQ 75MG BASE

A075254 001 Jan 14, 2000

EQ 150MG BASE

A075000 001 Jan 30, 1998

EQ 300MG BASE

A075000 002 Jan 30, 1998

SANDOZ

EQ 75MG BASE

A075519 001 Sep 26, 2002

SUN PHARM INDS LTD

EQ 75MG BASE

A075132 001 Jan 14, 2000

EQ 150MG BASE

A075439 001 Apr 19, 2000

EQ 300MG BASE

A075439 002 Apr 19, 2000

WATSON LABS

EQ 75MG BASE

A075212 001 Jan 14, 2000

EQ 150MG BASE

A074864 001 Oct 20, 1997

EQ 300MG BASE

A074864 002 Oct 20, 1997

WATSON LABS INC

EQ 150MG BASE

A077426 001 Dec 19, 2005

EQ 300MG BASE

A077426 002 Dec 19, 2005

WOCKHARDT

EQ 75MG BASE

A078884 001 Jul 31, 2008

EQ 150MG BASE

A078653 001 Nov 26, 2007

EQ 150MG BASE

A078701 001 Nov 12, 2009

EQ 300MG BASE

A078701 002 Dec 11, 2009

TABLET, EFFERVESCENT; ORAL

ZANTAC 150

GLAXO GRP LTD

EQ 150MG BASE

N020251 001 Mar 31, 1994

ZANTAC 25

GLAXO GRP LTD

EQ 25MG BASE

N020251 003 Apr 01, 2004

ZANTAC 75

BOEHRINGER INGELHEIM

EQ 75MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020745 001 Feb 26, 1998

RAPACURONIUM BROMIDE

INJECTABLE; INJECTION

RAPLON

ORGANON USA INC

100MG/VIAL

N020984 001 Aug 18, 1999

200MG/VIAL

N020984 002 Aug 18, 1999

DISCONTINUED DRUG PRODUCT LISTRAUWOLFIA SERPENTINA ROOT

TABLET; ORAL

HIWOLFIA

BOWMAN PHARMS	50MG	N009276 003
	50MG	N009276 005
	100MG	N009276 004

HYSERPIN

PHYS PRODS VA	50MG	N010581 001
---------------	------	-------------

KOGLUCOID

PANRAY	50MG	N009278 001
	100MG	N009278 002

RAUDIXIN

APOTHECON	50MG	N008842 001
	100MG	N008842 002

RAUSERPIN

FERNDALE LABS	50MG	N009926 002
	100MG	N009926 004

RAUVAL

PAL PAK	50MG	N009108 002
	100MG	N009108 004

RAUWOLFIA SERPENTINA

BUNDY	50MG	N009477 001
	100MG	N009477 002

HALSEY	50MG	A080498 001
	100MG	A080498 002

IMPAX LABS	50MG	N009273 001
	100MG	N009273 002

IVAX SUB TEVA PHARMS	50MG	N011521 001
	100MG	N011521 002

PUREPAC PHARM	50MG	A080842 001
	100MG	A080842 002

PVT FORM	50MG	A080583 001
	100MG	A080583 002

SOLVAY	50MG	A080500 001
	100MG	A080500 002

TABLICAPS	50MG	A083867 001
	100MG	A083444 001

VALEANT PHARM INTL	50MG	N009668 001
	100MG	N009668 002

WATSON LABS	50MG	A080907 001
	100MG	A080914 001

WOLFINA

FOREST PHARMS	50MG	N009255 008
	100MG	N009255 006

RESCINNAMINE

CAPSULE; ORAL

CINNASIL

PANRAY	0.5MG	A084736 001
--------	-------	-------------

TABLET; ORAL

MODERIL

PFIZER	0.25MG	N010686 003
	0.5MG	N010686 006

RESERPINE

ELIXIR; ORAL

SERPASIL

NOVARTIS	0.2MG/4ML	N009115 005
----------	-----------	-------------

INJECTABLE; INJECTION

SANDRIL

LILLY	2.5MG/ML	N010012 001
-------	----------	-------------

SERPASIL

NOVARTIS	2.5MG/ML	N009434 002
----------	----------	-------------

TABLET; ORAL

HISERPIA

BOWMAN PHARMS	0.1MG	N009631 002
	0.25MG	N009631 004

RAU-SED

BRISTOL MYERS SQUIBB	0.1MG	N009357 001
	0.25MG	N009357 004
	0.5MG	N009357 006
	1MG	N009357 008

DISCONTINUED DRUG PRODUCT LIST

RESERPINE

TABLET; ORAL

RESERPINE

BARR	0.25MG	A080721	002	
BELL PHARMA	0.1MG	A083058	001	
	0.25MG	A083058	002	
BUNDY	0.1MG	N009663	001	
	0.25MG	N009663	003	
CYCLE PHARMS LTD	0.1MG	N009859	001	
	0.25MG	N009859	002	
ELKINS SINN	0.1MG	A083145	001	
	0.25MG	A083145	002	
EVERYLIFE	0.1MG	N010441	001	
	0.25MG	N010441	002	
	0.5MG	N010441	003	
	1MG	N010441	004	
HALSEY	0.1MG	A080457	002	
	0.25MG	A080457	001	
	1MG	A080457	003	
HIKMA INTL PHARMS	0.1MG	A080975	001	
	0.25MG	A080975	002	
	1MG	A080975	003	
IMPAX LABS	0.1MG	N009627	001	
	0.25MG	N009627	002	
IVAX SUB TEVA PHARMS	0.1MG	N011185	001	
	0.25MG	N011185	002	
MARSHALL PHARMA	0.1MG	A080492	001	
	0.25MG	A080492	002	
MK LABS	0.1MG	A080525	002	
	0.25MG	A080525	001	
MYLAN	1MG	A084974	001	
PHARMAVITE	0.25MG	A084663	001	
PUREPAC PHARM	0.1MG	A080753	002	
	0.25MG	A080753	001	
PVT FORM	0.1MG	A086117	001	
	0.25MG	A080582	001	
	0.25MG	A085775	001	
	1MG	A080582	002	
REXALL	0.25MG	A080637	001	
SOLVAY	0.25MG	A080446	001	
TABLICAPS	0.25MG	A085207	001	
TEVA	0.1MG	A089020	001	Mar 07, 1985
	0.25MG	A089019	001	Mar 07, 1985
VALEANT PHARM INTL	0.1MG	N009667	001	
	0.25MG	N009667	002	
WATSON LABS	0.1MG	A080679	001	
	0.25MG	A080393	001	
	0.25MG	A085401	001	
	1MG	A080749	001	
WHITEWORTH TOWN PLSN	0.1MG	A080723	001	
	0.25MG	A080723	002	
	1MG	A080723	003	
SANDRIL				
LILLY	0.1MG	N009376	004	
	0.25MG	N009376	001	
SERPALAN				
LANNETT	0.1MG	N010124	001	
	0.25MG	N010124	002	
SERPANRAY				
PANRAY	0.1MG	N009391	001	
	0.25MG	N009391	002	
	1MG	N009391	004	
SERPASIL				
NOVARTIS	0.1MG	N009115	001	
	0.25MG	N009115	003	
	1MG	N009115	004	
SERPATE				
VALE	0.1MG	N009453	001	
	0.25MG	N009453	002	
SERPIVITE				
VITARINE	0.25MG	N009645	002	

DISCONTINUED DRUG PRODUCT LISTRESERPINE; TRICHLORMETHIAZIDE

TABLET; ORAL

METATENSIN #2

SANOFI AVENTIS US 0.1MG;2MG N012972 001

METATENSIN #4

SANOFI AVENTIS US 0.1MG;4MG N012972 002

NAQUIVAL

SCHERING 0.1MG;4MG N012265 003

TRICHLORMETHIAZIDE W/ RESERPINE

WATSON LABS 0.1MG;4MG A085248 001

RIBAVIRIN

CAPSULE; ORAL

REBETOL

MERCK SHARP DOHME 200MG**Indicated for use and comarketed with Interferon ALFA-2B, Recombinant (INTRON A), as Rebetrone Combination Therapy** N020903 001 Jun 03, 1998

TABLET; ORAL

COPEGUS

ROCHE 400MG N021511 002 Jun 21, 2005

RIMANTADINE HYDROCHLORIDE

SYRUP; ORAL

FLUMADINE

FOREST LABS 50MG/5ML N019650 001 Sep 17, 1993

TABLET; ORAL

RIMANTADINE HYDROCHLORIDE

ACTAVIS ELIZABETH 100MG A076375 001 Jan 14, 2003

COREPHARMA 100MG A075916 001 Nov 02, 2001

RIMEXOLONE

SUSPENSION/DROPS; OPHTHALMIC

VEXOL

ALCON 1% N020474 001 Dec 30, 1994

RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL

APIL 75MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** N020835 004 Apr 16, 2007

RISPERIDONE

SOLUTION; ORAL

RISPERIDONE

SILARX PHARMS INC 1MG/ML A202386 001 Jan 12, 2015

WOCKHARDT 1MG/ML A078744 001 Oct 08, 2009

TABLET; ORAL

RISPERDAL

JANSSEN PHARMS 5MG N020272 005 Dec 29, 1993

RISPERIDONE

CADISTA PHARMS 0.25MG A078828 001 Mar 23, 2009

0.5MG A078828 002 Mar 23, 2009

1MG A078828 003 Mar 23, 2009

2MG A078828 004 Mar 23, 2009

3MG A078828 005 Mar 23, 2009

4MG A078828 006 Mar 23, 2009

RATIOPHARM 0.25MG A077784 001 Jun 08, 2010

0.5MG A077784 002 Jun 08, 2010

1MG A077784 003 Jun 08, 2010

2MG A077784 004 Jun 08, 2010

3MG A077784 005 Jun 08, 2010

4MG A077784 006 Jun 08, 2010

SYNTHON PHARMS 0.25MG A078187 001 Oct 22, 2009

0.5MG A078187 002 Oct 22, 2009

1MG A078187 003 Oct 22, 2009

2MG A078187 004 Oct 22, 2009

3MG A078187 005 Oct 22, 2009

4MG A078187 006 Oct 22, 2009

WATSON LABS 0.25MG A077860 001 Dec 05, 2008

0.5MG A077860 002 Dec 05, 2008

1MG A077860 003 Dec 05, 2008

2MG A077860 004 Dec 05, 2008

3MG A077860 005 Dec 05, 2008

DISCONTINUED DRUG PRODUCT LIST

RISPERIDONE

TABLET; ORAL

RISPERIDONE

	4MG	A077860 006	Dec 05, 2008
WEST WARD PHARMS	0.25MG	A078740 001	May 29, 2009
	0.5MG	A078740 002	May 29, 2009
	1MG	A078740 003	May 29, 2009
	2MG	A078740 004	May 29, 2009
	3MG	A078740 005	May 29, 2009
	4MG	A078740 006	May 29, 2009

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION

RITODRINE HYDROCHLORIDE

ABRAXIS PHARM	10MG/ML	A071188 001	Jul 23, 1987
	15MG/ML	A071189 001	Jul 23, 1987
HOSPIRA	10MG/ML	A071618 001	Feb 28, 1991
	15MG/ML	A071619 001	Feb 28, 1991
RITODRINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER			
HOSPIRA	30MG/100ML	A071438 001	Jan 22, 1991
YUTOPAR			
ASTRAZENECA	10MG/ML	N018580 001	
	15MG/ML	N018580 002	

TABLET; ORAL

YUTOPAR

ASTRAZENECA	10MG	N018555 001	
-------------	------	-------------	--

RITONAVIR

CAPSULE; ORAL

NORVIR

ABBOTT	100MG	N020680 001	Mar 01, 1996
--------	-------	-------------	--------------

RIVASTIGMINE TARTRATE

SOLUTION; ORAL

EXELON

NOVARTIS	EQ 2MG BASE/ML	N021025 001	Apr 21, 2000
----------	----------------	-------------	--------------

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ZEMURON

ORGANON USA INC	50MG/5ML (10MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020214 001	Mar 17, 1994
	10MG/ML (10MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020214 002	Mar 17, 1994
	100MG/10ML (10MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020214 003	Mar 17, 1994

ROFECOXIB

SUSPENSION; ORAL

VIOXX

MERCK	12.5MG/5ML	N021052 001	May 20, 1999
	25MG/5ML	N021052 002	May 20, 1999

TABLET; ORAL

VIOXX

MERCK	12.5MG	N021042 001	May 20, 1999
	25MG	N021042 002	May 20, 1999
	50MG	N021042 003	Feb 25, 2000

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

COREPHARMA	EQ 0.25MG BASE	A078230 001	May 20, 2008
	EQ 0.5MG BASE	A078230 002	May 20, 2008
	EQ 1MG BASE	A078230 003	May 20, 2008
	EQ 2MG BASE	A078230 004	May 20, 2008
	EQ 3MG BASE	A078230 005	May 20, 2008
	EQ 4MG BASE	A078230 006	May 20, 2008
	EQ 5MG BASE	A078230 007	May 20, 2008

DISCONTINUED DRUG PRODUCT LISTROPINIROLE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
 REQIIP XL

GLAXOSMITHKLINE LLC	EQ 3MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N022008 002	Jun 13, 2008
---------------------	--	-------------	--------------

ROIIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION
 NAROPIN

FRESENIUS KABI USA	50MG/10ML (5MG/ML)	N020533 013	May 01, 1998
	75MG/10ML (7.5MG/ML)	N020533 012	Sep 24, 1996

ROSE BENGAL SODIUM I-131

INJECTABLE;INJECTION
 ROBENGATOPE

BRACCO	0.5mCi/VIAL	N016224 001	
	1mCi/VIAL	N016224 002	
	2mCi/VIAL	N016224 003	

SODIUM ROSE BENGAL I 131
 SORIN

0.5mCi/ML	N017318 001	
-----------	-------------	--

RUFINAMIDE

TABLET;ORAL
 BANZEL

EISAI INC	100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021911 001	Nov 14, 2008
-----------	--	-------------	--------------

SAFFLOWER OIL

INJECTABLE;INJECTION
 LIPOSYN 10%

ABBOTT	10% (10GM/100ML)	N018203 001	
--------	------------------	-------------	--

LIPOSYN 20%

ABBOTT	20% (20GM/100ML)	N018614 001	
--------	------------------	-------------	--

SAFFLOWER OIL; SOYBEAN OIL

INJECTABLE;INJECTION
 LIPOSYN II 10%

HOSPIRA	5%;5% (5GM/100ML)	N018997 001	Aug 27, 1984
---------	-------------------	-------------	--------------

LIPOSYN II 20%

HOSPIRA	10%;10% (10GM/100ML)	N018991 001	Aug 27, 1984
---------	----------------------	-------------	--------------

SALMETEROL XINAFOATE

AEROSOL, METERED;INHALATION
 SEREVENT

GLAXOSMITHKLINE	EQ 0.021MG BASE/INH	N020236 001	Feb 04, 1994
-----------------	---------------------	-------------	--------------

SAQUINAVIR

CAPSULE;ORAL
 FORTOVASE

HOFFMANN LA ROCHE	200MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020828 001	Nov 07, 1997
-------------------	--	-------------	--------------

SARALASIN ACETATE

INJECTABLE;INJECTION
 SARENIN

PROCTER AND GAMBLE	EQ 0.6MG BASE/ML	N018009 001	
--------------------	------------------	-------------	--

SECOBARBITAL SODIUM

CAPSULE;ORAL

SECOBARBITAL SODIUM

ANABOLIC	100MG	A084422 001	
BARR	100MG	A084225 001	
EVERYLIFE	100MG	A085895 001	
HALSEY	100MG	A084676 001	
IVAX PHARMS	100MG	A085869 001	
KV PHARM	100MG	A085285 001	
LANNETT	50MG	A085909 001	
	100MG	A085903 001	
PARKE DAVIS	100MG	A084762 001	
PERRIGO	100MG	A084561 001	
PUREPAC PHARM	100MG	A085867 001	
VALEANT PHARM INTL	100MG	A085477 001	

DISCONTINUED DRUG PRODUCT LISTSECOBARBITAL SODIUM

CAPSULE; ORAL

SECOBARBITAL SODIUM

VITARINE	100MG	A085898	001
	100MG	A086273	001
WATSON LABS	100MG	A085792	001
WEST WARD	100MG	A084926	001
WHITEWORTH TOWN PLSN	100MG	A085798	001
WYETH AYERST	100MG	A086390	001

INJECTABLE; INJECTION

SECOBARBITAL SODIUM

ELKINS SINN	100MG/VIAL	A083281	001
WYETH AYERST	50MG/ML	A083262	001

SECONAL SODIUM

LILLY	50MG/ML	N007392	002
-------	---------	---------	-----

SUPPOSITORY; RECTAL

SECONAL SODIUM

LILLY	30MG	A086530	001
	60MG	A086530	002
	120MG	A086530	003
	200MG	A086530	004

SECRETIN

INJECTABLE; INJECTION

SECRETIN-FERRING

FERRING	75CU/VIAL	N018290	001
---------	-----------	---------	-----

SECRETIN SYNTHETIC PORCINE

FOR SOLUTION; INTRAVENOUS

SECREFLO

CHIRHOCLIN	16MCG/VIAL	N021136	001	Apr 04, 2002
------------	------------	---------	-----	--------------

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL

SELEGILINE HYDROCHLORIDE

LANNETT HOLDINGS INC	5MG	A075145	001	Sep 15, 2003
----------------------	-----	---------	-----	--------------

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

DAVA PHARMS INC	5MG	A074641	001	Aug 02, 1996
G AND W LABS INC	5MG	A074537	001	Aug 02, 1996
	5MG	A074744	001	Jan 27, 1997
	5MG	A074756	001	Nov 25, 1998
SIEGFRIED	5MG	A074672	001	Apr 01, 1997
SOMERSET	5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019334	001	Jun 05, 1989
VINTAGE PHARMS LLC	5MG	A074565	001	Aug 02, 1996

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL

EXSEL

ALLERGAN HERBERT	2.5%	A083892	001
------------------	------	---------	-----

SELENIUM SULFIDE

ACTAVIS MID ATLANTIC	2.5%	A084394	001
G AND W LABS INC	2.5%	A086209	001
IVAX PHARMS	2.5%	A085777	001

SELENOMETHIONINE SE-75

INJECTABLE; INJECTION

SELENOMETHIONINE SE 75

GE HEALTHCARE	250uCi/ML	N017257	001
MALLINCKRODT	100uCi/ML	N017098	001
PHARMALUCENCE	500uCi/ML	N017322	001
SETHOTOPE			
BRACCO	85-550uCi/ML	N017047	001

SERACTIDE ACETATE

INJECTABLE; INJECTION

ACTHAR GEL-SYNTHETIC

ARMOUR PHARM	40 UNITS/ML	N017861	001
	80 UNITS/ML	N017861	002

DISCONTINUED DRUG PRODUCT LISTSERMORELIN ACETATE

INJECTABLE; INJECTION

GEREF

EMD SERONO	EQ 0.05MG BASE/AMP **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019863	001	Dec 28, 1990
EMD SERONO INC	EQ 0.5MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020443	001	Sep 26, 1997
	EQ 1MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020443	002	Sep 26, 1997

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

SERTRALINE HYDROCHLORIDE

RANBAXY LABS LTD	EQ 20MG BASE/ML	A078053	001	Feb 05, 2007
ROXANE	EQ 20MG BASE/ML	A076934	001	Jun 30, 2006

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

ACTAVIS ELIZABETH	EQ 25MG BASE	A077345	001	Feb 06, 2007
	EQ 50MG BASE	A077345	002	Feb 06, 2007
	EQ 100MG BASE	A077345	003	Feb 06, 2007
CIPLA LTD	EQ 25MG BASE	A077162	001	Feb 06, 2007
	EQ 50MG BASE	A077162	002	Feb 06, 2007
	EQ 100MG BASE	A077162	003	Feb 06, 2007
DR REDDYS LABS LTD	EQ 25MG BASE	A076442	001	Apr 30, 2007
	EQ 50MG BASE	A076442	002	Apr 30, 2007
	EQ 100MG BASE	A076442	003	Apr 30, 2007
FRONTIDA BIOPHARM	EQ 25MG BASE	A077818	001	Feb 06, 2007
	EQ 50MG BASE	A077818	002	Feb 06, 2007
	EQ 100MG BASE	A077818	003	Feb 06, 2007
HIKMA PHARMS	EQ 25MG BASE	A077864	001	Aug 10, 2009
	EQ 50MG BASE	A077864	002	Aug 10, 2009
	EQ 100MG BASE	A077864	003	Aug 10, 2009
IVAX SUB TEVA PHARMS	EQ 25MG BASE	A075719	003	Jun 30, 2006
	EQ 50MG BASE	A075719	001	Jun 30, 2006
	EQ 100MG BASE	A075719	002	Jun 30, 2006
MYLAN PHARMS INC	EQ 25MG BASE	A076540	001	Mar 20, 2007
	EQ 50MG BASE	A076540	002	Mar 20, 2007
	EQ 100MG BASE	A076540	003	Mar 20, 2007
PLIVA HRVATSKA DOO	EQ 25MG BASE	A077299	001	Feb 06, 2007
	EQ 50MG BASE	A077299	002	Feb 06, 2007
	EQ 100MG BASE	A077299	003	Feb 06, 2007
ROXANE	EQ 25MG BASE	A076881	001	Feb 06, 2007
	EQ 50MG BASE	A076881	002	Feb 06, 2007
	EQ 100MG BASE	A076881	003	Feb 06, 2007
SANDOZ	EQ 25MG BASE	A077713	001	Feb 06, 2007
	EQ 50MG BASE	A077713	002	Feb 06, 2007
	EQ 100MG BASE	A077713	003	Feb 06, 2007
WATSON LABS	EQ 25MG BASE	A077663	001	Feb 06, 2007
	EQ 50MG BASE	A077663	002	Feb 06, 2007
	EQ 100MG BASE	A077663	003	Feb 06, 2007

ZOLOFT

PFIZER

	EQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019839	003	Dec 30, 1991
	EQ 200MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019839	004	Dec 30, 1991

SEVELAMER HYDROCHLORIDE

CAPSULE; ORAL

RENAGEL

GENZYME	403MG	N020926	001	Oct 30, 1998
---------	-------	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

SIBUTRAMINE HYDROCHLORIDE

CAPSULE; ORAL

MERIDIA

ABBOTT

5MG

N020632 001 Nov 22, 1997

10MG

N020632 002 Nov 22, 1997

15MG

N020632 003 Nov 22, 1997

SILDENAFIL CITRATE

TABLET; ORAL

SILDENAFIL CITRATE

ACTAVIS GRP PTC

EQ 20MG BASE

A200149 001 Feb 25, 2013

TEVA

EQ 25MG BASE

A077342 001 Mar 09, 2016

EQ 50MG BASE

A077342 002 Mar 09, 2016

EQ 100MG BASE

A077342 003 Mar 09, 2016

SILVER SULFADIAZINE

DRESSING; TOPICAL

SILDAFLO

FRANKLIN PHARMS

1%

N019608 001 Nov 30, 1989

SIMETHICONE-CELLULOSE

SUSPENSION; ORAL

SONORX

BRACCO

7.5MG/ML

N020773 001 Oct 29, 1998

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

SANDOZ INC

5MG

A077766 001 Dec 20, 2006

10MG

A077766 002 Dec 20, 2006

20MG

A077766 003 Dec 20, 2006

40MG

A077766 004 Dec 20, 2006

80MG

A077766 005 Dec 20, 2006

SUN PHARM INDS LTD

5MG

A076285 001 Dec 20, 2006

10MG

A076285 002 Dec 20, 2006

20MG

A076285 003 Dec 20, 2006

40MG

A076285 004 Dec 20, 2006

80MG

A076285 005 Jun 23, 2006

TABLET, ORALLY DISINTEGRATING; ORAL

SIMVASTATIN

SYNTHON PHARMS

10MG

N021961 001 Oct 09, 2007

20MG

N021961 002 Oct 09, 2007

40MG

N021961 003 Oct 09, 2007

80MG

N021961 004 Oct 09, 2007

SIMVASTATIN; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JUVISYNC

MERCK SHARP DOHME

10MG;EQ 50MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N202343 004 Sep 18, 2012

10MG;EQ 100MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N202343 001 Oct 07, 2011

20MG;EQ 50MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N202343 005 Sep 18, 2012

20MG;EQ 100MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N202343 002 Oct 07, 2011

40MG;EQ 50MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N202343 006 Sep 18, 2012

40MG;EQ 100MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N202343 003 Oct 07, 2011

DISCONTINUED DRUG PRODUCT LISTSIROLIMUS

TABLET; ORAL

RAPAMUNE

PF PRISM CV

5MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021110 003 Feb 23, 2004

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION; ORAL

UCEPHAN

B BRAUN

100MG/ML; 100MG/ML

N019530 001 Dec 23, 1987

SODIUM BICARBONATE

INJECTABLE; INJECTION

SODIUM BICARBONATE IN PLASTIC CONTAINER

ABBOTT

0.9MEQ/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N019443 001 Jun 03, 1986

1MEQ/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N019443 002 Jun 03, 1986

SODIUM BICARBONATE; TARTARIC ACID

GRANULE, EFFERVESCENT; ORAL

BAROS

MALLINCKRODT INC

460MG/GM; 420MG/GM

N018509 001 Aug 07, 1985

SODIUM CHLORIDE

INJECTABLE; INJECTION

BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

ABRAXIS PHARM

9MG/ML

A088909 001 Feb 07, 1985

SODIUM CHLORIDE

ABBOTT

20GM/100ML

N017013 001

B BRAUN

20GM/100ML

N017038 001

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN

450MG/100ML

N018184 001

MILES

450MG/100ML

N018503 001

SODIUM CHLORIDE 0.9%

MEDEFIL INC

18MG/2ML (9MG/ML)

N202832 002 Jan 06, 2012

22.5MG/2.5ML (9MG/ML)

N202832 003 Jan 06, 2012

27MG/3ML (9MG/ML)

N202832 004 Jan 06, 2012

45MG/5ML (9MG/ML)

N202832 005 Jan 06, 2012

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

ABBOTT

9MG/ML

N019218 001 Jul 13, 1984

MEDEFIL INC

9MG/ML (9MG/ML)

N202832 001 Jan 06, 2012

MILES

900MG/100ML

N018502 001

SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER

ABRAXIS PHARM

234MG/ML

N019329 001 Apr 22, 1987

SODIUM CHLORIDE 3% IN PLASTIC CONTAINER

B BRAUN

3GM/100ML

N019635 003 Mar 09, 1988

SODIUM CHLORIDE 5% IN PLASTIC CONTAINER

B BRAUN

5GM/100ML

N019635 004 Mar 09, 1988

SOLUTION; IRRIGATION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

BAXTER HLTHCARE

450MG/100ML

N017864 001

450MG/100ML

N018497 001 Feb 19, 1982

HOSPIRA

450MG/100ML

N017670 001

450MG/100ML

N018380 001

SODIUM CHLORIDE IN PLASTIC CONTAINER

MILES

900MG/100ML

N018247 001

SODIUM CHROMATE CR-51

INJECTABLE; INJECTION

CHROMITOPE SODIUM

BRACCO

2mCi/VIAL

N013993 002

200uCi/ML

N013993 001

SODIUM CHROMATE CR 51

MALLINKRODT NUCLEAR

100uCi/ML

N016708 001

DISCONTINUED DRUG PRODUCT LISTSODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS

FLUORINE F-18

GE HEALTHCARE

2mCi/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N017042 001

SODIUM FLUORIDE F 18

NIH NCI DCTD

10-200mCi/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N022494 001 Jan 26, 2011

SODIUM IODIDE I-123

CAPSULE; ORAL

SODIUM IODIDE I 123

CARDINAL HEALTH 418

400uCi

N018671 003 May 27, 1982

GE HEALTHCARE

100uCi

N017630 001

SOLUTION; ORAL

SODIUM IODIDE I 123

GE HEALTHCARE

2mCi/ML

N017630 002

SODIUM IODIDE I-131

CAPSULE; ORAL

IODOTOPE

BRACCO

1-130mCi

N010929 001

1-150mCi

N010929 003

SODIUM IODIDE I 131

CIS

50uCi

N017316 001

100uCi

N017316 002

JUBILANT DRAXIMAGE

2-200mCi

N021305 004 Nov 18, 2004

MALLINKRODT NUCLEAR

0.8-100mCi

N016515 002

15-100uCi

N016517 002

SOLUTION; ORAL

HICON

JUBILANT DRAXIMAGE

1-250mCi/0.25ML

N021305 002 Jan 24, 2003

1-500mCi/0.5ML

N021305 003 Jan 24, 2003

1-1000mCi/ML

N021305 005 Apr 04, 2006

IODOTOPE

BRACCO

7-106mCi/BOT

N010929 002

SODIUM IODIDE I 131

CIS

50mCi/ML

N017315 001

SODIUM LACTATE

INJECTABLE; INJECTION

SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER

B BRAUN

1.87GM/100ML

N018186 001

BAXTER HLTHCARE

1.87GM/100ML

N016692 001

HOSPIRA

1.87GM/100ML

N018249 001

SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER

B BRAUN

1.87GM/100ML

N020004 001 Apr 21, 1992

SODIUM MONOFLUOROPHOSPHATE

GEL; DENTAL

EXTRA-STRENGTH AIM

CHESEBROUGH PONDS

1.2%

N019518 002 Aug 06, 1986

PASTE; DENTAL

EXTRA-STRENGTH AIM

CHESEBROUGH PONDS

1.2%

N019518 001 Jun 03, 1987

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

NIPRIDE

ROCHE

50MG/VIAL

N017546 001

NITROPRESS

ABBOTT

50MG/VIAL

A071555 001 Nov 16, 1987

ABBVIE

50MG/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N018450 001

HOSPIRA

50MG/VIAL

A070566 001 Jun 09, 1986

SODIUM NITROPRUSSIDE

ABRAXIS PHARM

50MG/VIAL

A070031 001 Jan 17, 1985

BAXTER HLTHCARE

50MG/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or

N018581 001 Jul 28, 1982

DISCONTINUED DRUG PRODUCT LISTSODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

SODIUM NITROPRUSSIDE

TEVA PARENTERAL	efficacy reasons** 25MG/ML	A073465 001	Mar 30, 1992
-----------------	-------------------------------	-------------	--------------

SODIUM PHOSPHATE P-32

SOLUTION; INJECTION, ORAL

PHOSPHOTOPE

BRACCO	1-8mCi/VIAL	N010927 001	
--------	-------------	-------------	--

SODIUM PHOSPHATE P 32

MALLINCKRODT	0.67mCi/ML	N011777 001	
--------------	------------	-------------	--

	1.5mCi/VIAL	N011777 002	
--	-------------	-------------	--

SODIUM PHOSPHATE, DIBASIC ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL

VISICOL

SALIX PHARMS	0.398GM; 1.102GM	N021097 001	Sep 21, 2000
--------------	------------------	-------------	--------------

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL

MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE

NOVEL LABS INC	0.398GM; 1.102GM	A079247 001	Dec 30, 2011
----------------	------------------	-------------	--------------

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

CITRUSPHRMA	454GM/BOT	A040909 001	Dec 03, 2008
-------------	-----------	-------------	--------------

WOCKHARDT	453.6GM/BOT	A088786 001	Sep 11, 1984
-----------	-------------	-------------	--------------

SUSPENSION; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

MORTON GROVE	15GM/60ML	A088717 001	Sep 11, 1984
--------------	-----------	-------------	--------------

ROXANE	15GM/60ML	A088453 001	Nov 17, 1983
--------	-----------	-------------	--------------

SODIUM SUCCINATE

INJECTABLE; INJECTION

SODIUM SUCCINATE

ELKINS SINN	30%	A080516 001	
-------------	-----	-------------	--

SODIUM TETRADECYL SULFATE

INJECTABLE; INJECTION

SOTRADECOL

ELKINS SINN	1% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N005970 004	
-------------	--	-------------	--

	3% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N005970 005	
--	--	-------------	--

SODIUM THIOSULFATE

INJECTABLE; INJECTION

SODIUM THIOSULFATE

US ARMY	250MG/ML	N020166 001	Feb 14, 1992
---------	----------	-------------	--------------

SOMATREM

INJECTABLE; INJECTION

PROTROPIN

GENENTECH	5MG/VIAL	N019107 001	Oct 17, 1985
-----------	----------	-------------	--------------

	10MG/VIAL	N019107 002	Oct 24, 1989
--	-----------	-------------	--------------

SOMATROPIN

INJECTABLE; INJECTION

ASELLACRIN 10

SERONO	10 IU/VIAL	N017726 001	
--------	------------	-------------	--

ASELLACRIN 2

SERONO	2 IU/VIAL	N017726 002	Jul 21, 1983
--------	-----------	-------------	--------------

CRESCORMON

GENENTECH	4 IU/VIAL	N017992 001	
-----------	-----------	-------------	--

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

ACCRETROPIN

EMERGENT	5MG/ML (5MG/ML)	N021538 001	Jan 23, 2008
----------	-----------------	-------------	--------------

BIO-TROPIN

FERRING	4.8MG/VIAL	N019774 001	May 25, 1995
---------	------------	-------------	--------------

DISCONTINUED DRUG PRODUCT LISTSOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

HUMATROPE

LILLY 2MG/VIAL N019640 001 Jun 23, 1987

NORDITROPIN

NOVO NORDISK INC 4MG/VIAL N019721 001 May 08, 1995

5MG/1.5ML N021148 001 Jun 20, 2000

8MG/VIAL N019721 002 May 08, 1995

10MG/1.5ML N021148 002 Jun 20, 2000

15MG/1.5ML N021148 003 Jun 20, 2000

NORDITROPIN NORDIFLEX

NOVO NORDISK INC 5MG/1.5ML N021148 004 Oct 01, 2004

10MG/1.5ML N021148 005 Oct 01, 2004

15MG/1.5ML N021148 006 Oct 01, 2004

30MG/3ML N021148 007 Mar 10, 2009

NUTROPIN

GENENTECH 5MG/VIAL N020168 001 Nov 17, 1993

10MG/VIAL N020168 002 Nov 17, 1993

NUTROPIN AQ

GENENTECH 10MG/2ML (5MG/ML) N020522 001 Dec 29, 1995

NUTROPIN DEPOT

GENENTECH 13.5MG/VIAL N021075 001 Dec 22, 1999

18MG/VIAL N021075 002 Dec 22, 1999

22.5MG/VIAL N021075 003 Dec 22, 1999

SAIZEN

EMD SERONO 4MG/VIAL N019764 005 Jan 16, 2007

6MG/VIAL N019764 001 Oct 08, 1996

SEROSTIM

EMD SERONO 8.8MG/VIAL N020604 004 Sep 06, 2001

ZORBTIVE

EMD SERONO 4MG/VIAL N021597 001 Dec 01, 2003

5MG/VIAL N021597 002 Dec 01, 2003

6MG/VIAL N021597 003 Dec 01, 2003

INJECTABLE; SUBCUTANEOUS

SEROSTIM LQ

EMD SERONO 6MG/0.5ML (6MG/0.5ML) N020604 005 Feb 11, 2005

SORBITOL

SOLUTION; IRRIGATION

SORBITOL 3% IN PLASTIC CONTAINER

BAXTER HLTHCARE 3GM/100ML N018512 001 May 27, 1982

SOTALOL HYDROCHLORIDE

TABLET; ORAL

BETAPACE

COVIS PHARMA SARL 320MG N019865 004 Oct 30, 1992

BETAPACE AF

COVIS PHARMA SARL 40MG N021151 006 Apr 02, 2003

60MG N021151 007 Apr 02, 2003

100MG N021151 005 Mar 14, 2003

SOTALOL HYDROCHLORIDE

IMPAX PHARMS 80MG A075663 001 Nov 07, 2000

120MG A075663 002 Nov 07, 2000

160MG A075663 003 Nov 07, 2000

240MG A075663 004 Nov 07, 2000

SUN PHARM INDS 80MG A075515 001 Oct 15, 2001

80MG A076576 001 Apr 08, 2004

120MG A075515 004 Oct 15, 2001

120MG A076576 002 Apr 08, 2004

160MG A075515 002 Oct 15, 2001

160MG A076576 003 Apr 08, 2004

240MG A075515 003 Oct 15, 2001

WATSON LABS 80MG A075238 001 Jul 13, 2000

120MG A075238 002 Jul 13, 2000

160MG A075238 003 Jul 13, 2000

240MG A075238 004 Jul 13, 2000

SOYBEAN OIL

INJECTABLE; INJECTION

LIPOSYN III 10%

HOSPIRA 10% N018969 001 Sep 24, 1984

LIPOSYN III 20%

HOSPIRA 20% N018970 001 Sep 25, 1984

DISCONTINUED DRUG PRODUCT LIST

SOYBEAN OIL

INJECTABLE; INJECTION

LIPOSYN III 30%

HOSPIRA

30%

N020181 001 Jan 13, 1998

SOYACAL 10%

ALPHA THERA

10%

N018465 001 Jun 29, 1983

SOYACAL 20%

ALPHA THERA

20%

N018786 001 Jun 29, 1983

TRAVAMULSION 10%

BAXTER HLTHCARE

10%

N018660 001 Feb 26, 1982

TRAVAMULSION 20%

BAXTER HLTHCARE

20%

N018758 001 Feb 15, 1983

SPARFLOXACIN

TABLET; ORAL

ZAGAM

MYLAN

200MG

N020677 001 Dec 19, 1996

SPECTINOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

TROBICIN

PFIZER

EQ 2GM BASE/VIAL

N050347 001

EQ 4GM BASE/VIAL

N050347 002

SPIRAPRIL HYDROCHLORIDE

TABLET; ORAL

RENORMAX

SCHERING

3MG

N020240 001 Dec 29, 1994

6MG

N020240 002 Dec 29, 1994

12MG

N020240 003 Dec 29, 1994

24MG

N020240 004 Dec 29, 1994

SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE

ASCOT

25MG

A087687 001 Oct 20, 1982

IVAX PHARMS

25MG

A087108 001

LEDERLE

25MG

A087634 001

MUTUAL PHARM

25MG

A087265 001

MYLAN

25MG

A087086 001

PUREPAC PHARM

25MG

A087998 001 Oct 14, 1983

25MG

A088053 001 Aug 25, 1983

SUPERPHARM

25MG

A089364 001 Nov 07, 1986

UPSHER SMITH

25MG

A087554 001

VANGARD

25MG

A087648 001 Feb 01, 1982

WARNER CHILCOTT

25MG

A087952 001 Nov 18, 1982

WATSON LABS

25MG

A086898 002 Mar 02, 1982

25MG

A087078 001

STANOZOLOL

TABLET; ORAL

WINSTROL

LUNDBECK INC

2MG

N012885 001 May 14, 1984

STAVUDINE

CAPSULE; ORAL

ZERIT

BRISTOL MYERS SQUIBB

5MG

N020412 001 Jun 24, 1994

CAPSULE, EXTENDED RELEASE; ORAL

ZERIT XR

BRISTOL MYERS SQUIBB

37.5MG

N021453 001 Dec 31, 2002

50MG

N021453 002 Dec 31, 2002

75MG

N021453 003 Dec 31, 2002

100MG

N021453 004 Dec 31, 2002

STERILE WATER FOR INJECTION

LIQUID; N/A

BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

ABRAXIS PHARM

100%

A089099 001 Dec 29, 1987

100%

A089100 001 Dec 29, 1987

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

B BRAUN

100%

N019077 001 Mar 02, 1984

DISCONTINUED DRUG PRODUCT LIST

STERILE WATER FOR IRRIGATION

LIQUID; IRRIGATION

STERILE WATER IN PLASTIC CONTAINER

MILES 100% N018246 001

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION

STREPTOMYCIN SULFATE

COPANOS EQ 500MG BASE/ML A060684 001

LILLY EQ 1GM BASE/VIAL A060107 001

EQ 1GM BASE/2ML A060404 001

EQ 5GM BASE/VIAL A060107 002

PFIZER EQ 1GM BASE/VIAL A060076 001

EQ 1GM BASE/2.5ML A060111 001

EQ 5GM BASE/VIAL A060076 002

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

ANECTINE

SANDOZ 50MG/ML N008453 003

500MG/VIAL N008453 001

1GM/VIAL N008453 004

QUELICIN PRESERVATIVE FREE

HOSPIRA 50MG/ML N008845 002

100MG/ML N008845 004

SUCCINYLCHOLINE CHLORIDE

INTL MEDICATION 100MG/VIAL A085400 001 Feb 04, 1982

ORGANON USA INC 20MG/ML A080997 001

SUCOSTRIN

APOTHECON 20MG/ML N008847 001

100MG/ML N008847 003

SUFENTANIL CITRATE

INJECTABLE; INJECTION

SUFENTANIL CITRATE

WATSON LABS EQ 0.05MG BASE/ML A074406 001 Dec 15, 1995

SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

BLEPH-10

ALLERGAN 10% A084015 001

CETAMIDE

ALCON 10% A080021 001

SODIUM SULAMYD

SCHERING 10% **Federal Register determination N005963 002

that product was not discontinued or
withdrawn for safety or efficacy
reasons**

SULFAIR 10

PHARMAFAIR 10% A088000 001 Dec 22, 1982

SOLUTION/DROPS; OPHTHALMIC

BLEPH-30

ALLERGAN 30% A080028 002

ISOPTO CETAMIDE

ALCON 15% A080020 002

OCUSULF-10

MIZA PHARMS USA 10% A080660 001

OCUSULF-30

MIZA PHARMS USA 30% A080660 002

SODIUM SULAMYD

SCHERING 10% **Federal Register determination N005963 001

that product was not discontinued or
withdrawn for safety or efficacy
reasons**

30% **Federal Register determination N005963 003

that product was not discontinued or
withdrawn for safety or efficacy
reasons**

SODIUM SULFACETAMIDE

AKORN 10% A083021 001

15% A083021 002

30% A083021 003

SOLA BARNES HIND 10% A084143 001

10% A084145 001

30% A084146 001

30% A084147 001

DISCONTINUED DRUG PRODUCT LISTSULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC

SULF-10			
NOVARTIS	10%	A080025	001
SULF-15			
NOVARTIS	15%	A089047	001 Oct 31, 1995
SULFACEL-15			
OPTOPICS	15%	A080024	001
SULFACETAMIDE SODIUM			
AKORN	30%	A040216	001 May 25, 1999
ALCON PHARMS LTD	30%	A089068	001 May 05, 1987
PHARMAFAIR	10%	A088947	001 May 17, 1985
SULFAIR 10			
PHARMAFAIR	10%	A087949	001 Dec 13, 1982
SULFAIR FORTE			
PHARMAFAIR	30%	A088385	001 Oct 13, 1983
SULFAIR-15			
PHARMAFAIR	15%	A088186	001 May 25, 1983
SULTEN-10			
BAUSCH AND LOMB	10%	A087818	001 Feb 03, 1983

SULFACYTINE

TABLET;ORAL

RENOQUID			
GLENWOOD	250MG	N017569	001

SULFADIAZINE

TABLET;ORAL

SULFADIAZINE			
ABBVIE	300MG	N004125	005
EVERYLIFE	500MG	A080088	001
IMPAX LABS	500MG	A080081	001
LANNETT	500MG	A080084	001
LEDERLE	500MG	N004054	001
LILLY	500MG	N004122	002

SULFADIAZINE SODIUM

INJECTABLE; INJECTION

SULFADIAZINE SODIUM			
LEDERLE	250MG/ML	N004054	002

SULFADIAZINE; SULFAMERAZINE

SUSPENSION;ORAL

SULFONAMIDES DUPLEX			
LILLY	250MG/5ML; 250MG/5ML	N006317	007

SULFAMETER

TABLET;ORAL

SULLA			
BAYER HLTHCARE	500MG	N016000	002

SULFAMETHIZOLE

TABLET;ORAL

MICROSUL			
FOREST PHARMS	1GM	A086012	001
PROKLAR			
FOREST PHARMS	500MG	A080273	001
THIOSULFIL			
WYETH AYERST	250MG	N008565	001
	500MG	N008565	004

SULFAMETHOXAZOLE

SUSPENSION;ORAL

GANTANOL			
ROCHE	500MG/5ML	N013664	002

TABLET;ORAL

GANTANOL			
ROCHE	500MG	N012715	002
GANTANOL-DS			
ROCHE	1GM	N012715	003

SULFAMETHOXAZOLE

ASCOT	500MG	A087662	001 Oct 20, 1982
AUROLIFE PHARMA LLC	500MG	A085844	001
BARR	500MG	A087189	001 Jul 25, 1983
HEATHER	500MG	A086163	001
WATSON LABS	500MG	A085053	001

DISCONTINUED DRUG PRODUCT LIST

SULFAMETHOXAZOLE

TABLET; ORAL

SULFAMETHOXAZOLE

1GM A086000 001

UROBAK

SHIONOGI

500MG A087307 001

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

BACTRIM

MUTUAL PHARM

80MG/ML;16MG/ML N018374 001

SEPTRA

MONARCH PHARMS

80MG/ML;16MG/ML N018452 001

SULFAMETHOXAZOLE AND TRIMETHOPRIM

ABRAXIS PHARM

80MG/ML;16MG/ML A070223 001 Dec 29, 1987

BEDFORD

80MG/ML;16MG/ML A072383 001 Apr 29, 1992

HOSPIRA

80MG/ML;16MG/ML A073199 001 Sep 11, 1992

WATSON LABS

80MG/ML;16MG/ML A071556 001 Dec 29, 1987

WEST-WARD PHARMS INT

80MG/ML;16MG/ML A070627 001 Dec 29, 1987

80MG/ML;16MG/ML A070628 001 Dec 29, 1987

SUSPENSION; ORAL

BACTRIM

SUN PHARM INDS

200MG/5ML;40MG/5ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons** N017560 001

BACTRIM PEDIATRIC

SUN PHARM INDS

200MG/5ML;40MG/5ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons** N017560 002

SEPTRA

MONARCH PHARMS

200MG/5ML;40MG/5ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons** N017598 001

SEPTRA GRAPE

MONARCH PHARMS

200MG/5ML;40MG/5ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons** N017598 002 Feb 12, 1986

SULFAMETHOXAZOLE AND TRIMETHOPRIM

ANI PHARMS INC

200MG/5ML;40MG/5ML A070028 001 Jun 02, 1987

200MG/5ML;40MG/5ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons** A077612 001 Nov 13, 2006

TEVA

200MG/5ML;40MG/5ML N018812 001 Jan 28, 1983

200MG/5ML;40MG/5ML N018812 002 Jun 10, 1983

SULFATRIM

STI PHARMA LLC

200MG/5ML;40MG/5ML N018615 002 Jan 07, 1983

SULMEPRIM

USL PHARMA

200MG/5ML;40MG/5ML A070063 001 Aug 01, 1986

SULMEPRIM PEDIATRIC

USL PHARMA

200MG/5ML;40MG/5ML A070064 001 Aug 01, 1986

TRIMETH/SULFA

ALPHARMA US PHARMS

200MG/5ML;40MG/5ML A072289 001 May 23, 1988

200MG/5ML;40MG/5ML A072398 001 May 23, 1988

NASKA

200MG/5ML;40MG/5ML A072399 001 May 23, 1988

TABLET; ORAL

COTRIM

TEVA

400MG;80MG A070034 001 May 16, 1985

COTRIM D.S.

TEVA

800MG;160MG A070048 001 Mar 18, 1985

SULFAMETHOPRIM

NOVEL LABS INC

400MG;80MG A070022 001 Feb 15, 1985

SULFAMETHOPRIM-DS

NOVEL LABS INC

800MG;160MG A070032 001 Feb 15, 1985

SULFAMETHOXAZOLE AND TRIMETHOPRIM

HEATHER

400MG;80MG N018946 001 Aug 10, 1984

800MG;160MG N018946 002 Aug 10, 1984

INTERPHARM

400MG;80MG A071299 001 Oct 27, 1987

800MG;160MG A071300 001 Oct 27, 1987

MARTEC USA LLC

400MG;80MG A072408 001 Dec 07, 1988

MUTUAL PHARM

400MG;80MG A070006 001 Nov 14, 1984

DISCONTINUED DRUG PRODUCT LISTSULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

	400MG; 80MG	A071016 001	Aug 25, 1986
PLIVA	400MG; 80MG	A070215 001	Sep 10, 1985
	800MG; 160MG	A070216 001	Sep 10, 1985
ROXANE	400MG; 80MG	A072768 001	Aug 30, 1991
SANDOZ	400MG; 80MG	A070889 001	Nov 13, 1986
	400MG; 80MG	N018598 003	May 19, 1982
	800MG; 160MG	A070890 001	Nov 13, 1986
TEVA	400MG; 80MG	N018242 001	
	800MG; 160MG	N018242 002	
USL PHARMA	400MG; 80MG	A070203 001	Nov 08, 1985
	800MG; 160MG	A070204 001	Nov 08, 1985
WATSON LABS	400MG; 80MG	A070002 001	Nov 07, 1984
	400MG; 80MG	N018852 001	May 09, 1983
	800MG; 160MG	A070000 001	Nov 07, 1984

SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH

MARTEC USA LLC	800MG; 160MG	A072417 001	Dec 07, 1988
MUTUAL PHARM	800MG; 160MG	A070007 001	Nov 14, 1984
ROXANE	800MG; 160MG	A072769 001	Aug 30, 1991
SANDOZ	800MG; 160MG	N018598 004	May 19, 1982
WATSON LABS	800MG; 160MG	N018854 001	May 09, 1983

SULFATRIM-DS

SUPERPHARM	800MG; 160MG	A070066 001	Jun 24, 1985
------------	--------------	-------------	--------------

SULFATRIM-SS

SUPERPHARM	400MG; 80MG	A070065 002	Jun 24, 1985
------------	-------------	-------------	--------------

UROPLUS DS

SHIONOGI	800MG; 160MG	A071816 001	Sep 28, 1987
----------	--------------	-------------	--------------

UROPLUS SS

SHIONOGI	400MG; 80MG	A071815 001	Sep 28, 1987
----------	-------------	-------------	--------------

SULFANILAMIDE

CREAM; VAGINAL

SULFANILAMIDE

G AND W LABS INC	15%	A088718 001	Sep 19, 1985
------------------	-----	-------------	--------------

SUPPOSITORY; VAGINAL

AVC

MEDA PHARMS	1.05GM	N006530 004	Jan 27, 1987
-------------	--------	-------------	--------------

SULFAPHENAZOLE

SUSPENSION; ORAL

SULFABID

PHARM RES ASSOC	500MG/5ML	N013093 001	
-----------------	-----------	-------------	--

TABLET; ORAL

SULFABID

PURDUE FREDERICK	500MG	N013092 002	
------------------	-------	-------------	--

SULFAPYRIDINE

TABLET; ORAL

SULFAPYRIDINE

LILLY	500MG	N000159 001	
-------	-------	-------------	--

SULFASALAZINE

SUSPENSION; ORAL

AZULFIDINE

PHARMACIA AND UPJOHN	250MG/5ML	N018605 001	
----------------------	-----------	-------------	--

TABLET; ORAL

S.A.S.-500

SOLVAY	500MG	A083450 001	
--------	-------	-------------	--

SULFASALAZINE

HERITAGE PHARMS INC	500MG	A080197 001	
---------------------	-------	-------------	--

SANDOZ	500MG	A086184 001	
--------	-------	-------------	--

SUN PHARM INDS	500MG	A089590 001	Oct 19, 1987
----------------	-------	-------------	--------------

SUPERPHARM	500MG	A089339 001	Oct 26, 1987
------------	-------	-------------	--------------

WATSON LABS	500MG	A084964 001	
-------------	-------	-------------	--

	500MG	A087197 001	
--	-------	-------------	--

TABLET, DELAYED RELEASE; ORAL

SULFASALAZINE

WATSON LABS	500MG	A088052 001	May 24, 1983
-------------	-------	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

SULFINPYRAZONE

CAPSULE; ORAL

ANTURANE

NOVARTIS	200MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011556 004
----------	---	-------------

SULFINPYRAZONE

BARR	200MG	A087666 001 Sep 17, 1982
IVAX PHARMS	200MG	A087770 001 Nov 19, 1982
PAR PHARM	200MG	A088934 001 Sep 06, 1985
VANGARD	200MG	A088666 001 Feb 17, 1984

TABLET; ORAL

ANTURANE

NOVARTIS	100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011556 003
----------	---	-------------

SULFINPYRAZONE

BARR	100MG	A087665 001 Sep 17, 1982
IVAX PHARMS	100MG	A087769 001 Jun 01, 1982
PAR PHARM	100MG	A088933 001 Sep 06, 1985
WATSON LABS	100MG	A087667 001 May 26, 1982

SULFISOXAZOLE

TABLET; ORAL

GANTRISIN

ROCHE	500MG	N006525 001
-------	-------	-------------

SOSOL

MK LABS	500MG	A080036 001
---------	-------	-------------

SOXAZOLE

ALRA	500MG	A080366 001
------	-------	-------------

SULFALAR

PARKE DAVIS	500MG	A084955 001
-------------	-------	-------------

SULFISOXAZOLE

ANI PHARMS INC	500MG	A080142 001
AUROLIFE PHARMA LLC	500MG	A085628 001
BARR	500MG	A084031 001
HEATHER	500MG	A080189 001
IMPAX LABS	500MG	A080109 001
LANNETT	500MG	A080085 001
LEDERLE	500MG	A087649 001
PHARMERAL	500MG	A084385 001
PUREPAC PHARM	500MG	A080087 001
ROXANE	500MG	A080082 001
VALEANT PHARM INTL	500MG	A080268 002
VITARINE	500MG	A087332 001
WATSON LABS	500MG	A085534 001
WEST WARD	500MG	A080379 001

SULSOXIN

SOLVAY	500MG	A080040 001
--------	-------	-------------

SULFISOXAZOLE ACETYL

EMULSION; ORAL

LIPO GANTRISIN

ROCHE	EQ 1GM BASE/5ML	N009182 009
-------	-----------------	-------------

SUSPENSION; ORAL

GANTRISIN PEDIATRIC

ROCHE	EQ 500MG BASE/5ML	N009182 004
-------	-------------------	-------------

SYRUP; ORAL

GANTRISIN

ROCHE	EQ 500MG BASE/5ML	N009182 002
-------	-------------------	-------------

SULFISOXAZOLE DIOLAMINE

INJECTABLE; INJECTION

GANTRISIN

ROCHE	EQ 400MG BASE/ML	N006917 001
-------	------------------	-------------

OINTMENT; OPHTHALMIC

GANTRISIN

ROCHE	EQ 4% BASE	N008414 002
-------	------------	-------------

SOLUTION/DROPS; OPHTHALMIC

GANTRISIN

ROCHE	EQ 4% BASE	N007757 002
-------	------------	-------------

DISCONTINUED DRUG PRODUCT LIST

SULFISOXAZOLE DIOLAMINE

SOLUTION/DROPS;OPHTHALMIC

SULFISOXAZOLE DIOLAMINE

SOLA BARNES HIND EQ 4% BASE A084148 001

SULFOXONE SODIUM

TABLET, DELAYED RELEASE;ORAL

DIASONE SODIUM

ABBVIE 165MG N006044 003

SULFUR

POWDER;TOPICAL

BENSULFOID

POYTHRESS 33.32% N002918 001

SULINDAC

TABLET;ORAL

CLINORIL

MERC

150MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons** N017911 001200MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons** N017911 002

SULINDAC

ANI PHARMS INC

150MG A072972 001 Feb 28, 1992

200MG A072973 001 Feb 28, 1992

SANDOZ 150MG A072712 001 Aug 30, 1991

200MG A072713 001 Aug 30, 1991

SUMATRIPTAN

SPRAY;NASAL

IMITREX

GLAXOSMITHKLINE

10MG/SPRAY N020626 002 Aug 26, 1997

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS

ALSUMA

MERIDIAN MEDCL

EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) N022377 001 Jun 29, 2010

SUMATRIPTAN SUCCINATE

FRESENIUS KABI USA

EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A079240 002 Sep 18, 2009

EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) A079240 001 Sep 18, 2009

SANDOZ

EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) A078067 002 Feb 06, 2009

EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A078067 001 Feb 06, 2009

TEVA PARENTERAL

EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) A078318 001 Feb 06, 2009

EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A078318 002 Feb 06, 2009

TABLET;ORAL

SUMATRIPTAN SUCCINATE

HIKMA PHARMS

EQ 25MG BASE A078298 001 May 21, 2013

EQ 50MG BASE A078298 002 May 21, 2013

EQ 100MG BASE A078298 003 May 21, 2013

MYLAN

EQ 25MG BASE A077163 001 Nov 02, 2009

EQ 50MG BASE A077163 002 Nov 02, 2009

EQ 100MG BASE A077163 003 Nov 02, 2009

ROXANE

EQ 25MG BASE A078241 001 Aug 10, 2009

EQ 50MG BASE A078241 002 Aug 10, 2009

EQ 100MG BASE A078241 003 Aug 10, 2009

SANDOZ

EQ 25MG BASE A076976 001 Aug 10, 2009

EQ 50MG BASE A076976 002 Aug 10, 2009

EQ 100MG BASE A076976 003 Aug 10, 2009

TEVA

EQ 25MG BASE A076840 001 Feb 09, 2009

EQ 50MG BASE A076840 002 Feb 09, 2009

EQ 100MG BASE A076840 003 Feb 09, 2009

SUPROFEN

SOLUTION/DROPS;OPHTHALMIC

PROFENAL

ALCON

1% N019387 001 Dec 23, 1988

DISCONTINUED DRUG PRODUCT LISTSUTILAINS

OINTMENT; TOPICAL

TRAVASE

ABBOTT

82,000 UNITS/GM **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N012828 001

TACRINE HYDROCHLORIDE

CAPSULE; ORAL

COGNEX

SHIONOGI INC

EQ 10MG BASE

N020070 001 Sep 09, 1993

EQ 20MG BASE

N020070 002 Sep 09, 1993

EQ 30MG BASE

N020070 003 Sep 09, 1993

EQ 40MG BASE

N020070 004 Sep 09, 1993

TACROLIMUS

CAPSULE; ORAL

TACROLIMUS

WATSON LABS

EQ 5MG BASE

A090402 001 Jul 01, 2010

TALBUTAL

TABLET; ORAL

LOTUSATE

SANOFI AVENTIS US

120MG

N009410 005

TAMOXIFEN CITRATE

TABLET; ORAL

NOLVADEX

ASTRAZENECA

EQ 10MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N017970 001

EQ 20MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N017970 002 Mar 21, 1994

TAMOXIFEN CITRATE

ACTAVIS LABS FL INC

EQ 10MG BASE

A076179 001 Feb 20, 2003

EQ 20MG BASE

A076179 002 Feb 20, 2003

AEGIS PHARMS

EQ 10MG BASE

A076398 001 Mar 31, 2003

EQ 20MG BASE

A076398 002 Mar 31, 2003

IVAX SUB TEVA PHARMS

EQ 10MG BASE

A075740 001 Feb 20, 2003

EQ 20MG BASE

A075740 002 Feb 20, 2003

PHARMACHEMIE

EQ 10MG BASE

A074539 001 Mar 31, 2003

ROXANE

EQ 10MG BASE

A076027 001 Feb 20, 2003

EQ 20MG BASE

A076027 002 Feb 20, 2003

TEVA

EQ 10MG BASE

A074504 001 Apr 28, 2003

EQ 20MG BASE

A074504 002 Apr 28, 2003

TECHNETIUM TC-99M ALBUMIN AGGREGATED

INJECTABLE; INJECTION

TC 99M-LUNGAGGREGATE

GE HEALTHCARE

5mCi/ML

N017848 001

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION

A-N STANNOUS AGGREGATED ALBUMIN

SYNCOR PHARMS

N/A

N017916 001

AN-MAA

PHARMALUCENCE

N/A

N017792 001

LUNGAGGREGATE REAGENT

GE HEALTHCARE

N/A

N017838 001

MACROTEC

BRACCO

N/A

N017833 001

TECHNESCAN MAA

MALLINCKRODT

N/A

N017842 001

TECHNETIUM TC 99M MAA

GE HEALTHCARE

N/A

N017773 001

TECHNETIUM TC-99M ALBUMIN COLLOID KIT

INJECTABLE; INJECTION

MICROLITE

PHARMALUCENCE

N/A

N018263 001 Mar 25, 1983

DISCONTINUED DRUG PRODUCT LIST

TECHNETIUM TC-99M ALBUMIN KIT

INJECTABLE; INJECTION

TECHNETIUM TC 99M HSA

GE HEALTHCARE N/A

N017775 001

TECHNETIUM TC-99M ALBUMIN MICROSPHERES KIT

INJECTABLE; INJECTION

INSTANT MICROSPHERES

3M N/A

N017832 001

TECHNETIUM TC-99M APCITIDE

INJECTABLE; INJECTION

ACUTECT

CIS BIO INTL SA N/A

N020887 001 Sep 14, 1998

TECHNETIUM TC-99M DEPREOTIDE

INJECTABLE; INJECTION

NEO TECT KIT

CIS BIO INTL SA N/A

N021012 001 Aug 03, 1999

TECHNETIUM TC-99M ETIDRONATE KIT

INJECTABLE; INJECTION

CINTICHEM TECHNETIUM 99M HEDSPA

GE HEALTHCARE N/A

N017653 001

MPI STANNOUS DIPHOSPHONATE

GE HEALTHCARE N/A

N017667 001

OSTEOSCAN

MALLINCKRODT N/A

N017454 001

TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT

GE HEALTHCARE N/A

N017562 001

TECHNETIUM TC-99M FERPENTETATE KIT

INJECTABLE; INJECTION

RENOTEC

BRACCO N/A

N017045 001

TECHNETIUM TC-99M GLUCEPTATE KIT

INJECTABLE; INJECTION

GLUCOSCAN

BRISTOL MYERS SQUIBB N/A

N017907 001

TECHNESCAN GLUCEPTATE

DRAXIMAGE N/A

N018272 001 Jan 27, 1982

TECHNETIUM TC-99M LIDOFENIN KIT

INJECTABLE; INJECTION

TECHNESCAN HIDA

DRAXIMAGE N/A

N018489 001 Oct 31, 1986

TECHNETIUM TC-99M MEDRONATE

INJECTABLE; INJECTION

DRAXIMAGE MDP-10

JUBILANT DRAXIMAGE N/A

N018035 001

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION

AMERSCAN MDP KIT

GE HEALTHCARE N/A

N018335 001 Aug 05, 1982

OSTEOLITE

PHARMALUCENCE N/A

N017972 001

TECHNETIUM TC 99M MPI MDP

GE HEALTHCARE N/A

N018141 001

N/A

N018141 002 Jun 12, 1989

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION

MPI DTPA KIT - CHELATE

GE HEALTHCARE N/A

N017255 001

TECHNETIUM TC-99M PENTETATE KIT

GE HEALTHCARE N/A

N017264 002

TECHNETIUM TC-99M POLYPHOSPHATE KIT

INJECTABLE; INJECTION

SODIUM POLYPHOSPHATE-TIN KIT

GE HEALTHCARE N/A

N017664 001

DISCONTINUED DRUG PRODUCT LISTTECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT

INJECTABLE; INJECTION

PYROLITE

PHARMALUCENCE

N/A

N017684 001

TECHNETIUM TC-99M PYROPHOSPHATE KIT

INJECTABLE; INJECTION

PHOSPHOTEC

BRACCO

N/A

N017680 001

TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE; INJECTION

RBC-SCAN

CADEMA

N/A

N020063 001 Jun 11, 1992

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION

MIRALUMA

LANTHEUS MEDCL

N/A

N019785 003 May 23, 1997

TECHNETIUM TC-99M SODIUM PERTECHNETATE

SOLUTION; INJECTION, ORAL

SODIUM PERTECHNETATE TC 99M

GE HEALTHCARE

2-100mCi/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N017471 001

MALLINCKRODT

10-60mCi/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N017725 001

PHARMALUCENCE

12mCi/ML

N017321 001

24mCi/ML

N017321 002

48mCi/ML

N017321 003

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INJECTION, ORAL

MINITEC

BRACCO

0.22-2.22 CI/GENERATOR

N017339 001

SOLUTION; INTRAVENOUS

TECHNELITE

LANTHEUS MEDCL

0.0083-2.7 CI/GENERATOR

N017771 001

ULTRA-TECHNEKOW FM

MALLINCKRODT NUCLEAR

0.25-3 CI/GENERATOR

N017243 002

SOLUTION; INTRAVENOUS, ORAL

TECHNETIUM TC 99M GENERATOR

GE HEALTHCARE

830-16600mCi/GENERATOR

N017693 001

TECHNETIUM TC-99M SUCCIMER KIT

INJECTABLE; INJECTION

MPI DMSA KIDNEY REAGENT

GE HEALTHCARE

N/A

N017944 001 May 18, 1982

TECHNETIUM TC-99M SULFUR COLLOID

SOLUTION; INJECTION, ORAL

TECHNETIUM TC 99M SULFUR COLLOID

GE HEALTHCARE

4mCi/ML

N017456 001

SOLUTION; ORAL

TECHNETIUM TC 99M SULFUR COLLOID

MALLINCKRODT

3mCi/ML

N017724 001

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION; INJECTION, ORAL

TECHNECOLL

MALLINCKRODT

N/A

N017059 001

TECHNETIUM TC 99M TSC

GE HEALTHCARE

N/A

N017784 001

TESULOID

BRACCO

N/A

N016923 001

TECHNETIUM TC-99M TEBOROXIME KIT

INJECTABLE; INJECTION

CARDIOTEC

BRACCO

N/A

N019928 001 Dec 19, 1990

DISCONTINUED DRUG PRODUCT LIST

TEGASEROD MALEATE

TABLET; ORAL

ZELNORM

US WORLDMEDS LLC

EQ 2MG BASE

N021200 001 Jul 24, 2002

EQ 6MG BASE

N021200 002 Jul 24, 2002

TELAPREVIR

TABLET; ORAL

INCIVEK

VERTEX PHARMS

375MG

N201917 001 May 23, 2011

TELBIVUDINE

SOLUTION; ORAL

TYZEKA

NOVARTIS

100MG/5ML

N022154 001 Apr 28, 2009

TELITHROMYCIN

TABLET; ORAL

KETEK

SANOFI AVENTIS US

300MG

N021144 002 Feb 09, 2005

400MG

N021144 001 Apr 01, 2004

TEMAZEPAM

CAPSULE; ORAL

TEMAZ

QUANTUM PHARMICS

15MG

A070564 001 Oct 15, 1985

30MG

A070547 001 Oct 15, 1985

TEMAZEPAM

DURAMED PHARMS BARR

15MG

A071708 001 Sep 29, 1988

30MG

A071709 001 Sep 29, 1988

SUN PHARM INDS

15MG

A071174 001 Jul 10, 1986

30MG

A071175 001 Jul 10, 1986

USL PHARMA

15MG

A070489 001 Jul 07, 1986

30MG

A070490 001 Jul 07, 1986

WATSON LABS

15MG

A070383 001 Mar 23, 1987

15MG

A071446 001 May 21, 1993

30MG

A070384 001 Mar 23, 1987

30MG

A071447 001 May 21, 1993

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

HYTRIN

ABBOTT

EQ 1MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020347 001 Dec 14, 1994

EQ 2MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020347 002 Dec 14, 1994

EQ 5MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020347 003 Dec 14, 1994

EQ 10MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020347 004 Dec 14, 1994

TERAZOSIN HYDROCHLORIDE

MYLAN TECHNOLOGIES

EQ 1MG BASE

A075384 001 Dec 01, 2000

EQ 2MG BASE

A075384 002 Dec 01, 2000

EQ 5MG BASE

A075384 003 Dec 01, 2000

EQ 10MG BASE

A075384 004 Dec 01, 2000

RANBAXY LABS LTD

EQ 1MG BASE

A076021 001 Aug 22, 2002

EQ 2MG BASE

A076021 002 Aug 22, 2002

EQ 5MG BASE

A076021 003 Aug 22, 2002

EQ 10MG BASE

A076021 004 Aug 22, 2002

SANDOZ

EQ 1MG BASE

A075667 001 Jul 28, 2000

EQ 2MG BASE

A075667 002 Jul 28, 2000

EQ 5MG BASE

A075667 003 Jul 28, 2000

EQ 10MG BASE

A075667 004 Jul 28, 2000

TABLET; ORAL

HYTRIN

ABBOTT

EQ 1MG BASE

N019057 001 Aug 07, 1987

EQ 2MG BASE

N019057 002 Aug 07, 1987

EQ 5MG BASE

N019057 003 Aug 07, 1987

DISCONTINUED DRUG PRODUCT LIST

TERAZOSIN HYDROCHLORIDE

TABLET; ORAL

HYTRIN

	EQ 10MG BASE	N019057 004	Aug 07, 1987
TERAZOSIN HYDROCHLORIDE			
IVAX SUB TEVA PHARMS	EQ 1MG BASE	A074530 001	Apr 21, 2000
	EQ 2MG BASE	A074530 002	Apr 21, 2000
	EQ 5MG BASE	A074530 003	Apr 21, 2000
	EQ 10MG BASE	A074530 004	Apr 21, 2000
SANDOZ	EQ 1MG BASE	A074315 001	Dec 31, 1998
	EQ 1MG BASE	A074657 001	Apr 28, 2000
	EQ 2MG BASE	A074315 002	Dec 31, 1998
	EQ 2MG BASE	A074657 002	Apr 28, 2000
	EQ 5MG BASE	A074315 003	Dec 31, 1998
	EQ 5MG BASE	A074657 003	Apr 28, 2000
	EQ 10MG BASE	A074315 004	Dec 31, 1998
	EQ 10MG BASE	A074657 004	Apr 28, 2000
TEVA	EQ 1MG BASE	A074446 001	May 18, 2000
	EQ 2MG BASE	A074446 002	May 18, 2000
	EQ 5MG BASE	A074446 003	May 18, 2000
	EQ 10MG BASE	A074446 004	May 18, 2000

TERBINAFINE

GEL; TOPICAL

LAMISIL

GLAXOSMITHKLINE CONS 1% N020846 001 Apr 29, 1998

TERBINAFINE HYDROCHLORIDE

CREAM; TOPICAL

LAMISIL

NOVARTIS 1% N020192 001 Dec 30, 1992

SOLUTION; TOPICAL

LAMISIL

GLAXOSMITHKLINE CONS 1% N020749 001 Oct 17, 1997

TABLET; ORAL

TERBINAFINE HYDROCHLORIDE

GEDEON RICHTER USA EQ 250MG BASE A077065 001 Jul 02, 2007

MYLAN EQ 250MG BASE A077136 001 Jul 02, 2007

ROXANE EQ 250MG BASE A077223 001 Jul 02, 2007

WOCKHARDT EQ 250MG BASE A078229 001 Jul 02, 2007

TERBUTALINE SULFATE

AEROSOL, METERED; INHALATION

BRETHAIRE

NOVARTIS 0.2MG/INH N018762 001 Aug 17, 1984

BRICANYL

SANOFI AVENTIS US 0.2MG/INH N018000 001 Mar 19, 1985

INJECTABLE; INJECTION

BRETHINE

PHARMACARE 1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** N018571 001

BRICANYL

SANOFI AVENTIS US 1MG/ML N017466 001

TERBUTALINE SULFATE

TEVA PHARMS USA 1MG/ML A076853 001 Jul 20, 2004

TABLET; ORAL

BRETHINE

PHARMACARE LTD 2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** N017849 001

5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** N017849 002

BRICANYL

SANOFI AVENTIS US 2.5MG N017618 001

5MG N017618 002

TERBUTALINE SULFATE

IMPAX LABS 2.5MG A075877 001 Jun 26, 2001

5MG A075877 002 Jun 26, 2001

DISCONTINUED DRUG PRODUCT LISTTERCONAZOLE

SUPPOSITORY; VAGINAL

TERCONAZOLE

FOUGERA PHARMS

80MG

A076850 001 Jul 12, 2006

TERIPARATIDE ACETATE

INJECTABLE; INJECTION

PARATHAR

SANOFI AVENTIS US

200 UNITS/VIAL

N019498 001 Dec 23, 1987

TERIPARATIDE RECOMBINANT HUMAN

INJECTABLE; SUBCUTANEOUS

FORTEO

LILLY

0.75MG/3ML (0.25MG/ML)

N021318 001 Nov 26, 2002

TESAMORELIN ACETATE

POWDER; SUBCUTANEOUS

EGRIFTA

THERATECHNOLOGIES

EQ 2MG BASE/VIAL

N022505 002 Nov 29, 2011

TESTOLACTONE

INJECTABLE; INJECTION

TESLAC

BRISTOL MYERS SQUIBB

100MG/ML

N016119 001

TABLET; ORAL

TESLAC

BRISTOL MYERS SQUIBB

50MG

N016118 001

250MG

N016118 002

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL

ANDRODERM

ALLERGAN SALES LLC

2.5MG/24HR

N020489 001 Sep 29, 1995

5MG/24HR

N020489 002 May 02, 1997

TESTODERM

ALZA

4MG/24HR

N019762 001 Oct 12, 1993

6MG/24HR

N019762 002 Oct 12, 1993

TESTODERM TTS

ALZA

5MG/24HR

N020791 001 Dec 18, 1997

INJECTABLE; INJECTION

TESTOSTERONE

WATSON LABS

25MG/ML

A086420 001 May 10, 1983

50MG/ML

A086419 001 Aug 23, 1983

100MG/ML

A086417 001 Jul 07, 1983

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

DEPO-TESTOSTERONE

PHARMACIA AND UPJOHN

50MG/ML

A085635 001

TESTOSTERONE CYPIONATE

WATSON LABS

100MG/ML

A084401 001

100MG/ML

A086029 001

200MG/ML

A084401 002

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

DELATESTRYL

ENDO PHARMS

200MG/ML

N009165 001

TESTOSTERONE ENANTHATE

WATSON LABS

100MG/ML

A083667 001

100MG/ML

A085599 001

200MG/ML

A083667 002

TESTOSTERONE PROPIONATE

INJECTABLE; INJECTION

TESTOSTERONE PROPIONATE

BEL MAR

25MG/ML

A080741 001

50MG/ML

A080742 001

100MG/ML

A080743 001

ELKINS SINN

25MG/ML

A080276 001

LILLY

50MG/ML

A080254 002

WATSON LABS

25MG/ML

A080188 001

25MG/ML

A085490 001

50MG/ML

A080188 002

50MG/ML

A085490 002

100MG/ML

A080188 003

DISCONTINUED DRUG PRODUCT LISTTESTOSTERONE PROPIONATE

INJECTABLE; INJECTION

TESTOSTERONE PROPIONATE

100MG/ML

A083595 003

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

BRISTACYCLINE

BRISTOL

250MG

A061658 001

250MG

A061888 001

500MG

A061658 002

500MG

A061888 002

CYCLOPAR

WARNER CHILCOTT

250MG

A061725 001

250MG

A062175 001

250MG

A062332 001

500MG

A061725 002

500MG

A062332 002

PANMYCIN

PHARMACIA AND UPJOHN

250MG

A060347 001

RETET

SOLVAY

250MG

A061443 001

500MG

A061443 002

ROBITET

WYETH AYERST

250MG

A061734 001

500MG

A061734 002

SUMYCIN

APOTHECON

100MG

A060429 002

125MG

A060429 004

250MG

A060429 001

500MG

A060429 003

TETRACHEL

ANGUS

250MG

A060343 001

500MG

A060343 003

TETRACYCLINE HYDROCHLORIDE

ABBOTT

250MG

A061802 001

500MG

A061802 002

ELKINS SINN

250MG

A060059 001

FERRANTE

125MG

A060173 001

250MG

A060173 002

HEATHER

250MG

A061148 001

500MG

A061148 002

HIKMA PHARMS LLC

250MG

A060768 001

500MG

A060768 002

IDT AUSTRALIA LTD

250MG

A061471 001

IVAX SUB TEVA PHARMS

250MG

A060704 001

500MG

A060704 002

MAST MM

250MG

A062085 001

MYLAN

250MG

A060783 001

500MG

A060783 002

PUREPAC PHARM

250MG

A060290 001

500MG

A060290 002

PVT FORM

250MG

A062686 001

Jul 24, 1986

500MG

A062686 002

Jul 24, 1986

ROXANE

500MG

A061214 002

SUN PHARM INDS

250MG

A060736 001

500MG

A060736 002

SUPERPHARM

250MG

A062540 001

Mar 21, 1985

500MG

A062540 002

Mar 21, 1985

VALEANT PHARM INTL

250MG

A060471 001

500MG

A060471 002

WARNER CHILCOTT

250MG

A062300 001

500MG

A062300 002

WATSON LABS

250MG

A062103 001

250MG

A062343 001

500MG

A062103 002

500MG

A062343 002

WYETH AYERST

250MG

A061685 001

500MG

A061685 002

TETRACYN

PFIPHARMECS

250MG

A060082 003

500MG

A060082 004

DISCONTINUED DRUG PRODUCT LISTTETRACYCLINE HYDROCHLORIDE

FIBER, EXTENDED RELEASE; PERIODONTAL

ACTISITE

SCHIFF AND CO 12.7MG/FIBER

N050653 001 Mar 25, 1994

FOR SOLUTION; TOPICAL

TOPICYCLINE

SHIRE 2.2MG/ML

N050493 001

INJECTABLE; INJECTION

ACHROMYCIN

LEDERLE 250MG/VIAL

N050273 002

500MG/VIAL

N050273 003

TETRACYN

PFIZER 250MG/VIAL

A060096 001

500MG/VIAL

A060096 002

OINTMENT; OPHTHALMIC

ACHROMYCIN

STORZ 10MG/GM

N050266 001

SUSPENSION; ORAL

ACHROMYCIN V

LEDERLE 125MG/5ML

N050263 002

SUMYCIN

PAR PHARM 125MG/5ML

A060400 001

TETRACYCLINE HYDROCHLORIDE

ALPHARMA US PHARMS 125MG/5ML

A060633 001

FERRANTE 125MG/5ML

A060174 001

PROTER 125MG/5ML

A060446 001

PUREPAC PHARM 125MG/5ML

A060291 001

TETRACYN

PFIPHARMECS 125MG/5ML

A060095 001

TETRAMED

IVAX SUB TEVA PHARMS 125MG/5ML

A061468 001

SUSPENSION/DROPS; OPHTHALMIC

ACHROMYCIN

STORZ 1%

N050268 001

TABLET; ORAL

PANMYCIN

PHARMACIA AND UPJOHN 250MG

A061705 001

500MG

A061705 002

SUMYCIN

PAR PHARM 50MG

A061147 003

100MG

A061147 002

250MG

A061147 001

500MG

A061147 004

TETRACYCLINE PHOSPHATE COMPLEX

CAPSULE; ORAL

TETREX

BRISTOL EQ 100MG HCL

A061653 001

EQ 250MG HCL

A061653 002

EQ 250MG HCL

A061889 002

EQ 250MG HCL

N050212 002

EQ 500MG HCL

A061653 003

EQ 500MG HCL

A061889 001

EQ 500MG HCL

N050212 003

THALLOUS CHLORIDE TL-201

INJECTABLE; INJECTION

THALLOUS CHLORIDE TL 201

BRACCO 1mCi/ML

N018548 001 Dec 30, 1982

TRACE LIFE 1mCi/ML

A075569 001 Nov 21, 2001

INJECTABLE; INTRAVENOUS

THALLOUS CHLORIDE TL 201

MALLINKRODT NUCLEAR 2mCi/ML

A077698 001 Nov 09, 2006

THEOPHYLLINE

CAPSULE; ORAL

BRONKODYL

SANOFI AVENTIS US 100MG

A085264 001

200MG

A085264 002

ELIXOPHYLLIN

FOREST LABS 100MG

A085545 001 Jul 31, 1984

200MG

A083921 001 Jul 31, 1984

DISCONTINUED DRUG PRODUCT LIST

THEOPHYLLINE

CAPSULE;ORAL

SOMOPHYLLIN-T

FISONS

100MG

A087155 001 Feb 25, 1985

200MG

A087155 002 Feb 25, 1985

250MG

A087155 003 Feb 25, 1985

THEOPHYLLINE

KV PHARM

100MG

A085263 001

200MG

A085263 002

SCHERER RP

100MG

A084731 002 Nov 07, 1986

200MG

A084731 001 Nov 07, 1986

250MG

A084731 003 Nov 07, 1986

CAPSULE, EXTENDED RELEASE;ORAL

AEROLATE III

FLEMING PHARMS

65MG

A085075 003 Nov 24, 1986

AEROLATE JR

FLEMING PHARMS

130MG

A085075 002 Nov 24, 1986

AEROLATE SR

FLEMING PHARMS

260MG

A085075 001 Nov 24, 1986

ELIXOPHYLLIN SR

FOREST LABS

125MG

A086826 001 Jan 29, 1985

250MG

A086826 002 Jan 29, 1985

SLO-BID

SANOFI AVENTIS US

50MG

A088269 001 Jan 31, 1985

75MG

A089539 001 May 10, 1989

100MG

A087892 001 Jan 31, 1985

125MG

A089540 001 May 10, 1989

200MG

A087893 001 Jan 31, 1985

300MG

A087894 001 Jan 31, 1985

SLO-PHYLLIN

SANOFI AVENTIS US

60MG

A085206 001 May 24, 1982

125MG

A085203 001 May 24, 1982

250MG

A085205 001 May 24, 1982

SOMOPHYLLIN-CRT

GRAHAM DM

50MG

A087763 001 Feb 27, 1985

100MG

A087194 001

200MG

A088382 001 Feb 27, 1985

250MG

A087193 001

300MG

A088383 001 Feb 27, 1985

THEO-DUR

SCHERING

50MG

A088022 001 Sep 10, 1985

75MG

A088015 001 Sep 10, 1985

125MG

A088016 001 Sep 10, 1985

200MG

A087995 001 Sep 10, 1985

THEOBID

WHITBY

260MG

A085983 001 Mar 20, 1985

THEOBID JR.

WHITBY

130MG

A087854 001 Mar 20, 1985

THEOCLEAR L.A.-130

SCHWARZ PHARMA

130MG

A086569 001 May 27, 1982

THEOCLEAR L.A.-260

SCHWARZ PHARMA

260MG

A086569 002 May 27, 1982

THEOPHYL-SR

ORTHO MCNEIL PHARM

125MG

A086480 001 Feb 08, 1985

250MG

A086471 001 Feb 08, 1985

THEOPHYLLINE

CENT PHARMS

125MG

A088654 001 Feb 12, 1985

250MG

A088689 001 Feb 12, 1985

HOSPIRA

100MG

A089976 001 Jan 04, 1995

200MG

A089977 001 Jan 04, 1995

300MG

A089932 001 Jan 04, 1995

INWOOD LABS

100MG

A040052 001 Feb 14, 1994

125MG

A040052 002 Feb 14, 1994

200MG

A040052 003 Feb 14, 1994

300MG

A040052 004 Feb 14, 1994

SANDOZ

260MG

A087462 001 May 11, 1982

THEOPHYLLINE-SR

SCHERER RP

300MG

A088255 001 Jun 12, 1986

THEOVENT

SCHERING

125MG

A087010 001 Jan 31, 1985

250MG

A087910 001 Jan 31, 1985

DISCONTINUED DRUG PRODUCT LIST

THEOPHYLLINE

ELIXIR; ORAL

ELIXOMIN

CENCI	80MG/15ML	A088303	001	Jan 25, 1984
LANOPHYLLIN				
LANNETT	80MG/15ML	A084578	001	
THEOLIXIR				
PANRAY	80MG/15ML	A084559	001	
THEOPHYL-225				
ORTHO MCNEIL PHARM	112.5MG/15ML	A086485	001	
THEOPHYLLINE				
ALPHARMA US PHARMS	80MG/15ML	A089223	001	May 27, 1988
CENCI	80MG/15ML	A087679	001	Apr 15, 1982
HALSEY	80MG/15ML	A085169	001	
FERRIGO	80MG/15ML	A085952	001	
PHARM ASSOC	80MG/15ML	A086720	001	
PRECISION DOSE	80MG/15ML	A085863	001	
ROXANE	80MG/15ML	A084739	001	
TARO	80MG/15ML	A089626	001	Oct 28, 1988
WOCKHARDT	80MG/15ML	A086748	001	

INJECTABLE; INJECTION

THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	40MG/100ML	N019083	001	Nov 07, 1984
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	80MG/100ML	N019083	002	Nov 07, 1984
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	160MG/100ML	N019083	003	Nov 07, 1984
THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	200MG/100ML	N019212	001	Nov 07, 1984
	200MG/100ML	N019826	004	Aug 14, 1992
THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	4MG/ML	N019212	003	Nov 07, 1984
	400MG/100ML	N019212	002	Nov 07, 1984
	400MG/100ML	N019826	005	Aug 14, 1992
THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4MG/ML	N018649	007	Jul 26, 1982
	40MG/100ML	N018649	001	Jul 26, 1982
	80MG/100ML	N018649	002	Jul 26, 1982
	160MG/100ML	N018649	003	Jul 26, 1982
	200MG/100ML	N018649	004	Jul 26, 1982
	320MG/100ML	N018649	006	Nov 13, 1985
	400MG/100ML	N018649	005	Jul 26, 1982
THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER				
HOSPIRA INC	80MG/100ML	N019211	002	Dec 14, 1984
	200MG/100ML	N019211	004	Dec 14, 1984
	400MG/100ML	N019211	005	Dec 14, 1984

SOLUTION; ORAL

AEROLATE

FLEMING PHARMS	150MG/15ML	A089141	001	Dec 03, 1986
THEOLAIR				
3M	80MG/15ML	A086107	001	
THEOPHYLLINE				
ROXANE	80MG/15ML	A087449	001	Sep 15, 1983

SUSPENSION; ORAL

ELIXICON

FOREST LABS	100MG/5ML	A085502	001	
-------------	-----------	---------	-----	--

SYRUP; ORAL

ACCURBRON

SANOFI AVENTIS US	150MG/15ML	A088746	001	Nov 22, 1985
AQUAPHYLLIN				
FERNDALE LABS	80MG/15ML	A087917	001	Jan 18, 1983
SLO-PHYLLIN				
SANOFI AVENTIS US	80MG/15ML	A085187	001	
THEOCLEAR-80				
CENT PHARMS	80MG/15ML	A087095	001	Mar 01, 1982
THEOPHYLLINE				
ALPHARMA US PHARMS	80MG/15ML	A086001	001	
	150MG/15ML	A086545	001	

TABLET; ORAL

QUIBRON-T

MONARCH PHARMS	300MG	A088656	001	Aug 22, 1985
----------------	-------	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

THEOPHYLLINE

TABLET; ORAL

SLO-PHYLLIN

SANOFI AVENTIS US	100MG	A085202 001
	200MG	A085204 001

THEOCLEAR-100

CENT PHARMS	100MG	A085353 002
-------------	-------	-------------

THEOCLEAR-200

CENT PHARMS	200MG	A085353 001
-------------	-------	-------------

THEOLAIR

MEDICIS	125MG	A086399 001
	250MG	A086399 002

THEOPHYL-225

ORTHO MCNEIL PHARM	225MG	A084726 001
--------------------	-------	-------------

TABLET, CHEWABLE; ORAL

THEOPHYL

ORTHO MCNEIL PHARM	100MG	A086506 001	Sep 12, 1985
--------------------	-------	-------------	--------------

TABLET, EXTENDED RELEASE; ORAL

DURAPHYL

FOREST LABS	100MG	A088503 001	Apr 03, 1985
	200MG	A088504 001	Apr 03, 1985
	300MG	A088505 001	Apr 03, 1985

LABID

WARNER CHILCOTT	250MG	A087225 001
-----------------	-------	-------------

QUIBRON-T/SR

MONARCH PHARMS	300MG	A087563 001	Jun 21, 1983
----------------	-------	-------------	--------------

SUSTAIRE

ROERIG	100MG	A085665 001
	300MG	A085665 002

T-PHYL

PHARM RES ASSOC	200MG	A088253 001	Aug 17, 1983
-----------------	-------	-------------	--------------

THEO-DUR

SCHERING	100MG	A085328 001	
	200MG	A086998 001	
	300MG	A085328 002	
	450MG	A089131 001	Jun 25, 1986

THEOCHRON

NOSTRUM LABS INC	300MG	A087400 002	Jan 11, 1983
------------------	-------	-------------	--------------

THEOLAIR-SR

3M	200MG	A088369 001	Jul 16, 1987
	250MG	A086363 002	Jul 16, 1987
	300MG	A088364 001	Jul 16, 1987
	500MG	A089132 001	Jul 16, 1987

THEOPHYLLINE

ABLE	300MG	A040548 001	Apr 30, 2004
	400MG	A040543 001	Apr 27, 2004
	450MG	A040546 001	Apr 30, 2004
	600MG	A040539 001	Apr 27, 2004
INWOOD LABS	450MG	A040034 001	Apr 28, 1995
TEVA PHARMS	450MG	A081236 001	Nov 09, 1992

UNI-DUR

SCHERING	400MG	A089822 001	Jan 04, 1995
	600MG	A089823 001	Jan 04, 1995

THEOPHYLLINE SODIUM GLYCINATE

ELIXIR; ORAL

SYNOHYLATE

CENT PHARMS	EQ 165MG BASE/15ML	N006333 008
-------------	--------------------	-------------

TABLET; ORAL

ASBRON

NOVARTIS	EQ 150MG BASE	A085148 001
----------	---------------	-------------

THIABENDAZOLE

SUSPENSION; ORAL

MINTEZOL

MERCK SHARP DOHME	500MG/5ML	N016097 001
-------------------	-----------	-------------

TABLET, CHEWABLE; ORAL

MINTEZOL

MERCK SHARP DOHME	500MG	N016096 001
-------------------	-------	-------------

DISCONTINUED DRUG PRODUCT LIST

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

BETALIN S

LILLY

100MG/ML

A080853 001

THIAMINE HYDROCHLORIDE

ABRAXIS PHARM

100MG/ML

A080509 001

AKORN

100MG/ML

A087968 001

Oct 01, 1982

BEL MAR

100MG/ML

A080718 001

200MG/ML

A080712 001

DELL LABS

100MG/ML

A083775 001

EUROHLTH INTL SARL

100MG/ML

A080575 001

HOSPIRA

100MG/ML

A040079 001

May 03, 1996

LUITPOLD

100MG/ML

A080667 001

PARKE DAVIS

100MG/ML

A080770 001

WATSON LABS

100MG/ML

A080571 001

100MG/ML

A083534 001

200MG/ML

A080571 002

200MG/ML

A083534 002

WYETH AYERST

100MG/ML

A080553 001

THIAMYLAL SODIUM

INJECTABLE; INJECTION

SURITAL

PARKEDALE

1GM/VIAL

N007600 003

5GM/VIAL

N007600 005

10GM/VIAL

N007600 009

THIETHYLPERAZINE MALATE

INJECTABLE; INJECTION

TORECAN

NOVARTIS

5MG/ML

N012754 002

THIETHYLPERAZINE MALEATE

SUPPOSITORY; RECTAL

TORECAN

NOVARTIS

10MG

N013247 001

TABLET; ORAL

TORECAN

NOVARTIS

10MG

N012753 001

THIOPENTAL SODIUM

SUSPENSION; RECTAL

PENTOTHAL

ABBOTT

400MG/GM

N011679 001

THIORIDAZINE

SUSPENSION; ORAL

MELLARIL-S

NOVARTIS

EQ 25MG HCL/5ML

N017923 001

EQ 100MG HCL/5ML

N017923 002

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

MELLARIL

NOVARTIS

30MG/ML

N011808 012

100MG/ML

N011808 018

THIORIDAZINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC

100MG/ML

A088229 001

Aug 23, 1983

ALPHARMA US PHARMS

30MG/ML

A087766 001

Apr 26, 1983

ANI PHARMS INC

100MG/ML

A089603 001

Nov 09, 1987

HI TECH PHARMA

30MG/ML

A040125 001

Aug 16, 1996

100MG/ML

A040126 001

Aug 16, 1996

PHARM ASSOC

30MG/ML

A040187 001

Aug 28, 1997

100MG/ML

A040213 001

May 29, 1998

SANDOZ

30MG/ML

A088307 001

Nov 23, 1983

100MG/ML

A088308 001

Nov 23, 1983

TEVA PHARMS

30MG/ML

A089602 001

Nov 09, 1987

WOCKHARDT

30MG/ML

A088258 001

Jul 25, 1983

100MG/ML

A088227 001

Jul 05, 1983

THIORIDAZINE HYDROCHLORIDE INTENSOL

ROXANE

30MG/ML

A088941 001

Dec 16, 1985

100MG/ML

A088942 001

Dec 16, 1985

TABLET; ORAL

MELLARIL

NOVARTIS

10MG **Federal Register determination

N011808 003

DISCONTINUED DRUG PRODUCT LIST

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

MELLARIL

that product was not discontinued or
 withdrawn for safety or efficacy
 reasons**

15MG **Federal Register determination N011808 016

that product was not discontinued or
 withdrawn for safety or efficacy
 reasons**

25MG **Federal Register determination N011808 006

that product was not discontinued or
 withdrawn for safety or efficacy
 reasons**

50MG **Federal Register determination N011808 011

that product was not discontinued or
 withdrawn for safety or efficacy
 reasons**

100MG **Federal Register determination N011808 009

that product was not discontinued or
 withdrawn for safety or efficacy
 reasons**

150MG **Federal Register determination N011808 017

that product was not discontinued or
 withdrawn for safety or efficacy
 reasons**

200MG **Federal Register determination N011808 015

that product was not discontinued or
 withdrawn for safety or efficacy
 reasons**

THIORIDAZINE HYDROCHLORIDE

ANI PHARMS INC

10MG A088270 001 Apr 14, 1983

10MG A088493 001 May 17, 1985

15MG A088271 001 Apr 14, 1983

25MG A088272 001 Apr 14, 1983

50MG A088194 001 Apr 14, 1983

100MG A088273 001 Oct 03, 1983

100MG A088456 001 May 17, 1985

MUTUAL PHARM

10MG A088375 001 Nov 18, 1983

25MG A087264 001 Nov 18, 1983

50MG A088370 001 Nov 18, 1983

100MG A088379 001 Nov 16, 1983

MYLAN

10MG A088332 001 Jun 27, 1983

25MG A088333 001 Jun 27, 1983

50MG A088334 001 Jun 27, 1983

100MG A088335 001 Nov 18, 1983

PAR PHARM

10MG A088351 001 Dec 05, 1983

15MG A088352 001 Dec 05, 1983

25MG A088336 001 Dec 05, 1983

50MG A088322 001 Dec 05, 1983

100MG A088480 001 Dec 29, 1983

150MG A089764 001 Feb 09, 1988

200MG A089765 001 Feb 09, 1988

ROXANE

10MG A088663 001 Mar 15, 1984

25MG A088664 001 Mar 15, 1984

50MG A088665 001 Mar 15, 1984

100MG A089048 001 Feb 26, 1985

SANDOZ

10MG A088131 001 Aug 30, 1983

15MG A088132 001 Aug 30, 1983

25MG A088133 001 Aug 30, 1983

50MG A088134 001 Aug 30, 1983

100MG A088135 001 Nov 20, 1984

150MG A088136 001 Sep 17, 1986

200MG A088137 001 Sep 17, 1986

SUN PHARM INDS

15MG A088461 001 Nov 18, 1983

150MG A088737 001 Sep 26, 1984

200MG A088738 001 Oct 16, 1984

SUPERPHARM

10MG A089103 001 Jul 02, 1985

25MG A089104 001 Jul 02, 1985

50MG A089105 001 Jul 02, 1985

WATSON LABS

10MG A088412 001 Sep 12, 1983

10MG A088476 001 Nov 08, 1983

10MG A088561 001 May 11, 1984

15MG A088345 001 Jul 28, 1983

15MG A088477 001 Nov 08, 1983

DISCONTINUED DRUG PRODUCT LIST

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

15MG	A088562	001	May 11, 1984	
25MG	A088296	001	Jul 28, 1983	
25MG	A088478	001	Nov 08, 1983	
25MG	A088567	001	May 11, 1984	
25MG	A088755	001	Jul 24, 1984	
50MG	A088323	001	Jul 28, 1983	
50MG	A088479	001	Nov 08, 1983	
50MG	A088563	001	May 11, 1984	
100MG	A088284	001	Aug 25, 1983	
100MG	A088564	001	May 11, 1984	
100MG	A088736	001	Jul 24, 1984	
150MG	A088410	001	Mar 05, 1984	
150MG	A088869	001	Jun 28, 1985	
200MG	A088381	001	Mar 14, 1984	
200MG	A088872	001	Apr 26, 1985	
WEST WARD	10MG	A088658	001	Mar 26, 1984
	15MG	A088659	001	Mar 26, 1984
	25MG	A088660	001	Mar 26, 1984
	50MG	A088661	001	Mar 26, 1984

THIOTEPA

INJECTABLE; INJECTION

THIOPLEX

IMMUNEX

15MG/VIAL	**Federal Register	N020058	001	Dec 22, 1994
determination that product was not discontinued or withdrawn for safety or efficacy reasons**				

THIOTEPA

FRESENIUS KABI USA

15MG/VIAL		A075698	001	Sep 20, 2001
-----------	--	---------	-----	--------------

IMMUNEX

15MG/VIAL		N011683	001	
-----------	--	---------	-----	--

TEVA PARENTERAL

15MG/VIAL	**Federal Register	A075730	001	Apr 20, 2001
determination that product was not discontinued or withdrawn for safety or efficacy reasons**				

30MG/VIAL	**Federal Register	A075730	002	Apr 20, 2001
determination that product was not discontinued or withdrawn for safety or efficacy reasons**				

THIOTHIXENE

CAPSULE; ORAL

NAVANE

PFIZER

1MG		N016584	001	
2MG		N016584	002	
5MG		N016584	003	
10MG		N016584	004	
20MG		N016584	005	

THIOTHIXENE

AM THERAP

1MG		A071884	001	Aug 12, 1987
2MG		A071885	001	Aug 12, 1987
5MG		A071886	001	Aug 12, 1987
10MG		A071887	001	Aug 12, 1987
20MG		A072200	001	Dec 17, 1987

SANDOZ

1MG		A071529	002	Jun 24, 1987
2MG		A071529	003	Jun 24, 1987
5MG		A071529	001	Jun 24, 1987
10MG		A071529	004	Jun 24, 1987

WATSON LABS

1MG		A070600	001	Jun 05, 1987
2MG		A070601	001	Jun 05, 1987
2MG		A071626	001	Jun 25, 1987
5MG		A070602	001	Jun 05, 1987
5MG		A071627	001	Jun 25, 1987
10MG		A070603	001	Jun 05, 1987
10MG		A071628	001	Jun 25, 1987

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL

NAVANE

PFIZER

EQ 5MG BASE/ML		N016758	001	
----------------	--	---------	-----	--

THIOTHIXENE HYDROCHLORIDE

ALPHARMA US PHARMS

EQ 5MG BASE/ML		A070969	001	Oct 16, 1987
----------------	--	---------	-----	--------------

PACO

EQ 1MG BASE/ML		A071917	001	Sep 20, 1989
----------------	--	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL

THIOTHIXENE HYDROCHLORIDE

	EQ 5MG BASE/ML	A071939 001	Dec 16, 1988
TEVA	EQ 5MG BASE/ML	A071184 001	Jun 22, 1987
TEVA PHARMS	EQ 5MG BASE/ML	A071554 001	Oct 16, 1987
THIOTHIXENE HYDROCHLORIDE INTENSOL			
CYCLE PHARMS LTD	EQ 5MG BASE/ML	A073494 001	Jun 30, 1992

INJECTABLE; INJECTION

NAVANE

PFIZER	EQ 2MG BASE/ML	N016904 001	
	EQ 10MG BASE/VIAL	N016904 002	

THYROGLOBULIN

TABLET; ORAL

PROLOID

PARKE DAVIS	16MG	N002245 009	
	32MG	N002245 005	
	65MG	N002245 002	
	100MG	N002245 008	
	130MG	N002245 010	
	200MG	N002245 007	
	325MG	N002245 004	

THYROGLOBULIN

IMPAX LABS	64.8MG	A080151 001	
------------	--------	-------------	--

THYTROPIN

INJECTABLE; INJECTION

THYTROPAR

SANOFI AVENTIS US	10 IU/VIAL	N008682 001	
-------------------	------------	-------------	--

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRIL

CEPHALON	6MG	N020646 006	Nov 29, 2005
	8MG	N020646 007	Nov 29, 2005
	10MG	N020646 008	Nov 29, 2005
	20MG	N020646 004	Sep 30, 1997

TICARCILLIN DISODIUM

INJECTABLE; INJECTION

TICAR

GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	N050497 001	
	EQ 3GM BASE/VIAL	A062690 001	Dec 19, 1986
	EQ 3GM BASE/VIAL	N050497 002	
	EQ 6GM BASE/VIAL	N050497 003	
	EQ 20GM BASE/VIAL	N050497 004	
	EQ 30GM BASE/VIAL	N050497 005	Apr 04, 1984

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLID

ROCHE PALO	125MG	N019979 001	Mar 24, 1993
	250MG	N019979 002	Oct 31, 1991

TICLOPIDINE HYDROCHLORIDE

ACTAVIS ELIZABETH	250MG	A075253 001	Aug 20, 1999
MYLAN	250MG	A075161 001	Sep 13, 1999
	250MG	A075316 001	Nov 02, 1999
SANDOZ	250MG	A075318 001	Aug 20, 1999
	250MG	A075326 001	Aug 20, 1999
WATSON LABS	250MG	A075309 001	Apr 26, 2000

TILUDRONATE DISODIUM

TABLET; ORAL

SKELID

SANOFI AVENTIS US	EQ 200MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020707 001	Mar 07, 1997
-------------------	--	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

TIMOLOL MALEATE

AKORN	EQ 0.25% BASE	A074465 001	Mar 25, 1997
	EQ 0.25% BASE	A074515 001	Mar 25, 1997
APOTEX INC	EQ 0.25% BASE	A075411 001	Sep 08, 2000
	EQ 0.5% BASE	A075412 001	Sep 08, 2000
FOUGERA	EQ 0.25% BASE	A074667 001	Mar 25, 1997
	EQ 0.5% BASE	A074668 001	Mar 25, 1997

TABLET;ORAL

BLOCADREN

MERCK	5MG	N018017 001	
	10MG	N018017 002	
	20MG	N018017 004	

TIMOLOL MALEATE

QUANTUM PHARMICS	5MG	A072466 001	May 19, 1989
	10MG	A072467 001	May 19, 1989
	20MG	A072468 001	May 19, 1989
SANDOZ	5MG	A072550 001	Apr 13, 1989
	10MG	A072551 001	Apr 13, 1989
	20MG	A072552 001	Apr 13, 1989
TEVA	5MG	A072648 001	Jun 16, 1993
	10MG	A072649 001	Jun 16, 1993
	20MG	A072650 001	Jun 16, 1993
USL PHARMA	5MG	A072001 001	Apr 11, 1989
	10MG	A072002 001	Apr 11, 1989
	20MG	A072003 001	Apr 11, 1989
WATSON LABS	5MG	A072269 001	Apr 11, 1989
	5MG	A072917 001	Jul 31, 1991
	10MG	A072270 001	Apr 11, 1989
	10MG	A072918 001	Jul 31, 1991
	20MG	A072271 001	Apr 11, 1989
	20MG	A072919 001	Jul 31, 1991

TINZAPARIN SODIUM

INJECTABLE;INJECTION

INNOHEP

LEO PHARMA AS	20,000 IU/ML	N020484 001	Jul 14, 2000
---------------	--------------	-------------	--------------

TIOCONAZOLE

CREAM;TOPICAL

TZ-3

PFIZER	1%	N018682 001	Feb 18, 1983
--------	----	-------------	--------------

TIROFIBAN HYDROCHLORIDE

INJECTABLE;INJECTION

AGGRASTAT

MEDICURE	EQ 12.5MG BASE/50ML (EQ 0.25MG BASE/ML)	N020912 001	May 14, 1998
	EQ 25MG BASE/500ML (EQ 0.05MG BASE/ML)	N020913 001	May 14, 1998

TIZANIDINE HYDROCHLORIDE

TABLET;ORAL

TIZANIDINE HYDROCHLORIDE

ACTAVIS ELIZABETH	EQ 2MG BASE	A076283 001	Jul 12, 2002
	EQ 4MG BASE	A076283 002	Jul 12, 2002
BARR	EQ 2MG BASE	A076371 001	Apr 09, 2003
	EQ 4MG BASE	A076371 002	Apr 09, 2003
IVAX SUB TEVA PHARMS	EQ 2MG BASE	A076321 001	Sep 30, 2004
	EQ 4MG BASE	A076321 002	Sep 30, 2004
MYLAN PHARMS INC	EQ 2MG BASE	A076282 001	Dec 16, 2003
	EQ 4MG BASE	A076282 002	Dec 16, 2003

ZANAFLEX

ACORDA	EQ 2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020397 002	Feb 04, 2000
--------	--	-------------	--------------

TOBRAMYCIN

SOLUTION/DROPS;OPHTHALMIC

TOBRAMYCIN

ALCON PHARMS LTD	0.3%	A063176 001	May 25, 1994
APOTEX INC	0.3%	A065087 001	Feb 25, 2002

DISCONTINUED DRUG PRODUCT LISTTOBRAMYCIN SULFATE

INJECTABLE; INJECTION

NEBCIN

LILLY	EQ 10MG BASE/ML	A062008	004	
	EQ 10MG BASE/ML	A062707	001	Apr 29, 1987
	EQ 10MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050477	005	
	EQ 40MG BASE/ML	A062008	001	
	EQ 1.2GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050519	001	

TOBRAMYCIN SULFATE

APOTHECON	EQ 10MG BASE/ML	A064021	001	May 31, 1994
	EQ 40MG BASE/ML	A064021	002	May 31, 1994
	EQ 40MG BASE/ML	A064026	001	May 31, 1994
HOSPIRA	EQ 10MG BASE/ML	A063080	001	Apr 30, 1991
	EQ 40MG BASE/ML	A063161	001	May 29, 1991
IGI LABS INC	EQ 10MG BASE/ML	A063119	001	Oct 31, 1994
	EQ 40MG BASE/ML	A063120	001	Oct 31, 1994
	EQ 40MG BASE/ML	A063121	001	Oct 31, 1994
	EQ 40MG BASE/ML	A063122	001	Oct 31, 1994
WATSON LABS INC	EQ 10MG BASE/ML	A062945	001	Aug 09, 1989
	EQ 40MG BASE/ML	A062945	002	Aug 09, 1989
WEST-WARD PHARMS INT	EQ 10MG BASE/ML	A063113	001	Apr 26, 1991
	EQ 10MG BASE/ML	A063128	001	Nov 27, 1991
	EQ 40MG BASE/ML	A063118	001	Jul 29, 1991
	EQ 40MG BASE/ML	A063127	001	Nov 27, 1991

TOBRAMYCIN SULFATE (PHARMACY BULK)

HOSPIRA	EQ 40MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A063116	001	May 18, 1992
---------	---	---------	-----	--------------

TOCAINIDE HYDROCHLORIDE

TABLET; ORAL

TONOCARD

ASTRAZENECA	400MG	N018257	001	Nov 09, 1984
	600MG	N018257	002	Nov 09, 1984

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

BARR	100MG	A070162	001	Jan 14, 1986
	250MG	A070163	001	Jan 14, 1986
	500MG	A070164	001	Jan 14, 1986
DURAMED PHARMS BARR	100MG	A070165	001	Jan 10, 1986
	250MG	A070166	001	Jan 10, 1986
	500MG	A070167	001	Jan 10, 1986
G AND W LABS INC	100MG	N018894	001	Nov 02, 1984
	250MG	N018894	002	Nov 02, 1984
	500MG	N018894	003	Nov 02, 1984
INTERPHARM	250MG	A071270	001	Sep 23, 1986
	500MG	A071271	001	Sep 23, 1986
PAR PHARM	100MG	A070159	001	Jan 06, 1986
	250MG	A070160	001	Jan 06, 1986
	500MG	A070161	001	Jan 06, 1986
SANDOZ	100MG	A071633	001	Dec 09, 1987
	250MG	A070289	001	Mar 13, 1986
	500MG	A070290	001	Mar 13, 1986
SUN PHARM INDS	100MG	A071357	001	Jul 16, 1987
	250MG	A071358	001	Jul 16, 1987
	500MG	A071359	001	Jul 16, 1987
SUPERPHARM	250MG	A070763	001	Jun 16, 1986
	500MG	A070764	001	Jun 16, 1986
USL PHARMA	100MG	A071355	001	Jan 11, 1988
	250MG	A070168	001	Apr 02, 1986
	500MG	A070169	001	Apr 02, 1986
WATSON LABS	100MG	A070242	001	Aug 01, 1986
	100MG	A070513	001	Jan 09, 1986
	250MG	A070243	001	Aug 01, 1986
	250MG	A070514	001	Jan 09, 1986
	500MG	A070244	001	Aug 01, 1986

DISCONTINUED DRUG PRODUCT LIST

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

500MG

A070515 001 Jan 09, 1986

TOLINASE

PHARMACIA AND UPJOHN

100MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N015500 002

250MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N015500 004

500MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N015500 005

TOLAZOLINE HYDROCHLORIDE

INJECTABLE; INJECTION

PRISCOLINE

NOVARTIS

25MG/ML

N006403 005 Feb 22, 1985

TOLBUTAMIDE

TABLET; ORAL

ORINASE

PHARMACIA AND UPJOHN

250MG

N010670 002

500MG

N010670 001

TOLBUTAMIDE

ALRA

500MG

A086141 001

ASCOT

500MG

A087541 001 Mar 01, 1983

BARR

500MG

A087121 001

DAVA PHARMS INC

500MG

A086926 001

IVAX PHARMS

500MG

A087093 001

PARKE DAVIS

500MG

A086047 001

PUREPAC PHARM

500MG

A088950 001 Jun 17, 1985

SANDOZ

500MG

A086574 001

500MG

N012678 001

SUPERPHARM

500MG

A088893 001 Nov 19, 1984

VANGARD

500MG

A087876 001 Apr 20, 1982

WATSON LABS

250MG

A089110 001 May 29, 1987

500MG

A086109 001

500MG

A087318 001

500MG

A089111 001 May 29, 1987

TOLBUTAMIDE SODIUM

INJECTABLE; INJECTION

ORINASE DIAGNOSTIC

PHARMACIA AND UPJOHN

EQ 1GM BASE/VIAL

N012095 001

TOLCAPONE

TABLET; ORAL

TASMAR

VALEANT PHARMS LLC

200MG

N020697 002 Jan 29, 1998

TOLMETIN SODIUM

CAPSULE; ORAL

TOLECTIN DS

ORTHO MCNEIL JANSSEN

EQ 400MG BASE

N018084 001

TOLMETIN SODIUM

ACTAVIS ELIZABETH

EQ 400MG BASE

A073308 001 Jan 24, 1992

IVAX SUB TEVA PHARMS

EQ 400MG BASE

A073392 001 Jan 24, 1992

SANDOZ

EQ 400MG BASE

A073462 001 Apr 30, 1992

SUN PHARM INDS

EQ 400MG BASE

A073311 001 Nov 27, 1991

TEVA

EQ 400MG BASE

A073519 001 May 29, 1992

TABLET; ORAL

TOLECTIN

ORTHO MCNEIL JANSSEN

EQ 200MG BASE

N017628 001

TOLECTIN 600

ORTHO MCNEIL JANSSEN

EQ 600MG BASE

N017628 002 Mar 08, 1989

TOLMETIN SODIUM

ACTAVIS ELIZABETH

EQ 600MG BASE

A073527 001 Jun 30, 1992

G AND W LABS INC

EQ 600MG BASE

A074399 001 Mar 28, 1996

EQ 600MG BASE

A074729 001 Feb 27, 1997

SANDOZ

EQ 200MG BASE

A073588 001 Jul 31, 1992

EQ 600MG BASE

A074002 001 Sep 27, 1993

DISCONTINUED DRUG PRODUCT LIST

TOLVAPTAN

TABLET; ORAL

SAMSCA

OTSUKA AMERICA PHARM	60MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N022275	003	May 19, 2009
----------------------	---	---------	-----	--------------

TOPIRAMATE

CAPSULE; ORAL

TOPAMAX SPRINKLE

JANSSEN PHARMS	50MG	N020844	003	Oct 26, 1998
----------------	------	---------	-----	--------------

TOPIRAMATE

BARR	15MG	A076448	001	Apr 15, 2009
	25MG	A076448	002	Apr 15, 2009
SANDOZ	15MG	A079206	001	Oct 14, 2009
	25MG	A079206	002	Oct 14, 2009

TABLET; ORAL

TOPAMAX

JANSSEN PHARMS	300MG	N020505	003	Dec 24, 1996
	400MG	N020505	006	Dec 24, 1996

TOPIRAMATE

ACTAVIS TOTOWA	25MG	A078637	001	Feb 27, 2013
	50MG	A078637	002	Feb 27, 2013
	100MG	A078637	003	Feb 27, 2013
	200MG	A078637	004	Feb 27, 2013
BARR	25MG	A076315	001	Mar 27, 2009
	100MG	A076315	002	Mar 27, 2009
	200MG	A076315	003	Mar 27, 2009
PLIVA HRVATSKA DOO	25MG	A077905	001	Mar 30, 2009
	50MG	A077905	002	Mar 30, 2009
	100MG	A077905	003	Mar 30, 2009
	200MG	A077905	004	Mar 30, 2009
ROXANE	25MG	A076306	001	Mar 27, 2009
	50MG	A076306	002	Mar 27, 2009
	100MG	A076306	003	Mar 27, 2009
	200MG	A076306	004	Mar 27, 2009
WATSON LABS	25MG	A077643	001	Mar 27, 2009
	50MG	A077643	002	Mar 27, 2009
	100MG	A077643	003	Mar 27, 2009
	200MG	A077643	004	Mar 27, 2009
WOCKHARDT USA	25MG	A090353	001	Sep 01, 2010
	50MG	A090353	002	Sep 01, 2010
	100MG	A090353	003	Sep 01, 2010
	200MG	A090353	004	Sep 01, 2010
TOPIRAMATE				
HIKMA PHARMS	25MG	A091185	001	Nov 25, 2013
	50MG	A091185	002	Nov 25, 2013
	100MG	A091185	003	Nov 25, 2013
	200MG	A091185	004	Nov 25, 2013

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

TOPOTECAN HYDROCHLORIDE

FRESENIUS KABI ONCOL	EQ 4MG BASE/VIAL	A091376	001	Nov 29, 2010
----------------------	------------------	---------	-----	--------------

SOLUTION; INTRAVENOUS

TOPOTECAN

SANDOZ INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N200199	001	Feb 25, 2011
	EQ 3MG BASE/3ML (EQ 1MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N200199	002	Feb 25, 2011
	EQ 4MG BASE/4ML (EQ 1MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N200199	003	Feb 25, 2011

DISCONTINUED DRUG PRODUCT LISTTORSEMIDE

INJECTABLE; INJECTION

DEMADEX

ROCHE	50MG/5ML (10MG/ML)	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020137	002	Aug 23, 1993
	20MG/2ML (10MG/ML)	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020137	001	Aug 23, 1993

TORSEMIDE

LUITPOLD	20MG/2ML (10MG/ML)		A090656	001	Apr 21, 2010
	50MG/5ML (10MG/ML)		A090656	002	Apr 21, 2010
WEST-WARD PHARMS INT	20MG/2ML (10MG/ML)		A078007	001	Jun 11, 2008
	50MG/5ML (10MG/ML)		A078007	002	Jun 11, 2008

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

ACTAVIS ELIZABETH	50MG		A075960	001	Jun 19, 2002
ASTA	50MG		A075974	001	Jul 12, 2002
IVAX SUB TEVA PHARMS	50MG		A075963	001	Jul 03, 2002
SANDOZ	50MG		A075968	001	Jun 25, 2002
WATSON LABS	50MG		A075962	001	Jun 24, 2002

ULTRAM

JANSSEN PHARMS	100MG		N020281	001	Mar 03, 1995
----------------	-------	--	---------	-----	--------------

TABLET, EXTENDED RELEASE; ORAL

RYZOLT

PURDUE PHARMA	100MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021745	001	Dec 30, 2008
	200MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021745	002	Dec 30, 2008
	300MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021745	003	Dec 30, 2008

ULTRAM ER

VALEANT PHARMS	100MG		N021692	001	Sep 08, 2005
	200MG		N021692	002	Sep 08, 2005
	300MG		N021692	003	Sep 08, 2005

TABLET, ORALLY DISINTEGRATING; ORAL

RYBIX ODT

SHIONOGI INC	50MG		N021693	001	May 05, 2005
--------------	------	--	---------	-----	--------------

TRANDOLAPRIL

TABLET; ORAL

TRANDOLAPRIL

CIPLA	1MG		A077307	002	Jun 12, 2007
	2MG		A077307	001	Jun 12, 2007
	4MG		A077307	003	Jun 12, 2007
COREPHARMA	1MG		A077256	001	Jun 12, 2007
	2MG		A077256	002	Jun 12, 2007
	4MG		A077256	003	Jun 12, 2007
DR REDDYS LABS LTD	1MG		A078493	001	Aug 25, 2008
	2MG		A078493	002	Aug 25, 2008
	4MG		A078493	003	Aug 25, 2008

TRANEXAMIC ACID

TABLET; ORAL

CYKLOKAPRON

PHARMACIA AND UPJOHN	500MG		N019280	001	Dec 30, 1986
----------------------	-------	--	---------	-----	--------------

TRANEXAMIC ACID

AMERIGEN PHARMS LTD	650MG		A203256	001	Jul 25, 2016
---------------------	-------	--	---------	-----	--------------

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC

IZBA

NOVARTIS PHARMS CORP	0.003%	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N204822	001	May 15, 2014
----------------------	--------	--	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

TRAVOPROST

SOLUTION/DROPS;OPHTHALMIC

TRAVATAN

ALCON PHARMS LTD

0.004% **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021257 001 Mar 16, 2001

TRAZODONE HYDROCHLORIDE

TABLET;ORAL

DESYREL

PRAGMA PHARMS LLC

50MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N018207 001

100MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N018207 002

150MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N018207 003 Mar 25, 1985

300MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N018207 004 Nov 07, 1988

TRAZODONE HYDROCHLORIDE

AM THERAP

50MG

A071139 001 Oct 29, 1986

100MG

A071140 001 Oct 29, 1986

AUROLIFE PHARMA LLC

50MG

A072484 001 Apr 30, 1990

MYLAN

50MG

A071405 001 Feb 27, 1991

100MG

A071406 001 Feb 27, 1991

QUANTUM PHARMICS

100MG

A070921 001 Dec 01, 1986

SANDOZ

100MG

A072483 001 Apr 30, 1990

TEVA

150MG

A074357 001 Apr 30, 1997

USL PHARMA

50MG

A070491 001 Apr 29, 1987

100MG

A070492 001 Apr 29, 1987

WATSON LABS

50MG

A070857 001 Oct 10, 1986

50MG

A071112 001 Nov 17, 1986

100MG

A070858 001 Oct 10, 1986

100MG

A071113 001 Nov 17, 1986

TRIALODINE

QUANTUM PHARMICS

50MG

A070942 001 Dec 01, 1986

TABLET, EXTENDED RELEASE;ORAL

OLEPTRO

ANGELINI PHARMA

150MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N022411 001 Feb 02, 2010

300MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N022411 002 Feb 02, 2010

TRETINOIN

CAPSULE;ORAL

VESANOID

ROCHE

10MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N020438 001 Nov 22, 1995

SOLUTION;TOPICAL

TRETINOIN

TEVA PHARMS

0.05%

A074873 001 Jun 19, 1998

WOCKHARDT

0.05%

A075260 001 Jan 25, 1999

SWAB;TOPICAL

RETIN-A

VALEANT INTL

0.05%

N016921 002

TRIAMCINOLONE

TABLET;ORAL

ARISTOCORT

ASTELLAS

1MG

N011161 009

2MG

N011161 004

4MG

N011161 007

8MG

N011161 011

DISCONTINUED DRUG PRODUCT LIST

TRIAMCINOLONE

TABLET; ORAL

ARISTOCORT

16MG N011161 010

KENACORT

DELCOR ASSET CORP

1MG N011283 003

2MG N011283 008

4MG N011283 006

8MG N011283 010

TRIAMCINOLONE

BARR

2MG A084286 001

2MG A084318 001

4MG A084267 001

4MG A084319 001

8MG A084268 001

8MG A084320 001

IMPAX LABS 4MG A084340 001

IVAX SUB TEVA PHARMS 4MG A083750 001

MYLAN 2MG A084406 001

PUREPAC PHARM 2MG A084020 002

4MG A084020 003

ROXANE 2MG A084708 001

4MG A084709 001

8MG A084707 001

SANDOZ 4MG A085601 001

TEVA 4MG A084775 001

WATSON LABS 4MG A084270 001

4MG A085834 001

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; INHALATION

AZMACORT

ABBVIE

0.1MG/INH

N018117 001 Apr 23, 1982

AEROSOL, METERED; NASAL

NASACORT

SANOFI AVENTIS US

0.055MG/INH

N019798 001 Jul 11, 1991

CREAM; TOPICAL

ARISTOCORT

ASTELLAS

0.025%

A083017 003

0.1% A083016 004

0.5% A083015 002

ARISTOCORT A

ASTELLAS

0.025%

A083017 004

0.025% A088818 001 Oct 16, 1984

0.1% A083016 005

0.1% A088819 001 Oct 16, 1984

0.5% A083015 003

0.5% A088820 001 Oct 16, 1984

FLUTEX

IVAX PHARMS

0.025%

A085539 001

0.1% A085539 002

0.5% A085539 003

KENALOG

DELCOR ASSET CORP

0.5%

A083943 001

KENALOG-H

DELCOR ASSET CORP

0.1%

A086240 001

TRIACET

TEVA

0.025%

A084908 001

0.1% A084908 002

0.5% A084908 003

TRIACORT

SOLVAY

0.1%

A087113 001

TRIAMCINOLONE ACETONIDE

ACTAVIS MID ATLANTIC

0.1%

A087798 001 Jun 04, 1982

ALPHARMA US PHARMS

0.025%

A087797 001 Jun 07, 1982

AMBIX

0.025%

A087932 001 May 09, 1983

MORTON GROVE

0.025%

A088094 001 Sep 01, 1983

0.1% A088095 001 Sep 01, 1983

0.5% A088096 001 Sep 01, 1983

PHARMADERM

0.025%

A087990 001 Jul 07, 1983

0.1% A087991 001 Jul 07, 1983

0.5% A087992 001 Jul 07, 1983

PHARMAFAIR

0.025%

A087921 001 Aug 10, 1982

DISCONTINUED DRUG PRODUCT LIST

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

	0.1%	A087912 001	Aug 10, 1982
	0.5%	A087922 001	Aug 10, 1982
TARO	0.025%	A040038 001	Oct 26, 1994
	0.025%	A086277 001	
	0.1%	A086276 001	
	0.5%	A086275 001	
TOPIDERM	0.025%	A089274 001	Feb 21, 1989
	0.1%	A089275 001	Feb 21, 1989
	0.5%	A089276 001	Feb 21, 1989
TRIALEX			
IVAX PHARMS	0.025%	A087430 001	Nov 01, 1988
	0.1%	A087429 001	Nov 01, 1988
	0.5%	A087428 001	Nov 01, 1988
TRYMEX			
SAVAGE LABS	0.025%	A088196 001	Mar 25, 1983
	0.1%	A088197 001	Mar 25, 1983
	0.5%	A088198 001	Mar 25, 1983
GEL; TOPICAL			
ARISTOGEL			
ASTELLAS	0.1%	A083380 001	
INJECTABLE; INJECTION			
TRIAMCINOLONE ACETONIDE			
PARNELL	3MG/ML	N019503 001	Oct 16, 1987
SANDOZ	10MG/ML	A090166 001	May 27, 2009
SANDOZ CANADA INC	40MG/ML	A090164 001	Jun 01, 2009
WATSON LABS	40MG/ML	A085825 001	
INJECTABLE; INTRA-ARTICULAR, INTRAMUSCULAR, INTRAVITREAL			
TRIVARIS			
ALLERGAN	8MG/0.1ML (8MG/0.1ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N022220 001	Jun 16, 2008
LOTION; TOPICAL			
KENALOG			
DELCOR ASSET CORP	0.025% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A084343 001	
	0.025% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011602 003	
	0.1% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A084343 002	
	0.1% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011602 001	
TRIAMCINOLONE ACETONIDE			
ALPHARMA US PHARMS	0.025%	A087191 001	Sep 08, 1982
	0.1%	A087192 001	Sep 08, 1982
OINTMENT; TOPICAL			
ARISTOCORT			
ASTELLAS	0.1%	A080750 004	
	0.5% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A080745 002	
ARISTOCORT A			
ASTELLAS	0.1%	A080750 003	
	0.1%	A088780 001	Oct 01, 1984
	0.5% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A080745 003	
	0.5%	A088781 001	Oct 05, 1984
FLUTEX			
IVAX PHARMS	0.025%	A087375 001	Nov 01, 1988
	0.1%	A087377 001	Nov 01, 1988
	0.5%	A087376 001	Nov 01, 1988

DISCONTINUED DRUG PRODUCT LISTTRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL

KENALOG

DELCOR ASSET CORP	0.5% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A083944	001
-------------------	---	---------	-----

TRIAMCINOLONE ACETONIDE

ACTAVIS MID ATLANTIC	0.1%	A087799	001 Jun 07, 1982
ALPHARMA US PHARMS	0.5%	A089913	001 Dec 23, 1988
MORTON GROVE	0.025%	A088090	001 Sep 01, 1983
	0.1%	A088091	001 Sep 01, 1983
	0.5%	A088092	001 Sep 01, 1983
PHARMADERM	0.025%	A088692	001 Aug 02, 1984
	0.1%	A088690	001 Aug 02, 1984
TARO	0.025%	A040040	001 Sep 30, 1994
	0.025%	A040374	001 Jun 05, 2001
	0.1%	A087902	001 Dec 27, 1982
	0.5%	A040386	001 Jun 05, 2001

TRYMEX

SAVAGE LABS	0.025%	A088693	001 Aug 02, 1984
	0.1%	A088691	001 Aug 02, 1984

PASTE; DENTAL

KENALOG IN ORABASE

DELCOR ASSET CORP	0.1% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012097	001
-------------------	---	---------	-----

ORALONE

TARO	0.1%	A071383	001 Jul 06, 1987
------	------	---------	------------------

SPRAY, METERED; NASAL

ALLERNAZE

LUPIN ATLANTIS	0.05MG/SPRAY	N020120	001 Feb 04, 2000
----------------	--------------	---------	------------------

NASACORT HFA

SANOFI AVENTIS US	0.055MG/SPRAY	N020784	001 Apr 07, 2004
-------------------	---------------	---------	------------------

TRIAMCINOLONE ACETONIDE

TEVA PHARMS	0.055MG/SPRAY	A078104	001 Jul 30, 2009
-------------	---------------	---------	------------------

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION

ARISTOCORT

SANDOZ	25MG/ML	N011685	003
	40MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012802	001

TRIAMCINOLONE DIACETATE

AKORN	25MG/ML	A085122	001
	40MG/ML	A086394	001
WATSON LABS	40MG/ML	A084072	001
	40MG/ML	A085529	001

SYRUP; ORAL

ARISTOCORT

ASTELLAS	2MG/5ML	N011960	004
----------	---------	---------	-----

KENACORT

DELCOR ASSET CORP	EQ 4MG BASE/5ML	N012515	001
-------------------	-----------------	---------	-----

TRIAZOLAM

TABLET; ORAL

HALCION

PHARMACIA AND UPJOHN	0.5MG	N017892	002 Nov 15, 1982
----------------------	-------	---------	------------------

TRIAZOLAM

WATSON LABS	0.125MG	A074445	001 Oct 20, 1995
	0.25MG	A074445	002 Oct 20, 1995

TRICHLORMETHIAZIDE

TABLET; ORAL

METAHYDRIN

SANOFI AVENTIS US	2MG	N012594	001 Jun 16, 1988
	4MG	N012594	002 Jun 16, 1988

NAQUA

SCHERING	2MG	N012265	001
	4MG	N012265	002

TRICHLOREX

LANNETT	4MG	A083436	001
---------	-----	---------	-----

DISCONTINUED DRUG PRODUCT LIST

TRICHLORMETHIAZIDE

TABLET; ORAL

TRICHLOREX

4MG

A085630 001

TRICHLORMAS

MAST MM

4MG

A086259 001

TRICHLORMETHIAZIDE

IMPAX LABS

4MG

A083967 001

PAR PHARM

2MG

A087007 001

4MG

A087005 001

SANDOZ

4MG

A086171 001

TG UNITED LABS

4MG

A085568 001

WATSON LABS

2MG

A083847 001

2MG

A086458 001

4MG

A083462 001

4MG

A083855 001

4MG

A085962 001

TRICLOFOS SODIUM

SOLUTION; ORAL

TRICLOS

SANOFI AVENTIS US

1.5GM/15ML

N016830 001

TABLET; ORAL

TRICLOS

SANOFI AVENTIS US

750MG

N016809 002

TRIDIHETHYL CHLORIDE

INJECTABLE; INJECTION

PATHILON

LEDERLE

10MG/ML

N009729 001

TABLET; ORAL

PATHILON

LEDERLE

25MG

N009489 005

TRIFLUOPERAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

STELAZINE

GLAXOSMITHKLINE

EQ 10MG BASE/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N011552 006

TRIFLUOPERAZINE HYDROCHLORIDE

SANDOZ

EQ 10MG BASE/ML

A085787 001 Apr 15, 1982

WOCKHARDT

EQ 10MG BASE/ML

A088143 001 Jul 26, 1983

INJECTABLE; INJECTION

STELAZINE

GLAXOSMITHKLINE

EQ 2MG BASE/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N011552 005

TABLET; ORAL

STELAZINE

GLAXOSMITHKLINE

EQ 1MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N011552 001

EQ 2MG BASE **Federal Register

N011552 002

determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

EQ 5MG BASE **Federal Register

N011552 003

determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

EQ 10MG BASE **Federal Register

N011552 004

determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

TRIFLUOPERAZINE HYDROCHLORIDE

DURAMED PHARMS BARR

EQ 1MG BASE

A088967 001 Apr 23, 1985

EQ 2MG BASE

A088968 001 Apr 23, 1985

EQ 5MG BASE

A088969 001 Apr 23, 1985

EQ 10MG BASE

A088970 001 Apr 23, 1985

IVAX PHARMS

EQ 1MG BASE

A087612 001 Nov 19, 1982

EQ 2MG BASE

A087613 001 Nov 19, 1982

EQ 5MG BASE

A087328 001 Nov 19, 1982

DISCONTINUED DRUG PRODUCT LISTTRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL

TRIFLUOPERAZINE HYDROCHLORIDE

	EQ 10MG BASE	A087614 001	Nov 19, 1982
SANDOZ	EQ 1MG BASE	A040153 001	Oct 25, 1996
	EQ 2MG BASE	A040153 002	Oct 25, 1996
	EQ 5MG BASE	A040153 003	Oct 25, 1996
	EQ 10MG BASE	A040153 004	Oct 25, 1996
WATSON LABS	EQ 1MG BASE	A085975 001	Jun 23, 1988
	EQ 2MG BASE	A085976 001	Jun 23, 1988
	EQ 5MG BASE	A085973 001	Jun 23, 1988
	EQ 10MG BASE	A088710 001	Jun 23, 1988

TRIFLUPROMAZINE

SUSPENSION; ORAL

VESPRIN

APOTHECON	EQ 50MG HCL/5ML	N011491 004	
-----------	-----------------	-------------	--

TRIFLUPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

VESPRIN

APOTHECON	3MG/ML	N011325 005	
	10MG/ML	N011325 004	
	20MG/ML	N011325 001	

TABLET; ORAL

VESPRIN

BRISTOL MYERS SQUIBB	10MG	N011123 001	
	25MG	N011123 002	
	50MG	N011123 003	

TRIHENXYPHENIDYL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

ARTANE

LEDERLE	5MG	N006773 010	
	5MG	N012947 001	

ELIXIR; ORAL

ARTANE

LEDERLE	2MG/5ML	N006773 009	
---------	---------	-------------	--

TRIHENXYPHENIDYL HYDROCHLORIDE

PHARM VENTURES	2MG/5ML	A089514 001	Apr 07, 1989
----------------	---------	-------------	--------------

TABLET; ORAL

ARTANE

LEDERLE	2MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N006773 005	
	5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N006773 003	

TREMIN

SCHERING	2MG	A080381 001	
	5MG	A080381 003	

TRIHENXYPHENIDYL HYDROCHLORIDE

HIKMA PHARMS LLC	2MG	A040337 002	Feb 16, 2000
	5MG	A040337 001	Feb 16, 2000
NYLOS	5MG	A085622 001	
VANGARD	2MG	A088035 001	Jul 30, 1982
WATSON LABS	2MG	A040184 001	Feb 06, 1998
	2MG	A085117 001	
	5MG	A040184 002	Feb 06, 1998
	5MG	A085105 001	

TRILOSTANE

CAPSULE; ORAL

MODRASTANE

BIOENVISION	30MG	N018719 002	Dec 31, 1984
	60MG	N018719 001	Dec 31, 1984

TRIMEPRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

TEMARIL

ALLERGAN HERBERT	EQ 5MG BASE	N011316 004	
------------------	-------------	-------------	--

DISCONTINUED DRUG PRODUCT LISTTRIMEPRAZINE TARTRATE

SYRUP; ORAL

TEMARIL

ALLERGAN HERBERT EQ 2.5MG BASE/5ML N011316 003

TRIMEPRAZINE TARTRATE

ALPHARMA US PHARMS EQ 2.5MG BASE/5ML A085015 001 Feb 18, 1982

MORTON GROVE EQ 2.5MG BASE/5ML A088285 001 Apr 11, 1985

TABLET; ORAL

TEMARIL

ALLERGAN HERBERT EQ 2.5MG BASE N011316 001

TRIMETHADIONE

CAPSULE; ORAL

TRIDIONE

ABBVIE 300MG N005856 005

SOLUTION; ORAL

TRIDIONE

ABBVIE 200MG/5ML N005856 002

TRIMETHAPHAN CAMSYLATE

INJECTABLE; INJECTION

ARFONAD

ROCHE 50MG/ML N008983 001

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

TRIMETHOBENZAMIDE HYDROCHLORIDE

HOSPIRA 100MG/ML A088804 001 Apr 03, 1987

SMITH AND NEPHEW 100MG/ML A088960 001 Apr 04, 1986

100MG/ML A089043 001 Apr 04, 1986

SOLOPAK 100MG/ML A089094 001 Apr 04, 1986

WATSON LABS 100MG/ML A086577 001 Oct 19, 1982

100MG/ML A087939 001 Dec 28, 1982

TRIMETHOPRIM

TABLET; ORAL

PROLOPRIM

MONARCH PHARMS 100MG N017943 001

200MG N017943 003 Jul 14, 1982

TRIMETHOPRIM

SUN PHARM INDS 100MG A070494 001 Jan 22, 1986

200MG A070495 001 Sep 24, 1986

TEVA 200MG **Federal Register determination

that product was not discontinued or

withdrawn for safety or efficacy

reasons**

A071259 001 Jun 18, 1987

TRIMPEX

ROCHE 100MG N017952 001

TRIMPEX 200

ROCHE 200MG N017952 002 Nov 09, 1982

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION; ORAL

PRIMSOL

AYTU PHARMS EQ 25MG BASE/5ML N074374 001 Jun 23, 1995

TRIMETREXATE GLUCURONATE

INJECTABLE; INJECTION

NEUTREXIN

MEDIMMUNE ONCOLOGY EQ 25MG BASE/VIAL N020326 001 Dec 17, 1993

EQ 200MG BASE/VIAL N020326 002 Jul 31, 1998

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

TRIMIPRAMINE MALEATE

USL PHARMA EQ 25MG BASE A071283 001 Dec 08, 1987

EQ 50MG BASE A071284 001 Dec 08, 1987

EQ 100MG BASE A071285 001 Dec 08, 1987

TRIOXSALEN

TABLET; ORAL

TRISORALEN

VALEANT PHARM INTL 5MG N012697 001

DISCONTINUED DRUG PRODUCT LISTTRIPLENNAMINE CITRATE

ELIXIR;ORAL

PBZ

NOVARTIS EQ 25MG HCL/5ML N005914 004

TRIPLENNAMINE HYDROCHLORIDE

TABLET;ORAL

PBZ

NOVARTIS 25MG A083149 001

50MG N005914 002

TRIPLENNAMINE HYDROCHLORIDE

ANABOLIC 50MG A083037 001

BARR 50MG A080744 001

HEATHER 50MG A083989 001

IMPAX LABS 50MG A080785 001

LANNETT 50MG A083557 001

NYLOS 50MG A085412 001

PARKE DAVIS 25MG A083625 001

50MG A083626 001

WATSON LABS 50MG A080713 001

50MG A080790 001

50MG A085188 001

TABLET, EXTENDED RELEASE;ORAL

PBZ-SR

NOVARTIS 50MG N010533 002

100MG N010533 001

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)

CREAM;VAGINAL

GYNE-SULF

G AND W LABS 3.7%;2.86%;3.42% A088607 001 Jun 09, 1986

SULTRIN

ORTHO MCNEIL PHARM 3.7%;2.86%;3.42% N005794 001

TRIPLE SULFA

ALPHARMA US PHARMS 3.7%;2.86%;3.42% A087864 001 Sep 01, 1982

FOUGERA 3.7%;2.86%;3.42% A086424 001

PERRIGO NEW YORK 3.7%;2.86%;3.42% A087285 001 Nov 15, 1982

TRYSUL

SAVAGE LABS 3.7%;2.86%;3.42% A087887 001 Jul 23, 1982

VAGILIA

G AND W LABS INC 3.7%;2.86%;3.42% A088821 001 Nov 09, 1987

TABLET;VAGINAL

SULTRIN

ORTHO MCNEIL PHARM 184MG;143.75MG;172.5MG N005794 002

TRIPLE SULFA

FOUGERA 184MG;143.75MG;172.5MG A088463 001 Jan 03, 1985

PHARMADERM 184MG;143.75MG;172.5MG A088462 001 Jan 03, 1985

TRIPROLIDINE HYDROCHLORIDE

SYRUP;ORAL

ACTIDIL

GLAXOSMITHKLINE 1.25MG/5ML N011496 002 Jul 01, 1983

MYIDYL

USL PHARMA 1.25MG/5ML A087963 001 Jan 18, 1983

TRIPROLIDINE HYDROCHLORIDE

ALPHARMA US PHARMS 1.25MG/5ML A085940 001

HALSEY 1.25MG/5ML A088735 001 Jan 17, 1985

PHARM ASSOC 1.25MG/5ML A087514 001 Feb 10, 1982

TABLET;ORAL

ACTIDIL

GLAXOSMITHKLINE 2.5MG N011110 002 Jul 01, 1983

TRIPROLIDINE HYDROCHLORIDE

VITARINE 2.5MG A085610 001

WATSON LABS 2.5MG A085094 001

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

SUSPENSION;ORAL

LANTRISUL

LANNETT 167MG/5ML;167MG/5ML;167MG/5ML A080123 002

NEOTRIZINE

LILLY 167MG/5ML;167MG/5ML;167MG/5ML N006317 012

SULFALOID

FOREST PHARMS 167MG/5ML;167MG/5ML;167MG/5ML A080100 001

DISCONTINUED DRUG PRODUCT LISTTRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

SUSPENSION;ORAL

SULFOSE

WYETH AYERST	167MG/5ML;167MG/5ML;167MG/5ML	A080013	002
--------------	-------------------------------	---------	-----

TERFONYL

BRISTOL MYERS SQUIBB	167MG/5ML;167MG/5ML;167MG/5ML	N006904	002
----------------------	-------------------------------	---------	-----

TRIPLE SULFA

ALPHARMA US PHARMS	167MG/5ML;167MG/5ML;167MG/5ML	A080280	001
--------------------	-------------------------------	---------	-----

TRIPLE SULFAS

LEDERLE	167MG/5ML;167MG/5ML;167MG/5ML	N006920	003
---------	-------------------------------	---------	-----

TABLET;ORAL

NEOTRIZINE

LILLY	167MG;167MG;167MG	N006317	011
-------	-------------------	---------	-----

SULFA-TRIPLE #2

IMPAX LABS	167MG;167MG;167MG	A080079	001
------------	-------------------	---------	-----

SULFALOID

FOREST PHARMS	167MG;167MG;167MG	A080099	001
---------------	-------------------	---------	-----

SULFOSE

WYETH AYERST	167MG;167MG;167MG	A080013	001
--------------	-------------------	---------	-----

TERFONYL

BRISTOL MYERS SQUIBB	167MG;167MG;167MG	N006904	001
----------------------	-------------------	---------	-----

TRIPLE SULFA

PUREPAC PHARM	167MG;167MG;167MG	A080086	001
---------------	-------------------	---------	-----

TRIPLE SULFAS

LEDERLE	167MG;167MG;167MG	N006920	002
---------	-------------------	---------	-----

TRIPLE SULFOID

PAL PAK	167MG;167MG;167MG	A080094	001
---------	-------------------	---------	-----

TROGLITAZONE

TABLET;ORAL

PRELAY

SANKYO	200MG	N020719	001	Jan 29, 1997
	300MG	N020719	003	Aug 04, 1997
	400MG	N020719	002	Jan 29, 1997

REZULIN

PFIZER PHARMS	200MG	N020720	001	Jan 29, 1997
	300MG	N020720	003	Aug 04, 1997
	400MG	N020720	002	Jan 29, 1997

TROLAMINE POLYPEPTIDE OLEATE CONDENSATE

SOLUTION/DROPS;OTIC

CERUMENEX

PHARM RES ASSOC	10%	N011340	002
-----------------	-----	---------	-----

TROLEANDOMYCIN

CAPSULE;ORAL

TAO

PFIZER	EQ 250MG BASE	N050336	002
--------	---------------	---------	-----

SUSPENSION;ORAL

TAO

PFIZER	EQ 125MG BASE/5ML	N050332	001
--------	-------------------	---------	-----

TROPICAMIDE

SOLUTION/DROPS;OPHTHALMIC

MYDRIACYL

ALCON	0.5%	N012111	002
	1%	N012111	004

MYDRIAFAIR

PHARMAFAIR	0.5%	A088274	001	Sep 16, 1983
	1%	A088230	001	Sep 16, 1983

TROPICAMIDE

AKORN	1%	A088447	001	Aug 28, 1985
ALCON PHARMS LTD	1%	A089172	001	Dec 28, 1990
MIZA PHARMS USA	0.5%	A087636	001	Jul 30, 1982
	1%	A087637	001	Aug 09, 1982
WATSON LABS	0.5%	A089171	001	Dec 28, 1990

TROSPIDIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

SANCTURA XR

ALLERGAN	60MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N022103	001	Aug 03, 2007
----------	---	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

TROSPIUM CHLORIDE

UPSHER-SMITH LABS 60MG

A091635 001 Apr 29, 2015

TABLET;ORAL

SANCTURA

ALLERGAN 20MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021595 001 May 28, 2004

TROVAFLOXACIN MESYLATE

TABLET;ORAL

TROVAN

PFIZER EQ 100MG BASE
EQ 200MG BASE

N020759 001 Dec 18, 1997

N020759 002 Dec 18, 1997

TUBOCURARINE CHLORIDE

INJECTABLE; INJECTION

TUBOCURARINE CHLORIDE

BRISTOL MYERS SQUIBB 3MG/ML
HOSPIRA 3MG/ML
LILLY 3MG/ML

N005657 001

N006095 001

N006325 001

TYROPANOATE SODIUM

CAPSULE;ORAL

BILOPAQUE

GE HEALTHCARE 750MG

N013731 001

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS;OPHTHALMIC

RESCULA

SUCAMPO PHARMA LLC 0.15% **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021214 001 Aug 03, 2000

URACIL MUSTARD

CAPSULE;ORAL

URACIL MUSTARD

SHIRE 1MG

N012892 001

UREA

INJECTABLE; INJECTION

STERILE UREA

HOSPIRA 40GM/VIAL

N017698 001

UREAPHIL

HOSPIRA 40GM/VIAL

N012154 001

UREA C-13

FOR SOLUTION;ORAL

BREATHTEK UBT FOR H-PYLORI

OTSUKA AMERICA EQ 75MG/POUCH

N020586 002 May 10, 2001

HELICOSOL

METABOLIC SOLUTIONS 125MG/VIAL

N021092 001 Dec 17, 1999

MERETEK UBT KIT (W/ PRANACTIN)

OTSUKA AMERICA 125MG/VIAL

N020586 001 Sep 17, 1996

PYLORI-CHEK BREATH TEST

DXS DEVICES 100MG/VIAL

N020900 001 Feb 04, 1999

UROFOLLITROPIN

INJECTABLE; INTRAMUSCULAR

METRODIN

SERONO 75 IU/AMP
150 IU/AMP

N019415 002 Sep 18, 1986

N019415 003 Sep 18, 1986

INJECTABLE; SUBCUTANEOUS

FERTINEX

SERONO 75 IU/AMP
150 IU/AMP

N019415 005 Aug 23, 1996

N019415 004 Aug 23, 1996

UROKINASE

INJECTABLE; INJECTION

KINLYTIC

MICROBIX BIOSYSTEMS 5,000 IU/VIAL
9,000 IU/VIAL
250,000 IU/VIAL

N021846 003

N021846 002

N021846 001

DISCONTINUED DRUG PRODUCT LIST

URSODIOL

CAPSULE; ORAL

ACTIGALL

ALLERGAN SALES LLC

150MG

N019594 001 Dec 31, 1987

TABLET; ORAL

URSODIOL

TEVA PHARMS USA

250MG

A079184 001 May 13, 2009

500MG

A079184 002 May 13, 2009

VALDECOXIB

TABLET; ORAL

BEXTRA

GD SEARLE

10MG

N021341 002 Nov 16, 2001

20MG

N021341 003 Nov 16, 2001

VALPROIC ACID

CAPSULE; ORAL

VALPROIC ACID

PAR PHARM

250MG

A070431 001 Feb 28, 1986

SCHERER RP

250MG

A070195 001 Jul 02, 1987

USL PHARMA

250MG

A070631 001 Jun 11, 1987

CAPSULE, DELAYED RELEASE; ORAL

STAVZOR

BIONPHARMA INC

125MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N022152 001 Jul 29, 2008

250MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N022152 002 Jul 29, 2008

500MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N022152 003 Jul 29, 2008

SYRUP; ORAL

VALPROIC ACID

APOTEX INC

250MG/5ML

A077105 001 Jul 29, 2005

VALSARTAN

CAPSULE; ORAL

DIOVAN

NOVARTIS

80MG

N020665 001 Dec 23, 1996

160MG

N020665 002 Dec 23, 1996

VANCOMYCIN HYDROCHLORIDE

FOR SOLUTION; ORAL

VANCOCIN HYDROCHLORIDE

ANI PHARMS INC

EQ 250MG BASE/5ML

A061667 002 Jul 13, 1983

EQ 500MG BASE/6ML

A061667 001

VANCOLED

LEDERLE

EQ 250MG BASE/5ML

A063321 002 Oct 15, 1993

EQ 500MG BASE/6ML

A063321 003 Oct 15, 1993

INJECTABLE; INJECTION

VANCOCIN HYDROCHLORIDE

ANI PHARMS INC

EQ 500MG BASE/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

A060180 001

EQ 500MG BASE/VIAL

A062476 001 Mar 15, 1984

EQ 500MG BASE/VIAL

A062716 001 Mar 13, 1987

EQ 500MG BASE/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

A062812 001 Nov 17, 1987

EQ 1GM BASE/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

A060180 002 Mar 21, 1986

EQ 1GM BASE/VIAL

A062476 002 Mar 21, 1986

EQ 1GM BASE/VIAL

A062716 002 Mar 13, 1987

EQ 1GM BASE/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

A062812 002 Nov 17, 1987

EQ 10GM BASE/VIAL **Federal Register
determination that product was not

A062812 003 Nov 17, 1987

DISCONTINUED DRUG PRODUCT LIST

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANOCIN HYDROCHLORIDE

discontinued or withdrawn for safety or efficacy reasons**

VANCOLED

WEST-WARD PHARMS INT

EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

A062682 001 Jul 22, 1986

EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

A062682 002 Mar 30, 1988

EQ 2GM BASE/VIAL **Federal Register determination that product was discontinued or withdrawn for safety or efficacy reasons**

A062682 003 May 11, 1988

EQ 5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

A062682 004 May 11, 1988

EQ 10GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

A062682 005 May 11, 1988

VANCOMYCIN HYDROCHLORIDE

WEST-WARD PHARMS INT

EQ 500MG BASE/VIAL

A062879 001 Aug 02, 1988

EQ 1GM BASE/VIAL

A062879 002 Aug 02, 1988

VANCOR

PHARMACIA AND UPJOHN

EQ 500MG BASE/VIAL

A062956 001 Aug 01, 1988

EQ 1GM BASE/VIAL

A062956 002 Aug 01, 1988

VASOPRESSIN TANNATE

INJECTABLE; INJECTION

PITRESSIN TANNATE

PARKE DAVIS

5PRESSOR UNITS/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N003402 001

VECURONIUM BROMIDE

INJECTABLE; INJECTION

NORCURON

ORGANON USA INC

10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N018776 002 Apr 30, 1984

20MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N018776 003 Jan 03, 1992

VECURONIUM BROMIDE

EUROHLTH INTL SARL

10MG/VIAL

A075218 001 Aug 23, 1999

20MG/VIAL

A075218 002 Aug 23, 1999

HOSPIRA

4MG/VIAL

A075558 001 Sep 11, 2001

WATSON LABS

10MG/VIAL

A074334 001 Aug 31, 1995

20MG/VIAL

A074334 002 Aug 31, 1995

VELAGLUCERASE ALFA

POWDER; IV (INFUSION)

VPRIV

SHIRE HUMAN GENETIC

200 UNITS/VIAL

N022575 002 Feb 26, 2010

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

EFFEXOR XR

WYETH PHARMS INC

EQ 100MG BASE

N020699 003 Oct 20, 1997

TABLET; ORAL

EFFEXOR

WYETH PHARMS INC

EQ 12.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N020151 001 Dec 28, 1993

EQ 25MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N020151 002 Dec 28, 1993

EQ 37.5MG BASE **Federal Register

N020151 006 Dec 28, 1993

DISCONTINUED DRUG PRODUCT LISTVENLAFAXINE HYDROCHLORIDETABLET; ORAL
EFFEXOR

determination that product was not discontinued or withdrawn for safety or efficacy reasons**

EQ 50MG BASE **Federal Register N020151 003 Dec 28, 1993

determination that product was not discontinued or withdrawn for safety or efficacy reasons**

EQ 75MG BASE **Federal Register N020151 004 Dec 28, 1993

determination that product was not discontinued or withdrawn for safety or efficacy reasons**

EQ 100MG BASE **Federal Register N020151 005 Dec 28, 1993

determination that product was not discontinued or withdrawn for safety or efficacy reasons**

VENLAFAXINE HYDROCHLORIDE

PLIVA HRVATSKA DOO

EQ 25MG BASE A078517 001 Jun 13, 2008

EQ 37.5MG BASE A078517 002 Jun 13, 2008

EQ 50MG BASE A078517 003 Jun 13, 2008

EQ 75MG BASE A078517 004 Jun 13, 2008

EQ 100MG BASE A078517 005 Jun 13, 2008

SANDOZ

EQ 25MG BASE A077515 001 Jun 13, 2008

EQ 37.5MG BASE A077515 002 Jun 13, 2008

EQ 50MG BASE A077515 003 Jun 13, 2008

EQ 75MG BASE A077515 004 Jun 13, 2008

EQ 100MG BASE A077515 005 Jun 13, 2008

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

CALAN

GD SEARLE LLC

2.5MG/ML

N019038 001 Mar 30, 1984

ISOPTIN

MT ADAMS

2.5MG/ML

N018485 001

VERAPAMIL HYDROCHLORIDE

ABRAXIS PHARM

2.5MG/ML

A070348 001 May 01, 1986

BEDFORD

2.5MG/ML

A072888 001 Jul 28, 1995

HOSPIRA

2.5MG/ML

A070577 001 Feb 02, 1987

2.5MG/ML

A070739 001 May 06, 1987

2.5MG/ML

A070740 001 May 06, 1987

INTL MEDICATION

2.5MG/ML

A070451 001 Dec 16, 1985

LUITPOLD

2.5MG/ML

A070225 001 Nov 12, 1985

2.5MG/ML

A070617 001 Nov 12, 1985

MARSAM PHARMS LLC

2.5MG/ML

A072233 001 Feb 26, 1993

2.5MG/ML

A073485 001 Sep 27, 1993

SMITH AND NEPHEW

2.5MG/ML

A070696 001 Jul 31, 1987

2.5MG/ML

A070697 001 Jul 31, 1987

SOLOPAK

2.5MG/ML

A070695 001 Jul 31, 1987

TABLET; ORAL

CALAN

GD SEARLE LLC

40MG

N018817 003 Feb 23, 1988

160MG

N018817 004 Feb 23, 1988

ISOPTIN

MT ADAMS

40MG

N018593 003 Nov 23, 1987

80MG

N018593 001 Mar 08, 1982

120MG

N018593 002 Mar 08, 1982

VERAPAMIL HYDROCHLORIDE

ACTAVIS ELIZABETH

80MG

A071019 001 Sep 24, 1986

120MG

A070468 001 Sep 24, 1986

MUTUAL PHARM

80MG

A070482 001 Sep 24, 1986

120MG

A070483 001 Sep 24, 1986

PLIVA

40MG

A072751 001 Feb 23, 1996

80MG

A072124 001 Jan 26, 1989

120MG

A072125 001 Jan 26, 1989

SANDOZ

40MG

A073168 001 Jul 31, 1992

80MG

A071423 001 May 24, 1988

120MG

A071424 001 May 25, 1988

SUN PHARM INDS

80MG

A071489 002 Jan 13, 1988

120MG

A071489 001 Jan 13, 1988

WARNER CHILCOTT

80MG

A070340 001 Sep 24, 1986

120MG

A070341 001 Sep 24, 1986

WATSON LABS

40MG

A072799 001 Apr 28, 1989

DISCONTINUED DRUG PRODUCT LIST

VERAPAMIL HYDROCHLORIDE

TABLET; ORAL

VERAPAMIL HYDROCHLORIDE

40MG	A072923	001	Jun 29, 1993
80MG	A070855	001	Sep 24, 1986
80MG	A071366	001	Oct 01, 1986
120MG	A070856	001	Sep 24, 1986
120MG	A071367	001	Oct 01, 1986

TABLET, EXTENDED RELEASE; ORAL

CALAN SR

PFIZER

180MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019152	002	Dec 15, 1989
--	---------	-----	--------------

VERAPAMIL HYDROCHLORIDE

PLIVA

240MG	A072922	001	Mar 01, 1996
-------	---------	-----	--------------

VERATRUM VIRIDE ROOT

TABLET; ORAL

VERTAVIS

MEDPOINTE PHARM HLC

130CSR UNIT	N005691	002	
-------------	---------	-----	--

VIDARABINE

INJECTABLE; INJECTION

VIRA-A

PARKEDALE

EQ 187.4MG BASE/ML	N050523	001	
--------------------	---------	-----	--

OINTMENT; OPHTHALMIC

VIRA-A

PARKEDALE

3%	N050486	001	
----	---------	-----	--

VINBLASTINE SULFATE

INJECTABLE; INJECTION

VELBAN

LILLY

10MG/VIAL	N012665	001	
-----------	---------	-----	--

VINBLASTINE SULFATE

ABRAXIS PHARM

10MG/VIAL	A089011	001	Nov 18, 1985
-----------	---------	-----	--------------

HOSPIRA

10MG/VIAL	A089565	001	Aug 18, 1987
-----------	---------	-----	--------------

VINCRIStINE SULFATE

INJECTABLE; INJECTION

ONCOVIN

LILLY

1MG/VIAL	N014103	001	
1MG/ML	N014103	003	Mar 07, 1984
5MG/VIAL	N014103	002	

VINCASAR PFS

TEVA PARENTERAL

1MG/ML	A071426	001	Jul 17, 1987
--------	---------	-----	--------------

VINCREX

BRISTOL MYERS SQUIBB

5MG/VIAL	A070867	001	Jul 12, 1988
----------	---------	-----	--------------

VINCRIStINE SULFATE

ABIC

1MG/ML	A070873	001	Feb 19, 1987
--------	---------	-----	--------------

ABRAXIS PHARM

1MG/ML	A070411	001	Sep 10, 1986
--------	---------	-----	--------------

FRESENIUS KABI USA

1MG/ML	A076296	001	Dec 20, 2002
--------	---------	-----	--------------

HOSPIRA

1MG/ML	A076401	001	Oct 28, 2003
--------	---------	-----	--------------

HOSPIRA

1MG/VIAL	A071559	001	Apr 11, 1988
----------	---------	-----	--------------

2MG/VIAL	A071560	001	Apr 11, 1988
----------	---------	-----	--------------

5MG/VIAL	A071561	001	Apr 11, 1988
----------	---------	-----	--------------

VINORELBINE TARTRATE

INJECTABLE; INJECTION

VINORELBINE TARTRATE

EBEWE PHARMA

EQ 10MG BASE/ML	A078408	001	Feb 13, 2008
-----------------	---------	-----	--------------

VIOMYCIN SULFATE

INJECTABLE; INJECTION

VIOCIN SULFATE

PFIZER

EQ 1GM BASE/VIAL	A061086	001	
------------------	---------	-----	--

EQ 5GM BASE/VIAL	A061086	002	
------------------	---------	-----	--

VITAMIN A

CAPSULE; ORAL

AQUASOL A

ASTRAZENECA

25,000USP UNITS	A083080	002	
-----------------	---------	-----	--

50,000USP UNITS	A083080	001	
-----------------	---------	-----	--

VITAMIN A

BANNER PHARMACAPS

50,000USP UNITS	A083973	001	
-----------------	---------	-----	--

CHASE CHEM

50,000 IU	A083351	001	
-----------	---------	-----	--

DISCONTINUED DRUG PRODUCT LIST

VITAMIN A

CAPSULE; ORAL

VITAMIN A

EVERYLIFE	50,000 IU	A083134 001
IMPAX LABS	50,000USP UNITS	A080952 001
WEST WARD	50,000USP UNITS	A080985 001

VITAMIN A PALMITATE

CAPSULE; ORAL

AFAXIN

STERLING WINTHROP	EQ 50,000 UNITS BASE	A083187 001
-------------------	----------------------	-------------

ALPHALIN

LILLY	EQ 50,000 UNITS BASE	A080883 001
-------	----------------------	-------------

DEL-VI-A

DEL RAY LABS	EQ 50,000 UNITS BASE	A080830 001
--------------	----------------------	-------------

VI-DOM-A

BAYER PHARMS	EQ 50,000 UNITS BASE	A080972 001
--------------	----------------------	-------------

VITAMIN A

BANNER PHARMACAPS	EQ 50,000 UNITS BASE	A080702 001
-------------------	----------------------	-------------

BRISTOL MYERS SQUIBB	EQ 50,000 UNITS BASE	A080860 001
----------------------	----------------------	-------------

CHASE CHEM	EQ 50,000 UNITS BASE	A080746 001
------------	----------------------	-------------

	EQ 50,000 UNITS BASE	A083207 001
--	----------------------	-------------

ELKINS SINN	EQ 50,000 UNITS BASE	A085479 001
-------------	----------------------	-------------

EVERYLIFE	EQ 50,000 UNITS BASE	A080943 001
-----------	----------------------	-------------

	EQ 50,000 UNITS BASE	A083114 001
--	----------------------	-------------

IMPAX LABS	EQ 50,000 UNITS BASE	A080953 001
------------	----------------------	-------------

	EQ 50,000 UNITS BASE	A080955 001
--	----------------------	-------------

IVAX SUB TEVA PHARMS	EQ 50,000 UNITS BASE	A083035 001
----------------------	----------------------	-------------

	EQ 50,000 UNITS BASE	A083190 001
--	----------------------	-------------

MK LABS	EQ 25,000 UNITS BASE	A083457 002
---------	----------------------	-------------

	EQ 50,000 UNITS BASE	A083457 001
--	----------------------	-------------

WEST WARD	EQ 50,000 UNITS BASE	A080967 001
-----------	----------------------	-------------

WHARTON LABS	EQ 50,000 UNITS BASE	A083665 001
--------------	----------------------	-------------

VITAMIN A PALMITATE

ARCUM	EQ 50,000 UNITS BASE	A083311 001
-------	----------------------	-------------

	EQ 50,000 UNITS BASE	A083321 001
--	----------------------	-------------

BANNER PHARMACAPS	EQ 50,000 UNITS BASE	A083948 001
-------------------	----------------------	-------------

	EQ 50,000 UNITS BASE	A083981 001
--	----------------------	-------------

VITAMIN A SOLUBILIZED

TEVA	EQ 50,000 UNITS BASE	A080921 001
------	----------------------	-------------

INJECTABLE; INJECTION

VITAMIN A PALMITATE

BEL MAR	EQ 50,000 UNITS BASE/ML	A080819 001
---------	-------------------------	-------------

WARFARIN POTASSIUM

TABLET; ORAL

ATHROMBIN-K

PHARM RES ASSOC	2MG	N011771 007
-----------------	-----	-------------

	5MG	N011771 004
--	-----	-------------

	10MG	N011771 005
--	------	-------------

	25MG	N011771 006
--	------	-------------

WARFARIN SODIUM

INJECTABLE; INJECTION

COUMADIN

BRISTOL MYERS SQUIBB	5MG/VIAL	N009218 024	Feb 07, 1995
----------------------	----------	-------------	--------------

	50MG/VIAL	N009218 020
--	-----------	-------------

	75MG/VIAL	N009218 012
--	-----------	-------------

TABLET; ORAL

ATHROMBIN

PHARM RES ASSOC	5MG	N011771 003
-----------------	-----	-------------

	10MG	N011771 002
--	------	-------------

	25MG	N011771 001
--	------	-------------

PANWARFIN

ABBOTT	2MG	N017020 001
--------	-----	-------------

	2.5MG	N017020 002
--	-------	-------------

	5MG	N017020 003
--	-----	-------------

	7.5MG	N017020 004
--	-------	-------------

	10MG	N017020 005
--	------	-------------

WARFARIN SODIUM

SANDOZ	1MG	A040196 001	Sep 30, 1997
--------	-----	-------------	--------------

	2MG	A040196 002	Sep 30, 1997
--	-----	-------------	--------------

	2.5MG	A040196 003	Sep 30, 1997
--	-------	-------------	--------------

	3MG	A040196 008	Jul 26, 2000
--	-----	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

WARFARIN SODIUM

TABLET; ORAL

WARFARIN SODIUM

4MG	A040196 004	Sep 30, 1997
5MG	A040196 005	Sep 30, 1997
6MG	A040196 009	Jul 26, 2000
7.5MG	A040196 006	Sep 30, 1997
10MG	A040196 007	Sep 30, 1997
USL PHARMA	2MG	A088719 001 Jun 27, 1985
	2.5MG	A088720 001 Aug 06, 1985
	5MG	A088721 001 Jul 02, 1985
WATSON LABS	2MG	A086123 001 Aug 17, 1982
	2.5MG	A086120 001 Aug 17, 1982
	5MG	A086119 001 Aug 17, 1982
	7.5MG	A086118 001 Aug 17, 1982
	10MG	A086122 001 Aug 17, 1982

XENON XE-127

GAS; INHALATION

XENON XE 127

MALLINCKRODT

5mCi/VIAL	N018536 001	Oct 01, 1982
10mCi/VIAL	N018536 002	Oct 01, 1982

XENON XE-133

GAS; INHALATION

XENON XE 133

GE HEALTHCARE

1 CI/AMP	N017256 002	
10mCi/VIAL	N017687 002	
20mCi/VIAL	N017687 003	
GEN ELECTRIC	5-100 CI/CYLINDER	N017550 001
	0.25-5 CI/AMP	N017550 003

XENON XE 133-V.S.S.

GE HEALTHCARE

10mCi/VIAL	N017687 001	
------------	-------------	--

INJECTABLE; INJECTION

XENON XE 133

GE HEALTHCARE

1.3-1.7 CI/AMP	N017256 001	
----------------	-------------	--

LANTHEUS MEDCL

6.3mCi/ML	N017283 001	
-----------	-------------	--

SOLUTION; INHALATION, INJECTION

XENEISOL

MALLINCKRODT

18-25mCi/AMP	N017262 002	
--------------	-------------	--

XYLOSE

POWDER; ORAL

XYLO-PFAN

SAVAGE LABS

25GM/BOT	N017605 001	
----------	-------------	--

XYLOSE

LYNE

25GM/BOT	N018856 001	Mar 26, 1987
----------	-------------	--------------

ZALCITABINE

TABLET; ORAL

HIVID

ROCHE

0.375MG	N020199 001	Jun 19, 1992
0.75MG	N020199 002	Jun 19, 1992

ZALEPLON

CAPSULE; ORAL

ZALEPLON

UPSHER SMITH

5MG	A078706 001	Jun 06, 2008
10MG	A078706 002	Jun 06, 2008

UPSHER-SMITH LABS

5MG	A078095 001	Jun 06, 2008
10MG	A078095 002	Jun 06, 2008

ZICONOTIDE ACETATE

INJECTABLE; INTRATHECAL

PRIALT

JAZZ PHARMS INTL

200MCG/2ML (100MCG/ML)	N021060 003	Dec 28, 2004
------------------------	-------------	--------------

ZIDOVUDINE

INJECTABLE; INJECTION

ZIDOVUDINE

LIAONING CHENGDA

10MG/ML	A204538 001	Nov 26, 2013
---------	-------------	--------------

TABLET; ORAL

RETROVIR

VIIIV HLTHCARE

200MG	N020518 001	Dec 19, 1995
300MG **Federal Register determination that product was not discontinued or	N020518 002	Oct 04, 1996

DISCONTINUED DRUG PRODUCT LIST

ZIDOVUDINE

TABLET; ORAL
RETROVIR

withdrawn for safety or efficacy
reasons**

ZIDOVUDINE

AUROBINDO PHARMA	60MG	N022294	001	Jul 23, 2009
MATRIX LABS LTD	100MG	N200732	001	Feb 23, 2011
RANBAXY LABS LTD	300MG	A077327	001	Sep 19, 2005
SUNSHINE LAKE	300MG	A202058	001	Oct 07, 2011

ZILEUTON

TABLET; ORAL
ZYFLO

CHIESI USA INC	300MG	N020471	001	Dec 09, 1996
----------------	-------	---------	-----	--------------

ZINC SULFATE

INJECTABLE; INJECTION
ZINC SULFATE

ABRAXIS PHARM	EQ 1MG ZINC/ML	N019229	002	May 05, 1987
---------------	----------------	---------	-----	--------------

ZIPRASIDONE HYDROCHLORIDE

SUSPENSION; ORAL
GEODON

PFIZER INC	EQ 10MG BASE/ML	N021483	001	Mar 29, 2006
------------	-----------------	---------	-----	--------------

ZOLEDRONIC ACID

INJECTABLE; IV (INFUSION)
ZOMETA

NOVARTIS	EQ 4MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021223	001	Aug 20, 2001
----------	--	---------	-----	--------------

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

DR REDDYS LABS LTD	5MG	A077985	001	Apr 23, 2007
	10MG	A077985	002	Apr 23, 2007
HIKMA	5MG	A078129	001	Apr 30, 2008
	10MG	A078129	002	Apr 30, 2008
MYLAN PHARMS INC	5MG	A078016	001	Apr 23, 2007
	10MG	A078016	002	Apr 23, 2007
SUN PHARM INDS	5MG	A077288	001	Apr 23, 2007
	10MG	A077288	002	Apr 23, 2007
SYNTHON PHARMS	5MG	A077540	001	Apr 23, 2007
	10MG	A077540	002	Apr 23, 2007
VIVIMED LABS	5MG	A076062	001	Apr 23, 2007
	10MG	A076062	002	Apr 23, 2007
WATSON LABS	5MG	A077773	001	Apr 23, 2007
	10MG	A077773	002	Apr 23, 2007

TABLET, ORALLY DISINTEGRATING; ORAL

TOVALT ODT

BIOVAIL LABS INTL	5MG	N021412	001	Apr 25, 2007
	10MG	N021412	002	Apr 25, 2007

ZONISAMIDE

CAPSULE; ORAL

ZONISAMIDE

ANI PHARMS INC	25MG	A077639	001	Dec 22, 2005
	25MG	A077641	003	Dec 22, 2005
	50MG	A077639	002	Dec 22, 2005
	50MG	A077641	002	Dec 22, 2005
	100MG	A077639	003	Dec 22, 2005
	100MG	A077641	001	Dec 22, 2005
COREPHARMA	25MG	A077876	001	Feb 21, 2007
	50MG	A077876	002	Feb 21, 2007
	100MG	A077876	003	Feb 21, 2007
DR REDDYS LABS LTD	25MG	A077645	002	Sep 29, 2006
	50MG	A077645	003	Sep 29, 2006
	100MG	A077645	001	Dec 22, 2005
ROXANE	25MG	A077648	001	Dec 22, 2005
	50MG	A077648	002	Dec 22, 2005
	100MG	A077648	003	Dec 22, 2005
SUN PHARM INDS	25MG	A077635	001	Dec 22, 2005
	50MG	A077635	002	Dec 22, 2005

DISCONTINUED DRUG PRODUCT LISTZONISAMIDE

CAPSULE; ORAL

ZONISAMIDE

	100MG	A077635 003	Dec 22, 2005
UPSHER-SMITH LABS	25MG	A077644 001	Dec 22, 2005
	50MG	A077644 002	Dec 22, 2005
	100MG	A077644 003	Dec 22, 2005
WATSON LABS	25MG	A077650 001	Apr 20, 2006
	50MG	A077650 002	Apr 20, 2006
	100MG	A077650 003	Apr 20, 2006

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:
<http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/default.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

ACETAMINOPHEN;ASPIRIN;BUTALBITAL
CAPSULE OR TABLET; ORAL
160-165MG;160-165MG;50MG
325MG;325MG;50MG

ASPIRIN;CAFFEINE;CARISOPRODOL;
CODEINE PHOSPHATE
TABLET; ORAL
160MG;32MG;200MG;16MG

ACETAMINOPHEN;ASPIRIN;BUTALBITAL;
CAFFEINE
CAPSULE OR TABLET; ORAL
160-165MG;160-165MG;50MG;40MG
325MG;325MG;50MG;40MG

ASPIRIN;CARISOPRODOL
TABLET; ORAL
325MG;200MG

ACETAMINOPHEN;BUTALBITAL
CAPSULE OR TABLET; ORAL
325MG;50MG

ASPIRIN;CARISOPRODOL;
CODEINE PHOSPHATE
TABLET; ORAL
325MG;200MG;16MG

ACETAMINOPHEN;BUTALBITAL;CAFFEINE
CAPSULE OR TABLET; ORAL
325MG;50MG;40MG

ASPIRIN;MEPROBAMATE
TABLET; ORAL
325MG;200MG

AMINOPHYLLINE
TABLET; ORAL
100MG;200MG

ASPIRIN;METHOCARBAMOL
TABLET; ORAL
325MG;400MG

ASPIRIN;BUTALBITAL
CAPSULE OR TABLET; ORAL
325MG;50MG
650MG;50MG

CHLOROTHIAZIDE
TABLET; ORAL
250MG

ASPIRIN;BUTALBITAL;CAFFEINE
CAPSULE OR TABLET; ORAL
325MG;50MG;40MG
650MG;50MG;40MG

HYDROXYZINE HYDROCHLORIDE
TABLET; ORAL
10MG;25MG;
50MG;100MG

ASPIRIN;CAFFEINE;CARISOPRODOL
TABLET; ORAL
160MG;32MG;200MG

PREDNISONE
TABLET; ORAL
1MG;2.5MG;5MG;10MG;
20MG;25MG;50MG

APPENDIX A - PRODUCT NAME INDEX

** 8 **

8-MOP, METHOXSALEN

** A **

A-HYDROCORT, HYDROCORTISONE SODIUM SUCCINATE
 A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE
 ABACAVIR SULFATE, ABACAVIR SULFATE
 ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
 ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE, ABACAVIR SULFATE
 ABELCET, AMPHOTERICIN B
 ABILIFY, ARIPIPIRAZOLE
 ABILIFY MAINTENA KIT, ARIPIPIRAZOLE
 ABRAXANE, PACLITAXEL
 ABREVA, DOCOSANOL (OTC)
 ABSORICA, ISOTRETINOIN
 ABSTRAL, FENTANYL CITRATE
 ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
 ACANYA, BENZOYL PEROXIDE
 ACARBOSE, ACARBOSE
 ACCOLATE, ZAFIRLUKAST
 ACCUNEB, ALBUTEROL SULFATE
 ACCUPRIL, QUINAPRIL HYDROCHLORIDE
 ACCURETIC, HYDROCHLOROTHIAZIDE
 ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
 ACEON, PERINDOPRIL ERBUMINE
 ACEPHEN, ACETAMINOPHEN (OTC)
 ACETADOTE, ACETYLCYSTEINE
 ACETAMINOPHEN, ACETAMINOPHEN (OTC)
 ACETAMINOPHEN, ACETAMINOPHEN
 ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)
 ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE, ACETAMINOPHEN
 ACETASOL HC, ACETIC ACID, GLACIAL
 ACETAZOLAMIDE, ACETAZOLAMIDE
 ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
 ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
 ACETIC ACID, ACETIC ACID, GLACIAL
 ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
 ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE, ACETIC ACID, GLACIAL
 ACETYLCYSTEINE, ACETYLCYSTEINE
 ACHROMYCIN V, TETRACYCLINE HYDROCHLORIDE
 ACIPHEX, RABEPRAZOLE SODIUM
 ACIPHEX SPRINKLE, RABEPRAZOLE SODIUM
 ACITRETIN, ACITRETIN
 ACTHREL, CORTICORELIN OVINE TRIFLUTATE
 ACTICLATE, DOXYCYCLINE HYCLATE
 ACTICLATE CAP, DOXYCYCLINE HYCLATE
 ACTIGALL, URSODIOL
 ACTIQ, FENTANYL CITRATE
 ACTIVELLA, ESTRADIOL
 ACTONEL, RISEDRONATE SODIUM
 ACTOPLUS MET, METFORMIN HYDROCHLORIDE
 ACTOPLUS MET XR, METFORMIN HYDROCHLORIDE
 ACTOS, PIOGLITAZONE HYDROCHLORIDE
 ACULAR, KETOROLAC TROMETHAMINE
 ACULAR LS, KETOROLAC TROMETHAMINE
 ACUVAIL, KETOROLAC TROMETHAMINE
 ACYCLOVIR, ACYCLOVIR
 ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
 ACZONE, DAPSONE
 ADAGEN, PEGADEMASE BOVINE
 ADALAT CC, NIFEDIPINE
 ADAPALENE, ADAPALENE
 ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
 ADASUVE, LOXAPINE
 ADCIRCA, TADALAFIL

APPENDIX A - PRODUCT NAME INDEX

** A **

ADDERALL XR 10, AMPHETAMINE ASPARTATE
 ADDERALL XR 15, AMPHETAMINE ASPARTATE
 ADDERALL XR 20, AMPHETAMINE ASPARTATE
 ADDERALL XR 25, AMPHETAMINE ASPARTATE
 ADDERALL XR 30, AMPHETAMINE ASPARTATE
 ADDERALL XR 5, AMPHETAMINE ASPARTATE
 ADDYI, FLIBANSERIN
 ADEFOVIR DIPIVOXIL, ADEFOVIR DIPIVOXIL
 ADEMPAS, RIOCIGUAT
 ADENOCARD, ADENOSINE
 ADENOSINE, ADENOSINE
 ADIPEX-P, PHENTERMINE HYDROCHLORIDE
 ADLYXIN, LIXISENATIDE
 ADRENACLICK, EPINEPHRINE
 ADRENALIN, EPINEPHRINE
 ADREVIEW, IOBENGUANE SULFATE I-123
 ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE
 ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE
 ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE
 ADVAIR HFA, FLUTICASONE PROPIONATE
 ADVIL, IBUPROFEN (OTC)
 ADVIL, IBUPROFEN SODIUM (OTC)
 ADVIL ALLERGY AND CONGESTION RELIEF, CHLORPHENIRAMINE MALEATE (OTC)
 ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
 ADVIL COLD AND SINUS, IBUPROFEN (OTC)
 ADVIL CONGESTION RELIEF, IBUPROFEN (OTC)
 ADVIL LIQUI-GELS, IBUPROFEN (OTC)
 ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN (OTC)
 ADVIL PM, DIPHENHYDRAMINE CITRATE (OTC)
 ADVIL PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
 ADZENYS XR-ODT, AMPHETAMINE
 AEROSPAN HFA, FLUNISOLIDE
 AFEDITAB CR, NIFEDIPINE
 AFINITOR, EVEROLIMUS
 AFINITOR DISPERZ, EVEROLIMUS
 AFIRMELLE, ETHINYL ESTRADIOL
 AFREZZA, INSULIN RECOMBINANT HUMAN
 AFRINOL, PSEUDOEPHEDRINE SULFATE (OTC)
 AGGRASTAT, TIROFIBAN HYDROCHLORIDE
 AGGRENOLX, ASPIRIN
 AGRYLIN, ANAGRELIDE HYDROCHLORIDE
 AK-FLUOR 10%, FLUORESCEIN SODIUM
 AK-FLUOR 25%, FLUORESCEIN SODIUM
 AKBETA, LEVOBUNOLOL HYDROCHLORIDE
 AKNE-MYCIN, ERYTHROMYCIN
 AKOFAZ, EPHEDRINE SULFATE
 AKPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
 AKTEN, LIDOCAINE HYDROCHLORIDE
 AKTIPAK, BENZOYL PEROXIDE
 AKTOB, TOBRAMYCIN
 AKYNZEO, NETUPITANT
 ALA-CORT, HYDROCORTISONE
 ALA-SCALP, HYDROCORTISONE
 ALAVERT, LORATADINE (OTC)
 ALAWAY, KETOTIFEN FUMARATE (OTC)
 ALBENZA, ALBENDAZOLE
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
 ALCALINE, PROPARACAINE HYDROCHLORIDE
 ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
 ALDACTAZIDE, HYDROCHLOROTHIAZIDE
 ALDACTONE, SPIRONOLACTONE
 ALDARA, IMIQUIMOD
 ALECENSA, ALECTINIB HYDROCHLORIDE
 ALENDRONATE SODIUM, ALENDRONATE SODIUM
WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1086, p. 842 of 1400

APPENDIX A - PRODUCT NAME INDEX

** A **

ALEVE, NAPROXEN SODIUM (OTC)
 ALEVE PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
 ALEVE-D SINUS & COLD, NAPROXEN SODIUM (OTC)
 ALFENTA, ALFENTANIL HYDROCHLORIDE
 ALFENTANIL, ALFENTANIL HYDROCHLORIDE
 ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
 ALIMTA, PEMETREXED DISODIUM
 ALINIA, NITAZOXANIDE
 ALKERAN, MELPHALAN
 ALKERAN, MELPHALAN HYDROCHLORIDE
 ALLEGRA, FEXOFENADINE HYDROCHLORIDE
 ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 ALLEGRA HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
 ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
 ALLI, ORLISTAT (OTC)
 ALLOPURINOL, ALLOPURINOL
 ALLOPURINOL SODIUM, ALLOPURINOL SODIUM
 ALLZITAL, ACETAMINOPHEN
 ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
 ALOCRI, NEDOCROMIL SODIUM
 ALOMIDE, LODOXAMIDE TROMETHAMINE
 ALOPRIM, ALLOPURINOL SODIUM
 ALORA, ESTRADIOL
 ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
 ALOXI, PALONOSETRON HYDROCHLORIDE
 ALPHAGAN P, BRIMONIDINE TARTRATE
 ALPRAZOLAM, ALPRAZOLAM
 ALPROSTADIL, ALPROSTADIL
 ALREX, LOTEHPREDNOL ETABONATE
 ALTABAX, RETAPAMULIN
 ALTACE, RAMIPRIL
 ALTAVERA, ETHINYL ESTRADIOL
 ALTOPREV, LOVASTATIN
 ALVESCO, CICLESONIDE
 ALYACEN 1/35, ETHINYL ESTRADIOL
 ALYACEN 7/7/7, ETHINYL ESTRADIOL
 AMABELZ, ESTRADIOL
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 AMARYL, GLIMEPIRIDE
 AMBIEN, ZOLPIDEM TARTRATE
 AMBIEN CR, ZOLPIDEM TARTRATE
 AMBISOME, AMPHOTERICIN B
 AMCINONIDE, AMCINONIDE
 AMELUZ, AMINOLEVULINIC ACID HYDROCHLORIDE
 AMERGE, NARATRIPTAN HYDROCHLORIDE
 AMICAR, AMINOCAPROIC ACID
 AMIDATE, ETOMIDATE
 AMIFOSTINE, AMIFOSTINE
 AMIKACIN SULFATE, AMIKACIN SULFATE
 AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
 AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
 AMINO ACIDS, AMINO ACIDS
 AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE
 AMINOCAPROIC, AMINOCAPROIC ACID
 AMINOCAPROIC ACID, AMINOCAPROIC ACID
 AMINOCAPROIC ACID IN PLASTIC CONTAINER, AMINOCAPROIC ACID
 AMINOPHYLLINE, AMINOPHYLLINE
 AMINOSYN 10%, AMINO ACIDS
 AMINOSYN 10% (PH6), AMINO ACIDS
 AMINOSYN 3.5%, AMINO ACIDS
 AMINOSYN 3.5% M, AMINO ACIDS
 AMINOSYN 5%, AMINO ACIDS
 AMINOSYN 7%, AMINO ACIDS
 AMINOSYN 7% (PH6), AMINO ACIDS

APPENDIX A - PRODUCT NAME INDEX

** A **

AMINOSYN 7% W/ ELECTROLYTES, AMINO ACIDS
 AMINOSYN 8.5%, AMINO ACIDS
 AMINOSYN 8.5% (PH6), AMINO ACIDS
 AMINOSYN 8.5% W/ ELECTROLYTES, AMINO ACIDS
 AMINOSYN II 10%, AMINO ACIDS
 AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS
 AMINOSYN II 10% W/ ELECTROLYTES, AMINO ACIDS
 AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS
 AMINOSYN II 7%, AMINO ACIDS
 AMINOSYN II 8.5%, AMINO ACIDS
 AMINOSYN II 8.5% W/ ELECTROLYTES, AMINO ACIDS
 AMINOSYN-HBC 7%, AMINO ACIDS
 AMINOSYN-HF 8%, AMINO ACIDS
 AMINOSYN-PF 10%, AMINO ACIDS
 AMINOSYN-PF 7%, AMINO ACIDS
 AMINOSYN-RF 5.2%, AMINO ACIDS
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 AMITIZA, LUBIPROSTONE
 AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
 AMMONIA N 13, AMMONIA N-13
 AMMONIUM CHLORIDE IN PLASTIC CONTAINER, AMMONIUM CHLORIDE
 AMMONIUM LACTATE, AMMONIUM LACTATE
 AMMONUL, SODIUM BENZOATE
 AMNESTEEM, ISOTRETINOIN
 AMOXAPINE, AMOXAPINE
 AMOXICILLIN, AMOXICILLIN
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 AMOXICILLIN PEDIATRIC, AMOXICILLIN
 AMOXIL, AMOXICILLIN
 AMPHADASE, HYALURONIDASE
 AMPHOTERICIN B, AMPHOTERICIN B
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 AMPICILLIN SODIUM, AMPICILLIN SODIUM
 AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
 AMPYRA, DALFAMPRIDINE
 AMRINONE LACTATE, INAMRINONE LACTATE
 AMRIX, CYCLOBENZAPRINE HYDROCHLORIDE
 AMYVID, FLORBETAPIR F-18
 AN-DTPA, TECHNETIUM TC-99M PENTETATE KIT
 AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
 ANADROL-50, OXYMETHOLONE
 ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE
 ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
 ANAPROX, NAPROXEN SODIUM
 ANAPROX DS, NAPROXEN SODIUM
 ANASTROZOLE, ANASTROZOLE
 ANCEF IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
 ANCOBON, FLUCYTOSINE
 ANDRODERM, TESTOSTERONE
 ANDROGEL, TESTOSTERONE
 ANDROID 25, METHYLTESTOSTERONE
 ANECTINE, SUCCINYLCHOLINE CHLORIDE
 ANEXSIA 5/325, ACETAMINOPHEN
 ANEXSIA 7.5/325, ACETAMINOPHEN
 ANGELIQ, DROSPIRENONE
 ANGIOMAX, BIVALIRUDIN
 ANORO ELLIPTA, UMECLIDINIUM BROMIDE
 ANTABUSE, DISULFIRAM
 ANTARA (MICRONIZED), FENOFIBRATE
WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1086, p. 844 of 1400

APPENDIX A - PRODUCT NAME INDEX

** A **

ANTHELIOS 20, AVOBENZONE (OTC)
 ANTHELIOS 40, AVOBENZONE (OTC)
 ANTHELIOS SX, AVOBENZONE (OTC)
 ANTIZOL, FOMEPIZOLE
 ANUSOL HC, HYDROCORTISONE
 ANZEMET, DOLASETRON MESYLATE
 APIDRA, INSULIN GLULISINE RECOMBINANT
 APIDRA SOLOSTAR, INSULIN GLULISINE RECOMBINANT
 APLENZIN, BUPROPION HYDROBROMIDE
 APOKYN, APOMORPHINE HYDROCHLORIDE
 APRACLONIDINE HYDROCHLORIDE, APRACLONIDINE HYDROCHLORIDE
 APREPITANT, APREPITANT
 APRISO, MESALAMINE
 APTENSIO XR, METHYLPHENIDATE HYDROCHLORIDE
 APTIOM, ESLICARBAZEPINE ACETATE
 APTIVUS, TIPRANAVIR
 AQUASOL A, VITAMIN A PALMITATE
 ARALEN, CHLOROQUINE PHOSPHATE
 ARANELLE, ETHINYL ESTRADIOL
 ARAVA, LEFLUNOMIDE
 ARCAPTA NEOHALER, INDACATEROL MALEATE
 ARESTIN, MINOCYCLINE HYDROCHLORIDE
 ARGATROBAN, ARGATROBAN
 ARGATROBAN IN 0.9% SODIUM CHLORIDE, ARGATROBAN
 ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
 ARICEPT, DONEPEZIL HYDROCHLORIDE
 ARICEPT ODT, DONEPEZIL HYDROCHLORIDE
 ARIMIDEX, ANASTROZOLE
 ARIPIPRAZOLE, ARIPIPRAZOLE
 ARISTADA, ARIPIPRAZOLE LAUROXIL
 ARISTOSPAN, TRIAMCINOLONE HEXACETONIDE
 ARIXTRA, FONDAPARINUX SODIUM
 ARMODAFINIL, ARMODAFINIL
 ARNUITY ELLIPTA, FLUTICASONE FUROATE
 AROMASIN, EXEMESTANE
 ARRANON, NELARABINE
 ARTHROTEC, DICLOFENAC SODIUM
 ARTICAINA HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, ARTICAINA HYDROCHLORIDE
 ASACOL HD, MESALAMINE
 ASCLERA, POLIDOCANOL
 ASHLYNA, ETHINYL ESTRADIOL
 ASMANEX HFA, MOMETASONE FUROATE
 ASMANEX TWISTHALER, MOMETASONE FUROATE
 ASPIRIN, ASPIRIN (OTC)
 ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
 ASTAGRAF XL, TACROLIMUS
 ASTELIN, AZELASTINE HYDROCHLORIDE
 ASTEPRO, AZELASTINE HYDROCHLORIDE
 ASTRAMORPH PF, MORPHINE SULFATE
 ATACAND, CANDESARTAN CILEXETIL
 ATACAND HCT, CANDESARTAN CILEXETIL
 ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
 ATELVIA, RISEDRONATE SODIUM
 ATENOLOL, ATENOLOL
 ATENOLOL AND CHLORTHALIDONE, ATENOLOL
 ATHENTIA NEXT, LEVONORGESTREL (OTC)
 ATIVAN, LORAZEPAM
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 ATOVAQUONE, ATOVAQUONE
 ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE
 ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
 ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
 ATRALIN, TRETINOIN
 ATRIDOX, DOXYCYCLINE HYCLATE
 ATRIPLA, EFAVIRENZ

APPENDIX A - PRODUCT NAME INDEX

** A **

ATROPEN, ATROPINE
 ATROPINE SULFATE, ATROPINE SULFATE
 ATROPINE SULFATE ANSYR PLASTIC SYRINGE, ATROPINE SULFATE
 ATROVENT, IPRATROPIUM BROMIDE
 ATROVENT HFA, IPRATROPIUM BROMIDE
 AUBAGIO, TERIFLUNOMIDE
 AUGMENTIN '125', AMOXICILLIN
 AUGMENTIN '200', AMOXICILLIN
 AUGMENTIN '250', AMOXICILLIN
 AUGMENTIN '400', AMOXICILLIN
 AUGMENTIN '500', AMOXICILLIN
 AUGMENTIN '875', AMOXICILLIN
 AUGMENTIN ES-600, AMOXICILLIN
 AUGMENTIN XR, AMOXICILLIN
 AURYXIA, FERRIC CITRATE
 AUVI-Q, EPINEPHRINE
 AVAGARD, ALCOHOL (OTC)
 AVAGE, TAZAROTENE
 AVALIDE, HYDROCHLOROTHIAZIDE
 AVANDIA, ROSIGLITAZONE MALEATE
 AVAPRO, IRBESARTAN
 AVC, SULFANILAMIDE
 AVEED, TESTOSTERONE UNDECANOATE
 AVELOX, MOXIFLOXACIN HYDROCHLORIDE
 AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER, MOXIFLOXACIN HYDROCHLORIDE
 AVIANE-28, ETHINYL ESTRADIOL
 AVITA, TRETINOIN
 AVODART, DUTASTERIDE
 AVYCAZ, AVIBACTAM SODIUM
 AXERT, ALMOTRIPTAN MALATE
 AXID AR, NIZATIDINE (OTC)
 AXIRON, TESTOSTERONE
 AXUMIN, FLUCICLOVINE F-18
 AYGESTIN, NORETHINDRONE ACETATE
 AYUNA, ETHINYL ESTRADIOL
 AZACITIDINE, AZACITIDINE
 AZACTAM, AZTREONAM
 AZACTAM IN PLASTIC CONTAINER, AZTREONAM
 AZASAN, AZATHIOPRINE
 AZASITE, AZITHROMYCIN
 AZATHIOPRINE, AZATHIOPRINE
 AZATHIOPRINE SODIUM, AZATHIOPRINE SODIUM
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 AZELEX, AZELAIC ACID
 AZILECT, RASAGILINE MESYLATE
 AZITHROMYCIN, AZITHROMYCIN
 AZOPT, BRINZOLAMIDE
 AZOR, AMLODIPINE BESYLATE
 AZTREONAM, AZTREONAM
 AZULFIDINE, SULFASALAZINE
 AZULFIDINE EN-TABS, SULFASALAZINE

** B **

BACIIM, BACITRACIN
 BACITRACIN, BACITRACIN
 BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
 BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN
 BACLOFEN, BACLOFEN
 BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM
 BACTRIM, SULFAMETHOXAZOLE
 BACTRIM DS, SULFAMETHOXAZOLE
 BACTROBAN, MUPIROCIN
 BACTROBAN, MUPIROCIN CALCIUM

APPENDIX A - PRODUCT NAME INDEX

** B **

BAL, DIMERCAPROL
 BALANCED SALT, CALCIUM CHLORIDE
 BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
 BALZIVA-28, ETHINYL ESTRADIOL
 BANZEL, RUFINAMIDE
 BARACLUDE, ENTECAVIR
 BASAGLAR, INSULIN GLARGINE
 BECONASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
 BEKYREE, DESOGESTREL
 BELBUCA, BUPRENORPHINE HYDROCHLORIDE
 BELEODAQ, BELINOSTAT
 BELSOMRA, SUVOREXANT
 BELVIQ, LORCASERIN HYDROCHLORIDE
 BELVIQ XR, LORCASERIN HYDROCHLORIDE
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
 BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
 BENDEKA, BENDAMUSTINE HYDROCHLORIDE
 BENICAR, OLMESARTAN MEDOXOMIL
 BENICAR HCT, HYDROCHLOROTHIAZIDE
 BENTYL, DICYCLOMINE HYDROCHLORIDE
 BENTYL PRESERVATIVE FREE, DICYCLOMINE HYDROCHLORIDE
 BENZACLIN, BENZOYL PEROXIDE
 BENZAMYCIN, BENZOYL PEROXIDE
 BENZONATATE, BENZONATATE
 BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
 BEPREVE, BEPOTASTINE BESILATE
 BESIVANCE, BESIFLOXACIN HYDROCHLORIDE
 BETA-VAL, BETAMETHASONE VALERATE
 BETADINE, POVIDONE-IODINE
 BETAGAN, LEVOBUNOLOL HYDROCHLORIDE
 BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE ACETATE
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
 BETAPACE, SOTALOL HYDROCHLORIDE
 BETAPACE AF, SOTALOL HYDROCHLORIDE
 BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
 BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
 BETHKIS, TOBRAMYCIN
 BETIMOL, TIMOLOL
 BETOPTIC, BETAXOLOL HYDROCHLORIDE
 BETOPTIC S, BETAXOLOL HYDROCHLORIDE
 BEVESPI AEROSPHERE, FORMOTEROL FUMARATE
 BEXAROTENE, BEXAROTENE
 BEYAZ, DROSPIRENONE
 BIAXIN, CLARITHROMYCIN
 BICALUTAMIDE, BICALUTAMIDE
 BICILLIN C-R, PENICILLIN G BENZATHINE
 BICILLIN C-R 900/300, PENICILLIN G BENZATHINE
 BICILLIN L-A, PENICILLIN G BENZATHINE
 BICNU, CARMUSTINE
 BIDIL, HYDRALAZINE HYDROCHLORIDE
 BILTRICIDE, PRAZIQUANTEL
 BIMATOPROST, BIMATOPROST
 BINOSTO, ALENDRONATE SODIUM
 BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)
 BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
 BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
 BIVALIRUDIN, BIVALIRUDIN
 BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
 BLEPH-10, SULFACETAMIDE SODIUM
 BLEPHAMIDE, PREDNISOLONE ACETATE
 BLEPHAMIDE S.O.P., PREDNISOLONE ACETATE
 BLISOVI 24 FE, ETHINYL ESTRADIOL

APPENDIX A - PRODUCT NAME INDEX

** B **

BLISOVI FE 1.5/30, ETHINYL ESTRADIOL
 BLISOVI FE 1/20, ETHINYL ESTRADIOL
 BLOXIVERZ, NEOSTIGMINE METHYLSULFATE
 BONIVA, IBANDRONATE SODIUM
 BONJESTA, DOXYLAMINE SUCCINATE
 BONTRIL PDM, PHENDIMETRAZINE TARTRATE
 BOSULIF, BOSUTINIB MONOHYDRATE
 BRAVELLE, UROFOLLITROPIN
 BREO ELLIPTA, FLUTICASONE FUROATE
 BREVIBLOC, ESMOLOL HYDROCHLORIDE
 BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
 BREVIBLOC IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
 BREVICON 28-DAY, ETHINYL ESTRADIOL
 BREVITAL SODIUM, METHOHEXITAL SODIUM
 BRIAN CARE, CHLORHEXIDINE GLUCONATE (OTC)
 BRIDION, SUGAMMADEX SODIUM
 BRIELLYN, ETHINYL ESTRADIOL
 BRILINTA, TICAGRELOR
 BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
 BRISDELLE, PAROXETINE MESYLATE
 BRIVIACT, BRIVARACETAM
 BROMFED-DM, BROMPHENIRAMINE MALEATE
 BROMFENAC SODIUM, BROMFENAC SODIUM
 BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
 BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE,
 BROMSITE, BROMFENAC SODIUM
 BRONCHO SALINE, SODIUM CHLORIDE (OTC)
 BROVANA, ARFORMOTEROL TARTRATE
 BSS, CALCIUM CHLORIDE
 BSS PLUS, CALCIUM CHLORIDE
 BUDESONIDE, BUDESONIDE (OTC)
 BUDESONIDE, BUDESONIDE
 BUMETANIDE, BUMETANIDE
 BUMEX, BUMETANIDE
 BUNAVAIL, BUPRENORPHINE HYDROCHLORIDE
 BUPHENYL, SODIUM PHENYLBUTYRATE
 BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
 BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
 BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
 BUPIVACAINE HYDROCHLORIDE W/EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
 BUPRENEX, BUPRENORPHINE HYDROCHLORIDE
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE , BUPRENORPHINE HYDROCHLORIDE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 BUSULFAN, BUSULFAN
 BUSULFEX, BUSULFAN
 BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
 BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
 BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE PHOSPHATE, ASPIRIN
 BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
 BUTAPAP, ACETAMINOPHEN
 BUTISOL SODIUM, BUTABARBITAL SODIUM
 BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
 BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
 BUTRANS, BUPRENORPHINE
 BYDUREON, EXENATIDE SYNTHETIC
 BYDUREON PEN, EXENATIDE SYNTHETIC
 BYETTA, EXENATIDE SYNTHETIC
 BYSTOLIC, NEBIVOLOL HYDROCHLORIDE
 BYVALSON, NEBIVOLOL HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

** C **

CABERGOLINE, CABERGOLINE
CABOMETYX, CABOZANTINIB S-MALATE
CADUET, AMLODIPINE BESYLATE
CAFACIT, CAFFEINE CITRATE
CAFERGOT, CAFFEINE
CAFFEINE CITRATE, CAFFEINE CITRATE
CALAN, VERAPAMIL HYDROCHLORIDE
CALAN SR, VERAPAMIL HYDROCHLORIDE
CALCIPOTRIENE, CALCIPOTRIENE
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCITONIN-SALMON, CALCITONIN SALMON
CALCITRIOL, CALCITRIOL
CALCIUM ACETATE, CALCIUM ACETATE
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CALCIUM DISODIUM VERSENATE, EDTATE CALCIUM DISODIUM
CALDOLOR, IBUPROFEN
CAMBIA, DICLOFENAC POTASSIUM
CAMILA, NORETHINDRONE
CAMPTOSAR, IRINOTECAN HYDROCHLORIDE
CANASA, MESALAMINE
CANCIDAS, CASPOFUNGIN ACETATE
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CANTIL, MEPENZOLATE BROMIDE
CAPASTAT SULFATE, CAPREOMYCIN SULFATE
CAPECITABINE, CAPECITABINE
CAPEX, FLUOCINOLONE ACETONIDE
CAPITAL AND CODEINE, ACETAMINOPHEN
CAPITAL SOLEIL 15, AVOBENZONE (OTC)
CAPRELSA, VANDETANIB
CAPTOPRIL, CAPTOPRIL
CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
CARAC, FLUOROURACIL
CARAFATE, SUCRALFATE
CARBAGLU, CARGLUMIC ACID
CARBAMAZEPINE, CARBAMAZEPINE
CARBATROL, CARBAMAZEPINE
CARBIDOPA, CARBIDOPA
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CARBOCAINE, MEPIVACAINE HYDROCHLORIDE
CARBOPLATIN, CARBOPLATIN
CARDENE, NICARDIPINE HYDROCHLORIDE
CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82
CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT
CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CARDIZEM, DILTIAZEM HYDROCHLORIDE
CARDIZEM CD, DILTIAZEM HYDROCHLORIDE
CARDIZEM LA, DILTIAZEM HYDROCHLORIDE
CARDURA, DOXAZOSIN MESYLATE
CARDURA XL, DOXAZOSIN MESYLATE
CARISOPRODOL, CARISOPRODOL
CARISOPRODOL AND ASPIRIN, ASPIRIN
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
CARNEXIV, CARBAMAZEPINE
CARNITOR, LEVOCARNITINE
CARNITOR SF, LEVOCARNITINE
CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE
CARTIA XT, DILTIAZEM HYDROCHLORIDE
CARVEDILOL, CARVEDILOL

APPENDIX A - PRODUCT NAME INDEX

** C **

CASODEX, BICALUTAMIDE
 CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
 CATAPRES, CLONIDINE HYDROCHLORIDE
 CATAPRES-TTS-1, CLONIDINE
 CATAPRES-TTS-2, CLONIDINE
 CATAPRES-TTS-3, CLONIDINE
 CAVERJECT, ALPROSTADIL
 CAVERJECT IMPULSE, ALPROSTADIL
 CAYSTON, AZTREONAM
 CEFACLOR, CEFACLOR
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
 CEFAZOLIN AND DEXTROSE, CEFAZOLIN SODIUM
 CEFAZOLIN IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
 CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
 CEFDINIR, CEFDINIR
 CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER, CEFEPIME HYDROCHLORIDE
 CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
 CEFEPIME IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
 CEFIXIME, CEFIXIME
 CEFOTAN, CEFOTETAN DISODIUM
 CEFOTAXIME, CEFOTAXIME SODIUM
 CEFOTAXIME SODIUM, CEFOTAXIME SODIUM
 CEFOTETAN, CEFOTETAN DISODIUM
 CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER, CEFOTETAN DISODIUM
 CEFOXITIN, CEFOXITIN SODIUM
 CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER, CEFOXITIN SODIUM
 CEFOXITIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
 CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
 CEFPROZIL, CEFPROZIL
 CEFTAZIDIME, CEFTAZIDIME
 CEFTAZIDIME IN DEXTROSE CONTAINER, CEFTAZIDIME
 CEFTIN, CEFUROXIME AXETIL
 CEFTRIAXONE, CEFTRIAXONE SODIUM
 CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER, CEFTRIAXONE SODIUM
 CEFTRIAXONE IN PLASTIC CONTAINER, CEFTRIAXONE SODIUM
 CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER, CEFUROXIME SODIUM
 CEFUROXIME AXETIL, CEFUROXIME AXETIL
 CEFUROXIME SODIUM, CEFUROXIME SODIUM
 CELEBREX, CELECOXIB
 CELECOXIB, CELECOXIB
 CELESTONE SOLUSPAN, BETAMETHASONE ACETATE
 CELEXA, CITALOPRAM HYDROBROMIDE
 CELLCEPT, MYCOPHENOLATE MOFETIL
 CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
 CELONTIN, METHSUXIMIDE
 CENTANY, MUPIROCIN
 CEPHALEXIN, CEPHALEXIN
 CERDELGA, ELIGLUSTAT TARTRATE
 CEREBYX, FOSPHENYTOIN SODIUM
 CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT
 CEREZYME, IMIGLUCERASE
 CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
 CERVIDIL, DINOPROSTONE
 CESAMET, NABILONE
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CETRAXAL, CIPROFLOXACIN HYDROCHLORIDE
 CETROTIDE, CETRORELIX
 CETYLEV, ACETYLCYSTEINE
 CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
 CHANTIX, VARENICLINE TARTRATE
 CHEMET, SUCCIMER
WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1086, p. 850 of 1400

APPENDIX A - PRODUCT NAME INDEX

** C **

CHENODIOL, CHENODIOL
 CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)
 CHILDREN'S ADVIL, IBUPROFEN (OTC)
 CHILDREN'S ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
 CHILDREN'S ADVIL COLD, IBUPROFEN (OTC)
 CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)
 CHILDREN'S ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S ALLEGRA HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CLARITIN, LORATADINE (OTC)
 CHILDREN'S ELIXSURE, IBUPROFEN (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S IBUPROFEN, IBUPROFEN (OTC)
 CHILDREN'S MOTRIN, IBUPROFEN (OTC)
 CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)
 CHILDREN'S ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CHIRHOSTIM, SECRETIN SYNTHETIC HUMAN
 CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE (OTC)
 CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE
 CHLORAPREP ONE-STEP, CHLORHEXIDINE GLUCONATE (OTC)
 CHLORAPREP ONE-STEP FREPP, CHLORHEXIDINE GLUCONATE (OTC)
 CHLORAPREP ONE-STEP SEPP, CHLORHEXIDINE GLUCONATE (OTC)
 CHLORAPREP SINGLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
 CHLORAPREP TRIPLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
 CHLORAPREP WITH TINT, CHLORHEXIDINE GLUCONATE (OTC)
 CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
 CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE
 CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
 CHLOROTHIAZIDE, CHLOROTHIAZIDE
 CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
 CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
 CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
 CHLORPROPAMIDE, CHLORPROPAMIDE
 CHLORTHALIDONE, CHLORTHALIDONE
 CHLORZOAZONE, CHLORZOAZONE
 CHOLAC, LACTULOSE
 CHOLBAM, CHOLIC ACID
 CHOLEDYL SA, OXTRIPHYLLINE
 CHOLESTYRAMINE, CHOLESTYRAMINE
 CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
 CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT
 CHOLINE C-11, CHOLINE C-11
 CHOLOGRAFIN MEGLUMINE, IODIPAMIDE MEGLUMINE
 CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
 CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE
 CIALIS, TADALAFIL
 CICLOPIROX, CICLOPIROX
 CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)
 CIDOFOVIR, CIDOFOVIR
 CILOSTAZOL, CILOSTAZOL
 CILOXAN, CIPROFLOXACIN HYDROCHLORIDE
 CIMETIDINE, CIMETIDINE (OTC)
 CIMETIDINE, CIMETIDINE
 CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
 CIPRO, CIPROFLOXACIN
 CIPRO, CIPROFLOXACIN HYDROCHLORIDE
 CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE
 CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
 CIPRODEX, CIPROFLOXACIN

APPENDIX A - PRODUCT NAME INDEX

** C **

CIPROFLOXACIN, CIPROFLOXACIN
 CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
 CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT
 CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT
 CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
 CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
 CISPLATIN, CISPLATIN
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 CITANEST FORTE DENTAL, EPINEPHRINE BITARTRATE
 CLADRIBINE, CLADRIBINE
 CLAFORAN, CEFOTAXIME SODIUM
 CLARAVIS, ISOTRETINOIN
 CLARINEX, DESLORATADINE
 CLARINEX D 24 HOUR, DESLORATADINE
 CLARINEX-D 12 HOUR, DESLORATADINE
 CLARITHROMYCIN, CLARITHROMYCIN
 CLARITIN, LORATADINE (OTC)
 CLARITIN HIVES RELIEF, LORATADINE (OTC)
 CLARITIN HIVES RELIEF REDITAB, LORATADINE (OTC)
 CLARITIN REDITABS, LORATADINE (OTC)
 CLARITIN-D, LORATADINE (OTC)
 CLARITIN-D 24 HOUR, LORATADINE (OTC)
 CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
 CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
 CLEOCIN, CLINDAMYCIN PALMITATE HYDROCHLORIDE
 CLEOCIN, CLINDAMYCIN PHOSPHATE
 CLEOCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
 CLEOCIN T, CLINDAMYCIN PHOSPHATE
 CLEVIPREX, CLEVIDIPINE
 CLIMARA, ESTRADIOL
 CLIMARA PRO, ESTRADIOL
 CLINDA-DERM, CLINDAMYCIN PHOSPHATE
 CLINDAGEL, CLINDAMYCIN PHOSPHATE
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
 CLINDAMYCIN PHOSPHATE AND TRETINOIN, CLINDAMYCIN PHOSPHATE
 CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
 CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE
 CLINDESSE, CLINDAMYCIN PHOSPHATE
 CLINDETS, CLINDAMYCIN PHOSPHATE
 CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,

APPENDIX A - PRODUCT NAME INDEX

** C **

CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
 CLINOLIPID 20%, OLIVE OIL
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
 CLOBEX, CLOBETASOL PROPIONATE
 CLODERM, CLOCORTOLONE PIVALATE
 CLOLAR, CLOFARABINE
 CLOMID, CLOMIPHENE CITRATE
 CLOMIPHENE CITRATE, CLOMIPHENE CITRATE
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
 CLONAZEPAM, CLONAZEPAM
 CLONIDINE, CLONIDINE
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
 CLORPRES, CHLOROTHALIDONE
 CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
 CLOTRIMAZOLE, CLOTRIMAZOLE
 CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CLOZAPINE, CLOZAPINE
 CLOZARIL, CLOZAPINE
 COARTEM, ARTEMETHER
 CODEINE SULFATE, CODEINE SULFATE
 COGENTIN, BENZTROPINE MESYLATE
 COL-PROBENECID, COLCHICINE
 COLAZAL, BALSALAZIDE DISODIUM
 COLCRYS, COLCHICINE
 COLESTID, COLESTIPOL HYDROCHLORIDE
 COLESTIPOL HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE
 COLGATE TOTAL, SODIUM FLUORIDE (OTC)
 COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
 COLOCORT, HYDROCORTISONE
 COLPREP KIT, MAGNESIUM SULFATE
 COLY-MYCIN M, COLISTIMETHATE SODIUM
 COLY-MYCIN S, COLISTIN SULFATE
 COLYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
 COMBIGAN, BRIMONIDINE TARTRATE
 COMBIPATCH, ESTRADIOL
 COMBIVENT RESPIMAT, ALBUTEROL SULFATE
 COMBIVIR, LAMIVUDINE
 COMETRIQ, CABOZANTINIB S-MALATE
 COMMIT, NICOTINE POLACRILEX (OTC)
 COMPLERA, EMTRICITABINE
 COMPRO, PROCHLORPERAZINE
 COMTAN, ENTACAPONE
 CONCERTA, METHYLPHENIDATE HYDROCHLORIDE
 CONDYLOX, PODOFILOX
 CONRAY, IOTHALAMATE MEGLUMINE
 CONRAY 30, IOTHALAMATE MEGLUMINE
 CONRAY 43, IOTHALAMATE MEGLUMINE
 CONSTILAC, LACTULOSE
 CONTRAVE, BUPROPION HYDROCHLORIDE
 CONZIP, TRAMADOL HYDROCHLORIDE
 COPAXONE, GLATIRAMER ACETATE
 COPEGUS, RIBAVIRIN
 CORDARONE, AMIODARONE HYDROCHLORIDE
 CORDRAN, FLURANDRENOLIDE
 CORDRAN SP, FLURANDRENOLIDE
 COREG, CARVEDILOL

APPENDIX A - PRODUCT NAME INDEX

** C **

COREG CR, CARVEDILOL PHOSPHATE
 CORGARD, NADOLOL
 CORLANOR, IVABRADINE HYDROCHLORIDE
 CORLOPAM, FENOLDOPAM MESYLATE
 CORMAX, CLOBETASOL PROPIONATE
 CORTEF, HYDROCORTISONE
 CORTENEMA, HYDROCORTISONE
 CORTIFOAM, HYDROCORTISONE ACETATE
 CORTISONE ACETATE, CORTISONE ACETATE
 CORTISPORIN, BACITRACIN ZINC
 CORTISPORIN, HYDROCORTISONE
 CORTISPORIN, HYDROCORTISONE ACETATE
 CORTROSYN, COSYNTROPIN
 CORVERT, IBUTILIDE FUMARATE
 CORZIDE, BENDROFLUMETHIAZIDE
 COSMEGEN, DACTINOMYCIN
 COSOPT, DORZOLAMIDE HYDROCHLORIDE
 COSOPT PF, DORZOLAMIDE HYDROCHLORIDE
 COSYNTROPIN, COSYNTROPIN
 COTELLIC, COBIMETINIB FUMARATE
 COUMADIN, WARFARIN SODIUM
 COVERA-HS, VERAPAMIL HYDROCHLORIDE
 COZAAR, LOSARTAN POTASSIUM
 CREON, PANCRELIPASE (AMYLASE
 CRESEMBA, ISAVUCONAZONIUM SULFATE
 CRESTOR, ROSUVASTATIN CALCIUM
 CRINONE, PROGESTERONE
 CRIXIVAN, INDINAVIR SULFATE
 CROLOM, CROMOLYN SODIUM
 CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
 CROMOLYN SODIUM, CROMOLYN SODIUM
 CROTAN, CROTAMITON
 CRYSELLE, ETHINYL ESTRADIOL
 CUBICIN, DAPTOMYCIN
 CUBICIN RF, DAPTOMYCIN
 CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE
 CUPRIMINE, PENICILLAMINE
 CUROSURF, PORACTANT ALFA
 CUTIVATE, FLUTICASONE PROPIONATE
 CUVPOSA, GLYCOPYRROLATE
 CYANOCOBALAMIN, CYANOCOBALAMIN
 CYANOKIT, HYDROXOCOBALAMIN
 CYCLAFEM 0.5/35, ETHINYL ESTRADIOL
 CYCLAFEM 1/35, ETHINYL ESTRADIOL
 CYCLAFEM 7/7/7, ETHINYL ESTRADIOL
 CYCLESSA, DESOGESTREL
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE
 CYCLOMYDRIL, CYCLOPENTOLATE HYDROCHLORIDE
 CYCLOPENTOLATE HYDROCHLORIDE, CYCLOPENTOLATE HYDROCHLORIDE
 CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
 CYCLOSET, BROMOCRIPTINE MESYLATE
 CYCLOSPORINE, CYCLOSPORINE
 CYKLOKAPRON, TRANEXAMIC ACID
 CYMBALTA, DULOXETINE HYDROCHLORIDE
 CYONANZ, ETHINYL ESTRADIOL
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 CYSTADANE, BETAINE HYDROCHLORIDE
 CYSTAGON, CYSTEAMINE BITARTRATE
 CYSTARAN, CYSTEAMINE HYDROCHLORIDE
 CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE
 CYSTOGRAFIN, DIATRIZOATE MEGLUMINE
 CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE
 CYSVIEW KIT, HEXAMINOLEVULINATE HYDROCHLORIDE
 CYTARABINE, CYTARABINE

APPENDIX A - PRODUCT NAME INDEX

** C **

CYTOMEL, LIOTHYRONINE SODIUM
 CYTOSAR-U, CYTARABINE
 CYTOTEC, MISOPROSTOL
 CYTOVENE, GANCICLOVIR SODIUM

** D **

D.H.E. 45, DIHYDROERGOTAMINE MESYLATE
 DACARBAZINE, DACARBAZINE
 DACOGEN, DECITABINE
 DACTINOMYCIN, DACTINOMYCIN
 DAKLINZA, DACLATASVIR DIHYDROCHLORIDE
 DALIRESP, ROFLUMILAST
 DALVANCE, DALBAVANCIN HYDROCHLORIDE
 DANAZOL, DANAZOL
 DANTRIUM, DANTROLENE SODIUM
 DANTROLENE SODIUM, DANTROLENE SODIUM
 DAPSONE, DAPSONE
 DAPTOMYCIN, DAPTOMYCIN
 DARAPRIM, PYRIMETHAMINE
 DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
 DASATINIB, DASATINIB
 DASETTA 1/35, ETHINYL ESTRADIOL
 DASETTA 7/7/7, ETHINYL ESTRADIOL
 DATSCAN, IOFLUPANE I-123
 DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
 DAYPRO, OXAPROZIN
 DAYSEE, ETHINYL ESTRADIOL
 DAYTRANA, METHYLPHENIDATE
 DDAVP, DESMOPRESSIN ACETATE
 DDAVP (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
 DECITABINE, DECITABINE
 DEFERASIROX, DEFERASIROX
 DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
 DEFINITY, PERFLUTREN
 DEFITELIO, DEFIBROTIDE SODIUM
 DELATESTRYL, TESTOSTERONE ENANTHATE
 DELESTROGEN, ESTRADIOL VALERATE
 DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)
 DELZICOL, MESALAMINE
 DEMADEx, TORSEMIDE
 DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
 DEMEROL, MEPERIDINE HYDROCHLORIDE
 DEMSER, METYROSINE
 DENAVIR, PENCICLOVIR
 DENDRID, IDOXURIDINE
 DEPACON, VALPROATE SODIUM
 DEPAKENE, VALPROIC ACID
 DEPAKOTE, DIVALPROEX SODIUM
 DEPAKOTE ER, DIVALPROEX SODIUM
 DEPEN, PENICILLAMINE
 DEPO-ESTRADIOL, ESTRADIOL CYPIONATE
 DEPO-MEDROL, METHYLPREDNISOLONE ACETATE
 DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE
 DEPO-SUBQ PROVERA 104, MEDROXYPROGESTERONE ACETATE
 DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE
 DEPOCYT, CYTARABINE

APPENDIX A - PRODUCT NAME INDEX

** D **

DERMA-SMOOTH/FS, FLUOCINOLONE ACETONIDE
 DERMABET, BETAMETHASONE VALERATE
 DERMATOP, PREDNICARBATE
 DERMATOP E EMOLLIENT, PREDNICARBATE
 DERMOTIC, FLUOCINOLONE ACETONIDE
 DESCOVY, EMTRICITABINE
 DESFERAL, DEFEROXAMINE MESYLATE
 DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
 DESLORATADINE, DESLORATADINE
 DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR, DESLORATADINE
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
 DESOGEN, DESOGESTREL
 DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
 DESONATE, DESONIDE
 DESONIDE, DESONIDE
 DESOWEN, DESONIDE
 DESOXIMETASONE, DESOXIMETASONE
 DESOXYN, METHAMPHETAMINE HYDROCHLORIDE
 DESVENLAFAXINE, DESVENLAFAXINE
 DESVENLAFAXINE, DESVENLAFAXINE FUMARATE
 DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
 DETROL, TOLTERODINE TARTRATE
 DETROL LA, TOLTERODINE TARTRATE
 DEXAMETHASONE, DEXAMETHASONE
 DEXAMETHASONE INTENSOL, DEXAMETHASONE
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
 DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE, DEXAMETHASONE SODIUM PHOSPHATE
 DEXASPORIN, DEXAMETHASONE
 DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE, DEXBROMPHENIRAMINE MALEATE (OTC)
 DEXCHLORPHENIRAMINE MALEATE, DEXCHLORPHENIRAMINE MALEATE
 DEXEDRINE, DEXTROAMPHETAMINE SULFATE
 DEXFERRUM, IRON DEXTRAN
 DEXILANT, DEXLANSOPRAZOLE
 DEXILANT SOLUTAB, DEXLANSOPRAZOLE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 DEXTROMETHORPHAN POLISTIREX, DEXTROMETHORPHAN POLISTIREX (OTC)
 DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 25%, DEXTROSE
 DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE

APPENDIX A - PRODUCT NAME INDEX

** D **

DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER,
 DEXTROSE 50% , DEXTROSE
 DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 60% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
 DIABETA, GLYBURIDE
 DIABINESE, CHLORPROPAMIDE
 DIAMOX, ACETAZOLAMIDE
 DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIASTAT, DIAZEPAM
 DIASTAT ACUDIAL, DIAZEPAM
 DIAZEPAM, DIAZEPAM
 DIAZEPAM INTENSOL, DIAZEPAM
 DIBENZYLINE, PHENOXYBENZAMINE HYDROCHLORIDE
 DICLEGIS, DOXYLAMINE SUCCINATE
 DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DICLOFENAC SODIUM , DICLOFENAC SODIUM
 DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
 DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
 DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE), DICYCLOMINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

** D **

DIDANOSINE, DIDANOSINE
 DIDRONEL, ETIDRONATE DISODIUM
 DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
 DIFFERIN, ADAPALENE (OTC)
 DIFFERIN, ADAPALENE
 DIFICID, FIDAXOMICIN
 DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
 DIFLUCAN, FLUCONAZOLE
 DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
 DIFLUCAN IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
 DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 DIFLUNISAL, DIFLUNISAL
 DIGOXIN, DIGOXIN
 DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
 DILANTIN, PHENYTOIN
 DILANTIN, PHENYTOIN SODIUM
 DILANTIN-125, PHENYTOIN
 DILATRATE-SR, ISOSORBIDE DINITRATE
 DILAUDID, HYDROMORPHONE HYDROCHLORIDE
 DILAUDID-HP, HYDROMORPHONE HYDROCHLORIDE
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DILTZAC, DILTIAZEM HYDROCHLORIDE
 DIMENHYDRINATE, DIMENHYDRINATE
 DIMETHYL SULFOXIDE, DIMETHYL SULFOXIDE
 DIOVAN, VALSARTAN
 DIOVAN HCT, HYDROCHLOROTHIAZIDE
 DIPENTUM, OLSALAZINE SODIUM
 DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
 DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
 DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
 DIPRIVAN, PROPOFOL
 DIPROLENE, BETAMETHASONE DIPROPIONATE
 DIPROLENE AF, BETAMETHASONE DIPROPIONATE
 DIPYRIDAMOLE, DIPYRIDAMOLE
 DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
 DISULFIRAM, DISULFIRAM
 DISULFIRAM, DISULFIRAM
 DITROPAN XL, OXYBUTYNIN CHLORIDE
 DIURIL, CHLOROTHIAZIDE
 DIURIL, CHLOROTHIAZIDE SODIUM
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DIVIGEL, ESTRADIOL
 DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
 DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
 DOCEFREZ, DOCETAXEL
 DOCETAXEL, DOCETAXEL
 DOFETILIDE, DOFETILIDE
 DOLOPHINE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
 DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%, DOPAMINE HYDROCHLORIDE
 DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
 DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
 DOPRAM, DOXAPRAM HYDROCHLORIDE
 DORAL, QUAZEPAM
 DORIBAX, DORIPENEM
 DORYX, DOXYCYCLINE HYCLATE
 DORYX MPC, DOXYCYCLINE HYCLATE
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
 DOTAREM, GADOTERATE MEGLUMINE
 DOVONEX, CALCIPOTRIENE
 DOXAPRAM HYDROCHLORIDE, DOXAPRAM HYDROCHLORIDE
 DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
 DOXEPIH HYDROCHLORIDE, DOXEPIH HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

** D **

DOXERCALCIFEROL, DOXERCALCIFEROL
 DOXIL (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
 DOXY 100, DOXYCYCLINE HYCLATE
 DOXY 200, DOXYCYCLINE HYCLATE
 DOXYCYCLINE, DOXYCYCLINE
 DOXYCYCLINE, DOXYCYCLINE HYCLATE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
 DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE, DOXYLAMINE SUCCINATE
 DRAXIMAGE MDP-25, TECHNETIUM TC-99M MEDRONATE
 DRISDOL, ERGOCALCIFEROL
 DRONABINOL, DRONABINOL
 DROPERIDOL, DROPERIDOL
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
 DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM, DROSPIRENONE
 DROXIA, HYDROXYUREA
 DTIC-DOME, DACARBAZINE
 DTPA, TECHNETIUM TC-99M PENTETATE KIT
 DUAC, BENZOYL PEROXIDE
 DUAVEE, BAZEDOXIFENE ACETATE
 DUETACT, GLIMEPIRIDE
 DUEXIS, FAMOTIDINE
 DULERA, FORMOTEROL FUMARATE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 DUODOTE, ATROPINE
 DUOPA, CARBIDOPA
 DURACLON, CLONIDINE HYDROCHLORIDE
 DURAGESIC-100, FENTANYL
 DURAGESIC-12, FENTANYL
 DURAGESIC-25, FENTANYL
 DURAGESIC-50, FENTANYL
 DURAGESIC-75, FENTANYL
 DURAMORPH PF, MORPHINE SULFATE
 DURAPREP, IODINE POVACRYLEX (OTC)
 DUREZOL, DIFLUPREDNATE
 DURLAZA, ASPIRIN
 DUTASTERIDE, DUTASTERIDE
 DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE
 DUTOPROL, HYDROCHLOROTHIAZIDE
 DUVOID, BETHANECHOL CHLORIDE
 DYANAVAL XR, AMPHETAMINE
 DYAZIDE, HYDROCHLOROTHIAZIDE
 DYLOJECT, DICLOFENAC SODIUM
 DYMISTA, AZELASTINE HYDROCHLORIDE
 DYNA-HEX, CHLORHEXIDINE GLUCONATE (OTC)
 DYNACIN, MINOCYCLINE HYDROCHLORIDE
 DYRENIUM, TRIAMTERENE

** E **

E-Z SCRUB 201, POVIDONE-IODINE (OTC)
 E-Z SCRUB 241, POVIDONE-IODINE (OTC)
 E-Z-HD, BARIUM SULFATE
 E.E.S., ERYTHROMYCIN ETHYLSUCCINATE
 E.E.S. 400, ERYTHROMYCIN ETHYLSUCCINATE
 EC-NAPROSYN, NAPROXEN
 ECONAZOLE NITRATE, ECONAZOLE NITRATE
 ECOZA, ECONAZOLE NITRATE
 EDARBI, AZILSARTAN KAMEDOXOMIL
 EDARBYCLOR, AZILSARTAN KAMEDOXOMIL
 EDECRIN, ETHACRYNATE SODIUM
 EDECRIN, ETHACRYNIC ACID
 EDEX, ALPROSTADIL
 EDLUAR, ZOLPIDEM TARTRATE

APPENDIX A - PRODUCT NAME INDEX

** E **

EDURANT, RILPIVIRINE HYDROCHLORIDE
 EFAVIRENZ, EFAVIRENZ
 EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE
 EFFIENT, PRASUGREL HYDROCHLORIDE
 EFUDEX, FLUOROURACIL
 EGRIFTA, TESAMORELIN ACETATE
 ELDEPRYL, SELEGILINE HYDROCHLORIDE
 ELELYSO, TALIGLUCERASE ALFA
 ELESTAT, EPINASTINE HYDROCHLORIDE
 ELESTRIN, ESTRADIOL
 ELIDEL, PIMECROLIMUS
 ELIFEMME, ETHINYL ESTRADIOL
 ELIGARD, LEUPROLIDE ACETATE
 ELIMITE, PERMETHRIN
 ELINEST, ETHINYL ESTRADIOL
 ELIPHOS, CALCIUM ACETATE
 ELIQUIS, APIXABAN
 ELIXOPHYLLIN, THEOPHYLLINE
 ELLA, ULIPRISTAL ACETATE
 ELLENCE, EPIRUBICIN HYDROCHLORIDE
 ELLIOTTS B SOLUTION, CALCIUM CHLORIDE
 ELMIRON, PENTOSAN POLYSULFATE SODIUM
 ELOCON, MOMETASONE FUROATE
 ELOXATIN, OXALIPLATIN
 EMADINE, EMEDASTINE DIFUMARATE
 EMBEDA, MORPHINE SULFATE
 EMBELINE, CLOBETASOL PROPIONATE
 EMBELINE E, CLOBETASOL PROPIONATE
 EMCYT, ESTRAMUSTINE PHOSPHATE SODIUM
 EMEND, APREPITANT
 EMEND, FOSAPREPITANT DIMEGLUMINE
 EMLA, LIDOCAINE
 EMOQUETTE, DESOGESTREL
 EMSAM, SELEGILINE
 EMTRIVA, EMTRICITABINE
 EMVERM, MEBENDAZOLE
 ENABLEX, DARIFENACIN HYDROBROMIDE
 ENALAPRIL MALEATE, ENALAPRIL MALEATE
 ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
 ENALAPRILAT, ENALAPRILAT
 ENDOMETRIN, PROGESTERONE
 ENDOSOL EXTRA, CALCIUM CHLORIDE
 ENJUVA, ESTROGENS, CONJUGATED SYNTHETIC B
 ENLON, EDROPHONIUM CHLORIDE
 ENLON-PLUS, ATROPINE SULFATE
 ENOXAPARIN SODIUM, ENOXAPARIN SODIUM
 ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
 ENPRESSE-28, ETHINYL ESTRADIOL
 ENSKYCE, DESOGESTREL
 ENSTILAR, BETAMETHASONE DIPROPIONATE
 ENTACAPONE, ENTACAPONE
 ENTECAVIR, ENTECAVIR
 ENTEREG, ALVIMOPAN
 ENTOCORT EC, BUDESONIDE
 ENTRESTO, SACUBITRIL
 ENULOSE, LACTULOSE
 ENVARUS XR, TACROLIMUS
 EOVIIST, GADOXETATE DISODIUM
 EPANED, ENALAPRIL MALEATE
 EPANED KIT, ENALAPRIL MALEATE
 EPANOVA, OMEGA-3-CARBOXYLIC ACIDS
 EPCLUSA, SOFOSBUVIR
 EPIDUO, ADAPALENE
 EPIDUO FORTE, ADAPALENE
 EPIFOAM, HYDROCORTISONE ACETATE

APPENDIX A - PRODUCT NAME INDEX

** E **

EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
 EPINEPHRINE, EPINEPHRINE
 EPIPEN, EPINEPHRINE
 EPIPEN JR., EPINEPHRINE
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 EPITOL, CARBAMAZEPINE
 EPIVIR, LAMIVUDINE
 EPIVIR-HBV, LAMIVUDINE
 EPLERENONE, EPLERENONE
 EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM
 EPROSARTAN MESYLATE, EPROSARTAN MESYLATE
 EPTIFIBATIDE, EPTIFIBATIDE
 EPZICOM, ABACAVIR SULFATE
 EQUETRO, CARBAMAZEPINE
 ERAXIS, ANIDULAFUNGIN
 ERGOCALCIFEROL, ERGOCALCIFEROL
 ERGOLOID MESYLATES, ERGOLOID MESYLATES
 ERGOMAR, ERGOTAMINE TARTRATE
 ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE
 ERIVEDGE, VISMODEGIB
 ERRIN, NORETHINDRONE
 ERTACZO, SERTACONAZOLE NITRATE
 ERY-TAB, ERYTHROMYCIN
 ERYC, ERYTHROMYCIN
 ERYGEL, ERYTHROMYCIN
 ERYPED, ERYTHROMYCIN ETHYLSUCCINATE
 ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
 ERYTHROCIN STEARATE, ERYTHROMYCIN STEARATE
 ERYTHROMYCIN, ERYTHROMYCIN
 ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
 ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
 ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL, ERYTHROMYCIN ETHYLSUCCINATE
 ESBRIET, PIRFENIDONE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
 ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
 ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
 ESOMEPRAZOLE STRONTIUM, ESOMEPRAZOLE STRONTIUM
 ESTARYLLA, ETHINYL ESTRADIOL
 ESTAZOLAM, ESTAZOLAM
 ESTRACE, ESTRADIOL
 ESTRADERM, ESTRADIOL
 ESTRADIOL, ESTRADIOL
 ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
 ESTRADIOL AND NORGESTIMATE, ESTRADIOL
 ESTRADIOL VALERATE, ESTRADIOL VALERATE
 ESTRADIOL VALERATE AND DIENOGEST, DIENOGEST
 ESTRASORB, ESTRADIOL HEMIHYDRATE
 ESTRING, ESTRADIOL
 ESTROGEL, ESTRADIOL
 ESTROPIPATE, ESTROPIPATE
 ESTROSTEP FE, ETHINYL ESTRADIOL
 ESZOPICLONE, ESZOPICLONE
 ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
 ETHACRYNIC ACID, ETHACRYNIC ACID
 ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
 ETHAMOLIN, ETHANOLAMINE OLEATE
 ETHOSUXIMIDE, ETHOSUXIMIDE
 ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 ETHYOL, AMIFOSTINE
 ETIDRONATE DISODIUM, ETIDRONATE DISODIUM
 ETODOLAC, ETODOLAC
 ETOMIDATE, ETOMIDATE

APPENDIX A - PRODUCT NAME INDEX

** E **

ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE
 ETOPOSIDE, ETOPOSIDE
 EUCRISA, CRISABOROLE
 EURAX, CROTAMITON
 EVAMIST, ESTRADIOL
 EVEKEO, AMPHETAMINE SULFATE
 EVISTA, RALOXIFENE HYDROCHLORIDE
 EVOCLIN, CLINDAMYCIN PHOSPHATE
 EVOMELA, MELPHALAN HYDROCHLORIDE
 EVOTAZ, ATAZANAVIR SULFATE
 EVOXAC, CEVIMELINE HYDROCHLORIDE
 EVZIO, NALOXONE HYDROCHLORIDE
 EXALGO, HYDROMORPHONE HYDROCHLORIDE
 EXCEDRIN (MIGRAINE), ACETAMINOPHEN (OTC)
 EXELDERM, SULCONAZOLE NITRATE
 EXELON, RIVASTIGMINE
 EXELON, RIVASTIGMINE TARTRATE
 EXEMESTANE, EXEMESTANE
 EXFORGE, AMLODIPINE BESYLATE
 EXFORGE HCT, AMLODIPINE BESYLATE
 EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)
 EXJADE, DEFERASIROX
 EXONDYS 51, ETEPLIRSEN
 EXPAREL, BUPIVACAINE
 EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
 EXTINA, KETOCONAZOLE
 EXTRANEAL, ICODextrin
 EZETIMIBE, EZETIMIBE

** F **

FABIOR, TAZAROTENE
 FACTIVE, GEMIFLOXACIN MESYLATE
 FALLBACK SOLO, LEVONORGESTREL (OTC)
 FALMINA, ETHINYL ESTRADIOL
 FAMCICLOVIR, FAMCICLOVIR
 FAMOTIDINE, FAMOTIDINE (OTC)
 FAMOTIDINE, FAMOTIDINE
 FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
 FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
 FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE, CALCIUM CARBONATE (OTC)
 FAMVIR, FAMCICLOVIR
 FANAPT, ILOPERIDONE
 FARESTON, TOREMIFENE CITRATE
 FARXIGA, DAPAGLIFLOZIN PROPANEDIOL
 FARYDAK, PANOBINOSTAT LACTATE
 FASLODEX, FULVESTRANT
 FAYOSIM, ETHINYL ESTRADIOL
 FAZACLO ODT, CLOZAPINE
 FELBAMATE, FELBAMATE
 FELBATOL, FELBAMATE
 FELDENE, PIROXICAM
 FELODIPINE, FELODIPINE
 FEMARA, LETROZOLE
 FEMCON FE, ETHINYL ESTRADIOL
 FEMHRT, ETHINYL ESTRADIOL
 FEMRING, ESTRADIOL ACETATE
 FEMSTAT 3, BUTOCONAZOLE NITRATE (OTC)
 FEMTRACE, ESTRADIOL ACETATE
 FENOFIBRATE, FENOFIBRATE
 FENOFIBRATE (MICRONIZED), FENOFIBRATE
 FENOFIBRIC ACID, CHOLINE FENOFIBRATE
 FENOGLIDE, FENOFIBRATE
 FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
 FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
 FENTANYL CITRATE, FENTANYL CITRATE

APPENDIX A - PRODUCT NAME INDEX

** F **

FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
 FENTANYL-100, FENTANYL
 FENTANYL-12, FENTANYL
 FENTANYL-25, FENTANYL
 FENTANYL-37, FENTANYL
 FENTANYL-50, FENTANYL
 FENTANYL-62, FENTANYL
 FENTANYL-75, FENTANYL
 FENTANYL-87, FENTANYL
 FENTORA, FENTANYL CITRATE
 FERAHEME, FERUMOXYTOL
 FERRIPROX, DEFERIPRONE
 FERRLECIT, SODIUM FERRIC GLUCONATE COMPLEX
 FETZIMA, LEVOMILNACIPRAN HYDROCHLORIDE
 FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
 FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 FIBRICOR, FENOFIBRIC ACID
 FINACEA, AZELAIC ACID
 FINACEA, AZELAIC ACID
 FINASTERIDE, FINASTERIDE
 FIORICET, ACETAMINOPHEN
 FIORICET W/ CODEINE, ACETAMINOPHEN
 FIORINAL, ASPIRIN
 FIORINAL W/CODEINE, ASPIRIN
 FIRAZYR, ICATIBANT ACETATE
 FIRMAGON, DEGARELIX ACETATE
 FLAGYL, METRONIDAZOLE
 FLAGYL ER, METRONIDAZOLE
 FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
 FLAREX, FLUOROMETHOLONE ACETATE
 FLAVORED COLESTID, COLESTIPOL HYDROCHLORIDE
 FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
 FLECAINIDE ACETATE, FLECAINIDE ACETATE
 FLECTOR, DICLOFENAC EPOLAMINE
 FLOLAN, EPOPROSTENOL SODIUM
 FLOMAX, TAMSULOSIN HYDROCHLORIDE
 FLONASE ALLERGY RELIEF, FLUTICASONE PROPIONATE (OTC)
 FLONASE SENSIMIST ALLERGY RELIEF, FLUTICASONE FUROATE (OTC)
 FLOVENT DISKUS 100, FLUTICASONE PROPIONATE
 FLOVENT DISKUS 250, FLUTICASONE PROPIONATE
 FLOVENT DISKUS 50, FLUTICASONE PROPIONATE
 FLOVENT HFA, FLUTICASONE PROPIONATE
 FLOWTUSS, GUAIFENESIN
 FLOXURIDINE, FLOXURIDINE
 FLUCONAZOLE, FLUCONAZOLE
 FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 FLUCYTOSINE, FLUCYTOSINE
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
 FLUMADINE, RIMANTADINE HYDROCHLORIDE
 FLUMAZENIL, FLUMAZENIL
 FLUNISOLIDE, FLUNISOLIDE
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 FLUOCINONIDE, FLUOCINONIDE
 FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
 FLUORESCITE, FLUORESCEIN SODIUM
 FLUOROPLEX, FLUOROURACIL
 FLUOROURACIL, FLUOROURACIL
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FLUOXYMESTERONE, FLUOXYMESTERONE

APPENDIX A - PRODUCT NAME INDEX

** F **

FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
 FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
 FLURANDRENOLIDE, FLURANDRENOLIDE
 FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM HYDROCHLORIDE
 FLURBIPROFEN, FLURBIPROFEN
 FLURBIPROFEN SODIUM, FLURBIPROFEN SODIUM
 FLUTAMIDE, FLUTAMIDE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE (OTC)
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
 FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
 FML, FLUOROMETHOLONE
 FML FORTE, FLUOROMETHOLONE
 FOAMCOAT, ALUMINUM HYDROXIDE (OTC)
 FOCALIN, DEXMETHYLPHENIDATE HYDROCHLORIDE
 FOCALIN XR, DEXMETHYLPHENIDATE HYDROCHLORIDE
 FOLIC ACID, FOLIC ACID
 FOLLISTIM AQ, FOLLITROPIN ALFA/BETA
 FOLOTYN, PRALATREXATE
 FOMEPIZOLE, FOMEPIZOLE
 FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
 FORADIL, FORMOTEROL FUMARATE
 FORANE, ISOFLURANE
 FORFIVO XL, BUPROPION HYDROCHLORIDE
 FORTAMET, METFORMIN HYDROCHLORIDE
 FORTAZ, CEFTAZIDIME
 FORTAZ IN PLASTIC CONTAINER, CEFTAZIDIME SODIUM
 FORTEO, TERIPARATIDE RECOMBINANT HUMAN
 FORTESTA, TESTOSTERONE
 FOSAMAX, ALENDRONATE SODIUM
 FOSAMAX PLUS D, ALENDRONATE SODIUM
 FOSAMPRENAVIR CALCIUM, FOSAMPRENAVIR CALCIUM
 FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
 FOSCARNET SODIUM, FOSCARNET SODIUM
 FOSCAVIR, FOSCARNET SODIUM
 FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
 FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 FOSRENOL, LANTHANUM CARBONATE
 FRAGMIN, DALTEPARIN SODIUM
 FREAMINE HBC 6.9%, AMINO ACIDS
 FREAMINE III 10%, AMINO ACIDS
 FREAMINE III 3% W/ ELECTROLYTES, AMINO ACIDS
 FREAMINE III 8.5%, AMINO ACIDS
 FREAMINE III 8.5% W/ ELECTROLYTES, AMINO ACIDS
 FROVA, FROVATRIPTAN SUCCINATE
 FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
 FULYZAQ, CROFELEMER
 FURADANTIN, NITROFURANTOIN
 FUROSEMIDE, FUROSEMIDE
 FUSILEV, LEVOLEUCOVORIN CALCIUM
 FUZEON, ENFUVIRTIDE
 FYAVOLV, ETHINYL ESTRADIOL
 FYCOMPA, PERAMPANEL

** G **

GABAPENTIN, GABAPENTIN
 GABITRIL, TIAGABINE HYDROCHLORIDE
 GABLOFEN, BACLOFEN
 GADAVIST, GADOBUTROL
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67
 GALZIN, ZINC ACETATE
 GANCICLOVIR, GANCICLOVIR SODIUM
 GANIRELIX ACETATE, GANIRELIX ACETATE

APPENDIX A - PRODUCT NAME INDEX

** G **

GASTROCROM, CROMOLYN SODIUM
 GASTROGRAFIN, DIATRIZOATE MEGLUMINE
 GATIFLOXACIN, GATIFLOXACIN
 GATTEX KIT, TEDUGLUTIDE RECOMBINANT
 GAVISCON, ALUMINUM HYDROXIDE (OTC)
 GELNIQUE, OXYBUTYNIN CHLORIDE
 GELNIQUE 3%, OXYBUTYNIN
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 GEMFIBROZIL, GEMFIBROZIL
 GEMIFLOXACIN MESYLATE, GEMIFLOXACIN MESYLATE
 GEMZAR, GEMCITABINE HYDROCHLORIDE
 GEN-XENE, CLORAZEPATE DIPOTASSIUM
 GENERLAC, LACTULOSE
 GENGRAF, CYCLOSPORINE
 GENOPTIC, GENTAMICIN SULFATE
 GENOTROPIN, SOMATROPIN RECOMBINANT
 GENOTROPIN PRESERVATIVE FREE, SOMATROPIN RECOMBINANT
 GENTAK, GENTAMICIN SULFATE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
 GENVOYA, COBICISTAT
 GEODON, ZIPRASIDONE HYDROCHLORIDE
 GEODON, ZIPRASIDONE MESYLATE
 GIAZO, BALSALAZIDE DISODIUM
 GILDAGIA, ETHINYL ESTRADIOL
 GILDESS 1.5/30, ETHINYL ESTRADIOL
 GILDESS 1/20, ETHINYL ESTRADIOL
 GILDESS 24 FE, ETHINYL ESTRADIOL
 GILDESS FE 1.5/30, ETHINYL ESTRADIOL
 GILDESS FE 1/20, ETHINYL ESTRADIOL
 GILENYA, FINGOLIMOD
 GILOTTRIF, AFATINIB DIMALEATE
 GLATOPA, GLATIRAMER ACETATE
 GLEEVEC, IMATINIB MESYLATE
 GLEOSTINE, LOMUSTINE
 GLIADEL, CARMUSTINE
 GLIMEPIRIDE, GLIMEPIRIDE
 GLIPIZIDE, GLIPIZIDE
 GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
 GLOFIL-125, IOTHALAMATE SODIUM I-125
 GLUCAGEN, GLUCAGON HYDROCHLORIDE RECOMBINANT
 GLUCAGON, GLUCAGON HYDROCHLORIDE
 GLUCAGON, GLUCAGON RECOMBINANT
 GLUCOPHAGE, METFORMIN HYDROCHLORIDE
 GLUCOPHAGE XR, METFORMIN HYDROCHLORIDE
 GLUCOTROL, GLIPIZIDE
 GLUCOTROL XL, GLIPIZIDE
 GLUCOVANCE, GLYBURIDE
 GLUMETZA, METFORMIN HYDROCHLORIDE
 GLYBURIDE, GLYBURIDE
 GLYBURIDE (MICRONIZED), GLYBURIDE
 GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
 GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
 GLYCOLAX, POLYETHYLENE GLYCOL 3350 (OTC)
 GLYCOLAX, POLYETHYLENE GLYCOL 3350
 GLYCOPYRROLATE, GLYCOPYRROLATE
 GLYDO, LIDOCAINE HYDROCHLORIDE
 GLYNASE, GLYBURIDE
 GLYSET, MIGLITOL
 GLYXAMBI, EMPAGLIFLOZIN
 GOLYTELY, POLYETHYLENE GLYCOL 3350
 GONAL-F, FOLLITROPIN ALFA/BETA
 GONAL-F RFF, FOLLITROPIN ALFA/BETA
 GONAL-F RFF REDI-JECT, FOLLITROPIN ALFA/BETA
 GONITRO, NITROGLYCERIN

APPENDIX A - PRODUCT NAME INDEX

** G **

GRALISE, GABAPENTIN
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
 GRIS-PEG, GRISEOFULVIN, ULTRAMICROSIZE
 GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
 GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
 GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
 GUAIFENESIN, GUAIFENESIN (OTC)
 GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
 GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
 GUANABENZ ACETATE, GUANABENZ ACETATE
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 GUANIDINE HYDROCHLORIDE, GUANIDINE HYDROCHLORIDE
 GYNAZOLE-1, BUTOCONAZOLE NITRATE
 GYNE-LOTRIMIN, CLOTRIMAZOLE (OTC)
 GYNE-LOTRIMIN 3, CLOTRIMAZOLE (OTC)
 GYNE-LOTRIMIN 3 COMBINATION PACK, CLOTRIMAZOLE (OTC)
 GYNE-LOTRIMIN COMBINATION PACK, CLOTRIMAZOLE (OTC)

** H **

H.P. ACTHAR GEL, CORTICOTROPIN
 HABITROL, NICOTINE (OTC)
 HALAVEN, ERIBULIN MESYLATE
 HALCION, TRIAZOLAM
 HALDOL, HALOPERIDOL DECANOATE
 HALDOL, HALOPERIDOL LACTATE
 HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
 HALOG, HALCINONIDE
 HALOPERIDOL, HALOPERIDOL
 HALOPERIDOL, HALOPERIDOL LACTATE
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
 HARVONI, LEDIPASVIR
 HEATHER, NORETHINDRONE
 HECTOROL, DOXERCALCIFEROL
 HEMABATE, CARBOPROST TROMETHAMINE
 HEMANGEOL, PROPRANOLOL HYDROCHLORIDE
 HEPARIN SODIUM, HEPARIN SODIUM
 HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
 HEPATAMINE 8%, AMINO ACIDS
 HEPATOLITE, TECHNETIUM TC-99M DISOFENIN KIT
 HEPSERA, ADEFOVIR DIPIVOXIL
 HER STYLE, LEVONORGESTREL (OTC)
 HETLIOZ, TASIMELTEON
 HEXALEN, ALTRETAMINE
 HIBICLENS, CHLORHEXIDINE GLUCONATE (OTC)
 HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)
 HICON, SODIUM IODIDE I-131
 HIPREX, METHENAMINE HIPPURATE
 HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE
 HORIZANT, GABAPENTIN ENACARBIL
 HUMALOG, INSULIN LISPRO RECOMBINANT
 HUMALOG KWIKPEN, INSULIN LISPRO RECOMBINANT
 HUMALOG MIX 50/50, INSULIN LISPRO PROTAMINE RECOMBINANT
 HUMALOG MIX 50/50 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT

APPENDIX A - PRODUCT NAME INDEX

** H **

HUMALOG MIX 75/25, INSULIN LISPRO PROTAMINE RECOMBINANT
 HUMALOG MIX 75/25 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT
 HUMATROPE, SOMATROPIN RECOMBINANT
 HUMULIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
 HUMULIN 70/30 PEN, INSULIN RECOMBINANT HUMAN (OTC)
 HUMULIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
 HUMULIN R, INSULIN HUMAN
 HUMULIN R, INSULIN RECOMBINANT HUMAN (OTC)
 HUMULIN R KWIKPEN, INSULIN HUMAN
 HUMULIN R PEN, INSULIN RECOMBINANT HUMAN (OTC)
 HYCAMTIN, TOPOTECAN HYDROCHLORIDE
 HYCOFENIX, GUAIFENESIN
 HYDERGINE, ERGOLOID MESYLATES
 HYDRA-ZIDE, HYDRALAZINE HYDROCHLORIDE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDREA, HYDROXYUREA
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
 HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
 HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
 HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE, HYDROCODONE BITARTRATE
 HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE,
 HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE,
 HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE,
 HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX, CHLORPHENIRAMINE POLISTIREX
 HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX, CHLORPHENIRAMINE POLISTIREX
 HYDROCORTISONE, HYDROCORTISONE
 HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
 HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
 HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
 HYDROCORTISONE IN ABSORBASE, HYDROCORTISONE
 HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 HYDROXOCOBALAMIN, HYDROXOCOBALAMIN
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
 HYDROXYUREA, HYDROXYUREA
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
 HYLENEX RECOMBINANT, HYALURONIDASE RECOMBINANT HUMAN
 HYSINGLA, HYDROCODONE BITARTRATE
 HYZAAR, HYDROCHLOROTHIAZIDE

** I **

IBANDRONATE SODIUM, IBANDRONATE SODIUM
 IBRANCE, PALBOCICLIB
 IBU-TAB, IBUPROFEN
 IBU-TAB 200, IBUPROFEN (OTC)
 IBUPROFEN, IBUPROFEN (OTC)
 IBUPROFEN, IBUPROFEN
 IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
 IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
 IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE, IBUPROFEN (OTC)
 IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
 IBUPROFEN LYSINE, IBUPROFEN LYSINE
 IBUPROFEN SODIUM, IBUPROFEN SODIUM (OTC)
 IBUPROHM, IBUPROFEN (OTC)
 IBUPROHM COLD AND SINUS, IBUPROFEN (OTC)
 IBUTILIDE FUMARATE, IBUTILIDE FUMARATE
 IC-GREEN, INDOCYANINE GREEN
 ICLUSIG, PONATINIB HYDROCHLORIDE
 IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE
 IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
 IDARUBICIN HYDROCHLORIDE PFS, IDARUBICIN HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

** I **

IDKIT:HP, CITRIC ACID
 IFEX, IFOSFAMIDE
 IFOSFAMIDE, IFOSFAMIDE
 IFOSFAMIDE/MESNA KIT, IFOSFAMIDE
 ILEVRO, NEPAFENAC
 ILOPERIDONE, ILOPERIDONE
 ILUVIEN, FLUOCINOLONE ACETONIDE
 IMATINIB MESYLATE, IMATINIB MESYLATE
 IMBRUVICA, IBRUTINIB
 IMIPENEM AND CILASTATIN, CILASTATIN SODIUM
 IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
 IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
 IMIQUIMOD, IMIQUIMOD
 IMITREX, SUMATRIPTAN
 IMITREX, SUMATRIPTAN SUCCINATE
 IMITREX STATDOSE, SUMATRIPTAN SUCCINATE
 IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)
 IMODIUM A-D EZ CHEWS, LOPERAMIDE HYDROCHLORIDE (OTC)
 IMODIUM MULTI-SYMPTOM RELIEF, LOPERAMIDE HYDROCHLORIDE (OTC)
 IMPAVIDO, MILTEFOSINE
 IMURAN, AZATHIOPRINE
 INAPSINE, DROPERIDOL
 INCASSIA, NORETHINDRONE
 INCRELEX, MECASERMIN RECOMBINANT
 INCRUSE ELLIPTA, UMECLIDINIUM BROMIDE
 INDAPAMIDE, INDAPAMIDE
 INDERAL LA, PROPRANOLOL HYDROCHLORIDE
 INDICLOR, INDIUM IN-111 CHLORIDE
 INDIUM IN 111 CHLORIDE, INDIUM IN-111 CHLORIDE
 INDIUM IN 111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE
 INDOCIN, INDOMETHACIN
 INDOCIN, INDOMETHACIN SODIUM
 INDOCYANINE GREEN, INDOCYANINE GREEN
 INDOMETHACIN, INDOMETHACIN
 INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
 INFANTS' FEVERALL, ACETAMINOPHEN (OTC)
 INFASURF PRESERVATIVE FREE, CALFACTANT
 INFED, IRON DEXTRAN
 INFUMORPH, MORPHINE SULFATE
 INFUVITE ADULT, ALPHA-TOCOPHEROL ACETATE
 INFUVITE PEDIATRIC, ASCORBIC ACID
 INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE), ASCORBIC ACID
 INJECTAFER, FERRIC CARBOXYMALTOSIDE
 INLYTA, AXITINIB
 INNOPRAN XL, PROPRANOLOL HYDROCHLORIDE
 INOMAX, NITRIC OXIDE
 INSPRA, EPLERENONE
 INTEGRILIN, EPTIFIBATIDE
 INTELENCE, ETRAVIRINE
 INTERMEZZO, ZOLPIDEM TARTRATE
 INTRALIPID 10%, SOYBEAN OIL
 INTRALIPID 20%, SOYBEAN OIL
 INTRALIPID 30%, SOYBEAN OIL
 INTRAROSA, PRASTERONE
 INTROVALE, ETHINYL ESTRADIOL
 INTUNIV, GUANFACINE HYDROCHLORIDE
 INVANZ, ERTAPENEM SODIUM
 INVEGA, PALIPERIDONE
 INVEGA SUSTENNA, PALIPERIDONE PALMITATE
 INVEGA TRINZA, PALIPERIDONE PALMITATE
 INVIRASE, SAQUINAVIR MESYLATE
 INVOKAMET, CANAGLIFLOZIN
 INVOKAMET XR, CANAGLIFLOZIN
 INVOKANA, CANAGLIFLOZIN
 IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE

APPENDIX A - PRODUCT NAME INDEX

** I **

IONSYS, FENTANYL HYDROCHLORIDE
 IOPIDINE, APRACLONIDINE HYDROCHLORIDE
 IOSAT, POTASSIUM IODIDE (OTC)
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
 IPRIVASK, DESIRUDIN RECOMBINANT
 IRBESARTAN, IRBESARTAN
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRESSA, GEFITINIB
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 ISENTRESS, RALTEGRAVIR POTASSIUM
 ISIBLOOM, DESOGESTREL
 ISOCAINE HYDROCHLORIDE, MEPIVACAINE HYDROCHLORIDE
 ISOFLURANE, ISOFLURANE
 ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 ISONIAZID, ISONIAZID
 ISOPTO ATROPINE, ATROPINE SULFATE
 ISOPTO CARPINE, PILOCARPINE HYDROCHLORIDE
 ISORDIL, ISOSORBIDE DINITRATE
 ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
 ISOSULFAN BLUE, ISOSULFAN BLUE
 ISOVUE-200, IOPAMIDOL
 ISOVUE-250, IOPAMIDOL
 ISOVUE-300, IOPAMIDOL
 ISOVUE-370, IOPAMIDOL
 ISOVUE-M 200, IOPAMIDOL
 ISOVUE-M 300, IOPAMIDOL
 ISRADIPINE, ISRADIPINE
 ISTALOL, TIMOLOL MALEATE
 ISTODAX, ROMIDEPSIN
 ISUPREL, ISOPROTERENOL HYDROCHLORIDE
 ITRACONAZOLE, ITRACONAZOLE
 IVERMECTIN, IVERMECTIN
 IVY BLOCK, BENTOQUATAM (OTC)
 IXEMPRA KIT, IXABEPILONE

** J **

JADENU, DEFERASIROX
 JAKAFI, RUXOLITINIB PHOSPHATE
 JALYN, DUTASTERIDE
 JANTOVEN, WARFARIN SODIUM
 JANUMET, METFORMIN HYDROCHLORIDE
 JANUMET XR, METFORMIN HYDROCHLORIDE
 JANUVIA, SITAGLIPTIN PHOSPHATE
 JARDIANCE, EMPAGLIFLOZIN
 JEANATOPE, ALBUMIN IODINATED I-125 SERUM
 JENCYCLA, NORETHINDRONE
 JENTADUETO, LINAGLIPTIN
 JENTADUETO XR, LINAGLIPTIN
 JEVTANA KIT, CABAZITAXEL
 JUBLIA, EFINACONAZOLE
 JUNEL 1.5/30, ETHINYL ESTRADIOL
 JUNEL 1/20, ETHINYL ESTRADIOL
 JUNEL FE 1.5/30, ETHINYL ESTRADIOL
 JUNEL FE 1/20, ETHINYL ESTRADIOL
 JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)
 JUNIOR STRENGTH IBUPROFEN, IBUPROFEN (OTC)
 JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)
 JUXTAPID, LOMITAPIDE MESYLATE

** K **

APPENDIX A - PRODUCT NAME INDEX

** K **

K-TAB, POTASSIUM CHLORIDE
 KABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
 KADIAN, MORPHINE SULFATE
 KAITLIB FE, ETHINYL ESTRADIOL
 KALETRA, LOPINAVIR
 KALEXATE, SODIUM POLYSTYRENE SULFONATE
 KALYDECO, IVACAFTOR
 KANAMYCIN SULFATE, KANAMYCIN SULFATE
 KAPVAY, CLONIDINE HYDROCHLORIDE
 KARBINAL ER, CARBINOXAMINE MALEATE
 KARIVA, DESOGESTREL
 KAYEXALATE, SODIUM POLYSTYRENE SULFONATE
 KAZANO, ALOGLIPTIN BENZOATE
 KEFLEX, CEPHALEXIN
 KEFZOL, CEFAZOLIN SODIUM
 KELNOR, ETHINYL ESTRADIOL
 KENALOG, TRIAMCINOLONE ACETONIDE
 KENALOG-10, TRIAMCINOLONE ACETONIDE
 KENALOG-40, TRIAMCINOLONE ACETONIDE
 KENGREAL, CANGRELOR
 KEPPRA, LEVETIRACETAM
 KEPPRA XR, LEVETIRACETAM
 KERYDIN, TAVABOROLE
 KETALAR, KETAMINE HYDROCHLORIDE
 KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
 KETOCONAZOLE, KETOCONAZOLE
 KETOPROFEN, KETOPROFEN
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
 KETOZOLE, KETOCONAZOLE
 KEVEYIS, DICHLORPHENAMIDE
 KHEDEZLA, DESVENLAFAXINE
 KIMIDESS, DESOGESTREL
 KINEVAC, SINCALIDE
 KIONEX, SODIUM POLYSTYRENE SULFONATE
 KITABIS PAK, TOBRAMYCIN
 KLARON, SULFACETAMIDE SODIUM
 KLONOPIN, CLONAZEPAM
 KLOR-CON, POTASSIUM CHLORIDE
 KLOR-CON M10, POTASSIUM CHLORIDE
 KLOR-CON M15, POTASSIUM CHLORIDE
 KLOR-CON M20, POTASSIUM CHLORIDE
 KOMBIGLYZE XR, METFORMIN HYDROCHLORIDE
 KORLYM, MIFEPRISTONE
 KOVANAZE, OXYMETAZOLINE HYDROCHLORIDE
 KURVELO, ETHINYL ESTRADIOL
 KUVAN, SAPROPTERIN DIHYDROCHLORIDE
 KYBELLA, DEOXYCHOLIC ACID
 KYLEENA, LEVONORGESTREL
 KYNAMRO, MIPOMERSEN SODIUM
 KYPROLIS, CARFILZOMIB

** L **

LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 LACOSAMIDE, LACOSAMIDE
 LACRISERT, HYDROXYPROPYL CELLULOSE
 LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 LACTULOSE, LACTULOSE
 LAMICTAL, LAMOTRIGINE
 LAMICTAL CD, LAMOTRIGINE
 LAMICTAL ODT, LAMOTRIGINE
 LAMICTAL XR, LAMOTRIGINE
 LAMISIL, TERBINAFINE HYDROCHLORIDE (OTC)
 LAMISIL, TERBINAFINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

** L **

LAMISIL AT, TERBINAFINE (OTC)
 LAMISIL AT, TERBINAFINE HYDROCHLORIDE (OTC)
 LAMIVUDINE, LAMIVUDINE
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
 LAMOTRIGINE, LAMOTRIGINE
 LAMPRENE, CLOFAZIMINE
 LANIAZID, ISONIAZID
 LANORINAL, ASPIRIN
 LANOXIN, DIGOXIN
 LANOXIN PEDIATRIC, DIGOXIN
 LANSOPRAZOLE, LANSOPRAZOLE (OTC)
 LANSOPRAZOLE, LANSOPRAZOLE
 LANSOPRAZOLE , LANSOPRAZOLE
 LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN, AMOXICILLIN
 LANTUS, INSULIN GLARGINE RECOMBINANT
 LANTUS SOLOSTAR, INSULIN GLARGINE RECOMBINANT
 LARIN 1.5/30, ETHINYL ESTRADIOL
 LARIN 1/20, ETHINYL ESTRADIOL
 LARIN 24 FE, ETHINYL ESTRADIOL
 LARIN FE 1.5/30, ETHINYL ESTRADIOL
 LARIN FE 1/20, ETHINYL ESTRADIOL
 LAROTID, AMOXICILLIN
 LARYNG-O-JET KIT, LIDOCAINE HYDROCHLORIDE
 LASIX, FUROSEMIDE
 LASTACAFT, ALCAFTADINE
 LATANOPROST, LATANOPROST
 LATISSE, BIMATOPROST
 LATUDA, LURASIDONE HYDROCHLORIDE
 LAX-LYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
 LAZANDA, FENTANYL CITRATE
 LEFLUNOMIDE, LEFLUNOMIDE
 LENVIMA, LENVATINIB MESYLATE
 LERIBANE, ETHINYL ESTRADIOL
 LESCOL, FLUVASTATIN SODIUM
 LESCOL XL, FLUVASTATIN SODIUM
 LESSINA-28, ETHINYL ESTRADIOL
 LETAIRIS, AMBRISENTAN
 LETROZOLE, LETROZOLE
 LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
 LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
 LEUKERAN, CHLORAMBUCIL
 LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
 LEVAQUIN, LEVOFLOXACIN
 LEVEMIR, INSULIN DETEMIR RECOMBINANT
 LEVEMIR FLEXTOUCH, INSULIN DETEMIR RECOMBINANT
 LEVETIRACETAM, LEVETIRACETAM
 LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
 LEVITRA, VARDENAFIL HYDROCHLORIDE
 LEVO-T, LEVOTHYROXINE SODIUM **
 LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE
 LEVOCARNITINE, LEVOCARNITINE
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LEVOFLOXACIN, LEVOFLOXACIN
 LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
 LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
 LEVONEST, ETHINYL ESTRADIOL
 LEVONORGESTREL, LEVONORGESTREL (OTC)
 LEVONORGESTREL, LEVONORGESTREL
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LEVOPHED, NOREPINEPHRINE BITARTRATE
 LEVORA 0.15/30-28, ETHINYL ESTRADIOL
 LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
 LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM

APPENDIX A - PRODUCT NAME INDEX

** L **

LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
 LEVOXYL, LEVOTHYROXINE SODIUM **
 LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE
 LEXAPRO, ESCITALOPRAM OXALATE
 LEXISCAN, REGADENOSON
 LEXIVA, FOSAMPRENAVIR CALCIUM
 LIALDA, MESALAMINE
 LIBRAX, CHLORDIAZEPOXIDE HYDROCHLORIDE
 LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE
 LIDEX, FLUOCINONIDE
 LIDOCAINE, LIDOCAINE
 LIDOCAINE AND PRILOCAINE, LIDOCAINE
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE
 LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE VISCOUS, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
 LIDODERM, LIDOCAINE
 LIGNOSPAN FORTE, EPINEPHRINE BITARTRATE
 LIGNOSPAN STANDARD, EPINEPHRINE BITARTRATE
 LILETTA, LEVONORGESTREL
 LINCOCIN, LINCOMYCIN HYDROCHLORIDE
 LINCOMYCIN, LINCOMYCIN HYDROCHLORIDE
 LINDANE, LINDANE
 LINEZOLID, LINEZOLID
 LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, LINEZOLID
 LINZESS, LINACLOTIDE
 LIORESAL, BACLOFEN
 LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
 LIPIODOL, ETHIODIZED OIL
 LIPITOR, ATORVASTATIN CALCIUM
 LIPOFEN, FENOFIBRATE
 LISINOPRIL, LISINOPRIL
 LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LITHIUM CARBONATE, LITHIUM CARBONATE
 LITHIUM CITRATE, LITHIUM CITRATE
 LITHOBID, LITHIUM CARBONATE
 LITHOSTAT, ACETOHYDROXAMIC ACID
 LIVALO, PITAVASTATIN CALCIUM
 LO LOESTRIN FE, ETHINYL ESTRADIOL
 LO MINASTRIN FE, ETHINYL ESTRADIOL
 LOCID, HYDROCORTISONE BUTYRATE
 LOCID LIPOCREAM, HYDROCORTISONE BUTYRATE
 LODOSYN, CARBIDOPA
 LOESTRIN 21 1.5/30, ETHINYL ESTRADIOL
 LOESTRIN 21 1/20, ETHINYL ESTRADIOL
 LOESTRIN 24 FE, ETHINYL ESTRADIOL
 LOESTRIN FE 1.5/30, ETHINYL ESTRADIOL
 LOESTRIN FE 1/20, ETHINYL ESTRADIOL
 LOMAIRA, PHENTERMINE HYDROCHLORIDE
 LOMOTIL, ATROPINE SULFATE
 LONSURF, TIPIRACIL HYDROCHLORIDE
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
 LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
 LOPID, GEMFIBROZIL
 LOPINAVIR AND RITONAVIR, LOPINAVIR
 LOPRESSOR, METOPROLOL TARTRATE
 LOPRESSOR HCT, HYDROCHLOROTHIAZIDE

APPENDIX A - PRODUCT NAME INDEX

** L **

LOPROX, CICLOPIROX
 LOPURIN, ALLOPURINOL
 LORATADINE, LORATADINE (OTC)
 LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
 LORATADINE REDIDOSE, LORATADINE (OTC)
 LORAZEPAM, LORAZEPAM
 LORAZEPAM INTENSOL, LORAZEPAM
 LORAZEPAM PRESERVATIVE FREE, LORAZEPAM
 LORYNA, DROSPIRENONE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSEASONIQUE, ETHINYL ESTRADIOL
 LOTEMAX, LOTEPRDNOL ETABONATE
 LOTENSIN, BENAZEPRIL HYDROCHLORIDE
 LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE
 LOTREL, AMLODIPINE BESYLATE
 LOTRIMIN ULTRA, BUTENAFINE HYDROCHLORIDE (OTC)
 LOTRISONE, BETAMETHASONE DIPROPIONATE
 LOTRONEX, ALOSETRON HYDROCHLORIDE
 LOVASTATIN, LOVASTATIN
 LOVAZA, OMEGA-3-ACID ETHYL ESTERS
 LOVENOX, ENOXAPARIN SODIUM
 LOVENOX (PRESERVATIVE FREE), ENOXAPARIN SODIUM
 LOW-OGESTREL-28, ETHINYL ESTRADIOL
 LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
 LTA II KIT, LIDOCAINE HYDROCHLORIDE
 LUMASON, SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES
 LUMIGAN, BIMATOPROST
 LUNESTA, ESZOPICLONE
 LUPANETA PACK, LEUPROLIDE ACETATE
 LUPRON DEPOT, LEUPROLIDE ACETATE
 LUPRON DEPOT-PED, LEUPROLIDE ACETATE
 LUVOX, FLUVOXAMINE MALEATE
 LUVOX CR, FLUVOXAMINE MALEATE
 LUXIQ, BETAMETHASONE VALERATE
 LUZU, LULICONAZOLE
 LYMPHOSEEK KIT, TECHNETIUM TC-99M TILMANOCEPT
 LYNPARZA, OLAPARIB
 LYRICA, PREGABALIN
 LYSODREN, MITOTANE
 LYSTEDA, TRANEXAMIC ACID

** M **

M-ZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 M.V.I. ADULT, ASCORBIC ACID
 M.V.I. ADULT (PHARMACY BULK PACKAGE), ASCORBIC ACID
 M.V.I. PEDIATRIC, ASCORBIC ACID
 M.V.I.-12 (WITHOUT VITAMIN K), ASCORBIC ACID
 MACROBID, NITROFURANTOIN
 MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE
 MACUGEN, PEGAPTANIB SODIUM
 MAFENIDE ACETATE, MAFENIDE ACETATE
 MAGNESIUM SULFATE, MAGNESIUM SULFATE
 MAGNESIUM SULFATE, MAGNESIUM SULFATE
 MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 MAGNEVIST, GADOPENTETATE DIMEGLUMINE
 MAKENA, HYDROXYPROGESTERONE CAPROATE
 MAKENA PRESERVATIVE FREE, HYDROXYPROGESTERONE CAPROATE
 MALARONE, ATOVAQUONE
 MALARONE PEDIATRIC, ATOVAQUONE
 MALATHION, MALATHION
 MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE
 MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
 MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL

APPENDIX A - PRODUCT NAME INDEX

** M **

MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 25%, MANNITOL
MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
MAPROTILINE HYDROCHLORIDE, MAPROTILINE HYDROCHLORIDE
MARCAINE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARINOL, DRONABINOL
MARLISSA, ETHINYL ESTRADIOL
MARPLAN, ISOCARBOXAZID
MARQIBO KIT, VINCRISTINE SULFATE
MATULANE, PROCARBAZINE HYDROCHLORIDE
MAVIK, TRANDOLAPRIL
MAXALT, RIZATRIPTAN BENZOATE
MAXALT-MLT, RIZATRIPTAN BENZOATE
MAXIDEX, DEXAMETHASONE
MAXIPIME, CEFEPIME HYDROCHLORIDE
MAXITROL, DEXAMETHASONE
MAXZIDE, HYDROCHLOROTHIAZIDE
MAXZIDE-25, HYDROCHLOROTHIAZIDE
MD-76R, DIATRIZOATE MEGLUMINE
MD-GASTROVIEW, DIATRIZOATE MEGLUMINE
MDP-BRACCO, TECHNETIUM TC-99M MEDRONATE KIT
MECAMYLAMINE HYDROCHLORIDE, MECAMYLAMINE HYDROCHLORIDE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MEDROL, METHYLPREDNISOLONE
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MEFENAMIC ACID, MEFENAMIC ACID
MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
MEFOXIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
MEGACE, MEGESTROL ACETATE
MEGACE ES, MEGESTROL ACETATE
MEGATOPE, ALBUMIN IODINATED I-131 SERUM
MEGESTROL ACETATE, MEGESTROL ACETATE
MEKINIST, TRAMETINIB DIMETHYL SULFOXIDE
MELAMISA, DROSPIRENONE
MELOXICAM, MELOXICAM
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MEMBRANEBLUE, TRYPAN BLUE
MEN'S ROGAINE, MINOXIDIL (OTC)
MENEST, ESTROGENS, ESTERIFIED
MENOPUR, MENOTROPINS (FSH)
MENOSTAR, ESTRADIOL
MENTAX, BUTENAFINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MEPHYTON, PHYTONADIONE
MEPIVACAINE HYDROCHLORIDE, MEPIVACAINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
MEPRON, ATOVAQUONE
MERCAPTOPYRINE, MERCAPTOPYRINE
MEROPENEM, MEROPENEM
MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER, MEROPENEM
MERREM, MEROPENEM
MESALAMINE, MESALAMINE
MESNA, MESNA
MESNEX, MESNA
MESTINON, PYRIDOSTIGMINE BROMIDE
METADATE CD, METHYLPHENIDATE HYDROCHLORIDE
METADATE ER, METHYLPHENIDATE HYDROCHLORIDE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE

APPENDIX A - PRODUCT NAME INDEX

** M **

METARAMINOL BITARTRATE, METARAMINOL BITARTRATE
 METASTRON, STRONTIUM CHLORIDE SR-89
 METAXALONE, METAXALONE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 METHADONE HYDROCHLORIDE INTENSOL, METHADONE HYDROCHLORIDE
 METHADOSE, METHADONE HYDROCHLORIDE
 METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE
 METHAZOLAMIDE, METHAZOLAMIDE
 METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
 METHERGINE, METHYLERGONOVINE MALEATE
 METHIMAZOLE, METHIMAZOLE
 METHOCARBAMOL, METHOCARBAMOL
 METHOCARBAMOL AND ASPIRIN, ASPIRIN
 METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
 METHOXSALEN, METHOXSALEN
 METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
 METHYLCLOTHIAZIDE, METHYLCLOTHIAZIDE
 METHYLDOPA, METHYLDOPA
 METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 METHYLDOPATE HYDROCHLORIDE, METHYLDOPATE HYDROCHLORIDE
 METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
 METHYLIN, METHYLPHENIDATE HYDROCHLORIDE
 METHYLIN ER, METHYLPHENIDATE HYDROCHLORIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 METHYLPREDNISOLONE, METHYLPREDNISOLONE
 METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
 METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
 METHYLTESTOSTERONE, METHYLTESTOSTERONE
 METIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
 METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 METOLAZONE, METOLAZONE
 METOPIRONE, METYRAPONE
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 METOZOLV ODT, METOCLOPRAMIDE HYDROCHLORIDE
 METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE
 METROCREAM, METRONIDAZOLE
 METROGEL, METRONIDAZOLE
 METROGEL-VAGINAL, METRONIDAZOLE
 METROLOTION, METRONIDAZOLE
 METRONIDAZOLE, METRONIDAZOLE
 METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
 MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
 MIACALCIN, CALCITONIN SALMON
 MIBELAS 24 FE, ETHINYL ESTRADIOL
 MICARDIS, TELMISARTAN
 MICARDIS HCT, HYDROCHLOROTHIAZIDE
 MICONAZOLE 3, MICONAZOLE NITRATE (OTC)
 MICONAZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 MICONAZOLE 7, MICONAZOLE NITRATE (OTC)
 MICONAZOLE 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
 MICONAZOLE NITRATE, MICONAZOLE NITRATE
 MICONAZOLE NITRATE COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 MICORT-HC, HYDROCORTISONE ACETATE
 MICRO-K, POTASSIUM CHLORIDE
 MICRO-K 10, POTASSIUM CHLORIDE
 MICROGESTIN 1.5/30, ETHINYL ESTRADIOL
 MICROGESTIN 1/20, ETHINYL ESTRADIOL
 MICROGESTIN FE 1.5/30, ETHINYL ESTRADIOL

APPENDIX A - PRODUCT NAME INDEX

** M **

MICROGESTIN FE 1/20, ETHINYL ESTRADIOL
 MICRONOR, NORETHINDRONE
 MICROZIDE, HYDROCHLOROTHIAZIDE
 MIDAMOR, AMILORIDE HYDROCHLORIDE
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
 MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
 MIDOL LIQUID GELS, IBUPROFEN (OTC)
 MIDOZALAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MIFEPREX, MIFEPRISTONE
 MIGERGOT, CAFFEINE
 MIGLITOL, MIGLITOL
 MIGRANAL, DIHYDROERGOTAMINE MESYLATE
 MILI, ETHINYL ESTRADIOL
 MILNACIPRAN HYDROCHLORIDE, MILNACIPRAN HYDROCHLORIDE
 MILRINONE LACTATE, MILRINONE LACTATE
 MILRINONE LACTATE IN DEXTROSE 5%, MILRINONE LACTATE
 MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
 MILRINONE LACTATE IN PLASTIC CONTAINER, MILRINONE LACTATE
 MINASTRIN 24 FE, ETHINYL ESTRADIOL
 MINIPRESS, PRAZOSIN HYDROCHLORIDE
 MINIRIN, DESMOPRESSIN ACETATE
 MINITRAN, NITROGLYCERIN
 MINIVELLE, ESTRADIOL
 MINOCIN, MINOCYCLINE HYDROCHLORIDE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MINOXIDIL, MINOXIDIL (OTC)
 MINOXIDIL, MINOXIDIL
 MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
 MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
 MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
 MIOCHOL-E, ACETYLCHOLINE CHLORIDE
 MIOSTAT, CARBACHOL
 MIRALAX, POLYETHYLENE GLYCOL 3350 (OTC)
 MIRAPEX, PRAMIPEXOLE DIHYDROCHLORIDE
 MIRAPEX ER, PRAMIPEXOLE DIHYDROCHLORIDE
 MIRENA, LEVONORGESTREL
 MIRTAZAPINE, MIRTAZAPINE
 MIRVASO, BRIMONIDINE TARTRATE
 MISOPROSTOL, MISOPROSTOL
 MITIGARE, COLCHICINE
 MITOMYCIN, MITOMYCIN
 MITOSOL, MITOMYCIN
 MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
 MIVACRON, MIVACURIUM CHLORIDE
 MOBIC, MELOXICAM
 MODAFINIL, MODAFINIL
 MODICON 28, ETHINYL ESTRADIOL
 MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
 MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 MOLINDONE HYDROCHLORIDE, MOLINDONE HYDROCHLORIDE
 MOMETASONE FUROATE, MOMETASONE FUROATE
 MONISTAT 1 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 MONISTAT 3, MICONAZOLE NITRATE (OTC)
 MONISTAT 3, MICONAZOLE NITRATE
 MONISTAT 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 MONISTAT 3 COMBINATION PACK (PREFILLED), MICONAZOLE NITRATE (OTC)
 MONISTAT 7, MICONAZOLE NITRATE (OTC)
 MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 MONO-LINYAH, ETHINYL ESTRADIOL
 MONODOX, DOXYCYCLINE
 MONOKET, ISOSORBIDE MONONITRATE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 MONUROL, FOSFOMYCIN TROMETHAMINE

APPENDIX A - PRODUCT NAME INDEX

** M **

MORPHABOND, MORPHINE SULFATE
MORPHINE SULFATE, MORPHINE SULFATE
MOTOFEN, ATROPINE SULFATE
MOTRIN IB, IBUPROFEN (OTC)
MOVANTIK, NALOXEGOL OXALATE
MOVIPREP, ASCORBIC ACID
MOXATAG, AMOXICILLIN
MOXEZA, MOXIFLOXACIN HYDROCHLORIDE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
MOZOBIL, PLERIXAFOR
MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM
MS CONTIN, MORPHINE SULFATE
MUCINEX, GUAIFENESIN (OTC)
MUCINEX D, GUAIFENESIN (OTC)
MUCINEX DM, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
MULTAQ, DRONEDARONE HYDROCHLORIDE
MULTIHANCE, GADOBENATE DIMEGLUMINE
MULTIHANCE MULTIPACK, GADOBENATE DIMEGLUMINE
MUPIROCIN, MUPIROCIN
MUPIROCIN, MUPIROCIN CALCIUM
MUSE, ALPROSTADIL
MUSTARGEN, MECHLORETHAMINE HYDROCHLORIDE
MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE
MYCAMINE, MICAFUNGIN SODIUM
MYCELEX-7, CLOTRIMAZOLE (OTC)
MYCELEX-7 COMBINATION PACK, CLOTRIMAZOLE (OTC)
MYCOBUTIN, RIFABUTIN
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
MYDRIACYL, TROPICAMIDE
MYFORTIC, MYCOPHENOLIC ACID
MYKACET, NYSTATIN
MYLERAN, BUSULFAN
MYORISAN, ISOTRETINOIN
MYOVIEV, TECHNETIUM TC-99M TETROFOSMIN KIT
MYOVIEV 30ML, TECHNETIUM TC-99M TETROFOSMIN KIT
MYRBETRIQ, MIRABEGRON
MYSOLINE, PRIMIDONE
MYZILRA, ETHINYL ESTRADIOL

** N **

NABUMETONE, NABUMETONE
NADOLOL, NADOLOL
NADOLOL AND BENDROFLUMETHIAZIDE, BENDROFLUMETHIAZIDE
NAFCILLIN SODIUM, NAFCILLIN SODIUM
NAFTIFINE HYDROCHLORIDE, NAFTIFINE HYDROCHLORIDE
NAFTIN, NAFTIFINE HYDROCHLORIDE
NALBUPHINE HYDROCHLORIDE, NALBUPHINE HYDROCHLORIDE
NALFON, FENOPROFEN CALCIUM
NALLPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM
NALOXONE, NALOXONE HYDROCHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
NAMENDA, MEMANTINE HYDROCHLORIDE
NAMENDA XR, MEMANTINE HYDROCHLORIDE
NAMZARIC, DONEPEZIL HYDROCHLORIDE
NANDROLONE DECANOATE, NANDROLONE DECANOATE
NAPHAZOLINE HYDROCHLORIDE, NAPHAZOLINE HYDROCHLORIDE
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)
NAPHCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
NAPRELAN, NAPROXEN SODIUM
NAPROSYN, NAPROXEN
NAPROXEN, NAPROXEN

APPENDIX A - PRODUCT NAME INDEX

** N **

NAPROXEN AND ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 NAPROXEN SODIUM, NAPROXEN SODIUM
 NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
 NARCAN, NALOXONE HYDROCHLORIDE
 NARDIL, PHENELZINE SULFATE
 NAROPIN, ROPIVACAINE HYDROCHLORIDE
 NASACORT ALLERGY 24 HOUR, TRIAMCINOLONE ACETONIDE (OTC)
 NASCOBAL, CYANOCOBALAMIN
 NASONEX, MOMETASONE FUROATE
 NATACYN, NATAMYCIN
 NATAZIA, DIENOGEST
 NATEGLINIDE, NATEGLINIDE
 NATESTO, TESTOSTERONE
 NATRECOR, NESIRITIDE RECOMBINANT
 NATROBA, SPINOSAD
 NAVELBINE, VINORELBINE TARTRATE
 NEBUPENT, PENTAMIDINE ISETHIONATE
 NEDOCROMIL SODIUM, NEDOCROMIL SODIUM
 NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE
 NEMBUTAL SODIUM, PENTOBARBITAL SODIUM
 NEO-FRADIN, NEOMYCIN SULFATE
 NEO-SYNALAR, FLUOCINOLONE ACETONIDE
 NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
 NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
 NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
 NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
 NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
 NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
 NEOMYCIN SULFATE, NEOMYCIN SULFATE
 NEOPAP, ACETAMINOPHEN (OTC)
 NEOPROFEN, IBUPROFEN LYSINE
 NEORAL, CYCLOSPORINE
 NEOSPORIN, GRAMICIDIN
 NEOSPORIN G.U. IRRIGANT, NEOMYCIN SULFATE
 NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
 NEPHRAMINE 5.4%, AMINO ACIDS
 NESACAINE, CHLOROPROCAINE HYDROCHLORIDE
 NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE
 NESINA, ALOGLIPTIN BENZOATE
 NETSPOT, GALLIUM DOTATATE GA-68
 NEUPRO, ROTIGOTINE
 NEURACEQ, FLORBETABEN F-18
 NEUROLITE, TECHNETIUM TC-99M BICISATE KIT
 NEURONTIN, GABAPENTIN
 NEVANAC, NEPAFENAC
 NEVIRAPINE, NEVIRAPINE
 NEXAVAR, SORAFENIB TOSYLATE
 NEXIUM, ESOMEPRAZOLE MAGNESIUM
 NEXIUM 24HR, ESOMEPRAZOLE MAGNESIUM (OTC)
 NEXIUM IV, ESOMEPRAZOLE SODIUM
 NEXPLANON, ETNOGESTREL
 NEXTERONE, AMIODARONE HYDROCHLORIDE
 NIACIN, NIACIN
 NIACOR, NIACIN
 NIASPAN, NIACIN
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 NICODERM CQ, NICOTINE (OTC)
 NICORETTE, NICOTINE POLACRILEX (OTC)
 NICORETTE (MINT), NICOTINE POLACRILEX (OTC)
 NICOTINE, NICOTINE (OTC)
 NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
 NICOTROL, NICOTINE
 NIFEDIPINE, NIFEDIPINE

APPENDIX A - PRODUCT NAME INDEX

** N **

NIKKI, DROSPIRENONE
 NILANDRON, NILUTAMIDE
 NILUTAMIDE, NILUTAMIDE
 NIMBEX, CISATRACURIUM BESYLATE
 NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE
 NIMODIPINE, NIMODIPINE
 NINLARO, IXAZOMIB CITRATE
 NIPENT, PENTOSTATIN
 NISOLDIPINE, NISOLDIPINE
 NITHIODOTE, SODIUM NITRITE
 NITRO-DUR, NITROGLYCERIN
 NITROFURANTOIN, NITROFURANTOIN
 NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
 NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
 NITROGLYCERIN, NITROGLYCERIN
 NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
 NITROLINGUAL PUMPSPRAY, NITROGLYCERIN
 NITROMIST, NITROGLYCERIN
 NITROPRESS, SODIUM NITROPRUSSIDE
 NITROSTAT, NITROGLYCERIN
 NIX, PERMETHRIN (OTC)
 NIZATIDINE, NIZATIDINE
 NIZORAL, KETOCONAZOLE
 NIZORAL A-D, KETOCONAZOLE (OTC)
 NOR-QD, NORETHINDRONE
 NORCO, ACETAMINOPHEN
 NORDITROPIN FLEXPOR, SOMATROPIN RECOMBINANT
 NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
 NORETHINDRONE, NORETHINDRONE
 NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE,
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NORETHINDRONE AND ETHINYL ESTRADIOL (10/11), ETHINYL ESTRADIOL
 NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NORINYL 1+35 21-DAY, ETHINYL ESTRADIOL
 NORINYL 1+35 28-DAY, ETHINYL ESTRADIOL
 NORINYL 1+50 28-DAY, MESTRANOL
 NORITATE, METRONIDAZOLE
 NORMOCARB HF 25, MAGNESIUM CHLORIDE
 NORMOCARB HF 35, MAGNESIUM CHLORIDE
 NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 NORPACE, DISOPYRAMIDE PHOSPHATE
 NORPACE CR, DISOPYRAMIDE PHOSPHATE
 NORPRAMIN, DESIPRAMINE HYDROCHLORIDE
 NORTHERA, DROXIDOPA
 NORTREL 0.5/35-28, ETHINYL ESTRADIOL
 NORTREL 1/35-21, ETHINYL ESTRADIOL
 NORTREL 1/35-28, ETHINYL ESTRADIOL
 NORTREL 7/7/7, ETHINYL ESTRADIOL
 NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
 NORVASC, AMLODIPINE BESYLATE
 NORVIR, RITONAVIR
 NOVOLIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
 NOVOLIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
 NOVOLIN R, INSULIN RECOMBINANT HUMAN (OTC)
 NOVOLOG, INSULIN ASPART RECOMBINANT
 NOVOLOG FLEXPEN, INSULIN ASPART RECOMBINANT
 NOVOLOG FLEXTOUCH, INSULIN ASPART RECOMBINANT
 NOVOLOG MIX 70/30, INSULIN ASPART PROTAMINE RECOMBINANT

APPENDIX A - PRODUCT NAME INDEX

** N **

NOVOLOG MIX 70/30 FLEXPEN, INSULIN ASPART PROTAMINE RECOMBINANT
 NOVOLOG PENFILL, INSULIN ASPART RECOMBINANT
 NOXAFIL, POSACONAZOLE
 NUCYNTA, TAPENTADOL HYDROCHLORIDE
 NUCYNTA ER, TAPENTADOL HYDROCHLORIDE
 NUEDEXTA, DEXTROMETHORPHAN HYDROBROMIDE
 NULYTELY, POLYETHYLENE GLYCOL 3350
 NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350
 NUPLAZID, PIMAVANSERIN TARTRATE
 NUTRESTORE, GLUTAMINE
 NUTRILIPID 10%, SOYBEAN OIL
 NUTRILIPID 20%, SOYBEAN OIL
 NUTROPIN AQ NUSPIN, SOMATROPIN RECOMBINANT
 NUTROPIN AQ PEN, SOMATROPIN RECOMBINANT
 NUVARING, ETHINYL ESTRADIOL
 NUVESSA, METRONIDAZOLE
 NUVIGIL, ARMODAFINIL
 NYLIA 1/35, ETHINYL ESTRADIOL
 NYLIA 7/7/7, ETHINYL ESTRADIOL
 NYMALIZE, NIMODIPINE
 NYSTATIN, NYSTATIN
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 NYSTOP, NYSTATIN

** O **

OBREDON, GUAIFENESIN
 OCALIVA, OBETICHOLIC ACID
 OCTOCAINE, EPINEPHRINE
 OCTREOSCAN, INDIUM IN-111 PENTETREOTIDE KIT
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
 OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
 OCUCLEAR, OXYMETAZOLINE HYDROCHLORIDE (OTC)
 OCUFEN, FLURBIPROFEN SODIUM
 OCUFLOX, OFLOXACIN
 OCUPRESS, CARTEOLOL HYDROCHLORIDE
 ODEFSEY, EMTRICITABINE
 ODOMZO, SONIDEGIB PHOSPHATE
 OFEV, NINTEDANIB ESYLATE
 OFIRMEV, ACETAMINOPHEN
 OFLOXACIN, OFLOXACIN
 OGEN .625, ESTROPIPATE
 OGEN 1.25, ESTROPIPATE
 OGEN 2.5, ESTROPIPATE
 OGEN 5, ESTROPIPATE
 OGESTREL 0.5/50-28, ETHINYL ESTRADIOL
 OLANZAPINE, OLANZAPINE
 OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
 OLUX, CLOBETASOL PROPIONATE
 OLUX E, CLOBETASOL PROPIONATE
 OLYSIO, SIMPREVIR SODIUM
 OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
 OMEPRAZOLE, OMEPRAZOLE (OTC)
 OMEPRAZOLE, OMEPRAZOLE
 OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN, AMOXICILLIN
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
 OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
 OMIDRIA, KETOROLAC TROMETHAMINE
 OMNARIS, CICLESONIDE
 OMNIPAQUE 140, IOHEXOL
 OMNIPAQUE 180, IOHEXOL

APPENDIX A - PRODUCT NAME INDEX

** O **

OMNIPAQUE 240, IOHEXOL
 OMNIPAQUE 300, IOHEXOL
 OMNIPAQUE 350, IOHEXOL
 OMNIPRED, PREDNISOLONE ACETATE
 OMNISCAN, GADODIAMIDE
 OMNITROPE, SOMATROPIN RECOMBINANT
 OMTRYG, OMEGA-3-ACID ETHYL ESTERS TYPE A
 ONDANSETRON, ONDANSETRON
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONEXTON, BENZOYL PEROXIDE
 ONFI, CLOBAZAM
 ONGLYZA, SAXAGLIPTIN HYDROCHLORIDE
 ONIVYDE, IRINOTECAN HYDROCHLORIDE
 ONMEL, ITRACONAZOLE
 ONZETRA XSAIL, SUMATRIPTAN SUCCINATE
 OPANA, OXYMORPHONE HYDROCHLORIDE
 OPANA ER, OXYMORPHONE HYDROCHLORIDE
 OPCICON ONE-STEP, LEVONORGESTREL (OTC)
 OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
 OPSUMIT, MACITENTAN
 OPTIMARK, GADOVERSETAMIDE
 OPTIMARK IN PLASTIC CONTAINER, GADOVERSETAMIDE
 OPTIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
 OPTIRAY 240, IOVERSOL
 OPTIRAY 300, IOVERSOL
 OPTIRAY 320, IOVERSOL
 OPTIRAY 350, IOVERSOL
 OPTISON, ALBUMIN HUMAN
 OPTIVAR, AZELASTINE HYDROCHLORIDE
 ORABLOC, ARTICAIN HYDROCHLORIDE
 ORACEA, DOXYCYCLINE
 ORALTAG, IOHEXOL
 ORAP, PIMOZIDE
 ORAPRED ODT, PREDNISOLONE SODIUM PHOSPHATE
 ORAQIX, LIDOCAINE
 ORAVERSE, PHENTOLAMINE MESYLATE
 ORAVIG, MICONAZOLE
 ORBACTIV, ORITAVANCIN DIPHOSPHATE
 ORENITRAM, TREPROSTINIL DIOLAMINE
 ORFADIN, NITISINONE
 ORKAMBI, IVACAFTOR
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE, ASPIRIN
 ORSYTHIA, ETHINYL ESTRADIOL
 ORTHO CYCLEN-28, ETHINYL ESTRADIOL
 ORTHO TRI-CYCLEN, ETHINYL ESTRADIOL
 ORTHO TRI-CYCLEN LO, ETHINYL ESTRADIOL
 ORTHO-NOVUM 1/35-28, ETHINYL ESTRADIOL
 ORTHO-NOVUM 7/7/7-28, ETHINYL ESTRADIOL
 ORVATEN, MIDODRINE HYDROCHLORIDE
 OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
 OSENI, ALOGLIPTIN BENZOATE
 OSMITROL 10% IN WATER, MANNITOL
 OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 15% IN WATER, MANNITOL
 OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 20% IN WATER, MANNITOL
 OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 5% IN WATER, MANNITOL
 OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMOPREP, SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
 OSPHENA, OSPEMIFENE
 OTEZLA, APREMILAST
 OTICAIR, HYDROCORTISONE

APPENDIX A - PRODUCT NAME INDEX

** O **

OTIPRIO, CIPROFLOXACIN
 OTOVEL, CIPROFLOXACIN HYDROCHLORIDE
 OTREXUP, METHOTREXATE
 OVIDE, MALATHION
 OVIDREL, CHORIOGONADOTROPIN ALFA
 OXACILLIN SODIUM, OXACILLIN SODIUM
 OXALIPLATIN, OXALIPLATIN
 OXANDRIN, OXANDROLONE
 OXANDROLONE, OXANDROLONE
 OXAPROZIN, OXAPROZIN
 OXAYDO, OXYCODONE HYDROCHLORIDE
 OXAZEPAM, OXAZEPAM
 OXCARBAZEPINE, OXCARBAZEPINE
 OXICONAZOLE NITRATE, OXICONAZOLE NITRATE
 OXISTAT, OXICONAZOLE NITRATE
 OXSORALEN, METHOXSALEN
 OXSORALEN-ULTRA, METHOXSALEN
 OXTELLAR XR, OXCARBAZEPINE
 OXYBUTYNIN, OXYBUTYNIN
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 OXYCET, ACETAMINOPHEN
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE AND ASPIRIN, ASPIRIN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN
 OXYCONTIN, OXYCODONE HYDROCHLORIDE
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 OXYTOCIN, OXYTOCIN
 OXYTROL, OXYBUTYNIN
 OXYTROL FOR WOMEN, OXYBUTYNIN (OTC)
 OZURDEX, DEXAMETHASONE

** P **

PACERONE, AMIODARONE HYDROCHLORIDE
 PACITAXEL, PACLITAXEL
 PACLITAXEL, PACLITAXEL
 PALIPERIDONE, PALIPERIDONE
 PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
 PAMELOR, NORTRIPTYLINE HYDROCHLORIDE
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PANCREAZE, PANCRELIPASE (AMYLASE)
 PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
 PANDEL, HYDROCORTISONE PROBUTATE
 PANRETIN, ALITRETINOIN
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PARAGARD T 380A, COPPER
 PAREMYD, HYDROXYAMPHETAMINE HYDROBROMIDE
 PARICALCITOL, PARICALCITOL
 PARLODEL, BROMOCRIPTINE MESYLATE
 PARNATE, TRANYLCPROMINE SULFATE
 PAROEX, CHLORHEXIDINE GLUCONATE
 PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
 PAROXETINE, PAROXETINE HYDROCHLORIDE
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PASER, AMINOSALICYLIC ACID
 PATADAY, OLOPATADINE HYDROCHLORIDE
 PATANASE, OLOPATADINE HYDROCHLORIDE
 PATANOL, OLOPATADINE HYDROCHLORIDE
 PAXIL, PAROXETINE HYDROCHLORIDE
 PAXIL CR, PAROXETINE HYDROCHLORIDE
 PAZEO, OLOPATADINE HYDROCHLORIDE
 PCE, ERYTHROMYCIN
 PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE
 PEDIATRIC ADVIL, IBUPROFEN (OTC)

APPENDIX A - PRODUCT NAME INDEX

** P **

PEG 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
 PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE, POLYETHYLENE GLYCOL
 PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL, BISACODYL
 PEGANONE, ETHOTOIN
 PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
 PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM
 PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
 PENICILLIN G SODIUM, PENICILLIN G SODIUM
 PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
 PENICILLIN-VK, PENICILLIN V POTASSIUM
 PENLAC, CICLOPIROX
 PENNSAID, DICLOFENAC SODIUM
 PENTAM, PENTAMIDINE ISETHIONATE
 PENTASA, MESALAMINE
 PENTETATE CALCIUM TRISODIUM, PENTETATE CALCIUM TRISODIUM
 PENTETATE ZINC TRISODIUM, PENTETATE ZINC TRISODIUM
 PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
 PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE
 PENTOSTATIN, PENTOSTATIN
 PENTOXIFYLLINE, PENTOXIFYLLINE
 PENTOXIL, PENTOXIFYLLINE
 PEPCID, FAMOTIDINE
 PEPCID AC, FAMOTIDINE (OTC)
 PEPCID AC, FAMOTIDINE (OTC)
 PEPCID COMPLETE, CALCIUM CARBONATE (OTC)
 PERCOCET, ACETAMINOPHEN
 PERCODAN, ASPIRIN
 PERFOROMIST, FORMOTEROL FUMARATE
 PERIDEX, CHLORHEXIDINE GLUCONATE
 PERIKABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
 PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
 PERIOCHIP, CHLORHEXIDINE GLUCONATE
 PERIOGARD, CHLORHEXIDINE GLUCONATE
 PERMAPEN, PENICILLIN G BENZATHINE
 PERMETHRIN, PERMETHRIN (OTC)
 PERMETHRIN, PERMETHRIN
 PERPHENAZINE, PERPHENAZINE
 PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 PERSANTINE, DIPYRIDAMOLE
 PERTZYE, PANCRELIPASE (AMYLASE)
 PEXEVA, PAROXETINE MESYLATE
 PFIZERPEN, PENICILLIN G POTASSIUM
 PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
 PHENELZINE SULFATE, PHENELZINE SULFATE
 PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE
 PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
 PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
 PHENYTEK, PHENYTOIN SODIUM
 PHENYTOIN, PHENYTOIN
 PHENYTOIN SODIUM, PHENYTOIN SODIUM
 PHILITH, ETHINYL ESTRADIOL
 PHOSLO GELCAPS, CALCIUM ACETATE
 PHOSLYRA, CALCIUM ACETATE
 PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE
 PHOTOFRIN, PORFIMER SODIUM
 PHOTREXA, RIBOFLAVIN 5'-PHOSPHATE SODIUM
 PHOTREXA VISCOUS IN DEXTRAN 20%, RIBOFLAVIN 5'-PHOSPHATE SODIUM
 PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 PHYTONADIONE, PHYTONADIONE
 PICATO, INGENOL MEBUTATE

APPENDIX A - PRODUCT NAME INDEX

** P **

PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
 PIMOZIDE, PIMOZIDE
 PIMTREA, DESOGESTREL
 PINDOLOL, PINDOLOL
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE, GLIMEPIRIDE
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 PIPERACILLIN, PIPERACILLIN SODIUM
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 PIRMELLA 1/35, ETHINYL ESTRADIOL
 PIRMELLA 7/7/7, ETHINYL ESTRADIOL
 PIROXICAM, PIROXICAM
 PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM
 PITOCIN, OXYTOCIN
 PLAN B ONE-STEP, LEVONORGESTREL (OTC)
 PLAQUENIL, HYDROXYCHLOROQUINE SULFATE
 PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 PLAVIX, CLOPIDOGREL BISULFATE
 PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PLIAGLIS, LIDOCAINE
 PODOFILOX, PODOFILOX
 POLOCAINE, MEPIVACAINE HYDROCHLORIDE
 POLOCAINE-MPF, MEPIVACAINE HYDROCHLORIDE
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350
 POLYMYCIN B SULFATE, POLYMYXIN B SULFATE
 POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 POLYTRIM, POLYMYXIN B SULFATE
 POMALYST, POMALIDOMIDE
 PONSTEL, MEFENAMIC ACID
 PORTIA-28, ETHINYL ESTRADIOL
 POTASSIUM ACETATE, POTASSIUM ACETATE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,

APPENDIX A - PRODUCT NAME INDEX

** P **

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CITRATE, POTASSIUM CITRATE
 POTASSIUM IODIDE, POTASSIUM IODIDE (OTC)
 POTIGA, EZOGABINE
 POVIDONE IODINE, POVIDONE-IODINE (OTC)
 PRADAXA, DABIGATRAN ETEXILATE MESYLATE
 PRALIDOXIME CHLORIDE, PRALIDOXIME CHLORIDE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PRAMOSONE, HYDROCORTISONE ACETATE
 PRANDIMET, METFORMIN HYDROCHLORIDE
 PRANDIN, REPAGLINIDE
 PRAVACHOL, PRAVASTATIN SODIUM
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
 PRE-OP, HEXACHLOROPHENE
 PRE-OP II, HEXACHLOROPHENE
 PRE-PEN, BENZYL PENICILLOYL POLYLYSINE
 PRECEDEX, DEXMEDETOMIDINE HYDROCHLORIDE
 PRECOSE, ACARBOSE
 PRED FORTE, PREDNISOLONE ACETATE
 PRED MILD, PREDNISOLONE ACETATE
 PRED-G, GENTAMICIN SULFATE
 PREDNICARBATE, PREDNICARBATE
 PREDNISOLONE, PREDNISOLONE
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 PREDNISONE, PREDNISONE
 PREDNISONE INTENSOL, PREDNISONE
 PREGNYL, GONADOTROPIN, CHORIONIC
 PRELONE, PREDNISOLONE
 PREMARIN, ESTROGENS, CONJUGATED
 PREMASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
 PREMASOL 6% IN PLASTIC CONTAINER, AMINO ACIDS
 PREMPHASE 14/14, ESTROGENS, CONJUGATED
 PREMPRO, ESTROGENS, CONJUGATED
 PREPIDIL, DINOPROSTONE
 PREPOPIK, CITRIC ACID
 PRESTALIA, AMLODIPINE BESYLATE
 PREVACID, LANSOPRAZOLE
 PREVACID 24 HR, LANSOPRAZOLE (OTC)
 PREVALITE, CHOLESTYRAMINE
 PREVANTICS MAXI SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
 PREVANTICS SWAB, CHLORHEXIDINE GLUCONATE (OTC)
 PREVANTICS SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
 PREVIFEM, ETHINYL ESTRADIOL
 PREVPAC, AMOXICILLIN
 PREZCOBIX, COBICISTAT
 PREZISTA, DARUNAVIR ETHANOLATE
 PRIALT, ZICONOTIDE ACETATE
 PRIFTIN, RIFAPENTINE
 PRILOCAINE HYDROCHLORIDE, PRILOCAINE HYDROCHLORIDE
 PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, EPINEPHRINE BITARTRATE
 PRILOSEC, OMEPRAZOLE MAGNESIUM
 PRILOSEC OTC, OMEPRAZOLE MAGNESIUM (OTC)
 PRIMAQUINE, PRIMAQUINE PHOSPHATE
 PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE
 PRIMAXIN, CILASTATIN SODIUM
 PRIMIDONE, PRIMIDONE
 PRIMISOL, TRIMETHOPRIM HYDROCHLORIDE
 PRINIVIL, LISINAPRIL
 PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE

APPENDIX A - PRODUCT NAME INDEX

** P **

PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL BGK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISTIQ, DESVENLAFAXINE SUCCINATE
 PROAIR HFA, ALBUTEROL SULFATE
 PROAIR RESPICLICK, ALBUTEROL SULFATE
 PROBALAN, PROBENECID
 PROBENECID, PROBENECID
 PROBENECID AND COLCHICINE, COLCHICINE
 PROBUPHINE, BUPRENORPHINE HYDROCHLORIDE
 PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
 PROCALAMINE, AMINO ACIDS
 PROCARDIA, NIFEDIPINE
 PROCARDIA XL, NIFEDIPINE
 PROCHLORPERAZINE, PROCHLORPERAZINE
 PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
 PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
 PROCOMP, PROCHLORPERAZINE MALEATE
 PROCTOFOAM HC, HYDROCORTISONE ACETATE
 PROCYSBI, CYSTEAMINE BITARTRATE
 PROFEN, IBUPROFEN (OTC)
 PROFERDEX, IRON DEXTRAN
 PROGESTERONE, PROGESTERONE
 PROGLYCEM, DIAZOXIDE
 PROGRAF, TACROLIMUS
 PROHANCE, GADOTERIDOL
 PROHANCE MULTIPACK, GADOTERIDOL
 PROLENSA, BROMFENAC SODIUM
 PROMACTA, ELTROMBOPAG OLAMINE
 PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE PHOSPHATE
 PROMETH VC PLAIN, PHENYLEPHRINE HYDROCHLORIDE
 PROMETH VC W/ CODEINE, CODEINE PHOSPHATE
 PROMETH W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
 PROMETHAZINE DM, DEXTROMETHORPHAN HYDROBROMIDE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN
 PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
 PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
 PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
 PROMETHAZINE PLAIN, PROMETHAZINE HYDROCHLORIDE
 PROMETHAZINE W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
 PROMETHAZINE WITH CODEINE, CODEINE PHOSPHATE
 PROMETHEGAN, PROMETHAZINE HYDROCHLORIDE
 PROMETRIUM, PROGESTERONE
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
 PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
 PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
 PROPECIA, FINASTERIDE
 PROPOFOL, PROPOFOL
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 PROPYLTHIOURACIL, PROPYLTHIOURACIL
 PROSCAR, FINASTERIDE
 PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
 PROSTIN E2, DINOPROSTONE
 PROSTIN VR PEDIATRIC, ALPROSTADIL
 PROTAMINE SULFATE, PROTAMINE SULFATE
 PROTONIX, PANTOPRAZOLE SODIUM
WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1086, p. 887 of 1400

APPENDIX A - PRODUCT NAME INDEX

** P **

PROTONIX IV, PANTOPRAZOLE SODIUM
 PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE
 PROTOPIC, TACROLIMUS
 PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
 PROVAYBLUE, METHYLENE BLUE
 PROVENTIL-HFA, ALBUTEROL SULFATE
 PROVERA, MEDROXYPROGESTERONE ACETATE
 PROVIGIL, MODAFINIL
 PROVOCHOLINE, METHACHOLINE CHLORIDE
 PROZAC, FLUOXETINE HYDROCHLORIDE
 PROZAC WEEKLY, FLUOXETINE HYDROCHLORIDE
 PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
 PULMICORT FLEXHALER, BUDESONIDE
 PULMICORT RESPULES, BUDESONIDE
 PULMOLITE, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
 PUR-WASH, PURIFIED WATER (OTC)
 PURINETHOL, MERCAPTOPYRIMIDINE
 PURIXAN, MERCAPTOPYRIMIDINE
 PYLERA, BISMUTH SUBCITRATE POTASSIUM
 PYRAZINAMIDE, PYRAZINAMIDE
 PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
 PYRIDOXINE HYDROCHLORIDE, PYRIDOXINE HYDROCHLORIDE
 PYTEST, UREA, C-14
 PYTEST KIT, UREA, C-14

** Q **

QBRELIS, LISINAPRIL
 QNASL, BECLOMETHASONE DIPROPIONATE
 QOLIANA, BRIMONIDINE TARTRATE
 QSYMIA, PHENTERMINE HYDROCHLORIDE
 QUADRAMET, SAMARIUM SM-153 LEXIDRONAM PENTASODIUM
 QUALAQUIN, QUININE SULFATE
 QUARTETTE, ETHINYL ESTRADIOL
 QUASENSE, ETHINYL ESTRADIOL
 QUDEXY XR, TOPIRAMATE
 QUELICIN, SUCCINYLCHOLINE CHLORIDE
 QUELICIN PRESERVATIVE FREE, SUCCINYLCHOLINE CHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 QUILLICHEW ER, METHYLPHENIDATE HYDROCHLORIDE
 QUILLIVANT XR, METHYLPHENIDATE HYDROCHLORIDE
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 QUINARETIC, HYDROCHLOROTHIAZIDE
 QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
 QUINIDINE SULFATE, QUINIDINE SULFATE
 QUININE SULFATE, QUININE SULFATE
 QUTENZA, CAPSAICIN
 QVAR 40, BECLOMETHASONE DIPROPIONATE
 QVAR 80, BECLOMETHASONE DIPROPIONATE

** R **

R-GENE 10, ARGININE HYDROCHLORIDE
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 RADIOGARDASE (PRUSSIAN BLUE), FERRIC HEXACYANOFERRATE(II)
 RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
 RAMELTEON, RAMELTEON
 RAMIPRIL, RAMIPRIL
 RANEXA, RANOLAZINE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RANOLAZINE, RANOLAZINE
 RAPAFLO, SILODOSIN
 RAPAMUNE, SIROLIMUS
 RAPIVAB, PERAMIVIR
 RASAGILINE MESYLATE, RASAGILINE MESYLATE

APPENDIX A - PRODUCT NAME INDEX

** R **

RASUVO, METHOTREXATE
 RAVICTI, GLYCEROL PHENYL BUTYRATE
 RAYALDEE, CALCIFEDIOL
 RAYOS, PREDNISONE
 RAZADYNE, GALANTAMINE HYDROBROMIDE
 RAZADYNE ER, GALANTAMINE HYDROBROMIDE
 READI-CAT 2, BARIUM SULFATE
 READI-CAT 2 SMOOTHIES, BARIUM SULFATE
 REBETOL, RIBAVIRIN
 RECLAST, ZOLEDRONIC ACID
 RECTIV, NITROGLYCERIN
 REGITINE, PHENTOLAMINE MESYLATE
 REGLAN, METOCLOPRAMIDE HYDROCHLORIDE
 REGONOL, PYRIDOSTIGMINE BROMIDE
 RELENZA, ZANAMIVIR
 RELISTOR, METHYLNALTREXONE BROMIDE
 RELPAX, ELETRIPTAN HYDROBROMIDE
 REMERON, MIRTAZAPINE
 REMERON SOLTAB, MIRTAZAPINE
 REMODULIN, TREPROSTINIL
 RENACIDIN, CITRIC ACID
 RENAGEL, SEVELAMER HYDROCHLORIDE
 RENOGRAFIN-76, DIATRIZOATE MEGLUMINE
 RENOVA, TRETINOIN
 RENVELA, SEVELAMER CARBONATE
 REPAGLINIDE, REPAGLINIDE
 REPAGLINIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 REPREXAIN, HYDROCODONE BITARTRATE
 REQUIP, ROPINIROLE HYDROCHLORIDE
 REQUIP XL, ROPINIROLE HYDROCHLORIDE
 RESCRIPTOR, DELAVIRDINE MESYLATE
 RESECTISOL IN PLASTIC CONTAINER, MANNITOL
 RESERPINE, RESERPINE
 RESTASIS, CYCLOSPORINE
 RESTASIS MULTIDOSE, CYCLOSPORINE
 RESTORIL, TEMAZEPAM
 RETIN-A, TRETINOIN
 RETIN-A MICRO, TRETINOIN
 RETIN-A-MICRO, TRETINOIN
 RETISERT, FLUOCINOLONE ACETONIDE
 RETROVIR, ZIDOVUDINE
 REVATIO, SILDENAFIL CITRATE
 REVLIMID, LENALIDOMIDE
 REVONTO, DANTROLENE SODIUM
 REXULTI, BREXPIPIRAZOLE
 REYATAZ, ATAZANAVIR SULFATE
 REZIRA, HYDROCODONE BITARTRATE
 RHINOCORT ALLERGY, BUDESONIDE (OTC)
 RIBASPHERE, RIBAVIRIN
 RIBAVARIN, RIBAVIRIN
 RIBAVIRIN, RIBAVIRIN
 RIDAURA, AURANOFIN
 RIFABUTIN, RIFABUTIN
 RIFADIN, RIFAMPIN
 RIFAMATE, ISONIAZID
 RIFAMPIN, RIFAMPIN
 RIFATER, ISONIAZID
 RILUTEK, RILUZOLE
 RILUZOLE, RILUZOLE
 RIMACTANE, RIFAMPIN
 RIMANTADINE HYDROCHLORIDE, RIMANTADINE HYDROCHLORIDE
 RIMSO-50, DIMETHYL SULFOXIDE
 RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 RIOMET, METFORMIN HYDROCHLORIDE
 RISEDRONATE SODIUM, RISEDRONATE SODIUM

APPENDIX A - PRODUCT NAME INDEX

** R **

RISPERDAL, RISPERIDONE
 RISPERDAL CONSTA, RISPERIDONE
 RISPERIDONE, RISPERIDONE
 RITALIN, METHYLPHENIDATE HYDROCHLORIDE
 RITALIN LA, METHYLPHENIDATE HYDROCHLORIDE
 RITALIN-SR, METHYLPHENIDATE HYDROCHLORIDE
 RITONAVIR, RITONAVIR
 RIVASTIGMINE, RIVASTIGMINE
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 ROBAXIN, METHOCARBAMOL
 ROBAXIN-750, METHOCARBAMOL
 ROBINUL, GLYCOPYRROLATE
 ROBINUL FORTE, GLYCOPYRROLATE
 ROCALTROL, CALCITRIOL
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 ROGAINE (FOR MEN), MINOXIDIL (OTC)
 ROGAINE (FOR WOMEN), MINOXIDIL (OTC)
 ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
 ROSIGLITAZONE MALEATE, ROSIGLITAZONE MALEATE
 ROSIGLITAZONE MALEATE AND GLIMEPIRIDE, GLIMEPIRIDE
 ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 ROWASA, MESALAMINE
 ROXICET, ACETAMINOPHEN
 ROXICODONE, OXYCODONE HYDROCHLORIDE
 ROZEREM, RAMELTEON
 RUBRACA, RUCAPARIB CAMSYLATE
 RUBY-FILL, RUBIDIUM CHLORIDE RB-82
 RUFINAMIDE, RUFINAMIDE
 RYANODEX, DANTROLENE SODIUM
 RYTARY, CARBIDOPA
 RYTHMOL, PROPAFENONE HYDROCHLORIDE
 RYTHMOL SR, PROPAFENONE HYDROCHLORIDE
 RYZODEG 70/30, INSULIN ASPART

** S **

SABRIL, VIGABATRIN
 SAFYRAL, DROSPIRENONE
 SAIZEN, SOMATROPIN RECOMBINANT
 SALAGEN, PILOCARPINE HYDROCHLORIDE
 SALONPAS, MENTHOL (OTC)
 SALURON, HYDROFLUMETHIAZIDE
 SAMSCA, TOLVAPTAN
 SANCUSO, GRANISETRON
 SANDIMMUNE, CYCLOSPORINE
 SANDOSTATIN, OCTREOTIDE ACETATE
 SANDOSTATIN LAR, OCTREOTIDE ACETATE
 SAPHRIS, ASENAPINE MALEATE
 SARAFEM, FLUOXETINE HYDROCHLORIDE
 SAVAYSA, EDOXABAN TOSYLATE
 SAVELLA, MILNACIPRAN HYDROCHLORIDE
 SAXENDA, LIRAGLUTIDE RECOMBINANT
 SCANDONEST L, LEVONORDEFRIN
 SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE
 SCANLUX-300, IOPAMIDOL
 SCANLUX-370, IOPAMIDOL
 SCLEROSOL, TALC
 SCOPOLAMINE, SCOPOLAMINE
 SEASONALE, ETHINYL ESTRADIOL
 SEASONIQUE, ETHINYL ESTRADIOL
 SECONAL SODIUM, SECOBARBITAL SODIUM
 SECTRAL, ACEBUTOLOL HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

** S **

SEEBRI, GLYCOPYRROLATE
 SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
 SELENIUM SULFIDE, SELENIUM SULFIDE
 SELFEMRA, FLUOXETINE HYDROCHLORIDE
 SELSUN, SELENIUM SULFIDE
 SELZENTRY, MARAVIROC
 SEMPRES-D, ACRIVASTINE
 SENSIPAR, CINACALCET HYDROCHLORIDE
 SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
 SEPTOCAINE, ARTICAINE HYDROCHLORIDE
 SEPTRA, SULFAMETHOXAZOLE
 SEPTRA DS, SULFAMETHOXAZOLE
 SEREVENT, SALMETEROL XINAFOATE
 SERNIVO, BETAMETHASONE DIPROPIONATE
 SEROMYCIN, CYCLOSERINE
 SEROQUEL, QUETIAPINE FUMARATE
 SEROQUEL XR, QUETIAPINE FUMARATE
 SEROSTIM, SOMATROPIN RECOMBINANT
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SETLAKIN, ETHINYL ESTRADIOL
 SEVOFLURANE, SEVOFLURANE
 SFROWASA, MESALAMINE
 SHADE UVAGUARD, AVOBENZONE (OTC)
 SIGNIFOR, PASIREOTIDE DIASPARTATE
 SIGNIFOR LAR, PASIREOTIDE PAMOATE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SILENOR, DOXEPIN HYDROCHLORIDE
 SILVADENE, SILVER SULFADIAZINE
 SIMBRINZA, BRIMONIDINE TARTRATE
 SIMVASTATIN, SIMVASTATIN
 SINE-AID IB, IBUPROFEN (OTC)
 SINEMET, CARBIDOPA
 SINEMET CR, CARBIDOPA
 SINGULAIR, MONTELUKAST SODIUM
 SINOGRAFIN, DIATRIZOATE MEGLUMINE
 SIROLIMUS, SIROLIMUS
 SIRTURO, BEDAQUILINE FUMARATE
 SITAVIG, ACYCLOVIR
 SIVEXTRO, TEDIZOLID PHOSPHATE
 SKELAXIN, METAXALONE
 SKLICE, IVERMECTIN
 SKYLA, LEVONORGESTREL
 SMOFLIPID 20%, FISH OIL
 SODIUM ACETATE IN PLASTIC CONTAINER, SODIUM ACETATE ANHYDROUS
 SODIUM BICARBONATE, SODIUM BICARBONATE
 SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9% , SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE, SODIUM FERRIC GLUCONATE COMPLEX
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18
 SODIUM IODIDE I 123, SODIUM IODIDE I-123
 SODIUM IODIDE I 131, SODIUM IODIDE I-131
 SODIUM LACTATE IN PLASTIC CONTAINER, SODIUM LACTATE
 SODIUM NITRITE, SODIUM NITRITE
 SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
 SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE
 SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE
 SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
 SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
 SODIUM THIOSULFATE, SODIUM THIOSULFATE

APPENDIX A - PRODUCT NAME INDEX

** S **

SOJOURN, SEVOFLURANE
 SOLARAZE, DICLOFENAC SODIUM
 SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
 SOLIQUA 100/33, INSULIN GLARGINE
 SOLODYN, MINOCYCLINE HYDROCHLORIDE
 SOLTAMOX, TAMOXIFEN CITRATE
 SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE
 SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE
 SOMA, CARISOPRODOL
 SOMATULINE DEPOT, LANREOTIDE ACETATE
 SOMAVERT, PEGVISOMANT
 SONATA, ZALEPLON
 SOOLANTRA, IVERMECTIN
 SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL
 SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL
 SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL
 SORIATANE, ACITRETIN
 SORILUX, CALCIPOTRIENE
 SORINE, SOTALOL HYDROCHLORIDE
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
 SOTRADECOL, SODIUM TETRADECYL SULFATE
 SOTYLIZE, SOTALOL HYDROCHLORIDE
 SOVALDI, SOFOSBUVIR
 SPINRAZA, NUSINERSEN SODIUM
 SPIRIVA, TIOTROPIUM BROMIDE
 SPIRIVA RESPIMAT, TIOTROPIUM BROMIDE
 SPIRONOLACTONE, SPIRONOLACTONE
 SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 SPORANOX, ITRACONAZOLE
 SPRINTEC, ETHINYL ESTRADIOL
 SPRITAM, LEVETIRACETAM
 SPRIX, KETOROLAC TROMETHAMINE
 SPRYCEL, DASATINIB
 SPS, SODIUM POLYSTYRENE SULFONATE
 SSD, SILVER SULFADIAZINE
 SSD AF, SILVER SULFADIAZINE
 STALEVO 100, CARBIDOPA
 STALEVO 125, CARBIDOPA
 STALEVO 150, CARBIDOPA
 STALEVO 200, CARBIDOPA
 STALEVO 50, CARBIDOPA
 STALEVO 75, CARBIDOPA
 STARLIX, NATEGLINIDE
 STAVUDINE, STAVUDINE
 STAXYN, VARDENAFIL HYDROCHLORIDE
 STENDRA, AVANAFIL
 STERILE WATER, STERILE WATER FOR IRRIGATION
 STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
 STIE-CORT, HYDROCORTISONE
 STIMATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
 STIOLTO RESPIMAT, OLODATEROL HYDROCHLORIDE
 STIVARGA, REGORAFENIB
 STRATTERA, ATOMOXETINE HYDROCHLORIDE
 STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
 STRIANT, TESTOSTERONE
 STRIBILD, COBICISTAT
 STRIVERDI RESPIMAT, OLODATEROL HYDROCHLORIDE
 STROMECTOL, IVERMECTIN
 STRONTIUM CHLORIDE SR-89, STRONTIUM CHLORIDE SR-89
 SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE
 SUBOXONE, BUPRENORPHINE HYDROCHLORIDE
 SUBSYS, FENTANYL
 SUCRAID, SACROSIDASE
WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1086, p. 892 of 1400

APPENDIX A - PRODUCT NAME INDEX

** S **

SUCRALFATE, SUCRALFATE
 SUDAFED 12 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
 SUDAFED 24 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
 SUFENTA PRESERVATIVE FREE, SUFENTANIL CITRATE
 SUFENTANIL CITRATE, SUFENTANIL CITRATE
 SULAR, NISOLDIPINE
 SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
 SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 SULFADIAZINE, SULFADIAZINE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH, SULFAMETHOXAZOLE
 SULFAMYLON, MAFENIDE ACETATE
 SULFASALAZINE, SULFASALAZINE
 SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE
 SULINDAC, SULINDAC
 SUMATRIPTAN, SUMATRIPTAN
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 SUMAVEL DOSEPRO, SUMATRIPTAN SUCCINATE
 SUPPRELIN LA, HISTRELIN ACETATE
 SUPRANE, DESFLURANE
 SUPRAX, CEFIXIME
 SUPREP BOWEL PREP KIT, MAGNESIUM SULFATE ANHYDROUS
 SURMONTIL, TRIMIPRAMINE MALEATE
 SURVANTA, BERACTANT
 SUSTIVA, EFAVIRENZ
 SUSTOL, GRANISETRON
 SUTENT, SUNITINIB MALATE
 SYEDA, DROSPIRENONE
 SYMBICORT, BUDESONIDE
 SYMBYAX, FLUOXETINE HYDROCHLORIDE
 SYMLIN, PRAMLINTIDE ACETATE
 SYNACORT, HYDROCORTISONE
 SYNALAR, FLUOCINOLONE ACETONIDE
 SYNALGOS-DC, ASPIRIN
 SYNAREL, NAFARELIN ACETATE
 SYNERA, LIDOCAINE
 SYNERCID, DALFOPRISTIN
 SYNJARDY, EMPAGLIFLOZIN
 SYNJARDY XR, EMPAGLIFLOZIN
 SYNRIPO, OMACETAXINE MEPESUCCINATE
 SYNTHROID, LEVOTHYROXINE SODIUM **
 SYPRINE, TRIENTINE HYDROCHLORIDE

** T **

TAB-PROFEN, IBUPROFEN (OTC)
 TACLONEX, BETAMETHASONE DIPROPIONATE
 TACROLIMUS, TACROLIMUS
 TAFINLAR, DABRAFENIB MESYLATE
 TAGAMET HB, CIMETIDINE (OTC)
 TAGRISSO, OSIMERTINIB MESYLATE
 TALC, TALC
 TALWIN, PENTAZOCINE LACTATE
 TAMBOCOR, FLECAINIDE ACETATE
 TAMIFLU, OSELTAMIVIR PHOSPHATE
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TAPAZOLE, METHIMAZOLE
 TARCEVA, ERLLOTINIB HYDROCHLORIDE
 TARGRETIN, BEXAROTENE
 TARKA, TRANDOLAPRIL
 TASIGNA, NILOTINIB HYDROCHLORIDE MONOHYDRATE
 TASMAR, TOLCAPONE
 TAVIST-1, CLEMASTINE FUMARATE (OTC)
 TAXOL, PACLITAXEL

APPENDIX A - PRODUCT NAME INDEX

** T **

TAXOTERE, DOCETAXEL
 TAYTULLA, ETHINYL ESTRADIOL
 TAZICEF, CEFTAZIDIME
 TAZORAC, TAZAROTENE
 TAZTIA XT, DILTIAZEM HYDROCHLORIDE
 TECFIDERA, DIMETHYL FUMARATE
 TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
 TECHNESCAN, TECHNETIUM TC-99M OXIDRONATE KIT
 TECHNESCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT
 TECHNESCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT
 TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
 TECHNETIUM TC 99M GENERATOR, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
 TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
 TECHNETIUM TC-99M MEBROFENIN, TECHNETIUM TC-99M MEBROFENIN KIT
 TECHNETIUM TC-99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
 TECHNIVIE, OMBITASVIR
 TEFLARO, CEFTAROLINE FOSAMIL
 TEGRETOL, CARBAMAZEPINE
 TEGRETOL-XR, CARBAMAZEPINE
 TEKTURNA, ALISKIREN HEMIFUMARATE
 TEKTURNA HCT, ALISKIREN HEMIFUMARATE
 TELMISARTAN, TELMISARTAN
 TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TEMAZEPAM, TEMAZEPAM
 TEMODAR, TEMOZOLOMIDE
 TEMOZOLOMIDE, TEMOZOLOMIDE
 TENEX, GUANFACINE HYDROCHLORIDE
 TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
 TENORETIC 100, ATENOLOL
 TENORETIC 50, ATENOLOL
 TENORMIN, ATENOLOL
 TENUATE, DIETHYLPROPION HYDROCHLORIDE
 TENUATE DOSPAN, DIETHYLPROPION HYDROCHLORIDE
 TERAZOL 3, TERCONAZOLE
 TERAZOL 7, TERCONAZOLE
 TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE (OTC)
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 TERBUTALINE SULFATE, TERBUTALINE SULFATE
 TERCONAZOLE, TERCONAZOLE
 TERIL, CARBAMAZEPINE
 TERRAMYCIN W/ POLYMYXIN B SULFATE, OXYTETRACYCLINE HYDROCHLORIDE
 TESSALON, BENZONATATE
 TESTIM, TESTOSTERONE
 TESTOPEL, TESTOSTERONE
 TESTOSTERONE, TESTOSTERONE
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
 TESTRED, METHYLTESTOSTERONE
 TETRABENAZINE, TETRABENAZINE
 TETRACAINE HYDROCHLORIDE, TETRACAINE HYDROCHLORIDE
 TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
 TEVETEN, EPROSARTAN MESYLATE
 TEXACORT, HYDROCORTISONE
 THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
 THALOMID, THALIDOMIDE
 THAM, TROMETHAMINE
 THEO-24, THEOPHYLLINE
 THEOCHRON, THEOPHYLLINE
 THEOPHYLLINE, THEOPHYLLINE
 THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE

APPENDIX A - PRODUCT NAME INDEX

** T **

THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THERMAZENE, SILVER SULFADIAZINE
 THEROXIDIL, MINOXIDIL (OTC)
 THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
 THIOGUANINE, THIOGUANINE
 THIOLA, TIOPRONIN
 THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE
 THIOTEPA, THIOTEPA
 THIOTHIXENE, THIOTHIXENE
 THRIVE, NICOTINE POLACRILEX (OTC)
 THYROGEN, THYROTROPIN ALFA
 THYROLAR-0.25, LIOTRIX (T4)
 THYROLAR-0.5, LIOTRIX (T4)
 THYROLAR-1, LIOTRIX (T4)
 THYROLAR-2, LIOTRIX (T4)
 THYROLAR-3, LIOTRIX (T4)
 THYROSAFE, POTASSIUM IODIDE (OTC)
 THYROSHIELD, POTASSIUM IODIDE (OTC)
 TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE
 TIAZAC, DILTIAZEM HYDROCHLORIDE
 TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
 TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE
 TIGECYCLINE, TIGECYCLINE
 TIKOSYN, DOFETILIDE
 TIMOLOL, TIMOLOL
 TIMOLOL MALEATE, TIMOLOL MALEATE
 TIMOPTIC, TIMOLOL MALEATE
 TIMOPTIC IN OCUDOSE, TIMOLOL MALEATE
 TIMOPTIC-XE, TIMOLOL MALEATE
 TINDAMAX, TINIDAZOLE
 TINIDAZOLE, TINIDAZOLE
 TIOCONAZOLE, TIOCONAZOLE (OTC)
 TIROSINT, LEVOTHYROXINE SODIUM
 TIROSINT-SOL, LEVOTHYROXINE SODIUM
 TIS-U-SOL, MAGNESIUM SULFATE
 TIS-U-SOL IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 TIVICAY, DOLUTEGRAVIR SODIUM
 TIVORBEX, INDOMETHACIN
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TOBI, TOBRAMYCIN
 TOBI PODHALER, TOBRAMYCIN
 TOBRADEX, DEXAMETHASONE
 TOBRADEX ST, DEXAMETHASONE
 TOBRAMYCIN, TOBRAMYCIN
 TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 TOBRAMYCIN SULFATE (PHARMACY BULK), TOBRAMYCIN SULFATE
 TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, TOBRAMYCIN SULFATE
 TOBEX, TOBRAMYCIN
 TODAY, NONOXYNOL-9 (OTC)
 TOFRANIL, IMIPRAMINE HYDROCHLORIDE
 TOLAK, FLUOROURACIL
 TOLAZAMIDE, TOLAZAMIDE
 TOLBUTAMIDE, TOLBUTAMIDE
 TOLCAPONE, TOLCAPONE
 TOLMETIN SODIUM, TOLMETIN SODIUM
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
 TOPAMAX, TOPIRAMATE
 TOPICORT, DESOXIMETASONE
 TOPIRAMATE, TOPIRAMATE
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 TOPROL-XL, METOPROLOL SUCCINATE
 TORISEL, TEMSIROLIMUS
 TORSEMIDE, TORSEMIDE
 TOTECT, DEXRAZOXANE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

** T **

TOUJEO SOLOSTAR, INSULIN GLARGINE RECOMBINANT
 TOVIAZ, FESOTERODINE FUMARATE
 TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 TRACLEER, BOSENTAN
 TRADJENTA, LINAGLIPTIN
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 TRANDATE, LABETALOL HYDROCHLORIDE
 TRANDOLAPRIL, TRANDOLAPRIL
 TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE, TRANDOLAPRIL
 TRANEXAMIC ACID, TRANEXAMIC ACID
 TRANSDERM SCOP, SCOPOLAMINE
 TRANXENE, CLORAZEPATE DIPOTASSIUM
 TRANLYCYPROMINE SULFATE, TRANLYCYPROMINE SULFATE
 TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
 TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS
 TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS
 TRAVATAN Z, TRAVOPROST
 TRAVOPROST, TRAVOPROST
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
 TREANDA, BENDAMUSTINE HYDROCHLORIDE
 TRECATOR, ETHIONAMIDE
 TRELSTAR, TRIPTORELIN PAMOATE
 TRESIBA, INSULIN DEGLUDEC
 TRETINOIN, TRETINOIN
 TREXALL, METHOTREXATE SODIUM
 TREXIMET, NAPROXEN SODIUM
 TREZIX, ACETAMINOPHEN
 TRI LO SPRINTEC, ETHINYL ESTRADIOL
 TRI-ESTARYLLA, ETHINYL ESTRADIOL
 TRI-LEGEST 21, ETHINYL ESTRADIOL
 TRI-LEGEST FE, ETHINYL ESTRADIOL
 TRI-LINYAH, ETHINYL ESTRADIOL
 TRI-LO-ESTARYLLA, ETHINYL ESTRADIOL
 TRI-LO-MILI, ETHINYL ESTRADIOL
 TRI-LUMA, FLUOCINOLONE ACETONIDE
 TRI-MILI, ETHINYL ESTRADIOL
 TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL
 TRI-PREVIFEM, ETHINYL ESTRADIOL
 TRI-SPRINTEC, ETHINYL ESTRADIOL
 TRIACIN-C, CODEINE PHOSPHATE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE (OTC)
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 TRIAMCINOLONE ACETONIDE IN ABSORBASE, TRIAMCINOLONE ACETONIDE
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TRIAZOLAM, TRIAZOLAM
 TRIBENZOR, AMLODIPINE BESYLATE
 TRICOR, FENOFIBRATE
 TRIDERM, TRIAMCINOLONE ACETONIDE
 TRIDIONE, TRIMETHADIONE
 TRISENCE, TRIAMCINOLONE ACETONIDE
 TRIFERIC, FERRIC PYROPHOSPHATE CITRATE
 TRIFERIC, FERRIC PYROPHOSPHATE CITRATE
 TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
 TRIFLURIDINE, TRIFLURIDINE
 TRIGLIDE, FENOFIBRATE
 TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
 TRILEPTAL, OXCARBAZEPINE
 TRILIPIX, CHOLINE FENOFIBRATE
 TRILYTE, POLYETHYLENE GLYCOL 3350
 TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE
 TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE, TRIMETHOBENZAMIDE HYDROCHLORIDE
 TRIMETHOPRIM, TRIMETHOPRIM
 TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE

APPENDIX A - PRODUCT NAME INDEX

** T **

TRINTELLIX, VORTIOXETINE HYDROBROMIDE
 TRIOSTAT, LIOTHYRONINE SODIUM
 TRISENOX, ARSENIC TRIOXIDE
 TRIUMEQ, ABACAVIR SULFATE
 TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)
 TRIVORA-28, ETHINYL ESTRADIOL
 TRIZIVIR, ABACAVIR SULFATE
 TROKENDI XR, TOPIRAMATE
 TROPHAMINE, AMINO ACIDS
 TROPHAMINE 10%, AMINO ACIDS
 TROPICACYL, TROPICAMIDE
 TROPICAMIDE, TROPICAMIDE
 TROSPIMUM CHLORIDE, TROSPIMUM CHLORIDE
 TROXYCA ER, NALTREXONE HYDROCHLORIDE
 TRUSOPT, DORZOLAMIDE HYDROCHLORIDE
 TRUVADA, EMTRICITABINE
 TUDORZA PRESSAIR, ACLIDINIUM BROMIDE
 TUSSICAPS, CHLORPHENIRAMINE POLISTIREX
 TUSSIGON, HOMATROPINE METHYLBROMIDE
 TUSSIONEX PENNKINETIC, CHLORPHENIRAMINE POLISTIREX
 TUZISTRA XR, CHLORPHENIRAMINE POLISTIREX
 TWYNSTA, AMLODIPINE BESYLATE
 TYBOST, COBICISTAT
 TYGACIL, TIGECYCLINE
 TYKERB, LAPATINIB DITOSYLATE
 TYLENOL, ACETAMINOPHEN (OTC)
 TYLENOL W/ CODEINE NO. 3, ACETAMINOPHEN
 TYLENOL W/ CODEINE NO. 4, ACETAMINOPHEN
 TYVASO, TREPROSTINIL
 TYZEKA, TELBIVUDINE
 TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE

** U **

U-CORT, HYDROCORTISONE ACETATE
 UCERIS, BUDESONIDE
 ULESFIA, BENZYL ALCOHOL
 ULORIC, FEBUXOSTAT
 ULTANE, SEVOFLURANE
 ULTIVA, REMIFENTANIL HYDROCHLORIDE
 ULTRA-TECHNEKOW FM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
 ULTRACET, ACETAMINOPHEN
 ULTRAM, TRAMADOL HYDROCHLORIDE
 ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT
 ULTRAVATE, HALOBETASOL PROPIONATE
 ULTRAVIST (PHARMACY BULK), IOPROMIDE
 ULTRAVIST 150, IOPROMIDE
 ULTRAVIST 240, IOPROMIDE
 ULTRAVIST 300, IOPROMIDE
 ULTRAVIST 300 IN PLASTIC CONTAINER, IOPROMIDE
 ULTRAVIST 370, IOPROMIDE
 ULTRESA, PANCRELIPASE (AMYLASE)
 UNASYN, AMPICILLIN SODIUM
 UNISOM, DOXYLAMINE SUCCINATE (OTC)
 UNITHROID, LEVOTHYROXINE SODIUM **
 UPTRAVI, SELEXIPAG
 URECHOLINE, BETHANECHOL CHLORIDE
 UREX, METHENAMINE HIPPURATE
 UROCIT-K, POTASSIUM CITRATE
 UROXATRAL, ALFUZOSIN HYDROCHLORIDE
 URSO 250, URSODIOL
 URSO FORTE, URSODIOL
 URSODIOL, URSODIOL
 UTIBRON, GLYCOPYRROLATE
 UVADEX, METHOXSALLEN

APPENDIX A - PRODUCT NAME INDEX

** v **

VAGIFEM, ESTRADIOL
 VAGISTAT-1, TIOCONAZOLE (OTC)
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VALCHLOR, MECHLORETHAMINE HYDROCHLORIDE
 VALCYTE, VALGANCICLOVIR HYDROCHLORIDE
 VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
 VALIUM, DIAZEPAM
 VALNAC, BETAMETHASONE VALERATE
 VALPROATE SODIUM, VALPROATE SODIUM
 VALPROIC ACID, VALPROIC ACID
 VALSARTAN, VALSARTAN
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VALSTAR PRESERVATIVE FREE, VALRUBICIN
 VALTRES, VALACYCLOVIR HYDROCHLORIDE
 VALTROPIN, SOMATROPIN RECOMBINANT
 VANCOCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
 VANDAZOLE, METRONIDAZOLE
 VANIQA, EFLORNITHINE HYDROCHLORIDE
 VANOS, FLUOCINONIDE
 VANTAS, HISTRELIN ACETATE
 VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER, CONIVAPTAN HYDROCHLORIDE
 VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE
 VARIBAR, BARIUM SULFATE
 VARITHENA, POLIDOCANOL
 VARUBI, ROLAPITANT HYDROCHLORIDE
 VASCEPA, ICOSAPENT ETHYL
 VASERETIC, ENALAPRIL MALEATE
 VASOSTRICT, VASOPRESSIN
 VASOTEC, ENALAPRIL MALEATE
 VAZCULEP, PHENYLEPHRINE HYDROCHLORIDE
 VECTICAL, CALCITRIOL
 VECURONIUM BROMIDE, VECURONIUM BROMIDE
 VELCADE, BORTEZOMIB
 VELETRI, EPOPROSTENOL SODIUM
 VELIVET, DESOGESTREL
 VELPHORO, SUCROFERRIC OXYHYDROXIDE
 VELTASSA, PATIROMER SORBITE X CALCIUM
 VELTIN, CLINDAMYCIN PHOSPHATE
 VEMLIDY, TENOFOVIR ALAFENAMIDE FUMARATE
 VENCLEXTA, VENETOCLAX
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 VENOFER, IRON SUCROSE
 VENTAVIS, ILOPROST
 VENTOLIN HFA, ALBUTEROL SULFATE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
 VERDESO, DESONIDE
 VEREGEN, SINECATECHINS
 VERELAN, VERAPAMIL HYDROCHLORIDE
 VERELAN PM, VERAPAMIL HYDROCHLORIDE
 VERMOX, MEBENDAZOLE
 VERSACLOZ, CLOZAPINE
 VESICARE, SOLIFENACIN SUCCINATE
 VFEND, VORICONAZOLE
 VIAGRA, SILDENAFIL CITRATE
 VIBATIV, TELAVANCIN HYDROCHLORIDE
 VIBERZI, ELUXADOLINE
 VIBISONE, CYANOCOBALAMIN
 VIBRAMYCIN, DOXYCYCLINE
 VIBRAMYCIN, DOXYCYCLINE CALCIUM
 VIBRAMYCIN, DOXYCYCLINE HYCLATE
 VICOPROFEN, HYDROCODONE BITARTRATE
 VICTOZA, LIRAGLUTIDE RECOMBINANT

APPENDIX A - PRODUCT NAME INDEX

** V **

VIDAZA, AZACITIDINE
 VIDEX, DIDANOSINE
 VIDEX EC, DIDANOSINE
 VIEKIRA PAK (COPACKAGED), DASABUVIR SODIUM
 VIEKIRA XR, DASABUVIR SODIUM
 VIENVA, ETHINYL ESTRADIOL
 VIGAMOX, MOXIFLOXACIN HYDROCHLORIDE
 VIIBRYD, VILAZODONE HYDROCHLORIDE
 VIMOVO, ESOMEPRAZOLE MAGNESIUM
 VIMPAT, LACOSAMIDE
 VINBLASTINE SULFATE, VINBLASTINE SULFATE
 VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE
 VINORELBINE TARTRATE, VINORELBINE TARTRATE
 VIOKACE, PANCRELIPASE (AMYLASE)
 VIORELE, DESOGESTREL
 VIRACEPT, NELFINAVIR MESYLATE
 VIRAMUNE, NEVIRAPINE
 VIRAMUNE XR, NEVIRAPINE
 VIRAZOLE, RIBAVIRIN
 VIREAD, TENOFOVIR DISOPROXIL FUMARATE
 VIROPTIC, TRIFLURIDINE
 VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)
 VISINE-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
 VISIONBLUE, TRYPAN BLUE
 VISIPAQUE 270, IODIXANOL
 VISIPAQUE 320, IODIXANOL
 VISTARIL, HYDROXYZINE PAMOATE
 VISTOGARD, URIDINE TRIACETATE
 VISUDYNE, VERTEPORFIN
 VITAMIN D, ERGOCALCIFEROL
 VITAMIN K1, PHYTONADIONE
 VITEKTA, ELVITEGRAVIR
 VITRASE, HYALURONIDASE
 VITUZ, CHLORPHENIRAMINE MALEATE
 VIVACTIL, PROTRIPTYLINE HYDROCHLORIDE
 VIVELLE, ESTRADIOL
 VIVELLE-DOT, ESTRADIOL
 VIVITROL, NALTREXONE
 VIVLODEX, MELOXICAM
 VIZAMYL, FLUTEMETAMOL F-18
 VOGELXO, TESTOSTERONE
 VOLNEA, DESOGESTREL
 VOLTAREN, DICLOFENAC SODIUM
 VORICONAZOLE, VORICONAZOLE
 VOSOL, ACETIC ACID, GLACIAL
 VOSOL HC, ACETIC ACID, GLACIAL
 VOSPIRE ER, ALBUTEROL SULFATE
 VOTRIENT, PAZOPANIB HYDROCHLORIDE
 VPRIV, VELAGLUCERASE ALFA
 VRAYLAR, CARIPRAZINE HYDROCHLORIDE
 VUMON, TENIPOSIDE
 VUSION, MICONAZOLE NITRATE
 VYFEMLA, ETHINYL ESTRADIOL
 VYTORIN, EZETIMIBE
 VYVANSE, LISDEXAMFETAMINE DIMESYLATE

** W **

WARFARIN SODIUM, WARFARIN SODIUM
 WELCHOL, COLESEVELAM HYDROCHLORIDE
 WELLBUTRIN SR, BUPROPION HYDROCHLORIDE
 WELLBUTRIN XL, BUPROPION HYDROCHLORIDE
 WERA, ETHINYL ESTRADIOL
 WOMEN'S ROGAINE, MINOXIDIL (OTC)

** X **

APPENDIX A - PRODUCT NAME INDEX

** X **

XALATAN, LATANOPROST
 XALKORI, CRIZOTINIB
 XANAX, ALPRAZOLAM
 XANAX XR, ALPRAZOLAM
 XARELTO, RIVAROXABAN
 KARTEMIS XR, ACETAMINOPHEN
 XELJANZ, TOFACITINIB CITRATE
 XELJANZ XR, TOFACITINIB CITRATE
 XELODA, CAPECITABINE
 XENAZINE, TETRABENAZINE
 XENICAL, ORLISTAT
 XENON XE 133, XENON XE-133
 XERESE, ACYCLOVIR
 XIFAXAN, RIFAXIMIN
 XIGDUO XR, DAPAGLIFLOZIN PROPANEDIOL
 XIIDRA, LIFITEGRAST
 XOFIGO, RADIUM RA-223 DICHLORIDE
 XOLEGEL, KETOCONAZOLE
 XOPENEX, LEVALBUTEROL HYDROCHLORIDE
 XOPENEX HFA, LEVALBUTEROL TARTRATE
 XTAMPZA ER, OXYCODONE
 XTANDI, ENZALUTAMIDE
 XTORO, FINAFLOXACIN
 XULANE, ETHINYL ESTRADIOL
 XULTOPHY 100/3.6, INSULIN DEGLUDEC
 XURIDEN, URIDINE TRIACETATE
 XYLOCAINE, LIDOCAINE HYDROCHLORIDE
 XYLOCAINE 4% PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
 XYLOCAINE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
 XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE
 XYREM, SODIUM OXYBATE
 XYZAL, LEVOCETIRIZINE DIHYDROCHLORIDE

** Y **

YAELA, DROSPIRENONE
 YASMIN, DROSPIRENONE
 YAZ, DROSPIRENONE
 YONDELIS, TRABECTEDIN
 YOSPRALA, ASPIRIN

** Z **

ZAFIRLUKAST, ZAFIRLUKAST
 ZALEPLON, ZALEPLON
 ZANAFLEX, TIZANIDINE HYDROCHLORIDE
 ZANOSAR, STREPTOZOCIN
 ZANTAC, RANITIDINE HYDROCHLORIDE
 ZANTAC 150, RANITIDINE HYDROCHLORIDE (OTC)
 ZANTAC 150, RANITIDINE HYDROCHLORIDE
 ZANTAC 300, RANITIDINE HYDROCHLORIDE
 ZANTAC 75, RANITIDINE HYDROCHLORIDE (OTC)
 ZARONTIN, ETHOSUXIMIDE
 ZAROXOLYN, METOLAZONE
 ZAVESCA, MIGLUSTAT
 ZECUITY, SUMATRIPTAN SUCCINATE
 ZEGERID, OMEPRAZOLE
 ZEGERID OTC, OMEPRAZOLE (OTC)
 ZELAPAR, SELEGILINE HYDROCHLORIDE
 ZELBORAF, VEMURAFENIB
 ZEMBRACE SYMTOUCH, SUMATRIPTAN SUCCINATE
 ZEMPLAR, PARICALCITOL
 ZENATANE, ISOTRETINOIN
 ZENPEP, PANCRELIPASE (AMYLASE)
 ZEPATIER, ELBASVIR
 ZERBAXA, CEFTOLOZANE SULFATE
 ZERIT, STAVUDINE

APPENDIX A - PRODUCT NAME INDEX

** Z **

ZESTORETIC, HYDROCHLOROTHIAZIDE
 ZESTRIL, LISINAPRIL
 ZETIA, EZETIMIBE
 ZETONNA, CICLESONIDE
 ZIAC, BISOPROLOL FUMARATE
 ZIAGEN, ABACAVIR SULFATE
 ZIANA, CLINDAMYCIN PHOSPHATE
 ZIDOVUDINE, ZIDOVUDINE
 ZINACEF, CEFUROXIME SODIUM
 ZINACEF IN PLASTIC CONTAINER, CEFUROXIME SODIUM
 ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE
 ZINECARD, DEXRAZOXANE HYDROCHLORIDE
 ZINGO, LIDOCAINE HYDROCHLORIDE
 ZIOPTAN, TAFLUPROST
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
 ZIPSOR, DICLOFENAC POTASSIUM
 ZIRGAN, GANCICLOVIR
 ZITHROMAX, AZITHROMYCIN
 ZMAX, AZITHROMYCIN
 ZOCOR, SIMVASTATIN
 ZOFRAN, ONDANSETRON HYDROCHLORIDE
 ZOFRAN ODT, ONDANSETRON
 ZOHYDRO ER, HYDROCODONE BITARTRATE
 ZOLADEX, GOSERELIN ACETATE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID
 ZOLINZA, VORINOSTAT
 ZOLMITRIPTAN, ZOLMITRIPTAN
 ZOLOFT, SERTRALINE HYDROCHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
 ZOLPIMIST, ZOLPIDEM TARTRATE
 ZOMACTON, SOMATROPIN RECOMBINANT
 ZOMETA, ZOLEDRONIC ACID
 ZOMIG, ZOLMITRIPTAN
 ZOMIG-ZMT, ZOLMITRIPTAN
 ZONALON, DOXEPIN HYDROCHLORIDE
 ZONEGRAN, ZONISAMIDE
 ZONISAMIDE, ZONISAMIDE
 ZONTIVITY, VORAPAXAR SULFATE
 ZORBTIVE, SOMATROPIN RECOMBINANT
 ZORTRESS, EVEROLIMUS
 ZORVOLEX, DICLOFENAC
 ZOSYN, PIPERACILLIN SODIUM
 ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM
 ZOVIA 1/35E-28, ETHINYL ESTRADIOL
 ZOVIA 1/50E-28, ETHINYL ESTRADIOL
 ZOVIRAX, ACYCLOVIR
 ZUBSOLV, BUPRENORPHINE HYDROCHLORIDE
 ZUPLENZ, ONDANSETRON
 ZURAMPIC, LESINURAD
 ZUTRIPRO, CHLORPHENIRAMINE MALEATE
 ZYBAN, BUPROPION HYDROCHLORIDE
 ZYCLARA, IMIQIMOD
 ZYDELIG, IDELALISIB
 ZYFLO, ZILEUTON
 ZYFLO CR, ZILEUTON
 ZYFREL, ACETAMINOPHEN
 ZYKADIA, CERITINIB
 ZYLET, LOTEHPREDNOL ETABONATE
 ZYLOPRIM, ALLOPURINOL
 ZYMAR, GATIFLOXACIN
 ZYMAXID, GATIFLOXACIN
 ZYPREXA, OLANZAPINE
 ZYPREXA RELPREVV, OLANZAPINE PAMOATE
 ZYPREXA ZYDIS, OLANZAPINE
 ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)

APPENDIX A - PRODUCT NAME INDEX

**** Z ****

ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
ZYRTEC-D 12 HOUR, CETIRIZINE HYDROCHLORIDE (OTC)
ZYTIGA, ABIRATERONE ACETATE
ZYVOX, LINEZOLID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** 3 ******3D IMAGING DRUG**

- * 3D IMAGING DRUG DESIGN AND DEVELOPMENT LLC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

3M

- * 3M CO
PERIDEX, CHLORHEXIDINE GLUCONATE
- * 3M HEALTH CARE INC
AVAGARD, ALCOHOL (OTC)
DURAPREP, IODINE POVACRYLEX (OTC)
- * 3M PHARMACEUTICALS INC
PROVENTIL-HFA, ALBUTEROL SULFATE

3M DRUG DELIVERY

- * 3M DRUG DELIVERY SYSTEMS DIVISION
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-75, FENTANYL

**** A ******AAA USA INC**

- * ADVANCED ACCELERATOR APPLICATIONS USA INC
NETSPOT, GALLIUM DOTATATE GA-68

AAIPHARMA LLC

- * AAIPHARMA LLC
AZASAN, AZATHIOPRINE

ABBVIE

- * ABBVIE INC
ANDROGEL, TESTOSTERONE
BIAXIN, CLARITHROMYCIN
CREON, PANCRELIPASE (AMYLASE)
CYCLOSPORINE, CYCLOSPORINE
DEPAON, VALPROATE SODIUM
DEPAKENE, VALPROIC ACID
DEPAKOTE ER, DIVALPROEX SODIUM
DEPAKOTE, DIVALPROEX SODIUM
GENGRAF, CYCLOSPORINE
K-TAB, POTASSIUM CHLORIDE
KALETRA, LOPINAVIR
MARINOL, DRONABINOL
MAVIK, TRANDOLAPRIL
MIVACRON, MIVACURIUM CHLORIDE
NIASPAN, NIACIN
NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE
NIMBEX, CISATRACURIUM BESYLATE
NORVIR, RITONAVIR
SURVANTA, BERACTANT
SYNTHROID, LEVOTHYROXINE SODIUM **
TARKA, TRANDOLAPRIL
TEVETEN, EPROSARTAN MESYLATE
TRICOR, FENOFIBRATE
TRIDIONE, TRIMETHADIONE
TRILIPIX, CHOLINE FENOFIBRATE
ULTANE, SEVOFLURANE
VICOPROFEN, HYDROCODONE BITARTRATE
ZEMPLAR, PARICALCITOL

ABBVIE ENDOCRINE

- * ABBVIE ENDOCRINE INC
LUPANETA PACK, LEUPROLIDE ACETATE

ABBVIE ENDOCRINE INC

- * ABBVIE ENDOCRINE INC
LUPRON DEPOT, LEUPROLIDE ACETATE
LUPRON DEPOT-RED, LEUPROLIDE ACETATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******ABBVIE INC**

* ABBVIE INC
 DUOPA, CARBIDOPA
 TECHNIVIE, OMBITASVIR
 VENCLEXTA, VENETOCLAX
 VIEKIRA PAK (COPACKAGED), DASABUVIR SODIUM
 VIEKIRA XR, DASABUVIR SODIUM

ABHAI

* ABHAI LLC
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

ABHAI INC

* ABHAI INC
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE

ABRAXIS BIOSCIENCE

* ABRAXIS BIOSCIENCE LLC
 ABRAXANE, PACLITAXEL

ABRAXIS PHARM

* ABRAXIS PHARMACEUTICAL PRODUCTS
 CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE

ACADIA PHARMS INC

* ACADIA PHARMACEUTICALS INC
 NUPLAZID, PIMAVANSERIN TARTRATE

ACCELRX LABS

* ACCELRX LABS LLC
 CARISOPRODOL, CARISOPRODOL

ACCORD HLTHCARE

* ACCORD HEALTHCARE INC
 ALLOPURINOL, ALLOPURINOL
 AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 ANASTROZOLE, ANASTROZOLE
 ARIPIPIRAZOLE, ARIPIPIRAZOLE
 BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
 BICALUTAMIDE, BICALUTAMIDE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 CAPECITABINE, CAPECITABINE
 CARBIDOPA AND LEVODOPA, CARBIDOPA
 CISPLATIN, CISPLATIN
 CLONAZEPAM, CLONAZEPAM
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 CLOZAPINE, CLOZAPINE
 DOCETAXEL, DOCETAXEL
 DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
 ETOPOSIDE, ETOPOSIDE
 FINASTERIDE, FINASTERIDE
 FLUOROURACIL, FLUOROURACIL
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 GLIMEPIRIDE, GLIMEPIRIDE
 GLIPIZIDE, GLIPIZIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 ITRACONAZOLE, ITRACONAZOLE
 LETROZOLE, LETROZOLE
 LEVETIRACETAM, LEVETIRACETAM
 LISINAPRIL, LISINAPRIL
 METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
 METHYLDOPA, METHYLDOPA
 MITOMYCIN, MITOMYCIN
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******* ACCORD HEALTHCARE INC**

NORETHINDRONE, NORETHINDRONE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 PARICALCITOL, PARICALCITOL
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SIMVASTATIN, SIMVASTATIN
 TACROLIMUS, TACROLIMUS
 TOPIRAMATE, TOPIRAMATE
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

ACCORD HLTHCARE INC*** ACCORD HEALTHCARE INC USA**

DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 FINASTERIDE, FINASTERIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RAMIPRIL, RAMIPRIL
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 SPIRONOLACTONE, SPIRONOLACTONE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

ACELLA PHARMS LLC*** ACELLA PHARMACEUTICALS LLC**

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
 GABAPENTIN, GABAPENTIN

ACI HEALTHCARE LTD*** ACI HEALTHCARE LTD**

GABAPENTIN, GABAPENTIN
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

ACIC FINE CHEMS*** ACIC FINE CHEMICALS INC**

TRANEXAMIC ACID, TRANEXAMIC ACID

ACORDA*** ACORDA THERAPEUTICS INC**

AMPYRA, DALFAMPRIDINE
 QUTENZA, CAPSAICIN
 ZANAFLEX, TIZANIDINE HYDROCHLORIDE

ACS DOBFAR*** ACS DOBFAR SPA**

AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
 CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
 CEFOXITIN, CEFOXITIN SODIUM
 CEFTAZIDIME, CEFTAZIDIME
 CEFTRIAXONE, CEFTRIAXONE SODIUM
 IMIPENEM AND CILASTATIN, CILASTATIN SODIUM
 KEFZOL, CEFAZOLIN SODIUM
 MEROPENEM, MEROPENEM

ACS DOBFAR INFO SA*** ACS DOBFAR INFO SA**

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

ACS DOBFAR SPA*** ACS DOBFAR SPA**

AMPICILLIN SODIUM, AMPICILLIN SODIUM
 CEFOXITIN, CEFOXITIN SODIUM

ACTAVIS ELIZABETH*** ACTAVIS ELIZABETH LLC**

ALPRAZOLAM, ALPRAZOLAM
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ACTAVIS ELIZABETH LLC
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 CARBIDOPA AND LEVODOPA, CARBIDOPA
 CLONAZEPAM, CLONAZEPAM
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 DEFERASIROX, DEFERASIROX
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 FENOFIBRIC ACID, CHOLINE FENOFIBRATE
 FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
 GABAPENTIN, GABAPENTIN
 GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 INDAPAMIDE, INDAPAMIDE
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
 LAMOTRIGINE, LAMOTRIGINE
 LEVETIRACETAM, LEVETIRACETAM
 LOVASTATIN, LOVASTATIN
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 MORPHINE SULFATE, MORPHINE SULFATE
 NIFEDIPINE, NIFEDIPINE
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
 OXAZEPAM, OXAZEPAM
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 PROPYLTHIOURACIL, PROPYLTHIOURACIL
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 SPIRONOLACTONE, SPIRONOLACTONE
 TEMAZEPAM, TEMAZEPAM
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

ACTAVIS GRP PTC

* ACTAVIS GROUP PTC EHF
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

ACTAVIS INC

* ACTAVIS INC
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DOCETAXEL, DOCETAXEL
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 METHOXSALEN, METHOXSALEN
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

ACTAVIS LABS FL INC

* ACTAVIS LABORATORIES FL INC
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CABERGOLINE, CABERGOLINE
 CARTIA XT, DILTIAZEM HYDROCHLORIDE
 CLARITHROMYCIN, CLARITHROMYCIN
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
 DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ACTAVIS LABORATORIES FL INC
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE, DOXYLAMINE SUCCINATE
 DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE
 DUTASTERIDE, DUTASTERIDE
 FLUTAMIDE, FLUTAMIDE
 GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
 GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
 GUAIFENESIN, GUAIFENESIN (OTC)
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 KETOPROFEN, KETOPROFEN
 LACOSAMIDE, LACOSAMIDE
 LEVETIRACETAM, LEVETIRACETAM
 LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
 LORATADINE, LORATADINE (OTC)
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 MIRTAZAPINE, MIRTAZAPINE
 NAPROXEN SODIUM, NAPROXEN SODIUM
 NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
 OMEPRAZOLE, OMEPRAZOLE
 OXYCODONE AND ASPIRIN, ASPIRIN
 PALIPERIDONE, PALIPERIDONE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 RAMELTEON, RAMELTEON
 RISPERIDONE, RISPERIDONE
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
 TAZTIA XT, DILTIAZEM HYDROCHLORIDE
 TRANEXAMIC ACID, TRANEXAMIC ACID
 TROSPIMUM CHLORIDE, TROSPIMUM CHLORIDE
 VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

ACTAVIS LABS NY INC

* ACTAVIS LABORATORIES NY INC
 NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)

ACTAVIS LABS UT INC

* ACTAVIS LABORATORIES UT INC
 CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
 CLONIDINE, CLONIDINE
 EMLA, LIDOCAINE
 FENTANYL-100, FENTANYL
 FENTANYL-25, FENTANYL
 FENTANYL-50, FENTANYL
 FENTANYL-75, FENTANYL
 FIORICET W/ CODEINE, ACETAMINOPHEN
 FIORICET, ACETAMINOPHEN
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 LIDOCAINE, LIDOCAINE
 NORINYL 1+50 28-DAY, MESTRANOL
 TENUATE DOSPAN, DIETHYLPROPION HYDROCHLORIDE
 TENUATE, DIETHYLPROPION HYDROCHLORIDE
 TESTOSTERONE, TESTOSTERONE

ACTAVIS LLC

* ACTAVIS LLC
 AZACITIDINE, AZACITIDINE
 LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
 MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE

ACTAVIS MID ATLANTIC

* ACTAVIS MID ATLANTIC LLC
 ACETASOL HC, ACETIC ACID, GLACIAL
 ACYCLOVIR, ACYCLOVIR
 ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ACTAVIS MID ATLANTIC LLC
 ADAPALENE, ADAPALENE
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 CICLOPIROX, CICLOPIROX
 CLINDAMYCIN PHOSPHATE AND TRETINOIN, CLINDAMYCIN PHOSPHATE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
 DESOXIMETASONE, DESOXIMETASONE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 ENULOSE, LACTULOSE
 FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
 GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
 HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
 HYDROCORTISONE, HYDROCORTISONE
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 LEVETIRACETAM, LEVETIRACETAM
 M-ZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 MICONAZOLE 7, MICONAZOLE NITRATE (OTC)
 MICONAZOLE NITRATE, MICONAZOLE NITRATE
 MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
 MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
 MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
 NITROFURANTOIN, NITROFURANTOIN
 NYSTATIN, NYSTATIN
 PERMETHRIN, PERMETHRIN
 PERMETHRIN, PERMETHRIN (OTC)
 PROMETH VC W/ CODEINE, CODEINE PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 VALNAC, BETAMETHASONE VALERATE

ACTAVIS TOTOWA

* ACTAVIS TOTOWA LLC
 BICALUTAMIDE, BICALUTAMIDE
 DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 FINASTERIDE, FINASTERIDE
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 OXALIPLATIN, OXALIPLATIN
 PACLITAXEL, PACLITAXEL
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 REPAGLINIDE, REPAGLINIDE
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 VINOURELBINE TARTRATE, VINOURELBINE TARTRATE

ACTELION PHARMS LTD

* ACTELION PHARMACEUTICALS LTD
 OPSUMIT, MACITENTAN
 TRACLEER, BOSENTAN
 UPTRAVI, SELEXIPAG
 VALCHLOR, MECHLORETHAMINE HYDROCHLORIDE
 VELETRI, EPOPROSTENOL SODIUM
 VENTAVIS, ILOPROST
 ZAVESCA, MIGLUSTAT

ACTIENT PHARMS

* ACTIENT PHARMACEUTICALS LLC
 THEO-24, THEOPHYLLINE

ADAPT

* ADAPT PHARMA OPERATIONS LTD
 NARCAN, NALOXONE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******ADARE PHARMS INC**

* ADARE PHARMACEUTICALS INC
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

AEGERION

* AEGERION PHARMACEUTICALS INC
JUXTAPID, LOMITAPIDE MESYLATE

AGOURON

* AGOURON PHARMACEUTICALS INC
VIRACEPT, NELFINAVIR MESYLATE

AILEX PHARMS PVT LTD

* AILEX PHARMACEUTICALS PVT LTD
SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE

AIPING PHARM INC

* AIPING PHARMACEUTICAL INC
FOLIC ACID, FOLIC ACID
IBUPROFEN, IBUPROFEN

AJANTA PHARMA

* AJANTA PHARMA LTD
LEVETIRACETAM, LEVETIRACETAM

AJANTA PHARMA LTD

* AJANTA PHARMA LTD
ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
ARIPIPIRAZOLE, ARIPIPIRAZOLE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
IRBESARTAN, IRBESARTAN
LANSOPRAZOLE, LANSOPRAZOLE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
OLANZAPINE, OLANZAPINE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
RISPERIDONE, RISPERIDONE
VORICONAZOLE, VORICONAZOLE
ZOLMITRIPTAN, ZOLMITRIPTAN

AKORN

* AKORN INC
ADENOSINE, ADENOSINE
AK-FLUOR 10%, FLUORESCHEIN SODIUM
AK-FLUOR 25%, FLUORESCHEIN SODIUM
AKBETA, LEVOBUNOLOL HYDROCHLORIDE
AKPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
AKTEN, LIDOCAINE HYDROCHLORIDE
AKTOB, TOBRAMYCIN
ALFENTA, ALFENTANIL HYDROCHLORIDE
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOCAPROIC, AMINOCAPROIC ACID
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
ATROPINE SULFATE, ATROPINE SULFATE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BAL, DIMERCAPROL
BALANCED SALT, CALCIUM CHLORIDE
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
CALCITRIOL, CALCITRIOL
CAPASTAT SULFATE, CAPREOMYCIN SULFATE
CARBOPLATIN, CARBOPLATIN
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CROMOLYN SODIUM, CROMOLYN SODIUM
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
DESOXIMETASONE, DESOXIMETASONE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
ENDOSOL EXTRA, CALCIUM CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******* AKORN INC**

ERYTHROMYCIN, ERYTHROMYCIN
 ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
 ETHOSUXIMIDE, ETHOSUXIMIDE
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 GENTAK, GENTAMICIN SULFATE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 IC-GREEN, INDOCYANINE GREEN
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
 LATANOPROST, LATANOPROST
 LEVOFLOXACIN, LEVOFLOXACIN
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LORAZEPAM, LORAZEPAM
 NEDOCROMIL SODIUM, NEDOCROMIL SODIUM
 NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
 NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
 OFLOXACIN, OFLOXACIN
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 PAREMYD, HYDROXYAMPHETAMINE HYDROBROMIDE
 PYRAZINAMIDE, PYRAZINAMIDE
 RIFAMPIN, RIFAMPIN
 SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE
 SUFENTA PRESERVATIVE FREE, SUFENTANIL CITRATE
 SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
 TERBUTALINE SULFATE, TERBUTALINE SULFATE
 TIMOLOL MALEATE, TIMOLOL MALEATE
 TIMOLOL, TIMOLOL
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 TRANEXAMIC ACID, TRANEXAMIC ACID
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 TROPICACYL, TROPICAMIDE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VORICONAZOLE, VORICONAZOLE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

AKORN INC*** AKORN INC**

ACETYLCYSTEINE, ACETYLCYSTEINE
 APRACLONIDINE HYDROCHLORIDE, APRACLONIDINE HYDROCHLORIDE
 CEFTRIAZONE, CEFTRIAZONE SODIUM
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
 CYCLOPENTOLATE HYDROCHLORIDE, CYCLOPENTOLATE HYDROCHLORIDE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
 DOXERCALCIFEROL, DOXERCALCIFEROL
 DRONABINOL, DRONABINOL
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 INAPSINE, DROPERIDOL
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)
 NAPHAZOLINE HYDROCHLORIDE, NAPHAZOLINE HYDROCHLORIDE
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
 PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
 ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
 TOBRAMYCIN, TOBRAMYCIN
 TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* AKORN INC
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

ALARA PHARM

* ALARA PHARMACEUTICAL CORPORATION
 LEVO-T, LEVOTHYROXINE SODIUM **

ALCON

* ALCON LABORATORIES INC
 BETOPTIC, BETAXOLOL HYDROCHLORIDE
 BSS PLUS, CALCIUM CHLORIDE
 BSS, CALCIUM CHLORIDE
 CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE
 CROMOLYN SODIUM, CROMOLYN SODIUM
 DENDRID, IDOXURIDINE
 MAXITROL, DEXAMETHASONE
 MIOSTAT, CARBACHOL
 MYDRIACYL, TROPICAMIDE
 NAPHCN-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
 NATACYN, NATAMYCIN
 TOBREX, TOBRAMYCIN

ALCON LABS INC

* ALCON LABORATORIES INC
 LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE

ALCON PHARMA

* ALCON RESEARCH LTD
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE

ALCON PHARMS LTD

* ALCON PHARMACEUTICALS LTD
 BETADINE, POVIDONE-IODINE
 BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
 NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
 OFLOXACIN, OFLOXACIN
 QOLIANA, BRIMONIDINE TARTRATE
 SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
 TRIFLURIDINE, TRIFLURIDINE

ALCON RES

* ALCON RESEARCH LTD
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
 LATANOPROST, LATANOPROST

ALCON RES LTD

* ALCON RESEARCH LTD
 BIMATOPROST, BIMATOPROST
 EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
 GATIFLOXACIN, GATIFLOXACIN
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE
 METIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
 TIMOLOL MALEATE, TIMOLOL MALEATE
 TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE

ALEMBIC LTD

* ALEMBIC LTD
 LITHIUM CARBONATE, LITHIUM CARBONATE
 METRONIDAZOLE, METRONIDAZOLE
 MODAFINIL, MODAFINIL
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 THEOPHYLLINE, THEOPHYLLINE
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

ALEMBIC PHARMS LTD

* ALEMBIC PHARMACEUTICALS LTD
WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1086, p. 911 of 1400

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******* ALEMBIC PHARMACEUTICALS LTD**

AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
 ARIPIPIRAZOLE, ARIPIPIRAZOLE
 CELECOXIB, CELECOXIB
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
 DESVENLAFAXINE, DESVENLAFAXINE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 FAMOTIDINE, FAMOTIDINE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN
 ITRACONAZOLE, ITRACONAZOLE
 LACOSAMIDE, LACOSAMIDE
 LAMOTRIGINE, LAMOTRIGINE
 LEFLUNOMIDE, LEFLUNOMIDE
 LINEZOLID, LINEZOLID
 LITHIUM CARBONATE, LITHIUM CARBONATE
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 MEPROBAMATE, MEPROBAMATE
 METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 METRONIDAZOLE, METRONIDAZOLE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
 TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TELMISARTAN, TELMISARTAN
 VALSARTAN, VALSARTAN
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 ZOLMITRIPTAN, ZOLMITRIPTAN

ALEXZA PHARMS

*** ALEXZA PHARMACEUTICALS INC**
 ADASUVE, LOXAPINE

ALIMERA SCIENCES INC

*** ALIMERA SCIENCES INC**
 ILUVIEN, FLUOCINOLONE ACETONIDE

ALKEM

*** ALKEM LABORATORIES LTD**
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 GABAPENTIN, GABAPENTIN
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

ALKEM LABS LTD

*** ALKEM LABORATORIES LTD**
 CEFUROXIME AXETIL, CEFUROXIME AXETIL
 CEPHALEXIN, CEPHALEXIN
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 FINASTERIDE, FINASTERIDE
 GABAPENTIN, GABAPENTIN
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 LAMOTRIGINE, LAMOTRIGINE
 LINEZOLID, LINEZOLID
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 OLANZAPINE, OLANZAPINE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RILUZOLE, RILUZOLE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE

ALKERMES

*** ALKERMES INC**
 VIVITROL, NALTREXONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******ALKERMES INC**

* ALKERMES INC
ARISTADA, ARIPIPIRAZOLE LAUROXIL

ALLEGIANCE HLTHCARE

* ALLEGIANCE HEALTHCARE CORP
POVIDONE IODINE, POVIDONE-IODINE (OTC)

ALLERGAN

* ALLERGAN
ACULAR LS, KETOROLAC TROMETHAMINE
ALPHAGAN P, BRIMONIDINE TARTRATE
BLEPH-10, SULFACETAMIDE SODIUM
GENOPTIC, GENTAMICIN SULFATE
ZYMEXID, GATIFLOXACIN

* ALLERGAN INC
ACULAR, KETOROLAC TROMETHAMINE
ACUVAIL, KETOROLAC TROMETHAMINE
ACZONE, DAPSONE
ALOCRIL, NEDOCROMIL SODIUM
ALPHAGAN P, BRIMONIDINE TARTRATE
AVAGE, TAZAROTENE
AZELEX, AZELAIC ACID
COMBIGAN, BRIMONIDINE TARTRATE
ELESTAT, EPINASTINE HYDROCHLORIDE
LASTACFT, ALCAFTADINE
LATISSE, BIMATOPROST
LUMIGAN, BIMATOPROST
OCUFLOX, OFLOXACIN
OZURDEX, DEXAMETHASONE
POLYTRIM, POLYMYXIN B SULFATE
RESTASIS MULTIDOSE, CYCLOSPORINE
RESTASIS, CYCLOSPORINE
TAZORAC, TAZAROTENE
ZYMEX, GATIFLOXACIN

* ALLERGAN PHARMACEUTICAL
BETAGAN, LEVOBUNOLOL HYDROCHLORIDE
BLEPHAMIDE S.O.P., PREDNISOLONE ACETATE
BLEPHAMIDE, PREDNISOLONE ACETATE
FML FORTE, FLUOROMETHOLONE
FML, FLUOROMETHOLONE
OCUFEN, FLURBIPROFEN SODIUM
PRED FORTE, PREDNISOLONE ACETATE
PRED MILD, PREDNISOLONE ACETATE
PRED-G, GENTAMICIN SULFATE

ALLERGAN HOLDINGS

* ALLERGAN HOLDINGS UNLTD CO
VIBERZI, ELUXADOLINE

ALLERGAN INC

* ALLERGAN INC
ACZONE, DAPSONE

ALLERGAN SALES LLC

* ALLERGAN SALES LLC
ACTIGALL, URSODIOL
ALORA, ESTRADIOL
ANDRODERM, TESTOSTERONE
BREVICON 28-DAY, ETHINYL ESTRADIOL
CONDYLOX, PODOFILOX
CORDRAN, FLURANDRENOLIDE
CRINONE, PROGESTERONE
ESTRACE, ESTRADIOL
FIORINAL W/CODEINE, ASPIRIN
FIORINAL, ASPIRIN
GELNIQUE 3%, OXYBUTYNIN
GELNIQUE, OXYBUTYNIN CHLORIDE
INFED, IRON DEXTRAN
KADIAN, MORPHINE SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******* ALLERGAN SALES LLC**

MICROZIDE, HYDROCHLOROTHIAZIDE
 NORINYL 1+35 21-DAY, ETHINYL ESTRADIOL
 NORINYL 1+35 28-DAY, ETHINYL ESTRADIOL
 NUVESSA, METRONIDAZOLE
 OXYTROL FOR WOMEN, OXYBUTYNIN (OTC)
 OXYTROL, OXYBUTYNIN
 PROGESTERONE, PROGESTERONE
 RAPAFLO, SILODOSIN
 TRELSTAR, TRIPTORELIN PAMOATE
 TRETINOIN, TRETINOIN

ALLERQUEST

*** ALLERQUEST LLC**
 PRE-PEN, BENZYLPENICILLOYL POLYLYSINE

ALLIED PHARMA INC

*** ALLIED PHARMA INC**
 CLARITHROMYCIN, CLARITHROMYCIN
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 METRONIDAZOLE, METRONIDAZOLE

ALLOS

*** ALLOS THERAPEUTICS INC**
 FOLOTYN, PRALATREXATE

ALPHARMA

*** ALPHARMA USPD INC**
 PREDNISOLONE, PREDNISOLONE
 VALPROIC ACID, VALPROIC ACID

ALPHARMA PHARMS

*** ALPHARMA PHARMACEUTICALS LLC**
 EMBEDA, MORPHINE SULFATE

ALRA

*** ALRA LABORATORIES INC**
 CHOLAC, LACTULOSE
 CONSTILAC, LACTULOSE
 GEN-XENE, CLORAZEPATE DIPOTASSIUM
 IBU-TAB 200, IBUPROFEN (OTC)
 IBU-TAB, IBUPROFEN

ALTAIRE PHARMS INC

*** ALTAIRE PHARMACEUTICALS INC**
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)
 OFLOXACIN, OFLOXACIN

ALTATHERA PHARMS LLC

*** ALTATHERA PHARMACEUTICALS LLC**
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

ALVOGEN

*** ALVOGEN GROUP HOLDINGS 2 LLC**
 DAPSONE, DAPSONE
 OFLOXACIN, OFLOXACIN

*** ALVOGEN GROUP HOLDINGS LLC**
 ADALAT CC, NIFEDIPINE

*** ALVOGEN INC**
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE

ALVOGEN INC

*** ALVOGEN INC**
 ACETYLCYSTEINE, ACETYLCYSTEINE
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE
 VORICONAZOLE, VORICONAZOLE

ALVOGEN MALTA

*** ALVOGEN MALTA OPERATIONS LTD**
 ATENOLOL AND CHLORTHALIDONE, ATENOLOL
 ATENOLOL, ATENOLOL
 BUDESONIDE, BUDESONIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******* ALVOGEN MALTA OPERATIONS LTD**

CARBIDOPA, CARBIDOPA
 DISULFIRAM , DISULFIRAM
 EXEMESTANE, EXEMESTANE
 FELBAMATE, FELBAMATE
 MACROBID, NITROFURANTOIN
 MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE
 NAPRELAN, NAPROXEN SODIUM
 NATEGLINIDE, NATEGLINIDE
 NEVIRAPINE, NEVIRAPINE
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
 RIVASTIGMINE, RIVASTIGMINE
 TENORETIC 100, ATENOLOL
 TENORETIC 50, ATENOLOL
 TENORMIN, ATENOLOL
 ZESTORETIC, HYDROCHLOROTHIAZIDE
 ZESTRIL, LISINOPRIL

AM ANTIBIOTICS*** AMERICAN ANTIBIOTICS INC**

AMOXICILLIN, AMOXICILLIN

AMAG PHARMA USA*** AMAG PHARMA USA INC**

MAKENA PRESERVATIVE FREE, HYDROXYPROGESTERONE CAPROATE
 MAKENA, HYDROXYPROGESTERONE CAPROATE

AMAG PHARMS INC*** AMAG PHARMACEUTICALS INC**

FERAHEME, FERUMOXYTOL

AMARIN PHARMS*** AMARIN PHARMACEUTICALS IRELAND LTD**

VASCEPA, ICOSAPENT ETHYL

AMEDRA PHARMS*** AMEDRA PHARMACEUTICALS LLC**

ADRENACLICK, EPINEPHRINE
 DEXEDRINE, DEXTROAMPHETAMINE SULFATE

AMEDRA PHARMS LLC*** AMEDRA PHARMACEUTICALS LLC**

ALBENZA, ALBENDAZOLE
 EMVERM, MEBENDAZOLE

AMERIGEN PHARMS LTD*** AMERIGEN PHARMACEUTICALS LTD**

CARBIDOPA, CARBIDOPA
 INDAPAMIDE, INDAPAMIDE
 TEMOZOLOMIDE, TEMOZOLOMIDE

AMGEN*** AMGEN INC**

SENSIPAR, CINACALCET HYDROCHLORIDE

AMGEN INC*** AMGEN INC**

CORLANOR, IVABRADINE HYDROCHLORIDE

AMHERST PHARMS LLC*** AMHERST PHARMACEUTICALS LLC**

ZOLPIMIST, ZOLPIDEM TARTRATE

AMNEAL PHARM*** AMNEAL PHARMACEUTICAL**

ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
 BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
 DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
 FLECAINIDE ACETATE, FLECAINIDE ACETATE
 FOLIC ACID, FOLIC ACID
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 PRIMIDONE, PRIMIDONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******AMNEAL PHARMS***** AMNEAL PHARMACEUTICALS**

ACYCLOVIR, ACYCLOVIR
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
 ARIPIPIRAZOLE, ARIPIPIRAZOLE
 ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
 ATOVAQUONE, ATOVAQUONE
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 CALCIUM ACETATE, CALCIUM ACETATE
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DUTASTERIDE, DUTASTERIDE
 ENTECAVIR, ENTECAVIR
 EPTIFIBATIDE, EPTIFIBATIDE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 ESTRADIOL, ESTRADIOL
 FELBAMATE, FELBAMATE
 GABAPENTIN, GABAPENTIN
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 IBUPROFEN, IBUPROFEN (OTC)
 INDOMETHACIN, INDOMETHACIN
 ITRACONAZOLE, ITRACONAZOLE
 LACOSAMIDE, LACOSAMIDE
 LEVETIRACETAM, LEVETIRACETAM
 LIDOCAINE, LIDOCAINE
 LINEZOLID, LINEZOLID
 LORAZEPAM, LORAZEPAM
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 MEROPENEM, MEROPENEM
 METAXALONE, METAXALONE
 MILNACIPRAN HYDROCHLORIDE, MILNACIPRAN HYDROCHLORIDE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 NIACIN, NIACIN
 NITROFURANTOIN, NITROFURANTOIN
 NIZATIDINE, NIZATIDINE
 NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
 OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXCARBAZEPINE, OXCARBAZEPINE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PARICALCITOL, PARICALCITOL
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
 QUININE SULFATE, QUININE SULFATE
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SPIRONOLACTONE, SPIRONOLACTONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

- * AMNEAL PHARMACEUTICALS
 - TELMISARTAN, TELMISARTAN
 - TEMAZEPAM, TEMAZEPAM
 - TEMOZOLOMIDE, TEMOZOLOMIDE
 - TOBRAMYCIN, TOBRAMYCIN
 - TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 - VALSARTAN, VALSARTAN
 - VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 - VORICONAZOLE, VORICONAZOLE
 - WARFARIN SODIUM, WARFARIN SODIUM
- * AMNEAL PHARMACEUTICALS HOLDINGS GMBH
 - DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
- * AMNEAL PHARMACEUTICALS LLC
 - TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
- * AMNEAL PHARMACEUTICALS OF NEW YORK LLC
 - LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 - NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 - NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 - NORETHINDRONE, NORETHINDRONE
 - NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL

AMNEAL PHARMS CO

- * AMNEAL PHARMACEUTICALS CO GMBH
 - DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
 - FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 - FUROSEMIDE, FUROSEMIDE
 - METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
 - VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

AMNEAL PHARMS LLC

- * AMNEAL PHARMACEUTICALS LLC
 - ACTIVELLA, ESTRADIOL
 - AZATHIOPRINE, AZATHIOPRINE
 - BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE

AMNEAL PHARMS NY

- * AMNEAL PHARMACEUTICALS NY LLC
 - ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 - ALPRAZOLAM, ALPRAZOLAM
 - AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 - CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 - CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 - CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 - EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
 - GABAPENTIN, GABAPENTIN
 - HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 - HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
 - IBUPROFEN, IBUPROFEN
 - IBUPROFEN, IBUPROFEN (OTC)
 - METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 - NAPROXEN SODIUM, NAPROXEN SODIUM
 - NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 - NAPROXEN, NAPROXEN
 - OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 - PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 - RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 - REPREXAIN, HYDROCODONE BITARTRATE
 - SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

AMPHASTAR PHARM

- * AMPHASTAR PHARMACEUTICAL INC
 - AMPHADASE, HYALURONIDASE
 - ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
 - KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE

AMPHASTAR PHARMS INC

- * AMPHASTAR PHARMACEUTICALS INC
 - BUMETANIDE, BUMETANIDE
 - CORTROSYN, COSYNTROPIN
 - DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******* AMPHASTAR PHARMACEUTICALS INC**

DIPYRIDAMOLE, DIPYRIDAMOLE
 DOXAPRAM HYDROCHLORIDE, DOXAPRAM HYDROCHLORIDE
 ENALAPRILAT, ENALAPRILAT
 FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 TERBUTALINE SULFATE, TERBUTALINE SULFATE
 VALPROATE SODIUM, VALPROATE SODIUM

ANACOR PHARMS INC

*** ANACOR PHARMACEUTICALS INC**
 EUCRISA, CRISABOROLE
 KERYDIN, TAVABOROLE

ANBEX

*** ANBEX INC**
 IOSAT, POTASSIUM IODIDE (OTC)

ANBISON LAB CO LTD

*** ANBISON LABORATORY CO LTD**
 MONTELUKAST SODIUM, MONTELUKAST SODIUM

ANCHEN PHARMS

*** ANCHEN PHARMACEUTICALS INC**
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE
 FENOFIBRIC ACID, CHOLINE FENOFIBRATE
 FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
 LAMOTRIGINE, LAMOTRIGINE
 LEVETIRACETAM, LEVETIRACETAM
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 TRETINOIN, TRETINOIN
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

*** ANCHEN PHARMACEUTICALS TAIWAN INC**
 DIVALPROEX SODIUM, DIVALPROEX SODIUM

*** ANCHEN PHARMACEUTICALS, INC**
 ALPRAZOLAM, ALPRAZOLAM
 CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

ANDRX LABS LLC

*** ANDRX LABS LLC**
 FORTAMET, METFORMIN HYDROCHLORIDE

ANI PHARMS

*** ANI PHARMACEUTICALS INC**
 CORTENEMA, HYDROCORTISONE
 LACTULOSE, LACTULOSE
 LUVOX, FLUVOXAMINE MALEATE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 REGLAN, METOCLOPRAMIDE HYDROCHLORIDE

ANI PHARMS INC

*** ANI PHARMACEUTICALS INC**
 ALPRAZOLAM, ALPRAZOLAM
 CEFUROXIME AXETIL, CEFUROXIME AXETIL
 CHLORPROPAMIDE, CHLORPROPAMIDE
 CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
 DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
 ETODOLAC, ETODOLAC
 FLECAINIDE ACETATE, FLECAINIDE ACETATE
 FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
 GLIPIZIDE, GLIPIZIDE
 GUANABENZ ACETATE, GUANABENZ ACETATE
 INDAPAMIDE, INDAPAMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ANI PHARMACEUTICALS INC
 INDERAL LA, PROPRANOLOL HYDROCHLORIDE
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
 LITHOBID, LITHIUM CARBONATE
 LORAZEPAM, LORAZEPAM
 METHAZOLAMIDE, METHAZOLAMIDE
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 NILUTAMIDE, NILUTAMIDE
 NIZATIDINE, NIZATIDINE
 OXCARBAZEPINE, OXCARBAZEPINE
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
 PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 RISPERIDONE, RISPERIDONE
 TESTOSTERONE, TESTOSTERONE
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VALPROIC ACID, VALPROIC ACID
 VANCOICIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

ANTARES PHARMA INC

* ANTARES PHARMA INC
 OTREXUP, METHOTREXATE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE

ANTIBIOTICE

* ANTIBIOTICE SA
 AMPICILLIN SODIUM, AMPICILLIN SODIUM
 NAFCILLIN SODIUM, NAFCILLIN SODIUM

ANTIBIOTICS SA

* ANTIBIOTICS SA
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM

ANTRIM PHARMS LLC

* ANTRIM PHARMACEUTICALS LLC
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE

APEX PHARMS INC

* APEX PHARMACEUTICALS INC
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE

APGDI

* ASTELLAS PHARMA GLOBAL DEVELOPMENT INC
 MYRBETRIQ, MIRABEGRON

APIL

* ALLERGAN PHARMACEUTICALS INTERNATIONAL LTD
 ACTONEL, RISEDRONATE SODIUM
 ASACOL HD, MESALAMINE
 ATELVIA, RISEDRONATE SODIUM
 DELZICOL, MESALAMINE
 DIDRONEL, ETIDRONATE DISODIUM
 ENABLEX, DARIFENACIN HYDROBROMIDE
 ESTROSTEP FE, ETHINYL ESTRADIOL
 FEMCON FE, ETHINYL ESTRADIOL
 FEMHRT, ETHINYL ESTRADIOL
 FEMRING, ESTRADIOL ACETATE
 FEMTRACE, ESTRADIOL ACETATE
 LO LOESTRIN FE, ETHINYL ESTRADIOL
 LO MINASTRIN FE, ETHINYL ESTRADIOL
 LOESTRIN 21 1.5/30, ETHINYL ESTRADIOL
 LOESTRIN 21 1/20, ETHINYL ESTRADIOL
 LOESTRIN 24 FE, ETHINYL ESTRADIOL
 LOESTRIN FE 1.5/30, ETHINYL ESTRADIOL
 LOESTRIN FE 1/20, ETHINYL ESTRADIOL
 MINASTRIN 24 FE, ETHINYL ESTRADIOL
 NOR-QD, NORETHINDRONE
 NORCO, ACETAMINOPHEN
 NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 SARAFEM, FLUOXETINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ALLERGAN PHARMACEUTICALS INTERNATIONAL LTD
TAYTULLA, ETHINYL ESTRADIOL

AOPHARMA INC

* AOPHARMA INC
FERRIPROX, DEFERIPRONE

APOTEX

* APOTEX CORP
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE

* APOTEX INC
ALENDRONATE SODIUM, ALENDRONATE SODIUM
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CIMETIDINE, CIMETIDINE
CIMETIDINE, CIMETIDINE (OTC)
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CYCLOSPORINE, CYCLOSPORINE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
EPLERENONE, EPLERENONE
ETODOLAC, ETODOLAC
FAMCICLOVIR, FAMCICLOVIR
FAMOTIDINE, FAMOTIDINE
FLUCONAZOLE, FLUCONAZOLE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
GEMFIBROZIL, GEMFIBROZIL
GLIPIZIDE, GLIPIZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LAMIVUDINE, LAMIVUDINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
OMEPRAZOLE, OMEPRAZOLE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PENTOXIFYLLINE, PENTOXIFYLLINE
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
RAMIPRIL, RAMIPRIL
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE

APOTEX CORP

* APOTEX CORP
AZITHROMYCIN, AZITHROMYCIN
CABERGOLINE, CABERGOLINE
CLARITHROMYCIN, CLARITHROMYCIN
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
RILUZOLE, RILUZOLE
SILDENAFIL CITRATE, SILDENAFIL CITRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******* APOTEX CORP**

TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

APOTEX INC*** APOTEX INC**

ABACAVIR SULFATE, ABACAVIR SULFATE
 ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
 ALKERAN, MELPHALAN
 ALKERAN, MELPHALAN HYDROCHLORIDE
 ALPRAZOLAM, ALPRAZOLAM
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
 ANASTROZOLE, ANASTROZOLE
 ARIPIPIRAZOLE, ARIPIPIRAZOLE
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 BENZONATATE, BENZONATATE
 BICALUTAMIDE, BICALUTAMIDE
 BIMATOPROST, BIMATOPROST
 BROMFENAC SODIUM, BROMFENAC SODIUM
 BUDESONIDE, BUDESONIDE
 BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
 CALCITONIN-SALMON, CALCITONIN SALMON
 CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
 CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
 CARBAMAZEPINE, CARBAMAZEPINE
 CARBIDOPA AND LEVODOPA, CARBIDOPA
 CEFPROZIL, CEFPROZIL
 CELECOXIB, CELECOXIB
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
 CICLOPIROX, CICLOPIROX
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 DASATINIB, DASATINIB
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 DUTASTERIDE, DUTASTERIDE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 FENOFIBRATE (MICRONIZED), FENOFIBRATE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE (OTC)
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 IMATINIB MESYLATE, IMATINIB MESYLATE
 IMIQUIMOD, IMIQUIMOD
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN
 LAMIVUDINE, LAMIVUDINE
 LAMOTRIGINE, LAMOTRIGINE
 LETROZOLE, LETROZOLE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LEVOFLOXACIN, LEVOFLOXACIN
 LOVASTATIN, LOVASTATIN
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 MODAFINIL, MODAFINIL
 MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
 MOMETASONE FUROATE, MOMETASONE FUROATE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
 NABUMETONE, NABUMETONE
 NEVIRAPINE, NEVIRAPINE
 OFLOXACIN, OFLOXACIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

- * APOTEX INC
 OLANZAPINE, OLANZAPINE
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
 OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
 OXCARBAZEPINE, OXCARBAZEPINE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RAMIPRIL, RAMIPRIL
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
 RASAGILINE MESYLATE, RASAGILINE MESYLATE
 RISEDRONATE SODIUM, RISEDRONATE SODIUM
 RISPERIDONE, RISPERIDONE
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TIMOLOL MALEATE, TIMOLOL MALEATE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 TRANEXAMIC ACID, TRANEXAMIC ACID
 TRAVOPROST, TRAVOPROST
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID
 ZOLMITRIPTAN, ZOLMITRIPTAN
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
- * APOTEX INC ETOBICOKE SITE
 ACYCLOVIR, ACYCLOVIR
 ALLOPURINOL, ALLOPURINOL
 BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CARBAMAZEPINE, CARBAMAZEPINE
 CARVEDILOL, CARVEDILOL
 CILOSTAZOL, CILOSTAZOL
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DILTIZAC, DILTIAZEM HYDROCHLORIDE
 ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
 ETODOLAC, ETODOLAC
 FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
 GABAPENTIN, GABAPENTIN
 LEFLUNOMIDE, LEFLUNOMIDE
 LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LISINOPRIL, LISINOPRIL
 LORATADINE, LORATADINE (OTC)
 MELOXICAM, MELOXICAM
 MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
 MIRTAZAPINE, MIRTAZAPINE
 OXAPROZIN, OXAPROZIN
 SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
 TOPIRAMATE, TOPIRAMATE
 TORSEMIDE, TORSEMIDE
 ZONISAMIDE, ZONISAMIDE
- * APOTEX INC RICHMOND HILL
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 BUDESONIDE, BUDESONIDE (OTC)
 DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
 FLUNISOLIDE, FLUNISOLIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

- * APOTEX INC RICHMOND HILL
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
RISPERIDONE, RISPERIDONE
- * APOTEX INC.
DILTZAC, DILTIAZEM HYDROCHLORIDE
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE

APOTEX TECHNOLOGIES

- * APOTEX TECHNOLOGIES INC
PAXIL CR, PAROXETINE HYDROCHLORIDE
PAXIL, PAROXETINE HYDROCHLORIDE

APOTHECON

- * APOTHECON INC DIV BRISTOL MYERS SQUIBB
KENALOG-10, TRIAMCINOLONE ACETONIDE
KENALOG-40, TRIAMCINOLONE ACETONIDE

APP PHARMS

- * APP PHARMACEUTICALS LLC
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE

APPCO PHARMA LLC

- * APPCO PHARMA LLC
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
LAMIVUDINE, LAMIVUDINE
METRONIDAZOLE, METRONIDAZOLE
VORICONAZOLE, VORICONAZOLE

APRECIA PHARMS CO

- * APRECIA PHARMACEUTICALS CO
SPRITAM, LEVETIRACETAM

AQUA PHARMS

- * AQUA PHARMACEUTICALS
ACTICLATE CAP, DOXYCYCLINE HYCLATE
CORDRAN SP, FLURANDRENOLIDE
CORDRAN, FLURANDRENOLIDE
MONODOX, DOXYCYCLINE
VERDESO, DESONIDE
- * AQUA PHARMACEUTICALS LLC
FLUOROPLEX, FLUOROURACIL
XOLEGEL, KETOCONAZOLE

AQUA PHARMS LLC

- * AQUA PHARMACEUTICALS LLC
ACTICLATE, DOXYCYCLINE HYCLATE
ALTABAX, RETAPAMULIN
VELTIN, CLINDAMYCIN PHOSPHATE

ARALEZ PHARMS

- * ARALEZ PHARMACEUTICALS TRADING DAC
YOSPRALA, ASPIRIN
ZONTIVITY, VORAPAXAR SULFATE

ARALEZ PHARMS INC

- * ARALEZ PHARMACEUTICALS INC
FIBRICOR, FENOFIBRIC ACID

ARBOR PHARMS LLC

- * ARBOR PHARMACEUTICALS LLC
BIDIL, HYDRALAZINE HYDROCHLORIDE
CETYLEV, ACETYLCYSTEINE
E.E.S. 400, ERYTHROMYCIN ETHYLSUCCINATE
E.E.S., ERYTHROMYCIN ETHYLSUCCINATE
EDARBI, AZILSARTAN KAMEDOXOMIL
EDARBYCLOR, AZILSARTAN KAMEDOXOMIL
ERY-TAB, ERYTHROMYCIN
ERYPED, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROCIN STEARATE, ERYTHROMYCIN STEARATE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN, ERYTHROMYCIN
EVEKEO, AMPHETAMINE SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ARBOR PHARMACEUTICALS LLC
 GLIADEL, CARMUSTINE
 HORIZANT, GABAPENTIN ENACARBIL
 NYMALIZE, NIMODIPINE
 PCE, ERYTHROMYCIN
 SKLICE, IVERMECTIN
 SOTYLIZE, SOTALOL HYDROCHLORIDE

ARCO PHARMS LLC

* ARCO PHARMACEUTICALS LLC
 THYROSHIELD, POTASSIUM IODIDE (OTC)

AREVA PHARMS

* AREVA PHARMACEUTICALS INC
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM

ARIAD

* ARIAD PHARMACEUTICALS INC
 ICLUSIG, PONATINIB HYDROCHLORIDE

ASCEND THERAPS US

* ASCEND THERAPEUTICS US LLC
 ESTROGEL, ESTRADIOL

ASCENT PHARMS INC

* ASCENT PHARMACEUTICALS INC
 DUTASTERIDE, DUTASTERIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

ASPEN GLOBAL

* ASPEN GLOBAL INC
 MYLERAN, BUSULFAN

ASPEN GLOBAL INC

* ASPEN GLOBAL INC
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
 CYCLESSA, DESOGESTREL
 HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
 LEUKERAN, CHLORAMBUCIL
 THIOGUANINE, THIOGUANINE

ASTELLAS

* ASTELLAS PHARMA US INC
 ADENOCARD, ADENOSINE
 AMBISOME, AMPHOTERICIN B
 ASTAGRAF XL, TACROLIMUS
 CRESEMBA, ISAVUCONAZONIUM SULFATE
 LEXISCAN, REGADENOSON
 MYCAMINE, MICAFUNGIN SODIUM
 PROGRAF, TACROLIMUS
 VESICARE, SOLIFENACIN SUCCINATE
 XTANDI, ENZALUTAMIDE

ASTRAZENECA

* ASTRAZENECA LP
 PULMICORT FLEXHALER, BUDESONIDE
 SYMBICORT, BUDESONIDE

* ASTRAZENECA PHARMACEUTICALS LP
 ATACAND HCT, CANDESARTAN CILEXETIL
 ATACAND, CANDESARTAN CILEXETIL
 FASLODEX, FULVESTRANT
 SEROQUEL XR, QUETIAPINE FUMARATE
 ZOMIG, ZOLMITRIPTAN
 ZOMIG-ZMT, ZOLMITRIPTAN

* ASTRAZENECA UK LTD
 ARIMIDEX, ANASTROZOLE
 CASODEX, BICALUTAMIDE
 MERREM, MEROPENEM
 ZOLADEX, GOSERELIN ACETATE

ASTRAZENECA AB

* ASTRAZENECA AB
 BYDUREON PEN, EXENATIDE SYNTHETIC
 BYDUREON, EXENATIDE SYNTHETIC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ASTRAZENECA AB
 BYETTA, EXENATIDE SYNTHETIC
 FARXIGA, DAPAGLIFLOZIN PROPANEDIOL
 KOMBIGLYZE XR, METFORMIN HYDROCHLORIDE
 ONGLYZA, SAXAGLIPTIN HYDROCHLORIDE
 SYMLIN, PRAMLINTIDE ACETATE
 XIGDUO XR, DAPAGLIFLOZIN PROPANEDIOL

ASTRAZENECA LP

* ASTRAZENECA LP
 BRILINTA, TICAGRELOR
 NEXIUM 24HR, ESOMEPRAZOLE MAGNESIUM (OTC)

ASTRAZENECA PHARMS

* ASTRAZENECA PHARMACEUTICALS LP
 DALIRESP, ROFLUMILAST
 EPANOVA, OMEGA-3-CARBOXYLIC ACIDS
 IRESSA, GEFITINIB
 LYNPARZA, OLAPARIB
 MOVANTIK, NALOXEGOL OXALATE
 NEXIUM IV, ESOMEPRAZOLE SODIUM
 NEXIUM, ESOMEPRAZOLE MAGNESIUM
 PRILOSEC OTC, OMEPRAZOLE MAGNESIUM (OTC)
 PRILOSEC, OMEPRAZOLE MAGNESIUM
 PULMICORT RESPULES, BUDESONIDE
 RHINOCORT ALLERGY, BUDESONIDE (OTC)
 SEROQUEL, QUETIAPINE FUMARATE
 TAGRISSO, OSIMERTINIB MESYLATE
 TOPROL-XL, METOPROLOL SUCCINATE
 TUDORZA PRESSAIR, ACLIDINIUM BROMIDE

ATLAS PHARMS LLC

* ATLAS PHARMACEUTICALS LLC
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN

ATNAHS PHARMA US

* ATNAHS PHARMA US LTD
 ANAPROX DS, NAPROXEN SODIUM
 ANAPROX, NAPROXEN SODIUM
 EC-NAPROSYN, NAPROXEN
 NAPROSYN, NAPROXEN

ATON

* ATON PHARMA INC
 CUPRIMINE, PENICILLAMINE
 EDECRIN, ETHACRYNATE SODIUM
 EDECRIN, ETHACRYNIC ACID
 LACRISERT, HYDROXYPROPYL CELLULOSE
 LODOSYN, CARBIDOPA
 SYPRINE, TRIENTINE HYDROCHLORIDE
 TIMOPTIC IN OCUDOSE, TIMOLOL MALEATE
 TIMOPTIC, TIMOLOL MALEATE

ATON PHARMA VPNA

* ATON PHARMA DIV VALEANT PHARMACEUTICALS NORTH AMERICA LLC
 DEMSER, METYROSINE

AUROBINDO

* AUROBINDO PHARMA LTD
 AMOXICILLIN, AMOXICILLIN
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 CLARITHROMYCIN, CLARITHROMYCIN
 DIDANOSINE, DIDANOSINE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 LISINAPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LISINAPRIL, LISINAPRIL
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 MIRTAZAPINE, MIRTAZAPINE
 NEVIRAPINE, NEVIRAPINE
 ZIDOVUDINE, ZIDOVUDINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******AUROBINDO PHARM**

* AUROBINDO PHARMA USA INC
 FLUCONAZOLE, FLUCONAZOLE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 GABAPENTIN, GABAPENTIN
 LEVETIRACETAM, LEVETIRACETAM
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

AUROBINDO PHARMA

* AUROBINDO PHARMA
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM

* AUROBINDO PHARMA LTD
 ALENDRONATE SODIUM, ALENDRONATE SODIUM
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 AMPICILLIN SODIUM, AMPICILLIN SODIUM
 ATENOLOL, ATENOLOL
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
 CARISOPRODOL, CARISOPRODOL
 CARVEDILOL, CARVEDILOL
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
 CEFDINIR, CEFDINIR
 CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
 CEFPROZIL, CEFPROZIL
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 DIDANOSINE, DIDANOSINE
 FINASTERIDE, FINASTERIDE
 FLUCONAZOLE, FLUCONAZOLE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
 GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
 GLYBURIDE, GLYBURIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LAMOTRIGINE, LAMOTRIGINE
 LEVETIRACETAM, LEVETIRACETAM
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 MELOXICAM, MELOXICAM
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON, ONDANSETRON
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
 PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
 QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 RIBAVARIN, RIBAVIRIN
 RIBAVIRIN, RIBAVIRIN
 RISPERIDONE, RISPERIDONE
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SIMVASTATIN, SIMVASTATIN
 STAVUDINE, STAVUDINE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 TOPIRAMATE, TOPIRAMATE
 TORSEMIDE, TORSEMIDE
 TRANDOLAPRIL, TRANDOLAPRIL
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 ZALEPLON, ZALEPLON
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******AUROBINDO PHARMA LTD**

* AUROBINDO PHARMA LIMITED

DIVALPROEX SODIUM, DIVALPROEX SODIUM
 FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 LEVOFLOXACIN, LEVOFLOXACIN
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

* AUROBINDO PHARMA LTD

ABACAVIR SULFATE, ABACAVIR SULFATE
 ACETAMINOPHEN, ACETAMINOPHEN (OTC)
 ACETYLCYSTEINE, ACETYLCYSTEINE
 ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
 AFIRMELLE, ETHINYL ESTRADIOL
 ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
 ALPRAZOLAM, ALPRAZOLAM
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 AMOXICILLIN, AMOXICILLIN
 ARIPIPIRAZOLE, ARIPIPIRAZOLE
 ATHENTIA NEXT, LEVONORGESTREL (OTC)
 ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
 ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
 AYUNA, ETHINYL ESTRADIOL
 AZITHROMYCIN, AZITHROMYCIN
 BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
 BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
 CAFFEINE CITRATE, CAFFEINE CITRATE
 CEFIXIME, CEFIXIME
 CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
 CELECOXIB, CELECOXIB
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 CLOZAPINE, CLOZAPINE
 CYONANZ, ETHINYL ESTRADIOL
 DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 ENTACAPONE, ENTACAPONE
 ENTECAVIR, ENTECAVIR
 EPTIFIBATIDE, EPTIFIBATIDE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
 ESZOPICLONE, ESZOPICLONE
 FAMCICLOVIR, FAMCICLOVIR
 FAMOTIDINE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE (OTC)
 FELODIPINE, FELODIPINE
 FENOFIBRATE, FENOFIBRATE
 FINASTERIDE, FINASTERIDE
 FLECAINIDE ACETATE, FLECAINIDE ACETATE
 GABAPENTIN, GABAPENTIN
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 GEMFIBROZIL, GEMFIBROZIL
 GLIMEPIRIDE, GLIMEPIRIDE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 INCASSIA, NORETHINDRONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* AUROBINDO PHARMA LTD
 INDOMETHACIN, INDOMETHACIN
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN
 ISOSULFAN BLUE, ISOSULFAN BLUE
 LACOSAMIDE, LACOSAMIDE
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
 LAMIVUDINE, LAMIVUDINE
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
 LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
 LEVETIRACETAM, LEVETIRACETAM
 LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
 LEVOFLOXACIN, LEVOFLOXACIN
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
 LINEZOLID, LINEZOLID
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
 METHOCARBAMOL, METHOCARBAMOL
 METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
 METRONIDAZOLE, METRONIDAZOLE
 MILI, ETHINYL ESTRADIOL
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MODAFINIL, MODAFINIL
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 NAFCILLIN SODIUM, NAFCILLIN SODIUM
 NAPROXEN SODIUM, NAPROXEN SODIUM
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 NEVIRAPINE, NEVIRAPINE
 NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
 NYLIA 1/35, ETHINYL ESTRADIOL
 NYLIA 7/7/7, ETHINYL ESTRADIOL
 OLANZAPINE, OLANZAPINE
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXACILLIN SODIUM, OXACILLIN SODIUM
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PARICALCITOL, PARICALCITOL
 PHENYTOIN SODIUM, PHENYTOIN SODIUM
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM
 POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
 RAMIPRIL, RAMIPRIL
 REPAGLINIDE, REPAGLINIDE
 RISEDRONATE SODIUM, RISEDRONATE SODIUM
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TELMISARTAN, TELMISARTAN
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* AUROBINDO PHARMA LTD
 TRANEXAMIC ACID, TRANEXAMIC ACID
 TRI-LO-MILI, ETHINYL ESTRADIOL
 TRI-MILI, ETHINYL ESTRADIOL
 VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VALSARTAN, VALSARTAN
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VORICONAZOLE, VORICONAZOLE
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID
 ZOLMITRIPTAN, ZOLMITRIPTAN

* AUROBINDO PHARMA LTD INC
 CEFPROZIL, CEFPROZIL
 CEFUROXIME AXETIL, CEFUROXIME AXETIL
 CEPHALEXIN, CEPHALEXIN
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 MIRTAZAPINE, MIRTAZAPINE
 ZIDOVUDINE, ZIDOVUDINE

AUROBINDO PHARMA USA

* AUROBINDO PHARMA USA INC
 ALPRAZOLAM, ALPRAZOLAM
 NAPROXEN, NAPROXEN
 OMEPRAZOLE, OMEPRAZOLE

AUROLIFE PHARMA LLC

* AUROLIFE PHARMA LLC
 ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 DUTASTERIDE, DUTASTERIDE
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 GLYCOPYRROLATE, GLYCOPYRROLATE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

AUSTARPHARMA LLC

* AUSTARPHARMA LLC
 ALENDRONATE SODIUM, ALENDRONATE SODIUM
 METHOCARBAMOL, METHOCARBAMOL
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE

AUXILIUM PHARMS

* AUXILIUM PHARMACEUTICALS INC
 TESTIM, TESTOSTERONE

AUXILIUM PHARMS INC

* AUXILIUM PHARMACEUTICALS INC
 EDEX, ALPROSTADIL
 SEMPREX-D, ACRIVASTINE
 STRIANT, TESTOSTERONE
 TESTOPEL, TESTOSTERONE
 THEO-24, THEOPHYLLINE

AUXILIUM PHARMS LLC

* AUXILIUM PHARMACEUTICALS LLC
 DILATRATE-SR, ISOSORBIDE DINITRATE
 ROBAXIN, METHOCARBAMOL
 ROBAXIN-750, METHOCARBAMOL
 THEO-24, THEOPHYLLINE

AVACOR PRODS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* AVACOR PRODUCTS LLC
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)

AVANIR PHARMS

* AVANIR PHARMACEUTICALS
ONZETRA XSAIL, SUMATRIPTAN SUCCINATE
* AVANIR PHARMACEUTICALS INC
NUEDEXTA, DEXTROMETHORPHAN HYDROBROMIDE

AVANTHI INC

* AVANTHI INC
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE, DEXBROMPHENIRAMINE MALEATE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
LOMAIRA, PHENTERMINE HYDROCHLORIDE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE

AVEDRO INC

* AVEDRO INC
PHOTREXA VISCOUS IN DEXTRAN 20%, RIBOFLAVIN 5'-PHOSPHATE SODIUM
PHOTREXA, RIBOFLAVIN 5'-PHOSPHATE SODIUM

AVEMA PHARMA

* AVEMA PHARMA SOLUTIONS
IBUPROFEN, IBUPROFEN (OTC)

AVENT

* AVENT INC
PYTEST KIT, UREA, C-14
PYTEST, UREA, C-14

AVEVA

* AVEVA DRUG DELIVERY SYSTEMS INC
CLONIDINE, CLONIDINE
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-75, FENTANYL
NICOTINE, NICOTINE (OTC)

AVID RADIOPHARMS INC

* AVID RADIOPHARMACEUTICALS INC
AMYVID, FLORBETAPIR F-18

AYTU BIOSCIENCE INC

* AYTU BIOSCIENCE INC
NATESTO, TESTOSTERONE
PRIMSOL, TRIMETHOPRIM HYDROCHLORIDE

**** B ******B BRAUN**

* B BRAUN MEDICAL INC
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
AMINO ACIDS, AMINO ACIDS
BALANCED SALT, CALCIUM CHLORIDE
CEFAZOLIN AND DEXTROSE, CEFAZOLIN SODIUM
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER, CEFEPIME HYDROCHLORIDE
CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER, CEFOTETAN DISODIUM
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER, CEFOXITIN SODIUM
CEFTAZIDIME IN DEXTROSE CONTAINER, CEFTAZIDIME
CEFTRIAAXONE AND DEXTROSE IN DUPLEX CONTAINER, CEFTRIAAXONE SODIUM
CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER, CEFUROXIME SODIUM
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

* B BRAUN MEDICAL INC

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM
 DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
 DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%, DOPAMINE HYDROCHLORIDE
 FREAMINE HBC 6.9%, AMINO ACIDS
 FREAMINE III 10%, AMINO ACIDS
 FREAMINE III 3% W/ ELECTROLYTES, AMINO ACIDS
 FREAMINE III 8.5% W/ ELECTROLYTES, AMINO ACIDS
 FREAMINE III 8.5%, AMINO ACIDS
 GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
 HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
 HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPATAMINE 8%, AMINO ACIDS
 ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
 LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
 LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
 MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
 MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
 MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
 MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
 METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE
 NEPHRAMINE 5.4%, AMINO ACIDS
 NUTRILIPID 10%, SOYBEAN OIL
 NUTRILIPID 20%, SOYBEAN OIL
 PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ******* B BRAUN MEDICAL INC**

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PROCALAMINE, AMINO ACIDS
 RESECTISOL IN PLASTIC CONTAINER, MANNITOL
 RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
 SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
 THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 TROPHAMINE 10%, AMINO ACIDS
 TROPHAMINE, AMINO ACIDS

B BRAUN MEDICAL INC*** B BRAUN MEDICAL INC**

MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER, MEROPENEM

BAJAJ MEDICAL LLC*** BAJAJ MEDICAL LLC**

DYNA-HEX, CHLORHEXIDINE GLUCONATE (OTC)

BARR*** BARR LABORATORIES INC**

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
 ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
 ARANELLE, ETHINYL ESTRADIOL
 ASPIRIN AND DIPYRIDAMOLE, ASPIRIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

- * BARR LABORATORIES INC
 BALZIVA-28, ETHINYL ESTRADIOL
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
 CHLORZOAZONE, CHLORZOAZONE
 CLONAZEPAM, CLONAZEPAM
 DANAZOL, DANAZOL
 DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 DIAZEPAM, DIAZEPAM
 DIDANOSINE, DIDANOSINE
 DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
 DIPYRIDAMOLE, DIPYRIDAMOLE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
 DUTASTERIDE, DUTASTERIDE
 ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL, ERYTHROMYCIN ETHYLSUCCINATE
 ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
 ESTRADIOL AND NORGESTIMATE, ESTRADIOL
 ESTROPIPATE, ESTROPIPATE
 ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
 FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
 FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 HYDROXYUREA, HYDROXYUREA
 HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
 ISONIAZID, ISONIAZID
 JUNEL 1.5/30, ETHINYL ESTRADIOL
 JUNEL 1/20, ETHINYL ESTRADIOL
 JUNEL FE 1.5/30, ETHINYL ESTRADIOL
 JUNEL FE 1/20, ETHINYL ESTRADIOL
 KARIVA, DESOGESTREL
 KELNOR, ETHINYL ESTRADIOL
 LEFLUNOMIDE, LEFLUNOMIDE
 LESSINA-28, ETHINYL ESTRADIOL
 MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
 MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
 MEGESTROL ACETATE, MEGESTROL ACETATE
 MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
 NIACIN, NIACIN
 NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
 NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORTREL 0.5/35-28, ETHINYL ESTRADIOL
 NORTREL 1/35-21, ETHINYL ESTRADIOL
 NORTREL 1/35-28, ETHINYL ESTRADIOL
 NORTREL 7/7/7, ETHINYL ESTRADIOL
 ONDANSETRON, ONDANSETRON
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 PORTIA-28, ETHINYL ESTRADIOL
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 SPRINTEC, ETHINYL ESTRADIOL
 TEMOZOLOMIDE, TEMOZOLOMIDE
 TREXALL, METHOTREXATE SODIUM
 TRI-LEGEST 21, ETHINYL ESTRADIOL
 TRI-LEGEST FE, ETHINYL ESTRADIOL
 TRI-SPRINTEC, ETHINYL ESTRADIOL
 WARFARIN SODIUM, WARFARIN SODIUM
- * BARR PHARMACEUTICALS
 LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ******BARR LABS DIV TEVA**

- * BARR LABORATORIES INC SUB TEVA PHARMACEUTICALS USA
ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
BUDESONIDE, BUDESONIDE
OXYBUTYNIN, OXYBUTYNIN

BARR LABS INC

- * BARR LABORATORIES INC
ACITRETIN, ACITRETIN
CLOZAPINE, CLOZAPINE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
ESTRADIOL, ESTRADIOL
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
OLANZAPINE, OLANZAPINE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN
TRETINOIN, TRETINOIN
TRI LO SPRINTAC, ETHINYL ESTRADIOL

BAUSCH AND LOMB

- * BAUSCH AND LOMB INC
ALWAY, KETOTIFEN FUMARATE (OTC)
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALREX, LOTEPIREDNOL ETABONATE
BESIVANCE, BESIFLOXACIN HYDROCHLORIDE
CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
FLURBIPROFEN SODIUM, FLURBIPROFEN SODIUM
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
ISTALOL, TIMOLOL MALEATE
LATANOPROST, LATANOPROST
LOTEMAX, LOTEPIREDNOL ETABONATE
MIOCHOL-E, ACETYLCHOLINE CHLORIDE
OFLOXACIN, OFLOXACIN
OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
PROLENSA, BROMFENAC SODIUM
RETISERT, FLUOCINOLONE ACETONIDE
TIMOLOL MALEATE, TIMOLOL MALEATE
VITRASE, HYALURONIDASE
ZIRGAN, GANCICLOVIR
ZYLET, LOTEPIREDNOL ETABONATE
- * BAUSCH AND LOMB PHARMACEUTICALS INC
ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE, ACETIC ACID, GLACIAL
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
CROLOM, CROMOLYN SODIUM
CROMOLYN SODIUM, CROMOLYN SODIUM
CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXASPORIN, DEXAMETHASONE
ERYTHROMYCIN, ERYTHROMYCIN
FLUNISOLIDE, FLUNISOLIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
OFLOXACIN, OFLOXACIN
OPTIPRANOLOL, METIPRANOLOL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ******* BAUSCH AND LOMB PHARMACEUTICALS INC**

OTICAIR, HYDROCORTISONE
 PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
 SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
 TIMOLOL MALEATE, TIMOLOL MALEATE
 TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE
 TOBRAMYCIN, TOBRAMYCIN
 TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 TROPICAMIDE, TROPICAMIDE

BAUSCH AND LOMB INC*** BAUSCH AND LOMB INC**

BEPREVE, BEPOTASTINE BESILATE
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
 LOTE MAX, LOTE PREDNOL ETABONATE
 PODOFILOX, PODOFILOX

BAXTER HLTHCARE*** BAXTER HEALTHCARE CORP**

ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
 AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE
 ANCEF IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
 BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM
 BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
 BREVIBLOC IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
 BREVIBLOC, ESMOLOL HYDROCHLORIDE
 CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 CEFAZOLIN IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
 CEFEPIME IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
 CEFTRIAOXONE IN PLASTIC CONTAINER, CEFTRIAOXONE SODIUM
 CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC
 CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC
 CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC
 CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC
 CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC
 CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
 CLINOLIPID 20%, OLIVE OIL
 CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
 DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER, DEXTROSE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

* BAXTER HEALTHCARE CORP

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC
 DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 60% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
 DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
 DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
 EXTRANEAL, ICODEXTRIN
 FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
 FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 FORANE, ISOFLURANE
 GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
 HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
 HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
 IFEX, IFOSFAMIDE
 LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
 LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
 LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
 MESNEX, MESNA
 MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
 NALLPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM
 NEXTERONE, AMIODARONE HYDROCHLORIDE
 NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
 OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

* BAXTER HEALTHCARE CORP

OSMITROL 10% IN WATER, MANNITOL
 OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 15% IN WATER, MANNITOL
 OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 20% IN WATER, MANNITOL
 OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 5% IN WATER, MANNITOL
 PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM
 PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM
 POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
 POTASSIUM CHLORIDE 0.224% IN SODIUM CHLORIDE 0.9%, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PREMASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
 PREMASOL 6% IN PLASTIC CONTAINER, AMINO ACIDS
 PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL BGK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 SEVOFLURANE, SEVOFLURANE
 SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
 STERILE WATER, STERILE WATER FOR IRRIGATION
 SUPRANE, DESFLURANE
 TIS-U-SOL IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 TIS-U-SOL, MAGNESIUM SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

- * BAXTER HEALTHCARE CORP
 - TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
 - TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS
 - TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS
 - VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
- * BAXTER HEALTHCARE INTERNATIONAL SPECIALTY THERAPIES DIV
 - PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS

BAXTER HLTHCARE CORP

- * BAXTER HEALTHCARE CORP ANESTHESIA AND CRITICAL CARE
 - PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE
- * BAXTER HEALTHCARE CORP ANESTHESIA CRITICAL CARE
 - PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

BAYER

- * BAYER HEALTHCARE LLC
 - ALEVE, NAPROXEN SODIUM (OTC)
 - ALEVE-D SINUS & COLD, NAPROXEN SODIUM (OTC)
 - FEMSTAT 3, BUTOCONAZOLE NITRATE (OTC)

BAYER HEALTHCARE LLC

- * BAYER HEALTHCARE LLC
 - CHILDREN'S CLARITIN, LORATADINE (OTC)
 - CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE (OTC)
 - CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE (OTC)
 - CLARITIN HIVES RELIEF REDITAB, LORATADINE (OTC)
 - CLARITIN HIVES RELIEF, LORATADINE (OTC)
 - CLARITIN REDITABS, LORATADINE (OTC)
 - CLARITIN, LORATADINE (OTC)
 - CLARITIN-D 24 HOUR, LORATADINE (OTC)
 - CLARITIN-D, LORATADINE (OTC)
 - GYNE-LOTRIMIN 3 COMBINATION PACK, CLOTRIMAZOLE (OTC)
 - GYNE-LOTRIMIN 3, CLOTRIMAZOLE (OTC)
 - GYNE-LOTRIMIN COMBINATION PACK, CLOTRIMAZOLE (OTC)
 - GYNE-LOTRIMIN, CLOTRIMAZOLE (OTC)
 - LOTRIMIN ULTRA, BUTENAFINE HYDROCHLORIDE (OTC)
 - MIRALAX, POLYETHYLENE GLYCOL 3350 (OTC)
 - MYCELEX-7 COMBINATION PACK, CLOTRIMAZOLE (OTC)
 - MYCELEX-7, CLOTRIMAZOLE (OTC)
 - OCUCLEAR, OXYMETAZOLINE HYDROCHLORIDE (OTC)
 - SHADE UVAGUARD, AVOBENZONE (OTC)
 - ZEGERID OTC, OMEPRAZOLE (OTC)

BAYER HLTHCARE

- * BAYER HEALTHCARE CONSUMER CARE
 - ALEVE PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
- * BAYER HEALTHCARE PHARMACEUTICALS INC
 - ADEMPAS, RIOCIQUAT
 - ANGELIQ, DROSPIRENONE
 - AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER, MOXIFLOXACIN HYDROCHLORIDE
 - AVELOX, MOXIFLOXACIN HYDROCHLORIDE
 - BEYAZ, DROSPIRENONE
 - BILTRICIDE, PRAZIQUANTEL
 - CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
 - CIPRO, CIPROFLOXACIN
 - CIPRO, CIPROFLOXACIN HYDROCHLORIDE
 - CLIMARA PRO, ESTRADIOL
 - CLIMARA, ESTRADIOL
 - DESONATE, DESONIDE
 - DTIC-DOME, DACARBAZINE
 - EOVIST, GADOXETATE DISODIUM
 - FINACEA, AZELAIC ACID
 - FINACEA, AZELAIC ACID
 - GADAVIST, GADOBUTROL
 - KYLEENA, LEVONORGESTREL
 - LEVITRA, VARDENAFIL HYDROCHLORIDE
 - MAGNEVIST, GADOPENTETATE DIMEGLUMINE
 - MENOSTAR, ESTRADIOL
 - MIRENA, LEVONORGESTREL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ******* BAYER HEALTHCARE PHARMACEUTICALS INC**

NATAZIA, DIENOEST
 NEXAVAR, SORAFENIB TOSYLATE
 PRECOSE, ACARBOSE
 SAFYRAL, DROSPIRENONE
 SKYLA, LEVONORGESTREL
 STAXYN, VARDENAFIL HYDROCHLORIDE
 STIVARGA, REGORAFENIB
 ULTRAVIST (PHARMACY BULK), IOPROMIDE
 ULTRAVIST 150, IOPROMIDE
 ULTRAVIST 240, IOPROMIDE
 ULTRAVIST 300 IN PLASTIC CONTAINER, IOPROMIDE
 ULTRAVIST 300, IOPROMIDE
 ULTRAVIST 370, IOPROMIDE
 XOFIGO, RADIUM RA-223 DICHLORIDE
 YASMIN, DROSPIRENONE
 YAZ, DROSPIRENONE

BAYSHORE PHARMS LLC

* BAYSHORE PHARMACEUTICALS LLC
 METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
 PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE

BECTON DICKINSON

* BECTON DICKINSON AND CO
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)
 E-Z SCRUB 201, POVIDONE-IODINE (OTC)
 E-Z SCRUB 241, POVIDONE-IODINE (OTC)

BECTON DICKINSON CO

* BECTON DICKINSON AND CO
 CHLORAPREP ONE-STEP FREPP, CHLORHEXIDINE GLUCONATE (OTC)
 CHLORAPREP ONE-STEP SEPP, CHLORHEXIDINE GLUCONATE (OTC)
 CHLORAPREP ONE-STEP, CHLORHEXIDINE GLUCONATE (OTC)
 CHLORAPREP SINGLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
 CHLORAPREP TRIPLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
 CHLORAPREP WITH TINT, CHLORHEXIDINE GLUCONATE (OTC)

BEDFORD

* BEDFORD LABORATORIES DIV BEN VENUE LABORATORIES INC
 CEFTRIAZONE, CEFTRIAZONE SODIUM

BEDFORD LABS

* BEDFORD LABORATORIES
 LORAZEPAM PRESERVATIVE FREE, LORAZEPAM

BELCHER PHARMS

* BELCHER PHARMACEUTICALS LLC
 CEPHALEXIN, CEPHALEXIN
 DESLORATADINE, DESLORATADINE

BELCHER PHARMS LLC

* BELCHER PHARMACEUTICALS LLC
 EPINEPHRINE, EPINEPHRINE
 SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE

BEXIMCO PHARMS USA

* BEXIMCO PHARMACEUTICALS USA INC
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

BEXIMCO USA

* BEXIMCO PHARMACEUTICALS USA INC
 CARVEDILOL, CARVEDILOL

BI-COASTAL PHARMA

* BI-COASTAL PHARMA INTERNATIONAL LLC
 DUVOID, BETHANECHOL CHLORIDE

BIO NUCLEONICS

* BIO NUCLEONICS INC
 STRONTIUM CHLORIDE SR-89, STRONTIUM CHLORIDE SR-89

BIO PHARM INC

* BIO PHARM INC
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

* BIO PHARM INC
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE

BIO-PHARM INC

* BIO-PHARM INC
 LACTULOSE, LACTULOSE
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE

BIOCON LIMITED

* BIOCON LIMITED
 SIMVASTATIN, SIMVASTATIN

BIOCON LTD

* BIOCON LTD
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

BIOCRYST

* BIOCRYST PHARMACEUTICALS INC
 RAPIVAB, PERAMIVIR

BIODELIVERY SCI INTL

* BIODELIVERY SCIENCES INTERNATIONAL INC
 BUNAVAIL, BUPRENORPHINE HYDROCHLORIDE

BIOFRONTERA

* BIOFRONTERA BIOSCIENCE GMBH
 AMELUZ, AMINOLEVULINIC ACID HYDROCHLORIDE

BIOGEN IDEC

* BIOGEN IDEC INC
 SPINRAZA, NUSINERSEN SODIUM

BIOGEN IDEC INC

* BIOGEN IDEC INC
 TECFIDERA, DIMETHYL FUMARATE

BIOKEY

* BIOKEY INC
 CILOSTAZOL, CILOSTAZOL

BIOMARIN PHARM

* BIOMARIN PHARMACEUTICAL INC
 KUVAN, SAPROPTERIN DIHYDROCHLORIDE

BIOMEDCL RES FDN

* BIOMEDICAL RESEARCH FOUNDATION NORTHWEST LOUISIANA
 AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

BIONPHARMA INC

* BIONPHARMA INC
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 BENZONATATE, BENZONATATE
 BEXAROTENE, BEXAROTENE
 CALCITRIOL, CALCITRIOL
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
 DUTASTERIDE, DUTASTERIDE
 ETHOSUXIMIDE, ETHOSUXIMIDE
 GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
 IBUPROFEN, IBUPROFEN (OTC)
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 MIDOL LIQUID GELS, IBUPROFEN (OTC)
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 NIMODIPINE, NIMODIPINE
 PARICALCITOL, PARICALCITOL
 PROGESTERONE, PROGESTERONE
 VALPROIC ACID, VALPROIC ACID
 VITAMIN D, ERGOCALCIFEROL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

* BIONPHARMA INC

ZONISAMIDE, ZONISAMIDE

BLAIREX

* BLAIREX LABORATORIES INC

BRONCHO SALINE, SODIUM CHLORIDE (OTC)

BLU CARIBE

* BLU CARIBE INC

GEMFIBROZIL, GEMFIBROZIL

BLU CARIBE INC

* BLU CARIBE INC

DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE

BLUE EARTH

* BLUE EARTH DIAGNOSTICS LTD

AXUMIN, FLUCICLOVINE F-18

BOEHRINGER INGELHEIM

* BOEHRINGER INGELHEIM

CATAPRES, CLONIDINE HYDROCHLORIDE

CATAPRES-TTS-1, CLONIDINE

CATAPRES-TTS-2, CLONIDINE

CATAPRES-TTS-3, CLONIDINE

GILOTRIF, AFATINIB DIMALEATE

GLYXAMBI, EMPAGLIFLOZIN

MICARDIS HCT, HYDROCHLOROTHIAZIDE

MICARDIS, TELMISARTAN

MIRAPEX, PRAMIPEXOLE DIHYDROCHLORIDE

ZANTAC 150, RANITIDINE HYDROCHLORIDE (OTC)

ZANTAC 75, RANITIDINE HYDROCHLORIDE (OTC)

* BOEHRINGER INGELHEIM PHARMACEUTICALS INC

AGGRENOX, ASPIRIN

APTIVUS, TIPRANAVIR

ATROVENT HFA, IPRATROPIUM BROMIDE

ATROVENT, IPRATROPIUM BROMIDE

COMBIVENT RESPIMAT, ALBUTEROL SULFATE

FLOMAX, TAMSULOSIN HYDROCHLORIDE

JARDIANCE, EMPAGLIFLOZIN

JENTADUETO XR, LINAGLIPTIN

JENTADUETO, LINAGLIPTIN

MIRAPEX ER, PRAMIPEXOLE DIHYDROCHLORIDE

MOBIC, MELOXICAM

OFEV, NINTEDANIB ESYLATE

PERSANTINE, DIPYRIDAMOLE

PRADAXA, DABIGATRAN ETEXILATE MESYLATE

SPIRIVA RESPIMAT, TIOTROPIUM BROMIDE

SPIRIVA, TIOTROPIUM BROMIDE

STIOLTO RESPIMAT, OLODATEROL HYDROCHLORIDE

STRIVERDI RESPIMAT, OLODATEROL HYDROCHLORIDE

SYNJARDY XR, EMPAGLIFLOZIN

SYNJARDY, EMPAGLIFLOZIN

TRADJENTA, LINAGLIPTIN

TWINSTA, AMLODIPINE BESYLATE

VIRAMUNE XR, NEVIRAPINE

VIRAMUNE, NEVIRAPINE

BRACCO

* BRACCO DIAGNOSTICS INC

CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82

CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT

CHOLOGRAFIN MEGLUMINE, IODIPAMIDE MEGLUMINE

CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE

CYSTOGRAFIN, DIATRIZOATE MEGLUMINE

E-Z-HD, BARIUM SULFATE

GASTROGRAFIN, DIATRIZOATE MEGLUMINE

ISOVUE-200, IOPAMIDOL

ISOVUE-250, IOPAMIDOL

ISOVUE-300, IOPAMIDOL

ISOVUE-370, IOPAMIDOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

* BRACCO DIAGNOSTICS INC
 ISOVUE-M 200, IOPAMIDOL
 ISOVUE-M 300, IOPAMIDOL
 KINEVAC, SINCALIDE
 LUMASON, SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES
 MDP-BRACCO, TECHNETIUM TC-99M MEDRONATE KIT
 MULTIHANCE MULTIPACK, GADOBENATE DIMEGLUMINE
 MULTIHANCE, GADOBENATE DIMEGLUMINE
 PROHANCE MULTIPACK, GADOTERIDOL
 PROHANCE, GADOTERIDOL
 READI-CAT 2 SMOOTHIES, BARIUM SULFATE
 READI-CAT 2, BARIUM SULFATE
 RENOGRAFIN-76, DIATRIZOATE MEGLUMINE
 SINOGRAFIN, DIATRIZOATE MEGLUMINE
 VARIBAR, BARIUM SULFATE

BRAEBURN PHARMS INC

* BRAEBURN PHARMACEUTICALS INC
 PROBUPHINE, BUPRENORPHINE HYDROCHLORIDE

BRAINTREE

* BRAINTREE LABORATORIES INC
 GOLYTELY, POLYETHYLENE GLYCOL 3350
 NULYTELY, POLYETHYLENE GLYCOL 3350
 NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350

BRAINTREE LABS

* BRAINTREE LABORATORIES INC
 SUPREP BOWEL PREP KIT, MAGNESIUM SULFATE ANHYDROUS

BRECKENRIDGE PHARM

* BRECKENRIDGE PHARMACEUTICAL INC
 BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CILOSTAZOL, CILOSTAZOL
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 DUTASTERIDE, DUTASTERIDE
 EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
 ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
 LEVETIRACETAM, LEVETIRACETAM
 MEFENAMIC ACID, MEFENAMIC ACID
 MELOXICAM, MELOXICAM
 METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
 OXCARBAZEPINE, OXCARBAZEPINE
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE

BRECKENRIDGE PHARMS

* BRECKENRIDGE PHARMACEUTICALS INC
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE

BRIGHAM WOMENS

* BRIGHAM AND WOMENS HOSP
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

BRIGHAM WOMENS HOSP

* BRIGHAM AND WOMENS HOSP INC
 AMMONIA N 13, AMMONIA N-13

BRISTOL MYERS SQUIBB

* BRISTOL MYERS SQUIBB
 AZACTAM, AZTREONAM
 BARACLUDE, ENTECAVIR
 GLUCOVANCE, GLYBURIDE
 LYSODREN, MITOTANE
 MEGACE, MEGESTROL ACETATE
 PRAVACHOL, PRAVASTATIN SODIUM

* BRISTOL MYERS SQUIBB CO
 AZACTAM IN PLASTIC CONTAINER, AZTREONAM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

- * BRISTOL MYERS SQUIBB CO
DROXIA, HYDROXYUREA
GLUCOPHAGE XR, METFORMIN HYDROCHLORIDE
HYDREA, HYDROXYUREA
REYATAZ, ATAZANAVIR SULFATE
SPRYCEL, DASATINIB
SUSTIVA, EFAVIRENZ
VIDEX EC, DIDANOSINE
- * BRISTOL MYERS SQUIBB CO PHARMACEUTICAL RESEARCH INSTITUTE
ELIQUIS, APIXABAN
ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE
GLUCOPHAGE, METFORMIN HYDROCHLORIDE
VIDEX, DIDANOSINE
ZERIT, STAVUDINE
- * BRISTOL MYERS SQUIBB PHARMA CO
COUMADIN, WARFARIN SODIUM

BRISTOL-MYERS SQUIBB

- * BRISTOL-MYERS SQUIBB CO
DAKLINZA, DACLATASVIR DIHYDROCHLORIDE
EVOTAZ, ATAZANAVIR SULFATE

**** C ******CADILA PHARMS LTD**

- * CADILA PHARMACEUTICALS LTD
ACYCLOVIR, ACYCLOVIR
FOLIC ACID, FOLIC ACID
GEMFIBROZIL, GEMFIBROZIL
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
OFLOXACIN, OFLOXACIN
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

CADISTA PHARMS

- * CADISTA PHARMACEUTICALS INC
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
OXCARBAZEPINE, OXCARBAZEPINE

CALL INC

- * CALL INC DBA ROCHESTER PHARMACEUTICALS
ADAPALENE, ADAPALENE

CARACO

- * CARACO PHARMACEUTICAL LABORATORIES LTD
BACLOFEN, BACLOFEN
FLUMADINE, RIMANTADINE HYDROCHLORIDE

CARDINAL HEALTH 414

- * CARDINAL HEALTH 414 LLC
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
- * CARDINAL HEALTH 414 LLC CARDINAL HEALTH NUCLEAR PHARMACY SERVICES
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

CARDINAL HEALTH 418

- * CARDINAL HEALTH 418 INC
SODIUM IODIDE I 123, SODIUM IODIDE I-123

CARLSBAD

- * CARLSBAD TECHNOLOGY INC
ACYCLOVIR, ACYCLOVIR
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
FAMOTIDINE, FAMOTIDINE
GLIMEPIRIDE, GLIMEPIRIDE
LOVASTATIN, LOVASTATIN

CAROLINA MEDCL

- * CAROLINA MEDICAL PRODUCTS CO
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ****

* CAROLINA MEDICAL PRODUCTS CO
 HYDROCORTISONE IN ABSORBASE, HYDROCORTISONE
 ISONIAZID, ISONIAZID
 SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
 SPS, SODIUM POLYSTYRENE SULFONATE
 TRIAMCINOLONE ACETONIDE IN ABSORBASE, TRIAMCINOLONE ACETONIDE

CASPER PHARMA LLC

* CASPER PHARMA LLC
 CORTISPORIN, HYDROCORTISONE
 FURADANTIN, NITROFURANTOIN
 ROBINUL FORTE, GLYCOPYRROLATE
 ROBINUL, GLYCOPYRROLATE

CATALENT

* CATALENT PHARMA SOLUTIONS LLC
 VALPROIC ACID, VALPROIC ACID

CEDAR PHARMS

* CEDAR PHARMACEUTICALS LLC
 SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE

CELGENE

* CELGENE CORP
 ISTODAX, ROMIDEPSIN
 POMALYST, POMALIDOMIDE
 REVLIMID, LENALIDOMIDE
 THALOMID, THALIDOMIDE
 VIDAZA, AZACITIDINE

CELGENE CORP

* CELGENE CORP
 OTEZLA, APREMILAST

CENTAUR PHARMS PVT

* CENTAUR PHARMACEUTICALS PVT LTD
 LAMIVUDINE, LAMIVUDINE

CEPHALON

* CEPHALON INC
 ACTIQ, FENTANYL CITRATE
 FENTORA, FENTANYL CITRATE
 GABITRIL, TIAGABINE HYDROCHLORIDE
 NUVIGIL, ARMODAFINIL
 PROVIGIL, MODAFINIL
 TREANDA, BENDAMUSTINE HYDROCHLORIDE
 TRISENOX, ARSENIC TRIOXIDE

CEREXA

* CEREXA INC
 TEFLARO, CEFTAROLINE FOSAMIL

CEREXA INC

* CEREXA INC
 AVYCAZ, AVIBACTAM SODIUM

CEROVENE INC

* CEROVENE INC
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN

CFT PHARMS LLC

* CFT PHARMACEUTICALS LLC
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

CHANGZHOU PHARM

* CHANGZHOU PHARMACEUTICAL FACTORY
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

CHARTWELL CIENCA

* CHARTWELL CIENCA DA VIDA LLC
 TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE

CHARTWELL LIFE SCI

* CHARTWELL LIFE SCIENCE LLC
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DOXYCYCLINE, DOXYCYCLINE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

CHARTWELL MOLECULES

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ****

* CHARTWELL MOLECULES LLC
 GEMFIBROZIL, GEMFIBROZIL
 NABUMETONE, NABUMETONE

CHATTEM

* CHATTEM INC
 SELSUN, SELENIUM SULFIDE
 UNISOM, DOXYLAMINE SUCCINATE (OTC)

CHEM WERTH INC

* CHEM WERTH INC
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE

CHEMI SPA

* CHEMI SPA
 TEMOZOLOMIDE, TEMOZOLOMIDE

CHEMISCH FBRK KRSSLR

* CHEMISCHE FABRIK KREUSSLER & CO. GMBH
 ASCLERA, POLIDOCANOL

CHIESI USA INC

* CHIESI USA INC
 BETHKIS, TOBRAMYCIN
 CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
 CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
 CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
 CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
 CARDENE, NICARDIPINE HYDROCHLORIDE
 CLEVIPREX, CLEVIDIPINE
 CUROSURF, PORACTANT ALFA
 KENGREAL, CANGRELOR
 ZYFLO CR, ZILEUTON
 ZYFLO, ZILEUTON

CHILDRENS HOSP MI

* CHILDRENS HOSP MICHIGAN
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

CHINA RESOURCES

* CHINA RESOURCES SAIKE PHARMACEUTICAL CO LTD
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE

CHIRHOCLIN

* CHIRHOCLIN INC
 CHIRHOSTIM, SECRETIN SYNTHETIC HUMAN

CIPHER PHARMS INC

* CIPHER PHARMACEUTICALS INC
 CONZIP, TRAMADOL HYDROCHLORIDE
 LIPOFEN, FENOFIBRATE

CIPHER PHARMS US

* CIPHER PHARMACEUTICALS US LLC
 SITAVIG, ACYCLOVIR

CIPLA

* CIPLA LTD
 NEVIRAPINE, NEVIRAPINE
 RISPERIDONE, RISPERIDONE
 ZIDOVUDINE, ZIDOVUDINE

CIPLA LTD

* CIPLA LTD
 ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
 ALENDRONATE SODIUM, ALENDRONATE SODIUM
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 ANASTROZOLE, ANASTROZOLE
 CARBOPLATIN, CARBOPLATIN
 CARVEDILOL, CARVEDILOL
 CELECOXIB, CELECOXIB
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CICLOPIROX, CICLOPIROX
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ******* CIPLA LTD**

ENTECAVIR, ENTECAVIR
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 FAMCICLOVIR, FAMCICLOVIR
 FENOFIBRATE, FENOFIBRATE
 FINASTERIDE, FINASTERIDE
 FLUTAMIDE, FLUTAMIDE
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
 IRBESARTAN, IRBESARTAN
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 LAMOTRIGINE, LAMOTRIGINE
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
 LEVOFLOXACIN, LEVOFLOXACIN
 MELOXICAM, MELOXICAM
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 NEVIRAPINE, NEVIRAPINE
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 STAVUDINE, STAVUDINE
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 TOPIRAMATE, TOPIRAMATE
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 ZALEPLON, ZALEPLON
 ZIDOVUDINE, ZIDOVUDINE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

CLARIS*** CLARIS PHARMASERVICES**

BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
 CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
 CIPROFLOXACIN, CIPROFLOXACIN
 FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
 FUROSEMIDE, FUROSEMIDE
 LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
 LEVOFLOXACIN, LEVOFLOXACIN
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
 MILRINONE LACTATE IN DEXTROSE 5%, MILRINONE LACTATE
 NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE

CLINIGEN HLTHCARE*** CLINIGEN HEALTHCARE LTD**

ETHYOL, AMIFOSTINE
 FOSCAVIR, FOSCARNET SODIUM
 TOTECT, DEXRAZOXANE HYDROCHLORIDE

CLOVER PHARMS*** CLOVER PHARMACEUTICALS CORP**

AMICAR, AMINOCAPROIC ACID

CLOVIS ONCOLOGY INC*** CLOVIS ONCOLOGY INC**

RUBRACA, RUCAPARIB CAMSYLATE

CNTY LINE PHARMS*** COUNTY LINE PHARMACEUTICALS LLC**

BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 DYNACIN, MINOCYCLINE HYDROCHLORIDE
 LIDEX, FLUOCINONIDE
 LOPROX, CICLOPIROX
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ****

* COUNTY LINE PHARMACEUTICALS LLC
 TAMBOCOR, FLECAINIDE ACETATE
 TRANDATE, LABETALOL HYDROCHLORIDE
 UREX, METHENAMINE HIPPURATE

COASTAL PHARMS

* COASTAL PHARMACEUTICALS
 BROMFENAC SODIUM, BROMFENAC SODIUM
 HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE, HYDROCODONE BITARTRATE

COLGATE

* COLGATE ORAL PHARMACEUTICALS INC
 PERIOGARD, CHLORHEXIDINE GLUCONATE

COLGATE PALMOLIVE

* COLGATE PALMOLIVE
 COLGATE TOTAL, SODIUM FLUORIDE (OTC)

COLGATE-PALMOLIVE CO

* COLGATE-PALMOLIVE CO
 PERIOGARD, CHLORHEXIDINE GLUCONATE

COLLEGIUM PHARM INC

* COLLEGIUM PHARMACEUTICAL INC
 XTAMPZA ER, OXYCODONE

CONCORDIA LABS INC

* CONCORDIA LABORATORIES INC
 PHOTOFRIN, PORFIMER SODIUM

CONCORDIA PHARMS INC

* CONCORDIA PHARMACEUTICALS INC
 DIBENZYLINE, PHENOXYBENZAMINE HYDROCHLORIDE
 DUTOPROL, HYDROCHLOROTHIAZIDE
 DYRENIUM, TRIAMTERENE
 KAPVAY, CLONIDINE HYDROCHLORIDE
 KAYEXALATE, SODIUM POLYSTYRENE SULFONATE
 LANOXIN, DIGOXIN
 NILANDRON, NILUTAMIDE
 ORAPRED ODT, PREDNISOLONE SODIUM PHOSPHATE
 PARNATE, TRANYLCPROMINE SULFATE
 PLAQUENIL, HYDROXYCHLOROQUINE SULFATE
 UROXATRAL, ALFUZOSIN HYDROCHLORIDE

CONTRACT PHARMACAL

* CONTRACT PHARMACAL CORP
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CIMETIDINE, CIMETIDINE (OTC)
 FOLIC ACID, FOLIC ACID
 IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 PREDNISONE, PREDNISONE
 PROFEN, IBUPROFEN (OTC)
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

CORCEPT THERAP

* CORCEPT THERAPEUTICS INC
 KORLYM, MIFEPRISTONE

CORDEN PHARMA

* CORDEN PHARMA LATINA SPA
 GLEOSTINE, LOMUSTINE

COREPHARMA

* COREPHARMA LLC
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 FELBAMATE, FELBAMATE
 GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ******* COREPHARMA LLC**

GLYBURIDE, GLYBURIDE
 LEVOCARNITINE, LEVOCARNITINE
 METAXALONE, METAXALONE
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 MOLINDONE HYDROCHLORIDE, MOLINDONE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 PHENYTOIN, PHENYTOIN
 POTASSIUM CITRATE, POTASSIUM CITRATE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 URSODIOL, URSODIOL

COVIS PHARMA SARL*** COVIS PHARMA SARL**

ALTOPREV, LOVASTATIN
 BETAPACE AF, SOTALOL HYDROCHLORIDE
 BETAPACE, SOTALOL HYDROCHLORIDE
 LANOXIN PEDIATRIC, DIGOXIN
 LANOXIN, DIGOXIN
 RILUTEK, RILUZOLE
 SULAR, NISOLDIPINE

CPDC*** CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION**

FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

CPPI CV*** CP PHARMACEUTICALS INTERNATIONAL CV**

SUTENT, SUNITINIB MALATE

CRANE PHARMS LLC*** CRANE PHARMACEUTICALS LLC**

DAPTOMYCIN, DAPTOMYCIN

CROSSMEDIKA SA*** CROSSMEDIKA SA**

MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE

CROWN LABS*** CROWN LABORATORIES INC**

ALA-CORT, HYDROCORTISONE
 ALA-SCALP, HYDROCORTISONE
 TRIDERM, TRIAMCINOLONE ACETONIDE

CSL BEHRING*** CSL BEHRING LLC**

STIMATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE

CSPC NBP PHARM CO*** CSPC NBP PHARMACEUTICAL CO LTD**

BENZONATATE, BENZONATATE

CSPC OUYI PHARM CO*** CSPC OUYI PHARMACEUTICAL CO LTD**

DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

CUBIST PHARMS*** CUBIST PHARMACEUTICALS INC**

ENTEREG, ALVIMOPAN

CUBIST PHARMS LLC*** CUBIST PHARMACEUTICALS LLC**

CUBICIN RF, DAPTOMYCIN
 CUBICIN, DAPTOMYCIN
 DIFICID, FIDAXOMICIN
 SIVEXTRO, TEDIZOLID PHOSPHATE
 ZERBAXA, CEFTOLOZANE SULFATE

CUMBERLAND PHARMS

WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1086, p. 948 of 1400

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ****

* CUMBERLAND PHARMACEUTICALS INC
 ACETADOTE, ACETYLCYSTEINE
 CALDOLOR, IBUPROFEN
 LACTULOSE, LACTULOSE
 VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER, CONIVAPTAN HYDROCHLORIDE

CUTANEA

* CUTANEA LIFE SCIENCES INC
 AKTIPAK, BENZOYL PEROXIDE

CUTIS HEALTH LLC

* CUTIS HEALTH LLC
 DORAL, QUAZEPAM

CYPRESS BIOSCIENCE

* CYPRESS BIOSCIENCE INC
 SAVELLA, MILNACIPRAN HYDROCHLORIDE

CYPRESS PHARM

* CYPRESS PHARMACEUTICAL INC
 CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
 ELIPHOS, CALCIUM ACETATE
 REZIRA, HYDROCODONE BITARTRATE
 VITUZ, CHLORPHENIRAMINE MALEATE
 ZUTRIPRO, CHLORPHENIRAMINE MALEATE

CYPRESS PHARM INC

* CYPRESS PHARMACEUTICAL INC
 ZYFREL, ACETAMINOPHEN

**** D ******DAEWOONG PHARM CO**

* DAEWOONG PHARMACEUTICAL CO LTD
 MEROPENEM, MEROPENEM

DAIICHI SANKYO

* DAIICHI SANKYO INC
 AZOR, AMLODIPINE BESYLATE
 BENICAR HCT, HYDROCHLOROTHIAZIDE
 BENICAR, OLMESARTAN MEDOXOMIL
 TRIBENZOR, AMLODIPINE BESYLATE
 WELCHOL, COLESEVELAM HYDROCHLORIDE

DAIICHI SANKYO INC

* DAIICHI SANKYO INC
 EVOXAC, CEVIMELINE HYDROCHLORIDE
 MORPHABOND, MORPHINE SULFATE
 SAVAYSA, EDOXABAN TOSYLATE

DANCO LABS LLC

* DANCO LABORATORIES LLC
 MIFEPREX, MIFEPRISTONE

DAVA INTL INC

* DAVA INTERNATIONAL INC
 ALPRAZOLAM, ALPRAZOLAM

DAVA PHARMS INC

* DAVA PHARMACEUTICALS INC
 ACYCLOVIR, ACYCLOVIR
 AMOXICILLIN, AMOXICILLIN
 AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
 ATENOLOL, ATENOLOL
 CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
 DIAZEPAM, DIAZEPAM
 DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
 GLYBURIDE (MICRONIZED), GLYBURIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 MORPHINE SULFATE, MORPHINE SULFATE
 PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
 PROPYLTHIOURACIL, PROPYLTHIOURACIL
 PYRAZINAMIDE, PYRAZINAMIDE
 SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** D ****

* DAVA PHARMACEUTICALS INC
VOSPIRE ER, ALBUTEROL SULFATE

DAVIS AND GECK

* DAVIS AND GECK DIV AMERICAN CYANAMID CO
PRE-OP II, HEXACHLOROPHENE
PRE-OP, HEXACHLOROPHENE

DELCOR ASSET

* DELCOR ASSET CORP
OLUX E, CLOBETASOL PROPIONATE
ZOVIRAX, ACYCLOVIR

DELCOR ASSET CORP

* DELCOR ASSET CORP
ERYGEL, ERYTHROMYCIN
EVOCLIN, CLINDAMYCIN PHOSPHATE
EXTINA, KETOCONAZOLE
KENALOG, TRIAMCINOLONE ACETONIDE
LITHIUM CARBONATE, LITHIUM CARBONATE
LUXIQ, BETAMETHASONE VALERATE
OLUX, CLOBETASOL PROPIONATE
PREDNISON, PREDNISON
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VUSION, MICONAZOLE NITRATE
ZONALON, DOXEPIN HYDROCHLORIDE
ZOVIRAX, ACYCLOVIR

DENCO ASSET

* DENCO ASSET LLC
DENA VIR, PENCICLOVIR

DENTSPLY PHARM

* DENTSPLY PHARMACEUTICAL INC
CITANEST FORTE DENTAL, EPINEPHRINE BITARTRATE
ORAQIX, LIDOCAINE

DEPOMED INC

* DEPOMED INC
CAMBIA, DICLOFENAC POTASSIUM
GRALISE, GABAPENTIN
LAZANDA, FENTANYL CITRATE
NUCYNTA ER, TAPENTADOL HYDROCHLORIDE
NUCYNTA, TAPENTADOL HYDROCHLORIDE
ZIPSOR, DICLOFENAC POTASSIUM

DEPROCO

* DEPROCO INC
LIGNOSPAN FORTE, EPINEPHRINE BITARTRATE
LIGNOSPAN STANDARD, EPINEPHRINE BITARTRATE
SCANDONEST L, LEVONORDEFIN
SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE
SEPTOCAINE, ARTICAINE HYDROCHLORIDE

DEXCEL LTD

* DEXCEL LTD
DICLOFENAC SODIUM, DICLOFENAC SODIUM
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE

DEXCEL PHARMA

* DEXCEL PHARMA TECHNOLOGIES LTD
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LEVETIRACETAM, LEVETIRACETAM
OMEPRAZOLE, OMEPRAZOLE (OTC)
PERIOCHIP, CHLORHEXIDINE GLUCONATE

DIAGNOSTIC GREEN

* DIAGNOSTIC GREEN GMBH
INDOCYANINE GREEN, INDOCYANINE GREEN

DIALYSIS SUPS

* DIALYSIS SUPPLIES INC
NORMOCARB HF 25, MAGNESIUM CHLORIDE
NORMOCARB HF 35, MAGNESIUM CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** D **

DIGESTIVE CARE INC

* DIGESTIVE CARE INC
PERTZYE, PANCRELIPASE (AMYLASE)

DORADO PHARMA

* DORADO PHARMA LLC
KETOPROFEN, KETOPROFEN

DORC

* DORC INTERNATIONAL BV
MEMBRANEBLUE, TRYPAN BLUE
VISIONBLUE, TRYPAN BLUE

DOUGLAS PHARMS

* DOUGLAS PHARMACEUTICALS AMERICA LTD
MYORISAN, ISOTRETINOIN

DOW PHARM

* DOW PHARMACEUTICAL SCIENCES
ACANYA, BENZOYL PEROXIDE
AKNE-MYCIN, ERYTHROMYCIN
ATRALIN, TRETINOIN
JUBLIA, EFINACONAZOLE
ONEXTON, BENZOYL PEROXIDE
OXSORALEN-ULTRA, METHOXSALEN

DR REDDYS LA

* DR REDDYS LABORATORIES LOUISIANA LLC
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LOPURIN, ALLOPURINOL
SSD AF, SILVER SULFADIAZINE
SSD, SILVER SULFADIAZINE

DR REDDYS LABS INC

* DR REDDYS LABORATORIES INC
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMOXIL, AMOXICILLIN
AUGMENTIN '125', AMOXICILLIN
AUGMENTIN '200', AMOXICILLIN
AUGMENTIN '250', AMOXICILLIN
AUGMENTIN '400', AMOXICILLIN
AUGMENTIN '500', AMOXICILLIN
AUGMENTIN '875', AMOXICILLIN
AUGMENTIN ES-600, AMOXICILLIN
AUGMENTIN XR, AMOXICILLIN
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
FINASTERIDE, FINASTERIDE
FLUCONAZOLE, FLUCONAZOLE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
HABITROL, NICOTINE (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LAROTID, AMOXICILLIN
LEVOFLOXACIN, LEVOFLOXACIN
MELOXICAM, MELOXICAM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE
NITROGLYCERIN, NITROGLYCERIN
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
SIMVASTATIN, SIMVASTATIN
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

DR REDDYS LABS INTL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** D ****

* DR REDDYS LABORATORIES INTERNATIONAL SA
 MERCAPTOPYRIMIDINE, MERCAPTOPYRIMIDINE
 RAMELTEON, RAMELTEON

DR REDDYS LABS LTD

* DR REDDYS LABORATORIES LIMITED
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE

* DR REDDYS LABORATORIES LTD
 ALENDRONATE SODIUM, ALENDRONATE SODIUM
 AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 ANASTROZOLE, ANASTROZOLE
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 AZACITIDINE, AZACITIDINE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
 CARVEDILOL, CARVEDILOL
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 DECITABINE, DECITABINE
 DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR, DESLORATADINE
 DESLORATADINE, DESLORATADINE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DOCETAXEL, DOCETAXEL
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 ESZOPICLONE, ESZOPICLONE
 FAMOTIDINE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE (OTC)
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
 FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
 FINASTERIDE, FINASTERIDE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 GLIMEPIRIDE, GLIMEPIRIDE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
 IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 LAMOTRIGINE, LAMOTRIGINE
 LANSOPRAZOLE, LANSOPRAZOLE
 LANSOPRAZOLE, LANSOPRAZOLE (OTC)
 LATANOPROST, LATANOPROST
 LETROZOLE, LETROZOLE
 LEVETIRACETAM, LEVETIRACETAM
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** D ****

* DR REDDYS LABORATORIES LTD
 NAPROXEN AND ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 NAPROXEN SODIUM, NAPROXEN SODIUM
 NATEGLINIDE, NATEGLINIDE
 NIZATIDINE, NIZATIDINE
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 OFLOXACIN, OFLOXACIN
 OLANZAPINE, OLANZAPINE
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
 OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
 OMEPRAZOLE, OMEPRAZOLE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXAPROZIN, OXAPROZIN
 PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PARICALCITOL, PARICALCITOL
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 RAMIPRIL, RAMIPRIL
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
 RISPERIDONE, RISPERIDONE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SIROLIMUS, SIROLIMUS
 TACROLIMUS, TACROLIMUS
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 VINORELBINE TARTRATE, VINORELBINE TARTRATE
 ZAFIRLUKAST, ZAFIRLUKAST
 ZEMBRACE SYMTOUCH, SUMATRIPTAN SUCCINATE
 ZENATANE, ISOTRETINOIN
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

DR REDDYS LABS SA

* DR REDDYS LABORATORIES SA
 FENOFIBRATE (MICRONIZED), FENOFIBRATE

DRAximAGE

* DRAximAGE INC
 DTPA, TECHNETIUM TC-99M PENTETATE KIT
 TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
 TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT

DUCHESNAY

* DUCHESNAY INC
 BONJESTA, DOXYLAMINE SUCCINATE
 DICLEGIS, DOXYLAMINE SUCCINATE

DURAMED PHARMS BARR

* DURAMED PHARMACEUTICALS INC SUB BARR LABORATORIES INC
 AVIANE-28, ETHINYL ESTRADIOL
 CRYSELLE, ETHINYL ESTRADIOL
 DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
 ENPRESSE-28, ETHINYL ESTRADIOL
 METHYLPREDNISOLONE, METHYLPREDNISOLONE
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VELIVET, DESOGESTREL

DURAMED RES

* DURAMED RESEARCH INC
 AYGESTIN, NORETHINDRONE ACETATE

DURATA THERAPS INTL

* DURATA THERAPEUTICS INTERNATIONAL BV
 DALVANCE, DALBAVANCIN HYDROCHLORIDE

DUSA**WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1086, p. 953 of 1400**

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** D ****

* DUSA PHARMACEUTICALS INC
LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE

REDDYS

* DOCTOR REDDYS LABORATORIES LTD
DESLORATADINE, DESLORATADINE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE

**** E ******EAGLE PHARMS**

* EAGLE PHARMACEUTICALS INC
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
BENDEKA, BENDAMUSTINE HYDROCHLORIDE
DOCETAXEL, DOCETAXEL
RYANODEX, DANTROLENE SODIUM

EASTMAN KODAK

* EASTMAN KODAK CO
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE

ECI PHARMS LLC

* ECI PHARMACEUTICALS LLC
CALCIUM ACETATE, CALCIUM ACETATE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
METHIMAZOLE, METHIMAZOLE
PARICALCITOL, PARICALCITOL

ECLAT PHARMS LLC

* ECLAT PHARMACEUTICALS LLC
BLOXIVERZ, NEOSTIGMINE METHYLSULFATE
VAZCULEP, PHENYLEPHRINE HYDROCHLORIDE

ECOLAB

* ECOLAB INC
CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)
CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)

ECR

* ECR PHARMACEUTICALS
DEXAMETHASONE, DEXAMETHASONE

ECR PHARMA

* ECR PHARMA
TUSSICAPS, CHLORPHENIRAMINE POLISTIREX

EDENBRIDGE PHARMS

* EDENBRIDGE PHARMACEUTICALS LLC
CARBIDOPA, CARBIDOPA
ETHACRYNIC ACID, ETHACRYNIC ACID
IVERMECTIN, IVERMECTIN
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
TINIDAZOLE, TINIDAZOLE

EDGEMONT PHARMS LLC

* EDGEMONT PHARMACEUTICALS LLC
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FORFIVO XL, BUPROPION HYDROCHLORIDE

EDISON THERAPS LLC

* EDISON THERAPEUTICS LLC
METHERGINE, METHYLERGONOVINE MALEATE

EGALET US INC

* EGALET US INC
OXAYDO, OXYCODONE HYDROCHLORIDE
SPRIX, KETOROLAC TROMETHAMINE

EI INC

* EI INC
THEROXIDIL, MINOXIDIL (OTC)

EISAI INC

* EISAI INC
ACIPHEX, RABEPRAZOLE SODIUM
ARICEPT ODT, DONEPEZIL HYDROCHLORIDE
ARICEPT, DONEPEZIL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** E ******* EISAI INC**

BANZEL, RUFINAMIDE
 BELVIQ XR, LORCASERIN HYDROCHLORIDE
 BELVIQ, LORCASERIN HYDROCHLORIDE
 FYCOMPA, PERAMPANEL
 HALAVEN, ERIBULIN MESYLATE
 HEXALEN, ALTRETAMINE
 LENVIMA, LENVATINIB MESYLATE
 PANRETIN, ALITRETINOIN
 SALAGEN, PILOCARPINE HYDROCHLORIDE

ELAN PHARMA INTL LTD*** ELAN PHARMA INTERNATIONAL LTD**

EVAMIST, ESTRADIOL
 PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE

ELI LILLY AND CO*** ELI LILLY AND CO**

AXIRON, TESTOSTERONE
 BASAGLAR, INSULIN GLARGINE
 EFFIENT, PRASUGREL HYDROCHLORIDE
 HUMALOG KWIKPEN, INSULIN LISPRO RECOMBINANT
 PROZAC, FLUOXETINE HYDROCHLORIDE

ELI LILLY CO*** ELI LILLY CO**

ADCIRCA, TADALAFIL
 ZYPREXA RELPREVV, OLANZAPINE PAMOATE

ELITE LABS*** ELITE LABORATORIES INC**

HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

ELITE LABS INC*** ELITE LABORATORIES INC**

DANTROLENE SODIUM, DANTROLENE SODIUM
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 ISRADIPINE, ISRADIPINE
 LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
 PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE

EMCURE PHARMS*** EMCURE PHARMACEUTICALS LTD**

ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE

EMCURE PHARMS INDIA*** EMCURE PHARMACEUTICALS LTD INDIA**

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM

EMCURE PHARMS LTD*** EMCURE PHARMACEUTICALS LTD**

ACARBOSE, ACARBOSE
 ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
 ADENOSINE, ADENOSINE
 AMIKACIN SULFATE, AMIKACIN SULFATE
 BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
 BICNU, CARMUSTINE
 CIDOFOVIR, CIDOFOVIR
 COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
 ETOMIDATE, ETOMIDATE
 FUROSEMIDE, FUROSEMIDE
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 LEVOFLOXACIN, LEVOFLOXACIN
 METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
 RIFAMPIN, RIFAMPIN
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 TRANEXAMIC ACID, TRANEXAMIC ACID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** E ****

* EMCURE PHARMACEUTICALS LTD
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

EMD SERONO

* EMD SERONO INC
 GONAL-F RFF REDI-JECT, FOLLITROPIN ALFA/BETA
 GONAL-F RFF, FOLLITROPIN ALFA/BETA
 GONAL-F, FOLLITROPIN ALFA/BETA
 OVIDREL, CHORIOGONADOTROPIN ALFA
 SAIZEN, SOMATROPIN RECOMBINANT
 SEROSTIM, SOMATROPIN RECOMBINANT
 ZORBTIVE, SOMATROPIN RECOMBINANT

EMD SERONO INC

* EMD SERONO INC
 CETROTIDE, CETRORELIX

EMMAUS MEDCL

* EMMAUS MEDICAL INC
 NUTRESTORE, GLUTAMINE

ENDO PHARM

* ENDO PHARMACEUTICAL SOLUTIONS INC
 SUPPRELIN LA, HISTRELIN ACETATE
 VALSTAR PRESERVATIVE FREE, VALRUBICIN
 VANTAS, HISTRELIN ACETATE

ENDO PHARMS

* ENDO PHARMACEUTICALS INC
 DELATESTRYL, TESTOSTERONE ENANTHATE
 FORTESTA, TESTOSTERONE
 FROVA, FROVATRIPTAN SUCCINATE
 OPANA ER, OXYMORPHONE HYDROCHLORIDE
 OPANA, OXYMORPHONE HYDROCHLORIDE
 PERCODAN, ASPIRIN

ENDO PHARMS INC

* ENDO PHARMACEUTICALS INC
 AVEED, TESTOSTERONE UNDECANOATE
 BELBUCA, BUPRENORPHINE HYDROCHLORIDE
 COLY-MYCIN S, COLISTIN SULFATE
 MEGACE ES, MEGESTROL ACETATE
 NASCOBAL, CYANOCOBALAMIN
 VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE

ENDO VENTURES LTD

* ENDO VENTURES LTD IRELAND
 SUMAVEL DOSEPRO, SUMATRIPTAN SUCCINATE

ENDOCEUTICS INC

* ENDOCEUTICS INC
 INTRAROSA, PRASTERONE

EPIC PHARMA

* EPIC PHARMA INC
 MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE

* EPIC PHARMA LLC
 BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
 SULINDAC, SULINDAC
 TRANDOLAPRIL, TRANDOLAPRIL
 URSODIOL, URSODIOL

EPIC PHARMA INC

* EPIC PHARMA INC
 ESTRADIOL, ESTRADIOL
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

EPIC PHARMA LLC

* EPIC PHARMA LLC
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** E ******* EPIC PHARMA LLC**

DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
 SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE

ERGOJECT*** ERGOJECT LLC**

METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE

ESSENTIAL ISOTOPES*** ESSENTIAL ISOTOPES LLC**

AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

ETHYPHARM*** ETHYPHARM**

BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE

ETHYPHARM USA CORP*** ETHYPHARM USA CORP**

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE

EUROHLTH INTL SARL*** EUROHEALTH INTERNATIONAL SARL**

ADENOSINE, ADENOSINE
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 BUMETANIDE, BUMETANIDE
 BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
 BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
 CEFOXITIN, CEFOXITIN SODIUM
 CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
 DIGOXIN, DIGOXIN
 DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
 ETOMIDATE, ETOMIDATE
 FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
 FLUMAZENIL, FLUMAZENIL
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
 MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
 MILRINONE LACTATE, MILRINONE LACTATE
 MITOMYCIN, MITOMYCIN
 MORPHINE SULFATE, MORPHINE SULFATE
 NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 PHENYTOIN SODIUM, PHENYTOIN SODIUM
 PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 RIFAMPIN, RIFAMPIN
 SODIUM CHLORIDE 0.9% , SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
 SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE, SODIUM FERRIC GLUCONATE COMPLEX

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** E ****

* EUROHEALTH INTERNATIONAL SARL
 STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 VECURONIUM BROMIDE, VECURONIUM BROMIDE
 VINORELBINE TARTRATE, VINORELBINE TARTRATE

EXALENZ BIOSCIENCE

* EXALENZ BIOSCIENCE LTD
 IDKIT:HP, CITRIC ACID

EXELA PHARMA SCIENCE

* EXELA PHARMA SCIENCES
 CAFFEINE CITRATE, CAFFEINE CITRATE
 IBUPROFEN LYSINE, IBUPROFEN LYSINE
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE

EXELA PHARMA SCS LLC

* EXELA PHARMA SCIENCES LLC
 CAFFEINE CITRATE, CAFFEINE CITRATE
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
 MAGNESIUM SULFATE, MAGNESIUM SULFATE
 POTASSIUM ACETATE, POTASSIUM ACETATE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

EXELIXIS

* EXELIXIS INC
 COMETRIQ, CABOZANTINIB S-MALATE

EXELIXIS INC

* EXELIXIS INC
 CABOMETYX, CABOZANTINIB S-MALATE

EXELTIS SUISSE

* EXELTIS SUISSE SA
 ECOZA, ECONAZOLE NITRATE

EXELTIS USA INC

* EXELTIS USA INC
 ESTRASORB, ESTRADIOL HEMIHYDRATE

FOUGERA

* E FOUGERA DIV ALTANA INC
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 FLUOCINONIDE, FLUOCINONIDE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 HYDROCORTISONE, HYDROCORTISONE
 LIDOCAINE, LIDOCAINE
 NITROGLYCERIN, NITROGLYCERIN
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 NYSTATIN, NYSTATIN

LILLY

* ELI LILLY AND CO
 ALIMTA, PEMETREXED DISODIUM
 CIALIS, TADALAFIL
 CYMBALTA, DULOXETINE HYDROCHLORIDE
 EVISTA, RALOXIFENE HYDROCHLORIDE
 FORTEO, TERIPARATIDE RECOMBINANT HUMAN
 GEMZAR, GEMCITABINE HYDROCHLORIDE
 GLUCAGON, GLUCAGON RECOMBINANT
 HUMALOG KWIKPEN, INSULIN LISPRO RECOMBINANT
 HUMALOG MIX 50/50 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT
 HUMALOG MIX 50/50, INSULIN LISPRO PROTAMINE RECOMBINANT
 HUMALOG MIX 75/25 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT
 HUMALOG MIX 75/25, INSULIN LISPRO PROTAMINE RECOMBINANT
 HUMATROPE, SOMATROPIN RECOMBINANT

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** E ****

* ELI LILLY AND CO
 HUMULIN 70/30 PEN, INSULIN RECOMBINANT HUMAN (OTC)
 HUMULIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
 HUMULIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
 HUMULIN R KWIKPEN, INSULIN HUMAN
 HUMULIN R PEN, INSULIN RECOMBINANT HUMAN (OTC)
 HUMULIN R, INSULIN HUMAN
 HUMULIN R, INSULIN RECOMBINANT HUMAN (OTC)
 PROZAC WEEKLY, FLUOXETINE HYDROCHLORIDE
 QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
 STRATTERA, ATOMOXETINE HYDROCHLORIDE
 SYMBYAX, FLUOXETINE HYDROCHLORIDE
 ZYPREXA ZYDIS, OLANZAPINE
 ZYPREXA, OLANZAPINE

**** F ******FACTA FARMA**

* FACTA FARMACEUTICI SPA
 CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
 CEFTRIAXONE, CEFTRIAXONE SODIUM
 CEFUROXIME SODIUM, CEFUROXIME SODIUM

FDC LTD

* FDC LTD
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 LATANOPROST, LATANOPROST
 OFLOXACIN, OFLOXACIN
 TIMOLOL MALEATE, TIMOLOL MALEATE

FEINSTEIN

* FEINSTEIN INSTITUTE MEDICAL RESEARCH
 AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

FERA PHARMS

* FERA PHARMACEUTICALS LLC
 TOBRAMYCIN, TOBRAMYCIN

FERA PHARMS LLC

* FERA PHARMACEUTICALS LLC
 LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
 SODIUM PHENYL BUTYRATE, SODIUM PHENYL BUTYRATE

FERNDALE LABS

* FERNDAL LABORATORIES INC
 HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE

FERRING

* FERRING PHARMACEUTICALS INC
 ACTHREL, CORTICORELIN OVINE TRIFLUTATE
 BRAVELLE, UROFOLLITROPIN
 CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
 ENDOMETRIN, PROGESTERONE
 FIRMAGON, DEGARELIX ACETATE
 MENOPUR, MENOTROPINS (FSH)
 MINIRIN, DESMOPRESSIN ACETATE
 ZOMACTON, SOMATROPIN RECOMBINANT

FERRING PHARMS AS

* FERRING PHARMACEUTICALS AS
 LYSTEDA, TRANEXAMIC ACID
 PREPOPIK, CITRIC ACID

FERRING PHARMS INC

* FERRING PHARMACEUTICALS INC
 CERVIDIL, DINOPROSTONE
 DDAVP (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
 DDAVP, DESMOPRESSIN ACETATE

FLAMEL IRELAND LTD

* FLAMEL IRELAND LIMITED
 AKOVAZ, EPHEDRINE SULFATE

FLAMINGO PHARMS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** F ****

* FLAMINGO PHARMACEUTICALS LTD
 METRONIDAZOLE, METRONIDAZOLE
 PIROXICAM, PIROXICAM

FOREST LABS

* FOREST LABORATORIES INC
 BYSTOLIC, NEBIVOLOL HYDROCHLORIDE
 CELEXA, CITALOPRAM HYDROBROMIDE
 LEXAPRO, ESCITALOPRAM OXALATE
 THYROLAR-0.25, LIOTRIX (T4
 THYROLAR-0.5, LIOTRIX (T4
 THYROLAR-1, LIOTRIX (T4
 THYROLAR-2, LIOTRIX (T4
 THYROLAR-3, LIOTRIX (T4

FOREST LABS INC

* FOREST LABORATORIES INC
 BENTYL PRESERVATIVE FREE, DICYCLOMINE HYDROCHLORIDE
 BENTYL, DICYCLOMINE HYDROCHLORIDE
 CARAFATE, SUCRALFATE
 FETZIMA, LEVOMILNACIPRAN HYDROCHLORIDE
 RECTIV, NITROGLYCERIN
 ULTRESA, PANCRELIPASE (AMYLASE
 URSO 250, URSODIOL
 URSO FORTE, URSODIOL
 VIOKACE, PANCRELIPASE (AMYLASE
 ZENPEP, PANCRELIPASE (AMYLASE

FOREST LABS LLC

* FOREST LABORATORIES LLC
 BYVALSON, NEBIVOLOL HYDROCHLORIDE
 CANASA, MESALAMINE
 LINZESS, LINACLOTIDE
 NAMENDA XR, MEMANTINE HYDROCHLORIDE
 NAMENDA, MEMANTINE HYDROCHLORIDE
 NAMZARIC, DONEPEZIL HYDROCHLORIDE
 PYLERA, BISMUTH SUBCITRATE POTASSIUM
 SAPHRIS, ASENAPINE MALEATE
 VIIBRYD, VILAZODONE HYDROCHLORIDE

FOREST RES INST INC

* FOREST RESEARCH INSTITUTE INC
 VRAYLAR, CARIPRAZINE HYDROCHLORIDE

FOUGERA PHARMS

* FOUGERA PHARMACEUTICALS INC
 ADAPALENE, ADAPALENE
 ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
 AMCINONIDE, AMCINONIDE
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CALCIPOTRIENE, CALCIPOTRIENE
 CICLOPIROX, CICLOPIROX
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CLOTRIMAZOLE, CLOTRIMAZOLE
 CUTIVATE, FLUTICASONE PROPIONATE
 DESONIDE, DESONIDE
 DESOXIMETASONE, DESOXIMETASONE
 DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
 ECONAZOLE NITRATE, ECONAZOLE NITRATE
 ERYTHROMYCIN, ERYTHROMYCIN
 FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
 FLUOCINONIDE, FLUOCINONIDE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
 HYDROCORTISONE, HYDROCORTISONE
 IMIQUIMOD, IMIQUIMOD
 KETOCONAZOLE, KETOCONAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** F ****

* FOUGERA PHARMACEUTICALS INC
 LIDOCAINE AND PRILOCAINE, LIDOCAINE
 METRONIDAZOLE, METRONIDAZOLE
 MOMETASONE FUROATE, MOMETASONE FUROATE
 MUPIROCIN, MUPIROCIN
 NYSTATIN, NYSTATIN
 OXISTAT, OXICONAZOLE NITRATE
 PANDEL, HYDROCORTISONE PROBUTATE
 PREDNICARBATE, PREDNICARBATE
 SOLARAZE, DICLOFENAC SODIUM
 SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
 TERCONAZOLE, TERCONAZOLE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE

FOUGERA PHARMS INC

* FOUGERA PHARMACEUTICALS INC
 ACYCLOVIR, ACYCLOVIR
 FLUOCINONIDE, FLUOCINONIDE
 TACROLIMUS, TACROLIMUS

FRESENIUS

* FRESENIUS KABI DEUTSCHLAND GMBH
 INTRALIPID 10%, SOYBEAN OIL
 INTRALIPID 20%, SOYBEAN OIL
 INTRALIPID 30%, SOYBEAN OIL

FRESENIUS KABI

* FRESENIUS KABI AUSTRIA GMBH
 LACTULOSE, LACTULOSE

FRESENIUS KABI ONCOL

* FRESENIUS KABI ONCOLOGY PLC
 ANASTROZOLE, ANASTROZOLE
 BICALUTAMIDE, BICALUTAMIDE
 CARBOPLATIN, CARBOPLATIN
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 LETROZOLE, LETROZOLE
 OXALIPLATIN, OXALIPLATIN
 PACLITAXEL, PACLITAXEL

FRESENIUS KABI USA

* FRESENIUS KABI USA LLC
 ACETAMINOPHEN, ACETAMINOPHEN
 ACETYLCYSTEINE, ACETYLCYSTEINE
 ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
 ADENOSINE, ADENOSINE
 AMIKACIN SULFATE, AMIKACIN SULFATE
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 ARGATROBAN, ARGATROBAN
 ASTRAMORPH PF, MORPHINE SULFATE
 AZITHROMYCIN, AZITHROMYCIN
 AZTREONAM, AZTREONAM
 BACITRACIN, BACITRACIN
 BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
 BIVALIRUDIN, BIVALIRUDIN
 BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
 CAFFEINE CITRATE, CAFFEINE CITRATE
 CARBOPLATIN, CARBOPLATIN
 CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
 CEFOTETAN, CEFOTETAN DISODIUM
 CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE
 CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
 CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
 CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
 CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
 CISPLATIN, CISPLATIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** F **

* FRESENIUS KABI USA LLC
 CLADRIBINE, CLADRIBINE
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
 CYTARABINE, CYTARABINE
 DACARBAZINE, DACARBAZINE
 DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
 DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
 DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE, DEXAMETHASONE SODIUM PHOSPHATE
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 DIMENHYDRINATE, DIMENHYDRINATE
 DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
 DIPRIVAN, PROPOFOL
 DIPYRIDAMOLE, DIPYRIDAMOLE
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 DOXY 100, DOXYCYCLINE HYCLATE
 DOXY 200, DOXYCYCLINE HYCLATE
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
 ETOPOSIDE, ETOPOSIDE
 FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE
 FLOXURIDINE, FLOXURIDINE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 FLUMAZENIL, FLUMAZENIL
 FLUOROURACIL, FLUOROURACIL
 FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
 FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
 FOLIC ACID, FOLIC ACID
 FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
 FUROSEMIDE, FUROSEMIDE
 GANCICLOVIR, GANCICLOVIR SODIUM
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 GLUCAGON, GLUCAGON HYDROCHLORIDE
 GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
 HALOPERIDOL, HALOPERIDOL LACTATE
 HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
 HEPARIN SODIUM, HEPARIN SODIUM
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
 IFOSFAMIDE, IFOSFAMIDE
 INDOMETHACIN, INDOMETHACIN
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 KABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
 KANAMYCIN SULFATE, KANAMYCIN SULFATE
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
 LEVETIRACETAM, LEVETIRACETAM
 LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
 LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
 LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
 LINEZOLID, LINEZOLID
 MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 MAGNESIUM SULFATE, MAGNESIUM SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** F **

* FRESENIUS KABI USA LLC
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MANNITOL 25%, MANNITOL
MESNA, MESNA
METARAMINOL BITARTRATE, METARAMINOL BITARTRATE
METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE, MILRINONE LACTATE
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NAROPIN, ROPIVACAINE HYDROCHLORIDE
NEBUPENT, PENTAMIDINE ISETHIONATE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
NESACAINE, CHLOROPROCAINE HYDROCHLORIDE
NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
OXYTOCIN, OXYTOCIN
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PENTAM, PENTAMIDINE ISETHIONATE
PERIKABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
POLOCAINE, MEPIVACAINE HYDROCHLORIDE
POLOCAINE-MPF, MEPIVACAINE HYDROCHLORIDE
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
POTASSIUM CHLORIDE IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROGESTERONE, PROGESTERONE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PROTAMINE SULFATE, PROTAMINE SULFATE
PYRIDOXINE HYDROCHLORIDE, PYRIDOXINE HYDROCHLORIDE
RIFAMPIN, RIFAMPIN
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
SMOFLIPID 20%, FISH OIL
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
TIGECYCLINE, TIGECYCLINE
TOBRAMYCIN SULFATE (PHARMACY BULK), TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
VALPROATE SODIUM, VALPROATE SODIUM
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VIBISONE, CYANOCOBALAMIN
VINBLASTINE SULFATE, VINBLASTINE SULFATE
VINORELBINE TARTRATE, VINORELBINE TARTRATE
XYLOCAINE 4% PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
XYLOCAINE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE
XYLOCAINE, LIDOCAINE HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

FRESENIUS MEDCL

WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1086, p. 963 of 1400

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** F ****

* FRESENIUS MEDICAL CARE NORTH AMERICA

DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM
 DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM
 DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM
 PHOSLO GELCAPS, CALCIUM ACETATE
 PHOSLYRA, CALCIUM ACETATE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

FRONTIDA BIOPHARM

* FRONTIDA BIOPHARM INC

CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 PRIMIDONE, PRIMIDONE

FSC THERAP

* FSC THERAPEUTICS LLC

ACIPHEX SPRINKLE, RABEPRAZOLE SODIUM

**** G ******G AND W LABS**

* G AND W LABORATORIES INC

ACEPHEN, ACETAMINOPHEN (OTC)
 CICLOPIROX, CICLOPIROX
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
 INDOMETHACIN, INDOMETHACIN
 METRONIDAZOLE, METRONIDAZOLE
 MICONAZOLE 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
 MOMETASONE FUROATE, MOMETASONE FUROATE
 PROCHLORPERAZINE, PROCHLORPERAZINE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PROMETHEGAN, PROMETHAZINE HYDROCHLORIDE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

G AND W LABS INC

* G AND W LABORATORIES INC

ALBUTEROL SULFATE, ALBUTEROL SULFATE
 BETA-VAL, BETAMETHASONE VALERATE
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CALCIPOTRIENE, CALCIPOTRIENE
 CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
 CICLOPIROX, CICLOPIROX
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 DESONIDE, DESONIDE
 DESOXIMETASONE, DESOXIMETASONE
 DOXYCYCLINE, DOXYCYCLINE
 ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 FLUOCINONIDE, FLUOCINONIDE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 IMIQUIMOD, IMIQUIMOD
 MESALAMINE, MESALAMINE
 METRONIDAZOLE, METRONIDAZOLE
 MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
 MYKACET, NYSTATIN
 NYSTATIN, NYSTATIN
 PROMETH VC PLAIN, PHENYLEPHRINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ****

* G AND W LABORATORIES INC
 PROMETH W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
 QUINIDINE SULFATE, QUINIDINE SULFATE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

GALDERMA LABS

* GALDERMA LABORATORIES INC
 CLOBEX, CLOBETASOL PROPIONATE
 EPIDUO FORTE, ADAPALENE

GALDERMA LABS LP

* GALDERMA LABORATORIES L P
 CLOBEX, CLOBETASOL PROPIONATE

* GALDERMA LABORATORIES LP
 CAPEX, FLUOCINOLONE ACETONIDE
 CLOBEX, CLOBETASOL PROPIONATE
 DESOWEN, DESONIDE
 DIFFERIN, ADAPALENE
 DIFFERIN, ADAPALENE (OTC)
 EPIDUO, ADAPALENE
 METROCREAM, METRONIDAZOLE
 METROGEL, METRONIDAZOLE
 METROLOTION, METRONIDAZOLE
 MIRVASO, BRIMONIDINE TARTRATE
 ORACEA, DOXYCYCLINE
 PLIAGLIS, LIDOCAINE
 SOOLANTRA, IVERMECTIN
 TRI-LUMA, FLUOCINOLONE ACETONIDE
 VECTICAL, CALCITRIOL

GALEN SPECIALTY

* GALEN SPECIALTY PHARMA US LLC
 SYNERA, LIDOCAINE

GASTROENTERO

* GASTROENTERO LOGIC LLC
 OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN, AMOXICILLIN

GATE PHARMS

* GATE PHARMACEUTICALS
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 LINEZOLID, LINEZOLID

GATOR PHARMS

* GATOR PHARMACEUTICALS INC
 COLPREP KIT, MAGNESIUM SULFATE

GAVIS PHARMS

* GAVIS PHARMACEUTICALS LLC
 NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 NYSTATIN, NYSTATIN
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 QUINARETIC, HYDROCHLOROTHIAZIDE
 TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE

GAVIS PHARMS LLC

* GAVIS PHARMACEUTICALS LLC
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE

GD SEARLE

* GD SEARLE LLC
 CELEBREX, CELECOXIB
 DAYPRO, OXAPROZIN

GD SEARLE LLC

* GD SEARLE LLC
 ALDACTAZIDE, HYDROCHLOROTHIAZIDE
 ALDACTONE, SPIRONOLACTONE
 ARTHROTEC, DICLOFENAC SODIUM
 CALAN, VERAPAMIL HYDROCHLORIDE
 COVERA-HS, VERAPAMIL HYDROCHLORIDE
 CYTOTEC, MISOPROSTOL
 FLAGYL ER, METRONIDAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ******* GD SEARLE LLC**

FLAGYL, METRONIDAZOLE
 INSPRA, EPLERENONE
 LOMOTIL, ATROPINE SULFATE
 NORPACE CR, DISOPYRAMIDE PHOSPHATE
 NORPACE, DISOPYRAMIDE PHOSPHATE
 SYNAREL, NAFARELIN ACETATE

GE HEALTHCARE*** GE HEALTHCARE**

ADREVIEW, IOBENGUANE SULFATE I-123
 CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT
 INDICLOR, INDIUM IN-111 CHLORIDE
 INDIUM IN 111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE
 METASTRON, STRONTIUM CHLORIDE SR-89
 MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM
 MYOVUE 30ML, TECHNETIUM TC-99M TETROFOSMIN KIT
 MYOVUE, TECHNETIUM TC-99M TETROFOSMIN KIT
 OMNIPAQUE 140, IOHEXOL
 OMNIPAQUE 180, IOHEXOL
 OMNIPAQUE 240, IOHEXOL
 OMNIPAQUE 300, IOHEXOL
 OMNIPAQUE 350, IOHEXOL
 OMNISCAN, GADODIAMIDE
 OPTISON, ALBUMIN HUMAN
 TECHNETIUM TC 99M GENERATOR, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
 THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
 VISIPAQUE 270, IODIXANOL
 VISIPAQUE 320, IODIXANOL
 VIZAMYL, FLUTEMETAMOL F-18

GE HLTHCARE INC*** GE HEALTHCARE INC**

DATSCAN, IOFLUPANE I-123

GEDEON RICHTER USA*** GEDEON RICHTER USA INC**

FINASTERIDE, FINASTERIDE

GEMINI LABS LLC*** GEMINI LABORATORIES LLC**

OXANDRIN, OXANDROLONE

GENENTECH*** GENENTECH INC**

ERIVEDGE, VISMODEGIB
 NUTROPIN AQ NUSPIN, SOMATROPIN RECOMBINANT
 NUTROPIN AQ PEN, SOMATROPIN RECOMBINANT

GENENTECH INC*** GENENTECH INC**

COTELLIC, COBIMETINIB FUMARATE
 ESBRIET, PIRFENIDONE

GENZYME*** GENZYME CORP**

CEREZYME, IMIGLUCERASE
 CLOLAR, CLOFARABINE
 MOZOBIL, PLERIXAFOR
 RENAGEL, SEVELAMER HYDROCHLORIDE
 RENVELA, SEVELAMER CARBONATE
 THYROGEN, THYROTROPIN ALFA

GENZYME CORP*** GENZYME CORP**

CAPRELSA, VANDETANIB
 CERDELGA, ELIGLUSTAT TARTRATE
 HECTOROL, DOXERCALCIFEROL

GILEAD*** GILEAD SCIENCES INC**

ATRIPLA, EFAVIRENZA
 CAYSTON, AZTREONAM
 EMTRIVA, AZDRCYTRABINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ****

* GILEAD SCIENCES INC
 HEPSERA, ADEFOVIR DIPIVOXIL
 LETAIRIS, AMBRISENTAN
 RANEXA, RANOLAZINE
 TRUVADA, EMTRICITABINE

GILEAD SCIENCES INC

* GILEAD SCIENCES INC
 COMPLERA, EMTRICITABINE
 DESCOVY, EMTRICITABINE
 EPCLUSA, SOFOSBUVIR
 GENVOYA, COBICISTAT
 HARVONI, LEDIPASVIR
 ODEFSEY, EMTRICITABINE
 SOVALDI, SOFOSBUVIR
 STRIBILD, COBICISTAT
 TYBOST, COBICISTAT
 VEMLIDY, TENOFOVIR ALAFENAMIDE FUMARATE
 VIREAD, TENOFOVIR DISOPROXIL FUMARATE
 VITEKTA, ELVITEGRAVIR
 ZYDELIG, IDELALISIB

GLAND PHARMA LTD

* GLAND PHARMA LTD
 ADENOSINE, ADENOSINE
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 AZITHROMYCIN, AZITHROMYCIN
 DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 HALOPERIDOL, HALOPERIDOL LACTATE
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 MEROPENEM, MEROPENEM
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MILRINONE LACTATE, MILRINONE LACTATE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 PACITAXEL, PACLITAXEL
 POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VECURONIUM BROMIDE, VECURONIUM BROMIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

GLAXO GRP ENGLAND

* GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE
 INCRUSE ELLIPTA , UMECLIDINIUM BROMIDE

GLAXO GRP LTD

* GLAXO GROUP LTD DBA GLAXOSMITHKLINE
 FLOVENT HFA, FLUTICASONE PROPIONATE
 * GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE
 ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE
 ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE
 ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE
 ADVAIR HFA, FLUTICASONE PROPIONATE
 BREO ELLIPTA, FLUTICASONE FUROATE
 FLOVENT DISKUS 100, FLUTICASONE PROPIONATE
 FLOVENT DISKUS 250, FLUTICASONE PROPIONATE
 FLOVENT DISKUS 50, FLUTICASONE PROPIONATE
 ZANTAC 150, RANITIDINE HYDROCHLORIDE
 ZANTAC 300, RANITIDINE HYDROCHLORIDE
 ZANTAC, RANITIDINE HYDROCHLORIDE

GLAXOSMITHKLINE

* GLAXOSMITHKLINE
 ABREVA, DOCOSANOL (OTC)
 AVODART, DUTASTERIDE
 BACTROBAN, MUPIROCIN
 BACTROBAN, MUPIROCIN CALCIUM
 BECONASE AQ, BECLMETHASONE DIPROPIONATE MONOHYDRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ****

- * GLAXOSMITHKLINE
 - CEFTIN, CEFUROXIME AXETIL
 - EPIVIR-HBV, LAMIVUDINE
 - FLONASE SENSIMIST ALLERGY RELIEF, FLUTICASONE FUROATE (OTC)
 - IMITREX STATDOSE, SUMATRIPTAN SUCCINATE
 - IMITREX, SUMATRIPTAN
 - IMITREX, SUMATRIPTAN SUCCINATE
 - JALYN, DUTASTERIDE
 - MALARONE PEDIATRIC, ATOVAQUONE
 - MALARONE, ATOVAQUONE
 - NICORETTE (MINT), NICOTINE POLACRILEX (OTC)
 - NICORETTE, NICOTINE POLACRILEX (OTC)
 - POTIGA, EZOGABINE
 - RELENZA, ZANAMIVIR
 - VALTREX, VALACYCLOVIR HYDROCHLORIDE
 - WELLBUTRIN SR, BUPROPION HYDROCHLORIDE
 - ZYBAN, BUPROPION HYDROCHLORIDE
- * GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND
 - ANORO ELLIPTA, UMECLIDINIUM BROMIDE
 - ARNUIITY ELLIPTA, FLUTICASONE FUROATE
- * GLAXOSMITHKLINE INTELLECTUAL PROPERTY LTD ENGLAND
 - SEREVENT, SALMETEROL XINAFOATE
 - VENTOLIN HFA, ALBUTEROL SULFATE

GLAXOSMITHKLINE CON

- * GLAXOSMITHKLINE CONSUMER HEALTH
 - TRANSDERM SCOP, SCOPOLAMINE

GLAXOSMITHKLINE CONS

- * GLAXOSMITHKLINE CONSUMER HEALTHCARE
 - ALLI, ORLISTAT (OTC)
 - COMMIT, NICOTINE POLACRILEX (OTC)
 - EXCEDRIN (MIGRAINE), ACETAMINOPHEN (OTC)
 - FLONASE ALLERGY RELIEF, FLUTICASONE PROPIONATE (OTC)
 - NICORETTE, NICOTINE POLACRILEX (OTC)
 - PREVACID 24 HR, LANSOPRAZOLE (OTC)
 - VOLTAREN, DICLOFENAC SODIUM

GLAXOSMITHKLINE LLC

- * GLAXOSMITHKLINE LLC
 - AMERGE, NARATRIPTAN HYDROCHLORIDE
 - DYAZIDE, HYDROCHLOROTHIAZIDE
 - FLOLAN, EPOPROSTENOL SODIUM
 - INNOPRAN XL, PROPRANOLOL HYDROCHLORIDE
 - LAMICTAL CD, LAMOTRIGINE
 - LAMICTAL ODT, LAMOTRIGINE
 - LAMICTAL XR, LAMOTRIGINE
 - LAMICTAL, LAMOTRIGINE
 - MEPRON, ATOVAQUONE
 - REQUIP XL, ROPINIROLE HYDROCHLORIDE
 - REQUIP, ROPINIROLE HYDROCHLORIDE
 - RYTHMOL SR, PROPAFENONE HYDROCHLORIDE
 - RYTHMOL, PROPAFENONE HYDROCHLORIDE

GLENMARK GENERICS

- * GLENMARK GENERICS INC USA
 - ADAPALENE, ADAPALENE
 - BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 - CALCIPOTRIENE, CALCIPOTRIENE
 - IMIQUIMOD, IMIQUIMOD
 - MOMETASONE FUROATE, MOMETASONE FUROATE
 - MUPIROCIN, MUPIROCIN CALCIUM
 - NIZATIDINE, NIZATIDINE
 - RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 - ZONISAMIDE, ZONISAMIDE
- * GLENMARK GENERICS LIMITED
 - BRIELLYN, ETHINYL ESTRADIOL
 - FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 - LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** G **

- * GLENMARK GENERICS LTD
 ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
 ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
 ALYACEN 1/35, ETHINYL ESTRADIOL
 ALYACEN 7/7/7, ETHINYL ESTRADIOL
 ASHLYNA, ETHINYL ESTRADIOL
 ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE
 CARVEDILOL, CARVEDILOL
 CICLOPIROX, CICLOPIROX
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 DESOXIMETASONE, DESOXIMETASONE
 ESZOPICLONE, ESZOPICLONE
 FELODIPINE, FELODIPINE
 FLUCONAZOLE, FLUCONAZOLE
 FLUOCINONIDE, FLUOCINONIDE
 GABAPENTIN, GABAPENTIN
 HEATHER, NORETHINDRONE
 HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
 LAMOTRIGINE, LAMOTRIGINE
 LEVOFLOXACIN, LEVOFLOXACIN
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LITHIUM CARBONATE, LITHIUM CARBONATE
 MARLISSA, ETHINYL ESTRADIOL
 MELOXICAM, MELOXICAM
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
 MOMETASONE FUROATE, MOMETASONE FUROATE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 NAPROXEN SODIUM, NAPROXEN SODIUM
 NAPROXEN, NAPROXEN
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NORETHINDRONE, NORETHINDRONE
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 OMEPRAZOLE, OMEPRAZOLE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON, ONDANSETRON
 OXCARBAZEPINE, OXCARBAZEPINE
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 RILUZOLE, RILUZOLE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 TELMISARTAN, TELMISARTAN
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 THEOPHYLLINE, THEOPHYLLINE
 TOPIRAMATE, TOPIRAMATE
 TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE, TRANDOLAPRIL
 TRETINOIN, TRETINOIN
 TROSPIMUM CHLORIDE, TROSPIMUM CHLORIDE
 URSODIOL, URSODIOL
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
 VIORELE, DESOGESTREL
 ZOLMITRIPTAN, ZOLMITRIPTAN
- * GLENMARK GENERICS LTD INDIA
 INDOMETHACIN, INDOMETHACIN
 NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

GLENMARK PHARMS

- * GLENMARK PHARMACEUTICALS INC USA
 CICLOPIROX, CICLOPIROX
 CLOTRIMAZOLE, CLOTRIMAZOLE
 MUPIROCIN, MUPIROCIN
- * GLENMARK PHARMACEUTICALS LTD
 MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
- * GLENMARK PHARMACEUTICALS SA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ****

* GLENMARK PHARMACEUTICALS SA
 CALCIPOTRIENE, CALCIPOTRIENE
 CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 LINEZOLID, LINEZOLID
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

GLENMARK PHARMS INC

* GLENMARK PHARMACEUTICALS INC USA
 LITHIUM CARBONATE, LITHIUM CARBONATE

GLENMARK PHARMS LTD

* GLENMARK PHARMACEUTICALS LTD
 BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
 EZETIMIBE, EZETIMIBE
 FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LEVONORGESTREL, LEVONORGESTREL (OTC)
 LIDOCAINE, LIDOCAINE
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
 RUFINAMIDE, RUFINAMIDE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 VORICONAZOLE, VORICONAZOLE

GLOBAL ISOTOPES LLC

* GLOBAL ISOTOPES LLC DBA ZEVACOR MOLECULAR
 AMMONIA N 13, AMMONIA N-13
 CHOLINE C-11, CHOLINE C-11
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

GRANULES INDIA

* GRANULES INDIA LTD
 IBUPROFEN, IBUPROFEN (OTC)
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)

GRANULES INDIA LTD

* GRANULES INDIA LTD
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)

GROUPE PARIMA INC

* GROUPE PARIMA INC
 DESOXIMETASONE, DESOXIMETASONE

GUARDIAN DRUG

* GUARDIAN DRUG CO INC
 FOAMCOAT, ALUMINUM HYDROXIDE (OTC)

GUERBET

* GUERBET LLC
 DOTAREM, GADOTERATE MEGLUMINE
 LIPIODOL, ETHIODIZED OIL

HANFORD GC

* GC HANFORD MANUFACTURING CO
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 AMPICILLIN SODIUM, AMPICILLIN SODIUM
 PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM

POHL BOSKAMP

* G POHL BOSKAMP GMBH AND CO KG
 GONITRO, NITROGLYCERIN

**** H ******HAEMONETICS**

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ******* HAEMONETICS CORP**

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

HALOCARBON PRODS*** HALOCARBON PRODUCTS CORP**ISOFLURANE, ISOFLURANE
SEVOFLURANE, SEVOFLURANE**HALOZYME THERAP***** HALOZYME THERAPEUTICS INC**

HYLENEX RECOMBINANT, HYALURONIDASE RECOMBINANT HUMAN

HAMELN PHARMA PLUS*** HAMELN PHARMA PLUS GMBH**PENTETATE CALCIUM TRISODIUM, PENTETATE CALCIUM TRISODIUM
PENTETATE ZINC TRISODIUM, PENTETATE ZINC TRISODIUM**HAMELN RDS GMBH***** HAMELN RDS GMBH**

GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE

HARRIS PHARM*** HARRIS PHARMACEUTICAL INC**FLUCONAZOLE, FLUCONAZOLE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE**HAUPT PHARMA***** HAUPT PHARMA INC**

NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL

HEC PHARM USA INC*** HEC PHARM USA INC**

CLARITHROMYCIN, CLARITHROMYCIN

HELSINN HLTHCARE*** HELSINN HEALTHCARE SA**AKYNZEO, NETUPITANT
ALOXI, PALONOSETRON HYDROCHLORIDE**HERCON PHARM***** HERCON PHARMACEUTICAL LLC**

NITROGLYCERIN, NITROGLYCERIN

HERITAGE LIFE*** HERITAGE LIFE SCIENCES BARBADOS INC**

CLOZARIL, CLOZAPINE

HERITAGE PHARMA*** HERITAGE PHARMA LABS INC**ACETAZOLAMIDE, ACETAZOLAMIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
DIFLUNISAL, DIFLUNISAL
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
LITHIUM CARBONATE, LITHIUM CARBONATE
METHIMAZOLE, METHIMAZOLE
NIFEDIPINE, NIFEDIPINE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE**HERITAGE PHARMS INC***** HERITAGE PHARMACEUTICALS INC**ACETAZOLAMIDE, ACETAZOLAMIDE
ACHROMYCIN V, TETRACYCLINE HYDROCHLORIDE
ALPRAZOLAM, ALPRAZOLAM
CALCIUM ACETATE, CALCIUM ACETATE
CARISOPRODOL AND ASPIRIN, ASPIRIN
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
ETHOSUXIMIDE, ETHOSUXIMIDE
FELODIPINE, FELODIPINE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ******* HERITAGE PHARMACEUTICALS INC**

GLYBURIDE, GLYBURIDE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 INDOMETHACIN, INDOMETHACIN
 LEFLUNOMIDE, LEFLUNOMIDE
 MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
 NIMODIPINE, NIMODIPINE
 NYSTATIN, NYSTATIN
 PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
 SULINDAC, SULINDAC
 TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

HERON THERAPS INC*** HERON THERAPEUTICS INC**

SUSTOL, GRANISETRON

HETERO LABS LTD III*** HETERO LABS LTD UNIT III**

ABACAVIR SULFATE, ABACAVIR SULFATE
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 FENOFIBRATE, FENOFIBRATE
 FINASTERIDE, FINASTERIDE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 INDOMETHACIN, INDOMETHACIN
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LITHIUM CARBONATE, LITHIUM CARBONATE
 METHOCARBAMOL, METHOCARBAMOL
 NEVIRAPINE, NEVIRAPINE
 SIMVASTATIN, SIMVASTATIN
 STAVUDINE, STAVUDINE
 TORSEMIDE, TORSEMIDE
 ZIDOVUDINE, ZIDOVUDINE

HETERO LABS LTD V*** HETERO LABS LTD UNIT V**

ACYCLOVIR, ACYCLOVIR
 ARIPIRAZOLE, ARIPIRAZOLE
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 ENTECAVIR, ENTECAVIR
 FAMCICLOVIR, FAMCICLOVIR
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 IRBESARTAN, IRBESARTAN
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
 LAMIVUDINE, LAMIVUDINE
 LEVOFLOXACIN, LEVOFLOXACIN
 LINEZOLID, LINEZOLID
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 TELMISARTAN, TELMISARTAN
 TETRABENAZINE, TETRABENAZINE
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
 VALSARTAN, VALSARTAN

HEYL CHEMISCH

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

* HEYL CHEMISCH PHARMAZEUTISCHE FABRIK
RADIOGARDASE (PRUSSIAN BLUE), FERRIC HEXACYANOFERRATE(II)

HI TECH PHARMA

* HI TECH PHARMACAL CO INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
CALCIPOTRIENE, CALCIPOTRIENE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CICLOPIROX, CICLOPIROX
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
CORMAX, CLOBETASOL PROPIONATE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
EMBELINE E, CLOBETASOL PROPIONATE
EMBELINE, CLOBETASOL PROPIONATE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
GABAPENTIN, GABAPENTIN
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
LACTULOSE, LACTULOSE
LEVOCARNITINE, LEVOCARNITINE
LEVOFLOXACIN, LEVOFLOXACIN
LIDOCAINE AND PRILOCAINE, LIDOCAINE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
NYSTATIN, NYSTATIN
OFLOXACIN, OFLOXACIN
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
TIMOLOL MALEATE, TIMOLOL MALEATE
VOSOL HC, ACETIC ACID, GLACIAL
VOSOL, ACETIC ACID, GLACIAL

HI TECH PHARMA CO

* HI TECH PHARMACAL CO INC
FLUNISOLIDE, FLUNISOLIDE
PREDNISOLONE, PREDNISOLONE

HI-TECH PHARMA CO

* HI-TECH PHARMACAL CO INC
FAMOTIDINE, FAMOTIDINE
GATIFLOXACIN, GATIFLOXACIN
LORAZEPAM, LORAZEPAM
PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE

HI-TECH PHARMACAL

* HI-TECH PHARMACAL CO INC
BROMFENAC SODIUM, BROMFENAC SODIUM
IBUPROFEN, IBUPROFEN
LEVETIRACETAM, LEVETIRACETAM
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE

HIGH TECH PHARMA

* HIGH TECHNOLOGY PHARMACAL CO INC
VALPROIC ACID, VALPROIC ACID

HIKMA

* HIKMA FARMACEUTICA LDA
CEFOTAXIME, CEFOTAXIME SODIUM

* HIKMA PHARMACEUTICALS
AMOXICILLIN, AMOXICILLIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ******* HIKMA PHARMACEUTICALS**

CEFACLOR, CEFACLOR
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
 CEPHALEXIN, CEPHALEXIN
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 GLYBURIDE (MICRONIZED), GLYBURIDE

HIKMA FARMACEUTICA

- * HIKMA FARMACEUTICA (PORTUGAL) SA**
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
 BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
 CEFOXITIN, CEFOXITIN SODIUM
 CEFTRIAZONE, CEFTRIAZONE SODIUM
 CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
 CIPROFLOXACIN, CIPROFLOXACIN
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 ENALAPRILAT, ENALAPRILAT
 FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 FLUMAZENIL, FLUMAZENIL
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 GLYCOPYRROLATE, GLYCOPYRROLATE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MILRINONE LACTATE IN PLASTIC CONTAINER, MILRINONE LACTATE
 MILRINONE LACTATE, MILRINONE LACTATE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 PROGESTERONE, PROGESTERONE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 TERBUTALINE SULFATE, TERBUTALINE SULFATE
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 VALPROATE SODIUM, VALPROATE SODIUM
- * HIKMA FARMACEUTICA PORTUGAL LDA**
 CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
 CEFUROXIME SODIUM, CEFUROXIME SODIUM
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
- * HIKMA FARMACEUTICA PORTUGAL SA**
 CEFOTETAN, CEFOTETAN DISODIUM
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 ETOMIDATE, ETOMIDATE
 METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
 OXYTOCIN, OXYTOCIN
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
- * HIKMA FARMACEUTICA SA**
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

HIKMA INTL PHARMS

- * HIKMA INTERNATIONAL PHARMACEUTICALS LLC**
 BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
 BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
 CAPTOPRIL, CAPTOPRIL
 CORTISONE ACETATE, CORTISONE ACETATE
 DIGOXIN, DIGOXIN
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 HYDROCORTISONE, HYDROCORTISONE
 ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
 LISINAPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LISINAPRIL, LISINAPRIL
 METHOCARBAMOL, METHOCARBAMOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

* HIKMA INTERNATIONAL PHARMACEUTICALS LLC
 MITIGARE, COLCHICINE
 NAPROXEN, NAPROXEN
 PRIMIDONE, PRIMIDONE

HIKMA PHARM CO LTD

* HIKMA PHARM CO LTD
 ARGATROBAN, ARGATROBAN

HIKMA PHARMS

* HIKMA PHARMACEUTICALS
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 AMOXICILLIN, AMOXICILLIN
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
 GEMFIBROZIL, GEMFIBROZIL
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
 LETROZOLE, LETROZOLE
 MODAFINIL, MODAFINIL
 PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
 RIFAMPIN, RIFAMPIN

* HIKMA PHARMACEUTICALS CO LTD
 PARICALCITOL, PARICALCITOL

* HIKMA PHARMACEUTICALS LLC
 PREDNISONE, PREDNISONE

HIKMA PHARMS LLC

* HIKMA PHARMACEUTICALS LLC
 ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
 DOXERCALCIFEROL, DOXERCALCIFEROL
 FOLIC ACID, FOLIC ACID
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
 ZALEPLON, ZALEPLON

HILL DERMAC

* HILL DERMACEUTICALS INC
 DERMA-SMOOTH/FS, FLUOCINOLONE ACETONIDE
 DERMOTIC, FLUOCINOLONE ACETONIDE

HILL DERMACEUTICALS

* HILL DERMACEUTICALS INC
 TOLAK, FLUOROURACIL

HISAMITSU PHARM CO

* HISAMITSU PHARMACEUTICAL CO INC
 SALONPAS, MENTHOL (OTC)

HISUN PHARM HANGZHOU

* HISUN PHARMACEUTICAL (HANGZHOU) CO LTD
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE

* HISUN PHARMACEUTICAL HANGZHOU CO LTD
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN

HOFFMANN LA ROCHE

* HOFFMANN LA ROCHE INC
 BONIVA, IBANDRONATE SODIUM
 INVIRASE, SAQUINAVIR MESYLATE
 VALCYTE, VALGANCICLOVIR HYDROCHLORIDE
 XELODA, CAPECITABINE
 XENICAL, ORLISTAT
 ZELBORAF, VEMURAFENIB

HOFFMANN-LA ROCHE

* HOFFMANN-LA ROCHE INC
 ALECENSA, ALECTINIB HYDROCHLORIDE
 INVIRASE, SAQUINAVIR MESYLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ******HOPE PHARMS**

- * HOPE PHARMACEUTICALS
 - NITHIODOTE, SODIUM NITRITE
 - SODIUM NITRITE, SODIUM NITRITE
 - SODIUM THIOSULFATE, SODIUM THIOSULFATE

HORIZON PHARMA

- * HORIZON PHARMA INC
 - DUEXIS, FAMOTIDINE
 - RAYOS, PREDNISONE
- * HORIZON PHARMA IRELAND LTD
 - PENNSAID, DICLOFENAC SODIUM
- * HORIZON PHARMA RHEUMATOLOGY LLC
 - MIGERGOT, CAFFEINE

HORIZON PHARMA INC

- * HORIZON PHARMA INC
 - BUPHENYL, SODIUM PHENYL BUTYRATE

HORIZON PHARMA USA

- * HORIZON PHARMA USA INC
 - VIMOVO, ESOMEPRAZOLE MAGNESIUM

HORIZON THERAPS INC

- * HORIZON THERAPEUTICS INC
 - RAVICTI, GLYCEROL PHENYL BUTYRATE

HOSPIRA

- * HOSPIRA INC
 - A-HYDROCORT, HYDROCORTISONE SODIUM SUCCINATE
 - A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE
 - ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
 - ACETYLCYSTEINE, ACETYLCYSTEINE
 - ALFENTANIL, ALFENTANIL HYDROCHLORIDE
 - AMIDATE, ETOMIDATE
 - AMINOCAPROIC ACID IN PLASTIC CONTAINER, AMINOCAPROIC ACID
 - AMINOPHYLLINE, AMINOPHYLLINE
 - AMINOSYN 10% (PH6), AMINO ACIDS
 - AMINOSYN 10%, AMINO ACIDS
 - AMINOSYN 3.5% M, AMINO ACIDS
 - AMINOSYN 3.5%, AMINO ACIDS
 - AMINOSYN 5%, AMINO ACIDS
 - AMINOSYN 7% (PH6), AMINO ACIDS
 - AMINOSYN 7% W/ ELECTROLYTES, AMINO ACIDS
 - AMINOSYN 7%, AMINO ACIDS
 - AMINOSYN 8.5% (PH6), AMINO ACIDS
 - AMINOSYN 8.5% W/ ELECTROLYTES, AMINO ACIDS
 - AMINOSYN 8.5%, AMINO ACIDS
 - AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS
 - AMINOSYN II 10% W/ ELECTROLYTES, AMINO ACIDS
 - AMINOSYN II 10%, AMINO ACIDS
 - AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS
 - AMINOSYN II 7%, AMINO ACIDS
 - AMINOSYN II 8.5% W/ ELECTROLYTES, AMINO ACIDS
 - AMINOSYN II 8.5%, AMINO ACIDS
 - AMINOSYN-HBC 7%, AMINO ACIDS
 - AMINOSYN-HF 8%, AMINO ACIDS
 - AMINOSYN-PF 10%, AMINO ACIDS
 - AMINOSYN-PF 7%, AMINO ACIDS
 - AMINOSYN-RF 5.2%, AMINO ACIDS
 - AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 - AMMONIUM CHLORIDE IN PLASTIC CONTAINER, AMMONIUM CHLORIDE
 - AQUASOL A, VITAMIN A PALMITATE
 - ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, ARTICAINE HYDROCHLORIDE
 - ATROPINE SULFATE ANSYR PLASTIC SYRINGE, ATROPINE SULFATE
 - AZITHROMYCIN, AZITHROMYCIN
 - BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 - BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 - BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
 - BUMETANIDE, BUMETANIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

* HOSPIRA INC

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
 BUPIVACAINE HYDROCHLORIDE W/EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
 BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
 CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 CARBOCAINE, MEPIVACAINE HYDROCHLORIDE
 CARBOPLATIN, CARBOPLATIN
 CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE
 CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE
 CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
 CIPROFLOXACIN, CIPROFLOXACIN
 CORLOPAM, FENOLDOPAM MESYLATE
 CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE
 CYTARABINE, CYTARABINE
 DACARBAZINE, DACARBAZINE
 DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
 DEMEROL, MEPERIDINE HYDROCHLORIDE
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 25%, DEXTROSE
 DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 50% , DEXTROSE
 DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
 DIAZEPAM, DIAZEPAM
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
 DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
 DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
 DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
 DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
 DROPERIDOL, DROPERIDOL
 ENALAPRILAT, ENALAPRILAT
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
 FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
 FENTANYL CITRATE, FENTANYL CITRATE
 FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 FOSCARNET SODIUM, FOSCARNET SODIUM
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 FUROSEMIDE, FUROSEMIDE
 GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
 HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
 HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN
 HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
 HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN
 HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

* HOSPIRA INC

HEPARIN SODIUM, HEPARIN SODIUM
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 ISOFLURANE, ISOFLURANE
 ISUPREL, ISOPROTERENOL HYDROCHLORIDE
 KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 LEVOPHED, NOREPINEPHRINE BITARTRATE
 LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE
 LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER, LIDOCAINE
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LORAZEPAM, LORAZEPAM
 LTA II KIT, LIDOCAINE HYDROCHLORIDE
 M.V.I. ADULT (PHARMACY BULK PACKAGE), ASCORBIC ACID
 M.V.I. ADULT, ASCORBIC ACID
 M.V.I. PEDIATRIC, ASCORBIC ACID
 M.V.I.-12 (WITHOUT VITAMIN K), ASCORBIC ACID
 MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 MAGNESIUM SULFATE, MAGNESIUM SULFATE
 MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE
 MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
 MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
 MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
 MANNITOL 25%, MANNITOL
 MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
 MARCAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
 MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
 MARCAINE HYDROCHLORIDE W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
 MARCAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
 MARCAINE, BUPIVACAINE HYDROCHLORIDE
 MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
 METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
 MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
 MORPHINE SULFATE, MORPHINE SULFATE
 NALBUPHINE HYDROCHLORIDE, NALBUPHINE HYDROCHLORIDE
 NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
 NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 PACLITAXEL, PACLITAXEL
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
 PHENYTOIN SODIUM, PHENYTOIN SODIUM
 PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 POTASSIUM ACETATE, POTASSIUM ACETATE
 POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC

WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1086, p. 978 of 1400

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

* HOSPIRA INC

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC
 POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PRECEDEX, DEXMEDETOMIDINE HYDROCHLORIDE
 PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
 PROPOFOL, PROPOFOL
 QUELICIN PRESERVATIVE FREE, SUCCINYLCHOLINE CHLORIDE
 QUELICIN, SUCCINYLCHOLINE CHLORIDE
 RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
 SODIUM ACETATE IN PLASTIC CONTAINER, SODIUM ACETATE ANHYDROUS
 SODIUM BICARBONATE, SODIUM BICARBONATE
 SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM LACTATE IN PLASTIC CONTAINER, SODIUM LACTATE
 SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
 SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
 SUFENTANIL CITRATE, SUFENTANIL CITRATE
 TALWIN, PENTAZOCINE LACTATE
 TAZICEF, CEFTAZIDIME
 THAM, TROMETHAMINE
 TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, TOBRAMYCIN SULFATE
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VECURONIUM BROMIDE, VECURONIUM BROMIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

- * HOSPIRA INC
 - VINORELBINE TARTRATE, VINORELBINE TARTRATE
 - VITAMIN K1, PHYTONADIONE
 - ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE
- * HOSPIRA WORLDWIDE, INC
 - DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
 - FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 - GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 - MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
 - NITROPRESS, SODIUM NITROPRUSSIDE
 - TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 - VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE

HOSPIRA INC

- * HOSPIRA INC
 - A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE
 - ADENOSINE, ADENOSINE
 - AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 - AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 - AMPICILLIN SODIUM, AMPICILLIN SODIUM
 - ARGATROBAN, ARGATROBAN
 - ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
 - ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
 - BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
 - BIVALIRUDIN, BIVALIRUDIN
 - CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
 - CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
 - CEFOTAXIME SODIUM, CEFOTAXIME SODIUM
 - CEFOXITIN, CEFOXITIN SODIUM
 - CEFTRIAZONE, CEFTRIAZONE SODIUM
 - CEFUROXIME SODIUM, CEFUROXIME SODIUM
 - DAPTOMYCIN, DAPTOMYCIN
 - DOCETAXEL, DOCETAXEL
 - GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 - HEPARIN SODIUM, HEPARIN SODIUM
 - HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 - IMIPENEM AND CILASTATIN, CILASTATIN SODIUM
 - INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
 - LEVETIRACETAM, LEVETIRACETAM
 - LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
 - LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, LINEZOLID
 - LINEZOLID, LINEZOLID
 - MAGNESIUM SULFATE, MAGNESIUM SULFATE
 - MAXIPIME, CEFEPIME HYDROCHLORIDE
 - MEPIVACAINE HYDROCHLORIDE, MEPIVACAINE HYDROCHLORIDE
 - MEROPENEM, MEROPENEM
 - MILRINONE LACTATE, MILRINONE LACTATE
 - MORPHINE SULFATE, MORPHINE SULFATE
 - NIPENT, PENTOSTATIN
 - OXACILLIN SODIUM, OXACILLIN SODIUM
 - OXALIPLATIN, OXALIPLATIN
 - PARICALCITOL, PARICALCITOL
 - PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 - SODIUM BICARBONATE, SODIUM BICARBONATE
 - THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 - TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 - VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 - ZOLEDRONIC ACID, ZOLEDRONIC ACID

HOSPIRA WORLDWIDE

- * HOSPIRA WORLDWIDE PTY
 - OXALIPLATIN, OXALIPLATIN

HOT SHOTS NM LLC

- * HOT SHOTS NUCLEAR MEDICINE LLC
 - FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 - SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

HOUSTON CYCLOTRON

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

* HOUSTON CYCLOTRON PARTNERS LP
 AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

HQ SPCLT PHARMA

* HQ SPECIALTY PHARMA CORP
 CISPLATIN, CISPLATIN
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
 ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
 MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 TAXOL, PACLITAXEL

HQ SPECIALITY PHARMA

* HQ SPECIALITY PHARMA LLC
 LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM

HQ SPECLT PHARMA

* HQ SPECIALTY PHARMA
 VUMON, TENIPOSIDE

HRA PHARMA

* HRA PHARMA LLC
 METOPIRONE, METYRAPONE

HUMANWELL PURACAP

* HUMANWELL PURACAP PHARMACEUTICAL WUHAN CO LTD
 IBUPROFEN, IBUPROFEN (OTC)

ROCHE

* HOFFMANN LA ROCHE INC
 BONIVA, IBANDRONATE SODIUM
 COPEGUS, RIBAVIRIN
 FUZEON, ENFUVIRTIDE
 KLONOPIN, CLONAZEPAM
 TAMIFLU, OSELTAMIVIR PHOSPHATE
 VALIUM, DIAZEPAM

**** I ******IBA MOLECULAR N AM**

* IBA MOLECULAR NORTH AMERICA INC
 AMMONIA N 13, AMMONIA N-13

IBSA INST BIO

* IBSA INSTITUT BIOCHIMIQUE SA
 TIROSINT-SOL, LEVOTHYROXINE SODIUM

IDENTI PHARMS INC

* IDENTI PHARMACEUTICALS INC
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE

IDT AUSTRALIA LTD

* IDT AUSTRALIA LTD
 TEMOZOLOMIDE, TEMOZOLOMIDE

IGI LABS INC

* IGI LABORATORIES INC
 FORTAZ IN PLASTIC CONTAINER, CEFTAZIDIME SODIUM
 FORTAZ, CEFTAZIDIME
 ZANTAC, RANITIDINE HYDROCHLORIDE
 ZINACEF IN PLASTIC CONTAINER, CEFUROXIME SODIUM
 ZINACEF, CEFUROXIME SODIUM

IMPAX LABS

* IMPAX LABORATORIES INC
 ACARBOSE, ACARBOSE
 ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
 BACLOFEN, BACLOFEN
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CARBIDOPA AND LEVODOPA, CARBIDOPA
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 COLESTIPOL HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE
 DANTROLENE SODIUM, DANTROLENE SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** I ****

* IMPAX LABORATORIES INC
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DIGOXIN, DIGOXIN
 DIPYRIDAMOLE, DIPYRIDAMOLE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 FENOFIBRATE (MICRONIZED), FENOFIBRATE
 FENOFIBRATE, FENOFIBRATE
 FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
 METHYLTESTOSTERONE, METHYLTESTOSTERONE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 NADOLOL AND BENDROFLUMETHIAZIDE, BENDROFLUMETHIAZIDE
 OMEPRAZOLE, OMEPRAZOLE
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
 PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
 RILUZOLE, RILUZOLE
 RIMANTADINE HYDROCHLORIDE, RIMANTADINE HYDROCHLORIDE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE

IMPAX LABS INC

* IMPAX LABORATORIES INC
 ACITRETIN, ACITRETIN
 ALENDRONATE SODIUM, ALENDRONATE SODIUM
 BUDESONIDE, BUDESONIDE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 DOXYCYCLINE, DOXYCYCLINE
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 FENOFIBRIC ACID, CHOLINE FENOFIBRATE
 GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
 HYDROCORTISONE, HYDROCORTISONE
 HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
 LAMOTRIGINE, LAMOTRIGINE
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
 METHYLTESTOSTERONE, METHYLTESTOSTERONE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 MIRTAZAPINE, MIRTAZAPINE
 MORPHINE SULFATE, MORPHINE SULFATE
 NABUMETONE, NABUMETONE
 NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
 RYTARY, CARBIDOPA
 URSODIOL, URSODIOL

IMPAX PHARMS

* IMPAX PHARMACEUTICALS
 GEMFIBROZIL, GEMFIBROZIL
 MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

INCYTE CORP

* INCYTE CORP
 JAKAFI, RUXOLITINIB PHOSPHATE

INDICUS PHARMA

* INDICUS PHARMA LLC
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 LETROZOLE, LETROZOLE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

INDIVIOR INC

* INDIVIOR INC
 BUPRENEX, BUPRENORPHINE HYDROCHLORIDE
 SUBOXONE, BUPRENORPHINE HYDROCHLORIDE

INDOCO REMEDIES

* INDOCO REMEDIES LTD

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** I ******* INDOCO REMEDIES LTD**

ALLOPURINOL, ALLOPURINOL
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
GLIMEPIRIDE, GLIMEPIRIDE

INGENUS PHARMS LLC

* INGENUS PHARMACEUTICALS LLC
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE

INGENUS PHARMS NJ

* INGENUS PHARMACEUTICALS NJ LLC
CARISOPRODOL AND ASPIRIN, ASPIRIN
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
CARISOPRODOL, CARISOPRODOL
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE
PROBENECID AND COLCHICINE, COLCHICINE

INJECTALIA

* INJECTALIA SRL
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE

INNOPHARMA LICENSING

* INNOPHARMA LICENSING LLC
BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE

INST BIOCHEM

* INSTITUT BIOCHEMIQUE SA
FLECTOR, DICLOFENAC EPOLAMINE

INST BIOCHIMIQUE

* INSTITUTE BIOCHIMIQUE SA (IBSA)
TIROSINT, LEVOTHYROXINE SODIUM

INSTITUT BIOCHIMIQUE

* INSTITUT BIOCHIMIQUE SA IBSA
TIROSINT, LEVOTHYROXINE SODIUM

INSYS THERAP

* INSYS THERAPEUTICS INC
SUBSYS, FENTANYL

INTELLIPHARMACEUTICS

* INTELLIPHARMACEUTICS CORP
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM

INTERCEPT PHARMS INC

* INTERCEPT PHARMACEUTICALS INC
OCALIVA, OBETICHOLIC ACID

INTERGEL PHARM

* INTERGEL PHARMACEUTICAL INC
NIFEDIPINE, NIFEDIPINE

INTERGEL PHARMS INC

* INTERGEL PHARMACEUTICALS INC
DUTASTERIDE, DUTASTERIDE

INTERPHARMA PRAHA AS

* INTERPHARMA PRAHA AS
ORALTAG, IOHEXOL

INTL MEDICATED

* INTERNATIONAL MEDICATED SYSTEMS LTD
MILRINONE LACTATE, MILRINONE LACTATE

INTL MEDICATION

* INTERNATIONAL MEDICATION SYSTEM
LARYNG-O-JET KIT, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
MANNITOL 25%, MANNITOL
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
PHYTONADIONE, PHYTONADIONE
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
* INTERNATIONAL MEDICATION SYSTEMS LTD
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** I ******INTL MEDICATION SYS**

* INTERNATIONAL MEDICATION SYSTEMS LTD
LORAZEPAM, LORAZEPAM

INTL SPECLT CHEMS

* INTERNATIONAL SPECIALTY CHEMICALS AND PHARMACEUTICALS INC
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

INVAGEN PHARMS

* INVAGEN PHARMACEUTICALS INC
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CALCIUM ACETATE, CALCIUM ACETATE
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FOLIC ACID, FOLIC ACID
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
GABAPENTIN, GABAPENTIN
GEMFIBROZIL, GEMFIBROZIL
GLIMEPIRIDE, GLIMEPIRIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LISINAPRIL, LISINAPRIL
MEPROBAMATE, MEPROBAMATE
NABUMETONE, NABUMETONE
NADOLOL, NADOLOL
NAPROXEN, NAPROXEN
OLANZAPINE, OLANZAPINE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RAMIPRIL, RAMIPRIL
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
TERBINAFFINE HYDROCHLORIDE, TERBINAFFINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TRANDOLAPRIL, TRANDOLAPRIL
TROSPIMUM CHLORIDE, TROSPIMUM CHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM
ZOLMITRIPTAN, ZOLMITRIPTAN
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
ZONISAMIDE, ZONISAMIDE

INVATECH PHARMA

* INVATECH PHARMA SOLUTIONS LLC
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE

INVENTIA HLTHCARE

* INVENTIA HEALTHCARE PRIVATE LTD
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ILOPERIDONE, ILOPERIDONE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
TELMISARTAN, TELMISARTAN

IPCA LABS LTD

* IPCA LABORATORIES LTD
ALLOPURINOL, ALLOPURINOL
ATENOLOL, ATENOLOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** I ****

* IPCA LABORATORIES LTD
 CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
 FUROSEMIDE, FUROSEMIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 WARFARIN SODIUM, WARFARIN SODIUM

IPR

* IPR PHARMACEUTICALS INC
 CRESTOR, ROSUVASTATIN CALCIUM
 ZOMIG, ZOLMITRIPTAN

IPSEN INC

* IPSEN BIOPHARMACEUTICALS INC
 INCRELEX, MECASERMIN RECOMBINANT

IPSEN PHARMA

* IPSEN PHARMA BIOTECH SAS
 SOMATULINE DEPOT, LANREOTIDE ACETATE

IROKO PHARMS

* IROKO PHARMACEUTICALS LLC
 INDOCIN, INDOMETHACIN

IROKO PHARMS LLC

* IROKO PHARMACEUTICALS LLC
 TIVORBEX, INDOMETHACIN
 VIVLODEX, MELOXICAM
 ZORVOLEX, DICLOFENAC

IRONWOOD PHARMS INC

* IRONWOOD PHARMACEUTICALS INC
 ZURAMPIC, LESINURAD

ISO TEX

* ISO TEX DIAGNOSTICS INC
 JEANATOPE, ALBUMIN IODINATED I-125 SERUM
 MEGATOPE, ALBUMIN IODINATED I-131 SERUM

ISOTEX

* ISOTEX DIAGNOSTICS
 GLOFIL-125, IOTHALAMATE SODIUM I-125

ISTITUTO BIO ITA SPA

* ISTITUTO BIOCHIMICO ITALIANO SPA
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 AMPICILLIN SODIUM, AMPICILLIN SODIUM
 NAFCILLIN SODIUM, NAFCILLIN SODIUM
 PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 PIPERACILLIN, PIPERACILLIN SODIUM

IVAX INTL

* IVAX INTERNATIONAL GMBH
 SYNRIPO, OMACETAXINE MEPESUCCINATE

IVAX PHARMS

* IVAX PHARMACEUTICALS INC
 VALSARTAN, VALSARTAN

IVAX PHARMS INC

* IVAX PHARMACEUTICALS INC
 OLANZAPINE, OLANZAPINE

IVAX SUB TEVA PHARMS

* IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA
 ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
 BACLOFEN, BACLOFEN
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 BUMETANIDE, BUMETANIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** I ****

* IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA
 CABERGOLINE, CABERGOLINE
 CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CIMETIDINE, CIMETIDINE (OTC)
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CLOZAPINE, CLOZAPINE
 CYCLOSPORINE, CYCLOSPORINE
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 DIAZEPAM, DIAZEPAM
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 FAMOTIDINE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE (OTC)
 FLUCONAZOLE, FLUCONAZOLE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FUROSEMIDE, FUROSEMIDE
 GABAPENTIN, GABAPENTIN
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 INDOMETHACIN, INDOMETHACIN
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LISINOPRIL, LISINOPRIL
 METHYLDOPA, METHYLDOPA
 MISOPROSTOL, MISOPROSTOL
 NADOLOL, NADOLOL
 OXAPROZIN, OXAPROZIN
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
 SIMVASTATIN, SIMVASTATIN
 TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

**** J ******J AND J CONSUMER INC**

* JOHNSON AND JOHNSON CONSUMER INC MCNEIL CONSUMER HEALTHCARE DIVISION
 CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)
 CHILDREN'S MOTRIN, IBUPROFEN (OTC)
 CHILDREN'S ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 IMODIUM A-D EZ CHEWS, LOPERAMIDE HYDROCHLORIDE (OTC)
 IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)
 IMODIUM MULTI-SYMPTOM RELIEF, LOPERAMIDE HYDROCHLORIDE (OTC)
 JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)
 MOTRIN IB, IBUPROFEN (OTC)
 PEPCID AC, FAMOTIDINE (OTC)
 PEPCID AC, FAMOTIDINE (OTC)
 PEPCID COMPLETE, CALCIUM CARBONATE (OTC)
 SINE-AID IB, IBUPROFEN (OTC)
 SUDAFED 24 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
 TYLENOL, ACETAMINOPHEN (OTC)
 ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 ZYRTEC-D 12 HOUR, CETIRIZINE HYDROCHLORIDE (OTC)

JACOBUS

* JACOBUS PHARMACEUTICAL CO
 DAPSONE, DAPSONE
 PASER, AMINOSALICYLIC ACID

JAI PHARMA LTD

* JAI PHARMA LTD
 DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
 ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1086, p. 986 of 1400

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** J ******* JAI PHARMA LTD**

LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LEVONORGESTREL, LEVONORGESTREL
 LEVONORGESTREL, LEVONORGESTREL (OTC)
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE,
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
 NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NORETHINDRONE, NORETHINDRONE
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL

JANSSEN BIOTECH*** JANSSEN BIOTECH INC**

ZYTIGA, ABIRATERONE ACETATE

JANSSEN PHARMS*** JANSSEN PHARMACEUTICALS INC**

AXERT, ALMOTRIPTAN MALATE
 CONCERTA, METHYLPHENIDATE HYDROCHLORIDE
 DITROPAN XL, OXYBUTYNIN CHLORIDE
 DURAGESIC-100, FENTANYL
 DURAGESIC-12, FENTANYL
 DURAGESIC-25, FENTANYL
 DURAGESIC-50, FENTANYL
 DURAGESIC-75, FENTANYL
 ELMIRON, PENTOSAN POLYSULFATE SODIUM
 HALDOL, HALOPERIDOL DECANOATE
 HALDOL, HALOPERIDOL LACTATE
 INVEGA SUSTENNA, PALIPERIDONE PALMITATE
 INVEGA TRINZA, PALIPERIDONE PALMITATE
 INVEGA, PALIPERIDONE
 INVOKAMET XR, CANAGLIFLOZIN
 INVOKAMET, CANAGLIFLOZIN
 INVOKANA, CANAGLIFLOZIN
 LEVAQUIN, LEVOFLOXACIN
 MICRONOR, NORETHINDRONE
 MODICON 28, ETHINYL ESTRADIOL
 NIZORAL, KETOCONAZOLE
 ORTHO CYCLEN-28, ETHINYL ESTRADIOL
 ORTHO TRI-CYCLEN LO, ETHINYL ESTRADIOL
 ORTHO TRI-CYCLEN, ETHINYL ESTRADIOL
 ORTHO-NOVUM 1/35-28, ETHINYL ESTRADIOL
 ORTHO-NOVUM 7/7/7-28, ETHINYL ESTRADIOL
 PANCREAZE, PANCRELIPASE (AMYLASE
 RAZADYNE ER, GALANTAMINE HYDROBROMIDE
 RAZADYNE, GALANTAMINE HYDROBROMIDE
 RISPERDAL CONSTA, RISPERIDONE
 RISPERDAL, RISPERIDONE
 SPORANOX, ITRACONAZOLE
 TERAZOL 3, TERCONAZOLE
 TERAZOL 7, TERCONAZOLE
 TOPAMAX, TOPIRAMATE
 TYLENOL W/ CODEINE NO. 3, ACETAMINOPHEN
 TYLENOL W/ CODEINE NO. 4, ACETAMINOPHEN
 ULTRACET, ACETAMINOPHEN
 ULTRAM, TRAMADOL HYDROCHLORIDE
 VERMOX, MEBENDAZOLE
 XARELTO, RIVAROXABAN

JANSSEN PRODS*** JANSSEN PRODUCTS LP**

EDURANT, RILPIVIRINE HYDROCHLORIDE
 OLYSIO, SIMEPREVIR SODIUM
 PREZCOBIX, COBICISTAT
 PREZISTA, DARUNAVIR ETHANOLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** J ****

* JANSSEN PRODUCTS LP
YONDELIS, TRABECTEDIN

JANSSEN R AND D

* JANSSEN RESEARCH AND DEVELOPMENT LLC
INTELENCE, ETRAVIRINE

JANSSEN RES AND DEV

* JANSSEN RESEARCH AND DEVELOPMENT LLC
DOXIL (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE

JANSSEN THERAP

* JANSSEN THERAPEUTICS DIV JANSSEN PRODUCTS LP
SIRTURO, BEDAQUILINE FUMARATE

JAVELIN PHARMS INC

* JAVELIN PHARMACEUTICALS INC A WHOLLY OWNED SUBSIDIARY OF HOSPIRA INC
DYLOJECT, DICLOFENAC SODIUM

JAZZ PHARMS

* JAZZ PHARMACEUTICALS INC
LUVOX CR, FLUVOXAMINE MALEATE
XYREM, SODIUM OXYBATE

JAZZ PHARMS III

* JAZZ PHARMACEUTICALS III INTERNATIONAL LTD
FAZACLO ODT, CLOZAPINE
* JAZZ PHARMACEUTICALS INTERNATIONAL III
VERSACLOZ, CLOZAPINE

JAZZ PHARMS INC

* JAZZ PHARMACEUTICALS INC
DEFITELIO, DEFIBROTIDE SODIUM

JAZZ PHARMS INTL

* JAZZ PHARMACEUTICALS INTERNATIONAL LTD
PRIALT, ZICONOTIDE ACETATE

JIANGSU HANSOH PHARM

* JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
VINORELBINE TARTRATE, VINORELBINE TARTRATE

JIANGSU HENGRUI MED

* JIANGSU HENGRUI MEDICINE CO LTD
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LETROZOLE, LETROZOLE
OXALIPLATIN, OXALIPLATIN

JOHNS HOPKINS UNIV

* JOHNS HOPKINS UNIV
AMMONIA N 13, AMMONIA N-13

JOHNSON AND JOHNSON

* JOHNSON AND JOHNSON CONSUMER INC
VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)
VISINE-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
* JOHNSON AND JOHNSON GROUP CONSUMER COMPANIES
MEN'S ROGAINE, MINOXIDIL (OTC)
ROGAINE (FOR MEN), MINOXIDIL (OTC)
ROGAINE (FOR WOMEN), MINOXIDIL (OTC)
ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
WOMEN'S ROGAINE, MINOXIDIL (OTC)
* JOHNSON AND JOHNSON HEALTHCARE PRODUCTS DIV MCNEIL-PPC INC
NIZORAL A-D, KETOCONAZOLE (OTC)

JUBILANT CADISTA

* JUBILANT CADISTA PHARMACEUTICALS INC
ALENDRONATE SODIUM, ALENDRONATE SODIUM
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LAMOTRIGINE, LAMOTRIGINE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
PREDNISONE, PREDNISONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** J ****

* JUBILANT CADISTA PHARMACEUTICALS INC
 PROCOMP, PROCHLORPERAZINE MALEATE
 TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE

JUBILANT DRAXIMAGE

* JUBILANT DRAXIMAGE INC
 AN-DTPA, TECHNETIUM TC-99M PENTETATE KIT
 DRAXIMAGE MDP-25, TECHNETIUM TC-99M MEDRONATE
 HICON, SODIUM IODIDE I-131
 PULMOLITE, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
 RUBY-FILL, RUBIDIUM CHLORIDE RB-82
 SODIUM IODIDE I 131, SODIUM IODIDE I-131

JUBILANT GENERICS

* JUBILANT GENERICS LTD
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 FELODIPINE, FELODIPINE
 INDOMETHACIN, INDOMETHACIN
 IRBESARTAN, IRBESARTAN
 LAMOTRIGINE, LAMOTRIGINE
 LEVOFLOXACIN, LEVOFLOXACIN
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 OLANZAPINE, OLANZAPINE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RISPERIDONE, RISPERIDONE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 SPIRONOLACTONE, SPIRONOLACTONE
 TELMISARTAN, TELMISARTAN
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VALSARTAN, VALSARTAN
 ZOLMITRIPTAN, ZOLMITRIPTAN

JUBILANT HOLLISTRSTR

* JUBILANT HOLLISTERSTIER LLC
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

JUBILANT LIFE

* JUBILANT LIFE SCIENCES LTD
 LEVETIRACETAM, LEVETIRACETAM

STEVENS J

* JEROME STEVENS PHARMACEUTICALS INC
 BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
 DIGOXIN, DIGOXIN
 METHOCARBAMOL AND ASPIRIN, ASPIRIN
 UNITHROID, LEVOTHYROXINE SODIUM **

**** K ******GRIFFEN**

* KW GRIFFEN CO
 BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)

KALEO INC

* KALEO INC
 AUVI-Q, EPINEPHRINE
 EVZIO, NALOXONE HYDROCHLORIDE

KASTLE THERAPS LLC

* KASTLE THERAPEUTICS LLC
 KYNAMRO, MIPOMERSEN SODIUM

KEN LIFESCIENCE

* KEN LIFESCIENCE
WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1086, p. 989 of 1400

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** K ******* KEN LIFESCIENCE**

OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

KERYX BIOPHARMS

* KERYX BIOPHARMACEUTICALS INC
 AURYXIA, FERRIC CITRATE

KETTERING MEDCTR

* KETTERING MEDCTR
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

KING PHARMS

* KING PHARMACEUTICALS INC
 ALTACE, RAMIPRIL
 BICILLIN C-R 900/300, PENICILLIN G BENZATHINE
 BICILLIN C-R, PENICILLIN G BENZATHINE
 BICILLIN L-A, PENICILLIN G BENZATHINE
 CORZIDE, BENDROFLUMETHIAZIDE
 PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
 SILVADENE, SILVER SULFADIAZINE
 SKELAXIN, METAXALONE
 SYNERCID, DALFOPRISTIN
 TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE

* KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT INC SUB KING PHARMACEUTICALS INC
 TAPAZOLE, METHIMAZOLE
 TUSSIGON, HOMATROPINE METHYLBROMIDE

KING PHARMS R AND D

* KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT INC
 CYTOMEL, LIOETHYRONINE SODIUM
 LEVOXYL, LEVOTHYROXINE SODIUM **

KNIGHT THERAPS

* KNIGHT THERAPEUTICS USA INC
 IMPAVIDO, MILTEFOSINE

KOWA CO

* KOWA CO LTD
 LIVALO, PITAVASTATIN CALCIUM

KREITCHMAN PET CTR

* KREITCHMAN PET CENTER
 AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

KREMERS URBAN DEV

* KREMERS URBAN DEVELOPMENT CO
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM

KREMERS URBAN PHARMS

* KREMERS URBAN PHARMACEUTICALS INC
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 GLYCOLAX, POLYETHYLENE GLYCOL 3350
 GLYCOLAX, POLYETHYLENE GLYCOL 3350 (OTC)
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
 LETROZOLE, LETROZOLE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 MONOKET, ISOSORBIDE MONONITRATE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 OMEPRAZOLE, OMEPRAZOLE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 TEMOZOLOMIDE, TEMOZOLOMIDE

KRKA TOVARNA ZDRAVIL

* KRKA TOVARNA ZDRAVIL DD NOVO MESTO
 LANSOPRAZOLE, LANSOPRAZOLE

KVK TECH

* KVK TECH INC
 BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** K ****

* KVK TECH INC
 BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 KALEXATE, SODIUM POLYSTYRENE SULFONATE
 PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

KYOWA KIRIN

* KYOWA KIRIN INC
 SANCUSO, GRANISETRON

KYTHERA BIOPHARMS

* KYTHERA BIOPHARMACEUTICALS INC
 KYBELLA, DEOXYCHOLIC ACID

**** L ******L PERRIGO CO**

* L PERRIGO CO
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE

LAB HRA PHARMA

* LABORATOIRE HRA PHARMA
 ELLA, ULIPRISTAL ACETATE

LABORATORIOS SALVAT

* LABORATORIOS SALVAT SA
 OTOVEL, CIPROFLOXACIN HYDROCHLORIDE

LABS LICONSA

* LABORATORIOUS LICONSA SA
 LANSOPRAZOLE, LANSOPRAZOLE

LANDELA PHARM

* LANDELA PHARMACEUTICAL
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE

LANNETT

* LANNETT CO INC
 ACETAZOLAMIDE, ACETAZOLAMIDE
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
 DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
 LANIAZID, ISONIAZID
 LANORINAL, ASPIRIN
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 PRIMIDONE, PRIMIDONE
 PROBALAN, PROBENECID
 SUMATRIPTAN, SUMATRIPTAN

* LANNETT HOLDINGS INC
 BACLOFEN, BACLOFEN
 BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 DANAZOL, DANAZOL
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DOXYCYCLINE, DOXYCYCLINE
 FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
 RIFAMPIN, RIFAMPIN
 TERBUTALINE SULFATE, TERBUTALINE SULFATE
 URSODIOL, URSODIOL

LANNETT HOLDINGS INC

* LANNETT HOLDINGS INC
 BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 CODEINE SULFATE, CODEINE SULFATE
 DIAZEPAM, DIAZEPAM
 DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
 LETROZOLE, LETROZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** L ****

* LANNETT HOLDINGS INC
 LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
 METAXALONE, METAXALONE
 MORPHINE SULFATE, MORPHINE SULFATE
 NEOMYCIN SULFATE, NEOMYCIN SULFATE
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

LANTHEUS MEDCL

* LANTHEUS MEDICAL IMAGING INC
 CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT
 DEFINITY, PERFLUTREN
 GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67
 NEUROLITE, TECHNETIUM TC-99M BICISATE KIT
 TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
 THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
 XENON XE 133, XENON XE-133

LANTHEUS MEDICAL

* LANTHEUS MEDICAL IMAGING INC
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 QUADRAMET, SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

LARKEN LABS

* LARKEN LABORATORIES INC
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 OFLOXACIN, OFLOXACIN

LARKEN LABS INC

* LARKEN LABORATORIES INC
 ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE, ACETAMINOPHEN
 ALLZITAL, ACETAMINOPHEN
 BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN

LAVIPHARM LABS

* LAVIPHARM LABORATORIES INC
 FENTANYL-100, FENTANYL
 FENTANYL-25, FENTANYL
 FENTANYL-50, FENTANYL
 FENTANYL-75, FENTANYL

LEADING PHARMA LLC

* LEADING PHARMA LLC
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
 FOLIC ACID, FOLIC ACID
 FUROSEMIDE, FUROSEMIDE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
 LORAZEPAM, LORAZEPAM

LEHIGH VALLEY

* LEHIGH VALLEY TECHNOLOGIES INC
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

LEO LABS

* LEO LABORATORIES LTD
 PICATO, INGENOL MEBUTATE

LEO PHARMA AS

* LEO PHARMA AS
 DOVONEX, CALCIPOTRIENE
 ENSTILAR, BETAMETHASONE DIPROPIONATE
 PROTOPIC, TACROLIMUS
 TACLONEX, BETAMETHASONE DIPROPIONATE

LG LIFE

* LG LIFE SCIENCES LTD
 VALTROPIN, SOMATROPIN RECOMBINANT

LG LIFE SCIENCES

* LG LIFE SCIENCES LTD

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** L ****

* LG LIFE SCIENCES LTD
FACTIVE, GEMIFLOXACIN MESYLATE

LIEBEL-FLARSHEIM

* LIEBEL-FLARSHEIM CO LLC
CONRAY 30, IOTHALAMATE MEGLUMINE
CONRAY 43, IOTHALAMATE MEGLUMINE
CONRAY, IOTHALAMATE MEGLUMINE
CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE
MD-76R, DIATRIZOATE MEGLUMINE
MD-GASTROVIEW, DIATRIZOATE MEGLUMINE
OPTIMARK IN PLASTIC CONTAINER, GADOVERSETAMIDE
OPTIMARK, GADOVERSETAMIDE
OPTIRAY 240, IOVERSOL
OPTIRAY 300, IOVERSOL
OPTIRAY 320, IOVERSOL
OPTIRAY 350, IOVERSOL
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

LIFESTAR PHARMA

* LIFESTAR PHARMA LLC
RISPERIDONE, RISPERIDONE

LNK

* LNK INTERNATIONAL INC
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)

LOREAL USA

* LOREAL USA PRODUCTS INC
ANTHELIOS 20, AVOBENZONE (OTC)
ANTHELIOS 40, AVOBENZONE (OTC)
ANTHELIOS SX, AVOBENZONE (OTC)
CAPITAL SOLEIL 15, AVOBENZONE (OTC)

LOTUS PHARM CO LTD

* LOTUS PHARMACEUTICAL CO LTD
LEVETIRACETAM, LEVETIRACETAM
LEVONORGESTREL, LEVONORGESTREL
LEVONORGESTREL, LEVONORGESTREL (OTC)

LUITPOLD

* LUITPOLD PHARMACEUTICALS INC
ACETYLCYSTEINE, ACETYLCYSTEINE
ADENOSINE, ADENOSINE
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOPHYLLINE, AMINOPHYLLINE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE ACETATE
BROMFENAC SODIUM, BROMFENAC SODIUM
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CAFFEINE CITRATE, CAFFEINE CITRATE
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CYANOCOBALAMIN, CYANOCOBALAMIN
CYCLOSPORINE, CYCLOSPORINE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXFERRUM, IRON DEXTRAN
DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DROPERIDOL, DROPERIDOL
ESTRADIOL VALERATE, ESTRADIOL VALERATE
ETOMIDATE, ETOMIDATE
FOMEPIZOLE, FOMEPIZOLE
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
GLYCOPYRROLATE, GLYCOPYRROLATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
IBUTILIDE FUMARATE, IBUTILIDE FUMARATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** L ****

* LUITPOLD PHARMACEUTICALS INC
 LATANOPROST, LATANOPROST
 LEVETIRACETAM, LEVETIRACETAM
 LEVOCARNITINE, LEVOCARNITINE
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 MANNITOL 25%, MANNITOL
 METHYLDOPATE HYDROCHLORIDE, METHYLDOPATE HYDROCHLORIDE
 METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
 NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
 NITROGLYCERIN, NITROGLYCERIN
 OLANZAPINE, OLANZAPINE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PHENYTOIN SODIUM, PHENYTOIN SODIUM
 PROGESTERONE, PROGESTERONE
 TRANEXAMIC ACID, TRANEXAMIC ACID
 TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE, TRIMETHOBENZAMIDE HYDROCHLORIDE
 TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE
 VENOFER, IRON SUCROSE
 ZIDOVUDINE, ZIDOVUDINE

LUITPOLD PHARMS INC

* LUITPOLD PHARMACEUTICALS INC
 BUSULFAN, BUSULFAN
 DACTINOMYCIN, DACTINOMYCIN
 ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
 GANCICLOVIR, GANCICLOVIR SODIUM
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 INJECTAFER, FERRIC CARBOXYMALTOSE
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE

LUKARE MEDICAL LLC

* LUKARE MEDICAL LLC
 ELLIOTTS B SOLUTION, CALCIUM CHLORIDE

LUNDBECK LLC

* LUNDBECK LLC
 CARNEXIV, CARBAMAZEPINE
 ONFI, CLOBAZAM
 SABRIL, VIGABATRIN

LUNDBECK NA LTD

* LUNDBECK NA LTD
 NORTHERA, DROXIDOPA

LUPIN

* LUPIN LTD
 AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 CARVEDILOL, CARVEDILOL
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
 CEFDINIR, CEFDINIR
 CEFOTAXIME SODIUM, CEFOTAXIME SODIUM
 CEFPROZIL, CEFPROZIL
 CEFTRIAZONE, CEFTRIAZONE SODIUM
 CEFUROXIME AXETIL, CEFUROXIME AXETIL
 CEPHALEXIN, CEPHALEXIN
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOFLOXACIN, LEVOFLOXACIN
 LISINAPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LISINAPRIL, LISINAPRIL
 LOVASTATIN, LOVASTATIN
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 RAMIPRIL, RAMIPRIL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** L ******* LUPIN LTD**

SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SIMVASTATIN, SIMVASTATIN
 TOPIRAMATE, TOPIRAMATE
 TRANDOLAPRIL, TRANDOLAPRIL

LUPIN ATLANTIS*** LUPIN ATLANTIS HOLDINGS SA**

ANTARA (MICRONIZED), FENOFIBRATE
 DESOXIMETASONE, DESOXIMETASONE
 MIBELAS 24 FE, ETHINYL ESTRADIOL

LUPIN LTD*** LUPIN LIMITED**

LEVETIRACETAM, LEVETIRACETAM
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL

*** LUPIN LTD**

ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE, ABACAVIR SULFATE
 AMABELZ, ESTRADIOL
 AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
 ARMODAFINIL, ARMODAFINIL
 AZITHROMYCIN, AZITHROMYCIN
 BEKYREE, DESOGESTREL
 BIMATOPROST, BIMATOPROST
 BLISOVI 24 FE, ETHINYL ESTRADIOL
 BLISOVI FE 1.5/30, ETHINYL ESTRADIOL
 BLISOVI FE 1/20, ETHINYL ESTRADIOL
 CALCIUM ACETATE, CALCIUM ACETATE
 CELECOXIB, CELECOXIB
 CIPROFLOXACIN, CIPROFLOXACIN
 CLARITHROMYCIN, CLARITHROMYCIN
 DAYSEE, ETHINYL ESTRADIOL
 DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DOXYCYCLINE, DOXYCYCLINE
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 ENSKYCE, DESOGESTREL
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 ESZOPICLONE, ESZOPICLONE
 FALLBACK SOLO, LEVONORGESTREL (OTC)
 FAMOTIDINE, FAMOTIDINE
 FAYOSIM, ETHINYL ESTRADIOL
 FENOFIBRATE, FENOFIBRATE
 FENOFIBRIC ACID, CHOLINE FENOFIBRATE
 FYAVOLV, ETHINYL ESTRADIOL
 GATIFLOXACIN, GATIFLOXACIN
 IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
 IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN
 JENCYCLA, NORETHINDRONE
 KAITLIB FE, ETHINYL ESTRADIOL
 KURVELO, ETHINYL ESTRADIOL
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
 LAMIVUDINE, LAMIVUDINE
 LAMOTRIGINE, LAMOTRIGINE
 LEVETIRACETAM, LEVETIRACETAM
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LORAZEPAM, LORAZEPAM
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 MEFENAMIC ACID, MEFENAMIC ACID
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** L ******* LUPIN LTD**

MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 NABUMETONE, NABUMETONE
 NIACIN, NIACIN
 NIKKI, DROSPIRENONE
 NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORETHINDRONE, NORETHINDRONE
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 OMEPRAZOLE, OMEPRAZOLE
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 PIRMELLA 1/35, ETHINYL ESTRADIOL
 PIRMELLA 7/7/7, ETHINYL ESTRADIOL
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 QUININE SULFATE, QUININE SULFATE
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 RANOLAZINE, RANOLAZINE
 REPAGLINIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 RIFABUTIN, RIFABUTIN
 SUPRAX, CEFIXIME
 TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VALSARTAN, VALSARTAN
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VYFEMLA, ETHINYL ESTRADIOL
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

LUPIN PHARMS*** LUPIN PHARMACEUTICALS INC**

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
 DESLORATADINE, DESLORATADINE
 MELOXICAM, MELOXICAM
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 RIFAMPIN, RIFAMPIN
 SUPRAX, CEFIXIME
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

LYMOL MEDCL*** LYMOL MEDICAL CORP**

SCLEROSOL, TALC
 TALC, TALC

LYNE*** LYNE LABORATORIES INC**

CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
 CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 DEXAMETHASONE, DEXAMETHASONE
 ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 LEVOCARNITINE, LEVOCARNITINE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

PERRIGO*** L PERRIGO CO**

ACETAMINOPHEN, ACETAMINOPHEN (OTC)
 ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)
 CHILDREN'S IBUPROFEN, IBUPROFEN (OTC)
 CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
 DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
 FAMOTIDINE, FAMOTIDINE (OTC)
 IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
 IBUPROFEN, IBUPROFEN (OTC)
 LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 LORATADINE, LORATADINE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** L ****

- * L PERRIGO CO
 - MICONAZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 - MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
 - MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
 - NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
 - NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 - RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
 - TAB-PROFEN, IBUPROFEN (OTC)
 - TIOCONAZOLE, TIOCONAZOLE (OTC)

**** M ******MA GENERAL HOSP**

- * MASSACHUSETTS GENERAL HOSP
 - AMMONIA N 13, AMMONIA N-13
 - FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

MACLEODS PHARMS LTD

- * MACLEODS PHARMACEUTICALS LTD
 - AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
 - AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 - ARIPIPIRAZOLE, ARIPIPIRAZOLE
 - CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
 - CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
 - CELECOXIB, CELECOXIB
 - CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 - DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 - ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 - ESZOPICLONE, ESZOPICLONE
 - FAMCICLOVIR, FAMCICLOVIR
 - IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 - IRBESARTAN, IRBESARTAN
 - LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 - LEVOFLOXACIN, LEVOFLOXACIN
 - LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 - LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 - MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 - METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 - MONTELUKAST SODIUM, MONTELUKAST SODIUM
 - OLANZAPINE, OLANZAPINE
 - PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 - PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 - PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 - PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 - QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 - RISEDRONATE SODIUM, RISEDRONATE SODIUM
 - RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
 - RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 - SILDENAFIL CITRATE, SILDENAFIL CITRATE
 - TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 - TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
 - TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 - VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 - VALSARTAN, VALSARTAN
 - ZOLMITRIPTAN, ZOLMITRIPTAN

MALLINCKRODT

- * MALLINCKRODT CHEMICAL INC
 - BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 - METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 - METHADOSE, METHADONE HYDROCHLORIDE
- * MALLINCKRODT INC
 - ANEXSIA 5/325, ACETAMINOPHEN
 - ANEXSIA 7.5/325, ACETAMINOPHEN
 - DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 - FENTANYL CITRATE, FENTANYL CITRATE
 - FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 - HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ******* MALLINCKRODT INC**

HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 METHYLIN, METHYLPHENIDATE HYDROCHLORIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
 OXYCET, ACETAMINOPHEN
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

MALLINCKRODT ARD*** MALLINCKRODT ARD INC**

H.P. ACTHAR GEL, CORTICOTROPIN

MALLINCKRODT HOSP*** MALLINCKRODT HOSPITAL PRODUCTS IP LTD**

INOMAX, NITRIC OXIDE
 UVADEX, METHOXSALEN

MALLINCKRODT INC*** MALLINCKRODT INC**

ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 EXALGO, HYDROMORPHONE HYDROCHLORIDE
 FENTANYL-100, FENTANYL
 FENTANYL-12, FENTANYL
 FENTANYL-25, FENTANYL
 FENTANYL-50, FENTANYL
 FENTANYL-75, FENTANYL
 GABLOFEN, BACLOFEN
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 METHADOSE, METHADONE HYDROCHLORIDE
 METHYLIN ER, METHYLPHENIDATE HYDROCHLORIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 RESTORIL, TEMAZEPAM
 ROXICODONE, OXYCODONE HYDROCHLORIDE
 TOFRANIL, IMIPRAMINE HYDROCHLORIDE
 XARTEMIS XR, ACETAMINOPHEN

MALLINCKRODT IP*** MALLINCKRODT IP**

OFIRMEV, ACETAMINOPHEN

MALLINCKRODT LLC*** MALLINCKRODT LLC**

ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE
 PAMELOR, NORTRIPTYLINE HYDROCHLORIDE

MALLINKRODT NUCLEAR*** MALLINCKRODT NUCLEAR MEDICINE LLC**

GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67
 INDIUM IN 111 CHLORIDE, INDIUM IN-111 CHLORIDE
 OCTREOSCAN, INDIUM IN-111 PENTETREOTIDE KIT
 SODIUM IODIDE I 123, SODIUM IODIDE I-123
 SODIUM IODIDE I 131, SODIUM IODIDE I-131
 TECHNESCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT
 TECHNESCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT
 TECHNESCAN, TECHNETIUM TC-99M OXIDRONATE KIT
 TECHNETIUM TC-99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
 THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
 ULTRA-TECHNEKOW FM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
 ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT
 XENON XE 133, XENON XE-133

MANNKIND**WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1086, p. 998 of 1400**

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ******* MANKIND CORP**

AFREZZA, INSULIN RECOMBINANT HUMAN

MARKSANS PHARMA*** MARKSANS PHARMA LTD**GABAPENTIN, GABAPENTIN
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LORATADINE, LORATADINE (OTC)
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NAPROXEN, NAPROXEN
PARICALCITOL, PARICALCITOL**MARNEL PHARMS***** MARNEL PHARMACEUTICALS LLC**

CROTAN, CROTAMITON

MATRIX LABS LTD*** MATRIX LABORATORIES LTD**NIFEDIPINE, NIFEDIPINE
STAVUDINE, STAVUDINE**MAYER LABS INC***** MAYER LABORATORIES INC**

TODAY, NONOXYNOL-9 (OTC)

MAYNE PHARMA*** MAYNE PHARMA INTERNATIONAL PTY LTD**DORYX MPC, DOXYCYCLINE HYCLATE
DORYX, DOXYCYCLINE HYCLATE
ERYC, ERYTHROMYCIN*** MAYNE PHARMA LLC**BUDESONIDE, BUDESONIDE
CAMILA, NORETHINDRONE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CLARITHROMYCIN, CLARITHROMYCIN
CLONIDINE, CLONIDINE
CLOZAPINE, CLOZAPINE
CYCLOSPORINE, CYCLOSPORINE
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIAZEPAM, DIAZEPAM
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
ERRIN, NORETHINDRONE
ESTAZOLAM, ESTAZOLAM
ESTRADIOL, ESTRADIOL
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVORA 0.15/30-28, ETHINYL ESTRADIOL
LOW-OGESTREL-28, ETHINYL ESTRADIOL
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MICROGESTIN 1.5/30, ETHINYL ESTRADIOL
MICROGESTIN 1/20, ETHINYL ESTRADIOL
MICROGESTIN FE 1.5/30, ETHINYL ESTRADIOL
MICROGESTIN FE 1/20, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL
TRIMETHOPRIM, TRIMETHOPRIM
TRIVORA-28, ETHINYL ESTRADIOL
ZOVIA 1/35E-28, ETHINYL ESTRADIOL**MAYNE PHARMA INC***** MAYNE PHARMA INC**BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE PHOSPHATE, ASPIRIN
HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE,

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MAYNE PHARMA INC
 LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
 METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 NYSTATIN, NYSTATIN
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE AND ASPIRIN, ASPIRIN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

MCNEIL

* MCNEIL CONSUMER PRODUCTS CO DIV MCNEILAB INC
 IBUPROFEN, IBUPROFEN (OTC)

MCNEIL CONS

* MCNEIL CONSUMER HEALTHCARE
 SUDAFED 12 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)

MCPRF

* MAYO CLINIC PET RADIOCHEMISTRY FACILITY
 AMMONIA N 13, AMMONIA N-13
 CHOLINE C-11, CHOLINE C-11
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

MEDA PHARMS

* MEDA PHARMACEUTICALS
 AEROSPAN HFA, FLUNISOLIDE
 DYMISTA, AZELASTINE HYDROCHLORIDE
 EDLUAR, ZOLPIDEM TARTRATE

* MEDA PHARMACEUTICALS INC
 ANADROL-50, OXYMETHOLONE
 ASTELIN, AZELASTINE HYDROCHLORIDE
 AVC, SULFANILAMIDE
 BUTISOL SODIUM, BUTABARBITAL SODIUM
 CESAMET, NABILONE
 COLYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
 CORTIFOAM, HYDROCORTISONE ACETATE
 DEMADEX, TORSEMIDE
 DEPEN, PENICILLAMINE
 DIPENTUM, OLSALAZINE SODIUM
 ELESTRIN, ESTRADIOL
 EPIFOAM, HYDROCORTISONE ACETATE
 FELBATOL, FELBAMATE
 GASTROCROM, CROMOLYN SODIUM
 MUSE, ALPROSTADIL
 OPTIVAR, AZELASTINE HYDROCHLORIDE
 PROCTOFOAM HC, HYDROCORTISONE ACETATE
 ROWASA, MESALAMINE
 SFROWASA, MESALAMINE
 TRILYTE, POLYETHYLENE GLYCOL 3350

* MEDA PHARMACEUTICALS MEDA PHARMACEUTICALS INC
 ASTEPRO, AZELASTINE HYDROCHLORIDE
 SOMA, CARISOPRODOL

MEDAC PHARMA INC

* MEDAC PHARMA INC
 RASUVO, METHOTREXATE

MEDEFIL INC

* MEDEFIL INC
 SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE

MEDICINES360

* MEDICINES360
 LILETTA, LEVONORGESTREL

MEDICIS

* MEDICIS PHARMACEUTICAL CORP
 ALDARA, IMIQUIMOD
 AMMONUL, SODIUM BENZOATE
 CALCIUM DISODIUM VERSENATE, EDETATE CALCIUM DISODIUM
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 LOPRQX, CLOMIPROX

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MEDICIS PHARMACEUTICAL CORP
 LUZU, LULICONAZOLE
 METROGEL-VAGINAL, METRONIDAZOLE
 MINITRAN, NITROGLYCERIN
 SOLODYN, MINOCYCLINE HYDROCHLORIDE
 SYNACORT, HYDROCORTISONE
 VANOS, FLUOCINONIDE
 ZIANA, CLINDAMYCIN PHOSPHATE
 ZYCLARA, IMIQUIMOD

MEDICURE

* MEDICURE INTERNATIONAL INC
 AGGRASTAT, TIROFIBAN HYDROCHLORIDE

MEDIGENE AG

* MEDIGENE AG
 VEREGEN, SINECATECHINS

MEDIMETRIKS PHARMS

* MEDIMETRIKS PHARMACEUTICALS INC
 LOPROX, CICLOPIROX
 NEO-SYNALAR, FLUOCINOLONE ACETONIDE
 SYNALAR, FLUOCINOLONE ACETONIDE

MEDTECH PRODUCTS

* MEDTECH PRODUCTS INC
 MONISTAT 1 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 MONISTAT 3 COMBINATION PACK (PREFILLED), MICONAZOLE NITRATE (OTC)
 MONISTAT 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 MONISTAT 3, MICONAZOLE NITRATE
 MONISTAT 3, MICONAZOLE NITRATE (OTC)
 MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 MONISTAT 7, MICONAZOLE NITRATE (OTC)
 NIX, PERMETHRIN (OTC)
 TAGAMET HB, CIMETIDINE (OTC)

MEM SLOAN-KETTERING

* MEMORIAL SLOAN-KETTERING CANCER CENTER
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

MERCK

* MERCK AND CO INC
 CANCIDAS, CASPOFUNGIN ACETATE
 EMEND, APREPITANT
 FOSAMAX PLUS D, ALENDRONATE SODIUM
 MAXALT, RIZATRIPTAN BENZOATE
 MAXALT-MLT, RIZATRIPTAN BENZOATE
 PRIMAXIN, CILASTATIN SODIUM
 PROSCAR, FINASTERIDE
 SINGULAIR, MONTELUKAST SODIUM
 ZOLINZA, VORINOSTAT

* MERCK RESEARCH LABORATORIES DIV MERCK CO INC
 PRINIVIL, LISINAPRIL
 PROPECIA, FINASTERIDE
 SINGULAIR, MONTELUKAST SODIUM
 TRUSOPT, DORZOLAMIDE HYDROCHLORIDE
 ZOCOR, SIMVASTATIN

MERCK AND CO INC

* MERCK AND CO INC
 EMEND, FOSAPREPITANT DIMEGLUMINE
 FOSAMAX, ALENDRONATE SODIUM

MERCK SHARP DOHME

* MERCK SHARP AND DOHME CORP
 ASMANEX HFA, MOMETASONE FUROATE
 ASMANEX TWISTHALER, MOMETASONE FUROATE
 BELSOMRA, SUVOREXANT
 CELESTONE SOLUSPAN, BETAMETHASONE ACETATE
 CLARINEX D 24 HOUR, DESLORATADINE
 CLARINEX, DESLORATADINE
 CLARINEX-D 12 HOUR, DESLORATADINE
 COZAAR, LOSARTAN POTASSIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MERCK SHARP AND DOHME CORP
 CRIXIVAN, INDINAVIR SULFATE
 DIPROLENE AF, BETAMETHASONE DIPROPIONATE
 DIPROLENE, BETAMETHASONE DIPROPIONATE
 DULERA, FORMOTEROL FUMARATE
 ELOCON, MOMETASONE FUROATE
 GUANIDINE HYDROCHLORIDE, GUANIDINE HYDROCHLORIDE
 HYZAAR, HYDROCHLOROTHIAZIDE
 INVANZ, ERTAPENEM SODIUM
 ISENTRESS, RALTEGRAVIR POTASSIUM
 JANUMET XR, METFORMIN HYDROCHLORIDE
 JANUMET, METFORMIN HYDROCHLORIDE
 JANUVIA, SITAGLIPTIN PHOSPHATE
 LOTRISONE, BETAMETHASONE DIPROPIONATE
 NASONEX, MOMETASONE FUROATE
 NITRO-DUR, NITROGLYCERIN
 NOXAFIL, POSACONAZOLE
 REBETOL, RIBAVIRIN
 SINEMET CR, CARBIDOPA
 SINEMET, CARBIDOPA
 STROMEKTOL, IVERMECTIN
 TEMODAR, TEMOZOLOMIDE
 ZEPATIER, ELBASVIR

MERIDIAN MEDCL

* MERIDIAN MEDICAL TECHNOLOGIES INC
 DUODOTE, ATROPINE

MERIDIAN MEDCL TECHN

* MERIDIAN MEDICAL TECHNOLOGIES INC
 ATROPEN, ATROPINE
 MORPHINE SULFATE, MORPHINE SULFATE
 PRALIDOXIME CHLORIDE, PRALIDOXIME CHLORIDE

MERRIMACK PHARMS

* MERRIMACK PHARMACEUTICALS INC
 ONIVYDE, IRINOTECAN HYDROCHLORIDE

MERRO PHARM

* MERRO PHARMACEUTICAL CO LTD
 IBUPROFEN, IBUPROFEN (OTC)

MERZ PHARMS

* MERZ PHARMACEUTICALS LLC
 CUVPOSA, GLYCOPYRROLATE

METHAPHARM

* METHAPHARM INC
 LEVETIRACETAM, LEVETIRACETAM
 PROVOCHOLINE, METHACHOLINE CHLORIDE

METUCHEN PHARMS

* METUCHEN PHARMACEUTICALS LLC
 STENDRA, AVANAFIL

MICRO LABS LTD

* MICRO LABS LTD
 MEFENAMIC ACID, MEFENAMIC ACID
 NEVIRAPINE, NEVIRAPINE
 SIMVASTATIN, SIMVASTATIN

MICRO LABS LTD INDIA

* MICRO LABS LTD INDIA
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 CROMOLYN SODIUM, CROMOLYN SODIUM
 GLIMEPIRIDE, GLIMEPIRIDE
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN

MIDATECH PHARMA US

* MIDATECH PHARMA US INC
 ORAVIG, MICONAZOLE
 SOLTAMOX, TAMOXIFEN CITRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MIDATECH PHARMA US INC
ZUPLLENZ, ONDANSETRON

MIDWEST MEDCL

* MIDWEST MEDICAL ISOTOPES LLC CYCLOTRON DIV
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

MIKAH PHARMA

* MIKAH PHARMA LLC
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE

MIKAH PHARMA LLC

* MIKAH PHARMA LLC
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

MIKART

* MIKART INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
BENZONATATE, BENZONATATE
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTAPAP, ACETAMINOPHEN
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CHLORZOXAZONE, CHLORZOXAZONE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE
ETHOSUXIMIDE, ETHOSUXIMIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
ISONIAZID, ISONIAZID
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
METHAZOLAMIDE, METHAZOLAMIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE

MIKART INC

* MIKART INC
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CHLORZOXAZONE, CHLORZOXAZONE

MILLENNIUM PHARMS

* MILLENNIUM PHARMACEUTICALS INC
NINLARO, IXAZOMIB CITRATE
VELCADE, BORTEZOMIB

MIPS CRF

* MIPS CYCLOTRON AND RADIOCHEMISTRY FACILITY
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

MISSION PHARMA

* MISSION PHARMACAL CO
BINOSTO, ALENDRONATE SODIUM
LITHOSTAT, ACETOHYDROXAMIC ACID
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
TEXACORT, HYDROCORTISONE
THIOLA, TIOPRONIN
TINDAMAX, TINIDAZOLE
UROCIT-K, POTASSIUM CITRATE

MISSION PHARMACAL CO

* MISSION PHARMACAL CO
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
FLOWTUSS, GUAIFENESIN
HYCOFENIX, GUAIFENESIN
POTASSIUM IODIDE, POTASSIUM IODIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ******MIST PHARMS LLC**

* MIST PHARMACEUTICALS LLC
NITROMIST, NITROGLYCERIN

MOBERG PHARMA NORTH

* MOBERG PHARMA NORTH AMERICA LLC
CHILDREN'S ELIXSURE, IBUPROFEN (OTC)

MOBIUS THERAP

* MOBIUS THERAPEUTICS LLC
MITOSOL, MITOMYCIN

MOLNLYCKE HLTH

* MOLNLYCKE HEALTH CARE
HIBICLENS, CHLORHEXIDINE GLUCONATE (OTC)
HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)

MONARCH PHARMS

* MONARCH PHARMACEUTICALS INC
CORTISPORIN, BACITRACIN ZINC
CORTISPORIN, HYDROCORTISONE ACETATE
CORTISPORIN, HYDROCORTISONE
MENEST, ESTROGENS, ESTERIFIED
NEOSPORIN G.U. IRRIGANT, NEOMYCIN SULFATE
NEOSPORIN, GRAMICIDIN
SEPTRA DS, SULFAMETHOXAZOLE
SEPTRA, SULFAMETHOXAZOLE
VIROPTIC, TRIFLURIDINE

MONTEREY PHARMS LLC

* MONTEREY PHARMACEUTICALS LLC
METHOCARBAMOL, METHOCARBAMOL

MORTON GROVE

* MORTON GROVE PHARMACEUTICALS INC
LACTULOSE, LACTULOSE

MORTON GROVE PHARMS

* MORTON GROVE PHARMACEUTICALS INC
GENERLAC, LACTULOSE

MSD INTL

* MSD INTERNATIONAL GMBH
VYTORIN, EZETIMIBE

MSD INTL GMBH

* MSD INTERNATIONAL GMBH
ZETIA, EZETIMIBE

MSD MERCK CO

* MERCK SHARP AND DOHME CORP A SUBSIDIARY OF MERCK AND CO INC
EMEND, APREPITANT

MSN LABS PVT LTD

* MSN LABORATORIES PRIVATE LTD
LACOSAMIDE, LACOSAMIDE

MURTY PHARMS

* MURTY PHARMACEUTICALS INC
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE

MUSTAFA NEVZAT ILAC

* MUSTAFA NEVZAT ILAC SANAYII AS (MN PHARMACEUTICALS)
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE

MUTUAL PHARM

* MUTUAL PHARMACEUTICAL CO INC
ACETAZOLAMIDE, ACETAZOLAMIDE
ALLOPURINOL, ALLOPURINOL
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MINOXIDIL, MINOXIDIL
PIROXICAM, PIROXICAM
PREDNISONE, PREDNISONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ******MYLAN**

* MYLAN LABORATORIES INC
 ACYCLOVIR, ACYCLOVIR
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
 CAPTOPRIL, CAPTOPRIL
 ETODOLAC, ETODOLAC
 OLANZAPINE, OLANZAPINE
 TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE

* MYLAN PHARMACEUTICALS
 FENOFIBRATE, FENOFIBRATE
 METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TRANEXAMIC ACID, TRANEXAMIC ACID

* MYLAN PHARMACEUTICALS INC
 ACARBOSE, ACARBOSE
 ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
 ACYCLOVIR, ACYCLOVIR
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 ALENDRONATE SODIUM, ALENDRONATE SODIUM
 ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
 ALLOPURINOL, ALLOPURINOL
 ALPRAZOLAM, ALPRAZOLAM
 AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
 ANASTROZOLE, ANASTROZOLE
 ATENOLOL AND CHLORTHALIDONE, ATENOLOL
 ATENOLOL, ATENOLOL
 AVITA, TRETINOIN
 AZATHIOPRINE, AZATHIOPRINE
 AZITHROMYCIN, AZITHROMYCIN
 BACLOFEN, BACLOFEN
 BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
 BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 BICALUTAMIDE, BICALUTAMIDE
 BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
 BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
 BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
 BUDESONIDE, BUDESONIDE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
 CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
 CARBIDOPA AND LEVODOPA, CARBIDOPA
 CARVEDILOL, CARVEDILOL
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHLOROTHIAZIDE, CHLOROTHIAZIDE
 CHLORPROPAMIDE, CHLORPROPAMIDE
 CHLORTHALIDONE, CHLORTHALIDONE
 CILOSTAZOL, CILOSTAZOL
 CIMETIDINE, CIMETIDINE
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 CLARITHROMYCIN, CLARITHROMYCIN
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
 CLONAZEPAM, CLONAZEPAM
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
 CLORPRES, CHLORTHALIDONE
 CLOZAPINE, CLOZAPINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MYLAN PHARMACEUTICALS INC
 CYSTAGON, CYSTEAMINE BITARTRATE
 DIAZEPAM, DIAZEPAM
 DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DOXYCYCLINE, DOXYCYCLINE
 ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
 ENALAPRIL MALEATE, ENALAPRIL MALEATE
 ESTRADIOL, ESTRADIOL
 ESTROPIPATE, ESTROPIPATE
 ETIDRONATE DISODIUM, ETIDRONATE DISODIUM
 ETOPOSIDE, ETOPOSIDE
 EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
 FAMCICLOVIR, FAMCICLOVIR
 FAMOTIDINE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE (OTC)
 FELODIPINE, FELODIPINE
 FENOFIBRATE, FENOFIBRATE
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
 FINASTERIDE, FINASTERIDE
 FLUCONAZOLE, FLUCONAZOLE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
 FLURBIPROFEN, FLURBIPROFEN
 FLUTAMIDE, FLUTAMIDE
 FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
 FUROSEMIDE, FUROSEMIDE
 GABAPENTIN, GABAPENTIN
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 GLIMEPIRIDE, GLIMEPIRIDE
 GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
 GLIPIZIDE, GLIPIZIDE
 GLYBURIDE (MICRONIZED), GLYBURIDE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 HALOPERIDOL, HALOPERIDOL
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 INDAPAMIDE, INDAPAMIDE
 INDOMETHACIN, INDOMETHACIN
 KETOCONAZOLE, KETOCONAZOLE
 KETOPROFEN, KETOPROFEN
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LAMOTRIGINE, LAMOTRIGINE
 LATANOPROST, LATANOPROST
 LETROZOLE, LETROZOLE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOFLOXACIN, LEVOFLOXACIN
 LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
 LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
 LISINAPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LISINAPRIL, LISINAPRIL
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
 LORATADINE, LORATADINE (OTC)
 LORAZEPAM, LORAZEPAM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MYLAN PHARMACEUTICALS INC
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 LOVASTATIN, LOVASTATIN
 LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
 MAPROTILINE HYDROCHLORIDE, MAPROTILINE HYDROCHLORIDE
 MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
 MELOXICAM, MELOXICAM
 MENTAX, BUTENAFINE HYDROCHLORIDE
 MERCAPTOPYRINE, MERCAPTOPYRINE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHIMAZOLE, METHIMAZOLE
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 METHYLDOPA, METHYLDOPA
 METOLAZONE, METOLAZONE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MIRTAZAPINE, MIRTAZAPINE
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 NADOLOL AND BENDROFLUMETHIAZIDE, BENDROFLUMETHIAZIDE
 NADOLOL, NADOLOL
 NAPROXEN, NAPROXEN
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 NIFEDIPINE, NIFEDIPINE
 NISOLDIPINE, NISOLDIPINE
 NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
 NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
 NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
 OMEPRAZOLE, OMEPRAZOLE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON, ONDANSETRON
 OXYBUTYRIN CHLORIDE, OXYBUTYRIN CHLORIDE
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PEG 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
 PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE, POLYETHYLENE GLYCOL
 PENTOXIFYLLINE, PENTOXIFYLLINE
 PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 PHENYTEK, PHENYTOIN SODIUM
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 PIROXICAM, PIROXICAM
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
 PROBENECID, PROBENECID
 PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
 RISPERIDONE, RISPERIDONE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
 SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 SPIRONOLACTONE, SPIRONOLACTONE
 STAVUDINE, STAVUDINE
 SULINDAC, SULINDAC
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TACROLIMUS, TACROLIMUS
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TEMAZEPAM, TEMAZEPAM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MYLAN PHARMACEUTICALS INC
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE
 THIOTHIXENE, THIOTHIXENE
 TIMOLOL MALEATE, TIMOLOL MALEATE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TOLMETIN SODIUM, TOLMETIN SODIUM
 TOPIRAMATE, TOPIRAMATE
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 TRANDOLAPRIL, TRANDOLAPRIL
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
 URSODIOL, URSODIOL
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
 WARFARIN SODIUM, WARFARIN SODIUM
 ZALEPLON, ZALEPLON
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
 ZONISAMIDE, ZONISAMIDE

MYLAN INSTITUTIONAL

* MYLAN INSTITUTIONAL INC
 SULFAMYLOL, MAFENIDE ACETATE

* MYLAN INSTITUTIONAL LLC
 ACETYLCYSTEINE, ACETYLCYSTEINE
 ALOPRIM, ALLOPURINOL SODIUM
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 ARGATROBAN, ARGATROBAN
 AZACITIDINE, AZACITIDINE
 CARBOPLATIN, CARBOPLATIN
 CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
 CIDOFOVIR, CIDOFOVIR
 COSYNTROPIN, COSYNTROPIN
 DANTROLENE SODIUM, DANTROLENE SODIUM
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
 DIMETHYL SULFOXIDE, DIMETHYL SULFOXIDE
 DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
 DURACLON, CLONIDINE HYDROCHLORIDE
 ENLON, EDROPHONIUM CHLORIDE
 ENLON-PLUS, ATROPINE SULFATE
 ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
 ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
 FOMEPIZOLE, FOMEPIZOLE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 IBUTILIDE FUMARATE, IBUTILIDE FUMARATE
 ISOSULFAN BLUE, ISOSULFAN BLUE
 KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
 MEFOXIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
 MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
 MESNA, MESNA
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 METHOCARBAMOL, METHOCARBAMOL
 MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
 NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
 PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
 PENTOSTATIN, PENTOSTATIN
 PYRIDOXINE HYDROCHLORIDE, PYRIDOXINE HYDROCHLORIDE
 RIMSO-50, DIMETHYL SULFOXIDE
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 SCANLUX-300, IOPAMIDOL
 SCANLUX-370, IOPAMIDOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MYLAN INSTITUTIONAL LLC
 SOTRADECOL, SODIUM TETRADECYL SULFATE
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
 THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
 TRANEXAMIC ACID, TRANEXAMIC ACID
 ULTIVA, REMIFENTANIL HYDROCHLORIDE

MYLAN IRELAND LTD

* MYLAN IRELAND LTD
 ARIXTRA, FONDAPARINUX SODIUM
 CARBAMAZEPINE, CARBAMAZEPINE
 MIACALCIN, CALCITONIN SALMON
 PIROXICAM, PIROXICAM
 SUCRALFATE, SUCRALFATE
 THEOPHYLLINE, THEOPHYLLINE

MYLAN LABS

* MYLAN LABORATORIES LTD
 CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
 NEVIRAPINE, NEVIRAPINE

MYLAN LABS LTD

* MYLAN LABORATORIES LTD
 ADENOSINE, ADENOSINE
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 AMPICILLIN SODIUM, AMPICILLIN SODIUM
 CARBOPLATIN, CARBOPLATIN
 CISPLATIN, CISPLATIN
 CLADRIBINE, CLADRIBINE
 CYTARABINE, CYTARABINE
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 DOXYCYCLINE, DOXYCYCLINE HYCLATE
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 ETOMIDATE, ETOMIDATE
 FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 FLUMAZENIL, FLUMAZENIL
 FLUOROURACIL, FLUOROURACIL
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
 HALOPERIDOL, HALOPERIDOL LACTATE
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
 IFOSFAMIDE, IFOSFAMIDE
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LEVETIRACETAM, LEVETIRACETAM
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 MESNA, MESNA
 METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
 MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
 NAFCILLIN SODIUM, NAFCILLIN SODIUM
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXACILLIN SODIUM, OXACILLIN SODIUM
 OXALIPLATIN, OXALIPLATIN
 PACLITAXEL, PACLITAXEL
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RIFAMPIN, RIFAMPIN
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ******* MYLAN LABORATORIES LTD**

VALSARTAN, VALSARTAN
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VECURONIUM BROMIDE, VECURONIUM BROMIDE
 VINORELBINE TARTRATE, VINORELBINE TARTRATE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

MYLAN PHARMS INC*** MYLAN PHARMACEUTICALS INC**

ABACAVIR SULFATE, ABACAVIR SULFATE
 ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
 ACITRETIN, ACITRETIN
 ACYCLOVIR, ACYCLOVIR
 ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
 ALPRAZOLAM, ALPRAZOLAM
 AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 AMNESTEEM, ISOTRETINOIN
 ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
 ARMODAFINIL, ARMODAFINIL
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE
 AVITA, TRETINOIN
 BACLOFEN, BACLOFEN
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 CABERGOLINE, CABERGOLINE
 CAPECITABINE, CAPECITABINE
 CELECOXIB, CELECOXIB
 CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 CILOSTAZOL, CILOSTAZOL
 CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
 CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
 CLONAZEPAM, CLONAZEPAM
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 CLOZAPINE, CLOZAPINE
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 CYTARABINE, CYTARABINE
 DESLORATADINE, DESLORATADINE
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DIDANOSINE, DIDANOSINE
 DIGOXIN, DIGOXIN
 DISULFIRAM, DISULFIRAM
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DOXYCYCLINE, DOXYCYCLINE
 DUTASTERIDE, DUTASTERIDE
 EFAVIRENZ, EFAVIRENZ
 ENTACAPONE, ENTACAPONE
 EPROSARTAN MESYLATE, EPROSARTAN MESYLATE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 ESZOPICLONE, ESZOPICLONE
 FENOFIBRATE (MICRONIZED), FENOFIBRATE
 FENOFIBRATE, FENOFIBRATE
 FENOFIBRIC ACID, CHOLINE FENOFIBRATE
 FENOPROFEN CALCIUM, FENOPROFEN CALCIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MYLAN PHARMACEUTICALS INC
 FINASTERIDE, FINASTERIDE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM HYDROCHLORIDE
 FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
 FOSAMPRENAVIR CALCIUM, FOSAMPRENAVIR CALCIUM
 FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
 GABAPENTIN, GABAPENTIN
 GLIPIZIDE, GLIPIZIDE
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
 INDAPAMIDE, INDAPAMIDE
 INDOMETHACIN, INDOMETHACIN
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN
 ISRADIPINE, ISRADIPINE
 ITRACONAZOLE, ITRACONAZOLE
 LACOSAMIDE, LACOSAMIDE
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
 LAMIVUDINE, LAMIVUDINE
 LANSOPRAZOLE, LANSOPRAZOLE
 LANSOPRAZOLE, LANSOPRAZOLE (OTC)
 LEVETIRACETAM, LEVETIRACETAM
 LINEZOLID, LINEZOLID
 LITHIUM CARBONATE, LITHIUM CARBONATE
 MAXZIDE, HYDROCHLOROTHIAZIDE
 MAXZIDE-25, HYDROCHLOROTHIAZIDE
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 MESALAMINE, MESALAMINE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHYLOTHIAZIDE, METHYLOTHIAZIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MIRTAZAPINE, MIRTAZAPINE
 MODAFINIL, MODAFINIL
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 MORPHINE SULFATE, MORPHINE SULFATE
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
 NABUMETONE, NABUMETONE
 NAPROXEN, NAPROXEN
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
 NEVIRAPINE, NEVIRAPINE
 OLANZAPINE, OLANZAPINE
 OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 PALIPERIDONE, PALIPERIDONE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PHENYTOIN, PHENYTOIN
 PINDOLOL, PINDOLOL
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 QUININE SULFATE, QUININE SULFATE
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 REPAGLINIDE, REPAGLINIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

- * MYLAN PHARMACEUTICALS INC
 RILUZOLE, RILUZOLE
 RISEDRONATE SODIUM, RISEDRONATE SODIUM
 RISPERIDONE, RISPERIDONE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 RUFINAMIDE, RUFINAMIDE
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SIMVASTATIN, SIMVASTATIN
 TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TELMISARTAN, TELMISARTAN
 TEMOZOLOMIDE, TEMOZOLOMIDE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TOLAZAMIDE, TOLAZAMIDE
 TOLBUTAMIDE, TOLBUTAMIDE
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
 TRIAZOLAM, TRIAZOLAM
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VORICONAZOLE, VORICONAZOLE
 ZIDOVUDINE, ZIDOVUDINE
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
 ZOLMITRIPTAN, ZOLMITRIPTAN
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
 ZONISAMIDE, ZONISAMIDE
- * MYLAN PHARMACEUTICALS INC.
 FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
 NIZATIDINE, NIZATIDINE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

MYLAN SPECLT

- * MYLAN SPECIALTY LP
 ACCUNEB, ALBUTEROL SULFATE
 CROMOLYN SODIUM, CROMOLYN SODIUM
 EPIPEN JR., EPINEPHRINE
 EPIPEN, EPINEPHRINE
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
 PERFORMIST, FORMOTEROL FUMARATE

MYLAN TECHNOLOGIES

- * MYLAN TECHNOLOGIES
 XULANE, ETHINYL ESTRADIOL
- * MYLAN TECHNOLOGIES INC
 CLONIDINE, CLONIDINE
 ESTRADIOL, ESTRADIOL
 FENTANYL-100, FENTANYL
 FENTANYL-12, FENTANYL
 FENTANYL-25, FENTANYL
 FENTANYL-37, FENTANYL
 FENTANYL-50, FENTANYL
 FENTANYL-62, FENTANYL
 FENTANYL-75, FENTANYL
 FENTANYL-87, FENTANYL
 LIDOCAINE, LIDOCAINE
 NITROGLYCERIN, NITROGLYCERIN

MYLAN TEORANTA

- * MYLAN TEORANTA
 LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM

**** N ******NAMIGEN LLC****WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1086, p. 1012 of 1400**

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ****

* NAMIGEN LLC

SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE

NANG KUANG PHARM CO

* NANG KUANG PHARMACEUTICAL CO LTD

LINEZOLID, LINEZOLID

NANJING KING-FRIEND

* NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL CO LTD

ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE

ATRACURIUM BESYLATE, ATRACURIUM BESYLATE

CARBOPLATIN, CARBOPLATIN

NAPO PHARMS INC

* NAPO PHARMACEUTICALS INC

FULYZAQ, CROFELEMER

NATCO PHARMA

* NATCO PHARMA LTD

GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE

NATCO PHARMA LTD

* NATCO PHARMA LIMITED

CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE

* NATCO PHARMA LTD

ALPRAZOLAM, ALPRAZOLAM

ANASTROZOLE, ANASTROZOLE

ARMODAFINIL, ARMODAFINIL

CARISOPRODOL, CARISOPRODOL

CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE

GLYCOPYRROLATE, GLYCOPYRROLATE

LANSOPRAZOLE, LANSOPRAZOLE

LANSOPRAZOLE, LANSOPRAZOLE (OTC)

LETROZOLE, LETROZOLE

ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE

OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE

RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE

TRIHENXYPHENIDYL HYDROCHLORIDE, TRIHENXYPHENIDYL HYDROCHLORIDE

NAVIDEA BIOPHARMS

* NAVIDEA BIOPHARMACEUTICALS INC

LYMPHOSEEK KIT, TECHNETIUM TC-99M TILMANOCEPT

NAVINTA LLC

* NAVINTA LLC

BENZTROPINE MESYLATE, BENZTROPINE MESYLATE

FAMOTIDINE, FAMOTIDINE

FOMEPIZOLE, FOMEPIZOLE

HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE

NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE

RIBAVIRIN, RIBAVIRIN

ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE

SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE

NCM USA BRONX LLC

* NCM USA BRONX LLC

AMMONIA N 13, AMMONIA N-13

FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

NEOS THERAP INC

* NEOS THERAPEUTICS INC

HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX, CHLORPHENIRAMINE POLISTIREX

NEOS THERAPS

* NEOS THERAPEUTICS

ADZENYS XR-ODT, AMPHETAMINE

NEPHRON

* NEPHRON CORP

ALBUTEROL SULFATE, ALBUTEROL SULFATE

IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE

* NEPHRON PHARMACEUTICALS CORP

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE

ALBUTEROL SULFATE, ALBUTEROL SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ******NESHER PHARMS**

- * NESHER PHARMACEUTICALS USA LLC
 - DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 - ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
 - MICRO-K 10, POTASSIUM CHLORIDE
 - MICRO-K, POTASSIUM CHLORIDE
 - MORPHINE SULFATE, MORPHINE SULFATE
 - OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

NEW HAVEN PHARMS

- * NEW HAVEN PHARMACEUTICALS INC
 - DURLAZA, ASPIRIN

NEW RIVER

- * NEW RIVER PHARMACEUTICALS INC
 - PROFERDEX, IRON DEXTRAN

NEWGEN PHARMS LLC

- * NEWGEN PHARMACEUTICALS LLC
 - AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE

NEXGEN PHARMA

- * NEXGEN PHARMA INC
 - BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
 - BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 - CHENODIOL, CHENODIOL
 - GLYCOPYRROLATE, GLYCOPYRROLATE
 - MECAMYLAMINE HYDROCHLORIDE, MECAMYLAMINE HYDROCHLORIDE
 - POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)

NEXGEN PHARMA INC

- * NEXGEN PHARMA INC
 - BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
 - BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
 - POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350

NEXTWAVE PHARMS

- * NEXTWAVE PHARMACEUTICALS INC
 - QUILLIVANT XR, METHYLPHENIDATE HYDROCHLORIDE

NIAGARA PHARMS

- * NIAGARA PHARMACEUTICALS INC
 - PUR-WASH, PURIFIED WATER (OTC)

NODEN PHARMA

- * NODEN PHARMA DAC
 - TEKTURNA HCT, ALISKIREN HEMIFUMARATE
 - TEKTURNA, ALISKIREN HEMIFUMARATE

NORTEC DEV ASSOC

- * NORTEC DEVELOPMENT ASSOC INC
 - PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

NORTH CREEK PHARMS

- * NORTH CREEK PHARMACEUTICALS LLC
 - DAPSONE, DAPSONE
 - TRANEXAMIC ACID, TRANEXAMIC ACID

NORTHSTAR HLTHCARE

- * NORTHSTAR HEALTHCARE HOLDINGS LTD
 - ALLOPURINOL, ALLOPURINOL
 - BACLOFEN, BACLOFEN
 - GEMFIBROZIL, GEMFIBROZIL
 - HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 - METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 - PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 - TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

NOSTRUM LABS INC

- * NOSTRUM LABORATORIES INC
 - ACETAZOLAMIDE, ACETAZOLAMIDE
 - CALCIUM ACETATE, CALCIUM ACETATE
 - CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 - CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 - CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 - DAPSONE, DAPSONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ****

* NOSTRUM LABORATORIES INC
 ELIXOPHYLLIN, THEOPHYLLINE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 NITROFURANTOIN, NITROFURANTOIN
 PINDOLOL, PINDOLOL
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 THEOCHRON, THEOPHYLLINE
 VALPROIC ACID, VALPROIC ACID

NOSTRUM PHARMS LLC

* NOSTRUM PHARMACEUTICALS LLC
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

NOVA LABS LTD

* NOVA LABORATORIES LTD
 PURIXAN, MERCAPTOPYRIMIDINE

NOVARTIS

* NOVARTIS CONSUMER HEALTH INC
 LAMISIL AT, TERBINAFINE (OTC)
 LAMISIL AT, TERBINAFINE HYDROCHLORIDE (OTC)
 LAMISIL, TERBINAFINE HYDROCHLORIDE (OTC)
 THRIVE, NICOTINE POLACRILEX (OTC)
 VAGISTAT-1, TIOCONAZOLE (OTC)

* NOVARTIS PHARMACEUTICALS CORP
 AFINITOR, EVEROLIMUS
 ARCAPTA NEOHALER, INDACATEROL MALEATE
 COARTEM, ARTEMETHER
 DESFERAL, DEFEROXAMINE MESYLATE
 DIOVAN HCT, HYDROCHLOROTHIAZIDE
 DIOVAN, VALSARTAN
 ESTRADERM, ESTRADIOL
 EXELON, RIVASTIGMINE
 EXELON, RIVASTIGMINE TARTRATE
 EXFORGE HCT, AMLODIPINE BESYLATE
 EXFORGE, AMLODIPINE BESYLATE
 EXJADE, DEFERASIROX
 FAMVIR, FAMCICLOVIR
 FOCALIN XR, DEXMETHYLPHENIDATE HYDROCHLORIDE
 FOCALIN, DEXMETHYLPHENIDATE HYDROCHLORIDE
 FORADIL, FORMOTEROL FUMARATE
 GILENYA, FINGOLIMOD
 GLEEVEC, IMATINIB MESYLATE
 HYDERGINE, ERGOLOID MESYLATES
 LAMISIL, TERBINAFINE HYDROCHLORIDE
 LAMPRENE, CLOFAZIMINE
 LESCOL XL, FLUVASTATIN SODIUM
 LESCOL, FLUVASTATIN SODIUM
 LOPRESSOR, METOPROLOL TARTRATE
 LOTREL, AMLODIPINE BESYLATE
 MYFORTIC, MYCOPHENOLIC ACID
 NEORAL, CYCLOSPORINE
 OCUPRESS, CARTEOLOL HYDROCHLORIDE
 RECLAST, ZOLEDRONIC ACID
 REGITINE, PHENTOLAMINE MESYLATE
 RITALIN LA, METHYLPHENIDATE HYDROCHLORIDE
 RITALIN, METHYLPHENIDATE HYDROCHLORIDE
 RITALIN-SR, METHYLPHENIDATE HYDROCHLORIDE
 SANDIMMUNE, CYCLOSPORINE
 SANDOSTATIN LAR, OCTREOTIDE ACETATE
 SANDOSTATIN, OCTREOTIDE ACETATE
 SIGNIFOR, PASIREOTIDE DIASPARTATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ****

* NOVARTIS PHARMACEUTICALS CORP
 STARLIX, NATEGLINIDE
 TASIGNA, NILOTINIB HYDROCHLORIDE MONOHYDRATE
 TAVIST-1, CLEMASTINE FUMARATE (OTC)
 TEGRETOL, CARBAMAZEPINE
 TEGRETOL-XR, CARBAMAZEPINE
 TOBI PODHALER, TOBRAMYCIN
 TRILEPTAL, OXCARBAZEPINE
 TYZEKA, TELBIVUDINE
 VIVELLE, ESTRADIOL
 VIVELLE-DOT, ESTRADIOL
 VOLTAREN, DICLOFENAC SODIUM
 ZOMETA, ZOLEDRONIC ACID
 ZORTRESS, EVEROLIMUS

NOVARTIS PHARM

* NOVARTIS PHARMACEUTICAL CORP
 AFINITOR DISPERZ, EVEROLIMUS

NOVARTIS PHARMS

* NOVARTIS PHARMACEUTICALS CORP
 FEMARA, LETROZOLE
 TOBI, TOBRAMYCIN

NOVARTIS PHARMS CORP

* NOVARTIS PHARMACEUTICALS CORP
 ALCaine, PROPARACaine HYDROCHLORIDE
 ALOMIDE, LODOXAMIDE TROMETHAMINE
 ARRANON, NELARABINE
 AZOPT, BRINZOLAMIDE
 BETOPTIC S, BETAXOLOL HYDROCHLORIDE
 CILOXAN, CIPROFLOXACIN HYDROCHLORIDE
 CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE
 CIPRODEX, CIPROFLOXACIN
 CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE
 CYCLOMYDRIL, CYCLOPENTOLATE HYDROCHLORIDE
 DUREZOL, DIFLUPREDNATE
 EMADINE, EMEDASTINE DIFUMARATE
 ENTRESTO, SACUBITRIL
 FARYDAK, PANOBINOSTAT LACTATE
 FLAREX, FLUOROMETHOLONE ACETATE
 FLUORESCITE, FLUORESCHEIN SODIUM
 Hycamtin, TOPOTECAN HYDROCHLORIDE
 ILEVRO, NEPAFENAC
 IOPIDINE, APRACLOnidine HYDROCHLORIDE
 ISOPTO ATROPINE, ATROPINE SULFATE
 ISOPTO CARPINE, PILOCARPINE HYDROCHLORIDE
 JADENU, DEFERASIROX
 MAXIDEX, DEXAMETHASONE
 MAXITROL, DEXAMETHASONE
 MEKINIST, TRAMETINIB DIMETHYL SULFOXIDE
 MOXEZA, MOXIFLOXACIN HYDROCHLORIDE
 MYDRIACYL, TROPICAMIDE
 NEVANAC, NEPAFENAC
 ODOMZO, SONIDEGIB PHOSPHATE
 OMNIPRED, PREDNISOLONE ACETATE
 PATADAY, OLOPATADINE HYDROCHLORIDE
 PATANASE, OLOPATADINE HYDROCHLORIDE
 PATANOL, OLOPATADINE HYDROCHLORIDE
 PAZEO, OLOPATADINE HYDROCHLORIDE
 PROMACTA, ELTROMBOPAG OLAMINE
 SEEBRI, GLYCOPYRROLATE
 SIGNIFOR LAR, PASIREOTIDE PAMOATE
 SIMBRINZA, BRIMONIDINE TARTRATE
 TAFINLAR, DABRAFENIB MESYLATE
 TETRACaine HYDROCHLORIDE, TETRACaine HYDROCHLORIDE
 TOBRADEX ST, DEXAMETHASONE
 TOBRADEX, DEXAMETHASONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ****

* NOVARTIS PHARMACEUTICALS CORP
 TOBEX, TOBRAMYCIN
 TRAVATAN Z, TRAVOPROST
 TRIESENCE, TRIAMCINOLONE ACETONIDE
 TYKERB, LAPATINIB DITOSYLATE
 UTIBRON, GLYCOPYRROLATE
 VIGAMOX, MOXIFLOXACIN HYDROCHLORIDE
 VOTRIENT, PAZOPANIB HYDROCHLORIDE
 XTORO, FINAFLOXACIN
 ZOFRAN ODT, ONDANSETRON
 ZOFRAN, ONDANSETRON HYDROCHLORIDE
 ZYKADIA, CERITINIB

NOVAST LABS

* NOVAST LABORATORIES CHINA LTD
 NORETHINDRONE, NORETHINDRONE

NOVAST LABS LTD

* NOVAST LABORATORIES LTD
 ACETAZOLAMIDE, ACETAZOLAMIDE
 DASETTA 1/35, ETHINYL ESTRADIOL
 DASETTA 7/7/7, ETHINYL ESTRADIOL
 DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
 ELINEST, ETHINYL ESTRADIOL
 FALMINA, ETHINYL ESTRADIOL
 HER STYLE, LEVONORGESTREL (OTC)
 LARIN 1.5/30, ETHINYL ESTRADIOL
 LARIN 1/20, ETHINYL ESTRADIOL
 LARIN 24 FE, ETHINYL ESTRADIOL
 LARIN FE 1.5/30, ETHINYL ESTRADIOL
 LARIN FE 1/20, ETHINYL ESTRADIOL
 LERIBANE, ETHINYL ESTRADIOL
 LEVONEST, ETHINYL ESTRADIOL
 MELAMISA, DROSPIRENONE
 MONO-LINYAH, ETHINYL ESTRADIOL
 NIFEDIPINE, NIFEDIPINE
 NORETHINDRONE, NORETHINDRONE
 PHILITH, ETHINYL ESTRADIOL
 PIMTREA, DESOGESTREL
 SETLAKIN, ETHINYL ESTRADIOL
 TRI-LINYAH, ETHINYL ESTRADIOL
 WERA, ETHINYL ESTRADIOL
 YAELA, DROSPIRENONE

NOVEL LABS INC

* NOVEL LABORATORIES INC
 AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
 CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 DESOXIMETASONE, DESOXIMETASONE
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 FAMOTIDINE, FAMOTIDINE
 HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 LEVONORGESTREL, LEVONORGESTREL (OTC)
 LINEZOLID, LINEZOLID
 METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 MISOPROSTOL, MISOPROSTOL
 MORPHINE SULFATE, MORPHINE SULFATE
 NITROFURANTOIN, NITROFURANTOIN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PEG 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
 PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE, POLYETHYLENE GLYCOL
WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1086, p. 1017 of 1400

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ****

* NOVEL LABORATORIES INC
 PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL,
 PHENELZINE SULFATE, PHENELZINE SULFATE
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 TEMAZEPAM, TEMAZEPAM
 TINIDAZOLE, TINIDAZOLE
 TRIMETHOPRIM, TRIMETHOPRIM
 VORICONAZOLE, VORICONAZOLE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

NOVEN

* NOVEN PHARMACEUTICALS INC
 MINIVELLE, ESTRADIOL

NOVEN PHARMS INC

* NOVEN PHARMACEUTICALS INC
 COMBIPATCH, ESTRADIOL
 DAYTRANA, METHYLPHENIDATE

NOVO NORDISK

* NOVO NORDISK PHARMACEUTICALS INC
 GLUCAGEN, GLUCAGON HYDROCHLORIDE RECOMBINANT

NOVO NORDISK INC

* NOVO NORDISK INC
 LEVEMIR FLEXTOUCH, INSULIN DETEMIR RECOMBINANT
 LEVEMIR, INSULIN DETEMIR RECOMBINANT
 NORDITROPIN FLEXPOR, SOMATROPIN RECOMBINANT
 NOVOLIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
 NOVOLIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
 NOVOLIN R, INSULIN RECOMBINANT HUMAN (OTC)
 NOVOLOG FLEXPEN, INSULIN ASPART RECOMBINANT
 NOVOLOG FLEXTOUCH, INSULIN ASPART RECOMBINANT
 NOVOLOG MIX 70/30 FLEXPEN, INSULIN ASPART PROTAMINE RECOMBINANT
 NOVOLOG MIX 70/30, INSULIN ASPART PROTAMINE RECOMBINANT
 NOVOLOG PENFILL, INSULIN ASPART RECOMBINANT
 NOVOLOG, INSULIN ASPART RECOMBINANT
 PRANDIMET, METFORMIN HYDROCHLORIDE
 PRANDIN, REPAGLINIDE
 RYZODEG 70/30, INSULIN ASPART
 SAXENDA, LIRAGLUTIDE RECOMBINANT
 TRESIBA, INSULIN DEGLUDEC
 VAGIFEM, ESTRADIOL
 VICTOZA, LIRAGLUTIDE RECOMBINANT
 XULTOPHY 100/3.6, INSULIN DEGLUDEC

NOVOCOL

* NOVOCOL PHARMACEUTICAL INC
 ISOCAINE HYDROCHLORIDE, MEPIVACAINE HYDROCHLORIDE

NPS PHARMS INC

* NPS PHARMACEUTICALS INC
 GATTEX KIT, TEDUGLUTIDE RECOMBINANT

NU PHARM

* NU PHARM INC
 DIVALPROEX SODIUM, DIVALPROEX SODIUM

NUVO PHARM INC

* NUVO PHARMACEUTICAL INC
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 FOLIC ACID, FOLIC ACID
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE

NUVO RES INC

* NUVO RESEARCH INC
 PENNSAID, DICLOFENAC SODIUM

NYCOMED US

* NYCOMED US INC
 TERCONAZOLE, TERCONAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** O **

OAK PHARMS

- * OAK PHARMACEUTICALS INC
NEMBUTAL SODIUM, PENTOBARBITAL SODIUM
XYLOCAINE, LIDOCAINE HYDROCHLORIDE

OAK PHARMS AKORN

- * OAK PHARMACEUTICALS INC SUB AKORN INC
COGENTIN, BENZTROPINE MESYLATE
DIURIL, CHLOROTHIAZIDE SODIUM

OAK PHARMS INC

- * OAK PHARMACEUTICALS INC
ZIOPTAN, TAFLUPROST
- * OAK PHARMACEUTICALS INC SUBSIDIARY OF AKORN INC
AZASITE, AZITHROMYCIN
BETIMOL, TIMOLOL
COSOPT PF, DORZOLAMIDE HYDROCHLORIDE
COSOPT, DORZOLAMIDE HYDROCHLORIDE
XOPENEX, LEVALBUTEROL HYDROCHLORIDE

OC PHARMA

- * OC PHARMA LLC
LEVONORGESTREL, LEVONORGESTREL (OTC)
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL

ODYSSEY PHARMS

- * ODYSSEY PHARMACEUTICALS INC
ANTABUSE, DISULFIRAM
NYSTATIN, NYSTATIN
SURMONTIL, TRIMIPRAMINE MALEATE
URECHOLINE, BETHANECHOL CHLORIDE
VIVACTIL, PROTRIPTYLINE HYDROCHLORIDE

OHM

- * OHM CORP
IBUPROFEN, IBUPROFEN (OTC)

OHM LABS

- * OHM LABORATORIES INC
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
IBUPROHM COLD AND SINUS, IBUPROFEN (OTC)
IBUPROHM, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)

OHM LABS INC

- * OHM LABORATORIES INC
VALSARTAN, VALSARTAN

OLTA PHARMS

- * OLTA PHARMACEUTICALS CORP
LINDANE, LINDANE

OMAN PHARM PRODUCTS

- * OMAN PHARMACEUTICAL PRODUCTS CO LLC
NEOMYCIN SULFATE, NEOMYCIN SULFATE

OMEROS

- * OMEROS CORP
OMIDRIA, KETOROLAC TROMETHAMINE

ONY

- * ONY INC
INFASURF PRESERVATIVE FREE, CALFACTANT

ONYX THERAP

- * ONYX THERAPEUTICS INC A WHOLLY OWNED SUB OF AMGEN INC
KYPROLIS, CARFILZOMIB

OPKO IRELAND GLOBAL

- * OPKO IRELAND GLOBAL HOLDINGS LTD
RAYALDEE, CALCIFEDIOL

ORAPHARMA

- * ORAPHARMA INC
ARESTIN, MINOCYCLINE HYDROCHLORIDE

ORCHID HLTHCARE

- * ORCHID HEALTHCARE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** O **

* ORCHID HEALTHCARE

CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
 CEFDINIR, CEFDINIR
 CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
 CEFPROZIL, CEFPROZIL
 CEFUROXIME AXETIL, CEFUROXIME AXETIL
 CEPHALEXIN, CEPHALEXIN
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 DESLORATADINE, DESLORATADINE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 ESZOPICLONE, ESZOPICLONE
 FELODIPINE, FELODIPINE
 GEMIFLOXACIN MESYLATE, GEMIFLOXACIN MESYLATE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 LEVETIRACETAM, LEVETIRACETAM
 LEVOFLOXACIN, LEVOFLOXACIN
 MODAFINIL, MODAFINIL
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
 OLANZAPINE, OLANZAPINE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 RASAGILINE MESYLATE, RASAGILINE MESYLATE
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 ZALEPLON, ZALEPLON

OREXIGEN

* OREXIGEN THERAPEUTICS INC
 CONTRAVE, BUPROPION HYDROCHLORIDE

OREXO US INC

* OREXO US INC
 ZUBSOLV, BUPRENORPHINE HYDROCHLORIDE

ORGANON SUB MERCK

* ORGANON USA INC A SUBSIDIARY OF MERCK AND CO INC
 BRIDION, SUGAMMADEX SODIUM

ORGANON USA INC

* ORGANON USA INC
 DESOGEN, DESOGESTREL
 FOLLISTIM AQ, FOLLITROPIN ALFA/BETA
 GANIRELIX ACETATE, GANIRELIX ACETATE
 NEXPLANON, ETNOGESTREL
 NUVARING, ETHINYL ESTRADIOL
 PREGNYL, GONADOTROPIN, CHORIONIC
 REMERON SOLTAB, MIRTAZAPINE
 REMERON, MIRTAZAPINE

ORIENT PHARMA CO LTD

* ORIENT PHARMA CO LTD
 CARISOPRODOL, CARISOPRODOL
 MIGLITOL, MIGLITOL

ORION CORP ORION

* ORION CORP ORION PHARMA
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 NADOLOL, NADOLOL
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
 SPIRONOLACTONE, SPIRONOLACTONE

ORION PHARMA

* ORION PHARMA
 COMTAN, ENTACAPONE
 STALEVO 100, CARBIDOPA
 STALEVO 125, CARBIDOPA
 STALEVO 150, CARBIDOPA
 STALEVO 200, CARBIDOPA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** O **

* ORION PHARMA

STALEVO 50, CARBIDOPA
STALEVO 75, CARBIDOPA

ORIT LABS LLC

* ORIT LABORATORIES LLC

BENZONATATE, BENZONATATE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
ERGOCALCIFEROL, ERGOCALCIFEROL
LEVETIRACETAM, LEVETIRACETAM

ORPHAN EUROPE

* ORPHAN EUROPE

CARBAGLU, CARGLUMIC ACID

OSI PHARMS

* OSI PHARMACEUTICALS INC

TARCEVA, ERLOTINIB HYDROCHLORIDE

OSMOTICA

* OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT

HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE

OSMOTICA PHARM

* OSMOTICA PHARMACEUTICAL CORP

NIFEDIPINE, NIFEDIPINE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

OSMOTICA PHARM CORP

* OSMOTICA PHARMACEUTICAL CORP

KHEDEZLA, DESVENLAFAXINE

OSMOTICA PHARM US

* OSMOTICA PHARMACEUTICAL US LLC

DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
NIFEDIPINE, NIFEDIPINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

OTONOMY INC

* OTONOMY INC

OTIPRIO, CIPROFLOXACIN

OTSUKA

* OTSUKA PHARMACEUTICAL CO LTD

ABILIFY, ARIPIPRAZOLE

OTSUKA AMERICA PHARM

* OTSUKA AMERICA PHARMACEUTICAL INC

SAMSCA, TOLVAPTAN

OTSUKA PHARM

* OTSUKA PHARMACEUTICAL CO LTD

BUSULFEX, BUSULFAN

OTSUKA PHARM CO LTD

* OTSUKA PHARMACEUTICAL CO LTD

ABILIFY MAINTENA KIT, ARIPIPRAZOLE
DACOGEN, DECITABINE
REXULTI, BREXPIPRAZOLE

OUTLOOK PHARMS

* OUTLOOK PHARMACEUTICALS INC

DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE

OXFORD PHARMS

* OXFORD PHARMACEUTICALS LLC

BACLOFEN, BACLOFEN
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CARISOPRODOL AND ASPIRIN, ASPIRIN
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
RIMACTANE, RIFAMPIN
RISPERIDONE, RISPERIDONE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE

** P **

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ******P AND L DEV LLC**

- * P AND L DEVELOPMENT LLC DBA PLD DEVELOPMENTS LLC
IBUPROFEN, IBUPROFEN (OTC)

PACIFIC PHARMA

- * PACIFIC PHARMA
TIMOLOL MALEATE, TIMOLOL MALEATE
- * PACIFIC PHARMA INC
TIMOLOL MALEATE, TIMOLOL MALEATE

PACIRA PHARMS INC

- * PACIRA PHARMACEUTICALS INC
DEPOCYT, CYTARABINE
EXPAREL, BUPIVACAINE

PACK PHARMS LLC

- * PACK PHARMACEUTICALS LLC
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
CROMOLYN SODIUM, CROMOLYN SODIUM

PADDOCK

- * PADDOCK LABORATORIES INC
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE

PADDOCK LABS

- * PADDOCK LABORATORIES INC
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE

PADDOCK LLC

- * PADDOCK LABORATORIES LLC
ACETAMINOPHEN, ACETAMINOPHEN
BROMFENAC SODIUM, BROMFENAC SODIUM
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
CALCIUM ACETATE, CALCIUM ACETATE
CICLOPIROX, CICLOPIROX
CLINDA-DERM, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
COLOCORT, HYDROCORTISONE
COMPRO, PROCHLORPERAZINE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE, HYDROCODONE BITARTRATE
HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE ,
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
KIONEX, SODIUM POLYSTYRENE SULFONATE
LAX-LYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
LORAZEPAM, LORAZEPAM
MIDAMOR, AMILORIDE HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
NYSTOP, NYSTATIN
PODOFILOX, PODOFILOX
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
REPAGLINIDE, REPAGLINIDE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
TROSPIMUM CHLORIDE, TROSPIMUM CHLORIDE

PANACEA BIOTEC LTD

- * PANACEA BIOTEC LTD
TACROLIMUS, TACROLIMUS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

* PAR FORMULATIONS PRIVATE LTD

DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 MAFENIDE ACETATE, MAFENIDE ACETATE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

PAR PHARM

* PAR PHARMACEUTICAL

OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
 TESTOSTERONE, TESTOSTERONE

* PAR PHARMACEUTICAL INC

ALPRAZOLAM, ALPRAZOLAM
 AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
 CABERGOLINE, CABERGOLINE
 CALCITONIN-SALMON, CALCITONIN SALMON
 CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
 CHOLESTYRAMINE, CHOLESTYRAMINE
 CLOMIPHENE CITRATE, CLOMIPHENE CITRATE
 CLONAZEPAM, CLONAZEPAM
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 DEXAMETHASONE, DEXAMETHASONE
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 DOXYCYCLINE, DOXYCYCLINE
 ESTAZOLAM, ESTAZOLAM
 FENTANYL CITRATE, FENTANYL CITRATE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FLUTAMIDE, FLUTAMIDE
 GLIPIZIDE, GLIPIZIDE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 HYDRA-ZIDE, HYDRALAZINE HYDROCHLORIDE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROXYUREA, HYDROXYUREA
 IBUPROFEN, IBUPROFEN (OTC)
 IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
 ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
 LAMOTRIGINE, LAMOTRIGINE
 LEVETIRACETAM, LEVETIRACETAM
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
 MEGESTROL ACETATE, MEGESTROL ACETATE
 METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
 METRONIDAZOLE, METRONIDAZOLE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MINOXIDIL, MINOXIDIL
 NATEGLINIDE, NATEGLINIDE
 NIFEDIPINE, NIFEDIPINE
 OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 OLANZAPINE, OLANZAPINE
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
 OXANDROLONE, OXANDROLONE
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 PIMOZIDE, PIMOZIDE
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TORSEMIDE, TORSEMIDE
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

* PAR PHARMACEUTICAL INC
 TRANYLCPROMINE SULFATE, TRANYLCPROMINE SULFATE
 TRAVOPROST, TRAVOPROST
 URSODIOL, URSODIOL
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

PAR PHARM INC

* PAR PHARMACEUTICAL INC
 ACCOLATE, ZAFIRLUKAST
 AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
 ANTIZOL, FOMEPIZOLE
 BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 DAPSONE, DAPSONE
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 ENTECAVIR, ENTECAVIR
 FENTANYL-100, FENTANYL
 FENTANYL-25, FENTANYL
 FENTANYL-50, FENTANYL
 FENTANYL-75, FENTANYL
 ITRACONAZOLE, ITRACONAZOLE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 OLMESARTAN MEDOXMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
 OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 TOLCAPONE, TOLCAPONE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

PAR STERILE PRODUCTS

* PAR STERILE PRODUCTS LLC
 ADRENALIN, EPINEPHRINE
 ARGATROBAN, ARGATROBAN
 BREVITAL SODIUM, METHOHEXITAL SODIUM
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 COLY-MYCIN M, COLISTIMETHATE SODIUM
 DANTRIUM, DANTROLENE SODIUM
 DELESTROGEN, ESTRADIOL VALERATE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
 ETOMIDATE, ETOMIDATE
 FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
 GANCICLOVIR, GANCICLOVIR SODIUM
 KETALAR, KETAMINE HYDROCHLORIDE
 LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
 MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
 MEROPENEM, MEROPENEM
 MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
 PITOCIN, OXYTOCIN
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE
 TRIOSTAT, LIOETHYRONINE SODIUM
 VASOSTRICT, VASOPRESSIN

PARAGON BIOTECK

* PARAGON BIOTECK INC
 PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE

PARAPRO LLC

* PARAPRO LLC
 NATROBA, SPINOSAD

PARKE DAVIS

* PARKE DAVIS DIV WARNER LAMBERT CO
 CELONTIN, METHSUXIMIDE
 CEREBYX, FOSPHENYTOIN SODIUM
 DILANTIN, PHENYTOIN SODIUM
 DILANTIN-125, PHENYTOIN
 NARDIL, PHENELZINE SULFATE
 NEURONTIN, GABAPENTIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

* PARKE DAVIS DIV WARNER LAMBERT CO
ZARONTIN, ETHOSUXIMIDE

* PARKE DAVIS PHARMACEUTICAL RESEARCH DIV WARNER LAMBERT CO
ZARONTIN, ETHOSUXIMIDE

PATRIN PHARMA INC

* PATRIN PHARMA INC
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE

PEARL THERAPS INC

* PEARL THERAPEUTICS INC
BEVESPI AEROSPHERE, FORMOTEROL FUMARATE

PERNIX IRELAND LTD

* PERNIX IRELAND LTD
TREXIMET, NAPROXEN SODIUM

PERNIX IRELAND PAIN

* PERNIX IRELAND PAIN LIMITED
ZOHYDRO ER, HYDROCODONE BITARTRATE

PERNIX THERAPS LLC

* PERNIX THERAPEUTICS LLC
SILENOR, DOXEPIN HYDROCHLORIDE

PERRIGO

* PERRIGO CO
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CICLOPIROX, CICLOPIROX
CIMETIDINE, CIMETIDINE (OTC)
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
CLINDETS, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
ERYTHROMYCIN, ERYTHROMYCIN
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
IBUPROFEN, IBUPROFEN (OTC)
JUNIOR STRENGTH IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
MICONAZOLE NITRATE COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
MOMETASONE FUROATE, MOMETASONE FUROATE
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
STIE-CORT, HYDROCORTISONE

PERRIGO CO TENNESSEE

* PERRIGO CO TENNESSEE INC
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BACITRACIN, BACITRACIN
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN
ERYTHROMYCIN, ERYTHROMYCIN
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM

PERRIGO ISRAEL

* PERRIGO ISRAEL PHARMACEUTICALS
FLUOCINONIDE, FLUOCINONIDE

* PERRIGO ISRAEL PHARMACEUTICALS LTD
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DESOXIMETASONE, DESOXIMETASONE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
GYNAZOLE-1, BUTOCONAZOLE NITRATE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

* PERRIGO ISRAEL PHARMACEUTICALS LTD
 IMIQUIMOD, IMIQUIMOD
 KETOCONAZOLE, KETOCONAZOLE
 MESALAMINE, MESALAMINE
 MINOXIDIL, MINOXIDIL (OTC)
 NITROGLYCERIN, NITROGLYCERIN
 TESTOSTERONE, TESTOSTERONE

PERRIGO NEW YORK

* PERRIGO NEW YORK INC
 ACETAMINOPHEN, ACETAMINOPHEN (OTC)
 AMMONIUM LACTATE, AMMONIUM LACTATE
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CENTANY, MUPIROCIN
 CICLOPIROX, CICLOPIROX
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 DESONIDE, DESONIDE
 DESOXIMETASONE, DESOXIMETASONE
 ECONAZOLE NITRATE, ECONAZOLE NITRATE
 ERYTHROMYCIN, ERYTHROMYCIN
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
 HYDROCORTISONE, HYDROCORTISONE
 KETOCONAZOLE, KETOCONAZOLE
 MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
 MOMETASONE FUROATE, MOMETASONE FUROATE
 MUPIROCIN, MUPIROCIN
 NYSTATIN, NYSTATIN
 PERMETHRIN, PERMETHRIN
 PERMETHRIN, PERMETHRIN (OTC)
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 SELENIUM SULFIDE, SELENIUM SULFIDE
 TERCONAZOLE, TERCONAZOLE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

PERRIGO PHARMA INTL

* PERRIGO PHARMA INTERNATIONAL DAC
 CLINDESSE, CLINDAMYCIN PHOSPHATE
 ENTOCORT EC, BUDESONIDE
 LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
 LORATADINE, LORATADINE (OTC)
 TRETINOIN, TRETINOIN

PERRIGO PHARMS CO

* PERRIGO PHARMACEUTICALS CO
 SCOPOLAMINE, SCOPOLAMINE

PERRIGO R AND D

* PERRIGO R AND D CO
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 DESLORATADINE, DESLORATADINE
 FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE, CALCIUM CARBONATE (OTC)
 GUAIFENESIN, GUAIFENESIN (OTC)
 IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
 IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE, IBUPROFEN (OTC)
 IBUPROFEN SODIUM, IBUPROFEN SODIUM (OTC)
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 LANSOPRAZOLE, LANSOPRAZOLE (OTC)
 LEVONORGESTREL, LEVONORGESTREL
 LEVONORGESTREL, LEVONORGESTREL (OTC)
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
 NAPROXEN, NAPROXEN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

* PERRIGO R AND D CO
 NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
 OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

PERRIGO UK FINCO

* PERRIGO UK FINCO LTD PARTNERSHIP
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 FLURANDRENOLIDE, FLURANDRENOLIDE
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

PETNET

* PETNET SOLUTIONS INC
 AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

PF PRISM CV

* PF PRISM CV
 BOSULIF, BOSUTINIB MONOHYDRATE
 INLYTA, AXITINIB
 LYRICA, PREGABALIN
 RAPAMUNE, SIROLIMUS
 TORISEL, TEMSIROLIMUS
 TYGACIL, TIGECYCLINE
 VFEND, VORICONAZOLE
 XALKORI, CRIZOTINIB
 XELJANZ, TOFACITINIB CITRATE
 ZMAX, AZITHROMYCIN

PFIZER

* PFIZER CENTRAL RESEARCH
 DIFLUCAN, FLUCONAZOLE
 ZITHROMAX, AZITHROMYCIN

* PFIZER CHEMICALS DIV PFIZER INC
 DIFLUCAN, FLUCONAZOLE
 ZITHROMAX, AZITHROMYCIN

* PFIZER INC
 ADVIL ALLERGY AND CONGESTION RELIEF, CHLORPHENIRAMINE MALEATE (OTC)
 ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
 ADVIL COLD AND SINUS, IBUPROFEN (OTC)
 ADVIL CONGESTION RELIEF, IBUPROFEN (OTC)
 ADVIL LIQUI-GELS, IBUPROFEN (OTC)
 ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN (OTC)
 ADVIL PM, DIPHENHYDRAMINE CITRATE (OTC)
 ADVIL PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
 ADVIL, IBUPROFEN (OTC)
 ALAVERT, LORATADINE (OTC)
 ARGATROBAN, ARGATROBAN
 AXID AR, NIZATIDINE (OTC)
 CADUET, AMLODIPINE BESYLATE
 CALAN SR, VERAPAMIL HYDROCHLORIDE
 CARDURA XL, DOXAZOSIN MESYLATE
 CHILDREN'S ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
 CHILDREN'S ADVIL COLD, IBUPROFEN (OTC)
 CHILDREN'S ADVIL, IBUPROFEN (OTC)
 CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)
 DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
 DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 DIFLUCAN IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
 ELELYSO, TALIGLUCERASE ALFA
 GEODON, ZIPRASIDONE HYDROCHLORIDE
 GEODON, ZIPRASIDONE MESYLATE
 GLUCOTROL XL, GLIPIZIDE
 GLUCOTROL, GLIPIZIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

- * PFIZER INC
 - HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
 - HEPARIN SODIUM, HEPARIN SODIUM
 - JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)
 - LIPITOR, ATORVASTATIN CALCIUM
 - LORATADINE, LORATADINE (OTC)
 - NORVASC, AMLODIPINE BESYLATE
 - PEDIATRIC ADVIL, IBUPROFEN (OTC)
 - PROCARDIA, NIFEDIPINE
 - REVATIO, SILDENAFIL CITRATE
 - SONATA, ZALEPLON
 - TESSALON, BENZONATATE
 - TOVIAZ, FESOTERODINE FUMARATE
 - UNASYN, AMPICILLIN SODIUM
 - ZITHROMAX, AZITHROMYCIN
- * PFIZER LABORATORIES DIV PFIZER INC
 - CARDURA, DOXAZOSIN MESYLATE
 - DIABINESE, CHLORPROPAMIDE
 - FELDENE, PIROXICAM
 - MINIPRESS, PRAZOSIN HYDROCHLORIDE
 - PERMAPEN, PENICILLIN G BENZATHINE
 - PFIZERPEN, PENICILLIN G POTASSIUM
 - PROCARDIA XL, NIFEDIPINE
 - TERRAMYCIN W/ POLYMYXIN B SULFATE, OXYTETRACYCLINE HYDROCHLORIDE
 - UNASYN, AMPICILLIN SODIUM
 - VIBRAMYCIN, DOXYCYCLINE
 - VIBRAMYCIN, DOXYCYCLINE CALCIUM
 - VIBRAMYCIN, DOXYCYCLINE HYCLATE
 - VISTARIL, HYDROXYZINE PAMOATE
- * PFIZER PHARMACEUTICALS INC
 - ZOLOFT, SERTRALINE HYDROCHLORIDE
- * PFIZER PHARMACEUTICALS PRODUCTION CORP LTD
 - TIKOSYN, DOFETILIDE

PFIZER CONS HLTHCARE

- * PFIZER CONSUMER HEALTHCARE
 - ADVIL, IBUPROFEN SODIUM (OTC)

PFIZER INC

- * PFIZER INC
 - CAMPTOSAR, IRINOTECAN HYDROCHLORIDE
 - CHANTIX, VARENICLINE TARTRATE
 - ELLENCE, EPIRUBICIN HYDROCHLORIDE
 - FRAGMIN, DALTEPARIN SODIUM
 - IBRANCE, PALBOCICLIB
 - NICOTROL, NICOTINE
 - QUILLICHEW ER, METHYLPHENIDATE HYDROCHLORIDE
 - TROXYCA ER, NALTREXONE HYDROCHLORIDE
 - XELJANZ XR, TOFACITINIB CITRATE

PFIZER IRELAND

- * PFIZER IRELAND PHARMACEUTICALS
 - RELPAX, ELETRIPTAN HYDROBROMIDE
 - VIAGRA, SILDENAFIL CITRATE

PFIZER LABS

- * PFIZER LABS
 - DOCETAXEL, DOCETAXEL

PFIZER PHARMS

- * PFIZER PHARMACEUTICALS LTD
 - ACCUPRIL, QUINAPRIL HYDROCHLORIDE
 - ACCURETIC, HYDROCHLOROTHIAZIDE
 - DILANTIN, PHENYTOIN
 - LOPID, GEMFIBROZIL
 - NEURONTIN, GABAPENTIN
 - NITROSTAT, NITROGLYCERIN

PHARM ASSOC

- * PHARMACEUTICAL ASSOC INC
 - CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

- * PHARMACEUTICAL ASSOC INC
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LORAZEPAM, LORAZEPAM
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
- * PHARMACEUTICAL ASSOC INC DIV BEACH PRODUCTS
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
ETHOSUXIMIDE, ETHOSUXIMIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL LACTATE
LACTULOSE, LACTULOSE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
NYSTATIN, NYSTATIN
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PREDNISOLONE, PREDNISOLONE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
TRIHENXYPHENIDYL HYDROCHLORIDE, TRIHENXYPHENIDYL HYDROCHLORIDE
VALPROIC ACID, VALPROIC ACID
- * PHARMACEUTICAL ASSOCIATES INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LEVETIRACETAM, LEVETIRACETAM
MORPHINE SULFATE, MORPHINE SULFATE
THEOPHYLLINE, THEOPHYLLINE

PHARMA RES SOFTWARE

- * PHARMA RESEARCH SOFTWARE SOLUTION LLC
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

PHARMACEUTICS

- * PHARMACEUTICS INTERNATIONAL INC
ZOLEDRONIC ACID, ZOLEDRONIC ACID

PHARMACEUTICS INTL

- * PHARMACEUTICS INTERNATIONAL INC
BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
HYDROCORTISONE, HYDROCORTISONE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

PHARMACHEMIE BV

- * PHARMACHEMIE BV
CARBOPLATIN, CARBOPLATIN
CISPLATIN, CISPLATIN
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM

PHARMACIA AND UPJOHN

- * PHARMACIA AND UPJOHN
XANAX XR, ALPRAZOLAM
- * PHARMACIA AND UPJOHN CO
AROMASIN, EXEMESTANE
AZULFIDINE EN-TABS, SULFASALAZINE
AZULFIDINE, SULFASALAZINE
BACITRACIN, BACITRACIN
CAVERJECT IMPULSE, ALPROSTADIL
CAVERJECT, ALPROSTADIL
CLEOCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLEOCIN T, CLINDAMYCIN PHOSPHATE
CLEOCIN, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLEOCIN, CLINDAMYCIN PHOSPHATE
COLESTID, COLESTIPOL HYDROCHLORIDE
CORTEF, HYDROCORTISONE
CORVERT, IBUTILIDE FUMARATE
CYKLOKAPRON, TRANEXAMIC ACID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** P **

- * PHARMACIA AND UPJOHN CO
 DEPO-ESTRADIOL, ESTRADIOL CYPIONATE
 DEPO-MEDROL, METHYLPREDNISOLONE ACETATE
 DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE
 DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE
 DETROL LA, TOLTERODINE TARTRATE
 DETROL, TOLTERODINE TARTRATE
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 EMCYT, ESTRAMUSTINE PHOSPHATE SODIUM
 ESTRING, ESTRADIOL
 FLAVORED COLESTID, COLESTIPOL HYDROCHLORIDE
 GENOTROPIN PRESERVATIVE FREE, SOMATROPIN RECOMBINANT
 GENOTROPIN, SOMATROPIN RECOMBINANT
 GLYNASE, GLYBURIDE
 GLYSET, MIGLITOL
 HALCION, TRIAZOLAM
 HEMABATE, CARBOPROST TROMETHAMINE
 IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE
 LINCOCIN, LINCOMYCIN HYDROCHLORIDE
 MEDROL, METHYLPREDNISOLONE
 MYCOBUTIN, RIFABUTIN
 NICOTROL, NICOTINE
 OGEN .625, ESTROPIPATE
 OGEN 1.25, ESTROPIPATE
 OGEN 2.5, ESTROPIPATE
 OGEN 5, ESTROPIPATE
 PREPIDIL, DINOPROSTONE
 PROSTIN E2, DINOPROSTONE
 PROSTIN VR PEDIATRIC, ALPROSTADIL
 PROVERA, MEDROXYPROGESTERONE ACETATE
 R-GENE 10, ARGININE HYDROCHLORIDE
 SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE
 SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE
 SOMAVERT, PEGVISOMANT
 XALATAN, LATANOPROST
 XANAX, ALPRAZOLAM
 ZINECARD, DEXRAZOXANE HYDROCHLORIDE
 ZYVOX, LINEZOLID
- * PHARMACIA AND UPJOHN SUB PFIZER INC
 DEPO-SUBQ PROVERA 104, MEDROXYPROGESTERONE ACETATE
- PHARMACYCLICS INC**
- * PHARMACYCLICS INC
 IMBRUVICA, IBRUTINIB
- PHARMADAX INC**
- * PHARMADAX INC
 GLYBURIDE, GLYBURIDE
 LEVETIRACETAM, LEVETIRACETAM
- PHARMAFORCE**
- * PHARMAFORCE INC
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 NANDROLONE DECANOATE, NANDROLONE DECANOATE
- PHARMALUCENCE**
- * PHARMALUCENCE INC
 AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
 CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT
 CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT
 HEPATOLITE, TECHNETIUM TC-99M DISOFENIN KIT
 TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
 TECHNETIUM TC-99M MEBROFENIN, TECHNETIUM TC-99M MEBROFENIN KIT
- PHARMAX**
- * PHARMAX GROUP INC
 BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
- PHARMS**
- * PHARMACEUTICALS INTERNATIONAL
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ******PHOTOCURE ASA**

* PHOTOCURE ASA
 CYSVIEW KIT, HEXAMINOLEVULINATE HYDROCHLORIDE

PIERRE FABRE

* PIERRE FABRE MEDICAMENT
 NAVELBINE, VINORELBINE TARTRATE

PIERRE FABRE DERMA

* PIERRE FABRE DERMATOLOGIE
 HEMANGEOL, PROPRANOLOL HYDROCHLORIDE

PIERREL

* PIERREL S.P.A.
 ORABLOC, ARTICAINA HYDROCHLORIDE

PIRAMAL CRITICAL

* PIRAMAL CRITICAL CARE INC
 ISOFLURANE, ISOFLURANE
 SOJOURN, SEVOFLURANE

PIRAMAL ENT

* PIRAMAL ENTERPRISES LTD
 ISOFLURANE, ISOFLURANE

PIRAMAL IMAGING

* PIRAMAL IMAGING SA
 NEURACEQ, FLORBETABEN F-18

PLIVA

* PLIVA INC
 AZITHROMYCIN, AZITHROMYCIN
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
 CIMETIDINE, CIMETIDINE
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 METRONIDAZOLE, METRONIDAZOLE
 NAPROXEN, NAPROXEN
 THEOPHYLLINE, THEOPHYLLINE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 WARFARIN SODIUM, WARFARIN SODIUM

PLIVA HRVATSKA DOO

* PLIVA HRVATSKA DOO
 ADAPALENE, ADAPALENE
 CARVEDILOL, CARVEDILOL
 CILOSTAZOL, CILOSTAZOL
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE

PLIVA LACHEMA

* PLIVA LACHEMA AS
 CARBOPLATIN, CARBOPLATIN
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM

PLIVA PHARM IND

* PLIVA PHARMACEUTICAL INDUSTRY INC
 TORSEMIDE, TORSEMIDE

PLX PHARMA

* PLX PHARMA INC
 ASPIRIN, ASPIRIN (OTC)

POHL BOSKAMP

* POHL BOSKAMP
 NITROLINGUAL PUMPSPRAY, NITROGLYCERIN

POLYGEN PHARMS

* POLYGEN PHARMACEUTICALS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

* POLYGEN PHARMACEUTICALS INC
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

POLYMEDICA

* POLYMEDICA INDUSTRIES INC
 NEOPAP, ACETAMINOPHEN (OTC)

POWDER PHARMS

* POWDER PHARMACEUTICALS INC
 ZINGO, LIDOCAINE HYDROCHLORIDE

PRAGMA PHARMS LLC

* PRAGMA PHARMACEUTICALS LLC
 KEFLEX, CEPHALEXIN

PRECISION DERMAT

* PRECISION DERMATOLOGY INC
 CLINDAGEL, CLINDAMYCIN PHOSPHATE
 LOCOID LIPOCREAM, HYDROCORTISONE BUTYRATE
 LOCOID, HYDROCORTISONE BUTYRATE
 MINOCIN, MINOCYCLINE HYDROCHLORIDE

PRECISION DOSE

* PRECISION DOSE INC
 RISPERIDONE, RISPERIDONE

PRECISION NUCLEAR

* PRECISION NUCLEAR LLC
 AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

PRINSTON INC

* PRINSTON PHARMACEUTICAL INC
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CAPTOPRIL, CAPTOPRIL
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN
 LEVETIRACETAM, LEVETIRACETAM
 LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LISINOPRIL, LISINOPRIL
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 METHOCARBAMOL, METHOCARBAMOL
 NEVIRAPINE, NEVIRAPINE
 PAROXETINE, PAROXETINE HYDROCHLORIDE
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VALSARTAN, VALSARTAN
 VORICONAZOLE, VORICONAZOLE

PROF DSPLS

* PROFESSIONAL DISPOSABLES INC
 PREVANTICS MAXI SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
 PREVANTICS SWAB, CHLORHEXIDINE GLUCONATE (OTC)
 PREVANTICS SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)

PROMIUS PHARMA

* PROMIUS PHARMA LLC
 SECTRAL, ACEBUTOLOL HYDROCHLORIDE
 TENEX, GUANFACINE HYDROCHLORIDE

PROMIUS PHARMA LLC

* PROMIUS PHARMA LLC
 CLODERM, CLOCORTOLONE PIVALATE
 SERNIVO, BETAMETHASONE DIPROPIONATE

PROSTRAKAN INC**WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1086, p. 1032 of 1400**

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

* PROSTRAKAN INC
FARESTON, TOREMIFENE CITRATE

PROVENSIS

* PROVENSIS LTD
VARITHENA, POLIDOCANOL

PROVEPHARM SAS

* PROVEPHARM SAS
PROVAYBLUE, METHYLENE BLUE

PROVIDENT PHARM

* PROVIDENT PHARMACEUTICAL INC
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

PULMOFLOW INC

* PULMOFLOW INC
KITABIS PAK, TOBRAMYCIN

PURACAP PHARM

* PURACAP PHARMACEUTICAL LLC
MELOXICAM, MELOXICAM

PURACAP PHARM LLC

* PURACAP PHARMACEUTICAL LLC
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE

PURDUE GMP

* PURDUE GMP CENTER LLC DBA THE CHAO CENTER INDUSTRIAL PHARMACY
SEROMYCIN, CYCLOSERINE

PURDUE PHARM PRODS

* PURDUE PHARMACEUTICAL PRODUCTS LP
DILAUDID, HYDROMORPHONE HYDROCHLORIDE
DILAUDID-HP, HYDROMORPHONE HYDROCHLORIDE

PURDUE PHARMA

* PURDUE PHARMA PRODUCTS LP
INTERMEZZO, ZOLPIDEM TARTRATE

PURDUE PHARMA LP

* PURDUE PHARMA LP
BUTRANS, BUPRENORPHINE
HYSINGLA, HYDROCODONE BITARTRATE
MS CONTIN, MORPHINE SULFATE
OXYCONTIN, OXYCODONE HYDROCHLORIDE

**** Q ******QILU PHARM CO LTD**

* QILU PHARMACEUTICAL CO LTD
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CEFTRIAZONE, CEFTRIAZONE SODIUM
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
OLANZAPINE, OLANZAPINE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN

QOL MEDCL

* QOL MEDICAL LLC
ETHAMOLIN, ETHANOLAMINE OLEATE
SUCRAID, SACROSIDASE

QUEEN HAMAMATSU PET

* QUEEN HAMAMATSU PET IMAGING CENTER
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**** R ******R-PHARM US LLC**

* R-PHARM US LLC
IXEMPRA KIT, IXABEPILONE

R2 PHARMA LLC

* R2 PHARMA LLC
ESOMEPRAZOLE STRONTIUM, ESOMEPRAZOLE STRONTIUM

RANBAXY

* RANBAXY LABORATORIES INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** R ****

* RANBAXY LABORATORIES INC
 ABSORICA, ISOTRETINOIN
 EURAX, CROTAMITON
 EXELDERM, SULCONAZOLE NITRATE
 HALOG, HALCINONIDE
 ULTRAVATE, HALOBETASOL PROPIONATE

RANBAXY LABS LTD

* RANBAXY LABORATORIES LTD
 KENALOG, TRIAMCINOLONE ACETONIDE

RAPTOR INC

* RAPTOR PHARMACEUTICALS INC
 PROCYSBI, CYSTEAMINE BITARTRATE

RARE DIS THERAP

* RARE DISEASE THERAPEUTICS INC
 CYSTADANE, BETAINE HYDROCHLORIDE

RARITAN PHARMS INC

* RARITAN PHARMACEUTICALS INC
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)

RECIP

* RECIP AB
 THYROSAFE, POTASSIUM IODIDE (OTC)

RECKITT BENCKISER

* RECKITT BENCKISER LLC
 DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)
 MUCINEX D, GUAIFENESIN (OTC)
 MUCINEX DM, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
 MUCINEX, GUAIFENESIN (OTC)

RECORDATI RARE

* RECORDATI RARE DISEASES INC
 CHEMET, SUCCIMER
 COSMEGEN, DACTINOMYCIN
 DESOXYN, METHAMPHETAMINE HYDROCHLORIDE
 INDOCIN, INDOMETHACIN SODIUM
 MUSTARGEN, MECHLORETHAMINE HYDROCHLORIDE
 NEOPROFEN, IBUPROFEN LYSINE
 PEGANONE, ETHOTOIN
 TRANXENE, CLORAZEPATE DIPOTASSIUM

RECRO GAINESVILLE

* RECRO GAINESVILLE LLC
 VERELAN PM, VERAPAMIL HYDROCHLORIDE
 VERELAN, VERAPAMIL HYDROCHLORIDE

RELYPSA INC

* RELYPSA INC
 VELTASSA, PATIROMER SORBITEX CALCIUM

REMPEX PHARMS INC

* REMPEX PHARMACEUTICALS INC
 MINOCIN, MINOCYCLINE HYDROCHLORIDE

RENAISSANCE PHARMA

* RENAISSANCE PHARMA US HOLDINGS INC
 ELIMITE, PERMETHRIN

RHODES PHARMS

* RHODES PHARMACEUTICALS LP
 APTENSIO XR, METHYLPHENIDATE HYDROCHLORIDE
 FENOFIBRATE (MICRONIZED), FENOFIBRATE
 FENOFIBRATE, FENOFIBRATE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 MORPHINE SULFATE, MORPHINE SULFATE
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 THEOPHYLLINE, THEOPHYLLINE

RICONPHARMA LLC

* RICONPHARMA LLC
 GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** R ****

* RICONPHARMA LLC
QUININE SULFATE, QUININE SULFATE

RISING PHARMS INC

* RISING PHARMACEUTICALS INC
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DOXERCALCIFEROL, DOXERCALCIFEROL
DUTASTERIDE, DUTASTERIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROCORTISONE, HYDROCORTISONE
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN, AMOXICILLIN
LEVOFLOXACIN, LEVOFLOXACIN
METHIMAZOLE, METHIMAZOLE
PARICALCITOL, PARICALCITOL
TEMOZOLOMIDE, TEMOZOLOMIDE

ROCHE PALO

* ROCHE PALO ALTO LLC
CELLCEPT, MYCOPHENOLATE MOFETIL
CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
CYTOVENE, GANCICLOVIR SODIUM

ROCKWELL MEDICAL INC

* ROCKWELL MEDICAL INC
TRIFERIC, FERRIC PYROPHOSPHATE CITRATE
TRIFERIC, FERRIC PYROPHOSPHATE CITRATE

ROMARK

* ROMARK LABORATORIES
ALINIA, NITAZOXANIDE

ROSEMONT PHARMS LTD

* ROSEMONT PHARMACEUTICALS LTD
SIMVASTATIN, SIMVASTATIN

ROUSES POINT PHARMS

* ROUSES POINT PHARMACEUTICALS LLC
LEVETIRACETAM, LEVETIRACETAM

ROXANE

* ROXANE LABORATORIES INC
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CODEINE SULFATE, CODEINE SULFATE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DIGOXIN, DIGOXIN
DOLOPHINE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
FUROSEMIDE, FUROSEMIDE
LEVETIRACETAM, LEVETIRACETAM
LITHIUM CARBONATE, LITHIUM CARBONATE
LITHIUM CITRATE, LITHIUM CITRATE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

RP SCHERER

* RP SCHERER TECHNOLOGIES LLC
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

RTRX

* RETROPHIN INC
CHOLBAM, CHOLIC ACID

RUBICON RES PVT LTD

* RUBICON RESEARCH PVT LTD
METOPROLOL TARTRATE, METOPROLOL TARTRATE
SILDENAFIL CITRATE, SILDENAFIL CITRATE

**** S ******SAGE PRODS**

* SAGE PRODUCTS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ******* SAGE PRODUCTS INC**

CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)

SAGENT AGILA*** SAGENT AGILA LLC**ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE**SAGENT PHARMS***** SAGENT PHARMACEUTICALS INC**AMIKACIN SULFATE, AMIKACIN SULFATE
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
CAFFEINE CITRATE, CAFFEINE CITRATE
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUMAZENIL, FLUMAZENIL
FLUOROURACIL, FLUOROURACIL
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GLYDO, LIDOCAINE HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
IBANDRONATE SODIUM, IBANDRONATE SODIUM
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
MESNA, MESNA
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
NAFCILLIN SODIUM, NAFCILLIN SODIUM
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXACILLIN SODIUM, OXACILLIN SODIUM
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PROPOFOL, PROPOFOL
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID**SAGENT STRIDES***** SAGENT STRIDES LLC**ADENOSINE, ADENOSINE
AZITHROMYCIN, AZITHROMYCIN
BACITRACIN, BACITRACIN
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
MIDOZALAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE**SALIX PHARMS***** SALIX PHARMACEUTICALS INC**ANUSOL HC, HYDROCORTISONE
DIURIL, CHLOROTHIAZIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ******* SALIX PHARMACEUTICALS INC**

METOZOLV ODT, METOCLOPRAMIDE HYDROCHLORIDE
 MOVIPREP, ASCORBIC ACID
 OSMOPREP, SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
 PEPCID, FAMOTIDINE
 RELISTOR, METHYLNALTREXONE BROMIDE
 XIFAXAN, RIFAXIMIN

SALIX PHARMS INC*** SALIX PHARMACEUTICALS INC**

RELISTOR, METHYLNALTREXONE BROMIDE

SAMSON MEDCL*** SAMSON MEDICAL TECHNOLOGIES LLC**

CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
 CEFOXITIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
 CEFTRIAXONE, CEFTRIAXONE SODIUM
 VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE

SANDOZ*** SANDOZ**

DOCETAXEL, DOCETAXEL

*** SANDOZ CANADA INC**

ANECTINE, SUCCINYLMCHOLINE CHLORIDE
 ARISTOSPAN, TRIAMCINOLONE HEXACETONIDE
 BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
 DIGOXIN, DIGOXIN
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
 FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
 FLUMAZENIL, FLUMAZENIL
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 INFUVITE ADULT, ALPHA-TOCOPHEROL ACETATE
 INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE), ASCORBIC ACID
 INFUVITE PEDIATRIC, ASCORBIC ACID
 ISONIAZID, ISONIAZID
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
 METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 REGONOL, PYRIDOSTIGMINE BROMIDE
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE

*** SANDOZ INC**

ALPRAZOLAM, ALPRAZOLAM
 ALTAVERA, ETHINYL ESTRADIOL
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 AMOXICILLIN, AMOXICILLIN
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 AMPICILLIN SODIUM, AMPICILLIN SODIUM
 AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
 APREPITANT, APREPITANT
 ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
 ATENOLOL, ATENOLOL
 AZITHROMYCIN, AZITHROMYCIN
 BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 BICALUTAMIDE, BICALUTAMIDE
 BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
 BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
 BUMETANIDE, BUMETANIDE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CAFERGOT, CAFFEINE
 CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SANDOZ INC
 CARISOPRODOL AND ASPIRIN, ASPIRIN
 CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
 CARVEDILOL, CARVEDILOL
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
 CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
 CEFDINIR, CEFDINIR
 CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
 CEFPROZIL, CEFPROZIL
 CEFTRIAXONE, CEFTRIAXONE SODIUM
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
 CHOLESTYRAMINE, CHOLESTYRAMINE
 CILOSTAZOL, CILOSTAZOL
 CLARITHROMYCIN, CLARITHROMYCIN
 CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
 CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
 CLONAZEPAM, CLONAZEPAM
 COSYNTROPIN, COSYNTROPIN
 CYCLOSPORINE, CYCLOSPORINE
 DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
 DESLORATADINE, DESLORATADINE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
 DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
 ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
 EPLERENONE, EPLERENONE
 ESTARYLLA, ETHINYL ESTRADIOL
 ETODOLAC, ETODOLAC
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 FLUOROURACIL, FLUOROURACIL
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
 FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
 FUROSEMIDE, FUROSEMIDE
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 GLIPIZIDE, GLIPIZIDE
 HALOPERIDOL, HALOPERIDOL
 HEPARIN SODIUM, HEPARIN SODIUM
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
 IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
 INDOMETHACIN, INDOMETHACIN
 INTROVALE, ETHINYL ESTRADIOL
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN
 ISONIAZID, ISONIAZID
 ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
 ITRACONAZOLE, ITRACONAZOLE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 LANSOPRAZOLE, LANSOPRAZOLE
 LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
 LEVOFLOXACIN, LEVOFLOXACIN
 LISINAPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LISINAPRIL, LISINAPRIL
 LORATADINE, LORATADINE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SANDOZ INC
 LORAZEPAM, LORAZEPAM
 LORYNA, DROSPIRENONE
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 LOVASTATIN, LOVASTATIN
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
 MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
 MEROPENEM, MEROPENEM
 METAXALONE, METAXALONE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 METHAZOLAMIDE, METHAZOLAMIDE
 METHIMAZOLE, METHIMAZOLE
 METHYLPREDNISOLONE, METHYLPREDNISOLONE
 METOLAZONE, METOLAZONE
 MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 NABUMETONE, NABUMETONE
 NADOLOL, NADOLOL
 NAFICILLIN SODIUM, NAFICILLIN SODIUM
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
 NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
 NIZATIDINE, NIZATIDINE
 OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 OMEPRAZOLE, OMEPRAZOLE
 OMNITROPE, SOMATROPIN RECOMBINANT
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON, ONDANSETRON
 ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE, ASPIRIN
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 OXACILLIN SODIUM, OXACILLIN SODIUM
 OXALIPLATIN, OXALIPLATIN
 OXAPROZIN, OXAPROZIN
 OXAZEPAM, OXAZEPAM
 PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
 PENICILLIN G SODIUM, PENICILLIN G SODIUM
 PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
 PERPHENAZINE, PERPHENAZINE
 PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE, GLIMEPIRIDE
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 QUINIDINE SULFATE, QUINIDINE SULFATE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RESERPINE, RESERPINE
 RIBAVIRIN, RIBAVIRIN
 RIFAMPIN, RIFAMPIN
 RISPERIDONE, RISPERIDONE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 SPIRONOLACTONE, SPIRONOLACTONE
 SULFADIAZINE, SULFADIAZINE
 SYEDA, DROSPIRENONE
 TACROLIMUS, TACROLIMUS
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TEMAZEPAM, TEMAZEPAM
 TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ******* SANDOZ INC**

TRI-ESTARYLLA, ETHINYL ESTRADIOL
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

SANDOZ CANADA INC*** SANDOZ CANADA INC**

PARICALCITOL, PARICALCITOL

SANDOZ INC*** SANDOZ INC**

ACETAMINOPHEN, ACETAMINOPHEN
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 BIMATOPROST, BIMATOPROST
 BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
 BUDESONIDE, BUDESONIDE
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CARBOPLATIN, CARBOPLATIN
 CEFTRIAXONE, CEFTRIAXONE SODIUM
 CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
 CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
 CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
 DECITABINE, DECITABINE
 DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DOXERCALCIFEROL, DOXERCALCIFEROL
 ELIFEMME, ETHINYL ESTRADIOL
 ENALAPRIL MALEATE, ENALAPRIL MALEATE
 ENOXAPARIN SODIUM, ENOXAPARIN SODIUM
 GLATOPA, GLATIRAMER ACETATE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 ISIBLOOM, DESOGESTREL
 LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN, AMOXICILLIN
 LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
 LINEZOLID, LINEZOLID
 METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 NEVIRAPINE, NEVIRAPINE
 OLANZAPINE, OLANZAPINE
 PACLITAXEL, PACLITAXEL
 PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 REPAGLINIDE, REPAGLINIDE
 RIBAVIRIN, RIBAVIRIN
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 TELMISARTAN, TELMISARTAN
 TIGECYCLINE, TIGECYCLINE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TRI-LO-ESTARYLLA, ETHINYL ESTRADIOL
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VIENVA, ETHINYL ESTRADIOL
 VOLNEA, DESOGESTREL
 VORICONAZOLE, VORICONAZOLE
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

SANJA PHARMS CO**WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1086, p. 1040 of 1400**

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SANJA PHARMACEUTICALS CO
CARBOPLATIN, CARBOPLATIN

SANOFI AVENTIS US

* SANOFI AVENTIS US INC
JEVTANA KIT, CABAZITAXEL

* SANOFI AVENTIS US LLC
ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA, FEXOFENADINE HYDROCHLORIDE
ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
AMARYL, GLIMEPIRIDE
AMBIEN CR, ZOLPIDEM TARTRATE
AMBIEN, ZOLPIDEM TARTRATE
APIDRA SOLOSTAR, INSULIN GLULISINE RECOMBINANT
APIDRA, INSULIN GLULISINE RECOMBINANT
ARALEN, CHLOROQUINE PHOSPHATE
ARAVA, LEFLUNOMIDE
AUBAGIO, TERIFLUNOMIDE
AVALIDE, HYDROCHLOROTHIAZIDE
AVAPRO, IRBESARTAN
CANTIL, MEPENZOLATE BROMIDE
CHILDREN'S ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S ALLEGRA HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CLAFORAN, CEFOTAXIME SODIUM
CLOMID, CLOMIPHENE CITRATE
DIABETA, GLYBURIDE
ELOXATIN, OXALIPLATIN
FERRLECIT, SODIUM FERRIC GLUCONATE COMPLEX
GAVISCON, ALUMINUM HYDROXIDE (OTC)
LANTUS SOLOSTAR, INSULIN GLARGINE RECOMBINANT
LANTUS, INSULIN GLARGINE RECOMBINANT
LOVENOX (PRESERVATIVE FREE), ENOXAPARIN SODIUM
LOVENOX, ENOXAPARIN SODIUM
MULTAQ, DRONEDARONE HYDROCHLORIDE
NASACORT ALLERGY 24 HOUR, TRIAMCINOLONE ACETONIDE (OTC)
NICODERM CQ, NICOTINE (OTC)
PLAVIX, CLOPIDOGREL BISULFATE
PRIFTIN, RIFAPENTINE
PRIMAQUINE, PRIMAQUINE PHOSPHATE
RIFADIN, RIFAMPIN
RIFAMATE, ISONIAZID
RIFATER, ISONIAZID
TAXOTERE, DOCETAXEL

SANOFI US SERVICES

* SANOFI US SERVICES INC
TOUJEO SOLOSTAR, INSULIN GLARGINE RECOMBINANT

SANOFI-AVENTIS US

* SANOFI-AVENTIS US LLC
ADLYXIN, LIXISENATIDE
SOLIQUA 100/33, INSULIN GLARGINE

SANTARUS INC

* SANTARUS INC
FENOGLIDE, FENOFIBRATE
GLUMETZA, METFORMIN HYDROCHLORIDE
ZEGERID, OMEPRAZOLE

SANTOS BIOTECH

* SANTOS BIOTECH INDUSTRIES INC
ANASTROZOLE, ANASTROZOLE

SAOL THERAPS RES LTD

* SAOL THERAPEUTICS RESEARCH LTD
LIORESAL, BACLOFEN

SAREPTA THERAPS INC

* SAREPTA THERAPEUTICS INC
EXONDYS 51, FETEPLIRSEN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

SAVIOR LIFETEC CORP

* SAVIOR LIFETEC CORP
MEROPENEM, MEROPENEM

SB PHARMCO

* SB PHARMCO PUERTO RICO INC
AVANDIA, ROSIGLITAZONE MALEATE

SCHERING

* SCHERING CORP
INTEGRILIN, EPTIFIBATIDE
NOXAFIL, POSACONAZOLE
REBETOL, RIBAVIRIN

SCHERING PLOUGH

* SCHERING PLOUGH HEALTHCARE PRODUCTS INC
AFRINOL, PSEUDOEPHEDRINE SULFATE (OTC)

SCIEGEN PHARMS INC

* SCIEGEN PHARMACEUTICALS INC
ARIPIPIRAZOLE, ARIPIPIRAZOLE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CARISOPRODOL, CARISOPRODOL
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LAMOTRIGINE, LAMOTRIGINE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NEVIRAPINE, NEVIRAPINE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE

SCIOS LLC

* SCIOS LLC
NATRECOR, NESIRITIDE RECOMBINANT

SEBELA IRELAND LTD

* SEBELA IRELAND LTD
BRISDELLE, PAROXETINE MESYLATE
IMURAN, AZATHIOPRINE
LOTRONEX, ALOSETRON HYDROCHLORIDE
MICORT-HC, HYDROCORTISONE ACETATE
MOTOFEN, ATROPINE SULFATE
NAFTIN, NAFTIFINE HYDROCHLORIDE
ONMEL, ITRACONAZOLE
PEXEVA, PAROXETINE MESYLATE
PRAMOSONE, HYDROCORTISONE ACETATE
RIDAURA, AURANOFIN
ZYLOPRIM, ALLOPURINOL

SECAN PHARMS

* SECAN PHARMACEUTICALS INC
LEVETIRACETAM, LEVETIRACETAM

SENTYNL THERAPS INC

* SENTYNL THERAPEUTICS INC
ABSTRAL, FENTANYL CITRATE
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE

SEPTODONT

* SEPTODONT INC
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
OCTOCAINE, EPINEPHRINE

SEPTODONT HOLDING

* SEPTODONT HOLDING SAS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SEPTODONT HOLDING SAS
ORAVERSE, PHENTOLAMINE MESYLATE

SEPTODONT INC

* SEPTODONT INC
LIDOCAINE, LIDOCAINE
PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, EPINEPHRINE BITARTRATE
PRILOCAINE HYDROCHLORIDE, PRILOCAINE HYDROCHLORIDE

SERB SA

* SERB SA
CYANOKIT, HYDROXOCOBALAMIN

SETON PHARM

* SETON PHARMACEUTICAL LLC
PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE

SHANGHAI HENGRUI

* SHANGHAI HENGRUI PHARMACEUTICAL CO LTD
SEVOFLURANE, SEVOFLURANE

SHENZHEN TECHDOW

* SHENZHEN TECHDOW PHARMACEUTICAL CO LTD
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM

SHERTECH LABS LLC

* SHERTECH LABORATORIES LLC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

SHILPA MEDICARE

* SHILPA MEDICARE LTD
AZACITIDINE, AZACITIDINE

SHILPA MEDICARE LTD

* SHILPA MEDICARE LTD
CAPECITABINE, CAPECITABINE

SHIONOGI INC

* SHIONOGI INC
DORIBAX, DORIPENEM
OSPHENA, OSPEMIFENE
PONSTEL, MEFENAMIC ACID
ULESFIA, BENZYL ALCOHOL

SHIRE

* SHIRE DEVELOPMENT INC
ADDERALL XR 10, AMPHETAMINE ASPARTATE
ADDERALL XR 15, AMPHETAMINE ASPARTATE
ADDERALL XR 20, AMPHETAMINE ASPARTATE
ADDERALL XR 25, AMPHETAMINE ASPARTATE
ADDERALL XR 30, AMPHETAMINE ASPARTATE
ADDERALL XR 5, AMPHETAMINE ASPARTATE
CARBATROL, CARBAMAZEPINE
INTUNIV, GUANFACINE HYDROCHLORIDE
LIALDA, MESALAMINE
PENTASA, MESALAMINE

SHIRE DEV LLC

* SHIRE DEVELOPMENT LLC
FOSRENOL, LANTHANUM CARBONATE
XIIDRA, LIFITEGRAST

SHIRE DEVELOPMENT

* SHIRE DEVELOPMENT INC
VYVANSE, LISDEXAMFETAMINE DIMESYLATE

SHIRE HUMAN GENETIC

* SHIRE HUMAN GENETIC THERAPIES INC
VPRIV, VELAGLUCERASE ALFA

SHIRE LLC

* SHIRE DEVELOPMENT LLC
AGRYLIN, ANAGRELIDE HYDROCHLORIDE
FOSRENOL, LANTHANUM CARBONATE
SALURON, HYDROFLUMETHIAZIDE

WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1086, p. 1043 of 1400

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

SHIRE ORPHAN THERAP

* SHIRE ORPHAN THERAPIES INC
FIRAZYR, ICATIBANT ACETATE

SIDMAK LABS INDIA

* SIDMAK LABORATORIES INDIA PVT LTD
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE

SIGMA TAU

* SIGMA TAU PHARMACEUTICALS INC
ABELCET, AMPHOTERICIN B
ADAGEN, PEGADEMASE BOVINE
CARNITOR SF, LEVOCARNITINE
CARNITOR, LEVOCARNITINE
CYSTARAN, CYSTEAMINE HYDROCHLORIDE
MATULANE, PROCARBAZINE HYDROCHLORIDE

SIGMAPHARM LABS LLC

* SIGMAPHARM LABORATORIES LLC
ACITRETIN, ACITRETIN
ADEFOVIR DIPIVOXIL, ADEFOVIR DIPIVOXIL
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
DISULFIRAM, DISULFIRAM
ERGOCALCIFEROL, ERGOCALCIFEROL
FLUCYTOSINE, FLUCYTOSINE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
GRISEOFULVIN, ULTRAMICROSIZED, GRISEOFULVIN, ULTRAMICROSIZED
LIOETHYRONINE SODIUM, LIOETHYRONINE SODIUM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE

SILARX

* SILARX PHARMACEUTICALS INC
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL LACTATE
LEVETIRACETAM, LEVETIRACETAM
LORATADINE, LORATADINE (OTC)
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXYBUTYNYN CHLORIDE, OXYBUTYNYN CHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE

SILARX PHARMS INC

* SILARX PHARMACEUTICALS INC
ARIPIRAZOLE, ARIPIRAZOLE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
LAMIVUDINE, LAMIVUDINE
LOPINAVIR AND RITONAVIR, LOPINAVIR
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE

SILVERGATE PHARMS

* SILVERGATE PHARMACEUTICALS INC
EPANED KIT, ENALAPRIL MALEATE
EPANED, ENALAPRIL MALEATE
QBRELIS, LISINAPRIL

SINETICA SA

* SINETICA SA
BACLOFEN, BACLOFEN

SKINMEDICA

* SKINMEDICA INC
VANIQA, EFLORNITHINE HYDROCHLORIDE

SKYEPHARMA AG

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SKYEPHARMA AG
TRIGLIDE, FENOFIBRATE

SMITHKLINE BEECHAM

* SMITHKLINE BEECHAM
LOVAZA, OMEGA-3-ACID ETHYL ESTERS
* SMITHKLINE BEECHAM (CORK) LTD IRELAND
COREG CR, CARVEDILOL PHOSPHATE
COREG, CARVEDILOL

SOAPCO

* SOAPCO INC
BRIAN CARE, CHLORHEXIDINE GLUCONATE (OTC)

SOFGEN PHARMS

* SOFGEN PHARMACEUTICALS
NIMODIPINE, NIMODIPINE
* SOFGEN PHARMACEUTICALS LLC
IBUPROFEN, IBUPROFEN (OTC)
PROGESTERONE, PROGESTERONE

SOMERSET

* SOMERSET PHARMACEUTICALS INC
ELDEPRYL, SELEGILINE HYDROCHLORIDE
EMSAM, SELEGILINE

SOMERSET THERAPS LLC

* SOMERSET THERAPEUTICS LLC
CYANOCOBALAMIN, CYANOCOBALAMIN
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE

SOVEREIGN PHARMS

* SOVEREIGN PHARMACEUTICALS LLC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
OBREDON, GUAIFENESIN

SPEAR PHARMS

* SPEAR PHARMACEUTICALS INC
FLUOROURACIL, FLUOROURACIL

SPEAR PHARMS INC

* SPEAR PHARMACEUTICALS INC
FLUOROURACIL, FLUOROURACIL
TRETINOIN, TRETINOIN

SPECTRON MRC LLC

* SPECTRON MRC LLC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

SPECTRUM PHARMS

* SPECTRUM PHARMACEUTICALS INC
BELEODAQ, BELINOSTAT
EVOMELA, MELPHALAN HYDROCHLORIDE
FLUOROURACIL, FLUOROURACIL
FUSILEV, LEVOLEUCOVORIN CALCIUM

SPROUT PHARMS

* SPROUT PHARMACEUTICALS INC
ADDYI, FLIBANSERIN

ST RENATUS

* ST RENATUS LLC
KOVANAZE, OXYMETAZOLINE HYDROCHLORIDE

STAND HOMEOPATH

* STANDARD HOMEOPATHIC CO
IVY BLOCK, BENTOQUATAM (OTC)

STANDARD CHEM PHARM

* STANDARD CHEM AND PHARM CO LTD
REPAGLINIDE, REPAGLINIDE

STASON

* STASON INDUSTRIAL CORP
ACYCLOVIR, ACYCLOVIR
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

STASON PHARMS

* STASON PHARMACEUTICALS INC
 ARIPIPIRAZOLE, ARIPIPIRAZOLE
 BICALUTAMIDE, BICALUTAMIDE
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 PURINETHOL, MERCAPTOPURINE

STI PHARMA LLC

* STI PHARMA LLC
 BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
 DEXAMETHASONE, DEXAMETHASONE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE
 SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE
 TRIACIN-C, CODEINE PHOSPHATE

STIEFEL

* STIEFEL LABORATORIES INC
 DUAC, BENZOYL PEROXIDE

STIEFEL LABS INC

* STIEFEL LABORATORIES INC
 FABIOR, TAZAROTENE
 SORIATANE, ACITRETIN
 SORILUX, CALCIPOTRIENE

STRIDES ARCOLAB LTD

* STRIDES ARCOLAB LTD
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE, POLYETHYLENE GLYCOL

STRIDES PHARMA

* STRIDES PHARMA GLOBAL PTE LTD
 ABACAVIR SULFATE, ABACAVIR SULFATE
 ACARBOSE, ACARBOSE
 BENZONATATE, BENZONATATE
 CALCITRIOL, CALCITRIOL
 CARISOPRODOL, CARISOPRODOL
 DUTASTERIDE, DUTASTERIDE
 ERGOCALCIFEROL, ERGOCALCIFEROL
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 IMIQUIMOD, IMIQUIMOD
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
 MELOXICAM, MELOXICAM
 METHOXSALLEN, METHOXSALLEN
 METRONIDAZOLE, METRONIDAZOLE
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 NEVIRAPINE, NEVIRAPINE
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
 TACROLIMUS, TACROLIMUS
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

STRONGBRIDGE US

* STRONGBRIDGE US INC
 KEVEYIS, DICHLORPHENAMIDE

SUCAMPO PHARMA LLC

* SUCAMPO PHARMA AMERICAS LLC
 AMITIZA, LUBIPROSTONE

SUN PHARM INDS

* SUN PHARMACEUTICAL INDUSTRIES INC
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 ALLOPURINOL, ALLOPURINOL
 ATENOLOL AND CHLORTHALIDONE, ATENOLOL
 ATENOLOL, ATENOLOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

- * SUN PHARMACEUTICAL INDUSTRIES INC
 BACTRIM DS, SULFAMETHOXAZOLE
 BACTRIM, SULFAMETHOXAZOLE
 CARISOPRODOL, CARISOPRODOL
 CHLORTHALIDONE, CHLORTHALIDONE
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 ERGOLOID MESYLATES, ERGOLOID MESYLATES
 FELODIPINE, FELODIPINE
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
 LEVETIRACETAM, LEVETIRACETAM
 LOVASTATIN, LOVASTATIN
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MINOXIDIL, MINOXIDIL
 NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
 NYSTATIN, NYSTATIN
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 PINDOLOL, PINDOLOL
 PREDNISONE, PREDNISONE
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
 QUALAQUIN, QUININE SULFATE
 QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
 QUINIDINE SULFATE, QUINIDINE SULFATE
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
 SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 SPIRONOLACTONE, SPIRONOLACTONE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 SULINDAC, SULINDAC
 SYNALGOS-DC, ASPIRIN
 TEMAZEPAM, TEMAZEPAM
 THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE
 TOLMETIN SODIUM, TOLMETIN SODIUM
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
 TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE
 ULTRAVATE, HALOBETASOL PROPIONATE
- * SUN PHARMACEUTICAL INDUSTRIES LTD
 CARBIDOPA AND LEVODOPA, CARBIDOPA
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 DESLORATADINE, DESLORATADINE
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
 EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
 OLANZAPINE, OLANZAPINE
 ONDANSETRON, ONDANSETRON
 OXCARBAZEPINE, OXCARBAZEPINE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE
 TORSEMIDE, TORSEMIDE

SUN PHARM INDS (IN)

- * SUN PHARMACEUTICAL INDUSTRIES LTD

WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1086, p. 1047 of 1400

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ******* SUN PHARMACEUTICAL INDUSTRIES LTD**

CEPHALEXIN, CEPHALEXIN
 EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 ZONISAMIDE, ZONISAMIDE

SUN PHARM INDS INC*** SUN PHARMACEUTICAL INDUSTRIES INC**

ALLOPURINOL, ALLOPURINOL
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 ATENOLOL, ATENOLOL
 BACLOFEN, BACLOFEN
 BENZONATATE, BENZONATATE
 CARVEDILOL, CARVEDILOL
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 CLONAZEPAM, CLONAZEPAM
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 CLOZAPINE, CLOZAPINE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DIGOXIN, DIGOXIN
 ERGOCALCIFEROL, ERGOCALCIFEROL
 FLURBIPROFEN, FLURBIPROFEN
 FUROSEMIDE, FUROSEMIDE
 GEMFIBROZIL, GEMFIBROZIL
 GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
 GLIPIZIDE, GLIPIZIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 INDOMETHACIN, INDOMETHACIN
 ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
 LITHIUM CARBONATE, LITHIUM CARBONATE
 MELOXICAM, MELOXICAM
 MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHIMAZOLE, METHIMAZOLE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MIRTAZAPINE, MIRTAZAPINE
 NIMODIPINE, NIMODIPINE
 OXAPROZIN, OXAPROZIN
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 REPAGLINIDE, REPAGLINIDE
 RISPERIDONE, RISPERIDONE
 TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

SUN PHARM INDS LTD*** SUN PHARMACEUTICAL INDUSTRIES LTD**

ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN

WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1086, p. 1048 of 1400

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SUN PHARMACEUTICAL INDUSTRIES LTD
 ACETAMINOPHEN, ACETAMINOPHEN (OTC)
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 AZITHROMYCIN, AZITHROMYCIN
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE , BUPRENORPHINE HYDROCHLORIDE
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 CARISOPRODOL, CARISOPRODOL
 CARVEDILOL, CARVEDILOL
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CLARITHROMYCIN, CLARITHROMYCIN
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DOXYCYCLINE, DOXYCYCLINE
 EXELDERM, SULCONAZOLE NITRATE
 FAMOTIDINE, FAMOTIDINE (OTC)
 FELODIPINE, FELODIPINE
 FENOFIBRATE, FENOFIBRATE
 FLECAINIDE ACETATE, FLECAINIDE ACETATE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 GABAPENTIN, GABAPENTIN
 GLYCOPYRROLATE, GLYCOPYRROLATE
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 LANSOPRAZOLE, LANSOPRAZOLE
 LETROZOLE, LETROZOLE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
 LISINAPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LISINAPRIL, LISINAPRIL
 LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
 LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
 LORATADINE REDIDOSE, LORATADINE (OTC)
 LORATADINE, LORATADINE (OTC)
 LORAZEPAM, LORAZEPAM
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON, ONDANSETRON
 OPCICON ONE-STEP, LEVONORGESTREL (OTC)
 OXCARBAZEPINE, OXCARBAZEPINE
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
 QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 RILUZOLE, RILUZOLE
 RIOMET, METFORMIN HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

- * SUN PHARMACEUTICAL INDUSTRIES LTD
 TOPIRAMATE, TOPIRAMATE
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VALPROIC ACID, VALPROIC ACID
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
- * SUN PHARMACEUTICAL INDUSTRIES LTD.
 ANASTROZOLE, ANASTROZOLE
- SUN PHARMA GLOBAL**
- * SUN PHARMA GLOBAL FZE
 ALENDRONATE SODIUM, ALENDRONATE SODIUM
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 BROMSITE, BROMFENAC SODIUM
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CAFFEINE CITRATE, CAFFEINE CITRATE
 CARBIDOPA AND LEVODOPA, CARBIDOPA
 CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 DECITABINE, DECITABINE
 DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
 DESVENLAFAXINE, DESVENLAFAXINE FUMARATE
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DOCEFREZ, DOCETAXEL
 DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 ENTACAPONE, ENTACAPONE
 ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
 ESZOPICLONE, ESZOPICLONE
 FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
 FINASTERIDE, FINASTERIDE
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 IMATINIB MESYLATE, IMATINIB MESYLATE
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
 LACOSAMIDE, LACOSAMIDE
 LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
 NIACIN, NIACIN
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 OXALIPLATIN, OXALIPLATIN
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RISEDRONATE SODIUM, RISEDRONATE SODIUM
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TEMOZOLOMIDE, TEMOZOLOMIDE
 TETRABENAZINE, TETRABENAZINE
 TOPIRAMATE, TOPIRAMATE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 VECURONIUM BROMIDE, VECURONIUM BROMIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID
 ZOLMITRIPTAN, ZOLMITRIPTAN
- * SUN PHARMA GLOBAL INC
 ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
 ALPRAZOLAM, ALPRAZOLAM
 AMIFOSTINE, AMIFOSTINE
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 BICALUTAMIDE, BICALUTAMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SUN PHARMA GLOBAL INC
 CARBOPLATIN, CARBOPLATIN
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM

SUNEVA MEDCL

* SUNEVA MEDICAL INC
 TRETINOIN, TRETINOIN

SUNOVION

* SUNOVION PHARMACEUTICALS INC
 BROVANA, ARFORMOTEROL TARTRATE
 XOPENEX HFA, LEVALBUTEROL TARTRATE

SUNOVION PHARMS INC

* SUNOVION PHARMACEUTICALS INC
 APTIOM, ESLICARBAZEPINE ACETATE
 LATUDA, LURASIDONE HYDROCHLORIDE
 LUNESTA, ESZOPICLONE
 ZONEGRAN, ZONISAMIDE

SUNSTAR AMERICAS

* SUNSTAR AMERICAS INC
 PAROEX, CHLORHEXIDINE GLUCONATE

SUPERNUS PHARMS

* SUPERNUS PHARMACEUTICALS INC
 OXTELLAR XR, OXCARBAZEPINE
 TROKENDI XR, TOPIRAMATE

SUVEN LIFE

* SUVEN LIFE SCIENCES LTD
 MALATHION, MALATHION

SVADS HOLDINGS SA

* SVADS HOLDINGS SA
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

SVC PHARMA

* SVC PHARMA LP
 DRONABINOL, DRONABINOL

SWAN PHARMS LLC

* SWAN PHARMACEUTICALS LLC
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE

SWEDISH ORPHAN

* SWEDISH ORPHAN BIOVITRUM AB PUBL
 ORFADIN, NITISINONE

SYMLMED PHARMS LLC

* SYMLMED PHARMACEUTICALS LLC
 ACEON, PERINDOPRIL ERBUMINE
 PRESTALIA, AMLODIPINE BESYLATE

SYNTHON PHARMS

* SYNTHON PHARMACEUTICALS INC
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**** T ******METHODIST HOSP RES**

* THE METHODIST HOSP RESEARCH INSTITUTE
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

RITEDOSE CORP

* THE RITEDOSE CORP
 ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE

TAIHO ONCOLOGY

* TAIHO ONCOLOGY INC

WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1086, p. 1051 of 1400

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

* TAIHO ONCOLOGY INC
LONSURF, TIPIRACIL HYDROCHLORIDE

TAKEDA GMBH

* TAKEDA GMBH
ALVESCO, CICLESONIDE
OMNARIS, CICLESONIDE
ZETONNA, CICLESONIDE

TAKEDA PHARMS USA

* TAKEDA PHARMACEUTICALS USA INC
ACTOPLUS MET XR, METFORMIN HYDROCHLORIDE
ACTOPLUS MET, METFORMIN HYDROCHLORIDE
ACTOS, PIOGLITAZONE HYDROCHLORIDE
COLCRYS, COLCHICINE
DEXILANT SOLUTAB, DEXLANSOPRAZOLE
DEXILANT, DEXLANSOPRAZOLE
DUETACT, GLIMEPIRIDE
KAZANO, ALOGLIPTIN BENZOATE
NESINA, ALOGLIPTIN BENZOATE
OSENI, ALOGLIPTIN BENZOATE
PREVACID, LANSOPRAZOLE
PREVPAC, AMOXICILLIN
ROZEREM, RAMELTEON
TRINTELLIX, VORTIOXETINE HYDROBROMIDE
ULORIC, FEBUXOSTAT

TALON THERAP

* TALON THERAPEUTICS INC
MARQIBO KIT, VINCRISTINE SULFATE

TAMARANG

* TAMARANG SA
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE

TARO

* TARO PHARMACEUTICAL INDUSTRIES LTD
ACETAZOLAMIDE, ACETAZOLAMIDE
CARBAMAZEPINE, CARBAMAZEPINE
CARVEDILOL, CARVEDILOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
DESLORATADINE, DESLORATADINE
DESONIDE, DESONIDE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
FLUCONAZOLE, FLUCONAZOLE
FLUOROURACIL, FLUOROURACIL
GABAPENTIN, GABAPENTIN
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
IMIQUIMOD, IMIQUIMOD
KETOCONAZOLE, KETOCONAZOLE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LORATADINE, LORATADINE (OTC)
MELOXICAM, MELOXICAM
METRONIDAZOLE, METRONIDAZOLE
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXCARBAZEPINE, OXCARBAZEPINE
PHENYTOIN, PHENYTOIN

* TARO PHARMACEUTICALS INC
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** T **

- * TARO PHARMACEUTICALS INC
 CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
 DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 FLUOCINONIDE, FLUOCINONIDE
 HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
 MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
 NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
 TOPICORT, DESOXIMETASONE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 WARFARIN SODIUM, WARFARIN SODIUM
- * TARO PHARMACEUTICALS USA INC
 ACETIC ACID, ACETIC ACID, GLACIAL
 ACYCLOVIR, ACYCLOVIR
 ADAPALENE, ADAPALENE
 ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 AMMONIUM LACTATE, AMMONIUM LACTATE
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CICLOPIROX, CICLOPIROX
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
 CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CLOTRIMAZOLE, CLOTRIMAZOLE
 DERMABET, BETAMETHASONE VALERATE
 DESONIDE, DESONIDE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
 ECONAZOLE NITRATE, ECONAZOLE NITRATE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
 FLUOCINONIDE, FLUOCINONIDE
 FLUOROURACIL, FLUOROURACIL
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
 HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
 HYDROCORTISONE, HYDROCORTISONE
 KETOZOLE, KETOCONAZOLE
 LIDOCAINE, LIDOCAINE
 LORATADINE, LORATADINE (OTC)
 MICONAZOLE 3, MICONAZOLE NITRATE (OTC)
 MOMETASONE FUROATE, MOMETASONE FUROATE
 MUPIROCIN, MUPIROCIN
 NAFTIFINE HYDROCHLORIDE, NAFTIFINE HYDROCHLORIDE
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 NYSTATIN, NYSTATIN
 OXICONAZOLE NITRATE, OXICONAZOLE NITRATE
 PHENYTOIN, PHENYTOIN
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
 TERBINAFFINE HYDROCHLORIDE, TERBINAFFINE HYDROCHLORIDE (OTC)
 TERCONAZOLE, TERCONAZOLE
 TERIL, CARBAMAZEPINE
 TOPICORT, DESOXIMETASONE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)
 U-CORT, HYDROCORTISONE ACETATE
- * TARO PHARMACEUTICALS, INC.
 HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

* TARO PHARMACEUTICALS, INC.
TOPICORT, DESOXIMETASONE

TARO PHARM INDS

* TARO PHARMACEUTICAL INDUSTRIES LTD
AMCINONIDE, AMCINONIDE
CARBAMAZEPINE, CARBAMAZEPINE
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
DES LorATADINE, DES LorATADINE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
LAMOTRIGINE, LAMOTRIGINE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE

TARO PHARMS IRELAND

* TARO PHARMACEUTICALS IRELAND LTD
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION

TARO PHARMS NORTH

* TARO PHARMACEUTICALS NORTH AMERICA INC
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
INFANTS' FEVERALL, ACETAMINOPHEN (OTC)
OVIDE, MALATHION
TOPICORT, DESOXIMETASONE

TEDOR PHARM

* TEDOR PHARMA INC
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE

TEDOR PHARMA INC

* TEDOR PHARMA INC
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE

TEIKOKU PHARMA USA

* TEIKOKU PHARMA USA INC
LIDODERM, LIDOCAINE

TELIGENT PHARMA INC

* TELIGENT PHARMA INC
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
CEFOTAN, CEFOTETAN DISODIUM
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DESOXIMETASONE, DESOXIMETASONE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
ECONAZOLE NITRATE, ECONAZOLE NITRATE
FLURANDRENOLIDE, FLURANDRENOLIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE, LIDOCAINE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

TERSERA THERAP

* TERSERA THERAPEUTICS LLC
ERGOMAR, ERGOTAMINE TARTRATE

TESARO INC

* TESARO INC
VARUBI, ROLAPITANT HYDROCHLORIDE

TEVA

* TEVA NEUROSCIENCE INC
AZILECT, RASAGILINE MESYLATE
* TEVA PHARMACEUTICALS USA INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACYCLOVIR, ACYCLOVIR
ADIPEX-P, PHENTERMINE HYDROCHLORIDE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** T **

* TEVA PHARMACEUTICALS USA INC
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 AMOXICILLIN PEDIATRIC, AMOXICILLIN
 AMOXICILLIN, AMOXICILLIN
 ATENOLOL, ATENOLOL
 AZITHROMYCIN, AZITHROMYCIN
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 BICALUTAMIDE, BICALUTAMIDE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 CALCITRIOL, CALCITRIOL
 CAPTOPRIL, CAPTOPRIL
 CARVEDILOL, CARVEDILOL
 CEFACLOR, CEFACLOR
 CEFPROZIL, CEFPROZIL
 CELECOXIB, CELECOXIB
 CEPHALEXIN, CEPHALEXIN
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
 CILOSTAZOL, CILOSTAZOL
 CIMETIDINE, CIMETIDINE
 CLARITHROMYCIN, CLARITHROMYCIN
 CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
 CLONAZEPAM, CLONAZEPAM
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 CLOTRIMAZOLE, CLOTRIMAZOLE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
 DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
 DIFLUNISAL, DIFLUNISAL
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
 ENALAPRIL MALEATE, ENALAPRIL MALEATE
 ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
 EPITOL, CARBAMAZEPINE
 ESZOPICLONE, ESZOPICLONE
 ETODOLAC, ETODOLAC
 FAMOTIDINE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE (OTC)
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
 FINASTERIDE, FINASTERIDE
 FLUCONAZOLE, FLUCONAZOLE
 FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
 FLUOCINONIDE, FLUOCINONIDE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FLURBIPROFEN, FLURBIPROFEN
 FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
 FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
 GALZIN, ZINC ACETATE
 GEMFIBROZIL, GEMFIBROZIL
 GLIMEPIRIDE, GLIMEPIRIDE
 GLYBURIDE (MICRONIZED), GLYBURIDE
 GLYBURIDE, GLYBURIDE
 HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 KETOCONAZOLE, KETOCONAZOLE
 KETOPROFEN, KETOPROFEN
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LAMOTRIGINE, LAMOTRIGINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

* TEVA PHARMACEUTICALS USA INC
 LEVOFLOXACIN, LEVOFLOXACIN
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
 LORATADINE, LORATADINE (OTC)
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 LOVASTATIN, LOVASTATIN
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
 MIRTAZAPINE, MIRTAZAPINE
 MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
 MUPIROCIN, MUPIROCIN
 NAPROXEN SODIUM, NAPROXEN SODIUM
 NAPROXEN, NAPROXEN
 NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE
 NEOMYCIN SULFATE, NEOMYCIN SULFATE
 NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
 NYSTATIN, NYSTATIN
 OFLOXACIN, OFLOXACIN
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON, ONDANSETRON
 ORAP, PIMOZIDE
 OXAPROZIN, OXAPROZIN
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PENICILLIN-VK, PENICILLIN V POTASSIUM
 PIROXICAM, PIROXICAM
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PRELONE, PREDNISOLONE
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RIBAVIRIN, RIBAVIRIN
 RISPERIDONE, RISPERIDONE
 ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 ROSIGLITAZONE MALEATE, ROSIGLITAZONE MALEATE
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
 SUCRALFATE, SUCRALFATE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TOLMETIN SODIUM, TOLMETIN SODIUM
 TOPIRAMATE, TOPIRAMATE
 TORSEMIDE, TORSEMIDE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

TEVA BRANDED PHARM

* TEVA BRANDED PHARMACEUTICAL PRODUCTS R AND D INC
 DIAMOX, ACETAZOLAMIDE
 LOSEASONIQUE, ETHINYL ESTRADIOL
 PLAN B ONE-STEP, LEVONORGESTREL (OTC)
 PROAIR HFA, ALBUTEROL SULFATE
 PROAIR RESPICLICK, ALBUTEROL SULFATE
 PROGLYCEM, DIAZOXIDE
 QNASL, BECLOMETHASONE DIPROPIONATE
 QUARTETTE, ETHINYL ESTRADIOL
 QVAR 40, BECLOMETHASONE DIPROPIONATE
 QVAR 80, BECLOMETHASONE DIPROPIONATE
 SEASONALE, ETHINYL ESTRADIOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

* TEVA BRANDED PHARMACEUTICAL PRODUCTS R AND D INC
SEASONIQUE, ETHINYL ESTRADIOL
ZECUITY, SUMATRIPTAN SUCCINATE

TEVA PARENTERAL

* TEVA PARENTERAL MEDICINES INC
DAPTOMYCIN, DAPTOMYCIN
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE

TEVA PHARMS

* TEVA PHARMACEUTICALS USA
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
ANASTROZOLE, ANASTROZOLE
AZITHROMYCIN, AZITHROMYCIN
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BUDESONIDE, BUDESONIDE
CARBAMAZEPINE, CARBAMAZEPINE
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFDINIR, CEFdinIR
CEFPROZIL, CEFPROZIL
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CROMOLYN SODIUM, CROMOLYN SODIUM
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
ETHOSUXIMIDE, ETHOSUXIMIDE
FAMCICLOVIR, FAMCICLOVIR
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
GABAPENTIN, GABAPENTIN
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL LACTATE
HYDROCORTISONE, HYDROCORTISONE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
IRBESARTAN, IRBESARTAN
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LANSOPRAZOLE, LANSOPRAZOLE
LEFLUNOMIDE, LEFLUNOMIDE
LETROZOLE, LETROZOLE
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LINEZOLID, LINEZOLID
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MEGESTROL ACETATE, MEGESTROL ACETATE
MELOXICAM, MELOXICAM
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
OLANZAPINE, OLANZAPINE
OXALIPLATIN, OXALIPLATIN
PACLITAXEL, PACLITAXEL
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROGESTERONE, PROGESTERONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ******* TEVA PHARMACEUTICALS USA**

QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 QUININE SULFATE, QUININE SULFATE
 RAMIPRIL, RAMIPRIL
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH, SULFAMETHOXAZOLE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TRANDOLAPRIL, TRANDOLAPRIL
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE (OTC)
 URSODIOL, URSODIOL
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VANDAZOLE, METRONIDAZOLE
 VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE
 VORICONAZOLE, VORICONAZOLE
 ZALEPLON, ZALEPLON

TEVA PHARMS INTL

*** TEVA PHARMACEUTICALS INTERNATIONAL GMBH**
 AMRIX, CYCLOBENZAPRINE HYDROCHLORIDE

TEVA PHARMS USA*** TEVA PHARMACEUTICALS USA**

ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
 ACITRETIN, ACITRETIN
 ADENOSINE, ADENOSINE
 ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
 ALPROSTADIL, ALPROSTADIL
 AMIKACIN SULFATE, AMIKACIN SULFATE
 AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
 ARGATROBAN IN 0.9% SODIUM CHLORIDE, ARGATROBAN
 ARIPIPIRAZOLE, ARIPIPIRAZOLE
 ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
 BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
 BUDESONIDE, BUDESONIDE
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 CARBOPLATIN, CARBOPLATIN
 CLARAVIS, ISOTRETINOIN
 CLOZAPINE, CLOZAPINE
 COPAXONE, GLATIRAMER ACETATE
 CYTOSAR-U, CYTARABINE
 DACARBAZINE, DACARBAZINE
 DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 DOCETAXEL, DOCETAXEL
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 ENALAPRILAT, ENALAPRILAT
 ENTECAVIR, ENTECAVIR
 EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM
 EPTIFIBATIDE, EPTIFIBATIDE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 ETOPOSIDE, ETOPOSIDE
 FLUOROURACIL, FLUOROURACIL
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
 HALOPERIDOL, HALOPERIDOL LACTATE
 IDARUBICIN HYDROCHLORIDE PFS, IDARUBICIN HYDROCHLORIDE
 IFOSFAMIDE, IFOSFAMIDE
 IFOSFAMIDE/MESNA KIT, IFOSFAMIDE
 IMATINIB MESYLATE, IMATINIB MESYLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

- * TEVA PHARMACEUTICALS USA
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN, AMOXICILLIN
 LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
 LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
 LINEZOLID, LINEZOLID
 MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
 MESNA, MESNA
 METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
 NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
 OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
 OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
 PARICALCITOL, PARICALCITOL
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
 RISEDRONATE SODIUM, RISEDRONATE SODIUM
 ROSIGLITAZONE MALEATE AND GLIMEPIRIDE, GLIMEPIRIDE
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 TOBRAMYCIN, TOBRAMYCIN
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VECURONIUM BROMIDE, VECURONIUM BROMIDE
 VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE
 VINOURELBINE TARTRATE, VINOURELBINE TARTRATE
 ZANOSAR, STREPTOZOCIN
 ZOLMITRIPTAN, ZOLMITRIPTAN
- * TEVA PHARMACEUTICALS USA INC
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 CAPECITABINE, CAPECITABINE
 ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
 METRONIDAZOLE, METRONIDAZOLE
 OXYBUTYNYN CHLORIDE, OXYBUTYNYN CHLORIDE
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 SELFEMRA, FLUOXETINE HYDROCHLORIDE
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE

TEVA WOMENS

- * TEVA WOMENS HEALTH INC
 ENJUVIA, ESTROGENS, CONJUGATED SYNTHETIC B
 PARAGARD T 380A, COPPER
 ZIAC, BISOPROLOL FUMARATE

THE FEINSTEIN INST

- * THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

THE MEDICINES CO

- * THE MEDICINES CO
 ANGIOMAX, BIVALIRUDIN
 IONSYS, FENTANYL HYDROCHLORIDE
 ORBACTIV, ORITAVANCIN DIPHOSPHATE

THE PHARMA NETWORK**WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1086, p. 1059 of 1400**

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

* THE PHARMA NETWORK LLC
BENZONATATE, BENZONATATE

THE PHARMANETWORK

* THE PHARMANETWORK LLC
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE

THEPHARMANETWORK LLC

* THEPHARMANETWORK LLC
BENZONATATE, BENZONATATE
ISONIAZID, ISONIAZID
NIMODIPINE, NIMODIPINE
THERMAZENE, SILVER SULFADIAZINE

THERATECHNOLOGIES

* THERATECHNOLOGIES INC
EGRIFTA, TESAMORELIN ACETATE

THERAVANCE BIOPHARMA

* THERAVANCE BIOPHARMA ANTIBIOTICS INC
VIBATIV, TELAVANCIN HYDROCHLORIDE

THREE RIVERS PHARMS

* THREE RIVERS PHARMACEUTICALS LLC
RIBASPHERE, RIBAVIRIN
RIBAVIRIN, RIBAVIRIN

TIGER PHARMS LLC

* TIGER PHARMACEUTICALS LLC
DOFETILIDE, DOFETILIDE

TOLMAR

* TOLMAR INC
ADAPALENE, ADAPALENE
ATRIDOX, DOXYCYCLINE HYCLATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCIPOTRIENE, CALCIPOTRIENE
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
IMIQUIMOD, IMIQUIMOD
KETOCONAZOLE, KETOCONAZOLE
LEVETIRACETAM, LEVETIRACETAM
LIDOCAINE AND PRILOCAINE, LIDOCAINE
METRONIDAZOLE, METRONIDAZOLE
MOMETASONE FUROATE, MOMETASONE FUROATE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

TOLMAR THERAP

* TOLMAR THERAPEUTICS INC
ELIGARD, LEUPROLIDE ACETATE

TORPHARM

* TORPHARM INC
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE

TORRENT PHARM

* TORRENT PHARMA INC
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

TORRENT PHARMA INC

* TORRENT PHARMA INC
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE

TORRENT PHARMS

* TORRENT PHARMACEUTICALS LIMITED
LEVOFLOXACIN, LEVOFLOXACIN
* TORRENT PHARMACEUTICALS LTD
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
CARBAMAZEPINE, CARBAMAZEPINE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

- * TORRENT PHARMACEUTICALS LTD
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
 LAMOTRIGINE, LAMOTRIGINE
 LEVETIRACETAM, LEVETIRACETAM
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 TOPIRAMATE, TOPIRAMATE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
- * TORRENT PHARMACEUTICALS LTD.
 ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
- TORRENT PHARMS LLC**
- * TORRENT PHARMACEUTICALS LLC
 AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 OLANZAPINE, OLANZAPINE
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
- TORRENT PHARMS LTD**
- * TORRENT PHARMACEUTICALS LTD
 AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
 ARIPIPIRAZOLE, ARIPIPIRAZOLE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CELECOXIB, CELECOXIB
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 FELODIPINE, FELODIPINE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
 LAMOTRIGINE, LAMOTRIGINE
 LEVETIRACETAM, LEVETIRACETAM
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 OLANZAPINE, OLANZAPINE
 OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TELMISARTAN, TELMISARTAN
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
 VALSARTAN, VALSARTAN
- TRIAD ISOTOPES INC**
- * TRIAD ISOTOPES INC
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

TRIS PHARMA INC

- * TRIS PHARMA INC
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ******* TRIS PHARMA INC**

DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 DEXTROMETHORPHAN POLISTIREX, DEXTROMETHORPHAN POLISTIREX (OTC)
 DYANAVEL XR, AMPHETAMINE
 GABAPENTIN, GABAPENTIN
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
 HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE, HYDROCODONE BITARTRATE
 HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE,
 HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX, CHLORPHENIRAMINE POLISTIREX
 IBUPROFEN, IBUPROFEN (OTC)
 KARBINAL ER, CARBINOXAMINE MALEATE
 LEVETIRACETAM, LEVETIRACETAM
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 THEOPHYLLINE, THEOPHYLLINE

TRUSTEES UNIV PA

*** TRUSTEES OF THE UNIV OF PENNSYLVANIA**
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

TRYGG

*** TRYGG PHARMA INC**
 OMTYRG, OMEGA-3-ACID ETHYL ESTERS TYPE A

TURING PHARMS AG

*** TURING PHARMACEUTICALS AG**
 DARAPRIM, PYRIMETHAMINE

TWI PHARMS INC

*** TWI PHARMACEUTICALS INC**
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 MEGESTROL ACETATE, MEGESTROL ACETATE
 NIFEDIPINE, NIFEDIPINE

**** U ******UCB INC**

*** UCB INC**
 BRIVIACT, BRIVARACETAM
 KEPPRA XR, LEVETIRACETAM
 KEPPRA, LEVETIRACETAM
 METADATE CD, METHYLPHENIDATE HYDROCHLORIDE
 METADATE ER, METHYLPHENIDATE HYDROCHLORIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 NEUPRO, ROTIGOTINE
 TUSSIONEX PENNKINETIC, CHLORPHENIRAMINE POLISTIREX
 VIMPAT, LACOSAMIDE
 XYZAL, LEVOCETIRIZINE DIHYDROCHLORIDE
 ZAROXYLYN, METOLAZONE

UCLA BIOMEDICAL

*** UCLA BIOMEDICAL CYCLOTRON**
 AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UCSF RODIOPHARM

*** UCSF RADIOPHARMACEUTICAL FACILITY**
 AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

UIHC PET IMAGING

*** UNIV IOWA HOSPS AND CLINICS PET IMAGING CENTER**
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

UNICHEM

*** UNICHEM LABORATORIES, LTD**
WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1086, p. 1062 of 1400

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** U ******* UNICHEM LABORATORIES LTD**

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 MELOXICAM, MELOXICAM
 ZALEPLON, ZALEPLON

UNICHEM LABS LTD*** UNICHEM LABORATORIES LIMITED**

DIVALPROEX SODIUM, DIVALPROEX SODIUM

*** UNICHEM LABORATORIES LTD**

ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 IRBESARTAN, IRBESARTAN
 LAMOTRIGINE, LAMOTRIGINE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METRONIDAZOLE, METRONIDAZOLE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TOPIRAMATE, TOPIRAMATE

UNICHEM PHARMS (USA)*** UNICHEM PHARMACEUTICALS (USA) INC**

BISOPROLOL FUMARATE, BISOPROLOL FUMARATE

UNIMARK REMEDIES LTD*** UNIMARK REMEDIES LTD**

MONTELUKAST SODIUM, MONTELUKAST SODIUM

UNIQUE PHARM LABS*** UNIQUE PHARMACEUTICAL LABORATORIES**

ATENOLOL, ATENOLOL
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 FLUCONAZOLE, FLUCONAZOLE
 GLIPIZIDE, GLIPIZIDE
 LITHIUM CARBONATE, LITHIUM CARBONATE
 OXYBUTYNYN CHLORIDE, OXYBUTYNYN CHLORIDE
 TINIDAZOLE, TINIDAZOLE

UNITED BIOMEDCL*** UNITED BIOMEDICAL INC**

TERBUTALINE SULFATE, TERBUTALINE SULFATE

UNITED GUARDIAN*** UNITED GUARDIAN INC**

RENACIDIN, CITRIC ACID

UNITED THERAP*** UNITED THERAPEUTICS CORP**

ORENITRAM, TREPROSTINIL DIOLAMINE
 REMODULIN, TREPROSTINIL
 TYVASO, TREPROSTINIL

UNIV MICHIGAN*** UNIV MICHIGAN PET RADIOPHARMACEUTICAL PRODUCTION PROGRAM**

FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UNIV NORTH DAKOTA*** UNIV NORTH DAKOTA**

FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UNIV TX MD ANDERSON*** UNIV TEXAS MD ANDERSON CANCER CENTER**

AMMONIA N 13, AMMONIA N-13
 CHOLINE C-11, CHOLINE C-11
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** U ****

* UNIV TEXAS MD ANDERSON CANCER CENTER
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

UNIV UTAH CYCLOTRON

* UNIV UTAH CYCLOTRON RADIOCHEMISTRY LAB
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

UPSHER SMITH

* UPSHER SMITH LABORATORIES INC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MORPHINE SULFATE, MORPHINE SULFATE
NIACOR, NIACIN
NYSTATIN, NYSTATIN
ORVATEN, MIDODRINE HYDROCHLORIDE
OXANDROLONE, OXANDROLONE
PACERONE, AMIODARONE HYDROCHLORIDE
PENTOXIL, PENTOXIFYLLINE
PREVALITE, CHOLESTYRAMINE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
SORINE, SOTALOL HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE

UPSHER SMITH LABS

* UPSHER SMITH LABORATORIES INC
KLOR-CON M10, POTASSIUM CHLORIDE
KLOR-CON M15, POTASSIUM CHLORIDE
KLOR-CON M20, POTASSIUM CHLORIDE

UPSHER-SMITH LABS

* UPSHER-SMITH LABORATORIES INC
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
KLOR-CON, POTASSIUM CHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
QUDEXY XR, TOPIRAMATE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
VOGELXO, TESTOSTERONE

US PHARM HOLDINGS

* US PHARMACEUTICAL HOLDINGS II LLC
ANZEMET, DOLASETRON MESYLATE
CLAFORAN, CEFOTAXIME SODIUM
DEMEROL, MEPERIDINE HYDROCHLORIDE
DRISDOL, ERGOCALCIFEROL
HIPREX, METHENAMINE HIPPURATE
LASIX, FUROSEMIDE
NORPRAMIN, DESIPRAMINE HYDROCHLORIDE

US PHARMS HOLDINGS I

* US PHARMACEUTICALS HOLDINGS I LLC
LOPRESSOR HCT, HYDROCHLOROTHIAZIDE
LOPRESSOR, METOPROLOL TARTRATE
LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE
LOTENSIN, BENAZEPRIL HYDROCHLORIDE
PARLODEL, BROMOCRIPTINE MESYLATE

US WORLDMEDS

* US WORLDMEDS LLC
APOKYN, APOMORPHINE HYDROCHLORIDE
REVONTO, DANTROLENE SODIUM

US WORLDMEDS LLC

* US WORLDMEDS LLC
CORGARD, NADOLOL

USL PHARMA

* USL PHARMA INC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
BACLOFEN, BACLOFEN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** U ****

- * USL PHARMA INC
 - BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
 - CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
 - CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
 - FLUOXYMESTERONE, FLUOXYMESTERONE
 - JANTOVEN, WARFARIN SODIUM
 - OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

USV NORTH AMERICA

- * USV NORTH AMERICA INC
 - OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
 - ZOLEDRONIC ACID, ZOLEDRONIC ACID

**** V ******VALEANT**

- * VALEANT PHARMACEUTICALS INTERNATIONAL
 - ANCOBON, FLUCYTOSINE
 - BONTRIL PDM, PHENDIMETRAZINE TARTRATE
 - D.H.E. 45, DIHYDROERGOTAMINE MESYLATE
 - MIGRANAL, DIHYDROERGOTAMINE MESYLATE
 - MYSOLINE, PRIMIDONE

VALEANT BERMUDA

- * VALEANT INTERNATIONAL BERMUDA
 - BENZAACLIN, BENZOYL PEROXIDE
 - DERMATOP E EMOLLIENT, PREDNICARBATE
 - ELIDEL, PIMECROLIMUS
 - PENLAC, CICLOPIROX
 - RETIN-A, TRETINOIN
 - XERESE, ACYCLOVIR
 - ZOVIRAX, ACYCLOVIR

VALEANT INTL

- * VALEANT INTERNATIONAL BARBADOS SRL
 - ATIVAN, LORAZEPAM
 - CARDIZEM CD, DILTIAZEM HYDROCHLORIDE
 - CARDIZEM LA, DILTIAZEM HYDROCHLORIDE
 - CARDIZEM, DILTIAZEM HYDROCHLORIDE
 - RETIN-A MICRO, TRETINOIN
 - RETIN-A, TRETINOIN
 - RETIN-A-MICRO, TRETINOIN
 - VASERETIC, ENALAPRIL MALEATE
 - WELLBUTRIN XL, BUPROPION HYDROCHLORIDE
- * VALEANT INTERNATIONAL SRL
 - BENZAMYCIN, BENZOYL PEROXIDE

VALEANT LUXEMBOURG

- * VALEANT PHARMACEUTICALS LUXEMBOURG SARL
 - ERTACZO, SERTACONAZOLE NITRATE
 - TARGRETIN, BEXAROTENE
 - VISUDYNE, VERTEPORFIN

VALEANT PHARM INTL

- * VALEANT PHARMACEUTICALS INTERNATIONAL
 - 8-MOP, METHOXSALEN
 - ANDROID 25, METHYLTESTOSTERONE
 - EFUDEX, FLUOROURACIL
 - LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE
 - MESTINON, PYRIDOSTIGMINE BROMIDE
 - OXSORALEN, METHOXSALEN
 - TESTRED, METHYLTESTOSTERONE
 - VIRAZOLE, RIBAVIRIN
 - ZELAPAR, SELEGILINE HYDROCHLORIDE

VALEANT PHARMS

- * VALEANT PHARMACEUTICALS NORTH AMERICA
 - MEPHYTON, PHYTONADIONE
- * VALEANT PHARMACEUTICALS NORTH AMERICA LLC
 - LIBRAX, CHLORDIAZEPOXIDE HYDROCHLORIDE
 - MESTINON, PYRIDOSTIGMINE BROMIDE
 - MINITRAN, NITROGLYCERIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** V **

* VALEANT PHARMACEUTICALS NORTH AMERICA LLC
PENTOXIFYLLINE, PENTOXIFYLLINE

VALEANT PHARMS INC

* VALEANT PHARMACEUTICALS INTERNATIONAL INC
GRIS-PEG, GRISEOFULVIN, ULTRAMICROSIZ

VALEANT PHARMS INTL

* VALEANT PHARMACEUTICALS INTERNATIONAL
APRISO, MESALAMINE
COLAZAL, BALSALAZIDE DISODIUM
GIAZO, BALSALAZIDE DISODIUM
UCERIS, BUDESONIDE

VALEANT PHARMS LLC

* VALEANT PHARMACEUTICALS NORTH AMERICA LLC
CAPITAL AND CODEINE, ACETAMINOPHEN
MACUGEN, PEGAPTANIB SODIUM
MESTINON, PYRIDOSTIGMINE BROMIDE
TASMAR, TOLCAPONE
TIMOPTIC-XE, TIMOLOL MALEATE

VALEANT PHARMS NORTH

* VALEANT PHARMACEUTICALS NORTH AMERICA LLC
APLENZIN, BUPROPION HYDROBROMIDE
CARAC, FLUOROURACIL
DERMATOP, PREDNICARBATE
DIASTAT ACUDIAL, DIAZEPAM
DIASTAT, DIAZEPAM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
FENOFIBRATE, FENOFIBRATE
IPRIVASK, DESIRUDIN RECOMBINANT
ISORDIL, ISOSORBIDE DINITRATE
KLARON, SULFACETAMIDE SODIUM
MINITRAN, NITROGLYCERIN
NIFEDIPINE, NIFEDIPINE
NORITATE, METRONIDAZOLE
PEPCID, FAMOTIDINE
RENOVA, TRETINOIN
RETIN-A, TRETINOIN
SECONAL SODIUM, SECOBARBITAL SODIUM
TIAZAC, DILTIAZEM HYDROCHLORIDE
VASOTEC, ENALAPRIL MALEATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
XENAZINE, TETRABENAZINE

VALIDUS PHARMS

* VALIDUS PHARMACEUTICALS LLC
NIFEDIPINE, NIFEDIPINE
ROCALTROL, CALCITRIOL

VALIDUS PHARMS INC

* VALIDUS PHARMACEUTICALS INC
BUMEX, BUMETANIDE
EQUETRO, CARBAMAZEPINE
MARPLAN, ISOCARBOXAZID

VANDA PHARMS INC

* VANDA PHARMACEUTICALS INC
FANAPT, ILOPERIDONE
HETLIOZ, TASIMELTEON

VELOXIS PHARMS INC

* VELOXIS PHARMACEUTICALS INC
ENVARUS XR, TACROLIMUS

VERNALIS R AND D LTD

* VERNALIS R AND D LTD
MOXATAG, AMOXICILLIN
TUZISTRA XR, CHLORPHENIRAMINE POLISTIREX

VEROSCIENCE

* VEROSCIENCE LLC
CYCLOSET, BROMOCRIPTINE MESYLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** V ******VERTEX PHARMS**

* VERTEX PHARMACEUTICALS INC
KALYDECO, IVACAFTOR

VERTEX PHARMS INC

* VERTEX PHARMACEUTICALS INC
KALYDECO, IVACAFTOR
ORKAMBI, IVACAFTOR

VERTICAL PHARMS LLC

* VERTICAL PHARMACEUTICALS LLC
DIVIGEL, ESTRADIOL

VIB

* VALEANT INTERNATIONAL BERMUDA
ZOVIRAX, ACYCLOVIR

VICURON

* VICURON PHARMACEUTICALS INC
ERAXIS, ANIDULAFUNGIN

VIFOR FRESENIUS

* VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE
VELPHORO, SUCROFERRIC OXYHYDROXIDE

VIIV HLTHCARE

* VIIV HEALTHCARE CO
COMBIVIR, LAMIVUDINE
EPIVIR, LAMIVUDINE
EPZICOM, ABACAVIR SULFATE
LEXIVA, FOSAMPRENAVIR CALCIUM
RESCRIPTOR, DELAVIRDINE MESYLATE
RETROVIR, ZIDOVUDINE
SELZENTRY, MARAVIROC
TIVICAY, DOLUTEGRAVIR SODIUM
TRIUMEQ, ABACAVIR SULFATE
TRIZIVIR, ABACAVIR SULFATE
ZIAGEN, ABACAVIR SULFATE

VINTAGE

* VINTAGE PHARMACEUTICALS LLC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETIC ACID, ACETIC ACID, GLACIAL
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALPRAZOLAM, ALPRAZOLAM
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
FOLIC ACID, FOLIC ACID
GLIMEPIRIDE, GLIMEPIRIDE
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
HYDROCORTISONE, HYDROCORTISONE
LIDOCAINE HYDROCHLORIDE VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LISINAPRIL, LISINAPRIL
NYSTATIN, NYSTATIN
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PREDNISOLONE, PREDNISOLONE
PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
PROMETHAZINE DM, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE WITH CODEINE, CODEINE PHOSPHATE
RISPERIDONE, RISPERIDONE
SPIRONOLACTONE, SPIRONOLACTONE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VALPROIC ACID, VALPROIC ACID
VENLATAIXINE HYDROCHLORIDE, VENLATAIXINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** V ****

* VINTAGE PHARMACEUTICALS LLC
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

VINTAGE PHARMS

* VINTAGE PHARMACEUTICALS
ALPRAZOLAM, ALPRAZOLAM
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CYCLAFEM 0.5/35, ETHINYL ESTRADIOL
DISULFIRAM, DISULFIRAM
GILDAGIA, ETHINYL ESTRADIOL
GILDESS 24 FE, ETHINYL ESTRADIOL
GLYCOPYRROLATE, GLYCOPYRROLATE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
KIMIDESS, DESOGESTREL
LEVETIRACETAM, LEVETIRACETAM
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

* VINTAGE PHARMACEUTICALS INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ALLOPURINOL, ALLOPURINOL
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
BACLOFEN, BACLOFEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
CARISOPRODOL, CARISOPRODOL
CLONAZEPAM, CLONAZEPAM
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DEXAMETHASONE, DEXAMETHASONE
DIAZEPAM, DIAZEPAM
FUROSEMIDE, FUROSEMIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
HYDROCORTISONE, HYDROCORTISONE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LACTULOSE, LACTULOSE
LEVETIRACETAM, LEVETIRACETAM
LORAZEPAM, LORAZEPAM
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
NYSTATIN, NYSTATIN
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PERPHENAZINE, PERPHENAZINE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PREDNISONE, PREDNISONE
PRIMIDONE, PRIMIDONE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
SULFASALAZINE, SULFASALAZINE
TEMAZEPAM, TEMAZEPAM
TORSEMIDE, TORSEMIDE
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** V ******VINTAGE PHARMS LLC**

* VINTAGE PHARMACEUTICALS LLC
 CYCLAFEM 1/35, ETHINYL ESTRADIOL
 CYCLAFEM 7/7/7, ETHINYL ESTRADIOL
 DUTASTERIDE, DUTASTERIDE
 EMOQUETTE, DESOGESTREL
 FELODIPINE, FELODIPINE
 GILDESS 1.5/30, ETHINYL ESTRADIOL
 GILDESS 1/20, ETHINYL ESTRADIOL
 GILDESS FE 1.5/30, ETHINYL ESTRADIOL
 GILDESS FE 1/20, ETHINYL ESTRADIOL
 LETROZOLE, LETROZOLE
 LEVETIRACETAM, LEVETIRACETAM
 MEFENAMIC ACID, MEFENAMIC ACID
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 MORPHINE SULFATE, MORPHINE SULFATE
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 MYZILRA, ETHINYL ESTRADIOL
 ORSYTHIA, ETHINYL ESTRADIOL
 PERCOCET, ACETAMINOPHEN
 PREVIFEM, ETHINYL ESTRADIOL
 TRI-PREVIFEM, ETHINYL ESTRADIOL

VIRTUS PHARM

* VIRTUS PHARMACEUTICAL INC
 ACARBOSE, ACARBOSE

VIRTUS PHARMS

* VIRTUS PHARMACEUTICALS LLC
 PROMETRIUM, PROGESTERONE

VISTA PHARMS

* VISTA PHARMACEUTICALS INC
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

VISTAPHARM

* VISTAPHARM INC
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 LACTULOSE, LACTULOSE
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 NYSTATIN, NYSTATIN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PHENYTOIN, PHENYTOIN

VIVIMED LABS

* VIVIMED LABS ALATHUR PRIVATE LTD
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 METRONIDAZOLE, METRONIDAZOLE

VIVUS

* VIVUS INC
 QSYMIA, PHENTERMINE HYDROCHLORIDE

VPNA

* VALEANT PHARMACEUTICALS NORTH AMERICA
 DICLOFENAC SODIUM, DICLOFENAC SODIUM

**** W ******WA UNIV SCH MED**

* WASHINGTON UNIV SCHOOL MEDICINE
 AMMONIA N 13, AMMONIA N-13
 CHOLINE C-11, CHOLINE C-11

WARNER CHILCOTT LLC

* WARNER CHILCOTT CO LLC
 CHOLEDYL SA, OXTRIPHYLLINE

WATSON LABS**WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1086, p. 1069 of 1400**

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ****

* WATSON LABORATORIES
 FOLIC ACID, FOLIC ACID
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE

* WATSON LABORATORIES INC
 ACARBOSE, ACARBOSE
 AFEDITAB CR, NIFEDIPINE
 ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 ALENDRONATE SODIUM, ALENDRONATE SODIUM
 ALLOPURINOL, ALLOPURINOL
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 AMOXAPINE, AMOXAPINE
 ATENOLOL AND CHLORTHALIDONE, ATENOLOL
 CAPTOPRIL, CAPTOPRIL
 CARISOPRODOL, CARISOPRODOL
 CHLORZOXAZONE, CHLORZOXAZONE
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 CLONAZEPAM, CLONAZEPAM
 COL-PROBENECID, COLCHICINE
 DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
 ESTAZOLAM, ESTAZOLAM
 ESTROPIPATE, ESTROPIPATE
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 GLIPIZIDE, GLIPIZIDE
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 HYDROXOCOBALAMIN, HYDROXOCOBALAMIN
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
 ISRADIPINE, ISRADIPINE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 LAMOTRIGINE, LAMOTRIGINE
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LISINOPRIL, LISINOPRIL
 LORAZEPAM, LORAZEPAM
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
 MEPROBAMATE, MEPROBAMATE
 METHOCARBAMOL, METHOCARBAMOL
 METHYLDOPA, METHYLDOPA
 METHYLPREDNISOLONE, METHYLPREDNISOLONE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 METRONIDAZOLE, METRONIDAZOLE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MINOXIDIL, MINOXIDIL
 MIRTAZAPINE, MIRTAZAPINE
 NABUMETONE, NABUMETONE
 NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 NATEGLINIDE, NATEGLINIDE
 NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
 NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
 NIZATIDINE, NIZATIDINE
 NORETHINDRONE AND ETHINYL ESTRADIOL (10/11), ETHINYL ESTRADIOL
 NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 OGESTREL 0.5/50-28, ETHINYL ESTRADIOL
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PREDNISOLONE, PREDNISOLONE
 PREDNISON, PREDNISON

WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1086, p. 1070 of 1400

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ****

* WATSON LABORATORIES INC
 PRIMIDONE, PRIMIDONE
 PROBENECID, PROBENECID
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 QUASENSE, ETHINYL ESTRADIOL
 QUINIDINE SULFATE, QUINIDINE SULFATE
 RAMIPRIL, RAMIPRIL
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
 SIMVASTATIN, SIMVASTATIN
 SULFASALAZINE, SULFASALAZINE
 SULINDAC, SULINDAC
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TELMISARTAN, TELMISARTAN
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
 TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
 TOPIRAMATE, TOPIRAMATE
 TRANDOLAPRIL, TRANDOLAPRIL
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
 TRIMETHOPRIM, TRIMETHOPRIM
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
 ZOVIA 1/50E-28, ETHINYL ESTRADIOL

* WATSON LABS INC
 LISINAPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

WATSON LABS FLORIDA

* WATSON LABORATORIES INC FLORIDA
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

WATSON LABS INC

* WATSON LABORATORIES INC
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
 AMMONIUM LACTATE, AMMONIUM LACTATE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CELECOXIB, CELECOXIB
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
 DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM, DROSPIRENONE
 ESTRADIOL VALERATE AND DIENOGEST, DIENOGEST
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 INDOMETHACIN, INDOMETHACIN
 LEVOFLOXACIN, LEVOFLOXACIN
 LEVONORGESTREL, LEVONORGESTREL (OTC)
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 METRONIDAZOLE, METRONIDAZOLE
 MODAFINIL, MODAFINIL
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
 PERPHENAZINE, PERPHENAZINE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
 PROPOFOL, PROPOFOL
 RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
 RASAGILINE MESYLATE, RASAGILINE MESYLATE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VALSARTAN, VALSARTAN
 VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE

WATSON LABORATORIES, INC. , IPR2017-01622, Ex. 1086, p. 1071 of 1400

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ******WATSON PHARMS INC**

* WATSON PHARMACEUTICALS INC
RIFAMPIN, RIFAMPIN

WELLSTAT THERAP

* WELLSTAT THERAPEUTICS CORP
VISTOGARD, URIDINE TRIACETATE
XURIDEN, URIDINE TRIACETATE

WES PHARMA INC

* WES PHARMA INC
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

WEST WARD PHARM CORP

* WEST WARD PHARMACEUTICAL CORP
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE

WEST-WARD PHARM CORP

* WEST-WARD PHARMACEUTICAL CORP
CEFOTETAN, CEFOTETAN DISODIUM

WEST-WARD PHARMS INT

* WEST-WARD PHARMACEUTICALS INTERNATIONAL LTD
ACARBOSE, ACARBOSE
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALLOPURINOL SODIUM, ALLOPURINOL SODIUM
ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
ALPRAZOLAM, ALPRAZOLAM
ALPROSTADIL, ALPROSTADIL
AMIKACIN SULFATE, AMIKACIN SULFATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMRINONE LACTATE, INAMRINONE LACTATE
ANASTROZOLE, ANASTROZOLE
ATIVAN, LORAZEPAM
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
AZATHIOPRINE SODIUM, AZATHIOPRINE SODIUM
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CAFCIT, CAFFEINE CITRATE
CALCITRIOL, CALCITRIOL
CALCIUM ACETATE, CALCIUM ACETATE
CAPECITABINE, CAPECITABINE
CARBOPLATIN, CARBOPLATIN
CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE
CILOSTAZOL, CILOSTAZOL
CISPLATIN, CISPLATIN
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLADRIBINE, CLADRIBINE
CLARITHROMYCIN, CLARITHROMYCIN
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOTRIMAZOLE, CLOTRIMAZOLE
CYANOCOBALAMIN, CYANOCOBALAMIN
CYCLOSPORINE, CYCLOSPORINE
CYTARABINE, CYTARABINE
DACARBAZINE, DACARBAZINE
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DEXAMETHASONE INTENSOL, DEXAMETHASONE
DEXAMETHASONE, DEXAMETHASONE
DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
DIAZEPAM INTENSOL, DIAZEPAM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ****

* WEST-WARD PHARMACEUTICALS INTERNATIONAL LTD
 DIAZEPAM, DIAZEPAM
 DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE), DICYCLOMINE HYDROCHLORIDE
 DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
 DIPYRIDAMOLE, DIPYRIDAMOLE
 DISULFIRAM, DISULFIRAM
 DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
 DOPRAM, DOXAPRAM HYDROCHLORIDE
 DOXERCALCIFEROL, DOXERCALCIFEROL
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 DOXYCYCLINE, DOXYCYCLINE HYCLATE
 DURAMORPH PF, MORPHINE SULFATE
 DUTASTERIDE, DUTASTERIDE
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
 ESZOPICLONE, ESZOPICLONE
 ETOPOSIDE, ETOPOSIDE
 EXEMESTANE, EXEMESTANE
 FAMCICLOVIR, FAMCICLOVIR
 FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
 FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
 FLECAINIDE ACETATE, FLECAINIDE ACETATE
 FLOXURIDINE, FLOXURIDINE
 FLUCONAZOLE, FLUCONAZOLE
 FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE (OTC)
 FUROSEMIDE, FUROSEMIDE
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
 HALOPERIDOL, HALOPERIDOL LACTATE
 HEPARIN SODIUM, HEPARIN SODIUM
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
 IFOSFAMIDE, IFOSFAMIDE
 IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
 INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
 INFUMORPH, MORPHINE SULFATE
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN
 KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 LACTULOSE, LACTULOSE
 LETROZOLE, LETROZOLE
 LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
 LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
 LEVOCARNITINE, LEVOCARNITINE
 LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
 LINEZOLID, LINEZOLID
 LITHIUM CARBONATE, LITHIUM CARBONATE
 LORAZEPAM INTENSOL, LORAZEPAM
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
 MEGESTROL ACETATE, MEGESTROL ACETATE
 MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
 MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
 MERCAPTOPYRINE, MERCAPTOPYRINE
 MESNA, MESNA
 METHADONE HYDROCHLORIDE INTENSOL, METHADONE HYDROCHLORIDE
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ****

* WEST-WARD PHARMACEUTICALS INTERNATIONAL LTD
 METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE
 METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 NALOXONE, NALOXONE HYDROCHLORIDE
 NAPROXEN, NAPROXEN
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
 OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 OXCARBAZEPINE, OXCARBAZEPINE
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 OXYTOCIN, OXYTOCIN
 PACLITAXEL, PACLITAXEL
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PENTOSTATIN, PENTOSTATIN
 PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
 PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
 PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE
 POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 PREDNISONE INTENSOL, PREDNISONE
 PREDNISONE, PREDNISONE
 PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RAMIPRIL, RAMIPRIL
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 RITONAVIR, RITONAVIR
 ROBAXIN, METHOCARBAMOL
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 ROXICET, ACETAMINOPHEN
 RUFINAMIDE, RUFINAMIDE
 SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
 SUFENTANIL CITRATE, SUFENTANIL CITRATE
 THIOTEPA, THIOTEPA
 TINIDAZOLE, TINIDAZOLE
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 TORSEMIDE, TORSEMIDE
 TRIAZOLAM, TRIAZOLAM
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VINBLASTINE SULFATE, VINBLASTINE SULFATE
 ZALEPLON, ZALEPLON
 ZIDOVUDINE, ZIDOVUDINE

WI MEDCL CYCLOTRON

* WISCONSIN MEDICAL CYCLOTRON LLC
 AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

WILSHIRE PHARMS INC

* WILSHIRE PHARMACEUTICALS INC
 CARISOPRODOL, CARISOPRODOL
 LAMOTRIGINE, LAMOTRIGINE
 PERPHENAZINE, PERPHENAZINE

WOCKHARDT

* WOCKHARDT AMERICAS INC
 CAPTOPRIL, CAPTOPRIL
 FAMOTIDINE, FAMOTIDINE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** W **

- * WOCKHARDT EU OPERATIONS (SWISS) AG
 ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 ACETIC ACID, ACETIC ACID, GLACIAL
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 AMOXICILLIN, AMOXICILLIN
 BROMFED-DM, BROMPHENIRAMINE MALEATE
 CARBAMAZEPINE, CARBAMAZEPINE
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
 CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
 CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CROMOLYN SODIUM, CROMOLYN SODIUM
 CYCLOSPORINE, CYCLOSPORINE
 DEXCHLORPHENIRAMINE MALEATE, DEXCHLORPHENIRAMINE MALEATE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 ERYTHROMYCIN, ERYTHROMYCIN
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 FUROSEMIDE, FUROSEMIDE
 HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 LEVETIRACETAM, LEVETIRACETAM
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LINDANE, LINDANE
 LITHIUM CITRATE, LITHIUM CITRATE
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 LORATADINE, LORATADINE (OTC)
 MEGESTROL ACETATE, MEGESTROL ACETATE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
 MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
 NYSTATIN, NYSTATIN
 OXYBUTYNYN CHLORIDE, OXYBUTYNYN CHLORIDE
 PHENYTOIN, PHENYTOIN
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 PREDNISOLONE, PREDNISOLONE
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 PROMETHAZINE PLAIN, PROMETHAZINE HYDROCHLORIDE
 PROMETHAZINE W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
 SELENIUM SULFIDE, SELENIUM SULFIDE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 VALPROIC ACID, VALPROIC ACID
- * WOCKHARDT LTD
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 AZITHROMYCIN, AZITHROMYCIN
 BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
 BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
 CEFOTAXIME SODIUM, CEFOTAXIME SODIUM
 CEFOTAXIME, CEFOTAXIME SODIUM
 CEFPROZIL, CEFPROZIL
 CEFTAZIDIME, CEFTAZIDIME
 CEFTRIAXONE, CEFTRIAXONE SODIUM
 CEFUROXIME AXETIL, CEFUROXIME AXETIL
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CLARITHROMYCIN, CLARITHROMYCIN
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 FAMOTIDINE, FAMOTIDINE (OTC)
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 FUROSEMIDE, FUROSEMIDE
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LEVETIRACETAM, LEVETIRACETAM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ******* WOCKHARDT LTD**

LEVOFLOXACIN, LEVOFLOXACIN
 LISINOPRIL, LISINOPRIL
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 NIACIN, NIACIN
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
 RISPERIDONE, RISPERIDONE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TIMOLOL MALEATE, TIMOLOL MALEATE
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
 ZONISAMIDE, ZONISAMIDE

WOCKHARDT BIO AG*** WOCKHARDT BIO AG**

OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

WOCKHARDT EU OPERATN*** WOCKHARDT EU OPERATIONS SWISS AG**

AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 DEXAMETHASONE, DEXAMETHASONE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

WOCKHARDT LTD*** WOCKHARDT LTD**

BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 ENTACAPONE, ENTACAPONE
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 LAMOTRIGINE, LAMOTRIGINE
 LANSOPRAZOLE, LANSOPRAZOLE (OTC)
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

WOCKHARDT USA*** WOCKHARDT USA INC**

GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE

*** WOCKHARDT USA LLC**

ENALAPRIL MALEATE, ENALAPRIL MALEATE
 LANSOPRAZOLE, LANSOPRAZOLE

WRASER PHARMS*** WRASER PHARMACEUTICALS LLC**

CETRAXAL, CIPROFLOXACIN HYDROCHLORIDE

WRASER PHARMS LLC*** WRASER PHARMACEUTICALS LLC**

TREZIX, ACETAMINOPHEN

WUSM CYCLOTRON*** WASHINGTON UNIV SCH MEDICINE CYCLOTRON FACILITY**

FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

WYETH PHARMS INC*** WYETH PHARMACEUTICALS INC**

CORDARONE, AMIODARONE HYDROCHLORIDE
 EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE
 PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE
 PREMARIN, ESTROGENS, CONJUGATED
 PREMPHASE 14/14, ESTROGENS, CONJUGATED

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ****

* WYETH PHARMACEUTICALS INC
 PREMPRO, ESTROGENS, CONJUGATED
 PRISTIQ, DESVENLAFAXINE SUCCINATE
 PROTONIX IV, PANTOPRAZOLE SODIUM
 PROTONIX, PANTOPRAZOLE SODIUM
 TRECATOR, ETHIONAMIDE
 ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM
 ZOSYN, PIPERACILLIN SODIUM

WYETH PHARMS PFIZER

* WYETH PHARMACEUTICALS INC WHOLLY OWNED SUB PFIZER INC
 DUAVEE, BAZEDOXIFENE ACETATE

**** X ******X GEN PHARMS**

* X GEN PHARMACEUTICALS INC
 ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
 AMPHOTERICIN B, AMPHOTERICIN B
 BACIIM, BACITRACIN
 COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
 LEVETIRACETAM, LEVETIRACETAM
 LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
 NEO-FRADIN, NEOMYCIN SULFATE
 NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
 NEOMYCIN SULFATE, NEOMYCIN SULFATE
 NYSTATIN, NYSTATIN
 POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE

X-GEN PHARMS

* X-GEN PHARMACEUTICALS INC
 PHENYTOIN SODIUM, PHENYTOIN SODIUM
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

X-GEN PHARMS INC

* X-GEN PHARMACEUTICALS INC
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 LINCOMYCIN, LINCOMYCIN HYDROCHLORIDE
 TRANEXAMIC ACID, TRANEXAMIC ACID

XELLIA PHARMS APS

* XELLIA PHARMACEUTICALS APS
 BACITRACIN, BACITRACIN
 COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
 POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

XSPIRE

* XSPIRE LLC
 NALFON, FENOPROFEN CALCIUM

XTTRIUM

* XTTRIUM LABORATORIES INC
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
 EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)

**** Y ******YAOPHARMA CO LTD**

* YAOPHARMA CO LTD
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

YUNG SHIN PHARM

* YUNG SHIN PHARMACEUTICAL INDUSTRIAL CO LTD
 CEFACLOR, CEFACLOR
 CEPHALEXIN, CEPHALEXIN
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 MELOXICAM, MELOXICAM
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**** Z ****

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** Z ******ZACH SYSTEM SPA**

* ZACH SYSTEM SPA
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE

ZACH SYSTEMS

* ZACH SYSTEMS SPA
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE

ZAMBON SPA

* ZAMBON SPA ITALY
MONUROL, FOSFOMYCIN TROMETHAMINE

ZEVACOR PHARMA INC

* ZEVACOR PHARMA INC
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

ZYDUS HLTHCARE

* ZYDUS HEALTHCARE USA LLC
LANSOPRAZOLE, LANSOPRAZOLE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

ZYDUS PHARMS USA

* ZYDUS PHARMACEUTICALS USA INC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ATENOLOL, ATENOLOL
AZATHIOPRINE, AZATHIOPRINE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BENZONATATE, BENZONATATE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL
LAMOTRIGINE, LAMOTRIGINE
MELOXICAM, MELOXICAM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN, NAPROXEN
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RAMIPRIL, RAMIPRIL
RIBAVIRIN, RIBAVIRIN
RISPERIDONE, RISPERIDONE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM
ZONISAMIDE, ZONISAMIDE

ZYDUS PHARMS USA INC

* ZYDUS PHARMACEUTICALS USA INC
ACETAZOLAMIDE, ACETAZOLAMIDE
ACYCLOVIR, ACYCLOVIR
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
ANASTROZOLE, ANASTROZOLE
BICALUTAMIDE, BICALUTAMIDE
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CARVEDILOL, CARVEDILOL
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DIPYRIDAMOLE, DIPYRIDAMOLE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ETODOLAC, ETODOLAC
ETOMIDATE, ETOMIDATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** Z ****

* ZYDUS PHARMACEUTICALS USA INC
 FINASTERIDE, FINASTERIDE
 GABAPENTIN, GABAPENTIN
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
 GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
 GLYBURIDE, GLYBURIDE
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 INDOMETHACIN, INDOMETHACIN
 IRBESARTAN, IRBESARTAN
 LAMOTRIGINE, LAMOTRIGINE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOFLOXACIN, LEVOFLOXACIN
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 METRONIDAZOLE, METRONIDAZOLE
 NATEGLINIDE, NATEGLINIDE
 OMEPRAZOLE, OMEPRAZOLE
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 POTASSIUM CITRATE, POTASSIUM CITRATE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 SIROLIMUS, SIROLIMUS
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TELMISARTAN, TELMISARTAN
 TOPIRAMATE, TOPIRAMATE
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 VORICONAZOLE, VORICONAZOLE
 ZOLMITRIPTAN, ZOLMITRIPTAN

ZYDUS WORLDWIDE

* ZYDUS WORLDWIDE DMCC
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE

APPENDIX C**UNIFORM TERMS*****DOSAGE FORMS***

AEROSOL, FOAM	OINTMENT
AEROSOL, METERED	OINTMENT, AUGMENTED
CAPSULE	PASTE
CAPSULE, DELAYED REL PELLETS	PATCH
CAPSULE, DELAYED RELEASE	PELLET
CAPSULE, EXTENDED RELEASE	POWDER
CLOTH	POWDER, EXTENDED RELEASE
CONCENTRATE	POWDER, METERED
CREAM	RING
CREAM, AUGMENTED	SHAMPOO
ELIXIR	SOLUTION
EMULSION	SOLUTION FOR SLUSH
ENEMA	SOLUTION, GEL FORMING/DROPS
FILM	SOLUTION, METERED
FILM, EXTENDED RELEASE	SOLUTION/DROPS
FOR SOLUTION	SPONGE
FOR SUSPENSION	SPRAY
FOR SUSPENSION, DELAYED RELEASE	SPRAY, METERED
FOR SUSPENSION, EXTENDED RELEASE	SUPPOSITORY
GAS	SUSPENSION
GEL	SUSPENSION, EXTENDED RELEASE
GEL, AUGMENTED	SUSPENSION/DROPS
GEL, METERED	SWAB
GRANULE	SYRUP
GRANULE, DELAYED RELEASE	SYSTEM
GUM, CHEWING	SYSTEM, EXTENDED RELEASE
IMPLANT	TABLET
INHALANT	TABLET, CHEWABLE
INJECTABLE	TABLET, COATED PARTICLES
INJECTABLE, LIPID COMPLEX	TABLET, DELAYED RELEASE
INJECTABLE, LIPOSOMAL	TABLET, EFFERVESCENT
INSERT	TABLET, EXTENDED RELEASE
INSERT, EXTENDED RELEASE	TABLET, EXTENDED RELEASE, CHEWABLE
INTRAUTERINE DEVICE	TABLET, FOR SUSPENSION
JELLY	TABLET, ORALLY DISINTEGRATING
LIQUID	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE
LOTION	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE
LOTION, AUGMENTED	TAPE
LOTION/SHAMPOO	TROCHE/LOZENGE
OIL	
OIL/DROPS	

Note: Terms comprise currently marketed products

APPENDIX C

UNIFORM TERMS

ROUTES OF ADMINISTRATION

BUCCAL	IRRIGATION
DENTAL	IV (INFUSION)
ENDOCERVICAL	N/A
ENTERAL	NASAL
FOR RX COMPOUNDING	OPHTHALMIC
IMPLANTATION	ORAL
INHALATION	ORAL-21
INJECTION	ORAL-28
INTRA-ANAL	OTIC
INTRACRANIAL	PERFUSION, CARDIAC
INTRAMUSCULAR	PERIODONTAL
INTRAOCULAR	RECTAL
INTRAPERITONEAL	SPINAL
INTRAPLEURAL	SUBCUTANEOUS
INTRATHECAL	SUBLINGUAL
INTRATRACHEAL	TOPICAL
INTRAUTERINE	TRANSDERMAL
INTRAVENOUS	TRANSMUCOSAL
INTRAVESICAL	URETHRAL
INTRAVITREAL	VAGINAL
IONTOPHORESIS	

Note: Terms comprise currently marketed products

APPENDIX C**UNIFORM TERMS*****ABBREVIATIONS***

AMP	AMPULE
AMPICIL	AMPICILLIN
APPROX	APPROXIMATELY
BOT	BOTTLE
CI	CURIE
CSR	CAROTID SINUS REFLEX
CU	CLINICAL UNITS
DIPROP	DIPROPIONATE
ELECT	ELECTROLYTE
EQ	EQUIVALENT TO
ER	EXTENDED RELEASE
GM	GRAM
HBR	HYDROBROMIDE
HCL	HYDROCHLORIDE
HR	HOUR
IM	INTRAMUSCULAR
INH	INHALATION
IU	INTERNATIONAL UNITS
IV	INTRAVENOUS
KIU	KALLIKREIN INHIBITOR UNITS
MCG	MICROGRAM
mCi	MILLICURIE
MEQ	MILLIEQUIVALENT
MG	MILLIGRAM
ML	MILLILITER
N/A	NOT APPLICABLE
PPM	PARTS PER MILLION
REL	RELEASE
SQ CM	SQUARE CENTIMETER
U	UNITS
uCi	MICROCURIE
UMOLAR	MICROMOLAR
USP	UNITED STATES PHARMACOPEIA

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM

This *Addendum* identifies drugs that qualify under the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Amendments) for periods of exclusivity and provides patent information concerning the listed drug products. During exclusivity periods, certain abbreviated new drug applications (ANDAs) and applications described in Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (505(b)(2) applications) for those drug products in some instances may not be submitted or approved as described below. Those drugs that have qualified for Orphan Drug Exclusivity pursuant to Section 527 of the FD&C Act, those drugs that have qualified for Pediatric Exclusivity pursuant to Section 505A of the FD&C Act, and those drugs that have qualified for Generating Antibiotics Incentives Now (GAIN) exclusivity pursuant to Section 505E of the FD&C Act are also included in this *Addendum*. This section is arranged in alphabetical order by active ingredient name followed by the trade name. Active ingredient headings for multiple ingredient fixed-combination drug products are arranged alphabetically. For an explanation of the codes used in the *Addendum*, see the *Patent and Exclusivity Terms* Section. The exclusivity codes are general shorthand descriptions and do not necessarily identify, with specificity, the actual scope of exclusivity. These exclusivities do not prevent the submission or approval of an application submitted pursuant to Section 505(b)(1) of the FD&C Act that would otherwise be blocked if it had been submitted pursuant to Section 505(b)(2) or 505(j), except in the case of Orphan Drug Exclusivity. Drugs that may qualify for periods of exclusivity include:

- (1) A new chemical entity, submitted in a new drug application under section 505(b) of the FD&C Act and approved after September 24, 1984. A new chemical entity is an active ingredient that contains "no active ingredient (including any ester or salt of the active ingredient)" that has been approved by FDA in any other application submitted under section 505(b) of the FD&C Act. No subsequent ANDA or 505(b)(2) application for a drug that contains the same "active ingredient (including any ester or salt of the active ingredient)" may be *submitted* for a period of *five years* from the date of approval of the original application, except that such an application may be *submitted* after *four years* if it contains a certification that a patent claiming the drug is invalid or will not be infringed by the product for which approval is sought. See sections 505(j)(5)(F)(ii) and 505(c)(3)(E)(ii) of the FD&C Act.
- (2) A new drug application approved after September 24, 1984, for a drug product containing "an active ingredient (including any ester or salt of the active ingredient)" that has been approved in an earlier new drug application and that includes reports of new clinical investigations (other than bioavailability studies). Such investigations must have been conducted or sponsored by the applicant and must have been essential to approval of the application. If these requirements are met, a subsequent ANDA or a 505(b)(2) application may not be approved for the exclusivity-protected "conditions of approval of such drug" before the expiration of *three years* from the date of approval of the original application. If a NDA or 505(b)(2) applicant has exclusivity only for a new indication or use, this exclusivity generally does not preclude the approval of an ANDA or 505(b)(2) application for indications and uses not covered by the exclusivity, assuming the

proposed drug product will be safe and effective as labeled. See sections 505(j)(5)(F)(iii) and 505(c)(3)(E)(iii) of the FD&C Act.

- (3) A supplement to a new drug application for a drug containing a previously approved "active ingredient (including any ester or salt of the active ingredient)" approved after September 24, 1984, that contains reports of new clinical investigations (other than bioavailability studies) essential to the approval of the supplement and conducted or sponsored by the applicant. A subsequent ANDA or 505(b)(2) application may not be approved for an exclusivity-protected change approved in the supplement for *three years* from the date of approval of the original supplement. See sections 505(j)(5)(F)(iv) and 505(c)(3)(E)(iv) of the FD&C Act.

The FD&C Act requires that patent information be filed with all newly submitted Section 505(b) drug applications. No NDA may be approved after September 24, 1984, without the submission of patent information to the Agency. Effective August 18, 2003, this information must be filed using Form FDA 3542a "Patent Information Submitted with the Filing of an NDA, Amendment or Supplement".

Effective August 18, 2003, upon approval of an application, patent information for purposes of listing in the Orange Book must be submitted to the Agency within 30 days of the date of approval on Form FDA 3542 "Patent Information Submitted Upon and After Approval of an NDA or Supplement." Please note that the date of approval for an NDA for which FDA recommends controls under the Controlled Substances Act is the later of the date on the approval letter for the NDA or the date of issuance of the interim final rule controlling the drug (see section 505(x)(1) and (2) of the FD&C Act). Patent information on unapproved applications or on patents beyond the scope of the FD&C Act (i.e., process or manufacturing patents) will not be published. Form FDA 3542 will be the only form used for the purposes of this publication.

The patents that FDA regards as covered by the statutory provisions for submission of patent information are: patents that claim the active ingredient(s); drug product patents, which include formulation/composition patents; method-of-use patents that claim one or more approved methods of using the approved drug product; and certain other patents as detailed on Form FDA 3542. This information, as provided by the sponsor on Form FDA 3542, will be published as described above. As of December 5, 2016, an NDA holder submitting information on a patent that claims both the drug substance and the drug product (and is eligible for listing on either basis) is required only to specify that the patent claims either the drug substance or the drug product.

A requirement for submission of patent information to FDA for certain old antibiotics became effective October 7, 2008 under section 4(b)(1) of the QI Program Supplemental Funding Act (Public Law 110-379) (QI Act).

Upon approval, patent numbers and expiration dates, in addition to certain other information on appropriate patents claiming drug products that are the subject of approved applications, will be published daily in the [Electronic Orange Book](#). The Addendum lists patent and exclusivity information up to January of the Edition year. The monthly Cumulative Supplements to the annual edition list patent and exclusivity information changes since the Annual Edition Addendum. Since all parts of this publication are subject to changes, additions, or deletions, the Electronic

Orange Book, updated daily, should be consulted for the most recent patent and exclusivity information.

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE - ZIAGEN</u>						
N 020977	001 6294540	May 14, 2018	DS DP U-65		D-147	Mar 23, 2018
<u>ABACAVIR SULFATE - ZIAGEN</u>						
N 020978	001 6294540 6641843	May 14, 2018 Feb 04, 2019	DS DP U-65 DP		D-147	Mar 23, 2018
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEO</u>						
N 205551	001 5905082*PED 6294540 6294540*PED 6417191*PED 8129385 9242986	Nov 18, 2016 May 14, 2018 Nov 14, 2018 Sep 28, 2016 Oct 05, 2027 Dec 08, 2029	DS DP U-1572 DS DP DS DP		NCE	Aug 12, 2018
<u>ABACAVIR SULFATE; LAMIVUDINE - ABACAVIR SULFATE AND LAMIVUDINE</u>						
A 079246	001				PC	Mar 28, 2017
<u>ABACAVIR SULFATE; LAMIVUDINE - EPZICOM</u>						
N 021652	001 6294540 6417191*PED	May 14, 2018 Sep 28, 2016	DS DP U-257			
<u>ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE - TRIZIVIR</u>						
N 021205	001 6294540	May 14, 2018	DS DP U-65			
<u>ABARELIX - PLENAXIS</u>						
N 021320	001 5968895 6180608 6699833	Dec 11, 2016 Dec 11, 2016 Dec 11, 2016	DP DP U-549 DP			
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N 202379	001 5604213 5604213 8822438 8822438	Dec 13, 2016 Dec 13, 2016 Aug 24, 2027 Aug 24, 2027	DS DP U-1126 DS DP U-1314 U-1579 U-1580			
<u>ACETAMINOPHEN - OFIRMEV</u>						
N 022450	001 6028222 6028222*PED 6992218 6992218*PED 9399012 9399012*PED	Aug 05, 2017 Feb 05, 2018 Jun 06, 2021 Dec 06, 2021 Sep 11, 2031 Mar 11, 2032	DP DP U-1882			
<u>ACETAMINOPHEN; ASPIRIN; CAFFEINE - EXCEDRIN (MIGRAINE)</u>						
N 020802	001 5972916	Jul 14, 2017	U-296			
<u>ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR</u>						
N 204031	001 6488962 7976870 8372432 8377453 8394408 8597681 8658631 8668929 8741885 8980319 8992975 9050335 9468636	Jun 20, 2020 Jun 01, 2027 Mar 11, 2029 Nov 19, 2029 Mar 11, 2029 Dec 21, 2030 May 16, 2032 Mar 11, 2029 May 16, 2032 Dec 21, 2030 May 16, 2032 May 16, 2032 May 16, 2032	DP U-1498 DP U-1499 DP U-1499 DP DP DP U-1499 DP U-1499 DP DP DP U-1499		NP	Mar 11, 2017
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N 021539	001 8148356 8399445 8653061 8722738 9327028	May 21, 2026 Aug 24, 2025 Aug 24, 2025 Apr 06, 2032 Jul 21, 2031	DP U-1373 U-1373 U-1373 U-1839			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 001	8747894	May 08, 2032	DP U-1373			
	9427421	May 08, 2032	DP			
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 002	8747894	May 08, 2032	DP U-1373			
	9427421	May 08, 2032	DP			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	6681768	Aug 07, 2022	DP		NCE	Jul 23, 2017
	6750226	Sep 05, 2020	DS DP U-1264			
	7078412	Jul 16, 2020	DS DP U-1263			
	8051851	Apr 22, 2027	DP			
	9056100	Jul 07, 2020	DP U-1263			
	9333195	Jul 07, 2020	DP U-1263			
<u>ACYCLOVIR - SITAVIG</u>						
N 203791 001	8592434	Jun 16, 2030	DP U-1460			
	8747896	Jun 03, 2027	DP U-1460			
	8791127	Mar 23, 2027	DP U-1460			
<u>ACYCLOVIR; HYDROCORTISONE - XERESE</u>						
N 022436 001	6514980	Jul 24, 2018	DP U-1006		NPP	Jan 22, 2017
	6514980	Jul 24, 2018	DP U-1484			
	7223387	Nov 13, 2022	DP U-1006			
	7223387	Nov 13, 2022	DP U-1484			
	RE39264	Aug 02, 2016	DP U-1006			
	RE39264	Aug 02, 2016	DP U-1484			
<u>ADAPALENE - DIFFERIN</u>						
N 020380 002					RTO	Jul 08, 2019
<u>ADAPALENE - DIFFERIN</u>						
N 021753 001	7579377	Feb 23, 2025	U-818			
	7737181	Aug 29, 2024	DP			
	7834060	Mar 12, 2023	U-1078			
	7838558	Mar 12, 2023	DP			
	7868044	Mar 12, 2023	U-1078			
	8703820	Mar 12, 2023	U-1078			
<u>ADAPALENE - DIFFERIN</u>						
N 022502 001	7998467	May 31, 2028	DP U-1078			
	8435502	Sep 15, 2026	DP U-1078			
	8709392	Sep 15, 2026	DP U-1078			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N 022320 001	7820186	Nov 23, 2025	DP			
	7964202	Sep 01, 2024	DP U-1078			
	8071644	Jul 18, 2027	DP U-1078			
	8080537	Jul 18, 2027	U-1078			
	8105618	Dec 23, 2022	U-1078			
	8129362	Jul 18, 2027	U-1078			
	8241649	Dec 23, 2022	DP			
	8445543	Jul 12, 2027	U-1078			
	8809305	Dec 23, 2022	U-1078			
	8936800	Dec 23, 2022	DP U-1078			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE</u>						
N 207917 001	8445543	Jul 12, 2027	U-1078		NP	Jul 15, 2018
	8703820	Mar 12, 2023	U-1078			
	8729127	Mar 12, 2023	U-1078			
	8785420	Dec 23, 2022	U-1078			
	8809305	Dec 23, 2022	U-1078			
	8936800	Dec 23, 2022	DP U-1078			
	9381179	Mar 12, 2023	U-1078			
	9387187	Mar 12, 2023	U-1078			
<u>ADEFOVIR DIPIVOXIL - HEPSERA</u>						
N 021449 001	6451340	Jul 23, 2018	DS DP U-470			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 001	6251912	Jul 29, 2018	DS DP U-1067		NCE	Jul 12, 2018
	8426586	Oct 10, 2029	DS		ODE	Jul 12, 2020
	8545884	Dec 19, 2029	DP		ODE	Apr 15, 2023
	RE43431	Jan 22, 2022	DS			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 002	6251912	Jul 29, 2018	DS DP U-1067		NCE	Jul 12, 2018
	8426586	Oct 10, 2029	DS		ODE	Jul 12, 2020
	8545884	Dec 19, 2029	DP		ODE	Apr 15, 2023
	RE43431	Jan 22, 2022	DS			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 003	6251912	Jul 29, 2018	DS DP U-1067		I-730	Apr 15, 2019
	8426586	Oct 10, 2029	DS		NCE	Jul 12, 2018
	8545884	Dec 19, 2029	DP		ODE	Jul 12, 2020
	RE43431	Jan 22, 2022	DS		ODE	Apr 15, 2023
<u>ALBUMIN HUMAN - OPTISON</u>						
N 020899 001	6723303	Apr 20, 2021	DP			
<u>ALBUTEROL SULFATE - PROVENTIL-HFA</u>						
N 020503 001	6006745	Dec 28, 2016	DP			
<u>ALBUTEROL SULFATE - ACCUNEE</u>						
N 020949 001	6702997	Dec 28, 2021		U-558		
<u>ALBUTEROL SULFATE - ACCUNEE</u>						
N 020949 002	6702997	Dec 28, 2021		U-558		
<u>ALBUTEROL SULFATE - VENTOLIN HFA</u>						
N 020983 001	6161724	Jan 16, 2018	DP			
	6170717	Dec 23, 2017	DP			
	6315173	Dec 23, 2017	DP			
	6431168	Jun 08, 2018	DP			
	6435372	Jan 16, 2018	DP			
	6510969	Dec 23, 2017	DP			
	6558651	Dec 19, 2016	DP	U-716		
	6743413	Jun 01, 2021		U-716		
	6938796	Jan 16, 2018	DP			
	6966467	Dec 23, 2017	DP			
	6997349	Jan 16, 2018	DP			
	7107986	Jun 08, 2018	DP			
	7143908	Jan 16, 2018	DP			
	7350676	Aug 24, 2018	DP			
	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
	7832351	Jun 19, 2023	DP			
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N 021457 001	6446627	Dec 18, 2017	DP			
	7105152	Sep 12, 2023	DP			
	7566445	Jun 04, 2017	DP			
	8132712	Sep 07, 2028	DP			
	8834849	Jun 04, 2017	DP			
	9463289	May 18, 2031	DP			
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	6446627	Dec 18, 2017	DP		NP	Mar 12, 2018
	6701917	Jun 23, 2021	DP		NPP	Apr 28, 2019
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - DUONEB</u>						
N 020950	001 6632842	Dec 28, 2021	U-532			
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT</u>						
N 021747	001 5964416	Oct 04, 2016	DP			
	6149054	Dec 19, 2016	DP			
	6176442	Oct 04, 2016	DP			
	6453795	Dec 05, 2016	DP			
	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6977042	Aug 28, 2018	DP			
	6988496	Feb 23, 2020	DP			
	7104470	Oct 04, 2016	DP			
	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP			
	7802568	Feb 26, 2019	DP			
	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	7988001	Aug 04, 2021	DP			
	8733341	Dec 16, 2029	DP			
	9027967	Mar 31, 2027	DP			
<u>ALCAFTADINE - LASTACFT</u>						
N 022134	001 8664215	Dec 23, 2027	U-1493			
<u>ALCOHOL; CHLORHEXIDINE GLUCONATE - AVAGARD</u>						
N 021074	001 7081246	Aug 03, 2016	DP			
<u>ALECTINIB HYDROCHLORIDE - ALECENSA</u>						
N 208434	001 9126931	May 29, 2031	DS		NCE	Dec 11, 2020
	9365514	Mar 04, 2032	DP		ODE	Dec 11, 2022
	9440922	Jun 09, 2030	DP			
<u>ALENDRONATE SODIUM - FOSAMAX</u>						
N 021575	001 5994329	Jul 17, 2018			Y	
	6015801	Jul 17, 2018			Y	
	6225294	Jul 17, 2018			Y	
<u>ALENDRONATE SODIUM - BINOSTO</u>						
N 202344	001 7488496	Aug 11, 2023	DS DP			
	7964212	Mar 06, 2023	DS DP			
<u>ALENDRONATE SODIUM; CHOLECALCIFEROL - FOSAMAX PLUS D</u>						
N 021762	001 5994329	Jul 17, 2018	U-647		Y	
<u>ALFUZOSIN HYDROCHLORIDE - UROXATRAL</u>						
N 021287	001 6149940	Aug 22, 2017				
<u>ALISKIREN HEMIFUMARATE - TEKTURN</u>						
N 021985	001 5559111	Jul 21, 2018	DS DP U-3			
	8617595	Feb 19, 2026	DP			
<u>ALISKIREN HEMIFUMARATE - TEKTURN</u>						
N 021985	002 5559111	Jul 21, 2018	DS DP U-3			
	8617595	Feb 19, 2026	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545	001 5559111	Jul 21, 2018	DS DP U-3			
	8613949	Dec 21, 2029	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545	002 5559111	Jul 21, 2018	DS DP U-3			
	8613949	Dec 21, 2029	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545	003 5559111	Jul 21, 2018	DS DP U-3			
	8613949	Dec 21, 2029	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 004	5559111	Jul 21, 2018	DS DP U-3			
	8613949	Dec 21, 2029	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 001	5559111	Jul 21, 2018	DS DP U-3			
	8183295	May 16, 2023	DP			
	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 002	5559111	Jul 21, 2018	DS DP U-3			
	8183295	May 16, 2023	DP			
	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 003	5559111	Jul 21, 2018	DS DP U-3			
	8183295	May 16, 2023	DP			
	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 004	5559111	Jul 21, 2018	DS DP U-3			
	8183295	May 16, 2023	DP			
	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 005	5559111	Jul 21, 2018	DS DP U-3			
	8183295	May 16, 2023	DP			
	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT</u>						
N 022107 001	5559111	Jul 21, 2018	DS DP U-3			
	8618172	Jul 13, 2028	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT</u>						
N 022107 002	5559111	Jul 21, 2018	DS DP U-3			
	8618172	Jul 13, 2028	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT</u>						
N 022107 003	5559111	Jul 21, 2018	DS DP U-3			
	8618172	Jul 13, 2028	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT</u>						
N 022107 004	5559111	Jul 21, 2018	DS DP U-3			
	8618172	Jul 13, 2028	DP			
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N 022217 001	5559111	Jul 21, 2018	DS DP U-3			
	8168616	Jul 03, 2026	DP			
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N 022217 002	5559111	Jul 21, 2018	DS DP U-3			
	8168616	Jul 03, 2026	DP			
<u>ALITRETINOIN - PANRETIN</u>						
N 020886 001	5932622	Aug 03, 2016			U-562	
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 001	6303640	Aug 09, 2016			U-1332	
	6303661	Apr 24, 2017			U-1333	M-177 Apr 05, 2019
	6890898	Feb 02, 2019			U-1335	NCE Jan 25, 2018
	7078381	Feb 02, 2019			U-1335	
	7459428	Feb 02, 2019			U-1336	
	7807689	Jun 27, 2028	DS DP		U-1337	
	8173663	Mar 15, 2025			U-1338	
	8288539	Mar 15, 2025	DS			
	8697125	Jan 22, 2029			DP	
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002	6303640	Aug 09, 2016			U-1332	M-177 Apr 05, 2019
	6303661	Apr 24, 2017			U-1333	NCE Jan 25, 2018

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002	7078381	Feb 02, 2019		U-1335		
	7459428	Feb 02, 2019		U-1336		
	7807689	Jun 27, 2028	DS DP	U-1337		
	8173663	Mar 15, 2025		U-1338		
	8288539	Mar 15, 2025	DS			
	8697125	Jan 22, 2029		DP		
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 003	6303640	Aug 09, 2016		U-1332	M-177	Apr 05, 2019
	6303661	Apr 24, 2017		U-1333	NCE	Jan 25, 2018
	6890898	Feb 02, 2019		U-1335		
	7078381	Feb 02, 2019		U-1335		
	7459428	Feb 02, 2019		U-1336		
	7807689	Jun 27, 2028	DS DP	U-1337		
	8173663	Mar 15, 2025		U-1338		
	8288539	Mar 15, 2025	DS			
	8697125	Jan 22, 2029		DP		
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 001	6303640	Aug 09, 2016		U-1332	M-177	Apr 05, 2019
	6303661	Apr 24, 2017		U-1333	NCE	Jan 25, 2018
	6890898	Feb 02, 2019		U-1335		
	7078381	Feb 02, 2019		U-1335		
	7459428	Feb 02, 2019		U-1336		
	7807689	Jun 27, 2028	DS DP	U-1337		
	8173663	Mar 15, 2025		U-1338		
	8288539	Mar 15, 2025	DS			
	8900638	May 24, 2029		DP		
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 002	6303640	Aug 09, 2016		U-1332	M-177	Apr 05, 2019
	6303661	Apr 24, 2017		U-1333	NCE	Jan 25, 2018
	6890898	Feb 02, 2019		U-1335		
	7078381	Feb 02, 2019		U-1335		
	7459428	Feb 02, 2019		U-1336		
	7807689	Jun 27, 2028	DS DP	U-1337		
	8173663	Mar 15, 2025		U-1338		
	8288539	Mar 15, 2025	DS			
	8900638	May 24, 2029		DP		
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 001	6303640	Aug 09, 2016		U-1332	M-177	Apr 05, 2019
	6303661	Apr 24, 2017		U-1333	NCE	Jan 25, 2018
	6890898	Feb 02, 2019		U-1335		
	7078381	Feb 02, 2019		U-1335		
	7459428	Feb 02, 2019		U-1336		
	7807689	Jun 27, 2028	DS DP	U-1337		
	8173663	Mar 15, 2025		U-1338		
	8288539	Mar 15, 2025	DS			
	8637079	Jun 04, 2029		DP		
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 002	6303640	Aug 09, 2016		U-1332	M-177	Apr 05, 2019
	6303661	Apr 24, 2017		U-1333	NCE	Jan 25, 2018
	6890898	Feb 02, 2019		U-1335		
	7078381	Feb 02, 2019		U-1335		
	7459428	Feb 02, 2019		U-1336		
	7807689	Jun 27, 2028	DS DP	U-1337		
	8173663	Mar 15, 2025		U-1338		
	8288539	Mar 15, 2025	DS			
	8637079	Jun 04, 2029		DP		
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 003	6303640	Aug 09, 2016		U-1332	M-177	Apr 05, 2019
	6303661	Apr 24, 2017		U-1333	NCE	Jan 25, 2018
	6890898	Feb 02, 2019		U-1335		
	7078381	Feb 02, 2019		U-1335		
	7459428	Feb 02, 2019		U-1336		
	7807689	Jun 27, 2028	DS DP	U-1337		
	8173663	Mar 15, 2025		U-1338		
	8288539	Mar 15, 2025	DS			
	8637079	Jun 04, 2029		DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 003	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8637079	Jun 04, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 004	6303640	Aug 09, 2016	U-1332		M-177	Apr 05, 2019
	6303661	Apr 24, 2017	U-1333		NCE	Jan 25, 2018
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8637079	Jun 04, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005	6303640	Aug 09, 2016	U-1332		M-177	Apr 05, 2019
	6303661	Apr 24, 2017	U-1333		NCE	Jan 25, 2018
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8637079	Jun 04, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 006	6303640	Aug 09, 2016	U-1332		M-177	Apr 05, 2019
	6303661	Apr 24, 2017	U-1333		NCE	Jan 25, 2018
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8637079	Jun 04, 2029	DP			
<u>ALPRAZOLAM - NIRAVAM</u>						
N 021726 001	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>ALPRAZOLAM - NIRAVAM</u>						
N 021726 002	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>ALPRAZOLAM - NIRAVAM</u>						
N 021726 003	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>ALPRAZOLAM - NIRAVAM</u>						
N 021726 004	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>ALVIMOPAN - ENTEREG</u>						
N 021775 001	6469030	Nov 29, 2020	U-879		M-128	Oct 18, 2016
	8112290	Jul 31, 2030	U-1443			
	8645160	Jun 18, 2029	U-1485			
	8946262	Feb 12, 2030	U-1655			
<u>AMBRISANTAN - LETAIRIS</u>						
N 022081 001	8377933	Dec 11, 2027	U-1754		I-716	Oct 02, 2018
	9474752	Dec 11, 2027	U-1754			
	RE42462	Jul 29, 2018	DS			
<u>AMBRISANTAN - LETAIRIS</u>						
N 022081 002	8377933	Dec 11, 2027	U-1754		I-716	Oct 02, 2018
	9474752	Dec 11, 2027	U-1754			
	RE42462	Jul 29, 2018	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMIFOSTINE - ETHYOL</u>						
N 020221	001	5994409	Dec 08, 2017	U-305		
<u>AMIFOSTINE - ETHYOL</u>						
N 020221	002	5994409	Dec 08, 2017	U-305		
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N 020965	001	5954703	Oct 31, 2017	U-289		
		6709446	May 01, 2018	U-289		
		7723910	Jun 17, 2019	U-289		
		8216289	May 01, 2018	U-289		
		8758418	May 01, 2018	U-289		
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - AMELUZ</u>						
N 208081	001	6559183	Nov 12, 2019	DP U-804	NP	May 10, 2019
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
N 022325	001	6869939	May 04, 2022	DP		
		7635773	Mar 13, 2029	DP		
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
N 022325	002	6869939	May 04, 2022	DP		
		7635773	Mar 13, 2029	DP		
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
N 022325	003	6869939	May 04, 2022	DP		
		7635773	Mar 13, 2029	DP		
<u>AMLODIPINE BESYLATE - AMLODIPINE BESYLATE</u>						
N 022026	001	6828339	Nov 20, 2022	DS		
<u>AMLODIPINE BESYLATE - AMLODIPINE BESYLATE</u>						
N 022026	002	6828339	Nov 20, 2022	DS		
<u>AMLODIPINE BESYLATE - AMLODIPINE BESYLATE</u>						
N 022026	003	6828339	Nov 20, 2022	DS		
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540	001	5969156	Jul 08, 2016	DS		
		6455574	Aug 11, 2018	U-552		
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540	002	5969156	Jul 08, 2016	DS		
		6455574	Aug 11, 2018	U-552		
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540	003	5969156	Jul 08, 2016	DS		
		6455574	Aug 11, 2018	U-552		
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540	004	5969156	Jul 08, 2016	DS		
		6455574	Aug 11, 2018	U-552		
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540	005	5969156	Jul 08, 2016	DS		
		6455574	Aug 11, 2018	U-552		
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540	006	5969156	Jul 08, 2016	DS		
		6455574	Aug 11, 2018	U-552		
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540	007	5969156	Jul 08, 2016	DS		
		6455574	Aug 11, 2018	U-552		
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540	008	5969156	Jul 08, 2016	DS		
		6455574	Aug 11, 2018	U-552		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540	009	5969156 6455574	Jul 08, 2016 Aug 11, 2018	DS U-552		
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540	010	5969156 6455574	Jul 08, 2016 Aug 11, 2018	DS U-552		
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540	011	5969156 6455574	Jul 08, 2016 Aug 11, 2018	DS U-552		
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N 020364	002	6162802	Dec 19, 2017	U-367		
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N 020364	003	6162802	Dec 19, 2017	U-367		
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N 020364	004	6162802	Dec 19, 2017	U-367		
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N 020364	005	6162802	Dec 19, 2017	U-367		
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N 020364	006	6162802	Dec 19, 2017	DS DP U-185		
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N 020364	007	6162802	Dec 19, 2017	DS DP U-185		
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314	001	6294197 8101599 8475839 8475839*PED	Jun 18, 2017 May 16, 2023 May 16, 2023 Nov 16, 2023	DP U-3 DP DP		
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314	002	6294197 8101599 8475839 8475839*PED	Jun 18, 2017 May 16, 2023 May 16, 2023 Nov 16, 2023	DP U-3 DP DP		
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314	003	6294197 8101599 8475839 8475839*PED	Jun 18, 2017 May 16, 2023 May 16, 2023 Nov 16, 2023	DP U-3 DP DP		
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314	004	6294197 8101599 8475839 8475839*PED	Jun 18, 2017 May 16, 2023 May 16, 2023 Nov 16, 2023	DP U-3 DP DP		
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314	005	6294197 8101599 8475839 8475839*PED	Jun 18, 2017 May 16, 2023 May 16, 2023 Nov 16, 2023	DP U-3 DP DP		
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003	001	6696481 7846961	Apr 15, 2023 Oct 05, 2029	DS DP U-3 DS DP U-3		
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003	002	6696481 7846961	Apr 15, 2023 Oct 05, 2029	DS DP U-3 DS DP U-3		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003	003	6696481	Apr 15, 2023	DS DP U-3		
		7846961	Oct 05, 2029	DS DP U-3		
<u>AMLODIPINE BESYLATE; VALSARTAN - EXFORGE</u>						
N 021990	002	6294197	Jun 18, 2017	DP U-3		
		6395728	Jul 08, 2019	DP		
<u>AMLODIPINE BESYLATE; VALSARTAN - EXFORGE</u>						
N 021990	003	6294197	Jun 18, 2017	DP U-3		
		6395728	Jul 08, 2019	DP		
<u>AMLODIPINE BESYLATE; VALSARTAN - EXFORGE</u>						
N 021990	004	6294197	Jun 18, 2017	DP U-3		
		6395728	Jul 08, 2019	DP		
<u>AMLODIPINE BESYLATE; VALSARTAN - EXFORGE</u>						
N 021990	005	6294197	Jun 18, 2017	DP U-3		
		6395728	Jul 08, 2019	DP		
<u>AMOXICILLIN - MOXATAG</u>						
N 050813	001	6544555	Oct 13, 2020	DS DP U-897		
		6669948	Oct 13, 2020	DS DP U-897		
		6723341	Oct 13, 2020	DS DP U-897		
		8299052	May 07, 2027	U-1304		
		8357394	Dec 08, 2026	DP		
		8778924	Dec 08, 2026	DS DP U-897		
<u>AMOXICILLIN; CLAVULANATE POTASSIUM - AUGMENTIN XR</u>						
N 050785	001	6746692	Apr 04, 2020	DP		
		6783773	Apr 04, 2020	DP		
		6878386	Apr 04, 2020	U-926		
		7217430	Apr 04, 2020	DP U-926		
		7250176	Apr 04, 2020	U-926		
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326	001	8709491	Jun 28, 2032	DP		
		8840924	Apr 09, 2026	DP		
		9017731	Jun 28, 2032	DP		
		9265737	Jun 28, 2032	DP		
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326	002	8709491	Jun 28, 2032	DP		
		8840924	Apr 09, 2026	DP		
		9017731	Jun 28, 2032	DP		
		9265737	Jun 28, 2032	DP		
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326	003	8709491	Jun 28, 2032	DP		
		8840924	Apr 09, 2026	DP		
		9017731	Jun 28, 2032	DP		
		9265737	Jun 28, 2032	DP		
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326	004	8709491	Jun 28, 2032	DP		
		8840924	Apr 09, 2026	DP		
		9017731	Jun 28, 2032	DP		
		9265737	Jun 28, 2032	DP		
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326	005	8709491	Jun 28, 2032	DP		
		8840924	Apr 09, 2026	DP		
		9017731	Jun 28, 2032	DP		
		9265737	Jun 28, 2032	DP		
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326	006	8709491	Jun 28, 2032	DP		
		8840924	Apr 09, 2026	DP		
		9017731	Jun 28, 2032	DP		
		9265737	Jun 28, 2032	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMPHETAMINE - DYANAVEL XR</u>						
N 208147	001	8062667				
		Mar 29, 2029	DP		NP	Oct 19, 2018
		8597684		DP		
		Mar 15, 2027	DP			
		8747902		DP		
		Mar 15, 2027	DP			
		8883217		DP		
		Mar 15, 2027	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 10</u>						
N 011522	007	6384020				
		Jul 06, 2020				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 20</u>						
N 011522	008	6384020				
		Jul 06, 2020				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 5</u>						
N 011522	009	6384020				
		Jul 06, 2020				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 30</u>						
N 011522	010	6384020				
		Jul 06, 2020				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 7.5</u>						
N 011522	011	6384020				
		Jul 06, 2020				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 12.5</u>						
N 011522	012	6384020				
		Jul 06, 2020				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 15</u>						
N 011522	013	6384020				
		Jul 06, 2020				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 10</u>						
N 021303	001	6322819				
		Oct 21, 2018				
		6605300				
		Oct 21, 2018				
		RE41148		DP		
		Oct 21, 2018				
		RE42096		DP		
		Oct 21, 2018				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 20</u>						
N 021303	002	6322819				
		Oct 21, 2018				
		6605300				
		Oct 21, 2018				
		RE41148		DP		
		Oct 21, 2018				
		RE42096		DP		
		Oct 21, 2018				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 30</u>						
N 021303	003	6322819				
		Oct 21, 2018				
		6605300				
		Oct 21, 2018				
		RE41148		DP		
		Oct 21, 2018				
		RE42096		DP		
		Oct 21, 2018				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 25</u>						
N 021303	004	6322819				
		Oct 21, 2018				
		6605300				
		Oct 21, 2018				
		RE41148		DP		
		Oct 21, 2018				
		RE42096		DP		
		Oct 21, 2018				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 5</u>						
N 021303	005	6322819				
		Oct 21, 2018				
		6605300				
		Oct 21, 2018				
		RE41148		DP		
		Oct 21, 2018				
		RE42096		DP		
		Oct 21, 2018				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 15</u>						
N 021303	006	6322819				
		Oct 21, 2018				
		6605300				
		Oct 21, 2018				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 15</u>						
N 021303 006	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>AMPHOTERICIN B - ABELCET</u>						
N 050724 001	6406713	Jun 18, 2019	DS			
<u>AMPHOTERICIN B - AMBISOME</u>						
N 050740 001	5965156	Oct 12, 2016	DP U-922			
<u>AMPRENAVIR - AGENERASE</u>						
N 021007 001	6730679	Nov 11, 2017	DP			
<u>AMPRENAVIR - AGENERASE</u>						
N 021007 002	6730679	Nov 11, 2017	DP			
<u>ANIDULAFUNGIN - ERAXIS</u>						
N 021632 001	5965525	Feb 17, 2020	DS DP U-540			
	6960564	Apr 12, 2021	DP U-540			
	7709444	Apr 12, 2021	DP U-540			
<u>ANIDULAFUNGIN - ERAXIS</u>						
N 021632 002	5965525	Feb 17, 2020	DS DP U-540			
	6960564	Apr 12, 2021	DP U-540			
	7709444	Apr 12, 2021	DP U-540			
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	6413980	Dec 22, 2019	DS DP U-1200		I-661	Aug 21, 2017
	6413980	Dec 22, 2019	DS DP U-1301		I-681	Mar 03, 2017
	6413980	Dec 22, 2019	DS DP U-1302		I-690	Aug 21, 2017
	6413980	Dec 22, 2019	DS DP U-1501		I-691	Aug 21, 2017
	6967208	Feb 03, 2023	DS DP U-1167		NCE	Dec 28, 2017
	6967208	Feb 03, 2023	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1301			
	6967208	Feb 03, 2023	DS DP U-1302			
	6967208	Feb 03, 2023	DS DP U-1323			
	6967208	Feb 03, 2023	DS DP U-1501			
	6967208	Feb 03, 2023	DS DP U-1502			
	6967208	Feb 03, 2023	DS DP U-1729			
	6967208	Feb 03, 2023	DS DP U-1730			
	9326945	Feb 24, 2031	DP			
<u>APIXABAN - ELIQUIS</u>						
N 202155 002	6413980	Dec 22, 2019	DS DP U-1200		I-661	Aug 21, 2017
	6413980	Dec 22, 2019	DS DP U-1301		I-690	Aug 21, 2017
	6413980	Dec 22, 2019	DS DP U-1302		I-691	Aug 21, 2017
	6967208	Feb 03, 2023	DS DP U-1200		NCE	Dec 28, 2017
	6967208	Feb 03, 2023	DS DP U-1301			
	6967208	Feb 03, 2023	DS DP U-1302			
	6967208	Feb 03, 2023	DS DP U-1323			
	9326945	Feb 24, 2031	DP			
<u>APREMILAST - OTEZLA</u>						
N 205437 001	6020358	Oct 30, 2018	DS DP U-1504		I-694	Sep 23, 2017
	6962940	Mar 19, 2023	U-1504		NCE	Mar 21, 2019
	7208516	Mar 19, 2023	U-1505			
	7427638	Nov 17, 2024	DS DP			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7893101	Dec 09, 2023	DS DP			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8802717	Mar 19, 2023	U-1561			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
<u>APREMILAST - OTEZLA</u>						
N 205437 002	6020358	Oct 30, 2018	DS DP U-1504		I-694	Sep 23, 2017
	6962940	Mar 19, 2023	U-1504		NCE	Mar 21, 2019

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>APREMILAST - OTEZLA</u>						
N 205437 002	7208516	Mar 19, 2023	U-1505			
	7427638	Nov 17, 2024	DS DP			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7893101	Dec 09, 2023	DS DP			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8802717	Mar 19, 2023	U-1561			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
<u>APREMILAST - OTEZLA</u>						
N 205437 003	6020358	Oct 30, 2018	DS DP U-1504		I-694	Sep 23, 2017
	6962940	Mar 19, 2023	U-1504		NCE	Mar 21, 2019
	7208516	Mar 19, 2023	U-1505			
	7427638	Nov 17, 2024	DS DP			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7893101	Dec 09, 2023	DS DP			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8802717	Mar 19, 2023	U-1561			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
<u>APREPITANT - EMEND</u>						
N 021549 001	6096742	Jul 01, 2018	DS DP U-745		NPP	Aug 28, 2018
	6096742	Jul 01, 2018	DS DP U-1743			
	6096742	Jul 01, 2018	DS DP U-1744			
	8258132	Sep 26, 2027	DP U-901			
	8258132	Sep 26, 2027	DP U-1743			
<u>APREPITANT - EMEND</u>						
N 021549 002	6096742	Jul 01, 2018	DS DP U-745		NPP	Aug 28, 2018
	6096742	Jul 01, 2018	DS DP U-1743			
	6096742	Jul 01, 2018	DS DP U-1744			
	8258132	Sep 26, 2027	DP U-901			
	8258132	Sep 26, 2027	DP U-1743			
<u>APREPITANT - EMEND</u>						
N 021549 003	6096742	Jul 01, 2018	DS DP U-745		NPP	Aug 28, 2018
	6096742	Jul 01, 2018	DS DP U-1743			
	6096742	Jul 01, 2018	DS DP U-1744			
	8258132	Sep 26, 2027	DP U-901			
	8258132	Sep 26, 2027	DP U-1743			
<u>APREPITANT - EMEND</u>						
N 207865 001	6096742	Jul 01, 2018	DS DP U-1916		NPP	Aug 28, 2018
	8258132	Sep 26, 2027	DP U-1916			
<u>ARFORMOTEROL TARTRATE - BROVANA</u>						
N 021912 001	6040344	Nov 12, 2016	DS			
	6472563	Nov 09, 2021	DS			
	6667344	Jun 22, 2021	DP			
	6720453	Nov 09, 2021	DS			
	6814953	Jun 22, 2021	U-793			
	7145036	Nov 09, 2021	DS			
	7348362	Jun 22, 2021	DP U-793			
	7462645	Jun 22, 2021	U-793			
	7465756	Jun 22, 2021	DP			
	7473710	Jun 22, 2021	U-793			
	7541385	Jun 22, 2021	U-793			
	8110706	Nov 09, 2021	DP			
<u>ARGATROBAN - ARGATROBAN IN SODIUM CHLORIDE</u>						
N 022434 001	7589106	Sep 26, 2027	DP U-1163			
	7687516	Sep 26, 2027	DP U-1164			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 001	7053092	Jan 28, 2022		U-839	I-700	Dec 12, 2017
	8017615	Jun 16, 2024	DP		M-137	Jun 09, 2017
	8017615*PED	Dec 16, 2024			ODE	Dec 12, 2021
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027		U-1529		
	9089567	Jan 28, 2022		U-543		
	9125939	Jul 28, 2026		U-1749		
	9359302	Sep 25, 2022	DS DP	U-1859		
	9387182	Dec 25, 2023		U-1529		
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 002	7053092	Jan 28, 2022		U-839	I-700	Dec 12, 2017
	8017615	Jun 16, 2024	DP		M-137	Jun 09, 2017
	8017615*PED	Dec 16, 2024			ODE	Dec 12, 2021
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027		U-1529		
	9089567	Jan 28, 2022		U-543		
	9125939	Jul 28, 2026		U-1749		
	9359302	Sep 25, 2022	DS DP	U-1859		
	9387182	Dec 25, 2023		U-1529		
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 003	7053092	Jan 28, 2022		U-839	I-700	Dec 12, 2017
	8017615	Jun 16, 2024	DP		M-137	Jun 09, 2017
	8017615*PED	Dec 16, 2024			ODE	Dec 12, 2021
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027		U-1529		
	9089567	Jan 28, 2022		U-543		
	9125939	Jul 28, 2026		U-1749		
	9359302	Sep 25, 2022	DS DP	U-1859		
	9387182	Dec 25, 2023		U-1529		
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 004	7053092	Jan 28, 2022		U-839	I-700	Dec 12, 2017
	8017615	Jun 16, 2024	DP		M-137	Jun 09, 2017
	8017615*PED	Dec 16, 2024			ODE	Dec 12, 2021
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027		U-1529		
	9089567	Jan 28, 2022		U-543		
	9125939	Jul 28, 2026		U-1749		
	9359302	Sep 25, 2022	DS DP	U-1859		
	9387182	Dec 25, 2023		U-1529		
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 005	7053092	Jan 28, 2022		U-839	I-700	Dec 12, 2017
	8017615	Jun 16, 2024	DP		M-137	Jun 09, 2017
	8017615*PED	Dec 16, 2024			ODE	Dec 12, 2021
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIPIRAZOLE - ABILIFY</u>						
N 021436 005	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027		U-1529		
	9089567	Jan 28, 2022		U-543		
	9125939	Jul 28, 2026		U-1749		
	9359302	Sep 25, 2022	DS DP	U-1859		
	9387182	Dec 25, 2023		U-1529		
<u>ARIPIPIRAZOLE - ABILIFY</u>						
N 021436 006	7053092	Jan 28, 2022		U-839	I-700	Dec 12, 2017
	8017615	Jun 16, 2024	DP		M-137	Jun 09, 2017
	8017615*PED	Dec 16, 2024			ODE	Dec 12, 2021
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027		U-1529		
	9089567	Jan 28, 2022		U-543		
	9125939	Jul 28, 2026		U-1749		
	9359302	Sep 25, 2022	DS DP	U-1859		
	9387182	Dec 25, 2023		U-1529		
<u>ARIPIPIRAZOLE - ABILIFY</u>						
N 021713 001	6977257	Apr 24, 2022		DP	I-700	Dec 12, 2017
	6977257*PED	Oct 24, 2022			M-137	Jun 09, 2017
	7053092	Jan 28, 2022		U-839	ODE	Dec 12, 2021
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				
	8759350	Mar 02, 2027		U-1529		
	9387182	Dec 25, 2023		U-1529		
<u>ARIPIPIRAZOLE - ABILIFY</u>						
N 021729 002	7053092	Jan 28, 2022		U-839	I-700	Dec 12, 2017
	8017615	Jun 16, 2024	DP		M-137	Jun 09, 2017
	8017615*PED	Dec 16, 2024			ODE	Dec 12, 2021
	8518421	Jan 24, 2021		DP		
	8518421*PED	Jul 24, 2021				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027		U-1529		
	9089567	Jan 28, 2022		U-543		
	9125939	Jul 28, 2026		U-1749		
	9358207	Apr 12, 2020		DP		
	9359302	Sep 25, 2022	DS DP	U-1859		
	9387182	Dec 25, 2023		U-1529		
<u>ARIPIPIRAZOLE - ABILIFY</u>						
N 021729 003	7053092	Jan 28, 2022		U-839	I-700	Dec 12, 2017
	8017615	Jun 16, 2024	DP		M-137	Jun 09, 2017
	8017615*PED	Dec 16, 2024			ODE	Dec 12, 2021
	8518421	Jan 24, 2021		DP		
	8518421*PED	Jul 24, 2021				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027		U-1529		
	9089567	Jan 28, 2022		U-543		
	9125939	Jul 28, 2026		U-1749		
	9359302	Sep 25, 2022	DS DP	U-1859		
	9387182	Dec 25, 2023		U-1529		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIPIRAZOLE - ABILIFY</u>						
N 021729 003	9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP	U-1859		
	9387182	Dec 25, 2023		U-1529		
<u>ARIPIPIRAZOLE - ABILIFY</u>						
N 021729 004	7053092	Jan 28, 2022		U-839	I-700	Dec 12, 2017
	8017615	Jun 16, 2024	DP		M-137	Jun 09, 2017
	8017615*PED	Dec 16, 2024			ODE	Dec 12, 2021
	8518421	Jan 24, 2021	DP			
	8518421*PED	Jul 24, 2021				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP	U-1859		
	9387182	Dec 25, 2023		U-1529		
<u>ARIPIPIRAZOLE - ABILIFY</u>						
N 021729 005	7053092	Jan 28, 2022		U-839	I-700	Dec 12, 2017
	8017615	Jun 16, 2024	DP		M-137	Jun 09, 2017
	8017615*PED	Dec 16, 2024			ODE	Dec 12, 2021
	8518421	Jan 24, 2021	DP			
	8518421*PED	Jul 24, 2021				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022		U-1492		
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP	U-1859		
	9387182	Dec 25, 2023		U-1529		
<u>ARIPIPIRAZOLE - ABILIFY</u>						
N 021866 001	7115587	Jul 21, 2024	DP	U-764	I-700	Dec 12, 2017
	7115587*PED	Jan 21, 2025			M-137	Jun 09, 2017
	7550445	Jul 21, 2024	DP		ODE	Dec 12, 2021
<u>ARIPIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	7807680	Oct 19, 2024	DP		M-150	Dec 05, 2017
	8030313	Oct 19, 2024		U-543		
	8030313	Oct 19, 2024		U-1632		
	8338427	Mar 15, 2025	DP	U-543		
	8338427	Mar 15, 2025	DP	U-1633		
	8338428	Aug 06, 2023	DP	U-543		
	8338428	Aug 06, 2023	DP	U-1633		
	8399469	Jun 29, 2025	DS			
	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP	U-1530		
	8759351	Aug 06, 2023	DP	U-1633		
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022		U-543		
<u>ARIPIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	7807680	Oct 19, 2024	DP		M-150	Dec 05, 2017
	8030313	Oct 19, 2024		U-543		
	8030313	Oct 19, 2024		U-1632		
	8338427	Mar 15, 2025	DP	U-543		
	8338427	Mar 15, 2025	DP	U-1633		
	8338428	Aug 06, 2023	DP	U-543		
	8338428	Aug 06, 2023	DP	U-1633		
	8399469	Jun 29, 2025	DS			
	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP	U-1530		
	8759351	Aug 06, 2023	DP	U-1633		
	8993761	Sep 25, 2022	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971	002	9089567	Jan 28, 2022	U-543		
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971	003	7807680	Oct 19, 2024	DP	M-150	Dec 05, 2017
		8030313	Oct 19, 2024	U-543		
		8030313	Oct 19, 2024	U-1632		
		8338427	Mar 15, 2025	DP U-543		
		8338427	Mar 15, 2025	DP U-1633		
		8338428	Aug 06, 2023	DP U-543		
		8338428	Aug 06, 2023	DP U-1633		
		8399469	Jun 29, 2025	DS		
		8722679	Oct 19, 2024	DP		
		8759351	Aug 06, 2023	DP U-1530		
		8759351	Aug 06, 2023	DP U-1633		
		8993761	Sep 25, 2022	DS		
		9089567	Jan 28, 2022	U-543		
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971	004	7807680	Oct 19, 2024	DP	M-150	Dec 05, 2017
		8030313	Oct 19, 2024	U-543		
		8030313	Oct 19, 2024	U-1632		
		8338427	Mar 15, 2025	DP U-543		
		8338427	Mar 15, 2025	DP U-1633		
		8338428	Aug 06, 2023	DP U-543		
		8338428	Aug 06, 2023	DP U-1633		
		8399469	Jun 29, 2025	DS		
		8722679	Oct 19, 2024	DP		
		8759351	Aug 06, 2023	DP U-1530		
		8759351	Aug 06, 2023	DP U-1633		
		8993761	Sep 25, 2022	DS		
		9089567	Jan 28, 2022	U-543		
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533	001	8431576	Oct 26, 2030	DS	NCE	Oct 05, 2020
		8796276	Jun 24, 2030	U-543		
		9034867	Nov 07, 2032	DP U-543		
		9193685	Oct 24, 2033	DP U-543		
		9452131	Mar 19, 2035	U-543		
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533	002	8431576	Oct 26, 2030	DS	NCE	Oct 05, 2020
		8796276	Jun 24, 2030	U-543		
		9034867	Nov 07, 2032	DP U-543		
		9193685	Oct 24, 2033	DP U-543		
		9452131	Mar 19, 2035	U-543		
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533	003	8431576	Oct 26, 2030	DS	NCE	Oct 05, 2020
		8796276	Jun 24, 2030	U-543		
		9034867	Nov 07, 2032	DP U-543		
		9193685	Oct 24, 2033	DP U-543		
		9452131	Mar 19, 2035	U-543		
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200043	001				PC	Nov 28, 2016
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200043	002				PC	Nov 28, 2016
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200043	003				PC	Nov 28, 2016
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200156	004				PC	Nov 28, 2016
<u>ARMODAFINIL - NUvigil</u>						
N 021875	001	7132570	Dec 18, 2023	DS DP		
		7297346	Nov 29, 2023	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARMODAFINIL - NUVIGIL</u>						
N 021875	002	7132570	Dec 18, 2023	DS DP		
		7297346	Nov 29, 2023	DP		
<u>ARMODAFINIL - NUVIGIL</u>						
N 021875	003	7132570	Dec 18, 2023	DS DP		
		7297346	Nov 29, 2023	DP		
<u>ARMODAFINIL - NUVIGIL</u>						
N 021875	004	7132570	Dec 18, 2023	DS DP		
		7297346	Nov 29, 2023	DP		
<u>ARMODAFINIL - NUVIGIL</u>						
N 021875	005	7132570	Dec 18, 2023	DS DP		
		7297346	Nov 29, 2023	DP		
<u>ARSENIC TRIOXIDE - TRISENOX</u>						
N 021248	001	6723351	Nov 10, 2018	U-573		
		6855339	Nov 10, 2018	U-617		
		6861076	Nov 10, 2018	U-617		
		6884439	Nov 10, 2018	U-651		
		6982096	Nov 10, 2018	U-651		
		8273379	Nov 10, 2018	U-1291		
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - MOVIPREP</u>						
N 021881	001	7169381	Sep 01, 2024	DS DP		
		7658914	Sep 01, 2024	DS DP		
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117	001	5763476	Jun 09, 2020	DP U-326	M-158	Mar 17, 2018
		5763476*PED	Dec 09, 2020		NPP	Mar 17, 2018
		7741358	Apr 06, 2026	DS DP U-1064	PED	Sep 17, 2018
		7741358*PED	Oct 06, 2026		PED	Sep 17, 2018
		8022228	Apr 06, 2026	DS DP		
		8022228*PED	Oct 06, 2026			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117	002	5763476	Jun 09, 2020	DP U-326	M-158	Mar 17, 2018
		5763476*PED	Dec 09, 2020		NPP	Mar 17, 2018
		7741358	Apr 06, 2026	DS DP U-1064	PED	Sep 17, 2018
		7741358*PED	Oct 06, 2026		PED	Sep 17, 2018
		8022228	Apr 06, 2026	DS DP		
		8022228*PED	Oct 06, 2026			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117	003	5763476	Jun 09, 2020	DP U-1893		
		5763476*PED	Dec 09, 2020			
		7741358	Apr 06, 2026	DS DP U-1893		
		7741358*PED	Oct 06, 2026			
		8022228	Apr 06, 2026	DS DP		
		8022228*PED	Oct 06, 2026			
<u>ASPIRIN - ASPIRIN</u>						
N 203697	001	8865187	Mar 23, 2022	DP		
		9101637	Mar 23, 2022	U-1731		
		9101637	Mar 23, 2022	U-1732		
		9101637	Mar 23, 2022	U-1733		
		9216150	Sep 29, 2032	DP		
		9226892	Sep 29, 2032	U-1731		
		9226892	Sep 29, 2032	U-1732		
		9226892	Sep 29, 2032	U-1733		
		9351984	Dec 19, 2021	DP		
<u>ASPIRIN; DIPYRIDAMOLE - AGGRENOLX</u>						
N 020884	001	6015577	Jan 18, 2017	U-302		
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103	001	6926907	Feb 28, 2023	DP U-1902	NC	Sep 14, 2019
		8206741	Feb 28, 2023	DP U-1902		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103	001	6926907	Feb 28, 2023	DP U-1902	NC	Sep 14, 2019
		8206741	Feb 28, 2023	DP U-1902		
		9364439	May 31, 2022	DP U-1902		
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103	002	6926907	Feb 28, 2023	DP U-1902	NC	Sep 14, 2019
		8206741	Feb 28, 2023	DP U-1902		
		9364439	May 31, 2022	DP U-1902		
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567	001	5849911	Jun 20, 2017	DS DP U-167		
		5849911*PED	Dec 20, 2017			
		6087383	Dec 21, 2018	DS DP		
		6087383*PED	Jun 21, 2019			
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567	002	5849911	Jun 20, 2017	DS DP U-167		
		5849911*PED	Dec 20, 2017			
		6087383	Dec 21, 2018	DS DP		
		6087383*PED	Jun 21, 2019			
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567	003	5849911	Jun 20, 2017	DS DP U-167		
		5849911*PED	Dec 20, 2017			
		6087383	Dec 21, 2018	DS DP		
		6087383*PED	Jun 21, 2019			
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567	004	5849911	Jun 20, 2017	DS DP U-167		
		5849911*PED	Dec 20, 2017			
		6087383	Dec 21, 2018	DS DP		
		6087383*PED	Jun 21, 2019			
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 206352	001	5849911	Jun 20, 2017	DS DP U-167	NP	Jun 02, 2017
		5849911*PED	Dec 20, 2017		NPP	Sep 24, 2018
		6087383	Dec 21, 2018	DS DP	PED	Dec 02, 2017
		6087383*PED	Jun 21, 2019		PED	Mar 24, 2019
<u>ATAZANAVIR SULFATE; COBICISTAT - EVOTAZ</u>						
N 206353	001	5849911	Jun 20, 2017	DS DP U-167		
		5849911*PED	Dec 20, 2017			
		6087383	Dec 21, 2018	DS DP		
		6087383*PED	Jun 21, 2019			
		8148374	Sep 03, 2029	DS DP U-1279		
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N 021411	001	5658590	Nov 26, 2016	U-494		
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N 021411	002	5658590	Nov 26, 2016	U-494		
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N 021411	003	5658590	Nov 26, 2016	U-494		
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N 021411	004	5658590	Nov 26, 2016	U-494		
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N 021411	005	5658590	Nov 26, 2016	U-494		
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N 021411	006	5658590	Nov 26, 2016	U-494		
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N 021411	007	5658590	Nov 26, 2016	U-494		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N 021411	008 5658590	Nov 26, 2016	U-494			
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N 020702	001 5969156	Jul 08, 2016	DS			
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N 020702	002 5969156	Jul 08, 2016	DS			
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N 020702	003 5969156	Jul 08, 2016	DS			
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N 020702	004 5969156	Jul 08, 2016	DS			
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153	001 5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	RE42461	Oct 25, 2016	DS DP	U-1400		
	RE42461*PED	Apr 25, 2017				
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153	002 5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	RE42461	Oct 25, 2016	DS DP	U-1400		
	RE42461*PED	Apr 25, 2017				
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153	003 5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	RE42461	Oct 25, 2016	DS DP	U-1400		
	RE42461*PED	Apr 25, 2017				
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153	004 5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	RE42461	Oct 25, 2016	DS DP	U-1400		
	RE42461*PED	Apr 25, 2017				
<u>ATOVAQUONE - MEPRON</u>						
N 020500	001 6649659	Jul 10, 2016	DS DP	U-69		
<u>AVANAFIL - STENDRA</u>						
N 202276	001 6656935	Apr 27, 2025	DS DP	U-155	D-140	Sep 17, 2017
	7501409	May 05, 2023	DP		NCE	Apr 27, 2017
<u>AVANAFIL - STENDRA</u>						
N 202276	002 6656935	Apr 27, 2025	DS DP	U-155	D-140	Sep 17, 2017
	7501409	May 05, 2023	DP		NCE	Apr 27, 2017
<u>AVANAFIL - STENDRA</u>						
N 202276	003 6656935	Apr 27, 2025	DS DP	U-155	D-140	Sep 17, 2017
	7501409	May 05, 2023	DP		NCE	Apr 27, 2017
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494	001 7112592	Feb 24, 2022	DS DP	U-282		
	7612087	Nov 12, 2026	DP			
	8178554	Jul 24, 2021	DS DP	U-282		
	8471025	Aug 12, 2031	DS			
	8835455	Oct 08, 2030	DP			
	8969566	Jun 15, 2032	DS			
<u>AXITINIB - INLYTA</u>						
N 202324	001 6534524	Apr 29, 2025	DS DP		NCE	Jan 27, 2017
	7141581	Jun 30, 2020		U-1220		
	8791140	Aug 05, 2030	DS			
<u>AXITINIB - INLYTA</u>						
N 202324	002 6534524	Apr 29, 2025	DS DP		NCE	Jan 27, 2017
	7141581	Jun 30, 2020		U-1220		
	8791140	Aug 05, 2030	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AXITINIB - INLYTA</u>						
N 202324	002	6534524	Apr 29, 2025	DS DP	NCE	Jan 27, 2017
		7141581	Jun 30, 2020	U-1220		
		8791140	Aug 05, 2030	DS		
<u>AZELAIC ACID - FINACEA</u>						
N 021470	001	6534070	Nov 18, 2018			
<u>AZELAIC ACID - FINACEA</u>						
N 207071	001	6730288	Sep 08, 2019	DP	NP	Jul 29, 2018
		7700076	Sep 18, 2027	DP		
		8435498	Mar 01, 2024	U-1727		
		8722021	Oct 24, 2023	DP		
		8900554	Oct 24, 2023	DP		
		9211259	Jan 26, 2029	U-1796		
		9265725	Dec 08, 2027	DP		
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022203	001	8071073	Jun 04, 2028	DP	M-129	Aug 30, 2016
		8518919	Nov 22, 2025	U-1430	NPP	Aug 30, 2016
					NPP	Feb 20, 2018
					NPP	Feb 20, 2018
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022203	002	8071073	Jun 04, 2028	DP	M-129	Aug 30, 2016
		8518919	Nov 22, 2025	U-1430	NPP	Aug 30, 2016
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N 202236	001	8163723	Aug 29, 2023	U-77	NPP	Feb 20, 2018
		8163723	Aug 29, 2023	U-81	PED	Aug 20, 2018
		8163723	Aug 29, 2023	U-644		
		8163723	Aug 29, 2023	U-707		
		8163723	Aug 29, 2023	U-1667		
		8163723*PED	Feb 29, 2024			
		8168620	Feb 24, 2026	DP		
		9259428	Jun 13, 2023	U-644		
		9259428*PED	Dec 13, 2023			
<u>AZILSARTAN KAMEDOXOMIL - EDARBI</u>						
N 200796	001	7157584	May 22, 2025	DS		
		7572920	Jan 07, 2025	DP U-3		
		9066936	Mar 26, 2028	DP		
<u>AZILSARTAN KAMEDOXOMIL - EDARBI</u>						
N 200796	002	7157584	May 22, 2025	DS		
		7572920	Jan 07, 2025	DP U-3		
		9066936	Mar 26, 2028	DP		
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331	001	7157584	May 22, 2025	DS		
		7572920	Jan 07, 2025	DP U-3		
		9066936	Mar 26, 2028	DP		
		9169238	Feb 04, 2030	DP		
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331	002	7157584	May 22, 2025	DS		
		7572920	Jan 07, 2025	DP U-3		
		9066936	Mar 26, 2028	DP		
		9169238	Feb 04, 2030	DP		
<u>AZITHROMYCIN - ZITHROMAX</u>						
N 050693	001	6268489	Jul 31, 2018	DS		
<u>AZITHROMYCIN - ZITHROMAX</u>						
N 050710	001	6268489	Jul 31, 2018	DS		
<u>AZITHROMYCIN - ZITHROMAX</u>						
N 050710	002	6268489	Jul 31, 2018	DS		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AZITHROMYCIN - ZITHROMAX</u>						
N 050711	001 6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N 050730	001 6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N 050733	001 6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N 050784	001 6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZMAX</u>						
N 050797	001 6068859	May 30, 2017		DP		
	6268489	Jul 31, 2018	DS			
	6984403	Feb 14, 2024		DP U-282		
	7887844	Feb 14, 2024		DP		
<u>AZITHROMYCIN - AZASITE</u>						
N 050810	001 6159458	Nov 04, 2017		DP U-709		
	6239113	Mar 31, 2019		U-709		
	6569443	Mar 31, 2019		DP U-709		
	6861411	Nov 25, 2018		U-709		
	7056893	Mar 31, 2019		DP U-709		
<u>AZTREONAM - CAYSTON</u>						
N 050814	001 7208141	Dec 20, 2021		DP U-1031	ODE	Feb 22, 2017
	7214364	Dec 20, 2021		DP		
	7427633	Dec 20, 2021		DP U-1031		
	8399496	Dec 20, 2021		DP U-1377		
<u>BACLOFEN - KEMSTRO</u>						
N 021589	001 6024981	Apr 09, 2018		DP		
	6221392	Apr 09, 2018		DP		
<u>BACLOFEN - KEMSTRO</u>						
N 021589	002 6024981	Apr 09, 2018		DP		
	6221392	Apr 09, 2018		DP		
<u>BALSALAZIDE DISODIUM - COLAZAL</u>						
N 020610	001 7452872	Aug 24, 2026		U-141		
	7625884	Aug 24, 2026		U-141		
<u>BALSALAZIDE DISODIUM - GIAZO</u>						
N 022205	001 6197341	Mar 13, 2018		DP U-1229		
	7452872	Aug 24, 2026		U-1229		
	7625884	Aug 24, 2026		U-1229		
	8497256	Jun 23, 2031		U-1229		
	9192616	Aug 02, 2026		U-1229		
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247	001 5998402	Apr 04, 2017	DS DP	U-594	NP	Oct 03, 2016
	6479535	May 06, 2019		DP U-594		
	6479535	May 06, 2019		DP U-904		
	7138392	Apr 04, 2017	DS DP	U-594		
	7683051	Mar 10, 2027	DS DP	U-594		
	7683051	Mar 10, 2027	DS DP	U-904		
	8815934	May 06, 2019		DP		
<u>BECLOMETHASONE DIPROPIONATE - QVAR 80</u>						
N 020911	001 6446627	Dec 18, 2017		DP		
	9463289	May 18, 2031		DP		
<u>BECLOMETHASONE DIPROPIONATE - QVAR 40</u>						
N 020911	002 6446627	Dec 18, 2017		DP		
	9463289	May 18, 2031		DP		
<u>BECLOMETHASONE DIPROPIONATE - QNASL</u>						
N 202813	001 7780038	Jan 24, 2027		DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BECLOMETHASONE DIPROPIONATE - QNASL</u>						
N 202813	002 7780038	Jan 24, 2027	DP		NS	Dec 17, 2017
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384	001 7498343	Oct 02, 2024	DS DP U-1321		NCE	Dec 28, 2017
	8546428	Mar 19, 2029	DS DP U-1321		ODE	Dec 28, 2019
<u>BELINOSTAT - BELEODAO</u>						
N 206256	001 6888027	Sep 27, 2021	DS DP U-1544		NCE	Jul 03, 2019
	8835501	Oct 27, 2027	DP		ODE	Jul 03, 2021
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249	001 8436190	Oct 26, 2030	DP			
	8436190*PED	Apr 26, 2031				
	8445524	Mar 26, 2029	DS DP U-1402			
	8445524*PED	Sep 26, 2029				
	8609863	Jan 12, 2026	DP			
	8609863*PED	Jul 12, 2026				
	8669279	Mar 26, 2029	DP U-1402			
	8669279*PED	Sep 26, 2029				
	8791270	Jan 12, 2026	DP U-1542			
	8791270*PED	Jul 12, 2026				
	8883836	Mar 26, 2029	DP U-1402			
	8883836*PED	Sep 26, 2029				
	8895756	Jan 12, 2026	DP			
	8895756*PED	Jul 12, 2026				
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249	002 8436190	Oct 26, 2030	DP			
	8436190*PED	Apr 26, 2031				
	8445524	Mar 26, 2029	DS DP U-1402			
	8445524*PED	Sep 26, 2029				
	8609863	Jan 12, 2026	DP			
	8609863*PED	Jul 12, 2026				
	8669279	Mar 26, 2029	DP U-1402			
	8669279*PED	Sep 26, 2029				
	8791270	Jan 12, 2026	DP U-1542			
	8791270*PED	Jul 12, 2026				
	8883836	Mar 26, 2029	DP U-1402			
	8883836*PED	Sep 26, 2029				
	8895756	Jan 12, 2026	DP			
	8895756*PED	Jul 12, 2026				
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249	003 8344006	Sep 23, 2029	DP U-1402			
	8344006*PED	Mar 23, 2030				
	8445524	Mar 26, 2029	DS			
	8445524*PED	Sep 26, 2029				
	8791270	Jan 12, 2026	DP U-1542			
	8791270*PED	Jul 12, 2026				
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249	004 8344006	Sep 23, 2029	DP U-1402			
	8344006*PED	Mar 23, 2030				
	8445524	Mar 26, 2029	DS			
	8445524*PED	Sep 26, 2029				
	8791270	Jan 12, 2026	DP U-1542			
	8791270*PED	Jul 12, 2026				
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194	001 8609707	Aug 11, 2031	DP U-1542			
	8791270	Jan 12, 2026	DP U-1790			
	8791270*PED	Jul 12, 2026				
	9000021	Mar 15, 2033	U-1542			
	9034908	Mar 15, 2033	U-1542			
	9144568	Mar 15, 2033	U-1542			
	9265831	Jan 28, 2031	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N 050819	001	8288434	Aug 05, 2029	DP U-124		
		8663699	Jun 03, 2029	U-124		
		8895070	Jun 03, 2029	U-124		
		9078870	Jun 03, 2029	DP		
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON</u>						
N 050819	002	8288434	Aug 05, 2029	DP U-124		
		8288434	Aug 05, 2029	DP U-134		
		8288434	Aug 05, 2029	DP U-818		
		8288434	Aug 05, 2029	DP U-916		
		8288434	Aug 05, 2029	DP U-921		
		8288434	Aug 05, 2029	DP U-1033		
		9504704	Jun 03, 2029	DP U-124		
		9504704	Jun 03, 2029	DP U-134		
		9504704	Jun 03, 2029	DP U-818		
		9504704	Jun 03, 2029	DP U-916		
<u>BENZYL ALCOHOL - ULESFIA</u>						
N 022129	001	5858383	Aug 11, 2017	U-970		
		6139859	Aug 11, 2017	U-970		
		6793931	Jul 11, 2022	DP U-970		
		7294342	May 19, 2024	U-970		
<u>BEPOTASTINE BESILATE - BEPREVE</u>						
N 022288	001	6780877	Sep 19, 2019	DS DP		
		8784789	Sep 05, 2024	DP		
		8877168	Jul 30, 2023	DP		
<u>BESIFLOXACIN HYDROCHLORIDE - BESIVANCE</u>						
N 022308	001	6685958	Jun 29, 2021	DP U-80		
		6699492	Mar 31, 2019	DP U-80		
		8415342	Nov 07, 2030	U-80		
		8481526	Jan 09, 2031	DS		
		8604020	Mar 12, 2030	DP		
		8937062	Nov 13, 2029	U-80		
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079	001	9364485	Aug 31, 2030	DP U-1858	NDF	Feb 05, 2019
		9433630	Aug 31, 2030	DP U-1858		
		9439911	Aug 31, 2030	DP U-1858		
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - ENSTILAR</u>						
N 207589	001	6753013	Jan 27, 2020	DP U-1761	NP	Oct 16, 2018
		9119781	Jun 10, 2031	DP U-1761		
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX</u>						
N 021852	001	6753013	Jan 27, 2020	DP U-88	NPP	Dec 23, 2017
		6753013	Jan 27, 2020	DP U-193		
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX</u>						
N 022185	001	6753013	Jan 27, 2020	DP U-88	NPP	Aug 29, 2017
		6753013	Jan 27, 2020	DP U-193		
		6753013	Jan 27, 2020	DP U-1761		
		6787529	Jan 27, 2020	DP U-88		
		6787529	Jan 27, 2020	DP U-193		
		6787529	Jan 27, 2020	DP U-1761		
<u>BETAMETHASONE VALERATE - LUXIQ</u>						
N 020934	001	7078058	May 24, 2017	DP		
<u>BEXAROTENE - TARGRETIN</u>						
N 021055	001	5962731	Oct 05, 2016	U-475	M-164	Jul 29, 2018
<u>BEXAROTENE - TARGRETIN</u>						
N 021056	001	5962731	Oct 05, 2016			
<u>BIMATOPROST - LUMIGAN</u>						
N 022184	001	7851504	Jun 13, 2027	DS DP		
		8278353	Mar 16, 2025	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BIMATOPROST - LUMIGAN</u>						
N 022184	001	8299118	Mar 16, 2025	U-1295		
		8309605	Mar 16, 2025	U-1293		
		8309605	Mar 16, 2025	U-1294		
		8338479	Mar 16, 2025	DP U-1295		
		8524777	Mar 16, 2025	U-1235		
		8586630	Mar 16, 2025	U-1458		
		8772338	Mar 16, 2025	DP U-1528		
		8933120	Mar 16, 2025	DP		
		8933127	Mar 16, 2025	DP		
		9155716	Mar 16, 2025	DP U-1528		
		9241918	Mar 16, 2025	DP U-1814		
<u>BIMATOPROST - LATISSE</u>						
N 022369	001	7351404	May 25, 2024	U-939	Y	M-140
		7388029	Jan 21, 2022	U-938	Y	
		8038988	Aug 25, 2023	DS DP U-1208		Sep 04, 2017
		8101161	May 25, 2024	U-1217		
		8101161	May 25, 2024	U-1218		
		8263054	Jan 15, 2023	U-1277		
		8541466	Jan 31, 2021	U-1217		
		8632760	Jan 15, 2023	U-1487		
		8758733	Jan 15, 2023	U-1487		
		8906962	Jan 31, 2021	U-1217		
		8926953	Jan 15, 2023	U-1217		
		8986715	Jan 15, 2023	U-1217		
		9216183	Jan 15, 2023	U-1487		
		9226931	Jan 15, 2023	U-1799		
<u>BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - HALFLYTELY</u>						
N 021551	003	7291324	Oct 22, 2022	U-837		
<u>BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE - PYLERA</u>						
N 050786	001	6350468	Dec 14, 2018	U-932		
		6350468	Dec 14, 2018	U-956		
<u>BIVALIRUDIN - ANGIOMAX</u>						
N 020873	001	7582727	Jul 27, 2028	DP		
		7598343	Jul 27, 2028	DP		
<u>BOCEPREVIR - VICTRELIS</u>						
N 202258	001	7772178	Nov 11, 2027	DP U-1128		
		8119602	Mar 17, 2027	U-1233		
		RE43298	Dec 22, 2024	DS DP U-1128		
<u>BORTEZOMIB - VELCADE</u>						
N 021602	001	5780454	May 03, 2017	DS DP	D-141	Oct 08, 2017
		5780454*PED	Nov 03, 2017		D-142	Oct 08, 2017
		6713446	Jan 25, 2022	DS DP	I-695	Oct 08, 2017
		6713446*PED	Jul 25, 2022		M-139	Aug 08, 2017
		6958319	Jan 25, 2022	DS DP	M-165	Sep 14, 2018
		6958319*PED	Jul 25, 2022		ODE	Oct 08, 2021
					PED	Feb 08, 2018
					PED	Apr 08, 2018
					PED	Apr 08, 2018
					PED	Apr 08, 2018
					PED	Mar 14, 2019
					PED	Apr 08, 2022
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341	001	6002008	Mar 27, 2018	DS DP U-1284	NCE	Sep 04, 2017
		7417148	Jan 23, 2026	U-1283	ODE	Sep 04, 2019
		7767678	Nov 23, 2026	DS DP		
		7919625	Dec 11, 2025	DP		
		RE42376	Apr 13, 2024	DS		
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341	002	6002008	Mar 27, 2018	DS DP U-1284	NCE	Sep 04, 2017
		7417148	Jan 23, 2026	U-1283	ODE	Sep 04, 2019
		7767678	Nov 23, 2026	DS DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 002	7919625	Dec 11, 2025	DP			
	RE42376	Apr 13, 2024	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 001	7888362	Feb 23, 2027	DS		M-186	Sep 23, 2019
	8349840	Apr 12, 2026	DP	U-1529	NCE	Jul 10, 2020
	8618109	Apr 12, 2026		U-543		
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 002	7888362	Feb 23, 2027	DS		M-186	Sep 23, 2019
	8349840	Apr 12, 2026	DP	U-1529	NCE	Jul 10, 2020
	8618109	Apr 12, 2026		U-543		
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 003	7888362	Feb 23, 2027	DS		M-186	Sep 23, 2019
	8349840	Apr 12, 2026	DP	U-1529	NCE	Jul 10, 2020
	8618109	Apr 12, 2026		U-543		
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 004	7888362	Feb 23, 2027	DS		M-186	Sep 23, 2019
	8349840	Apr 12, 2026	DP	U-1529	NCE	Jul 10, 2020
	8618109	Apr 12, 2026		U-543		
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 005	7888362	Feb 23, 2027	DS		M-186	Sep 23, 2019
	8349840	Apr 12, 2026	DP	U-1529	NCE	Jul 10, 2020
	8618109	Apr 12, 2026		U-543		
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 006	7888362	Feb 23, 2027	DS		M-186	Sep 23, 2019
	8349840	Apr 12, 2026	DP	U-1529	NCE	Jul 10, 2020
	8618109	Apr 12, 2026		U-543		
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021262 001	6562873	Jul 10, 2021				
	6627210	Jul 18, 2021	DP			
	6641834	Jul 28, 2021	DP			
	6673337	Jul 26, 2021	DP			
	9295641	Jul 10, 2021		U-1833		
	9295641*PED	Jan 10, 2022				
<u>BRIMONIDINE TARTRATE - QOLIANA</u>						
N 021764 001	7265117	Aug 19, 2025	DP			
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021770 001	6562873	Jul 10, 2021	DP			
	6627210	Jul 18, 2021	DP			
	6641834	Jul 28, 2021	DP			
	6673337	Jul 26, 2021	DP			
	8858961	Sep 02, 2023	DP			
	8858961*PED	Mar 02, 2024				
	9295641	Jul 10, 2021		U-1833		
	9295641*PED	Jan 10, 2022				
<u>BRIMONIDINE TARTRATE - MIRVASO</u>						
N 204708 001	7439241	Aug 25, 2025		U-1428	NDF	Aug 23, 2016
	8053427	Jun 13, 2031	DP	U-1428		
	8163725	Jun 13, 2031	DP			
	8231885	May 24, 2025	DP			
	8410102	May 24, 2025		U-1428		
	8426410	May 24, 2025		U-1428		
	8513247	Mar 25, 2031	DP	U-1428		
	8513249	Mar 25, 2031	DP	U-1428		
	8859551	May 25, 2024		U-1428		
<u>BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA</u>						
N 204251 001	6316441	Dec 07, 2019		U-778		
	9044484	Oct 30, 2030	DP			
	9421265	Jun 17, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N 021398 001	7030149	Apr 19, 2022	U-849			
	7320976	Apr 19, 2022	U-849			
	7323463	Jan 19, 2023	DP	Y		
	7642258	Apr 19, 2022	DS DP U-1024			
	8133890	Apr 19, 2022	U-1235			
	8354409	Apr 19, 2022	DP U-1371			
	8748425	Apr 19, 2022	DP U-1524			
	9474751	Apr 19, 2022	DP U-1524			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 002	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 003	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 004	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 005	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205837 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205838 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BROMFENAC SODIUM - PROLENSA</u>						
N 203168 001	8129431	Sep 11, 2025	DS DP			
	8669290	Jan 16, 2024	DP			
	8754131	Jan 16, 2024	DP			
	8871813	Jan 16, 2024	DP			
	8927606	Jan 16, 2024	U-100			
	8927606	Jan 16, 2024	U-810			
	8927606	Jan 16, 2024	U-1095			
	9144609	Jan 16, 2024	DP			
<u>BROMFENAC SODIUM - BROMSITE</u>						
N 206911 001	8778999	Sep 03, 2029	DP U-1834		NP	Apr 08, 2019
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	7888310	Jul 25, 2023	U-1433			
	8137992	Jul 25, 2023	U-1433			
	8137993	Jul 25, 2023	U-1433			
	8137994	Jul 25, 2023	U-1433			
	8431155	Apr 30, 2032	DP U-976			
	8613947	Apr 30, 2032	DP U-976			
	8877708	Jun 07, 2030	DP U-1706			
	9192576	Apr 30, 2032	DP U-976			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUDESONIDE - PULMICORT RESPULES</u>						
N 020929	001	6598603	Dec 23, 2018	U-529		
		6899099	Dec 23, 2018	U-529		
		7524834	Nov 11, 2018	DP U-966		
<u>BUDESONIDE - PULMICORT RESPULES</u>						
N 020929	002	6598603	Dec 23, 2018	U-529		
		6899099	Dec 23, 2018	U-529		
		7524834	Nov 11, 2018	DP U-966		
<u>BUDESONIDE - PULMICORT RESPULES</u>						
N 020929	003	6598603	Dec 23, 2018	U-529		
		6899099	Dec 23, 2018	U-529		
		7524834	Nov 11, 2018	DP U-966		
<u>BUDESONIDE - ENTOCORT EC</u>						
N 021324	001				M-178 NPP	Apr 29, 2019 Apr 29, 2019
<u>BUDESONIDE - PULMICORT FLEXHALER</u>						
N 021949	001	6027714	Jan 09, 2018	DP U-787		
		6142145	May 08, 2018	DP		
		6287540	Jan 09, 2018	DP		
		7143764	Mar 13, 2018	DP		
<u>BUDESONIDE - PULMICORT FLEXHALER</u>						
N 021949	002	6027714	Jan 09, 2018	DP U-787		
		6142145	May 08, 2018	DP		
		6287540	Jan 09, 2018	DP		
		7143764	Mar 13, 2018	DP		
<u>BUDESONIDE - UCERIS</u>						
N 203634	001	7410651	Jun 09, 2020	DP U-1325		
		7431943	Jun 09, 2020	DP		
		8293273	Jun 09, 2020	DP		
		8784888	Jun 09, 2020	DP		
		8895064	Sep 07, 2031	DP		
		9132093	Sep 07, 2031	DP		
		9192581	Sep 07, 2031	DP U-1325		
		9320716	Jun 09, 2020	DP U-1325		
		RE43799	Jun 09, 2020	DP U-1325		
<u>BUDESONIDE - UCERIS</u>						
N 205613	001				NP	Oct 07, 2017
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929	001	6123924	Sep 26, 2017	DP		
		7367333	Nov 11, 2018	DP		
		7587988	Apr 10, 2026	DP		
		7759328	Jan 29, 2023	DP U-1073		
		7967011	Aug 11, 2021	DP		
		8143239	Jan 29, 2023	DP U-1073		
		8387615	Nov 10, 2024	DP		
		8528545	Oct 16, 2028	DP		
		8575137	Jan 29, 2023	DP U-1073		
		8616196	Apr 07, 2029	DP		
		8875699	Nov 10, 2024	DP		
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929	002	6123924	Sep 26, 2017	DP		
		7367333	Nov 11, 2018	DP		
		7587988	Apr 10, 2026	DP		
		7759328	Jan 29, 2023	DP U-1073		
		7897646	Sep 09, 2018	U-1118		
		7967011	Aug 11, 2021	DP		
		8143239	Jan 29, 2023	DP U-1073		
		8387615	Nov 10, 2024	DP		
		8461211	Sep 09, 2018	U-1118		
		8528545	Oct 16, 2028	DP		
		8575137	Jan 29, 2023	DP U-1073		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929	002	8616196	Apr 07, 2029	DP		
		8875699	Nov 10, 2024	DP		
<u>BUPIVACAINE - EXPAREL</u>						
N 022496	001	8182835	Sep 18, 2018	DP	U-1246	
		8834921	Sep 18, 2018	DP	U-1587	
<u>BUPIVACAINE - EXPAREL</u>						
N 022496	002	8182835	Sep 18, 2018	DP	U-1246	
		8834921	Sep 18, 2018	DP	U-1587	
		9205052	Sep 18, 2018		U-1246	
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306	001	RE41408	Sep 29, 2017		U-1072	
		RE41408	Sep 29, 2017		U-1556	
		RE41489	Sep 29, 2017		U-1072	
		RE41489	Sep 29, 2017		U-1556	
		RE41571	Sep 29, 2017		U-1072	
		RE41571	Sep 29, 2017		U-1556	
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306	002	RE41408	Sep 29, 2017		U-1072	
		RE41408	Sep 29, 2017		U-1556	
		RE41489	Sep 29, 2017		U-1072	
		RE41489	Sep 29, 2017		U-1556	
		RE41571	Sep 29, 2017		U-1072	
		RE41571	Sep 29, 2017		U-1556	
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306	003	RE41408	Sep 29, 2017		U-1072	
		RE41408	Sep 29, 2017		U-1556	
		RE41489	Sep 29, 2017		U-1072	
		RE41489	Sep 29, 2017		U-1556	
		RE41571	Sep 29, 2017		U-1072	
		RE41571	Sep 29, 2017		U-1556	
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306	004	RE41408	Sep 29, 2017		U-1072	
		RE41408	Sep 29, 2017		U-1556	
		RE41489	Sep 29, 2017		U-1072	
		RE41489	Sep 29, 2017		U-1556	
		RE41571	Sep 29, 2017		U-1072	
		RE41571	Sep 29, 2017		U-1556	
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306	005	RE41408	Sep 29, 2017		U-1072	
		RE41408	Sep 29, 2017		U-1556	
		RE41489	Sep 29, 2017		U-1072	
		RE41489	Sep 29, 2017		U-1556	
		RE41571	Sep 29, 2017		U-1072	
		RE41571	Sep 29, 2017		U-1556	
<u>BUPRENORPHINE HYDROCHLORIDE - PROBUPHINE</u>						
N 204442	001	7736665	Apr 25, 2024		U-1878	NP May 26, 2019
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932	001	6159498	Oct 18, 2016	DP		NP Oct 23, 2018
		7579019	Jan 22, 2020		U-1769	
		8147866	Jul 23, 2027	DP	U-1769	
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932	002	6159498	Oct 18, 2016	DP		NP Oct 23, 2018
		7579019	Jan 22, 2020		U-1769	
		8147866	Jul 23, 2027	DP	U-1769	
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932	003	6159498	Oct 18, 2016	DP		NP Oct 23, 2018
		7579019	Jan 22, 2020		U-1769	
		8147866	Jul 23, 2027	DP	U-1769	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 004	6159498	Oct 18, 2016	DP		NP	Oct 23, 2018
	7579019	Jan 22, 2020	U-1769			
	8147866	Jul 23, 2027	DP U-1769			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 005	6159498	Oct 18, 2016	DP		NP	Oct 23, 2018
	7579019	Jan 22, 2020	U-1769			
	8147866	Jul 23, 2027	DP U-1769			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 006	6159498	Oct 18, 2016	DP		NP	Oct 23, 2018
	7579019	Jan 22, 2020	U-1769			
	8147866	Jul 23, 2027	DP U-1769			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 007	6159498	Oct 18, 2016	DP		NP	Oct 23, 2018
	7579019	Jan 22, 2020	U-1769			
	8147866	Jul 23, 2027	DP U-1769			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001	8017150	Feb 13, 2023	DP			
	8475832	Mar 26, 2030	DP U-1411			
	8603514	Apr 03, 2024	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 002	8017150	Feb 13, 2023	DP			
	8475832	Mar 26, 2030	DP U-1411			
	8603514	Apr 03, 2024	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 003	8017150	Feb 13, 2023	DP			
	8475832	Mar 26, 2030	DP U-1411			
	8603514	Apr 03, 2024	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 004	8017150	Feb 13, 2023	DP			
	8475832	Mar 26, 2030	DP U-1411			
	8603514	Apr 03, 2024	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	8454996	Sep 24, 2019	U-1421		I-713	Aug 10, 2018
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	8454996	Sep 24, 2019	U-1421		I-713	Aug 10, 2018
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 003	8454996	Sep 24, 2019	U-1421		I-713	Aug 10, 2018
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 004	8454996	Sep 24, 2019	U-1421		I-713	Aug 10, 2018
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
	9259421	Sep 18, 2032	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 004	9439900	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 005	8454996	Sep 24, 2019	U-1421		I-713	Aug 10, 2018
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 006	8454996	Sep 24, 2019	U-1421		I-713	Aug 10, 2018
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP	Y		
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 001	6159498	Oct 18, 2016	DP		NP	Jun 06, 2017
	7579019	Jan 22, 2020	U-1521			
	8147866	Jul 23, 2027	DP U-1521			
	8703177	Aug 20, 2032	DP			
	9522188	Apr 24, 2035	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 002	6159498	Oct 18, 2016	DP		NP	Jun 06, 2017
	7579019	Jan 22, 2020	U-1521			
	8147866	Jul 23, 2027	DP U-1521			
	8703177	Aug 20, 2032	DP			
	9522188	Apr 24, 2035	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 003	6159498	Oct 18, 2016	DP		NP	Jun 06, 2017
	7579019	Jan 22, 2020	U-1521			
	8147866	Jul 23, 2027	DP U-1521			
	8703177	Aug 20, 2032	DP			
	9522188	Apr 24, 2035	DP			
<u>BUPROPION HYDROBROMIDE - APLENZIN</u>						
N 022108 001	7241805	Jun 27, 2026	DP			
	7569610	Jun 27, 2026	U-997			
	7572935	Jun 27, 2026	DP			
	7585897	Jun 27, 2026	DP			
	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			
<u>BUPROPION HYDROBROMIDE - APLENZIN</u>						
N 022108 002	7241805	Jun 27, 2026	DP			
	7569610	Jun 27, 2026	U-997			
	7572935	Jun 27, 2026	DP			
	7585897	Jun 27, 2026	DP			
	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			
<u>BUPROPION HYDROBROMIDE - APLENZIN</u>						
N 022108 003	7241805	Jun 27, 2026	DP			
	7569610	Jun 27, 2026	U-997			
	7572935	Jun 27, 2026	DP			
	7585897	Jun 27, 2026	DP			
	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPROPION HYDROCHLORIDE - WELLBUTRIN XL</u>						
N 021515	001	6096341	Oct 30, 2018			
<u>BUPROPION HYDROCHLORIDE - WELLBUTRIN XL</u>						
N 021515	002	6096341	Oct 30, 2018			
<u>BUPROPION HYDROCHLORIDE - FORFIVO XL</u>						
N 022497	001	7674479	Jun 25, 2027	DP		
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063	001	7375111	Mar 26, 2025	DP	NC	Sep 10, 2017
		7462626	Jul 20, 2024	U-1583		
		8088786	Feb 03, 2029	DP		
		8318788	Nov 08, 2027	U-1584		
		8722085	Nov 08, 2027	U-1585		
		8815889	Jul 20, 2024	U-1586		
		8916195	Feb 02, 2030	U-1639		
		9107837	Jun 04, 2027	U-1639		
		9125868	Nov 08, 2027	U-1585		
		9248123	Jan 13, 2032	U-1808		
<u>BUTOCONAZOLE NITRATE - BUTOCONAZOLE NITRATE</u>						
N 019881	001	5993856	Nov 17, 2017	DP U-457		
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023	001	5847170	Mar 26, 2021	DS DP		
		7241907	Dec 10, 2025	DS		
		8927592	Oct 27, 2030	U-1630		
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756	001	7579473	Aug 14, 2026	DS DP	NCE	Nov 29, 2017
		8877776	Oct 08, 2030	DS DP U-1617	ODE	Nov 29, 2019
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756	002	7579473	Aug 14, 2026	DS DP	NCE	Nov 29, 2017
		8877776	Oct 08, 2030	DS DP U-1617	ODE	Nov 29, 2019
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692	001	7579473	Aug 14, 2026	DS DP	NCE	Nov 29, 2017
		8497284	Sep 24, 2024	U-1220	NP	Apr 25, 2019
		8877776	Oct 08, 2030	DS DP		
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692	002	7579473	Aug 14, 2026	DS DP	NCE	Nov 29, 2017
		8497284	Sep 24, 2024	U-1220	NP	Apr 25, 2019
		8877776	Oct 08, 2030	DS DP		
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692	003	7579473	Aug 14, 2026	DS DP	NCE	Nov 29, 2017
		8497284	Sep 24, 2024	U-1220	NP	Apr 25, 2019
		8877776	Oct 08, 2030	DS DP		
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010	001	6582727	Aug 22, 2020	DP	NP	Jun 17, 2019
		8207149	Apr 25, 2028	U-1871		
		8361488	Jul 19, 2028	DP		
		8426391	Aug 27, 2028	DP U-1872		
		8778373	Apr 25, 2028	U-1873		
		8906410	Feb 02, 2027	DP		
		9408858	Apr 25, 2028	U-1888		
		9498486	Apr 25, 2028	U-1920		
<u>CALCIPOTRIENE - SORILUX</u>						
N 022563	001	8263580	Sep 27, 2028	DP U-1280		
		8629128	May 26, 2026	DP U-1280		
		8629128	May 26, 2026	DP U-1767		
<u>CALCITONIN SALMON RECOMBINANT - FORTICAL</u>						
N 021406	001	6440392	Feb 02, 2021	DP U-227		
		RE40812	Feb 02, 2021	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CALCITONIN SALMON RECOMBINANT - FORTICAL</u>						
N 021406	001	6440392	Feb 02, 2021	DP U-227		
		RE40812	Feb 02, 2021	DP		
		RE43580	Feb 02, 2021	DP U-227		
<u>CALCITRIOL - CALCIJEX</u>						
N 018874	001	6051567	Aug 02, 2019			
		6265392	Aug 02, 2019			
		6274169	Aug 02, 2019			
<u>CALCITRIOL - CALCIJEX</u>						
N 018874	002	6051567	Aug 02, 2019			
		6265392	Aug 02, 2019			
		6274169	Aug 02, 2019			
<u>CALCIUM ACETATE - PHOSLO</u>						
N 021160	002	6576665	Apr 03, 2021			
<u>CALCIUM ACETATE - PHOSLO GELCAPS</u>						
N 021160	003	6576665	Apr 03, 2021			
		6875445	Jul 30, 2021	DP		
<u>CALCIUM ACETATE - PHOSLYRA</u>						
N 022581	001	8591938	Feb 23, 2030	DP U-1469		
		8592480	Jul 20, 2027	U-1469		
		9089528	Jul 20, 2027	U-1469		
<u>CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE - PEPCID COMPLETE</u>						
N 020958	001	5989588	Sep 30, 2017	DP U-349		
		5989588*PED	Mar 30, 2018			
		6814978	Aug 26, 2021	DP		
<u>CALCIUM CARBONATE; RISEDRONATE SODIUM - ACTONEL WITH CALCIUM (COPACKAGED)</u>						
N 021823	001	5994329	Jul 17, 2018	U-353		
		6015801	Jul 17, 2018	U-353		
		6165513	Jun 10, 2018	DP		
		6432932	Jul 17, 2018	U-595		
		6465443	Aug 14, 2018	DP		
<u>CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATONE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - NAVSTEL</u>						
N 022193	001	7084130	Nov 29, 2021	DP U-891		
<u>CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER</u>						
N 207026	001				ODE	Jan 13, 2022
<u>CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER</u>						
N 207026	002				ODE	Jan 13, 2022
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042	001	7943582	Feb 26, 2029	DS DP U-493	I-733	May 20, 2019
		7943788	Jul 14, 2027	DS DP	NCE	Mar 29, 2018
		8222219	Jul 30, 2024	U-493		
		8513202	Dec 03, 2027	DS DP U-493		
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042	002	7943582	Feb 26, 2029	DS DP U-493	I-733	May 20, 2019
		7943788	Jul 14, 2027	DS DP	NCE	Mar 29, 2018
		8222219	Jul 30, 2024	U-493		
		8513202	Dec 03, 2027	DS DP U-493		
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	001	7943582	Feb 26, 2029	DS DP U-493	I-733	May 20, 2019
		7943788	Jul 14, 2027	DS DP	NC	Aug 08, 2017
		8222219	Jul 30, 2024	U-493	NCE	Mar 29, 2018
		8513202	Dec 03, 2027	DS DP U-493		
		8785403	Jul 30, 2024	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002	7943582	Feb 26, 2029	DS DP U-493		I-735	May 20, 2019
	7943788	Jul 14, 2027	DS DP		NC	Aug 08, 2017
	8222219	Jul 30, 2024	U-493		NCE	Mar 29, 2018
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003	7943582	Feb 26, 2029	DS DP U-493		I-735	May 20, 2019
	7943788	Jul 14, 2027	DS DP		NC	Aug 08, 2017
	8222219	Jul 30, 2024	U-493		NCE	Mar 29, 2018
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004	7943582	Feb 26, 2029	DS DP U-493		I-735	May 20, 2019
	7943788	Jul 14, 2027	DS DP		NC	Aug 08, 2017
	8222219	Jul 30, 2024	U-493		NCE	Mar 29, 2018
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 001	6723340	Oct 25, 2021	DP		I-735	May 20, 2019
	7943582	Feb 26, 2029	DS DP U-493		NC	Aug 08, 2017
	7943788	Jul 14, 2027	DS DP		NCE	Mar 29, 2018
	8222219	Jul 30, 2024	U-493			
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 002	7943582	Feb 26, 2029	DS DP U-493		I-735	May 20, 2019
	7943788	Jul 14, 2027	DS DP		NC	Aug 08, 2017
	8222219	Jul 30, 2024	U-493		NCE	Mar 29, 2018
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 003	6723340	Oct 25, 2021	DP		I-735	May 20, 2019
	7943582	Feb 26, 2029	DS DP U-493		NC	Aug 08, 2017
	7943788	Jul 14, 2027	DS DP		NCE	Mar 29, 2018
	8222219	Jul 30, 2024	U-493			
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 004	7943582	Feb 26, 2029	DS DP U-493		I-735	May 20, 2019
	7943788	Jul 14, 2027	DS DP		NC	Aug 08, 2017
	8222219	Jul 30, 2024	U-493		NCE	Mar 29, 2018
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
<u>CANGRELOR - KENGREAL</u>						
N 204958 001	6114313	Dec 11, 2017	DP U-1715		NCE	Jun 22, 2020
	6130208	Jun 29, 2018	DP U-1715			
	8680052	Mar 09, 2033	U-1715			
	8759316	May 13, 2029	U-1715			
	9295687	Jul 10, 2035	DP			
	9427448	Nov 10, 2030	U-1926			
	9439921	Jul 10, 2035	DP			
<u>CAPECITABINE - XELODA</u>						
N 020896 001					M-131	Dec 10, 2016
					PED	Jun 10, 2017
<u>CAPECITABINE - XELODA</u>						
N 020896 002					M-131	Dec 10, 2016
					PED	Jun 10, 2017

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CAPSAICIN - OUTENZA</u>						
N 022395	001 6239180	Nov 06, 2017	DP		ODE	Nov 16, 2016
<u>CARBAMAZEPINE - EQUETRO</u>						
N 021710	001 6977253	May 19, 2024	U-693			
<u>CARBAMAZEPINE - EQUETRO</u>						
N 021710	002 6977253	May 19, 2024	U-693			
<u>CARBAMAZEPINE - EQUETRO</u>						
N 021710	003 6977253	May 19, 2024	U-693			
<u>CARBAMAZEPINE - CARNEXIV</u>						
N 206030	001 7635773	Mar 13, 2029	DP		ODE	Oct 07, 2023
	8410077	Mar 13, 2029	DP			
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 50</u>						
N 021485	001 6500867	Jun 29, 2020	DP U-219			
	6797732	Jun 29, 2020	DP			
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 100</u>						
N 021485	002 6500867	Jun 29, 2020	DP U-219			
	6797732	Jun 29, 2020	DP			
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 150</u>						
N 021485	003 6500867	Jun 29, 2020	DP U-219			
	6797732	Jun 29, 2020	DP			
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 200</u>						
N 021485	004 6500867	Jun 29, 2020	DP U-219			
	6797732	Jun 29, 2020	DP			
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 75</u>						
N 021485	005 6500867	Jun 29, 2020	DP U-219			
	6797732	Jun 29, 2020	DP			
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 125</u>						
N 021485	006 6500867	Jun 29, 2020	DP U-219			
	6797732	Jun 29, 2020	DP			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	001 7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
	9463246	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	002 7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	002 9463246	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	003 7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
	9463246	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	004 7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
	9463246	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - DUOPA</u>						
N 203952	001				NP ODE	Jan 09, 2018 Jan 09, 2022
<u>CARBINOXAMINE MALEATE - KARBINAL ER</u>						
N 022556	001 8062667	Mar 29, 2029	DP			
	9522191	Mar 15, 2027	DP			
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714	001 7232818	Apr 14, 2025	DS DP		I-712	Jul 24, 2018
	7417042	Jul 20, 2026	DS DP		I-722	Jan 21, 2019
	7491704	Apr 14, 2025		U-1260	I-723	Jan 21, 2019
	7737112	Dec 07, 2027	DP		NCE	Jul 20, 2017
	8129346	Apr 14, 2025		U-1260	ODE	Jul 20, 2019
	8207125	Apr 14, 2025	DS DP			
	8207126	Apr 14, 2025	DP			
	8207127	Apr 14, 2025		U-1260		
	8207297	Apr 14, 2025	DS DP			
	9511109	Oct 21, 2029		U-1924		
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714	002 7232818	Apr 14, 2025	DS DP		I-712	Jul 24, 2018
	7417042	Jul 20, 2026	DS DP		I-722	Jan 21, 2019
	7491704	Apr 14, 2025		U-1260	I-723	Jan 21, 2019
	7737112	Dec 07, 2027	DP		NCE	Jul 20, 2017
	8129346	Apr 14, 2025		U-1260	ODE	Jul 20, 2019
	8207125	Apr 14, 2025	DS DP			
	8207126	Apr 14, 2025	DP			
	8207127	Apr 14, 2025		U-1260		
	8207297	Apr 14, 2025	DS DP			
	9511109	Oct 21, 2029		U-1924		
<u>CARGLUMIC ACID - CARBAGLU</u>						
N 022562	001				ODE	Mar 18, 2017

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 001	7737142	Mar 27, 2027	DS DP U-1750		NCE	Sep 17, 2020
	7943621	Dec 16, 2028	DS DP			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 002	7737142	Mar 27, 2027	DS DP U-1750		NCE	Sep 17, 2020
	7943621	Dec 16, 2028	DS DP			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 003	7737142	Mar 27, 2027	DS DP U-1750		NCE	Sep 17, 2020
	7943621	Dec 16, 2028	DS DP			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 004	7737142	Mar 27, 2027	DS DP U-1750		NCE	Sep 17, 2020
	7943621	Dec 16, 2028	DS DP			
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N 022012 001	7268156	Jun 27, 2023	DS DP U-3			
	7268156	Jun 27, 2023	DS DP U-313			
	8101209	Sep 11, 2025	DP			
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N 022012 002	7268156	Jun 27, 2023	DS DP U-3			
	7268156	Jun 27, 2023	DS DP U-313			
	8101209	Sep 11, 2025	DP			
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N 022012 003	7268156	Jun 27, 2023	DS DP U-3			
	7268156	Jun 27, 2023	DS DP U-313			
	8101209	Sep 11, 2025	DP			
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N 022012 004	7268156	Jun 27, 2023	DS DP U-3			
	7268156	Jun 27, 2023	DS DP U-313			
	8101209	Sep 11, 2025	DP			
<u>CASPOFUNGIN ACETATE - CANCIDAS</u>						
N 021227 001	5952300	Mar 28, 2017	DP			
	6136783	Mar 28, 2017	U-607			
<u>CASPOFUNGIN ACETATE - CANCIDAS</u>						
N 021227 002	5952300	Mar 28, 2017	DP			
	6136783	Mar 28, 2017	U-607			
<u>CEFDITOREN PIVOXIL - SPECTRACEF</u>						
N 021222 001	5958915	Oct 14, 2016				
<u>CEFDITOREN PIVOXIL - SPECTRACEF</u>						
N 021222 002	5958915	Oct 14, 2016	DP			
<u>CEFIXIME - SUPRAX</u>						
N 202091 001	9233112	Dec 14, 2028	DP U-1676			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 001	6417175	Apr 11, 2022	DS DP U-1676		NPP	May 27, 2019
	6906055	Dec 15, 2021	DS DP		NPP	May 27, 2019
	7419973	Dec 15, 2021	DP			
	8247400	Feb 10, 2031	DP U-282			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 002	6417175	Apr 11, 2022	DS DP U-1676		NPP	May 27, 2019
	6906055	Dec 15, 2021	DS DP		NPP	May 27, 2019
	7419973	Dec 15, 2021	DP			
	8247400	Feb 10, 2031	DP U-282			
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	7129232	Oct 21, 2024	DS DP U-36		NCE	Dec 19, 2019
	8476425	Sep 27, 2032	DS		GAIN	Dec 19, 2024
	8685957	Sep 27, 2032	DS U-36			
	8906898	May 28, 2034	DS DP			
	8968753	Mar 14, 2034	U-1676			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>Ceftolozane Sulfate; Tazobactam Sodium - Zerbaxa</u>						
N 206829	001	8968753	Mar 14, 2034	U-1673		
		9320740	Mar 14, 2034	DP		
<u>Ceritinib - Zykadia</u>						
N 205755	001	7153964	Feb 26, 2021	DS DP	NCE	Apr 29, 2019
		7893074	Apr 25, 2026	DS DP	ODE	Apr 29, 2021
		7964592	Jan 13, 2027	DS DP		
		8039479	Jun 29, 2030	DS DP		
		8377921	Nov 20, 2027	U-1179		
		8703787	Feb 02, 2032	U-1179		
		9309229	Jan 18, 2032	DS DP		
<u>Cetirizine Hydrochloride - Children's Zyrtec Allergy</u>						
N 021621	003	6455533	Jul 02, 2018	DP U-295		
<u>Cetirizine Hydrochloride - Children's Zyrtec Allergy</u>						
N 021621	004	6455533	Jul 02, 2018	DP U-295		
<u>Cetirizine Hydrochloride - Children's Zyrtec Hives Relief</u>						
N 021621	005	6455533	Jul 02, 2018	DP U-295		
<u>Cetirizine Hydrochloride - Children's Zyrtec Hives Relief</u>						
N 021621	006	6455533	Jul 02, 2018	DP U-295		
<u>Cetirizine Hydrochloride; Pseudoephedrine Hydrochloride - Zyrtec-D 12 Hour</u>						
N 021150	002	6469009	Jul 13, 2019	DP U-295		
		7014867	Jun 10, 2022	DP		
		7226614	Jun 10, 2022	U-295		
<u>Cetorelix - Cetrotide</u>						
N 021197	001	6319192	Apr 23, 2019	U-426		
<u>Cetorelix - Cetrotide</u>						
N 021197	002	6319192	Apr 23, 2019	U-426		
<u>Chlorhexidine Gluconate - Chlorhexidine Gluconate</u>						
N 021669	001	7066916	Feb 17, 2024	U-737		
		7427574	Apr 25, 2026	DP		
		7595021	May 12, 2023	DP U-1022		
		7717889	Feb 27, 2025	DP U-1022		
		7935093	Oct 02, 2027	DP U-1022		
<u>Chlorhexidine Gluconate; Isopropyl Alcohol - Chloraprep One-Step</u>						
N 020832	001	5690958	Sep 30, 2016	DP		
		6536975	Nov 10, 2020	DP		
<u>Chlorhexidine Gluconate; Isopropyl Alcohol - Chloraprep with Tint</u>						
N 020832	002	5690958	Sep 30, 2016	DP		
		6729786	Mar 14, 2023	DP		
		6991394	Jan 31, 2024	DP		
		7182536	Dec 30, 2023	DP		
		7241065	Mar 14, 2023	DP		
		7422388	Apr 25, 2027	DP U-1397		
<u>Chlorhexidine Gluconate; Isopropyl Alcohol - Chloraprep One-Step Frepp</u>						
N 020832	003	5690958	Sep 30, 2016	DP		
		5772346	Apr 22, 2017	DP		
<u>Chlorhexidine Gluconate; Isopropyl Alcohol - Chloraprep One-Step</u>						
N 020832	004	5690958	Sep 30, 2016	DP		
		6536975	Nov 10, 2020	DP		
<u>Chlorhexidine Gluconate; Isopropyl Alcohol - Chloraprep with Tint</u>						
N 020832	005	5690958	Sep 30, 2016	DP		
		6536975	Nov 10, 2020	DP		
		6729786	Mar 14, 2023	DP		
		7241065	Mar 14, 2023	DP		
		7422388	Apr 25, 2027	DP U-1397		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP</u>						
N 020832	006	5690958	Sep 30, 2016	DP		
		6991394	Jan 31, 2024	DP		
		7182536	Dec 30, 2023	DP		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832	007	5690958	Sep 30, 2016	DP		
		6536975	Nov 10, 2020	DP		
		6729786	Mar 14, 2023	DP		
		7241065	Mar 14, 2023	DP		
		7422388	Apr 25, 2027	DP U-1397		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS MAXI SWABSTICK</u>						
N 021524	003	D468424	Jan 07, 2017			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP SEPP</u>						
N 021555	001	5690958	Sep 30, 2016	DP		
<u>CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE - CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE</u>						
N 206323	001	6248363	Nov 23, 2019	DP U-1716		
		6383471	Apr 06, 2019	DP U-1716		
		9066942	Jan 03, 2032	U-1716		
		9107921	Jan 03, 2032	DP		
<u>CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - ADVIL ALLERGY SINUS</u>						
N 021441	001	7863287	Feb 28, 2027	DP		
<u>CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX - TUZISTRA XR</u>						
N 207768	001	8062667	Mar 29, 2029	DP		
		8790700	Mar 15, 2027	DP		
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750	001				NCE	Mar 17, 2020
					ODE	Mar 17, 2022
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750	002				NCE	Mar 17, 2020
					ODE	Mar 17, 2022
<u>CHOLINE C-11 - CHOLINE C-11</u>						
N 203155	001				NCE	Sep 12, 2017
					W	Sep 12, 2017
<u>CHOLINE FENOFIBRATE - TRILIPIX</u>						
N 022224	001	7259186	Jan 07, 2025	DS		
<u>CHOLINE FENOFIBRATE - TRILIPIX</u>						
N 022224	002	7259186	Jan 07, 2025	DS		
<u>CHORIOGONADOTROPIN ALFA - OVIDREL</u>						
N 021149	002	6706681	Mar 16, 2021	DP		
<u>CICLESONIDE - ALVESCO</u>						
N 021658	002	5482934	Oct 24, 2017	DS DP U-1002		
		6006745	Dec 28, 2016	DP		
		6120752	May 13, 2018	DP		
		6264923	May 13, 2018	DP		
		8371292	Feb 01, 2028	U-1355		
<u>CICLESONIDE - ALVESCO</u>						
N 021658	003	5482934	Oct 24, 2017	DS DP U-1002		
		6006745	Dec 28, 2016	DP		
		6120752	May 13, 2018	DP		
		6264923	May 13, 2018	DP		
		8371292	Feb 01, 2028	U-1355		
<u>CICLESONIDE - OMNARIS</u>						
N 022004	001	5482934	Oct 24, 2017	DS DP U-557		
		6767901	Oct 21, 2020	DP		
		6939559	Apr 21, 2019	DP		
		7335247	Apr 21, 2019	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CICLESONIDE - OMNARIS</u>						
N 022004 001	8371292	Feb 01, 2028	U-1356			
	8383611	Oct 20, 2020	DP			
<u>CICLESONIDE - ZETONNA</u>						
N 202129 001	5482934	Oct 24, 2017	DS DP U-1002			
	6006745	Dec 28, 2016	DP			
	6120752	May 13, 2018	DP			
	6264923	May 13, 2018	DP			
	8371292	Feb 01, 2028	U-1357			
<u>CICLOPIROX - LOPROX</u>						
N 020519 001	7018656	Sep 05, 2018	DP			
	7026337	Nov 21, 2016	U-714			
<u>CICLOPIROX - LOPROX</u>						
N 021159 001	7981909	Sep 16, 2017	U-1162			
	8227490	Sep 16, 2017	U-1256			
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 001	6011068	Mar 08, 2018	DS DP		ODE	Feb 25, 2018
	6031003	Dec 14, 2016	U-559		ODE	Nov 21, 2021
	6313146	Dec 14, 2016	DS DP			
	7829595	Sep 22, 2026	DP U-1098			
	9375405	Sep 22, 2026	DP			
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 002	6011068	Mar 08, 2018	DS DP		ODE	Feb 25, 2018
	6031003	Dec 14, 2016	U-559		ODE	Nov 21, 2021
	6313146	Dec 14, 2016	DS DP			
	7829595	Sep 22, 2026	DP U-1098			
	9375405	Sep 22, 2026	DP			
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 003	6011068	Mar 08, 2018	DS DP		ODE	Feb 25, 2018
	6031003	Dec 14, 2016	U-559		ODE	Nov 21, 2021
	6313146	Dec 14, 2016	DS DP			
	7829595	Sep 22, 2026	DP U-1098			
	9375405	Sep 22, 2026	DP			
<u>CIPROFLOXACIN - OTIPRIO</u>						
N 207986 001	8318817	Apr 27, 2030	U-1792		NP	Dec 10, 2018
	9205048	Apr 21, 2029	U-1793			
	9220796	Jul 01, 2035	DP			
	9233068	Dec 11, 2029	DP			
<u>CIPROFLOXACIN HYDROCHLORIDE - PROQUIN XR</u>						
N 021744 001	5972389	Sep 19, 2016	DP U-663			
	6340475	Sep 19, 2016	DP U-663			
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP U-663			
<u>CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE - OTOVEL</u>						
N 208251 001	8932610	Mar 24, 2030	DP U-1578		NC	Apr 29, 2019
<u>CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR</u>						
N 021473 001	7709022	Jun 23, 2021	DP			
	8187632	Jun 23, 2021	DP			
	8187632*PED	Dec 23, 2021				
<u>CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR</u>						
N 021473 002	7709022	Jun 23, 2021	DP			
	8187632	Jun 23, 2021	DP			
	8187632*PED	Dec 23, 2021				
<u>CIPROFLOXACIN; DEXAMETHASONE - CIPRODEX</u>						
N 021537 001	6284804	Aug 10, 2020				
	6359016	Aug 10, 2020				
	8846650	Jun 04, 2025	DP U-1578			
	9149486	Sep 13, 2022	DP U-1578			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CIPROFLOXACIN; DEXAMETHASONE - CIPRODEX</u>						
N 021537	001	9345714	Sep 13, 2022	DP U-1578		
		9402805	Sep 13, 2022	DP U-1578		
		9402805	Sep 13, 2022	DP U-1679		
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - PREPOPIK</u>						
N 202535	001	8450338	Oct 10, 2028	DP		
		8481083	Oct 10, 2028	DP		
<u>CLARITHROMYCIN - BIAXIN XL</u>						
N 050775	001	6010718	Apr 11, 2017	DP U-924		
		6551616	Jun 15, 2017	U-924		
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156	001	5856346	Jan 05, 2021	DS DP U-893		
		8658676	Oct 10, 2031	DP		
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156	002	5856346	Jan 05, 2021	DS DP U-893		
		8658676	Oct 10, 2031	DP		
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156	003	5856346	Jan 05, 2021	DS DP U-893		
		8658676	Oct 10, 2031	DP		
<u>CLINDAMYCIN PHOSPHATE - CLEOCIN</u>						
N 050767	001	6495157	Jul 20, 2020	DP		
<u>CLINDAMYCIN PHOSPHATE - CLINDAGEL</u>						
N 050782	001	6387383	Aug 03, 2020	DP U-818		
<u>CLINDAMYCIN PHOSPHATE - CLINDESSE</u>						
N 050793	001	5993856	Nov 17, 2017	DP U-137		
		6899890	Apr 27, 2023	DP U-137		
<u>CLINDAMYCIN PHOSPHATE - EVOCLIN</u>						
N 050801	001	7141237	Jan 23, 2024	DS DP		
		7374747	Aug 09, 2026	DS DP U-921		
<u>CLINDAMYCIN PHOSPHATE; TRETINOIN - ZIANA</u>						
N 050802	001	6387383	Aug 03, 2020	DP U-916		
<u>CLINDAMYCIN PHOSPHATE; TRETINOIN - VELTIN</u>						
N 050803	001	9492384	Aug 31, 2025	DP U-1412		
<u>CLOBAZAM - ONFI</u>						
N 202067	001				NCE	Oct 21, 2016
					ODE	Oct 21, 2018
<u>CLOBAZAM - ONFI</u>						
N 202067	002				NCE	Oct 21, 2016
					ODE	Oct 21, 2018
<u>CLOBAZAM - ONFI</u>						
N 202067	003				NCE	Oct 21, 2016
					ODE	Oct 21, 2018
<u>CLOBAZAM - ONFI</u>						
N 203993	001				NCE	Oct 21, 2016
					ODE	Oct 21, 2018
<u>CLOBETASOL PROPIONATE - CLOBEX</u>						
N 021535	001	6106848	Sep 22, 2017			
<u>CLOBETASOL PROPIONATE - CLOBEX</u>						
N 021644	001	7316810	Jun 17, 2019	DP		
		7700081	Jan 03, 2022	U-1044		
		8066975	Jun 17, 2019	DP		
		8066976	Jun 17, 2019	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CLOBETASOL PROPIONATE - CLOBEX</u>						
N 021835	001	5972920	Feb 12, 2018	DP		
		5990100	Mar 24, 2018	DP U-742		
<u>CLOBETASOL PROPIONATE - OLUX E</u>						
N 022013	001	6730288	Sep 08, 2019	DP		
		7029659	Sep 08, 2019	DP		
		8460641	Nov 05, 2028	DP U-1410		
		8962000	Aug 31, 2025	DP U-1410		
<u>CLOFARABINE - CLOLAR</u>						
N 021673	001	5661136	Jan 14, 2018	U-626		
<u>CLONIDINE HYDROCHLORIDE - KAPVAY</u>						
N 022331	003				M-149	Nov 20, 2017
<u>CLONIDINE HYDROCHLORIDE - KAPVAY</u>						
N 022331	004				M-149	Nov 20, 2017
<u>CLOPIDOGREL BISULFATE - PLAVIX</u>						
N 020839	001	6429210	Jun 10, 2019	DS DP		
		6504030	Jun 10, 2019	DS		
<u>CLOPIDOGREL BISULFATE - PLAVIX</u>						
N 020839	002	6429210	Jun 10, 2019	DS DP		
		6504030	Jun 10, 2019	DS		
<u>CLOZAPINE - FAZACLO ODT</u>						
N 021590	001	6024981	Apr 09, 2018	DP		
		6106861	Dec 05, 2017	DP		
		6221392	Apr 09, 2018	DP		
<u>CLOZAPINE - FAZACLO ODT</u>						
N 021590	002	6024981	Apr 09, 2018	DP		
		6106861	Dec 05, 2017	DP		
		6221392	Apr 09, 2018	DP		
<u>CLOZAPINE - FAZACLO ODT</u>						
N 021590	003	6024981	Apr 09, 2018	DP		
		6106861	Dec 05, 2017	DP		
		6221392	Apr 09, 2018	DP		
<u>CLOZAPINE - FAZACLO ODT</u>						
N 021590	004	6024981	Apr 09, 2018	DP		
		6106861	Dec 05, 2017	DP		
		6221392	Apr 09, 2018	DP		
<u>CLOZAPINE - FAZACLO ODT</u>						
N 021590	005	6024981	Apr 09, 2018	DP		
		6106861	Dec 05, 2017	DP		
		6221392	Apr 09, 2018	DP		
<u>CLOZAPINE - FAZACLO ODT</u>						
N 021590	006	6024981	Apr 09, 2018	DP		
		6106861	Dec 05, 2017	DP		
		6221392	Apr 09, 2018	DP		
<u>COBICISTAT - TYBOST</u>						
N 203094	001	8148374	Sep 03, 2029	DS DP U-1279	NP	Sep 24, 2017
<u>COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX</u>						
N 205395	001	7470506	Jun 23, 2019	U-1660		
		7470506*PED	Dec 23, 2019			
		7700645	Dec 26, 2026	DS DP		
		7700645*PED	Jun 26, 2027			
		8148374	Sep 03, 2029	DS DP U-1660		
		8518987	Feb 16, 2024	DS DP		
		8518987*PED	Aug 16, 2024			
		8597876	Jun 23, 2019	U-1660		
		8597876*PED	Dec 23, 2019			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX</u>						
N 205395	001	RE42889*PED	Apr 19, 2017			
		RE43596	May 09, 2017	DS DP		
		RE43596*PED	Nov 09, 2017			
		RE43802	Oct 19, 2016		U-1660	
		RE43802*PED	Apr 19, 2017			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561	001	5914331	Jul 02, 2017	DS	NCE	Nov 05, 2020
		5914331*PED	Jan 02, 2018			
		6642245	Nov 04, 2020		U-257	
		6642245*PED	May 04, 2021			
		6703396	Mar 09, 2021	DS DP		
		6703396*PED	Sep 09, 2021			
		7176220	Nov 20, 2023	DS DP	U-257	
		7390791	May 07, 2022	DS DP		
		7635704	Oct 26, 2026	DS DP	U-257	
		7803788	Feb 02, 2022		U-257	
		8148374	Sep 03, 2029	DS DP	U-1279	
		8633219	Apr 24, 2030	DP	U-257	
		8754065	Aug 15, 2032	DS DP	U-257	
		8981103	Oct 26, 2026	DS DP		
		9296769	Aug 15, 2032	DS DP	U-257	
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100	001	5914331	Jul 02, 2017	DS	I-704	Dec 17, 2017
		5922695	Jul 25, 2017	DS	U-257	
		5935946	Jul 25, 2017	DS DP	U-257	
		5977089	Jul 25, 2017	DS DP	U-257	
		6043230	Jul 25, 2017		U-257	
		6642245	Nov 04, 2020		U-257	
		6703396	Mar 09, 2021	DS DP		
		7176220	Nov 20, 2023	DS DP	U-257	
		7635704	Oct 26, 2026	DS DP	U-257	
		8148374	Sep 03, 2029	DS DP	U-1279	
		8592397	Jan 13, 2024	DP	U-257	
		8633219	Apr 24, 2030	DP	U-257	
		8716264	Jan 13, 2024	DP	U-257	
		8981103	Oct 26, 2026	DS DP		
		9457036	Jan 13, 2024	DP	U-257	
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192	001	7803839	Feb 01, 2027	DS DP	NCE	Nov 10, 2020
		8362002	Oct 05, 2026		ODE	Nov 10, 2022
<u>COLCHICINE - COLCRYS</u>						
N 022352	001	7601758	Feb 10, 2029		ODE	Jul 29, 2016
		7619004	Dec 03, 2028		U-1020	
		7820681	Feb 17, 2029		U-1020	
		7906519	Feb 17, 2029		U-1116	
		7915269	Feb 17, 2029		U-1007	
		7935731	Dec 03, 2028		U-1116	
		7964647	Oct 06, 2028		U-1007	
		7964648	Oct 06, 2028		U-1161	
		7981938	Oct 06, 2028		U-1166	
		8093296	Oct 06, 2028		U-1007	
		8093297	Oct 06, 2028		U-1161	
		8093298	Oct 06, 2028		U-1116	
		8097655	Oct 06, 2028		U-1020	
		8415395	Oct 06, 2028		U-1007	
		8415396	Oct 06, 2028		U-1007	
		8440721	Feb 17, 2029		U-1007	
		8440722	Feb 17, 2029		U-1020	
<u>COLCHICINE - MITIGARE</u>						
N 204820	001	8927607	Aug 22, 2033		U-1020	
		9399036	Aug 22, 2033		U-1020	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N 021176	001	7229613	Apr 17, 2022	U-851		
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N 022362	001	7229613	Apr 17, 2022	U-493		
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N 022362	002	7229613	Apr 17, 2022	U-493		
<u>CONIVAPTAN HYDROCHLORIDE - VAPRISOL</u>						
N 021697	001	5723606	Dec 15, 2019	DS DP U-698		
		5723606	Dec 15, 2019	DS DP U-868		
<u>CONIVAPTAN HYDROCHLORIDE - VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER</u>						
N 021697	002	5723606	Dec 15, 2019	DS DP U-698		
		5723606	Dec 15, 2019	DS DP U-868		
<u>CORTICOTROPIN - H.P. ACTHAR GEL</u>						
N 008372	008				ODE	Oct 15, 2017
<u>CRIZOTINIB - XALKORI</u>						
N 202570	001	7230098	Aug 26, 2025	DS	M-163	Sep 14, 2018
		7825137	May 12, 2027	U-1179	NCE	Aug 26, 2016
		7858643	Oct 08, 2029	DS DP	ODE	Aug 26, 2018
		8217057	Nov 06, 2029	DS DP	ODE	Mar 11, 2023
		8785632	Mar 01, 2025	DS		
<u>CRIZOTINIB - XALKORI</u>						
N 202570	002	7230098	Aug 26, 2025	DS	M-163	Sep 14, 2018
		7825137	May 12, 2027	U-1179	NCE	Aug 26, 2016
		7858643	Oct 08, 2029	DS DP	ODE	Aug 26, 2018
		8217057	Nov 06, 2029	DS DP	ODE	Mar 11, 2023
		8785632	Mar 01, 2025	DS		
<u>CROFELEMER - FULYZAQ</u>						
N 202292	001	7323195	Jun 07, 2018	DP	NCE	Dec 31, 2017
		7341744	Jun 16, 2018	U-1319		
		8574634	Jan 11, 2018	U-1319		
		8962680	Oct 31, 2031	U-1319		
<u>CYANOCOBALAMIN - NASCOBAL</u>						
N 021642	001	7229636	Aug 01, 2024	DP U-817		
		7404489	Mar 12, 2024	DP		
		7879349	Aug 01, 2024	DP U-1152		
		8003353	Aug 01, 2024	U-817		
		8940714	Feb 26, 2024	U-1152		
		9415007	Jul 28, 2024	U-1896		
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N 021777	001	7387793	Feb 26, 2025	DP		
		7544372	Nov 14, 2023	U-979		
		7790199	Nov 14, 2023	DP		
		7820203	Nov 14, 2023	DP		
		7829121	Nov 14, 2023	U-1088		
		9375410	Nov 14, 2023	U-1088		
		9399025	Nov 14, 2023	DP U-979		
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N 021777	002	7387793	Feb 26, 2025	DP		
		7544372	Nov 14, 2023	U-979		
		7790199	Nov 14, 2023	DP		
		7820203	Nov 14, 2023	DP		
		7829121	Nov 14, 2023	U-1088		
		9375410	Nov 14, 2023	U-1088		
		9399025	Nov 14, 2023	DP U-979		
<u>CYCLOSPORINE - RESTASIS</u>						
N 050790	001	8629111	Aug 27, 2024	DP		
		8633162	Aug 27, 2024	U-1479		
		8642556	Aug 27, 2024	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CYCLOSPORINE - RESTASIS</u>						
N 050790 001	8648048	Aug 27, 2024	U-1483			
	8685930	Aug 27, 2024	DP			
	9248191	Aug 27, 2024	U-1479			
<u>CYCLOSPORINE - RESTASIS MULTIDOSE</u>						
N 050790 002	8629111	Aug 27, 2024	DP			
	8633162	Aug 27, 2024	U-1479			
	8642556	Aug 27, 2024	DP			
	8648048	Aug 27, 2024	U-1483			
	8685930	Aug 27, 2024	DP			
	9248191	Aug 27, 2024	U-1479			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	8026284	Sep 22, 2027	U-1399		NPP	Aug 14, 2018
	9173851	Jun 17, 2034	DP		ODE	Apr 30, 2020
	9192590	Jan 26, 2027	U-1399		ODE	Aug 14, 2022
	9198882	Jan 26, 2027	U-1399			
	9233077	Jun 17, 2034	DP			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	8026284	Sep 22, 2027	U-1399		NPP	Aug 14, 2018
	9173851	Jun 17, 2034	DP		ODE	Apr 30, 2020
	9192590	Jan 26, 2027	U-1399		ODE	Aug 14, 2022
	9198882	Jan 26, 2027	U-1399			
	9233077	Jun 17, 2034	DP			
<u>CYSTEAMINE HYDROCHLORIDE - CYSTARAN</u>						
N 200740 001					ODE	Oct 02, 2019
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 001	6087380	Feb 18, 2018	DS DP U-1089		I-682	Apr 04, 2017
	7866474	Aug 31, 2027	DP		I-683	Apr 04, 2017
	7932273	Sep 07, 2025	DS DP		M-168	Nov 20, 2018
	9034822	Jan 20, 2031	U-1759			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 002	6087380	Feb 18, 2018	DS DP U-1089		I-682	Apr 04, 2017
	7866474	Aug 31, 2027	DP		I-683	Apr 04, 2017
	7932273	Sep 07, 2025	DS DP		M-168	Nov 20, 2018
	9034822	Jan 20, 2031	U-1759			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 003	6087380	Feb 18, 2018	DS DP U-1089		NS	Nov 20, 2018
	7866474	Aug 31, 2027	DP			
	7932273	Sep 07, 2025	DS DP			
	9034822	Jan 20, 2031	U-1759			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	7994185	Jan 20, 2030	DS DP U-1406		I-678	Jan 08, 2017
	8415345	Jan 20, 2030	DS DP U-1406		M-170	Nov 20, 2018
	8703781	Oct 15, 2030	DS DP U-1713		NCE	May 29, 2018
	9233956	May 04, 2029	U-1811		ODE	May 29, 2020
					ODE	Jan 09, 2021
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	7994185	Jan 20, 2030	DS DP U-1406		I-678	Jan 08, 2017
	8415345	Jan 20, 2030	DS DP U-1406		M-170	Nov 20, 2018
	8703781	Oct 15, 2030	DS DP U-1713		NCE	May 29, 2018
	9233956	May 04, 2029	U-1811		ODE	May 29, 2020
					ODE	Jan 09, 2021
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 001	8329159	Apr 13, 2028	DS		D-161	Feb 05, 2019
	8629171	Jun 13, 2031	DS DP U-1724		D-162	Feb 05, 2019
	8642025	Aug 11, 2027	DS DP U-1724		I-726	Feb 05, 2019
	8642025	Aug 11, 2027	DS DP U-1725		I-727	Feb 05, 2019
	8900566	Aug 08, 2027	U-1724		NCE	Jul 24, 2020
	8900566	Aug 08, 2027	U-1725			
	9421192	Aug 08, 2027	DS U-1724			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843	001	9421192	Aug 08, 2027	DS U-1725		
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843	002	8329159	Apr 13, 2028	DS	D-161	Feb 05, 2019
		8629171	Jun 13, 2031	DS DP U-1724	D-162	Feb 05, 2019
		8642025	Aug 11, 2027	DS DP U-1724	I-726	Feb 05, 2019
		8642025	Aug 11, 2027	DS DP U-1725	I-727	Feb 05, 2019
		8900566	Aug 08, 2027	U-1724	NCE	Jul 24, 2020
		8900566	Aug 08, 2027	U-1725		
		9421192	Aug 08, 2027	DS U-1724		
		9421192	Aug 08, 2027	DS U-1725		
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843	003	9421192	Aug 08, 2027	DS U-1724		
		9421192	Aug 08, 2027	DS U-1725		
<u>DALBAVANCIN HYDROCHLORIDE - DALVANCE</u>						
N 021883	001	6900175	Dec 25, 2023	U-1517	D-154	Jan 20, 2019
		7115564	Nov 14, 2023	DP	NCE	May 23, 2019
		7119061	Nov 14, 2023	DP	GAIN	May 23, 2024
		8143212	Nov 14, 2023	U-1517		
<u>DALFAMPRIDINE - AMPYRA</u>						
N 022250	001	5540938	Jul 30, 2018	U-1030	ODE	Jan 22, 2017
		8007826	May 26, 2027	U-1030		
		8354437	Dec 22, 2026	U-1030		
		8440703	Apr 08, 2025	U-1030		
		8663685	Jan 18, 2025	U-1030		
<u>DANTROLENE SODIUM - RYANODEX</u>						
N 205579	001	7758890	Jul 01, 2025	DP	ODE	Jul 22, 2021
		8110225	Dec 24, 2022	DP		
		8604072	Dec 24, 2022	DP		
		8685460	Feb 15, 2023	U-1546		
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293	001	6414126	Oct 04, 2020	DS DP U-493	M-157	Mar 11, 2018
		6515117	Oct 04, 2020	DS DP U-493	NCE	Jan 08, 2019
		6936590	Oct 04, 2020	U-493		
		7851502	Aug 19, 2028	DP		
		7919598	Dec 16, 2029	DS		
		8221786	Mar 21, 2028	DP		
		8361972	Mar 21, 2028	U-493		
		8501698	Jun 20, 2027	DP U-493		
		8685934	May 26, 2030	U-1522		
		8716251	Mar 21, 2028	DP		
		9198925	Oct 04, 2020	U-493		
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293	002	6414126	Oct 04, 2020	DS DP U-493	M-157	Mar 11, 2018
		6515117	Oct 04, 2020	DS DP U-493	NCE	Jan 08, 2019
		6936590	Oct 04, 2020	U-493		
		7851502	Aug 19, 2028	DP		
		7919598	Dec 16, 2029	DS		
		8221786	Mar 21, 2028	DP		
		8361972	Mar 21, 2028	U-493		
		8501698	Jun 20, 2027	DP U-493		
		8685934	May 26, 2030	U-1522		
		8716251	Mar 21, 2028	DP		
		9198925	Oct 04, 2020	U-493		
<u>DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649	001	6414126	Oct 04, 2020	DS DP U-493	NCE	Jan 08, 2019
		6515117	Oct 04, 2020	DS DP U-493		
		6936590	Oct 04, 2020	U-493		
		7919598	Dec 16, 2029	DS		
		8501698	Jun 20, 2027	DP U-493		
		8685934	May 26, 2030	U-1522		
		9198925	Oct 04, 2020	U-493		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 001	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	9198925	Oct 04, 2020	U-493			
<u>DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 002	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	9198925	Oct 04, 2020	U-493			
<u>DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 003	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	9198925	Oct 04, 2020	U-493			
<u>DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 004	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	9198925	Oct 04, 2020	U-493			
<u>DAPSONE - ACZONE</u>						
N 021794 001	5863560	Sep 11, 2016	DP			
	6060085	Sep 11, 2016	U-124			
	6620435	Sep 11, 2016	DP			
<u>DAPSONE - ACZONE</u>						
N 207154 001	5863560	Sep 11, 2016	DP		NS	Feb 24, 2019
	6060085	Sep 11, 2016	U-124			
	6620435	Sep 11, 2016	DP			
	9161926	Nov 18, 2033	DP			
	9517219	Nov 18, 2033	U-1033			
<u>DAPTOMYCIN - CUBICIN</u>						
N 021572 001	6468967	Sep 24, 2019	U-282			
	6852689	Sep 24, 2019	U-282			
	8058238	Nov 28, 2020	DS DP			
<u>DAPTOMYCIN - CUBICIN</u>						
N 021572 002	6468967	Sep 24, 2019	U-282			
	6852689	Sep 24, 2019	U-282			
	8003673	Sep 04, 2028	U-1180			
	8058238	Nov 28, 2020	DS DP			
	8129342	Nov 28, 2020	DS DP			
<u>DAPTOMYCIN - CUBICIN RF</u>						
N 021572 003	9138456	Nov 23, 2030	DP			
<u>DARIFENACIN HYDROBROMIDE - ENABLEX</u>						
N 021513 001	6106864	Aug 21, 2016	DP U-630			
<u>DARIFENACIN HYDROBROMIDE - ENABLEX</u>						
N 021513 002	6106864	Aug 21, 2016	DP U-630			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 001	7470506	Jun 23, 2019		U-935	PED	Aug 01, 2016
	7470506	Jun 23, 2019		U-1209		
	7470506	Jun 23, 2019		U-1305		
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019		U-1305		
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016		DP		
	RE43596	May 09, 2017	DS DP			
	RE43802	Oct 19, 2016		U-1305		
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 002	7470506	Jun 23, 2019		U-935	PED	Aug 01, 2016
	7470506	Jun 23, 2019		U-1209		
	7470506	Jun 23, 2019		U-1305		
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019		U-1305		
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016		DP		
	RE43596	May 09, 2017	DS DP			
	RE43802	Oct 19, 2016		U-1305		
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 003	7470506	Jun 23, 2019		U-935	PED	Aug 01, 2016
	7470506	Jun 23, 2019		U-1209		
	7470506	Jun 23, 2019		U-1305		
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019		U-1305		
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016		DP		
	RE43596	May 09, 2017	DS DP			
	RE43802	Oct 19, 2016		U-1305		
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 004	7470506	Jun 23, 2019		U-935	PED	Aug 01, 2016
	7470506	Jun 23, 2019		U-1209		
	7470506	Jun 23, 2019		U-1305		
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019		U-1305		
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016		DP		
	RE43596	May 09, 2017	DS DP			
	RE43802	Oct 19, 2016		U-1305		
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 005	7470506	Jun 23, 2019		U-935	PED	Aug 01, 2016
	7470506	Jun 23, 2019		U-1209		
	7470506	Jun 23, 2019		U-1305		
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019		U-1305		
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016		DP		
	RE43596	May 09, 2017	DS DP			
	RE43802	Oct 19, 2016		U-1305		
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 006	7470506	Jun 23, 2019		U-935	PED	Aug 01, 2016
	7470506	Jun 23, 2019		U-1209		
	7470506	Jun 23, 2019		U-1305		
	7700645	Dec 26, 2026	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 006	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019		U-1305		
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE43596	May 09, 2017	DS DP			
	RE43802	Oct 19, 2016		U-1305		
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 202895 001	7470506	Jun 23, 2019		U-1209	PED	Aug 01, 2016
	7470506	Jun 23, 2019		U-1305		
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019		U-1305		
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE43596	May 09, 2017	DS DP			
	RE43802	Oct 19, 2016		U-1305		
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619 001	7148359	Jul 19, 2019	DP		D-163	Apr 22, 2019
	7364752	Nov 10, 2020	DP		NCE	Dec 19, 2019
	8188104	May 17, 2029	DS DP	U-1636		
	8268349	Aug 25, 2024	DP			
	8399015	Aug 25, 2024	DP			
	8420596	Apr 10, 2031	DS DP			
	8466159	Sep 04, 2032		U-1637		
	8492386	Sep 04, 2032		U-1840		
	8501238	Sep 17, 2028	DS DP	U-1636		
	8642538	Sep 10, 2029	DS DP	U-1638		
	8680106	Sep 04, 2032		U-1637		
	8685984	Sep 04, 2032		U-1840		
	8686026	Jun 09, 2031	DP			
	8691938	Apr 13, 2032	DS DP			
	9006387	Jun 10, 2030		U-1687		
	9044480	Apr 10, 2031		U-1638		
	9139536	Nov 09, 2028		U-1753		
<u>DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA XR</u>						
N 208624 001	7148359	Jul 19, 2019	DP		NCE	Dec 19, 2019
	7364752	Nov 10, 2020	DP			
	8188104	May 17, 2029	DS DP	U-1636		
	8268349	Aug 25, 2024	DP			
	8399015	Aug 25, 2024	DP			
	8420596	Apr 10, 2031	DS DP			
	8466159	Sep 04, 2032		U-1637		
	8492386	Sep 04, 2032		U-1840		
	8501238	Sep 17, 2028	DS DP	U-1636		
	8642538	Sep 10, 2029	DS DP	U-1638		
	8680106	Sep 04, 2032		U-1637		
	8685984	Sep 04, 2032		U-1840		
	8686026	Jun 09, 2031	DP			
	8691938	Apr 13, 2032	DS DP			
	9006387	Jun 10, 2030		U-1687		
	9044480	Apr 10, 2031		U-1638		
	9139536	Nov 09, 2028		U-1753		
	9333204	Jan 02, 2035	DP	U-1889		
<u>DASATINIB - SPRYCEL</u>						
N 021986 001	6596746	Jun 28, 2020	DS DP	U-748		
	6596746	Jun 28, 2020	DS DP	U-780		
	7125875	Apr 13, 2020		U-779		
	7125875	Apr 13, 2020		U-780		
	7153856	Apr 28, 2020		U-780		
	7491725	Mar 28, 2026	DS DP			
	8680103	Feb 04, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DASATINIB - SPRYCEL</u>						
N 021986	002	6596746	Jun 28, 2020	DS DP	U-748	
		6596746	Jun 28, 2020	DS DP	U-780	
		7125875	Apr 13, 2020		U-779	
		7125875	Apr 13, 2020		U-780	
		7153856	Apr 28, 2020		U-780	
		7491725	Mar 28, 2026	DS DP		
		8680103	Feb 04, 2025	DP		
<u>DASATINIB - SPRYCEL</u>						
N 021986	003	6596746	Jun 28, 2020	DS DP	U-748	
		6596746	Jun 28, 2020	DS DP	U-780	
		7125875	Apr 13, 2020		U-779	
		7125875	Apr 13, 2020		U-780	
		7153856	Apr 28, 2020		U-780	
		7491725	Mar 28, 2026	DS DP		
		8680103	Feb 04, 2025	DP		
<u>DASATINIB - SPRYCEL</u>						
N 021986	004	6596746	Jun 28, 2020	DS DP	U-748	
		6596746	Jun 28, 2020	DS DP	U-780	
		7125875	Apr 13, 2020		U-779	
		7125875	Apr 13, 2020		U-780	
		7153856	Apr 28, 2020		U-780	
		7491725	Mar 28, 2026	DS DP		
		8680103	Feb 04, 2025	DP		
<u>DASATINIB - SPRYCEL</u>						
N 021986	005	6596746	Jun 28, 2020	DS DP	U-748	
		6596746	Jun 28, 2020	DS DP	U-780	
		7125875	Apr 13, 2020		U-779	
		7125875	Apr 13, 2020		U-780	
		7153856	Apr 28, 2020		U-780	
		7491725	Mar 28, 2026	DS DP		
		8680103	Feb 04, 2025	DP		
<u>DASATINIB - SPRYCEL</u>						
N 021986	006	6596746	Jun 28, 2020	DS DP	U-748	
		6596746	Jun 28, 2020	DS DP	U-780	
		7125875	Apr 13, 2020		U-779	
		7125875	Apr 13, 2020		U-780	
		7153856	Apr 28, 2020		U-780	
		7491725	Mar 28, 2026	DS DP		
		8680103	Feb 04, 2025	DP		
<u>DEFERASIROX - EXJADE</u>						
N 021882	001	6465504	Apr 05, 2019	DS DP		ODE Jan 23, 2020
		6596750	Jun 24, 2017	DS	U-735	
<u>DEFERASIROX - EXJADE</u>						
N 021882	002	6465504	Apr 05, 2019	DS DP		ODE Jan 23, 2020
		6596750	Jun 24, 2017	DS	U-735	
<u>DEFERASIROX - EXJADE</u>						
N 021882	003	6465504	Apr 05, 2019	DS DP		ODE Jan 23, 2020
		6596750	Jun 24, 2017	DS	U-735	
<u>DEFERASIROX - JADENU</u>						
N 206910	001	6465504	Apr 05, 2019	DS DP		ODE Jan 23, 2020
		6596750	Jun 24, 2017	DS	U-735	
		9283209	Nov 21, 2034	DS DP		
<u>DEFERASIROX - JADENU</u>						
N 206910	002	6465504	Apr 05, 2019	DS DP		ODE Jan 23, 2020
		6596750	Jun 24, 2017	DS	U-735	
		9283209	Nov 21, 2034	DS DP		
<u>DEFERASIROX - JADENU</u>						
N 206910	003	6465504	Apr 05, 2019	DS DP		ODE Jan 23, 2020
		6596750	Jun 24, 2017	DS	U-735	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEFERASIROX - JADENU</u>						
N 206910	003 9283209	Nov 21, 2034	DS DP			
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825	001 7049328	Jun 28, 2021		U-735	NCE ODE	Oct 14, 2016 Oct 14, 2018
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030	001 7049328 8703156	Jun 28, 2021 Oct 29, 2029		U-735 DP U-735	NCE ODE	Oct 14, 2016 Oct 14, 2018
<u>DEFIBROTIDE SODIUM - DEFITELIO</u>						
N 208114	001				NCE ODE	Mar 30, 2021 Mar 30, 2023
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201	001 5925730 9415085	May 18, 2021 Apr 27, 2032	DS DP	U-943 U-1895		
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201	002 5925730 9415085	May 18, 2021 Apr 27, 2032	DS DP	U-943 U-1895		
<u>DELAVIRDINE MESYLATE - RESCRIPTOR</u>						
N 020705	002 6177101	Jun 07, 2019				
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333	001 7622130 7754230 8101593 8242294 8298556 8367649 8461140 8546367 8653058 8846066 8883770	Dec 10, 2027 Dec 10, 2027 Mar 02, 2030 May 16, 2028 Aug 03, 2025 Mar 02, 2030 Feb 21, 2028 Feb 21, 2028 Mar 02, 2030 Feb 08, 2025 Feb 21, 2028		U-1690 U-1690 DP DS U-1690 DP DP DP U-1690 DP U-1690 DP		
<u>DESLORATADINE - CLARINEX</u>						
N 021165	001 6100274 7405223	Jul 07, 2019 Jul 07, 2019			U-886	
<u>DESLORATADINE - CLARINEX</u>						
N 021300	001 6514520	Jun 01, 2018	DP			
<u>DESLORATADINE - CLARINEX</u>						
N 021312	001 6100274 7618649	Jul 07, 2019 Dec 19, 2020		DP DP U-1017		
<u>DESLORATADINE - CLARINEX</u>						
N 021312	002 6100274 7618649	Jul 07, 2019 Dec 19, 2020		DP DP U-1017		
<u>DESLORATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX-D 12 HOUR</u>						
N 021313	001 6100274 6709676 7618649 8187630	Jul 07, 2019 Feb 18, 2021 Dec 19, 2020 Dec 19, 2020		DP DP U-707 DP U-1017 DP U-1017		
<u>DESLORATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX D 24 HOUR</u>						
N 021605	001 6100274 6979463 7618649 7820199	Jul 07, 2019 Mar 28, 2022 Dec 19, 2020 Mar 28, 2022		DP DP DP U-1017 DP		
<u>DESONIDE - DESONATE</u>						
N 021844	001 6387383	Aug 03, 2020	DS DP	U-783		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DESONIDE - VERDESO</u>						
N 021978	001	6730288	Sep 08, 2019	DP		
		7029659	Sep 08, 2019	DP		
		8460641	Nov 05, 2028	DP U-1412		
		8962000	Aug 31, 2025	DP U-1412		
		9492384	Aug 31, 2025	DP U-1412		
<u>DESOXIMETASONE - TOPICORT</u>						
N 204141	001	5990100	Mar 24, 2018	DP U-1408		
		8277780	Sep 01, 2028	DP U-1408		
		8715624	May 26, 2026	DP U-1408		
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992	001	6673838	Mar 01, 2022	DS U-860		
		6673838	Mar 01, 2022	DS U-1364		
		8269040	Jul 05, 2027	DS		
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992	002	6673838	Mar 01, 2022	DS U-860		
		6673838	Mar 01, 2022	DS U-1364		
		8269040	Jul 05, 2027	DS		
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992	003	6673838	Mar 01, 2022	DS U-860		
		6673838	Mar 01, 2022	DS U-1364		
		8269040	Jul 05, 2027	DS		
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315	001	6726918	Oct 20, 2020	DP U-1204	I-686	Jun 29, 2017
		6726918	Oct 20, 2020	DP U-1205	ODE	Sep 24, 2017
		6899717	Nov 01, 2023	U-1206		
		7033605	Oct 20, 2020	DP		
		7767223	Nov 28, 2021	DP		
		8034366	Jan 09, 2023	DP U-1204		
		8034366	Jan 09, 2023	DP U-1205		
		8034370	Jan 09, 2023	DP		
		8043628	Oct 20, 2020	U-1205		
		8063031	Oct 20, 2020	DP		
		8088407	Oct 20, 2020	U-1205		
		8506987	Jan 09, 2023	U-1204		
		8506987	Jan 09, 2023	U-1205		
		9012437	Oct 20, 2020	U-1205		
		9192511	Jan 09, 2023	DP		
		9283178	Oct 20, 2020	U-1205		
<u>DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST</u>						
N 050818	001	7795316	Aug 03, 2028	DP U-1082		
		8101582	Dec 19, 2027	DP U-1082		
		8450287	Dec 19, 2027	DP		
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287	001	6462058	Jun 15, 2020	DS DP U-949	NPP	Jul 08, 2019
		6462058	Jun 15, 2020	DS DP U-950	NPP	Jul 08, 2019
		6462058	Jun 15, 2020	DS DP U-951	NPP	Jul 08, 2019
		6664276	Jan 30, 2023	DS DP U-949		
		6664276	Jan 30, 2023	DS DP U-950		
		6664276	Jan 30, 2023	DS DP U-951		
		6664276	Jan 30, 2023	DS DP U-1507		
		6664276*PED	Jul 30, 2023			
		6939971	Jun 15, 2020	U-949		
		6939971	Jun 15, 2020	U-950		
		6939971	Jun 15, 2020	U-951		
		7285668	Jun 15, 2020	DS		
		7790755	Aug 02, 2026	DP		
		8105626	Sep 27, 2026	DP		
		8173158	Mar 17, 2030	U-949		
		8173158	Mar 17, 2030	U-950		
		8173158	Mar 17, 2030	U-951		
		8461187	Jan 17, 2026	DP		
		8461187*PED	Jul 17, 2026			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001	8722084	Oct 15, 2023	DP			
	8722084*PED	Apr 15, 2024				
	8784885	Oct 15, 2023	DP U-1552			
	8784885	Oct 15, 2023	DP U-1553			
	8784885	Oct 15, 2023	DP U-1554			
	8784885*PED	Apr 15, 2024				
	8871273	Jan 11, 2028	DP			
	9011926	Feb 24, 2026	DP			
	9145389	Jun 15, 2020	DS DP			
	9233103	Mar 05, 2032		U-1805		
	9238029	Jan 17, 2026	DP			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	6462058	Jun 15, 2020	DS DP U-949		NPP	Jul 08, 2019
	6462058	Jun 15, 2020	DS DP U-950		NPP	Jul 08, 2019
	6462058	Jun 15, 2020	DS DP U-951		NPP	Jul 08, 2019
	6664276	Jan 30, 2023	DS DP U-949			
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276	Jan 30, 2023	DS DP U-1507			
	6664276*PED	Jul 30, 2023				
	6939971	Jun 15, 2020		U-949		
	6939971	Jun 15, 2020		U-950		
	6939971	Jun 15, 2020		U-951		
	7285668	Jun 15, 2020	DS			
	7790755	Aug 02, 2026	DP			
	8105626	Sep 27, 2026	DP			
	8173158	Mar 17, 2030		U-949		
	8173158	Mar 17, 2030		U-950		
	8173158	Mar 17, 2030		U-951		
	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
	8722084	Oct 15, 2023	DP			
	8722084*PED	Apr 15, 2024				
	8784885	Oct 15, 2023	DP U-1552			
	8784885	Oct 15, 2023	DP U-1553			
	8784885	Oct 15, 2023	DP U-1554			
	8784885*PED	Apr 15, 2024				
	8871273	Jan 11, 2028	DP			
	9011926	Feb 24, 2026	DP			
	9145389	Jun 15, 2020	DS DP			
	9233103	Mar 05, 2032		U-1805		
	9238029	Jan 17, 2026	DP			
<u>DEXLANSOPRAZOLE - DEXILANT SOLUTAB</u>						
N 208056 001	6328994	May 17, 2019	DP			
	6328994*PED	Nov 17, 2019				
	6462058	Jun 15, 2020	DS DP U-950			
	6462058	Jun 15, 2020	DS DP U-951			
	6462058*PED	Dec 15, 2020				
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276*PED	Jul 30, 2023				
	6939971	Jun 15, 2020		U-950		
	6939971	Jun 15, 2020		U-951		
	6939971*PED	Dec 15, 2020				
	7285668	Jun 15, 2020	DS			
	7285668*PED	Dec 15, 2020				
	7399485	May 26, 2018	DP			
	7399485*PED	Nov 26, 2018				
	7431942	May 17, 2019	DP			
	7431942*PED	Nov 17, 2019				
	7875292	May 17, 2019	DP			
	7875292*PED	Nov 17, 2019				
	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
	8784885	Oct 15, 2023	DP			
	8784885*PED	Apr 15, 2024				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXLANSOPRAZOLE - DEXILANT SOLUTAB</u>						
N 208056 001	8871273	Jan 11, 2028	DP			
	8871273*PED	Jul 11, 2028				
	9011926	Feb 24, 2026	DP			
	9145389	Jun 15, 2020	DS DP			
	9238029	Jan 17, 2026	DP			
	9241910	Mar 10, 2029	DP			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 001	6716867	Mar 31, 2019	U-1472			
	6716867*PED	Oct 01, 2019				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 002	6716867	Mar 31, 2019	U-1472			
	6716867*PED	Oct 01, 2019				
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032	U-421			
	8455527*PED	Jul 04, 2032				
	8648106	Jan 04, 2032	DP			
	8648106*PED	Jul 04, 2032				
	9320712	Jan 04, 2032	DP			
	9320712*PED	Jul 04, 2032				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 003	6716867	Mar 31, 2019	U-1472			
	6716867*PED	Oct 01, 2019				
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032	U-421			
	8455527*PED	Jul 04, 2032				
	8648106	Jan 04, 2032	DP			
	8648106*PED	Jul 04, 2032				
	9320712	Jan 04, 2032	DP			
	9320712*PED	Jul 04, 2032				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 004	6716867	Mar 31, 2019	U-1472			
	6716867*PED	Oct 01, 2019				
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032	U-421			
	8455527*PED	Jul 04, 2032				
	8648106	Jan 04, 2032	DP			
	8648106*PED	Jul 04, 2032				
	9320712	Jan 04, 2032	DP			
	9320712*PED	Jul 04, 2032				
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 202842 005					PC	Jul 04, 2017
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 202842 007					PC	Jul 04, 2017
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802 001	6228398	Nov 01, 2019	DP U-676			
	6730325	Nov 01, 2019	DP U-676			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802 002	6228398	Nov 01, 2019	DP U-676			
	6730325	Nov 01, 2019	DP U-676			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802 003	6228398	Nov 01, 2019	DP U-676			
	6730325	Nov 01, 2019	DP U-676			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802 004	6228398	Nov 01, 2019	DP U-676			
	6730325	Nov 01, 2019	DP U-676			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802 005	6228398	Nov 01, 2019	DP U-676			
	6730325	Nov 01, 2019	DP U-676			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802 006	6228398	Nov 01, 2019	DP U-676			
	6730325	Nov 01, 2019	DP U-676			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802 007	6228398	Nov 01, 2019	DP U-676			
	6730325	Nov 01, 2019	DP U-676			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802 008	6228398	Nov 01, 2019	DP U-676			
	6730325	Nov 01, 2019	DP U-676			
<u>DEXRAZOXANE HYDROCHLORIDE - TOTECT</u>						
N 022025 001	6727253	Mar 13, 2020		U-829		
<u>DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN - MUCINEX DM</u>						
N 021620 001	6372252	Apr 28, 2020	DP			
	6955821	Apr 28, 2020	DP U-685			
	7838032	Apr 28, 2020	DP			
<u>DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN - MUCINEX DM</u>						
N 021620 002	6372252	Apr 28, 2020	DP			
	6955821	Apr 28, 2020	DP U-685			
	7838032	Apr 28, 2020	DP			
<u>DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE - NUEDEXTA</u>						
N 021879 001	7659282	Aug 13, 2026		U-1093		
	8227484	Jul 17, 2023		U-1093		
<u>DEXTROMETHORPHAN POLISTIREX - DELSYM</u>						
N 018658 001	5980882	Apr 16, 2017	DP			
<u>DICHLORPHENAMIDE - KEVEYIS</u>						
N 011366 002					ODE	Aug 07, 2022
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 001	8679544	Apr 23, 2030	DP		I-692	Aug 22, 2017
	8999387	Apr 23, 2030	U-55		NP	Oct 18, 2016
	9017721	Apr 23, 2030	DP			
	9173854	Apr 23, 2030	DP			
	9180095	Apr 23, 2030	U-55			
	9180096	Apr 23, 2030	DP			
	9186328	Apr 23, 2030	U-55			
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 002	8679544	Apr 23, 2030	DP		I-692	Aug 22, 2017
	8999387	Apr 23, 2030	U-55		NP	Oct 18, 2016
	9017721	Apr 23, 2030	DP			
	9173854	Apr 23, 2030	DP			
	9180095	Apr 23, 2030	U-55			
	9180096	Apr 23, 2030	DP			
	9186328	Apr 23, 2030	U-55			
<u>DICLOFENAC EPOLAMINE - FLECTOR</u>						
N 021234 001	5607690	Apr 13, 2019	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DICLOFENAC POTASSIUM - CAMBIA</u>						
N 022165	001 6974595	May 15, 2017	U-436			
	7482377	May 15, 2017	DS DP U-436			
	7759394	Jun 16, 2026	DS DP U-436			
	8097651	Jun 16, 2026	DS DP U-436			
	8927604	Jun 16, 2026	U-436			
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N 022202	001 6287594	Jan 15, 2019	DP			
	6365180	Jul 15, 2019	DP U-980			
	7662858	Feb 24, 2029	U-1035			
	7884095	Feb 24, 2029	U-1111			
	7939518	Feb 24, 2029	U-980			
	8110606	Feb 24, 2029	U-980			
	8623920	Feb 24, 2029	U-1482			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 020947	001 8217078	Jul 10, 2029	U-1248			
	8546450	Aug 09, 2030	U-1435			
	8546450	Aug 09, 2030	U-1436			
	8618164	Jul 10, 2029	U-1477			
	8741956	Jul 10, 2029	U-1435			
<u>DICLOFENAC SODIUM - DYLOJECT</u>						
N 022396	001 6407079	Jun 18, 2019	DP		NP	Dec 23, 2017
	8946292	Mar 22, 2027	U-1659			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623	001 8217078	Jul 10, 2029	U-1477		NP	Jan 16, 2017
	8252838	Apr 21, 2028	DP U-1489			
	8546450	Aug 09, 2030	U-1435			
	8546450	Aug 09, 2030	U-1436			
	8563613	Oct 17, 2027	DP U-1488			
	8618164	Jul 10, 2029	U-1477			
	8741956	Jul 10, 2029	U-1435			
	8871809	Oct 17, 2027	U-1614			
	9066913	Oct 17, 2027	DP U-1488			
	9101591	Oct 17, 2027	DP U-1488			
	9132110	Oct 17, 2027	U-1488			
	9168304	Oct 17, 2027	DP			
	9168305	Oct 17, 2027	U-1488			
	9220784	Oct 17, 2027	U-1488			
	9339551	Oct 17, 2027	U-1488			
	9339552	Oct 17, 2027	DP U-1488			
	9370501	Jul 10, 2029	U-1614			
	9375412	Jul 10, 2029	U-1614			
	9415029	Jul 10, 2029	U-1614			
<u>DIENOGEST; DIENOGEST; DIENOGEST; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE - NATAZIA</u>						
N 022252	001 6133251	Oct 25, 2016	DP U-1	Y		
	6133251	Oct 25, 2016	DP U-112	Y		
	6133251	Oct 25, 2016	DP U-828	Y		
	6884793	Oct 25, 2016	DP	Y		
	8071577	May 13, 2026	DP U-1			
	8153616	Jan 30, 2028	U-1240			
<u>DIFLUPREDNATE - DUREZOL</u>						
N 022212	001 6114319	May 18, 2019	DP		ODE	Jun 13, 2019
	6114319*PED	Nov 18, 2019			PED	Sep 22, 2016
					PED	Dec 13, 2019
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392	001 6923984	Feb 25, 2021	DP			
	7108866	Dec 17, 2019	DP U-107			
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392	002 6923984	Feb 25, 2021	DP			
	7108866	Dec 17, 2019	DP U-107			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392 003	6923984	Feb 25, 2021	DP			
	7108866	Dec 17, 2019	DP U-107			
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392 004	6923984	Feb 25, 2021	DP			
	7108866	Dec 17, 2019	DP U-107			
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392 005	6923984	Feb 25, 2021	DP			
	7108866	Dec 17, 2019	DP U-107			
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392 006	6923984	Feb 25, 2021	DP			
	7108866	Dec 17, 2019	DP U-107			
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 001	6509376	Oct 29, 2019	DP		NCE	Mar 27, 2018
	7320999	May 18, 2020	U-1384			
	7619001	Apr 01, 2018	U-1384			
	7803840	Apr 01, 2018	U-1385			
	8399514	Feb 07, 2028	U-1384			
	8524773	Apr 01, 2018	U-1384			
	8759393	Oct 29, 2019	DP			
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 002	6509376	Oct 29, 2019	DP		NCE	Mar 27, 2018
	7320999	May 18, 2020	U-1384			
	7619001	Apr 01, 2018	U-1384			
	7803840	Apr 01, 2018	U-1385			
	8399514	Feb 07, 2028	U-1384			
	8524773	Apr 01, 2018	U-1384			
	8759393	Oct 29, 2019	DP			
<u>DIPHENHYDRAMINE CITRATE; IBUPROFEN - ADVIL PM</u>						
N 021394 001	8263647	May 30, 2022	DP			
<u>DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN - ADVIL PM</u>						
N 021393 001	8883849	Jan 17, 2022	U-1618			
	9155718	Jan 17, 2022	DP			
<u>DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM - ALEVE PM</u>						
N 205352 001					NC	Jan 17, 2017
<u>DIVALPROEX SODIUM - DEPAKOTE ER</u>						
N 021168 001	6419953	Dec 18, 2018				
	6511678	Dec 18, 2018				
	6528090	Dec 18, 2018	DP			
	6528091	Dec 18, 2018	U-106			
	6713086	Dec 18, 2018	DP U-579			
	6720004	Dec 18, 2018	DP			
<u>DIVALPROEX SODIUM - DEPAKOTE ER</u>						
N 021168 002	6511678	Dec 18, 2018				
	6528090	Dec 18, 2018	DP			
	6713086	Dec 18, 2018	DP U-579			
	6720004	Dec 18, 2018	DP			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 001	8940786	Sep 30, 2033	DP U-1789			
	9308195	Sep 30, 2033	DP			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 002	8940786	Sep 30, 2033	DP U-1789			
	9308195	Sep 30, 2033	DP			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 003	8940786	Sep 30, 2033	DP U-1789			
	9308195	Sep 30, 2033	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DOFETILIDE - DOFETILIDE</u>						
A 207058	001				PC	Dec 04, 2016
<u>DOFETILIDE - DOFETILIDE</u>						
A 207058	002				PC	Dec 04, 2016
<u>DOFETILIDE - DOFETILIDE</u>						
A 207058	003				PC	Dec 04, 2016
<u>DOFETILIDE - TIKOSYN</u>						
N 020931	001 6124363	Oct 09, 2018				
<u>DOFETILIDE - TIKOSYN</u>						
N 020931	002 6124363	Oct 09, 2018				
<u>DOFETILIDE - TIKOSYN</u>						
N 020931	003 6124363	Oct 09, 2018				
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790	001 8129385	Oct 05, 2027	DS DP		M-166	Jul 30, 2018
	9242986	Dec 08, 2029	DS DP		NCE	Aug 12, 2018
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790	002 8129385	Oct 05, 2027	DS DP		NCE	Aug 12, 2018
	9242986	Dec 08, 2029	DS DP			
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790	003 8129385	Oct 05, 2027	DS DP		NCE	Aug 12, 2018
	9242986	Dec 08, 2029	DS DP			
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT</u>						
N 022568	001 8481565	Oct 04, 2026		DP		
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439	001 8039009	Mar 24, 2029		U-1641		
	8039009*PED	Sep 24, 2029				
	8058291	Dec 05, 2029		U-1641		
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025		U-1641		
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025		U-1641		
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8338485	Nov 22, 2025	DP			
	8338486	Nov 22, 2025		U-1641		
	8362085	Nov 22, 2025		U-1641		
	8362085*PED	May 22, 2026				
	8580858	Nov 22, 2025		U-1641		
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439	002 8039009	Mar 24, 2029		U-1641		
	8039009*PED	Sep 24, 2029				
	8058291	Dec 05, 2029		U-1641		
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025		U-1641		
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025		U-1641		
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8338485	Nov 22, 2025	DP			
	8338486	Nov 22, 2025		U-1641		
	8362085	Nov 22, 2025		U-1641		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439	002	8362085*PED	May 22, 2026			
		8580858	Nov 22, 2025		U-1641	
		8598233	Nov 22, 2025	DP		
		8598233*PED	May 22, 2026			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439	003	8039009	Mar 24, 2029		U-1641	
		8039009*PED	Sep 24, 2029			
		8058291	Dec 05, 2029		U-1641	
		8168209	Nov 22, 2025	DP		
		8168209*PED	May 22, 2026			
		8173708	Nov 22, 2025		U-1641	
		8173708*PED	May 22, 2026			
		8283379	Nov 22, 2025		U-1641	
		8283379*PED	May 22, 2026			
		8293794	Nov 22, 2025	DP		
		8329752	Nov 22, 2025	DP		
		8329752*PED	May 22, 2026			
		8338485	Nov 22, 2025	DP		
		8338486	Nov 22, 2025		U-1641	
		8362085	Nov 22, 2025		U-1641	
		8362085*PED	May 22, 2026			
		8580858	Nov 22, 2025		U-1641	
		8598233	Nov 22, 2025	DP		
		8598233*PED	May 22, 2026			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439	004	8039009	Mar 24, 2029		U-1641	
		8039009*PED	Sep 24, 2029			
		8058291	Dec 05, 2029		U-1641	
		8168209	Nov 22, 2025	DP		
		8168209*PED	May 22, 2026			
		8173708	Nov 22, 2025		U-1641	
		8173708*PED	May 22, 2026			
		8283379	Nov 22, 2025		U-1641	
		8283379*PED	May 22, 2026			
		8293794	Nov 22, 2025	DP		
		8329752	Nov 22, 2025	DP		
		8329752*PED	May 22, 2026			
		8338485	Nov 22, 2025	DP		
		8338486	Nov 22, 2025		U-1641	
		8362085	Nov 22, 2025		U-1641	
		8362085*PED	May 22, 2026			
		8580858	Nov 22, 2025		U-1641	
		8598233	Nov 22, 2025	DP		
		8598233*PED	May 22, 2026			
<u>DORIPENEM - DORIBAX</u>						
N 022106	001	8247402	Mar 30, 2021	DS DP		
<u>DORIPENEM - DORIBAX</u>						
N 022106	002	8247402	Mar 30, 2021	DS DP		
<u>DOXEPIIN HYDROCHLORIDE - SILENOR</u>						
N 022036	001	6211229	Feb 17, 2020		U-620	
		7915307	Aug 24, 2027		U-620	
		8513299	Sep 07, 2030		U-620	
		9107898	May 01, 2028		U-620	
		9486437	May 18, 2027		U-620	
<u>DOXEPIIN HYDROCHLORIDE - SILENOR</u>						
N 022036	002	6211229	Feb 17, 2020		U-620	
		7915307	Aug 24, 2027		U-620	
		8513299	Sep 07, 2030		U-620	
		9107898	May 01, 2028		U-620	
		9486437	May 18, 2027		U-620	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DOXYCYCLINE - ORACEA</u>						
N 050805	001	5789395	Aug 30, 2016	U-925	Y	
		5919775	Aug 30, 2016	U-925	Y	
		7211267	Apr 05, 2022	U-925		
		7232572	Apr 05, 2022	U-925		
		7749532	Dec 19, 2027	DP U-1063		
		8206740	Dec 24, 2025	DP U-925		
		8394405	Apr 07, 2024	DP U-925		
		8394406	Apr 07, 2024	DP U-925		
		8470364	Apr 07, 2024	DP U-925		
		8603506	Apr 05, 2022	U-1063		
		8709478	Apr 07, 2024	U-1063		
		9241946	Apr 05, 2022	U-1063		
<u>DOXYCYCLINE HYCLATE - DOXYCYCLINE HYCLATE</u>						
A 090431	003				PC	Nov 19, 2016
<u>DOXYCYCLINE HYCLATE - DOXYCYCLINE HYCLATE</u>						
A 090431	005				PC	Nov 15, 2016
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795	001	6958161	Dec 15, 2022	DP U-918		
		8715724	Feb 03, 2028	DP		
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795	002	6958161	Dec 15, 2022	DP U-918		
		8715724	Feb 03, 2028	DP		
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795	003	6958161	Dec 15, 2022	DP U-918		
		8715724	Feb 03, 2028	DP		
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795	004	6958161	Dec 15, 2022	DP U-918		
		8715724	Feb 03, 2028	DP		
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795	005	6958161	Dec 15, 2022	DP U-918		
		8715724	Feb 03, 2028	DP		
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795	006	6958161	Dec 15, 2022	DP U-918		
		8715724	Feb 03, 2028	DP		
<u>DOXYCYCLINE HYCLATE - DORYX MPC</u>						
N 050795	007	6958161	Dec 15, 2022	DP U-918		
		8715724	Feb 03, 2028	DP		
		9295652	Oct 23, 2034	DP U-918		
		9446057	Dec 23, 2034	DP U-918		
		9511031	Oct 23, 2034	DP		
<u>DOXYCYCLINE HYCLATE - DORYX MPC</u>						
N 050795	008	6958161	Dec 15, 2022	DP U-918		
		8715724	Feb 03, 2028	DP		
		9295652	Oct 23, 2034	DP U-918		
		9446057	Dec 23, 2034	DP U-918		
		9511031	Oct 23, 2034	DP		
<u>DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - DICLEGIS</u>						
N 021876	001	6340695	Jun 21, 2021	DP U-1382		
		7560122	Jan 25, 2019	DP		
<u>DRONEDARONE HYDROCHLORIDE - MULTAQ</u>						
N 022425	001	5223510	Jul 26, 2016	DS DP U-992		
		5223510	Jul 26, 2016	DS DP U-1261		
		7323493	Jun 19, 2018	DP		
		8318800	Jun 19, 2018	DP		
		8410167	Apr 16, 2029	U-1387		
		8410167	Apr 16, 2029	U-1388		
		8602215	Jun 30, 2031	U-1473		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DRONEDARONE HYDROCHLORIDE - MULTAQ</u>						
N 022425	001	9107900	Apr 16, 2029	U-1726		
		9107900	Apr 16, 2029	U-1728		
<u>DROSPIRENONE; ESTRADIOL - ANGELIO</u>						
N 021355	001	8906890	Oct 22, 2031	DP		
<u>DROSPIRENONE; ESTRADIOL - ANGELIO</u>						
N 021355	002	6933395	Aug 11, 2017	DS		
<u>DROSPIRENONE; ETHINYL ESTRADIOL - YASMIN</u>						
N 021098	001	6787531	Aug 31, 2020	DP		
		6933395	Aug 11, 2017	DS		
<u>DROSPIRENONE; ETHINYL ESTRADIOL - YAZ</u>						
N 021676	001	6787531	Aug 31, 2020	DP		
		6933395	Aug 11, 2017	DP		
		6958326	Dec 20, 2021	DP		
		6987101	Dec 22, 2017	U-758		
		7163931	Dec 20, 2021	U-1		
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM</u>						
A 203593	001				PC	Apr 09, 2017
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ</u>						
N 022532	001	6441168	Jul 30, 2022	DS		
		6958326	Dec 20, 2021	DP		
		7163931	Mar 03, 2022	U-1		
		8617597	Feb 08, 2030	DP		
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL</u>						
N 022574	001	6441168	Apr 17, 2020	DS		
		6958326	Dec 20, 2021	DP		
		7163931	Mar 03, 2022	U-1		
		8617597	Feb 08, 2030	DP		
<u>DROXIDOPA - NORTHERA</u>						
N 203202	001				NCE	Feb 18, 2019
					ODE	Feb 18, 2021
<u>DROXIDOPA - NORTHERA</u>						
N 203202	002				NCE	Feb 18, 2019
					ODE	Feb 18, 2021
<u>DROXIDOPA - NORTHERA</u>						
N 203202	003				NCE	Feb 18, 2019
					ODE	Feb 18, 2021
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427	001	6596756	Sep 10, 2019	U-882	NPP	Oct 16, 2017
					NPP	Oct 16, 2017
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427	002	6596756	Sep 10, 2019	U-882	NPP	Oct 16, 2017
					NPP	Oct 16, 2017
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427	004	6596756	Sep 10, 2019	U-882	NPP	Oct 16, 2017
					NPP	Oct 16, 2017
<u>ECONAZOLE NITRATE - ECOZA</u>						
N 205175	001	5993830	Jan 16, 2018	DP U-1449	NDF	Oct 24, 2016
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316	001	7365205	Jun 12, 2023	DS	NCE	Jan 08, 2020
		9149532	Mar 28, 2028	DP		
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316	002	7365205	Jun 12, 2023	DS	NCE	Jan 08, 2020
		9149532	Mar 28, 2028	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316	002	7365205	Jun 12, 2023	DS	NCE	Jan 08, 2020
		9149532	Mar 28, 2028	DP		
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316	003	7365205	Jun 12, 2023	DS	NCE	Jan 08, 2020
		9149532	Mar 28, 2028	DP		
<u>EFAVIRENZ - SUSTIVA</u>						
N 020972	001	6238695	Apr 06, 2019	DP	PED	Nov 02, 2016
		6238695*PED	Oct 06, 2019			
		6555133	Apr 06, 2019	U-248		
		6555133*PED	Oct 06, 2019			
		6639071	Feb 14, 2018	DS		
		6639071*PED	Aug 14, 2018			
		6939964	Jan 20, 2018	DS		
		6939964*PED	Jul 20, 2018			
<u>EFAVIRENZ - SUSTIVA</u>						
N 020972	002	6238695	Apr 06, 2019	DP		
		6238695*PED	Oct 06, 2019			
		6555133	Apr 06, 2019	U-248		
		6555133*PED	Oct 06, 2019			
		6639071	Feb 14, 2018	DS		
		6639071*PED	Aug 14, 2018			
		6939964	Jan 20, 2018	DS		
		6939964*PED	Jul 20, 2018			
<u>EFAVIRENZ - SUSTIVA</u>						
N 020972	003	6238695	Apr 06, 2019	DP	PED	Nov 02, 2016
		6238695*PED	Oct 06, 2019			
		6555133	Apr 06, 2019	U-248		
		6555133*PED	Oct 06, 2019			
		6639071	Feb 14, 2018	DS		
		6639071*PED	Aug 14, 2018			
		6939964	Jan 20, 2018	DS		
		6939964*PED	Jul 20, 2018			
<u>EFAVIRENZ - SUSTIVA</u>						
N 021360	001	6639071	Feb 14, 2018	DS		
		6639071*PED	Aug 14, 2018			
		6939964	Jan 20, 2018	DS		
		6939964*PED	Jul 20, 2018			
<u>EFAVIRENZ - SUSTIVA</u>						
N 021360	002	6639071	Feb 14, 2018	DS	PED	Nov 02, 2016
		6639071*PED	Aug 14, 2018			
		6939964	Jan 20, 2018	DS		
		6939964*PED	Jul 20, 2018			
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937	001	5914331	Jul 02, 2017	DS		
		5922695	Jul 25, 2017	DS	U-750	
		5922695	Jul 25, 2017	DS	U-1170	
		5935946	Jul 25, 2017	DS DP	U-750	
		5935946	Jul 25, 2017	DS DP	U-1170	
		5977089	Jul 25, 2017	DS DP	U-750	
		5977089	Jul 25, 2017	DS DP	U-1170	
		6043230	Jul 25, 2017		U-750	
		6043230	Jul 25, 2017		U-1170	
		6639071	Feb 14, 2018	DS		
		6639071*PED	Aug 14, 2018			
		6642245	Nov 04, 2020		U-750	
		6642245	Nov 04, 2020		U-1170	
		6703396	Mar 09, 2021	DS DP		
		6939964	Jan 20, 2018	DS		
		6939964*PED	Jul 20, 2018			
		8592397	Jan 13, 2024	DP	U-750	
		8592397	Jan 13, 2024	DP	U-1170	
		8598185	May 01, 2028	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937	001	8716264	Jan 13, 2024	DP U-257		
		9018192	Jun 13, 2026	U-750		
		9018192	Jun 13, 2026	U-1170		
		9457036	Jan 13, 2024	DP U-257		
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567	001	7214506	Oct 05, 2021	U-281	NCE	Jun 06, 2019
		8039494	Jul 08, 2030	U-281		
		8486978	Oct 24, 2030	DP		
		9302009	Oct 24, 2030	DP		
<u>ELBASVIR; GRAZOPREVIR - ZEPATIER</u>						
N 208261	001	7973040	Jul 24, 2029	DS DP U-1813	NCE	Jan 28, 2021
		8871759	May 04, 2031	DS DP U-1813		
<u>ELETRIPTAN HYDROBROMIDE - RELPAX</u>						
N 021016	001	5545644	Dec 26, 2016	DS DP U-876		
		6110940	Aug 29, 2017			
<u>ELETRIPTAN HYDROBROMIDE - RELPAX</u>						
N 021016	002	5545644	Dec 26, 2016	DS DP U-876		
		6110940	Aug 29, 2017			
<u>ELIGLUSTAT TARTRATE - CERDELGA</u>						
N 205494	001	6916802	Apr 29, 2022	U-1571	NCE	Aug 19, 2019
		7196205	Apr 29, 2022	DS	ODE	Aug 19, 2021
		7615573	Apr 29, 2022	U-1571		
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291	001	6280959	Oct 30, 2018	DS DP U-930	D-149	Jun 11, 2018
		6280959	Oct 30, 2018	DS DP U-1306	I-711	Jun 11, 2018
		6280959	Oct 30, 2018	DS DP U-1575	ODE	Aug 26, 2021
		6280959	Oct 30, 2018	DS DP U-1714	PED	Dec 11, 2018
		6280959*PED	Apr 30, 2019		PED	Dec 11, 2018
		7160870	Nov 20, 2022	DS DP U-930	PED	Feb 26, 2022
		7160870	Nov 20, 2022	DS DP U-1306		
		7160870	Nov 20, 2022	DS DP U-1575		
		7160870	Nov 20, 2022	DS DP U-1714		
		7160870*PED	May 20, 2023			
		7332481	May 24, 2021	U-930		
		7332481	May 24, 2021	U-1306		
		7332481	May 24, 2021	U-1575		
		7332481	May 24, 2021	U-1714		
		7332481*PED	Nov 24, 2021			
		7452874	May 24, 2021	DS DP U-1714		
		7452874*PED	Nov 24, 2021			
		7473686	May 24, 2021	DS DP U-930		
		7473686	May 24, 2021	DS DP U-1306		
		7473686	May 24, 2021	DS DP U-1575		
		7473686	May 24, 2021	DS DP U-1714		
		7473686*PED	Nov 24, 2021			
		7547719	Jul 13, 2025	DS DP U-930		
		7547719	Jul 13, 2025	DS DP U-1306		
		7547719	Jul 13, 2025	DS DP U-1575		
		7547719	Jul 13, 2025	DS DP U-1714		
		7547719*PED	Jan 13, 2026			
		7790704	May 24, 2021	U-930		
		7790704	May 24, 2021	U-1306		
		7790704	May 24, 2021	U-1575		
		7790704	May 24, 2021	U-1714		
		7790704*PED	Nov 24, 2021			
		7795293	May 21, 2023	U-930		
		7795293	May 21, 2023	U-1306		
		7795293	May 21, 2023	U-1575		
		7795293	May 21, 2023	U-1714		
		7795293*PED	Nov 21, 2023			
		8052993	Aug 01, 2027	DP U-930		
		8052993	Aug 01, 2027	DP U-1306		
		8052993	Aug 01, 2027	DP U-1575		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 001	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 002	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1714		PED	Dec 11, 2018
	6280959*PED	Apr 30, 2019			PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-930		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-930			
	8052994	Aug 01, 2027	DP U-1306			
	8052994	Aug 01, 2027	DP U-1575			
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
	8828430*PED	Feb 01, 2028				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 003	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1714		PED	Dec 11, 2018
	6280959*PED	Apr 30, 2019			PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-930		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-714			
	8062665	Aug 01, 2027	DP U-930			
	8062665	Aug 01, 2027	DP U-1306			
	8062665	Aug 01, 2027	DP U-1575			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 004	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1714		ODE	Aug 26, 2021
	6280959*PED	Apr 30, 2019			PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-930		PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-1306		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 004	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-930			
	8071129	Aug 01, 2027	DP U-1306			
	8071129	Aug 01, 2027	DP U-1575			
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 005	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1714		ODE	Aug 26, 2021
	6280959*PED	Apr 30, 2019			PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-930		PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-1306		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 005	7790704	May 24, 2021	U-1575			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293*PED	Nov 21, 2023				
	8052995	Aug 01, 2027	DP U-1306			
	8052995	Aug 01, 2027	DP U-1575			
	8052995*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 207027 001	6280959	Oct 30, 2018	DS DP U-1736		D-149	Jun 11, 2018
	7160870	Nov 20, 2022	DS DP U-1736		I-711	Jun 11, 2018
	7332481	May 24, 2021	U-1736		PED	Dec 11, 2018
	7452874	May 24, 2021	DS DP		PED	Dec 11, 2018
	7473686	May 24, 2021	DS DP U-1736			
	7547719	Jul 13, 2025	DS DP U-1736			
	7790704	May 24, 2021	U-1736			
	7795293	May 24, 2023	U-1736			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	7741356	Mar 25, 2028	DS DP		NCE	May 27, 2020
	7786158	Mar 14, 2025	DS			
	8344011	Mar 14, 2025	U-1709			
	8609709	Mar 14, 2025	DS			
	8691860	Jul 07, 2028	DS U-1709			
	9115091	Jul 07, 2028	DS DP U-1738			
	9205076	Mar 14, 2025	U-1709			
	9364489	Jul 07, 2028	U-1709			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	7741356	Mar 25, 2028	DS DP		NCE	May 27, 2020
	7786158	Mar 14, 2025	DS			
	8344011	Mar 14, 2025	U-1709			
	8609709	Mar 14, 2025	DS			
	8691860	Jul 07, 2028	DS U-1709			
	9115091	Jul 07, 2028	DS DP U-1738			
	9205076	Mar 14, 2025	U-1709			
	9364489	Jul 07, 2028	U-1709			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 001	7176220	Nov 20, 2023	DS DP U-257		NP	Sep 24, 2017
	7635704	Oct 26, 2026	DS DP U-257			
	8981103	Oct 26, 2026	DS DP			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 002	7176220	Nov 20, 2023	DS DP U-257		NP	Sep 24, 2017
	7635704	Oct 26, 2026	DS DP U-257			
	8981103	Oct 26, 2026	DS DP			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	7579449	Nov 05, 2025	DS		I-739	Dec 02, 2019
	7713938	Apr 15, 2027	DS DP		M-160	Jun 26, 2018
	8551957	Oct 14, 2029	U-1651		M-161	Jun 26, 2018
					M-174	Mar 18, 2019
					NCE	Aug 01, 2019
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	7579449	Nov 05, 2025	DS		I-739	Dec 02, 2019
	7713938	Apr 15, 2027	DS DP		M-160	Jun 26, 2018
	8551957	Oct 14, 2029	U-1651		M-161	Jun 26, 2018
					M-174	Mar 18, 2019
					NCE	Aug 01, 2019
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	6303661	Apr 24, 2017	U-1651		I-739	Dec 02, 2019
	6890898	Feb 02, 2019	U-1652		NC	Jan 30, 2018
	7078381	Feb 02, 2019	U-1651		NCE	Aug 01, 2019
	7407955	May 02, 2025	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	7459428	Feb 02, 2019		U-1651		
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023		U-1651		
	8178541	Aug 12, 2023	DP	U-1653		
	8178541	Aug 12, 2023	DP	U-1654		
	8551957	Oct 14, 2029	DP	U-1651		
	8673927	May 04, 2027	DP	U-1652		
	8846695	Jun 04, 2030		U-1652		
	8883805	Nov 26, 2025	DP			
	9173859	May 04, 2027	DP	U-1772		
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	6303661	Apr 24, 2017		U-1651	I-739	Dec 02, 2019
	6890898	Feb 02, 2019		U-1652	NC	Jan 30, 2018
	7078381	Feb 02, 2019		U-1651	NCE	Aug 01, 2019
	7407955	May 02, 2025	DS DP			
	7459428	Feb 02, 2019		U-1651		
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023		U-1651		
	8178541	Aug 12, 2023	DP	U-1653		
	8178541	Aug 12, 2023	DP	U-1654		
	8551957	Oct 14, 2029	DP	U-1651		
	8673927	May 04, 2027	DP	U-1652		
	8846695	Jun 04, 2030		U-1652		
	8883805	Nov 26, 2025	DP			
	9173859	May 04, 2027	DP	U-1772		
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	7579449	Nov 05, 2025	DS		I-739	Dec 02, 2019
	7713938	Apr 15, 2027	DS DP		M-174	Mar 18, 2019
					NCE	Aug 01, 2019
					NP	Aug 26, 2018
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	7579449	Nov 05, 2025	DS		I-739	Dec 02, 2019
	7713938	Apr 15, 2027	DS DP		M-174	Mar 18, 2019
					NCE	Aug 01, 2019
					NP	Aug 26, 2018
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	7579449	Nov 05, 2025	DS		I-739	Dec 02, 2019
	7713938	Apr 15, 2027	DS DP		M-174	Mar 18, 2019
					NCE	Aug 01, 2019
					NP	Aug 26, 2018
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	7579449	Nov 05, 2025	DS		I-739	Dec 02, 2019
	7713938	Apr 15, 2027	DS DP		M-174	Mar 18, 2019
					NCE	Aug 01, 2019
					NP	Aug 26, 2018
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 001	6488962	Jun 20, 2020	DP		I-739	Dec 02, 2019
	7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	7713938	Apr 15, 2027	DS DP			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 002	6488962	Jun 20, 2020	DP		I-739	Dec 02, 2019
	7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	7713938	Apr 15, 2027	DS DP			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 003	6488962	Jun 20, 2020	DP		I-739	Dec 02, 2019
	7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	7713938	Apr 15, 2027	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658	004	6488962	Jun 20, 2020	DP	I-739	Dec 02, 2019
		7579449	Nov 05, 2025	DS	NCE	Aug 01, 2019
		7713938	Apr 15, 2027	DS DP		
<u>EMTRICITABINE - EMTRIVA</u>						
N 021500	001	5914331	Jul 02, 2017	DS		
		6642245	Nov 04, 2020	U-257		
		6642245	Nov 04, 2020	U-541		
		6703396	Mar 09, 2021	DS DP		
<u>EMTRICITABINE - EMTRIVA</u>						
N 021896	001	5914331	Jul 02, 2017	DS		
		6642245	Nov 04, 2020	U-257		
		6703396	Mar 09, 2021	DS DP		
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY</u>						
N 208351	001	5914331	Jul 02, 2017	DS	NCE	Nov 05, 2020
		5914331*PED	Jan 02, 2018			
		6642245	Nov 04, 2020	U-257		
		6642245*PED	May 04, 2021			
		6703396	Mar 09, 2021	DS DP		
		6703396*PED	Sep 09, 2021			
		6838464	Feb 26, 2021	DS DP		
		7067522	Dec 20, 2019	DS DP		
		7125879	Apr 21, 2025	DS DP	U-257	
		7390791	May 07, 2022	DS DP		
		7803788	Feb 02, 2022	U-257		
		8080551	Apr 11, 2023	DS DP		
		8101629	Aug 09, 2022	DP		
		8754065	Aug 15, 2032	DS DP	U-257	
		9296769	Aug 15, 2032	DS DP	U-257	
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N 202123	001	5914331	Jul 02, 2017	DS	NPP	Dec 13, 2016
		5922695	Jul 25, 2017	DS	U-257	
		5935946	Jul 25, 2017	DS DP	U-257	
		5977089	Jul 25, 2017	DS DP	U-257	
		6043230	Jul 25, 2017		U-257	
		6642245	Nov 04, 2020		U-257	
		6703396	Mar 09, 2021	DS DP		
		6838464	Feb 26, 2021	DS DP		
		7067522	Dec 20, 2019	DS DP		
		7125879	Apr 21, 2025	DS DP	U-257	
		8080551	Apr 11, 2023	DS DP		
		8101629	Aug 09, 2022	DP		
		8592397	Jan 13, 2024	DP	U-257	
		8716264	Jan 13, 2024	DP	U-257	
		8841310	Dec 09, 2025	DP	U-257	
		9457036	Jan 13, 2024	DP	U-257	
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215	001	5914331	Jul 02, 2017	DS	NCE	Nov 05, 2020
		5914331*PED	Jan 02, 2018			
		6642245	Nov 04, 2020	U-257		
		6642245*PED	May 04, 2021			
		6703396	Mar 09, 2021	DS DP		
		6703396*PED	Sep 09, 2021			
		7390791	May 07, 2022	DS DP		
		7803788	Feb 02, 2022	U-257		
		8754065	Aug 15, 2032	DS DP	U-257	
		9296769	Aug 15, 2032	DS DP	U-257	
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752	001	5914331	Jul 02, 2017	DS		
		5914331*PED	Jan 02, 2018			
		5922695	Jul 25, 2017	DS	U-248	
		5922695	Jul 25, 2017	DS	U-541	
		5922695	Jul 25, 2017	DS	U-1170	
		5922695	Jul 25, 2017	DS	U-1250	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 001	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-541			
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-1259			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6703396	Mar 09, 2021	DS DP			
	8592397	Jan 13, 2024	DP U-248			
	8592397	Jan 13, 2024	DP U-541			
	8592397	Jan 13, 2024	DP U-1170			
	8716264	Jan 13, 2024	DP U-257			
	9457036	Jan 13, 2024	DP U-257			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 002	5914331	Jun 02, 2017	DS			
	5914331*PED	Dec 02, 2017				
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5922695	Jul 25, 2017	DS U-1170			
	5922695	Jul 25, 2017	DS U-1259			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-541			
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-1259			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245	Nov 04, 2020	U-1259			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 003	5914331	Jun 02, 2017	DS			
	5914331*PED	Dec 02, 2017				
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5922695	Jul 25, 2017	DS U-1170			
	5922695	Jul 25, 2017	DS U-1259			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-541			
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-1170			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 003	5977089	Jul 25, 2017	DS DP U-1259			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245	Nov 04, 2020	U-1259			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 004	5914331	Jun 02, 2017	DS			
	5914331*PED	Dec 02, 2017				
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5922695	Jul 25, 2017	DS U-1170			
	5922695	Jul 25, 2017	DS U-1259			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-541			
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-1259			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245	Nov 04, 2020	U-1259			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
<u>ENALAPRIL MALEATE - EPANED KIT</u>						
N 204308 001	8568747	Nov 06, 2032	DP			
	8778366	Nov 06, 2032	U-3			
	8778366	Nov 06, 2032	U-71			
	8778366	Nov 06, 2032	U-185			
	8778366	Nov 06, 2032	U-1723			
	8778366	Nov 06, 2032	U-1892			
<u>ENTACAPONE - COMTAN</u>						
N 020796 001	6599530	Sep 14, 2018	DP U-219			
<u>ENTECAVIR - BARACLUDE</u>						
N 021797 001					NPP	Mar 20, 2017
					PED	Sep 20, 2017
<u>ENTECAVIR - BARACLUDE</u>						
N 021797 002					NPP	Mar 20, 2017
					PED	Sep 20, 2017
<u>ENTECAVIR - BARACLUDE</u>						
N 021798 001					NPP	Mar 20, 2017
					PED	Sep 20, 2017

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415	001	7709517	Aug 13, 2027	DS DP	I-693	Sep 10, 2017
		8183274	May 15, 2026	U-1281	NCE	Aug 31, 2017
		8183274	May 15, 2026	U-1588		
		9126941	May 15, 2026	U-1588		
<u>EPINEPHRINE - EPIPEN</u>						
N 019430	001	7449012	Sep 11, 2025	DP		
		7794432	Sep 11, 2025	DP		
		8048035	Sep 11, 2025	DP		
		8870827	Sep 11, 2025	DP		
<u>EPINEPHRINE - EPIPEN JR.</u>						
N 019430	002	7449012	Sep 11, 2025	DP		
		7794432	Sep 11, 2025	DP		
		8048035	Sep 11, 2025	DP		
		8870827	Sep 11, 2025	DP		
<u>EPINEPHRINE - TWINJECT 0.3</u>						
N 020800	001	7297136	Jan 18, 2025	DP		
		7621891	Feb 04, 2025	DP		
<u>EPINEPHRINE - TWINJECT 0.15</u>						
N 020800	002	7297136	Jan 18, 2025	DP		
		7621891	Feb 04, 2025	DP		
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739	001	7731686	Jun 01, 2026	DP		
		7731690	Jan 15, 2025	DP		
		7749194	Oct 30, 2028	DP		
		7918823	Nov 23, 2024	DP		
		7947017	Mar 12, 2028	DP		
		8016788	Mar 21, 2025	DP		
		8021344	Nov 02, 2029	DP		
		8206360	Feb 27, 2027	DP		
		8226610	Apr 10, 2029	DP		
		8231573	Nov 25, 2028	DP		
		8313466	Nov 23, 2024	DP		
		8361029	Nov 23, 2024	DP		
		8425462	Nov 23, 2024	DP		
		8608698	Nov 23, 2024	DP		
		8920377	Nov 23, 2024	DP		
		8926594	Mar 31, 2026	DP		
		9056170	Nov 23, 2024	DP		
		9149579	Jul 19, 2025	U-1758		
		9238108	Feb 20, 2027	DP		
		9259539	Feb 01, 2026	DP		
		9278182	Feb 01, 2026	DP		
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739	002	7731686	Jun 01, 2026	DP		
		7731690	Jan 15, 2025	DP		
		7749194	Oct 30, 2028	DP		
		7918823	Nov 23, 2024	DP		
		7947017	Mar 12, 2028	DP		
		8016788	Mar 21, 2025	DP		
		8021344	Nov 02, 2029	DP		
		8206360	Feb 27, 2027	DP		
		8226610	Apr 10, 2029	DP		
		8231573	Nov 25, 2028	DP		
		8313466	Nov 23, 2024	DP		
		8361029	Nov 23, 2024	DP		
		8425462	Nov 23, 2024	DP		
		8608698	Nov 23, 2024	DP		
		8920377	Nov 23, 2024	DP		
		8926594	Mar 31, 2026	DP		
		9056170	Nov 23, 2024	DP		
		9149579	Jul 19, 2025	U-1758		
		9238108	Feb 20, 2027	DP		
		9259539	Feb 01, 2026	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739	002 9278182	Feb 01, 2026	DP			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204200	001 9119876	Mar 13, 2035	DP			
	9295657	Mar 13, 2035	U-1829			
	9295657	Mar 13, 2035	U-1830			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204640	001 9119876	Mar 13, 2035	DP			
	9295657	Mar 13, 2035	U-1829			
<u>EPINEPHRINE - EPINEPHRINE</u>						
N 205029	001 9283197	Aug 15, 2034	DP U-1828			
	9283197	Aug 15, 2034	DP U-1829			
	9283197	Aug 15, 2034	DP U-1830			
<u>EPINEPHRINE; LIDOCAINE HYDROCHLORIDE - LIDOSITE TOPICAL SYSTEM KIT</u>						
N 021504	001 6629968	Jun 30, 2020	DS DP			
	6635045	Jun 29, 2021	DS DP			
<u>EPLERENONE - INSPIRA</u>						
N 021437	001 6410054	Dec 08, 2019	U-3			
	6410054	Dec 08, 2019	U-537			
	6410524	Nov 05, 2019	U-467			
	6495165	Dec 08, 2019	U-3			
	6495165	Dec 08, 2019	U-537			
	6534093	Dec 08, 2019	U-3			
	6534093	Dec 08, 2019	U-537			
	6558707	Dec 08, 2019	DP U-537			
	6747020	Nov 05, 2019	U-587			
	7157101	Dec 08, 2019	DP U-664			
<u>EPLERENONE - INSPIRA</u>						
N 021437	002 6410054	Dec 08, 2019	U-3			
	6410054	Dec 08, 2019	U-537			
	6410524	Nov 05, 2019	U-467			
	6495165	Dec 08, 2019	U-3			
	6495165	Dec 08, 2019	U-537			
	6534093	Dec 08, 2019	U-3			
	6534093	Dec 08, 2019	U-537			
	6558707	Dec 08, 2019	DP U-537			
	6747020	Nov 05, 2019	U-587			
	7157101	Dec 08, 2019	DP U-664			
<u>EPLERENONE - INSPIRA</u>						
N 021437	003 6410054	Dec 08, 2019	U-3			
	6410054	Dec 08, 2019	U-537			
	6410524	Nov 05, 2019	U-467			
	6495165	Dec 08, 2019	U-3			
	6495165	Dec 08, 2019	U-537			
	6534093	Dec 08, 2019	U-3			
	6534093	Dec 08, 2019	U-537			
	6558707	Dec 08, 2019	DP U-537			
	6747020	Nov 05, 2019	U-587			
	7157101	Dec 08, 2019	DP U-664			
<u>EPOPROSTENOL SODIUM - VELETRI</u>						
N 022260	001 8318802	Mar 15, 2027	DP			
	8598227	Feb 02, 2027				
<u>EPOPROSTENOL SODIUM - VELETRI</u>						
N 022260	002 8318802	Mar 15, 2027	DP			
	8598227	Feb 02, 2027				
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N 201532	001 6214865	Jul 20, 2023	DS		I-721	Jan 28, 2019
	6469182	Jun 16, 2019	U-1096		ODE	Jan 28, 2023
	6469182	Jun 16, 2019	U-1812			
	7470720	Jun 16, 2019	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N 201532	001 8097648	Jan 22, 2021	U-1096			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743	001 5747498	Nov 08, 2018	DS DP U-659		D-164	May 20, 2019
	5747498*PED	May 08, 2019			M-181	Jun 01, 2019
	6900221	Nov 09, 2020	DS DP U-659		M-190	Oct 18, 2019
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743	002 5747498	Nov 08, 2018	DS DP U-659		D-164	May 20, 2019
	5747498*PED	May 08, 2019			M-181	Jun 01, 2019
	6900221	Nov 09, 2020	DS DP U-659		M-190	Oct 18, 2019
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743	003 5747498	Nov 08, 2018	DS DP U-659		D-164	May 20, 2019
	5747498*PED	May 08, 2019			M-181	Jun 01, 2019
	6900221	Nov 09, 2020	DS DP U-659		M-190	Oct 18, 2019
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				
<u>ERTAPENEM SODIUM - INVANZ</u>						
N 021337	001 5952323	May 15, 2017	DP			
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N 021323	001 6916941	Aug 12, 2022	DS DP			
	7420069	Aug 12, 2022	DP			
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N 021323	002 6916941	Aug 12, 2022	DS DP			
	7420069	Aug 12, 2022	DP			
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N 021323	003 6916941	Aug 12, 2022	DS DP			
	7420069	Aug 12, 2022	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416	001 5753646	Jun 27, 2017	DS DP U-1451		D-150	Aug 27, 2018
	5753646	Jun 27, 2017	DS DP U-1746		I-715	Aug 27, 2018
	5753646	Jun 27, 2017	DS DP U-1842		NCE	Nov 08, 2018
	8372431	Apr 17, 2030	DP			
	9206135	Apr 21, 2026	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	5753646	Jun 27, 2017	DS DP U-1451		D-150	Aug 27, 2018
	5753646	Jun 27, 2017	DS DP U-1746		I-715	Aug 27, 2018
	5753646	Jun 27, 2017	DS DP U-1842		NCE	Nov 08, 2018
	8372431	Apr 17, 2030	DP			
	9206135	Apr 21, 2026	DS			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	5753646	Jun 27, 2017	DS DP U-1451		D-150	Aug 27, 2018
	5753646	Jun 27, 2017	DS DP U-1746		I-715	Aug 27, 2018
	5753646	Jun 27, 2017	DS DP U-1842		NCE	Nov 08, 2018
	8372431	Apr 17, 2030	DP			
	9206135	Apr 21, 2026	DS			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	5753646	Jun 27, 2017	DS DP U-1451		D-150	Aug 27, 2018
	5753646	Jun 27, 2017	DS DP U-1746		I-715	Aug 27, 2018
	5753646	Jun 27, 2017	DS DP U-1842		NCE	Nov 08, 2018
	8372431	Apr 17, 2030	DP			
	9206135	Apr 21, 2026	DS			
<u>ESMOLOL HYDROCHLORIDE - BREVIBLOC IN PLASTIC CONTAINER</u>						
N 019386 004	6310094	Jan 12, 2021				
	6528540	Jan 12, 2021				
<u>ESMOLOL HYDROCHLORIDE - BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER</u>						
N 019386 005	6310094	Jan 12, 2021				
	6528540	Jan 12, 2021				
<u>ESMOLOL HYDROCHLORIDE - BREVIBLOC</u>						
N 019386 006	6310094	Jan 12, 2021				
	6528540	Jan 12, 2021				
<u>ESMOLOL HYDROCHLORIDE - BREVIBLOC</u>						
N 019386 007	6310094	Jan 12, 2021				
	6528540	Jan 12, 2021				
<u>ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER</u>						
N 205703 001	6310094	Jan 12, 2021	DP			
	6528540	Jan 12, 2021	DP			
	8829054	Mar 15, 2033	DP			
	8835505	Mar 15, 2033	DP			
<u>ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER</u>						
N 205703 002	6310094	Jan 12, 2021	DP			
	6528540	Jan 12, 2021	DP			
	8829054	Mar 15, 2033	DP			
	8835505	Mar 15, 2033	DP			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021153 001	6147103	Oct 09, 2018				
	6166213	Oct 09, 2018				
	6191148	Oct 09, 2018				
	6369085	May 25, 2018	DS DP U-729			
	6369085	May 25, 2018	DS DP U-770			
	6428810	Nov 03, 2019	DP U-469			
	6428810	Nov 03, 2019	DP U-729			
	6428810	Nov 03, 2019	DP U-770			
	7411070	May 25, 2018	DS			
	8466175	May 25, 2018		U-1417		
	8466175*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021153 002	6147103	Oct 09, 2018				
	6166213	Oct 09, 2018				
	6191148	Oct 09, 2018				
	6369085	May 25, 2018	DS DP U-729			
	6369085	May 25, 2018	DS DP U-770			
	6428810	Nov 03, 2019	DP U-469			
	6428810	Nov 03, 2019	DP U-729			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021153	002	6428810	Nov 03, 2019	DP U-770		
		7411070	May 25, 2018	DS		
		8466175	May 25, 2018		U-1417	
		8466175*PED	Nov 25, 2018			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021957	001	6369085	May 25, 2018	DS DP U-729		
		6369085	May 25, 2018	DS DP U-773		
		6369085	May 25, 2018	DS DP U-1207		
		6428810	Nov 03, 2019	DP U-729		
		6428810	Nov 03, 2019	DP U-773		
		6428810	Nov 03, 2019	DP U-1207		
		7411070	May 25, 2018	DS		
		8466175	May 25, 2018		U-1417	
		8466175*PED	Nov 25, 2018			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021957	002	6369085	May 25, 2018	DS DP U-729		
		6369085	May 25, 2018	DS DP U-773		
		6369085	May 25, 2018	DS DP U-1207		
		6428810	Nov 03, 2019	DP U-729		
		6428810	Nov 03, 2019	DP U-773		
		6428810	Nov 03, 2019	DP U-1207		
		7411070	May 25, 2018	DS		
		8466175	May 25, 2018		U-1417	
		8466175*PED	Nov 25, 2018			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021957	003	6369085	May 25, 2018	DS DP U-1207		
		6428810	Nov 03, 2019	DP U-1207		
		7411070	May 25, 2018	DS		
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021957	004	6369085	May 25, 2018	DS DP U-1207		
		6428810	Nov 03, 2019	DP U-1207		
		7411070	May 25, 2018	DS		
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 022101	001	6369085	May 25, 2018	DS DP U-858		
		6428810	Nov 03, 2019	DP U-858		
		7411070	May 25, 2018	DS		
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 204655	001	5900424*PED	Nov 04, 2016			RTO Mar 28, 2017
		6369085	May 25, 2018	DS DP U-1509		
		6369085	May 25, 2018	DS DP U-1875		
		6369085*PED	Nov 25, 2018			
		6428810	Nov 03, 2019	DP U-1509		
		6428810	Nov 03, 2019	DP U-1874		
		6428810*PED	May 03, 2020			
		7411070	May 25, 2018	DS		
		7411070*PED	Nov 25, 2018			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 207920	01	5900424*PED	Nov 04, 2016			
		6369085	May 25, 2018	DS DP U-1784		
		6369085*PED	Nov 25, 2018			
		6428810	Nov 03, 2019	DP U-1785		
		6428810*PED	May 03, 2020			
		7411070	May 18, 2018	DS		
		7411070*PED	Nov 18, 2018			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511	001	6369085	May 25, 2018	DS DP U-1053		
		6926907	Feb 28, 2023	DP U-1052		
		7411070	May 25, 2018	DS U-1053		
		7745466	Oct 13, 2018	DP U-1053		
		8557285	May 31, 2022	DP		
		8852636	May 31, 2022	DP U-1052		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511	001	8858996	May 31, 2022	DP	U-1052	
		8945621	Oct 17, 2031		U-1661	
		9161920	May 31, 2022		U-1760	
		9198888	May 31, 2022		U-1781	
		9220698	Mar 10, 2031		U-1781	
		9345695	May 31, 2022	DP		
		9393208	Sep 03, 2029		U-1781	
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511	002	6369085	May 25, 2018	DS DP	U-1053	
		6926907	Feb 28, 2023		DP U-1052	
		7411070	May 25, 2018	DS	U-1053	
		7745466	Oct 13, 2018		DP U-1053	
		8557285	May 31, 2022		DP	
		8852636	May 31, 2022		DP U-1052	
		8858996	May 31, 2022		DP U-1052	
		8945621	Oct 17, 2031		U-1661	
		9161920	May 31, 2022		U-1760	
		9198888	May 31, 2022		U-1781	
		9345695	May 31, 2022	DP		
		9393208	Sep 03, 2029		U-1781	
<u>ESOMEPRAZOLE SODIUM - NEXIUM IV</u>						
N 021689	001				D-138	Mar 04, 2017
					I-679	Mar 04, 2017
<u>ESOMEPRAZOLE SODIUM - NEXIUM IV</u>						
N 021689	002				D-138	Mar 04, 2017
					I-679	Mar 04, 2017
<u>ESTRADIOL - VAGIFEM</u>						
N 020908	002	5860946	Jul 01, 2017	DP		
		7018992	Sep 17, 2022		U-1023	
<u>ESTRADIOL - MENOSTAR</u>						
N 021674	001	5891868	Nov 21, 2017	DP	U-594	
		6692763	Nov 21, 2017	DP	U-594	
<u>ESTRADIOL - ELESTRIN</u>						
N 021813	001	7198801	Jun 25, 2022	DP		
		7470433	Aug 03, 2021	DP		
<u>ESTRADIOL - EVAMIST</u>						
N 022014	001	6299900	Feb 19, 2017	DP	U-888	
		6299900	Feb 19, 2017	DP	U-889	
		6818226	Feb 19, 2017	DP	U-888	
		6818226	Feb 19, 2017	DP	U-889	
		6923983	Feb 19, 2017	DP	U-888	
		6923983	Feb 19, 2017	DP	U-889	
		6978945	Jul 31, 2022	DP		
<u>ESTRADIOL - MINIVELLE</u>						
N 203752	001	6841716	Apr 27, 2020	DP		
		8231906	Jul 04, 2030	DS DP		
<u>ESTRADIOL - MINIVELLE</u>						
N 203752	002	6841716	Apr 27, 2020	DP		
		8231906	Jul 04, 2030	DS DP		
<u>ESTRADIOL - MINIVELLE</u>						
N 203752	003	6841716	Apr 27, 2020	DP		
		8231906	Jul 04, 2030	DS DP		
<u>ESTRADIOL - MINIVELLE</u>						
N 203752	004	6841716	Apr 27, 2020	DP		
		8231906	Jul 04, 2030	DS DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESTRADIOL - MINIVELLE</u>						
N 203752	005	6841716	Apr 27, 2020	DP		
		8231906	Jul 04, 2030	DS DP		
<u>ESTRADIOL ACETATE - FEMTRACE</u>						
N 021633	001	6962908	Dec 21, 2021	DP		
		7572779	Oct 02, 2025	U-904		
		7799771	Dec 21, 2021	DP		
<u>ESTRADIOL ACETATE - FEMTRACE</u>						
N 021633	002	6962908	Dec 21, 2021	DP		
		7572779	Oct 02, 2025	U-904		
		7799771	Dec 21, 2021	DP		
<u>ESTRADIOL ACETATE - FEMTRACE</u>						
N 021633	003	6962908	Dec 21, 2021	DP		
		7572779	Oct 02, 2025	U-904		
		7799771	Dec 21, 2021	DP		
<u>ESTRADIOL; ESTRADIOL; NORGESTIMATE - PREFEST</u>						
N 021040	001	6747019	Mar 20, 2020	U-311		
		7320970	Mar 30, 2020	DP U-844		
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUWIA</u>						
N 021443	001	6660726	Mar 08, 2021	DS DP U-904		
		6660726	Mar 08, 2021	DS DP U-905		
		6855703	Feb 12, 2021	DS DP U-904		
		6855703	Feb 12, 2021	DS DP U-905		
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUWIA</u>						
N 021443	002	6660726	Mar 08, 2021	DS DP U-904		
		6660726	Mar 08, 2021	DS DP U-905		
		6855703	Feb 12, 2021	DS DP U-904		
		6855703	Feb 12, 2021	DS DP U-905		
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUWIA</u>						
N 021443	003	6660726	Mar 08, 2021	DS DP U-904		
		6660726	Mar 08, 2021	DS DP U-905		
		6855703	Feb 12, 2021	DS DP U-904		
		6855703	Feb 12, 2021	DS DP U-905		
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUWIA</u>						
N 021443	004	6660726	Mar 08, 2021	DS DP U-904		
		6660726	Mar 08, 2021	DS DP U-905		
		6855703	Feb 12, 2021	DS DP U-904		
		6855703	Feb 12, 2021	DS DP U-905		
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUWIA</u>						
N 021443	005	6660726	Mar 08, 2021	DS DP U-904		
		6660726	Mar 08, 2021	DS DP U-905		
		6855703	Feb 12, 2021	DS DP U-904		
		6855703	Feb 12, 2021	DS DP U-905		
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488	001	8486907	Jun 28, 2025	U-1904	NCE	Sep 19, 2021
		9018368	Jun 28, 2025	DS DP	ODE	Sep 19, 2023
		9416361	May 04, 2021	DS		
		9506058	Mar 14, 2034	U-1918		
		9506058	Mar 14, 2034	U-1919		
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488	002	8486907	Jun 28, 2025	U-1904	NCE	Sep 19, 2021
		9018368	Jun 28, 2025	DS DP	ODE	Sep 19, 2023
		9416361	May 04, 2021	DS		
		9506058	Mar 14, 2034	U-1918		
		9506058	Mar 14, 2034	U-1919		
<u>ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; NORGESTIMATE; NORGESTIMATE; NORGESTIMATE - ORTHO TRI-CYCLEN LO</u>						
N 021241	001	6214815	Jun 09, 2019	U-112		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONIQUE</u>						
N 021840	001	7320969	Jan 30, 2024	U-828		
		7615545	Jun 15, 2023	U-1		
		7855190	Dec 05, 2028	U-1		
		7858605	Jun 23, 2023	DP		
<u>ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; LEVONORGESTREL - LOSEASONIQUE</u>						
N 022262	001	7615545	Jun 15, 2023	U-1		
		7855190	Dec 05, 2028	U-1		
		7858605	Jun 23, 2023	DP		
<u>ETHINYL ESTRADIOL; ETONOGESTREL - NUVARING</u>						
N 021187	001	5989581	Apr 08, 2018			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - PREVEN EMERGENCY CONTRACEPTIVE KIT</u>						
N 020946	001	6156742	Dec 05, 2020	U-374		
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONALE</u>						
N 021544	001	5898032	Jun 23, 2017	U-1		
		RE39861	Jun 23, 2017	U-828		
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - LYBREL</u>						
N 021864	001	6500814	Sep 03, 2018	U-1		
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - QUARTETTE</u>						
N 204061	001	8415332	Mar 11, 2029	DP		
		8450299	Oct 07, 2025	U-1		
<u>ETHINYL ESTRADIOL; NORETHINDRONE - FEMCON FE</u>						
N 021490	001	6667050	Apr 06, 2019	DP U-1		
<u>ETHINYL ESTRADIOL; NORETHINDRONE - NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE</u>						
N 022573	001	6667050	Apr 06, 2019	DP U-828		
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LO LOESTRIN FE</u>						
N 022501	001	7704984	Feb 02, 2029	U-1090		
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MINASTRIN 24 FE</u>						
N 203667	001	6667050	Apr 06, 2019	DP U-1		
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - TAYTULLA</u>						
N 204426	001	6652880	Mar 29, 2020	DP		
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LO MINASTRIN FE</u>						
N 204654	001	6667050	Apr 06, 2019	DP U-1		
		7704984	Feb 02, 2029	U-1		
<u>ETHIODIZED OIL - LIPIODOL</u>						
N 009190	001				ODE	Apr 04, 2021
<u>ETONOGESTREL - NEXPLANON</u>						
N 021529	002	8722037	Sep 28, 2027	DP		
		8888745	Aug 28, 2026	DP		
<u>ETRAVIRINE - INTELENCE</u>						
N 022187	001	6878717	Nov 05, 2019	U-256		
		6878717	Nov 05, 2019	U-1016		
		6878717	Nov 05, 2019	U-1237		
		7037917	Dec 13, 2020	DS DP U-256		
		7037917	Dec 13, 2020	DS DP U-1016		
		7037917	Dec 13, 2020	DS DP U-1237		
		7887845	Mar 25, 2019	DP		
		8003789	Nov 01, 2019	DS DP		
<u>ETRAVIRINE - INTELENCE</u>						
N 022187	002	6878717	Nov 05, 2019	U-256		
		6878717	Nov 05, 2019	U-1016		
		6878717	Nov 05, 2019	U-1237		
		7037917	Dec 13, 2020	DS DP U-256		
		7037917	Dec 13, 2020	DS DP U-1016		
		7037917	Dec 13, 2020	DS DP U-1237		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ETRAVIRINE - INTELENCE</u>						
N 022187	002	7887845				
		8003789				
		Mar 25, 2019	DP			
		Nov 01, 2019	DS DP			
<u>ETRAVIRINE - INTELENCE</u>						
N 022187	003	6878717			U-256	
		6878717			U-1016	
		6878717			U-1237	
		7037917	DS DP		U-1237	
		7887845			DP	
		8003789	DS DP			
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560	001	5665772				
		5665772				
		5665772*PED				
		6004973			DP U-1049	
		6004973			DP U-1365	
		6004973*PED				
		6239124			U-1049	
		6455518			U-1049	
		6455518			U-1365	
		6455518*PED				
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560	002	5665772				
		5665772				
		5665772*PED				
		6004973			DP U-1049	
		6004973			DP U-1365	
		6004973*PED				
		6239124			U-1049	
		6455518			U-1049	
		6455518			U-1365	
		6455518*PED				
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560	003	5665772				
		5665772				
		5665772*PED				
		6004973			DP U-1049	
		6004973			DP U-1365	
		6004973*PED				
		6239124			U-1049	
		6455518			U-1049	
		6455518			U-1365	
		6455518*PED				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334	001	5665772				
		6004973				
		7297703				
		7741338				
		8410131				
		8410131*PED				
		8436010				
		8436010*PED				
		8778962				
		8778962*PED				
		9006224				
		Sep 09, 2019	DS DP		I-724	Feb 26, 2019
		Jul 12, 2016	DP		ODE	Oct 29, 2017
		Dec 06, 2019	DP		ODE	May 05, 2018
		Dec 06, 2019	DP		ODE	Apr 26, 2019
		Nov 01, 2025			PED	Apr 29, 2018
		May 01, 2026			PED	Nov 05, 2018
		Feb 22, 2022			PED	Oct 26, 2019
		Aug 22, 2022				
		Feb 18, 2022			U-1541	
		Aug 18, 2022				
		Jul 01, 2028			U-1681	
<u>EVEROLIMUS - AFINITOR</u>						
N 022334	002	5665772				
		6004973				
		7297703				
		7741338				
		8410131				
		8410131*PED				
		8436010				
		8436010*PED				
		8778962				
		8778962*PED				
		9006224				
		Sep 09, 2019	DS DP		I-724	Feb 26, 2019
		Jul 12, 2016	DP		ODE	Oct 29, 2017
		Dec 06, 2019	DP		ODE	May 05, 2018
		Dec 06, 2019	DP		ODE	Apr 26, 2019
		Nov 01, 2025			PED	Apr 29, 2018
		May 01, 2026			PED	Nov 05, 2018
		Feb 22, 2022			PED	Oct 26, 2019
		Aug 22, 2022				
		Feb 18, 2022			U-1396	
		Aug 18, 2022				
		Jul 01, 2028			U-1681	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - AFINITOR</u>						
N 022334	002	8778962				
		8778962*PED		U-1541		
		9006224				
						U-1681
<u>EVEROLIMUS - AFINITOR</u>						
N 022334	003	5665772		DS DP	I-724	Feb 26, 2019
		6004973		DP	ODE	Oct 29, 2017
		7297703		DP	ODE	May 05, 2018
		7741338		DP	ODE	Apr 26, 2019
		8410131			PED	Apr 29, 2018
		8410131*PED		U-1368	PED	Nov 05, 2018
		8436010			PED	Oct 26, 2019
		8436010*PED		U-1396		
		8778962				
		8778962*PED		U-1541		
		9006224				
						U-1681
<u>EVEROLIMUS - AFINITOR</u>						
N 022334	004	5665772		DS DP	I-724	Feb 26, 2019
		6004973		DP	ODE	Oct 29, 2017
		7297703		DP	ODE	May 05, 2018
		7741338		DP	ODE	Apr 26, 2019
		8410131			PED	Apr 29, 2018
		8410131*PED		U-1368	PED	Nov 05, 2018
		8436010			PED	Oct 26, 2019
		8436010*PED		U-1396		
		8778962				
		8778962*PED		U-1541		
		9006224				
						U-1681
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985	001	5665772		DS DP	ODE	Oct 29, 2017
		6004973		DP	PED	Apr 29, 2018
		7297703		DP		
		8617598		DP		
		8617598*PED				
		8778962				
		8778962*PED		U-1541		
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985	002	5665772		DS DP	ODE	Oct 29, 2017
		6004973		DP	PED	Apr 29, 2018
		7297703		DP		
		8617598		DP		
		8617598*PED				
		8778962				
		8778962*PED		U-1541		
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985	003	5665772		DS DP	ODE	Oct 29, 2017
		6004973		DP	PED	Apr 29, 2018
		7297703		DP		
		8617598		DP		
		8617598*PED				
		8778962				
		8778962*PED		U-1541		
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N 021773	001	5424286			M-148	Nov 24, 2017
		5424286		U-653		
		6858576		U-1108		
		6858576		U-656		
		6872700		U-1108		
		6902744		U-654		
		6956026		DP		
		6956026		U-687		
		6956026		U-1074		
		6956026		U-1623		
		7297761		DP		
		7521423		DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N 021773	001	7741269	Jan 07, 2018	U-653		
		7741269	Jan 07, 2018	U-1074		
		7741269	Jan 07, 2018	U-1108		
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N 021773	002	5424286	Dec 01, 2016	U-653	M-148	Nov 24, 2017
		5424286	Dec 01, 2016	U-1108		
		6858576	Jan 06, 2017	U-656		
		6858576	Jan 06, 2017	U-1108		
		6872700	Jan 14, 2020	U-654		
		6902744	Jan 14, 2020	DP		
		6956026	Jan 07, 2018	U-687		
		6956026	Jan 07, 2018	U-1074		
		6956026	Jan 07, 2018	U-1623		
		7297761	Oct 15, 2017	DP		
		7521423	Oct 15, 2017	DP		
		7741269	Jan 07, 2018	U-653		
		7741269	Jan 07, 2018	U-1074		
		7741269	Jan 07, 2018	U-1108		
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200	001	5424286	Dec 01, 2016	U-1108	M-162	Sep 24, 2018
		6479065	Aug 10, 2020	DP		
		6495164	May 25, 2020	DP		
		6667061	May 25, 2020	DP		
		6824822	Oct 09, 2022	DP		
		6858576	Jan 06, 2017	U-656		
		6872700	Jan 14, 2020	U-654		
		6956026	Jan 07, 2018	U-687		
		7223440	Aug 31, 2021	DP		
		7456254	Jun 30, 2025	DP U-1223		
		7563871	Apr 15, 2024	DP		
		7612176	Apr 13, 2025	DP U-1223		
		7741269	Jan 07, 2018	U-1224		
		8329648	Aug 18, 2026	U-1313		
		8431685	Apr 13, 2025	DP U-412		
		8461105	Apr 13, 2025	DP U-412		
		8906851	Aug 18, 2026	U-1313		
		9238076	Apr 15, 2024	DP U-412		
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200	002	5424286	Dec 01, 2016	U-1108		
		6479065	Aug 10, 2020	DP		
		6495164	May 25, 2020	DP		
		6667061	May 25, 2020	DP		
		6824822	Oct 09, 2022	DP		
		6858576	Jan 06, 2017	U-656		
		6872700	Jan 14, 2020	U-654		
		6956026	Jan 07, 2018	U-687		
		7223440	Aug 31, 2021	DP		
		7456254	Jun 30, 2025	DP U-1223		
		7563871	Apr 15, 2024	DP		
		7612176	Apr 13, 2025	DP U-1223		
		7741269	Jan 07, 2018	U-1224		
		8216180	Jan 12, 2028	DP		
		8329648	Aug 18, 2026	U-1313		
		8431685	Apr 13, 2025	DP U-412		
		8439864	Mar 25, 2028	DP		
		8461105	Apr 13, 2025	DP U-412		
		8906851	Aug 18, 2026	U-1313		
		9238076	Apr 15, 2024	DP U-412		
<u>EZETIMIBE - EZETIMIBE</u>						
A 078560	001				PC	Jun 10, 2017
<u>EZETIMIBE - ZETIA</u>						
N 021445	001	7030106	Jan 25, 2022	DP		
		7612058	Oct 30, 2025	U-1027		
		7612058	Oct 30, 2025	U-1173		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EZETIMIBE - ZETIA</u>						
N 021445	001	7612058*PED	Apr 30, 2026			
		RE37721	Oct 25, 2016	DS DP	U-473	
		RE42461	Oct 25, 2016	DS DP	U-473	
		RE42461	Oct 25, 2016	DS DP	U-1173	
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N 021687	001	RE37721	Oct 25, 2016	DS DP	U-473	
		RE42461	Oct 25, 2016	DS DP	U-473	
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N 021687	002	RE37721	Oct 25, 2016	DS DP	U-473	
		RE42461	Oct 25, 2016	DS DP	U-473	
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N 021687	003	RE37721	Oct 25, 2016	DS DP	U-473	
		RE42461	Oct 25, 2016	DS DP	U-473	
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N 021687	004	RE37721	Oct 25, 2016	DS DP	U-473	
		RE42461	Oct 25, 2016	DS DP	U-473	
<u>FAMOTIDINE - PEPCID AC</u>						
N 020801	002	6814978	Aug 26, 2021	DP		
<u>FAMOTIDINE - FLUXID</u>						
N 021712	001	6024981	Apr 09, 2018	DP		
		6221392	Apr 09, 2018	DP		
<u>FAMOTIDINE - FLUXID</u>						
N 021712	002	6024981	Apr 09, 2018	DP		
		6221392	Apr 09, 2018	DP		
<u>FAMOTIDINE; IBUPROFEN - DUEXIS</u>						
N 022519	001	8067033	Jul 18, 2026	DP		
		8067451	Jul 18, 2026	DP	U-1196	
		8309127	Jul 18, 2026	DP		
		8318202	Jul 18, 2026	DP		
		8449910	Jul 18, 2026	DP		
		8501228	Jul 18, 2026		U-1196	
<u>FEBUXOSTAT - ULORIC</u>						
N 021856	001	5614520	Mar 25, 2019	DS DP	U-954	
		6225474	Jun 18, 2019	DS		
		7361676	Mar 08, 2024	DP		
		8372872	Sep 08, 2031		U-1346	
		9107912	Sep 08, 2031		U-1346	
<u>FEBUXOSTAT - ULORIC</u>						
N 021856	002	5614520	Mar 25, 2019	DS DP	U-954	
		6225474	Jun 18, 2019	DS		
		7361676	Mar 08, 2024	DP		
		8372872	Sep 08, 2031		U-1346	
		9107912	Sep 08, 2031		U-1346	
<u>FENOFIBRATE - TRICOR</u>						
N 021203	001	6074670	Jan 09, 2018			
		6277405	Jan 09, 2018			
		6589552	Jan 09, 2018			
		6652881	Jan 09, 2018	DP		
		7037529	Jan 09, 2018	DP		
		7041319	Jan 09, 2018	DP		
<u>FENOFIBRATE - TRICOR</u>						
N 021203	003	6074670	Jan 09, 2018			
		6277405	Jan 09, 2018			
		6589552	Jan 09, 2018			
		6652881	Jan 09, 2018	DP		
		7037529	Jan 09, 2018	DP		
		7041319	Jan 09, 2018	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENOFIBRATE - TRIGLIDE</u>						
N 021350	001	6696084	Sep 11, 2021	DS DP	U-680	
<u>FENOFIBRATE - TRIGLIDE</u>						
N 021350	002	6696084	Sep 11, 2021	DS DP	U-680	
<u>FENOFIBRATE - TRICOR</u>						
N 021656	001	6277405	Jan 09, 2018	DS		
		6375986	Sep 21, 2020	DP	U-615	
		6652881	Jan 09, 2018	DS		
		7037529	Jan 09, 2018	DP		
		7041319	Jan 09, 2018	DP		
		7276249	Feb 21, 2023	DP		
		7320802	Feb 21, 2023		U-847	
<u>FENOFIBRATE - TRICOR</u>						
N 021656	002	6277405	Jan 09, 2018	DS		
		6375986	Sep 21, 2020	DP	U-615	
		6652881	Jan 09, 2018	DS		
		7037529	Jan 09, 2018	DP		
		7041319	Jan 09, 2018	DP		
		7276249	Feb 21, 2023	DP		
		7320802	Feb 21, 2023		U-847	
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695	001	7101574	Aug 20, 2020	DS DP		
		7863331	Aug 08, 2020		U-1106	
		7863331	Aug 08, 2020		U-1107	
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695	003	7101574	Aug 20, 2020	DS DP		
		7863331	Aug 08, 2020		U-1106	
		7863331	Aug 08, 2020		U-1107	
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695	004	8026281	Apr 22, 2025		U-1447	
		8026281	Apr 22, 2025		U-1448	
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695	005	8026281	Apr 22, 2025		U-1447	
		8026281	Apr 22, 2025		U-1448	
		9314447	May 31, 2033	DP	U-1447	
		9314447	May 31, 2033	DP	U-1448	
<u>FENOFIBRATE - FENOGLIDE</u>						
N 022118	001	7658944	Dec 09, 2024	DP		
		8124125	Oct 01, 2024	DP	U-1234	
		8481078	Oct 01, 2024	DP	U-1416	
		9173847	Oct 01, 2024	DP		
<u>FENOFIBRATE - FENOGLIDE</u>						
N 022118	002	7658944	Dec 09, 2024	DP		
		8124125	Oct 01, 2024	DP	U-1234	
		8481078	Oct 01, 2024	DP	U-1416	
		9173847	Oct 01, 2024	DP		
<u>FENOFIBRIC ACID - FIBRICOR</u>						
N 022418	001	7569612	Aug 20, 2027		U-1000	
		7741373	Aug 20, 2027		U-1059	
		7741374	Aug 20, 2027		U-1060	
		7741374	Aug 20, 2027		U-1061	
		7915247	Aug 20, 2027		U-1000	
		7915247	Aug 20, 2027		U-1059	
		7915247	Aug 20, 2027		U-1061	
<u>FENOFIBRIC ACID - FIBRICOR</u>						
N 022418	002	7569612	Aug 20, 2027		U-1000	
		7741373	Aug 20, 2027		U-1059	
		7741374	Aug 20, 2027		U-1060	
		7741374	Aug 20, 2027		U-1061	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENOFIBRIC ACID - FIBRICOR</u>						
N 022418	002	7915247	Aug 20, 2027			U-1000
		7915247	Aug 20, 2027			U-1059
		7915247	Aug 20, 2027			U-1061
<u>FENTANYL - SUBSYS</u>						
N 202788	001	8486972	Apr 27, 2030			DP
		8486973	Apr 27, 2030			U-55
		8835459	Jan 25, 2027			DP
		8835460	Jan 25, 2027			DP U-55
		9241935	Jan 25, 2027			DP
<u>FENTANYL - SUBSYS</u>						
N 202788	002	8486972	Apr 27, 2030			DP
		8486973	Apr 27, 2030			U-55
		8835460	Jan 25, 2027			DP U-55
		9241935	Jan 25, 2027			DP
<u>FENTANYL - SUBSYS</u>						
N 202788	003	8486972	Apr 27, 2030			DP
		8486973	Apr 27, 2030			U-55
		8835459	Jan 25, 2027			DP
		8835460	Jan 25, 2027			DP U-55
		9241935	Jan 25, 2027			DP
<u>FENTANYL - SUBSYS</u>						
N 202788	004	8486972	Apr 27, 2030			DP
		8486973	Apr 27, 2030			U-55
		8835459	Jan 25, 2027			DP
		8835460	Jan 25, 2027			DP U-55
		9241935	Jan 25, 2027			DP
<u>FENTANYL - SUBSYS</u>						
N 202788	005	8486972	Apr 27, 2030			DP
		8486973	Apr 27, 2030			U-55
		8835460	Jan 25, 2027			DP U-55
		9241935	Jan 25, 2027			DP
<u>FENTANYL - SUBSYS</u>						
N 202788	006	8486972	Apr 27, 2030			DP
		8486973	Apr 27, 2030			U-55
		8835459	Jan 25, 2027			DP
		8835460	Jan 25, 2027			DP U-55
		9241935	Jan 25, 2027			DP
<u>FENTANYL - SUBSYS</u>						
N 202788	007	8486972	Apr 27, 2030			DP
		8486973	Apr 27, 2030			U-55
		8835459	Jan 25, 2027			DP
		8835460	Jan 25, 2027			DP U-55
		9241935	Jan 25, 2027			DP
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947	001	6200604	Mar 26, 2019			U-767
		6974590	Mar 26, 2019			U-767
		7862832	Jun 15, 2028			DP
		7862833	Jun 15, 2028			DP
		8092832	Dec 30, 2024			DP
		8728441	Mar 26, 2019			U-1514
		8753611	Mar 26, 2019			U-1514
		8765100	Mar 26, 2019			DP
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947	002	6200604	Mar 26, 2019			U-767
		6974590	Mar 26, 2019			U-767
		7862832	Jun 15, 2028			DP
		7862833	Jun 15, 2028			DP
		8092832	Dec 30, 2024			DP
		8119158	Dec 30, 2024			DP
		8728441	Mar 26, 2019			U-1514

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 002	8753611	Mar 26, 2019				
	8765100	Mar 26, 2019				
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 003	6200604	Mar 26, 2019				
	6974590	Mar 26, 2019				
	7862832	Jun 15, 2028				
	7862833	Jun 15, 2028				
	8092832	Dec 30, 2024				
	8119158	Dec 30, 2024				
	8728441	Mar 26, 2019				
	8753611	Mar 26, 2019				
	8765100	Mar 26, 2019				
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 004	6200604	Mar 26, 2019				
	6974590	Mar 26, 2019				
	7862832	Jun 15, 2028				
	7862833	Jun 15, 2028				
	8092832	Dec 30, 2024				
	8119158	Dec 30, 2024				
	8728441	Mar 26, 2019				
	8753611	Mar 26, 2019				
	8765100	Mar 26, 2019				
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 005	6200604	Mar 26, 2019				
	6974590	Mar 26, 2019				
	7862832	Jun 15, 2028				
	7862833	Jun 15, 2028				
	8092832	Dec 30, 2024				
	8119158	Dec 30, 2024				
	8728441	Mar 26, 2019				
	8753611	Mar 26, 2019				
	8765100	Mar 26, 2019				
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 006	6200604	Mar 26, 2019				
	6974590	Mar 26, 2019				
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 001	6159498	Oct 18, 2016				
	7579019	Jan 22, 2020				
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 002	6159498	Oct 18, 2016				
	7579019	Jan 22, 2020				
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 003	6159498	Oct 18, 2016				
	7579019	Jan 22, 2020				
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 004	6159498	Oct 18, 2016				
	7579019	Jan 22, 2020				
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 005	6159498	Oct 18, 2016				
	7579019	Jan 22, 2020				
<u>FENTANYL CITRATE - ABSTRAL</u>						
N 022510 001	6759059	Sep 24, 2019				
	6761910	Sep 24, 2019				
	7910132	Sep 24, 2019				
<u>FENTANYL CITRATE - ABSTRAL</u>						
N 022510 002	6759059	Sep 24, 2019				
	6761910	Sep 24, 2019				
	7910132	Sep 24, 2019				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL CITRATE - ABSTRAL</u>						
N 022510 003	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N 022510 004	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N 022510 005	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N 022510 006	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 001	6432440	Apr 20, 2018	DP U-1169			
	8216604	Oct 03, 2024	U-767			
	8889176	Jan 16, 2024	U-767			
	9078814	Jan 08, 2024	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 002	6432440	Apr 20, 2018	DP U-1169			
	8216604	Oct 03, 2024	U-767			
	8889176	Jan 16, 2024	U-767			
	9078814	Jan 08, 2024	DP			
<u>FENTANYL HYDROCHLORIDE - IONSYS</u>						
N 021338 001	5697896	Dec 16, 2016	DP			
	6169920	Jan 02, 2018	DP U-736			
	6181963	Nov 02, 2019	DP			
	6195582	Jan 28, 2019	DP U-736			
	6881208	Apr 19, 2022	U-736			
	6975902	Apr 01, 2024	DP			
	8301238	Sep 30, 2031	DP			
	8428708	May 21, 2032	U-736			
	8428709	Jun 11, 2032	DP U-736			
	8781571	Mar 31, 2032	DP U-736			
	9095706	Feb 03, 2033	DP			
	9364656	Sep 30, 2031	U-736			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	7612109	Feb 05, 2024	DS DP		NP	Jul 25, 2016
	7754702	Feb 13, 2027	DP U-1432			
	8895612	Jan 08, 2027	DP U-1620			
	9376505	Oct 20, 2023	DS DP			
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	5753706	Feb 03, 2017	DP U-1577			
	7767851	Feb 18, 2024	DS DP			
	8093423	Apr 21, 2026	U-1577			
	8299298	Feb 18, 2024	DP			
	8338642	Feb 18, 2024	DS DP U-1577			
	8609896	Feb 18, 2024	DP			
	8754257	Feb 18, 2024	DP			
	8754258	Feb 18, 2024	DP			
	8846976	Feb 18, 2024	U-1577			
	8901349	Feb 18, 2024	U-1577			
	9050316	Feb 18, 2024	U-1577			
	9328133	Feb 18, 2024	DS DP U-1577			
	9387191	Jul 21, 2030	DP			
<u>FERRIC PYROPHOSPHATE CITRATE - TRIFERIC</u>						
N 206317 001	6689275	Dec 31, 2016	U-1656			
	6779468	Dec 31, 2016	U-1656			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC PYROPHOSPHATE CITRATE - TRIFERIC</u>						
N 206317	001	7816404	Apr 17, 2029	DP	U-1656	
<u>FERUMOXYTOL - FERAHEME</u>						
N 022180	001	6599498	Jun 30, 2023	DS	DP	
		7553479	Mar 08, 2020	DS	DP	
		7871597	Mar 08, 2020	DS	DP	
		8501158	Mar 08, 2020		U-1422	
		8591864	Mar 08, 2020	DP		
		8926947	Mar 08, 2020	DS	DP	
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N 022030	001	6858650	Jul 03, 2022	DS	U-913	
		7384980	May 11, 2019	DS	DP U-913	
		7807715	Jun 07, 2027	DP	U-913	
		7855230	May 11, 2019		U-913	
		7985772	May 11, 2019	DS	DP U-913	
		8088398	Jun 07, 2027	DP	U-913	
		8338478	May 11, 2019	DS	DP U-913	
		8501723	Jun 07, 2027	DP		
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N 022030	002	6858650	Jul 03, 2022	DS	U-913	
		7384980	May 11, 2019	DS	DP U-913	
		7807715	Jun 07, 2027	DP	U-913	
		7855230	May 11, 2019		U-913	
		7985772	May 11, 2019	DS	DP U-913	
		8088398	Jun 07, 2027	DP	U-913	
		8338478	May 11, 2019	DS	DP U-913	
		8501723	Jun 07, 2027	DP		
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA</u>						
N 020625	001	6037353	Mar 14, 2017		U-138	
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N 020872	005	6037353	Mar 14, 2017		U-1160	
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N 020872	006	6037353	Mar 14, 2017		U-1160	
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA ALLERGY</u>						
N 020872	007	6037353	Mar 14, 2017		U-1160	
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA HIVES</u>						
N 020872	008	6037353	Mar 14, 2017		U-1160	
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA HIVES</u>						
N 020872	009	6037353	Mar 14, 2017		U-1160	
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA ALLERGY</u>						
N 020872	010	6037353	Mar 14, 2017		U-1160	
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N 021909	002	6037353	Mar 14, 2017		U-1158	
		6037353	Mar 14, 2017		U-1466	
		6723348	Nov 26, 2021	DP	U-1466	
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N 021909	003	6037353	Mar 14, 2017			
		6723348	Nov 26, 2021	DP		
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA</u>						
N 021963	001	6037353	Mar 14, 2017		U-772	
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N 201373	001	6037353	Mar 14, 2017		U-1157	
		8933097	Aug 16, 2032	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N 201373	002 6037353	Mar 14, 2017	U-1157			
	8933097	Aug 16, 2032	DP			
<u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION</u>						
N 020786	002 6037353	Mar 14, 2017	U-1159			
	6039974	Jul 31, 2018	DP			
<u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION</u>						
N 021704	002 6037353	Mar 14, 2017	U-1159			
	6613357	Dec 25, 2020	DP U-1159			
	RE39069	May 29, 2018	DP			
<u>FIDAXOMICIN - DIFICID</u>						
N 201699	001 7378508	Jul 31, 2027	DS DP			
	7863249	Jul 31, 2027	DS DP			
	7906489	Mar 04, 2027		U-319		
	8586551	Jul 15, 2023	DS DP			
	8859510	Jul 31, 2027		U-319		
<u>FINAFLOXACIN - XTORO</u>						
N 206307	001 6133260	Apr 12, 2017	DS DP		NCE	Dec 17, 2019
	6432948	Apr 12, 2017	DS DP		PED	Jun 17, 2020
	8536167	Aug 08, 2031		U-1679		
	9119859	Jul 02, 2030		U-1679		
	9504691	Nov 21, 2033	DP U-1679			
<u>FINASTERIDE - PROSCAR</u>						
N 020180	001 5942519	Oct 23, 2018		U-280		
<u>FINGOLIMOD - GILENYA</u>						
N 022527	001 5604229	Feb 18, 2019	DS	U-1086		
	6004565	Sep 23, 2017		U-1086		
	8324283	Mar 29, 2026				
	9187405	Jun 25, 2027		U-1086		
<u>FLIBANSERIN - ADDYI</u>						
N 022526	001 7151103	May 09, 2023		U-1734	NCE	Aug 18, 2020
	7420057	Aug 01, 2022	DS DP			
	8227471	May 09, 2023		U-1734		
	9468639	Oct 16, 2022		U-1734		
<u>FLORBETABEN F-18 - NEURACEQ</u>						
N 204677	001 7807135	Mar 18, 2029	DS DP	U-1497	NCE	Mar 21, 2019
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 202008	001 7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
	8506929	Apr 30, 2027	DS DP	U-1423		
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 202008	002 7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
	8506929	Apr 30, 2027	DS DP	U-1423		
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 202008	003 7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
	8506929	Apr 30, 2027	DS DP	U-1423		
<u>FLUCICLOVINE F-18 - AXUMIN</u>						
N 208054	001 5808146	Nov 09, 2017	DS		NCE	May 27, 2021
	9387266	Nov 28, 2026		U-1879		
<u>FLUDARABINE PHOSPHATE - OFORTA</u>						
N 022273	001 7148207	Dec 20, 2022		DP U-944		
	7547776	Dec 10, 2018	DS			
<u>FLUNISOLIDE - AEROSPAN HFA</u>						
N 021247	001				M-128	Aug 28, 2016

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUOCINOLONE ACETONIDE - RETISERT</u>						
N 021737	001 6217895	Mar 22, 2019	DP U-708			
	6548078	Mar 22, 2019	DP U-708			
<u>FLUOCINOLONE ACETONIDE - ILLUVIEN</u>						
N 201923	001 6217895	Mar 22, 2019	DP U-1597		NP	Sep 26, 2017
	6375972	Apr 26, 2020	DP U-1597			
	6548078	Mar 22, 2019	DP U-1597			
	8252307	Jun 27, 2019	DP			
	8871241	Aug 12, 2027	DP			
<u>FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA</u>						
N 021112	001 7915243	Mar 22, 2026	DP			
	7939516	May 04, 2025	DP			
	8247395	Oct 22, 2022	DP			
	8653053	Oct 25, 2022	DP			
<u>FLUOCINONIDE - VANOS</u>						
N 021758	001 6765001	Dec 21, 2021	DP			
	7220424	Jan 07, 2023	U-861			
	7794738	Sep 11, 2022	U-1084			
	8232264	Mar 09, 2023	DP			
<u>FLUOROURACIL - CARAC</u>						
N 020985	001 6670335	Jun 02, 2021	DP U-68			
<u>FLUOROURACIL - TOLAK</u>						
N 022259	001 7169401	Jul 18, 2023	DP		NP	Sep 18, 2018
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936	001 6960577	Nov 01, 2017	U-963		NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936	003 6960577	Nov 01, 2017	U-963		NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936	004				NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936	006 6960577	Nov 01, 2017	U-963		NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE - PROZAC WEEKLY</u>						
N 021235	001 5910319	May 29, 2017	U-396			
	5985322	May 29, 2017	U-397			
	RE39030	May 29, 2017	DP U-396			
	RE39030	May 29, 2017	DP U-397			
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520	001 6960577	Nov 01, 2017	U-962		M-142 NPP	Oct 10, 2017 Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520	002 5945416	Mar 24, 2017	DS DP	Y	M-142	Oct 10, 2017
	6960577	Nov 01, 2017	U-962		NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520	003 5945416	Mar 24, 2017	DS DP	Y	M-142	Oct 10, 2017
	6960577	Nov 01, 2017	U-962		NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520	004 5945416	Mar 24, 2017	DS DP	Y	M-142	Oct 10, 2017
	6960577	Nov 01, 2017	U-962		NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520	005 5945416	Mar 24, 2017	DS DP	Y	M-142	Oct 10, 2017
	6960577	Nov 01, 2017	U-962		NPP	Jul 26, 2016
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137	001 7270800	Sep 03, 2025	DS DP U-336		NCE	Oct 25, 2018
	7351401	Jan 24, 2023	DS DP U-336			
	8236282	May 21, 2024	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 001	8691185	Jan 24, 2023	U-336			
	8916131	Sep 16, 2028	DP			
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 002	7270800	Sep 03, 2025	DS DP U-336		NCE	Oct 25, 2018
	7351401	Jan 24, 2023	DS DP U-336			
	8236282	May 21, 2024	DS DP			
	8691185	Jan 24, 2023	U-336			
	8916131	Sep 16, 2028	DP			
<u>FLUTICASONE FUROATE - FLONASE SENSIMIST ALLERGY RELIEF</u>						
N 022051 002	6858596	Aug 03, 2021	DP U-1890			
	7101866	Aug 03, 2021	DS DP U-1890			
	7541350	Aug 03, 2021	DP U-1890			
	8062264	Apr 05, 2026	DP			
	8147461	Oct 15, 2028	DP			
	8347879	Jul 15, 2028	DP			
	8752543	Apr 05, 2026	DP			
	9320862	Nov 06, 2024	DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 001	7101866	Aug 03, 2021	DS DP U-1559		NP	Aug 20, 2017
	7629335	Aug 03, 2021	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8201556	Feb 05, 2029	DP			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			
	9333310	Oct 02, 2027	DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 002	7101866	Aug 03, 2021	DS DP U-1559		NP	Aug 20, 2017
	7629335	Aug 03, 2021	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8201556	Feb 05, 2029	DP			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			
	9333310	Oct 02, 2027	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	6537983	Aug 03, 2021	DP U-1401		I-708	Apr 30, 2018
	6537983	Aug 03, 2021	DP U-1691			
	6759398	Aug 03, 2021	DP U-1401			
	6759398	Aug 03, 2021	DP U-1691			
	6878698	Aug 03, 2021	U-1401			
	7101866	Aug 03, 2021	DS DP U-1401			
	7101866	Aug 03, 2021	DS DP U-1691			
	7439393	Sep 11, 2022	DS DP U-1401			
	7439393	Sep 11, 2022	DS DP U-1691			
	7629335	Aug 03, 2021	DP			
	7776895	Sep 11, 2022	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8511304	Jun 14, 2027	DP U-1424			
	8511304	Jun 14, 2027	DP U-1691			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			
	9333310	Oct 02, 2027	DP			
	RE44874	Mar 23, 2023	DS DP U-1548			
	RE44874	Mar 23, 2023	DS DP U-1691			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002	6537983	Aug 03, 2021	DP U-1691		NP	Apr 30, 2018
	6759398	Aug 03, 2021	DP U-1691			
	7101866	Aug 03, 2021	DS DP U-1691			
	7439393	Sep 11, 2022	DS DP U-1691			
	7629335	Aug 03, 2021	DP			
	7776895	Sep 11, 2022	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275	002	8113199	Oct 23, 2027	DP		
		8161968	Feb 05, 2028	DP		
		8511304	Jun 14, 2027	DP	U-1691	
		8534281	Aug 10, 2029	DP		
		8746242	Oct 11, 2030	DP		
		9333310	Oct 02, 2027	DP		
		RE44874	Mar 23, 2023	DS DP	U-1691	
<u>FLUTICASONE PROPIONATE - CUTIVATE</u>						
N 021152	001	7300669	Oct 20, 2019	DP	U-835	NPP Jan 16, 2018
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433	001	6161724	Jan 16, 2018	DP		
		6170717	Dec 23, 2017	DP		
		6315173	Dec 23, 2017	DP		
		6431168	Jun 08, 2018	DP		
		6435372	Jan 16, 2018	DP		
		6510969	Dec 23, 2017	DP		
		6743413	Jun 01, 2021		U-581	
		6938796	Jan 16, 2018	DP		
		6966467	Dec 23, 2017	DP		
		6997349	Jan 16, 2018	DP		
		7107986	Jun 08, 2018	DP		
		7107986*PED	Dec 08, 2018			
		7143908	Jan 16, 2018	DP		
		7350676	Aug 24, 2018	DP		
		7500444	Feb 26, 2026	DP		
		7500444*PED	Aug 26, 2026			
		7832351	Jun 19, 2023	DP		
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433	002	6161724	Jan 16, 2018	DP		
		6170717	Dec 23, 2017	DP		
		6315173	Dec 23, 2017	DP		
		6431168	Jun 08, 2018	DP		
		6435372	Jan 16, 2018	DP		
		6510969	Dec 23, 2017	DP		
		6743413	Jun 01, 2021		U-581	
		6938796	Jan 16, 2018	DP		
		6966467	Dec 23, 2017	DP		
		6997349	Jan 16, 2018	DP		
		7107986	Jun 08, 2018	DP		
		7107986*PED	Dec 08, 2018			
		7143908	Jan 16, 2018	DP		
		7350676	Aug 24, 2018	DP		
		7500444	Feb 26, 2026	DP		
		7500444*PED	Aug 26, 2026			
		7832351	Jun 19, 2023	DP		
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433	003	6161724	Jan 16, 2018	DP		
		6170717	Dec 23, 2017	DP		
		6315173	Dec 23, 2017	DP		
		6431168	Jun 08, 2018	DP		
		6435372	Jan 16, 2018	DP		
		6510969	Dec 23, 2017	DP		
		6743413	Jun 01, 2021		U-581	
		6938796	Jan 16, 2018	DP		
		6966467	Dec 23, 2017	DP		
		6997349	Jan 16, 2018	DP		
		7107986	Jun 08, 2018	DP		
		7107986*PED	Dec 08, 2018			
		7143908	Jan 16, 2018	DP		
		7350676	Aug 24, 2018	DP		
		7500444	Feb 26, 2026	DP		
		7500444*PED	Aug 26, 2026			
		7832351	Jun 19, 2023	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - FLONASE ALLERGY RELIEF</u>						
N 205434	001				M-147	Jul 23, 2017
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254	001	6161724	Jan 16, 2018	DP		
		6170717	Dec 23, 2017	DP		
		6315173	Dec 23, 2017	DP		
		6431168	Jun 08, 2018	DP		
		6435372	Jan 16, 2018	DP		
		6510969	Dec 23, 2017			
		6743413	Jun 01, 2021	U-1591		
		6743413*PED	Dec 01, 2021			
		6938796	Jan 16, 2018	DP		
		6966467	Dec 23, 2017	DP		
		6997349	Jan 16, 2018	DP		
		7107986	Jun 08, 2018	DP		
		7143908	Jan 16, 2018	DP		
		7350676	Aug 24, 2018	DP		
		7500444	Feb 26, 2026	DP		
		7500444*PED	Aug 26, 2026			
		7832351	Jun 19, 2023	DP		
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254	002	6161724	Jan 16, 2018	DP		
		6170717	Dec 23, 2017	DP		
		6315173	Dec 23, 2017	DP		
		6431168	Jun 08, 2018	DP		
		6435372	Jan 16, 2018	DP		
		6510969	Dec 23, 2017	DP		
		6743413	Jun 01, 2021	U-1591		
		6743413*PED	Dec 01, 2021			
		6938796	Jan 16, 2018	DP		
		6966467	Dec 23, 2017	DP		
		6997349	Jan 16, 2018	DP		
		7107986	Jun 08, 2018	DP		
		7143908	Jan 16, 2018	DP		
		7350676	Aug 24, 2018	DP		
		7500444	Feb 26, 2026	DP		
		7500444*PED	Aug 26, 2026			
		7832351	Jun 19, 2023	DP		
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254	003	6161724	Jan 16, 2018	DP		
		6170717	Dec 23, 2017	DP		
		6315173	Dec 23, 2017	DP		
		6431168	Jun 08, 2018	DP		
		6435372	Jan 16, 2018	DP		
		6510969	Dec 23, 2017	DP		
		6743413	Jun 01, 2021	U-1591		
		6743413*PED	Dec 01, 2021			
		6938796	Jan 16, 2018	DP		
		6966467	Dec 23, 2017	DP		
		6997349	Jan 16, 2018	DP		
		7107986	Jun 08, 2018	DP		
		7143908	Jan 16, 2018	DP		
		7350676	Aug 24, 2018	DP		
		7500444	Feb 26, 2026	DP		
		7500444*PED	Aug 26, 2026			
		7832351	Jun 19, 2023	DP		
<u>FLUVASTATIN SODIUM - LESCOL XL</u>						
N 021192	001	6242003	Apr 13, 2020			
<u>FLUVOXAMINE MALEATE - LUVOX CR</u>						
N 022033	001	7465462	May 10, 2020	DP	U-929	
<u>FLUVOXAMINE MALEATE - LUVOX CR</u>						
N 022033	002	7465462	May 10, 2020	DP	U-929	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N 020378	004	7563763	Aug 23, 2019	DP		
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N 020378	005	7563763	Aug 23, 2019	DP		
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211	001	5929028	Jan 14, 2018	DP	U-567	
		5929028	Jan 14, 2018	DP	U-1366	
		7446090	Aug 23, 2019	DP		
		7563763	Aug 23, 2019		U-993	
		7563763	Aug 23, 2019		U-1183	
		7563763	Aug 23, 2019		U-1367	
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211	002	5929028	Jan 14, 2018	DP	U-567	
		5929028	Jan 14, 2018	DP	U-1366	
		7446090	Aug 23, 2019	DP		
		7563763	Aug 23, 2019		U-993	
		7563763	Aug 23, 2019		U-1183	
		7563763	Aug 23, 2019		U-1367	
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211	003	5929028	Jan 14, 2018	DP	U-567	
		5929028	Jan 14, 2018	DP	U-1366	
		7446090	Aug 23, 2019	DP		
		7563763	Aug 23, 2019		U-993	
		7563763	Aug 23, 2019		U-1183	
		7563763	Aug 23, 2019		U-1367	
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211	004	5929028	Jan 14, 2018	DP	U-567	
		5929028	Jan 14, 2018	DP	U-1366	
		7446090	Aug 23, 2019	DP		
		7563763	Aug 23, 2019		U-993	
		7563763	Aug 23, 2019		U-1183	
		7563763	Aug 23, 2019		U-1367	
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021273	001	5929028	Jan 14, 2018	DP	U-1366	
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021273	002	5929028	Jan 14, 2018	DP	U-1366	
<u>FOLLITROPIN ALFA/BETA - GONAL-F RFF REDI-JECT</u>						
N 021684	001	7446090	Aug 23, 2019	DP		
		7741268	Apr 02, 2024	DP		
<u>FOLLITROPIN ALFA/BETA - GONAL-F RFF REDI-JECT</u>						
N 021684	002	7446090	Aug 23, 2019	DP		
		7741268	Apr 02, 2024	DP		
<u>FOLLITROPIN ALFA/BETA - GONAL-F RFF REDI-JECT</u>						
N 021684	003	7446090	Aug 23, 2019	DP		
		7741268	Apr 02, 2024	DP		
<u>FOMEPIZOLE - ANTIZOL</u>						
N 020696	001	7553863	Jun 30, 2027	DS DP		
<u>FORMOTEROL FUMARATE - FORADIL</u>						
N 020831	001	6488027	Mar 08, 2019			
		6887459	Nov 28, 2020		U-762	
<u>FORMOTEROL FUMARATE - PERFOROMIST</u>						
N 022007	001	6667344	Jun 22, 2021	DP		
		6814953	Jun 22, 2021	DP	U-813	
		7348362	Jun 22, 2021	DP		
		7462645	Jun 22, 2021	DP	U-813	
		8623922	Jun 22, 2021	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FORMOTEROL FUMARATE; GLYCOPYRROLATE - BEVESPI AEROSPHERE</u>						
N 208294	001	8324266	May 28, 2030	U-1841	NP	Apr 25, 2019
		8703806	May 28, 2030	U-1841		
		8808713	May 28, 2030	DP U-1841		
		8815258	Mar 17, 2031	U-1841		
		9415009	May 28, 2030	U-1841		
		9463161	May 28, 2030	DP U-1841		
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518	001	6068832	Aug 27, 2017	DP U-1068		
		7067502	May 21, 2020	DP U-1068		
		7566705	May 21, 2020	DP U-1068		
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518	002	6068832	Aug 27, 2017	DP U-1068		
		7067502	May 21, 2020	DP U-1068		
		7566705	May 21, 2020	DP U-1068		
<u>FOSAMPRENAVIR CALCIUM - LEXIVA</u>						
N 021548	001	6436989	Dec 24, 2017	DS DP U-257		
		6514953	Jul 15, 2019	DS DP U-257		
<u>FOSAMPRENAVIR CALCIUM - LEXIVA</u>						
N 022116	001	6436989	Dec 24, 2017	DS DP U-257		
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023	001	5691336	Mar 04, 2019	DS DP		
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023	002	5691336	Mar 04, 2019	DS DP	D-155	Feb 01, 2019
<u>FOSPROPOFOL DISODIUM - LUSEDRA</u>						
N 022244	001	6204257	Jul 01, 2022	DS DP U-945		
		6872838	Aug 07, 2018	DS		
<u>FULVESTRANT - FASLODEX</u>						
N 021344	001	6774122	Jan 09, 2021	U-596	I-725	Feb 19, 2019
		6774122	Jan 09, 2021	U-1826		
		6774122*PED	Jul 09, 2021			
		7456160	Jan 09, 2021	U-596		
		7456160	Jan 09, 2021	U-1826		
		7456160*PED	Jul 09, 2021			
		8329680	Jan 09, 2021	U-596		
		8329680	Jan 09, 2021	U-1826		
		8329680*PED	Jul 09, 2021			
		8466139	Jan 09, 2021	U-596		
		8466139	Jan 09, 2021	U-1826		
		8466139*PED	Jul 09, 2021			
<u>GABAPENTIN - NEURONTIN</u>						
N 020235	001	6054482	Apr 25, 2017			
<u>GABAPENTIN - NEURONTIN</u>						
N 020235	002	6054482	Apr 25, 2017			
<u>GABAPENTIN - NEURONTIN</u>						
N 020235	003	6054482	Apr 25, 2017			
<u>GABAPENTIN - NEURONTIN</u>						
N 020882	001	6054482	Apr 25, 2017			
<u>GABAPENTIN - NEURONTIN</u>						
N 020882	002	6054482	Apr 25, 2017			
<u>GABAPENTIN - NEURONTIN</u>						
N 021129	001	6054482	Apr 25, 2017			
		7256216	May 28, 2022	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GABAPENTIN - GRALISE</u>						
N 022544 001	6340475	Sep 19, 2016	DP		ODE	Jan 28, 2018
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6723340	Oct 25, 2021	DP			
	7438927	Feb 26, 2024	U-1114			
	7731989	Oct 25, 2022	DP			
	8192756	Oct 25, 2022	DP U-1114			
	8252332	Oct 25, 2022	DP U-1114			
	8333992	Oct 25, 2022	DP U-1114			
<u>GABAPENTIN - GRALISE</u>						
N 022544 002	6340475	Sep 19, 2016	DP		ODE	Jan 28, 2018
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6723340	Oct 25, 2021	DP			
	7438927	Feb 26, 2024	U-1114			
	7731989	Oct 25, 2022	DP			
	8192756	Oct 25, 2022	DP U-1114			
	8252332	Oct 25, 2022	DP U-1114			
	8333992	Oct 25, 2022	DP U-1114			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399 001	6818787	Nov 06, 2022	DS DP		ODE	Jun 06, 2019
	8026279	Nov 10, 2026	DS DP			
	8048917	Nov 06, 2022	DS DP U-1247			
	8114909	Apr 11, 2026	U-1231			
	8686034	Jan 24, 2025	U-1231			
	8686034	Jan 24, 2025	U-1247			
	8795725	Jun 10, 2029	DP U-1231			
	8795725	Jun 10, 2029	DP U-1247			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399 002	6818787	Nov 06, 2022	DS DP		ODE	Jun 06, 2019
	8026279	Nov 10, 2026	DS DP			
	8048917	Nov 06, 2022	DS DP U-1247			
	8114909	Apr 11, 2026	U-1231			
	8686034	Jan 24, 2025	U-1231			
	8686034	Jan 24, 2025	U-1247			
	8795725	Jun 10, 2029	DP U-1231			
	8795725	Jun 10, 2029	DP U-1247			
<u>GADOBUTROL - GADAVIST</u>						
N 201277 001	5980864	Nov 09, 2016	DS DP U-1119		I-688	Jun 11, 2017
<u>GADOBUTROL - GADAVIST</u>						
N 201277 002	5980864	Nov 09, 2016	DS DP U-1119		I-688 I-731	Jun 11, 2017 Apr 27, 2019
<u>GADOBUTROL - GADAVIST</u>						
N 201277 003	5980864	Nov 09, 2016	DS DP U-1119		I-688	Jun 11, 2017
<u>GADOBUTROL - GADAVIST</u>						
N 201277 004	5980864	Nov 09, 2016	DS DP U-1119		I-688	Jun 11, 2017
<u>GADOBUTROL - GADAVIST</u>						
N 201277 005	5980864	Nov 09, 2016	DS DP U-1119		I-688	Jun 11, 2017
<u>GADOBUTROL - GADAVIST</u>						
N 201277 006	5980864	Nov 09, 2021	DS DP U-1119		I-688	Jun 11, 2017
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N 021711 001	6676929	May 04, 2020	DP			
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N 021711 002	6676929	May 04, 2020	DP			
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 001					NCE	Mar 20, 2018

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781	002				NCE	Mar 20, 2018
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781	003				NCE	Mar 20, 2018
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781	004				NCE	Mar 20, 2018
<u>GADOXETATE DISODIUM - EOVI</u>						
N 022090	001 6039931	Nov 13, 2021	U-1239		M-155	Mar 27, 2018
<u>GADOXETATE DISODIUM - EOVI</u>						
N 022090	002				M-155	Mar 27, 2018
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE</u>						
N 021169	001 6099863	Jun 06, 2017				
	6358527	Jun 06, 2017	DP U-322			
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE</u>						
N 021169	002 6099863	Jun 06, 2017				
	6358527	Jun 06, 2017	DP U-322			
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE</u>						
N 021169	003 6099863	Jun 06, 2017				
	6358527	Jun 06, 2017	DP U-322			
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE ER</u>						
N 021615	001 7160559	Dec 20, 2019			DP	
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE ER</u>						
N 021615	002 7160559	Dec 20, 2019			DP	
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE ER</u>						
N 021615	003 7160559	Dec 20, 2019			DP	
<u>GALLIUM DOTATATE GA-68 - NETSPOT</u>						
N 208547	001				NCE ODE	Jun 01, 2021 Jun 01, 2023
<u>GANCICLOVIR - ZIRGAN</u>						
N 022211	001				ODE	Sep 15, 2016
<u>GANIRELIX ACETATE - GANIRELIX ACETATE</u>						
N 021057	001 6653286	Jun 16, 2018	U-1354			
<u>GATIFLOXACIN - ZYMAR</u>						
N 021493	001 6333045	Aug 20, 2019	DP		Y	
	6333045*PED	Feb 20, 2020				
<u>GEFITINIB - IRESSA</u>						
N 021399	001 5770599	May 05, 2017	DS DP U-881			
<u>GEFITINIB - IRESSA</u>						
N 206995	001 5770599	May 05, 2017	DS DP U-1755		NP ODE	Jul 13, 2018 Jul 13, 2022
<u>GEMIFLOXACIN MESYLATE - FACTIVE</u>						
N 021158	001 5776944	Apr 04, 2017	DS DP			
	6262071	Sep 21, 2019		U-513		
	6331550	Sep 21, 2019		U-511		
	6340689	Sep 14, 2019		U-512		
	6455540	Sep 21, 2019		U-511		
	6723734	Mar 20, 2018	DS DP			
	6803376	Sep 21, 2019	DS DP U-608			
	6803376	Sep 21, 2019	DS DP U-609			
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N 020622	003 8232250	Aug 19, 2030	U-441		NP	Jan 28, 2017
	8399413	Aug 19, 2030	U-441			
	8969302	Aug 19, 2030	U-441			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N 020622	003 9155776	Aug 19, 2030	U-441			
	9402874	Aug 19, 2030	U-441			
<u>GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT</u>						
N 021925	001 6303640	Aug 09, 2016	U-753			
	7700128	Jan 30, 2027	DP			
	8071130	Jun 08, 2028	DP			
<u>GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT</u>						
N 021925	002 6303640	Aug 09, 2016	U-753			
	7700128	Jan 30, 2027	DP			
	8071130	Jun 08, 2028	DP			
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700	001 7358366	Apr 19, 2020	DS			
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700	002 7358366	Apr 19, 2020	DS			
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700	003 7358366	Apr 19, 2020	DS			
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700	004 7358366	Apr 19, 2020	DS			
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700	005 7358366	Apr 19, 2020	DS			
<u>GLIPIZIDE - GLIPIZIDE</u>						
A 202298	001				PC	Jul 27, 2016
<u>GLIPIZIDE - GLUCOTROL XL</u>						
N 020329	001 RE44459	Mar 26, 2019	U-1431			
<u>GLIPIZIDE - GLUCOTROL XL</u>						
N 020329	002 RE44459	Mar 26, 2019	U-1431			
<u>GLIPIZIDE - GLUCOTROL XL</u>						
N 020329	003 RE44459	Mar 26, 2019	U-1431			
<u>GLYBURIDE; METFORMIN HYDROCHLORIDE - GLUCOVANCE</u>						
N 021178	001 6303146	Jul 14, 2019	U-412			
<u>GLYBURIDE; METFORMIN HYDROCHLORIDE - GLUCOVANCE</u>						
N 021178	002 6303146	Jul 14, 2019	U-412			
<u>GLYBURIDE; METFORMIN HYDROCHLORIDE - GLUCOVANCE</u>						
N 021178	003 6303146	Jul 14, 2019	U-412			
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284	001 5968979	Jul 28, 2018	DS DP U-1378		ODE	Feb 01, 2020
	8404215	Mar 09, 2032	U-1383			
	8642012	Sep 22, 2030	U-1383			
	9095559	Mar 09, 2032	U-1383			
	9254278	Mar 09, 2032	U-1816			
	9326966	Mar 09, 2032	U-1816			
<u>GLYCOPYRROLATE - CUVPOSA</u>						
N 022571	001 7638552	Aug 20, 2023	U-1076		ODE	Jul 28, 2017
	7816396	Aug 20, 2023	U-1076			
<u>GLYCOPYRROLATE - SEEBRI</u>						
N 207923	001 6582678	Apr 24, 2018	DP		NP	Oct 29, 2018
	7229607	Apr 09, 2021	U-1773			
	7736670	Jun 27, 2021	DP			
	8029768	Apr 09, 2021	U-1773			
	8048451	Jun 27, 2021	DP			
	8182838	Oct 20, 2028	DP			
	8303991	Jun 27, 2021	DP			
	8435567	Jun 27, 2021	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GLYCOPYRROLATE - SEEBRI</u>						
N 207923	001	8479730				
		Oct 11, 2028	DP			
		8580306				
		Jun 27, 2021	DP			
		8956661				
		Jun 27, 2021	DP			
<u>GLYCOPYRROLATE ; INDACATEROL MALEATE - UTIBRON</u>						
N 207930	001	6582678				
		Apr 24, 2018	DP		NCE	Jul 01, 2016
		6878721				
		Feb 25, 2025	DS DP U-1773		NP	Oct 29, 2018
		7229607				
		Apr 09, 2021	U-1773			
		7736670				
		Jun 27, 2021	DP			
		7820694				
		Jun 02, 2020	DP U-1773			
		8029768				
		Apr 09, 2021	U-1773			
		8048451				
		Jun 27, 2021	DP			
		8067437				
		Jun 02, 2020	U-1773			
		8182838				
		Oct 20, 2028	DP			
		8283362				
		Jun 02, 2020	DP U-1773			
		8303991				
		Jun 27, 2021	DP			
		8435567				
		Jun 27, 2021	DP			
		8479730				
		Oct 11, 2028	DP			
		8580306				
		Jun 27, 2021	DP			
		8658673				
		Jun 02, 2020	DP U-1773			
		8796307				
		Jun 02, 2020	DP			
		8956661				
		Jun 27, 2021	DP			
<u>GOSERELIN ACETATE - ZOLADEX</u>						
N 019726	001	7118552				
		Apr 13, 2022	DP			
		7220247				
		Apr 09, 2022	DP			
		7500964				
		Feb 26, 2021	DP			
<u>GOSERELIN ACETATE - ZOLADEX</u>						
N 020578	001	7118552				
		Apr 13, 2022	DP			
		7220247				
		Apr 09, 2022	DP			
		7500964				
		Feb 26, 2021	DP			
<u>GRANISETRON - SANCUSO</u>						
N 022198	001	7608282				
		Jan 22, 2025	DP U-1011			
<u>GRANISETRON - SUSTOL</u>						
N 022445	001	6613355				
		Jun 28, 2021	DP		NDF	Aug 09, 2019
		6790458				
		May 11, 2021	DP			
		8252304				
		Sep 28, 2024	DP			
		8252305				
		Sep 28, 2024	U-1891			
		8715710				
		Sep 28, 2024	DP			
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N 020239	001	5952340				
		Sep 14, 2016	U-519			
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N 020239	002	5952340				
		Sep 14, 2016	U-519			
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N 020239	004	5952340				
		Sep 14, 2016	U-519			
<u>GUAIFENESIN - MUCINEX</u>						
N 021282	001	6372252				
		Apr 28, 2020	U-489			
		6955821				
		Apr 28, 2020	DP U-489			
		7838032				
		Apr 28, 2020	DP			
<u>GUAIFENESIN - MUCINEX</u>						
N 021282	002	6372252				
		Apr 28, 2020	U-489			
		6955821				
		Apr 28, 2020	DP U-489			
		7838032				
		Apr 28, 2020	DP			
<u>GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE - MUCINEX D</u>						
N 021585	001	6372252				
		Apr 28, 2020	DP			
		6955821				
		Apr 28, 2020	DP U-686			
		7838032				
		Apr 28, 2020	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GUAFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE - MUCINEX D</u>						
N 021585	002	6372252	Apr 28, 2020	DP		
		6955821	Apr 28, 2020	DP U-686		
		7838032	Apr 28, 2020	DP		
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037	001	6287599	Dec 20, 2020	DP	D-145	Nov 19, 2017
		6287599*PED	Jun 20, 2021		M-154	Mar 18, 2018
		6811794	Jul 04, 2022	DP U-494	PED	May 19, 2018
		6811794*PED	Jan 04, 2023			
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037	002	6287599	Dec 20, 2020	DP	D-145	Nov 19, 2017
		6287599*PED	Jun 20, 2021		M-154	Mar 18, 2018
		6811794	Jul 04, 2022	DP U-494	PED	May 19, 2018
		6811794*PED	Jan 04, 2023			
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037	003	6287599	Dec 20, 2020	DP	D-145	Nov 19, 2017
		6287599*PED	Jun 20, 2021		M-154	Mar 18, 2018
		6811794	Jul 04, 2022	DP U-494	PED	May 19, 2018
		6811794*PED	Jan 04, 2023			
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037	004	6287599	Dec 20, 2020	DP	D-145	Nov 19, 2017
		6287599*PED	Jun 20, 2021		M-154	Mar 18, 2018
		6811794	Jul 04, 2022	DP U-494	PED	May 19, 2018
		6811794*PED	Jan 04, 2023			
<u>HALOBETASOL PROPIONATE - ULTRAVATE</u>						
N 208183	001	8962028	Jun 19, 2033	DP U-1775	NP	Nov 06, 2018
<u>HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT</u>						
N 022555	001	7348361	Nov 06, 2020	DP U-1087		
		7530461	Jan 11, 2017	DP U-1087		
<u>HISTRELIN ACETATE - SUPPRELIN LA</u>						
N 022058	001	8062652	Jun 16, 2026	U-1197		
<u>HYALURONIDASE RECOMBINANT HUMAN - HYLENEX RECOMBINANT</u>						
N 021859	001	7767429	Sep 23, 2027	DS DP		
<u>HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE - BIDIL</u>						
N 020727	001	6465463	Sep 08, 2020	U-71		
		6784177	Sep 08, 2020	U-71		
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE</u>						
A 078827	001				PC	Apr 24, 2017
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE</u>						
A 078827	002				PC	Apr 24, 2017
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE</u>						
A 078827	003				PC	Apr 24, 2017
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - BENICAR HCT</u>						
N 021532	002	6878703	Nov 19, 2021	U-3	Y	
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - BENICAR HCT</u>						
N 021532	003	6878703	Nov 19, 2021	U-3	Y	
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - BENICAR HCT</u>						
N 021532	005	6878703	Nov 19, 2021	U-3	Y	
<u>HYDROCHLOROTHIAZIDE; TELMISARTAN - MICARDIS HCT</u>						
N 021162	001	6358986	Jan 10, 2020			
<u>HYDROCHLOROTHIAZIDE; TELMISARTAN - MICARDIS HCT</u>						
N 021162	002	6358986	Jan 10, 2020			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>						
N 020818 001	6294197	Jun 18, 2017	U-3			
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>						
N 020818 002	6294197	Jun 18, 2017	U-3			
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>						
N 020818 003	6294197	Jun 18, 2017	U-3			
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>						
N 020818 004	6294197	Jun 18, 2017	U-3			
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>						
N 020818 005	6294197	Jun 18, 2017	U-3			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	6228398	Nov 01, 2019	DP		NP	Oct 25, 2016
	6902742	Nov 01, 2019	DP			
	9132096	Sep 12, 2034	DP			
	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	6228398	Nov 01, 2019	DP		NP	Oct 25, 2016
	6902742	Nov 01, 2019	DP			
	9132096	Sep 12, 2034	DP			
	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	6228398	Nov 01, 2019	DP		NP	Oct 25, 2016
	6902742	Nov 01, 2019	DP			
	9132096	Sep 12, 2034	DP			
	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	6228398	Nov 01, 2019	DP		NP	Oct 25, 2016
	6902742	Nov 01, 2019	DP			
	9132096	Sep 12, 2034	DP			
	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	6228398	Nov 01, 2019	DP		NP	Oct 25, 2016
	6902742	Nov 01, 2019	DP			
	9132096	Sep 12, 2034	DP			
	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	005	9339499	Jul 25, 2033	U-1810		
		9421200	Jul 25, 2033	U-1810		
		9433619	Jul 25, 2033	U-1810		
		9452163	Sep 12, 2034	U-55		
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	006	6228398	Nov 01, 2019	DP	NP	Oct 25, 2016
		6902742	Nov 01, 2019	DP		
		9132096	Sep 12, 2034	DP		
		9265760	Jul 25, 2033	U-1810		
		9326982	Jul 25, 2033	U-1810		
		9333201	Jul 25, 2033	U-1810		
		9339499	Jul 25, 2033	U-1810		
		9421200	Jul 25, 2033	U-1810		
		9433619	Jul 25, 2033	U-1810		
		9452163	Sep 12, 2034	U-55		
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627	001	6488963	Jun 24, 2017	DP		
		6733783	Oct 30, 2021	DP U-1556		
		8309060	Nov 20, 2023	DP U-1556		
		8361499	Oct 30, 2021	DP		
		8529948	Aug 06, 2022	DP		
		8551520	Oct 30, 2021	DP		
		8647667	Oct 30, 2021	DP		
		8808740	Dec 21, 2031	DP U-1556		
		9023401	Oct 30, 2021	DP		
		9056052	Oct 30, 2021	DP		
		9060940	Oct 30, 2021	U-1556		
		9084816	Aug 24, 2027	DP		
		9095614	Aug 24, 2027	U-1556		
		9095615	Aug 24, 2027	DP		
		9198863	Oct 30, 2021	DP		
		9205056	Oct 30, 2021	DP		
		9289391	Oct 30, 2021	DP		
		9486412	Aug 24, 2027	DP		
		9486413	Aug 24, 2027	DP		
		9492389	Aug 24, 2027	DP		
		9492390	Aug 24, 2027	U-1556		
		9492391	Aug 24, 2027	U-1556		
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627	002	6488963	Jun 24, 2017	DP		
		6733783	Oct 30, 2021	DP U-1556		
		8309060	Nov 20, 2023	DP U-1556		
		8361499	Oct 30, 2021	DP		
		8529948	Aug 06, 2022	DP		
		8551520	Oct 30, 2021	DP		
		8647667	Oct 30, 2021	DP		
		8808740	Dec 21, 2031	DP U-1556		
		9023401	Oct 30, 2021	DP		
		9056052	Oct 30, 2021	DP		
		9060940	Oct 30, 2021	U-1556		
		9084816	Aug 24, 2027	DP		
		9095614	Aug 24, 2027	U-1556		
		9095615	Aug 24, 2027	DP		
		9198863	Oct 30, 2021	DP		
		9205056	Oct 30, 2021	DP		
		9289391	Oct 30, 2021	DP		
		9486412	Aug 24, 2027	DP		
		9486413	Aug 24, 2027	DP		
		9492389	Aug 24, 2027	DP		
		9492390	Aug 24, 2027	U-1556		
		9492391	Aug 24, 2027	U-1556		
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627	003	6488963	Jun 24, 2017	DP		
		6733783	Oct 30, 2021	DP U-1556		
		8309060	Nov 20, 2023	DP U-1556		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	8361499	Oct 30, 2021	DP			
	8529948	Aug 06, 2022	DP			
	8551520	Oct 30, 2021	DP			
	8647667	Oct 30, 2021	DP			
	8808740	Dec 21, 2031	DP	U-1556		
	9023401	Oct 30, 2021	DP			
	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021		U-1556		
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027		U-1556		
	9095615	Aug 24, 2027	DP			
	9198863	Oct 30, 2021	DP			
	9205056	Oct 30, 2021	DP			
	9289391	Oct 30, 2021	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027		U-1556		
	9492391	Aug 24, 2027		U-1556		
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	6488963	Jun 24, 2017	DP			
	6733783	Oct 30, 2021	DP	U-1556		
	8309060	Nov 20, 2023	DP	U-1556		
	8361499	Oct 30, 2021	DP			
	8529948	Aug 06, 2022	DP			
	8551520	Oct 30, 2021	DP			
	8647667	Oct 30, 2021	DP			
	8808740	Dec 21, 2031	DP	U-1556		
	9023401	Oct 30, 2021	DP			
	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021		U-1556		
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027		U-1556		
	9095615	Aug 24, 2027	DP			
	9198863	Oct 30, 2021	DP			
	9205056	Oct 30, 2021	DP			
	9289391	Oct 30, 2021	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027		U-1556		
	9492391	Aug 24, 2027		U-1556		
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 005	6488963	Jun 24, 2017	DP			
	6733783	Oct 30, 2021	DP	U-1556		
	8309060	Nov 20, 2023	DP	U-1556		
	8361499	Oct 30, 2021	DP			
	8529948	Aug 06, 2022	DP			
	8551520	Oct 30, 2021	DP			
	8647667	Oct 30, 2021	DP			
	8808740	Dec 21, 2031	DP	U-1556		
	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021		U-1556		
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027		U-1556		
	9095615	Aug 24, 2027	DP			
	9198863	Oct 30, 2021	DP			
	9205056	Oct 30, 2021	DP			
	9289391	Oct 30, 2021	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027		U-1556		
	9492391	Aug 24, 2027		U-1556		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006	6488963	Jun 24, 2017	DP			
	6733783	Oct 30, 2021	DP	U-1556		
	8309060	Nov 20, 2023	DP	U-1556		
	8361499	Oct 30, 2021	DP			
	8529948	Aug 06, 2022	DP			
	8551520	Oct 30, 2021	DP			
	8647667	Oct 30, 2021	DP			
	8808740	Dec 21, 2031	DP	U-1556		
	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021		U-1556		
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027		U-1556		
	9095615	Aug 24, 2027	DP			
	9198863	Oct 30, 2021	DP			
	9205056	Oct 30, 2021	DP			
	9289391	Oct 30, 2021	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027		U-1556		
	9492391	Aug 24, 2027		U-1556		
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007	6488963	Jun 24, 2017	DP			
	6733783	Oct 30, 2021	DP	U-1556		
	8309060	Nov 20, 2023	DP	U-1556		
	8361499	Oct 30, 2021	DP			
	8529948	Aug 06, 2022	DP			
	8551520	Oct 30, 2021	DP			
	8647667	Oct 30, 2021	DP			
	8808740	Dec 21, 2031	DP	U-1556		
	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021		U-1556		
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027		U-1556		
	9095615	Aug 24, 2027	DP			
	9198863	Oct 30, 2021	DP			
	9205056	Oct 30, 2021	DP			
	9289391	Oct 30, 2021	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027		U-1556		
	9492391	Aug 24, 2027		U-1556		
<u>HYDROCODONE BITARTRATE; IBUPROFEN - VICOPROFEN</u>						
N 020716 001	6348216	Jun 10, 2017				
	6599531	Jun 10, 2017				
<u>HYDROCORTISONE BUTYRATE - LOCOID</u>						
N 022076 001	7378405	Dec 19, 2026	DP			
	7981877	Jan 23, 2025	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP</u>						
N 019034 001	6589960	Nov 09, 2020	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP</u>						
N 019034 002	6589960	Nov 09, 2020	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034 003	6589960	Nov 09, 2020	DS DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034 004	6589960	Nov 09, 2020	DS DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034 005	6589960	Nov 09, 2020	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019891	001 6589960	Nov 09, 2020	DS DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019892	001 6589960	Nov 09, 2020	DS DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019892	002 6589960	Nov 09, 2020	DS DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019892	003 6589960	Nov 09, 2020	DS DP			
<u>HYDROMORPHONE HYDROCHLORIDE - PALLADONE</u>						
N 021044	001 6589960	Nov 09, 2020	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - PALLADONE</u>						
N 021044	002 6589960	Nov 09, 2020	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - PALLADONE</u>						
N 021044	003 6589960	Nov 09, 2020	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - PALLADONE</u>						
N 021044	004 6589960	Nov 09, 2020	DP			
<u>HYDROXOCOBALAMIN - CYANOKIT</u>						
N 022041	001 5834448	Nov 14, 2016	DP			
<u>HYDROXOCOBALAMIN - CYANOKIT</u>						
N 022041	002 5834448	Nov 14, 2016	DP U-789			
<u>HYDROXYPROGESTERONE CAPROATE - MAKENA</u>						
N 021945	001				ODE	Feb 03, 2018
<u>IBANDRONATE SODIUM - BONIVA</u>						
N 021455	001 6143326	Apr 21, 2017	U-642			
	6294196	Oct 07, 2019	DP			
<u>IBANDRONATE SODIUM - BONIVA</u>						
N 021455	002 6294196	Oct 07, 2019	DP			
	7192938	May 06, 2023	U-798			
	7410957	May 06, 2023	U-887			
	7718634	May 06, 2023	U-642			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552	001 7514444	Dec 28, 2026	DS DP		D-165	May 06, 2019
	8008309	Dec 28, 2026	DS DP		I-680	Feb 12, 2017
	8476284	Dec 28, 2026		U-1456	I-689	Jul 28, 2017
	8476284	Dec 28, 2026		U-1491	I-702	Jan 29, 2018
	8497277	Dec 28, 2026		U-1456	I-729	Mar 04, 2019
	8497277	Dec 28, 2026		U-1491	I-736	May 06, 2019
	8497277	Dec 28, 2026		U-1650	I-737	May 06, 2019
	8697711	Dec 28, 2026	DS DP		NCE	Nov 13, 2018
	8703780	Dec 28, 2026		U-1491	ODE	Nov 13, 2020
	8735403	Dec 28, 2026	DS DP		ODE	Feb 12, 2021
	8754090	Jun 03, 2031		U-1456	ODE	Jul 28, 2021
	8754091	Dec 28, 2026	DP		ODE	Jan 29, 2022
	8957079	Dec 28, 2026	DS DP		ODE	Mar 04, 2023
	8999999	Jun 03, 2031		U-1683	ODE	May 06, 2023
	8999999	Jun 03, 2031		U-1684		
	9125889	Jun 03, 2031		U-1745		
	9181257	Dec 28, 2026	DS DP			
	9296753	Oct 30, 2033	DS DP			
<u>IBUPROFEN - MIDOL LIQUID GELS</u>						
N 021472	001 6251426	Jun 25, 2018				
<u>IBUPROFEN - CALDOLOR</u>						
N 022348	001 6727286	Nov 27, 2021	DP U-981			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	6727286	Nov 27, 2021	DP U-981		D-152	Nov 20, 2018
	8735452	Sep 30, 2029	U-981		NPP	Nov 20, 2018
	8871810	Sep 30, 2029	U-1599			
	9012508	Sep 14, 2030	U-981			
	9114068	Sep 30, 2029	U-1735			
	9138404	Sep 30, 2029	U-1756			
	9295639	Sep 30, 2029	U-1756			
<u>IBUPROFEN LYSINE - NEOPROFEN</u>						
N 021903 001	6342530	Nov 14, 2020	DP U-794			
	6342530	Nov 14, 2020	DP U-1127			
	6344479	Mar 20, 2021	DS DP U-794	Y		
	8415337	Mar 02, 2032	DS DP			
<u>IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - CHILDREN'S MOTRIN COLD</u>						
N 021128 001	6211246	Jun 10, 2019				
<u>ICATIBANT ACETATE - FIRAZZR</u>						
N 022150 001	5648333	Jul 15, 2019	DS DP U-1187		NCE ODE	Aug 25, 2016 Aug 25, 2018
<u>ICODEXTRIN - EXTRANEAL</u>						
N 021321 001	6077836	Jun 20, 2017	U-495			
	6248726	Jun 19, 2018	U-495			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	8188146	Jan 27, 2020	DS DP		NCE	Jul 26, 2017
	8293727	Feb 09, 2030	U-1287			
	8293728	Feb 09, 2030	U-1287			
	8298554	Apr 29, 2030	DP			
	8314086	Feb 09, 2030	U-1287			
	8318715	Feb 09, 2030	U-1287			
	8357677	Feb 09, 2030	U-1287			
	8367652	Feb 09, 2030	U-1287			
	8377920	Feb 09, 2030	U-1287			
	8399446	Feb 09, 2030	U-1287			
	8415335	Feb 09, 2030	U-1287			
	8426399	Feb 09, 2030	U-1287			
	8431560	Feb 09, 2030	U-1287			
	8440650	Feb 09, 2030	U-1287			
	8445003	Apr 29, 2030	U-1287			
	8445013	Apr 29, 2030	U-1287			
	8501225	Apr 29, 2030	U-1287			
	8518929	Apr 29, 2030	U-1287			
	8524698	Apr 29, 2030	U-1287			
	8546372	Apr 29, 2030	U-1287			
	8551521	Apr 29, 2030	U-1287			
	8563608	Apr 29, 2030	U-1287			
	8617593	Apr 29, 2030	U-1478			
	8617594	Apr 29, 2030	U-1287			
	8623406	Apr 29, 2030	U-1478			
<u>IDELALISIB - ZYDELIG</u>						
N 205858 001	6800620	Apr 24, 2021	DS U-1560		NCE	Jul 23, 2019
	6949535	Apr 24, 2021	DS U-1560		ODE	Jul 23, 2021
	8138195	Apr 24, 2021	DS DP U-1549		ODE	Jul 23, 2021
	8492389	Apr 24, 2021	DS DP			
	8637533	Apr 24, 2021	DS DP			
	8865730	Mar 05, 2033	DS DP U-1615			
	8980901	May 12, 2025	U-1678			
	9149477	May 12, 2025	U-1757			
	9469643	Sep 02, 2033	DS			
	9492449	Mar 11, 2030	U-1914			
	RE44599	Jul 21, 2025	U-1558			
	RE44599	Jul 21, 2025	U-1615			
	RE44638	Aug 05, 2025	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IDELALISIB - ZYDELIG</u>						
N 205858	002	6800620	Apr 24, 2021	DS U-1560	NCE	Jul 23, 2019
		6949535	Apr 24, 2021	DS U-1560	ODE	Jul 23, 2021
		8138195	Apr 24, 2021	DS DP U-1549	ODE	Jul 23, 2021
		8492389	Apr 24, 2021	DS DP		
		8637533	Apr 24, 2021	DS DP		
		8865730	Mar 05, 2033	DS DP U-1615		
		8980901	May 12, 2025	U-1678		
		9149477	May 12, 2025	U-1757		
		9469643	Sep 02, 2033	DS		
		9492449	Mar 11, 2030	U-1914		
		RE44599	Jul 21, 2025	U-1558		
		RE44599	Jul 21, 2025	U-1615		
		RE44638	Aug 05, 2025	DS DP		
<u>ILOPERIDONE - FANAPT</u>						
N 022192	001	8586610	Nov 02, 2027	U-1625	M-180	May 26, 2019
		8652776	Aug 31, 2030	U-1685		
		8999638	Oct 28, 2030	U-1674		
		9072742	Jan 16, 2031	U-1674		
		9074254	Dec 28, 2031	U-1674		
		9074255	Dec 17, 2030	U-1674		
		9074256	Feb 10, 2031	U-1674		
		9138432	Sep 30, 2025	U-1737		
		9157121	Apr 05, 2030	U-1674		
		RE39198	Nov 15, 2016	DS DP U-971		
<u>ILOPERIDONE - FANAPT</u>						
N 022192	002	8586610	Nov 02, 2027	U-1625	M-180	May 26, 2019
		8652776	Aug 31, 2030	U-1685		
		8999638	Oct 28, 2030	U-1674		
		9072742	Jan 16, 2031	U-1674		
		9074254	Dec 28, 2031	U-1674		
		9074255	Dec 17, 2030	U-1674		
		9074256	Feb 10, 2031	U-1674		
		9138432	Sep 30, 2025	U-1737		
		9157121	Apr 05, 2030	U-1674		
		RE39198	Nov 15, 2016	DS DP U-971		
<u>ILOPERIDONE - FANAPT</u>						
N 022192	003	8586610	Nov 02, 2027	U-1625	M-180	May 26, 2019
		8652776	Aug 31, 2030	U-1685		
		8999638	Oct 28, 2030	U-1674		
		9072742	Jan 16, 2031	U-1674		
		9074254	Dec 28, 2031	U-1674		
		9074255	Dec 17, 2030	U-1674		
		9074256	Feb 10, 2031	U-1674		
		9138432	Sep 30, 2025	U-1737		
		9157121	Apr 05, 2030	U-1674		
		RE39198	Nov 15, 2016	DS DP U-971		
<u>ILOPERIDONE - FANAPT</u>						
N 022192	004	8586610	Nov 02, 2027	U-1625	M-180	May 26, 2019
		8652776	Aug 31, 2030	U-1685		
		8999638	Oct 28, 2030	U-1674		
		9072742	Jan 16, 2031	U-1674		
		9074254	Dec 28, 2031	U-1674		
		9074255	Dec 17, 2030	U-1674		
		9074256	Feb 10, 2031	U-1674		
		9138432	Sep 30, 2025	U-1737		
		9157121	Apr 05, 2030	U-1674		
		RE39198	Nov 15, 2016	DS DP U-971		
<u>ILOPERIDONE - FANAPT</u>						
N 022192	005	8586610	Nov 02, 2027	U-1625	M-180	May 26, 2019
		8652776	Aug 31, 2030	U-1685		
		8999638	Oct 28, 2030	U-1674		
		9072742	Jan 16, 2031	U-1674		
		9074254	Dec 28, 2031	U-1674		
		9074255	Dec 17, 2030	U-1674		
		9074256	Feb 10, 2031	U-1674		
		9138432	Sep 30, 2025	U-1737		
		9157121	Apr 05, 2030	U-1674		
		RE39198	Nov 15, 2016	DS DP U-971		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ILOPERIDONE - FANAPT</u>						
N 022192 005	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
	RE39198	Nov 15, 2016	DS DP U-971			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 006	8586610	Nov 02, 2027	U-1625		M-180	May 26, 2019
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
	RE39198	Nov 15, 2016	DS DP U-971			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 007	8586610	Nov 02, 2027	U-1625		M-180	May 26, 2019
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
	RE39198	Nov 15, 2016	DS DP U-971			
<u>IMATINIB MESYLATE - IMATINIB MESYLATE</u>						
A 078340 001					PC	Jul 30, 2016
<u>IMATINIB MESYLATE - IMATINIB MESYLATE</u>						
A 078340 002					PC	Jul 30, 2016
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 001	6894051	May 23, 2019	DS DP U-649			
	6958335	Dec 19, 2021	U-791			
	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 002	6894051	May 23, 2019	DS DP U-649			
	6958335	Dec 19, 2021	U-791			
	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 001	6894051	May 23, 2019	DS DP U-649		ODE	Jan 25, 2020
	6958335	Dec 19, 2021	U-791			
	6958335	Dec 19, 2021	U-1883			
	6958335*PED	Jun 19, 2022				
	7544799	Jul 16, 2018	DS DP	Y		
	7544799*PED	Jan 16, 2019				
	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 002	6894051	May 23, 2019	DS DP U-649		ODE	Jan 25, 2020
	6958335	Dec 19, 2021	U-791			
	6958335	Dec 19, 2021	U-1883			
	6958335*PED	Jun 19, 2022				
	7544799	Jul 16, 2018	DS DP	Y		
	7544799*PED	Jan 16, 2019				
	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IMIQUIMOD - ALDARA</u>						
N 020723	001 7696159	Apr 01, 2024	DS U-1047			
	7696159	Apr 01, 2024	DS U-1048			
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483	001 8236816	Dec 11, 2029	U-68			
	8299109	Dec 11, 2029	U-68			
	8598196	Aug 18, 2029	U-172			
	8598196	Aug 18, 2029	U-1455			
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483	002 8222270	Dec 11, 2029	U-68			
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N 022383	001 6878721	Feb 25, 2025	DS DP U-1168		NCE	Jul 01, 2016
	8067437	Jun 02, 2020	U-1168			
	8479730	Oct 11, 2028	DP			
	8658673	Jun 02, 2020	DS DP U-1168			
	8796307	Jun 02, 2020	DS DP			
<u>INDINAVIR SULFATE - CRIXIVAN</u>						
N 020685	001 6645961	Mar 04, 2018	DP			
	6689761	Feb 10, 2021	U-554			
<u>INDINAVIR SULFATE - CRIXIVAN</u>						
N 020685	003 6645961	Mar 04, 2018	DP			
	6689761	Feb 10, 2021	U-554			
<u>INDINAVIR SULFATE - CRIXIVAN</u>						
N 020685	005 6645961	Mar 04, 2018	DP			
	6689761	Feb 10, 2021	U-554			
<u>INDINAVIR SULFATE - CRIXIVAN</u>						
N 020685	006 6645961	Mar 04, 2018	DP			
	6689761	Feb 10, 2021	U-554			
<u>INDIUM IN-111 PENTETREOTIDE KIT - OCTREOSCAN</u>						
N 020314	001 6123916	Sep 26, 2017	U-1125			
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768	001 8734847	Apr 23, 2030	DP		NP	Feb 24, 2017
	8992982	Apr 23, 2030	DP			
	9089471	Apr 23, 2030	U-55			
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768	002 8734847	Apr 23, 2030	DP		NP	Feb 24, 2017
	8992982	Apr 23, 2030	DP			
	9089471	Apr 23, 2030	U-55			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833	001 6432452	Aug 19, 2018	U-68		M-169	Nov 19, 2018
	6787161	Aug 19, 2018	U-68		NCE	Jan 23, 2017
	6844013	Dec 13, 2018	U-1221			
	7410656	Oct 10, 2020	U-1222			
	8278292	Jul 06, 2027	DP			
	8372827	Dec 18, 2026	DP			
	8372828	Dec 18, 2026	DP			
	8377919	Dec 18, 2026	DP			
	8536163	Dec 18, 2026	U-1440			
	8716271	Dec 18, 2026	U-1440			
	8735375	Dec 18, 2026	U-1440			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833	002 6432452	Aug 19, 2018	U-68		NCE	Jan 23, 2017
	6787161	Aug 19, 2018	U-68			
	6844013	Dec 13, 2018	U-1221			
	7410656	Oct 10, 2020	U-1222			
	8278292	Jul 06, 2027	DP			
	8372827	Dec 18, 2026	DP			
	8372828	Dec 18, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833	002	8377919	Dec 18, 2026	DP		
		8536163	Dec 18, 2026	U-1440		
		8716271	Dec 18, 2026	U-1440		
		8735375	Dec 18, 2026	U-1440		
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30</u>						
N 021172	001	5866538	Jun 20, 2017	DP		
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 PENFILL</u>						
N 021172	002	5866538	Jun 19, 2017	DP		
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 PENFILL</u>						
N 021172	003	5866538	Jun 19, 2017	DP		
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 FLEXPEN</u>						
N 021172	004	5866538	Jun 20, 2017	DP		
		6004297	Jan 28, 2019	DP		
		9265893	Sep 23, 2032	DP		
		RE41956	Jan 21, 2021	DP		
		RE43834	Jan 28, 2019	DP		
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 50/50</u>						
N 021810	001	5866538	Jun 20, 2017	DP		
<u>INSULIN ASPART RECOMBINANT - NOVOLOG</u>						
N 020986	001	5866538	Jun 20, 2017	DP		
<u>INSULIN ASPART RECOMBINANT - NOVOLOG PENFILL</u>						
N 020986	002	5866538	Jun 20, 2017	DP		
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXPEN</u>						
N 020986	003	5866538	Jun 20, 2017	DP		
		6004297	Jan 28, 2019	DP		
		9265893	Sep 23, 2032	DP		
		RE41956	Jan 21, 2021	DP		
		RE43834	Jan 28, 2019	DP		
<u>INSULIN ASPART RECOMBINANT - NOVOLOG INNOLET</u>						
N 020986	004	5866538	Jun 20, 2017	DP		
		RE41956	Jan 21, 2021	DP		
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986	005	5866538	Jun 20, 2017	DP		
		5866538*PED	Dec 20, 2017			
		6899699	Jan 02, 2022	DP		
		7686786	Aug 03, 2026	DP		
		8672898	Jan 02, 2022	DP		
		8684969	Oct 20, 2025	DP		
		8920383	Jul 17, 2026	DP		
		9108002	Jan 20, 2026	DP		
		9132239	Feb 01, 2032	DP		
		9457154	Sep 27, 2027	DP		
		9486588	Jan 02, 2022	DP		
<u>INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30</u>						
N 203313	001	5866538	Jun 20, 2017	DP	NCE	Sep 25, 2020
		6899699	Jan 02, 2022	DP	NPP	Dec 16, 2019
		7615532	May 25, 2025	DS DP		
		7686786	Aug 03, 2026	DP		
		8672898	Jan 02, 2022	DP		
		8684969	Oct 20, 2025	DP		
		8920383	Jul 17, 2026	DP		
		9108002	Jan 20, 2026	DP		
		9132239	Feb 01, 2032	DP		
		9457154	Sep 27, 2027	DP		
		9486588	Jan 02, 2022	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 001	6899699	Jan 02, 2022	DP		NCE	Sep 25, 2020
	7615532	May 25, 2025	DS DP		NPP	Dec 16, 2019
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 002	6899699	Jan 02, 2022	DP		NCE	Sep 25, 2020
	7615532	May 25, 2025	DS DP		NPP	Dec 16, 2019
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
<u>INSULIN DEGLUDEC; LIRAGLUTIDE - XULTOPHY 100/3.6</u>						
N 208583 001	6268343	Aug 22, 2022	DS DP		NC	Nov 21, 2019
	6458924	Aug 22, 2017	DS DP		NCE	Sep 25, 2020
	6899699	Jan 02, 2022	DP			
	7235627	Aug 22, 2017	DS			
	7615532	May 25, 2025	DS DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8846618	Jun 27, 2022	DS DP			
	8920383	Jul 17, 2026	DP			
	8937042	May 05, 2029	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR</u>						
N 021536 001	5750497	Jun 16, 2019	DS DP	U-668		
	5866538	Jun 20, 2017	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXPEN</u>						
N 021536 002	5750497	Jun 16, 2019	DS DP	U-668		
	5866538	Jun 20, 2017	DP			
	6004297	Jan 28, 2019	DP			
	9265893	Sep 23, 2032	DP			
	RE41956	Jan 21, 2021	DP			
	RE43834	Jan 28, 2019	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR INNOLET</u>						
N 021536 003	5750497	Jun 16, 2019	DS DP	U-668		
	5866538	Jun 20, 2017	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR PENFILL</u>						
N 021536 004	5750497	Jun 16, 2019	DS DP	U-668		
	5866538	Jun 20, 2017	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	5750497	Jun 16, 2019	DS DP	U-668		
	5866538	Jun 20, 2017	DP			
	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
<u>INSULIN GLARGINE - BASAGLAR</u>						
N 205692 001					NP	Dec 16, 2018
<u>INSULIN GLARGINE RECOMBINANT - LANTUS</u>						
N 021081 001	7476652	Jul 23, 2023	DP			
	7713930	Jun 13, 2023	DP			
	7918833	Sep 23, 2027	DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024		U-1832		
	9233211	Mar 02, 2024	DP			
	9408979	Mar 02, 2024	DP			
	9526844	Mar 02, 2024	DP			
	9533105	Aug 17, 2024	DP			
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538 001	7918833	Sep 23, 2027	DP		NP	Feb 25, 2018
	7918833*PED	Mar 23, 2028				
	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024		U-1832		
	9233211	Mar 02, 2024	DP			
	9345750	May 18, 2031	DP	U-1855		
	9408979	Mar 02, 2024	DP			
	9526844	Mar 02, 2024	DP			
	9533105	Aug 17, 2024	DP			
<u>INSULIN GLARGINE; LIXISENATIDE - SOLIOUA 100/33</u>						
N 208673 001	7918833	Sep 23, 2027	DP		NC	Nov 21, 2019
	8512297	Sep 15, 2024	DP		NCE	Jul 27, 2021
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024		U-1923		
	9233211	Mar 02, 2024	DP			
	9408979	Mar 02, 2024	DP			
	9526844	Mar 02, 2024	DP			
	9533105	Aug 17, 2024	DP			
	RE45313	Jul 12, 2020	DS DP			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA</u>						
N 021629 001	6221633	Jun 18, 2018	DS DP	U-471		
	6960561	Jan 25, 2023	DP	U-471		
	7452860	Mar 22, 2022	DP			
	7696162	Mar 22, 2022	DP	U-471		
<u>INSULIN GLULISINE RECOMBINANT - APIDRA</u>						
N 021629 002	6221633	Jun 18, 2018	DS DP	U-471		
	6960561	Jan 25, 2023	DP	U-471		
	7452860	Mar 22, 2022	DP			
	7696162	Mar 22, 2022	DP	U-471		
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	6221633	Jun 18, 2018	DS DP	U-471		
	6960561	Jan 25, 2023	DP	U-471		
	7452860	Mar 22, 2022	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629	003	7696162	Mar 22, 2022	DP U-471		
		7918833	Sep 23, 2027	DP		
		8512297	Sep 15, 2024	DP		
		8556864	Mar 03, 2024	DP		
		8603044	Mar 02, 2024	DP		
		8679069	Apr 12, 2025	DP		
		8992486	Jun 05, 2024	DP		
		9011391	Mar 26, 2024	U-1832		
		9233211	Mar 02, 2024	DP		
		9408979	Mar 02, 2024	DP		
		9526844	Mar 02, 2024	DP		
		9533105	Aug 17, 2024	DP		
<u>INSULIN HUMAN - HUMULIN R</u>						
N 018780	004	7291132	Aug 09, 2024	DP		
<u>INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 75/25 KWIKPEN</u>						
N 021017	002	7291132	Aug 09, 2024	DP		
<u>INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 50/50 KWIKPEN</u>						
N 021018	002	7291132	Aug 09, 2024	DP		
<u>INSULIN LISPRO RECOMBINANT - HUMALOG KWIKPEN</u>						
N 020563	003	7291132	Aug 09, 2024	DP		
<u>INSULIN LISPRO RECOMBINANT - HUMALOG KWIKPEN</u>						
N 205747	001	6034054	Jun 11, 2018	DP U-1707		
		6034054	Jun 11, 2018	DP U-1708		
		6551992	Jun 11, 2018	DP U-1707		
		6551992	Jun 11, 2018	DP U-1708		
		7291132	Aug 09, 2024	DP		
<u>INSULIN RECOMBINANT HUMAN - EXUBERA</u>						
N 021868	001	6257233	May 14, 2019	U-704		
		6546929	May 14, 2019	U-704		
		6582728	Jun 24, 2020	DP		
		6685967	Sep 11, 2018	DP		
<u>INSULIN RECOMBINANT HUMAN - EXUBERA</u>						
N 021868	002	6257233	May 14, 2019	U-704		
		6546929	May 14, 2019	U-704		
		6582728	Jun 24, 2020	DP		
		6685967	Sep 11, 2018	DP		
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472	001	6444226	Jun 29, 2020	DP U-1534	NP	Jun 27, 2017
		6652885	Jun 29, 2020	U-1535		
		7305986	Jan 16, 2023	DP		
		7464706	Mar 02, 2023	DP		
		7648960	Jun 29, 2020	U-1535		
		7943178	Jun 29, 2020	DP U-1535		
		7943572	Aug 10, 2026	U-1539		
		8119593	Aug 11, 2029	U-1537		
		8146588	Apr 24, 2023	DP		
		8156936	Jan 16, 2023	DP		
		8215300	Nov 24, 2022	DP		
		8258095	Aug 11, 2029	U-1537		
		8389470	Jun 29, 2020	DP		
		8424518	Oct 17, 2031	DP		
		8485180	Mar 25, 2030	DP		
		8499757	Feb 19, 2032	DP		
		8551528	Jun 11, 2030	DP		
		8623817	Sep 18, 2029	U-1537		
		8636001	Jul 12, 2032	DP		
		8729019	Dec 26, 2028	DP		
		8734845	Jun 11, 2030	DP		
		8778403	Jun 11, 2030	DP U-1538		
		8889099	Jun 29, 2020	DP U-1621		
		8912193	Jun 12, 2029	DP U-1538		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	8950397	Jul 20, 2021	DP			
	9192675	Jun 12, 2029	DP U-1788			
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
	9358352	Feb 15, 2031	DP U-1861			
	9393372	Jul 04, 2029	DP			
	9446133	Jun 12, 2029	DP U-1861			
	9511198	Feb 16, 2030	U-1929			
	9511198	Feb 16, 2030	U-1930			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	6444226	Jun 29, 2020	DP U-1534		NP	Jun 27, 2017
	6652885	Jun 29, 2020	U-1535			
	7305986	Jan 16, 2023	DP			
	7464706	Mar 02, 2023	DP			
	7648960	Jun 29, 2020	U-1535			
	7943178	Jun 29, 2020	DP U-1535			
	7943572	Aug 10, 2026	U-1539			
	8119593	Aug 11, 2029	U-1537			
	8146588	Apr 24, 2023	DP			
	8156936	Jan 16, 2023	DP			
	8215300	Nov 24, 2022	DP			
	8258095	Aug 11, 2029	U-1537			
	8389470	Jun 29, 2020	DP			
	8424518	Oct 17, 2031	DP			
	8485180	Mar 25, 2030	DP			
	8499757	Feb 19, 2032	DP			
	8551528	Jun 11, 2030	DP			
	8623817	Sep 18, 2029	U-1537			
	8636001	Jul 12, 2032	DP			
	8729019	Dec 26, 2028	DP			
	8734845	Jun 11, 2030	DP			
	8778403	Jun 11, 2030	DP U-1538			
	8889099	Jun 29, 2020	DP U-1621			
	8912193	Jun 12, 2029	DP U-1538			
	8950397	Jul 20, 2021	DP			
	9192675	Jun 12, 2029	DP U-1788			
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
	9358352	Feb 15, 2031	DP U-1861			
	9393372	Jul 04, 2029	DP			
	9446133	Jun 12, 2029	DP U-1861			
	9511198	Feb 16, 2030	U-1929			
	9511198	Feb 16, 2030	U-1930			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	6444226	Jun 29, 2020	DP U-1534		NP	Jun 27, 2017
	6652885	Jun 29, 2020	U-1535			
	7305986	Jan 16, 2023	DP			
	7464706	Mar 02, 2023	DP			
	7648960	Jun 29, 2020	U-1535			
	7943178	Jun 29, 2020	DP U-1535			
	7943572	Aug 10, 2026	U-1539			
	8119593	Aug 11, 2029	U-1537			
	8146588	Apr 24, 2023	DP			
	8156936	Jan 16, 2023	DP			
	8215300	Nov 24, 2022	DP			
	8258095	Aug 11, 2029	U-1537			
	8389470	Jun 29, 2020	DP U-1697			
	8424518	Oct 17, 2031	DP			
	8485180	Mar 25, 2030	DP			
	8499757	Feb 19, 2032	DP			
	8551528	Jun 11, 2030	DP			
	8623817	Sep 18, 2029	U-1537			
	8636001	Jul 12, 2032	DP			
	8729019	Dec 26, 2028	DP			
	8734845	Jun 11, 2030	DP			
	8778403	Jun 11, 2030	DP U-1538			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	8889099	Jun 29, 2020	DP U-1621			
	8912193	Jun 12, 2029	DP U-1538			
	8950397	Jul 20, 2021	DP			
	9192675	Jun 12, 2029	DP U-1788			
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
	9358352	Feb 15, 2031	DP U-1861			
	9393372	Jul 04, 2029	DP			
	9446133	Jun 12, 2029	DP U-1861			
	9511198	Feb 16, 2030	U-1929			
	9511198	Feb 16, 2030	U-1930			
<u>INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN - HUMULIN 70/30</u>						
N 019717 001	7291132	Aug 09, 2024	DP			
<u>INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN - HUMULIN 70/30 PEN</u>						
N 019717 002	7291132	Aug 09, 2024	DP			
<u>INSULIN SUSP ISOPHANE RECOMBINANT HUMAN - HUMULIN N</u>						
N 018781 001	7291132	Aug 09, 2024	DP			
<u>IPRATROPIUM BROMIDE - ATROVENT HFA</u>						
N 021527 001	6739333	May 26, 2020	DP			
	6983743	May 26, 2020	DP			
	8474447	Jan 17, 2030	DP			
<u>IRINOTECAN HYDROCHLORIDE - CAMPTOSAR</u>						
N 020571 001	6403569	Apr 28, 2020		U-449		
	6794370	May 01, 2020		U-606		
<u>IRINOTECAN HYDROCHLORIDE - CAMPTOSAR</u>						
N 020571 002	6403569	Apr 28, 2020		U-449		
	6794370	May 01, 2020		U-606		
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001	8147867	Aug 29, 2028	DS DP		NP	Oct 22, 2018
	8329213	May 02, 2025	DS DP		ODE	Oct 22, 2022
	8703181	May 02, 2025		U-1434		
	8992970	May 02, 2025	DS DP			
	9339497	Jun 12, 2033		U-1848		
	9364473	Jun 12, 2033		U-1856		
	9452162	Jun 12, 2033		U-1899		
	9492442	Jun 12, 2033		U-1848		
	9492442	Jun 12, 2033		U-1899		
	9492442	Jun 12, 2033		U-1917		
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500 001	6812238	Oct 31, 2020	DS		NCE	Mar 06, 2020
	7459561	Oct 31, 2020	DS		ODE	Mar 06, 2022
					GAIN	Mar 06, 2025
					GAIN	Mar 06, 2027
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207501 001	6812238	Oct 31, 2020	DS		NCE	Mar 06, 2020
	7459561	Oct 31, 2020	DS		ODE	Mar 06, 2022
					GAIN	Mar 06, 2025
					GAIN	Mar 06, 2027
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 001	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021		U-1347		
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 002	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021		U-1347		
	8952064	Sep 21, 2021	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 002	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 003	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	DP	U-1347		
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 004	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	DP	U-1347		
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 005	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	DP	U-1347		
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 006	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	DP	U-1347		
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ITRACONAZOLE - SPORANOX</u>						
N 020657 001	6407079	Jun 18, 2019				
<u>ITRACONAZOLE - SPORANOX</u>						
N 020966 001	6407079	Jun 18, 2019				
<u>ITRACONAZOLE - ONMEL</u>						
N 022484 001	6509038	May 12, 2017	DP	U-1054		
	7081255	May 12, 2017	DP	U-1054		
	8486456	Oct 03, 2028	DP	U-1054		
	8591948	May 12, 2017	DP	U-1054		
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 001	7361649	Apr 17, 2026	DS DP	U-1694	NCE	Apr 15, 2020
	7361650	Apr 14, 2026	DS DP	U-1694		
	7867996	Feb 22, 2026	DS DP	U-1694		
	7879842	Feb 22, 2026	DS DP	U-1694		
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 002	7361649	Apr 17, 2026	DS DP	U-1694	NCE	Apr 15, 2020
	7361650	Apr 14, 2026	DS DP	U-1694		
	7867996	Feb 22, 2026	DS DP	U-1694		
	7879842	Feb 22, 2026	DS DP	U-1694		
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	7495103	May 20, 2027	DS DP		I-705	Dec 30, 2017
	8324242	Aug 05, 2027		U-1311	I-740	Feb 21, 2017
	8324242	Aug 05, 2027		U-1906	NCE	Jan 31, 2017
	8354427	Jul 06, 2026		U-1311	ODE	Jan 31, 2019
	8354427	Jul 06, 2026		U-1905		
	8410274	Dec 28, 2026	DP			
	8754224	Dec 28, 2026	DS DP			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	7495103	May 20, 2027	DS DP		I-740	Feb 21, 2017
	8324242	Aug 05, 2027		U-1311	NCE	Jan 31, 2017
	8324242	Aug 05, 2027		U-1906	ODE	Jan 31, 2019
	8354427	Jul 06, 2026		U-1311		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR - KALYDECO</u>						
N 207925	001	8354427		U-1905		
		8410274		DP		
		8754224	DS	DP		
		8883206		DP		
<u>IVACAFTOR - KALYDECO</u>						
N 207925	002	7495103	DS	DP	I-740	Feb 21, 2017
		8324242		U-1311	NCE	Jan 31, 2017
		8324242		U-1906	ODE	Jan 31, 2019
		8354427		U-1311		
		8354427		U-1905		
		8410274		DP		
		8754224	DS	DP		
		8883206		DP		
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038	001	7495103	DS	DP	NCE	Jul 02, 2020
		8324242		U-1311	ODE	Jul 02, 2022
		8324242		U-1911	ODE	Sep 28, 2023
		8410274		DP		
		8507534	DS	DP		
		8653103		DP		
		8716338		DP	U-1718	
		8716338		DP	U-1910	
		8741933		U-1717		
		8741933		U-1909		
		8754224	DS	DP		
		8846718		U-1717		
		8846718		U-1908		
		8993600		DP		
		9150552		U-1908		
		9192606		DP	U-1912	
		9216969	DS	DP		
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038	002	7495103	DS	DP	NCE	Jul 02, 2020
		8324242		U-1911	NPP	Sep 28, 2019
		8410274		DP	ODE	Jul 02, 2022
		8507534	DS	DP	ODE	Sep 28, 2023
		8653103		DP		
		8716338		DP	U-1910	
		8741933		U-1909		
		8754224	DS	DP		
		8846718		U-1908		
		8993600		DP		
		9150552		U-1908		
		9192606		DP	U-1912	
		9216969		DP		
<u>IVERMECTIN - SKLICE</u>						
N 202736	001	6103248		DP		
		8791153		DP		
		8927595		U-1782		
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255	001	5952372	Sep 18, 2018	U-1631	NP	Dec 19, 2017
		6133310	Apr 26, 2019	U-1631		
		7550440	Apr 22, 2024	DP	U-1631	
		8080530	Apr 22, 2024	DP	U-1631	
		8093219	Apr 22, 2024	DP	U-1631	
		8415311	Apr 22, 2024	DP	U-1631	
		8470788	Apr 22, 2024	DP	U-1631	
		8815816	Apr 22, 2024	DP	U-1631	
		9089587	Mar 13, 2034	U-1631		
		9233117	Mar 13, 2034	U-1631		
		9233118	Mar 13, 2034	U-1631		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IXABEPILONE - IXEMPRA KIT</u>						
N 022065	001	6670384	Jan 23, 2022	DP U-959		
		6670384	Jan 23, 2022	DP U-960		
		7022330	Jan 23, 2022	DP U-958		
		7125899	May 26, 2018	DS DP U-957		
		7312237	Aug 21, 2024	U-965		
		RE41393	Feb 08, 2022	U-961		
		RE41911	Sep 28, 2020	DS DP U-961		
<u>IXABEPILONE - IXEMPRA KIT</u>						
N 022065	002	6670384	Jan 23, 2022	DP U-959		
		6670384	Jan 23, 2022	DP U-960		
		7022330	Jan 23, 2022	DP U-958		
		7125899	May 26, 2018	DS DP U-957		
		7312237	Aug 21, 2024	U-965		
		RE41393	Feb 08, 2022	U-961		
		RE41911	Sep 28, 2020	DS DP U-961		
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462	001	7442830	Aug 06, 2027	DS DP U-1780	NCE	Nov 20, 2020
		7687662	Aug 06, 2027	DS DP	ODE	Nov 20, 2022
		8003819	Aug 06, 2027	DS DP U-1780		
		8530694	Aug 06, 2027	DS DP U-1780		
		8546608	Aug 12, 2024	DS		
		8859504	Jun 16, 2029	DS DP		
		8871745	Aug 06, 2027	U-1779		
		9175017	Jun 16, 2029	U-1778		
		9233115	Aug 12, 2024	U-1778		
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462	002	7442830	Aug 06, 2027	DS DP U-1780	NCE	Nov 20, 2020
		7687662	Aug 06, 2027	DS DP	ODE	Nov 20, 2022
		8003819	Aug 06, 2027	DS DP U-1780		
		8530694	Aug 06, 2027	DS DP U-1780		
		8546608	Aug 12, 2024	DS		
		8859504	Jun 16, 2029	DS DP		
		8871745	Aug 06, 2027	U-1779		
		9175017	Jun 16, 2029	U-1778		
		9233115	Aug 12, 2024	U-1778		
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462	003	7442830	Aug 06, 2027	DS DP U-1780	NCE	Nov 20, 2020
		7687662	Aug 06, 2027	DS DP	ODE	Nov 20, 2022
		8003819	Aug 06, 2027	DS DP U-1780		
		8530694	Aug 06, 2027	DS DP U-1780		
		8546608	Aug 12, 2024	DS		
		8859504	Jun 16, 2029	DS DP		
		8871745	Aug 06, 2027	U-1779		
		9175017	Jun 16, 2029	U-1778		
		9233115	Aug 12, 2024	U-1778		
<u>KETOCONAZOLE - EXTINA</u>						
N 021738	001	7553835	Oct 19, 2018	DP U-245		
		8026238	Oct 19, 2018	DP U-1213		
<u>KETOCONAZOLE - XOLEGEL</u>						
N 021946	001	7179475	Dec 04, 2018	DP U-792		
		8232276	Nov 24, 2020	DP		
		8735393	Dec 04, 2018	DP		
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528	001	8008338	May 24, 2027	DS DP U-1181		
		8207215	May 28, 2024	U-1251		
		8377982	May 28, 2024	U-1363		
		8377982*PED	Nov 28, 2024			
		8541463	May 28, 2024	U-1441		
		8541463*PED	Nov 28, 2024			
		8648107	May 28, 2024	DP		
		8906950	May 28, 2024	U-1626		
		8946281	May 28, 2024	U-1662		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528	001 9216167	May 28, 2024	U-1800			
<u>KETOROLAC TROMETHAMINE - SPRIX</u>						
N 022382	001 6333044	Dec 25, 2018	DP U-1057			
<u>KETOROLAC TROMETHAMINE - ACUVAIL</u>						
N 022427	001 7842714	Aug 15, 2029	DS DP			
	8512717	Mar 07, 2028	DP			
	8992952	Aug 05, 2024	DP			
	9192571	Mar 07, 2028	DP			
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - OMIIDRIA</u>						
N 205388	001 8173707	Jul 30, 2023	U-1518		NP	May 30, 2017
	8586633	Jul 30, 2023	DP			
	9066856	Oct 23, 2033	DP			
	9278101	Jul 30, 2023	U-1518			
	9399040	Jul 30, 2023	DP			
	9486406	Oct 23, 2033	DP			
<u>LACOSAMIDE - VIMPAT</u>						
N 022253	001 RE38551	Mar 17, 2022	DS DP U-1566		D-143	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1567		D-144	Aug 29, 2017
					I-696	Aug 29, 2017
<u>LACOSAMIDE - VIMPAT</u>						
N 022253	002 RE38551	Mar 17, 2022	DS DP U-1566		D-143	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1567		D-144	Aug 29, 2017
					I-696	Aug 29, 2017
<u>LACOSAMIDE - VIMPAT</u>						
N 022253	003 RE38551	Mar 17, 2022	DS DP U-1566		D-143	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1567		D-144	Aug 29, 2017
					I-696	Aug 29, 2017
<u>LACOSAMIDE - VIMPAT</u>						
N 022253	004 RE38551	Mar 17, 2022	DS DP U-1566		D-143	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1567		D-144	Aug 29, 2017
					I-696	Aug 29, 2017
<u>LACOSAMIDE - VIMPAT</u>						
N 022254	001 RE38551	Mar 17, 2022	DS DP U-1565		D-143	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1568		D-144	Aug 29, 2017
					I-696	Aug 29, 2017
<u>LACOSAMIDE - VIMPAT</u>						
N 022255	001 RE38551	Mar 17, 2022	DS DP U-1566		D-143	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1567		D-144	Aug 29, 2017
					I-696	Aug 29, 2017
<u>LAMIVUDINE - EPIVIR</u>						
N 020564	001 5905082*PED	Nov 18, 2016			D-147	Mar 23, 2018
<u>LAMIVUDINE - EPIVIR</u>						
N 020564	003 5905082*PED	Nov 18, 2016			D-147	Mar 23, 2018
<u>LAMIVUDINE - EPIVIR</u>						
N 020596	001 5905082*PED	Nov 18, 2016			D-147	Mar 23, 2018
	6004968	Mar 20, 2018	DP U-248			
	6004968*PED	Sep 20, 2018				
<u>LAMIVUDINE - EPIVIR-HBV</u>						
N 021004	001 6004968	Mar 20, 2018				
<u>LAMIVUDINE; RALTEGRAVIR POTASSIUM - DUTREBIS</u>						
N 206510	001 7169780	Oct 03, 2023	DS DP			
	7217713	Oct 21, 2022	U-1663			
	7435734	Oct 21, 2022	U-1663			
	7754731	Mar 11, 2029	DS DP U-1663			
	7820660	Apr 25, 2023	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241	001				M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241	002				M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241	003				M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241	004				M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241	005				M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241	006				M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764	001				M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764	002				M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764	003				M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764	004				M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115	001	8637512 9144547	Jun 14, 2028 Sep 22, 2023	DP DP		
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115	002	8637512 9144547	Jun 14, 2028 Sep 22, 2023	DP DP		
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115	003	8637512 9144547	Jun 14, 2028 Sep 22, 2023	DP DP		
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115	004	8637512 9144547	Jun 14, 2028 Sep 22, 2023	DP DP		
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115	005	8637512 9144547	Jun 14, 2028 Sep 22, 2023	DP DP		
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115	006	8637512 9144547	Jun 14, 2028 Sep 22, 2023	DP DP		
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251	001	7919115 8840925 9339504	Jan 04, 2029 Jul 02, 2028 Jul 02, 2028	DS DP DP U-1596 DP U-1596	M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251	002	7919115 8840925 9339504	Jan 04, 2029 Jul 02, 2028 Jul 02, 2028	DS DP DP U-1596 DP U-1596	M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251	003	7919115 8840925 9339504	Jan 04, 2029 Jul 02, 2028 Jul 02, 2028	DS DP DP U-1596 DP U-1596	M-159	May 18, 2018

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 004	7919115	Jan 04, 2029	DS DP		M-159	May 18, 2018
	8840925	Jul 02, 2028	DP U-1596			
	9339504	Jul 02, 2028	DP U-1596			
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074 001	5595760	Mar 08, 2020	DP U-831		I-701 ODE	Dec 19, 2017 Dec 16, 2021
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074 002	5595760	Mar 08, 2020	DP U-831		I-701 ODE	Dec 19, 2017 Dec 16, 2021
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074 003	5595760	Mar 08, 2020	DP U-831		I-701 ODE	Dec 19, 2017 Dec 16, 2021
<u>LANSOPRAZOLE - PREVACID</u>						
N 021428 001	6328994	May 17, 2019				
	7399485	May 26, 2018	DP			
	7431942	May 17, 2019	DP			
	7875292	May 17, 2019	DP			
<u>LANSOPRAZOLE - PREVACID</u>						
N 021428 002	6328994	May 17, 2019				
	7399485	May 26, 2018	DP			
	7431942	May 17, 2019	DP			
	7875292	May 17, 2019	DP			
<u>LANSOPRAZOLE - PREVACID IV</u>						
N 021566 001	7396841	Aug 17, 2021	DP U-947			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 021468 001	5968976	Oct 26, 2018	DP U-613			
	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 021468 002	5968976	Oct 26, 2018	DP U-613			
	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 021468 003	5968976	Oct 26, 2018	DP U-613			
	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 021468 004	5968976	Oct 26, 2018	DP U-613			
	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 204734 001	5968976	Oct 26, 2018	DP U-1592			
	7465465	Aug 26, 2024	DP			
	8980327	Dec 01, 2030	DP			
	9023397	Dec 01, 2030	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 204734 002	5968976	Oct 26, 2018	DP U-1592			
	7465465	Aug 26, 2024	DP			
	8980327	Dec 01, 2030	DP			
	9023397	Dec 01, 2030	DP			
<u>LAPATINIB DITOSYLATE - TYKERB</u>						
N 022059 001	6391874	Jul 11, 2017	DS DP U-800			
	6391874	Jul 11, 2017	DS DP U-1429			
	6713485	Sep 29, 2020	DS DP U-800			
	6713485	Sep 29, 2020	DS DP U-1429			
	6727256	Jan 08, 2019	DS DP U-800			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LAPATINIB DITOSYLATE - TYKERB</u>						
N 022059 001	6828320	Jul 11, 2017	U-800			
	6828320	Jul 11, 2017	U-1429			
	7157466	Nov 19, 2021	DS DP			
	8513262	Jan 08, 2019	DS DP			
	8821927	Sep 18, 2029	DS DP			
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001	7964580	Mar 26, 2029	DS DP U-1470		D-153	Nov 12, 2018
	8088368	May 12, 2030	DS DP		D-158	Feb 12, 2019
	8273341	May 12, 2030	U-1470		D-159	Feb 12, 2019
	8334270	Mar 21, 2028	DS DP U-1470		D-160	Feb 12, 2019
	8580765	Mar 21, 2028	DS DP U-1470		I-718	Nov 12, 2018
	8618076	Dec 11, 2030	DS DP U-1470		I-719	Nov 12, 2018
	8633309	Mar 26, 2029	DS DP U-1470		I-720	Nov 12, 2018
	8735372	Mar 21, 2028	U-1470		NCE	Oct 10, 2019
	8822430	May 12, 2030	DS DP U-1470		NPP	Nov 12, 2018
	8841278	May 12, 2030	DP U-1470			
	8889159	Mar 26, 2029	DP U-1470			
	9085573	Mar 21, 2028	DS DP U-1470			
	9284342	Sep 13, 2030	DS DP U-1470			
	9393256	Sep 14, 2032	U-1470			
	9511056	May 12, 2030	DP U-1470			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	5635517	Oct 04, 2019	DS U-1211		I-706	Feb 17, 2018
	6045501	Aug 28, 2018	U-1210		ODE	Jun 05, 2020
	6281230	Jul 24, 2016	U-1212		ODE	Feb 17, 2022
	6281230	Jul 24, 2016	U-1414			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023	U-1414			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8204763	Aug 28, 2018	U-1249			
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1215			
	8530498	May 15, 2023	U-1216			
	8589188	Aug 28, 2018	U-1210			
	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
	9056120	Apr 11, 2023	U-1215			
	9101621	May 15, 2023	U-1216			
	9101622	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	5635517	Oct 04, 2019	DS U-1211		I-706	Feb 17, 2018
	6045501	Aug 28, 2018	U-1210		ODE	Jun 05, 2020
	6281230	Jul 24, 2016	U-1212		ODE	Feb 17, 2022
	6281230	Jul 24, 2016	U-1414			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023	U-1414			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	7968569	Oct 07, 2023		U-1216		
	8204763	Aug 28, 2018		U-1249		
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020		U-1249		
	8404717	Apr 11, 2023		U-1215		
	8530498	May 15, 2023		U-1216		
	8589188	Aug 28, 2018		U-1210		
	8626531	Oct 23, 2020		U-1210		
	8648095	May 15, 2023		U-1216		
	8741929	Mar 08, 2028		U-1414		
	9056120	Apr 11, 2023		U-1215		
	9101621	May 15, 2023		U-1216		
	9101622	May 15, 2023		U-1216		
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	5635517	Oct 04, 2019	DS	U-1211	I-706	Feb 17, 2018
	6045501	Aug 28, 2018		U-1210	ODE	Jun 05, 2020
	6281230	Jul 24, 2016		U-1212	ODE	Feb 17, 2022
	6281230	Jul 24, 2016		U-1414		
	6315720	Oct 23, 2020		U-1210		
	6555554	Jul 24, 2016	DP	U-1211		
	6561976	Aug 28, 2018		U-1210		
	6561977	Oct 23, 2020		U-1210		
	6755784	Oct 23, 2020		U-1210		
	6908432	Aug 28, 2018		U-1210		
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023		U-1215		
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023		U-1414		
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023		U-1216		
	8204763	Aug 28, 2018		U-1249		
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020		U-1249		
	8404717	Apr 11, 2023		U-1215		
	8530498	May 15, 2023		U-1216		
	8589188	Aug 28, 2018		U-1210		
	8626531	Oct 23, 2020		U-1210		
	8648095	May 15, 2023		U-1216		
	8741929	Mar 08, 2028		U-1414		
	9056120	Apr 11, 2023		U-1215		
	9101621	May 15, 2023		U-1216		
	9101622	May 15, 2023		U-1216		
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	5635517	Oct 04, 2019	DS	U-1211	I-706	Feb 17, 2018
	6045501	Aug 28, 2018		U-1210	ODE	Jun 05, 2020
	6281230	Jul 24, 2016		U-1212	ODE	Feb 17, 2022
	6281230	Jul 24, 2016		U-1414		
	6315720	Oct 23, 2020		U-1210		
	6555554	Jul 24, 2016	DP	U-1211		
	6561976	Aug 28, 2018		U-1210		
	6561977	Oct 23, 2020		U-1210		
	6755784	Oct 23, 2020		U-1210		
	6908432	Aug 28, 2018		U-1210		
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023		U-1215		
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023		U-1414		
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023		U-1216		
	8204763	Aug 28, 2018		U-1249		
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020		U-1249		
	8404717	Apr 11, 2023		U-1215		
	8530498	May 15, 2023		U-1216		
	8589188	Aug 28, 2018		U-1210		
	8626531	Oct 23, 2020		U-1210		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
	9056120	Apr 11, 2023	U-1215			
	9101621	May 15, 2023	U-1216			
	9101622	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	5635517	Oct 04, 2019	DS U-1211		I-706	Feb 17, 2018
	6045501	Aug 28, 2018	U-1210		ODE	Jun 05, 2020
	6281230	Jul 24, 2016	U-1212		ODE	Feb 17, 2022
	6281230	Jul 24, 2016	U-1414			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023	U-1414			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8204763	Aug 28, 2018	U-1249			
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1215			
	8530498	May 15, 2023	U-1216			
	8589188	Aug 28, 2018	U-1210			
	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
	9056120	Apr 11, 2023	U-1215			
	9101621	May 15, 2023	U-1216			
	9101622	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	5635517	Oct 04, 2019	DS U-1211		I-706	Feb 17, 2018
	6045501	Aug 28, 2018	U-1210		ODE	Jun 05, 2020
	6281230	Jul 24, 2016	U-1212		ODE	Feb 17, 2022
	6281230	Jul 24, 2016	U-1414			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023	U-1414			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8204763	Aug 28, 2018	U-1249			
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1215			
	8530498	May 15, 2023	U-1216			
	8589188	Aug 28, 2018	U-1210			
	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
	9056120	Apr 11, 2023	U-1215			
	9101621	May 15, 2023	U-1216			
	9101622	May 15, 2023	U-1216			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENAVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	7253286	Oct 19, 2021	DS DP		I-734	May 13, 2019
	7612208	Sep 19, 2026	DS DP		NCE	Feb 13, 2020
	9006256	Jul 27, 2027		U-1695	ODE	Feb 13, 2022
<u>LENAVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	7253286	Oct 19, 2021	DS DP		I-734	May 13, 2019
	7612208	Sep 19, 2026	DS DP		NCE	Feb 13, 2020
	9006256	Jul 27, 2027		U-1695	ODE	Feb 13, 2022
<u>LESINURAD - ZURAMPIC</u>						
N 207988 001	8003681	Aug 25, 2025	DS		NCE	Dec 22, 2020
	8084483	Aug 17, 2029		U-1801		
	8283369	Nov 26, 2028		U-1802		
	8283369	Nov 26, 2028		U-1804		
	8357713	Nov 26, 2028	DP	U-1801		
	8357713	Nov 26, 2028	DP	U-1802		
	8357713	Nov 26, 2028	DP	U-1803		
	8546436	Feb 29, 2032	DS DP			
	8546437	Apr 29, 2029		U-1803		
	9216179	Aug 01, 2031		U-1806		
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 019732 001	6036976	Dec 13, 2016				
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N 020263 002	6036976	Dec 13, 2016				
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N 020263 005	6036976	Dec 13, 2016				
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N 020263 006	6036976	Dec 13, 2016				
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N 020263 007	6036976	Dec 13, 2016		DP		
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N 020263 008	6036976	Dec 13, 2016		DP		
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 020517 001	6036976	Dec 13, 2016				
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 020517 002	6036976	Dec 13, 2016				
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 020517 003	6036976	Dec 13, 2016		DP		
	7429559	Jan 13, 2019		DP		
	8815801	Jun 28, 2022		DP		
	8921326	Feb 05, 2031		DP	U-1666	
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 020708 001	6036976	Dec 13, 2016				
<u>LEUPROLIDE ACETATE - VIADUR</u>						
N 021088 001	5728396	Jan 30, 2017		U-316		
	5932547	Jun 13, 2017				
	5985305	Jan 30, 2017				
	6113938	Jul 24, 2018				
	6124261	Jun 13, 2017				
	6132420	Jan 30, 2017				
	6156331	Jan 30, 2017				
	6235712	Jun 13, 2017				
	6375978	Dec 17, 2018				
	6395292	Jan 30, 2017				
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021343 001	6565874	Oct 28, 2018		DP	U-801	
	6626870	Mar 27, 2020		DP		
	6713714	Oct 28, 2018		DP	U-801	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021343	001	6565874	Oct 28, 2018	DP U-801		
		6626870	Mar 27, 2020	DP		
		6773714	Oct 28, 2018	DP U-801		
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021379	001	6565874	Oct 28, 2018	DP U-801		
		6626870	Mar 27, 2020	DP		
		6773714	Oct 28, 2018	DP U-801		
		9283282	Oct 28, 2018	DS DP		
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021488	001	6565874	Oct 28, 2018	DP U-801		
		6626870	Mar 27, 2020	DP		
		6773714	Oct 28, 2018	DP U-801		
		9283282	Oct 28, 2018	DS DP		
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021731	001	6565874	Oct 28, 2018	DP U-621		
		6626870	Mar 27, 2020	DP		
		6773714	Oct 28, 2018	U-621		
		9283282	Oct 28, 2018	DS DP		
<u>LEUPROLIDE ACETATE; NORETHINDRONE ACETATE - LUPANETA PACK</u>						
N 203696	001	6036976	Dec 13, 2016	DP		
<u>LEUPROLIDE ACETATE; NORETHINDRONE ACETATE - LUPANETA PACK</u>						
N 203696	002	6036976	Dec 13, 2016	DP		
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837	001	6451289	Mar 21, 2021		M-151	Jan 22, 2018
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837	002	6451289	Mar 21, 2021		M-151	Jan 22, 2018
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837	003	6451289	Mar 21, 2021		M-151	Jan 22, 2018
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837	004	6451289	Mar 21, 2021	DP	M-151	Jan 22, 2018
<u>LEVALBUTEROL TARTRATE - XOPENEX HFA</u>						
N 021730	001	7256310	Oct 08, 2024	DS DP U-636	M-156	Mar 12, 2018
		8765153	Dec 08, 2023	DP		
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035	001	8802142	Jun 07, 2031	DP		
		8802142*PED	Dec 07, 2031			
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035	002	8802142	Jun 07, 2031	DP		
		8802142*PED	Dec 07, 2031			
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035	003	8802142	Jun 07, 2031	DP		
		8802142*PED	Dec 07, 2031			
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035	004	8802142	Jun 07, 2031	DP		
		8802142*PED	Dec 07, 2031			
<u>LEVETIRACETAM - KEPPRA XR</u>						
N 022285	001	7858122	Sep 17, 2028	DP		
<u>LEVETIRACETAM - KEPPRA XR</u>						
N 022285	002	7858122	Sep 17, 2028	DP		
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958	001	6471992	Feb 20, 2018	DP		
		9463160	Feb 20, 2018	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958	002	6471992				
		Feb 20, 2018	DP			
		9339489				
		Mar 14, 2034	DP U-1850			
		9463160				
		Feb 20, 2018	DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958	003	6471992				
		Feb 20, 2018	DP			
		9339489				
		Mar 14, 2034	DP U-1850			
		9463160				
		Feb 20, 2018	DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958	004	6471992				
		Feb 20, 2018	DP			
		9339489				
		Mar 14, 2034	DP U-1850			
		9463160				
		Feb 20, 2018	DP			
<u>LEVOCARNITINE - CARNITOR</u>						
N 020182	001	6335369				
		Jan 18, 2021		U-433		
		6429230				
		Jan 18, 2021		U-433		
		6696493				
		Jan 18, 2021		U-433		
<u>LEVOFLOXACIN - LEVAQUIN</u>						
N 021721	001	6806256				
		Feb 26, 2022	DP			
<u>LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN CALCIUM</u>						
A 206263	001				PC	Feb 11, 2017
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N 020140	001	6500829				
		Mar 07, 2022	DS DP		ODE	Apr 29, 2018
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N 020140	002	6500829				
		Mar 07, 2022	DS DP		ODE	Apr 29, 2018
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N 020140	003	6500829				
		Mar 07, 2022	DS DP		ODE	Apr 29, 2018
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168	001	8481598				
		Mar 02, 2031		U-839	NCE*	Jul 25, 2018
		8865937				
		May 23, 2032	DS DP			
		RE43879				
		Jun 03, 2023		U-839		
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168	002	8481598				
		Mar 02, 2031		U-839	NCE*	Jul 25, 2018
		8865937				
		May 23, 2032	DS DP			
		RE43879				
		Jun 03, 2023		U-839		
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168	003	8481598				
		Mar 02, 2031		U-839	NCE*	Jul 25, 2018
		8865937				
		May 23, 2032	DS DP			
		RE43879				
		Jun 03, 2023		U-839		
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168	004	8481598				
		Mar 02, 2031		U-839	NCE*	Jul 25, 2018
		8865937				
		May 23, 2032	DS DP			
		RE43879				
		Jun 03, 2023		U-839		
<u>LEVONORGESTREL - SKYLA</u>						
N 203159	001	7252839				
		Nov 13, 2023	DP			
<u>LEVONORGESTREL - LILETTA</u>						
N 206229	001				NP	Feb 26, 2018
<u>LEVONORGESTREL - KYLEENA</u>						
N 208224	001	7252839				
		Nov 13, 2023	DP		NP	Sep 16, 2019
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301	001	6555581				
		Feb 15, 2022				
		7067148				
		Feb 15, 2022	DP			
		7101569				
		Oct 02, 2023		U-759		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 002	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 003	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 004	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 005	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 006	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 007	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 008	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 009	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 010	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 011	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 012	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 001	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 002	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 003	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 004	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 005	6399101	Mar 30, 2020				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342	006	6399101				Mar 30, 2020
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342	007	6399101				Mar 30, 2020
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342	008	6399101				Mar 30, 2020
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342	009	6399101				Mar 30, 2020
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342	010	6399101				Mar 30, 2020
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342	011	6399101				Mar 30, 2020
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924	002	7691411		DP		Mar 14, 2024
		7723390		DP		Mar 14, 2024
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924	003	7691411		DP		Mar 14, 2024
		7723390		DP		Mar 14, 2024
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924	004	7691411		DP		Mar 14, 2024
		7723390		DP		Mar 14, 2024
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924	005	7691411		DP		Mar 14, 2024
		7723390		DP		Mar 14, 2024
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924	006	7691411		DP		Mar 14, 2024
		7723390		DP		Mar 14, 2024
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924	007	7691411		DP		Mar 14, 2024
		7723390		DP		Mar 14, 2024
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924	008	7691411		DP		Mar 14, 2024
		7723390		DP		Mar 14, 2024
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924	009	7691411		DP		Mar 14, 2024
		7723390		DP		Mar 14, 2024
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924	010	7691411		DP		Mar 14, 2024
		7723390		DP		Mar 14, 2024
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 022121	001	7723390		DP		Mar 14, 2024
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231	001	9006289		DP		Oct 03, 2032
		9168238		DP		Aug 29, 2032
		9168239		DP		Aug 29, 2032
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231	002	9006289		DP		Oct 03, 2032
		9168238		DP		Aug 29, 2032
		9168239		DP		Aug 29, 2032
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231	003	9006289		DP		Oct 03, 2032
		9168238		DP		Aug 29, 2032
		9168239		DP		Aug 29, 2032

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231	003	9006289	Oct 03, 2032	DP		
		9168238	Aug 29, 2032	DP		
		9168239	Aug 29, 2032	DP		
<u>LIDOCAINE HYDROCHLORIDE - ZINGO</u>						
N 022114	001	6004286	Mar 17, 2017	DP		
		8540665	Oct 22, 2029	U-1438		
		9358338	Apr 27, 2035	U-1870		
		9370622	Sep 28, 2035	U-1870		
<u>LIDOCAINE HYDROCHLORIDE - AKTEN</u>						
N 022221	001	8759401	Jul 24, 2026	DP	U-1523	
<u>LIDOCAINE; PRILOCAINE - ORAOIX</u>						
N 021451	001	6031007	Apr 01, 2017	DP	U-553	
<u>LIDOCAINE; TETRACAINE - SYNERA</u>						
N 021623	001	6465709	Jul 07, 2020	DP		
<u>LIDOCAINE; TETRACAINE - PLIAGLIS</u>						
N 021717	001	6528086	Sep 28, 2019	DP		
<u>LIFITEGRAST - XIIDRA</u>						
N 208073	001	7314938	Mar 10, 2025	DS DP	NCE	Jul 11, 2021
		7745460	Nov 05, 2024	DS DP	U-1880	
		7790743	Nov 05, 2024		U-1880	
		7928122	Nov 05, 2024	DS DP		
		8084047	May 17, 2026	DS DP		
		8168655	May 09, 2029		U-1880	
		8367701	Apr 15, 2029	DP	U-1880	
		8592450	May 17, 2026		U-1880	
		8927574	Nov 12, 2030	DP		
		9085553	Jul 25, 2033	DP		
		9216174	Nov 05, 2024	DP		
		9353088	Oct 21, 2030	DP		
		9447077	Apr 15, 2029		U-1900	
<u>LINACLOTIDE - LINZESS</u>						
N 202811	001	7304036	Aug 30, 2026	DS DP	U-1278	NCE
		7304036	Aug 30, 2026	DS DP	U-1516	Aug 30, 2017
		7371727	Jan 28, 2024	DS		
		7704947	Jan 28, 2024	DS DP		
		7745409	Jan 28, 2024	DS DP		
		8080526	Jan 28, 2024	DS DP		
		8110553	Jan 28, 2024		U-1278	
		8748573	Oct 30, 2031		U-1515	
		8748573	Oct 30, 2031		U-1516	
		8802628	Nov 17, 2031	DP		
		8933030	Feb 17, 2031	DP		
<u>LINACLOTIDE - LINZESS</u>						
N 202811	002	7304036	Aug 30, 2026	DS DP	U-1278	NCE
		7304036	Aug 30, 2026	DS DP	U-1516	Aug 30, 2017
		7371727	Jan 28, 2024	DS		
		7704947	Jan 28, 2024	DS DP		
		7745409	Jan 28, 2024	DS DP		
		8080526	Jan 28, 2024	DS DP		
		8110553	Jan 28, 2024		U-1278	
		8748573	Oct 30, 2031		U-1515	
		8748573	Oct 30, 2031		U-1516	
		8802628	Nov 17, 2031	DP		
		8933030	Feb 17, 2031	DP		
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280	001	6303661	Apr 24, 2017		U-774	
		6303661	Apr 24, 2017		U-1270	
		6890898	Feb 02, 2019		U-493	
		6890898	Feb 02, 2019		U-1270	
		7078381	Feb 02, 2019		U-493	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	7078381	Feb 02, 2019		U-1270		
	7407955	May 02, 2025	DS DP			
	7459428	Feb 02, 2019		U-493		
	7459428	Feb 02, 2019		U-1270		
	8119648	Aug 12, 2023		U-774		
	8119648	Aug 12, 2023		U-1270		
	8178541	Aug 12, 2023		U-775		
	8178541	Aug 12, 2023		U-1244		
	8178541	Aug 12, 2023		U-1245		
	8178541	Aug 12, 2023		U-1270		
	8673927	May 04, 2027		U-1503		
	8846695	Jun 04, 2030		U-1503		
	8853156	Mar 05, 2031		U-1642		
	8883805	Nov 26, 2025	DP			
	9173859	May 04, 2027	DP	U-1503		
	9173859	May 04, 2027	DP	U-1768		
	9486526	Aug 05, 2029		U-1915		
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	6303661	Apr 24, 2017		U-802	M-146	Jul 30, 2017
	6890898	Feb 02, 2019		U-1039		
	7078381	Feb 02, 2019		U-1039		
	7407955	May 02, 2025	DS DP			
	7459428	Feb 02, 2019		U-1039		
	8119648	Aug 12, 2023		U-802		
	8178541	Aug 12, 2023	DP	U-775		
	8673927	May 04, 2027		U-1503		
	8846695	Jun 04, 2030		U-1503		
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP	U-1503		
	9415016	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	6303661	Apr 24, 2017		U-802	M-146	Jul 30, 2017
	6890898	Feb 02, 2019		U-1039		
	7078381	Feb 02, 2019		U-1039		
	7407955	May 02, 2025	DS DP			
	7459428	Feb 02, 2019		U-1039		
	8119648	Aug 12, 2023		U-802		
	8178541	Aug 12, 2023	DP	U-775		
	8673927	May 04, 2027		U-1503		
	8846695	Jun 04, 2030		U-1503		
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP	U-1503		
	9415016	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	6303661	Apr 24, 2017		U-802	M-146	Jul 30, 2017
	6890898	Feb 02, 2019		U-1039		
	7078381	Feb 02, 2019		U-1039		
	7407955	May 02, 2025	DS DP			
	7459428	Feb 02, 2019		U-1039		
	8119648	Aug 12, 2023		U-802		
	8178541	Aug 12, 2023	DP	U-775		
	8673927	May 04, 2027		U-1503		
	8846695	Jun 04, 2030		U-1503		
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP	U-1503		
	9415016	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	6303661	Apr 24, 2017		U-802		
	6340475	Sep 19, 2016	DP	U-1852		
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6890898	Feb 02, 2019		U-802		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	7078381	Feb 02, 2019	U-803			
	7407955	May 02, 2025	DS DP			
	7459428	Feb 02, 2019	U-803			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-1853			
	8673927	May 04, 2027	U-1503			
	8846695	Jun 04, 2030	U-1503			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP U-1503			
	9415016	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	6303661	Apr 24, 2017	U-802			
	6340475	Sep 19, 2016	DP U-1852			
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6890898	Feb 02, 2019	U-803			
	7078381	Feb 02, 2019	U-803			
	7407955	May 02, 2025	DS DP			
	7459428	Feb 02, 2019	U-803			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-1853			
	8673927	May 04, 2027	U-1503			
	8846695	Jun 04, 2030	U-1503			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP U-1503			
	9415016	Apr 02, 2029	DP			
<u>LINEZOLID - ZYVOX</u>						
N 021130 001	6514529	Mar 15, 2021	DP			
	6559305	Jan 29, 2021	DS			
<u>LINEZOLID - ZYVOX</u>						
N 021130 002	6514529	Mar 15, 2021	DP			
	6559305	Jan 29, 2021	DS			
<u>LINEZOLID - ZYVOX</u>						
N 021131 001	6559305	Jan 29, 2021	DS			
<u>LINEZOLID - ZYVOX</u>						
N 021131 002	6559305	Jan 29, 2021	DS			
	6559305*PED	Jul 29, 2021				
<u>LINEZOLID - ZYVOX</u>						
N 021131 003	6559305	Jan 29, 2021	DS			
	6559305*PED	Jul 29, 2021				
<u>LINEZOLID - ZYVOX</u>						
N 021132 001	6559305	Jan 29, 2021	DS			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	6004297	Jan 28, 2019	DP		M-176	Apr 22, 2019
	6268343	Aug 22, 2022	DS DP U-968			
	6458924	Aug 22, 2017	DS DP U-968			
	7235627	Aug 22, 2017	DS DP			
	8114833	Aug 13, 2025	DP			
	8846618	Jun 27, 2022	DP			
	9265893	Sep 23, 2032	DP			
	RE41956	Jan 21, 2021	DP			
	RE43834	Jan 28, 2019	DP			
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	6268343	Aug 22, 2022	DS DP U-1255		NP	Jan 25, 2017
	6458924	Aug 22, 2017	DS DP U-1255			
	6899699	Jan 01, 2022	DP			
	7235627	Aug 22, 2017	DS DP			
	7686786	Aug 03, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	8114833	Aug 13, 2025	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8846618	Jun 27, 2022	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 26, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 001	7105486	Feb 24, 2023		U-727	I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP	U-727		
	7659254	Feb 24, 2023		U-1034		
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023		U-727		
	7671030	Feb 24, 2023	DP	U-727		
	7671031	Feb 24, 2023		U-727		
	7674774	Feb 24, 2023	DP	U-842		
	7678770	Feb 24, 2023		U-842		
	7678771	Feb 24, 2023	DP	U-842		
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP	U-842		
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023		U-727		
	7718619	Feb 24, 2023	DP	U-842		
	7723305	Feb 24, 2023	DP	U-842		
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 002	7105486	Feb 24, 2023		U-727	I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP	U-727		
	7659254	Feb 24, 2023		U-1034		
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023		U-727		
	7671030	Feb 24, 2023	DP	U-727		
	7671031	Feb 24, 2023		U-727		
	7674774	Feb 24, 2023	DP	U-842		
	7678770	Feb 24, 2023		U-842		
	7678771	Feb 24, 2023	DP	U-842		
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP	U-842		
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023		U-727		
	7718619	Feb 24, 2023	DP	U-842		
	7723305	Feb 24, 2023	DP	U-842		
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 003	7105486	Feb 24, 2023		U-727	I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP	U-727		
	7659254	Feb 24, 2023		U-1034		
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023		U-727		
	7671030	Feb 24, 2023	DP	U-727		
	7671031	Feb 24, 2023		U-727		
	7674774	Feb 24, 2023	DP	U-842		
	7678770	Feb 24, 2023		U-842		
	7678771	Feb 24, 2023	DP	U-842		
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP	U-842		
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023		U-727		
	7718619	Feb 24, 2023	DP	U-842		
	7723305	Feb 24, 2023	DP	U-842		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 003	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP U-842			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 004	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7105486	Feb 24, 2023	U-842		M-188	Oct 14, 2019
	7223735	Feb 24, 2023	DP			
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP U-842			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 005	7105486	Feb 24, 2023	U-842		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP U-842			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 006	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7105486	Feb 24, 2023	U-842		M-188	Oct 14, 2019
	7223735	Feb 24, 2023	DP			
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP U-842			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 006	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP U-842			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 007	7223735	Feb 24, 2023	DP		I-703	Jan 30, 2018
	7655630	Feb 24, 2023	DS		M-188	Oct 14, 2019
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
<u>LISINAPRIL - OBRELIS</u>						
N 208401 001	9463183	Nov 06, 2035	DP			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 001	8475414	Dec 28, 2030	DP U-1881		NCE	Jul 27, 2021
	8882721	Jun 28, 2031	DP			
	8915888	Jun 08, 2030	DP U-1881			
	9072836	Mar 15, 2032	DP			
	9084853	Oct 05, 2031	DP			
	9308329	Dec 28, 2030	DP U-1881			
	9408893	Aug 27, 2032	U-1894			
	9511193	Jan 19, 2032	DP			
	RE45313	Jul 12, 2020	DS DP			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 002	8475414	Dec 28, 2030	DP U-1881		NCE	Jul 27, 2021
	8882721	Jun 28, 2031	DP			
	8915888	Jun 08, 2030	DP U-1881			
	9072836	Mar 15, 2032	DP			
	9084853	Oct 05, 2031	DP			
	9308329	Dec 28, 2030	DP U-1881			
	9408893	Aug 27, 2032	U-1894			
	9511193	Jan 19, 2032	DP			
	RE45313	Jul 12, 2020	DS DP			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	5712279	Feb 21, 2020	DS DP U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	5712279	Feb 21, 2020	DS DP U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858	002	9265758	Mar 07, 2025	U-1316		
		9364470	Mar 07, 2025	U-1851		
		9433617	Mar 07, 2025	U-1316		
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858	003	5712279	Feb 21, 2020	DS DP U-1317	NCE	Dec 21, 2017
		6492365	Dec 10, 2019	U-1318	ODE	Dec 21, 2019
		7932268	Aug 19, 2027	U-1316		
		8618135	Mar 07, 2025	U-1316		
		9265758	Mar 07, 2025	U-1316		
		9364470	Mar 07, 2025	U-1851		
		9433617	Mar 07, 2025	U-1316		
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858	004	5712279	Feb 21, 2020	DS DP U-1317	NCE	Dec 21, 2017
		6492365	Dec 10, 2019	U-1318	ODE	Dec 21, 2019
		7932268	Aug 19, 2027	U-1316		
		8618135	Mar 07, 2025	U-1316		
		9265758	Mar 07, 2025	U-1316		
		9364470	Mar 07, 2025	U-1851		
		9433617	Mar 07, 2025	U-1316		
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858	005	5712279	Feb 21, 2020	DS DP U-1317	NCE	Dec 21, 2017
		6492365	Dec 10, 2019	U-1318	ODE	Dec 21, 2019
		7932268	Aug 19, 2027	U-1316		
		8618135	Mar 07, 2025	U-1316		
		9265758	Mar 07, 2025	U-1316		
		9364470	Mar 07, 2025	U-1851		
		9433617	Mar 07, 2025	U-1316		
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858	006	5712279	Feb 21, 2020	DS DP U-1317	NCE	Dec 21, 2017
		6492365	Dec 10, 2019	U-1318	ODE	Dec 21, 2019
		7932268	Aug 19, 2027	U-1316		
		8618135	Mar 07, 2025	U-1316		
		9265758	Mar 07, 2025	U-1316		
		9364470	Mar 07, 2025	U-1851		
		9433617	Mar 07, 2025	U-1316		
<u>LOPERAMIDE HYDROCHLORIDE - IMODIUM A-D EZ CHEWS</u>						
N 020448	001	6814978	Aug 26, 2021	DP		
<u>LOPERAMIDE HYDROCHLORIDE; SIMETHICONE - IMODIUM MULTI-SYMPTOM RELIEF</u>						
N 021140	001	6103260	Jul 17, 2017	DP		
<u>LOPINA VIR; RITONAVIR - KALETRA</u>						
N 021226	001	6232333	Nov 07, 2017			
		6458818	Nov 07, 2017			
		6521651	Nov 07, 2017	DP		
		7141593	May 22, 2020	DP		
		7432294	May 22, 2020	DP		
<u>LOPINA VIR; RITONAVIR - KALETRA</u>						
N 021251	001	6911214	Nov 28, 2021	DP U-895		
		8501219	Nov 28, 2021	DP		
<u>LOPINA VIR; RITONAVIR - KALETRA</u>						
N 021906	001	7148359	Jul 19, 2019	DP		
		7364752	Nov 10, 2020	DP U-688		
		8025899	Dec 14, 2027	DP		
		8025899*PED	Jun 14, 2028			
		8268349	Aug 25, 2024	DP		
		8309613	Dec 24, 2024	U-688		
		8377952	Oct 22, 2027	U-1372		
		8377952*PED	Apr 22, 2028			
		8399015	Aug 25, 2024	DP		
		8399015*PED	Feb 25, 2025			
		8470347	Sep 17, 2026	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021906	001	8470347*PED	Mar 17, 2027			
		8691878	Aug 25, 2024	U-1513		
		8691878*PED	Feb 25, 2025			
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021906	002	7148359	Jul 19, 2019	DP		
		7364752	Nov 10, 2020	DP	U-688	
		8025899	Dec 14, 2027	DP		
		8025899*PED	Jun 14, 2028			
		8268349	Aug 25, 2024	DP		
		8309613	Dec 24, 2024		U-688	
		8377952	Oct 22, 2027		U-1372	
		8377952*PED	Apr 22, 2028			
		8399015	Aug 25, 2024	DP		
		8399015*PED	Feb 25, 2025			
		8470347	Sep 17, 2026	DP		
		8470347*PED	Mar 17, 2027			
		8691878	Aug 25, 2024		U-1513	
		8691878*PED	Feb 25, 2025			
<u>LORATADINE - CLARITIN</u>						
N 020641	002	6132758	Jun 01, 2018	DP		
<u>LORCASERIN HYDROCHLORIDE - BELVIO</u>						
N 022529	001	6953787	Apr 10, 2023	DS DP	U-1252	NCE Jun 27, 2017
		6953787	Apr 10, 2023	DS DP	U-1253	
		6953787	Apr 10, 2023	DS DP	U-1254	
		6953787	Apr 10, 2023	DS DP	U-1255	
		7514422	Apr 10, 2023		U-1252	
		7514422	Apr 10, 2023		U-1253	
		7514422	Apr 10, 2023		U-1254	
		7514422	Apr 10, 2023		U-1255	
		7977329	Apr 10, 2023	DS DP	U-1252	
		7977329	Apr 10, 2023	DS DP	U-1253	
		7977329	Apr 10, 2023	DS DP	U-1254	
		7977329	Apr 10, 2023	DS DP	U-1255	
		8168624	Apr 18, 2029	DS DP		
		8207158	Apr 10, 2023		U-1252	
		8207158	Apr 10, 2023		U-1253	
		8207158	Apr 10, 2023		U-1254	
		8207158	Apr 10, 2023		U-1255	
		8273734	Apr 10, 2023		U-1254	
		8273734	Apr 10, 2023		U-1255	
		8367657	Apr 10, 2023	DS DP	U-1252	
		8367657	Apr 10, 2023	DS DP	U-1253	
		8367657	Apr 10, 2023	DS DP	U-1254	
		8367657	Apr 10, 2023	DS DP	U-1255	
		8546379	Apr 10, 2023	DS DP	U-1252	
		8546379	Apr 10, 2023	DS DP	U-1253	
		8546379	Apr 10, 2023	DS DP	U-1254	
		8546379	Apr 10, 2023	DS DP	U-1255	
		8575149	Apr 10, 2023		U-1452	
		8697686	Dec 20, 2025	DS DP		
		8946207	Jun 16, 2024	DP		
		8980881	Dec 20, 2025		U-1252	
		8980881	Dec 20, 2025		U-1253	
		8980881	Dec 20, 2025		U-1254	
		8980881	Dec 20, 2025		U-1255	
		8999970	Feb 07, 2033		U-1688	
		8999970	Feb 07, 2033		U-1689	
		8999970	Feb 07, 2033		U-1692	
		9169213	Dec 06, 2032		U-1762	
		9169213	Dec 06, 2032		U-1763	
		9169213	Dec 06, 2032		U-1764	
		9169213	Dec 06, 2032		U-1765	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LORCASERIN HYDROCHLORIDE - BELVIO XR</u>						
N 208524 001	6953787	Apr 10, 2023	DS DP U-1252		NCE	Jun 27, 2017
	6953787	Apr 10, 2023	DS DP U-1253			
	6953787	Apr 10, 2023	DS DP U-1254			
	6953787	Apr 10, 2023	DS DP U-1255			
	7514422	Apr 10, 2023	U-1252			
	7514422	Apr 10, 2023	U-1253			
	7514422	Apr 10, 2023	U-1254			
	7514422	Apr 10, 2023	U-1255			
	7977329	Apr 10, 2023	DS DP U-1252			
	7977329	Apr 10, 2023	DS DP U-1253			
	7977329	Apr 10, 2023	DS DP U-1254			
	7977329	Apr 10, 2023	DS DP U-1255			
	8168624	Apr 18, 2029	DS DP			
	8207158	Apr 10, 2023	U-1252			
	8207158	Apr 10, 2023	U-1253			
	8207158	Apr 10, 2023	U-1254			
	8207158	Apr 10, 2023	U-1255			
	8273734	Apr 10, 2023	U-1254			
	8273734	Apr 10, 2023	U-1255			
	8367657	Apr 10, 2023	DS DP U-1252			
	8367657	Apr 10, 2023	DS DP U-1253			
	8367657	Apr 10, 2023	DS DP U-1254			
	8367657	Apr 10, 2023	DS DP U-1255			
	8546379	Apr 10, 2023	DS DP U-1252			
	8546379	Apr 10, 2023	DS DP U-1253			
	8546379	Apr 10, 2023	DS DP U-1254			
	8546379	Apr 10, 2023	DS DP U-1255			
	8575149	Apr 10, 2023	U-1452			
	8697686	Dec 20, 2025	DS DP			
	8946207	Jun 16, 2024	DP			
	8980881	Dec 20, 2025	U-1252			
	8980881	Dec 20, 2025	U-1253			
	8980881	Dec 20, 2025	U-1254			
	8980881	Dec 20, 2025	U-1255			
	8999970	Feb 07, 2033	U-1688			
	8999970	Feb 07, 2033	U-1689			
	8999970	Feb 07, 2033	U-1692			
	9169213	Dec 06, 2032	U-1884			
	9169213	Dec 06, 2032	U-1885			
	9169213	Dec 06, 2032	U-1886			
	9169213	Dec 06, 2032	U-1887			
<u>LOTEPREDNOL ETABONATE - LOTEMAX</u>						
N 202872 001	5800807	Jan 29, 2017	DP			
<u>LOVASTATIN - ALTOPREV</u>						
N 021316 001	5916595	Dec 12, 2017				
	6080778	Mar 23, 2018	U-456			
	6485748	Dec 12, 2017	DP			
<u>LOVASTATIN - ALTOPREV</u>						
N 021316 002	5916595	Dec 12, 2017				
	6080778	Mar 23, 2018	U-456			
	6485748	Dec 12, 2017	DP			
<u>LOVASTATIN - ALTOPREV</u>						
N 021316 003	5916595	Dec 12, 2017				
	6080778	Mar 23, 2018	U-456			
	6485748	Dec 12, 2017	DP			
<u>LOVASTATIN - ALTOPREV</u>						
N 021316 004	5916595	Dec 12, 2017				
	6080778	Mar 23, 2018	U-456			
	6485748	Dec 12, 2017	DP			
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	6716416	May 20, 2022	DP			
	7052679	Oct 26, 2021	DP			
	7078020	Oct 26, 2021	DP U-1375			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	7090830	Oct 26, 2021	DP			
	7458374	Aug 18, 2024	DP			
	7537009	Oct 28, 2024	DP			
	7585493	Oct 26, 2021	DP			
	7601337	Oct 26, 2021	DP			
	8074644	Jul 25, 2022	DP			
	8173107	Oct 26, 2021	DP			
	8235037	Oct 26, 2021	DP			
	8387612	Oct 23, 2026	DP			
	8955512	Oct 26, 2021	DP			
	8991387	May 21, 2024	DP			
	9370629	May 20, 2024	DP			
	9439907	Oct 26, 2021	DP			
	9440034	Oct 26, 2021	DP			
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 001	6414016	Sep 05, 2020		U-717		
	6414016	Sep 05, 2020		U-1392		
	6583174	Oct 16, 2020	DP			
	6982283	Dec 04, 2022		U-1391		
	7064148	Aug 30, 2022		U-739		
	7064148	Aug 30, 2022		U-1404		
	7417067	Oct 16, 2020	DP			
	8026393	Oct 25, 2027	DP			
	8071613	Sep 05, 2020		U-1203		
	8071613	Sep 05, 2020		U-1393		
	8088934	May 18, 2021	DS			
	8097649	Oct 16, 2020	DP			
	8097653	Nov 14, 2022		U-1214		
	8097653	Nov 14, 2022		U-1394		
	8114890	Sep 05, 2020	DP			
	8338639	Jan 23, 2027	DP			
	8389542	Nov 14, 2022	DP	U-1345		
	8389542	Nov 14, 2022	DP	U-1395		
	8748481	Sep 01, 2025		U-1520		
	8779187	Jul 23, 2027	DP			
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 002	6414016	Sep 05, 2020		U-874		
	6583174	Oct 16, 2020	DP			
	7064148	Aug 30, 2022		U-739		
	7064148	Aug 30, 2022		U-873		
	7417067	Oct 16, 2020	DP			
	7795312	Sep 17, 2024		U-1085		
	8026393	Oct 25, 2027	DP			
	8071613	Sep 05, 2020		U-1202		
	8088934	May 18, 2021	DS			
	8097649	Oct 16, 2020	DP			
	8114890	Sep 05, 2020	DP			
	8338639	Jan 23, 2027	DP			
	8748481	Sep 01, 2025		U-1519		
	8779187	Jan 23, 2027	DP			
<u>LULICONAZOLE - LUZU</u>						
N 204153 001	5900488	Jul 05, 2017	DS DP	U-540	NCE	Nov 14, 2018
	8980931	Apr 28, 2034		DP		
	9012484	Sep 06, 2033	DS DP	U-540		
	9199977	Sep 06, 2033	DS DP			
	9453006	Sep 06, 2033	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	5532372	Jul 02, 2018	DS			
	5532372*PED	Jan 02, 2019				
	8729085	May 26, 2026	DP			
	8729085*PED	Nov 26, 2026				
	8883794	May 26, 2026	DP			
	8883794*PED	Nov 26, 2026				
	9174975	Jun 25, 2026		U-1770		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603	001	9259423	May 23, 2031		U-1822	
		9259423*PED	Nov 23, 2031			
		RE45573	Jun 23, 2025	DS		
		RE45573*PED	Dec 23, 2025			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603	002	5532372	Jul 02, 2018	DS		
		5532372*PED	Jan 02, 2019			
		8729085	May 26, 2026	DP		
		8729085*PED	Nov 26, 2026			
		8883794	May 26, 2026	DP		
		8883794*PED	Nov 26, 2026			
		9174975	Jun 25, 2026		U-1770	
		9174975*PED	Dec 25, 2026			
		9259423	May 23, 2031		U-1822	
		9259423*PED	Nov 23, 2031			
		RE45573	Jun 23, 2025	DS		
		RE45573*PED	Dec 23, 2025			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603	003	5532372	Jul 02, 2018	DS		
		5532372*PED	Jan 02, 2019			
		8729085	May 26, 2026	DP		
		8729085*PED	Nov 26, 2026			
		8883794	May 26, 2026	DP		
		8883794*PED	Nov 26, 2026			
		9174975	Jun 25, 2026		U-1770	
		9174975*PED	Dec 25, 2026			
		9259423	May 23, 2031		U-1822	
		9259423*PED	Nov 23, 2031			
		RE45573	Jun 23, 2025	DS		
		RE45573*PED	Dec 23, 2025			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603	004	5532372	Jul 02, 2018	DS		
		5532372*PED	Jan 02, 2019			
		8729085	May 26, 2026	DP		
		8729085*PED	Nov 26, 2026			
		8883794	May 26, 2026	DP		
		8883794*PED	Nov 26, 2026			
		9174975	Jun 25, 2026		U-1770	
		9174975*PED	Dec 25, 2026			
		9259423	May 23, 2031		U-1822	
		9259423*PED	Nov 23, 2031			
		RE45573	Jun 23, 2025	DS		
		RE45573*PED	Dec 23, 2025			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603	005	5532372	Jul 02, 2018	DS		
		5532372*PED	Jan 02, 2019			
		8729085	May 26, 2026	DP		
		8729085*PED	Nov 26, 2026			
		8883794	May 26, 2026	DP		
		8883794*PED	Nov 26, 2026			
		9174975	Jun 25, 2026		U-1770	
		9174975*PED	Dec 25, 2026			
		9259423	May 23, 2031		U-1822	
		9259423*PED	Nov 23, 2031			
		RE45573	Jun 23, 2025	DS		
		RE45573*PED	Dec 23, 2025			
<u>MACITENTAN - OPSUMIT</u>						
N 204410	001	7094781	Oct 12, 2022	DS DP	NCE	Oct 18, 2018
		8268847	Apr 18, 2029		ODE	Oct 18, 2020
		8367685	Oct 04, 2028	DP	U-1445	
		9265762	May 29, 2027	DP	U-1820	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXPIRATION DATE
<u>MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - NORMOCARB HF 25</u>						
N 021910	001	5945449	Oct 31, 2017	DP U-785		
		7300674	Mar 04, 2023	DP U-785		
<u>MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - NORMOCARB HF 35</u>						
N 021910	002	5945449	Oct 31, 2017	DP U-785		
<u>MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021850	001	6489346	Jul 16, 2016	DS DP U-588		
		6645988	Jul 16, 2016	DS DP U-588		
		6699885	Jul 16, 2016	U-588		
		7399772	Jul 16, 2016	U-588		
<u>MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021850	002	6489346	Jul 16, 2016	DS DP U-623		
		6645988	Jul 16, 2016	DS DP U-623		
		6699885	Jul 16, 2016	U-623		
		7399772	Jul 16, 2016	U-623		
<u>MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE</u>						
N 022456	001	6489346	Jul 16, 2016	DP U-588		
		6489346	Jul 16, 2016	DP U-1021		
		6645988	Jul 16, 2016	DP		
		6699885	Jul 16, 2016	DP U-588		
		6699885	Jul 16, 2016	DP U-1021		
		7399772	Jul 16, 2016	DP U-588		
		7399772	Jul 16, 2016	DP U-1021		
<u>MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE</u>						
N 022456	002	6489346	Jul 16, 2016	DP U-588		
		6489346	Jul 16, 2016	DP U-1021		
		6645988	Jul 16, 2016	DP		
		6699885	Jul 16, 2016	DP U-588		
		6699885	Jul 16, 2016	DP U-1021		
		7399772	Jul 16, 2016	DP U-588		
		7399772	Jul 16, 2016	DP U-1021		
<u>MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATE - SUPREP BOWEL PREP KIT</u>						
N 022372	001	6946149	Mar 07, 2023	DP U-837		
<u>MALATHION - OVIDE</u>						
N 018613	001	7560445	Feb 01, 2027	DS DP U-986		
		7977324	Aug 14, 2026	DP		
<u>MARAVIROC - SELZENTRY</u>						
N 022128	001	6586430	Dec 01, 2019	DS DP U-824		
		6667314	Aug 06, 2021	DS DP U-824		
		7368460	Nov 25, 2022	U-824		
		7576097	May 25, 2021	DS		
<u>MARAVIROC - SELZENTRY</u>						
N 022128	002	6586430	Dec 01, 2019	DS DP U-824		
		6667314	Aug 06, 2021	DS DP U-824		
		7368460	Nov 25, 2022	U-824		
		7576097	May 25, 2021	DS		
<u>MARAVIROC - SELZENTRY</u>						
N 208984	001	6586430	Dec 01, 2019	DS DP U-824		
		6667314	Aug 06, 2021	DS DP U-824		
		7368460	Nov 25, 2022	U-824		
		7576097	May 25, 2021	DS		
<u>MEBENDAZOLE - VERMOX</u>						
N 208398	001				NS	Oct 19, 2019
<u>MECASERMIN RECOMBINANT - INCRELEX</u>						
N 021839	001	5681814	Sep 18, 2017	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MECHLORETHAMINE HYDROCHLORIDE - VALCHLOR</u>						
N 202317	001	7838564	Mar 07, 2026	DP	NDF	Aug 23, 2016
		7872050	Jul 08, 2029	U-1427	ODE	Aug 23, 2020
		8450375	Mar 07, 2026	DP		
		8501818	Mar 07, 2026	DP		
		8501819	Mar 07, 2026	U-1427		
		9382191	Mar 07, 2026	DP		
<u>MEDROXYPROGESTERONE ACETATE - DEPO-SUBO PROVERA 104</u>						
N 021583	001	6495534	May 15, 2020	DP		
<u>MEGESTROL ACETATE - MEGACE ES</u>						
N 021778	001	6592903	Sep 21, 2020	DP		
		7101576	Apr 22, 2024	U-755		
		9040088	Apr 22, 2024	U-755		
		9101540	Apr 22, 2024	DP U-755		
		9101549	Apr 22, 2024	U-755		
		9107827	Apr 22, 2024	U-755		
<u>MELOXICAM - MOBIC</u>						
N 021530	001	6184220	Mar 25, 2019	DP		
<u>MELOXICAM - VIVLODEX</u>						
N 207233	001	9526734	Mar 31, 2033	DP	NP	Oct 22, 2018
<u>MELOXICAM - VIVLODEX</u>						
N 207233	002	9526734	Mar 31, 2033	DP	NP	Oct 22, 2018
<u>MELPHALAN HYDROCHLORIDE - EVOMELA</u>						
N 207155	001	8410077	Mar 13, 2029	DP	ODE	Mar 10, 2023
		9200088	Mar 13, 2029	DP		
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525	001	8039009	Mar 24, 2029	U-539	M-138	Jul 03, 2017
		8039009*PED	Sep 24, 2029		PED	Jan 03, 2018
		8168209	Nov 22, 2025	DP		
		8168209*PED	May 22, 2026			
		8173708	Nov 22, 2025	U-539		
		8173708*PED	May 22, 2026			
		8283379	Nov 22, 2025	U-539		
		8283379*PED	May 22, 2026			
		8329752	Nov 22, 2025	DP		
		8329752*PED	May 22, 2026			
		8362085	Nov 22, 2025	U-539		
		8362085*PED	May 22, 2026			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525	002	8039009	Mar 24, 2029	U-539	M-138	Jul 03, 2017
		8039009*PED	Sep 24, 2029		PED	Jan 03, 2018
		8168209	Nov 22, 2025	DP		
		8168209*PED	May 22, 2026			
		8173708	Nov 22, 2025	U-539		
		8173708*PED	May 22, 2026			
		8283379	Nov 22, 2025	U-539		
		8283379*PED	May 22, 2026			
		8329752	Nov 22, 2025	DP		
		8329752*PED	May 22, 2026			
		8362085	Nov 22, 2025	U-539		
		8362085*PED	May 22, 2026			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525	003	8039009	Mar 24, 2029	U-539	M-138	Jul 03, 2017
		8039009*PED	Sep 24, 2029		PED	Jan 03, 2018
		8168209	Nov 22, 2025	DP		
		8168209*PED	May 22, 2026			
		8173708	Nov 22, 2025	U-539		
		8173708*PED	May 22, 2026			
		8283379	Nov 22, 2025	U-539		
		8283379*PED	May 22, 2026			
		8329752	Nov 22, 2025	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525	003	8329752*PED 8362085	May 22, 2026 Nov 22, 2025	U-539		
		8362085*PED	May 22, 2026			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525	004	8039009	Mar 24, 2029	U-539	M-138	Jul 03, 2017
		8039009*PED	Sep 24, 2029		PED	Jan 03, 2018
		8168209	Nov 22, 2025	DP		
		8168209*PED	May 22, 2026			
		8173708	Nov 22, 2025	U-539		
		8173708*PED	May 22, 2026			
		8283379	Nov 22, 2025	U-539		
		8283379*PED	May 22, 2026			
		8329752	Nov 22, 2025	DP		
		8329752*PED	May 22, 2026			
		8362085	Nov 22, 2025	U-539		
		8362085*PED	May 22, 2026			
		8598233	Nov 22, 2025	DP		
		8598233*PED	May 22, 2026			
<u>MENOTROPINS (FSH;LH); MENOTROPINS (FSH;LH) - MENOPUR</u>						
N 021663	001				D-139	Feb 19, 2017
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029	001	8809615	Jan 03, 2030	DP		
		9233184	Aug 01, 2027	DP		
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029	002	8809615	Jan 03, 2030	DP		
		9233184	Aug 01, 2027	DP		
<u>MEQUINOL; TRETINOIN - SOLAGE</u>						
N 020922	001	6353029	Aug 24, 2020			
<u>MERCAPTOPYRINE - PURIXAN</u>						
N 205919	001				ODE	Apr 28, 2021
<u>MESALAMINE - SFROWASA</u>						
N 019618	002	7645801	Jul 24, 2027	DS DP		
<u>MESALAMINE - CANASA</u>						
N 021252	001				M-187	Sep 02, 2019
<u>MESALAMINE - CANASA</u>						
N 021252	002	8217083	Jun 06, 2028	DP		
		8436051	Jun 06, 2028	DP		
<u>MESALAMINE - ASACOL HD</u>						
N 021830	001	6893662	Nov 15, 2021	DP	U-141	
		8580302	Nov 15, 2021	DP		
		9089492	Nov 15, 2021	DP		
<u>MESALAMINE - LIALDA</u>						
N 022000	001	6773720	Jun 08, 2020	DP		
<u>MESALAMINE - APRISO</u>						
N 022301	001	6551620	Apr 20, 2018	DS DP	U-907	
		8337886	Apr 20, 2018	DP	U-1310	
		8496965	Apr 20, 2018	DP		
		8865688	May 01, 2030		U-1310	
		8911778	Apr 20, 2018	DP	U-1310	
		8940328	Apr 20, 2018	DP		
		8956647	Apr 20, 2018	DP		
<u>MESALAMINE - DELZICOL</u>						
N 204412	001	6649180	Apr 13, 2020	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METAXALONE - SKELAXIN</u>						
N 013217	003	7122566				
		Feb 06, 2026	U-915			
	7714006	Dec 03, 2021	U-1050			
<u>METFORMIN HYDROCHLORIDE - METFORMIN HYDROCHLORIDE</u>						
A 091664	001				PC	Jul 30, 2016
<u>METFORMIN HYDROCHLORIDE - METFORMIN HYDROCHLORIDE</u>						
A 091664	002				PC	Jul 30, 2016
<u>METFORMIN HYDROCHLORIDE - GLUCOPHAGE XR</u>						
N 021202	001	6475521				
		Mar 19, 2018				
	6660300	Mar 19, 2018	U-542			
<u>METFORMIN HYDROCHLORIDE - GLUCOPHAGE XR</u>						
N 021202	004	6475521				
		Mar 19, 2018				
	6660300	Mar 19, 2018	U-542			
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N 021574	001	6099859		DP		
		Mar 20, 2018				
	6495162	Mar 20, 2018	DP			
	6790459	Mar 17, 2021	U-604			
	6866866	Mar 17, 2021	DP			
	7919116	Mar 20, 2018	DP			
	8475841	Mar 20, 2018	U-604			
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N 021574	002	6099859		DP		
		Mar 20, 2018				
	6495162	Mar 20, 2018	DP			
	6790459	Mar 17, 2021	U-604			
	6866866	Mar 17, 2021	DP			
	7919116	Mar 20, 2018	DP			
	8475841	Mar 20, 2018	U-604			
<u>METFORMIN HYDROCHLORIDE - RIOMET</u>						
N 021591	001	6890957		DP		
		Sep 14, 2023				
<u>METFORMIN HYDROCHLORIDE - GLUMETZA</u>						
N 021748	001	6340475		DS DP	U-669	
		Sep 19, 2016				
	6488962	Jun 20, 2020	DS DP			
	6635280	Sep 19, 2016	DS DP			
	6723340	Oct 25, 2021	DS DP			
<u>METFORMIN HYDROCHLORIDE - GLUMETZA</u>						
N 021748	002	6488962		DS DP		
		Jun 20, 2020				
	7780987	Mar 23, 2025	DS DP			
	8323692	Mar 23, 2025	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842	001	9101660		DP		
		Jan 22, 2027				
	9320714	Feb 03, 2029	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842	002	9101660		DP		
		Jan 22, 2027				
	9320714	Feb 03, 2029	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024	001	6099859		DP		
		Mar 20, 2018				
	6495162	Mar 20, 2018	DP			
	6790459	Mar 17, 2021	U-974			
	6866866	Mar 17, 2021	DP			
	7785627	Jul 31, 2026	DP			
	7919116	Mar 20, 2018	U-973			
	7919116	Mar 20, 2018	U-1120			
	7959946	Jul 31, 2026	DP			
	8470368	Sep 19, 2023	DP			
	8475841	Mar 20, 2018	U-973			
	8668931	Sep 19, 2023	DP			
	9060941	Sep 19, 2023	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 002	6099859	Mar 20, 2018	DP			
	6495162	Mar 20, 2018	DP			
	6790459	Mar 17, 2021		U-974		
	6866866	Mar 17, 2021	DP			
	7785627	Jul 31, 2026	DP			
	7919116	Mar 20, 2018		U-973		
	7919116	Mar 20, 2018		U-1120		
	7959946	Jul 31, 2026	DP			
	8470368	Sep 19, 2023	DP			
	8475841	Mar 20, 2018		U-973		
	8668931	Sep 19, 2023	DP			
	9060941	Sep 19, 2023	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410 001	6288095	Feb 11, 2017		U-493		Y
	7358366	Apr 19, 2020	DS			
	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410 002	6288095	Feb 11, 2017		U-493		Y
	7358366	Apr 19, 2020	DS			
	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410 003	6288095	Feb 11, 2017		U-493		Y
	7358366	Apr 19, 2020	DS			
	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410 004	7358366	Apr 19, 2020	DS			
	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410 005	7358366	Apr 19, 2020	DS			
	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 001	8628799	Jul 13, 2025	DP		M-175	Apr 05, 2019
	9339472	Jul 13, 2025	DP			
	RE44186	Jul 31, 2023	DS DP	U-1097		
	RE44186	Jul 31, 2023	DS DP	U-1838		
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002	RE44186	Jul 31, 2023	DS DP	U-1097	M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP	U-1838		
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003	RE44186	Jul 31, 2023	DS DP	U-1097	M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP	U-1838		
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001	6699871	Jul 26, 2022	DS DP	U-802		
	7125873	Jul 26, 2022		DP U-803		
	7125873	Jul 26, 2022		DP U-1036		
	7125873	Jul 26, 2022		DP U-1038		
	7326708	Nov 24, 2026	DS DP	U-802		
	8414921	Jul 21, 2028		DP U-1036		
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002	6699871	Jul 26, 2022	DS DP	U-802		
	7125873	Jul 26, 2022		DP U-803		
	7125873	Jul 26, 2022		DP U-1036		
	7125873	Jul 26, 2022		DP U-1038		
	7326708	Nov 24, 2026	DS DP	U-802		
	8414921	Jul 21, 2028		DP U-1036		
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 001	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 001	6699871	Jul 26, 2022	DS DP U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Nov 24, 2026	DS DP U-1227			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 002	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Nov 24, 2026	DS DP U-1227			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 003	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Nov 24, 2026	DS DP U-1227			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	6746429	Apr 12, 2020	DP			
	7744582	Aug 10, 2019	DP U-1442			
	7776015	Aug 10, 2019	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	6746429	Apr 12, 2020	DP			
	7744582	Aug 10, 2019	DP U-1442			
	7776015	Aug 10, 2019	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	6746429	Apr 12, 2020	DP			
	7744582	Aug 10, 2019	DP U-1442			
	7776015	Aug 10, 2019	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	6746429	Apr 12, 2020	DP			
	7744582	Aug 10, 2019	DP U-1442			
	7776015	Aug 10, 2019	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	6746429	Apr 12, 2020	DP			
	7744582	Aug 10, 2019	DP U-1442			
	7776015	Aug 10, 2019	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 005	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 006	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 007	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 008	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 001	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 002	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 003	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 004	8664231	Jun 01, 2029	U-1442			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHOTREXATE - RASUVO</u>						
N 205776	005	8664231	Jun 01, 2029	U-1442		
<u>METHOTREXATE - RASUVO</u>						
N 205776	006	8664231	Jun 01, 2029	U-1442		
<u>METHOTREXATE - RASUVO</u>						
N 205776	007	8664231	Jun 01, 2029	U-1442		
<u>METHOTREXATE - RASUVO</u>						
N 205776	008	8664231	Jun 01, 2029	U-1442		
<u>METHOTREXATE - RASUVO</u>						
N 205776	009	8664231	Jun 01, 2029	U-1442		
<u>METHOTREXATE - RASUVO</u>						
N 205776	010	8664231	Jun 01, 2029	U-1442		
<u>METHYLENE BLUE - PROVAYBLUE</u>						
N 204630	001				ODE	Apr 08, 2023
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964	001	6559158	Nov 03, 2017	U-1185		
		8247425	Dec 31, 2030	U-1185		
		8420663	Sep 30, 2029	U-1185		
		8552025	Apr 08, 2024	DP		
		8822490	Sep 30, 2029	DP U-1185		
		9180125	Sep 30, 2029	DP U-1185		
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964	002	6559158	Nov 03, 2017	U-1185		
		8247425	Dec 31, 2030	U-1185		
		8420663	Sep 30, 2029	U-1185		
		8552025	Apr 08, 2024	DP		
		8822490	Sep 30, 2029	DP U-1185		
		9180125	Sep 30, 2029	DP U-1185		
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964	003	8247425	Dec 31, 2030	U-1185		
		8420663	Sep 30, 2029	U-1185		
		8552025	Apr 08, 2024	DP		
		8822490	Sep 30, 2029	DP U-1185		
		9180125	Sep 30, 2029	DP U-1185		
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 208271	001	6559158	Nov 03, 2017	U-1185	NP	Jul 19, 2019
		8420663	Sep 30, 2029	U-1185		
		8524276	Mar 10, 2031	DP		
		8956651	Mar 10, 2031	DP		
		9180125	Sep 30, 2029	DP U-1185		
		9314461	Mar 10, 2031	DP		
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514	001	6210705	Sep 30, 2018	DP U-727		
		6348211	Sep 30, 2018	DP U-727		
		8632802	Oct 07, 2025	DP		
		9034370	Oct 07, 2025	DP		
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514	002	6210705	Sep 30, 2018	DP U-727		
		6348211	Sep 30, 2018	DP U-727		
		8632802	Oct 07, 2025	DP		
		9034370	Oct 07, 2025	DP		
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514	003	6210705	Sep 30, 2018	DP U-727		
		6348211	Sep 30, 2018	DP U-727		
		8632802	Oct 07, 2025	DP		
		9034370	Oct 07, 2025	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 004	6210705	Sep 30, 2018	DP U-727			
	6348211	Sep 30, 2018	DP U-727			
	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 001	6919373	Jul 31, 2017		U-666		
	6930129	Jul 31, 2017		U-666		
	8163798	Jul 31, 2017	DP			
	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
	9000038	Jul 31, 2017		U-666		
	9000038	Jul 31, 2017		U-1693		
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
	9144549	Jul 31, 2017		U-1747		
	9144549	Jul 31, 2017		U-1748		
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 002	6919373	Jul 31, 2017		U-666		
	6930129	Jul 31, 2017		U-666		
	8163798	Jul 31, 2017	DP			
	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
	9000038	Jul 31, 2017		U-666		
	9000038	Jul 31, 2017		U-1693		
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
	9144549	Jul 31, 2017		U-1747		
	9144549	Jul 31, 2017		U-1748		
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 003	6919373	Jul 31, 2017		U-666		
	6930129	Jul 31, 2017		U-666		
	8163798	Jul 31, 2017	DP			
	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
	9000038	Jul 31, 2017		U-666		
	9000038	Jul 31, 2017		U-1693		
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
	9144549	Jul 31, 2017		U-1747		
	9144549	Jul 31, 2017		U-1748		
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 004	6919373	Jul 31, 2017		U-666		
	6930129	Jul 31, 2017		U-666		
	8163798	Jul 31, 2017	DP			
	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
	9000038	Jul 31, 2017		U-666		
	9000038	Jul 31, 2017		U-1693		
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
	9144549	Jul 31, 2017		U-1747		
	9144549	Jul 31, 2017		U-1748		
<u>METHYLPHENIDATE HYDROCHLORIDE - METADATE CD</u>						
N 021259 001	6344215	Oct 27, 2020	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - METADATE CD</u>						
N 021259 002	6344215	Oct 27, 2020	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - METADATE CD</u>						
N 021259 003	6344215	Oct 27, 2020	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - METADATE CD</u>						
N 021259 004	6344215	Oct 27, 2020	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA</u>						
N 021284 001	6228398	Nov 01, 2019	DP U-472			
<u>METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA</u>						
N 021284 002	6228398	Nov 01, 2019	DP U-472			
<u>METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA</u>						
N 021284 003	6228398	Nov 01, 2019	DP U-472			
<u>METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA</u>						
N 021284 004	6228398	Nov 01, 2019	DP U-472			
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLIN</u>						
N 021419 001	7691880	Oct 07, 2024	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLIN</u>						
N 021419 002	7691880	Oct 07, 2024	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - OUILIVANT XR</u>						
N 202100 001	8062667	Mar 29, 2029	DP			
	8287903	Feb 15, 2031	DP			
	8465765	Feb 15, 2031	DP U-1415			
	8563033	Feb 15, 2031	DP U-1415			
	8778390	Feb 15, 2031	DP U-1543			
	8956649	Feb 15, 2031	DP U-1665			
	9040083	Feb 15, 2031	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 001	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP	Y		
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 002	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP	Y		
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 003	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP	Y		
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 004	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP	Y		
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 005	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP	Y		
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 006	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831	006	7247318	Dec 16, 2019	DP		
		7438930	Dec 16, 2019	DP	Y	
		8580310	Dec 16, 2019	DP		
		9066869	Dec 16, 2019	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831	007	6419960	Dec 16, 2019	DP		NP Apr 17, 2018
		7083808	Dec 16, 2019	DP		
		7247318	Dec 16, 2019	DP		
		7438930	Dec 16, 2019	DP	Y	
		8580310	Dec 16, 2019	DP		
		9066869	Dec 16, 2019	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - OUILICHEW ER</u>						
N 207960	001	8202537	Mar 15, 2027	DP		NP Dec 04, 2018
		8287903	Feb 15, 2031	DP		
		8999386	Aug 14, 2033	DP		
		9295642	Aug 14, 2033	DP U-1827		
<u>METHYLPHENIDATE HYDROCHLORIDE - OUILICHEW ER</u>						
N 207960	002	8202537	Mar 15, 2027	DP		NP Dec 04, 2018
		8287903	Feb 15, 2031	DP		
		8999386	Aug 14, 2033	DP		
		9295642	Aug 14, 2033	DP U-1827		
<u>METHYLPHENIDATE HYDROCHLORIDE - OUILICHEW ER</u>						
N 207960	003	8202537	Mar 15, 2027	DP		NP Dec 04, 2018
		8287903	Feb 15, 2031	DP		
		8999386	Aug 14, 2033	DP		
		9295642	Aug 14, 2033	DP U-1827		
<u>METOCLOPRAMIDE HYDROCHLORIDE - REGLAN ODT</u>						
N 021793	001	6024981	Apr 09, 2018	DP		
		6221392	Apr 09, 2018	DP		
<u>METOCLOPRAMIDE HYDROCHLORIDE - REGLAN ODT</u>						
N 021793	002	6024981	Apr 09, 2018	DP		
		6221392	Apr 09, 2018	DP		
<u>METOCLOPRAMIDE HYDROCHLORIDE - METOZOLV ODT</u>						
N 022246	001	6413549	Jul 11, 2017	DP		
<u>METOCLOPRAMIDE HYDROCHLORIDE - METOZOLV ODT</u>						
N 022246	002	6413549	Jul 11, 2017	DP		
<u>METRONIDAZOLE - METROGEL</u>						
N 021789	001	6881726	Feb 21, 2022	DP U-743		
		7348317	Feb 21, 2022	DP U-743		
<u>METRONIDAZOLE - VANDAZOLE</u>						
N 021806	001	7456207	Sep 22, 2024	DP		
<u>METRONIDAZOLE - NUVESSA</u>						
N 205223	001	7893097	Feb 19, 2028	DP		NP Mar 24, 2017
		8658678	Jun 27, 2028	U-1682		
		8877792	Feb 02, 2028	DP		
		8946276	Jun 28, 2032	U-1664		
		9198858	Jun 28, 2032	U-1664		
<u>MICAFUNGIN SODIUM - MYCAMINE</u>						
N 021506	002	6107458	Mar 16, 2019	DS DP U-650		
		6107458	Mar 16, 2019	DS DP U-845		
		6774104	Jan 08, 2021	DP U-650		
		6774104	Jan 08, 2021	DP U-845		
<u>MICAFUNGIN SODIUM - MYCAMINE</u>						
N 021506	003	6107458	Mar 16, 2019	DS DP U-650		
		6107458	Mar 16, 2019	DS DP U-845		
		6774104	Jan 08, 2021	DP U-650		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MICAFUNGIN SODIUM - MYCAMINE</u>						
N 021506	003	6107458	Mar 16, 2019	DS DP U-650		
		6107458	Mar 16, 2019	DS DP U-845		
		6774104	Jan 08, 2021	DP U-650		
		6774104	Jan 08, 2021	DP U-845		
<u>MICONAZOLE - ORAVIG</u>						
N 022404	001	6916485	Sep 11, 2022	DP U-1051		
		7651698	Sep 11, 2022	U-1051		
		8518442	Sep 11, 2022	DP		
<u>MICONAZOLE NITRATE; MICONAZOLE NITRATE - MONISTAT 1 COMBINATION PACK</u>						
N 021308	001	6153635	Nov 28, 2020		Y	
<u>MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE - VUSION</u>						
N 021026	001	8147852	Mar 30, 2028		U-1426	
<u>MIFEPRISTONE - KORLYM</u>						
N 202107	001	8921348	Aug 27, 2028	U-1643	ODE	Feb 17, 2019
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N 022256	001	6602911	Jan 14, 2023		U-882	
		6992110	Nov 05, 2021		U-882	
		7888342	Nov 05, 2021		U-882	
		7994220	Sep 19, 2029		U-819	
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N 022256	002	6602911	Jan 14, 2023		U-882	
		6992110	Nov 05, 2021		U-882	
		7888342	Nov 05, 2021		U-882	
		7994220	Sep 19, 2029		U-819	
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N 022256	003	6602911	Jan 14, 2023		U-882	
		6992110	Nov 05, 2021		U-882	
		7888342	Nov 05, 2021		U-882	
		7994220	Sep 19, 2029		U-819	
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N 022256	004	6602911	Jan 14, 2023		U-882	
		6992110	Nov 05, 2021		U-882	
		7888342	Nov 05, 2021		U-882	
		7994220	Sep 19, 2029		U-819	
<u>MILTEFOSINE - IMPAVIDO</u>						
N 204684	001				NCE	Mar 19, 2019
					ODE	Mar 19, 2021
<u>MINOCYCLINE HYDROCHLORIDE - MINOCIN</u>						
N 050444	001	9084802	May 12, 2031		U-282	
		9278105	May 12, 2031		U-282	
<u>MINOCYCLINE HYDROCHLORIDE - ARESTIN</u>						
N 050781	001	6682348	Mar 29, 2022	DP		
		7699609	Mar 29, 2022	DP		
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808	001	5908838	Feb 19, 2018		U-917	
		7790705	Jun 24, 2025		U-1078	
		7919483	Mar 07, 2027		U-1078	
		8252776	Jun 24, 2025		U-124	
		8268804	Jun 24, 2025		U-1078	
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808	002	5908838	Feb 19, 2018		U-917	
		7541347	Apr 02, 2027		U-917	
		7544373	Apr 02, 2027	DP		
		7790705	Jun 24, 2025		U-1078	
		7919483	Mar 07, 2027		U-1078	
		8252776	Jun 24, 2025		U-124	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808	002	5908838	Feb 19, 2018	U-917		
		7541347	Apr 02, 2027	U-917		
		7544373	Apr 02, 2027	DP		
		7790705	Jun 24, 2025	U-1078		
		7919483	Mar 07, 2027	U-1078		
		8252776	Jun 24, 2025	U-124		
		8268804	Jun 24, 2025	U-1078		
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808	003	5908838	Feb 19, 2018	U-917		
		7790705	Jun 24, 2025	U-1078		
		7919483	Mar 07, 2027	U-1078		
		8252776	Jun 24, 2025	U-124		
		8268804	Jun 24, 2025	U-1078		
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808	004	5908838	Feb 19, 2018	U-917		
		7790705	Jun 24, 2025	U-1078		
		7919483	Mar 07, 2027	U-1078		
		8252776	Jun 24, 2025	U-124		
		8268804	Jun 24, 2025	U-1078		
		9192615	Nov 17, 2031	DP		
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808	005	5908838	Feb 19, 2018	U-917		
		7790705	Jun 24, 2025	U-1078		
		7919483	Mar 07, 2027	U-1078		
		8252776	Jun 24, 2025	U-124		
		8268804	Jun 24, 2025	U-1078		
		9192615	Nov 17, 2031	DP		
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808	006	5908838	Feb 19, 2018	U-917		
		7790705	Jun 24, 2025	U-1078		
		7919483	Mar 07, 2027	U-1078		
		8252776	Jun 24, 2025	U-124		
		8268804	Jun 24, 2025	U-1078		
		8722650	Jun 24, 2025	U-1078		
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808	007	5908838	Feb 19, 2018	U-917		
		7790705	Jun 24, 2025	U-1078		
		7919483	Mar 07, 2027	U-1078		
		8252776	Jun 24, 2025	U-124		
		8268804	Jun 24, 2025	U-1078		
		8722650	Jun 24, 2025	U-1078		
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808	008	5908838	Feb 19, 2018	U-917		
		7790705	Jun 24, 2025	U-1078		
		7919483	Mar 07, 2027	U-1078		
		8252776	Jun 24, 2025	U-124		
		8268804	Jun 24, 2025	U-1078		
		8722650	Jun 24, 2025	U-1078		
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922	001	5908838	Feb 19, 2018	U-1376		
		7541347	Apr 02, 2027	U-917		
		7544373	Apr 02, 2027	DP		
		7790705	Jun 24, 2025	U-124		
		7919483	Mar 07, 2027	U-124		
		8252776	Jun 24, 2025	U-124		
		8268804	Jun 24, 2025	U-124		
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922	003	5908838	Feb 19, 2018	U-1376		
		7541347	Apr 02, 2027	U-917		
		7544373	Apr 02, 2027	DP		
		7790705	Jun 24, 2025	U-124		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922	003	7919483	Mar 07, 2027	U-124		
		8252776	Jun 24, 2025	U-124		
		8268804	Jun 24, 2025	U-124		
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922	005	5908838	Feb 19, 2018	U-1376		
		7541347	Apr 02, 2027	U-917		
		7544373	Apr 02, 2027	DP		
		7790705	Jun 24, 2025	U-124		
		7919483	Mar 07, 2027	U-124		
		8252776	Jun 24, 2025	U-124		
		8268804	Jun 24, 2025	U-124		
<u>MINOXIDIL - MEN'S ROGAINE</u>						
N 021812	001	6946120	Apr 20, 2019	DP U-702		
<u>MINOXIDIL - WOMEN'S ROGAINE</u>						
N 021812	002	6946120	Apr 20, 2019	DP U-702	NP	Feb 28, 2017
<u>MIPOMERSEN SODIUM - KYNAMRO</u>						
N 203568	001	6166197	Dec 26, 2017	DS	NCE	Jan 29, 2018
		6451991	Feb 11, 2017	DS	ODE	Jan 29, 2020
		7015315	Mar 21, 2023	DS		
		7101993	Sep 05, 2023	DS		
		7407943	Aug 01, 2021	U-1353		
		7511131	Jan 29, 2027	DS		
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611	001	6346532	Mar 27, 2022	DS DP	NCE	Jun 28, 2017
		6562375	Aug 01, 2020	DP		
		7342117	Nov 04, 2023	DS		
		7982049	Nov 04, 2023	DP		
		8835474	Nov 04, 2023	U-1527		
		RE44872	Nov 04, 2023	U-1527		
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611	002	6346532	Mar 27, 2022	DS DP	NCE	Jun 28, 2017
		6562375	Aug 01, 2020	DP		
		7342117	Nov 04, 2023	DS		
		7982049	Nov 04, 2023	DP		
		8835474	Nov 04, 2023	U-1527		
		RE44872	Nov 04, 2023	U-1527		
<u>MITOMYCIN - MITOSOL</u>						
N 022572	001	7806265	Feb 01, 2029	DP	ODE	Feb 07, 2019
		8186511	Jul 19, 2026	DP		
		9205075	Jul 19, 2026	DP		
<u>MODAFINIL - PROVIGIL</u>						
N 020717	001	7297346	Nov 29, 2023	DP		
<u>MODAFINIL - PROVIGIL</u>						
N 020717	002	7297346	Nov 29, 2023	DP		
<u>MOMETASONE FUROATE - NASONEX</u>						
N 020762	001	6127353	Oct 03, 2017	DS DP		
<u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u>						
N 021067	001	6240918	Feb 20, 2017	DP		
		6503537	Mar 17, 2018	DP		
		8173172	Mar 17, 2018	DP		
<u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u>						
N 021067	002	6240918	Feb 20, 2017	DP		
		6503537	Mar 17, 2018	DP		
		8173172	Mar 17, 2018	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MOMETASONE FUROATE - ASMANEX HFA</u>						
N 205641	001	6068832	Aug 27, 2017	DP	U-645	
<u>MOMETASONE FUROATE - ASMANEX HFA</u>						
N 205641	002	6068832	Aug 27, 2017	DP	U-645	
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N 021409	001	8007830	Oct 24, 2022	DP		
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260	001	6066339	Nov 25, 2017	DP		
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260	002	6066339	Nov 25, 2017	DP		
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260	003	6066339	Nov 25, 2017	DP		
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260	004	6066339	Nov 25, 2017	DP		
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260	005	6066339	Nov 25, 2017	DP		
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260	006	6066339	Nov 25, 2017	DP		
<u>MORPHINE SULFATE - DEPODUR</u>						
N 021671	001	5891467	Jan 31, 2017	DP		
		5962016	Jan 31, 2017	DP	U-584	
		5997899	Sep 01, 2016	DP		
		6171613	Oct 01, 2016	DP		
		6193998	Sep 01, 2016	DP		
		6241999	Sep 01, 2016	DP		
<u>MORPHINE SULFATE - DEPODUR</u>						
N 021671	002	5891467	Jan 31, 2017	DP		
		5962016	Jan 31, 2017	DP	U-584	
		5997899	Sep 01, 2016	DP		
		6171613	Oct 01, 2016	DP		
		6193998	Sep 01, 2016	DP		
		6241999	Sep 01, 2016	DP		
<u>MORPHINE SULFATE - DEPODUR</u>						
N 021671	003	5891467	Jan 31, 2017	DP		
		5962016	Jan 31, 2017	DP	U-584	
		5997899	Sep 01, 2016	DP		
		6171613	Oct 01, 2016	DP		
		6193998	Sep 01, 2016	DP		
		6241999	Sep 01, 2016	DP		
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223	001	9072781	Mar 12, 2034	DP		
		9192608	Mar 12, 2034		U-43	
		9192608	Mar 12, 2034		U-55	
		9248229	Mar 12, 2034	DP		
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223	002	9072781	Mar 12, 2034	DP		
		9192608	Mar 12, 2034		U-43	
		9192608	Mar 12, 2034		U-55	
		9248229	Mar 12, 2034	DP		
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223	003	9072781	Mar 12, 2034	DP		
		9192608	Mar 12, 2034		U-43	
		9192608	Mar 12, 2034		U-55	
		9248229	Mar 12, 2034	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 004	9072781	Mar 12, 2034	DP			
	9192608	Mar 12, 2034		U-43		
	9192608	Mar 12, 2034		U-55		
	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 005	9072781	Mar 12, 2034	DP			
	9192608	Mar 12, 2034		U-43		
	9192608	Mar 12, 2034		U-55		
	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 001	7955619	Aug 12, 2028	DP		M-189	Oct 02, 2018
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 002	7955619	Aug 12, 2028	DP		M-189	Oct 02, 2018
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 003	7955619	Aug 12, 2028	DP		M-189	Oct 02, 2018
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 004	7955619	Aug 12, 2028	DP		M-189	Oct 02, 2018
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 001	7682633	Jun 19, 2027		U-1510		
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027		U-1510		
	8623418	Nov 07, 2029		U-1640		
	8685443	Jul 03, 2025		U-1508		
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 002	7682633	Jun 19, 2027		U-1510		
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027		U-1510		
	8623418	Nov 07, 2029		U-1640		
	8685443	Jul 03, 2025		U-1508		
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 003	7682633	Jun 19, 2027		U-1510		
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027		U-1510		
	8623418	Nov 07, 2029		U-1640		
	8685443	Jul 03, 2025		U-1508		
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 004	7682633	Jun 19, 2027		U-1510		
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027		U-1510		
	8623418	Nov 07, 2029		U-1640		
	8685443	Jul 03, 2025		U-1508		
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 005	7682633	Jun 19, 2027	U-1510			
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027	U-1510			
	8623418	Nov 07, 2029	U-1640			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 006	7682633	Jun 19, 2027	U-1510			
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027	U-1510			
	8623418	Nov 07, 2029	U-1640			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
<u>MOXIFLOXACIN HYDROCHLORIDE - AVELOX</u>						
N 021085 001	5849752	Dec 05, 2016	U-298		M-185	Sep 27, 2019
	6610327	Oct 29, 2019	DP U-298			
<u>MOXIFLOXACIN HYDROCHLORIDE - AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER</u>						
N 021277 001	5849752	Dec 05, 2016	U-298		M-185	Sep 27, 2019
	6548079	Jul 25, 2020	DP U-298			
<u>MOXIFLOXACIN HYDROCHLORIDE - VIGAMOX</u>						
N 021598 001	6716830	Sep 29, 2019	DP			
	7671070	Sep 29, 2019	U-709			
<u>MOXIFLOXACIN HYDROCHLORIDE - MOXEZA</u>						
N 022428 001	6716830	Sep 29, 2019	DP			
	7671070	Sep 29, 2019	DP U-709			
	8450311	May 29, 2029	DP			
	9114168	May 29, 2029	DP			
<u>MUPIROCIN - CENTANY</u>						
N 050788 001	6013657	Jul 08, 2018	DP			
<u>MYCOPHENOLIC ACID - MYFORTIC</u>						
N 050791 001	6025391	Apr 10, 2017	DP U-908			
	6172107	Apr 10, 2017	DP U-908			
	6306900	Feb 27, 2018	DP			
<u>MYCOPHENOLIC ACID - MYFORTIC</u>						
N 050791 002	6025391	Apr 10, 2017	DP U-908			
	6172107	Apr 10, 2017	DP U-908			
	6306900	Feb 27, 2018	DP			
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N 019599 002					M-191	Nov 10, 2019
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N 204286 001	8778365	Jan 31, 2033	DP			
	9161914	Jan 31, 2033	U-540			
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 001	7056500	Jun 29, 2024	DP U-1185		NCE	Sep 16, 2019
	7662365	Oct 18, 2022	DS DP			
	7786133	Dec 19, 2027	DS DP			
	8067431	Dec 16, 2024	U-1185			
	8617530	Oct 18, 2022	U-1185			
	9012469	Apr 02, 2032	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 002	7056500	Jun 29, 2024	DP	U-1185	NCE	Sep 16, 2019
	7662365	Oct 18, 2022	DS	DP		
	7786133	Dec 19, 2027	DS	DP		
	8067431	Dec 16, 2024		U-1185		
	8617530	Oct 18, 2022		U-1185		
	9012469	Apr 02, 2032	DS	DP		
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	7731686	Jun 10, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			
	8627816	Feb 04, 2032	DP			
	8926594	Mar 31, 2026	DP			
	8939943	Feb 28, 2031	DP			
	9022022	Feb 28, 2031	DP			
	9056170	Nov 23, 2024	DP			
	9238108	Feb 20, 2027	DP			
	9278182	Feb 01, 2026	DP			
	9474869	Feb 28, 2031	DP	U-1907		
	9517307	Jul 18, 2034	DP	U-1925		
<u>NALOXONE HYDROCHLORIDE - NARCAN</u>						
N 208411 001	9211253	Mar 16, 2035	DP			
	9468747	Mar 16, 2035	DP	U-1903		
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 209862 001	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			
	8627816	Feb 04, 2032	DP			
	8926594	Mar 31, 2026	DP			
	8939943	Feb 28, 2031	DP			
	9022022	Feb 28, 2031	DP			
	9056170	Nov 23, 2024	DP			
	9238108	Feb 20, 2027	DP			
	9278182	Feb 01, 2026	DP			
	9474869	Feb 28, 2031	DP	U-1907		
	9517307	Jul 18, 2034	DP	U-1925		
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001	6277384	Dec 22, 2018	DP		NC	Jul 23, 2017
	6696066	Dec 22, 2018	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	8673355	Dec 22, 2018	DP			
	8932487	Dec 22, 2018	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIO</u>						
N 205777	001	8846090	Apr 04, 2023	DP		
		8846091	Apr 04, 2023	DP		
		8969369	May 10, 2022	DP U-1556		
		9056051	May 10, 2022	DP U-1556		
		9073933	Mar 30, 2025	DS		
		9084729	May 10, 2022	DP U-1556		
		9161937	May 10, 2022	DP U-1556		
		9168252	May 10, 2022	DP U-1556		
		9205082	Dec 22, 2018	DP U-1556		
		9283216	May 10, 2022	DP U-1819		
		9283221	May 10, 2022	DP U-1819		
		9345701	May 10, 2022	DP U-1819		
		9474750	Dec 22, 2018	DP U-1556		
		9511066	May 10, 2022	U-1921		
		9522919	Mar 30, 2025	DS DP		
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIO</u>						
N 205777	002	6277384	Dec 22, 2018	DP	NC	Jul 23, 2017
		6696066	Dec 22, 2018	DP		
		7674799	Mar 30, 2025	DP		
		7674800	Mar 30, 2025	DS		
		7683072	Mar 30, 2025	DS		
		8673355	Dec 22, 2018	DP		
		8822487	Dec 22, 2018	DP		
		8846090	Apr 04, 2023	DP		
		8846091	Apr 04, 2023	DP		
		8969369	May 10, 2022	DP U-1556		
		9056051	May 10, 2022	DP U-1556		
		9073933	Mar 30, 2025	DS		
		9084729	May 10, 2022	DP U-1556		
		9161937	May 10, 2022	DP U-1556		
		9168252	May 10, 2022	DP U-1556		
		9205082	Dec 22, 2018	DP U-1556		
		9283216	May 10, 2022	DP U-1819		
		9283221	May 10, 2022	DP U-1819		
		9345701	May 10, 2022	DP U-1819		
		9474750	Dec 22, 2018	DP U-1556		
		9511066	May 10, 2022	U-1921		
		9522919	Mar 30, 2025	DS DP		
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIO</u>						
N 205777	003	6277384	Dec 22, 2018	DP	NC	Jul 23, 2017
		6696066	Dec 22, 2018	DP		
		7674799	Mar 30, 2025	DP		
		7674800	Mar 30, 2025	DS		
		7683072	Mar 30, 2025	DS		
		8673355	Dec 22, 2018	DP		
		8822487	Dec 22, 2018	DP		
		8846090	Apr 04, 2023	DP		
		8846091	Apr 04, 2023	DP		
		8969369	May 10, 2022	DP U-1556		
		9056051	May 10, 2022	DP U-1556		
		9073933	Mar 30, 2025	DS		
		9084729	May 10, 2022	DP U-1556		
		9161937	May 10, 2022	DP U-1556		
		9168252	May 10, 2022	DP U-1556		
		9205082	Dec 22, 2018	DP U-1556		
		9283216	May 10, 2022	DP U-1819		
		9283221	May 10, 2022	DP U-1819		
		9345701	May 10, 2022	DP U-1819		
		9474750	Dec 22, 2018	DP U-1556		
		9511066	May 10, 2022	U-1921		
		9522919	Mar 30, 2025	DS DP		

NALTREXONE - VIVITROL

N 021897	001	5792477	May 02, 2017	DP		
		5916598	May 02, 2017	DP		
		6194006	Dec 30, 2018	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NALTREXONE - VIVITROL</u>						
N 021897	001	6331317	Nov 12, 2019	DP		
		6379703	Dec 30, 2018	DP		
		6379704	May 19, 2020	DP		
		6395304	Nov 12, 2019	DP		
		6403114	May 02, 2017	DP		
		6495164	May 25, 2020	DP		
		6495166	Nov 12, 2019	DP		
		6534092	May 19, 2020	DP		
		6537586	Nov 12, 2019	DP		
		6596316	Dec 30, 2018	DP		
		6667061	May 25, 2020	DP		
		6713090	Nov 12, 2019	DP		
		6939033	Nov 12, 2019	DP		
		7799345	May 25, 2020	DP		
		7919499	Oct 15, 2029	U-1123		
		7919499	Oct 15, 2029	U-1124		
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621	001	7815934	Dec 12, 2027	DP	NC	Aug 19, 2019
		8685443	Jul 03, 2025	U-1508		
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621	002	7815934	Dec 12, 2027	DP	NC	Aug 19, 2019
		8685443	Jul 03, 2025	U-1508		
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621	003	7815934	Dec 12, 2027	DP	NC	Aug 19, 2019
		8685443	Jul 03, 2025	U-1508		
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621	004	7815934	Dec 12, 2027	DP	NC	Aug 19, 2019
		8685443	Jul 03, 2025	U-1508		
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621	005	7815934	Dec 12, 2027	DP	NC	Aug 19, 2019
		8685443	Jul 03, 2025	U-1508		
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621	006	7815934	Dec 12, 2027	DP	NC	Aug 19, 2019
		8685443	Jul 03, 2025	U-1508		
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET</u>						
N 021926	001	6060499	Aug 14, 2017	DP U-867		
		6060499*PED	Feb 14, 2018			
		6586458	Aug 14, 2017	DP U-867		
		6586458*PED	Feb 14, 2018			
		7332183	Oct 02, 2025	DP U-867		
		7332183*PED	Apr 02, 2026			
		8022095	Aug 14, 2017	DP U-867		
		8022095*PED	Feb 14, 2018			
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET</u>						
N 021926	002	5872145	Aug 14, 2017	DP U-1719	NP	May 14, 2018
		5872145*PED	Feb 14, 2018		PED	Nov 14, 2018
		6060499	Aug 14, 2017	DP U-1719		
		6060499*PED	Feb 14, 2018			
		6586458	Aug 14, 2017	DP U-1719		
		6586458*PED	Feb 14, 2018			
		7332183	Oct 02, 2025	DP U-1719		
		7332183*PED	Apr 02, 2026			
<u>NATEGLINIDE - STARLIX</u>						
N 021204	001	6559188	Sep 15, 2020	DP U-827		
		6641841	Nov 14, 2017	DP U-214		
		6844008	Nov 14, 2017	DP U-214		
		6878749	Sep 15, 2020	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NATEGLINIDE - STARLIX</u>						
N 021204	002	6559188	Sep 15, 2020	DP U-827		
		6641841	Nov 14, 2017	DP U-214		
		6844008	Nov 14, 2017	DP U-214		
		6878749	Sep 15, 2020	DP		
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N 021742	002	6545040	Dec 17, 2021	DP U-3		
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N 021742	003	6545040	Dec 17, 2021	DP U-3		
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N 021742	004	6545040	Dec 17, 2021	DP U-3		
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N 021742	005	6545040	Dec 17, 2021	DP U-3		
<u>NEBIVOLOL HYDROCHLORIDE; VALSARTAN - BYVALSON</u>						
N 206302	001	7803838	Aug 29, 2026	DP	NC	Jun 03, 2019
		7838552	Oct 04, 2027	U-185		
<u>NELARABINE - ARRANON</u>						
N 021877	001	5424295	Jun 13, 2017	DS DP		
<u>NEPAFENAC - NEVANAC</u>						
N 021862	001	7834059	Jan 31, 2027	U-1095		
		8071648	Dec 02, 2025	DP		
		8324281	Dec 02, 2025	DP		
<u>NEPAFENAC - ILEVRO</u>						
N 203491	001	6403609	Jul 17, 2018	DP		
		7947295	Jun 08, 2024	DP		
		8921337	Mar 31, 2032	DP		
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718	001	6297375	Feb 22, 2020	DS	NCE	Oct 10, 2019
		8623826	Nov 18, 2030	U-528		
		8951969	Nov 18, 2030	DP		
		9186357	Nov 18, 2030	U-528		
		9271975	Sep 09, 2031	U-528		
<u>NEVIRAPINE - VIRAMUNE XR</u>						
N 201152	001	8460704	Mar 12, 2029	U-1409		
<u>NIACIN - NIASPAN</u>						
N 020381	001	6080428	May 27, 2017	U-331		
<u>NIACIN - NIASPAN</u>						
N 020381	002	6080428	May 27, 2017	U-331		
		6080428	May 27, 2017	U-1138		
		6080428	May 27, 2017	U-1139		
		6080428	May 27, 2017	U-1140		
		6080428	May 27, 2017	U-1141		
		6469035	Mar 15, 2018	U-768		
		6469035	Mar 15, 2018	U-1142		
		6469035	Mar 15, 2018	U-1143		
		6469035	Mar 15, 2018	U-1144		
		6469035	Mar 15, 2018	U-1145		
<u>NIACIN - NIASPAN</u>						
N 020381	003	6080428	May 27, 2017	U-331		
		6080428	May 27, 2017	U-1138		
		6080428	May 27, 2017	U-1139		
		6080428	May 27, 2017	U-1140		
		6080428	May 27, 2017	U-1141		
		6469035	Mar 15, 2018	U-768		
		6469035	Mar 15, 2018	U-1142		
		6469035	Mar 15, 2018	U-1143		
		6469035	Mar 15, 2018	U-1144		
		6469035	Mar 15, 2018	U-1145		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN - NIASPAN</u>						
N 020381 003	6080428	May 27, 2017	U-331			
	6080428	May 27, 2017	U-1138			
	6080428	May 27, 2017	U-1139			
	6080428	May 27, 2017	U-1140			
	6080428	May 27, 2017	U-1141			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1142			
	6469035	Mar 15, 2018	U-1143			
	6469035	Mar 15, 2018	U-1144			
	6469035	Mar 15, 2018	U-1145			
<u>NIACIN - NIASPAN</u>						
N 020381 004	6080428	May 27, 2017	U-331			
	6080428	May 27, 2017	U-1138			
	6080428	May 27, 2017	U-1139			
	6080428	May 27, 2017	U-1140			
	6080428	May 27, 2017	U-1141			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1142			
	6469035	Mar 15, 2018	U-1143			
	6469035	Mar 15, 2018	U-1144			
	6469035	Mar 15, 2018	U-1145			
<u>NIACIN - NIASPAN TITRATION STARTER PACK</u>						
N 020381 005	6080428	May 27, 2017	U-331			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 002	7612102	Dec 26, 2027	DP			
	7659291	Apr 18, 2027	U-1029			
	8455524	Apr 18, 2027	U-1029			
	9364564	Dec 26, 2027	DP			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 003	7612102	Dec 26, 2027	DP			
	7659291	Apr 18, 2027	U-1029			
	8455524	Apr 18, 2027	U-1029			
	9364564	Dec 26, 2027	DP			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 004	7612102	Dec 26, 2027	DP			
	7659291	Apr 18, 2027	U-1029			
	8455524	Apr 18, 2027	U-1029			
	9364564	Dec 26, 2027	DP			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 005	7612102	Dec 26, 2027	DP			
	7659291	Apr 18, 2027	U-1029			
	8455524	Apr 18, 2027	U-1029			
	9364564	Dec 26, 2027	DP			
<u>NICOTINE - NICODERM CO</u>						
N 020165 004	8075911	May 22, 2021	DP			
	8663680	Feb 13, 2020	DP			
	8999379	Feb 13, 2020	U-1686			
	9205059	Dec 15, 2019	DP			
<u>NICOTINE - NICODERM CO</u>						
N 020165 005	8075911	May 22, 2021	DP			
	8663680	Feb 13, 2020	DP			
	8999379	Feb 13, 2020	U-1686			
	9205059	Dec 15, 2019	DP			
<u>NICOTINE - NICODERM CO</u>						
N 020165 006	8075911	May 22, 2021	DP			
	8663680	Feb 13, 2020	DP			
	8999379	Feb 13, 2020	U-1686			
	9205059	Dec 15, 2019	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 018612	002 8323683	Apr 30, 2028				
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 020066	002 8323683	Apr 30, 2028	DP			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360	001 8501164	Jun 14, 2029	DP			
	8940772	Apr 30, 2029	DP			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360	002 8501164	Jun 14, 2029	DP			
	8940772	Apr 30, 2029	DP			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068	001 7169791	Jul 04, 2023	DS DP	U-836		
	8163904	Aug 23, 2028	DS DP			
	8293756	Sep 25, 2027	DP			
	8389537	Jul 18, 2026	DS DP	U-1374		
	8415363	Jul 18, 2026	DS DP	U-1407		
	8501760	Jul 18, 2026	DS DP			
	9061029	Apr 07, 2032	DP	U-1374		
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068	002 7169791	Jul 04, 2023	DS DP	U-836		
	8163904	Aug 23, 2028	DS DP			
	8293756	Sep 25, 2027	DP			
	8389537	Jul 18, 2026	DS DP	U-1374		
	8415363	Jul 18, 2026	DS DP	U-1407		
	8501760	Jul 18, 2026	DS DP			
	9061029	Apr 07, 2032	DP	U-1374		
<u>NIMODIPINE - NYMALIZE</u>						
N 203340	001				ODE	May 10, 2020
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832	001 6762180	Dec 10, 2020	DS DP		NCE	Oct 15, 2019
	7119093	Feb 21, 2024	DS DP		ODE	Oct 15, 2021
	7989474	Apr 06, 2024		U-1677		
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832	002 6762180	Dec 10, 2020	DS DP		NCE	Oct 15, 2019
	7119093	Feb 21, 2024	DS DP		ODE	Oct 15, 2021
	7989474	Apr 06, 2024		U-1677		
<u>NITAZOXANIDE - ALINIA</u>						
N 021497	001 5968961	May 07, 2017	DP			
<u>NITAZOXANIDE - ALINIA</u>						
N 021498	001 5965590	Jul 03, 2017		U-523		
	5968961	May 07, 2017				
	6117894	May 07, 2017				
<u>NITISINONE - ORFADIN</u>						
N 206356	001 9301932	Feb 28, 2033	DP	U-1836		
<u>NITRIC OXIDE - INOMAX</u>						
N 020845	002 5732693	Dec 13, 2016	DP	U-1230		
	5752504	Dec 13, 2016	DP	U-1230		
	6125846	May 16, 2017	DP	U-1457		
	6125846*PED	Nov 16, 2017				
	8282966	Jun 30, 2029		U-1286		
	8291904	Jan 06, 2031	DP	U-1226		
	8293284	Jun 30, 2029		U-1286		
	8431163	Jun 30, 2029		U-1286		
	8431163*PED	Dec 30, 2029				
	8573209	Jan 06, 2031	DP			
	8573209*PED	Jul 06, 2031				
	8573210	Jan 06, 2031	DP	U-1453		
	8573210*PED	Jul 06, 2031				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 002	8776794	Jan 06, 2031	DP U-1226			
	8776794*PED	Jul 06, 2031				
	8776795	Jan 06, 2031	DP U-1226			
	8776795*PED	Jul 06, 2031				
	8795741	Jun 30, 2029	U-1286			
	8795741*PED	Dec 30, 2029				
	8846112	Jun 30, 2029	U-1286			
	8846112*PED	Dec 30, 2029				
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003	5732693	Dec 13, 2016	DP U-1230		M-167	Oct 09, 2018
	5752504	Dec 13, 2016	DP U-1230			
	6125846	May 16, 2017	DP U-1457			
	6125846*PED	Nov 16, 2017				
	8282966	Jun 30, 2029	U-1286			
	8291904	Jan 06, 2031	DP U-1226			
	8293284	Jun 30, 2029	U-1286			
	8431163	Jun 30, 2029	U-1286			
	8431163*PED	Dec 30, 2029				
	8573209	Jan 06, 2031	DP			
	8573209*PED	Jul 06, 2031				
	8573210	Jan 06, 2031	DP U-1453			
	8573210*PED	Jul 06, 2031				
	8776794	Jan 06, 2031	DP U-1226			
	8776794*PED	Jul 06, 2031				
	8776795	Jan 06, 2031	DP U-1226			
	8776795*PED	Jul 06, 2031				
	8795741	Jun 30, 2029	U-1286			
	8795741*PED	Dec 30, 2029				
	8846112	Jun 30, 2029	U-1286			
	8846112*PED	Dec 30, 2029				
	9265911	Jan 06, 2031	DP U-1824			
	9265911*PED	Jul 06, 2031				
	9279794	Feb 19, 2034	DP U-1823			
	9279794*PED	Aug 19, 2034				
	9295802	Jan 06, 2031	DP U-1226			
	9295802*PED	Jul 06, 2031				
	9408993	Jan 06, 2031	DP U-1824			
	9408993*PED	Jul 06, 2031				
<u>NITROGLYCERIN - NITROLINGUAL PUMPSPRAY</u>						
N 018705 002	7872049	Mar 14, 2028	DP U-39			
<u>NITROGLYCERIN - NITROSTAT</u>						
N 021134 001	6500456	Sep 16, 2018				
<u>NITROGLYCERIN - NITROSTAT</u>						
N 021134 002	6500456	Sep 16, 2018				
<u>NITROGLYCERIN - NITROSTAT</u>						
N 021134 003	6500456	Sep 16, 2018				
<u>NITROGLYCERIN - GONITRO</u>						
N 208424 001	9101592	Mar 11, 2032	DP			
<u>NIZATIDINE - AXID</u>						
N 021494 001	6930119	Jul 17, 2022	DP			
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531 001					NCE	Dec 23, 2021
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 001	7138390	Nov 16, 2022	DS DP		NCE	May 27, 2021
	8058267	Feb 21, 2022	U-1854		ODE	May 27, 2023
	8377916	Feb 21, 2022	U-1854			
	9238673	Jun 17, 2033	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999	002	7138390	Nov 16, 2022	DS DP	NCE	May 27, 2021
		8058267	Feb 21, 2022		ODE	May 27, 2023
		8377916	Feb 21, 2022		U-1854	
		9238673	Jun 17, 2033	DP		
<u>OCTREOTIDE ACETATE - SANDOSTATIN LAR</u>						
N 021008	001	5922338	Jul 13, 2016	DP		
		5922682	Jul 13, 2016	DP		
<u>OCTREOTIDE ACETATE - SANDOSTATIN LAR</u>						
N 021008	002	5922338	Jul 13, 2016	DP		
		5922682	Jul 13, 2016	DP		
<u>OCTREOTIDE ACETATE - SANDOSTATIN LAR</u>						
N 021008	003	5922338	Jul 13, 2016	DP		
		5922682	Jul 13, 2016	DP		
<u>OLANZAPINE - ZYPREXA</u>						
N 020592	001	6960577	Nov 01, 2017		U-963	NPP
						Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592	002	6960577	Nov 01, 2017		U-963	NPP
						Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592	003	6960577	Nov 01, 2017		U-963	NPP
						Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592	004	6960577	Nov 01, 2017		U-963	NPP
						Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592	005	6960577	Nov 01, 2017		U-963	NPP
						Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592	006	6960577	Nov 01, 2017		U-963	NPP
						Jul 26, 2016
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086	001	6960577	Nov 01, 2017		U-964	NPP
						Jul 26, 2016
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086	002	6960577	Nov 01, 2017		U-964	NPP
						Jul 26, 2016
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086	003	6960577	Nov 01, 2017		U-964	NPP
						Jul 26, 2016
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086	004	6960577	Nov 01, 2017		U-964	NPP
						Jul 26, 2016
<u>OLANZAPINE PAMOATE - ZYPREXA RELPREVV</u>						
N 022173	001	6169084	Sep 30, 2018	DS DP	U-1026	
<u>OLANZAPINE PAMOATE - ZYPREXA RELPREVV</u>						
N 022173	002	6169084	Sep 30, 2018	DS DP	U-1026	
<u>OLANZAPINE PAMOATE - ZYPREXA RELPREVV</u>						
N 022173	003	6169084	Sep 30, 2018	DS DP	U-1026	
<u>OLAPARIB - LYNPARZA</u>						
N 206162	001	7151102	Apr 29, 2022	DS DP		NCE
		7449464	Oct 11, 2024	DS DP		ODE
		7981889	Oct 11, 2024	DS DP		
		8143241	Aug 12, 2027		U-1634	
		8247416	Sep 24, 2028	DS		
		8859562	Aug 04, 2031		U-1634	
		8912187	Mar 12, 2024		U-1634	
<u>OLIVE OIL; SOYBEAN OIL - CLINOLIPID 20%</u>						
N 204508	001					NP
						Oct 03, 2016

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OLMESARTAN MEDOXOMIL - OLMESARTAN MEDOXOMIL</u>						
A 078276	001				PC	Apr 24, 2017
<u>OLMESARTAN MEDOXOMIL - OLMESARTAN MEDOXOMIL</u>						
A 078276	002				PC	Apr 24, 2017
<u>OLMESARTAN MEDOXOMIL - OLMESARTAN MEDOXOMIL</u>						
A 078276	003				PC	Apr 24, 2017
<u>OLMESARTAN MEDOXOMIL - BENICAR</u>						
N 021286	001 6878703	Nov 19, 2021	U-3	Y		
<u>OLMESARTAN MEDOXOMIL - BENICAR</u>						
N 021286	003 6878703	Nov 19, 2021	U-3	Y		
<u>OLMESARTAN MEDOXOMIL - BENICAR</u>						
N 021286	004 6878703	Nov 19, 2021	U-3	Y		
<u>OLODATEROL HYDROCHLORIDE - STRIVERDI RESPIMAT</u>						
N 203108	001 5964416	Oct 04, 2016	DP		NCE	Jul 31, 2019
	6149054	Dec 19, 2016	DP			
	6176442	Oct 04, 2016	DP			
	6453795	Dec 05, 2016	DP			
	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6977042	Aug 28, 2018	DP			
	6988496	Feb 23, 2020	DP	U-1547		
	7056916	Dec 07, 2023	DS DP			
	7104470	Oct 04, 2016	DP			
	7220742	May 12, 2025	DS DP	U-1547		
	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP	U-1547		
	7491719	Nov 10, 2023	DS DP			
	7727984	Nov 10, 2023	DS			
	7786111	Nov 10, 2023	DP			
	7802568	Feb 26, 2019	DP			
	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	7988001	Aug 04, 2021	DP			
	8034809	May 12, 2025		U-1547		
	8044046	Nov 10, 2023		U-1547		
	8733341	Dec 16, 2029	DP			
	9027967	Mar 31, 2027	DP			
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756	001 5964416	Oct 04, 2016	DP		M-173	Mar 18, 2019
	6149054	Dec 19, 2016	DP		NC	May 21, 2018
	6176442	Oct 04, 2016	DP		NCE	Jul 31, 2019
	6453795	Dec 05, 2016	DP			
	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6977042	Aug 28, 2018	DP			
	6988496	Feb 23, 2020	DP			
	7056916	Dec 07, 2023	DS DP			
	7104470	Oct 04, 2016	DP			
	7220742	May 12, 2025	DS DP	U-1703		
	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP			
	7491719	Nov 10, 2023	DS DP			
	7727984	Nov 10, 2023	DS			
	7786111	Nov 10, 2023	DP			
	7802568	Feb 26, 2019	DP			
	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	7988001	Aug 04, 2021	DP			
	8034809	May 12, 2025		U-1702		
	8044046	Nov 10, 2023		U-1702		
	8733341	Dec 16, 2029	DP			
	9027967	Mar 31, 2027	DP			
	RF39820	Jan 30, 2018	DS DP	U-1702		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756	001	5964416	Oct 04, 2016	DP	M-173	Mar 18, 2019
		6149054	Dec 19, 2016	DP	NC	May 21, 2018
		6176442	Oct 04, 2016	DP	NCE	Jul 31, 2019
		6453795	Dec 05, 2016	DP		
		6726124	Oct 04, 2016	DP		
		6846413	Aug 28, 2018	DP		
		6977042	Aug 28, 2018	DP		
		6988496	Feb 23, 2020	DP		
		7056916	Dec 07, 2023	DS DP		
		7104470	Oct 04, 2016	DP		
		7220742	May 12, 2025	DS DP	U-1703	
		7284474	Aug 26, 2024	DP		
		7396341	Oct 10, 2026	DP		
		7491719	Nov 10, 2023	DS DP		
		7727984	Nov 10, 2023	DS		
		7786111	Nov 10, 2023	DP		
		7802568	Feb 26, 2019	DP		
		7837235	Mar 13, 2028	DP		
		7896264	May 26, 2025	DP		
		7988001	Aug 04, 2021	DP		
		8034809	May 12, 2025		U-1702	
		8044046	Nov 10, 2023		U-1702	
		8733341	Dec 16, 2029	DP		
		9027967	Mar 31, 2027	DP		
		RE39820	Jan 30, 2018	DS DP	U-1702	
<u>OLOPATADINE HYDROCHLORIDE - PATADAY</u>						
N 021545	001	6995186	Nov 12, 2023	DP	U-765	
		7402609	Jun 19, 2022	DP		
<u>OLOPATADINE HYDROCHLORIDE - PATANASE</u>						
N 021861	001	7977376	Feb 02, 2023	DP		
		8399508	Sep 17, 2022		U-726	
		8399508*PED	Mar 17, 2023			
<u>OLOPATADINE HYDROCHLORIDE - PAZEO</u>						
N 206276	001	8791154	May 19, 2032	DP	U-1680	
					NP	Jan 30, 2018
					PED	Jul 30, 2018
<u>OMACETAXINE MEPESUCCINATE - SYNRIBO</u>						
N 203585	001	6987103	Jun 28, 2023		U-1300	
		RE45128	Mar 16, 2019	DS DP	U-1576	
					NCE	Oct 26, 2017
					ODE	Oct 26, 2019
<u>OMBITASVIR; PARITAPRE VIR; RITONAVIR - TECHNIVIE</u>						
N 207931	001	6037157*PED	Dec 26, 2016		NCE	Dec 19, 2019
		6703403*PED	Dec 26, 2016		NP	Jul 24, 2018
		7148359	Jul 19, 2019	DP		
		7148359*PED	Jan 19, 2020			
		7364752	Nov 10, 2020	DP		
		7364752*PED	May 10, 2021			
		8268349	Aug 25, 2024	DP		
		8268349*PED	Feb 25, 2025			
		8399015	Aug 25, 2024	DP		
		8399015*PED	Feb 25, 2025			
		8420596	Apr 10, 2031	DS DP		
		8420596*PED	Oct 10, 2031			
		8642538	Sep 10, 2029	DS DP	U-1638	
		8686026	Jun 09, 2031	DP		
		8691938	Apr 13, 2032	DS DP		
		9006387	Jun 10, 2030		U-1687	
		9044480	Apr 10, 2031		U-1638	
<u>OMEGA-3-ACID ETHYL ESTERS TYPE A - OMTRYG</u>						
N 204977	001				NCE	Apr 23, 2019
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060	001	5792795	May 13, 2017	DP	NCE	May 05, 2019
		5948818	May 13, 2017	DP		
		7960370	Feb 07, 2025	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060	001	8383678	Feb 07, 2025	DP U-1511		
		9012501	Feb 07, 2025	DP U-1511		
		9050308	Jan 04, 2033	U-1511		
		9050309	Jan 04, 2033	DS		
		9132112	Feb 07, 2025	DP U-1511		
<u>OMEPRAZOLE - PRILOSEC</u>						
N 019810	001	6147103	Oct 09, 2018			
		6150380	Nov 10, 2018			
		6166213	Oct 09, 2018			
		6191148	Oct 09, 2018			
<u>OMEPRAZOLE - PRILOSEC</u>						
N 019810	002	6147103	Oct 09, 2018			
		6150380	Nov 10, 2018			
		6166213	Oct 09, 2018			
		6191148	Oct 09, 2018			
<u>OMEPRAZOLE - PRILOSEC</u>						
N 019810	003	6147103	Oct 09, 2018			
		6150380	Nov 10, 2018			
		6166213	Oct 09, 2018			
		6191148	Oct 09, 2018			
<u>OMEPRAZOLE - OMEPRAZOLE</u>						
N 022032	001	9023391	Aug 16, 2025	DP		
<u>OMEPRAZOLE MAGNESIUM - PRILOSEC OTC</u>						
N 021229	001	6403616	Nov 15, 2019			
		6428810	Nov 03, 2019			
<u>OMEPRAZOLE MAGNESIUM - PRILOSEC</u>						
N 022056	001	6428810	Nov 03, 2019	DP U-864		
		6428810	Nov 03, 2019	DP U-1817		
<u>OMEPRAZOLE MAGNESIUM - PRILOSEC</u>						
N 022056	002	6428810	Nov 03, 2019	DP U-864		
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021636	001	5840737	Jul 15, 2016	U-588		
		6489346	Jul 15, 2016	DP U-588	Y	
		6645988	Jul 15, 2016	DP	Y	
		6699885	Jul 15, 2016	U-588	Y	
		6780882	Jul 15, 2016	DS DP		
		7399772	Jul 15, 2016	U-588		
		RE45198	Jul 15, 2016	U-588		
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021636	002	5840737	Jul 15, 2016	U-623		
		5840737	Jul 15, 2016	U-624		
		6489346	Jul 15, 2016	DP U-623	Y	
		6489346	Jul 15, 2016	DP U-624	Y	
		6645988	Jul 15, 2016	DP	Y	
		6699885	Jul 15, 2016	U-623	Y	
		6699885	Jul 15, 2016	U-624	Y	
		6780882	Jul 15, 2016	DS DP		
		7399772	Jul 15, 2016	U-623		
		7399772	Jul 15, 2016	U-624		
		RE45198	Jul 15, 2016	U-623		
		RE45198	Jul 15, 2016	U-624		
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021849	001	7399772	Jul 15, 2016	U-588		
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021849	002	7399772	Jul 15, 2016	U-623		
		7399772	Jul 15, 2016	U-624		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID OTC</u>						
N 022281	001 6489346	Jul 15, 2016	DP U-1025	Y		
	6645988	Jul 15, 2016	DP	Y		
	6699885	Jul 15, 2016	DP	Y		
	7399772	Jul 15, 2016	U-1025			
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID OTC</u>						
N 022283	001 5840737	Jul 15, 2016	U-1025			
	6780882	Jul 15, 2016	DP			
	7399772	Jul 15, 2016	U-1025			
<u>ONDANSETRON - ZUPLENZ</u>						
N 022524	001 8580830	Nov 23, 2029	DP			
	9095577	Jul 13, 2030	DP			
<u>ONDANSETRON - ZUPLENZ</u>						
N 022524	002 8580830	Nov 23, 2029	DP			
	9095577	Jul 13, 2030	DP			
<u>ORITAVANCIN DIPHOSPHATE - ORBACTIV</u>						
N 206334	001 5840684	Nov 24, 2017	DS DP U-1569		NCE	Aug 06, 2019
	5998581	Nov 12, 2017	DS		GAIN	Aug 06, 2024
	8420592	Aug 29, 2029	U-1570			
<u>ORLISTAT - XENICAL</u>						
N 020766	001 6004996	Jan 06, 2018				
<u>ORLISTAT - ALLI</u>						
N 021887	001 6004996	Jan 06, 2018	DP			
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087	001 5763483	Aug 23, 2016	DS DP U-1113			
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087	002 5763483	Aug 23, 2016	DS DP U-1113			
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087	003 5763483	Aug 23, 2016	DS DP U-1113			
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021246	001 5763483	Dec 27, 2016	DS	U-376		
	5763483	Dec 27, 2016	DS	U-1113		
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021246	002 5763483	Aug 23, 2016	DS DP U-1113			
	5763483*PED	Feb 23, 2017				
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065	001 8946235	Aug 08, 2032	DS DP U-1777		NCE	Nov 13, 2020
					ODE	Nov 13, 2022
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065	002 8946235	Aug 08, 2032	DS DP U-1777		NCE	Nov 13, 2020
					ODE	Nov 13, 2022
<u>OSPENIFENE - OSPHENA</u>						
N 203505	001 6245819	Jul 21, 2020	U-1369		NCE	Feb 26, 2018
	8236861	Aug 11, 2026	U-1369			
	8236861	Aug 11, 2026	U-1370			
	8470890	Feb 13, 2024	U-1369			
	8470890	Feb 13, 2024	U-1370			
	8642079	Jul 09, 2028	DP			
	8772353	Feb 13, 2024	U-1369			
	8772353	Feb 13, 2024	U-1370			
	9241915	Feb 13, 2024	U-1369			
	9241915	Feb 13, 2024	U-1370			
<u>OXALIPLATIN - ELOXATIN</u>						
N 021492	001 5420319	Aug 09, 2016	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXALIPLATIN - ELOXATIN</u>						
N 021492	002 5420319	Aug 09, 2016	DS			
<u>OXALIPLATIN - ELOXATIN</u>						
N 021759	001 5420319	Aug 09, 2016	DS			
<u>OXALIPLATIN - ELOXATIN</u>						
N 021759	002 5420319	Aug 09, 2016	DS			
<u>OXALIPLATIN - ELOXATIN</u>						
N 021759	003 5420319	Aug 09, 2016	DS			
<u>OXANDROLONE - OXANDRIN</u>						
N 013718	001 5872147	Dec 05, 2017		U-585		
	6090799	Jul 18, 2017		U-585		
	6576659	Dec 05, 2017		U-585		
	6828313	Dec 05, 2017		U-585		
<u>OXANDROLONE - OXANDRIN</u>						
N 013718	002 5872147	Dec 05, 2017		U-585		
	6090799	Jul 18, 2017		U-585		
	6576659	Dec 05, 2017		U-585		
	6828313	Dec 05, 2017		U-585		
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N 021014	001 7037525	Feb 12, 2018		U-724		
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N 021014	002 7037525	Feb 12, 2018		U-724		
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N 021014	003 7037525	Feb 12, 2018		U-724		
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N 021285	001 7037525	Feb 12, 2018		U-724		
	8119148	Dec 19, 2020	DP	U-724		
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810	001 7722898	Apr 13, 2027		DP		
	7910131	Apr 13, 2027		U-1298		
	8617600	Apr 13, 2027		DP		
	8821930	Apr 13, 2027		DP		
	9119791	Apr 13, 2027		U-1298		
	9351975	Apr 13, 2027		DP		
	9370525	Apr 13, 2027		DP		
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810	002 7722898	Apr 13, 2027		DP		
	7910131	Apr 13, 2027		U-1298		
	8617600	Apr 13, 2027		DP		
	8821930	Apr 13, 2027		DP		
	9119791	Apr 13, 2027		U-1298		
	9351975	Apr 13, 2027		DP		
	9370525	Apr 13, 2027		DP		
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810	003 7722898	Apr 13, 2027		DP		
	7910131	Apr 13, 2027		U-1298		
	8617600	Apr 13, 2027		DP		
	8821930	Apr 13, 2027		DP		
	9119791	Apr 13, 2027		U-1298		
	9351975	Apr 13, 2027		DP		
	9370525	Apr 13, 2027		DP		
<u>OXYBUTYNIN - OXYTROL</u>						
N 021351	002 6743441	Apr 26, 2020		DP U-318		
	7081249	Apr 26, 2020		DP U-318		
	7081250	Apr 26, 2020		DP U-318		
	7081251	Apr 26, 2020		DP U-318		
	7081252	Apr 26, 2020		DP U-318		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYBUTYNYNIN - OXYTROL</u>						
N 021351	002	6743441	Apr 26, 2020	DP U-318		
		7081249	Apr 26, 2020	DP U-318		
		7081250	Apr 26, 2020	DP U-318		
		7081251	Apr 26, 2020	DP U-318		
		7081252	Apr 26, 2020	DP U-318		
		7179483	Apr 26, 2020	DS DP U-318		
<u>OXYBUTYNYNIN - OXYTROL FOR WOMEN</u>						
N 202211	001	6743441	Apr 26, 2020	DP U-1329		
		7081249	Apr 26, 2020	DP U-1329		
		7081250	Apr 26, 2020	DP U-1329		
		7081251	Apr 26, 2020	DP U-1329		
		7081252	Apr 26, 2020	DP U-1329		
		7179483	Apr 26, 2020	U-1329		
<u>OXYBUTYNYNIN - GELNIQUE 3%</u>						
N 202513	001	7029694	Apr 26, 2020	DP U-318		
		7179483	Apr 26, 2020	U-318		
		7198801	Jun 25, 2022	DP		
		8241662	Apr 26, 2020	U-318		
<u>OXYBUTYNYNIN CHLORIDE - GELNIQUE</u>						
N 022204	001	7029694	Apr 26, 2020	DP U-318		
		7179483	Apr 26, 2020	U-318		
		8241662	Apr 26, 2020	U-318		
		8920392	Mar 26, 2031	U-1644		
		9259388	Nov 06, 2029	U-1644		
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090	001	7399488	Mar 24, 2025	DP	NP	Apr 26, 2019
		7771707	Mar 24, 2025	DP		
		8449909	Mar 24, 2025	DP		
		8557291	Mar 21, 2025	DP		
		8758813	Jun 10, 2025	U-1556		
		8840928	Jul 07, 2023	DP U-1556		
		9044398	Jul 07, 2023	DP		
		9248195	Jul 07, 2023	DP		
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090	002	7399488	Mar 24, 2025	DP	NP	Apr 26, 2019
		7771707	Mar 24, 2025	DP		
		8449909	Mar 24, 2025	DP		
		8557291	Mar 21, 2025	DP		
		8758813	Jun 10, 2025	U-1556		
		8840928	Jul 07, 2023	DP U-1556		
		9044398	Jul 07, 2023	DP		
		9248195	Jul 07, 2023	DP		
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090	003	7399488	Mar 24, 2025	DP	NP	Apr 26, 2019
		7771707	Mar 24, 2025	DP		
		8449909	Mar 24, 2025	DP		
		8557291	Mar 21, 2025	DP		
		8758813	Jun 10, 2025	U-1556		
		8840928	Jul 07, 2023	DP U-1556		
		9044398	Jul 07, 2023	DP		
		9248195	Jul 07, 2023	DP		
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090	004	7399488	Mar 24, 2025	DP	NP	Apr 26, 2019
		7771707	Mar 24, 2025	DP		
		8449909	Mar 24, 2025	DP		
		8557291	Mar 21, 2025	DP		
		8758813	Jun 10, 2025	U-1556		
		8840928	Jul 07, 2023	DP U-1556		
		9044398	Jul 07, 2023	DP		
		9248195	Jul 07, 2023	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090	005	7399488	Mar 24, 2025	DP	NP	Apr 26, 2019
		7771707	Mar 24, 2025	DP		
		8449909	Mar 24, 2025	DP		
		8557291	Mar 21, 2025	DP		
		8758813	Jun 10, 2025	U-1556		
		8840928	Jul 07, 2023	DP U-1556		
		9044398	Jul 07, 2023	DP		
		9248195	Jul 07, 2023	DP		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272	001	6488963	Jun 24, 2017	DP	NPP	Aug 13, 2018
		7674799	Mar 30, 2025	DP		
		7674800	Mar 30, 2025	DS		
		7683072	Mar 30, 2025	DS		
		7776314	Apr 19, 2025	DP	Y	
		8114383	Oct 10, 2024	DP		
		8309060	Nov 20, 2023	DP U-1556		
		8808741	Aug 24, 2027	U-1556		
		8894987	Mar 29, 2030	DP		
		8894988	Aug 24, 2027	DP		
		9060976	Aug 06, 2022	DP		
		9073933	Mar 30, 2025	DS		
		9492389	Aug 24, 2027	DP		
		9492391	Aug 24, 2027	U-1556		
		9492392	Aug 24, 2027	DP		
		9492393	Aug 24, 2027	U-1556		
		9522919	Mar 30, 2025	DS DP		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272	002	6488963	Jun 24, 2017	DP	NPP	Aug 13, 2018
		7674799	Mar 30, 2025	DP		
		7674800	Mar 30, 2025	DS		
		7683072	Mar 30, 2025	DS		
		7776314	Apr 19, 2025	DP	Y	
		8114383	Oct 10, 2024	DP		
		8309060	Nov 20, 2023	DP U-1556		
		8808741	Aug 24, 2027	U-1556		
		8894987	Mar 29, 2030	DP		
		8894988	Aug 24, 2027	DP		
		9060976	Aug 06, 2022	DP		
		9073933	Mar 30, 2025	DS		
		9492389	Aug 24, 2027	DP		
		9492391	Aug 24, 2027	U-1556		
		9492392	Aug 24, 2027	DP		
		9492393	Aug 24, 2027	U-1556		
		9522919	Mar 30, 2025	DS DP		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272	003	6488963	Jun 24, 2017	DP	NPP	Aug 13, 2018
		7674799	Mar 30, 2025	DP		
		7674800	Mar 30, 2025	DS		
		7683072	Mar 30, 2025	DS		
		7776314	Apr 19, 2025	DP	Y	
		8114383	Oct 10, 2024	DP		
		8309060	Nov 20, 2023	DP U-1556		
		8808741	Aug 24, 2027	U-1556		
		8894987	Mar 29, 2030	DP		
		8894988	Aug 24, 2027	DP		
		9060976	Aug 06, 2022	DP		
		9073933	Mar 30, 2025	DS		
		9492389	Aug 24, 2027	DP		
		9492391	Aug 24, 2027	U-1556		
		9492392	Aug 24, 2027	DP		
		9492393	Aug 24, 2027	U-1556		
		9522919	Mar 30, 2025	DS DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	6488963	Jun 24, 2017	DP		NPP	Aug 13, 2018
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP	Y		
	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP	U-1556		
	8808741	Aug 24, 2027		U-1556		
	8894987	Mar 29, 2030	DP			
	8894988	Aug 24, 2027	DP			
	9060976	Aug 06, 2022	DP			
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027		U-1556		
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027		U-1556		
	9522919	Mar 30, 2025	DS DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	6488963	Jun 24, 2017	DP		NPP	Aug 13, 2018
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP	Y		
	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP	U-1556		
	8808741	Aug 24, 2027		U-1556		
	8894988	Aug 24, 2027	DP			
	9060976	Aug 06, 2022	DP			
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027		U-1556		
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027		U-1556		
	9522919	Mar 30, 2025	DS DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	6488963	Jun 24, 2017	DP		NPP	Aug 13, 2018
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP	Y		
	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP	U-1556		
	8808741	Aug 24, 2027		U-1556		
	8894988	Aug 24, 2027	DP			
	9060976	Aug 06, 2022	DP			
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027		U-1556		
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027		U-1556		
	9522919	Mar 30, 2025	DS DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	6488963	Jun 24, 2017	DP		NPP	Aug 13, 2018
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP	Y		
	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP	U-1556		
	8808741	Aug 24, 2027		U-1556		
	8894988	Aug 24, 2027	DP			
	9060976	Aug 06, 2022	DP			
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027		U-1556		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272	007	9492393				
		Aug 24, 2027			U-1556	
	9522919	Mar 30, 2025	DS DP			
<u>OXYCODONE HYDROCHLORIDE - OXAYDO</u>						
N 202080	001	7201920				
		Mar 16, 2025			DP	
	7510726	Nov 26, 2023			DP	
	7981439	Nov 26, 2023			DP	
	8409616	Nov 26, 2023			DP	
	8637540	Nov 26, 2023			DP	
	9492443	May 26, 2024	DS DP			
<u>OXYCODONE HYDROCHLORIDE - OXAYDO</u>						
N 202080	002	7201920				
		Mar 16, 2025			DP	
	7510726	Nov 26, 2023			DP	
	7981439	Nov 26, 2023			DP	
	8409616	Nov 26, 2023			DP	
	8637540	Nov 26, 2023			DP	
	9492443	May 26, 2024	DS DP			
<u>OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE - KOVANAZE</u>						
N 208032	001	6413499				
		Mar 20, 2020			U-1876	
	8580282	Apr 02, 2030			DP U-1876	
	9308191	Apr 02, 2030			DP U-1876	
						NC Jun 29, 2019
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610	001	7276250				
		Feb 04, 2023			DP U-826	
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610	002	7276250				
		Feb 04, 2023			DP U-826	
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610	003	7276250				
		Feb 04, 2023			DP U-826	
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610	004	7276250				
		Feb 04, 2023			DP U-826	
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610	005	7276250				
		Feb 04, 2023			DP U-826	
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610	006	7276250				
		Feb 04, 2023			DP U-826	
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610	007	7276250				
		Feb 04, 2023			DP U-826	
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655	001	7851482				
		Jul 10, 2029			DS	
	8075872	Nov 20, 2023			DP	
	8114383	Aug 08, 2024			DP	
	8192722	Sep 15, 2025			DP	
	8309060	Nov 20, 2023			DP	
	8309122	Feb 04, 2023			DP	
	8329216	Feb 04, 2023			DP	
	8808737	Jun 21, 2027			U-1598	
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655	002	7851482				
		Jul 10, 2029			DS	
	8075872	Nov 20, 2023			DP	
	8114383	Aug 08, 2024			DP	
	8192722	Sep 15, 2025			DP	
	8309060	Nov 20, 2023			DP	
	8309122	Feb 04, 2023			DP	
	8329216	Feb 04, 2023			DP	
	8808737	Jun 21, 2027			U-1598	
	8871779	Nov 22, 2029	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 003	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027		U-1598		
	8871779	Nov 22, 2029	DS			
	<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>					
N 201655 004	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027		U-1598		
	8871779	Nov 22, 2029	DS			
	<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>					
N 201655 005	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027		U-1598		
	8871779	Nov 22, 2029	DS			
	<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>					
N 201655 006	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027		U-1598		
	8871779	Nov 22, 2029	DS			
	<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>					
N 201655 007	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027		U-1598		
	8871779	Nov 22, 2029	DS			
	<u>PACLITAXEL - ABRAXANE</u>					
N 021660 001	7758891	Feb 21, 2026		U-1434	I-676	Sep 06, 2016
	7820788	Oct 27, 2024	DP	U-1092	ODE	Sep 06, 2020
	7820788	Oct 27, 2024	DP	U-1290		
	7820788	Oct 27, 2024	DP	U-1434		
	7923536	Dec 09, 2023		U-1117		
	7923536	Dec 09, 2023		U-1290		
	7923536	Dec 09, 2023		U-1434		
	8034375	Aug 13, 2026		U-1290		
	8138229	Dec 09, 2023	DP	U-1092		
	8138229	Dec 09, 2023	DP	U-1290		
	8138229	Dec 09, 2023	DP	U-1434		
	8268348	Feb 21, 2026		U-1290		
	8314156	Dec 09, 2023		U-1290		
	8314156	Dec 09, 2023		U-1434		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PACLITAXEL - ABRAXANE</u>						
N 021660	001	8853260	Oct 10, 2020	DP U-1092		
		8853260	Oct 10, 2020	DP U-1290		
		8853260	Oct 10, 2020	DP U-1434		
		9101543	Feb 21, 2026	U-1434		
		9393318	Aug 03, 2032	U-1290		
		9511046	Oct 17, 2033	U-1434		
		RE41884	Aug 14, 2016	U-1117		
		RE41884	Aug 14, 2016	U-1290		
		RE41884	Aug 14, 2016	U-1434		
<u>PALBOCICLIB - IBRANCE</u>						
N 207103	001	6936612	Jan 22, 2023	DS DP	I-725	Feb 19, 2019
		7208489	Jan 16, 2023	DS DP	NCE	Feb 03, 2020
		7456168	Jan 16, 2023	U-1658		
		7456168	Jan 16, 2023	U-1818		
<u>PALBOCICLIB - IBRANCE</u>						
N 207103	002	6936612	Jan 22, 2023	DS DP	I-725	Feb 19, 2019
		7208489	Jan 16, 2023	DS DP	NCE	Feb 03, 2020
		7456168	Jan 16, 2023	U-1658		
		7456168	Jan 16, 2023	U-1818		
<u>PALBOCICLIB - IBRANCE</u>						
N 207103	003	6936612	Jan 22, 2023	DS DP	I-725	Feb 19, 2019
		7208489	Jan 16, 2023	DS DP	NCE	Feb 03, 2020
		7456168	Jan 16, 2023	U-1658		
		7456168	Jan 16, 2023	U-1818		
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264	001	6077843	May 12, 2017	DP U-543	I-698	Nov 12, 2017
		6555544	Nov 10, 2018	DP U-543		
		9439906	Jan 26, 2031	U-543		
		9439906	Jan 26, 2031	U-1901		
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264	002	6077843	May 12, 2017	DP U-543	I-698	Nov 12, 2017
		6555544	Nov 10, 2018	DP U-543		
		9439906	Jan 26, 2031	U-543		
		9439906	Jan 26, 2031	U-1901		
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264	003	6077843	May 12, 2017	DP U-543	I-698	Nov 12, 2017
		6555544	Nov 10, 2018	DP U-543		
		9439906	Jan 26, 2031	U-543		
		9439906	Jan 26, 2031	U-1901		
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264	004	6077843	May 12, 2017	DP U-543	I-698	Nov 12, 2017
		6555544	Nov 10, 2018	DP U-543		
		9439906	Jan 26, 2031	U-543		
		9439906	Jan 26, 2031	U-1901		
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264	005	6077843	May 12, 2017	DP U-543	I-698	Nov 12, 2017
		6555544	Nov 10, 2018	DP U-543		
		9439906	Jan 26, 2031	U-543		
		9439906	Jan 26, 2031	U-1901		
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946	001	6077843	May 12, 2017	DP U-543	NP	May 18, 2018
		6077843*PED	Nov 12, 2017			
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946	002	6077843	May 12, 2017	DP U-543	NP	May 18, 2018
		6077843*PED	Nov 12, 2017			
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946	003	6077843	May 12, 2017	DP U-543	NP	May 18, 2018
		6077843*PED	Nov 12, 2017			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 004	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	7947724	Jan 30, 2024	DP		I-684	May 27, 2017
	7947724*PED	Jul 30, 2024			M-136	May 27, 2017
	7947725	Jan 30, 2024	DP		PED	Nov 27, 2017
	7947725*PED	Jul 30, 2024			PED	Nov 27, 2017
	7960424	Jan 30, 2024	DP			
	7960424*PED	Jul 30, 2024				
	8518981	Jan 30, 2024	DP			
	8518981*PED	Jul 30, 2024				
	8598218	Jan 30, 2024	DP			
	8598218*PED	Jul 30, 2024				
	8598219	Jan 30, 2024	DP			
	8598219*PED	Jul 30, 2024				
	8729094	Jan 30, 2024	DP U-528			
	8729094*PED	Jul 30, 2024				
	9066980	Jan 30, 2024	DP U-528			
	9066980*PED	Jul 30, 2024				
	9125905	Jan 30, 2024	DP			
	9125905*PED	Jul 30, 2024				
	9173942	Jan 30, 2024	DP			
	9173942*PED	Jul 30, 2024				
	9457020	Jan 30, 2024	DP			
	9457021	Jan 30, 2024	DP			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	7947724	Jan 30, 2024	DP		I-684	May 27, 2017
	7947724*PED	Jul 30, 2024			M-136	May 27, 2017
	7947725	Jan 30, 2024	DP		PED	Nov 27, 2017
	7947725*PED	Jul 30, 2024			PED	Nov 27, 2017
	7960424	Jan 30, 2024	DP			
	7960424*PED	Jul 30, 2024				
	8518981	Jan 30, 2024	DP			
	8518981*PED	Jul 30, 2024				
	8598218	Jan 30, 2024	DP			
	8598218*PED	Jul 30, 2024				
	8598219	Jan 30, 2024	DP			
	8598219*PED	Jul 30, 2024				
	9173942	Jan 30, 2024	DP			
	9173942*PED	Jul 30, 2024				
	9457020	Jan 30, 2024	DP			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PERTZYE</u>						
N 022175 001					NCE	May 17, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PERTZYE</u>						
N 022175 002					NCE	May 17, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 007	8221747	Feb 20, 2028	DP			
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP U-1274			
	8562980	Feb 20, 2028	DP U-1274			
	8562981	Feb 20, 2028	U-1274			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N 020725 001	9198871	Feb 07, 2030	DP U-1787			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N 020725 002	9198871	Feb 07, 2030	DP U-1787			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N 020725 003	9198871	Feb 07, 2030	DP U-1787			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N 020725 004	9198871	Feb 07, 2030	DP U-1787		M-93	Jul 29, 2019
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N 020725 005	9198871	Feb 07, 2030	DP U-1787		M-93	Jul 29, 2019
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 001	7658918	Feb 20, 2028	DP			
	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028		U-1274		
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP	U-1274		
	8562980	Feb 20, 2028	DP	U-1274		
	8562981	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 002	7658918	Feb 20, 2028	DP			
	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028		U-1274		
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP	U-1274		
	8562980	Feb 20, 2028	DP	U-1274		
	8562981	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 003	7658918	Feb 20, 2028	DP			
	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028		U-1274		
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP	U-1274		
	8562980	Feb 20, 2028	DP	U-1274		
	8562981	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 004	7658918	Feb 20, 2028	DP			
	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028		U-1274		
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP	U-1274		
	8562980	Feb 20, 2028	DP	U-1274		
	8562981	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 005	8221747	Feb 20, 2028	DP			
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP	U-1274		
	8562980	Feb 20, 2028	DP	U-1274		
	8562981	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 006	8221747	Feb 20, 2028	DP			
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP	U-1274		
	8562980	Feb 20, 2028	DP	U-1274		
	8562981	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N 022222 001					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N 022222 002					NCE	Mar 01, 2017

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N 022222	003				NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE</u>						
N 022542	001				NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE</u>						
N 022542	002				NCE	Mar 01, 2017
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353	001	6552065	Aug 31, 2021	DS DP	NCE	Feb 23, 2020
		6833384	Sep 30, 2021	DS DP U-1669	ODE	Feb 23, 2022
		7067551	Aug 31, 2021	U-1669		
		7989494	Jan 17, 2028	DS DP		
		8883842	Jun 13, 2028	U-1669		
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353	002	6552065	Aug 31, 2021	DS DP	NCE	Feb 23, 2020
		6833384	Sep 30, 2021	DS DP U-1669	ODE	Feb 23, 2022
		7067551	Aug 31, 2021	U-1669		
		7989494	Jan 17, 2028	DS DP		
		8883842	Jun 13, 2028	U-1669		
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353	003	6552065	Aug 31, 2021	DS DP	NCE	Feb 23, 2020
		6833384	Sep 30, 2021	DS DP U-1669	ODE	Feb 23, 2022
		7067551	Aug 31, 2021	U-1669		
		7989494	Jan 17, 2028	DS DP		
		8883842	Jun 13, 2028	U-1669		
<u>PANTOPRAZOLE SODIUM - PROTONIX</u>						
N 020987	001	5997903	Dec 07, 2016			
<u>PANTOPRAZOLE SODIUM - PROTONIX</u>						
N 020987	002	5997903	Dec 07, 2016			
<u>PANTOPRAZOLE SODIUM - PROTONIX IV</u>						
N 020988	001	6780881	Nov 17, 2021	DP		
		7351723	Nov 17, 2021	DP		
		8754108	Nov 17, 2021	DP		
		8754108*PED	May 17, 2022			
<u>PANTOPRAZOLE SODIUM - PROTONIX</u>						
N 022020	001	7544370	Jun 07, 2026	DP		
		7550153	Sep 30, 2024	U-859		
		7553498	Sep 30, 2024	U-859		
		7838027	Sep 30, 2024	DP U-859		
<u>PARICALCITOL - ZEMPLAR</u>						
N 020819	001	6136799	Apr 08, 2018			
		6361758	Apr 08, 2018	DP		
<u>PARICALCITOL - ZEMPLAR</u>						
N 020819	002	6136799	Apr 08, 2018			
		6361758	Apr 08, 2018	DP		
<u>PARICALCITOL - ZEMPLAR</u>						
N 020819	003	6136799	Apr 08, 2018			
		6136799*PED	Oct 08, 2018			
		6361758	Apr 08, 2018	DP		
		6361758*PED	Oct 08, 2018			
<u>PARICALCITOL - ZEMPLAR</u>						
N 021606	001				NPP	Oct 18, 2019
					NPP	Oct 18, 2019
					ODE	Oct 18, 2023

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PARICALCITOL - ZEMPLAR</u>						
N 021606	002				NPP	Oct 18, 2019
					NPP	Oct 18, 2019
					ODE	Oct 18, 2023
<u>PARICALCITOL - ZEMPLAR</u>						
N 021606	003				NPP	Oct 18, 2019
					NPP	Oct 18, 2019
					ODE	Oct 18, 2023
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020031	001	6121291	Mar 17, 2017	U-286		
		6121291	Mar 17, 2017	U-431		
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020031	002	6121291	Mar 17, 2017	U-286		
		6121291	Mar 17, 2017	U-431		
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020031	003	6121291	Mar 17, 2017	U-286		
		6121291	Mar 17, 2017	U-431		
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020031	004	6121291	Mar 17, 2017	U-286		
		6121291	Mar 17, 2017	U-431		
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020031	005	6121291	Mar 17, 2017	U-286		
		6121291	Mar 17, 2017	U-431		
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020710	001	6121291	Mar 17, 2017	U-286		
		6121291	Mar 17, 2017	U-431		
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020885	001	6063927	Apr 23, 2019			
		6121291	Mar 17, 2017	U-286		
		6121291	Mar 17, 2017	U-431		
		6172233	Jan 15, 2018			
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020885	002	6063927	Apr 23, 2019			
		6121291	Mar 17, 2017	U-286		
		6121291	Mar 17, 2017	U-431		
		6172233	Jan 15, 2018			
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020885	003	6063927	Apr 23, 2019			
		6121291	Mar 17, 2017	U-286		
		6121291	Mar 17, 2017	U-431		
		6172233	Jan 15, 2018			
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020885	004	6063927	Apr 23, 2019			
		6121291	Mar 17, 2017	U-286		
		6121291	Mar 17, 2017	U-431		
		6172233	Jan 15, 2018			
<u>PAROXETINE HYDROCHLORIDE - PAXIL CR</u>						
N 020936	001	6121291	Mar 17, 2017	U-286		
		6548084	Jul 19, 2016			
		7229640	Jul 19, 2016	DP U-816		
<u>PAROXETINE HYDROCHLORIDE - PAXIL CR</u>						
N 020936	002	6121291	Mar 17, 2017	U-286		
		6548084	Jul 19, 2016			
		7229640	Jul 19, 2016	DP U-816		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PAROXETINE HYDROCHLORIDE - PAXIL CR</u>						
N 020936	003	6121291	Mar 17, 2017	U-286		
		6548084	Jul 19, 2016			
		7229640	Jul 19, 2016	DP U-816		
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299	001	5874447	Jun 10, 2017	U-46		
		5874447	Jun 10, 2017	U-286		
		5874447	Jun 10, 2017	U-518		
		7598271	May 04, 2025	DS		
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299	002	5874447	Jun 10, 2017	U-46		
		5874447	Jun 10, 2017	U-286		
		5874447	Jun 10, 2017	U-518		
		7598271	May 04, 2025	DS		
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299	003	5874447	Jun 10, 2017	U-46		
		5874447	Jun 10, 2017	U-286		
		5874447	Jun 10, 2017	U-518		
		7598271	May 04, 2025	DS		
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299	004	5874447	Jun 10, 2017	U-46		
		5874447	Jun 10, 2017	U-286		
		5874447	Jun 10, 2017	U-518		
		7598271	May 04, 2025	DS		
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516	001	5874447	Jun 10, 2017	DS		
		7598271	May 04, 2025	DS		
		8658663	Apr 06, 2029	DS DP U-904		
		8946251	Aug 04, 2026	DS DP U-904		
		9393237	Aug 04, 2026	U-904		
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N 200677	001	7473761	Jul 29, 2025	DS DP	NCE	Dec 14, 2017
		8299209	Dec 27, 2025	DS DP	ODE	Dec 14, 2019
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N 200677	002	7473761	Jul 29, 2025	DS DP	NCE	Dec 14, 2017
		8299209	Dec 27, 2025	DS DP	ODE	Dec 14, 2019
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N 200677	003	7473761	Jul 29, 2025	DS DP	NCE	Dec 14, 2017
		8299209	Dec 27, 2025	DS DP	ODE	Dec 14, 2019
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR</u>						
N 203255	001	7473761	Jul 29, 2025	DS DP	NCE	Dec 14, 2017
		7759308	Oct 25, 2026	DP	NP	Dec 15, 2017
		8822637	Aug 06, 2023	U-1629	ODE	Dec 15, 2021
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR</u>						
N 203255	002	7473761	Jul 29, 2025	DS DP	NCE	Dec 14, 2017
		7759308	Oct 25, 2026	DP	NP	Dec 15, 2017
		8822637	Aug 06, 2023	U-1629	ODE	Dec 15, 2021
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR</u>						
N 203255	003	7473761	Jul 29, 2025	DS DP	NCE	Dec 14, 2017
		7759308	Oct 25, 2026	DP	NP	Dec 15, 2017
		8822637	Aug 06, 2023	U-1629	ODE	Dec 15, 2021
<u>PATIROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739	001	7556799	Feb 27, 2025	U-1766	NCE	Oct 21, 2020
		8147873	Mar 11, 2026	DP		
		8216560	Mar 14, 2027	U-1766		
		8282913	Mar 11, 2026	DP		
		8287847	Mar 30, 2024	U-1766		
		8337824	May 29, 2030	DS U-1766		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PATSIROMER SORBITE X CALCIUM - VELTASSA</u>						
N 205739	001	8475780	Mar 30, 2024	U-1766		
		8778324	Mar 30, 2024	U-1766		
		8889115	Mar 30, 2024	U-1766		
		9492476	Oct 08, 2033	U-1766		
<u>PATSIROMER SORBITE X CALCIUM - VELTASSA</u>						
N 205739	002	7556799	Feb 27, 2025	U-1766	NCE	Oct 21, 2020
		8147873	Mar 11, 2026	DP		
		8216560	Mar 14, 2027	U-1766		
		8282913	Mar 11, 2026	DP		
		8287847	Mar 30, 2024	U-1766		
		8337824	May 29, 2030	DS	U-1766	
		8475780	Mar 30, 2024	U-1766		
		8778324	Mar 30, 2024	U-1766		
		8889115	Mar 30, 2024	U-1766		
		9492476	Oct 08, 2033	U-1766		
<u>PATSIROMER SORBITE X CALCIUM - VELTASSA</u>						
N 205739	003	7556799	Feb 27, 2025	U-1766	NCE	Oct 21, 2020
		8147873	Mar 11, 2026	DP		
		8216560	Mar 14, 2027	U-1766		
		8282913	Mar 11, 2026	DP		
		8287847	Mar 30, 2024	U-1766		
		8337824	May 29, 2030	DS	U-1766	
		8475780	Mar 30, 2024	U-1766		
		8778324	Mar 30, 2024	U-1766		
		8889115	Mar 30, 2024	U-1766		
		9492476	Oct 08, 2033	U-1766		
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N 022465	001	7105530	Oct 19, 2023	DS DP	ODE	Apr 26, 2019
		7262203	Dec 19, 2021	DS DP		
		8114885	Dec 19, 2021	DS DP		
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N 022465	002	7105530	Oct 19, 2023	DS DP	ODE	Apr 26, 2019
		7262203	Dec 19, 2021	DS DP		
		8114885	Dec 19, 2021	DS DP		
<u>PEGAPTANIB SODIUM - MACUGEN</u>						
N 021756	001	5932462	Aug 03, 2016	DS		
		6011020	Jan 04, 2017	DS		
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799	001	7084245	May 12, 2024	DS DP	U-1238	NCE
		7414105	May 12, 2024	DS DP	U-1238	
		7528104	May 12, 2024	DS DP		
		7550433	Jun 02, 2026		U-1238	
		7919118	May 12, 2024	DS DP		
		7919461	Jun 02, 2026		U-1238	
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799	002	7084245	May 12, 2024	DS DP	U-1238	NCE
		7414105	May 12, 2024	DS DP	U-1238	
		7528104	May 12, 2024	DS DP		
		7550433	Jun 02, 2026		U-1238	
		7919118	May 12, 2024	DS DP		
		7919461	Jun 02, 2026		U-1238	
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799	003	7084245	May 12, 2024	DS DP	U-1238	NCE
		7414105	May 12, 2024	DS DP	U-1238	
		7528104	May 12, 2024	DS DP		
		7550433	Jun 02, 2026		U-1238	
		7919118	May 12, 2024	DS DP		
		7919461	Jun 02, 2026		U-1238	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799 004	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026		U-1238		
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026		U-1238		
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799 005	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026		U-1238		
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026		U-1238		
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799 006	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026		U-1238		
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026		U-1238		
<u>PEGINESATIDE ACETATE - OMONTYS</u>						
N 202799 007	7084245	May 12, 2024	DS DP U-1238			
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026		U-1238		
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026		U-1238		
<u>PEGINESATIDE ACETATE - OMONTYS</u>						
N 202799 008	7084245	May 12, 2024	DS DP U-1238			
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026		U-1238		
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026		U-1238		
<u>PEGVISOMANT - SOMAVERT</u>						
N 021106 001	5849535	Mar 25, 2017	DS			
<u>PEGVISOMANT - SOMAVERT</u>						
N 021106 002	5849535	Mar 25, 2017	DS			
<u>PEGVISOMANT - SOMAVERT</u>						
N 021106 003	5849535	Mar 25, 2017	DS			
<u>PEGVISOMANT - SOMAVERT</u>						
N 021106 004	5849535	Mar 25, 2017	DS			
<u>PEGVISOMANT - SOMAVERT</u>						
N 021106 005	5849535	Mar 25, 2017	DS			
<u>PEMETREXED DISODIUM - ALIMTA</u>						
N 021462 001	5344932	Jul 24, 2016	DS DP			
	7772209	Nov 24, 2021		U-1077		
	7772209	Nov 24, 2021		U-1296		
<u>PEMETREXED DISODIUM - ALIMTA</u>						
N 021462 002	5344932	Jul 24, 2016	DS DP			
	7772209	Nov 24, 2021		U-1296		
<u>PENCICLOVIR - DENAVIR</u>						
N 020629 001	6469015	Oct 22, 2019		U-501		
	6579981	Jun 17, 2020		U-501		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PERAMIVIR - RAPIVAB</u>						
N 206426	001	6503745	Nov 05, 2019	DS		Dec 19, 2019
		6562861	Dec 17, 2018	DS		
		8778997	May 07, 2027		U-1627	
<u>PERAMPANEL - FYCOMPA</u>						
N 202834	001	6949571	Jun 08, 2021	DS DP U-106	I-710	Jun 19, 2018
		8772497	May 16, 2026	DS	NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N 202834	002	6949571	Jun 08, 2021	DS DP U-106	I-710	Jun 19, 2018
		8772497	May 16, 2026	DS	NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N 202834	003	6949571	Jun 08, 2021	DS DP U-106	I-710	Jun 19, 2018
		8772497	May 16, 2026	DS	NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N 202834	004	6949571	Jun 08, 2021	DS DP U-106	I-710	Jun 19, 2018
		8772497	May 16, 2026	DS	NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N 202834	005	6949571	Jun 08, 2021	DS DP U-106	I-710	Jun 19, 2018
		8772497	May 16, 2026	DS	NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N 202834	006	6949571	Jun 08, 2021	DS DP U-106	I-710	Jun 19, 2018
		8772497	May 16, 2026	DS	NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N 208277	001	6949571	Jun 08, 2021	DS DP U-106	NCE	Oct 22, 2017
		8772497	May 16, 2026	DS		
<u>PERFLUTREN - DEFINITY</u>						
N 021064	001	8658205	Jun 18, 2019	DP		
		8685441	Jan 13, 2019		U-665	
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088	001	6149938	Jul 23, 2018	DP		
		8440170	Mar 14, 2029	DP		
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088	002	6149938	Jul 23, 2018	DP		
		8440170	Mar 14, 2029	DP		
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088	003	6149938	Jul 23, 2018	DP U-1243		
		8440170	Mar 14, 2029	DP		
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMIA</u>						
N 022580	001	6071537	Jun 23, 2017		U-1262	
		7056890	Jun 14, 2020	DP	U-1262	
		7553818	Jun 14, 2020		U-1262	
		7659256	Jun 14, 2020	DP	U-1262	
		7674776	Jun 14, 2020	DP	U-1262	
		8580298	May 15, 2029	DP		
		8580299	Jun 14, 2029		U-1262	
		8895057	Jun 09, 2028		U-1262	
		8895058	Jun 09, 2028	DP		
		9011905	Jun 09, 2028	DP		
		9011906	Jun 09, 2028		U-1262	
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMIA</u>						
N 022580	002	6071537	Jun 23, 2017		U-1262	
		7056890	Jun 14, 2020	DP	U-1262	
		7553818	Jun 14, 2020		U-1262	
		7659256	Jun 14, 2020	DP	U-1262	
		7674776	Jun 14, 2020	DP	U-1262	
		8580298	May 15, 2029	DP		
		8580299	Jun 14, 2029		U-1262	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580	002	8895058	Jun 09, 2028	DP		
		9011905	Jun 09, 2028	DP		
		9011906	Jun 09, 2028		U-1262	
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580	003	6071537	Jun 23, 2017		U-1262	
		7056890	Jun 14, 2020	DP	U-1262	
		7553818	Jun 14, 2020		U-1262	
		7659256	Jun 14, 2020	DP	U-1262	
		7674776	Jun 14, 2020	DP	U-1262	
		8580298	May 15, 2029	DP		
		8580299	Jun 14, 2029		U-1262	
		8895057	Jun 09, 2028		U-1262	
		8895058	Jun 09, 2028	DP		
		9011905	Jun 09, 2028	DP		
		9011906	Jun 09, 2028		U-1262	
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580	004	6071537	Jun 23, 2017		U-1262	
		7056890	Jun 14, 2020	DP	U-1262	
		7553818	Jun 14, 2020		U-1262	
		7659256	Jun 14, 2020	DP	U-1262	
		7674776	Jun 14, 2020	DP	U-1262	
		8580298	May 15, 2029	DP		
		8580299	Jun 14, 2029		U-1262	
		8895057	Jun 09, 2028		U-1262	
		8895058	Jun 09, 2028	DP		
		9011905	Jun 09, 2028	DP		
		9011906	Jun 09, 2028		U-1262	
<u>PHENTOLAMINE MESYLATE - ORAVERSE</u>						
N 022159	001	6764678	May 11, 2021		U-967	
		6872390	May 11, 2021	DP		
		7229630	Jun 20, 2023	DP		
		7569230	Oct 17, 2023		U-967	
		7575757	Apr 21, 2025	DP		
<u>PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE</u>						
N 203510	001	8859623	Nov 14, 2033		U-1594	
<u>PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE</u>						
N 203510	002	8859623	Nov 14, 2033		U-1594	
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318	001	6756393	Mar 06, 2021	DS DP		
		6815458	Mar 06, 2021	DS DP	U-1843	
		7115634	Oct 06, 2021	DS DP		
		7601740	Jun 17, 2027	DS DP		
		7659285	Aug 24, 2026		U-1844	
		7732615	Jun 03, 2028	DS DP		
		7858789	Dec 13, 2020	DS DP		
		7923564	Sep 26, 2025	DS DP		
		8110574	Dec 13, 2020	DS DP		
		8618130	Jan 15, 2024		U-1845	
		8921393	Jan 15, 2024		U-1846	
		9296694	Mar 06, 2021	DS DP		
<u>PIMECROLIMUS - ELIDEL</u>						
N 021302	001	6423722	Jun 26, 2018			
<u>PIOGLITAZONE HYDROCHLORIDE - ACTOS</u>						
N 021073	001	6303640	Aug 09, 2016		U-425	
<u>PIOGLITAZONE HYDROCHLORIDE - ACTOS</u>						
N 021073	002	6303640	Aug 09, 2016		U-425	
<u>PIOGLITAZONE HYDROCHLORIDE - ACTOS</u>						
N 021073	003	6303640	Aug 09, 2016		U-425	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N 050684 001	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N 050684 002	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N 050684 003	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N 050684 004	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N 050750 001	6207661	Feb 22, 2019	DP			
	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N 050750 002	6207661	Feb 22, 2019	DP			
	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N 050750 003	6207661	Feb 22, 2019	DP			
	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
<u>PIRFENIDONE - ESBRIET</u>						
N 022535 001	7566729	Apr 22, 2029	U-1600		NCE	Oct 16, 2019
	7635707	Apr 22, 2029	U-1609		ODE	Oct 15, 2021
	7696236	Dec 18, 2027	U-1601			
	7767225	Sep 22, 2026	DP U-1602			
	7767700	Dec 18, 2027	U-1601			
	7816383	Jan 08, 2030	U-1603			
	7910610	Jan 08, 2030	U-1604			
	7988994	Sep 22, 2026	DP U-1602			
	8013002	Jan 08, 2030	U-1603			
	8084475	Jan 08, 2030	U-1605			
	8318780	Jan 08, 2030	U-1606			
	8383150	Sep 22, 2026	DP U-1607			
	8420674	Dec 18, 2027	DP U-1608			
	8592462	Apr 22, 2029	U-1609			
	8609701	Apr 22, 2029	U-1610			
	8648098	Jan 08, 2030	U-1611			
	8753679	Sep 22, 2026	DP U-1602			
	8754109	Jan 08, 2030	U-1612			
	8778947	Aug 30, 2033	U-1613			
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 001	5856336	Dec 25, 2020	DS U-998			
	6465477	Dec 20, 2016	DP			
	7022713	Feb 19, 2024	U-998			
	8557993	Feb 02, 2024	DP			
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 002	5856336	Dec 25, 2020	DS U-998			
	6465477	Dec 20, 2016	DP			
	7022713	Feb 19, 2024	U-998			
	8557993	Feb 02, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 002	5856336	Dec 25, 2020	DS U-998			
	6465477	Dec 20, 2016	DP			
	7022713	Feb 19, 2024	U-998			
	8557993	Feb 02, 2024	DP			
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 003	5856336	Dec 25, 2020	DS U-998			
	6465477	Dec 20, 2016	DP			
	7022713	Feb 19, 2024	U-998			
	8557993	Feb 02, 2024	DS DP			
<u>PLERIXAFOR - MOZOBIL</u>						
N 022311 001	6987102	Jul 22, 2023	U-936			
	7897590	Jul 22, 2023	U-936			
	RE42152	Dec 10, 2018	DP			
<u>POLIDOCANOL - VARITHENA</u>						
N 205098 001	6572873	May 26, 2020	U-1461			
	6846412	Jul 19, 2022	DP			
	6942165	May 26, 2020	DP			
	7025290	May 26, 2020	DP U-1461			
	7357336	May 26, 2020	U-1461			
	7604185	May 26, 2020	DS DP U-1462			
	7731986	Nov 17, 2024	DS DP U-1463			
	7814943	Nov 19, 2027	DP U-1461			
	7842282	May 26, 2020	U-1461			
	7842283	May 26, 2020	DP			
	8122917	Sep 09, 2024	DP			
	8323677	May 26, 2020	DS			
	8734833	May 26, 2020	DS DP			
	9480652	May 12, 2032	DP			
	RE40640	Oct 14, 2016	DS DP U-1462			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001	5635517	Jul 24, 2016	U-1359		I-707	Apr 23, 2018
	6045501	Aug 28, 2018	U-1361		NCE	Feb 08, 2018
	6315720	Oct 23, 2020	U-1361		ODE	Feb 08, 2020
	6316471	Aug 10, 2016	DP U-1360			
	6476052	Jul 24, 2016	DP U-1360			
	6561976	Aug 28, 2018	U-1361			
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
	8589188	Aug 28, 2018	U-1361			
	8626531	Oct 23, 2020	U-1361			
	8673939	May 15, 2023	U-1360			
	8735428	May 15, 2023	U-1360			
	8828427	Jun 21, 2031	DS DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002	5635517	Jul 24, 2016	U-1359		I-707	Apr 23, 2018
	6045501	Aug 28, 2018	U-1361		NCE	Feb 08, 2018
	6315720	Oct 23, 2020	U-1361		ODE	Feb 08, 2020
	6316471	Aug 10, 2016	DP U-1360			
	6476052	Jul 24, 2016	DP U-1360			
	6561976	Aug 28, 2018	U-1361			
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
	8589188	Aug 28, 2018	U-1361			
	8626531	Oct 23, 2020	U-1361			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002	8673939	May 15, 2023	U-1360			
	8735428	May 15, 2023	U-1360			
	8828427	Jun 21, 2031	DS DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003	5635517	Jul 24, 2016	U-1359		I-707	Apr 23, 2018
	6045501	Aug 28, 2018	U-1361		NCE	Feb 08, 2018
	6315720	Oct 23, 2020	U-1361		ODE	Feb 08, 2020
	6316471	Aug 10, 2016	DP U-1360			
	6476052	Jul 24, 2016	DP U-1360			
	6561976	Aug 28, 2018	U-1361			
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
	8589188	Aug 28, 2018	U-1361			
	8626531	Oct 23, 2020	U-1361			
	8673939	May 15, 2023	U-1360			
	8735428	May 15, 2023	U-1360			
	8828427	Jun 21, 2031	DS DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004	5635517	Jul 24, 2016	U-1359		I-707	Apr 23, 2018
	6045501	Aug 28, 2018	U-1361		NCE	Feb 08, 2018
	6315720	Oct 23, 2020	U-1361		ODE	Feb 08, 2020
	6316471	Aug 10, 2016	DP U-1360			
	6476052	Jul 24, 2016	DP U-1360			
	6561976	Aug 28, 2018	U-1361			
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
	8589188	Aug 28, 2018	U-1361			
	8626531	Oct 23, 2020	U-1361			
	8673939	May 15, 2023	U-1360			
	8735428	May 15, 2023	U-1360			
	8828427	Jun 21, 2031	DS DP			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001	8114874	Dec 22, 2026	DS DP		NCE	Dec 14, 2017
	9029533	Dec 22, 2026	U-836		ODE	Dec 14, 2019
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
	9493470	Dec 12, 2033	DS DP U-1700			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002	8114874	Dec 22, 2026	DS DP		NCE	Dec 14, 2017
	9029533	Dec 22, 2026	U-836		ODE	Dec 14, 2019
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
	9493470	Dec 12, 2033	DS DP U-1700			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003	9029533	Dec 22, 2026	U-836		NCE	Dec 14, 2017
	9029533	Dec 22, 2026	U-1283		ODE	Dec 14, 2019
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
	9493470	Dec 12, 2033	DS DP U-1700			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469	003	9029533	Dec 22, 2026	U-836	NCE	Dec 14, 2017
		9029533	Dec 22, 2026	U-1283	ODE	Dec 14, 2019
		9029533	Dec 22, 2026	U-1699		
		9029533	Dec 22, 2026	U-1700		
		9029533	Dec 22, 2026	U-1701		
		9493470	Dec 12, 2033	DS DP U-1700		
<u>POSACONAZOLE - NOXAFIL</u>						
N 022003	001	5661151	Jul 19, 2019	DS DP U-760		
		6958337	Oct 05, 2018	DS DP U-760		
		8263600	Apr 01, 2022	DP		
<u>POSACONAZOLE - NOXAFIL</u>						
N 205053	001	5661151	Jul 19, 2019	DS DP U-1454		
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596	001	5661151	Jul 19, 2019	DS DP U-1454		
		8410077	Mar 13, 2029	DP		
		9023790	Jul 04, 2031	DP U-1698		
		9358297	Jun 24, 2031	DP U-1454		
		9493582	Feb 27, 2033	DP		
<u>PRALATREXATE - FOLOTYN</u>						
N 022468	001	6028071	Jul 16, 2022	DS DP U-1004	ODE	Sep 24, 2016
		7622470	May 31, 2025	U-1015		
		8299078	May 31, 2025	U-1004		
<u>PRALATREXATE - FOLOTYN</u>						
N 022468	002	6028071	Jul 16, 2022	DS DP U-1004	ODE	Sep 24, 2016
		7622470	May 31, 2025	U-1015		
		8299078	May 31, 2025	U-1004		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE</u>						
A 202206	006				PC	Jan 01, 2017
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N 020667	001	6001861	Jan 16, 2018	U-784		
		6194445	Jan 16, 2018	U-784		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N 020667	002	6001861	Jan 16, 2018	U-784		
		6194445	Jan 16, 2018	U-784		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N 020667	003	6001861	Jan 16, 2018	U-784		
		6194445	Jan 16, 2018	U-784		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N 020667	005	6001861	Jan 16, 2018	U-784		
		6194445	Jan 16, 2018	U-784		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N 020667	006	6001861	Jan 16, 2018	U-784		
		6194445	Jan 16, 2018	U-784		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N 020667	007	6001861	Jan 16, 2018	U-784		
		6194445	Jan 16, 2018	U-784		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421	001	7695734	Apr 26, 2028	DP		
		8679533	Sep 08, 2029	DP U-219		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421	002	7695734	Apr 26, 2028	DP		
		8679533	Sep 08, 2029	DP U-219		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421	003	7695734	Apr 26, 2028	DP		
		8679533	Sep 08, 2029	DP U-219		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421	004	7695734	Apr 26, 2028	DP		
		8679533	Sep 08, 2029	DP U-219		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421	005	7695734	Apr 26, 2028	DP		
		8679533	Sep 08, 2029	DP U-219		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421	006	7695734	Apr 26, 2028	DP		
		8679533	Sep 08, 2029	DP U-219		
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421	007	7695734	Apr 26, 2028	DP		
		8679533	Sep 08, 2029	DP U-219		
<u>PRAMLINTIDE ACETATE - SYMLIN</u>						
N 021332	001	5686411	Mar 16, 2019	DS DP	U-638	
		6114304	Sep 05, 2017		U-640	
<u>PRAMLINTIDE ACETATE - SYMLIN</u>						
N 021332	002	5686411	Mar 16, 2019	DS DP	U-638	
		6114304	Sep 05, 2017		U-637	
		6114304	Sep 05, 2017		U-640	
<u>PRAMLINTIDE ACETATE - SYMLIN</u>						
N 021332	003	5686411	Mar 16, 2019	DS DP	U-638	
		6114304	Sep 05, 2017		U-637	
		6114304	Sep 05, 2017		U-640	
<u>PRASTERONE - INTRAROSA</u>						
N 208470	001	8268806	Mar 19, 2031	DP	NCE	Nov 16, 2021
		8629129	Aug 07, 2028	DP		
		8957054	Aug 07, 2028	U-1922		
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307	001	5288726	Apr 14, 2017	DS DP	U-991	M-182
		5288726*PED	Oct 14, 2017			PED
		8404703	Jan 02, 2023		U-1381	
		8404703*PED	Jul 02, 2023			
		8569325	Jan 02, 2023		U-1381	
		8569325*PED	Jul 02, 2023			
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307	002	5288726	Apr 14, 2017	DS DP	U-991	M-182
		5288726*PED	Oct 14, 2017			PED
		8404703	Jan 02, 2023		U-1381	
		8404703*PED	Jul 02, 2023			
		8569325	Jan 02, 2023		U-1381	
		8569325*PED	Jul 02, 2023			
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N 022067	001	6071523	Jun 03, 2018	DP		
		6399079	Jun 03, 2018	DP		
		6656482	Jun 03, 2018	DP		
		7799331	Oct 11, 2028	DP	U-139	
		7799331	Oct 11, 2028	DP	U-1068	
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N 022067	002	6071523	Jun 03, 2018	DP		
		6399079	Jun 03, 2018	DP		
		6656482	Jun 03, 2018	DP		
		7799331	Oct 11, 2028	DP	U-139	
		7799331	Oct 11, 2028	DP	U-1068	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT</u>						
N 021959 001	6740341	Nov 24, 2019	DP			
<u>PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT</u>						
N 021959 002	6740341	Nov 24, 2019	DP			
<u>PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT</u>						
N 021959 003	6740341	Nov 24, 2019	DP			
<u>PREDNISONE - RAYOS</u>						
N 202020 001	6488960	Mar 14, 2020	DP U-1267			
	6677326	Mar 14, 2020	DP U-1268			
	8309124	Apr 23, 2024	U-1292			
	8394407	Apr 23, 2024	DP U-1362			
	9040085	Apr 23, 2024	U-1362			
	9186332	Apr 23, 2024	U-1362			
	9504699	Aug 03, 2027	U-1362			
<u>PREDNISONE - RAYOS</u>						
N 202020 002	6488960	Mar 14, 2020	DP U-1267			
	6677326	Mar 14, 2020	DP U-1268			
	8309124	Apr 23, 2024				
	8394407	Apr 23, 2024	DP U-1362			
	9040085	Apr 23, 2024	U-1362			
	9186332	Apr 23, 2024	U-1362			
	9504699	Aug 03, 2027	U-1362			
<u>PREDNISONE - RAYOS</u>						
N 202020 003	8168218	Jan 07, 2028	DP U-1269			
	8309124	Apr 23, 2024	U-1292			
	8394407	Apr 23, 2024	DP U-1362			
	9040085	Apr 23, 2024	U-1362			
	9186332	Apr 23, 2024	U-1362			
	9504699	Aug 03, 2027	U-1362			
<u>PREGABALIN - LYRICA</u>						
N 021446 001	6001876	Dec 30, 2018	U-55	Y	M-193	Dec 22, 2019
	6001876	Dec 30, 2018	U-819	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N 021446 002	6001876	Dec 30, 2018	U-55	Y	M-193	Dec 22, 2019
	6001876	Dec 30, 2018	U-819	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N 021446 003	6001876	Dec 30, 2018	U-55	Y	M-193	Dec 22, 2019
	6001876	Dec 30, 2018	U-819	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N 021446 004	6001876	Dec 30, 2018	U-55	Y	M-193	Dec 22, 2019
	6001876	Dec 30, 2018	U-819	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N 021446 005	6001876	Dec 30, 2018	U-55	Y	M-193	Dec 22, 2019
	6001876	Dec 30, 2018	U-819	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N 021446 006	6001876	Dec 30, 2018	U-55	Y	M-193	Dec 22, 2019
	6001876	Dec 30, 2018	U-819	Y		
	6197819	Dec 30, 2018	DS DP			
	RE41920	Dec 30, 2018	U-1250			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PREGABALIN - LYRICA</u>						
N 021446	007	6001876	Dec 30, 2018	U-55	Y	M-193
		6001876	Dec 30, 2018	U-819	Y	Dec 22, 2019
		6197819	Dec 30, 2018	DS DP		
		RE41920	Dec 30, 2018	U-1250		
<u>PREGABALIN - LYRICA</u>						
N 021446	008	6001876	Dec 30, 2018	U-55	Y	M-193
		6001876	Dec 30, 2018	U-819	Y	Dec 22, 2019
		6197819	Dec 30, 2018	DS DP		
		RE41920	Dec 30, 2018	U-1250		
<u>PREGABALIN - LYRICA</u>						
N 022488	001	6001876	Dec 30, 2018	U-55	Y	M-193
		6001876	Dec 30, 2018	U-819	Y	Dec 22, 2019
		6197819	Dec 30, 2018	DS DP		
		RE41920	Dec 30, 2018	U-1250		
<u>PROGESTERONE - ENDOMETRIN</u>						
N 022057	001	7300664	Nov 17, 2019	U-856		
		7320800	Nov 17, 2019	U-856		
		7393543	Nov 17, 2019	DP U-880		
<u>PROPOFOL - DIPRIVAN</u>						
N 019627	002	8476010	Dec 01, 2024	DS DP		
		8476010*PED	Jun 01, 2025			
<u>PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL</u>						
N 021438	001	6500454	Oct 04, 2021	DP		
<u>PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL</u>						
N 021438	002	6500454	Oct 04, 2021	DP		
<u>PROPRANOLOL HYDROCHLORIDE - HEMANGEOL</u>						
N 205410	001	8338489	Oct 16, 2028	U-1496	NP ODE	Mar 14, 2017 Mar 14, 2021
<u>QUAZEPAM - DORAL</u>						
N 018708	001	7608616	Jun 03, 2028	U-1012		
<u>QUAZEPAM - DORAL</u>						
N 018708	003	7608616	Jun 03, 2028	U-1012		
<u>QUETIAPINE FUMARATE - QUETIAPINE FUMARATE</u>						
A 090681	004				PC	Apr 30, 2017
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
N 022047	001	5948437	May 28, 2017	DP U-601		
		5948437	May 28, 2017	DP U-814		
		5948437	May 28, 2017	DP U-839		
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
N 022047	002	5948437	May 28, 2017	DP U-601		
		5948437	May 28, 2017	DP U-814		
		5948437	May 28, 2017	DP U-839		
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
N 022047	003	5948437	May 28, 2017	DP U-601		
		5948437	May 28, 2017	DP U-814		
		5948437	May 28, 2017	DP U-839		
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
N 022047	004	5948437	May 28, 2017	DP U-601		
		5948437	May 28, 2017	DP U-814		
		5948437	May 28, 2017	DP U-839		
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
N 022047	005	5948437	May 28, 2017	DP U-601		
		5948437	May 28, 2017	DP U-814		
		5948437	May 28, 2017	DP U-839		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RABEPRAZOLE SODIUM - ACIPHEX SPRINKLE</u>						
N 204736	001				PED	Sep 26, 2016
<u>RABEPRAZOLE SODIUM - ACIPHEX SPRINKLE</u>						
N 204736	002				PED	Sep 26, 2016
<u>RADIUM RA-223 DICHLORIDE - XOFIGO</u>						
N 203971	001	6635234	Jan 03, 2020	U-1405	NCE	May 15, 2018
<u>RALOXIFENE HYDROCHLORIDE - EVISTA</u>						
N 020815	001	6458811	Mar 10, 2017	DS DP U-825		
		6797719	Mar 10, 2017	DP		
		6894064	Mar 10, 2017	DP U-657		
		8030330	Mar 10, 2017	DP		
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 022145	001	7169780	Oct 03, 2023	DS DP		
		7217713	Oct 21, 2022		U-257	
		7435734	Oct 21, 2022		U-257	
		7435734	Oct 21, 2022		U-900	
		7754731	Mar 11, 2029	DS DP	U-257	
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 203045	001	7169780	Oct 03, 2023	DS DP		
		7217713	Oct 21, 2022		U-257	
		7435734	Oct 21, 2022		U-257	
		7754731	Mar 11, 2029	DS DP	U-257	
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 203045	002	7169780	Oct 03, 2023	DS DP		
		7217713	Oct 21, 2022		U-257	
		7435734	Oct 21, 2022		U-257	
		7754731	Mar 11, 2029	DS DP	U-257	
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 205786	001	7169780	Oct 03, 2023	DS DP	NDF	Dec 20, 2016
		7217713	Oct 21, 2022		U-257	
		7435734	Oct 21, 2022		U-257	
		7754731	Mar 11, 2029	DS DP	U-257	
<u>RAMELTEON - ROZEREM</u>						
N 021782	001	6034239	Jul 22, 2019	DS DP	U-674	
<u>RAMIPRIL - ALTACE</u>						
N 019901	001	7368469	Aug 30, 2020		U-871	
<u>RAMIPRIL - ALTACE</u>						
N 019901	002	7368469	Aug 30, 2020		U-871	
<u>RAMIPRIL - ALTACE</u>						
N 019901	003	7368469	Aug 30, 2020		U-871	
<u>RAMIPRIL - ALTACE</u>						
N 019901	004	7368469	Aug 30, 2020		U-871	
<u>RAMIPRIL - ALTACE</u>						
N 022021	001	7368469	Aug 30, 2020		U-871	
<u>RAMIPRIL - ALTACE</u>						
N 022021	002	7368469	Aug 30, 2020		U-871	
<u>RAMIPRIL - ALTACE</u>						
N 022021	003	7368469	Aug 30, 2020		U-871	
<u>RAMIPRIL - ALTACE</u>						
N 022021	004	7368469	Aug 30, 2020		U-871	
<u>RANOLAZINE - RANEXA</u>						
N 021526	001	6303607	May 27, 2019	U-705		
		6369062	May 27, 2019	DP		
		6479496	May 27, 2019	U-705	Y	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RANOLAZINE - RANEXA</u>						
N 021526 001	6503911	May 27, 2019	DP			
	6525057	May 27, 2019	U-705			
	6562826	May 27, 2019	U-705			
	6617328	May 27, 2019	DP			
	6620814	May 27, 2019	U-705			
	6852724	May 27, 2019	U-705			
	6864258	May 27, 2019	U-705			
<u>RANOLAZINE - RANEXA</u>						
N 021526 002	6303607	May 27, 2019	U-705			
	6369062	May 27, 2019	DP			
	6479496	May 27, 2019	U-705			
	6503911	May 27, 2019	DP			
	6525057	May 27, 2019	U-705			
	6562826	May 27, 2019	U-705			
	6617328	May 27, 2019	DP			
	6620814	May 27, 2019	U-705			
	6852724	May 27, 2019	U-705			
	6864258	May 27, 2019	U-705			
<u>RASAGILINE MESYLATE - AZILECT</u>						
N 021641 001	5453446	Feb 07, 2017	U-219		I-685	May 29, 2017
	6126968	Sep 18, 2016	DP			
	7572834	Dec 05, 2026	DP			
	7815942	Aug 27, 2027	DS DP U-219			
<u>RASAGILINE MESYLATE - AZILECT</u>						
N 021641 002	5453446	Feb 07, 2017	U-219		I-685	May 29, 2017
	6126968	Sep 18, 2016	DP			
	7572834	Dec 05, 2026	DP			
	7815942	Aug 27, 2027	DS DP U-219			
<u>REGADENOSON - LEXISCAN</u>						
N 022161 001	6403567	Apr 10, 2022	DS DP U-869			
	6642210	Jun 22, 2019	DS DP U-869			
	7144872	Jun 22, 2019	DS DP U-116			
	7144872	Jun 22, 2019	DS DP U-869			
	7144872	Jun 22, 2019	DS DP U-870			
	7183264	Jun 22, 2019	DP U-116			
	7183264	Jun 22, 2019	DP U-869			
	7183264	Jun 22, 2019	DP U-870			
	7582617	Jun 22, 2019	U-1003			
	7655636	Jun 22, 2019	U-869			
	7655637	Jun 22, 2019	DS DP U-869			
	7683037	Jun 22, 2019	U-1042			
	8106029	Jun 22, 2019	U-1042			
	8106183	Feb 02, 2027	DS			
	8133879	Jun 22, 2019	DP			
	8183226	Jun 22, 2019	U-116			
	8470801	Jun 22, 2019	U-116			
	8536150	Jun 22, 2019	U-116			
	9045519	Jun 22, 2019	DP			
	9085601	Feb 02, 2027	DP			
	9289446	Jun 22, 2019	DP U-116			
<u>REGORAFENIB - STIVARGA</u>						
N 203085 001	7351834	Jan 12, 2020	DS		NCE	Sep 27, 2017
	8637553	Feb 16, 2031	DS DP		ODE	Feb 25, 2020
	8680124	Jun 02, 2030	U-1506			
	9458107	Apr 08, 2031	DP			
<u>REMIFENTANIL HYDROCHLORIDE - ULTIVA</u>						
N 020630 001	5866591	Sep 10, 2017	DP			
<u>REMIFENTANIL HYDROCHLORIDE - ULTIVA</u>						
N 020630 002	5866591	Sep 10, 2017	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>REMIFENTANIL HYDROCHLORIDE - ULTIVA</u>						
N 020630	003 5866591	Sep 10, 2017	DP			
<u>RETAPAMULIN - ALTABAX</u>						
N 022055	001 7875630	Feb 14, 2027	DS			
	8207191	Aug 30, 2024		U-805		
	RE39128	Apr 12, 2021	DS DP	U-805		
	RE43390	Apr 12, 2021	DS DP	U-805		
<u>RIBAVIRIN - VIRAZOLE</u>						
N 018859	001 6150337	Nov 21, 2017		U-400		
<u>RIBAVIRIN - REBETOL</u>						
N 020903	001 6172046	Sep 21, 2017		U-377		
	6172046	Sep 21, 2017		U-1014		
	6177074	Nov 01, 2016		U-454		
	6177074	Nov 01, 2016		U-1013		
	6461605	Nov 01, 2016		U-478		
	6461605	Nov 01, 2016		U-1013		
	6472373	Sep 21, 2017		U-479		
	6472373	Sep 21, 2017		U-1014		
	6524570	Nov 01, 2016		U-499		
	6524570	Nov 01, 2016		U-1013		
<u>RIBAVIRIN - REBETOL</u>						
N 020903	002 6172046	Sep 21, 2017		U-377		
	6172046	Sep 21, 2017		U-1014		
	6177074	Nov 01, 2016		U-454		
	6177074	Nov 01, 2016		U-1013		
	6461605	Nov 01, 2016		U-478		
	6461605	Nov 01, 2016		U-1013		
	6472373	Sep 21, 2017		U-479		
	6472373	Sep 21, 2017		U-1014		
	6524570	Nov 01, 2016		U-499		
	6524570	Nov 01, 2016		U-1013		
<u>RIBAVIRIN - REBETOL</u>						
N 021546	001 6172046	Sep 21, 2017		U-521		
	6172046	Sep 21, 2017		U-1014		
	6177074	Nov 01, 2016		U-1013		
	6461605	Nov 01, 2016		U-521		
	6461605	Nov 01, 2016		U-1013		
	6472373	Sep 21, 2017		U-521		
	6524570	Nov 01, 2016		U-1013		
	6790837	Apr 05, 2023	DP			
<u>RIBOFLAVIN 5'-PHOSPHATE SODIUM - PHOTREXA</u>						
N 203324	001				NP	Apr 15, 2019
					ODE	Apr 15, 2023
					ODE	Jul 15, 2023
<u>RIBOFLAVIN 5'-PHOSPHATE SODIUM - PHOTREXA VISCOUS IN DEXTRAN 20%</u>						
N 203324	002				NP	Apr 15, 2019
					ODE	Apr 15, 2023
					ODE	Jul 15, 2023
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361	001 7045620	Jun 19, 2024	DS DP			
	7612199	Jun 19, 2024	DS DP			
	7902206	Jun 19, 2024	DS DP			
	7906542	Jun 01, 2025	DS DP			
	7928115	Jul 24, 2029		U-1121		
	8158644	Jun 19, 2024	DP			
	8158781	Jun 19, 2024	DS			
	8193196	Sep 02, 2027	DS DP			
	8518949	Feb 27, 2026	DP			
	8741904	Feb 27, 2026	DS	U-1526		
	8835452	Jun 19, 2024	DS DP			
	8853231	Jun 19, 2024	DP			
	9271968	Feb 27, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 001	7045620	Jun 19, 2024	DS DP			
	7612199	Jun 19, 2024	DS DP			
	7902206	Jun 19, 2024	DS DP			
	7906542	Jun 01, 2025	DS DP			
	7928115	Jul 24, 2029		U-1121		
	8158644	Jun 19, 2024	DP			
	8158781	Jun 19, 2024	DS			
	8193196	Sep 02, 2027	DS DP			
	8518949	Feb 27, 2026	DP			
	8741904	Feb 27, 2026	DS	U-1526		
	8835452	Jun 19, 2024	DS DP			
	8853231	Jun 19, 2024	DP			
	9271968	Feb 27, 2026	DP			
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	6861053	Aug 11, 2019		U-1707	I-709	May 27, 2018
	6861053	Aug 11, 2019		U-1708	ODE	Mar 24, 2017
	7045620	Jun 19, 2024	DS			
	7452857	Aug 11, 2019		U-1707		
	7452857	Aug 11, 2019		U-1708		
	7605240	Aug 11, 2019		U-1707		
	7605240	Aug 11, 2019		U-1708		
	7612199	Jun 19, 2024	DS DP			
	7718608	Aug 11, 2019		U-1707		
	7718608	Aug 11, 2019		U-1708		
	7902206	Jun 19, 2024	DS DP			
	7906542	Jun 01, 2025	DS DP			
	7915275	Feb 23, 2025		U-1707		
	7915275	Feb 23, 2025		U-1708		
	7935799	Aug 11, 2019		U-1707		
	7935799	Aug 11, 2019		U-1708		
	8158644	Jun 19, 2024	DP			
	8158781	Jun 19, 2024	DS			
	8193196	Sep 02, 2027	DS DP	U-1707		
	8193196	Sep 02, 2027	DS DP	U-1708		
	8309569	Jul 18, 2029		U-1707		
	8309569	Jul 18, 2029		U-1708		
	8518949	Feb 27, 2026	DP			
	8642573	Oct 02, 2029		U-1481		
	8741904	Feb 27, 2026	DS	U-1526		
	8741904	Feb 27, 2026	DS	U-1707		
	8741904	Feb 27, 2026	DS	U-1708		
	8829017	Jul 24, 2029		U-1562		
	8835452	Jun 19, 2024	DS DP			
	8853231	Jun 19, 2024	DP			
	8946252	Jul 24, 2029		U-1481		
	8969398	Oct 02, 2029		U-1481		
	9271968	Feb 27, 2026	DP			
	9421195	Mar 10, 2030		U-1481		
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001	6838464	Feb 26, 2021	DS DP		NPP	Aug 26, 2018
	7067522	Dec 20, 2019	DS DP			
	7125879	Apr 21, 2025	DS DP	U-1153		
	7125879	Apr 21, 2025	DS DP	U-1307		
	7125879	Apr 21, 2025	DS DP	U-1740		
	7638522	Apr 14, 2023	DP			
	8080551	Apr 11, 2023	DS DP			
	8101629	Aug 09, 2022	DP			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 001	6743798	Jul 16, 2019	DS DP		NCE	Oct 08, 2018
	7173037	Apr 25, 2023	DS DP		ODE	Oct 08, 2020
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 002	6743798	Jul 16, 2019	DS DP		NCE	Oct 08, 2018
	7173037	Apr 25, 2023	DS DP		ODE	Oct 08, 2020

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 003	6743798	Jul 16, 2019	DS DP		NCE	Oct 08, 2018
	7173037	Apr 25, 2023	DS DP		ODE	Oct 08, 2020
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 004	6743798	Jul 16, 2019	DS DP		NCE	Oct 08, 2018
	7173037	Apr 25, 2023	DS DP		ODE	Oct 08, 2020
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 005	6743798	Jul 16, 2019	DS DP		NCE	Oct 08, 2018
	7173037	Apr 25, 2023	DS DP		ODE	Oct 08, 2020
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N 020835 001	6165513	Jun 10, 2018				
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N 020835 002	6165513	Jun 10, 2018				
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N 020835 003	5994329	Jul 17, 2018		U-353		
	6015801	Jul 17, 2018		U-353		
	6165513	Jun 10, 2018	DP			
	6432932	Jul 17, 2018		U-595		
	6465443	Aug 14, 2018	DP			
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N 020835 004	6165513	Jun 10, 2018	DP			
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N 020835 005	6165513	Jun 10, 2018	DP			
	7192938	May 06, 2023		U-353		
	7718634	May 06, 2023		U-662		
<u>RISEDRONATE SODIUM - ATELVIA</u>						
N 022560 001	7645459	Jan 09, 2028	DP	U-662		
	7645460	Jan 09, 2028	DP	U-662		
	8246989	Jan 16, 2026	DP			
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
N 021346 001	5792477	May 02, 2017	DP			
	5916598	May 02, 2017	DP			
	6194006	Dec 30, 2018	DP			
	6379703	Dec 30, 2018	DP			
	6403114	May 02, 2017	DP			
	6596316	Dec 30, 2018	DP			
	6667061	May 25, 2020	DP			
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
N 021346 002	5792477	May 02, 2017	DP			
	5916598	May 02, 2017	DP			
	6194006	Dec 30, 2018	DP			
	6379703	Dec 30, 2018	DP			
	6403114	May 02, 2017	DP			
	6596316	Dec 30, 2018	DP			
	6667061	May 25, 2020	DP			
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
N 021346 003	5792477	May 02, 2017	DP			
	5916598	May 02, 2017	DP			
	6194006	Dec 30, 2018	DP			
	6379703	Dec 30, 2018	DP			
	6403114	May 02, 2017	DP			
	6596316	Dec 30, 2018	DP			
	6667061	May 25, 2020	DP			
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
N 021346 004	5792477	May 02, 2017	DP			
	5916598	May 02, 2017	DP			
	6194006	Dec 30, 2018	DP			
	6379703	Dec 30, 2018	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
N 021346 004	6403114	May 02, 2017	DP			
	6596316	Dec 30, 2018	DP			
<u>RISPERIDONE - RISPERDAL</u>						
N 021444 001	6224905	Jun 10, 2017	DP			
<u>RISPERIDONE - RISPERDAL</u>						
N 021444 002	6224905	Jun 10, 2017	DP			
<u>RISPERIDONE - RISPERDAL</u>						
N 021444 003	6224905	Jun 10, 2017	DP			
<u>RISPERIDONE - RISPERDAL</u>						
N 021444 004	6224905	Jun 10, 2017	DP			
<u>RISPERIDONE - RISPERDAL</u>						
N 021444 005	6224905	Jun 10, 2017	DP			
<u>RITONAVIR - NORVIR</u>						
N 020945 001	6232333	Nov 07, 2017				
	7141593	May 22, 2020	DP			
	7432294	May 22, 2020	DP			
<u>RITONAVIR - NORVIR</u>						
N 022417 001	7148359	Jul 19, 2019	DP			
	7364752	Nov 10, 2020	DP	U-688		
	8268349	Aug 25, 2024	DP			
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8470347	Sep 17, 2026	DP			
	8470347*PED	Mar 17, 2027				
	8691878	Aug 25, 2024		U-688		
	8691878*PED	Feb 25, 2025				
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	7157456	Aug 28, 2024	DS DP	U-1301	NCE	Jul 01, 2016
	7157456	Aug 28, 2024	DS DP	U-1302		
	7585860	Dec 11, 2020	DS			
	7592339	Dec 11, 2020		U-1167		
	7592339	Dec 11, 2020		U-1200		
	7592339	Dec 11, 2020		U-1301		
	7592339	Dec 11, 2020		U-1302		
	7592339	Dec 11, 2020		U-1303		
	9415053	Nov 13, 2024	DP	U-1167		
	9415053	Nov 13, 2024	DP	U-1200		
	9415053	Nov 13, 2024	DP	U-1301		
	9415053	Nov 13, 2024	DP	U-1302		
	9415053	Nov 13, 2024	DP	U-1303		
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	7157456	Aug 28, 2024	DS DP	U-1301	NCE	Jul 01, 2016
	7157456	Aug 28, 2024	DS DP	U-1302		
	7585860	Dec 11, 2020	DS			
	7592339	Dec 11, 2020		U-1167		
	7592339	Dec 11, 2020		U-1200		
	7592339	Dec 11, 2020		U-1301		
	7592339	Dec 11, 2020		U-1302		
	7592339	Dec 11, 2020		U-1303		
	9415053	Nov 13, 2024	DP	U-1167		
	9415053	Nov 13, 2024	DP	U-1200		
	9415053	Nov 13, 2024	DP	U-1301		
	9415053	Nov 13, 2024	DP	U-1302		
	9415053	Nov 13, 2024	DP	U-1303		
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	7157456	Aug 28, 2024	DS DP	U-1301	NCE	Jul 01, 2016
	7157456	Aug 28, 2024	DS DP	U-1302		
	7585860	Dec 11, 2020	DS			
	7592339	Dec 11, 2020		U-1167		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RIVAROXABAN - XARELTO</u>						
N 022406	003	7592339	Dec 11, 2020	U-1200		
		7592339	Dec 11, 2020	U-1301		
		7592339	Dec 11, 2020	U-1302		
		7592339	Dec 11, 2020	U-1303		
		9415053	Nov 13, 2024	DP U-1167		
		9415053	Nov 13, 2024	DP U-1200		
		9415053	Nov 13, 2024	DP U-1301		
		9415053	Nov 13, 2024	DP U-1302		
		9415053	Nov 13, 2024	DP U-1303		
<u>RIVASTIGMINE - EXELON</u>						
N 022083	001	6316023	Jan 08, 2019	DP		
		6335031	Jan 08, 2019	DP		
<u>RIVASTIGMINE - EXELON</u>						
N 022083	002	6316023	Jan 08, 2019	DP		
		6335031	Jan 08, 2019	DP		
<u>RIVASTIGMINE - EXELON</u>						
N 022083	005	6316023	Jan 08, 2019	DP		
		6335031	Jan 08, 2019	DP		
<u>ROFECOXIB - VIOXX</u>						
N 021042	001	6063811	May 06, 2017	U-602		
<u>ROFECOXIB - VIOXX</u>						
N 021042	002	6063811	May 06, 2017	U-602		
<u>ROFECOXIB - VIOXX</u>						
N 021042	003	6063811	May 06, 2017	U-602		
<u>ROFECOXIB - VIOXX</u>						
N 021052	001	6063811	May 06, 2017	U-266		
<u>ROFECOXIB - VIOXX</u>						
N 021052	002	6063811	May 06, 2017	U-266		
<u>ROFLUMILAST - DALIRESP</u>						
N 022522	001	5712298	Jan 27, 2020	DS DP U-1115		
		8431154	Feb 19, 2023	DP		
		8536206	Mar 08, 2024	U-1115		
		8604064	Mar 08, 2024	U-1115		
		8618142	Mar 08, 2024	DP		
		9468598	Feb 19, 2023	DP		
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 206500	001	7049320	Dec 08, 2023	DS DP U-1741	NCE	Sep 01, 2020
		7563801	Apr 04, 2027	DP		
		7981905	Apr 04, 2027	U-1741		
		8178550	Apr 04, 2027	DS DP		
		8361500	Oct 09, 2029	DP		
		8404702	Oct 09, 2029	U-1741		
		8470842	Jan 18, 2029	U-1741		
		8796299	Dec 17, 2022	U-1741		
<u>ROMIDEPSIN - ISTODAX</u>						
N 022393	001	7608280	Aug 22, 2021	DS	ODE	Nov 05, 2016
		7611724	Aug 22, 2021	DS	ODE	Jun 16, 2018
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008	001	7927624	Dec 02, 2021	DP U-20		
		8303986	Apr 12, 2021	DP		
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008	002	7927624	Dec 02, 2021	DP U-20		
		8303986	Apr 12, 2021	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 003	7927624	Dec 02, 2021	DP U-20			
	8303986	Apr 12, 2021	DP			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 004	7927624	Dec 02, 2021	DP U-20			
	8303986	Apr 12, 2021	DP			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 005	7927624	Dec 02, 2021	DP U-20			
	8303986	Apr 12, 2021	DP			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 006	7927624	Dec 02, 2021	DP U-20			
	8303986	Apr 12, 2021	DP			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 006	7828787	Oct 18, 2025	DP			
	7857802	Nov 28, 2026	DP			
	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 007	7828787	Oct 18, 2025	DP			
	7857802	Nov 28, 2026	DP			
	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071 002	6288095	Feb 11, 2017	U-420	Y		
	7358366	Apr 19, 2020	DS			
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071 003	6288095	Feb 11, 2017	U-420	Y		
	7358366	Apr 19, 2020	DS			
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071 004	6288095	Feb 11, 2017	U-420	Y		
	7358366	Apr 19, 2020	DS			
<u>ROSUVASTATIN CALCIUM - ROSUVASTATIN CALCIUM</u>						
A 079168 001					PC	Oct 29, 2016
<u>ROSUVASTATIN CALCIUM - ROSUVASTATIN CALCIUM</u>						
A 079168 002					PC	Oct 29, 2016
<u>ROSUVASTATIN CALCIUM - ROSUVASTATIN CALCIUM</u>						
A 079168 003					PC	Oct 29, 2016
<u>ROSUVASTATIN CALCIUM - ROSUVASTATIN CALCIUM</u>						
A 079168 004					PC	Oct 29, 2016
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 002	6316460	Aug 04, 2020	DP		NPP	Nov 20, 2018
	6858618	Dec 17, 2021	U-618		ODE	May 27, 2023
	6858618	Dec 17, 2021	U-1032			
	6858618	Dec 17, 2021	U-1807			
	6858618*PED	Jun 17, 2022				
	7030152	Apr 02, 2018	U-1032			
	7964614	Apr 02, 2018	U-1032			
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 003	6316460	Aug 04, 2020	DP		NPP	Nov 20, 2018
	6858618	Dec 17, 2021	U-618		ODE	May 27, 2023
	6858618	Dec 17, 2021	U-1032			
	6858618	Dec 17, 2021	U-1807			
	6858618*PED	Jun 17, 2022				
	7030152	Apr 02, 2018	U-1032			
	7964614	Apr 02, 2018	U-1032			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 004	6316460	Aug 04, 2020	DP		I-732	May 27, 2019
	6858618	Dec 17, 2021	U-618		NPP	Nov 20, 2018
	6858618	Dec 17, 2021	U-1032		ODE	May 27, 2023
	6858618	Dec 17, 2021	U-1807			
	6858618*PED	Jun 17, 2022				
	7030152	Apr 02, 2018	U-1032			
	7964614	Apr 02, 2018	U-1032			
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 005	6316460	Aug 04, 2020	DP		ODE	May 27, 2023
	6858618	Dec 17, 2021	U-618			
	7030152	Apr 02, 2018	U-1032			
	7964614	Apr 02, 2018	U-1032			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 001	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 002	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 003	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 004	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 005	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 006	6699498	Nov 27, 2020	DP			
	6884434	Mar 30, 2021	DP			
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 001	6495541	Jan 10, 2020	DS DP		NCE	Dec 19, 2021
	7351701	Jul 23, 2024		U-1927		
	7531530	Jul 23, 2024		U-1927		
	8071579	Aug 12, 2027		U-1927		
	8143241	Aug 12, 2027		U-1927		
	8754072	Feb 10, 2031	DS DP			
	8859562	Aug 04, 2031		U-1927		
	9045487	Feb 10, 2031	DS DP			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 002	6495541	Jan 10, 2020	DS DP		NCE	Dec 19, 2021
	7351701	Jul 23, 2024		U-1927		
	7531530	Jul 23, 2024		U-1927		
	8071579	Aug 12, 2027		U-1927		
	8143241	Aug 12, 2027		U-1927		
	8754072	Feb 10, 2031	DS DP			
	8859562	Aug 04, 2031		U-1927		
	9045487	Feb 10, 2031	DS DP			
<u>RUFINAMIDE - BANZEL</u>						
N 021911 001	6740669	Nov 14, 2022	DS DP			
	6740669*PED	May 14, 2023				
	7750028	Oct 19, 2018		U-106		
	7750028*PED	Apr 19, 2019				
	8076362	Jun 08, 2018	DP			
	8076362*PED	Dec 08, 2018				
<u>RUFINAMIDE - BANZEL</u>						
N 021911 002	6740669	Nov 14, 2022	DS DP			
	6740669*PED	May 14, 2023				
	7750028	Oct 19, 2018		U-106		
	7750028*PED	Apr 19, 2019				
	8076362	Jun 08, 2018	DP			
	8076362*PED	Dec 08, 2018				
<u>RUFINAMIDE - BANZEL</u>						
N 021911 003	6740669	Nov 14, 2022	DS DP			
	6740669*PED	May 14, 2023				
	7750028	Oct 19, 2018		U-106		
	7750028*PED	Apr 19, 2019				
	8076362	Jun 08, 2018	DP			
	8076362*PED	Dec 08, 2018				
<u>RUFINAMIDE - BANZEL</u>						
N 201367 001	6740669	Nov 14, 2022	DS DP			
	6740669*PED	May 14, 2023				
	7750028	Oct 19, 2018		U-106		
	7750028*PED	Apr 19, 2019				
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 001	7598257	Dec 24, 2027	DS DP	U-1201	I-699	Dec 04, 2017
	7598257	Dec 24, 2027	DS DP	U-1622	NCE	Nov 16, 2016
	8415362	Dec 24, 2027	DS DP		ODE	Nov 16, 2018
	8722693	Jun 12, 2028	DS DP		ODE	Dec 04, 2021
	8822481	Jun 12, 2028		U-1573		
	8829013	Jun 12, 2028		U-1201		
	8829013	Jun 12, 2028		U-1622		
	9079912	Dec 12, 2026		U-1573		
	9079912	Dec 12, 2026		U-1721		
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002	7598257	Dec 24, 2027	DS DP	U-1201	I-699	Dec 04, 2017
	7598257	Dec 24, 2027	DS DP	U-1622	NCE	Nov 16, 2016
	8415362	Dec 24, 2027	DS DP		ODE	Nov 16, 2018
	8722693	Jun 12, 2028	DS DP		ODE	Dec 04, 2021
	8822481	Jun 12, 2028		U-1573		
	8829013	Jun 12, 2028		U-1201		
	8829013	Jun 12, 2028		U-1622		
	9079912	Dec 12, 2026		U-1573		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002	9079912	Dec 12, 2026	U-1721			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 003	7598257	Dec 24, 2027	DS DP U-1201		I-699	Dec 04, 2017
	7598257	Dec 24, 2027	DS DP U-1622		NCE	Nov 16, 2016
	8415362	Dec 24, 2027	DS DP		ODE	Nov 16, 2018
	8722693	Jun 12, 2028	DS DP		ODE	Dec 04, 2021
	8822481	Jun 12, 2028	U-1573			
	8829013	Jun 12, 2028	U-1201			
	8829013	Jun 12, 2028	U-1622			
	9079912	Dec 12, 2026	U-1573			
	9079912	Dec 12, 2026	U-1721			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004	7598257	Dec 24, 2027	DS DP U-1201		I-699	Dec 04, 2017
	7598257	Dec 24, 2027	DS DP U-1622		NCE	Nov 16, 2016
	8415362	Dec 24, 2027	DS DP		ODE	Nov 16, 2018
	8722693	Jun 12, 2028	DS DP		ODE	Dec 04, 2021
	8822481	Jun 12, 2028	U-1573			
	8829013	Jun 12, 2028	U-1201			
	8829013	Jun 12, 2028	U-1622			
	9079912	Dec 12, 2026	U-1573			
	9079912	Dec 12, 2026	U-1721			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005	7598257	Dec 24, 2027	DS DP U-1201		I-699	Dec 04, 2017
	7598257	Dec 24, 2027	DS DP U-1622		NCE	Nov 16, 2016
	8415362	Dec 24, 2027	DS DP		ODE	Nov 16, 2018
	8722693	Jun 12, 2028	DS DP		ODE	Dec 04, 2021
	8822481	Jun 12, 2028	U-1573			
	8829013	Jun 12, 2028	U-1201			
	8829013	Jun 12, 2028	U-1622			
	9079912	Dec 12, 2026	U-1573			
	9079912	Dec 12, 2026	U-1721			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 001	7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
	8101659	Jan 14, 2023	DP			
	8404744	Jan 14, 2023	DP			
	8796331	Jan 14, 2023	U-1723			
	8877938	May 27, 2027	DS DP			
	9388134	Nov 08, 2026	U-1723			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 002	7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
	8101659	Jan 14, 2023	DP			
	8404744	Jan 14, 2023	DP			
	8796331	Jan 14, 2023	U-1723			
	8877938	May 27, 2027	DS DP			
	9388134	Nov 08, 2026	U-1723			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 003	7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
	8101659	Jan 14, 2023	DP			
	8404744	Jan 14, 2023	DP			
	8796331	Jan 14, 2023	U-1723			
	8877938	May 27, 2027	DS DP			
	9388134	Nov 08, 2026	U-1723			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 022181 001	7566462	Nov 16, 2025	DP		NPP	Apr 23, 2017
	7566462*PED	May 16, 2026			PED	Oct 23, 2017
	7566714	Nov 17, 2024	U-989			
	7566714*PED	May 17, 2025				
	7612073	Nov 17, 2024	U-1010			
	7612073*PED	May 17, 2025				
	7727987	Nov 17, 2024	DP			
	7727987*PED	May 17, 2025				
	7947681	Nov 17, 2024	U-1156			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 022181	001	7947681*PED	May 17, 2025			
		8003126	Nov 16, 2025			
		8003126*PED	May 16, 2026			
		8067416	Nov 17, 2024	U-989		
		8067416*PED	May 17, 2025			
		8318745	Nov 17, 2024	DP		
		8318745*PED	May 17, 2025			
		9433624	Nov 17, 2024	U-1589		
		RE43797	Nov 17, 2024	U-1156		
		RE43797*PED	May 17, 2025			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065	001	7566714	Nov 17, 2024	U-1589		
		7566714*PED	May 17, 2025			
		7612073	Nov 17, 2024	U-1010		
		7612073*PED	May 17, 2025			
		8067416	Nov 17, 2024	U-1589		
		8067416*PED	May 17, 2025			
		9216178	Nov 01, 2032	DP		
		9433624	Nov 17, 2024	U-1589		
		RE43797	Nov 17, 2024	U-1590		
		RE43797*PED	May 17, 2025			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065	002	7566714	Nov 17, 2024	U-1589		
		7566714*PED	May 17, 2025			
		7612073	Nov 17, 2024	U-1010		
		7612073*PED	May 17, 2025			
		8067416	Nov 17, 2024	U-1589		
		8067416*PED	May 17, 2025			
		9216178	Nov 01, 2032	DP		
		9433624	Nov 17, 2024	U-1589		
		RE43797	Nov 17, 2024	U-1590		
		RE43797*PED	May 17, 2025			
<u>SAQUINAVIR - FORTOVASE</u>						
N 020828	001	6352717	Nov 16, 2019			
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350	001	7951400	Nov 30, 2028	DP	M-175	Apr 05, 2019
		RE44186	Jul 31, 2023	DS DP U-995		
		RE44186	Jul 31, 2023	DS DP U-1837		
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350	002	7951400	Nov 30, 2028	DP	M-175	Apr 05, 2019
		RE44186	Jul 31, 2023	DS DP U-995		
		RE44186	Jul 31, 2023	DS DP U-1837		
<u>SELEGILINE - EMSAM</u>						
N 021336	001	7070808	May 10, 2018	DS DP		
		7150881	Jun 12, 2018	DS DP		
		7638140	May 10, 2018	DP		
<u>SELEGILINE - EMSAM</u>						
N 021336	002	7070808	May 10, 2018	DS DP		
		7150881	Jun 12, 2018	DS DP		
		7638140	May 10, 2018	DP		
<u>SELEGILINE - EMSAM</u>						
N 021336	003	7070808	May 10, 2018	DS DP		
		7150881	Jun 12, 2018	DS DP		
		7638140	May 10, 2018	DP		
<u>SELEXIPAG - UPTRAVI</u>						
N 207947	001	7205302	Apr 04, 2023	DS DP U-1797	NCE	Dec 21, 2020
		8791122	Aug 01, 2030	DS DP	ODE	Dec 21, 2022
		9173881	Aug 12, 2029	U-1798		
		9284280	Jun 25, 2030	U-1831		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 002	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
	8791122	Aug 01, 2030	DS DP		ODE	Dec 21, 2022
	9173881	Aug 12, 2029		U-1798		
	9284280	Jun 25, 2030		U-1831		
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 003	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
	8791122	Aug 01, 2030	DS DP		ODE	Dec 21, 2022
	9173881	Aug 12, 2029		U-1798		
	9284280	Jun 25, 2030		U-1831		
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 004	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
	8791122	Aug 01, 2030	DS DP		ODE	Dec 21, 2022
	9173881	Aug 12, 2029		U-1798		
	9284280	Jun 25, 2030		U-1831		
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 005	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
	8791122	Aug 01, 2030	DS DP		ODE	Dec 21, 2022
	9173881	Aug 12, 2029		U-1798		
	9284280	Jun 25, 2030		U-1831		
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 006	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
	8791122	Aug 01, 2030	DS DP		ODE	Dec 21, 2022
	9173881	Aug 12, 2029		U-1798		
	9284280	Jun 25, 2030		U-1831		
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 007	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
	8791122	Aug 01, 2030	DS DP		ODE	Dec 21, 2022
	9173881	Aug 12, 2029		U-1798		
	9284280	Jun 25, 2030		U-1831		
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 008	7205302	Apr 04, 2023	DS DP U-1797		NCE	Dec 21, 2020
	8791122	Aug 01, 2030	DS DP		ODE	Dec 21, 2022
	9173881	Aug 12, 2029		U-1798		
	9284280	Jun 25, 2030		U-1831		
<u>SERTRALINE HYDROCHLORIDE - ZOLOFT</u>						
N 020990 001	6727283	Oct 11, 2019	DP U-580			
	7067555	Oct 11, 2019	DP			
	7067555*PED	Apr 11, 2020				
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022127 001	7985418	Oct 27, 2025	DP		NPP	Nov 25, 2019
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022318 001	9095509	Dec 06, 2030	DP		NPP	Nov 25, 2019
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022318 002	9095509	Dec 06, 2030	DP		NPP	Nov 25, 2019
<u>SEVELAMER HYDROCHLORIDE - RENAGEL</u>						
N 021179 001	6733780	Oct 18, 2020	DP			
<u>SEVELAMER HYDROCHLORIDE - RENAGEL</u>						
N 021179 002	6733780	Oct 18, 2020	DP			
<u>SEVOFLURANE - ULTANE</u>						
N 020478 001	5990176	Jan 27, 2017				
	6074668	Jan 09, 2018				
	6288127	Jan 27, 2017				
	6444859	Jan 27, 2017				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N 020895 001	6469012	Oct 22, 2019	U-155			
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N 020895 002	6469012	Oct 22, 2019	U-155			
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N 020895 003	6469012	Oct 22, 2019	U-155			
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 021845 001					D-137 M-133	Jan 31, 2017 Jan 31, 2017
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 022473 001					D-137 M-133	Jan 31, 2017 Jan 31, 2017
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 203109 001					D-137 M-133	Jan 31, 2017 Jan 31, 2017
<u>SILODOSIN - RAPAFLO</u>						
N 022206 001	5387603	Dec 01, 2018	DS DP			
<u>SILODOSIN - RAPAFLO</u>						
N 022206 002	5387603	Dec 01, 2018	DS DP			
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001	7671032	May 19, 2025	DS DP		D-151	Oct 05, 2018
	8148399	Sep 05, 2029	DS DP U-1467		I-697	Nov 05, 2017
	8349869	Jul 28, 2026	DS DP U-1467		I-717	Oct 05, 2018
	8741926	Jul 28, 2026	DS U-1467		M-171	Feb 26, 2019
	8754106	Jul 28, 2026	DS U-1467		M-179	May 20, 2019
	9040562	Jul 28, 2026	DS DP U-1467		NCE	Nov 22, 2018
	9353103	Jul 28, 2026	U-1467			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343 001	6303661	Apr 24, 2017			U-1188	
	6699871	Jul 26, 2022	DS DP U-1188			
	6890898	Feb 02, 2019			U-1189	
	6890898	Feb 02, 2019			U-1190	
	6890898	Feb 02, 2019			U-1191	
	7078381	Feb 02, 2019			U-1188	
	7125873	Jul 26, 2022	DP U-1189			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1193			
	7326708	Apr 11, 2026	DS DP U-1188			
	7459428	Feb 02, 2019			U-1189	
	8168637	Jun 26, 2022	DP U-1188			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343 002	6303661	Apr 24, 2017			U-1188	
	6699871	Jul 26, 2022	DS DP U-1188			
	6890898	Feb 02, 2019			U-1189	
	6890898	Feb 02, 2019			U-1190	
	6890898	Feb 02, 2019			U-1191	
	7078381	Feb 02, 2019			U-1188	
	7125873	Jul 26, 2022	DP U-1189			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1193			
	7326708	Apr 11, 2026	DS DP U-1188			
	7459428	Feb 02, 2019			U-1189	
	8168637	Jun 26, 2022	DP U-1188			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343 003	6303661	Apr 24, 2017			U-1188	
	6699871	Jul 26, 2022	DS DP U-1188			
	6890898	Feb 02, 2019			U-1189	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343 003	6890898	Feb 02, 2019	U-1190			
	6890898	Feb 02, 2019	U-1191			
	7078381	Feb 02, 2019	U-1188			
	7125873	Jul 26, 2022	DP U-1189			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1193			
	7326708	Apr 11, 2026	DS DP U-1188			
	7459428	Feb 02, 2019	U-1189			
	8168637	Jun 26, 2022	DP U-1188			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343 004	6303661	Apr 24, 2017	U-1188			
	6699871	Jul 26, 2022	DS DP U-1188			
	6890898	Feb 02, 2019	U-1189			
	6890898	Feb 02, 2019	U-1190			
	6890898	Feb 02, 2019	U-1191			
	7078381	Feb 02, 2019	U-1188			
	7125873	Jul 26, 2022	DP U-1189			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1193			
	7326708	Apr 11, 2026	DS DP U-1188			
	7459428	Feb 02, 2019	U-1189			
	8168637	Jun 26, 2022	DP U-1188			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343 005	6303661	Apr 24, 2017	U-1188			
	6699871	Jul 26, 2022	DS DP U-1188			
	6890898	Feb 02, 2019	U-1189			
	6890898	Feb 02, 2019	U-1190			
	6890898	Feb 02, 2019	U-1191			
	7078381	Feb 02, 2019	U-1188			
	7125873	Jul 26, 2022	DP U-1189			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1193			
	7326708	Apr 11, 2026	DS DP U-1188			
	7459428	Feb 02, 2019	U-1189			
	8168637	Jun 26, 2022	DP U-1188			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343 006	6303661	Apr 24, 2017	U-1188			
	6699871	Jul 26, 2022	DS DP U-1188			
	6890898	Feb 02, 2019	U-1189			
	6890898	Feb 02, 2019	U-1190			
	6890898	Feb 02, 2019	U-1191			
	7078381	Feb 02, 2019	U-1188			
	7125873	Jul 26, 2022	DP U-1189			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1193			
	7326708	Apr 11, 2026	DS DP U-1188			
	7459428	Feb 02, 2019	U-1189			
	8168637	Jun 26, 2022	DP U-1188			
<u>SINCALIDE - KINEVAC</u>						
N 017697 001	6803046	Aug 16, 2022	DP			
<u>SINECATECHINS - VEREGEN</u>						
N 021902 001	5795911	Oct 31, 2020	U-172			
	5968973	Apr 10, 2017	U-172			
	7858662	Oct 02, 2026	DP U-172			
<u>SIROLIMUS - RAPAMUNE</u>						
N 021083 001						

ODE

May 28, 2022

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 001	5989591	Mar 11, 2018	DP		ODE	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 002	5989591	Mar 11, 2018	DP		ODE	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 003	5989591	Mar 11, 2018	DP		ODE	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 004	5989591	Mar 11, 2018	DP		ODE	May 28, 2022
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001	6699871	Jul 26, 2022	DS DP U-774			
	7125873	Jul 26, 2022		U-775		
	7125873	Jul 26, 2022		U-1036		
	7125873	Jul 26, 2022		U-1037		
	7125873	Jul 26, 2022		U-1038		
	7326708	Nov 24, 2026	DS DP U-802			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002	6699871	Jul 26, 2022	DS DP U-774			
	7125873	Jul 26, 2022		U-775		
	7125873	Jul 26, 2022		U-1036		
	7125873	Jul 26, 2022		U-1037		
	7125873	Jul 26, 2022		U-1038		
	7326708	Nov 24, 2026	DS DP U-802			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003	6699871	Jul 26, 2022	DS DP U-774			
	7125873	Jul 26, 2022		U-775		
	7125873	Jul 26, 2022		U-1036		
	7125873	Jul 26, 2022		U-1037		
	7125873	Jul 26, 2022		U-1038		
	7326708	Nov 24, 2026	DS DP U-802			
<u>SODIUM NITRITE - SODIUM NITRITE</u>						
N 203922 001	8568793	Dec 24, 2031	DS DP		ODE	Jan 14, 2018
<u>SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOLE</u>						
N 201444 001	8496973	Mar 29, 2031	DS DP U-1419		ODE	Jan 14, 2018
	8568793	Dec 24, 2031	DS DP			
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	6780889	Jul 04, 2020	DP			
	7262219	Jul 04, 2020	DP			
	7668730	Jun 16, 2024		U-1110		
	7765106	Jun 16, 2024		U-1069		
	7765107	Jun 16, 2024		U-1070		
	7851506	Dec 22, 2019		U-1101		
	7851506	Dec 22, 2019		U-1102		
	7895059	Dec 17, 2022		U-1110		
	8263650	Dec 22, 2019	DP U-1101			
	8263650	Dec 22, 2019	DP U-1102			
	8324275	Dec 22, 2019		U-1101		
	8324275	Dec 22, 2019		U-1102		
	8457988	Dec 17, 2022		U-1110		
	8589182	Dec 17, 2022		U-1110		
	8731963	Dec 17, 2022		U-1110		
	8772306	Mar 15, 2033		U-1532		
	8859619	Dec 22, 2019	DP			
	8952062	Dec 22, 2019		U-1101		
	8952062	Dec 22, 2019		U-1102		
	9050302	Mar 15, 2033		U-1532		
	9486426	Mar 15, 2033		U-1532		
<u>SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE - OSMOPREP</u>						
N 021892 001	7687075	Jun 22, 2028	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u>						
N 203923	001 8496973	Mar 29, 2031	DS DP U-1419		ODE	Jan 14, 2018
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671	001 7964580	Mar 26, 2029	DS DP U-1470		NCE	Dec 06, 2018
	8334270	Mar 21, 2028	DS DP U-1470			
	8580765	Mar 21, 2028	DS DP U-1470			
	8618076	Dec 11, 2030	DS DP U-1470			
	8633309	Mar 26, 2029	DS DP U-1470			
	8889159	Mar 26, 2029	DP U-1470			
	9085573	Mar 21, 2028	DS DP U-1470			
	9284342	Sep 13, 2030	DS DP U-1470			
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341	001 7964580	Mar 26, 2029	DS DP U-1470		NCE	Jun 28, 2021
	8334270	Mar 21, 2028	DS DP U-1470			
	8575135	Nov 16, 2032	DS DP U-1470			
	8580765	Mar 21, 2028	DS DP U-1470			
	8618076	Dec 11, 2030	DS DP U-1470			
	8633309	Mar 26, 2029	DS DP U-1470			
	8735372	Mar 21, 2028	U-1470			
	8889159	Mar 26, 2029	DP U-1470			
	8921341	Nov 16, 2032	DS DP U-1470			
	8940718	Nov 16, 2032	DS DP U-1470			
	9085573	Mar 21, 2028	DS DP U-1470			
	9284342	Sep 13, 2030	DS DP U-1470			
<u>SOLIFENACIN SUCCINATE - VESICARE</u>						
N 021518	001 6017927	Nov 19, 2018	DS DP			
<u>SOLIFENACIN SUCCINATE - VESICARE</u>						
N 021518	002 6017927	Nov 19, 2018	DS DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280	001 6152897	Nov 20, 2018	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280	002 6152897	Nov 20, 2018	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280	003 6152897	Nov 20, 2018	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280	005 6152897	Nov 20, 2018	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280	008 6152897	Nov 20, 2018	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280	009 6152897	Nov 20, 2018	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N 021148	004 6004297	Jan 28, 2019	DP			
	6235004	Jan 28, 2019	DP			
	RE41956	Jan 21, 2021	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N 021148	005 6004297	Jan 28, 2019	DP			
	6235004	Jan 28, 2019	DP			
	RE41956	Jan 21, 2021	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N 021148	006 6004297	Jan 28, 2019	DP			
	6235004	Jan 28, 2019	DP			
	RE41956	Jan 21, 2021	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N 021148	007 6004297	Jan 28, 2019	DP			
	8841252	Dec 26, 2017	DP			
	RE41956	Jan 21, 2021	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N 021148 007	6004297	Jan 28, 2019	DP			
	8841252	Dec 26, 2017	DP			
	RE41956	Jan 21, 2021	DP			
	RE43834	Jan 28, 2019	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 008	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8841252	Dec 26, 2017	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 009	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8841252	Dec 26, 2017	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 010	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8841252	Dec 26, 2017	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 011	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8841252	Dec 26, 2017	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
<u>SONIDEGIB PHOSPHATE - ODOMZO</u>						
N 205266 001	8063043	Sep 15, 2029	DS DP		NCE	Jul 24, 2020
	8178563	Feb 06, 2029	DS	U-1722		
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N 021923 001	7235576	Jan 12, 2020	DS DP		I-677	Nov 22, 2016
	7351834	Jan 12, 2020	DS		ODE	Nov 22, 2020
	7897623	Jan 12, 2020		DP		
	8124630	Jan 12, 2020			U-1459	
	8618141	Feb 11, 2023			U-1480	
	8841330	Jan 12, 2020			U-1696	
	8877933	Dec 24, 2027	DS DP	U-1624		
<u>SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE</u>						
N 022306 001					ODE	Jul 02, 2016

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SPINOSAD - NATROBA</u>						
N 022408	001 6063771	Jul 25, 2023	DP U-1670		M-152	Nov 30, 2017
	6342482	Jun 22, 2019	DP U-1105			
	7030095	Jul 02, 2021	DP U-1105			
<u>STAVUDINE - ZERIT XR</u>						
N 021453	001 7135465	Feb 18, 2023	DP U-167			
<u>STAVUDINE - ZERIT XR</u>						
N 021453	002 7135465	Feb 18, 2023	DP U-167			
<u>STAVUDINE - ZERIT XR</u>						
N 021453	003 7135465	Feb 18, 2023	DP U-167			
<u>STAVUDINE - ZERIT XR</u>						
N 021453	004 7135465	Feb 18, 2023	DP U-167			
<u>SUCROFERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109	001 6174442	Dec 19, 2017	DS U-1468		NP	Nov 27, 2016
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225	001 6949527	Jan 27, 2021	U-1795		NCE	Dec 15, 2020
	7265099	Aug 07, 2020	U-1795			
	RE44733	Jan 27, 2021	DS DP U-1794			
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225	002 6949527	Jan 27, 2021	U-1795		NCE	Dec 15, 2020
	7265099	Aug 07, 2020	U-1795			
	RE44733	Jan 27, 2021	DS DP U-1794			
<u>SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON</u>						
N 203684	001 5686060	Nov 11, 2017	DS DP		I-728 NCE	Mar 31, 2019 Oct 10, 2019
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N 022239	001 6135979	Mar 21, 2017	DP			
	6251091	Dec 09, 2016	DP			
	6280410	Mar 27, 2017	DP			
	7776007	Nov 22, 2026	DP			
	7901385	Jul 31, 2026	DP			
	8118771	Aug 10, 2023	DP			
	8241243	Aug 10, 2023	DP			
	8241244	Nov 21, 2022	DP			
	8267903	Mar 18, 2023	DP			
	8287489	Dec 06, 2024	DP			
	8343130	Oct 18, 2022	DP			
	8491524	Nov 21, 2022	DP			
<u>SUMATRIPTAN SUCCINATE - ALSUMA</u>						
N 022377	001 7811254	Aug 26, 2027	DP U-1083			
<u>SUMATRIPTAN SUCCINATE - ZECUITY</u>						
N 202278	001 6745071	Feb 21, 2023	DP			
	7973058	Apr 12, 2027	U-1328			
	8155737	Apr 12, 2027	U-1328			
	8366600	Apr 21, 2029	U-1327			
	8470853	Apr 12, 2027	U-1328			
	8597272	Apr 12, 2027	DP			
	8983594	Nov 19, 2030	DP U-1328			
	9272137	Sep 07, 2027	DP			
	9327114	Oct 08, 2032	DP U-1328			
	9427578	Apr 12, 2027	DP U-1328			
<u>SUMATRIPTAN SUCCINATE - ONZETRA XSAIL</u>						
N 206099	001 6715485	Mar 03, 2020	DP			
	7975690	Aug 18, 2025	DP U-1809			
	8047202	Jul 02, 2023	DP			
	8327844	Oct 03, 2023	U-1809			
	8550073	Oct 22, 2029	DP			
	8555877	Mar 03, 2020	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SUMATRIPTAN SUCCINATE - ONZETRA XSAIL</u>						
N 206099	001	8590530	Sep 15, 2025	DP	U-1809	
		8875704	Apr 07, 2028	DP	U-1809	
		8899229	Aug 18, 2030	DP		
		8978647	Dec 06, 2030	DP		
		9108015	Sep 15, 2025	DP		
		9119932	Apr 23, 2024	DP		
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938	001	6573293	Feb 15, 2021	DS DP	U-1154	
		7125905	Feb 15, 2021	DS DP		
		7211600	Dec 22, 2020		U-883	
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938	002	6573293	Feb 15, 2021	DS DP	U-1154	
		7125905	Feb 15, 2021	DS DP		
		7211600	Dec 22, 2020		U-883	
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938	003	6573293	Feb 15, 2021	DS DP	U-1154	
		7125905	Feb 15, 2021	DS DP		
		7211600	Dec 22, 2020		U-883	
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938	004	6573293	Feb 15, 2021	DS DP	U-1154	
		7125905	Feb 15, 2021	DS DP		
		7211600	Dec 22, 2020		U-883	
<u>SUVOREXANT - BELSOMRA</u>						
N 204569	001	7951797	Nov 20, 2029	DS DP	U-620	NCE Aug 13, 2019
<u>SUVOREXANT - BELSOMRA</u>						
N 204569	002	7951797	Nov 20, 2029	DS DP	U-620	NCE Aug 13, 2019
<u>SUVOREXANT - BELSOMRA</u>						
N 204569	003	7951797	Nov 20, 2029	DS DP	U-620	NCE Aug 13, 2019
<u>SUVOREXANT - BELSOMRA</u>						
N 204569	004	7951797	Nov 20, 2029	DS DP	U-620	NCE Aug 13, 2019
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096	001	6440458	Mar 25, 2019	DP		NDF Jul 19, 2016
		6576259	Mar 25, 2019	DP	U-1420	
		6884433	Mar 25, 2019	DP	U-1420	
		8551522	Mar 25, 2019	DP		
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096	002	6440458	Mar 25, 2019	DP		NDF Jul 19, 2016
		6576259	Mar 25, 2019	DP	U-1420	
		6884433	Mar 25, 2019	DP	U-1420	
		8551522	Mar 25, 2019	DP		
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096	003	6440458	Mar 25, 2019	DP		NDF Jul 19, 2016
		6576259	Mar 25, 2019	DP	U-1420	
		6884433	Mar 25, 2019	DP	U-1420	
		8551522	Mar 25, 2019	DP		
<u>TACROLIMUS - ENVARUS XR</u>						
N 206406	001	7994214	Aug 30, 2024	DP		ODE Jul 10, 2022
		8486993	Aug 30, 2024	DP	U-1752	
		8586084	Aug 30, 2024		U-1752	
		8591946	Aug 30, 2024	DP		
		8617599	Aug 30, 2024	DP		
		8623410	Aug 30, 2024	DP		
		8623411	Aug 30, 2024		U-1752	
		8664239	May 30, 2028		U-1752	
		8685998	May 30, 2028	DP	U-1752	
		8889185	Aug 30, 2024		U-1752	
		8889186	Aug 30, 2024		U-1752	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406	001	9161907	Aug 30, 2024	DP U-1752		
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406	002	7994214	Aug 30, 2024	DP	ODE	Jul 10, 2022
		8486993	Aug 30, 2024	DP U-1752		
		8586084	Aug 30, 2024	U-1752		
		8591946	Aug 30, 2024	DP		
		8617599	Aug 30, 2024	DP		
		8623410	Aug 30, 2024	DP		
		8623411	Aug 30, 2024	U-1752		
		8664239	May 30, 2028	U-1752		
		8685998	May 30, 2028	DP U-1752		
		8889185	Aug 30, 2024	U-1752		
		8889186	Aug 30, 2024	U-1752		
		9161907	Aug 30, 2024	DP U-1752		
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406	003	7994214	Aug 30, 2024	DP	ODE	Jul 10, 2022
		8486993	Aug 30, 2024	DP U-1752		
		8586084	Aug 30, 2024	U-1752		
		8591946	Aug 30, 2024	DP		
		8617599	Aug 30, 2024	DP		
		8623410	Aug 30, 2024	DP		
		8623411	Aug 30, 2024	U-1752		
		8664239	May 30, 2028	U-1752		
		8685998	May 30, 2028	DP U-1752		
		8889185	Aug 30, 2024	U-1752		
		8889186	Aug 30, 2024	U-1752		
		9161907	Aug 30, 2024	DP U-1752		
<u>TADALAFIL - CIALIS</u>						
N 021368	001	5859006	Nov 21, 2017	DS DP		
		6140329	Jul 11, 2016	DP U-155		
		6140329	Jul 11, 2016	DP U-1184		
		6821975	Nov 19, 2020	DS DP U-533		
		6821975	Nov 19, 2020	DS DP U-614		
		6821975	Nov 19, 2020	DS DP U-1184		
		6943166	Apr 26, 2020	U-155		
		6943166	Apr 26, 2020	U-614		
		6943166	Apr 26, 2020	U-1184		
		7182958	Apr 26, 2020	DP U-155		
		7182958	Apr 26, 2020	DP U-1184		
<u>TADALAFIL - CIALIS</u>						
N 021368	002	5859006	Nov 21, 2017	DS DP		
		6140329	Jul 11, 2016	DP U-155		
		6821975	Nov 19, 2020	DS DP U-533		
		6821975	Nov 19, 2020	DS DP U-614		
		6943166	Apr 26, 2020	U-155		
		6943166	Apr 26, 2020	U-614		
		7182958	Apr 26, 2020	DP U-155		
<u>TADALAFIL - CIALIS</u>						
N 021368	003	5859006	Nov 21, 2017	DS DP		
		6140329	Jul 11, 2016	DP U-155		
		6821975	Nov 19, 2020	DS DP U-533		
		6821975	Nov 19, 2020	DS DP U-614		
		6943166	Apr 26, 2020	U-614		
		7182958	Apr 26, 2020	DP U-155		
<u>TADALAFIL - CIALIS</u>						
N 021368	004	5859006	Nov 21, 2017	DS DP		
		6140329	Jul 11, 2016	DP U-155		
		6821975	Nov 19, 2020	DS DP U-533		
		6821975	Nov 19, 2020	DS DP U-614		
		6943166	Apr 26, 2020	U-155		
		7182958	Apr 26, 2020	DP U-155		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TADALAFIL - ADCIRCA</u>						
N 022332	001	5859006	Nov 21, 2017	DS DP U-975		
		6821975	Nov 19, 2020	DS DP		
		7182958	Apr 26, 2020	DP		
<u>TAFLUPROST - ZIOPTAN</u>						
N 202514	001	5886035	Dec 18, 2022	DS DP U-778	NCE	Feb 10, 2017
<u>TALIGLUCERASE ALFA - ELELYSO</u>						
N 022458	001	8227230	Feb 24, 2024	DS DP	NCE	May 01, 2017
		8741620	Feb 24, 2024	DS DP	NPP	Aug 27, 2017
		8790641	Oct 18, 2025	U-1564		
		8790641	Oct 18, 2025	U-1574		
<u>TAMOXIFEN CITRATE - SOLTAMOX</u>						
N 021807	001	6127425	Jun 26, 2018	DP		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304	001	6071970	Jun 06, 2017	U-931		
		7994364	Jun 27, 2025	DS DP U-931		
		RE39593	Aug 05, 2022	DS DP U-931		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304	002	6071970	Jun 06, 2017	U-931		
		7994364	Jun 27, 2025	DS DP U-931		
		RE39593	Aug 05, 2022	DS DP U-931		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304	003	6071970	Jun 06, 2017	U-931		
		7994364	Jun 27, 2025	DS DP U-931		
		RE39593	Aug 05, 2022	DS DP U-931		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533	001	6071970	Jun 06, 2017	U-1178		
		6071970	Jun 06, 2017	U-1276		
		7994364	Jun 27, 2025	DS DP U-1178		
		7994364	Jun 27, 2025	DS DP U-1276		
		8075872	Nov 20, 2023	DP		
		8114383	Oct 10, 2024	DP	Y	
		8309060	Nov 20, 2023	DP U-1178		
		8309060	Nov 20, 2023	DP U-1276		
		8420056	Nov 20, 2023	DP		
		8536130	Sep 22, 2028	U-1276		
		RE39593	Aug 05, 2022	DS DP U-1178		
		RE39593	Aug 05, 2022	DS DP U-1276		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533	002	6071970	Jun 06, 2017	U-1178		
		6071970	Jun 06, 2017	U-1276		
		7994364	Jun 27, 2025	DS DP U-1178		
		7994364	Jun 27, 2025	DS DP U-1276		
		8075872	Nov 20, 2023	DP		
		8114383	Oct 10, 2024	DP	Y	
		8309060	Nov 20, 2023	DP U-1178		
		8309060	Nov 20, 2023	DP U-1276		
		8420056	Nov 20, 2023	DP		
		8536130	Sep 22, 2028	U-1276		
		RE39593	Aug 05, 2022	DS DP U-1178		
		RE39593	Aug 05, 2022	DS DP U-1276		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533	003	6071970	Jun 06, 2017	U-1178		
		6071970	Jun 06, 2017	U-1276		
		7994364	Jun 27, 2025	DS DP U-1178		
		7994364	Jun 27, 2025	DS DP U-1276		
		8075872	Nov 20, 2023	DP		
		8114383	Oct 10, 2024	DP	Y	
		8309060	Nov 20, 2023	DP U-1178		
		8309060	Nov 20, 2023	DP U-1276		
		8420056	Nov 20, 2023	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533	003	8536130	Sep 22, 2028	U-1276		
		RE39593	Aug 05, 2022	DS DP U-1178		
		RE39593	Aug 05, 2022	DS DP U-1276		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533	004	6071970	Jun 06, 2017	U-1178		
		6071970	Jun 06, 2017	U-1276		
		7994364	Jun 27, 2025	DS DP U-1178		
		7994364	Jun 27, 2025	DS DP U-1276		
		8075872	Nov 20, 2023	DP		
		8114383	Oct 10, 2024	DP	Y	
		8309060	Nov 20, 2023	DP U-1178		
		8309060	Nov 20, 2023	DP U-1276		
		8420056	Nov 20, 2023	DP		
		8536130	Sep 22, 2028	U-1276		
		RE39593	Aug 05, 2022	DS DP U-1178		
		RE39593	Aug 05, 2022	DS DP U-1276		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533	005	6071970	Jun 06, 2017	U-1178		
		6071970	Jun 06, 2017	U-1276		
		7994364	Jun 27, 2025	DS DP U-1178		
		7994364	Jun 27, 2025	DS DP U-1276		
		8075872	Nov 20, 2023	DP		
		8114383	Oct 10, 2024	DP	Y	
		8309060	Nov 20, 2023	DP U-1178		
		8309060	Nov 20, 2023	DP U-1276		
		8420056	Nov 20, 2023	DP		
		8536130	Sep 22, 2028	U-1276		
		RE39593	Aug 05, 2022	DS DP U-1178		
		RE39593	Aug 05, 2022	DS DP U-1276		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА</u>						
N 203794	001	6071970	Jun 06, 2017	U-1289		
		7994364	Jun 27, 2025	DS DP U-1289		
		RE39593	Aug 05, 2022	DS DP U-1289		
<u>TASIMELTEON - HETLIOZ</u>						
N 205677	001	5856529	Dec 09, 2017	DS DP U-1486	NCE	Jan 31, 2019
		8785492	Jan 25, 2033	U-1486	ODE	Jan 31, 2021
		9060995	Jan 25, 2033	U-1710		
<u>TAVABOROLE - KERYDIN</u>						
N 204427	001	7582621	May 26, 2027	U-718	NCE	Jul 07, 2019
		7767657	May 22, 2027	DP		
<u>TAZAROTENE - FABIOR</u>						
N 202428	001	8808716	Feb 24, 2030	DP		
<u>TECHNETIUM TC-99M SULFUR COLLOID KIT - AN-SULFUR COLLOID</u>						
N 017858	001				ODE	Aug 13, 2019
<u>TECHNETIUM TC-99M TEBOROXIME KIT - CARDIOTEC</u>						
N 019928	001	6056941	Jul 28, 2019	DP		
<u>TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT</u>						
N 202207	001	6409990	May 12, 2020	DS	I-687	Jun 13, 2017
		9439985	Sep 27, 2033	DS DP	NCE	Mar 13, 2018
					ODE	Jun 13, 2021
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205435	001	7816379	Feb 23, 2028	DS DP U-282	NCE	Jun 20, 2019
		8420676	Feb 23, 2028	DS DP U-282	GAIN	Jun 20, 2024
		8426389	Dec 31, 2030	DS DP U-282		
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205436	001	7816379	Feb 23, 2028	DS DP U-282	NCE	Jun 20, 2019
		8420676	Feb 23, 2028	DS DP U-282	GAIN	Jun 20, 2024
		8426389	Dec 31, 2030	DS DP U-282		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441	001	5789379	Apr 14, 2020	DS DP U-1320	NCE	Dec 21, 2017
		7056886	Sep 18, 2022	DP U-1320	ODE	Dec 21, 2019
		7847061	Nov 01, 2025	U-1320		
		9060992	Nov 01, 2025	U-1320		
<u>TELAPREVIR - INCIVEK</u>						
N 201917	001	7820671	Feb 25, 2025	DS DP		
		8431615	May 30, 2028	U-1398		
		8529882	Aug 31, 2021	U-1398		
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N 022110	001	6635618	Sep 11, 2023	DS DP U-728		
		6858584	Aug 24, 2022	DP		
		6872701	Jun 05, 2021	DP		
		7008923	May 06, 2021	U-1005		
		7208471	May 01, 2021	DS DP		
		7351691	May 01, 2021	DS DP U-728		
		7531623	Jan 01, 2027	DS		
		7544364	May 01, 2021	DP		
		7700550	May 01, 2021	U-282		
		8101575	May 01, 2021	DP		
		8158580	May 01, 2021	DP		
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N 022110	002	6635618	Sep 11, 2023	DS DP U-728		
		6858584	Aug 24, 2022	DP		
		6872701	Jun 05, 2021	DP		
		7008923	May 06, 2021	U-1005		
		7208471	May 01, 2021	DS DP		
		7351691	May 01, 2021	DS DP U-728		
		7531623	Jan 01, 2027	DS		
		7544364	May 01, 2021	DP		
		7700550	May 01, 2021	U-282		
		8101575	May 01, 2021	DP		
		8158580	May 01, 2021	DP		
<u>TELBIVUDINE - TYZEKA</u>						
N 022011	001	6395716	Aug 10, 2019	U-782		
		6444652	Aug 10, 2019	U-782		
		6566344	Aug 10, 2019	U-782		
		6569837	Oct 25, 2020	U-782		
		6569837	Oct 25, 2020	U-999		
		7589079	Sep 11, 2023	DS DP U-999		
		7795238	Aug 10, 2019	U-999		
		7858594	Sep 11, 2023	DS DP U-999		
<u>TELBIVUDINE - TYZEKA</u>						
N 022154	001	6395716	Aug 10, 2019	U-999		
		6444652	Aug 10, 2019	U-999		
		6566344	Aug 10, 2019	U-999		
		6569837	Oct 25, 2020	U-999		
		7795238	Aug 10, 2019	U-999		
		7858594	Sep 11, 2023	DS DP U-999		
<u>TELITHROMYCIN - KETEK</u>						
N 021144	001	5635485	Apr 01, 2018	DS DP U-578		
<u>TELITHROMYCIN - KETEK</u>						
N 021144	002	5635485	Apr 01, 2018	DS DP U-578		
<u>TELMISARTAN - MICARDIS</u>						
N 020850	001	6358986	Jan 10, 2020			
<u>TELMISARTAN - MICARDIS</u>						
N 020850	002	6358986	Jan 10, 2020			
		7998953	Jun 06, 2020	U-1177		
		8003679	Oct 06, 2022	U-1176		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TELMISARTAN - MICARDIS</u>						
N 020850	003 6358986	Jan 10, 2020				
<u>TEMOZOLOMIDE - TEMODAR</u>						
N 022277	001 6987108	Sep 08, 2023	DP			
	7786118	Feb 21, 2023	DP			
	8623868	Feb 21, 2023	DP			
<u>TEMSIROLIMUS - TORISEL</u>						
N 022088	001 5362718	Feb 15, 2019	DS DP	Y		
	5362718*PED	Aug 15, 2019				
	8026276	Jan 20, 2026	DP			
	8299116	Jul 25, 2023	DP			
	8455539	Jul 25, 2023	DP			
	8455539*PED	Jan 25, 2024				
	8722700	Jul 25, 2023	DP			
	8722700*PED	Jan 25, 2024				
	8791097	May 10, 2032		U-1550		
	8791097	May 10, 2032		U-1551		
	8791097*PED	Nov 10, 2032				
	RE44768	Feb 15, 2019	DS DP			
	RE44768*PED	Aug 15, 2019				
<u>TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY</u>						
N 208464	001 7390791	May 07, 2022	DS DP		NCE	Nov 05, 2020
	7803788	Feb 02, 2022		U-999	NP	Nov 11, 2019
	8754065	Aug 15, 2032	DS DP	U-999		
	9296769	Aug 15, 2032	DS DP	U-999		
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356	001 5922695	Jul 25, 2017	DS	U-248	M-128	Jul 24, 2016
	5922695	Jul 25, 2017	DS	U-250	ODE	Mar 24, 2017
	5922695	Jul 25, 2017	DS	U-256	PED	Sep 24, 2017
	5922695	Jul 25, 2017	DS	U-999		
	5922695	Jul 25, 2017	DS	U-1275		
	5935946	Jul 25, 2017	DS DP	U-248		
	5935946	Jul 25, 2017	DS DP	U-250		
	5935946	Jul 25, 2017	DS DP	U-256		
	5935946	Jul 25, 2017	DS DP	U-999		
	5935946	Jul 25, 2017	DS DP	U-1275		
	5977089	Jul 25, 2017	DS DP	U-248		
	5977089	Jul 25, 2017	DS DP	U-250		
	5977089	Jul 25, 2017	DS DP	U-256		
	5977089	Jul 25, 2017	DS DP	U-999		
	5977089	Jul 25, 2017	DS DP	U-1275		
	6043230	Jul 25, 2017		U-248		
	6043230	Jul 25, 2017		U-250		
	6043230	Jul 25, 2017		U-256		
	6043230	Jul 25, 2017		U-999		
	6043230	Jul 25, 2017		U-1275		
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356	002 5922695	Jul 25, 2017	DS	U-248	M-128	Jul 24, 2016
	5922695	Jul 25, 2017	DS	U-250	ODE	Mar 24, 2017
	5922695	Jul 25, 2017	DS	U-256	PED	Sep 24, 2017
	5922695	Jul 25, 2017	DS	U-999		
	5922695	Jul 25, 2017	DS	U-1275		
	5935946	Jul 25, 2017	DS DP	U-248		
	5935946	Jul 25, 2017	DS DP	U-250		
	5935946	Jul 25, 2017	DS DP	U-256		
	5935946	Jul 25, 2017	DS DP	U-999		
	5935946	Jul 25, 2017	DS DP	U-1275		
	5977089	Jul 25, 2017	DS DP	U-248		
	5977089	Jul 25, 2017	DS DP	U-250		
	5977089	Jul 25, 2017	DS DP	U-256		
	5977089	Jul 25, 2017	DS DP	U-999		
	5977089	Jul 25, 2017	DS DP	U-1275		
	6043230	Jul 25, 2017		U-248		
	6043230	Jul 25, 2017		U-250		
	6043230	Jul 25, 2017		U-256		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 002	6043230	Jul 25, 2017	U-999			
	6043230	Jul 25, 2017	U-1275			
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 003	5922695	Jul 25, 2017	DS U-248		M-128	Jul 24, 2016
	5922695	Jul 25, 2017	DS U-250		ODE	Mar 24, 2017
	5922695	Jul 25, 2017	DS U-256		PED	Sep 24, 2017
	5922695	Jul 25, 2017	DS U-999			
	5922695	Jul 25, 2017	DS U-1275			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-250			
	5935946	Jul 25, 2017	DS DP U-256			
	5935946	Jul 25, 2017	DS DP U-999			
	5935946	Jul 25, 2017	DS DP U-1275			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230	Jul 25, 2017	U-1275			
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 004	5922695	Jul 25, 2017	DS U-248		M-128	Jul 24, 2016
	5922695	Jul 25, 2017	DS U-250		ODE	Mar 24, 2017
	5922695	Jul 25, 2017	DS U-256		PED	Sep 24, 2017
	5922695	Jul 25, 2017	DS U-999			
	5922695	Jul 25, 2017	DS U-1275			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-250			
	5935946	Jul 25, 2017	DS DP U-256			
	5935946	Jul 25, 2017	DS DP U-999			
	5935946	Jul 25, 2017	DS DP U-1275			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230	Jul 25, 2017	U-1275			
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 022577 001	5922695	Jul 25, 2017	DS U-248		M-128	Jul 24, 2016
	5922695	Jul 25, 2017	DS U-250		ODE	Mar 24, 2017
	5922695	Jul 25, 2017	DS U-256		PED	Sep 24, 2017
	5922695	Jul 25, 2017	DS U-999			
	5922695	Jul 25, 2017	DS U-1275			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-250			
	5935946	Jul 25, 2017	DS DP U-256			
	5935946	Jul 25, 2017	DS DP U-999			
	5935946	Jul 25, 2017	DS DP U-1275			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230	Jul 25, 2017	U-1275			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 001	6794410	Sep 12, 2026	U-1285		NCE	Sep 12, 2017
	8802735	Sep 14, 2030	DP			
	9186346	Feb 04, 2034	U-1786			
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 002	6794410	Sep 12, 2026	U-1285		NCE	Sep 12, 2017
	8802735	Sep 14, 2030	DP			
	9186346	Feb 04, 2034	U-1786			
<u>TERIPARATIDE RECOMBINANT HUMAN - FORTEO</u>						
N 021318 001	6770623	Dec 08, 2018	DP U-597			
	6977077	Aug 19, 2019	U-597			
	7144861	Dec 08, 2018	DP			
	7163684	Aug 19, 2019	U-790			
	7351414	Aug 19, 2019	U-865			
	7517334	Mar 25, 2025	DP			
	7550434	Dec 08, 2018	DP U-982			
<u>TERIPARATIDE RECOMBINANT HUMAN - FORTEO</u>						
N 021318 002	6770623	Dec 08, 2018	DP U-982			
	6977077	Aug 19, 2019	U-982			
	6977077	Aug 19, 2019	U-994			
	7144861	Dec 08, 2018	DP			
	7163684	Aug 19, 2019	U-983			
	7163684	Aug 19, 2019	U-994			
	7351414	Aug 19, 2019	U-984			
	7351414	Aug 19, 2019	U-994			
	7517334	Mar 25, 2025	DP			
	7550434	Dec 08, 2018	DP U-982			
<u>TESAMORELIN ACETATE - EGRIFTA</u>						
N 022505 001	5861379	May 26, 2020	DS DP U-1100			
	7144577	Jul 14, 2020	U-1100			
	7316997	Aug 14, 2023	U-1100			
<u>TESAMORELIN ACETATE - EGRIFTA</u>						
N 022505 002	7144577	Jul 14, 2020	U-1100			
	7316997	Aug 14, 2023	U-1100			
<u>TESTOSTERONE - TESTODERM</u>						
N 019762 001	5840327	Aug 15, 2016				
<u>TESTOSTERONE - TESTODERM</u>						
N 019762 002	5840327	Aug 15, 2016				
<u>TESTOSTERONE - TESTODERM TTS</u>						
N 020791 001	6348210	Nov 10, 2019	U-440			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 001	6503894	Aug 30, 2020	U-490			
	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 002	6503894	Aug 30, 2020	U-490			
	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 003	6503894	Aug 30, 2020	U-490			
	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE - TESTIM</u>						
N 021454 001	7320968	Jan 18, 2025				
	7608605	Apr 21, 2023			U-843	
	7608606	Apr 21, 2023			U-1009	
	7608607	Apr 21, 2023			U-1009	
	7608608	Apr 21, 2023			U-1009	
	7608609	Apr 21, 2023			U-1009	
	7608610	Apr 21, 2023			U-1009	
	7935690	Apr 21, 2023			U-1009	
	8063029	Apr 21, 2023			U-843	
	8178518	Apr 21, 2023			DP	
<u>TESTOSTERONE - FORTESTA</u>						
N 021463 001	6319913	Nov 09, 2018			U-490	
	6579865	Nov 09, 2018			DP	
<u>TESTOSTERONE - STRIANT</u>						
N 021543 001	6248358	Aug 23, 2019			U-527	
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 001	6503894	Aug 30, 2020			U-1103	
	6503894*PED	Mar 02, 2021				
	8466136	Oct 12, 2026			DP	
	8466137	Oct 12, 2026			U-1103	
	8466138	Oct 12, 2026			U-1103	
	8486925	Oct 12, 2026			DP	
	8729057	Oct 12, 2026			DP	
	8741881	Oct 12, 2026			U-1103	
	8754070	Oct 12, 2026			DP	
	8759329	Oct 12, 2026			DP	
	9125816	Aug 30, 2020			U-1103	
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020			U-1103	
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 002	6503894	Aug 30, 2020			U-1103	
	6503894*PED	Mar 02, 2021				
	8466136	Oct 12, 2026			DP	
	8466137	Oct 12, 2026			U-1103	
	8466138	Oct 12, 2026			U-1103	
	8486925	Oct 12, 2026			DP	
	8729057	Oct 12, 2026			DP	
	8741881	Oct 12, 2026			U-1103	
	8754070	Oct 12, 2026			DP	
	8759329	Oct 12, 2026			DP	
	9125816	Aug 30, 2020			U-1103	
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020			U-1103	
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 003	6503894	Aug 30, 2020			U-1103	
	6503894*PED	Mar 02, 2021				
	8466136	Oct 12, 2026			DP	
	8466137	Oct 12, 2026			U-1103	
	8466138	Oct 12, 2026			U-1103	
	8486925	Oct 12, 2026			DP	
	8729057	Oct 12, 2026			DP	
	8741881	Oct 12, 2026			U-1103	
	8754070	Oct 12, 2026			DP	
	8759329	Oct 12, 2026			DP	
	9125816	Aug 30, 2020			U-1103	
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020			U-1103	
	9132089*PED	Mar 02, 2021				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE - AXIRON</u>						
N 022504 001	6299900	Feb 19, 2017	DP U-1103			
	6818226	Feb 19, 2017	DP U-1103			
	6923983	Feb 19, 2017	DP U-1103			
	8071075	Feb 19, 2017	DP U-1103			
	8419307	Feb 26, 2027	U-1386			
	8435944	Sep 27, 2027	U-1390			
	8784878	Jul 13, 2023	DP U-1545			
	8807861	Feb 26, 2027	DP U-1563			
	8993520	Jun 02, 2026	U-1390			
	9180194	Jun 02, 2026	U-1390			
	9289586	Feb 26, 2027	U-1390			
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 002	8785426	Feb 11, 2034	DP U-1531		NP	Jun 04, 2017
	9295675	Feb 11, 2034	DP U-1531			
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 003	8785426	Feb 11, 2034	DP U-1531		NP	Jun 04, 2017
	9295675	Feb 11, 2034	DP U-1531			
<u>TESTOSTERONE - NATESTO</u>						
N 205488 001	8574622	Feb 04, 2024	DP		NP	May 28, 2017
	8784869	Feb 04, 2024	DP			
	8784882	Feb 04, 2024	DP U-1557			
	8877230	Feb 04, 2024	U-1616			
<u>TESTOSTERONE UNDECANOATE - AVEED</u>						
N 022219 001	7718640	Mar 14, 2027	DP		NP	Mar 05, 2017
	8338395	Feb 27, 2026	U-1500			
<u>THALIDOMIDE - THALOMID</u>						
N 020785 001	6045501	Aug 28, 2018	U-371			
	6045501	Aug 28, 2018	U-731			
	6315720	Oct 23, 2020	U-442			
	6315720	Oct 23, 2020	U-731			
	6561976	Aug 28, 2018	U-371			
	6561976	Aug 28, 2018	U-731			
	6561977	Oct 23, 2020	U-371			
	6561977	Oct 23, 2020	U-731			
	6755784	Oct 23, 2020	U-371			
	6755784	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-371			
	6869399	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-732			
	6869399	Oct 23, 2020	U-733			
	6908432	Aug 28, 2018	U-371			
	6908432	Aug 28, 2018	U-731			
	7141018	Oct 23, 2020	U-371			
	7141018	Oct 23, 2020	U-731			
	7141018	Oct 23, 2020	U-732			
	7141018	Oct 23, 2020	U-733			
	7230012	Dec 09, 2023	DP			
	7435745	Nov 03, 2017	U-899			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			
	8204763	Aug 28, 2018	U-1249			
	8315886	Oct 23, 2020	U-1249			
	8589188	Aug 28, 2018	U-1465			
	8626531	Oct 23, 2020	U-1465			
<u>THALIDOMIDE - THALOMID</u>						
N 020785 002	6045501	Aug 28, 2018	U-371			
	6045501	Aug 28, 2018	U-731			
	6315720	Oct 23, 2020	U-442			
	6315720	Oct 23, 2020	U-731			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>THALIDOMIDE - THALOMID</u>						
N 020785 002	6561976	Aug 28, 2018	U-371			
	6561976	Aug 28, 2018	U-731			
	6561977	Oct 23, 2020	U-371			
	6561977	Oct 23, 2020	U-731			
	6755784	Oct 23, 2020	U-371			
	6755784	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-371			
	6869399	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-732			
	6869399	Oct 23, 2020	U-733			
	6908432	Aug 28, 2018	U-371			
	6908432	Aug 28, 2018	U-731			
	7141018	Oct 23, 2020	U-371			
	7141018	Oct 23, 2020	U-731			
	7141018	Oct 23, 2020	U-732			
	7141018	Oct 23, 2020	U-733			
	7230012	Dec 09, 2023		DP		
	7435745	Nov 03, 2017	U-899			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			
	8204763	Aug 28, 2018	U-1249			
	8315886	Oct 23, 2020	U-1249			
	8589188	Aug 28, 2018	U-1465			
	8626531	Oct 23, 2020	U-1465			
<u>THALIDOMIDE - THALOMID</u>						
N 020785 003	6045501	Aug 28, 2018	U-371			
	6045501	Aug 28, 2018	U-731			
	6315720	Oct 23, 2020	U-442			
	6315720	Oct 23, 2020	U-731			
	6561976	Aug 28, 2018	U-371			
	6561976	Aug 28, 2018	U-731			
	6561977	Oct 23, 2020	U-371			
	6561977	Oct 23, 2020	U-731			
	6755784	Oct 23, 2020	U-371			
	6755784	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-371			
	6869399	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-732			
	6869399	Oct 23, 2020	U-733			
	6908432	Aug 28, 2018	U-371			
	6908432	Aug 28, 2018	U-731			
	7141018	Oct 23, 2020	U-371			
	7141018	Oct 23, 2020	U-731			
	7141018	Oct 23, 2020	U-732			
	7141018	Oct 23, 2020	U-733			
	7230012	Dec 09, 2023		DP		
	7435745	Nov 03, 2017	U-899			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			
	8204763	Aug 28, 2018	U-1249			
	8315886	Oct 23, 2020	U-1249			
	8589188	Aug 28, 2018	U-1465			
	8626531	Oct 23, 2020	U-1465			
<u>THALIDOMIDE - THALOMID</u>						
N 020785 004	6045501	Aug 28, 2018	U-731			
	6315720	Oct 23, 2020	U-731			
	6561976	Aug 28, 2018	U-731			
	6561977	Oct 23, 2020	U-731			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>THALIDOMIDE - THALOMID</u>						
N 020785	004	6755784	Oct 23, 2020	U-731		
		6869399	Oct 23, 2020	U-731		
		6908432	Aug 28, 2018	U-731		
		7141018	Oct 23, 2020	U-731		
		7435745	Nov 03, 2017	U-899		
		7874984	Aug 28, 2018	U-371		
		7874984	Aug 28, 2018	U-442		
		7874984	Aug 28, 2018	U-732		
		7874984	Aug 28, 2018	U-733		
		7874984	Aug 28, 2018	U-1109		
		7959566	Oct 23, 2020	U-1155		
		8204763	Aug 28, 2018	U-1249		
		8315886	Oct 23, 2020	U-1249		
		8589188	Aug 28, 2018	U-1465		
		8626531	Oct 23, 2020	U-1465		
<u>TIAGABINE HYDROCHLORIDE - GABITRIL</u>						
N 020646	001	5958951	Jun 10, 2017			
<u>TIAGABINE HYDROCHLORIDE - GABITRIL</u>						
N 020646	002	5958951	Jun 10, 2017			
<u>TIAGABINE HYDROCHLORIDE - GABITRIL</u>						
N 020646	003	5958951	Jun 10, 2017			
<u>TIAGABINE HYDROCHLORIDE - GABITRIL</u>						
N 020646	004	5958951	Jun 10, 2017			
<u>TIAGABINE HYDROCHLORIDE - GABITRIL</u>						
N 020646	005	5958951	Jun 10, 2017			
<u>TICAGRELOR - BRILINTA</u>						
N 022433	001	6251910	Jul 15, 2018	DS	I-714	Sep 03, 2018
		6525060	Dec 02, 2019	DS DP U-1171	NCE	Jul 20, 2016
		6525060	Dec 02, 2019	DS DP U-1860		
		6525060	Dec 02, 2019	DS DP U-1862		
		6525060	Dec 02, 2019	DS DP U-1863		
		7250419	Dec 02, 2019	DS DP U-1171		
		7250419	Dec 02, 2019	DS DP U-1860		
		7250419	Dec 02, 2019	DS DP U-1864		
		7250419	Dec 02, 2019	DS DP U-1865		
		7250419	Dec 02, 2019	DS DP U-1866		
		7250419	Dec 02, 2019	DS DP U-1867		
		7265124	Jul 09, 2021	DS DP U-1171		
		7265124	Jul 09, 2021	DS DP U-1860		
		7265124	Jul 09, 2021	DS DP U-1868		
		7265124	Jul 09, 2021	DS DP U-1869		
		8425934	Apr 17, 2030	DP		
<u>TICAGRELOR - BRILINTA</u>						
N 022433	002	6251910	Jul 15, 2018	DS	NCE	Jul 20, 2016
		6525060	Dec 02, 2019	DS DP U-1171	NS	Sep 03, 2018
		6525060	Dec 02, 2019	DS DP U-1860		
		6525060	Dec 02, 2019	DS DP U-1862		
		6525060	Dec 02, 2019	DS DP U-1863		
		7250419	Dec 02, 2019	DS DP U-1171		
		7250419	Dec 02, 2019	DS DP U-1860		
		7250419	Dec 02, 2019	DS DP U-1864		
		7250419	Dec 02, 2019	DS DP U-1865		
		7250419	Dec 02, 2019	DS DP U-1866		
		7250419	Dec 02, 2019	DS DP U-1867		
		7265124	Jul 09, 2021	DS DP U-1171		
		7265124	Jul 09, 2021	DS DP U-1860		
		7265124	Jul 09, 2021	DS DP U-1868		
		7265124	Jul 09, 2021	DS DP U-1869		
		8425934	Apr 17, 2030	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TIGECYCLINE - TYGACIL</u>						
N 021821	001	7879828	Feb 05, 2029	DP		
		8372995	Oct 08, 2030	DP		
		8975242	Oct 24, 2028	DP		
		9254328	Mar 13, 2026	DP		
<u>TIMOLOL MALEATE - TIMOLOL MALEATE</u>						
N 020963	001	6174524	Mar 26, 2019	DP		
<u>TIMOLOL MALEATE - TIMOLOL MALEATE</u>						
N 020963	002	6174524	Mar 26, 2019	DP		
<u>TIMOLOL MALEATE - ISTALOL</u>						
N 021516	001	6335335	Nov 02, 2018	DP		
		6645963	Nov 16, 2018	DP		
<u>TIOTROPIUM BROMIDE - SPIRIVA</u>						
N 021395	001	6777423	Sep 24, 2021	DS DP		
		6908928	Sep 24, 2021	DS DP U-566		
		6908928	Sep 24, 2021	DS DP U-762		
		7070800	Jan 22, 2022	DP U-566		
		7309707	Sep 24, 2021	DS DP		
		7642268	Sep 24, 2021	DS DP		
		7694676	Mar 12, 2027	DP		
		8022082	Jan 19, 2026	DP U-1186		
		RE38912	Oct 11, 2021	DP		
		RE39820	Jan 30, 2018	DS DP U-566		
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936	001	5964416	Oct 04, 2016	DP	NP	Sep 24, 2017
		6149054	Dec 16, 2016	DP	PED	Mar 24, 2018
		6453795	Dec 05, 2016	DP		
		6726124	Oct 04, 2016	DP		
		6846413	Aug 28, 2018	DP		
		6977042	Aug 28, 2018	DP		
		6988496	Feb 23, 2020	DP		
		7104470	Oct 04, 2016	DP		
		7284474	Aug 26, 2024	DP		
		7396341	Oct 10, 2026	DP		
		7802568	Feb 26, 2019	DP		
		7837235	Mar 13, 2028	DP		
		7896264	May 26, 2025	DP		
		7988001	Aug 04, 2021	DP		
		8733341	Dec 16, 2029	DP		
		9027967	Mar 31, 2027	DP		
		RE39820	Jan 30, 2018	DS DP U-1593		
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936	002	5964416	Oct 04, 2016	DP	NP	Sep 15, 2018
		6149054	Dec 16, 2016	DP	PED	Mar 15, 2019
		6453795	Dec 05, 2016	DP		
		6726124	Oct 04, 2016	DP		
		6846413	Aug 28, 2018	DP		
		6977042	Aug 28, 2018	DP		
		6988496	Feb 23, 2020	DP		
		7104470	Oct 04, 2016	DP		
		7284474	Aug 26, 2024	DP		
		7396341	Oct 10, 2026	DP		
		7802568	Feb 26, 2019	DP		
		7837235	Mar 13, 2028	DP		
		7896264	May 26, 2025	DP		
		7988001	Aug 04, 2021	DP		
		8733341	Dec 16, 2029	DP		
		9027967	Mar 31, 2027	DP		
		RE39820	Jan 30, 2018	DS DP		
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURE</u>						
N 207981	001	6479500	Mar 16, 2020	U-1751	NCE	Sep 22, 2020
		7799783	Dec 16, 2026	U-1751		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TIPRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURE</u>						
N 207981	002	6479500	Mar 16, 2020	U-1751	NCE	Sep 22, 2020
		7799783	Dec 16, 2026	U-1751		
<u>TIPRANA VIR - APTIVUS</u>						
N 021814	001	5852195	Jun 22, 2019	DS		
		6147095	Oct 29, 2019	U-670		
		6231887	Jul 27, 2018	DP		
<u>TIPRANA VIR - APTIVUS</u>						
N 022292	001	5852195	Jun 22, 2019	DS		
		6147095	Oct 29, 2019	U-670		
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020912	001	5733919	Oct 23, 2016			
		5965581	Oct 23, 2016			
		5972967	Oct 23, 2016			
		5978698	Oct 08, 2017			
		6136794	Jan 29, 2019			
		6770660	May 01, 2023	U-1444		
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020912	002	5733919	Oct 23, 2016	DS		
		5965581	Oct 23, 2016	DP		
		5972967	Oct 23, 2016	DP		
		5978698	Oct 08, 2017	U-1897		
		6136794	Jan 29, 2019	U-1898		
		6770660	May 01, 2023	U-1444		
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913	001	5733919	Oct 23, 2016			
		5965581	Oct 23, 2016			
		5972967	Oct 23, 2016			
		5978698	Oct 08, 2017			
		6136794	Jan 29, 2019			
		6770660	May 01, 2023	U-1444		
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913	002	5733919	Oct 23, 2016			
		5965581	Oct 23, 2016			
		5972967	Oct 23, 2016			
		5978698	Oct 08, 2017			
		6136794	Jan 29, 2019			
		6770660	May 01, 2023	U-1444		
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913	003	5733919	Oct 23, 2016			
		5965581	Oct 23, 2016			
		5972967	Oct 23, 2016			
		5978698	Oct 08, 2017			
		6136794	Jan 29, 2019			
		6770660	May 01, 2023	U-1444		
<u>TOBRAMYCIN - TOBI PODHALEK</u>						
N 201688	001	7368102	Dec 19, 2022	DP	U-909	
		7442388	May 10, 2020	DP		
		7516741	Jan 11, 2024	DP		
		7559325	Oct 27, 2025	DP		
		8069851	Sep 24, 2024	DP		
		8349294	May 10, 2020	DP		
		8715623	Dec 19, 2022	DP	U-909	
<u>TOBRAMYCIN - BETHKIS</u>						
N 201820	001	6987094	Sep 22, 2022	DP		
		7696178	Mar 17, 2023	DP		
		7939502	Jun 14, 2022	U-1324		
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214	001	6956041	Dec 08, 2020	DP	M-135	Feb 21, 2017
		6965027	Mar 25, 2023	DS	NCE	Nov 06, 2017

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214	001	7091208				
		Dec 08, 2020		U-247		
		7265221	DS			
		Dec 08, 2020				
		7301023	DS			
		May 23, 2022				
		RE41783	DS			
		Dec 08, 2020				
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246	001	6956041		DP	NCE	Nov 06, 2017
		Dec 08, 2020				
		6965027	DS			
		Mar 25, 2023				
		7091208		U-247		
		Dec 08, 2020				
		7265221	DS			
		Dec 08, 2020				
		7301023	DS			
		May 23, 2022				
		RE41783	DS			
		Dec 08, 2020				
<u>TOLTERODINE TARTRATE - DETROL LA</u>						
N 021228	001	6630162		DP U-544		
		Nov 11, 2019				
		6770295		DP U-544		
		Aug 26, 2019				
		6911217		DP U-544		
		Nov 11, 2019				
		6911217*PED				
		May 11, 2020				
<u>TOLTERODINE TARTRATE - DETROL LA</u>						
N 021228	002	6630162		DP U-544		
		Nov 11, 2019				
		6770295		DP U-544		
		Aug 26, 2019				
		6911217		DP U-544		
		Nov 11, 2019				
		6911217*PED				
		May 11, 2020				
<u>TOLVAPTAN - SAMSCA</u>						
N 022275	001	5753677				
		May 19, 2020		U-978		
		8501730	DS			
		Sep 01, 2026				
<u>TOLVAPTAN - SAMSCA</u>						
N 022275	002	5753677			U-978	
		May 19, 2020				
		8501730	DS			
		Sep 01, 2026				
<u>TOLVAPTAN - SAMSCA</u>						
N 022275	003	5753677			U-978	
		May 19, 2020				
		8501730	DS			
		Sep 01, 2026				
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505	001				NPP	Mar 28, 2017
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505	002				NPP	Mar 28, 2017
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505	003				NPP	Mar 28, 2017
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505	004				NPP	Mar 28, 2017
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505	005				NPP	Mar 28, 2017
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505	006				NPP	Mar 28, 2017
<u>TOPIRAMATE - TOPAMAX</u>						
N 020844	001	7125560	Mar 01, 2019	U-766	NPP	Mar 28, 2017
<u>TOPIRAMATE - TOPAMAX</u>						
N 020844	002	7125560	Mar 01, 2019	U-766	NPP	Mar 28, 2017
<u>TOPIRAMATE - TOPAMAX SPRINKLE</u>						
N 020844	003	7125560	Mar 01, 2019	U-766	NPP	Mar 28, 2017
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635	001	8298576	Apr 04, 2028	DP U-106		
		8298580	Nov 16, 2027	DP U-106		
		8663683	Nov 16, 2027	DP U-106		
		8877248	Nov 16, 2027	DP U-106		
		8889191	Nov 16, 2027	U-106		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635	001 8992989	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635	002 8298576	Apr 04, 2028	DP U-106			
	8298580	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-106			
	8889191	Nov 16, 2027	U-106			
	8992989	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635	003 8298576	Apr 04, 2028	DP U-106			
	8298580	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-106			
	8889191	Nov 16, 2027	U-106			
	8992989	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635	004 8298576	Apr 04, 2028	DP U-106			
	8298580	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-106			
	8889191	Nov 16, 2027	U-106			
	8992989	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122	001 8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
	9101545	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122	002 8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
	9101545	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122	003 8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
	9101545	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122	004 8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
	9101545	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122	005 8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
	9101545	Mar 19, 2033	DP			
<u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u>						
N 020981	001 8158645	Dec 10, 2024	DP			
<u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u>						
N 020981	002 8158645	Dec 10, 2024	DP			
<u>TRABECTEDIN - YONDELIS</u>						
N 207953	001 8895557	Jan 07, 2028	DP		NCE ODE	Oct 23, 2020 Oct 23, 2022
<u>TRAMADOL HYDROCHLORIDE - ULTRAM</u>						
N 020281	001 6339105	Oct 12, 2019	U-435			
<u>TRAMADOL HYDROCHLORIDE - ULTRAM</u>						
N 020281	002 6339105	Oct 12, 2019	U-435			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TRAMADOL HYDROCHLORIDE - RYBIX ODT</u>						
N 021693	001 6106861	Dec 05, 2017	DP			
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N 021745	001 6607748	Jun 29, 2020	DP			
	7988998	Oct 27, 2023	DP			
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N 021745	002 6607748	Jun 29, 2020	DP			
	7988998	Oct 27, 2023	DP			
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N 021745	003 6607748	Jun 29, 2020	DP			
	7988998	Oct 27, 2023	DP			
<u>TRAMADOL HYDROCHLORIDE - CONZIP</u>						
N 022370	001 7858118	Apr 11, 2022	DP U-1104			
<u>TRAMADOL HYDROCHLORIDE - CONZIP</u>						
N 022370	002 7858118	Apr 11, 2022	DP U-1104			
<u>TRAMADOL HYDROCHLORIDE - CONZIP</u>						
N 022370	003 7858118	Apr 11, 2022	DP U-1104			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114	001 7378423	Sep 13, 2025	DS DP		I-678	Jan 08, 2017
	8580304	Jan 28, 2032	DP		M-170	Nov 20, 2018
	8703781	Oct 15, 2030	DS DP U-1712		NCE	May 29, 2018
	8835443	Sep 13, 2025	U-1581		ODE	May 29, 2020
	8835443	Sep 13, 2025	U-1582		ODE	Jan 08, 2021
	9155706	Jan 28, 2032	DP			
	9271941	Jan 28, 2032	DP			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114	002 7378423	Sep 13, 2025	DS DP		I-678	Jan 08, 2017
	8580304	Jan 28, 2032	DP		NCE	May 29, 2018
	8703781	Oct 15, 2030	DS DP U-1712		ODE	May 29, 2020
	8835443	Sep 13, 2025	U-1581		ODE	Jan 08, 2021
	8835443	Sep 13, 2025	U-1582			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114	003 7378423	Sep 13, 2025	DS DP		I-678	Jan 08, 2017
	8580304	Jan 28, 2032	DP		M-170	Nov 20, 2018
	8703781	Oct 15, 2030	DS DP U-1712		NCE	May 29, 2018
	8835443	Sep 13, 2025	U-1581		ODE	May 29, 2020
	8835443	Sep 13, 2025	U-1582		ODE	Jan 08, 2021
	9155706	Jan 28, 2032	DP			
	9271941	Jan 28, 2032	DP			
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N 022430	001 7947739	Mar 04, 2025	DP			
	8022106	Mar 04, 2025	U-1182			
	8273795	Mar 04, 2025	U-1182			
	8487005	Mar 04, 2025	DP U-1182			
	8791160	Mar 04, 2025	DP U-1182			
	8809394	Mar 04, 2025	DP U-1182			
	8957113	Mar 04, 2025	DP U-1182			
	9060939	Mar 04, 2025	DP			
<u>TRAVOPROST - TRAVATAN Z</u>						
N 021994	001 8268299	Oct 13, 2029	DP			
	8323630	Sep 20, 2027	DP			
	8388941	Sep 20, 2027	DP			
<u>TRAVOPROST - IZBA</u>						
N 204822	001 8178582	Oct 10, 2029	DP		NP	May 15, 2017
	8722735	Oct 10, 2029	DP			
	8754123	May 19, 2029	DP			
	9144561	Mar 13, 2029	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207 001	8133893	Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207 002	8133893	Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207 003	8133893	Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207 004	8133893	Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N 022411 001	6607748	Jun 29, 2020	DP			
	7829120	Mar 27, 2027	DP U-796			
	8133893	Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N 022411 002	6607748	Jun 29, 2020	DP			
	7829120	Mar 27, 2027	DP U-796			
	8133893	Mar 13, 2029	DS DP			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 001	6765117	Oct 24, 2017	DS			
	7999007	Mar 29, 2029	DP U-1437			
	8497393	Dec 15, 2028	DS			
	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
	9199908	May 24, 2024	U-1771			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 002	6765117	Oct 24, 2017	DS			
	7999007	Mar 29, 2029	DP U-1437			
	8497393	Dec 15, 2028	DS			
	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
	9199908	May 24, 2024	U-1771			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 003	6765117	Oct 24, 2017	DS			
	7999007	Mar 29, 2029	DP U-1437			
	8497393	Dec 15, 2028	DS			
	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
	9199908	May 24, 2024	U-1771			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004	6765117	Oct 24, 2017	DS			
	7999007	Mar 29, 2029	DP U-1437			
	8497393	Dec 15, 2028	DS			
	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
	9199908	May 24, 2024	U-1771			
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	6521212	Nov 13, 2018	U-1018		M-145	May 20, 2017
	6756033	Nov 13, 2018	U-1018		ODE	Jul 30, 2016
	6765117	Oct 24, 2017	DS			
	8497393	Dec 15, 2028	DS			
	9339507	Mar 10, 2028	DP			
	9358240	May 05, 2028	U-1849			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	6765117	Oct 24, 2017	DS		D-156	Jan 28, 2019
	7417070	Jul 30, 2026	DS		D-157	Jan 28, 2019
	7544713	Jul 14, 2024	U-1475		NDF	Dec 20, 2016
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	8747897	Oct 08, 2029	DP			
	9050311	May 24, 2024	DS DP			
	9278901	May 24, 2024		U-1475		
	9393203	Apr 27, 2026	DP	U-1877		
	9422223	May 24, 2024	DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	6765117	Oct 24, 2017	DS		D-156	Jan 28, 2019
	7417070	Jul 30, 2026	DS		D-157	Jan 28, 2019
	7544713	Jul 14, 2024		U-1475	NDF	Dec 20, 2016
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS			
	8747897	Oct 08, 2029	DP			
	9050311	May 24, 2024	DS DP			
	9278901	May 24, 2024		U-1475		
	9393203	Apr 27, 2026	DP	U-1877		
	9422223	May 24, 2024	DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	6765117	Oct 24, 2017	DS		D-156	Jan 28, 2019
	7417070	Jul 30, 2026	DS		D-157	Jan 28, 2019
	7544713	Jul 14, 2024		U-1475	NDF	Dec 20, 2016
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS			
	8747897	Oct 08, 2029	DP			
	9050311	May 24, 2024	DS DP			
	9278901	May 24, 2024		U-1475		
	9393203	Apr 27, 2026	DP	U-1877		
	9422223	May 24, 2024	DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	6765117	Oct 24, 2017	DS		D-156	Jan 28, 2019
	7417070	Jul 30, 2026	DS		D-157	Jan 28, 2019
	7544713	Jul 14, 2024		U-1475	NDF	Dec 20, 2016
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS			
	8747897	Oct 08, 2029	DP			
	9050311	May 24, 2024	DS DP			
	9278901	May 24, 2024		U-1475		
	9393203	Apr 27, 2026	DP	U-1877		
	9422223	May 24, 2024	DP			
<u>TRETINOIN - RETIN-A MICRO</u>						
N 020475 001	5955109	Sep 21, 2016	DP	U-134		
<u>TRETINOIN - RETIN-A MICRO</u>						
N 020475 002	5955109	Sep 21, 2016		U-134		
<u>TRETINOIN - RETIN-A-MICRO</u>						
N 020475 003	5955109	Sep 21, 2016	DP	U-134		
<u>TRETINOIN - RENOVA</u>						
N 021108 001	6531141	Mar 07, 2020				
<u>TRIAMCINOLONE ACETONIDE - NASACORT ALLERGY 24 HOUR</u>						
N 020468 002	5976573	Jul 03, 2016	DP			
	6143329	Jul 03, 2016	DP			
	7977045	Jul 03, 2016	DP			
<u>TRIAMCINOLONE ACETONIDE - TRIESENC</u>						
N 022048 001	6395294	Jan 13, 2020	DP	U-846		
	8128960	Dec 17, 2029	DP			
	8211880	Mar 10, 2029		U-1257		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TRIAMCINOLONE ACETONIDE - TRIESENC</u>						
N 022048	001 8211880	Mar 10, 2029	U-1258			
<u>TRIMETHOPRIM HYDROCHLORIDE - PRIMSO</u>						
N 074973	001 5763449	Aug 07, 2016				
	5962461	Aug 07, 2016				
<u>TRIMETREXATE GLUCURONATE - NEUTREXIN</u>						
N 020326	001 6017922	May 18, 2018				
<u>TRIMETREXATE GLUCURONATE - NEUTREXIN</u>						
N 020326	002 6017922	May 18, 2018				
<u>TROGLITAZONE - PRELAY</u>						
N 020719	001 5859037	Nov 13, 2017	U-251			
	6011049	Nov 13, 2017	U-301			
<u>TROGLITAZONE - PRELAY</u>						
N 020719	002 5859037	Nov 13, 2017	U-251			
	6011049	Nov 13, 2017	U-301			
<u>TROGLITAZONE - PRELAY</u>						
N 020719	003 5859037	Nov 13, 2017	U-251			
	6011049	Nov 13, 2017	U-301			
<u>TROSPIMUM CHLORIDE - SANCTURA XR</u>						
N 022103	001 7410978	Feb 01, 2025	DP			
	7759359	Nov 04, 2024	U-1071			
	7763635	Nov 04, 2024	U-1071			
	7781448	Nov 04, 2024	U-1071			
	7781449	Nov 04, 2024	U-1071			
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474	001 8426392	Jun 12, 2030	U-1389			
	8512745	Jun 02, 2030	DP			
	8735380	Feb 20, 2029	DP			
	8962603	Jun 12, 2030	U-1657			
	9283233	Apr 13, 2030	U-1821			
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382	001 7488827	Apr 27, 2025	DS DP		M-172	Feb 24, 2019
	7498440	Apr 27, 2025	DS DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8183257	Jul 27, 2025	U-1476			
	8201556	Feb 05, 2029	DP			
	8309572	Apr 27, 2025	U-1476			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			
	9333310	Oct 02, 2027	DP			
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975	001 7439393	Sep 11, 2022	DS DP U-1476		NP	Dec 18, 2016
	7488827	Apr 27, 2025	DS DP			
	7498440	Apr 27, 2025	DS DP			
	7776895	Sep 11, 2022	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8183257	Jul 27, 2025	U-1476			
	8309572	Apr 27, 2025	U-1476			
	8511304	Jun 14, 2027	DP U-1476			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			
	9333310	Oct 02, 2027	DP			
	RE44874	Mar 23, 2023	DS DP U-1476			
<u>UNOPROSTONE ISOPROPYL - RESCULA</u>						
N 021214	001 6458836	Jul 09, 2021	U-333			
	6458836	Jul 09, 2021	U-1315			
	6770675	Nov 24, 2018	DP U-1322			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>URIDINE TRIACETATE - VISTOGARD</u>						
N 208159 001	5968914	Oct 19, 2016	U-1791		NCE	Sep 04, 2020
	6258795	Jul 10, 2018	DP		NP	Dec 11, 2018
	7776838	Aug 17, 2027	U-1791		ODE	Dec 11, 2022
<u>URIDINE TRIACETATE - XURIDEN</u>						
N 208169 001	6258795	Jul 10, 2018	DP		NCE ODE	Sep 04, 2020 Sep 04, 2022
<u>UROFOLLITROPIN - BRAVELLE</u>						
N 021289 001					D-139	Feb 19, 2017
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 021304 001					D-148 NPP	Apr 23, 2018 Apr 23, 2018
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 022257 001					D-148 NPP	Apr 23, 2018 Apr 23, 2018
<u>VALSARTAN - DIOVAN</u>						
N 021283 001	5972990	Oct 26, 2016	U-692			
	6294197	Jun 18, 2017	U-3			
<u>VALSARTAN - DIOVAN</u>						
N 021283 002	5972990	Oct 26, 2016	U-692			
	6294197	Jun 18, 2017	U-3			
<u>VALSARTAN - DIOVAN</u>						
N 021283 003	5972990	Oct 26, 2016	U-692			
	6294197	Jun 18, 2017	U-3			
<u>VALSARTAN - DIOVAN</u>						
N 021283 004	5972990	Oct 26, 2016	U-692			
	6294197	Jun 18, 2017	U-3			
<u>VANDETANIB - CAPRELSA</u>						
N 022405 001	8067427	Aug 08, 2028	DP		ODE	Apr 06, 2018
	RE42353	Jun 27, 2022	DS DP			
<u>VANDETANIB - CAPRELSA</u>						
N 022405 002	8067427	Aug 08, 2028	DP		ODE	Apr 06, 2018
	RE42353	Jun 27, 2022	DS DP			
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N 021400 001	6362178	Oct 31, 2018	DS DP U-533			
	7696206	Oct 31, 2018	DS DP U-533			
	8273876	Jul 23, 2027	U-1288			
	8841446	Jul 03, 2023	DP			
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N 021400 002	6362178	Oct 31, 2018	DS DP U-533			
	7696206	Oct 31, 2018	DS DP U-533			
	8273876	Jul 23, 2027	U-1288			
	8841446	Jul 03, 2023	DP			
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N 021400 003	6362178	Oct 31, 2018	DS DP U-533			
	7696206	Oct 31, 2018	DS DP U-533			
	8273876	Jul 23, 2027	U-1288			
	8841446	Jul 03, 2023	DP			
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N 021400 004	6362178	Oct 31, 2018	DS DP U-533			
	7696206	Oct 31, 2018	DS DP U-533			
	8273876	Jul 23, 2027	U-1288			
	8841446	Jul 03, 2023	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VARDENAFIL HYDROCHLORIDE - STAXYN</u>						
N 200179	001	6362178	Oct 31, 2018	U-155		
		7696206	Oct 31, 2018	U-155		
		8613950	Dec 23, 2028	DP		
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928	001	6410550	May 10, 2020	DS DP U-56	M-143	Oct 15, 2017
		6890927	May 06, 2022	DS DP U-56	M-144	Oct 15, 2017
		7265119	Aug 03, 2022	DS DP U-56	M-183	Aug 12, 2019
					M-192	Dec 16, 2019
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928	002	6410550	May 10, 2020	DS DP U-56	M-143	Oct 15, 2017
		6890927	May 06, 2022	DS DP U-56	M-144	Oct 15, 2017
		7265119	Aug 03, 2022	DS DP U-56	M-183	Aug 12, 2019
					M-192	Dec 16, 2019
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485	001	9375478	Jan 30, 2035	U-1857		
<u>VELAGLUCERASE ALFA - VPRIV</u>						
N 022575	001				M-130	Nov 21, 2016
<u>VELAGLUCERASE ALFA - VPRIV</u>						
N 022575	002				M-130	Nov 21, 2016
<u>VEMURAFENIB - ZELBORAF</u>						
N 202429	001	7504509	Oct 22, 2026	DS DP	M-184	Aug 31, 2019
		7863288	Jun 20, 2029	DS DP	NCE	Aug 17, 2016
		8143271	Jun 21, 2026	DS DP	ODE	Aug 17, 2018
		8470818	Aug 02, 2026	U-1418		
		8741920	Jul 27, 2030	DS DP		
		9447089	Jun 06, 2032	DP		
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573	001	8546399	Jun 27, 2031	DS DP	NCE	Apr 11, 2021
		9174982	May 26, 2030	U-1835	ODE	Apr 11, 2023
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573	002	8546399	Jun 27, 2031	DS DP	NCE	Apr 11, 2021
		9174982	May 26, 2030	U-1835	ODE	Apr 11, 2023
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573	003	8546399	Jun 27, 2031	DS DP	NCE	Apr 11, 2021
		9174982	May 26, 2030	U-1835	ODE	Apr 11, 2023
<u>VENLAFAXINE HYDROCHLORIDE - EFFEXOR XR</u>						
N 020699	001	6274171	Mar 20, 2017			
		6403120	Mar 20, 2017	U-451		
		6403120	Mar 20, 2017	U-535		
		6419958	Mar 20, 2017	U-459		
		6419958	Mar 20, 2017	U-535		
<u>VENLAFAXINE HYDROCHLORIDE - EFFEXOR XR</u>						
N 020699	002	6274171	Mar 20, 2017			
		6403120	Mar 20, 2017	U-451		
		6403120	Mar 20, 2017	U-535		
		6419958	Mar 20, 2017	U-459		
		6419958	Mar 20, 2017	U-535		
<u>VENLAFAXINE HYDROCHLORIDE - EFFEXOR XR</u>						
N 020699	003	6274171	Mar 20, 2017			
		6403120	Mar 20, 2017	U-451		
		6403120	Mar 20, 2017	U-535		
		6419958	Mar 20, 2017	U-459		
		6419958	Mar 20, 2017	U-535		
<u>VENLAFAXINE HYDROCHLORIDE - EFFEXOR XR</u>						
N 020699	004	6274171	Mar 20, 2017			
		6403120	Mar 20, 2017	U-451		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VENLAFAXINE HYDROCHLORIDE - EFFEXOR XR</u>						
N 020699	004	6419958	Mar 20, 2017	U-459		
		6419958	Mar 20, 2017	U-535		
<u>VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE</u>						
N 022104	001	6403120	Mar 20, 2017	U-535		
		6403120	Mar 20, 2017	U-839		
		6419958	Mar 20, 2017	U-535		
		6419958	Mar 20, 2017	U-839		
<u>VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE</u>						
N 022104	002	6403120	Mar 20, 2017	U-535		
		6403120	Mar 20, 2017	U-839		
		6419958	Mar 20, 2017	U-535		
		6419958	Mar 20, 2017	U-839		
<u>VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE</u>						
N 022104	003	6403120	Mar 20, 2017	U-535		
		6403120	Mar 20, 2017	U-839		
		6419958	Mar 20, 2017	U-535		
		6419958	Mar 20, 2017	U-839		
<u>VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE</u>						
N 022104	004	6403120	Mar 20, 2017	U-535		
		6403120	Mar 20, 2017	U-839		
		6419958	Mar 20, 2017	U-535		
		6419958	Mar 20, 2017	U-839		
<u>VERAPAMIL HYDROCHLORIDE - COVERA-HS</u>						
N 020552	001	6096339	Apr 04, 2017	U-365		
<u>VERAPAMIL HYDROCHLORIDE - COVERA-HS</u>						
N 020552	002	6096339	Apr 04, 2017	U-365		
<u>VIGABATRIN - SABRIL</u>						
N 020427	001				NPP PED	Oct 26, 2016 Apr 26, 2017
<u>VIGABATRIN - SABRIL</u>						
N 022006	001				NPP ODE PED PED	Oct 26, 2016 Aug 21, 2016 Feb 21, 2017 Apr 26, 2017
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567	001	5532241	Sep 29, 2019	DS DP	D-146	Mar 16, 2018
		7834020	Jun 05, 2022	DS DP U-839		
		8193195	Jun 05, 2022	U-839		
		8236804	Jun 05, 2022	U-839		
		8673921	Jun 05, 2022	DS DP		
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567	002	5532241	Sep 29, 2019	DS DP	D-146	Mar 16, 2018
		7834020	Jun 05, 2022	DS DP U-839		
		8193195	Jun 05, 2022	U-839		
		8236804	Jun 05, 2022	U-839		
		8673921	Jun 05, 2022	DS DP		
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567	003	5532241	Sep 29, 2019	DS DP	D-146	Mar 16, 2018
		7834020	Jun 05, 2022	DS DP U-839		
		8193195	Jun 05, 2022	U-839		
		8236804	Jun 05, 2022	U-839		
		8673921	Jun 05, 2022	DS DP		
<u>VINCRIStINE SULFATE - MARQIBO KIT</u>						
N 202497	001	6723338	Mar 31, 2020	U-1271	ODE	Aug 09, 2019
		7247316	Sep 25, 2020	DP		
		7887836	Mar 31, 2020	U-1271		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VISMODEGIB - ERIVEDGE</u>						
N 203388	001	7888364	Nov 11, 2028	DS DP	NCE	Jan 30, 2017
		9278961	Dec 15, 2028	U-1825		
<u>VORAPAXAR SULFATE - ZONTIVITY</u>						
N 204886	001	7235567	Jun 13, 2021	DS DP	NCE	May 08, 2019
		7304078	Apr 06, 2024	DS DP U-1512		
<u>VORICONAZOLE - VFEND</u>						
N 021267	001	6632803	Jun 02, 2018	DP		
<u>VORINOSTAT - ZOLINZA</u>						
N 021991	001	7399787	Feb 09, 2025	U-892		
		7456219	Mar 11, 2027	DS		
		7652069	Mar 04, 2023	DP		
		7732490	Mar 04, 2023	U-892		
		7851509	Feb 21, 2024	DP U-892		
		8067472	Mar 04, 2023	U-892		
		8093295	May 16, 2026	DP		
		8101663	Mar 04, 2023	U-892		
		8450372	Mar 18, 2028	U-892		
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447	001	7144884	Jan 09, 2023	DS DP U-1439	NCE	Sep 30, 2018
		8476279	Oct 02, 2022	DP U-1439		
		8722684	Jun 30, 2031	DS DP		
		8969355	Jun 15, 2027	U-1668		
		9227946	Jun 15, 2027	U-1668		
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447	002	7144884	Jan 09, 2023	DS DP U-1439	NCE	Sep 30, 2018
		8476279	Oct 02, 2022	DP U-1439		
		8722684	Jun 30, 2031	DS DP		
		8969355	Jun 15, 2027	U-1668		
		9227946	Jun 15, 2027	U-1668		
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447	003	7144884	Jan 09, 2023	DS DP U-1439	NCE	Sep 30, 2018
		8476279	Oct 02, 2022	DP U-1439		
		8722684	Jun 30, 2031	DS DP		
		8969355	Jun 15, 2027	U-1668		
		9227946	Jun 15, 2027	U-1668		
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447	004	7144884	Jan 09, 2023	DS DP U-1439	NCE	Sep 30, 2018
		8476279	Oct 02, 2022	DP U-1439		
		8722684	Jun 30, 2031	DS DP		
		8969355	Jun 15, 2027	U-1668		
		9227946	Jun 15, 2027	U-1668		
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060	001	5364842	Dec 30, 2016	U-48		
		5364842	Dec 30, 2016	U-55		
		8653033	Oct 01, 2024	U-48		
		8653033	Oct 01, 2024	U-55		
		8765680	Oct 01, 2024	U-48		
		8765680	Oct 01, 2024	U-55		
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060	002	5364842	Dec 30, 2016	U-48		
		5364842	Dec 30, 2016	U-55		
		8653033	Oct 01, 2024	U-48		
		8653033	Oct 01, 2024	U-55		
		8765680	Oct 01, 2024	U-48		
		8765680	Oct 01, 2024	U-55		
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060	003	5364842	Dec 30, 2016	U-48		
		5364842	Dec 30, 2016	U-55		
		8653033	Oct 01, 2024	U-48		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060	003	8653033	Oct 01, 2024	U-55		
		8765680	Oct 01, 2024	U-48		
		8765680	Oct 01, 2024	U-55		
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060	004	5364842	Dec 30, 2016	U-48		
		5364842	Dec 30, 2016	U-55		
		8653033	Oct 01, 2024	U-48		
		8653033	Oct 01, 2024	U-55		
		8765680	Oct 01, 2024	U-48		
		8765680	Oct 01, 2024	U-55		
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825	001	6150366	May 27, 2019	DP		
		6245766	Dec 18, 2018	U-601		
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825	002	6150366	May 27, 2019	DP		
		6245766	Dec 18, 2018	U-601		
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825	003	6150366	May 27, 2019	DP		
		6245766	Dec 18, 2018	U-601		
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825	004	6150366	May 27, 2019	DP		
		6245766	Dec 18, 2018	U-601		
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 021483	001	6150366	May 27, 2019	DP	U-719	
		6245766	Dec 18, 2018		U-601	
		7175855	May 18, 2020	DP		
<u>ZIPRASIDONE MESYLATE - GEODON</u>						
N 020919	001	6110918	Mar 26, 2017			
		6232304	Apr 01, 2017			
		6399777	Apr 01, 2017			
<u>ZOLEDRONIC ACID - ZOMETA</u>						
N 021223	002	8324189	May 29, 2025	U-53		
		8324189	May 29, 2025	U-1308		
		8324189	May 29, 2025	U-1309		
<u>ZOLEDRONIC ACID - ZOMETA</u>						
N 021223	003	7932241	Feb 05, 2028	DP		
		8324189	May 29, 2025	U-53		
		8324189	May 29, 2025	U-1308		
		8324189	May 29, 2025	U-1309		
<u>ZOLEDRONIC ACID - RECLAST</u>						
N 021817	001	7932241	Feb 05, 2028	DP		
		8052987	Oct 27, 2023	U-1199		
<u>ZOLMITRIPTAN - ZOMIG</u>						
N 021450	003	6750237	Nov 28, 2020	DP	NPP	Jun 12, 2018
		6750237*PED	May 28, 2021			
		7220767	Nov 28, 2020	DP		
		7220767*PED	May 28, 2021			
<u>ZOLMITRIPTAN - ZOMIG</u>						
N 021450	004	6750237	Nov 28, 2020	DP	NPP	Jun 12, 2018
		7220767	Nov 28, 2020	DP		
<u>ZOLPIDEM TARTRATE - ZOLPIDEM TARTRATE</u>						
A 204299	001				PC	Sep 18, 2016
<u>ZOLPIDEM TARTRATE - ZOLPIDEM TARTRATE</u>						
A 204299	002				PC	Sep 18, 2016

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ZOLPIDEM TARTRATE - AMBIEN CR</u>						
N 021774	001 6514531	Dec 01, 2019	DP			
<u>ZOLPIDEM TARTRATE - AMBIEN CR</u>						
N 021774	002 6514531	Dec 01, 2019	DP			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997	001 6761910	Sep 24, 2019	DP	U-674		
	8512747	Sep 24, 2019		U-674		
	9265720	May 13, 2030		U-674		
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997	002 6761910	Sep 24, 2019	DP	U-674		
	8512747	Sep 24, 2019		U-674		
	9265720	May 13, 2030		U-674		
<u>ZOLPIDEM TARTRATE - ZOLPIMIST</u>						
N 022196	001 7632517	Oct 01, 2017		U-70		
	8236285	Aug 07, 2032	DS DP	U-70		
<u>ZOLPIDEM TARTRATE - INTERMEZZO</u>						
N 022328	001 7658945	Apr 15, 2027	DP	U-1194		
	7682628	Feb 16, 2025		U-1194		
	8242131	Aug 20, 2029		U-1266		
	8252809	Feb 16, 2025	DP			
<u>ZOLPIDEM TARTRATE - INTERMEZZO</u>						
N 022328	002 7658945	Apr 15, 2027	DP	U-1194		
	7682628	Feb 16, 2025		U-1194		
	8242131	Aug 20, 2029		U-1266		
	8252809	Feb 16, 2025	DP			

Footnote:

1. Patent information is published on or after the submission date as defined in 21 CFR 314.53(d)(5).
2. Patent listings published prior to August 18, 2003, only identify method-of-use claims. The listed patents may include drug substance and/or drug product claims that are not indicated in the listing.
3. As of December 5, 2016, an NDA holder submitting information on a patent that claims both the drug substance and the drug product (and is eligible for listing on either basis) is required only to specify that it claims either the drug substance or the drug product. Orange Book users should not rely on an Orange Book patent listing, regardless of when first published, to determine the range of patent claims that may be asserted by an NDA holder or patent owner.

PATENT AND EXCLUSIVITY TERMS**PATENT & EXCLUSIVITY ABBREVIATIONS**

D	NEW DOSING SCHEDULE (SEE INDIVIDUAL REFERENCES)
GAIN	GAIN EXCLUSIVITY
I	NEW INDICATION (SEE INDIVIDUAL REFERENCES)
M	MISCELLANEOUS EXCLUSIVITY CODES (SEE INDIVIDUAL REFERENCES)
NC	NEW COMBINATION
NCE	NEW CHEMICAL ENTITY
NCE*	NEW CHEMICAL ENTITY (AN ENANTIOMER OF PREVIOUSLY APPROVED RACEMIC MIXTURE. SEE SECTION 505(U) OF THE FEDERAL FOOD AND DRUG COSMETIC ACT).
NDF	NEW DOSAGE FORM
NE	NEW ESTER OR SALT OF AN ACTIVE INGREDIENT
NP	NEW PRODUCT
NP*	NEW PRODUCT (MINT FLAVORED)
NPP	NEW PATIENT POPULATION
NR	NEW ROUTE
NS	NEW STRENGTH
ODE	ORPHAN DRUG EXCLUSIVITY
PC	PATENT CHALLENGE
PED	PEDIATRIC EXCLUSIVITY
RTO	RX TO OTC SWITCH OR OTC USE
RTO*	OTC USE FOR WOMEN AGES 15 AND 16
RTO**	OTC USE FOR WOMEN 14 AND BELOW
U	PATENT USE CODE
W	EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR - SEE SECTION 1.8 OF ORANGE BOOK PREFACE WAIVED EXCLUSIVITY

EXCLUSIVITY DOSING SCHEDULE

D-1	ONCE A DAY APPLICATION
D-2	ONCE DAILY DOSING
D-3	SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE
D-4	SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE
D-5	TEN DAYS/ELEVEN DAYS DOSING SCHEDULE
D-6	SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE
D-7	BID DOSING
D-8	INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING
D-9	NARCOTIC OVERDOSE IN ADULTS
D-10	NARCOTIC OVERDOSE IN CHILDREN
D-11	POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN
D-12	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER
D-13	INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION
D-14	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
D-15	SINGLE DAILY DOSE OF 25MG/37.5MG
D-16	CONTINUOUS INTRAVENOUS INFUSION
D-17	400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS
D-18	LOWER RECOMMENDED STARTING DOSE GUIDELINES
D-19	BOLUS DOSING GUIDELINES
D-20	SINGLE 32MG DOSE
D-21	ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL
D-22	REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE
D-23	INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN
D-24	FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M2 OR 175MG/M2 INTRAVENOUSLY OVER THREE HOURS EVERY THREE WEEKS
D-25	ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF THE ORIGINAL DOSING REGIMEN
D-26	ONCE WEEKLY APPLICATION
D-27	BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATE EMETOGENIC CANCER CHEMOTHERAPY
D-28	USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300
D-29	INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF CNS IN ADULTS
D-30	5000 IU DOSE FOR PROPHYLAXIS AGAINST DEEP VEIN THROMBOSIS
D-31	CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID)
D-32	REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY DOSING SCHEDULE**

- D-33 ONCE DAILY DOSING FOR PLAQUE PSORIASIS
- D-34 EVERY FOUR MONTHS DOSAGE REGIMEN
- D-35 FOR A ONE WEEK DOSING OF INTERDIGITAL TINEA PEDIS
- D-36 FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE 1MG DOSE GIVEN TWICE DAILY
- D-37 DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID)
- D-38 CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION
- D-39 CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM "...1/2 TO 1 HOUR BEFORE EATING" TO "... RIGHT BEFORE EATING OR UP TO 60MIN BEFORE CONSUMING..."
- D-40 ONCE-A-DAY DOSING REGIMEN
- D-41 DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS
- D-42 TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN, FOR THE ERADICATION OF H.PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
- D-43 INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD
- D-44 IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY 3 DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED
- D-45 ONCE DAILY DOSING FOR MAINTENANCE ONLY
- D-46 NEW DOSING REGIMEN OF 80MG DAILY
- D-47 PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL
- D-48 ADMINISTRATION OF CISATRACURIUM A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRACURIUM FOLLOWING INDUCTION WITH THIOFENTAL
- D-49 PEDIATRIC DOSING GUIDELINES
- D-50 INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS
- D-51 OPTIONAL STARTING DOSE OF 40MG/DAY
- D-52 ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY
- D-53 USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE
- D-54 USE OF ZYBAN FOR MAINTENANCE THERAPY. TREATMENT UP TO 6 MONTHS WAS SHOWN EFFICACIOUS
- D-55 ADDITION OF A HIGHER DOSE OF NUTROPIN FOR PUBERTAL PATIENTS (PUBERTAL DOSE LESS THAN OR EQUAL TO 0.7MG/KG/WEEK)
- D-56 ADDITION OF POSTPRANDIAL DOSING
- D-57 3-HOUR INFUSION OF TAXOL GIVEN EVERY THREE WEEKS AT A DOSE OF 175MG/M2 FOLLOWED BY CISPLATIN AT A DOSE OF 75MG/M2 FOR THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER
- D-58 CHANGE IN DOSING INTERVAL TO ONCE-DAILY ADMINISTRATION
- D-59 REDUCTION OF ELEVATED LDL-C IN A NEW, HIGHER STRENGTH TABLET, 0.8MG, AND FOR EXTENSION OF THE DOSAGE RANGE TO 0.8MG DAILY
- D-60 ADDITION OF A POST-OPERATIVE DOSING REGIMEN
- D-61 ONCE WEEKLY DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
- D-62 ONCE WEEKLY DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- D-63 TO ALLOW A TITRATION DOSING REGIMEN USING A 25MG DOSE
- D-64 INCREASING DOSAGE FOR NERVE BLOCK ANESTHESIA USING NAROPIN 7.5MG/ML AND FOR EXTENDING THE DURATION OF TREATMENT FOR POSTOPERATIVE ANALGESIA USING NAROPIN 2MG/ML
- D-65 CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS
- D-66 DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI
- D-67 SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES
- D-68 CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS
- D-69 SHORTENED DOSING REGIMEN TO 5 DAYS FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS
- D-70 80MG ONCE DAILY DOSING REGIMEN
- D-71 EIGHT WEEK DOSING REGIMEN
- D-72 INFORMATION REGARDING INCREASED RATE OF INFUSION FOR DEPACON
- D-73 ONCE A WEEK DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
- D-74 ONCE A WEEK DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- D-75 INTERMITTENT DOSING REGIMEN, STARTING DAILY DOSE 14 DAYS PRIOR TO THE ANTICIPATED

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY DOSING SCHEDULE**

- ONSET OF MENSTRUATION THROUGH THE FIRST FULL DAY OF MENSES AND REPEATING WITH EACH NEW CYCLE
- D-76 FOR USE ON AN "AS NEEDED" OR PRN BASIS FOR THE MANAGEMENT OF NASAL SYMPTOMS IN PATIENTS FOR WHOM THE DRUG IS INDICATED
- D-77 ADDITION OF 20MG AND 40MG DAILY AS OPTIONAL STARTING DOSES WITH 40MG INTENDED FOR PATIENTS WHO REQUIRE A LARGE REDUCTION IN LDL-C (MORE THAN 45%)
- D-78 USE OF FLEXERIL 5MG FOR THE RELIEF OF MUSCLE SPASM ASSOCIATED WITH ACUTE, PAINFUL, MUSCULOSKELETAL CONDITIONS
- D-79 NEW LOWER STARTING DOSE FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS AND/OR MODERATE TO SEVERE SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED W/ THE MENOPAUSE
- D-80 CHANGE OF DOSING SCHEDULE FOR LANTUS FROM ONCE DAILY AT BEDTIME TO FLEXIBLE DAILY DOSING
- D-81 NEW LOWER STARTING DOSE FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- D-82 USE OF PREMARIN 0.3 MG AND 0.45 MG FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- D-83 750 MG, ONCE DAILY FOR 5 DAYS FOR COMMUNITY ACQUIRED PNEUMONIA (CAP)
- D-84 ONCE-A-DAY DOSING OF FLOXACIN OTIC FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS (AGES 6 MO & OLDER) W/ OTITIS EXTERNA CAUSED BY SUSCEPTIBLE STRAINS OF E.COLI, P.AERUGINOSA AND S.AUREUS
- D-85 LOWER RECOMMENDED STARTING DOSE GUIDELINES FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE
- D-86 FOR USE IN SELECT EXTERNAL INSULIN PUMPS
- D-87 ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
- D-88 NEW DOSING RANGE OF 200-400MG PER DAY IN TWO DIVIDED DOSES FOR ADULTS WITH PARTIAL SEIZURES
- D-89 USE OF REYATAZ 300 MG/RITONAVIR 100 MG ONCE DAILY FOR TREATMENT IN HIV-INFECTED ANTIRETROVIRAL-EXPERIENCED PATIENTS
- D-90 ADDITION OF DAYTIME ADMINISTRATION TO TREAT VULVOVAGINAL CANDIDIASIS
- D-91 ALTERNATE INTERMITTENT DOSING REGIMEN
- D-92 ALTERNATIVE DOSAGE OF 1000MG ONCE DAILY AT BEDTIME
- D-93 ALTERNATE TWO OR THREE TIMES DAILY DOSING REGIMENS
- D-94 NEW MAXIMUM DOSAGE OF 72 MG/DAY IN ADOLESCENTS 13-17 YEARS OF AGE WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
- D-95 BROADENED INITIAL STARTING DOSE FOR HYPERTENSION FROM 50 MG TO 100 MG TO 25 MG TO 100 MG DOSE RANGE
- D-96 ONCE-MONTHLY TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH BONIVA (IBANDRONATE SODIUM) 150 MG TABLETS
- D-97 PED CANCER PT POPULATION EXPANDED TO INCLUDE PTS 6 MOS UP TO BUT NOT INCLUDING 4 YRS AND DOSING INSTRUCTIONS TO ADMIN 30 MIN BEFORE CHEMO WITH SECOND AND THIRD DOSES 4 & 8 HOURS AFTER FIRST DOSE
- D-98 DOSING FOR PED SURGICAL PTS EXPANDED TO INCLUDE PTS 1 MONTH UP TO BUT NOT INCLUDING 2 YEARS OF AGE
- D-99 ONCE DAILY ADMINISTRATION FOR THE TREATMENT OF HIV INFECTION IN THERAPY NAIVE ADULT PATIENTS
- D-100 750 MG ONCE DAILY FOR FIVE DAYS FOR THE TREATMENT OF ACUTE BACTERIAL SINUSITIS
- D-101 ONCE DAILY IN CHRONIC IDIOPATHIC URTICARIA FOR ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
- D-102 NEW DOSING REGIMEN OF ONE SPRAY TWICE DAILY FOR SEASONAL ALLERGIC RHINITIS IN PATIENTS 12 YRS OF AGE AND OLDER
- D-103 NEW DOSING RECOMMENDATION FOR THE TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT PATIENTS, SPECIFICALLY A REDUCTION IN COURSE OF THERAPY FROM FAMCICLOVIR 125 MG TWICE-A-DAY FOR 5 DAYS TO 1000 MG TWICE-A-DAY FOR 1 DAY.
- D-104 0.5MG/0.1MG FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE IN WOMEN WHO HAVE A UTERUS
- D-105 USE OF ACTONEL 75MG TWO CONSECUTIVE DAYS PER MONTH FOR THE PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
- D-106 FIVE DAY TREATMENT OF SELECTED SUSCEPTIBLE STRAINS OF STREPTOCOCCUS PNEUMONIAE, HAEMOPHILUS INFLUENZA, MYCOPLASMA PNEUMONIAE, AND CHLAMYDIA PNEUMONIAE FOR COMMUNITY-ACQUIRED PNEUMONIA
- D-107 PROVIDES FOR THE COMBINATION TABLET OF 70MG ALENDRONATE AND 5600 IU OF VITAMIN D3 FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
- D-108 TREATMENT OF COMPLICATED URINARY TRACT INFECTION AND ACUTE PYELONEPHRITIS WITH LEVAQUIN 750MG ONCE DAILY FOR FIVE DAYS
- D-109 PROVIDE FOR THE USE OF A LOWER DOSE FOR THE TREATMENT OF ADULTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY

PATENT AND EXCLUSIVITY TERMS

ADB 4 of 78

EXCLUSIVITY DOSING SCHEDULE

- INCLUDING IMATINIB MESYLATE
- D-110 TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGED 13-17
- D-111 PROVIDES FOR ONCE DAILY USE OF CIALIS, 2.5 MG AND 5 MG, FOR THE TREATMENT OF ERECTILE DYSFUNCTION
- D-112 PROVIDES FOR PEDIATRIC PUMP USE
- D-113 ONCE DAILY DOSING REGIMEN FOR PATIENTS WHO BECOME CONSTIPATED ON TWICE DAILY REGIMEN
- D-114 NEW DOSING RECOMMENDATIONS FOR USE OF SIROLIMUS IN COMBINATION WITH CYCLOSPORINE FOR THE PROPHYLAXIS OF REJECTION IN HIGH-RISK RENAL TRANSPLANT RECIPIENTS
- D-115 STARTING DOSE OF 15MG/DAY FOR MONOTHERAPY IN ACUTE TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED
- D-116 ALTERNATIVE DOSING REGIMEN ATAZANAVIR SULATE CO-ADMINISTERED WITH RITONAVIR FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT NAIVE PATIENTS
- D-117 50 MG TABLET FOR INITIATION OF DOSE TITRATION FOR BIPOLAR DISORDER
- D-118 TWO 400MG TABLETS ONCE DAILY, CO-ADMINISTERED WITH 100MG RITONAVIR
- D-119 DOSING RECOMMENDATIONS FOR HIV INFECTED PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OF AGE
- D-120 DOSING REGIMEN ADJUSTMENTS
- D-121 CHANGE TO REMOVE 20 MG MAXIMUM DOSAGE RESTRICTION
- D-122 USE OF VAGIFEM 10 MCG FOR THE TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE
- D-123 ALTERNATIVE DOSING REGIMEN DOSE OF 20 MG/METER SQUARE BY CONTINUOUS INTRAVENOUS INFUSION OVER 1 HOUR REPEATED DAILY FOR 5 DAYS
- D-124 ONCE DAILY DOSING REGIMEN IN ADULT PATIENTS WITH LESS THAN THREE LOPINAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS
- D-125 EXTEND CURRENT DOSING REGIMEN TO 900MG (2-450MG TABLETS) ONCE A DAY WITHIN 10 DAYS OF TRANSPLANTATION UNTIL 200 DAYS POST-TRANSPLANTATION FOR THE PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN ADULT KIDNEY TRANSPLANT PATIENTS AT HIGH RISK.
- D-126 CHANGE DOSAGE REGIMEN FROM 250MG TO 500MG
- D-127 DOSING REGIMEN FOR ADULT PATIENTS WITH CHRONIC HEPATITIS B (CHB) AND DECOMPENSATED LIVER DISEASE
- D-128 SINGLE IV DOSE OF FOSAPREPITANT 150MG, DOSED CONCOMITANTLY WITH 5HT3 RECEPTOR ANTAGONIST & CORTICOSTEROID, FOR PREVENTION OF ACUTE & DELAYED NAUSEA & VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMO
- D-129 800/100 MG DARUNAVIR/RITONAVIR, ONCE DAILY, IN TREATMENT-EXPERIENCED HIV-1 INFECTED PATIENTS WITH NO DARUNAVIR RESISTANCE ASSOCIATED SUBSTITUTIONS
- D-130 DOSING RECOMMENDATIONS FOR TREATMENT OF HIV-1 INFECTION DURING PREGNANCY BASED ON DATA FROM STUDY AI424-182, A STUDY OF ATAZANAVIR/RITONAVIR IN COMBINATION WITH ZIDOVUDINE/LAMIVUDINE IN HIV INFECTED PREGNANT WOMEN
- D-131 EVERY 6 TO 8 WEEKS FOR THE 120MG STRENGTH FOR PATIENTS WHO ARE CONTROLLED ON SOMATULINE DEPOT 60MG OR 90MG
- D-132 45MG FOR 6 MONTH ADMINISTRATION
- D-133 NEW EFFICACY DATA AND DOSING REGIMEN FOR PREGNANCY IN NORMAL OVULATORY WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION AS PART OF AN IVF OR INTRACYTOPLASMIC SPERM INJECTION (ICSI) CYCLE
- D-134 INCREASING MAXIMUM DOSING OF PATIENTS WITH SCHIZOPHRENIA TO 160 MG/DAY
- D-135 UPDATE LABELING WITH ONCE DAILY DOSING IN HIV-1 INFECTED, TREATMENT-NAIVE PEDIATRIC PATIENTS 12 TO LESS THAN 18 YEARS OF AGE
- D-136 ALTERNATE DOSING REGIMEN FOR UNCOMPLICATED URETHRAL OR ENDOCERVICAL INFECTION CAUSED BY CHLAMYDIA TRACHOMATIS, ADMINISTER 200 MG BY MOUTH ONCE-A-DAY FOR 7 DAYS
- D-137 NEW LOWER DOSING REGIMEN FOR REVATIO IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP 1) IN ADULTS
- D-138 80 MG DOSING REGIMEN FOR THE RISK REDUCTION OF REBLEEDING OF GASTRIC AND DUODENAL ULCERS IN THE FIRST 72 HOURS FOLLOWING THERAPEUTIC ENDOSCOPY IN ADULTS
- D-139 ADDITIONAL INFORMATION ADDED TO THE DOSING AND ADMINISTRATION SECTION OF THE LABELING REGARDING THE ADMINISTRATION OF BRAVELLE AND MENOPUR IN THE SAME SYRINGE TO OVULATORY WOMEN AS PART OF AN ART CYCLE
- D-140 REVISED DOSING SCHEDULE TO ADMINISTER AVANAFIL 15 MINUTES PRIOR TO SEXUAL ACTIVITY
- D-141 DOSING INFORMATION IN PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA
- D-142 DOSE MODIFICATION GUIDELINES FOR BORTEZOMIB WHEN GIVEN IN COMBINATION WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE
- D-143 INITIATION OF VIMPAT THERAPY WITH A LOADING DOSE OF 200MG
- D-144 LOWER LIMIT OF 15 MINUTES FOR THE INFUSION DURATION
- D-145 UPDATES TO THE DOSAGE AND ADMINISTRATION SECTION OF THE LABELING TO REFLECT THE RESULTS OF TWO SHORT TERM STUDIES EVALUATING THE SAFETY AND EFFICACY OF INTUNIV IN CHILDREN AND ADOLESCENTS AGES 6 TO 17 WITH ADHD.
- D-146 CHANGE IN TARGET DOSING TO 20MG TO 40MG ORALLY ONCE DAILY
- D-147 ONCE DAILY DOSING IN PEDIATRIC PATIENTS 3 MONTHS OF AGE AND OLDER IN COMBINATION

PATENT AND EXCLUSIVITY TERMS

ADB 5 of 78

EXCLUSIVITY DOSING SCHEDULE

- WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION
- D-148 EXTENDED THE DURATION OF THE DOSING REGIMEN FROM 100 DAYS TO 200 DAYS POST-TRANSPLANTATION FOR THE PREVENTION OF CMV DISEASE IN PEDIATRIC KIDNEY TRANSPLANT
- D-149 DOSING INFORMATION ADDED TO THE LABELING REGARDING PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH ITP
- D-150 1600MG DAILY FOR PATIENTS ON ADJUNCTIVE THERAPY WHO DID NOT ACHIEVE A SATISFACTORY RESPONSE ON 1200MG DAILY DOSE
- D-151 DOSING RECOMMENDATIONS FOR THE TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS CO-INFECTED WITH HIV-1
- D-152 DOSING RECOMMENDATIONS AS NECESSARY FOR FEVER AND PAIN FOR AGES 6MO TO LESS THAN 12 YEARS AND 12 TO 17 YEARS.
- D-153 IN COMBINATION WITH RIBAVIRIN FOR 12 WEEKS, FOR THE TREATMENT OF GENOTYPE 1, CHRONIC HEPATITIS C TREATMENT EXPERIENCED PATIENTS WITH COMPENSATED CIRRHOSIS BASED UPON THE RESULTS OF THE SIRIUS STUDY
- D-154 ADDITION OF A 1500MG-SINGLE-DOSE REGIMEN FOR THE TREATMENT OF ADULT PATIENTS WITH ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSI)
- D-155 SINGLE IV DOSE OF FOSAPREPITANT 150MG DOSED CONCOMITANTLY WITH 5HT3 RECEPTOR ANTAGONIST & CORTICOSTEROID FOR PREVENTION OF DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF MODERATELY EMETOGENIC CANCER CHEMOTHERAPY
- D-156 DOSING INFORMATION ADDED TO THE LABELING PROVIDING INFORMATION ON TRANSITIONING FROM SUBCUTANEOUS OR INTRAVENOUS ROUTES OF ADMINISTRATION OF TREPROSTINIL
- D-157 UPDATED INFORMATION ADDED TO THE DOSAGE AND ADMINISTRATION SECTION OF THE LABELING PROVIDING DOSAGE RECOMMENDATIONS FOR INTERRUPTIONS AND DISCONTINUATION OF THERAPY
- D-158 REVISED DOSING TO EXPAND PATIENT POPULATION TO INCLUDE LIVER TRANSPLANT RECIPIENTS WITH GENOTYPE 1 HCV INFECTION
- D-159 REVISED DOSING TO EXPAND PATIENT POPULATION TO INCLUDE LIVER TRANSPLANT RECIPIENTS WITH GENOTYPE 4 HCV INFECTION
- D-160 REVISED DOSING TO EXPAND PATIENT POPULATION TO INCLUDE PATIENTS WITH DECOMPENSATED CIRRHOSIS WITH GENOTYPE 1 HCV INFECTION
- D-161 DOSAGE RECOMMENDATIONS ADDED TO INCLUDE TREATMENT OF HCV GENOTYPE 3 SUBJECTS CO-INFECTED WITH HIV-1
- D-162 DOSING TO INCLUDE PATIENTS WITH CHRONIC HCV GENOTYPE 1 INFECTION WITH COMPENSATED (CHILD-PUGH A) OR DECOMPENSATED (CHILD-PUGH B OR C) CIRRHOSIS AND TREATMENT OF CHRONIC HCV GENOTYPE 3 INFECTION IN SUBJECTS WITH DECOMPENSATED (CHILD-PUGH B OR C) CIRRHOSIS
- D-163 DOSING TO INCLUDE PATIENTS WITH CHRONIC HCV GENOTYPE 1A INFECTION WITH COMPENSATED (CHILD-PUGH A) CIRRHOSIS AND GENOTYPE 1B WITH OR WITHOUT COMPENSATED (CHILD-PUGH A) CIRRHOSIS
- D-164 UPDATES TO THE DOSAGE AND ADMINISTRATION, DOSE MODIFICATIONS SECTION OF THE LABELING
- D-165 DOSING RECOMMENDATION ADDED TO THE LABELING FOR IMBRUVICA USE IN COMBINATION WITH BENDAMUSTINE AND RITUXIMAB FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LEUKEMIA (SLL)

EXCLUSIVITY INDICATION

- I-1 DYSMENORRHEA
- I-2 CHOLANGIOPANCREATOGRAPHY
- I-3 INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY
- I-4 PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY)
- I-5 HYSTEROSALPINGOGRAPHY
- I-6 TREATMENT OF JUVENILE ARTHRITIS
- I-7 BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN
- I-8 ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY
- I-9 PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
- I-10 PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY
- I-11 RELIEF OF MILD TO MODERATE PAIN
- I-12 TREATMENT OF CUTANEOUS CANDIDIASIS
- I-13 URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI
- I-14 SEBORRHEIC DERMATITIS
- I-15 PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT
- I-16 STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

	PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM
I-17	MANAGEMENT OF CONGESTIVE HEART FAILURE
I-18	ENDOSCOPIC RETROGRADE PANCREATOGRAPHY
I-19	HERNIOGRAPHY
I-20	KNEE ARTHROGRAPHY
I-21	HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR
I-22	RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA
I-23	SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
I-24	TREATMENT OF RHEUMATOID ARTHRITIS
I-25	ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS
I-26	TREATMENT OF LIVER FLUKES
I-27	ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE
I-28	SELECTIVE ADULT VISCERAL ARTERIOGRAPHY
I-29	METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION
I-30	TREATMENT OF TINEA PEDIS
I-31	CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES
I-32	PEDIATRIC MYELOGRAPHY
I-33	ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN
I-34	ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT
I-35	PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING
I-36	ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS
I-37	RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS
I-38	CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER)
I-39	TREATMENT OF ACUTE MYOCARDIAL INFARCTION
I-40	PRIMARY NOCTURNAL ENURESIS
I-41	MIGRAINE HEADACHE PROPHYLAXIS
I-42	HERPES ZOSTER
I-43	HERPES SIMPLEX ENCEPHALITIS
I-44	MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY
I-45	ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS
I-46	USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING
I-47	TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE
I-48	PEDIATRIC ANGIOCARDIOGRAPHY
I-49	TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI
I-50	FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER
I-51	TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS
I-52	PEDIATRIC EXCRETORY UROGRAPHY
I-53	TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA
I-54	RENAL CONCENTRATION CAPACITY TEST
I-55	HYPERTENSION
I-56	EROSIVE GASTROESOPHAGEAL REFLUX DISEASE
I-57	SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER
I-58	INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS
I-59	ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSION AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE
I-60	SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE
I-61	FEMALE ANDROGENETIC ALOPECIA
I-62	PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-63	ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION
I-64	PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS
I-65	PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

I-66	UNCOMPLICATED GONORRHEA
I-67	TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER
I-68	CENTRAL PRECOCIOUS PUBERTY
I-69	SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY
I-70	USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER
I-71	VARICELLA INFECTIONS (CHICKENPOX)
I-72	PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE
I-73	INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES
I-74	INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY
I-75	TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIVE ESOPHAGITIS
I-76	PREVENTION OF OSTEOPOROSIS
I-77	DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM
I-78	CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY
I-79	MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM
I-80	DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE
I-81	PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS
I-82	TREATMENT OF TRAVELERS' DIARRHEA
I-83	ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN
I-84	INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION
I-85	TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS
I-86	TREATMENT OF SECONDARY CARNITINE DEFICIENCY
I-87	RENAL IMAGING AGENT FOR USE IN CHILDREN
I-88	MANAGEMENT OF ENDOMETRIOSIS
I-89	EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE
I-90	INTENSIVE CARE UNIT SEDATION
I-91	MONOTHERAPY USE FOR HYPERTENSION
I-92	ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE
I-93	PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS
I-94	USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART]
I-95	TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
I-96	TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
I-97	ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT
I-98	TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY
I-99	PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER
I-100	TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY
I-101	TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY
I-102	TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER
I-103	PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA
I-104	TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY
I-105	TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY
I-106	TREATMENT OF ACROMEGALY
I-107	VAGINAL CANDIDIASIS
I-108	EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION
I-109	TYPHOID FEVER
I-110	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY
I-111	TREATMENT OF PAGET'S DISEASE OF BONE
I-112	MANAGEMENT OF MODERATE TO SEVERE PAIN
I-113	TREATMENT OF PROSTATITIS

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

- I-114 USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE, AND ASSOCIATED TISSUE
- I-115 USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK
- I-116 MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS
- I-117 TO SLOW THE PROGRESSION FO CORONANY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE
- I-118 PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM FOLLOWING KNEE REPLACEMENT SURGERY
- I-119 TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY
- I-120 MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS
- I-121 EXPANDED PATIENT POPULATION -- USE IN ICU PATIENTS
- I-122 PSORIASIS OF THE SCALP
- I-123 RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER
- I-124 LEUCOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE
- I-125 EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES
- I-126 ADJUNCT TO THALLIUM- 201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY
- I-127 TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS
- I-128 IN PT W/ CH DISEASE AND HYPERCHOLESTEROLEMIA: REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE RISK NON-FATAL MI; REDUCE RISK UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION ELEVATED TOTAL AND LDL CHOL LEVELS...
- I-129 TREATMENT OF ALCOHOL DEPENDENCE
- I-130 MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS
- I-131 PERIPHERAL ARTERIOGRAPHY
- I-132 TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER
- I-133 MANAGEMENT OF CHRONIC STABLE ANGINA
- I-134 HEART FAILURE POST MYOCARDIAL INFARCTION
- I-135 BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA
- I-136 IDIOPATHIC CHRONIC URTICARIA
- I-137 PREVENTION OF METAL-INDUCED HEART BURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES
- I-138 TREATMENT OF ACUTE RECURRENT GENITAL HERPES
- I-139 PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE- AND PERIMENOPAUSAL WOMEN
- I-140 PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMV DISEASE
- I-141 TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL
- I-142 LOCALIZE MYOCARDIAL ISCHEMIA (REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTION
- I-143 EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTS
- I-144 ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS
- I-145 0.1MMOL/KG AS A SINGLE INTRAVEOUS BOLUS FOR MRI OF THE CNS IN CHILDREN
- I-146 CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS
- I-147 PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS
- I-148 TREATMENT OF ACUTE PNEUMOCYSTIC CARINI PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE (AaDO₂) IS LESS THAN OR EQUAL TO 55 TORR
- I-149 TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER
- I-150 TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER
- I-151 PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA
- I-152 SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS
- I-153 MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASSES SPINAL AND CEREBRAL ORIGIN]
- I-154 PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE
- I-155 TREATMENT OF ONCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT
- I-156 ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE
- I-157 TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES
- I-158 TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER
- I-159 FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES

PATENT AND EXCLUSIVITY TERMS

ADB 9 of 78

EXCLUSIVITY INDICATION

I-160	TREATMENT OF BACTERIAL CORNEAL ULCERS
I-161	TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY
I-162	FOR USE IN PATIENTS 6-11 YEARS OF AGE
I-163	TREATMENT OF PHOTOPHOBIA
I-164	CHRONIC BACTERIAL PROSTATITIS
I-165	MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO HAVE HAD INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
I-166	TREATMENT OF BULIMIA
I-167	COMPLICATED INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH METRONIDAZOLE) CAUSED BY MIXED AEROBIC/ANAEROBIC PATHOGENS
I-168	MANAGEMENT OF LOCALLY CONFINED STAGE B2-C METASTATIC CARCINOMA OF THE PROSTATE (IN COMBINATION WITH LHRH AGONISTS)
I-169	USE IN COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PAIN RELATED TO ADVANCED HORMONE-REFRACTORY PROSTATE CANCER
I-170	PROPHYLACTIC USE DURING HEAD LICE EPIDEMICS
I-171	RELIEF OF SYMPTOMS OF THE COMMON COLD
I-172	TREATMENT OF INITIAL EPISODE OF GENITAL HERPES
I-173	PREOPERATIVELY FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE BIOPSY
I-174	PELVIC INFLAMMATORY DISEASE
I-175	TREATMENT OF TINEA CORPORIS AND TINEA CRURIS
I-176	TREATMENT OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION
I-177	TX OF MODERATE ACNE VULGARIS IN FEMALES, GREATER OR EQUAL TO 15YRS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, DESIRE CONTRACEPTION, HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS
I-178	TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN
I-179	NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE
I-180	TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE)
I-181	TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION
I-182	TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME
I-183	MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11
I-184	TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2MG/DAY (MAXIMUM OF 4MG)
I-185	PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-186	TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE)
I-187	PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-188	TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS
I-189	TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS
I-190	PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS
I-191	ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING
I-192	THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION
I-193	TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY
I-194	CONGESTIVE HEART FAILURE
I-195	FOR USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER
I-196	ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
I-197	MAINTENANCE OF HEALING OF DUODENAL ULCER
I-198	FOR THE USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A DUODENAL ULCER
I-199	MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYLUREA IN THE TREATMENT OF TYPE II DIABETES
I-200	TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR
I-201	EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

I-202	SECOND-LINE TREATMENT OF AIDS-RELATED KAPOSI'S SARCOMA
I-203	MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
I-204	USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
I-205	INITIAL ANTICONVULSANT TREATMENT OF STATUS EPILEPTICUS
I-206	TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE
I-207	FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS
I-208	TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION
I-209	PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT)
I-210	TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS
I-211	FOR USE IN PEDIATRIC POPULATION
I-212	TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME
I-213	TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY
I-214	TREATMENT OF OSTEOPOROSIS
I-215	PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS
I-216	FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
I-217	PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY
I-218	USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV)
I-219	USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET
I-220	TREATMENT OF EPISODIC- HEARTBURN, ACID INDIGESTION AND SOUR STOMACH
I-221	TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY
I-222	PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN
I-223	USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH ALLERGIC AND NONALLERGIC-PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS
I-224	FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
I-225	USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS
I-226	FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN
I-227	SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESOPHAGEAL REFLUX DISEASE (GERD)
I-228	PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60MIN PRIOR TO A MEAL
I-229	PRIOLOSEC (OMEPRAZOLE), AMOXICILLIN, AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
I-230	IN COMBINATION WITH CIS-PLATIN, FOR THE FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION
I-231	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY
I-232	TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY
I-233	PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSUSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY
I-234	FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER
I-235	PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER
I-236	PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
I-237	MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
I-238	ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS
I-239	TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

- I-240 MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (CCR 15 TO 55ML/MIN) NOT YET ON DIALYSIS
- I-241 USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER
- I-242 TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS
- I-243 USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS
- I-244 REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER
- I-245 TREATMENT OF ACUTE SINUSITIS
- I-246 TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS
- I-247 USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG
- I-248 INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM
- I-249 TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY
- I-250 PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPATOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C
- I-251 TREATMENT OF GENERALIZED ANXIETY DISORDER
- I-252 NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN
- I-253 COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN
- I-254 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS)
- I-255 PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP)
- I-256 USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY
- I-257 TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMATION
- I-258 FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES 4 AND ABOVE
- I-259 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY
- I-260 EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER)
- I-261 TREATMENT OF SOCIAL ANXIETY DISORDER
- I-262 TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12
- I-263 TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY
- I-264 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION
- I-265 TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER
- I-266 USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES
- I-267 USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER - FOR CORTICOSTEROID-RESPONSIVE DERMATOSES
- I-268 PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE
- I-269 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN
- I-270 ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTERED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY
- I-271 TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- I-272 TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICOIDS IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY
- I-273 ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NON FAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)
- I-274 USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
- I-275 USE IN COMBINATION WITH METFORMIN AND SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES
- I-276 USE OF REZULIN IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

TYPE 2 DIABETES

- I-277 TREATMENT OF TYPE III HYPERLIPOPROTEINEMIA
- I-278 TREATMENT OF PATIENTS WITH ISOLATED HYPERTRIGLYCERIDEMIA (FREDERICKSON TYPE IV)
- I-279 TREATMENT OF POST-TRAUMATIC STRESS DISORDER
- I-280 USE OF CARNITOR INJECTION FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS
- I-281 INCREASING HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)
- I-282 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY
- I-283 TO REDUCE THE INCIDENCE OF MODERATE TO SEVERE XEROSTOMIA IN PATIENTS UNDERGOING POST-OPERATIVE RADIATION TREATMENT FOR HEAD AND NECK CANCER, WHERE THE RADIATION PORT INCLUDES A SUBSTANTIAL PORTION OF THE PAROTID GLANDS
- I-284 TO REDUCE THE NUMBER OF ADENOMATOUS COLORECTAL POLYPS IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS AS AN ADJUNCT TO USUAL CARE
- I-285 TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN ADULTS AND CHILDREN 3 YEARS OF AGE AND OLDER
- I-286 TREATMENT OF PATIENTS WITH FREDERICKSON TYPE III
- I-287 USE OF PRAVASTATIN IN PATIENTS WITH EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH
- I-288 CHANGES IN SEVERAL SECTIONS OF THE INSERT TO INCORPORATE STATEMENTS CONCERNING THE USE OF HIGH DOSES OF LISINAPRIL TO REDUCE THE RISK OF THE COMBINED OUTCOMES OF MORTALITY AND HOSPITALIZATION IN PATIENTS WITH CONGESTIVE HEART FAILURE
- I-289 USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN DIET AND EXERCISE WITH EITHER SINGLE AGENT DOES NOT ACHIEVE ADEQUATE GLYCEMIC CONTROL
- I-290 PREVENTION OF CORTICOSTEROID-INDUCED OSTEOPOROSIS
- I-291 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- I-292 TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
- I-293 TREATMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS
- I-294 TREATMENT OF UNCOMPLICATED ACUTE ILLNESS DUE TO INFLUENZA A AND B IN PEDIATRIC PATIENTS 7 YEARS AND OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 2 DAYS
- I-295 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR WOMEN WITH AN INTACT UTERUS
- I-296 LONG-TERM INTRAVENOUS TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH THE SCLERODERMA SPECTRUM OF DISEASE IN NYHA CLASS III AND CLASS IV PATIENTS WHO DO NOT RESPOND TO CONVENTIONAL THERAPY
- I-297 SHORT-TERM TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
- I-298 TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IIA AND IIB HYPERLIPOPROTEINEMIA
- I-299 USE OF CAMPTOSAR AS A COMPONENT OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVARIN FOR PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR RECTUM
- I-300 PROPHYLAXIS FOR ASTHMA IN CHILDREN 2-5 YEARS OF AGE
- I-301 TREATMENT OF SIGNS AND SYMPTOMS OF ALLERGIC CONJUNCTIVITIS
- I-302 TREATMENT OF PEDIATRIC PATIENTS WITH PRADER-WILLI SYNDROME
- I-303 INCREASING HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIAS
- I-304 TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IV
- I-305 TREATMENT OF LEVOFLOXACIN SUSCEPTIBLE STRAINS OF PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA
- I-306 INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY HYPOGONADOTROPIC HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR FAILURE
- I-307 NEW COMBINATION USE OF METFORMIN AND INSULIN IN TYPE 2 DIABETES
- I-308 TREATMENT OF PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS WHO RESPONDED INADEQUATELY TO SALICYLATES OR OTHER NSAIDS
- I-309 USE OF ACTONEL 35MG ONCE A WEEK TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
- I-310 REDUCTION IN RISK OF MYOCARDIAL INFARCTION, STROKE, AND DEATH FROM CARDIOVASCULAR CAUSES
- I-311 ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS AGE 3 TO 12 YEARS
- I-312 FIRST LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER
- I-313 EXTENSION OF INDICATION TO PROVIDE FOR MAINTENANCE OF RESPONSE
- I-314 TOPICAL ANESTHETIC FOR SUPERFICIAL MINOR SURGERY OF GENITAL MUCOUS MEMBRANES AND AS AN ADJUNCT FOR LOCAL INFILTRATION ANESTHESIA IN GENITAL MUCOUS MEMBRANES
- I-315 THROMBOPROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

- SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS
- I-316 TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER PATIENTS WHO CONTINUE NSAID USE AND REDUCING RISK OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS WITH HISTORY OF DOCUMENTED GASTRIC ULCER WHO REQUIRE USE OF AN NSAID
- I-317 PROPHYLAXIS OF INFLUENZA IN ADULTS AND ADOLESCENTS 13 YEARS AND OLDER
- I-318 FIRSTLINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER
- I-319 USE FOR SUSPECTED OR CONFIRMED METHANOL POISONING, EITHER ALONE OR IN COMBINATION WITH HEMODIALYSIS
- I-320 TREATMENT OF TYPE 2 DIABETES IN PEDIATRIC PATIENTS (AGES 10-16 YEARS)
- I-321 JUVENILE RHEUMATOID ARTHRITIS
- I-322 USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS
- I-323 COLORECTAL CANCER
- I-324 REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS
- I-325 PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION
- I-326 GENERALIZED ANXIETY DISORDER
- I-327 SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN PATIENTS 5 YEARS AND OLDER
- I-328 PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE
- I-329 UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
- I-330 MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYMPTOMS IN PATIENTS WITH GERD
- I-331 TREATMENT OF MODERATE ACNE VULGARIS
- I-332 EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS (EFTN)
- I-333 TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR (FORMERLY PITYROSPORUM ORBICULARE)
- I-334 LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE
- I-335 ADJUNCTIVE THERAPY IN PATIENTS TWO YEARS AND OLDER WITH SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME
- I-336 EXPANSION OF INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH PREDOMINATELY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION DUE TO PATHOLOGIC MYOPIA OR PRESUMED OCULAR HISTOPLASMOSIS
- I-337 PATHOLOGICAL HYPERSECRETION ASSOCIATED WITH ZOLLINGER-ELLISON SYNDROME
- I-338 MANAGEMENT OF ACUTE PAIN IN ADULTS AND TREATMENT OF PRIMARY DYSMENORRHEA
- I-339 TREATMENT OF HEPATITIS B IN PEDIATRIC PATIENTS AGES 2-17 YEARS
- I-340 ATOPIC DERMATITIS IN PEDIATRIC PATIENTS AGES 2-5
- I-341 BREAST CANCER COMBINATION THERAPY
- I-342 USE OF FORADIL FOR LONG-TERM, TWICE DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHO-CONSTRICTION IN PATIENTS WITH COPD INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
- I-343 USE OF COREG FOR SEVERE HEART FAILURE
- I-344 ACNE VULGARIS
- I-345 TREATMENT OF POSTTRAUMATIC STRESS DISORDER
- I-346 TREATMENT OF SYMPTOMATIC GASTRO ESOPHAGEAL REFLUX DISEASE (GERD)
- I-347 TREATMENT OR PREVENTION OF BRONCHOSPASM IN CHILDREN 6 YEARS OF AGE AND OLDER WITH OBSTRUCTIVE AIRWAY DISEASE
- I-348 LONG-TERM, TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD (INCLUDING EMPHYSEMA AND CHRONIC BRONCHITIS)
- I-349 ACUTE CORONARY SYNDROME
- I-350 TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND GIRLS AT LEAST ONE YEAR POSTMENARCHAL, AGES 10 TO 17 YEARS, WITH A RECOMMENDED DOSING RANGE OF 10 TO 40MG ONCE DAILY
- I-351 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR ALL STRENGTHS
- I-352 ANTICOAGULANT IN PATIENTS WITH OR AT RISK FOR HEPARIN-INDUCED THROMBOCYTOPENIA UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI)
- I-353 TREATMENT OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS
- I-354 MANAGEMENT OF POST HERPETIC NEURALGIA
- I-355 PREMENSTRUAL DYSPHORIC DISORDER
- I-356 TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROME
- I-357 TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

- I-358 TREATMENT OF PANIC DISORDER
- I-359 TREATMENT OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH MENOPAUSE
- I-360 TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN CHILDREN AGES TWO UP TO AGE THREE
- I-361 TREATMENT OF MULTIPLE MYELOMA AND DOCUMENTED BONE METASTASES FROM SOLID TUMORS, IN CONJUNCTION WITH STANDARD ANTINEOPLASTIC THERAPY. PROSTATE CANCER SHOULD HAVE PROGRESSED AFTER TREATMENT WITH AT LEAST ONE HORMONAL THERAPY
- I-362 TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA
- I-363 ADJUVANT TREATMENT OF POST MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER
- I-364 TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
- I-365 TREATMENT OF HEART FAILURE (NYHA CLASS II-IV) IN PATIENTS WHO ARE INTOLERANT TO AN ACE INHIBITOR
- I-366 PREVENTION OF RELAPSE FOLLOWING LONG-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER
- I-367 COMBINATION THERAPY WITH THIAZOLIDINEDIONE TO LOWER BLOOD GLUCOSE IN PTS WHOSE HYPERGLYCEMIA CANNOT BE CONTROLLED BY DIET/EXERCISE PLUS MONOTHERAPY WITH ANY OF THE FOLLOWING AGENTS: METFORMIN, SULFONYLUREAS, REPAGLINIDE, OR THIAZOLIDINEDIONES
- I-368 USE OF GLUCOVANCE WITH A THIAZOLIDINEDIONE WHEN GLYCEMIC CONTROL IS NOT OBTAINED WITH GLUCOVANCE ALONE
- I-369 PREVENTION AND TREATMENT OF POSTOPERATIVE NAUSEA AND VOMITING
- I-370 TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN CHILDREN, AGES 8-13 YEARS, WITH RECOMMENDED DOSE OF 20MG ONCE DAILY AND IN ADOLESCENTS, AGES 14-18 WITH A RECOMMENDED DOSE OF 40MG ONCE DAILY
- I-371 HELICOBACTER PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
- I-372 NOSOCOMIAL PNEUMONIA
- I-373 TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
- I-374 SHORT TERM TOPICAL TREATMENT OF MILD TO MODERATE PLAQUE-TYPE PSORIASIS OF NON SCALP REGIONS
- I-375 FIRST LINE THERAPY FOR THE REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
- I-376 TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (CML)
- I-377 USE OF BRAVELLE FOR MULTIPLE FOLLICULAR DEVELOPMENT (CONTROLLED OVARIAN STIMULATION) DURING ASSISTED REPRODUCTIVE TECHNOLOGY CYCLES IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED PITUITARY SUPPRESSION
- I-378 RELIEF OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
- I-379 USE TAXOTERE IN COMBINATION WITH CISPLATIN FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE NOT PREVIOUSLY RECEIVED CHEMOTHERAPY FOR THIS CONDITION
- I-380 TO TREAT PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AT RISK FOR EMERGENT SUICIDAL BEHAVIOR
- I-381 TREATMENT OF COLD SORES (HERPES LABIALIS) IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER
- I-382 FOR NEWLY-DIAGNOSED HIGH GRADE MALIGNANT GLIOMA PATIENTS AS AN ADJUNCT TO SURGERY AND RADIATION
- I-383 TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
- I-384 USE IN COMBINATION WITH INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS
- I-385 MODIFICATION OF THE INDICATION FOR COMMUNITY ACQUIRED PNEUMONIA TO ADD"INCLUDING PENICILLIN-RESISTANT STRAINS, MIC PENICILLIN \geq 2MCG/ML TO STREPTOCOCCUS PNEUMONIAE
- I-386 RAPAMUNE (SIROLIMUS) WITHIN AN IMMUNOSUPPRESSIVE REGIMEN THAT WOULD ALLOW FOR THE WITHDRAWAL OF CYCLOSPORINE 2 TO 4 MONTHS AFTER RENAL TRANSPLANTATION IN PATIENTS CONSIDERED AT LOW TO MODERATE IMMUNOLOGIC RISK FOR RENAL TRANSPLANT REJECTION
- I-387 ADJUNCTIVE THERAPY OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS GREATER THAT OR EQUAL TO 2 YEARS OF AGE
- I-388 TREATMENT OF PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
- I-389 SUPPRESSION OF RECURRENT GENITAL HERPES IN HIV-INFECTED INDIVIDUALS
- I-390 USE IN PTS AT HIGH RISK CORONARY EVENTS DUE TO EXISTING CORONARY HEART DISEASE, DIABETES, PERIPHERAL VESSEL DISEASE, STROKE HISTORY, OTHER CV DISEASE TO REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH, REDUCE NONFATAL MI & STROKE.....
- I-391 ABLATION OF HIGH-GRADE DYSPLASIA IN BARRETT'S ESOPHAGUS PATIENTS WHO DO NOT UNDERGO ESOPHAGECTOMY
- I-392 TX OF PED PATIENTS W/PH+ CHRONIC PHASE CML DISEASE RECURRENCE AFTER STEM CELL TRANSPLANT OR RESISTANCE TO INTERFERON ALPHA THERAPY. NO CONTROLLED TRIALS DEMONSTRATING A CLINICAL BENEFIT SUCH AS IMPROVEMENT IN DISEASE RELATED SX OR INCREASED SURVIVAL

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

- I-393 CHRONIC BACTERIAL PROSTATITIS
- I-394 USE IN PATIENTS WITH CORONARY HEART DISEASE TO REDUCE THE RISK OF UNDERGOING CORONARY REVASCLARIZATION PROCEDURES
- I-395 TO IMPROVE PHYSICAL FUNCTION
- I-396 EXPANDED INDICATION TO INCLUDE THE ASSESSMENT OF VENTRICULAR FUNCTION IN SUBJECTS BEING EVALUATED FOR HEART DISEASE AND/OR VENTRICULAR FUNCTION
- I-397 EXTENDED PROPHYLAXIS IN PATIENTS UNDERGOING HIP FRACTURE SURGERY
- I-398 IDIOPATHIC SHORT STATURE
- I-399 TREATMENT OF CANDIDEMIA AND THE FOLLOWING CANDIDA INFECTIONS: INTRA-ABDOMINAL ABSCESSSES, PERITONITIS AND PLEURAL SPACE INFECTIONS
- I-400 USE OF OLANZAPINE IN COMBINATION WITH LITHIUM OR VALPROATE FOR THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR DISORDER
- I-401 LONGER-TERM EFFICACY OF ARIPIPRAZOLE IN THE TREATMENT OF SCHIZOPHRENIA
- I-402 DIABETIC FOOT INFECTIONS WITHOUT CONCOMITANT OSTEOMYELITIS
- I-403 USE OF VALTREX IN COMBINATION WITH SAFER SEX PRACTICES FOR THE REDUCTION OF THE RISK OF TRANSMISSION OF GENITAL HERPES DURING SUPPRESIVE THERAPY OF THE SOURCE PARTNER IN A HETEROSEXUAL COUPLE
- I-404 MAINTENANCE TREATMENT OF BIPOLAR I DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES (DEPRESSION, MANIA, HYPOMANIA, MIXED EPISODES) IN PATIENTS TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY
- I-405 TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD) USING AN INTERMITTENT DOSING REGIMEN
- I-406 PREVENTION OF CYTOMEGALOVIRUS DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)
- I-407 IMPROVE SURVIVAL OF STABLE PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (EJECTION FRACTION<=40%) AND CLINICAL EVIDENCE OF CONGESTIVE HEART FAILURE AFTER AN ACUTE MYOCARDIAL INFARCTION
- I-408 STIMULATION OF PANCREATIC SECRETIONS TO FACILITATE THE IDENTIFICATION OF THE AMPULLA OF VATER AND ACCESSORY PAPANILLA DURING ENDOSCOPIC RETROGRADE CHOLANGIO-PANCREATOGRAPHY (ERCP)
- I-409 ESOPHAGEAL CANDIDIASIS
- I-410 USE OF ADVAIR DISKUS 250/50 FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ASSOCIATED WITH CHRONIC BRONCHITIS
- I-411 EXPANDED INDICATION FOR USE IN COMBINATION WITH ANTIDIABETIC DRUGS IN THE THIAZOLIDINEDIONE CLASS
- I-412 MONOTHERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
- I-413 ADJUNCTIVE THERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
- I-414 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM (PE) IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS
- I-415 SEVERE HYPERTENSION WHEN THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY
- I-416 THE USE OF CIPRO XR FOR COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS
- I-417 USE IN THE LONG TERM TREATMENT OF BIPOLAR I DISORDER
- I-418 ADJUNCTIVE THERAPY W/ MOOD STABILIZERS (LITHIUM OR DIVALPROEX) IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDERS
- I-419 MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
- I-420 TOPICAL TREATMENT OF CLINICALLY TYPICAL, NONHYPERKERATOTIC, NONHYPERTROPHIC ACTINIC KERATOSES ON THE FACE OR SCALP IN IMMUNOCOMPETENT ADULTS
- I-421 TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND PYELONEPHRITIS DUE TO E.COLI FOR PED PATIENTS (1-17) NOT AS FIRST CHOICE
- I-422 INDICATED FOR THE IN-HOSPITAL SHORT-TERM (UP TO 4 HOURS) REDUCTION IN BLOOD PRESSURE IN PEDIATRIC PATIENTS
- I-423 ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
- I-424 MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL INSUFFICIENCY NOT YET ON DIALYSIS
- I-425 ELOXATIN IN COMBINATION WITH INFUSIONAL 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) FOR THE TREATMENT OF PATIENTS PREVIOUSLY UNTREATED FOR ADVANCED COLORECTAL CANCER
- I-426 TREATMENT OF ACUTE PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
- I-427 TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
- I-428 FOR USE IN COMBINATION WITH PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS

PATENT AND EXCLUSIVITY TERMS

ADB 16 of 78

EXCLUSIVITY INDICATION

- WITH METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR ANTHRACYCLINE CONTAINING ADJUVANT CHEMOTHERAPY UNLESS ANTHRACYCLINES WERE CLINICALLY CONTRAINDICATED
- I-429 FOR USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER
- I-430 FOR USE IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS
- I-431 NOSOCOMIAL PNEUMONIA AND COMMUNITY-ACQUIRED PNEUMONIA CAUSED BY STREPTOCOCCUS PNEUMONIAE INDICATION EXPANDED TO INCLUDE MULTI-DRUG RESISTANT STRAINS
- I-432 TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA CAUSED BY MULTI-DRUG RESISTANT STREPTOCOCCUS PNEUMONIAE
- I-433 TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA IN IMMUNOCOMPETENT ADULTS, WITH A MAXIMUM TUMOR DIAMETER OF 2.0CM, LOCATED ON THE TRUNK (EXCLUDING ANOGENITAL SKIN), NECK, OR EXTREMITIES (EXCLUDING HANDS AND FEET)
- I-434 PREVENTION OF CARDIOVASCULAR DISEASE IN ADULT PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE, BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE TO REDUCE RISK OF MI AND RISK FOR REVASCLARIZATION PROCEDURES AND ANGINA
- I-435 CHRONIC IDIOPATHIC CONSTIPATION
- I-436 FOR USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR THE ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER
- I-437 TREATMENT OF ACUTE MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER
- I-438 EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS
- I-439 USED TO TREAT ADULTS WITH GROWTH HORMONE DEFICIENCY
- I-440 FOR THE REPLACEMENT OF ENDOGENOUS GROWTH HORMONE IN ADULTS WITH GROWTH HORMONE DEFICIENCY
- I-441 USE COMBINATION WITH INFUSIONAL 5-FU/LV FOR ADJUVANT TREATMENT STAGE III COLON CANCER PTS WHO HAVE UNDERGONE COMPLETE RESECTION PRIMARY TUMOR-BASED ON IMPROVEMENT IN DISEASE FREE SURVIVAL, NO DEMONSTRATED BENEFIT OVERALL SURVIVAL AFTER 4YRS
- I-442 USED FOR CANDIDEMIA IN NONNEUTROPENIC PATIENTS AND THE FOLLOWING CANDIDA INFECTIONS: DISSEMINATED INFECTIONS IN SKIN & INFECTIONS IN ABDOMEN, KIDNEY, BLADDER WALL, AND WOUNDS
- I-443 TREATMENT OF NASAL POLYPS IN PATIENTS 18 YEARS OF AGE AND OLDER
- I-444 USE OF PROTONIX IV FOR INJECTION AS STAND ALONE THERAPY FOR THE SHORT-TERM TREATMENT OF PATIENTS HAVING GASTROESOPHAGEAL REFLUX (GERD) WITH A HISTORY OF EROSIIVE ESOPHAGITIS
- I-445 TO IMPROVE (COMPARED TO 4.25% DEXTROSE) LONG-DWELL ULTRAFILTRATION AND CLEARANCE OF CREATININE AND UREA NITROGEN IN PATIENTS WITH HIGH AVERAGE OR GREATER TRANSPORT CHARACTERISTICS, AS DEFINED USING THE PERITONEAL EQUILIBRATION TEST (PET)
- I-446 EXTENDED ADJUVANT TREATMENT OF EARLY BREAST CANCER IN POSTMENOPAUSAL WOMEN WHO HAVE RECEIVED 5 YRS ADJUVANT TAMOXIFEN THERAPY-EFFECTIVENESS BASED ON AN ANALYSIS OF DISEASE FREE SURVIVAL IN PATIENTS TREATED FOR A MEDIAN 24 MONTHS
- I-447 USE OF COPEGUS (RIBAVIRIN) FOR TREATMENT OF CHRONIC HEPATITIS C IN ADULT PATIENTS COINFECTED WITH HIV IN COMBINATION WITH PEGASYS (PEGINTERFERON ALFA-2A)
- I-448 TREATMENT OF HEART FAILURE (NYHA CLASS II-IV AND EJECTION FRACTION <=40%) TO REDUCE THE RISK OF DEATH FROM CARDIOVASCULAR CAUSES AND TO REDUCE HOSPITALIZATIONS FOR HEART FAILURE
- I-449 TO IMPROVE WAKEFULNESS IN TWO NEW PATIENT POPULATIONS WITH EXCESSIVE SLEEPINESS: THOSE WITH OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME AND THOSE WITH SHIFT WORK SLEEP DISORDER
- I-450 TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED HIGH GRADE GLIOMAS CONCOMITANTLY WITH RADIOTHERAPY AND THEN AS ADJUVANT TREATMENT
- I-451 MANAGEMENT OF ENDOMETRIOSIS ASSOCIATED PAIN
- I-452 EXPANDED INDICATION TO INCLUDE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY
- I-453 USE IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN WHEN DIET, EXERCISE AND BOTH AGENTS DO NOT RESULT IN ADEQUATE GLYCEMIC CONTROL (TRIPLE THERAPY)
- I-454 MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON FOR UP TO 3 MONTHS
- I-455 MODIFIED HEART FAILURE INDICATION TO INCLUDE TREATMENT OF HEART FAILURE IN PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (NYHA CLASS II-IV; EJECTION FRACTION LESS THAN OR EQUAL TO 40%)
- I-456 TO REDUCE CARDIOVASCULAR DEATH AND TO REDUCE HEART FAILURE HOSPITALIZATIONS. INCLUDES ADDITIONAL INFORMATION ON THE ADDED EFFECT ON THESE OUTCOMES WHEN USED WITH AN ACE INHIBITOR
- I-457 TREATMENT OF PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS
- I-458 USE OF BIVALIRUDIN FOR INJECTION WITH PROVISIONAL USE OF GLYCOPROTEIN IIB/IIA INHIBITOR (GPI) AS LISTED IN THE CLINICAL TRIALS REPLACE-2 SECTION FOR USE AS AN ANTICOAGULANT IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI)

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

- I-459 NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) PATIENTS RECEIVING OR NOT RECEIVING AN ERYTHROPOIETIN
- I-460 TREATMENT OF DIARRHEA CAUSED BY CRYPTOSPORIDIUM PARVUM IN NON-HIV INFECTED PATIENTS 12 YEARS OF AGE AND OLDER
- I-461 USE AS A SINGLE AGENT FOR ADJUVANT TREATMENT IN PATIENTS WITH DUKES' C COLON CANCER WHO HAVE UNDERGONE COMPLETE RESECTION OF THE PRIMARY TUMOR WHEN TREATMENT WITH FLUOROPYRIMIDINE THERAPY ALONE IS PREFERRED
- I-462 LONG TERM TREATMENT OF IDIOPATHIC SHORT STATURE
- I-463 TREATMENT OF PATIENTS POST MYOCARDIAL INFARCTION
- I-464 TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME
- I-465 PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 6 MONTHS OF AGE AND OLDER
- I-466 FOR RELIEF OF THE SIGNS AND SYMPTOMS OF ANKYLOSING SPONDYLITIS
- I-467 USE OF TOPIRAMATE AS INITIAL MONOTHERAPY IN PATIENTS 10 YEARS OF AGE AND OLDER WITH PARTIAL ONSET OR PRIMARY GENERALIZED TONIC CLONIC SEIZURES
- I-468 USE IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE TO REDUCE THE RISK OF CARDIOVASCULAR MORTALITY OR NON-FATAL MYOCARDIAL INFECTION
- I-469 RELIEF OF THE SIGNS AND SYMPTOMS OF PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS IN PATIENTS 2 YEARS OF AGE AND OLDER
- I-470 DIABETIC PERIPHERAL NEUROPATHIC PAIN
- I-471 INDICATED TO REDUCE THE RISK OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH TYPE 2 DIABETES AND WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE
- I-472 USE IN PATIENTS WITH ANGIOGRAPHICALLY DOCUMENTED CORONARY ARTERY DISEASE
- I-473 USE IN COMBINATION WITH GEMCITABINE FOR THE FIRST LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER
- I-474 TREATMENT OF IRON DEFICIENCY ANEMIA IN PERITONEAL DIALYSIS DEPENDANT CHRONIC KIDNEY DISEASE IN PATIENTS RECIEVING AN ERYTHROPOIETIN
- I-475 PREVENTION OF NAUSEA AND VOMITTING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF MODERATELY EMETOGENIC CANCER CHEMOTHERAPY
- I-476 TREATMENT OF DIABETIC FOOT INFECTIONS WITHOUT OSTEOMYELITIS
- I-477 TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS, ESCHERICHIA COLI, KLEBSIELLA PNEUMONIAE, OR ENTEROBACTER CLOACAE
- I-478 FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN CHILDREN WITH EPILEPSY AGED 2-4 YEARS
- I-479 TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS CAUSED BY E.COLI, B. FRAGILIS, S.ANGINOSUS, S.CONSTELLATUS, E. FAECALIS, P. MIRABILIS, C. PERFRINGENS, B. THETAIOAOMICRON OR PEPTOSTREPTOCOCCUS SPECIES
- I-480 PROPHYLAXIS OF INFLUENZA FOR PATIENTS BETWEEN 1-12 YEARS OF AGE
- I-481 INDICATED FOR THE ADJUVANT TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER
- I-482 TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH OR WITHOUT PSYCHOTIC FEATURES
- I-483 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- I-484 FOR THE RISK REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS
- I-485 TREATMENT OF POSTOPERATIVE INFLAMMATION AND REDUCTION OF OCULAR PAIN IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION
- I-486 ANGIOMAX IS INDICATED FOR PATIENTS WITH, OR AT RISK OF, HIT/HITTS UNDERGOING PCI
- I-487 INDICATED FOR THE RELIEF OF THE INFAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YRS OF AGE OR OLDER
- I-488 MAINTENANCE THERAPY IN BIPOLAR I DISORDER
- I-489 FOR USE IN PEDIATRIC PATIENTS WITH TYPE I DIABETES
- I-490 FOR USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE TREATMENT OF PATIENTS WITH ADVANCED GASTRIC ADENOCARCINOMA, INCLUDING ADENOCARCINOMA OF GASTROESOPHAGEAL JUNCTION, WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY FOR ADVANCED DISEASE
- I-491 INFLUENZA PROPHYLAXIS
- I-492 MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC OR MIXED EPISODES IN BIPOLAR I DISORDER, WITH OR WITHOUT PSYCHOTIC FEATURES
- I-493 ADMINISTERED IN COMBINATION WITH FENOFIBRATE, AS ADJUNCTIVE THERAPY TO DIET FOR THE REDUCTION OF ELEVATED TOTAL-C, LDL-C, APO B, AND NON-HDL-C IN PATIENTS WITH MIXED HYPERLIPIDEMIA
- I-494 CLINICAL DATA IN SUPPORT OF AVANDAMET AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH DUAL ROSIGLITAZONE AND METFORMIN THERAPY IS APPROPRIATE
- I-495 ADJUVANT TX OF POSTMENOPAUSAL WOMEN WITH ESTROGEN-RECEPTOR POSITIVE EARLY BREAST

PATENT AND EXCLUSIVITY TERMS

ADB 18 of 78

EXCLUSIVITY INDICATION

- CANCER WHO HAVE RECEIVED 2 TO 3 YRS OF TAMOXIFEN AND ARE SWITCHED TO AROMASIN FOR COMPLETION OF A TOTAL OF 5 CONSECUTIVE YRS OF ADJUVANT HORMONAL THERAPY
- I-496 LONG TERM TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME IN PATIENTS WHO HAVE OPEN EPIPHYSES
- I-497 PREVENTION OF SEASONAL MAJOR DEPRESSIVE EPISODES IN PATIENTS WITH SEASONAL AFFECTIVE DISORDER
- I-498 PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
- I-499 USE OF GEMZAR IN COMBINATION WITH CARBOPLATIN FOR THE TREATMENT OF PATIENTS WITH ADVANCED OVARIAN CANCER THAT HAS RELAPSED AT LEAST 6 MONTHS AFTER COMPLETION OF PLATINUM-BASED THERAPY
- I-500 FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- I-501 TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN IMMUNOCOMPETANT PATIENTS WITH A SINGLE DOSE OF FAMCICLOVIR 1500 MG.
- I-502 FOR PTS WITH ST-SEGMENT ELEVATION ACUTE MYOCARDIAL INFARCTION, PLAVIX TO REDUCE RATE OF DEATH FROM ANY CAUSE AND THE RATE OF A COMBINED ENDPOINT OF DEATH, REINFARCTION OR STROKE. NOT KNOWN TO PERTAIN TO PTS WHO RECEIVE PRIMARY ANGIOPLASTY
- I-503 TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER
- I-504 TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME
- I-505 TREATMENT OF STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA), INCLUDING THOSE WITH RIGHT SIDED INFECTIVE ENDOCARDITIS, CAUSED BY METHICILLIN-SUSCEPTIBLE AND METHICILLIN-RESISTANT ISOLATES
- I-506 ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 12 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY
- I-507 ADJUNCT TO DIET TO REDUCE TOTAL-C, LDL-C AND APO B LEVELS IN ADOLESCENT BOYS AND GIRLS WHO ARE AT LEAST ONE YEAR POST-MENARCHE, 10-16 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
- I-508 PREMENSTRUAL DYSPHONIC DISORDER
- I-509 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
- I-510 ADULT DERMAFIBROSARCOMA PROTUBERANS (DFSP)
- I-511 ADULT MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE DISEASES (MDS/MDP)
- I-512 ADULT PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) MONOTHERAPY
- I-513 ADULT AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM)
- I-514 ADULT HYPEREOSINOPHILIC SYNDROME/CHRONIC EOSINOPHILIC LEUKEMIA (HES/CEL)
- I-515 PROPHYLAXIS OF SURGICAL SITE INFECTION FOLLOWING ELECTIVE COLORECTAL SURGERY
- I-516 PRIMARY GENERALIZED TONIC CLONIC SEIZURES IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
- I-517 TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEG SYNDROME (RLS)
- I-518 TREATMENT OF SHORT STATURE OR GROWTH FAILURE IN CHILDREN WITH SHOX (SHORT STATURE HOMEBOX CONTAINING GENE) DEFICIENCY WHOSE EPIPHYSES ARE NOT CLOSED
- I-519 USE OF TAXOTERE (DOCETAXEL) INJECTION CONCENTRATE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
- I-520 USE OF EXENATIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE USING A THIAZOLIDINEDIONE ALONE OR IN COMBINATION WITH METFORMIN BUT HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL
- I-521 TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 YEAR PRIOR THERAPY
- I-522 TREATMENT OF MODERATE ACNE VULGARIS IN WOMEN AT LEAST 14 YRS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, AND HAVE ACHIEVED MENARCHE, IF THE PATIENT DESIRES AN ORAL CONTRACEPTIVE FOR BIRTH CONTROL.
- I-523 USE IN ADULT PATIENTS WITH CLINICALLY EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF NONFATAL MYOCARDIAL INFARCTION, FATAL AND NONFATAL STROKE, ANGINA, REVASCULARIZATION PROCEDURES AND HOSPITALIZATION FOR CONGESTIVE HEART FAILURE
- I-524 GENERALIZED ANXIETY DISORDER (GAD)
- I-525 USE OF 0.5MG/0.1MG FOR PREVENTION OF POST-MENOPAUSAL OSTEOPOROSIS
- I-526 TREATMENT OF HYPONATREMIA IN HOSPITALIZED PATIENTS
- I-527 ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY
- I-528 TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH MENOPAUSE
- I-529 TREATMENT OF DEMENTIA OF THE ALZHEIMER'S TYPE IN PATIENTS WITH SEVERE ALZHEIMER'S DISEASE
- I-530 PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION IN PATIENTS 15 YEARS OF AGE AND

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

OLDER

- I-531 MAINTENANCE TREATMENT OF SCHIZOPHRENIA
- I-532 TREATMENT OF BACTERIAL VAGINOSIS IN NON-PREGNANT FEMALES
- I-533 ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI)
- I-534 EXTENDED TREATMENT OF SYMPTOMATIC VENOUS THROMBOEMBOLISM (VTE) AND/OR PULMONARY EMBOLISM TO REDUCE THE RECURRENCE OF VTE IN PATIENTS WITH CANCER
- I-535 MANAGEMENT OF FIBROMYALGIA
- I-536 FOR THE TREATMENT OF SHORT STATURE IN CHILDREN WITH NOONAN SYNDROME
- I-537 LONG TERM TREATMENT OF PANIC DISORDER
- I-538 SHORT TERM TREATMENT OF PANIC DISORDER
- I-539 REDUCTION IN RISK OF INVASIVE BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS OR AT HIGH RISK FOR INVASIVE BREAST CANCER
- I-540 TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGES 13-17
- I-541 TREATMENT OF BIPOLAR I DISORDER IN CHILDREN AGES 10-12 AND ADOLESCENTS AGES 13-17
- I-542 EXPANSION OF PATIENT POPULATION FOR HEAD AND NECK CANCER FROM "INOPERABLE" PATIENTS TO ALL PATIENTS
- I-543 USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
- I-544 ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 16 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY
- I-545 ADJUNCTIVE TREATMENT TO TREAT PATIENTS WITH MAJOR DEPRESSIVE DISORDER
- I-546 TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA
- I-547 ADJUNCTIVE THERAPY TO DIET TO SLOW THE PROGRESSION OF ARTEROSCLEROSIS IN ADULT PATIENTS AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL-C AND LDL-C TO TARGET LEVELS
- I-548 SEASONAL ALLERGIC RHINITIS IN PATIENTS 6 THROUGH LESS THAN 12 YEARS OF AGE
- I-549 USE OF AVALIDE TABLETS AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS
- I-550 TREATMENT OF HYPERTENSION IN PEDIATRIC PATIENTS 6-16 YEARS OF AGE
- I-551 TREATMENT OF SHORT STATURE IN CHILDREN WITH TURNER'S SYNDROME
- I-552 ADJUNCTIVE TREATMENT FOR RADIOIODINE ABLATION OF THYROID TISSUE REMNANTS IN PATIENTS WHO HAVE UNDERGONE THYROIDECTOMY FOR WELL-DIFFERENTIATED THYROID CANCER AND WHO DO NOT HAVE EVIDENCE OF METASTATIC THYROID CANCER
- I-553 FOR USE AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
- I-554 TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESES
- I-555 TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN PEDIATRIC PATIENTS AGED 10-17 YEARS
- I-556 PREVENTION OF POST OPERATIVE NAUSEA AND VOMITING FOR UP TO 24 HOURS FOLLOWING SURGERY
- I-557 USE OF AMITIZA (LUBIPROSTONE) 8 MCG TWICE DAILY FOR TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN WOMEN GREATER THAN OR EQUAL TO 18 YEARS OLD
- I-558 MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION AND REDUCING EXACERATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
- I-559 ADJUNCTIVE THERAPY ADDED TO LITHIUM OR VALPROATE IN SHORT TERM TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED
- I-560 MAINTENANCE TREATMENT FOR BIPOLAR I DISORDER, AS ADJUNCTIVE THERAPY TO LITHIUM OR DIVALPROEX
- I-561 LONG-TERM TREATMENT OF SOCIAL ANXIETY DISORDER
- I-562 MAINTENANCE TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS
- I-563 ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SIEZURES IN ADULTS AND CHILDREN 16 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY
- I-564 TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA
- I-565 USE OF DUTASTERIDE IN COMBINATION WITH TAMSULOSIN FOR THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (BPH)
- I-566 MANAGEMENT OF FIBROMYALGIA
- I-567 INITIAL THERAPY IN PATIENTS LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS
- I-568 USE OF APTIVUS, CO-ADMINISTERED W/RITONAVIR, FOR COMBINATION ANTIRETROVIRAL TREATMENT OF HIV-1 INFECTED PED (AGE 2-18 YRS) PATIENTS WHO ARE TREATMENT-EXPERIENCED AND INFECTED W/HIV-1 STRAINS RESISTANT TO MORE THAN ONE PROTEASE INHIBITOR

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

I-569	TREATMENT OF CHRONIC HEPATITIS B
I-570	TREATMENT OF CHICKEN POX IN IMMUNOCOMPETENT PEDIATRIC PATIENTS 2 TO <18 YEARS OF AGE
I-571	NON-SMALL CELL LUNG CANCER IN COMBINATION WITH CISPLATIN AND AS SINGLE AGENT FOR NONSQUAMOUS NON-SMALL CELL LUNG CANCER
I-572	TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE (SGA) WITH NO CATCH-UP BY AGE 2-4 YRS.
I-573	TO TREAT PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDRICKSON TYPE III HYPERLIPOPROTEINEMIA) AS AN ADJUNCT TO DIET
I-574	MONOTHERAPY IN THE TREATMENT OF BIPOLAR DEPRESSION
I-575	MONOTHERAPY IN THE TREATMENT OF BIPOLAR MANIA
I-576	ADJUNCTIVE THERAPY IN THE TREATMENT OF BIPOLAR MANIA
I-577	SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES
I-578	EXPANSION OF INDICATION TO INCLUDE TREATMENT OF HIV IN TREATMENT NAIVE ADULTS
I-579	TREATMENT OF MODERATE TO SEVERE DYSpareunia, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE AND NEW TWICE WEEKLY DOSING REGIMEN FOR THIS INDICATION
I-580	INDOLENT B-CELL NON-HODGKINS LYMPHOMA (NHL) THAT HAS PROGRESSED DURING OR WITHIN SIX MONTHS OF TREATMENT WITH RITUXIMAB OR A RITUXIMAB CONTAINING REGIMEN
I-581	TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
I-582	TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
I-583	ADJUVANT TREATMENT OF ADULT PATIENTS FOLLOWING COMPLETE GROSS RESECTION OF KIT (CD117) POSITIVE GASTROINTESTINAL STROMAL TUMORS (GIST)
I-584	TREATMENT AND PREVENTION OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN PATIENTS EXPECTED TO BE ON GLUCOCORTICIDS FOR AT LEAST 12 MONTHS
I-585	TREATMENT OF SHORT STATURE IN PEDIATRIC PATIENTS SMALL FOR GESTATIONAL AGE WHO DO NOT MANIFEST CATCH UP GROWTH BY AGE 2 TO 4 YEARS
I-586	COMMUNITY ACQUIRED BACTERIAL PNEUMONIA
I-587	ADDITIONAL PATHOGENS TO COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS INDICATION
I-588	ADDITIONAL PATHOGENS TO COMPLICATED INTRA-ABDOMINAL INFECTIONS INDICATION
I-589	TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH OLANZAPINE
I-590	ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH OLANZAPINE)
I-591	TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH FLUOXETINE
I-592	ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH FLUOXETINE)
I-593	TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD)
I-594	INDICATION EXPANDED TO INCLUDE PATIENTS WHO HAVE EXPERIENCED A FIRST CLINICAL EPISODE AND HAVE MRI FEATURES CONSISTENT WITH MULTIPLE SCLEROSIS
I-595	PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-596	USE AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
I-597	MONOTHERAPY FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
I-598	TREATMENT OF PULMONARY ARTERIAL HYPERTENSION INDICATION EXPANDED TO INCLUDE DELAY IN CLINICAL WORSENING
I-599	PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5 IN PATIENTS ON HEMODIALYSIS OR PERITONEAL DIALYSIS
I-600	FOR USE AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS
I-601	MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OR METASTATIC NONSQUAMOUS NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST LINE CHEMOTHERAPY
I-602	TREATMENT OF MEN AND WOMEN WITH OSTEOPOROSIS ASSOCIATED WITH SUSTAINED SYSTEMIC GLUCOCORTICOID THERAPY AT HIGH RISK FOR FRACTURE
I-603	GOUT FLARES
I-604	PREVENTION OF CMV DISEASE IN KIDNEY AND HEART TRANSPLANT PATIENTS 4 MONTHS TO 16 YEARS AT HIGH RISK
I-605	ADJUNCT TO MOOD STABILIZERS AND/OR ANTIDEPRESSANTS FOR SCHIZOAFFECTIVE DISORDER
I-606	TREATMENT OF SCHIZOAFFECTIVE DISORDER AS MONOTHERAPY
I-607	INDICATION EXPANDED TO INCLUDE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP I) IN PATIENTS WITH CLASS II SYMPTOMS
I-608	REDUCE LDL-C LEVELS IN BOYS AND POSTMENARCHAL GIRLS, 10 TO 17 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AS MONOTHERAPY OR IN COMBINATION WITH A STATIN AFTER FAILING AN ADEQUATE TRIAL OF DIET THERAPY
I-610	TREATMENT OF HEAVY MENSTRUAL BLEEDING FOR WOMEN WHO CHOOSE TO USE INTRAUTERINE CONTRACEPTION AS THEIR METHOD OF CONTRACEPTION
I-611	TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND

PATENT AND EXCLUSIVITY TERMS

ADB 21 of 78

EXCLUSIVITY INDICATION

- POSTMENARCHAL GIRLS, AGES 10 TO 17 YEARS, WITH A RECOMMENDATION DOSING RANGE OF 5 TO 20 MG ONCE DAILY
- I-612 MICARDIS 80 MG FOR REDUCTION OF THE RISK OF MYOCARDIAL INFARCTION, STROKE, OR DEATH FROM CARDIOVASCULAR CAUSES IN PATIENTS 55 YEARS OF AGE OR OLDER AT HIGH RISK OF DEVELOPING MAJOR CARDIOVASCULAR EVENTS WHO ARE UNABLE TO TAKE ACE INHIBITORS
- I-613 MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE TO LESS THAN 18 YEARS OF AGE
- I-614 SHORT TERM TREATMENT OF EROSIIVE ESOPHAGITIS ASSOCIATED WITH GERD IN PEDIATRIC PATIENTS AGES FIVE YEARS AND OLDER
- I-615 MAINTENANCE TREATMENT OF BIPOLAR DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE
- I-616 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER IN PEDIATRIC PATIENTS AGES 6-17 YEARS OF AGE
- I-617 MAINTENANCE OF GENERALIZED ANXIETY DISORDER (GAD)
- I-618 ADJUNCTIVE THERAPY IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
- I-619 INTRAVENOUS CONTRAST ENHANCED COMPUTER TOMOGRAPHY OF THE HEAD AND BODY
- I-620 FOR USE IN COMBINATION WITH LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER THAT OVEREXPRESSES THE HER2 RECEPTOR FOR WHOM HORMONAL THERAPY IS INDICATED
- I-621 PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE, BASED ON THE RESULTS OF JUSTIFICATION FOR THE USE OF STATINS IN PRIMARY PREVENTION; AN INTERVENTION TRIAL EVALUATING ROSUVASTATIN (JUPITER)
- I-622 ADJUNCTIVE THERAPY FOR PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN PATIENTS THIRTEEN YEARS OF AGE AND OLDER
- I-623 TREATMENT OF SIGNS AND SYMPTOMS OF ADVANCED IDIOPATHIC PARKINSON'S DISEASE
- I-624 MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST-LINE CHEMOTHERAPY
- I-625 PANCREATIC INSUFFICIENCY DUE TO CHRONIC PANCREATITIS AND PANCREATECTOMY
- I-626 RELIEF OF NASAL CONGESTION ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATENTS 2 YEARS OF AGE AND OLDER
- I-627 TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH & CML) IN CHRONIC PHASE.
- I-628 MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN ADULTS
- I-629 ADJUNCTIVE THERAPY WITH EITHER LITHIUM OR VALPROATE FOR THE ACUTE TREATMENT OF MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
- I-630 TREATMENT OF PATIENTS WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) ASSOCIATED WITH TUBEROUS SCLEROSIS (TS) WHO REQUIRE THERAPEUTIC INTERVENTION BUT ARE NOT CANDIDATES FOR CURATIVE SURGICAL RESECTION.
- I-631 PREVENTION OF RELAPSE TO OPIOID DEPENDENCE FOLLOWING OPIOID DETOXIFICATION
- I-632 MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN
- I-633 MAINTENANCE TREATMENT OF BIPOLAR I DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE
- I-634 TREATMENT OF SEVERE HYPERCALCEMIA IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY
- I-635 ADJUNCTIVE TREATMENT WITH LONG-ACTING ORAL PSYCHOSTIMULANTS FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
- I-636 TREATMENT OF EXTERNAL GENITAL AND PERIANAL WARTS/CONDYLOMA ACUMINATA IN PATIENTS 12 YEARS OR OLDER
- I-637 USE IN COMBINATION CHEMOTHERAPY WITH 5-FLUOROURACIL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED METASTATIC COLORECTAL CANCER
- I-638 FOR PATIENTS WITH PROGRESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC.
- I-639 TREATMENT OF PROGRESSIVE, WELL-DIFFERENTIATED PANCREATIC NEUROENDOCRINE TUMORS IN PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC DISEASE
- I-640 MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
- I-641 TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)
- I-642 TREATMENT OF ERECTILE DYSFUNCTION (ED) AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)
- I-643 REDUCE THE RISK OF STROKE AND SYSTEMIC EMBOLISM IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION.
- I-644 MONOTHERAPY IN PATIENTS 13 YEARS OF AGE AND OLDER WITH PARTIAL SEIZURES WHO ARE RECEIVING THERAPY WITH A SINGLE ANTIEPILEPTIC DRUG (AED)
- I-645 MAINTENANCE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS
- I-646 SIGNS AND SYMPTOMS OF ADVANCED PARKINSON'S DISEASE (APD)
- I-647 SIGNS AND SYMPTOMS OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)
- I-648 TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION
- I-649 TREATMENT OF PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA (STS) WHO HAVE RECEIVED

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY INDICATION**

PRIOR CHEMOTHERAPY

- I-650 TREATMENT OF ADULTS WITH RENAL ANGIOMYOLIPOMA AND TUBEROUS SCLEROSIS COMPLEX (TSC), NOT REQUIRING IMMEDIATE SURGERY
- I-651 MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH SPINAL CORD INJURY
- I-652 MANAGEMENT OF POSTHERPETIC NEURALGIA
- I-653 TREATMENT OF ENDOGENOUS ANTERIOR UVEITIS
- I-654 MAGNETIC RESONANCE ANGIOGRAPHY (MRA) TO EVALUATE ADULTS WITH KNOWN OR SUSPECTED RENAL OR AORTO-ILIO-FEMORAL OCCLUSIVE VASCULAR DISEASE
- I-655 TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED HORMONE RECEPTOR-POSITIVE,HER2-NEGATIVE BREAST CANCER (ADVANCED HR+BC) IN COMBINATION WITH EXEMESTANE, AFTER FAILURE OF TREATMENT WITH LETROZOLE OR ANASTROZOLE
- I-656 MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY (DPN) IN ADULTS WHEN A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME
- I-657 PLAQUE PSORIASIS OF THE SCALP
- I-658 FIRST-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER, IN COMBINATION WITH CARBOPLATIN, IN PATIENTS WHO ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION THERAPY
- I-659 PLAQUE PSORIASIS OF THE BODY
- I-660 TREATMENT OF DEEP VEIN THROMBOSIS
- I-661 TREATMENT OF PULMONARY EMBOLISM
- I-662 REDUCTION IN RISK FOR DEEP VEIN THROMBOSIS AND THE REDUCTION IN RISK FOR PULMONARY EMBOLISM
- I-663 IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
- I-664 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
- I-665 TREATMENT OF CHRONIC IRON OVERLOAD IN PATIENTS 10 YRS OF AGE AND OLDER WITH (NTDT)SYNDROMES AND WITH A (LIC) OF AT LEAST 5 MG OF IRON PER GRAM OF LIVER DRY WEIGHT (MG FE/G DW) AND SERUM FERRITIN GREATER THAN 300MCG/L
- I-666 TREATMENT OF PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL) IN COMBINATION WITH CHEMOTHERAPY
- I-667 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) WHO HAVE BEEN PREVIOUSLY TREATED WITH IMATINIB MESYLATE AND SUNITINIB MALATE
- I-668 PROPHYLAXIS OF ALLOGRAFT REJECTION IN ADULT PATIENTS RECEIVING A LIVER TRANSPLANT
- I-669 SCINTIGRAPHIC ASSESSMENT OF SYMPATHETIC INNERVATION OF THE MYOCARDIUM BY MEASUREMENT OF THE HEART TO MEDIASTINUM (H/M) RATIO OF RADIOACTIVITY UPTAKE IN PATIENTS WITH NYHA CLASS II OR CLASS III HEART FAILURE AND LVEF LESS THAN 35%
- I-670 TREATMENT OF OPIOID-INDUCED CONSTIPATION (OIC) IN ADULTS WITH CHRONIC, NON-CANCER PAIN
- I-671 FIRSTLINE TREATMENT OF PATIENTS WITH METASTATIC NON- SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21(L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
- I-672 USE IN PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
- I-673 TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA/VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) CAUSED BY SUSCEPTIBLE ISOLATES OF S. AUREUS (INCLUDING METHICILLIN-SUSCEPTIBLE AND RESISTANT ISOLATES) WHEN ALTERNATIVE TREATMENTS ARE NOT SUITABLE
- I-674 TREATMENT OF PATIENTS WITH DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER (BIPOLAR DEPRESSION) AS MONOTHERAPY AND AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE
- I-675 MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER
- I-676 FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC ADENOCARCINOMA OF THE PANCREAS, IN COMBINATION WITH GEMCITABINE
- I-677 TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA (DTC) THAT IS REFRACTORY TO RADIOACTIVE IODINE TREATMENT
- I-678 TRAMETINIB, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
- I-679 RISK REDUCTION OF REBLEEDING OF GASTRIC OR DUODENAL ULCERS FOLLOWING THERAPEUTIC ENDOSCOPY IN ADULTS
- I-680 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- I-681 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT) WHICH MAY LEAD TO PULMONARY EMBOLISM

PATENT AND EXCLUSIVITY TERMS

ADB 23 of 78

EXCLUSIVITY INDICATION

- (PE), IN ADULT PATIENTS WHO HAVE UNDERGONE HIP OR KNEE REPLACEMENT
- I-682 TREATMENT OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE) IN PATIENTS WHO HAVE BEEN TREATED WITH A PARENTERAL ANTICOAGULANT FOR 5-10 DAYS
- I-683 TO REDUCE THE RISK OF RECURRENCE OF DVT AND PE IN PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED
- I-684 PREVENTION OF ACUTE NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING HIGHLY EMETOGENIC CANCER CHEMOTHERAPY IN PEDIATRIC PATIENTS AGED 1 MONTH TO LESS THAN 17 YEARS
- I-685 EXPANDED INDICATION OF RASAGILINE AS AN ADD-ON THERAPY TO STABLE DOSES OF DOPAMINE AGONISTS IN THE TREATMENT OF EARLY PARKINSON'S DISEASE
- I-686 INDICATED FOR THE TREATMENT OF DIABETIC MACULAR EDEMA IN PATIENTS WHO ARE PSEUDOPHAKIC OR ARE PHAKIC AND SCHEDULED FOR CATARACT SURGERY
- I-687 GUIDING SENTINEL LYMPH NODE BIOPSY, USING A HAND-HELD GAMMA COUNTER IN PATIENTS WITH CLINICALLY NODE NEGATIVE SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY
- I-688 GADAVIST IS INDICATED WITH MRI TO DETECT THE PRESENCE AND EXTENT OF MALIGNANT BREAST DISEASE
- I-689 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION
- I-690 INDICATED FOR THE TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
- I-691 INDICATED TO REDUCE THE RISK OF RECURRENT DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE) FOLLOWING INITIAL THERAPY
- I-692 INDICATED FOR MANAGEMENT OF OSTEOARTHRITIS PAIN.
- I-693 TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
- I-694 TREATMENT OF PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WHO ARE CANDIDATES FOR PHOTOTHERAPY OR SYSTEMIC THERAPY
- I-695 REVISED INDICATION FOR BORTEZOMIB IN THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA
- I-696 USE AS MONOTHERAPY IN THE TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY AGE 17 YEARS AND OLDER
- I-697 FOR USE IN COMBINATION WITH SOFOSBUVIR FOR THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1 INFECTION
- I-698 SCHIZOAFFECTIVE DISORDER AS MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS
- I-699 FOR TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
- I-700 TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S DISORDER (6-18 YEARS)
- I-701 FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, WELL-OR MODERATELY-DIFFERENTIATED, LOCALLY ADVANCED OR METASTATIC GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEP-NETS) TO IMPROVE PROGRESSION AND FREE SURVIVAL.
- I-702 FOR THE TREATMENT OF PATIENTS WITH WALDENSTROM MACROGLOBULINEMIA
- I-703 MODERATE TO SEVERE BINGE EATING DISORDER (BED)
- I-704 EXPANDED INDICATION TO INCLUDE PATIENTS WHO ARE VIROLOGICALLY-SUPPRESSED (HIV-1 RNA <50 COPIES/ML) ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS WITH NO HISTORY OF TREATMENT FAILURE IN ORDER TO REPLACE THEIR CURRENT REGIMEN
- I-705 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 6 YEARS AND OLDER WHO HAVE AN R117H MUTATION IN THE CFTR GENE
- I-706 EXPANDED INDICATION FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA
- I-707 POMALYST, IN COMBINATION WITH DEXAMETHASONE, IS INDICATED FOR PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 2 PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY
- I-708 DAILY TREATMENT OF ASTHMA IN PATIENTS AGED 18 YEARS AND OLDER
- I-709 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS
- I-710 ADJUNCTIVE THERAPY FOR THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC (PG TC) SEIZURES IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE OR OLDER.
- I-711 INCLUSION OF PEDIATRIC PATIENTS AGES 6 YRS AND OLDER FOR THE TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC ITP WHO HAVE HAD AN INSUFFICIENT RESPONSE TO CORTICOSTEROIDS, IMMUNOGLOBULINS, OR SPLENECTOMY.
- I-712 EXPANDED INDICATION FOR USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE PRIOR LINES OF THERAPY
- I-713 REVISIONS TO THE LABELING TO PERMIT THE USE OF ZUBSOLV AS INITIAL ("INDUCTION") TREATMENT OF OPIOID DEPENDENCE
- I-714 EXTENDS THE 2011 APPROVAL OF BRILINTA FOR USE BEGINNING WITH ACS TO USE BEGINNING MORE REMOTE FROM MYOCARDIAL INFRACTION
- I-715 FOR THE ADDITION OF THE INDICATION FOR MONOTHERAPY TREATMENT IN PARTIAL-ONSET SEIZURES IN ADULTS.
- I-716 REVISED INDICATION TO INCLUDE LANGUAGE ABOUT THE BENEFITS OF USING LETAIRIS IN COMBINATION WITH TADALAFIL TO REDUCE THE RISK OF DISEASE PROGRESSION AND

PATENT AND EXCLUSIVITY TERMS

ADB 24 of 78

EXCLUSIVITY INDICATION

- HOSPITALIZATION FOR WORSENING PAH AND TO IMPROVE EXERCISE ABILITY, BASED ON THE AMBITION STUDY
- I-717 EXPANDED INDICATION TO INCLUDE THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 4
- I-718 EXPANDED INDICATION TO INCLUDE SUBJECTS INFECTED WITH CHRONIC HEPATITIS C, GENOTYPE 6 VIRUS INFECTION BASED UPON THE RESULTS OF THE ELECTRON- 2 STUDY
- I-719 EXPANDED INDICATION TO INCLUDE THE TREATMENT OF SUBJECTS WITH GENOTYPE 5 CHRONIC HEPATITIS C VIRUS INFECTION BASED ON THE RESULTS FROM STUDY GS-US-337-119.
- I-720 EXPANDED INDICATION TO INCLUDE TREATMENT OF GENOTYPE 4, CHRONIC HEPATITIS C VIRUS INFECTION BASED UPON THE RESULTS FROM STUDIES ION-4 AND GS-US-337-119.
- I-721 TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA WHO HAVE RECEIVED A PRIOR ANTHRACYCLINE-CONTAINING REGIMEN.
- I-722 REVISED INDICATION FOR USE IN COMBINATION WITH DEXAMETHASONE OR WITH LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY.
- I-723 AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE OR MORE LINES OF THERAPY
- I-724 TREATMENT OF ADULT PATIENTS WITH PROGRESSIVE, WELL DIFFERENTIATED, NON-FUNCTIONAL NEUROENDOCRINE TUMORS (NET) OF GI OR LUNG ORIGIN WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC DISEASE
- I-725 TREATMENT OF HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN COMBINATION THERAPY WITH PALBOCICLIB AND FULVESTRANT IN WOMEN WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY.
- I-726 EXPANSION OF THE PATIENT POPULATION TO INCLUDE PATIENTS WITH RECURRENCE OF HEPATITIS C VIRUS (HCV) GENOTYPE 1 OR 3 AFTER LIVER TRANSPLANTATION
- I-727 EXPANSION OF THE INDICATION TO INCLUDE TREATMENT OF SUBJECTS WITH GENOTYPE-1 CHRONIC HEPATITIS C VIRUS INFECTION, INCLUDING SUBJECTS WHO ARE CO-INFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS (HIV-1) BASED ON THE RESULTS FROM THE ALLY-2 CLINICAL TRIAL
- I-728 EXPANDED INDICATION FOR USE IN ULTRASONOGRAPHY OF THE LIVER FOR CHARACTERIZATION OF FOCAL LIVER LESIONS IN ADULT AND PEDIATRIC PATIENTS
- I-729 PROVIDES FOR THE FRONTLINE INDICATION FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
- I-730 NEW INDICATION FOR THE TREATMENT OF PATIENTS WITH METASTATIC, SQUAMOUS, NON-SMALL CELL LUNG CANCER PROGRESSING AFTER PLATINUM-BASED CHEMOTHERAPY
- I-731 FOR USE IN MAGNETIC RESONANCE ANGIOGRAPHY IN ADULT AND PEDIATRIC PATIENTS (INCLUDING TERM NEONATES) TO EVALUATE KNOWN OR SUSPECTED SUPRA-AORTIC OR RENAL ARTERY DISEASE
- I-732 TREATMENT OF PEDIATRIC PATIENTS 7 TO 17 YEARS OF AGE WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA TO REDUCE LDL-C, TOTAL C, NONHDL-C AND APOB AS AN ADJUNCT TO DIET, EITHER ALONE OR WITH OTHER LIPID-LOWERING TREATMENTS
- I-733 USE OF CANAGLIFLOZIN FOR INITIAL THERAPY IN COMBINATION WITH METFORMIN
- I-734 EXPANDED INDICATION FOR THE USE OF LENVIMA IN COMBINATION WITH EVEROLIMUS FOR THE TREATMENT OF PATIENTS WITH ADVANCED RCC FOLLOWING ONE PRIOR ANTI-ANGIOGENIC THERAPY.
- I-735 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH CANAGLIFLOZIN AND METFORMIN IS APPROPRIATE
- I-736 REVISED INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA (SLL)
- I-737 REVISED INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA (SLL) WITH 17P DELETION
- I-738 REVISIONS TO THE INDICATIONS AND USAGE SECTION WITH RESPECT TO COMPLICATED INTRA-ABDOMINAL INFECTIONS
- I-739 TO REDUCE THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE
- I-740 EXPANDED INDICATION FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 6 YEARS AND OLDER TO INCLUDE THE G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, OR S549R MUTATION IN THE CFTR GENE

EXCLUSIVITY MISCELLANEOUS

- M-1 INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION
- M-2 APPROVAL FOR ADDITION TO CLINICAL PHARMACOLOGY SECTION OF THE LABEL REGARDING (1) IMPROVEMENT IN BONE MINERAL DENSITY IN CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENT PATIENTS AND (2) INCREASES IN SERUM ALKALINE PHOSPHATASE
- M-3 ADDITION OF EFFICACY AND SAFETY INFORMATION IN WHICH FOSAMAX WAS USED CONCOMITANTLY WITH ESTROGEN ALONE OR WITH ESTROGEN PLUS PROGESTIN

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY MISCELLANEOUS**

- M-4 CHANGES TO PEDIATRIC USE SECTION TO PROVIDE INFORMATION REGARDING SAFETY AND EFFICACY IN PEDIATRIC PATIENTS AS YOUNG AS 2 YEARS OLD
- M-5 INFORMATION REGARDING EFFECTS IN PATIENTS WITH ASTHMA ON CONCOMITANT INHALED CORTICOSTEROIDS IN CLINICAL PHARMACOLOGY SECTION
- M-6 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUCOPHAGE/GLYBURIDE COMBINATION ADDED TO CLINICAL PHARMACOLOGY AND DOSING AND ADMINISTRATION
- M-7 CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION
- M-8 ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING
- M-9 ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART RATE, AND HEART RATE VARIABILITY
- M-10 INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF DOSING
- M-11 USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER
- M-12 NEW LANGUAGE FOR PEDIATRIC USE
- M-13 INFORMATION FROM PEDIATRIC STUDIES ADDED TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION
- M-14 ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION
- M-15 LONGER TERM EFFICACY INFORMATION FOR RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA
- M-16 CHANGE IN WORDING OF THE PEDIATRIC SECTION OF THE PACKAGE INSERT
- M-17 INFORMATION REGARDING USE OF ULTANE IN PEDIATRIC PATIENTS WITH CONGENITAL HEART DISEASE
- M-18 INFORMATION DENOTING THE EFFICACY OF REMERON IN MAINTAINING A RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)
- M-19 INFORMATION REGARDING USE IN PEDIATRIC PATIENTS TWO YEARS OF AGE AND OLDER
- M-20 LABELING REVISIONS RELATED TO MCCUNE ALBRIGHT SYNDROME
- M-21 COMPARISON DATA ON THE ANTIHYPERTENSIVE EFFECTS OF ATACAND AND COZAAR
- M-22 CHANGE IN TIME TO ONSET OF ACTION
- M-23 INFORMATION REGARDING ELIMINATION ADDED TO CLINICAL PHARMACOLOGY, STUDY RESULTS IN PATIENTS WITH HEPATIC AND RENAL IMPAIRMENT
- M-24 INFORMATION ON RESULTS OF A LONG TERM LONGITUDINAL GROWTH STUDY AND PEDIATRIC SAFETY INFORMATION
- M-25 ADDITIONAL SAFETY AND PHARMACOKINETICS INFORMATION IN CHILDREN 6 MONTHS TO LESS THAN 6 YEARS OF AGE ADDED TO PACKAGE INSERT
- M-26 INCORPORATION OF INFORMATION CONTAINED IN THE PEG-INTRON PACKAGE INSERT INTO THE REBETOL PACKAGE INSERT AND MEDGUIDE-PEG-INTRON WAS APPROVED FOR USE IN COMBINATION WITH REBETOL FOR TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION ON 8/7/01
- M-27 INFORMATION DESCRIBING ASPIRIN ENDOSCOPY STUDY AND THE MAXIMUM RECOMMENDED DOSE FOR PATIENTS WITH MODERATE HEPATIC INSUFFICIENCY
- M-28 INFORMATION FROM A STUDY IN PEDIATRIC PATIENTS IN ASSOCIATION WITH A NEUROLOGICAL CONDITION
- M-29 LABELING CHANGES TO PROVIDE INFORMATION IN THE MANAGEMENT OF OBESITY IN ADOLESCENTS AGED 12 TO 16 YEARS
- M-30 CHANGES TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION SECTIONS OF LABELING CONCERNING USE OF LOTENSIN IN PEDIATRIC PATIENTS WITH HYPERTENSION
- M-31 INFORMATION FOR USE IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5 (END-STAGE RENAL DISEASE)
- M-32 ADDITIONAL LANGUAGE TO CLINICAL PHARMACOLOGY AND CLINICAL STUDIES
- M-33 INFORMATION FOR USE OF ADVAIR DISKUS 100/50 IN CHILDREN 4 TO 11 YEARS OF AGE WITH ASTHMA
- M-34 EXPANDED INFORMATION TO PEDIATRIC USE SUBSECTION OF LABELING IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
- M-35 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH ACTOS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, OR INSULIN ADDED TO CLINICAL PHARMACOLOGY
- M-36 ADDITION OF INFORMATION TO CLINICAL STUDIES REGARDING PREVENTION OF CARDIOVASCULAR DISEASE
- M-37 INFORMATION ADDED TO THE LABELING THAT DETAILS INFORMATION RELATIVE TO STUDIES DONE IN PEDIATRIC POPULATIONS IN THE CLINICAL PHARMACOLOGY AND PEDIATRIC USE SUBSECTIONS
- M-38 SAFETY AND IOP-LOWERING EFFECTS OF TRUSOPT HAVE BEEN DEMONSTRATED IN PEDIATRIC PATIENTS IN A 3 MONTH, MULTI-CENTER DOUBLE MASKED ACTIVE-TREATMENT-CONTROLLED TRIAL
- M-39 FOR LABELING CHANGES BASED ON RESULTS OF THE SPD422-202 CLINICAL STUDY REPORT (CSR) SUBMITTED IN RESPONSE TO THE WRITTEN REQUEST
- M-40 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED IN PEDIATRIC PATIENTS WITH LEUKEMIA ADDED TO PRECAUTIONS

PATENT AND EXCLUSIVITY TERMS

ADB 26 of 78

EXCLUSIVITY MISCELLANEOUS

- M-41 REVISION TO THE PEDIATRIC USE PRECAUTIONS OF THE PRESCRIBING INFORMATION TO INCORPORATE THE RESULTS FROM THE CAPPS-169 STUDY ENTITLED "THE EFFECT OF ORTHO TRICYCLEN ON BONE MINERAL DENSITY IN PEDIATRIC SUBJECTS WITH ANOREXIA NERVOSA"
- M-42 ADDITION OF A GERIATRIC USE SUBSECTION TO THE PRECAUTIONS SECTION OF THE PACKAGE INSERT AND GERIATRIC DOSING INFORMATION
- M-43 INCLUSION OF RESULTS OF STUDY "PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY AND PILOT EFFICACY OF ILOPROST AS ADD ON THERAPY WITH BOSENTAN IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION"
- M-44 CLINICAL INFORMATION ADDED TO THE PEDIATRIC USE SUBSECTION OF PRECAUTIONS REGARDING THE USE OF NOVOLOG IN ADOLESCENTS WITH TYPE I DIABETES AGE 6 TO 18
- M-45 INFORMATION ADDED TO CLINICAL TRIALS SECTION OF LABELING, "EFFECTS OF HUMATROPE TREATMENT IN ADULTS WITH GROWTH HORMONE DEFICIENCY"
- M-46 PROVISION OF RESULTS OF STUDY AND PROPOSED REVISIONS TO PACKAGE INSERT SEE SECTION ON CARDIAC ELECTROPHYSIOLOGY
- M-47 PROVIDES FOR USE OF ANTARA WITHOUT REGARD TO MEALS
- M-48 CHANGES TO THE LABELING DESCRIBING THE RESULTS OF A STUDY OF THE USE OF NOVOLOG MIX 70/30 WITH ORAL ANTIDIABETIC AGENTS IN PATIENTS WITH TYPE 2 DIABETES
- M-49 CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING EFFECT OF SINGULAIR ON GROWTH RATES IN PREPUBERTAL CHILDREN
- M-50 NEW INFO TO THE CLINICAL STUDIES, ADULT GROWTH HORMONE DEFICIENCY (GHD) SUBSECTION OF THE NUTROPIN AQ PACKAGE INSERT DESCRIBING THE EFFECTS OF SOMATROPIN ON VISCERAL ADIPOSE TISSUE IN THE ADULT GROWTH HORMONE DEFICIENT PATIENT POPULATION
- M-51 INFORMATION ADDED TO LABELING REGARDING OSTEOGENESIS IMPERFECTA STUDY
- M-52 INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY/CLINICAL STUDIES SECTION REGARDING THE USE OF RISEDRONATE ADMINISTERED ONCE A WEEK IN THE PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- M-53 FOR LABELING CHANGES TO THE QUALITY OF LIFE (QOL) STATEMENT IN THE APPROVED PACKAGE INSERT
- M-54 INFORMATION FROM PEDIATRIC STUDIES ADDED TO LABEL
- M-55 INFORMATION ON RESULTS OF A STUDY OF THE USE OF SANDOSTATIN LAR DEPOT IN PEDIATRIC PATIENTS WITH HYPOTHALAMIC OBESITY.
- M-56 INFORMATION ADDED TO CLINICAL TRIAL SECTION WITH INFORMATION ON "GEMINI" TRIAL
- M-57 CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING THE PHARMACOKINETICS OF EZETIMIBE IN ASIAN SUBJECTS
- M-58 CHANGES TO THE CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, VYTORIN SUBSECTION OF THE PACKAGE INSERT TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR AN ATORVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PRMTRS
- M-59 RESULTS OF THE T20-310 STUDY WHICH EVALUATED THE PHARMACOKINETICS, SAFETY, AND ANTIVIRAL ACTIVITY OF FUZEON IN TREATMENT EXPERIENCED PEDIATRIC SUBJECTS AND ADOLESCENTS WAS ADDED TO THE PEDIATRIC SUBSECTION OF PRECAUTIONS
- M-60 CHANGES TO CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR A ROSUVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PARAMETERS IN PATIENTS WTH HYPERCHOLESTEROLEMIA
- M-61 REVISIONS TO LABELING BASED ON DATA SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
- M-62 CLINICAL INFORMATION FROM ONE CLINICAL STUDY INVESTIGATING THE USE OF AVANDAMET PLUS INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL WITH PREVIOUS ANTI-DIABETIC THERAPIES
- M-63 DETAILED INFORMATION ON AN INCONCLUSIVE PEDIATRIC STUDY
- M-64 CHANGES TO CLINICAL PHARMACOLOGY DETAILING STUDY RESULTS
- M-65 ADDITION OF INFORMATION TO LABEL TO INCLUDE INFORMATION REGARDING USE IN PATIENTS WITH HIV-ASSOCIATED ADIPOSE REDISTRIBUTION SYNDROME (HARS)
- M-66 USE IN SPECIFIC POPULATIONS - PATIENTS WITH CONCOMITANT ILLNESS SUBSECTION OF THE LABELING REGARDING USE OF STRATTERA IN PATIENTS WITH ADHD WHO HAVE COMORBID TIC DISORDER
- M-67 INDICATION EXPANDED TO INCLUDE PATIENTS ON PERITONEAL DIALYSIS
- M-68 DESCRIPTION OF RESULTS OF STUDY OF INITIAL THERAPY IN COMBINATION WITH METFORMIN WHEN DIET AND EXERCISE DO NOT PROVIDE GLYCEMIC CONTROL
- M-69 RESULTS OF STUDY OF COMBINATION THERAPY AND NON-INFERIORITY STUDY
- M-70 PROVISION OF INFORMATION OF THE RESULTS OF A PHASE 2 RANDOMIZED TRIAL OF SPRYCEL 70MG TWICE DAILY OR IMATINIB 800MG DAILY
- M-71 REVISIONS TO PROVIDE FOR RESULTS OF MAINTENANCE DATA IN ADULT PATIENTS WITH MAJOR DEPRESSIVE DISORDER
- M-72 INFORMATION ABOUT USE OF INSPRA (EPLERENONE) FOR HYPERTENSION IN PEDIATRIC PATIENTS
- M-73 NEW INFORMATION ADDED REGARDING THE TUMOR SHRINKING POTENTIAL OF SANDOSTATIN LAR DEPOT INJECTION ON GH - SECRETING PITUITARY ADENOMAS

PATENT AND EXCLUSIVITY TERMS

EXCLUSIVITY MISCELLANEOUS

- M-74 REVISIONS TO CLINICAL STUDIES - CHILDREN AND ADOLESCENTS BASED ON CLINICAL TRIAL DATA TO SUPPORT A DURATION OF ACTION CLAIM UP TO 12 HOURS
- M-75 PROVISION FOR USE OF ARGATROBAN IN CERTAIN PEDIATRIC PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OR HEPARIN-INDUCED THROMBOCYTOPENIA WITH THROMBOSIS (HITTS)
- M-76 REMOVAL OF SCREEN REQUIREMENT IN PTS WITH G6PD DEFICIENCY PRIOR TO INITIATING ACZONE TREATMENT; REMOVAL OF BLOOD COUNT & RETICULOCYTE MONITORING DURING TREATMENT IN G6PD DEFICIENT PTS AND IN PATIENTS WITH HISTORY OF ANEMIA
- M-77 USE IN COMBINATION WITH THE NEW AKTILITE CL128 LAMP FOR THE TREATMENT OF THIN AND MODERATELY THICK, NON-HYPERKERATOTIC, NON-PIGMENTED ACTINIC KERATOSES OF THE FACE AND SCALP IN IMMUNOCOMPETENT PATIENTS
- M-78 CLINICAL TRIAL INFO ON USE OF STRATTERA IN PATIENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) AND COMORBID ANXIETY DISORDER WITHOUT CAUSING WORSENING OF ANXIETY
- M-79 LABELING REVISIONS RELATED TO SMOKING AND ERLOTINIB EXPOSURE
- M-80 ADDITIONAL TIME POINT OF 30 MINUTES (0.5 HOUR) IN CHILDREN AGED 6-12 YEARS WITH A DIAGNOSIS OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD)
- M-81 ADDITIONAL INFO FOR PEDIATRIC USE FOR CASODEX (STUDIED IN COMBINATION WITH ARIMIDEX) IN THE PEDIATRIC POPULATION, SPECIFICALLY BOYS WITH FAMILIAL MALE-LIMITED PRECOCIOUS PUBERTY (TESTOXICOSIS)
- M-82 LABELING REVISIONS RELATED TO CLINICAL STUDIES
- M-83 ADDITIONAL INFORMATION ADDED TO LABELING REGARDING ESTABLISHMENT OF EFFICACY IN ADDITIONAL CLINICAL TRIALS AND ONE MAINTENANCE TRIAL
- M-84 STUDY INFORMATION ADDED TO LABEL REGARDING BONE MINERAL DENSITY
- M-85 INFORMATION ADDED TO LABELING REGARDING USE OF PREVACID IN PATIENTS LESS THAN 1 YEAR WITH SYMPTOMATIC GERD
- M-86 LABELING CHANGES SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST FOR INFANTS AGES BIRTH TO 11 MONTH INCLUSIVE REFLECTING LACK OF EFFICACY FOR GERD INDICATION FOR THIS PATIENT POPULATION
- M-87 INCLUSION OF RESULTS FROM TWO DRUG INTERACTION STUDIES WITH LIPITOR AND CRESTOR IN CLINICAL PHARMACOLOGY SECTION
- M-88 ADDITION OF INFORMATION REGARDING ABUSE POTENTIAL OF CONCERTA VERSUS IMMEDIATE-RELEASE METHYLPHENIDATE
- M-89 PROVIDES FOR REVISIONS TO MULTIPLE SECTIONS OF THE PACKAGE INSERT TO REFLECT RESULTS OF CLINICAL TRIALS 205.235 (UPLIFT) AND 205.266 (VA STUDY) IN SUPPORT OF EXACERBATION CLAIM
- M-90 LABELING CHANGES BASED ON DATA FROM CLINICAL STUDIES NV20235 AND NV20236 STUDIES OF SEASONAL PROPHYLAXIS OF INFLUENZA IN IMMUNOCOMPROMISED PATIENTS AND CHILDREN AGES 1-12
- M-91 UPDATED LABELING BASED UPON STUDY: A SINGLE-DOSE, SINGLE-BLIND, PLACEBO-AND MOXIFLOXACIN-CONTROLLED 2-PERIOD, RANDOMIZED, CROSSOVER, 3RD PERIOD SEQUENTIAL STUDY OF SIDE EFFECTS OF TEMSIROLIMUS ON CARDIAC REPOLARIZATION IN HEALTHY SUBJECTS
- M-92 UPDATES TO THE PACKAGE INSERT BASED UPON THE TRIAL ENTITLED "A PHASE I PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF TEMSIROLIMUS IN PATIENTS WITH ADVANCED MALIGNANCIES AND NORMAL AND IMPAIRED LIVER FUNCTION"
- M-93 EXPANSION OF LABELING TO INCLUDE INFORMATION ON SAFETY AND EFFICACY OF CREON IN PATIENTS AGES 7 YEARS THROUGH 11 YEARS WITH PANCREATIC EXOCRINE INSUFFICIENCY DUE TO CYSTIC FIBROSIS
- M-94 INFO ADDED TO LABEL RELATED TO NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA IC CHRONIC PHASE
- M-95 INFORMATION FOR TREATMENT OF CHRONIC HEPATITIS B (CHB) IN ADULT PATIENTS WITH DECOMPENSATED LIVER DISEASE BASED ON DATA FROM CLINICAL TRIAL GS-US-174-0108
- M-96 UPDATED INFORMATION IN THE CLINICAL STUDIES SECTION RELATED TO THE LOSS AND RECOVERY OF BONE MINERAL DENSITY IN ADOLESCENT GIRLS DURING AND FOLLOWING THE USE OF DEPO-PROVERA CONTRACEPTIVE INJECTION
- M-97 LABELING CHANGES IN RESPONSE TO PEDIATRIC STUDIES - NOT INDICATED FOR USE IN PEDIATRIC POPULATION
- M-98 NEW INFORMATION FROM A STUDY WHICH EVALUATED THE SAFETY AND EFFICACY OF FAMVIR IN TREATING RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT BLACK/AFRICAN AMERICAN SUBJECTS.
- M-99 ADDITION OF FINDINGS FROM A SINGLE PEDIATRIC CLINICAL TRIAL (P04292) OF NASONEX NASAL SPRAY IN THE TREATMENT OF NASAL POLYPS IN PATENTS 6 TO <18 YEARS OF AGE TO THE PACKAGE INSERT.
- M-100 INFORMATION ADDED TO LABEL BASED UPON COMPLETED CLINICAL TRIAL REPORTS
- M-101 INCLUSION OF DATA FROM AN ADDITIONAL 19 SUBJECTS WITH HYPERCALCEMIA FROM PARATHYROID CARCINOMA TO THE INFORMATION CURRENTLY PRESENTED IN THE LABEL
- M-102 INFORMATION FROM PEDIATRIC STUDY REPORT ML16633, "INTRAVENOUS GRANISETRON (KYTRIL) IN THE PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING (PONV) IN PEDIATRIC

PATENT AND EXCLUSIVITY TERMS

ADB 28 of 78

EXCLUSIVITY MISCELLANEOUS

- SUBJECTS UNDERGOING TONSILLECTOMY OR ADENOTONSILLECTOMY."
- M-103 SAFETY, EFFICACY AND PHARMACOKINETIC INFO FOR FASLODEX IN THE PEDIATRIC POPULATION, SPECIFICALLY FOR GIRLS WITH PROGRESSIVE PRECOCIOUS PUBERTY ASSOCIATED WITH MCCUNE-ALBRIGHT SYNDROME ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING INFORMATION ADDED TO DOSING AND ADMINISTRATION REGARDING A 26 WEEK STUDY
- M-104 NEW LANGUAGE ADDED TO CLINICAL STUDIES REGARDING USE IN SMOKERS WITH
- M-105 CARDIOVASCULAR DISEASE, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND USE ACCORDING TO AN ALTERNATIVE SET OF DIRECTIONS FOR SETTING A QUIT DATE
- M-106 ADDITION OF THE T1-WEIGHTED GD-ENHANCED LESION EFFICACY VARIABLE IN THE CLINICAL STUDIES SECTION 14 OF THE PACKAGE INSERT
- M-107 INFORMATION TO THE CLINICAL STUDIES SECTION OF THE LUPRON DEPOT-PED 1-MONTH BASED UPON THE PHASE 3/4 COMPLETED CLINICAL STUDY REPORT FOR STUDY M90-516 ENTITLED "STUDY OF LUPRON DEPOT IN THE TREATMENT OF CENTRAL PRECOCIOUS PUBERTY".
- M-108 CHANGES ARE BASED ON RESULTS FROM STUDY CV181057
- M-109 CHANGES TO THE PACKAGE INSERT TO REFLECT THE RESULTS OF THE STUDY OF HEART AND RENAL PROTECTION (SHARP) TRIAL
- M-110 CHANGES TO THE PACKAGE INSERT TO REFLECT THE RESULTS OF THE STUDY OF HEART AND RENAL PROTECTION (SHARP) TRIAL
- M-111 LABELING CHANGES BASED ON STUDY HW80-EW-GWCI ENTITLED A PLACEBO AND POSITIVE CONTROLLED STUDY OF THE ELECTROPHYSIOLOGICAL EFFECTS OF A SINGLE 10 MCG DOSE OF EXENATIDE ON THE 12 LEAD ELECTROCARDIOGRAM QT INTERVAL IN HEALTHY SUBJECTS
- M-112 REVISIONS TO THE PEDIATRIC USE SECTION OF THE PACKAGE INSERT TO ADD INFORMATION FROM A PEDIATRIC STUDY IN PATIENTS AGED 12 YEARS TO LESS THAN 18 YEARS OF AGE WITH RECURRENT HERPES LABIALIS
- M-113 LABELING CHANGES BASED ON STUDY H80-US-GWCO ENTITLED A RANDOMIZED TRIAL COMPARING EXENATIDE WITH PLACEBO IN SUBJECTS WITH TYPE 2 DIABETES ON INSULIN GLARGINE WITH OR WITHOUT ORAL ANTIHYPERGLYCEMIC MEDICATIONS
- M-114 CHANGES IN SECTION 14 OF THE PACKAGE INSERT TO INCLUDE DATA FROM THE SWITCHMRK STUDIES (SWITCH OF SUPPRESSED SUBJECTS FROM LOPINAVIR/RITONAVIR TO RALTEGRAVIR)
- M-115 REVISIONS TO THE PI BASED ON RESULTS FROM STUDY NN2211-1842, ENTITLED THE EFFECT OF INSULIN DETEMIR IN COMBINATION WITH LIRAGLUTIDE AND METFORMIN COMPARED TO LIRAGLUTIDE AND METFORMIN IN SUBJECTS WITH TYPE 2 DIABETES
- M-116 LABELING CHANGES BASED ON RESULTS FROM CLINICAL STUDY 01-06-TL-OPIMET-008
- M-117 ADDITION OF RESULTS OF PEDIATRIC TRIAL TO LABEL
- M-118 LABELING CHANGES BASED UPON SAFETY AND EFFICACY RESULTS FROM TRIAL 1218.36
- M-119 LABELING CHANGES REGARDING MISSED DOSES
- M-120 CHANGES TO CLINICAL TRIALS DETAILING STUDY RESULTS
- M-121 LABELING CHANGES BASED UPON SAFETY AND EFFICACY RESULTS FROM TRIAL 1218.43
- M-122 LABELING CHANGES TO INCLUDE THE RESULTS OF THE PARAMOUNT TRIAL
- M-123 UPDATED RESULTS OF OVERALL SURVIVAL FROM 'CONFIRM' STUDY
- M-124 LONG TERM SAFETY AND EFFICACY DATA FROM STUDY CLDT600A2303 FOR SUBJECTS PREVIOUSLY ENROLLED IN THE ORIGINAL TWO YEAR GLOBE (NV-02B-007/CLDT600A2302) AND NV02B-015 STUDIES WHO CONTINUED TELBIVUDINE TREATMENT FOR UP TO 208 WEEKS
- M-125 LABELING CHANGES TO INCLUDE LACK OF EFFICACY IN CHILDREN 6 MONTHS TO 4 YEARS OF AGE
- M-126 UPDATES TO THE CLINICAL STUDIES SECTION 14, OF THE PACKAGE INSERT (PI), WITH THE RESULTS OF CLINICAL TRIAL P06086
- M-127 REVISIONS TO THE PEDIATRIC USE SECTION OF THE PACKAGE INSERT TO REFLECT THE RESULTS FROM CLINICAL STUDY C-10-004
- M-128 CLINICAL TRIAL STUDY RESULTS
- M-129 RESULTS OF A CLINICAL STUDY REPORT WHICH ASSESSES THE SAFETY AND EFFICACY IN CHILDREN AGES 6 TO 12 YEARS OF AGE
- M-130 ADDITION OF INFORMATION ON LONG-TERM TREATMENT WITH VPRIV IN THE CLINICAL TRIALS SECTION OF THE PACKAGE INSERT
- M-131 INFORMATION FROM STUDIES CONDUCTED IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED NON-DISSEMINATED DIFFUSED INTRINSIC BRAINSTEM GLIOMAS
- M-132 REVISIONS TO THE CLINICAL TRIALS SECTION IN THE INOMAX LABEL TO REFLECT RESULTS FROM THE PEDIATRIC STUDY REPORTS
- M-133 INFORMATION ADDED TO THE LABELING REGARDING THE ADDITION OF SILDENAFIL TO BOSENTAN THERAPY
- M-134 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED WITH SAXAGLIPTIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA ADDED TO THE LABELING
- M-135 ADDITION OF INFORMATION TO THE CLINICAL STUDIES - RADIOGRAPHIC RESPONSE SECTION OF THE PACKAGE INSERT
- M-136 ADDITIONAL INFORMATION ADDED TO THE USE IN SPECIFIC POPULATIONS SECTION OF THE LABELING REGARDING POST-OPERATIVE NAUSEA AND VOMITING STUDIES IN PEDIATRIC PATIENTS

PATENT AND EXCLUSIVITY TERMS

EXCLUSIVITY MISCELLANEOUS

- M-137 LABELING REVISIONS RESULTING FROM A MAINTENANCE TRIAL IN PEDIATRIC PATIENTS WITH IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
- M-138 INFORMATION ADDED TO THE 8.4 PEDIATRIC USE SECTION ON THE USE OF MEMANTINE IN CHILDREN AGES 6-12 YEARS WITH AUTISM SPECTRUM DISORDER
- M-139 INFORMATION ADDED TO THE DOSING AND ADMINISTRATION SECTION OF THE PACKAGE INSERT REGARDING RETREATMENT WITH VELCADE FOR PATIENTS WITH MULTIPLE MYELOMA
- M-140 INFORMATION ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING REGARDING USE OF LATISSE IN PATIENTS WHO WERE POST-CHEMOTHERAPY OR HAD ALOPECIA AREATA, AND ADOLESCENTS WHO HAD HYPERTRICHOSIS WITH NO ASSOCIATED MEDICAL CONDITION
- M-141 REVISIONS TO THE PEDIATRIC USE SECTION OF THE LABELING TO INCORPORATE STUDY RESULTS FOR TREATMENT OF MAJOR DEPRESSIVE DISORDER IN ADOLESCENTS (AGES 12-17)
- M-142 ADDITIONS TO THE LABELING DESCRIBING RESULTS FROM STUDY H6P-MC-HDAY
- M-143 INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN PATIENTS WITH CURRENT OR PAST HISTORY OF MAJOR DEPRESSIVE DISORDER
- M-144 INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN PATIENTS WHO HAD BEEN PREVIOUSLY TREATED WITH VARENICLINE
- M-145 ADDITION OF INFORMATION ABOUT LONG-TERM TREATMENT OF PULMONARY ARTERIAL HYPERTENSION TO THE CLINICAL STUDIES SECTION OF THE LABELING
- M-146 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION ON INITIAL COMBINATION THERAPY WITH LINAGLIPTIN AND METFORMIN VS. LINAGLIPTIN MONOTHERAPY IN TREATMENT NAIVE PATIENTS
- M-147 OTC USE FOR TEMPORARY RELIEF OF OCULAR SYMPTOMS DUE TO HAY FEVER OR OTHER UPPER RESPIRATORY ALLERGIES
- M-148 LABELING CHANGES BASED ON STUDY H80-EW-GWDM
- M-149 INFORMATION ADDED TO THE LABELING REGARDING MAINTENANCE MONOTHERAPY FOR ADHD
- M-150 ADDITION OF THE RESULTS OF A CONTROLLED CLINICAL STUDY TREATING ADULT PATIENTS WITH SCHIZOPHRENIA EXPERIENCING AN ACUTE RELAPSE
- M-151 REVISIONS TO THE LABELING BASED ON THE OUTCOMES OF PEDIATRIC STUDIES CONDUCTED TO ASSESS THE SAFETY AND EFFICACY OF XOPENEX IN SUBJECTS LESS THAN 6 YEARS OF AGE
- M-152 INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY SECTION OF THE LABELING REGARDING A SAFETY STUDY IN PEDIATRIC SUBJECTS AGES 6 MONTHS TO 4 YEARS OF AGE WITH AN ACTIVE HEAD LICE INFESTATION
- M-153 ADDITION OF INFORMATION REGARDING THE INTRANASAL ABUSE POTENTIAL OF OXYCONTIN
- M-154 UPDATE TO THE LABELING TO REFLECT THE RESULTS OF A LONG-TERM MAINTENANCE TREATMENT STUDY OF ADHD IN CHILDREN AND ADOLESCENTS AGES 6-17.
- M-155 ADDITION OF CLINICAL FINDINGS FROM AN OBSERVATIONAL STUDY IN A PEDIATRIC AGE GROUP GREATER THAN 2 MONTHS TO 18 YEARS IN SECTION 8.4 PEDIATRIC USE OF THE PACKAGE INSERT
- M-156 UPDATE TO THE LABELING WITH INFORMATION REGARDING A CLINICAL TRIAL IN CHILDREN LESS THAN 4 YEARS OF AGE.
- M-157 INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF DAPAGLITFLOZIN 10MG ONCE DAILY IN PATIENTS WITH TYPE 2 DIABETES WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A BACKGROUND COMBINATION OF METFORMIN AND SULFONYLUREA
- M-158 UPDATES TO THE LABELING TO REFLECT SAFETY RESULTS FROM CLINICAL TRIALS IN SCHIZOPHRENIA ADOLESCENT PATIENTS AGED 12 TO 17 YEARS
- M-159 ADDITION OF PED SAFETY INFORMATION DERIVED FROM A MAINTENANCE TREATMENT STUDY OF BIPOLAR 1 DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES IN PATIENTS (> THAN OR = TO 13 YRS OF AGE) TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY
- M-160 UPDATED LABELING WITH DATA FROM A RANDOMIZED, DOUBLE-BLIND ACTIVE-CONTROLLED STUDY COMPARING EMPAGLIFLOZIN TO GLIMEPIRIDE IN PATIENTS WITH TYPE 2 DIABETES AND INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN TREATMENT
- M-161 UPDATED LABELING WITH DATA FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND INSUFFICIENT GLYCEMIC CONTROL ON A MULTIPLE DAILY INJECTION INSULIN REGIMEN ALONE OR WITH METFORMIN
- M-162 INCLUSION OF EFFICACY AND SAFETY DATA TO THE PRESCRIBING INFORMATION OF BYDUREON BASED ON STUDY GWDE
- M-163 INFORMATION ADDED TO THE LABELING REGARDING PREVIOUSLY UNTREATED ALK-POSITIVE METASTATIC NON SMALL CELL LUNG CANCER (NSCLC)
- M-164 REVISES THE CLINICAL TRIALS SECTION OF THE PRESCRIBING INFORMATION TO INCORPORATE THE RESULTS FROM STUDY E7273-G000-401 ENTITLED "PHASE IV RANDOMIZED STUDY OF TWO DOSE LEVELS OF TARGRETIN CAPSULES IN SUBJECTS WITH REFRACTORY CUTANEOUS T-CELL LYMPHOMA"
- M-165 PROVIDES FOR UPDATES TO THE PEDIATRIC USE SECTION BASED ON THE PEDIATRIC STUDY REPORT ENTITLED, "A PHASE II PILOT TRIAL OF BORTEZOMIB IN COMBINATION WITH INTENSIVE RE-INDUCTION THERAPY IN CHILDREN WITH RELAPSED ACUTE LYMPHOBLASTIC

PATENT AND EXCLUSIVITY TERMS

ADB 30 of 78

EXCLUSIVITY MISCELLANEOUS

- LYMPHOMA (LL) "
- M-166 UPDATE TO LABELING WITH WEEK 48 RESULTS FROM VIKING-4 IN ANTIRETROVIRAL THERAPY (ART) - EXPERIENCED INTEGRASE STRAND TRANSFER INHIBITOR (INSTI) - RESISTANT SUBJECTS
- M-167 APPROVED FOR REVISIONS TO THE LABELING BASED ON THE CLINICAL STUDY ENTITLED "BRONCHOPULMONARY DYSPLASIA (BPD) IN PRETERM INFANTS REQUIRING MECHANICAL VENTILATION OR POSITIVE PRESSURE SUPPORT ON DAYS 5 TO 14 AFTER BIRTH".
- M-168 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING REGARDING THE RE-NOVATE AND RE-NOVATE LL STUDIES (PROPHYLAXIS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM FOLLOWING HIP REPLACEMENT SURGERY)
- M-169 UPDATES TO LABELING DESCRIBING RESPONSE TO A REPEAT COURSE OF PICATO GEL 0.015% ON THE FACE OR SCALP IF AN INCOMPLETE RESPONSE IS OBSERVED AT A FOLLOW-UP EXAMINATION.
- M-170 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION REGARDING USE FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
- M-171 UPDATES TO LABELING WITH RESULTS TO THE TIGER CLINICAL TRIAL
- M-172 UPDATES TO THE CLINICAL TRIALS SECTION OF THE LABELING TO INCLUDE RESULTS OF STUDIES PERFORMED TO EVALUATE THE BENEFIT OF ADDING INCRUSE ELLIPTA TO PATIENTS WHO ARE ON BACKGROUND THERAPY WITH BREO ELLIPTA AND ADVAIR DISKUS
- M-173 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING DESCRIBING THE EFFECTS OF STIOLTO RESPIMAT ON COPD PATIENTS
- M-174 INFORMATION ADDED TO CLINICAL STUDIES SECTION OF THE LABELING REGARDING INITIAL COMBINATION THERAPY OF EMPAGLIFLOZIN WITH METFORMIN
- M-175 INFORMATION ADDED TO THE LABELING DESCRIBING SAVOR, A PHASE IV TRIAL EVALUATING THE EFFECT OF SAXAGLIPTIN ON THE INCIDENCE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION OR ISCHAEMIC STROKE IN PATIENTS WITH TYPE 2 DIABETES
- M-176 INFORMATION ADDED TO THE LABELING DESCRIBING TRIAL NN2211-3916, A TRIAL EVALUATING THE SAFETY AND EFFICACY OF LIRAGLUTIDE IN SUBJECTS WITH TYPE 2 DIABETES AND MODERATE RENAL IMPAIRMENT
- M-177 INFORMATION ADDED TO THE LABELING DESCRIBING EXAMINE, A TRIAL EVALUATING CARDIOVASCULAR ISCHEMIC RISKS ASSOCIATED WITH ALOGLIPTIN USE IN PATIENTS WITH TYPE 2 DIABETES AT HIGH RISK OF ISCHEMIC CARDIOVASCULAR DISEASE
- M-178 INFORMATION ADDED TO THE LABELING REGARDING MAINTENANCE OF REMISSION IN CROHN'S DISEASE IN PEDIATRIC PATIENTS
- M-179 UPDATES TO THE PRODUCT LABELING WITH STUDY REPORTS FROM THE OPTIMIST-1 AND OPTIMIST-2 CLINICAL TRIALS
- M-180 INFORMATION ADDED TO THE LABELING REGARDING THE ADDITION OF MAINTENANCE TREATMENT IN PATIENTS WITH SCHIZOPHRENIA
- M-181 UPDATE TO THE DOSAGE AND ADMINISTRATION, PATIENT SELECTION (2.1), SECTION OF THE PACKAGE INSERT TO INCLUDE THE USE OF AN FDA-APPROVED PLASMA TEST FOR THE IDENTIFICATION OF EGFR EXON 19 DELETION OR EXON 21 (L858R) SUBSTITUTION MUTATIONS
- M-182 UPDATES TO THE PRODUCT LABELING BASED ON THE RESULTS OF STUDY H7T-MC-TADO TITLED, "A PHASE 3 DOUBLE-BLIND, RANDOMIZED, MULTICENTER, EFFICACY AND SAFETY STUDY OF PRASUGREL COMPARED TO PLACEBO IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE"
- M-183 CHANGES TO THE DOSAGE AND ADMINISTRATION AND CLINICAL STUDIES SECTIONS OF THE LABELING TO SUPPORT THE REDUCE-TO-QUIT PARADIGM
- M-184 UPDATES MADE TO THE LABELING TO INCLUDE INFORMATION FROM STUDY MO25743 ON THE ANTI-TUMOR ACTIVITY OF VEMURAFENIB IN THE TREATMENT OF PATIENTS WITH BRAF V600E MUTATION-POSITIVE MELANOMA WITH BRAIN METASTASES
- M-185 UPDATES TO THE LABELING TO INCLUDE RESULTS OF A TRIAL TO EVALUATE THE SAFETY OF MOXIFLOXACIN IN PEDIATRIC PATIENTS WITH COMPLICATED INTRA-ABDOMINAL INFECTIONS
- M-186 UPDATES TO THE PRODUCT INFORMATION REGARDING MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN ADULTS BASED UPON THE RESULTS FROM STUDY 331-10-232
- M-187 ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING
- M-188 PROVIDES FOR DATA SUPPORTING THE SAFETY AND EFFECTIVENESS FOR THE MAINTENANCE TREATMENT OF MODERATE TO SEVERE BINGE EATING DISORDER (BED)
- M-189 LABELING DESCRIBING THE EXPECTED REDUCTION OF ABUSE OF SINGLE-ENTITY EXTENDED-RELEASE MORPHINE BY THE INTRANASAL ROUTE OF ADMINISTRATION DUE TO PHYSICOCHEMICAL PROPERTIES
- M-190 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING REGARDING THE LACK OF EFFICACY OF TARCEVA IN MAINTENANCE TREATMENT OF PATIENTS WITHOUT EGFR MUTATIONS
- M-191 ADDITION OF DATA BASED ON PEDIATRIC STUDIES TO FULFILL THE POSTMARKETING REQUIREMENT 1857-2
- M-192 PROVIDES FOR DATA EVALUATING THE NEUROPSYCHIATRIC SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN SUBJECTS WITH AND WITHOUT A HISTORY OF

PATENT AND EXCLUSIVITY TERMS**EXCLUSIVITY MISCELLANEOUS**

PSYCHIATRIC DISORDERS

M-193 INFORMATION ADDED TO THE LABELING REGARDING A 15-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED FLEXIBLE-DOSE SAFETY AND EFFICACY STUDY OF PREGABALIN IN ADOLESCENTS (12 THROUGH 17 YEARS OLD) WITH FIBROMYALGIA

PATENT USE

U-1 PREVENTION OF PREGNANCY
 U-2 TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA
 U-3 TREATMENT OF HYPERTENSION
 U-4 PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS
 U-5 METHOD OF PRODUCING BRONCHODILATION
 U-6 METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS
 U-7 INCREASING CARDIAC CONTRACTILITY
 U-8 ACUTE MYOCARDIAL INFARCTION
 U-9 CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT
 U-10 DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALAMIC MALFUNCTIONS OR LESIONS IN HUMANS
 U-11 TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS
 U-12 METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION
 U-13 A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT
 U-14 ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES
 U-15 METHOD OF LOWERING INTRAOCULAR PRESSURE
 U-16 USE IN LUNG SCANNING PROCEDURES
 U-17 TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS
 U-18 METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS
 U-19 TREATMENT OF INFLAMMATION
 U-20 A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT
 U-21 TREATMENT OF HUMANS SUFFERING UNDESIRE UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS
 U-22 METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS
 U-23 METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE
 U-24 METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST
 U-25 REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS
 U-26 REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF
 U-27 DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF
 U-28 CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY
 U-29 CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY
 U-30 CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY
 U-31 INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY
 U-32 PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN
 U-33 TREATING VIRAL INFECTIONS IN A MAMMAL
 U-34 TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL
 U-35 TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION
 U-36 METHODS OF TREATING BACTERIAL ILLNESSES
 U-37 METHOD OF TREATING GASTROINTESTINAL DISEASE
 U-38 TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA
 U-39 ANGINA PECTORIS
 U-40 METHOD OF TREATMENT OF BURNS
 U-41 METHOD OF TREATING CARDIAC ARRHYTHMIAS
 U-42 ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER
 U-43 MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA
 U-44 RELIEF OF NAUSEA AND VOMITING
 U-45 TREATMENT OF INFLAMMATION AND ANALGESIA
 U-46 TREATMENT OF PANIC DISORDER
 U-47 STIMULATION OF THE RELEASE OF GROWTH HORMONE

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-48	ANALGESIA
U-49	SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA
U-50	USE IN TREATING INFLAMMATORY DERMATOSES
U-51	BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING
U-52	TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION
U-53	HYPERCALCEMIA OF MALIGNANCY
U-54	REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS
U-55	TREATMENT OF PAIN
U-56	AID TO SMOKING CESSATION
U-57	OPHTHALMIC USE OF NORFLOXACIN
U-58	METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES
U-59	METHOD OF TREATING HYPERCHOLESTEROLEMIA
U-60	NASAL ADMINISTRATION OF BUTORPHANOL
U-61	CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD
U-62	CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY
U-63	ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE
U-64	TREATMENT OF VIRAL INFECTIONS
U-65	METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV
U-66	TRIPHASIC REGIMEN
U-67	METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL
U-68	TREATMENT OF ACTINIC KERATOSIS
U-69	TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS
U-70	TREATMENT OF TRANSIENT INSOMNIA
U-71	METHOD OF TREATMENT OF HEART FAILURE
U-72	TREATMENT OF MIGRAINE
U-73	METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES
U-74	METHOD OF PROVIDING HYPNOTIC EFFECT
U-75	RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS
U-76	USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM
U-77	TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS
U-78	ULCERATIVE COLITIS
U-79	SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURN DUE TO GERD
U-80	METHOD OF TREATING OCULAR BACTERIAL INFECTIONS
U-81	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS
U-82	TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE
U-83	TREATMENT OF SEIZURES
U-84	A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS
U-85	NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
U-86	METHOD OF TREATING CERTAIN FORMS OF EPILEPSY
U-87	METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS
U-88	TREATMENT OF MODERATE PLAQUE PSORIASIS
U-89	TREATMENT OR PROPHYLAXIS OF EMESIS
U-90	TREATMENT OF PSYCHOTIC DISORDERS
U-91	ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS
U-92	TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATY
U-93	USE AS AN ANTIHISTAMINE/DECONGESTANT
U-94	TREATMENT-ADULTS W/ ADVANCED HIV, INTOLERANT OF APPROVED THERAPIES, INTOLERANT OF APPROVED THERAPIES W/PROVEN BENEFIT OR HAVE EXPERIENCED CLINICAL/IMMUNOLOGICAL DETERIORATION WHILE RECEIVING..OR FOR WHOM SUCH THERAPIES-CONTRAINDICATED
U-95	SHORT TERM MANAGEMENT OF MODERATE PRURITIS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS
U-96	METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS
U-97	A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT
U-98	A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL
U-99	METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM
U-100	METHOD OF TREATING OCULAR INFLAMMATION
U-101	ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED
U-102	METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-103 TREATMENT OF OCULAR HYPERTENSION
U-104 TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE
U-105 EMESIS
U-106 TREATMENT OF EPILEPSY
U-107 TREATMENT OF HYPERTENSION AND ANGINA PECTORIS
U-108 SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD AND PATHOLOGICAL HYPERSECRETORY CONDITIONS AND MAINTENANCE HEALING OF EROSIVE ESOPHAGITIS
U-109 ADJUNCT DIET IN THE TX OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PTS W/PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SAT FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE USE AS A RETRIEVABLE PESSARY
U-110
U-111 DIABETES
U-112 CONTRACEPTION
U-113 METHOD OF CONDUCTING RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE
U-114 USE FOR INHIBITING BONE RESORPTION
U-115 USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS
U-116 METHOD OF MYOCARDIAL IMAGING
U-117 TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES
U-118 METHOD OF LOWERING BLOOD SUGAR LEVEL
U-119 TREATMENT OF NASAL HYPERSECRETION
U-120 CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES
U-121 METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS
U-122 A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS
U-123 METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS
U-124 TREATMENT OF ACNE
U-125 TREATMENT NEUROGENERATIVE DISEASES
U-126 TREATMENT OF GASTRITIS
U-127 METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE
U-128 METHOD FOR TREATMENT OF TUMORS
U-129 METHOD TO DESTROY OR IMPAIR TARGET CELLS
U-130 MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS
U-131 PHOTODAMAGED SKIN
U-132 INHIBITING HIV PROTEASE
U-133 MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET
U-134 TREATMENT OF ACNE VULGARIS
U-135 ANTITUMOR AGENT
U-136 PROCESS FOR WASTE NITROGEN REMOVAL
U-137 METHOD OF TREATING BACTERIAL VAGINOSIS
U-138 TREATMENT OF ALLERGIC RHINITIS
U-139 TREATMENT OF ALLERGIC REACTIONS
U-140 USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION
U-141 TREATMENT OF ULCERATIVE COLITIS
U-142 METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE
U-143 BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING
U-144 BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS
U-145 BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS
U-146 METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS
U-147 DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF ¹³CO₂
U-148 DEVICE FOR COLLECTING A BREATH SAMPLE
U-149 METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES
U-150 METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE
U-151 RELIEF OF SYMPTOMS OF THE COMMON COLD
U-152 METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

DISORDER

U-153 TREATMENT OF INITIAL EPISODE GENITAL HERPES

U-154 METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER

U-155 TREATMENT OF ERECTILE DYSFUNCTION

U-156 METHOD OF PROVIDING ANESTHESIA

U-157 TREATMENT OF A HUMAN SUFFERING FROM VITAMIN B12 DEFICIENCY

U-158 ANGINA

U-159 TREATMENT OF INTERSTITIAL CYSTITIS

U-160 TREATMENT OF BACTERIAL INFECTIOUS DISEASE

U-161 METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT

U-162 METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA

U-163 METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS

U-164 METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS

U-165 TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA

U-166 TREATMENT OF H.PYLORI-ASSOCIATED DUODENAL ULCER

U-167 METHOD FOR TREATING HIV-1 INFECTION

U-168 METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA

U-169 METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING

U-170 METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT

U-171 METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT

U-172 TREATMENT OF GENITAL WARTS

U-173 ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES

U-174 USE AS AN ANTIHISTAMINE AGENT

U-175 METHOD OF TREATING MALIGNANT TUMORS

U-176 METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES

U-177 FUNGICIDE

U-178 FACILITATED ADHERENCE OF AGENTS TO SKIN

U-179 ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT

U-180 TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER 6 MONTHS OF AGE) WITH ADVANCED HIV INFECTION

U-181 PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST

U-182 USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION

U-183 TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION

U-184 TREATING ALLERGIC EYE DISEASES IN HUMANS

U-185 METHOD OF TREATING HYPERTENSION

U-186 METHOD FOR TREATING GI DISORDERS CAUSED BY H. PYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT

U-187 THERAPEUTIC TREATMENT OF CALCIFIC TUMORS

U-188 TREATMENT OF H.PYLORI ASSOCIATED DUODENAL ULCER

U-189 ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE

U-190 USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR

U-191 METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN

U-192 USE IN TREATING ALLERGIC REACTIONS

U-193 PSORIASIS

U-194 TREATING ANGINA PECTORIS AND HIGH BLOOD PRESSURE

U-195 METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOPE OR NITROGEN LABELED CARBON

U-196 TREATMENT OF METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS

U-197 USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER

U-198 TREATMENT METASTATIC CARCINOMA OF OVARY AFTER 1ST LINE FAILURE OR SUBSEQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND 2ND LINE TREATMENT OF AIDS RELATED KAPOSI'S SARCOMA

U-199 METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER

PATENT AND EXCLUSIVITY TERMS

PATENT USE

- PYLORIDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT
- U-200 METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT
- U-201 METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT
- U-202 METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORIDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS
- U-203 TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
- U-204 USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA
- U-205 METHOD FOR TREATING HEARTBURN
- U-206 METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENEOUS LH, IN IN VITRO FERTILIZATION
- U-207 USE AS NASAL SPRAY
- U-208 VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION
- U-209 VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION
- U-210 METHOD OF TREATING CONGESTIVE HEART FAILURE
- U-211 USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION
- U-212 METHOD OF TREATMENT OF PARKINSON'S DISEASE
- U-213 METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA
- U-214 USE AS A BLOOD GLUCOSE-LOWERING AGENT
- U-215 TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS
- U-216 TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C BY ADMINISTERING AN AGONIST OF LH-RH AND FLUTAMIDE
- U-217 METHOD OF PRODUCING ANESTHESIA
- U-218 METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT
- U-219 TREATMENT OF PARKINSON'S DISEASE
- U-220 METHOD OF DIAGNOSIS
- U-221 SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION
- U-222 METHOD OF TREATING PAGET'S DISEASE USING ACTONEL
- U-223 TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS
- U-224 CONTROLLING INTRAOCULAR PRESSURE
- U-225 METHOD FOR DELIVERY
- U-226 METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE
- U-227 NASAL ADMINISTRATION
- U-228 ASTHMA
- U-229 CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE)
- U-230 PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS
- U-231 USE IN PARKINSON'S DISEASE
- U-232 METHOD OF TREATING MIGRAINE
- U-233 DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE
- U-234 METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS
- U-235 METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE
- U-236 TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3.0MG/DAY
- U-237 METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS
- U-238 IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IS ENHANCED....
- U-239 TREATING OR CONTROLLING OCULAR INFLAMMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO AFFECTED EYE A COMPOSITION COMPRISING AN NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID
- U-240 TREATMENT OF ACUTE MIGRAINE ATTACKS
- U-241 FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS

PATENT AND EXCLUSIVITY TERMS

PATENT USE

U-242 USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION
 U-243 TOPICAL ADMINISTRATION
 U-244 PLATELET AGGREGATION INHIBITORS
 U-245 TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS
 U-246 PHOSPHATE BINDING
 U-247 TREATMENT OF RHEUMATOID ARTHRITIS
 U-248 TREATMENT OF HIV
 U-249 METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING AEROSOLIZED PARTICLES OF MOMETASONE FUROATE
 U-250 TREATMENT OF HEPATITIS B INFECTION
 U-251 USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES
 U-252 METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER'S DISEASE
 U-253 ORAL TRANSMUCOSAL USE
 U-254 USE OF AGGRASTAT IN COMBINATION WITH HEPARIN
 U-255 IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY
 U-256 TREATMENT OF HIV INFECTION IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS
 U-257 TREATMENT OF HIV INFECTION
 U-258 TREATMENT OF NEURODEGENERATIVE DISEASES
 U-259 TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION DRUG SUBSTANCE
 U-260 REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION
 U-261 TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE
 U-262 TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE
 U-263 METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN
 U-264 METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN
 U-265 USE AS LAXATIVE
 U-266 RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS; MANAGEMENT OF ACUTE PAIN IN ADULTS; TREATMENT OF PRIMARY DYSMENORRHEA; ACUTE TREATMENT OF MIGRAINE ATTACKS IN ADULTS
 U-267 PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE
 U-268 ACROMEGALY
 U-269 EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS
 U-270 METHOD OF IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT
 U-271 METHOD OF TREATING TUMORS
 U-272 METHOD OF TREATING CARCINOMA
 U-273 CUTANEOUS T-CELL LYMPHOMA
 U-274 ZANAMIVIR FOR INHALATION
 U-275 METHOD OF USE OF THE DRUG SUBSTANCE
 U-276 METHOD OF USE OF LEVOBUPIVACAINE
 U-277 NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)
 U-278 METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT
 U-279 METHOD OF USE OF THE APPROVED PRODUCT
 U-280 TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE
 U-281 ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS
 U-282 METHOD OF TREATING BACTERIAL INFECTIONS
 U-283 METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE
 U-284 MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS
 U-285 DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA
 U-286 DEPRESSION
 U-287 TREATMENT OR PREVENTION OF OSTEOPOROSIS
 U-288 THERAPY OF INFLUENZA
 U-289 TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-290 INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS)
U-291 INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH CYCLOSPORIN
U-292 INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE
U-293 INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID
U-294 TREATMENT OF HYPERPIGMENTARY DISORDERS
U-295 TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
U-296 TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA NAUSEA AND FUNCTIONAL DISABILITY
U-297 PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS
U-298 METHOD OF COMBATING BACTERIA IN A PATIENT
U-299 TREATMENT OF ADENOMATOUS POLYPS
U-300 INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA
U-301 USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES
U-302 TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS
U-303 METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPOROSIS, PAGET'S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID INDUCED OSTEOPOROSIS
U-304 A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION
U-305 METHODS FOR USING THE DRUG PRODUCT
U-306 TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY
U-307 CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES, EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA
U-308 CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES, EMPLOYING OLANZAPINE AS PER THE INDICATIONS OF THIS NDA
U-309 TREATING SJOEGREN SYNDROME
U-310 TREATMENT OF XEROSTOMIA
U-311 HORMONE REPLACEMENT
U-312 PANIC DISORDER, OBSESSIVE-COMPULSIVE DISORDER, POSTTRAUMATIC STRESS DISORDER
U-313 TREATMENT OF CONGESTIVE HEART FAILURE
U-314 METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY
U-315 METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT
U-316 METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER
U-317 METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE
U-318 TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE
U-319 TREATMENT OF MICROBIAL INFECTIONS
U-320 INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA
U-321 REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS
U-322 TREATMENT OF ALZHEIMER'S DEMENTIA
U-323 USE AS A BILE ACID SEQUESTRANT
U-324 METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE
U-325 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING "BIPOLAR DISORDER NOS" EMPLOYING OLANZAPINE
U-326 METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER
U-327 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITONS EMPLOYING OLANZAPINE
U-328 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING "A PSYCHOTIC CONDITION" EMPLOYING AN OLANZAPINE POLYMORPH
U-329 USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
U-330 TREATMENT OF NAUSEA AND VOMITING
U-331 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

PATENT AND EXCLUSIVITY TERMS

PATENT USE

- U-332 TREATMENT OR PREVENTION OF BRONCHOSPASM
- U-333 METHOD OF TREATING OCULAR HYPERTENSION
- U-334 TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR
- U-335 USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS
- U-336 DIAGNOSTIC RADIOIMAGING
- U-337 USE OF CARDIOLITE/MIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI
- U-338 METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME
- U-339 PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN
- U-340 THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN
- U-341 METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER
- U-342 METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER
- U-343 REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION
- U-344 METHOD FOR INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH ANOTHER HIV PROTEASE INHIBITOR
- U-345 RITONAVIR AND ANOTHER HIV PROTEASE INHIBITOR FOR CONCOMITANT ADMINISTRATION FOR THE TREATMENT OF AN HIV INFECTION
- U-346 METHOD FOR INHIBITING CYTOCHROME P450 MONOOXYGENASE WITH RITONAVIR AND A METHOD FOR IMPROVING THE PHARMCOKINETICS OF A DRUG THAT IS METABOLIZED BY CYTOCHROME P450 MONOOXYGENASE BY ADMIN THE DRUG AND RITONAVIR
- U-347 METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS
- U-348 METHOD OF USE FOR INHIBITING HIV INFECTION
- U-349 METHOD OF USE WHICH IS SUBJECT OF THE APPLICATION
- U-350 PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR CONCOMITANT ADMIN WITH A REVERSE TRANSCRIPTASE INHIBITOR
- U-351 INHIBITING PROTEASE WITH LOPINAVIR AND INHIBITING AN HIV INFECTION WITH LOPINAVIR
- U-352 INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH A REVERSE TRANSCRIPTASE INHIBITOR
- U-353 PREVENTION AND TREATMENT OF OSTEOPOROSIS
- U-354 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-355 METHOD OF ASSISTING PERSON TO QUIT SMOKING...TRANSDERMALLY ADMIN NICOTINE VIA..PATCH ADHERED TO SKIN AT DOSING RATE APPROX SAME AS ABSORBED FROM SMOKING
- U-356 DELIVERING A MEDICINAL AEROSOL FORMULATION USING CFC-FREE PROPELLANT 134A.
- U-357 USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE
- U-358 DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER
- U-359 METHOD OF USE OF VISICOL
- U-360 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS INCLUDING MENTAL DISORDERS EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011
- U-361 MANAGEMENT OF ANXIETY DISORDERS AND THE SHORT-TERM RELIEF OF THE SYMPTOMS OF ANXIETY
- U-362 USE OF APPROVED FORMULATIONS TO TREAT ALL APPROVED DISEASE INDICATIONS
- U-363 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS THAT RELATE TO THE USE OF A PSYCHOACTIVE SUBSTANCE EMPLOYING OLANZAPINE AS PER THE INDICATION THE SUBJECT MATTER OF SUPPLEMENT 011
- U-364 TREATING A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ANY NUMBER OF LISTED CONDITIONS INCLUDING PSYCHOSIS, EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011
- U-365 METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION
- U-366 METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN A DELAYED RELEASE FORMULATION
- U-367 TREATMENT OF CARDIOVASCULAR DISORDERS
- U-368 HEARTBURN
- U-369 METHOD OF CONTROLLING AND LOWERING INTRAOCULAR PRESSURE
- U-370 INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS
- U-371 APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)
- U-372 METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH

PATENT AND EXCLUSIVITY TERMS

PATENT USE

- METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...
- U-373 GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING "PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OF GERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
- U-374 KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX
- U-375 METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C
- U-376 TREATMENT OF INFLUENZA
- U-377 METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS
- U-378 METHOD FOR TREATING INCONTINENCE
- U-379 METHOD OF TREATING ONYCHROMYCOSIS
- U-380 COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS
- U-381 TREATMENT OF HYPERPHOSPHATEMIA
- U-382 METHOD OF STABILIZING PROSTAGLANDIN
- U-383 METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION
- U-384 TREATMENT OF CMV RETINITIS
- U-385 TREATMENT OF PEPTIC ULCERS
- U-386 TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA
- U-387 TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS
- U-388 SMOKING CESSATION AID APPLIED TO THE SKIN
- U-389 SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS
- U-390 METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS)
- U-391 USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER
- U-392 TREATMENT OF PATIENTS FOR INFLAMMATION
- U-393 MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT
- U-394 METHOD OF USE OF ALPHAGAN
- U-395 METHOD OF USE OF ALPHAGAN P
- U-396 METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION
- U-397 METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA
- U-398 TREATMENT OF GENERALIZED ANXIETY DISORDER
- U-399 IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS
- U-400 USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESPONSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS
- U-401 USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS
- U-402 TREATMENT OF ACTINIC KERATOSES
- U-403 ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES
- U-404 TREATMENT OF ALLERGIC CONJUNCTIVITIS
- U-405 FOR WOMEN WITH SEVERE DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS)
- U-406 METHOD OF USE OF ATOVAQUONE AND PROGUANIL
- U-407 METHOD OF TREATING OTOPTHY
- U-408 FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION
- U-409 METHOD OF TREATING INFLAMMATION USING DRUG SUBSTANCE
- U-410 METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
- U-411 METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION
- U-412 TREATMENT OF TYPE 2 DIABETES
- U-413 USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND TREATMENT OF ATHEROSCLEROSIS
- U-414 A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN

PATENT AND EXCLUSIVITY TERMS

ADB 40 of 78

PATENT USE

- U-415 SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE
A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS
- U-416 A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS
- U-417 COMBINATION USE OF AD-4833 WITH A BIGUANIDE
- U-418 A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
- U-419 A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE
- U-420 METHOD OF TREATMENT OF TYPE II DIABETES
- U-421 USE FOR SEDATION
- U-422 METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER
- U-423 METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, OR AIDS RELATED DEMENTIA
- U-424 FOR ONCE DAILY, BOLUS ADMINISTRATION TO A PATIENT IN ORDER TO ENGENDER TREATMENT FOR A NERVOUS DISORDER FOR SUBSTANTIALLY AN ENTIRE DAY ON A CHRONIC BASIS
- U-425 METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
- U-426 PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION
- U-427 METHOD OF TREATING ALLERGIC REACTIONS IN MAMMALS
- U-428 METHOD OF TREATING ALLERGY IN A MAMMAL USING THIS ACTIVE METABOLITE
- U-429 METHOD OF USING DESLORATADINE TO TREAT ALLERGIC RHINITIS
- U-430 METHOD OF TREATING A DIABETIC BY ADMINISTERING AN INSULIN SENSITIZER IN COMBINATION WITH AN INSULIN SECRETION ENHANCER, AND A DRUG PRODUCT COMPRISING AN INSULIN SENSITIZER AND AN INSULIN SECRETION ENHANCER
- U-431 POSTTRAUMATIC STRESS DISORDER
- U-432 REDUCTION OF ATHEROSCLEROTIC EVENTS (MYOCARDIAL INFARCTION, STROKE, AND VASCULAR DEATH) IN PATIENTS WITH ATHEROSCLEROSIS DOCUMENTED BY RECENT STROKE, RECENT MYOCARDIAL INFARCTION OR ESTABLISHED PERIPHERAL ARTERIAL DISEASE
- U-433 USE OF LEVOCARNITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS
- U-434 CONTROLLED SYMPTOMS OF DIARRHEA, BLOATING PRESSURE AND CRAMPS, COMMONLY REFERRED TO AS GAS
- U-435 A TITRATION DOSING REGIMEN FOR THE TREATMENT OF PAIN USING AN INITIAL DOSE OF ABOUT 25MG
- U-436 ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
- U-437 METHOD OF USE EQUAL TO PROCESS OF PREPARATION
- U-438 TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASE
- U-439 TREATMENT OF OBESITY
- U-440 METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE
- U-441 METHOD OF TREATING MS BY ADMINISTERING COPAXONE
- U-442 METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG
- U-443 MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME
- U-444 TREATMENT OF MIGRAINE
- U-445 USE AS AN ANTIMYCOTIC AGENT
- U-446 TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA
- U-447 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-448 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-449 USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER WHERE THE DOSE OF LEUCOVORIN IS AT LEAST 200MG PER SQUARE METER
- U-450 INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES

PATENT AND EXCLUSIVITY TERMS

ADB 41 of 78

PATENT USE

- RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS, SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING
- U-451 TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
- U-452 USE OF LANSOPRAZOLE FOR COMBATTING DISEASES CAUSED BY THE GENUS CAMPYLOBACTER (C.PYLORI=H.PYLORI)
- U-453 TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS
- U-454 METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KG, ONCE WEEKLY, AND RIBAVIRIN
- U-455 TREATMENT OF PULMONARY HYPERTENSION WITH UT-15
- U-456 METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE
- U-457 METHOD OF TREATING A VAGINAL FUNGAL INFECTION IN A FEMALE HUMAN
- U-458 METHOD OF USE OF IMAGENT
- U-459 TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
- U-460 METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING SERTRALINE
- U-461 METHOD OF TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER (PMDD) USING SERTRALINE
- U-462 SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND ADULT RHEUMATOID ARTHRITIS AND TREATMENT OF PRIMARY DYSMENORRHEA
- U-463 VENOGRAPHY
- U-464 PERIPHERAL ARTERIOGRAPHY
- U-465 CT IMAGING OF THE HEAD
- U-466 TREATMENT OF IRRITABLE BOWEL SYNDROME
- U-467 USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR FOR TREATING HYPERTENSION
- U-468 METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS
- U-469 TREATMENT OF GASTROESOPHAGEAL REFLEX DISEASE (GERD) AND ERADICATION OF H.PYLORI TO REDUCE RISK OF DUODENAL ULCER RECURRENCE
- U-470 THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION
- U-471 METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS
- U-472 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING METHYLPHENIDATE BI-MODAL RELEASE PROFILE EXTENDED-RELEASE CAPSULES
- U-473 TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL
- U-474 TO REDUCE PLASMA CHOLESTEROL LEVELS BY ADMIN EZETIMIBE IN COMBO WITH CHOLESTEROL BIOSYNTHESIS INHIB SELECTED FROM GROUP CONSISTING OF HMG COA REDUCTASE INHIBITORS INCL SIMVASTATIN
- U-475 TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
- U-476 METHOD OF TREATING ANDROGEN RESPONSIVE/MEDIATED CONDITION IN MAMMAL BY ADMIN A SAFE, EFFECTIVE AMOUNT OF DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE THEREOF..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY
- U-477 METHOD OF INHIBITING 5 ALPHA TESTOSTERONE REDUCTASE ENZYME WITH DUTASTERIDE OR ITS DERIVATIVE AND TREATING ANDROGEN RESPONSIVE/MEDIATED DISEASE INCLUDING BENIGN PROSTATIC HYPERPLASIA
- U-478 METHOD OF TREATING HEPATITIS C VIRAL INFECTION BY CONTINUOUS PARENTERAL ADMIN INTERFERON ALPHA 2-10 MILLION IU WEEKLY, SUBCUTANEOUSLY, INJECTION OF POLYMER-INTERFERON ALPHA CONJUGATE-POLYMER IS PEG-INTERFERON IS ALPHA 2B
- U-479 METHOD OF USING PEG-INTRON/REBETOL COMBINATION THERAPY AND INTRON/REBETOL COMBINATION THERAPY
- U-480 CONTRAST AGENT FOR MRI
- U-481 DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY
- U-482 METHOD OF IN VITRO FERTILIZATION THERAPY INCLUDING MEANS FOR INDUCING OVULATION....
- U-483 METHOD FOR THE ADMINISTRATION OF DRUGS USING THAT COMPOUND
- U-484 METHOD OF TREATING A SKIN DISEASE WITH A CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION
- U-485 METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)
- U-486 EXTERNAL PREPARATION FOR APPLICATION TO THE SKIN CONTAINING LIDOCAINE-DRUG RETAINING LAYER PLACED ON SUPPORT AND COMPRISES ADHESIVE GEL BASE 1-10% BY WEIGHT OF LIDOCAINE
- U-487 METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)

PATENT AND EXCLUSIVITY TERMS

PATENT USE

U-488 METHOD FOR REDUCING THE PAIN ASSOCIATED WITH HERPES-ZOSTER AND POST-HERPETIC NEURALGIA

U-489 EXPECTORANT

U-490 TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE

U-491 METHOD OF DELIVERING A DRUG TO THE LUNG

U-492 METHOD FOR THE TREATMENT OF SKIN, SUFFERING FROM A CONDITION SELECTED FROM A GROUP CONSISTING OF NONACNE INFLAMMATORY DERMATOSES... COMPRISING APPLYING TO AFFECTED AREA. A THERAPEUTICALLY EFFECTIVE AMT AZELAIC ACID

U-493 TREATMENT OF TYPE 2 DIABETES MELLITUS

U-494 TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER

U-495 PERITONEAL DIALYSIS SOLUTION

U-496 METHOD FOR TREATING CHRONIC RENAL FAILURE

U-497 RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS

U-498 INTRA-ARTERIAL AND INTRAVENOUS USES OF ULTRAVIST

U-499 METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL (PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION

U-500 USE AS AN ANTIHYPERTENSIVE AGENT

U-501 TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS

U-502 PITYRIASIS VERSICOLOR

U-503 GENERATOR MUST BE USED WITH INFUSION SYSTEM SPECIFICALLY LABELED FOR USE WITH GENERATOR

U-504 TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS

U-505 ULTRASOUND CONTRAST AGENT

U-506 PHARM PRODUCT CONTAINER 1ST CHAMBER IS DISPOSED AQUEOUS DILUENT SOL 2ND CHAMBER PHARM ACTIVE AGENT COMPRISING ACETYLCHOLINE, BUFFER IN 1ST CHAM IS SUFFICIENT TO BUFFER PH OF MIXED SOL RESULTING MIXTURE OF AQUEOUS DILUENT SOL & PHARM ACTIVE..

U-507 ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE

U-508 METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS

U-509 TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY

U-510 TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES

U-511 USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA

U-512 USE OF QUINOLONE COMPOUNDS AGAINST ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA

U-513 METHODS OF USE OF ANTIMICROBIAL COMPOUNDS AGAINST PATHOGENIC AMYCOPLASMA BACTERIA

U-514 PREVENTION OF OVULATION IN A WOMAN

U-515 TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON THE LAST THERAPY

U-516 METHOD OF TREATING A PSYCHOTIC DISEASE

U-517 STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS

U-518 OBSESSIVE COMPULSIVE DISORDER

U-519 POST OPERATIVE NAUSEA AND VOMITING

U-520 PREMENOPAUSAL OSTEOPOROSIS

U-521 METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C

U-522 TREATMENT OF CMV RETINITIS BY INTRAVITREAL ADMIN OF A PHOSPHOROTHIOATE OLIGONUCLEOTIDE CAPABLE OF HYBRIDIZING WITH CMV MRNA

U-523 METHOD OF TREATING INFECTION BY CRYPTOSPORIDIUM PARVUM IN AN IMMUNOCOMPROMISED MAMMAL

U-524 METHOD OF TREATING DIARRHEA

U-525 METHOD OF TREATING PARASITIC INFECTIONS

U-526 METHOD OF PROVIDING CONTROLLED RELEASE OF A TREATING AGENT USING A CONTROLLED RELEASE COMPOSITION

U-527 METHOD OF DELIVERING AN ACTIVE INGREDIENT USING A PROGRESSIVE HYDRATION BIOADHESIVE

U-528 PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING

U-529 ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE

U-530 TREATMENT OF HERPES ZOSTER, TREATMENT OF GENITAL HERPES, TREATMENT OF COLD SORES, SUPPRESSION OF GENITAL HERPES IN IMMUNOCOMPETENT AND HIV-INFECTED INDIVIDUALS, REDUCTION OF RISK OF HETEROSEXUAL TRANSMISSION OF GENITAL HERPES

U-531 TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION. MAY BE USED ALONE OR GIVEN

PATENT AND EXCLUSIVITY TERMS

ADB 43 of 78

PATENT USE

- WITH OTHER CLASSES OF ANTIHYPERTENSIVES, ESPECIALLY THIAZIDE DERIVATIVES
- U-532 TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD IN PATIENTS REQUIRING MORE THAN ONE BRONCHO DILATOR
- U-533 ERECTILE DYSFUNCTION
- U-534 HUMALOG IS AN INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS FOR THE CONTROL OF HYPERGLYCEMIA
- U-535 TREATMENT OF SOCIAL ANXIETY DISORDER
- U-536 CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING
- U-537 TREATMENT OF CONDITIONS RELATED TO HYPERALDOSTERONISM SUCH AS HYPERTENSION AND CARDIAC INSUFFICIENCY, WITH EPLERENONE
- U-538 FIRST LINE TREATMENT OF SEVERE HYPERTENSION, IN PATIENTS WITH HYPERTENSION SEVERE ENOUGH THAT THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY IN THESE PATIENTS
- U-539 TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
- U-540 TREATMENT OF FUNGAL INFECTIONS
- U-541 METHOD OF TREATMENT OF ADULTS INFECTED WITH HIV-1
- U-542 METHOD OF TREATING PATIENT WITH TYPE 2 DIABETES BY ONCE DAILY ADMINISTRATION
- U-543 TREATMENT OF SCHIZOPHRENIA
- U-544 TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE.
- U-545 METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOTIC EPISODES, SUCH AS MYOCARDIAL INFARCTION, IN A HUMAN PATIENT AND METHOD FOR THE PREVENTION OF VENOUS THROMBOSIS IN A POSTOPERATIVE HUMAN PATIENT
- U-546 USE OF REPAGLINIDE IN COMBINATION WITH METFORMIN TO LOWER BLOOD GLUCOSE
- U-547 MAINTENANCE MONOTHERAPY FOR BIPOLAR DISORDER
- U-548 A METHOD OF REDUCING FLUSH IN AN INDIVIDUAL BEING TREATED FOR A LIPIDEMIC DISORDER AND EFFECTIVELY TREATING THE LIPIDEMIC DISORDER
- U-549 USE IN THE TREATMENT OF MEN WITH ADVANCED SYMPTOMATIC PROSTATE CANCER
- U-550 TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA
- U-551 METHOD FOR REDUCING TOXICITY OF ALIMTA TREATED PATIENTS BY ADMINISTERING FOLIC ACID
- U-552 TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION
- U-553 MANAGEMENT OF PAIN AND DISCOMFORT ASSOCIATED WITH PERIODONTAL SCALING AND ROOT PLANNING PROCEDURES BY APPLICATION OF AN EUTECTIC MIXTURE OF LOCAL ANESTHETICS TO PERIODONTAL POCKETS
- U-554 TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS
- U-555 TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS
- U-556 USE AS ADJUNCT DIAGNOSTIC FOR SERUM THYROGLOBULIN (TG) TESTING
- U-557 NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
- U-558 INDICATED FOR THE RELIEF OF BRONCHOSPASM IN PATIENTS 2-12 YEARS OF AGE WITH ASTHMA (REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE)
- U-559 METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING PARATHYROID HORMONE SECRETION;METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF REDUCING SERUM IONIZED CALCIUM LEVEL
- U-560 METHOD OF DECREASING PARATHYROID HORMONE LEVEL;METHOD OF TREATING HYPERPARATHYROIDISM
- U-561 COSOPT IS INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION WHO ARE INSUFFICIENTLY RESPONSIVE TO BETA BLOCKERS
- U-562 TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA
- U-563 MARINOL IS INDICATED FOR, INTER ALIA, ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS
- U-564 TREATMENT OF HIV IN CONCOMITANT THERAPY
- U-565 TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS, AND CHRONIC URTICARIA
- U-566 FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
- U-567 METHOD OF TREATING INFERTILITY
- U-568 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION
- U-569 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THEREAFTER AN OVULATORY INDUCING AMOUNT OF HCG IS ADMINISTERED
- U-570 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THE DAILY AMOUNT OF FSH IS ABOUT 5-10 IU/KG
- U-571 TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR I MANIA

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-572 INTENSIVE CARE UNIT SEDATION
- U-573 TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)
- U-574 PROPHYLAXIS AND TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND TREATMENT OF THE NASAL SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
- U-575 LOTEMAX OPHTHALMIC SUSPENSION IS INDICATED FOR THE TREATMENT OF STEROID RESPONSIVE CONDITIONS OF THE PALPEBRAL BULBAR CONJUNCTIVA, CORNEA AND ANTERIOR SEGMENT OF THE GLOBE.
- U-576 ALREX OPHTHALMIC SUSPENSION IS INDICATED FOR THE TEMPORARY RELIEF OF THE SIGNS AND SYMPTOMS OF SEASONAL ALLERGIC CONJUNCTIVITIS.
- U-577 TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH FINASTERIDE IN COMBINATION WITH DOXAZOSIN
- U-578 TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER.
- U-579 TREATMENT OF EPILEPSY AND/OR MIGRAINE.
- U-580 TREATMENT OF DISORDERS OF THE SEROTONERGIC SYSTEM SUCH AS DEPRESSION AND ANXIETY-RELATED DISORDERS
- U-581 METHOD OF TREATING A CONDITION CAPABLE OF TREATMENT BY INHALATION, E.G. ASTHMA, COMPRISING ADMINISTRATION OF A FORMULATION CLAIMED IN US PATENT NO. 6743413
- U-582 METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6253762
- U-583 METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING TO A PATIENT BY INHALATION, A METERED AEROSOL DOSE OF A DRUG FORMULATION FROM THE METERED DOSE INHALER SYSTEM CLAIMED IN US 6546928
- U-584 SINGLE-DOSE ADMINISTRATION BY THE EPIDURAL ROUTE, AT THE LUMBAR LEVEL, FOR THE TREATMENT OF PAIN FOLLOWING MAJOR SURGERY
- U-585 TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS
- U-586 AN INTERMEDIATE RELEASE NICOTINIC ACID FORMULATION SUITABLE FOR ORAL ADMINISTRATION ONCE-A-DAY AS A SINGLE DOSE FOR TREATING HYPERLIPIDEMIA WITHOUT CAUSING DRUG-INDUCED HEPATOTOXICITY OR ELEVATIONS IN URIC ACID OR GLUCOSE OR BOTH
- U-587 USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR (AND OPTIONALLY A DIURETIC) FOR TREATING CONGESTIVE HEART FAILURE AND HYPERTENSION
- U-588 SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS
- U-589 METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN U.S. PATENT NO. 6131966
- U-590 METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING TO A PATIENT BY ORAL OR NASAL INHALATION A DRUG FORMULATION BY USING THE METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6532955
- U-591 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING A DOSAGE FORM WHICH PROVIDES ONCE-DAILY ORAL ADMINISTRATION OF A PHENIDATE DRUG
- U-592 TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
- U-593 TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
- U-594 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- U-595 35 MG ORALLY ONCE A WEEK FOR PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN; 35 MG ORALLY ONCE A WEEK FOR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
- U-596 TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
- U-597 FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE
- U-598 PROPHYLACTIC TREATMENT OF MIGRAINE
- U-599 METHOD FOR TREATING ALLERGIC CONJUNCTIVITIS
- U-600 A METHOD OF TREATING A PATIENT IN NEED OF OPHTHALMIC ANTIMICROBIAL THERAPY WITH LEVOFLOXACIN
- U-601 TREATMENT OF BIPOLAR DISORDER
- U-602 SIGNS AND SYMPTOMS OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS IN ADULTS, AND/OR PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS, ACUTE PAIN IN ADULTS; PRIMARY DYSMENORRHEA; AND/OR ACUTE MIGRAINE ATTACKS IN ADULTS
- U-603 METHOD OF TREATING INFECTIONS COMPRISING ORALLY ADMINISTERING AN EFFECTIVE AMOUNT OF THE FDA APPROVED ORAL SUSPENSION
- U-604 METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION

PATENT AND EXCLUSIVITY TERMS

PATENT USE

- U-605 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD); ALTHOUGH THE MECHANISM OF THE ANTI-DEPRESSANT ACTION OF DULOXETINE IN HUMANS IS UNKNOWN, IT IS BELIEVED TO BE RELATED TO ITS POTENTIATION OF SERATONERGIC AND NORADRENERGIC ACTIVITY IN THE CNS
- U-606 USE OF IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER
- U-607 CANCIDAS IS INDICATED FOR EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS.
- U-608 USE OF QUINOLONE COMPOUNDS AGAINST PNEUMOCOCCAL PATHOGENIC BACTERIA
- U-609 USE OF QUINOLONE COMPOUNDS AGAINST QUINOLONE-RESISTANT PNEUMOCOCCAL PATHOGENIC BACTERIA
- U-610 ATROVENT HFA (IPRATROPIUM BROMIDE HFA) INHALATION AEROSOL IS INDICATED AS A BRONCHODILATOR FOR MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA.
- U-611 METHOD OF USING DESLORATADINE TO TREAT SEASONAL AND PERENNIAL ALLERGIC RHINITIS, PRURITIS, AND CHRONIC IDIOPATHIC URTICARIA IN PATIENTS 2 YEARS OF AGE AND OLDER
- U-612 TREATMENT OF SEASONAL ALLERGY SYMPTOMS WITH NASAL CONGESTION IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
- U-613 REDUCTION OF SERUM PHOSPHATE
- U-614 TREATMENT OF SEXUAL DYSFUNCTION
- U-615 ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TOTAL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)
- U-616 MANAGEMENT OF PERSISTENT, MODERATE TO SEVERE PAIN IN PATIENTS REQUIRING CONTINUOUS, AROUND-THE-CLOCK ANALGESIA WITH A HIGH POTENCY OPIOID FOR AN EXTENDED PERIOD OF TIME GENERALLY WEEKS TO MONTHS OR LONGER
- U-617 TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)
- U-618 USE OF ROSUVASTATIN CALCIUM TO REDUCE ELEVATED TOTAL-C, LDL-C, APOB, NONHDL-C OR TG LEVELS; TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA; AND TO SLOW THE PROGRESSION OF ATHEROSCLEROSIS.
- U-619 TREATMENT OF MALIGNANT NEOPLASM
- U-620 TREATMENT OF INSOMNIA
- U-621 METHOD OF TREATING CANCER
- U-622 TREATMENT OF VEGF MEDIATED OCULAR DISEASE.
- U-623 SHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
- U-624 REDUCTION OF RISK OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS
- U-625 ALLERGIC RHINITIS OR NASAL POLYPS
- U-626 CLOLAR IS INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 TO 21 YEARS OLD WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AFTER AT LEAST TWO PRIOR REGIMENS
- U-627 TREATMENT OF PATIENTS USING EXTENDED-RELEASE CARBAMAZEPINE
- U-628 USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA, AND IN COMBINATION WITH METFORMIN AND A SULFONYLUREA TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
- U-629 METHOD OF INDUCING A HYPNOTIC OR SEDATIVE EFFECT IN A HUMAN BY ADMINISTERING ESZOPICLONE
- U-630 TREATING URINARY INCONTINENCE BY ADMINISTERING AN EXTENDED-RELEASE FORM OF DARIFENACIN
- U-631 TREATING A DISEASE OF ALTERED MOTILITY OR TONE OF SMOOTH MUSCLE BY ADMINISTERING A MUSCARINIC RECEPTOR ANTAGONIZING AMOUNT OF DARIFENACIN
- U-632 METHOD OF TREATMENT OF CANCER BY ADMINISTERING PARTICLES OF PACLITAXEL THAT HAVE A PROTEIN COATING
- U-633 METHOD FOR TREATMENT OF TUMORS BY ADMINISTERING PACLITAXEL AT A DOSE IN THE RANGE OF ABOUT 30MG/METER SQUARE TO ABOUT 100MG/METER SQUARE IN A PHARMACEUTICALLY ACCEPTABLE FORMULATION THAT DOES NOT CONTAIN CREMOPHOR
- U-634 METHOD FOR DELIVERY OF A BIOLOGIC (INCLUDING ANTINEOPLASTIC AGENTS) BY ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF A BIOLOGIC AS A SOLID OR LIQUID WITH A POLYMERIC BIOCOMPATIBLE MATERIAL
- U-635 TREATMENT OF GERD, MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS AND RISK REDUCTION OF NSAID ASSOCIATED GASTRIC ULCERS
- U-636 TREATMENT OR PREVENTION OF BRONCHOSPASM OR ASTHMATIC SYMPTOMS
- U-637 TREATMENT OF DIABETES WITH AN AMYLIN AGONIST
- U-638 TREATMENT OF DIABETES WITH AN AMYLIN AGONIST, INCLUDING WITH INSULIN
- U-639 TREATMENT OF A MAMMAL HAVING A NEED OF OR REDUCED ABILITY TO PRODUCE INSULIN WITH AN INSULIN AND AN AMYLIN SUCH AS PRAMLINTIDE
- U-640 USE OF AN AMYLIN AGONIST TO REDUCE GASTRIC MOTILITY AND TREAT POST PRANDIAL HYPERGLYCEMIA
- U-641 USE OF AN AMYLIN AGONIST HAVING SPECIFIED BINDING ACTIVITY TO REDUCE GASTRIC

PATENT AND EXCLUSIVITY TERMS

PATENT USE

MOTILITY, INCLUDING USE THROUGH PARENTERAL ADMINISTRATION

U-642 TREATMENT AND PREVENTION OF OSTEOPOROSIS

U-643 THE SHORT TERM TREATMENT (UP TO 10 DAYS) IN PTS HAVING GASTROESOPHAGEAL REFLUX DISEASE (GERD) AS AN ALTERNATIVE TO ORAL THERAPY IN PTS WHEN THERAPY WITH NEXIUM CAPSULES IS NOT POSSIBLE OR APPROPRIATE

U-644 TREATMENT OF SEASONAL ALLERGIC RHINITIS

U-645 TREATMENT OF ASTHMA

U-646 METHOD OF TREATING OTITIS

U-647 TREATMENT OF OSTEOPOROSIS IN POST MENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS

U-648 THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN

U-649 A METHOD FOR TREATING A TUMOR DISEASE

U-650 TREATMENT OF ESOPHAGEAL CANDIDIASIS AND PROPHYLAXIS OF CANDIDA INFECTIONS IN HSCT PATIENTS

U-651 TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL)

U-652 TREATMENT OF CARDIAC ARRHYTHMIA

U-653 STIMULATING INSULIN RELEASE BY ADMINISTERING EXENATIDE

U-654 LOWERING PLASMA GLUCAGON IN A SUBJECT IN NEED THEREOF, INCLUDING ONE WITH TYPE 2 DIABETES, BY ADMINISTERING AN EXENDIN OR ANALOG, SUCH AS EXENDIN-4

U-655 TREATMENT OF MILD TO MODERATE ACTIVE CHROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON AND THE MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR ASCENDING COLON FOR UP TO 3 MONTHS

U-656 REDUCING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4

U-657 PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

U-658 TREATMENT OF ADVANCED HORMONE-DEPENDENT BREAST CANCER

U-659 TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN

U-660 TREATMENT OF HYPERTENSION AND TREATMENT OF HEART FAILURE

U-661 TREATMENT OF SEIZURE DISORDER

U-662 TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

U-663 THE TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS

U-664 TREATMENT OF CONDITIONS FOR WHICH AN ALDOSTERONE RECEPTOR BLOCKER IS INDICATED, SUCH AS HYPERTENSION, HEART FAILURE, AND POST-MYOCARDIAL INFARCTION

U-665 METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING

U-666 METHOD OF TREATING ADHD

U-667 MANAGEMENT OF INCONTINENCE; METHOD FOR TREATING INCONTINENCE

U-668 LEVEMIR IS A LONG-ACTING BASAL INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS

U-669 INDICATION OF TYPE II DIABETES

U-670 TREATMENT OF HIV-1 INFECTION BY THE CO-ADMINISTRATION OF TIPRANAVIR AND RITONAVIR.

U-671 PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 3 AND 4

U-672 TREATMENT OF INFLAMMATION OR AN INFLAMMATION-ASSOCIATED DISORDER

U-673 METHOD OF TREATMENT WITH ONCE-DAILY DOSES OF 625MG/5ML

U-674 METHOD OF TREATING INSOMNIA CHARACTERIZED BY DIFFICULTY WITH SLEEP ONSET

U-675 PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA; RELIEF OF SYMPTOMS OF ALLERGIC RHINITIS

U-676 METHOD OF TREATING ATTENTION DEFICIT DISORDER USING ORAL ADMINISTRATION OF A BI-MODAL OR PULSATILE RELEASE COMPOSITION

U-677 A METHOD OF TREATING DISEASE AMENABLE TO TREATMENT WITH A PHENIDATE DRUG BY ONCE DAILY ORAL ADMINISTRATION OF AN EXTENDED RELEASE DOSAGE FORM

U-678 METHOD OF TREATING ATTENTION DEFICIT DISORDER AND/OR ATTENTION DEFICIT HYPERACTIVITY DISORDER

U-679 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN

U-680 A METHOD OF TREATING DYSLIPIDEMIA AND DYSLIPOPROTEINEMIA USING A DOSAGE FORM THAT CAN PROVIDE AN EFFECTIVE AMOUNT OF FENOFIBRATE TO A PATIENT IN A FASTED STATE WHICH IS AT LEAST 90% OF THE AUC AMOUNT PROVIDED BY THE DOSAGE FORM

U-681 TREATMENT OF PRIMARY IGF-1 DEFICIENCY

U-682 NON-BENZODIAZEPINE HYPNOTIC AGENT INDICATED FOR TREATMENT OF INSOMNIA, CHARACTERIZED BY DIFFICULTIES WITH SLEEP ONSET AND/OR SLEEP MAINTENANCE

U-683 PREVENTION OR TREATMENT OF ISCHEMIC HEART DISEASE

U-684 TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER

PATENT AND EXCLUSIVITY TERMS

PATENT USE

U-685	EXPECTORANT AND COUGH SUPPRESSANT
U-686	EXPECTORANT AND NASAL DECONGESTANT
U-687	REDUCING FOOD INTAKE IN A SUBJECT WITH TYPE 2 DIABETES BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4
U-688	TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
U-689	TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS
U-690	TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
U-691	USE AS A MONOTHERAPY, IN COMBINATION WITH A SULFONYLUREA, METFORMIN OR INSULIN OR IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
U-692	USE OF VALSARTAN TO REDUCE CARDIOVASCULAR MORTALITY IN CLINICALLY STABLE PATIENTS WITH LEFT VENTRICULAR FAILURE OR LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
U-693	THE RECOMMENDED INITIAL DOSE OF EQUETRO IS 400MG/DAY GIVEN IN DIVIDED DOSES, TWICE DAILY. THE DOSE SHOULD BE ADJUSTED IN 200MG DAILY INCREMENTS TO ACHIEVE OPTIMAL CLINICAL RESPONSE.
U-694	LENALIDOMIDE IS AN ANALOGUE OF THALIDOMIDE. THALIDOMIDE IS A KNOWN HUMAN TERATOGEN THAT CAUSES SEVERE LIFE-THREATENING HUMAN BIRTH DEFECTS. IF LENALIDOMIDE IS TAKEN DURING PREGNANCY, IT MAY CAUSE BIRTH DEFECTS OR DEATH TO AN UNBORN BABY.
U-695	TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS
U-696	TREATMENT OF PATIENTS WITH T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS
U-697	A METHOD OF USING RINFABATE RECOMBINANT (RHIGFBP-3) WITH MECASERMIN RECOMBINANT (RHIGF-1) TO PROMOTE LINEAR GROWTH IN THE TREATMENT OF PRIMARY IGF-1 DEFICIENCY
U-698	METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH EUVOLEMIC HYPONATREMIA
U-699	NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
U-700	TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
U-701	TREATMENT OF HYPERCHOLESTEROLEMIA AND/OR HYPERTRIGLYCERIDEMIA
U-702	TOPICAL AEROSOL HAIR REGROWTH TREATMENT
U-703	TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMOR AND RENAL CELL CARCINOMA WITH SUNITINIB
U-704	METHOD OF ADMINISTERING INSULIN VIA INHALATION
U-705	TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE
U-706	TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
U-707	ALLERGIC RHINITIS
U-708	TREATMENT OF CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE
U-709	METHOD OF COMBATING BACTERIA IN A PATIENT
U-710	A METHOD OF TREATING RESPIRATORY DISORDERS, E.G., ASTHMA, WHICH COMPRISES ADMINISTRATION BY INHALATION OF AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT NO. 5658549
U-711	ACUTE AND LONGER-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER
U-712	A METHOD OF USING A NICOTINIC ACID FORMULATION TO REDUCE ELEVATED TC, LDL-C AND TG LEVELS, AND RAISE HDL-C LEVELS IN PATIENTS WITH HYPERLIPIDEMIA
U-713	TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE
U-714	TOPICAL TREATMENT OF INTERDIGITAL TINEA PEDIS AND TINEA CORPORIS DUE TO TRICHOPHYTON RUBRUM, TRICHOPHYTON MENTAGROPHYTES OR EPIDERMOPHYTON FLOCCOSUM
U-715	FOR CLEANSING THE BOWEL IN PREPARATION FOR COLONOSCOPY, IN ADULTS 18 YEARS OF AGE OR OLDER
U-716	THE TREATMENT OR PREVENTION OF BRONCHOSPASM IN ADULTS AND CHILDREN 4 YEARS OF AGE AND OLDER WITH REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE AND THE PREVENTION OF EXERCISED-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
U-717	METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT
U-718	TREATMENT OF FUNGAL INFECTIONS
U-719	TREATMENT OF PSYCHOSIS
U-720	TREATMENT OF NEUROLEPTIC DISEASES
U-721	TREATMENT OF INFLUENZA
U-722	PROPHYLAXIS OF INFLUENZA
U-723	PROPHYLACTIC TREATMENT OF MIGRAINE
U-724	METHOD OF TREATING SEIZURES

PATENT AND EXCLUSIVITY TERMS

PATENT USE

U-725 ALLERGIC RHINITIS AND URTICARIA
U-726 ALLERGIC RHINITIS
U-727 FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
U-728 METHOD FOR TREATING BACTERIAL INFECTION
U-729 TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER, H. PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
U-730 USE AS A NASAL SPRAY FOR TREATMENT OF THE SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND VASOMOTOR RHINITIS
U-731 USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
U-732 ACUTE TREATMENT OF THE CUTANEOUS MANIFESTATIONS OF MODERATE TO SEVERE ERYTHEMA NODOSUM LEPROSUM (ENL)
U-733 MAINTENANCE THERAPY FOR PREVENTION AND SUPPRESSION OF THE CUTANEOUS MANIFESTATIONS OF ENL RECURRENCE
U-734 FIRST LINE THERAPY FOR TYPE 2 DIABETES MELLITUS
U-735 METHOD OF TREATING CHRONIC IRON OVERLOAD
U-736 METHOD FOR IONTOPHORETIC TRANSDERMAL DELIVERY OF FENTANYL HYDROCHLORIDE
U-737 DISINFECTION OF PATIENT SKIN PRIOR TO AN INVASIVE PROCEDURE
U-738 INDICATED FOR THE LONG-TERM, TWICE-DAILY MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE OR OLDER
U-739 METHOD FOR TREATING CONSTIPATION BY OPENING CIC CHANNELS IN A MAMMALIAN SUBJECT
U-740 FOR THE TREATMENT OF PATIENTS WITH PRIMARY BILIARY CIRRHOSIS
U-741 COMBINATION THERAPY WITH CISPLATIN FOR THE TREATMENT OF LATE STAGE CERVICAL CANCER
U-742 TWICE DAILY TOPICAL TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS.
U-743 ONCE A DAY TOPICAL TREATMENT OF THE INFLAMMATORY LESIONS OF ROSACEA
U-744 TREATMENT OF HIV INFECTION IN ANTIRETROVIRAL TREATMENT-EXPERIENCED ADULT PATIENTS
U-745 TREATMENT OR PREVENTION OF EMESIS
U-746 PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT
U-747 PREVENTION OR TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING
U-748 A METHOD FOR THE TREATMENT OF A PROTEIN TYROSINE KINASE-ASSOCIATED DISORDER
U-749 METHOD OF CONTRACEPTION
U-750 TREATMENT OF HIV-1 INFECTION IN ADULTS
U-751 ONCE DAILY DOSING OF BUDESONIDE VIA NEBULIZER FOR THE TREATMENT OF ASTHMA
U-752 SUNSCREEN
U-753 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES
U-754 USE FOR THE LONG-TERM MAINTENANCE TREATMENT OF ASTHMA
U-755 TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
U-756 ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
U-757 USE AS A BILE ACID SEQUESTANT FOR LOWERING CHOLESTEROL
U-758 TREATMENT OF SYMPTOMS OF PREMENSTRUAL DYSPHORIC DISORDER
U-759 METHOD OF USE OF ADMINISTERING LEVOTHYROXINE
U-760 PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS AND TREATMENT OF OROPHARYNGEAL CANDIDIASIS
U-761 TREATMENT OF SCHIZOPHRENIA INCLUDING MAINTAINING STABILITY IN PATIENTS WITH SCHIZOPHRENIA
U-762 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
U-763 ADMINISTRATION OF ARIPIPRAZOLE BY INJECTION
U-764 TREATMENT OF SCHIZOPHRENIA
U-765 METHOD OF TREATING ALLERGIC CONJUNCTIVITIS
U-766 TREATMENT OF SEIZURES
U-767 MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER
U-768 A METHOD OF REDUCING THE CAPACITY OF EXTENDED RELEASE NICOTINIC ACID TO PROVOKE A FLUSHING REACTION BY PRETREATING AN INDIVIDUAL WITH A FLUSH INHIBITING AGENT PRIOR TO THE ADMINISTRATION OF THE EXTENDED RELEASE NICOTINIC ACID
U-769 REVLIMID (LENALIDOMIDE) IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-770 LONG-TERM TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS
U-771 METHOD FOR THE TREATMENT OF DIABETES MELLITUS, SUCH AS TYPE 1 DIABETES MELLITUS OR TYPE 2 DIABETES MELITUS, IN A HUMAN PATIENT

PATENT AND EXCLUSIVITY TERMS

PATENT USE

- U-772 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS
- U-773 PATHOLOGICAL HYPERSECRETORY CONDITIONS
- U-774 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
- U-775 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA
- U-776 TREATMENT OF CUTANEOUS MANIFESTATION IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL) WHO HAVE PROGRESSIVE, PERSISTENT OR RECURRENT DISEASE ON OR FOLLOWING TWO SYSTEMIC THERAPIES.
- U-777 DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE
- U-778 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
- U-779 A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA
- U-780 A METHOD FOR THE TREATMENT OF CANCER
- U-781 FOR TREATMENT OF ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE NAIVE TO PHARMACOLOGIC THERAPY
- U-782 TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS WITH EVIDENCE OF VIRAL REPLICATION AND EITHER EVIDENCE OF PERSISTANT ELEVATIONS IN SERUM AMINOTRANSFERASES (ALT OR AST) OR HISTOLOGICALLY ACTIVE DISEASE
- U-783 DESONATE GEL IS INDICATED FOR THE TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE AND OLDER
- U-784 TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)
- U-785 USE AS REPLACEMENT SOLUTION, HEMOFILTRATION SOLUTION OR HEMODIAFILTRATION SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY
- U-786 PRODUCT IS APPROVED FOR THE TOPICAL TREATMENT OF TINEA PEDIS
- U-787 MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND PEDIATRIC PATIENTS SIX YEARS OF AGE OR OLDER, INCLUDING PATIENTS REQUIRING ORAL CORTICOSTEROID THERAPY FOR ASTHMA
- U-788 METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING PAROXETINE
- U-789 TREATMENT OF KNOWN OR SUSPECTED CYANIDE POISONING
- U-790 FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT RISK FOR FRACTURE. FORTEO CAN BE USED BY PEOPLE WHO HAVE HAD A FRACTURE RELATED TO OSTEOPOROSIS
- U-791 GLEEVEC IS ALSO INDICATED FOR THE TREATMENT OF PATIENTS WITH KIT (CD117) POSITIVE UNRESECTABLE AND/OR METASTATIC MALIGNANT GASTROINTESTINAL STROMAL TUMORS (GIST)
- U-792 TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS
- U-793 FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
- U-794 CLOSURE OF A CLINICALLY SIGNIFICANT PATENT DUCTUS ARTERIOSUS IN PREMATURE INFANTS WEIGHING BETWEEN 500 AND 1500G, WHO ARE NO MORE THAN 32 WEEKS GESTATIONAL AGE WHEN USUAL MEDICAL MANAGEMENT IS INEFFECTIVE
- U-795 METHOD FOR INHIBITING NOREPINEPHRINE UPTAKE
- U-796 METHOD OF TREATING DEPRESSION
- U-797 METHOD OF TREATING ANXIETY
- U-798 TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN BY ONCE-MONTHLY ORAL ADMINISTRATION OF IBANDRONATE SODIUM MONOHYDRATE EQUIVALENT TO 150MG OF IBANDRONIC ACID
- U-799 METHOD FOR INHIBITING SEROTONIN UPTAKE
- U-800 TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER WHOSE TUMORS OVEREXPRESS HER2 AND WHO HAVE RECEIVED PRIOR THERAPY INCLUDING ANTHRACYCLINE, A TAXANE AND TRASTUZUMAB
- U-801 METHOD OF TREATING CANCER
- U-802 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
- U-803 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN
- U-804 TREATMENT OF ACTINIC KERATOSES BY PHOTODYNAMIC THERAPY
- U-805 TREATMENT OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS OR STREPTOCOCCUS PYOGENES
- U-806 INTRATHECAL TREATMENT OF LYMPHOMATOUS MENINGITIS
- U-807 PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION
- U-808 THE TREATMENT OF THE SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN PATIENTS 2 YEARS OF AGE AND OLDER

PATENT AND EXCLUSIVITY TERMS

ADB 50 of 78

PATENT USE

U-809 TREATMENT OF CHRONIC IDIOPATHIC URTICARIA

U-810 METHOD OF TREATMENT TO ALLEVIATE INFLAMMATION OF THE EYE

U-811 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS AND TREATMENT OF THE UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA

U-812 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS

U-813 MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

U-814 TREATMENT OF SCHIZOPHRENIA

U-815 TREATS COLD SORES/FEVER BLISTERS ON THE FACE OR LIPS. SHORTENS HEALING TIME AND DURATION OF SYMPTOMS: TINGLING, PAIN, BURNING AND/OR ITCHING

U-816 DEPRESSION, PANIC DISORDER, PREMENSTRUAL DISORDERS AND SOCIAL ANXIETY DISORDER

U-817 NASAL ADMINISTRATION OF CYANOCOBALAMIN

U-818 TOPICAL TREATMENT OF ACNE VULGARIS

U-819 MANAGEMENT OF FIBROMYALGIA

U-820 IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY, OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME, AND SHIFT WORK SLEEP DISORDER

U-821 METHOD OF INHIBITING ENTHOTHELIN RECEPTORS BY ADMINISTERING AMBRISENTAN TO A PATIENT TO TREAT PULMONARY ARTERIAL HYPERTENSION.

U-822 USE IN LIPID MANAGEMENT

U-823 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS AND FOR THE TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 TO 11 YEARS OF AGE

U-824 METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1

U-825 USE FOR PREVENTION OF BREAST CANCER

U-826 RELIEF OF MODERATE TO SEVERE PAIN

U-827 USE FOR TREATMENT OF DIABETES, PARTICULARLY TYPE 2 DIABETES

U-828 PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION

U-829 TREATMENT OF EXTRAVASATION RESULTING FROM IV ANTHRACYCLINE CHEMOTHERAPY

U-830 TREATMENT OF RELAPSED SMALL CELL LUNG CANCER

U-831 METHOD OF ADMINISTERING LANREOTIDE ACETATE

U-832 ZINGO IS INDICATED FOR THE USE ON INTACT SKIN TO PROVIDE LOCAL ANALGESIA PRIOR TO VENIPUNCTURE OR INTRAVENOUS CANNULATION.

U-833 METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.25% BY WEIGHT OF ROPIVACAINE

U-834 INVIRASE IN COMBINATION WITH RITONAVIR AND OTHER ANTIRETROVIRAL AGENTS IS INDICATED FOR THE TREATMENT OF HIV INFECTION

U-835 RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF ATOPIC DERMATITIS IN PATIENTS ONE YEAR OF AGE OR OLDER

U-836 A METHOD FOR THE TREATMENT OF LEUKEMIAS

U-837 GASTROINTESTINAL LAVAGE INDICATED FOR CLEANSING OF THE COLON AS A PREPARATION FOR COLONOSCOPY IN ADULTS

U-838 METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.5% BY WEIGHT OF ROPIVACAINE

U-839 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)

U-840 TREATMENT FOR TYPE 2 DIABETES MELLITUS

U-841 INDICATED FOR THE LONG-TERM, MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE AND OLDER

U-842 INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)

U-843 METHOD FOR ADMINISTRATION OF TESTOSTERONE

U-844 PREFEST IS INDICATED IN WOMEN WHO HAVE A UTERUS FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE; TREATMENT OF VULVAR AND VAGINAL ATROPHY; PREVENTION OF OSTEOPOROSIS

U-845 TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESSSES

U-846 USE FOR DELINEATION (VISUALIZATION) DURING A VITRECTOMY SURGICAL PROCEDURE

U-847 ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)

U-848 ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA

U-849 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP. DOSE IS ONE DROP OF COMBIGAN IN THE AFFECTED EYE TWICE DAILY

PATENT AND EXCLUSIVITY TERMS

PATENT USE

U-850 PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT

U-851 TREATMENT OF TYPE 2 DIABETES MELLITUS

U-852 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS

U-853 TREATMENT OR PREVENTION OF EMESIS

U-854 PREVENTION OF CMV DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)

U-855 METHOD TO INDUCE NATRIURESIS, DIURESIS AND/OR VASODILATION

U-856 SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN

U-857 INHIBITION OF TRANSPLANT REJECTION

U-858 PEDIATRIC USE AGED 1-11 YEARS, GERD AND EROSIIVE ESOPHAGITIS

U-859 EROSIIVE ESOPHAGITIS, HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME, MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS AND REDUCTION OF SYMPTOMS IN PATIENTS WITH GERD

U-860 FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION

U-861 RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER

U-862 ADJUNCT TO DIET TO REDUCE ELEVATED TOTAL-C, LDL-C, NON-HDL-C, APO B, TG, AND LP(A) LEVELS AND TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, MIXED DYSLIPIDEMIA, AND HYPERTRIGLYCERIDEMIA

U-863 TAKING ASPIRIN OR NON-STEROIDAL ANTI-INFLAMMATORY MEDICATIONS APPROXIMATELY 30 MINUTES BEFORE DOSING CAN MINIMIZE FLUSHING, A COMMON SIDE EFFECT OF NIACIN THERAPY

U-864 PEDIATRIC USE AGES 1-2 YEARS, GERD AND EROSIIVE ESOPHAGITIS

U-865 TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND A HIGH RISK FOR BONE FRACTURE BY REDUCING THE RISK OF VERTEBRAL AND NONVERTEBRAL BONE FRACTURE

U-866 THE LABEL REFERENCES THE EFFECTS OF THE ACTIVE INGREDIENT OF REVLIMID UPON CYTOKINES

U-867 TREATMENT OF MIGRAINE

U-868 METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH HYPERVOLEMIC HYPONATREMIA

U-869 METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART

U-870 METHOD OF PRODUCING CORONARY VASODILATION WITHOUT PERIPHERAL VASODILATION

U-871 METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH

U-872 TWICE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA. TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS

U-873 METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME BY OPENING CHLORIDE CHANNELS (CIC)

U-874 METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME

U-875 FIRST-LINE TREATMENT OF LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER, IN COMBINATION WITH GEMCITABINE

U-876 TREATMENT OF MIGRAINE WITH OR WITHOUT AURA

U-877 FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PEPTIC ULCER

U-878 A METHOD FOR BINDING A PERIPHERAL OPIOID RECEPTOR

U-879 A METHOD OF TREATING OR PREVENTING ILEUS

U-880 ENDOMETRIN IS A PROGESTERONE INDICATED TO SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN

U-881 TREATMENT OF NON-SMALL CELL LUNG CANCER

U-882 MANAGEMENT OF FIBROMYALGIA (FM)

U-883 TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB

U-884 TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA

U-885 TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY

U-886 ADMINISTERING DESLORATADINE TO TREAT THE SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS, SEASONAL ALLERGIC RHINITIS, OR CHRONIC IDIOPATHIC URTICARIA

U-887 TREATMENT AND PREVENTION OF OSTEOPOROSIS

U-888 FEMALE HORMONE REPLACEMENT THERAPY FOR POSTMENOPAUSAL WOMEN

U-889 MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE)

U-890 REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE

U-891 USE AS AN INTRAOCULAR IRRIGATING SOLUTION DURING SURGICAL PROCEDURES INVOLVING PERFUSION OF THE EYE

PATENT AND EXCLUSIVITY TERMS

PATENT USE

- U-892 TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL)
- U-893 CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE
- U-894 TREATMENT OF COLD SORES IN PEDIATRIC PATIENTS TWELVE YEARS OF AGE AND OLDER
- U-895 TREATMENT OF HIV INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
- U-896 TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN TWO YEARS OF AGE AND OLDER
- U-897 METHOD OF TREATING TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES IN A ONCE-A-DAY AMOXICILLIN PRODUCT
- U-898 USE OF GLUTAMINE TOGETHER WITH GROWTH HORMONE FOR THE TREATMENT OF PATIENTS WITH SHORT BOWEL SYNDROME
- U-899 USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
- U-900 INTEGRASE INHIBITION FOR THE TREATMENT OF HIV INFECTION
- U-901 PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
- U-902 USE IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)
- U-903 TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ADULT PATIENTS
- U-904 TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE
- U-905 TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE
- U-906 PROPHYLAXIS OF ORGAN REJECTION IN KIDNEY, LIVER AND HEART ALLOGENIC TRANSPLANTS; TREATMENT OF PATIENTS WITH SEVERE ACTIVE, RHEUMATOID ARTHRITIS; TREATMENT OF ADULT, NONIMMUNOCOMPROMISED PATIENTS WITH SEVERE, RECALCITRANT, PLAQUE PSORIASIS FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS IN SUBJECTS 18 YEARS OF AGE AND OLDER
- U-907 PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS RECEIVING ALLOGENEIC RENAL TRANSPLANTS
- U-908 TREATMENT OF CYSTIC FIBROSIS PATIENTS WITH PSEUDOMONAS AERUGINOSA
- U-909 TREATMENT OF METASTATIC CARCINOMA OF THE OVARY AFTER FAILURE OF INITIAL OR SUBSEQUENT CHEMOTHERAPY
- U-911 METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL TREATMENT IS TEMPORARILY NOT FEASIBLE
- U-912 SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES
- U-913 TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY
- U-914 METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER
- U-915 TREATMENT OF MUSCULOSKELETAL CONDITIONS
- U-916 TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER
- U-917 TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET
- U-919 FOR THE TREATMENT OF DERMATITIS
- U-920 STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A CORTICOSTEROID IS INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK OF BACTERIAL OCULAR INFECTION EXISTS
- U-921 TREATMENT OF ACNE VULGARIS
- U-922 FOR THE TREATMENT OF FUNGAL INFECTIONS
- U-923 METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION
- U-924 TREATMENT OF MILD TO MODERATE INFECTION CAUSED BY SUSCEPTIBLE STRAINS
- U-925 TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA
- U-926 MGT SPECIFIC BACTERIAL INFECTIONS. TREATMENT PTS W/ COMMUNITY ACQUIRED PNEUMONIA OR BACTERIAL SINUSITIS DUE TO CONFIRMED, OR SUSPECTED B-LACTAMASE PRODUCING PATHOGENS & S. PNEUMONIAE WITH REDUCED SUSCEPTIBILITY TO PENICILLIN (MIC=2MC/ML)
- U-927 METHOD FOR INCREASING TEAR PRODUCTION
- U-928 TREATMENT OF BACTERIAL INFECTIOUS DISEASE
- U-929 TREATMENT OF OBSESSIVE COMPULSIVE DISORDER TREATABLE WITH AN SSRI
- U-930 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
- U-931 RELIEF OF MODERATE TO SEVERE ACUTE PAIN
- U-932 PYLERA CAPSULES, IN COMBINATION WITH OMEPRAZOLE ARE INDICATED FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI
- U-933 FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL

PATENT AND EXCLUSIVITY TERMS

ADB 53 of 78

PATENT USE

- ULCER DISEASE TO ERADICATE H. PYLORI. THE ERADICATION OF HELICOBACTER PYLORI HAS BEEN SHOWN TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
- U-934 IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELL TO THE PERIPHERAL BLOOD FOR COLLECTION AND SUBSEQUENT AUTOLOGOUS TRANSPLANTATION WITH NON-HODGKINS LYMPHOMA AND MULTIPLE MYELOMA
- U-935 TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER
- U-936 USE IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELLS TO PERIPHERAL BLOOD FOR COLLECTION & SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA & MULTIPLE MYELOMA
- U-937 TREATMENT OF PROSTATE CANCER
- U-938 TREATMENT OF HAIR LOSS AND HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS
- U-939 TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING AND STIMULATING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS
- U-940 METHOD TO TREAT AIDS-RELATED KAPOSI'S SARCOMA
- U-941 METHOD TO TREAT OVARIAN CANCER
- U-942 METHOD TO TREAT MULTIPLE MYELOMA
- U-943 GNRH ANTAGONIST INDICATED FOR TREATMENT OF PATIENTS WITH ADVANCED PROSTATE CANCER
- U-944 TREATMENT OF PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
- U-945 SEDATIVE-HYPNOTIC AGENT INDICATED FOR MONITORED ANESTHESIA CARE (MAC) SEDATION
- U-946 TREATMENT OF BREAST CANCER
- U-947 WHEN PATIENTS ARE UNABLE TO TAKE THE ORAL FORMULATIONS, PREVACID IV, FOR INJECTION IS INDICATED AS AN ALTERNATIVE FOR THE SHORT-TERM TREATMENT (UP TO 7 DAYS) OF ALL GRADES OF EROSIIVE ESOPHAGITIS
- U-948 TREATMENT OF DIABETES MELLITUS
- U-949 HEALING OF ALL GRADES OF EROSIIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS
- U-950 MAINTAIN HEALING OF EROSIIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS
- U-951 TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS
- U-952 USE AS AN ANALGESIC
- U-953 METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION
- U-954 CHRONIC MANAGEMENT OF HYPERURICEMIA IN PATIENTS WITH GOUT. NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA
- U-955 PROPHYLACTIC TREATMENT OF MIGRAINE
- U-956 TREATMENT OF PATIENTS WITH H. PYLORI INFECTION AND DUODENAL ULCER DISEASE
- U-957 A METHOD OF TREATING CANCER IN A PATIENT COMPRISING ADMINISTERING IXABEPILONE OR PHARMACEUTICAL COMPOSITIONS COMPRISING IXABEPILONE
- U-958 METHOD OF TREATING PATIENT COMPRISING MIXING FIRST AND SECOND VIALS OF PRODUCT COMPRISING LYOPHILIZED IXABEPILONE TO PROVIDE AN EPOTHILONE ANALOG SOLUTION, DILUTING SOLUTION WITH A SUITABLE DILUENT TO PREPARE INTRAVENOUS FORMULATION FOR PT
- U-959 METHOD OF TREATING CANCER, IV ADMIN, LYOPHILIZED IXABEPILONE DILUTED, EVERY WEEK OR 3 WEEKS; LYOPHILIZED IXABEPILONE WITH SOLVENT(DEHYDRATED ETHANOL) DILUTED TO CONCENTRATION OF 0.1MG/ML TO 0.9MG/ML
- U-960 METHOD OF TREATING CANCER IN A PATIENT COMPRISING INTRAVENOUSLY ADMINISTERING TO THE PATIENT IXABEPILONE DILUTED IN A PARENTERAL DILUENT
- U-961 METHOD OF TREATING BREAST CANCER BY ADMINISTERING IXABEPILONE; A METHOD OF TREATING A CANCER RESPONSIBLE TO MICROTUBULE STABILIZATION BY ADMINISTERING IXABEPILONE
- U-962 SYMBYAX IS INDICATED FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
- U-963 PROZAC AND OLANZAPINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
- U-964 ZYPREXA ZYDIS AND FLUOXETINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
- U-965 USE OF IXABEPILONE IN COMBINATION WITH CAPECITABINE IN TREATMENT OF METASTASIS BREAST CANCER
- U-966 TREATMENT OF ASTHMA (MAINTENANCE AND PROPHYLACTIC THERAPY)
- U-967 A METHOD OF REVERSING SOFT-TISSUE ANESTHESIA I.E. ANESTHESIA OF THE LIP AND TONGUE, AND THE ASSOCIATED FUNCTIONAL DEFICITS RESULTING FROM AN INTRAORAL SUBMUCOSAL INJECTION OF A LOCAL ANESTHETIC
- U-968 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
- U-969 TREATMENT OF MIGRAINE
- U-970 TOPICAL TREATMENT OF LICE INFESTATIONS

PATENT AND EXCLUSIVITY TERMS

ADB 54 of 78

PATENT USE

U-971 INDICATED FOR THE ACUTE TREATMENT OF ADULTS WITH SCHIZOPHRENIA

U-972 MONOTHERAPY OR AS ADJUNCTIVE THERAPY TO LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER

U-973 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH PIOGLITAZONE AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON PIOGLITAZONE OR METFORMIN ALONE

U-974 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN

U-975 TREATMENT OF PULMONARY HYPERTENSION

U-976 IMPROVEMENT OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES

U-977 TREATMENT OF ACUTE, UNCOMPLICATED MALARIA INFECTION DUE TO PLASMODIUM FALCIPARUM IN PATIENTS OF 5KG BODYWEIGHT AND ABOVE

U-978 METHOD OF TREATING HYPONATREMIA

U-979 RELIEF OF MUSCLE SPASM

U-980 NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN

U-981 MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI-INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY

U-982 A METHOD OF TREATING OSTEOPOROSIS

U-983 METHOD OF TREATING OSTEOPOROSIS IN A POST-MENOPAUSAL WOMAN AT RISK FOR FRACTURE

U-984 METHOD FOR THE TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND AT RISK FOR BONE FRACTURE

U-985 TREATMENT OF MACULAR EDEMA FOLLOWING BRANCH RETINAL VEIN OCCLUSION (BRVO) OR CENTRAL RETINAL VEIN OCCLUSION (CRVO)

U-986 TREATMENT OF PATIENTS INFECTED WITH PEDICULUS HUMANUS CAPITIS (HEAD LICE AND THEIR OVA) OF THE SCALP HAIR

U-987 TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH CHRONIC KIDNEY DISEASE ON DIALYSIS

U-988 TREATMENT OF RHINITIS COMPRISING THE NASAL APPLICATION OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT 7541350

U-989 FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA

U-990 TREATMENT OF PROTOZOAL INFECTION

U-991 TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISMS

U-992 REDUCTION OF THE RISK OF CARDIOVASCULAR HOSPITALIZATION

U-993 METHOD OF TREATING INFERTILITY

U-994 METHOD OF TREATMENT OF OSTEOPOROSIS WHEREIN THE OSTEOPOROSIS IS STEROID-INDUCED

U-995 METHOD FOR TREATING TYPE II DIABETES BY ADMINISTERING SAXAGLIPTIN

U-996 AN ADJUNCTIVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL (TC), LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, TRIGLYCERIDES, AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIX DYSLIPIDEMIA

U-997 TREATMENT OF MAJOR DEPRESSIVE DISORDER BY DOSING AT INTERVALS OF 24 HOURS

U-998 ADJUNCTIVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPRTEIN B, TRIGLYCERIDES AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA

U-999 TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS

U-1000 ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH HYPERLIPIDEMIAS

U-1001 METHOD FOR DELIVERING DRUG TO LUNG OF MAMMAL, COMPRISING ADMINISTERING DRUG PRODUCT BY INHALATION. TREATING A MAMMAL HAVING A CONDITION CAPABLE OF TREATMENT BY INHALATION, COMPRISING ADMINISTERING TO THE LUNG THE DRUG PRODUCT BY INHALATION

U-1002 METHOD OF TREATING INFLAMMATORY CONDITIONS

U-1003 A METHOD OF MYOCARDIAL PERFUSION IMAGING AND INCREASING CORONARY BLOOD FLOW

U-1004 TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA

U-1005 METHOD OF TREATING A STAPHYLOCOCCAL INFECTION

U-1006 NEW COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND ADOLESCENTS (12 YEARS OF AGE AND OLDER)

U-1007 METHOD OF TREATING GOUT FLARES

U-1008 APPLICATION OF ANTISEPTIC WITH MOISTURIZERS FOR SURGICAL AND HEALTHCARE PERSONNEL SKIN DISINFECTION

U-1009 METHOD FOR ADMINISTRATION OF TESTOSTERONE

U-1010 TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA DUE TO TETRA HYDROBIOPTERIN RESPONSIVE PHENYLKETONURIA. KUVAN SHOULD BE TAKEN ORALLY WITH FOOD TO INCREASE ABSORPTION

U-1011 USE OF GRANISETRON TRANSDERMAL SYSTEM TO TREAT/PREVENT CHEMOTHERAPY INDUCED NAUSEA

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

AND VOMITING

U-1012 METHOD FOR TREATING INSOMNIA WHILE REDUCING THE RISK OF AN ADVERSE DRUG INTERACTION

U-1013 METHOD OF USING RIBAVIRIN IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2B TO TREAT PATIENTS WITH CHRONIC HEPATITIS C

U-1014 METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTERFERON ALPHA-2B (PEGYLATED AND NONPEGYLATED) TO TREAT PATIENTS WITH CHRONIC HEPATITIS C

U-1015 TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA

U-1016 IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-EXPERIENCED ADULT PATIENTS, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO AN NNRTI AND OTHER ANTIRETROVIRAL AGENTS

U-1017 A METHOD OF TREATING NASAL AND NON-NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS

U-1018 TREATMENT OF PULMONARY HYPERTENSION BY INHALATION

U-1019 TREATMENT OF PULMONARY HYPERTENSION

U-1020 METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES

U-1021 SHORT-TERM TREATMENT (4-8 WEEKS) OF ACTIVE BENIGN GASTRIC ULCER

U-1022 FOR THE PREPARATION OF SKIN PRIOR TO SURGERY; HELPS REDUCE BACTERIA THAT CAN POTENTIALLY CAUSE SKIN INFECTION

U-1023 TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE

U-1024 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP

U-1025 TREATING FREQUENT HEARTBURN

U-1026 A METHOD OF TREATING HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS.

U-1027 REDUCTION OF ELEVATED PLASMA STEROL AND/OR STANOL LEVELS IN A MAMMAL

U-1028 A METHOD OF DISTRIBUTING SODIUM OXYBATE UNDER CONTROL OF A CENTRAL PHARMACY

U-1029 METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF

U-1030 IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS)

U-1031 IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA

U-1032 USE OF ROSUVASTATIN CALCIUM FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN INDIVIDUALS WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH INCREASED RISK FACTORS

U-1033 TOPICAL TREATMENT OF ACNE VULGARIS

U-1034 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS

U-1035 NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN

U-1036 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN

U-1037 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH A PPAR-GAMMA AGONIST

U-1038 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN AND A PPAR-GAMMA AGONIST

U-1039 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN

U-1040 INHIBITION OF THROMBIN IN A PATIENT

U-1041 TREATMENT OF DISORDERS RESPONSIVE TO GROWTH HORMONE

U-1042 METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART

U-1043 MANAGEMENT OF MODERATE TO SEVERE PAIN

U-1044 TOPICAL TREATMENT OF SCALP PSORIASIS

U-1045 MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHO HAVE NOT PROGRESSED ON 1ST-LINE TREATMENT WITH PLATINUM-BASED CHEMOTHERAPY

U-1046 MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES PLATINUM-BASED CHEMOTHERAPY

U-1047 TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA (SBCC)

U-1048 WORKS THROUGH THE INDUCTION OF INTERFERON AND OTHER CYTOKINES

U-1049 PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A RENAL TRANSPLANT

U-1050 USE OF METAXALONE FOR TREATMENT OF MUSCULOSKELETAL CONDITIONS

U-1051 TREATMENT OF OROPHARYNGEAL CANDIDIASIS

U-1052 RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER

U-1053 RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER

U-1054 ONYCHOMYCOSIS OF THE TOENAIL CAUSED BY TRICOPHYTON RUBRUM OR TRICHOPHYTON

PATENT AND EXCLUSIVITY TERMS

ADB 56 of 78

PATENT USE

MENTAGROPHYTES, ONCE DAILY USE FOR 12 CONSECUTIVE WEEKS

U-1055 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH A THIAZOLIDINEDIONE (TZD) AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A TZD OR METFORMIN ALONE

U-1056 TREATMENT OF PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE

U-1057 TREATMENT OF INFLAMMATION AND PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE

U-1058 USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

U-1059 ADJUNCTIVE THERAPY TO DIET TO PATIENTS WITH HYPERTRIGLYCERIDEMIA

U-1060 ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH ELEVATED CHOLESTEROL AND/OR LIPID LEVELS

U-1061 ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH MIXED DYSLIPIDEMIA

U-1062 ADMINISTRATION OF APPROVED PRODUCT FOR TREATMENT OF ALZHEIMER'S DISEASE

U-1063 TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA

U-1064 TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA

U-1065 METHOD OF TREATING ANDROGEN RESPONSIVE OR MEDICATED CONDITION IN A MAMMAL BY ADMINISTERING A SAFE & EFFECTIVE AMOUNT OF DUTASTERIDE OR A PHARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF.. CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY

U-1066 METHOD OF TREATING AN ANDROGEN RESPONSE OR MEDIATED DISEASE IN A MAMMAL BY ADMINISTERING AN EFFECTIVE ANDROGEN RESPONSIVE OR MEDICATED DISEASE AMOUNT OF DUTASTERIDE..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERPLASIA

U-1067 TREATMENT OF CANCER

U-1068 TREATMENT OF ASTHMA

U-1069 A METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING AN EXCLUSIVE COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION

U-1070 A METHOD TO CONTROL ABUSE OF A SENSITIVE DRUG BY CONTROLLING WITH A COMPUTER PROCESSOR THE DISTRIBUTION OF THE SENSITIVE DRUG VIA AN EXCLUSIVITY CENTRAL PHARMACY THAT MAINTAINS A CENTRAL DATABASE

U-1071 METHOD OF TREATING BLADDER DYSFUNCTION WITH ONCE A DAY TROSPIDIUM SALT FORMULATION

U-1072 THE MANAGEMENT OF MODERATE TO SEVERE CHRONIC PAIN IN PATIENTS REQUIRING A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC FOR AN EXTENDED PERIOD OF TIME

U-1073 USE FOR THE TREATMENT OF ASTHMA AND COPD

U-1074 USE OF EXENATIDE MAY RESULT IN REDUCTION IN BODY WEIGHT

U-1075 USE FOR THE TREATMENT OF ASTHMA

U-1076 REDUCE CHRONIC SEVERE DROOLING (I.E., SIALORRHEA) IN PATIENTS WITH NEUROLOGIC CONDITIONS ASSOCIATED WITH PROBLEM DROOLING

U-1077 PRETREATMENT OF PATIENTS WITH VITAMIN B12 AND FOLIC ACID PRIOR TO PEMETREXED DISODIUM ADMINISTRATION

U-1078 TREATMENT OF ACNE

U-1079 REVLIMID (LENALIDOMIDE) IS INDICATED FOR THE TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)

U-1080 METHOD TO TREAT PULMONARY HYPERTENSION BY ADMINISTERING AMBRISENTAN TO A PATIENT

U-1081 LUMIGAN IS A PROSTAGLANDIN ANALOG INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION

U-1082 USE OF A COMBINATION OF TOBRAMYCIN AND DEXAMETHASONE TO TREAT OCULAR INFLAMMATION WHERE AN INFECTION OR RISK OF INFECTION EXISTS

U-1083 ACUTE TREATMENT OF MIGRAINE ATTACKS, WITH OR WITHOUT AURA, AND THE TREATMENT OF CLUSTER HEADACHE EPISODES

U-1084 RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER

U-1085 METHOD FOR TREATING IRRITABLE BOWEL SYNDROME AND METHOD FOR TREATING ABDOMINAL DISCOMFORT ASSOCIATED WITH IRRITABLE BOWEL SYNDROME

U-1086 TREATMENT OF AUTOIMMUNE DISEASE

U-1087 DETECTION OF NON-MUSCLE INVASIVE PAPILLARY CANCER OF THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY

U-1088 RELIEF OF MUSCLE SPASM

U-1089 INHIBITION OF THROMBIN

U-1090 LO OESTRIN FE IS INDICATED FOR THE PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION

U-1091 ASSESSMENT OF BRONCHIAL HYPERRESPONSIVENESS IN PATIENTS 6 YEARS OF AGE OR OLDER WHO DO NOT HAVE CLINICALLY APPARENT ASTHMA

U-1092 TREATMENT OF BREAST CANCER

U-1093 TREATMENT OF PSEUDOBULBAR AFFECT

U-1094 MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN

U-1095 METHOD OF TREATING OCULAR INFLAMMATION

U-1096 TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER

PATENT AND EXCLUSIVITY TERMS

ADB 57 of 78

PATENT USE

- U-1097 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH SAXAGLIPTIN AND METFORMIN IS APPROPRIATE
- U-1098 METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA
- U-1099 TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA
- U-1100 REDUCTION OF EXCESS ABDOMINAL FAT IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY
- U-1101 METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY
- U-1102 METHOD OF TREATING CATAPLEXY IN PATIENTS WITH NARCOLEPSY
- U-1103 TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
- U-1104 USE OF TRAMADOL FOR THE MANAGEMENT OF MODERATE TO MODERATELY SEVERE CHRONIC PAIN
- U-1105 TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS FOUR (4) YEARS OF AGE AND OLDER
- U-1106 TREATING HYPERTRIGLYCERIDEMIAS WITH REDUCTION OF FOOD EFFECT
- U-1107 TREATING HYPERCHOLESTEROLEMIAS WITH REDUCTION OF FOOD EFFECT
- U-1108 TREATING TYPE 2 DIABETES MELLITUS WITH EXENATIDE BY STIMULATING INSULIN RELEASE
- U-1109 TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL) IN CONNECTION WITH A SPECIAL PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)
- U-1110 METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING A COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION
- U-1111 NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
- U-1112 METHOD OF MR IMAGING OF A MAMMAL
- U-1113 TREATMENT AND PROPHYLAXIS OF INFLUENZA
- U-1114 TREATMENT WITH GABAPENTIN, INCLUDING TREATMENT OF NEUROPATHIC PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH POSTHERPETIC NEURALGIA
- U-1115 TREATMENT TO REDUCE THE RISK OF COPD EXACERBATIONS IN PATIENTS WITH SEVERE COPD ASSOCIATED WITH CHRONIC BRONCHITIS AND A HISTORY OF EXACERBATIONS
- U-1116 METHOD OF ADMINISTERING COLCHICINE TO FAMILIAL MEDITERRANEAN FEVER PATIENTS
- U-1117 TREATMENT OF BREAST CANCER
- U-1118 USE FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
- U-1119 CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING
- U-1120 TO REDUCE GASTROINTESTINAL SIDE EFFECTS ADMINISTER WITH A MEAL; AS STARTING DOSE ADMINISTER ONCE DAILY WITH EVENING MEAL
- U-1121 METHOD OF TREATING TRAVELERS' DIARRHEA
- U-1122 TREATMENT OF SECONDARILY INFECTED TRAUMATIC SKIN LESIONS DUE TO S. AUREUS AND S. PYOGENES
- U-1123 TREATMENT OF ALCOHOL DEPENDENCE
- U-1124 PREVENTION OF RELAPSE TO OPIOID DEPENDENCE, FOLLOWING OPIOID DETOXIFICATION
- U-1125 METHOD FOR THE DETECTION OF NEUROENDOCRINE TUMORS
- U-1126 USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE RECEIVED PRIOR CHEMOTHERAPY CONTAINING DOCETAXEL
- U-1127 TREATMENT OF PATENT DUCTUS ARTERIOSUS
- U-1128 TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN IN ADULT PATIENTS (≥ 18 YEARS OF AGE) WITH COMPENSATED LIVER DISEASE
- U-1129 TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN
- U-1130 SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR A NIGHT WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
- U-1131 TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN
- U-1132 TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-1133 SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-1134 TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-1135 TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A) AND INCREASE OF HDL-C
- U-1136 SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C

PATENT AND EXCLUSIVITY TERMS

ADB 58 of 78

PATENT USE

- U-1137 TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C
- U-1138 TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-1139 REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-1140 REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-1141 REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-1142 TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
- U-1143 REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
- U-1144 REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
- U-1145 REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
- U-1146 REDUCTION IN TG WITH REDUCED FLUSHING BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-1147 TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C
- U-1148 REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C
- U-1149 TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
- U-1150 TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, TG, LP(A), AND INCREASE OF HDL-C
- U-1151 TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, LP(A), AND INCREASE OF HDL-C
- U-1152 CYANOCOBALAMIN ADMINISTRATION THROUGH NASAL INFUSION
- U-1153 IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS, IS INDICATED FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTION IN ANTIRETROVIRAL TREATMENT-NAIVE ADULT PATIENTS, AS SET FORTH IN THE LABELING, INCLUDING I&U SECTION
- U-1154 TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMORS, RENAL CELL CARCINOMA AND ADVANCED PANCREATIC ENDOCRINE TUMORS, WITH SUNITINIB
- U-1155 USE OF THALIDOMIDE IN TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL)
- U-1156 TO REDUCE BLOOD PHENYLALANINE (PHE) LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA (HPA)
- U-1157 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES IN ADULTS AND CHILDREN 2 YEARS OF AGE AND OLDER AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
- U-1158 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
- U-1159 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES, SWELLING OF THE NASAL PASSAGES AND SINUS CONGESTION AND PRESSURE IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
- U-1160 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER AND 12 YEARS OF AGE AND OLDER
- U-1161 FOR THE TREATMENT AND PROPHYLAXIS OF GOUT FLARES & THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER
- U-1162 TREATMENT OF SEBORRHEIC DERMATITIS OF THE SCALP
- U-1163 METHOD OF TREATING THROMBOSIS
- U-1164 METHOD OF TREATING AN ARGATROBAN TREATABLE CONDITION
- U-1165 USE FOR THE TREATMENT OF MULTIPLE MYELOMA
- U-1166 A METHOD FOR TREATMENT OF GOUT FLARES DURING PROPHYLAXIS
- U-1167 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT)
- U-1168 THE LONG TERM, ONCE-DAILY MAINTENANCE BRONCHODILATOR TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
- U-1169 MANAGEMENT OF BREAKTHROUGH PAIN IN CANCER PATIENTS 18 YEARS OF AGE AND OLDER WHO ARE RECEIVING AND TOLERANT TO OPIOID THERAPY FOR THEIR UNDERLYING PERSISTENT CANCER PAIN

PATENT AND EXCLUSIVITY TERMS

ADB 59 of 78

PATENT USE

U-1170 TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
U-1171 REDUCTION OF THE RATE OF THROMBOTIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME
U-1172 TO REDUCE ELEVATED TOTAL-C, APO B, AND NON-HDL-C IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE IN COMBINATION WITH A STATIN
U-1173 TO REDUCE ELEVATED TOTAL-C, LDL-C, APO B AND NON-HDL-C IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE ALONE OR IN COMBINATION WITH A STATIN OR WITH FENOFIBRATE
U-1174 ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE WATER FOR INJECTION, 0.9% SODIUM CHLORIDE INJECTION, OR FLOLAN STERILE DILUENT FOR INJECTION PRIOR TO ADMINISTRATION
U-1175 REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION
U-1176 TREATMENT OR PREVENTION OF STROKE
U-1177 REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION
U-1178 RELIEF OF MODERATE TO SEVERE CHRONIC PAIN
U-1179 TREATMENT OF A CANCER MEDIATED BY AN ANAPLASTIC LYMPHOMA KINASE (ALK)
U-1180 TREATMENT OF THE FOLLOWING INFECTIONS: COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS
U-1181 A METHOD OF TREATING OR PREVENTING OCULAR PAIN IN A PATIENT
U-1182 TREATMENT OF CYCLIC HEAVY MENSTRUAL BLEEDING
U-1183 A METHOD FOR ADMINISTERING FOLLICLE STIMULATING HORMONE (FSH) FOR OVARIAN FOLLICLE OR TESTICULAR STIMULATION IN THE HUMAN
U-1184 TREATMENT OF ERECTILE DYSFUNCTION AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA
U-1185 TREATMENT OF OPIOID-INDUCED CONSTIPATION
U-1186 ADMINISTRATION OF AN INHALABLE POWDER COMPRISING TIOTROPIUM VIA DEVICE
U-1187 TREATMENT OF PATHOLOGICAL STATE BY ANTAGONIZING BRADYKININ RECEPTOR INCLUDING TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA (HAE)
U-1188 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE
U-1189 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH METFORMIN
U-1190 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH INSULIN
U-1191 METHOD OF TX TYPE 2 DM IN PTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBO WITH AN AGENT ACTING ON AN ATP-DEPENDENT CHANNEL IN BETA CELLS SUCH AS A SULFONYLUREA (INCL GLIPIZIDE, GLIMEPIRIDE & GLYBURIDE)
U-1192 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A SULFONYLUREA (SUCH AS GLIPIZIDE, GLIMEPIRIDE AND GLYBURIDE)
U-1193 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A PPAR-GAMMA AGONIST (SUCH AS PIOGLITAZONE AND ROSIGLITAZONE)
U-1194 METHOD FOR TREATING INSOMNIA
U-1195 PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5, WHICH MAY RESULT IN RENAL OSTEODYSTROPHY, WHILE AVOIDING HYPERPHOSPHATEMIA
U-1196 RELIEF OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS AND TO DECREASE RISK OF DEVELOPING UPPER GASTROINTESTINAL ULCERS IN PATIENTS WHO ARE TAKING IBUPROFEN FOR THOSE INDICATIONS
U-1197 METHOD OF TREATMENT OF CHILDREN WITH CENTRAL PRECOCIOUS PUBERTY
U-1198 RECTIV IS A NITRATE VASODILATOR INDICATED FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH CHRONIC ANAL FISSURE
U-1199 TREATMENT AND PREVENTION OF POSTMENOPAUSAL OR GLUCOCORTICOID-INDUCED OSTEOPOROSIS AND TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
U-1200 REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM
U-1201 FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
U-1202 METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME
U-1203 METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT
U-1204 TREATMENT OF UVEITIS
U-1205 TREATMENT OF MACULAR EDEMA
U-1206 DELIVERING AN OCULAR IMPLANT AS DESCRIBED IN THE DOSAGE AND ADMINISTRATION SECTION OF THE APPROVED LABELING OF OZURDEX
U-1207 INFANT USE AGED 1 MONTH TO LESS THAN ONE YEAR, GERD AND EROSIIVE ESOPHAGITIS

PATENT AND EXCLUSIVITY TERMS

ADB 60 of 78

PATENT USE

- U-1208 TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS
- U-1209 TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER
- U-1210 USE OF REVLIMID (LENALIDOMIDE) WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO REVLIMID (LENALIDOMIDE)
- U-1211 USE OF REVLIMID (LENALIDOMIDE) TO INHIBIT THE SECRETION OF PRO-INFLAMMATORY CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA
- U-1212 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA AND TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)
- U-1213 TOPICAL TREATMENT OF SEBORRHEIC DERMATITIS IN IMMUNOCOMPETENT PATIENTS 12 YEARS OF AGE AND OLDER
- U-1214 METHOD FOR RELIEVING CONSTIPATION IN A HUMAN PATIENT THAT COMPRISES ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING (I) 24MCG+/- 10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT
- U-1215 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)
- U-1216 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA
- U-1217 METHOD OF INCREASING HAIR GROWTH
- U-1218 METHOD OF STIMULATING HAIR GROWTH
- U-1219 METHOD OF INCREASING THE NUMBER OF HAIRS
- U-1220 TREATMENT OF RENAL CELL CARCINOMA
- U-1221 TO STIMULATE THE IMMUNE SYSTEM TO INDUCE T CELL PROLIFERATION
- U-1222 TO INHIBIT THE PROLIFERATIVE ACTIVITY OF NEOPLASTIC CELLS
- U-1223 METHOD FOR TREATING TYPE 2 DIABETES USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENATIDE
- U-1224 REDUCTIONS IN BODY WEIGHT ARE OBSERVED WITH EXENATIDE
- U-1225 ACCELERATING THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING PARTIAL LARGE OR SMALL BOWEL RESECTION SURGERY WITH PRIMARY ANASTOMOSIS
- U-1226 A METHOD OF PROVIDING A PREDETERMINED CONCENTRATION OF NITRIC OXIDE TO A PATIENT
- U-1227 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
- U-1228 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE ALONE OR IN COMBINATION WITH INSULIN
- U-1229 TREATMENT OF MILDLY TO MODERATELY ACTIVE ULCERATIVE COLITIS IN MALE PATIENTS
- U-1230 A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT
- U-1231 TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS
- U-1232 USE AS ANTICOAGULANT IN PTS W/ UNSTABLE ANGINA UNDERGOING PTCA; W/ PROVISIONAL USE OF GLYCOPROTEIN IIB/IIIA INHIBITOR, AS ANTICOAGULANT IN PTS UNDERGOING PCI AND FOR PTS W/, OR AT RISK OF, HIT/HITTS UNDERGOING PCI. INTENDED FOR USE W/ASPIRIN
- U-1233 TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION, ADMINISTERED WITH FOOD
- U-1234 FOR REDUCING TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES, AND TREATING HYPERTRIGLYCERIDEMIA
- U-1235 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION
- U-1236 USE OF THALOMID (THALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA
- U-1237 COMBO W/ OTHER ANTIRETROVIRALS FOR TX OF HIV-1 IN ANTIRETROVIRAL TX-EXPERIENCED PT 6 YEARS UP, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR AND OTHER ANTIRETROVIRALS
- U-1238 TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE
- U-1239 MAGNETIC RESONANCE IMAGING OF THE LIVER
- U-1240 TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION
- U-1241 MANAGEMENT OF MODERATE TO SEVERE PAIN BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED
- U-1242 PREVENTION OF RESPIRATORY DISTRESS (RDS) IN PREMATURE INFANTS
- U-1243 WITH DRY HANDS, GENTLY REMOVE THE SUPRENZA (PHENTERMINE HYDROCHLORIDE ODT) TABLET FROM THE BOTTLE. IMMEDIATELY PLACE THE SUPRENZA TABLET ON TOP OF THE TONGUE WHERE IT WILL DISSOLVE, THEN SWALLOW WITH OR WITHOUT WATER
- U-1244 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH SULFONYUREA
- U-1245 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH PIOGLITAZONE
- U-1246 SINGLE DOSE ADMINISTRATION INTO THE SURGICAL SITE TO PRODUCE POSTSURGICAL

PATENT AND EXCLUSIVITY TERMS

ADB 61 of 78

PATENT USE

ANALGESIA

- U-1247 MANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS
- U-1248 USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL MEDICATION ON THE SAME KNEE
- U-1249 TREATMENT OF MALE PATIENT HAVING A DISEASE OR CONDITION RESPONSIVE TO A TERATOGENIC DRUG
- U-1250 TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY OR SPINAL CORD INJURY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA
- U-1251 A METHOD OF CONTROLLING POSTOPERATIVE OCULAR PAIN AND BURNING/STINGING IN A PATIENT
- U-1252 METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE
- U-1253 METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY
- U-1254 METHOD FOR CHRONIC WIEGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN
- U-1255 METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY
- U-1256 TREATMENT OF SEBORRHEIC DERMATITIS
- U-1257 TREATMENT OF OPHTHALMIC DISORDERS
- U-1258 VISUALIZATION DURING VITRECTOMY PROCEDURES
- U-1259 PROPHYLAXIS OF HIV-1 INFECTION
- U-1260 TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY
- U-1261 REDUCTION OF THE RISK OF HOSPITALIZATION FOR ATRIAL FIBRILLATION
- U-1262 USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
- U-1263 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) OR CHRONIC BRONCHITIS
- U-1264 TREATMENT OF A RESPIRATORY DISEASE
- U-1265 PATENTED METHOD OF USING REPAGLINIDE IN COMBINATION WITH METFORMIN AS INDICATED FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
- U-1266 METHOD OF TREATING MIDDLE-OF-THE-NIGHT INSOMNIA
- U-1267 TREATMENT OF RHEUMATOID ARTHRITIS BY DELAYED RELEASE FORMULATION OF 1MG OR 2MG OF PREDNISONE
- U-1268 TREATMENT OF PULMONARY, GASTROINTESTINAL AND/OR RHEUMATOLOGICAL DISEASES OR CONDITIONS BY USE OF DELAYED RELEASE FORMULATIONS OF 1MG OR 2MG PREDNISONE
- U-1269 TREATMENT OF RHEUMATOLOGIC, ALLERGIC, PULMONARY, GASTROINTESTINAL, DERMATOLOGIC DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 5MG PREDNISONE TABLET
- U-1270 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH INSULIN (WITH OR WITHOUT METFORMIN AND/OR PIOGLITAZONE)
- U-1271 TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE (PH-) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN SECOND OR GREATER RELAPSE OR WHOSE DISEASE HAS PROGRESSED FOLLOWING TWO OR MORE ANTI-LEUKEMIA THERAPIES
- U-1272 TREATMENT OF SIGNS AND SYMPTOMS OF PARKINSON'S DISEASE BY APPLICATION OF CLAIMED TRANSDERMAL SYSTEM
- U-1273 TREATMENT OF RESTLESS LEGS SYNDROME BY APPLICATION OF CLAIMED TRANSDERMAL DELIVERY SYSTEM
- U-1274 TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY DUE TO CYSTIC FIBROSIS OR OTHER CONDITIONS
- U-1275 TREATMENT OF CHRONIC HEPATITIS B IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
- U-1276 MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
- U-1277 METHOD OF INCREASING EYELASH GROWTH INCLUDING LENGTH, THICKNESS, DARKNESS AND/OR NUMBER OF EYELASHES BY ADMINISTERING BIMATOPROST TO AN EYELID MARGIN
- U-1278 METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULTS
- U-1279 TREATMENT OF HIV INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE
- U-1280 USE OF A CALCIPOTRIENE CONTAINING FOAM FOR THE TREATMENT OF PSORIASIS
- U-1281 THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE PREVIOUSLY RECEIVED DOCETAXEL
- U-1282 PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING
- U-1283 A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA
- U-1284 A METHOD OF TREATING A NEOPLASM
- U-1285 TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS
- U-1286 A METHOD OF REDUCING THE RISK OF PULMONARY EDEMA IN PATIENTS IN NEED OF TREATMENT WITH INHALED NITRIC OXIDE
- U-1287 METHOD OF REDUCING TG LEVELS IN PATIENT SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA
- U-1288 TREATMENT OF ERECTILE DYSFUNCTION BY ADMINISTERING A FILM-COATED TABLET
- U-1289 MANAGEMENT OF MODERATE TO SEVERE ACUTE PAIN

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

U-1290 TREATMENT OF LUNG CANCER

U-1291 TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN PATIENTS WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE (15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION

U-1292 TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 1, 2, OR 5 MG PREDNISONE TABLET

U-1293 A METHOD OF LOWERING INTRAOCULAR PRESSURE IN A PATIENT WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION

U-1294 METHOD OF TREATING GLAUCOMA IN A PATIENT

U-1295 A METHOD OF TREATING A PATIENT WITH GLAUCOMA OR OCULAR HYPERTENSION

U-1296 USE OF PEMETREXED WITH PRIOR AND/OR REPEATED VITAMIN B12 AND FOLIC ACID ADMINISTRATION

U-1297 TREATMENT OF PULMONARY ARTERIAL HYPERTENSION BY INHIBITING ENDOTHELIN RECEPTORS

U-1298 ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES

U-1299 TREATMENT OF PATIENTS WITH LEUKEMIA INCLUDING CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML)

U-1300 TREATMENT OF PATIENTS WITH TYROSINE KINASE INHIBITOR (TKI) RESISTANT OR INTOLERANT CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML)

U-1301 TREATMENT OF DEEP VEIN THROMBOSIS (DVT)

U-1302 TREATMENT OF PULMONARY EMBOLISM (PE)

U-1303 REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM

U-1304 USE OF ONCE-A-DAY AMOXICILLIN PRODUCT TO TREAT TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES

U-1305 TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS, AND TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER, CO-ADMINISTERED WITH RITONAVIR (PREZISTA/RITONAVIR) AND WITH OTHER ANTIRETROVIRAL AGENTS

U-1306 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY

U-1307 IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-NAIVE ADULT PATIENTS WITH HIV-1 RNA LESS THAN OR EQUAL TO 100,000 AT THE START OF THERAPY

U-1308 MULTIPLE MYELOMA

U-1309 BONE METASTASES

U-1310 FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS

U-1311 METHOD OF TREATING CYSTIC FIBROSIS

U-1312 USE FOR THE TREATMENT OF HYPERGLYCEMIA

U-1313 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS

U-1314 USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

U-1315 THE LONG TERM TREATMENT OF PROPHYLACTIC MANAGEMENT OF OCULAR HYPERTENSION AND GLAUCOMA

U-1316 A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES

U-1317 TREATMENT OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA AND HYPERLIPOPROTEINEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

U-1318 TREATMENT OF HYPERCHOLESTEROLEMIA BY DECREASING THE AMOUNT OR ACTIVITY OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

U-1319 SYMPTOMATIC RELIEF OF NON-INFECTIOUS DIARRHEA

U-1320 TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME WHO ARE DEPENDENT ON PARENTERAL SUPPORT

U-1321 TREATMENT OF PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS

U-1322 METHOD OF REDUCING OCULAR HYPERTENSION

U-1323 REDUCING THE RISK OF STROKE

U-1324 MANAGEMENT OF CYSTIC FIBROSIS PATIENTS

U-1325 INDUCTION OF REMISSION IN PATIENTS WITH ACTIVE, MILD TO MODERATE ULCERATIVE COLITIS

U-1326 METHOD OF INDUCING CONTRACEPTION IN A FEMALE OF REPRODUCTIVE AGE WHO HAS NOT YET REACHED PREMENOPAUSE

U-1327 METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF, USING A FLOWABLE HYDROGEL FORMULATION

U-1328 METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF

PATENT AND EXCLUSIVITY TERMS

ADB 63 of 78

PATENT USE

- U-1329 TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER
- U-1330 METHODS OF TREATING LIPID METABOLISM AND GLYCOMETABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
- U-1331 METHODS OF REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
- U-1332 METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
- U-1333 METHODS OF LOWERING ELEVATED POST PRANDIAL BLOOD GLUCOSE LEVELS COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR
- U-1334 METHODS OF TREATING DIABETES COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
- U-1335 METHODS OF MODIFYING GLUCOSE METABOLISM AND TREATING DIABETES COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR AND ONE OR MORE OTHER THERAPEUTIC AGENTS SUCH AS METFORMIN
- U-1336 METHODS OF TREATING DIABETES COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR AND METFORMIN
- U-1337 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
- U-1338 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
- U-1339 METHODS OF TREATING DIABETES COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
- U-1340 METHODS OF TREATING LIPID METABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
- U-1341 METHODS OF TREATING GLYCOMETABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
- U-1342 METHODS OF REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
- U-1343 METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
- U-1344 METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN PREPARATION
- U-1345 USE IN RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN PATIENT WITH A DOSAGE UNIT COMPRISING 24MICROG+/- 10% OF A DRUG SUBSTANCE AND A PHARMACEUTICALLY SUITABLE EXCIPIENT
- U-1346 USE OF FEBUXOSTAT FOR THE MANAGEMENT OF HYPERURICEMIA IN PATIENTS SUFFERING FROM GOUT AND, WHEN USED WITH THEOPHYLLINE WITHOUT THE NEED FOR DOSE ADJUSTMENT OF THEOPHYLLINE
- U-1347 TREATMENT OF A SKIN DISORDER
- U-1348 TREATMENT OF OSTEOARTHRITIS
- U-1349 TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS
- U-1350 TREATMENT OF ANKYLOSING SPONDYLITIS
- U-1351 TREATMENT OF ACUTE PAIN
- U-1352 TREATMENT OF PRIMARY DYSMENORRHEA
- U-1353 ADJUNCTIVE THERAPY TO LIPID-LOWERING MEDICATIONS AND DIET TO REDUCE LOW DENSITY LIPOPROTEIN-CHOLESTEROL, APOLIPOPROTEIN B, TOTAL CHOLESTEROL, AND NON-HIGH DENSITY LIPOPROTEIN CHOLESTEROL IN PTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
- U-1354 INHIBITION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN HYPERSTIMULATION WITH FSH
- U-1355 MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHOD FOR TREATING A RESPIRATORY DISEASE IN A CHILD
- U-1356 TREATMENT OF NASAL SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER. TREATMENT OF NASAL SYMPTOMS ASSOCIATED W PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER
- U-1357 TREATMENT OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHODS FOR TREATING A RESPIRATORY DISEASE IN A CHILD
- U-1358 TREATMENT OF BACTERIAL INFECTIONS IN THE NASAL PASSAGE OF ADULT PATIENTS AND HEALTH CARE WORKERS WITH METHICILLIN RESISTANT S. AUREUS
- U-1359 USE OF POMALIDOMIDE TO INHIBIT THE SECRETION OF PRO-INFLAMMATION CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA

PATENT AND EXCLUSIVITY TERMS

PATENT USE

U-1360	USE OF POMALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA
U-1361	USE OF POMALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO POMALIDOMIDE
U-1362	TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG PREDNISONE TABLET
U-1363	A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING/STINGING FOLLOWING CORNEAL SURGERY
U-1364	MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
U-1365	PROPHYLAXIS OF ALLOGRAFT REJECTION IN ADULT PATIENTS RECEIVING A LIVER TRANSPLANT
U-1366	TREATMENT OF INFERTILITY THROUGH INDUCTION OF OVULATION AND PREGNANCY TO ANOVULATORY INFERTILE WOMEN
U-1367	METHOD OF ADMINISTERING FSH FOR THE TREATMENT OF INFERTILITY THROUGH INDUCTION OF OVULATION AND PREGNANCY IN ANOVULATORY INFERTILE WOMEN
U-1368	TREATMENT OF SOLID EXCRETORY SYSTEM TUMORS; ADVANCED RENAL CELL CARCINOMA (RCC), AFTER FAILURE OF TREATMENT WITH SUNITINIB OR SORAFENIB
U-1369	TREATMENT OF VAGINAL SYMPTOMS OF UROGENITAL ATROPHY BY ORALLY ADMINISTERING OSPEMIFENE WITH FOOD TO ENHANCE BIOAVAILABILITY OF OSPEMIFENE
U-1370	TREATMENT OF DYSpareunia ASSOCIATED WITH MENOPAUSE
U-1371	REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH ELEVATED INTRAOCULAR PRESSURE OR GLAUCOMA
U-1372	ADMINISTRATION WITHOUT FOOD FOR TREATMENT OF HIV-1 INFECTION
U-1373	METHOD OF TREATING ACETAMINOPHEN OVERDOSE WITH ACETYLCYSTEINE SOLUTIONS
U-1374	TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML)
U-1375	ADASUVE IS A TYPICAL ANTIPSYCHOTIC INDICATED FOR THE ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I DISORDER IN ADULTS
U-1376	TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS
U-1377	IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA
U-1378	TREATMENT OF A NITROGEN METABOLISM DISORDER
U-1379	IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS
U-1380	IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS WHEREIN THE PATIENT HAS CARDIOVASCULAR DISEASE
U-1381	USE OF PRASUGREL AND ASPIRIN IN PATIENTS REQUIRING THE REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS
U-1382	TREATMENT OF NAUSEA AND VOMITING OF PREGNANCY IN WOMEN WHO DO NOT RESPOND TO CONSERVATIVE MANAGEMENT
U-1383	DOSAGE ADJUSTMENT OF A NITROGEN SCAVENGING DRUG IN THE TREATMENT OF A UREA CYCLE DISORDER
U-1384	METHOD OF TREATING MULTIPLE SCLEROSIS
U-1385	METHOD OF TREATING AN AUTOIMMUNE DISEASE SELECTED FROM AUTOIMMUNE POLYARTHRITIS AND MULTIPLE SCLEROSIS BUT NOT TREATING PSORIATIC ARTHRITIS
U-1386	A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF A PERSON IN NEED THEREOF
U-1387	REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAILY WITH MORNING AND EVENING MEALS
U-1388	TREATMENT OF PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS
U-1389	ELLA IS A PROGESTERONE AGONIST/ANTAGONIST EMERGENCY CONTRACEPTION INDICATED FOR THE PREVENTION OF PREGNANCY FOLLOWING UNPROTECTED INTERCOURSE OR A KNOWN OR SUSPECTED CONTRACEPTIVE FAILURE. ELLA CAN BE TAKEN WITH OR WITHOUT FOOD
U-1390	A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF AN ADULT MALE SUBJECT IN NEED THEREOF
U-1391	METHOD FOR TREATING OPIOID-INDUCED CONSTIPATION
U-1392	METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN PATIENT WITH OPIOID- INDUCED CONSTIPATION
U-1393	METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION
U-1394	METHOD FOR RELIEVING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION THAT COMPRISES ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING (I) 24MICROG +/- 10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT
U-1395	USE IN RELIEVING OR PREVENTING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION WITH A DOSAGE UNIT COMPRISING 24MICROG +/- 10% OF A DRUG SUBSTANCE AND A PHARMACEUTICALLY SUITABLE EXCIPIENT
U-1396	TREATMENT OF ADVANCED HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE BREAST CANCER IN

PATENT AND EXCLUSIVITY TERMS

ADB 65 of 78

PATENT USE

COMBINATION WITH EXEMESTANE AFTER FAILURE OF TREATMENT WITH LETROZOLE OR ANASTROZOLE

U-1397 USE AS AN ANTISEPTIC FOR THE PREPARATION OF A PATIENT'S SKIN PRIOR TO SURGERY

U-1398 METHOD OF TREATING CHRONIC HEPATITIS C

U-1399 MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES

U-1400 FOR THE TREATMENT OF PRIMARY HYPERLIPIDEMIA, MIXED HYPERLIPIDEMIA OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

U-1401 INDICATED FOR LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PTS WITH A HISTORY OF EXACERBATIONS

U-1402 FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR INDOLENT B-CELL NON-HODGKIN LYMPHOMA (NHL)

U-1403 FIRST-LINE TREATMENT OF METASTATIC NON SMAL-CELL LUNG CANCER (NSCLC) WITH EGFR EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST

U-1404 METHOD FOR TREATING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION BY OPENING CIC CHANNELS

U-1405 THERAPEUTIC TREATMENT OF BONE METASTASES

U-1406 TREATMENT OF MELANOMA

U-1407 TREATMENT OF NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH + CML)

U-1408 TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE OR OLDER

U-1409 TREATMENT OF HIV-1 BY ONCE DAILY ADMINISTRATION

U-1410 TREATMENT OF CORTICOSTEROID-RESPONSIVE DERMATOSES

U-1411 THIS DRUG IS ADMINISTERED BY SUBLINGUAL ROUTE TO HUMANS FOR MAINTENANCE TREATMENT OF OPIOID DEPENDENCE

U-1412 TREATMENT OF ATOPIC DERMATITIS

U-1413 ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH FLOLAN STERILE DILUENT FOR INJECTION PRIOR TO INFUSION

U-1414 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL)

U-1415 TREATING A PATIENT HAVING A CONDITION SUSCEPTIBLE TO TREATMENT WITH METHYLPHENIDATE, SUCH AS ADHD, BY ADMINISTERING THE FORMULATION RECITED IN CLAIMS 1 OR 2

U-1416 USE OF FENOFIBRATE FOR REDUCING ELEVATED TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES

U-1417 USE FOR TREATMENT OF HELICOBACTER INFECTIONS

U-1418 TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAFV600E MUTATION AS DETECTED BY AN FDA APPROVED TEST

U-1419 TREATMENT OF ACUTE CYANIDE POISONING THAT IS JUDGED TO BE LIFE THREATENING

U-1420 METHOD OF ONCE A DAY ADMINISTRATION

U-1421 SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE

U-1422 METHOD OF TREATING PATIENTS NEEDING AN IRON SUPPLEMENT

U-1423 AMYVID IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE BETA-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT

U-1424 LONG-TERM, ONCE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS

U-1425 SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE

U-1426 USE FOR TREATMENT OF DIAPER DERMATITIS COMPLICATED BY CANDIDIASIS

U-1427 ALKYLATING DRUG INDICATED FOR THE TOPICAL TREATMENT OF STAGE IA AND IB MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN DIRECTED THERAPY

U-1428 TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA

U-1429 TREATMENT OF PATIENTS WITH BREAST CANCER WHOSE TUMORS OVEREXPRESS THE HER2 RECEPTOR

U-1430 TREATMENT OF ALLERGIC RHINITIS, INCLUDING SEASONAL AND PERENNIAL ALLERGIC RHINITIS

U-1431 METHOD OF TREATING HYPERGLYCEMIA TO IMPROVE GLYCEMIC CONTROL IN A PATIENT BY ORAL ADMIN OF ONCE A DAY OSMOTIC DOSAGE FORM OF GLIPIZIDE WITH POLYETHYLENE OXIDE, HYDROXYPROPYLMETHYLCELLULOSE, CELLULOSE ACETATE, AND SODIUM CHLORIDE

U-1432 METHOD OF TREATMENT OF IRON-RELATED CONDITIONS WITH AT LEAST 0.6 GRAMS OF ELEMENTAL IRON VIA AN IRON CARBOHYDRATE COMPLEX

U-1433 IMPROVEMENTS OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS

U-1434 TREATMENT OF PANCREATIC CANCER

PATENT AND EXCLUSIVITY TERMS

PATENT USE

- U-1435 COMBINATION USE OF TOPICAL DICLOFENAC ON THE KNEE AND ADMINISTRATION OF AN ORAL NSAID.
- U-1436 USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL AGENT SELECTED FROM SUNSCREEN AND INSECT REPELLANT
- U-1437 ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE DILUENT FOR FLOLAN OR STERILE DILUENT FOR EPOPROSTENOL SODIUM PRIOR TO ADMINISTRATION
- U-1438 ZINGO INTRADERMAL INJECTION SYSTEM IS A DRUG DELIVERY SYSTEM THAT IS CAPABLE OF DELIVERING FINE DRY POWDERED LIDOCAINE HYDROCHLORIDE MONOHYDRATE FOR LOCAL ANESTHETIC ACTION
- U-1439 METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION
- U-1440 USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS
- U-1441 A METHOD OF TREATING OR REDUCING OCULAR PAIN AND BURNING/STINGING
- U-1442 SUBCUTANEOUS INJECTION OF METHOTREXATE
- U-1443 ACCELERATING THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING SURGERIES THAT INCLUDE PARTIAL BOWEL RESECTION WITH PRIMARY ANASTOMOSIS
- U-1444 A DOSING REGIMEN OF AGGRASTAT (TIROFIBAN HYDROCHLORIDE) (25MCG/KG FOLLOWED BY 0.15MCG/KG/MIN INFUSION) TO REDUCE THE RATE OF THROMBOTIC CORONARY EVENTS ASSOCIATED WITH ACUTE CORONARY SYNDROME (ACS) IN PATIENTS WITH NON-ST ELEVATION
- U-1445 METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION BY ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN AND A POLYSORBATE, WHEREIN THE POLYSORBATE REPRESENTS 0.1 TO 1% OF THE WEIGHT OF SAID PHARMACEUTICAL COMPOSITION
- U-1446 METHOD OF TREATING PULMONARY HYPERTENSION COMPRISING ADMINISTERING MACITENTAN IN COMBINATION WITH A COMPOUND HAVING PHOSPHODIESTERASE-5 INHIBITORY PROPERTIES
- U-1447 TREATING PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIA
- U-1448 TREATING SEVERE HYPERTRIGLYCERIDEMIA
- U-1449 METHOD OF ALLEVIATING A SKIN CONDITION
- U-1450 TREATMENT OF ALLERGIC RHINITIS SYMPTOMS
- U-1451 APPROVED INDICATIONS: APTIOM (ESLICARBAZEPINE ACETATE) IS INDICATED AS ADJUNCTIVE TREATMENT OF PARTIAL-ONSET SEIZURES AND APPROVED IN PATIENTS WITH EPILEPSY. PATENT CLAIMS: IN A METHOD OF TREATING A SUBJECT AFFLICTED WITH EPILEPSY
- U-1452 METHOD FOR CHRONIC WEIGHT MANAGEMENT
- U-1453 A METHOD OF TREATING HYPOXIC RESPIRATORY FAILURE BY VERIFYING GAS INFORMATION OF NITRIC OXIDE PRIOR TO DELIVERY TO PATIENT
- U-1454 PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS
- U-1455 TREATMENT OF PERIANAL WARTS
- U-1456 TREATMENT OF MANTLE CELL LYMPHOMA
- U-1457 A METHOD OF PURGING A NITRIC OXIDE DELIVERY SYSTEM
- U-1458 A METHOD OF REDUCING INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
- U-1459 TREATMENT OF CARCINOMA OF THE THYROID
- U-1460 TREATMENT OF HERPES LABIALIS
- U-1461 A METHOD OF GENERATING AN INJECTABLE FOAM OF CONTROLLED DENSITY AND BUBBLE SIZE
- U-1462 A METHOD OF USING A SCLEROSING AGENT FOR THE TREATMENT OF INCOMPETENT GREAT SAPHENOUS VEINS, ACCESSORY SAPHENOUS VEINS AND VISIBLE VARICOSITIES OF THE GREAT SAPHENOUS (GSV) SYSTEM ABOVE AND BELOW THE KNEE
- U-1463 A METHOD OF INTRAVENOUS INJECTION USING ULTRASOUND GUIDANCE, ADMINISTERED VIA A SINGLE CANNULA INTO THE LUMEN OF THE TARGET INCOMPETENT TRUNK VEINS OR BY DIRECT INJECTION INTO VARICOSITIES
- U-1464 TREATMENT OF OPIOID DEPENDENCE/SUBLINGUAL OR BUCCAL APPLICATION
- U-1465 USE OF THALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO THALIDOMIDE
- U-1466 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
- U-1467 METHOD OF TREATING HEPATITIS C
- U-1468 CONTROL OF PHOSPHOROUS LEVELS IN PATIENTS
- U-1469 USE OF PHOSYLRA FOR REDUCTION OF SERUM PHOSPHOROUS IN PATIENTS
- U-1470 FOR THE TREATMENT OF HEPATITIS C
- U-1471 A METHOD FOR TREATING CARDIOVASCULAR DISEASE COMPRISING ADMINISTERING A RECONSTITUTED LYOPHILIZED PHARMACEUTICAL COMPOSITION COMPRISING EPOPROSTENOL, ARGININE AND SODIUM HYDROXIDE.
- U-1472 INTENSIVE CARE UNIT SEDATION, INCLUDING SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES
- U-1473 MANAGEMENT OF RISK OF DRONEDARONE/BETA-BLOCKER INTERACTION IN PATIENTS IN SINUS RYTHM WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF
- U-1474 A METHOD FOR THE TREATMENT OF A PATIENT SUFFERING FROM A DISEASE TREATABLE WITH ROTIGOTINE, COMPRISING APPLYING THE CLAIMED TRANSDERMAL DELIVERY SYSTEM (TDS) TO THE SKIN OF THE PATIENT

PATENT AND EXCLUSIVITY TERMS

ADB 67 of 78

PATENT USE

U-1475 USE OF ORENITRAM FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1).

U-1476 INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA.

U-1477 USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL PRESCRIPTION MEDICATION ON THE SAME KNEE

U-1478 METHOD OF REDUCING TG LEVELS IN PATIENT ON STATIN THERAPY SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA

U-1479 INCREASE TEAR PRODUCTION TO TREAT PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE).

U-1480 TREATMENT OF ADVANCED RENAL CELL CARCINOMA

U-1481 REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE

U-1482 DICLOFENAC POTASSIUM FOR RELIEF OF MILD TO MODERATE ACUTE PAIN

U-1483 INCREASE TEAR PRODUCTION IN PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE).

U-1484 COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND CHILDREN (6 YEARS OF AGE AND OLDER)

U-1485 TREATING A SUBJECT UNDERGOING ABDOMINAL SURGERY BY ADMINISTERING ALVIMOPAN TO ACCELERATE THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING SURGERIES THAT INCLUDE PARTIAL BOWEL RESECTION WITH PRIMARY ANASTOMOSIS

U-1486 TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER

U-1487 METHOD OF INCREASING EYELASH GROWTH

U-1488 USE OF TOPICAL DICLOFENAC FOR TREATING PAIN

U-1489 USE OF TOPICAL DICLOFENAC ON A JOINT FOR TREATING OSTEOARTHRITIS

U-1490 FOR USE IN PATIENTS HAVING SYMPTOMATIC OR PROGRESSIVE MEDULLARY THYROID CANCER, WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC DISEASE

U-1491 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

U-1492 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER

U-1493 METHOD FOR PREVENTING ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS

U-1494 SUBLINGUAL OR BUCCAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE

U-1495 RISK REDUCTION OF REBLEEDING IN PTS FOLLOWING THERAPEUTIC ENDOSCOPY FOR ACUTE BLEEDING GASTRIC OR DUODENAL ULCERS IN ADULTS.

U-1496 METHOD TO TREAT HEMANGIOMA.

U-1497 NEURACEQ IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE P-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT

U-1498 METHOD OF TREATING PATIENTS WITH GASTRIC RETENTIVE DOSAGE FORM

U-1499 MANAGEMENT OF ACUTE PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA

U-1500 TESTOSTERONE REPLACEMENT THERAPY IN ADULT MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE; PRIMARY HYPOGONADISM (CONGENITAL OR ACQUIRED); HYPOGONADOTROPIC HYPOGONADISM (CONGENITAL OR ACQUIRED).

U-1501 PROPHYLAXIS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM

U-1502 PROPHYLAXIS OF PULMONARY EMBOLISM

U-1503 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN

U-1504 USE OF OTEZLA (APREMILAST) FOR INHIBITING PDE4

U-1505 USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIATIC ARTHRITIS

U-1506 TREATMENT OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR (GIST), INCLUDING BUT NOT LIMITED TO PATIENTS PREVIOUSLY TREATED WITH IMATINIB AND PATIENTS WITH GIST HAVING RESISTANCE TO A KIT TYROSINE KINASE INHIBITOR

U-1507 TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN

U-1508 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT BY ORALLY ADMINISTERING A PLURALITY OF COMPOSITE SUBUNITS AS CLAIMED

U-1509 TREATMENT OF FREQUENT HEARTBURN BY ADMINISTERING A GASTRIC ACID REDUCER

U-1510 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED.

U-1511 TREATMENT OF HYPERTRIGLYCERIDEMIA

U-1512 REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS

U-1513 TREATMENT OF HIV-1 INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS

U-1514 MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER BY BUCCAL OR SUBLINGUAL ADMINISTRATION OF FENTANYL

U-1515 METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULT PATIENTS.

U-1516 METHOD OF TREATING CHRONIC IDIOPATHIC CONSTIPATION IN ADULT PATIENTS.

PATENT AND EXCLUSIVITY TERMS

ADB 68 of 78

PATENT USE

- U-1517 TREATMENT OF BACTERIAL INFECTIONS USING A TWO-DOSE REGIMEN OF DALBAVANCIN.
- U-1518 MAINTAINING PUPIL SIZE BY PREVENTING INTRAOPERATIVE MIOSIS AND REDUCING POSTOPERATIVE OCULAR PAIN
- U-1519 METHOD FOR THE LONG TERM TREATMENT OF CHRONIC CONSTIPATION IN A HUMAN SUBJECT WITH IRRITABLE BOWEL SYNDROME
- U-1520 METHOD FOR THE LONG TERM TREATMENT OF CHRONIC CONSTIPATION IN A HUMAN SUBJECT
- U-1521 MAINTENANCE TREATMENT OF OPIOID DEPENDENCE
- U-1522 TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE
- U-1523 METHOD OF INDUCING TOPICAL ANESTHESIA IN THE EYE
- U-1524 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
- U-1525 METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY
- U-1526 THE TREATMENT OF PATIENTS WITH TRAVELERS' DIARRHEA (TD) OR THE REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE
- U-1527 FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY
- U-1528 A METHOD OF LOWERING INTRAOCULAR PRESSURE
- U-1529 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
- U-1530 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION
- U-1531 METHOD FOR TRANSDERMAL DELIVERY OF TESTOSTERONE
- U-1532 METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS AND/OR CATAPLEXY IN NARCOLEPSY PATIENTS WITH SODIUM OXYBATE WHEN DIVALPROEX SODIUM IS CONCOMITANTLY ADMINISTERED.
- U-1533 PULMONARY ADMINISTRATION OF PARTICLES COMPRISING A DIKETOPIPERAZINE AND INSULIN.
- U-1534 ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN COMPLEXED WITH A DIKETOPIPERAZINE.
- U-1535 ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN COMPLEXED WITH MICROPARTICLES OF A DIKETOPIPERAZINE.
- U-1536 ADMINISTRATION OF A COMPOSITION COMPRISING A DIKETOPIPERAZINE AND INSULIN.
- U-1537 TREATMENT OF A PATIENT HAVING DIABETES MELLITUS WITH A PRANDIAL RAPID ACTING INSULIN.
- U-1538 ADMINISTRATION OF FDKP MICROPARTICLES COMPRISING INSULIN.
- U-1539 PULMONARY ADMINISTRATION OF AN INSULIN COMPOSITION COMPRISING FDKP AT THE BEGINNING OF A MEAL TO A PATIENT ALSO BEING TREATED WITH A LONG-ACTING INSULIN.
- U-1540 BUTRANS IS A PARTIAL OPIOID AGONIST PRODUCT INDICATED FOR THE MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.
- U-1541 TREATMENT OF PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX (TSC) WHO HAVE SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) THAT REQUIRES THERAPEUTIC INTERVENTION BUT CANNOT BE CURATIVELY RESECTED.
- U-1542 FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND/OR NON-HODGKINS LYMPHOMA
- U-1543 TREATMENT OF A PATIENT BY ADMINISTERING THE FORMULATION RECITED IN CLAIM 1 OR CLAIM 23
- U-1544 TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA (PTCL).
- U-1545 A METHOD OF TRANSDERMALLY DELIVERING TESTOSTERONE
- U-1546 FOR USE IN THE TREATMENT OF MALIGNANT HYPERTHERMIA IN CONJUNCTION WITH APPROPRIATE SUPPORTIVE MEASURES AND FOR THE PREVENTION OF MALIGNANT HYPERTHERMIA IN PATIENTS AT HIGH RISK.
- U-1547 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), CHRONIC BRONCHITIS OR EMPHYSEMA
- U-1548 FOR THE LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS
- U-1549 FOR THE TREATMENT OF PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA
- U-1550 METHOD OF TREATING METASTATIC PAPILLARY RENAL CELL CARCINOMA WITH TEMSIROLIMUS.
- U-1551 METHOD OF TREATING PAPILLARY RENAL CELL CARCINOMA WITH TEMSIROLIMUS, IN THE ABSENCE OF INTERFERON ALPHA.
- U-1552 FOR HEALING OF ALL GRADES OF EROSIIVE ESOPHAGITIS (EE)
- U-1553 TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN
- U-1554 FOR THE TREATMENT OF HEARTBURN ASSOCIATED WITH SYMPTOMATIC NON-EROSIVE GASTROESOPHAGEAL DISEASE (GERD)
- U-1555 MANAGEMENT OF MODERATE TO SEVERE PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.
- U-1556 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM

PATENT AND EXCLUSIVITY TERMS

PATENT USE

- U-1557 OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.
A METHOD OF TESTOSTERONE REPLACEMENT THERAPY COMPRISING THE STEP OF NASALLY ADMINISTERING TO A PATIENT IN NEED OF SUCH TREATMENT AN EFFECTIVE AMOUNT OF TESTOSTERONE GEL FORMULATION.
- U-1558 FOR THE TREATMENT OF PATIENTS WITH RELAPSED FOLLICULAR B-CELL NON-HODGKIN LYMPHOMA OR [RELAPSED] SMALL LYMPHOCYTIC LYMPHOMA
- U-1559 INDICATED FOR THE ONCE-DAILY MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN PATIENTS AGED 12 YEARS OF AGE AND OLDER
- U-1560 A METHOD OF DISRUPTING LEUKOCYTE FUNCTION, INCLUDING AS AN INHIBITOR OF PI3KDELTA KINASE
- U-1561 USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIATIC ARTHRITIS
- U-1562 TREATMENT OF PATIENTS WITH HEPATIC ENCEPHALOPATHY (HE)
- U-1563 A METHOD OF TRANSDERMAL ADMINISTRATION OF A PHYSIOLOGICALLY ACTIVE AGENT TO A SUBJECT.
- U-1564 A METHOD OF TREATING GAUCHER'S DISEASE
- U-1565 METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE
- U-1566 METHOD OF TREATING, AS MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER
- U-1567 METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER
- U-1568 METHOD OF TREATING, AS MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE
- U-1569 TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS
- U-1570 TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS USING A SINGLE DOSE
- U-1571 TREATMENT OF GAUCHER DISEASE TYPE 1
- U-1572 TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION.
- U-1573 USE OF RUXOLITINIB (JAKAFI) FOR INHIBITING JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2.
- U-1574 A METHOD OF CATALYZING THE HYDROLYSIS OF GLUCOCEREBROSIDE TO GLUCOSE AND CERAMIDE.
- U-1575 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
- U-1576 TREATMENT OF LEUKEMIA
- U-1577 CONTROL OF SERUM PHOSPHOROUS LEVELS
- U-1578 TREATMENT OF ACUTE OTITIS MEDIA
- U-1579 USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
- U-1580 USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAD RECEIVED PRIOR DOCETAXEL CHEMOTHERAPY
- U-1581 IN COMBINATION WITH DABRAFENIB FOR THE TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA.
- U-1582 TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA
- U-1583 FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY
- U-1584 USE OF NALTREXONE AND BUPROPION IN A LAYERED FORMULATION FOR CHRONIC WEIGHT MANAGEMENT FOR AFFECTING WEIGHT LOSS
- U-1585 USE OF NALTREXONE AND BUPROPION BASED ON AN ESCALATING DOSE SCHEDULE
- U-1586 FOR EFFECT ON BLOOD GLUCOSE PARAMETERS IN PATIENTS WITH INSULIN RESISTANCE
- U-1587 SINGLE-DOSE INFILTRATION INTO THE SURGICAL SITE TO PRODUCE POSTSURGICAL ANALGESIA.
- U-1588 THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC) .
- U-1589 METHOD OF USE FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA
- U-1590 KUVAN IS INDICATED TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA
- U-1591 TREATMENT OF ASTHMA IN PATIENTS AGED 12 YEARS AND OLDER
- U-1592 TO REDUCE SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE
- U-1593 MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA, AND REDUCTION OF EXACERBATIONS IN COPD PATIENTS.
- U-1594 DILATION OF THE PUPIL
- U-1595 USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIASIS
- U-1596 LAMICTAL IS AN ANTIEPILEPTIC DRUG (AED) INDICATED FOR: EPILEPSY-ADJUNCTIVE THERAPY IN PATIENTS GREATER THAN OR EQUAL TO 2 YEARS OF AGE: (1.1) PARTIAL SEIZURES PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
- U-1597 TREATMENT OF DIABETIC MACULAR EDEMA

PATENT AND EXCLUSIVITY TERMS**PATENT USE**

- U-1598 METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE
- U-1599 MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY
- U-1600 DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
- U-1601 DOSE ESCALATION OVER 14 DAYS FOR TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
- U-1602 METHOD OF ADMINISTERING PIRFENIDONE CAPSULES TO TREAT A FIBROTIC CONDITION
- U-1603 METHOD FOR ADMINISTERING PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE
- U-1604 METHOD FOR ADMINISTERING PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH A STRONG INHIBITOR OF CYP1A2
- U-1605 METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY DISCONTINUING SMOKING OR BY DISCONTINUING OR AVOIDING ANOTHER STRONG CYP1A2 INDUCER
- U-1606 METHOD FOR ADMINISTERING PIRFENIDONE WHILE AVOIDING OR DISCONTINUING CONCOMITANT USE OF A MODERATE TO STRONG INHIBITOR OF BOTH CYP1A2 AND ANOTHER CYP ENZYME INVOLVED IN PIRFENIDONE METABOLISM
- U-1607 METHOD OF ADMINISTERING A DOSAGE FORM THAT INCLUDES A GRANULATE FORMULATION OF PIRFENIDONE TO TREAT A FIBROTIC CONDITION
- U-1608 DOSE ESCALATION OVER 14 DAYS FOR TREATMENT OF A FIBROSIS CONDITION
- U-1609 CONTINUED DOSING OR DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
- U-1610 CONTINUED DOSING OR DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN USE OF PIRFENIDONE
- U-1611 METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY DISCONTINUING SMOKING OR BY DISCONTINUING A STRONG CYP1A2 INDUCER
- U-1612 METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY AVOIDING SMOKING OR BY AVOIDING ANOTHER STRONG CYP1A2 INDUCER
- U-1613 DOSAGE MODIFICATION IN TREATMENT WITH PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH CIPROFLOXACIN
- U-1614 USE OF TOPICAL DICLOFENAC SODIUM FOR TREATING PAIN
- U-1615 FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL
- U-1616 NASAL ADMINISTRATION OF A TESTOSTERONE GEL TO A PATIENT TO TREAT THE PATIENT FOR A CONDITION ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
- U-1617 METHOD OF TREATING MEDULLARY THYROID CANCER
- U-1618 A METHOD OF TREATING A PATIENT SUFFERING FROM A PAIN ASSOCIATED SLEEP DISTURBANCE COMPRISING ADMINISTERING A LIQUID COMPOSITION FORMULATED INSIDE A SOFT GEL CAPSULE, AS CLAIMED, TO THE PATIENT
- U-1619 TREATMENT OF IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
- U-1620 METHOD OF TREATMENT OF IRON-RELATED CONDITIONS WITH AT LEAST 0.6 GRAMS OF ELEMENTAL IRON VIA AN IRON CARBOHYDRATE COMPLEX, WITH A SUBSTANTIALLY NON-IMMUNOGENIC CARBOHYDRATE COMPONENT, IN ABOUT 15 MINUTES OR LESS.
- U-1621 PULMONARY ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN BOUND TO A COMPLEXING AGENT.
- U-1622 FOR THE TREATMENT OF POLYCYTHEMIA VERA
- U-1623 USE OF EXENATIDE MAY RESULT IN REDUCTION IN APPETITE.
- U-1624 TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA, ADVANCED RENAL CELL CARCINOMA, OR DIFFERENTIATED THYROID CARCINOMA.
- U-1625 METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING ILOPERIDONE TO A PATIENT BY REDUCING THE DOSE IN PATIENTS WHO ARE POOR METABOLIZERS OF CYP2D6
- U-1626 A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING
- U-1627 TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN ADULTS
- U-1628 METHOD OF TREATING DISORDERS WITH AN ETIOLOGY COMPRISING OR ASSOCIATED WITH EXCESS GH-SECRETION
- U-1629 METHOD OF TREATING ACROMEGALY
- U-1630 TREATMENT IN COMBINATION WITH A CORTICOID SUCH AS PREDNISONE OF PROSTATE CANCER PREVIOUSLY TREATED WITH DOCETAXEL
- U-1631 TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
- U-1632 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
- U-1633 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
- U-1634 TREATMENT OF BRCA MUTATED OVARIAN CANCER USING PARP INHIBITOR
- U-1635 USE OF RITONAVIR AS A POTENT CYP3A INHIBITOR TO INCREASE PLASMA DRUG CONCENTRATION OF PARITAPREVIR AND OVERALL DRUG EXPOSURE FOR TREATMENT OF HCV INFECTION
- U-1636 USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.
- U-1637 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.

PATENT AND EXCLUSIVITY TERMS

PATENT USE

U-1638 TREATMENT OF HCV INFECTION USING PARITAPREVIR

U-1639 USE OF NALTREXONE AND BUPROPION IN EXTENDED-RELEASE FORM FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY

U-1640 TREATMENT OF MODERATE TO SEVERE CHRONIC PAIN BY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED

U-1641 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE

U-1642 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS WITH SEVERE CHRONIC RENAL IMPAIRMENT AND FOR WHOM METFORMIN THERAPY IS INAPPROPRIATE BY ADMINISTERING LINAGLIPTIN

U-1643 TREATING CUSHING'S SYNDROME

U-1644 TREATMENT OF OVERACTIVE BLADDER BY APPLICATION OF OXYBUTYNIN CHLORIDE GEL TO SKIN

U-1645 TREATMENT OF PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION

U-1646 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION

U-1647 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION

U-1648 TREATMENT OF PATIENTS WITH PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION

U-1649 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM

U-1650 TREATMENT OF WALDENSTROM'S MACROGLOBULINEMIA

U-1651 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN

U-1652 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN

U-1653 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT METFORMIN)

U-1654 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT INSULIN OR A SULFONYLUREA)

U-1655 A METHOD TO ACCELERATE THE TIME TO GASTROINTESTINAL RECOVERY BY ADMINISTERING ABOUT 12 MG OF ALVIMOPAN TO THE PATIENT FROM ABOUT 30 TO 60 MINUTES PRIOR TO SURGERY

U-1656 METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT

U-1657 METHOD FOR PROVIDING POST COITAL CONTRACEPTION TO A WOMAN BY ADMINISTERING ABOUT 30 MG OF ULIPRISTAL ACETATE WITHIN ABOUT 120 HOURS AFTER INTERCOURSE, WHEREIN THE WOMAN IS OVERWEIGHT HAVING A BMI OF 25 TO 29.99

U-1658 TREATMENT OF ER-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER IN COMBINATION WITH LETROZOLE AS INITIAL ENDOCRINE-BASED THERAPY FOR METASTATIC DISEASE IN POSTMENOPAUSAL WOMEN

U-1659 MANAGEMENT OF PAIN

U-1660 TREATMENT OF HIV-1 INFECTION IN ADULTS WITH NO DARUNAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS

U-1661 RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS ALSO TAKING LOW DOSE ASPIRIN

U-1662 A METHOD OF TREATING OCULAR PAIN

U-1663 TREATMENT OF HIV-1 INFECTION

U-1664 TREATMENT OF BACTERIAL VAGINOSIS WITH METRONIDAZOLE GEL

U-1665 METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER BY ADMINISTERING THE COMPOSITION OF CLAIM 1

U-1666 PALLIATIVE TREATMENT OF PROSTATE CANCER

U-1667 TREATMENT OF ALLERGIC RHINITIS, INCLUDING SEASONAL ALLERGIC RHINITIS

U-1668 METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER

U-1669 TREATMENT OF MULTIPLE MYELOMA, IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE

U-1670 NATROBA TOPICAL SUSPENSION IS A PEDICULICIDE INDICATED FOR THE TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS SIX (6) MONTHS OF AGE AND OLDER.

U-1671 TREATMENT OF OCULAR ITCHING ASSOCIATED WITH CONJUNCTIVITIS

U-1672 TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION

U-1673 TREATMENT OF COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS

U-1674 DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE

U-1675 USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY

U-1676 METHODS FOR TREATING BACTERIAL INFECTIONS

U-1677 TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS (IPF)

U-1678 FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL

U-1679 TREATMENT OF ACUTE OTITIS EXTERNA

PATENT AND EXCLUSIVITY TERMS

PATENT USE

U-1680 TREATMENT OF OCULAR ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS

U-1681 TREATMENT OF PATIENTS WITH PROGRESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC

U-1682 TREATMENT OF BACTERIAL VAGINOSIS

U-1683 TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION

U-1684 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

U-1685 DOSAGE MODIFICATION TO REDUCE THE RISK ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE

U-1686 A METHOD TO REDUCE WITHDRAWAL SYMPTOMS, INCLUDING NICOTINE CRAVING, ASSOCIATED WITH SMOKING CESSATION

U-1687 TREATMENT OF HCV INFECTION USING OMBITASVIR

U-1688 METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD

U-1689 METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD

U-1690 METHOD FOR REDUCTION OF SUBMENTAL FAT

U-1691 INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER

U-1692 METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD

U-1693 METHOD OF TREATING ADHD IN CHILDREN 6 YEARS OF AGE AND OLDER AND ADOLESCENTS

U-1694 A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE

U-1695 METHOD FOR TREATING THYROID CARCINOMA INCLUDING DIFFERENTIATED THYROID CANCER

U-1696 TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA

U-1697 PULMONARY ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN BOUND TO A DIKETOPIPERAZINE.

U-1698 PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS

U-1699 A METHOD FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA

U-1700 A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA

U-1701 A METHOD FOR TREATING LEUKEMIA RESULTING FROM A MUTATION IN THE BCR-ABL KINASE DOMAIN

U-1702 TREATMENT OF COPD

U-1703 TREATMENT OF RESPIRATORY COMPLAINTS

U-1704 USE FOR TREATMENT IN PATIENTS WITH DIABETES

U-1705 USE FOR TREATMENT IN PATIENTS WITH HYPERGLYCEMIA

U-1706 TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE WHEREIN THE COMBINED THERAPEUTIC EFFECT IS GREATER THAN THE ADDITIVE EFFECT OF ADMINISTERING EACH AGENT ALONE

U-1707 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS AND SYMPTOMS THEREOF.

U-1708 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS.

U-1709 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE).

U-1710 TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH FLUVOXAMINE

U-1711 FOR THE TREATMENT OF PATIENTS WITH CLL, FL OR SLL

U-1712 MEKENIST IN COMBINATION WITH DABRAFENIB FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA

U-1713 TAFINLAR IN COMBINATION WITH TRAMETINIB FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA

U-1714 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)

U-1715 P2Y12 PLATELET INHIBITOR FOR USE AS ADJUNCT TO PERCUTANEOUS CORONARY INTERVENTION TO REDUCE RISK OF VARIOUS DISEASES/CONDITIONS IN PATIENTS NOT TREATED WITH A P2Y12 PLATELET INHIBITOR AND NOT GIVEN A GLYCOPROTEIN IIB/IIIA INHIBITOR

U-1716 TREATMENT OF COUGH AND SYMPTOMS ASSOCIATED WITH UPPER RESPIRATORY ALLERGIES OR A COMMON COLD WITH CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE ORALLY ADMINISTERED EXTENDED RELEASE TABLETS

U-1717 METHOD OF TREATING CYSTIC FIBROSIS IN PATIENTS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE

U-1718 METHOD OF TREATING CYSTIC FIBROSIS IN PATIENTS WHO HAVE THE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE.

U-1719 ACUTE TREATMENT OF MIGRAINE

U-1720 METHOD OF PROVIDING A THERAPEUTICALLY EFFECTIVE AND STABLE MEDIAN BLOOD PLASMA LEVEL OF LEVODOPA

PATENT AND EXCLUSIVITY TERMS

ADB 73 of 78

PATENT USE

U-1721 USE OF RUXOLITINIB (JAKAFI) FOR BLOCKING SIGNAL TRANSDUCTION OF JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2

U-1722 TREATMENT OF BASAL CELL CARCINOMA

U-1723 TREATMENT OF HEART FAILURE

U-1724 METHOD OF INHIBITING HEPATITIS C VIRUS

U-1725 METHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY

U-1726 REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH CORONARY HEART DISEASE AND A HISTORY OF PAROXYSMAL OR PERSISTENT AF AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS

U-1727 TOPICAL TREATMENT OF INFLAMMATORY PAPULES AND PUSTULES OF MILD TO MODERATE ROSACEA

U-1728 REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH STABLE NYHA CLASS III HEART FAILURE AND A HISTORY OF PAROXYSMAL OR PERSISTENT AF AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS

U-1729 REDUCE THE RISK OF RECURRENT DEEP VEIN THROMBOSIS (DVT)

U-1730 REDUCE THE RISK OF RECURRENT PULMONARY EMBOLISM

U-1731 TEMPORARY RELIEF OF MINOR ACHES AND PAINS

U-1732 TEMPORARY REDUCTION OF FEVER

U-1733 TREATMENT/PREVENTION OF CARDIOVASCULAR DISEASE

U-1734 USE OF FLIBANSERIN OR A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF TO TREAT HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)

U-1735 METHODS OF TREATING PAIN, INFLAMMATION AND/OR FEVER WITH INTRAVENOUS IBUPROFEN SUCH THAT MEAN ARTERIAL BLOOD PRESSURE DOES NOT INCREASE THE DOSAGE INTERVAL

U-1736 TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)

U-1737 METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING ILOPERIDONE TO A PATIENT BY REDUCING THE DOSE IN PATIENTS WHO ARE BEING TREATED WITH FLUOXETINE

U-1738 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE)

U-1739 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND -THE-CLOCK, LONG-TERM OPIOID TREATMENT, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY

U-1740 IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-NAIVE PATIENTS WITH HIV-1 RNA LESS THAN OR EQUAL TO 100,000 AT THE START OF THERAPY

U-1741 PREVENTION OF DELAYED NAUSEA AND VOMITING ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY

U-1742 ROLAPITANT IS APPROVED FOR THE PREVENTION OF DELAYED NAUSEA AND VOMITING (I.E., EMESIS) ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY

U-1743 FOR THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY

U-1744 PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING

U-1745 FOR THE TREATMENT OF PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA

U-1746 MONOTHERAPY OR ADJUNCTIVE THERAPY FOR TREATMENT OF PARTIAL-ONSET SEIZURES AND APPROVED IN PATIENTS WITH EPILEPSY

U-1747 FOR CLAIMS 1-3,6-13,16-24 AND 26-32: METHOD OF TREATING ADHD

U-1748 FOR CLAIMS 1-4,6-14,16-24 AND 26-32: METHOD OF TREATING ADHD IN CHILDREN 6 YEARS OF AGE AND OLDER AND ADOLESCENTS

U-1749 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER

U-1750 TREATMENT OF SCHIZOPHRENIA AND/OR ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH CARIPRAZINE

U-1751 TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER WHO HAVE BEEN PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE-, OXALIPLATIN- AND IRINOTECAN-BASED CHEMOTHERAPY, AN ANTI-VEGF BIOLOGICAL THERAPY, AND IF RAS WILD-TYPE, AN ANTI-EGFR THERAPY

U-1752 PROPHYLAXIS OF ORGAN REJECTION

U-1753 TREATMENT OF HCV INFECTION USING DASABUVIR

U-1754 FOR THE TREATMENT OF PULMONARY HYPERTENSION (PAH) IN COMBINATION WITH TADALAFIL

U-1755 FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS

U-1756 METHODS OF TREATING PAIN, INFLAMMATION AND/OR FEVER IN A CRITICALLY ILL PATIENT WITH INTRAVENOUS IBUPROFEN IN NEED THEREOF

U-1757 INHIBITION ON PI3K KINASE

U-1758 METHOD OF TREATING ALLERGIC REACTION VIA INJECTION

U-1759 METHOD OF REVERSING THE ANTICOAGULANT EFFECT OF DABIGATRAN USING IDARUCIZUMAB

U-1760 RISK-REDUCTION OF NSAID GASTRIC ULCER IN PATIENTS REQUIRING CHRONIC NSAID TREATMENT

U-1761 PLAQUE PSORIASIS

PATENT AND EXCLUSIVITY TERMS

ADB 74 of 78

PATENT USE

U-1762 USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT

U-1763 USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT

U-1764 USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT

U-1765 USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT

U-1766 TREATMENT OF HYPERKALEMIA

U-1767 USE OF CALCIPOTRIENE FOAM FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS AGED 18 YEARS AND OLDER

U-1768 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN

U-1769 TREATMENT OF PAIN BY TRANSMUCOSAL DELIVERY OF BUPRENORPHINE

U-1770 TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN NEGATIVE SYMPTOMS AND/OR COGNITIVE DYSFUNCTION OF SCHIZOPHRENIA

U-1771 ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE WATER FOR INJECTION OR 0.9% SODIUM CHLORIDE INJECTION PRIOR TO ADMINISTRATION

U-1772 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN

U-1773 LONG - TERM MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

U-1774 USE OF A LOTION CONTAINING HALOBETASOL PROPIONATE FOR THE TREATMENT OF CORTICOSTEROID-RESPONSIVE

U-1775 USE OF A LOTION CONTAINING HALOBETASOL PROPIONATE FOR THE TREATMENT OF CORTICOSTEROID-RESPONSIVE DERMATOSES INCLUDING PSORIASIS

U-1776 METHOD OF USING COBIMETINIB FOR THE TREATMENT OF MELANOMA

U-1777 TREATMENT OF PATIENTS WITH METASTATIC EPIDERMAL GROWTH FACTORE RECEPTOR (EGFR) T790M MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC), WHO HAVE PROGRESSED ON OR AFTER EGFR TKI THERAPY

U-1778 METHOD FOR TREATING MULTIPLE MYELOMA

U-1779 METHOD FOR TREATING MULTIPLE MYELOMA WITH ONE OR MORE OTHER THERAPEUTIC AGENTS

U-1780 METHOD FOR TREATING CANCER, INCLUDING MULTIPLE MYELOMA

U-1781 RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER IN PATIENTS REQUIRING NSAID TREATMENT

U-1782 FOR HEAD LICE INFESTATIONS

U-1783 METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN ESOMEPRAZOLE MAGNESIUM AS CLAIMED

U-1784 METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN ESOMEPRAZOLE MAGNESIUM TRIHYDRATE AS CLAIMED

U-1785 METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN ESOMEPRAZOLE MAGNESIUM FORMULATION AS CLAIMED

U-1786 TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS WHILE MANAGING THE RISK OF TERIFLUNOMIDE AND ROSUVASTATIN INTERACTION BY LIMITING THE ROSUVASTATIN DOSE TO NO MORE THAN 10MG AND/OR ADMINISTERING ABOUT HALF THE NORMAL DOSE

U-1787 TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY

U-1788 TREATMENT OF PATIENT HAVING DIABETES MELLITUS VIA ORAL INHALATION OF FDKP MICROPARTICLES COMPRISING INSULIN

U-1789 METHOD OF ADMINISTERING AN ETHANOL-FREE TAXANE LIQUID NANODISPERSION FORMULATION TO A SUBJECT COMBINING THE FORMULATION WITH AN AQUEOUS MEDIUM TO PROVIDE AN ETHANOL-FREE TAXANE DILUTED SOLUTION

U-1790 FOR USE IN TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR NON-HODGKIN'S LYMPHOMA

U-1791 EMERGENCY TREATMENT OF ADULT & PEDIATRIC PATIENTS FOLLOWING FLUOROURACIL OR CAPECITABINE OVERDOSE, OR WHO EXHIBIT EARLY-ONSET, SEVERE OR LIFE-THREATENING CARDIAC OR CNS TOXICITY OR UNUSUALLY SEVERE ADVERSE REACTIONS WITHIN 96 HOURS

U-1792 TREATMENT OF OTIC INFECTION OR INFLAMMATION

U-1793 TREATMENT OF PEDIATRIC PATIENTS WITH OTITIS MEDIA WITH EFFUSION UNDERGOING TYMPANOSTOMY TUBE PLACEMENT

U-1794 REVERSAL OF DRUG-INDUCED NEUROMUSCULAR BLOCK

U-1795 REVERSAL OF NEUROMUSCULAR BLOCKAGE INDUCED BY ROCURONIUM BROMIDE OR VECURONIUM BROMIDE

U-1796 TOPICAL TREATMENT OF INFLAMMATORY PAPULES AND PUSTULES OF MILD TO MODERATE ROSACEA

PATENT AND EXCLUSIVITY TERMS

PATENT USE

- U-1797 METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG
- U-1798 METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN
- U-1799 METHOD OF INCREASING GROWTH OF HAIR INCLUDING EYELASHES
- U-1800 A METHOD OF TREATING OCULAR PAIN AND/OR ENHANCING OCULAR COMFORT
- U-1801 REDUCTION OF SERUM URIC ACID LEVELS
- U-1802 TREATMENT OF GOUT
- U-1803 TREATMENT OF HYPERURICEMIA
- U-1804 ACHIEVING A THERAPEUTIC BENEFIT IN A SUBJECT WITH GOUT
- U-1805 USE OF DEXLANSOPRAZOLE IN PATIENTS TAKING CLOPIDOGREL WITHOUT MEANINGFUL CYP2C19 INTERACTIONS
- U-1806 COADMINISTERING WITH ALLOPURINOL TO REDUCE SERUM URIC ACID (SUA) BELOW 4 MG/DL; BELOW 6MG/DL IN PATIENTS HAVING URIC ACID DEPOSITS; AND/OR BELOW 6MG/DL WITH SUA INTRADAY CHANGE MORE THAN 50% AND/OR ADVERSE EVENT RATE LESS THAN 15%
- U-1807 TREATMENT OF PEDIATRIC PATIENTS 8 TO 17 YEARS OF AGE WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)
- U-1808 USE OF NALTREXONE AND BUPROPION FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER
- U-1809 METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY
- U-1810 TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
- U-1811 TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATIONS AFTER CONFIRMING THE PRESENCE OF BRAF V600E MUTATION
- U-1812 TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA
- U-1813 TREATMENT OF PATIENTS INFECTED WITH HEPATITIS C VIRUS
- U-1814 METHOD OF TREATING GLAUCOMA OR ELEVATED INTRAOCULAR PRESSURE
- U-1815 TREATMENT OF PARTIAL-ONSET SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY
- U-1816 TREATMENT OF A UREA CYCLE DISORDER
- U-1817 PEDIATRIC USE AGES 1 MONTH TO 2 YEARS, GERD AND EROSIIVE ESOPHAGITIS
- U-1818 TREATING HR-POS., HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER WITH PALBOCICLIB IN COMBO WITH LETROZOLE AS INITIAL ENDOCRINE BASED THERAPY IN POSTMENOPAUSAL WOMEN, OR FULVESTRANT IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
- U-1819 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
- U-1820 METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION BY ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN AND A POLYSORBATE, WHEREIN THE POLYSORBATE REPRESENTS 0.1 TO 3% OF THE WEIGHT OF SAID PHARMACEUTICAL COMPOSITION
- U-1821 METHOD FOR CONTRACEPTION TO A WOMAN COMPRISING ADMINISTERING TO THE WOMAN 30MG OF ULIPRISTAL ACETATE MORE THAN 72 HOURS AND UP TO 120 HOURS AFTER AN UNPROTECTED INTERCOURSE
- U-1822 TREATMENT OF SCHIZOPHRENIA OR BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA AND/OR BIPOLAR DISORDER
- U-1823 A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY COMPENSATING LONG-TERM SENSITIVITY DRIFT OF ELECTROCHEMICAL GAS SENSORS USED IN SYSTEMS FOR DELIVERING THERAPEUTIC NITRIC OXIDE TO A PATIENT
- U-1824 A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY VERIFYING GAS INFORMATION OF NITRIC OXIDE PRIOR TO DELIVERY TO PATIENT
- U-1825 METHOD OF USING VISMODEGIB TO TREAT CANCER IN A MAMMAL
- U-1826 TREATMENT OF HR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN COMBINATION WITH PALBOCICLIB IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
- U-1827 A METHOD OF PROVIDING A SUBJECT WITH THERAPEUTICALLY EFFECTIVE AMOUNT OF RACEMIC METHYLPHENIDATE BY ORALLY ADMINISTERING TO SAID SUBJECT A SINGLE METHYLPHENIDATE EXTENDED RELEASE CHEWBLE TABLET ACCORDING TO CLAIM 1
- U-1828 INCREASING MEAN ARTERIAL BLOOD PRESSURE IN ADULT PATIENTS WITH HYPOTENSION ASSOCIATED WITH SEPTIC SHOCK
- U-1829 EMERGENCY TREATMENT OF ALLERGIC REACTIONS (TYPE I), INCLUDING ANAPHYLAXIS
- U-1830 INDUCTION AND MAINTENANCE OF MYDRIASIS DURING INTRAOCULAR SURGERY
- U-1831 METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A CRYSTALLINE FORM OF SELEXIPAG
- U-1832 IMPROVEMENT IN GLYCEMIC CONTROL IN DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR WITH A THREADED DRIVE SLEEVE
- U-1833 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
- U-1834 TREATMENT OF POSTOPERATIVE INFLAMMATION AND PREVENTION OF OCULAR PAIN IN PATIENTS UNDERGOING CATARACT SURGERY

PATENT AND EXCLUSIVITY TERMS

ADB 76 of 78

PATENT USE

U-1835 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION, AS DETECTED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY

U-1836 TREATMENT OF HEREDITARY TYROSINEMIA TYPE 1 (HT-1) IN COMBINATION WITH DIETARY RESTRICTION OF TYROSINE AND PHENYLALANINE

U-1837 METHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN ALONE OR IN COMBINATION WITH INSULIN, METFORMIN, A THIAZOLIDINEDIONE, GLYBURIDE OR METFORMIN PLUS A SULFONYLUREA

U-1838 METHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN IN COMBINATION WITH METFORMIN

U-1839 COMPOSITION AND METHOD FOR PROVIDING A REDUCTION IN SIDE EFFECTS FOR HUMAN PATIENTS IN NEED OF ACETYLCYSTEINE THERAPY

U-1840 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR, WITHOUT RIBAVIRIN

U-1841 USE IN THE LONG-TERM, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

U-1842 METHOD OF TREATING EPILEPSY

U-1843 TREATMENT OF PSYCHOSIS

U-1844 TREATMENT OF PARKINSON'S DISEASE PSYCHOSIS

U-1845 TREATMENT OF PSYCHOSIS OR A SYMPTOM THEREOF

U-1846 TREATMENT OF A NEURODEGENERATIVE DISEASE OR A SYMPTOM THEREOF

U-1847 METHOD OF TREATING A BACTERIAL INFECTION

U-1848 TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN

U-1849 METHOD OF TREATING PULMONARY HYPERTENSION BY ADMINISTERING TREPROSTINIL OR A SALT THEREOF BY INHALATION USING A DEVICE

U-1850 METHOD OF ADMINISTERING LEVETIRACETAM

U-1851 A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES

U-1852 METHOD OF TREATING TYPE 2 DIABETES

U-1853 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND, OPTIONALLY, A SULFONYLUREA

U-1854 TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC)

U-1855 IMPROVEMENT IN GLYCEMIC CONTROL IN DIABETES MELLITUS PATIENTS

U-1856 TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN, IN A PATIENT HOMOZYGOUS FOR THE UGT1A1*28 ALLELE

U-1857 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES

U-1858 TREATMENT OF PLAQUE PSORIASIS

U-1859 TREATMENT OF SCHIZOPHRENIA, ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER, ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER, AND TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER

U-1860 REDUCTION OF THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION

U-1861 USE OF AN INHALER TO ADMINISTER DRY POWDER MEDICAMENT

U-1862 TREATMENT OF POST-MYOCARDIAL INFARCTION

U-1863 TREATMENT OF STROKE

U-1864 TREATMENT OF MYOCARDIAL INFARCTION

U-1865 TREATMENT OF THROMBOTIC STROKE

U-1866 TREATMENT OF STABLE AND UNSTABLE ANGINA

U-1867 METHOD OF INHIBITING PLATELET AGGREGATION

U-1868 TREATMENT OF ARTERIAL THROMBOTIC COMPLICATIONS SELECTED FROM THE GROUP CONSISTING OF UNSTABLE ANGINA, THROMBOTIC OR EMBOLIC STROKE, TRANSIENT ISCHAEMIC ATTACKS, PERIPHERAL VASCULAR DISEASE AND MYOCARDIAL INFARCTION

U-1869 TREATMENT OF AN ARTERIAL THROMBOTIC COMPLICATION IN A PATIENT WITH CORONARY ARTERY, CEREBROVASCULAR OR PERIPHERAL VASCULAR DISEASE

U-1870 ZINGO IS A POWDER INTRADERMAL SYSTEM THAT IS CAPABLE OF DELIVERING FINE DRY POWDERED LIDOCAINE HYDROCHLORIDE MONOHYDRATE FOR LOCAL ANESTHETIC ACTION

U-1871 TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH STAGE 3 OR 4 CHRONIC KIDNEY DISEASE USING CONTROLLED RELEASE, ORAL 25-HYDROXYVITAMIN D

U-1872 USE OF SUSTAINED RELEASE 25-HYDROXYVITAMIN D IN TREATING PATIENTS HAVING 25-HYDROXYVITAMIN D INSUFFICIENCY OR DEFICIENCY

U-1873 ADMINISTRATION OF 25-HYDROXYVITAMIN D3 BY CONTROLLED RELEASE

U-1874 TREATMENT OF FREQUENT HEARTBURN BY ADMINISTERING OMEPRAZOLE ACCORDING TO CLAIMS 1-8

PATENT AND EXCLUSIVITY TERMS

ADB 77 of 78

PATENT USE

- U-1875 TREATMENT OF FREQUENT HEARTBURN BY ADMINISTERING S-OMEPRAZOLE TRIHYDRATE ACCORDING TO CLAIMS 1-3
- U-1876 METHOD OF ANESTHETIZING AT LEAST A PORTION OF THE MAXILLARY DENTAL ARCH
- U-1877 METHOD OF TREATING PULMONARY HYPERTENSION BY ORALLY ADMINISTERING A FORMULATION OF A PHARMACEUTICALLY ACCEPTABLE SALT OF TREPROSTINIL
- U-1878 FOR OPIOID DEPENDENCE
- U-1879 METHOD OF DIAGNOSING TUMORS USING POSITRON EMISSION TOMOGRAPHY
- U-1880 TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
- U-1881 IMPROVEMENT IN GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR
- U-1882 MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANALGESIC AND ANTIPYRETIC ACTIVITY
- U-1883 TREATMENT OF GASTROINTESTINAL STROMAL TUMORS (GIST)
- U-1884 USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
- U-1885 USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
- U-1886 USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
- U-1887 USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
- U-1888 USE OF CONTROLLED RELEASE 25-HYDROXYVITAMIN D IN TREATING SECONDARY HYPERPARATHYROIDISM IN PATIENTS HAVING CHRONIC KIDNEY DISEASE
- U-1889 TREATMENT OF HCV INFECTION USING DASABUVIR/OMBITASVIR/PARITAPREVIR/RITONAVIR FIXED DOSE COMBINATION
- U-1890 OTC USE: ALLERGY SYMPTOM RELIEVER; TEMPORARILY RELIEVES THESE SYMPTOMS DUE TO HAY FEVER OR OTHER UPPER RESPIRATORY ALLERGIES; NASAL CONGESTION, RUNNY NOSE, SNEEZING, ITCHY NOSE, AND (ITCHY WATER EYES (AGES 12 AND UP))
- U-1891 TREATMENT OR PREVENTION OF NAUSEA AND VOMITING
- U-1892 METHOD OF TREATING LEFT VENTRICULAR DYSFUNCTION
- U-1893 METHOD OF TREATING MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER IN PEDIATRIC PATIENTS
- U-1894 COMBINATION TREATMENT WITH A GLITAZONE FOR IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS
- U-1895 METHOD OF TREATING PROSTATE CANCER
- U-1896 SUPPLEMENT FOR VITAMIN B12 DEFICIENCIES
- U-1897 METHOD OF TREATING ACS USING ANGIOPLASTY WITH AGGRASTAT (TIROFIBAN HYDROCHLORIDE)
- U-1898 METHOD OF INHIBITING PLATELET AGGREGATION WITH AGGRASTAT (TIROFIBAN HYDROCHLORIDE)
- U-1899 TREATMENT OF PANCREATIC CANCER THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN
- U-1900 TREATMENT OF THE SIGNS SYMPTOMS OF DRY EYE DISEASE (DED)
- U-1901 TREATMENT OF SCHIZOAFFECTIVE DISORDER AS A MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS
- U-1902 TREATMENT OR SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE, CARDIOVASCULAR EVENTS, OR CEREBROVASCULAR EVENTS AND RISK-REDUCTION OF ASPIRIN-ASSOCIATED GASTRIC ULCERS
- U-1903 USE OF NALOXONE HYDROCHLORIDE FOR EMERGENCY TREATMENT OF KNOWN OR SUSPECTED OPIOID OVERDOSE, AS MANIFESTED BY RESPIRATORY AND/OR CENTRAL NERVOUS SYSTEM DEPRESSION.
- U-1904 (I) TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY; (II) RESTORING/INCREASING FUNCTIONAL DYSTROPHIN PROTEIN; OR (III) INDUCING SKIPPING; EACH OF (I)-(III) IN PATIENTS HAVING A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
- U-1905 METHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS, THE PATIENT HAVING A R117H MUTATION IN CFTR, USING N-(5-HYDROXY-2,4-DI-TERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE
- U-1906 METHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS, SUCH AS A PATIENT HAVING A G551D MUTATION IN CFTR, USING N-(5-HYDROXY-2,4-DI-TERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE
- U-1907 USE OF A DELIVERY DEVICE TO ADMINISTER A DOSE OF NALOXONE
- U-1908 METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING IVACAFTOR AND FORM I LUMACAFTOR
- U-1909 METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING IVACAFTOR AND LUMACAFTOR

PATENT AND EXCLUSIVITY TERMS

ADB 78 of 78

PATENT USE

- U-1910 METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING THE DOSAGE UNIT OF CLAIM 1 OF U.S. PATENT NO. 8,716,338
- U-1911 METHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS USING IVACAFTOR AND LUMACAFTOR
- U-1912 METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING A DOSAGE UNIT AS DEFINED IN CLAIM 1 OF U.S. PATENT NO. 9,192,606
- U-1913 TREATMENT OF PEDIATRIC PATIENTS WITH BILATERAL OTITIS MEDIA WITH EFFUSION UNDERGOING TYMPANOSTOMY TUBE PLACEMENT
- U-1914 IN COMBINATION WITH RITUXIMAB, FOR THE TREATMENT OF PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
- U-1915 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS WITH SEVERE CHRONIC RENAL IMPAIRMENT AND WHO ARE INELIGIBLE FOR METFORMIN THERAPY BY ADMINISTERING LINAGLIPTIN
- U-1916 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY (CINV)
- U-1917 TREATMENT OF EXOCRINE PANCREATIC CANCER THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN
- U-1918 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
- U-1919 RESTORING AN MRNA READING FRAME TO INDUCE DYSTROPHIN PROTEIN PRODUCTION IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
- U-1920 USE OF EXTENDED RELEASE ORAL 25-HYDROXYVITAMIN D3 IN TREATING SECONDARY HYPERPARATHYROIDISM IN ADULT PATIENTS HAVING CHRONIC KIDNEY DISEASE STAGE 3 OR STAGE 4
- U-1921 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE BY PROVIDING AN ABUSE-DETERRENT ORAL CONTROLLED RELEASE COMBINATION DRUG PRODUCT
- U-1922 INTRAVAGINAL PRASTERONE (DEHYDROEPIANDROSTERONE) AT A DAILY DOSE OF 6.5MG FOR THE TREATMENT OF DYSpareunia, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE
- U-1923 IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY BASAL INSULIN OR LIXISENATIDE BY USE OF A PEN INJECTOR WITH A THREADED DRIVE SLEEVE
- U-1924 KYPROLIS IS INDICATED IN COMBINATION WITH LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY
- U-1925 USE OF AN AUTO INJECTOR TO ADMINISTER NALOXONE HCl
- U-1926 METHOD OF TREATING, REDUCING THE INCIDENCE OF, OR PREVENTING AN ISCHEMIC EVENT IN A PATIENT UNDERGOING PCI BY ADMINISTERING INTRAVENOUSLY 30 UG/KG BOLUS BEFORE PCI AND CONTINUOUS IN FUSION OF 4 UG/KG/MIN FOR AT LEAST 2 HOURS OR THE DURATION OF THE PCI
- U-1927 A METHOD FOR TREATING OVARIAN CANCER BY ADMINISTERING RUBRACA, WHEREIN THE CANCER IS ASSOCIATED WITH A GENETIC DEFECT IN AT LEAST ONE OF THE BRCA1 AND BRCA2 GENES.
- U-1928 RUBRACA IS INDICATED AS MONOTHERAPY FOR THE TREATMENT OF PATIENTS WITH DELETERIOUS BRCA MUTATION (GERMLINE AND/OR SOMATIC) ASSOCIATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH TWO OR MORE CHEMOTHERAPIES.
- U-1929 TREATMENT OF DIABETES MELLITUS WITH AN INHALED INSULIN TO IMPROVE GLYCEMIC CONTROL USING A DRY POWDER INHALATION SYSTEM COMPRISING AN INHALER, A CARTRIDGE AND A DRY POWDER MEDICAMENT COMPRISING INSULIN IN A SINGLE INHALATION
- U-1930 METHOD OF AEROSOLIZING/DEAGGLOMERATING AN INSULIN DRY POWDER FOR USE IN TREATING DIABETES MELLITUS VIA ORAL INHALATION USING AN INHALER WITH A CARTRIDGE CONTAINING THE INSULIN DRY POWDER.
- U-1931 PROPHYLAXIS OR TREATMENT OF VENOUS AND ARTERIAL THROMBOTIC DISEASE